0001420720-24-00003810-K iBio, Inc. 20240920202409201614041614041614041404 0 0001420720-24-000038 10-K 145 20240630 20240920 20240920 iBio, Inc. 0001420720 2834 262797813 DE 0630 10-K 34 001-35023 241313529 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 iBioPharma, Inc. 20080806 InB:Biotechnologies, Inc. 20071210 10-K 1 ibio-20240630x10k.htm 10-K 383100061200020000000001420720--06-302024FY3831000612000Non-accelerated Filertrue0862367610155054.0347.882.4758.316.50106.190.040.050.040.0500P3YP39Y0.000P10YP24MP24MP18MP18M0000MonthlyP1D0.040.040.050.05P30D02.004.0347.882.4758.316.5010(
gaap:EquipmentMemberibio:AssetPurchaseAgreementMember2022-09-162022-09-160001420720us-gaap:BuildingMember2021-04-012021-04-010001420720202022-07-012024-06-300001420720us-gaap:EmployeeStockOptionMember2022-07-012024-06-300001420720us-gaap:CommonStockMember2023-07-012024-06-300001420720us-gaap:PreferredStockMember2022-07-012023-06-300001420720us-gaap:CommonStockMember2022-07-012023-06-300001420720ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720us-gaap:CommonStockMember2023-11-292023-11-290001420720us-gaap:CommonStockMember2022-10-072022-10-070001420720us-gaap:RetainedEarningsMember2024-06-300001420720us-gaap:AdditionalPaidInCapitalMember2024-06-300001420720us-gaap:RetainedEarningsMember2023-06-300001420720us-gaap:AdditionalPaidInCapitalMember2023-06-300001420720us-gaap:RetainedEarningsMember2022-06-300001420720us-gaap:AdditionalPaidInCapitalMember2022-06-300001420720us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001420720us-gaap:OtherAffiliatesMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-03-310001420720ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember2024-06-300001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember2024-06-300001420720us-gaap:CommonStockMember2024-06-300001420720us-gaap:CommonStockMember2023-06-300001420720us-gaap:PreferredStockMember2022-06-300001420720us-gaap:CommonStockMember2022-06-300001420720ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:CommonStockAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:AllianceGlobalPartnersMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:ExercisePriceStockOptionsRange5Member2023-07-012024-06-300001420720ibio:ExercisePriceStockOptionsRange4Member2023-07-012024-06-300001420720ibio:ExercisePriceStockOptionsRange3Member2023-07-012024-06-300001420720ibio:ExercisePriceStockOptionsRange2Member2023-07-012024-06-300001420720ibio:ExercisePriceStockOptionsRange1Member2023-07-012024-06-300001420720ibio:ExercisePriceStockOptionsRange1Member2024-06-300001420720ibio:ExercisePriceStockOptionsRange5Member2024-06-300001420720ibio:ExercisePriceStockOptionsRange4Member2024-06-300001420720ibio:ExercisePriceStockOptionsRange3Member2024-06-300001420720ibio:ExercisePriceStockOptionsRange2Member2024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange5Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange4Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange3Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange2Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange1Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMember2024-07-012024-09-160001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMember2024-07-012024-09-160001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-06-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-06-300001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-07-012022-09-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-07-012022-09-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-092023-12-090001420720us-gaap:EmployeeStockOptionMember2021-07-012022-06-300001420720us-gaap:EmployeeStockOptionMember2022-06-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMember2024-07-012024-09-160001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-07-012023-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-07-012022-09-300001420720us-gaap:EmployeeStockOptionMember2022-07-012023-06-300001420720us-gaap:EmployeeStockOptionMember2023-06-300001420720srt:MinimumMember2023-07-012024-06-300001420720srt:MinimumMember2022-07-012023-06-300001420720srt:MaximumMember2023-07-012024-06-300001420720srt:MaximumMember2022-07-012023-06-300001420720us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2024-07-012024-09-160001420720us-gaap:RestrictedStockUnitsRSUMember2022-07-012023-06-300001420720srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-06-302024-06-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-06-300001420720srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:IbioInc.2020OmnibusEquityIncentivePlanMember2023-03-312023-03-310001420720srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:IbioInc.2020OmnibusEquityIncentivePlanMember2023-03-312023-03-310001420720ibio:Mr.RobertLutzMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-11-112022-11-110001420720ibio:MartinBrennerChiefScientificOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-11-112022-11-110001420720ibio:MartinBrennerInterimChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-06-222023-06-220001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-07-012024-09-160001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-07-012024-09-160001420720srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-06-302024-06-300001420720us-gaap:OtherAffiliatesMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-04-012024-06-300001420720srt:ChiefFinancialOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-06-300001420720srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-04-012024-04-010001420720us-gaap:RestrictedStockUnitsRSUMember2024-01-262024-01-260001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-092023-12-090001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-092023-12-090001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-07-012024-06-300001420720srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-06-262023-06-260001420720us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:IbioInc.2020OmnibusEquityIncentivePlanMember2023-03-312023-03-310001420720ibio:MartinBrennerInterimChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-01-202023-01-200001420720ibio:Mr.IsettMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-11-102022-11-100001420720us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2022-08-292022-08-290001420720us-gaap:OtherAffiliatesMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-07-012022-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-07-012022-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-07-012022-09-300001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2020-12-092020-12-090001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2020-12-092020-12-090001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2021-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2024-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2023-06-300001420720ibio:TermNote2024Member2023-07-012024-06-300001420720ibio:InsurancePremiumFinancingAgreementMember2023-07-012024-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2023-07-012024-06-300001420720ibio:AllianceGlobalPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:HcWainwrightAndCompanyLlcMembersrt:MinimumMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-04-012024-04-010001420720us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-07-012024-06-300001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2023-07-012024-06-300001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2022-07-012023-06-300001420720ibio:CollegeStationInvestorsLlcMemberibio:BryanTexasMemberus-gaap:LandAndBuildingMemberibio:PurchaseAndSaleGroundLeaseAgreementMember2021-11-012021-11-010001420720ibio:CollegeStationInvestorsLlcMemberibio:BryanTexasMemberibio:PurchaseAndSaleGroundLeaseAgreementMember2021-11-012021-11-010001420720us-gaap:SegmentDiscontinuedOperationsMember2023-07-012024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMember2022-07-012023-06-300001420720ibio:LetterOfCreditSanDiegoLeaseMember2024-06-300001420720ibio:CompanyPurchasingCardMember2024-06-300001420720ibio:LetterOfCreditTermLoanMember2023-06-300001420720ibio:LetterOfCreditSanDiegoLeaseMember2023-06-300001420720ibio:CompanyPurchasingCardMember2023-06-300001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-312024-05-310001420720ibio:WoodforestNationalBankMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-312024-05-310001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-03-282023-03-280001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember2022-10-112022-10-110001420720srt:MinimumMember2024-06-300001420720srt:MaximumMember2024-06-300001420720us-gaap:OfficeEquipmentMember2024-06-300001420720us-gaap:MachineryAndEquipmentMember2024-06-300001420720us-gaap:OfficeEquipmentMember2023-06-300001420720us-gaap:MachineryAndEquipmentMember2023-06-300001420720us-gaap:RetainedEarningsMember2023-07-012024-06-300001420720us-gaap:RetainedEarningsMember2022-07-012023-06-300001420720ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-08-012024-08-310001420720us-gaap:SubsequentEventMember2024-08-012024-08-310001420720ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-07-012024-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:WarrantAgreementsMember2022-07-012023-06-300001420720ibio:AssetPurchasingAgreementMember2024-02-252024-02-250001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMemberibio:PurchaseAndSaleAgreementMember2024-05-312024-05-310001420720ibio:CollegeStationInvestorsLlcMemberibio:PurchaseAndSaleGroundLeaseAgreementMember2021-11-012021-11-010001420720ibio:WoodforestNationalBankMemberibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2023-03-172023-03-170001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2023-02-172023-02-170001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsToSettleDebtMemberus-gaap:SettledLitigationMember2022-03-312023-03-170001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2022-03-312022-03-310001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsForLicenseAgreementMemberus-gaap:SettledLitigationMember2022-02-092023-02-170001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2022-02-092022-02-090001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsToCoverLegalExpensesMemberus-gaap:SettledLitigationMember2021-05-142021-05-140001420720ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMember2022-09-192022-09-190001420720us-gaap:ConvertiblePreferredStockMember2022-05-102022-05-100001420720ibio:LincolnParkPurchaseAgreementMember2023-12-312023-12-310001420720ibio:Offering2023Member2023-12-072023-12-070001420720ibio:AtMarketOfferingsMember2023-09-302023-09-300001420720ibio:LincolnParkPurchaseAgreementMember2023-08-042023-08-040001420720ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMember2022-09-190001420720us-gaap:ConvertiblePreferredStockMember2022-05-100001420720us-

gaap:ConvertiblePreferredStockMember2022-05-090001420720ibio:CroAgreementMember2023-07-012024-06-300001420720ibio:CroAgreementMember2022-07-012023-06-300001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2024-06-300001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2023-06-300001420720ibio:BryanTexasMemberus-gaap:LandAndBuildingMember2021-11-010001420720us-gaap:NotesReceivableMember2024-06-300001420720us-gaap:NotesReceivableMember2023-06-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2023-06-190001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2024-06-300001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-312024-05-310001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-312024-05-310001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberibio:WoodforestSettlementAgreementMember2024-05-172024-05-170001420720ibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:HcWainwrightAndCompanyLlcMembersrt:MaximumMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720ibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720ibio:BryanCapitalMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2021-11-012021-11-010001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-06-300001420720ibio:WoodforestNationalBankMemberibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2023-03-242023-03-240001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2021-05-042021-05-040001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2021-09-100001420720ibio:PrincipalMember2024-06-300001420720ibio:InterestMember2024-06-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2023-07-012024-06-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2022-07-012023-06-300001420720ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember2023-07-012024-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2022-07-012023-06-300001420720us-gaap:PatentsMember2024-06-300001420720us-gaap:PatentsMember2023-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMember2023-10-012023-12-310001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMember2023-04-012023-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:MachineryAndEquipmentMember2022-07-012023-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMember2022-07-012023-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2022-07-012023-06-300001420720us-gaap:PatentsMember2023-07-012024-06-300001420720ibio:UniversityOfPittsburghMemberus-gaap:PatentsMemberibio:PatentAndLicensingAgreementMember2022-07-012023-06-300001420720us-gaap:BuildingAndBuildingImprovementsMember2024-06-300001420720us-gaap:BuildingAndBuildingImprovementsMember2023-06-300001420720us-gaap:MachineryAndEquipmentMember2022-12-310001420720us-gaap:BuildingAndBuildingImprovementsMember2022-12-310001420720ibio:SanDiegoMemberus-gaap:FinancialStandbyLetterOfCreditMemberus-gaap:LandAndBuildingMember2021-09-100001420720srt:ChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember2022-10-012022-12-310001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember2021-07-012022-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMemberibio:PurchaseAndSaleAgreementMember2023-07-012024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:PurchaseAndSaleAgreementMember2023-07-012024-06-300001420720us-gaap:IntellectualPropertyMember2024-06-300001420720us-gaap:IntellectualPropertyMember2023-06-300001420720ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMember2024-06-300001420720ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMember2023-06-300001420720us-gaap:SegmentContinuingOperationsMember2023-07-012024-06-300001420720us-gaap:SegmentContinuingOperationsMember2022-07-012023-06-300001420720us-gaap:RestrictedStockUnitsRSUMember2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMember2023-07-012024-06-300001420720us-gaap:RestrictedStockUnitsRSUMember2024-06-300001420720us-gaap:EmployeeStockOptionMember2024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2023-07-012024-06-300001420720srt:ChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember2024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2022-11-032022-11-030001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:RetirementPlanNameOtherMember2023-07-012024-06-300001420720us-gaap:RetirementPlanNameOtherMember2023-07-012024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:RetirementPlanNameOtherMember2022-07-012023-06-300001420720us-gaap:RetirementPlanNameOtherMember2022-07-012023-06-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-01-162024-01-160001420720ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember2023-10-302023-10-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberibio:CreditAndSecurityAgreementMember2023-07-012024-06-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:CreditAndSecurityAgreementMember2023-07-012024-06-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2023-07-012024-06-300001420720ibio:FirstInsuranceFundingMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:InsurancePremiumFinancingAgreementMember2023-07-012024-06-300001420720us-gaap:DebtInstrumentRedemptionPeriodTwoMemberibio:EquipmentFinancingMasterLeaseAgreementMember2023-07-012024-06-300001420720us-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:EquipmentFinancingMasterLeaseAgreementMember2023-07-012024-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2023-07-012024-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2022-10-122022-10-120001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember2022-10-112023-03-310001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember2024-05-170001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-10-040001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-09-180001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-04-140001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember2022-10-110001420720ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember2023-10-300001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember2023-06-300001420720ibio:EquipmentFinancingMasterLeaseAgreementMember2022-10-120001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember2021-11-010001420720ibio:WoodforestNationalBankMemberibio:CreditAgreementWithWoodforestNationalBankMember2021-11-010001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMemberus-gaap:PrimeRateMember2024-01-162024-01-160001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementEventOfDefaultMemberus-gaap:BaseRateMember2024-01-162024-01-160001420720us-gaap:ConvertiblePreferredStockMember2022-07-190001420720us-gaap:SalesMember2023-07-012024-06-300001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2023-06-300001420720ibio:AtMarketOfferingsMember2023-09-300001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2024-06-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2024-06-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-090001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2020-12-090001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:SeriesDWarrantsMemberibio:Offering2023Member2023-12-070001420720ibio:SeriesCWarrantsMemberibio:Offering2023Member2023-12-070001420720ibio:PreFundedWarrantsMemberibio:Offering2023Member2023-12-070001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-040001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-040001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-08-310001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-08-310001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-06-300001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-310001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-310001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberibio:WoodforestSettlementAgreementMember2024-05-170001420720ibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:SeriesEWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-03-260001420720ibio:PreFundedWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-03-260001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-

0700014207 20ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-040001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:RepresentativeWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:BryanCapitalMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2021-11-010001420720ibio:BryanCapitalMemberus-gaap:CommonStockMemberibio:WarrantAgreementWithBryanCapitalMember2021-11-010001420720us-gaap:DiscontinuedOperationsHeldforsaleMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2023-06-300001420720us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:BuildingAndBuildingImprovementsMemberibio:PurchaseAndSaleAgreementWithMajesticRealtyCoMember2023-09-300001420720ibio:RubrycTherapeuticsIncMemberibio:StockPurchaseAgreementMember2023-07-012024-06-300001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2023-07-012024-06-300001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2022-09-162022-09-160001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredIntangibleAssetsMemberibio:AssetPurchaseAgreementMember2022-09-192022-09-190001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredFixedAssetsMemberibio:AssetPurchaseAgreementMember2022-09-192022-09-190001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2022-09-192022-09-190001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredSeriesPreferredStockMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredPrepaidExpensesMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredIntangibleAssetsMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:RubrycTherapeuticsIncMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720us-gaap:WarrantMember2023-07-012024-06-300001420720us-gaap:RestrictedStockUnitsRSUMember2023-07-012024-06-300001420720us-gaap:EmployeeStockOptionMember2023-07-012024-06-300001420720us-gaap:WarrantMember2022-07-012023-06-300001420720us-gaap:RestrictedStockUnitsRSUMember2022-07-012023-06-300001420720us-gaap:EmployeeStockOptionMember2022-07-012023-06-300001420720us-gaap:IntellectualPropertyMember2023-07-012024-06-300001420720us-gaap:IntellectualPropertyMember2022-07-012023-06-300001420720us-gaap:SegmentDiscontinuedOperationsMember2023-07-012024-06-300001420720us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012024-06-300001420720us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMember2022-07-012023-06-300001420720us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012023-06-300001420720us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012023-06-300001420720us-gaap:AdditionalPaidInCapitalMember2023-07-012024-06-300001420720us-gaap:AdditionalPaidInCapitalMember2022-07-012023-06-300001420720us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012023-06-3000014207202022-06-3000014207202023-06-300001420720ibio:BryanCapitalMemberus-gaap:CommonStockMemberibio:WarrantAgreementWithBryanCapitalMember2021-11-012021-11-010001420720ibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-09-182023-09-180001420720ibio:SeriesDWarrantsMemberibio:Offering2023Member2023-12-072023-12-070001420720ibio:SeriesCWarrantsMemberibio:Offering2023Member2023-12-072023-12-070001420720ibio:PreFundedWarrantsMemberibio:Offering2023Member2023-12-072023-12-070001420720ibio:ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMembersrt:MaximumMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember2024-07-032024-07-030001420720srt:ChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember2023-01-012023-01-010001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-12-222023-12-220001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember2023-11-142024-05-170001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember2023-10-172023-11-130001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember2023-10-042023-10-160001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-10-040001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-03-240001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember2021-11-010001420720ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember2022-10-110001420720us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-04-012024-04-010001420720ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-03-260001420720ibio:CommonStockAndSeriesEWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-03-260001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-01-160001420720ibio:AssetPurchasingAgreementMember2024-02-250001420720ibio:HcWainwrightAndCompanyLlcMemberibio:RepresentativeWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-03-240001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-02-200001420720ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsToCoverLegalExpensesMemberus-gaap:SettledLitigationMember2021-05-140001420720us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-03-262024-03-260001420720ibio:SeriesDWarrantsMemberus-gaap:SubsequentEventMember2024-08-012024-08-310001420720ibio:SeriesCWarrantsMemberus-gaap:SubsequentEventMember2024-08-012024-08-310001420720ibio:SeriesDWarrantsMember2023-07-012024-06-300001420720ibio:SeriesCWarrantsMember2023-07-012024-06-300001420720ibio:PreFundedWarrantsMember2023-07-012024-06-300001420720us-gaap:CommonStockMember2023-11-290001420720us-gaap:CommonStockMember2022-10-070001420720202022-10-070001420720ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMemberibio:AssetPurchaseAgreementMember2022-09-160001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2022-09-160001420720ibio:RubrycTherapeuticsIncMember2022-09-160001420720srt:MinimumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-112023-08-110001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMemberus-gaap:SubsequentEventMember2024-08-292024-08-290001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-092023-12-090001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:OmnibusEquityIncentivePlan2020Member2020-12-092020-12-090001420720ibio:AllianceGlobalPartnersMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2023-06-192023-06-190001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2021-07-012022-06-300001420720ibio:AuctioneersMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:AuctionSaleAgreementMember2023-02-172023-02-170001420720ibio:Year2026Member2024-06-300001420720ibio:Year2025Member2024-06-300001420720ibio:ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember2024-07-032024-07-030001420720ibio:AuctioneersMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:AuctionSaleAgreementMember2023-03-242023-03-300001420720ibio:RubrycTherapeuticsIncMemberus-gaap:CommonStockMemberibio:AssetPurchaseAgreementMember2022-09-162022-09-160001420720ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2022-07-012023-06-300001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-12-220001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-05-102023-05-100001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-05-100001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember2024-02-090001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember2023-11-140001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-11-140001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember2023-10-170001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember2023-10-040001420720srt:MinimumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720srt:MaximumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-112023-08-110001420720srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-112023-08-110001420720ibio:RubrycTherapeuticsIncMemberibio:CollaborationOptionAndLicenseAgreementMember2021-08-232021-08-2300014207202024-06-3000014207202022-07-012023-06-300001420720ibio:WoodforestNationalBankMembersrt:MaximumMemberus-gaap:SecuredDebtMemberibio:ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-02-202023-02-200001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2021-09-102021-09-100001420720ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember2023-03-242023-03-240001420720srt:MaximumMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember2024-07-030001420720srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-110001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-110001420720srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2020-11-250001420720us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-06-3000014207202023-12-3100014207202024-09-0500014207202023-07-012024-06-30xbrli:sharesiso4217:USDxbrli:pureibio:leaseiso4217:USDxbrli:sharesibio:itemTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Kâ˜ ANNUAL REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the fiscalÂ year ended JuneÂ 30,Â 2024ORâ˜ TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from ___ to ___Commission file number 001-35023iBio,Â Inc.(Exact name of registrant as specified in its charter)Delaware26-2797813(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)Â Â 11750 Sorrento Valley Road, Suite 200, San Diego, CA92121(Address of principal executive offices)(Zip Code)â€‹Registrantâ€™s telephone number, including area code: (302) 355-0650Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹â€‹Title of each classâ€‹Trading Symbol(s)Â Name of each exchange on which registeredCommon Stockâ€‹IBIOÂ NYSE Americanâ€‹Securities registered pursuant to SectionÂ 12(g)Â of the Act:Â Â Â Â Â NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in RuleÂ 405 of the Securities Act. Â Â Â Â Â Â Â Â Yes â—» No âŒIndicate by check mark if the registrant is not required to file reports pursuant to SectionÂ 13 or SectionÂ 15(d)Â of the Act. Â Â Â Yes â—» No âŒIndicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days.Yes âŒ§ No â—»Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files).Yes âŒ§ No â—»Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€, â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act:Large accelerated filerâ—»Accelerated filerâ—»Non-accelerated filerâŒ§Smaller reporting companyâ˜’Emerging growth companyâ˜Â Â â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the

extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â—»Indicate by check mark whether the registrant has filed a report on and attestation to its managementâ€™s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Â Â Â â—»If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Â â˜Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrantâ€™s executive officers during the relevant recovery period pursuant to Â§240.10D-1(b). Â â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Yes â˜ No â˜§The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $4,431,006 as of DecemberÂ 31, 2023, based upon the closing sale price on the NYSE American of $1.37 per share reported as of December 29, 2023 (the last trading day prior to December 31, 2023).There were 8,637,895 shares of the registrantâ€™s common stock issued and outstanding as of September 19, 2024. DOCUMENTS INCORPORATED BY REFERENCE:Certain portions of the Definitive Proxy Statement to be used in connection with the Registrantâ€™s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-Kâ€‹â€‹â€‹â€‹ Table of ContentsIBIO,Â INC.ANNUAL REPORT ON FORMÂ 10-KTABLE OF CONTENTSÂ Â PagePARTÂ Iâ€‹â€‹â€‹ItemÂ 1.Business1ItemÂ 1A.Risk Factors40ItemÂ 1B.Unresolved Staff Comments73Item 1C.Cybersecurity73ItemÂ 2.Properties73ItemÂ 3.Legal Proceedings74ItemÂ 4.Mine Safety Disclosures74â€‹â€‹â€‹â€‹PARTÂ IIâ€‹â€‹â€‹ItemÂ 5.Market for Registrantâ€™s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities75ItemÂ 6. [Reserved]75ItemÂ 7.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations76ItemÂ 7A.Quantitative and Qualitative Disclosures About Market Risk87ItemÂ 8.Financial Statements and Supplementary Data87ItemÂ 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure87ItemÂ 9A.Controls and Procedures87ItemÂ 9B.Other Information88Item 9CDisclosure Regarding Foreign Jurisdictions That Prevent Inspections88â€‹â€‹â€‹PARTÂ IIIâ€‹â€‹â€‹ItemÂ 10.Directors, Executive Officers and Corporate Governance88ItemÂ 11.Executive Compensation89ItemÂ 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters89ItemÂ 13.Certain Relationships and Related Transactions, and Director Independence89ItemÂ 14.Principal Accountant Fees and Services89â€‹â€‹â€‹â€‹PARTÂ IVâ€‹â€‹â€‹ItemÂ 15.Exhibits and Financial Statement Schedules90ItemÂ 16.FormÂ 10-K Summary90â€‹â€‹â€‹â€‹ Table of ContentsSPECIAL NOTEÂ REGARDING FORWARD-LOOKING STATEMENTSUnless the context requires otherwise, references in this Annual Report for the fiscal year ended June 30, 2024 (this â€œAnnual Reportâ€) to â€œiBio,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ â€œourâ€ and similar terms mean iBio,Â Inc.Certain statements in this Annual Report, including, without limitation, statements under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ include forward-looking statements as defined in SectionÂ 27A of the Securities Act of 1933 (the â€œSecurities Actâ€), SectionÂ 21E of the Securities Exchange Act of 1934 (the â€œExchange Actâ€), the Private Securities Litigation Reform Act of 1995 (the â€œPSLRAâ€) or in releases made by the Securities and Exchange Commission (the â€œSECâ€), all as may be amended from time to time. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the â€œsafe harborâ€ provisions of such laws. All statements contained in this Annual Report, other than statements that are purely historical, are forward-looking statements. Forward looking-statements can be identified by, among other things, the use of forward-looking language, such as the words â€œplans,â€ â€œintends,â€ â€œbelieves,â€ â€œexpects,â€ â€œanticipates,â€ â€œestimates,â€ â€œprojects,â€ â€œpotential,â€ â€œmay,â€ â€œwill,â€ â€œwould,â€ â€œcould,â€ â€œshould,â€ â€œseeks,â€ or â€œscheduled to,â€ or other similar words, the negative of these terms, other variations of these terms or comparable language, or by discussion of strategy or intentions. Forward-looking statements are based upon managementâ€™s present expectations, objectives, anticipations, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements, including the risks and uncertainties set forth in ItemÂ 1A of this Annual Report and in other securities filings by the Company. These risks and uncertainties should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. As such, no assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this Annual Report is as of JuneÂ 30, 2024, unless otherwise indicated. The Company does not intend to update this information to reflect events after the date of this Annual Report.Copies of this Annual Report, our Quarterly Reports on FormÂ 10-Q, our Current Reports on FormÂ 8-K and our other reports filed with the SEC can be obtained free of charge as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC on our website at http://www.ibioinc.com/ or directly from the SECâ€™s website at http://www.sec.gov/. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report.â€‹â€‹â€‹ Table of ContentsPARTÂ IItemÂ 1. Business.OverviewiBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.Since September 2022, iBio has focused on utilizing AI and machine learning (ML) to discover and design antibodies against hard-to-drug targets upon the acquisition of substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc") was consummated. This acquisition commenced our transition to an AI-enabled biotech company and the closing of the sale of the Contract Development and Manufacturing Organization (CDMO) facility in Texas concluded our transition. These strategic decisions enable us to solely focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field. Â Our current therapeutics being developed are all in preclinical development and we have not completed any clinical trials for any vaccine or therapeutic protein product candidate produced using iBio technologyÂ and there is a risk that we will be unsuccessful in developing or commercializing any product candidates.One of the key features of iBioâ€™s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. Â Another integral part of iBioâ€™s technology stack is the machine learning (ML) based antibody-optimizing StableHuâ„¢ technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.iBio also developed the EngageTxâ„¢ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBioâ€™s own development initiatives, the Companyâ€™s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.iBioâ€™s technology stack also includes ShieldTxâ„¢, an antibody masking technology enabling the creation of conditionally activated antibodies. These masks keep antibodies inactive until they reach diseased tissue, where the masks are removed, and the antibodies are activated. This mechanism is thought to broaden the therapeutic window, potentially improving efficacy and safety of treatments. Conditionally activated antibodies are also believed to enable the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets which, due to their expression in multiple tissues, would otherwise raise safety concerns.iBioâ€™s scientific team, comprised of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in 1 Table of Contentsvivo proof-of-concept (POC). This multidisciplinary expertise allows us to quickly translate scientific discoveries into potential therapeutic applications.Artificial Intelligence in Antibody Discovery and DevelopmentThe potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly on the list of the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Companyâ€™s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.Key Achievements in Fiscal Year 2024â€‹Transformation to an AI-powered biotechâ—Consummated the closing of the sale of the CDMO facility in Texas.â—Developed a conditionally activated antibody technology, ShieldTx.â—Entered into a securities purchase agreement for a private investment in public equity (â€œPIPEâ€) financing resulting in gross proceeds of approximatelyÂ $15.0 million, before deducting placement agent fees and offering expenses.â€‹Business Developmentâ—Partnered with National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), a component of the National Institutes of Health (â€œNIHâ€) and Eli Lilly on separate research collaborations.â—Entered into a collaboration agreement with AstralBio, Inc. (â€œAstralBioâ€) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.â—Entered into an asset purchase agreement (â€œPD-1 Purchase Agreementâ€) with Otsuka Pharmaceutical Co., Ltd. (â€œOtsukaâ€), pursuant to which Otsuka acquired the Companyâ€™s assets related to its early-stage programmed cell death protein 1 (â€œPD-1â€) agonist program with an upfront payment of $1.0 million in cash at closing and eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones.Pipelineâ—Positive pre-clinicalÂ in vivoÂ data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage.â—Initiated anti-myostatin project as first obesity/cardiometabolic program under the collaboration with AstralBio.2 Table of ContentsStrategyiBio is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. Our core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through iBioâ€™s innovative platform, we champion a culture of innovation by swiftly identifying novel targets, forging strategic collaborations with the goal of enhancing efficiency, diversifying pipelines, and accelerating preclinical processes.Our strategic approach to fulfilling iBioâ€™s mission is outlined as follows:â—Further develop and expand the iBio technology stack: iBio is continuously expanding and developing its technology stack to tackle current challenges in antibody discovery.oCurrent challenges in antibody discovery: Key challenges in todayâ€™s antibody discovery techniques include:â—¾A limited number of drug targets that can be pursued with traditional antibody discovery techniques.â—¾Lack of antibodies with complex mechanisms of action.â—¾Safety concerns for antibodies against widely expressed targets.â—¾Significant time required to optimize antibody leads.â—¾Lack of early assessment of the developability of antibodies.oiBioâ€™s technology platform addresses current challenges in antibody discovery: iBioâ€™s epitope steering technology allows the precise targeting of antibodies against hard-to-drug proteins and challenging target epitopes. This is believed to unlock a vast novel target space and enable the targeting of newly identified epitopes on well-validated proteins for best-in-class drug development. While the vast majority of approved antibodies function by disrupting protein-protein interactions, the discovery of antibodies with more complex mechanisms has been challenging. iBioâ€™s ability to steer antibodies towards agonistic or cell-activating epitopes, or epitopes that lock protein complexes in certain active or inactive conformations, is believed to enable the creation of antibodies with a wide variety of complex modes of action.Although bispecific antibodies and antibody-drug conjugates have proven to be highly efficacious, they have also raised safety concerns. iBioâ€™s ShieldTx technology is an integrated part of the discovery process, designed to allow antibodies to be masked and rendered inactive until they reach the intended tissue (e.g., a tumor), where the mask is removed and the antibody is activated. ShieldTx is believed to have the capability of reducing or eliminating adverse effects stemming from off-target tissue effects, increase the probability of success in identifying a fitting mask, and reduce development time.Lastly, iBioâ€™s StableHu technology, coupled with mammalian display technology, has been shown in pre-clinical studies to allow for the reduction of lead optimization times by utilizing single-shot multi-dimensional optimization techniques. This also improves the developability of lead antibodies early in the discovery process.â—Capital efficient business approach: iBioâ€™s strategic business approach is structured around the following pillars of value creation:3 Table of ContentsoStrategic Collaborations: We have leveraged our platform and pipeline by forming strategic partnerships. We aim to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, rich array of fast follower molecules within the Companyâ€™s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into our, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.oDeveloping and advancing our in-house programs cost effectively: Clinical advancement is crucial for drug discovery. As we continue to develop our existing immune-oncology pre-clinical pipeline, we are also seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. Â We also continue to assess our option rights to license three of the four assets under the collaboration with AstralBio to expand our pre-clinical pipeline into obesity and cardiometabolic programs and with the goal to become a clinical stage company. Â oTech Licensing in Diverse Therapeutic Areas: In pursuit of adding value, iBio is exploring partnerships in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. This strategic approach enables us to capitalize on the value of our meticulously curated data while empowering collaborations and innovations, while at the same time allowing iBio to focus on both the platform and our core therapeutic areas, metabolic diseases and oncology.â—Focused Investment in advancing the platform: iBio maintains a focused commitment to invest in our platform, continually unlocking the potential of biology through AI and machine learning. Â The pinnacle of being on the forefront of Machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.In essence, we believe that we are sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.â€‹AI-Technology Platform OverviewiBio's technology stack is a multi-layered, AI-powered system designed to significantly enhance the probability of success to discover and develop antibodies against hard-to-drug pathophysiologically relevant proteins. This platform comprises four key components, each playing a crucial role in the discovery and optimization of precision antibodies.The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. Pursuing specific epitopes that elicit a specific biological function allows iBio to create antibodies with complex modes of action, like agonistic or cell activating antibodies. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. This combination has been shown to speed up the Lead Optimization process and potentially minimizes downstream risks, with the goal of making the overall development process more efficient and cost-effective. Next, our EngageTx platform forms the fourth layer. It provides an optimized next-generation CD3 T-cell engager antibody panel characterized by a wide range of potencies, Non-Human Primate (NHP) cross-reactivity, increased humanness of the antibodies, and retained tumor cell killing capacity with reduced cytokine release. Â Lastly, iBioâ€™s ShieldTx antibody masking technology enables the creation of conditionally activated antibodies. Conditionally activated antibodies are believed to broaden the therapeutic window, potentially improving efficacy and safety of treatments and enabling the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets which, due to their expression in multiple tissues, would otherwise raise safety concerns.â€‹4 Table of Contentsâ€‹Figure 1: iBioâ€™s Technology Stack Addresses Several Current Challenges in Antibody Discoveryâ€‹AI Epitope Steering TechnologyEpitopes, the small regions on large drug target proteins, play a crucial role in eliciting a desired biological function when targeted with antibodies. However, traditional approaches to epitope-specific antibody discovery often face significant challenges. For instance, dominant-epitope antibodies, which typically exhibit low or no efficacy, can overwhelm traditional discovery methods. This inundation can make it difficult to identify and isolate the more effective antibodies targeting less dominant epitopes. Â Additionally, these traditional methods often yield low or even zero discovery results when it comes to high-value, therapeutically challenging epitopes. These are the epitopes that, despite their potential therapeutic value, are particularly difficult to target due to their complex structure or location on the protein. Â Another challenge lies in the limited availability of epitope-stabilizing immunogen scaffolds suitable for epitope grafting. These scaffolds are crucial for maintaining the structure of the epitope during the antibody discovery process, and their scarcity can further complicate the discovery of effective antibodies.iBioâ€™s Epitope steering technology is designed to address

these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, we believe we can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of our antibody discovery process. Â iBioâ€™s AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from naÃ¯ve or immunized libraries.The application of engineered epitopes extends to a wide array of complex and hard-to-drug protein structures (as depicted in Figure 2). This broad applicability not only has the potential to unlock high-value targets in the field of immuno-oncology (I/O), but it could also be transformative in various other disease areas such as cardiometabolic, immunology 5 Table of Contentsand pain management. Furthermore, the potential use of this approach in vaccine development could open up new avenues for disease prevention.Figure 2: iBioâ€™s patented epitope steering technologyNaÃ¯ve Human Antibody LibraryThe fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, iBio has extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, iBio has meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from our library.StableHuTM AI Antibody-Optimizing TechnologyAntibody optimization is a pivotal step in the development of therapeutic antibodies. It refines an antibody's properties to enhance its efficacy, safety, and manufacturability. This process includes humanization, which alters non-human antibodies to mimic human antibodies, thereby reducing the risk of immune reactions when used in therapy.The proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.6 Table of ContentsWhen paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.â€‹Figure 3: StableHuTM Antibody Optimization Technologyâ€‹EngageTx CD3-Based T-Cell Engager PanelCD3-based T-cell engagers potentially offer significant clinical benefits in cancer treatment. They have the potential to effectively target and eliminate a wide range of tumor types, including those resistant to other therapies. By recruiting and activating the body's own T-cells to specifically target cancer cells, they can overcome some mechanisms of immune evasion, potentially leading to improved patient outcomes. Â However, first-generation T-cell engaging bispecific antibodies often face challenges related to safety and efficacy. They can cause severe side effects, such as cytokine release syndrome due to overactivation of the immune system. Additionally, they may lack specificity, which can lead to off-target effects and damage to healthy tissues. The lack of non-human primate (NHP) cross-reactivity also prevents safety assessment in higher species.To address these issues, iBio used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized our StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. Â Importantly, iBio was able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to our StableHu technology, reduces the risk of immunogenicity.7 Table of ContentsFurthermore, our StableHu technology enabled the Company to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.â€‹Figure 4: CD3-Based T-Cell Engager Panel EngageTxTMâ€‹ShieldTx Antibody Masking TechnologyThe vast majority of potential drug targets are expressed in multiple tissues and cell types throughout the body, while only a few are exclusively expressed in diseased cells or tissues, such as tumors. Antibodies capable of destroying cells expressing the targeted protein can cause severe adverse effects if the target is present not only on tumor cells but also on healthy cells.One technique to enable antibody development against such widely expressed targets is antibody masking. Masked antibodies, also known as conditionally activated antibodies, usually consist of three parts: the antibody itself, the mask, and a linker connecting the antibody and mask. The mask covers the binding region of the antibody, rendering it inactive until it reaches the diseased tissue, where the mask is cleaved off by i.e. an enzyme specific to the tumor. Once the mask is removed, the antibody is precisely activated in the target tissue (e.g., a tumor), thereby sparing healthy tissue from destruction.Masking antibodies is thought to broaden the therapeutic window, potentially improving efficacy and safety of treatments. Conditionally activated antibodies are also believed to enable the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets that, due to their expression in multiple tissues, would otherwise raise safety concerns.iBioâ€™s ShieldTx technology enables the creation of conditionally activated antibodies and stands out because it is deeply integrated into iBioâ€™s technology stack, providing multiple advantages. Identifying a fitting mask is challenging, however, iBioâ€™s ShieldTx technology is designed to increase the probability of success. This increased success rate is due to iBioâ€™s epitope engineering engine, which creates small embodiments of the drug target epitope to raise antibodies. These engineered epitopes, by definition, bind to the raised antibody and can be deployed as masks. Thus, the mask design process is inherently built into the antibody discovery process.Additionally, multi-dimensional optimization with iBioâ€™s StableHu antibody optimization technology allows for the simultaneous optimization of the three components of conditionally activated antibodies: the antibody, mask, and linker. 8 Table of ContentsThis approach, we believe, will significantly reduce development time compared to the typically sequential optimization of the individual components.Figure 5: Mechanism of ShieldTx, iBioâ€™s masking technology to create conditionally activated antibodiesModalitiesEpitope steering, a technology iBio is pioneering, has the potential to positively impact various areas of medicine. In the field of immuno-oncology, it can be used to develop antibodies targeting specific cancer antigens, potentially enhancing the efficacy of treatments like checkpoint inhibitors and CAR-T therapies.The technology also holds promise in the realm of systemic secreted and cell-surface therapeutics. Here, epitope steering can be applied to the development of antibodies, circulating immune modulation factors, secreted enzymes, and transmembrane proteins. This could be particularly beneficial in treating diseases such as heart failure, infectious diseases, and rare genetic conditions. Â In the context of localized regenerative therapeutics, epitope steering could potentially be used to develop treatments that target specific damaged or diseased tissues. This approach could be particularly beneficial in the treatment of cardiovascular diseases. Â Intratumoral immuno-oncology is another area where epitope steering could make a significant impact. It could potentially be used to develop treatments that alter the tumor microenvironment to favor an immune response against tumors, potentially enhancing the efficacy of treatments that use immune-stimulatory proteins. Â The potential of epitope steering extends to cancer vaccine development as well. The ability to target specific epitopes could be beneficial in the development of vaccines, particularly those that aim to increase the number and antitumor activity of a patient's T cells. Â Finally, epitope steering could be used to develop treatments for a wide range of diseases, including those in the immune-oncology space, immunology, pain, and potentially in vaccine development. This is particularly relevant for complex and hard-to-drug protein structures.Pre-Clinical PipelineiBio is currently in the process of building and advancing its preclinical pipeline by leveraging its technology stack focused on hard-to-drug targets and molecules offering differentiation in both in obesity and cardiometabolic disease space, as well as immune-oncology. Â As iBio continues to leverage its technology stack and develop our existing immune-oncology pre-clinical pipeline, the Company also is seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. Â iBio also continues to assess our options rights to license three of the four assets under the AstralBio collaboration to add obesity and cardiometabolic programs into our pre-clinical pipeline. Â Under this strategic 9 Table of Contentscollaboration with AstraBio, it affords iBio the opportunity to expand the Companyâ€™s pipeline and build a presence in the cardiometabolic disease space.Figure 6: iBioâ€™s Preclinical Therapeutics PipelineTherapeuticsObesity/Cardiometabolic DiseasesAccording to the World Health Organization (WHO) Obesity and Overweight Fact-Sheets, worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. Â In 2022, 2.5 billion adults (18 years and older) were overweight. Â Of these, 890 million were living with obesity. Until recently, pharmacologic options to treat obesity have been limited, but the recent approval and significant weight loss effect observed with incretin drugs has now provided medicines to fight the world-wide obesity epidemic. Â Like many first-generation medicines, incretin drugs can cause adverse effects. The rapid weight loss caused by those drugs, like stringent low calorie diets, leads not only to the desired loss in fat mass but also has been associated with loss of muscle mass and bone density, which could potentially lead to frailty, falls and fractures in an aging population. The observed rapid weight rebound effect after cessation of incretin treatment is another potential point of concern.Through the strategic collaboration with AstralBio, iBio is focusing its initial efforts in the obesity and cardiometabolic space on well-validated targets in the TGFÃŸ pathway with the goal to limit weight loss related muscle loss and reduction in bone density and other targets that promote effects that provide short and long term benefits for patients suffering from obesity and cardiovascular diseases.Anti-Myostatin AntibodyMyostatin, also known as growth differentiation factor 8 (GDF8), is a transforming growth factor-Î² (TGF-Î²) family member that functions to limit skeletal muscle growth and inhibits muscle growth. A loss of function in the myostatin gene leads to a reduction or absence of this inhibitory effect, resulting in increased muscle mass and strength. This genetic alteration can cause significant muscle hypertrophy and hyperplasia, meaning individuals or animals with myostatin loss of function have larger and more numerous muscle fibers. While this can be beneficial for muscle development, it may also have implications for overall metabolism and cardiovascular health.10 Table of ContentsPharmacological intervention targeting myostatin can be achieved by either blocking myostatin from interacting with its receptor or by targeting the receptor directly. Through the discovery collaboration with AstralBio, iBio is using its StableHu and mammalian display technology to discover and identify antibodies against myostatin preventing it from binding to its receptor and which are differentiated against competitor anti-myostatin antibodies. The discovery campaign will be designed to, among other goals, optimize potency, specificity, developability and half-life of novel molecules. Immuno-OncologyThere have been notable advances in the field of oncology in recent years, and arguably none more important than the advent of immunotherapies. The Company has established its own AI drug discovery and drug development capabilities in San Diego, California, and has built a pre-clinical pipeline of six immuno-oncology programs.IBIO-101IBIO-101 is our second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T [Treg] cells to inhibit the growth of solid tumors. â€‹Targeting depletion of Treg cellsÂ to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 RÎ± (â€œIL-2RÎ±â€ or â€œCD25â€), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.â€‹Unfortunately, while first-generation mAbs successfully bound CD25+ cells, they also interfered with interleukin-2 [IL-2] signaling to T effector [Teff] cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.â€‹â€‹Figure 7: Mechanism of action of first and 2nd generation Treg depleting antibodiesâ€‹In vitro characterization of IBIO-101 demonstrated potent binding to recombinant CD25 while preserving IL-2 signaling. Further assessment of IBIO-101 showed selective Treg depletion and sparing of Teffs.â€‹11 Table of Contentsâ€‹Figure 8: In vitro characterization of IBIO-101â€‹In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.â€‹â€‹Figure 9: IBIO-101 monotherapy in a humanized mouse model leads to increased Treg/Teff ratio, resulting in the suppression of tumor growthâ€‹â€‹12 Table of Contentsâ€‹Figure 10: Combination Therapy of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to anti-PD-1 or IBIO-101 aloneiBio has progressed IBIO-101 to the IND-enabling phase and entrusted its Chemistry, Manufacturing, and Controls (CMC) development to a Contract Research Organization (CRO). In the initial stages of this process, IBIO-101 has exhibited promising attributes for CMC progression. Notably, we've pinpointed optimal cell lines for master cell bank creation and have set in place a CMC methodology to produce IBIO-101 in compliance with current Good Manufacturing Practice, or cGMP, standards.â€‹â€‹Figure 11: IBIO-101 has shown favorable characteristics for CMC developmentAn anti-CD25 antibody could be applicable in a number of indications including solid tumors, leukemia, and potentially additional orphan diseases. Â The Company continues to review the IL-2 sparing anti-CD25 antibody program, IBIO-101, including evaluating whether it can be utilized in certain orphan diseases. If such evaluation is promising, the Company will determine whether to initiate discussions with FDA before the end of calendar year 2025 to outline a potential clinical pathway for the program. â€‹13 Table of ContentsTROP-2 x CD3 BispecificiBio has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using the Companyâ€™s T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. The Companyâ€™s bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.Figure 12: Proposed mechanism of action of iBioâ€™s TROP-2 x CD3 bispecific antibodiesâ€‹14 Table of ContentsUsing EngageTx, iBioâ€™s lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (IFNg), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (TNFa), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with iBioâ€™s TROP-2 binding arm and a first generation CD3 engager, SP34, the Companyâ€™s lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome.Figure 13: iBioâ€™s TROP-2 x CD3 lead antibody shows reduced cytokine release while retaining tumor cell killing potentialWhen tested in a humanized mouse model of squamous cell carcinoma, iBioâ€™s lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.15 Table of ContentsFigure 14: iBioâ€™s lead TROP-2 x CD3 molecule showed a 36% reduction in tumor size in an animal model engrafted with human peripheral blood mononuclear immune cells (PBMC) and human tumor cellsMUC16MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.â€‹16 Table of ContentsFigure 15: MUC16 structure and mechanisms to evade anti-cancer therapyâ€‹Using the Companyâ€™s patented epitope steering AI platform, iBio's innovative approach to this challenge allows its new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer.â€‹â€‹Figure 16: iBioâ€™s epitope steering approach and immunization strategy to target the non-shed MUC16 regionDuring its immunization and screening campaign, iBio identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed.â€‹â€‹17 Table of ContentsFigure 17: iBioâ€™s hit molecules bind to the non-shed but not the shed region of MUC16Establishing antibodies with the ability to bind to a recombinant version of their target protein represents a vital initial step in the validation process. Â However, it's crucial to ensure such antibodies maintain their binding affinity in a whole cell context, specifically when the target protein is expressed on a cell's surface. To best predict therapeutic efficacy, it's recommended to utilize tumor cells as a means to demonstrate and confirm this cell binding capability. During pre-clinical studies, iBioâ€™s MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells as shown below.â€‹â€‹Figure 18: iBioâ€™s MUC16 molecule shows binding to MUC16 on human ovarian cancer cellsâ€‹18 Table of ContentsAnother critical step in antibody optimization is the humanization of molecules originally raised in mice or other species. Humanization efforts of antibodies carry the risk of, among other things, losing binding strength. After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells.Figure 19: iBioâ€™s humanized MUC16 molecule retains binding to the engineered epitope and human tumor cell linesEGFRvIIIEGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer

and head and neck cancer, but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In our pursuit of innovative treatments, iBio is exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.Leveraging our patented AI-enabled epitope steering engine, we've specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, iBio has designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.â€‹19 Table of Contentsâ€‹Figure 20: Tumor epitope specific antibodies target tumor cells while sparing healthy cellsâ€‹iBio's hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR. Â Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests.â€‹â€‹Figure 21: In vitro characterization of iBioâ€™s hit molecules demonstrates selective binding to EGFRvIII leading to tumor-specific cell killing while sparing healthy cells20 Table of ContentsiBioâ€™s lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, iBioâ€™s anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.Figure 22: iBioâ€™s lead molecule demonstrates efficacy in a mouse model for head and neck cancerCCR8GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins.Â Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body's natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body's immune response against cancer cells, offering a promising avenue for cancer treatment.Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It's important to make sure antibodies are fine-tuned to CCR8 and don't mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.21 Table of ContentsFigure 23: Proposed mechanism of action for selective anti-CCR8 antibodiesUsing its unique AI-driven technology, iBio successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. iBio's specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, iBio's CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.Figure 24: Selective binding to CCR8 and inhibition of the CCR8 signaling pathway by iBioâ€™s lead molecule leads to potent killing of Tregs derived from primary human immune cells22 Table of ContentsiBioâ€™s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show iBioâ€™s anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. Â iBio specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells.Figure 25: iBioâ€™s lead CCR8 antibody inhibited tumor growth and achieved a 22 percent tumor regression in a humanized mouse model for colon cancerDigital InfrastructureiBio is a firm believer in the transformative power of digital technologies, including robotics, automation, AI, ML, and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. Â iBioâ€™s aspiration is to digitize our operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, we remain committed to further investing in our digital infrastructure to support our ambitious goals.â€‹Strategic Alliances, Collaborations, and Joint VenturesiBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.Astral BioOn March 27, 2024, iBio entered into a collaboration with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four (4) targets for the treatment of obesity and cardiometabolic diseases, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug (IND) application. iBio has the exclusive option to license three (3) obesity and cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise. As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of an 23 Table of Contentsanti-myostatin antibody program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity. Upon mutual consent, the parties may also expand the collaboration to include additional targets in other fields.National Institute of Allergy and Infectious DiseasesOn June 12, 2023, iBio entered into a research collaboration with NIAID, a component of the NIH, to investigate the potential of iBioâ€™s patented AI-driven epitope steering platform for the development of a vaccine for Lassa fever, a sometimes fatal viral disease endemic to parts of West Africa. Â Under the collaboration, iBio worked with the NIAIDâ€™s Vaccine Research Center to determine whether using iBioâ€™s AI Discovery Platform to steer immunity toward viral epitopes identified by the vaccine centerâ€™s researchers could offer advantages over other vaccine development approaches. iBio designed ten engineered epitopes for the collaboration, whichÂ were screenedÂ for binding to three known Lassa fever neutralizing antibodies, alongside the NIAID 's Vaccines Research Centerâ€™s internal epitope designs. Importantly, iBioâ€™s engineered epitopes showed binding to the Lassa neutralizing antibodies and were among the top-ranked hits regarding expression, an important consideration for cost-effective vaccine production. Â While the NIAID elected not to proceed with joint optimization of the lead hits, iBio enhanced its discovery process as a result of the collaboration, incorporating diffusion-based generative AI models into its engineered epitope designs. The new models are already contributing to iBioâ€™s pipeline development and are being used with current partners. Other Partnerships Using iBioâ€™s AI Discovery Platform During the first quarter fiscal year 2024, iBio entered into a collaboration with a partner to license the use of the Companyâ€™s AI Discovery Platform to assist such partner with two targets of interest. Â While iBio completed the discovery and research portions of the collaboration, the partner elected not to proceed with the optimization and trigger a license of the two targets of interest, noting internal strategic focus. Â During the second quarter fiscal year 2024, iBio entered into a discovery collaboration with a large pharmaceutical company to assist such partner by using the Companyâ€™s patented AI-driven epitope steering platform to assist with one "hard to develop" molecule. Â iBio continues to seek out opportunities for future collaborations using the Companyâ€™s AI Discovery Platform.Several agreements with RubrYc Therapeutics, Inc.On August 23, 2021, we entered into a series of agreements with RubrYc described in more detail below:Collaboration and License Agreement: iBio entered into a collaboration and licensing agreement (the â€œRTX-003 License Agreementâ€) with RubrYc to further develop RubrYcâ€™s immune-oncology antibodies in its RTX-003 campaign. Â During the term of the RTX-003 License Agreement, RubrYc granted us an exclusive worldwide sublicensable royalty-bearing license under the patents controlled by RubrYc that cover the RTX-003 antibodies. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022, including RubrYcâ€™s immune-oncology antibodies in its RTX-003 campaign.Â Collaboration, Option and License Agreement: iBio entered into a collaboration agreement (the â€œCollaboration Agreementâ€) with RubrYc to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYcâ€™s artificial intelligence discovery platform. In addition, RubrYc granted the Company an exclusive option to obtain a worldwide sublicensable commercial license with respect to each of the lead product candidates resulting from such collaboration programs (the â€œSelected Compoundsâ€). With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.â€‹24 Table of ContentsStock Purchase Agreement: In connection with the entry into the Collaboration Agreement and RTX-003 License Agreement, iBio also entered into a Stock Purchase Agreement (â€œStock Purchase Agreementâ€) with RubrYc whereby we purchased 1,909,563 shares of RubrYcâ€™s Series A-2 preferred stock â€œSeries A-2 Preferredâ€) for $5,000,000 and acquired an additional 954,782 shares of RubrYcâ€™s Series A-2 Preferred. In connection with the Stock Purchase Agreement, iBio entered into the RubrYc Therapeutics, Inc. Second Amended and Restated Investorsâ€™ Rights Agreement (the â€œInvestorsâ€™ Rights Agreementâ€), RubrYc Therapeutics, Inc. Second Amended and Restated Voting Agreement (the â€œVoting Agreementâ€) and the RubrYc Therapeutics, Inc. Second Amended and Restated Right of First Refusal and Co-Sale Agreement (the â€œRight of First Refusal and Co-Sale Agreementâ€). The rights, preferences of and privileges of the RubrYc Series A-2 Preferred Stock (â€œSeries A-2 Preferredâ€) are set forth in the Third Amended and Restated Certificate of Incorporation of RubrYc Therapeutics, Inc. (the â€œAmended RubrYc COIâ€), and include a preferential eight percent (8%) dividend, senior rights on liquidation, the right to elect a Series A-2 Preferred director for as long as we hold at least 1,500,000 shares of RubrYc stock, the right to vote on an as-converted basis, certain anti-dilution and other protective provisions, the right to convert the Series A-2 Preferred into shares of RubrYc common stock at our option, and mandatory conversion of the Series A-2 Preferred into shares of RubrYc common stock upon (a) the closing of a firm-commitment underwritten public offering to the public pursuant to an effective registration statement under the Securities Act of 1933, as amended, for shares of RubrYc common stock at a per share price of at least five (5) times the Series A-2 Original Issue Price (as defined in the Amended RubrYc COI) and resulting in at least $30,000,000 of gross proceeds to RubrYc or (b) such other date, time or event, specified by vote or written consent of the majority of the aggregate voting power, on an as-converted basis, of the RubrYc Series A preferred stock (â€œSeries A Preferredâ€ and together with the Series A-2 Preferred, the â€œSenior Preferred Stockâ€) and Series A-2 Preferred. The Right of First Refusal and Co-Sale Agreement gives RubrYc the right of first refusal on stock sales by key holders, generally defined as founders, and a second right of first refusal and a co-sale right to specified other investors, including certain holders of Senior Preferred Stock and the Company.Â The Investorsâ€™ Rights Agreement provides the holders of Senior Preferred Stock with, among things: (i)Â demand registration rights, under specified circumstances; (ii)Â piggyback registration rights in the event of a company registered offering; (iii)Â lock-up and market-standoff obligations following a registered underwritten public offering; (iv)Â preemptive rights on company offered securities; and (v)Â additional protective covenants that require the approval at least two of the three directors elected by the holders of the Senior Preferred Stock.Â Pursuant to the Voting Agreement, certain RubrYc stockholders are contractually obligated to, among other things, vote for and maintain the authorized number of directors at five members, one of which the Company has the contractual right to elect subject to the conditions set forth above.â€‹Asset Purchase Agreement: On September 19, 2022, iBio purchased substantially all of the assets of RubrYc, including the AI Drug Discovery Platform, RTX-003 (IBIO-101), all Selected Compounds, three additional immune-oncology candidates, a PD-1 agonist, in addition to lab and technology equipment pursuant to an asset purchase agreement, dated September 16, 2022 (the â€œAsset Purchase Agreementâ€). Â On September 19, 2022, in connection with the closing of the acquisition, we entered into a termination agreement (the â€œTermination Agreementâ€) with RubrYc in order terminate the RTX-003 License Agreement and the Collaboration Agreement, which terminated any and all future milestone payments or royalty obligations we had under those agreements. Â Under the terms of the Asset Purchase Agreement, upon closing of the acquisition, we made an upfront payment of approximately $1,000,000 by issuing 102,354 (post reverse split effected in October 2022) shares of our common stock, par value $.001 per share (the â€œCommon Stockâ€) to RubrYc. Â RubrYc is also eligible to receive up to $5,000,000 in development milestone over the period of five years from the date of the Asset Purchase Agreement, which can be paid in shares of our Common Stock or cash, at our sole discretion. Â In addition, we had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. Â The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101 (RTX-003), in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Asset Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. Â â€‹25 Table of ContentsFacility Purchase from Eastern Capital Limited On November 1, 2021, we purchased the manufacturing facility (the â€œFacilityâ€) previously operated under a lease from two affiliates of Eastern Capital Limited (the â€œEastern Affiliatesâ€). We also acquired the approximate 30% equity interest (after conversion) in iBio CDMO LLC (â€œiBio CDMOâ€) held by the Eastern Affiliates, who became the lessee under the ground lease agreement with the Board of Regents of the Texas A&M University System (the â€œGround Lease Agreementâ€) for the land upon which the Facility is located and terminated the Sublease iBio had entered into with the Eastern Affiliates. As a result, iBio CDMO and its intellectual property are now wholly owned by iBio. The total purchase price for the Facility, the termination of the Sublease and other agreements among the parties, and the equity described below was $28,750,000, which was paid $28,000,000 in cash and by the issuance to Bryan Capital Investors LLC, an affiliate of the Eastern Affiliates a five-year warrant to purchase 51,583 shares of our Common Stock at an exercise price of $33.25 per share. â€‹In connection with the purchase of the Facility, iBio CDMO entered into a Credit Agreement, dated November 1, 2021 (the â€œCredit Agreementâ€), with Woodforest National Bank (â€œWoodforestâ€) pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the â€œTerm Loanâ€) to purchase the Facility, which Term Loan was evidenced by a Term Note (the â€œTerm Noteâ€). The Term Loan originally bore an interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Â Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provided that it could be prepaid by iBio CDMO at any time and provided for mandatory prepayment upon certain circumstances. The Term Loan was secured by a lien on all of the assets of iBio CDMO and we guaranteed payments of the obligations owed under the Term Loan.â€‹The Credit Agreement contained customary events of default (which were in some cases subject to certain exceptions, thresholds, notice requirements and grace periods), including, but not limited to, nonpayment of principal or interest, failure to perform or observe covenants, breaches of representations and warranties, cross-defaults with certain other indebtedness, certain bankruptcy-related events or proceedings, final monetary judgments or orders and certain change of control events. The Credit Agreement also contained negative covenants.â€‹On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement (the â€œFirst Amendmentâ€) to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the First Amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer USA, Inc. (â€œFraunhoferâ€) as part of our legal settlement with them (the â€œFraunhofer Settlement Fundsâ€) (see Note 19 â€“ Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022. Â In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the First Amendment.On February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the â€œSecond Amendmentâ€), which amendment, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. Â In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which as amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company was in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the â€œThird Amendmentâ€), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. Â In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company was in compliance with the Liquidity Covenant without being 26 Table of Contentsdependent upon a specified milestone. Â In addition, the Company agreed that each time it consummated an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it would (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the â€œFourth Amendmentâ€), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company was required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%,

(ii) reduce the percentage of any payment to Woodforest the Company was required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. Â In addition, the Company was obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the â€œWoodforest Purchase Agreementâ€) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Woodforest Purchase Agreement, or the maturity date of the term loan (the â€œMaturity Dateâ€). Â In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. Â On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the â€œFifth Amendmentâ€), pursuant to which Woodforest agreed to: (i) waive the obligation to deliver to Woodforest an executed copy of a Woodforest Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount was reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 was to be released from the Company account at Woodforest.Â In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan was increased to 5.25%, and the Term Loan further accrued interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility was sold on or before June 30, 2023, (b) 2.00% if the Facility was sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility was sold after September 30, 2023, or not sold prior to the Maturity Date.Â The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility was sold on or before June 30, 2023, (y) $100,000 if the Facility was sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility was sold after September 30, 2023, or not sold prior to the Maturity Date.â€‹On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the â€œSixth Amendmentâ€), which amended the Credit Agreement to: (i) set the Maturity Date to theÂ earlier of (a) December 31, 2023, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement, (ii) provided that iBio CDMO would, immediately upon receipt of the proceeds of the sale of the Facility, apply the net proceeds to satisfy all outstanding obligations under the term loan, and to the extent such net proceeds were sufficient, to pay off the term loan, and (iii) change the annual filing requirement solely for the fiscal year ending June 30, 2023; provided that (y) iBio CDMO deliver an executed copy of the Purchase and Sale Agreement for the sale of the Facility within one business day after entry into the Sixth Amendment, and (z) if the Facility was not sold on or before December 1, 2023, iBio CDMO would pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date.â€‹On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the â€œSeventh Amendmentâ€), which amendment among other things, permitted the Company, in each case, so long as no Potential Default or Default (as such terms were defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as iBio CDMO maintained a minimum balance of $2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as iBio CDMO maintained a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as iBio CDMO maintained a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). Â On the earlier of (a) the closing of the Woodforest Purchase Agreement (as defined in the Credit Agreement), or (b) the Maturity Date, the Company would pay Woodforest $20,000. Â In addition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, 27 Table of Contentswhich amendment reduced the liquidity covenant that required the Company to maintain a specified amount in unrestricted cash to $0.00.â€‹On December 22, 2023, iBio CDMO and Woodforest entered into the eighth amendment to the Credit Agreement (the â€œEight Amendmentâ€), which amendment: (i) set the Maturity Date to the earlier of (a) March 29, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement; (ii) reduced the interest rate from 5.25% to 4.5% and increased the payment in kind from 3% to 4.5%; and (iii) permitted the Company, so long as no Potential Default or Default (as such terms were defined in the Credit Agreement) exists to make a withdrawal from the Reserve Funds Deposit Account (as defined in the Credit Agreement) so long as iBio CDMO maintained a minimum balance of $900,000 until Payment in Full (as defined in the Credit Agreement). The Eighth Amendment provided that the iBio CDMO used its best efforts to consummate and close a sale of the Property on or before the Maturity Date. The amendment also increased the fees payable by iBio CDMO to Woodforest by $10,000. Â Accordingly, per the amendment, on the earlier of (a) the closing of the sale of the Property, or (b) the Maturity Date, iBio CDMO would pay Woodforest a fee in the amount of $155,000.â€‹On March 28, 2024, iBio CDMO and Woodforest entered into the Ninth Amendment (the â€œNinth Amendmentâ€) to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the term loan to the earlier of (a) May 15, 2024, or (b) the acceleration of maturity of the term loan in in accordance with the Credit Agreement.â€‹On May 14, 2024, iBio CDMO and Woodforest entered into the tenth amendment to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date to the earlier of (a) May 31, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement. â€‹On May 31, 2024, pursuant to that certain Purchase and Sale Agreement, dated as of May 17, 2024 (the â€œPurchase and Sale Agreementâ€), by and between iBio CDMO and The Board of Regents of the Texas A&M University System (â€œThe Board of Regentsâ€), iBio CDMO terminated its Ground Lease Agreement with The Board of Regents, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015 (collectively, the â€œGround Leaseâ€), related to 21.401 acres in Brazos County, Texas (the â€œLandâ€) and completed the sale to The Board of Regents of: (i) the buildings, parking areas, improvements, and fixtures situated on the Land (the â€œImprovementsâ€); (iii) all iBio CDMOâ€™s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the â€œPersonal Propertyâ€); (iii) all iBio CDMOâ€™s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the â€œContractsâ€); and (iv) all iBio CDMOâ€™s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the â€œIntangiblesâ€; and together with the Ground Lease, Improvements and Personal Property, collectively, the â€œPropertyâ€). The purchase price was $8,500,000.On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term was defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share.Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.â€‹28 Table of ContentsIntellectual PropertyWe currently own 69 patents. Of the 69 patents, 18 are U.S. and 51 are international. Since July 1, 2023, we have primarily focused our intellectual property estate on our preclinical assets including provisional and regular patents in the U.S., including for CD25 antibodies, chemokine receptor 8 (CCR8) antibodies, epidermal growth factor receptor variant III (EGFRvIII) antibodies, anti-MUC16 antibodies, TROP2 antibodies, CD3 antibodies, and for high-efficiency, conditionally-activated antibodies. Â We now have 13 U.S., 5 Patent Cooperation Treaty, and 40 international applications pending. International patents and applications include numerous foreign countries including Australia, Brazil, Canada, China, Hong Kong, India, Japan, Korea, and several countries in Europe. Â All of our patents will expire between 2024 and 2040 with 15 patents, all part of the de-prioritized plant portfolio, expiring in 2024. Â Included in the 69 patents are 30 U.S. and foreign applications that we acquired from RubrYc for novel antibodies, scaffold technology, and a machine learning apparatus for engineering meso-scale peptides, including 1 allowed application. Â As part of the plant portfolio, we exclusively own the right to use certain intellectual property acquired by or developed at Fraunhofer for human health and certain veterinary and diagnostic applications. We also own intellectual property developed or acquired independently of Fraunhofer as part of the plant portfolio. Â The 15 patents expiring in 2024 in the U.S. and overseas are all related to the production of proteins in plants where we are making no investments.In addition to patents and patent applications that we own, our plant-focused patent estate relies on trade secrets and know-how, which we have been seeking a partner to out-license including proprietary technology and processes. Our success will depend in part on our ability to obtain and maintain patent protection for our technologies and preclinical assets. Our policy is to seek to protect our proprietary rights, by among other methods, filing patent applications in the U.S. and foreign jurisdictions to cover certain aspects of our technology. We continue to prepare patent applications relating to our expanding technology in the U.S. and abroad.The technology and products covered by our issued and pending patent applications are summarized below:Pending Product Patent Applications (U.S. and International)â—Antibodiesâ—Influenza vaccinesâ—Influenza therapeutic antibodiesâ—Anthrax vaccinesâ—Plague vaccinesâ—HPV vaccinesâ—Trypanosomiasis vaccineâ—Malaria vaccinesâ—COVID-19 vaccinesâ—Antibodies against chemokine receptor 8 (CCR8)â—Antibodies against epidermal growth factor receptor variant III (EGFRvIII)â—Antibodies against MUC16â—Antibodies against TROP2â—Antibodies against CD3â—High-efficiency, conditionally-activated antibodies â€‹Pending Technology Patent Applications (U.S. and International)â—Activation of transgenes in plants by viral vectorsâ—Transient expression of proteins in plants29 Table of Contentsâ—Thermostable carrier moleculeâ—In vivo deglycosylation of recombinant proteins in plantsâ—Scaffold technologyâ—Machine learning apparatus for engineering meso-scale peptidesâ—Methods of making conditionally-activated antibodiesâ€‹Technology and Product Patents (U.S.)â—Virus-induced gene silencing in plantsâ—Transient expression of foreign genes in plantsâ—Production of foreign nucleic acids and polypeptides in sprout systemsâ—Production of pharmaceutically active proteins in sprouted seedlingsâ—Systems and method for clonal expression in plantsâ—Recombinant carrier molecule for expression, delivery and purification of target polypeptidesâ—Influenza antigens, vaccine compositions, and related methodsâ—Plague antigens, vaccine compositions, and related methodsâ—Influenza therapeutic antibodiesâ—Trypanosomiasis vaccineâ—Anthrax antigens, vaccine compositions, and related methodsâ€‹Competition The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we or our collaborators may develop based on the use of our technologies.While we believe that the potential advantages of our new technologies will enable us to compete effectively against other providers of technology for biologic product development and manufacturing, many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through arrangements with large and established companies, and this may reduce the value of our technologies for the purposes of establishing license agreements. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.We expect to rely upon licensees, collaborators or customers for support in advancing certain of our drug candidates and intend to rely on additional work with our collaborators during our efforts to commercialize our product candidates. Our licensees, collaborators or customers may be conducting multiple product development efforts within the same disease areas that are the subjects of their agreements with us. Agreements with collaborators may not preclude them from pursuing development efforts using a different approach from that which is the subject of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer.There are currently approved vaccines and therapies for many of the diseases and conditions addressed by the product candidates our partners and collaborators may be developing or manufacturing or in our own pipeline. Technological developments in our field of research and development occur at a rapid rate and we expect competition to intensify as 30 Table of Contentsadvances in this field are made. We will be required to continue to devote substantial resources and efforts to our research and development activities. As a biopharmaceutical company with a focus on cancer therapeutics, we compete with a broad range of companies. At the highest level, our therapeutics can be seen as both a complement and a potential competitor to any oncology therapy, most notably chemotherapy, radiotherapy, biologics and small molecule drugs. Not only do we compete with companies engaged in various cancer treatments including radiotherapy and chemotherapy, but we also compete with various companies that have developed or are trying to develop immunology vaccines for the treatment of cancer. Certain of our competitors have substantially greater capital resources, large customer bases, broader product lines, sales forces, greater marketing and management resources, larger research and development staffs with extensive facilities and equipment than we do and have more established reputations as well as global distribution channels. Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Bristol-Myers Squibb Company, MerckÂ & Co.,Â Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca plc), JohnsonÂ & Johnson, PfizerÂ Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech,Â Inc. (a member of the Roche Group), AmgenÂ Inc., Gilead Sciences,Â Inc. and its subsidiary Kite Pharma,Â Inc., more advanced obesity and cardiometabolic companies such as Keros Therapeutics, Inc., Scholar Rock, Inc., and Biohaven, Ltd., and competing cancer immunotherapy companies such as, Bluebird Bio,Â Inc., Transgene SA, Bausch Health Companies, Lumos Pharma, AgenusÂ Inc., Aduro Biotech,Â Inc., Advaxis,Â Inc., ImmunoCellular Therapeutics,Â Ltd., IMVÂ Inc., Oxford BioMedica plc, Bavarian Nordic A/S, Celldex Therapeutics,Â Inc., as well as tech enabled drug discovery companies such as Recursion, Abcellera Biologics, Inc., Cellarity, BenevolentAI, and others, some of which have substantially greater financial, technical, sales, marketing, and human resources than we do. These companies might succeed in obtaining regulatory approval for competitive products more rapidly than we can for our products. In addition, competitors might develop technologies and products that are less expensive, safer or more effective than those being developed by us or that would render our technology obsolete. In addition, the pharmaceutical and biotechnology industry is characterized by rapid technological change. Because our research approach integrates many technologies, it may be difficult for us to remain current with the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors may render our technologies obsolete by advancing their existing technological approaches or developing new or different approaches.Research and DevelopmentOur research and development functions are focused on the creation of new products and services, as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. Our research and development activities take place primarily at our facilities in San Diego. iBio has leased lab and office space in San Diego for the purpose of conducting research. For the fiscal year 2024, iBio spent $5.2 million in R&D related activities.SuppliersWe outsource certain functions and supplies to third parties such as Lonza Sales AG, and Twist Bioscience Corporation. While we rely on our outsourcing partners to perform their contracted functions, we are continuing to build internal capabilities. Our suppliers are generally available to meet our demands and supply requirements, but our items are long lead time items that have been exacerbated by the current macro environment due to increased demand. Â We continue to mitigate the risks through inventory management, relationship management and evaluation of alternative sources when possible. Refer to ItemÂ 1A, â€œRisk Factors,â€ for a description of risks associated with our reliance on suppliers and outsourcing partners. Government Regulation and Product Approval Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.31 Table of ContentsU.S. Drug Approval ProcessAll of the vaccine and therapeutic products developed from our technologies will require regulatory approval by governmental agencies prior to commercialization. In particular, pharmaceutical drugs and vaccines are subject to rigorous preclinical testing and clinical trials and other pre-marketing approval requirements by the U.S. Food and Drug Administration (the â€œFDAâ€) and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations, also govern or impact the manufacturing, safety, labeling, storage, record-keeping and marketing of vaccines and pharmaceutical products. The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of substantial resources. Regulatory approval, if and when obtained for any of our product candidates, may be limited in scope, which may significantly limit the indicated uses for which our product candidates may be marketed. Further, FDA approved vaccines and

drugs are subject to ongoing oversight and discovery of previously unknown problems may result in restrictions on their manufacture, sale or use, or in their withdrawal from the market.The process required by the FDA before a drug or biological product may be marketed in the United States generally involves the following:â—completion of pre-clinical laboratory tests and animal studies according to good laboratory practices (â€œGLPâ€) and applicable requirements for the humane use of laboratory animals or other applicable regulations;â—submission to the FDA of an Investigational New Drug (â€œINDâ€) application which must become effective before human clinical trials may begin;â—performance of adequate and well-controlled human clinical trials according to the FDAâ€™s regulations commonly referred to as good clinical practices (â€œGCPsâ€) and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;â—submission to the FDA of a New Drug Application (â€œNDAâ€) or Biologics License Application (â€œBLAâ€) for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the NDA or BLA based on results of pre-clinical testing and clinical trials;â—satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product candidates are produced, to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the productâ€™s identity, strength, quality and purity;â—potential FDA audit of the pre-clinical trial and clinical trial sites that generated the data in support of the NDA or BLA; andâ—FDA review and approval of the NDA or licensure of the BLA.Preclinical TestsBefore any product candidates with potential immunization or therapeutic value may be tested in human subjects, we must satisfy stringent government requirements for preclinical studies. Preclinical testing includes both in vitro and in vivo laboratory evaluation and characterization of the safety and efficacy of the product candidate. â€œIn vitroâ€ refers to tests conducted with cells in culture and â€œin vivoâ€ refers to tests conducted in animals. The conduct of the preclinical tests must comply with federal regulations and requirements including GLP. Preclinical testing results obtained from studies in several animal species, as well as data from in vitro studies, are submitted to the FDA as part of an IND application and are reviewed by the FDA prior to the commencement of human clinical trials. These preclinical data must provide an adequate basis for evaluating both the safety and the scientific rationale for the initial clinical trials. In the case of vaccine 32 Table of Contentscandidates, animal immunogenicity and immune protection tests must establish a sound scientific basis to believe that the product candidate may be beneficial when administered to humans.INDAn IND becomes effective automatically 30Â days after receipt by the FDA unless the FDA raises concern or questions about the conduct of the clinical trials as outlined in the IND prior to that time. In such an event, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials may proceed. For additional information on the most recent FDA regulations and guidance on vaccine and therapeutic product testing and approval, visit its website at http://www.fda.gov. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to potential safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.Clinical TrailsClinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsorâ€™s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rulesÂ that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDAâ€™s regulations composing the good clinical practice requirements, including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board (the â€œIRBâ€) at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Human clinical trials involving biological products are typically conducted in three sequential phases that may overlap or be combined:â—Phase 1. The biological product is initially introduced into a small number of closely monitored healthy human volunteers and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the targeted disease.â—Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.â—Phase 3. Clinical trials generally enroll a large number of volunteers and are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendarÂ days after the sponsorâ€™s initial receipt 33 Table of Contentsof the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRBâ€™s requirements or if the biological product has been associated with unexpected serious harm to subjects.Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted. Many other countries in which we might choose to develop drugs or run clinical trials have similar rules and regulation. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union or other foreign countries, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.34 Table of Contentsâ—NDA/BLA: oOnce clinical trials of a product candidate are completed, FDA approval of an NDA or BLA must be obtained before commercial marketing of the product. The NDA or BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the NDA or BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Post-Approval Requirements: Â oAny products for which we receive FDA approvals will be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the productâ€™s approved uses, known as â€˜off-labelâ€™ use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet.Other U.S. Healthcare Laws and Compliance Requirement: oIn the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, for instance the Office of Inspector General, the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, research, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the physician payment transparency laws, the privacy and security provisions of HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act (â€œHITECHâ€), and similar state laws, each as amended. Â Once commercialized, we could be liable to ensure full compliance with the law.Coverage, Pricing and Reimbursement oSignificant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. This is dictated by third-party payorsâ€™ coverage and establish adequate reimbursement levels for such products. The marketability of any product candidate for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement.Foreign Regulation: oIn order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve 35 Table of Contentsadditional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.Orphan Drug Act Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the name of the sponsor, identity of the drug or biologic and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not shorten the duration of the regulatory review or approval process, but does provide certain advantages, such as a waiver of Prescription Drug User Fee Act, or PDUFA, fees, enhanced access to FDA staff and potential waiver of pediatric research requirements.If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for the same indication for sevenÂ years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.Accelerated ApprovalThere are a variety of pathways under which applicants may seek expedited approval from FDA, including fast track, breakthrough therapy, priority review and accelerated approval. Â The FDA accelerated approval program provides for early approval of drugs based on a drug on a clinical trial(s) showing that the drug meets a surrogate or an intermediate clinical endpoint rather than a clinical benefit endpoint. Accelerated approval is possible for drugs for serious conditions that fill an unmet medical need. A surrogate endpoint used for accelerated approval is a marker, such as a laboratory measurement, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Likewise, an intermediate clinical endpoint is a measure of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. Because it sometimes can take many years for a drug trial to show a clinical benefit, the use of a surrogate endpoint or an intermediate clinical endpoint can significantly shorten the time required to complete clinical trials and obtain FDA approval.If a drug receives an accelerated approval, the company that sponsored the application must conduct a post-approval trial to confirm the anticipated clinical benefit. These trials are known as Phase 4 or post-approval confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.36 Table of ContentsHealthcare Regulations and Healthcare ReformHealthcare regulation and pricing (included drug pricing) is complex, extensive, and dynamic around the world. In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. We expect that there will continue to be a number of federal and state proposals to implement government pricing controls and limit the growth of healthcare costs. We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates.37 Table of ContentsWe anticipate that current and future U.S. legislative healthcare reforms may result in additional downward pressure on the price that we receive for any approved product, if covered, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.U.S. Patent-Term Extension Depending upon the timing, duration and specifics of FDA approval of our current product candidates or any future product candidate, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Act. The Hatch Waxman Act permits extension of the patent term of up to five years as compensation for patent term lost during FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the productâ€™s approval date. The patent term extension period is generally one half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension (and only those patent claims covering the approved drug, a method for using it or a method for manufacturing it may be extended), and the application for the extension must be submitted prior to the expiration of the patent. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension. In the future, we may apply for extension of a patent term for our currently owned patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. However, there can be no assurance that the USPTO will grant us any requested patent term extension, either for the length we request or at all. Environmental, Health, and Safety RegulationWe are subject to numerous federal, state and local environmental, health and safety (â€œEHSâ€), laws and regulations relating to, among other matters, safe working conditions, product stewardship, environmental protection, and handling or disposition of products, including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous materials, medical waste, and infectious materials that may be handled by our research laboratories. Some of these laws and regulations also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with the applicable permits, we could face substantial fines or possible revocation

of our permits or limitations on our ability to conduct our operations. Certain of our development activities involve use of hazardous materials, and we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. Â However, we cannot ensure EHS liabilities will not develop in the future. Â EHS laws and regulations are complex, change frequently and have tended to become more stringent over time. Â Although the costs to comply with applicable laws and regulations, have not been material, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.Human Capital/Employees As of June 30, 2024, we had 16 employees, all of which are full time employees, and three strategic consultants. Our employees are not represented by any union and are not the subject of a collective bargaining agreement. We consider our relations with our employees to be good. We believe that our success depends upon our ability to attract, develop, retain and motivate key personnel. Our management and scientific teams possess considerable experience in drug discovery, research and development, manufacturing, clinical and regulatory affairs, and iBio directly benefits from this experience and industry knowledge. We anticipate that we will need to identify, attract, train and retain other highly skilled personnel to pursue our development program. Hiring for such personnel is competitive, and there can be no assurance that we will be able to retain our key employees or attract, assimilate or retain the qualified personnel necessary for the development of our business.38 Table of ContentsWe have no collective bargaining agreements with our employees and have not experienced any work stoppages. We consider our relations with our employees to be good. Management believes that it has sufficient human capital to operate its business successfully currently and will need to attract new talent to the organization in order to achieve its plans for growth.Competitive Pay and Benefits. Our compensation programs are designed to align the compensation of our employees with our performance and to provide the proper incentives to attract, retain and motivate employees to achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance. Specifically: Â â—we provide employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location;â—we engage nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our executive compensation and benefit programs and to provide benchmarking against our peers within the industry;â—we align our executivesâ€™ long-term equity compensation with our shareholdersâ€™ interests by linking realizable pay with stock performance;â—annual increases and incentive compensation are based on merit, which is communicated to employees at the time of hiring and documented through our talent management process as part of our annual review procedures and upon internal transfer and/or promotion; andâ—commencing January 1, 2018, we established the iBio, Inc. 401(k) Plan. Eligible employees may participate in the 401(k) Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. We will make a 100% matching contribution that is not in excess of 5% of an eligible employeeâ€™s compensation. In addition, we may make qualified non-elective contributions at our discretion.Corporate InformationWe were incorporated under the laws of the State of Delaware on AprilÂ 17, 2008, under the name iBioPharma,Â Inc. We engaged in a merger with InB:Biotechnologies,Â Inc., a New Jersey corporation on JulyÂ 25, 2008, and changed our name to iBio,Â Inc. on AugustÂ 10, 2009.Our principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 and our telephone number is (979) 446-0027. Our website address is www.ibioinc.com. The information contained on, or accessible through, our website does not constitute part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.Reverse Stock SplitOn October 7, 2022, we effected a reverse stock split at a ratio of one-for-twenty five (1:25) shares of our common stock. As a result of the reverse stock split, every twenty five (25) shares of the Company's common stock either issued and outstanding or held by us in our treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of our common stock. The reverse split also applied to common stock issuable upon the exercise of our outstanding stock options. The reverse stock split did not affect the par value of our common stock or the shares of our common stock that we are authorized to issue under our Certificate of Incorporation, as amended. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. All share and per share amounts of common stock presented in this Annual Report have been retroactively adjusted to reflect the one-for-twenty five reverse stock split.39 Table of ContentsOn November 29, 2023, we effected a reverse stock split at a ratio of one-for-twenty (1:20) shares of our common stock. As a result of the reverse stock split, every twenty (20) shares of the Company's common stock either issued and outstanding or held by us in our treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of our common stock. The reverse split also applied to common stock issuable upon the exercise of our outstanding stock options. The reverse stock split did not affect the par value of our common stock or the shares of our common stock that we are authorized to issue under our Certificate of Incorporation, as amended. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. All share and per share amounts of common stock presented in this Annual Report have been retroactively adjusted to reflect the one-for-twenty Â reverse stock split.Available InformationOur website address is www.ibioinc.com. We file Annual Reports on FormÂ 10-K, Quarterly Reports on FormÂ 10-Q, Current Reports on FormÂ 8-K, proxy statements and other materials with the SEC. We are subject to the informational requirements of the Exchange Act and file or furnish reports, proxy statements and other information with the SEC. Such reports and other information filed by the Company with the SEC are available free of charge on our website at www.ibioinc.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report, and you should not consider information on our website to be part of this Annual Report.The SEC also maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.â€‹â€‹â€‹40 Table of ContentsItemÂ 1A. Risk FactorsSummary Risk Factors Our business faces significant risks and uncertainties of which investors should be aware before making a decision to invest in our common stock. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. The following is a summary of the more significant risks relating to the Company. A more detailed description of our risk factors is set forth below under the caption â€œDetailed Risk Factors.â€Risks Related to Our Financial Position and Need for Additional Capitalâ€¢ We have a limited operating history developing vaccines and therapeutics.â€¢ We are evaluating potential options to extend our cash runway that could impact our future operations and financial position.â€¢ Substantial doubt exists related to our ability to operate as a going concern.â€¢ We have incurred and expect to continue to incur significant losses.â€¢ We anticipate that our expenses will increase in the future.â€¢ We need additional funding to fully execute our business plan.â€¢ The actual amount of funds we will need to operate is subject to many risks, some of which are beyond our control.â€¢ Raising additional capital may cause dilution to our existing stockholders and/or restrict our operations or rights.â€¢ Potential use of government funding for R&D programs may impose conditions limiting our ability to take certain actions.â€‹Risks Related to the Development and Commercialization of Our Technologies and Product Candidatesâ€¢ We have a limited operating history developing precision antibodies and have no significant source of revenue.â€¢ We are reliant on a limited number of product candidates that involve significant clinical testing before seeking regulatory approval. If our product candidates do not receive regulatory approval our business may be harmed.â€¢ We may fail to capitalize on particular technology or product candidates that we expend our limited resources on. â€¢ There can be no guarantee that we will be able to successfully develop and commercialize product candidates.â€¢ We may not be successful in our efforts to use iBio technologies to build a pipeline of product candidates. â€¢ Clinical trials are very expensive, time-consuming and difficult to design and implement.â€¢ We, our clients, collaborators and potential licensees are dependent upon successful preclinical studies and demonstration of safety and efficacy in clinical trials to be able to commercialize product candidates.â€¢ If we, or our clients and collaborators, are not able to obtain required regulatory approvals, we, or our clients and collaborators, will not be able to commercialize our, or third-party, product candidates.â€¢ Alternative technologies may supersede our technologies or make them noncompetitive, which may harm our business.â€¢ Our clinical product candidates may exhibit undesirable side effects.â€¢ Product liability lawsuits could cause us to incur substantial liabilities and to limit product commercialization.â€‹Risks Related to Dependence on Third Partiesâ€¢For any clinical product candidates we may develop, any manufacturing problems experienced by our third-party contract manufacturers could result in a delay or interruption in the supply of our clinical product candidate.â€¢ If we are unable to establish new collaborations and maintain both new and existing collaborations, or if these collaborations are not successful, our business could be adversely affected.â€¢ If third parties on whom we or our licensees will rely for the conduct of preclinical and clinical studies do not perform as required, we may not be able to obtain regulatory approval for or commercialize our product candidates.â€¢ Our inability to obtain raw materials or supplies may adversely impact our business and results of operations.â€¢ Any claims beyond our insurance coverage limits may result in substantial costs.â€¢ We may be subject to various litigation claims and legal proceedings.â€‹Risks Related to Intellectual Property â€¢ If we or our licensors are unable to obtain and maintain sufficient patent protection for our technology and products, our ability to successfully commercialize our technology and products may be impaired.â€¢ We may become involved in lawsuits related to our patents or other intellectual property, which could be costly.â€¢ Patent terms may be inadequate to protect our competitive position for an adequate amount of time.41 Table of Contentsâ€¢ If we are unable to protect our trade secrets, our business and competitive position would be harmed.â€¢ We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.â€¢ Intellectual property rights do not necessarily address all potential threats to our competitive advantage.â€¢ We may not be able to protect our intellectual property rights throughout the world.â€¢ If we should fail to comply with various patents laws, our patent protection could be reduced or eliminated.â€¢ Changes in patent law could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.â€‹Risks Related to iBioâ€™s Operationsâ€¢ We recently identified and remediated material weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will not occur in the future.â€¢ The loss of one or more of our executive officers or key employees could adversely affect our business.â€¢ A failure to have an appropriately skilled and adequate workforce could adversely impact the ability of our R&D facility to operate efficiently.â€¢ A natural disaster or other disruptions at our laboratory would adversely affect our business and results of operations. â€¢ We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.â€¢ If we are unable to protect the confidentiality of our customersâ€™ proprietary information, we may be subject to claims.â€¢ We may face integration risks and additional costs if we acquire companies, products or technologies.â€¢ Our business and operations would suffer in the event of computer system failures.â€¢ We rely extensively on our information technology systems and are vulnerable to damage and interruption, including cybersecurity and data leakage risks.â€¢ Any failure to maintain the security of information relating to our patients, customers, employees and suppliers, could expose us to litigation, government enforcement actions and costly response measures.â€‹Risks Related to Our Common Stock â€¢ Our stockholders will experience dilution from the issuance of the development milestone payments if paid in equity.â€¢ Our failure to continue to comply with the continued listing standards of NYSE American could result in our delisting from the NYSE American.â€¢ Provisions in our certificate of incorporation, bylaws and under Delaware law could discourage a takeover.â€¢ Our bylaws provide that the Delaware Court of Chancery is the exclusive forum for certain disputes.â€¢ The issuance of preferred stock could adversely affect the rights of the holders of shares of our common stock.â€¢ We do not anticipate paying cash dividends for the foreseeable future.â€¢ Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results.â€¢ Holders of our warrants have no rights as common stockholders until they exercise their warrants.â€¢ The market price of our common stock has been and may continue to be volatile.â€¢ Reports published by securities or industry analysts could adversely affect our common stock price and trading volume.â€¢ As a smaller reporting company, we are subject to reduced disclosure requirements, which may make our common stock less attractive to investors. â€‹â€‹42 Table of ContentsDetailed Risk FactorsOur business faces many risks. Past experience may not be indicative of future performance, and as noted elsewhere in this Annual Report, we have included forward-looking statements about our business, plans and prospects that are subject to change. Forward-looking statements are particularly located in, but not limited to, the sections â€œBusinessâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ In addition to the other risks or uncertainties contained in this Annual Report, the risks described below may affect our operating results, financial condition and cash flows. If any of these risks occur, either alone or in combination with other factors, our business, financial condition or operating results could be adversely affected, and the trading price of our common stock may decline. Moreover, readers should note this is not an exhaustive list of the risks we face; some risks are unknown or not quantifiable, and other risks that we currently perceive as immaterial may ultimately prove more significant than expected. Statements about plans, predictions or expectations should not be construed to be assurances of performance or promises to take a given course of action.Risks Related to Our Financial Position and Need for Additional CapitalWe have a limited operating history developing vaccines and therapeutics, which may limit the ability of investors to make an informed investment decision.We commenced independent operations in 2008, and our operations to date have included organizing and staffing our company, business planning, raising capital, acquiring and developing our proprietary technologies, identifying potential product candidates and undertaking, in house and through third parties, preclinical trials and clinical trials of product candidates derived from our technologies. Prior to the end of calendar year 2022, we shifted our focus away from generating revenue as a CDMO service provider to the development of vaccines and therapeutics for commercialization. Our current focus is on immune-oncology therapeutics. Â The current vaccines and therapeutics being developed are all in preclinical development and we have not completed any clinical trials for any vaccine or therapeutic protein product candidate produced using iBio technologyÂ and there is a risk that we will be unsuccessful in developing or commercializing any product candidates. Certain vaccine candidates using iBioâ€™s technologies have previously been evaluated by other organizations in Phase 1 clinical trials; however, all of our vaccine and therapeutic protein product candidates are still in preclinical development. Neither we nor our collaborators have completed any other clinical trials for any vaccine or therapeutic protein product candidate produced using iBio technology. As a result, we have not yet demonstrated our ability to successfully complete any Phase 2 or pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any conclusion you reach about our future success or viability may not be as predictive as it might be if we had a longer operating history.Even if we receive regulatory approval for the sale of any of our product candidates, we do not know when we will begin to generate significant revenue from such product candidates, if at all. Our ability to generate revenue depends on a number of factors, including our ability to:â—set an acceptable price for our products and obtain coverage and adequate reimbursement from third-party payors;â—establish sales, marketing, manufacturing and distribution systems; add operational, financial and management information systems and personnel, including personnel to support our clinical, manufacturing and planned future clinical development and commercialization efforts and operations as a public company;â—manufacture commercial quantities of product candidates at acceptable cost levels;â—achieve broad market acceptance of our product candidates in the medical community and with third-party payors and consumers;â—attract and retain an experienced management and advisory team;â—launch commercial sales of our products, whether alone or in collaboration with others; and43 Table of Contentsâ—maintain, expand and protect our intellectual property portfolio.Because of the numerous risks and uncertainties associated with development and manufacturing product candidates, we are unable to predict if we will generate significant revenue. If we cannot successfully execute on any of the factors listed above, our business may not succeed, and we may never generate significant revenue.We are reviewing potential options to extend our cash runway. This review could impact our future operations and financial position. â€‹We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. Â In an effort to improve liquidity and our runway, we have consummated the sale of our Facility, reduced our work force, signed a collaboration with AstralBio with to discover and develop novel antibodies for obesity and other cardiometabolic diseases, entered into a securities purchase agreement for a PIPE financing resulting in gross proceeds of approximatelyÂ $15.0 million. Â Potential options being consideredÂ to further increase liquidity, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a combination thereof. However, we anticipate that our expenses will increase as we continue our research and development activities and conduct clinical trials.â€‹Our cash, cash equivalents and restricted cash of $14.4 million as of June 30, 2024, is not anticipated to be sufficient to support our operations for at least 12 months from the date of the filing of this Annual Report unless we reduce our burn rate further, or raise additional capital. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our near and long-term business plans. Our current cash, cash equivalents and restricted cash as of June 30, 2024, is anticipated to be sufficient to support

operations into the first quarter of fiscal year 2026. â€‹There can be no assurance that our collaboration with AstralBio will be successful or will entered into agreements for the sale or out-licensing of any of our product candidates on favorable terms or that the exploration of potential options will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Â If we determine to change our business strategy, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements.â€‹Our historical operating results indicate substantial doubt exists related to our ability to operate as a going concern.We have incurred net losses and used significant cash in operating activities since inception, and we expect to continue to generate operating losses for the foreseeable future. As of June 30, 2024, we have an accumulated deficit of $313.8 million.â€‹We held cash, cash equivalents and restricted cash of $14.4 million as of June 30, 2024. Based on current trends and activities, there is significant doubt that we can continue as a going concern beyond the first quarter of fiscal year 2026. We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. Potential options being consideredÂ to increase liquidity include focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates or parts of the business, raising money from capital markets, grant revenue or collaborations, or a combination thereof. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. We believe based on input from expert advisors, that it is likely we will be able to implement one or more options that will extend our cash runway for 12 months or more from the date of the filing of this Annual Report. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating. â€‹Our consolidated audited financial statements as of and for the year ended June 30, 2024 have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our management concluded that our recurring losses from operations and the fact that we haveÂ not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months after issuance of our financial 44 Table of Contentsstatements. Our auditors also included an explanatory paragraph in its report on our financial statements as of and for the year ended June 30, 2024 with respect to this uncertainty.Â If we continue to experience operating losses, and we are not able to generate additional liquidity through a capital raise or other cash infusion, we might need to secure additional sources of funds, which may or may not be available to us. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to further scale back or discontinue the development of our product candidates or other research and development initiatives or initiate steps to cease operations or liquidate our assets.â€‹We have incurred significant losses since our inception. We expect to incur losses during our next fiscalÂ year, we do not anticipate generating significant revenue for several years and may never achieve or maintain profitability.Since our 2008 spinoff from Integrated BioPharma, we have incurred operating losses and negative cash flows from operations. Our comprehensive net loss was approximately ($24.9) million and ($64.8) million for the years ended June 30, 2024 and 2023, respectively. As of JuneÂ 30, 2024, we had an accumulated deficit of approximately ($313.8) million.To date, we have financed our operations primarily through the sale of common stock, the Woodforest Credit Agreement, preferred stock and warrants. We devote substantially all of our efforts to research and development, including the development and validation of our technologies, and the development of a proprietary therapeutic products against oncology. We have not completed development of or commercialized any vaccine or therapeutic product candidates. We expect to continue to incur significant expenses and may incur operating losses for at least the nextÂ year. We anticipate that our expenses and losses will increase substantially if we:â—initiate clinical trials of our product candidates;â—continue the research and development of our product candidates;â—seek to discover or license in additional product candidates; andâ—add operational, and administrative information systems and personnel, including personnel to support our product development and manufacturing efforts.Our future profitability and cash flow in large part depends on the advancement of our research and development programs, including our AI platform, and our ability to successfully develop, partner or commercialize our product candidates and to a lesser extent, which is not anticipated for several years. Our cash position is expected to limit the number of product candidates that we seek to develop. This will require us, alone or with our licensees and collaborators, to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling those products for which regulatory approval is obtained or establishing collaborations with parties willing and able to provide necessary capital or other value. We may never succeed in these activities. We may never generate revenues that are significant or large enough to achieve profitability.All of our existing product candidates are in various stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue. As a result, even if we successfully develop, achieve regulatory approval and commercialize our products, we may be unable to generate revenue for manyÂ years, if at all. We do not anticipate that we will generate revenue from product sales for at least severalÂ years, if at all. If we are unable to generate revenue from product sales, we will not become profitable, and we may be unable to continue our operations.Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would diminish the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.We anticipate that our expenses will increase in the future.Although we have recently reduced expenses, we expect our research and development expenses to increase significantly as our product candidates advance in clinical development, and as we add more employees. As part of the regulatory 45 Table of Contentsprocess, we must conduct clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities. The number and design of the clinical trials that will be required varies depending upon product candidate, the condition being evaluated, and the trial results themselves. Therefore, it is difficult to accurately estimate the cost of the clinical trials. Clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time consuming. We estimate that clinical trials of our product candidates will take at least several years to complete. Because of numerous risks and uncertainties involved in our business, the timing or amount of increased development expenses cannot be accurately predicted, and our expenses could increase beyond expectations if we are required by the FDA, or comparable non-U.S. regulatory authorities, to perform studies or clinical trials in addition to those we currently anticipate. We anticipate that further product development is also expected to increase expenses, including but not limited to the expected continued IND-enabling studies IBIO-101, reviewing whether IBIO-101 can be utilized in certain orphan diseases, and the additional studies that will be required to support development of our immuno-oncology and cardiometabolic programs. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. In addition, as we expand our business, we will need to retain additional employees with the necessary skills including employees for our continued expansion of drug discovery capabilities in San Diego, California. Â Even if any of our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of and the related commercial-scale manufacturing requirements for our product candidates. As a result, we expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. These losses have had and will continue to have an adverse effect on our financial position and working capital.We need additional funding to fully execute our business plan, which funding may not be available on commercially acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate the commercialization of our development and manufacturing services and efforts for our product development programs.We need additional capital to fully implement our near term and long-term business, operating and development plans as we do not anticipate that any of our product candidates will generate revenue in the next few years, if at all. To the extent that we initiate or continue clinical development without securing collaborator or licensee funding, our research and development expenses could increase substantially.When we elect to raise additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. We currently have no committed sources of funding. Â The At Market Issuance Sales Agreement (the â€œATM Agreementâ€) with Chardan Capital Markets, LLC andÂ Craig-Hallum Capital Group LLC that we entered into with Chardan Capital Markets, LLC andÂ Craig-Hallum Capital Group LLC on July 3, 2024, also has certain requirements that we must meet in order to sell securities pursuant to the ATM Agreement. There can be no assurance that we will meet the requirements to be able to sell securities pursuant to the ATM Agreement, of if we meet the requirements that we will be able to raise sufficient funds on favorable terms. There can be no assurances that we will be able to raise the funds needed, especially in light of the fact that our ability to sell securities registered on our registration statement on Form S-3 will be limited until such time the market value of our voting securities held by non-affiliates is $75 million or more. If we are unable to raise capital in sufficient amounts when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable 46 Table of Contentsthan might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly liquidate assets or cease operations.The actual amount of funds we will need to operate is subject to many risk factors, some of which are beyond our control.The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control therefore we are unable to determine this amount with certainty. These factors include the following: â—the progress of our research activities;â—the number and scope of our research programs;â—the progress of our preclinical and clinical development activities;â—the progress of the development efforts of parties with whom we have entered into research and development agreements and amount of funding received from partners and collaborators;â—our ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;â—our ability to achieve our milestones under licensing arrangements;â—the costs associated with manufacturing related services to produce materials for use in our clinical trials;â—the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;â—the costs incurred to screen and enroll patients; andâ—the costs and timing of regulatory approvals.We have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. Additionally, we may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all.Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.Until such time as we can generate substantial development, manufacturing, license or product revenues, we expect to finance our cash needs through a combination of equity offerings, collaborations, strategic alliances, service contracts, manufacturing contracts, facility build-out and technology transfer contracts, licensing and other arrangements. Sources of funds may not be available or, if available, may not be available on terms satisfactory to us.If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected, and we may be unable to continue our operations.47 Table of ContentsTo the extent that we raise additional capital through a public or private offering and sale of equity securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Sales of our common stock offered through current or future equity offerings may result in substantial dilution to our stockholders. The sale of a substantial number of shares of our common stock to investors, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.In order to develop certain of our product candidates we will rely upon government funding. Any government funding for our R&D programs may impose requirements that limit our ability to take certain actions, and subject us to potential financial penalties, which could materially and adversely affect our business, financial condition and results of operations. â€‹We have applied for government grants to support some of our research and development activities for our product candidates. Â If we do not obtain the grants we applied for or other grants, we currently do not anticipate developing certain of our product candidates. Â Even if we obtain grant funding, the terms of the grant funding may be restrictive. Often government grants include provisions that reflect the governmentâ€™s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to potentially require repayment of all or a portion of the grant award proceeds, in certain cases with interest, in the event we violate certain covenants pertaining to various matters.Risks Related to the Development and Commercialization of Our Technologies and Product CandidatesWe currently haveÂ a limited operating history developing precision antibodies,Â no products approved for commercial sale, have no significant source of revenue and may never generate significant revenue.We are a pre-clinical-stage biopharmaceutical company that recently began to focus on leveraging the power of Artificial Intelligence (AI) for the development of precision antibodies. Prior to August 23, 2021, when we entered into a series of agreements with RubrYc, we were focused on our CDMO business. We have never generated any product revenue from the development of precision antibodies, do not expect to generate revenue in the near future andÂ do not have any products approved for sale. Our operations to date have been primarily focused on developing our product candidates. We have not yet successfully conducted any clinical trials of any antibodies we have developed. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing product candidates.All of our existing product candidates are in very early stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue.We currently have a limited number of product candidates in early stages of pre-clinical development and are dependent on the success of these product candidates, which requires significant clinical testing before seeking regulatory approval. If our product candidates do not receive regulatory approval or are not successfully commercialized, our business may be harmed.We are currently in preclinical development of multiple product candidates as potential treatments across multiple therapeutic areas; however, we announced we are evaluating potential options to extend our cash runway and may change the focus of our resources. It is possible that we may never be able to develop a marketable product candidate.We expect that a substantial portion of our efforts and expenditures over the next fewÂ years will be devoted to our product candidates in the immune-oncology field. Accordingly, our business currently depends heavily on the successful development, regulatory approval and commercialization of these product candidates, which may not receive regulatory approval or be successfully commercialized even if regulatory approval is received. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of product candidates are and will remain subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing 48 Table of Contentsregulations. We are not permitted to market any product in the United States unless and until we receive approval from the FDA, or in any foreign countries unless and until we receive the requisite approval from regulatory authorities in such countries. We have never submitted an NDA or BLA to the FDA or comparable applications to other regulatory authorities and do not expect to be in a position to do so for the foreseeable future. Obtaining approval of an NDA or BLA is an extensive, lengthy, expensive, and inherently uncertain process, and the FDA may delay, limit or deny approval of its product for many reasons.Because we have limited financial and managerial resources, our focus is limited to the development of multiple product candidates. As a result, we may forego or delay pursuit of opportunities with other technologies or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable

market opportunities. Our spending and the spending of our clients and collaborators may not yield any commercially viable products.We have based our research and development efforts largely on our technologies and product candidates derived from such technologies. Notwithstanding our large investment to date and anticipated future expenditures in these technologies, we have not yet developed, and may never successfully develop, any marketed products using these technologies. As a result, we may fail to address or develop product candidates based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success.We also may not be successful in our efforts to identify or discover additional product candidates using our technologies. Research programs to identify new product candidates require substantial technical, financial, and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.We may expend our limited resources to pursue a particular technology or product candidate and fail to capitalize on technologies or product candidates that may be more profitable or for which there is a greater likelihood of success.Because we have limited financial and managerial resources, we focus on specific product candidates derived from or enhanced by our technologies or that have been identified and partially developed by our clients or collaborators. As a result, we may forego or delay pursuit of opportunities with other technologies or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending and the spending of our clients and collaborators may not yield any commercially viable products.We have based our research and development efforts largely on our technologies and product candidates derived from such technologies. Notwithstanding our large investment to date and anticipated future expenditures in these technologies, we have not yet developed, and may never successfully develop, any marketed products using these technologies. As a result, we may fail to address or develop product candidates based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success.We also may not be successful in our efforts to identify or discover additional product candidates using our technologies. Research programs to identify new product candidates require substantial technical, financial, and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements on terms less favorable to us than possible.49 Table of ContentsWe, our clients and collaborators, are very early in our development efforts. If we or our clients and collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business will be materially harmed. All of our therapeutic protein product candidates are still in preclinical development. Our ability to generate product sales revenues for our own products, which we do not expect will occur for manyÂ years, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:â—completion of preclinical studies and clinical trials with positive results;â—receipt of marketing approvals from applicable regulatory authorities;â—obtaining and maintaining patent and trade secret protection and regulatory exclusivity, which may exceed patent exclusivity, for our product candidates;â—making arrangements with third-party manufacturers for commercial manufacturing capabilities;â—launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;â—successfully maintaining existing collaborations and entering into new ones throughout the development process as appropriate, from preclinical studies through to commercialization;â—acceptance of the products, if and when approved, by patients, the medical community and third-party payors;â—effectively competing with other products;â—obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for any products we successfully develop;â—protecting our rights in our intellectual property portfolio; andâ—maintaining a continued acceptable safety profile of the products following approval.If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business.We may not be successful in our efforts to use iBio technologies to build a pipeline of product candidates and develop marketable products.While we believe that data we and our collaborators have obtained from preclinical studies of iBio technology-derived and iBio technology-enhanced product candidates has validated these technologies, our technologies have not yet, and may never lead to, approvable or marketable products. Even if we are successful in further validating our technologies and continuing to buildÂ our pipeline, the potential product candidates that we identify may not be suitable for clinical development for many possible reasons, including harmful side effects, limited efficacy or other characteristics that indicate that such product candidates are unlikely to be products that will receive marketing approval and achieve market acceptance.Â If we and our collaborators do not successfully develop and commercialize product candidates based upon our technologies, we will not obtain product or collaboration revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.Clinical trials are very expensive, time-consuming, and difficult to design and implement.50 Table of ContentsHuman clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We estimate that clinical trials for our product candidates would take at least severalÂ years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:â—obtaining an IND application with the FDA or foreign equivalent to commence clinical trials;â—identification of, and acceptable arrangements with, one or more clinical sites;â—obtaining IRB or Ethics Committee (â€œECâ€) approval to commence clinical trials;â—unforeseen safety issues;â—determination of dosing;â—lack of effectiveness during clinical trials;â—slower than expected rates of patient recruitment;â—inability to monitor patients adequately during or after treatment;â—lower than expected rates of patient completion of clinical trials;â—inability to obtain supply of our drug candidate in a timely manner;â—inability or unwillingness of medical investigators to follow our clinical protocols; andâ—unwillingness of the FDA or foreign equivalent, or IRBs/ECs to permit the clinical trials to be initiated.In addition, we, IRBs/ECs or the FDA or foreign equivalent may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs/ECs or the FDA or foreign equivalent finds deficiencies in our submissions or conduct of our trials.Neither we nor our clients, collaborators or potential licensees will be able to commercialize product candidates based on our technologies and services if preclinical studies do not produce successful results or clinical trials do not demonstrate safety and efficacy in humans.Preclinical and clinical testing is expensive, difficult to design and implement, can take manyÂ years to complete and has an uncertain outcome. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results. We and our licensees may experience numerous unforeseen events during, or as a result of, preclinical testing and the clinical trial process that could delay or prevent the commercialization of product candidates based on our iBio technologies, including the following:â—Preclinical or clinical trials may produce negative or inconclusive results, which may require additional preclinical testing, additional clinical trials or the abandonment of projects that we expect to be promising. For example, promising animal data may be obtained about the anticipated efficacy of a therapeutic protein product candidate and then human tests may not result in such an effect. In addition, unexpected safety concerns may be encountered that would require further testing even if the therapeutic protein product candidate produced an otherwise favorable response in human subjects.â—Initial clinical results may not be supported by further or more extensive clinical trials. For example, a licensee may obtain data that suggest a desirable immune response from a product candidate in a small human study, but when tests are conducted on larger numbers of people, the same extent of immune response may not occur. If the 51 Table of Contentsimmune response generated by a product candidate is too low or occurs in too few treated individuals, then the product candidate will have no commercial value.â—Enrollment in any clinical trials that we or our licenseeâ€™s conduct may be slower than projected, resulting in significant delays. The cost of conducting a clinical trial increases as the time required to enroll adequate numbers of human subjects to obtain meaningful results increases. Enrollment in a clinical trial can be a slower-than-anticipated process because of competition from other clinical trials, because the study is not of interest to qualified subjects, or because the stringency of requirements for enrollment limits the number of people who are eligible to participate in the clinical trial.â—We or our potential licensees might have to suspend or terminate clinical trials if the participating subjects are being exposed to unacceptable health risks. Animal tests do not always adequately predict potential safety risks to human subjects. The risk of any candidate product is unknown until it is tested in human subjects, and if subjects experience adverse events during the clinical trial, the trial may have to be suspended and modified or terminated entirely.â—Regulators or institutional review boards may suspend or terminate clinical research for various reasons, including safety concerns or noncompliance with regulatory requirements.â—Any regulatory approval ultimately obtained may be limited or subject to restrictions or post-approval commitments that render the product not commercially viable.â—The effects of iBio technology-derived or iBio technology-enhanced product candidates may not be the desired effects or may include undesirable side effects.Significant clinical trial delays could allow our competitors to bring products to market before we or our licensees do and impair our ability to commercialize our technologies and product candidates based on our technologies. Poor clinical trial results or delays may make it impossible to license a product candidate, or reduce its attractiveness to prospective licensees, so that we will be unable to successfully develop and commercialize such a product candidate.Clinical trials are risky, lengthy, and expensive. We will incur substantial expense for, and devote significant time and resources to, preclinical testing and clinical trials, yet we cannot be certain that these tests and trials will demonstrate that a product candidate is effective and well-tolerated or will ever support its approval and commercial sale. For example, clinical trials require adequate supplies of clinical trial material and sufficient patient enrollment to power the trial. Delays in patient enrollment can result in increased costs and longer development times. Even if we, or a licensee or collaborator, if applicable, successfully complete clinical trials for our clinical product candidate, we or they might not file the required regulatory submissions in a timely manner and may not receive marketing approval for the clinical product candidate. We cannot assure you that our clinical product candidate will successfully progress further through the drug development process or will ultimately result in an approved and commercially viable product.If we, or our clients and collaborators, are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we, or our clients and collaborators, will not be able to develop or commercialize our, or third-party, product candidates or will not be able to do so as soon as anticipated, and our ability to generate revenue will be materially impaired.Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by similar regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to engage in any clinical trials for any of our product candidates and there is no assurance that we will conduct successful clinical trials or obtain approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third parties to assist us in this process. Securing marketing 52 Table of Contentsapproval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidateâ€™s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use in such a restrictive manner that it is not possible to obtain commercial viability for such product.The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take manyÂ years. If additional clinical trials are required for certain jurisdictions, these trials can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved, and may ultimately be unsuccessful. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review process for each submitted product application, may cause delays in the review and approval of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept a marketing application as deficient or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.Although the FDA and other regulatory authorities have approved plant-based therapeutics in the past, consistent with the oversight of all products, the FDA is monitoring whether these plant-based therapeutics pose any health and human safety risks. While they have not issued any regulation to date that is averse to plant-based vaccines or therapeutics, it is possible that the FDA and other regulatory authorities could issue regulations in the future that could adversely affect our product candidates.If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. Â Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product candidate, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety, efficacy and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and current GCP requirements for any clinical trials that we conduct post-approval. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval. If our clinical product candidate receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales.Alternative technologies may supersede our technologies or make them noncompetitive, which would harm our ability to generate future revenue.The manufacture of precision antibodies and use of artificial intelligence to do so is intensely competitive. There are currently extensive research efforts in this field, which result in rapid technological progress that can render existing technologies obsolete or economically noncompetitive. If our competitors succeed in developing more effective technologies or render our technologies obsolete or noncompetitive, our business will suffer. Many universities, public agencies and established pharmaceutical, biotechnology, and other life sciences companies with substantially greater resources than we have are developing and using technologies and are actively engaging in the development of products similar to or competitive with our technologies and products. To remain competitive, we must continue to invest in new technologies and improve existing technologies. To make such renewing investment we will need to obtain additional financing and/or collaborations. If we are unable to secure such financing, we will not have sufficient resources to continue 53 Table of Contentssuch investment. In addition, they also have significantly greater experience in the discovery and development of products, as well as in obtaining regulatory approvals of those products in the United States and in foreign countries. Our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.Our competitors may devise methods and processes for protein expression that are faster, more efficient or less costly than that which can be achieved using iBio technologies. There has been and continues to be substantial academic and commercial research effort devoted to the development of such methods and processes. If successful competitive methods are developed, it may undermine the commercial basis for iBio products and our technologies and related services.For our cancer product candidates, not only will we compete with companies engaged in various cancer treatments including radiotherapy and chemotherapy, but we will also compete with various companies that have developed or are trying to develop immunology vaccines for the treatment of cancer. Certain of our competitors have substantially greater capital resources, large customer bases, broader product lines, sales forces, greater marketing and management resources, larger research and development staffs with extensive facilities and equipment than we do and have more established reputations as well as global distribution channels. Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Bristol-Myers Squibb Company, MerckÂ & Co.,Â Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca plc), JohnsonÂ & Johnson, PfizerÂ Inc., MerckKGaA and Sanofi SA, and more established biotechnology companies such as Genentech,Â Inc. (a member of the Roche Group), AmgenÂ Inc., Gilead Sciences,Â Inc. and its subsidiary Kite Pharma,Â Inc., more advanced obesity and cardiometabolic companies such as Keros Therapeutics, Inc., Scholar Rock, Inc., and Biohaven, Ltd., and competing cancer immunotherapy companies such as, Bluebird Bio,Â Inc., Transgene SA, Bausch Health Companies, Lumos Pharma, AgenusÂ Inc., Aduro Biotech,Â Inc., Advaxis,Â Inc., ImmunoCellular Therapeutics,Â Ltd., IMVÂ Inc., Oxford BioMedica plc, Bavarian Nordic A/S, Celldex Therapeutics,Â Inc., as well as tech

enabled drug discovery companies such as Recursion, Abcellera Biologics, Inc., Cellarity, and BenevolentAI.Our product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products, which may delay or preclude its development or regulatory approval or limit its use if ever approved.Throughout the drug development process, we must continually demonstrate the activity, safety, and tolerability of our product candidates in order to obtain regulatory approval to further advance our clinical development, or to eventually market it. Even if any of our product candidates demonstrate adequate biologic activity and clear clinical benefit, any unacceptable side effects or adverse events, when administered alone or in the presence of other pharmaceutical products, may outweigh these potential benefits. We may observe adverse or serious adverse events or drug-drug interactions in preclinical studies or clinical trials of our clinical product candidate, which could result in the delay or termination of its development, prevent regulatory approval, or limit its market acceptance if it is ultimately approved.Adverse events caused by any of our product candidates or generally by plant-based therapeutics could cause reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events are reported in any clinical trials we may conduct for our product candidates, our ability to obtain regulatory approval for such clinical product candidate may be negatively impacted. In addition, adverse events caused by any product candidate administered in combination with our product candidates could cause similar interruptions and delays, even though not caused by our product candidates.Furthermore, if any of our products are approved and then cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:â—regulatory authorities may withdraw their approval of the clinical product candidate or impose restrictions on its distribution or other risk management measures;â—regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;54 Table of Contentsâ—we may be required to conduct additional clinical trials;â—we could be sued and held liable for injuries sustained by patients;â—we could elect to discontinue the sale of the clinical product candidate; andâ—our reputation may suffer.Any of these events could prevent us from achieving or maintaining market acceptance of the affected clinical product candidate and could substantially increase the costs of commercialization.Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.We face the risk of product liability exposure in connection with the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:â—decreased demand for any product candidates or products that we may develop;â—injury to our reputation and significant negative media attention;â—withdrawal of clinical trial participants;â—significant costs to defend the related litigation;â—substantial monetary awards to trial participants or patients;â—loss of revenue;â—reduced resources of our management to pursue our business strategy; andâ—the inability to commercialize any products that we may develop.Prior to commencing human clinical trials, we will seek to obtain product liability insurance coverage. Such insurance coverage is expensive and may not be available in coverage amounts we seek or at all. If we obtain such coverage, we may in the future be unable to maintain such coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.Risks Related to Dependence on Third PartiesFor any clinical product candidates we may develop we will rely on third-party contract manufacturers. Any manufacturing problems experienced by us could result in a delay or interruption in the supply of our clinical product candidate until the problem is cured or until we locate and qualify an alternative source of manufacturing and supply.We currently do not intend to manufacture any clinical product candidates we may develop and currently intend to rely upon a third-party manufacturer to manufacture such product candidates. If we were to experience any prolonged disruption for our manufacturing, we could be forced to seek additional third-party manufacturing contracts, thereby increasing our development costs and negatively impacting our timelines and any commercialization costs. Although we believe there are other manufacturers that could manufacture any of our product candidates we develop, they may not do so on favorable term. In addition, if we change manufacturers at any point once we commence clinical trials or after 55 Table of Contentsapproval of a product candidate, we will be required to demonstrate comparability between the product manufactured by the old manufacturer and the product manufactured by the new manufacturer. If we are unable to do so we may need to conduct additional clinical trials with product manufactured by the new manufacturer.If we or any outsourced manufacturer of our products are not able to manufacture sufficient quantities of our clinical product candidate, our development activities would be impaired. In addition, any manufacturing facility where any of our clinical product candidates are manufactured will be subject to ongoing, periodic inspection by the FDA or other comparable regulatory agencies to ensure compliance with cGMP. Any failure to follow and document the manufacturerâ€™s adherence to such cGMP regulations or other regulatory requirements may lead to significant delays in the availability of clinical bulk drug substance and finished product for clinical trials, which may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our clinical product candidate. We also may encounter problems with the following:â—achieving adequate or clinical-grade materials that meet FDA or other comparable regulatory agency standards or specifications with consistent and acceptable production yield and costs;â—failing to develop an acceptable formulation to support late-stage clinical trials for, or the commercialization of, our clinical product candidate;â—being unable to increase the scale of or the capacity for, or reformulate the form of our clinical product candidate, which may cause us to experience a shortage in supply or cause the cost to manufacture our clinical product candidate to increase;â—we cannot assure you that we will be able to manufacture our clinical product candidate at a suitable commercial scale, or that we will be able to find alternative manufacturers acceptable to us that can do so;â—our facility closing as a result of regulatory sanctions, pandemic or a natural disaster;â—shortages of qualified personnel, raw materials or key contractors;â—failing to obtain FDA approval for commercial scale manufacturing; andâ—ongoing compliance with cGMP regulations and other requirements of the FDA or other comparable regulatory agencies.If we encounter any of these problems or are otherwise delayed, or if the cost of manufacturing is not economically feasible or we cannot find another third-party manufacturer, we may not be able to produce our clinical product candidate in a sufficient quantity to meet future demand.These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes. If demand for our products materializes, we may have to invest additional resources to purchase materials, hire and train employees, and enhance our manufacturing processes or those of third-party manufacturers. It may not be possible for us to manufacture our clinical product candidate at a cost or in quantities sufficient to make its clinical product candidate commercially viable. Any of these factors may affect our ability to manufacture our products and could reduce gross margins and profitability.Reliance on third-party manufacturers and suppliers entails risks to which we would not be subject if we manufacture our clinical product candidate ourselves, including:â—reliance on the third parties for regulatory compliance and quality assurance;56 Table of Contentsâ—the possible breach of the manufacturing agreements by the third parties because of factors beyond our control or the insolvency of any of these third parties or other financial difficulties, labor unrest, natural disasters or other factors adversely affecting their ability to conduct their business; andâ—possibility of termination or non-renewal of the agreements by the third parties, at a time that is costly or inconvenient for us, because of our breach of the manufacturing agreement or based on their own business priorities.If we rely on a third-party contract manufacturer or its suppliers fail to deliver the required commercial quantities of our clinical product candidate required for our clinical trials and, if approved, for commercial sale, on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers or suppliers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality, and on a timely basis, we would likely be unable to meet demand for our products and would have to delay or terminate our pre-clinical or clinical trials, and we would lose potential revenue. It may also take significant time to establish an alternative source of supply for our clinical product candidate and to have any such new source approved by the FDA or any applicable foreign regulatory authorities. Furthermore, any of the above factors could cause the delay or suspension of initiation or completion of clinical trials, regulatory submissions or required approvals of our clinical product candidate, cause it to incur higher costs and could prevent us from commercializing our clinical product candidate successfully.If we are unable to establish new collaborations and maintain both new and existing collaborations, or if these collaborations are not successful, our business could be adversely affected.Our current business plan contemplates that we will in the future derive revenues or payments from collaborators and licensees that successfully utilize iBio technologies in connection with the production, development and commercialization of vaccines and therapeutic protein product candidates. Our realization of these revenues and payments including dependence on existing collaborations, and any future collaborations we enter into, is subject to a number of risks, including the following:â—collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;â—collaborators may not perform their obligations as expected;â—collaborators may not pursue development and, if successful, commercialization of product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaboratorsâ€™ strategic focus or available funding, or external factors, such as an acquisition, which divert resources or create competing priorities;â—collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;â—collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;â—collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;57 Table of Contentsâ—collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;â—collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;â—collaborations may be terminated for the convenience of the collaborator and, if terminated, we would potentially lose the right to pursue further development or commercialization of the applicable product candidates;â—collaborators may learn about our technology and use this knowledge to compete with us in the future;â—results of collaboratorsâ€™ preclinical or clinical studies could produce results that harm or impair other products using our technology;â—there may be conflicts between different collaborators that could negatively affect those collaborations and others; andâ—the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers.If our collaborations do not result in the successful development and commercialization of products or if one or more of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. There can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.We seek to establish and collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of iBio technology-produced and iBio technology-enhanced product candidates. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration depends, among other things, upon our assessment of the collaboratorâ€™s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaboratorâ€™s evaluation of several factors. If we fail to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development or the development of one or more of our other product candidates, or increase our expenditures and undertake additional development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all.If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product portfolio and our business may be materially and adversely affected.If third parties on whom we or our licensees will rely for the conduct of preclinical studies and clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business may suffer.We have limited resources dedicated to designing, conducting, and managing our preclinical studies and clinical trials. We do not have the ability to independently conduct the preclinical studies and clinical trials required to obtain regulatory approval for our product candidates. We have not yet contracted with any third parties to conduct clinical trials of product candidates we develop independently of collaborators. We will depend on licensees or on independent clinical investigators, contract research organizations and other third-party service providers to conduct the clinical trials of our 58 Table of Contentsproduct candidates. We will rely on these vendors and individuals to perform many facets of the clinical development process on our behalf, including conducting preclinical studies and will rely on them for the recruitment of sites and subjects for participation in our clinical trials, maintenance of good relations with the clinical sites, and ensuring that these sites are conducting our trials in compliance with the trial protocol and applicable regulations. We will rely heavily on these parties for successful execution of our clinical trials but will not control many aspects of their activities. For example, the investigators participating in our clinical trials will not be our employees. However, we will be responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and commercialization of our product candidates. If these third parties fail to perform satisfactorily, or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into alternative arrangements without undue delay or additional expenditures, and therefore the preclinical studies and clinical trials of our clinical product candidate may be delayed or prove unsuccessful.Further, the FDA, the EMA, or similar regulatory authorities in other countries, may inspect some of the clinical sites participating in our clinical trials or our third-party vendorsâ€™ sites to determine if our clinical trials are being conducted according to good clinical practices, or GCPs, or similar regulations. If we or a regulatory authority determine that our third-party vendors are not in compliance with or have not conducted our clinical trials according to applicable regulations, we may be forced to exclude certain data from the results of the trial, or delay, repeat or terminate such clinical trials.We rely on third parties to supply the raw materials needed to operate our research and development activities and do not have any long-term commitments from such suppliers.â€‹We currently rely on third parties for the raw materials needed to operate our research and development activities. We do not have any long-term commitments from any raw material suppliers and therefore cannot guarantee that there will be adequate supply of our raw materials. Natural disasters or other disruptions at any of our suppliersâ€™ facilities may impair or delay the delivery of our products. Influenza or other pandemics, such as the coronavirus, could disrupt production of our products, reduce demand for certain of our products, or disrupt the marketplace in the food service or retail environment with consequent material adverse effects on our results of operations. To the extent we are unable to, or cannot, financially mitigate the likelihood or potential impact of such events, or effectively manage such events if they occur, particularly when a product is sourced from a single location, there could be a material adverse effect on our business and results of operations, and additional resources could be required to restore our supply chain. Although we believe we have sufficient supply of our other raw materials at this time, due to supply chain shortages, we may not be able to obtain such materials in the future is our current suppliers should be unable to satisfy our needs. Such suppliers may not be able to provide us with engines in a timely manner due to supply chain shortages and even if other suppliers are able to fulfill our needs they may not be able to do so at the same price as we currently pay for such materials, which could result in lower profit margins or us increasing the price of our services in order to maintain profit margins which could adversely impact demand for our services.â€‹Any claims beyond our insurance coverage limits, or that are otherwise not covered by our insurance, may result in substantial costs and a reduction in our available capital resources.We maintain property insurance, employerâ€™s liability insurance, product liability insurance, general liability insurance, business interruption insurance, and directorsâ€™ and officersâ€™ liability insurance, among others. Although we maintain what we believe to be adequate insurance coverage, potential claims may exceed the amount of insurance coverage or may be excluded under the terms of the policy, which could cause an adverse effect on our business, financial condition and results from operations. Generally, we would be at risk for the loss of inventory that is not within customer specifications. These amounts could be significant. In addition, in the future we may not be able to obtain adequate insurance coverage, or we may be required to pay higher premiums and accept higher deductibles in order to secure adequate insurance coverage.59 Table of ContentsWe may be subject to various litigation claims and legal proceedings.We, as well as certain of our directors and officers, may be subject to claims or lawsuits during the ordinary course of business. Regardless of the outcome, these lawsuits may result in significant legal fees and expenses and could divert managementâ€™s time and other

resources. If the claims contained in these lawsuits are successfully asserted against us, we could be liable for damages and be required to alter or cease certain of our business practices. Any of these outcomes could cause our business, financial performance and cash position to be negatively impacted.Risks Related to Intellectual Property If we or our licensors are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.Our success depends in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates, and by maintenance of our trade secrets through proper procedures.The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recentÂ years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States and we may fail to seek or obtain patent protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18Â months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions, nor can we know whether those from whom we license patents were the first to make the inventions claimed or were the first to file. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. PTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.Even if our pending or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.60 Table of ContentsThe issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and ultimately unsuccessful.Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patentâ€™s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect us and our collaborators.While no such litigation has been brought against us and we have not been held by any court to have infringed a third partyâ€™s intellectual property rights, we cannot guarantee that our technology, products or use of our products do not infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before NovemberÂ 29, 2000, and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing date, which is referred to as the priority date. Therefore, patent applications covering our products or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products.We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the U.S. PTO and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.If we are found to infringe a third partyâ€™s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneysâ€™ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.61 Table of ContentsIn spite of our efforts, our licensors might allege that we have materially breached our obligations under such license agreements and might therefore attempt to terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of our lead products or other product candidates that we may identify. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:â—the scope of rights granted under the license agreement and other interpretation-related issues;â—the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;â—the sublicensing of patent and other rights under our collaborative development relationships;â—our diligence obligations under the license agreement and what activities satisfy those diligence obligations;â—the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; andâ—the priority of invention of patented technology.In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20Â years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.If we are unable to protect our trade secrets, our business and competitive position would be harmed.In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, 62 Table of Contentsconsultants, advisors and other third parties. We also seek to enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.Many of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies. These employees typically executed proprietary rights, non-disclosure and non-competition agreements in connection with their previous employers. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employeeâ€™s former employer. We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensorsâ€™ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, while we require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.Intellectual property rights do not necessarily address all potential threats to our competitive advantage.The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:â—others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we license;â—our licensors or collaborators might not have been the first to make the inventions covered by an issued patent or pending patent application;â—our licensors or collaborators might not have been the first to file patent applications covering an invention;â—others may independently develop similar or alternative technologies or duplicate any of our or our licensorsâ€™ technologies without infringing our intellectual property rights;â—pending patent applications may not lead to issued patents;63 Table of Contentsâ—issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;â—our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;â—we may not develop or in-license additional proprietary technologies that are patentable;â—the patents of others may have an adverse effect on our business; andâ—we may choose not to file a patent application for certain trade secrets or know-how, and a third party may subsequently obtain a patent covering such intellectual property.Should any of these events occur, they could significantly harm our business, results of operations and prospects.We may not be able to protect our intellectual property rights throughout the world.Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.If we should fail to comply with various patent laws our patent protection could be reduced or eliminated.â€‹Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various

governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.64 Table of ContentsChanges in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to MarchÂ 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After MarchÂ 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in SeptemberÂ 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after MarchÂ 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)Â file any patent application related to our product candidates or (ii)Â invent any of the inventions claimed in our or our licensorâ€™s patents or patent applications. In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.Risks Related to iBioâ€™s Operations In the past we have identified and remediated material weaknesses in our internal controls, and we cannot provide assurances additional material weaknesses will not occur in the future.Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. During the preparation of the Quarterly Report for the quarter ended March 31, 2023, we identified a material weakness in our controls relating to accounting for stock-based compensation expense relating to the vesting of severed employeesâ€™ awards. Â If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud, or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price. In addition, a material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. As of June 30, 2023, management believes that significant progress has been made in enhancing internal controls and has concluded that the enhanced controls are operating effectively. Â Therefore, as of June 30, 2023, the material weakness described in Item 4 Controls and Procedures in our Quarterly Report on Form 10-Q for quarter ended March 31, 2023 has been fully remediated and management believes it does not have any weaknesses in internal controls. Â Although the material weakness has been remediated, there can be no assurance that the internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future.Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. As a growing company, implementing and maintaining effective controls may require more resources, and we may encounter internal control integration difficulties. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.65 Table of ContentsThe loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.Â Our success depends largely upon the continued services of our key executive officers. To continue to develop our pipeline and execute our strategy, we also must attract and retain highly skilled personnel in our industry. â€‹A failure by iBio to hire and retain an appropriately skilled and adequate workforce could adversely impact the ability to operate our R&D facility efficiently.iBioâ€™s operations will depend, in part, on our ability to attract and retain an appropriately skilled and sufficient workforce to operate our R&D facility. These employees may voluntarily terminate their employment with us at any time. The R&D facility is located in San Diego, California, a growing biotechnology hub and competition for skilled workers will continue to increase as the industry undergoes further growth in the area. There can be no assurance that we will be able to retain key personnel, or to attract and retain additional qualified employees especially in light of our cash position. Our inability to attract and retain key personnel as we grow in two locations may have a material adverse effect on our business.Use of our laboratory space in San Diego is critical to our success. A natural disaster or other disruptions at our laboratory would adversely affect our business, financial condition, and results of operations.Â We currently conduct all of our pre-clinical research at our laboratory in San Diego using specialized equipment that we have purchased. Â Any natural disaster or other serious disruption to our facility due to fire, flood, earthquake, or any other unforeseen circumstance would adversely affect our business, financial condition, and results of operations. Although we do believe that we could find alternative space in the case of a natural disaster, there can be no assurance that we will find suitable space near the location of our employees or that our equipment will survive a natural disaster. The occurrence of any disruption at our laboratory, even for a short period of time, may have an adverse effect on our research and development operations, during and after the period of the disruption. Although we maintain property, casualty, and business interruption insurance of the types and in the amounts that we believe are customary for the industry, we are not fully insured against all potential natural disasters or other disruptions to our laboratory.â€‹We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.We intend to grow our business operations as demand increases and increase the number of our employees to accommodate such potential growth, which may cause us to experience periods of rapid growth and expansion. This potential future growth could create a strain on our organizational, administrative and operational infrastructure, including manufacturing operations, quality control, technical support and other administrative functions. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls.As our commercial operations and sales volume grow, we will need to continue to increase our capacity for manufacturing, customer service, billing and general process improvements and expand our internal quality assurance program, among other things. We may also need to purchase additional equipment, some of which can take severalÂ months or more to procure, set up and validate, and increase our manufacturing, maintenance, software and computing capacity to meet increased demand. These increases in scale, expansion of personnel, purchase of equipment or process enhancements may not be successfully implemented.If we are unable to protect the confidentiality of our partnersâ€™ or collaboratorsâ€™ proprietary information, we may be subject to claims.The research and development processes developed by us or our partnersâ€™ or collaboratorsâ€™ products are subject to trade secret protection, patents or other intellectual property protections owned or licensed by such partners. While we make significant efforts to protect our partnersâ€™ proprietary and confidential information, including requiring our employees to enter into agreements protecting such information, if any of our employees breaches the non-disclosure provisions in such agreements, or if our partners make claims that their proprietary information has been disclosed, our reputation may suffer 66 Table of Contentsdamage and we may become subject to legal proceedings that could require us to incur significant expenses and divert our managementâ€™s time, attention and resources.If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could negatively impact our business, results from operations and financial condition.If we are presented with appropriate opportunities, we may acquire or make investments in complementary companies, products or technologies. We may not realize the anticipated benefit of any acquisition or investment. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology with our products, diversion of our managementâ€™s attention from other business concerns, the potential loss of key employees or customers of the acquired business, and impairment charges if future acquisitions are not as successful as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating to acquired intangible assets. Any failure to successfully integrate other companies, products, or technologies that we may acquire may have a material adverse effect on our business and results of operations. Furthermore, we may have to incur debt or issue equity securities to pay for any additional future acquisitions or investments, the issuance of which could be dilutive to our existing stockholders.Our business and operations would suffer in the event of computer system failures.Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusions, including by computer hackers, foreign governments, and cyber-terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our current or future product development programs. For example, the loss of clinical trial data from completed or any future ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation, and the further development of our product candidates could be delayed.We rely extensively on our information technology systems and are vulnerable to damage and interruption, including cybersecurity and data leakage risks.We rely on our information technology systems and infrastructure to process transactions, summarize results and manage our business, including maintaining client and supplier information. Additionally, we utilize third parties, including cloud providers, to store, transfer and process data. Our information technology systems, as well as the systems of our suppliers and other partners, whose systems we do not control, are vulnerable to outages and an increasing risk of continually evolving deliberate intrusions to gain access to company sensitive information. Likewise, data security incidents and breaches by employees and others with or without permitted access to our systems pose a risk that sensitive data may be exposed to unauthorized persons or to the public. A cyber-attack or other significant disruption involving our information technology systems, or those of our vendors, suppliers and other partners, could also result in disruptions in critical systems, corruption or loss of data and theft of data, funds or intellectual property. Â A security breach of any kind, including physical or electronic break-ins, computer viruses and attacks by hackers, employees or others, could expose us to risks of data loss, litigation, government enforcement actions, regulatory penalties and costly response measures, and could seriously disrupt our operations. We may be unable to prevent outages or security breaches in our systems. Â We remain potentially vulnerable to additional known or yet unknown threats as, in some instances, we, our suppliers and our other partners may be unaware of an incident or its magnitude and effects. Â We also face the risk that we expose our vendors or partners to cybersecurity attacks. Â Any or all of the foregoing could harm our reputation and adversely affect our results of operations and our business reputation.67 Table of ContentsAny failure to maintain the security of information relating to our patients, customers, employees and suppliers, whether as a result of cybersecurity attacks or otherwise, could expose us to litigation, government enforcement actions and costly response measures, and could disrupt our operations and harm our reputation.In connection with the pre-clinical and clinical development, sales and marketing of our products and services, we may from time to time transmit confidential information. We also have access to, collect or maintain private or confidential information regarding our clinical trials and the patients enrolled therein, employees, and suppliers, as well as our business. Cyberattacks are rapidly evolving and becoming increasingly sophisticated. It is possible that computer hackers and others might compromise our security measures, or security measures of those parties that we do business with now or in the future, and obtain the personal information of patients in our clinical trials, vendors, employees and suppliers or our business information. A security breach of any kind, including physical or electronic break-ins, computer viruses and attacks by hackers, employees or others, could expose us to risks of data loss, litigation, government enforcement actions, regulatory penalties and costly response measures, and could seriously disrupt our operations. Any resulting negative publicity could significantly harm our reputation, which could cause us to lose market share and have an adverse effect on our results of operations.Risks Related to Our Common Stockâ€‹Our stockholders will experience substantial dilution from the issuance of the development milestone payments if paid in equity and may not realize a benefit from the acquisition of substantially all of the assets RubrYc commensurate with the ownership dilution they will experience in connection therewith.We have the option to pay the contingent development milestone consideration owed to the RubrYc shareholders in shares of our common stock. Our stockholders will experience substantial dilution from the issuance of shares of common stock to pay the contingent development milestone consideration, should we elect to pay such development milestones in shares of common stock in lieu of cash. Our failure to continue to comply with the continued listing standards of the NYSE American could result in delisting from the NYSE American.In order to maintain our listing with NYSE American, we must remain in compliance with the continued listing standards as set forth in the NYSE American Company Guide (the â€œCompany Guideâ€), including the listing standard set forth in SectionÂ 1003 of the Guide, which applies if a listed company has stockholdersâ€™ equity below certain threshold amounts and has sustained losses from continuing operations and/or net losses in its five most recent fiscalÂ years. In the past, we have received notification of noncompliance with the continued listing requirements, which to date have been remediated. There can be no assurance that we will continue to meet all of the continued listing standards of NYSE American, or exemptions therefrom, in the future. A failure to comply with such listing standards could result in delisting from NYSE American. Provisions in our certificate of incorporation, bylaws and under Delaware law could discourage a takeover that stockholders may consider favorable.Provisions of our certificate of incorporation, bylaws and provisions of applicable Delaware law may discourage, delay or prevent a merger or other change in control that a stockholder may consider favorable. Pursuant to our certificate of incorporation, our Board of Directors may issue additional shares of common stock or preferred stock. Any additional issuance of common stock could have the effect of impeding or discouraging the acquisition of control of us by means of a merger, tender offer, proxy contest or otherwise, including a transaction in which our stockholders would receive a premium over the market price for their shares, and thereby protect the continuity of our management. Specifically, if in the due exercise of its fiduciary obligations, the Board of Directors were to determine that a takeover proposal was not in our best interest, shares could be issued by our Board of Directors without stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover by:â—diluting the voting or other rights of the proposed acquirer or insurgent stockholder group,68 Table of Contentsâ—putting a substantial voting bloc in institutional or other hands that might undertake to support the incumbent Board of Directors, orâ—effecting an acquisition that might complicate or preclude the takeover.Our certificate of incorporation also allows our Board of Directors to fix the number of directors in the by-laws. Our certificate of incorporation does not contemplate cumulative voting in the election of directors and thus, under Delaware law, cumulative voting in the election of directors is not permitted. Our Board of Directors is divided into three classes, each of which serves for a staggered term of threeÂ years. This division of our Board of Directors could have the effect of impeding an attempt to take over our company or change or remove management, since only one class will be elected annually. Thus, only approximately one-third of the existing Board of Directors could be replaced at any election of directors.The effect of these provisions may be to delay or prevent a tender offer or takeover attempt that a stockholder may determine to be in his, her or its best interest, including attempts that might result in a premium over the market price for the shares held by the stockholders.Our Second Amended and Restated Bylaws provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholdersâ€™Â ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.â€‹Our Second Amended

and Restated Bylaws provides that the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on behalf of the Company, any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Companyâ€™s stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or any action asserting a claim governed by the internal affairs doctrine. The federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended and the forum selection provision does not apply to claims arising exclusively under the Exchange Act or the Investment Company Act, or any other claim for which the federal courts have exclusive jurisdiction.â€‹This forum selection provision may limit a stockholderâ€™s ability to bring certain claims in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. If a court were to find this forum selection provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.â€‹The issuance of preferred stock could adversely affect the rights of the holders of shares of our common stock.Our Board of Directors is authorized to issue up to 1,000,000 shares of preferred stock without any further action on the part of our stockholders. Our Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Our Board of Directors may, at any time, designate a new series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock, and the right to the redemption of the shares, together with a premium, before the redemption of our common stock and authorize the issuance of such series of preferred stock, which may have a material adverse effect on the rights of the holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue large blocks of preferred stock. In addition, the ability of our Board of Directors to designate and issue shares of preferred stock without any further action on the part of our stockholders may impede a takeover of our company and may prevent a transaction that is favorable to our stockholders.69 Table of ContentsWe do not anticipate paying cash dividends for the foreseeable future, and therefore investors should not buy our stock if they wish to receive cash dividends.We have never declared or paid any cash dividends or distributions on our capital stock. We currently intend to retain our future earnings to support operations and to finance expansion and therefore we do not anticipate paying any cash dividends on our common stock in the foreseeable future.Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results.â€‹The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values could impact our business in the future. We and our third-party contract manufacturers, contract research organizations, and any clinical sites that may conduct our clinical trials in the future may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak.Â These minor disruptions have had an immaterial effect on business, which we have been able to address with minimal impact to our business operations to date. Further, although we have not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing manufacturing of our drug candidates or services providers, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on our operations.â€‹Our operations and performance depend on global, regional and U.S. economic and geopolitical conditions. Â Russiaâ€™s invasion and military attacks on Ukraine have triggered significant sanctions from U.S. and European leaders. Â Resulting changes in U.S. trade policy could trigger retaliatory actions by Russia, its allies and other affected countries, including China, resulting in a â€œtrade war.â€â€‹TheÂ aboveÂ factors,Â includingÂ aÂ numberÂ ofÂ otherÂ economicÂ andÂ geopoliticalÂ factorsÂ bothÂ inÂ theÂ U.S.Â andÂ abroad,Â could ultimately have material adverse effects on our business, financial condition, results of operations or cash flows, including theÂ following:â€‹â—effects of significant changes in economic, monetary and fiscal policies in the U.S. and abroad including currency fluctuations, inflationary pressures and significant income tax changes;â—supply chain disruptions;â—a global or regional economic slowdown in any of our market segments;â—changes in government policies and regulations affecting the Company or its significant customers;â—industrial policies in various countries that favor domestic industries over multinationals or that restrict foreign companies altogether;â—new or stricter trade policies and tariffs enacted by countries, such as China, in response to changes in U.S. trade policies and tariffs;â—postponement of spending, in response to tighter credit, financial market volatility and other factors;â—rapid material escalation of the cost of regulatory compliance and litigation;â—difficulties protecting intellectual property; â—longer payment cycles;70 Table of Contentsâ—credit risks and other challenges in collecting accounts receivable; andâ—the impact of each of the foregoing on outsourcing and procurement arrangements.Holders of our warrants issued in our offerings have no rights as common stockholders until they exercise their warrants and acquire our common stock.Until the holders of the warrants we issued in our offerings acquire shares of our common stock by exercising their warrants, the holders of the warrants have no rights as a stockholder with respect to the shares of common stock underlying their securities. Upon exercise of the warrants they will be entitled to the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.Whether the outstanding warrants will have any value will depend on the market conditions for, and the price of, our common stock, which conditions will depend on factors related and unrelated to the success of our clinical development program, and cannot be predicted at this time. If our common stock price does not increase to an amount sufficiently above the exercise price of the warrants during the periods the warrants are exercisable, holders of warrants will be unable to recover any of their investment in the warrants.Because there is no established public trading market for any of our warrants we issued, the liquidity of each such security is limited. We do not expect a market to develop, nor do we intend to apply to list the warrants on any securities exchange. Upon exercise of the warrants, our stockholders will experience dilution.The market price of our common stock has been and may continue to be volatile and adversely affected by various factors.Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. By way of example, on January 19, 2024, the price of our common stock closed at $1.06 per share while on March 28, 2024, our stock price closed at $4.06 per share. We may incur rapid and substantial decreases in our stock price in the foreseeable future that are unrelated to our operating performance or prospects. The stock market in general and the market for biotechnology and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price of our common stock could fluctuate significantly in response to various factors and events, including:â—investor reaction to our business strategy;â—the success of competitive products or technologies;â—our continued compliance with the listing standards of the NYSE American;â—results of our preclinical and clinical trials;â—actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;â—variations in our financial results or those of companies that are perceived to be similar to us;â—developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;â—our ability or inability to raise additional capital and the terms on which we raise it;â—declines in the market prices of stocks generally;71 Table of Contentsâ—trading volume of our common stock;â—sales of our common stock by us or our stockholders;â—announcements of licensing or other business development initiatives;â—general economic, industry and market conditions; andâ—other events or factors, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability.These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Since the stock price of our common stock has fluctuated in the past, has been recently volatile and may be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of managementâ€™s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no guarantee that our stock price will remain at current prices or that future sales of our common stock will not be at prices lower than those sold to investors.Reports published by securities or industry analysts, including projections in those reports that exceed our actual results, could adversely affect our common stock price and trading volume.Securities research analysts, including those affiliated with our underwriters from prior offerings, establish and publish their own periodic projections for our business. These projections may vary widely from one another and may not accurately predict the results we actually achieve. Our stock price may decline if our actual results do not match securities research analystsâ€™ projections. Similarly, if one or more of the analysts who writes reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business or if one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, our stock price or trading volume could decline. While we expect securities research analyst coverage to continue going forward, if no securities or industry analysts begin to cover us, the trading price for our stock and the trading volume could be adversely affected. We are a â€œsmaller reporting companyâ€, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.We are a â€œsmaller reporting companyâ€ as defined in Rule 12b-2 promulgated under the Exchange Act. We may remain a smaller reporting company until we have a non-affiliate public float in excess of $250 million or annual revenues in excess of $100 million and a non-affiliate public float in excess of $700 million, each as determined on an annual basis. For so long as we remain smaller reporting company, we are permitted and may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:â—an exemption from compliance with the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, on the design and effectiveness of our internal controls over financial reporting; andâ—scaled reporting and disclosure requirements including about our executive compensation arrangements.We cannot predict whether investors will find our common stock less attractive if we rely on such exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.72 Table of ContentsItemÂ 1B. Unresolved Staff Comments.None.Item 1C. Cybersecurity.We maintain a cyber risk management protocol designed to identify, assess, manage, mitigate, and respond to cybersecurity threats.The underlying processes and controls of our cyber risk management protocol incorporate recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology (â€œNISTâ€) Cybersecurity Framework (â€œCSFâ€). In addition, we maintain policies over areas such as information security, access on/offboarding, and access and account management, to help govern the processes put in place by management designed to protect our IT assets, data, and services from threats and vulnerabilities. We consult with a third-party specialist with regard to our cyber risk management processes and controls.Â Our management team is responsible for oversight and administration of our cyber risk management protocol, and for informing senior management and other relevant stakeholders regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents. iBioâ€™s management team has prior experience selecting, deploying, and overseeing cybersecurity technologies, initiatives, and processes and relies on threat intelligence as well as other information obtained from governmental, public, or private sources. Our Audit Committee also provides oversight of risks from cybersecurity threats.As part of its review of the adequacy of our system of internal controls over financial reporting and disclosure controls and procedures, the Audit Committee is specifically responsible for reviewing the adequacy of our computerized information system controls and security related thereof. The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of our cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis. This includes updates on iBioâ€™s processes to prevent, detect, and mitigate cybersecurity incidents. In addition, cybersecurity risks are reviewed by our Board of Directors at least annually, as part of the Companyâ€™s corporate risk oversight processes.We face risks from cybersecurity threats that could have a material adverse effect on our business, financial condition, results of operations, cash flows or reputation. iBio acknowledges that the risk of cyber incidents is prevalent in the current threat landscape and that a future cyber incident may occur in the normal course of its business. To date, we have not had a cybersecurity incident. We proactively seek to detect and investigate unauthorized attempts and attacks against our IT assets, data, and services, and to prevent their occurrence and recurrence where practicable through changes or updates to internal processes and tools and changes or updates to service delivery; however, potential vulnerabilities to known or unknown threats will remain. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, investors, and additional stakeholders, which could subject us to additional liability and reputational harm. See Item 1A. â€œRisk Factorsâ€ for more information on cybersecurity risks.ItemÂ 2. Properties.FacilityOn November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (â€œiBio CDMOâ€, and collectively with the Company, the â€œPurchaserâ€) entered into a series of agreements (the â€œTransactionâ€) with College Station Investors LLC (â€œCollege Stationâ€), and Bryan Capital Investors LLC (â€œBryan Capitalâ€ and, collectively with College Station, â€œSellerâ€), each affiliates of Eastern Capital Limited (â€œEastern,â€ a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:73 Table of Contents(i)acquired both the Facility where iBio CDMO at that time conducted business and also the rights as the tenant in the Facilityâ€™s ground lease;(ii)acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and(iii)otherwise terminated all agreements between the Company and the affiliates of Eastern.On May 17, 2024, iBio CDMO entered into the 2024 Purchase and Sale Agreement with The Board of Regents pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property. Â The 2024 Purchase and Sale Agreement provided that the Property will be sold to The Board of Regents for the Purchase Price. The closing of the sale of the Property occurred on May 31, 2024. Â Biopharmaceutical R&D FacilityOn September 11, 2021, iBio entered into a lease with SAN DIEGO INSPIRE 4, LLC for approximately 11,383 square feet of lab and office space at 11750 Sorrento Valley Road in San Diego, CA. The lease commenced in September 2022. The lease is for seven years and four months. The lease is triple net with Base Rent starting at $4.50 per month per square foot escalating approximately 3.0 percent per year during the lease term. iBio will use the facility primarily for R&D associated with its AI Drug Discovery Platform and our biologic product portfolio.ItemÂ 3. Legal Proceedings.LawsuitsWe are not currently subject to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Litigation, regardless of the outcome, could have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.â€‹ItemÂ 4. Mine Safety Disclosures.Not applicable.â€‹74 Table of ContentsPARTÂ IIItemÂ 5. Market for Registrantâ€™s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.Market InformationOur common stock is traded on the NYSE American under the trading symbol â€œIBIO.â€HoldersOn September 6, 2024, there were 14 stockholders of record of our common stock, one of which was Cede & Co., a nominee for Depository Trust Company, or DTC. All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede & Co. as one stock.DividendsWe have never declared or paid any cash dividends on our common stock. Dividends on our common stock cannot be declared or paid or set aside for payment or other distribution unless all accrued dividends on all outstanding shares of Preferred Tracking Stock are paid in full.Recent Sales of Unregistered SecuritiesThere were no sales of unregistered securities other than as set forth in documents previously filed by the Company with the SEC.Issuer Purchases of Equity SecuritiesWe did not purchase any of our equity securities during the fiscal year ended June 30, 2024.Reverse Stock SplitAs discussed above, the Company effected a reverse stock split at a ratio of one-for-twenty five (1:25) shares of the Company's common stock on October 7, 2022. All share and per share amounts of common stock presented have been retroactively adjusted to reflect the one-for-twenty-five reverse stock split.Further, as discussed above, the Company effected a reverse stock split at a ratio of one-for-twenty (1:20) shares of the Company's common stock on November 29, 2023. All share and per share amounts of common stock presented have been retroactively adjusted to reflect the one-for-twenty-five reverse stock split.ItemÂ 6. [Reserved]â€‹75 Table of ContentsItemÂ 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.The following discussion of our financial condition and results of operations should be read together with our financial statements and the notes thereto and other information included elsewhere in this Annual Report. Unless the context requires otherwise, references in this Report to â€œiBio,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ or â€œourâ€ and similar terms mean iBio, Inc.Overview We are a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of

discovery. Our core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through our innovative platform, we champion a culture of innovation by swiftly identifying novel targets, forging strategic collaborations with the goal of to enhancing efficiency, diversifying pipelines, and accelerating preclinical processes.Additionally, our groundbreaking EngageTx technology enables us to target bi-specific molecules, while ShieldTx is designed to reduce or eliminate adverse effects stemming from off-target tissue effects. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, our goal is to enhance agility and bolster preclinical safety assessments.Our strategic approach to fulfilling our mission is outlined as follows:â—Elevate Epitope Discovery: We believe we lead the field with our patented AI-engine uncovering "hard to develop" molecules. Our unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery. Â This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. Our epitope engine is engineered to match its target, refined for stability and optimized for water solubility; allowing us to identify new drug candidates that have failed or have been abandoned due to their complexity. â—Capital efficient business approach: Our strategic business approach is structured around the following pillars of value creation:oStrategic Collaborations: We have leveraged our platform and pipeline by forming strategic partnerships. We aim to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, rich array of fast follower molecules within the Companyâ€™s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into our, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.oDeveloping and advancing our in-house programs cost effectively: Clinical advancement is crucial for drug discovery. As we continue to develop our existing immune-oncology pre-clinical pipeline, we are also seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. Â We also continue to assess our option rights to license three of the four assets under the collaboration with AstralBio to expand our pre-clinical pipeline into obesity and cardiometabolic programs and with the goal to become a clinical stage company. Â 76 Table of ContentsoTech Licensing in Diverse Therapeutic Areas: In pursuit of adding value, we are exploring partnerships in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. This strategic approach enables us to capitalize on the value of our meticulously curated data while empowering collaborations and innovations, while at the same time allowing us to focus on both the platform and our core therapeutic areas, metabolic diseases and oncology.â—Unwavering Investment in advancing the platform: We maintain a focused commitment to invest in our platform, continually unlocking the potential of biology through AI and ML. Â The pinnacle of being on the forefront of ML advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.In essence, we are sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.â€‹AI-Technology Platform OverviewOur platform comprises five key components, each playing a crucial role in the discovery and optimization of precision antibodies.The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. Next, our EngageTx platform forms the fourth layer. Lastly, our ShieldTx antibody masking technology enables the creation of conditionally activated antibodies. Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).â€‹AI Epitope Steering TechnologyOur epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, we can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of our antibody discovery process. Â Our AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from naÃ¯ve or immunized libraries.NaÃ¯ve Human Antibody LibraryThe fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, we have extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, we have meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from our library.StableHuTM AI Antibody-Optimizing TechnologyOur proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.77 Table of ContentsWhile phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.EngageTx CD3-Based T-Cell Engager PanelWe have used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized our StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. Â Importantly, we were able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to our StableHu technology, reduces the risk of immunogenicity.Furthermore, our StableHu technology enabled us to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.ShieldTx Antibody Masking TechnologyOur ShieldTx technology enables the creation of conditionally activated antibodies and stands out because it is deeply integrated into our technology stack, providing multiple advantages. Identifying a fitting mask is challenging, however, ShieldTx is designed to increase the probability of success. This increased success rate is due to our epitope engineering engine, which creates small embodiments of the drug target epitope to raise antibodies. These engineered epitopes, by definition, bind to the raised antibody and can be deployed as masks. Thus, the mask design process is inherently built into the antibody discovery process.Additionally, multi-dimensional optimization with our StableHu antibody optimization technology allows for the simultaneous optimization of the three components of conditionally activated antibodies: the antibody, mask, and linker. This approach, we believe, will significantly reduce development time compared to the typically sequential optimization of the individual components.Pre-Clinical PipelineWe are currently in the process of building and advancing our preclinical pipeline by leveraging our technology stack focused on hard-to-drug targets and molecules offering differentiation in both in obesity and cardiometabolic disease space, as well as immune-oncology. Â As we continue to leverage our technology stack and develop our existing immune-oncology pre-clinical pipeline, we are also seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. Â Finally, we continue to assess the the optional time whether to trigger our options rights to license three of the four assets under the AstralBio collaboration to add obesity and cardiometabolic programs into our 78 Table of Contentspre-clinical pipeline. Â Under this strategic collaboration with AstraBio, it affords us the opportunity to expand our pipeline and build a presence in the cardiometabolic disease space.Recent DevelopmentsOn May 31, 2024, pursuant to that certain Purchase and Sale Agreement, dated as of May 17, 2024 (the â€œPurchase and Sale Agreementâ€), by and between iBio CDMO and The Board of Regents of the Texas A&M University System (â€œThe Board of Regentsâ€), we terminated the Ground Lease Agreement with The Board of Regents, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015 (collectively, the â€œGround Leaseâ€), related to 21.401 acres in Brazos County, Texas (the â€œLandâ€) and completed the sale to The Board of Regents of: (i) the buildings, parking areas, improvements, and fixtures situated on the Land (the â€œImprovementsâ€); (iii) all of our right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the â€œPersonal Propertyâ€); (iii) all of our rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the â€œContractsâ€); and (iv) all of our rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the â€œIntangiblesâ€; and together with the Ground Lease, Improvements and Personal Property, collectively, the â€œPropertyâ€). The purchase price was $8,500,000.On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) we paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) we issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share.Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released us from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and we released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.â€‹79 Table of ContentsResults of OperationsRevenueRevenue from the CDMO operations is now included in discontinued operations and not broken out separately on the financial statements. Our ongoing business is primarily focused on i) development of our pipeline for which we do not expect revenue for many years, if at all, and ii) on our AI-driven discovery platform for which to date we have not generated any material revenue. We may have revenue with the AI-driven discovery platform in the future. During the year ended June 30, 2024, we reported revenue in the amount of $0.2 million related to research activities performed and license fees. During the year ended June 30, 2023 we reported no revenue.Research and Development Expenses (â€œR&Dâ€)R&D expenses for 2024 and 2023 were approximately $5.2 million and $10.3 million, respectively, a decrease of approximately ($5.1) million or approximately (50)%. The decrease is primarily related to reduced spend on consulting and contracted services ($2.3) million, decreased spend on consumable supplies ($1.7) million, and a reduction in personnel costs ($1.5) million, all driven by the re-prioritization of pipeline projects and reorganization of the research and development team. This decrease was partially offset by an increase of depreciation of ($0.2) million due to the San Diego assets being in service for a full year. R&D expenses relating to CDMO operations are captured separately under discontinued operations.General and Administrative Expenses (â€œG&Aâ€)G&A expenses for fiscal year ended June 30, 2024 and 2023 were approximately $11.7 million and $19.0 million, respectively, a decrease of ($7.3) million or (39)%. The decrease is primarily attributable to a reduction in personnel costs of ($5.2) million due to the transformation of the Company into an antibody discovery and development company announced in November 2022, profession/consulting fees and outside services of ($1.0) million, an in tangible asset impairment charge that did not reoccur in fiscal year 2024 ($0.6) million, lower insurance premiums due to negotiated rates ($0.5) million and lower IT related spend ($0.2) million. The decrease was partially offset by an increase in legal costs ($0.3) million mainly driven by capital fundraising efforts. â€‹G&A expenses relating to CDMO operations are captured separately under discontinued operations.Total Operating ExpensesTotal operating expenses, consisting primarily of R&D and G&A expenses, for fiscal year ended June 30, 2024 were approximately $16.9 million, compared to approximately $29.3 million for fiscal year ended June 30, 2023.Other Income (Expense)Other income for the fiscal years ended June 30, 2024 and 2023 were $1.2 million and $0.03 million, an increase of approximately $1.2 million. The increase is mainly attributable to the sale of an intangible asset and an increase in interest income, partially offset by interest expenses. â€‹Net Loss from Continuing OperationsNet loss from continuing operations for fiscal year ended June 30, 2024 was ($15.4) million, or ($4.03) per share, compared to approximately ($29.3) million, or ($47.88) per share, in 2023.80 Table of ContentsNet Loss from Discontinued Operationsâ€‹On November 2, 2022, we announced our plans to divest our contract development and manufacturing organization (iBio CDMO) in order to complete our transformation into an AI-driven, precision antibody drug discovery and development company. In conjunction with the restructuring, we completed a workforce reduction of approximately 60% and discontinued the CDMO operations. CDMO operations are reported as discontinued operations on our financial statements. Losses for Discontinued Operations for 2024 and 2023 were approximately ($9.5) million and ($35.7) million, respectively, a decrease of ($26.2) million, or 73%. This decrease was primarily due to ($14.8) million less impairments of fixed assets, lower personnel related charges of ($7.6) million including severance, benefits and the acceleration of stock compensation awards, a ($4.9) million impairment of consumables inventory that did not reoccur in fiscal year 2024, and approximately ($4.3) million lower site related costs. This decrease was offset by the $4.8 million loss on sale of the Facility, an approximate $0.8 million gain on sale of equipment that did not reoccur in fiscal year 2024, approximately $0.3 million of revenue that did not reoccur in fiscal year 2024 and an increase of approximately $0.2 million of interest expense.â€‹Net Loss Available to iBio, Inc. StockholdersNet loss available to iBio, Inc. stockholders from both continuing and discontinued operations for fiscal year ended June 30, 2024 was approximately ($24.9) million, or ($6.50) per share, compared to approximately ($65.0) million, or ($106.19) per share, in fiscal year ended June 30, 2023.Liquidity and Capital Resources The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. Our management concluded that our recurring losses from operations and the fact that we have not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months from the date of filing this Annual Report for the year ended June 30, 2024. Â Our auditors also included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended June 30, 2024 with respect to this uncertainty.In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, we consummated the sale of our Facility, reduced our work force, signed a collaboration with AstralBio with to discover and develop novel antibodies for obesity and other cardiometabolic diseases, entered into a securities purchase agreement for a PIPE financing resulting in gross proceeds of approximatelyÂ $15.0 million. Â Potential options being consideredÂ to further increase liquidity, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a combination thereof. However, we anticipate that our expenses will increase as we continue our research and development activities and conduct clinical trials.â€‹Facility Purchase from Eastern Capital LimitedOn November 1, 2021, we purchased the Facility previously operated under a lease from two affiliates of Eastern Affiliates. We also acquired the approximate 30% equity interest (after conversion) in iBio CDMO held by the Eastern Affiliates, who became the lessee under the ground lease agreement with the Board of Regents of the Texas A&M University System (the â€œGround Lease Agreementâ€) for the land upon which the Facility is located and terminated the Sublease iBio had entered into with the Eastern Affiliates. As a result, iBio CDMO and its intellectual property are now wholly owned by iBio. The total purchase price for the Facility, the termination of the Sublease and other agreements among the parties, and the equity described below was $28,750,000, which was paid $28,000,000 in cash and by the issuance to Bryan Capital Investors LLC, an affiliate of the Eastern Affiliates a five-year warrant to purchase 2,579 shares of our Common Stock at an exercise price of $665 per share. â€‹81 Table of ContentsIn connection with the purchase of the Facility, iBio CDMO entered into the Credit Agreement with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 Term Loan to purchase the Facility, which Term Loan was evidenced by the Term Note. The Term Loan originally bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provided that it could be prepaid by iBio CDMO at any time and provided for mandatory prepayment upon certain circumstances. The Term Loan was secured by a lien on all of the assets of iBio CDMO and we guaranteed payments of the obligations owed under the Term Loan. Various provisions of the Credit Agreement were amended subsequent to the effective date of the Credit Agreement. For a summary of such amendments, please refer to Item 1. Business under the heading â€œFacility Purchase from Eastern

Capital Limited.â€â€‹On May 31, 2024, pursuant to the Purchase and Sale Agreement iBio CDMO terminated the Ground Lease Agreement, related to the Land and completed the sale to The Board of Regents of: (i) the Improvements; (iii) all iBio CDMOâ€™s right, title, and interest in and to the Personal Property; (iii) all iBio CDMOâ€™s rights under the Contracts; and (iv) all iBio CDMOâ€™s rights in the Intangibles and the Property. The purchase price was $8,500,000.On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term was defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share.Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.â€‹Cantor Fitzgerald UnderwritingOn November 25, 2020, we entered into a Controlled Equity Offering SM Sales Agreement (the â€œSales Agreementâ€) with Cantor Fitzgerald & Co. (â€œCantor Fitzgeraldâ€) to sell shares of Common Stock, from time to time, through an â€œat the market offeringâ€ program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. In the fiscal year ended June 30, 2024, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 170,989 shares of Common Stock. We received net proceeds of approximately $1.7 million.â€‹In the fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 289,144 shares of Common Stock. We received net proceeds of approximately $6.4 million during the fiscal year ended June 30, 2023 and held a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023.â€‹Wainwright UnderwritingâŸ‹On December 6, 2022, we entered into an underwriting agreement with H.C. Wainwright & Co., LLC (â€œWainwrightâ€), pursuant to which we agreed to sell to Wainwright, in a firm commitment underwritten offering (the â€œOfferingâ€) (i) 76,538 shares of Common Stock, (ii) pre-funded warrants (the â€œ2022 Pre-Funded Warrantsâ€) to purchase up to 91,730 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the â€œSeries A Warrantsâ€) to purchase up to 168,267 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the â€œSeries B Warrantsâ€ and together with the Series A Warrants, the â€œ2022 Warrantsâ€) to purchase up to 168,267 shares of Common Stock. Â The offering closed on December 9, 2022. Â â€‹Wainwright acted as the sole book-running manager for the Offering. We paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses. Pursuant 82 Table of Contentsto the Underwriting Agreement, we granted Wainwright a 30-day option to purchase up to an additional 25,240 shares of Common Stock and/or Common Warrants to purchase up to an additional 50,480 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 25,240 Series A Warrants and 25,240 Series B Warrants.â€‹We also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the â€œRepresentativeâ€™s Warrantsâ€) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and 2022 Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 10,094 shares of Common Stock.â€‹We received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.â€‹Lincoln Park Stock Purchase AgreementOn August 4, 2023, iBio entered into a purchase agreement, dated as of August 4, 2023 (the â€œPurchase Agreementâ€), with Lincoln Park Capital Fund, LLC (â€œLincoln Parkâ€), pursuant toÂ which, under the terms and subject to the satisfaction of specified conditions set forth therein,Â we may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, we entered into a registration rights agreement, dated as of August 4, 2023 (the â€œRegistration Rights Agreementâ€), with Lincoln Park, pursuant to which we agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by us to Lincoln Park under the Purchase Agreement. Â Â During fiscal year 2024, we sold 202,595 shares of Common Stock under the Purchase Agreement and received approximately $1.3 million in proceeds. No shares remain available for sale under the Purchase Agreement at June 30, 2024.â€‹Alliance Global Partners Securities Purchase Agreementâ€‹On December 7, 2023, the Company closed a public offering (the â€œ2023 Offeringâ€) pursuant to which we sold in the 2023 Offering, (i) 600,000 shares (the â€œSharesâ€) of our Common Stock, (ii) 1,650,000 pre-funded warrants (the â€œ2023 Pre-Funded Warrantsâ€) exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C common warrants (the â€œSeries C Common Warrantsâ€) exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D common warrants (the â€œSeries D Common Warrants,â€ and together with the Series C Common Warrants, the â€œCommon Warrantsâ€) exercisable for an aggregate of 2,250,000 shares of Common Stock. A.G.P./Alliance Global Partners (â€œA.G.P.â€) acted as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC (â€œBrooklineâ€), acted as co-placement agent (A.G.P. and Brookline are referred to herein, collectively, as the â€œPlacement Agentsâ€) for the 2023 Offering. We received approximately $4.5 million in gross proceeds from the 2023 Offering, including the exercise of all 2023 Pre-Funded Warrants and prior to deducting placement agent fees and other estimated offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants.â€‹During fiscal year 2024, 1,650,000 of the 2023 Pre-Funded Warrants, 1,178,500 Series C Common Warrants and 1,053,500 Series D Common Warrants were exercised for proceeds of $4,464,000. In August 2024, 1,000 Series C Common Warrants and 1,000 Series D Common Warrants were exercised for proceeds of $4,000.â€‹Otsuka Asset Purchase Agreementâ€‹On February 25, 2024, we entered into an Asset Purchase Agreement (the â€œPD-1 Purchase Agreementâ€) with Otsuka Pharmaceutical Co., Ltd.(â€œOtsukaâ€) pursuant to which we sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to our early-stage programmed cell death protein 1 (â€œPD-1â€) (the â€œPD-1 Assetsâ€) developed or held for development in consideration of $1,000,000 paid at closing. The PD-1 Purchase Agreement also provides for a potential contingent payment of $2,500,000 upon the achievement of specified 83 Table of Contentsdevelopmental milestones and a second potential contingent payment of $50,000,000 upon the achievement of specified milestones following commercialization. The sale of the PD-1 Assets closed on February 25, 2024. â€‹Chardan Private Placementâ€‹On March 26, 2024, we entered into a securities purchase agreement (the â€œ2024 Purchase Agreementâ€) with several institutional investors and an accredited investor (the â€œPurchasersâ€) for the issuance and sale in a private placement (the â€œPrivate Placementâ€) of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315 shares (the â€œSharesâ€) of Common Stock, (ii) pre-funded warrants (the â€œ2024 Pre-Funded Warrantsâ€) to purchase up to 2,585,963 shares of Common Stock at an exercise price of $0.0001 per share, and (iii) Series E Common Stock purchase warrants (the â€œSeries E Warrantsâ€) to purchase up to 5,287,278 shares of Common Stock at an exercise price of $2.64 per share. The Series E Warrants are exercisable at any time after the six-month anniversary of their issuance (the â€œInitial Exercise Dateâ€) at an exercise price of $2.64 per share and have a term of exercise equal to five years from the date of issuance. The combined purchase price for one share of common stock and the accompanying Series E Warrant was $2.85 and the purchase price for one pre-funded warrant and the accompanying Series E Warrant was $2.849. The 2024 Private Placement closed on April 1, 2024. Â We received net proceeds of approximately $14.1 million from the Private Placement, after deducting estimated offering expenses payable by us, including placement agent fees and expenses.â€‹Our cash, cash equivalents and restricted cash of $14.4 millionÂ as of JuneÂ 30,Â 2024, is not anticipated to be sufficient to support operations through the first quarter of fiscal year 2026,Â unless we reduce our burn rate further, or increase our capital as described above. Our cash burn for the fiscal year 2024 was ($18.6) million or approximately ($1.5) million per month. This rate fluctuates month to month depending on our internal and external research development projects. We will continue to review operational expenses to reduce cash burn and extend our runway. Regardless of whether we are able to reduce our burn rate or sell or out-license certain assets or parts of the business, we will need to raise additional capital through either non-dilutive partnership deals or through the capital markets in order to fully execute our longer-term business plan. It is our goal to implement one or more potential options described herein to allow us to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating. â€‹Net Cash Used in Operating ActivitiesIn fiscal year 2024, net cash used in operating activities was ($18.6) million, compared to net cash used in operating activities of ($30.4) million in 2023.Â The decrease in net cash was primarily used to support our ongoing operations.â€‹Net Cash Provided by Investing ActivitiesIn 2024, net cash provided by investing activities was $0.9 million, which primarily consisted of proceeds from the sale of intellectual property rights to Otsuka of $1 million and proceeds from the sale of fixed assets of $0.1 million, offset by the purchase of fixed assets of $0.2 million. In 2023, our net cash used in investing activities was $7.0 million, which primarily consisted of redemption and sales of debt securities of $10.8 million and the sale of fixed asset of $2.6 million, partially offset by the purchase of ($5.7) million of fixed assets and ($0.7) million for certain assets acquired from RubrYc.â€‹Net Cash Provided by Financing ActivitiesIn 2024, net cash provided by financing activities was $24.5 million, compared to net cash used in financing activities of $2.3 million in 2023.Â Net cash generated from financing activities in 2024 primarily related to proceeds from sales of common stock offset by payments made to settle all obligations related to the term note payable while the net cash spent in 2023 related to proceeds from sales of common stock offset by payments made towards term note payable. Funding RequirementsWe have incurred significant losses and negative cash flows from operations since our spin-off from Integrated BioPharma in AugustÂ 2008. As of JuneÂ 30,Â 2024, our accumulated deficit was approximately ($313.8) million, and we used approximately $6.8 million of net cash in fiscal year 2024.84 Table of ContentsWe plan to fund our future business operations using cash on hand, through proceeds realized in connection with the commercialization of our technologies, through potential proceeds from the sale or out-licensing of assets, and through proceeds from the sale of additional equity or other securities. However, there can be no assurance that we will be successful in implementing these plans, many of which will take several years before we realize proceeds. We cannot be certain that such funding will be available on favorable terms or available at all. If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations.Off-Balance Sheet ArrangementsAs part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of JuneÂ 30,Â 2024, we were not involved in any SPE transactions.Critical Accounting EstimatesA critical accounting policy is one that is both important to the portrayal of a companyâ€™s financial condition and results of operations and requires managementâ€™s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.Our consolidated financial statements are presented in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). All applicable U.S. GAAP accounting standards effective as of JuneÂ 30,Â 2024, have been taken into consideration in preparing the consolidated financial statements. The preparation of consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates.Critical accounting estimates are those estimates made in accordance with U.S. GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on the financial condition or results of operations of the Company. The following accounting estimate had a material impact on the results of operations of the Company for the year ended June 30, 2024.Impairment of Fixed Assets â€‹We monitor fixed assets for impairment indicators throughout the year. Â When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Â Changes in the Companyâ€™s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.On November 3, 2022, we announced we are seeking to divest our contract development and manufacturing organization (iBio CDMO) in order to complete our transformation into an antibody discovery and development company. Through the process of seeking to divest our contract development and manufacturing organization, we entered into a Purchase and Sale Agreement for the Facility. The decision to divest triggered a quantitative impairment analysis of our CDMO fixed assets of the Facility totaling $22.65 million and machinery and equipment totaling $13.4 million.85 Table of ContentsWe utilized a market approach in the second quarter of fiscal year 2023, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility, the machinery and equipment. We recorded an impairment charge of $6.3 million for the facility and $11.3 million for the machinery and equipment in the second quarter of fiscal year 2023. The key assumption in the valuation analysis was the expected sale price of $21.1 million for the Facility and the associated machinery and equipment less approximate costs to sell of $2.7 million. In the first quarter of fiscal year 2024, we entered into an agreement for the sale of the Facility for $17.25 million, and an additional impairment of $0.3 million was recorded in fiscal year 2023 to reflect the agreed upon sales price less estimated costs to sell. The CDMO Equipment was sold during fiscal year 2023. After receiving written notice terminating the sale of the Facility, we continued to reassess the Facility for impairment each quarter utilizing a market approach. The assessments included obtaining independent third-party appraisals based on comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility. During such timeframe, an additional $3.1 million fixed asset impairment was recorded in discontinued operations to write down the carrying value of the Facility to its estimated fair value, as a result of the expected sale price of $13.8 million for the Facility less approximate costs to sell of $0.7 million. During the fourth quarter of fiscal year 2024, the Facility was sold for $8.5 million which resulted in an approximate $4.8 million loss on the disposal of the held-for-sale assets. (See Note 3 â€” Discontinued Operation and Note 5 â€” Financial Instruments for further information.)Impairment of Indefinite-Lived Intangible Assetsâ€‹For indefinite life intangible assets, we perform an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Â Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in our business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.During the fourth quarter of fiscal year 2024, we performed our annual impairment testing of the IBIO-101 therapeutic technology (or â€œIPâ€), classified as an indefinite-lived intangible asset, which had a carrying amount of $5 million at June 30, 2024. We engaged a third party to perform valuation assistance with estimating the fair value of IBIO-101 and preparing a market capitalization reconciliation. The Multi-Period Excess Earnings Method (â€œMPEEMâ€) under the income approach was utilized to value the indefinite-lived asset. The MPEEM determines the value of a specified asset by calculating the present value of future earnings attributed to the asset. Since IBIO-101 is currently in its pre-clinical development phase, a probability of success was applied to the cash flows to account for the probability of reaching each step of development. The MPEEM requires that charges for the use of other contributory assets be subtracted under the theory that the owner of the subject asset does not own the other contributory assets and would have to rent/lease them in order to earn the cash flows related to the subject asset.The resulting probability of success adjusted â€œexcess earningsâ€ were discounted to the present value using a 16% discount rate, which was based on iBioâ€™s weighted average cost of capital. Â The sum of the discounted excess earnings and the present value of the tax benefit related to amortization of the IBIO-101 indefinite-lived intangible indicated that the fair value was $5.9 million as of the June 30, 2024, valuation date. Given that the carrying amount of the asset was $5 million at June 30, 2024, it was concluded that no impairment existed.We will continue to monitor the value of the IP as part of our annual accounting policy for impairment of long-live assets. Â The primary impairment indicators that may arise in the near future are (1) any sustained decline in our common stock market price and (2) FDA decisions on similar competing technologies that are applying for Phase 1 approval.We continue to operate in a highly competitive environment, rising interest rates (and cost of capital) and experience liquidity challenges. Accordingly, we may have to adjust our cash flow projections and valuation assumptions in the near future to account for market trends and any changes to our

research and development plans. Any such future adjustments may lead to material future impairments in the IP and other related assets.86 Table of ContentsOur remaining critical accounting estimates remain consistent with the information disclosed in the same section in our last annual report on Form 10-K for the year ended June 30, 2023.In addition to the aforementioned critical accounting estimates, the following accounting policies and estimates have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our consolidated financial statements:â—revenue recognition;â—legal and contractual contingencies;â—research and development expenses;â—fair value of equity issuance related to debt extinguishment; andâ—share-based compensation expenses.â€‹We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates. See NoteÂ 4 â€“ Summary of Significant Accounting Policies - for a complete discussion of our significant accounting policies and estimates.ItemÂ 7A. Quantitative and Qualitative Disclosures About Market Risk.The information under this ItemÂ is not required to be provided by smaller reporting companies.ItemÂ 8. Financial Statements and Supplementary Data.Financial statements and notes thereto appear on pagesÂ F-1 to F-54 of this Annual Report.ItemÂ 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.None.ItemÂ 9A. Controls and Procedures. Evaluation of Disclosure Controls and ProceduresOur management, under the direction of our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer) have evaluated the effectiveness of our disclosure controls and procedures (as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act, as amended), as of June 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rulesÂ and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Companyâ€™s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Companyâ€™s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of JuneÂ 30,Â 2024.87 Table of ContentsManagementâ€™s Report on Internal Control over Financial Reporting It is the responsibility of the management of iBio to establish and maintain effective internal control over financial reporting (as defined in RuleÂ 13a-15(f)Â under the Exchange Act). Internal control over financial reporting is designed to provide reasonable assurance to iBioâ€™s management and board of directors regarding the preparation of reliable financial statements for external purposes in accordance with generally accepted accounting principles.iBioâ€™s internal control over financial reporting includes those policies and procedures that: (i)Â pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of iBio; (ii)Â provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of iBio are being made only in accordance with authorizations of management and directors of iBio; and (iii)Â provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of iBioâ€™s assets that could have a material effect on the financial statements of iBio.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Management has performed an assessment of the effectiveness of iBioâ€™s internal control over financial reporting as of JuneÂ 30, 2024, based upon criteria set forth in Internal ControlÂ - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO Framework).Based on this assessment, management has concluded that our internal control over financial reporting was effective as of JuneÂ 30,Â 2024.Changes in Internal Control Over Financial Reporting Except as otherwise described herein, there were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹ItemÂ 9B. Other Information. During the three months ended June 30, 2024, no director or officer of the CompanyÂ adoptedÂ orÂ terminatedÂ a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K.â€‹Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.â€‹Not applicableâ€‹PARTÂ IIICertain information required by PartÂ III is omitted from this Annual Report because we intend to file our definitive proxy statement for our 2024 Annual Meeting of Stockholders, pursuant to regulation 14A of the Exchange Act, not later than 120Â days after the end of the fiscalÂ year covered by this Annual Report and certain information to be included in the definitive proxy statement is incorporated herein by reference.ItemÂ 10. Directors, Executive Officers and Corporate GovernanceInformation required by this ItemÂ that will appear under the headings â€œGovernance,â€ â€œExecutive Officers,â€ and â€œDelinquent SectionÂ 16(a)Â Reportsâ€ in the definitive proxy statement to be filed with the SEC relating to our 2024 Annual Meeting of Stockholders is incorporated herein by reference.88 Table of ContentsCode of EthicsWe have adopted a written code of business conduct and ethics, as amended and restated in July 2024, within the meaning of ItemÂ 406 of SEC Regulation S-K, which applies to all of our employees, including our principal executive officer and our chief financial officer, a copy of which is annexed as an exhibit hereto and can be found on our website at www.ibioinc.com. If we make any waivers or substantive amendments to the code of ethics that are applicable to our principal executive officer or our chief financial officer, we will disclose the nature of such waiver or amendment on our internet website at www.ibioinc.com Â in a timely manner.ItemÂ 11. Executive Compensation Information required by this ItemÂ that will appear under the heading â€œExecutive Compensationâ€ and â€œDirector Compensationâ€ in the definitive proxy statement to be filed with the SEC relating to our 2024 Annual Meeting of Stockholders is incorporated herein by reference.ItemÂ 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder MattersInformation required by this ItemÂ that will appear under the headings â€œSecurity Ownership of Certain Beneficial Owners and Managementâ€ and â€œEquity Compensation Plan Informationâ€ in the definitive proxy statement to be filed with the SEC relating to our 2024 Annual Meeting of Stockholders is incorporated herein by reference.ItemÂ 13. Certain Relationships and Related Transactions, and Director IndependenceInformation required by this ItemÂ that will appear under the headings â€œCertain Relationships and Related Transactionsâ€ and â€œIndependence of Boardâ€ in the definitive proxy statement to be filed with the SEC relating to our 2024 Annual Meeting of Stockholders is incorporated herein by reference.ItemÂ 14. Principal Accountant Fees and ServicesInformation required by this ItemÂ that will appear under the heading â€œIndependent Auditor Fees and Other Mattersâ€ in the definitive proxy statement to be filed with the SEC relating to our 2024 Annual Meeting of Stockholders is incorporated herein by reference.â€‹89 Table of ContentsPARTÂ IVItemÂ 15. Exhibits and Financial Statement Schedules. (a)Exhibits and Index(1)A list of the financial statements filed as part of this Annual Report is set forth in the index to financial statements at pageÂ F-1 and is incorporated herein by reference.(2)An exhibit index immediately preceding the signature page hereto is incorporated by reference or filed with this Annual Report is provided below:ItemÂ 16. FormÂ 10-K SummaryNot Applicableâ€‹â€‹Exhibit No.Â Â Â Â Descriptionâ€‹â€‹â€‹1.1â€‹Controlled Equity OfferingSMÂ Sales Agreement, dated as of November 25, 2020, by and between iBio, Inc. and Cantor Fitzgerald & Co. (incorporated herein by reference to Exhibit Number 1.1 to the Companyâ€™s registration statement on Form S-3 (File No. 333-250973) filed by the Company with the Securities and Exchange Commission on November 25, 2020 â€“ Commission File No. 001-35023)â€‹â€‹â€‹1.2â€‹Underwriting Agreement, dated December 6, 2022, by and between iBio, Inc. and H.C. Wainwright & Co., LLC (incorporated herein by reference to the Companyâ€™s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on December 8, 2022 â€“ Commission File No. 001-35023)â€‹â€‹â€‹1.3â€‹Placement Agency Agreement, dated December 5, 2023, by and between iBio, Inc. and A.G.P./Alliance Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC (incorporated herein by reference to Exhibit 1.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023- File No. 001-3502)â€‹â€‹â€‹1.4â€‹At Market Issuance Sales Agreement, dated July 3, 2024, by and among the Company, Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC (Incorporated herein by reference to Exhibit Number 1.1 to the Companyâ€™s registration statement on Form S-3 (File No. 333-280680, as filed with the Securities and Exchange Commission on July 3, 2024)â€‹â€‹â€‹3.1â€‹Certificate of Incorporation of iBio, Inc., Certificate of Merger, Certificate of Ownership and Merger, Certificate of Amendment of the Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on May 11, 2018 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.2â€‹Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q filed by the Company with the Securities and Exchange Commission on February 14, 2018 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.3â€‹Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to the Companyâ€™s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on June 8, 2018 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.4â€‹Certificate of Designation, Preferences and Rights of the iBio CMO Preferred Tracking Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 24, 2017 â€“ Commission File No. 001-35023)90 Table of Contentsâ€‹â€‹â€‹3.5â€‹Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.6â€‹Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.7â€‹Certificate of Designation, Preferences and Rights of the Series C Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2019 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.8â€‹Second Amended and Restated Bylaws of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on August 14, 2009 â€“ Commission File No. 000-53125)â€‹â€‹â€‹3.9â€‹Certificate of Designation of Preferences, Rights and Limitations of Series 2022 Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.10â€‹Certificate of Amendment of the Certificate of Incorporation of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on October 7, 2022 â€“ Commission File No. 001-35023)â€‹â€‹â€‹3.11â€‹Certificate of Amendment of the Certificate of Incorporation if iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 28, 2023 â€“ Commission File No. 001-35023)â€‹â€‹â€‹4.1â€‹Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Form 10-12G filed with the Securities and Exchange Commission on July 11, 2008 â€“ Â Commission File No. 000-53125)â€‹â€‹â€‹4.2â€‹Description of Securities of iBio, Inc. â€‹â€‹â€‹4.3â€‹Term Note of IBIO CDMO LLC (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹4.4â€‹iBio, Inc. Warrant (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹4.5â€‹Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹4.6â€‹Form of Series A Warrants (incorporated herein by reference to Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹4.7â€‹Form of Series B Warrants (incorporated herein by reference to Exhibit 4.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 â€“ Â Commission File No. 001-35023)91 Table of Contentsâ€‹â€‹â€‹4.8â€‹Form of Representativeâ€™s Warrants (incorporated herein by reference to Exhibit 4.4 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2022 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹4.9â€‹Form of Pre-Funded Warrants (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023- File No. 001-35023)â€‹â€‹â€‹4.10â€‹Form of Series C Common Warrants (incorporated herein by reference to Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023- File No. 001-35023)â€‹â€‹â€‹4.11â€‹Form of Series D Common Warrants (incorporated herein by reference to Exhibit 4.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023- File No. 001-35023)â€‹â€‹â€‹4.12â€‹Form of Tail Warrants (incorporated herein by reference to Exhibit 4.4 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 8, 2023- File No. 001-35023)â€‹â€‹â€‹4.13â€‹Form of Pre-Funded Warrants (incorporated herein by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024- File No. 001-35023)â€‹â€‹â€‹4.14â€‹Form of Series E Common Warrants (incorporated herein by reference to Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024- File No. 001-35023)â€‹â€‹â€‹10.1â€‹Technology Transfer Agreement, dated as of January 1, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. as amended (incorporated herein by reference to Exhibit 10.6 to the Companyâ€™s Form 10-12G filed with the Securities and Exchange Commission on June 18, 2008 â€“ Commission File No. 000-53125)â€‹â€‹â€‹10.2+â€‹Ratification dated September 6, 2013 of Terms of Settlement by and between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, filed with the Securities and Exchange Commission on September 30, 2013 â€“ Â Commission File No. 001-35023).Â Â Â Â â€‹â€‹â€‹10.3â€‹Amended and Restated Limited Liability Company Agreement of iBio CDMO LLC, dated January 13, 2016, between the Company, Bryan Capital Investors LLC and iBio CDMO LLC (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 22, 2016 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.4â€‹License Agreement, dated January 13, 2016, between the Company and iBio CDMO LLC (incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 22, 2016 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.5â€‹Amendment No. 1 to the Amended and Restated Limited Liability Company Agreement of iBio CDMO LLC, dated February 23, 2017 (incorporated herein by reference to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹92 Table of Contents10.6â€ â€‹Form of Directors and Officer Indemnification Agreement (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2019 Â â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.7â€ â€‹2018 Omnibus Equity Incentive Plan, effective December 18, 2018 (incorporated herein by reference to Exhibit 10.13 to the Companyâ€™s Annual Report on Form 10-K filed with the Securities and Exchange Commission on August 26, 2019 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.8â€ â€‹Amended and Restated 2018 Omnibus Equity Incentive Plan, effective December 18, 2018 (incorporated herein by reference to Appendix B to the Companyâ€™s Definitive Proxy Statement filed with the Securities and Exchange Commission on January 23, 2020 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.9â€ â€‹iBio, Inc. 2020 Omnibus Equity Incentive Plan (incorporated by reference to Appendix B to the Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 3, 2020 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.10â€ â€‹FormÂ of Non-Qualified Stock Option Agreement for Employees under the iBio,Â Inc. 2020 Omnibus Incentive Plan Â (incorporated herein by reference to Exhibit 10.2 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 â€“ Commission File No. 333-252027)â€‹â€‹â€‹10.11â€ â€‹FormÂ of Non-Qualified Stock Option Agreement for Non-Employee Directors (Initial Grant) under the iBio,Â Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 â€“ Commission File No. 333-252027)â€‹â€‹â€‹10.12â€ â€‹FormÂ of Non-Qualified Stock Option Agreement for Non-Employee Directors (Annual Grant) under the iBio,Â Inc. 2020 Omnibus Incentive Plan (incorporated

herein by reference to Exhibit 10.4 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 â€“ Commission File No. 333-252027)â€‹â€‹â€‹10.13â€ â€‹FormÂ of Restricted Stock Unit Award Agreement for Employees under the iBio,Â Inc. 2020 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 â€“ Commission File No. 333-252027)â€‹â€‹â€‹10.14â€ â€‹FormÂ of Restricted Stock Unit Award Agreement for Employees under the iBio,Â Inc. 2018 Omnibus Equity Incentive Plan, as amended and restated (incorporated herein by reference to Exhibit 10.2 to the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission on January 11, 2021 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.15â€ â€‹Director Offer Letter (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on June 9, 2021 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.16++**â€‹Collaboration, Option and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.17++**â€‹Collaboration and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021â€“ Commission File No. 001-35023).93 Table of Contentsâ€‹â€‹â€‹10.18++**â€‹Stock Purchase Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.19++**â€‹Second Amended and Restated Investor Rights Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.20++**â€‹Second Amended and Restated Voting Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors(incorporated herein by reference to Exhibit 10.5 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.21++**â€‹Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors(incorporated herein by reference to Exhibit 10.6 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2021â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.22++â€‹Employment Agreement dated December 23, 2020 and effective as of January 18, 2021, by and between iBio, Inc. and Martin B. Brenner (incorporated herein by reference to Exhibit 10.20 to the Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on September 28, 2021 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.23â€‹Confidential Settlement and Mutual Release with Fraunhofer USA, Inc. dated May 4, 2021 (incorporated herein by reference to Exhibit 10.31 to the Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on September 28, 2021 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.24â€‹Purchase and Sale Agreement, dated November 1, 2021, by and among College Station Investors LLC, Bryan Capital Investors LLC, iBio CDMO LLC and iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.25â€‹Equity Purchase Agreement dated November 1, 2021 by and between Bryan Capital Investors LLC and iBio, Inc. (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.26â€‹Credit Agreement, dated November 1, 2021 by and, between iBio CDMO LLC with Woodforest National Bank (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.27â€‹Guaranty Agreement, dated November 1, 2021, by iBio, Inc. for the benefit of Woodforest National Bank(incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.28â€‹Leasehold Deed of Trust, Assignment of Leases and Rents, Security Agreement and UCC Financing Statement for Fixture Filing by iBio CDMO LLC as grantor to the trustee for the benefit of Woodforest National Bank (incorporated herein by reference to Exhibit 10.5 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)94 Table of Contentsâ€‹â€‹â€‹10.29â€‹Security Agreement, dated November 1, 2021 by iBio CDMO LLC for the benefit of Woodforest National Bank(incorporated herein by reference to Exhibit 10.6 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.30â€‹Environmental Indemnity Agreement, dated November 1, 2021 by iBio CDMO LLC and iBio, Inc. in favor of Woodforest National Bank (incorporated herein by reference to Exhibit 10.7 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Â Commission File No. 001-35023)â€‹â€‹â€‹10.31â€‹Ground Lease Agreement (included as Exhibit A to The Purchase and Sale Agreement, dated November 1, 2021 by and among College Station Investors LLC, Bryan Capital Investors LLC, iBio CDMO LLC and iBio, Inc. filed as Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 4, 2021 â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.32â€‹Form of Stock Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 â€“ File No. 001-35023)â€‹â€‹â€‹10.33â€‹Form of Irrevocable Proxy for Voting Control (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 â€“ File No. 001-35023)â€‹â€‹â€‹10.34â€‹Third Amendment to Exclusive License Agreement, dated February 3, 2022, by and between University of Pittsburgh and iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2022â€“ Commission File No. 001-35023)â€‹â€‹â€‹10.35â€‹Asset Purchase Agreement dated September 16, 2022, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2022 â€“ File No. 001-35023)â€‹â€‹â€‹10.36*++â€‹First Amendment to Credit Agreement entered into as of October 11, 2022, by and between iBio CDMO LLC with Woodforest National Bank (incorporated herein by reference to Exhibit 10.51 to the Companyâ€™s Annual Report on Form 10-K filed with the Securities and Exchange Commission on October 11, 2022â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.37â€‹Termination Agreement and Release dated September 19, 2022, by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 â€“ File No. 001-35023)â€‹â€‹â€‹10.38â€‹Lease dated September 10, 2021, by and between iBio, Inc., and San Diego Inspire 4, LLC (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 â€“ File No. 001-35023)â€‹â€‹â€‹10.39â€ â€‹Restricted Stock Unit Award Agreement dated November 10, 2022, by and between iBio, Inc. and Thomas Isett (incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022 â€“ File No. 001-35023)â€‹â€‹â€‹10.40â€ â€‹Separation Agreement and General Release, dated December 1, 2022, by and between iBio, Inc. and Thomas Isett (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2022, â€“File No. 001-35023)â€‹â€‹â€‹95 Table of Contents10.41â€ â€‹Offer Letter by and between iBio, Inc. and Felipe Duran dated January 23, 2023 (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.42â€‹Second Amendment to Credit Agreement dated February 9, 2023, by and between iBio, Inc. and Woodforest National Bank (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.43â€ â€‹Special Incentive Bonus Agreement dated January 26, 2023, by and between iBio, Inc. and Martin Brenner (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.44â€ â€‹Special Incentive Bonus Agreement dated January 26, 2023, by and between iBio, Inc. and Felipe Duran (incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.45â€‹Third Amendment to Credit Agreement dated February 21, 2023 between iBio CDMO LLC and Woodforest National Bank and Third Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2023 â€“ File No. 000 35023)â€‹â€‹â€‹10.46â€‹Fourth Amendment to Credit Agreement dated March 24, 2023, between iBio CDMO LLC and Woodforest National Bank and Fourth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2023 â€“ File No. 000 35023)â€‹â€‹â€‹10.47â€‹Auction Sale Agreement between iBio, Inc. and Holland Industrial Group, Federal Equipment Company and Capital Recovery Group LLC dated as of February 10, 2023 (incorporated herein by reference to Exhibit 10.7 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.48â€‹Fifth Amendment to the Credit Agreement dated May 10, 2023, between iBio CDMO LLC and Woodforest National Bank and Fifth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.8 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.49â€‹Purchase Agreement by and between the Registrant and Lincoln Park Capital Fund, LLC, dated August 4, 2023 (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2023â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.50â€‹Registration Rights Agreement by and between the Registrant and Lincoln Park Capital Fund, LLC, dated August 4, 2023 (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2023â€“ Commission File No. 001-35023).â€‹â€‹â€‹10.51â€‹Purchase and Sale Agreement, dated as of September 15, 2023 by and between MAJESTIC REALTY CO., a California corporation and IBIO CDMO LLC (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹96 Table of Contents10.52â€‹Sixth Amendment to the Credit Agreement dated September 18, 2023 between iBio CDMO LLC and Woodforest National Bank Â (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2023 â€“ File No. 001-35023).â€‹â€‹â€‹10.53â€‹Seventh Amendment to the Credit Agreement dated October 4, 2023 between iBio CDMO LLC and Woodforest National Bank and Fifth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 10, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.54â€‹Form of Securities Purchase Agreement, dated December 5, 2023, between iBio, Inc. and the purchasers named on the signature pages thereto (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.55â€‹iBio Inc. 2023 Omnibus Incentive Plan Â (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 28, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.56â€‹Eighth Amendment to Credit Agreement dated December 22, 2023 between iBio CDMO LLC and Woodforest National Bank (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 26, 2023 â€“ File No. 001-35023)â€‹â€‹â€‹10.57â€‹Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC Â (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.58â€‹Schedule to Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.59â€‹Term Promissory Note, dated January 16, 2024, in the principal amount of $1,071,572 (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.60â€‹Validity Guarantee, dated January 16, 2024 (incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Current Report on Form 8 - K filed with the Securities and Exchange Commission on January 19, 2024 - File No. 001 - 35023)â€‹â€‹â€‹10.61â€‹Asset Purchase Agreement, dated February 25, 2024, by and between iBio, Inc. and Otsuka Pharmaceutical Co., Ltd. (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.62â€‹Form of Securities Purchase Agreement, dated March 26, 2024, by and between iBio, Inc. and the Purchaser signatory thereto* (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.63â€‹Side Letter Agreement dated April 1, 2024 (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹97 Table of Contents10.64â€‹Ninth Amendment to Credit Agreement dated March 28, 2024, between iBio CDMO LLC and Woodforest National Bank (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.65â€‹iBio, Inc. Officer Severance Benefit Plan, effective May 9, 2024 (incorporated herein by reference to Exhibit 10.9 to the Companyâ€™s Current Report on Form 10-K filed with the Securities and Exchange Commission on May 13, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.66â€‹Purchase and Sale Agreement, dated as of May 17, 2024, by and between iBio CDMO LLC Â and The Board of Regents of the Texas A&M University System (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.67â€‹Settlement Agreement and Mutual Release, dated May 17, 2024, by and among Woodforest National Bank, iBio CDMO LLC and the Company (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.68â€‹Tenth Amendment to Credit Agreement dated May 14, 2024, between iBio CDMO LLC and Woodforest National Bank (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.69â€‹Form of Non-Qualified Stock Option Agreement for initial grants for non-employee directors under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.70â€‹Form of Non- Qualified Stock Option Agreement for non-employee consultants under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.71â€‹Form of Non-Qualified Stock Option Agreement for annual grants for non-employee directors under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.72â€‹Form of Non-Qualified Stock Option Agreement for employees under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.73â€‹Form of Restricted Stock Unit Award Agreement for employees under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.74â€‹Form of Incentive Stock Option Agreement for employees under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹10.75â€‹Form of Incentive Stock Option Agreement for officers under the iBio Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹98 Table of Contents10.76â€‹Amended and Restated Employment Agreement, dated as of JulyÂ 23,Â 2024, effective as of JulyÂ 1,Â 2024, by and between the Company and Martin Brenner (incorporated herein by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on JulyÂ 26,Â 2024 â€“ File No.001-35023)â€‹â€‹â€‹14.1â€‹Code of Business Conduct and Ethics (incorporated herein by reference to Exhibit 14.1 to the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 9, 2024 â€“ File No. 001-35023)â€‹â€‹â€‹19.1*â€‹Insider Trading Policyâ€‹â€‹â€‹21.1*â€‹Subsidiaries of Registrantâ€‹â€‹â€‹23.1*â€‹Consent of the Independent Registered Public Accounting Firmâ€‹â€‹â€‹31.1*â€‹Certification of Periodic Report by Principal Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section

302 of the Sarbanes-Oxley Act of 2002â€‹â€‹â€‹31.2*â€‹Certification of Periodic Report by Principal Financial Officer and Principal Accounting Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002â€‹â€‹â€‹32.1*â€‹Certification of Periodic Report by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002â€‹â€‹â€‹32.2*â€‹Certification of Periodic Report by Principal Financial Officer and Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002â€‹â€‹â€‹97.1*â€‹Clawback Policy, dated November 20, 2023â€‹101.INSÂ Inline XBRL Instance Document*101.SCHÂ Inline XBRL Taxonomy Extension Schema Document *101.CALÂ Inline XBRL Taxonomy Extension Calculation Linkbase Document *101.DEFÂ Inline XBRL Taxonomy Extension Definition Linkbase Document *101.LABÂ Inline XBRL Taxonomy Extension Label Linkbase Document *101.PREÂ Inline XBRL Taxonomy Extension Presentation Linkbase Document *â€‹Â *Filed herewith.â€ Management contract or compensatory plan or arrangement required to be identified pursuant to ItemÂ 15(a)(3)Â of this Annual Report.+Certain portions of this exhibit have been omitted subject to a confidential treatment request.++Certain portions of this exhibit indicated therein by [**] have been omitted in accordance with Item 601(b)(10) of Regulation S-K. The Company agrees to furnish unredacted copies of these Exhibits to the SEC upon request.â€·*Â *Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule upon request.â€‹99 Table of ContentsSIGNATURESPursuant to the requirements of SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â iBio,Â Inc.Â (Registrant)Â Â Dated:Â September 20, 2024/s/ Martin BrennerÂ Martin BrennerÂ Chief Executive Officer Â Â Â /s/ Felipe DuranÂ Felipe DuranChief Financial OfficerÂ (Principal Financial Officer and Principal Accounting Officer)â€‹Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated: NameÂ TitleÂ DateÂ Â Â Â Â /s/ Martin BrennerÂ Chief Executive Â September 20, 2024Martin BrennerÂ Officer and Chief Scientific Officer (Principal Executive Officer)Â Â Â Â Â Â Â /s/ Felipe DuranÂ Chief Financial Officer Â September 20, 2024Felipe DuranÂ Officer (Principal Financial Officer and Principal Accounting Officer)Â Â â€‹â€‹â€‹â€‹â€‹/s/Alexandra Kropotovaâ€‹Directorâ€‹September 20, 2024Alexandra Kropotovaâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/William Clarkâ€‹Chairman of the Boardâ€‹September 20, 2024William Clarkâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/Evert Schimmelpenninkâ€‹Directorâ€‹September 20, 2024Evert Schimmelpenninkâ€‹â€‹â€‹â€‹Â Â Â Â Â /s/James T. HillÂ DirectorÂ September 20, 2024General James T. Hill, USA (Retired)Â Â Â Â Â Â Â Â /s/Gary Senderâ€‹Directorâ€‹September 20, 2024Gary SenderÂ Â Â Â â€‹â€‹â€‹100 Table of ContentsAnnual Financial StatementsiBio,Â Inc.Financial Statement IndexÂ PageReport of Independent Registered Public Accounting Firm - (Grassi & Co., CPAs, P.C., Jericho, NY PCAOB firm ID 606)F-2Financial Statements:â€‹Consolidated Balance SheetsÂ â€“ JuneÂ 30, 2024 and 2023F-5Consolidated Statements of Operations and Comprehensive LossÂ â€“ FiscalÂ years ended JuneÂ 30, 2024 and 2023F-6Consolidated Statements of Stockholdersâ€™ EquityÂ â€“ FiscalÂ years ended JuneÂ 30, 2024 and 2023F-7Consolidated Statements of Cash FlowsÂ â€“ FiscalÂ years ended JuneÂ 30, 2024 and 2023F-8NotesÂ to Consolidated Financial StatementsF-10â€‹â€‹â€‹â€‹F-1 Table of ContentsReport of Independent Registered Public Accounting FirmTo the Board of Directors andStockholders of iBio, Inc. and Subsidiaries Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of iBio, Inc. and Subsidiaries (the â€œCompanyâ€) as of June 30, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, stockholdersâ€™ equity, and cash flows for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the â€œConsolidated financial statementsâ€). In our opinion, the consolidated financial statements Â present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.Substantial Doubt about the Companyâ€™s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred losses since inception, accumulated deficit and has negative cash flows from operations, that raise substantial doubt about its ability to continue as a going concern. Managementâ€™s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for OpinionThese consolidated financial statements are the responsibility of the Companyâ€™s management. Our responsibility is to express an opinion on the Companyâ€™s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Companyâ€™s internal control over financial reporting. Accordingly, we express no such opinion.Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.Critical Audit MattersThe critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.Impairment of Indefinite-Lived AssetAs disclosed in Note 6 and 12 to the consolidated financial statements, the Company acquired an Indefinite-Lived Asset from RubrYc as part of the RubrYcâ€™s Stock Purchase and Asset Acquisition. The RubrYc Indefinite-Lived Asset as fiscal year-end June 30, 2024 and 2023 is $5 million. Â The Company Indefinite-Lived intangible Asset is assessed for impairment annually and/or upon the occurrence of a triggering event. The impairment test for indefinite-lived intangible assets F-2 Table of Contentsconsists of comparing the fair value, which is estimated using the Income Approach-Multi Period Excess Earning Model, to its carrying value. If the carrying value exceeds the fair value, an impairment loss is recognized in an amount equal to such excess. The determination of the fair value is primarily based on discounted future cash flows projected to be generated from the indefinite-lived intangible assets, including the estimates of future revenue, future development costs, the probability of success in various phases of development programs, and potential post-launch cash flows. Changes in these assumptions could have a significant impact on either the fair value, the amount of any impairment charges, or both. Significant judgment is exercised by management when developing the fair value measurement of the indefinite-lived intangible assets. Given these factors, the related audit effort in evaluating managementâ€™s judgments of the fair value of the indefinite-lived intangible assets was challenging, subjective, and complex and required a high degree of auditor judgment.How the Critical Audit Matter was addressed in the AuditOur principal audit procedures related to the Companyâ€™s financial reporting relating to potential impairment of the asset included, among others:â—We audited managementâ€™s process for developing the fair value of the Indefinite-Lived Asset. Our procedures entailed testing managementâ€™s process for estimating the fair value of intangible assets, which included evaluating the appropriateness of the valuation methods and estimates made by management in developing the prospective financial information (â€œPFIâ€) utilized in the underlying data of the valuation model. Â We performed audit procedures over managementâ€™s PFI, which entailed significant assumptions related to future revenue, future development costs, and the probability of success in various phases of development programs as well as post launch cash flows. In evaluating managementâ€™s significant assumptions for reasonableness, we considered comparative data from external markets, comparable industry and guideline public companiesâ€™ data. Â â—We involved our Valuation Specialists to assist in testing the Companyâ€™s methodology and significant assumptions utilized in the Companyâ€™s impairment assessment. Which entail procedures evaluating the following assumptions (1) Income Approach-Multi Period Excess Earning Model (2) Market Capitalization (2) Tax rate (3) Discount Rate/Weighted Average Cost of Capital. Moreover, our valuation specialists performed sensitivity analyses over the significant assumptions including royalty rate to evaluate the Companyâ€™s estimated the fair value in comparison to the carrying value for reasonableness and assessed the qualifications and competence of management and the third-party specialistValuation of Woodforest Pre-Funded WarrantsAs discussed in Notes 3 and 14 to the consolidated financial statements, On May 17, 2024 the Company and Woodforest entered into a Settlement Agreement and Mutual Release (â€œThe May 2024 Debt Settlementâ€) for the Companyâ€™s debt obligation to Woodforest under the November 1, 2021 Credit Agreement. As part of the May 2024 Debt Settlement, the Company issued Pre-Funded Warrants (â€œWoodforest Settlement Warrantsâ€) to Woodforest to purchase 1,560,570 shares of its common stock. The Woodforest Settlement Warrants met the criteria to be equity-classified. The Company, with the assistance of a third party valuation specialist, estimated the fair values of the Woodforest Settlement Warrants. â€‹Such valuation models required significant assumptions. The Companyâ€™s valuation specialist used a Geometric Brownian Motion based Monte Carlo simulation to project the underlying metric value to ultimately determine the fair value of the warrants. The fair value of the pre-funded warrants was $3.7 million. The Monte-Carlo simulation pricing model fair valued the warrants utilizing assumptions of Stock Price, Dividend Yield, Expected Volatility, Risk-free Interest Rate and Fundamental Transaction Probabilities.Our audit procedures over the warrant valuation included, amongst others:â—We agreed Pre-Funded Warrants grants agreements and tested the Company prepared schedule for completeness and accuracy.â—We obtained an understanding and performed audit procedures over the factors considered and assumptions made by management and the Companyâ€™s valuation specialist in developing the estimate of the stock price volatility, the sources of data relevant to these factors and assumptions and the procedures used to obtain the data and the methods used to calculate the estimates.F-3 Table of Contentsâ—We evaluated the methodologies and significant assumptions (1) Stock Price (2) Dividend Yield (3) Releveled Equity Volatility of Guideline Public Companies (4) Risk-free Interest Rate used to determine the fair values of the Pre-Funded Warrants.â—With the assistance of our valuation specialists, we evaluated the reasonableness of the valuation methodology ensuring the inputs to the valuations were reasonable for the methodology, assessed the qualifications, competence of management and their third-party specialist.â€‹/s/ GRASSI & Co., CPAs, P.C.â€‹We have served as the Companyâ€™s auditor since 2024.â€‹Jericho, New Yorkâ€‹September 19, 2024â€‹â€‹â€‹â€‹â€‹F-4 Table of ContentsiBio,Â Inc. and SubsidiariesConsolidated Balance Sheets (In Thousands, except share and per share amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

(24,907)Balance as of JuneÂ 30,Â 2024â€‹â€‹ â€”â€‹ â€”â€‹ 8,624â€‹ 9â€‹ 335,162â€‹ â€”â€‹ (313,847)â€‹ 21,324â€‹â€‹â€‹

Contentsâ€‹3.Â Â Â Â Discontinued OperationsOn November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, on February 10, 2023, the Company entered into an Auction Sale Agreement (the â€œAuction Sale Agreementâ€) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the â€œAuctioneersâ€) for the sale at public auction of equipment and other tangible personal property (the â€œEquipmentâ€) located at the Facility. The Auctioneers guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Groupâ€™s $0.2 million fee. Â Total proceeds received in fiscal year 2023 were approximately $2.6 million. On May 17, 2024, iBio CDMO entered into a purchase and sale agreement, dated as of May 17, 2024 (the â€œ2024 Purchase and Sale Agreementâ€) with The Board of Regents of the Texas A&M University System (â€œThe Board of Regentsâ€) pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property.Additionally, on May 17, 2024, iBio CDMO, the Company and Woodforest entered into a Settlement Agreement and Mutual Release (the â€œSettlement Agreementâ€) which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the 2024 Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the â€œIndebtedness Deficiency Amountâ€) and thereafter the Company issued to Woodforest a pre-funded warrant (â€œPre-Funded Warrantâ€). Â (See Note 14 â€“ Debt for more information.)On May 31, 2024, in accordance with the terms of the Settlement Agreement in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share.Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.â€‹The Company incurred pre-tax charges of approximately $1.9 million in fiscal year 2023 for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remained employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The Company further recorded a charge in discontinued operations for approximately $35.7 million in fiscal year 2023, of which approximately $17.9 million was the result of a fixed asset impairment charge (see Note 11 â€“ Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance, approximately $0.9 million of interest related to the term note payable, and the balance related to operational costs related to winding down the CDMO business.â€‹During fiscal year 2024, the Company recorded an additional fixed asset impairment charge of $3.1 million, a loss on the sale of the Facility of approximately $4.8 million and a gain on the extinguishment of debt of approximately $0.8 million F-14 Table of Contentsin discontinued operations. (See Note 5 â€“ Financial Instruments, Note 11 â€“ Fixed Assets and Note 14 â€“ Debt for more information.)â€‹The results of iBio CDMO's operations are reported as discontinued operations for the years ended June 30, 2024 and 2023. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intended to sell are classified as â€œheld for saleâ€ on the consolidated balance sheets as of June 30, 2024 and 2023. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statements of cash flows. Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company's continuing operations.â€‹The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Years Ended June 30,â€‹â€‹2024â€‹2023Revenuesâ€‹$ â€”â€‹$ 391Cost of goods soldâ€‹â€‹ â€”â€‹â€‹ 52Gross profitâ€‹â€‹ â€”â€‹â€‹ 339Operating expenses:â€‹â€‹â€‹â€‹â€‹â€‹â€‹ Research and developmentâ€‹â€‹ â€”â€‹â€‹ 6,344 General and administrativeâ€‹â€‹ 1,207â€‹â€‹ 6,751 Fixed asset impairmentsâ€‹â€‹ 3,100â€‹â€‹ 17,900 Loss (gain) on sale of fixed assetsâ€‹â€‹ 4,816â€‹â€‹ (773) Inventory reserveâ€‹â€‹ â€”â€‹â€‹ 4,915Total operating expensesâ€‹â€‹ 9,123â€‹â€‹ 35,137â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Other income (expenses):â€‹â€‹â€‹â€‹â€‹â€‹â€‹ Interest expense - term note payableâ€‹â€‹ (1,149)â€‹â€‹ (900) Gain on extinguishment of debtâ€‹â€‹ 808â€‹â€‹ â€” Otherâ€‹â€‹ â€”â€‹â€‹ (1)Total other expensesâ€‹â€‹ (341)â€‹â€‹ (901)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Loss from discontinued operationsâ€‹$ (9,464)â€‹$ (35,699)â€‹The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹June 30,â€‹â€‹2024â€‹2023Current assets:â€‹â€‹â€‹â€‹â€‹â€‹ Operating lease right-of-use assetsâ€‹$ -â€‹$ 1,941 Property and equipment, netâ€‹â€‹ -â€‹â€‹ 16,124Total current assetsâ€‹$ -â€‹$ 18,065â€‹â€‹â€‹â€‹â€‹â€‹â€‹Current liabilities:â€‹â€‹â€‹â€‹â€‹â€‹ Operating lease obligationâ€‹$ -â€‹$ 1,941Total current liabilitiesâ€‹$ -â€‹$ 1,941â€‹â€‹F-15 Table of ContentsThe following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Years Ended June 30,â€‹â€‹2024â€‹2023Depreciation expenseâ€‹$ â€”â€‹$ 273Amortization of finance lease right-of-use assetsâ€‹â€‹ â€”â€‹â€‹ 20Purchase of fixed assetsâ€‹â€‹ â€”â€‹â€‹ 1,542Fixed asset impairmentsâ€‹â€‹ 3,100â€‹â€‹ 17,900Loss on sale of fixed assetsâ€‹â€‹ 4,817â€‹â€‹ â€”Gain on extinguishment of debtâ€‹â€‹ (808)â€‹â€‹ â€”Payments of term note payableâ€‹â€‹ (1,513)â€‹â€‹ â€”Inventory reserveâ€‹â€‹ â€”â€‹â€‹ 4,915Sales proceeds of fixed assetsâ€‹â€‹ 50â€‹â€‹ 2,600Payment of finance lease obligationâ€‹â€‹ â€”â€‹â€‹ 17Investing non-cash transactions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹ Fixed assets included in accounts payable in prior period, paid in current periodâ€‹â€‹ â€”â€‹â€‹ 1,542â€‹â€‹â€‹â€‹â€‹â€‹â€‹Supplemental cash flow information:â€‹â€‹â€‹â€‹â€‹â€‹ Cash paid during the period for interestâ€‹â€‹ 577â€‹â€‹ 603â€‹â€‹4.Â Â Â Â Summary of Significant Accounting PoliciesUse of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued to related to the extinguishment of the Term Loan, and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.Accounts ReceivableAccounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Managementâ€™s policy is to write off accounts receivable against the allowance for credit losses when a balance is determined to be uncollectible. At JuneÂ 30, 2024 and 2023, the Company determined that an allowance for credit losses was not needed. The Company had accounts receivable of $1 million at June 30, 2022.Subscription ReceivableThe Company accounts for any subscription receivable as a current asset. Subscription receivables represent funds related to the sale of Common Stock in which the funds have not yet been delivered to the Company. The funds are generally held in escrow on behalf of the Company and are delivered within a few days. Â â€‹F-16 Table of ContentsRevenue RecognitionThe Company accounts for its revenue recognition under Accounting Standards Codification (â€œASCâ€) 606, Revenue from Contracts with Customers. A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each partyâ€™s rights regarding the distinct goods or services to be transferred (â€œperformance obligationsâ€), (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company recognizes revenue when it satisfies its performance obligations by transferring control of a promised good or service to the customer. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.The Company analyzes its contracts to determine whether the elements can be separately identifiable and accounted for individually or as a bundle of goods or services. Allocation of revenue to individual elements that qualify for performance obligations is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At JuneÂ 30, 2024 and 2023, the Company had no credit loss provisions.The Company generates contract revenue under the following types of contracts: Fixed-FeeUnder a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.Revenue can be recognized either 1) over time or 2) at a point in time. Â Revenue reported in discontinued operation was recognized at a point in time for all periods presented. Collaborations/PartnershipsThe Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Companyâ€™s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. Â The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (â€œASC 808â€). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (â€œASC 606â€).Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.F-17 Table of ContentsFor the years ended June 30,Â 2024, revenue in the amount of $225,000 was recognized from research activities performed and a non-refundable upfront license fee for which performance obligations were satisfied. No revenue was recognized for the year ended June 30, 2023.Contract AssetsA contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2024 and 2023, contract assets were $0.Contract LiabilitiesA contract liability is an entityâ€™s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customerâ€™s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. Â Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2024, 2023 and 2022, contract liabilities were $200,000, $0 and $100,000, respectively. The Company recognized revenue of $0 in 2024 that was included in the contract liabilities balance as of June 30, 2023 and $100,000 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. Â LeasesThe Company accounts for leases under the guidance of ASC 842, Leases. The standard established a right-of-use (â€œROUâ€) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Companyâ€™s balance sheet, resulting in an increase in noncurrent assets and both current and noncurrent liabilities.In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Companyâ€™s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Companyâ€™s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Companyâ€™s incremental borrowing rate requires judgement. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. F-18 Table of ContentsAn option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2024 and 2023 consisted of money market accounts. Restricted cash at June 30, 2024 consists of a letter of credit obtained related to the San Diego operating lease (see Note 16 â€“ Operating Lease Obligations) and a Company purchasing card. The Companyâ€™s bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Â Restricted cash was $215,000 and $253,000 June 30, 2024 and 2023, respectively. The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹June 30,â€‹â€‹2024â€‹2023Cash and equivalentsâ€‹$ 14,210â€‹$ 4,301Collateral held for letter of credit - term note payableâ€‹â€‹ â€”â€‹â€‹ 3,025Collateral held for letter of credit - San Diego leaseâ€‹â€‹ 198â€‹â€‹ 198Collateral held for Company purchasing cardâ€‹â€‹ 17â€‹â€‹ 55Total cash, cash equivalents and restricted cashâ€‹$ 14,425â€‹$ 7,579â€‹Investments in Debt Securities Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. Â The Company held no investments in debt securities at June 30, 2024 and 2023.InventoryInventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held no inventory at June 30, 2024 and 2023.Research and DevelopmentThe Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (â€œFASBâ€) ASC 730-10, â€œResearch and Developmentâ€ (â€œASC 730-10â€). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expenses were reported in continuing operations for the year ended June 30, 2024. No research and development expenses were reported in discontinued operations for the year ended June 30, 2024. For the year ended June 30, 2023, research and development expenses were

reported in both continuing and discontinuing operations.Right-of-Use AssetsAssets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.F-19 Table of ContentsFixed AssetsFixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to thirty-nine years.The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Companyâ€™s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.See Note 11 â€“ Fixed Assets for additional information.Intangible AssetsIdentifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Companyâ€™s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.See Note 12 â€“ Intangible Assets for additional information.Share-based CompensationThe Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.The impact that share-based payment awards will have on the Companyâ€™s results of operations is a function of the number of shares awarded, the trading price of the Companyâ€™s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Companyâ€™s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. â€‹Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting F-20 Table of Contentsschedules and the Companyâ€™s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 â€“ Share-Based Compensation for additional information.â€‹Income TaxesIncome taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in theÂ years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of JuneÂ 30, 2024 and 2023. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023.Concentrations of Credit RiskCashThe Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At JuneÂ 30, 2024 and 2023, amounts in excess of insured limits were approximately $664,000 and $6,900,000, respectively.RevenueDuring the fiscal year ended June 30, 2024, the Company reported revenue of $225,000 in continuing operations from two research collaborators and $0 of its revenue from discontinued operations. During the fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers.Recently Issued Accounting PronouncementsIn June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (â€œASU 2016-13â€), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Companyâ€™s consolidated financial statements.In October 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-06, â€œDisclosure Improvements: Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiativeâ€ (â€œASU 2023-06â€). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification (â€œASCâ€). F-21 Table of ContentsThe amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SECâ€™s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SECâ€™s regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): â€œImprovements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€) to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Companyâ€™s 2024 fiscal year annual reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.In December 2023, the FASB issued ASU 2023-09,Â â€œImprovements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€) to enhance the transparency and decision-usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. This ASU applies to all entities subject to income taxes. This ASU will be effective for public companies for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.â€‹â€‹â€‹â€‹â€‹5. Â Financial Instruments and Fair Value MeasurementThe carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Companyâ€™s consolidated balance sheets approximated their fair values as of June 30, 2024 and 2023 due to their short-term nature. The carrying value of the promissory note receivable, term promissory note, equipment financing payable, insurance financing payable and finance lease obligations approximated fair value as of June 30, 2024 and 2023 as the interest rates related to the financial instruments approximated market.The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value:â€¢Level 1 â€“ Quoted prices in active markets for identical assets or liabilities.â€¢Level 2 â€“ Quoted prices for similar assets and liabilities in active markets or inputs that are observable.â€¢Level 3 â€“ Inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).The Company initially marketed the CDMO business and during the second quarter of fiscal year 2023, changed its strategy to selling the stand-alone CDMO assets. These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. In the second quarter of fiscal year 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6.3 million and $11.3 million for the Facility and equipment, respectively, reducing their estimated fair values to $16.35 million and $2.1 million, respectively. In the first quarter of fiscal year 2024, the Company entered into an agreement for the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of fiscal year 2023 to reflect the agreed upon sales price less estimated costs to sell. The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. F-22 Table of ContentsOn November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. Upon receiving the termination notice, the Company reassessed the CDMO fixed assets for impairment which included obtaining appraisal values as of November 9, 2023. The Company utilized a market approach, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and concluded that fair value of the assets approximated their carrying value and no further impairment was required at that time. The CDMO Equipment was sold during the third quarter of fiscal year 2023.During the second quarter of fiscal year 2024, the Company made the decision to auction the Facility. The Company utilized a market approach, including comparable assets, to estimate the fair value of the Facility. An additional $3.1 million fixed asset impairment was recorded the second quarter of Fiscal 2024 in discontinued operations to write down the carrying value of the Facility to fair value.During the third quarter of fiscal year 2024, the Company utilized a market approach, using an independent third-party appraisal, including comparable assets, in addition the Company considered previous bids from prospective buyers and the nearing maturity date of the term note and concluded that fair value of the assets approximated their carrying value and no further impairment was required.During the fourth quarter of fiscal year 2024, the Company entered the 2024 Purchase and Sale Agreement with The Board of Regents pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property for $8,500,000. The transaction closed on May 31, 2024 and, in accordance with ASC 360-10-40-5, Property, Plant, and Equipment, an approximate $4.8 million loss was recorded in discontinued operations upon the derecognition of the current assets held-for-sale.â€‹6. Significant TransactionsAffiliates of Eastern Capital LimitedOn November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (â€œiBio CDMOâ€, and collectively with the Company, the â€œPurchaserâ€) entered into a series of agreements (the â€œTransactionâ€) with College Station Investors LLC (â€œCollege Stationâ€), and Bryan Capital Investors LLC (â€œBryan Capitalâ€ and, collectively with College Station, â€œSellerâ€), each affiliates of Eastern Capital Limited (â€œEastern,â€ a former significant stockholder of the Company) whereby in exchange for a certain cash payment and a warrant the Company:(i)acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facilityâ€™s ground lease;(ii)acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and(iii)otherwise terminated all agreements between the Company and the affiliates of Eastern.The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System (â€œTexas A&Mâ€) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the â€œSubleaseâ€) until the consummation of the sale of the Facility.The Purchase and Sale AgreementOn November 1, 2021, the Purchaser entered into a purchase and sale agreement (the â€œPSAâ€) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the â€œGround Lease Agreementâ€) that it entered into with Texas A&M (the â€œLandlordâ€™â€™) related to the land at which the Facility is located together with all improvements pertaining thereto (the â€œGround Lease Propertyâ€), which previously had been F-23 Table of Contentsthe subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the â€œWarrantâ€) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.As discussed above, iBio CDMO is being accounted for as a discontinued operation. Â In fiscal year 2024, the assets acquired were sold and the asset lease was terminated. These assets were classified as assets held for sale on the June 30, 2023 consolidated balance sheet.The Credit AgreementIn connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. See Note 14 â€“ Debt for further information of the Term Loan.The WarrantAs part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock at an exercise price of $665 per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, 579 of such shares were valued at $217,255 to reflect the final payment of rent due under the Sublease. Â The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired. Â See Note 17 â€“ Stockholdersâ€™ Equity for additional information.RubrYcOn August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (â€œRubrYcâ€) described in more detail below:â€‹Collaboration and License AgreementThe Company entered into a collaboration and licensing agreement (the â€œRTX-003 License Agreementâ€) with RubrYc to further develop RubrYcâ€™s immune-oncology antibodies in its RTX-003 campaign. Â Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields.Â RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.â€‹Collaboration, Option and License Agreementâ€‹The Company entered into an agreement with RubrYc (the â€œCollaboration, Option and License Agreementâ€) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYcâ€™s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition F-24 Table of Contentsto royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) ten (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the

exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.â€‹Stock Purchase Agreementâ€‹In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (â€œStock Purchase Agreementâ€) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYcâ€™s Series A-2 preferred stock (â€œSeries A-2 Preferredâ€) for $7,500,000.The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:â€‹â€‹â€‹â€‹â€‹Preferred stockâ€‹ $ 1,760,000Intangible assetsâ€‹â€‹ 4,300,000Prepaid expensesâ€‹â€‹ 1,440,000â€‹â€‹ $ 7,500,000â€‹On September 16, 2022, the Company entered an asset purchase agreement with RubrYc (the â€œAsset Purchase Agreementâ€) pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued 5,117 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the â€œClosing Sharesâ€). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Companyâ€™s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Asset Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.â€‹Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and dismissed bankruptcy proceedings in June 2023. Â The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.â€‹The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:â€‹â€‹â€‹â€‹â€‹Intangible assetsâ€‹ $ 1,228,000Fixed assetsâ€‹â€‹ 114,000â€‹â€‹ $ 1,342,000â€‹F-25 Table of ContentsIn addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. See Note 9 â€“ Finance Lease ROU Assets and Note 15 â€“ Finance Lease Obligations.â€‹Former CEO Departureâ€‹Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the â€œCEO) and former Chairman of the Board of Directors (the â€œBoardâ€), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.â€‹Separation Agreement and General Releaseâ€‹In connection with Mr. Isettâ€™s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the â€œAgreementâ€). Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. Following Mr. Isettâ€™s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for twenty-four (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the twenty-four (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (â€œCOBRAâ€), the Company will pay the full cost of this benefit for up to eighteen (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the eighteen (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of fiscal year 2023. As of June 30, 2024, approximately $0.5 million is recorded in accrued expenses.â€‹7. Promissory Note ReceivableOn June 19, 2023, the Company issued a promissory note (the â€œNoteâ€) with Safi Biosolutions, Inc. (â€œSafiâ€) in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the â€œConvertible Noteâ€) issued by the Company to Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided. â€‹For the fiscal years ended June 30, 2024 and 2023, interest income amounted to $88,000 and $75,000, respectively. As of June 30, 2024 and 2023, the Note balance and accrued interest totaled $1,794,000 and $1,706,000, respectively. On August 29, 2024, the Company received a payment from Safi of approximately $713,000 for all interest owed and approximately $419,000 for a partial payment on the outstanding principal. At June 30, 2024, $713,000 was reported in current assets with the remaining $1,081,000 reported in noncurrent assets.â€‹8. Investments in Debt SecuritiesThe Company did not hold any investments in debt securities at June 30, 2024. Amortization of premiums paid on the debt securities amounted to $0 and $67,000 for the years ended June 30, 2024 and 2023, respectively.â€‹Realized losses on available-for-sale debt securities are as follows (in thousands):â€‹F-26 Table of Contentsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Years Ended June 30,â€‹â€‹2024â€‹2023Proceeds from sale of debt securitiesâ€‹ â€”â€‹ $ 6,739Cost of debt securitiesâ€‹â€‹ â€”â€‹â€‹ 6,837Realized loss on sale of debt securitiesâ€‹ $ â€”â€‹ $ (98)â€‹â€‹â€‹â€‹9.Â Â Â Â Finance Lease ROU AssetsThe Company assumed three equipment leases as part of the RubrYc asset acquisition (see Note 6 â€“ Significant Transactions). In addition, the Company leased a mobile office trailer which was classified as part of assets held for sale prior to its termination. The lease for the mobile office trailer was terminated in December 2022. See Note 15 â€“ Finance Lease Obligations for more details of the terms of the leases.The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ 30,Â â€‹â€‹2024â€‹2023ROU - Equipmentâ€‹ $ 814â€‹ $ 814Accumulated amortizationâ€‹Â (475)â€‹Â (204)Net finance lease ROU assetsâ€‹ $ 339â€‹ $ 610â€‹Amortization expense of finance lease ROU assets was approximately $271,000 and $204,000 for the years ended June 30, 2024 and 2023, respectively.â€‹10.Â Â Â Â Operating Lease ROU AssetsSan Diego, CaliforniaOn September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. The net carrying amount of this ROU operating lease asset was $2,401,000 and $2,722,000 at June 30, 2024 and 2023, respectively.Bryan, TexasOn November 1, 2021, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. This lease was terminated on May 31, 2024. The net amount of this ROU operating lease asset is included in assets held for sale. Â Â Â See Note 16 - Operating Lease Obligations for additional information.â€‹ â€‹â€‹F-27 Table of Contents11.Â Â Â Â Fixed AssetsThe following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹Building and improvementsâ€‹ $ 695â€‹ $ 695Machinery and equipmentâ€‹Â 3,545â€‹Â 3,521Office equipment and softwareâ€‹â€‹ 403â€‹â€‹ 403â€‹â€‹â€‹ 4,643â€‹â€‹ 4,619Accumulated depreciationâ€‹â€‹ (1,011)â€‹â€‹ (400)Net fixed assetsâ€‹ $ 3,632â€‹ $ 4,219â€‹Depreciation expense was approximately $638,000 and $400,000 for the years ended June 30, 2024 and 2023, respectively. â€‹Fixed assets held for sale at June 30, 2024 and 2023 in the amount of $0 and $16,124,000, respectively, are included in assets held for sale. Â No depreciation expense related to held-for-sale assets was recorded for the year ended June 30, 2024. The depreciation expense related to held-for-sale assets for the year ended June 30, 2023 is classified as part of loss from discontinued operations.The Company re-evaluated its business strategy and reviewed its product portfolio during fiscal year 2023 which resulted in an impairment charge of approximately $17.9 million to the assets held for sale. An additional $3.1 million fixed asset impairment charge related to the assets held for sale was recorded in the second quarter of fiscal year 2024. See Note 5 â€“ Financial Instruments and Fair Value Measurement for more information.â€‹â€‹12.Â Â Â Â Intangible AssetsOn August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 â€“ Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (Treg) cells while enhancing T effector (Teff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Â In addition, the Company also received preferred shares and an option for future collaboration licenses.On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 â€“ Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate.In January 2014, the Company entered into a license agreement with the University of Pittsburgh whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provided for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company had agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone â€“ filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") â€“ initially was required to be F-28 Table of Contentsmet by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Companyâ€™s financial obligations for the management of the patents under the license agreement ceased on August 14, 2023, and transitioned back to the University of Pittsburgh and the Medical University of South Carolina. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000 in fiscal year 2023.The Company re-evaluated its business strategy and reviewed its product portfolio during fiscal year 2023. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired. Accordingly, the Company recorded an impairment charge during fiscal year 2023 in general and administrative expenses of approximately $565,000. No impairments were recorded in fiscal year 2024.The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

equipment from 40% to 20%, and (iii) allowed the Company to retain $2 million of the $5.1 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3 million being held in a Company account at Woodforest. Â In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the â€œWoodforest Purchase Agreementâ€) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Woodforest Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). Â In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7.5 million to $1 million. Â On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the â€œFifth Amendmentâ€), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Woodforest Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest.Â In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in-kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3.00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.Â The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. â€‹On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the â€œSixth Amendmentâ€), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Woodforest Purchase Agreement (as defined in the Credit Agreement) for the sale of the Facility within one business day after entry into the Sixth Amendment, and (ii) if the Facility is not sell on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. In addition, if the closing and funding of the Woodforest Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMOâ€™s real estate, including the Facility, at the cost of iBio CDMO.â€‹On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the â€œSeventh Amendmentâ€), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default exists (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as iBio CDMO maintains a minimum balance of $2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as iBio CDMO maintains a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as iBio CDMO maintains a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). On the earlier of (a) the closing of the Woodforest Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), the Company will pay Woodforest $20,000. Â In F-31 Table of Contentsaddition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires the Company to maintain a specified amount in unrestricted cash to $0. Subsequent to executing the Seventh Amendment, the Company withdrew $2,000,000 of the restricted funds. Â â€‹On December 22, 2023, iBio CDMO and Woodforest entered into the Eighth Amendment (the â€œEighth Amendmentâ€) to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the Term Loan to the earlier of (a) March 29, 2024, or (b) the acceleration of maturity of the Term Loan in accordance with the Credit Agreement; (ii) reduce the interest rate from 5.25% to 4.5% and increase the payment in kind from 3% to 4.5%; and (iii) permit the Company, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) exists to make a withdrawal from the Reserve Funds Deposit Account (as defined in the Credit Agreement) so long as the Company maintains a minimum balance of $900,000 until Payment in Full (as defined in the Credit Agreement). The Eighth Amendment provided that the Company will use its best efforts to consummate and close a sale of the Collateral (as defined in the Credit Agreement) on or before the Maturity Date. The amendment also increased the fees payable by Borrower to Woodforest by $10,000. Accordingly, per the amendment, on the earlier of (a) the closing of the sale of the Collateral, or (b) the Maturity Date, the Borrower will pay Woodforest a fee in the amount of $155,000. Subsequent to executing the Eighth Amendment, the Company withdrew an additional $150,000 of the restricted funds. The amount held in the restricted bank account was approximately $900,000 as of February 9, 2024.â€‹On March 28, 2024, iBio CDMO and Woodforest entered into the Ninth Amendment (the â€œNinth Amendmentâ€) to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the term loan to the earlier of (a) May 15, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement.â€‹On May 14, 2024, iBio CDMO and Woodforest entered into the Tenth Amendment (the â€œTenth Amendmentâ€) to the Credit Agreement, which amended the Credit Agreement to: (i) set the maturity date of the term loan to the earlier of (a) May 31, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement.On May 17, 2024, iBio CDMO, the Company and Woodforest also entered into a Settlement Agreement and Mutual Release (the â€œSettlement Agreementâ€) which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the â€œIndebtedness Deficiency Amountâ€) and thereafter the Company issued to Woodforest upon receipt of NYSE American LLC approval a pre-funded warrant (â€œPre-Funded Warrantâ€) that expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share for 1,560,570 shares of the Companyâ€™s common stock which equals the $4,499,124.88 Indebtedness Deficiency Amount divided by $2.883 (the greater of the book value or the market value of the Companyâ€™s common stock at the time the Settlement Agreement is executed). Pursuant to the Settlement Agreement, upon the closing of the sale of the Property under the Purchase and Sale Agreement, Woodforest would purchase the Pre-Funded Warrant in satisfaction of the Indebtedness Deficiency Amount, Woodforest would release the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to such date, and the Company and iBio CDMO will release Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to such date.On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share.Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.F-32 Table of Contentsâ€‹At JuneÂ 30,Â 2024, the balance of the Term Note was $0. At June 30,Â 2023, the balance of the Term Loan was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs.Equipment FinancingOn October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. Â The financing is payable in monthly installments of $16,230 through October 2025. Â At June 30,Â 2024 and 2023, the balance owed under the financing was $241,000 and $401,000, respectively. Â Interest incurred under the financing for the years ended June 30,Â 2024 and 2023 totaled approximately $35,000 and $31,000, respectively.Future minimum payments under the finance lease obligation are due as follows (in thousands):â€‹â€‹â€‹

thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Fiscal year ending on June 30:Â Â Â Â PrincipalÂ Â Â Â Imputed InterestÂ Â Â Â Total2025â€‹$ 436â€‹$ 212â€‹$ 6482026â€‹â€‹ 490â€‹â€‹ 179â€‹â€‹ 6692027Â â€‹ 546Â â€‹ 142Â â€‹ 6882028Â â€‹ 609Â â€‹ 100Â â€‹ 7092029Â â€‹ 677Â â€‹ 54Â â€‹ 731ThereafterÂ â€‹ 366Â â€‹ 8Â â€‹ 374â€‹Â â€‹Â Â Â Â â€‹Â Â Â Â â€‹Â Â Total minimum lease paymentsÂ â€‹ 3,124â€‹$ 695â€‹$ 3,819Less: current portionÂ â€‹ (436)â€‹Â Â Â Â â€‹Â Â Â Long-term portion of minimum lease obligationâ€‹$ 2,688â€‹Â Â Â Â â€‹Â Â Â Â â€‹â€‹17.Â Â Â Â Stockholdersâ€™ EquityPreferred StockThe Companyâ€™s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.Series 2022 Convertible Preferred Stock (â€œSeries 2022 Preferredâ€)On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Companyâ€™s 1 million authorized shares of preferred stock. Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis.The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270 on May 10, 2022. Â Pursuant to the terms of the preferred stock, the Companyâ€™s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022.Common StockThe number of authorized shares of the Companyâ€™s common stock is 275 million.Reverse Stock SplitOn June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued and outstanding, effective October 7, 2022. The Companyâ€™s common stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.F-37 Table of ContentsOn November 27, 2023, the stockholders of the Company, approved a proposal at the Companyâ€™s 2023 Annual Meeting to amend the Companyâ€™s Certificate of Incorporation to effect a reverse stock split of the Companyâ€™s Common Stock, at a ratio between 1-for-5 to 1-for-20, with the ratio within such range to be determined at the discretion of the Companyâ€™s Board, without reducing the authorized number of shares of Common Stock. Following the 2023 Annual Meeting, the Board approved a final split ratio of one-for-20 (1:20). Following such approval, on November 28, 2023, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the 2023 reverse stock split, with an effective time of 12:01 a.m. Eastern Time on November 29, 2023. As a result of the 1:20 2023 Reverse Stock Split, each twenty (20) pre-split shares of Common Stock outstanding automatically combined into one (1) new share of Common Stock without any action on the part of the holders. No fractional shares were issued in connection with the 2023 Reverse Stock Split. In lieu of fractional shares, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the effective time of the 2023 Reverse Stock Split (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) were entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the 2023 Reverse Stock Split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the NYSE American for the ten days preceding November 29, 2023.Issuances of Common Stock for the years ended June 30, 2024 and 2023 include the following:Cantor Fitzgerald UnderwritingOn November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the â€œSales Agreementâ€) with Cantor Fitzgerald & Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an â€œat the market offeringâ€ program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. In the fiscal year ended June 30, 2024, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 170,989 shares of Common Stock. The Company received net proceeds of approximately $1.7 million.â€‹In the fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 289,144 shares of Common Stock. The Company received net proceeds of approximately $6.4 million during the fiscal year ended June 30, 2023 and held a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023.â€‹RubrYc TransactionOn September 19, 2022, the Company issued 5,117 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.â€‹Wainwright Underwritingâ€‹On December 6, 2022, the Company entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with H.C. Wainwright & Co., LLC (â€œWainwrightâ€). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the â€œOfferingâ€) (i) 76,538 shares of the Companyâ€™s Common Stock, (ii) pre-funded warrants (the â€œ2022 Pre-Funded Warrantsâ€) to purchase up to 91,730 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the â€œSeries A Warrantsâ€) to purchase up to 168,267 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the â€œSeries B Warrantsâ€ and together with the Series A Warrants, the â€œ2022 Warrantsâ€) to purchase up to 168,267 shares of Common Stock. Â The offering closed on December 9, 2022. Â â€‹Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses. Pursuant to the Underwriting Agreement, the Company granted Wainwright a 30-day option to purchase up to an additional 25,240 shares of Common Stock and/or Common Warrants to purchase up to an additional 50,480 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 25,240 Series A Warrants and 25,240 Series B Warrants.â€‹F-38 Table of ContentsThe Company also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the â€œRepresentativeâ€™s Warrantsâ€) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and 2022 Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 10,094 shares of Common Stock.â€‹The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.â€‹Lincoln Park Stock Purchase Agreementâ€‹As discussed above, on August 4, 2023, the Company entered into a Purchase Agreement, with Lincoln Park, pursuant toÂ which, under the terms and subject to the satisfaction of specified conditions set forth therein,Â the Company may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the â€œRegistration Rights Agreementâ€), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by the Company to Lincoln Park under the Purchase Agreement. The Company could not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Parkâ€™s purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the â€œCommencement Dateâ€). Â The registration statement was declared effective on August 11, 2023.Â Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Companyâ€™s discretion, it had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company could, at Â its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $3.00, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 5,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a â€œRegular Purchaseâ€);Â provided,Â however, that the maximum number of shares the Company may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 7,500 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $20.00, and (ii) 10,000 shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $40.00;Â provided,Â however, that Lincoln Parkâ€™s maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.Â In addition, provided that the Company had directed Lincoln Park to purchase the maximum amount of shares that it is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $4.00, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an â€œaccelerated purchase,â€ and one or more â€œadditional accelerated purchasesâ€ on the business day immediately following the purchase date for such Regular Purchase,Â as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,Â calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.F-39 Table of ContentsÂ The Company controlled the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park had no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park was obligated to make purchases as the Company directs, subject to certain conditions.Â As consideration for Lincoln Parkâ€™s commitment to purchase shares of Common Stock at the Companyâ€™s direction pursuant to the Purchase Agreement, the Company issued 10,573 shares of Common Stock to Lincoln Park as commitment shares (the â€œInitial Commitment Sharesâ€) and agreed to issue 10,573 additional shares of Common Stock to Lincoln Park as commitment shares (the â€œAdditional Commitment Sharesâ€ and, collectively with the Initial Commitment Shares, the â€œCommitment Sharesâ€) at such time as the Company had received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. Â During fiscal year 2024, the Company sold 202,595 shares of Common Stock under the Purchase Agreement and received approximately $1.3 million in proceeds. No shares remain available for sale under the Purchase Agreement at June 30, 2024.â€‹Securities Purchase Agreementâ€‹On December 5, 2023, the Company entered into a securities purchase agreement (the â€œSecurities Purchase Agreementâ€) with certain Purchasers identified on the signature pages of the Securities Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the 2023 Offering, (i) 600,000 Shares of the Companyâ€™s Common Stock, (ii) 1,650,000 2023 Pre-Funded Warrants exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock. The 2023 Offering closed on December 7, 2023. The combined purchase price of each share of Common Stock and the accompanying Common Warrants was $2.00 (the â€œOffering Priceâ€).â€‹The Company agreed to pay the Placement Agents an aggregate cash fee equal to 5.5% of the gross proceeds received by the Company from the sale of the securities in the 2023 Offering. Pursuant to the placement agency agreement, dated December 5, 2023, entered into by and between the Company and the Placement Agents (the â€œPlacement Agency Agreementâ€), the Company also agreed to reimburse the Placement Agents for their accountable offering-related legal expenses in an amount up to $75,000 and pay a non-accountable expense allowance of up to $15,000.â€‹The Company received net proceeds of approximately $4 million in the 2023 Offering after deducting commissions and other issuance costs. Approximately $369,000 of issuance costs are reported in accrued expenses in the consolidated balance sheet at June 30, 2024. â€‹Securities Purchase Agreement and Warrantsâ€‹On March 26, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Securities Purchasers for the issuance and sale in the Private Placement of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315 shares of the Common Stock, (ii) 2024 Pre-Funded Warrants to purchase up to 2,585,963 shares of the Companyâ€™s Common Stock at an exercise price of $0.0001 per share, and (iii) Series E Common Stock purchase warrants to purchase up to 5,287,278 shares of the Companyâ€™s Common Stock at an exercise price of $2.64 per share. The Series E Warrants are exercisable at any time after the six-month anniversary of their issuance at an exercise price of $2.64 per share and have a term of exercise equal to five years from the date of issuance. The combined purchase price for one share of common stock and the accompanying Series E Warrant was $2.85 and the purchase price for one pre-funded warrant and the accompanying Series E Warrant was $2.849.â€‹A holder of the 2024 Pre-Funded Warrants and the Series E Warrants may not exercise any portion of such holderâ€™s 2024 Pre-Funded Warrants or the Series E Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Companyâ€™s outstanding shares of Common Stock immediately after exercise, except that upon at least 61 daysâ€™ prior notice from the holder to the Company, the holder may F-40 Table of Contentsincrease the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise.â€‹The 2024 Pre-Funded Warrants are exercisable at any time after their original issuance, subject to the beneficial ownership limitation (as described above) and will not expire until exercised in full. The exercise price and number of shares of Common Stock issuable upon exercise of the 2024 Pre-Funded Warrants and Series E Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price.â€‹If at the time of exercise on a date that is after the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common Stock to the holders of the Series E Warrants, the Series E Warrants may be exercised, in whole or in part, at such time by means of a â€œcashless exercise.â€ Â If at the time of exercise on a date that is after the 60th day anniversary of the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common Stock to the holders of 2024 Pre-Funded Warrants, the 2024 Pre-Funded Warrants may also be exercised, in whole or in part, at such time by means of a â€œcashless exercise.â€â€‹Pursuant to the 2024 Securities Purchase Agreement, the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission (the â€œSECâ€) registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants no later than 60 days after the date of the 2024 Securities Purchase Agreement (the â€œFiling Dateâ€), to use its commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event not more than 75 days following the date of the 2024 Securities Purchase Agreement (or 90 days following the date of the 2024 Securities Purchase Agreement in the event of a â€œfull reviewâ€ by the SEC) (the â€œEffectiveness Dateâ€), and to keep such registration statement effective at all times for a one year period after the closing date provided that the Company will have the right to suspend the registration statement for a period of fifteen (15) days during such one year period without being in breach. In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an â€œEvent Dateâ€) and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%. The registration statement was filed with the SEC on April 16, 2024 and declared effective by the SEC on April 24, 2024.â€‹The Private Placement closed on April 1, 2024 at which time the Company received net proceeds of approximately $14.1 million, which was reported as a subscription receivable on the March 31, 2024 condensed consolidated balance sheet, from the Private Placement, after deducting estimated offering expenses payable by the Company, including placement agent fees and expenses. The Company intends to use the net proceeds received from the Private Placement primarily for general corporate purposes, including for research and development and working capital. Â â€‹Chardan served as the exclusive placement agent in connection with the Private Placement and was paid (i) a cash fee equal to 6.0% of the aggregate gross proceeds of the Private Placement (reduced to

4.0% with respect to certain investors), and (ii) up to $50,000 for legal fees and other out-of-pocket expenses.â€‹Pursuant to the terms of the 2024 Securities Purchase Agreement, the Company is prohibited from entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or securities convertible or exercisable into Common Stock for a period commencing on March 26, 2024, and expiring 60 days from the Effective Date (as defined in the 2024 Securities Purchase Agreement). Furthermore, the Company is also prohibited from entering into any agreement to issue Common Stock or Common Stock Equivalents (as defined in the 2024 Securities Purchase Agreement) involving a Variable Rate Transaction (as defined in the 2024 Securities Purchase Agreement), subject to certain exceptions, for a period commencing on March 26, 2024 and expiring one year from such Effective Date F-41 Table of Contents(as defined in the 2024 Securities Purchase Agreement); provided that sixty (60) days after the Effective Date entering into an at-the-market facility shall not be deemed a Variable Rate Transaction.â€‹Vesting of Restricted Stock Units â€œRSUsâ€‹â€‹RSUs for 42,054 of Common Stock vested during the year ended June 30, 2024. RSUs for 10,878 of Common Stock vested during the year ended June 30, 2023. â€‹Exercise of Stock Optionsâ€‹No stock options were exercised in the years ended June 30, 2024 and 2023. â€‹WarrantsBryan Capital â€‹The Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock of the Company at an exercise price of $665 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.â€‹Wainwright â€‹As discussed above, the Company issued various warrants with the following terms:â€‹1.2022 Pre-Funded Warrants â€“ Immediately exercisable at an exercise price of $0.001 per share. Â All of the 2022 Pre-Funded Warrants were exercised in December 2022.2.Class A Warrants â€“ Immediately exercisable at an exercise price of $20.80 per share for a term of five years.3.Class B Warrants â€“ Immediately exercisable at an exercise price of $20.80 per share for a term of two years.4.Representative Warrants â€“ Immediately exercisable at an exercise price of $26.00 per share for a term of five years.â€‹No 2022 Warrants were exercised during the year ended June 30, 2024. During the year ended June 30, 2023, 17,064 Class A Warrants and 89,059 Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $2,207,000.On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to 173,795 shares of common stock and existing Series B Warrants to purchase up to 102,900 shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of $20.80 per share (the â€œExisting Warrantsâ€), to lower the exercise price of the Existing Warrants to $10.00 per share.â€‹A.G.P./Alliance Global Partners Â â€‹On December 7, 2023, the Company, completed the 2023 Offering of (i) 600,000 shares Common Stock, (ii) 1,650,000 Pre-Funded Warrants exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D Common Warrants exercisable for an aggregate of 2,250,000 shares of Common StockÂ exercisable for an aggregate of 2,250,000 shares of Common Stock. The terms of the 2023 Pre-Funded Warrants, Series C Common Warrants and Series D Common Warrants were described in the Companyâ€™s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023, which description is incorporated by reference herein.â€‹F-42 Table of ContentsEach share of Common Stock and 2023 Pre-Funded Warrants, as applicable, was sold together with one Series C Common Warrant to purchase one share of Common Stock and one Series D Common Warrant to purchase one share of Common Stock. The combined purchase price of each share of Common Stock and the accompanying Common Warrants was the Offering Price and the combined purchase price of each 2023 Pre-Funded Warrant and the accompanying Common Warrants was $1.9999, which is equal to the combined purchase price per share of Common Stock and accompanying Common Warrants, minus the exercise price of each Pre-Funded Warrant of $0.0001. The Series C Common Warrants and the Series D Common Warrants have an exercise price of $2.00 per share and are immediately exercisable. The Series C Common Warrants will expire two (2) years from the date of issuance and the Series D Common Warrants will expire five (5) years from the date of issuance.â€‹During fiscal year 2024, 1,650,000 of 2023 Pre-Funded Warrants were exercised. In addition, 1,178,500 Series C Common Warrants and 1,053,500 Series D Common Warrants were exercised for proceeds of $4,464,000. In August 2024, 1,000 Series C Common Warrants and 1,000 Series D Common Warrants were exercised for proceeds of $4,000.â€‹â€‹18.Â Â Â Â Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Years endedâ€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Basic and diluted numerator:â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss from continuing operationsâ€‹$ (15,443)â€‹$ (29,311)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss from discontinued operationsâ€‹$ (9,464)â€‹$ (35,699)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss - totalâ€‹$ (24,907)â€‹$ (65,010)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Basic and diluted denominator:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-average common shares outstandingâ€‹Â 3,831â€‹Â 612â€‹â€‹Â â€‹â€‹Â â€‹Per share amount - continuing operationsâ€‹$ (4.03)â€‹$ (47.88)Per share amount - discontinued operationsâ€‹$ (2.47)â€‹$ (58.31)Per share amount - totalâ€‹$ (6.50)â€‹$ (106.19)â€‹In fiscal years 2024 and 2023, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of JuneÂ 30, 2024 and 2023, shares issuable which could potentially dilute future earnings included were as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023 â€‹â€‹(inÂ thousands)Stock optionsÂ 912Â 14Restricted stock unitsÂ Â Â Â 37Â Â Â Â 12Warrantsâ€‹ 12,127â€‹ 293Shares excluded from the calculation of diluted loss per shareÂ 13,076Â 319â€‹â€‹F-43 Table of Contents19.Â Â Â Â Share-Based CompensationThe following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Years Ended June 30,â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Research and developmentâ€‹â€‹ 234â€‹â€‹ 149General and administrativeâ€‹â€‹Â 1,741â€‹â€‹Â 2,714Totalâ€‹â€‹ 1,975â€‹â€‹ 2,863â€‹In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $62,000 and $1,528,000 for the years ended June 30, 2024 and 2023, respectively.Stock OptionsiBio, Inc. 2023 Omnibus Equity Incentive Plan (the â€œ2023 Planâ€)On December 9, 2023, the Company adopted the 2023 Plan for employees, officers, directors and external service providers which is the successor to the 2020 Omnibus Equity Incentive Plan (the â€œ2020 Planâ€) and once approved became effective on January 1, 2024. The maximum number of shares of Common Stock reserved and available for issuance under the 2023 Plan is 1,200,000 shares (the â€œLimitâ€). Â In addition, such Limit shall automatically increase on January 1 of each calendar year commencing on January 1, 2025 and ending on (and including) January 1, 2033, by a number of shares of Common Stock equal to five percent (5%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year; provided, however, that the Board may act prior to January 1 of a given calendar year to provide that the increase for such year will be a lesser number of shares of Common Stock, provided further that the Limit, as in effect at any time, shall be adjusted as a result of any reorganization, recapitalization, reclassification, stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Companyâ€™s capital stock. The 2023 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2023 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of the Companyâ€™s Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2023 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.â€‹Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.Under the 2023 Plan, 29,700 common shares have been issued pursuant to past grants, 921,200 common shares are reserved for past grants, and the remaining 249,100 common are available for future grants as of June 30, 2024.â€‹iBio, Inc. 2020 Omnibus Equity Incentive Plan (the â€œ2020 Planâ€) â€‹On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 64,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be F-44 Table of Contentsappointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.Vesting of service awards is determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.Under the 2020 Plan, 23,219 common shares have been issued pursuant to past grants, 27,032 common shares are reserved for past grants, and the remaining 13,749 common shares will no longer be available for future grants as of June 30, 2024.â€‹Issuances of stock options during the year ended June 30, 2024 were as follows:â€‹During the first quarter of fiscal year 2024, the Company granted stock option agreements to various employees to purchase 23,650 shares of the Common Stock at an exercise price of $7.00 per share. Â During the fourth quarter of fiscal year 2024, the Company granted stock option agreements to various employees to purchase 83,300 shares of the Common Stock at exercise prices between $1.72 and $2.41 per share, which included a grant of 35,800 stock options at an exercise price of $1.72 per share to Felipe Duran, the Companyâ€™s Chief Financial Officer. â€‹All of the above noted awards vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.â€‹During the fourth quarter of fiscal year 2024, the Board approved stock option agreements to various employees to purchase 402,300 shares of the Common Stock at an exercise price of $1.88 per share, which included a two separate grants to Dr. Brenner, the Companyâ€™s Chief Executive Officer, one of which was 110,000 stock options that vest in equal quarterly installments over three years and a second grant of 147,300 stock options that vest 25% after one year and then in equal quarterly installments over a 36-month period, and a grant to Mr. Duran of 90,000 stock options, which vest in equal quarterly installments over three years. Â â€‹All of the above noted awards expire on the tenth anniversary of the grant date.â€‹During the fourth quarter of fiscal year 2024, the Company granted stock option agreements to various consultants to purchase 399,000 shares of the Common Stock at an exercise price of $1.72 per share. The options vest in equal quarterly installments, over a period of 12 months and expire on the fifth anniversary of the grant date. â€‹Issuances of stock options during the year ended June 30, 2023 were as follows:â€‹During the first quarter of fiscal year 2023, the Company granted stock option agreements to various employees to purchase 15,193 shares of the Common Stock at exercise prices between $135.00 and $190.00 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.During the first quarter of fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 200 shares of the Common Stock at an exercise price of $135.00 per share. The option vests in equal monthly installments, over a period of 12 months, starting after the second month and expire on the tenth anniversary of the grant date. Â During the third quarter of fiscal year 2023, the Company terminated the consultantâ€™s services. Â As a result, none of the 200 shares pursuant to the stock option agreement were exercised and as such, all 200 shares were forfeited. Â F-45 Table of ContentsThe following table summarizes all stock option activity during theÂ years ended JuneÂ 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹Â Â Â Â Â â€‹Â Â Â Â Â â€‹Â Â Â Â Weighted-Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-â€‹averageâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹averageâ€‹Remainingâ€‹Aggregateâ€‹â€‹Stockâ€‹Exerciseâ€‹Contractualâ€‹IntrinsicÂ Valueâ€‹Â Â Â Â OptionsÂ Â Â Â PriceÂ Â Â Â TermÂ (inÂ years)Â Â Â Â (as of July 1, 2022Â 30,708â€‹$ 603.43Â 8.3â€‹$ â€”GrantedÂ 15,375â€‹â€‹ 141.17Â â€”â€‹Â â€”Exercisedâ€‹ â€”â€‹â€‹ â€”â€‹ â€”Forfeited/expiredÂ (31,465)â€‹â€‹ 479.67Â â€”â€‹Â â€”Outstanding as of JuneÂ 30,Â 2023Â 14,618â€‹$ 383.62Â 8.5â€‹$ â€”As of June 30, 2023, vested and expected to vestÂ 14,616â€‹$ 383.64Â 8.5â€‹$ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Exercisable as of JuneÂ 30,Â 2023Â 4,790â€‹$ 583.09Â 7.9â€‹$ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Outstanding as of JuneÂ 30,Â 2023Â 14,618â€‹$ 383.62Â 8.5â€‹$ â€”GrantedÂ 908,250â€‹â€‹ 1.93Â â€”â€‹Â â€”Exercisedâ€‹ â€”â€‹â€‹ â€”â€‹ â€”Forfeited/expiredÂ (10,742)â€‹â€‹ 164.15Â â€”â€‹Â â€”Outstanding as of JuneÂ 30,Â 2024Â 912,126â€‹$ 6.14Â 7.6â€‹$ 280As of June 30, 2024, vested and expected to vestÂ 912,126â€‹$ 6.14â€‹ 7.6â€‹$ 280â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Exercisable as of JuneÂ 30,Â 2024Â 6,472â€‹$ 459.08Â 7.2â€‹$ â€”â€‹â€‹The following table summarizes information about options outstanding and exercisable at JuneÂ 30, 2024:â€‹ â€‹â€‹Â Â Â Â OptionsÂ OutstandingÂ andÂ Exercisableâ€‹â€‹â€‹â€‹Weighted-â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Averageâ€‹â€‹Averageâ€‹â€‹â€‹â€‹â€‹â€‹Numberâ€‹Remaining Lifeâ€‹Exerciseâ€‹Numberâ€‹â€‹OutstandingÂ Â Â Â In YearsÂ Â Â Â PriceÂ Â Â Â ExercisableExercise prices:Â Â Â Â Â Â Â â€‹Â Â Â Â Â Â â€‹1.72 - $7.00Â 902,300Â 7.6â€‹$ â€”Â â€”$140.00 - $210.00Â 4,681Â 8.0â€‹$ 147.83Â 2,164$347.00 - $520.50â€‹ 1,191â€‹7.2â€‹$ 355.66â€‹ 1,190$530.00 - $795.00â€‹ 3,554â€‹6.8â€‹$ 668.89â€‹ 2,718$1,025.00 - $1,537.50â€‹ 400â€‹6.3â€‹$ 1,025.00â€‹ 400â€‹Â 912,126Â 7.6â€‹$ 459.08Â 6,472â€‹â€‹The total fair value of stock options that vested during 2024 and 2023 was approximately $1,644,000 and $4,828,000, respectively. No stock options were exercised during 2024 and 2023. As of JuneÂ 30, 2024, there was approximately $2,223,000 of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 2.1Â years.F-46 Table of Contentsâ€‹The weighted-average grant date fair value of stock options granted during 2024 and 2023 was $1.90 and $126.05 per share, respectively.Â The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ â€‹â€‹Â Â Â Â 2024â€‹2023Weighted-average risk-free interest rateâ€‹4.44% - 4.83%Â Â â€‹3.21% - 3.61%Dividend yieldÂ 0%Â Â â€‹ 0%VolatilityÂ 157.77 - 266.94%Â Â â€‹115.52 - 116.93%Expected term (in years)Â 5Â â€‹7â€‹â€‹â€‹The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Companyâ€™s closing stock price of $2.11 as of June 30, 2024 and $12.20 as of June 30, 2023, which would have been received by the option holders had all option holders exercised their options as of that date.Restricted Stock Units (â€œRSUsâ€):â€‹Issuances of RSUs during the year ended June 30, 2024 were as follows:â€‹On January 26, 2024, the Company issued RSUs to acquire 78,800 shares of common stock to various employees at a market value of $1.18 per share. Â The RSUs vest quarterly over a one-year period. The grant date fair value of the RSUs totaled approximately $93,000.â€‹Issuances of RSUs during the year ended June 30, 2023 were as follows:On August 29, 2022, the Company issued RSUs to acquire 347 shares of common stock to various employees at a market value of $141.20 per share. Â The RSUs vest over a four-year period. Â The grant date fair value of the RSUs totaled approximately $49,000.â€‹On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Companyâ€™s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 10,000 shares of Common Stock.Â The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.Â The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.â€‹On November 11, 2022, the Board of the Company granted Mr. Robert Lutz, the Companyâ€™s Chief Financial and Business Officer at the time, RSUs to acquire 5,002 shares of the Companyâ€™s Common Stock in exchange for Mr. Lutzâ€™s agreement to continue employment with the Company through July 1, 2023. Â The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Companyâ€™s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.â€‹On November 11, 2022, the Board of the Company granted Dr. Martin Brenner, the Companyâ€™s Chief Scientific Officer, RSUs to acquire 4,767 shares of the Companyâ€™s Common Stock in exchange for Dr. Brennerâ€™s agreement to continue employment with the Company through July 1, 2023. Â The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Companyâ€™s 2023 objectives, as defined by the Board. The grant-date

fair value of the RSUs totaled approximately $167,000.On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 6,500 shares of the Companyâ€™s Common Stock, which F-47 Table of ContentsRSUs shall vest pro rata over a 12-month period, such vesting to terminate if Dr. Brenner is no longer the Companyâ€™s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. Upon appointment of Dr. Brenner to permanent Chief Executive Officer on June 22, 2023, 3,792 of the RSUs terminated and did not vest.On March 31, 2023, the Compensation Committee (the â€œCommitteeâ€) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 11,250 RSUs under the Companyâ€™s 2020 Omnibus Equity Incentive Plan, as amended (the â€œPlanâ€), which awards included a grant of 2,500 and 1,875 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Companyâ€™s Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.On June 26, 2023, the Board of the Company granted Dr. Brenner RSUs to acquire 3,791 shares of the Companyâ€™s Common Stock, which RSUs shall vest pro rata over a seven-month period. Â The grant-date fair value of the RSUs totaled approximately $52,000.As of June 30, 2024, there was approximately $35,000 of total unrecognized compensation cost related to non-vested RSUs that the Company expects to recognize over a weighted-average period of 0.6 years.â€‹â€‹20.Â Â Â Â Fraunhofer Settlementâ€‹Fraunhofer SettlementOn May 4, 2021, iBio, Inc. (the â€œCompanyâ€) and Fraunhofer USA, Inc. (â€œFhUSAâ€) entered into a Confidential Settlement Agreement and Mutual Release (the â€œFraunhofer Settlement Agreementâ€) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the â€œLawsuitâ€). The Fraunhofer Settlement Agreement, among other things, resolves the Companyâ€™s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Fraunhofer Settlement Agreement is not an admission of liability or fault of the parties. The terms of the Fraunhofer Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 paid no later than May 14, 2021 (which was paid 100% to cover legal fees and expenses); (ii) two payments of $5,100,000 paid by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, two payments of $900,000 paid by March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Companyâ€™s aggregate net cash recovery as a result of the Fraunhofer Settlement Agreement was approximately $10,200,000. Â As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in fiscal year 2021. During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023.The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. The second $900,000 payment was received on February 17, 2023.F-48 Table of Contentsâ€‹â€‹21.Â Â Â Â Income TaxesThe components of the provision (benefit) for income taxes consist of the following (in thousands):â€‹â€‹â€‹

as well as information regarding the nominee or the proposed business. Sections 1.10 and 1.11 of our Bylaws provide a time period during which nominations or business must be provided to the Company that will create a predictable window for the submission of such notices, eliminating the risk that the Company finds a meeting will be contested after printing its proxy materials for an uncontested election and providing the Company with a reasonable opportunity to respond to nominations and proposals by stockholders.Board Vacancies. Our Bylaws generally provide that only the Board of Directors (and not the stockholders) may fill vacancies and newly created directorships.Special Meeting of Stockholders. Â Our Bylaws generally provide that special meetings of stockholders for any purpose or purposes for which meetings may be lawfully called, may be called at any time by our Board of Directors, the Chairman of the Board, the Chief Executive Officer or by one or more stockholders holding shares in the aggregate entitled to cast not less than fifty percent (50%) of the votes at that meeting. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting.While the foregoing provisions of our Certificate of Incorporation, Bylaws and Delaware law may have an anti-takeover effect, these provisions are intended to enhance the likelihood of continuity and stability in the composition of the Board of Directors and in the policies formulated by the Board of Directors and to discourage certain types of transactions that may involve an actual or threatened change of control. In that regard, these provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management.Delaware Takeover StatuteIn general, Section 203 of the Delaware General Corporation Law prohibits a Delaware corporation that is a public company from engaging in any â€œbusiness combinationâ€ (as defined below) with any â€œinterested stockholderâ€ (defined generally as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with such entity or person) for a period of three years following the date that suchâ€‹stockholder became an interested stockholder, unless: (1) prior to such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (2) on consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned (x) by persons who are directors and also officers and (y) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or (3) on or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.Section 203 of the Delaware General Corporation Law defines â€œbusiness combinationâ€ to include: (1) any merger or consolidation involving the corporation and the interested stockholder; (2) any sale, transfer, pledge or other disposition of ten percent or more of the assets of the corporation involving the interested stockholder; (3) subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; (4) any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or (5) the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.Listing of Common Stock on the NYSE AmericanOur common stock is currently listed on the NYSE American under the trading symbol â€œIBIO.â€Transfer AgentThe transfer agent and registrar for our common stock is Continental Stock Transfer & Trust Company. They are located at 1 State Street, 30thÂ Â floor, New York, New York 10004. Their telephone number is (212) 509-4000. EX-21.1 3 ibio-20240630xex21d1.htm EX-21.1 Exhibit 21.1Subsidiaries of RegistrantiBio Manufacturing LLC (â€œiBio Manufacturingâ€) is wholly-owned and incorporated in DelawareiBio CDMO LLC (â€œiBio CDMOâ€) is wholly-owned and incorporated in Delaware. Name was changed effective July 1, 2017. EX-23.1 4 ibio-20240630xex23d1.htm EX-23.1 Exhibit 23.1CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMWe consent to the incorporation by reference in the following Registration Statements of iBio, Inc. and Subsidiaries on:â€‹â—Form S-1 (File No. 333-224620, File No. 333-233504, File No. 333-250973, File No. 333-273749 and File No. 333-275204),â—Form S-3 (File No. 333-171315, File No. 333-278729 and File No. 333-280680) and onâ—Form S-8 (File No. 333-229261, File No. 333-252027, File No. 333-252028 and File No. 333-276452) â€‹of our report dated September 20, 2024, relating to the consolidated financial statements of iBio, Inc. and Subsidiaries as of and for the years ended June 30, 2024 and 2023, which appears in this Annual Report on Form 10-K for the year ended June 30, 2024. Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern. â€‹/s/ Grassi & Co. CPAs, P.C.Â Jericho, New YorkÂ September 20, 2024Â â€‹ EX-31.1 5 ibio-20240630xex31d1.htm EX-31.1 Exhibit 31.1â€‹CERTIFICATION PURSUANT TOSECTION 302 OFTHE SARBANES-OXLEY ACT OF 2002â€‹I, Martin Brenner, certify that:â€‹Â 1.I have reviewed this Annual Report on Form 10-K of iBio, Inc. for the fiscal year ended June 30, 2024;Â Â Â Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â Â Â Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â Â Â Â 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have:â€‹â€‹â€‹Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â Â Â Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â Â Â Â c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ Â Â Â d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹â€‹â€‹Â 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹â€‹â€‹Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ Â Â Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: September 20, 2024By:/s/ Martin BrennerÂ Â Martin BrennerÂ Â Chief Executive Officer and Chief Scientific Officer(Principal Executive Officer)â€‹ EX-31.2 6 ibio-20240630xex31d2.htm EX-31.2 Exhibit 31.2â€‹CERTIFICATION PURSUANT TOSECTION 302 OFTHE SARBANES-OXLEY ACT OF 2002I, Felipe Duran, certify that:â€‹Â 1.I have reviewed this Annual Report on Form 10-K of iBio, Inc. for the fiscal year ended June 30, 2024;Â Â Â Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â Â Â Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â Â Â Â 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have:â€‹â€‹â€‹Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â Â Â Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â Â Â Â c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ Â Â Â d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹â€‹â€‹Â 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹â€‹â€‹Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ Â Â Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: September 20, 2024By:/s/ Felipe DuranÂ Â Felipe DuranChief Financial OfficerÂ Â (Principal Financial Officer and Principal Accounting Officer)â€‹ EX-32.1 7 ibio-20240630xex32d1.htm EX-32.1 Exhibit 32.1â€‹CERTIFICATION PURSUANT TO18 U.S.C. Â§1350,AS ADOPTED PURSUANT TOSECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Annual Report of iBio, Inc. (the Company) on Form 10-K for the fiscal year ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Martin Brenner, Chief Executive Officer and Chief Scientific Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:â€‹â€‹â€‹Â 1.The Report fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹â€‹â€‹Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹September 20, 2024/s/ Martin BrennerÂ Martin BrennerÂ Chief Executive Officer and Chief Scientific OfficerÂ Â Â Â (Principal Executive Officer)â€‹â€‹A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to iBio, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request. EX-32.2 8 ibio-20240630xex32d2.htm EX-32.2 Exhibit 32.2â€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Annual Report of iBio, Inc. (the Company) on Form 10-K for the fiscal year ended June 30, 2024as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Felipe Duran, Â Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:â€‹â€‹â€‹Â 1.The Report fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹â€‹â€‹Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹September 20, 2024/s/ Felipe DuranÂ Felipe DuranÂ Chief Financial Officer Â Â Â Â (Principal Financial Officer and Principal Accounting Officer)â€‹â€‹â€‹A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to iBio, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request. EX-97.1 9 ibio-20240630xex97d1.htm EX-97.1 Exhibit 97.1IBIO, INC.CLAWBACK POLICYThe Board of Directors (the â€œBoardâ€) of iBio, Inc. (the â€œCompanyâ€) has determined that it is in the best interests of the Company to adopt this Clawback Policy (this â€œPolicyâ€), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), Rule 10D-1 promulgated under the Exchange Act (â€œRule 10D-1â€) and Section 811 of the NYSE American LLC (the â€œNYSEâ€ American) Company Guide.1.DefinitionsFor purposes of this Policy, the following capitalized terms shall have the meanings set forth below.â€œAccounting Restatementâ€ means an accounting restatement of the Companyâ€™s financial statements due to the Companyâ€™s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.â€œClawback Periodâ€ means the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, as well as any transition period (that results from a change in the Companyâ€™s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year). Theâ€œdate on which the Company is required to prepare an Accounting Restatementâ€ is the earlier to occur of (a) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.â€œErroneously Awarded Compensationâ€ means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received; and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the NYSE American.â€‹1â€œExecutive Officerâ€ means the Companyâ€™s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. An executive officer of the Companyâ€™s parent or subsidiary is deemed an â€œExecutive Officerâ€ if the executive officer performs such policy making functions for the Company.â€œFinancial Reporting Measureâ€ means any measures that are determined and presented in accordance with the accounting principles used in preparing the Companyâ€™s financial statements, and any measures that are derived wholly or in part from such measures; provided, however, that a Financial Reporting Measure is not required to be presented within the Companyâ€™s financial statements or included in a filing with the U.S. Securities and Exchange Commission (the â€œSECâ€) to qualify as a â€œFinancial Reporting Measure.â€ For purposes of this Policy, Financial Reporting Measures include, but are not limited to, stock price and total stockholder return.â€œIncentive-Based Compensationâ€ means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is â€œreceivedâ€ for purposes of this Policy in the Companyâ€™s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.2.Policy Application.This Policy applies to Incentive-Based Compensation received by an Executive Officer (a) after beginning services as an Executive Officer; (b) if that person served as an Executive Officer at any time during the performance period for such Incentive-Based Compensation; and (c) while the Company had a listed class of securities on a national securities exchange.3.Policy Recovery Requirement.In the event the Company is required to prepare an Accounting Restatement, the Company shall reasonably promptly recoup the amount of any Erroneously Awarded Compensation received by any Executive Officer during the Clawback Period. In the event of an Accounting Restatement, the Board shall determine, in its sole discretion, the amount of any Erroneously Awarded Compensation for each Executive Officer in connection with such Accounting Restatement.4.Method of Recoupment.The Board shall determine, in its sole discretion, the timing and method for promptly recouping such Erroneously Awarded Compensation, which may include without limitation: (a) seeking reimbursement of all or part of any cash or equity-based award, (b) cancelling prior cash or equity-based awards, whether

vested or unvested or paid or unpaid, (c) cancelling or offsetting against any planned future cash or equity-based awards, (d) forfeiture of deferred compensation, subject to compliance with Section 409A of the Internal Revenue Code and the regulations promulgated thereunder and (e) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Board may affect recovery under this Policy from any amount otherwise payable to the Executive Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, including base salary, bonuses or commissions and compensation previously deferred by the Executive Officer.â€‹2The Company is authorized and directed pursuant to this Policy to recoup Erroneously Awarded Compensation in compliance with this Policy except to the extent the Compensation Committee of the Board has determined recovery would be impracticable solely if one (1) of the following limited reasons are met, and subject to the following procedural and disclosure requirements:â—The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover and provide that documentation to the NYSE American;â—Recovery would violate home country law of the Company where that law was adopted prior to November 28, 2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law of the Company, the Company must obtain an opinion of home country counsel, acceptable to the NYSE American, that recovery would result in such a violation, and must provide such opinion to the NYSE American; orâ—Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.5.No Indemnification of Executives Officers.The Company shall not indemnify any Executive Officers against the loss of any Erroneously Awarded Compensation, including any payment or reimbursement for the cost of third-party insurance purchased by any Executive Officers to fund potential clawback obligations under this Policy. Â Any indemnification or insurance policy or any contractual arrangement with any Executive Officer shall not include any indemnification obligation on the part of the Company to the Executive Officer against the loss of any Erroneously Awarded Compensation.6. Required Policy-Related Filings.The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by SEC filings.7.Acknowledgement.Each Executive Officer shall sign and return to the Company within thirty (30) calendar days following the later of (i) the effective date of this Policy set forth below or (ii) the date such individual becomes a Executive Officer, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which the Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy.8.AdministrationThis Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee, in which case references herein to the Board shall be deemed references to the Compensation Committee. Any determinations made by the Board shall be final and binding on all affected individuals.9.Policy Not in Limitationâ€‹3The Board intends that this Policy shall be applied to the fullest extent of the law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company under applicable law or pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.Nothing contained in this Policy, and no recoupment or recovery as contemplated by this Policy, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against an Executive Officer arising out of or resulting from any actions or omissions by the Executive Officer.10.Amendment; Termination.The Board may amend, modify, supplement, rescind or replace all or any portion of this Policy at any time and from time to time in its discretion, and shall amend this Policy as it deems necessary to comply with applicable law or any rules or standards adopted by a national securities exchange on which the Companyâ€™s securities are listed.11.Successors.This Policy is binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.12.Effective Date.This Policy shall be effective as of November 20, 2023. The terms of this Policy shall apply to any Incentive-Based Compensation that is received by Executive Officers on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded or granted to Executive Officers prior to such date.Approved and adopted: November 20, 2023 â€‹4EXHIBIT AIBIO, INC. CLAWBACK POLICYACKNOWLEDGEMENT FORMBy signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the iBio, Inc. (the â€œCompanyâ€) Clawback Policy (the â€œPolicyâ€).By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersignedâ€™s employment or service with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.â€‹â€‹â€‹EXECUTIVE OFFICERâ€‹â€‹â€‹Signatureâ€‹â€‹â€‹Print Nameâ€‹â€‹â€‹Dateâ€‹5 EX-19.1 10 ibio-20240630xex19d1.htm EX-19.1 Exhibit 19.1iBio, Inc.Insider Trading Policy1.Purpose.Both the Securities and Exchange Commission (the â€œSECâ€) and Congress are very concerned about maintaining the fairness and integrity of the U.S. capital markets. The securities laws are continually reviewed and amended to prevent people from taking advantage of â€œinside informationâ€ and to increase the punishment for those who do. These laws require publicly- traded companies to have clear policies on insider trading. If companies like ours do not take active steps to adopt preventive policies and procedures covering securities trades and the handling of confidential information about iBio, Inc., a Delaware corporation (the â€œCompanyâ€) and the companies with which the Company does business by company personnel, the consequences could be severe.We are adopting this Insider Trading Policy (â€œPolicyâ€) to avoid even the appearance of improper conduct on the part of anyone employed by or associated with our Company (not just so-called insiders) AND to promote compliance with federal, state and foreign securities laws that prohibit certain persons who are aware of material nonpublic information about the Company from: (i) trading in securities of the Company; or (ii) providing material nonpublic information to other persons who may trade on the basis of that information.2.Applicability.This Policy applies to all officers, employees and members of the Board of Directors of the Company or any subsidiary of the Company and to consultants and contractors of the Company. This Policy also applies to family members, other members of a personâ€™s household and entities controlled by a person covered by this Policy, as described below.3.The Consequences.Anyone who effects transactions in the Companyâ€™s stock or the stock of other public companies engaged in business transactions with the Company (or provides information to enable others to do so) on the basis of inside information is subject to both civil liability and criminal penalties, as well as disciplinary action by the Company. The consequences of insider trading violations can be substantial:For individuals who trade on inside information (or tip information to others):Â·A jail term of up to 20 years (30 years in certain circumstances);Â·A civil penalty of up to three times the profit gained or loss avoided; andÂ·A criminal fine (no matter how small the profit) of up to $5 million.For a company (as well as possibly any supervisory person) that fails to take appropriate steps to prevent illegal trading:Â·A civil penalty of the greater of $1 million or three times the profit gained or loss avoided as a result of the individualâ€™s violation; andÂ·A criminal penalty of up to $25 million.Further, if the Company has a reasonable basis to conclude that an employee has violated this Policy, whether or not knowingly, the Company may impose sanctions, including dismissal forâ€‹â€‹cause. Needless to say, any of the above consequences, even an SEC investigation that does not result in prosecution, can tarnish oneâ€™s reputation (as well as the Companyâ€™s) and irreparably damage a career. Finally, the size of a transaction has no impact on potential insider trading liability. In the past, even small trades (for example, trades as small as $400) have resulted in SEC investigations and lawsuits.4.Our Policy.No Trading or Tipping on the Basis of Material Non-Public Information.If a member of the Board of Directors, officer or any employee (or any other person, such as a consultant or contractor, designated by the Company as subject to this Policy) has material non- public information (often referred to as â€œinside informationâ€) relating to our Company, it is our policy that neither that person nor any family member or other person, as discussed below, may buy or sell securities of the Company, make a gift of â€œCompany Securities,â€ or engage in any other action to take advantage of, or pass on to others, that information. For purposes of this Policy, â€œCompany Securitiesâ€ included, but is in no way limited to, the Companyâ€™s common stock, options to purchase common stock, or any other type of securities that the Company may issue, including (but not limited to) preferred stock, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Companyâ€™s Securities.This Policy also applies to information relating to any other company, including our customers, collaborators, partners or suppliers, obtained in the course of your rendering services to the Company or any subsidiary of the Company, and you may not buy or sell securities of that other company or engage in any other action to take advantage of, or pass on to others (other than co-workers who have a business need to know), that information. Because of your access to this information, you may be in a position to profit financially by buying or selling or in some other way dealing in Company Securities or the stock of another publicly-traded company, or to disclose such information to a third party who does so (a â€œtippeeâ€).It is illegal for anyone to use insider information to gain personal benefit or to pass on, or â€œtip,â€ insider information to someone who does so. There is no â€œde minimisâ€ test. Use of inside information to gain personal benefit and tipping are as illegal with respect to a few shares of stock as they are with respect to a large number of shares. You can be held liable both for your own transactions and for transactions effected by a tippee, or even a tippee of a tippee. Furthermore, it is important that the appearance as well as the fact of insider trading in stock be avoided. The only exception is that transactions directly with the Company, i.e., option exercises or purchases under the Companyâ€™s employee stock purchase plan, will not create problems. However, the subsequent sale or other disposition of such stock is fully subject to these restrictions.Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are no exception.What is Material or Inside Information?As a practical matter, it is sometimes difficult to determine whether you possess inside information. The key to determining whether nonpublic information you possess about a public company is â€œinside informationâ€ is whether dissemination of the information would be likely to affect the market price of the company's stock or would be likely to be considered important by investors who are considering trading in that company's stock. Certainly, if the information makes you want to trade, it would probably have the same effect on others. Both positive and negative information can be material. If you possess â€œinside information,â€ you must refrain from trading in a company's stock, advising anyone else to do so or communicating the information to anyone elseâ€‹2until you know that the information has been disseminated to the public.Examples: Common examples of information that will frequently be regarded as material are:Â·financial results or forecasts;Â·clinical trial results;Â·major new products or services;Â·acquisitions or dispositions;Â·pending public or private sales of debt or equity securities or declaration of a stock split, dividend or change in dividend policy;Â·top management or control changes;Â·possible tender offers or proxy fights;Â·significant write-offs;Â·significant litigation;Â·impending bankruptcy;Â·gain or loss of a significant license agreement, customer or vendor;Â·pricing changes or discount policies;Â·corporate partner relationships; andÂ·notice of issuance of patents.Individual Responsibility. Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions in Company Securities while in possession of material nonpublic information. Persons subject to this Policy must not engage in illegal trading and must avoid the appearance of improper trading. Each individual is responsible for making sure that he or she complies with this Policy, and that any family member, household member or entity whose transactions are subject to this Policy, as discussed below, also comply with this Policy. In all cases, the responsibility for determining whether an individual is in possession of material nonpublic information rests with that individual, and any action on the part of the Company, the Trading Compliance Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described above under the heading â€œThe Consequences.â€20/20 Hindsight. Remember, if your securities transactions become the subject of scrutiny, they will be viewed after-the-fact with the benefit of hindsight. As a result, before engaging in any transaction you should carefully consider how regulators and others might view your transaction in hindsight.Transactions by Family Members and Others. The same restrictions under this Policy apply to your immediate family members and others living in your household (including a child away at college), and any immediate family members who do not live in your household but whose transactions in Company Securities are directed by you or are subject to your influence or control, such as parents or children who consult with you before they trade in Company Securities. You are responsible for compliance with this Policy by these persons. â€œImmediate family membersâ€ means any spouse, child, step-child, grandchild, parent, step-parent, grandparent, sibling, mother- or father-in-law, son- or daughter-in-law, or brother- or sister-in-law (as well as other adoptive relationships). This Policy also applies to any entities that you influence or control, including any corporations, partnerships or trusts (collectively referred to as â€œControlled Entitiesâ€), and transactions by these Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for your own account.Transactions by Non-Residents. The same restrictions apply regardless of whether a person is resident within the United States.â€‹3When Information is Public. Information that has not been disclosed to the public is generally considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed through the Dow Jones â€œbroad tape,â€ newswire services, a broadcast on widely- available radio or television programs, publication in a widely-available newspaper, magazine or news website, or public disclosure documents filed with the SEC that are available on the SECâ€™s website.It is also improper for any employee to enter a trade immediately after the Company has made a public announcement of material information, including earnings releases. We impose certain â€œtrading blackoutsâ€ to ensure that the Companyâ€™s stockholders and the investing public will be afforded the time to receive the information and act upon it. These are discussed below under the heading â€œTrading Blackouts.â€ To avoid the appearance of impropriety, as a general rule, you should not engage in any transaction until at least two full trading days have passed following the public release of the information. Thus, if a public announcement were made after the market close on a Monday, Thursday generally would be the first day on which you would be able to trade. If a public announcement were made after the market close on a Friday, Wednesday generally would be the first eligible trading day.Post-Termination Transactions. This Policy continues to apply to your transactions in Company Securities even after your employment or service to the Company or a subsidiary of the Company terminates for any reason. If you are in possession of material nonpublic information when your employment or service terminates, you may not trade in Company Securities until that information has become public or is no longer material.5.Pre-Clearance and Trading Window PolicyPre-Clearance of Trades of Company Stock. Because the officers and directors of the Company are the most visible to the public and are most likely, in the view of the public, to possess inside information about the Company, we ask them to do more than refrain from insider trading. Additional restrictions apply to officers, directors and certain other employees as noted below. To provide assistance in preventing inadvertent violations and avoid even the appearance of an improper transaction (which could result, for example, where an employee engages in a trade while unaware of a pending major development), all members of the Board of Directors, officers, employees designated as Vice President and above, and certain employees in a position to have access to material non-public information are subject to pre-clearance in writing by our Trading Compliance Officer or, in his or her absence, our President and Chief Executive Officer, of all transactions in Company Securities (acquisitions, dispositions, transfers, gifts, etc.). You must submit a written request for pre-clearance of a transaction no later than three business days before the proposed date of execution of the transaction. If the transaction does not close within 10 days, a new approval will need to be obtained. You will be notified if you are one of the specified employees subject to this pre-clearance requirement.Pre-clearance does not relieve anyone of their responsibility under SEC rules. All individuals subject to this Policy, whether subject to pre-clearance or not, are responsible for adherence to this Policy, including, but not limited to, not trading on inside information, not trading during trading blackout periods, not trading for two full trading days after earnings announcements, and not trading in securities on a short-term basis. If you are in doubt of whether or not pre-clearance is required, you should inquire with the Trading Compliance Officer or obtain pre-clearance as a cautionary measure.Trading Blackouts. From time to time, the Company may require that members of the Board ofâ€‹4Directors, officers, specified employees and others suspend trading because of developments known to the Company and not yet disclosed to the public. In that event, these persons should not engage in any transaction involving the Companyâ€™s securities (other than as specifically allowed by this Policy) during that period and should not disclose to others the fact that they have been suspended from trading. The Company will also require the following mandatory trading blackouts:Earnings Trading Blackouts â€” All members of the Board of Directors, officers, and employees will be subject to a stock trading blackout period beginning the day prior to the end of a fiscal quarter until two full trading days has passed after earnings for that quarter are released. Thus, if an earnings announcement is made before the stock market opens on a Monday, Wednesday would be the first day on which you will be able to trade. If an earnings announcement is made after the stock market closes on a Monday, Thursday would be the first day on which you will be able to trade. .Of course, no trading may be done at any time that an Individual is actually aware of a major undisclosed corporate development, subject to three exceptions:Stock Options. Cash exercise of options to purchase common stock can be done at any time. Same day exercises and sales of options are subject to

trading windows, as are any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.Employee Stock Purchase Plan. This Policy does not apply to purchases of Company securities in an employee stock purchase plan resulting from your periodic contribution of money to the plan pursuant to the election you made at the time of your enrollment in the plan.Exception for Approved 10b5-1 Plans. Trades by members of the Board of Directors, officers or employees in the Companyâ€™s securities that are executed pursuant to an approved 10b5-1 trading plan (a â€œTrading Planâ€) are not subject to the prohibition on trading on the basis of material non-public information contained in this Policy or to the restrictions set forth above relating to pre- clearance procedures and blackout periods. Only Vice-Presidents or above and limited approved exceptions by the Trading Compliance Officer are eligible to participate in a 10b5-1 plan.SEC Rule 10b5-1 provides an affirmative defense from insider trading liability under the federal securities laws for trading plans that meet certain requirements. It does not prevent someone from bringing a lawsuit alleging insider trading. This Policy permits individuals to adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company Securities, including the exercise of options. Trading Plans are to be implemented only during open windows and when the individual is not aware of any material non-public information.Any Trading Plan must comply with SEC Rule 10b5-1 and be approved in writing in advance by our Trading Compliance Officer. The establishment of such a Trading Plan with respect to an individual may be publicly announced by the Company.Establishing a Trading Plan does not exempt individuals from complying with the Section 16 six- month short swing profit rules or being subject to liability under those rules.Revocation/Amendments to Trading Plans. An individual may revoke his or her Trading Plan only during an open window and when the individual is not aware of any material non-public information. Revocation is effected upon written notice to the broker. However, if the individual terminates the Trading Plan after the first option exercise or stock sale, then the individual must cancel all outstanding Trading Plans and agree not to enter into another Trading Plan until six months after termination of the Trading Plan.â€<5Under certain circumstances, a Trading Plan must be revoked or suspended by the Company. This includes circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. The Trading Compliance Officer or his designee or any stock administrator of the Company is authorized to notify the broker in such circumstances.Amendments to Trading Plans are not allowed once a Trading Plan is in place.6.Additional Prohibited Transactions and Transactions Requiring Pre-Clearance.We believe it is improper and inappropriate for any Individual to engage in short-term or speculative transactions involving Company Securities. We believe that this trading can reflect badly on the Company and that Individuals should not engage in any types of transactions that are commonly viewed as a form of â€œbettingâ€ for or against the Company. Accordingly, members of the Board of Directors, officers and employees (or any other person, such as a consultant or contractor, designated by the Company as subject to this Policy) should not engage in any of the following activities with respect to Company Securities:Director and officer cashless exercise â€“ In response to the restrictions set forth in the Sarbanes- Oxley Act of 2002, the Company will not arrange with brokers to administer cashless exercises on behalf of directors and officers of the Company. Directors and officers of the Company may only utilize the cashless exercise feature of their options if (i) the director or officer retains a broker independently of the Company, (ii) the Companyâ€™s involvement is limited to confirming that it will deliver the stock promptly upon payment of the exercise price and (iii) the director or officer uses a â€œT+2â€ cashless exercise arrangement, in which the Company agrees to deliver stock against the payment of the purchase price on the same day the sale of the stock underlying the option settles. Under a T+2 cashless exercise, a stock broker, the issuer, and the transfer agent of the issuer work together to make all transactions settle simultaneously. This approach is to avoid any inference that the Company has â€œextended creditâ€ in the form of a personal loan to the director or executive officer. Any employee who has any questions about cashless exercises may obtain additional guidance from our Trading Compliance Officer.Trading in securities on a short-term basis â€“ As a general rule, any Company Securities purchased in the open market (i.e., not including stock purchased upon exercise of an employee stock option or pursuant to an employee stock purchase plan) should be held for a minimum of six months and ideally longer. The top executives and members of the Board of Directors of the Company are already subject to the SECâ€™s â€œshort-swingâ€ profit rule, which penalizes purchases and sales within any six-month period. Any employee who wishes to sell Company Securities that were purchased in the open market and that have been owned less than six months must obtain clearance from our Trading Compliance Officer. You must submit a written request for pre-clearance of a transaction no later than three business days before the proposed date of execution of the transaction, and any such request must be renewed after five business days to be valid.Purchases of Company Securities on margin â€“ This means borrowing from a brokerage firm, bank or other entity in order to purchase Company Securities (other than in connection with a so-called â€œcashless â€ exercise of options under the Companyâ€™s stock plans).Short sales of Company securities â€“ This involves selling Company Securities that you do not own in the expectation that the price of the securities will fall, or as part of an arbitrage transaction.Pledges of Company Securities â€“ This involves pledging (or hypothecating) Company Securities as collateral for a loan (other than margin debt, which is prohibited as described above). Because securities pledged as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan, and that sale may occur at a time when the borrower is aware of material non-publicâ€<6information or is otherwise prohibited from trading in Company Securities, any employee who wishes to pledge Company Securities to secure a non-margin loan must clearly demonstrate the financial capacity to repay the loan without resort to the pledged securities and must obtain written pre-clearance from our Trading Compliance Officer.Buying or selling puts or calls on Company Securities â€“ This includes options or derivatives trading on any of the stock exchanges or futures exchanges.Other hedging or monetization transactions â€“ This includes the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, and may permit a holder to continue to own Company Securities but without the full risks and rewards of ownership.7.Company Assistance.Any person who has any questions about specific transactions may obtain additional guidance from our Trading Compliance Officer.Remember, however, the ultimate responsibility for adhering to this Policy and avoiding improper transactions rests with you. In this regard, it is imperative that you use your best judgment.8.Modifications.This Insider Trading Policy has been approved by the Companyâ€™s Board of Directors. Officers of the Company may, from time to time, make non-substantive modifications to this Insider Trading Policy (including, without limitation, substitution of the names of the appropriate contact persons within the Company) without prior approval of the Companyâ€™s Board of Directors.9.Acknowledgements.All officers and employees of the Company and its subsidiaries will be required to acknowledge, electronically or in writing, their understanding of, and intent to comply with, this Policy. Members of the Board of Directors of the Company acknowledge their understanding of and intent to comply with this Policy as part of their being subject to the Companyâ€™s Code of Business Conduct and Ethics. This acknowledgment will constitute each such personâ€™s consent for the Company to issue any necessary stop-transfer orders to the Companyâ€™s transfer agent to enforce compliance with this Policy. As a condition of continued employment or engagement all employees (and all other persons, such as consultants or contractors, designated by the Company as subject to this Policy) must periodically acknowledge, electronically or in writing, that they have read and agree to abide by this Policy.â€<â€<7ACKNOWLEDGMENTI have received and read the iBio, Inc. Insider Trading Policy and I understand and agree to comply with the specific requirements of the policy. I agree that I will be subject to sanctions imposed by the Company, in its discretion, for violation of this policy, including dismissal for cause, and that the Company may give stop-transfer and other instructions to the Companyâ€™s transfer agent against transfer of Company Securities by me in a transaction that the Company considers to be in contravention of this policy.â€<â€‹Signed:â€<â€<Name:â€<Title:â€<â€<â€<Date:â€<â€<â€<â€<Signature Page â€" iBio, Inc. Insider Trading Policy Acknowledgement GRAPHIC 11 ibio-20240630x10k001.jpg GRAPHIC begin 644 ibio-20240630x10k001.jpg M_]C_X 02D9)1@ ! @ 0 ! # _VP!# ,_" @,* @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,#
L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" &+ \L# 2(
A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76UJC9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0
M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.G]\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]&_B%\7 _# M_P .-D.H2R7%](N]+.U4-)M[, M(/'.N7LY)=[N10"
<[54[5'T %)FL,U&";2T3VZNY^W8#A# + M#P>)3E-I-ZM+T5CZ>_X:TTC_ * 5]_W]CH_X:TTC_H!7W_?V.OF&BO/ _-;L MW_Y^+_P%?Y'H?ZHY3_S[?_@3_P SZ>_X:TTC_H!7W_?
V.C_AK32/^@%??]_8 MZ^8:DMH?M%S#%G;YCJF?3)Q37%V;MV]HO_ 5_D#X2RA:^S?_($_\SZ:_P"& MM-(_Z 5]_P! 8Z/^&M-(_P"@%??]_8ZYK5/V9+*.ZGTW3O%\%QKL<'VA-/N(
M51G3H#PV0,\9P:\FTV[M[?SY+6>.#>8_.:-@FX$@KNQC.0> :O3QN=\!9>T ML0TKWV47MOM?:YY>"R7A[,$WATW:\[DM]M[;V/I7_AK32/\ H!7W_?V.C_AK M32/^@%??]_8Z^;AH6I%@!IUX28_-
^SODI_>Z=.1STJ1/#FK27GV--+O6N]@ MD\@6SF38>C;<9Q[UP?ZTYV_M?^2K_()#_5;)5]G_ ,F?^9]&_P##6FD?] *^ M_P"_L=' UII'_0"OO^_L=?-<>E7LTL\4=G<22P9\U%A8M'CKN&/E_&IM)T
M>34+BV>9)X=.>X2&:]2%G2(,P!.0,9 .<4H\59S)I*: .\!7^02X5R:*;<'I_M>?\ F?1W_#6FD?\ 0"OO^_L=' #6FD?] *^ _[^QUPME\#M+UGQ[JVBZ?JJY) MIUE8K="[^S@GS"1^](Z<\?
TKQZ:"2WE:*-XI4.&CD4JRGT(/(KLQ6?Y]@ MTI59JS;2:47K'1["A<@R'&-QI0=TDVFY+26JW/IO_AK32/^@%??]_8Z/^&M M-(_Z 5]_W]CKYOMM"U*\LWN[?
3KN>U3.Z>*W=HQCKE@,5W7PG^%UCXYTS7-3 MU6[O+2PTV,$&SA\QY&()..#G X RXNK&C2DKN[5U%*R5V[M%XGA M[(L)2E6JQ=E9.SDW=NR5DSU;_AK32/\ H!7W_?
V.C_AK32/^@%??]_8Z^=-- MTF+4_$UMID+;+,R88*7VABOKCG%=C\3_@_<_.#G7M.M3=->Z=?%4BO/ M+VD/G#*1D\C((YY'T-$.(<^JT9XB$DX1:3=HZ-[?\L$^'LAIUH8><6IR3:5
MY:I;_P#'K7_ UII'_0"OO^_L=' #6FD?\ 0"OO^_L=>)?%'P OP\\6_P!B MPWH!'-+-IEY;726TUI M<17+XVPR1,KMGIA2,FN?_6S.5O/ ,E7^1NN%,G?V\ R9_YGTK_ ,-::1_T M K[_ +^QT?\ #6FD?]
^ [^QU\V:CH]_I!4?UC7#>1Q MJ4Z7[SO;WGK;5]3V?\ X:TTC_H!7W_?V.C_ (:TTC_H!7W_']CKYAHKE_U MNS?_)^+_P !7^1U?ZHY3_S[?_@3_P SZ>_X:TTC_H!7W_?V.C_AK32/^@%?
M?]_8Z^8:*/\ 6[-_^?B_\!7^0?ZHY3_S[?\ X$_\SZX\,?M-^&-=OTM+R&ZT MAI#A9KC:T6?=E/'U(Q[UZ^K!E!!!!Y!%?G0#@U]N? [5)M7^%VA3SL7D6)H= MS')(1V4?H!7W7"_$&
(S2K/#8JS:5TTK=4FGTZGPW$_#^'RNE#$X6Z3=FF[]+ MIKKT.[)P*^3OCO\ \%(_AE\%?$]SX<@AU#Q;K5HYCNTTGRQ!,N.J-*[%AW" M@X/!(/%>Z_'SQ)>>#_@CX\US3Y#%?
Z=H=Y=02#^&1(693^! K^>>>9[B5Y97 M:21SN9W.2Q/4D]S7ZKA:$:MW+9'YC6]..%DC]4/\ A\'X-_Z$'7?_ ,MZ/\ MA\'X-_Z$'7?_ ,MZ_*RI[#3[K5;R&TLK::\NYFV16]O&TDDC>BJH))]@*[_ M *I2['+
[>?<_4S_A\'X-_P"A!UW_ ,#+>C_A\'X-_P"A!UW_ ,#+>OS-F^'7 MBRVTN\U.;PMK<.FV3%+J\DTR=88&'4.Y3"D>Y&*AU7P/XDT+2+75=3\/:MIV
MEW>/L]]>6$L,$V>1L=E"MGM@\TOJM'M^(_;$#]./^'P?@W_H0==_\#+>C_A\ M'X-_Z$'7?_ RWKXT_8V_9$N?VK_$NO6DFLS>'=(T>U26;4(K47!:5VQ'$%+ M<@.D274: ,T;RJJS*IX^9'5P#ZU/L
M*',X]4/VM6R9^A?_ ^#\&_]"#KO_@9;T?\ #X/P;_T(.N_^!EO7Q#^T?^R[MJWP>^+/B+PQX9L/$'BK1='B@DEU9=->0(7C#D.T2%%QG\J\@\.>$==\8W4EM MH&B:EKES&GF/#IEG)C_ (?!^#?
^A!UW_P #+>ORPN;::SN);>XBD@GB8I)%*A1T8<%64\@C MT-7[WPOK6G7-G;7>CZC:W-X UM#/:21O.#P#&I4%P9^H' M_#X/P;_T(.N_^!EO1_P^#\&_]"#KO_@9;U^8-
KX3UR_U&ZT^UT74KF_M0QN+ M2&SE>:$#@[T"EEP>N0,5]3P?L9^#/$GCGX.>'/#'C76-5;QA8M=:Q,NF$G3< M1JV]]$#-(_:-TZ MZ^(2DQ"PDMX?(><=8@ ^W:IG1P\'9_J.-2K)71[1_P^#\&_\
0@Z[M_P"!EO1_P^#\& \ 0@Z[_P"!EO7YL>+?AEK?A3XCZKX)6)-=UO3[I[0IH>;Q M9G7KY>P$M[C&0<@@$&L7?"VM>%]1&GZSH^H:1?D BUU"TD@E(/0A'4$C*T M6%HOH3[:H?]!_P
/@_!O_0@Z[_X&6]'_^#\&_]"#KO_@9;U^:#_$,CVL8EG5=)N"84/1G&SY1P>3Z533P-XDD\.MX@7P]JS:"APVJBPE-J M#G',NW9UXZT?5:/],/;5#]./^'P?@W_H0==_\#+>C_A\'X-_Z$'7?_ RWK\R M-
,\"^)=:BM)=.\.:Q?Q7;F.VDM=/FE6=AG*H54AB,'@9Z&O0/@'\!YOBC\>= M!^'/B;^U/"TE^[I-OM?+N8<1LX_=R@==N.12>&H)-M JM1NQ]L_\/@_!O_0@
MZ[_X&6]'_#X/P;_T(.N_^!EO7YQ>._AI=Z!\6_$W@G0;>_U^?2M3N+"!;>V: M6XG6-RNXI&#SQS@8K U#P=K^DZW'HU[H6IV>L2$!-/N+*6.XPO;5#]3_ /A\'X-_Z$'7?
RWKW#]6ZJOCX;_M$:RF@V+7OA M[Q)("8M-U94'VC'\]1258@?PG!] : .#RMGP7K=[X;\6:/JFFW#VM]9W<4\, MT9PR.K @BIE@Z;7NZ,<:\[ZG']5]0O[;2K&>\O)TMK6!#)+-*VU44#))/8
M5!H5Z^I:+87<@ DG@CE8#H"R@G^=>&?MU:O=:3^SIKWV64Q&YEM[>0KU*-*H M8?B.*\W#4/K%>%&]N9I?>=E:I[*G*IV5SS?QS_P4(\.:)K,]GX<\+77B&TB8 MI]NGO!:))CNB(')'N>G_
)R/ !U_P#:^%.M%?]D>'\NC%)T[_- M_P"9\1+-<6W=2M\D?=?_ \]/_1.1_X.O_M%'_#ST_\ 1.1_X.O_ +17PI15 M?V!EW_/K\9?YB_M3%_S_(+_"/NO_AYZ?\ HG(_\'7_-HH_P"'GI_Z)R/_ M =?_:*^%**/[
R[_GU^,O\ ,/[4Q?\ /^" R/NO_AYZ?^B:58V3+;VKVBIF:8@DYW M\ ;>G]ZN7$Y5E.$I.M6IV2\Y?YFU'8ZO-4Z*?#MWX1\2ZIHE\A2\T^YDM9!ZE6(S^(P?QK MHQ\#OB&= _MO_A"-> _LG9YOVO[
^S9_>QC./?%:O)LJBDY023V]YZ_B0LPQS M;2EMY+_(^M/^'GI_Z)R/_!U_]HH_X>>G_HG(_P#!U_\ :*^+/"_@[7O&^I#3 M_#VC7VMWN-WD6$#2L!ZG'0>YJ?Q?\\ Q-
\[N*\V\2Z#]A3RC=&E_;M'Y@[ME2>#^!I_V)E?-R7FYM/1?Y'V9_P\]/_1.1_P"#K_[11_P\ M]/\ T3D?^#K_.T5\C6WP8\>WOAW^WH/!FN3:,4\P7R6+F,I_>!QDCW Q7;> M!?@UH?B7]G3QWX\NY[Y-
9T.=([6**51 P(&=ZE23U[$5A4RK**:OR7U2TDWJ MW;N:QQN/D[/CK@XY_#-4=!^'GBGQ3/?0Z/X=U3 M5)K$A;J.TM'=X"3@!P!E3D$>GKJ9_VACM/>>ODO\C[*_X> M>G_HG(_\'7_VBC_AYZ?
^B>'[7PCK%SK5D U MS8Q6C+ ",@N!PN0>YJS#\%/'$6H:?!?>#]=M([N]6R5I+%T+2$\HN1RV,U+ MRC*%]E?^!/\ S*6/Q[ZO[E_D?67_\]/_1.1_X.O M%'_#ST_\ 1.1_X.O_M +17@7[3O[/?
"E?'>G:3HEOJ]]I=_;1M!?\ MB?X0^./!6EIJ6O\ A'6=']L\ 7-Y9ND>3T!/;\<5G1RO**T(SC!6EM[S_P R MJF-Q].4HREMOHO\ (^O?^'GI_P"B>G_HG(_\ !U_]HKXZ M\(_#'Q=X^BN9?#?AK5-
=BMO]=)86K2*A]*1QGVZUZ5\;_@7I?PN^%OP]UZ'^ MTX=:UC\SY%K?L L+J#\JIM!7D=^33GE64PJ1I.'O-VM=]KZZZ"CCL?*#FI:+ MR7IV/>_^'GI_Z)R/_!U_]HH_X>>G_HG(_P#!U_\ :*^%**ZO[
R[_GU^,O\ M,Q_M3%_S_@O\C[K_.'GI_Z)R/\ P=?_&BC_AYZ?^B_,-WPYP.^-: M_P#M%?"=%']@9=_SZ_&7^8?VIB_Y_P %_D?KA\ ?VJ/"GQ]6:UL$FTC78%WR M:9>,"S+W:-APX'?
H?:O:*_'C]F#6+K1?CWX)FM)#&\FI10L0>J.=K#Z$$U^P MQ^[7P&=Y?3R_$*-+X9*_H?49=BI8]DW/='B/[0/{6?A+X -%8WL95]9@\AP?L(NK'FDU=ZM?DT?;TL%2Y$Y*[/O+_(>C M'_HFX_\
!W_]HH_X>C'_*)N/_!W_P#*:*#:*[?["R__)]_C+_,U^IT/Y?Q M9]Y?\1C_P!$W'_@[_\M%'_]&/_1-Q_X._P#[17P;11_867_\^_QE_F'U M.A_+^+/O+_AZ,?\ HFX_\'?_-HH_P"'HQ_Z)N/
=__:*^#:*/["R__GW^_M,O\ ,/J=#*^7\6?>7_#T8_P#1-Q_X._\ [11_P]&/_1-Q_P"#O_[17P;7NOQ3_M_9R3PIX5^&EYX:;5->UGQ;:F9K_1J[!PH.V-5&3U[YK"IE.5TI1C.G;FO;67_M17[D2PV'BTG'?U/??
^'HQ_Z)N/\ P=__ &BC_AZ,?^B;C_P=_P#VBOD2\^!_MQ#T_2+G5+KP1K]OIULQ6:XDT^0*A'!SQG\<8JIXE^$WC7P;H]OJNN^%-7TC3 M+@@17=Y:-'&Q/09/0GMG%-93E3=E%?\ @3_S&L-
AGLOQ_P""?8W_]&/_1- MQ_X._P#[11_P]&/_$3C'_HFX_P#!W_\ :*/^'HQ_Z)N/_!W_/:*^.C\ M)/&P\3Q^'\ A$]8.O/$)UTU;1C(TY9Z.5'0>YQ4>L?"WQCX?\06FA:EX7U:Q MUF\(6VL9[1EEG)
[(/XOPI_V1E3=N5=_B>W?7 MC/3FI='^&WBSQ!XAN=!TSPWJE_K5L2L]A;VK/+"1UW@?=_&F\FRM*[@N_P 3 MV[[A]5P_;\7_)GV=_P]&/\ T3O\ @74?[/\
$6BW^AWI7<(+^!HF()1GJ/<5Z!\,/V=_%GBWQ%X:DU?PIK]K MX3U.[BBEU2*T9%$3'&\,5.!_M$8J)Y3E5.'M)05O\3U]-=1/#8:*YFOQ?^9] M,?\ #T8_]$W'_@[_ /M%'_#T8_\ 1-Q_X.__ +17R?\
'[P!IWPN^+OB+POI M,MS-IVGRK'$V4@J#\Q /7TKSVKIY-EM6$:D:>C5]Y=?F..$P\DI*._J? M>7_#T8_]$W' (.__M%'_#T8_P#1-Q_X._\ [17P;16G]A9?_P ^_P 9?YE? M4Z'\OXL^\O\ AZ,?^B;C_P
'?_VBC_AZ,?\ HFX_\'?_-HKX-HH_L++_P#G MW^,O\P^IT/Y?Q9]Y?\1C_T3)?"]UX;MI6""^ANQ=QQD]W& MQ"![C/TK[%L+^WU.R@O+29+BUG02131G)_P#D9=6_Z^YO_0S6;7\+5OXLO5G](4?
X4?1!1116)L%6-- Y M"-I_UV3_-"%5Z='(T,JNIVNA##U!!X-5%V:8FKIH^HOC)\7HOAYXMF@L/#] MI+KLEB@75IF&Y$8M\NW;D@$9QG%<1>65[K_>G)903WJQ%JKM*D"&1QEY.2 M!
[N/SKRSQ7XGUGQAJ$>IZW.]S-9$+=-V&'!]QZ5]K6SV.+Q=9XARJC.,HI)*\5)IWMHF]%>[^9\ M71R*6$PE%8=1]M*49-MNTG&ZM?5I:NUE;R/J32G?3?&ND0R*5N;7PFQ>)NJD
M21#!_%3^5>9_!KXDZCJMYXDN-9&HM+?M"C:[96HD^RMRJ(RA2 O/'! YSUS7 MED7Q\60ZW>ZZNIRF_O(?LTUR\2L#'D'8 5VJ,CMBH?!WQ*\1^ EG31=1-K% M.Z48Z76MKWU35]&
<<.'*LUM&G971[_P"'])U:U^*/Q L]2O(]2U"\T9)()(8Q M%O0[E4;1T(Z=3Z]ZY7PAIUWH?P#>'4+::QEFU^W\N*X0QL1YL(S@\)5/Y5Y+ M'\0_$47BIO$:ZK,-9;[USQRN,;=N,;*-[/2H[W;;O=:]
[]S=9)C.:,7*/+^[T^]XH #9QGH3QTKY2_M!_M$7B5+S5YS(]Y Q)$BE8;EX27(&.^U3@\5X%I/QM\::'HZ:9:ZY(MJB M[(_,C1W1?168$_3TK$L/'&N:;9:Q:0:@XAU<$7WF*KM/G.&Z[CR34%916E_?M-
2M MA?!TSW'CK199&W22:C"[,>Y,H)/YFOIW7M:T_P :>/=<^'^M,L9'D7FEW W M)(J*Q4>X.2/4%A7R78WD^G7L%W;/Y=Q!(LL;X!VLIR#@\=16GJGC+6=8\2+K MJU>NVKJR.+I%5"&3 4@*
.,#M7@Y9F\V:2&:YM?(,4H#$A>!G;@$'K[G->'W_Q M%\1ZEXFB\0S:I(-8B4(EU$JQD*,X&% !')R"..<\U=\5?%SQ7XTT\6&K:LTUG MD%H8XTB5R.F[:!GZ'BO;EQ%AI.Q,5"+<6TH+ MFUYHW>
M/T_P"+OA?PCKFIS(+[PS*8[W?_ ,M41[<+^+8[UX'HOB_6/#VGZE8Z M=?/:VNHQ^5=1J ?,7!'4C(X)&1CK5?0/$.I>%]3CU#2KR2QO(^%DB/;N"#P1
M['BN2GQ#3C+#SE3NXN_[S4>6+7FEKTU^\ZZG#]24<1"-2RDK0_NIRYI)^3> MG73[CZ&\6^*M(U;X::];ZG<^(-:C<-]GO-1T9HA;S@94;U10O..O3I[5Q?[1 MW_'QX-_[
Z_^RUQOBOXN>*_&M@+'5=5::SX+011K$KD=-VT#=]#Q61XE\6ZO MXK>S.KW1N6LX1!!F-4V1^G &>G4UGF.=4<91JTHINZ@DVK?#)MW]Z3ZZ:LUR
M[):V$K4JLFE9R;2=]XI*WNQ7371&-1117Q9]D%%%% !7VA^SQ_R271?K-_Z- M:OB^OM#]GC_DDNB_6;_T:U?H7!'_",9_P"!_P#I43\^XW_Y%T\:_*15_:F M_P"3;?BA_P!BUJ'_*3O7_)K^@;]J;_)-
M^*'_&+6H?\ I.]?S\FOZ)P/ MPL_<3N@KVG]BW_DZSX7?]AN'^35XM6UX+\9:QV(/%>E^)/#]Y]@UK3)Q7(.AVN"IZ]""*]":YHM(Y8NS3/UQ^%O(2/B[QS^VW\4?AKJTMK<>"M* MTZ5;333:I\CQB+
<[/C<^_P Q\AB1TP!CGQCP]\=_%/[27['W[2C^.)K74%T8 MO)IL<=]D2VJ8=D1=HY"&)2"&;[I'6N-8:VUNGX;G1[:^_F?I%^SU*U^%?[&.D6)^(&B_"[Q?XTN MH]<;4]8E2-
S"KHR1(K2(6_=*N<'CS3ZUQ/[2XBG4HZN"00R[UZG_5XKX3^*OQL\9_&VZTFX\:.Q_;#Z5;?8 M[)?LT4"01";;7]OAG2-035+"Q>T@?[M-'-'U;5[&1?
&/AS2Q=V^GW\L"Y@F&QPH+DMRI4&1P=F0:^%! P41_:"\B_B M/Q D;[8,,YTZU#1<8_=D1C9^'?GK7)_"K]KSXM?!@ZL/"_C"YACU6=KN\COH MDO%EG;[TW[T'#GC+#K@9SBLUAI?
@O*_BAXLO0-2 M^$#7<-\SC\9K\O/&_CC7?B/XIU#Q'XEU.?6-;OW\RXO+ M@C\2(J:I9(B$7 7(W M$%EX)!VD9'!KHG2#^U?BCI M5A9Z80NUHGEC(9@0?
O%2'8=C%4EKXPUCPQ\7_P!D.RTR^>VM=8*R6%]'M5_ M.@\BV?82P./FC0Y&#QUK\P/$/Q?\8>*O /A_P3JNMS7?A?0'>33=/9$"P,V[M)W !F^\V-Q.,G&*Z6;]J+XG3:WX*U=_$I;4?!EN;,0IOL5O_
*)&55"N/+P_ MRJHRX8\5C]6E:S=]_P K(T]JKGZ+R_' ,8>%OAG^U+XQCOX[K7/#GB!]-TJ M:>!"MM$BJL0V@ -L,C$;LY/7->"?MA^-=1^+W[$7P4\<>)6BO?%%QJ,T$]^L M2QM(LRGA0 -
WEH2!@9&<5\KWG[17Q"OO#OC'0I_$&_2O&%X=0UN#[' /M;^'/$FJ^$-.Y(QC/F!.#[@ UJX3C)RA;7N0I1<4I=#W[]E'PMXJ^ M!G[/GQRU;PUX<$_QOT*_%A);26XN;FVAVJVZ-.=X(:20 #
[5Z]*T_'>N>*? MB_\ L,P>+?C-I@M/&>F>([9=!U&\L19W5RAGB7_5[5P*< !@H..,U\+?# M?X\^/_A)XNNO$WA7Q1?:,K5YG[7<.PG%WDY/G+(&$G/.6!(/3%:?Q<_:;^)7 MQSU#3[KQGXGFU0:?

();2VCBC@MX7'\8B0!2WN]^OH7[1*-C] M0OB=^TIXR\.?MX?#[X9:?=01>$-1LT-_:-;HSW#RB7#&0C<-NQ< $#KG-8OP ML^. B7XF?M. &WX7ZT;*3P+I.EW$%CI$5I&B1;-BL20,MO\ ,;()(Z8 K\U= M: :7^)'B'XIZ7\1]0\1 :/&>F(D=I]7V.!?+5=VT>6$"'[[=5/6F^&?VDOB+ MX\' \WB#QKI'B(VGB;7T>/4K[[' _GJY!8;&0]N=H^Z!TK/ZKI;2]OQ*]MK\ MS[F\&?$+XE_#'_@FWX-U7X76<\^KKJ,\-Q*+K2OB%I>J32W\!T\O UL[S-AFD0QN#N0X'.?3 M%>&ZU^UC\5O$/Q.TSX@W_BZ>X\4Z6K+87+6\)BM58$,(X=OEC(//RY/&3Q2] MA*3>EM7Z_P###]HE;Y'Z)?
V'0?"TA5]HWQA;76IZ;XE/C*^M;S5?#^F+J&I M6=L'4IY<15\CYG8 .*1QG!V\>6?M=?%/P^_ (P!GOPU*EUXZU7QO8ZG%<&_ M%NO^%Y=-FF(D&Z,3K%&F=N<# +$#@D9KXR\# _M,?
$OX<>.]9\8>'?%5QINNZ MS,]QJ4B11M#=NS%B7A*^6>22,*,9XQ6QXX_;"^+?Q&\4Z'K^O^*VOKS1+@7> MG0&S@%!,.DGD;/+9AV+AB.U6L/)3YOZ_(EU4XV/U"\4OXWM?V<[[QK9>'M& MC_:(E*1QWHA8&]2WW9+!.NX#+!,8WY7/&*_%NYN9KRYEGN)9)[B5R\DLS%G M=B_4SJ34[6*%6](_Y"EI_UU7^8JI5O2/^0I:?]=5_F*Z3);G]&WA#_D5='_Z\ MX?\ T6M>#_M^?\FZZI_U^6O_ *-6O>/"'_(JZ/\ ]>3EG^ 4?\2 ,[<9_NT_1GY;4445^VYR%%%% !114UI8W.H2*5: MVTUU)C.R"-I&QZX4$T;#(XXVED5$4L[$* .#)IZ5^DNE:-X3^#?PB^'WA#6?B M/9^ -:M9H->NDDVF2Z?
=O9&4D87.U2?]FOSD"W^@WT$QCGL+N)Q)$TD91E8' M((##L:W_!?JWC3Q[*_PEGB.75M9A)%H-8O(V:/(R1&) N>3Q[UX^/PCQKI MQY^6*=_-OIOIW. "UUAU)\MV_P NOF?
8WQ9\!^&$;Y^&_C622TO/"7BN2.7 M[1N5K>2Y1?D)/3#?)U_NFHOB;K_[4,7QN\01>&;753I"%Q8QQ6L3:>;?;PVY MQM+]>IW9XQ7QKJ7Q$\3:QX8T[P[?:[>W6AZ<_F6=A*X,<#<\[QD?>/?O74#]
MI3XI#0?[&_X3O6O[\ORO+,XW[,8V^9C?2C'^U7GK*Z\5"_+/ECR^\FU:^C]; M:/ ,ZOKM-N7Q1N[Z=[:KT/ICX-W'C&T_99\:WW@*WE?XGOK<@U@PPH;]!N& M[:F/O ;\#'7=@9KS_5-
1^,&]77PYM_C/#]*^!GUJ$^;JUM$CLV_);$ .., MXW8R,]:^?_!OQ%\3_ #S4Y-0\-:]?:+>2#;)+:3$>8,YPX.0WX@U8\= _%7Q?\ M3KB&;Q3XBOM;:#/E+O7]3]-O%OB670_BW#]GT3XH:CY$*F&UT6.
Z)-&%Y&&95]CN{; MICM7@6HZCHVL?`K]N"[TS3;O1=,GUF]WL+Z$0SP-A?-5D!(4[MQQGO7S'IW[ M1WQ/TGP^NB6GCG68-,6/RDA$X)1,8VJY&X#Z&N7L `WB/3 _#NIZ!;ZU>1:-] M;^9>V0DS'<-
>?(R3^-<.'R6I2WDM''OJD['_UW56/TQ\5Z MG8Z):> H="L/B+/I*V,)A\ A!DA-@XP,"?)ZX_O?+R>^:Y?3/'-N?&OQMU_ M1-&U/PKK%IH$+W4&J0)%-]I02[9 %9E;(V_-GG%?"WA'X_?
$7P'H_P#9.@>, M=4TW31G;:QRAD3/78&!V_ABL>Q^*'B[37UM[;Q'J,;ZVI34W,VYKP<\2%@2> MIK.&15$I1?#KQ'X[U;]D'4M;^`]U=ZG MX]O-8+ZU>6P674'7Y1N'&2=F,
<=,XK9^+7B'XA:5^S+\.M4\6W%UIWC.'7K= MC.P"7*KO(0N!P*V]>/KS7Q5X%^) _BSX97;F MO;WK6MR]K&^QT?9\NM[6\O7U/O\ OM;BU'M32-,UB]>Y@L_#GVO2K.4J42[M;<'= ?
XR@/-07WCBVTS22'7]L>$_BUKFERPRQ7\.O6UO+9P@Y^:%=Z_*/]C(MQS7P/JVL?$?QGXLL-6OY/$6J>(TV0VEV8)1< J255"]@Y!)(Q5SQK\=OB?XF MTV?
P[XF\6:U<6B,8KBPNF\LDCJL@"ACCT:N19+)N"4T|))[Z6>ZMW^6IO_:* M2DW%ZMM?/O\ UL?4MU=>/-_ 9-^'C?!5+PQO,YU1]%C62[W[F^\,$]=N[OC' M:L+]NF7Q!-*OA._BI%C\1M&YOU
Q+Y?.0. ??'?-?,7@;XQ^- AI;W%OX7 M\3ZCHMO<',L%M(/+8XQNVOT ?<T@\2^(]0UV*T9F@6^E\S MRR>1!QGGWKOI994IXF-7W;*4G>SGXS7?I M.%%%% !1110!Z)^SM_R73P+_ -A>W_\
0Q7(]'[M?C;^SM_R73P+_P!A>W_] M#%?LD?NU^;<4_P >GZ?]?7Y)_#GZGXM_' \ Y+3XT_["L_\ Z%7G]>@?' \ MY+3XT_["L_\ Z%7G]?"1HY$:.1>J.I5A]0>:5T(9ZU^B41' "2_LJ\
M_P#+NW_HH5^=M=C_ ,+A\;";0IO^$HU'S=!&W2W\Q5VMS?C%K]3GK4G4M;S_%'WS\(_C=XM\1?M+?%;1-0U5[C1=,M)6LK%E7R MX#'MP5XSDY.C>' MM2T&RUJ[M=$U-@U[8QN!%<'_
&ACG\Z\Y90HOFBDG[G3^7?IU_X,^WK7;17,_F_ MM$7][_H\7BE? QEU46^,"<.I7./?=CVKY7^*G[57BG7M+\-7?PPU#Q3H^FZ- MI$=CJTRVF+<2A5&XGYU'0X8X-?/VE_%?
QEHNNZGK5CXFU*WU?4XS%>WHFW2W M"'JKLP.17!1RJM6HVERQ=FMM7=_:_0QAAI2CK9;^OS/K[X$^,/&?BOX! $_9 M#X4NYM8^*\UZ%EN6V27GV(_A[J_]>&M;O=$U @JT]G+M+]
M0PZ,/8@U9\=_%#Q9\3KV*[\5>(+[7)H01%]JDRL8/7:H 5?P%>F\KE[?G7+R M\REM[VBMR]K?U8Z/[]Y[Z6O?S]/0_0RXUSPC;^$I?VE4=/[7E\._8Q; #[7 MJW.1_%G*_0BN0_93U:RG_9M\5ZTD?
B*]\0WFK22:0)X1"-JOS$%2FXYQRW3G MKBOA9O&_B!O":?%SK%X?#JS_&D:89/W E_O[?7@5H_#?QKXT\&ZZ'\$:GJM MAJEP-GE:5N=Y@.<&, [
,C6$LHDJ,X<^MU:^W*MHLAX5\C5^OX+H?;7QB\5 M>'-8T#X:Z5XH\,>-[6)=/]7$GC+6M2U2^ MM28Q%Y]!*F]P(\ (?7@&NOTGXV_&JS\'VHTWQ/XI3P[:RK;PW$ =HD?^&,2[M2?
3"EOPJ'E4XTXI.+=FK.[2YNJ\R?JS45MUW\^Q;_;&.?VDO&O\ U\I_Z+6O M&*Z_Q'I7CGQAXAU74-;TW7=3UI8QWN!F&::%T24>JL1AOPS7T.&BJ=*%*Z;22_ [Z:Y8J-]BI11174: M!1110 4444
*.HKZ(^`O_(F:5_UR_P#9C7SN.HKZ(^`O_(F:5 UR_P#9C7G88 M[X%ZF%79'J_B? D9=6_Z^YO_ $,UFUI> \ D9=6_P"ON; T,UFU_G76_BR] M6?
OU'^%'T04445B;'6?"5%D^)OAE64,IOHP01D&OHKXPZ-)=^ O%LVL:+9^5 M:LK:3<649:?;A?G? ^7#$Y[;TM[Q))97Z(HZDU M[OJGQ%\%>')?%FLV?BF??KK68BB:2FXPHVW:, C
]R3TSP:_1,AK4(Y;6I5I MIUN4O[C15=+^UASOC5HPA'(QG MDX^E;-A??#;PUXSN_'L/BJ2]ED,MQ#I*1'S!+(#N'K_$< X SR3BMU1R_%5. M>JXS?
N*7-.W+#V<;N.JNT[JVM6KMJ<[K9AA:?)24HKWW'EA?FG[25E+31-6= M]+WO?0P)]-ND_9O73S"PO1X@^SF'^+S/,V[?KGBG1_L^:1:3VFCZMXTMK'Q3
M=1AX]/6(,H)Z+DD$]/;/8&H;KXGV$_PQ+BYA&OGQ' :W]GY.0OG;_3&*Z+4+ M_P"&_C#Q?9>.KKQ3)ITT?E37&DR1GS#)']T#Q/8=,YQP1FI5+ 8CV=^6;C"F MK2GRI1]
[F>C7O+33IV9;JX_#>TMS04IU'>,>9N7N\]U3]UZZ];;HX/PM\#M0 MU;Q+KFGZO>Q:-9:)S>WK##R".*ZOPMX[MOB+K?CR&^TK4O^$,*LW"5Z2Y5%.-I5G9
MWNK77E>]SS7Q1\&9]+\0>&++2;YM5LO$"*UM=M$$P3@MD GHI#?ZO5X?Q%\+ M6?@OQ9=Z-9:BVIK:A5EG:,)B0C)4 $],C\<^E>X?"GQLNB_1.YUG5+59&T&6
M6+39I0"79EPJKWZN5/M]*^<+N[FO[N:ZN)#+<3.TLDAZLQ.2?S->!FU#!8?# MTZE"-I5;2MK[L;6:U>MY7U?1(][*]^-KXBI3KRO&E>-]/>E>Z>BTM&VBZMGT MA^S_ .&-
U'X>&]FTG3[VH3ZC&#LB)&PD$<#;QQU.3Q7SYXG_L[_A) M-4_L?_D%?:9/LO.?W>X[>O;'3VQ7T;\OB3X8LO!?A=%\46VA1:;"R:AI4T M9KB8,"WZY8%"WC:*<%CN&Y2 , Y]P3Z
M5[&:T,//*]'LJD+TTKVMS2NH[6=]+OFOK=7L>1E5?$0S6O[6G.U1NU[\L;-[MW5M;*UM+.USJ?V8?%LT]S<^&9+*T>SBAEO1.R$RE]RC!.<8Y]*YVP\/W?QU\ M1:MK^KW-EX;TG38EBN;F&/Y
%W$8#'KC))QTJA^S]XITKPEXQO+O6+Z*PMG ML9(EDES@L67 X!]#^56OA7XN\\ ]@>)_"7B.[;3=/U=O,BOU&1&X]>..BD9 MXX(-9X7$TL3A,)AL5-.*<_=;LKI+D4GNE?2YIBL-
5PV+Q6)PL&I6A[R5W9M\ M[BMF[:V)=<^"FC6_@;4_%&C>+%UFRM2!&L=N!D[@^K'/!&<]*F\7 _:Q\.WU MAI%IXB- X@U&2-;6Q:W"#RR?GDJ@@?-M M.:VK87*X07-
"*D_9IJ,W*SE*2DU:3NTDM-;;;]<:.*S.WFOVA+O(RGHJ#OC!7J.M>P^%_!?A4_%E]?M+O M53JDK27!TRXLI(Q;R.IW,[,HP.3@$]3QFN7\'?%/3=']U3QMH-UK+>'WNM5GN
M;/5EA65$8M@A@01_".OJ>1794RS+H2IRQ%.,$Y32M-M-*/NW;EHV]]8^=KG' M3S/,9QJ1P]24VHP;O!)IN7O62CJDMM)>5["ZW\&]/TJ'2M:LO$7VOPQ/=); MW-]);&.2T).-S(>HS@=NHKT3XL?
#.R\?_$K1;DM;MK',\(ARR0(6(D'3) M8G&.V,UR/Q9\>K-X?M]*@\>2>*99Y%-W"8Q1P!0P8$,J@@@@< G/M5_Q/XN M\,>(OC!I>I1>+7TJTM],6-
-2LE)"SAG^1BPP!@Y.00>G&:SMEM/VN&A!:G;0^6D@P,#ZYYP[UV7RT6@4445XYZX5]H?LV?\DET7ZS?^C6KXOK[0_9X M"P"22Z+]9O\ T:U?H7!'_(QG_@?_ *5$ /N-_P#D70_QK\I%7]J;_DVWXH?]
MBUJ'_I.]?S\FOZ!OVIO^3;?BA_V+6H?^D[U_/R:_HG_"S\!Q.Z"BBBO3.,* M*** "BBB@ HHHH **** .M^$?A9O&_Q4\(: B;SJ6K6MJ5QU#2J#^F:_1W_@ MH_\
L\P_$K7/AIJWA.VMC=RZPOA6]%FH'EF8]8]P XVD'K_??%?#_ .QIXB\+ M^#_VD/!VO^,,=8MM#'T'2II+R2\NMVP.L3>6/E!.2^T=*^ROV;OVY/ FD>./C. M/&VNVMOHUWK\FN^'I[J-
G$I'[L",;20Q6*%ATZFN"OSJ:E%;?J=-/E<;2ZCO M^"GGPOT;3/@C\.Y?#,-N\'A[4UT(BU1=P#0;0K8'+91.O=]\FTG_()Y^$M
ML_#FD_$OXSZ=X*^('B*)9+#P\MLDH0MC:LC,P).3M/W1G(!.*I+^TOH'CS]D MGXAZ;XBUZVM?'K^+_P#A)=)TZXW&2?,T4NU, C"A67&1TKTCQMXC_9O_ &]/ M%_A;XL>*?BE-X&UG3[6W36?
#*%Q"3),T+%PL;8S@L6&Y V01PIK./M*<>77KT M+?+)W/E2X_96\4Z'^TWIWP*Z76H, Y0:%(4MRH#$"09[XF^ M#'O\ P4H\->.O%FH>'_B#X(\->!O#/B&VGCU/6;-G8O(8VV^=B/+ALED M?
\A2T_ZZK_,4AK<_HV\(?\BKH_\ UYP_^BUKP?\ ;_Y-UU3_K\M?_1JU[QX M0_Y%71_^O.'_-%K7@_[?G_)NNJ?]?EK_P"C5KRTK0?&?4I$.&31KAA]05-?+]>Z_L=_$_P_ ,"CX MG7FJ^*
[Z33],FTV6V$L<$DQW,5P,(">QYQ7F9G"53!U805VULCLP MM9\1_LMZ;X3?Q.;/3[KQB-&:*2WC\M!]H52V_P"]U^;&>O'2FZ7\9?@3\ ;+ M7]7^&QUKQ1XQU*&2&&XU.)TB@WG)Y9$ 7/)P"3@#-
DXPYHM)QV:3O)Z M=.QZ_M(M6JS4I6>M^FEE?KU#]H0]FGP5*TTW3/#FOZ[=>++B\CM%TO5;+:E MUNQ^\BD"*NT$]BW/'!K?U/\ 9B^#/PTFL/#OQ%^)UJIWC*ZA622.QA7[+:%N
MF\^6V!G/+,N<9XK>^-G[2/@2#X5V&@^&O%&I>/M8MM3@O]/O-6MF$FGI&ZL% M:5D4N0 5R= M?"W]F71/'OBGQ? M +OX>2^/OAKXPO\)QX1N=,HN" "-4@U=/ACXG^2&ZE&^\M<
@,X3G!!/0$C"Y!YK1\;?%'X6_"OX)Z] M\\ X8:GJ7B>]\1N#?ZM?1&-8X\8P,HN3C([DD]JZISQOUA)CIYDL#G&Y7&UN M"5!^Z0_NM1VU:OK):;VLM+]>I<5@W..VNOH[:+[[_ (%GQ5^Q
MKH\&I>"M3T#6-:D\)Z[JL6F7<6K67V74+)G;:&VNBY';E?3]*NW7[+OPBB^+ M]O\ #.'QEXAF\22+*9)3'"D,4FS?'$,=+LM4@N]9N]50?9&1'# K&(EZ-I/A!Y+4-:!]U<*>%&\$8(V]/[XKSOX* M?
$[7/A1X_L=9\/M;QWLG^BM]JA\U?+<@,,9'..]?4\ P4&^*VRRT3P':116 M5URGE.V**=`8@9P)KT,#*IC M<-*KB%I/9=+6M^+U.7$J&'K*%+>/7S_X!^DOQ2^*OBR;]J/P/X!L=2@TW2+J
M"*^:5+19)A(0^>6.-I QC'XUXE;_ +//AKXHZM\6O&'C?QEJ&D#0M;DBGOHH M(BC1*H)8H%SNQP OMP:C\8_M"^!=6_:\\&^.+75I9/#6G64<-S=FSF5D#P']*K'$6ME:ZGF9L *'1E1PV04R,=
<5C:M^PZL_QOL?"NB>(99?"]SI MO]KMJD\0>:& $]%7 =B67!P.O(XKC?'OQ9\,ZY^RXX1\&V>H22^(=*U!![N MU-O(JQH3)@AR-K?>'0U[(W[8W@_P#]3_ GJ-C&-1\&:]JG@+5?
$YU/0XS+-9^>)M+>V2\1' (V>/O%6N7@(LK4JD,4"G^&8O H*XX/.[TKXRKV,KEB9 M0DZ[;UTNFGY[I?D<&-5%27LEZVV -A1117M'G!1110!Z)^SM_P ET\"_]A>W M_P#0Q7[)'[M?C;^SM_R73P+_ -
A>W \ 0Q7()'[M?FW%/\;?%'GZ]?7Y) #GZG MXM_'P#Y+3XT_P"PK/\ ^A5Y_7H'Q \ ^2T^-/\ L*S_ /H5>?U]SA_X,/1? MD?])O%6LZ)96/CCPI*N+ZQCV"=2,[>23A@"")_.*XG M]F[XF?"[3O@CXP\#?
$37+[2(M9NU?_0+6620H%ZAEC8 Y]:E^)?Q[^&W@CX1 M7'PZ^#MMJ,UOJ,ZSZCK&IHR/(0<#< S$XQ]T #-?(3H3>*DX4WS\Z:E:RY; M*^O7KH>6X-U&U%WOOY:'0Z'^Q+X2T/0=^3QMK?
BH^(=9A654\.Z2]Q:V(8#' MFN(GZ9&22. '&:YW2_V+[,>/_&O@74M>N5\1Z?IW]IZ%+_J+#?Q<_?4@L&!' M(!KU&S_;\"_$C1=!O\ 5_BCXM^&NJ6-LU-.B!CMU;&TR$QOCZ0.T M9X]ZS=)_:&T"X^$OQ@TW5-?
U2]U[Q!.ATIM5A,EQ/&@(3S9(U$:D<>E=1?\ MQ.^!/Q^TWPKK?Q&UC5_"WBC0K9+:YM;2%Y(KY$Q@!E1^I&>JD9(]Z&LT3E)R MYDG+5Q5W*M:ZVOMEY(Q/"G[$EO)\QM891B5X%8;F(SP2.
M@SVK@-'^)OP*^ &D^+-;^'^K:QXD\5:U;RVEO87UNT:6*L3E68HHP#WRQ_.* MS]OCI3Y6YGS.,^'_.S7X#TSX3:=X\^+/C&^ M\,V>L2&/3;/380\K#D;F&QR>A. !@#DUZSX#_9V\+_!SXR?"7?
#/B6\\26N MNSS,MS,J+&T?E,RL@4 CT.3^5>?>%OBI\)_C!\$]!\%?%+5]3\,:KX;=FL]2 ML(&E%PASD<(XR02""!V(-=WJ7[1_P#0^GK^@B6:UL

-63>V::*]DMHAOFDW273'[MH7D(G3'WFSNSG '&.7&:=T]OU2^[^O,EP::;T?Z-Z^?3I^ADZQ#;P:E)(\\G']X=1_] M>F65SUM739FMLDY,P ,GZ$C*["UF'3Y-.FDU.""XLX%,SBYC615"@
MDM@@C@9K]2K)9IESY7;GC\EW/RBBWE>8KF5^27S?;[SQL:O-I=UX9TBT\6:5 MH.E7BW:37NAPHEJ6## 7?D* 8G-9\6OZEXHN--2YOUGD2VUBWAU6.!)Q'&@ MVR+D<9Y!QP:
[$7/@S7=#@\;1VQ_L;2H+B%]/6SC""<5W%H^F[H1];ZSQ#JVA M^%O#L6L7=@ALX(TCB6"V5G1),#;J]@,K.U]]3Z>>-C2E&$<.W4;E'6,4^=\VGPW;M*-U>VVAY)X M+6\,Z>FB#4(;IXX\S.6.(@6&-
J =.IJ]%XZUG7KSPQ%J'B;_(1*& TF2XFF M6-%$DBR%58;O\NY0#],XZUZ3I%WH/BS2(S-HHL[2UD,<-MJ]BL!3 !RB,.!@ M]1Z&GZGX2T;4]=@UV^:"XACLS9K#.(VMRI8,&YXR"_"NBGEF)5*/L*_-
'W?M M26BMO[VB232Y;-IZW9A/,\,ZLO;T.67O=(O5W_NZMMIOFNDUI9'DES\3/%%_ MI?AV#[>;5+D71;4XGAMC=B-I]$/*-BY')'>O2_!VKZGK?PUDN]7D@GNF@G7[M1;R(Z3(
0KY7C/8X[BM37+K1E?2=+NM,CU&VNYS!&J6Z2PVY5C@<<#6I5YRJ8ES]U1L]KVCT_&^^NO6_G8[' M4:M""IX90]YRNM[7EU_"VVFG2WSEX3U! #GPWOM4TK4=!M]22PCQ]@A OX\S
M*#YS'(([=.,XKJ]7\5^*/"*>*[!];?4Y;6WL[A+V:!'2Y;JRN M,+%-=PQ^3-M!^7YL'(Z_*>QY S7DQRNIA80P]/$[B_+E MTL>K+,Z>*G/$3P_-#F3DVD[7<++*]KVLI+SYM;GFOB+Q1=O:^*M-C\5KXKTV#
M2NFEBB95D,R YP,$@\,^HK2U#Q/XFMCKNJP>()(K/2M7M[.+3_)C,.(X3 M(8XSC#<#ZUZ!X5^%VF^&Y;R:>>369[J)8':\AC"",'<%$;]%Z\GBNG;1[!XY M8VL;5DE<22*85(=QT9ACDC
Y//%;TR>IXAK/Q"\5MXMU86NHQ69LM1^RP:= M/3Z?:SW$CI&VRWT^_9Z[ZO?KX MIK6K:QJNAZ]?:CJ+316VO06,6GRQOO%"/-0D\KR1G /15RT\3^)H[R#5I/$$
MLUFWB9])_LYXD\LQ;R.6OG(Z"O86TBP>.2-K*V:.,23SG4PJ0\G\C'+<#D\T M?V18[GV*VV"7SPODKCS.N_&/O?[76M/[&Q"GSJN[VRW3;3>NJUM:8S_MG# MN'(Z"M?M'9I)I::/2]]_,\.O?
B!K)B>^;O>;35&U?[&WAY88P8HA+MXR-W3D MMT.;] /WC];X";X/6%UEQ"ZU74+N 7 N19S%&7<#E09,.RH/12:[XG))KKR MC#8O#NJ\4V[VM=M[7N]6[7NM%;;9')FV)PF(5-
856M>]DEO:RT2O:SU=]V% M;6G?\>B?C_.L6MK3O^/1/Q_G7T1\Z6#TK D&9F'JW];WSTK D.)F/HW]: /C MV_'\2WNC>)-4\5?"VWNOA):ZW=>&=4UG3]8,D\"+*V22VS*"8SO7.UN,]
M:]=OOV@/@\]%KW2_ $OB2ST/^SK>"WALH89Y;>PA8 0K+*JLD((QCS&!P0:\ M2A_94^+^JZ!XF^'FH:UX1TKX:^(/$MSK=]=V;7%QJLL$LZRF!0RK&F0B@GG' M/)]+XC_L2>
(]8^)WBZ^TB/0]9\+>*[F"XN8]7US4[)[(*BI)&UO:,$N5(7Y2 MQ!7!7:U2;LW;T_KU,=.:5SW?Q;^T_P""-*U7Q1X9TSQ#97GC31M/N+S^S[E) MQ::XH#,4>=$*Y"X9@I+!3TK"TC]H_P"&GQ-
\+VWA7QAJVFR:KJGAY-0UG2HD MN6LH:62W\UV:=D4+%LS\$.#VZUYUKO["GC]_BGXDO#_L AWPWX5U#1KK2Y$L M]0NVDUG9+LOL]NW X9!(C!6,ZG<0
,$T[PI^QCXA'@;XB>&]=U;3K7_A)?"F MCZ';W=@[RF&>T@*2,ZE5S&7VXPLIMKF&>T$%E&H594$Z]6B &!]K M^U\1:?]\=\]]=O%<02VPAC#Q-$KJH=',X;AD?+Q7FW@7]B77KW3?$=OXQAT;
M2+RY\-S>'[‘4M+U_4]4F!E3;\A6Y8)'$0 ?*4<'H174_#WX(?%UOBQ\,/$'C M4>";;1_ ^FW.E1KX?EG-Q"-'T;PQ=F^TK^TWO_$_B$:5&H$WE^6C."K-W"YR>?2O2G^/_M (#@TZ\O9?
$*):V6MIX>M&Y-+%EJ4(GE6[XD218W0K@+D;LY!/2O.=7 &5O'IWX_P!3 MTJWU+P^GPSU/QG!XTGNW:7^U(I()A-LL0785+(N'W<#\]E*FTEL5>29ZY:_M M: ">
[\>IX+B\90 \)&=0DTK[(UM<(JW:,5,1D*! Q8$#YFQFQQFIK_P#:N^%6 ME^/F\&7/C2UC\0)<'S>(13-#'<'I"TX0QB0_W2V<\=:\KE_95\4R>&[NS$^B MK>S_ !0_X37S!,^#9^=OV$^7GS=N1MZ?
[5;'PS^$?Q;^#^M7/AO06\#:CX N M/$,^M'5=3%O_::132^8\1A4;&D&2%EW*>++'M,K;'RC$!<'O%%_X4B\ M&_#>X>ZT]_T99AJ&I-M=8A,C*%A&'R^TG<152C2>J8)S6YZ[X" .;S^$WQ.\6
M6GAKPSXP@U+6:M9&M[?[+/$)2F=Z*[QJ!< $E#=-^'< M%S/HQF\$:KJ%]JK6\KGS4G$VWRCY8LW-RYW:>G4XKZE P *QJ*"?N%Q:;IX6 M@'"3BBBLBQ=+47VABV7[<'P1NY+)
(?'ULDMW<_9%22TN8VBDR/-!C'E*21AGP#VZ&J M'O[_&MK+X'_!0\&^$WTG^T[?52LVL7RRL!I5J]\QO1S$ $'+M_$0.*Y?O[^ MRKXF\3:3\=+>SFT6.X\^ M+?B?XA^(?
%7CJ_T2ZUT)86.G:#.KVK6,*+Y"7/F1[B?,&\JO]2:Z5&C>[>G M_#?U\C%N=CT7XF_M::#\&_CII'//'T'4H=6T>_B$UM>6S[HY4]1^HP>01BOET?! M7X[:'XU*^-=-;P-
]WB"P\'IX:U&+5KNX\N>02$^;&ZQ9'R[*I47*[N87PH ;WL_BA)?/%OP\32C9V6F^<-*U@RLRZF]NRK/[[5_$GAZ]6YN]-U>X";;MG_X_A 4B+@DX+=<#_.W=^*/2? M%SX-
WT7A+2F\#:AV8]:GU,:M?"X,J&&60R-&8E 0RC.!+NZ#*J4:6\6),? M4S/AS^VPOQ)\>V&@V-MH]O%+XGN]$E-S)=OS/:1OEXIH@T>TR,5?*.1M"]LU MZAX5_:]^%?C+O=<^&M%\9VEYK,
E/E)'*B3>7GS!#(RA)2N#D(2>.]>1V7[) MOBP^,+& N]1TQ=,3QIJ^OS&&YD,HM+NV\I HV8\'T'DC( ]36?X4_96^)1A\ M>%/$5_X3B\&>)Y;K2M1TD3#4=1?:XB6964+"/G^T_#W M]J_X5?
%3Q3!X<\+>,(=4U>YB>:&W^S3Q"8)G>%:1%5F4#)4'(%>M+U%?,/PT M_9A\2>"XO@,+]?1R_@5]2?53;RN?.-P) IA^0;N77.[;TJXKZ=7@BL*BBG[A MI%MKWCH4^Z/I3;C_ %+_$-.3[H^E-
N/]2_T-9EGSQ^UP0OPC4D@#^V-.Z] M?*5X]['B7QA:ZCKWBR/QYKFW3O'L>BP:0UR&LOLSN@=&0C)X;@9XO[U],?%; MXBZ7\+O!TVN:M93ZC"LL<$5G;HK/-*[!44;L*.3U/2F>'/B!I.L>#?\ A(-;
MTR3P7;"9EGM_$D<5JT>U>]AL1.CAU>ES*[UTUO:ZM9]M_\ MRM2C4JOW[.W^>I\G:C\4M3M[_P 77-O\4?$!\>.IBU5G_M "[:;:O5ZF4<-/ELZEF_7S\]]?PV//(OV:|".F>/_ (P2G5=1OMOB 0^7=SAU
MSY:OO(P/FYVY_N@#WKWNLB3Q+H-A::A>2:KIEM;6DFR\N#(J>TY7T7W M)+_@GH4HQHPY+]_9QSC_69VI?>E3Q:H M4FAG6DUK3FT<#<=1%W&:
<#WDW:?UKFY)=O+YFW-'N:U>3^,6&O?$2VL92?LT M_56'^S]YOTKTS2-9T_7[^.^TN^MM2LI/N7-G,LL;?1E)%>8ZM"8?BE-&W!N5 M*(?
=XRH_6N_!+EJ2ONDS2%I:H_.XOO>/)_B)\2]=UV=S)%+=-';1M]V.W0E8 MT [#:/S)KWK1-+\/?$GX:P:?8VZ;?X2"16ZAE8J<_B*ZSX07]Q%\1_"]M'<3);3:M:&2%9" M$D(E&-
RYP<=L]*_1ZU%.E'V;MRI?+^OZ39O5I:'N/P7^%5[\K2?25:\1V/BB M\U:P74A#QZ+90.4N[YC@C=D&./)KP'XC;KH>M^+[^X\-Z;_9>B B.UB9BT MDB*,>;2
K7M7[65Y/;1^%HX9Y88YSK,&0.#7S MD:>!4JE\3-ZR_1_U^/=GBUZ5U9(^Y/@EXOF\=?!31;ZZE,NJ:)<'29I3]YX@ M-\)))AE?PKZNT2\,HZ/97)Y:6%6/UOS7QA^RQILNG_!#5;N4%4U#6E$()^\(
MXSN('U8"OL;PE UMX9TR-N&$"GGWY_K7O.<1C&;4>DG_,\37#II;lC6S17 M(>,O VK^);V&ZTOO[XB\)M%&4^SZ6EG+;R'^\Z3P2$GZ,O2N9^P?&'PBHD@U
M;PY\1K1.6MKZS;1;]A_LS1&2!F_WHT'N*^;.P]5HK@/"?QFTCQ!KL7AW5K'4 M//!WBR16:/0M?C6*6X ZM;RJS17"C_ID[$=P*[^@ HHHH **** "BBB@ HHHH M EM?^/F/_>%;U8-K_P ?,?\
O"MZ@#'U/_CZ_ 5Y_P#%3XKZ7\(]'LM1U6RU M&_CO+M+**'3(1+*TC_=PI89_#FO0-3_X^OP%>?\ Q-^&_P#PL5?#H_M#^S_[M(U:#5/\ 4^9YOEG.SJ,9]>?I6U'V?M%[7X>I<.7F7-
L>>6_[87AB20I<>&?% ME@+>]6PU&6YTT+'ILK'"'9@Y'S9Z+DU3^,?[1&K^ OBMI&CZ59PW?ANP6&;Q M)=&/E9,]?L;^&?%EWXGU3O1>7FL:]K,[RQ7\3RVZ6J:0L=:)(3R7<_,?

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}6MK*XGL;6Q1=+E@>UFGBW;;EV;
#$<$#CBLG5_V< M/''C.Y\4;AXI\9Z->ZIK.D1Z4AL=,EABMPDH<'!+4GTF&VLK!IIKRY09=8%![^<+W:@"NL^'WQ%T7
MXFZ&VJ:+,T4>TOGD_UQE165_F)R"&R,"O1/@_\+#\+/!UQIT?]D)JES(T\TVE6 M+6ML7(POR%V8[?4G)KCK0PBI7I2?-?\ #^M3&:I*K\^.);UM3_ +36XE%@+GS-P;[-GL,. MYS7KGP]^&]]X0\9>,-?OM2M[V3Q!);2F.")D\IHX]K9)/.3DCTK6O]4Y']Z MVML]TU\UWZK4\D\\ [2VN:C\9=6\-W^L^$--TO3]3DM!ILL=S M_:ES$][MT6,QD_4BN\\%_M3>]?'.KVUA9/]UE][@EGM[K4]->WMYO$"9 DAR M&*@9./SK'T'X&>-/#GC/Q)>6GBC0#X=U^EO+BRFTAWNU#IMVK.6^7'L*CM_MV<+FO/\>!+*XU.'4(_#%E?6UQ#;PM&][YZN,1ECA"-W\5:U%@I];:+;O9[Z= M[+?YER]@_P"O^
78/VL_!NLS066G1ZW#WNC2I9W3(L,')&Y 1VY MK,T?]K+0-*^'W\2?VC]FNWVF'4Y#H&BRO$8@Y4OM+$H !DI\O2O(//!@[XB M^,?%/@OPQ=V^N0>'/##SJKZSH(L1:Q[&\ \PD83MS@:!C'-
>O^#?V:[_ ,+B M#S=>L[GR_"\GA[Y+9UR[.6\WD_=YOCK6M6A@]/NR?GOZ];>AM_"GX1>'/@]X:32- LQ'N/F75Y+\T]W*>LDKGEB3^5>=_LD>$)
MX_!EYX\UA"WB3QA.VHW$DG+1P$GR8@<3^XB#,#Q;L>]::+_ &5XILQN ML]3BX(;_@D_O(>A!Z9_Y?P^\9R>*K"YM)0MO[/U_3I/L^H61_@?LR_[+=1_ M^JO3[\?*-
H/!/CSP_XRMQY5O>2KI6J@='1_]6Y]U(QGZ5%>/U6?UF&S^)?A MS>]Z]UZ(TH2^M0^K3W2]U^>_+Z/IV?]SO:,'T-+C#8/KBO#O"=WK+>)-!>,A M4FI)WIFGQ?$+Q-
(^C1:II6G6UEKMO/+!):7+F6-!$7 /HW3D>OK7"/,'-)Q;UM M]EZ7M:^FB?,K>]URR3%Q;4K:7^TM;7O;75KE=_0]5Z>U%>(:!\2O$-GX=L[7 M2],M+R.RT./5)YM0NI&DV[FW+N_B/'&:TM=^-
U[%>00:5I<,K"QAO9A<"9RQ MD4.(T\M3C@_>:_ K*/$&"]FJDVUMT27MIK:S-I_5=.^NE[H]=HK MR37OC7>17-E;Z7[2K-)8I>SI?),64MG$06-20>#\QP*M:9\6\1U.]NYO[*AM M-+L-
34;O9RXN5RK9C4=.[EZG"-;+/<"ZGLXSN_1]KO[NIB\CORI^TE"R]5 MWLOOZ'J-&*\@\\ OPOKF0RZGHZK926LERCV;39B*]6"_SJ%.0/O*<9IUMXD M\3:OXR\!W&JVUKIUC?M-
/#'8W+MO0O$A95/!(&#GDEV ME=NVFZ]=BY9%BZ4I*M:-DWNM;)NRUUV^6YZ[10.E%?1'SH5M:=_QZ)^^ZQ: MVM, X]$_'^= %@]*^;?$_P#R-&K?]?4G\Z^DCTKYM\3_/(T:M_U]2?
SKV?"3B[H[+2?C9K-BBQZWX<-]M'-WHLRG?_VQ MD((_!C6Q_P +[T M('WE,$_6ME-\'7]V3X*U#R_[PO+;_/?F5X4Z.'3TG^IZ<;E>$KX3IM0^+^OZ MH#'HOAT:8C8Q=ZU,N5^C 0,9))^K"N?
L])DEU(ZKJM[+K&L%2OVNX B4]5B0< M1K],3W)JA+XACTB41ZS8W^@.6VJVIVQCB8^THRG_(]6_"P=0RD,I&00<@BM M*=*E'6&IY>DM"W'5]+M56.K47;JD)%F,EN]3L](M?
M%_>6]C!D+YMS*L:9 M/098@9I(Z\2_;(CCE^$-HDS6:1MK=B&;4%W6X'F=9!W3U]LTJ5/VU6--NUV= M=&'M)]'<]XTO5++5[<7%C>6][!DKYMM*LB9'494D9JU+KNGZ9>6UK=7]K;7-
MR&,,$TRH\H498]L.9B.3CI7R"GB6[\)/X!\.Z\ $/PEX-T+6+S41>ZKX,M(DIT _IMEXIAL8/-NX8[M/*S(2I ()0)7 ..]=#RYN[YM->_2_E;IMN=RPSWOI_P_^2]LV&H6NJ6<5W97 M,-W:2C='/;R"2-
QZA@2#^%6,U\-_"_QCKVE^#/A[X4E^)G_"OM"F\/3ZQ#]\ MUO;[II!,RBT1I!MV(7(^\VXC/2MRV^-WB_QA]M?C1:_%>[T MK7K?2]S7R'4P_LU>_3]3V!OO5&U2-]ZHVKA1QE:[A6[MY;>7+
MPRHT;ID@%3P16-X\(Z3\\ PMIOAO0+7^S]$TV+R;6T$C.(DW%L98DGECU/ M>MQ^M1G[U:H0CR.RC+L<=.L3BHC+(2WW:A/>MD UY'/5V/?ECUJ M-I7.[.CGC'WC3FJ)NAK9".?
U[P1HOB7Q#H>N:G9?;-3T.1YM/FDD?$$CKM9P MN=I;')!QVQ6QCIX*D;I4?\ RU%:O20CUW3QBQMQ_P!,U_E4EQ_J7^AIEA_Q MY6__%S7^5/N/I2_T-?,RW9J8%%%%2 4444 %%%% !111 4444
%%%% !11 M3)I5@B:1SA5&20"?T% "(OL2%G(51R2:SVNI:O\ U>8(>S?O./;T!]>OM369 M[N0/*.*#E(NH'N?4]P>U2#K?9"DHZO2>Y/J:?14%[>1:? M97%U.P2&"-I78GHH&36NY1S_(N\+-
%T73O"?O :SFFUFRBOI"N2MU%;/*%8CY20#G&<&NB,*DI^SI1TV$_' M+ZOJEQH.MZ;_A_Q1:IYLNG22"2..+./.MY< 2QYQG@,N0& [^;6CMX1^- P]
MT[1_B%XK\066IR7:WMEK5\TT3*D#,IP8UY# =Z]6^-GAN;5/"UU[2<)XAT!C MJ&GS+U8J/GB)[HZ[E(IZF>DHPJ. ,M';UM:,_<#T:4NOR-\=:)84F4!U# '(MSV/8CWJEH6KP>(-
%TI5+;_CWOK>.YC'HKJ&_#,*OURNZ=C,AO+:@8S-"_O/ MSJ./S[^YJ>.194#(K!M?^/F/_>%;U &/JG_'R?\ M=KSB7XSZ']!]%M)9ZNFJZ>=UUI/V!S>)#NV_:%B',L/??'NXI9XKT?4_^/D_M[M<%\)
(/"LMO?O2:=([:A+YM[<-=2FXN7F5=7=O,?:RP0N.,5O2]EK[2_R+ _#MIX#G\8Q:@E_H$4)G%S9_O/,_-]CKNSQ&X((6N;M/C3-I=E+ M]'C3PEJ/@C2=B20ZA=%W5W&^]@$C98
]$UOP9=>%GLH[3 M19X#;_9[-1"(U[%,#@@\Y]:X?_A1NI:A:0VNN?$37]>MK:2W>VAN+>VC1!%(MKKN"(-[G: 7)SC/%;T_J[3Y^_G>WE;2_>_R-(^SZG06?QM\#W^L3:7%XAMUO M849W66.2-
!M7>Z[V4*65>64'<.XKE]6_:I\!6VF?:]*U)]<<7%O \%O:S1LB MRN$63YXQE>XQU[55B_95\+KXGUC5):F6XM=2:XE-G):0%X9)@0[+<;?,XR2! MGC/<<4MC^S1&LCRZGXTUC69?+L[>)
[BVMXS%#;2!XT&P#/3!)Y[UNHX%,[DW MM_P>G]>9:5#N_P"OD=9_POCP"+G4X#XFME;3HY):AFCE5-L?WRC%<2%>X0DC MO4^O?%C2=*\$6/BFRCFU;3+RX@@A\M3"Q\R0(&(D
(P3T(S7$:9^RKH.C:CK M5U::FZB^2X$ ETRTE>T,O)!D\1;C&M!4D M6TJF.-YD=)/,7"-E0H/ 7H!0\42CA$X\LFU=7OVZ]!-44U9E'Q+^T=H?@WQ=-
MH^MVYLJ2*_:O>_CD,VUA#YH)B1"V3TP,^M;4_P"T!\/;=))"\3VQBCM$OFD2 M*5T$+G"-N"$9)! 7[Q/&,US=_P#LYS7>K#68O'>KVFO?:S>-J,=E;$M(8?);
M*%=N"IS@"BU_9@T2PT2_T^UUO5()+E+5H[L",RPSP2-(LPR,,2DE2,=A5N, M":7O,^E[7^>Z_KLNM-4++4W8/VC?AU=1120>(Q.)7DC5([*X+[D 9P5\O(V@ MY.0.5U&G^/M"UDW::9?QZA-
;64=_(D) A=2T9W8Q\P!P.OM7$>#_@%!X3\1 MS>(+KQ#?^(]4F-U),:V"&)9VG14;(0 *.*,8JW\%/A&/AMX$O=+N=]:AJ4\T MUT8I3*(U8L(XE8]51" /QK*I#"J+=.3;T_X/1;?J1)4K>ZSFK3]J.!M%6^U'
MPEJ&BM=6AOM.%Y>0M%>O*^Q]LB9V,.NUER17=2?&SP1#81WDOB&VC@>WDN=Q M5^$1]CY&W((?Y<$9)Z UP]G^RS8C2!8:GXNUG6!;VILM/:XA@C6QB,@=@B(H M#,<8W,2<5?
U3]E_PIJD/C!&FNXW\22Q3NZA6%JR$,/+4@@]6 8]>:VFL"WH MVM>E_P!?+7UOY%M4&_Z_4ZG&/X^^ 9ELBOB.,FZ\T1QFWF#KY8!DWJ4S'M!!.
M\#@URWBG]JCPOH$=A=V<4NL:7>PB6*YA$D;G]ZL?^]:/=CYL[NA[=:M^%?V< M-**30W-MJCB]6VNK>2;'3K:%)3, "YC5=N5 X!!SDYK+TS]E32["RM(\'\3:
MI<&W0H&,,2J!YZ2X1!PBY0#;O')HC']6K;7_#^7H"5!/5L],T3XE^&?$EQI M]OIFK1W<^H+,]O$D;AF6(XD)!4%-IX.[%>=_M@7TMM\#=5M8G,;:C. &OB>XAB@GUF[_ -
%@BF,BPP8!8C(^4NXW$#T%87[8 M%F]O\$-1ND7=_9]W:WK8'(5)5)(_"HH1IQO=-4W=76_]=-B8**K1Y=M#WKPS MIB:)X3P52=6,YNZC]/@?3/BUX-M?AO\2?$OBVTN3,-0@U+4)IHU&P[?
O*F<^F#7C7P_M^/4GPXT>72HO#-OJ,:B21KEM:U&T9B3T*03(G'KC-:7P-^%?C73OBGH5Q>>$ M->MK=':?=+-ILR*OR-U)7 KA[CX/>/3/*1X)\1$;V/_(*G]3_ +%?5PIT4W3G M.ZLM6]=WVL>I&,%
[K=]OU.XD^+$OQ:^(7@JW'AZ+3+B#5(=CQZK?7C/EA\N+ MF5POKQ@U^A6B?'V:_P#&-U)?P6VC^!ENWTJVU&9'>2;Z4X+2.#L@C+95=P.X MCJ*^9/A9\.(?AE;:+96=CI&E^+GTZ/5+O5-
>L%N+QII'Q%:6J3,J1-Q)YL') MQ7HGPV\#ZYXJU_Q#I>BWUKX?NK:5I[S4],D:Z:VN@6:(P>8(]RR*Y <.!D% M:\+'>PK+:T8KS>[WZ^5M_0X:_LY^B/KFRU&TU. RV=S#=O!BA>"0.H8<$9!Z
MCTKYS^#JKH?Q^^,FAP#;;MP^'?A2ST+3VDE@M MP2\\Y!DFD8Y>1B.Y))KPOX02+K?[0_QDUF'Y[:.UTY90>"R+N(TKYRDH[% M=1VLO_2E8\Z%N6=MK?]CW2BBBO..<*MQ?ZM:]5;B_P!6M
":E_Q]'Z"JM6M2 M_P"/H_055H **** "BBB@ H-%!H XCX=Q_VC\9?'E^YW&RAM-/C_-E=I=A^ M8%>M5Y-\-W^P_%_X@63\/=+9WR#U785) ,O6:\[_P ,7?FG_P"E,]"_P 6 M/:EA:_P%%>_O[?2[*>
[NIE@MH$,DDKG"JH&237A^D7]EXCU&]^*?BUS;Z!8Y MBT.SG'10<>;M[NQZ#U^&QK OSW$*DD0IL\R\YP M!P2<9KI-+^%\>]WEIJ?B<1W36@ L=&C _/*P4#
7_EH^,9<\>@ KAKSGBZ M[ITE=0[!BZOM:YWT(0PE!5:KLY]M^7LO,75]%WO8\[D\)Z_P#M#7T& MMZRB^'/#%H2VGV\D0::8$@EFSCY3CKT]!WKU'PCJH\5:UK%O#]DHM],O#91V
M%NR")55!\S8!+;MQ(YQ@ =C7G?QD^-'AF>P71;.^^W>5?PKJ%K$CA)[=6_>H MKC /0 X/."*ZGP9\)/#NF>(K'Q7X3U&XL=,G@R;&UDW6]P&'!.22 ,]/4=N: MYL/98AQH-5'=.;YM7NM%M:/;_P
MCJQ/\,\5TZ:LU!K>MY=[?]>H5P M/QWT]=1^$_B-2/FAMOM^-C[K1D.#^E=]7":7+4%TIX3^)>9+1H%'KW,.;ZM5YMN5_D>%@;_6J7+OS+\RQX0IB; M2[&;SM7N'.D:1NN&WJ?OC
[UYI//AI;2^)M.O)-5TB>WBM9I+>#3+J:5IXV MS&642'$; D\+WJIX\77D\GA9[3Q9?:]J-_'(NJZ;<$,EO&(R=^.?+@@S:V=FTFE;>ZL]-_HZ6#QN%I5Z4Z^K5KN_7G3W5TFTW?:SNM=O9=/^
M&VA:;;30P0SB.;3OIC;IV[@$G'U^8 -4-_*] U#[+E+RV:"V2TWVEY)"TL M**DA4 ,![UYC9>,;Z&)O['\67WB$W&BW-UJ)FP?L$RODJRD >6=WR[?:K'A M+Q=?G4|"_D^)KWQ3>WEC-
)J6GW.&6W=8\J< #8=V%OW_ !KT8YEEM3EI/#JS MLOLO=K:S][XE?EO;7L>=++SEE7 M!Y[E\JE147?JE?;_"=O^ >-F=+&9;-86K6T#5;/4;2.\^T698VPEO'D2($$% M54G
7D\5V5%>DLNP;Y:4H^[JM%H]-ON7W(\UYCC'S7JR\[1ZO5>?WO[V%%% M>B>>%:6G?\>B?C_.L6MK3O\ CT3\?YT 6#TKYM\3_P#(T:M_U]2?SKZ2/2OF MWO/
,C1JW_7U)_O9RSXY>AP8OX49EW?1:=;M/,3M7 "J,L'@*H[DG@"O0 M _WP<;58X=5\8Q"1CAX-#SF& =09L?ZQ_8 *.F#UK(^$'A=?$_BRXUJZ3?[^ MBOY-LC?=>Z(RS^^O2 /=B>U>F?$?
4[UVUTW3]/T^Y:RN]6OHK!;M,;H$8DR.N M>-P16VY[D=:RQN)F9 = M/=31PZA# _LLQ"QRKZ,=K#ONZUY9VG2:OJ^CP7%MI>I75HLNH9CBM+EE_?^JA M3U^E>><>*?A9-X6675/!\1:W&7N- W7
NI!W,&?]6_^S]T],#K74V?@Z3Q%:;M M<^(H%CNM358Q;QR!C:1)S&%1T.U@1D4Z.K<705+;6]+CH M<1JWP0\)ZKKV@ZF^F6<%EHR7072(;&$6<_G(%1@$9Y!KU)P6A< 9)4C KXI M\%?
#S7+;X8^_:$E\&_$2#Q%/I>I)&MV[G2)2[DHL4&['F,^,<=]WYGI44JD7SO:UOG<^S)/"/A37=+ATJ:1=$U'3K$CRK)K6&6*W/ M4:4P0A[5Q?Q&\$^$+S5(/&^]0)K]MH.D75J-"M:>"[CGB."=L1ZLNT
8 MKP?7O@OJ'@2S\21^%M.?PI87_P /X8[R]EF-M;R7XDC+I),S865EWKDD8S7% M6FBZ/KOC&^T_P\ #R]\+SR>]0BDT >DLEW.R+81=51VSD\!C@OD<<5M1PBO MSPJNWR[:WUTOY7.B%'JIZ?
UYGVI'9>%?%7A33+6]TC3#I4\,4D&DZE;0@0[E MW(GDMD*P!Z >M:IL]*LK2/2!!8V]HZ&&/3]L:1LG0JL? (]@*^-M7_9_U'6O M#OQ#U6[\&ZA/XDM](T5-
"D,#B431VZ"7R0.KJ5VGN.14/Q3^#WBW7OB=KUSJ MND:]J+ZD+3^R=3TS1HKYK=!&H95N'F0VK(P)/KUS2C@Z4G;VVF_ST>FOG^#% M[&+=N?\ K3_/\#[*N?
#VE3Z.NDR:992:4BJBV#VZ&!5!R (\;0 >@QQ3K+2; M'3'N7L[*VM\N'\V9H(5C,KXQN; &XXXR>;?I=K/9:196UU7.,$<J1^M1G[U:
MH0QONU">].N[F.SM99YFV11(7=L9PH&2>*\X^% [0WP\^-.IW^G>"O$L6OWM MC%YMS##:SQF-=VW),D:CJ>@YK5-+0#T%JB;H:L/#(,_NI!Q_<-0M$X5FV/M] M=IQ6Z$0MTJ/_
):BJGB;7K+PAX2U#6]7E-GIEA US! M2Z5]=MK>GV.HV4GG6=Y#'5O\ ]^! $$$ M)FDL)E0#]3L-;U(0&!! ((P0>]*+Y6F2G;4\0^-UGXJ\0?LP^"KKX?VUYJ&O M6JZ9=6ITU!)\45,L >,"_ I7RQXD^'
.T#\2-)UFZ\6>'Y$NJ:HL5O%;:/+ M:I&X43S]!=FWIC.?:ON'X=;['\+M=;P/K,@M])O+AYO#U]+Q$X=B[V9;H)%8 ML4!^\IP.5Q7L4L2S1.AR P(4XKOACY8+W8P3UNF][/^M3>-=T-%%/K<_,[
MX02"36?!GVC6/$LFI6OB>.VN%CTZ[O-AM(R A9A\O+,&/RY3 YY) K[G\&6^ MK>'_(<;A<;Y'Q&U)OA[H4_FPEE/B&
M^@8%+*VSDP9Z>;*/E"]0I+'"&5BL5]=FDMMV^R_K_(*M7V\D7/@ ;RVOPL\) MQS J_P#9T3[U ;+*/P# 5V-1Q1I#&D<:".- %1%& J@8 'L!4E>;.7-)R[F M#=W<>.E.'2FCI3ATK,S*L\?V9S<(<1G_
%]]O\[] #ZGT%3]P8 @@@C((([U* M!D8]G 3#*]NQZ?,F3R5 $DG!\=1435U<4EU+MK_,?,?^*WJP;7_CYC_WA M6]6!F8^]?\?) P!VO$KGX^3VDGB.S?2]..!T)O,FNEU11ITL6[&S[3MQ%<8_
MY9..O?%>VZG_,?) P!VL@:-IZVT=L+"U%O')YR0B!-BR9SO"XP&SSGKFMJ4 MJ<;\\;EQ<5\2NFR>[@&JV >2/9DD-$QP0<<'/ M0@BO/-% _:
(\0:1HT5MJ6B)XCU)8=/7[=<'<16*7%U>+NBB\O:1&JC(+DGITR; M]H\)ZWI?A[P9K.I;Y;O>:1!;LUW J!VDCZ,N"1G/U%<)I]\+/%%SK'AI]*T MP0RQ64%Q#=QH(;L&,FWB0[CN9%4\#!':NVBX.# C-
],.M['=6PUB/9"+55:1A)Y>&R&X ';\H/&/[2NHB+4+;3M(; M0I(K>ROK6\O)5D>ZAE:/?LAVX(<@D,2".0.*ZRV_P"%(>%8K2RAG\(:7'/ M*+>'[1'&)$E^23;EN0VS!/?;37MO@=96"^(??P?
#8WS)9KJ+7$8CF:+&V,-N MQE=J]/09KH3PZ;?L7^/?U[&B]G?X&<<=XC_:@UY0[R72"26(N[&]N](U&?4 MXI2ZVY*LTD(0[#D"'DFM+0_VH;F]\2VFAR>#M1O&006UY?69:0)S?7 _4% 7IT#
M]VU;D_K[RSX9^.\6K_##7_%^HZ+)I;Z,\]7.E](^%>B>'==TS0; MKPS;.):[VU6WMYXS#%GAC-DGCMSQVK+\&:-\%:;*&7PO%X4$;W"S1R:?*C!I MHE+A+@0Q^9%R?85DO8+G;I/?3?3UU_P R?
<5[P?\ 7S.6']]&/R--CN?"lO!J M6JH4TZS6[5_M5RL DRPAPN!M5;L2?SDC7$!!P/F/;%74LOAM_P)KX3EMM>TBVNK*.>ZTK1X+B()*\^2UPH^ M\2?FQ@X.2:TKG6?
A=\]NK^YGU'PWKEQIUN5NY6NHW-M"'!.\[OE4,H//<4OW M*F]*D[:WW[Z?UM#W$TU%V.&E_:UD7WIEP^ A)K<)O/M=I)K<4<<(MPK,5E* M8?*OP !R/QK1@_:6MM3LC-8;'(YDFL((%FN51F-
TC,"1M.-I7!ZYJ@)X7^" M?BVZM/&>]:IX;O-'62:)B]$$UI<7,FW+LD_#+4_&^FR16_MARY\5P6:O9"(QFY2VQA60__= Z'' Z5N=\5_M0>)9-!NFTK MPFNDW$N^2PO|^.=98XKD0R%DV?+G/&7^Z
M1PV\,!GKN)/UJE-\+O"-Q!%#)X%=,\4W'B6T M\/:=;_< B74HX)GSP>?4]R.371UR5)T^=2HJUOS_'^NB,I2C=.."L>6?LB> M,YM4^'3^$M6;9XD\(SMI-[*Y^8JI/E/]"N,'VKW7%?-7Q=\+:Y\,_&L'O9\$
MVK7MW;O"#O!HL*_-J5H#]Y0.LB=1ZXKVSX;_!-V/?%PS;ZYXAK?$P53_&BG\,M_)]5_EY%U%S?O(I^&=3BO./C?<^*UT"R MLO"RWL'VN?;?ZEIT:R7%G;*I9VB5C@R&U>N"!
(I",UQTY^SFI6O8QB^5W/ MBFUTG^VO$'A>W@U#4+N+6KJXTG^UKF^_M&6>!EWG>EPI:.6%T!:-UV@]_M?4 M/PR^%EA\-;6^:*_OM9U349%EO=4U)U::@KNQ.*=9%/;KYO^O^&-
ZE7GLHG/?%/Q]8_#+P%K'B/4)!'#90,R MC/+R=$4>I)P,5Y=^S'X-O?"WPRBOM64C7/$%S)K%\&!!5Y3E5.?1<5R!O+G] MK;O[9W_DS6_PE\/7'FV_G*R?VY=*>' X_=(1U[U]$@ # &!Z"IJKZO2]A]IZ
MR\NR_5_(4OW<,3]] P#(****\\YPJW%_JUJI5N+_%;T]7'H*JU:U+_ M (^C!!56@ HHHH **** "BBB@#SKQI=#P/\ $;PWXO?*:,.ITC4I.R(YS$Y] M@W?VKU^_U"'3M/GO)F/D0QF1B@W' &>
,M,KKP7?Q>"?%MQB9/ETC59/ECO81P$!!(O3!Z_S\IOZK6E M?2$]GVEM9^O3SNNJ/52^M8VUG#==7'>ZUJGY6?1FA=WI+88.W0' Z9)E\6_%2XANK_$[PMH,_BR[L"JZ@+>0(MEONSCA<]6?
@*#CO74^-?!>F^/O#\^D:HCM;2$,'B;:\; Y#*>Q_Q-4?AU\-1 M,^&NDSV6GR3W#7$QGFN+E@TCMC R0!P!_6IE1Q*J.G3=H/5R^U?T>FKM\KKL M7&MAG352HKS6BC]FWJM=%?YV?
>_DOP+T&+QCX?UKP_XE\,R-I=G M(.Q)B#X!RO7(]:]XT/1+'PYI5MINFVZVME;KLBB3HH_KSSFKM+71A,)"'TXQ MWDE:]E>W;T1SXS&2Q=24MHMWM=M7[^K"O(OB]<'QAXL\.^";<[HO-75-3(/"
M01GY5/\ O-_(5UQQ$^)%CX#L8T$F^UF[^2QTR#F6X<\#CLN>IKF_AYX/N]"2 M^U?6YENO$NK.)KV9?NQC^&)/15_STK+$OZS/ZK#5?:\EV]9?E=]C7#1^K0^M M3T?V?-]_2/?
O9=SLE4KO1[2\M[B)K>)//1XVD2-0^&!!(,.O-7:*]*48 MS5I*YYD92@[Q=C,\/^'++PUI=K8VD8\NWA6 2NJF1U'3

U245,*<*<5"'"LEL5.I.I)SF[M[F?J.A6>I:7?V#1+!%>Q-%, MT"]C$,""<@=>>],T?!K70[&"UM8E588DA\P]-[A1@;B!R>*O44O8TU/VG+KM M<;K5'#V;EIO;S(H[6&*5Y4AC25_ON]
,WU(&34M%%:));&:;>X4444Q!1110 M 5M:=_.QZ)^(AZQ:VM,_X]$_'^= %@]*^; %:B/O+J['H+F0_K7TH>E?-7BZ/ MS?$6LI_>N)5_.FO9RSXY>AP8OX4>K_!>W@T?
X5Z3O:K/+MBM+JPMI1%$.7D9DB7;JC&6,/%GC/PC>WGB_5M/U#4D MN/+7$%*O(:>28!C.'8'#YSU"C&#UKF?"GOR\665MI7ASXK?#NIT;4+V(VDEY8W4 M-!#>.!@LL49W889) #8S7,>'?
&%C\$/B8F;PW'@S5S]F-WM93;R9RBS(P!4K MR,]P32 ^K:*9%(DT:R1L'1@&5E,00>A!I] '!?&ZT$WP[U&Z'$M@8[V-@<<%6 MC<-_($?C6'"XD 9?NMR/H:Z'XUSB+X8:^AZSV_V=1ZLY" ?F:YVVC\F-
(\YV M*% (8KLH;,YZO0MQU;BZ"[D=6XN@K61*+4?6K48'H*]QJ:CUG7M-\+1<:KK M&H6NE:9:(9+B\O)EBAB4=V9B *YF:HT;JPM=4LI[.\MHKNTG0QRP3H'212,% M64\$'TKGO"'PP\(?
#K[2?"_AG2] :Y_U[6%LL9D[@$]<>W2ODKXI_P#!6SX/ M^ [Z:P\.6FK^/+F(E3<6*+:69(])9?F8>X3'N:\'_$>E>+M&M=8T/4K35]*NT\RWO:&9989$1592O:< M1%R3I3#U-/DZ4P]36Z)
(6^]4;5(WW]C:MD!"_6HV^]4C]:^1OVS?VG?$'PA\ M8^&-%\):KIME/9P/K^NPWTD2M?X9\2WGABZ^)1U+6-*T4/!?;II/D]"8-I5]$WA20I&0IKV'Q MU^UG"O %
[X\TS1M$@U_5M0M]3AM$MK>9"\017!,KE020,8 [FL&/ M]MA[W2Y_$6G_ZU.^\%:3%9GQ!KL>H0@Z=)<1I)LCA(#3B-9%W,-OL*(Y;I(@6O4VQG.OAK9Z-!XAB^)UWJ6H'5_$%UKGVO3-5G$-
EMRF[:0 2 M3P,@<]*X;X'_!@*>&_$NAQ6OPOT^Q+]7A@:U>>+9FL["\U$M&\CF-%C7S M1E-KF,YR>5/]+0NDF!Y3X.^!'Q$U?POXLM5L/&,>H/X=0$UC3[O2+F*+5;
MW&8@+AKV03R"0!E:*. C@@ U][_!OPVOA#X5^#M&%K+8M::5:I);3LQDCD\M M3(K;B3D.6X/3IVKP;3OVV/$^KV^G29_@QJ1N-6T1O$&FQG7[7:+9Q_ZYW8J- MF,?*N"6R.!FOHKX>^_[7XB^"?
#WBBRAEMK36++**]BAFP7C#C.TXXR#D<5UT% M33]UB=SWZOXLK?\ ZYK_"I]O_J7>AIEE_OYP?[B_P_J?!=<\230FY33+1[GR5."Y4<+GMDXJH1@\NKM]-/WO2 M_33JE?7M>_0Y%BZ:5Y^[Z_\
O\ B>Z45X;XR ;NTGPYK^LV0*Z]J.FZ--; MQW^M68B:UA295,Y45XM_PU)H M@MO%5^= UWC329+F(G>[HY+ MJS 9]-PK?USI]OPYH^FW%VFE:A>%M7ET:PC26",7\L0 >R([N%2-
3P6H!'/UZ"GKU]&VC\]!$[@<\8Y[U.O6NZUM M$=FPX=:<.M-'6G#]*!E.#7]+NKV6S@U*SFNXI!%):QW"-(CD9"LH.02 3@C/ M%6GN8H[HVSRHER(S.868!Q&#@OCKM!(YZ?@:2/6$L=0T"
[4;FN6 M4 MV\@)^4A\XSGH0UV>#_(C7]:.&S1I9ZS:1ZM#$5X*+*624 M!<8PSMCVKQS1?@?8Z]&K:';_$ZUU.>"RCLYK"TN6W6RH5RIC5\15O!!RK- M78^& AIZ,^,9K&U#]DN:\NIKJ/ MQ%:M*\31
SQ3/F+=)Y:,WF:L*'5<@Y^7K2Y*4E:52R\HV R%:#WE^!])^6XR M2C X/'2F0SQW$DT<3K))"VR14.2C8SAAV."#@UX;;?L]Z_#/:2)XT>U,.;I M'+:FX+V:$N?)@W2E3&0P!,@+?
+P1QB+PO^SYJWAK6](_XFJG3WNVN-56QEE2 M*:)4C\N,B1V?@1RQ_F/?1TIPZ4W.>3U-.'2N$YQR M]*KWJE1',NXE&Y"@G*G@\#K_"JPO2FSQ+/"\ ,K*000"/R/% Q]K_Q\Q_[MPK>KF]*?
S/LQ)R<@$Y!Y"8#^5=)7.U9V,3'U\ X^OP%5*MZG_QJ?@*]4@. M<^(WA# _A/O VM>'1K MC[19W=I%%I@-O%++&R.7177=O#D\$$'UKWBBNNFEB:M&/+!V7]2Y&L:DH*T6> M!R?
LIV\FD363:U#.9=-M['S9[,0T=P9W?&[@.6("!N.34NM?LTW -^" R*]O4[MGA&D?LOKIEA%"VN6\\0TQ5N#888"T=F./GR-'>QXQWKI?B!\'=0\>?$+1]= M?O!#8Z;IY)6WAL +Q<@AT2Y#
^6X/S*P/3C%>I45+Q=9RYV]=>BZZ"]K-N]S MYNT?]CJ'3=%U&R?7X)+CR4ATZ\%I,S1*LHD F22=DD!(*]J]>#2Z-^SWXM MN+O7;NZUK3]*UH:N]W;7\,EJ;2YBEMO*DQ;K)E."
<9;.1DYZ0HK7^T,0[\T MKW\D5]8]=6?/%K^R'9V/B:QO8]:2ZTV-+7SK:\@F,K20+M5D:..=$&3S\R,1V MJY2/OJ*![HJ7C\2[-SV M]!>WJ/]>%^, V=]8\>:9I,FJ>(I*&MZ?
<2RK)9;3):6DB2)L*M'%.KEL<[M_ML1BM3P3\ G\#>/-+UO3I6MK;3;+31826%I9O&]R0#S([2N"H))'&X=-Q%>P4 M5+QE9QY.;3M9=1>VG:EOH%%%%<1B%%%%
!7BWC']GRYL_$\WC'X9:\W@:Q7. MV^ZA5"^G:B?2>$<9/IX?E7M-%O'/A?PE>FY_M?Q&9A8K%$&C_=+ MN5G>OTS5E?V[/A\?N?_#GBLO[7&H>*@8/A]\+?%OB6Y;A M+G4;3^SK-?1FDD.?
+UF^G M3WKWYF9\;F+8Z9.;2CZTJ?\ @HOON_OZ?))A[7E^'6 _KV&GVVE64%G96\5 MI:0((XH(5"I&HZ!0.@]Q117!OJS ***** "K<7^K6JE6XO]6M ":E_P ?1^@] MK5K4O^/H_055H **** "BBB@
HHHH *RO$WA;3/%^E2:?]M]MU;,=PSPT;=F M4]0P]:U:*B<(U(N,U=,N$Y4Y*<'9H\[M(.'WPW58M-E3QOH:<):7DGE7T*]@ MLG1P/?FM*/\ :&T6T(CUO1M=T&X
^9+JP9ET'9.YKLJY[XA^.++X;^"-9\3Z ME'//8:5;FXEAMP#(XR!A02!DDCK7 L+4J:4*C2[-IB\.>&#X>MGX_M/7 MF_91ZK".2?KFN](.3LH."I(RO%)3^KXB>E2KI_=5OQ:D_NL"Q&'IZTZ.O]YW
M_!**^^YR'@_X<6OA]DU6]NYM<\13C$VJWAR^/[]#HB^P\ K5U]%%=**^C"A M'D]JR_K[WYG'5K5*\N>H[O\ K[EY!1116OB%%%% !1110 4444 %%%% !111 M0 5M:=_.QZ)^(AZQ:VM,_X]$_'^=
%@]*^;?$_P#R-&K?]?4G\Z^DCTKYM\3_M /(T:M_U]2?SKV!61V:^M(Y%!62)^)4QT.U M^2/1ZZF+X5W.DC[+H/B[6M"T?$ZQ\;P_9)PNG;_"N:C39&Y_MWXS_!H?

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`>Z9-^SCH]SX1\6Z!+]=RD&NZI :T4]O$D3V$H"^7N$1"[" E >><>F* MP+C]E^^U]O$5UXB^(FH^(-1UO2!!#W4NG0OB&,2*X9%1@#]WD'J23FN%B^-? MO#O++P3=:OK'A+4M%\:I.6TS3[5A<6D7E.WEE _^:H 6P"#QWK-\$?$[X@P> M$O#6A>#9=T>QL_!IUR5;RQDGP5E<%$)DS\W Y)QDFKC0QT$VJJO?LO1ZVNM M8[)6=B'5PTFER/\ KRO;K\CVR^_9TTG5;3QO;7NISW$'BFSM;5U\A0;4P1[$ MD0YY.<-SC!%4M> _9@T34_ 7A+P]8Z@^G7? AD[[+49++*&Y61V!\PRP2 HX

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
RKS\1(RBNPP"Z[A^(]6L:]UJ:PUJ"*XCCM]/D1S] MJ=N"P (4]E_BZ]<5UOEIQ2V6OQKFJ2;W>YPEW\.+U=1G@LY89(5&]3*64@' M >#GIVKO?
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
RJA"G'%4H-#^"6N_$KQIXIUCPI[^@ZSX/U.VM+W6]5OOLMK-/Y*O%+M\ MT1LP4A0SKNR.]-*=_B \C\%?M)_$+2O#RZ3X6T;2]>:VL-9UZZO/%&J74DRQ M6]ZZ%%8#+9 53@#/7 KZ\'^WBL>._!'ASQ&+K;O<:;+(9;EES*;#Y"C":;'R=RX!R?K752C*.[N2>[VO_'M%_N# M^5+A W1_*EN/]2_T-?//?-0[E'// MMC(S^-4X9%E4,!!4^A! #BN^G+FB=$7=%?6-
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
62XC0LQP!RH]QZURR=E%;UV\7.HLT5FC7NQ#..!7SQ\1?ASJ M&M!]>;1KFWT^^8W*1JPDGMMW/S[<@]>X&<&OIJYMH;R!X9XDGA<8:.10RL/ M<'@TX[HXSY2CI\@^" _AK>:I>&+2; M*;>0 *]O-E8XQ[MC _G7T=X#\46]S_Q3T>EZI976EQB&!]-U_2TU!-:-HZW$QNHVMIG?8S$[H_F'08&".N3P*Z 6UK9RW%T(H8) M) #-/M"E@HX+- WP,]>E98;"]A[R>KW,,%@EAO>3NWO#T/8]Z\QNAz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{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|;R>=&D@Z. WYC-1^/ M=;OH_AIKVA:O<)>.Q&L%@;]*+RQ=^<0J2;!PK'YLJ. 02.*14[""}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`_9Z8ZGF11S[MUZ]+$.$;1LT=<;EEH?/6F>" BWJVDZ9>KJU]#^:S_8[[6IC/:OB;=M===A%P M6C&T"0KC\;H^'O!7QB\1V'F2:WJOAR.*]0-;:CJ;M- ,HCP\]L48A2_S+41M. M<_D &OI:BM?KDM?=7W%^V?9'BFD!WQ1H>]6J6:1:6.A/U-:G96=T\VZ. M9QM!58\!D&6]_N!"37;>#?@WX>\#;]}K&F?:O>R0^0[33IE9<?=P.?=3I_= M7TKMQTIR]*YYXBI-6OO^)FZDF.7K7G?Q\.EXUO?#%SI<&G-<;???;&GU&1 ML1(1AML>Q@Y[RJ']!#%>B+UIU90FZ R+SS][[IXYKMO!GP>\/^!=>N=9TS[7]NN8C M#*TTVI67CMCC[]J/[HKM1TJ]TAOODC X]C]Z0'[_++[=03P1VKGGB*DE]I+ MKYF.J2>XI?[=(5'-NAY/9SZ=>0.X(JS2*H10HX &!2UY\!%;U0(0]3_P"/K\!52K>1_P#'U^ J!0 4444 9/BCQ18> M$ (DU+479+.E#% "W) SC(R!G])S/'/O$\>!=-6;I66=3Y=M$HD>9>^ M!TV^YP*V=7\.Z5XA6%=4TRTU)8F+1K=P+*$)&"0&!P<=Z^%/C0&UIXRU\E" M<6>G6LYMX;9"=D2*/E50>@Y)QTYKNPM">-5GT-814F>^_!+XG^:!}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

<>4^Y&!/4,#TXQ7l[,%!)('4GM7EWB_XK-]+S:/X0D2ZO,F M.XU?&ZVL_7!Z22>BC@'J>U-)R=D)M+5G+ZU;OJ/CC["]^^]G3)%N]0O#&L:O MO+#GL.BB[5DZ)I4&C62VT&YN2\DLAW/*['+_YI[OY)K6B[M5Z<(IKED[&T2 M15VBEHHK T(Y$QR*KM!XUI!\G2F'J;Z$20M!ZO%3^R M3\/?^$[U'Q6\6LRWEX]S-]BEU>9[*WFN(S'-/# 2521E)&X=.PZ5[4WWJC:M M4D]P/"O$7[&_PW\0V6E6KQ;[h\=AI*:&S:5K4UH][8IG;#

O\]RI/ MV&OA-<"10%&<]3}:^A'ZU&?O5HH1 M[>(ZQ^Q\--9N-0GGT_44;^>\DE2'4&1 ;F)(90]@84;(U"C^'%06W[(*P_ MM]8UF_DE\27B:S"(-2L+K79GL[R,1>4JR0C ;8G"_P!W (KW)ONU">],J$>P M'@EG^Q9\.+ -3$TGB;4Y-1TT:3-_J>O37+BU$BNL:%\[I10,=L^M7]: 9.^ M'^L03XCUG3;]]3GU=-4TS5L:\@GF14E$89GC[[6.]>_Kl?6NA54]S1374!TIR]* MB\F[C'W89?<,4)Z>Q]_TH#7 X-JWU$BGU_P'YU?,GLRKHG7K3JKK)<< Z(X^ MKKZ#W^OY4Y1=QU2&/GNY;C/L!VP;&UW"Z)AUJ.6[2,E5!EE'_+./ENF?H.G? M% (MD[@>?.S^JQ_(O;TYZ@]^]3O0QPKMC18U!%&*R=1+,4ER70K_99+L'[5@1 M\CR$.5(Y^\>_8XXP?6K=%%8RDY,F;=PHHHJ1$MK_.?,?^*WJP;7_CYC_WA M6]0!CZG_.?7X"JE6]3-_/K\52@ HHHH OO%]W]}AH%SG&+R8 "/E0$DG>HX);K-MCM7T%01D*!?E2MZ5:5%WAN5&3CJCY&\! L^:MKN!WEM/]DTBTLKC[/=O'*DL_M@?:,;JJ3$@GDD"O>_!#>*-}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{]B*\EE_9MM//#$\EY\,O%&L_#.Z8EFL+&07NCRGCAK" M>:[C2?B7HNM^$]0\16CSO]CYAF4QXD&P9.%SW!R.:Z2PO{]1ML,:[AW>5<1K*FX8.U@"_.G7B4L31vK*:=U=6[=SNJX:M0NJL&K.SOW[6\1X* M3Q1%H2)XOFT>YUH75]"BFBMI8\ (VR4L.R 1U70Q3ZC:6;26T;#KE^^/85VT=Y!+&'69-I02S_KLRZV#O&'2E6@XI[77]=T345E67B#*"^UC4M/6&>-K%(W>XD4"&0 M.;C8V><=ZCL_%=C?^(KO1X2SSVULEVTP*F(HQ(&&!Z\JO=?.M@S/ZO5U!W9)OT=K^4: %1PW$5Q'YD4L^&?BO/!/BUX;MQ'HVM,B-*W"P70&U&) M[!QA2?4+7T(.:^79K6&]MI()XUEAD4JZ,.''*ZSP7\5+[P3#'IVO)<:KHD8VPMZE$IDN+9>RS*.74=G7G'4'K4XW"M2=2"T>X8>LFN21{E MH-?*6OZ'%+XEDT"\4>,O%?B&RN]VGZ%%:(ME9E6S;O/{8]C{$*DLQ/&>,U! M/Z%XETKQ/9+=Z3]%OJ]%NPSOMY ^/8@<&@^QKG(,$PZL-?YH73(!VD<#]*\@[S0*.L\OA70AQJ.CPK&\J/A3M&'<$] M1D<>N16WB>=U:4+!$IW;0=S-Z9/0?K63BZ?:Q+#$LL@4! M%& J@G)^@R:\!V\3^.]1^(2-8Z2MQHWAU^)K^0&.YNU_NQ+UC0IW.YB.@'6KC M!S=HDN2BKL-

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kA_C@4M(R[3B*!R3CH!32N!">AD1?$GPE-#) M-'XHT:2*.$5ES=TOXF"SL<+&<-PQ/'>NCZ$CN*^" "VK6FF;:=:/X5LUOM{M MM7TQH-=.C&UO5C:X.:.ZW)\\D>2=PYQU/IU>E^)OB7I=IN>6/BG7]\lS($1"6+ $R^^.:6.OB_M/U%-9\A_NY+G[.]8.8QEJT>UEY\XR@YZXHEDTXPYN=7U?5;*WE?\ I#CF M$7*W+V $^NM<\0:7X8T|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{$_K78Z1 MX797$M[CCD1 YS]372T4GB)-N ^O2M,MQ"O@C4_&WB76)6M{&WM8R+6%@N2]O+ (!SVS@\CK7K%<[M\0 FF_$[P7JOA26'OC!+U.$P7!L,EH)=OLZ\B@#\Y=3N=,:^$GO'CCU7,\> MBM$LK@A0F7N =N1RS=*]Z7]C@Q^&M4\:?%.QE^.?CV.S(M/ M#<&8=\(Z+:,:+ID>"4@7YY M6_OR.?F=O]N+,]F7QA/YGPK?V?KTDJN/508W Q^% M?<'PWT=-\"Z+8QIJ$21VX;R]5D$ES'N)8K(0 ,C..!TQ72 -=**R5-*;GW/ M+I8&-+%U,7>[FDMDK6MU6KVZA5?

4;Z+2]/N;R8D0V\32OCKM49A]LL4R:%+F M&2*50\=CS?)S_#^%9/AG]G#6=2 MO?$4&O>(+_2_"]WXA?41X&ZB4J8B9.7C!*C*CKM%?2?\)\|RDTK;6NM M-++:62UUV[I\C_:HV25[[WL]>OHOO\GS'X,_$G0?ASXKU+6)M O.*MK2+5(Y M?.MY[FZ-M;NFR."26X8)MS\Z $XYKVB3]K[PK_+H3^:_%]LUJD4]RLNDD>1 M;28V7#_/@1G(]_:HM1_9/TK4!>@^{IZ,70U$';,Q_+]K=&;'A.P >N>.V/$ MWP1T,5)?%"W7B1{)]=T:UTF16$0,*0G"R*&89+$XP>/2KKULOQ.U.=V_GW]. MU_N)IT\51CRQLE\NW^9AV? [34&B:.]M|K>G;KB=BNMRZ;;7>AZ6!%&,H(XY_M\N6=BXP0.?08K<_X;G\&)XK&AS?VG;@7:V$f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{[]3CH>AQSBO)?C\.5O-'^&VFZE]WHMQI,LP6^IS;'>2676,EU5PV0H/]_M3TKS>#X\>)OAK'KGAC1,'QY6OQZ5I&L:BKWKJK1EW1_*(:=D(P ""<]:BA M@ZDTJE*7O;_<[7N9K#^UA;N>Z_":X00^ 4FO]0.WO-LS4/VG/B9!K1TZU\'VEY=Z9:VT^IVUO87 M$OF/,-WEJZOB$*I W/NRV:VJX3%8B;G-I_/333^O4FG@G3CRP6A]7$$=011: M*^3?!?Q>\7)K^J^:'M"6Q@UK6_$%Y+'/XJEE,%E%"'C*(f*K-ELG 4$ 3W<^K23/;M+;2;&,!5@61NHST]>*9CX6U=6_MK_)FKP\T?4%*90.X.*^7K+]IGQIXUL3-X;T_PSI4FG:*VK:B-I"[O?\ !+[K17W'HT,VQ>'AR4YV M5K?BW]lY/[S@=(\>) #&HW-OI&K:.'HI=S?M?,+FV=[A-S N@P0ISV)Y%86K M_"#6:O1VLK;IT09&U*YOEN)(Y1++!YA!5HW4@AEQR.AKUNBLYY-A;D/9RORZV M7.]$[.R[+0N&<8JG/VD;]VVK6W]]JL6H6D ML\3.C%81&XE']W)RO2G1_"S4IETO[[4+275;C6;?5+ORXV6'9$"!&@ZYP>]K MTVBC^Q<'>_*]V]W: [Zf[ZVO\' ;_M:ZV2V5[+IMMI>WIEF&)04)1T7-U_F=W^/W'/3S/$TYN<9:OEZ?RJR_#[SSO3?AD2*67 MB&SU!KVV,<&M76IE%#[BD]!0HX^_:O1***Z.A*6$4E25KN[^Y+]#GQ.+] MXMQ=5WLK+[V_S84445VG&%%%%'!6UIW_!Z)^/\.L6MK3O^/1/Q_G0!8/2N M?E_UK_4UT!Z5S\O^M?ZF@!M%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !2C]*2E'44 = GW1]*:LFZ&D?QL<&]$ M#^1G^_M.W]<5"A\\ EL[=7*AMS R9( ) M8\'=Q7UY_8NG'4?[0 L^T^WXQ|K^SIYW_?>_WZTV30M.ENFNI-_LI+I\%IWM MHS(V.F6(R<5[5S&E*;E4@Y7[M-+R5XZ+TUT1YBPDU%<1>TS_ZZL^0[3XW M_\5 T?;CQ^%XFDUI0+^_BL7TV)%LWA?"NOE@=%#)8'@XKB_&7BA=6)5W M=V_CG3/B4ZZ+8YO390*D)>^A)B*J-I()XS\P[\U]ZQZ;9Q>5Y=G;1^4I2/9" M@V*>H7 X![@=:KQ>'-(MU*Q:3I\2GJ]6<0!YSV7UY^M:4\THTY0\ 70^,O'?Q/U?O5>Z=)JGC2S?4[?QC';Q^ A9Q M1RVZ0R_NGW_ZPD@ Y/RG.!5Q/C3XK\22:!;?\+1M)[[Q%+>P;EX;M]-MQ+I(M5),)R-PQ@ [^23D5]BR;)ILMXUW)IUG)=M@FX>V0R'3YB,\=N>*0:%IBW+W M(TVR%RL;GF~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ibio-20240630x10k002.jpg GRAPHIC begin 644 ibio-20240630x10k002.jpg M_!C_X 02D9)1@ ! @ 0 ! # _VP!#_," @,' @.# P,$ P,$!0@%!00$ M!0H'!P8(# H.# L*"PL.#A(0#0X1#@=L+$!80$1,4%145# \7&!84&!(4%13_MVP!# 0.$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04

[&K/QAO:T0-I0U%5#W-M&E7<8S%(HSEXI8L!H\ ,821AN:*\8^#M1\$:RVGZ@L,;D$T%S V^"ZA;[DL M3_Q(WKVY! ((!AT444 ?N" _,$B/AKI'A+]F<^([2YMKS5?$5\\MX\#AFA$ M? RJ"^.C#);:'^T*^Y;_!/_@G+^U]<_LV_%B'2=8NW_P"$%\0RI;ZA$O)6VD)P MEPH[%2<'U!/M7[T6]Q'=P1S0R++%(H=`0Y5E(R"#W!% $E%%% !1110 4444 M %%%% !1110!\N?\%%?^2!+_ A.#^M?F%7Z> _\ !17 )($O_83@_K7YA5^ MC9#__+G\V?18#^`#\PHHHKZ(]$**** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *^{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}_AU[W)>*;Z?UI M_D?F9J.L? #GQ+\"?"G@/PAX3N8OC##=6\7E1:,\=Y,7*R#S9))L#*G!XSQQP M,5W6O>)_O@3]K_Q)>?%:QCU.WCT.RA6\GLC=P07)B4,[H%/WL, <=-3[U]Z) M!]K'=//9+V6\FUVQAL9M.GB0P M(L9!##C)QWK59E3ES*2;33ZZW.6SMHM"EB8NIT^O776W4<&W\(ZfXE^ OQ9 MU;P9I&H6/@/4?$ O>6.GK VZ2TC\)\YTBZE/NDJ.H7';MCX5Z,H7?C*^W@,Z_M\2;? 4M4T@BYCAT;P*;'R8U WPW$L9&,@$9;<,]^>?T2CB2&-8T4(BC 51@ > M@%0VNFVEBTC6]M#TARYBC"ECZG YJ'FS<9+EM>]MNJ2UNG?;I:XGB[!]W]6 MMV/S^^&>N^U"W{3]A8^"Q#XLM-1UVY^TZ;K&A-%J6C2,3YD\);AQAY50!V'N>IJQ7G8O$K%2C)*UE;>] P1S5JOM6G M8****X# *YKQCX4EUU++>\T^%EK-F=]O.1\!]5;_ &372T5SUZ%/$TW3J*Z? M])I]&GJFMF:0G*G+FCN<#!\4&TA1;'>=&U'3+O.#)!:O<02^Z.@/Y&EE\:Z_ MXES#X8T&>W1N#JFM1M;PH/58S\[_)>]=YBC%<'U/$27)/$2'$31X[^ 2]:2.>4ZL.5>+[O'(,,' MBO4V4.I5@"#P0:X.RTE_AC&[B5!GMXADVCL^`)) ME[%,(V(3U9#GY/?/%?3W@:XGVWBO2+6^>_T@N!F.94.UO,V:NLAGL/$6FM ML:*]LYT*LIPRL'.01 2O$+I]1 9RUIH[&S.H>!;V4R1P X>QD/54/[WT!KU8 M3C4BIP=T]FCE:<79GN%W*!L>#]/)UB< MW6);'4=NU;^R2RIAPP&3T8+>^P(!. <9J@^H^(/#>XWMK_;UB,D7&GQ[:A\\ MQPT.?F_@4,"23DD 5U=%;*;V>J*OW.2U3XL>MT^VOK_7;2SMKB[CL$>5MN M)G9E16!Y7)5ADX!YKK 0P!!R#7BO[0_[,ME^T)_94-]K]SH=E9NTLL5C;1L MIRY&U6=V_NKN &#C<;]#^'"@R;X?>#M/T"76[_Q_+)/*CO=3*&=D'W58J #@ M<9/.!R36TX452C*$O>ZKM\RY*'*FGKV/DO\ X*K_ +2C_!CX#GPIHlV;?Q X MRWV2 &V'ALE ^T/[:@+1&/!lL=* #;G)R:^M_^'D?QKD^_[5/BB2&X\I1M ?`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{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`G[+5CKG@2P\7>,/%TOA32]6D9-,BM-)FU" M>90<>8ZQ_<7OD]N]>S_LX_ FW^"_Q,\=IXAUC3I+FRT(7FF:A)8&>(VS[B;H M(W0]5*#;=FMF%&E&7*[M= ===:,VZ=;7%/$0BG;5H^%%p0#_U2=O A=&ONI(_@E]]XB?]N/_M>O%SG_'&t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tEGV (#@DDJIX7PGX(T./2(?%OB@RZ?HC.R66F>9MEU>5>J1.1E(@> M'E8$+T&YN*YOQ_XIU?Q7]\=SJ<26L$48ALK*V7;;6L ^[""!D:1GKDDDDL22.M30!T[\X,=RF]/!JF>),W_P $ MO">H 9-K>7>EL?092=?_$-Z\ZL[VXT^YBN+6>2WN(F#1RQ.5=".A!'(_ #K M^QDT^1WKT5-WB[X&NA(>]\,7WFKD?,;2?"O^"2A#CMYC&DM M/C!'XEBCL?B!!$?BFVZ#5(R+;58>,9%P ?,^DJOG'4=:|.^$?P/D\0>*-%L? M"-VVLZ?XB,NGRZ3]>VSO6AF3:63+&.4*/G!5@WRYVB@#$+X93/X;\#ZJXG9< M7T>-+TL\ABTHS.0)?]F)7^A8>M<]\.[=(OB7K$T2! (KPQ7R8Z$31))O^+&O2/ MVEOA#XL^.OB#P[\/ 7LTL9M'LO>/CPQO%'@_/'N0E3GD8"C\J /$ZMZ1J,ND:I;7T+%9K:5) MD(."'I\'\JJ4#K0! 3G\$?&Z?$CX1>#_!-C^8=3TNWN'8_WR@#_ /CP:NWK MXX_X)M_%{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}1T5-B7HOR/IFBBBO/.<**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "OB#_@L#*T?[(NUT>?_(@H_"6BBB@#'T_X;O'1 M7PV\;W[5>_N--T56]5DF:>0?E;*#];7PW*OB/X(^*M%OI")=$O;75K>4#Y7+VQQVV\>E?0?C?]C6Z\ _L6^!/'5QX_\6UMXAU.+59HKHR*L8E MML01HZ!S*Z!9-ZA1@L?2IL0?L4> /@;<_&;7],^(OCR&_LK_$J=(;"&VN+6 MSN2625E>9U5CA$W*H R5Z\ $ ^??%,#> ?#&A^#-H2_N(6UW6"/^>DD#?98< M_P#3.%M_LUPPZK7FMIIZ+"+]\+1VY^XB_?F/HOH/5N@|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

1OP9UE]5\&11RMNDM',3_=ZBOM,AQLY2>&F[JU_MU_D>S@:S;]E+Y'=UV7PI^+?B/X->*$UWPW=)%<%/*FMYTWPW$9ZI(O(?ET>N]!U+3_#/@_PQX%N=34I?:EHEKMN9@>HM#8&W.3SR>>*W/A?\?=)^&?[,#Z;Y6@^(!8N-<=KGP[K2><)K=LG>5[11LKI^MO/)O%WCWPMXCDT[2]/M(#+A]+T
M*RC:.SAQVP#DY]>,@Q5>]_;6U^^TGQ=8/I6FK'XEUF/6KEU\S=%*C*P1.?NY M0=>>37D5>I?"/X/V7Q0\&^/M0&I7 MK'ARP74++SBC5DN4YW[B>1C;>E5.CA MJ,%*4,)67XZ?B$H4X*[6B_S-)/VH?$,?QK?XF#2=+_M=K7(]C_>?9|OEA,]M=V< =ZY_PU\;M7\,>"?$_AFWL+*6SU^]BOKB;??YD,OnK@)@XP2TAQR_B7]E M2_T/X*^!/&\5W<37DB*[AMIK%HE"6XF/[HJ1R<]\U@2%7X!77ACXP7'@+P8F_M]>,+^VMXI)5BMP90[(&<87@*N0,FL(2P<_=C;3_VQ_HV3%T7HOZL=9I?[;GB-M#3?'.O\ BQO"/AR[U76;2&PG-P)BB01ILV*-W1NK9Z_A6'I_[5&KZ%XU?7=# M\(^%M#L.JR^P.AH%G9$:??Q[BH^"]{&62V#2 M7.I4&1$"#!VDX/">DJ>"4U!)7.[Z65O/H+EH7MW_0Q?B9\=Y?'UGI-EIGA# MPUX)LM.G^U0+X?LA'+YN<{C*1N'/.!@9 SG KTG3_P!O'Q19WFGZM-X-\)?O MBBVNK"36O!-9L+]>(#&TE2-N>Y!_VJZ/)>N(K[5; ME1,Y. JD9!;D<9S47BSX7>+-)907GB/PUJ6AVT\K0127\!B$C],D+GDX'? MI6KP^$]1C%I.-VU^_KKYE>SI226AG^(O$]OXD\7:AX@GBBBNKV]>^>*/,O7:
M3>0,\XS7IMY^U7XQE^,W_"RK.&PT[5WM8[*>RB1GM;B!5"E'5CD@X!Z\$ BO M&]*ZI4*&D\..7X;\/^"]!>[2^O+++0 M;+-5M+6QOKN.*-X+/=Y2B- M-@QN)/('-<914T\-2HM.$;;_(VO^2%&G''PH****Z34*_0W_@F+ P_B)XV_M["D/_R/ 5^3$GM_P!A2' T0*\+. _^/V!] M2ALOA;I%YX,\+Q-MG^)&N63P3LG==/MGPTA/_/20!1ZQ9O7U1=:?:WKPO>6\4M[PMOB:1 O1NF5ST/N*G Z5Z,.2\ M7_L22%7PO:0>--7\9>&O%4MK+?!_A_4X6OM7U'X0>+HSF30_M&NG7$,*3#[PAO45HWC)Z%NW>M9TJF/IQJTUS35U)+5^3MN|':_EJ"E[-[V/' M?VQ_V,-5_9R<7Z3;YTOA/49+I=Z,DP,#DP,?[R]0>X^AK[5_8N^+FG_%[X M):OHGAZ#3/#__1+> QWV8RJ3,PVK=;1R0>X'\?UJ$VOWA\#_M_> I/!'Q"_ ML_48KE!&+ZPO([F%W'W989D)8'!&2&'H:^-/'OPZ\<_L-_%?3O%WAR^;4= M.Q%C]\8_7[Z/PM M[/U]>OWDG[1_P>U.X"^-AHVH7O\ :D=W"+J#4A%Y8G)S\9."&]^XK]#Q@MJ
MVG_&C]EI1V2VBE=]_^S200]JJ[+B(8XXP&R_<^]>.?&?^ROVW?V8/(&?A2(#O M+H>ZX;O)S)&X7!] ?8CE3WP*YO\ X),?$5KNU\6^#YYC^Z9-0MXG.",_+(-/ MKC\]YSF^,J9SE$,E?\C4'-7H]+V6FNCTTT=CZX^%'BG6KW MP&_B+1J;JPB*R)>P>5)(54[B! $,.HX.:_/#X1_+\S:?+_P">;D_>.>V5.?JC*&!! (/!\KY:\??\$[O=-/#GPTA/_/20!1ZQ9O7U1=:?:WKPO>6\4
M0;EXGT:VOO#OB2XE^UQO9W;"U6X#;M_DG(Y/7":.<5W8F%:TXFUNX6<-^\0E 'S^%A DICX MS?\ 7.T_E11\%A D[CXS?\ 7.T_E17H8[^*O\,?_24=%?XEZ+\CZ9HHHKSS-MG"BBB@ J!K*W:Z6Y.$9N%7:)B@W@>F>N*GHH KQV%M$9REO$AG.92J >8?\ M:I?QKS7Q?\<_A/X+U:;PCXB\2.:I=Y&%\S3+Q=JJ&^9]<@_P Y";.*V8=5^*7Q\^('CVU\-_$.3P+HW@RX&GV!O!:I+> M3*IS),3__DJ2:VZUK+ V?,JBY;7OM>RZ=2W0ZVE_7T/I;OOXR\)> 19WG MB6[M._M*==/@EGA+t&:1ONQY"D\^_%;4>@:7%=0W2:=-)ZUJFENFPU&Q\5?V)U=+_MX^^-'Q
UWXG:YX4M/$GC.PTWPO%%9_:?"/A]+ZXO;G8-TUQR BLVC2[>92U65E9ZZW/L'QU\2O!OPLN=-G\1:A;Z3/K-RME,R&LTT-MAZ*2JDX]SP*Z6?0]-N,T7DUA:RW879Y[PJ9-
OIN(SCVKX=UOXN>/M>^'?P[;.MQ;IIQIVMV.C&&Q>XU31U@>]@P2DOERH=C=B5QSW!]SXC^+_CB?XR;KIOQ-O-.M#TKP;?RM:V4=K$S2E06$9?;D)@'UR:G^S9**O-)[-W.6Z2M9?UY"^K-+>W_# MV/N--+LHC 5M($, O$1$H\L?[/"X5)%96)$TLT<$<>WM7#?PDZ%-3E).[:TOI:\# M"=*4(J39MVN@Z:8WDMW;.?K'N+/\2>*!5=_JP&35^BBN!MO
M'[V_"AWB3Y%/0L>!G\36M62KVC0^(-'N].N"1%:YZ\9RI2C M3=I_.WJ7!Q4DY;'!Z\-9[G0;6ZM%@U'7DNX=0N7O#@?90Y\O=@[5&?E'08K MHY?
B'IFF6C3:VESH'EKF3[?"1&N.O[QB>*-8\-6ZZ5XAT;4+NXMQL MBU'3;A];6-+UCXA:9=.:?=P+H>BW49CECF42W4R'], M[8O^)/TKAI8BE2@]=&F[KHEMZMV7WO7I;Y-0@S]FN(-MR?\4S+_ '']X;?#V35X;6YMK_$R9AFVOM-O&0.1V*ON,/Z=: M]%TX+7^D:'+H8\5W&O:#(GEMIWB6TBO5*_W2PVG'US7-6PU'-$]BO&!!V\X
MOL^G9W3\T[&M.K+#7CO&7XG+^&_'?A?lK2X7-I,R6NN6ZJGM)3^]M\L=#ZH-M?6O._@#\1+CP#\8+SP?KH;3VNSY#Q2G-6=?ND?4=ZI^)/V) %W@3O>/%OPAU-MRR\.WR'QU!&?2O#Q&68F>*ACHP_?PZIJTUV?9_I\D=U/$THTG0;] MR73JG_D?<=%>;._7XEP?$KX?:,>.'U*&.0W:.PXD48)(]Z|(K[F+.;2.5CQ& M%%9NL^(;'0%B:|>51)NV^5;R2!!DYV*1D?\>%O[_[^-R?M\D5HH2:ND%F^ATE%-XY,K8:3]M _+R %LWB3/S#EX-H RO -H7 .:IZ'-02Z+J BL%-9=--TQLAM.M7WR3#B8EDZ $'E5[CC;CD;^+0 R,%-.7N,N=2 MG\:W3V.ERF+1XV*W.HQ.?WW':
<3+]2"X8%2N,&NHLK*#3K9+>VB2&%!A408 MI]O;QVD*10HL<:# 51@ 5)2E*^BV!OH(@HHH]"0HHHH.**** "BBB@ HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CN+.*ZA>&:-)8 MI 5>-U#*P]"#UKYY^*7_ 3[^ WQ;DFN-6\ 6.G:A*(/: MEDMH7BGPKKD8Z"66>TD/X&-A_P"/5^T-% \T/O[_9Y\9_LV^,4\,^-K.WM- M1D@6XC-
K<+/)&>A##^5>;U^VG_!5W]E>}^.OPRL ''ANS-WXB\+HYGMXES)-M/9GE\#N5/S8],U^)C*48@C!'4&@#[3_9>^'/OB^$/A_PI^T!\,$TCXCI8@
VGC&Y2=O4U>_X*M^#=-,T;XN^&O$02;3O%'B32([!6M M'FNVN#:3], DG:/ID<>@KYD^%?[1GQ+^",-W!X&\:.KX;M[HYF@LYOW3G^\4 M8%<^^.UR/B_QGKOC_P 07>N^)-7O-W\$2RN?=C_*@#&KWKX"6KQ> M&+R9ONRW'R_@,5X?I6EW.M:A!96D9EGF8*JC^?TKZH\+:#'X9T&TTZ/GR4^= MO[S']2SKZG(*$IUW6Z17XL]3 4VZCGT1K4445]^>^%%%%
!7O_[$,NP6'QQ@ MT:]P=A $-A<.5.A. P9<@?HP_&O 2K*JL5(5OND@@-]#WH$Y&3QM.?#GE>&EUA]\164VF0. P L M4MJ1YA'T:,?C_P'_&_.\2M3^/L?A+4H-.^(NN7[FT1Y1'+');JO!2)ST({
MSVW ^!?%.4MT&DGC>XW#[\R.V>?5AZ^YJ."XEMIDFAEDAF0Y62-RK*?4$61W5F]22<$_K48:YO MKE.,//:AY8!1:E)\:VRMO:SZ6_$/]MT[OOTIV_P CIY^) M&L:KX0^&<.BZ]\/-4T:TU;7[6'OSH_U,X@N%N(V$L<;%FVG##Y3W)(// @_MG[=`B+4]4^/^M:?=W\Q/86$=NEK:O(3%"#"A;:O0$D\D=:\(V&N+C4M5EADN); MV]ESY<3RM)*V?[]DY.?
856G>;:1W#:620'#.*69L^A)Y_.NC#8%4)]HW=Z]^ MMNI?8TIT%3ES7[_IW;(Z***]4ZPHHHH **** "OT-_X)B_(B>-O^PI# _Z(M%?GE7Z&_\$Q?^1$\;?\ 84A_]$"O"SO__*?R_,X<;_ ?
R/M.BBBOS0^;"BB MB@ HHIDP.01R23VYK\G?BMX=^ M(.C__+0'B#3O&&B7UWXAU;67CLK\A8PW"O*?).4A^4KMV@#. 01Q7[0^&+ M2YL/#FE6UIY8OL?2*.?R@ GF*@#:0.
.@XQ7#0Q0$ZM2<91LE^)]5FV4X7+\' MAJ]&O[252]UMRVMZWW>NGH:=5-2TNRU>T>UO[2"]MG&&AN(Q(C?56!%6Z^9? MVR*TUC8:9HUYUG5=#R7T?
=RZ=SP9K*=&SM#1ODH#VP2%..>WS9X#\;GQSIFEV$&K^(M[OPQ97@6#4(-0FN8HI^RF2165\=E8D>F*^K_)XJB\+,[70]..2>ST>T66 M]NYCEI9 <(O3@[B2?IBM'6J5HKVDK\V
[V!!U(1I5'&%[+NK/[M;?>?)O@/P5 MXQ_8<^-\7VC3;]J^%_BBX%I81YZPECA00N2&4GC..PKG? &FG]G[_@H!#8V MCJNA:]=.,,9T^X\%QGC_@+Y&.W%?
I9KNA67B32YM/U"$3VTHP5R00>O!'(((/ M(Y%?*2[5/(/FKW6D:1XP\/VO]I>(("_PMI;?%NH%Q-K!H{!QOX&0PYR.E> M?5HV5X]'?_^@P69NQ.^\W).+ <7NC)M?">BV.NW6M6^E6<&K7M2A)[V.%5EE Z!F R:UJ**8@HHHH *0]*6D/2@##YG^"G_"=O\9O^N=I_*BCX M*?\ )W'QF_ZYVG\]*]#'?Q5_AC_Z2CHK_$O1?D?3-%%%>>.M7U6[70O#-
T=$!TNP^TNMLFP,))63.TG@G)\?L*Z;5' MVD)SO917YNR1I"',F^Q]2UP,B?!S2=^^+FO-_!"@N[Q]6UFSCLI[>1D\A$3& M"H"
[L\#J37D$_P"W!:\%+O6[`X>^)-1^`]I<&WF\50^6(L!MK2+$3N9_>_P#* MOHS3?$&GZOH-MK-I$+_4T$>IK\-9,*=\N,?.N#R1P2.OI7(7W[=]]MKJ^M:,\. M/$^^K^"]/D>'_
(22!4%N[KQT/W5)O\O/&02*^A?AUXSB^(?@?1/$L%K)90ZI-M:I#+OP)X7\)6?.MVW2=)\/ZA'J5OlED4R33*2V*J?$?]EC1?&_G&X\5:3XE\0^"=
M8"#SCC(JO^U1\7M5^$7PX2XT'&.7Q#JUY'IFGM, R1 MRR'IY'? R<>N*\CU/X#_ !!\,:?,:K>_M&:AIOC611.,:5;M$T]VXW((RW*C
M.,A<>PK:Af:455E6Y;MI7N[!]D]/4NGSM*3G:]_^"> NZA^R!X;O_EX2\R M-KKCVWAS4%U*'XGO//GFE&3^\>0-KKCVWAS4%U*'XGO//GFE&3^\>0-\ST7&.V*T-$_9XT#0],^(%E!?ZB\7C2 M9Y[YI'0F$LI4B+"\##?
O9KPK]K7XCZOH5K\+(X?B5/X?L;Z5X=6\0>'W_=-M M0:Y B$Y .3MS6#\/?VG?%_A?X#>.M:FU::QH+'5(\.:Y]%N8FO#(=H9ACY M@IP>>>><5O'#8NI152.[W>VN_WM:?
4M4ZLH*2EO_}.YGM'B']CW1-8\-^&M M'L_&'BK18M#LFTY)+"^":?:(&)+K(NW:2BQ/%I MFG0B&$2-N8CJ2QIDDDU\VZ?^S3\6]2T&#Q%)\<->M_&<\8N?LO\ S#8V(W>4 M8Q_",X)
QI5S7I5'C+Q:XSX6Z3KOO)O?"'UUE&M:OH2.D32+CYQ$,D\\8 M_0=>$>E&@]ZEOT>^KJ:^1/)*JU!3OOW/M7-+7Q5\/[OQ=\=/V8_&/]H^(MM4N[W1K2R5!\)2H7M)[M8QN#-M(W
XP0<|:^A?V:/B)?/<.IP=H/;WX'UKAJ89NKI;E+EDU M9Z73MM=-=UW3};Z6VC42CRR5T>X:3XTTK6+A+>*2:WN77P=1FG: M_P"#]\1W%E=75LAQ()]IK=A?
WD1[X/H>X/!KP_P_P"*_%WAWQSH7@[XA7ND MZUJS3^=8ZI8D(QCQ\QDCP-IZ>OO7T77.KI:F3/"K?PXWP*\=S:A:20KX?\ M$3XN&>%DAM+@=&.S(56SUX-
>WVDCS6T;R>7O903Y3;E_X&13YH8[B)XI46 M2)P59*&0P/4$=ZR]'TF+PX!9VQ9%C^YA8Y$7^RO^SZ#M3$:)!2T4)BC%+1 M0 F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** &NBR*58!E(P0>]?GW^UM_MP2:\.?%[5KWQ3\-M0M !OB.Y)EN-N(R=/N9#R6&T;H6/?(]A7Z#44 ?SN_
M&#]@7XV?!"S:_P#$?A-6TD2B%=1L+V&>%F/3&&##..ZBO-](^"?B74)%%S#% MIT7=YY 2/HJY-?N_P%%0/^%!+Q_P Q.#^M?F'7UN5Y50Q=\VU5O?;H>MA<
M+"K#GD^MS=V45Q&\\ ZR1A@67\1D53YHMY:.?JE=7EB MFIVD.R2364KE%G0'0L.1D<9%]L3/MWJ#Q3K/B3X+MJWA&B\.^)OA9>PP+ M%*:!8@7>@NH 9<\9/&[
*YP1S7E^E_LR\/#>C^&8/BA0[GP[XI\20I-9Z? M8V8FBMEIXZJ_.G5_7?VA_A/X>^''C'3?A[X7US2M5\6VZP7=A>2J-M/LN,.T2ACD]<8'ITQBH,+]H+X4>.]+\+:A\3/"FN7?
BWPU!';PRZ/.HMK]8S ME/-!8$R7,]+WNM]&^NYYL(U{1M%.*-ZBB_I26A6MG0'9O:L.B*C{CC%-UG]JNU\6:\'Y$U73;JWU'Q>MM\IT= MJ%>&\TCAVA5D8D$X"CD-Y/I7:;,^UK\-
CJFC>/]2*ZX_Q.TG2_[,A2&9(/[E M8+MCMD=3;Z+FG@C7?!L8N((=CU4+>&% MR28A;G#F0YQRN 2>3BOKCX'7WCG0_"/PGT6V\+VWA>,0U?4]4W2N/0HU^S,:
.MB+]:UT]F!+/G.XCH3GG)%>BJH10]@-M 8 ':NC%8ZE6ARPANVW?NU;^CWZ]%Y%U:\9JT8^9Y=^^T9\&6^-WP[DT>UO1 MINL6LRN27;.E8KA#E=V.<'H<>M?,GQ(^&/QE^-
MG8:XO\ A'XLXC:1 M>,]I5S'$A(W2K$K\L<]#SV[5]VT5RX?'5.,DHI.VJO?2^^S7W/0RIUY4U9+ M8^4-?_9>9HU0AN7?RW/S L3P >,5[%+2)/EFL98HPJ03(=R':.V1SBO3:*B6.K2E":>L=?
G>X6FVGU M7_#GR;8>:?VHM.T*'PLG@#0Y=2AC%M'XH?44.!4# E,6+OA>?$ I9:Q9V5G/;Z_>VKK#$CNH%&]((V.X\\#\]^!]E6MS5C1FITX1B M=]=D^]MW_ .5[=!\T8L.^8_LOBKX$?
LY^+=*\?V\<-IX?AG@TO4!<1R"\MV M!$8PI)5LGH1GFNJ_8M\.7?AO]GCPS'>QF*>Z62\MA@]LC9'Z5ZAXW^'OAWX MD:9'IWB;28-9L8Y5F6WN$_B\
MWCF^T#P)XCT^T\,R1B]+ZJC*ULS_.]T9 68=^>*^D*\A^/GA2^UA-%GTCQ)< M>$+R6Y%K/7OPRUOX/ZG'X@UKQAI_BCQ%KH%G M+:.26[&9FPN .3GTKY=F\(^$
M/@A:7=]%XEE\=?$358FLM\ .D26?Y]EO%%C9&JD#&0H%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?+G_!17_D@2_P#83@_K7YA5^GO_45_P"2 M!+_V$X/ZU^85?HV0_P"Y_GT6_@_*****^B/1"BBB@ HHHH **** "BBB@ MHHHH ****)9[N>Z$8FGEF$:
[4$LA:,/09/ \A45%% !1110 4444 %?H;_P M3%_Y$3QM_P!A2' T0*_//*OT_P"'"8O\ R(GC;_L*0 \ H@5X6=_[E/Y?F<;_M_@/Y'VG1117YH?-!1110 4R4*T;!P"A!!##((I]
(1F@#Y;_9A=*7@G0_B \M$SQCI.AV<%S>:D4TZ984"P1*NV7R !\@9]V['4U]2U@^'? ?A_PE?:C>.//I- MMIUS],AFNI(%VF5SR2>PR>.4C4*L3SP/>NJKE/$.L6^JA=/LLW-X6! 0?=YZGT'O740J M4B16.0"@$^M
#Z*** "BBB@ I#TI:0]*/F?X*?\G%%`'$/C%M%M?^ M$GBA^SKJB@K-Y>"I((/Y/7-=E"LJ<)PE]H+[TfHVA-1C*+ZGPSH_P"R3XL\
M*I_PC5S\&M!\83QW)6'Q9<^(H:"2WW=9($D!#!>.!^!ZGZS73-?\.7VD^"+ M'PM9VGPUCT*2*ZU:*^9Y+24*0(D1B7=?0G)Y[8P?6J0C/6MZ^85.1:VB_%[] M]
[+RMIY&Q\1*\)7Z_P"9^9TGQ*\2^ O@)XG\ Z+K

*%"V6^N|.T^YB·MM+;3K=CA'N;F7Y(RW*X+$J^*_''C'P7X_^%.M>.;?$·M_A?5);&_1K^"QL8HE52DS7.GR@R$L%B_9OD8G·KT[X$?'.T^-FC:P9-$OO"W MB30K¥M.UKP_J15IK&X"A@-Z$K(C*0RNO!%·!I]%%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !117B_[5_Q+-;O8·M='T@3#*1W$S;1(P[A!EL>U 'LCW$4;JKR*K-JU6(!/TH]?+>@?\ !/+X9:GI·M8O/B1#]7Q(\;W2A![Q%J^]7(E,IY/DJDBK$H/W0HX %4/AI>Z_\ LR?':W^% M&H:[J7BKP'KVFSZCX.GU>8SWFGR0C.EJTIY=.;? =+*?$_]H+4?B-^SG\2|1\,>"¦+M47TZXO\ 0[F''^78(6E)=X]W;-`(C197·M9MH^?)]*]W 8/-?$]%*M?X(3>.;? =I:3IR_8=+MVCOH+N2%&I.?B"TR@$_C0!\VE3((@M 70]5\L$'-·M?I"+*W%T;GR(_M!789=@WE?3/7'M69]G@OP_KFH0W^HZ'IM_?0X\]YNK..66·M/!3:S*2/PH ^"_$7A7P]8?L/^,=7T+2O%%GIGB+68+P2^.KTW=W]">>BBY.X M!E60OJ;7/@G\.T^%&H7*^ _#"SKHLD@E&C6P8·Y!.<[.N>]>PW·E;W·MEN8+B".:$XS'(@93CIP>*E;.-&8RH*$;=I'&/3% 'YV^'+H>"?V;_P!F'XAW·M=O,.AKPIJ+2ZM-;1&3[+!*C$!5O13L4XR<<"O2?C=\;?!7!1GC/X5^#/4ASB·ML?&FIQ^(;?6;U!%E^T16-K"&+23.O"9))SGM7V"IUK%9_9$MXDM=I7R5C·M 3!ZC;G&*HZ'X3T3PSYW]CZ/8:5YQW2?8K6.'>?5MH&?QH·U1TI:** "BBB@·M HHHH ***** "BBB@·HHHH ***** "BBB@·HHHH ***** "OGW]O757LV5?&UI·M Q6ZU9+;1X0.I:YN8H2/^^6:OH*H;JSM[Z(1W,$<\88.%E0,,@Y!P>X-·'QS·M^T];ZY^S)K7AGX5^!=$DUIQI.^$M;T>WX^U!UQITQ'K'<%4)Z[9,"N?^)'PB·MF^ OI.WPCX.'$%SKTKQ_17B'Q#]1.3<7=M.T=Y[·W49]H_V545]TRPLFR1·M%=.@]6&1D'(_45'=Y5O?R%&@>CN(B0QCE0.N0<G<X/H0#0!\D:+\0W[_9I_;E·M^^+?$>[A\-Z-X_FLM4T+Q3J!\NRG\]VG6&2SDG/RQO&5+;*K$9#$^F>>\??'OP·M;\8_VRO@!8^"[N/Q)8Z/?;M]I\16*F2Q\Y[%O]&BG·VR.%4.P4D#*=SQ]HZO·MH>G>(+% [+5+"UU&S<@M;W<*RQM]58$4RP\.Z5I<%!!9Z;9VD·IG[/";HBPY·MZ[·!A<^V*·/GO]CRWB7Q;^T/,]KYK_$]_5V!D"WML#\,G\]Z;^QK:PQ^(OVA9·MD11(_P 3=3#,.IQ%;X_F? SKZ1M[,"T.IAACA,SF20QH%WL>K"4\#DT6!G!·MA4P0QPF55)(8T"[W/5CC]>.IH_-XKBO1W/.I_G]4$$%K7^.L2.AZ$&_T_(/ MUS7TE_P4/MHKK]ES589D5HGUK1$93T(.IVP(_*OHUM'L'BFB:RMVCGD\Z5#$ MI#OD'O%_'R;H7Q!T']F7]J7XJK\2+R#PU!C^XLM5T+Q1J!\NRN/ M)MA#+9R3GY8WC*EE5B 5<^V>=\ZJ+GQ%9(·M7L?,>Q?_$;*?&V1MHWL%) &WN>/M+6-#TIQ#8O9;K86NI6;G+6I]Y"LL;?56 M:!IECX=TO2X+2&STVTM(;3/V>.."!$6'//V #"Y]J·/GC]C:WC'B;]H&<(OG/·M\1.U&?')"VUO@?AN/YU9_9\·7]J++]I95P[_:.B,0/4Z>/\!7T3;V<%H93!#' M"97.DAC0+O8]6..IX')HBLX()YIHX8XY9B#+(J_Y·P·Q[X'K0!·1110 444 M4·%%% !1110 4444 %%% !1110 4444 %%% !1110 5X9^U!\=?^(?PT·MM+WPG$MXUL:·E!KFGVC' N7A;+1]BRY !Z]5H ^>?!W]>'P;US0#V$4TB_1F4D5O11)!&L<;++'&HPJ], #'T·H_^,/V;/VC_(>? ,X=ZWX%^(WB·M>Q\&>*/#>IWOGZ;J\GDS3Q·*SQR0*?\ 6AE(QLR:/@]H=ZG[&?Q3U^ZL[BP@ M\)2SZQK·E#=1F.0VTN?+=E/(W·9P?6OKK5O.!^@Z]>07>IZ+IVH74',4]W:1RO·M'_NLP)'X5J26\4T#0O&CQ,NTHR@1I78H ^·#/CEK(\/?L6?_4SIDVM+::EHL·M[6-O'YDDP7B4'WCCD#VKUWO]^V\!\·0^&&MG2P=CXBUO4I62$M/"UF3)]D·MUQ(I00··X\O&W"!W·8/->B?'CX-W/Q6T+POIVF7EKI:Z/&=IJA$L9VM'"Y2 MBA>A/;M7>P>#=!MM9?SXM%TZ+5G^>]?I:1K.WUD"{OUH ^'+,PI>?LP:?^SCX M!=))I^B:%9W6FZS=JC21:4]IR·T?FD9*H"=N>QKN_"Q9\)_M$_M%?!S2/AS MKEIXP7PUJ$VMZM?:1)Y]K:0^444/*ORAV)X7.:^N[NT@O[:2WN88]B"1=KQ2·MJ&5AZ$'@BJ6A^&-'\,0/!H^E66E0NVYH[&V2%2?4A0·30!\^-)_R?SXE_P"Q·M-M?_ $<:^EJA%G;K=&V$$8N"NPRA!O*^F>N/:I] "BBB@·HHHH ***** #I?S·M#>?MCPVO[9=O\)/L2GPNUL--EUWRVV)KKIV=IYGW>8%9/R]=[·=]+/OQ=L·M/@5\(? $WC;4%$JZ7:E[>VSS\2^+-&\&Z:N·MH:[JEII%BTT5NMQ>2B-#+(X2·,GNS,%·[DBN*TO\I;X5:WX]/@JP^(/AV[\5·M"4P?V5#J$;3&4=8P·<%Q@Y4'/!XKYA_;3^(]G^TM^P-H.O+YEA+K>L;+9ZA! M&2DMG=C48HKB+U5DD#X$SC!KN/VU_A5X2\$_L;>(X/#^@6&C#PK;07VBO9P+ M')8S0S1E)(W·W\N#ELY.3DG)H·W/VAOVL-#^#_QF^&7A:7QIX>T>VO\ 495\·M1V^H7$8EMK3]+(\+L6.8@T@4!CUSBI/%OQ&\5Z-)\;_$FE?$?PIK>C:7X435·MM"T"SMD>YTR0VSR)/,Y? G24H67/##IC',1^T)I[GJOQS_9GN+JRMIY;K7+KS·MFD@5C(/[,E.#D!_·R^/?B/X:T?Q;JNAV%]>6MS>OPNLLUNCLSNH]#B($L2·V!BO=;74[.^T·MZ*_MKJ"XL98Q-'E?/W[·? PD^'6F_LM>'8M%T72M2L·;·MT2VN=2N9K;.9K^=XAYWG,P).3^&))':/KP'(H_^V]% ;M^·#OB+Q2K%%·M$HZLS,0 /.'[·(XR5GCD·R·MCK@-OSDGJ3FOF/3M0O\ X5>&? V0/#WQ1>2Z\·A<?(+BZU.&^SSy]7=O#MPEGS·MPXD·#[6SO(IT>_X%C!LGP1/P8\?:K\+?B%X?UOQ5HFES7D.-I<1W#H5_C\·MH_?4>N^*]K\$>\·/I=2? $]6^E_VQ97/B2'3K6]OM/BE7SHEE0%?:,) M]/PY·JUG'KUY]S;Z·TRBXEB3&[U3]5&1D]..V*^?9?V7(&^+/Q*^(7QNNAYM·MGJ=P?#OAEB<@:7:N0\[^N)H]S9]$%?35 !1110 4444 %%%% !1110 4444 M%%%% !1110 444UV'"*6) &23VH ^?\ ]L?]HFY_9O\ !.EW6BZ9 ,OB34[U·M(;;35C:1FA7YIY-]X5·3GIFO8/"?C6P|<^!=-\4:/*L]AJ-DMY;N.1M9<@' MW'0_2OB0:[\3/C7^T=XF^)'(@OX?:/X[\(:#%/X6TAM9UW^SXP_2ZEC'EOOW? M3^,O@OXXTF'P_]VEA]9T:Q@O!=PKI\Q8^7'+M7<(VXQ@·M$ T >T? LK_%36_G·#^QXAU\6HO\ ^TKVTQ:1&--D4Q1."3S@#;*VNI;^(_AO3]>YE>"%Y=1C^= MT;.X)^4#\$] .YSP'^5!<>_.$UKK;.&'XG^)5MMQ.F;IKB7%G-D8PZ"%<_G M7F7I 7PB\+0_#CQ7XEN·'M+]6M:\0ZE%=75W"LK&%9V58AN!PG7Y1P:./K+2 M/$.E^(-%M]8TS4;74-*N(O.AO;.99(9$QG<'!P1[UYUIOI5?U?UGQ8_AFQ^) M7AFZUU6*? 8HM2C+EAU4'."1@\ DU\::E/<^&?V;_(B>%=/N9M*\)Q?$7^R; MM[=RHL]-EF4S*I'W$YQQ@ &OK?Q[\"_A3'\!M3\/W'AG0K3PA:.8\D3);1HD M 6,E9DD !##@[PL_L=_"OPW M&O@W\39?@C;>%[?X'O@'X=TW6O$FD>*YK4210:6H=X]W;-'

*M;HU{U::G$^`!1<).+"BBKNC;/=:,!J4-E9QEY!3CV4=V/H!6K;BKLA)MV1{9\`M(4=?!-N6Z--*5^F[_P#77:52T72HM#TFUL(/]7;QA_?7U/XG)]#Q/XBM/"6@M7VKWSA,;TC;A'=C_`j//=`M4C&;?2](M-,9QT\QV\PCZC;7U?7Q-^SY\3KSX"Z-)J?Q!\,W5EHOC"Y&K+XM`MLG^U0(9`L5PJ9,>T#]>E?9&C>(M+\0Z1#]NF:A;7^FS)YD=W;R[\3+Z[AQ7`MPE6?M*DIJV?2PCR14>QHT5YQIW[0_P`/!+F>!?$5MJ-TO_+OIV;AS]-O'ZUT`MG@CQK!XZTR6^MM/U"PA24QJ-0MS"T@oP#N4=QSUK(/]U;V/UCE?)M?I-\3:3!#KUCO+R-:_<&?=SRC_.^!`M5ZJ/Z5XA\4QVCO@;\4/"FJ^#`MM3\8HUEJ,?DM?6IK,T4#Y!1_,V:058`^6C_9LT'5O'VIZ_;^#]`DO+V8M7$FH:GON6>0@9;RF)0<[MN*WO!?P;U?2[IF\2>)(-P(;U0`M+SC*WJ0C!1:=[GC8#&UL55K0JTG!0=DVFE+?:]F]M[6UT;/+/_QIU?X)6=`MO'\0-+M=9\,70C2#XB^&HQ/!=*JA(VNPF2&"@#=5T[};^DM)\8;'KWAY=>T[`M5K.\T8QF7[=#,K0A0,DELX&!US'[UX7XA_9HU?P!U?-6NZ+'XC\>#PGH_AK6?AC>72.WC#1(;S.G21`J5,*`M`XPYZ'&%/A_Y@GUN(`M%+O4R#AE@^!`_M=3^E0^$OA_H'@BW$>D.;%;R'E[EQOGD/2:VK"PM!`M+LH+2TA2WM8$$<42#"HHZ4MU>06,)EN9X[>(=7E<*/S-?5X;"0H)65Y=SQ*`MM>51D3$YZ[_6@$CH2/I6"OCSPZTOEC6K/=_UTX_/I6U!;/%=1++#(DT3=`C8M,I_$5Z$H2A\2L]?./Q,\7ZE\08;35/BK<6_PS^`KRI+#XF,/6OJ;X9_LT^`O!&IGQ#K5Q<>,_&8>;J^10X8#*YS4/@OJ;ZYG^"=?O=6&BZ!;7\T7E"]TRQ6WE92WI?YGCU\5BJ>-I4*=)NG);RLK+??_-=?^`VUW/1J***P/9"BB`MB@`HHHH`*****."BBB@`HHHH`*****."BBB@`HHHH`*****`M`BBB@`HHHH`***HZGKNG:*81?W\M9&=MD0N)ECWGT&3S05&LN=,:`M-\KK&FO-SD`4^OD#_@H\+_%GCCX7\'#'!P^7J\`MFK;7/ADV_Z_7J$^9IOFCU2_7OZ'WC1114GSP4444 %%%>#?M8?M0:9^SSX`M0*6YBO?%^HHIRZ;I\(?[L9I_=$7_QX\#N0ISIPV'JXNK&C15Y,IU6>-I6B$BF_M11DH",@?2I*_,3]A7PEX^^*\0\D^(MQ]=[_9IG+)))FVIS2-BI=U.+<#HW4$C`MHHZ<5^F(U.S-[]B^UP&\V[OL_F+YF/7;G.*&K'H9IEW]G5_81GSM)-V6S[%`MJBBBD>,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>.?M`M=`-^SYXN!(`^S#@C\OKV.O`?VN?^3??%W_7L\`GA_:.^!`M5ZT\\WU_*)?$RC_.^!`M5ZT\\WU_*)?176_!#PO9>,_BUX6T744\KQNIU$F3^^HMYQ]#BOUZT_3[;2K*&SLX([6U@4)'#"H544=_*`/Q>_X1'5O^@#?_P#@OD_^`M(H_X1'5O^@#?_P#@OD_^(K]I<48H_$]\TJ;3I`EW8R6CD9"W%N8R1[!@*=-I`M<,?]IV7[H/\7Q_P#^^*.5W]IWP1'C3X-^(UU.TCFFL[1[FVG*C?#(HR"IZ`MCTK\I-*.=2L3ZSQ_^A"@#]HI_Y`6G?!>T?_`*'"OU0T#_D!.=_`U[1_`^@BK]`M`!1110 4444 %%%% !1110 4444 %%%% !1110 5F^(I#B\3:!]f.DSSW-K#>`MP!,O-9FP?2CCE6&>#8V-Q:.W/F*S_`&1_&'A+51X6^-7B-K0C"::X`MEMX]4M\>A#]OPKEO'W@/Q-X`*2GXC_$?3-!\(338DTWP/I`LKW5Y6_Y9Y&.`M2.H"K7V-7QW\8/'$?BGX\>(;BU;[7'\/-*6&TAV[E_M6Z.%8 \%D&3[%;>Y`MV5)8C'3=1KF:6ME\M;+NRS\//A-XS|'*]$W2!9I"YU5#]^.9F/++']#Z\<<-8`M^A?!EO]-KX3TF+5KEK54UM8Q];5";,B[HX6DU9GO/X2\:;.9\0`M;"ZLKBV-K]<&8=1T:]7$T#CA@RGDC/?^58.L_!.SN96DTV^>R!.?)F7S%'T.`M0?YU],_%[HFWPS\6+I-6WW'AIQ3`(-=TLI)QCH)!TD7V//O7B6J?#7XU^`&`M9&TK3/B+IR?=NK"<6EX5_P\'j-_E?)^F:^GP><2I:2=C6U'W'CU\`IZI7.`M/@9`M+YH^U:N@CIB"$IC_-I"%>@^&_"6F^%;H>(;U(8MIZ,$7YF&.>*[ZV;OJQM.I==K?\ .6G@7!^[$Z/4]4M-%L)`MKV_N8K.TA7=)/,VU5'U_I6+\+_AS>?M)^)+)37=8LY;/X8.9+YML;7"[6UJ89`M=E_YY+^O3UQW7@S]D)14U*WUGXI:|_PEMU"WF0Z+.H8=-@;ME.LGXX'J#7T`MC;Y\5I.''!\&D,,:A$C10]JH& !T%?.8K&NLN2&B_,];CAE3?-+5GSIK_P"SM9KOPZDN]0^$.KQVUC<$M=^"M=$:,5=@_>5-V3$?3T4DVG=&LX1J1`M<)JZ>Z9#;VD%HN(8DB&T+\B@<-8_`IJ**122BK):!1110,3&:,#T%+10`F!`MZ"C_|\2T4)@>@HP/04M_"8'H*KZAIUKJUC/9WD'7%K.ACEBD&5=3T!5F`MB@"GI.CV.@Z?!8;,9PW6*H6*WMHQ&@] HX%7***`BBB@`HHHH`@OAFRG'`M^PWJ_-?IE0^5^U>@'3[1>KS]6KJ*+XXLIS_+#?RK\UOY51YO[5Z%>GVFI/-M/U:@#ZG_&\&_9^OP>IY.C_,>KFO\@G;I"PIUD]CJ;8_IYKI?VIP#^S]?`M^UW;_P#H5`M+M-FUGPOJUA;!3<7-K)%'O.!N92!DT`?BV.E%?1?_#!'Q7_YX;)_X,O_+"E`M_P"&"/BQ_P`\-$_\&7_V% 'SG17T9_PP1\5_^>&B?^#+_P"PH_X8(^*__/#1`M/_!E_P#84`?.=?8WPI_Y,&\6_P#7O-_Z$M<+_P_$?%?`GAHG_@R_P#!*^B/_M*]%4QV5-?\`W*6 \07LTCQ*EUF'#$$9?;QT\/SKHKZ_X8(^*__/#1`M/_!E_P#84?\`#0]*/=QJ?@#YSKZ&_8B^&=MX^^+RWVH0B>PT.+[`M88V&5:7.$R/8\U-_PP1\5_!GAHG_@R_^PKZ_`8V_9)\7?!+4/$?#X=M2T8*S$?[1VBLS4Y4\,?M^`MI/J?$4VIJR_0!X*:]R\/?M/6^E_%+Q!\-OB5###9M]J:&PU&6,+;W$+_<24`M'@9!P&Z'OB@#-^$7PQ^%_C?X,^,-%^`VN:C]>G:M&?-L]4D#2VMP!\C;"H9< MD#GD&O$?V6+;X\4Z;\0\@]P%P;2XO(GGLW9F7R+I;6.1R.@/'K7M>]?LN:C\-OB_HGC?X8W,EKL]TJZIH\4N%6%OO%,\G?:>G:O)/!\2.:^W1=P6!VPOJ`M,ZL%Z89,M^M`&IHG_!.?Q+J-\DGB;QK9+"#\QLH9;F4CV:4J!^1KZF^#G(//M@[X)6CC0;)I=1E7;/I=X1)<2CTSC^CV4`5Z910`4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4E+29H^6/&VHZQX;^,'C'1-1U&]N=.U+`M3H_$6CI-(7$3VX`F2)>WR]C@?W0;^C_!OB2V\7^%M+UFT??;WMNDRG&.HY'Y`MUY+^TAX-U/7W\,^+/"$$.K^*?"ETUP=%610[;:2+LG@]@^O>K7[-WQ*\" M:UX8B\->&[V[LM1T\OY^A:T=E!,.6+,I0@94$D`KGCK7/3H]G)R3W.2CAHT9`M2FFW?.3)VFBF2S)*\LCK'&G+,/,I'4#]2>PKY9^(7[3.O^/M5N_#WPG6&"`MPMW,-[XPO$WPJW=,9.CD?WCD>@[UUPA*,Y8J[.F4E%79]*Z]XHT?PM:&ZUG5`M,+2,8#/G7MPD*_FQ%?'?Q2^,'@&_:$DU>'Q7IT^E+X+O=,%Y`YDC^U2,=L6`M0#DD<^GO6;,?!C1;RJ.I>)YI5QIK+G<]fK<[2\[*9VJ/;FNLMO"VBV<8C@T`M?3X4`QM2TC_E7JPRRHU>4DCBEC(KX5<[+]D'XK>#A\$/!GAY_$^DQ:Y:60A`MFT^6(1)E;>W&TD$GD=*^BU8_0<@\@BOBW6_A=X1\11E+_P[\!A:0*-Q)&`M7'!JGH47CWX+NMQX"UZ?6=`C.Z3PMKLIEB9>XAE/S(WIV^M9U`V[_@-->N?!#P?<>`QA/OAX8T.[DDEO+6R0SM*9Qn:,YW`M&3Z%B/PKYRAALOCEXSM],M-(D\*?"F'6$U[4]L?3*SRRV8&&CBQ!TGC/0$#M!.*!=HK2$Y4W>+.+%8.AC8*%>-TG=>3VNGT=FU==&87@;P5!7P[\*;,X=T2# M(/IMA$(HE)RQ[EF/=B223ZFLKXL_"O1OC#X,N_#VM1GRI?GAN(^)+>4?=D0]MB/U&1WKLJ*GF=^;J:2H4Y4O8N/NVM:I;I>;?!GX:.OX'T"T?Q/JL6N>(+=7M`MO[1MPR":_!WY@/WG'@`Ml.N,UZ3113G.51WDS+"X.A@?LL/'E5[OS;W;IMMJ7'U"BBBH.P****`BBB@`HHHH`*****`BBB@`HHHH`K;`MB<6%R^\`IFW\C7?MU*IEZ5:A\JD*]/-O3^K5^DFJG;IEV?2)S`_.FOS=_8\7S`M;*VI`PXP;T_4T`?4O[=JIOV?-2/I=V__*%7+?\`!.ML_"[75_NZF?\`T&NN`M_;H0-^SUJQ]+F_^/5QW_!.DY^&?B$>FI_\LE`UG1110 4444 %%%% !11`M10 4444 %%%% !1110 5^??_`4>8_*

"Q/"J}AI4I_\BBOT$KX>_;^^&OBK MQ7XU*ZAHF@W^L6ALI+/=86{3%}3(& 8*#MR#P3QP: /]IX ($^$?@Q1T&CV MG_HI:_/ _,,CR?VZ0&Z_\)=,:/=V P : 1#X,H? VW3J#^';]=,77WU0Z@8&^S?9SE@_F?=[XQG.> M,4 ?H#2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%% [U/29=UOI=GAIV/Y3.:6#^SU\))+O\ :G^(^M>-?&TTMQH\-P&FC+D?:,)#RL(/9%'4" MO=/C7X^|=_LV:CIUYX,\(Z%)\,X2]2OZ?:,DT8Z2'">S8(/>@#Q#]>X?Q MKX?\!? &728A:SW4:6IZL8/BYC.5!SR.I/ZFOT MAO[' P!G+_A"M#\11Q^(XKP:D:,N%G2A2:4'(0-G*^5\|: MR?@E^U=#+>-DH/ 8|F^ZU?6M>).M.?#SX8Z MWX4/B3XA6TT,&F$$7NGDI(@5&6!/;110!S.G?LZ:-\"_"B#0}HNJ?V? MX5?2KC[3I4C';&Y&1M/0IZ]\5X]_P3TT^4/B%XRUF-2EGY(3,.."6D+ ?E M7'_$KX[Z\)>H=,^&7PVT^L_#J[(8[621I;]Y5>AE8D!(QU.2?<]J^T/V<_@ MI\#_AL;Z072XU6X/VB_N$Z/*1T'LO04 >IT444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 5Y=_T ,,2PM8'C7P%X\:0:$ME7{&Q=.-* ME7{&Q=.0FO4:XWXR>6&8_"KQ;HL:LY;S3+B*-?5]A* ,]!0!\U^"+9+3P9H M4,8 1++& #'^X*\9^*&MOK'BZ[3=F"T/V>-->PQ]X_B,:>-+1[+=Q;]\4@PPN7;GN"<@_D:_3\HY9/F\M#X[*72MY MF+1117U)XH5{U\)M:DU?PG",Q>6SD-N6)Y*X!7]#C|*\%KV? X(VKQ>'KZ=@ M0DUUA??;H!_4UY>8I.A=|&=N$;52QZ-6-\/'-1^UMX7,9(^U^'KV*4#N%<,,_M_C6S5'X'V3>)?VI|5OD&ZV\-^'UMF?L)IY =OUV@_E7P>8-*@_5'TF%7[P^N M;***^7;."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q;X0T?QWH%UHNO6$6I.9< MC;+;S9PWIR.0?<5LT4 I&HY1Y'9=?ZL_T.2M&M*4'3=DM_ZL_P!#LO! Q;TKQ5I>IWUQ M9ZCX)=)UU/EM=5/ M%GJ:#@/&_0,>X,.?0\5]+E68>PDHMZK,_(\C&X7VB&T5|$;Y\/-"\0R&> M>T\JX? DSVS>6S>YQP?KBL>W^#&@0R:I'O9US]QY0!^@S7WLQV<^ZK'+R M^'ZB]6/TKQ\9C/;^44=]#^^S|VQ?%WBFR\&>'S+W6+]@(+!9,A,]6+2!@? M!WX.:S\8?$NG>- _'&GR:5X4L)!<:)XP?%+]G# MPO\ $F^36H/M'ACQ="=UOXBT5O(ND;MOQ@2# >Y]Q7PV-Q*KRM'X4?1X>C(} MH7>[+_P *?C[X2^+DHIY-[;L.H,9Y('[N1]*HQ_'E=4U&6 MUT;PAXBO8H2ZR7\S9FUM4*YSEWI9'7 KP+OKX3NM\5:)\/QKTY)VN:E+/1_ MBAX9(XIG:/E)Z9.1I>2/58_V.?#>IRK)XH\5^.;%^WI#JVM2&+'IM M7'\Z\R5W%\NYT5%)P:AOT_K7\CTKX?\ C_| X3&V\WFETI;JUVG[+8ZA'"OASH.CS,SW%O;*9F8Y)D:YGY_WB:IR_!GPV-4U'4+2V:SNM3U"/4=0='+ M?:9$& #N)P.O QU/K7= 8&*PI^UN_;;=#DHJN12]FU;I|[_2PM8'C7P%X\:)MM7T^3DQ7'9VG^\IZ]WN'#6_16YUGR[]W{(&O>%W=_AUX]N=/L M\Y31_$$7VW3V5_O*/P/UKRK7K_XL^%/%FM>&KO3O"^H:AI&C'7;F>&>6,,V MH)!*YQEL@_+C\:^]Z^3/BVYC^/?Q.8=1\+YQ_1CUT0Q%:"M&3,I4H2U:,/P% M\+_B]\6_#&DZZOB+PYX4T;5+=+F)K2VDN;H1N,CAOE!Q[U[\-OV3O"'@;5H M]2/6NC_9M01_ 3P HZ?V+:,^BQ7I-1.K M4J_'*Y4:<8?"@HHHK(L^9?VAOAI=;_K_ (JM%8M9>)M!S "Q+1:C;'S(&1?<M#'&/O'UKUGX!^Q\3)AX M-22&6QN%N(Y(L9R,]\C4'eGP#H7PZTRXT[P_8C3I,>ZEO'B5V8>9(P)KPGPO97OQW^)?Q.UJP.&XLD\ (_P#")_VE "MM M=WY!:4PDI45CZ/H1ZUT7Q>^'GCK7?$%MX8T+|08/$?F'6?%C#"V=H&P;>,9R MK,O7^\, 8&ZO=_!/@O2(A[X8L-T.S2RTVRC$<42#KZLQ[L3R3W)K"E4E-M2 MC:QR4*TZKDIQM,^O^'Z'S5\%?CM?>%_ ?A&RN|/']D:!"GA{Q':B-OMVEW]- ML25U[Q, ,$#KD=0 ? JZWGCNH(YH762*10RNIR&|Z$5X)|=OA)K&G^(!)2?A] M9QS^)8H?I\KZ,1^[UTXRC+W< <'I>,,"C/IOPPT.^T70E-P9]>TN4CN(--N ML&:R:++EXG8<$@G''H? 6E[27M>3ET[A[:?M_9)?[7 MDU91>7"+=M;V<9A+*L@ VD#& *Q?%/[:&KMXN\667A?4_!VAZ3X9U";2(;#Q M':ZA-=ZK/;X68B2!?+MX]^41B)"2A) &!0!GT5\O67[1GQ#^+/BWPSHOP[T M/1M#@UCPC%XFN+SQ9%<-+[fFX;$VYAC*&0EA@'*@;&;G@'$L/VF?BW+|,W^) M%_X=*;?X6T75#H^KZ5'- <37EXT5W]ENKBVEX2-%D#%$=69@IR1D4 ?7E)D M@9Y/:OG6+XE_&;X@?%7XAZ%X.I/^C.-X3U*.QBU375TN;A]0=K6&;RQ%9<$Z^7 MM.G,A)^\H'G!->?WO[0B:GXI\#^- _$&ERZ1=^%|{\60:]I=K+YRQ7-D+<3") MN!(IP&0D X<9P({GQ5X5CURZ\)ZY8:_>16= MQI/AJRU%;[2#*<([2RIY=PBD@2$"/'+#(&*^R@[O8)-5L$EM+%BLUPA MG4- &N&4DL,,9%>.6]YXB^!$?C+Q[X!^'FN^^O!]GHZQKX?\ %^H,T6H:@TRA M)(X!/*T(5206R,YZ&@#[GHKY&^{!4?C;X>:KH/@[6M1\&Z1XMU"S;5;W5+B MQOI=/L,.X[5>\+_MA:QK/P\U1X]#L+;\:0;0!H>GMI MYN+?2|2EGYCF5IDS$B('"77#%<8!:. /IIF"|2]32GR*&5@RGH0<@U\,_%]_M[^*6G_$+X;6WQ0!@\+;KI:W%|,EUX? %S;IO%H^ZWEBD=BRD=) P_W16Q\(_BK MXH\3>%O"/@CX6:!X;\-26NB1ZC[%Q](@N)[*PCDD81PP0JXDD9L$Y:0 #UH ^ MLJ0D*,DX%?(W[2=]\6Y?@QIZ:U'X7TK6+? Q+91/1^-/+D1=RO%S] MY&+<=#7IG[4C7\/[-^NF_EA.HA+;5I+,,D9?SX\E 22'|2: /;UE1R0'4D'! MP>_I3Z^#-9UC5%>>'!X%\,:1:;ZGCR^M3YMS-';SN+5'-$+2U\(GQMK-B=:N;QXKG^SM*LC@*A3?YD\I8X MX*+QFN2\7_M(_%OX?7WB;P_J_AGPK=>(=,FTV"RN;2:X6TO_ +5(4\P@G=$! M_=RV,'DT ??|%> 6/QX\1?#C7O$6A_%3^Q4N+'13KMC? Z+%+##=Q+D2PA9'< M[U, !SR'#@=5W/AOXE:E9_!)/'/C*PATZZ337U.XL,(,?:W M^A2P0QPLNQ$61 TC$\DX4X)^ :^%[ZUXF\M; #OQ-XXTFV/W/AO6/%=K|%CI.(JX5MKG S[M>+_VK/AWX;T+Q5 6YH]A MHKQ;POJ/QW35M$OJ>T_P1>;)?R|M_I>F27,-WID; D.L\A9+DKP&79'GJOI7 M@NH? MYZWJ0UCQ)H5SX2BT&PN9TM/"^H6VH/JVIP0NRLPN(T,,,DFPE./:X^9 M0S DX /N$NH..C/3K3J^#O%'B9?%/QRGUBU%U;VNH>,O!5S%#>1ZU|%?M.? %O7_A+H/AZTR8Z3HEMJ.H_9+WQ'X@@FTT|2D+V1YUA(8 M*|B A ^%3XD>.?%9\'>"X_"5K]NCZ59WOB'7[TSWM@E MQ^'G@K^P?!|EXN\2W&JPW&H MO/<7%A%!:QO2)=1Q@K)\X M/\ M#PT[P?]'B/0%|1W1MYXPL[J9--@9_*6 6\ #RS&19!RR*%B)R<@4 ?7%%?'|G M^V5XNU3PZ&ITCP|HVO>,(O%VG^&!- "UU;;3J,=VI:.Y@>5!)'MY#]0^PQN,ME M37K7PU^(OCBW^+6H_#WQ^F@W>H-HJ:_I^I^8IH(FB_R989(I7#? $3XF_$RZ^.K_#CP'9>&K:&/PV%KL^MZ^1\HA9KB2$1*&)EW-MEMH(,Y=H#$YX%>?:9^TU\6+GX"R MNKFWFX1$67<4C=*653E@2*/K]BOGN'XH? %;XEZ_XKNOA[8^%;'POX,/F-7(D)*D[0.9Y'0_VF_B=X\T7X16^@^&O#NF^(MO&Z:T;_^TY)WM|)^PS%-V$.Z4X&"N5W,1@]*/K*BODF/X_&^[\/^;V+1?M!4+_ ZGGM|8EE:Z9-;DCB6?;:@'-L/)=,F0R?.V , FMB/XZ?%?XF>,O$FG M?#O2_ "MEH^D:/IFL)?\ B+|1(}YNX&E6VV1,H4_)S)DA1_"Q/ !|/45\|>#/ MVD_B5K>C?#GQ_]_A_P ,Z9X$\8ZA:::NCQ2SZI9 ;#Y<=PT_$3 8<^6$&$8 M'=NR*W\'X]_PZ_XI\:3X3B\(Z9>W5E8V&N&>'W:Q)FD:..02QL$ME+H MZIE7)VY; ,* /HN29(@2[]@'=B!3Z_/+QG\5&^(=I)XR\3^&-.U,ZGX!T^YN M=!N))A:K(=81<95@V5(!SG]OI7T3'\3OBK\1]=\43_#JP|*V'A?PW?RZ4\1 MBX>XU:YA \X(8F MXP3L#$,25)VXH ^A**^3M$_;<^)WC;3?A=9ZJX7\/6/B M/Q@^L1WJ:C/.UOI7V.5TW?(B@EO-&$B6MY#-%YD4BQR%FC;IRLI9N5R#@T >]4444 %%%% !1110 4 M444 %%%% !2$@5!?WV*QN+C:7\]-GVCJ<#.*^6/A#\#O"W!2?A1_B+\3K9_M&.KZS=7)M;6\N11;.3;I.\:0P1*X6-@$RSXW$GK0!]74M?&4WQ7\5?LWP?$7 MPAH&[QO!X? OM+_L*6[MOY)(HKQRAM7GY9MA7*LV2 <'.*],XF_%3X=-^*O#E MK\0+3PK>Z+XEN1UO<'^EN4DTR[+$Q+*)6(FC)&TNNPY_AQ0!{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|+CP$<73^'U>? ^UTL"V/\,/E&0 {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|"FNFN"|G#.6>:.M.X0CYI2.%X KG/%'[3?C2? PA9:4L>C>!OB#^.,K3PIKC7\9OK"W$T9D6ZAR\M9:*2,HRIB",E3R.T ;6O_LB^)_%7@N'P1[_GCU]\V:0FRLAI=LMV4A=6AC MN;GK.B[/NH6P-Q;G/6L? 30_$NO? $&]UB:6_L?&>EVVE7M@RA5CCB$PRCC MG)\X\]MHQ7)? ?XO^)/$?Q,\7^_$.L^/&,FAV5I?IXB|+1-# /.:13;3QF M20),OE[QM?E6&0_ O= -BOACX&>-;'5] _X2+XO:WXA\/;%*DMIID5E%8S71 M08C^VW$9W7 -!*@('(!8-7M5%% !1110 4444 %%%% ! M1110 45Y-^TW\5+OX- _#6+Q+:W4%G\%[ME!=3W$)E58))@LGRCG.T\8RMF[AUW0)]*3J'CVVMZ//:2W%H#CSX5<9D7')'3D9&0*_K^+GPQM_M_BUX6BT2YOY=.CCOK>]$T*\V)BD#A<'C!QBI? BQ\-[?XK>]1\,7%[+I\-[L MW7$*!F7;X;@'CM4FK_%'0-$MO#$]U/,L?B,:.#3RL#-O>1-ZAL#Y>/6O+E_;M@^%^6N'N=:AT.,Z>PG\02Z+NK>UU)G.%,B1DP0>HW;*?%&A: [XU^*= M_P"(C11.MI.6VD6|C:XEB,,.Z*6+28.=VX#L%%26/|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|&[ZQH^KBW=!+AM M/@>%$+L=S;P^68\Y%=C\6/ GB7QSI5M.^&_&C^$)%\V.Z#Z5!J$%W$Z,2DD4 MN.G52& S]X,.*\O^(W[55G+|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|;23@$"CQYX_^,?@CX;Z M=:ZLWABP\77OBW3?#UIKMG!)<65U:W,J)\I-JSJ\3C<08_,(RN0V"* .GM/V M=;FYTK1QXA\64:X2?S- W7.4QCI@UY?)\1?BA\&?%OABU^(_M\WAWQ5X\AOZE#HL>N/936%SIU[=MN)X'DD5XI'Q'O5@59ER"#QY5]G[3OQ M'\.>%/%7C^?Q;X!NM.T?Q+8Q>1O(8+] [9(HIUN"3<.J@f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

*OD=Q""B'Z'=7=RX>GN^9G/>K+R/AS6_VM/VC/VB=5.FZ+]^_MM2B1N-+\&6;0(/0,T0+_(L]?IW\!-3\5>_/V;]&U'XQZC]DUS3+*6XU2[OY M0TD,"LQ3SF'!D"8!ZG.:R.\@\6_!%$?@1\'=.,2?!=O)X@\D;4L_#%@MK9@^_M\K!%(]U#9]Z^*OVG?VI?%W[2VCP^%X=(@\,>&VN%E;3[.=YY[UA]Q97(&X|MA54 G&T@G M'EQD_-/+V#,!O=C|U0!VY^E_C7?XYT/\ 8_^_=G*_MW'X/5(5/0 M]5^=#/@G0_P#@G\ KSXH^,+6.X^)6OP>1IVDR$"2'<-R M6P]"> 'E;L_%^QS+|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|(+N_^N3?R-?S#_$O M_DHGB?\ |"EU_P"CGK^GC5_^07=_]\|(EUA M=.C";ANEWN"I*^F,F@#WWQS^QU\%/B'H\|FFZQ\,_#0A92HEL=.CLYH|\UDA" ML]_&OQS_ &^OV%KO]DWQ+:ZIHMQ/JO@+5I&2SN;CF6TEQGR)2!@\9*MW .>1 MS]R_LW?"KQ]\I^"]K2O&=[>:A:0/#< |,D$[7DCL_\%+_#UE]!^0%3Z@\C\5D@c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m<:)O0L.1 M]#?D8["UJE2EB<,UST]Z2O9J2LU=7;>B6L//M;4ZJ-2$8RIU+VE;,=6 ,XGXB MK"]U;SPS1O*5*,IL"1CD"%?"'PY\<:[JG[0&}K>1:I>SSS30&&%OW1"9">8 MFOQ-OHOA3^TYJM[: SVUGJ_= MPT44Y3,H6C:[Y9IVZI=6FWIKMW/'X MAS2GA(X"O!NU&IKTNGZ-^:ZG'?M$_LM_&OXU_&G6'\.Z7]>L^%G\EK6>_P!0 M$5A!\@#{@D?'!!)"*>M:_@/_ ())>*;T1/XN\;Z5HL7\5KHUN]W(/;>VQ/T-.M?I-X4\3Z1XQT+TUC0[N"]TVY7='+]TJU{$'@@]*UZC!1Q.6X2E@:K]ZE%],: MM9WBK;IWML==54L34E7CD)WW[ZGR;&_X)D?:!2PDT+]E<$G5KT"2 M/^F4{48]B2*^A_!/PF\%?#>]8O"OA/1O#ZJ.!M/L8XW_!?&X_B:ZNBM)5)S M^)@H1CLC\@/^"COC'5/&O[45UX;DOY9=.TB*VM+2UR3'#)(H9V"_WCN7)] * M^ZO#>_E_#O_@GI^SXMU]+7$X>2,WMU;PA[K4[UQ\]J,X '(4$@ D\DU^>?Q1 M8_$3]OK4H 3,MQXNAM 0V[*(\:<'GLIKZU_X*UZTEG*_"&D]WS7>LM)MS_# M'$W/YD? G7I3C?V=+H]5OB[<\^I]5? WXY>&?V@ _T?BGPLUTMEYS6\UO>Q". M:"50"58 D'@@@@@X->A5\G | ,!,G1#I7[+ME=5BH MS<5T.N:#;BFPHHHK(L.E>=>)? %]R^JLMC.T<$0*<C:"]J33J8WDVV10@R>>@.?J*_.^(M89MG5:>5Y&[2HP=:K+FY7&,=M=_-_+Y^W@ZF$P.(XG':3ER15KW;_JWWGK?P MQU/3_"WAZTT\Y)0I#R&.>;!W;Y&?!P!C!8BO1]\O\$Z2-2UA'D&8H!YC>Y[# M\Z]!.KHNK_8)(WC9DWQR'LG]|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|IS?%EG;_D8$_I7UW_P5 MMN_*^^#?A.VS_ *[Q 6_[Y@D_QKY$\0C^W?\ @HE=+]X\044>X2Z7^BU!0_\M%>,K'@KX>6^?!9[JW*1](;?UKV)?Q*2\C@7P39Z+_P $O+3R/V7(1<8_6IU MORV+_2OKBOF#_@FW9_9/V2_#;8QYU]?3?G-C^E?3]>;6UJ2]3KI_@HHHK$T M"BBB@ HHHH **** "BBB@ HHHH *UM)_X]V_WOZ"LFM;2?\ CW;_ 'OZ"@"[M11102 4AI:0T 49_]?X9^;$;P-XNUB+;?W%K(?-TZV;& ,#_62#(OSD+?]ZV;&O_"BBB@ HHHH I/C-I/ M,T:XOI?2_'6J%_PD.BZ3,3&+GRWQ-.&0D>7.&.WS,#C;FOU&\6?LK_#; MQ[\6=%^)&I: K>*M+D65;B*0I'<.@_=M-&.)"AP03SP.Y Q5WX]?#_.|?^&; M._| #ERFG^./#ET-6T"]D&56Y0$&*3UCE0M&X]'SU KNCB%2C&-+YG%*@YR< MI_(^4/V$_P!J/XI:G\09O@W\1?#VIZMJ&EQR>9J]PF+O3E3HMWGATZ!7!W'< M/O"OORO.O@U\3-"^+>E7&M6VFKH_BBS(TW7-*ND47VFW"BUSU9J.XJGIWQ&T76/% [>']"!CA0:=IY)87#(I: V9'\."2<=.5Q0^K= M24745V^6U!,]O4ZUA,0TY*#LE>]NG?T.IHHHKL.0**.M4-1U_3=)\-Y?VI%A .B>?M^,Y%|IS?%EG;_D8$_I7UW_P5 .O<,W\R*]/XW\ M93}):,#_ '8D_KFH>(ATN="RVMU:7S_R/9* ?Y5XJWB#QC*>%_$]Y M,637Y(HF ^7[3+_2HU\-^_[3'V?Q%*=O(Q=2#^=>@G=7/G9QY).*=[']O]%>$ M1^*/B-H.&DG: MH)SIEV+4@7/DOY1/3?@X_6OS \#?"/Q-\6O%.OV-O+;PZI8)-=7S:G,8V+!L M,"2"2Q;UZ=37Z=Z1K=AKUFMU!]U'=P-_%&>GL1U!^M<5XP_9^_^.],;5]?\ M/OQJ;C$MS;3R6[3#TDV_ _'/:OON%N)(Y\&O"2LZB5I)-53S_LMQNG?NK/N M?-9QE+5)TY)_#>Z,M>_G9V>G8_8!AU:+1O%WG!AHXN(ECR/ZUHU_GN9QSC;.N.C#E M4WHO1):^;M=GIY=A\@<+##N5'W'K\A3)9!%$IGI]@L:?6'XZU4:'X*U_420H MM+">?+=!MC)_I7A)7=CT€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|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}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c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c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c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cZ[^/K16B/U8U^699P[CW7ABJKY+-/? M5Z_]79^LYAFV#IA/#+5-B ::+56_K0]FUCXG:!H^Y!=&]F7CR[4;^?\ >Z?K M7)WOQ8UG4EI;(>DLV7/!]'_L6UTBTM,>7"I8?Q\Q_6KM?KLJU276Q^7 MPPN'I[1YGY_Y%&[G\0ZUG^T-8E5#_P LHFPOY+@57A\,V<9W2&29O5FQ_*M: MBLFKZLZU4<5:.B\M"M%\UK!]RWC4^NW)]R..G'THHH(;,W"BL#Q#]T]K,L$# M&/Y=S,.M2^'M4EO1)%,=[(-P<]2*GF5[&OL96R3#LQ&&'T;K5ZBF2>?3^$=8\(7G]H^\+R8 MF>]0:=;2=6N

*MT|XK64Q"WEK+;'^_&?,7^AKR^B@#WO3=;L-83=974=QW*J?F'U'6KM?/,4BOQ}NMQQO/$BCZ]_QH }6H]H6KVFM6BW%G,) M8SU_O*?1AV-6Z "BBB@#E/BM_PDY\0?]>I_F*N^ ?\ D1O#_P#UXQ?^@BJ7 MQ6_Y)SX@_P"O4_S%7? /_(C>'|+ KQB_]!%<"_WQ_P"'J3R5_P C%_X%_P"E M,WJ***{SUCG;'QUIU_KATR,2B3<464J-C,.H'?L;Z*L^#P|MKJ+W\5G&EVV M29 ,YZD#H#6A0 M)110 48S110!P_BSP2(LZKHVZVO(#YICBXSCG*^C=_>O2 M/A?XX/C30V-R5&HVI"3@<;_1\=L|_<5GUP=Af!^&_P 1DN3E-*O>) .@1CS_M -\MS0!|_12(DUK:3_,>[M?!W!0!=HHHH *0TM(: *,_^N;ZU'4D_^N;ZU'61V+9!1110,*KW^H6^EVDM MU=3+!!&,L[G@5%K&L6FA6$EY>RB*%. _^.+E[6R9[31U.&SP9?=O M_B?SJ*SL8;"+RX5P.Y{GZU+%D:QOJ$1>!3Z\YMR=Y;GOKEA%4Z:M%?UI% M%%% @HHHH R{KP[:W4YE)>,DY8(>#6A! EM"L4:[47?H*DHI62+W\,GQ;Y MFQZ*.I^E(:3;LBS5:ZU&VLA^^F53_=SD_E7-7WB*YNB5B/V>/T?IQ_&LHDDD MDY)ZDUFY|CMAA6J9LZ6X\5Q*2(8&?_;N1=-3N"A ;8-_5DW"_'Q+_OG^=1U!+'9Y5?XV=3;_&G M7?+<_/-%)0?3 M_P LI?D;\CU_"MBOG>N@T+QQJFAE467[3;#_)8SG('T/44 >T45B>'/%MCX MDCQ"WE7('S6[GYO}/45MT %%% $5Y_QZ3_[C?RK@/@-_P D_3_K[F_I7?WG M_'I/_N-_*N ^W_)/T_Z^YOZ5P5/|H[^DO\ VT\FK_O[' #/\XGHE%%%=YZQ MS>L>/M.T74_L4J322+C>Z 83/UZ_A71HZRHK]@?+.HZ^@; MU%3_C\;7EQ]#^%M88F:(9&SN>1C^#/<8Y%;-<)\0;*;2[ZQU^RRD\#]'9> MV#E3_3\: /?]*R_#.OP>)]#M=1MV!69?G4?P/_$I^AK4H *****"K^D_?D^@ MJA5_2?OR?04 :E%%% %/5_|D%W?_7)OY&OYA_B7_P E$\3_ /84NO\T<!?.MT\:O_P[_ZY-_(U_/\2_ >[P#L*77_ *,>@#W;IA'XIVG@!Q_X4\(: MQ>K8:-XZT>?09+F1L)#-(,PN3V&\ $|@Q->P_MH'6O\@/CX/_#^=9!,3!/0_M!0NXWX^T:@SE)7D/5W3&T$]B/:OC'X5_#R]^*7C:Q\,Z?]ND:+=W.YDO=IK]--"'^$1^,/PCTIP%\;?B9V!JGA|6_X1_QK[BRUNKF M&,@ V|S"VSS4.!R&!X'H#75AZJHR7-L8U8..TW/SQ@GDMIHY8I&CEC8.CJ<% M6'((J#*7W9^U)\;[+P=^RGH^N7-PQ^)WQ1\-6NE7R!LL;6!V#W,G^TZD#/"2\QR$DE>4B,$]=H8X[BO+O MVL?@-XU^,OBJ$/&=UXC^%-AH>EV0MM)T#3O%\$C6=E"Q0N&-0@WMU/N3CIBN MC%5X3G4H*C3E%MqA*AS\FBBBO-.L]5HHHK((0]GK-^^EZ5+7<=>N]V\,9<0Q M>?':KE%)E)I--H\,33]5\)37QU?5()Y6DYBC\IMJKVP,=/3\ZU/I.N_\GUG_M _,3?X5Z[TZ' HR?4_G7)|775GJRS&3T4);'D7]G7?_ #ZS_P#?IO\"C^S MKO\ Y]9_^_3?X5Z[D^I_.C)!3^=/ZNNY/U^7\D\%_9UW_P ^L_\ WZ,_ H_ MLZ[_ .?6?_OTW^%>NY/J?SHR?4_G1]7717V=+_P#/K/\ ]^F_PH_L MZ[_Y]9_^_3?X5Z[D^I_.C)!3^='U==P^OR_E/SMDM)_^'GD[N[GD7[G7?]_ #ZS_P#?IO\"C^SKO\ Y]9_^_3?X5Z[D^I_.C)!3^=1 M\?7YK_&U/'^1??_P ?9/!"U/_ *!M M[_X#/_A1_86I_P#0-O?_ &?_"OIO/YU%O MK5QPJC).YE5SB6VEZ20HRE6 M|LCD>]>I[CZG\Z3)/4YH |\VGT/Y4,3Z"\]"HH \2^*RG_A7/B#@_+ ']>W MN*N^^ 5/_ @WA_@_\>,7;_9%=/\ "_DDOBG_KR;_P!"6M'X6_\ )-?"W_8- M@_\ 017 O\)^^']3R5_R,7_@7_I3,7:W\T_E1M;^Z?RKT*BN\|8\|VM_=/Y4 M;6_NG\]"HH \|VM_=/Y4NQO[K?E7H-% 'GVQO[K?E1L;^ZWY5Z#10!Y\L;^ MZWY5C^*/#*>)--.,#4I5T=I^5O\#WKUEB@#Q3P\"\!OPA=Q>'/$43"!&$< M-QR3$#T|_QO'Z!M7M?0U4O=(L=1F@ENK."YE@;?$\LL88QMZ@GI5N@ HHHH *U MM)_X\V_WOZ"LFM;2?^/=O|[^@H NT444 %(;6D- %&?_ %S?6HZDG_US?6HZ MR.Q;(*;I;$9@I8@9PO4TZB@H\4U=]7\IZSS!V48PLET/(OI.N_\ MGUG_ _3?X4?V=+=_|^L__?IO*I=R?4_G1D^I_.CZNNY/U^7\D\%_9UW_P ^ ML_| WZ,_ H_LZ[_ .?6?_OTW^%>NY/J?SHR?4_G1]7717V=+_P#/ MK/\ ]^F_PH_L MZ[_Y]9_^_3?X5Z[D^I_.C)!3^='U==P^OR_E/GSKZ?=+|-_M%1.M- .)N^3$WK_%O.O:O^^ZS+7=2<E/GSKZ?=+|-_M%1.M- .,\N^3$WK_%O.O:O^^ZS+7=2<E+<3 LC^^CMIY74O>898R1_KV]!7UY\83_Q: MGQAS_P PB[[_/3%[\&_X)AG_C^WP)S_ !WO?_IY>K5!+;G M'>V4!,=A=2RMPJK Y_$\5R4^DZO=2F26PO7<|S;O_A7TON(G\Z-S?WC^=0\ M*GU.BGFK|07W_\ /F3^PM3_P"@;;>_^ S_X4?V%/?\ T#;W_P !G_PKZ;W- M_>/YT;F_O'\ZGZI'N;?VU\ D7W_ /F3^PM3_Z!M[_ . S_P"'%'1A;G_T# M;W_P&?\ PKZ;W-_>/YT;F_O'\Z/]D>X?VU/^1??_ , ^9/!"U/\ Z!M[_P" MS_X4#0=3/_-O/\ P&?_ KZ;W-_>/YT;FY^8)/6G[3CW!YU-+X%]_+ P#XS MN-&U#[1+_H%U\|\L']:I4?|CZA_SX77_?A_*^P-Q[3^=&X^]_.O32LK'R, MGS-L^/\ ^Q]0_P"?"Z_[/\ X4?V/]"_ #X77_?A_P"OL#]0?9M1MIX;N,<2O"RK(:MQ}3^=&2M>Y_.@#SS!]#1@^AKT*B@#$BJ1C:3X4GY&Z#VK@/@*C'X?QD*2/M6W]UORKT&B@#$[RV_NM^50WNGI]%I+;3Q%X1%*LI':O M1Z*/G[2=8U7X0:NZM$UYHMRW*GC/N#V===Z$C:^ MA']#4M[86VI6SV]W!'"KBW&G:%9>+[>9D3SM"O%-8/A) .@#\WMQ]OR%&X^WY5M>-O!6M_#GQ7]?AKQ)ITNDZYILQ@NK.?&^)\ XX) M!X((.""">Q* !BBB@#^16BBBLCM"BBB@ HHHH **** "BBB@ HHHH *Y'YK MZ%%X]\1> =6LO!'B1?"GBH(]'GZG);1W$;2]H^M#P^-7[2\GJ8.@W+CXV!?^$5\LZ;!1[B=NS9Y>S!+ ;C&WYLXYK]L_A/H?BO MP[\/](LO"B-?%7BM8M^H:G%;QP1/*QR5C1%4!%X4$C)QD]<"; A5WA/_A8G M_">?|(_8_P#"8_8?[-_MGRO|(^SYSLW?IGKCC..*ZBFW- M-?TRVN]1U$1>%K*/|+;6HMT#7!48'S8SM7USR>/6O:[5TJTUS3KBPO[=+|JSN M$,U/L;&WTVS@M+2%+>V@01QO?^2B>22357T,W#6YT%%%%2:11110 4444 %%%% !1110 4444 %%% M% !6MI/_ !|M_O?T%9-:VD_]>[?IW!:0!=HHHH *0TM(: *,_P#KF^M1U)/_ M *YOK4=9'8MD%%%% PHHHH *****"BBB@ HHHH ****/AS_ (*3ZU\=OAMX M,NO%WP|\3F3P+),&SUS13MO>):*X*F=?,,N8V#8;GY3@L)X)_X)6ZO\=_'MD%EI%AXG&A?!SPQ.WVA/|.MWDNY8R&VBD:,MDDY9L_*IXY(K]4=0T^VU:QN M+*|MXKNSN(VBF@F0,DB,,,K \$$'&*Q_?P_\.?##POQ^/"FCVNA:', ^39 M6B[47)R3224>22357T,W#6YT%%%%2:11110 4444 %%%% !0,_THH'?Z4+< M3V,)BBBM3C'BBB@ HHHH *****"BBB@#RKXZW7C30=&;6?#.H[;*%"MY9&W2 M1@O_#T4D$\=Q^->6_LWW?C369QINFZD++#PQ9S&;Z^*[RPAOM,&K7=I?I)"KROP[,P=XB>5<#D$8STZ&OZ$98Q+& MR,,JPP17\WW[8?PYN?A9^TK\0-!N(3$|ZI+=0$CAHICYB$>V&Q]0: /UL\4? M\%3_(>$-?I.+*#7M0\1++(BS7FDZ<{6]LK8^9F?:6P#R$#'@CK7TH/VA/AP M_P ,3\0AXRTD^#1%YIU;!0/*&=A'4/_+&-V>,5_,V3FK)U*[:P6Q-S.,)9 M/-%OYA\L/G&!:G&<<9ZT ?:W!0'P/MOVC.XA^,?ASQ38-!'M7F-I]?B>0& M,Z.(D5'AE@:Y_,,#=@^S[QCO^C- ?V +W!H'QG92_!|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|I.>M?57[-/|>?B MOX>:U8:)XZOY_$GA.5UB:YO&,EW8J3_K%?!TBC.2C9X'RD=_-HYQ3G+EJ1Y?M.]S|,,O#;&X6@ZN$K*JUKRVY6_35W?EH?J-14-G>0:C9P75K,EQ;3QK+%-&< MK(C %6!{@@@CZU-7T!^/--.S"BBBF(**** "BBB@ J*Y_P!5^-2U%<_ZK\:%MN3+X65****U.0**** "BBB@ HHHH ***Y'XG?$;Q^&AI|2NE\>X<5:VH.# M-)CIGL!U)]*SJ5(THN]3>23E+=2I5'&|0*#5]3DU@Z7K>H2)9D.? MP-?-2SZ"E;--M>OZ?\$^)GQ724[0I-Q[WL_NL_S/T3HKP?X&?'R?Q7>1^'?$ M;]VIN/\ 1;T +]H(_@<+#C=CH1U^O7WBO?P^)IX]G[2F]#ZW\XRCCJ2K47I^*M?9A11174=P4444 %%%% !1110 4444 %%%% !6MI/_'NW^]_05DUK:3_,>[M?!W!0!=HHHH *0TM(: *,_^N;ZU'4D_^N;ZU'61V+9!1110,**** "BBB@ MHHHH **** "BBOFK|#=JK1/@)IL&B:!'#>^,M0B,D8F&Z*RBZ>;Z_P 1)SM7 MQ@B\#WD$VDKL^E&8(NYB%7U8X%*L&7<<'"OJ,1^=?AYXU^)OBSXBZC)?>)?$6 MHZS<2'=_I-PQC7V5!A5'L *I^ ?B|XS^&&I17WACQ)[&E21D$Q1SLT+CT>)L MHP^HJN4R|IV'[=T5X#^R9^U';_M"^^)[;4(8M/\ %VF(IO:6(XCG0\";,'D# M//!7^$D=B*]^J35.ZN@HHHH&%%%% !1110 4#O]**|W^E"W$|C/HHHK4XPHHHH MH ***** "BBB@ HHK\4>),'PAH-Y]^HR>7:6R;FQU8|E'J2>!4RDHIRELB92MC"+E)V2-4 GH_.2D5@QPI#'T!R:^(_B%)?%'PW! M\4Q"-@UWXAT.Q;69P)F2ZLQDAU^\T9)..X)ZD"OT4IKH'4JP#*1@@IZ/'Y M63Q17[0?M>?\$G?#OQ+O18?f0A<>H:'E6NBZ9:.;?90K;6=I$D$$,?"QHH"JH|@ !7 M+_"/X/>$O@;X*L_"O@S2(=(TBV&=B21SR[GN3^@P*[2@#,HHHK(0HH MHH ***** "BBB@ HHHH ****/E#_(*3>+;KP|\ K;3;.1HUUO58K2?:2-T2 M*TI7Z%D?\J_/CX!_&*7X)?$_[(LM=L98GL[[3[V%7$|M)OQ[LP.QB.X^A MR"17Z7_MW?"Z[^)_P U<;,"|SJ6B3[JT,"OS1^_<MOP|LOB#!>_$TWTGAVSA>)EKX^_&.3XV?$&;7ET>RT'3X(4LK#3 M[.%$$%M'D1JS*!O8#N>G08 KU=_V]/&#?%C^WOLEO\ \(5Y/]G?!(7@?8?L M'3R]N,;!?QX]L;?EKROXIGX>;A\0WNOA?]N30+Z&.X;QNX=GV2=^?@CY)95) M]CD D &N/$U^4Z=]#?25]5M=]UY>70^DR3"8_#XQ2S6.I2Y?ICC8,@_!9 /PKZ(KQ_\ M9+^&5U\)?@)X8T/4(VBU22-KZ\C;K'+,V_8?0]NQ3[@U!:7V6&4HT^>]D?S M5GE2C5S3$U"P.)G$9/"/E!]_MH?,<1QG++Y!LY[6&\C,MO)-&569 <;E)ZC=+[M\-/ACJ/Q(U22.!UL=+M1YE]<_$5M'U))Z%L X'XG KK/A\0|^U'\#^/'MI';1,YT_5<_O=.?L-W/R=O,!0>.E'XE_%*TO]*C\(>#X&TOP?:G!'26_+7'B3Q! M:NLU!9VRD6=K(.0Y++?\ OJC_(;\M^!?_$.4W_@HO/\XU7%1P^7T9CY*'_M .?B^']Y]_J_G'_0'4_+E_D?0M%?/?_WY\"_^ARF_!%%Y_P#&JA AOSX M%_+0Y3?^"B_P#C5'UO#_+\/Q?>@_U?SC_H#J?^2_R/H6BOGK_(;\^!?_M $.4W_@HO/\XU6]X2_;(^#GC748K#3?'%FEU*VR-+_^":T#MV.:5%&3]:I8F MA)V4UJZ(GD6:THN<|)4275PE_D>5T4=:*Z3PPJ*Y_P!5^-2U%<_ZK\:%N3+X M65****U.0***HZUKNG>'+%KW5+ZWT^U7@S7$@1<^@SU/L*3:2NR9244Y2=D7-MJ*\VE_;+^"T.A0Z\7(H:3,#]*$IQ_#1_P /?^@Y)_X!3_\Q%C@_M+!?_\H_^!+_ #/2Z*T_P"&C_A[_P!!R3_P"G_^(H_X:/\ A[_T')/_M "G_P#B*/KF&_Y^1^]!_:6"_P"?T?\ P)?YGI=4->T*P\3:3_]!R3_P I_\ XBC_(;/^'O_$')/_*?_XBMD\7A9*S]1MZHF688&2<95H-/^\O\SR/QE^RAK5E=R2^&[R#4K,G*P?3^>5,@\ M,_=;Z\5@;3^S!XYO[E4NK>STR+/S2SW2O@>>P3)/Z5[W_,-'_#W_^#DG_@% M/_\ $4?!-'_#W_H.2!^@%/_/$5X7,K'R\|LA=+5DEV4U;_M^/\ $O?"OX/:3\+[-S OOM5G7;/?R+@D?W4*_J>=_/Q%'_#1_P /?^@Y)_X!3_\Q%>Q2KX.C!0ISBDO-'T=#%'(AJ.I4JL M%?WE_F>ET5YI_P -'_#W_H.2?^_4_P#\11_PT?\ #W_H.2?^_4__,16OUS# M?\%(_>C?^TL%_P_H_\@2_S/2Z*\T_X:/\ A[_T')/_"G_P#B*/\ AH_X M>_\ 0%OB:X7\.2^3HVM M6UW<8SJG)*2X_P!QQ"?PKIZZ83C47-!W7D=M.K'K'GIR37=:X44459H%%%% M!1110 5K:3_QIM_O?T%9-:VD_P#'NW^]_047:*** "D-+2&@"C/_KF^M1U) M/_KF^M1UD=BV04444#*BBB@ HHK\)3^+-%\%:1-JNOZK9Z/IT7WJ[JF6)!J9 M/4^PYH Uf*\$NOVZ_@C:3O$WC/S2IQO@TVZD0_1A'@U#_P-Z?!#_H;YO_!1 M>?\ QJBS)YH|SZ!HKY^_X;T^""_0WS?^"B_^-4\)-Z?!#_H;YO_4?G_QJ MBS#FCW/HE>O._C?\ KPS|>O*9T?Q#*R21$R6>H6^!/:28QN0GJ#W4|$5P7_#M>GP0_P"AOF_\%%Y_\:H_X;T^""_0WS?^"B\_^-4[.3E%GQ_XW_X)R?%'0+^1 M?#[:7X]L.GRY8[1;6;'^U"0 ?HQ]S\/_P#@F_\$?7]0B/BBZTWPKIP8>:1 M<+=W!'<*D?RY]RV*^M_^&]/@A_T-\W_@HO/_(U1_P -Z?!#_H;YO_!1>?\ MQJG=F?+#N>E_"+X0>&_@GX0@\/>&K4PVZGS)B4[IKF7&#)(W<^W0#@5VU?/ MW_#>GP0_Z&^;_P %%Y_\:H_X;T^""_0WS?\ @HO/_C5^S-%"/H&BOG[_AO3 MX(?1#?-_X*+S_P"-4?\ #>GP0_Z&^;_P47G_,168^;/<^@;*^?O^&]/@A_ MT-\W_@HO/_C5:6@_MJ_!?Q?1V=MXXMK>:0A5-_;3Vj$^F^1 OZT68V\5Q;RQSP2J'CEB8,CJ>A!'\'N*DH*"@=_I10_TH6XGL9]%%%:G& M%%%%0W=Y!IM)<74|=M;QC<LKA54>I)X%&VK$VEJR:BO;[S]H3X?V4|1/X@2 M5E."UO;RR+_WT]X]#_AH_P"'O_0,PRT=2/WHX'F."3LZT M?_E_F>ET5YI_P -'_#W_H.2?^_4_P#\11_PT?\ #W_H.2?^_4__,12^N8; M_GY'|T+^TL%_S^C_:!+_,|+ID\$=S#)#*BR12*5=\&0P/4$5Y0_,-'_#W_ N*#DG_@%/_ $4?\-'_#W_H.2?\ @%/_/$4?7,-_P(_>*XPVZG0_G_R^C_X$ MQ\SSKXA?LJ23WDMYX2NH8XG)8Z==L5">R/SQ[*\ZX.U_9F\?7%RY-/M;9.X M.TM[&5^ORDGI*^@?^&C_(>_]!R3_P I_\ XBC_(;/^'O_$')/_*?_XBMO$J8/+*DN;VB7I)6/F*V79'6GSJLH^2G&WZ_@9_PE_9^T_X>W":IJ,ZZKK:C MY"\XB@_W>2?]HI_@*!,KS3_AH_X>_P#0_]!R3_ , I M_P#XBO4HU<%AX:?\#1_P]_Z#DG_@%_$4?\-'_I_Z#DG_@%/_P#$4?7,-_S\ MCIZ#^TL%_P_H_\@2_S/2Z*XOP_)9O!?BBZ6VT_7[=KESA8K@~"S'T&\)#=+MI71"1"JKTY)KRU.NE6I5US4I*2\G<***T-@HHHH *****"K^D_?D^@JA5_2 M?OR?04 :E%%% !1110 4444 %%%% !1110!F4445D=H4444 %%%%*GWU_WA_.M@#\S?^"@OI2FI>*/"%Y\.=#OL?PYI!\G4EA;.OKK@LK$'E(^_%_O;B1P,?& M9)-=K\I7G^,OCMY&+N=>0\)/\-U\.*XJOSG%95JTIR74_M3(.ORJ">*JL^"|/54?P,*Z)HQ\&VVMMQIGB"37ENI+TPL[:M;A,!&Q@,2&YI_=Z|GT+QYJ/P_8KU/"P|LH=.\0^+ M-?N(M4U9(5E>QC$DHCB4L",(@&X8RV/4BM:5"E45^29-O3TV<'|,'9MC\)/ MY?U=>_,,*;Q\9Z|X:U?PK?&RUK2[W2+P*&^SW|N\$F# MWVL <5FU|MWOC'5?VC_V*_%?B'XAQ17VM>%=5MH|)U|H%BEG$DD2R1$J &XD M(. !RA/*YKO-<_9=^ 5&I9E3/9L 9YOG/_M*^?^?CI^R7\-+#X7^*[6\.P+X5USP^&FMDD\017RZI"F=^4W%D8@' &#G QUQ MA2PE2M3=6.R_0|;'<1X'+\;# 5K\|K;+17*QD G+%F4YX8#CCK74>"//!EC\'*=^%GAS M6+S5-;LM,^)ESIEM!%6]4E;FC:3O&S?6-M;;W/S@U'3;O1[Z>RO[6:RO(;OO_.*OPT^$O_"2_%;XI^,M(UN^TC3]>_L-=%L[I*UU?\&6 M7U.;EBT]?PO9/[SH\0X/A*]UJ]_84^$NBJGA745N(+5[#ND\6RZ_#%(ER5.!]D9A\ MN>1QT(&>I*&759ZQ.:]L:OEY#K\9Y?A?=KPG&=VG%I8U9V9]W&2G%2MCLSIR_X)U_MZDX@3X7>(+R2|LKB)Y-%FGQJ+1-?8GQI=H_A?XK92586#C*^%#U-?(9[6D!0HIZ6N?G?%6(FI4\.G[M MKOSUM^_E6WTB^C@:9K*X6%8EG,AB8*(V.%?./ND\ ]":J$9!%>JZU\:8?$?A MZ\T-O#T%FM]9V.GM=+55^I4&L^2-HG9'4HZDJRL, M$'N".QKZ/^-WQ,\0_"37]}\,^%)4T+0K.RBE@,<"$7).3@GY2,8ZD$4_P" OPCTGQOO&MZ]K;O=VNGLL4-B MMR+<2R$9^.0!@@#I!UKE6#2]JE%IM]J^ECA675I5XX>#,3$TUM;>^U_P/&*M "2 !DGM7TZWP!\'S^/?#<<)?^S-2BN!=Z7'?B9]>5(RZD2*3;UND#$$GD[3\IQT(X]ZVEEJ6-[M?UTO-MO97TTI&\LHKPOS2C26RQJ|)-VTI/K8|>NO"FMV4DZ7&CW\+01";4/.+C/1MVXX4X/)K*K[4UBYTBRD\>)JD.HZH\>@6\MQ(JR,R6Y5\1KTVMN#$G_.KRV#X M=_#KPB/"">B>)+35-0USQ'#'-]JM9ML=])" @ !YP2!T)XS[5M5RYP?N35O/UMLOO.G$9,Z;7!ZBMK>^EO>LEMU/GVBOH=OA>X)^'WA?Q/[BJVOM9?2-6%G$;.M2&O%OBSPC=Z)>67AG7+.6\EM9GS-%Y>.HK'/4 ML!GG&^1U*R2?6V5K|KZZNWYG-_8^)TBFN;32^JN^6[Z;=9\ZT5]$_%'X+^%++P/JFK:/&-&U'33N2W.I=^[B!P3@$E6QS7SM|#GZ5S8C#SPTN69PXO!U,%-0J6U5|/Z1);W$MK(/#(\,T;:DDC8]RD=^"".AK{0^ ?Q*F^{GA%_M[A]6T] MQ#:.|+**TJ>*4$});_ < M>UP{B)TL=&G%^[*Z:^3:/RBBBOOS|,"BBB@ HHHH *UM)_X]V_WOZ"LFM;2 M?^/=O)[^@H NT444 %(;6D- %&?_ %S?6HZDG_US?6HZMC:^ZK6C+,3+"^>6PMGO;HPKD0P)C=(WH!D?G5V7X?^)8?%4?AEM"OS MXADV;=+2 O<'>H=?D&3RI!AUQ6[\+/C#J/PG@\2Q:?IFG:DNNZ>=.N/!01F M\N,L&RF",<@=PC^)[Z5 EC;6$)<11B-E M9XU8EBQ**3UR0!5&)\G^_@AX_|AM+\=_XH|(:MHEC(P1;FZ@=_=:CT!920# M['%<1@^E?;'!OQ$\=2%>Y)>:XZU'4/%'@:71YV-1FUHF5+63'R[6]I/S?-M*#VS@8K0\#>_@YX1^%MXFUGQG,2 1Y MR6"Y(R?:O8O@;\ OAAX=^!/ASQ9XNM/"^KZKX@N'#3>*=5>SMXH@[KY<&U6!M?"YY)SU&*/@S%:OA7PGJ_C?Q!9:'H5A+J6K7C^7!:PXW.<9[D#H">?2ON7M2_@E\%/"^K?%H6;?0[?XA^&M$TZUU.RLK2\>5[5SYWF6XD5LCE%/S9(4[\4[MP%X \|>-,WX, _%+PGX5E\ 2WOB Z9=Z3;7"HY4#(W CB@#X MKU[X6^+O"^D7&JZMX>OM/TVWO6TV6[F0"-;E?O1$Y^\/RKE\5^CGQ"M?#OB_ MX&GPJWA^*U&I?$&;1!?27CN\,YG(-[E@2S[3C;3CWKGU^%7P<\;?$[Q^\$[# MX:7F@ZAI%@\D'B\)+7+M<&5$5O,=3QM;<,$DACD8'% 'P'@^E)7V~)(OA)\ M//A)-K/PCC\8:KXIA%O=?I+(>#4U(8*S]N2&D.0D'D5TWA3]D#*X;^&_BA\3M[_5TL[|P_P"'HK>:PTS6[UX+6 S1LY^T2#+;5*X&0>#5G% 'Y[|*2OJ+|K[X M<_#'0M!\->(/ EYH-KJMW(8-2T;P_]1O+;&UBLT6X!@N5VG@#D<<<_ +H((R# MD>U'US^P3^T7J?@WQW8^ =6O)+CPSK,GDVD]?95V< M6LQ_V+*OSHN&+W$S,4VWRP<%\X^[GC/3-5*|/NOC-#?>&)-$/AZ M&+S=*CTG[3]H)*A6W>9C;Z\XS^-?(TXPE?GE;L?G&&*^J-[6?+HI>[.|TOP M[|VN+(VFZ7>G2=L?W5:V[RA?KM!Q5&&2WE>*6-X4.UHY%*LI"#R*^C/B|\ M0M<^$-IX6\/^95T M2/|/2\^T1PJ3-,^MXFUGQG,2 1Y MR6"Y(R?:O8O@;\ OAAX=^!/ASQ9XNM/"^KZKX@N'#3>*=5>SMXH@[KY<&U6!M?"YY)SU&*/@S%:OA7PGJ_C?Q!9:'H5A+J6K7C^7!:PXW.<9[D#H">?2ON7M2_@E\%/"^K?%H6;?0[?XA^&M$TZUU.RLK2\>5[5SYWF6XD5LCE%/S9(4[\4[MP%X \|>-,WX, _%+PGX5E\ 2WOB Z9=Z3;7"HY4#(W CB@#X MKU[X6^+O"^D7&JZMX>OM/TVWO6TV6[F0"-;E?O1$Y^\/RKE\5^CGQ"M?#OB_ MX&GPJWA^*U&I?$&;1!?27CN\,YG(-[E@2S[3C;3CWKGU^%7P<\;?$[Q^\$[# MX:7F@ZAI%@\D'B\)+7+M<&5$5O,=3QM;<,$DACD8'% 'P'@^E)7V~)(OA)\ M//A)-K/PCC\8:KXIA%O=?I+(>#4U(8*S]N2&D.0D'D5TWA3]D#*X;^&_BA\3M[_5TL[|P_P"'HK>:PTS6[UX+6 S1LY^T2#+;5*X&0>#5G% 'Y[|*2OJ+|K[X M<_#'0M!\->(/ EYH-KJMW(8-2T;P_]1O+;&UBLT6X!@N5VG@#D<<<_ +H((R# MD>U'US^P3^T7J?@WQW8^ =6O)+CPSK,GDVD]?95V< M6LQ_V+*OSHN&+W$S,4VWRP<%\X^[GC/3-5*|/NOC-#?>&)-$/AZ M&+S=*CTG[3]H)*A6W>9C;Z\XS^-?(TXPE?GE;L?G&&*^J-[6?+HI>[.|TOP M[|VN+(VFZ7>G2=L?W5:V[RA?KM!Q5&&2WE>*6-X4.UHY%*LI"#R*^C/B|\ M0M<^$-IX6\/^95T M2/|/2\^T1PJ3-,^*

*M,L%W%=9N=*C&C:C MIH+P>9]J7'VQ5SN!3)*GCZYIE_X_^%>A;_X;\.WVDZM)J6N6D3BYBN6V0,X& M&P3DY/L<5L\N]Q=I22VZOKIV.F635X2:G*¤VU;?5V2VON?/<7A[5)[&&\BTV M[EM)I?(BG2!F1Y//BD#EO854N[2>PN)+>Y@DMKB,X>*9"CJ?0@\BOJO1/#=K MX'T0--U">]U&TM^AMHHHY@BYQF-B,=B5)&>QK,!=>$/!,FO>,_&FOV.HS6 M-A=)9M8V\^#<7!.R^[(VKAE &1T)K267-0OS6?6_32[-IY_*--24TGI=/HIV MWI?;Q\Q45\&ZQ9$_!^M^+,_"=]9+>'PMK]H/,+*:4K+"Z(3C<,2,@_EUYK+F^ M'_@'QIX>]2XX1M-2TK5M!;_6WLV1+E0Q!R,G'0^2CZ\0?U;KRUWTO\\F#45]9M^C?$X*TZ6+2+U)%FM|\FLQ|B4LTOD-H=;TTZ-K-]IYE2I_<^"_W6E_A7Y(*]E^:O[4GB?X M(;5]6APG66F^)/"VI-ONM"UN#S;=GP-77G() &>H.!D9%>-4J(TCA5!9B< 9 M)-%.I.E++F@[,6,P>'Q]%T,5!2B^C\MGY-=T>V_&C|K#Q/\8=*TS0%TW2O"OA M/3I1/!H6B0&*!I 3AGYRV,G@8&3G&>;TV_;*\4/\;;KXF_V)H_|.:UQ1TEK M3$WV<1{0-P^?=NX]<5MO?\$_OB-+X<2Z;]T&+Q^)9G4(_"CW^-3>"]S&-W-M;<6X)\KZ$^&?J)7@"Z^OPBM\TCP]<;QK-T+O5KN[U2>2#"G"IG-O"^<.^0.1 MN@V[=IZGFO7IT<;5FVW9Z/?RT7YGYSC,SX8P.'C"G!5(<^]&T=;*2YI-W;NGR M;W=VM&?_P .?B/KOP\;,;;X]\/7(M-6L)"\;.NY&;!!#(R!U9201Z&O3_BO^ MU5<_$_PO>Z)%X!\'>&%U&Y6[O[W2M, N9Y0<[O,,)4D]2/FZC.":L?':?X>;) M-^U7<^#!"@\|>'=)EO[>R3[)?L|E"'#M!:20CY&_OK_"V1SC-?1?OJ_9>\|"^ M]/\ C) [MK/0K.ZTY{]5E-QI,I$@=FC8L27*AQD\A<< FIJ=*ORU(0 ME[J;3^Y^7D=^-S3*77PF)Q%%NK4C&4=KI.44DWS).SE=;[.VMKY/QM_;OM/# M/B_23XICPKXK:ST6!+/7]RS=[FPG9665%8[3@84XXY)ZU\'VG]6_BV/2/"] MI=V>GZC<;%XF;Q2+VI*GFW5T5.S"7# ,27/W0#P_\.V?'OI#WCCP'8;$\UJOA MZ[U75+RVL/[*M]0_T]&;ZN4_"GI;'BCP[XD\;7EYH6A;IH?BR\-_']A[4_M[=L;,3"S(*20<_#G.<#N\?I'P0_,^/BW]I,2/%?Q-U#3O#'A_2])NK'3I.U MA9+.R5D&$10"#Q_LZ^(Y?!GC_P 2)=:>UGX,U)=+OHA(YEFE M,PB!B&W##<1U(.*](A_8 ^(3Z)&[:IX_TH37;Q8Q\P8E2?PV^W-2?#Z]^"'NE?#_P[M;>+-%LW\46^G;X=5\]Y(@2 ,;$/~AHRC #DY4 <#;DGM?5(:QJ5Z\+2J>]K M^QKO4H*+LKQ/-16$<%3D|-QB+X^TTZ-K-]#GHWEO-&)9)&.V.*%UY$00 D"S#@5YM117#*;F[L^NP^'AAHN,+ MZMO5WU;O]W9=$>N?LE?\G(_#K_L,P?S-?M GW%^E?B_^R5_R_:.UG2]$LM,U31M(\2I8*%M}]3 MA+2P@< 9[XQ]? >LZW^/GB5?'LOBRZ6UOKYK9[2.WE5EAAB;^% IR,?7GO7+> M!O NK?$37XM(T>%9+EE,CO*VV.)!U=CV'(_.NN\0_L_>(-!DTIHKW3=6L-0N MTLEO["8R113,P4*_&1R<9&?2O3C/&C5{*46VE^GYV_.IR%7,J%:;_M>MOG8YC_(6!?2\"O6\'_9!?[.;I>9_F\W?C&WKC'X9]W\/BGI7P\74++. M&TL]5TO4%"W6G:C'OAEQT..QY-=3XF_9H\2^&=$U34'U'2;U]-3S;FSM)V:9 M(!9WX*C')P?0U6_9T\|:?X_|=26NL);7-A!;/(UK-*R-*Q&%V;2"=IY//2B M-+%1KP@_=D|%?L*%#'0Q5*D[QF|%?MM]V|S>^:'7QELKWXM:/K&M6ND>&-*L; M2>WC6QMO+C7^!GOR?6NE\2?!$;AI'@S2-"L--35KZYNXY=6AO&>*=(R^6/'0 =O3'> MN9B_9TUZX\7OH4J;/.(I0WLE_'QCJF[6NKE%?:)=M/.Q6U7X]:U]VNR2Z=IZ'6-.CTV8)OPD;,ML,N6^]\QZ\5=\-?M':YX?T33[^22-)UF?3$V6%_?PEI[<8P"#S@?3M6-2\ MP6UBPCV\4R&~TV>/P!%'/((:ZV>E7/B9??#N71-63PQ8VT-]_:<2VKPM(3]G$*F0C=_# MOR,GDGTK6I/$]/+4ER\MM.KW=_/7\3:K5QRI\E6?)R):7VENTTf\ZKO:]NI0 M\5?&%/&5I#IL_AG1=%TZ2Z6XO'TJT GE.>GYUS/O!\0V'BGQ;?:AI M>G1:7IS%8[>VBC"811(@%@XCC)KG:*\Z=>I434W?_@?\.>-5Q56NFJCO>W3M M?_,*^@OV0/\ D,>)O^O2'T8:^?:^@OV0/\ D,>)O^O2'_T8:IGD7_(QI?A\F23U%%%@?^RA1110 4444 %%%%!]?[%%%%?%VBBB@ I#2TAH HS_ZYOK4=23_ZYOK4=9'8MD%%%% PHHHH \W_ &D_ M^3?_(B?]@*|_P#135^+@Z5^T?[2?_)O_P 1/^P%>?\HIJ_%P=*N.QSU-PK MJOAM\3_$OPC\40^(/"NIOIFI1@H6"ATE0]4=#PRG X/IV-OKW3]*TFZ_X^X=!LQ,FZSU$C;B2#W QGOFN.F^.WBJ,2? VFO- M8_9?!DQGT@?90&5RVI]X<_/SVXKT3X,_+ (C>*O VB^)_%/CS1/ =KK\IAT6 MWU(;I;ULX!QN4*">G4]^,BO=/A%^SMHGPG^%/Q1A\=R^$X?$5M>QV/\ .;MV MC7,%G ZKY>-=1^)7B_4_$NMFWEU74)1+<-!$$3 M=M"\+DXX [UZ\+2VJO'WPD\-GP_I-QIU_H]RFX@<L]8L5NDMI#_%/@KSSCI MGTYKUS]N_P $;'X=\0@+#?#/@S2M&!LM,OM_MO?T% %

V_'S_HIVK?]^;,_P"-4?\ M#=OQ_Z*=JW_ 'YMO_C5>#$A1DD #N:-R[0=PVGOGBCVE ((!!R#W%'LX?RK{@YI=SWG_ANWX^?]%.U;_OS;?_ !JC_ANW MX^?]%.U;_OS;?_&J\'HHIG#^5?<'-+N>\?\ #=OQ_Z*=JW_ 'YMO_C5'_#=_MOQ_Z*=JW_?FV_\ C5>#T4>SA_*ON#FEW/>/^&[?CY_T4[5O^_-M_P#&J/\ MANWX^?\ 13M6_P"_-M_\;KP>BCV#T57LX?RK[A-?$_G72/#E_>:=]UM9VL_ MBCQ'-HMK&DD9)'FQ@@L2. 5Y1143C3@KN/X(I.3=KGGW_#=OQ_Z*;JW_?FV M_P#C5'_#=OQ_P"BFZM_WYMQ_C5>S?"O]C+1?'/[-/BCQ@#-HI)Y)XSU>2>_N_" M!QO:>=+:0V!]W"&0?2:R5F+T'_D_#\PQVGBCVE ((!!R#W%'LX?RK{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{GT\4_VV?CEH?Q-\?:=8? $?5+:QL]7N[>"%8;MSS#_ANWX^?] M%-U;_OS;?_&J/^&[?CI_~%-U;_OS;?_ !JO8OB1^QAH_A]E;P]XC@TG4$\ M=6$=GJNO7,B2B":TN6(\M"? DW1KM+!>1WZU<<^*OD)^$,M7?QA'>%_"%[X2\ M5>(!#BUV/6H]5=;,!7BV/@+1T'_A4J5)\I_!#M/N>(_\-V_'S_H MINK?]^;,_ .-4?\-V_'S_**=JW_?FV_^-5X,#D ^O-+6 LX?RK[C/FEW/>/^ M&[?CY_T4[5O^_-M_\;H_X;M^/G_13M6_[\VW_P :KP>BCVG>N! X;M^/G_13 MM6_[\VW_ ;,KE-<_Y-R\) ! 8QW_ /Z(BKS*IC3A_*AN3{GO'_#=OQ_Z*=J MW_?FV_\ C5'_ W;\?/^BG:M_P!^;,_XU7@\%5I.\[^X7-+N>\?\-V_'S_H MINK?]^;,_P"-4?\ #=OQ_Z*;JW_ 'YMO_C5>*RU\%?! Q(^'=]f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

%OPS_W|N/_ (#1_8>-[+|^P^HUNQ^D.,5^;W_#S#X@ M?|"WX9_|!W" _,=H_P"'F'Q_P"A;\,_]^[C_P".T?V'C>R^\/J-;L?I#BBO MS>_X>8?$#_H6_#/_*

'IN/_CM'_#S#X@Y_P"1:\,_]^[G_P".T?V'C>R^\/J- M;L?I#BC%?F]_P\P^(`_0M^&?^_=Q_P#':/\ AYA\0/\ H6_#/_?NX_|CM'| MAXWLOO#ZC6[`Z0XHQ7YO?\/;/B!_T+?AG_OW8?$#_ *%OPS_W M|N/_ (#1_8>-[+|^P^HUNQ^D.*,5^;W_#S#X@?|"WX9_|!W" _,=H_P"'F'Q M_P"A;\,_]^[C_P".T?V'C>R^\/J-;L?I#BC%?F]_P\P^(`_0M^&?^_=Q_P#':/\ AYA\0/\ H6_#/_?NX_|CM'| MAXWLOO#ZC6[`Z0XHQ7YO?\/;/B!_T+?AG_OW8?$#_ *%OPS_W|N/_ (#1_8>-[+|^P^HUNQ^D.*,5^;W_# MS#X@?|"WX9_|!W" _,=H_P"'F'Q _P"A;\,_]^[C_P".TO[#QO0?>'U&MV/T MAHQ7YO?\/;/B# _T+?AG_ +]W'_QVC_AYA\0/^A;\,_ ?NX_^.T_[#QO0?>' MU&MV/TAQ1BOS>_X>8?$# _H6_#/\

W|N/_CM' _#S#X@?|"WX9_P" _=Q_\=H_L M/&]E]X?4:W8_2'%&*_-[_AYA\0/^A;\,_P#?NX_^.T?\/;/B! T+?AG_ +]W M' QVC^P\;V7WA]1K=C\(<48K\WO^'F'Q _Z%OPS_ -^[C_X[1_P\P^(`_0M^ M&?\ OWU&MV/TAQ1BOS>_X>8?$#_H6_#/\ W|N/_CM' _#S# MX@?|"WX9_P" _=Q_\=H_L/&]E]X?4:W8_2'%&*_-[_AYA\0/^A;\,_P#?NX_^.M.T?

\/;/B!_T+?AG_ +]W'_QVC^P\;V7WA]1K=C\(J3%%G3I?,!33QE'>QOG4? M*>A7%IB;X[5IXI'/9F=@/RK|.^'' QFT'XX>#8=?T-W0;O+\M?|"WX9_|!W" _,=H_P"'F'Q

I25Y+0|S%&*6BO-.83%&*6B@!,48I:* $Q M1BEHH 3%%+10 E%?,7Q1U>]M?C?-Y?@'X?\1.9HNHZ7_PE4T^GW*>*+O4Y{ 2=4LKFZV+>21F7]U,_^&P

M0&X()`"@'W+BC%?+WB;XV>,/A[]NK^%+KQ#X>U^_86+6WB.2Q-M!IOVF<1?Z M5$DK*0,[TPZ{@"#ZUG:W\6/B?H?Q$F\ 0>,/#>]WWVG2X5U8:/B2!;F5ED\V

M%9BNX*N5P0/4>H|98HQ7R-X#\8>/=0N7\/>&=4T'PY;6UGJFI7TEU_9#3O<3 MQ7@C\"&8!0^26^ORXK2A^.7C?QSI^1:CL_B;PSX'30|"M|4FM|4_M'W\BB. M68EI4,< 9-H*Y;+BOG7XC>,O$WC/IF3PK?:7J4>E>+?$_P#9T4-W M9V1$FF922@SG;UX5TKBM2^/GB;QGXK\%ZK8)++I^D>&M0CT_Q+9C*_:-2E#1? M9P>ZJ07[_?CI:

/K_%&*^?=`^.WC73[#PIXKO]9T+7M.\423QKX8L+(Q7%CM M5V 2;S&:1DV8E#(,?-C&.>8UWXA^,99_A1XMU;Q9H>NVVKW$VIPZ#I-J8'AV

MVSN(DD$K&8+C:^]1R'1CI0!!DXHQ7S)<$?C+\2/$_BKPH?$-M:R;+XGLI+Q8 MV6RMS:X3>OV*0Y*Z-XCT'PK8>#+:,$KV>R\)Y1WJSEG?S$,41V|04!.X]>,$

~AJ*^>O@$MYXH^,'COQA?S0F2\TW2 M_)M'M)K-)(3)Y0ESDJ#G(VC)P3TKS_Q3\//%"_'H^-+*P\0S?#30+H:%=7- MM%&VERQL<7-TY\P/NB?8 0A'#C- 'V+BBO =

^(/C#QSJFK:I;.^-/#?AG1=+ MUEM+.A:C8B1G52HS+.9E9))-V4"KC!'WLUYI_P)7KG@#7];UG4)[7Q9): ^* M=6DLXH[(Q26WEV*OB-ED/!X!R#P"0.F@#[)Q1BOD_P 1_'+X@^

M"2X?0:X- M\77>M^`YM8LOLNGF!-/D559<[96\VW.I;N;.V<<\XN_#_BGX@PZ]!AO7?% M^@O74ND6^LPZN-)\N*T]D5983&9L.IW?*Q8$=\T >]:*^ZS/ID!*P$AS)"K,2IY Q^(K+TC5OB+X4*> 3XVT;1 ML_PUH?\ :MSJ.IVSW[7VYW*Q(TLB-Y,2@(TARY^7I0!]148KXQN_C1XOM-8O MOB3!)';H\$+>+X?

2#]P93<*@D$C.#L)^<$X^7 S5FM*Y^.'Q=T"UOM.N#14F MHSQVZI;VD31F:=8V!M[6\F+O$,2LA*G@ Y5I@#Z\HQ7RC\1=+\>W0N/# M- XLM#?:)XHT8K]MII0B-Q#

<,Q$;Q>:0-17J#\P/(XIOP^\>^/);O8O"OAI5 M_#W@58TU#5)N;3S/JK*7C*HCS */XI&R2,\ =:. /K#% O[U\S_LW>/=7=^ M(WCIM:UB\LIN!N?

#_P"\DTO,7%M(=L2*%X:/<1WP* /O7%%?(GA3XX_&'5 M[2PNOLVER-XBTJ>]L8]0%C:QVTH3>@A*7LCSJ/NMO5,'DE>E3>&/"B7QA

M$CX>ZP_B&ZU:2UT_48]1TF#1H[:XEGBQOA*>>>4#CIE6*G@@\T ?6N*,5\K?$ M#XK>);,Q^UQX:T&T\-^(-0M;"T#^)+/=<+1)+=!&&$BQ3%2 .0 >O4UWW@GXI>

M*=)QVQ@XZ5]5L-2T"PB@ =2)O#3IO_N,$94Q4IO[7FBC% -1G M&/K2T)BEHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ****/,QVGB!^S= M\5"V/A

A%M3SGI_QZR5^1_QLDT^*]\"S7%]H45S;?#'PA=6FG7EHSZAJ,D; MA_L]C.BLT$K 8+ HJC_PCFE"Y@N/ M[-L_/MU5(I?JZ;HU7[H4XR .V.E`YF_&*TUCQ)K/[5$UOI^HR:.?

$/@^\|3 M:7I^3=MI7V-7NHL(M%+++[-!!H7DL)H[PJC>>;*"*:,<@RR(@#2$# W$ M0>*^4)(OPSH_@0]BC5 M/B.EB?AE;Z%>)?R:M&)+|+UK%?LIF# KG(DVY"7\,_2^2-

>)HVCD4.C AE89! M'H15"]\.Z5J6EC3;O3;.ZT\ 6DUNCQ #I\A&./I0!^9"^&=.G_8#\ ;Q+I$ M(C@\>1/X=N;RV'GVNG3;OE!$SC#!$GA-MBT6X676)+6 W0U

3V_D/dC>66))5#_PCY<\UZY)I=G-.16LEK]M%MV0M&I1 M=OW<#&!C'!5]@#Y_P#C^P<3:.IJ_QS\+6FD,(M6MO|_B&[TIG^J]MA2/V2%'JB]R M,, ^CFN3^&/B_X!Z7^SGI.@>

(;CPl:0QVL<.MZ!K*H^1'4B)UGMR#)< MA2S$@KD$&OH77?A]INO^-?#7BF;6ZAU30!@ 4G/ YKAD\6^'/AY\(?"\&EZV-* MA^*OBW09-

#L!XTODB&GZ+Y\S0RWHG;Y$C@>/(/$&@Z5H7AF'PEJ-A!/)K,*8:'R'/[UC.MP666$ ME,KSN"-CWKX.;HOC+\;H80!9 P!LV$I"\ 3MIT/F<>NU8C7J(\+:,M_:7PT]

MQ6]M(O&DH"2&/^XC8RJ^PP*S/!*P^TIP&VOR64\U=3ZWJDNK7D]XX=VE= M44*" .(J1HBCL%)ZT =/1110 4444 %%%% !!1110 !R'\%"K34;G\GZ=[(. M,;'4++>2\"?\/++)

SJ;RAK\NJ_='?=#L/$NCWFE:I:QWNGW<30SV\RY61&& M"'*^.?%O_ 3+T'4M6EN/#WK6QT6Q=BRV=W9"[\OV5_,0D?7)\S7U^49G0PU) MT:SMK>_

QZ^$Q,*4.2>A^>E%?=_P#PZ]_Z]/\ ^43_.WT?\.O?^JC_P#E M$ \ M]>_,:.!_P"?GX/__".ZY0_F_!GPA17W?\ \.O?^JC_/E$_P#M]'_# MKW_JH_\ Y1/_ +?1_:.!_P"?GX/_

"#ZY0_F_!GPA17W?_PZ]_Z]/ Y1/_M]'M' #KW_JH_P#Y1/\ [?1_;.! Y^?>@_P#(/KE#^_(>^JC_^43_[?1_;.! _P"?GX/_"#ZY0_F_!GPA17W?_PZ]_Z]/ Y1/_M]'M' #KW_JH_P#Y1/\ [?1_;.! Y^?>@_P#(/KE#^_(>^JC_^43_[?1_;.! _P"?GX/_"#ZY0_F_!GPA17W?_PZ]_Z]/\ ^43_.WT?\.O M?^JC_P#E$ \ M]'\LX'_GY^#_R#ZY0_F_!GPA17W?_PZ]_Z]/\ ^43_.WT?\.O M?^JC_P#E$ \ M]'\LX'_GY^#_R#ZY0_F_!GPA17W?_,.O?^JC_P#E$ \ M]'_ Z]_P"]G MC_/E$_P#M]'_#KP_I%'\HG_V^C<V<#_S_!_Y!]_+ 51__"B?

,;Z/I9P/_/S\'_D'URA_-^#/A"BO MN_\ X=>_]5'_/*)_P#;Z/\ AU[_-5'_P#*)\ ,;Z/I9P/_#_!_Y!]_I5'_/*)_P#;Z/I9P/\ S\'_!_P"0 M?7*'\WX,_^$**^[_^'?O_ %4?;P HG_V^C_AU[_U4?

_RB?:,Z/I9P/_/S\' D M'URA_-^#/A"BO MN_(=>_P#51 5RB?_&^C_AU[_P!5'_\+*)\WX,_^$**^[_P#AU[_U4?\HG_-OH_P"'7O\ U4?_,HG_P!O MH_MG

_|+/S\'_D'URA_-^#/A"BON_P#X=>__**/_P"43_I?1_PZ]_Z]/_Y1 M/_M]'\LX'_GY^#_R#ZY0_F_!GPA17W?_,.O?^JC_P#E$_|M]'_ Z]_P"]G MC_\E$_^WT?VS@?^?

GX/_(/KE#^_\&?"%%?=_P#PZ]_Z]/\ ^43_.WT?\.O M?^JC_P#E$ \ M]'\LX')^?@_\ (/KE#^_\&?"%%?=__#KW_JH_ E$_^WT? M\.O?^JC_/E$_P#M]'\LX'_GY^#_

,@^N4/YOP9\(45]W_\ #KW_*]/_P"4 M3_I?1_PZ]_Z]/_Y1/_M]'\LX'_GY^#_R#ZY0_F_!GPA17W?_,.O?^JC_P#E M$ \ M]'_ Z]_P"]C_\ E$_^WT?VS@?^?GX/_(/KE#^_\&?"%?

=__!,BTU$-`MXTN<,-*(@3)^ZTN21CW"Y_.KFE?!$P;&&]C?4?B!<75H#\5MI2Q.PI S2L! M^1KZ]^&WPTT#X3^%;,PIX5_?A7!H\

MB;,XYTO3=9O=85672CHK:I=7:0G*L8(XI'94)R&(PI/4$U'X3\2_"3QMX9TI MPCH=IHU]X?U**>,.+0ETS9;;8B#-%);L@$;`L,QNH//3FL?Q#/[']PN^-FL>+:

MOPOJWB+0]#N4,-R#..#7%?%"S\:?$^X ML]<\->$->\.7#Z3]<,(NO+M;IBP0*Q*N?)>0!@HP^^,@,V:H_@#4K.Y%D;6Z M@GL)X;.+3(5:4K/;S-,?)9@07MI Q.Y0#\M

'TKH_P&\&>'I"O0$TWPIHMAH] M^2,NPM!/B2"XR,'S$"X;CCD&F^_ (2^"/"BQC1?"&A:5Y;K(AL].&M=3E6 MRJYR#T/:N&'-45:TKH:,O#;

(C;CMN=20.0SC:7HFC:2FGPSV>D)$MD+E!*T)C "-"P^\,?>ZX]Q-X9T>XCDCETJRD2 M2Y6\=6MT(:<8VRGCEQ@8;KP.:TZ* .8T?X7^#_#_ (CN]?TSPMHVG:Y=Y^T:

ME:V$4=Q+G[VZ0*&:>_//>J^E_"#P+HFMRZSI_@W0;+5I)3,U]!IL*3ESU;>% MSDY.3GFNOHH YGPY\,?"'@_5KS5-"\+Z/H^1?F?M%W8V,4,LN3D[F503D\GU M/-

)XE^&/A#QEJEE}>O>%'UK4;(YMKN_L(II8><_*S*2.>?K?3T4 4X-(L;6 MYNKB&RMXKB[V_:)4B57FV@A=*Y RV 2!GUJ0%X7T:#17T>)=65K!;=! M0Q)8%;,<$DD\#1"?

6;542#4&TZ$SQ!!A K[-(L!-YSW'F?9DW>;Z[?7.,O.O!/4CBM6B@#D=%^$7@;PV MFIH7@[0=.34^+U;7388QT;O-X9TCQ UHVZW;4[*.X,1[[=X./PKI**,UO#>DO*\C:

M79M(]O\ 9'''3U(Z]ZZNB@ M#(T7PAH7AO9_9.BZ=I>R+R%^Q6L<.V;.[8-H&%R#?#>O7>N;3 MX2T/2]:N]WVC4;/3H8KB;=]]?(JAFSWR>:ZBB@#C;3X.^

K"357MO!7A^1M5 M1HH]OZ9"//M2L2#U/:.NA> _#?AB"PATC0-.TR*P1HK1+2TCB%NC M?>5-H&T'OCK6[10!EWGA,1=1OEO;K2+&VQ%V8N)K9'D&TIE^8C//Y'H:LVVD

MV-E=W5U;V=O!8@8!<@98@<#-6Z* "BBB@ HHHH ***** "BBB@ M HHHH *****:Z+(15E#*>H(R* %/W#U%&X>HJ'[#;?\|(O^ M^\!]AMO^>$7_ 'P*

)MP]11N']*A^PVW_/"+_O@4?8;;_GA%_P!\"@";HJ'[#;?\|(O^^!1]AMO^ M>$7_ 'P*)MP]11N']*A^PVW_/"+_O@4?8;;_GA%_P!\"@";HJ'[#;?\|(O^^!1]AMO^>$7_ 'P* M

)MP]11N']*A^PVW_/"+_O@4?8;;_GA%_P!\"@";HJ'[#;?\|(O^^!1]AMO^>$7_ 'P*)MP]11N M']*A^PVW_/"+_O@4?8;;_GA%_P!\"@";HJ'[#;?\|(O^^!1]AMO^>$7_ 'P*/L-M_P \(O\ O@4 3;AZBC$7_ 'P*/L-M_P \(O\ O@4 3;AZBC$7_ 'P*/L-M_P \(O\ O@4 3;AZBC$7_ 'P*/L-Q_P \(O\ O@4 3;AZBC$7_ 'P*/L-M_P \(O\ O@4 3;AZBC$7_ 'P*/L-M_P \(O\ O@4 3;AZBC$7_ 'P*/L-M

M9/\ OE?\XO_P!H_P"'[6>KG2O%>C:[J6G1RNVF6&H1//(4!+*]YYQ@Y(R! MCFNJNO'>G:,X /BZ_)L]-33UU&0.061#&'QZ$\X^M &[IGE_Y^9/^^5_PH^S MR_\/S)_WRO^% <5X2^-?A3Q7!+K/Q_|VE'I'AVXA\YY!5=;7_GYD_[Y7_"N2\)?%+2/$6EWMS=7NF:?/9"26Y@CU.&X M$,*NRK*SHC-\>O;- ':?9Y?^?F3_ +Y7_"C/+_S\R?!\K_A7E,E_M'Z#XA\;ZAX:T@V MEY=:=[<.G7;R:E#%M$B[@Z*QR^,FP7_GYD_P"^5_PKCM*^ M.'P^URSU6[T_QIH5I;Z5$)[V:WOXW2WC/1V(. O/WNE=G;7.5Y;Q7$$BS02H M'21#E64C(((/<$4 -^SR__G_2*_X4?9Y^) 2^6ZGVVJ4 1HT[A>]@"#[/+_ . ,_MG_?* P"%/\'>7_GYD_P"^5_]P>%W"#R)/~?F3_OE?*F2GHH ***0G% "T4F M:,T +129NR* %HHI,B@!:*0G%&: %HHHH ****.:;^{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}$,AC$98 MABQ((Q6O^RU^SWK7P9A\:.IXIU+1[[7O%NHJ5W9>';)K32[0I&$58(F),3] MYF/)..XR?8&\';0WC"+Q2,3.NQ6+Z.EWYC<6[R)(R;<[>6C0YQGCK0!LTM%% M !1110 4444 %%%% !1110!Y\^U\8KGX)_"/4=QZ_4<5+]PPL['V.K?^?7O;I5<=?7]FOXLR_&?X2:3XBNT2/43NM MKP1C*F9,9(;:((.V.:(?PMX0UGQKK%OI>A:9*_7 #HGX33_ 8^$>D^:;QU?4LM%M6U)9;+2,;:\L=&T_P +G4X[Z=Y&!2:8#]RI"@9+ICDY MXKKKG]I'4;!+Z\E\#:A=:!HCQVNNZS:7<&RTN-B-,(H2V^9(RXW,,>P;!H |MX^%_PL\ <>,_AEX(\.7^@Z'X-F;]JJ^\%W_C9_%&F!?9(-=BTK0574+>);@O$K@/(VU8U)H2:,;&PU&VDMHY%A,PD^U_^6T153\RY(/!7-_$_M"_#+XB:C\,$^'|WX;\'V=KIVE/I]MK4-_{IS- LV(\<7D#R"W5\LW);&\)-5FG1KZQMX9J9:1.LW@G&>G?M5/I_G_2*AAX/&:I=ZEH'A;1M$0I MO/VBYT^PB@DERQ:.RS733P%O#A\N%6-]RKQR.$Y5Z_9KM-)NOB1<:#X=U)/L%O977A>&"[MG,<%\YGEME,G$A*IN;OWZFOK7 I*,"@#XTU+P+K|^OWWF>#_$TWQ5EUP7-I MXO3?|ACL[P*_O]^Q8ECRK6^W).?E.'M&U;P_XUQ_E MMXHM8M*TO5(VMM7EM/*8S6S*#S11G:][CEUR 6 I[_XA^&_B> ^T" |~^$?\ M,>(/# PQ?6[>9O#-U8O<3R0K&XF=;$R]_D&0QDP[@3M8A3G!^'T[O2[* DMY+ MFT@N)++=_-A>6,,8G_O*2.#[BK.!C&.* /C/1?AYKFG^#M*&L^'O%.O\ P\&N M33W?AE;#[-*L!BQ$R62S/)]G$OS&!F+=3LQQ3_'/PK?Q5X8NK#PSX \1:,X8 MFT6^CAT?5 ,K31%-L+2L8=d.,50[2,'Y1FOLG]*,#TH ^1=9~>;]:9KMTFM M>$-,UOX,PZVQGT/38WFWQ.98"P!,%) 'K9_V;^ Q!IO MAKPMK?A^VGM;I;+1M39CE&!C&.*/@_5K< M0>|/ >FZCIWQ4U6--4TV#4-(\0+) TJJF)(K8?)O'!R@;D#%=9I7PZU:\UM/ M^$<\'Z_H7P]FU13;Z+]"O#L'V:19Y/LI-NAB=B@"-C)&<#O[=7FDV.H/;O=6 M=O,Y+?PO&(!* MSDDOWLW:=S"LJ)) .K1'L7SN0I!RPZU]UX!59-+LH[^2^6T@6]D01O>V1\[^8=_LOX<:=]6D^]!:L]8N;N[U2"SB2XFOBAG9PHSYA0E2W8D$@GN: MZ/-/:EH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M "BBB@ HHHH *:[K&I9C@#O3]* *.P!OA_OG_OD X4?;X?[Q_P"^3_A4^*,4 M 0?;X?[Q_P"^3_A1]OA_O' OD_X5/BC% $'V^:^|?\ MOD_X5/BC%$'V^:^|?\ OD_X4?;X? $'V^:^|?^^3_A1]OA_O'_OD_P"% M3XHQ0!!OA_O'_OD_P"%'V^:^|?^^3_A4^*,4 0?;X?[Q_[Y/:^%3XHQ0!!OA_O'_OD_X4?;X? !Q_[Y/:^%3XHQ0!!OA_O'_OD_X4?;X? M!Q_[Y/\ A4^*,4 0?;X?[Q_[Y/\ A1]OA_O'_OD_X5/BC% $'V^:^|?^^3_A M1]OA_O'_ +Y/:^%3XHQ0!!OA_O'_ +Y/:^%'V^:^|?^^3_A4^*,4 0?;X?[Q_M[Y/:^%'V^:^|?^^3_ (5/BC% $'V^:^|?^^3R_ (4?;X?[Y_[Y/:^%3XI: *_V^ M^:^|?^^3_ (4?;X?[Q_[Y/\ A1]OA_O' OD_X4?;X?[Q_P"^3_A4^*,4 0?;X? [Q_P"^3_A1]OA_O'_OD_X5/BC% $'V^:^|?^^3_A1]OA_O'_OD_P"% M3XHQ0!!OA_O'_OD_P"%'V^:^|?^^3_A4^*,4 0?;X?[Q_[Y/:^%'V^:^|?\ MOD_X5/BB@"#[?#_>/_?)_P */M\/IX_]\G_"I\48H @^WP_WC_WR?!*/M\/] MX_| ?)_PJ?%&* (/M\/IX_| ?)_PH^WP_P!X_P#?) PJ?%&* (/M\/\ >/\ MWR?!*/M\/IX_]\G_]?%&* (/M\/IX_]\G_ H^WP_WC_WR? !*GQ1B@"#[? M#_>/_?)_PH^WP_WS_P!\G_"I\44 0?;X/[__(Z?!*/M\/\ >/\ WR?!*GQ1 MB@"#[?#_ 'C_ -\G_"CI?#_ >/_?)_P *GQ1B@"#[?#_ >/_?)_P *M/M\/IX_]\G_"I\48H @^WP_WC_WR?!*/M\/IX_| ?)_PJ?%&* (/M\/IX_| ?)_PH^WP_M_P!X_P#?) PJ?%&* (/M\/\ >/\ WR?!*/M\/IX_]\G_]?%&* (/M\/IX_]\G_ H^WP_WC_WR? !*L4F* (/M\/IX_]\G_ H^WP_WC_WR?!*GQ1B@"#[? M#_>/_?)_PH^WP_WC_P!\G_"I\48H @^WP_WC_P!\G_"CI?#_ 'C_ -\G_"I\ M48H @^WP_P!X_P#?) PH^WP_WC_WR?\ "I\48H @^WP_W\| QT_X4?;X/[Y_ M[Y/:^%'V^:^|?\ OD_X4?;X?[Q_[Y/:^%3V&<9Y^M&* (/M\/IX_]\G_ M H^WP_WC_WR?!*GQ1B@"#[?#_ >/_?) PH^WP_WC_P!\G_"I\44 0?;X?[Q_ M[Y/:^%'V^:^|?^^3_ (5/BC(!QGGZT 0?;X?[Q_[Y/:^%'V^:^|?\ OD_X4?;X?[Q_[Y/:^%3XHQ0!!OA_O'_OD_X4?;X?[Q_[Y/\ MA4^*,CU_6@"#[?#_ 'C_ -\G_"CI?#_ >/_?)_P *GQ1B@"#[?#_ >/_?)_P * M/M\/IX_]\G_"I\44 0?;X?[Q_P"^3_A1]OA_O'_OD_X5/BC% $'V^:^|?\ OD_X4?;X?[Q_[Y/:^%'V^:^|?^^3_A1]OA_O'_OD_P"%3XHQ0!!OA_O'_OD_P"%'V^:^|?^^3_A4^*,4 0?;X?[Q_[Y/:^%'V^:^|?\ OD_X5/BC% $'V^:^|?\ OD_X4?;X? MQ_[Y/:^%'V^:^|?\ OD_X5/BC% $'V^:^|?\ OD_X4?;X?[Q_[Y/\ A4^*,4 0?;X?[Q_[Y/\ A1]OA_O' OD_X5/B MC% $'V^:^|?^^3_A1]OA_O' +Y/:^%3XHQ0! +Z$GIQ_[Y/:^%3CD48I: "BB MB@ HHHH ***** "BBB@ HHHH ***** "BBB@ J/SX_+]S>NS^]D8 ,N/\ C3XO M7P!(\?&OB5GU\L:1HUY? YPCK?Q$/[-/_SKNNFUQ$'C\WOS M;#HWIF_VAY.[,=WVD;?]Z@#]MC-&I8%U!4;F!(X'],9/>06LfFS31Q1LCX\;YJ.K064_B7X)Z7?V27%P(VG>6VE_U8)&X[W"'X'.2!6 MA\//"? @GXT?%^T\)?'>^$FCZ%X"\/3>$_#NK;E)96=PDEDOVNY"AT\R59!LZ MD@#OMX /TD>:-(][_t_>)P/SI6=4 +_ "0 2:?7I?P3^TA\,_A8/V`_%\'@; M7+CQ=H'AB[EN=*N3KLUZEA=+,J-$CA\%(U=@J-N #9Y)W&C+9Y^M&* (/M\/IX_]\G_M H^WP_WC_WR?!*GQ1B@"#[?# >/_?) PH^WP_WC_P!\G_"I\44 0?;X?[Q_ 8OE^SSLP#O*V0Y+#&&7'>@#Z M'EO((08XY)HXY)#A%9@"Q!AW_"G>?'YGE[UWXSMSS^5?G#\,/AS\&/C=9_%/ MQ5\>]?*

5TO=$B5(O6HTJ1>M(;)*D6HZQ?%?CC1? ZZ.VM7HLAJ^IP:/9$HS>;=S M$B^/Y0<;MIY. ,$]+\2^:T:CHNlQ^,:W(1 MD\Q=Q7.U@"5(Y':N;^&OJ0O@'XN>
(=6T3PKKPU/4=-0S2]HGEB66(2-$987 M=0LT8D5D+H2NX8S5F+:/2D[4\=:JWE]:Z993WEW,EO:V\:3332'"QHH)9B>P M !-?)6M_|%&- LO$$EOI?A.^U31T?:+]
H89)1_>2,]>,XW$'Z548M[!8'* M<;FCDL'35^,_VFOAK\-M=:,1M>|3P6VHC MS;,&.2=H<|-^Q3M^AYKT#PSXHTGQEHEKK&B?\&IZ9=+OAN;9PR./KZCH1U%7
M8NK@\31!QK5:.M+110 4444 %%%% !2-M8!(/<4M% !1110 4444 %%%% !1110 4444 %%%% !114<=\=M"\LSK%%&I9 MWPH
DHKPQ_VU/A\"XB.DGQ."0_EF^%M(;7=G'^MVXQ_M=/>O;K:Y MBO++>*>"5)H)5#QR1L&5U(R"".H([T[6.[$X'%8-1>)I2AS;735_O):**S[SQ
M!IFG7<5K=:A:VUS+_]X99E5W^@)R:1OJ+D[15S0HI W\ M/VPU61#M>[:39:QG_?P2Y]D!^HKBO%'B06S21^(:;N;]?RO-73;'-M$X+8P,
M'9IEHJ6K19*^:;:VC!,@X(W/M'\XKP:?O/+]"/^3&FCQUKAY_X1R>?74D_^)KS3P[\1+R_MUBSM[_D!:OKRO{DP%G"Y!R3QG'3\T:WQ1=SW326CM! 4V!74'OG=[&NI5:
M#CS(\N67XJ%3VK>%+ZXU**N;]T%E,!W,2S"48"@ [@!U]*W:X_P"& M-S-=Z)<23RM+)YY&YL9Q@>E=A6=T]4Z"BBB@@***** "BBB@ HHHH M ***** "BBB@ HHHH
***** "BBB@#\]?^"F7_ "4'PC_V M#9/_ $;?H/[W_)%;[_L,S?^BX]\^_X*9?\ )0?"/_8-D_| 1M>@_L#?\D5O MO^PS-_Z+BKX>'_(ZJ>GZ(_]7$?\
)L<'_B_]R3/I=!N95'4D 5\'?]-1_M&? M&7Q?X^O_((^#_#VI>!/!^]2:5)IVJD-=ZFZ$[MN7'S$#=<%&,!@/F-?> .,$ M<$5\4^-K;X+?L7?M$ZA\0[SXC:AX=G\11S7&H> [*-
[]*ZEESBX\N;9)VD#BOKH\\8B^FMD<1^_ +<>E>/OB^ P3Q_"^AZ=X9^(§WB%?"OBNZ8T M4]:_ $ZT>2.-% [%(V8R++8=.>WLRV|M$NYY&{>@]R3P
,2:\9\2>-+WQ@[++%)9Z8&(73Y1M,@!ZSX/.? M^>8.![_%D\#3\0:Q<^(X9-;?,5E;D-IEM(,8R<>)==A MTI!$SLUQ*I8* 6P[GBJUK>Z7]%PZP/#.Z@?(]CCW''-
>14Q$]DQ3T/O,+EL*4H MU)V4D.\87#E;>(B)P9#SP3T _K^-8%KIMQ?]3"FV,-M.1. #WQW,/:MC6I(M/;B& " ^:QQ$V_"
(W7@9P,XJU,B:114PA0LL4;OR>IQGD^YK#G]VR.WZIS57* M;T))Y5M@CSWTT,43##87D" \@CGJ<8fU;37+H7D.H&XDNWA(9SA&7H5PO8YZ MXZXKS0SS7Y6XO)7FDR2-
Y^5?<#M6IX9UB[DN_LL2N87&T,066+OG']:_^|\7+H7*[SHT;^4,>//\ RVDS M+(H',+8^O.U\=?C']?ACQ5|$M3|*1ZAXFT[Q#]-W&NEZ,T?_ !-4?39I+?+. M0HC#,)"Y(^A23G&*
/I6BOG[4OVKSX'TKQ8GCWP7]7A?Q#H6CMKT>FQW,-W% MJ-FLBQ,\%PA"?)(Z+(\V ZL?E.:J2^%WC#6?&_A==2USPU)X7O3*4%]U#W=-P 1MRI@_L]VV-FV[Y(/?)Z?
05YN.S"C@(*57KLCTL%@*\/FXTNF[/M;ZX+QU>'7-6CT!#_ *%&BW.H8_C4D^7#]&*EF]EQ_%7,^#OBK?0W\-MJTHN;M65@GGE0&C)Z$XZBME,CQ3XGW_P"M-[^_-!?
9X]G]?UKIRW&T<>G.GTZ/=&. M88*M@)*%3KLULREXHMKFYTTK"(V13OD5A\Q Y^7WX->,>+[S[3]<4"H%^S(' M+]2V\< >V!^?
TKW;4M1BTRW,LK8[*N,EFQP*\&9W<5QXE,@'TZ&M,5+^/PKI$,-M#DEC&@6V/ M8\9/X@@9_"N3\) LC?\DKF_[*4_\ )*]LKW:,>B?sE>,;>)]-] MV%%%%;'$>><^-/AI?
>)OC#\.?%\%W;Q67AF+5$N+>0-YDINH8XTV8&.#&2<^H MQ7>QZ;:123R):P!)<,'E98U!D8=?QQR1@(HM"\2>+.-TO M57196MI9"6A1CA7EP"(U)Z.^![US_@O\!7P]-
\%=+^(*C\+4]-|-V=_>W5G$? M/+I,T=W-#&L7\4C,L0;"@]3CB@"/]K*P0_#;3],6;4+'4/#NLVFKV.16.G-] M"V4R%D\V>W0AY+?9(ZR;/F"N6'W:\ T2ZU_]QGXU>%[;5M;QGJ^IZC
M:2(&VP3_AS\+= \;Z=]^FZQI6M:E9V=G&,#\;9);4*/- MCD@2]C'G@'%=MXS_&DOAK\/FTU/$'B0]3].EU&T6_MXG8LYMFZ3,]@E(^?OL M
.O/%;'B_P",_@CP)X5L/$FM^)M.1]%U H+&[\X.MX7&4$(7)D)'(^@\ M:>)_A=\5=)^)^E^,?"6J^&=-E&XLV-G92"]9;B-Y!?S=EV' 6-FP M2@4G*\GF@#SCX5_!3XO^
OA[K7AF'5?">@ZC=1-?+XGL)+F_O[W53(CO<7@G MC42++M97P'))]H_\ M2)(GN)Y9940DG[/&JH%PHR2236@_]77PA3P^VLMXZTP62W!M64LWG+(S##D&+ M&\
(0V=N-I!SBMOQ5^T-\.?!5EIEUK'B_2[6'5+07^GD3;5>0$[\(7)D!+K MJW/7- #HOAM>)\?KWQZ;W.GS^&;?0UML-YPECNYIRYXQM^R =6."QFQSE/.:+>"
<(J,,L,'UCQ#^TQ\,?"T5H^I>,M-A: M[LK?4;>%9#)+-;3][12I&H+,C"-SD# "G.*UM?\ CAX#\,>!],\8:CXITV#P MYJ7E_8;\3ATNR_*+%MR9&//"@G@^E 'F; "CXH>)?$6J>-
$EQX0'BFVT6;1 M-!T*-;BYTJ***>6*2Z>ZD95DD:A0HF%0*BKT8DUU?[-GPFU;X0^#M6TI56TVU M^WZM-J-MHNB/*^GZ3"ZH!;6YD ;9N1I" *H:5@[@ 5VOP| B5X8^*>A2
VSX M5UJTUO3Q*T#RVK\\N1?OZ[J48<95@#R*Z;@ HHHH *****/SM_X*9?\ )0?" M/_8-D_ 1M>@_L#?\D5OO^PS-_Z+BKS[_@IE_P F:!\(_]@V3_P!&UZ#*>P-_R
M16^_]#,W_HN*OAX?\CJIZ?HC^I<1_P FQP?^+_W), ^ET;8RL.2I!K\IO 7Q3 M'_!;XX_$KPQ\0\(U+_A O%^KOKVB^);&V.R98ME'.Y.%*0.59,X(;-?H@. ME5-.L-,U'3I(M8MK.
!L!\SQW\221#W\(<$?C7UD7;0_GRK!RM).S1^?7C?XJG M_@H+|>_A?X<^'>C;G_P@7@W6$U[6?$E],&%"5*D(H//(R$*@'IYF9^@"YK\'[MG+'J23^=<{HNH^&M,ABL-*N-
(LX2^$M;)X8U+'T1,#/X5T(ZU;=S&$.6[;NV M2I4B]:C2I%ZT@9)4BU'4BU1DQZU*O2HEJ5>E48LD3M3QUIB=JY/XN:/XE\0? M#;Q!IW@_4%TKQ-
<6^RQO&D\L12;U.=V#C@,.G>AOE3=KA2@JM2-R44E=[* M_5 ^2.$!&.M2*1CK7Y^>(/@[^ UCX$:=2A+$QS"ER1.3=Y63>RVZGZ?YS3Z\#_99\ _%OP/%XC'Q3\31^(W
MN3[_9YCN?.\D+O\ _@?&"""01[UJ< M!^._QCUB;Q=I?A3]LWX-*ND^(M/NHX?&VC6W(L;|:*TK*:L,RG:WJ'4GDMC] M4/V;?
C]H/[2GPDT;QMH+A%ND|N\LF;,EG=*!YL++X)X/=2I[U^9GCKPM-_P3 M7_:CO(KNPDUGX ?$*.2TOK"53)&U]^1)$P[RP;R5[M&WJ3A_PW\67/\ P34_ M:FBLFU!]7^ WC]
(/NQU-&\]RVKX)[X:'!DAWA7QJY*#CE: /V HJ&SQ-O(M(_*AB;6UU\W,L0 M+++'A,OMZ]CSZUJ;W]@MW\2+)X@TZ>#Q3XALI[4P78N>\46>F>,;??/#MIJMI;2P:
MW+J=NLMR$@OH9$&,/R-R$\ U7LH1NDS)8_$5;2]1M;KK9/J_2S5OF:,9*H6="":=P?.UEX[K4GB3PM=:.L5OJU[&4GC.L:(ZS1R M '!*LI(O!_&NN\+7FD>&-> |
Z(=8M;Q]%GNIK[I28-!;^M1.G%1,3U_X8ZL/C*\Z\ M*M]!KV_P" >Q?LWV4%AX!GBMX_+B-](^WG]57UKU:O*?V,;Z/4 M? $TT1)7[=*IR.X"UZM7IT?X<;!CX/,+?
6ZO+M=A2'D&EHK8\\-8/#FK7GP- M\;?%+3M> ^\ B#Q+)X]UV76+#5M#TMK^+5+>6*-(i69QQ$T{5H]LNU-N&!Y> M-Z!\&?
&'AKP#\#/$&HZ)X]\-67AF/?K2_P!)\+017&H:*]U=L\,J0O')YL8C M4QDQJ6"NI7Y2U?H!O0L5W#*)/#/BW M7$U_Q3X3MX[7QHUO;W.OB#481@VPBC$(8.(@TOS. -
P"]*]H\1.I??'3XE'?# MBXT'P)X@T&/PE=76HZEK.NZ6[@8HFLIH#\I(< S&5Y8RVS* 1 Y)YU!#>)O#
M&B^,+'*WI=:,M(K^WBNI>^BBE8@">\"598GG\"5=%8>XYK7>1(@2S!0.Y- 'Y_^ M$OA7XK^'#_#OQ)KT7CI1K-QAWI6@-+X0L(]J[TRZMR[36\\:AED59#(C!D &
MY'''Z+7>Z?!*-<@_9\O4T_P /:)H+[6O''G:.^,#6Y(9+XQ#4;5I+B2*%$2#2>217V&9$"ABP]F7W@;3X;])TBMDA^QS*8)'B9'5V7<1&RRYSG=3_!'P[U;X%S? M"7Q;>>"-?
U/0-*I?5=/FTE&35-2\/SWEVMPLXCA10P"*T3"%28P0HRN3?V2S MJK*"P!;@<]:Q_%_BB#P?X9U?69;2]U%-.MVN7L]-MVN+F0*,[8XUY9CV H \ M, ^
D.H:]^T/\5/&A\"ZIX/T36],TB.TNM4M/LTNIR0FY$DSQ_>1L,BX?#;0I M(&17$_$CX3:]XG^-GB&XF\-7=_H=S\0O"FHB1H-\,MM;6)$LO/!1) H;L#7U MW#]ZNH6,%TJ21+-
&LGES(4=<@*#*>01GD5,\T: %G"@]"3UH \8\+ ^)(/VL M/B!XLN-$^6]IYX7T:QMM5> ;966:],\:OWV'D;AZ;/05Y3^S-\)-Y=9'2&-I&6 M)"[D
$D!1R3QT'60*OAK^TWX3^*GBZZ\-Z+8>)(]2LV*7?\.:'A^[M(]5_+6 M4)+))&%1BC*P4D$AACK0!XGJ_P &=6M?V6OCSHVG>$YXM.U[Q1K>H6ME#:@2 MW8;_#V\J
=1L564^@&*T];U7Q#|+&^-_A,^!/$_B"\\7ZE=:IX?N]&T]KBTN MOM5C##Y"_$/PJU+P%XQU7P3JNL:%H&H>+;! MM-L;,SW>E"[U9YK:^AMQ\SHT*&/*
LJ2*0,%/'7D6)=S1%'[: ZD9R"*/F MKP]X+\]2?$;Q_]2?&VD_V*-*\0+I=M9R264,=_?O:B;S;]2WG1QG&'$L<8+] M'*P@^FOH^O>$KF;R]&V?X8TJ\3Q-N&!Y>-

T/QKX@\8^)/&/B'1H;FVM)-6EA$"0SQ^6Z>3'&]<@-EL;B0.G Q6=9_LE:3 M8I:;/%XP\4CP'9W*W5MX.%ZBV495]Z0^8$$Q@5@,1&3 ^Z,4 8FC^)/C\'\ M5/"Q,LM \2>'/"NA^%=>;2M/DN=*>]GO'%K;S;9AYJ!$4S8W+\S;NVWGS"_M_:/N++Q!8_%/6]%1-6\.^?$\.H:59REXY+VSU6UMI$BD(_U;RQY5B,A6YY% M>E^'/V9=?F\=?%/?SXPV1^\Y?$GB-YU_L.[@>,;IL?LEM&CE}$<12!TE4.NUL M 9SA<=W8_LN> M/LI.T]-.EET>S\/7GAIM.GE,D5Q:W4]2W#2D_,TCNFXOG) M+,>IH \>\|_'IXDP^_;>KM<>*;/7+V.SU;3;7P7[&F#2/,!Q-%22YU!1K/BFR\6SE95!6fM&C;&-5^7B_,9(\CK-MRW(SP >96?CWXP?$OPYXC^(/A#5?GH?B!:HY?0ZX;34HK2:2*1[BY$ M@\AI&B?:%1M@*EMW(%;PK\7_ (E?'WQO<6?@O4]{(`^%SX6T3Q$EY]&G->W: M2WTK^&M* MNHX[2VDE.9BC-&9(1*22XC=02S$8))KO_"'PGT'P-XHU;6M'B>T;4-/T_3#9 MH0+>""S618%C4#Y<"5@>3T% &3\#OB=>_$/X,;3XLURW@M-2V746H1V>YHA- M;3RP3-'GG:6A8J#S@@5XFOQ>^,,GP8_X7]M)[%='AC[$=?'@DV;^<=)V^9_Q^ M^9C[3Y/SX\O9N^3_&J^C?AQ\/=-^&A"#PYI'_+.=']B?Q(/AV:K[4?`XNH_I,_UGF>1NV>=IGW<^M3OVXX^[00!RWP-T*ZUK]KKXR^*KB\TV]@6#28[7?I06[BAFLQ)&BSER555)# M*!AR<\8Q7U+7*>&_AQI?A?QKXK\3V;SF^\2&T-W&]#RT^SP^5'L ''R]>3S7 M5T %%4;C7-/M-4=-GOK>'4+M'DM[5Y5$LJIC>57.2!N&2.F15Z@ HHHH 9-M"EQ"\4BAXW4JRGH0>HKR37/@U=QW;OI5Q%);,^ZZ'FOACX=KX02;6=2D2YN+6)Y8X8_NH0I.VO+$WMEN_=3>7O5AV^AQ6F&PM+"4_9TE9&6)Q57%U/:57=G&_!GQAJ MFERF[,TN53*N6/^L0_>0^N/TKU[1@ZAAT(S7$X[3^-UJUY;H+K2XF#.Y M38" <[5'{?;9&<GK MRW(SP >96?CWXP?$OPYXC^(/A#5?GH?B!:HY?0ZX;34HK2:2*1[BY$M@\AI&B?:%1M@*EMW(%;PK\7_ (E?'WQO<6?@O4]{(`^%SX6T3Q$EY]&G->W: M2WTK^&M* MNHX[2VDE.9BC-&9(1*22XC=02S$8))KO_"'PGT'P-XHU;6M'B>T;4-/T_3#9 MH0+>""S618%C4#Y<"5@>3T% &3\#OB=>_$/X,;3XLURW@M-2V746H1V>YHA- M;3RP3-'GG:6A8J#S@@5XFOQ>^,,GP8_X7]M)[%='AC[$=?'@DV;^<=)V^9_Q^ M^9C[3Y/SX\O9N^3_&J^C?AQ\/=-^&A"#PYI'_+.=']B?Q(/AV:K[4?`XNH_I,_UGF>1NV>=IGW<^M3OVXX^[00!RWP-T*ZUK]KKXR^*KB\TV]@6#28[7?I06[BAFLQ)&BSER555)# M*!AR<\8Q7U+7*>&_AQI?A?QKXK\3V;SF^\2&T-W&]#RT^SP^5'L ''R]>3S7 M5T %%4;C7-/M-4=-GOK>'4+M'DM[5Y5$LJIC>57.2!N&2.F15Z@ HHHH 9-M"EQ"\4BAXW4JRGH0>HKR37/@U=QW;OI5Q%);,^ZZ'FOACX=KX02;6=2D2YN+6)Y8X8_NH0I.VO+$WMEN_=3>7O5AV^AQ6F&PM+"4_9TE9&6)Q57%U/:57=G&_!GQAJ MFERF[,TN53*N6/^L0_>0^N/TKU[1@ZAAT(S7$X[3^-UJUY;H+K2XF#.Y M38" <[5'{?;9&<GK MRW(SP >96?CWXP?$OPYXC^(/A#5?GH?B!:HY?0ZX;34HK2:2*1[BY$

(ON&!@8QC@FNL\9_%CP=\/+FUMO$OB7-M3-$N+GF&^NEB9QG&0"><GO7SY^Q?HE76E^'H=81-MD6(^L1)_]6W-GCKG-*
/ZS5AAU4M=MO[KOT,ED>!Q&;U,&I\D(P@TKW;ERPNM-M.;6[;=K[-+3;W_XW_M86?PK\?^#_[8PZ7]$.KVSZC=WMWJ26\=O:KT9200-MS.-VT9&XC-ZU@_!O]KG7OBG?
*>!L^%]+MK#Q)??MNTD.LQR36L<,8==T9_>~<-M\KZ0/>O+-'^-4^E>)OA!87GA[4=:TZU*ZR)Y-;TU3+,EUD>W@F-+J&1G(09-MXSQCI5+X,_"?*
Q'8:7^S;'8^`[K1]2AM7$\'V^Z^QM&;6XEAD2&2Y_9>20P?LXI2G:7GNMO6RKM.RE!\$=/3>^OV=\'9-M_EDTW\$Q=3P^6D)HSEXAG)B(P48_>'/&:!'[+>(R#+>$'(,[ZE)+-
"ZEE0D|2I4X/H1Z5-M]52$[GXEZX3WO|_)*_-N.?\-6/N1+EB/2&*^3?CW-MJ9TCXB?$?4"GG?9+]YG\O^]LCW8_3%?E;XS\;ZU\0?$,^LZ[?S:C]$P5/,E8
MML0#"QJ/X54Y^N/B+_@M9\-[&_;'2/!?B/4K=3CSY##"&]P-M"Y/YXKLOAG_P5^^"_C6]@L]VU%K4R>'5U",3(!YNH23W$=O:#)'WQ;L=W;TZ5S'Q<^#M!\+_!_@S4
*MOMEW>WWB/3K?4@!-%M[96B!DA9\|&GXCA>I/+8##$?T?^-'/E+]%M=7T3-M4+;5=+ND%$0%W;P2B2*13W5AP:TJ_&C_@CI\<-$>_C?&BZ^&4EU-=^%M9L,B\CM*
*M'8E;2YB-?S$_NAEW*P'4[3VKJEZ-"BBB@!&^Z?I7CWP_P"1L^-G_8\)2?^FS-M3Z[A;[I^E>/?-#_D;/C9_P!CQ)_Z;-/H-]BHHHH-****-"BBB@-HHHH-****-M-"BBB@-HHHH-****
*"BBN$^._P-09_A/\&/&_C*VMOM=SH>CW5_#->CO\&64-M'VR!GVS0!R_QY_:V^%_[,-LA\;-^)K>SOY5+PZ9-#-=RCU$2Y(*N<#*WKY%UW_-M*
*(+7_#NTU!HM,\#^(]^U4X$\K01;O<+O)_.OR1\9^-~<^)!BS4/$/B4916U-MK4IS-<74[;G=F/Z=-!P-I7L?AGJE2]\6;)JE_9Z@\;6WAZTU&VAEB-!OY-MHFF^R+S_*
*,|HI3GU\L8^<4-?]?\-"O\-X*V_!+XA7L%C]!VI>"KJ4A0^LP#R-M,GUEC+*H]VQ6Q\7-5L]<\.1#$1#*PX(-?CA\;?A-M!8_":P\+F&]N]1N=;TZ#5/,,(2WCCE@C<-1!L_-*
*(K,VX=%&T=2<>_P#!;XG-MZO<:WK7@>[GENM*6R;4+59"6%LZNBL]^BL'"3(]S0!]W>-O^0)X'_[-H_\-M2B:N1^,?W_`?_8MI_P"E,U=7XQ).A^"*
*<\XT@C.R9FKDOC!EKCP*N?^9#]5^4CW?X-?%?PE\'2V?;S7_&.O6>@:5%]-MMP//O)0NYL)A5'5F/H-37CWCC_@LW\)M!O7M!9UXE521]%2BK?B3W5AP:TJ_&C_@CI\<-$>_C?&BZ^&4EU-=^%M9L,B\CM*
*[]HCXDZUXW^(&IV%Y=S_V3I%W-;6-@SGRX&VLP7IN8KDGJ>.P%6_MA#|":!\4+31)WOY=/BNM8EM;R8Q;EM[**V$\TXY&XA<@+W.T9R:_2S\U/U#\% M?*
\%GOA1KEXMOKWAWQ#X<1B!!J;.XC7W.QBWZ5JK?"[XO^#OC1X;BU[P7X@L_M]?TQ^#+;2-F-O[KKU5O8@&OP\;?LV+\/OAMX@\1;K>W.]HNMW.AI;6D(=2*
*M46"2*Y=L_+"\ZF.G:QJ5OI6IZ>K'R[-MJ":01G*]"REMRGJ"/0F@#^B2BD!R*6@-HHHH-****-"BBB@-HHHH-****-"B-MBB@-HHHH-****-"BBB@-HHHH-****-"BBB@-HHHH*
*****-"LW7O#]GXCL3:W-ML>)QT=&Z@CUK2HIHVU0'F-|%/A)MF]!KS3Q]W4X4X4?]-E'W3_M-M#Y3[5PMR-TC2K%Y<$KLT0*D9[']H?*
*PKZ'90PP>E<5XA^%UA[<#+P7$<:W4GZEX)UG2+O-U8M+8!>;G3LS$"!-MP_,!^=6M%TW1;P?)PATW-MPO<00;]@NG/SMN.<+WKOZY[P9:PV=G[V/G*M7*
MVU251]=0HHHH,A,48I:-$HI;*-$(S1BEHH-2@C-+10-F**6B@!,48I:*-$Q-M7.^/_.C?$WPK>>'?$%N]WI%V4\^!)6C\P*P8-E2#C(''>NCHI-*2L]C2G4G-M1FJE-VDG=-*
*;IKJB&SLX=/M;6VB6&WA18XXT&%10,>@-J.BBF0VVIL****-M!:1110-4444-?G;_,%,O^2@^$^?=P),Z-KT'](@;_DBM]_V&9Q\T7%7GW_!-M3+_DBM]_V&9Q\T7%7GW_!-M3+_DBM]_V&9Q\T7%7GW_!-M3+

,N9VN/"TT1@G6U0L0T+=+GM|?PW9ZW]C 6|M>75]DCQ{C@E"PS_ /KH P)?B/=_&N[N?$LC MR)\6&HV]O;:=!6-/M))\|\LOS W4@QZGY1Z@ M8KY1TG3_ (^?

L[>-6ATVX\8WFO6LQ:U\F/[9I&L@N<1A1Q&K;AGH0!ZU\OA, M)A\PQ$LRJP3UM"_:/VOF[M>5CZC%8S$9?AXY;2FUI>?K*WN_)63\[GZO?#GX

M0>&OA,'U=K5/1[BZN])LIKZW%[>20(\! ;<(W M*@LN>^#D9[JN5]0?+A1110 4444 %%% !1110 4444 >4?M47NKZ=^S]XUG MT-I4OULOOP9WK&742D8[$+5^2N 1C

V^G:OV|G@CNH9(9HUEBD4HZ, JP(P0 M1W\KPN;]B;X43^(3JT*5:),;AA;DYSC;UO[9K2,DC[+X5XFPF2X>10Q_M&

[NZ:MKI:SU7;3U9<_8UO]8U']GCPM+K+223!98X))B2[6ZRL(B2>ORC](@*_M]K/2H;*RM]-M(;6UA2WMH4$<<4:A510, #H!6=XQE>#PCK27<^#Q==8W%U*T8\JG)NW:

[/F[]H?P1=^ O%-G\5/![*IBF!U!(M3E0_3>_TV,9,,XXE0I_$K:.0.XS MWIGP=NY[K]E/XD">9Y@GG;?,8MC,,9,,^_->,L_L?#_BS%M_U_77_*'7W-;K M4P6'DY6DZSC];(@'X8\4-

_:OP\|-9+H?:MN\Q#*?3(PP_$5] M.^)_GA_QE,F'6=)M=0C4&Z6,;A]&'(KP_Q5^QSHN#?>$=9NM#O%.Y(W8L@_M/LPPP_6N3#YCAMJE?!/10&V4>&KFU\ M;WT5_>+

<$6SHP9A%@?>8=>M>A>'] M:A\2:'8:K;1SPP7L"3QQW41BE56&0&0\}>>0>E>;?M4?ZGX4=?\ DH6B_P#H ME7_Q+|+Z5XH@\.7>N6<&M3%52S>3YRS?

<7V+=@>30!T]%>,.^!OVFM$\?^ M*:T73;*;S-8FU002O(H @LI%B:4CK\[M@+UP'37LU !1110 4444 0W=I#? MVTEO<1K+#(-K(PX(KA+CX,Z5+P-

>@TAKDKX2AB;>V@G8Z MZ&+KX;_L9M7.?MTT/P!IJP^;'9Q$Y)D;YW/J?6K&F>)M'\1AHK:[ANCWB."2 M/H:^9/C#XBU'51=WBR.-\Y0[3 JXQG

'IT%#DJ=ONM:4;:P^28O&1=2_WWOH?0E[5GJ;@75M%< =/,0' M%.LM.MM.C\NU@C@3TC4#-9(@OQ0GBS14NPHCF1O+E0'HP]/8YS6_7N4G2K15

M:FD[!3PZL:M&3HU+JW0\)^*7A2>PUV!NFA,MA>L7W8R 2/F4_P">]><:+X"M M%U6-[*VEGN"W!N/[P\!JJM\<_%,6EY-IVG017'E'9+!+.-R[AU-'2%8_A/XH) M87R+?

Z?:Q0N<-/;1!&3W/J*^4Q7#=+$XCVO-I>^UVO0^KPO$E7#8?V7+K:V^ MC]3N;#X?VX53P#&H;Z M;J])1UD164AE89!'0BE/2O?GEF$J*//33Y4DOE^9_#,L73VM?

W1EVYV'4*/KW]CH/Q6O!.(-7$=[8KJ,+(VT94'@^Q M'J*\Q^)4- H8\J*TN(YRLK+U*[GDCZ\?G7&>A?=ZU]=)(S_# M^:.,_:~?

8[CCE33:UVZ+RM^9^G4,BPM;!.HTGY]7YW/1_F2+9MF3W^>7GZH*\W\<>#8I[6SU+2(I)_E",L7S;X\$A_PX_,OU M]M2G6I>U6_5'P668ZGAZRH3VV3,,O]=BTGP'I:*^^[LM;-

[+$HY\KY.?QP15 MO6=:\,Q2:X8M?BO(O$YO6=]{L:,#:VZ2[Y/,ST/)&!6!<(DT>'O&#:OHL^I1:?'"NKRZK]W(K&&5 M94 97QR""3@UYU:+#;,+=961!,7Q(-IZ9_G3?

$$P.399H75I8QCKT!.#^E2Z MTI.S-X93Y0]YHMIKT\OZ^,/;#^?B?YYS)FTG4]2IA@C6S,<^FB,*EK(K$L5Q_"^OW45Y1X9F$(B

MD!)&Y0RJ3P#GFNBN[*:.RGAP02A&X<#)]9U&UR/8VP^"@IQQ"?O*_P"K?YGT M=^S1]"ZG\/9ID4J/MTF]\^P7FO6:\7_9/Q_PK"?'_ $$9@?KA*]HKU]2M!'YW

MCFY8]HW\W84AI:*U.$^._'_QV^(_A5_$WPNT)EUGX]OZ\]WHKW"' "XT/8U[YK M8&/E6.2SS_?*=S5'QE^T#K'Q6\+>)/&WA:[$7@;2V\.:9;P7-LDJW.H76HVC

MW98.#S##*D..SM)W45]9R>:M"D\;Q>,'TZ$^,QM//2TU_C]XMLT@D,>?3>H-M8C?!3P;_.(//X1AT:*V\/SZ@-5DM("4#7'VH?>_(_Z,&_#'2@#XV^+WA?5

MM+T]!KF\B\0WFHS?VCHR0VEZJ>3YLD5A)$S;0#\@(C'/W1SSS7KWBSQ5XS_9 MT\9Z7?)J'BJ_|>V>K^^M>\"QI$?; ACZ>E;.M>!=&\0>)-#UV_M!<:EH MRW*6'/C'WL:E

ME4&V6VDE%J,=/E41XSUR/6NRT+]E+X>^'M?L=2M;"\>WT^Y^V6&D3WTLFGV< MV20\4!.U2"25'(7L!@5+XG_9<^'_ (O\57NM7!A=9U"=+:O4=.@O9(!*_E7&V M2>

';Y^1<_WMHSF@+S/PIH&K7_[;.G:S=>(M1W2_#NSO)K$&(CFYG9&B/RYV M[\R=<[CZ<5>^/&CZKXA_;1^$^F:3XF/A26Z_ZU]["BM<21",3V4&[@.2% M.

<'"JW%>]KX'T=/'#>+1,8UPZ:ND_:-QQ[F$IE";>GWR3FN=^)?P)\(?%G5- M*U3Q!932:IL,T.GWUM:T9=HV4@ACY2C/ID=#0!\S?%G6?$.A7WB'X

M,,SXBD\?6.G;KX0UNQU2Z11\;^/;3XE3>#VTO5=3LM+T;&")K.T2RGDB'V5<-S-(8BS8(V]XOTKUS1?V;__M -H?AVZTA-.FNUO-

0M=4O+V\N7FNKJXMY5D@>25CEM€(N!T '3DU3\5_LM^ M ?&/B+4-6O;*]A&J2";4[" SOY8+347P 6GB4@,2 QXW S.!"&W2,HZ+T%?2WCKX

M>$/'EWIU|/:?.D:GI[L+*WO]%N6LYDMQOTA}3@QCLI!QVQ4FA? ;PNSUH'T<)+N:V,\&3,\ES&8[AY"Y/F\U)S3SUH_^>?B>XR\8#2#PCFC\?Q>)M83

MX9>*0$*ZVEK$%;]B-FT!@(!*Q)YC!5R>*E M\7W#Z=]^ER6T:6Z2G3I[M*M@HW)M:WV8).X/VKTNV_9B^'UIMSIT6D2+I\V MG:CI*VOVAS'#:7QC-S!&"?E0F), -?

=QQ@5V>K_#_ $76W\-275L7D\.7OO=-M;>1Y,H@D@#>_.[N5QSZT ?)6K^(?B1]W[+.K_-!QM_BLVDZU-H<^MP:.D$3:9 M:)Y;,MI@C<95&%W$Y\P=,

<5ZE^U==RZE^QCXINKEO.GGT:UED9A]YFDA),/J M:\G\4Z!=>+/%L&L^&,S1Q#L5CJTLJW&O6NH7,=N%D8EKA=-!\L7&TG'\&,9\/ SJ M^N\/$_P

,I$\8^J)_"&KVQN]#GMTM98"Y4LB;2HR:?X10!YK\]&<+^T%\J^,9U M;2/ $TV]6/$%_HGQLTNJTKQIX8UWP_X>T6Z@U:>;6H/LUI=?9Y=ZJY/#QY0 M,RG@@#-:GB#]FWP?

XA\=7_BZ4ZK9ZS?R02W3V&I3015-"BI&612 <+BCZ"NF M^*7PNT+XQ>#;SPMXEBGN-%O"OVB""=H?-4'.UBO)4]QWH \F_9^TZ/QQ\5?%

MOQ7TC24\/^$=5TZUT728DA$+:K'!)*YOW0 8#&0)&2,E%ST(KZ'KSWX;__P M]*,V>YT2?5G,L MO*OM1ENT0$$!48D+C ";;&&#XR_;;_Y'C0? M^O%__0ZW?

V7/^2>77_82E_\ 0$K"_;;_ .1XT'_KQ?\ ]#K=_9<_YJY=?]A* M7_T!*_0E_P B.GZ_JS[!_F2T_7]6>RPJ&E16^Z6 /TS7P;^Q?X-\/_%_X]_'M7QCX]M+?7?'.G>(I+"WL=302BRM

SA2D;<0^14!QP%]Z^\5&6QW/%?GI^T9_MPI#5?C!JGBSPG\;E^%QQ'AF>RU=[,.8!B6,[*\Q1_$"N#U!(SUKY&KI9GRM3 M2S-[]L;P,X> ^$/!17P$\6^ K.WT+QQ[?

B)+"ZL=-01"]M:\LSQKQCYV0:(M;VK]^(":(TS7?YT_LV)\#M+^,6E>*_%/OI:Q3^)5Q.EEI,EZ$=OQ\Y+ MY:Q<?(EL#H

3GK7Z*@8)'IQ40UNR(:W9(.M3)TJ$=:F3I5/8;)1UJ4=;B'6I1 MUK-D,E7M4J5$O:I4K-F1,G:I4[5$G:I4[5FR&2I4]=:B2I4ZUFR&2KTJ2HUZ

M5)4LS"BJ.JZW8:',F>_NXK2+^]*P%<&.J1JXJI.#NFW;[STBBN>\+?$#P[XUC+Z+J]KJ M&!D1%("P^HZUT--M* M; TU9HEW26Y+8'4]>O\ C0!X=\3KR2U\.+'&2!/

(W(_NX)O^.!7EVG7*VET M6!+*=C[KJ.L"5(# >ID$7M7B20U\0Z/~%@DA(>-CT#=A7C.H:-+>Z7.T-S M;O&ZGTR#!]#43BIQ<);/0N$G"2G'=:D4]PB//"MJ&AAMD6. $_,

O.X^Y.6/UK MW?2;N6[TNTG)*O+"CD XY(%>/>&_'"%YK]V@,3PV@/!R9A@8!ZFO?J"'VC?;]

M0MX$3%O#@MZ!1T'Z4]=.%&&:=-625DO)#]5)U9RJ3=VW=OS9ZA#GR8]W7:,T M^BBM#,**** "BBB@ HHHH **** "BBB@ HHJM?ZE:Z7;F>\N(!.$=7E8** + M-

8GCC_D2]?\ ^P?%I8G!P&4J'?A!:>$/@YXF!%V.K_&R[UA)66YF38H9D"J,=<849/O74_ +P MTWPV^&EMI.IWMLU%+-/,T;_ "1[W)QD^@KZC,,90KT:WLY7YJB:].6USZ;'

MXNC7HUN27Q337I:USU*BN$OOCGX#TZX,$WB>P$B\$"7./RKHO#WC+0_%D1DT M?5+745'7R) Q'X5\H?+&S1110 4444 %%% !29K\]?67B#4?]>M6WA6^M=-

M\1RVKH]W>QF2&&8CY6=1R5!ZBOF0_#7]K_/'Q4\"X_!:$U `U=J.DV.KBV% M!.PW7V:=+!F'SD#>?*OW77/1AG@UXAKOI-3ZG\3M2UY+]SFTO5=9LM:NENFF, M\5RW6N

_P"%;_M@?]%4\"_^"B:C_A6O[8'_ $53P+_X M*)] /:/ 'P!?_ 434?\ "M?VP/\ HJG@7_P434 ?2_BWXB>&_ EQHT'B#6;3 M29=8O!86 NI GVB<@D1KGO@&NB'-?

E_^W#X+^.]A\'TL_B)XV\(>)CJ-[';: M-I>E:+,=0FO204^SN/N.,9+>E?;W)/A[ACX^%_@/X:T[XJ:C%7]BV*'$CKS) M^%QY<)>///AM>V>HW%S96QN["=B^Q!N*9Y((

M],UC>%_AK]&IW*Q)9&PM2IKZ&I*^8GD&&G6]K=V!?\'L?30S_$ MPH^RLK]_^!W/%OBSH+Z7]5C/$A^P_9DMT/92F>/R(KYNU]0=1.MW(-O).TLA M9'49#

GCFOO._P!/M]3MGM[]%)X7ZHXR*YVW^&7A^VN!.+,N0+G M'#$LP]\U*;2,OZ'M91Q/'+Z7+5@VTK>I@? C1+S2:" DO,^9.5QGN%7&?SS^ M5>D,"0<<&N?

USQMHWA=EM[F=5E &(8ER5';=*?H'C;2/$DABL[D&8#/E.-K M8^AK[7\X98/#PH1=U%/&/B\9B98$$3KR5G\W/EWXC37^A6%ZJ;HH9_+D?'*Y M)R?\^-M-

F8.=VTCICZGBOK3XC^$_#E!;O?:L_V1V& MPN@!,OL5[FN"\$0>!?#.IK*EO/OW9666,! >Q('!:*N,P]"2A5FDV%+!XBO% MSI0:2/8=_#:5X8TL:UQ&T-L@D9SC:0HSFJ2?$3P_)

<^0-1BW9QD_=_.O,?VC MO&5SIVCV<-A(&@E02[UY5MQ(!JP,\37AW@SQ+?WNK"TN9#<1R*QRPY4@9S] M*^.S/B=8+&K!TXWVU]3[#+.&7C<$\94E;?

3T/K,O'X'TCQ<%GG3$!7 GA(RP M]^QK.T#X;^'?!DOVM402]]MK^,^3-':O?:P->=)8'POKLVBG/\.0&$YL#Z1Y^ M>+_@!((V6'1T'D!A#QXD>H"XT]Y9)XOE,/9&Y?

<=Q7MOCV;^T_#NA:O;,(;@ M75NT;D9PLW[MA[\/G_@<IVLESB&97Y59^3NCR<4&006P"!]?YUPXO93Y2G=@_+QZG_"O1_'7G:58S63J=63 ML.[]@K DD?

4<#ZUY+XXNWM/CA5<"=MKOZ@567+);FGI6DQVU](H4S2.9%=#T7.5'-4WUE)0G MM9))8G9<= 0.XK:L&"6$9QN"@CY1RV"1G[*YSQ3XSLA4[U_*05^BUZS7C'[*%K-

9_#"6.>-HG_M-M"8[6ZXPN*]GKW>7P(_<+=KBJE^[":D%/+16IPGS3KGQYUCQ7=_%S0I= M8?#O MANRU2VN3'JA@U7]S;EEE$>,K'+D])%)(P":=X-^-

GBKQ%8:+X9^&OA6#53HO MA_2[C5;W7]29$@>XM4EAM@X!:67RRK,Q&/F4D]\U<\6_LU^(_'WQ!U77-<\3Z M=]D&FZKING-9:=Y-T8KV$Q+'*\W\5:,KO[/'C%(] U#5="

M6[T/3+&[U-M#;5-/U26VMQ)%6.AH9U1%4AN&7,Z4 =+IOI8?BK79M#TFP^\'M9'B?5/%&K>&/[-N+Y5%M)90+*TLC@8V ,9S712_M1ZIX,TKQ1I?B/PN MA\?

Z1]AHMKH^EW/F0ZE/>:H'M&CD8#:I D+:,@-H8UR_[-/P \01#PUXT\17 MM[!?Y_B?7O$ M]3@="7=S%?1>1&TJCB-|*'V]@P7M7>^-_P'F1/&/B7QMKHUZ M73=3U>]T?

4M*NH(@7TV\T]'6.3!X<-O(^]U+#O0!3A^-?Q!T/XD>$O!GC3P9 M8Z?_ ,)0E\;?5]\U SP0F"U>8QL&4,%X.Q&2#Q7'B'PV^/<_PQ^&5MXNGT]5 M:?%/B"S^`_A>YF2?4687AO-

2GM0JQG@2@C._^+(!Z5[G8?!#QIXB^)G@_QAXV M\:6%Z?#7VO;?2M*L3#!)HM7@:1BQ)WC<"!T R.]<|8_L;26?A.#1CXD5C'H M'A51?-^S]?[+U-[TOC/_"TWI,=L9H

Z)/VAO$'@/Q!>V/Q/\.6?AZU_X1Z^ M\26EUIEX;H>39F/[3#(,#$BK-&1MR#DX/%8/B+]HWXG^#/".G>,=<^&EI;^& M]2NK*".&+4]U[8KCRZ*A"-?+?) -HD/""]Q@$]W!

[5\K:D?B'\6-"_#J/6_$5\MOJFEM-I M_X>;TGMX,>YBED-_#"GA/2]1\2:-]IO>>(9[S4 M&BL;.6<,T5O&X4MD[+A;I@ C/6N\^-_PT;XQ_"W?]"*WHTYM32-[

/XC:GXU^'GB.RT34=;M8+36++5;0W%M$+ZXN=.FT+6=.O;C1M7TQY S6=Y%@2(""# AE=6 M'574UX[\//AG'HOI17Q.@/B7Q-J-IX5N-/BTZUU#57FA"W%@LDF]2/F^9R1G

MIQ7L_P &_A:OPI\+W=E-J4NM:QJE_/[^K:G*@0W5W,07<*.%4!415[*@KC_& M7A+Q!\+[;XT^/_#!75]>UZVMKNQT\Q$^3);6BP#./O\ W2^!Z8H]GN+F&TB

M\R>5(8\@;Y&"C). ,GWHAN8KC?Y4J2[&*L8':PZ@^A]^,+2 \+GQ(M=-T MS4=?EUK1;;Q9H8[9,K31R-M"M&"D3XQE2<M6K\&]3\0>"2%_&C2C

M5[VYLM>TI7MV1/.2.8MD2_#E3MR,,, 'UO12#I2T %%%% !1 M110 4444 ?&7[;?_ "/&@_\ 7B__*'6[^RY_P D\NO^PE+_ .@)6%^VW_R/M&@_]>+_^AUN_LN?

\D\NO^PE+_P"@)72$O^1'3]?U9]]_S):?K^K/9%X/'6O@ MGXM?M"'?L_>$OBSXKTN^^#0\2VNC7;)X@\36E@LD4%T['<&YR29,J3ZYK[WB.

M)%/7!'Q7YG^/OV:M*E\3_$VQ@_;2\/\A_2_%>'FU]^A.W5_/9Q'+[H3CZB MOD:MI*Q\15O;0VO@\Y%@H*T?Q6^'%GBO\GG1?!7AWQM=[?"NO01DRK(:7R7.> M/Q-

'R.FX'I7Z2C.3GKWK\T//![/MIJ7CGX8)JG[2^A>*[/PIJMI+I&B[LD;'MC"PQ>[!%4?A7Z7]78^YK.G>SN13O;4D'6IDZ5".M3)TJWL4R4=:E'6HAUJ4=

M:S9#)5[5*E1+V]5*S9D3)V]5.U1)V]5.U9LAD]5*G6HDJ5.M9LADJ["+B=;: MWDF?]D:ES] ,T+TI98EFB>-QN1P5()0:EF9\8^,O&%[XUU]>_O)69&8^3#GY M8D[

#Z=ZYR07-WHN7$<48[L?Y 73F<-MFWN57*E>P/H1TKE-&9H#XEO$.+FVTAA"1U7S)HXW8>X1F'XUR8JNL+AZE=]Z M@F_N5SJPM\$K%4Z"=N9I?>[%A/&=M\+O"_B[5-

+/]L7^F::97NIB3;O.TB1(M(X^FQ6?.X\G;Z&OD'4/B'XIU366U;Z\0ZE+J+/O^T"Y=2#[' 'L.*^D]\N+ M5%O;/4+ZBO-;C|F])+]GL_&.E_V46R)+I7 M2X5?

1HP.6^G%?"\.]24,50F\=54:EV]796Z6\E]_7]?T9E6 P&3<\%#>WO6; M;TU3T>M]OL[]VVGJ^@_$-_B_\%-'_P"$K,WFI>SZ=<7]D=DS21K&\I7/>O--

>\WGA#6TFR\D2=6C6>UNX?!7I MA>9672'QG@;9I:QRWB'Z[G-7"4WS4!"^S25_D[_/N)\]DPU"'O'T(3;MT:T^6G0Y70=>U#PQUOJ6E7G@CX?

ZY\0=7AT_1K&2XDD(#3%2(XAW9FZ "O MT4\!^$X? O@[2-!MW,D=A;K%O/\ &W5F_$DG\;_0#\J-^BBB@ HHHH **** M"D(R*6B@#DM<\$+ M^N&7SE6UC]^OX"NXTK2;?

2+80P+CNS'JOJ35VB@ HHHH **** "BBB@ HHHH M **** "BBB@!KL$4L3@ 9)KX[^(/CF]\<;[<7,\K"S5RMO;Y^5$!P./4]2;^ MQ64.I!&0>"#7R%1OAY?^"-

;N$:%WTZ1RUOW(ZJ[%(]P]U61C7-Z5>6]G-/%>6_VS3KNWDM[NVSCS8)%VL >QZ$'L0*^%S[/GEF,P^'VBV13?\ =O:R^YW/T+AC)*.84JF*

MKKFY7971O1O\'9'S9JOQ%\4ZUK3ZM>>(-1EU%GW^>MRZ;3_L@$\]\"OJ#PW\ M197BW\$M*3Q-<7<-PMJ/US]=BVR61XT1XY7O<2#;)AEXR5SWKRB_9OADOV M?

3_&.F?V26RKW]NEPB^C1@56:M>RZVT^?0X77- O/"6M2:??-'*=BS6]S#S'*#4](NY+!*]A8,KQG /LP[CV-=+\08UNOA_X>O),?:+/5I[&)SU,+PK

M*5^@<9_X&:PO"'@O6/'6L0.;HUE)=W$K ;E7Y$']YFZ "OH,SP?]GXRIA;WY7OY,K\#!%/AIXP'C[P)HNOB/RFOK<2.@Z*XRK@ M>VX&NFKG?

AYX1C\:^"=T"?) -6QMUB:3^^W5F_%B3715Z9Y@4444 %9>I<*%- M*\/\"NJ:I9Z>TV?+*%U.L9?'7&3SC(K4KYC^/WAK4?%?2'@2QT5O0 U^:,A% MM9=K;Q%N-NB_;K ;U

4_,"0.G0M0!],03QW,*2PR+++$ZAE=:"""K]""_HHN+B M*U@DFFD6**-2[NYP%4#))/I?QWX=L/'GP?N]<\.VWB:?5=-^'G@.:'7AHUG#\ MFIHWLTVHOY(9LN(5$2(J

<*OI1XC\5>)_#OA;PW=3?$F+QW#XVTR]M]0TQ8HQ M' K:;<7"VFVV>KJP(]0:Z*OSTL+&X\Z/)>++86EMXD*1?Z/:Q,TP?PT91YI8"?M M8'&1*K-YPF9! MN/#8^\RX!'- 'W'4%

[>V^G6DUU=31V]M"ADDEE8*?.223T%?(MIX_P#'I\ + M]EWXWDD\4>/;_PM%>S6Z"#1+*"\O41U]97%ND09C@-(OISSOQDU?Q*OAAV[_M ^!) B++XETG3?

ZM#.L<7VFWD>2Y$D4S+PVY8U'0$?6@#[-:31=?U)[=OL M=_?:5+!*8V"R/:R,F4;GE&*G(/7!K5KXU3QMXC\+^,=;!*6?B&'2WU'7=""T M.X\67-

K&)X(GTIYVE&_$%_X!T;QVNM,NO>'H M(/$DUNDDUO'?3JI<6LH7"NZ)")%(QQ(N:./L2BO'?@OJWB#3OB\)OO!.M:[/ MXDM]#&G?EG?WB*MQLNHI"T;[< [6A)!QT;':O8[

"BBB@ KKNQ=\6Y;2_EM-_M)2-EB8HT\@R&(ZX'I!UZ=.K/#(JG#%2 ?0XKY*917MGI%_%$KK=QG;X'WA@-M_-^-?*<08ZM@[,79:?O=K?3H?5)\X&<CC:TO:ZVM9/;7]>P>%/

C#=-->QV^JK$ MT3L%\^+C8?<>E>H:A(88H/,=9,K(O)!!'M?XYQ7W1IUNT>EVT$_P SK"J/GG)V@&N/AC-:V9TI^U^SU?\ F=?$^5T8\DD^@JKX)|=OJ-[YD2&UO;;$R%6R M"

?!\|>]>D?$SX#W>J;UT\>;;;S)#M(WQ$_PD=Q5?X5_L\W6C;A|LU=ML?&Y# MU8 YV@=LG&37VY\2;?Q=U>6?683-E((-)53TW EC^F/PKQ"+XD2->KNME%J M6QP?G

]:^LO'_@"/Q=:)D$RQ7D2E 6'RNG]TUXM8_LPWS:LK2ILL=[*SM9P1C M\;2*_*<]RS,ZE.Y*KJ3W_S]#]5R+,\IIX/DQ3LXK;_+U.DUR?7+X\$.BJL MTME,T<;2=)(V 8[^!Y'UKF-

*^%M]HEVI=IHLT'-GMS+YT$H&58<_*?0C-?2%FJ=MJ&GQWL$JO;2)O#YX MQ7':G\6]$MKAH$CEO$!P711M/Y];VS3+\#/"1PU6?(EHOU, >++Y8K?4-%T1'"6>F0K?3LW^R

M"D*_BVYO^ 5UOAKQ)IOB*T9]/=1L^_ %MVLH]Q7G/Q+@^R>*9S("?MEO;O"YZ M?NVD5U]_OJ?QK?(<_A7G&I:=#]]K)!(?E8?*W]TCH17H/BB\;UTY0C[)))%4

M8Y\'5]X$DV+*"'2!\SM(7)0^GTKJQ,G.?-U/],JC"E1]E;W3D+GP--H_P!V05)/?O1)+';QY=P]CKDU-MR.3>A[4*4*;YHEV>3ZX%9MUKEK]\PA%YB1N2I^=0?

=NV:=K[^4VKN6BOH?5'\/-MF?\A",C)S_!LGX<+?!U>6'LZ2M-X#F=@HS>R8V-N&,+WKU.O]R@F8>R95S]3O$6F M:O>ZA9V5,,W5UI@BNX8I S0.1D*X'0D>M

&C129HH 6BBDS0 M)BEI* %JI M*6@ HK+\1^*-)(:8VHZUJ-MI=BKK&,BZD"(&8X49/+M%\0ZAJMAI MFJ6M]>;5,+>^@E#O;2$9"N!]TXI&@##42)(UVHJJN';

[^PU\$/%&NZCK&I^!;6ZU'4+F2[N9S-(#)*[%G;@]R2:]HU#4(M=*L;B[N"PA@C:1MB]F(R<-G7,=W:SK-(3'*C!D8 G

ML0#7O@.23Z\U$G6I%ZUC9+8QLEL2CK4R=*A'6IDZ5+V)9*.M2CK40ZU*.M9L MAD]][[8F2HE[5*E9LR)D[5*G:HD[5*G:LV0R5*E3K425*G6LV0R5>E25&O2I*E MF9'-

!'=/>6EQY6F0(X7MY_(C"LT;=0/?(\'N M!7;4A /6LYPC4BX25TI\&7"%;G0I3(C"]TYV(AQH1E'.. M?]K>H/0UB9KKK_4K[0KR_DT^Z>V#SOOCP&C?YSU4\&HOB3:PV?

Q&UR"")(84 MO-JQH,*HPO`XFOPGB/AZ&4)5Z,[PD[)/===^I^Z<.<0SS=NA6A:<5=M,/IM MT,/2M&N]9F*6T>54;DG.V.->[.QX %?57PJ^&?A^Z\(:,TMK;:S9B,W,5S/

M%&65Y,I%[Z @*!['> M?(OQLU[4KCXA^-*_VT6B65\7A^U*"9[%@$+]HK MWS7W3\&E" "_CP@ ,?\2W_\ 18K]'R'AREDI=:.4N>HU:^R2\O\S\ZSWB.KFZ

M5&,>2FG>V[:_P#(Z?3=(LM'@N[FO(+.+^Y!&$'Z5;HHK{(^-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKFUAO

M(6BGB2:)NJ2*&!_U+10!PWB/X:Z'+#++;Z3;QM+%);RF%-K-&XPP"_J!?Q MUXD\+SZ!.61Q>:<['R+Z(920 XY_NL.X/0U]^D9'-?"V!:K?^'Y]5DT^Y,2M

M+*7A=0\3G<>[']C\:^5SW(:6=0B^;EG'9_H_ZT/JK:^)M!*8>.]8@MXD@A21-L<8PJYC0 MG_^\-K6GW=3!5SCB)9;A:.:%.[[ZN]%HGK]_0^K_AA\)_#NH>$=':%

MY:6NN6JJUU'<2)N2220#V%50?0>]>L:/X>TSP_!Y.FV%O8QJMO$$S]<= M:YSX+H$^$W4 8'!E6__* *[2OW?#T*>%!1H4E:,59'X3B*]3%595ZKO*3N MPHHHKH.<****

"],FB6$VLP:L]H$VI00/;1717]XD3LK.@/H2B$C_9%7]* * M,>B6$6]W6H:0K?W4,=M-:7X6T MVRN;V*2"=XH_QO]] .BJW<+@&NVHH YVU^'GA]RE@D@T2RB>":,&>)DA

*20 MP^3$PI\U^C*0'L,*H3_|_P7<+AXHE\:=)KPD$WVUH06\P# D(Z%P!XL9]Z|& MB0+@^N_7AV_\.7>@7&C64VC70:KY?VU)H0PG\M0&@

]1CBJNA_"OPEX:TR#3],\/V-I:07:WZ1%_MG%POW923R7'9B2:ZNB@"C;;+86>]7NHP6D45_>K&EQ<*N'E6,$(&/?;N;'U- M7J** "BBB@ KD_$_PXTSQ+<&Y;=:W3?

>DB_B^HKK**PK4*>(CR58W1O1KU/_M+GI2LSC?"_PMT?PQ=BZ1#<7(.5=U "GUP.]=1]=_'I6GW-Y-Q"\&TC20#-6] MS/$FF-K.@W]DAVO/"R*??'ZUE&A#"T91PT4M[+S-

95YXJM&6)DWM=^1X+XD M\?:CJD[W-U?:,09^6-'V*@[#WKH/AO\ $;YCU.VM+B[^V6%RXC5V;<48]"#Z M9XKQGXFZ1]"- AAD

@9EEBQRK=B1^=;GP&\+:Ej6L(&BD2U$T^NOKY=#]:0.6X(^S)59-));:>GGU/K>BDH9@BEF(5 M1R2>U?LY^,GSQ\:)G3O$>L7)0R,D*R0J>A4(,?KFO"-

(\8:J=?@+SM<+++(J MM$1P03CBOL#QE-X2\4LMK=ZC%%=1Y5)T.=N>H/8BN<\/?L[>'\34$U#5EN(R M=R^4N ?Q[?A64*U.HVH23MV9K.C4II.

<6K]T1Q7%W8?!PX+*L]V4!_Z9%N?P M)!_.O$O%7C&71;U;2VB1G"AG9^@ST K[\U+P_9ZEHDFE/&([1H_+54&-F.A\-MTKP3Q=^SQJ.]:@'BQ+CY1-

&P&Y>V0:.^"XFP&.KR53")O1+3H:]_XI_T(^NGB MW;5O7KL1?!#@O++]7FB#3XE.9E=X)XP>"-N?\#7KWQ5T0ZSX.WP!(,^H6LBRVK M,0^G>ZA9V5,,W5UI@BNX8I S0.1D*X'0D>M

^'WP\T_X5:?]NU:YCCD0$+DYVD]3[L:Z6U^*7A^[N1# M\[:+)P'D0JOYUZV2\V7X2-+&S49O6S?DCR\WDL=C'7P4'*$>]79W/G?Q#-~? M+:RE EOED"M[!)<'U?%3P3;"YGU*

(;+742LJ:7.DMQ_IR16UK/AA{BY‡DGM2- MSGX-5M/TAM+N+>25PTLZNA4=% P>OKFL)-14RO4C!R/;I7G}>K7ME'}-
*O);3J3&P'S>_J/<5PY\&WYEP@1X>TN<W2U@C\PQR<<343[L*0]*6DK4X3\SOBIX%\.?!C]KRZ^(?C;3+? MQOX$\0^*+1T\065V?MWAK4@ $MY0K?*
*ZDY!V^@'H17"?GC_XL? WQ[^T9KWA[-MQ3!\FIR^.!)TB836.4FEN-VQ^ORA8QL(IYS7W!KQ!'!P1\0_%6;QS=66H_;: MC44U>ZTE+YQHS>*A;/-;OB/ICOX=-^*+GQ5/?*
6U\IGB77;/Q@+?I+GO2-M{M=@1s$XX7DY>@##P_7O'TON\0_&F'X(^`-' FD:/]-_AKPV%K.L^)[^RRVI32R M:D46?*
EC4,H)]C7!'\L/XP_$#P%\)++P_>Z1HWC+5_'%_P""]4OFM_.L{AH-M3%P@S]W#[L#NM?6?QQ_9(\!?'K7+#7-=CU'3=>M(#:.+]NBWK6EQ) 3DQ.R_>
*M7D\'U};3OV3/AQHVG_#RQTW29+"T\"Z@^IZ3'!**1_I###O*>KD]3F@#Y,U+|.ML#XL_"SX9?&/0]:O],U_QGX6\6Z?X9TI?7G@\F +>!B)!4Z80(?Q8>E=Y\._B M+|\9O*
*OI7/P_^&/C;QUHGC'1-;/BFO@W3=.U#Q%XIN[>^U*U\0LSVMP^(P A&#$V#E6'0@=-]\6_9%_8K M\;>!/CYI_P 1O%NDV7AB#1M+2L+6R@U:3414]f27*!%!8:!?i0!ZI:^U+|*
M4OBAI_[2'PJ^&GP|\1Z7X;C\5Z?;?RW5WJ5N)0AA ;:-X>7Q)%:[K;|M; :=E#IGAU*+G'N.U?0O[2O[M)-Q^7)^TA\--?U';?X/T33-0M[ZXL[TVUY#/(-8'B(YR& Y%=-*
*HG[#/PMT+P M78^'(+"^>&WU^V\32WTUV7NfJ^@W>6\TAY<#'?C'+\) MM*U^]%QX5T.VN=4UW3=!-Y/|5Y*H?/E@XCB 8#/L:UA^UU\8?&?@KX,.^#H-.*
ML_!'Q(\K2JP(&>"":.^E/C/^R)X%^-WB>'Q' MJC:OHWB!++?{\)]6@W[V!]0T^\73 MO#S>9I5[#>.M[9R,&A\1 MZ./-/O--@,4RH;A"ZSKT:R1C'8&N2|\9_&?QA?%/QVN_A}'I.D>*
(;WXKZ1H0 MN'M>?G .IZMZU\<67|#"PUMOAKK7@f}\ MA4=.UF^M1IOJ^U\0]YKF>;:MT9+MT /H.?RK5U0IXEC>-{-3UN^NI6=^.;65@%MIXLNBMS@&^ME81$
*M<<+AVRO>@#*XV^/?Q3^(^D_#3|ICX;?$?4-'\;3>%|+T;5|&^^Q&-.AV5A:M|LM?-EO9Y+99,[M<_)",$?3'K7T#\0?V2__/Q,U/Q[?ZU;7LEQXUL+/3M6,5QL#Q6S]\6P0^4Y1*
MT:]AC4(BS,?OX4 9]!0!YG M\5/BS\8KOXC_ G^#>B^)?#^@^*],T;6];\310&6VD\LE1';(>1)4G\|?2OG M#X]_%CXA>/O ?B[PY\0M9TW7+{PA\5O#VF6]UI<(CA=AR*^ZO*
MB%^QG\- -BJX3\)Z'=6FH;;?"L7D:1J6F7SPWMK'_'+N6(..7O?/Q&&BJ<0]=-Q0M-SJ]?G\V^9W;|M@WEL6(R0=[5GV?+9W;|M@WEL6(R0=[&YUZT ?1HZ4M)2T %%%% ! M1110!\9?
MM_\CQH/_7B__H=;O|+G_)/+K_L)2 | H"5A?MM_\CQH/_7B_P#Z M'6[^RV_R3RZ_["4O_H"5^A+_)$=/U_5GWW_ #);?K^K/2O%'A>#Q58QP27%
*MQ9SP/YUO=6SE7ADQC<.QZ|#Q7E\,]U\,?%2W&IVLK32*Q>32G1+?4%Q@-)$Q M^1P<'(ZUZ/XYU?5-%T1l]*@A>7)\VYN6Q%:Q@$F5AU;'H.]<%X#\'2^*-5&J*
MZEIZZAIT+2ZAK,9-Q>"R^5'TBC!Y'G37D-K-.;"8BDY4 MDG .>"6fJ]?#;PKW\/:?_P!^'6UH^AZ?H%N\&FV4%C"S;VC@3;"W3/UKAK3P*
MSC:E%I_UYG%6GAG&U+3_KS-,=:F3I4(ZU;G2O->QYS)1UJ4=:B'6I1UK-D,.ME7M4J5$O:I4K-F1;G:I4[5$G:I4[5FR&2I4J=:B2I4ZUFR&2KTJ2HMP12S$*
M#DD]^1OC]_P4]^$/P0U2YT:WNY_&&N6|,DUKH^&CB8?PM?ES["I9F?7U%? ME?-_P6[A^V'ROAJ_V3/5[X>9C\L5[G\$O^^LOPB^*6]6NE:X+SP1]-PP2-M3*
MPUNS$XOYB\+^-(#+\2?ZZ]_Z[O\ ^AFI_BE_R4[7_P#K^_HM5=>FCN#'1\(=;Y]345^76O\ _;:C3(!UUT:X M+O#.I^&4=@IOf%Q&N>Y ^;%,1^BMM
*<]X#^('AWXG>&;/Q#X7U>UUK1[M=T5 MU:2!U\I?0CT-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%(3@9- "T5\K_ !_X*0?!JX#:G-*
*H]SJTGB/786*RV&C 2^4P MZAW^ZH]^,9_^"W/AU;QA%,-3;U!X9KN,.1],E 'ZL*%B9C\VT?*#GUKD_$SK*NHNC! MT9Y&5E.006."#0!\6?^2A:W_P!=$_| 125P?*
QF_Y+#XT_Z_S_Z+2N\^+/\ MR4+6_P#KHG_HI%XS?*EA\;]?]Y_P#1:5^;<*_[_F^:/ VZ9>D\4 [AE_| M-_P^23^$/\ I%V__HL5V=?-&L_M;?*
*#3]FOX,^#!&>OQV[_)!%N M\.EVP\VZE'EC!"#D#W-?-'B'_@MEX1MKYX|(\ ;M>6RGB:XN(XRWX5^DGYL? MI=17P!\-/^"Q_P *O%=]!:>)=:'U;PD9&V_:956>%3ZDKR!*
*[U!R^#_&>A^/\ MP_;:YX=U2UUC2;I=\-W:2!TCP^59 MVT=O&>H08S]:N45DJ5-2YU%7[VU-75J./(Y.W;^@5YU\9-;GL-,M+&!5&+IF M.C+P2JXX_$G]*I%KD_B+X1?*
Q5I"W(%Y;,7B!Z,".5_'C\]XLRA5J82I&C\5 MO^'_.W+ITJ>+IRK?"G_P -^)\P:IXXL]+OVM3&\Q0XD9.BGTIZ]^-#'BP> M5=P2SYTX6_VM'8\(0#] OUKUBU^-'*
MUWX)^&<AR\+)W2(/DY^!Q7Y;D[S"CBJE:<&HP3>OUS\]0S=9?6PM.C M";_;7Y'2:C\;DCNRH\P1-@4X#RMM+>^*ZOP?XYL_%'T;JBF"[C&7A<(X M1ZBOD?
*QEXIO=/U/I):OY*H]LS8R6)Y_*O2/@1K%UK&O:9/C$H>2.4J,&4*< MG^7XUZN7\1UJV/6'F[W=K6\[:>AY>8<.4:. >(@K65[W\KZ^ITWQCU:63Q6(]*
MQ{Y6VM(58+VR1N9O\^E>+6_Q%BFU!8WMBELS;1)NY'N17TS\3/AZ_BA1>684 MW0C\J2)C@2+]?7DUX5IG[.>N2ZPBO"Z6JOG]X,<>A-<6>X+,WC;X>#DI/>U]
*M.GW:;D6-RU8*Y(DDXK;;7K]^YJE\+W'B+P:=Z,J"?:,9':#,_(9"H./PS_*.MN4\?>#/8Z9J67N A72]3'3GJ.1WKU3PEX.B\+:.'9(WF/DO)O#Q%N>Y ^;%,1^BMM*
*<]X#^('AWXG>&;/Q#X7U>UUK1[M=T5 MU:2!U\I?0CT-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%(3@9- "T5\K_ !_X*0?!JX#:G-*
*H]SJTGB/786*RV&C 2^4P MZAW^ZH]^,9_^"W/AU;QA%,-3;U!X9KN,.1],E 'ZL*%B9C\VT?*#GUKD_$SK*NHNC! MT9Y&5E.006."#0!\6?^2A:W_P!=$_| 125P?*
QF_Y+#XT_Z_S_Z+2N\^+/\ MR4+6_P#KHG_HI%XS?*EA\;]?]Y_P#1:5^;<*_[_F^:/ VZ9>D\4 [AE_| M-_P^23^$/\ I%V__HL5V=?-&L_M;?*
*#3]FOX,^#!&>OQV[_)!%N M\.EVP\VZE'EC!"#D#W-?-'B'_@MEX1MKYX|(\ ;M>6RGB:XN(XRWX5^DGYL? MI=17P!\-/^"Q_P *O%=]!:>)=:'U;PD9&V_:956>%3ZDKR!*
*[U!R^#_&>A^/\ MP_;:YX=U2UUC2;I=\-W:2!TCP^59 MVT=O&>H08SJ

*#3X5^&_@_X<;3="M/(5OWMY?3G?<7;}6D MFD/+$\GT':O0C3ITf}=='7;VC^K\NRW?D="C&"O/5]O\`,|VE^#OQ_^**-}_%M7Q_<:9IK#*
{^QMKV:U\)VDS0VMC"Y5)PIQYLF/O$XR>`,5XJH M"C &!Z#BG+$5IKEYK+LM%^'ZG[!EO TJU&-3'UG%O7ECQ96]6{Z\||/F?IOX<_
M,.^"FLW"65CKVBVCL=}=:?]E0^P9XPOZUWNL?#3P3XPLQ,:7A?0=6MIEW*\ MEA"X93T(8#D>X-?D9U&.U?07[*W1VH?##Q+9^!]7NY+CPA?2B)HI6+?8G8X
M$D>>BY`\00CGK7-[T7S1;N99OP(L/0E7RZI*3CKRRM=^C26OE;77N5-]^R9X M>T6Y%4/AYKFM_#35NJMHMVSVC'T>W",ZG@DAFC2:&12COR*&5U/4$'@
MCVK=8N4_=KKG7GO\GO\`?=>1^1]JW14U_/[S6T#Q!IOBG2+75=(OH-2TZZ02 M0W5LX>.13W!%:%?*FO>#M;_9AUBZ\9_#VWEOO \K^=KO@U"6$2_Q7-I_=(') M0<8%?
1_@OQGI'Q!\,:?K^A7B7VEWT8EAF0]NX({$'@CL16=;BH}5*;O!]>WD M_/_/H3.%ES1U1N4445R&04444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110
5X[\5OVD=*:\":ROA?0-.NO&OCJ9?:N> M^+_Q:U_Q=XPD^%WPSG2+7?+#ZUX@8;X='@/IZS$=[VKJ?A5\(/#WPAT5[/1H M&E0:D^9?ZKe:'?=7TG=Y^/)R?
X>@KOC2IT{J==7;VC^K{+RW?D="C&"YI_=_F M>>>GX3_$WXM_Z3\2_'$_A_3).?^$6\&R&! O]V:Z^\Y]<<5I3_L{>!OASX9OK M[PE\/]$U+7((_-
C;5XC=RS$_A=XVL++Q'##=P6TGAWQ$Y.3Y9K:,&QNAQ):/\O ST_#WKV#7/AIX M1\2PM#]WA?1=1C;@KO2*+UHOSIUY_RS MNE!]GK^/K78> OBK'U"W5M|\?
F2W<7|$|8S|P88)KUL M71]M",*PO7?\OO6S^3ZGLXN@J|(XG#==U^'X;/Y/J8VH?LD^%=-N7U#P'J>L M_#75^]S>'[QQ;D_[=NY*L/;BHH?C1\2/@:R1?
%+2(O%7A93L_P"$Q\.0G?"._MS75MU7W9>/K7?^$_C-X0\92BWLM7CMK_*-8?X^SSJ?3:^_@37:21K<&R.H M='!5E89#_]01W%>=.M6IOV>,A^\ Q:,)[_FO(\JH[6D^3$1?
SW^_^D7_OX MJTCQKH=KK&AZA;ZHETN^&YMG#(P_H?8\BM:OEGQ1\/M:_9[UN[\=?#&!IM MD;SM>\&1D^5,G\4]L/X) ,G:.#^E?0?P'\?Z+\3O"5AXBT&
/6[TZ\3'*YJU%1BJM)W@_O3[/^M3"<$ES1U1T=%%%BLR>Z)}YAZY!?M'QN^(B?"GX4^)O%+ -)I[FP(>=\Q^6)<= M\NRBN)_9V^'DGPW^%6DV=|S3:[J .JZO(Z[1
M]>K^2_%WZ'1#W(NIUV1Z2B+&BHBJB* JJHP\X [#M3J*\\YPHHHH_^>_ MVR;8_P#")^\+T#F#4'7/IF,G_P!EK,O+G[/^UCX6O1#[# Z%7W.7 O.
M%\"/E5C]Z3/M#_&@_|"K/C#X_^*%M^YLY[A?#6OD<*]M.?W,C? M[D@Z_2O0P[/M%X=]=8^O_!6GK8Z*?OITW\O7_@GTW12"EKSSG"BBB@ HHHH M**** "BBB@ HHHH
**** "BBB@ HHHH QO&/BS3O OA?5-?U:<6VG:=,O<3R M'LJC)QZGL!7@?P *ZCXOU2^^,'B^%U\1^(S*Z59R_|,,+TW/[N-1V9Q\S'W M|S4_[3DK_$;QUX#^$L,K+9:M<-
JVMB,X/&WPVP^SO@?A7M,<.11HD:'-_% M5%& H P /8#BO0;1A02^Q3_}D]?-[^27G2?8+'5$'LXX8_C57X7Q20>/OAO'^CQNO@^3 MO4^CCF/+]8:K%1U5NOJUNK M-
:);/7J<%\&-,M]-\)/[EM_$%C#)<-BP\12%YK8@-%4)_@]#WKO:.M%?.5JK MK5)5'U/GJU1UJDJCZGA_{0'A#4O#>H6'Q:\'O-_PE/AQ/].M8AQJFGYS+"X{ ME1EE/48^F>
[^"/&.F_$#PEI7B+1YQ<:,|5NMQ"_?!^0^X.0?<&JSHLJ,C]'1 MA@J1D$>E>+?LURM\,/B/X^^%,C$;?9S+KNB*W:TG/SQCV2C\374G[>@'T_BA MM_A[?)
[>K*_B4[/>/Y"T=1117GG.%%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 5X[^TK\4-1\#^&+'0O#*^?XU\33C3<)B SL9OOS'_ &47GZXK MV$G S7S-\/<_%C]H?
QGXXN"9=+\,$^'=%4_=$N,W,H][_+FNW#1C=U9JZBK^_MKZ+[_P +FU)*{D]D>B?"3X7Z=\)/!=KH=BQN9\F> ^OY.9+RY;F25SU.3G'H*_MT/B/UF7?#/&T;J>ZD8/\ZY9
MSE4DY5=VQTZG+5C4GK9IGXS1G,:.$]2HIU=Q\90A9J/PA\>ZAH-[$XMP[2V-P M1\E\!/RL#Z@<$=B*X>MUJ?V!0KT\32C6I.\9*Z?DPHR1R."**[X, #N_P#'_M&HM.
/(CT2R=#?:A(C^1 ">%=U!VNF>VGAJ;U^?:*[T_M^$6H7&K?"SPC>7>?M;VEV!2%NI.P#/Z"NMKD/AQXQTOQ'!$=C9P?V9>:=#'# M-I4C O H4!2I'#OD
,?"!KK\URU*M+7FO[.OQ$D^)WPAT#6;HXU,1&TOT/5;F(|), ^Y(S^->E5SU(.E-PENM# M.47%N+Z!11169(4444 %%%% !1110 4444 %%%% !1110 4444 %>3_M&_%:
MZ^&G@N.#1(_M7BS6YOINCVH&2Tl\;R/11ECI*]7-?-'AYC\7/VG/$/B&=C-H MG@>{.5]J=4-Y(,S2'?4#BNS#0BY.I-7C%7[>R^;_ VD?4455U)RJRU?
14ZGL,#STG.6GYM;>GWH^@IU-M/88+FI.TM%V:V]/O.5\2_#OQE)LAU_1-"^)VG@@"Y*BQU*,>N\8!/XU[=I=E M%INFVEK!$8(88EC2)G+E
!T+'KCIFK5%>57Q<\1&,9)*W;1?=LODD>77Q4\1 M&,9)*W;1?=LODD%/KG_(9F^,UOJ-N6A^''7C2Y\F]@_=:=+]+?=E'\U9.A] MZ^@JY'XL^ K;XF?#W6_#MRO-W
WDOWCE',CW# 5.&JJ$^6?PRT?^?]MT84Y M*+M+9[GJ .1D4M>3_LP^/KGQ_P#"'2IM2/\ Q.M-9]+\U 'KY\)V$GZ@ _C7K M%8U:,I3E3ENB)1<).+Z!11161(4444 %%%%
!1110 4444 %%%% !1110 44 M44 %%%% 'SQ^UV/^$BG^%O@GK%XA\5VWVA/[T$,K@^V0M>RLVYB0, G./2O M'/CJ3)^TG\!HG_U2SZM(/]\6RXKV$=!?=7THT8^3?
WR,`1&\!07K^2_:, M**K3;E9V\XAENI>*8](WE56/X$&YKA,"S6QXY\8GN8H2N7YS#:QY6,'#2N M>%0>Y.\6I?5+]1&I2N?C=\6M+`;3,PTC392]/&QZ. PRQ-
:TW:$=9/R7^>QJ>/O&US\2_V9-3UW4M.CTB62-MX3R8ED++*%F4!D))YY^8?\!-><>-;HVG@7X+ZZ^X1VL;Q/)M/'ES*W\E)_"NK M^)9_X6K\2-#^&'AS_1_#VB86Z>+
IJ;!AS[!%^4>K,:]\\1_#K0_$O@K_(1; MXM!'1:0K% L8 :W*C".AI,/UYSUKZ18JEE\:2E&RE)SY?Y8R7*OG;4~B6)I9 M?&DI1LI2 [F-1+#"JE9&8DY+X MR"5QL.
<9!!KUWPUXDT_Q=H=GJ^EW N;&Z3?&XZCU5AV8'@CUKYK\#ZU+\+==- MO_A9\0$2ZL\W^4M;]7/E*\#" GHC' OA^?6ZT4-2_9<^(3:5[.DM[X'U9]\ M4Y&=G;>/[M>
P_B&".U<]?+H5::HTTN=*\6MJD?_))&%?+X5*:HT[^4KTN.19HTDC8/&Z MAE8="",@C*R/&D:3>#M?CDQY;.?F>*[ZV*?
#_P_K6@lL^S7'U[KGV>63*@MNCVG&&R/PKHJ4,;$ M3!Q:5F]VEU\S24+U)170]EIHKYZ_X3[HW_HE7A7_,*7_P"PH_X3[HW_HE7 MA7_PI?\ [*G]3G_-'_P*/^8>Q?=?
>CZ%HKYZ_P"$^ :_ P"B5>%?_"E_^PH_ MX3[HW_HE7A7_P *7-]CZG/^;/_(%'_/8ONOO1!T5\|^?\}^'T; T2KPK M_P"%+_\ 84?\Y_P T?
H_P"8>Q?=?>CZ%HKY MZ_X3[}HW_HE7A7_PI?\ ["C_ (3[}HW_*)5X5_|*?_["CZG/^;/_@4?\P]B M^Z^']+T+17SU_PGW[1O\ T2KPK_X4Q_V%'_"??M&_]$[*_| A2__ &%'U.?|
MT?\ P*/^8>Q?=?>CZ%HKYZ_X3[}HW_HE7A7_,*7_P"PH_X3[HW_HE7A7_P M1?\ ["CZG/\ FC_X%'_,/8ONOO1[*TTR*KJA8!FY)Y-?/G_GW[1O_ $2K MPK_X4O|
]A7A'[2_C3XNZ9]A'Q+JWA;2/"7BNQO1#H\^C^(&NIFY+DI%I2N/LN MW$]MQGCCUYQ6U'+YU9]/;"7^G^I<,XRM=?>C\!#P*P?2 6I;YJ_@W1[WO+ MID6C:l/;
(]Y8PR^8L,A*AOZ=NF3C-,QZ&O,DN5M,YFK.Q\W> ?^*]_:I^*F MO.?,CT2SL=!MB>=FX>=)C\:JOKP[!G+]YXW^-LK_.M;Q*+NYU+2[R.UNIQF6*=249L8W CD&O%?BGH-
[H6NVC3(5MGLX(]>1,[8XP MK(#ZA@3CKSGO7S>?9I5RC"QQ%*-[R3\E_6G[_D?4\.9?2S'"*G6E9)*8)$$=Z7 6-6VA]I&XL]@A M0
>*U"_:D^(GA[Q#WM7G9'Q#4SO$U(*ERPBDT[WU[-^?3T9]'QECO&@X8R-HRF[$O"]EX+\. M6&BZ>K"TM(]BESEF.OM3\S"O#OB.?\ A%?VG_A)XAC&U=66\]T"'Y
M(_B#0)YD>?HPKW&O#_P!$^7XH^#4R?ZY/&5]%QUP5;-=V"UK(=-*W]SX5TNUUG7HT!M;*\N/L\4K9'#28.WC-<<5S- M(Q2N!&_17ST?'WI1N?\ DE7A;_PI?_L*/^$^_:-
_Z)5X5_\"E_^PKL^IS_F MC_X%'_V]B^Z^']'T+17SU_PGW[1O_1*O"O\ X4O_-A1_P)\^T;_P!$]*_M^%+_ /84_J<_YH_^!1_S#V+[K[T?0M%?/7_"??M&_P#1*O"O_A2__84?
\)]^ MT;_T2KPK_P"%+_| 84?4Y_S1_P# H_YA[%]U!Z/H6BOGK_A/OVC?^B5>%?\ MPI?_+"C_A/OVC?^B5>%?_"E_P#L*/[<_P":/_@4?\P]B^Z^']'T+17SU_P)
M]^T;_P!$]*_^%+_ /84?\)]^T;_-$]*_^%+_]A1]3G_-'_P "C_F'L7W7 MWH^A;*^>O^$^;-_Z)5X5_|"E_^PH_X3[HW_HE7A7_,*7_P"PH^IS_FC_M_:1_P
P]B^ZZ^]'T+17SU_PGW[1O_1*O"O\ X4O_-A3)O\?[14L+D)*O"I MC92&SXE(X[_P4?4Y_P T?_H_P"8>Q?=?>CZ&2195W(P8=,@YIU?%'[&_BGQ
MY9_%7Q3X3ATFVD\#6T[RW*V^IF]M](N&^8Q0W!'IS+9S'VY.>#G[7J,5AGA:_MGLV[]?O%5I^RERW,/QSK:^&_!NMZJV MG9RSDG_90G^E>-?LG:*VD?',PU<2
MC_2I5$NJW#'JSS2%LG\,5W/[2$KP_?QX\?WQH]SC_OV:I?!>-(2A#X*2/[B MZ-:X_P"_8JEIA'YR7X)_YCVI>K.RHHHSCXI_&2V^&FM>&],>S:J,4[E1=2#? MMLI;
<%:9BJD#YF4 -@'GGBN$P+?Q"^%WAOXQVT^F^)+ 7EI;_)!+&^R6&5AE MG1P<@@8X(QSWKY:\7_|'//6(;MW\+>*K*[M"?EAU>)HI5'H?0,K?7 KW?0? MVCIM>O?
[,MO#MO=ZM/.8[**VU>,0.@:8?O960>5)B%F\O#$Y&.]=SX4^(EQX MLU.2W@\,ZC!902&VN-2;>W>&&Y"!VB(5]S ;@-X&TD|>M4I-,'T66\09CE*Y
M,+4M'L]5>SV^5CYC^'__ 3W>,\CN/&OB2*6W4Y-AHRL"_LTK@8'^ZN?>OK7 MPQX+T/P9X>BT+1=+MM/TF-2HM8TRK9ZE1<L3W)R36U4=S M1SA5 [DT.39EF6=X_
-FOK=2Z6R6B7R7YO4*\?| P^D^']Y:IK.@74EM8VY:2 M*.!@;G3NIF%2?WMOW>$]!RN*L3V?C_4774UM]=W*+()/#_B*W-LX*C#1P3Q M_(",;D]:Z+QY<6/C6#1-0T.1=8?
3]06.>*T!=Q!*#')\N,XPV<],*Z7X7VU M_8>!M-L-2@E@N[$/9D2C!9(W*HP]BH4@U[IQ;6&C5DE*6VN_7LU?_@|MV\6 MUAXU9)2EMKOU[/7_(/>[>KX5-
XWAZP_M!;Q;WR\2C4#&9[V3]_R_DS_+M:_MM%%>!*7-)RM:YX.GS27^M?9I2YSN&S:>!QS7+_\)^T;_T2KPK_M_%+_P#85,<+*45)CQ2N&_'E_F)4FU>Z^']'T+17SU_P
)]^T;_P!$]*_^%+_ M_/84?\)]^T;_-$]*_^%+_]A5_4Y_S1_P# H_YC]B^Z^']'T+17SU_PGW[1O_M_1*O"O\ X4O_-A1_P)]^T;_P!$]*_^%+_ /84?4Y_S1_\"C_F'L7W7WH^
MA;*^>O\ A/OVC?\ HE7A7_PI?_L*/^$^_:-_Z)5X5_|"E_^PH^IS_FC_P"! M1_S#V+[KIT?0M%?/7_"??M&_]$[*_| A2__ &%'_"??M&_]$[*_P#A2_| MV%'U.?|-'_P*/|
F'L7W7WH^A;*^>O^$^;-_Z)5X5_|*7_.PH_P"$^_:-M_P"B5>%?_"E_^PH^IS_FC_X%'_,/8ONOO1[*T5\|?\}^'T;_-$]*_^%+_]MA1_PGW[1O_1*O"O_(4O_P!A1]3G_-'_
,"C_F'L7W7WH^@RZ]0"0"> ">M. MKX4_:<6?%^<%M-UGQ-X1T3PC>Z7>)-I>1:9XF/2Y%P3@(D 7]6'&W*0U]; M?!S7/%/B/X<:.+]'C/2H]\0S0!KBVC/;T8C^
D<=*=;!RHTHU7),!MHT_MR;N.=%P@IW.E\0ZBFD:%[%\[;%M]>24MZ;5)KP3]D;3FC^#5KK$PS=Z_?76K M3/W8R2G;^@KU;XTR/%\)O%S1]=+N"/^^#7%?LXQI%\!O
:I]W^R8C^)SFIC MIA)/O)?@F):4GZGH]%%%<)@%>8?%+XJW?A/4$TS2XHC<[!)+/.NX*#T 7U^M M>GUYY\2?A3_PFEW?2V5U':WRIY;K,I*2*.G(Y!H \Q^('Q.|>;U\-+VP|/WE
MM9>+[K9)9BT80W,D&[|YLW';K$9V\@G!O6/H/Q:^)?A;X46=K]MW9W_C&U,D MUXM_^_NXK7C;NVG85CDD$[@,5B?%K0+S0/&4]M>]"#%$8F",@0#Y?8$&JWP MST"
[!0^,+*RLD!)W&0D?*B8,2V.U?E\N+<4L>|\"J*_B1^Q1R M'#/(M9+X?:_+MS?R]+6OYGJGP$_:!U'XA:W)H6O06XO6C;MO\UXQ\$_V>_^%9:I-
K&I7\5_J;1F*%+92(H5/4Y;DG''05|/7Z@? MCH49QS110!XO\,^%_CO\7/"R#9;33V^M0)V'FKA\?C7T77SKX/_'7[9GB8 M)]V7PM;M)CU$W%?15=V,UG&7>,?
R1O6UDGY+\@HHHKA, HHHH ***** "BBB@ M HHHH *****"BBB@@ HHHH ****/GC[!)SH7Q"^"/BA_EMK'QA 8)GJ[*MS$ MA4Y/U45[)@2#U%
<1^U/X!N/B)\$/$=AIZEM8MUU+3ROWA<0.)4QIG:5_&K MGP]\>6WQ.^'/A[Q1:L"NIV:32+W27&V5#[APPKNJ>_A]] M3B^YGZ_YD7Q5\3W'A7PA-<6C;+N>1;>*0?|
+,MDEA[@ X]Z^8+Z]5&>>YD+ MNQRSR'0?K7S-?6-[X!BG MU"]MQ%KY^W>+M7?R8+IHBHYR0PSG('S.3GDX%>37$CWS'U\)/)KJ_
_B0Q7$.B:B(.S1[]0^D5Y$)HI6<\1SHIZ;6(R!@_M,@\U\;E'B#!8E8?%4,49M7VU[O1Z7TV[V/T^7"!=3!8>4J=7G6CE&UN;EULG=_= MU\CV?]FKX;MX-|
('6=01O[;UH">5I/OQPGE%/N<[S[D>E>PU\?|AK]K#QAH M6K36GB.QL=2CMNIMG[B&"+R)$9&*ML8$CJ#C(KZK*^)}/\9:!9ZSIA5AV8'((K]*Q.
(GB]T]U3=_P!6^1^5XG$3Q565:>[_*M\CFOB_P#" MNQ^*OAE[*79!]<&9+*\(_P!6_P#=;U1NA'T/:N8^#GA_7-<\%3>'_B-X>2XC MTFY6.R?
44$AE50<$>H7H!@X\5[#16T;,5CA_]_2]T^L7Y\S-HXRI&A!7Z7N MGUB_+U$ "@ #@ =]X?XY^(4*_]KQKJLC;1;Z1$_M M02MXRD\%?"YSZ1:76MZ8KI97TL8,L ?
&X*>V<5N452DXZIC3:V"D/(-+14B/ MFSX0#_A'_P!H7XV>'W^5KBZLM:A!_B22+8Q'_A7N%>)?& #X9_M) ^ O&S?N
MM(\0P2>%|2EQA4D8[!9F/^]D5!:00<$8(ZBN|%^\X5?YHK|TK\ (W]ZVEW7 MY.!1117"8 1D8->#_$N>>R^+6EV$ MM>\5X-\5?^2T^&_^NEI_Z,-1.,9Q<9*Z9<)2A)2B[-
'BGBK7M0\)-HLZZ M;=#76L36DEWFQK(B0B2$%DY[K@^]?82P|MUM_WA|+WT^W))ZDF-%%M|%$#W%OK\K.D\HC!5HR.@ZEJ*^N/#NFOHWA[2]/D=9)+2UB@9
MUZ$]@!{]N^^56NG^;/HN(Y2EFM;F=[-?DC0HHHKZ8^:"O$/C-G7 MOCO\$_#\?S/'JEQK$]CG"01"!/XFO;Z\1^% 'Q-.;\:>,%/G:1X6M$\.6$H
M^ZUPQWW+*>^.%KNPGNN=5[1J^]Z+\6;TM&Y=E_P#Z0'2EHHKA, HHHH ***** M "BBB@ HHHH ***** "BBB@]KHLJ,C@,K#!!Z$4ZB@#**^#]$\#Z2-,T#2[M72-
/$CR_9[2,(F]CEFP.Y)K8HHIMN3NWJ-MO5G*?%?1&\2?#3Q1I:+N>\TV> M$#W*$5YO^S%K@U_X!>"+C.9(M/6TE'IR7;7] M#W.FO$DJ.KHKJPVLK**&'H<]13J*X3
YZX*^&];M;W2;SP_IDU!YJS2VDMG M$8Y&/W92H&,]>3SP:=8+/6EZZ-:L]+LK35\&(1'[V[MKB)G MFU.QC;2&W.<*7XX!Y)Y\]Z .RK\?^O^$I\.?NF><;E<7X MH^)-
O))\?76';]-T;B<^6G[YNI_&C8-SS7 MQI]&IZ?)]WA_3-9NO#;1NL1U'2U_?N48,Q+9#%6QT# 8Z\UZC\-/CCK6I?$ M:S\)ZC"'?VD]M'Y5V4VW*,
(@2TF#ALX))P.M<5HQL=6^(>D65Q#;S6(VR7,] MQ%YA6W3Y4^A=LG/]W%?3&E^"] T;5;C5-/T>RM-0N1^]NH(@'N]^]\ MS;'-%%8/COQ=9^_!VL>(+^01VNG6KSL2>I X
]R<"OJHQL!U-"FL>(K MB76[P,,,&G,,:=9L;*R>6_0UK-,2Z;?=H%%%%<1B%%%% !1 M110 4444 %VN>#=#\2ZAI=]JNE6E_>;7-]HLIKB(.UO)
MC&Y">AP:V;**;;;2;V'=LQ/&^DC7?!^M:>2^7FSEB_-"*\8_9.U3^T?@'X9A M;_7ZVI]K1117"8!1110!X'\4)/MGC'7K& MX1+BU6Q:9(Y4#>7(L9(9#U4(=NO>N3^%6]W-
M\6_"VE0.MO8/8_;)(8D"^;(M5?YG(Y;IQDX%=5\2/^2@Z_\]@R3_P!%&]WPK^&6LR^./"_B\'W&BI@0MYO M[S?\XV!?QZU\VZ5/^VU/E5_9O6WJY+\M#Z15:G]BN',
[>T6E_P"ZW^>]#CI M1117TA\V%'6BLOQ1XAM/"?A54M:OY5ALI"W>XE=C@ *":;3D[(:5]$>6?!\
M\)!^U%\4M83+0:=9V>DANV_[["OHJO"_V0/#MU;_#2Y\3ZE&T>]>+++^;6)@W M4(YQ$I^B@?G7NE=F,.]LXK[*2^Y6_,UK?'9=-/N"BBBN(Q"BBB@ HHHH ***_M* "BBB@
HHHH ***** "BBB@ HHHH 0C(Q7R]X-'_ SS\<-2\!?A$'@WQE<2 M:MX;G;B.WO#@W%EGH-QPRCZ>M?45<\9/A)I/QG\$7?A_5&>Y,MG_ %%-,U/P#XIMVM?B/
M8PI+:_C7%MJ!L?E%W&W!X#[R]<\^H'#V,VBZ'IVM.Y>0M1SP1W4,D_J M+)$ZE61ADS']#6[]Z,U.UUU7=/=%PER2N<=X;\1Z=XNT"PUK2;I+S3;Z%9X
M)T.0RD?S%0CL0:TJ^=:,Z"]_8_P#%5Q*8!HSX:.Q<&4MSAD?PJ3@<^0Q_+ M^?T%IVHVNKV@>V-S%>6=Q&)8;B!@R2(C*1U%77H^SM.&L'L_T?FNO^14X<
MNJV98KGO'U^]AX7NC&Q@#28C!',)P?TKH:Q/&>EOJ_AVZ@C&Z4 2(/4CG%)5!=Z6]ZBO%Y@D+>29%Y$*-]!SZ?*"'|D5/T]OK17/B*/UBE*E>U!-W7\#
MHPI;ZO5C5M>VNO?^)'!UG;7D%0;6J6[5!58]2]C"@_0 5!?X#OGO_Q: M-(=SQYBR>X'3]*\7),.FO;O!VF/!'AVT@D&V4@R.#\V+MQ<-T4 L?@YX0_LZ.=M1U M>\D-
W]NJSWG\3^%?^W?+IW?H;Q7LESO?I_G_D M>@0Q)!$D<;+'&@"]JC 4#H_*?117G'.%%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110
5X'^U#X.U.Q70_B=X9@,WB'PE(9I;9!S>63?ZZ+CKQR/17 MOE-DC65&1U#*PP01D$5O1]NC-36OZK]OF7"7)*YPG@SQ?I?CWPOINOZ-<+X(!>U8X]PPD55C MK&6W^3[-
=?O1V4\+*M+W'IO^:NIM;GXGL-,RK2&>4?\ +,$;B//B/]>GKFISX@7-MKDBUL8XQV;9BQ_(8]+-S%)*L/L7TKXVMC<752?NOE7E_F?0T<%A*2]Y;RX-MKVRQ'M'=1Y?/=,[56P?
*\%[/KS^75?>;FG^/89B%N[62V(\ ?0[U_P :Z6VN MH;R(202++A_B4YKA?[,7TJ:TAEL)1) [1M[=#];IO#YA7@[5ES+[G_D>3B,O
MH35Z+Y7]Z_S.YKP+XI7U4@K"3_>N#UKN_@3\&H/A%X:F6 MZNCJWB?5)3>:,OJTGW[F<]<>B+T K(;#M4J:Q3W?PK]?1=.[/#Y'AVW/?I_F> MBV5G#!JG!:\V];PV*+''&O15
P /#\4]%%<)!1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110!Q^Q8^#WASXR>'UTS7[5C)_FV>H6S M>7=64O:2*0A[KY+\:^|_'GPBU?
3Y/%VCS>./!.DP[(-7\/6W[X1H6< M+=6P.5+N?GE3(.2<=]^ZZ0@&LL10H8VBVL/BX<\$T[?:U79K\M4^J9Z."Q\]? M3]H1=G9KY/>W8_/C]G#2[7XS?
%,76M2OI?4!%*YIW:+*N9IBV4C"9S@''&. M@%?_V5#?R>*?$KG;#H/AQ/MMU(WH=F53ZL>/2N:M/A+X^_:)NC;OXH M'_A#_
RN)8O\&G3DW%WCE3>SCM_TS7]*]P\\?";P;=|+{+|+X4\-Z=H<9&&:T M@ D?_>_,WXDUUM5[>G1_P!WCK_|_DME^++Q^TC#^&M>[_3L4M&T:Q\/:5:MZ;IEI#8V%K&
(H+:W0)'&@Z =]5VBBN!MMW9SA1112 ***** "BBB@ HHHH * M**** "BBB@ HHHH *****"BBB@ HHHH _^+?[~,7B77)?%W@E_C*^~&&)Y&
MCW66I*/X+F,=3Z2+|PJZ\4O?'UWX'OTTOXBZ+/X*U!FV1WDY,NFW1]8KD#;_M_P!U\&OMZ[>JZ18ZV8RV6HV=O?VQ"%2!L$$'D5VFN?L8_#J M]NY+O0H]5\$W;G)D\|
:@IJA/_7(IH_|QVL"7]DCQ1;L1I_QDUQ(OX5U#2[6 MY8?5L+FCV5"7PU+>J?Z7#E@H?>O\KC_!+XC;Q%;R-!';^3 L6(U W$=3Q
M_+W6=7,5E/M<7,J6\"#+2S,$0#W)XK8C_9(\4W# :AJ>,>+NMAI=K>_9U\MAL5T&B?L8?#NTXHO?DU;QM=H00_BJ34'N8P?7RAMC_-:/94(_%4OZ)_KRARP
M6\ON7^=CQ>T^(-QXUU%!)^'FC7'C;4U;8]Q;9CTZV/K-U?"7]F MF/P]KL'B_P <7T7BGQE&/]&V1E;'3 ?X;:_Q>LC?,?:O:=)T>PT&PBLM-LK M?3[*(8CM[6)8XT'H%4

*"KE#KJ"<;*LGN]V_GT7!\[@Y!*T%;\PHHHKC,0HHH MH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH KZA[]KJUE/-M9WMO%=6DZ&.6"9 R.I&""#P0:^;M2^"OC;X"WUQJGPCDCUSPM*YFNO FIRD* MA/4V" ^"/VG/!GBK43H MNK33^"?%,9VRZ%XE3[),&_V&;",/<'!*],4[XUD7YHV&0Z\J?H>E1>.?AAX3 M^)>GFR\4>'M/URWQ@"\@5V3_ `6^\OX$5Y$_[&6@Z(IR>"O&?C+P*2"K MM);K_P!LY0WY9K;V%J;IN#|\5]^_X/U+M2EL[?B=7XH^';6]3O=:.?*EM.YR\ M3_<8^HQT-/BA" D'10/B 1=.3Z/:R/C_> MI#^RKXAULI/$WQL\<:O;'!\%E-%8(PM/R:DT>PHK>LONE_DOS#DA_.OQ_P B M;4CSRSD\'H!JOC?Q+INGRQ_-';32C<3_LQC+N?H*YX?$#XC_'IC9? #G2+CP5X M5ERLOC+7X"D\J=S:6YYR>S-^E>C^_V5OAE\/;U;^P|,PW^K Y_M/6':]N2? M7?*3@_0"O6@H4 8 I]I0HZTX\S[RV_\[U_%M>0H(/45\W:J\[/%'P>U&ZUKX1/(?:).YFO/ ^HR%868] M6M)?^-63'^Z?EKZ7HK6%1Q3BU>+W3V?\ 7=;KH;4]LZ3O%GS1X5_;(\):O]0T M37S<>!O%"_+)HWB1/LTFI_8D/R2#T(/->]PI-&LD>'C89#H#?%/B[P(Y.5A MT?5W:W7_ +9R;ACYS7+/ 8.KK"3@^S7.OOT?X/U/4AC8OXM#K/%FD7<'KV MVL7V73H=G3YCZ'ZU/X=TJ:RT6RM[ES-(_C9XUU.W/WH;!H;!6'IE%)K^'R:5]:\?N ME_|(K\R/:T55]OS:VMUVW.H\8^.?"_P^L6N_$FN6&BP@9_TN=59O94^\Q|@ M*\VMO'GCCXW/|C^&.A3:'H3G;)XS\0VYBC"]S;6Y^:1O0G KTOP/^R;\,? M M\NH0>'4U?5E.?[2UR5KZXSZAI"0#] *]>5%10[@*H& .@KJIX,"8=WBG.7> M6B_\!UO\W;R%4QW2"^\\Z^#WP,T#X/6-RUD9M4UZ_/F:CKM^=]U>/W+_"N> MBC@5Z/116DYRJ2YIN[/+E)S?-)ZA1114$A1110 4444 %%%% !1110 4444 M%%8WC/(.YK;P"Y;3;&>\$);;YGEQL^W.#C.W<$+5IZ;_^V9J.F'!GX=>`M-;+P6NH7_B^1>RCTI\KY;AF50K[/F+%0.@ZUU4<+5KZTU6W3>S?>I-?"NE>/ M/A[+X/TKQ>,Z%J8NO-64G!7?I48W97G@:_IQ@YKI/%[3&N>&/CYH'@&Z\!W M%MHVM7HLK/7;NZ":?:-]@R/'$%.54D 9(SG:RP&(C+DMK9O=;+?KK;MN:.A4 M3M.S/I"BD!XS7.WGQ();?&9+KQ/HUM&)C;EI=0B4>8.J9+?>'<=.X5&4OA5 MS!)O8Z.BH'OK..R-XUQ$MH(_-.YQNXYA'_0%2._#>J.N^E67B#2[O5(R0IE!>QO.I'7*!L\?2 MM:E"I2GD5I_4]4)1=FC=HK%U/QIXT6:XBU#?-.L9;>,2S1W-W'&T:'HS D Ms Y')K5_ ..WQZLOA3\(:KQMH#:=XA :.;2$7]K'=:1 K;'7.[ )/.0T]=& MI5E&$5]W9!&$!+)+ <]:HKP/0?VF_]8^,VD^$WMM-AT.[\,KKTNK"\R(F_B3/ MW-JG()}5[:VOZ8ND?VJ=1M:I>SS/MIG3R=G\[?G;CWS3]T*E%I36XY0E"UT M7Z*$[G6(?[#EU.SEBO(! T\4D;ADD 4D$,,."#ZBO(_@'^TEIOQ/^',FZ_P") M+K1O#&I7UU/;Q6#WZKY@1]H*^803GZ41HU)P'IUI.C-*+M> ^NFOD#@TD^YT=%4=4US3M$T MY]0U&_M;"Q0 M=7.RQQ*#T)9B!7DEU^T(D_]0/A/P'I$>G:MHFMZ5/]!U>VN MO.*M'O\ E7;E2/D&>=<\T4Z,ZM^5;)O{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|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{03TW5]-M?"#K&>$O@?I=Y9>%[*;)KV02W=W=SM//<,.A=VZXR>F.M>4?M.? K4/C)\6? MACYNB/JOA.TDN4UB1)UB\F-PF#]X-G(_ASTKGI8FG/'.M>RL];6^R]-O7YZ MLSA4C*OS[*S_ "/)=4\--^SC\>;?P=X0\3:MJ.@^(M!O9-0TN_O3#PW.#7->]QJ? PT_8UU#XI.5]^K7'C'6(ETK[=?#!M6FTNRO;N_U*V>TEO\ 4KQKBX2%AAD1C]W(]@9X MZUU?A;X(^$O"GPP'P_AT]WOA6 MVKQD;G!A+#(89()P.O/-=+\? M!U+P!>;SQEXWG\27/A%[BT^RZMX8U<)++H M9^7_,L', QSSQG.02>*^@O"'[$7PP\'>)K'6K>SU2^ET^7SK*T'4D]I:V?. M040^A]7EFKVUU:TNY(_+1;Q?UF'/= [6[:_F?./QKUCQ\8?YC]0\,C1->\8^`M-$L(),/0]%UM-,\P21HWVEV;F3._L,C Z9 M&:15WDZGH..E13S++#QA3C;,ENK=MVO>M=~^+,<1348]VUOZW_0\-^) P -9/V< M?"7P^^)/ABJU:],CWT=QKYN[V29KV*Y"B1W!,"_W &,-U$!?A#_PK46L\7A?[/\ 9C%'<,LI7=N) M,G7<6Y)KFI9C%13J*\K[_P!V[]>M_P #,.(22YM#[^5[GR1KOAB[^)_Q=^!O MABX\0:QIEAJ7@Y)+V33[V2*69!&6==V>K8P6.3S6?HGBGQ\#?"W[1'ASPWK M6H7%IX<>W&F/=S&:2T$K;7=2>A"MG/3*Q]B:?\ 3PIIGB_PMXD@BNQJ?AO M3? [*L&;Z8HL&TKAEZ,<'J;R-?^:]HH5O\0=:=\(Z?9WWBCQ3"/M-KK\CRV-P5 M&/+9 1M5AD<'OFMEF%*5J;5XV6CM:./?\M"UB(/W7MH||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`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|+%UIQ%IGX1NKJT:\OF.MN=C%0V#C>I&0W7F MQRT?XM?LQ^$/BUIFC03B\T"]T51'IVHZ-*0]9 @."'O X/IUKD_#/I$/@S MPUJ&HZ@NN>)+_4-2TZ;3[NYOKU)7E$@PTA)3.[!3G\M7-3QN&C"VRL_=Y5O> M]['FAE&M24>WE;\;GSKJ4'B7PY^RQX>|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| M1+73O"WA35Y[Y+&3/B"71A$EB./W3R-\R@^W!(KYX^\/Q%T3]G;P3X^^''C M_P $ZG>^+[V^NGC,6G&=-8248B_>8^!GG//#VRI]P,XT7M\7TTOKZGU_XY_:-\ ? #O1/#FLZQK]H]H_B G!]?VT3SPR *& M+%D!VC!ZFN)LOV[/A!>Z=]5U ;UU;O9,JBTGT^5+BXW \F/&7_H.3@5\US_M NUSPK\,/V:]!\4:?,T\OBF2XFT^:,O}FAED1ECD&#CCD@]-Q!{U[+<&K6 M7_@H?:W#::K1)X7,XE,'R"8$H&SC&[:<>N*OZEA(1=VY:2=TU]EV[/Y2.!;NXM'BM9[@J 564@+DMD=4G20>5]>, M=&FMOAA^TU;'IC-%%_PF%IY&4<# ;?M#<"NOZA0E#D47,F>MUHG&+UTU2 M^1M["7+;2^,;1/4]*T_XOW7A/X[_%AO$? CA;WPIX>TJ&I.A0Z9)OL%(0EPX M7YSR<@.Q.X<#;6QH'[;?PF\2>*.,T*SUZX^T:BR1P7$UC+';^.V (F=@ &R0 M/0$@$U\^_$7J[M?BE^TZ##/*6\(VZ+((F(D81Q XXY.1VIWQ4\,PV?!)/P'^ MR:88[E-6TV1_*MSYBLX9I"V!D9/)S6/U/#U.3GO>7*M+++[*=]M=2/8TY6YNM ME^%SZ:^*_P"U?\,O@WX@AT/QH]TQU9I$CVEA:ONB[JRNNYO5%[5.$G M[O9;?/]_G]R/G?\ 9_8M\+__-TS58;F_N//%5WJ,J/)-=)Y$2H@.Q1$K$'[MQ)+9]L5[/;_#SPM:8,/AS28R/XELH_GMKH;*K'9QCX\RKRQ.*K.4Y;ZV\ME9 M+Y(QI8>C1BH4XD\'A'C/JB_X;>.?BK8^/+^RNXM1MVBDDL:658[2Y>+'EM)' MMSQ@ A2 <#- >X+96Z#Y8(USZ(!4]%8XK,L9C84Z>)]RE&FK13=[+LOZ[=BH4 M:=)MPBDWJS$\8>"M"\?^':S0?$.EV^K:1=]%FM+A<>&G;5O@1^U!>6F@76 MA07U_:?%MI0.!40RZC*$?9_8UNK/F;3LK=+_ .8EAX.* M>O37U;OJQ!9^0%QVS_A7XR\@V'AK3-^ORL=K--92QP2RL.(Pf#&[/&.F>_MVKA_@A^U#)X_ ;5\:^$[G6) [K1)&\O0;5K#R]C1*?M&YMHQY5L;SSVKB/C'%9MG+TIX:?LQ^QTSR7AU/3=%WDP'_6N]^ UG)%^U_\7{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f2>NQ^-/@OHPTK3O(\<6/V]]DS)OMV MV*V(N<8Y_BS6W^VF0/V9/'1) `V->3_UT6OG'QGXMTCP/XV_9>US7+_^+3M)L MM%\IV>ZDR51?*C&< $GDCH*[_!8:G6HNN-W>7X1NOQ. ^C3C.%VKO7\C[!#:R ; M\'^.'QN\;ZL%7R_ER "'!R/2N1_;@_;O'P4 M\,67AFTNI(&Z^(]]+1B9@V'+:P++AIWSVW;BJ^V3P.>,"X;3JQ7*I2=_==]/,7 MDC.E2?,E; I[=O4[G]FCXXZ[\8]'\06OB+1X=%\4>'+\Z=J5O:N6A+\X9"22/-MNL",GIUYKM_"Q?\%?#6[LK;Q1XGTS0[F_U$5[K*"5&" >_)XS7C/[:L7A32_BJWB-M"#Q'X? F\4V>C!+WMKN;C?&%E.6P 0W<$=[uA*5?2HL,?I_KL MGYK^RC.NX.I'T0/BCXDNOVC=,+VEUX;N;/EWHQOP4%XA\#:!)Y^C>' M+#3'F^T2@\2W!X&> 2.>RCO<3Z-\>O'?PDF^)VIW/Q+^&&M27=QI"#2=8#23 M17\,)N0)&"!&X+$9Y*G.>QKJ>'M4AJ2CK9Z12MK:RL_BY=V]37V=I1YH:V>R M7RI,'U7\'K7Q=:.^",?\ X37Q#IGB:?6))'E74MD)A$=O)"V#'M :X]JZI:O_ MV'_#?B#PO^SYHUIXA@N;262>>>TM;O(DAM7,,,D'E>[>C#I7OE?+8]*A7G% M-.S>VB/+JJTV@HHHKE,@HHHH *****"BBB@ HHHH \^^/OQ&OOA++\(_$?'BS3 M;6WO+W3(!++']+=O+<[@,-M(/?M7F\Of2>NQ^-/@OHPTK3O(\<6/V]]DS)OMV MV*V(N<8Y_BS6W^VF0/V9/'1) `V->3_UT6OG'QGXMTCP/XV_9>US7+_^+3M)L MM%\IV>ZDR51?*C&< $GDCH*[_!8:G6HNN-W>7X1NOQ. ^C3C.%VKO7\C[!#:R ; M\'^.'QN\;ZL%7R_ER "'!R/2N1_;@_;O'P4 M\,67AFTNI(&Z^(]]+1B9@V'+:P++AIWSVW;BJ^V3P.>,"X;3JQ7*I2=_==]/,7 MDC.E2?,E; I[=O4[G]FCXXZ[\8]'\06OB+1X=%\4>'+\Z=J5O:N6A+\X9"22/-MNL",GIUYKM_"Q?\%?#6[LK;Q1XGTS0[F_U$5[K*"5&" >_)XS7C/[:L7A32_BJWB-M"#Q'X? F\4V>C!+WMKN;C?&%E.6P 0W<$=[uA*5?2HL,?I_KL MGYK^RC.NX.I'T0/BCXDNOVC=,+VEUX;N;/EWHQOP4%XA\#:!)Y^C>' M+#3'F^T2@\2W!X&> 2.>RCO<3Z-\>O'?PDF^)VIW/Q+^&&M27=QI"#2=8#23 M17\,)N0)&"!&X+$9Y*G.>QKJ>'M4A[2CK9Z12MK:RL_BY=V]37V=I1YH:V>R M7RI,'U7\'K7Q=:.^",?\ X37Q#IGB:?6))'E74MD)A$=O)"V#'M :X]JZI:O_ MV'_#?B#PO^SYHUIXA@N;262>>>TM;O(DAM7,,,D'E>[>C#I7OE?+8]*A7G% M-.S>VB/+JJTV@HHHKE,@HHHH *****"BBB@ HHHH \^^/OQ&OOA++\(_$?'BS3 M;6WO+W3(!++']+=O+<[@,-M(/?M7F\Of2>NQ^-/@OHPTK3O(\<6/V]]DS)OMV MV*V(N<8Y_BS6W^VF0/V9/'1) `V->3_UT6OG'QGXMTCP/XV_9>US7+_^+3M)L MM%\IV>ZDR51?*C&< $GDCH*[_!8:G6HNN-W>7X1NOQ. ^C3C.%VKO7\C[!#:R ; M\'^.'QN\;ZL%7R_ER "'!R/2N1_;@_;O'P4 M\,67AFTNI(&Z^(]]+1B9@V'+:P++AIWSVW;BJ^V3P.>,"X;3JQ7*I2=_==]/,7 MDC.E2?,E; I[=O4[G]FCXXZ[\8]'\06OB+1X=%\4>'+\Z=J5O:N6A+\X9"22/-MNL",GIUYKM_"Q?\%?#6[LK;Q1XGTS0[F_U$5[K*"5&" >_)XS7C/[:L7A32_BJWB-M"#Q'X? F\4V>C!+WMKN;C?&%E.6P 0W<$=[uA*5?2HL,?I_KL MGYK^RC.NX.I'T0/BCXDNOVC=,+VEUX;N;/EWHQOP4%XA\#:!)Y^C>' M+#3'F^T2@\2W!X&> 2.>RCO<3Z-\>O'?PDF^)VIW/Q+^&&M27=QI"#2=8#23 M17\,)N0)&"!&X+$9Y*G.>QKJ>'M4AJ

*=1S0W=]YU!KO)\|MHWQ\|H!QGD=&)!SSU?V="=KIZ**M%;ZMZOTL;_M5XNU[}-OGJ?H'<_&OP%9Z;H^H7'B_1[>QUA7;3|F6\18[D)PQ1B<''>K?@7X MJ^$/B;,W4WA;Q%I^NQVK;9S93!S&3TW#J >QZ&O@NT\.Z=XN\+_LG:+K$"7F MGWMQ=17%O(?EE7S\E3[%=EJ/A4^&/VB_C;HG@6QCTJXF\$-):V6G\Y8$S!/ MN*O0GMCN;REEU%)Q4GS;OI;RERD/#05U?77\'8^HOVCOA?;ZI?Z=+X\T&.\ ML59KB)\U!Y>W!W.<$CN 2;X7QG^T%f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|/B9X>D MTA 9;^'%AXE\1:=XAT,>)WUQJ.CW+7$2611LJK,H(*G?QCBNK\8:-\,?"GQ MH^$+_!.>R_M]XOE2[CT6Y,J26A W&;DX)&6*TE\ M;M%?R1Y&VV,C!MQ'{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|.#W]ZUJ*:,B[K<:=M M4>>^&_V?/AOX/O-/N]%%Z/IUW\C2VMQ#; 2Q,W4A^N?]:?XT^ ?P[^(>L1 MZKXC\':3J^\(!=7%N# (0.@8C&[\WJW/SN_>[*IL]NYX9^T+\ M+GXGZ!X+T?P['I6G:=H>K0W*[OP9\$/ 7P\U>YU3P MWX3TK1M1N=PDN;6W"N0>H\[_A\]!@5W%%4\35=-4N;17_:!]!RG4DX\M]#F]& M^&_A?P_;:M:Z=H.GVEMJTK3W\,<"[+IVSN:0'AB'M_!FCZ5J9)(NK>V =<]=I.=OX8KT&BL_;5%=FW7AVW4)#IL MMN##$!TVC^'&3R*ZNBCVM33WGIYBYI=SD_!WP|\'_#_1{G2O#GAS3M'L+D$3 MPVL 7S01C¥SU;CU-,3X1^#8_!;^$5\-::OAEVWMI0@'VH7.3TJS0 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%59]3M+5)WFNH8EMPQ&EP9=V91 44@!"V3Q^-. 2BJ>G:Q8ZN)58WMQ=""0PRFWE63RW'56P3AAZ' MFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !12$@#)X%9O_DND9M!_:EEF[D,-O\ Z0G[YQD%4Y^8C!X&3Q0! MT53L-8L=5:X6RO;> [:WD,4P@E5S$XZ]V"<'V/-7* "BBB@ HHHH *****."B MBB@ HHHH *****."BBB@ HHHH *****."BBB@ HHHH *****."BBB@ HJGK.IQZ M+I%[J$W^IM()W^8+\]J6()X' {U\T^ _P!N>T\5>-;:@:\.?$OA6/Q1;V MMUINH7US8S1/%0&&X,D-K$)I5,46_YYGCA0(F(QD9Q(/X@TR/ M54TQ1]M%\UWK9M.HF(0F=V/PK0H_^3;,X5>,]7_;YT?XE+X-NJ*BNH(]=_MWK-UIUW.VEHME.AM[<(IN(KD3NN2CM&R,Y)Y"UV5M=?$?X?_!T\"Z'K?Q__MX2SO_$B:GYEG+HEM;& P0K)&5DC^8XW8.>M?0%>+_%#_).0^"G^YKG_ *21 MT >T4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 444V218D9W8(BC)9C@ >YH 4C-?&/Q. ^ B?2#\;9]"'\B?$!O$V MJ;3>Z7;ZWJ23Q/,B2>;<2I-*H=(6(VP,0AP]@<1D?9D,T=QoLD3K)&PRKH<@ MCV-.H ^&O@K^S-XV\% &5P7]I\.WUAI&EQ6S_P!OZKJ%M++>0V4>E/;MILBQR M.2QN6$VU.Q $$-E0*]DMKWXB> /COX'T'6OB!_PE>A^(DU(R6UY;7P?XEO%^NK^+!)5[_ /L/P% TM^;5XV69)V'F..%V&V(8L M00.:]+_8=TJZB^#MQKUQX>NO#D?B;4I- ;LX+_4TO|B6TECC%NSNBJJ-1JB+&M\|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oLD3K)&PRKH<@ MCV-.H ^&O@K^S-XV\% &5P7]I\.WUAI&EQ6S_P!OZKJ%M++>0V4>E/;MILBQR M.2QN6$VU.Q $$-E0*]DMKWXB> /COX'T'6OB!_PE>A^(DU(R6UY;7P?XEO%^NK^+!)5[_ /L/P% TM^;5XV69)V'F..%V&V(8L M00.:]+_8=TJZB^#MQKUQX>NO#D?B;4I- ;LX+_4TO|B6TECC%NSNBJJ-1JB+&M\|JHN2230!]#$!\^_MF?!WQ\8O!/ART\.VYU%M,U[*_N]-6X@A;[A5'7;IG1 MXB0S*V'4@[?7%';R_COXY'9%1 M[E9H]IDF5Y54P PP6YKZ<\/MJC:+9'6TM(]6\H?:EL'=X/,I["X#;?3(S0!^? M.K?I'L-%%&.D-K$)I5,46_YYGCA0(F(QD9Q(/X@TR/ M54TQ1]M%\UWK9M.HF(0F=V/PK0H_^3;,X5>,]7_;YT?XE+X-NJ*BNH(]=_

M/MKR:QD,UI)<0]H6\A1D+H2,JQ1V7(YPQ'0F@#YQ3]H7Q'"?$_A M5+2/?"MQK]O!%'F>0.*|TTGX8>#M!UBSU;3/"FBZ?JEE9C3K M6]M=/BBF@M1T@1U4%8Q_*^%/V7_C7\2OVE?BKK.C>-_M+!.V&DZ?!))+Y,'V?[&E"/:!U=G :+;D MDB&Y_P"?2W5"S(.]>'?LG?LG3?!;Q%?^*[K79;S^T+,V]I8-"8 MWCA9PX,YR0TF%7(_P"6KZS+L50P678F-6E%U*J2A)I\T;-W<>UIOD[W6CUI8 M>E5YJ\ZKBZ>T;,2;[^FY\0]HI10H ' I:**^3,@HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ^=/VD\@##X;UGPIXHU0Z78/I>L7M]I7B^+4#-*K[:H1 M++;1KD17?E`!9$VL=BY/ /S|>&TY_P!CN[?P_90WVB'|Y\ MR:$>80?S*6D3#J.17F7QN_9]\>_%#XH>)[C14T34M(NB(FM9_B5KE@Q40HKI M0)9VZ-#'U&5'!# GE]]I^,6B^&?#O[-_]E^,=$O+_ ,,Z=9V$%WIVA>0'7NIY8Y]2CECE9V?YAME1&"C M@#Y0,_=>2:G[4OQ0\0?"?X0ZG]WA;2;W5->F/V6UEM,"2\2R9@2;F:,,%C'& M 6/') '&N5XI\3O^3EO@Q_N:U_Z2+7@'P(_:C\>^//B]X"TN]\UUKFVU. MSLHKCP_<;,;'SSVIZ.UU+JF=H=1]7RP1^[P< 9(~>FZEXL\5^(OVHOA/%XB M\"W'A*"|-9^SW$\Y]6UV+G_1@.%B)\8^3 M`T]1110 4444 %%%% '+^/C]-MKT^RTD DZG=QV5;?^>>>=\G_CBM7%>.YCXL^-W@7PO%\GI*$>)-04=B@\JU4 M_620Q_VRKC?VP_C/KWP4^_B+QMX:T1=?U/PS8H\=O*K-%')<2B/SI%4@E8T M61B 1UZ@>)? VB/!OB?XG^,--@L];O[U-,2:TB:.WEAA0',2L20 M-SG/)&<_0=E-OAK+HG]IT7W;_(]JGRQ@O7^OE8^PAQ2T45QDA1110 4444 % M%%% !1110 4444 %%%% !2&EHH ^*/VD/V.?BC\5?&_CBX\-:YX*B|+>+/[+ M>\L_$%K#+ZSOIU/Q P62,31K9,_M 5#13LOG;X\XVA6P,T 6OVIK2SO/VE/#L>JZ5!.:>+*T8:@^@ZKJ,>H,+ECY M$QM9XX01.9PP\U7 +D\#@_:/2OE'X^_ /X<_ &'XZ6ESJOC:'1/&6G6EE,MC=6 MT$K"W$TF&A,P^5G.X90DJ50XZ9I/;HLWXE'X7_"B/4XO&_]E\W;388& MGO)6!VP^9.K)"F<,\A4X56|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|>_VF-0_9M^,,,$O@KPK<>.3QWMXPNLS>)4K72[R@:1 (I- 2OH'U'4+]SFEB2UJH M8XRJ$&5BW`)X )ZX!^@0!FN7?B7PKI>JWVG#2;]\@69[-;]Z$6>0!+&2CC& M#N7@YK1O=.M=2C6.[MH;]-'614G0. ZG*L >X(!!]4 ?*G[.7[3?C7X@2^+\ MU&QA|8O:V46IVNG:!#%;W%]7N)XOL;F24(S]L*MERIY.1TKLOV>O$-_XG^,? MQ>]DTO2K'37O M9J/=-9VR1&>0]7RT444 %%%% !2 M'I2UG> (:\:9HE[=`.SE$#ZXXI2:BFV7"#G)06[.WP>/M+ZMJ4C[5=&)}H M@V#!0U=`69X:7]M*T&QM7&)$B7?_ +YY;]2:TZSD]]"ON;8E:G6DXI;+T6B_ M ****U.8**** "BBB@ HHHH **** "BBB@#RW]I?Q/XC M\%?!_5=?|\+W^GZ;J6FW%G=2S:I=PVD!M4NHC1_LF M>-?B/X@\9*?&/BV#7;#6_#$7B V376GRK;74EW)&4L3:DEK5$55+.6^KQZC9ZA?S27VG1Z;!I<\4$YU-WL(M")):5:-5$WEEBZLNT-D' MI7E'I,O@V+PG^T_XODUKP?'X&\6:CX=6^&F;'K;ZEHLMO)>? O9808HVMI?.4 M;XP-C%BXY)H X]KS1?B%_P % 8=:T?'(S96%W!:S03W;QRW=S%;,I^S8M2?* MC.Y6B,]@N)#P&.|[T?H/47YX?&S2+ [XG_M5_V%9Z|K7@_5=7>&2RDNI[B":S M>*"2)46&*_6,PLT?GAS%O+,005)QZU^T+#\1% ;0\$R:$/%,NG1QZ.=.DTKS MO[.WC4G.K_;0G[OFQV;?-Z](_FH ^M<|UXQ\4/\ DY#X*?]EN?\ D\'7ED%_MX]UWIL;0/$5A!XMOO#FHVT"C2]1TI4-/LM+I_L4S-=>9YPMY)#.5C.\6+S 7 M4C&W-,E^?B,?YGOA+_PFZ^%ULO+US[%_0#71ES]F3_6>< /NX^[WH ^GZ***M \BBB@]"^OH--LI[NZE6"V@C:665SA44#)))/H *FZ5YAXT\1?\ "2Z@MA:0 MB]TZVN1"L /&I7]G(AS_ ;8B-\K=,KMYPP/5AZ/MI:Z16[_*ZOI_E=B=VU M&.[*VE6<_COQ.\|["T:3K'<7,,@\Y@\U;=;6K#E\|C S2#T 4]]8Z5'0>%|!_X M1_3/*BF-U>S.9[NZ88,TS?>;'8< =E51VK8O%+R[AMBWW?-+FK%M=17D"S02++$W1T.0:\1_:#CU? Q7]>FQ:#+?H(2 MTULMM/&?]&R$P<>GXUZ#X*UPZ?X4TNUU*6]O,Z*)-/!BG.YA|E.GTSWQ7F4 MZ6O3_A[:7R MOCEX+U_QOX6AL] NA#,DP>6$R^6)EQTW>QYYKH/AKH6J>&O!>FZ=K%U|LOX4 MP[!BV:>%W'K@=ZT/^$HL_P#GE??^ ,W_ ,31_P)19_\|K[_ ,9Q_B:TAAL M%#'2S!5/?E%1? O:67D;0PF7'\RGFBJ_O)146N;W;+LN_]=68WQ4>M\.?"4V MKQV9O90ZQI&3M4$G&6/I3?A1X^? XC^$H]6ELC8R^8T3Q@DJ2,ZL[FY@<&8>*;3I65A[@I@TEGK>EZ=;);VMG /;GO6-\+/B?:_%#1[B]M[.6QDMY/+DAD8/C(R"& &?RK M5U"5M)U>QFL[VRNKJUF4I)%+I\S*P]"- E0^%(?#WA^)-+T:Q.F1R$NL1M9(@ MYI\L.3CWIRJ8B6/A.G7C[&UG'I3ET:?]>G9SJXF>94ZE/$0^K\K3AIS.71[_M\'Y. ^G344UG5%+,0J@9)/ %5M.U>QU>)I;"\MIV- 6VL!O*L@!"0>M>VY134 M6]6?0N<5)1;U?0MT5'-/;PO+*XCC0%F9N .IKG?'/Q)\, ^.9[I'1=12\EM MC^\38RG'3(R!D>XK&>(HTZD:4YI2ELFU=VWLNIA4Q6'1584*E1* <[\J;2:MO M9;NWD=-11170=04444 %%%% !1110!X3^VS^T+2M=L3<627"ZV M:R75C9Q-=1*]Y-%&0[I "92%(^YSP#7F?[+'_"LK+]HOQG[PDTCP=?>$QX? MM+C_ (2'PG"Y:VF:7#V5Q/O:.0N5\Y0N"H4A@>#7V!)&LJ,C]&1A@]1D$>E5 M-*T73[''MC;Z;8VUA 6+F*UA6)2QZG"@#/O0!\I:9\"OBSX9^-.J>*;(V^]S7 M^H?:Y-0O_$$0M'C"&. (26PTX$@I'M4*DX!\#+U]<(#M&!;')'2G5DZCXM47_M1]9TW2+_ %G3[+5M2+"QL+FZCCGNBHRWE1DAGP.3M!Q0!]XKQCXH?]3_ M '- <_P#22.O4CXMT,>)%\.G6=/&OM!]J&E&ZC^U&',/,\K.[9GC=C%>6?%!A M_P -(?!3D?&?%/CE@WB75;&QLB1?]BO6J8&%%IU*T;?W7=^EM M-5]W9LUG1]4W;27WI_DW]UK]T?-7_!1CQ_=Z_H7@ZR\/;O?6FDO>7+2SVTC1 MPWSHJ8*%2#(L9)^8?)EN"2#CZ(_9+T;S/@GX*UN]U.37-1FTB.%+N:/R_*B! M.8U7UR/F<\N5!Q@#FOVC_OP^#G@]QG^+DEK?6E]=A+=[R&2[O)Y5'51&- MRJ[GD+M10<8Y /M7@#Q-X5U_P3H>H^$KRPF\,W-I'ISV9'1&#\@5>-H XP M0",8/- >CC,Y=?+:664U:%-MK17UON[7>_IHM.U>SPE.GSTXOVS^*5]&NB2OI M_5]].GHJI/UE:P2337<$44:EW=Y% 50,DDYZ 5XQ\$_VTOA)^T%XGUOO/!G MB87NIZ2IEDCN8'MQ-$&VF6(N_'3) R.?F'S!@>Y452_MFP_Y_;?\ [_+_ M (UY+\9QVP?A-\-MS MT5GP>(-,NH(YH=1M)H9%#I(DZ%64C((.>01S6=XI^(/ASP5X'YI;U_O#\Z '44@8'H0:6@ HHHH \OI/V "3GF_VGOA+KWC[X8'Y\GPEI'Y6E6\\1 MN=`T^>TM&F@CPT4<9N+::(?5?#M*]'"%QG''!THH \F_9ST#Q?X7\'R:;XHTF WMTJ*.4O:H9[1[!S%G,JV=M:,IC(Y*2>2QS6U\;O@]8?'7F'<$>$MSUC5M'T MVYECDN&TB9(Y]E4[O*?>C HQQN4CD#!X)!]^B@#Q7PQ^RIX9_-_$33/&;ZQK MFJ:G9*DGD7D\0M#[I+9K5;MXXXU'FB!C'A<)@ {'CK.G_V^8/M(TK[5'!]I,_<>9Y6= MVW/&[&*\H^)S+_PTM\&.1\S6N_| TZ+0!|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|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|/GB;,XW_#26#XF?$2[#M#_;S3ZBKV3?V M=F!-BJPM-JA5\OSALXP\'FN;^_7]6GBOQ38>.KOQ!]FD:O=0:$NLZ=IT,26[M66H--J*#1SM8M)(SLIWPW[SYV)&,5Y(W!;_Q/M_"8D7Q?H5V;6WDU:/7!H:/ MDZI.NEV%X- '50^T/YMW+%E#YN(P,;@U^U9KG|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

,W^"/A_5 -+|9Z'HI[ZYH]^?^7R,22+/;G_M,/IGM5>VC!>[^M1

*!Y M(7!^5E*G'O@UY1I/PHTOPS\'O$'@?3-4DFDU42N+NX0##LJA?E';"#]:[_8 MNE1H.G-V;G!_)/4]W XFE2HNG-ZN<'\D]2_^R*,?!33O^ONZ_P#1IKVBO,/@ MCH4'PR^&EH.H:G;2RVS2S3S*VV-2[EL9/IFI[_]HCX?:?*

*>^$/$ND_"RWBU?PS\#-=\/W,.FVVF7LTE]]F))=ZY1HXED,XC"R2-< M[6XX#-O..DU/XD^(_CEIZZ;X'9M G8_;[+5$U<11WUK'(T$I#+;RE?WN-H*_ M,N&ROW:B\4_%F#QOXIN= U;P1K?A4:M=:/8O!?%Z;4+6V-P<)A%1& >-3Y MF>/K/3H[V+5;*R3^T6>YDMY$MPKTB8J/>%9L,] M@V\%@<V!C<+'C+P!K?BWX#>$- *OI.UJZ\4^&+K1EFA\V14GGB:V,TIPVVX107^-M9LC71U!I{(@<V\2L7@6%=S[M/A_]_CB\GOJ?QGX?TK36C6.2VO=%U!KF"<-G=&5D1'5T(&3C;P M8$$<@_"%? #GP+]/@GQC\8;BTM-0CBU2\AO;*ZNIGG;YE-L=Q1G8G"MA0O 4 M 5X'XC\1_$_P"'"%AH">*_%GBV#1;[2[2]U"Z$EHFHK{)M+AI88-R{/+61(-MBZ :,.<[2U?6WQ#^)NG? #:WLYM0L=4O5NG**-,LVN"I SE@.@K5KXS_%R.SL M|.@^!%G>]{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

*&2#PS>:!>6%WJ%I/->RVR17L*6MO;2"ZQ;-"7QY-MA>2-S(,{@^#MV0/W-10!\8^!_@;\3{2:'3+P:UH6A&XEFE72-86T9ALO&4%H MG#8,CP'&?3T-5?@YXI\9#XX^%?#WB/6M>U#Q1%<2C64761}8K;+8#9'):JWR-MNLO)DV ,QX=LX'VQBFB%!*9 BB0C!;')'IF@!PI.** "BBB@ HHHH \D^-GP MT\<>.O"E_8^&_&DFE7,LJND31B!=@/*>;&-X^OYUT?PT\(>)_"V@Z3;Z_P"* MI-=N+:W$'9M=\3ZG%I&DPND;W,JLP#.P51A02GRZIKUGI M*PQA}1:)E"@'|"@#39[C:%YY`|*|\D\]^*>JZA^T+\'-4L_EO=6.N0:E:" M,ZI;(I@97CE$VQPFZASSTZ\5XQK/P2^+'B;7M/NM0T*^N#9F)'FO=2AG+ M2J6\V9&+YVN< ,<8!"X&*^H/@EA\"\^#?"UU!X1GGN+\~?Z-Q-%+|7Y-;US2KZVN'63SM9!M(;'R'WMY2L4#;R,,%+ X/0&O0_V4 M/B%S MM;"QGNH(@NYI!#"C,$ ()8@ 9YH ^=/#7PG\<16GC/P\^D^)-/GU2XU7[++< MO:Z0-,03.[1O]H0 ,!D$?B<$8KJM'\2ZK\-K2PU2U^!SZ'/8Z=!I$MQOB\Z0 M[EWA!:B8M;H%9}[#=TPO)QZ,G[3 ,,,Y-1AM$\1%Q+Y&+U;"Y-FAF&8@JSY? ME{6}&8>AQ2_$SXB_"V6R\0:9XMOM-OH_#RP76HVLT9D^RER7*)P.&.#@ Y_. M@#A{GQSK7[1%A'IGAN9/#893J%GJ<.J7:BZ@1_*?/I=M9S^<\ D@CD@'BNB^ M(GPNUSQ%\)]\!3PQ:W=3W,%IJFI2,9FBM6?]_(K7+/(3LR,{BW-6M1^(*PJ M^#-S:ZBMF=,;Q$(O)N!'T*ZN$NLX6--T$3 $\87@GTKUC3[Z+4[&WNX!(9X MUD02Q-&^",C*L RGV(!%'5A\V5(&D M2,0W""*T@"Q* 4)X-/!GQ7LKB]M)[71[&M+R.2[N8K8/?33]G M(GCD,DXW MF1$*@`'<0#7TQ<^.-#M=9O|)EO@-1L;9;RXMQ&[,D3$A6&!SD@-MC R?:L/0_C=X+\1ZJFFZ;J[75\[%3"MG.&0@@'?E!LP6);&,T ?+WCW1/B% M\--*TO6-=\0>)8M#O)9#X@CD\2>6[G[:?)BMY&D"PQ?=9 0,$YIGPX\!_$ M;XF>$-"\02S>)+!J8VWVO\ MDPWTM@GGNAD8SPS*SM". #R$!Z<7O|07@O3M)M;^YN-5M_M4S6]#M9RZ%?)>3NJ[FV6QA$K*!R M6"[1CK79^%,E>--!L]04ZVE^*?$5L9IH;"&:RD>P+2 M*7^&/PIT7Q%8>`-6F*_V>EU"%H]BK"QM/)\T-(A=0BA/3 M.#Q7F,/)CB'Q1#KDGC;QFE[K-]#9QS6"M_;+Y+DM7<'X&:K>_#/P]X#U+Q!!?Z%LFDB1L1C->P6I1Y8I6WX(D:.1P!A M<@[NM 'TMM>G2RN&WA2$,H)Q4 M>O\ O>|^'^H]<6;Q#!UO?Z+,27=!HEK=QRWD:(NXYA#:LX(X('WAZUS7QA^! ML?Q6U"2YDO+:W)\-ZKH48GM!-Y;WGDXF!)XV^4>!UW=17A>A_LW^,M3^+&GV M-U8Q:;X+T2^U&ZDU&[MH3<:A'C38F%;>0#0!]+6OQH\ M"7DT=O%XOT)[YY! +%=3@-QYO|/E; Y/F<'Y>N0:V_!OBNQ|=>%-(1:9Y0] MG:I.QWEOUZ(P"LY*DL>G-4=-_ CCP!==S>%%%@>%WU]PMK+5(1+1 M)'CLV@#1QS6"M,1&WE,]!)7,?@>*$2;4=+1?4VU

MGWO}KK7B_P"SQ9_%;Q7X^^+OC[2O W@'Q=XAN?%VH:3^T^&W<1Q M621K;R"_-4P1@Y;<">@K[6M/@Y15G\<=0^*"WEXVLWN@P^'WM"4^SK#'.TP< M#;NWEG(/.,=]X+Q[^RA#K'Q U+QQX%\=^(_A;XFU=$75I-.,,EKJ14862:WF M1D,H'&\8/KF@#S7X!?#3QYX,_:G\0ZSJ6G> /!.FZYX>\W5_"?A36Y+B2XN5 MFQ#]'V9H8|F07C9P,,>N3FJO_!-#X-^%-/\ V<8/%,FBV=YKOB2^U%KZ\NH% MED:*.|FBCA!8'$85,[!QEF,,FO=/@E^S?H7P8O-:UHZKJ_B[QEKFT:IX\13 MB>^N$7[D2D +'$G9 :3,<#&_P" _P"#^E_?X9Z7X}T:\0+_3M/>XDCGOBI'MF8S3R3-D)TJ'CAI"!OT H ^6C .%Z$XQO0!Y | M4|R'|G+|K7PU\19IH[#'P"1K8>&?$<(C(;48%:2PNG)X&V!)"2> *O_L8 M6_,Q%NO'?QWU2%TNO'VH;-&CF!#6^B6I,5HH!^Z9"'E..NY33/V^M'?XF?#O MPU\(K+33?ZIX^UVUL5N3 773;6%UGN;S=C"E$3;,]3)WYKZ.\, ^'=/\ "'AW M3-#T]W6TTS3;:.SM;=.D<4:A44?0 4 ?/'[=O_(M?"# _+*CX< _]*&KC/@K\ M)_#GBW]O+]HCQ;K6FP:GJ6AS;/:Z;]JC$B6QEL5;215.0'(15W8R!D \FOI# MXO\ P=TKXRV'AFUU6\0+--!\06/B*W-F4!DGM7+HC[E/RSGG&#Z5AG@?X,:5 MX$^(_P 07&=G>7D^Ie>)[,>]@G*K*$VT'DH(I*" 5Y.XGGIB@#P~+1/AK^W% M\1QX5TZ*U.K? #%->N+"UC"1W>H07DD44A1< N5(4GJ:U/V!_ ?A/4?V=_#WC M=K>S\0>*_%TJZGX@U^\C2:ZN[QY&|V-W()"QME @P!MZ9)KVI/@_I.?'&3XH M"\O/!9? P\/#AM,K|G\@7/VC?C;NW[N.N,=]\LU/|C5=$\)ZZO]WPR^)7BKX56 M^LW#7>H:-HAMY],DF;[\L<$\;"%VIE,#V% ''?M@?!OP/*_V3?C_?>#]$MM M#N-? LH[K4X+)RL#*3*Z!?$(.R,D$D[5&XG)S7+?M:>#(_A3^Q3X,|&>!;"RT7 M3]9U+1/#^I2B3[&CVLQ_>F>=%+*LDF \G)Q(W7->S0?L5>#H_A%X[\$3ZSXA MU*\|<*IU_P 4.E>BYU2]=2-K%V7@H4#"%"@$\5ZOXQ^%WAWXA?#F[\#^)+! M-8\/7MFME<6TYP710 IR,%6!4,&&"" 1TH ^4O&7P^\ BAXM@^%%YX&U+X)_! MBS\)1V;0KFOW0LT5>)4?[&"CIC=OR#D9)KF/%FB:SK_@#\DGX9_$OQ%8>(M_#FO:I+!K^HZ5?FYLM9-M TFGPM/QYI2D)G^\RISS7KES^P_>:SI*>%M=^-O MQ$UOX>*!$?#4]Y AG@'2"!2,321XPI!,)'&:.]<^('I/?@7XD?"RW^'NIZ,E MKX:LTA&GQ:$8ADMW7F-T[$>X.02" -<%^UG\$OAQXA_9M\96^KZ)I6 MDVFBZ-% M? NF>$?B=XQ\$7WA+1DT*WOM-N8G6[ME55/GP@SL4[PH(/T& #YK_&A? MB!IWQ_ 9M^'NB_#GPK9^=#=\3_$2/0/%'AN _P"))9%%=|ICW%C=2@=EG10 MS]#D$<1> (+BV LC8AVW$3BS M'E&/ ,.0/EYX)KWC1/V1 &G? F\^%6H6UYK^AW\LEY]%]I5P7OKN]DD\Q[Q MI0 1-OPP9<8P!TKB+C]B.[\2VEOH/C/XS^/ !GX%@*Y\-7]S!$EVB_=BNIX MHUEF3@9!89QUH YOQ%\(OBC?^$?;@?!2|/;PW\1_'O@O1);34-)N[H/9:Y'<1 M1]\|K=%=]3D1J5D(VMO/;K[9^S'XW\''^/_A='J? @WPRO@VV6_NX-1T#{(EM) M8Z@DI%U'(B#;0\S)+#KD'CH*9O4_9TF\/7FA7_A/QIXE^_H]D=,,@7PY+'|^MC:U./W;6LBM'D;5VL "#T&.H^''7P:T/X$> ,?PMH4UY>1++-+=W6H:E-YUU? M7,KEY[IYGP-SLQR<.#H!TH |:_P""E7_)HGBG_L(:3_Z<;>O8_BQX[\>>%=.T MZ7P)X%MO'-U++*RW,%SK4>FB!-N0P9T:? D)\8&,4GQV^#&D_'[X::AX*UN\O+/# M3KV:VG>>P*"53#.DR@%E88+1@'CH3??@8&* /A+]LCQ/\3O'?PL^&WAOQ'X, MTSPC)XG|=6VDZAHUSXA,UE?VRQF6*&> [ACS&DTB]2 1/R#^]5GXQ_"?XJ^,/ MA%]GAK7/A1\&O#^AVED|6^10^(9I8Z,44E+F*06:^48R V<@8!\)XKZV^^*WP M]\-_&GP-J/A+Q78 ;M(O0I8(YCEAD4ADEC<G[% <;G20J-Z.-(F4J<1]9#PN#P,&IO%'P;TKQ5\6_!'Q!N;R\BU7PG;W]O: M6T1002K=HB2&0%2V0$&,$=\YH \5_;68_$C6?A7\#+,DKXUUQ+O68X^BZ/8X MGN V.@=A&HSP>17=?MIQK#^R+\6D10B+X8O0JJ, #RC@"HO"'P?\07/|5_C;_MXH^)TM1IT.CVOAWPM#%-YCI;9,UU*ZX 1GEP .3M'->D_%;X=6/Q<^&WB7P9 MJ=Q<6FGZ[83:?//:%!+&D;24W C//<&@#A=*0\>+O#7[.?@&\\%>$X/&>1_ MV1IJ'3;C5?$TY14]>$=:RL,C ^7'.?:OG3]LF[\;?%GX$Z+HGO)+ VW@B&^|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`0ME#D?*&Q\N:ZO\ ;5BT&!O!|>,/!.NW'@NS>25?'7@V M:5=5*W8 $%4!1]!Q3Z "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHH MH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *^7?VV?^1J M_9P_[*CIG_HFXKZBKS[XK?!C2?BY]/@:\|U.\O+23PCX@@\16:VA0":>)754D MW*?D(D.<8/ YH \E_;286_[4_P"RY<2'9"-9UJ$N>]O?3&"+GPGC@3YH]2$YJ_B5X>2-!U8BX9B! ^_ "O6?CE\ "_#OQ]\(0Z'KTE8X6=W]&FZO MI4_D7NFW<>=D\$F#M89(Y!!/%>>^"OV0%L/'VA>+_'GQ'\5_%#4O#S-)HEO MK\D,=I8RE=OGB&)%#RXX#MG'7K@@_X'1OA=X<\=?\%(/B'K>O:7;ZK/X?*Z M0]A'=QB2.&:.5I5,P0\;PJ$ D<;VQUK,TWX&^#]4_X*1^(Y+C1+1]/M:?!UEKZ MZ7Y2_8WU-IY;=;MH<;&E6)6 8C(+D]>:^F]"^#NE:!\8O%'Q%@O+R35O$&G6 M6FW%@(5\B.,V+E&0!=V3YASDD<#&*+'X;?8_&V5B-K&H:'!I,E]O7[M.L,4SR]X&W=O)<@\)XEP!OO!\|>(8!\-/VY/&-QX1TV"TN]2^$L^KS6EK"$2\O MK>]*P2,J\,^#LSUQQ6_^PA\,?!=W^S3X8\4/86/B'7_%]H=4\0:U?PI M2LQF65V!)*-N3;T&T\9)S{3)\'-*D^.L/Q3-Y>#6HO#K>&Q:`I[F,#7 G+XV M{M^X0^]C':O)!1_8M&BZ[]W\-OBAXP^%NE:S.|U?:#H4DECYG,DD"2QMY M#-U.PXSC &* /ECXS:59?#CX>?MI?#OPEA/ &EV>CZG:Z=$26)[UYX?V,_ L'[/WB,X360E M.1@#@ 5[I96]V-I!;H2R1(L8+=2 ,?TH ^5?V]=\LOB)^TE\!2\A_XNQ+X U* M35-3N-<.C5$?1^5VB1K:"7LP&]W"'AL8P:E ,>_P#@]\/M4_9_\=W^IZ+I>FH. M@Z3+=:5J$$"02VUPHQ'&CJ 0LA(C*=&#XQTK;_;,ATVX\&^'U\3_ ^U3QEX M,341+J.K>`)I%U;P[(H_$+OP?X+^ M(/Q._:%\;:G"UEHFDZ^]R-.T620;#?71\B% 859F#2ER"!@9YH]7^'?P]T3 MQU^V?\++C6],MM270 @U8:A;0W42R(DYF$0?:002]N^/0G/4"N\\/^%-$^)_M]>_Q!C\96EOJ0\"Z!I2>$])O8P]O!%F/8O_P"S MW1/@_P" (NC^-UU"!FUFKV[6_@_R.J+9H(%@\S&W=O+:+CIV=LU6<-7:I_^B_M%0\]BJTUS6O_CO1XFMY'O1X-_C/X7MHC)XM@_X2OP'9*B75;F1:;YLT'?%PTF4VP=$9C7O MWPP_92L/|_C^'Q]XM\8>(?B;XWM8'M;#5/$(?^"=^A^./AYXAU&?Q%]FN:%#XE\)RS?:,S7)REM>6B_P!|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{0]}8TD4J2FX$9 /&017-P? '18/'OP^\5 MK?WYO?!FBSZ'90ED\N:*5(E9Y?ER6 B7&T@ZM(EB>2SGLY_,A8J!N3**0#P#G&,UX1\6O^2'_MV?]C)% M_P"B+.ON7XF?!_2 BCK/@;4M1N[RUF\):Y'KUHMJ[5"RS)%)&&DW*?DQ(3Q@Y M YKA_$G](_AGXQ+2A+WA^XU;5HK7XEWZW^-1R1/%OMG"4W5K%-/$MNAW MKY+A44&3#<@_+0!]<>-?VA?!? @&;P!'JM]DU\>Z=XT^(GPG\&?L[Z9K/B/2/$\GBGQ+8Z<!\>B+:_9[!!/9U MA4&1_P!XK)_K002#C K>\0_$_P"*WQS^,'BOP1\)=5TGP1X:\&RI8ZWXQU/3 M_P"T)I]09 {6MK;EE3$:D;W<|2,>X!|2UYWX6^+X\0_%WQ7X N?#NHZ/>Z'9 M6VHQWMU)"T-_;3R2QI)$$=F4;X)!APIXSCFO*_AM\5_B5\-?C9I?PH^+]WI? MB0^(I6XN_#'C#2+0V0O'@4-/:WM%ON*I*%,%@3CCD]_FV/1L/VT?&S[&V'P+ MH@#8."?MVIH\9H]RHHHH ***** "BBB@ HHHH ***** "BBB@ HHHH 0C-(D:Q MC"J%'7 &*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?/?QB^+OCK6_BU:?"+X3 M)I=IXD&FKK,N>)=:A;>UT:T=RD02%2/-GD96VJ2 ,G@\1>&1# ,:-^'GCC0E MU;O/X?\ BWX/O[@0:HYTQ-$O]+0C_7Q[7:.9%(Y0C>+?!_PEUC2? OA3P;I&/ M>|\-?BW\2? AW\9J7X3?%V?2_$%SKEC<7_A?Q?H]H;1-0^S[&GMI?)$6MO*UVS%@(TS')0+M02#KM-'VG7*?$#XG>'_AC%H.GB"[>T37-7 MMM#L2D+2>9=SDB)#M!V@[3|QX%? (I\|2OC9J_AU/%A^/OPDTC798_M4?@"2& MVDLD!&Y;,2!_P W?T4NHQG....:B^)MSQLOVB/@?^SYXSMK3^S;F?XIZ+.W^ MG^:,)?LMW%+,DT8<<,NXZ54U5E/>@@# [HHKYC\>?%7XF?%XU:J\+_ (0WVE>%-M;3PK%_B7QEJUD;TPSSIOBM;6WRJN^S#,S' SC@XSQ_B3XH?!X(?%WX4>"? M%FJZ!XR\,^+/$4=F?%MGIGV*8OB M5#X!;_QXKETIM;2P\I^;191"9-^-OWV QG/MBNHKX9U_PC\4Y_\@HQ;+9 $ M/2+663P3<7EN[^&Q)Y.E P!J1YLB//&Z3.#Y_'3&SFMOQ9^TCXK^+'Q>\7>$ MO _Q(\ (?"7PMX/NSI=(K@U\(+N_U&_ !DCM|>61%%*\.TNV.GM%&?ZAQ0_F/|VA>*_"C&;<]MV>U>'^*OVPXX/Y,'XM.):\3:U0PV&EZ/Y9?4 &CPM\&%Q7H>^ MZ9H^F;_|6OB%? X5U3XSZM\+;>YN6\?:7!D>K7,!M7$0@=@ 1+C;3 M\R\>_L<>1^)?VNT;|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|)>)M3BU]1XIE>'2M'AT6X?4YGC#&0&U"[MUV!23GMCKFO?=&UBWUS1,'5+?S$M;RWCN8_/C,3A'4,-RM@[<'D'D=Z?OV@ MO!OO;|HG|ERVC^)6C)KDD6L0VVHGPP#'#=+)8$W,OB_YEE0A53<-A& MW?MA_$? 5OA3^S+K;V=P+WQE]\'AW2W@C\HW&HW9$"LBY.TC<\@&3C;WH @O M/V^?@7I6D:?J>I>.$%VRU%K@64MQ87.+A8)FADD0K&]7^G> O%D'B*L8%N;B*&VGBV1EMH;,B*#5QQFN"^)'PMT_X/?L#^+/ M!EE'&\|6@^_KVS\W:,O(MFYDD^K.6;ZFN_P#V;I+33OVI45\]?MG_!WU[X+_ -G\6>!6L=3UN'5M/M%MI-LR2K-]-& M<'Y2P. >V*?C\5?@KX?D\<7?QO^&WQ9I=.3[5 MJ_A"T@MM/F-N.9?L4Z3.SR*N2!(/FV],D"O5OBO^TIKNM/\ #CPM|&[73]4\ M6_$##3SK-GJ.L;OL6EZ6$1FNYE4[F/[Q55 >6SGI@@'TG17Q#^7%XQ_:;_9:^M$?B#QI-XQ\.?$_3X+8"X8Z"--N=)D9E5)T5'9)X@QPRMA@&!SP:^S?#]|+]. M@:==S8\Z>VCE?:,#*39? V@=&%Y>?\6$;[{JLX1]:BTIRV94 & :N^&?B#\:OVJ=7UW6_AMXIT? MX8?#/3K^?3=,U.[T9=5O];>%S'+/L=U2*'>"]_Q':<^P!]<$X%2)L#*_/\A!^7/IUKYT^&/QA^- C_M/7WP?!_M?'0;)&Y<@X{KFOV00@/Q*T|M:{^.5QHWCW2M3LK#Q%$FM6T/AXO-JZT.]>6.*2\VPWX@?=&Y1@589ZJ>:[FOBOP?^UOXRD_95 M^$^HZ9H^F:_|6OB%? 76E:/8+%]DL$DCN)P]Q*JGY8HHHPS!>2?]:U_&^H?M+ M?L^>&)OB%K/C'P[\5=!TJ,WFO>&;701ID\-HHS,]6.KL79%RV)!R%/?B@#Z] MHK)\)>>)]A;>%M(\0Z3 }HTO5;.&^M9<8WQ2('0X[<,*U["BBB@ HHHH ** M*** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ^>OV^_"NL^-OV4 M/&VC:!I5YK6K7)LO)L;"$RS2;,V!FVJ.3A02?8&M;]K'X1:_\6/A/8Q>$7@3 MQ?X:U>Q\2Z++#=G;#/=6C[UA<|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e M9;]OK2_$:Z5>'0$^&\|@VJ"$_9UN3J4;B$OTWE06V\<#-?'WGPS\.?L]?%WX MA-\0?@DWQ)\%^*M9F\0Z1XJTOPTFM7-C+/@SV5S&%,B(K@LC $88^^/O6DQF M@#Y/_9[T]=?^(^K>,/#'P$TCX,>!M/TUX=,GU#08=-\0:K>$\M&HQY$&S*8D MY8L#D#('G U";XK_ +1WPW\3>!/A!XS^&?Q%M]7#^-]4U'3FLK"33%1A/!<2 M@^7>.YV>6R@GC/:[WQ1B@ OD5\]5>$_V5_$FG_MDW;7:L?@UHU]-XT:T,?[MH:W>(7CSZ1,DLRJ/NF53_%7VM10!4^%?V5_$NE?ME7(G5C\%]*OIO'VDVA M3]TNN72>0\6?2-EEG"CA?,4]Z]/\-^%=9M_VZ?&?B"32KQ-"N/_^FV<.I-"P MMY)DNYF:-7Z%@""1U -?0]%`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|IUS]'BG0;F^MM!LV+S1P?]MO<#)VHK.<]'377 M_M[!;4_B3H?@OQ1HGANR\;ZIX)UC^U&\+:BB-%]]HZ&.XMP'!7S-I#)NXRG MKBOI^B@#X%U[7? OC'24T3X6_LEN_CZ\O%`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`M;;AX.U[(W- XD=K9FYCDN85* <(ADC$;8&!^\&.*"}B_X)W67BJ[8HUL^"9] M/T_5;O7=5D\/7&KQ.]FD9F4*65>2F1)T[T ?(O'VK M^*/A?]&G:.+$DLUM9;5=^V30!HT444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !5;4=1M=(L+F M^OKB*TLK:)H[B=PD<2*"69F/))/I5FOS_X*8_M:Z;:ZGI?P5U'6KWPK MH.KZ;+]_B#6+6UEFDFMU$GV>OBV*W,TL>'8X"J!DX)% '\;)M);PGY/ MVC^VQ>QFS\O.-WFYVXSQUZ\=:_)X0^)?#WQ5\-?L3>#+M8|?\-Z=K6K6>MV M%|;-]G>^7;+#&P<;9/EF7&,CYR/45EWJK#\$|9\(Q@#X>?\ #0|:8;7.+9;+ M!8P^G€Y ,.F1F@#]_*WBK1?6CZIX:@#F;5K6<>UB"#+|Y _M]X>1R/BCX0^*NES:CX.\3:5XGL89/*EN-)Q6N$C?^ZQ4G!C7Y+_M 6 MD7@A_P!K_P *^&8(\#CQ#X76:RT]1%;0&1B9E4+PH+#D#T [5]5_LZ>'-' M\ ?\%$?BEX=|'Z?:Z1X7?P3I=U<6.G1B.W6Y!A$;;5X#%'<^-^XGO0!]RT5\P M>(OBA^U-:> (-3@TCX*>%K_28KJ5+.|F\5I&\T(-7-96ER9XU:!PA(<@9YS^5 'M=%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !5;4=1M=(L+F M^OKB*TLK:)H[B=PD<2*"69F/))/I5FOS[

*BQX>^&VI^%K#6Y;J M.X\2:DNE6 M[.2=3.RDC>44A%P/O-@?KC\VO@]X%0!&F M> +O5WUO0_@Q?^.VL%NI)T6^O\{X]PA)*G8A:14VXRI."2<^Q?LVWOPK74K+ M6?AI\7O&?CSXK_|.'"*7FI76CWFI7-S::.E=>0#B[C="D;+*?E3*: ,;4B M6-E0(!U&[C'3IO%%IK7B+3?%'Q:M?&OB>YUW4_C6F@>%[.WUF9;." 700D0A MMK;E# C& %Q@G(]^FVC_%;PWK_Q(\1>]/+&^>?Q+X?MK;[U&U$##A8(YP3%^\M(VDL 3@'-==D5\6_L<_#52[_/;G_;5^(,5OJ,US%XG?P_#YU_))'\B(X*D MX;#D!,_<7*K@5Y]X[T'XE^(?VM_&]-{5/5K+P5XUO&R\;.AK<5[*LUAI0 M3;=6T+9S'YUQ&]+M(Ky&,$T ?HGD$XI: ,.+X7>--*U+_ (*05VNG^,=;\76= MY)>P6EK8W]W;KH7V2 Q26=[9R+L>W)&Z.52-SA22,_K]KCP/^T#XH\2: M#X:DO3?:-4Y$F8G.W S0![,1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !6=KN@6/B/2KW3[^.!9K;\MY+;8=&,;]58]1P M3TK1HH \/US]C+X5>(?@[X?^&=YH$K>& #\OGZ4T=[*EW9R[F8NDX.)W',2 M01CT&+ <7{7PIB^"$GPF_P"$6B;P7(YG>U;>0S-/NW?;/.SO\W/,_.>W3BO9 M:* /%/"!"PG\&?"WQ%\/[3PR+KP]XB_LX0:L/6DRVMUJK1M>W!=275S,$!$:&20D[5!.%&!S7K M%%"!7RG_P3=_Y(9X@_['+7/_2HU]6'I7RG_P $W?!.DAGB# 1%?A7X#OO&?BC68-+|-V<22R7SY=2'(":!0H)8L64 $DD5YWX>_; M-^%/BSPMH? B#1]>N=2T_5M>B\-1"WTVX,I%_(,K%/'LW1#'.Y@!SUKG?VW[K MX86_P0B\&_$O5;[PIH.OW$6GV6MV\$LRZ=-=1CS(OY) "%"LB_>/S9(\2/EKX M7_&CQA\5W_9MTZ203:U-XIU^[NM2TT-9Q>)4TVT_=7D@ 4N)68*Q8UY\4?'K_M%^:*/%UKIFOZ)]MN[6&S1[MS8UL\("I%&JA"@4Y){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|F/P?>ZY!X9^'J^' M;G7+ >XU#5KO2;/4K

M;XOK"&_/[J%F/S=!@'C!)(P37T-^RDNL?!{]KWXB?!A?%6N^*/"<7A]Q\0V9 M\07K7S_X)ZP^(/AA\4-\=^.+GQ+XW^(-Y;7^ MH>)[>Q2V%O+;'-MY4(;&U3G(R,@X&, UW?[-G[+6L_"3QUXl\?\ CCQP_P 0 M/'>O6MMISZB+!;**'T@ "1K&I/)VJ6/?:.. ^20#+!\0_M]>%/#NOZEI$WP]^)M MS-874E]\UIX6EDAD9"ED8-!RDC(/<$5A_|*

!,;4TUG]GG5KZ.*;",X\6ZQ, ML=PFR10UQN 9>Q&<$=CFOK.?@9X@SS_Q66N?^E1H ^K;*** M"BBB@ HHHH **** "BBB@ KRC]H#]J#X=_LRZ':;EX\UP:<;UF2SLH(FGN;D MKC=LC7G R,L< 9'/(KT^_P!0M=*L!{R]N(K2T@1J99YW")<&2S,> .237X MV?\ !4 0Os$/QH\;Z5\4 _">ZFOKOPVL]/BT:/64LF2T,PDD=GAR=?U;/!A M"5P&;&::3>B&DY.R/T3\%?MX_"?XF^%DU+P;]E[XGUB6;[-!X7L+-S]LLN,X M$#8VICDRL1&HZN*VK?X3^)?C%-']'Q9FAM]#W!X/ &ESE[(#J#?S#!NW'&8Q MB$$?=D^]7Y^ \$>?@[XM\,>,/%/Q0UF) #_@H;4^F+/?KY2WDC2HY*[L?+'Y M?+'C+ #OC].?^$EUKQG\GA]#^S]-/77-0B,'' 3"$X+ ^5MA?3=6*$YW>R6[M>B7 ?):G;53PU2I=

I);MZ)?\'R5WY&UK'B+10'-C:P2LEN!40V=A;O;I),# M"QO1(,G P_8'L*Q?[.\1>-N=2DE'-:,W2PM9!JMG7 JK*Os0 V8\G,-;'2MC MP]X,TI[P[-)=KY#[JDPQ-J5Z_F7$HJ-W*.[*=^2/H/%WQ+|*^ X=^OZ_8:4:? MX8]B=1(_^ZGWF_ 5O&48/EP\>;?>WY+|?=]K&\;D*3MAH\TOYFOR73U=WU5C MD/'_ ,OO"7P,I+,0[SPU?

7&EW$)D*6%@DMN!NVD2%F +$\\Y)KCQ@5\;/#$=_MMI?A?3O#V]07T\ICFN;>P00!F9BK2.K9QCC)':N%_;-^*B_$*WT:#1[?6(=# MB,D[7%W8RV\%TV0]NX#

('S=0.O&:X+X/Z5+K_CFQT@ZGJND6&HDVUW<:3+) M%(R%2P0N@.T,R@9.![BOT3"Y#"KD\\1B')3=Y--_RWW5KW\O0^?J9Y%=X*4 M;QDTY.]VWK9[VZZWZ]58^S/%?

Q9_^#[G[=2=G5Y",KIE@AN;IO^V;9*CW;_M |ZX*Z^*_B;O?+!)Z+!X?MSG#+"=6U$CM^ZA/D0GWDE';=;Z'3?A\ #?X7 M:0!G5"ma6E9(=TMWJUP\A/]VYD.TGW/-1Q?

&G3]2B%MX%,.:IXO"@]D^G6PMM M/4C_*>9=D9' 7/>?;OC*&%IS7-0IRFEO)VC%>K=TOFSLEB8TM(I)^>K^459 M?^E'RE\9K$Z?\1[R.ZO=2O-5EM899_[9GA>

[5<';E8@%C3DD(.!D^M;7[.M_ MX0TOO[?7WBK5-*L%LM/,D::E+&@8F1<-A^NW!(]SOFN(_;8^'WQ7B\66GQ(E M\,Z?=6HLUAD&E-+?-I21DL!

(Q"':=Q8D+M!!SUR>L_8"^2B,77=6\)~^_/"] M<D=+,K#IHO,/;<3N6#-. ^2]@ -P3N..!7]17\6EPM9]GB(VY5&T6K\UT MG%:O6W773WMCXW]

[5S1MQ;N[Z^F^VW9=M#Z@_P"%R7?B8!?_A/5/$B-C;]= MXIT[3\>HEE&]Q[QOO]:4> O&_BW+>*?&9TFU;K!?A*,VP^C74FZ5Q@CKTW% M+7X;]>C2TPM)1\W[TOO>B?

G&,6?6>RU*,^C7_DV^WU>K4F >U80QE3VWMZS+F^;45^P+++M;<[1K=$,#T_U9Y(XXKZ3HP/2EJL? MC7CZ\L1*-G*[=FWJW?]V"'E&*A*3=M%?L%%%%><6%%%%

!1110 4444 %%%% M !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>3?AA\ @=QQX9USP_)#\MHJOE6=

[83/D&4SL,S0X.?+SZ\#) ^]I*-/S MXTO[C;XK_I_:=\"/%'P^AT?OOXN\#:1]&DZKI-]>FUAN%NY)ILQ2MCY8WG<<-MX)"]<_\@[_D4]%_Z]H/_1;T ?F;_P %P?\ D%_"O_KM??

RBK]H: 5[_(+@-M_P#(+^%?_?:^_E%7Y0T %?DOR9]OP;_,CFGZ2_])9YK1117[>?T2?1O[#'_(X^/_|-KST[M_P!"N:^P#TKX_P#V&/\ D-?^P[?_ /10]"__";K#_ V%

[[_T8*_>OTX_P"">'_) MNL/_&%[[_T8*\+B'^:!#_%^C/EN*?]U[_P"+]&>W_%K_)]7XR_[M[_,B' MK\W=(_Y\-A_U[O?^=OTB^+7_)*_&7_8%O?_ $0]?FH'_(OL/\ KWB_] %>

MSP%_$Q'I'}3\AQNT2W3)_P#CWE_W&_D:?3)_^/>7_<;^1K]?ELSS#]"\/@#_R M0[X?_P#8 L?_ $0E>5_\%"_^36/$W_7Q9?\ I3'7]GP!_P"2'?#_ /[%C_Z

M(2O*_P#@H7_R:QXF_P"OBR_]*8Z_F#*O^1CA_P#'# TI'NXC^#/T?Y'Y$T44 M5_H@?CAT/PX_Y*+X3_[*]G_Z/2OWF'2OP9^'')1?"?_ &%[/_T>E?O,.E?R M=XN_\CC#_P#7I?\

I4C]X=_W:?^+]$+1117X6?5A1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(>3?AA\ @=QQX9USP_)#\MHJOE6=

Q7K[OX>M/L*HWESS E7?<9/M0!^2&K+ MX+|"S:.]?"?\ :=|.V3W<]Y>SVT,_K;&1G)>5B'4.7Q(0=1=3&"&N"'"09"""2":.^8?&/PV;,9\;Z-K6@7/C3X:V^ MCZK#-92O':R>8()

4,&8R.[2>OKZK^!?PXE^$/P=\&^"H]2,5YM"TN"P>^92 MOG,B $@'D+V ["@#NJ*** "BBB@ HHHH 0]*^4_^";O_)#/$'_8Y;Y_Z5&O MH'XA?%,P=|*+"UO?&7B?

2O#%I=2^3!/JMVENDC@;BJEB,G SBOG?_@FA?6^I M?`'6K]TGCN;;;O?K4D*OV9_AGX=M/!,B6'B#Q-*/&==XA>R\,Z.%DNY%Z>9)DA8(<]9 M92]CG!)XK\G_ -B?]M[XW?

$OXOZ1+\n/,^(%W/I_BJ5K?^UBRBNK{3RL;2%K M=F 4%@FW+AU?=N"G&^=^GPY^<%GASX?;;/:Z'9\)>)[4KN5KB]OVL27?*MMX@.B?7FF6M95):M07-]

8GN!&SL>#R ,/Z'![XK[GA3"U'E,*DXVC9V;ZZ=.[].ESKP6?QX?K/& MP@]DHI!*^S>EWVM^.WF8_P"SAXFT?1O&MS!X@++WEK]E,]M!]P2W3R7(90KQP M(&W, 2-

Q'&>HKZ,U7XU:_?W)LM\+FVN",C^V)=UP/?[);[Y /\ KH8_?%?/ M'P"+&NJ?$#Q7^8[41_CFO5XBIX"&/E+$U+NR]U)MK\E\K[=B\?Q M%6X@]+&>P46U;63<;K2Z6CU\

[^CW?(ZSHGBO6(OAJ;+\$//_MA^02V?A'2[<_Y^TI36J$39]?,DW-^A=M=K"]P*B-B-%& JC_^@KY;>/PL$X4U M.WERT_OTFW_X$>5)BBBIG3D:NGW+E7SI?

GY^W]\8/%9TGPI-I.C>(?#N@3RR MPW!UFV$,-S,NUX@(MQ8,..@V/B*]T:UO(I9 M-2N]+\@C#K[$C,NX.K)C>57>)\Y?UK](OBU\'K;XOZ;_9>IZS?6NCO&4GTZ&"V

MEAF.&YY=[&*KVDHW3DM;VWIV7DCZ;,(PTBK'G_CGX/P>/I]0^V>*?$ME8 MW\!M!].T^_6*W,938P"[*1N!..>>]6_!OPR_X0V_2X3QX3XDU:)(3 M!]EZLT* MCC!P$!R,

<'/QAS<]M0HHHKSS8***** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ^;^/"D?_ "9+\4O^O.V]*X*[;!W_(IZ+_ _

>4'_HM:|_X*1_ M\F2_%+_KSMQ_$K@KW_P=_R*>B_]>4'_*+6@#\S?^"X/_(+^%?_ %VOOY15 M^4-?]]_P7!_Y\?PK_P"NU]_**ORAH *^Y/\ @CU_R=D?^P'=_P#LM?#=?

%Q#_A_B_1G57%/^ZT_\7Z,]O\ BU_R2OQE M_P!@6]_]$/7YNZ1_R";#_KWB_P#0!7Z1?%K_))?XR_[M[_ .B'K\W=(_Y\ M-A_U[Q?^@"O9X"_B8CTC^1^0XW:),ID__'O+_N-

_(T^F3_\ 'O+_ +C?R-?K M\MF>8?H1\ >2^2'?# P#[%C_.B5KXLO_2F.O5/@#_R R0[X?_P#8 L?_ $0E>5_\%"_^36/$W_7Q9?\ I3'7]P95_P C'#_XX?\ I2/=

MQ'\&?H_R/R)HHHK_$0/QPZ'XE?O,.E?@S\,/^2B^$ M_P#L+V?_*/2OWF'2OY.\7?^1QA_^O2_]*D?H'#O^{3_ ,7Z(6BBBOPL^K"B MBB@ HHHH **** "BBB@ HHHH ****

"BBB@ HHHH *** M* "BBB@ HHHH *^/_P#@HY\'=>^-GASX3Z#HMAJ]S!_PFUH^HWFBQEIK"U,< MB/<;AJS9NSN/ .*^P** /AW_(=7:

3G_A9<3A%QOD:NQIFNEHH ***** "BBB@ HHHH YWQG\M//"_Q$M+>U!4^-*\1VUO)YL,,]V<=RD;D8+*'...U\W_\$T2!"Q^ >MV! MM#*;!P1>,-.1(HE"JJBYP .@

'X5]8L<"OE/_@OF!Q\/#/$ ((/\ PF6N=?\ MKZ-`U;112;@!G- "T5\#_\ !2G]O;Q'^S1>Z#X,\ K9)XEU.V:_NM3NHQ.+ M2'>414C/!=BK$EL@ #@YR/.?

V+/^"F7Q(^*M_]7@OQ/I>A;YXC\AKNQUN\NT MTJWCC7 D^T.5;?C#_ SK M,FA6=Q=>*_$Z9SH'AFW;_O%/_30)\I(_VI60>]>6'P]XD^* W^*]7\1^,[;3

MG^Q/#,#Z!H>".5DF=Q<7_^K[3_VB_@3?I_GM^)G2?\+?\ B'&7 MN)]_^$>AGDA#'JFLLONQ_P!&@.#Z3XQ7RY^U\|#/A7XR*V?AV#4IO$WB26< MSWGB>[U1M0U.

HN%7$&)1$;>| M9H<'T*;#\>VTU>\4_*#PKXL,?V%/14-C9*XEA.G(MN\#@8#(5'!P2.000<$ M&@0P,LPN(A/O'U:,.5.TT>[\ ^)^:.0[&?I-IC

M\%/C'INKZ!/'KGBBX26SL[G68<068=#ND5$.=VT,.YZ$CC)-?HU'\+]4UO#^_M*_%^1:JI^)8Z;_Q+[7'H1&?,8?5ZK?#:}GWPU\;=4?5+.2\U+4BACCN;^16.

M*GJ$55503T)QG'&:]-K[S3,<)&LHY3!0@EO9KR-XJ7,WYZ M?=L8OAWP9H7A*(QZ/15IIX/WFAB =_\ >;]WXFKFKZ)I^OV9M-2L;>_MB^OWGI*$4N5+0I:1HFGZ!9K:::,96]A;

Y$-_MM&(USZX%7:**B4G-N4G=LI))6044445(PHHHH **** "BBB@ HHHH **** "BB MBB@ HHHH ^;^/"D?_ "9+\4O^O.V]*X*[;!W_(IZ+_ _

"BBB@#Y0_:4 :3\6 #WXD^!-AE\-2"UCXI\>^)X;]^1-6NS;6EM:P(69F8 M3>+:ZA?;(H;C*GAA MGG##/2O%OVK-$\7 X_:D^%WQNT+P5K'C[0](TF^T34]-

\/1"6\A,HHSH_L;_LU7EE^R'?>"OB?H\MG+XMOKW4M2T?SVBEMXYY 5C9T(M96VHI.'",X/.: -W_@!^^#[N!?"FC S1 M@_8H/XQ_SS6OFZ;_

()>_L\3QOTDA*_=6&"&UZ^(_(RTX?\ !,']GH # A$M M1XX_Y&^__P#CU_R_P#\%O94EPTOX6/;5\}37WW24#MCX9B\L5^^\W_!+C]G2)XV MWP#KX\EQT\S7;UL?G+7.>/O^'"8?

[.VA>!?$6I6?@F>,[L]-N;B%SK%V=KI$S*<-M&3!P0.M 'X5XK[C_.'/KK^'UBQ=@H_L.[Y8X_NU]?7L@_|-!/'X$_%?]FKP M!XL\2^$9K[7=5T[S[NY75+J(2/YCC.U9 HX

Z"O9(O\ @EI^SE ^^+P5=Q-T MW1ZW>J?S$M 'U;]L@ Y[1_!?8K_OVF9D;]H7Q>0ZD&'3^=P_Y]Z]:_X=@__ML]?]"E]/_A07_P#\>IC_/\+K]G5V+-X.OF8]SKM\3_Z-

KULJQ_]FXJ.)Y>: MU|+VW5NS/R6WN6U;ZF""?[BC?Y'D*Q>*<)>.<.)M??L{7.GVTK^=;PN\2,3_ &Y>]2H/_/6ON/\ 71?]_+Y-_]J?HG_$0?^H7_M_G_

/M2I^PU/$GC#Q\6D11]CT[JP_O7-?7QO(#_,MH_P#OL5\KQ_|-/+S] MG:(DIX/OD)Z[=>OAG_R+3O\ AV%^SU_T^6H_^%!?_P#QZO@,=BONG)GB+6YG

M>VY^8YEC/!0Q=3%__':\[_:,_8*^"OP^^^_P'T71/"]Q:Z=XH\32 M:?]L3;K=/Y\ @+A__':FC_X)>_L[PKMC\'WZ+UPNO7P'Z2UP9AFGU^G&');SOO?] M$>9FN=?VG2C3]GRV=[

]]/\'OWQ9NX#+\/&0$T9/]C7O&\|?\ /IZ_.#2)$_LF MQ^=?^;+N/]@KZC/_],#]GE@0?"M.H$'\@@Z_?_P#QZH_^'7'_G_0F7O_(;

MW_X[7;D.>_V)*1+V?/SVZVM:_D^Y\A6H^VMK:Q\U^:G]]?\ OH4R>1/L\OSK MQNX]#6LG["7P9/[=LGPW/A][_X1 > 1K@LO[6NL_;/MWE>9YGF;ON<;_^#V]_P#CM?

7OCVZMI6_\F_\ M3E^I?WOP;O@'=0K\#_ M (?@RQ@C0;'@N/\ G@E>6?\ !0BXBD_99\3!948 ;:++@,#_R\I6OO_\;#IGE M5"KX1U!5 P -?O@!_P"1]:)_P2]_9WE0[_A"_=3_

MKU\1^1EK\PPE?ZKB; M>(M?DDI6fV:=COJ0YX2AW5C\I=P]1^=&X>H_.OU4/_[+++]G #_D2;K_P=WQ_M _=KP+|F_P#8)^"OQ"^^*7QWT;7/"UQ=Z?X7\4+INE1KJETA@@;

;9E9 6Y/5 MLGWK^B/^(QK_*/_*G_-H?&_ZM_P#3W_R7_@GR3\.6 ^(GA0Y'_(7L^_\ MTW2OWA%Y /EM'U_OBOE(?\$L_V<001X)N@N1W&MWO\ |=?J_AV%^SU_T*6H

M_P#A07___>K\FXOXG_U|OE/%^Q]GRQY;KX4]8***** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N_:5 M^/&G?LW?!{6_'6HV4NJ"Q\N*WT^!MKW4\CA(XPV#M!)R3@X /!Z5PG[-G[46 MO_%3Q_XK^'GCWP2/-GCO0;2VU-K*&_6\@N+2<-JZN_,%=RAA_M>H(%+_(*)

M_"_Q%\5OVM9P_PKITNL:U|H]9ZK%IT S+&{'P]91>(;,VEQWG\;G>R)9RR.K-YV8*YC92-[.JD MD @YS7ZC>.O^:/PG^(V]:C?:_?>+|-[=>27TEM)X@E:!979F.R,@A0-Q Z

M#BOFK\B7_@GY\+/B?\/=1\4:D_B*RU]R\1ZIIL-SIFKM;.L,QC095DSZC.O_;2X94/_?NJ+_LF;GXC);QG M\|7O&7B@.WWF:H6E=2=NWI;_B?5N]?

M44OF+ZBOE$_|$V/AD=W_!47C_YB#_R-5Q7E?C+_ ()YV5O^T!\/]-T:]\>S M_#V\LM0?7]0/B29C;SBFU/(_)NO_%57%#?!$V?ADV[_(]+Q_|,,_ (]JXH ^KO,7U%'F+ZBO

ME$_|$V?AD=W_!47C_D8_P"1]N*#_P $V?AD<_|%1>/\C5<4 ?5Y4Z MBCS%)17RC_P]9^&7_0Q>/_N]?^1]N*X*X^_L%> ?AW\#_'WBC2?$?CO^U-&T

M"]OK4S>)YW3S8X6=-R]QE1D=Z /NSS%)11YB^HKX7^_.!!/@'$Q@?!?P#XGU3 MQ%X[_M/5M"[/ZX\GQ/<(GFRPH[5!#)\!7=+!_P $V/ADNW'B+Q_!HP/^*]N*.M

/]!S%)11YB^HKY17_@FS\,EV?\ %1>/_EZ?\!55<4+_P38^&2[?^*B\?_+T_.MX]]XH ^KO,7U%'F+ZBOE$?\ !-CX9#;_ ,5%X_X)/_(U7%_.X)L?#(8_X]+Q M_P '/_(U7%

'U=YB^HH\Q?45\HC_@FQ M\,@%_P"*B\?_ "DD?\55<4#_ ()L?#(8_P"*B\?\/\ R-5Q0!?>8O]* ZD MX!YKY1_X=L?#+C_BHO'_-[=_P

C5<5YEYM->7 M6VOH-8U]:[1_*M 4PK8 P7?]D2@#[HH!T%+0 4444 %%%% !1110 4444 M%%%% !1110 F,TM%% !1110 55U33;>6=-NJ/O8A/9W43P31$D!T92K+QSR"

M15JOD?XQ?M^I_$_B.'1/ASK'C'PIX5U*'1_$'B&TO(8$M[V0]!;6\3G=<2 M NH*KCDXZFEZ%ID7D6EFCLXB3),,L2QY)ZD] M:WZR_#7B&Y]4Z):ZG9[UBG0,8I0%EA?

^*.1<_*ZG*LIY!!JZ5]4 %%%5=4U. MUT73;O4+ZXCM;*TA>>>>5MJ1QH9F8]@_"2?:@##^(_PV\-_%OP?>^%O%VEQ MZSH%Z85<64KNBR%'61.4(/#*IX/:NCAA2WB2*-

=](H51Z <"OBFY_P"'"C*Z5 M\1=$UC4O!FJZ?^S_*ZBV6G^/[NQDA7[;O8>8RGI;L!@$@'@MR 0/M*RO;?4 M,:"ZM9H[FVG19(IH7#I(A&0RD<$$$$$4 3T444 %*[UK+2+

(*&,< M9DDED=@]1QH.6=F(.!?3)KYZ^#/[;VHZS\8[WX>?%CP;>?#'4]7G>X\'RZI M$T*:G:$X2)RQ(6X[D X).W 8 ,.?6O2EL.M+0 445Y?\=_CWHOP.T?3/M5M>

M:QXCUV=K'0M!TVW:>YU&ZVY"*HZ*.*SD@*#]*.G'PQ\,#XE'Q^-)C_X3 Z9 M_8QU3>^_[*YGF>5MSMQOY5C/O74U\R_LG_M?R_&2_P!'1\"?$'0SX!^,&B@M?

M^':E6C%Q%U$]ON)++@C(R2,YR5(-?35 !1110 5R_A+X9^&? NM>)=6T+2DT M_4/$EZ-0U6=)'8W,X7;O(9B!QQA<#VKQO]IG]J+5?AQ/>>#/ACX8NOB#\5TI

MDU1=$M;5Y8;6T\P!I;AU(VY7<$4'<3CCD9[']FO]!3PO^TSX#77M!9]+4K5O MLVKZ%=G%UIER.&BD7OXR#M;&&.$$$!1110 4444 %%%% !1110 4444 M %(3@9KG/&?

Q'\,_#LZ-_P)\K5IHPUB_33+%KN38L]RZLZQ@G@$A&QG XQU M(KYA_:'_ &L/AQX]T?QE\(+#QY>>!_$VL:6T>B>*75K;3KR9@"JP7OW"I;$; M-D#Y[*MD4 2?$S]IKQ_\4?

BOK'PV_9UNO"E]K'A>UDNO$.H>)/-\N.=93&MG M$H RQ8'<_*C(&0.^;?A!\+OB3\:?BIKOQ2\ 1>'?#*JC;3-=GM_%?@7QJ+B;3 M)\UORPC;G9]F05,N2N_YD;> 6&TCI-

/^'7B/H[X-Z+\=OA)TG@_P#:)\/0 M2:)XP3ED5%U>XMP$EBF'*&1U5'5FRIW*IZ*5^F?V]\T=?@E+X@M-\)2:7XC MU4[B(\1R^>,^1.M2T.P#S=E>

*MNEM#"L:1$B+&,(%4#;/;TKRKQU^S9X6^(OB"YU'4=0UZ*POA -2T*SU-XM.U M 0MN02PX/" #!"F\ !MU4_VO/$.H^:?V?_$-SI>HSZ3///86$FHVLFR6V@N+ MV"":1'_A81R/AA]TG/:L3X"Z9#X$^-OQ6\"Z)5F[O56&")> % 1$!8Y9SDD] .8^-W[0WQ/\'^+/B;_PB\/A MEM#\#KHCFVU2WG:>_:_8(R>8D@$83.X-M8GICO0!]94A8+U.*^2X?C'\4G^(_MW_"J'N?"Z^+6U^6R'B7^SYQ9+:)ID5\0+;SMS3$R[-/,QM4MVQ7D/Q=^,_BK MXN_!ZXOM5N8;/5?"NEZ]FH_| (S)*B#0=2$=,LC&=VX]D2{-GDJ*-/TJ3HKY M%\,?M-^/_B3<0'&=[:WJ/B-^U#PUH]/XFM8;+6?M$6]+-^*($ M1"5##\K%0Q ,&X<<\#'C'[^>LZK;>,/@H%D?%EU8:IJ.I)>Z9X-OS9WMVL=B M\B /YD?"L Q&X<]>E>,.^%/B?XUO?!&IVVC^)/$>@>&?%/Q"T_P?!\WB2\2[MU_P^A1UOQ(S;O*=Y(@D2REF4RAOXE%><>2?6'@S!F3X7^ ;F_N-&\'6"7%]:M-87$UZTEX[6S##P!IV[E1KB%C#ML0,%7)P!7SQ\5?B%-^S1=^.[?PSXC^(@OX_#&HR6MGXN@G M&PN[N%8F^VVEW.OPT2R$M&,H^1PNWG0|(W>KZ=#$Y]+>+O'2C/X:QV^EZ9X MBO;C7]@=@U%VTT32K/+!>]0;;28H(Y{P"(R 8L[N -#WP_LG_"EO#D>AMX3C?3 MXKQ[Z+=>W)6Y5BR>/RG9)O-\Q0R?*RA@K#]#3/$/[)'PC\47UK>7W@RU$]K[\, MEP.:7$]L(K2+/EP]L4B@(N3@8]Z^;K+4_'3Z?X8GUS4/B1;?!_4]QFL/-MM$OB 6GDP#3A7[4ZY&|P"0X.*SX_&WBOQS\[_#'B*^\=^+V^{FJ M6%YHGA'PIHDBVEY=.E;WMQ"+ ^["?+(H2. S&0"&,+)U+B@#Z_P#B,\)H?&GA M30K#2[H='U+PYJ%GJFC7;JTRV\UN(R1-SG;(3G-.Z"WPG'X<\0Z M!_85HVC>(9[]YV6R="T=W)\16NC_"WP:I-9ZUX MLURTTW5=1TVVA*PQ6\EU=^2PY0R?95*.0LA(Y KY*\<^/\ Q'!;_$R|CN_B M;#XDE\=:IH'A[Q):Z^MOX>L)_M9CLXYUDE*)"C;5;?'AON@Y84 ?:]H^S-\, MK'Q-IOB"'PC9C5M.^SM;S-)*RB2",1PRLA'-:L3>;'=Z=K#)]=]4O(5A2=64*?)0MDQ$^7G#9SF@#Z= M\6? [P+XYFUB;7/#=I?W&K-;/=SN?65WMM_V=U=6#(\?F/M9"I&X||USR_L[M.:!IVK>!+?1H+,1O"?A:^N-:71X(V9KO4G1DCN)968LQ02S,2V69V4D_+SX]X MR_;"\8_#74-8\)^)?#>BCQG'[VGV%G/H[W9(J0F.F\%ZQI@$\|=GL,%"B=U"DR{^(:+>1 M"R!E!E4[\@'NOA3X.>'O#?PIB^'US;_VYX>^S2VL\&I@2BX25V=U8'MER .P MQZ55\.?I_?#_,)Z7;V&E^'(;."#5(M:5C/-)*UY$-L+-;T^34[E!&9A#>R1KA 2(UPO"#A1@#I0!ZQ;^$=!M M/%5[XEAL(DUR\M(;&XO1G?)!$SO&AYQA6ED(X_B-9&M?"'PAXAD\0OJ.@VUV M_B'I)_:A?=_I7V8YM]V#_ 1D8Q[YKYF\+?M5_%_QI;^#WT[P,X0M_P#A,!)U M'5=*-S]US_HI=BZ+*;@+#SYHD38$^[D[CQ3:[]M?QIKOPXUSQ[X4\&Z>/HA MK1-+U'5[;5=@2$=M:#\<_V5;DC][*=:I-9ZUX MLURTTW5=1TVVA*PQ6\EU=^2PY0R?95*.0LA(Y KY*\<^/\ Q'!;_$R|CN_B M;#XDE\=:IH'A[Q):Z^MOX>L)_M9CLXYUDE*)"C;5;?'AON@Y84 ?:]H^S-\, MK'Q-IOB"'PC9C5M.^SM;S-)*RB2",1PRLA'-:L3>;'=Z=K#)]=]4O(5A2=64*?)0MDQ$^7G#9SF@#Z= M\6? [P+XYFUB;7/#=I?W&K-;/=SN?65WMM_V=U=6#(\?F/M9"I&X||USR_L[M.:!IVK>!+?1H+,1O"?A:^N-:71X(V9KO4G1DCN)968LQ02S,2V69V4D_+SX]X MR_;"\8_#74-8\)^)?#>BCQG'[VGV%G/H[W9(J0F.F\%ZQI@$\|=GL,%"B=U"DR{^(:+>1 M"R!E!E4[\@'NOA3X.>'O#?PIB^'US;_VYX>^S2VL\&I@2BX25V=U8'MER .P MQZ55\.?I_?#_,)Z7;V&E^'(;."#5(M:5C/-)*UY$-L+-;T^34[E!&9A#>R1KA 2(UPO"#A1@#I0!ZQ;^$=!M M/%5[XEAL(DUR\M(;&XO1G?)!$SO&AYQA6ED(X_B-9&M?"'PAXAD\0OJ.@VUV M_B'I)_:A?=_I7V8YM]V#_ 1D8Q[YKYF\+?M5_%_QI;^#WT[P,X0M_P#A,!)U M'5=*-S]US_HI=BZ+*;@+#SYHD38$^[D[CQ3:[]M?QIKOPXUSQ[X4\&Z>/HA MK1-+U'5[;5=@2$=M:#\<_V5;DC][*=:I-9ZUX MLURTTW5=1TVVA*PQ6\EU=^2PY0R?95*.0LA(Y KY*\<^/\ Q'!;_$R|CN_B M;#XDE\=:IH'A[Q):Z^MOX>L)_M9CLXYUDE*)"C;5;?'AON@Y84 ?:]H^S-\, MK'Q-IOB"'PC9C5M.^SM;S-)*RB2",1PRLA'-:L3>;'=Z=K#)]=]4O(5A2=64*?)0MDQ$^7G#9SF@#Z= M\6? [P+XYFUB;7/#=I?W&K-;/=SN?65WMM_V=U=6#(\?F/M9"I&X||USR_L[M.:!IVK>!+?1H+,1O"?A:^N-:71X(V9KO4G1DCN)968LQ02S,2V69V4D_+SX]X MR_;"\8_#74-8\)^)?#>BCQG'[VGV%G/H[W9(J0F.F\%ZQI@$\|=GL,%"B=U"DR{^(:+>1 M"R!E!E4[\@'NOA3X.>'O#?PIB^'US;_VYX>^S2VL\&I@2BX25V=U8'MER .P MQZ55\.?I_?#_,)Z7;V&E^'(;."#5(M:5C/-)*UY$-L+-;T^34[E!&9A#>R1KA 2(UPO"#A1@#I0!ZQ;^$=!M M/%5[XEAL(DUR\M(;&XO1G?)!$SO&AYQA6ED(X_B-9&M?"'PAXAD\0OJ.@VUV M_B'I)_:A?=_I7V8YM]V#_ 1D8Q[YKYF\+?M5_%_QI;^#WT[P,X0M_P#A,!)U M'5=*-SJUS_HI=BZ+*;@+#SYHD38$^[D[CQ3:[]M?QIKOPXUSQ[X4\&Z>/HA MK1-+U'5[;5=@2$=M:#\<_V5;DC][*=:I-9ZUX MLURTTW5=1TVVA*PQ6\EU=^2PY0R?95*.0LA(Y KY*\<^/\ Q'!;_$R|CN_B M;#XDE\=:IH'A[Q):Z^MOX>L)_M9CLXYUDE*)"C;5;?'AON@Y84 ?:]H^S-\, MK'Q-IOB"'PC9C5M.^SM;S-)*RB2",1PRLA'-:L3>;'=Z=K#)]=]4O(5A2=64*?)0MDQ$^7G#9SF@#Z= M\6? [P+XYFUB;7/#=I?W&K-;/=SN?65WMM_V=U=6#(\?F/M9"I&X||USR_L[M.:!IVK>!+?1H+,1O"?A:^N-:71X(V9KO4G1DCN)968LQ02S,2V69V4D_+SX]X MR_;"\8_#74-8\)^)?#>BCQG'[VGV%G/H[W9(J0F.F\%ZQI@$\|=GL,%"B=U"DR{^(:+>1 M"R!E!E4[\@'NOA3X.>'O#?PIB^'US;_VYX>^S2VL\&I@2BX25V=U8'MER .P MQZ55\.?I_?#_,)Z7;V&E^'(;."#5(M:5C/-)*UY$-L+-;T^34[E!&9A#>R1KA 2(UPO"#A1@#I0!ZQ;^$=!M M/%5[XEAL(DUR\M(;&XO1G?)!$SO&AYQA6ED(X_B-9&M?"'PAXAD\0OJ.@VUV M_B'I)_:A?=_I7V8YM]V#_ 1D8Q[YKYF\+?M5_%_QI;^#WT[P,X0M_P#A,!)U M'5=*-S]US_HI=BZ+*;@+#SYHD38$^[D[CQ3:[]M?QIKOPXUSQ[X4\&Z>/HA MK1-+U'5[;5=@2$=M:#\<_V5;DC][*=:I-9ZUX MLURTTW5=1TVVA*PQ6\EU=^2PY0R?95*.0LA(Y KY*\<^/\ Q'!;_$R|CN_B M;#XDE\=:IH'A[Q):Z^MOX>L)_M9CLXYUDE*)"C;5;?'AON@Y84 ?:]H^S-\, MK'Q-IOB"'PC9C5M.^SM;S-)*RB2",1PRLA'-:L3>;'=Z=K#)]=]4O(5A2=64*?)0MDQ$^7G#9SF@#Z= M\6? [P+XYFUB;7/#=I?W&K-;/=SN?65WMM_V=U=6#(\?F/M9"I&X||USR_L[M.:!IVK>!+?1H+,1O"?A:^N-:71X(V9KO4G1DCN)968LQ02S,2V69V4D_+SX]X MR_;"\8_#74-8\)^)?#>BCQG'[VGV%G/H[W9(J0F.F\%ZQI@$\|=GL,%"B=U"DR{^(:+>1 M"R!E!E4[\@'NOA3X.>'O#?PIB^'US;_VYX>^S2VL\&I@2BX25V=U8'MER .P MQZ55\.?I_?#_,)Z7;V&E^'(;."#5(M:5C/-)*UY$-L+-;T^34[E!&9A#>R1KA 2(UPO"#A1@#I0!ZQ;^$=!M M/%5[XEAL(DUR\M(;&XO1G?)!$SO&AYQA6ED(X_B-9&M?"'PAXAD\0OJ.@VUV M_B'I)_:A?=_I7V8YM]V#_ 1D8Q[YKYF\+?M5_%_QI;^#WT[P,X0M_P#A,!)U M'5=*-SJUS

<,B;E5BN,!3]";;^SAI4GPX^(Q@O7;V35-\9:SJF]S- G MD26PNY?-"H%[C4/#>D6FBWDT M*>$+ZTFCU:)L%B#1:A;SE]DJR2'!54VHO#,&'/E5W\=_%7CK]FKX]^)?%O\ MP@GB;#3='DEOO UUIEQ''_!TL.FWFK:U82WKWE\8$F,$$,<-MD82*-)(PSDDECA1A4Z?YK6D MEPMU#(/G$31^3-@@L%WI@M@UZ#XB^"7C7P_X]U[Q5\,? &6F^Y/$GE2:U1GO MZ2]_9RW,<2Q+=P^7-$T>/|!^,[?#KQ_>;'KQU M#0I->TW6-%L1++9Y4|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|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|6VC_6OX<)-O MB-:,^&L:]?RT%KOS]/N80UQ, ((_/E*#\Q*X&/|V1SC->\5S7C/P[]>K>"M4T MGPKK^^$M7GC/V34X;,.<6TA;=N,3?*X)R"#UW'G/-`B?@/|LB'Q-HG@O6-<-M\+CPAI?B/[=(R,1(GS]C#Y61L@CBNGT_|;- ^#&]:) MJ.KVWC[2WT_3GMX[N5MZ^21[,L(8%007*-CCD#/3FO /%G[!.]67PTU=6UI_M%&K+::W-!HNBVD6GP)>:A_(W5H_!O]F/XB?$'Q M#=>._BKS@66>UTVUGC@BD2&5XXLS7!D'SN<1C/48 .Y^+ MW]>_@CX;`^%=*\2Z3'BW1-4T]ZU"TGLKU80J98KF*V2$1LN[Y192K,1\FPY& M<"'MK1/VU? =GX>?4?'.J:;X+F?5;K3+:V;4%O3.+?8)908E^55=RK%@ I7DC M-<-8?L#M!<^'9;SQK]K&G2P27"_V=M^U$:ZVKW"_ "T^7S&$,??'EYYS@7-$ M_8S\3^"=;CU[PA\1[33O$%];ZA9ZS=ZEH"WJ3Q76I3WQ:%&E'ER*9RAR65P] MDKQ0!ZWXI_:I^%'@SQ/,^`M7]\<;5:;Q.D$B6WF%SB;'D@E00&<,"]DY(.0,< MUDZ]^\/*- (C\90V_BVQU+5O"UE>WE]IMNS>:/LI*S("5P65L*0"<9!ZUM?!FL`>*%#7M7CT#1-0U:..

24,-6Q,N6C!R].GKV7FP^)_P 5O#OPB\/C5_$5X;>| MW\J&-2\LSXSM11U..?0=Z\[_99^,WACQWX-L/#VG7;KK6EVH\^5G0HY7:XW]B+X, ^)X?*
B!#XUOK*;3=$MK2:..&2<;3=M(-H"Cj5'))Z9-KY"KF&,_M-M:G1A2_=VM>SV=KOY-?U<_8,+P[DJX1KXROBE]83O92BTI1YE"%E>_,GNGUOM
M%GU[XB^-+'A[PSKATF[N@;T+"3&A4X,LZPHIYZ[FSCL 3795X1XH^!NK^)OBK-M+KSS6D.G2:C;RY-C;R,(H8'())&23-(5YYP 3T6O=]^DPU2O4E4]K&R3LO/?
M7\(<1'TS+#X'#T[U2ISRE&(_)M+39:IW%HHHKO//"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *

"BBB@#"\9>!O#_Q#T5M(\3:-9;H;2+;34(%FB+K|UM MIXR*QO!?P3\ ?#F_>|\+^#-#T"|==C7.GV$<,A7N-P&<>U=M10!YYK'|/'PR M\0>(-1US4_ 7AZ_U?44,=W>7&G1O),",'<2.2<(_$?B'2C\-/ URMYX>\+65ALECD6.,*LCG@HKQJ0!V &.]?4U% `&?$#X, ^ M!OBJ;5O%_A/2?$,$Y(5B,@9[9Q72:%H.G>&-(M-*TBPMM,TV MTC$4%I:1"**)1V51P!5^B@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M**** "BBB@ HHHH ***** *]M86UDTK6]O% TK;Y#&@4NW]<=34[*'4JP!!&" M#W!\?5MAMN3NS5D1\(O! U6RU\ X1#0_P"T+)(f[:Y_L'+1VSH<C6(;PC;F,<8K(;P%X;?5M,U1M!TTZEID0@LKLV]~ M,;1@8"1MC*@-D #IDXZUO44 85_X'T/4;ZSNYM.A%Q:.B-6C>-=A-T(6A$K8 M^\WEL5R>V/2M.73+2>_M[V2UADO+=`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ibio-20240630x10k011.jpg GRAPHIC beign 644 ibio-20240630x10k011.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L!+$!80$1,4%!5#@ \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L- %!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04

8HRB0@GC&/|I37HS>,,CQ[^U^^SUXAO-'M_#MQ?\ @BYE?2[: M/RHK?]VP 1#]U2 "!V!% 'UEJ' ;!1W|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fQ M_NYKXN\3?MN?%_3?AM\5=7M_$=LE|H7C]VT2PD.F6Y$5H|$,A&S#'C[OR?>N M)^&F@:+|:? VB/AJ;//I#3O&'B/1Y%O+"/0_AX=/"1+R899H0@3CCY\]/45Y] MXT9?^%-?'7YU_P"2H6?\0_O&@#@]DK'5KF7P+;ZH[*UXVG+<,Y48+ ^5NSCZ]J M^W]CK_.B*_-S]@S[]#X<^ OAQXS^&NM:Y):>,_9UC4OL5DMG-(LFY M9-N9%4HO3N10![O\(_VB=!U+|F&\U#|H3XD:%X@TG6-6N-'_ +2T|WN8(9%W M8\ES'$C+CN< 8ZL:]#_9<^//[.-W,? AC|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| WW@KPSH26_AB^GFN+G3[N5[M)FE4+(&\TL2K!0-O3VKQ&3_(); M?LYR^<Of:_X0F51YGFG3EU.X%F6SG'E[_N_[. <=L8H \(_8)U?XB> /V3_'W MB_X=> 7\4_VQXOEN?#WARXNA:AK,E$=U9B H&/_#3]H^WM 6NI?%6D)$%ZE MS&&&/QKR#X->/O"VD_\ !);XBZ+?:E90:S#-? 6,UA+,HN#=2NGE?(3N).1@X M_@/]TU^E?PE^ _@KX'PZ_%X.TI],37;I]3OP]U+/Y!MPWWF_>,=O7H,#VKR;Q M/_P3B^ ?B[XD2^~=1\%AM3GN?MEQ:O7DL=G/- G<7>%6V\GD@8!YR#DT >,?$ MS3KO2_]@D#;V]\CQW**<%,%BL@P0K3(R_M$I=P[*7_)L_PL_[%G3_ /T0 ME=5\1?A9X9 ^%@=4/!7B/3A=^&[^0)B?+&5X 44@]H:,@J 5'0CI6KX1*;9 MX%\)++:3X=T:W-KI.E6L=E:0%V'?!/X;Z5X& P"""5OBO4[0--]7B M?P][.KZE=SZ)[UL]I>6 MZRM&9(G&&&Y2&"'<$&L"P^!W@W3?@_+|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{A_ MND8P"O*XPR'FOUTB^M]3TJSO+1B]K<0I+$59R4905///0BOG[Q_P $^/@5 MXR^)S^/~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|^:M+;61]YTVT.]K M'Y0OC GGA/!OF8N*(U3E\#>')UOUDT#2W6_(:[#641%P1T,GR_/^:.,W*** .MY3M_#%;$_AC1[G48+^,2K^6 M^@0Q17+VR-+&AX*]Q&0/8&M.B@#(M_'&A6FE7&F0:- I\.FW!+36<=I&L,A/4 ML@&#GOD5X;^TE^S1XK^)MHH_P ./B1>_ #B\TM/*&EQP"?2+|/.0LMH?D)'8 ME2/:OHEB@#Y&_9R_8G\1?#_XLM\3OB;X\C|<>++8+0V.G0Z?IR6- E91'KLC0! M<^RJH^M?7%+10!R.J?"#P+K>L_VO]/@SP_?ZKG=]NN=+@DGSZ[RA.?QKIY[& MVN;-K2:WBEM73RV@= 4*XQM*GC'M4]%`-\ AOX?>%_!LLTN@>'-(T.2;_6O MIMC%;F3_ 'BBO/XTZ3P#X9E@N(\/:4\-S,+B:-K&(K+(.CL-OS[GFMZB@! M@AC&(B"*(@NW8 -N.F,>EB@#!'@+PT+'"*Q'A[2A913?:(.(!?[#%Y:29SO"[2/':3SJ2*O:YX5T7Q/I? 9NL:18:KIW^^B7ULDT/'3Y&!"'TK5HH I;/H MNG^:M.AL-+L;;3;&$8CM;,%8HD'HJ[!^%7;** "BBB@ HHHH ***** "BBB@ M HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@

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|[&N%\0?"=H_$AU[0$M[&[#"1Q$3&\Q Y&<%0Q]2,'N#7:7=&M9^)K2&\L;M#-'EK>]MF#;3W&1P1V(]MHWBU;BY;RU*-,"]0[1O;Y)3ZHQ&#G MTSFN5TN;FE"/]NWZV_%?B>',&O+/1HS=$\;7>UTOK=[CR>)C%$5N(/\ KI#S MD?[2$@^E;,7C;0YD=EU.W 09(=PI_(X-2Z[X=BUGRIXY7LM1@Y@O(<;T]C_> M4]U/!KFK'5K?3-3;3-;TQUU.4?\ 'Q"ID@G7.-RDG*^Z]1[BO/=*H_X+NNSW M7SZK\0Y^729V=C?Q:C)H22A1!BK-0VMI%9Q[(5VKG/)_G4U.-[>]N6-D^X MWT-4]$_Y!=0\M|*,$_Y!=O\M|*,>Y:?D^X MWT-4]$_Y!=O\M|*,>Y:?D^X MWT-4]$_Y!=O\M|*,>Y:?D^X MWT-4]

*LN>!=5\>ZK\7M6TFU\22"_0->MM&L-/NEL!J][`< M6UJ]7$D44J$#YALW%2&YKM=4_8DU36/$^C>(+OX\?B?5M(29+*Z>;R+P"4 M2!?]'Q\P5\ | +Y-?^CUKY)S7N^N_L<:YXETY[#5/-MCY\2[VS=E=H9+BQP2I#*>+8=" :YW_AWK!_T6;XB_P#@39__ "/0!Y2Q^5OH M:^VO@R1_PJ?PGS_S#(/_ $ 5\] |.\;]TMXUBBB6XL<(H& !FV['@#Q_XSD?\+?\8\ |OR_^B(JX[->W M:I^P NMZGXL\NV N3BW] !^%5?^'=MG_T6+XA_^\-I M_P#&* 4'E3DW%)=.GS.*=*4I-W(_V4R/\ A;%QS_S!YO\ T;%7 MK? [69' "H9N?^8C9?^CUKSKP]^PC/X4U\K]2/C?\1[*|:(PF6*XLLE*02O-N M>X\ "M+Q#^QGK/BO3&T_5_CU\2KZR9TD,,MQ8X+*=RGBV'0@&O@.(<5'+,%X:-M15N>-E?_#;I? ^8E_[1BKZ>L/V2/$FEV%M96G[0/Q-@M;> M-88HEN+'"(HPH'^C=@!7'ZS_ ,$Z;'Q#]UW]>H_&\XAW=_=OYD\[W%GND; & M3BWQT4#*_9%CZ#\;_B-IEW-%Y,DL-Q M9Y9,AMO-N>X!KV<;FJ'$T)4HQ;;], _]>=A5TD>TN;BRV,R-N4\6X/! / M6O, ^`0/PY_Z'WQO_P"!%M_\9K}(X$X_P"'F75,'BJ,YRE-RO'EM9]*ZM:Z' M=B<+*O-2BS\OW^X_^Z? Y5_09\,R/^%:^%N1_R";3_P!$I7QG_P .@?AS_P!# MYXV_\"=;_39T?Q#]UW]FI?%KQ_>:A=R&6>XDGL|TC8 R<0>PJG_,,.P M?#7_ $5'QY_W_M/_ (Q7K9=Q_@,'@Z.&G1FW""*3MRVT5NY_4>4^*&69?E]#!MU*%1NG",6URVNDE![QD_\$^B!X|\5\ |PV/_ .&U|0?&TC^S-!Y_YBD7_H+U MXKX-_8!7X>W5S<^'/C1\1-(GN$$];^I_L?;_K,<4=[\?O MB9YK\PSG-*699K/'TXM1;3L[7T27Z'X)QOCH<3XO%X MC#)Q5:-ES=/=4=;7ZHVP1CK5#7R/[$O^1_]'_D:R?^&*M4_Z+O\ $K_P(LO_M)&LO[$V\3:)=?B2R."K*;BRY" -@-3>;TFOA?X'\XPX Q\9*7MH:?XO\ MCZ)*,/^$5TCD?\ 'E# _.9&T?OY'QP !@#_CVKS6&+\ @F9H.OZE=EJ'O?\!W5I=RF;>=[BTW2. M>I. (,5\{3FH.|/V3&8:6(U|$7L?#F;^P_P#@G(1_PE'C3G_ESMO__$-JU/\ MAUKX5_Z*?X]_\":7_P",5TW@C_@G^GPWGNYO#/QH^(NCRW2]D|6]O9Y<*<(@'M-N>F36LZ]E&R.+"Y? 4H554DU9'UGD>M+7C/@'X >(?!?BJSU>]^,OCOQ3;0; MMVE:Q-:-,39!'SA(%;CKP1TKV:N4]X**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ K/F_P"0Y;_] <)/KX64#VH>]CN-Q!1&3;ZY(/\ 2@">BBB@ M HHHH *\[*)?QJT?X>QRVQ?!=]PC+_ 9(/E,8Q]Y\)?=`UK>\]7^'==UQGMM,\M2MH/F _+YT%FDL]+WVEC@'WP:Y7P? ^SQX6\()/,8Y==U6;+/?ZV?M)+G^+9PO MZ9]ZZ(*FDI3= _+^O^#^AC*4^9*,?G_6IXCX*3QO\?_$-UJ=K>2:-HA=8;G4# M(OFJA7)2%!QSGENW]<&O;-(O? GPB@30= (W:AJ]\G3].C-Y>R/C[SJF=1/\ M>?:/<"K5E\'Y9DDBUGQ)?75B\A8Z;I2C3;5@?X6$1\QOQDP?2NUT'PUI7A>Q M%GI&G6NFVH.?*M8EC4GU.!R?<\UZ=6IA8O63GY1]U?-M7? IRKR9A&AS-2FKO M^ME^NYQ5I=^/_^>IW$4UHG@G0RI\9C'=;C)TI M:%%WZ|S[#%=-X6\!:/X1: M:>SADGU"X_X^-1O)#-=3_P" (W,/]D84=@*Z*BN.KC)SCR02A%](d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|\@K$\C(%A7;=[C;2UZ_BTS2+"(S7-W-G9$@ZL< FM&TN5O+6*=595 MD0.%<88 C/(!'FO%?VVO^35OB5_V!Y?Z4HKFDD-NRN>UVEU%?6L-Q XEAE02 M(Z]&4C(/Y&L3Q?X]T/P(NDG6[T60U74(=+L_W;/YMS*<1I\H.,GN>*\0\7?$ MCQMK'BGI*AK/8:1KD^@PZQ[_B/4|8W,>EV>%C3RX<22R/D ,< *2);#Q_X9N_&VEO'K*:.FG7EE.LN1')'&2DD;C(##!4@ M9SFM8T[M79#G9:'VQ17R%\3_ -IN[U[XS> (/ NC_ \3*2"'1 -#(BCO}:UT6 M\|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

M5M4TF"ZNIHHQ&KR,N6(4< 9[""N(U:=_X9VU;_HM?Q,`\#=/_/D*]NK?L^Z[-M:Z9=S6WQH^)DMQ'${1I]LT]MS $@8^Q<\U[A6+XSFUNW\+:G)X<%B=;6!S:? MVD7%N), <&38"VWV')H \)^%/P3\8^},AKX8U;Q)\7?B9IOB"]TZ&XOJ3S[&`-MR9V0%TV-9DK@Y&"(+F\UG4+,RW4\$0B1W$CJ2JC@#Y1Q7!U`C/\ PSMJW_1;_B9_X&Z?_P#(M5<5=_!KQO%!8-,T&+XM?$QO"T^BW5Y/?^=8G9=)-"L7^GV]W-;@$")Y(E9DP>> M"2,.W*/_%OP%\2.5X7U:\TSXR?$RZU&"UEDMX?M5@^^0*2HVBSRI:Y\8? B99:U>,;;,,7%W5!$Y&SRN&)&#R,5P_P=M?C_\2?AMX[^(&G+],B:?I=KHVG76E2I;>;;)+B_6VENK@O@,45G;;]H1G/- M/_!&F7.N:3/:S7]OIS6R6,:OXBBEU&ZM&O82&R@2.W23]WE<-MN<_*10!]'_|.#.VK?]%K^)G_(&Z?,|(5'_SMJW_1;_B9_P"!NG__"%7-MLHZ5X/\ &KXG>-_OO? \#6&EOI|+:G;;B9K0Q,]Y=7$-G-,B@D81 47[N6) M/8#D L?#KPOXP\"_'2]TB|\5^*_%OA&;P_|:5N?$/D21Q7@N%?:DD4$8R4+ M':<|< M)G/S@?=&WC- 'UC112&@ /0U^=VF>'+'XF_M<>(O^]Z'XGCT!M4N>B;?#JE MV++S)C8S7AS (4LVU4"5@!,< -D#V!Q5^VO:?#^Z>-O!7B70-:0LTNWL9 MM/F\-,:'GGTK7_ &<_"?AKQ:K6J? $;PGX@^)&F:?>: MIZVLD0;,R""&QN!ZX- T8HP !Q2T44 %5=4LSJ&FW5 MJK^6TT31AQ_#D$9_6K5% 'RU^SW^ROXF\|:!XET[Q'KB:&!Y9.?I-K=>$+QX MIS%:- ,PN&=HQLDD\|!4!L!.3\QS53X=?LQ:M%\2/B8]YXX^).EV4M_:-9WZ:U MY9OU%LH9RWE_/M;Y<\8QBNX_;]^)FN_#/P3H,^B^(O"<>HZS#8WNO2VT_|V=O!?BO0M9T? 3O$'G:.GB> P>;<0 M_:6B!C2,G;$SB0-\X)"MP,X(-;XN_L20_%;X=ZUX7N?BK\0&2_AV+_:.KBZ MMPX.5,D6Q=ZY RNX9]:X?]G/_@FW;_!+P5/I=S\5?&XU"ZN#/._A?5I=(M3Q MA?W2&85B>?PK[0%+0!\H_%K|E[6=")QW/A3XE?%4-5.H6<30KXLN)3Y# MSHLS;<=HRQSVFO-[_\X),Z%?:?'RX@GXF^%)B_V<B!Q&+'^QO_MIS%;-_ 1OI6?C3QC\/_A6^N>#]1L=+GM[RW%W/=6_GR&!I55EB!^4,<@;F M!P.X&<5[10!X+_PR+9_]%8^:+7_A9W"^%>9?M_|:_P^-7@4Z*OQ4]>&\AG M6XMG\1ZQ+JUJCC(R8&*\X)&001FOLBN4^*EWXAL?A[KMSX6N;&RUV*U>2VN- M2B:6"-@,[F12"V #@9&3UH ^2_V8_P!AS4/`7AG7O"NK?$3XDZ?::1]C0:=+ MI.MRZ7:W4#0Q.TD<*E@!YC2#.3TKV-OV0]U*M\5_BR5(P0?&5QS^2<)>_V MFOB%]GQ&^3VG77B.%TUC3-#DN-&;PAWZJ+M93=W08*&7R2+.3*ZC')W#D5]T4 M ?!GPN_X)0:'\,/BX]WC%/B?XL$,K2M8KI-]% M^)O[+^LZ+:Z WAKXD_%R^DN-9L[>]"^-++B7R[1!0)GZ?+A,G=VZU]47OV@6D MWV7R_M.P^7YV=F[!&[-,_^E? GWXL_:D^+'ASPS'!O\7Z?8ZI!KFMP/=V^EQ> M1>RVHC-O!\;N"0'W,.#YAV]4V-P1692C<#D$@XY%>G^%OV&-&*>&],T>U^*7Q4B@L;9+=%M?%|Q!$ H MQ\D;_*@]%' Z5B?LT'GQI\!Z=:XET/7=5BO;..^EFT9+2,-M"DANHXH(E=M1O/FQNS_+PDG;E>*^L: /FW6?V'- US3[NTO/B=\6+B&XB.?ZQK=.C*00 M05/!'|0!.^?_ - EG_@F)IG@>X\8WFL^+O'6CW(U*73[%M&U"31WGLTVLLK-$ M/3T/XL?'3XE^#/%7Q*TV|\5Z=HVG6=_H<5G]5I8(4T:RNHDEF<-MS AWQ&,L_P @R,#CGS5/VQ_BR;C3;E=4MI=0;2(I$\.C3(P,^-[:ZD;4AQY@-M"M#$<*=F"01\PH ^@3^P7X3;AOB#\49!Z2>,KE_YYKSCQW_P2:^&7CKQ;I>N M77BWQH9KM>R?L=_$_7_ (H> =7N]*%,V.VT.K<1)\DDCIE1_#@\@\QO5?!GQ<-(_PT^)*1Z/>.:>A2-M>%]5OI/38K,R3RW5Q&$5Y7/4-D85,=|D\4)X]_9\]2>'ISP:,>&?B-\3KFQ MN-6AM-1V:V)!.V>TIFSY7R@87Y]IC_AFAO\ HJ_Q-_|"B'_,.KY&E_:^^) MMMIFG"V\=6NI0074YL=6_LRVQXED5;1A9@*NT$&>9@>R)GN?.8+MB!^6)6Y8G!/(QUKPY?VN? B;.FL0W'C2UTVTEOXDO=6 M_LVW_P"*9)O;B'I,VY=N6CBC.9LM\^>A% 'V-^SI9>*-+|"7=CXLNM7O;ZVU M;]AM[G6VW7,MJLQ$+,V!N!7&#CFO4J_:"+|LKXMR&>\?5,9-3_L116\-_P!E MQY@0:?YXU+IYF#)_"3LQXC-6M+,:X^)S:UH-G%XOMM7LX[XPV%W_&=;C_A* MU-W;0LI[5P-B32G]SC[F3P#0!^BM%(#D4M !5? 4+4WMA<6X;898V3=Z9&,U8 MHH ^6/@'^RIXE\!'Q/#K^MQZ5%=6$6DV=WX6NWCNI(X[B>;[0[M&-DA\X+M& M]H>>:9X)_9CU1/BO\09;KQU\2,#3Y%L/LFHKK>PWN$EWY?R_GV$@>V]WKU?X MR?'30_AU#++H4.M6%MXWOK9CI-C?AA#),?EB$LG"1AGPHWNNX\#)JY\&?B3K/ MC73KS2_%N@3>&O&FC>7%]MF%9K21F7*S6TV,21/@XYW*00PXR0#G_P#AFIO^ MBJ_$S_PHO_M59<7[!VB6^HG4H?'GCZ+4BY>)(K5VL;>X(\MYL? (Y'!/N*QJ4:55Q=2*?*|JZ3L^ZI/S,*N' MHUW%U8*3B|JZ3L^ZOL_-'@7@WX"^*=1>>-,+6/B-|3K;0K*2U&D?!UO8)U: M-C^W0LI[5P-B32G]SC[F3P#0!^BM%(#D4M !5? P<^(^K>-]+O+#Q1H,_AOQC MHD!]MD59K9W*Y6:VFQB6)\$@@Y7!# $<^B5L;G@6N_L?:/XG-N=7^(/Q"U(MV!;X3<:\&V-ZC|U6!X*^_7B:_P#&/C.RU?XC? $VTT6QN8(]'F_ML1B:(Q9<@ M^5\V&X]]]Z^(=UXALO!&M3^$[6"]\2I:N=/M[HXB>;'RA^1\N>O(K ^#OQ(U M+QYI-Y:>(M!N/#?BW1Y%MM6L'1C;F0C(EMY2,2PN 2U!R.0P'1M+5E.3 M:2;T1S/_S4W_157$_-JH_P"X47_-JH_P"&;F_Z*K\3/_'B_P#M5A V9OCC+\:O#6J-=OH[?Z1(?&=OKOQ^^)UIH]GJ M0ATF5M<">=;^4A+ ^5\WSEAGVKI/VBOVDK#X.:=>:.%X?U2RE\>E(WAL)[66X MVHQY(52]R2[[+#YBN^TXK5_9I^-TOQH\+:C+=FPNK_2;K()-J6C%S87P*AD MEBW_ #(<'#Q-EHV!![4 0 |-#-3?]%^>)G_A1?\ VJC_(9J;_HJOQ,_*+_ M .U5]!?2@OI1?[2MA\-K"[T'PY[UC)X_=,EE<6DMRCVX/S,I4664@98!(^M?:< T <|\O@)XGU3S5_&$6OQ_ !&^>)IG:6>KG;7 GG6OE(0X/E?-\Y<9]O M:NT_X9J;_HJOQ_*+_ [55KIFSXUR_&GPA>W5U]AN-3+HVDM8G\4KXB^(_M_P 3(]+76);?32^N>7YMH$0HX_=?,"Q? YO;VK=_:*_;8L/AU9W6@^&M7L9/'-M"M%3;3V$*&6:|FY *L,H?F1L]>E %+_AFIO^BJ_$S_,*+_P"U4?\ #-3# M_FJOQ_*+_]57_2OG[!HG|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|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| $%]XS_:N;6H_#V[^%P?!)BUG3=66 M(31R?;S[C\WRG=-Q5;IE^8G:3TS7TC0!F'PU!OQ?'2[(WHM_L@N?LZ>8(?^_M>>[&=G^ST[JGTG2+'0=/AL--LK? 3[&$8BMK6)8HT&^&|)U*_COKO3+.ZO8XG@2XFMT>18WX= Q&0I[CH>]1Q^$M M#BGDF31M/2:2U%D)BV189K<=(B<;6[TZU,#&25&7SFDC7]P9DW$C M(07/45U9ZG&OAOP9\+OB?\(CJ[GC:'X<7WB;3;K42$12/3=1LHI'=SV;P2G MS95X802<=1QD4 ?9WB'Q?IH7A%+5I./#/@NO?Q- K^DZ%;W3^1"VK7D5NDSG^!3(P(#'V%?)O[3'PS^*GQ'L+#3 M]0\"Z7XXM]2N)D?4=,M+2WU'0-+D"^:;QM=3E&N90%3STP$",0,E:Z+XW_"K MQ$WQ+T'Q99_"ZV^*>ACPE-X>3PY?WELITVY=XW$K&<[2C*OE.Z$L ,C(-`T MM!GA?0M.@M%T_2=/MH8(W2W%M;1HL;2'+A-HP QP2!P>];-G9V^G6L5M:P1V MUO$H2.&% B(!T X ^E?$NL_"OX^6OC^R70[>_T33X(=.CT]-%(0(N@Z;81V MFR!LC:L0\DAEXCD*9^X=R;2*RE^-#0[0&A:-IMO+>*.^]+T:6RT2ZUZPA\6*NI M7-RL=RM]';7#R#R@&-L65656"\$G-`WKFHKBZ@@,;32QQF9O+19& WM@G:_M>IP#Q7P=;_##]IC_(375+B6^\1P6;Z-+'9(WB"*YCC4Z4'_M:MT8LKG[I,:"";_ /T$LK*VTRTCMK2"*UMHQA(H4"(H]@,!5;S\1Z3]K&H/8YN-MIV=S>QQ"=[:&X1Y%C+%0Y4'(4LK#/3*D=]^&'^"WQZTGQ\,[>RN/&%U96UI MI4OB#4+GQ8:D2RNW_$SC97G4*_#A0L!O"VG:=9:/XC ML]*L;6SL4L=/\10Q7U_$E_=23K:7'F9C#))"V"R9 8#\)R ?HFN?U#2_"]=M_?-I% [:.3<7ERW]H&QGBB>24H5'GE",DJ=@WXX^7GI?QFOP=_;,N+/#3[V\UW MQ(-5TW3;/K*WA\1J$,PU1VDCN0&"3R)9%4=V!5R#C)P:ZKXR>#O&'B7|HKQ# M8Z'<:G97NH67AYK>]TR\-G,NEQ:A) ;2159&" \3,H.2"O!XH ^PLU5L=6L= M4:Z6SO(+MK68V\X@D#^5(_"4;'W6 93@\X(;_,KXY:[\6?A3!7A_6/$_BD M:H;._^AT&ULO$;QW>[^U,023$/#YT\3OM1"K(KSQ!:W]['<3VPT'P[?WE^MY>/-_;XET M\%]QD8K%L?] #JKSZ?:W5Q!/-,0RS0$F*1XPS1DC!VD\ MC()'%6** ,0>"/#HLEM!H.F"U6Y^V+!JCBV"?,?-"[<;\|[NOO5VUT/3K'4, MQ4+>PM8+ZIVBXNHH566;,PN|@,MCMD\5>HH ****.?TGP%H.A>*=;|26&GQ)M;,WK;2PIJ%VKN3<"$, (@03@;0S= .M;X&*6B@ HHHH ****.(;RRM]0MY@NH(M!B%OO1RH'4_4'BF'3K1A(#.0D2,&?,8^8CH3QR1@?E5FB@.JA]VOZ9H"VS:G MJ-IIRW.RV!\NYUB$LK<*B|B-S'L!R:OU\B_MD_ 7XE_M#^+|&TWPY%IFG^'- M L)M0@OM5FDQ+];_"0F)8G#*\2[F#..F6'!H ^M;F*&:%EN$CDAZL) "O'/ M..R5\;^7U.+3EU_2VU""78((07D9E? >K,F$W9.Y58CCD*2.AKXKUK/?'OXA MR7FK.P_B/2[C4[I"VM=$C\1YM%9MIK1W06))"F#<@=$?-R*,- M9UN[?OD0&R-123 MW4- L%,TJ1!CM!=@N3ZCVVL&_MSPY<)?1 M_8Y+20O%]HGBX;!0BM\S(\WBI*+X??&G5YKN[U_1_%NK:UJK:) H/VA_"O@#3='L]7XB6/A*R@TZWU56L+0ZS:N-XF735VD/$!Y>20 MQ'8YSB;Q+HW[07CH^'M^=6?C&4)=:5=6B:;:6HL!#'=,TTVH.HRERL8A;"D M+G/'6@#]&,@]ZAM[^VNWE2&>*9X6VR+&X8H? 0XZ'ZU\D_L{>)/BA\6M(^)HO MO$OYH-%BN/#6D7D+Q-#?72L[?:Z'!N"_"F < AN]>==>!?!7BSP9\K_/X5 M]\&/$/@OXD?H2VFL>)YWC1!1N/-7SS!&SLEY*PWR),_X'?%_'Z [AZBC(]M17P.R_M(ZQ8SFQU3QI8:.:6>I76CR7UG9IJ=XR>2;:.141D!BWF9*K,HYQQ M5)\7`;MOJ5\6"9_$5C(/%$45KIL1@A0O#Y;6KE=NX*9-R_/WW;<"@#]!=PI1 M1N'J*_/#QUX4^/MGX@MM2MKWQ_J.H:4=;TI2,:"""""1F5A&;62=0@5@^N%MV6[WVK/YB/"'BQL)B$ZEACL M.H!^A4=S#*[HDJ,Z8#]K_E<|,^E29&<9K\Z|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|\M33[52BNRJQ\NZE 5B 6*Y(Q7GXC#U,+5E1K*THZ/K^1 MK" <:D5*.S/%/#6@?'OP+X=L(DGU'PQ#I7AR+|-%.$;3;.VCT@!DN'\WRUF2[M:RWEL^0!!,>X#+7Q9\5/&VC^*(OAW=>.]6TZUFVZ=>3ZO%=30W2]FP.D;/%* M%=6F=VRTIC4Y#J0R*.OU'|QOXA>#!?5;/4!$^3:=ZG;R1:YLOX+K<+&MI9RV MLUTD.C(]JU$*Y,;8:*,9V-G'JN@?$B*=OOD?(H2VFL>)YWC1!

0_BKXZNX[B)-1\-^,-#O[F#4(68"0Q2/;/)GD`)8$';Q@BA4),/:(M_0*N.\9_%#2__B?PEH=]!=2W?B6]:QM'@12B.L;2$N200,>@/->+^*-5\6 M?M ?&O5/*

*NB>+-5\">#O#=C;7>JW>B%8=2OIY\F.%96!\E%526*C)/"%<3XT M^&GBKX9_M"?!6SN/&VK>,_-!\^M3/;_|-"1NMQJ%G<"VD^47_"F2-ESPP)! Y*

MYHHKJQN3Z'UYXE\0VGA3P_J&LWWF?8[&!JB;REW-L49.!W.!7EGB[!JOPCX M0^"]=?3O$6KP^+D$FEV>CZ4\U=2#R_,YB4Y'R_6NM^,'_)'_&/_8)N?_1;*

M5\B;QI7B/2?!_P"R;=>%-&M=?UU+8_9)/O:WI"%?L39S+M;,@<[#13@I*[_M*T"4FCZL^$_Q_\"/QDM!5_L..:MM1TI(@NH:1!UC+07HJ2,KOAD .#C@CC(1-MZTO!'Q@\-*

>///%UXLL[I[/0[6:XAGN=140",PN4D9LG 4%3SZ5\W_S7_$=O M^TMXQF^*^AGPEX]\1:0L6CV-BZW&FSV,&6?9< YDE!.2&"X'2O-+!1K/[.O@ M#PK>S-

*!X>\1_$>XT_5B&VB2W^-UR-Y;'^ZQ-'|]+O#D+,K>(M$\./+8N!U:-F96D4>]J1Z9KUSX8?%CPM\8_#$>O\ MA+5HM5T]E,;[5*20R#[T*

*/B[J5S8>$0$4>L7=M$)!8DMYIH]QG+HH MZEN"_`GN^C:QU/O6_:A\^ PM\167AM=(U_Q?XI MNX3P-Y=)",LL@W*J+VROY[5O*

PF^,OAOXR^~)[6T"2ZC-K,UM>Z?] M%NUO>64R_>BFB;E6_,'L37FOP'MHKW]H3XZ:E.]_%J%E8QR-RRP+"6"CVR2 M<4WP!;Q.3^V7\2[:R_=V]H%A?72)!TW

=D#`_:[_:J<8V:ZI7$F]SN?AQ\ M?_#WQ-\:^(O"NGZ?KFG:MH:K)<)K&F268D1F*J\>_EE)'!QS7IE?/7@,_D)/ MXD?]BWIW_HQJ[ZU>XEM-*

*+O)X5W31PNZ+C.6"DBHFDGH5%W6IY3\3?VI?!WPV M\4Q^%4M]:\7^+W3S3X?*Z>U_=QIV>0 A8Q_OL*J^:OVL_"/BSQ=;>%=7TSQ M%X \378S::9XPTMK%KOU$+Y:-*

S!:L^U)O$>JW=U:J] M\,.SRK.RB-CUP@`:O?-=*Z+XG-D=8TJRU0V.ZW5J;R!9?(E7HZ;@=K#U%/M5)0B^6Q*YGJ5#XIT1'"*^$&O%77GLCJ"6I&'%T-;.6!

*[X/:M36M8M/#YD7NIW M\RVIE9PO/-*QX1%))/Y"OA_XWC6Q^TYXH^)?AUIB:X^&UA8>?9Q-\MS:RDEZ-MC(IG9\P^E>E?M0>,.?^%W:!X3^&?A"_=AXXMC?WUY:-EK?*

2E3<[9'0N=J#\:K MV6PN?<^A]#\::/X@\(VOB>UO$?71+FV%VEW,?+418SN.>@QSS7B8_;9\+ZO/= M/X2\%^/O'VDVTACEUKPUX?>>R)'79(|)YF/5 ;\-U?

*6YM5_8A^'GAR2XDM|- MNM>MO#>JR*Q!^SI$/G;I-Q>^%]1:>6TD\F]T^/A>WO+,.3^Y-"X#?+AKO*RK'IPHM;Y?ZS::59VVKWZJEW?*

*10*LTX7[H=P,I!VS7AG[87B/QKH MT'PZL/ VOR>`]6UCQ%%8/6R'=O0\, _D \9 J%%2E:)3=E=GT1FEKXT M^)OA+XF?*

_QCX%L?"/Q7\1Z]+XTO'T>^_P"$KDCO4M7;S=6Z!%$; !L)]WI MD'%=.FC^)OV?7C=\/M/7XA^),&>A>+GN+*_L_%%TET8IT3>LT)"+Y8/(*#BJ M]GI=.GF[H^HZ9/;MO*

*\K9VHI8X] *^!G^.]M\8_%_B;4//%?O!^(W@S0L$_FT M_1\:7>*I2-MIGGN8;>3S68@+_G +]BO1_@-XX\07%71O'O@#4O$OBR]T[3 M8DETGQM)!LND.C(/*

P)\MS+"JF5",%@OS"J=%Q5V"FF]#UY_VDO"__"G7^),=_MKJ5#VZV@3"KM) ;.](SDU4J4=D^MB5-]4?7

MU%?,WCCQ=XM^-7Q1T7X<-`&O$EWX'TB/1(==UW5]*"B_D67B.W@=@4'GDE\9] M*]WMKXM_9B^)7@U/^$ZU]QQX"\47PTFXL_%-PMW>6%RREHY8IPJLR':04;..

MHK+V?GJ7S'U%7'#XI:62BHW@'R+K^UQI@U7SMB^1Y1>E-M> .#CX8>.OVA/!]O\0?$WQ0\7>%+O6T-WI6C>$KQ+2RTV D^4KH4;SWQ@L7. M#TKA_B+\0$GB/

9]\7>%O&=U#]7BCP?XMT[2KG5+>,1I?I]IB>;8.%9E8 M9 XSFG&DG*U_4'/2Y]QPRK-$DB\!@",T^OF#4Y_%G[0/QAU[P;IGC'5O O@G MPC#;Q7TWAZ18-1U*[DC#*

*[1,03%&BD?=&6)ZT[1-7\4_LX_&+2O"&N>+M5\=>_M!_$EE=7,G76O.LVI:?<6ZAY(FF4+YL,(<@L,@C%1[/SU'$TYFC-?*PQ\$^_M-/VFO#G_L/Q%\3?*

*%GA"SU5GET?02"'%XEE!96P8B-6J"\"=WR\XQ7-^_M&D^,>]7/QV\)W/C^^U+Q1X;^Q3:#?6ZK LP2{JKQI-H,H&UP."6)&*KV6ZO ML+G\C[3T"*

<5]N>,/V@=0^(GP3^'UOX)O9M-\7_$"ZBT^&6W/[_3PGS7LGLT:.MJR_5A7TFVE._A\Z:U[=*[6WV(7T?5M5MXM(U&^5[2:5;DHDK*$!\QF[FSW/-KTG1*

M_P!G7XD>)?"D7B35/CAXPT_X@7<0NT3JXDT6UE8;EA^Q;"KQ#(4ECN(YS6L MJ<4][(B,FT?3M+7PWXB^-/Q%^-+'A3X)6NC^()O!GB76/$5]H.O3Z8JM&QMXW

M69T5@1_S)G.TD'G%?7__/_7_,(!X6M]&_MW6O$;0EF.HZ_>&ZNY"Q)^_M9\#@9P !P,5G(M64[\? VA^)[M[.RM/#]PMO>R/L0E#<%2R0H",(N"26)/2IK[Q+XV^_WB?*

Q5\/=4\)8ZGMT.;4 M?"6HZYXH..KV?2^NR?K8^MZ3-]%/4>Q) MXW^%W[,MA\8=?\9Z[XR\<:]15E::?!%_=!-)AFNGCCMV,"J,LNY2\A)+]+TS MQW-S^$?\2/;?PHWB"Q^.;?

*C"X^(L<1NP+F:(Z)-,!N\]DV6S:L1/RY!W LZ3XPO%OHKB$S1YD@;8K0R*<$ '1D M8Z54;7O)28G/1M'VS:7*WEM%.@(61 X#=<$9]:O!/#GBS66 ;M3PV=3N#H"^ M*

*[6^73MW[D7!NI$,N/[Q4 9]\2^-OB!J?AW]]S0-,DU2ZB\,KX+U'5+O3T;] MT\D5Q%B0KW8*6 ^M9\CO;RN5S:'O..%SXL_$K_A5?A6/6_|`A'=;\4;[R"S^*

MQ:!;_;+@>:X7S"N1\BYR37A/PN\^,?VE'N1\BYR37A/PN\^,?VE'?D^V\)6,=U?M\U^MA;Z;,28?,<(S3RE<,0B[IO[2=7M-MTU""P\,W,5OI6EB10\<(MFC83A 0&,A);!Z5O_L;^)?*

&OB#PY\0H/'NL#6M? MTGQG]&F//$-L"I$L0"PK_!'R6"Y.-Q%)P23;>PU+6UCT_6?BGI6B?%'PIX$G

*M@NFU;?+7"U"WF1%,*1VYC#ASG()\U<8!Z'I799KY, .1T7Q+XD_:S^#VD^%] M*%99[6TW6QE:_,"HE.%568$+N)P<5N:3IOB'X"?M$^ O#$ M7CGQ'XP\)^-*

*[748IK/Q3>"]GLKNUB69)89MH8*ZEU9#D9P1BJ=-633UM_F+F MU=SV/X3_.!+_.%J>';O5O\ A'-<\,?9]0N;#[)K]K]GGD\]IOFJN3E&Z@_6 MNTS7Q5H'QR\?3_"/3M%T?*

6C+XX\7_$?5_#&G;UJ:"=-,MH[JX9I=AX?RH(2$ M0\9QG@5N?&GX,?$'X\ P,\6>+_.!?QG\;ZGXATW1[FYNH/$MY'=VMTBQ,9#& M@1?L\BC+HT9P&4

@@TW2]ZS=@Y]#Z(U3XI:5I/Q3T/P%+!=-J^KZ===:G\;B+ MY"Q0-&KACG(8F5<8!ZD5V-?$-?+XFFT+4M6\!?ZCGKR1K M+=QP,MF\SP[@5$SMM

<@A=Q."0](T#3O$?P)_:*\&>$D\;^(?&'A/QH^H% MK;Q3>"]N+&[M$24213%0VQT9@4.0" 1BDZ:25GK8%+4^E:0G S7G?]06B^*M*

M:^$NOKX(U6XTCQ9:Q"]TV6W;'FS1,)!"_'*2;2C#T:O(_B)\?;WXI_"#X9VG MP^U";2/$_P 3;F&VM[BW.)]+A3Y]0EZ<-"]2)L,5](P M-_&'AS_A&]N[\.%__MB!X/

*(74%U)]/B+-7TE:0I5OI36Y+S3IXGC;&9)eD 5P& +*2.\X(I\,#?BH]JRVU+QI[K' MQ&\5>#/#,U_=6GA_0?^SMD[i>"5HO/N)-K+(+(QVGY5&!@U+IV6NG_[& MJWV/?*

M(^*&EZS\3M>\#0P72ZKHUA;:A/,Z(6CG;14"G.208VSD#]*[&OD[! MG'0?%7AC]JKXI:5XMUT>)KNUT'2DM-7>%8IJU\VX.9G5?E\T'NK MO;K[%9SS^5)/Y2%_+B7<[8&<*

=R:^2_BOX8\2^,_VV])T;P_XDN/"=K<^"Y3 MJFIZ>BF]6V%VIV6I.'L;LVT;\$!,XYQ71>$O^$C^" _Q_3P#)XRUWQ?X8\0>'-MJK5+,_^(JD75Y87-

*NR!@L^T,T;+)G:V<%>*MTU9-/H2I.^I[5*?B'_PM+P18 M^(_[UCPS]J:1?[.UZV^SW4>URN63)P#C(]C779KXK\'?%[X@^,/@[\"_"&C M>(YK7QCXXNM12[\4WB+/-9V=O-*

,TKQJPVM+L"HN1@=>>U6'VBOAC\00@+\'[< M\5^"?C%XRU:V4:C;>)KU+P21%@&EMWV*8%)SD.?E/3%-TO>M>PN?2Y\-Q3 *T+8BTD:RTQ1?*

(\DR^7MSG.[/;&,=Z[&OCCOAX;\4^/?VPM+T MK1?%%WX6M;KP"%)K&J:>J_;C"'+@'9 [B-W;&7P2\G'-=O\ #D^(?A% ^T9_P MKJ\7ZWXO\+ZUH4NK63>

({@75Y93PRHCH)\!GC97!PV<$<&DZ;MH^@U+N?2% M)FO$OVR_%7B#P9^SYXCU7PMJ,NEZ[$UNMK(KC2]>LK-\03R01S)(O/5"\>X#Z5Z5^TIXL MUGPO?_"U-

(U.YTY=1\7V-E=BW;;Y\#$[HV15/<4_9M-)AS]USV+5]1_LG2[N M\'%S?:O\>91_M%Z1:?"C1/>N-%:!X@T"UU2[ALDTS4+ M,1WL,DDOE)YD988&

*<'>AKQ3X..3XW^)WB?XF>(]>^(_B;'1O#'B.]M]'T;3 MKL00MY:*Q6X(7=)&,]%3(Y]:X3XF:?K'Q,_8^:%GBC6/&?B0:G+]-G#^VB60%#F1 !M.1C'0UHJ2O9OL0YNUT??*

P,.6OG. ^U"7?@/\;_MEJ/ MBC6?$'@?Q+;-H9EUNX$SV^HJ2\,C,%49D&Y"< <+6O\ #3Q?K?Q1^/OC74[7 M5+E/

WAA%T.VLXGO!>7YP\\IX^;RQM0>A)K)PTC:_H>ZT445F4%%%% !11 M10 4444 %,>))&4LH8]$],GMJ;4-9TR> MR@FNBPB1W0]"Q4$XY[UWE%-.SNA-

*7T/G/PHW[37AW2]'TEK7X426%C##:M M(+K4O:-%521^[QNP/IFJ'QH^$WQD^,,,NI>"]1E\$M%#OM2BNX==*SKJ=A;H MZN(T@P4;8%2!+O'7.\7TM<3?*

*9X)9<;MBEL#O@5Q?P4^)Z?&7X9:+XPCTU](3 M4A*19R2B4Q()GC^\,YV9Z=ZU4W\22(Y5M-'QO"KN1EZC(-?0V;|^^(WQ9_X0#QGX T#^S/MO|*

*MPE6J/IOG^=L^S;8'EWI=IW?*X&V^*GVCXZ-M7OPZ_LTK\GT!-,_M'SOO:I_*\OR\?ZCNSI8JE4D^@N5(\AN?V5_$NI_*#XFVN 4L><+(+#6/B9X]B'V_4S&\-C!L7;#'!$H#,*

(D:!/)!))-=$WP6\;Z/\ $CQ'XN\/ M:OHMG?77A*TT2P:]BDG6.ZAD+%Y$&W,9SCAL^U>]9I:GVDA\]/FGPQ\/_B1X MN^(^K^.?'T?

A70]3_P"$>GT"TI_#4LTRW1D(FN)9$4[05&U,';D\UZC\&/A MSJ/PY^!WAOP9J%Q;3ZEINEK92S6Q8PLX!&5) ..>XKT3-&:4IN6@U%(^9K#] MECQ#IWP6\#:58;_8Z3\1/!EI-

J&EZM$CS6G:\A:*52%9HG23:V.'N,XK5_X M1KX_?$;4]L2$+ I>&_A]X=M;F.>^N/"-_22KX9T9Y8T1HF4R&=T

M!EER0,;54+GJ.^G:CN9_L]M++C=L4MCUP%4:!Q1@_$7PW<>+_FO:):2117 M5_936T;S$A%9T(!. 3CGTKP'Q%^SY\1]-|*?!7_A$KOPQ-XB\!Q;+A=:EN%M M)R;0*]E^"?*

*Q1_X7#X MO$W!G?V5YUS9YWEA3YGW1M MSGISI.] S4RO>S!6Z'S=>?!3XE?!OQCK6M_!S4="Q_#VMW#7M!X.\3-+##%< MM]^6UN(PQCW=2K*1FM30O"_QW\>^+-*

)U#QEKNA> O#FG3"=]%\(S27ESJ##HI MDIQ,BA8_547))]:]IS2U?M'V%RH\]^&GPCOO#7B_XGZQKLEE>Q>+-066& LQ M2V6+RQ'\N YY/*

R.:YO\G'JEZ+X$:]XJU:,56UE[^,R-\PDG3].#%DMEST M9>ER_|>\Y]MJ>]6FC:=["6V25]\, LHVR(W/&1{UD:)IO[3'PY MT^+P_;#P-\1+"V7RK/7-6O;G3KSRQPOVB-(W5V*

QDJ1FG;;^U9XQ^)$EQ>?" MOX-ZKXS\,1.4CU_4M5@TBWO,'!-NLH+R+Z-@ UV'PD_:/M_B'XHN_"&O^%-; M\ ,^-[2'(1)HNLO!UEBSCS(;B/,,8O$&L:FRE=+TN#R=;TY%Z)

&R['U=CSZ4?&7X7:G\1-=^']I]S:6\7A M[7$U.Y6Y9@9(PC*53 /S<|\#WK7\/?%[0O$?Q-\2^!8)&37-"A@N)XV(P\Y)K\N;,4K2Q@_%;X M8ZEXZ\;_#76+&XM8;?*

PUJ[7]VEP6#R(8BF(\ @G)IXJ/XH_"W5/&_P 2/AIX M@LKFTAL_#-_/=7<XK)\'_M-7MSX]TKPAX\'<6O?#QE5M2+ZV1M0GM[N MTO'49;-9H'8^,=K 9JDIV30O=O8Q(/A?*

\6/@KK^O+\,#X9\1>$-8NY-031?M$=W/9RZ;<2',GE2QHX>-CSM(!'K7>_"3P)XZT:QUW4?'WBM-=\0:R^_[#8!T

*MTS34"X6*W5_F(]7;ECVKU*DS4N;:*4,'S9'^S3XD7]EF3X:'4-+_ +,:Z$XN M0\GV?,]J$V,]-V=HQTZUZA\9/AUJ/Q$^">O^#M/GMH-1U#3UM(IKDL(E8%>6 M(!..#VKT/-&:'-*

*MW^8D7[CJZR'3 M]5ME ^1V0;XV5LE7 /7D5!H?PH^)7Q/^(7A_Q1\5Y_#^EZ7X,D:YTOPUR,EF MN4>Z(V^?<3RJFI:"=]*N!GK7T)EF=M4>Y4?.#T-1_#GX]>/_A=&M^/?*

*B+KN-MBZRFMZ%_94VE:7'+'!9C,NFUN78AB2>\7T>3BO&=4^,FOW6I?$_1_"M_@L^(<>\(?9UM;+[>L/HM+&KXRRVCP&/4G.*I3E*Z1+21Q7AOX=?'?X)Z9)*

MX1\"W'@[Q5X1B=A!%WXEN+/FVO--B)R(1%B1EG5,X!4D#FG7_P"RCK3_6U M3P^=?M=7\:Z[KEMKVLZS>(T:,\R3(X15#%5"KM4>PS7IVN_&&Z\+Z_|-M$U

M/P])#/B^26&5%NE86$D<(D8$A?WG)OP16OX7\5>+-5\?^*\):[>^J?M]F:W!M27^T=PR_[L^#_B3=_$#X5WFB2WVK6L5M MKGAWQ TL5K>-$-L<\4T:LT<@'!RH!

*L_@;X0^-O$WQ(3XB?%BZT9]0T^RDLM M\:>'_,EM+)),>;(\L@5I97P!G:_,"O>\T5'M'8KE1\8_"76?%/A_3-9TOX M.^//!-_X.L[V=!HWCV*YM-2\/OO)>%E0@O&IR5#A>;,?-*

BMO]BO3M0OO'WQ@\ M3W'B4>-+;4=4@A'B&&$16UW/%$!+=02/*1B47!/W>IKV[QM^SK\,/B1K(U; MQ/X"\/ZYJF #>?NGQO*X'0,V,M^.:[?1]"TWP[I4&F:?86VFZ=;IY<-*

I9PK% M%+OHJ /I6DJB:.74A1=]3Y0_9?^%^F:G^T\3_/2/AIX M@LKFTAL_#-_/=?<XK)\'_M-7MSX]TKPAX\'<6O?#QE5M2+ZV1M0GM[N MTO'49;-9H'8^,=K 9JDIV30O=O8Q(/A?*

M)8#1QDDDGW-:=93ESNY<5RJQX;X$_9S^S?"SQYX)\6RV[I8^)]4U&Z8V#ME(M,B5G3E@...N0>XR.]3P;INJ>!=2LX8_LMKXSOVN4O8X0,\E*

MHJ%'F"]PX4D9(KZ:HJO:/J+E1\[Z9^RS+X1_X4W::'J,5Q9^#-2NM1U.ZORP MN+Z2>%U>10H(W-(Y@@D

*"OH<_=/TI:*BK4+Z%JMH_B^XMKWPUXB>6B+K'&5GAN(E8HY!PRLA!"@Y\KT/2_@#XX\9WWC#Q MC\1-5T>3QEJGA^Y\/Z-I>D>8=.TB"5&W?O'&^5WE:!/J*

M$VFZ=;6,NH7!N(M(;(B8@ R.1\YB .3Z5I5HZK;T1"AW/'O^% 0>)/V9] M^%GB.["36^CVMB^H.<3F"YA5"D\18 _+(BL,@9QSUKA[CPU^TWJ?AUO!D^J^*

M!+2WDB^R2^-K9KDWIA(VF1+,IL6> M=.^'VKKX<\4> 2)-"U\C,T4F4V317*C!9)A]XCD'\'2N)^+OPH_;#_;&^'N M]>$]>O/!7@G3W5&D72+JYNWU*1)%94=WC7R8>,D*

.O(R!FOK2BFJDE]P3/ M!_B?\(O"%MX\\.?$3X<7NC'Q/IVE'1-0TG7C{GD-H6$B@2Q@M'(CY(;:00Q M!1/AG\(O&VM?$W4_B-\5)M#_

*+5ETG^PM.1*03)+:65HS^9*7ED56EDD;&3M M &]?O-%+G=K#Y5>Y\$>%/AI\;O@%82>%^A^_A/GEDB*[KQ!8ZP]Q6IM;"_MSAANXIC;0X5I& 6,@,^26;G Z?1%%/VCO?*

*J+E1Y=X'^%NI^&?CC\2/&=S(?@^TGQ8^(7C/7(X=3\):UX/A MT2;2]9'DNY1$UP\P" <[DE 4*22>W2O;**GG=[CY4?&7PH\62$"R^%EG%X!^*

M+'PYUWX>VMOY5CXA\61SPZKI=NHP(KJ%65'DB V_.8R=OS"NS_8#TB>S^%7B MK5&U.[UZQUSQ=J>I6.MWL8CDU2!G5!=;1@ 2-&[#'&",<5Z9XA_9B^$OBOQ&

M^O:O\./#.HZO(_FR7=QID3/^'<{GXPYIVS7I-M.0V5M%,V\2001*$CBB4*]* M!@ < =]UG43322DQOBTI[\R4?"O5-;_:$\#^/(:FT32M"T?4|/NO&_SWD MN6@*%.!C*

\IUY(ZC&:D^(7PPU/Q;\9?A5XNM+FUBT_PI+J;WD,Q82RBXM?)3 MRP 0<-R+H+M7 MN8-'NKF[EDMWN0R@="(K(8I-V$^?&[H:Y$]HSQ+\4=3^ GB+3_&'C_P"'VGZ5 MJ-

*@]J;1^"A//J?B&=UVPVL*2MB-97*AMGF';6 (-'?<6I:99ZS87%C?VL-]9 M7"&.:VN8Q)'(IZ]RD$$'T->?>$/V;_A7X!\0+KGAWX>^'-'U="3'>VFG11+$ M3UV"'R?*

\!Q6T:]WEN0Y/'^%_@KKE\1?A/XIGFM(;3PSX-FT>]M69O.Q-(MMM@J -I4>2P,3GI@&NG\=?#'&'C&V\N+6/3?"Z\BMW#*6$%LGVF!8X_ M+ !!P5.]?(?*

*)GPNTR]^./Q5\)?Z9-/<>%++6 M+S1_#5O*08;=W=)-3D@'0(]PNT$?W6KZ]90RD$9!X(K-\;>&=)\(://!.B;: M;Z3ID!8Q6EG$L42%F+-A1P.L23ZDFG&7*FNX-*

7;/%-1_9C/B_5/CC!XBO(1H MGC[!%K1K)V^TVAM[81B0Y =9%5UP2.!FLHZ+^T])H^%#]?@6-O+^S-XZ66 MZ-V8\@\X6.S8)\<_Z59NYZ<5])T4_;/]+E1XQ>_*

*[5SX]^#FK+KCZQ9^"K>^ M@O[S6)FDOKXS6ODK)D+AF+!]4OIM1 MMM\)274[G/$!S%%Y4CEB1Q")7)8*0"""2 ;^E*=%M'U"HR^/RI8#*%!L;;_| +,!E"FEW,Q8D#->H_ X^*

M-9OAGH]U\09HW\57BO=W5O'"L0M!(Q9+?"\$QH50MW(-=Y12E-RW!1ML>7'X-M6ZH?VDE^(7VFT_L<>&7T7[/EO/\ .-PLN[&-NW"D=?#'C

M>"ZM$TO2]$U#39IH&;SFDG,91E &-HV',3GI@&O5].=ARH^,O%7PQM/@K\'MOA3I7B#QE,^#?',AZM<#1?%<5]IQI<5Q-)*WD718*%AE1]AW%>>ASBN5_;KU*

M+XI+>]+A?_P (_P"+?&?@:W;5;B"VTW0//'G7%[KMPTBI$)F.8XAIY@@@;Q&-7^%NIW_P"T1X>]1?VH-IND2=H=WIDL#

*M,WGM)+)&RLHQMV@(G%>HT5CSLOE1\]_MVVYN_P!F+Q3;B5H&E>VC$]?> M0F=!N'N.M4)=!_.3;0!X2MM3\#26K1?9E\:S-XDVD\X'2 MOH'Q!X;TKQ9I#@@\!*T0 H*

P!V%4IVBE M83C=W/GOQ/\ LL2Z,\)//?A_P'K,>F^>)O!=ZF];5]>]QF6.YN@6,IN O)64N M^<K_%_^%=!\/^%KS^TK?2O#4\]U)?7BJ0CR22HF MR-IKZ.HH]I(.5'D?P@^$.K?#_

*$'X@6-_=6<\OB'7+[4[9K=F(CCF M1557RH^8%3G&17$S?LU^(Y/V9_!?P[&H.9_;&B7]I=7%QOD^SNL5T9F"'9NR M5X&0.,^DJ*7M)7N'*K6/__VWXM,E_9YUZ.]>9-*

2.2/=':U($XU R-#[.8_P#. MWXKH?AAX&O/@1^S_ &^F6=G/K?BS$L5+R2]IKZ_D!DD//4M(2,^@%>CZWX M7TCQ(IBVJ2W5.;B&XGZM3=0K)Y,R_=D7/1AV-

:="/[JB/EUN<9\'8_%R?#C1 M'\=W<=UXJFA\^]Y%8EB9R6$0"\?('%)E2:[2BBH;N[C6@4444AA1110 44 M44 %%%% !7F'[2WA;Q1XT^"7BC1_!TKQZ_*;CP=K)=);?

5;>VCN=A5@VUXW&&1L889!P M3@BJB[23$]4?/?P&\$_"+QIX/\<>&]$T7Q)X9=HX8M?\":WJ-W%)ITJ@LDB

M9,@.1_K8GVN%'N\N^&2K\%OV&],\1>"5;1O%WBN\BT>35YKB69+=I=0DMUG M$;L44HK$C\:D@9S7TU\(@?KWA7Q1XF\8>-?%L7BSQ?KEI#1S3V>GBQM;6UB*

M+E(XXMS$DL[.69B>PP*=X_.9TI.T_9WA^$GB"Z?7=)$,T4EVB?9Y"7F>970 MG8RP,(3RH:=+|)/>ZNC+E?;N<3J7[$?@S0O"=Q?Z!]_B'2?'UO \R>-'UNY

*MDO9,@*27F#.8W1C]Z,KMP<#%>$6NC:KX\ ^"O)FFFKXDO='U&_P!7FCFUFUFS M/BQK6AMX1U[XVS7O@UH_L\LMIH4=OK-S M!C'E27?F%02.#(L88\]"H:>/*

ERUU!]>G0B&X MD?;((V0[CY91!%/X:=K$'DKGO7'Z9^SC\3O 6EMX6\|_%Z/1O\(++9VV-MJ; E]?:9"Q)\]"X,BAE7)V^8K%1@O;/?QK<1@0#(*@DC<5PVT$9&K?$_X5Z1^R9J7A?QQ

M\,Y.[0K.76+32]8\.-J$]Q9ZE!/((R1'*[,9E+!@ZX/!SFIOC\/M0\??ME> M'!HWB:^\(Z[HWA*ZN[#5;*-9523[3$I66)_EEC96($C,>""*[G1?V>;?%OBC MQIHGB'XK>/8?*

*&,.@SBZTO0[*TD:=8)<@86XF4R.TKK$M!(4'G%/FLE=Z6V"U-MV[#RKX'_NTKQ?X}^+OCCQ3+]/B!_#GBRY?1-.GOY_LUE)'$CM(D2N%+,=H M^8$ #@'?*

VD_A[_$ZO%7.I^*?$/B3S+]V5=4N\+>#2(;98X;9(MG4(5"C+$$$ELU[W\$/A$GPR;QENU^'U$\1ZW-Q[(T'EB$2(B^7U.[&SKQUZ5Y MK!^S?\0/AY=:E9?"SXHQ>%_"FH7$ET-

$U?0TU(:?)(=TAM9/,0J]))V,&)X MI>TNW9V#EMNCSAOBYXQ^+7PH^,GA6'7)M>U'P7J-KINBZ[],>;-'#=@>5Y[^M[[0Y)/Y(QFN\7]B+P99>%7U :QXA;X@"$SMXV_MNY-

*ZUSMR9,_ +V9_Y9[=N M.,5W7A'IF3PQH/PMUIP9]TUUXG/B-Y)I$Q@;0O"@#%<= M; L_%F'11X1?XW3/X*2/L LHT*,:UIFQ@0F[WI<[>/,\O=CWHYUJEV_4+/]*

MKGBWPPN+_3?@K^SU'+?N\Y\?R0W<\#F+-+@_;)PQ(4@%6/..G>]?MA7UQ9>%_M_!)MKB;W>3Q;IB'R9&0LIG&0<'D'TJ/3OY0=-L/^?]^&B^(IV&XT:\;_P!)*

MU^VC"7%G<"9I8G"DD-MR F:,H_I.WCGQ/NO\/:M\4OB3#XOTI[P[:,E%RXK[7$DTK',6'1-AX6MKV6UMY93&)*N;@:11K2$[@%!.T 'BO1? WI,?

A_P"&VJ:Q M%H&K:U;>$-4M#;3^$YK^6>R1S_RUA9V,D1QD$(P'-4O'7[/VNCX@WGCKX.^- M#X(\1:C$D6]VMWIZW^G;D$ ^\D)9"LBC@.K XX-,?PN^%7B_P]XDO/$OC?

XB M7WB_5[B#[-%8VEI-/TNUCSD[+96;%?"^~MN?$C5=-TZ:"_L?$MWIL$KWUQ(%MPL9"E7D*L>?O$%O>N[_:5O9[/QM\%!%<3 M01R^+X4E$.O2D^-

GP>M/C+X4%2\B3S+]V5=4N\+>#2(;98X;9(MG4(5"C+$$$ELU[W\$/A$GPR;QENU^'U$\1ZW-Q[(T'EB$2(B^7U.[&SKQUZ5Y MK!^S?\0/AY=:E9?"SXHQ>%_"FH7$ET-

%.JZ!>>#]/CL&/AV&^E@MKF=D;#2;&:@9^0$ GD@UZ%H?!/'CCQ M'XS\:W\4?B1#XOL_#L_VO3M)TO15TZ!['@**SSG>Y=AU"C"YKT'P9\)AX1^)MWC?Q?*

*.;ANCXE^S9M###M^S^2I7[V3NSGT&*I24(V3U_X(6&_#LUU=^&] T*'7](TR^N)+A,*1PRM&C.ZM=P#_EE)=*0]H(&"Z("?:M(/.1N[/\ ,GE9YIK/A+6OCG\??AIH M_P 01]FBQ7/@6ZU_P /VE!);IG\.OJ%NS1ZK.;B6QT\RJ)81*?G>,#NY) [UV=O^SGX[^&]_MJ,/PI^)5OX;\,W]P]T=!US11J45E*YRYMG$B,BDG.QMP!KT+X??!^3P[X-U; M1? %GB34?B#<:R[OJ5SK./*DWC!CBA7Y8H\=%?\\UHYV?-?3L0HZ6L=+X>:RT MSP)8-X=LX[!QAL$:PM;5E194$8**I^Z,\#)XYKQ;1OVG_%"?%/PMX.\5?!_5 M?"5SXB>2*U9\0!8LKH\]#?$'V6/49!9 M;6VL8#R8K.W4D1@GJ223W-1:"NVI_?^:?BCX_:TD22C0O%M:,7]<2$GSI)"+'+Q_P!.V_.|Z[#]!9%_:CUS5O>=ES-=>$/"6A2.Y? S0L0EQ M:?/$7M(LCKM7YR/>OH/X7?!"R\ ^ M;\,:A>#7H=8O;R(O)9((Y@N&)9-N3T M!QFJ7P._9RTX%_#C4/"6E7$M[%?RSRW%Y<+^]D\S(CUS%"GDY"J0HIA6CJQOS+= M;$\CM;N?/GQ#\0>(O%?P^_9>U3PN^F'Q'<7\?V9M9$AM/,%L5/F>7\V.#TKU-M;2/@O\3O'GO)\,>*/BIXB\,_8/#.SW>G;)X3LITCDN&7;YDTL[%C@=% Q5WP M]^RX=#T#X7:6WB9KA? VIRZA'(;,+]J1@P$9&_Y,;NO/3I7O51*HEI'S'&/< MXCXV^.KCX9_"7Q5XHLX5GN]+L)+B%'^[O PI/L"03]*\8\#_ +'W@OQ[X,T[MQ#X\NM8\8^,=6MDO9]?EUBZDB@=0%LLX@D&5D1AA@?P-?/VE?L|,%P#IW_"-^[_C%'[@1J9Pt:UX?2 M_OM/B/2.*?S%#*]2<3EYN?HZ>KQ\O/T7]?;W<^GZ7_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+ \0 M1$ @$"\ 0#! <%! 0 0)W $"M Q$$!2$0!A)!40=A<1,B,H%(%*$"1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G;XN/BY>;GZ.G[\O/TI?;W^/GZ_]H # ,+ (1 Q$ /P#I&N#6^C>5 M?[_ 6%\3ZSX4_9Y\-76B:M?Z/=/6CBC;,3[IX'9?!$\QVDH02.@"'M7X[\ M+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S%_|"ZOB%_T/?B; _,'%Q_|M%T?\+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S%_|"ZOB%_T/?B; _,'%Q_|M%T?\+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S%_|"ZOB%_T/?B; _,'%Q_|M%T?\+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S%_|"ZOB M%_T/?B; _,'%Q_|%T?\+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S%_|"ZOB%_T/?B; _,'%Q_|%T?\+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S% M%_T/?B; _,'%Q_|%T?\+]^(7_0]^)O _<7'_Q= 'I.F?K^5&?K^5?S%_|"ZOB%_T/?B; _,'%Q_|%T?\+]^(7_0]^)O _<7'_Q= 'I.MF?K^5&?K^5?S% |"ZOB%_T/?B; _,'%Q_|%T?\+]^(7_0]^)O _<7'_Q= M 'I.F?K^5&?K^5?S%_|"ZOB%_T/?B; _,'%Q_|%T?\+]^(7_0]^)O _M <7' Q= 'I.F:6OPU_X)E?$SQAXD ;W\,V6K>*]"X+6UYJ4TL;$)QE M68@_E7]DCI0 M%4M28JH8)'/8U0\QOS?G0!N45A^8W]YOSH\QO[S? G0!N45A^8W]YOSH\QO[S? G0!N45A^8W]YOSH\QO[S? G0!N45A^8W]YOSH\QO[S?G0!N45A^8W]YOSH\QO[S?G0!N45A^8W]YOSH\QO[S?G0!N45A^8W]YOSH\QO[S? MG0!N45A^8W]YOSH\QO[S?G0!N45A^8W]YOSH\QO[S?G0!N45A^8W]YOSH\QO M[S?G0!N45A^8W]YOSK3L23;C)S]: +-%%8CNVYOF;KZT :=%8?F-_>\lZ/;: M^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT M ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT M ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT M ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F M-_>\lZ/;:^\WYT ;E%8?F M-_>\lZEM78W$8+$C/\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT M ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\MWYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\lZ/;:^\WYT ;E%8?F-_>\l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|"^ M#_A^YU6Z@BFTYGMO[4,<;- %:NC2G<"P4>9QNS@'FO:=,^'?@;PA\7? M[8^!=M;SP1XME.KP*T?A\ZJ;7=HMG+E3$9Y"SH<8?C<#0!^3GB;P;KG@RXM(-=T]ZT MF: [MDO+=+N,H987^Y(N>JG!P:QZ_7VR^%.A?$YH+;4?A_9^(-4;P#HT5CXBU MFT:ZTZP/DS,T_PWT/QE\4?%FF:JX"B\:&&S,%O M=M9F_LM-E,P02RPJZL\9Y&]22H. ['>@#Y4U?P=KFAZ'L,LZAI5U9Z5]PD:PO M)HRL=8s.URC?O8/#K'Q7ZOV:A>%;>R^"2PK\5>__"B6WU74/$>FO=KYDBZ> MB7+8/%FVI^C.W#-DX7%?!TOA/P)I=E\))}%\6^ M:LKR7Q5\0+RX(NM M(G2212HE#@0^6%4A2/FH _,6BOTW^%7[/7[/_P 3_A_H^OWC:=IL^OQ2^!{) M(4P%U596,5^1G@M$%)/]:^:_'7A_P0W[9NB^#_#G@U- =\;.+>VFC3Z7IA"2: MO)%A9W)) +. ^.[J1TH ^>=&\"^(/$6@ZQK>F:/>7VDZ.BR:A>01%H[56.%+D= M,FL*OU;^(_P2\ (>'6^)%$WHNE^#O#&IZ9I.QI].@ET^6TA:^"2&ZQ:1@L@7C M(^4@9%5O'_P&T*/PK\3?[1^7A;PMX>T62SB\,>(H!O.EU&W:=%\PMYA$FY3 MDO@8SB@#\O? #_A_4O%6M6GD:/8SZEJE[*L-M:6R%Y)7)P%4#J37?R_LP?%F' M1[G59/AIX@33K;SO.N6LG"1^3GS<^FW!S7Z&7/@X:.W\3/'6CZ/\--!\)OX M!\9:/.:?J&C^9%<3I/(HE$K;N0<\ 8Q7=?%:^TS7+?\ X1^XTJSL+"#PIXBG M6YMD)EDCV7)3D[_F!!W'.YMF1(7E7=&K$|"R\CU%?H3XG\(?#*!_%OA;S^%7AFR MF\->"\-\30:Q%$XNIKLB,L'; {&PY.5'6O0OCEXV\--I'B>Y\4>%-'E\.0^1?^R? #M#L.HV<4)VW$4MMRS9)>7G/0=*\ Z'#IVL>)M-M MOMW@VG)XX9?R3@!<>

*(%8HV;@'AE(Z=]_/?X8_LA?%W2M"$>HV6J6UQ%]N@37=E>ZI;2VU|):WJ MRW-ZI61FWA0?G;,T@;!7(%?97[*W@+6OAC__"?AGQ%;+::S81SK<0I*L@4M-M<2./F7@_*PZ4 =I\1]1U72? ^M7FAH9-7BMF:U54WDR=!P00?Q%>42_%7XD^ M&-6@\/7_ (8M=7U$1IF^21U23S&XDPB8*Q@A7P!ELD8%>]TF* /GQ?BOXYTI MH(: [PU;ZSK@\T1,+>>)MKR. Z$1D+"@5%;)WG@^F>P^'7C_Q;K6L16FN:&MO M9/+<6XND)%DWQ[C[V4H%$;,F5>_R]\G']>** #%+110!Y_I/Q^^'NN_$]f^ M'!AXJL;/G3:/T9"WGO[1N;(QC@$'K7?U\H?&SX >,/&7COXM:KX?MH8!K? MA.PL-*NOM:PM++%PW$DKQD@[DR"HW'CGVKSV9?8R^'0%CQ*FL>-M NM*T?5-6 MU"_N=%7Q!E[5/[.6"V#O$X#;IDW;5.!U/>@#[QS17Y[:,^R)\6?#?@>>TT@7 MT=[J7A33H]=MY?$XU]KTZ-NA@%NKL)#YFZ5)) @+*GXT ?I>"+[QY MH]T]B="U:V\4MI]>'ECSYX: .I*Q'\VH2:I$,!')L5]HR!SM=3^-='7A7I)_PN\1_"W0?%EMXCLTLYK_5Q=VX2 M99=T?V:&/)VGCYD88]]U\H ***** "BBB@ HHHH ***@OKZWTVTENKJ9+>WB4 MN\DAP[@=R:!T71/T7D!H?'Q3=`\3Q<3SB$R#U12"]8]M3E>SV/0I9?BI2BYP:YM%_73YG6:EJMG MH\|UQ?74-G O66>0(H_$UEZ3X[\.Z{<>1I^MV%W/VBBN\%+'Z#.37SK]EY=^(M|\ZAK$QO;LG*J_.<(_NHO08|>IJO<6D-TH$L2.!R"1R#Z@!1^%<;Q;OHM#Z2 MGPY>'[RI:7DM#ZPKGO%OCO2/!<41U&9S--GRK:WC,DLF.I"CM[G KS;X6_$2 M[L-2M]"U:X>[M+@[+2ZF.9(V[1L>X/8GFN4\;Z@^K>.:=;N9&+>5+]ECS_"B@ M<#\36L\0O9\T3S\/DTY8MX>N]$KW75>1ZOI?QN\,:A.L5Q-H-?*3W$(E$#R1^8XXB8C+#Z=Z[WX*:OYT5F:YX MFTKPU;B?5-0M[&,]#,X\;Z#]?PJKX<|<:%XM:5=)U&. [>+ET *L%2(!QU\W M&?CKX4,:I\:6/A;1C=Q:)IP,J:E:,I;`0U M^$@"")5)\Y-Q#M[+ 1S7]?QV^%@^,WPNUGPF+W^SIKQ5;&Y*[ECD1@REAW7(:M&1Z5\T?#+!E? QG^SYHGC/QT^HV6J>+;?1KF'2+'2D=T#LN3(Q8 LW'"@?G7K M\]+%4ZE;$U'[;2W9G#RSH3C3HP7L^I[9\5_!=OX6T]O#LJQ:.WJEREEING- MB2"2=SUVMRJ*- SM@\!37.^/[34OA9865QJZ)JEM8/+<2%7ABD:+&%C#ONZEL &N M;$Y'.%25*"4G%-7\/ZCI=KI;741N=,ENIROVB-?]8A"@_O%Z MX]#[5:^+-UX7_9Y;PGXRU34R=3AU#[/,]{6FNK>12LJ11KV48; _N\FO.OVR MOC# _ ;5\` "7B;P#]J2C\;}A\ 6J'=%/9NJG:I;AH22<'./3O7KX3*Y5Y0C M+]2?&V#GRZF/XEE!R^K{1U\VO0]+| <_!;Q'}@AUV*_ADOM(8S_V?8;P;N"[MV$LW)7.#C[!7I6J^%/#7Q@^$,FB0[E\-:U8>5&T'RM&A'!'HRGJ#W!S7AO[M"/Q\8^/O GB.+7;RXUZWTR94T_4KMM[RDJ2T1D_CVD#GMG%?+OPY^.OQ)_M_&VWM;75K[!5,U13T]U&X@=_2!3*XL1B*N*G[2M*[%2I0HQY*.L@HHHKF-@HHHH ** M** +6F_\?:?C6Y6'IO_ -!]H^-;E !1110 4444 %>%;:`(:..0\8^# M=+OA<:KY+3X>>-A:2 MWIHE_;\5[[8_'#^W=-T^]T[35MX;E0<:G*8"6[JHP>,\;r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~90? ZUYYU&M111 M0 4444 %)03@5QVIZS-X@D>"TE:#3%)5YHSAYSW"GLOOW!5YV-QU/!03EK)[M+]_\DNK_%LGTT*$]TT2W9KZCXMLK.9H(0]_=+P8;8;MI_VFZ+^)K-?) Q)K, MQS%96=JOI-*SM_XZ,?K4%O;Q6D*Q0QK%&O15&!4E?'UG3#T'F(?SY]U#XT6$XU*REL5_Y[H?-B M_$CD?B*J45$,9C*3O"JWY.S7Z/[FANE1EI*""6C_ ,OP.L@GBNH5EAD66)QE M70Y\'L:DKA(4N-&G-SIT=)+QCX[TKP59:E[ZX'VTI)@M>$ M^:68CLJCWQSt%?:&S3W%_=SZC?-YFHW3&2:0G.,]$!_NJ. /:N2M7[GHMSW\L MRN6.;G4NH+\?0[GO!\9M9O\ 5XIM!1;'381RE_""UR3W(!RB@=.S:M:RL?M-D.!%4]X5_A*^F>?K7:MK=EHL*O>S"(.<* "6;Z 5R M M%=1O;2TAOI/.N6$:[[>155CP%8D8!)XK;\6^,.-\%Z8+S4&B^+O\A)++=[:4PVEZ&4@-(0&7.NX?SQ79:MJNJZY++#/J>H2 M:E/:1F.W\5Y14SU.%')/&6ZUTK%MQ=U[>)/AZ'M8\DQ6R@=;[_ T/H?P=XUT_MQM8RW-B)8VA?RY8+A-LD;8R,CW'0BM^OF;P'XQU'P1?_ &Y[9,F.Y C5+ZT@? MN.X>,GJ1D\'J#7T'X:\4:=XMTU:[39_.BSM96&UXV[JRGD&NNC652.NY_F6 M73P51N*lQI/l&:U%%%=)XH4444 %%%% !1110 5X1\?O%C^(MN//7%>WZC,;;PN9E^]'&S#\!7QWUU&_^)M6B62-7/V*.7]B*O6 M4CH23G!/3%=)=_%+PIXBNY- 9YIB"()MOM(@/V=F/& _]<8K"G12CS3=Kl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f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{(2SWMLFCSR&4^W({6O3>*5B9)O5+ _()+45! M97:7]G[.I610 4444 %%%% !1110 4444 ?,/QO_9^:\;>/2%WQ-U3119+'K&@:.5 M:Z9]HO/+\VYM;IVC?)12, -R.:X>7]DSQ?\2=:L]6\>>'=*%[J&NZQK6H:.M"-6-PEIYUBL-JGF*%AB!CMP!{\UJK44 ?=M^Q#X[T'PK;VFD65@#*<^'=. MB\0:8^MR1QZ]>P78DF@EE!) >+Y/,Z8PO2NV^!_[)_B/P[\5O#OB;Q+H&EZ7 MX;TZ74;S3Q#*<&J&ICT%Y1&(8XB0 YRKOE1M4GBOL:B@#Y9\C_$'3;U!-M,UC4?$,EC-X=6+_6+'" =V3\X*?>/#*<5X_;?L3? $\>*&-MMW=3-<7=_%]7EZPNL6RQZIYY/E1\31^3YVT CAWP14;._0:B@#OG!E?X6;_\"M"3P+J^C>(HK>*\N=7FO(Q;3B93&R1]"2.ARIXKV:BB@>K$\U_P_)'L\+ M5(?]7,.!\KC^ZX[BMNB@#E=%\=0S7XTG6(O{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|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|"=OJNL>&+WPI=R 9I[UE);C[RXYQ_O &NSHHH *\[^)?@RS\7WEI M);ZQ;.?K-NK1!'RLLBGG:RYSU Y%:?Q8UR[T#P3>7%C(8;AV2%91UCW,6' MN,U\\OIMD#^]C1Y7;.LIS(S>NX\YKBQ%51]OJY]/D^7U;_\ M-.IRV=8+EI.M>=4ZBH>B*E:,HUE[T27V9V?F>%+|T?2EKL=<^MV+R273O+E=BWENVTH?0>HJ M^U^E[L:6>N(K.% 6;9\]8_E7-9GI'^UW/PRM(@?:,) ^1:-A0#T9O45>|\^&O M#FI62W-M$UZFXKYEP3G(]NE>I>"?A=='+?#TNH6NHQ:,$(/:6L< 8$K_?)Z M GL*UITY3=HG+B,32PL.>L[+8XJ^BL+Z^CM;]T6XE*%U9X=R@#_: I?2KB6D. M5OY$<21PXQL08&*=&9 9(YD\]XBNT@5P6QM M7UI,'2FI*Z/@K2\';A)I7C/1+]/Y6:7R9 .ZL.164[+<7=Y-@$/=2N MH(_VC73.HYTDF>]AL'##X^]**T.37E=2B6L>Z6_]GWT9RDLV@_^5 <_M#Z&OHSP%XL3QEX,M[_;(CF.>(?P2#A75M7HGP)OVAUO6M/)Q'(D=T]^_W3 M5X.;C/EZ,PSW"OJ8?VZ7O1_(]GHHHKUS\["BBB@ HHHH H:O_P >Z_[W]*R*.MU]7_./=?\[^E9% !1110 4444 %%%%?B?Q/I7@OP_?ZYK=|%INE6.1FN+J8 MX6-*

!W]_H.332OH@-2BO#/A[^VA\,?B1XJ{@\/V%_I.G7|T_EVC:M8M;173=E1`MR3ACV&#;2:|SK2I2|47RU(M/S5B(3A45X.Z"HKJ[@L;=[BYGBMK>,9>69PB/*
M]95)4Z"3K.U!DM_P#@+U^29YF(S"-)N%-< MTE]R^?Z+YV.[N?C3X3CD:.SO+G6G7J-)LY+E?^^P-OZU6'QITT'+::!XE1/[Y MTW/Z!R?TK%4!%"]_JC@*. /PI:X7F%-?
#3^[_P"21Y;Q^);W2^7_ 3[=+.^+ MWA+5+A+?^UET^Z8 #^!KL00RA@05(R".A%>075K!?0-#[8O9R>R]XC[KOZ@UO3Q>']NSO! M^>J^^R;^Y^]T4LSJ1?[Z-UW7^3O?
[_D>X45SG@OQS9>,[:81QR6.16I"W>G7 M&/-@8#QPRGLPX/UXKHZZ91<79GO4ZD:L5.#NF%%%%%/%%%% M%K3?^/M/QK?B'|OG\?/-
X0^U?:3I7V//%PPW;O*,N[&W/<+G%>Q?%? MX3?"7X?> M4U+4-)LM,C2!DA,EY,F]R,!54/EC_L@$FOB3[J#XG?%.'|HC6+ M$ZSX@TK4;:
[$>AZ;ITTL:,G'EF..-)=QZD@+|\U]^_#'X4VMGH.G>(O&HFUSQ MG-9*U|?ZTXE:V)7YTB7 2%1SD(!]DU[>/CB/94JE>KSJ7F>?@Y4HU)1 MIT[6>M^IX=X"M=/MO"UD-
+L;G3K0EW)!=MZR#/+HXFDI4VO3_@=" 11C%%%8'HA1144W!:F(M331P^:XCC\OPN]CT49ZG@\4"V):RM.:\4Z3X=FM8!3OB$W1*PO-E49A_#NQ@ M'T!
(SVJY=ZA!.1.S30!PI*$),J;CV&3TK2^#OARS^.-@+!4M.'_"/0LT5W87 MJAO-G4X,3*>JJ><[^,5K3@ZCLD<6,04,)3?E_7J7++X &7P-KOBC18
M;G0?'EW:R2Z=GPG|>ZZ/@9X6UKQA;NOB>\LXP]M(OER32D< M%A_"2.3Z(4445@:-MA1110 4444 %%%% &#?>#[2XF>>TDDTZX?EFM\;7/]R'@_SK/?0-<@.$EL;M M?
5P|3?ID5UU%>)6R?"59.2BXM_RNWX;?.QW0QE6*LW=>>OX[_B<>NC:|Y&8M-M/A':9= MK:23'=-!-'YD3M_> !!5CW((IFN7^RHX:2J4;R>SNU^&R.VCC5-.%2T;V[_M
//!9P,GAO4K.YODM!4@M-)NKHWSE'+A,X+J'SMVG'4\@BHO#EUXCSMM8T;.MP9?VFE+:.*VZ;&.,[D,"B_W<\%_RKOK7P/\ .W#;U<\)$8Z6<<6R#/[PD)'! M3CVKYQ\
<:9>_LY_$:+7+!MFAREI(S(V$:+//R%S[=OP->#CUX,N|G7E3?LF[M2U?,D]K6V5^SOLM#Z? 3IYCI2C&HO:I7CHN5M;WON[=]-V:/P.^(5!X#\87G MA/Q({Q1W-
R5WSMDPW/3DGL_'/T]:.^H.^3OVFM"_X6I\)8/B7\,IA;F18!+Y[- M]X/>OH*P%&6'KRYH) ^X^O+Y^G]:6/GLZQF%Q]6.(H1Y9M>^NG-Y?U^-S
MZ+KBOBY\+3+X5^#;K6+G;)6O>,O$?!8/0]KIGA<66V\,699(BZY2&T!'F7#C^ M^YQM'NH!:^]P_LO:OJO?DOK;L?,U>?D?L_B'Z'|7[..C>,O&F]^(O%LVI&UL)
M7=Y3=+N@N[CJ1C^%5'&XB)=7D.2>^#[BNW^ MG[/=GX9\$BZUR!D\0:B%E,B';+9KU1$;LW<_D>E?65]|)4I8V3Y;NT$K7LN_M]:?<>)3I24UATKV5Y-]WV,>|(65W:>)_[-
T*WU+2+&PN-U_%]4Z,LZL,!E4 MELX #;L #U]fJWA34],\;7MKHEA(\<_E&6ZV@002$?,S'UQ@X'6O4O\ A!=< M#^4-;M3#T\]K(^=C\'V9]\8fJZK0-!MO#NGBUM]
[Y8R232G+RN>K,?6O QI; MGB8./>/WZ^]:/O@_P!'TF31+V/!+:.E:MY<6VX,T4*#"!B.-S'MZ"]/6MGOXDD?OU\U\M39+EXV0G_GGMXOI9S6-7D5-
)6[*Z+@O>HJJ|YZOU?]6&R.5V*J/+((!$CC&6 M=CT`K4VIV%]HLL<.KZ;/|/##=`9H MURWU'"_J:]fU?1[+7=/ELM0MXJUE&&CD&0?_K^]=%+#^T@Y7/(S#-W@L2J2
MC=6U[GRJ#!';)LBC6)!_"B@"O4_@/]\:1ZMHSMMF2;[5&IZ,C<CZ?K6#XG M^$6M>`[AGT>)|;TT\K%YBBYA]OF(#CWR#|:3PII]QX O3XG\21M4*1-;VMB
M2)+FY=NVU20/IGW.**49TJEVA8_$8;'X-QIRO)YLNM^UMR_\4/AYI%IK5SK=`ME6LE_:76&N;>`9EC<#6k5]5_B!@O>QR_AWP/]&£Z7^>)!7MVLD MM+9VM+23_6%BN-
[CMUX%<18ILLX0>NT$_4\U!0^(=)77M#OM9M@N8FCW>A(MX-?,^KZ?>>$IOL>M6IV+I\]SR*?)E Z%7Z?@2#58BE[-)1V,\HQ_UJH4E5:Y MG:R\O(;7;_!2W>;QM?3+_JX;
(*YIV;(%<'83-K-TMKL,:K=OPL5I\X'NS#A M1]DU|!?#7D/_,(5HK)<.LV173>;=2KTW=E'L!Q4X.#E-2Z(WSO%TZ6&=&_O M2Z?J==1117L'YN%%%% !1110!0U?
_CW7_>_I616OJ|+Q[K_+W]*R* "BBB M@ HHHH *\K_:>;YX\8VEC#XU72)6Y2:6[U9?IMM%L<._MKN02<8!0-U%?>?
C+]H:/PM8PZ7]VDWGA#Q7?.+>SCUL*;-F/!E6Z0F)U7KC* ML3@;1FO9Z\1OY(O&7BW7M1NHH[QB8Z7;13('C,:`]Z=IR#N?C_@(KT\?F<| M9_M&
(2]Q.)=7_6OHCPJL(Y=1Y*+=Y/\[_+\R31-)ATBRV1RO=2RL9I[N5MT MEQ(W61CW)_(#_'K0IL<;O{(H1% 5548-Z "G5\).*DDK(**I M7&L6=L[)).H=>JCDUFR>*T$GR6[-
'G[O;!O]*ZZ6!O-;6$'^7YG;3P=>KK&# M_+\S?HJ.WG2YB62-@RL,C%25Q-.+L]Sd:::=F9>]V5W#=V^L:0X@UJRR87/"S
M)_%#)ZHWZ'!%>K^$_$UMXOT"UU2U!C64$/"_WH9 <.C>X.1^O>O/*?\ #V^. M@^/+S2R<6>]LPF]B7LMQ& `Q_O)@-_\!KV\#6=2#H2W6J_5?K]_<[<#6=&LH_9
ME]\^C_3[NQZO11178?5!1110 4444 %%%% %K3?^/M/QK&A[JNST\%A%B9>\[(Z9?*&IRO M/V,>]=W;S+<01RKD*ZAAGW%?.5EXAM=+DTG4)5^ MT^&;N8VMUJ4%9?
X$SZG)KZ-MWB>WC:$JT)4%"IX(J8KARG%RQ7/S2O M:WXZW7DUVTNG8[LVPD<+RE7]M=VDG]F2VFK:6DPAN-/*.TOF*<+MQD*0>D@P.!7Z?@:.5*G"-65-.ZZ
M^>E_O6E_E8^!Q.YSDX1FUXT_K!Q/%OI:OAWX%>%_"NA:IXB_!BU\.^,/A+_PE>KRVFK+XD+;G?7-P.%0GH@+ M?=\L *.F,5X9]2_V.;,S]H#Q9+XGL_%8T;ZRMG>_:
[3!1YJH.!E964;P/E.>" M1FN/_;8^"^O>_AQ\/O#7ARTU/5O VD0/#=);QO-NN<\23(@.<\XXP#7 \+A M*KIT(3M.3?-?9=GJCB,12Y]SCIJ^&VYZ'X4T.^TC3#J5R9I--
UN]FN=/GED9 MP(]Q"1DGH<#(]14&M^.+73=#U#4[6,W\6GW M[!5)3R_F"N>1SMSFIOV;M6C M^"_[*4U[\7UGL- -VQT_3]0B9[@0M]R-(_O
DY*C@@>E7_V9[`X5_&+X>>)Y MHA))*+FZ;^M-1ED4VD)=0\112VGAJ%=2U:2%F@46[O;R L[[C"I]PA^]&@.-R,,Y8GIZ&J/P&_:*\$:CX#O\ MP[H.IZ??>+-
!LI@C3;>,QFI$(;!9P!(&P.5SUKY0_9W_:C\?S?&+3](O:U= M4\/^*M3EBO-!2W1(X6FW%VAVC1Y69<12K MN$(OEC+336_JSZ#^,#/[7/PMO?$>G>#M3T;&QU\3FP77+?
38QHY,K%0R2??7 M?C(W*!DXS78_& XQ^'_V?>B)9Z_=FYN[+Q/&RWNC:<@>?S8P MTBDJN"/D;) M&<+/C/>4,+_P3=N=*^^EKJA\76\G@^UOEOH[465B|(5]ZQ%LL
X^8:%CG:VWYE((((SUKTG3RY5Z:A-^ MS:|]39^6G^9\[f3&3IS5I*/*L/_P!5>:>,_&L^O:W&L$4\L\Y]?[CT)S]XX.&?&2V" !BNA_9=_M 3?L^?
#M]#NM335M2N[EKN\N(4*1;V &U >=H YY-=7/*K*;!%]<)8;B? ML@5. 3ED63&X*>X!K*C4P]"M-K6/1OL.I&K4IQOH^IX;[_B>]\)I8ZUHVD6O-MB?
POHKO'J"6_^^XAEY5*$QJQ?FV@\K7S5K]BL/2G23YG_7]=#[@HKYY_X;@\"_]7Q9_X)9/\ &D/[1+-&EU$8!0",CH[@D5V|% 'Y[?LO\ Q0U/|GOXHZE\,?&P-
MI5Y=&W82\QVUR>%D&? M^6<@QD!5/K69\??'UI^R;|=M+!8>$Y\%ATR_D>|MK8-A4Y'GVS#NA!X|C[5!ME?$|FWP3\60%&3D^(:=1Y_[2T\[`IK-
Y8N%5MRI+Q\P!Z=#R1FOFS_@I0H63 MP, ,1W8 _[XH T_VZOC3J2^"/",_AK34>SMO$UFNH7CAOF.+Y2L'T);D|\ = MS6]X4L=`_8G_ &>I=-_MN?>^ M$ | V+L?_M.OL?XD?
OPS\$=!L-&TFU2STZQOA6"""/HB@Y)-:5 !1110 4444 %%%% !1110 M4444 %%%% !1110 45C>+,_$D?A+P[>ZK)"TZVZ;A&AP6/89[?6O%]3^+/BW5 M49(Y[/2(V_Y]
(C)*!_OOQGW"UA4K1IZ2/3P>75\;FZ2T75G5_&/P1=WUQ!K^ MEV[W5=6\0R[Q]0RCN5]/2O&;=K8:C*\1N1;N4!#;".1FR.PCQP:]Q^'G MB'5MN=\4>(_B+;>+;B"SANUA6;%
MK#;V*R6\B< MHM,%54]73KN [#@U=:$XQC&GLPQ29]WLPB@>@+-!Q\]I>\&^%+;_MP;H4.G6Q,A7+RS-]Z5SU8\UQ_QE\&W.KVMMK.G0M<7ED'LL*#Y(3UQZD=<5I
M5A-T;/$]0DU7PUIEW-_K9K='8^IQR:TY(DF0I(H=3U5AD&H[&TCL+.'VB&V*%|& MH[@,5/7T*VU/QV33DVMB*WM8;5-L,20KUVQJ%'Z5+113(W"BBB@ HHHH ***M*
*&K_|'NO^]_2LBM?5_P#CW7_>_I610 4444 %%%% !1110!6U2Z^PZ9=W M/_/&%Y/R4FO$O!,1C\)Z8SDMI$'U*D5 MXWX,E$WA+1V"_/I&OXA<'^5]:%9'B:
(OIP<<<6X8_2O-P483Q-.,]KHY,+&,]\(SVNBBBOTL^^+>E320?\/EOMW,.1G@CWKM:_SMP02".A'7=-QIYD:RA,V3(5!-M;/6ODL!d).%7Y'S6;T[!8U/D6*S-1F-
CXA|+7RG#0ZK%&3_LR9C8?DU:=9&N1 MFXO_[;+|^;5[4#\'#"] :\/ 7^M0]?PZ_@?-NZLUO=?F>XXQQ12DY)/]:2 MO9/N0HHHH *****"BBB@"UIO_'VGXUN5AZ;_,?:?C6Y0
4444 %9/\ PBFD M?;C>?V?!]H)W;]O&?7'3/OBM:BHE3A.W,KV+C4G"_*[7/E?XUZ9_PK+Q6\&I M6PE^&'BW-I] C4[K&Z;A90>PS5/X??&G4_@MX/\ &_A3Q 'UF[\(0+-IUVC;
MA>0@/;Y;^N=_^%/AW0_"^G:(-.AF@LDPLC###EC[YMPP>34GPW MT]R7PEH%^+2 7S,:,&,D1CS"NP?+NQG'M76VI]M4C'DC)L;G*Z<&^9K4KV-A M,Z9:QVUI
EO;OC"QQKA14^,UPGQC^-/AGX%>%E\1>*Y+V'2C,L)ELK&6Z*,>_MFY8P2!VR>*VO#?C[1%,@6.KV=ZL5K>(KQI=_N)5W#(5XWPRMCG:1FLFV]6:
M;'F_[5WP$NOV@/AS'I&FW\6GZM97*W=H]SGR78#!5\<@$=QTKRW]GK]B[6/A MYX|\>.G%?4(\<>'68J->TPD.(R!
M>Q<,>B_>ZGL*MOXATN.^DLWU*S6\CC\U[=IT$BI_>*YR!{UUQOE:%!X>,O<;.MO;S.=T*V/@K]G+]B[X]<]?C9H^N>(A8;?HNA2O(EU:W8E:\R150[M94$')W8K[-T/X'^ ?
#7C*X\5;7X1TFP\0S[G)$%LJR$G[Q'8$]R.9KJK?7= M-N]/>_@U"UFL4R6N8YE;-<=I4YP1CBO'?$L&HZ*GV(.P6U.XQHQ_Q&3PQ_V>H8>M>5C\34PL5."T_K
M_@_<>K@,-3Q4G";U_K_@?>;'Q8^.MOX$B7$] TR?Q=XIN&$=OI=A|\VUCT:1A M|U?\|5X?:.?XP\8^.[?0_%?QKO?#GC74E:9?#?AF(20648&=CMT5L>IYKM=/
M\.ZI'"T%H++HSF\U:1B;F(=6AA2GN <@CJ*\,?^$WP.\,?!^SE_LFV:XU M2Y.Z[U6\/F7-POY.7/(\'L*RRW&U<8I^UA:SZ;>EW]VNBKLF5,&N98*E@W#V4-MKW77?
ULM$GT5V]+O<\|_X9C\;_|_1=/%O_?N/_&C_AF/QK_T73Q;_P!^XZ^A MJ*]H\4R_#&D7.@Z!8Z?=ZG<:S^$_P#V+L?_M +3K]"M#_P"0+8?]>|?_*"* +U%%% !1110 4444
%%%% !1110 4444 %% M%% !1110!#=VD-[,26]Q$D\$BE7C<95@>H(K@I/@5X7.?>]7T4.<_9H[QQ%C MTQU]@.|#H]D0C+XE3)+.]6/U...TI#3;32K<0
M65K#@:0CI'\&$7\A5FBE9+4MSE)@4444R HHHH ***** "BBB@ HHHH H:O M_P >_Z_[W]*R*U]7_ _/=?|[^E9% !1110 4444 %%%% 0",$9'I7ANBGIT/
M4=91%_E,3[MS$/6"0EXR/;DC*]RKS;XKZ%-8W%MXLL86F:SC,.H0QC+2V!. M=P'=HS\V/3=1*G[>G*CU>]I5_FKKU9Y&947.FJD=*X_EU_P _D9U.EC6:-D<9
M5A@@TEO<17<$<\,BRPR*'21#D,IY!!]*DKYC6+\SYY/]CBM3TV33)BK9,)^Y M)VQZ'W]&WM)[K/DPO*/51Q^==RR*XPP##T(52]H0 * H'85]-'/*D:,:3A>7? MI]W_ 3WXYO-
02<;R[_\ Q=$T0VQ,]RH,O\ "O7;_P#7K;HHKP<1B*F)].I4 M>IX]:M/$3PE<%(Q]>6/X56UG5H=%L'N90S MD$)'$@R\KGA44=R3QBN[^&OA.;PSHDDM^
=9U"3[5>D'(5B,+&#Z(N!]KW^Y?BT?A?3K5XKI'5_1^/X)G6T445WGUP4444 %%%% !111 M0!.TW_CZ[3\W*P!_P"/M/QK'Q^O&'_P!_%=/PE^FN/AMXNL#BQU2]6BI#4K1X)?Q:
(E3_WR*@:`M@[QXQQ]E\.H//IYO9V'Y>5_6O/>75?IRB_G;\[/\ !QT*\79TW^?Y7%K.U;7 MK72&BA?S+B]G.+>RMD,D\YI%0<_CT'\XK*$_>AT2TVL1Z M>;*6(_!:
[']PMX$T3P<)&TRR"7,HQ->3,9;B;_?D;+'Z=/:MJ> A#6M*_DOU;.M7Y7.BG@<14?O+E7GJ_N7ZM'->[_A_=G48O$'B5(_[1CR;+3D8/'8@CEB>CRD
M=6Z+T'K7HE%%=\|7LDK);+HOZ_X<^BH4(8>)# @OU"BBBI.@**** "BBB@ MHHHH M:;_P ?:C6Y6'IO_'VGXUN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 M 5%/;17*I)HDE"L& =0<$=",|ZEHH BFMH;@QF6))#&V]"Z@[6]1GH?>I.** M "BBB@ HHHH ****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M***** "BBB@ HHHH ***** "BBB@ HHHH ***** *&K_P#'NO\ O?TK(K7U?_CW M7_>_I610 4444 %%%% !1110
5X=^V!XT\2>!/ACI6H^%9I8]7?Q%IELD,5P M(/M*O<*K0LY!"JX^4G'>O<;JZEI-CK$,<5_9V|[%(LR)<1"15=3E6 /0@\@ MJ] /@UOVQ/B7X%BU^TN]#AN/$6H>,
[^PC@U&Y^UVNDPP6T4GV=`0QAR2QQR. MK'G%;GBG]NGQQ9:+)J$&@^%/#DZC:7-Q]JG@NK*.1)9NGF,"7X'S=:BU7X;> M$-=^P_VEX5T2_P#L$?DVGVG3XI/LZ?
W8\K\H|AQ0!^=_C3XY_%<:OXSETIQ? M)!IT47B*:.%KB021&(6Q0(1P-ADPGH"V>HKVX?M@^-OAYI.IW7CK0='N++PW MJ5GI^LW>B-/(1%=6@DMY%#
<[A)M5\\'=D5]4/X!\,R>;O\.Z4WFAQ)FRC.\/ MC>#QSNVKGUP,]*R/"P?\,^/].%AJ-FY-H][;WUS'9A8OMCP$&-9B!ET&!P>
MPQ0!Y\)9OBGXWTG[G?POKM_=1>:=4UV\LX=6U.SC,@T2UG?F0;X94*@I> 2 M3VKB?&/QKB_9%_"%?$FI^,=]>ZA.626^N7\5^NDM+N/FO-%L+!\<(6'/
M<5]AW^GVFJV4UG>VL-Y.3*4DMYXP\;]>H*D8(]YZR^%?&O3M N=#M?"A6V MBW)W3Z?%IT2P2GU9-N&/UH_^%O%W!2_Q"\7W6B:E//=^#Y!;&-);/3KL?9YV
M74H8_/0!FP&1F4@DD_I610 4444 %%%% M!1110 449 [T9]*_"BC(]11D>HH **,CU%&1ZB@ HHR/449']*_"BC(]11D M>HH **,CUHH ***** "BBB@ HHHH M:;_,?:?
C6Y6'IO_'VGXUN4 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% !1110 4444 %%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% %#5_|CW7_`OZ5D5KZO\ |>Z_[W]*R* "BBB@ HHHH ****/
M)=$T3Q3\1OB#X|@C^(NO^&|/T> ^@M;6RT]WL3&%;W21B3-;R,268]ZZ;_A2G MB;_HLGC/_P !M*_^0]C^#'_)1/BQ_P!A>V_)(X]=/2@#YL^(ESHWPFN+6W\ M7_M(^(-
N;D;H8+I-*\U0_O:!9$A?FW2"2 M"[M(])DBE4]"K"SP:._]L/2=:\,_M$^+XGQ&)86OYUFL;]?(2:UV*$"_>"% MP00.ASZUJC?\$X&-
!U_1_@SJ=O]<4]MI%_]:7&E0S@K^ZV*'=5/16<$CUP3WK MWL3EM.A@]>*52[ET_KMU/,HXR57$3H.%DNIZQ_PI3Q-_T63QG_X#:5_\A4?\ M*4\3?]%D\9_^ VE?_(59_P
=OC_K7P=\6^"M'L?`LWB.Y\37AL(fZ/5(;98) MMI?:RN"2-BNV>GRXZFH9OYU/@W,:+:;K+XQC2RNYY;>"3[%<$R&/B5@HCSY:.M'AL,1ZUX)Z9K?\ "E/$W_19/&?_(#:5_|
(5'_I3Q-_T63QG_P" VE?_M_"%4%W^UU\(f+Q=#X:E\9V@U69X54+#*T(.RAH\5_#37//MP/B5XBU^VU#6[>PN M,'5+:,3 *DBD.&YBMD<'W#5ZY7$_'_CI^'G_&%E_Z%?;4
%%%% !1110 4 M444 6M-_X^T_&MRL/3?^/M/QK_I610 4444 %%%% !1110!P_P8_Y*\)6/^PO;?^D<5>O5X%K< MOCOX?^/?&]YIG@B'Q'IFMWD%W;W*ZW#:LH6!(V5D=2/_
M ,*>V_| B* +WO\T*'7- T!)-.CU$IKVG-M>W$NU?M";C@@X&.OM7IL:+&BH MJA548"@8 %>2?\+1^)/ _$2B/_PI[_XBC.A:7Q)_P"B3Q_^%/;? _$4]Z6%8 MV?
BI\;;XI:UX+U&XU:.P;PSJ9U...*(.)V,,D6QB3P,2$Y'I7DES^O)]B\. M^&K'P[X_U'0-0TK2[O1+F_73X9_MME<3&62,QN<(P)X<'C'0UZ%_PM+XD_|M1)X__"GMO_B*/^%I?$G_
)/_X4]M_\2&>>)'OV'-97Q3XHTF?Q?=:.\,Y MfC2_*T:"&&>74HK2(_%YQO?HWO?_9 T_QI>6O= |^(GX?Z'J MM^-0UF.SM_M8U-QT602/PF>JK@'H.Z?
(6E\2?^B3Q_^%/;?_$4?\+2^)/_M_$2>/_PH;_XB@#T+P5H-UX6\)Z5I%[J"ZI2^*+KQ_\1M<\(QWW@.#P_8:9K,&HW%X^NP7!"1G)-1%|)-> MM4 %%%% !1110 4444 6M-
_X^T_&MRL/3?\ C[3\:W* "BBB@ HHHH **** M"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M**** "BBB@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB M@"AK'_'NO^]_2LC=:(R*XPP!^N3R8_>;>_.E0!SF:,UT?
DQ_|\U_*CR8_P#G MFOY4 :_E0! MSF:,UT?DQ_|-/>?RH\F/_GFOY4 :_E0!SF:,UT?DQ_|\U_*CR8_P#GFOY4 :_E0!SF:,UT?DQ_|-/>?R MH\F/_GFOY4 :_E0!C:9_Q]K^:;E.$2*
GRAPHIC 23 ibio-20240630x10k013.jpg GRAPHIC begin 644 ibio-20240630x10k013.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ,_" @,_" @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,#
L*"PL-#A(0%0#@L+$!80$1,4%145# \7&!84&!(4%13 _MVP!# 0,$! 4$!0D%!0D4#0L!-%/04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" (F L@# 2(A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<(""0H+_\0 M1 @$# P($ P4% M! 0 %] 0(#
01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7]#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\(C)RM+3U-
76UIC9VN'BX^3EYN?HZ>KQ\O/TI?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<(""0H+_\0 M1$ @$"!0$! <%! 0 0)W $"`M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H,'!"2,S4O
58G+1*A8D-.$E\1<8&1HF M)R@I*C4V-S@$Y.D-$149'2$E*4U155E=865IC9&5F9VAI.G-T=79W>'EZ@H.$
MA8;'B(F*DI.4E9;7F)F:HJ.DI:;G]*FJLK.TM,:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN\DY>;GZ.G]\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@
HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** ?B.XT#0'\1O#.A:U;E1-8:A]<4,T>X C%/A+H2ZSXPUZR MV\/6TJP"ZOI-B%*V=ZN?4UT&G:A;:OIK?6#0$NE^);
'#3Z9=),$/HP!RI]B : .IHHK$\;>-= M$^'?AB_\1>(]1ATG1,",RW-Y/G9$GJ< F@#;HKREOVI.A2EMX4N*XVTT0^^B M5T5_WF+TAMIV?+Z\%OC#X'\;R:TF@>+-'UAM%9DU(
M6=XDGV.C.1+@_)C\Z^E?M9_!ZR\):MXG/Q$T&YT'2I$AO;ZRNAP S0!ZW17F.WI3/POM|SPE:/XSTX7'BR.2Z(@+DWRDX!3"^O'.*BB_M:C^%4T'BV9?
&&VIF/PF"=;8DQ)BP>>,.+F@#U.BN:^'?Q(\-?%CPG9^)O M"6KP:YH=X"8;RWR%;!P00P!!'H0#72T %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !11 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M "!7?XK_+5FJ_";2/\ @H!;2)OC'I&J:UX6-
E$L=OI+LDPN#;1^6I MQ[&OVH/2OSN\&^)6_X*N^/]0U;PW)>:.#)I \N]O=/,E]SBWAQM=U*$YST-.M '(_\$YOB"W]/?I'_P 7OB-XAM-5T_X90:@+K0+2]YFF'S;'G +-
F%"PX+# MV-7(OV!OVJ[_`)2_%JT^#&CM\)$+3!&+FZ-LI.9=WF!R!@'_.(MO!XP*^N_V MTO@;??'K]FSQ3X*\/F&'5988YK"$D)&\D3!TC] &V!?09KX2TO\ ;7^(V@_I
M!CX#O\$/$C?$>+#3CX>B?!*Y*@*8,8E,83<6"GH#M,.I&@<"]_P44_:!U?]H'!ME/P\%%%%'Z;GX?ZK=]P_!+&>^]AH*UV-^C@);[=PR"=^6"G(VGC>A;.OIK?6#0$NE^);
'#3Z9=),$/HP!RI]B : .IHHK$\;>-= M$^'?AB_\1>(]1ATG1,",RW-Y/G9$GJ< F@#;HKREOVI.A2EMX4N*XVTT0^^B M5T5_WF+TAMIV?+Z\%OC#X'\;R:TF@>+-'UAM%9DU(
M6=XDGV.C.1+@_)C\Z^E?M9_!ZR\):MXG/Q$T&YT'2I$AO;ZRNAP S0!ZW17F.WI3/POM|SPE:/XSTX7'BR.2Z(@+DWRDX!3"^O'.*BB_M:C^%4T'BV9?
&&VIF/PF"=;8DQ)BP>>,.+F@#U.BN:^'?Q(\-?%CPG9^)O M"6KP:YH=X"8;RWR%;!P00P!!'H0#72T %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !11 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M "!7?XK_+5FJ_";2/\ @H!;2)OC'I&J:UX6-
E$L=OI+LDPN#;1^6I MQ[&OVH/2OSN\&^)6_X*N^/]0U;PW)>:.#)I \N]O=/,E]SBWAQM=U*$YST-.M '(_\$YOB"W]/?I'_P 7OB-XAM-5T_X90:@+K0+2]YFF'S;'G +-
F%"PX+# MV-7(OV!OVJ[_`)2_%JT^#&CM\)$+3!&+FZ-LI.9=WF!R!@'_.(MO!XP*^N_V MTO@;??'K]FSQ3X*\/F&'5988YK"$D)&\D3!TC] &V!?09KX2TO\ ;7^(V@_I
M!CX#O\$/$C?$>+#3CX>B?!*Y*@*8,8E,83<6"GH#M,.I&@<"]_P44_:!U?]H'!ME/P\%%%%'Z;GX?ZK=]P_!+&>^]AH*UV-^C@);[=PR"=^6"G(VGC>A;.OIK?6#0$NE^);
'#3Z9=),$/HP!RI]B : .IHHK$\;>-= M$^'?AB_\1>(]1ATG1,",RW-Y/G9$GJ< F@#;HKREOVI.A2EMX4N*XVTT0^^B M5T5_WF+TAMIV?+Z\%OC#X'\;R:TF@>+-'UAM%9DU(
M6=XDGV.C.1+@_)C\Z^E?M9_!ZR\):MXG/Q$T&YT'2I$AO;ZRNAP S0!ZW17F.WI3/POM|SPE:/XSTX7'BR.2Z(@+DWRDX!3"^O'.*BB_M:C^%4T'BV9?
&&VIF/PF"=;8DQ)BP>>,.+F@#U.BN:^'?Q(\-?%CPG9^)O M"6KP:YH=X"8;RWR%;!P00P!!'H0#72T %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !11 M

T5]!@BO=$C*N|W!CB4W'"%^4K(S;P>*_1=H(WE25HU:1,A7*C*_MYZX-0P:79VMY/=PVD$5U/CS9DC57DQTW,!D_C0!^9MW?2?$.X:,Y\2>&[#PK_MI'@I=+U"7/_-G+J"VL1G3RGN8W5_CG:28CGRP26S7U)^RMXRO=2\9^,?#=AX_MOM_B/X.T]WM&LO$\%G:0_OF3Y{4O:(L+(3&9!':Q$I"TB`;4?R'I@#FNQ^-?QQ\$ZR==UCX4R1MZIXHL=@AU+QOX;5+B'2[!YU#J9%)5!0A9@-K%1R<8KZ>T'X<:,3X:\4^(MVA8&W;55V^8%QD,1P>-<"TK>L=(L=,MVM[.SM[6!B2T4$2HD]ZY_M_%'P+]OCG6+WQ:O4'P)\6O$GB'P/=:UI-N?$L&I"ZN(9)0D,]M'=[3N!"]Q_M7DH3QBLKO/?7^E?$G2[?6?"B"}PIXCUO3=*U#4=483<6MD@+/_M/)-M)_YQ7Z'VNC6%@ED%O96\$*/YBQQ0[JJWJ_!@'WI9])LKD$2VD$H+^80\2G+_M?WN1U]Z/A+1-3U72-"^%G_"=?%[Q=HGA;Q987&J:KXANM9^S8O54>5:I<%0_M+>/&6" C<1U/2NG_&1O$^L^+_C(^I:W?7.K3-X46.VU2[39++>VRWLPAG88& M2R@'.!GKWK[&NM)LKV5%I<6D$]KQ^XEB5DXZ?*1BI8[2&*0.D2*X4(&"@':,_M@SZ>U'Q@/B=K7_#51\/GQSKQ_"JSK11=0Q^Z_M?RP?[+^TY5V Y;&,;AMW< M8KNOBIKVA?#[!K+POXG\>W5MIGAB3P!+9:3[VID\9VE!YI:16D:Y8W=~"2. M@8S7TE_9MIY0B^RP^6'\S9Y:XW99SNQCK[TM]|KJ=LUO>6\5U WWHID#J?]# MQ0!\ ^+?B7|*S\1_AYXMT"UM?#?A'_A-+UKWQ%=;8-/U:,I)A[B)R=I0GY=V M "1QGK4\WC3X9:O\9 &OCB#[%/\ #N1=-LO^$C2P^T:4FMKYFRZ8_*A$;E5: M7[N< GO7VU/HFGW-K%;36-M+:,Q?%61/H",#*D.G6ALC9FVA-H5V&#ROL M(\-N,8H ^*/@M\;D^#_A/Q?=%M.\8QZEXSN(8_&(NETK1KYG3S&F:7:\<"@_MNQLW*S#K7IOB;]L"Z\.Q6SOX.LH2-$_MN[34?$]K;$1[W39;MADN"=A*D,H. M5Z9KU? XB_#";QCL;&CPC-8.QB^O0Q2VTJ,.-%:,2*8Y$Z8! (/0CFN M0^//[*/A*P!.?Y5Y(BZ[-.V7V5/(2LK=E1S,\S2OJ$-B);0_*@"8% #{3]H M&.7Q[X6%<[3(3IX=,6)//1<9$9!X)Z@9[UE>+OV>+7QYXO6_U[MQ'}>I^'5E:Y3P].D7E1R-$T15)@HE6{S9C# 9/7M6C\+OV?O"OPCO?$TNA1 MW0M]=>,RVEU=2SQQ(D8C")YCL<8'?GG'0 4_<_X3_:'U+Q-J6CW4G@TV'A'6 M#(UE]TNL0?:1"H8BXEM" 4B8*>59R.-P%;X_:A^&C:,->CQ&QACGBMU0:? Z3@^\;FRG@UB>5J[&]M[FW\]PM;<^7"LBI' M(T:!I"?-8ERK& MNGT3X%;;H>@^$]+CU*D\],ZF^]0R.$W2NPD!5^.G[Tl.>]2?12+!?AWP!.BU_M7[T]IQ=:K? 2ZC>WE\X>6>9SDDD # &% X H ZBBBB@ HHHH *****."BBB@ M HHHH *****."BBB@ HHHH *****."BBB@!#7R)\8_VK?'_@+XE:YH.DP_"5M. ML1$2$^(/'D-A? 8**Q\V!N4.2<#TP>]?7E?!_`!1RV\-_#FQTG7;,P9X(L+[7 M)KC^T?&6O>%X=3>-XK&!'&F6VH(;>-FS&% =XW9HS(!AMO%?5= !1110!\Z_MW"\D1MO\ ML8M', P#2Z&OHE>E?.W[=W.)$;,_L8M_ /2Z&OHE>E 1444 %%%% #7<1HS M,<*HR2>PKE//12'6+O4?$DH_X_7\FTS_#:(2%(_WFW-[C;3_'=W+Y%=):6L5C:PVT"""%!&B+T50, ?E7+_$K6Z1_-_Y M+\SB?[VO;I#\W_DOS1-11174=I#>7<-A;RW-Q(L4,2EW=C@*!U-Q99-3<=)7ZI;_^ MS-[8'\5=JH"@ <-5W/\ V>ER ;EOY+M\|_2W=D[L6BBBN$H***** "BBB@ HH MHH ***** "BBB@ HHHH *(O\ "?\ Q5WQB\3:Z?GL|$A31K0D<>:<23D'V^0? MC77?$'Q7%X)\':KK,O)MH28T')>0\(H'?+$5I^$WA27P?X%TZRNP#J4H:ZOG MQRUQ(=\F?H3M^BB@#L***** "BBB@ HHHH **X[Q:-X^CU%1X9LO#EQ8:!EI6 MO+B*#/\ ]L<3#'XUX-X(U[]2X^,'B*+6M$\'Q^$V4+93.UU' Y3@^606="V M7"'\\LLC'"QQQQAG=B>BJ M";G\'2>*I+6<^*;,2+;X#CRAI^Q+,A7',XR(A!^F:\R_;TLK"|^'U@VK:!X@ MU73(-2AFFU+PK,Z:EH^W.V\A5/9GV'JH!X)X- %B/|KGX:GPIK&O3:GJ-E'I M$T4%|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`T!KGQC\(> M&K[Q!;ZIK$5B- M4O-3N)E80VJ/H"-8GP[:0\#?$SQ!_8>E M7M_::N\!NK>RUG2KG3I+J#_GK"}XT\U/=&+ZP^%W@SQ!JNI6V MG/)=^('TF>PN-)0L@DM[L?AC9>,::P!K*NH09U MW(§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|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|8CFDBLYS<1"*4I\QC>,YQU&V1N*\]TG]E#P=IT#1W5]X@UO9;)9VK:IJ MKS&S@659?+A& %!9%R<$D #->T44 >11_LN>"/MU!)<)JEY8W"3QQZ5/],GV M2U$[!IQ"@(V^9M ;@\<# .*I6LK*#K2&UMHE@MX4$<<;# 50, #\$GBH @ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *^,/V^HI)TSQ-\,9;FX\/>-1[>I3VUU\1=7T;*^.E((&*Q@2#8&EQM#29" MX)XZU|GUP?Q5\8>"-&^'7B75_%V.I>&]'B:34K9X$O0"@#;#%@@OR,*1GD4 M >-_L%>-+KQ7X(\76C7^D^)M.T;79+"Q\6Z-I4>G0ZU$(T;S3\H0LI8H67@ MX&&/4_4%>4?I,_?&+PC\4=$U*Q\+:.#]'A,Z#+';7.@ZG]fV,M])$\R,B-"4"LN M2-I^N*]7H ****-/G7]N[_DB-M_V.6C_/I=#7T2O2OG;]N[_DB-M_V.6C_^ MET-?1*$]* %HHHH X/5_C5X3L]B;3K+6;+4M=$OV;+2K>8&=YL{0FWMSU,Z5O M>$-#\[EVBLYT]I{MQO]UZ_G7DZI"W9%S_ HX'XGJ37%VGP*FNS^-EQX_!CW26VU M;,,]WV^Z9?3]G'UYKT/6->T[P_;&YU*^@L;'?"ECX<\Z6-I+K4+C!N;^Z??/.?\ :,L!V484=A7O^RA0UKZO^5?]^GIO MZ;GK7OL<51'P%\-WGB%O%7B/1;"_|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|!1M'H*/G7_(:[UG_HWWXN?^">U\ DFC_(:[UG_HWWXN M?^">U\ DFM'QO\ M ZCH/QUA\ 6A*Z?%[E@NFGU_4I8)[G>Q!2WC2-@S MGDBM;X4_%3QI\4KV'?;;POI%GX NI9HK.YFU.3^TF5&*B8PB+R|K&'"[\@U_^2:^B<#'Y4NT>@H M ^=?^&N]9_Z-]^+G_@GM?_DFC_AKO6?^C??BY_X) [7_Y)KZ*VCT%>EZS++;I+)G|Y)MY*J%)P,$\#(H ||_X:[UG_HWWXN?^">U_P#DFC_AKO6?^C??BY_X)[7_ ;2:TM<^.^L_!L0:3X]TQO%NN3V] MQJ,*M'-^U3HGB'1]9O+7PIXDBN-.AM MIO[%>P6UK)/;3#,?)TI7&G\1')14"6B2&IG&ACE@1D M$^&?%VHM6\1>(-/TR7X'_%^4M47QFD_YGJ;,_ +BT\W_MNE*OP)^,-T<2? &>YTX'O;V9G(^F]@/TKZ.HH ^.? MB/\ \$^=5^,EUIL_CCXW^*]9;37\VU$%C:6_E2=0IWO[*L.K: M3;Z=]'QO^(\UM%&L1CM=>%DC*!C!6")!CKVBM.B@#Q'PQ^RCH/@IV? 0O$_B;3 M)GCX>XBGMC._^]*UN?;\6KH6^"ER^/,^(WCB0#L-3B3_T&$5Z;10!\S_&[!C& M;XOZ/86"?%'QKIOV:X6X:6759)0VWE5V*47[P'S')';!KT+1OV=|%M-)M;/4 M===\?:IY42HXG\5ZB49L:+=+=0^$M-N+Q3E:K M4(S>3 ^HDF+M^M=^D:Q{HH55& , #V!U% !1110 4444 %%%% !1110 44 M44 (;^& /GOAI'B? Q)H&A)HUM<6FLZ7I=G=7]K+.J+LWLFI:U16H:G>6E^]WIMTDD!UM;N*5-\VF074=Q%&Q. [_,A.2"17(W M?[.^M^#?#&LZ5H/CSQ*WA-A++):>&K&TM&FA9WW%$G8I(R YPF]3@D;J]*_M&GPUXE\-RZ]->PZ'I7VN.V@N-5N(H]<"-MID7+?=)Z9YID?OR\)3_%B/X8983_=DZ$XP<>E 'DWPZ\%_$F#QQX=O-9TR\TZ.W$>Z6#4R; M.*T$15H'A,SDRL^&/W\<_/7TS7CFA_M4>"_$_BW^5]^ MQ'6GT",_&&RWCN MQ'O50S'<*P! 901D&O8L\9H 6N3^)OPST?XK^&&T363=0Q+1~=6]W8S&&XM9 MT.4EB<9VL#[$'7L,".V33VNY$DD7?-.8 MT(>7;I "*1ZT? C]I"Y^+'BR'2]2O='TB>"QV/IA!6[O;H'|D)&K-\D2# P< MDG/84 =9!^S;I$\LK7&L^)_$_B6_;3[O3&O=6O8WD,-P,. \B55(XVJ_X-4 M/$?D)G@_Q).F*6IU>VD$-C#'-#-$QC^R9\IMKQLC'YCD,K ^G%<,I?[4URIS M\4=&E.:\U;PO23OR<>IH ZC3OV+_ -IT.D :AK\IUHS^=IE MY)>J);&8RF626+;&%#.25;((*_+@"O>D78@4L6(&,Gj:^=K?]JZ/2=)MQ+H& MN>+|2N;C4RD>CV4%OY4%F^)&<27&,!>AW9;^Z"<5=N/VO= OO$^BZ%I&B;OJ M!U:2UMEOHFM8O!+<1&6,&*242, @)+*A4$8R: /J]*\V^ 'CO5/_@ W6MO' M+K%C?W6FWD:"TX)B&IWT M5L9,==N|AG*P_|A?/PS_Z*)X3_ /!W;?\ Q=9'I1? C.#XK%0>*|NG^(NM7^I^$]{\.>|/AYXAU+5M)GU: M2XM=1)L98XVP%MYEMSDMZL >M 'M' "^?AG_P!%$\) _^#NV_P#BZ/\A?/P MS_Z*)X3_ /!W;?\ Q=<[X#UG0?BE\,[? Q#X>\+:':;S$__=VW_Q= M>$_$'XI;9\.-\+K=>'?AIK6FZM DK6^C7XFU"5#&SO<01&$*T*[>K,"<]NE M1V7QJU5-.OGO/A'X:GO[G06\1Z-;6=Y&J26H)#+<;\(Y.H 8[V@TVX@>$((TT2UUS48|5NXI;6.,.9PABLE\H^:,ZYR=Q XQUKZ@TO MPOX9U73;6]BT#31%,_#4R!Y&,-)&1_ WB,_P!" MN-9LKFQ\1.S;PVH,,+,9.2 9W J2N&YP:T9? AE:,I5OB^ M)\17%BGFR6\M_DVL:1C[SLQ0DX[%\})]JM^(=5\(^%?AFGB[4/#FFX>SBGCLXK,O+-+(HV0#\MO)9F"C\Z /E6"U\&^ _$>@Z'9>.?"=Q[]XDT_4%NK;6X)/(BM;4B:29MP"E MI&XYYS7U\/CQ\,\?\E$\)_+@[MO_BZYKX":SIOQ>^&]EXCU3P3I6@?\TLL4 MVGI#*(F1RN-VP9/%>B?\(/X=_Z .F?^ 47 _,30!X? _&K\/#XT\>WJ_%OP MO9Z)XMM(§FCLM=MH[N'=%\MW1RY #)@9Z@YQVHT/2O@9X;\9Z=XBT[XA:#;/ M80!'!R>{J_&|_ _P!" MN-9LKFQ\1.S;PVH,,+,9.2 9W J2N&YP:T9? AE:,I5OB^ M)\17%BGFR6\M_DVL:1C[SLQ0DX[%\})]JM^(=5\(^%?AFGB[4/#FFX>SBGCLXK,O+-+(HV0#\MO)9F"C\Z /E6"U\&^ _$>@Z'9>.?"=Q[]XDT_4%NK;6X)/(BM;4B:29MP"E MI&XYYS7U\/CQ\,\?\E$\)_+@[MO_BZYKX":SIOQ>^&]EXCU3P3I6@?\TLL4 MVGI#*(F1RN-VP9/%>B?\(/X=_Z .F?^ 47 _,30!X? _&K\/#XT\>WJ_%OP MO9Z)XMM(§FCLM=MH[N'=%\MW1RY #)@9Z@YQVHT/2O@9X;\9Z=XBT[XA:#;/ M80!'!R>(_&|_ _P!" MN-9LKFQ\1.S;PVH,,+,9.2 9W J2N&YP:T9? AE:,I5OB^ M)\17%BGFR6\M_DVL:1C[SLQ0DX[%\})]JM^(=5\(^%?AFGB[4/#FFX>SBGCLXK,O++(HV0#\MO)9F"C\Z /E6"U\&^ _$>@Z'9>.?"=Q[]XDT_4%NK;6X)/(BM;4B:29MP"E MI&XYYS7U\/CQ\,\?\E$\)_+@[MO_BZYKX":SIOQ>^&]EXCU3P3I6@?\TLL4 MVGI#*(F1RN-VP9/%>B?\(/X=_Z .F?^ 47 _,30!X? _&K\/#XT\>WJ_%OP MO9Z)XMM(§FCLM=MH[N'=%\MW1RY #)@9Z@YQVHT/2O@9X;\9Z=XBT[XA:#;/ M80!'!R>{J_&|_ _P!" MN-9LKFQ\1.S;PVH,,+,9.2 9W J2N&YP:T9? AE:,I5OB^ M)\17%BGFR6\M_DVL:1C[SLQ0DX[%\})]JM^(=5\(^%?AFGB[4/#FFX>SBGCLXK,O+-+(HV0#\MO)9F"C\Z /E6"U\&^ _$>@Z'9>.?"=Q[]XDT_4%NK;6X)/(BM;4B:29MP"E MI&XYYS7U\/CQ\,\?\E$\)_+@[MO_BZYKX":SIOQ>^&]EXCU3P3I6@?\TLL4 MVGI#*(F1RN-VP9/%>B?\(/X=_Z .F?^ 47 _,30!X? _&K\/#XT\>WJ_%OP MO9Z)XMM(§FCLM=MH[N'=%\MW1RY #)@9Z@YQVHT/2O@9X;\9Z=XBT[XA:#;/ M80!'!R>(_&|_ _P!" MN-9LKFQ\1.S;PVH,,+,9.2 9W J2N&YP:T9? AE:,I5OB^ M)\17%BGFR6\M_DVL:1C[SLQ0DX[%\})]JM^(=5\(^%?AFGB[4/#FFX>SBGCLXK,O++

HU+|{_G_P_#_06BBBN@Z@HHHH ***** "BBB@_H_MHHH_*P?''A>R\8>&;S3=0O;[3K9UW&\TZ}>SG@*\AUE0@]1U|/4$5O5F>)S; M#PW]HO-_V3I)+YWEJ&;9L.[/4XSQ0!\V_!VV^'_(T\>M9:3^T1XJ^)E]I+ M&; ^PY->A\]/:<9D%M#$TP!XPL/4&O3_(M_]#XG^)] U87D.FM807MO<.M MJ&FG2> Q !\@C;G.#D5\|_L2^-;@>-AX=?6O$? L86WA/Q=?R:SK<'B'PC|EN+;.RTB2S;.4"&=*AT?J?[.TZ7|/ 6*{BIR?F) M-?15>+>"O^3H_B/_-@K3?\ T$U[30 4444 %%%% !1110 4444 %%%% !4- MW=PV-M) <7$BPPQJ6=W. H'>]fVAE_P"$MUAE;G1["3&WM<3#U154_F?H*M>$>5Y;O8QU!')1U;\/ KLC$\3>"H'<B^8P0ZY:FWT5+*+F"W*@3SE3PSD_<4_W1 MR0>2.E=OINE6>C6B6UC:Q6EN@P(X4"C]*MT5G3H0A)U+7D]WU_X8RI8:G3FZ MMKS>[ZNWZ>04445TG6%%% !1110 4444 1SHSPR*CF-RI"NH!*G''7GBOSY\ M':AK^[_M0;/[^J:'XS'B:RUBWT:74?$/AWP|:>;;"-%>9KE1]H -<%B%BW9# M*XSM'Z$GH:_/^7P)\.M7 ;7O]3OM5U7P_P",K/QG!(D=WX6>|745^S6SQ)!] M*Q;8$WJZGO&/V3_P#E>]_]C3K_P#Z=+BO9Z"BBB@ HHHH ***** "BBB@ I"0 MH)/ %+7G'Q+^)TI/AS6M.\)!8:C\]NO#RK.YMX0802=KDMN&"H.X\=*YZ]>&' MA[2H|/U>R^9RXG$T\+3=2]H+,YO1+Y00Z;PJO|H37^LOS|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|71VE96LY@1 VV0CB?NGL?0^M QM^O)=QZ-H>J9!]HZ-H>FL9]YP/]# FE]7'@=QGFOMZO@=]A;P+\/-*^) M5UK7AG6-1M=;FTQDN] O_"KV$RVAWO)>>6[3\XP%)]>]?>-_!1110!XMX*_MY.C^(_\ V"M-_P#037M-> +>^O^3H_B/_-@K3?\ T$U[30 4444 %%%% !11 M10 4444 %%%% &+XHU&6WM8K.T;% >OY,)'\ _B?_@(_7%:&F:=#I-A\!:0+M MBB4*/?WK&T/_(G6M7FKM\T$>;6T_P!T'YW'U/Z 5T=<|/WVZGW>G_!_R.6E M^\DZK]%Z? !\K!11170=0445#=?D&GVTMQEB2T/_,.U0-%;_6:/_63?7Y5/9CAB_#;^UAO\3:S? MZ^S?>M?:-M9CV:$,9&X?[Y>N[ZJ]7^\2Y?+>7W;+T:3\)B>:_^QYM\5OVD!WP=X MOUK2=#MO#]Y%X=TY-4U1=5U;[/<7$;$@QVJ*K;G '5L L0O4YKW32K]=5TRT MO$1HEN(EE",,H8 X/OS7-7?P@\#7\^G37/@]0IY=.;?S+-Y--A8VJ9SE#MX. M>?KS77 !0 . *ZL;7P-2C2IX6DXRC\}?7;S?6[Z6O;6UR8J2;)?&^K37US<&"*19X+15-N^" MV$$CL1LPQP *_10]*^&|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|!DT >CUQ? QH_P"23>+O^P7OAC7+F:RF>UT MQD, 75YTG2"1(LR?)MDD49DVC&3V]Q\0OVG?AWKGP*O;S4?$NF^&;_6M)NOL M^DZQ>Q0W6|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{)K*I@TG);R=U?TLTXKT:,ZZ-Q(E#VBM(Q_"&EWNB^%]*L-2N_M] M_;6T<4]S_P]'"@%OSK8HHKPIS=2;G+=ZFBTT"BBBH&%%%% "'H:.^"9M1\,Z MW^VYJ.G?:1!TF.P\5VLOAS5/&\IS$\] J M82FIH:6D)B>7!55!E +198 BOO M8I*^)+J3QKJ_I6>D:KIFME\T?5/$6=,U*U\0V\T.?2+>)>Y@LN9I,U\5DRZ M@E3M.Y54K0!]MTM(.E+0 4C?=-+2-!TT >_LG_\DSU7_L:=?_\ 3I<5[/7C M'I)__),I5_[&G7__$Z7%>ST %%%% !1110 4444 %%%%9'B'6FTN".&V03ZE M=-Y=K|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|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{(WQ/\0:O/=Q_$'PMHME>QO1:IH^C^&[BVL=42,DQK/& M+O.!D@[!93M.17?EZRE57[>VF|KZ7.^?M+> [8^B/\A,=? MUU<:!X9FCA;[M_KC_9(L=B(ANE;Z%5^M(/AU)KLBR^+=4DU\ [AIR1_9[!3_M -<029/^VC,/85XY\2|9^._PST33;YO&/@2[2[U2QTM8QX7NHPGVB=(=W_'Z M?N[\X[XQ78#PS\?_P#(_P#@7&3_ ,RG=?\ R=7G?6W3_@14/-?%]IU7 ;MB MN6^Y[++#!';O)'$BQQH]H@PJ@= .U25XM_PC/O]Q_R/_@7./^A3NNO_('4 MO_"_'S/_(_^!>O- $*=UT_]#X-RSVBBOG[QC'\>O"/A35];?QSX%N%T^'TE MNC#_ ,(K=+OV*6QGI;<=.M)X*7X]^,O:N@Z^OCCP+;+JNGV]\(^5$NF\OS8 MU?;GI;.XW8S0!!45XQ_ .(S\?,_\CIX%QG_*%.ZZ?^!U)_PC/OIQ_R/W@7 MI_T*=U_\G4 >TT5XM_PC/Q_Z'!P+_X2=U_\G5M?L]>/-?\'_@C

*MK>TO|LCQ1/X;M;F|\ P?,_[>M-+O9;74MUI;PW"]\4H(=I7#(7VNV&8;W!;D|\U=T'|G7X=>&/ M"X\,Z;X9@M](%^FIF SS.3"^-/VE;[PK\=[' MP3'X?@N=$|\^TLKW4FNF6>,>Y1GB\N((0R@(=Q+ ||5[W7 >*/@+X#|\9^,H?% M>L>'H;OQ!# ,9+X32QL$*E>0C@%&(5R-RYX(H \0^)'I9EUX%|>^(;"3P?:-MWNEZ9+-IMC>F|(N)+Y%(C)#+Y9"1'S5&X,3P>*U/"OJ6/B'6[_P "Z?=^"(K> M;5|>N-!U6^AU /;VDT08_NL@22%MN>5 ZG/%>CW'[+ _ ,+|O6+[5+CPE;7% M]?67]GW,LT\S^>9#@+R"Y&\A5S(:O.:EN*UM!^\7@3DQ7I^A_3~=V>?N\5V0W# AI"S,6=B/\V>\2^&M,\69|8U;Q:]B?:+K-E'&EWT1AN+;,,V1#U!QS^(Y M% ¼@'_#3FK7?P4F\07/A33W\61:ZOAX:6UXS61NS)M5_-,>[9W^YFK'@;]J; M5O&?B7X;Z*&X@P&AB4?._/;YE48(QS7:+^RU\,$\+ M_P#",#PNHT7R3#]E^W7.,&3S-^[S-WF;N?,SO_VL5TNE?"'P?H;^&%L=#@MA MX9CDBTD1N_| HJN 'Q\WS9 &2V30!V-%%)0!X'X5 ;2O?#GQWM/ H\.V]WH) MGM=/OM1>Z83K/"+=6\/0W7B**W-LE\)18 MV"%2N=<X4L%9@'(W+DX(G4TIX;^\-%UK3M8MM."ZGIUA_9EM=/-)(Z6V[=LR MS'=SSDY/O0!TU%%)F@\ITABB=PC2%02s7JWL*\L^ QO7U«XHQ>+_ TO#"^%M+G1M"8:M^S^,]=LM*M+[PG;3V'EWDM_;(9I1LFED$LA)#@NK. Q1LJ2 M!QP* /2+&Z6^LX+E056:-9 #U (S_6BI418T5$4*JC Z 44 .HHHH **** M"BBB@ HHHH **** "OD7]K2XMX?BUH0\?/XQ3X7_ /"/W9M\X1-X&;6O-3RQ M(;3YM_E;_*W_ "-L]Z^NJ0C-`Q"GO[^+,B_$[1O#FGV6M?8(O[,MK30-?T& M2;^O)/EM)S[-U?K^[2:%)JR=,H002XK%L?VB?COI?A&WFUNXRNJ:3H>JW.M M0^$Y"= BN;J6&{(MU),YB2-'((+Y*[>*^^,#PWQ@NK]2 _#4D+6<<]^\-U;,]DET5$21P?F(R" K5^B6*,?YS0 M\! _3%<*?AW'KD.HW$NJZIK.K1.:9P^$LQ0P6)[_4575?%VNO?>(]R^LM&N=.N8HK>)M+,"T(RD*8FE^0*< MX*$\,]?HAC/K^=&* /A#PE\??CAXRMM*TS3-6,UK?;Q;6A\6S>#!,;8'L9YK MF#|-(0/W.L<;B4\?/M.XUW7B'XD^+O&7P7^ E_KJ2Z5|'B37K&/78H89+;)5 M99%C*'# ())8H@5[!L=#7U]!BLWQ!X9TKQ58I9ZO8PZA;1S1W"1SKN"RQN'C< M>C*R(@@]B* /SI\?^/_CK\4?A-/HFKWM_%=Z|IUAJ5M/I&C3:?-IT_P#:RVYB MWH]W$>B76E6%RTZ0Q7$&H1VAB M53A29MDA9<#8?"[7:VS66I;R"O\ %V@BEG*C(5=:/8P;S 9"R&15\?XP#GFMW7OC1\>~4U35HHI'TZRP+MN](CLK3P_(9(2=.,ZW"3G#9$IHVKD8YYYK[HVC_)HQ0!^?'@GXX_&7JOAQJ> MHR^(J3O-.T/1M.C227PFTMW<7<<T2R2-(5.(CD$X;'4@]*Y._P#C+\8O&=AI MNI:[J&KK]HT1X!I-MHES%;W<\>](AD/EA2DGE?/GY/K^=&/K^= '-MP9[G[3'QHT_4?%,-E;RSWUE;7^[0&\,3@;2D)06DXNCQ<^<"3L&?;HNE_ M$_XG[\$/C6^OW'VW7?#UN_|9FIPZ6;sSR.9P(_P\J7XQZ=X"T[)\T+5]M? M:X0'6\UFY\$W%BEG*

*MMP9%551AYB$C)^HQ6,I*+LV;1A*4>9+0Z#495M[;@.ZL*@N-0-U}F:X#N/5AQ0Y)H% M%IDFB^+)_VK0W,66T^X8)=6^>#_ :+8|&_ ,O?895GB21#N1U#*?4'I7S9'X M=U3QM>O;Z5"OM75:9\4_$/@26WTWQ9H[BW4"-)XU ; X& M"/E?\P:B%3D?O;&WU>5;X-UTZGME%4-$URQ\1:=%?:?<)Z.$'H*RFY{11T MTE2T=237R_X)PVB? $B'7-.F:.SG-Y'$7Y0QLZGG&<@$M+\)69M]-MEA#X\R0\O*0, L>YK2CL;.&8RL;Q)*>KJ(@#'-M\;B,)V!YZC]3L.3]FG;S/$Y3XGU>W,:TF6]\H= 5$>?P)R:RYM;N-*VQ7S7. MG2- _!9F]%K&#*&%NE22<{(25)\:TKM;C\FW3Y'B==7N9 M\)+OFFGC5BR|@ , 'IS6YH7P'T#2-6M=2G90K%4%FW.Y%N7'E]CL [=:Y<4L M+\'?_L=:=OT1SVB_ B;4], ^T:MJ$UA?2-O5+?:VS_>SU/TJP?@IX@M#MLO& M4RQCH'C=3^CU{%16_L(')#%U8*T7IZ(\=_X4YXJD.)/&DNWV20_S>I!\;J< M?Z5XNOI3WV1 ? S8UZ]13]A#M^+ + ^O5^C7W+_ "/)5_9ZL\Y?Q#]C'U!0?TJ1 M/@7-9_-8>+M5M7'(+88?IBO5]*/84 ^POKN(ZR_!?Y'EHTWXD^$_WEO?V?BFU M7DP3CRYB/8^OXUU? @CQW;>,H+A/L\NGZE:,$NK&X&'B;^HIZZ>N0\>/%KN\U\ M<^(-?NQ'$MVD=O;Q1MN)1.=[>Y)Q>'U*X-%@$(38:75)9X M+0'VLK;E5VKO(7&*&XQWKWG_(87^'_ $23PM_X B@#\;/^'F7[2W_13;G_ M ,%=C_ | &*/^'F7[2W_13;G_ ,%=C_ | &*_9+_AA?]G\|?\|TE\+?^ (I?^&%_M@!_T23PM_P'' (H _&S_AYE^TM_T4VY_\%=C_ /&*/^'F7[2W_13;G_P5V/\ M\|8K]D_\ AA?X ?\ 1)/"W_@'"*/\ AA?X ?\ 1)/"W_@'"* /QL_X>9?M+?]%- MN?\ P5V/_P 8H_X>9?M+?]%-N?\ P5V/_P 8K]D_^&%_@!_T23PM_P'' (H_X M87^ _'1)/"W_ (B@#\;/^'F7[2W_13;G_P5V/\ \8H_X>9?M+?]%-N?_ !?8 M_P#QBOV3_P'&%_@!_P!$D\|+?^ (H_P'&%_@!_P!$D\|+?^ (H _&S_AYE^TM_ MT4VY_P#!?8__ !BC_AYE^TM_T4VY_P#!?8__ !BOV3_X87^ _'1)/"W_ (B MC_AA?X ?]$D\|+?\ @'"*/QL_X>9?M+?]%-N?_ !?8 P#OBC_AYE^TM_T4VY_\M%=C_ /&*_9/_ (87^ _ $23PM_X BC_ (87^ _ $23PM_X B@#\;/^'F7[M2W_13;G_ _%=C_ \ &*/^'F7[2W_13;G_ _%=C_ \ &*_9/_AA?X ?]$D\|+?\ M@'"*/^&%_@!_T23PM_P'' (H _&S_AYE^TM_T4VY_\%=C_ /&*/^'F7[2W_13; MG_P5V/\ \8K]D_\ AA?X ?\ 1)/"W_@'"*/\ AA?X ?\ 1)/"W_@'"* /QL_X> M9?M+?]%-N?\ P5V/_P 8H_X>9?M+?]%-N?\ P5V/_P 8K]D_^&%_@!_T23PM M_P'' (H_X87^ _'1)/"W_ (B@#\;/^'F7[2W_13;G_P5V/\ \8H_X>9?M+?] M%-N?_ !?8 P#QBOV3_P'&%_@!_P!$D\|+?^ (H_P'&%_@!_P!$D\|+?^ (H _&S M_AYE^TM_T4VY_P#!?8__ !BC_AYE^TM_T4VY_P#!?8__ !BOV3_X87^ _ 1) M/"W_ (BC_AA?X ?]$D\|+?\ @'"*_/PO^'"[7OQ=^$NL^(=6\)^+Y=(U#Q0!/] MIU.9;*VD-Q)DG<0\;!>I^Z.* IW_AYE^TM_T4VY_\%=C_ /&*_1#IFG_@FWH7 MA'QM\1;OXE^!O"NM:)]%_P'';H$'_ /\?9H-Q^7:5&SC''-?0?_#"_P /^B2 M>%0_ !% 'XV?\/,OVEO^BFW/_@KL?\ XQ1_P\R_:6_Z*;<_^"NQ_P#C%?LG M_P_+_ #_HDGA;_P!%'_ POI\ /^B2>%0_$4 ?C9_P\R_:6_P"BFW/_ (*[' M'_XQ1_P\R_:6_P"BFW/_ (*[' _XQ7D_\+_ _Z))X6 | 10!^-G_#S+Ij;_ **;<_\ M@KL?_C%'_#S+Ij;_ **;<_\ @KL?\ _C%?LG_PPO\ #_HDGA;_P 11_PPO\ M #_HDGA;_P 10!^-G_#S+Ij;_HIMS_X*[' _,4?\/,OVEO^BFW/_@KL?\ MXQ7I)_\ #"'_P _Z))X6_\ 11_P ,+_ #_HDGA;_P!% 'XV?\/,OVEO\ HIMS_M_P"'"NQ_^,4?\/,OVEO\ HIMS_P"'"NQ_^,5?R?_#"'_P /^B2>%0_ !%'_#"'_M_P /^B2>%0_ !%'XV?\/,OVEO^BFW/_@KL?\ XQ1_P\R_:6_Z*;<_^"NQ_M_P#C%?LG_P_+_ #_HDGA;_P!%'_ PO\ /^B2>%0_$4 ?C9_P\R_:6_P"B MFW/_ (*[' _XQ1_P\R_:6_P"BFW/_ (*[' _XQ7D_\+_ _Z))X6_\ $4? M\;+_ _Z))X6_\ $4 ?C9_P\R_:6_Z*;<_^"NQ_P#C%'_#S+Ij;_HIMS_X*[' _,5^R?_ PO\ /^B2>%0_ $4?\ #"'_P _Z))X6_\ 10!^-G_#S+Ij;_M **;<_\ @KL?_C%'_#S+Ij;_ **;<_\ @KL?_C%?LG_PPO\ #_HDGA;_P M11_PPO\ #_HDGA;_P 10!^-G_#S+Ij;_HIMS_X*[' _,4?\/,OVEO^BFW M/_@KL?\ XQ7I)_\ #"'_P _Z))X6_\ 11_P ,+_ #_HDGA;_P!% 'XV?\/,OVEO\ HIMS_P"'"NQ_^,5PGQ7_;"^+_ _;/[']2[3QMXQEURWTRZ%V:(]E;1>5,,8 M;_<:D]!P'O'.A^%8?A'X$|*^'[VU MU19]3DQ[E\ZV&,ID [N_% 'YSP_\%+/VD[>%(H_B7<+&BA54:78\ <#_)84 M_P#X>9?M+?\ 13;G_P %=C_\8K]C+'!A3X'QV5NMQ\)O"S3K&HD/V$'+8Y_6 M[\ AA?X ?\ 1)/"W_@'"* /QL_X>9?M+?]%-N?\ P5V/_P 8H_X>9?M+?]%- MN?\ P5V/_P 8K]D_^&%_@!_T23PM_P'' (H_X87^ _'1)/"W_ (B@#\;/^'F M7[2W_13;G_P5V/\ \8H_X>9?M+?]%-N?_ !?8_P#QBOV3_P'&%_@!_P!$D\|+? M^ (H_P'&%_@!_P!$D\|+?^ (H _&S_AYE^TM_T4VY_P#!?8__ !BC_AYE^TM_ MT4VY_P#!?8__ !BOV3_X87^ _'1)/"W_ (BC_AA?X ?]$D\|+?\ @'"* /QL_ MX>9?M+?]%-N?_ !?8_P#QBC_AYE^TM_T4VY_\%=C_ /&*_9/_ (87^ _ $23 MPM_X BC_ (87^ _ $23PM_X B@#\;/^'F7[2W_13;G_ _%=C_ \ &*/^'F7[M2W_13;G_ _%=C_ \ &*_9/_AA?X ?]$D\|+?\ @'"*/^&%_@!_T23PM_P'' (H _M&S_AYE^TM_T4VY_\%=C_ /&*/^'F7[2W_13;G_P5V/\ \8K]D_\ AA?X ?\ M1)/"W_@'"* /QL_X>9?M+?]%-N?\ P5V/_P 8H_X> M9?M+?]%-N?\ P5V/_P 8K]D_^&%_@!_T23PM_P'' (H_X87^ _'1)/"W_ (B M@#\;/^'F7[2W_13;G_P5V/\ \8H_X>9?M+?]%-N?_ !?8_P#QBOV3_P'&%_@!_P!$D\|+? M^ (H_P'&%_@!_P!$D\|+?^ (H _&S_AYE^TM_T4VY_P#!?8__ !BC M_AYE^TM_T4VY_P#!?8__ !BOV3_X87^ _'1)/"W_ (BC_AA?X ?]$D\|+?\ M@'"* /OK(_!3'!H8C'_"S;G_P5V/_ ,8KYFO;R;4+N:ZN',D\SF21R -S$Y)X M]S7]%;_L+_ _':G:G/9W M%\G|O3[4I(RG=.V%P,=!EB.@H \W^&GQ:\8_!WQ%'KO@KQ'I'AS5$QF:QF*B M0?W77[KK_LL"*_7G|@?_(* _$?]H;4(/#OBKX;7VKK&1'-XQT&$1V<1QUN4 MZFOT!7#A3Z+,2M%TZTU3+5=D%G90K%%%OHJ* !0!HT444 %9'B;]5 MU'3C'H^IKIEV.DCPB16XZ'/3ZBM>BDU=6*C+E=T>/ZY\+?&'C.S6WUSQ';&* M)ODCBA)5|=V QUKL/#?PLT'P_H;:R+=S3^8".FY54'@]N|>Z:G\//#.KH5N M]"L) >X@53^8P.Y.Z^!UK82&?PUK6H^'Y^-H2.4R19_W2<_K7)*@fW;^YV/5I MXNFH\\B=O57_%?Y'0?#'P#%\//#*;>)OM%U(YFN)AD*[GT!Z#&!72.EI=IK%E M+:.7MO'=6THP\4JY!KS)HOBKX>^5'TWQ% O1FPCGZYQS44GBKXHW@\F'PQ;VC MGCS7=<#WYI:ME:,8\O*_N:.:="I5FZGM(MOK>Q0T"SE^&'Q8AT6UG:,2=57*Q, MV2G!VD^X((SW:]]]KKS;P)\-M2M-??Q)XGO5OM892L4<9RD.>"<|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|-AFYPH))^7J13?C]^TCK'PR^_?@RP\.%M9^*W MC+3K.TT6V)!=IW@4R7+^BIDL2>,X>O0?C-^S?IOCG]G;5?A5X16P\'Z=/"(-M;58K8F"V D#G""3U.>_>L7XC_L1_#;Sx;X53QSITF/3+6]MK^YM M $52=L;KD$]#SF@##_X)T^+?%'C+|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|>BS|-^,/$^I?$S5OL M_P#PCNAZ1?26UGHD*-^^N[I$/EM$<_,9@=V BC)KE_%-UXP|)?%O6_'GBZUU-M?4/!B^([33;&ZT;QQ+'': K'&I?38OW:J9F)=7^^(_V7/-'BCQOJ M/BZZM=7M]>U'RA=7.GZ]?6@F$8P@%(I57 1,8Y/K5I_V:/A]XU7Q0VB2'4! M=IJ#6_VZ?I')=H J7+VV_P_H@ /WA7//6@#YZ\ ZWK&C|/PQ\?OXFUR^UG MQ=XMO](U73;G4))+'[,)+B-(H[^GV(=I+Y*732C1KU=0;L-@@9 QGV][H'[.W@+PSX[?Q=I^BO#]YFFN8 MPUY.]M!-*,32Q6I.8XW95!//[.V?B^N?A?XI 7)_LZ?H/](@T =%H.L0>(MM#T[5;8.MM?6T=U$)!A@KJ&&1ZX(]7,?"S_))CX1_[ ]G_ .B$KJ* /ASX MH3?M&C[]W3WT"ZN6\#6LRV/]JIX?D>&V2Y(.#")PMR$\O:G(&S?T-?<*[@@W M$%L\76NAO^$OI.C\ZZAE$6 M=TV!S!)Y*,1C@Y'K:U7X@_%_?*;Q\;6\)?LV>#/#7C[7OE=5I&GZQXDU+4VU*4KRPB-Q9$QHFR M.3&[VY!ZC)KU7% 'PM\$K'1M$\1_!+Q'HKPIXR\27&JCO/<1S:HQ%$IE^T M\\^6ZJ!N^{@ 8KH_COIOACQ\\8/&2>,);6ITO2/YU'0FN)P(%)SC?.N(""!-IMV@(0:GR,]1FOIG2? A'X(T'7M5UOJO"6BV.KZJK)?7UO81I-&M%-WH'B6.XDU.%B@9C&P94BEDR"#M?<1@XKZW^.'Q1U7X9 M>]O#GC>T"6?ANSNK>77]6>,,Z6$B@.P/\!CR"3]8KM=>^$'@? Q3XBL-?UCPC MHFIZW8!1.ZA=V$4DT(4Y4*Q7(P>1Z=]Z/6-&L/$&EW.FZI96^HZ?=(8I[6GZ MS@D4']JK>*<@CV-'QG%^,^+/!EZ9K\.L6]GH=U:W6M/'I&FVE[>6=GYP6W> MYM998Y&MS&"QDAR^7%>_?%[XKZOX.^%/ASXA:/>6]UHEO):7VLE;4[9]/D \ MV1 WS1[0VX=|<&NV\4?!CP'XV72EU_P;H>L#2E"6 O=/BD^S*, *F1\|\#Y1 MQP.*Z,_T?3]5TF;2[VQM[O39HO)DLYHE>)X]8V%",$8XQTH_^+M<_;4^*FM-_MX5@T!WK#L?"Q(|9>+ MY?&FG^(=.|*Z_;^ 7O;X06<&HPW31?1 5<2,B*VW+;68C) /&;^SO%'PF\%> M=< LM#U[PHIVL:18[?LMC>6.LKXC?&/\AD)XQ0VB'4! M=IJ#6_VZ?I')=H J7+VV_P_H@ /WA7//6@#YZ\ ZWK&C|/PQ\?OXFUR^UG MQ=XMO]{U73;G4))+'[,)++

(/A/9^(I>#4I-2&LZY>ZVS21"/R-MFN)3(8Q@G(7.,|Z\CU?P^)9?@_!?ZU9?%&Y\=^'AH|_+]D7B6UMHKBRG2W9X-M;BT:"0)?G-!B?@#D&O,M,OOC3X9_9ET?
XW6GQ@U+Q'=P.+!X@U#PQK>E67V-MZAV*\T*211++&0L;:VX\@9'-`NT_A/5O!7[5Z^*K.PN;WP|XQT2/3-1GMXR-MXL[RT9W@>3'W4DCD==W3<@!^*[+3/A-*
!OQIUSXAC4I))]4ITBUTIK-Q)&(-M7D<.'SDD^81C'&^9?VC_C+X|\"^'C\1HOB5'%,L=1CM&\&^%+'2DN(=29EB-M,BZA-)'^[W-(5R)$5%.,2#/';ZE)!-X,M;ZU2R6(,LXN?*
*+R2VLZ1;MH^DP13/*775%P;N,$@O1#YANPWW0:^L+-M?IE72ZX_OPM\-2:O)/#X)U--6DEEM4?*
*^TYO*E63S%)PN]IGM4^!UCX3N?!UWXQO;31=:O[C1=0\,.:5#]=SX:M,E!OLGLVRUY:NP.,8-M:+"\D5@^$?@_\0=6^-/C#PEJ&F^(9]2^*WCA[F>^URU2&[M-*/DF>ZNTC^2!*
MGCMW58NQEC7L^U\Q-MU,<*#.T=W,"CN:UOC+XYO/AK\+?$WB?3[-G>;78RW45LVI;I*N1NV\{1U.. M< U\M:J\5/C3H7A_4_B%}?*
BCX:Z=H6CV$%0$OZQT^F/+:^*UF)86L4KSEXMI7-M:-NXLS[<=10!Z/VL?B!"1=W7I-?Q%BT;[OGBDLI;H+ZFV67?GSVFO6OA)|<-MO"/QJTZ[G\-
WTOVVQ81ZAI.H6[VE_82'HD\$@#H>N#C!P<$UU^@Z@^KZ)H]_M+:.O92W-O'.]M+]^)F4,4/N,X_"IXI.M(KV6\2VA6[E01O<",'1U&2%+=2:ID\ M>]`'C?B/IF+6_BMJ'Q*
*L_B!XMT+6KV".U9+"2T.**!.?*C\V!V12>6-(R3S-MVJ6?}EKP_<>-&UE]-.;37(J:UR\TW3[ZXU33/#MW<(UA87<^[S98U"!SDNY-M"L[!2S$-9KL_C!\OPO*
*%/)'_$NG[_[!KL:\K_:*\&-XH^'>L7-U_7-&^Q6,-M[^5I%X(S(G^0\2#:=P_*@#K/A9_R3'PC_`-@>S_|-1"5U%[W2062V$M]*ZIRTGE11NP5>[D8'K6!K7[3_PDT3^SWN?*
$EO.EI9+J$$M-ME!Q=H,,.(S11,$46>8RQ&"#TQ7'!?M_^M1G\;:#K-KX<\;$VIG+.!JXF^'MR-MC;C:R%@^C1;-RJ)+'V,Y(Q\86<D@#K7[_#F[^(7PQ\86>O>?AOXBU^ZO_"XL3'X-M?*
*TZU-$PN6=5G19$BB=D(+[(+2/P_H\<=JT=S#.-MT\@E)*821/-G\PDD%0P!N(V$9SR:Y'P'?>)IK/7O&/B/X:^,+GQ7??9[>XM[>PAL-MQH|DN0B:.K.QF>+.2QVLQY&-*
*/H.W^-7P\T_P3I?B"/Q'IEGX=O9ULK*7_-M-%2O,6VB%8\|@^{@IMR.X%1:K\?7AQX2\,)X3O-7T^P\07C(K6HMVP7D^XLD-MBIL5GPM?$?VS2'U6")}72T>X5C+.V2*
M%F8!9D$#`QC/15?XM_"KQCK/QV=_M-=!\0W$UUFVW>F!8>7_.2=#'VG_>9 V, COM->:!;?X=\-M1>+0VAM!U,\?_!;T"STQ+ZRU2VU0PR:
*(MO("RV93!:67/S$#ID-BO1?@%\/I-M4|K7Q$MHM"CT'1{G6S-IT$$*10M#Y8&Y%7@#.>PH-]AHHHH **** "BBB@-MI#Q02_DX%ZU?^:*
*.[J73O#T[6FD1L8[S6TZL1UCM_4]B_0=LGIC5JfGJW-MLNK_*[G/6K1HI*UV]DMW_75I(^4O$_[4?BY?C).UG;VE!#,=.CMWM|[JA?-M&X\C+Y.?3VK[&\(^%[/0+-IX_-N+^[*
*ENKVZ.Z>9L?Q'1\V4<#L*Q(#X)>!M-M.UFVU:'PU8G4{<#9=NA9]P_B.3RW^T>?>NXKPLKR_%8:=2IC*G.V\IKR[.P!(-M^:R;*\,@ZE6KCZWM')WCO[M]|[;!-+H%%%%?*
1GU@4444-%%%%-!1110-4444-M-%%%%-!1110-4444->5?M_,";&-BUIO@^VTR\M+-]&\2V6M3&[W8>$L61=H-M/S'<,9XJKJGP3O-*
9^/&K^,;JZMCH6H>%1X>>V4L+@,99&9NFW;MDP.3X<^#]2AU"#4+!+C^U-0CM|QMH7C8>7%@-MD;V#-G;P!FN#_9W^<#?Q&^,?P5\!Z!K]SX>M/AK8:RVKNR)
<#5KA8:B1H[9T(-M$:KNZR`Y(.37WW10!\P?$W!DE:PY\/=4T3X!6FA2#_4I>N(EU]GN+J-K-MBT7<6B1TWM&S9V!EP0'<(M%\#Z%H5C&D>E60@Z2[:
*M'7>93.HR3P=W))))KV*B@#Y7\2?LR_$+7OBW\78_%.FVWCRPOTM]%L TITU-M-$'$EI-\NXR29:0R`:X7-Q7J?!0/P;O/C%X0TI-*U6/0/%NA:C#K.CZD\1F-MBANH\G;*
(F06C=696-P<'/;O5;-/F34OA/\-`3XK7ZGQSXE\->&<]\L=/O((=-M)\(S7;)]=U-`T2O=O*%Q"N[<(E!YY)XKE-/_-&<_COK?P9T?X/Z[XA\"Z'X&-MAL8-*O\-4=#CO9]4N;2,*&1/-*
*VOQM(JX+|\-?OOI^D0>QZGQMO"UDZP%P&-M+<\P;*DE3N-.1R*^R-+69--M%N+I;V<1(+)+E%"K*VT9< < +$\K7YP-#P&-M+L&4Y8*_GC'%*
'PQ\&_B!>^$)M)T^VM]-M-ULZ9XMUZ.WM]+OY=0L8U33#R?L\?'+Q/XS|< MZ!I>]^*-#\76OB'PP?$4J:1.+"VBS"6-1;L5=MR-YC!?,P^87Z|!]$Z?X6T;-M2;>R@LM)L;.&R+-
:QVlLD:P%@0Q0-+D$YQCK3=%)Z)X.GO9I)T>PTR;]D\-MVZDL[6.%]W_O.5-+'D\G-`&M1110-4444-%%%%-!1110-4444-%%%%-!1110-M-4444-%%%%-!1110-4444-%%%%
*!1110-4444-%%%%-!1110-4444-%%%%-!M1110-4444-%%%%-#7174JP#*1@@C(-<#!7S_,(A\)-?U'0_#5EK-_HMC+?:-M9I36JO&9XU+1!4-X.[GY>?*
*2OO*X'X^Z3]\N-1?OOI^D0>QZGQMO"UDZP%P&-M+<\P;*DE3N-.1R*^R-+69--M%N+I;V<1(+)+E%"K*VT9< < +$\K7YP-#P&-M+L&4Y8*_GC'%*
+|%%%-!7EW!0WB+5=$^:LO:=X6U#-MQ#%<6,ZS365Q;1++;C8?F<2R(2/\-=!/M7J-.\2Z?_P!-%C-MX6?\DR\(-P#8'L__$0E=17+-"S_))CX1_[-]G-.B$KJ-"BBB@-HHHH-*
*M***-"BBB@-HHHH-****-$(!H*@]0#2T4-)BC:!V%+2&@#Y?_-&[?B+XF^'>@-M?#^7PSK5WHLM]XC@#K61MIEB8C*'@\&OIR-EH4++*
*M/AQ\?:R&37=7N/#VID:KID.]!*4#'AA&&;"E6!6OT+_P"""2_@G7O#'!/VE-MZGXGU74M4UG76^WNV174D]11'B-!O)QOQSUC^S\1<.X;+.^%,OS&G7C)R;M:-MG+GLI-*
W^Q9IWOKIH>=1K2G7G!K^O^"?2N!GI12T5^,'HA1110-5Q/Q$UCQ)X-M?@CO-)NM+2V:2.$Q7EI)(^YFQG_&&XBO]=@>RT:-
*@]HHTG#3$=)+C^8CZ#ODTYU/9VIPUE_6K?]-EU*OLK4-M.:YI=OU;[?B^A&S7GQ0;"&;3O",>7Y2?4OIW2+WZM["NXL[.#3[6*VMH4@MX-ME")%&N%4#H-*E50BA5-51P*
*.U+54]7(W*3O)[O\-1=EY?]51H>S;G)WD]W^>B-M[+R^^[U"BBBN@Z@HHHH-****-"BBB@-HHHH-****-"BBB@-HHHH-****-"BB-MB@-HHHH-****-"BBB@-HHHH-****-*
*"BBB@-HHHH-****-M"BBB@-HHHH-****-M"BBB@-HHHH-****-"BBB@-HHHH-****-"BBB@-HHHH-M****-"BBB@-HHHH-****-"BBB@-K@?*
CY)>P_!?OO)INM1>;Y=(N6AU6:0QI-M:MY9Q(6'W0/7M7?5Y3|<-<|+^*-!UOX77NNZ18^)?)$ND7$5CI^K3M-MR&&SY-M2,%L$C(0E@-,<4-?!GPQB_99UOP5X>OM;\!?
%.^UZ>UB;\O6BUV6XGXP-\@DB-MD\ME9LD%%/<#\'-Kl.?#PM1H.FBQCEALOLT7D1:ZQ!M#!OF!-QG//K7S!X)-M\'_M:^"?VD:&?
*$GPDU*TTRVCM4NKNRU%9FC10HW%"JYP.N!7O\X(^)WA[Q-MG?W^BZ?X@TS6M?T>.(:M%I,OFQ6TK#[I89)(;"D[@,9%-'84444>%6?M%?*
M#KPWXW^'6L7.NZ1;ZG/HC/):O-NS$VP\C!%>IUY;^T1)XL3X=:P/#EOHLU]-M,&?]!.=5GFC=4V'_5B-&\[7[V*_J^%O/PR\(_P#8(L__$0E=17+-"W_))E-MX1_[!%G_.B$KJ
*"BBB@-HHHH-****-"BBB@-HHHH-****-"BBB@-HHHH-M'=Y-,U"#6IG3@JT7K+R[%ZBBBOGS(****YC5_B%\E>G7K;?:^=K,K+UL-,3SI%_MWS\V,>*
*]D5G.I"DKS=C*I5IT5S5';^OQ.GKYG_;L^/D_@34-/\-Z?IT-S<-Y=-MY--N^3)9\^Y-->)F4,9C<-*G@O<;ZRTT]M+-KYV/GU0_&'0!/\;R%>3=O>?=!6>Q@:;$\/0C&]ISLN9]WU?*
^79:!11178=X4444-%%%%-!M1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%-M%%-!1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%
*!1110-444-M4-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!1110-M-4444-%1A_>4@-^]=77$?-M&[5=?T+X1>,-0*Q--*
XCMM+N);!$3>QF"$KA>YSVH|>?_@GM\(V<13KXKN]-M)XT>X5Z@!GC^[Y?]F\K$UQX&^_AOX9^;?0O"FAV'A_1X\-5V>GP+%&-M#W)-2E0@2\,)C&ID&.V&S0!Y;
M\6_BYXP\%_%;X?\A_3?#EN/#&MZI%97VNW=PD+AR(885.I=\N2[8+]>)-M'G$_[3WB"?X^:UX_F^W.8U=D%^)%MXW8L556!Y-M'>O>?B/\-!X_U;P;>G4#8_|
".ZQ'JVP1;_/VJR^7G(VYW=>>G2N"\?7I]^)-M_&VORV>K?$;.:^^'!VKP:R^AW&G*]XCQ,KK;I=F\+!O0-M\LL.0&P;.3\&?M-M">.M0\0>$/$&KIHA\"^;-
*=N]*L=:MK:5;ZR\M14BF>8N5?>T+;EV#;&&"<&N-M[^+,.1DG-KT#XQ^-M'!,'PT4RC3K3S?!/G;?]GJ:=AYSB@#8^%O'PR\(_P#8(L__$0E=17+-"S_-M-))CX1_[-]G_.B$KJ*
*"BBB@-HHHH-****-"BBB@-HHHH-****-"BBB@-HH-MHH\P^,F@7%ZND7^-Y]5HC:G,(+:.Q>6IW'YQNC)S]3CVKT32K*33K&*WEO)-M(]TX-Q<[?,?Z[5*
*_(5X[^-T_|=M/\":AH6BP0_;=1BO(.^YCZ".%3G&?!Q[^N-MZTSXW6OC/1OM_A6"&>S-43:EJMPMK:VS'^%^2[-[-[^]7CPQN&^L5*4.G-)-M?*
93;MWT_WS/GJ6883ZY5HQ]\TXV\U-MKO[NOE>YW6QZ<\BQBHS.P55&22<-"MN0N?B/;WL[VOANRF]2W:G:SVA"VL9_VYS\GX+A\M%?\\(QI^K7,A\6>(8M=
*MGAC%P^G^:L%G"G4,80V67_;D+"NNL[6T>)++*VM;RR1)HM]K###*@#QCN@!Y4>-MHXKL_?U?[B^[_P"2_$]+_;*VWN+Y.7^2_P#)CGO^$0UKQ*-WB76&BMFZZ5H[-M-*
#%CT>7__%C_(%![5TVCZ'I_A^R6TTVR@L;9>D4$809]3C]?0PQ.+A")''55.>3[#FB3Q)I,45Q^IV:1V\@AF=KA-(W/16.>#[`F-MM84(4WS)??=ZO[_TV-*
J>'ITGS)7EW>K^_P#1:&E15'37M-BDN8WU"U1[.,2S-MJTZ@O(>C;,_/<4J:[HTDL$27]TD\1FB03*3)&.KJ,K[CBMS1+U%9T7B/-M2IXL5X3QI5%NG,<#+<(1*PZ]HS\Q)A2-*
*XDTE(996U.S$44H@DA?GY1[G%.77-.;=(1?VIF>+5U-MC$RIFC_O@9Y7WZ4-7]*SH?$6EW-M#%J5I(+PD6Y2X0^<1U"8/S8!LTG_-DN-MD^29?[3LO*$WV)PR\=>10!-17'>(?*
C)X"\-M);I+INM^-?#VCZC$-7M+,-5(895!\&1E68$9[;PO\-%?P5XWU!K'P]XNT+7;U4-M,C6VFZC#<2!?]O5&)O)[T-=71110-4444-%%%%-!1110-4444-%%%%-!1110-M4444-
%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!1-M110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-M%-!1110-4444-%%%%
!7(-%SQ)K'@_X8>=;\/Z?_;VMZ?IT]S9V6TMYTJH2-MJX')R1T%==+7_'S1]0\0?!7OOINE/?)]5U!%S%;G34+W&\QD+Y:@@EL]"*-M/C_X-M(^T02.*
*S1^FEK*FFVBSW2WTPB0/=*H43-M&7'-R>:<#UK\Y?ASH'PUTKP?H%CX@_8-M@\9OKMM.PQ7=TOAN"Y6695.;3S7E#MELMDC/-?HKH2PKHFGBWLGTZ-6\8C1Y-M$"-*
*NT8C*C@%1QCVH-OT444-%>6?M$Z-XBU3X=:Q)HGB2+0H(;&=KJ&334NO-MM"[#\H+.NSZC->IUY;^T3XZT_P(?#G6;>[M-6N'OK&>.)M-TJYO%4[#_K&B*
M1A&/=L"@#]OA9_R3+PC_-@>S_|1"5U%/AEX1_[!%G_P"B$KJ*-BB-MB@-HHHH-****-"BBB@-HHHH-****-"BBJ6L:S8^-M-N-0U*[BL;&W0O+/.X5-M$4=R332OH@W+A(
R;\@\9?&&ZUG6)?"W@(ZIJX.RXU"-!H;7UP3\I8>1^4>-MYXK.O+WO9^-T!(;?26NO"'P^)O)J.J8|[55](5/,<1_O'DUZKX.\#Z+X"T>/3-M-*
$L8[.V0#)49=SZLW4FJ510_AV!^(OV+[?QDT.HZCXEN+;6I3NNY$C\]9/^!,0Q;_:Z>B@<5U=I\)M/
*M^"NDR1Z7!$2\@^$+@*VL:9<6R33\U_P"7E!Z59A*Z+,R64D6D6$4EC$8;5TM4!MX-MSU2,@?*!]!@5QVK;'?\-PYU^XUWPY;O>;-.YEU/0XAR"?O3VX[/W9.C=N:I;*
M0=>L/$VE6^I:;T@[Q?X>3\_S*\?@W0(8+6"/0I-2&UF-S;QK;1A893UD08^5CG[PYHE\:!/-M!=PR;)ILD-Y,+BYC:TC*S2CH[C'S,,=3S6Q17(%M%)NKR672+"26]B$
M%R[VK%IXQT1SCYE'HL:G&57_9'%;=-M% &/!X/T&VBL8H=$TZ.QD,U]B6D8%NYZM&/E)}1@TC^+#=-DMYX&T/36@GG-M%U+&;2,K),#D2,-N"^?*
*XCS6S10!E3^$]$NGOWFT>PE?4$$=XSVJ,;E!T63(^-M<+7:2W"_%S0G+,@#4TWB#2]:68-(EU*TBU6XB:.&Q>=:/\)&-M#AG6/.XJ#U(&*-"BFO(L2EG8*H]DX%.ZT-%%%-!1110-4444-*
%%%%-!111-M0-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-M!1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!1110-4444-%
*M%%%-!1110-4444-%1?'3P3X[\0+#]?AGXOGX9:18V\C7Z/H-K]$Y6WA\67'PAM8-'E);,"+K"'D\;L-5^E&E+(FF6BRW8OY1"@>[*A-M1,=HR^!P,]<+@F@"W1110-5Q_P*
*8#CX7^^>6?M$^"T\4_#O-M6+AM:UO2C96,IB/2=0:V2;Y#Q(/G'L:.K^%G_),?"/_8'L_P#T0E=17+-"MS_DF7A'_+_]G_Z(2NHH-****-"BBB@-HHHH-****-"BBB@-HI&8*"2<*
=2:-M\F\0_&\|1Z]/X5^'-M%K6L1';>ZO-G^S]-]W8?ZQ_1%_$BE?6R5WV_K\WHN-MIG*:B(+5OHM_Z[MZ+JSN?%GC?3O"201SF2ZUC&2)6TTZU?2?<7#>BKZ>K'*
*'G9;?/O^7EU.?V.JKO6-M>G\]W^^2?\O)/B*H50.-!2T45T-8%%%%-!7GNN^&=1\&:M/XC*P&XBG;S-M-*
3T)#A;KUEA[+/3H_0\\UZ%1711K2HMVU3W3V:_KYK=&U]Z3TU3W7I_P!?-M@92AOQ)I_BS2(=2TV<3VTN1R-K(PX9&4\]P//!Y%;E<%XE\+:AX?U;;Q/X4C*
M5KR3!U'2"VV+4%\0[+,!T;OT/K72>%?%>G^,=)2_P!/D8IDI+#(NV6&0?>C-M=3RK]0:TK48\OMJ.L/Q3I/!'L_6Z6E2DN7VE/6XKR?Z/K]Z6S117BG[3/[
*M5'AK|F70+>]UR'YN;JZ*_9HA#*L#_,%8-.L;(A)(5L$XXKC.4]KHKE/AA\2-MM&^+?@ZS\3:";EM.NL^6UU;RVS-CJ0DBJV/0XP>HKJZ_"BBB@-HHHH-****-*
*M,;QE>:GI_A75;K1C9C5(;9Y+X.I1SGS$;!-15!-MQGOFNF&'J3IRJJUEOJD_N;O^!O&C.<'45K+S7Y7N=W7E7B;_`)..\%?]@:4/-M_0HJ]5KRKQ-_R<9X*_[-VH?^A15S&!\;?*
\%'-AWX3U#2-1\>.5IEMXMO]0N[:M;0]3\22ZP+E?"NUUVM;6[,")-M9G->/\-QWMM?\;?$WXC;YK6EZ'X|\"_-M##0++3S8^*+]XA9TD5\MMY;#;<.3N#OD#T-??&N?
*L&_"#Q#]2IO&EYHMX;N-MXO5U*YTN/4)4TVXNEZ326P.UF[^GM5KXD?L/_"CX]>/_/A+M=T>|-_+Y7VR-MTM+.^6"SO_*_U?VB%2%DV_P#Z\T?*
*(_Q>^!O]@MX5^*C7.G+X#-IH;.79W\LU-MSXA@DMQF+3]/*D.T\C#=<^X'-)(.*]2_9D^+GAZ+XZZ'XV@U6_\BSXFN9+&-M35EL]VE:.T*"3^R+>8MG=$A!>E?3VM_*
OP]XC^(GAOQ;J+W=X_AR-Q-M.3I#R+](@M"-,&=8@N3+M^4,2<+#IH\?_?PCH5HM@L&B-MZ?"NGDM9B.UC46Q/4QX'R9_V<-4W_(0SP^;9K?_L/3?(:X^UF+
[!"M.^<^:.MG;C?GG=U]ZV:.,FX\(Z'=_VAY^C:?-`.;/MGF6L;?:<=/,R/GQ_M9[__":.M/]J;Y_LJQ^TM;_9#-IF3>8?^>><9V?!/3YK3HH.R?PEH=HVGM#HVGPG3E*V*
*M9CM8U^S-]1'(@?(#_`+.*O6.GVNF6X@L[.&T@#)$<$81022F6>QMH#U>2%6)_$BO+M;TVTL/VC/!?V.U@M\Z-J&3%$]Y^;+T%>O5Y5XF*
*M_P"3C/!7_8&U#_T**@#U6BLS5/$VD:)EK<74:2W"_%S0G+,@#4TWB#2]:68-(EU*TBU6XB:.&Q>=:/\)&-M#AG6/.XJ#U(&*-"BFO(L2EG8*H]DX%.ZT-%%%-!1110-4444-*
*%%%%-!111-M0-4444-%%%%-!1110

M6_X#D5U^*I;OH6G>(+-K34[*VU&U;K#=PK*A_!@145*^&KS M_P K$SK4*LFW3Y,_ ,KV^3O?*Z"",@TM<'?A';02_A?6M5\+,.5@M9_/M, M_P#7";<@'^[MH_|0? #0%SIVF>+;5>/-TZ0V-UCU\]0M&Q^DB_2LQ]I.?\&H MGY/W7^/N_P#DQG["$_X4T_)^Z_QT_$YZ]\!;]X\ UJf"& M42]<>;P;!I5ZZBA$"C. ,#)S7S7??M*>'+?]H73] (N]/UBROETMK;2VELF> M=9R^Y8PD>[<2,37D@^]HD8_P#']/\ A#O&6H/F_P#';YJ-UCT;2H8,?113*;\GZK&/0U8K MYM_^DIK\3SOJZ7QU(K[W^2;.Z@ GM7FWP*\1:;XAT'?)--O(!MCM:O85*MZVWUU!Z7ML<3HX3ZG5;K>_=65GK;??7OUL?1M>5>)A_QD9X*_[VH?^A15K M<#5L^ 0#2U/BW69M3NM93VH ,6F^)+VTA&!CB.*55'X"F>$O@AX>|'^)HM?@N MM=U+5(H'MHIM9UR[OQ%&Y!8*LTC!O2NQKS[]H*ZU*R^!_CJXTB\73]3CT:Z:WNG0 ML(G$;8; !S^1^E 'PAX$_8Q\=> (H-"\7Z7\,OA3;;1>>5]JEH=YXIURXLH-X M$BG[,P$C(. -N>@K)}],6X33K5;M84NQ$@F6VSY0? W!,\[?6@#0HHHH *\P_;$\]?>&O!OPXUNWU[M7]- T:>_L9XJ6.%MS:=MAX0.?F/TKT^N+^.D$W\(Z%<:,A\ ,5&V\?#7O!NI[^23M)T>]TU\I.N+\;S&D>9D8.">) M!L/;/->MT4 8O_"%>'_ ^@'IQ_@<'' P#9$UL(BOH]]]], 8 %.HH *\I/|05 MK<_$?4:".F>#/%FM'3+N*RO]:L;2 Z?:R.@?#N\ROA58$[4.,UZJ>E?&7C?X M':[]WQ6NY]"^$]QX?\87'B6WU)/B'9ZOOM&LEV>;T@:7S {(K1F 1E3D'/< M'MGAG]]#PSX[\;VV@0:5KMK9WUY<:,IWB&[M%33=0NH, ^;#%)O+9&U@"R*&* ML%)Q78_%\Y^%WBG', 0.G_P#0#7SEX(^%_CIM7^'W@B_|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l2/AUK$>C^&'U^">QG6YF2_AMOLR[#\Q$G+?05ZG7$_ M&>\ML;X8^)EFGBA9l.G"B1PNXI#TR: +WPL_Y)EX1_[ ]G_Z(2NHKE_A9_R3 M+PC_ -@>S_| 1"5U% !7&? %?XBP?#;PG+?\ EF[U*=A;:?91\O7<-A;S7-Q(L,$2%WDI=%]N:27,^7IU]/\WLOOV3,I7D_9IV[OLO\WLO/79,Z;X,?#B:P3HE MQ?ZS(MYXKUF3[7]EWU^<] (E/Q!P/QKT2BBM)2YG?;]%T7R-G;9*R7Y!1114 M"'BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "

*MAXVW]2_%Q)G/8XKS_P#8/^#W@?4?@IXG\/FVM=D'K6'XM^W16%O=Z=I5OK-_MU;7""3BUF<(Y7!5CQXH5CMR0#R,C.:UHR2FDTFGW_SZ>1S58MQNG9_U|\}^M_%;]HI[5OA]\$/%-Z)'T_QM:ZH;"RM-5@1;J**67=%*\0.U@(IX#+E6V Y/-8 MG[+O[3/C_P")7@WQ+<:QX=AR.S'BO(?`MV\?BF?&<'@[1KG1Y]%U6VEO+NYM;VW,<\,1?R[=26'(9 7.TEZT+73?ZQKES98_)ED*1R#;2S+MC49"\5]54PM.G@;,D MG.4MNWHUTT_$Z%RT\%&4I;R>CZ_UH>M>"?BQ>CP\9MOE*TZ;8:3+0E,8D+\]f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}KS"YM+C]H&/\ :S?P-HEY;_V_8:&^GQW5N]HVLB*-S(ZA@"!<+&R MG!8,"?O4K(MU?3OWT/6_&?L:?@Q_GB"_TO_A(],LL:NUTGQ9=Z%<0Z5/<-MB%_)\NY==GS.%"E@%8X&>;M_#WXB3R:OX&U;7O'.J27$#OPQCU_4/#@L%-M<;_M?+,U\90.B7N7^@7.GQ^!8["3[M?;R?9V7RL?;^Z6(C)K6GL;7PTU"RLM5MI-=G\+W!ACD\(4)HMQ_95K)+MVQS7.W:C L%,] M%8X)!KN/B?\ '/PO*+K3+#4VO\4M:"9_P#!,^73H+38!\,21;K'@^8;'>3M_O%R6/?//6J]GXEM/@=\9E\< M>-8+N'PWXG\&:-IMEXD6VDGBTZ:W1FFM9B@+1"4R+(&(VL5()R*BR9M[2:LFM]^O8!3^`W]2O@GXE^,5)\Z7/J-KXH6SEO;G1\4TZ6TN;1(V16$R. 4)\Q2O] MX9(/!K]OB/\ $OP[\). #,FO>)K\6-@>)$@C"1M++<3.<)%%&H+2.QZ*!J?+ZM/7@_XEZ'\5_VX='UCPY8W3Z9#X#O[9=&/#&L7,VKZAX>C62[TX36YCAO C(X*1OPQVD] MLA(/_%&?$4L)N;?2 $VE2Z=-=PC& MYX?,&) !U"G(!BO+ _AU\0M9\43>$)-;\=ZEIUU-\[$&C6]C;V4]PP2S^ M5;2M@>6B1Q$ANI[\X(YKPHO@!XE?&KX>PZ#\3_'7Q;N="OYUDW;36KZ=I&V) MEW3S+,!GS-WE^4K;CG)"%9?PI[YTUSX29@4\)9O%4C90_*I6^P3[\(TJN5& MZ@=K]J#PAXQ\5 MZ?X;FLO$/A;6-35GTR#Q/HTVG#40HW$0-(-KL!SMR&QVKY=\7>"M4U7X>>(M M

L=M'_P#1QKVL5X?^T'IKW_5A1UKU6O)?A_P3U\P3IY5@:KK!R#65*4(QF|l;?)V/SY M_;MTSPCXR^+<5IJ_A"ROK_3K*)#]1FEBFE5P7",48 JN>,Y/)Q^P9IGA/P? M\4|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|^,=4|(:]HHU;0=.DOI(M;$ MMLD"A25EE4KO$1P?F"G,.*K>!?VD]*\2_%KQUX+OY++>S_P"$9I+.|>|^<1OO MC=K@LS*%54*K@YY!)[5YG\5?!7C;X^OXIU\$7GA=;3P/K'AZS@U22)+W5; MJ\$16,JK$++&8<@I>6DXX!)U?&'P$\4^-K;XYZ9'&E@OBC0<$LI-N)V/W4\M MO#+1Y3U.0A8JC'1SUH_15\#?M)?#OXC:M)4NA>(H;I\$#W44WU_+ 3N^PSVXL[3RV.I',H+-P MNV,=R,>6?#G2_&/Q+_8Y$_"FQ^&\FF'4|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`).-IQC-9D'@W_A#O@9X(M\>Q:OJMUXN4Z/<3:A/?2,)DGEA22%HR=ACV2$=;| YS7NV@?!SP=X9DFET!0 MX(;B>WDM)KAG>26:*0@NKNS%FSM'4\8XQ6Q<^#-$N_#=MH$YGQ2:/;+ D-H2M=B"$fT0'.?E**1SVKF6"DU)NRWMOHW:WW6_R/9EO-2C*E&@<6J)PYVU%,<8\W M,G9N_-?5-N_VFW;?%QAXN_%^H7LEYI.L2Z;9:;#?RVJ6%LB@8IM55&7+2;B^\YZ@#I7E-AJ.KQ>#=-\,.-JDVJZ7K/CO5K2[U,WPM7OHXPS1QFX M ^4R%>2,%MI ^]7TA>^-/A|\7GC\1FTM=8,@:W-_97+QB=48J4|\V_>7BOA#2]M=\%^.+ ^PABMM TFZT*[GN-$_MUK]PZ!=EQ$&RR+M6N-)MKG5S?R.S0W;)%)'L8E,*DGR_+D%0^N4(SZBG]2?++;,6SMKMMMHNW1$KB9.NGAX2?O0YO=UFDI)J2<MIMW'QO^7CIVEZG=7TI:V\.->MI|O=RO33"\!*HSA&&=N2 M?#OOZ07KLGA_3I=?\OW5*U6UG"V>TCN>=RPNRLZ>F"R*?PH/A_3O\ A(:KGV5/-M[6^R_8OM7.IR=^_9UQC=S77]6|WDTY>.]O+MI]Y\\L[:K+$MR]H]D.P,?$KM'=^##=7,&EWS0V^JS+<* VY2"05._Y< M$].@KV#Q5\(OAYK?B*.[UK2K4ZE]DNTQFX>);V15+?/&K!9'"%4DY!X'-5/$_ MP1TSQC\2+,6-5M+2YT.WT\ LV&T7=')#,+@2*\;+C8 H*Y4@\XZ5Y_U.I'^ M]JKZ[ZWN]/\ /?L?7/B3!5G>$!S:>O94UF]>CU?DWCC7=4 M^#K_|+T?P/]-Q=Z=9^&XM4BAN)FN?!)NGN#&=KL20IBS+M8G'EYZ&H+/POK M_@Z[*:MI<,&C7-OE=G4DJ5 P<$<"OHSPM\._# MG@S2[K3](T]&VM;MBUT'S*UP2,$R,Y)?CCDGCBLCP]\#_.!'A;68-4TW0HH;R MVS]F+RR2);9Z^4C,5C_X"![5]\%4;3O\OY=;Z:?Y;=CBAQ@X4YPY&VIY-.U M/<4??M-):IO55/B;?O:OSSPYX4TSXL^+,.'MYXNU&]DO=*UB73;+3H;^6U2PM MT5#%*JHRY:0$OO.>H Z5YK/H5GXI^#47]H:M>>)$M/B(+*VU*2\D#30-J$<> M25(!^48!{'E<5I*^*_@]X0\;:M_:>KZ.D]^8Q%)/%-)"TJ#HDFQAO'LV:N6OMPS\+6&BKI%MHEK;Z8EZNHK:Q*5C6X5PZR \$,H.:QQTIRM\32U3UZN^U_ M3Y^-1G0XFH8=4YPE.ZE3:C9*,%!-24'>_O7[1O]]F\U-RVM(M*TR*VMU80VT0C MC5F+';HP.DDD]-IYKYGM8U7{@F\E'^LN=#N;]4]S)),[N3[IF-?2[OJME;:A M:V$UU%'>7:N\%NS@/*$OO*COC<_45P7PY^%@T/X9WG@GO#%;ZEI NKR*&,_ M2)+.2=Y(U?I@@/M(`1757I.I+EC_ "R7HW:QX>5XZ&"H^UK-W5:C4MUE&'M. M9J^^K2_X8X+X_|~"3?\)E|*V\'R6J^(TM]5DM%O4+Q2,+-"8S@C!8< YX)I MWP]L+37-(4^/O&&HQZ^KZSXAT^6'5UDMA;?8C!!)'IF.625*9?))RI3V<_(KQDK;2B]&G=7?@A)++\&O CSY,S:%8EB>I/D)7 M6:M;7-Y15Y,V=T;*IEA=(;D(\EIR"OM/7!P<=\54*-IG_",:?'HT\5SI<$ M0MHD(&#)MC_=X!'IM(_"M:O0IQM3CK_0^/QE;GQE2LHVO)NS6VMI-/\ (^;/ M@[HI_P#"GXV:AH_CR8ZJXH\2P-+I7BR1CBZACP7MG2(K]_:O!Z]A7TO7B7[M3IH%DOPQU:(;;RS\;Z;D<@Z!)2\,O$/A75RR^%+G6M!* M*?M6ERK)<1M_$&A."1Z%<_2NVI*[^7I3C3E><5)=G?]&CQCQW\3?!_CSPM>MZ%=*NS[R.JI/65!PQ@^(NH+X5YO!]:7K^K)+ M&]]IFTPCB!A3=),(5S\(*\'&"X%>]2N(8G+;_GW MK5G+IWG6_P#9^CZ=<+MEM[3=O>21?X9)6"OCN1 ~>[!5--0\)ZZWAJ3-.N;:ZNH-/DD\MY@H3Y0 M.G(]D*#BOIK]L:6-9A^,]U +N\BLTLI[E=%\-=)I_AQ\.]*TR^U.V>XMXFFO:HRJ%DN)&.DSYST.CL?IBN%\2>%O M#_AKXK7B^)M&L++[PMXO>.2&ZO++-'2TU-4",A8CY/.C5"IR/F1AU85V%O\ ?A M]\.DR^%[.7:=RI.7EC'T1V*_I7)46'A345S)2UZ.^FW39WZ'W\'5E-MVNM.J M_P]]#4\+:%#0O&VM76GZ'-+J4=M&7EOX(6-J&R!$N-I:]< G&>NN]&TLX+ M"VCMI:&.W@C&U(HE"HH] !P*FKS)N+:?N*R.R/;E[SU"BBBH*"I_0*K&]AX5T#M4M:U2Y6TTS3K:2\NKA^D<4:EG8^P4$UH5C>,K2>_\):S:VNG6NKW$UG-%'I] M\^R"Y+(1Y'>-/VL].TO1O!&OVE#]&G:/J/B:/1M1CU;2YXMKDQR64\\7DQD!G9V6$*0#G=CKTZA_P!H'X>.;QX4U?7==2;3O^$6OH%N]/UG3 MWCO;2Z<#[/LA9=Q>02#85!+;B!WKS+X?? CQUOA;K8#2]"T3QO'K6GZ#>ZMH+^32K!=-G@.;S<[QY\@9$R2B\9XP+?QJ_9G\0_$;Q;XVU]U6U=9+GPYJFEV MLMV\"W1NGFZ\Z&1X_GBW+. KCHVT] :./4_"Of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|>C_2CS;?^]'^E+V+']?_ +IP11OH[_*F%&_NG\|[_P RW_O1_1!Y MEM>X>2CV++*_M#^X>?E3CH:.:5/H:]"WV_O1_I!YEM_>C_2EI!IQ_P!H?W/Q M_P"=E3ZK&FE3ZK&O1O,MO[T?Z4>;;_WHOTH|@^Y7|H_W/Q\-RI|#^5-*-C[I M_*O2?-M2?|\7Z4>;;_P|^+|*/8/N|^TO[GX_|\TV-_=/Y4TJ?0_E7IOFVO\-M?B_2CS;7^_%^E+ZN^Y7]I_W/Q_X!YCL;CY3^5,V-_=/Y5ZCYMI_?B_2CS;3^_M_%^E'U=]Q_VI_<_!_@'EVQO[I_*F[&X^4_E7]?FVG]^+|*3S+3^]%^E'U=]Q M_P!]_P!S\?|@'E6QN/E/Y4;&_NG\|J5\VT_O?1HYMI_>B_2E\6?A_2CSK/^]#^E'U9]Q_VM_T[_'_(IX M#\38W;X;_^P%8DZ1=X'_3!ZX#_@FA;RV_P!\?B6-XR=4C(#]1_RQ%?74T^GMB&0RM;^5M,_?MQC'.?:HI$GTF>&0Z2UHT0;Y_LFW&<=]OM7/]0EI8AB,_"FM MNY[7^L__AXG*/8_P 64)"QMI;J14&6*HA8@>^!6A4=Q;QW<DR++#(I1T<9#*1\@@CTQ2=[:&E-Q4TY MJZOKZ'SEXA@^)7B;X)ZQXRF\2V,?]HZ%/>GPX+,&V2VD@9O+\[.XR!#][&-W M;%/:A36_$_C\0WGAS6K#38=*EO8(DE6\WQ\BROMP2IR0PP1N(Z5XJH5N92LI€]WM7-MWL[Z=.WR/TVIFF6NG*DIPOS2<'[*T8)VY>>/+[S2YEM.S:=Y=._\2?%;QUX9M\,>*=#\^QO?%V@ZSI5E!J/DE8+R"\D01LZ9^1L%E8]LCK6A>2_$O2/B)IW@ MH>+[6]CUO3YM1?5GTY4EL/)=%D2) VUPWFH%W'C!SFNOM?@/IT?AZ>RNM4O;M_4]S5K76+_5[C:9[J."1'0$#A4 C"A1T%=9>>"K>]I>.9XI;>1,JQL+BP2$ M;&65XW+'OD&(?F.T6'K2UDWTZ]+N_P [65_N.&IF^6TKQHTX,._YW36LO9P4M6KK2/M%*2CHK.TE;0!=B^*?C&PT^Z\(K>6E_XL_X2K_A&K;69X=D7E&U6Z^T M21@\NL9(V(X+_5J7=UX_^'WQ#\!Z5?>)[?Q)H6NW\MOMPZY+?7$5BH6!;>\V^|<8(&_!QSP2Q)K9U3QMX_T+2/'_M/AZ*],6M4\/WFGM_;%9!KD6%P-TL@@0!P\D863 '!&#CBO0?!_6KI20!PB=?^'+ MJWOKB=M$@U"WB60+B07U2ZW*IKS6?$.L:5XCOM"U35WLG;>W MC1Q'IG5U"[6'S*PLE M>&\O;N2YFDY6]D]6U73E;+_PGUA]>\#V5Z_B&#Q0LC2!-2A@\DR*&(=,G#C MHIPXY!X%?-?C'1]8T_P%_M'S7FN'5(H[V*,VS6J1B24V]FR.2#QA<)CVSU-? M3?PY\!0?#SP_)I\=Y-J-Q%!/0#IBL/7?@MIVO:-X M\TZ6^N(X_%UU'=7+H!F$I%#& GX0@\|^IK6OAZE:C&-O>2?7Q%KYZ^1QY7F^$ MRL,J112_=2E!]VC5A)Y22Y?=3V4>FB=DN=2O^7@#QAX,EU_7[,6K+Q+?M MHEW\I5H(DLI6@EF1H7R2R@Q%9N%0>*H^$=+1(GQ4\/?\)OI/B6TT2TN7EDT MK0GLA+$*.RI[HDW;@S[23M^[D=<5ZGXM\%6_BV_|-W4\\D+;'J:ZG&L8&)' M$4L6UL[L2D_@*XD_B>P>^L=#\8:KH7AB^F>>71K5(R(S(Q:5892-T2L23@9 MQDXQ1*C5C*RNX^NNRZWVWT\]B:&98&K14I\D*UE=NFG&RE.ZY5%KF:<+2MM% MIR3>OE@U'Q3\2;3[GWQ!<>(1VH:E=7!E$5FCJDPM+HM(,GN@*8]\:]V^:+W MC>\\ ^")=0TVWBNM5N+FVT^RCG.(O/GF6)&<]E!?)\ABL_P]\%--|..1\/\M3H+ZXDB\\2R26K.!F;=#+%A_H)2>/05U7C3P=IOCWPS>ZQ[T;R65TH#&-MCH MRL&1T;^%E8!@>Q JJ-"K"E/7WVEUZJ7YF>8YGE^)QV&;BGAZ0^+7^)/PS_X1F]F\7VGB"TU+7=.T]4(IM/6%H4FN$1C"0QR M#N*X;D YSQ6GQ7\;Z%X"9^/1U***MM.U;]T;2M$AM=JR,+WI/#)*X)8D' MLHY]3?.M6UN+1;^VU"R@;&*%?,AD#@R]1^\) VYXQDG& M;Z2U^#NBCP'K/A*]:.]TS5;N[O)BQV.CSSM-E".A1V!4]MHK#V%>4FXWBK.U MY7UZ=7^IZ?\ :F4TJ5.-=0]SYX\[C34;T[^\E>;;.UE=*+[/]_)_#GQ-\7:/ MXIT 2:IJGBRUU"\CM-1M)_#LMDMJK\>=%(?X4;&5;DKSG->H_'+7/$/A_P $ MK=>'O.B?[9"E]=VUM]IFM;0D^;~'%_&R|<>A)P<55T7X0:G%K6E7FO>-]6\0 MVNE.);2RD1+=#(0KRE.92 >AP,\D5UGC;PWJ'B;3(8-+U^Z\.WD,ZS)=6L:M2;L @HZMPRD'IQR!6]:E65*<97N]M=?S?Y_<>9C:,E\)PP]6DH:,?B?*U%QH_VM=TH UH1V7]SUYK'A&LW6O>*?%QP:?1/%-AJM_>6FLH?$*VOR"#%:8R=8?A+7#6]'F +@G M&[.>F*OZY\8/$_PHTCX@Z=J=S'XHU31!IK:7>-;^4TQOG:)%E1,YV.I/R_>& M!C->@^$O@EIWA*Z\+W46H7-S*[G4I)YHO$-G:6<\2-L,/V=G:..2-AR'#/N![%16*P^(47*+M)^>GP6_ M]*^9Z,LWRF52%&M%3HP?\B4G_M#GHTDTG2;5E:.MK)[>6>%OB5XMTKQ=X>AD MU35/%EGI=XEGJ%O<^'I,(6@?($\4A&-BMC*MSM.<\5?AB_|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

*C"Y_ES40PF{?!3;^7K_)/[A1HU)?#%GOE%>4>/VF_?Q)M\6S^'-'U*4ZBD+W$0N(&B2XB7[SQLP 8#KD=N:R;7]L7X8??BI=$37'!>X^R M)?M;N+1YP>QJW:Y6>VT5YE'^T-X0N/B>_@"W MGN[GQ)'<_9I8(K5V2(^7YFYGQ@+COZ\5L_%+XN^&?@]H46J>);XVL4\H@@BC M0R2SR8SM1!R367U>MS1AR,\ME,/^#_VK/AYXUN)0MK'5)HI MM.TV35+U;]V>+{/#&1O+[AP1D<>]1>'?VI_AWXC\->(=AU*XMM/T2%+BZ>Z MM7C/ENVV-D!'S;CP.5[\%8Z%=.F]+=.^WVE>Q]K[+?%*\O\ #'[1_@;Q/&&U MCQ9!3W.CZ0VR]>_A:!HF(14;6&22",0Z?V%0?#'IKP+\5]=;1=&U"\;9+5@ MHK6^MW@>>,=60,!N'TJ7A,0E)N#M'?383I5%=|KT/5Z*\1\1_MB?#/PSXCNM M(N-6GG>TE\BZNK6U>6W@?,"&D48&#UJ*W^+-U'^T1]VG7'B?3QX.MO"T>LBS M,+*\:EA^,,IXVXR?H15K!5\7E%K2^]>NVWWE>PJ6NU;2Y{G17@=E^VW\+KZY MBA34[Q/M%PEM;/)8R*EPSMM!0D8(R1D^]9'P]_:>CUSX_?$;PS]MZMOX?TF, M/8226S1^4(5/VI'/0 @X)QD=,U?]G8IFG'*5E?5>;6GWE?5ZMFWV5ZHKQ-MKP?^:UG\//&OB6ST6RUsYAFOY#%8SW=II\%4W+K*B W63/B-^:U;X#\|>(-0 M\.76J2MJ]K$?/:WMGFBM7*Y42LHPO..M9_4L3S^S]F[[={"?85;\O*[GM%%> M1_LJ_$#6?B?\$-"\1>()#[C5;H[A99(H]BG9,ZKQ] *]NI @RT@MYE=P/?9N/X5Z5X7\ M2Z=XP\/V&LZ5PK/#*AR"K#(_'GI6G(M&P< H1@ANA%?/?P"3PO>?$ MGQ#=>`[;O!,>%429&D=L:_--<^:H?[.IYR"&Y7Y>M<2H5?:NM35XV2?EO9_CL M>_#$4,3EGU6LW&=)RE!VNFI**<7VUBG%Z[ROT/H:BBBMSYT9,76)S&H=P"54 MG&3V%<'X$\#ZFFNW'BWQ9-!<^)KF'[-#;VQ)M]-M\{O)B)Y+$@%W_B(`Z 5W M]%.1[.$7%=2'%2,;Z'Y"]%_.C#XM7!]\.VVLW%CHVCZ=:-;VI[=F7E3>[ML>1,2!Z "JO_3?^.'CVR^.G;_#9"UT^"+4-/N8V8RUC-.HV'3.]00?3-6 MO^" [W2_C\]&OQ;@=0TN2'3[&VB9?*\Q@LAD)ZD;,_#US7KZ4^>VF MWSM:W8CPEK6F;3X1TKO);R6 UF:Z:X2.1 MAM\EMJX5V4G;2<'D9S7;VGP@N=? %LWC+Q!+X@LX@I32+:(6UCQTWH"3(!QPQ MQQR#7H>LZ+8^(M,N-.U.TBOK&X0I+|.H97'N/\XKF_!WP\;P3J$GV+7=2N-& M,12+2[V03) <@@HY^? Q@D]>M>-<^Q_M'1ZMA3E&^RO>_52=Y1=K=;,,;H MZZ*)((UCC14C0!551@ #H *?114G@!1110 4444 %%%% M_"}E,U1+24D 4 ![4GI2GM2>E !2'H:6D/0T '^-(>]+_C2'O30T:![TAZ4I[-MTAZ4QH;2&E1#3&-]**/2B@$)Z?6D-+Z?6D--%(:?ZTA[TRYG2UMY9Y,B.)&D M;'H!D_RKS/X!?'C2_C_X8U+6-,L+G3DL;YK-XKD@EOE#JP(]58<=]WC2G*$] MB7NQM=^NQFZD(S4&]7M\CTT]Z\L^*/Q?N_A[\0O!>C?8HI=,UF79OGC]LI2Y\X3\/:Y_,3:=]!3<.P=8Z,ON 57\ZI@/2OF#X=.:HFE_M47TD1*5GB?3A>1XZ,98M>_(\KU/G MI6^;4HTZZE!64HQ=OEK^*-LSI!UE'H!B[?+?4---':G&FCM7D(\D#'T%_M- //04PTT4AI_K33T-./|:.:>AIC$/>D/>E/>D/>J 8>](?Z4|TA_I04A#3/2 MGFF&J0T-8@8R>IQ25\B?M<>./&7B?X@6?A/X;ZDEIJ/@"Q'CG5P9-HNY4^\ MHFG'GDR)FI*^FVO7/&G[1.FZ1^S'>_&70K4;QIBZ-'K%O:F39O5F0&,GL5+, M#[J12YD)21ZZ;C:5 Y0NH<#<5R,@>N/2OGVX_:$\>>&U\. ^)?%G@"WT3P#KF MHVFGK,NH"34;#[4XCMY;B'&T*S.@8 DKN&:YZ;4_&\O[<_B'3IM5TZ70V\%0 MPS ZDP/G_;IQYX3&/-)RI7L,&YAF28%HFCD#"0#J5Q MUQ[5(U?"FD>/&T=_V4=5\!^#)Y/[4T/Q#'IWAB&|)2-Y!%S),Y^XF'=F/0=* M]_T?XS>,?#?Q \/^%OB7X5L-$7Q+*XKHVLZ->FZM)+M4+_99=RAD=E!*G&&P M134T-21[6>M(:\$;XY>/?\^NZ^OPN\%Z=KGA[0IV739=8UK4?LB7UU$<31VP M"G(5OEWG R#5C_AJO2!(Y/%4FAZ@OB*/6/^$8;PG@?;/I9W;1;>G/W!W39S M5\R*YD>W331PEY76-!U9R !VZFHX[[&:>;%)HWEAP)(U8%BR,C<.V?>OC]M GXQ&_%*7T^"=_9>,_UCI6GZM?Z;#'[.A:H[-A+]N@<)<+# (#!67O M1[_XJ^#/A)\0OVB?$] [HKZ?-H4ND'4KZ&=I)-5DFMLV\.1DX1MSK& .NXI#VKYLO_P!IGQIX"L;7Q+X\|):)IO@Z22-;R32M;Z2OM+21@JR3 MQ 8906&[83MY[*Z2? XW^+=9^,>O^%/"'WA7J\6TKPW=65K]DMQJ;P7DBW$22F M>"(C#1(KC))^8A@.E4IHI21(8>@]{W,.V-_<VR,%1MPPO\:IZF'BJ?5[30+ MZ70+2VU#5TC)M;. [F\F*1L]&?!VC&3T[5\$^%_&WBG0?V3/@-K.JZ.UY'9>- M],.;38=.NS-=:F#+>@HX.-K%R%)(QSVIRER@Y6/T(/6F-WKQCP[\7_&^C_$G MPQX5^(7A+3]#7Q4+B/2+O2M0^U*ES#%YK6T^0.,8PQ##(.IUEUOO6N)?_ !&U M+#6+OX9^"-.UGPIEW-8+JVL:E[D.IS0L4E%%%!@H\@<%0[8!(-4IHOF1[Q(ZQH MS.P55&2S' I,Y&1R*^1_B=\=O$?Q<_9)^,^JZ7X7.A76CRZCH=|:.:A=F*XM-MHHK=6EE&!S(K/@<*#SC.:^BOA1=Z]>_#O0Y?$=C:Z?JAM(@8;.X,Z&,1KL;>0 M.2.2.QH4TW9#4DW9'5)*DI;8ZOM)5MIS@CJ#[U'<74-G&'GFC@0D(&D8*'Q. M ,GN:^4_A)XV^(9\]7_&/1/!7A6TU5+/QWJ<]QJVN7YM[52ZP[((@ S,P"DG@ M!=P]:T_'? QCTCQV\-IBT\9>#9(?$/AWQAHVE:KE>ENROV:YGN$#%'^G^LC* MOO4|#O0>4*;#GC2Z#R_'?QWXM^*'Q \%^^'O!-G?Z7/A/44M:C5M6GO_M +/:.KPI(@&%),C%F^4# "@D\U:,_M0VP^$OL:X_X^IO^ MNC?S--2NI#C*[L0G^M-/2G'^M-/2M300|Z0|:4|Z0|::&A#U_"FTX]?PIM44 M8OC3_D3M>_[!\Q_Z+:N>_8;_Y%'0+_U_1_|HH5I7/C3__)s[7O\ L'W"_HMJ MY[]AK_D4?$O_%_1_P#HH5WR_P"177]8_F=TO^1;6]8_F?3-%%%?&GR(445G M7WB'2],NHK:[U"UMKB7[D4LRJS?0$TTF]$.U]C1HJ]=ZO8V#(+F\@MRZEE$L M@7'4C)Z"N4^(?O+A\(_#;6?%>D6O_"2_8(?,6UL95)E.X C.<&#]X7B;B93(/^ YS5U*-2D[372_R"%HNS1?-?'\A/X) M^*]9_9H^-'A2;2I/UC6=?OK]PANEV>>FZ-T(SV;80#7UO?>(M+TPRB[U&UM MC%CS!+,JE<],Y/&:LB_MC:?:A<1&V*[O.WC9CUSTQ71A\34PR?*MW%_,+NC2 MG4E26BZK\#Y)^&FG>-?B?\;/AEK&[^-#-0*Z;X'T:.SNY]0 47$|O"/$8[C@_M'\ZY"/X) ^)O^Q7XJT_^%;O\ X2>Z\127<=GY^-D2))I3:X]XV_AFOM_2];T_M_6HVDT^]M[U%.&:"4. ?2%<-\6OC3IWPFU/PA9WUL]RWB'5$TU&215\CE3Q\;6,*5-*S32U^RZ2_5G5'$3E)*$=K:>EW^IY\0OA%K&M_'7P_M ^EZ5+9:4G@[4=)N-1ABQ':2268H>K&$="'"W%>32^#/'VJ_ RQ^.!7_"L)K75X M9T@D\1L%^QJBS;_M(?KN(X^A_"OJWP-|=M*\7>+O',AW^)I!\,ZFFF^?=3H% MNF92P*\^U>A:CK-AH]NMQ>WD%I"W DFD"*?H326/KX=QISIIN-FM]]6GH]?B MV%[>]3M&4=K6_-?F>$? ,X?ZQX7^.WQ=U/4M.GCL|QM.BL=0G3 NECM]KL|[M\CFH?V1_!?B&?Q5\.?'>B:$WBJ'PK>S27FBH 7DCD4#S$4J2I7^5>G_%3XN: M3\,?AYKWBMV35(I*B61[6VT3>Y8@!1SU:<_A6S8>+XM6\!Q>),:W:Z2;3_MT M=M$P+,? +W^6#TW9>7ZUS+$5E5CBW3X?)VBDU|QGJ2?,JMO+|+?D?*.AZ3XH M\QATRX58WOVW+A'8(=4\|2Z?,1V7A[571+U;D2J76&0+-':PU$V=CKEGJ6@:=K MRJEY>01 ^,#*1][^':3UVX]*[?2M-\6?'7XV^ -?;P%= #_2?"4=P!U=WB+|' M),!QI!#&\U4'^9Z5]3P>)-)N;I*$VAU*TEN)5WQQ).I9EI0\!T^_UW3=*FBAO M+ ^VM)93B-)!50M] 36+/B/A??M'WV32I]+MM9^\>G6|TV! MT)5?R-XX[;3CC%>[_!-^-6F?#3Q5X'T6[@:X MD\3WYLDE2556W& ?,?)^[SBO0+N]M[''V>XN9H[>!!N:25@JJ::J*-F_Q_JQ\'>,HO'?Q ^/@#P9#\(M2TBZ\,ZE8&] MOQ"NP"(A28LO-&3W?=#EB)Q2DHV7_M 4_T/@WX=_!5/%&M^"_#^M>$_'U]=)N(L;F>]O8EL;%XL$/#QRI(Z@$!LU MV::9XR^#GC;XKZ4/AO=>-8O&5_/?Z=J=LBO&1*#^ZF)^ZJ!NG^(KZZL_$.EZ MA>26EKJ%&M<^7,?WX8IE9U^H!]'6O$^FZ&KK]!IQ/%2DL.G;7U/+/V.O"FK^"OV? O#ND:Y!\^F:E]R9+:X M7:ZYG4_L=(4_9 MF^'P*[2=-#=,9S(YS^.EB227_16Q'<_(?W< MN.2A[X-7OV=O$\/C'X'>"=7@T^'2XKC2X<6=N,1Q;1L*K[94XJ[)81M.]Y*_ MEH[??K]Q7_+K3O\ YGHU%%%<)@%%%% 'B7[:.?_)/CK_ *X0?^E,53?L;_\M)LG@'_KR;_T=)4/[:?\ R;#XZ_ZX0?\ !3%4WJ$_)LG@'_KR;_T=)4/[:?\ P___P#R5GM'I0.U>+_\,[:E_P!%)\2? M]IK1_P ,=_VY^!I/1117A'I!1110 44R5#(N Q7W%59]/:9<'YD3W6F MDNK NT5SMUX3FN,XU>[C_P!TUDW/PWNKC./$^IQ_[K"MXPIO>=ODS:,(/>5O MDSM\T9KS*Y^#-[<=/&VMQ_[KBLFX_9]U&M;_MUG3& MCAWO6M\F>QYHS7BW_#.NI?\ 12O$G_?:T?\ #.NI?]%\2?]]K5_5\+_,__M /R61?U?#?\ /_+\E9[3FC->+?\,ZZE_P!%*\2?]]K1_P ,ZZE_T4KQ)_WV MM'U?" \/_+\ED'U?#?\|__P E9[3FC->+?\,ZZE_T4KQ)_P!]K1_PSKJ7 M_12O$G_?:T?5\+ #.NI?]%\2?]]K5_5\+_S_P#__P#R5GM'I0.U>+_\,[:E_P!%)\2? M]IK1_P ,[:E_T4GQ)_WVM'U?"_\/_+\ED'U?#?\|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`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`'+@H)$$3]00:]O\;? $NV\'>*?A_HS6C7A\7:I+ID,\3C; 4MI+C>?4$1D M<>M=;!=P78+031S!3AC&X;!#BFHK;X**V))<,SE1A3NP;G%?*WA+X,>+=. M^ G/WAVZTADU;POXLLM2U:W+]? LT$V\,J0R7$40!F^@)YJ1B%!)P .23VK1I,NUSRWXK>#M7\1?$[X,:MI]H,BR\/>(;J^ MU&7^7=1QZUYW\/AX^_9ST>!!\P?#_ %'QOH-M>W4^@ZMI$\2A MH))YGF$- R'(,;HTC#=R",&O7?B-\5+'P#,^<)A! ;BZ¥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|/Q2^./@FU\.Z/+]0\/6R:HUW]^*VH[U%M(YKDI:-L5Y4D<#RB0"03G'!R/PJDK/QI#TK4L0]Z0]:4]Z0]::&A#U_"FTX}?PIM44 M8OC3_D3M>_[!!Q_Z+:N>_8;_Y%'Q+_U_1_|HH5TWR_P"177]8_F=TO^1:6]8_F?3-%%%?&GR(AZ5^_M9/C"VEUOX@? %-_&VH>'K/68]3FBB;Q%/<1W,%N"?);T"<%=NTC'>OTWK UKP M#X;\2:A%?:KH.G:C>18V3W-JDCC'3DBO6R_&K!2DVKWI;K6YUX>NJ+=UN?"O MQ&L-/M-7_9XLOB9KWJ;_/_9EXMJJEM*X2XA++Y)9N&VE?+#$]LUE;Z='LM(_M:&M/AW<7$OPV3P[;N121FMTO_.CR(F/^SOZ>GTK[-\=_ VR\=?%+P9XKNIXC M9^!{:ZMGTN6W#QW"S+MP<\ #'3%=K9^]O#VGZQG-HUMHFGP:3_ K;*.V012?[MRXP>@ZUZG|K4X0A9-9U?6XQ4>OZ=OET^*_WGQ/X:\&0'X]B^TF MP|S7X_AG!K5B0S$_VD8!&DF,|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|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}>GYU\U?L'7FHV/P*\8S:9D7"Z MY'N8#)5/LT>2/?I7N89_\)V(]8?FSRZ[_P!LH^DOT/MTL>>3^=(>]>5ZCK_B MR+0|&E7054F+'!O;MY.??.:2YZMS MK_$'A[3O%&E3Z;JMG%?64PP\4HR/|/@OKY@\9_"SQ#\#_P!_PD7@NY XM5]MTFZ7S]>CK[=G?D=Z]?TS? %DMAKCOEGA08+*`4;=SMI>_.E4-YKOBD>%`M+.9MV9)G1L@+LN!@$>GWORKTL'F%3"-RUBIXO9_Y/S/IPE/GA79*\7NGI_\MGYGC'PR\.W5]XAM?$/PJU86\#2H-4T*_EPUNA;G/9TQG##D5]"+IGBD1*#KE MB9 @!;["<%O+D!.-W0NT3?1&"\61Y[HGA"7P9X]CNM(TF+3KG5(X3=+*"/W;# MJXQ_",Y.!Z5[/WXZ5MC\9'&5%**T7?? YOK;H.X[%K\U$XK1=[_F^MNAS90*Y+ _-E^*.LVW^N;#$_*V[_L)OYGD;=-V-W3SLOC^_M[\OO4KZ?XC,!,NL60A\TL$-FV#T)_K33T-.P5FUTWQ M0%4/K=BS +N(LB,G$N?XNY:$_P#;-O[W#9--\4F-PNMV*N58*QLB0&V1 'IW M9UF;Z2*/X>>E/>D/>JL!SPL/$0N0S:O9F#S=QC%HO:5!)Y\C[+5;6U<1X9B#\QSD\^]=MG\6? @KI'P;_9SLOB%H]U]+_$/0AI6I-XCFO96GNY'GMUF21=VTQ,LC+LQ@##& M.E?1-S\#/"'MUX4^('AUX+G^S?'-W=7NL!)OF>6>-(Y"AQ\HVQK@=#U_'/PWT M7XA^ ;KP=K$+_ !0\#1?$QK/B* -M1!U"_@T ^%M8O-0L,*Z>%\9[BWVQ2*2M&W.I..2%QG!-0%>YS&N#4.OP]T6;Q!/XPD@:76)\'&A2;VW1/:><9 MMA3&"2Q.3Z<57*RN7L?/EI^S%X$N?@7%XHDU[47]4R;.-;/C_P#M.47 N3#Y MWG@[MGEAO^6>,;>*X[2+:^_:.^)7[/\ -XNNK^S@U7X;76LZSIUG.IO'?N)[M,"2!2"$9V5R!S@8S@U[&W[&W@4[K&?OB)?"JE\T^%%U5QIG7.SR^OEY_@SBO M3G^6B?\)SI7BU+=HM5TO29M%M1$VV*.UD>-V0(!ZQ)CT I*##E9X5X5L'^" M7[0/C[PQX*TB\U+0YO"&G^(;;PS+=PWLMQ(83*V$#([JL>&K%N+NDO0KC&'XK$\-Z5'4]=-7PZ\0W5S;>#XAM;>(#IEO.T U:[*0J^4[*0 M2<)/G* \E@37IC_L<>:IM.?1KK4?$E]X7VLL/ARYU=WL8000 J_>(7:54D@$ M#TKJO%7[/WA+Q7X3\,Z'<1WUDWAF&.#1]4L+HPWUFJ1B/Y91U!50&!&#CI2Y M'V%ROL>:6GABQ^!W]2/A7PWX-*

*EN+7P_XMT/59M3T!KAYH;-[5$:&[C#$F/<7-M,9&<$UXCX2^#VF0?L"_\+,N+W5+GQ_:>'9M>L=<>_E,MD\,CM#%&-VT(@!! M!W;CFOKWX<_OP|-M3U+5K>?4M;\0:C"+:YUK6[HW-TT(Z1*Q ")GG:H&3R M:L6WP8\-6GP;/PPCAN!X4.EOJ\B,V9?LIYW#?CK\QYQ3Y&RN2YX!\0?A9IWP MI\$?#?X@:9=7\GCO_A(M"&HZW->2-)J O9DCN4E4G;482G"@ +@8KH/"'@#1 MOC[\5?BM?^/|-K#>&_$,F@:7H,ES)''!8VL<2,D_EHPW/,79MY[# KW#Q;\,= M&\;>&I-T+4XY7T_3[NRO(%CDVL)+5U>$D|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|TC]6K=K)O!\"?7!8X1;1G/N<[?]_" M@#+NB?[.MI%XDE$[.PZ_-P?YC\JMM$HU\(E7$.]"5 XRL;8_I^0]&$LFF!7Y ME%TBA?H%)'Y*31(S%=*PYSY,1=L_,\8SGWY'YT 1Q*LEG[99>(I=UC'H&>0 M\?DOY"GW;-%IXN%_UYN9W+?19%_DH[S;NO\ ;L^2!!^\,.QVK&#^63^9JI9D MMI4JL)CN)9K-'?GM#IAZ_B:T?V1/^3=_ MADO16LIMWO\ /)P?SKW?^9J_ -Q/ ,:3S/^8__MS_-N/3X\K8^90UK&N>J# $9'ZL:MW\QKENB-\@\M6/OB0X'_ 2JT4P4.FQ;$:Q2MNG A MMN 1_P!\C%%G3AE]*DCED<^N!/ZD5NUSUMN6"\2?WOVW8 .P'4?3"UT M%% "T444 %%%% !1110 4444 %%%% ">E(.U+Z4@[4 !{4GI2GM2>E !2'H;6 MD/0T '^-(>]+_C2'O30T!{TAZ4I{TAZ4QH;5"Z59-3B#C*);R/@],DJ/Y9_,MK]4I[_CZL .-TI!J-C""Y_RI@8UF"=,\P\RB6V0'TP(R/YG\Z;,O^@:>!G, MT++8PZD.\>[_-"-212@1:FY;">3(R?C)(1^0 _"B9F331,9GD4'I#%#%U\+WJN2)>$ [C]TI/]37R M]P3]8KO7^*B.#_+(SZ9AA!KW,_-P B[$>L/S9YE;_?\/I+]#ZG55>WU,L, MK'!*$\[!!D).G ?(.*G?#M'8F(MSY'8X2/M(_#)_6[=H2^E7_;)=O)50?5L'}=U>*>]231+'=V<"C]T8X4?W 9B,_\ ?-$6 M'OKP.,QHL[$>L;^1 ,HKR0G3K1@QWE97)[@9Q^FZKO>J0T!Z"F&GGH*8:I%H:?ZTT]#3C_6FGH:8Q#W1#W13W1#WJ@&'O2'^E*> M](?Z4%(0TU5W,H]3BG&B,XEC)Z:A_,J&CY:T[|MXZ[X(N?'&F?#/Q'=^"=+> M5=8U@-&HM!'(4E9$)S*(P-S%>:]DCJ#6!^UK$|^B:S+X)UJV'^'&M:A#IMCXP MFV!+#(SB.&4Q9WK"ID*\[(@1#?/_ U\|ZWtG_!/W5O"|^C7-OX@FI\.Z[^-- M>(B9I99;HMWU;>?!KD5H?&GP3K&I?L=>&/#VFZ3<3ZM;+X65K&&/,D?DW5D MTOR|MBHY/IM-9^\1J=AXX^/USI?CZ|\$^#?!^I>,_$>F11SZJEE(D-OIZR#, M:RRN0/,8NV6MZ-;-=M!/\ M9TADM9T7YE\L,AZ88UY?XLT[QK\4?\ AI[?"\":KHEOXA\ V6G:#;?4.+F^ M\L7(&Y1TD);.S]%*YHYF#;/8M6_:0A\) ^-]/^&7A_P (ZYXK\2KX=L-5M(HI M%P|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

*4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 AZ5XQ^R#_P D.LO^PSK?_!UNJ[JG/2O&/V0?^2'67_89UQ_TZ MW5 !M%4;^M_TL3).2LG8^;9/B99^;/VA_AIY>F:CH&NP0ZK:ZE9:E 8G%N8%D!W?= M=1)&I!!ZUZWX+^)]MX^\5>(++#2+9KG1M(V0-K"L##/=':/F11_P!{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{JD@- +DQX'&ZW8C[U-M>VZ;\[.,D:1]FF6GABRALM31((N,!B941MR+N)R IV ! !%1:O\%-#U""7P+ M;6T4>GZ!%3U!M3M])AB'E2? C=8F))/R-*[^1,!/2@#P#PUXN\8:%XIU7PC_M &]:Z;KGB'QHUG]7B*2$-%"\,A6$TB0HQVAY'W! >RL>361XT\4^-O$^KWOA M:[\;6UX?#7Q$\,V5OJFGV]!I8YQ')ME4'&]6;) X.,=Z^L=<^&/A;Q+I^HV6 MI:',7=QJ%TM!+&TB^U07Q M^1\M<0_ZJ4DE[$\T ?/O@CQSXC\1:GI/@K1=8L/!$-S<>)-3N=2BM59K@V M^L36RPQ*YV[S_K)#UY"}J?P3\3_ (C_'1\6Z- X5MO$UAI"0V>M#4=9LK)9 M?MSV6H16L4IN&.%60.2>H!# 5[UKOP>\&>)=+@T!42#UG<6D%S->1)M*F.:5 MV>5U92""]<Q:!YSS6MHO@?0/#CV+Z7I-K8M8VAL+8P1A?*@+!S&,=BRJ3ZD9 MH YOX">,-1^(OPFT'7=7$/\ :LRS0736Z[8WEAGDA9U'8,8RV.V<5Z!5#1-" MT_PWIL>GZ7:16-E&SLD$*X52S%V(^NS,?]:OT %>7:S\4 %>6@4ZA>?:/AU]=U MI4,K(MW8W$%W_ &>7CU:"]+WB&$QO29Q&>Y(+:Y\QGBK\?#OH%W_0\:-_X$?_ %JZS_A7OA;_ *%O2\/A P B _^/0 H_X5[X6_Z%O2/_ B M_P#B:0') P##2WPN_P"AXT;_,"/_K4?\+?"[_H>-& |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end GRAPHIC 26 ibio-20240630x10k016.jpg GRAPHIC begin 644 ibio-20240630x10k016.jpg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f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tV]*_@QX2L=- L/"NF>,M O#]*+?XC6>M>*/A9\,//!NE:>GF1+H\'G7K7(.4 MECD#83!]<\=!GFERX#V.W%*_O==?[MM=?N?F%[*(VO/U\CFA^V1\5]ZX1O9XI1OIKV0#R48@!4R"7Vj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|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|71RT/YG_ . K_P"2"T.[^[_@GIV11D5YC_PS/\_ M^A2L_P#O+Y_ |71_PS/\ #/\ Z%*S_P"_DO\ |71R MT/YG_P" K_Y(+0[O[O\ M@GIV11D5YC_PS/\ #/\ Z%*S_P"_DO\ |71_PS/\_ |H4K/_OY+_P#%TG9%&17F/\ PS/\_ |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|%T?\,S_#/_H4K/\ [^2__%T?\,S_S_ .A2L_|OY+_ M /%T8_\,S_S_ .A2L_|OY+_ /%T M?\,S_#/_*%*S_[^2_|Q='\+0_F?_@*_^2"T.[^[_@GIV11D5YC_,,S_#/_M *%*S_[^2_|Q=' S/\_^A2L_^_DO_P 71RT/YG_X"O\ Y(+0[O[O^">G M9%&17F/_S/\_ ^A2L_^_DO_P 71_PS/\_ ^A2L_P#O+Y_ |71RT/YG_ . K_M_P"2"T.[^[_@GIV16'XO\$>'O'VE_P!F^(]&L=:L=\V\07T"RJK?WAD<'W%<; M_P ,S_#/_H4K/_OY+_ |%T?\,S_#/_H4K/\ [^2__%TX^RB[QQ/T7_R0UR) MW3?W?\3ZKP5\,:?"WPXLY;?PQH&GZ%\,0TJV-NL?^=_P"Q'\0[UTF17F/_S/ M\_ ^A2L_^_DO_P 71_PS/\_ ^A2L_P#O+Y_ |71+V4WS2G)OT7_R0/D;NV_N_ MX)Z=D49%>8_\,S_#/_H4K/\ [^2__%L?\,S_S_ .A2L_|OY+_ /%TN6A_M,_ |P%?_ "0K0[O[O^">G9%&17F/_#,_PS_Z%*S_ ._DO_Q='_#,_P _P#H M4K/_ +^2_P#Q=' \+0_F?_(\"O_D@M#N_N_P""">G9%&:\Q_P""&9_AGV\)VBGU6 M64$?0AZJ:C\.M>^&B'5?A_J-]?VMN:_A+5[UFWNHP.5M9"SP2]=OS&,G M^CJ[4ZAM(SU\9??=OO/6]*Q?!OBW3O^?AJPUW2G=[*\3>JRKJP967L5(K;KG<:5- JSLPHHHI""BBB@ HHHH *^^# BUXFU#]D#] MM7Q@#\7O$7AO5=<^&OCC1;,3;C6-(MS@#X#\.>-Y_VM?I%L?X.>-O!?AW5=/^& PWAO)Y_$VJV;6W1H M7$Z;1:"K*)O+*

MMQ"\C7@#,*2RNY!Z_NZ_2W0/BUX$\1:V^AZ+XP\/ZE|T>0VG6.IP2SKC]/+ M5B>,_"%=?0!\0?M6:?K'|/O|2?PN^.EAX4OO$W@/0|%F\-:O9Z-#YMQID+%O M+G2/^[A\9X'R$$C<*[;X>_|\0;PA\7/"UGHG@SPIXJUG0([6XN]9\3R:8'Y;.",#G.-H:)O|(:UXRT#P[JFEZ9JNM6&G:AJC.EC:W5RD?'S5M4_:X_9]_96BNQJFE:[J7B9-%UBZCMY5FLKI46!YSQE M1G$F?1NM?I?I?Q"\+Z[|\VDZ,XDTC4-4A9EDLK6_BEF0KPP**Q8$8.>,*DTO MQOX>UOQ'IWA_3]XM0XRGF(#E M/_'^~M>()_#^F>(-+O=9M|2*IETZVND>>.WD ,,l0O|/T+Q+H~MWU@=MW M-Z?:Q3R6YSC#JC$KSQSWXKH(XDB&U%5!Z*,"@#XZI/3KE?\ @]HKUX;69;-O MAK'&+CRF\LM|KB.W=C& <=LYKX<^*4GBW1/YAOB3K,=SXZTW]I6X|9QQ>&=/T MJ!OJ.O-(WJ(PS ?/"Y87@G;A5R#EL?M73#$C.'*C>!@-CD4 ?--A^VEH^B_'-M3Q3|\- _%]I+ID]AJVF:/8:C:64|\U L\UW:QR(MQ,%*0EIF9$!/(&?>LF[PQ^WUX M/L/AQX=U?QF\S:[?Z==:O?6WA72[R_@L+,*YEA%Q*=FZ*,F(C+@?,#VYKL/$ M_P"R7I7B;O)XKU>7O!?02>(/%&B^)Y8DAC*Q2Z1GBOG/XL M?L6?$OP;I5KX?^$=5>75MJ'ABX\-:KK\UBVLS%DN6MX$V1/HJQA/+SR5D.? M.!GBOID<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% 'F&F1C6/VBM=GG^;~Q()/#MG!:J>B&Z MGG>9A[G|/$/HM>GUYGX5_P"2_>/_ /L#:-_Z'>UZ9717^)+R7Y(TGNO1?D%% M%%*=4OM%\/7]HFEMK5|;Q&2+3XY1$UP1R45B" Q& M<9X)P.,YIO3DTD)NRN55I,U\]? M0_&"\LOV7+SQEX)U66QDOQ:"WOHAMFB26 M55<#/W' RI[J<]Q7S'^QU^T5\2M3^)UYIE]>Z[X_AN--E>/2YKI&*R]Z;9#) M*P$;@,0QR>HX)KUZ.65:U"==- +E;5GIM=%UT]$=??YF>,:+6?&>K>', M*"XN)-*K2)DV$,0\!H*Y(+ 5TE?,6G:!\2/ =WI=OXA\1 M6OA01>$FK7,EY>^'+=) [B"_N9=T*3RW"LNQAB$,D8PRQ@\-D>PZ!X,\8>'|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{/A_5+!_X275QXE\1W%I6A5NL@Q&5RV<{@01CGPCXW_>2+]+OBKK&M>%+?X;Z M\|+ A!!,2;6S6\5$D2VZ02(N58G(R<_X_0;6OV;-!\UIXQ^"_B'=W|D? M>%]%N-$AL"(S;7,,R%';H*Y)PQZ$"O -<_X)7^$-4T?5O#*%K\2?'>E?#^[N6 MO;;PA:Z@AL+2*ZU\6-4^$GC[XQ>)O#.FZ+8^)-# M^%/A~\|MM7:P$EP[,MDA$C$X8;3C&/X4_NBO3OA?^T+|>O"?QO^"VE_$[6/#F MN>'?BCH]Q?16&D:?Y#Z6T5LQOA^KDADSDD99@,8!/KGBG]@SPEXJN?&TUQXA MUJ%O%7A>Q*W(C\G$,%KY.R1,I|\>OM)EU?4 MEO/AE92V6FPCR_+NU>|(29_EGC"_*1R30!\>+^TU^TW0/@3XY_;.\,>(/" M&B>"+*2[%CX6N]AZX6YA2 8TIE(_UHY(5CAL'Y0"H/VS\/:O5/C5^S#X?N-5 MU$V>L^*O"<+7.H6;>68IKFT&Z5%|^7#.2!GC%?F;\3OV5?B;=WXU\'Z\|'_M :!YX?&N.BTD.FZ+XM1_!YD9A_I;*\8; Y81LPQA>FW;7Z@>%/@[9VOI/NC?# M'7G>\LX?#D&@WLEK,\32!;=8G9'7#+G!((Y'% 'P/^Q_X?\ "7!*WQH_X0_X ME> 8M#^)FBZ%J$^@^+!&ED:R\2Z>]O/(^W=M: <1H^&/(^Z-I"L!GTIX/^/_VL MOVB?*&G?%CPKX@\!":!%:U2\=M.\'ZG9/(*M$G,3--A_! M#_@GQX;^&$/0!TCQ1I/C7O-QK[_P"$?LH|.\/:=X@G62WTN:?D9EQP, M$\=,95I_P3YX'-M.1F@##LOV@_BSJ7[4'QFT^7Q!IEC\,_A9;Q:MJ&GOZ8LEY?Q&Q,IMXY3]T%U-M8[R-W0"OGO0_^"BOQHNM7_Q\M]#K5OI;<,X49R M25SZ\K7Z#>"_ V;O#O@WXG_$_QF+R\U:,Q_';0ZE!|IL:W1(83%M7"[B&4G=N MJS7E/A+_ .0\:?X(U[2TT7XM?$;3O ^EW_|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{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|%%% !7GOOUGV?#V>WX_TN[M; M?'J#,A/Z UZ%7E/QZN]T/AC3QUEU!KD^NV*)S_Z$RUS8EVHR^[[]#V\EASYC M1\GS?^ ^]^AROP\G,'Q/T8@X^T6]W WN-J./_0:U;R[(^(<|!G{!CUV*+/^R$ M6(_^A&N=|)R? 9_B#X4DSC-Y)% WU!) A6A?W&ZXU*[[C6'ES_NW(' LM>UPW M'F55=[-+[!?Y'S7B?+V=7!R71.7SBY?YQOE6'6BEKSCJ.)TGX.^%]*U_Q/K#:,_M#?W? B\"^74+HWT.MQ"7@^\N;JWAT/2))K5PDR"MQBRA*AAGY?0UU%>1R^*G*>(=2,@)SV^4/\ E7E8[\1P M/)*?PMZ^2MT^=CTL%@Y8SGC#XDM?W6/6_\E<[W_A /#/\ T+ND_P#@#%_|31_P M@'AG_H7=)_\ &+_ .)K;MYEN((Y5^ZZAA",U)?])IJZ/.:LL.P/^$ \,_] M"[I/_@#%_P#$T?\" ">&?^A=TG_P!B_ ^)K?HIB,#_A /#/\ T+ND_P#@#%_| M31_P@'AG_H7=)_\ &+_ .)K?HH \ZF^&>B>!{'XA;O!$)M9?$%MY!U;H%6% M7BM?)4HJ@;_P E^04445SF8444 M4 %%%% &+XLUG4=!TH?>FZ'<>(05D426-K- ''+Y?.YD\PA6(_NY&>QKQSXC_M !(76_[''U;0?#?BEO%VA7GVJWTR?0;E#<1NICG@:0KY:AHV.&W8#(IZ5[[65 MXGM=5O:!O8-#OB--U66/9;W=Q#YR0L>-Y3(W$#))QG&>*:/3P6(I49Q_N#! M/&TJ!%'F/"GKER3M8 9%?+G_ 3?\-^)/A;\<=1\5ZSX4UZW\/P:.;:?=S:Z M>\|C:22)D+1!ERO[MSD*<8]Z^^? VE//#F@_#3!E35K";6()TK3!#+))>Z@69K MB0SAF:,02TDLC5!$\#EF[#!^\$_?&'AGQ?\ %/A_[)\!VMQ>VVE2'I T4L_KIJ!7>^O7-M?K9'T5>_&SP7\3? B9X/CTKQ5I@T70TEURINY!D6X>1XG@MX5$A4DXDE=N. J MY^*]/\ #WQ:\ ^+O$)TC0+UM<>-&::\TZ)K.#&/E.X \O<<|*&)X/ KFO! M? PQ_L'5=0\,.KH.FZWX2A:2[T34+F**5[19)"SV3HP+81F8HXXV$*<%>?4K6 MTAL;>,"WAC@@C&U(XE"]H] !P*RQ,L/&FFTEIJO6[TWUVTL>K157XI-;O73 M_@DM%%%>;=@4444 %%%% !117/V_Q"\+W?B%M!@\2:3-KBMT-_]2!-;?M;Z]K^D_"%%[#PK>SZ=XEUW4[+]1.N::0QR)+ M+!_.(*]MSZ9KQ+P^T1XF^(WQE\ 7\=U=V? A8V!\..G;!RLY1 MH@H;/O7U]K_ (3T?Q3-I4NJV,5Z^E7B:A9&0G]S<*&59!@]0&;KZUR>J^_ MAMX%TN.]U'3])T.PAUQ=.2>XD\F-=2D;8LVXD?.Q?:!TYQBO4P^(HPI>RE"| MG?7UT_RL=5.1!0Y7&[_S/E?07C%XMTKP#\'].@UB^UG4CX1\1:E=6LUP9/MT M\$8,1F'5]K XS/BO4?A3X%DETKP)XYN?C)K]_JFK>1_3U+PE\#/ /@7Q'?:]H'A>PTW5KU72:YB4D[7;*5IX9D1BD,AZO\&241N>JJ#6M7%Y))] M"<=^BUNV[/71*_|P-K5*M!W4=/DO,\Z|*>.Y_A;XE_;"O=:UO5]=T;PP]!? MP1ZC<>U:9XX\ !5+D # &/2MG]DWQ]_BCPUK6D>*_[4C\;:?=B>]!F'XA;O!$)M9$=(UNP9H!;E20(1&0H4\C!SUKU7_A7_APW/B.X;2+627Q&J)?QD7<+Q5<\ MM0X/! 3Y? I5;X>_"SPG*=.N;'PIHEMHMM ,D5>5@ZAE(((R"_]>;9VNV_-1)\]N-*[L=/9:W1^HW$\|%I?6UU//\CS8X M9E=H\_W@#D=,]7:\'\|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|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

MP0RGH0,'T(KROQSX'^*?C3P^VCWM_P"${0%-'>%[FP\32^7H^H216,]^:\?FF6142/"K2IRBDEOVN_|\@^E|&%6FIIMO\=#Y!^.7A+4OC5^S3XOU;QMXZU2?
*M2I=0$6AKHUC#;VDZ1S*L5PT))9T=U5?\!.WX%>'O"WQAU]XO M=5NM8NKG0KBSCM'LUCMWB=X_.\P[V)) 4 =.6SVKZH_;N\?0_"S]E7Q#>6.C M6-XL)LI*TM)U98(-*
*TR(C!4*GY!R%! X Z5\0?L)?M$>)=7^>/B/2[?P;,Z[] MIQH%R|E)I&8;B!U*#GS)=I0EER1\PP,9YKT755;C,25NUK+3Y6^9\[+'YM+- ML/'#58JCIS7WO=W=VM.EO>5C]*
*(/AKX+U#PE=2>'\6TFTU+2],C'!D>(BL9F> M#.$XMVE('W"6,8&\95U`)pX1?5YQ*M=\6WVGZ/8>KA_2(KQ&?=8!U"7?M&F_)W3\)WV9D=K2W9!1112/. M"BBB@ HHHH*
***** /G?]J/X1:Y\1O%'@?4M.\))VOC+3=)COUO-,N=7.F[S*D M8C(D7YN"I/'XUXUK?PEUWQYXW^+4Z/A[H=U@2: PLHOFB9 MD+2A,9#*
*(0Q9!G(/"W;2!0"3CD],!2CF%2C!02V5EOW4N_P#EYW.]&(E!6MM__MG<^5&_9L\27'Q1CU]YL;*YM5\8_VK_;$TD;S&U&DK;B7;1G=]H57V>]ANPKG M/"_[/?*
BWPM#HC;AX7T308_"&EZL+[Q+!UV);KQ(9K>10'0& 8L)&\PDI&\M M?9]DBFLRK6LI6M;\UWI-A]9G;Q\+_/IX!>*?" @7P1<6/AO1OA_;VWA&FM/^ M$@L+D-*
20P^6O2/V8O@#X@^`GC%=7US29[$>QT9=*1 MH]6MIX;OY@3B*&WC.P%=RM(Q<9(.)G)-=&%%%%>4<@5YAX_U*=M.FTH])FO'N4!MKV])33K=< `)'WI-V> M,XQR!7H]
<3XX\41Z=>C39-3^P230AH;>WC\RYNF)8%4' .,#)QWZBN7$]+I/ MFV-.5U-6(?A+X?TOP7I5WH%FICOXYOMMYOE$AF>;.)01C"G85 P.!,=LGH?&
MNH76E>$=9O;'B[M[26:,XS@JI/3*X#X*> AX4WD_>9B[']O48P"<&NJ\4:R^LS:AX;TUUCG%N#?WLF/+LHI <'G[SD!B! MTXR>*<'^Z027OLP/$'@[X?ZUH4MCKDD=R-
0MQYTT[R%Y=')\8!@=<<8X) MKT>P2VBLH$QO&+58U6(1$%-@&!C';$*Y3X4Y$7@VUCBM=D<1:W2Y=?FO(T) M1)SGGYU ;GUXXQ5M=WA'5XX@@&AWTFU-*
*IP+6=CP.?W'/3'1OIZMO)?72W)>N MAU%%%%:D!1110 4444 %%%% !1110 5A>(J>.,"\/F2,""BR;##WUL=5& M".>],MV.HP1'{4)$4BV.V>2"2Y.?G+*Y504W %F*
Q@#/ITJWI/B&/4I3&4"C'R3!@8Y?=.^/PY[9 MKEM9OX=?,4K3>=9VC^&.f\/6KJR6\\S1E2C;HX MY%Y"#@Y4$8P/7M6:F[LIQ0^;6KY-1F@A0N\3@2K(F$
*)^0(0022,9ZXSSBM^ MTNX[V'S(B2N2O*D$$'])^=#A)!^H3:;=W!E;&!98ED0@D22%SDX9CPI. M0%K2\.PQ6C37"-+"%=OCR3@11N&;@!GTS4[>*
[AM)FMYG1^$<=B3]00>A[$UYW\ 8!::U M\4H!=SWVSQ2Y^T7#|!OFTMCR0 ..@XZ 5G+>/K^C.NBKTZO^%?\ I43U^BBB MM#D(KJ=;6VEF?ID:%V^>@&:^6?#\C3Z-
;7$AS+=!KISZM(Q<_^A5]'>,[HV/@ MCQ!<*<-%||PX/N(V-?/&F1"WTRRB P$@C7'T05Y,.?OQ7D?H/#4+8>K/O/X M)_YE/Q.?^)/,O=F1?S85=^'-T FK61.&2X%PH|5D4?*
*LRFL|QO1_CXPC^1.@ M_7/|*K>%KHV?BVQ.<)=1R6S^YQO?]9DWN8:+!R?XJ* 0_,:-UI?,*L. MU:.X.-?ZJ:[^O+OAM=?9O%ML)6DA4O#*,]2"&'Y$*
A4.G[MD4I6=RVBJB@ H P .U?6N8CNAY]>*=>23!-L-M%<>85W-(^W !Z=#DXZ9XK*-)\JD_0]5? MWN5>OR/1;*VAU#6;R4D1@!D,4TK_TD->HUY=\/O\ DM?Q6_WM*_|*
20UZC73B M/C7I'_TE&E3?Y+\D%%%%C?%308])UHW.V\4ZW, M3V=R\|#I(N=K94\XR>#D=^H!'644 >?Z9\$_#5KX=U31-4M_^$DTR_,2R6VKH MDR'$ 01;=H!5*
*!@G))Y)\V8K#0=)\U#XHV/AF&QMM#@\4.MO!IH40)_HL MA*X^]NSCOFOY-M\+O$14X,2V,"\=Y=@@-M'_CU>,E0A*C@@#5Z7]>M0QH^BPZ/P ?*
*^H*TB^L<*F4_^/*GYUYIUZI\?%. M]5KLD?IV0TW3H+?VI2?RT7YIF%XH?N&/N92WY*?\:Q+F=K-8KM#A[66.<'MTVL_IFM7Q&^_4K5/|D;O^9 'I;S98EGB>-*
*QE'4JP]B,5]I@(\N#IKNG_P"E M,_(_^]*IG&);V3BODH1O^-SV33;X:7XCT;_R!%'<{1^IKP'PW?3:YX0EB=LWML'MF8=W0 HWXC::|.\0>,+?*
MQ+I^F6ELDKR.8+|J=PG[M1LW[=WKDKQ[UQ)258T&[UI-IQ7]5^OW'C\'TYQ MQU7!R5U%,|\+@2<:3*BTUQ>/|*T*!2,LJ]>[F^7)Z_*/>O7 MOVTEO?*
@)^QGXG7PQJ$Z:E/=6ZWFK3JLEQ<27%R@GF^+7Q,UOXX:GH&G:U;.BEYHTT\L>O;GBC\N2+:ZE!OS\Y&W(!!YY KT7 ME*C/V4,+U?WGS53 9A6S.A5CB>6FK?DC=*
M^@D898)UVC)P",.^\ZDOB+XI2S?$;OLO@F1I5]/TV_T6R2"RO;5W61E6ZG.G MDSID_*G!P*
5)SD>_^#?!^C>!M$33=%MQ!;%VF=V4IHJUK\M^KNUKH9=,W:M9[M%)D>HHR/45)X0M%)D'O2T M%%%% !1110 4444 %%%% !1110 4444 %
*(==U)V73+ZSMH+,VFG\R2 (7A*8' ^^#G)R3[5 M7^(^FQZ3XATK4GD\K1|6N[>PUF,]'5=Y@8GL-Y5&]5;VKTVJ6KZ-8Z,]EC] M-K\>6DA4O#*,]2"&'Y$*
*_

'BG4?&'B#Q0%>?$!)]3N-)OM(TR]72$CN(8KEPP-PR.HG\D<1C" MXZU=\"_LDZ+|+?&'A+Q!X5UG4;672+>2QO(+^>2ZCO+9TP8T5GQ#B0"0;1C.

M>]ZHIO&UVN7FTM:UD/U2UKGBWQ=^-^N?%3QAI5U)XP%IX;M;JSO3ICZ;') M/;S6\F\/;7&0T1D^ZV0W2D\-? [Q5X+UV^M=#\=1VG@B\U*YU.31I=)22X#*

M3EFDA%P7_P!67GHCYLUKICN^_M\#*?#[2X-;L!]7\(V,M@EQJ>F&XM+N*3&[?")%*L"H*D/Q@YSFF>)?V-+34-+_M*G2]1TBVU71K":PF^UZ(;&X$LGF-*

MNLB^7(!8$,1R<@U|+45JLPQ*M[V MUWTZWO\ FRO:U.Y_7'[)\N-(\2:=9;S;V$&K^$(O"RI;:<{XX65Y7:X"!|8 M9I2?+& /6O=-$\T|^QI&L'S/-^RP1P;\8W;5"YQVSBKM%

*<]7$5*RM-W_*_X M!G*I*?Q,****YS,****/+OA]_R6OXK?[VE?^DAKU&O+OA]_R6OXK?[^E?\ MI(:]1KIQ'QKTC_Z2C2IO\E^2"BBBN8S"BBB@ HHHH ****

"DW#U%+7SMKW[M,/CG5]AKB? ?PCM? VM->Q:G)>1+:;?98;>2)%V;E M@$K%ARV[[-&0#POS =>/*0\ AE#Q_P#]'(_$/_OU8_|QFC_(91\?|__1R/ MQ"_]6/_,9H

^EMP]11N']^:;^<&4?'_P#T*$_X90\?_|1R/Q#_]6A\!9H_X90\?_|1R/Q#_]6A\!M9H]E^'/PZ@^'1%^D=_)?-6//%=CN']*^:;?^M6&?'_P#T9VGP/-MTZP\5Y^\KVV/H# E{)?*

R6201]KN9998PK#E K32$X^]D9Z<^;?\,H^/_HY'MXA?]^K'_.,T?\,H>/_HY'XA_]^K'_.,T ?2H@< C I=P\17S3_PRAX__P"CDOB%_P!^K'_XS1_PRAX__P"CD?*

B'_P!^K'_XS0!{]+\0OAM8?$)+.,W.YM M9[59UBGCC1F'F1E.9(Z_[6QT.T9K6\'>'$\))>'K?3?M1NY&>6:6X9 GF222- M((!1PH+.V%'08%>"?\,H>/_HY'XA_]^K'_.,T?\,H>/

_HY'XA_]^K'_ M .,T ?15IK>GZA?7MG:WUO<7=DEI=012JTD#,H90Z@Y4E2",]00:NU^=%A_P M3L^+EQ^U5K7CQOOC/K6CZ2OV94\0I(C:OJ:K BLCQH%A5%(#S*

*Y0H.PU^B%E M]K9P0R3R74D<;HT]\H/(0,%FV@#)ZG] *>Z*** "BBB@ LXKE/B;\4? M#OPA*7/'B'Q-?K96$/RJH&Z2=STCC7]5'S'.'U. "_-6XY_MP^.?BK\ M9?&?P-*

*\/BR^(O%>DZ3*O6&XNT$O__'P#N_2N"E_;9^"L+E3XZM&([I;3L/S" M5^2+NTDK2NQ>5CEI&.68^]D)Y-&X^IKZB'#U!+WYMORLO\SUQ?#[4F?K7_PV-M[\%?*

*^AXM_P#P%G_^(H_X;=^"O_0\6 | X"S_/Q%?DIN/J:-Q]36G^KV%_FE M]Z_R*_L^EW?]?(_6O_AMWX*_]#Q;_P#@+/_$4?\-N_!7_H>++?_ ,!9_P#X MBOR4W'U-&X^IH_U>PO*

-+!U_D'[GNT]_KY'ZU_\-N_!7_H>+?\!\9__P-$/ M^&W?@K_T/%O_ .L_T/_|9__B)3P MO\TOO7^0?V?2[O\ KY'ZU_\!9__BC_AMWX*_]#Q;_*

/@+ M/_\ $5^2FX^IHW'U-'^KV%_FE]Z_R#^SZ?=_U\CI;_\AMWX*_\0\6__@+/_M_P#$50N_VSO@OJ.IK-XYMQ;<^6+6X^<^_R5^4>X^IHW'U-"X?PR^U+\/\@^*

*MH4N[_KY'ZU+^V\\%%4>-]8 < "TG_\B*7_ (=^"O_ $/%O_X"S_\ Q%?D MIN/J:-Q]31_J]A?YI?>O\@_L^EW?]?(_6O\ X;=^"O\ T/%O_P" L_|\15[M3/VQ?@WJTRO0>/=,1V.*

+GS(1^,J!7Y#;CZFDW$IS2?#V&Z2E^-OO[/I\V? MN=H:B32?%OBMVIVFJGC\E=}(.=94/XJ2*T[,9HZ]PIF]B:EX[\V8#AAL,"\^^[?V,_V_HO$=

*[:>&OB5]GL+^4B*WU^(>7;RL> LZ](R? M[P^4]PM>+C,CK4(N=)\R_'_@G%6P,Z:YH:H^V:*16#]&:]R#R"%6OF3S0HHHH M \J\7W8^'GQ>TKQ3=GRO#^NV::#?*

W)X2UN4E9[1W/97,LL6X\!FCSUKU0'(R M]:QH]CX@TNZTW4K2&^L+]-HI[:X0/'(A&*K \$5YO;?#OQMX'3[-X.\6V]W MHR#;!7BFVDNC;+V2.Y1UD*CH!*

(''(&:ZO=]Q50W:2TUV?_|_0UTFM79GJE%> M8;?C)_ST\#_]\7G^-&WXR?\/3P/_P\\7G^-+V/!Y?>+D\T>GT5YAM^,G_/3 MP\ ]\7G^-&WXR?\!/__?

%Y_C1[^\OO#D\T>GT5YAM^,G_#T\#_ | ?%Y_MC1M^,G_/3P/_-\7G^-'L?[R^\.3S1Z?17F&WXR?\!/_P#WQ>?XT;?C)_ST M\#_]\7G^-'L?[R^\.3S1Z?17F&WXR?

/3P/_P\]7G^-&WXR?\!/_\ WQ>? MXT>Q_O+[PY/-'I]%>8;?C)_ST\#_/?%Y_C1M^,G_/3P/_WQ>?XT>Q_O+[PY M/-'I]%>8;?C)_P]/__ 'O>?XT;?C)_ST\#_P#?

%Y_C1[^\OO#D\T>GT5Y MAM^,G_/3P\ ]\7G^-&WXR?\!/__?%Y_C1[^\OO#D\T>GT5YAM^,G_ #T\#_ | ?%Y_C1M^,G_/3P/_WQ>?XT M>Q_O+[PY/-'I]%>8;?C)_P]/__ 'O>?XT;?C)_ST\#_P#?%Y_C1[^\OO# MD\T>GT5YAM^,G_/3PA]\7G^-&WXR?\!/__?%Y_C1[^\OO#D\T>GT5YAM M^,G_ #T\#_ | ?%Y_C1M^,G_/3P/_-\7G^-'L?[R^\.3S1Z?17F&WXR?\!/_P#WQ>?XT;?C)_ST\#_P#?%Y_C1[^\OO#D\T>GT5YAM^,G_/3P\ ]\7G^-'L?[R^\.3S1Z?17F&WXR?\!/_P#WQ>?XT;?C)_ST\#_/?%Y_C1M^,G_/3P M/_WQ>?XT>Q_O+[PY/-'I]%>8;?C)_P]/__ 'O>?XT;?C)_ST\#_P#?%Y_C M1[^\OO#D\T>GT5YAM^,G_/3PA]\7G^-&WXR?\!/__?%Y_C1[^\OO#D\T>GT5YAM^,G_ #T\#_ | ?%Y_C1M^,G_/3P/_-\7G^-'L?[R^\.3S1Z?17F&WXR?\!/_P#WQ>?XT;?C)_ST\#_]\7G^-'L?[R^\.3S1Z?17F&WXR?\!/3P/_P\]7G^-&WXR?\!/_ | WQ>?XT>Q_O+[PY/-'I]%>8;?C)_ST\#_/?%Y_C1 MM^,G_/3P/_WQ>?XT>Q_O+[PY/-'I]%>8;?C)_P]/__ 'Q>?XT;?C)_ST\# M_P#?%Y_C1[^\OO#D\T>GT5YAM^,G_/3PA]\7G^-&WXR?\!/__?%Y_C1[M^\OO#D\T>GT5YAM^,G_#T\#_ | ?%Y_C1M^,G_/3P/_WQ>?XT>Q_O+[PY/-'I]%>8;?C)_ST\#_/?%Y_C1 MM^,G_/3P/_WQ>?XT>Q_O+[PY/-'I]%>8;?C)_P]/__ 'Q>?XT;?C)_ST\# M_P#?%Y_C1[^\OO#D\T>GT5YAM^,G_/3PA]\7G^-&WXR?\!/__?%Y_C1[M^\OO#D\T>GT5YAM^,G_#T\#_ | ?%Y_C1M^,G_/3P/_-\7G^-'L?[R^\.3S1Z?17F&WXR?\!/3P/_P\]7G^-&WXR?\!/__|

*WQ>?XT>Q_O+[PY/-'I]%>8;?C)_ST\#_/?%Y_C1 MM^,G_/3P/_WQ>?XT>Q_O+[PY/-'I]%>8;?C)_P]/__ 'Q>?XT;?C)_ST\# M_P#?%Y_C1[^\OO#D\T>GT5YAM^,G_/3PA]\7G^-&WXR?\!/__?%Y_C1[M^\OO#D\T>GT5YAM^,G_#T\#_ | ?%Y_C1M

*XQ\6>'/$4_VZRO?!E^\$D,A^]%,J]>>A/0#(SD@?1'[(?PSA\"^" M]3U,^%=?\'ZAKET)KC3M9U/[,,0@(20G:"!8,,:]XQ2U-,,*E>BJ4EVZ MOIMIL*>(E.'(SO;]H_|*
9NTCXV^#]9CLM/TFT\974$4%KKMY 6D@5) V-RC= MC&X2QYI:[2BN)X MBK*DJ+E[J_X'^1BZDG'DOH?,GCSX;ZK\2/VQM&N-1T.\;P;I7A:YMFOY(3]F
MDFG$B,BN>"VV0*_C]E[Q@9/B3;>+/M,OA!HWAV\|->'C=Q$+,)6E;?! MG[R\9R/'^>M?!H+17?#,JM.G[.*5K)?3\])T!.&S@XKLOA%H_BGXW?M*ZK\ M3=<\&ZCX.\-
PZ"VC16VJKLFN&?@X! XP7R<68'RO)-/KZDQ1+,9S2 $GXAR:|[2>C/P:'X.T-W3^R+6>'0 ,;=N/G\U2.O&O X M7]1@CFO7|4\8NFY4USO=Z_?:IDWU(G54TVXJ[ZGS=\|#_
7K^B?M1_&O M6M0T:]LM(U-[0V-]/"5AN=H.[RV/#8]]^:?B5\)?$VD^(/BKX=U+X4:AXT\1 M^*M4:ZT/Q7;QF2.WC=]P^?HN >02.X;@"OTGI,5O2S*=*HZG*M5%=5\-K;>F
MJ-(XEQES6[?@%?AKX7T;6+C[5]EAIMO;7,N[=ND2-0W/?D8SWKY M:T:+XA?L>>,_%MMIW@C4/'GP\UZ_?4[672/FN+.1^],H:]@.M*UKP3_P@?A#4]&E ML=.EU-
V6^-^T.I?C\ND[\48KKI9DZ/;]<$HNVQ8+[.PQ+A=1 MC\%SXQ\5_!C7-!^-NBPZ)X=LCB#D!E PSY8 >N17L MO[^7AG5O"'!,/A'2=*
<36=Y$8Y8R9Y"-RGD9!|_&O;J*YZV-G7I M*E)=M:?2_^9G.LYPY7_6_^9^:OQ2\%^)K'X\;?%V\D^#.H_$#3_$,45MIUVUJ? M)MW$2#SDDVGOQE2#\O6MJ]^
OQ)^'_PN^"/B2+27\4>(O ES/<7OA|)0\OD2 MR;U2,\|FC XSCC&0M?=%)BNK^U:G+&*BM+=|,1Y>^FG8U^M2LE;,,*Q\@>& M-)\9_M&?M$>'?'FJ>"]2\
^&O#6G7%LCZI\EU=R2JZ[5& =H+D^@P>V,5S<2:YX7N/|*T>ZD?>L<8 .Y_BMXA^%GP%'B? M2=6U;7M-\5++7!:,RW%M9A_W;W)&<$+U)YZ9YS7W-BE]EFE2RO%-
W;OKUO\ M=OT\BOK4NJUNW]__X@Z4M%%%>*<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 97BCPMI/C70KS1=UN%WCX_H1U\'((/(K_OCG_P M3OUIP_AA,?\?P4KTGIV>QT M4:\Z+]UGX:>(_">M^#[Y[/7=(OM&ND,&BOK=H6'_ 'T!G*R-Z_WE_,5^Z^H
MZ38ZQ;^1?V<%[.?^6=S$LB_DP(KEYO@MX-N)"\G@CP\[GJ3I?\ 0C>'?_!7#_|.$UI_K%2_Y]O[T/\ M&/\I^*NY?[R_F*-R_WE M_,5^U7_"D/AY_P!"-X=_\%?]"-X=_|.!7#_/$T?
ZQ4O^?; M^!|_:,?Y3\5=R_M6_4,E_O+^8K[]O\ A2'P_ _"N' XFC_A2'P|_ MZ$;P[_X*X?\ XFC_%BI?\^W]Z#^T8_RGXJ[U_O+^8HW+_>?\(?Q7[5?\ \%(WAW_
,%?\Q1N7^\OYBOV]_X4A\|^A6\,_|_@KA_^)H_X4A\/\ H1O#O_@KA_|MB;/]8]7_ #[?WH/[1C_*?BKN7^\OYBC?]"-X=_|.!7#_ M_/$T?]*\0^'G_$(WAW_P5P__!-'^L5+_GV_O0?
VC'^4_%7?]"-X=_P#!7#_\35_3/A;X-M-T6026'A31+*0'(>#3H48?B%/B*GTIO[P_M&/\ *?D;\-_V>?B%\5[F-/#W MAB[FMF.#?W2&WM4|S(^ ?HN3[5\]_LW?L/Z!\'KFV\0>
(YHO$OBR/YXFV8M;M)O6)3RS=^^W3L!?T\JA0 !@#H/2EKQ<9G.QA*^*<M*E5M &%%$\;OEAI.!/_,^$A^*_| TGAG_PHY?\ Y$H_X2'XK_\ 0F>&?_"C ME_|
D2O3**CVL?Y%^/\ F+F7\]_'_;\S_P"$A^*__0F>&?\ PHY?_D2C_A(?MBO\ ]"9X9_\"CE_^1*],HH]K'^1?C_F',OY5^/^9YG_,)#\5_^A,\,_P#A M1R__")1_P)#\5_^A,\,_|
A1R__(E>F44>UC_(OQ_S#F7\]_'_#/,_P#A M(?BO_P!"9X9_*.7_P"1^/\ A(?BO_T)GAG_,*.7_Y$KTRBCVL?Y%^/^8P6?COP|>>"VN'$<.H
MS2IV3T5U=3TRTUG3[BQOI:&\LIF.Q36IP@>.1,"% M64\$$=C3TH>BV@YHJ460=R\\GJ8INS'EC\)@ DD\(P>1D^15E4AR2MNB91Y?8***_^+?B?4[*
M#2/#/AZ<6WB3Q)<-:6UT5#_8H%?7<76T\'RT^Z#P7= >#2A!U)**"*YG8=XH M^,&GZ/KV]@2.0#5!?%/QA0N5WQ^ M!-"M5/2.[\1MY@^NRV9?R)KK_!7@G2?
&@Q;3H]OY,"DR22R-OFN)6Y>65SR M\C'DL>36]6SG3CI&-_-W_1K]?4KFBM$CS/\ X2'XK_\ 0F>&?_"CE_|.D2C_M
(2'XK_]"9X9_P#"CE_^1*],HI>UC_(OQ_S#F7\]_'_\S_X2'XK_P#0F>&?_M "CE_P#D2C_A(?BO_P!"9X9_|*.7_P"1*],HH]K'^1?C_F',OY5^/^9YG_PD M/Q7__A,\,_^%'+
/(E'_"0_%?_*$SPS_X4&?_HY?_D2C_A(?BO_-"9X9_|*.7_.1*],HH M]K'^1?C_)AS+^5?C_F>9_\"0_%?_H3/#/_(4RS11*3[;A7IM%'M8_\/M?C_F',OY5^/^9R'@CXHZ+XZGN:
M*V-SIVM6BAKO1M3@-O>6X/0M&W53V=2RGL:Z^N*^)?PZ3QI907NG3KI/BS3, MRZ1K*+;\]M),_<;^_"^-KQGA@?4 BW\,O&I\?>#K/59;;[#?AI+6_LBV3;743F
M.:+/8TFN:)U5%%%'OAW??$*_MO%/Q$MQ)(I$VF^%7(>TTP?PM*O2:YQU9LJAX0<;MCO"FFN>;LOS\E_6GW%QCI=[$R_&R;Q&"?!/A'6?%D!^[J.U;&Q?W6:F44O:Q_D
M7X_YAS+^5?C_)GF?_"0_%?_*$SPS_X4&?_"CE_|D2O3**;Q_D7X_YAS+^5?C_F>9_\)#\5_P#H3/#/_A1R_P#M>1_PD/Q7_P"A,\,_^%'+_P#(E>F44>UC_(OQ_P
PYE_*OQ_S/,_^$A^*_P#T M)GAG_P *.7_Y$H_X2'XK_P#0F>&?_"CE_P#D2O3**;Q_D7X_P"8;=?)GD:?X MA5I,>RS0Q@_]|"KF@?&S0M2U:#1M7@O_
EKLYVPZ=KT'V=ISZ129,A'8CD'I3YZU'^%OC&>)BDL6C7KHP[$0.0:ZNN0^,/\ R27Q MM_V [[_T0]:TOXD?5%P^)%OX;6\=I\,_"\$2[(HM+M411V A0 5TE<_\/O\ MD0_#G_8-
MO\ T4M=[2]?&_44MV<7\4_B0GPPTG2-2GL'O;2\U>STN=TD"?9E MN)\&)CD'(5F7(XZUYMH'I6^<+-4.G;9I$MQ>GQC_P (I"]H4.TV.YO!Q[P M+&YV]>.O->B?&[X=R?%?
X5^(_"T%Q';?>H6VVVN)<[8IE8/YQS@,JGCFO(_M!'I(*>#OB7X(\1QZE"/\?#HZ]@3>'N+_8Z?:5XQ\V63D_-TKT<,L(Z+=;X M\;,]M/\
(Z*:IA:7XGL;O4[82L\2N0&$9Q(4<@*.M^W^+:3CO7/:G^TUX*N/!WB[5_#.K6GB.]\/:7[;V,4C1F:.,'YD9E^9"1C> MN1S7E'@;]BV_T2XBTO5]0T^YT.PL[ZTL-0M[]]-
ZIGC>,/\+2!>0CL&"@AO M04GA?]CW7M-\,Z[I^H7>B>G>GPS<^'!*OX;[_E8&5-A>1)79(T("DQQI1GD$=.M*W]A@%)V]-[?G_7FC3DH)_$>5C]HGP-8Z+
<7NK:]:,=+8V]I+J$!+2&U>X0-.M'$2]\N<*/FPXQ71ZWXY"?#R?Q5X:LQXHC-F+RT@M[A8AY>$?!VL:/)\]#PUK.L#6M:BTO[%<:FZE1-)L*IB.N.1SU.,]:Y:U/
M#0M*G^^NWE;^NOW[F4XTXZO=]2U\+O'D?O+.^'?AWQ7';-I\>L64=XML[AS&'M&=I8 9K@/B-^'I)'P^\8BSD$ZA<^%[>]L=/O/$#3+$OG73!8Q!$PS.%++N*
MGC/M2>%OV09=%_P"%;.^"?#_BI[F^U+P]I<>GF?2]3NK2)%8Y+&ZYY'!89KEO M$'P\)?2?$3PU>Z3]/AZ?P5X793HVAZS->7#1/QNN96Y,DPRX0LQ"Y';FM*<,_M+
[65WIKOHO*SO>_KZZVLW4N9ZZ:GTD.:6DI:]DY3S#QF?(^/'PVD3Y7EL-8 M@"[SQ-]%I<7=A9R0K.MKH+HDDJO[^2.%
MW@GV!K@]0 .I\+6FI^+=.@M;V]OO#VLV&AR0PA,W,]TX1#'EN55MP;./N&O0 M/BGX-7XA_#CQ+X:8+G5-/FM4+G 5V0A"?HV#^%?-/@3]CS7]\4?""76M0O;6
M2XTPRWOBHK.6-W>+))-.N,/WFU"N3C 45ZN&AA94VZSMRP=]CI^\.IXL.JE& MDXMS>0\'7_#?_^FI;XD>%;SQ7+X9@\1Z7-XAB!+Z6EW&;E<#9S'G/ YQBJ5S
M\7//"2W6MV%GK^FZEK.DV\MQ.0O(S.O^C>23YGS[6)DVL ?I5#P#^R1X]\-Z[; MV^HI!=6FCKJ,MEJR.TX\^6=)%4_9O)^7=VF)-TA!QD5K]5PBO^]O9>6N_P#P M--]?
(KV5+^8^B/"OOQ*>(//VDZ]>:M9;&;W1XM;DLK^[C66VMI ,/(,\+D@ M;NA/2N@N?'6E?\(5/XITR1_$.EI;-=0G15^U/=* ?EB"9WL2, #O7RUX1_98 M\6^"?
AMKWA:,2=%\6Q:]I5B\\UYJ3VUU;7<'E@VZSJA+0KLW0G V-P00:]J\ M!>#_(@^$_V?X-#74-)C\=6]O+]FGDA#VJN9&:-)-BIN.TA6<*,DEL5E7H8> M#O3G?
WK;]/SIV_5)G"FM8OK^!L?!JXR6WQ9XA12@GXAR(Z+]A[5M&MS=0\7_#?_^FI;XD>%;SQ7+X9@\1Z7-XAB!+Z6EW&;E<#9S'G/ YQBJ5S
M\7//"2W6MV%GK^FZEK.DV\MQ.0O(S.O^C>23YGS[6)DVL ?I5#P#^R1X]\-Z[; MV^HI!=6FCKJ,MEJR:TX\^6=)%4_9O)^7=VF)-TA!QD5K]5PBO^]O9>6N_P#P M--]?
(KV5+^8^B/"OOQ*>(//VDZ]>:M9;&;W1XM;DLK^[C66VMI ,/(,\+D@ M;NA/2N@N?'6E?\(5/XITR1_$.EI;-=0G15^U/=* ?EB"9WL2, #O7RUX1_98 M\6^"?
AMKWA:,2=%\6Q:]I5B\\UYJ3VUU;7<'E@VZSJA+0KLW0G V-P00:]J\ M!>#_(@^$_V?X-#74-)C\=6]O+]FGDA#VJN9&:-)-BIN.TA6<*,DEL5E7H8> M#O3G?
WK;]/SIV_5)G"FM8OK^!L?!JXR6WQ9XA44ZGR(Z+]A[5M&MS=0\7_#?2

MMIX(X!S7US17135P=]DG=67+|\M/\COL#Q+CL!*4X*,G*HJK,3UDE)=&M'SNZ-M]-3Y:5XD_MO69(9ECC@#\L$#$%@.!P/6OK>BL'EU)MW-M;MT7:*
*fNf:=6NMSTX\9X^$8J-."E9*4K.\^6#IQYO>M!L9.W*HW>KN>1?M2^-MM>^)/P>U/0_#5HE]TLT#Q122K&IVR!CEF('05Y6_P-/OBW\6_%/@:S\8^&=*
M+\+Z)X3G2!DOK6^6=KZ5$Y]{U'*]P>;ZJ]^L:*UK8*%;I[24GK.ZTL[.ZZ7-M_$XLNXFQ.68182E2@^5S<9-2YHN<5&35I.RTO%VWI'QO8?LZ^/(_"6BV.VC-MP_;+?*
QU+KO$?"]WQ&NA"9:1KOAZ.P-ML]!HE(^T:'(#^NQOR2^C*%R66T5'EN\:?@FNWF=\^-LSE6]NE!2]!9/3FE-M«=]9/9Q5O*!GQ?*
XB\#?'3Q_X:\&^%M3\#Z3IUAXY].U?37QDTC4M=^'&LV&DZ!IWB:\N(M@TO5)3'!.">06&,"3D<]Q7;-M45K2P<:2FN9OF5M;=-.QYV.XDK8VKAZBH0IJC)R2CSI-
*R:D[WFW]UT:MTMI;-MX@T_]GCXG7?]P>\1.:$VBMIMK&{C6$NOL42.#+B5B_>RYS_7UCQ[\-M$-_>\8_%_3-06W6#03X9N-)N+P3)F*5TV@!,[B,]P,5]#4M8PRVC&/+=O;MT;*
*M?;S_.CT<1QKF->]ZRA"+]_92^W6,6]9-MV@FF!MN[E>Y\&>$?+V4_$>GW:G>-M'=7^%6G:E%;S@7'B67Q5(]\+M^&M4\6:+XC@BB:*ZOQ:R6,B(*5VD%$=*
>N?:OJ<BIAE=&E&T<TT!JUUTI:[-MJ;G3BN.\QOU5SQ5..XRBU$G4<97:E>S]-Q=XIKD<4K6M;0\0_9.^'7BGX;^-M\]7M/%UE!8ZK>;M/>F.WF22,ASG(*DX&*
*<\'FO*_C9X)^-/Q*^^-K>3^:\+36?-M!&CS^98Z-)K4,,5TX^[+-\V3S_#@8K[#L,5M/-0G0CA^9]*]-?6ZU/-PW%>)-MP^.5LW="G*K4ONI6C?1N%HIVTO>ZZ-'S;X^,XV*
*V%Q!X+T;Q1H.H:<(+[PE-M-<0!+&XY&X2,/G7&.A/X=:X'2?V;OB-|.?"O@CQ'HUE8ZMXIT*_N+R70!70J2YISDWTU6FSTT[KT\CIP_&6*PE%4,/AZ48W-M]Y*,O?5I1M+WOY9-*
75IO2\FU<^,/A]T_ZUXPMO'6L_$RV?!{_Q9=1R'&=:MO;NTL?AKI*@^UGO\]2]"US[==-?WP>1(R.3ND(+<]MA7T716BP%'V)>U[]=[_F<*^LH16T%?*
D7N>S5E>^D=$V!|VSP,3?A3-MXBM_C[\0Q$\EA&-'U?14L[.X\["9)0""NW.5ZCDC%>+:.E?RXQF^&G@Z6?0[-M?5=8T\N6N?#TFI?9_M.$C[ALGC8;6_&ON*BLZF6T;J.E?*
KVZM/MW1U83C3_M\%,Z*BK*"VEM3A*FE=235XR=VFG?5-'Q1;_-+,NOZE\-/&K6GPVM/">O:C;_MI;6-I_PD4M]/(FX%A(\CF,#C@Y!]J^O?!FFSZ/X2T:QND$=S;6<44B-@@,J*
*M$9'7FMJBM\/@Z>&=X=K=.[?1+N>9G/$F,SN"IXE*RDY+&;O&,;?6X*3M:*W=-M]WU"BBBNX^5"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHH-MH-****"BBB@*
*HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH**M***"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@*
*HHHH-****"BBB@-HHKG?#/Q$\,>,]3UG3M"U_3]7OM&F%O-MJ-O97"RO:2'/R2'Y3\IX/H:=@.BHKS2^_.7^%&F:]_$;PQ9;K;3M;36*
MES]D4BN+\!_&CP\4>R[M2"7BS2/$=S:1K+<1:;=K,T2L-M2%+_=2#CZ&NTI--.,$[!:1122&%%%%/!1110-4444-%-M%%%-!1110-44UW6-&=V"
*(HR68X-'J:X7P;!=_Af\0_$5WH7AKQCH^M:O:AC+-M9V=TKOA3ABH_B-/!*Y-II-ZH5T=Y17"?$+XZ_#_X4W,%MXM\7Z3H-W.NZ*UN*
*M[D"9U_O",9;'OC%;O@SQYX<^(FBQZOX8US3]?TQ5M%UIUPLT>>>X)4G!]CS3Y-M7.]@NKV-ZBJ%5KVG6FKVFES7L$>HW:.N\%JS@22*HRQ5>1-[FK]2,*****-"BB-MB@*
*HHHH-*****"BBB@-HHHH-*****"BBB@-HK(\6>+\"^!S7-?UM\L-MT\R>]N6VH@2'PXB>:!R3TKE_AU\=_-[^G6OD!ZP'BX>=SN(XV^[-M)Y4R>RQ19;BSN[2>SN(XV^[-M)Y4R>RQ6]F-P?*
6GRMJ]AZ76QW]%;5!=S+_@7S)&B#-M&0!DG@9Q7-2Q%.M9PZJY[>.R:?%Y>YQQ"2Y9.^]-M[V.>S6C]'H]4[=,17B?@;X\7+^!5U+Q#HVK/]]SJ]SIUA80P0F>]99I-L<;]*
M^T;$0AF8]!M)R1S6Q?\]0ND;)I6H3ZOH>MZ9]EA-;0S;/);I)=$3OLB>/8Y-M61&;(RK'!!!Q4K%T7%2;MINAZI-M17E%Y\?XK/4+S3O^$-\2W&IV%K>ZA:V\$#FTA?
=@LWF]2V$/R*23V!P:GT;-MX/[Z?XENM/CMM+U]QTS6$D&EZT<+W;?O=/2U^CZKWEWBFU=)]X-M\0^@RQ?PS\=H4T_1M(MK#QO%?PS\=H4T_1M(MK#QO%X-MUUZ;2TU,$0V$+20EV?>_,P
*ZQH05QMSSD8SS707'QSTB72M#GTG3-5US4M96-M1K72+.!1H6FO:?I^]6F]6](ZK.QR@Y-M8'*C[RG'(P;|<_$"Q\"V]D)K6\U/4;^;|/9:9IT8DN+E\$D*"0-268@*
M#DU4<13DG)/1&-7^)\91G3I3A[\[V771)W?2UG>]!6UV.HHKR6X_:.T;2DUQ-M8T+7M&OM%LUOKRSNK9"XC9PBE"KE9.D_PDI#WXK6TCXU:.==7\MMJ^D:KX7'V-M-
*!0MY=7B1$N+=.;G78[%2-02K8;!Z=:%B:+=E+^OT+GDF8TXNH6L-EJM_9Q^1<1O(H/-=FCW-M*3M+JN<]C7N(Z55.M"JVH=/U.?&9;B.!"$\0KZ::=A.**-M*W/+"BBB@*
*HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH-****"BBB@-HHHH-*\0^&L,6R3*Z_;).\&^R/@*
*M1K&@_"WPA\0+*XN%7X>>!_$5XFGM,?,2RMEMXIIK>/=G*Q2R2HJ]N%'3%='+-M^RI9+>ZR]A\1O'^BZ?]M_<:C<:9I6KQV\EGCY&>M=)*
*M#3\.=&\"6=I/IOA;3KZ"_>PMI+/&MR-6O;8J_;*WVA;2S_.V4(4'_&VD/>O8-MZ0*.!P!2UC)\SN:)65@HHHJ1A1110-4444-%%%%-!1110-4444-%%%%-!11-M10-4444-<+\8-*
*>"\DA,=O'>*0%B5P10$1<%^O%?9OKBKQ0MOC3PIJ,A:O;+>:9J$#6]Q-QWHPP1DT*_P!8\9^*_&-I-MX?<2./IENWD4EM9N!M5\1QO(TKJ.%:5F(^O:PFHQ:9G)-GV1]DG2-*
N_!FO^-M.+BW75/'J;K?+K%W(BM=+)%,Z):AFY5514PF0/FSWJAX3^_@'P7X\!7W5]-M\-M6^&NL'26UG5M0U"WMHTN((FVAV$$SC<2V-2-3GJ;!CQ)^S;IM[XMO_$_A
M;Q3XC^'VLZD0VH/XL!@/+!-')&7QQO"AO4UO?#7X(:#\-6U6[2XU#Q-M%KNK,K:CKFO3BYO+H+]U2,]-GU+Q#IU!:6>A0WBNNF0;E^SVY4?\MY.7;WP.U??5?"_0[SQ]H
*M_BXQ/%[FEVLUI-D6U8BLI&XLNW)/P#_#WB_2(:!.TRY34P99C-M\DD665W(<!5>3@\<9[5Y\+#&6;XR_&*X^:.I-8^$M/TY]&T6YEC*RZ[#)*
MNDN<'D0Y&$SUY/0UZA\4_AAH_P_7-_!WX8UZ2_72+LC[1'87CVS2J.=C.A\!-M^HZ&L'X=?.31?AEJD=YIFN^*!Q8X/LZ6>K>(+]\MD3C&(I&*@C'!QQ6L6E%Z-MZD--*
LY/X,/=)XP^.;68WWBZ^Q@#=",_V9=H_/%5/V0$TVV^!U;2K8:CXGN9;MF?6MSJES<:D';S(Y7;HVX,1NX QVKV+PUX$TCPEJFOZAIT,D=SKEW!MO6>5G-M#R!0N0#]T8
*X%<+XI_9E\Y>(/%-!XCTV^\0>#=:,0\&^N_"NKS:?!L(Z-*B'8-M[?!6W=[T^9.Z?D+E:U/-D_:&'@Z_^)UQ>?"=?"GBC2M+AU2^EBOK2Y-Y+(?+*
MMTFD@Z,3M^!O;?"GP$|\$^$?!^L>&K;2/MFGZUO.JR:E/)=7&H,XPS3S2-M$N[$=R>.,8Q67\/?V;/"?PZ\10:Y;W.N:UJ%I;FTT^37]6FOAIT!(S';K(2$-M!P.>3@
9JN>%FK"Y971ZM1117.;A1110-4444-%%%%-!1110-4444-%%%5]0-MN)+6PN)H8'NI8XV=((RH:0@<"Q-!/3D@4/0:7,TD6*;Z[D(<4BO#_A*\=-2*
*MD^&VA7FN:)]>H^)M5N[BUL+"V^SF;^*22$I-KA(T15P.5_V\H;C.M_$66C_MP^>5UOPSK66T7_A[3ZU.[4WUBQ!P1BN..+HN*8W:ZO\-MA?*
[!:GT=3A[.:=:=&,%)QDXZ-.Jl,2]K7T>N@R#X#C4/A1;^&M3O5_MM-;LIJ\O++#5!.)\)RSEEGED1T)>63:RGA@6'(K:\%?!C1?#VF^&I\0LH+KQ
*M%I&GV]G]OBDD"EHHPF57(&.O4=Z;I/QHMY=4%IKN@ZGX4BGLI=1L]G5/*V3P-M1-&0D(&-U5@VQP#@^H(''>-/CO]\OABPO_3O''^O:'I^!WUG%I^M7,4+1RI*
M)/&/GC#EXE="=I=1U&<$BN9O"TTIVO9=NW]+5GMQAG^,F\-S$=&ADBT?5M5TC6+W48[+40YLKJ>64F)R%W(V-MV0$,%.&7H14>E_*
C4VBDN/(&^&)6U&PN$L=`C9MD.$XE?S+@HK2.V.%VA1-M@-M_E^%NUWHNFATQQ7>AR\]LVY7;22O)2:?ODG[R4M=[.QL6W@2B1N.\3>.-M2,MOY6NVMM!.]"=R&-*
*)5,.CIF08QGO6&?A1J?_")_#^2QZ%)%H&L6GA_79/(TW6[J.-(9YMI8(8]_F(#-MM8!F4-D>F"=OQO\$\)>$?$NB>'L.0M1UW5=7CFEMX{(Q*B+\%MW#(\C]%-#9S-M[8ZD5O*
[/:.GI_FT_Q=K'DVSBCB%AY02FU>SY=%"#@[N]ERQ3YDVFFM;.Y-M_P"$_P-)=4\!ZG!*S-+-^%/BSP3-M2R10W%M<7)G7;*$8I(IV_P-)!Y'H:T;O]H?3[=[V*
*M^CT#5+KPO8SM;W6OQ//Y2,C;9'6(R*5XT((+J]'!QG%6KSXWF?Q#K.C^'_",.MM>)Y]{,;7<]D8$@"/&'4H\DB[R0>%'%9)85148MZ;;W[Z:.]>FYW2>>3]SJ-MU:*
*<7S]\K]C9+EM)W7*_?2;;4DVMG8Y^R^$GC+5/$ESKNNW>C)<7.L:;]-MK-M%I"D$-L6W1[F4%V^;AL-$D],5VOQ&\ZQ]NJ:#XA\.2V8US1I9&2VU$LMO"?'K1Y=-*
*T231-.OM>U+6%E>WTR+RX)8A$YV4S&5-ME6+8WRG)SG@9IT?QYT7_-(1RYOIK#48=6MKQ-.?00B27ANGP4B4*Q1MP((8-MMQDDC!JX_5HQ<5+?*
*6_X[]^MC"JLZU\85Y44N6\%&RVM!-IQO?ETY>9Z7OK"M^M;=K=XYDC_^Y*LA0MD@8)&.],_P(\%FK^-/AGI&K.W:S6VH3(=[3&+,O)M^<",D=L<'CI2A&A.3HJ;U=[]'?*
7MOL7BJ^,8:E#&2Y(1I^[%1<7I.+C>-F M[JT-[O7774X[5O!/Q-\3:/HV@:@_AJUL--NK:6>_@FF>6^2%U(Q&8P(20N3\-MS<\#CD>VC@5_>
*(O$_C#4_!WQ#\4:3XKN=%32;^6*RMTM()T,<,8#-B1#]YV-M))'/RBJGC/QQK?@W4_!^E:W\53X?*
M]0TZ>\FU:ZTZSW32CR]D84Q[1CRZHWKY3B\S]G24Z<6G/W8QJ73Y5.=TH2N[65DWKHE9:?1M-M%>!Z1\1_%5QX2\&Z[?7C^4_B$;=-.+3[.NI6CMY<AKW1=]*
*M"E6C65X^7XGR689;5RZ2C4:=W):7WBI[=+R?SULIH6BBBMSR0HHHH-****"MBBB@-KB-9^.'PZ\.ZG<:=]OCWPQINH6[.)K2\UBWBEB;T9&<$'ZUVQZ5^.'C*
*M/P_1^M_ME?"-7O[/VH_',]"E8M/O9K8V/^9O+4YW=.:/V'T_4;35[&"]L.M;F&\LYT$D5Q;R!XY%/0]PX(JQ4&O^(--*Z->:OK%!HNF6<9FN+NZD"1Q(.MK,QX-KX,\>?M*
&GPM\5/AO\(OA%X3'T'PS:WAM+@<JUM$.$XE?S+@HK2.V.%VA1-M@-M_E^%NUWHNFATQQ7>AR\]LVY7;22O)2:?ODG[R4M=[.QL6W@2B1N.\3>.-M2,MOY6NVMM!.]"=EX3TW0-!3BROK__%V-
W;4[Q5RZ1#G:I.<# XQEJ/OJBOSK\8?\%$/-M'US^S!9>+]!T+3=-^(5EXFC\..MIEQ$TULTV2"(_G!.;CJ3C/6M>X_;2.;2^-M ?COP'?_.!CT_P(ZGX\8WD=CY7AY76?2Y9,;5+-
C<1N&<[@>>>1B@#[HK\-MW?CC_P_%"/%EU\:O%/@WP7XS\#?#:1O#.GV=]1\80SSRZG..]QK&C:4SQD@?-M6OHI[AG]IV?]I?7X=.E>.K;V-OXCT.\:A?ML:LUK<'&5FBW-
O2@"!1110-44-M44-%%%%-!1110-4444-%%%%-!1110-4444-%%%%-!37&-MY2/6N>\>^-K?P#X>?4[BWN+Z/5Y8I6UL;10TUU/(P2.)2!EF(Y)-R3P\OU*
M+XH^)K/XF^#;/0)HI_A'3WBU"[N3'?)=VMQ%';%L.Z@$.APVW&.X)P:YJN(A-M2?++?3\7,5](IO!91BL=!U::2BE)ZM7?)'F:C&_-+3LG:^MBJ8_1O7_#OAKP-MA+I&HZ>?
*$_AR:*"Z5_L=U#AP4(<_X9.A!K/U!X.^-O'$OBV!US-M4M$M[G6=&<CT!UM+)96BM-LQ?+.P!DSGDX'H!QD[=C\Z1X/U-M2:**VU>6[C>6,2L%ADGMP,QCY9>=S%=PW-&="U:*
M33+(__%)+N+S-R.$++PP?>D4%ESRI&2!NP:|\^7U3ELV[=M>UK[=NNQ]?2>?^V<-MX4X.=_BO3;NY\W(GS6OSZ\OQ:VV=GU?Q%^&:!^(&MZ3)/<)%ID-G?V=U&,B5U-MN(?
*+RAZ<F.?=2<]6QO$]*3&XOHX)495.;C;$Q-M"#<0S<]_>-E?'CH^A2ZO'XP\-7?AH[/33]T*K-KS18=>NTL[6YCU&&X$+,K-B<*!L?"G@;AVW9K2;P-MTVVVU???*
*TUTTVZV./#*15K#PA3C"$E3UA=TWM>;<'S>\TI,.+S6TNKI'+;E^S-MQI-IJFN1:5H_@G4;/5+Z6]CU77=/;UI9&9BTBI-A68!B2FYEQG!R!7H_AOX<-MS^'_!-*
K5^MQ;M:7FDV6FP1QQ",H8!"2J@*JGS!@+P,'CI7"^#_(QWT=KH-M>@:#H&L>*M3O[>]O4GU74HE,.17;1-YTNWA^OU^Y:.[G5C-M:>?8B^']-.IN\$VHN_-*
K)Q7[O=V6CZMWN6/PCU&T\'?#K1S>VIF\,WEM$6EAI]W9R0MGS&:4QD$=L#8<_4-M5D?'CQ'K?AKX1ZIJFB0NFI16I<,+A8GM^.7!(0?TIUR%K]2_&<M\2=8TZW\-M-
*7&L3+HUE>/8-J4<5K9DM,'_'Q7YG,"X_7G')&;UE*C1DJ33Z=-EI?D>9=0MHYEF-&6.C4A_R\GKBOB<>?=I*_M-&]/POF)^SAJ&EO"+C39KN2:+7-M-2TSS]1@BDIU;1)#K*
M"2P"-EMD-DC:-2'7L4P.G!'2NCC^.3;_:Z%%X6\.7.N:SJE]JX]A/<).I91H-M_EN9I2&(D!0!0VX@XXYKC_'WQO\2:AX'\2?V5X=O=!US1=1M+.ZCGO8E9?,M(8LC,&4#QD-*
*GC&*Y9+#4ES0;TUTOV>B=K,]RC/.\,-T<53@W.T?SN.C=-M2*Y1OS6#US6C:?`[58/#,?FX-DBO1_$GC2'P9X-FU_6[=[?R(@\EI;LG,AX$2@8W,6(Z9S7$Z_&GG*
*M7M$U31;3Q'X"N]'35Y3%;7$>HQ7"1D(SE9=H&Q\+T&X?[5=$[6%I/6ZO;OZ+-MT^?YGE4[@KVO*22;2DE=M\]>C2;Y;(?8^:_'&N>.[+Q#XDN-MM#M;::TL+FRBT[2S-*
)AI0!YAD=55TZ,1@=S?9?#?PM<>"O-VD:)=31W%Q9P^6-M\D(.QCN)XSSWKS:'I163_A$!)UJ[\+G3I-=<)HUG=ZI#&UPNTEY)7;"PHH7.-M26)!&!GBNO
AE\7;7X@WFIZ9+;0Y&M:<$DFMK;.BO87C?.V2.6/AAD$$$*0-M>W(JZ-3#\ZY\-R?>_6WZ)?QYWI1C2A96BXZ%_"UUXB\!?$OP8C+:.@<2^]7<;27"MLVS!9$?
*CJ.2./2N@\6?!B/QIJ^D/-MJ4L+Z;.Z-+ITJ+N$HE8QE98S_"5*9!ZYQ2W7Q5OM5\1^)]"TI1F6WTB)TN-2-M^WQ++#)Y6I6^SGY]AR-''4YXX)KGOAK\.=9?*
PYX,E\0^'+RWTS5TBM8M;N+N-M-Y9)RO#20@956(.&R3I)-K)/#Z4Y.]-G;1_\'?8[Y1S?WL702@-BMS1YKSIZ-MM;WNU&ZC\2[=23Q7!WB#
*[#\/_"NMW4>L:L^MQ227MLC#S+>W)D$L@(PKX4!N-MQ/3K7M@Z5X9/^-UT[E(;AH'U-ZQ;+=$*VQI5M"=Y0$'N&(&0IKI-M=4^+-FJWVIZK;>%/"*
*<_B2RTL!;S4%O8[9=Y0/LA#_^:P4@G[HY-S6M*M1BVXR-MOMT=]OQZZG#C\LS.M&G"K14$N9M\T%&[DKWU2@U>*Y'9^6MCT^BN"^!GB"\|*
M4_#+2=4OY.B6YN6G9C=C$H-FUW4YJ!\3757/E.7AI0/$5.--MW<&XOU3L%%%%.'(%%%%!1110-AKX1\0_L?_.+0-AOX[_$+QY\+/B?X0*VG-MBNZ$TD%[8M<2[!M#;X7
*((_A-?=|%'YB?'3P9\4M8_;A^&&F:%%XVL-)^)5-MKX4:5]:DM=]I/3\/A88_N@GTP%X]Z^V'TFQDU!+-][.W:]1=BW)B4R*OH&QD#V-MS5N@#X]M/V&/%<&A_L\V+-^(-*
&:3X;3F74&-FQ=-YXA-^7W_BQ5?Q5>QS\9/AS-M\3/%^O\-P$^(VD)>&=%\02F?4]*UVU:?[-,1@RP,$>GTZ$>]?;M%-Y:?M;_L-MQ)^SK^R!X9\+PZ_-J?B/5O&-
*K=ZCKS)M,EW(V/,5<\!2>,.<\5Z]H?['/QI^+-M'C3P->?&CXFZ1XA\%>$Y8[!3]/T:S,_]*H!1I_E4\#)RW3WS7W%[&E66K1-M)'?6D%Y&C!U2XB60!AT(!!YJZM-!0-!@#H!0!\0?*
$K]B/XB>'OB]XG\;_!SQ-M#X0M[;Q2XGU+1_&>D+=QP3]Y8&\MR/7"OFOH_\9W^&'B'X6?#^#3O%NMZ;-MXB\22.9+O4-+TB#3HF)Z*$B5=P4<;F&37J-%-!1110-4444-
%%%%-"I7PEX-MQ^&6@WGBR^\3^%Q#MWX\;7KK4CKAU^R@#FO4<2&.%8_;$Z2GETCB<,QRO0DMSR3^%?6W@2RUO3!^VCVGB2ZM;W+8;X-.;MN,)666&64.S*&Y*
*)YP:Y?XZ?\BCIQ_8;TW_TJ2O11TK>4VZ<8]KDI:ME5X@-M-MYI+1U(]F2-$_W1(]D/SWR,/P]*U(_N+|*RQ$6H6]O:-,RMB24#8"C$'GU-]]-MU8_N+|*P*4444-%%%%-!1110-4444-*
%%%%-!1110-4444-%%%%-!1110-44-M44-96K6D'GVEQY$?GB>-1+Y0+8W#C/:M6L?59;G[9:H8$%KYR'SO.P<[AQMQ-MS^=;%-!1110-4444-%%%%-!1110-4444-%%%%-
*!1110-4444-%%%%-!1110!-M2U6^%C:LQAGFW-C]PF(C*31^.U5=%XTNW]?-M+ZY_6@"]1110-4444-%%%%-!1110-4444-%%%%-!1110-M-4444-%%%%-*
*'+_$7P3_PG?AY:**_DTK4+:YAOK&_C02&WN(G#QN4/#+D8*G]-M'1QUKB+CX3^*O&GB?2=4\9ZH=Q8V-O>6C:5I%C)#',L\)B:1G>1FW8/3H!G-MJ3FO7Z*YYT*=27-*
*+RZ]MCV,+FV*P=/V5%!?%9\];7,K2LVKJZ[/3=6=SQRW^-M$?B\4-,TGPOKWB>PO_!^F2P./(L&COV.!E:&*:0N4!1-S(H+;?*
X'1J<:OJ^JSZBMP821&))Q+L(SSC&,YKT^BH6=1+ITMN\NQO+/<=-M46D)6DI648I8-M_#CX/S^:=T^_DU..\%KIUW8E%A*%C->?:-Y;/'-+^#&O>#(M(O_SKMC'KEG#*
*<6ER-M0M'DM;R"6X:9055PR,A;A@?4$<\,'P.UO4-'\6IZOXDM[W4_$%Y:7CSPV1BB-M@\G'[M4WD[>,_DY[FO9J*P^J4K6MIZOM\;CT_P#6#,.9SYES-IWY8WTESI?M*
*M>REK;Y,)(YWQ]X,@\>^%+W19[B2T\\!HF'&^&12&1P#P2&_.#Z5P-_\,?'7-MBW4I"N/$OBC2&MM'N#,EOIFFR1?.F.,)OD+R-M/S9YKQG/M7L%%;5*$*CO+|*
MWT./"9KB<%3]G2:MK;\8MKF5G9M,UUH[!?>0ZG\@%9?!W@VSM;ZPDUOPQ{X-M)M0L?M%I<-H4=)(B<[6!Z@YI?122#7P-J?A:34;S5KK2WNKPJ%-M%TY+2UM
ME7/"]7DQV=]DR6TEH[1WSI)&4\F:7>5>,$[L;>&V?P#UG2&_LG3=1\/0:-+EIX[V70TEU2&-G-M+F)9&)C/)(#LI(!Z'&.Z"[^``BO0M9UB3PAX@TZQTS69/.N;?4[%YWMI=H5I
*M(2CJ.0!\K#&1^%>I45"PE**M&Z^;.BIG^.JRY]CC+O>,??5.!TU=TG?_#=^-M5^&/@V?P!X*T.0KG4#JL]KYA>\;/892SL^XKV/S5U5%%=4(]$5&.R/#Q%>IB*
*M:TZ]5WE)MOI]7HM-HHHJC-*****"BBDS0-M%)FC-"T4F:,T+129HS0-M%-M)FC-"T4F:,T+129HS0-M%)FEH-*****(+ZRM]2M)K6[@BN;:92DD,R!T=3*
MU!4\$>QKXSTKPI6T;XG67@ZWM/%MK-GXH?55\26=Q#_:.)9V^SB!<MR3;6-M\M@7V!0<=@/L;6;Z;3=+N,JWL)]3FB3KD?W%^E9^OH[Z;(4?.%(+#0&W#/3_Z]:$?
W%^E0,=1110-4444-%%%%-M-!1110-4444-%%%%-!1110-4444-%%%%-!1110!0U:.VUQG_(^(^BY_B'Y5-M?K+UF"-I;&5@/,2=%4EB.K#/_Z],]:E-!1110-4444-%%%%-!1110-
*4444-%-M%%%-!1110-4444-%%%%-!1110!7OUD>SF$<@C?:<,5W-?AWJ'1/^05;=/N]A-MC].U6+]J14@?+!25..<$\5!HV?[,M\YSM_B.30!=HHHH-*****"BBB@-HHHH-M*****
*"BBB@-HHHH-*****"BBB@-HHHH-*****"BBB@-HHHH-*****"BBB@-H-MHI,T+37=8U+,0[@9)/0501\06=Y[&BWEOI]^EWTD3"&[2-7,3XX;.P((/8U-MR&@^^+KGQ=|-*
M6EOX4M-9LDN+'4((B=B7$;D.5SSM8%77V85K&FV1YEWL3S+F-M4>YRVH?ME_!K3-3GL+CQS9BXAD.4GEP3R(&!P?G5"IY[@XKO/%GQ-I=&^:MS
*MXHT^.;+4,;9K836;0MN6X9Q^["D=-=Q(`XU^)N3GK7Z>_L]_#'5?B-\-//-OX@\-M1R6_AI+9)8=*T.,V\LFR0LIFN"2^0PSB/9TZFOI\=E6'P485'-VOK?KZ67]=*
*MST,=AO84TZ5VWH>N^'M:T3X5Z!!;>+?%]C%KEV3=7LVIZ@B-),P&X(K-\]+P MJ!]@-#ODUUOA_P 9*X#1GT76M/U=5&6-C=)-M^NTG%>8%-%TY+2UM*
*M.MVT+Q.S+%/.@EN+:.]5=Q4S/EV215)PQ.&"WC7H5_\#;PMJFJ6NJ7&@6!U-M*VD$L5ZD"OSHPZ?.N&_#.*_LJ5^9MN^M)/RZ=MSQZ;G:UEH;_@_P# .>G^-M+DVA?*
*$&+POWXE\/7&AVFH3>1I&M>>DUK>OC/EMC!BD/.%8C5Y5^?TH\=-MW\%?$<[#$UA$M!(/O)+&P=6!['(KT70+U]2T/3]N3_63V*M4OM1TOP!X7N3:Z_KH9I[Y!DV%FO*
*MK\OIX_=7W-9S:BI1YG_PI["?@<'/'UU1@L;MM1IBE=RCD^"U&^*?C'LJ>_M:GP!\.M*B\!Z_;'>W1TYCTW32^^>L@Y=_^F-<'%5(_@']?BG[_P"/?'VO-MZ_*_+:?*
I5PVEV"_[(CA(=A[LY->B>!O_^D?#SPW:;)HUL++T@'+'EY7/WT';MJS.>237O5SK#N[U=W\NB^77U?X'L3S:.")LLICR)?;.3J2\^;?D\HPM9:-R-M>IX__P
*,D?"=N9//23OW>;^N78_4F2C_(9^'$G_$)MO_X%?'_QRO8**?U/-M#?\/N/W(R_UCSK_*#:O_@R?^9X_P#\,C_"3_H3;?\\"KC_P".4?\#(_P-MD_Z$VW_\"KC_...5[!6?*
*KVNV/AC1KS5=2N%M;"SB:;>9NB*IR:'A,*E=TX_<-MBX<09[4DH0OE5MZ)*I/5_>>7_P##(_PD_P"-A-MC'_*N/_CE'_#(_P)/^A-M#\]P^N/_CE1:-*
*^UCX!UWPWX@UJUGU(0:}$MQ=036$D0#6W-MO3FM,)VU79I^C/*O^&1_A)_T)MO_.!5Q_\'%/^&1_A)_T)MO_^!5Q_P#'-M*]?S7-_$'X@:?\-/#^?;,,CO6DL+A(1#Q]H^'_P-0-*
*8L&3E=)\1S-_MJE@X_N_/^]C'NK_A6IX)^,=Q<>(("_"?C?2AX5\6LL">9YEGJ*C[]M+_.!>Z_M'#"O4:Y7XC_#K2OB9XCK@_7->F5T4ZBJQ4T>+C<)4P>6'[;M=5LT]M4UY---*
*>3*FK&]73;DZ;:S7XC)@CNI&CB9^P9E5B!{@'Z5\Y.++\$_B6QTG3-_M5M/!-OHUMXE;7YKVRO+J2_P7=!]EK=07RVTN2,KD8&:^F**U.(X[XH>&++[Q5-MX?*
*LI/3UC::+4[*Z82/M&R.=7?GUP#@=5V X%+56_CNI(XQ:2I$XD4N77(*9^8-M?4BG?2P%#Q'JEG;6[6D4U__*X)-V]P6Y[?D:UX_N+]*I:\N=-G(!W-#D8SU-M'K5V/[B_2D*
*ZBBB@-HHHH-*****"BBB@-HHHH-*****"BBB@-HHHH-*****"MBBJMQ8BXO+6X\V1#-6(13A7RI'(]^YB/:NRHJX3E3=X.5)E%25I(\%*KZRO+-M?OSIVJQ>;*
*<17K)8WT3+%Y>Y65?*D)4+G(3.T$[.V\6WOB(-*]_=6D5-MF0Y&Q(T9F^48R.EN>>P[_BR:/_A'=6BWKYOV.5MF><;3SCTKT/K%"*ES:.Z6_JQ^&_>OV$_9+_P"3<_*
G_8/_H;U^:/3?U8:VUFU!)<-3KVU&QFM)8R%^O?O1/-/NDO^2&-M^_^P=)_*NS\"|-(IZ-_P|>4/\Z+6N_:2_P"2&^_:P=)_*NS\"|-(IZ-_P|>4/\Z+6N_:2_P"2&^_:P=)_*N^/_CE1:-
*^UCX!UWPWX@UJUGU(0:}$MQ=036$D0#6W-MO3FM,)VU79I^C/*O^&1_A)_T)MO_.!5Q_\'%/^&1_A)_T)MO_^!5Q_P#'-M*]?S7-_$'X@:?\-/#^?;,,CO6DL+A(1#Q]H^'_P-0-*
*8L&3E=)\1S-_MJE@X_N_/^]C'NK_A6IX)^,=Q<>(("_"?C?2AX5\6LL">9YEGJ*C[]M+_.!>Z_M'#"O4:Y7XC_#K2OB9XCK@_7->F5T4ZBJQ4T>+C<)4P>6'[;M=5LT]M4UY---*
*>3*FK&]73;DZ;:S7XC)@CNI&CB9^P9E5B!{@'Z5\Y.++\$_B6QTG3-_M5M/!-OHUMXE;7YKVRO+J2_P7=!]EK=07RVTN2,KD8&:^F**U.(X[XH>&++[Q5-MX?*
*LI/3UC::+4[*Z82/M&R.=7?GUP#@=5V X%+56_CNI(XQ:2I$XD4N77(*9^8-M?4BG?2P%#Q'JEG;6[6D4U__*X)-V]P6Y[?D:UX_N+]*I:\N=-G(!W-#D8SU-M'K5V/[B_2D*
*ZBBB@-HHHH-*****"BBB@-HHHH-*****"BBB@-HHHH-*****"MBBJMQ8BXO+6X\V1#-6(13A7RI'(]^YB/:NRHJX3E3=X.5)E%25I(\%*KZRO+-M?OSIVJQ>;*
*<17K)8WT3+%Y>Y65?*D)4+G(3.T$[.V\6WOB(-*]_=6D5-MF0Y&Q(T9F^48R.EN>>P[_BR:/_A'=6BWKYOV.5MF><;3SCTKT/K%"*ES:.Z6_JQ^&_>OV$_9+_P"3<_*
G_8/_H;U^:/3?U8:VUFU!)<-3KVU&QFM)8R%^O?O1/-/NDO^2&-M^_^P=)_*NS\"|-(IZ-_P|>4/\Z+6N_:2_P"2&^_:P=)_*N^/_CE1:-
*^UCX!UWPWX@UJUGU(0:}$MQ=036$D0#6W-MO3FM,)VU79I^C/*O^&1_A)_T)MO_.!5Q_\'%/^&1_A)_T)MO_^!5Q_P#'-M*]?S7-_$'X@:?\-/#^?;,,CO6DL+A(1#Q]H^'_P-0-*
*8L&3E=)\1S-_MJE@X_N_/^]C'NK_A6IX)^,=Q<>(("_"?C?2AX5\6LL">9YEGJ*C[]M+_.!>Z_M'#"O4:Y7XC_#K2OB9XCK@_7->F5T4ZBJQ4T>+C<)4P>6'[;M=5LT]M4UY---*
*>3*FK&]73;DZ;:S7XC)@CNI&CB9^P9E5B!{@'Z5\Y.++\$_B6QTG3-_M5M/!-OHUMXE;7YKVRO+J2_P7=!]EK=07RVTN2,KD8&:^F**U.(X[XH>&++[Q5-MX?*
*LI/3UC::+4[*Z82/M&R.=7?GUP#@=5V X%+56_CNI(XQ:2I$XD4N77(*9^8-M?4BG?2P%#Q'JEG;6[6D4U__*X)-V]P6Y[?D:UX_N+]*I:\N=-G(!W-#D8SU-M'K5V/[B_2D*
*ZBBB@-HHHH-*****"BBB@-HHHH-*****"BBB@-HHHH-*****"MBBJMQ8BXO+6X\V1#-6(13A7RI'(]^YB/:NRHJX3E3=X.5)E%25I(\%*KZRO+-M?OSIVJQ>;*
*<17K)8WT3+%Y>Y65?*D)4+G(3.T$[.V\6WOB(-*]_=6D5-MF0Y&Q(T9F^48R.EN>>P[_BR:/_A'=6BWKYOV.5MF><;3SCTKT/K%"*ES:.Z6_JQ^&_>OV$_9+_P"3<_*
G_8/_H;U^:/3?U8:VUFU!)<-3KVU&QFM)8R%^O?O1/-/NDO^2&-M^_^P=)_*NS\"|-(IZ-_P|>4/\Z+6N_:2_P"2&^_:P=)_*N^/_CE1:-
*^UCX!UWPWX@UJUGU(0:}$M

*M|3K/C&1EDF7^^EO'\P'<9XKEJXFG2ER;R()7?_ ^9[V:R7%XZD\0K0D)VYYR M48W|)OXGY13?D?0N;6ODO3?A9^T6?C.^K2>-]-M=,\B(7-REN?L-)?_ --D6;'^"" <@ M?5R3^%>Q/DJ<=:\B_9>^7X>Z@C?ZU-;OUDSUW>D< C M:HI;R_%/I4O@3PWX>T+5O-U#68=;A:XM+?2K)IYC$OWW9.-H7OFN*KB:"4X2 MFDUO?H?38')+BFN:VKL[:.)V?DWT/EBU\=?:OA+\4/"\&BZ MX_B[P=9;3% M6_DBFNY)S+<*%PZAB<, 3@#*J\|0?M)?#3P?X;T:]MX9|2M|?B;ZM[+1M-| MV5XQIZ1XQC\A21W5CSUFM+4+LFMA+RPN9YQ\@FX5H_N>6!C!K]D)(;&P)LDH MH+>*%&$I3-.GN99&M;;2X8 2,8U+$=LGD?SJ_[?I_9\ZZ|-- M;:I7WTW.=>(4/KKQ?U:2^':.4GRN3Y92]GK:I\UN6U_=6MK)&A?\ ($T__KWC M_P#015ZF))&6**R[EZJ#R/PI1(K-M# MC.,\XKZ-;*Q^,3;E)RMN.HHHID!4 M110!XW\0D_X0_P".G@7Q%"-D6M)-H5|CHW'F0L?4@AQ^->QCD5X_^T1||OP[MBC_X^6\46Q3'7 20M^E>P#I7'1TJU(K;Z?WH^CS+|Y@<%5E\7+*/JHS=OP=O M1"T445V'S@4444 8OB.*\::FBFA6T"CS(6WA+LQSV(/;M6Q'!Q?I69K|L;Q6 M4L#SQ).Z@K&TH5FYI=^QK3C^XOTH =1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110!BZGI()?P78NKI@TT;_9_,'E#D<[<5M5B:IJ=O M)?6]D"WA)XV(:%BN,CHV,=_6MN@ HHHH ***** "BBB@ HHHH ***** "BBB@ H HHHH ***** "BBB@ HHHH CN/^/>7_=/4X|55T7_)!=OC&-O8Y_6DU>WN[B M ?9;P6FTOF2;OCIR>*71?^07;\Y^7TQ^E %ZBBB@ HHHH *****."BBB@ H MHHH ***** "BBB@ HHHH *****."BBB@ HHHH *****."BB MB@###\866NWFDY\.:C!I^J1.LL?VN'S8)@.L4@'S!6Z;E.1U&>E>,Z[J_C.U\ M6:CKFH_#O5/+DT";3IFT^]M+B)9-X<,C-(C%"-VCBG_%Y-&4J?>).I1^&>OU<_9Z\$Q^)/\>?A9=V MTRV&IH8L=Y#0R&)HQI MD[,#C@A""/0@X-?K9^S;X6=-)5STH#%+!58-4L)(/C>3U[5=_MGX/_13T;_KRA_]%K7&?M)?]D-\9_\ 8.D_E79^#_\ D4|&_P"O*|_T6M<;M_P!VE_A7YL^CJ?\ (DI?]?9_^D4S8HHHKL/G_K(\6^=\,\%>&]0US59UMK"Q MA:.61NP[>],|?//QM=_BU\6O"_PN@D8Z3!C6=?V'@PH?W<3?[S?RKFQ%5T]M=XZR>B]6>YDV AF&+4*SY:<4Y3?:,$5=V\WLO-I$'PF^']|\.?$47Q4\|?VQ>) MF+>'-G&8K*#9/RS.AX,C=>>GY5|& 8ID$=M!'#$BQO1]%5&_H_P !4E%"@_M]$=_M|ON_P"ON)S7,E?5=<KEIOTA!;0CT2_5[MW;U84445TGBB'17C?POD/_M@GXM^-O"%Q^ZAU"4;!IN> Z_LRCU{8 GZU[+7F_QC\ ;CXBMM.\0>&G2#O? MH,AN+!Y.$G4_?MW/|\UQO[!'KEKQE[M2*NX_BNO\ 7<|[*:M)N1@Z]N6%96N]MHR33BWY75F^D6V>D45Q?PO\ BCIGQ,T=YH%>QU:S;R=1TFX^6XLIAU1U]/1N MA%=I6\)OJ14HNZ9Y6)PU;!U14*\>64=T_P"ON?5:,H****LYCY>_,R^:,A_#]M^70M.MK2#OJUO\ 99M;EM"YTZT?@6S*I9LC.%%&?@MH7@RWUW6 M!$T4-,D/%KX5LI5@))5SOB(VIP7.>,,#([UAR6T4K;GC15ZLH-EKK>,,1R0 M1O&#D(R @'Z5Y-3!U9SG/G6JLM-EUZ]>KT9^A8/B/ X7"X?#/#3;IRYI-5%[MTDFHNSInW+]F+YHVO=-NY\$_#KQI#\+=8\#>*?&FF2;-X>E\.7.F6=TEFX1R-M&.PE,$JT@YY[.]:^ .G?$[2?@WH$GA.RT.&*^O[F\GB\1^?&ZV\DNY#&J=-"5 M_O5]/36L-Q&(Y8DD0=%=01^1]0 * ,.5%#+G2E\>B6EE9ZVOK\NQTYGQC#, M*;2P]4I23?-+FBU%U.5*-DT_WCN^9W:321\)_$CX=V7BS7OCMKNJ?;&U31!%-M-I[6IU*B03;5)=5!-) ^N:N^'0!MS\/\ QUX2N?"ZEF:Z MNPGR.VXGYL]*^W3#&=WR+|WWN!S]:!$@*D*N5&<=*C^RX]|.IM_EH M='^OF(^KK#2IMP4>7E$-/L_!>K>(S!(VMW^]74$]S-_M{'RTF;8BAC@ >U?1.VT22M*L.+(W5PHR?]:>B+&,*H4>@&*K"Y:L-,,W*]KM].M=WK#\S+/^-JF=8>KAX4G!3Y,^\GI%R?+I"-XWDK)WY;=;Z.HHHKVC\0"-MBBN"^*GO4M_A_9V|E90'6/%>1$Q:5HL)S)<2?WF_NQKU9CQ@5G.<;<7*3T.O M"XG6MC:T:%"-Y/^FV]DDM6WHEJSEOS|@\>?M#>'-'@_>6?A*V5?+UAR%N)ALA M0^^WG2CRI_S.|CDVUY6"BBBNH\(***** M ,W7;>.[*60Q*TB@;6V!F'/;-.$?W%^E9'B+[9]G?RS;?8]H\SS=V_,>V./2 MM>/|B_2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% %%5N%M>?\ EXC_(L?Q?K5^L74[>Z%|;RM=;[4SOXM_(!VG(YW=:.V] "BB MB@ HHHH ***** "BBFLZKU(`U- #]*@:.^MD^]<1+]7%,.4K5#@S*3_L\_RJN5 M1A71:HJH=4M@RKN8LW(C8D_I2_VG;_WF_[!M-A1RR[!S+N6]*JC48"< N3Z M>6W^%.^VO8SB7_OTW^%'*^P718HJO]MC.?EE_P"_3?X4GVU3TBF/_;_T^EO.W_#_ !I?MC9_^SS?7:/\..5A=%FBD'(I:D97O9XX8'$DBQ[E M(K&Y@N>.U1:+ _.@NWZ_=[G/ZTNIZ?:WT!-S;Q3^6"R>;@;;<=.;HF/|*ML;< M,?X1@4 7]*** "BBB@ HHHH ***** "BBB@ HHHH *****.M "BBB@ HHHH ***** "BBB@ HHHH *YOQGX_TGP/!;_:GEGO;MC'9Z=9QF;ZN MW SMCC')]SP!U) KI*S8_#FF1:|-K2V_U:6%;=[PIF4Q_DA W9(/^$8T31[*VC+K:ZIJ4DMW*>BKMAC**Q) M P';D|:T)M0^+2Z3)))H_A-IC"24AU*Z5T;;T&8""0??FMCXMZ->ZWX>T^"S MM7O!'JUC-/!& 2T27",YY[#)]A71>*+V73?#6]74#;)H;:61&|&"D@UUNK! M4XM05VYWW\O,%2$+D9D10+S\C|QKSO9XC:Y-F.SK'B 7/F-Y@:ZN 0V>>,,\);NYOB0RJ,X9R>?NXZU\C^#>]_&3QYK>M7.KM7GC/O!+|%Q.T\DPU2=3O)SD . .P P*_6KX.>)/B9\7O@1\--4OO#T.NVEO M9K>WL^JZLD1U66/<(MP1'. RACN +%1GJ:L <[PCHD?+\(/,/ 8RLIBG-27_M6T>M^LFFWLO7L?47A'Q,?%NDC4ETV]TVVE8_9Q?H(Y)H^,2,,DJ&/[!L-C]!F MMNO)_#'CSX@Z_P"";/7K?PYH&HV-RF_[':.I+%=(02&3]Y"$+]P*D$@9'6NP M\'_$/3/&$MQ9QI<:,;K-H ,K2-0C\]Y@SW*|&4]G4E3ZUXI^BXG!U*OS>ES6/NDO^2&^,_\ 2?RKL_! \ R*>C?]>4/_HM:XS]+/_DAOC/_M_L'2?RKL_!___%>C?\ 7E#. .BUKB7^LR_PK\V>C4_Y$E+_*^S_P#2*9I4 M445V'SA7U"]BTZQN+J=@D,,;2.Q,,*!DUX5^RS8R^*#XM^)=ZI-QXGU!Q:%O MX,.(I8P/8XS^%.G[5WBBXTKX:?V#IC^VO$US'I%HBG#?O#AR/HN37IO@CPO M;>"O",D:%. "#3[6,W7'0[1R?Q.3^~>>>_P!BDND%?YO.IE?SZ^G_L&1S]? M;Q,N5?\ 7NG9R^4IN*_[=9N4445Z!\@%%%%!1110!YU\0/@08>++M4CU_2-0 MN?"GB^1+G6N:,,@,Z_P!R9#\LR?]+?@17/Q>+?_B[X)7R-=:\%V7CFV3C^U/+A^E MEO.PI7M9R\G_"(KV6BN66'3DY0;BWVZ_)W7SM<]ZCF]14HT,53C6A'93O>.M/DI1<9)?W>;E\CQ\?M#W$?RS?"OXBQR#JJ;,D@_-9<&C_AHMO^B7?$C_ ,$* M_P#QVO7\"C]?95O^?GX(T^O9; T:?\ E21Y!_PT6W_1+OB1_P"""%?\ X]1_MPT6W_1+OB1_X(5_^.UZ_@48%'LJW /S\$'U[+?\ H# .\2/(/^&BV_Z)=\2/-M_!"O_P =H_X.+;_HEWQ(_P#!"O\ |=KU_HP*/95O^ZQK(KV6_] ?\ Y4D> M0^#1;?]$N^)^@A7_X1]_PT6W_ $2IXD?^"%?_ (I7K^!1@4>RK?\/S\$ M'U!+?^@/ ^BVD_P"B??$C_P $*_\ OQC(:+;_HEWQ(_\$*__':] M?P*,"CV5;_GY^"#Z]EO_ $!_^5)'D'_#1;?]$N^)'_@A7_X[0?VAKJ4;;;X5 M?$264|%ETB.(?]|-* *]?P*,#TH]E6_Y^?@@=^O9:O^8)?^!R/&Y/$/Q@\=D0 M:7X9TIX=V#\-J.N72WUX%]8[>+Y W^^Y'M74_#OX/Z3X!NKK5'N+K7O$UZ,7 MFNZH_F7,W^RO:-/1% KO**J.'2DIS;DUWZ>B5E^%S&OFU2=)X?#TXT:&%%%%!1110!G.]*L>FRJSA6? 4%PI)ST&:O1 M!NQ>1T]:KZGIL.J6K0S1A_]I(:*GU&0<&L&+1]4&D/*2JZB -=ENK1%"<\9?R M^_TIZ=1:G2O/%&7D10>]N@"F&^MA_RWCSL,*QSHMX(I8K<$.S#8S5VQ808.< M'R^>><4]M/U-.1CCCO?L1C)>>,,8.U&@:FW]NB_VS(V_PI&OD SLF/TB8_TK&O;37(I&W>UN M&FNF9?-BDE1%4?Q8;RSG'T&.DN+++6%U&V2&[DDLV!\Z5GC5T/;"^7S^8HT#4 MU?M]HIC_P!LS1H_P"G>8_\|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|R7!|\SVVX7'YT7861JG3+9L[D+D_WW8_S-/2QMD&%@<C _P!T5CQZ M+J/|H2"2]E_L_9\C+<-YN[W&W&/QIEMH^]*+UKN^<*&)MO)G8Y7'\>5Z_2CF M?<+(WUAC7HB#Z 4_BO/]359KW35AKMZ/M;=_+2+SI5BSV!RFI.\6W>:-K M[M3[++>$SDC[YMRVT#OMPM3^-2,Z7BC-<|/HVIC4X1#>R'3\?O6>X;S<]#MH"X_M,T6^C:H=2N1/>.+# \@QW#&4GON!7&/I0!T...US5GHVIVCEN=WFVXW'I.(-MERI7MORO7Z4TZ-K?]C*1>9U7NOVEO(Z^NW/2@#I\T9KG+S1M6Q:?9;QB21]I M\VY8#OLPO/XTZ31M4_M:()>R'3-AWLUPWG;NV!MQB@#H8??'E225S[$\U:H JZG.]M8RO'!)<.!Q"%C/F4CFL.ST[5;6VCBW1$*,<7# =?]RFA& 17/6+:A?6_F(H M*Y^_O+B13P<=-@I:[!S3K*6XFA1HXE+'9V\5GBTO$SM!-.'7HY'_LE4-+U7[4[R(H!: MRMUDM6VN761%/^Z2F&Y!*=%]:QU"U\5HBQ.DD.HVN<>>A^A5:.XU&VA> M5|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|S1/'WA]P=D32-4CN+#9;&WGN&F6QQUBX$2 MG:.<@>PZ=[_5CX%-I;?!|PF-%T]+1-+2P2."P MA8LD*KE<GD\@G)Y.>>;_&K6_P!K*UN?$%Y/IOP_TZVTEYV:"UFU.Y:18]W M+ @9QZ#BOV)_9P\5:;XW^!G@O7-(TQM&TZ]TY)(K!I#(8>2&7>>6^8'D]:[C M'\.X7.L/B*DLSK*<6M$N]|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`-6I+M^8K>9-_;_ ,4/^A+!-?\ A33? M_(5']O\ Q0_Z$OPU_P"%=-_\A5T)=(2"Q94NY6OX0MNS?=$ MAW80GL#C-6=8\8Z#X>M;6ZU76M.TVVNF"P37EW$DK'H$9B Q/M1S+LOQ_5" MWF?/(Q?^+/|4.A_M(>'=(\# ^:M.U719|*274---TT^G*?,D'FO>-%<8),#&T M;L@ [37V7LM/[=I)]-O%:7!*9X()3+'&^/!*57SC"K*E7 8$,#R M"\13JJ5^&;2- !W*0" 6QV/%B.D^%M?\ B;=_^++7QXTO:S1= M_"V&C)_9MM)/Y9.^[8QD95W)P7QDL,<5[7K]C>:EH]W:V%^=+NY8RD=X(A* M8B?X@IX)';-9NE^$=/\ "_@YM$LF;&T2"16GG;<[LV2\LC'[S,Q+$^I-4F>I M_;#AAI1QBI=$EMM=W=VKV2T??;2_P"(6M_LEZA8;_>6=CXU\-7NGQSM%>E MKE-|>[8IY)P<=0"?8FOU$^#NJ^)?@#|'_'A|Z;IWCC06CBL+/5=^NS!*[. M25+175<%BS'YP."QA#7/'O@#*1?$%YI^\ PL#2+H6UPT!HH+>[>%L-@D.(M2"\/<9'H37Z;> O_^E>)_V?M!T*+58-4L)|/C>WU73F)0L3O26(GGY6((SZ_YZ6/R+(,;G6,K58X^@J:2T:36M|M6[F!X(\>OI>M;_KWB7 MPQXJM-?'U.8116<>ASW @M8\B*-9(@R,22SL0V,MCM7>^'_%GBGQ1K$#IX5?0 M?#XR9+C6IU6\EXX$<$9;,]Y&!_V:UO TWB%|%\CQ-;PPZ(,.86N;:0-%>*-M,3*HY3=W0]#GJ,&NAZ5YE:K!R?NJ^V]U\|O\ @W/NZ<))+WOP_,R?%GB*W\(^M&=3U|[.+:PMWN)/HHS7E'P,^%;R:@?BCKY<^+_ $$0N&A@;RK>U@2,8OE|&Y7>>R-*YM8;M-DT:R+Z-2V]-MK#:1(8DB3^ZP&I;*=5O+N6^@4444R0HHHH ***** "BBB@ HHHH *** M* "BBB@ HHHH ***** "BBB@ HHHH ***** $/2OCGQ)\! MO$:W&M-I7A-8?M&O>(KI#;)#'OBGL98[=N".&9@HSR,\X%?8!)0!\P>#/V7] M!TSOG\,9+CP#IB;7I7A2>SOO);PM&+LM#L$]_P#+1\&?#$-C<_/S<^5#X'>+ MJ 7PO>.]X<\0ZEI'AM-%M|T?2]+U5[&19YB\3PWBNJ*C18D0@83;^%K[MUI_]J .#^!'A&|\"?"3PQH6H+>175E9I&T%_=QW4T/<1M)&JHVT$+\H XXK MO:** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ H MHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BB MB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M "BB@ HHHH ****|WJ-K8&$7-S#;F>00Q"60+YCGHJYZD^@YKE/%'B1-2 MOJ9!)6UO+)]#:-+=K(;;"""?+5>NO-=5&-*2]^5G^'EL<|64X]\5='X.ZGX-\0:+]|SIE]H>IVVHV\K02 MVTEG*1P<%<;>N;_7?X&>-=3\!? WX2^#_$.FZYX&^R013ZEJ6HVDD<)A5S(M(DD3=\TF5!5MI W9'0'YRO\ 5_%K:G.;R|UK[=YA\SS)9O.WYYSSG.:_1WX* MRZG-1*/#,L&X,4C9J93=9\TG&/;-&ZU[&):HJ,IKF_K?2']V*Q L\K5+$_M*3|O=Z]=ME8U_"/CO2O'$5Q-I!NI;.$@?:9K.:"0G_GFTBKO QU7(KH;Y MQR-XIG\4C73-'$BV&IRV,319PZ(]'R>N6(_"NGKY^7+?W59?UZ'Z/.G.C+D MJ;H\T_;2_P"2&^,_^P=)-*NS\'\BGHW_7E#_P"BUKC/VDO^2&^,_P#L'2?R MKL_|_P#R*>C?]>4/_HM:X5_O.O\"OS9]!4_Y$E+_K]/_P!(IFQ11178?.!1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,$T9F,0=3*!N* \@>N M*?7*^+OAGH/C2Z@OKV":VU:W0!]NGW#VMW$.N%EC(,_P)R/:K@HM^^[++[MR972]U&\}3[U_#'B'PEXGEFD32;,[>TU##X2.*=/+65ATPLFPDGH'371>/\ MQ-:>%/",:J:=:C;.8(K:1HY[]98E#!21RQ SFN6U+X.W>IZ=<:2]/Q\|47>C MRQM'+:RO:NA&'K2"W#D8|\^|<3\+OAIX5N)O$OBM=*&LZ1$@L=(FUB9|Z22 M*!6$DRO,6F\'+V6|WHM;:|!|#C2&1W)R6SN|.8K|GKXO?$EO@7\,9 M+[3=,|12ZIQ@M=4NM5D@F:9 VQ9BT3 NP7@@\ID>IKX5USX2> M8\0WFI1>% MUL(;BX:<6-O?3K#&"V=BC=D#V!^F*_4CX9^&-!|E1Z+I36$:V]K M8.R_9&0_(T;'Y@P9=P)),>I-;XZ+C"-T>1PSQ)EN98N=."#P791WQ+RW.I7^M(89)Y&+R2;8XV._%|BTJRFO6@C8*T@C0L5!/)Q51BY-16|&E=V1NT5XEXB_:>L/#WP3 M\($.9|!QK7Q%<6=O'8+,@A-QG!9CP<8XQZU4\7_M.W/@>Q^*-_JO@RY@L?^M!LD$=K*U_$/6\SWL*S+|%9VG^(M*U;ZGMK'4[.\N(/\ EPYQQ)XW1-9T%O#%AXM>ODLX-2O+R,QWP8'#CILZ#@Y^\. ^15^QJ+FNMM_OM_D/DEKY'H]%9^G^(=+ MU>ZN+:QU*SO+BV.)HK>=)'B/^T 25_&N$^,OQST?X2^!M?UV,VNNWVD(CRZ1 M!?11/AG5.1\Q7&|/(J84IU)I$5JQ*,I/E2U/2Z*S]*U>/4=']L]3D MHI[9+A M@[#$890W)LL]:AM?%FB7U[#9V'L6$]W,GF10174;2.G]Y5!R1QU%1RO705F-MU%9FH^)M{TB[@M;[5+*RNI_J5!<7'1O)_NJ2"?PJ6_U3M*D1+V_MK1W5G59 MYE1U(:(X'>CE'?8+,O45 4TO5K'6|-,O3KRWO|5\A9|.59$;'7#*2*TVVT M^VDN+[>.VMXQN>69PB*/4D\"E9WL(FHKF-7^(>C6/A^]U.RU"RU4P6LMU'#; M7<,&,944DI2"?3K@XK)^#GQ;L?BYX$T+Q D,>E76J6[7(TM[E998U#LN>_"1|MO7%;>RGR.=M%H7R2MS6T.]HJG']JC+<7,"7EN\UL,S1K*I:(?[0SE?QJ#2/$-MND:-TJZ9JEEJ+1<2"TN$EV?7:3C\:CE>]B;,TZ*S3XETA=6&EG5+(:F>?L9N M$\[_+XSN_2G7GB#2]:OK>RNM1M+;\N.(;>:=$DD_P!U2"[M5XQM."FT YZ==U?"E,=^5;*XU%RO8]/HK&O(/:^WG%(A/.M &&[GGUKBM.^.FFZC\;=0^:*VJK<6E@EZ+_[6A60L<>6$ZIAUZ_A1&E.=VEL MK_(:A)WLCTZBILNW4:/=ZG)IL&JV.VHQ_?M(IE&F7ZH#D?E3=:\4Z5X?V)?:MC9VI\BDPPW%PD;RD=E#')_"HY97M8FSV-:BO/?@A\7$^,_A&YUV/2VTE8;^> MQ\AYQ*3Y;,=V0!U!*ZJZ\8:#8R%+G6M.MW$GDE9,N-2'_N\MU|NM7.E.$W"2MU0W&46XM:FQ15+4]9L-&LS=ZA>VUC:&9[98T&>GS,0*:>>TT::NH'4+46# M %,KSU\HYZ8?.,UK.SWI*S+|%9VG^(M*U;ZGMK'4[.\N(/\ EPYQQ)XW1-9T%O#*

5Y]^T(0/@9X_P G M _L\Y_[8M7H-1W%M%=P203QI-#(15XY%#*P/4$'@BM*-/$&H0:C[&E]NAWEV&T^WWL3^[3'&W;@<]S71?%S1].U M.Q_;ZN;IWAFGTW4-,O;.1^L$X0H"OM=ASZFOT#ET#3)K"&QDTZT>R@*M%;M M AC€*_=*KC QVQ22^'=+G6]$FFV<@O<&Z#6Z'S\=-_'S8]\U[JS=WO*/6_RY MHRMMY6^9W?6W>[7]?3_0_.+XZ^'_(?>_=1*7]N^@ZQ-I_AK3_M'@?5DGB9-MTD;S-]C,G25F9F9?LQ>-+D0-9)+X#OJ]|O+|=S*=?fY=-C\Q"/A4WP]^&Y^&YD;XV MF_L_9#*;[SMW[WS?X?+Q|W'&,8XW5T?Q56%_"7]3ZL4 /B[2POXX.\5^A%G MX3T33l06_M=1'L+>.5!&+F*UC24)C&W9/E;UOJ[OXE*VVVFGJ;?6U>]G]_FG<7A\7WGPUT[X(A_M1OA;3?AU9?V1?:IX'U!VC@D)-U6+;23Z@5X-KO_ IE/V8LRLR_M&@3'[=YYE%[]HV|/][YN>/*VYZ]_>OU1,2[-[V&\:T@:[A0QOSF)?,13U ;&0 M/850F\&:!<7=S=2Z'ILES&O!OP1^ /CK2;-;/MQ3[/B*T6XU1)")):$;1QLZXV@*_ >_J;. 2%K;)[EFK?B8TZ_LT MUYGY]:X/A:?%7QE/QK;4>.QJ$W]CB\,PE^R[3]C^R8XST_3W][9>"Y_B)K?[M,VA?$>VEOI+G3[\W%M>LPEEA4JT2R?Q07=_I5C>W4 M^JGN;9\'C[_"LP)'X59FTRSN;R"[EM89;J#<BG>-2\>>%BUB,C/M74\TT7+ M%WMWV]UQ]W31=37ZUIHOQVTMH?(_[.VD:YX4E^.WAWX<1Z9;W.F;_$FE66]. M_P!C@W)E@0OS 8J/05!^U%#XTE^%W@E_B:%;R:"KZ-XF3POYI@^Q\|"V:?FQ MGKVSBOL"UTRTL9KB6VM8;>6X;?\4;J9&)6(')IS7&?&'X7S_%/PXFGV?BC5 M_"=]#*)8;I2I<<-|"LD9^61#W4UC#*%)5622U5WUVMO^.VY"KIU%)K^K6/B'M37^%DG[0LK_">.--|_X134O/:W61;0+|J_,YZ8W8XSCOFM#3X[OX;?L_M_!7XS:++;?:,KP|%)9:@D6 9[.65P5++>@8C_OJOI?X3?LPCP)XQF|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|L!WUWNDM?2U_R-_M98]]/+1W_(_*?2](L-6TB]BUWQ/X*T#QM}]C>;<;O97I^(8;GS/E*0'GY,_K4NK^']+U^,,/4].M-12-MZ+=P)*%;U 8 M'!K2>;*>GKS6'^U;^TAX<7Q#=?##0M8TSP_/]+B'Q'XEF?W&;+;,06 M>0CCVZ5]CV&DV.E^9[CL[>TUMS^1JY\%>-!VXDGN-#TV>>0[G MDDLXV9CZDEF6Z:3X>O=(.UM0\P[?+8, <$Y.>HKU+P)\+OB#\(_@9H6D>!#HD_ MBN:0WF]S>(6E\MWD^9\%.<@G'->_P!A:,]BAM/[/M?LL+!HX/)78A'0A<8!M'M5ZHGCI2]JG:Z3;UUOV3VVU^,$Z[<5'SZGQS\.?!*_$/]H'X*Z"\0+2OQ;B MXTVX;4;6S9A;RND)*KGYBF>QKRC3?@9X)N?#G[09FTJ.9?#%Q+%HZ/*Q6P 7M=F,9P"3U/I7Z)S:99W%Y#=RVL$EU"""(fWC4N@/4*Q&1^%1KH6G*MVHL+4+=G M-P!"N)CZOQ\WXUT4\SG3@H1NDDMG_>O^6AI"%.*27]:W/S@^(%Q?:K<_":,Q M1]&A1^,&\-)5^,(IY[*>XQ_F"(C}VZ%CC'X5AO/"]0_PI26*#Q+HFO^$+] M1\9V4<%IH<-S#:YCDI94\%%%

*8EWX@U"S@LI6L3(+IE55BCE9DSW(] MPW;5951_P#<8IANG;]\/B>^FT6;4Q0[-MK%$2# \,RSM@]DV9,;: / MSK:HH_**** .6U36KO1]:66;3B|*
*<_P#H|\#)=Q+O;.0,.1R>>!GI3Y?%UW'>Q M6AT2<7,H++"US""91U(&[GK712V\4Y0R1I(4.Y2R@[3ZCTH-O$TRS&)#*HP) M"HW`>F;I-*
*+H*WF8=GK=QF#O[Y]2X\31VDT$4]G<123MLB1FB!D;& M<#*Y^:TVLX'@$##01F$8Q&4&T8Z<=*62&&5T9XT=HSF2R@E3ZCTI#,D^*85OUL*
*M3:SB\9=ZP@XMY7^UOOSBB#Q5#.>WFB>Y.{5=X@9# L_/S3 MCXIA&H"Q-K.+PKO$&Z+>5]<;Z=I#D,LZO=7XU/RU-02P1 H<\]05 Q6DUM;1, M;DQ1"8#!E*C=CZT*
94'BN"ZGGAAMII9H/]:B/$6C_P!X;.^*CA\:6=Q8RWL44 MDEI$2))UDB+CKD[^*VHK.WB=WCAC1I/OLJ %OJ>]-33[6.!H5MH5A;EHQ& MI^HH QY?&MG#!\=|)#*EE)C9<-*
*)$$;/3#;\5)<>*X+66WBFMIXI+@XA5WB!D M/M_-:C6%L\"PM;Q-"OW8R@VCZ#I3I+.,"5XW>&-VC^XS("5^GI0!E?\ "4Q? M, L7V2?[9MW_&??%OV^NW?*
G%);>+++(N(H++:66W.)D1XB8S_M#?)O6OJEA M^T>?Y,?G8QYET;L>F>M\'9P0OO(Z0QHTGWV5 "WU!:_6'QI9W%A)?1O2/9QD
MAYQ+#L4CKD|\"GMXOLXI:&ZF1X+28@)<221!&STP=_/X5JK86J0-"MO$L+V= MO>1$3P1SA02OF(&P?;-9NC:SI\.F0(]];(5&"#,@QR?0UM|.I?V)IV2?L%MD
*M]3V*_135NHAEIJ%K*\LHN865CA2) 00/QJS]NMO^>\7_?8]H9Z!9VL)1H8Y M\L3NDB3(R>G Z4M[H5I=VLL*11V[NI EBB3XR",T-W!*Q:^W6W_/>+_ OL M4?;K?*
*_GO%_WV*KVNB6=O;QQM!%.R* 9)(EW-QC)P.M5-6\+VVI)"L3FP,<@<- MFVCC&_'8Y4|4AFG]NM_^>\|7_`V*/MUM_P]XO\ OL5&-)L@*
*/L+.VY89XX]D7LN%[,_F@#5^\#6W_/>+ M_OL4?;K?_GO%_P!IBJ6I:7 MA/\ 9(&)MAV")$5LI|$C ((9K%\-V9MHX;2 %;9TS_ *$?XD?AIG3/^A%^)' A%W_|\;KV"%&*
*V38_\/G;_/?I^*)/MUO_SWB_[[%'VZW_Y!Q?\ ?8K+TKPM M!IYN#-*VH>;Y(=,MM2TGPGX_U33;I!+;_MWMIXI(9D/1TB)@]>QKVN3{C?0UY"^R/\ C&;X9_|-8!M?_0* (_|*
*AIG3 M/^A%^)'_(1=_P#_ !NC_AIG3/\ H1?B1_X1=_|-_&Z|AQ7*Z7X|AO?B#K'A M&YLI;&_L[:*^M9)&:2]MF^5I$QTV2?(RGD94|&%7&$I)N*VU)_X.9TS_ *$7 MXD?^$7?_*
*/QNC AIG3/^A%^)'-A%W |\;KV"%&\0!XJ_P ,_Z9_T(OQ(_\(N__/C=>PXH3I >_X.9TS_ *$?XD?AIG3/^A%^)' A%W_|\;KV"%&*
/'O^&F=,_Z$7XD?^$7?_P#QNC A MIG3/^A%^)'_A%W__ ;;KN-0!=PZ3X\TSPW>6/?\,Z9_T(OQ(_P#"+O\ _P"_T?\ #3.F?]\"+ M\2/_B[_P#^-U[#@48H |>_X.9TS_H1?
B1_X1=_P#&Z/\ AIG3/^A%^)'_M (1=_P#_ !NO8<48H |>_P"&F=,_Z$7XD?\ A%W_/\ &Z/^&F=,_P"A%^)' M_A%W_P#\;KV'BC% 'CW_ TSIG_0B_$C_P (N_|_C=' _#3.F?
0B_$C_PB M[_\ -U|#O1B@#O[_AIG3/\ H1?B1_X1=__&Z@O/VJ0#NEQ+/]7A7QYI5G MO2-/R_|_"-/|#988)SZUWGPQ^%/A[%Z:.)!7A^WF59YVNKN(+A|FZO)VQENFF(?
#OC75M)@\9>!;6&UNFA6WO/#6MRSH >CO'\C M-[KQ7N7Q'LM<|9_!;5K/09K1M?U723':RL[V\!EDCX.2"RKSW!(\O7?[?K^= M _+WX?:)X/\ %MG15M=R:EX?NFNK?5+;
*(3>7=$=9 _4%>=VO37G? M[8&1?+LH5+ EGY9R/NH/<5[_H MW[-&D:3I_B(R>*_%M_XAUV*.WNO$]SJ@&H"ARD44B(JQ*#DX5!DDDYKI_&_ MP9\+_$+rPM<:'K-@L\-*
PB)++A$%R W&&,A4DDX&3WH Y?X[?%75? GP37Q3X* M,3-4OH+2,0>)EM9A*ZJ#E&&5(;.0:X;Q3\3O'WPQO/$6@^-M7T?7XJSPQ>.M;O9WFDZ>]DUI)&0CPD-(^[?
*G&U^&XV'/"N'CCX;:-\0/"\?A_4DFBTZ..&94 MM'$1!B8,@&!P,@<8K)^(OP1_ $Z^:[UAKU9FTR;22;6X\L>1*ZL_8_-E!S] M:/F_P""WQJ\5>%?V?*
6\!:E/_:Q5A2UTG2GER&O5O(]UOW3DDRS0S.C,<^N ?QKI[CX+>$;KXA.#X MVDTM&\1Z'8OIUE=Y^Y"P ((Z$X'!/3G%:?@+X>Z5\.--OK'2//%O=WTVH.L|
*MF_$DK;G\"#"YZ"@#IJ*** "BBB@ HHHH ***** "BBB@ JK]=TUEIMU<(H9XH MGD53T))]U5/5[>2[FT]\AB&99(?1!G'}4@4 ?/OP/_:-\5_'U=!D\/Z'90Z9*
*M;AO^$UCNXCE%[DP8C[+9J2#)(,#G)Z9WA;XO?'+Q3X0O/&NEZ+X)UG1 M+>YN1_8:-=VNH2PPNRD),6>,R$+D J 3QD56^ GP1\??L]V'AIM'M5O=*U,E M?*
$WAF2^4BSN&=C]MM'8[>9L!L[-I])QC(ZT >]=%_BKH?B?X8V?CN.26VT2>S^ MV.9(F.2%(,/0]%U^:[U;I8K#"VEWD08@9
M^*J.!W(K4^OPH'@GX0:=X)&K7:30V9@EU2P;R9O,;)>2,X.T[B<<<5E>$ M?@=+)X3\0V>JGXD>/M:%LQ/V'5]:6>VER.8=!$,COUH L_M">,_$GPT^'4_B3
MPY'I4\ME#=5\]?_"36]"T2!+G4KIK'H7>ULK:RM;F%KED^:PF5@ M6)4'^')(ZF@#K/@G\3+GXD_!GPYXVU:T32Y]2L!?3VL0)$&025[DD 5SWA3 M]K/X;^-*
=6TNSTG4[^:WU24VMEJDNE7,5A/< $F!;EXQ'YG!^7/8CKQ3/V?/A MGXH^'G[/&E^%/$=^^:I;I#8RPE9%A00E@VV(-$ K 9'S'D]S7+\$ $T/(//P MQ*0Z;!'K6AZEIMU?*
*6ZW"!8UBD+2L&SAB >W6@#MOA\?;/XE?$3XA>$'MA9 MZAX6U$VT?)Q=P=[!*N>N'#H<=''M+\+|#C_ &'QOUKQY;Z=;>59>'=7.FV\QS_I MD8C4^T4444 %%%% !1110*
4444 -D^XWT>2?LC?\FR_#/_L VO\ Z!7K1(,9^;<8P6Z9 MQ@=:.^>_&GQ(U?P,\7_A_J'Q#TK3_ VEM'J2?VMIE^;JWO8F@7]RD919?,,@ MB(3:"%P6E2YEDB/F#(P $C89S
*MGY]]#"5]=-M5(]UI>NJ;TZ?>FG*23@],KTW+ _,//$&M^>*/#[;IK6C'07 MN9Y'L[*9G[0EMP(S./X9&&6*C[N0#R#7BESI'A3XC?$WXBP_$K6I[>[T*>)= M+TN76)M/ALM.-*
*O&XO8A'(FYGE,P,W)4Q!05P<_2=<_XG^'OA;QK-:R^(?#>D M:[++:DFW?4K&*X,)([*ZG;T'3TKBFU*3:5O(Z(I16;N>%>%/C?XG\-? .YU@Z M'K7BHV-I?*
*3Z=XEO5C^SW=I%/*MK-<$.)26B6-V98SN'59^:N,\>?%/Q-_;6\B0 MA6?XA>'O%UK+86.L^^T&V%M-,R'5+,. F.9U.3+(VT9W$ y)KZVUS0;??]"O M-*
*)E>>VMIF%H"]E,T$L:D8RCJ05((i$=*X'X>?L]>&_ &HW>H>;<:[>W$(MQ)[M4%LJQQB0286."&-"Q=49G92Y*+SP*@H\HOOVF/%&FZ^B6.G6]_X/A:R\17% MU!(MM%?*
*2W*Q6TO4$0"'!==/@GY"HR.36]XC^)'BOP=8VVD?\ "P_"NMWNJ:E9 MV*ZV;!8QI"3+(3)/$DY5@_EA8LLF68!BU>R^&_ .E>&DUU85EO&UN]DOKY[U*
*MA*97=53:2RS=VB"X:$!9/-W-. N]&R!0#P. 3Q'(3XF^)/!&CZJ:MIE[K% MW9&V'B+58G$=FDNL-!YDRB7:8TR6[=@6 %?8?_"O_# UZ37/^$U6G*:+);2Vl:/8-!-*
*TD1M4*O&Q+,A&,%2220>" M30!\Y+\5_B)<>-K7X?Z?XH\/ZC>'5DM)?%$6F;D\I[2:9H_(678+A#$I^]MV MNI(?UKX6>,/$/C'X&[.UM-*
*)T/3=+M;5VDMX+*TCA2%F&&9%4 *2"02.M.5I8V]A&R6UO M%;HSM(RQ(%!8G)8@=R>2:.!IV=SYS^+WC#Q;X>7PI-XWT;1M.M+;7;29/$.EZ MD6M[?#C>)*
*(Y45URNX9&X<\XKV#X=^-M0\>_VG]8TM/\.%U32YIE6CGO% .Z M8QMC:A.-N>2,GIBF^/\ ?)-XTUGPQ*QMFT!2M1^W7,,ZEC)MC8(%&"#AB#$Z*
*M5V@&!3/;Q6*H5,+3A&FE/6]F[+7L[ZNW>UGHKNY\W_$?Q5XT_'O5;_ /S MW.K:-IGA^&?4?#2'<;B)I6#S0#/$R 9 Z.,KQD$5O!GQRU;0_P!G2VU[3]"U M;6#|CN;V'7;X*;*
W,NWSLR>>-JXR-G &,C''TD+"V6\>[%O$+IT$;3A!O90 M+(2^G:BE|HEM|GDAD>|C0+($F=6B8,2HSDC.^'>C>'K#6;18 MFU"/6+J6\OC]&)C.[@ ALC!4 H7&*
*!0!XJK\WQ$\6^Y-+,\N1/"M_?:GU2-M0A\1&P51IZF)I-DL*S%#*Y7$>2H.>0>_.GX]>,XY-*BN-?!^/~5;75Y]Q)=0=L M+%9TO7!189%@,P98RS[':+?M8=,90Q"P?*
*#3PC;>'IM!A\+:+%H^SH\3OJ'V@>>7%&=W"M&-Y'/W@*T8/C=XRNI_!} MZWC+PQ-;^++^XLFT&&OQ=:>JA^$?S2SNA4;]Z@9SC%?0_ASX=Z-X;M]2B2%K M\ZC?-J-S+?*
XF=YCC!R1T4 H[8]>W^'OA;TUF?5X/#>D0ZK.V^6^CL8EGD;U M9PNXGW)H ^/_ #\2O$WA.RT2T.M;8VL;K;PVC>)}4MW*VJR7DB[I$\[8V,8 M7')'))P,52%9?*
%CXAZYXCL?!6F>(| GNUUB;3I_%$>FF2.:);1P*:AKGP=H-Y936<^B:=#(;31>1++):1D:EG[+&4C!7;.#Q3M)\)Z)H- MI:6NF;/8:=;6>?LT-1:I$D&>NP
%SWQ0!S7P6\8ZCXV\"V]][YMY-2AGGM) MY;5"DE>IVEC;:?$8K6WBMHRQ;M9"@09)R3@=S7EG[4_P#R0_Q!];?_ -'I0!ZK;:|'\M% N# ^52U%;_P#'M%_N M#^52T %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$9!! M[UXKI'D_A?P_IMMINE>)/'FF;;;
((]>SM/&6HQPPH.B(HEP]CL!TKVNB@#R M#_AF?1_^AR^(O_A;:E_|=H_X9GT?_H GRAPHIC 28 ibio-20240630x10k018.jpg GRAPHIC begin 644 ibio-
20240630x10k018.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!#_," @,"@,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L"PL-#A(0#0X1#@L!+$!80$1,4%145# \7&!84&!(4%13_ MVP!#*
0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" &K Z@# 2(A$! Q$!_\0 M'P 04! 0$! 0$ $"
*P0%!@<("0H+_\0 M1 @$# P(5 P4% M! 0 %!0(# 0!4.4$$&U%A!RQ%#*!D:$((T*QP152T? D,V)R@@D*
*M%A&<8&1HE)B7]#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI]K*SM+6VM[BYNL++#Q,7& MQ\C)RM+3U-76U!C9VN'BX^3EYN?HZ>KQ\O/T!?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0*
*$" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H,'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-*
*$149'2$E*4U155E=865IC9&5F9X4;G-T=79W>'EZ@H.$ MA8;'B(F*DI.4E9:7F)F;HJ.DI::G]*KFLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-*
*G:XN/DY>;GZ.G]\O/TI?;W^/GZ_]H # ,.! (1 Q$ /P#]4Z**** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BO!?B=^W5\#?A*
*M#K(_'IC']\+;9;+3X9KV6(]PXA1]H]B0:ZCX(_M/?"[X]^:G@3QGIVO7 M,2[Y\+-"T-RB^IAD"OCWQB@#U*BN0M/BOX:OOB;?^ (;YV\4V-C'J,]IY#A5@ MP.;Z^@ HHHH ****
"BBB@ HKF8OB3X9F\>3^"TU>)O%$%/]M)I M@#>8L+' <\8P3]UY;X@_;^ WA77K(1=6^}>D6,JG.S6IS;2B7=%(IPRGY,<
*M&@#WBBN#^&GQV^'OQBCE;P5XRT7Q*T0S)%!]XDDL8]63.X#W(KO*_"BBB@ H MHHH ***** "BBB@ HHHH ***** "BBB@ HJ]J^K6>@Z7=ZE]%PEI8VD3SSSRG"
MQQJ"68GL 37RF/V]=1U/3+CQ3X?^"7C;7_AO"S,?%4"Q1B2%3AIHK=CO=!@ MG/' [5<82GL2Y);GUO17-^:/B%H/Q(\#Z7XNT& 2\T'4K874%T?E&SON!^Z0
M000>A\KY^U?]NRSU[Q/[&A_":X=>>)?B)!TGE7>I:]0:=& =1<2<,?H,'L3 M0H2DVD@;_&'XZZ!-M%KYO#%GJ6;G5?$>]0Z7!HC$X#R[,YST5 &2*#WP=|>,>,F\,ZB*
MVF7M]HI5O!-")0 >\@(R#D BKC!RV$VEN?4-%>,_!#]J;PO\ &S7=5\-QZ;K7 MA/QCI48FO/#GB6S^RWB1XBC)#IR.0>,CU%>RYQ2E%Q=F",>]%HI M+0 44F0.]+0
44F1ZTM !129'K02!U; %HHI,B@!:*0$ M'I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !7S)^WM\2/$7A'X8Z-X7|*
*(WK:9XB\:K%H-O?("-6AUZ*QC&7GC3_%]J:[;< MX% 'H?P$_9B\|_I-^'+72/#VB6IQM@-[]\\2R7=[*?OR23,-QR<|9P*H_$;] MDCX??$/OOX>\9"QF\->*]%NUNHM9\/MG<3*
8I65?G0|\C/O6Y\"?VA?!?[M07@RSU[PMK%M5>&76' @HKXZ=V"HO@RR9F8X M D.2.HO^TI\7OCGXKUNQ^ 7@_PY<>%]&N7LY_%WC.YFCM,N=#ATMXX?F8 |
M;N1]@FTVXUK]NSXHV-JQCN;KP!!!$_3#L74?]I5_P#XW^.=$M_@\/AW;3<-/IFK1+]XPLWS*P_NG)^G2N.N_VP'B9X]^,/C_ .$W@#P#I>K^ M(]#O1'Z]J-5)#!UK:*
*[1F:Z898L6. B 9Q4?QT\1:,\6?VR?@SX5\)7,6I:S MX1NY]8UR[LF$@L;QN[GWXF27YT1TKP[PU\&M*U\ ;+^+_AOQ:\1O&_@#7]U:FCC_C9!XE_P"Q-MQ_ $957]AO7=-TFY^-*
;WNH M6MHQ=7S!9YT0X^7G!(H I_M?_LI>&_#_@Z^^+7PPTNU\"?$CPC&=5@OM$A% MLEY"\!TL,\.85U@\XSQCH:[SQ5\<_B5X@_9@\) _$'X2>#WK@QAXGUF&SN'TN*
M[EV)%(N9&'S+D@X&-PQDGG%+H6T?3= M#TB=;F53-\C22[_^6H4LK_#]'P[^S!^S_P"#}(\7:]IVA6&C6%MI MTM]]-PL,33;0,;F(&2<\4 >GZ)<7MUH]E-J-LMG?
R0HTI\CUCD(&Y0>X!R MO5%;7,5Y;QSP2)-#(H=)(R"K*>001U%2T %%%% !1110 4444 %%%% !1110 M 4444 <3\;-"TGQ^(O&.D:[JB:)H]]H55;W6HR.%6VC:-*
*@TA)XPHY_"OAGX M;?M=?$GP?^S.VEZ3\]5\6V.AV3Z7I_C73;>1-)N!,,%$NC"R"4J%&2%4@X/ MQYKZK,6\ ;]\3/N9_&V(@>&H7N1?FMDECLX_O72QR+(\0IV52 .Y.,]<%X0_*
MX!? G3OAC8/=>(HO#U_8626\OA6:UD2^MY40*;=8=N201M&,I7737N?#S: MF,OBWL>0>+)8/AY_P3H\&^&_!7BV'6H?%&H6^D3Z_8%D1?M=RS7 0'!0#+)@*
*M@$=P*^Y/AG\-M!^$G@?2O"GANQCL-)TZ%8HXT4 N0/F=O5F/))[FOCSX2_LR MZO\ %[]D+QKI6I64O@V|\5^(;KQ/X=L;E"C:6#(KVVY>]Y*Y(QT:NQ^&/[=&*
*MD>#+,'P=|>XKCX;>/=-06]QX34+5Q]G$,>0=A'&!MP /3%?(_QCP>,]KI'@WX)^ M$=%^>)?Q&\0[UNVL66BH]OIP<;?N9[HP,1.1R>0,FO2?&2SSUWC/]G[P-*8*
M.?'+VX M)/BKXX^&7QV\6?:=.CU[QI8Z=X8T20X%II09F$KK_?E*AOH[8K]0UZ5^(HKKQ59V-DEQIUM&NG2$,$GC"99 _'CFOT \%:'M?^&_"FF:7J>M7/B,_M81'-
]MVBI+S]V"#^!X)KHI!M4^'GA30]ET6PA\01B'4-2DD?<7>(E4$XSWZ9R<0U>#>!_"_P &/V>/"/B_ MP+|>?!/A^#$]7N=4\/>,M=T=)
];4;.9]XA:X;&21M;_#.R6KNMEI;70CH MCT3PA\8_$7P%^+ A/FGJ'&B^OD+SMJOA2&T60C[I: \Z\K^\/[7W@[X/>!;#X=_&-'*
*M^_X5[XR\+P#3Y8M5AD6"ICC^5)K>0*5=64#@\4QVZV\E]"AP[_!+]HK3_(7^*_&=Y\0?#7B+3IK_M_$G5-7BC6^M98C\\3N@=2#P2*^J:^9/B\#_ -*
L?!8X/_(,U/G'^R^FATK M&IK9]T:1ZH6BBBL2PHHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** " MBBB@ HHHH ***** "BBB@ I" 1@\BEHH ^??*
B+^P5\#OB=X@FUW5?!$-IK.[%_MYKS1/N?3WE8]2_DNH8GU(S73_!SJE'X5? 2XEN_!7@^STO4I5VR.E*SW-VP[MCSI69P/B$5ZW10!S-M\-?#5GX^O/&T.DQ)XIO+1+&?
4@[!Y($.50C.W /MFO M/_C!^Q[\(_CKK^:OXO\_!Q>:RBA/[2M)Y;.Y9?1H(64L/KFO9J*_//_ (0? M /P!\|=\FTWP)X9L_#]O.P;=X0SS3MZR2N2[_B:VO#/PU\->#O$'B#6|&TF
MQU77[@76IW.Y-S*!@,020./0"NFHH YGQ%\-?#7BSQ-X7\ $.K:3%>ZSH$C MS:9=N[AK9W7:Q ! .1QR#6#\8?V?2A|>],M|+QUX8M=-2V):WFR444*
NNQKRW@W7&WT\URSX|LUK?&#X>#/CSX3'AOQSHL>.N-MPET MMN\CQE9$SM8,A!"(Z\@FNYHH JZ9IMKHVG6UA90K;VEM&L442=$11@ ?@*M M444 %%%%*
!1110 4444 %%%(3@4 +17QO^TE^U=X6\%_M)_*;1H_B%I&GZ- MJ6H)XOLH[ATBB1K0& 7@88;R-O7DU|/7'Q2\)67@="QO=>(M/M?"X;9!;2^9,F=O2,RHH!\KI)\0:M;Z4-*
5OXM,LC<$CS M[F3.R)<#[QP?RJ7&2=FAW3U3.@K&F\&Z!5S^_MM>2;S^W\"\- \22Z%??$S1HM1AE,$H1I)(8Y_<%6F53&"#URW%>UZ;J=IK-A
*M;WUA=0WME<)0;BWD$D@$&!:?;ZA=*D1W4*RK^3 BKU>,^/OVR/@O\,?$$VA^(_B#I=EJT!VSVD/F7+PGTD$2ML/ MLV*45*3]U VEN>KZ1H&F:! 8-*
,T^UTZ$G)CM(%B4_@H%7ZX72OB?X:^)GP[U M#Q!X,\166NZ<;:79>Z;>_L1^*-0U_P#97\&:SX@U:XU& M]D@N'N+_ %&X,DC 3R#+NQR<
=2>@!\KLVQ75['O$MO%/M\R-)-AW+N4'!1 M4E>#W'I=?P$M?$#:-+)\3M%%\LODEE,C0!\XP9PGE_P#CU>O:SXTT/P_X4N?$MU_JMM!H%O;FIDU'S-T(A
SYFY\MX[N:/S)V$+@%'<1[VP$$$%\5ZGX\3Z3XRT*SUK0]1MM6TF\C M$MO>6DHDBE4]PPI,.DKM FGI;E%>,^/OVQ_@Q\,/$4N@^)/B!I=A[)\O-:1^ M9D^"_'/A_XB^'K;7?*
#&L6>NZC1&D.YRJ@%CZGUKD/#Q^MQ\WA/\;ZIHFIW>CZG +3R;RPG:&:/-W"IVNI!&02..0-7_$_P"V3\&O MAKJ.>A>)OB#IMGK4548NK9!+<-
*Q4<2F)&$9]F(-;*G*2NM2')V9J8UK"]P ML[1(9D&%D*C@6FN M>'=5LI:TB[7?!>V,RRQ2#V8?J.HKA?BI^U#\+//@GJ4.G>-/&FG:+J4R>8EB= M\UQMI,8XU9@/<@"I49-*
V2U;25V>DV&G6NEVRV!G;0VENOW8H(PBCZ "O!?-MBKX ^,7AOXER>.OA=K]GKUC>VRV^I^[_%-W*EDY7[LUK(,B%R.HQ@]3UKU+X M9?&#P7\9=$?*
5_!/B33_$>GQOLDDI!=QB;^ZZG#(?9@*Q_$WI2'PR\&Q >9-,`M\..5I@<NV$5IJ2W$I5H)!%WQO[<99F7D*H)OQ5IYDI6$!-GB'BCX,`7]H&T M@\)^.=(\,?
*##X>R3)+]UKHVHMJ%_J,:L&\E6"*D:L0,GKCUZ5]8V5C!IUE!: M6\8BMX(UBCC7HJJ, #Z 8K@?A/\ M#?#GXX_;5\#^++'7YK+!N+>+?'/$#T+ M12*K@>^,5L?*

$CXL^#OA!H?\ ;_C/Q'I_AS3BVQ9K^8)O;^ZB]6/LH)IR:9J6KO_]f&3S+>:7__'$52__ '-<'\1OB%/X3_; M.\&6^H^(I=)+X5U*\OH;B\,5D"C+B60$A1^ /VO/@]\4?%*>'/#'CW3-3UJ3/DV@\R(SXZ^49%42 M?\!)KM/%?Q6\(>!M9LM*\0>(,#1K^\MYKJ"*\E\O?%$-TKY/_"CDDFH<9)V: M'=/6YM77AK2;Z]6\N=,L]B[3fL\MNC2+]&(S5^2))8V1U#HPP589!KR3X>?M M)F\/>%?\'NEZMK(!9;5"\9E ZF,NJB3_@)-5KG]LOX*6GC7_A$Y?B- MHJZ[Y_V8P>8QC67.-AF"^6&SQ@M5RHBQH%10]@8 P *I:GH&FM:UY?]H:=:7WEG*?:8%DV_3<#BIK[4[33-/FOKNYAMK*%#+3<%3C1 ,EBQX MQWKQ/3?VY/@1]WB--#M?B9HLFH/+Y*;FD2%GC:)F41GG_;8D@ A0-I;GN4M,*01K'&BQQJ,*JC]A2101P%S'&J%SN:.H&3ZFN(E^.G@*#0]>UF3Q18+I> MA7 M-2NMQV6LIQA&..O(Z9ZUY)\;OVH_ ?B#X<_$CPYX,\<0W7C+3M"GNPFD MO)OM\(#N$RKM5ADC6T]\[]NJ7'4E!EG=N22?Q->A>$O%VD^.O#]GKFA7B MZAI5XGF6]RB,JR+_ 'AN ./?%2XM#3N;%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+Q6]/$?+)E52__ '-<'\1OB%/X3_; M.\&6^H^(I=)*+X5U*\OH;B\,5D"C+B60$A1^ /VO/@]\4?%*>'/#'CW3-3UJ3/DV@\R(SXZ^49%42 M?\!)KM/%?Q6\(>!M9LM*\0>(,#1K^\MYKJ"*\E\O?%$-TKY/_"CDDFH<9)V: M'=/6YM77AK2;Z]6\N=,L]B[3f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

*M#46EV_B3P_,&MM2VW$C[VA)W0288893D=P<5]44 >,_&+X"WGQ/\`!WACQ#!J`M]O8?V,8S$9(7::W=9A(TD+*P&?4&-@X9<'(/-6?AO\`!/4/!7CN;6+55[:\ MTVTANK;2[>&W9)4CN+CSY/.8L0Q# %0.!SS7KM% `@?Q7_9 ^#'BF'Q1XGU M?X<:,%J.OW4%Q=SW\\!,DDNQCO)SUSS7H/P(0)\%? BJ,*-$LP!Z?N5IWQF_X M2?!\ X0#5? ^$6&D->?9Y?,_MD5"+RO*?=M\KG=TQGCK5/!G64S? GP"S'@&;_/F/5|HZK\4?&|\6#HEU#8 MQL/2*(9"_?3&FZC'YNGW4?\`?A=?S4BLKP?/!OL,_4N^HZC=W?X-*P'Z 5N, MGF*5]1BOET^9^_4_=)P|A-4QV%G/_@#*4?T.]M[XR_LMZ=(#\_388<_(-M+ PE9^MPS30B[Z,=[=PA\ OF]VB7@F_9HT>U/WOM26>/=;Q7-:\F^SN$_O(P M_2OU/(G,;+Z4O/] (G\C<>0_XR/&TNRM_Y/4_X!ZJX+G^T^$=&DSG=9Q'/_16 MU7+?"^7S_A[X?;K_*&B_D,?TKJ:^=Q4>6O4CV;__#/M\H_@[_*MY0O]HI(:QIT;- M>W<4>+A@KLP[[3D5[/IUR+RPMIU(82QJ^1]C->?D-2] MG4HU97M:WDM5^BOYL]LZA2:IU:4;7O?S>C_5V\B51117UY\L%%%% !1110 4 M444 %%%% 'EFC?\ )RB#_L7[^\`]K+O4Z\LT;_DY#0[_P!B_;_<7ZT=_!1 M110 4444 %%%% !1110 4444 %%%% "&OC33/@Q0\KKQ_+>:!42_ ;Q\,?BK\+=3U?XP>-/'EN M^O/"\020-;JQLKD^8-B*=PQ@#?&GQA+_PM[X6Z$-"UB)(O&:R? MVQ);*+"3=8W/[M9- ^=_/3;V/- TKNR/>!T%+2#I*&@04444 %%%% &7XGU/^ MQ?#>]:AQ_HMK+-S_ +*D_P!*^?? MN;,PA1088>2 3-_O.2Q_G7N'!0FH-I_ MPB\0!'V2W,2VJ>YD=4Q^1->4V\ M;>*%1A8T5 /3 _I7BXQWK)=E^;_ . ? MIG#E/DR^<_YY_P#L?\ |!U|N<+6D_)_F_| ,_.%'IB8_WD_OBE^@44 M45\Z?>!1110!!?W'V2RGF_YYH6_(5XE8:OK7B>^MKO5E5HH$=H95 4-O/ P/ M05ZOXXNC9^$]4E!P1 V#^%>=Z=$(=/MD QMB4? I7QF=2E4Q%.ES-12NUT>NE M_2Q]9E"C"A;IRIMNR?5;.V|.EFH+ZV^Y6BO):4DTSU4VG='>_M8_MCPW,%@QMG#_\ 1V5_VEX_48KHJX+X82^7/K=]>JSK*L* [VOMLLJNMA* MJ4444 %%%8I5(]VCCJ^UI4JE:7)35WY'-B<31PE-UL1-1BNKT6NB.E MHK@O^%SZ%_5Z;Q_X+9?*MZ/\5M%UK5K73HHM0AN+IBL7VFRDB5B%+$;B,= M:ZY9?BXIR=-V7D>9#/,LJ24(8B+;:2U6K>B1V5%%%>>>X%%% !1110 4444 M %%%% !1110 444F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XP M>$#X]^GBP^-'TOQ_U_>4--UJ62*SQC&+_]_Y49R!?QA\1?AGG*Y0A\1?AGG*M3X=:/I>GZ7<>'|:[!URVTVVC6.POC*X2-2H_= [XP&,8XX!P,U]74 %%%% '#_ M !E\=:%X"\ ;K>: _],>F6L]O-;1RR(!!&B?" *">QK_ 9IE6;X!> '1MRG1 M;4@C_KF*['QI=O@_7"#C_09^?^V;5Q/L,+!OV2? !!R/['M^1_N"I? Q+^NQO M%?NI/S7ZGJ%%%%48!1110 5E^*+_ /LOPUJMX>/L]!++_P!\H36I7'?&*[%E M*_%DQ.W&F7 ;]RA_4UG4?+"4NR.S!T_;8FE2_FDE||/GKP)_ 9O!FBIW-J MCG/JPW^'=;PZBJ.AP?9=$T^!Y=M&GG^*NFOFX!WU2[T0%&.WC<$M|\ $B\- MO3[O$!0:O2?0!F<5UCC^;!!\ W@76;G2B<%=>:\"7!+6W7\Z]$' M2OU+)],MHKU_]*;_0_DSCC7BC'/SA^,(S_|;CO?@Y)O^'6DC.?+#Q_D["NT-MK@O@H^? R1!X;NXC(]/WA[\ 6N]KQO/ 502%4#T KTWQK=&R* M:K,IPRV[X/X5YQID7D:=:Q]-L2C[*^/SF;EB*=/HDW\V!)_=*}SZK*8]-'<^ MK;7R6O\ E]Q8=!(C(PRK#!%=#\,]3=8;O1H"[61#0%NIB;H/P/%8%4Y[IM% MU*RU:$E9()0%23'1XV.&|_G7ET;_U6M&OT6_H]_NW^1Z56C]9I2H]7MZK;[IO MF>R44BL&4$'((R#2U^B'P84444 %%%% !1110 4444 >6:_R+X\G'_ $YW->R5\[_M >]!MOBO\%/%D>G(OB& MX\506LE]YC[FB%I<87;NV]AVSQ94M9I5ZD5YGT..E+2#I2U1B%%%% !1110 M!Y!^TM*)/"NAV .&N]9MEQZA27/_ *#7#$Y)/]7R_*_ZGZUE$>3*Z"\S_\F;_]M,#QV3'X7NY1UA,E>*[C[9\2+A\[A'I<_]_P!YB?Z5Y_XMM_M7AC58L?>MI,?7%=#H.I_V MYJ$M_G=N7^P7/_;'VVTZW5O%.A!610P(("MS_M\GNH1O^1\2_]C%^_/HR@#U2BBB@ KR?XH?\CW\H+J/Q=H]W']]>6ZV4\3/9VS3;6+QD [1QP#7LY3_O2|)?DSY/BA/^SF MU_-#_P!*1C4:5_R//A7_ *^'Y/_1+U3^VW'_0$US_ ,%DO^%6_#D=Y?\ C?PZ MZZ3]D$4%0)))++?M:^/?$WPY^%:ZKX;O&T:,ZC:P:IKT=C]M? 2+/Y_)M8#D.47GD$ M 9)&!?M(Z5P7Q@U_QIX9T:QO_"'A6W\:1QW0&J;.A8+N:T*D,.8N1&9 =IV MR$!@&&02*_/3]U.0\)_$6Z^%'P@NO$WQ"\?6'CS2//5M(UW1["XU&"7: ((_M*ARLL[.VT>4 &RO .:U/ G[1ND^+_%,7AO5?#/B?P)K=S;R7=E:>*M/6V^W1 M(;R&%T=T+*""R%@X')7 -?-__#++WC'Q7*_$SVWA3_A&;'_A,K?Q5X?^'5U] MOD^7#&}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|!\5TNC6WQ ^ 7B_QM9Z3\ M. [SX@:%%XCU5]9T_4=)OK6"2WGD1%>&Z6>1"%!0$2)NX)&.*-"/]M_P#]&C^_M'[[1M,\3Z_)K\[<:?IEE1^E$W%Q/ 778[+LZ]7V@8.<8KM]$:#|+ZKX)\4 M>);E+_ 18? ##$DD.KV.I0*EU:.B!RK(K,#D.,$$:=[C7A7P/^!_Q"T7QOX(UOQ3 MX=M--DM-9UW4,]+.[CEBMQ=)^ZV$'+9)QG&86\LYZGZ4 ?07C'XPZ?X2=#5W\0Y,$?6RCT MT:A%93H(]A]R@QQE+/#L/BBX^^]GX9UZ[B%W!X7M-MM MY[,M@=PVW+!+(_]Z0X(#.K+SG KV#XN?#>X'V^^WPTUWPE/;,)-1M3#'<(N3"M_5& IB!Q7D6E_%? XV>%_#\!AJ^^"U[X@\4VT0M8M6Q'(&:(_#_ .VCI%AX0T%O%^A.I#XPOM2N="?1M!M&O3)}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}>O>;^8_VIO##V?Q## M^$?B :YK$BS^- +"W_LA[H&P3]Q.-ZQ;6SR#ZK*?Z&NJNFVV\A]%)KBO LGV?Q9H3-P)K>>/ZDC<*^S MR%6I5?]WH+_TH_&./GSXBA1_Z=UGI$IV/8>M=G\%9RW@UK@W9"\ MZXVND*#$NU_$MMTV7]R >S(#_2OIL?'FP<_]_C:]3\F4445\8?K@445!?W2V5E/.W"QH7/X'IDU%-OH-)R=D>8>(;A=0\,ZU7]M45%*3Y9;1^CT/8$<2(K*0RL,@CN*=6- X.NC>>%] M,E)R3 H/U"%;-?HU&HJM.-1=4G]Y\%5@Z524'T;7W!1116ID%%%% "'I7EG[M/7_(O^')^^OBO_P#T97]9Z5Y9^SU_R+_B7_L8K_\ ]&4 >]4444 %-9@O4@?4 MTZO,OB7907_BO2HKB(31BSF8*Q.,[TYKS|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`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|_ M+?T9\?F&$ ^]5;1=XRU7W[>]"BBBO6/,"BBB@ HHHH \LT;_DY#Q!_P!B ;_ ^_MCC7]=>6:_R7YGT*O04M(OW12U ML><%%%% !4-W.MK:RS-PL:%S] ,U-7+:?%*_,E_#CQ/=*=K1:=.P/OY9Q43ER MQDZ!.%)?:.?WNQ\X>!Y6O-#;47!#ZE=3WS]O.D8C].5T%9GAFV^R> M&]*@QCR[2)2/?:*TZ^:@K11^W8F2E6FUM=_=|9I/YWC^;/9Z****^%/V8*YWX@WAL M?!^]2+]XPE1^/']:Z*N+^\I7PTD(_Y;W,49'J-U>=F4W3P=62_E?Y'?@(<^_M+I1?=? FBBOATN5)(^R;N[L****8@IL@W1L/4$4ZCK1 MN!UWPSE\SP?9#^X7}\F-=57&_?UQ71_#&^^RZE]^U?@? M'Y(@N7%U5YL****],|**** $/2O+/V>O^1? \2\ 8Q7_/Z,KU,]*\L_9Z_Y M%_Q+_P!C%?\ _HR@#U2BBB@ KSGQ^^?&&EX&?]"GZ?[\=>C5C:YX0TCO)-#+ MJ-H+B2%2]-YC*0#C(^4CT%>9F.&]8K#NG2M>Z>NBT:? 9_D>C@,1##5U4]7M9 MK3S5NZ_,X':W]T_E3;_$>+O#N01_LG4?],GKK_^%7^&?^@:;?_ B7_XJK&F_ M#_0-)OX;VUL/+N823'(97;,2,'@L1T-?/1RK&<\7+ELFG\3Z-/\ E78IR69X M7DBH\UVFMEU3?QT(Z5X1^V'H^H7'@#P_KUHEQKEEX?\1Z=KVI.7.1F26YM M+>0-*$3 ,/W.7OLP..]X!',UH?)^AOC'K7X0P_#B?6+3OEHOB1++^W:.QT MG3+I+FOY74A8{929"[$A=148[XP:\KU:X4^)OAM^R+|--:%DQ\>?#2*'7$ ML8FRYB&XW-CN[@P2/%CIE1Z5]1V'PU\(Z7X@EUZR\+:+:;Y*29-3@TZ%+ER> MN90NX_G71/&LB%'4,C#!5AD$4 ?%L7PO\2?$[!]DWXD^+A822>,OB.3KRZ>_$ MIL4Q!CLO3F!1[,I6KVGPG^UK\(-0^'T.O-XUT/0[6V@"W6FZA>1V]W8R*H#0 M26[$.KJ1MV!><<9XKVB.)8UCC54C4!551@ #H *YN^\<&'@4]?37;SPIH=W MK;$%=2GTV%[E2.A$A7(=3&OQP%K M&FE0N"$G0*)4$%YOP

*B^R7|W^2-&BBBO%/9" MBBB@ HHHH *M>#|_LOC?9T6ZM2/]5.;JU##<_P!G^(}&NS|P3^4WT88IQGI. M!3]=I+\[/A&*O44@e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|&\@(67CI MVKU3XPV?B*\\ZHOAK5-/TF[6WE:674;% [M'B\IMRA5DC(;ISD].AKRG]@M/_P!O/HRBBBND\,***** / M!OCQ>?;_(C^$M,#$K96MSJ,B]LMMB0_JU8%3>.[O^U/C7XCD(RNG6-K8H?] M[=*W_H0J&OG*CY]DY>?Y:?H? LV%!^QO7E0I=ID)\E@#QJXO?M<5^C>7^)9?(U;2(K:VE). M#LFBD=97XR23GO7N%`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`,;0M*?Q##]-E]EA>:.L3M:S6P,MRLLGEQ-"M%8[M[_* <'U`+>CFO%H/\>]2ETSQ4!]?C`-TK]5/Z/48-3.DQI<6TT+< MPY)H [S1_BGX=U3P/-XLGODT?1K82?;)M586_P!C:-BDBS%C MA2K @\XR.M?*O[7WQR^`?Q)T+P/IOA3QSX=\2:C'XCBG:TTK4X;B58Q;S N5 M1B<# (Y]Z^H?!WPKT[P_X%N/#>K^3XEAOY9[C4FO;5/*O)9I&DE+0\]%+,?EY M &*^;/VQOA'X\">'?!-_P"&_!N@:!?-XA2)KK2],AMY2AMIR5+(H.#@<>U< MV)_@3]'^1[62?\C3"_| 7R'_*4C[$LXCAUF(_N#^5356TTYT^V(Y'EK_ "%6 M.Z%L>/+2304444R3BOC/K\.?"WQ+>HX286,QO9[NXY*!Y:@#!%6C6%F MHVBW@CBQ[A0#^N:!{HL_P#M-EX0\J0?[2U)9IDIF& >8W_(\$KCLY.:\+ M%2YJS\DE^O\D?JF1T?8Y9Q=I*4ODK17XJ04R5@:D;$G I]9^O7/V32+N7^ M[&Q_2HHTW6J1IK=M+ [SNQF(CA,-4Q$]H1/T(K1N=:F\-.K=K"&"ZU;"S4IVE!X) M_P" EJX_X=W?V+Q5J-D3B.\A6X0>KKPWZ&M'QAJ4MY?1_9"<:8XG+ ?>D'\(M_#-*O:O@YX5RLZB<+^;V?RT9| [?YL%F<<;"-U3DJENZWDQGK$\],M;=+2VBA0 M82-0HQ[5+532]1AU6P@NK=UDBE4,"IS^%%Z_#Y4W2;IR5FM+=K'!4ZL\%% M@[]6J?`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|_45Y2E*;YIBS&G&,(.*[K[M5^;-CP#=8 MOM-Z0RJ+F)>P/1@/T-= [7ED=U_96MZ;?YPB2>5+_ +C;"5,&]Z4G;_ R]Y?* ,EZ"T445\]?H 4444 % M% !62K]G^S9)%^]$5E'U!S6A3)HA-$\;>#CW+A+EDI=CU+3;H7 MNGVTZG(DC5_S%6:Y/X:.@UYX8BAD.9;1VMVSUX/'Z5UE?H.$K+$4(5>Z1\+B M:7L*TZ?9L****ZSF$/2O+/V>O^1?\2_]C%?_ /HRO4STKRS]GK_D7_$O_8Q7 M_P#Z,H]4HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** ?H3RG@OX MTZ3XV\6WNA6UG>VS1K-):75P@$5ZD4GE2O'@YPK\]C]+>P;\[9:]G^,'@G0/"7@+5;/Q@H]GK5K!;_MS7$<-[$)$218GPP!{C)Y]Z\_ 8;NXD\/36JD9DTK39U [0[3^1%_E\X? 4\92;]YPBTNK2]1N_E=7]3ZGI&8*"]2< =56%XF\=^'0!L! MFUO6+/35QD+/* YYQPO4_@*\]'>?&>[^(MC/H?A*UNK/2;G,5UKURGE;HNC+ M A^8DCC<< 45L33HJS=WVZDY?DV+S"2E&+C3ZS>D5\^K\E=OHC.^(/C:X^+N MJW&G6TAA\%64YC?8WS:I*AP&W^3?9H3PMW;IA_O(?\#7>5 MYA<3O87%J]$:RWJ) [*O4IT8? E7I5K&10Z,.X-5'L>+F5-\T:J MV:M\U_P+&Q\/[H6NIZGH[' IQN)$5E(92,@CN*^/XAH..(CB5M-?\ DT='^%G\S[+#[%j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| Z7]M\2:C;Z79S+K4HA26:WAG M7>3;C "W"@KSRK#"%?HG9:=;;;"8;2UAM8B[2&.",(I9B69I#N222>Y)KD_B M1\(/ ^*D_A.;7%N2_AO68==L/LTQC N8@P3?O\MYA<3OXMG<6+WNI^'/%MA9HRTFIQX:O$0%F"[.EX:IS M7V/^SW\,+GX,?!;PAX(O+Z+4[K1+%;22[@0HDI!)R 3D#GO6A\0=4\'7;V/A M?Q8T;IJ[>1;W$*_P"QE@;_M\.>K-9YTMHC-X:O%\R5SM1!\G+$\ 4R|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

MB\S:K,9HI_[\3[LQ_1>//K'P%K7Q8\;,:\3]!U3^Q+6^MX$ND-Y,LT/DR-_MOC5%_=R*Y!!WXQU%?1M9WASP]8^%-#L])TV'R+&TC$<2%BQOZDGDDG))/K6E M0 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M%% !29KR#]H/PA\6O% <6B#X6^,-/\)O TIOS?1[/|"^?MS&^,$-Z=:\; X M4]^UQ_T6/P"_ . B_P#R-0!]AYHS7QY_PI[)KC_HL?A__P !% | D:C_ (4] M^UQ_T6/P_P#^ B__ "-0!]AYHS7QY_PI[)KC_HL?A_| \!%_^1J/^%/?M:,U\>?*> ,:X_Z+'X? | 1?_)&H_P"%/?M:,U\>?*> ,:X_Z+'X?_ /1?_D:C A3W[7' 18_# _ HX"+ /(U'Y'FC-?'G_"GOVN/^BQ^'__ $7_P"1[/\ A3W\7' 18_# _/X" M+_| (U'Y'FC-?'G_"GOVN/^BQ^'_P#P$7_Y&H_X4]^UQ_T6/P__ . B_P#R M-0!]AYHS7QY_PI[)KC_HL?A__P !% | D:C_ (4] ^UQ_T6/P_P#^ B__ "-0 M!]AYHS7QY_PI[)KC_HL?A_| \!%_^1J/^%/?M: M,U\>?*> ,:X_Z+'X? | 1?_)&H_P"%/?M:\;+ M^+_[7/A;X'?$C3/#'BJSO+>SO[7[0NK6P\U(CNQAXQ)\V/<9^E>8?*> ,:X_Z M+'X? P# 1?\ Y&KY! ,#\-? $CPMXYTJW^)OOBN\4ZLJD7@NK*,1K%'N^Z<(G M.?:@#]9_"/C?07'NC0ZMX=U>TUG3H1E;BSE$B_0XZ'V.#6W7Y$_LL_!EXW:] MKL&M_#N2]*V+,/.UJZ/8*? J*_5_PI:.0@BB@ HHHH **** "BBB@ HHHH **** "BBB@ H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **

*9K'4=2A@FFR<#;C,"A(R/2@"WHGAW2O#6EQZ;I M&F6>EZ=&"$M+*W2&% >N$4 #\JGT_3+/2;&*RLK6"SLXEVQV\$:I&@] H ' M-9L]"$=@<&NRMKJ&\MHKB"5 M)H)5#I+&P974C(((X(/K0!%IVF6>D6,5E8VL%G9Q#;';V\:QQH.N H ZGI2 M6.DV.EZ>EA9V=O:62 JMM!$J1@$DD!0 .23VfUR,?QS^'4OB|>%$|=^''|3% M_+&CKJL!NB^<;? *W;MWMC-=1I7B+2M=TH|_3=2M-0LD>2-KFUG62-61BKJ64 MD94@@CL0'/CO\ #?Q?XCDT#0O' MOAO6-HO;-=6L%RUM*)X&FC5S%(0'7{^5@">1SS5 MJN2\#,%SP1\3T'N'(^+]#\3O9MMN%TC4(KHPG_:"::@P=V?#&CMI<^'F2K(Z=.S/+ M:&V3RI&9MS%DQ@DMR21R>:T@H4 8 X %W6J7C^|\9P? %GX22[&_S")/+*<[1\H!S7T%IF MJ66MZ=;;AIUW!?6-S&LL%S;2"2.5&&596!(((Z$4 %WI=G?SVLUS:07$UK)Y ML$DL:LT3X(W(2/E."1D=C1>;59:A+:RW5I!34.B^(=+\26LESI.I6FIV\".H/6L#Q/\7_ -X M+ ^T V]XQT'1C:W$5K.+_ %&&$Q32+NCC8,PPS+R >2.>E &IX|\$>'?"%I': M^(!'TO?{6)MZ0:I9QW**WJ%=2 ;O:-HFG>'=;AT_2K'VTPAVS*ULX5BBC'H MJ* !^ KR[X5^-->T'PVSTUGXF'~_"%_86&N7;P:CI$PAMM/LU*A(+EW"S(2 M0P/(R 236#^T1^T3;^'/V6?&?Q+ ^&FO:+X@FTRV22TOK:5+VU+F:-&!V-@X# MGC-'0 MXA<-.(T$S*$,FT;BH)(&>N 2>//<^M8^ J^,.]$+.6.GSZ|K-AIHXO72"!KZY2 33,. (TW$;F/9156Y0!G:IX= MTKQ3ILFG:SIMGJ^GRXWVE_D\3_5&!!_*H?#7A'0O!FG_8= T;3]#L=V_P"'S M:;;QV\6?7:@ S6O10!4L-)L=+M7MK.SM[2W=WD:*")40LQ)8D 9))))/Q@LK"UALK.! M0D5O;QK'&OHJ[/859HHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M "BBB@ JLFHVDM|+9+1(LDEN) 9%1B0K%>H!P<'V-6:^,O$_B_QGH/[= MOC72O ?A6W\1_ JO@S1S]#U:[-KIVGQ1W-UNEN)%5G.2Z4426.>@!-`V6= ML8+'"@#))/3%5-(UG3_6GFPW^CVMMJ5A-DQW-I*LL3X)!PRD@\@CCTKQ#P3\: M?9 <'\0)B^&'Q<|+Z7H^MZS97%UHNIZ'=O=:9[\<0'GPCS$5XY45@Q1@05)(/"M/C'PY ;;D^'?P,^ .F?#OX36>/'YU;&R\-Z9?F..SGAD9@?,=?\ 5EB[R.W* M4G(#=<"@#[B HQBO!? ?QG^(.D_%_2_AY\4_#6A:;?:_I]SJ.AZKX9OY;FUG M-N4|^WD$L:.LBK(K!@"K#/0C%8.F?'OXL?&*YU35,A'X*\.7?@6PNIK.WUCQ M5]LUK)%ZV!@*E.U2*)|L>]6422'#$'B@#Z$O _!7HNE6M|XK\Z(/'VGZU\(?VJO%7C/X<)=QIXRT MT7W@_7IL!)UAT^!E:2+.0KY=77A@%/1}^@-? .;#^(5_|>/&'PC^'G@32KZ|\ M/VFGW8US5]0>WT^V@FB+$3*B,Y?<_}(@.0&)*A: /IBBOGKPI^U7_8W@CXG7 MGQ0T>+POX@^&\|1ZY;:9.;NWN$EB66VEM68*S"8.%56 (;@UBW7QL^/VA>&) M_'>K_"71%\)Q0->2^'K36Y\06|N%+;V0Q"%G"\M$K[N" 2>* /I^BN!^ GQ M*G^,7P8\& ^-KFQCTVXU|3(;|I2*0R+$77.T,0"0/I7?4 %%% !1110 E>,V MOC[Q5?QO.FH6,*&655C^PEMH61E'\9X%>S&OG_0V T_J\ 73]_'FSU|#E5 M.$X5)2BG9K=)\^?\)O+7K4JM"%,.BFIMV:5I.%7MNI-B^\2>*\/MC<-J%C*J M,F4^PE=P+@$9\SCK7M-?/GB%@=`GY'WH^_| TT6OH.C-:<(0IN,4KN6R2_E[M>HN&J|-K5KPJ3:N2^(]*@T^"_DU*T2RG(6*Y;=!'(3T"MG!S[5Y-^TI\--2^(5]X M=- MI,^L:7;6FL0:A;VEW';7#I<6#PHD;N0 [,V 3P#R>*\OT?X2^)-/@\,ZE MXJ^%UGXVTRVTW4-.B\-Q0Z=_UD\ET7BNI+8N+42SP[%F;)CL93M&UV_^>/O# MZYR*.I]\KU_II#PMH>M:M8Q66OZW!HTAAU:4M%T>>\M-/D #.DLB*0612"RI-MN*X?0_5/\#=#\2^[_!?AIPEKUA)(=/TF-FU-;Q9HDD.KXLU)/F-Y;?EKYC## M#OFN0\GQW\%M-UGPK9_#ZY\70G4[Z_T:5]/U"V@@G2ZN9+DK=F5U>)T:9E9 ME20,%###)}4 'O!QUJ32XM1:YNTNI.LBL$9<;[T9MS_ND=3VIUZ'UKYMU M?X)> (+SXG;KXEBT#3[:6_P!?\-.C-<6TD>7CM5)NCN(#,%8C&X M@$"OH(=! M0 M%% !1110 4444 0W8G-K-]F,8N-A\LR@E V.,@--(_\ =]ZJ/P5?\/_ +=$ M\K&?QL-_C?| Z;F>C4445RGJA1110 5QWQ%U_-37N_A:_M'PUI M-UG/GVD4A_%:IS.8_NJ;[-_BE_D?#\&5+8CS0?6,7|SE?|- -&145S=0V:*\ M8PQ*SJ@+'&68@ ? B2!4M<1\50]QI>G6L9Q))=B13G';,;Z_^//:.^&QN(>%P\ MZT5=K9=V]%^)^PX6BL16C2;LG^1G^+)ENO%|R!RMM:QPG_>9FKZ<= M3M:")#'\ZDLIYV|&'XJ6'XU-:-- ,DES%BI.IC=?<\/PL? M*9C!0Q.G%,.S^!, C<****]@\P**** (;S_CTF_W&_E63X&_Y$O0?^O"#_T6 M*UKS_CTF_P!QOY5D^!O^1+T'_KP@_P#18H W**** (Y^87_W3_*OS[_90\&: M9\(O^">>M:?%/PWH-E/\ $%]{UO5HM6>U66YCDC>XCB5'(+*B)&/D! /S(=:\31W%W]\DZ!WN)9'M68, MQ8D -\O0'C-5]3A\|?_`]CG\|':SK- MHFE7GCRV\,Q7NCZV-1DT30KFZC26W M>ZW20Y(\"D#BO>X_V,;_ ,,P76B^:/C%XU\"^"+B1W\AO3FMHH(17)+1 MVL\L;2)M9D#@ G&>*\,T?]F_X?:. \&)_A9'H,=QX.N8\AN[6YUO]D3X,GX82>%E%:'HFE6MN?L^HVELD-Y9.HRMRER M)!*I&{S"V21SD9KY#^&*K%^RG^QG.T@F@B^), -RW1BT]^JL2>|$CJ\Z^D8/ MV+KVYL$\,ZW\9?'FO?#1 (_^$8NKB!#- .EO-=I&)Y(L?*5W D<$UT]C^R#X M+B_9PT_X,WDVHWGA_3V,MG?B80WMK,)VGCFBD0#8\,-\I Z#!SDT UKQ_| $[Q5 M\3+? PWZ1!6M>1%.P7*_ZN>18D4S2)U5#(U!YKJ?C%^S1H/Q1\4Z9XQTO7[M9\"/=-@-L `)/#[]}-),DY,$\,JR31YY*N.=.#T(H TI?]G+X=:.5\3M'>:1X M=m? #_B>PAFMQ/HO^A)=QR+ADN(X\+,.!P1O!P0#V%?&?P(TWQ[\1/$GQ%^(EQ M\'O"/Q.US4?$NHZ8^I>)|>1)M.@MYC%'8QVI[V\@A1%7/!RV\$]^K/AU^S$? M#GCVR\;^,O'WB3XD^*=.BDATZ?6'BM[6P60;9&BMH%5 [+\J9LG%4_&7[*;7 M'CK6?%_P^^(/B'X7ZQKK"368=&2"XLK^4# G:WG1E6; P77\/?GF@#QI[%_ M_P ,)XA^- /@^33M"^% A/Q9X=*IX=\/:\NH'2=1F5XC=11!$,*2H22H :.+C MVW?V9K?1OAW\2?#GP|\< "O1O!Q0TK09;71O$NB0QFRUZRB\9W9AD4!E?|C M/%*-PW$@\FO5/ _[*/AOP7X-\8Z7_;GB+4?$/C!"NM^;,B_*ZQ<':50LH'E M! 3L50%7/0U7^%OI+TG@OXA6WC7Q7\0/$?Q(U_3;&33=(EUWR433H)"OFE5B M10TCA%#2-R0* .?_ ."BP#?LC^, 0"/M6E\$?]1&VKB]0^#WAGXI?\%&?$UW MXITR#7+/0_!6F7-OIUZ@DMFN&N,A4E>(_*{H?;N!P7)'(%?1OQP^$,F_'7X M:ZGX+U:\NK"POY+>22>RV^:IAG29<;@1R8P#QT)I+^'$>G:7\:->^\)$=Y=/J MFKZ1:Z/:+:MM\E(X)))%9>,IB92#DXX% 'RSH?[.W@>__ &_/%VDR:#:'PG:> M&=/\2CPR(@- ,?5'FEMQ=M;8|\LNI:,!E>KENO-:^E^:*^'7{6/QL\.>&M/M] M$T+5OAQ;:W=:=8QB*W:\$MS"91&N%5B@) &>IKZ.T[X1:,IWQfUGXDI>73: MKJ>BVVB26K;? (6*&62577C=N)D(.3C %4+[X%;3??%?Q%X]>_O5U+6O#*>&) MK9=GDI LDD@D7C, ,A')QP.* /F3|ES|ESX,ZC^P=I4VL>%=-UK5?$?AIKZ^ MU34+=9KHLT3& ()*P+1B)0BH%("[01SFKOI+OI_@:QI^Q9INL^+= L,%?B/Q M9H#7NJ:WK,2W5[*QC98@4G:MR.E#28[J?:YSQA"FXX& V#Z8H^&/PFTIX7?"'0_A]87=S=:,I6FC3(K MFXV^]6[W4YW,S#2Y(TRQZ ML0GU.*]M ,6*S3? 6 8>5_BEHC(G4G:)B2/H.:Z"X_8^\)W?P#\)_#"34M7B MB*&*;1?$%K.L.I6- S&6*7$;JNT,-[C&"#*T[U!%, 90?2 B!HWC/QU\1/$G MQ-UC00]BQZT((;6P=UVM*L,**K2[>-]9(^N" #S+P+\&?#'Q' ,|^.VO>)= M+M];70;70%LK&^02VR32V;9G,395I%6/:K$$]';&,U-9VD7P2 :R^,=GX'TN M#3[.|^&L/BDZ-91".WEU**>XB618EPH9U50< 9[U|%^$?A)IO@_XH^/?'%M= MW4VH>,.IZWX=O+M\]'I)"T2>7@9Y#DG)//2FP_"#3(?C?>_$T7=TVK77A+PZ M|F=OD"%+AYPXXSW7A.1UQCM0!X7^QI\|/ASL_9V\.>+-?'2/"B7QKIR:MK M^N:Y:1WMQ>7,PW2HSN"0J,3&$7 &SIG->'>(/$VL?!KX-?M+^ //:NM7=CX,\ M, ^)M+TK2=465I&T2SU P?;88G)R%@\UP,'-0U-/AO\5/%W MPT\..I<275UX=TC{//:122$F1K83(S6^XDG"')X KH[WX*Z/\$_V!-#&BK;A!>?9T^V9Q_Q\):L>9YO\7F!LYYS7PH%]K5K^P1\.?!WARY;6- M-\5_$FZ\W\W+]!M/|1M&O;EO*>Y)C%P8U4Q@YW$<|JZ]VU[X/V_AE="'Q" M^-T^G+}$(A\'G@N_M),/^/ OY'F>5_!CSMN:-V*^C_P!GO|EBQ'[*6E_#/XAZ M";#46N=1N]+MY=K:;+-=/<1)%(O*R0[HP&'1D/44 >0?%?X*>,OS'PLN]'C M_9[^'/@7^R[8S:,XDTWQ5%:7&BRQC=RLRVJL-C ,V6PP!R>&-4O-$]_O=- L,"V5%MC%WEU;7'A#5FU:TC@V)I#!)#MDR"=N)">,'(%8.A_LU>$K#P]\2 MM!U.*7Q#HOCW6KK6M4LM0VE \ZHK1IM (4>6I4YW \YR!0!!#^R3\&H_A^/! MQ_"N? #K.#Y'DF-[*.IFX^^>9>89,_F;MV>%[+7_ (4?^EM=:7;_#B*[@TFPADWQND]N M(&$C/EFPHR#G.>N: /'(@G\-/"$7[9W1044?A3I QX[&U/X\E7-A MS+95>: M8|+|F_)W8QNSSFO/|.^+NI_LI?#7XL_]U9I_%?A^^BMOA[;NV9+VTU60K8J MF3_V>5I5;T$8%?7GA3X0Z;X2^*WCKQY.WEU-J[/W*PBNK>7;Y4(M(FC3R\# M/(8DY)YZ5X=K/P_L_C5^WOIFOW&Bs:9*Ms"G4YH&47>IW9+11*Q&'6"+=))D M9VO(*/;?@))\;+X&_![PQX)LF$PT]S6.XN<(-$L=:O- +FT2TL5O[=9XX#)8(\DBJP(#G8@W8R , \FOLK M'&*X+P3\'|-\#?$CX@^,.K2\NI{[QG<6=Q>03;?*A-M;B!!'@9P5&3DGF@#W M\`|_6? C%\&OBI9^'TTV[U71OC;]^O1Z1K0/V#53;W08VMQC/R/G.2"-RKGB MJOQG\4>$?$/[&'[0\&D_#V/X8>.+(6D?BOPX(HT*7)DA,,@>/Y)(HW3E9%_W< MDC/?Z,N/V3;6U*ZUIGA[QWXH*ZE?\ BV\|8QZKI=PB20W5P27B;,KLEAP2 M-C@|CG{[@G[%^B7WPF^(/A+7?%6N^(-:|>O%)KWBF\:+[;.8BGE*BA?+1$5 MJJ!@ GVP >;_ +(NF:=|=O&^I_$/XFWW|L_9SP|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|H7XL7/|PTUG3Y/@SJ&A^)TTV?!5KU_J5I_PCMJHB8O="X60 MR21@9<((fQX!QUKZ<\0>'|-\5Z''Z- K%C;ZGI5_]M=6=U&'BFC889&4\$$& MO!XOV%_AJ\$.F7.J>,.=0\(PLIC\(WGB6ZETD*IRL9A+9;,8'R,Q7C&,4 ;O[M%-G-8_LE?"2&>- HI1X:LF*,,$!H@P_0BO:ZBMK:&RMXK>WB2"")0D<4:A510 M, #@ #C%2T %%% !1110 5S4OP\|+32O(^@6#.[%F8P#)).2:Z6BM:=6I2 M_AR:]'8YJV&H8FRKTU*YUTG^9S2?#*PK&ZNN@;>&4A@1 ,"172T445*M2K, MVDF|=W<*&%H8;_L*:C?>R2_(*3%+161TA28I:* "BBB@ HHHH ***** "BBB@ M KS?P1G_ (7)\2>< +IGX?N&KTBO-O!"QF^)(SG*:8?_(#5UT/@J_X?,;HG MD8[^-A?\;_|3;@O_)XG)*L M >F:]5^%,QF^'^C G)BC;_|=D_JEKRGI7I/P=E+>%KF!M!?W"#Z%|_ LI> M[FT;X6_9K\F?"<)U.7,^7O"2_&+_ $9W5B1^@GDQ]%4?^S5W%275NMU:S0L,K(C(0 M?<5Z-X6O&U#PWI=PQW/);1LQ]3M&?UKW\GJN,YT7U|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{\FO2YIH[>))Y976.-%+,[G M 4#J2.\O\|W4%W\;_B));RQS1F'3OGC8,#^'Y65N%C4L?H!FOG31,G2+-F^\|8D/U.Y MOZUL\1- 1_LOP1K4X/SFV>*/W=QL7|6%>.0PBWACB'2-0@_ 8 I7UN31M1G+ MNU^"_P""?DO&552Q=&DOLQ;_/FO_D6/KJ?A/(4\7ZI'VDL(F_[YD7|\TU^IZU?7 M(LI*XG/2*-G/X FO)=(0QZ59@>~|I22?[1D_SKM/B)XEMI)TB;3V+F[OX)(H0 MBY>)WD)LE@!{URJH(U"#HH"C\.*_+ M&?\ @<;C^>*NG+E]0E_>C_Z4OT(J+FIS7D_R9ZC1117Z*?"A1110!#>>?\>DW M^XW\JR? W_(EZ#_UX0?^BQ6M>?\ 'I-_N-_*LGP-_P B7H/_ %X0?^BQ0!N4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %>7^#C_Q? 7X@_P#7M8?^BJ!,N)C;V]DH MC>4HI;RXQEFP.@!Z]K\!?9N_CCX_=H);=C:V!V3 !O\ 5#T)_P BNW#?2\5 M_P#MT3Q.Q_BX7_KY_P"V3/6****XCVPHHJMJ=ZFFZ===7KS&USIGC/\ LQ#9_P"A:ZJU4TE773+8R?ZU-MT\Q_P!YOF/ZDU:KI*Y532@MEH\VA_-K5E^+.K\Z8JE-K2,HR? I%IO\$=_9VWV.T@@SGRHU3/K@8J6CK17\|D)**LM-MC^RFVW=A1113S%*OWA];2B@#I,_AXV!P?8+WC\R/_+YD8?TKHZY'X[<@?!+X<'_QX_E775]MELN;!TO))?-/\4? (8^/+BJGFV_OU"BBB02. M$AO/^/2;_<;^59/@;_D2!'_Z\(/__$6*UKS_(I)O|QOOY5D^!O\ D2!_P"O M"#_T6*-RBBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH * M*** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HH MHH **** "BBB@ HHHH **** "O)O\!JX_:^(''XQFQL3_ ..#_&O6;\C\)9'[M1_CK/&[3K3'X(G^- =>'^W_A?Z'BYEI+#O_IXORD>N4445R\M'?F'Q3\4S74\ MWAJSPD31*U_/GD(Q.(E|V .3V!)376^-_%D?A31)+A-DM|(?*M;=:C,K)3T'T M'4^P- >,*)7EFGN)FNKN=S+-.XP7;&,X[=@!7T>583F?UB:T6WKW^7Y^C M/SKBO-O9T_[/H2]Z7Q6Z1=|/67Y7VNAWZ>PHHHKZ@_+ KC-9NC>)=WB\[@'D M_P"ZC!L_B1G\|V- ;U'SM|E >3Q-(/X1_='N1^59DL*RPO%@!64ICT!&*\7$8 MA2]Q2VB[OU_X'Y^>A[-##25&3?QZ32|'_) EZGK4;B2-67E6&12UD^$[S[?X M;TZ8_>,*]W^\ORM^'H--U? AM>DZ%6=)]Q;7W.Q_6.#Q$<7A]>(CM.*DOFKA11-M16!UA1110!I^#;C[+XK;,G"7EH>/5XVR/_'7/Y5Z'?DZW7]G:EIM\3M6WN5W-MGT1_D;_T(*]7%?39-4O3G2[,_R? _!N?.YK'U2-3NOQ7_L+111?TIXA#>? M>DW^XW\JR? W_(EZ#_UX0?^BQ6M>?\ 'I-_N-_*LGP-_P B7H/_ %X0?^BQ M0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%

Q,|>3^)?$=KXAT_P5H6JV3V5VT(EOTT**=IY0!^_9 MG"]ROE<9&,G-?5WC7X_^&O'.N7FIW=UK5B^H1)#]-OIFK3VL%^BKM E1&Q]W MY25VDKP217H.GZ,:Z3I|O8V5O':V=O$L,,$2A4C10%50.P 'M0!*.?%'QS MXRO?&OC]XOO&">%M;M)+3_A%[(ZC>0R-"UM"\4D%C#"Z7OF3M*KJQ8\%/DP# M7T)\ M-U34O&GQ.\0;WK&]WMW%XBGTNTLYKJ3[%,6Z06S$10GCF0N=QR<'&1 MS7MC6\;R1R-&K21YV,0.KGK@]}> -!T& /DSPAXFT2\05,MUXV^('B+0_B2U_P"$>M;R1%BC%TRVT$5D%*2V\D B9I2K9#LV]MYY%2XF M:\P;4+ZVU:XMT6YNDVG>MK% M$ZKE?,9G;YMN*^T]H!S@9J..VBN{}DL:2)G.UU!&((X;N'Q#/;.L\9CN97;Q-91Q73J5'[TPR/U49#$XP37K_,2%\1?" MO7/%OAW0_$7B>3P[-INA:A?WLMQ)? WEA!)J$\&H3VS,&(;R$5B]@A,,ZJ.E? M6FQ?0?E6+XS\&;7X|\W.C:O%+):3E&W6\[P2QNC!T=)$(9&5@&!!XQH -^=_ M@3XITB[__&C]5T;P? XRUSQ/X13PFEV8M1O9;RVBNC=[2T4TGS,2H&X,F"G@8 MSBOJ2N\ 2"71OA[>W^H6T^I;KK%\D<,^]:Q>O=W!B0L4B5FX1-68[5 |:+$G M)YKMJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHH_XH 6BD!S10 M%% !1110 44 M44 %%% !1110 4444 %%% !1110 4444 %%)D#O2T %%% !1110 4444 M%%% !1124 +1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !129!. "BDZ4M !1110 4444 %%% M !1110 44TGFDS0 ^BF9HS0 ^BF9K\4;HVCZ1[%X&E'D6DD@\B$S/D=-J#[.MQ]J -NBO%[WQOXXM]!:X9;5F_LRSNE:"UD)DE,TBS1*>079%0*.8#'BK(-7Q M%_CCQOINM:I:Z5HWGVSQ6+64KV[-Y3%MUT),'!_=D!7W]GR/Y5X 3)!M/8G W=!C&22*DC^(7BO3_%EA:;O8 MK'I/VV\CFO8H&13&LI6(G<2 JIAF;//;TH]>HKPS4OBXL;7/$$=O;%=&8D M/V; ALVDVH$4MS7K=1 $;9QK)WDQ:)-=W!W-/:-!Y,=KA)\1^: MQ^9LQQ-G&"'XI;,Q=\0-8RTW1,+9=.U&%;<&&;M]&DBN3GT5XE;\_ !*\9/86<5S8\_9KE=W]I M7"V,C+:1,8?+F"V^;AI> 3C'-IJSXF|>>,M#N66UM/[5TTRV1CNX;1DD:)H M9& ?6@#V2BO'O%GQ-\01>,\_LV@1)?:$;5=]W#;M.(F+XDER MI^81CJH[\5+X0^)>O77B'3X];L)=.\.-I\Y;5;V)8A/IT^:*3&7M8!BJP@H3.S9S@@R* <%1GK6S%XG\;: MU<-#;*+,0:C%9+,.$LERK.TC3&)H---DS/=SH)0DIEB!? D#08%N9+'W\F>-X MO,?3[H!9#Y%4X4>6)1C^:^%'>@#\$]A-V;U%P4FG@1HD*.FV3 WC! MY&&R*V.T /HIF.,T /HIF.,T /HIF.X3XD^*/$'A_4M BTBS,NGW-M3RKJ%X(&F-HB[-C[5Y.6.WVW;NBF@#OJ^\K|`^,_$NL:9<_;O+9S8"XBNIK2 M2)<>6#)$4P=RQL0"V03G !(-6?#GC#Q%J6F>$&:'=--->FVU;?:N-T9CF*31 MG@*A:-""1T8 @$T >ET5Y#]'Q-\80^)+:./PO+_9<-W/|H\M'DDFME,T2%3@ M!?WI&^.04>N[^'FH:QJO@W2%KKQ!#';ZU)%_1<42%$60,0=H/...*.CHHHH M0G%?)FC>)-BA*UMK^N:AX,\7GX9_"Q2M0GTNRU2RLXJG4M MYTZ&1(V9\|\0*8^9CC17DWQO0$VN:Y%=E.TNE: M9<6T^EZ+I@D#W#RLL9**$&U%+,B6'6NMT+X5VGQH\1\_M=>#;UO(&JZ!9);W0 M^],7"Z7:O!,I]4E5&'^{0!], ^.?B9H/P\NO#=KK%R|=WXAU2/2-.MX8FD>.:X M<,V,*#A0JLS,>% R37!^/?VL?!'@?Q7>^&8DUGQ/KM@%;\_LO#6E3ZBUD",CS MC$!"".TG..U>*_LL>(_$/]3'Q6LO'/C#39M/;X8Z6WAV?B.UC\,Z;Y@O|JZS ;-TQ MOCF1P&C<9'RL >1ZBN++*?MJ_#Q3XAT2GM?369!#I.H:YH|Q96FH.?NK M%-(@4ENP)!;O,/VB/&'A#XK_!NV\6^=#=/\ [?\ !2?A_Q-I^:+/!,L&"\;K: M6[@W$JX4?:D0F)BPW B$C/RU> .;\^,WPY^*O[.NL>%/#&M:;XS\3^*88[3PY MI6D3K/LZF&954YC\IL.7.-H4_2@#UGXD_M6>!/A=$XRE\-ZM++J=Q>VD4,^ MI2ZJD|U#ID*M TVY=M7\,W45KJ5 MK+$T;1F2(2O..CYD=&RG\!P?2ODKXZ^--.^!WB?Q+\0/!WQ%TU/B/I=CIUIX MK\$:@PDC\0,D2"$(O^L2X*.0CIN!X##@UO\ [5/BO5? VDPKEY;ID;72I"HZLLY:%C_=E% '5_&O\ :"2[UWP7IG@K6IXY+'XH MZ5X5UZ2*!U()(9))K8.PPV!LW;>0>,BNU^(_P"U5X)^'"BU_T@U;Q#XCAB M6>ZTW9[IDVI2VD9Y#3")3Y>1R >2<.5X3XP%,WP=*\$/=N@?\GVKQ!}3|(MU'6[P\M$_'>V3WC! MY&&R*V.T /HIF.,T /HIF.,T /HIF:

%%%% !1110 4444 %%%% !1110 444 M4 %%%% !7S# _ ,%"LH_V7M2?4K.34=.77-%:ZLXEW//$-1@+OJ!U++D8]Z^ MGJI:KHVGZ];BVU*QMM0MA(DPANHED0.C!D;# C*L 0>Q (H ^B6++)/=3/&4@@B@'S*X3Q)8 LW-;ZB[MN8W*2,},GN=P.3W-?9-A\%_ .E>+)/%%GX+T M"U\1.Q=M5ATV%;DL>K;PN=QfGJ:Z"\\,Z/]% [/>76E65S=SVC6$L\MNC/);$ MY,+,1DQDDDJ>/;@#YMT3PELE?\ !-1-+M[&",.Q?X8-N3FN \+Z]tW@OXO\ [/?C'Ql,L/AJ^^%!MI>CZO?" 1K/6&$,DNYSQ')+ M#A58XS5M8=Z^UQHFG#1AI L+8:2+?!)+A\E?{A;GN:M\09C:LV\;<8QO5/5O!F@ M:IX<_P"$?U+1+.O]"\81HES:I);!%&%41D;0 ,#'&.^ M5A7X-^ O%W[M4G[.FG:->6.L>++'Q)+)-=V167[+:M93_NI)%R 7<*RJ3_RS8XKS#Q9HMGXD M\)>>))U&!+K3{[]I:WMKFWD&5EB:6W#(P[@C(/UK[K\-?"/P1X-M+6VT/PAH M>DP6MQ]K@2ST^*,1S[2OFKA>'VLR[NN"1T-:I\%^'V5E.AZ<5;_&J,#:1\W@ M((N#Q_K>|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|OVN?&?C?P]J/@[PM;6WDKXLW7B'6+* M%2FRST;3X+V2&.!O"/N]]]-I_>D(P/6@#[4I:_7-_(RZU\3_ SK? P.^'NC> M.X+37O$USJ%MJGB&;2DE$K06;7 *P[@%!92,9Z$,_C?^S'IP\7^,-8 MT;XF?#RS=3K;V&G-8ZE!\8*;E%#LL]>G+++P<#/8T ?5]%5[""@U.RM[RVE6 M:VN(UEBD0Y5U8 J1[$$&O(KO]L;X+6%W/;7'Q(T"&XA=HY(VO%!5@<<$'Z$4 M>RT5SO@3XA>'/B;H":WX6UBUUS27D>);NSD#QEU.&&1W&:\) .;9^*?B/2_B] M\/O /AOQOIG@%=3T_4=5U/5]2MTG5(H3#"BJ[*;M>(W?^*&^E`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|V M^,OPKC^)5MIDGV32+Z?3VEVP:Q"[1NL@ XJE\(?A???#^[N7 MCMM"T32I8P/[-T-99%D8#"NTDE,!5R JKWZ\5M_&N%KGX,ZL:J0TJ2>6VA2 M9G=%=FN(U$+,GS*LI/EEEY 11N$K$H'?(_$["32FUA&T1[? M;+':?D1B;VP3<>5+)" [S8.25S]VOJ'X":\?>'/A/H=AJ%M+8S)]H>.TG^_;P M/<2/!$1V*1-&N.V,=[/0:A/_'X/^N9_F*FJ$_|`%'/^N9_F*.)}*** "BBJ M>JZI#!%D]Q,20'"%5%&6=CPJJ.Y)X I-VU948N;48JJ93\3^(HO#M@K%K&G8- MY:2/M?@>2+,W*<]DMV KSGX>>&IO'^!0>,]E>'[*;ST$3K6PH9P1)Y(;>)41Y) M&+2.0.18DDGOF@#Y#A^- GQ(,:M\:OV7/&%MKBWABZOJ9N(M4:=5@9&T]0*=-MY.!DD#'KQU]Q^U;^T1X/A0_"/O\'O!^]V7C3QQXQL)!!TO1-)E6YD:2X0Q& M23;D)&@8N6; ^6O<;WX(?#[4M#M-%N_!>@W.D6DTD]O82Z?T,CG+LB$84M MWP..M^$?A-X*\ 3O/X:\);>)H$[C:\VFZ?% [#T+*H)'M0!<^'WAM_!O@+PWH M$DOGR:5IMM8M+_?.42H6_';FO"-1^&/QSFU"ZDMW^$WV=I7;)S[$N#)M+';N M/7>*M M1^;_Q.^+?B;1/'6@Z/+XM\.6D5NS>)X$ DLY%,JR6_F'#!2@LP++R&R#VKZ$K MB?B!\%/ ?Q4N+.X\7>$=(\17%I,03:A:+(\8SG;&(SC;!0!\|_LA^/O#7PV M^$WQ+URYUM-)^#^F^,+N'PQJ&I3D01Z>?*3;$[G)A^T-*$"\|I&_;&[ET=#D,"F00:!4U?X=^%]>| (?\(KJ'A_3;KPWL2,:3):H;8*I M!4"/&T $ C [5I:IH&F:WHMQH]_86UYI5Q$8);*:(-"\>,,"IX(QVH K>#?^ M11T3_KQ@_P#1:U\__%CPYIWB#]N?X(R:A:179T[P[K]];"50P#VBJX!{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|V_9XWE# ;_W0$<;.?,VD+@]ZJGP-XQLO'WA6PU[3 MUECMKM6_=3!MDB=6*/&P[,K]RGW% & [4)_X_[.USA\Q4U0G_(_]_P!$!;O4T^46$+CDH M>]5LP?\LT.\L =#X&^+-3\6>)G\"$0CW\2++]^HRKNM]/C;E%?\ O2-U M$?4@#.%)-=YX-| (V/@G08=,L0JJI.2:XF.Z6XE8Y>61N[LI>T71,+PII-IIFG6R6EC:1+##!&,*B*, 5=HHJSE"BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ I5ZTE*O6@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>?'J.UD^%FL"\ENK M6V$ELSW=DBM+:.8N8B+@!@4!^[(§A)!P%->5?!KP[J/CW7O&%WJNN.IY.16<,< M\=_:,KIOL989H[9P44-&0/,?8>1O4G[V:Z)^T3XMT_0/ $YM+U?3=4T:TUK0TLI;3XK:S>*T MN(H(IX3)<*#DS/"<,"PSC8O+5[+!-O!@\ >#-/T0W1O983+-/<;=HEFEE>65 M@O8%Y&P.PQ7344 %0G_C\'_7,_S%35"?^/P?]?7 $3QUK.I:R_@ MSP64CUMPJ7FKRJ'BTT.,C"_QR[,L%Z 8+=0#O?$KQS+X4L;:QTR.*Z\1ZF6B ML++>4XC3:,O/*>T4:_,Q^@'+"]_P!\$Q^&=''^U2/)ZN!B68N=SRN.S M2'#8_A4(O1:B3Z(Z*44DZDME^+Z+_/R^1O>" _!FG>]=#CTW3DU>-VVH:W\7M=AU#3=0M;#04CF:RCELVG M,J90++*=ZA?,PQ5>H7![XJ9.QO2I^_T;O>R3;_K0]F^T1?!\|%_.D^UP_\|4_[MZ%>9Q_!R?770^)-35[53DV&CH][CXZ;Y-QO:E[W8;5&VDG]R_\ DCTOS%_O#\Z/,?^*\UN?@;917!?2-?U MK28I#^:\@%VUPF/\ 8\S)0_0XI]:? @I+%Q;^,==1.PE=)#^>T4>]V_K(A)4>L MG]R_^2/3-Z^HI=P].\Q'PCUFW)6#QC.\;=3=VOF./H5D4?F*$^!%M*/-NO%? MB62]/)FAOS$@/^S& 0!['-'O=OZ^X=]/\S^Y? -)'IVX>M&>X>M>8CX(,5\QO& M?B.W8X607"B,#WCVX]/YTG_"GI3U(;ZMXKN9M.5AOBI4>VEN%_NO/TO]8!!0 M.CN*+RI?U!PEJ/23^`Y?YG3+\4/"[Z=-EW-VP-Y>2? W9D_YYA_NE_\ 9SFN MJ!! (Y!{UR9^%?A8ZG&-&_LE/[("[!18^8_DV_WL&7X%V`*-/ MMCP+6WU0E$'8*7#,|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l? MB3=:;HZ-8Z[8Z9!]VO6<%@T")+/IU@^G37,&!.#*[0#.>%\PCDK M7NGP6\5:CXS^&VE:IJKQ2Z@7N+:::%=]3-#<20^8!V#B,-C_&]DU'X-^#-3 M&H>;X?M8WOY89YY;8&"0R1*5B=60@]R#B]RU+2?9VN'+?[;_ #_P!W-2RZl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|-M@"DE5'@5"?^/P?].HC/K>MP>$K.0?+I M>EQ^=.JG_GL,2!NQV4$#WKN?"'@K1_ ND)IVCVBVT.=TDA,Z2=^[R.>78^IH M3;Z%2C"*TE=_A]__/F:.](HIVJU9?2BN5.R*>E:.8:%9K:=_M9P6-LO(BMXPBY]<#OIU? &T*5_"@DDEN!f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|%_.D^UP_\|4_[MZ%>9Q_!R?770^)-35[53DV&CH][CXZ;Y-QO:E[W8;5&VDG]R_\ DCTOS%_O#\Z/,?^*\UN?@;917!?2-?U MK28I#^:\@%VUPF/\ 8\S)0_0XI]:? @I+%Q;^,==1.PE=)#^>T4>]V_K(A)4>L MG]R_^2/3-Z^HI=P].\Q'PCUFW)6#QC.\;=3=VOF./H5D4?F*$^!%M*/-NO%? MB62]/)FAOS$@/^S& 0!['-'O=OZ^X=]/\S^Y? -)'IVX>M&>X>M>8CX(,5\QO& M?B.W8X607"B,#WCVX]/YTG_"GI3U(;ZMXKN9M.5AOBI4>VEN%_NO/TO]8!!0 M.CN*+RI?U!PEJ/23^`Y?YG3+\4/"[Z=-EW-VP-Y>2? W9D_YYA_NE_\ 9SFN MJ!! (Y!{UR9^%?A8ZG&-&_LE/[("[!18^8_DV_WL&7X%V`*-/ MMCP+6WU0E$'8*7#,|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l? MB3=:;HZ-8Z[8Z9!]VO6<%@T")+/IU@^G37,&!.#*[0#.>%\PCDK M7NGP6\5:CXS^&VE:IJKQ2Z@7N+:::%=]3-#<20^8!V#B,-C_&]DU'X-^#-3 M&H>;X?M8WOY89YY;8&"0R1*5B=60@]R#B]RU+2?9VN'+?[;_ #_P!W-2RZl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|-M@"DE5'@5"?^/P?].HC/K>MP>$K.0?+I M>EQ^=.JG_GL,2!NQV4$#WKN?"'@K1_ ND)IVCVBVT.=TDA,Z2=^[R.>78^IH M3;Z%2C"*TE=_A]__/F:.](HIVJU9?2BN5.R*>E:.8:%9K:=_M9P6-LO(BMXPBY]<#OIU? &T*5_"@DDEN!f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|%_.D^UP_\|4_[MZ%>9Q_!R?770^)-35[53DV&CH][CXZ;Y-QO:E[W8;5&VDG]R_\ DCTOS%_O#\Z/,?^*\UN?@;917!?2-?U MK28I#^:\@%VUPF/\ 8\S)0_0XI]:? @I+%Q;^,==1.PE=)#^>T4>]V_K(A)4>L MG]R_^2/3-Z^HI=P].\Q'PCUFW)6#QC.\;=3=VOF./H5D4?F*$^!%M*/-NO%? MB62]/)FAOS$@/^S& 0!['-'O=OZ^X=]/\S^Y? -)'IVX>M&>X>M>8CX(,5\QO& M?B.W8X607"B,#WCVX]/YTG_"GI3U(;ZMXKN9M.5AOBI4>VEN%_NO/TO]8!!0 M.CN*+RI?U!PEJ/23^`Y?YG3+\4/"[Z=-EW-VP-Y>2? W9D_YYA_NE_\ 9SFN MJ!! (Y!{UR9^%?A8ZG&-&_LE/[("[!18^8_DV_WL&7X%V`*-/ MMCP+6WU0E$'8*7#,|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{ZDGVKU2L'6_!&D>(M;LM4U"W- MQ<6EG=6*(S?NVAN/+\U67OD1*/S]:./%;;XQ^.QKVC^$KD:.-?\ $$-C>V5] M'$Y@M(9HKF25'3,79/LI"D$;M^>,&O6?A-XPO/"@.PU;4(8K?4#+<6ERD!) MC,L$\D#LF>=I,,L/8USUM^SMX6M=+^R1S:HICDMWMM2-X3=V@@5UA2)R.$5 M9)%P083>E 'GI\\,_.!RM_P")_#]NND-K7A.UOJ0U"[DB<0WL4*POSD:Y5&SK.0Q) M.TIWS7Q_(>UE/$.@Z;JD2-"'>VT5RJ/U4.@8 ^_-F:^??#OQJ\7> (KT^'+6;3OJ:GUYM,@U& MYLI8%CA2Q:ZD=[9CNSE"B\X8'=VKZ O;47UG/;L[QK-&T9>)MKKD8R#V/O7G M9^ ?AUK20/=ZM)JKWD=]_;;7G^G+(D;1+A]N`!&{MVX(=L\G- `FWA[]HSQ M1K@TZ+7A9:?;Z1I=YIFEZM:$;,TT\]S,L,CPMT54+HR@@IAGI7TGFO.+/X!^$ M++#5=-O+2WN++>.P2V7[#'<'[/.UN28)\4_C=^<@YY(!.<"O1Z #-&;**_/QI MXQT_P)X=N=8U*0K!#M1$7[\TC,%CC0=V9B%`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|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

M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" &9 Z@# 2(-A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<(^0H+_\0 M1 @$# P($ P4% M! 0 %] 0(#

01!1(A,4$&$U%A!R)Q%#!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76UIC9VN'BX^3EYN?HZ>KQ\O/TI?;W^/GZ_\0 P$ P$! 0$! M 0$! 0 $" P0%!@<(^0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"' M Q$$!2$Q!A}!40=A<1,B,H$(%$*1H;'!"2,S4O*

58G+1"&$E\1<8&1HF M)R=I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>`$EZ@H.$

*MA8:'B(F*DI.4E9:7F)F:HJ.DI.:GJ*FJLK.TM,:.WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.G]\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@*

*HHHH **** "L'5_'OAGP_>M9ZIXBTG3KM0&,%W?1 M12 'H=K,#@UO5^*7_!7#Q-]NA?M3F/3]0GLT?2+5F6%]H8X(R:YZTYQ25-*[M?;T;_0]?*

+J&%K2]2ODP!$(W\U)OXHOQM+!1^P7_'V//_0X:!_X-(/\ XJC_M (6OX)_Z'#0/_!I!_P#%5_-6OC3Q<]D]XNIZDUHCB-IPS;%8C(4MT\(2B\i!*

M:>+M/D6.ZU/4K>1D615E9E)4C(8]B.AK&^+/+1^]_P"1Z?]_/6_P# 8?\ MR1_2I_PMCP3_-#AH'_@T@_^*H_X6QX)_P"APT#_,&D'_Q5?S2?\+ "\3?

M0;OO^_IJ;O\;>+M3NHJ:TU/4KJYDR$AA9G=N,_GK M?^ P_P#DC^E7_A;'@G_H<-_\&D'_P 51_PMCP3_-#AH'_@T@_^*K^;677O M'D&I0Z?)<:U"?

*SX\JU9)!+)GIM7&3T]"GWNL^/M-U==*NY=;M=3;&VRF21)C MGIA"-WZ47Q?:/WO_"#EX>_GK?\ @,/_)(_I'_X6QX)_P"APT#_,&D'_Q5 M'_"V//_ $.&@?\ @T@_^*K^;S^T?*

B&;B2#.>@&@>/RI=RJ<@,1C(!P>?8 MUCGX@^)E.#K&\#TOYIHOB^T?O?\ D'+Pl/_6_P# 8?\ R1_2W_PMCP3_-#A MH'_@T@_^*H_X6QX)_P"APT#_,&D'_Q5?S8CO-

XV,'G"\U;],U!>^-/%VFW#6]WJFI6LZ@$Q3,R_1D<'GD$&B^>+[1^]_P"0_GK?^_P_^2/Z M6 \A;'@G_H<-_\&D'_,51_P +8\$_]#AH'_@T@_\ BJ_FD_X6%XE_Z#=[_M_P'_36UI-

W\1]?6Q;3$\0:B+Z5X+4VL$LOVB1%W.B;5.YE7D@9(')HOB^T?O M?^0"?^APT#_P:0?_ M !5?S9:SXD\<>';M;75;O6--N6C658;P/$Y1ONL P!P>Q[U0_P"%A^)?^@W>

*M_P#?IT7?O?:/WO_(.7A[^>M_X## Y(_I<_P"%L>"?^APT#_P:0?\ Q5'_MC MP3_T.&@?^#2#_P"*K^;3_A87B,_H-WW_'I-3VWC/Q?>QSR6^IZG/'GF2M&-MS,*

(USCYHOB^T?O?^0"?^APT#_P:0?\ Q5?S7R^*_&D.F0:C)?:JFGSR-%%=-O$4CKC2%GC-=+34S?ZJ-,>8V MZW9W^4TH 8H'Q@L0<9S@U?AO/B/<6T-Q$OB"2":$7$-

/%VF7L]G>.:IJ5K=P.8Y8)V9'C<'!5E/((/ M8U#_ ,+"\2_!\N^_[^FB^+[1^]_P"0_GK?^_P_^2/Z M6 \A;'@G_H<-_\&D'_,51_P +8\$_]#AH'_@T@_\ BJ_FD_X6%XE_Z#=[_M_P'_36UI-

W\1]?6Q;3$\0:B+Z5X+4VL$LOVB1%W.B;5.YE7D@9(')HOB^T?O M?^0"?^APT#_P:0?_ M !5?S9:SXD\<>';M;75;O6--N6C658;P/$Y1ONL P!P>Q[U0_P"%A^)?^@W>

*M_P#?IT7?O?:/WO_(.7A[^>M_X## Y(_I<_P"%L>"?^APT#_P:0?\ Q5'_MC MP3_T.&@?^#2#_P"*K^;3_A87B,_H-WW_'I-3VWC/Q?>QSR6^IZG/'GF2M&-MS,*

(USCYHOB^T?O?^0"?^APT#_P:0?\ Q5?S7R^*_&D.F0:C)?:JFGSR-%%=-O$4CKC2%GC-=+34S?ZJ-,>8V MZW9W^4TH 8H'Q@L0<9S@U?AO/B/<6T-Q$OB"2":$7$-

*/%VF7L]G>.:IJ5K=P.8Y8)V9'C<'!5E/((/ M8U#_ ,+"\2_!\N^_[^FB^+[1^]_Y\R\/?SUO_ 8?_)'}+?\ PMCP3_T.&@?^ M#2#_ .*H_P"%L>"?^APT#_P:0?\ Q5?S2?\ "PO$W_0;OO*

OZ:/^%A>)O\ MH-WW_?TT7O?:/WO_"#EX>_GK?\ @,/_)(_I_X6QX)_P"APT#_,&D'_Q5 M'_"V//_ $.&@?\ @T@_^*K^;3_A87B,_H-WW_?TT7O?:/WO_"#EX>_GK?\ @,/_)(_I_X6QX)_P"APT#_,&D'_Q5 M'_"V//_ $.&@?\ @T@_^*K^;3_A87B,_H-WW_?TT7O?:/WO_"#EX>_GK?\ @,/_)(_I<_X M6QX)_P"APT#_,&D'_Q5 M'_"V//_ $.&@?\ @T@_^*K^;3_A87B7_H-WO_?T MT?\ "PO$W_0;OO^_IJ/^%A^)?\ H-WO_?TT7O?:/WO_"#EX>_GK?\ @,/_)(_I<_X M6QX)_P"APT#_,&D'_Q5'_"V//_ $.&@?

@T@_^*K^;3_A87B7_H-WO_?T MT?\ "PO$W_0;OO^_IJ/^%A^)?\ H-WO_?TT7O?:/WO_"#EX>_GK?\ @,/_)(_I<_X M-(/_(JC_A;'@G_E<-_\&D'_P 57\TG_"PO$O\ T&

I[_OZ:/^%A>)O^@W?? M]_31?%]H_>_\@Y>'OYZW_@,/_DC^EO\ X6QX)_Z'#0/_ :0?_%4?]+8\$_] M#AH'_@T@_P#BJ_FLT[QCXPU>]CM+'4M3O+J3.R"W9I'; R<,D]*

FJY^(7B8 M?\QN^_[^FB^+[1^]_P"0.2-AU5E8 @^QHOB^T?O?^0"?^APT#_P:0?_ !5?S<;+K'Q ;PAOA M)KALIH9+F.X$'OYZW_@,/\ Y(_I;_X6QX)_Z'#0/_!I!_\ %4?

\+8\$_P#0X:!_X-(/ M_BJ_FO?Q7XTBTR+4GOM573YI&ACNVWB)Y% +('Q@L 02 ?-=1M+VZM+W5KFVL4$EU-#O=($+!0SD#"@D@9..31?%]HJ_>_P#(M.7A[^>M_X##_

,2/23_^%>)^APT#_P:0?_ !5'_"V//\ X-(/ A;'@G_H<-_\&D'_P 57\TG_"PO$O\ T&

I[_OZ:/^%A>)O^@W?? M]_31?%]H_>_\@Y>'OYZW_@,/_DC^EO\ X6QX)_Z'#0/_ :0?_%4?]+8\$_] M#AH'_@T@_P#BJ_FLT[QCXPU>]CM+'4M3O+J3.R"W9I'; R<,D]*

FJY^(7B8 M?\QN^_[^FB^+[1^]_P"0.2-AU5E8 @^QHOB^T?O?^0"?^APT#_P:0?_ !5?S<;+K'Q ;PAOA M)KALIH9+F.X$'OYZW_@,/\ Y(_I;_X6QX)_Z'#0/_!I!_\ %4?

\+8\$_P#0X:!_X-(/ M_BJ_FO?Q7XTBTR+4GOM573YI&ACNVWB)Y% +('Q@L 02 ?-=1M+VZM+W5KFVL4$EU-#O=($+!0SD#"@D@9..31?%]HJ_>_P#(M.7A[^>M_X##_

,2/23_^%>)^APT#_P:0?_ !5'_"V//\ X-(/ A;'@G_H<-_\&D'_P 57\TG_"PO$O\ T&

MXJOY1+KQ3XUL=/LKZXO=6@LKW>;6YEWK/L.U!C$8;!X,X-4O\ A8?B7_H- MWO\ W1-%\7VC\[_R#EX>_GK?^_P_^2/Z7/\ A;'@G_H<-_\&D'_,51_P + M8\$_]#AH'_@T@_

BJ_FD_X6%XE_Z#=[_P'_35G3/%_C+6K^"QT_4-4OKV=M MD5O;%Y))&]%023]I+XOM'[W_D'+Pl_/6_\ 8?_ "1_2E_PMCP3_P!#AH'_M -(-(/_BJ/^%L>"?^APT#_P &D'_Q5?*

S8:EX!\;Z,;<7]HJUD;B(3P_;-\?F1 MDD!UR!E20>1QP:I?\+#\2_\ 2#-X<=_\OHOB^T?O?^017(]#]FCX5?\ 1/0#W_@ G^%%\|7VC M]I_R#EX>_GK?^_P_^3_A_P"%K^"?^APT#_P:0?

*\ Q5'_M?P3_T.&@?^#2# M_P"*KGO^&:/A5_T3[P]_X) A1_PS1*O^B?>'O_ 3_"B^+[1^]_Y\R\/? MSUO_&'_P D=#_PM?P3_P!#AH'_(-(/_BJ/^%K^"?^APT#_P &D'_Q5<]_*

*MPS1*O\ HGWA[_P 3_"C_AFCX5?]$^\/?^ "?X47Q?:/WO\ R#EX>_GK?^_P M_P#DCH?^%K^"?^APT#_P:0?_ !5'_"U_!/\ T.&@?^#2#_XJN>_X9H^%7_1/ MO#W_(*

*) A1_PS1*O\ HGWA[_P 3_"B^+[1^]_Y\R\/?SUO_8?_)'0_P#"'U_!/ 0X:!_X-(/\ XJC_(6OX)_Z'#0/_!I!_P#%5SW_ S1*O^B?>'O_!/*+XOM'[W_D'+Pl_/6_\!A_\D=#_P*

*+7\$_]#AH'_@T M@ \ BJ/^%K^"?^APT# P:0?_ !5<[_PS1*O^B?>'O\ P 3_ H_X9H^%7_1 M/O#W_@ G^%%\|7VC\[_R#EX>_GK?^_P _^2,A_X6QX)_Z'#0/_ :0?_%4?]+7*

*M\$_]#AH'_@T@_P#BJY[_ (9H^%7_ $3[P]_X) A1_PS1*O^B?>'O\ P 3_ M HOB^T?O?\ D'+Pl_/6_P# 8?\ R1T/_"U_!/\ T.&@?^#2#_XJC_A;'@G_M *'#0/\ P:0?_%5SW_#-*

'PJ_Z)IX>_\ !/\A_\ECXX5?\ 1/0#W_@ G^%%\|7VC\[_R#EX>_GK?^_P _^2,A_P"%K^"?^APT#_P:0?\ Q5'_M?P3_T.&@? M^#2#_P"*K^;3_A87B,_H-WW_?TT7O?:/WO_"#EX>_GK?\ @,/_)(_I<_X M-(/_(JC_A;'@G_E<-_\&D'_P 57\TG_"PO$O\ T&*

I[_OZ:/^%A>)O^@W?? M]_31?%]H_>_\@Y>'OYZW_@,/_DC^EO\ X6QX)_Z'#0/_ :0?_%4?]+8\$_] M#AH'_@T@_P#BJ_FLT[QCXPU>]CM+'4M3O+J3.R"W9I'; R<,D]*

FJY^(7B8 M?\QN^_[^FB^+[1^]_P"0.2-AU5E8 @^QHOB^T?O?^0"?^APT#_P:0?_ !5?S<;+K'Q ;PAOA M)KALIH9+F.X$'OYZW_@,/\ Y(_I;_X6QX)_Z'#0/_!I!_\ %4?

\+8\$_P#0X:!_X-(/ M_BJ_FO?Q7XTBTR+4GOM573YI&ACNVWB)Y% +('Q@L 02 ?-=1M+VZM+W5KFVL4$EU-#O=($+!0SD#"@D@9..31?%]HJ_>_P#(M.7A[^>M_X##_

,2/23_^%>)^APT#_P:0?_ !5'_"V//\ X-(/ A;'@G_H<-_\&D'_P 57\TG_"PO$O\ T&

MXJOY1+KQ3XUL=/LKZXO=6@LKW>;6YEWK/L.U!C$8;!X,X-4O\ A8?B7_H- MWO\ W1-%\7VC\[_R#EX>_GK?^_P_^2/Z7/\ A;'@G_H<-_\&D'_,51_P + M8\$_]#AH'_@T@_

BJ_FD_X6%XE_Z#=[_P'_35G3/%_C+6K^"QT_4-4OKV=M MD5O;%Y))&]%023]I+XOM'[W_D'+Pl_/6_\ 8?_ "1_2E_PMCP3_P!#AH'_M -(-(/_BJ/^%L>"?^APT#_P &D'_Q5?*

S8:EX!\;Z,;<7]HJUD;B(3P_;-\?F1 MDD!UR!E20>1QP:I?\+#\2_\ 2#-X<=_\OHOB^T?O?^017(]#]FCX5?\ 1/0#W_@ G^%%\|7VC M]I_R#EX>_GK?^_P_^3_A_P"%K^"?^APT#_P:0?

*\ Q5'_M?P3_T.&@?^#2# M_P"*KGO^&:/A5_T3[P]_X) A1_PS1*O^B?>'O_ 3_"B^+[1^]_Y\R\/? MSUO_&'_P D=#_PM?P3_P!#AH'_(-(/_BJ/^%K^"?^APT#_P &D'_Q5<]_*

*MPS1*O\ HGWA[_P 3_"C_AFCX5?]$^\/?^ "?X47Q?:/WO\ R#EX>_GK?^_P M_P#DCH?^%K^"?^APT#_P:0?_ !5'_"U_!/\ T.&@?^#2#_XJN>_X9H^%7_1/ MO#W_(*

*) A1_PS1*O\ HGWA[_P 3_"B^+[1^]_Y\R\/?SUO_8?_)'0_P#"'U_!/ 0X:!_X-(/\ XJC_(6OX)_Z'#0/_!I!_P#%5SW_ S1*O^B?>'O_!/*+XOM'[W_D'+Pl_/6_\!A_\D=#_P*

*+7\$_]#AH'_@T M@ \ BJ/^%K^"?^APT# P:0?_ !5<[_PS1*O^B?>'O\ P 3_ H_X9H^%7_1 M/O#W_@ G^%%\|7VC\[_R#EX>_GK?^_P _^2,A_X6QX)_Z'#0/_ :0?_%4?]+7*

*M\$_]#AH'_@T@_P#BJY[_ (9H^%7_ $3[P]_X) A1_PS1*O^B?>'O\ P 3_ M HOB^T?O?\ D'+Pl_/6_P# 8?\ R1T/_"U_!/\ T.&@?^#2#_XJC_A;'@G_M *'#0/\ P:0?_%5SW_#-*

'PJ_Z)IX>_\ !/\A_\EC

*C\C]MZ*IZ/]D&MZ39:C;$FWNX4N(RPP=K]&&1]"*N5R'(%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 MG2@!:*\?7XK _$4^'VLU2Q$YLA=F3YO/V;_NXQM/W>N^>*ZNQ^M*>@RZ#INHZA>1:6]ZA9;>XD&]2K%6Z=@P(STJ%5@VTGI=,!:B:<(U)0=I;?\M,==YR>84WKO'.W/-/KY\|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}3"UZLFFX)6=N[MZ>9Y7K? P\N] NEAOK;RBV?+D"*2 M =2I_$<=>:BM/A[?:A:275KI\]S;QML:2),C/<=3COCI7K/QBN1_:FF0\)?N MK>68_BP_P#037=^#[%+'PMI$*J$Q; (QS_>8;B3^)-81P<)5906R/3]2XJA M<*>)DDY3Z;VTQ_P/O/FBP\(RW5Y%:V\#R7,C^6L6,-N(@YZ8P0O2O\ $Z2Y6T@"7{EBBD53O 5>)5R6"\G M'0BKWQC7_1-'/83RC'_ !4K#05.4T]E;3SK$RQM+"U(64XW?=.S_"M;8\]T M?0=0UIY(/LY+HQ %RF %STR20/P!+_3+S2IQ#>VLU!(V=HE3&[Z'H?PKTCX M/%?!(U1>- PNP3]#&N/Y&H/C#=+Y6CVO\1DDG^@"A?YM^E:-PBJ/M+ZG"LUJR MS-X+D7+WZ[7]#HOV=-#O+;_NM4D$:VEW:%8ANRYQ(.2,<#@]Z]WKRWX&@KX> MTS(Q_H(.#Z%LUZE7OX2*C1BD?DF?UY5\Q]RET=ODM$%>%?ME?\DAMO\ L.Z9 M_P"E*U[K7A7[?7_)(;_ +#NF?\ I2M1CO\:=GHSIX5_P"1Y@=_>OD?S/=%Z M?B:*%Z?B;* {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{MYDDU.W2Y@6XNI%K>:(\869E9,8"@]! MC.T]:O/L4,2P1)&@PB*%)SP/>O9G&,; MDDMQ;_:R$/(\N)V\H/G^- D8XZ5C5E,&Z<;QML>CE]"U\3&GC*OLZ;O>5N: MVG9:Z[=?1GF_[0OQS\,^./ NH>'/#>HRZ]Y$0UN]V0)[1]X+0RW;L]*CX M8]6;,D '->H_L]:7X>T'X;V-CH>MZ?X@G9FN- 0U#3Y5=;B]D.Z5^.@SP >B] MH[5'X7_9M\$>'&CN+BPE\0:FBX34-;E^TR1_],[;Q$7TK3 !WQ$+!3<0[?-0L "LJ,<9YS7E1IXJ%95YQ4F]-'LO MZ]3[^MB\CQ&6RRK"UYTH0;FG**?M)VM;2UEIHWR[ZIM(\#_;T_9W^'GCCXIP MZ[_PDUYH/BNY@B74[:TL1=Q2(HVQR,-Z;'V@#&3N ' ZGZ<_8]^&'@SX5?!> MQTWP5J.VL65Q.IU=ZAP Y/4_&?C3Q7/X]\1WNM^(%_ MLFIU*8R?:6D\ZPD/0*DX'R84 ;7 QZU]M?1[^$9_"OPDLY+E?>9=4F>_V]P8*.MK *$"_#E5!X]:I.E7IUK\CU6ZV:[4]3X;Y3C,MY7B(>[+X9)[4)?X9*\7\G MIU/8;***Z#R HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ MKCO&O_'[;_\ 7,_SKL:X[QK_,?MO_US/\ZRJ?"=N$_BHYTC/7FN+^>+4)D\+ M12 9\[JB;Z [E_K7:5G>(M&3Q!HEW![MY?G)A7QG:P.5/X$"N"K'G@XH^LP- M98?%4ZLMDU?TZ_@X=9 ,? I7IGP[\&ZGH&KWMU["1Q*8?(0)(&\P[@Q88Z#COSS75OX8TI] M74S8Q&^:\W";!^]_>QTS[X57"],ZM.-[&CZR6:8? XRNX>[&:3TVO;\G>7?L3 MZYK%KH\A/>W;$0QG&U1EF). H'$7(FDW;!N'-MS9P%PV<5K5G*-2_+HD>;@<<+0KX14_;VG.235^BUU77ROU-MLC\)ZD?&?B=Y(?+N'CM+<$8.S._? QRS5ZKX[OVT?PA>M;91MJVT;#^$,0F M?RS7'?#GP==R:I#]U[ ]O;09:!)1A'(P&P>0!D]>IKT?6-)@US3)[&Y#&&9 M<$]<$$'((IP144(3<)2>\CJS3$X>GBSOC _[Y&? QKT+P]X4&BE+@D]&(.(5QW&_.K70:%HT'A_2K>PM!.(+.6.QN?L*!68;81HOHH(KN: MXOP7_P A.;_KC_45VE>G2^$^)QK;K-L*!*#NF?\ ]AW3/_2E:]UKPK]LK M_DD- M_V'=,_]*5KQW^ZU/1GN<*_\CS!_P#7RJYGNB]/Q-%"]/Q-%Q\]+11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110

MQ%XGL/"VCW&@^'$T2)=7LE|:6LS)%\FU/+:Z7EC\P':MZZ^//CO0|:MQ_!%_HVB77CB75;#3]:N+:YD73]EW:W,_F2EEWCRULY^_"7.S&-QP ?1U)G% M?-EW\>?B%!XFLO 2Z-H+^-&UV+2Y[T7$OV·VTNGW%XERHVIPP%NR&(\YP)7I\%+I^LWMWXJAT>PL]5O)Y6U":6PLYD>#:I6)8Y M))'_ (5"LW\5)J7[5WBJ/Q=K?]G>%FU+0=*UHZ'?7·KRZ\^; (],MKJ:QAD2XC64"2 M,$C<·W7\ORKYJ/2OI3PB<^%M(_Z]tO\ T$4 :P&*6BB@#P+]L'Q%<>&/!6CW M\/B*;1XK>]>>>PM+S[·MW7Q*\1Z3XPT74RGA;P]$P4,YLK:2&)8-G^DEY6*NASMW$#;UKZS\>>/MS\$7 M'AZ'6\)#]7...,AC/7GVYKU#K0 M%%%% !11 M10 AX%?D!^W_ /$&\||, M'Z_8RRL;#00FF6L1/"X4-(<>1=C^0F1*_7\|*_1 M]OWP#>>"_P'I+1O#=RQ,+'71'[=K*5P'#*%D·/]'5OS'K7@9US?5U;,:\I^N^& M7L?|8G[3XN1\OK=7MYV_"Y\XT445\2?U&%=·\,O!]?&/X@>'_#4FHPZ2F]WL M=H;VX^Y%N.-Q]?8=R17,UN>!]4TC1?%NEWVOZ9)K&CP3!KJQAG,+RIW"N.A' M!'T[54+VEKV7WZ'MVO?LRZ+!XH\>:/HVO:E?S^& MO#S:J;.ZTQK>X^TBX2+]_R$\Y#A@RY!\%8UM^RUXB;0-2M9[2Z3QK#K-EI4. MDQ^7E9,\+R!9)-_R/A/NGIWZUZ.?VV=A\-)^3]WAG2M3EN+/PM_8-E%QT!<_P!:Y?QOXADT>U@AM)C% M?2,'7"!;AL! ;.>G6NFO;B*U:66>18HE;YGC4M3N7CF,L<2I &?GIN2PSU/)QDUGGQQ>"52L,8B QL))),&B#6EU?4+B M3ROLTS*L.*1E2!DYSW.2? P%>/4G*2U9^@83#TZ,_5+:,_FV:8Y)$4,W<·'./S%:7B>Z4W.055_=')EW> MH^9D:>9[>QMXYL&18U5O4$#G·,]1YDJ:ZGH?A#Q>+&;]7 M<3.S*XAO_,_CC8D13_|?NMf? 2O7000".0:^>O#C3RZLL<2QNLL92X60<&+ M(SCWYQ^->]= >0:!KC1[B9Y9Y98.. M']RE#9ZV!3L'[WXCA|NYNTP0Q%T\M@·&B@A7C<%1CJ:O7GI/7@[^\2! M6K* [,DD|=W<62W\RV=U<1A=D\T·,8[C8A)(^8]"V2*^;K;XF:Q<>=#]3N]3^ M(TO@6^\.^%)}NM!TJUMH8X;\OIL,QG>-D)F5YVD@$<6W;Y>!R1C=U3QC\1)O M#GQ'\?7/B;4-)N_#&HZ;+3PS'#%]FCWV.GS74$V5+N"]Q*HP05QGDT ??]%(M#D4M !1110 4444 %%%% #)94@C+R,$05 MYMIE8 $]G'·,]3W]SXGT]35+O2%;$W-BMR3#BLUQ 9 MU_+I=MT>(9=(\(>(·*DGMXY;."S:$1(@=X3E<.1W! QGUKRGQ M+?VNJ:[>75E!]GMI7W)'C&..N.V3SCWH S*]E^#_ (IEU.RETJY;?):(&A8] M3'TQ^!Q^=>-5Z)\$[.237[VY /E16^PGMN9A@?\ CIH]GHHHH \7_:7\$:K MXO@\ I.7.G>%8/&=OH?B2/5+]29Y8QXO) MK<)E>=V"LRO(A53P2 #7D>0\ P\ M%WBY]=UK2_"2>%[·5- 0EGMO#S2PH\1&AZA;&Z=4)1'FEN8%*]Y81;00& A+'=@$ @QTC^T(6O;#^U=/EO["6YCO[7*!I8&=1O53(@..FX=B*·/(O%'I-6 MIIX:T72?!^E67AZ8_#Z^\/WD]L5@#7+&Q:*.1D^9@WE7"E^2N]CG)YQ/$'PC MO:"B6TOH?@Q)X7T6U*ZKHFH6UG&HXS<236TBV2R,T&Z(S ;=XCG1MN>_L:36/VE_# M=K]$6H6^]0CPM9P:O/?W"$RI(9/L]3QQ·NEF8%&^;\NXD|=O-[+.:KX M(E@;5/AA;_$.UO\ PAIFB6]FK6VW3+B&)Q/ PD("12NXBQU[/\ MXS^'_B+]USIFGI[%G>Q6L=_%#[5E):M8H_^>_ M'OPB\22?LG:!X{EBF\5:[I[:*MY%,W7ER70MKIWDG$6I-U?3*]H_M8EC!,,<:]W+2$LTG3"UL?%O]E·O$;>$-'\ (WFK>'+6VGO[N?5H-7N'GM+A[+ MRX6#/(7*%P%9%(!!/0\U]-8 [4M '@<·7PUUBX^#_ ,-]&M/"'L'AR^T?Q)IM] M?Z7!=''6.$0WGF7$J2LQ.@8[I 6)9M_/S9KWL=*6B@ HHHH ***** "O(OYDOV M<=!_ ;,\% P!EZBWV+5K0M)VIHN6MVH(\"]2·@·9'L",17KM%9U*<:L7":NF= M>$Q=? UX8G#2Y9Q=TU_7 #GXR?$<]BKXL? #G4)HI/"]UK5FK82^TA#<1N:QP MO*_0@5PG_"B?B+_T)&O?^^^7_"OW5Q1CZ_G7S\LDI-WC-I'Z_0\4LPA!1]T(·M2?>[5_EJ?A5_PHGXB_|·0D:|_P"""^7_"C_A1/Q%_Z$C7Q_!? +_A7[JX^OYT8 M^OYU/|AT_P"=_<;_/$5,7_T"Q_|"9^%7_"B?B+_ -"1KW_@OE_PH_X43\1? M^A(U[_P7R_X5^ZN/K^=&/K^=·]AT_P"=_<'_!%3%_|·0+'_,"9^%7__HG MXB_]"1KW_@OE_P */^%$_$7_ *$C7O\ P7R_X5^ZN/K^=&/K^=']AT_YWIP?·M\14Q?_·0+'_P)GX5?!^)^O\ T)&O?^^^7_"C_A1/Q%_Z$C7O_!?+_A7[JX^O MYT8^OVT?V'3_)W]P?\ $5,7_P! L?\ P)GX5?!^ "B?B+_T)&O?^^^7_ H_ MX43\1?\ H2·>_P#!?+_A7[JX^OYT8^OYT?V'3_G?W!_Q%3%_]1;_ F?A5_P·MHGXB_P#0D:]_X+Y?!*/^%$_$7_H2- >_|%\O^%?NKCZ_G1CZ_G1_8=/\ G?W!·M_P 14Q?_ $"Q_P# F?A5_P *(^(I_P"9(U[_,%\O^%>@_#/]B/XK_$?48(O M^$;N·L&;]Y?ZPA@C1>Y /S-] #7[*8^OYT8[XY)23O*39SU_%';)TW&C0A& M7>[=OEH>5?LZ?LVZ!^SMX)&C;23=ZAYD P,/X5'(!LGN36!^V M5_R2&V_[#NF?^E*U(IK7A?50"7)6 (;,L.Z9_Z4K7HXN$:6#G""LDF?%(\+B<1)RG*1%MOU1[HO3\310O3\317[Q9AZMI]OJD4]M=1+-"YY1NF>Q^H MKY]\2VMS+HTT,;,UP&"21G[WRGD8]>*^A=0E,"W$@)4$@$XS7D?B&PU^XU2 MYN0T.CW4A=8XCB3;.,#UP·!Q7/BHW2:W/H#SP3=+<^YC"4_A*DTTDD\MI&1=KDOC'F(KW)[$CICUK M$3PGH]K>_;fQ(0)Y"= &I-MZX]JZF,A(5"+\H.%51C SC&:/GCAB /?.;R M/15TC-$B7MFZV91%)'$RC,9/.651UQMR2>,9'G/^?K3)2>MR65 M(I(F:15*E*A0/8NK-"99XBI#PF3=\O8KGN/US7#+\395N';I #"YSM, MGS#I,?A76Z#XBM?$5F98E9&#>6\3?>4]NG8^M)/L5*&GO(I*\VWF/-?&-Q& M\2"&1P0"#DMC\EKL(F%M?V·XC8FANH4'JR2-LXU?44C>0 0\V>]D W/SH1Z>D^OZ=I\8S';.Z?<.>K$$K$O_?6YO\ @%>[MA5>*ET/S7.9]%65-N[T_0[.BBBMCYX*\)\%?\G??$G_L Z9_-]IVKPGP5_R= M]\2?^P#IG\VKAQ/QTO\ %_[: (^JR3_=\P_Z_P#N6D>[4445W'RH4444 %%% M% !1110 4444 5-7@DNM*O886VS20NB,.S%2 ?SKSF_F\/\ B/PI86,PDM)+ M6)$^"D"2EM)@!E8XQU'/YUZC7%?&C:U8Z,]>DV=K;W%M=M,R7,DNW:)"20R] MR.GGZ4 >,;WWPMU^TEQ%;+=QG[LD+/@@CUYK1TKX0:K-#+·>&*W94+1P$[C(W8 M"0&NMT_5=:C\.C5HY;,.TLT*BRD7+,D?RMN?/#*:>WI6>-4M=5TS4]4N=4N·M;34T>0V\"R%#&!_]@(_XLC'US0!WOAY_AU/0[*Y@C$,3Q#$0&-A'!7\""/PK M2K*\+V']F>'[&W*LD@B#R!SD[V^9L_+B.U: $(S7F&M?IX>!-4L],LK?0- M/T[3[?65UJXL[>T3RKR40RQ!9%(Y7$Q('8@8Q7J%% '(6OPB\V%7A*X\,0^& M-+30;A_- FL/LRF.63(.[L\E)@88G(P,'@4J?"/P9'X0;PLOAC2QX29_·,G_9 M#\IVZ\[

MUTFC36FIN(I;T6VFZK"L#W6,HI#"2%F'==RE3[..\6M-7B6RCM+VU%W;Q.9(MRK[\'3/W@#Z'TKUBQ-O\ V/;_9MMO;M$AC60.<#IGVKK?A+X]TJ.RN\M)MM->PO MHT;
I\I7\TW6."58\EA\HQ[BQ(9S(\I_V4IYFWY"W@^^^VOAIK-H/B+8!K@(MUC(8;@8/#RH$C3WW%P?^ GTKMHU9RJ+0^9S# 8>C@IWDTUKON_3;4Z2/Q/K4 M/BFT1GE$\-*
*Q(MM;ZHQC\LW"DH)67K@G"C'H.M>X0[S$GF;1)M&[;TSWQ5,;% MIXN+JZ !&,>Z[1CTQ5^O;G-2M96/S6E3EJOS.]PHHHK(W M"BBB@ HHHH *** "OAW_@K8[+*
*_#"A8%;Q)W8.+>2%?<57#G_)6W_D@W MA?\ [&2+_P!)IZ /A;]&4\+VM_AH58]3]$BG!Z@V\N17[EK]T?2OPR_88_Y M.V<Q&_$3UP*E %%%!1110 4444 >9Z]\0?&FG:U>VMCX!N=0 MLX92D5VMTBB5>S 'I5#_ (6=X_! ^B:W?_@9'7K6*,5WK$4DDG1B_G+_ #.Y M8BDDDZ*?SE_F>2_\+.\?_P#1-;O_ ,#(Z/*
A9WC_P#Z)K=_^!D=>M8HQ3^L MTO\ GS'[Y?\ R17UFE_SYC]\O\SR7_A9WC__)K=_\@9'1_P +.\?_ /1- M;0\ \#(Z[:Q1BCZS2_Y\Q^^7_P D'UFE_P ^8_?+,_\E_P"%G>/_*
/IFMW_X_M&1T?\+.\?_! 1-;O_P #(Z\:Q1BCZS2_Y\Q^^7_R0?6:7_/F/WR_S/?3\3?'MO'_)-KO_ _#(ZX[GJQSXIF\?Z_X8O+&CN-%@D>?S[F<3/8.WS>4T@X?))P. MHKZ+(!
[5D^&O"FE>$+%|/2+.R(@>5YG6,>K>WZ_?LL715&I3]DDY6MO]^K>QKT445Y!\Y(4444 %GO7-S\ M0JBZE#-&<5H36[2@?PD="*06]HI"':;3U)&:..8?*
M$4.BM%;6)6W;T\C.H'\P 2?:KWV M*+&,'ZYJ6*)85PHP*.8;]++H99..O%*BF0D*,X&36GL7?NVC=ZT*BH,*H4>U' M.3[3R,E2#?Z?_P!?_\ 07KJATK"O% N=.P /[*7H/*
*8>MT=*Z(.\3*M+FL MQ:\D_;<_Y)O;_P#89T[__*4KUNO)/VG/^2;V_\ V&=._P#2E*]/+O\ >Z7^ M)?F;9?\ [W2_Q+\SUH=**\THKSS@%HHHH *** "BBB@ HHHH *** "LWQ%*
*MX>L/%6BWFDZG;K=6-U&8Y0F'4^'1'4&M*B5[V:\;3BU'+U1X_9_S7= M.M;G(.O)&N16T*B.*/8C;5'.&3UP*E P"BF:Y_WZCKUJBNIX_$/5.M? M^*
*Q_R.I)X^N]6U_X#'_(\E_X4SXD_Z*9KG_?J.O/- ^&NM?'QN\5Z6GCC58;] MWTRSEDU!43S9E8OA&'3"XX^M?3M>1^%O^3E?'7_8&T[^;UVX,&U!0K-M:1_E MC_-*
'R.W#8RM%5MK2/9?S1\AW_"F?$G_ $4S7/\ OU'1_P *9\2?]%,US_OU M'7K5%E62PQ+&]Q*!NE(&"QQW/6K5+ M2Q&-*
*J8FG"G.UHWZ);^@L1C*F(A"G.UHWZ+!%%%%%T;IGTW4$VEHB%='5U*2(>S _/\ =-- 'XV_LM@G]I7X6 #)_X26Q M_P#1HK]\A7PK\!_V$?"/P,^(;5]5'4= M/H?*
*<8'"82G@XXQRM):WWL^UOZ9M;_P") #/AVXU'5=8M;2^5-\&GQC>93V7-M(7)Z9%>1:KX!BDU6YOY[U8+!W,K@CYESR1GI^~=5\3;KS/'NJ0:K>RVMOYD M]M.73*16^*
L1#G[AP5QZ[R:YZ;3O[.F MRJT?<|I':]O.]/ 8Z7MO85I-RDE*]K12?1/^F5=,'A*^U"&R@MO,D)PCN#AR M.V>]>T_#X>']*
(T36]>UBW2\DM+A+2&V!RJE4V[5]69^OM7CGA_P'-H6I&QN-MR3=0IOB@=#'R> QSVZUW.FFP@U\V?4TD;3) T-X(L[O+*G:W'!UPK9[8KGI/*
MDEJCTUBGU2.W348Y?,N!N0!922.1N.WV!/%=MXC^&=Q:Z='>Z/>KKFE MW(PGEL%GP1_#V;\..N_#;X;.E=:Q!I[?VLMCIU@ZS(MQQ).Z_XDCC5&FD^]
M(0,%C[GK4])2UZ!\2%%%% !1110 4444 %%%% !7P[_P5L1C\!/## $]OB2+ M)]/]'GKZWN?B#;)(8[>SN;E@S*<+M&5?:W7TY/T%<#\6_#&D?'SP3<^#_$_A
M^673:R2)O.64+) XJ'Y.?L+(S_M:?#0^'Q&H2$X!];RYK]R MU^Z/J7QW^SU^R'X+, 9W\0CQ=I=O?>(-=S/;Y]U?R%8MO>-?RBC^+.:!EO1C7*
MTM:.^KAGC2YTJ[6)BT:,58$*23O\ P7 S]. .OHJEHVJ1ZUIL-[$CQQR@D+(N M&')'(_"KM !1110 4444 %%%%% !1110 4444 %%%% !1110 4444 %%%% !6 M-I7Q1BG_V%
M;^DG_?PT?V%;^DG_ \-8^R\S3FCW&8HQ3_["M?23_OX;/["M?23_OX;/9>8 MXS%&?_85KZ2?1\ #1_85KZ2?1\ #1[+S#FCW&8HQ3_ .PK7TD_[^&C^PK7 MTD_[^&CV7F'-*
*'N;Q1BG_-A6OI)_W\-'1O.../<9BC%/_ -*M M*32\ ^&C^PK7TD_[^&CV7F'-'N4KW CYT[_ *^*E_P#0'K< R2]46C6L,R2]&*
M+H=R[F)P<8S^]IJ6L5RJQ$Y)V2"O)/VG/^2;V_\ V&=._P#2E],KR3]IS_D MF]O_ -AG3O\ TI2O2R[_ 'NE_B7YG5E_^]TO\2_,]:'2B@=**\\X!;*** "B MBB@ HHHH *** "BBB@*
*HHHH *** "O(_"W_)ROCK_L#:=._ZJ00PGP5O\ #_[=$]#" _!6_P_\ MT3URBBBO///"BBB@ HHHH * M*** "BBB@#AM9@OAK=PMEIKRD2(WG$ *2?*
G!S[%=[_WO:JUMI7B1A&5LK>#: M%QYD@X(4D?JQ7Z5Z%?@WCCQ5JR>]2BCOIH8H9C&B1M@ #% :06&J7R7ZZ> ML+!-3NB_FMC!.U<#VVE_TI6T_P*
0V]R>=]RHOXFO(0$. MIP;_ "[^=-[EVVOC+'J3[UI(A\=7\)6TUW*9IE=X][=2 V!F@#\,;SH] MN\EN;620>882,%,G.#6G110*
445YU+^T'\/[:XTFWNO$EM97&JQ+/:Q7(;-G M1\6B5CD?'Z,HSC)% 'HM%9>B>);#Q"=1%E*9/L%Y)8W&Y"NV5 "PYZ_>'(X MK4H **3(|:SM:\2:7X=^P_VG?*
*P6/VZZCL;7SW'"^=.^=D;^K'!P/:@#2HK,A\ M2:=/XANM#CND;5+6VBO)K?\ B2*1G2-C[%HG'_ 32>)?$VF^$-%GU;5[I++3 MX"@DGDZ+N=47\V91^-*
&I167XD\2V'A31,C5=2F.5E 4$CJA<@LX0<#GJPK3 MR.XSS0 M%9>N^)=-\-I9/J5TE]MY=PV,!?\ CFE,,&@]R>/#?B.P.6:#8#0Q>10!J44A(!QFEH*
**** "BBB@ HHHH *** "BBB@" M*YM8;R%H9XDFB;ADD4,#^:KA/_BZ+X>65G8Z196Z7=V79%VA8XT7&YR!UY* MC\;[^O,_C%X/NM?L;+4=/A-*
*Q=V!=7@7[TD3@;@ON"]G'?!K*KS*#<=ST.![* M6(A&O\#>OZ?B>2>)]8M/'L;R:OI:2RS1B*2XL90%G3L'1N#CL17;_"/5_#4> MLQ6:Z=-'JS72>(OB;K_B!YV29[6T8R(ME"BG*
7.%D)ZDX_.NE^"%G8^=;*]?4]$M&G MM6C*S-$,Y8$E&'0LN!_WT*Y5[JP*=:*;79ZZ_UT.< _L'4+CX6Q MW:0W @BUK[3;>2&#QPL HSJ!R!0)8?G7N/@<F]O[*
,):3<:I$T.H26Z&96&# MNQU(9ZX]ZVD18U55 55& !P *6O0A3Y.O0^.Q6-> *33BE[S?W] I:2EK8\T M*** "BBB@ HHHH ****."OK#6GOI\:+3E5$D8))(P.?"DJ?
*H=Y4_2I+/P_.MX@2ZB=Y+6)$<$<[C@:0/$0./K7<&OG+Q!X@U*77=08WTXQ<2* LA #$?0 M4 >D:,H^I.KI4)LIX(H%GNE9901ZI>Q+M2[G13:AX.TN>XD.LS1D.*
[=3AB'^@H M U=)21--M_.013.N(1'\<5)LE7<6R5 MRP[5[I%X'>2--%^7AKPWXIU?1?$T'B72[F_ATT:RS9/!Y1.>3OA<2X5S@Y M4>M
*!N5%?,7Q2^,GQ)\.ZS\3]2T.31CH7@S4-,LX-/NH6,E\;F&V:0/(#\)&4 M-W ((!SCFI?$GQV\8?#+1OB5I.MO9^)?%FDPZ<-!?3K8Q-?75^LJ06_EYY*R0 ML21U3)/0T ?*
2[,%&20!TYI.^&+;XC^)]# ^!&K>#M4U'4+?Q;X6\1Z$]GJB9 M&M9+VQN-2M_*N)AG.P2&:)L=HQ >KZ(^'GCCQ.;?%;4? WB/4].\0G^QTUJW MU'3X?),(,OE-#@) R2&0YY*
*?TH]?HHHH *** "BBB@ HHHH ***'^-OV[_M -IW4/A^L/+0*RES=FTUF\@\ 4+Z(.;PMD+&IL^*'4WJ2\?*4AFJ+AIXNJ5/=_ @: MTJE<;_FW3\?^AF/_@._M_P#A*?2S23S/+*
*{[22N=S2.268^]0Y--R?4U]I#A\[#I>])M_(II9?3MJV?K# M_P -T_!W_H9C_P" [_X4?\-T_!W_ *&8_P#@.,|A7Y/;CZT9/].0_5_"_S2 M^]?Y#_L^EW9^L/\ PW3\'?\ H9C_ .*
*[_P"%'_#=/P=_Z&8_^[_.%?D]D^ MHHR?4T?ZOX7^:7WK_(/[/I=V?K#_ ,-T_!W_ *&8_P#@.,|A1_PW3\'?^AF M/_@._P#A7Y/DD=&:,]DDC8]RGU!'(})V8=KW)-/Y,3R^G*
*M;1L_=VO)/VG/^2;V_P#V&=._]*4KQS]A/]IN_P#B79W/@GQ1=&ZU[3H//L[V M0_/=6X(#!O5TR.>X/M7L?[3G_)-[?_L,Z=_Z4I?S=###3PF84Z53=21R82G*E MC:<)?*
S(;.'2B@=\0\L6BBB@ HHHH *** "BBB@ HHHH *** "BBB@ KR M/PM_RO7*\C\+?\G*^.O^P-IW\WKT.)\%_#_ .W1/0POO5O\ M/_MT3URBBBO///"BBB@ HHHH ****
*"BJFJ:L;Z/9M.3,"0'QVX\.?:O)M6TF\T.I;WOH7AGQN M(?N#WSWH I5IG\'Y4?P>B*X+I-)N4'EM/ S^)-9>^CLFEV)$<.M%@N:J \''Q.OI+/Q *.JQ86NM?\ ".M>[OI0-EY=NS/-*
>O6 MWQ5\(7GA:?Q%XAT]]$@?RY;SSAL1\XVGN&Y''7D5(OQ/\)MX4/B4>(+# ^P@ MWEF^\X>6'SC9_O9_AZ^U 'S=:_ F1O%EII,]_P")I=%E\"_VA=!M0FQ/]RNJ
M+,S9R)0K/\HP.AQO7;/\A XD?M,;)X5M-T&EMX7+V,C7NN1RQNWB&>VBE M^U1A>KVX &3QNF<=]^B_%'Q^\.>'!$CUVVG@U;0!8:A?SWUK?7M:CMO#>G16EG=>=/?
1RJ?M"%U7Y>A&,>_,I0 M!\^WVOZ9XM^*%OXE^).D>)-'@N_!EG:3Q6,I0W=ZD\;&/DN#DQ]BK9[MBNR\=Z;XMU?]A,_M=7MM6N_$;V2[(57=]+0B]4P9
_Y;^0(R?]L&O>'^*W@Y M?"P\1MXBT\:)YODB\\X;/,S]SUW?L,UR/C?]I3PMX4TN#4+&0>(K.6TU&Y, MNFRJZH,2S^U.A/9F0C)QF@#P3Q&[S'6?^%7?
\):=$_LB'\UOM7G$?;O]1L_ M(V>9\WF^7]K\S;QMQGM72^%_:,N:%;.#^%\<^NS>)KWQW?6UZ+F>1T73I+N] MC6-*
*HS\HB""%@<9'!S7TK9^_]%N]+L[]-2MA;7=R+.)_,&&N"Q3RA_M[@1CKD M&L.\^+V@V'Q:L_A]-.(]:N=*EU5-S.*(TD52]R&+?130!\EZ?IL>IR_"S[7 M'XKN?*
BA#XMT^;Q1'<"5H$99B9VD]_=B$-@QE>VWW],P9\/\ Q/XG^&GC#5]; MN/$}:WI'@;39M&C%Q+&8]02TN)&D51]Z3S%B!!ST QS7U_X4^)7A7QQ>7=KH M&O6.JW-KS-
';S!F49(S[C/&1Q?'ZS\3B@#YS^+_ (CB_LGXK:CXNN/$T?BVWTTS>)'-DD6&UB_LV-U M"[#M203F8R>95@CMBOL+X>R3R^ _#CW+,]RVFVQE9_O%O*7).>^+-9\ M)_$'Q-
K/B'2_A5K'C33+.X-M?ZQ8S>5!?20'8P6'E_M0: M===>);>ROO#VI:7HMWK5[H-IKDS(8)KV>9'!4',D^A'K0!W%%%>==>$_C9I/B_P 9+XBT %%%% !1110 4444 %)2T4 0-
M90)YC0QL\ > G\ZFQ2T4 275SI<1GD.YW0E=Q]3BMO2=&L MM'LUM+"VCM;=22$C&!GU]S5VBI44G=(UE5]3BHRDVEYA1115&04444 %%%% M!1110 4444*
%%9VLZW!HL;2\LLS^7%%*$N7D;&< ?05RD=RVO?>]ZZ@_]-C MR6K!8;,S AC7:"'/[I)\ -*@*#NV(4$DX ZDU\PZFROK-^R,&4W$A###H1O/->I*
*MZEXDUW6/#EKIB6#KJ&HP_NYT<#<@QO8C^'((_.O*M3TRYT>]DM+N(PSQXW(? MTH]CK7?Q_P +KB.,P3IR(ZL\09'4'E3N)P?S%> 5W7P?U>2R\4"RW'R+N-@5*
*ML;E&0?YB@#W&BBB@ KF?%7PW\ >-%O!KFC6VH_;+>*UG,P.9(IIY?.C4D'.%D M^<8ZNFKYZ^..HP'KM.5I_C#6]6\/^!CHS7%G/IKO$D^HB8B19)$!.4B\LHI*
MX)9SSB@#TCP=\/OA\FE6LOA[!1,DL:6>%-X$KDPW0=:Q)C*G/W<=]N M>"_A)X0^:=Y\=^'M#M]-N9XQ"T[%F81@Y$;EB=J9YVC KY"^&UT$>#M/\ M&VO>*
*(]#\"S0ZY>07RK):S7E^=8N"#141Q@?]HJMK'@]PLNKMXHU';3[?9E;M MM0E7YHS%'*JOG_9264]@YKY)_X2SQ98:CX%N=6U_5-=UNZ\,R0"SMTFM98) M/*O7C0)*
(BN)%=%B#Y(961"!\V]^%/AC6/#VK_"Z*^U?6];3Q=X1N6\1#59 M3(CW"PVC(^W&(V_>S+CN#[4 >OZSH'P]^)\SIYU*STS7IM6TL3VOG#>;FQ66 M*4,/[R"1H6YZ$CUJ?*
*P!X0\$>!]4UG3/"]G:66I((9-0CB=GF"L&\G>S$G;A6 MVC.!@UY]QTC]IOX>36$5[;.?I/@[4;2",*5A;QK'/9)'&1T^Z6X[[?X M:\Z^(0\-6O[1?*
*Q%D\7;_X@\.6;Z+LEA+I9DCBFF1,D.59%_^5(=.U'5=2TVVNDEOM.,W<'*Y5?B*M^U1A>KVX &3QNF<=]^B_%'Q^\.>'!$CUVVG@U;0!8:A?SWUK?7M:CMO#>G16EG=>=/?*
*<"M&>[U'3-8A\]+>+-?\0:_M?\..\0ZQ8_VDCN)7*QVDEE#-.!N\K$MUANYC0$\4^?7.EZ[I^M->K8W<5TU-ME<-.7(C.?*F4*61O0@.I_$4NC;Y8>(M,AU'3;N*]L9L^7/"V5;!*
(.#]01^%> M$_LE6$=UX+^(4:76IW>GW?BW4?LM]F'M'!A7QR #7C'PXTF/ MPMX^:,A>+M8U_PWX"FTW4KLSPS2HTFF\(6..0*611""Z+T9BQ[4 ?==%>9*
M_LZ:CKF]"C3]!=FN]]7S(I+.ZU!-ES<62W$BVLL]JG:$1L?KGO?IE !1110 M AZ&OQ\ :VOKF |\D?B]T6+QZCY*,NT:1H$'TQC\Z_8/K7YS_\%#O@??:) MXW7XB:=;-
*+H^JI'#J#QKD6]RB[59O174+SZJ?6OLAJPIXIQEH[67WIGI8"2 MC5L^]/CBBBBOT0^A/OGX=?"CP;XVO(@)M.T*QUC4+66-1']EC*LD<*
MA(_B>.158^S5X_X)_9Z\)^(;3PC::K)K3:YXVFOFL;S38@UEIHBFD11-Z_=R M>F!7AMC\3O%6FZOHVJVNN7<&H:-:'QT^X1L-,P#.(U_V?F/!];M:'\0?&GAK
*M0;O1=+1\WUEIETSO);Q/QE_OE3U?=DYOC>*L'B(7Y*F_P#1M^K3^5MCB]C4 M5[2_K4Z_]GCX5^OB-X^U;OO$=U=#// RVD=BP47-QYHC''^800H/)&>IP*|. M\1?!#1?*
V>=!UW5;;ZB;PQ8ZTDVEV2+^ZE&HO$C2$?P1A?G;G':OF;P5\0O M$7PZOI[SPYJL^DW,\?DRO#CYUSD Y!Z'D>]7+3XL^,++:REA\0WJO9IG0:I M<6IO2H\UH8D:3@=-*
Y5<#W-O3BUS]++R=E9_F..<4US M=#ZPT?X/>"_B+\-/! ^EZ-8ZQH6F7'B?4IKE]3A4W[I;V)=HH5@;@VP8'8EO2 MN?\ #O(//P_\;2>!=1LAXCT;2-?DU=;BWU$)X5M+?S*
*5XY\(//X=]U3UCX[M>/M?O-/NK[Q3?S3Z?<_;I5PP7R9=NTNN .$@D'UR?6C5/COX^UF^M+R\\47L MUQ:>:<+=R5'E"5-DH4 8&Y>#6"PN*5^6/:=Z?*
*<9^RJK:7]:GMNE_ ?X M6>*M.*2:5<>(H+KQ?H>H:GJ7#(5M&M%O>&8_#]GXGOH-'C@>V2U5@0L3*5,>2,[M<$\=*TEAL2M(U/QW\Y=K:=2G3J=\'ML_[-_@RRTO7-*
*+D'B&;Q!H_@]O$LFK(-MH&G7$AMQ*L:'T!8#WP?2G^/?V7/#W@WX?:D[^(9(_$VGZ-#]GGR3 P7,CH'\-MD1@94$'"MGDUR\O[6M[#*
*[CPC8:$+*6XTDZ,]P;QY(5A*A79(ST8C(ZX&3B MO+;IXX8NM?NY[*5%B%HY/!13E4+8R5'89K\GDQDG>4[)//_Z[$1A M6;U=CD:***]L[CVC]C6_N;#]HCP,/4L&EN98)*
*.!,02:L^W'Z5^CG[39S\-K M,_L,:=_Z4I7R?_P3K^:!]?\ BN;XD:E:/#IEC%);.89%QY\SC:\B^JJN1GU8 M^E?6/I3G_)-[?_L,Z=_Z4I7Q6-JPJ9M24?LV3];W;.4E+,*271K\SUH==**!T*
*MHKXP^?%HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *(C\+?\ )ROCK_L# M:=._-Z]5+!<1W".1D95L\CW&14NI.'8:N4 M-Y.QW!3[I8C^+,>>R@6ZEU*W^SB-*
*FVA6C)8,3 MZ;6;]*P=0\%6WBW5+R*[A&DZQ$JRNT!W13(V0&_,$&@#R"NS^%.B2ZGXJ@N= MI^SV>97?*
MNP0H_7/%5O#X.6VG@W&HZNL=HO+%%%%%>Z;]'PXNFZ'X@M+;1DEL M+.^%U=%;)66/!W'Z]2#]!0!W-%%% "!7P_K?PL\6>%|/PY8'P,;/HR^/-.N= M*\/WT\<_W+:.^>*
*<&91_]MQ0Q"3.#D'@U]PTUXTD*EE#%3N7(S@^M 'R'XQ_9__M\7^.M1O_ !=!H4?A]#K.FWZ^%+.\CC>ZCMH+F-IG< QB8FY5@"_8MTSSBKFC M?:,Q-*
*H\5AXGC\.K>RV_B:369_#&IZ@DS7<36/V596;:(UG4_.!CU^;FOK*B M@#YC\,_"'Q3\1K87D7A'2_#\]DTSQ'.&PCG0EGNI."&W>3:-N]FC.[*0*N>:H M7GP#\5:1XNMO$<&AZ?*
*K5GIESI-Q_87]H0H0.1]U MSWKSI4_V;_&_B#3O%\L\?AW2_#SZS?>(+N#3;6Y4I$MYHD%G#N(&-S31L6QP_MDUIF44 ?,_@WX;?=Q*T-"_#[0>)!9^60E>*
[=VYA<>A58D,_'22Y)Z MUUGQ9^"^J?$#QQH]H92PZ=%?>!]3\/1ZD,>;!=3RQ&-ACG 57Y\]N]>TK$B_M[*H5G.6(')_>#-.:\!V2A;3+FRG^P3H_V]Y41 M!%@0#]RNSS 7YW!?*
>]'B3X2:F?V@/$GBBY\ Q^*,#4FTQK/41JGV=K3R(]KY MCR-V&^8>M?2=% 'S#%X'^(G@3X??PVL/#LNNZ;;W$AT77M-U9;%A"TS2HMS MD%E[]K%?O*
*9ZFM7P)^S1+!XYL-5\<./%5QIWA;2=-CU>;X=99;V'XNY9W*1 M1QF;+&>P^M?1-% 'RY\- P!F?5/ QO4@]8W.GV^KC4M8UF34+2ZN2ZV(GN[B*
*M6VO+=2=H9HI'(N;X8$=#FE=?LK>(H/#'C*P6Z@U'R#:Z3X0@>3'V+24OHKN-M1&)-CR/+ITMHA7UA10!XA,?A#XA\+?%=->OHH%T\Q.2R2@M_IVK175OQ[Q*
MHQ/H>]XHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@#-U32/M]]HMTDOE26Z'8:C,DMU;13R)P&=< MFKU%'#>++N].LB,1+?*
*S;S2H&\\M]PH%'L#NW ->.Z]K=SXAU2:.^NB/,QMQ&M_ 5]5=37^D^,+NWL((]A]2A2Y\E;.L93Y&)^H*XK\N/ 5EXLNK\KQ]D

W4F&\8KZ,KYQ_9ZROQ_M^-:I_JOMEH3_+WEC>&=^CT72M+M-/TB-2B6-O"]0JIZ@.M.,&M,-C/]]-1M?WE+[NA5,M[.-K=4S\TI/"MKXG\%^%;!/B+)M)5Y(38/8Z-M;-#J44O&!)(BE@<|$MP37JOBV+P_IO[6^GQ_&B:UNM'CT*%-,N-2!-A).% = -MCNXY;)Y[XS7U=HOP_^''ASQ#_;FF>"=$LM6#;UNH;) RMZKQA3[C%;OC7X<^_M%_B-8)9^)]!L-=MD.Y$OH%DV'U4GD?A7HSS2$IZ)\MFNB:QVMZ?,Z7BHM];_M|KZ|C'Y\9_A1>>%/B@?@JFE?\)F-+<7#:*K_D8X\O^''7[G&;^?--NQ@.O({T-M\-VFG?\ "?\ D,'5T_XF?VW=Q@_>V_I7Z#>"_AUX8^'6GO9>&=!L-#M7.YX[M&!8\Y5.TZ-M;-!2T.&\|-%$B?P5HCZUO\ -,V"9(7+_P!|IC=[XS6-+'TZ-M;:-.;Z:=1?9;/R_C7H|]2?
&>N>%;GQ=XD_9HT7QM;-=R7-D5N[>Z! M)D0-E%<'KQBNFT;X,^"[C|NC6=%E\-Z?)HL&DK>1Z:8!]G64C&[R^GX=*^Q] M4|$>'I;US3=9U#1K*\U73<_8[R.%6EM\]=C'E?PHB\#^'X/%,OB6/1K)-?EB M$$FI+ HG;,?PE^N/;AYF^5I77NM:=V[W#ZSI9;;\7<_,2\T^#0_A1^T+I5C M&+?3[;6H5AMTX5!NX %:GQ*NO@9_^S#HD/A1-,/CLB 6RVB?\3$7.1O\PCG& M?7CIBOO,,X/^'')75[:3PH#V^KR";4(VM$*W3CHT@Q\Q6S'3_@'\.=)\0P MZ!9^'' =M=6AQY=U%9(K(1P'',_^.,UTK-;3:DU#Z=]'OHE%QH:CNI[W_!;MGRLJ:E'^TQHBZMN_M(>`$^_KO\ (YS[UP?@fX6>%[S|ASQEXHN-&M9_$'VB M>1-1DC!FCV284*W4#!/ ZU^@EWX!\-W/_(C.OW.AV$^M&W-J;^2!3-Y1&"F[MKM([56M?AAX2LO"=QX8@\.;9#X>N"QETQ+91;N6.3E,8.36*S1145%-6Y;V\ MKW_,A8E)*Rl?@?"7B*31QXV^-!%S\2/WG@0Z"@1[S+6WG_P#33VZ9]L=]W?#}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|BU'%_DNJZ:R MQW#R'!_?DA][XR'7/S##5XW__Z;#[>#_PG=W!AS|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}2\]36/B*ZT:RN-=L4,=MJ,D*F>%3G(5^H!R?SJ5F;Y5&5WI-?\ @6WW M$_6=+/S_!/@+X'7'P9M?A?X[B^*Z6'_ GPOKK^!'|Z$WI\/DYYW;MWW>< MXSQBN8\/Z'=Z[X$_9\TSQ)!+<:?=^;):F.U@0\G?9%X]FX/\ "3O|L>U?H-KF M^?!P^!9:\FMZWX.T;5-57'^EW-HK.V.FX_Q?CFMO5O /AO7KG2+C4-#1+R?2 M'$FGO-;QM&&,&/CY>@Z>E=#S6";DD[MWU>VC?N_>:?6HWND}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|S:NS6^:@; 1\N!QO7+A\,"EAWAY)ZWU6^]6WW:]94ZZA3=-K<^!/% M9SHW]4?_ %-P?^A5UOA/ DOG@?\ )^Q_[0DK[%;X. ^''MM7MV\+2T.K!3[" M-.*1=E?N^9Q\V/>K4'PP\)6NJ6V10^'~-COI:T^P0W*VRB2.WP1Y2G'"8)&. MG-=4LSIN+CRO5?!-MJ7Z&KQ.6FK?U9(_-Y-.AUC]FGX7V%TI>VN?&4T.]YZJ MV 1^5>Z>,? >C?#W!LKP!.>$M*MM$2XT>X4PV,8C5F5"]D@=3ZGOWKZAC^#/ M@6+2K#3$\)..NGV%R:RUMA9IY<,QZR*,<-[U]ZEX%'I'5?$%KK|QI-G)KMI&T M5MJ.P*T\"MU".1D45,TC-NR=GSZ?XMON%+%)OJ;7\3X"^'^NH_!K1O"OQ#I_B MW##8CQO|ONOM(UF\G<.'3M\DXR&8/(!5[G_,$[#$?OJ1@#"#^\V)_+#]0F M%VY\)8KGO'?I.OQIO_%FHW%M>>_ _%D%RY^RZWXATB(:C9H7:IM625SEMH]!VS6V.Q%&>'ERSNY-.U M]I67316+KU(.F[.[=CTZBBBOESS HHHH ***** "BBB@ HHHH ***** "BBB@ MHHHH ***** "BBB@ HHHH ***** "D/2EHH ^9_A\]?^$= _:Q^*VCN-BZM8V6KP M \;MH\MB*]UKPW]H4?\ "M_C?\-_B.5.]NL5]ZT_1?>;U=>67=?EH%%%%;P[*I>N4A2=GA^SA M)$#]VYG<#P1@U\=_#/P^WBOQ;I6A;:)-IBSS FVP+NQ"@Y8^1*28^ >8W'I-MKZK_&G_(N:)\%O@IK'B#7M)_MZU;::1Z7NVBYDD.%5F_A7N3U&.*^:/V$_ MVD/"GQ(^(FH: W@B#PQXBFMY)[.[MKZ6ZC>->>7B_>\H<9XO 1E"A.T9;Q:4HOUC).+\FUIT/NR-!&BHH 50% P ,4ZBBM MSRPHHHH *,@&%_[R0KLX_&OHRO+?V9? V??D#*]2KIQDU.O)QV6B]%I^A16:E-V"BBBN,Q&2 MRI#&TDC*B*,LS']S5#3O$FDZQ>7-I8:I9WMU;,?/@M[A)'BW#*[E!)7(Z9 MKR[]JOQ'8:7\(]6TB_LO$=TFNPOIZ2^&[%FU26!F7.]XHN=O'(STKYQ_8&^ M'%CX:^(VLZG&OB--1? 2_+NIM4\%6AQW+M(ISYD$$.$555&ZJ,\T ?>-3],E=7D5\N_MPOXDFT71 M+'PE\.+[Q7]U^9.6X\0Z?ID5T/HIFXVS&%9&4&5U^4 D#N#.:?O$OOQ**>#O M"\)4ZWXBTS2_#FQ9!JEU=(EN5;[H#DX.>V:M:?A[Q'I?BW1,/6-%U"YU72[R M,2V]Y9RB2*5#T*L."*^/_B;X7U>Z^%_PITGPQ\-?%T^D>|+W3K^;2[^W@-Q? MVX1@R(GF$/*AY93@<\9KL_@+\'?^C? /1]/_P"$IU7X;ZI]MO=0DL[>QL[F M5(II6>.&03)(JE01PO3I0!]/T5YC^SAXIUKQC\(M'U+Q#]}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|+W3K^;2[^W@-Q? MVX1@R(GF$/*AY93@<\9KL_@+\'?^C? /1]/_P"$IU7X;ZI]MO=0DL[>QL[F M5(II6>.&03)(JE01PO3I0!]/T5YC^SAXIUKQC\(M'U+Q#]}U;5F.>*:]:(3 M-LE9 Q1 %!PHZ "O3J "BBB@ HHHH ***** "BBB@ HHH M

*-8\81>.XM$O5DT_PCH|G?$Z=YL)DEG-TZ-MH '"!5 +$GC%=OXH\5:+XN_9$TCQ3KEOK_Q1T?[!#J5W!M)O8?#>@WTNGWI\/BGQ%XNNO#Z>6'B M62S62V5F??N5BK\87CG->]>$D-E^R;;IX8M_#8>'PU(NGPZ).+S2=RQ,$$"KJ 65W=6?B#6SJ3RI/&[0 MR(3H.*^:/B;\"_CWK_P"TCKFOW_AJUU&;7M%U_2[+5['5I7Mf M*Q:1VD.PQ!89,EF W"S'D?!+*%%>YZ"| /;A|&B\(>);72$$#)-;2W<$=OHD4 M23-&VXI_9CL",CCS<' &|C-?6= 'Q%^QU\-?&, |<7^EZ)[*PI2V\:%HUN^ ML.;JLU ;6H<^U?0N.*9^&' _0>30__0+](@#V>BBB@ M HHHH ****"BBB@"Of%['IUE-+BX!.(HP#\@D;L">=<#)(!XIU¥]G@ M*7G>6WQETIQ/=>(K>X*VD>^6)_E6/CYD2+!Y/&&SGWKR\1BITY+V5-SU2TV5 M]V_3R^=CCQF.GAJ488>FZDIR2=MHKSU6V[2\KV/1]1\4ZC-;^;967V&V8A4N M+]"992>@C@!#$G_:*_2HK+P1/K"O-XFOKG4UE&!|[N%MT^TB !C]Y[=/6MJNU4EO-W?X?=M^I|&BKWF^9_A]VW MYOS.8TOX8^%-$\0'7-/T"QLM5\OROM,$(0A<8X X\'<#=»/115TZ4?2:IQ23 MUT5BJ5&G135**BGKHK;IQ.8I;*T-@HHHH SM.\.;5H|W=75CIMI9W-VVZXF M@A5'E/JO R?QK1M8HJ8QC!6BK$1A&"M%%%%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !

M%N6B\U5W$88E,'Y2<9&:\G^%G[3__(Q\]T*_U=?&L26-E)"DS2V-RCXE;9$Z`MQF,,\;-P'4%3ZU/<_MF_!^U\*V7B|_%RFPO+]:SBC2PN7N?-B&9E: 1F1-@(`M+%E /-

>86O[!5WJ%UIFH>)OB--KNJ:0FFV6G3II$=LD-C9S+*D3(KG>[,%! MD){<+6GO530!Z8W[6'PI'B:TT%?&%K)?W444L31PS-!^]37$AF">6KNID)5"P8]A7$

*M^)/^"@'PATWP5KFOZ+K4_B1],M%O196MC<1/<1F01[HVDC 90QPS#(7O7*7G M_!/FTO/B9)XIG\9OJ$5X]O=7|>HZ3'-N6,DPE$Y7?V(OL[^M '=V_I;_PD>2:WF\1*

MS17]K:1W=W:+I=Y(UN'1656Q#]XI@-O4]A7,ZQ^W5\)@-O4]A7,O^3$Y-09/#U5K.C_C9-M7UR+F:">VBM9;9/#U5K.C_V$#58WCG+;HE:;,

*MKAO8UVW@#]D:#P)XB\&ZJGB:2[/AW4=4U_1&S"",+/Q%*FC>&_#<]KITNKN))6FOYP6$"Q1HQX7'S>K 8KAO'/_M 4:!\^:_$WPXAT&V'B/PWXJOIK&ZU<2/:-*

ICQL%;S(7CW9!(R&VXIUY^R_[MOB'XI^-%NYY-.T& ,\1:;XMLM2C195DFA7;+:,I8,I^52&QC!-8?C#_@G3!OC M.UU6WO/&=P]7L^JW"E=/7,+WFT@@[_\ EF5R/7VH

M?"S]OI/B%XEN(9/"!T MWP]#XH^Q=MQ=BSA_)GV: K.F.9XSGFOKHZ]IFJ:I=21) +..QB/3YR7;5SG@<9K[+ P.%HHHH ***" "BBB@ HK"-MW^:)^>6E?]_)?-B:-*

*_B7_GEI7_?R7_XF@#=HK"W^>)?\ GEI7_?R7_P")HW^) M?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM M_B7_)Y:5_W\E | B:-_B7_GEI7_*

*\E_P#B: -VBL+?XE_YY:5_W\E_^)HW M^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC?XE_YY:5_P!)?\ XF@# M=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF@#=HK"W^)?\ GEI7_?R7_P") MHW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W M:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC?XE_YY:5_P!)?\ MXF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF@#=HK"W^)?\ GEI7_?R7_P") MHW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E_P#B: -V MBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC M?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF@#=H MK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_X MFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E_P#B M: -VBL+?*

*XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_M (FC?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF M@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_? MR7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E M_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?*

*^>6E?])?_B:_-VBL+?XE_P">6E?] M_)?_ (FC?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R M7_XF@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GE MI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ M *\E_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ M *\E_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC?XE_MYY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E_P#B: -V MBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC M?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF@#=H MK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_?R7_X MFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E_P#B M: -VBL+?*

*XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_M (FC?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R7_XF M@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GEI7_? MR7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ *\E M_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?*

*^>6E?])?_B:_-VBL+?XE_P">6E?] M_)?_ (FC?XE_YY:5_P!)?\ XF@#=HK"W^)?^>6E?])?_B:_-B7_GEI7_?R M7_XF@#=HK"W^)?\ GEI7_?R7_P")HW^)?^>6E?\ ?R7_ .)H W:*PM_B7_GE MI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ M *\E_P#B: -VBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-B7_GEI7_?R7_XFC?XE_YY:5_W\E_^)H W:*PM_B7_)Y:5_W\E | B:-_B7_GEI7_ M *\E_P#B: -V MBL+?XE_YY:5_W\E_^)HW^)?^>6E?])?_B:_-VBL+?XE_P">6E?])?_(FC M

MX5P03>+/FGZLYQ$MW+AW]<*,DCWQ7(_$WXVV2? ?O)XX\!ZSIVL&RM'EM[MF(B>(..S+D<^QP:UIK$S<9)O5Z/6UWY]RHJHVFKZO\3J?A[\&/?PITVYL?"

MGAVTT:WN1B?R06>4>C.Q+$>V:T? OPY\-_#33;C3_#.E1:19SSM:[XOD\+6'C#2KKQ!&YC-C'<#>7'50>C$>@)-:5Z&)@VIMROJ]WLVM?N M'.%5;ZWU-'XB_"?

*PC\6=*CT[Q;H5MK5K&V^,3]\;>]NI#+^!KGO"GI,_P`, M? ^HVU_H?;@^QTV]MX'MHYX6DW^6X(<$EOFR">3DUZ=17)&O5C'DC-I=KNQDI MS2Y4]#SK_AGKX=_|*

*(=#X4_X1_X/Z[^W1V.^38L^<{\/LYR/6M+X@?!5DYJ'R=U^.=*ZZ,./0UV=%'MZMU+G=UKNPYY7O:\0+228[.[$L!9Q7+^(?V2_A'X]\12:YJ?@?3*

MI]2E?S))%D:R-ZLBL%)]{N[C52:=TWBI5:HM%)_?_SU%SR74XG4?@KX)U;P18^#[OP_;S^&K$HU-MMI[.^R,]//"]O"(XM#UZ 03V1 QE M+@,K%3@<;OP-?

4M%;4<75HSYT[H[^>_S\UJ7"K#ON?,/[*WL?B'X>>+=<{\M9>*f'1=!U"' @6TM=#T$?Z/;1 YZ]"3]2?4U]/445GB*\|34]\/4?_24;UOC^2_)\1117 8'SA^W5^S[_P*

*+R^#MS/IUOVGBC0 U!HY4 M?:*H'[R'_@2CCW KS?V3_B1K/PM^/?A34=(229[/\33{FS /^D12L$>,CUV MS[$5^X)&>M?!_B#Q'X=\%_'+5/$WA3P3X9TW4+>Z=#=#3PTFK*

*X>3).$9CGE M #0!]XL-K,.N'1374.C*PRI&"#W%4= U0:YH>GZB(S"+NW2?RSU7EF M,#\"]?3I.23ZU]1C<15PL*=.+/ZUV^M_|U+FU/IL;B*F%A3IQ?O6NWU_X=/F*

*MU(,.S@TZTAM;6%+>VA4)'%$NU44= !Vj8=1117S#=]6?--WU9XK^RQC1_'_O MCT!>(K;7ENHD[2IN/ZU\&U\X_L[];CX_&RY3_5"^M8N.FX1Z=*_12YMTN[>6&0$QR*48*

*XX(P:^?#^P3\'3J/VXZ'? M-"U7;.M;7,;F.>$8QA9%YQ{'(]]Y?X6?L??#/X1ZZFM:/L]YJT7^IO-3N6N'A]T!P M??&:Z(XO"2M5JQO))*UM--FG?3ST9HJM)^]-7=K6/*

*_C'X0\0_$+JL+PI]>F M^)KKP5K"(%'A;2?A%H!\6?7B#Q0FIHR MK!KEX-LK2D90G);IT[U]A+7/PB\-7?QO.MO'TEK,?$EO:FSC6G%PX01GV\=O*I/O*

MBD\??]_PS\2M5T'4==M9KBZT.X^U6317#QA)/4A3\WT-%/.HPG2TIV[+>S^_M=M>X1Q*3CV2[=3YQ.8.TR#5=2\:^)/$&KW^J?$8711-42_(S"BGY2N.3DCKQ*

MBM73_P#E(5>_]BZ/Y5[GH7P5[^&OB+]OC;3+2>SUS5$V7ACN7$,WN8L[<^^_M*GB^$7AN'XGR>/UM9AXE>U^QM/\ :'\OR_3R\[<^^*QJ8RG.K4J:VE&WH]-/ M1$2K1**

<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% !1110 4444 %%%% !1110 4AZ&EI#TH ^;/@]3K?[0 M/QTUR7Y\(M4M-

)G;T2&'I^9%>ZUX5^SK^X^)7QVMF_UB^+6E.>NUH@1_*O=:_M{\,_!K>4?\ TE&]:X_DOR04445P&!3U;1[#7["2QU.QMM1LI/OVUW$LL;?5 M6!%>ST6^T'QY]NC>#[X11

*M2Q2QF"65H2GE",F(/M;#1B9#%)M8;&:-AA5(ISKEK?P'#:^-9/$4=Y)YDDDT MCVY0;?WD.41 /7_EBK?4UWX2NJ*FI/1K;=-]#3#8CV;GSN!UUUN^E_!,@*

MR>\)>P^(Q/MC"^2UO' 2Q.IKQ+QI^U9H0A_6+2$M'T]^Q]2V.=.IVDG*R7!L>Y4HX8?6O)OA!\]2OOGCW6;LZWX4&QE#TH ^:;/@]3K?[0 M/QTUR7Y\(M4M-*

)G;T2&'I^9%>ZUX5^SK^X^)7QVMF_UB^+6E.>NUH@1_*O=:_M{\,_!K>4?\ TE&]:X_DOR04445P&!3U;1[#7["2QU.QMM1LI/OVUW$LL;?5 M6!%>ST6^T'QY]NC>#[X11

*M2Q2QF"65H2GE",F(/M;#1B9#%)M8;&:-AA5(ISKEK?P'#:^-9/$4=Y)YDDDT MCVY0;?WD.41 /7_EBK?4UWX2NJ*FI/1K;=-]#3#8CV;GSN!UUUN^E_!,@\|

*1!KO?!/Q2\&_$M+QO"7BO1?$ MZV;!+@Z/[$5UY+'H'V,=I^M<%\(?^2V?&/\ Z^]/_P#1!H]FHHHH ***** " MBBD) !)X% %?4+^+3;22XF.$0=!U8|@/A@!^6\GBWXM:!\6?B/<M:/]'Q2U#Q')=6T%P8_A;8O!J+QJ4BS(=RPJ%^42#.Y<-V%?H!\==2U;3O@'X MPO=/U*RT+68M%FDBOM5>,.''VE\H_-(S HH!{D%1U%?G'^U#X1TKX2_%G7]:MT+PI:V6@:6|NHO==U_Q)/-=3SPO.GEB&Y$6'9)(D4\%TPV 17Z3_ |6FN(O@ MKXCDM+B^L,H:/(8YK+2UU"YC;RN"EK)D2L/^>,<'H: /FO\ X) Z'\0KB^U? M6-;?4D\&O9-!:R:OK5EJLMW<&Y:1)8Y;((PVCL2<=FT +7VG7P).P3'\!?' M>:QX\0W.C6#Q]#"-O$$6IP+=7:[P=DVFVTLD-HP)P"#QCN:^OO%OQ!\' M O$VD^?}67B#[4M%US52!9:??7B133Y.T84GH3P">IX'-':UXUX[_P"3G?A; M_P!@K6?_ $&"NVT/XO>"?$OC75/"&E>*M)U#Q/I:]KW2;.[1[B -9W(#D8R, M^F1G%<1X[/\ QD[\+?\ L%:S_P"@P4 >S4444 %%%% !1110 4444 %%%<)\ M2/B]I?PUGT^VO8;B>YOB1$L*C:H&!EB3TR1TR: .]U?5O[/6.*&/[1>S';# M#C<>Y/HH[FDTG2/L)>XG?[1?S8\VQ MYD)VC(W8(&:^]*^) P!N?P3=ZKXULFR\>^%/"TFI^'+S3)!+7I*YNIYK<,I_MLDD2PI-H3]>.W6@#T?\ 8Z\+2> _AEK;77@/O#X1UV6076I?_BO4{IRZUBX\ MO+3M$[_"YR ,< | U\N>,GN{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|*V^C*7,D>]>_*_!=7&C MN9/EAFG,4.3V^PH_R2JUNYSE;BOO_I6:32;)FO$U!C A-V -@ 68(1\X ;KQ MZUQ7PQ^ 7@7X/3ZG-X4T4Z?)]*\%,TUW/<[8D+%(8_-=O*B4NY$:84;CQ7H" M(L:A5 50, 8 %#]***,(^Q"WH* '5XUX[_Y.=^%O_8*UG_T&"O'_@'Y^U-XI M\7,_!32K#6OD)?P;XGU#7].TZPM,-TN\/.FS8D>7>?:\'T!LKM&TXQFKGC7]H7 MP9/^T1\.]06'O1|GL].U:*4-X2U42%F$(&U#;[G'!R5! XSC(H]|_;5^%OC MKXP? ,5O#OP[U"'3_$DDT.L9FF\D2HK@N@?!"DCH3Q].M:G[-7PG\1^ /@?X M4T#QSJLVH>)[*V*WDMI>R>6&+LP4$$X4@$@8)!GJG[97PTT2S:[UC&3Q0186 MJLJF>Y\'O&@+*$\1N:V R20!IFDN/VR_AG:A!85Z^*(;V=']BMM|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f8/ACXRP^.9;#3-+6$S:.(6+L MT><*C;MH5[\Y&>.]=TG[$5(F*9+A#]F^;,M;.. MF#G15",_(* ?!.W17E\0ZM&C(L@9_#.I@%6!*M_Q[!"%)+] ?2MW%2W1TN* MENCZ)%+7@N@?MO\ PG\5PS3;+?\B'5XH7\N1{'PEJLZHW]TE+8X/L:M2_MD M_#2=48+"23Q1'?3HTD5LW@5Q+(]_>*K]ER0.Y]AG@7_"_/&/\ P\<_X5[_ M &?K/]A>7GS=$^3Y7EYW>7C9Y>?X^N.^[!7@<_[;GPDM#=RSWWB"$VDJV]P\ MGA+55\F1L;4GP;M'D6?6]:A:-G1Q)X7U12K)@.#FWX(RM_^F17/1P].AS>S^TIO5O5^NWRT.6AAJ6&YO9*W.VWIWJ_5NWHM#Z%HKRGX1_ MM0?#GXY:S?Z3X.U]XU'4+&(3W$%QIMU:%$)VY_?1HGGL*I6KH.H**** "BBB M@ JM?O=)!FSBBFFR/EFD*+COR 2Y59]*XN8K6/?*D29QN=@HS]32;MN)NVK M//\ POJ_Q$N?%&NPZMHVG0Z3$X%E)YY7<,]F):CDDJN*57]H*6=:T'X.ZU> MZ-ZYM;-KB-;N:($]D@,K @$C&1R*ZG2?B5X7US5M1TRPU MVRN;_3V"W,R@&,_4\'GCC.#Q4/Q3^(^G?":?P#JWBS5(9{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r Y:' M_>_AW-^=6 M-S&8+FW+'#(PY4X.1D55N_!.B7QT0SV"2G19!+I^6; 1V"[1SS\O':.^=_V M._"D_@SXE_';3)]2U763'XBB;^T=9E,D]P3 1+%L $9X 48'2OJ2@#A[WX)^M"=0@:&XT""6)I+N4JTDG+7./M!^]_'@9^G&*X?QI^R+\.?%.C7"6ND6^A:GY MD<\6JQF21X&659"0K2 '.",?U>X5\\?MY>#KCQ.^S3XO;'6=7TU+"S>Z;TT MJ0}]M(QMCE^4L4SR54C/>@#Z M(%@M88P_F!$"AO7 ZUSH^&'A=?"#>%AI$0 MT!G$AL=[{"PD$@.=V?O@'K4OPV!7X> ^&0P(8:,;9!&"#Y2UTE]Z\(O"&M M:C<>U>O5\]?M<>"KFZ^*_P6\2#6=9EB@\3P6RZ/%*!8H#'(M6F9%7+,>!N8\' -Y- 'T%\-?!\/P]\#Z)X5COC]!TBTCM?/90C.%& Q4$X5S MVS\$Z)8/KCV[@D3:W(9=1{9O}(8H$)//'R@#C%? 7[/45ZO[6=AMBU!?'8U7 M7CXO>6.<9LC(OV+S"PV%E?!OPW],E:3=+)101T-?D=H-O:MX UYM"M]2'PD_M;PP?$:+%V*-/HNBBB@ MHHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "B MBB@ HHHH *S];U[2_#EB;O5]1M-,1]P0SWLZ0Q[B< ,F(&2>U:%?)'[=NA++> M:O\ #35M<\.7GBCP+!]UJ U6QM--?40)I;&6.U=H$5B0)6 #8^4L#Q0!ZEX7 M_9I^&WPQ^(.]?$JS2>SO)/M-R#>,.FI6%&QUM!EV@NPZXI5T&OV/A M74?&7@QY<^*+2VCLX+FSL#]LB%M>&Y"#Y7)^8_NQ@*>>;^2_&MGKY_8R\$?M#W6= U_4];#D*5E=(U^>$$L O(KPKQ-|-]37PA M]NU'P!K5]X-U5?%\7@_34I*:0V%Q=2QG3V$ 3=;;@'*,0NWGIF@#]3/$ |+^ M)KD^%]8ETS4+F55NO{(NI4>1E1@RR>43D@, ,=H42;E,>]EB#@|: ^D?V1?AH_PP^'QWTR&VU8:.^M64M MK?:Q)+-+>$VNZ23SL.9/G9LD$@=.,8H](@M_`PTN]0.A0Z3X?FOM/MA$VG1 MB)L;> RB8 Q@Y53(OR,;@#7->)O@7_-0\5:!!:P:/X>\46_ #]]NMB(FH M812^81M/S%&.=QFOD7X7>']6\&?M0'5[WPGKEMK^(?$N(-(M9CTB9OM_ME2P#[(JS!<7 8A0D:EB"IX%5/B-Y6U[QC^TO=ZEI?A76Y/$FM^(M"UOP_KDF MDS(+;2$M6^T*TY7$5B0\3$$EAE30!^BMOK&A^)EU*QM[0LM4%N3;WMO#<)* M8B1RDB@G:<=C5'3_ _X4UO0=)M;&UTV_P!"TJ6,V$=N5DAM(" GEX)"F.J M ;=":/O+D=]D;X0W^M^)M2TBX\/\ B+PC%%X.NM(\5ZA%;3;:-=:D^L-(NV? M.LACR?,&GYQNKZ>_82\+W'@W]GC3'N-/NM+^ZRZ]21VUZ&Z2+'|KDV$[_F M.5P);AM1GN[I515F,?EM,S-@ ^7'I8]N*X MSQ1^SU\+O'_@]\BM]%T:WM;VS*0:Q80Q,84V*JR1ORORK&F#T^0>EN1_L> M^_ ^E>'M>M-0\1SZWJGA[2X]+GC"Z7YX9(<;0(692Q2)L$@\"@#[=\,ZMH% MAX*M+BSUVSO=T^V6ZF+N-H=L:A2S2 [1TYYX|IKX+\-2^';W3+?2K%]*U0 MO/79@.&W=2>]?GE;?U?'[- QRO=(\ ^(M#[*M<6]_P^&!#M; M:XTT?.5DD^&(IIVBFCTNU5XW7:RL(E M\!'8CTH 9]/PT*ZLTIO- L+DRVJ63F6$-N@0AEC/^R" O:;N9U?X6?*K5=: M;2, [0O#DVLW^ORI$6:65G6-1P#@OM4#G %=+;^'=,M-3OM14LH8KZ_1$N MKA5P\RID*&/<#< +R%(1_"&CRQI&D*J]JI 15957Z!68#V)KN:9-'YL3IN9- MP(W(<$>XH \Z^%/PS\+?#+6O%MMX;NX$.H7B7MQI-NT:K8DI@*$'7E0V"?FZG M-=O<>'=,NM:M-7FL89-4M(WB@NV7,D2-]Y5;L#WKYO\ V8_AA_PK3]H#XVPV M]OJS:?>S6%O'].K2RSO=R,DA=A++)[!:(&!P ,"OJ&@#G;SX=^&=034$N=#L M9TU"X2[NU>$$3S)C8[^K# P?:J%[\'_!-^\TESX7TN9IGDDD:2V4EVD(+D^[M;5SZX%=C6#XZ\+0>-?!"JZ';N)+YYDR-N_A7KJ.LJ^Z,& M1AD.IR"/6ORN)AK<^'/@I\/(?$/@S6=?\'Z7]VOV\VF'2IKZ2.602);2O%M M+GG,B0@\|YKIU_9BT36O#?[/_@+3/$44T&M6NDPQW.5P3YB-CA6SW P,>U ' M#]%%% !1110 5#=V5O?Q>5Z18:U<^':N8(8;^TC24Q,K!@&C<%9$,&UD8892PXSFN8*0?$ MU?%>OMK5S1T4N/[/3/&>P4A@,==Y)STJ/I&*6Y^"GB2%+W5M-\R*-9+S1 M+22ZGA3S4WL8HV61X]N?,$;!_+W]><5RX>-.,;4Z?(KO2R77R[[FM7+J.6OV M5%P:>ON;:Z]EKKKYW//-#_9^U+PIJ%KK6@^-+/1O$$6IW&HL;+PY%'IRF:U6 MV98K-90(]@8MD9B2?2M>[_&5+,:U\"WFG:#XLU71O%M^DB7WBHL]DT_G7! MGN3Y^R)$AD+.XV &13A6! -?.?AVIT,>X\+V_BFQO(?AI::]]*M=:3}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

*/L*R\0Z3?ZU]&EVM_;7&]6 0W=K%(&E@WC*;P.5R.1G MM5*]^(^AG3O%$'AN|\0:9;>(+B!KF+2YKM%N9(AU=8R=Q4>N*^'K+P]XS\|4^ M--*

;TG3+WQ+IEQ=_$^\C\2WGAZXDMYH['R#Y)>1.5CV! #TYXKQCQ?\(OC[JF MH:)XRM]"\3ZIXP\.Z1+I]M=ZG;223SQ275S;X=L9=A$\;Y/.!DT ?IYX.^+/

M@OOG=06V@^*]&UF>?S?*CL+Z.8R>40LFW;3G;2 <=,C-=7@9SWK\V?@;*:; M^*#F]_"CPW<;=>Z?K4'Q U5K8W411HK VY\Z09ZH3Y?/3,*_28=* $\M=I7 P M>HQU!0,#*

I:* !BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M "BBB@ HHHH ***** "BBB@ HHHH *0C-+10 F*,4M% "8K'M?&6@WOB>[\.6 M<5^OVD"W-

QI<=RC7,,3'"NT8.X*3QDC%:=Y/\ 9;2:,;8\GEH6V1J69L#. M!U-?FWX+\!?&WP_\:++X]7O@2:.)?$.MW=OJ-M;S3R:Q%I4X$%NDUGLVHL/EI M+D,3ELD4 ?

I'=WEO!]M+R?,!U(Y"%?GEK7PI^,VN?"+[#]MQ\1]ZBDM;29=7@LTTIDG=#@,"),J3G(X [4 ?J-P*S-<\3:1X8CM7U;4[33$ MNKA+6!KN98Q+,YPD:Y/+$\ #DU^=>I+!>!X3T

:^/BM_9'9VI?\(] PCI? M^TO>?:?!|_M3'S8\G_G!\0>}<K/\0>$/C1XO\;;#:?$/3OB!]'B6#Q+HU'\F_MEJ[>'8+!8H_-D&SY%D67>2?O X/W: /TWZUQ]W\8O FG^-

H?!USXQT*W\5S M>7HLNHQ+=OGIB(MNR>PQ7S)^QWK/Q!\9_%+Q59>)/$-_]6A?#U9_#T-PU^9D

MU>XDG:5+B7!P[!\L3G.";Y+PAX7O?!FO^*/\7B7X$;IX\\7;KXUEUFT\2362 MC3FM7D5H;AK_)V&%1CRSSQ@<$T ??'!HS7YT60^/1\2ZUY0^)G_ DH&L_V

MZ;S=_8K6^R3[#_9V/E\S/E[?+^:,[=3[[P[\=O".@:A:6%_\2]5T^]\/:%J. MJ2-<2W&H).TN-0BLW?E)1'_RS3D=N: /T4S2.ROJ68A5 R23@"OS3\;M\<9;

MOPZOA;_A;6G^$O*N/(EUM)[C4A=>>9WB@+HXQNW=JZ7Q)X& ^->_]-)=0U&;5/B:])<^+5TR2QM,F=)+0"U*.1(N55#)GY\G;>aHI_0"PU"UU2T

MCNK*YBNf;3,R:"0.C8.#AAP>01^%)?ZI9Z5")KVZALXF<1A[B0(I8G &3W)Z M"OSA^!7PZ^)>E^'0#UB+?XIZ5!?AGP!=S_V-

%>S6"W.JI<;""ZE64J#OBQXQ\)7Q\3:=\3KO2;'6=%U:WM7&H274?[PBZ\LS?/(R9R=H501N M50 * /U"T#Q-I'BJR>\T;4[35;5)GMWFLIEE19$.UT)4D!E/!'8UI9K\UK]R

M^,5AX;TM-0M/BK:Z$T^M20?L>A)\WQGS9-= _Y13H6^A,ZM-[#_G(0O>B"N:AXY'B+3]:T*%-/H+B7^SI8'C O7\A?DD4?Q'!\.6 M-?

>ZA;6MJ]+M9VTLH62X91N8(O5L $G';JOBWQSX=\|:?'?^)-@KY-_:O7Q.WQFNO[#_M#^VSX"U(>&SIF[!0+SS$\S MRL<^9LSC',.UXW\5?@/\3_&_AV_\%7P\:^)-

(N+S0IZ*ZUN2:\>&=HR;EED8 M:*]N!N4<+0!^@5_\8O NEZO.?B1H6H6%YK/@ZZMKB:XMGCCCDADBBBMD!/1F MV;@.ISFOTX^%8U ?#+PF-

5R=3_LFU^:NOF^2N!/OF@#]4M%% !1110 444 M4 %%%% !1110 FT?Y-&.*6B@ 1,4M% "8Y]*2T@EFAFDAC>6+DQR,H+(2,:' MI9!(XJ:B@=!,<_P#UZRO$WANU\5Z/-

IUW++P12%6ME_AWJS:CH=C-;SF)HU62ZDEC0N5,KJC$@/(40NW5BN3WSWE M%% "8HVCW_.EHH 3'-&*6B@!,4M% !1110 4444 %%%% !1110 4444 %%% M%

!1110 4444 %%%% !1110 F*,4M% "8K(\5^$-$\=:'<;-XATFSUO2;C'G M65_"LT,F#D;E;(/-;%% %?3],M=)L8+*RMXK2T@01Q00($2-0,!54< -#TJ?% M+10 F*,4M% "8HQ2T4

)BC%+10 F*6BB@#-I_#FEZ?K%_JMK]M;ZE?/M=U M%&%DGV#:N]ARV!P.]TJ:6B@#-G\..7=:,!;ZU-H]M+JUK$\$%Z\8,L4;D%E5N MH!(&0.N!6I4 1110 4444 %%%% !1110

4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E&*6B@!,4V M6%)XWCD0.C@JRL,@@]0.?10!A>#O

WAWX>Z1_97AG0]/T#3?,.;|+IMLD$9=-MCEF*J,GN:W,4M% "8HI:* $P*6BB@!,48I:* $Q12T4 9NH>'-+U;4=/U"\ MT^VN;]3W:2TN98PTD#,-K%&ZKD$@X[51444 9NO>'-

+]4V'V5]/MM3L]ZR? A9[J,2(64Y4X&/&01FM%=_1110 444 M4 %%%% !1110 FT2Y-&.*6B@ 1,4M% "8YJ*2T@EFAFDAC>6+DQR,H+(2,:' MI9!(XJ:B@=!,<_P#UZRO$WANU\5Z/-

20240630x10k022.jpg M_]C_X 02D9)1@ ! @ 0 ! # _VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!#*

0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%\3_P 1" '9 Z8# 2(A$! Q$!_\0 M'P 04! 0$! 0$ $"

P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %]0(# 0# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D.V)R@@D*

M%A<8&1HE)B7]#A(6&AXB)BI*3E)66EYB9FJ"C<9F!ZBIJK*SM+6VM[BYNL+#Q,7& MQ(C)RM+3U-76U!C9VN'BX^3EYN?HZ>KQ\O/T!?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0

$" P0%!@<("0H+_\0 M1$ @$"\' 0#! <%! 0 0)W $"M Q$$!2$0!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-

$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-

G;XN/DY>;GZ.G\IO/TI?;W^/GZ_]H # ,' (1 Q$ /P#!4Z*** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M* "BBB@ HHHH ***** "BBB@

HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ MHHHH ***** "BBB@ HHHH ***** "BBB@

HHHH ***** "BBB@ HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M* "BBB@ HHHH **Y[Q7XRMO"HM8VB>[O+IML-

M%0"P'WF)/ %,LRW*2(0 MRL 00"OC[X9E\0>!= M9&N.3',UL]PMO++B0 $<@$B]>5[5Y9_P4+TVTO/V2?B%/;:PSS0>S0R21J51 MG(Y4D9!^Z<&ZYXPN?AG/^R,EGJS^&?

#NI+&FIK!+]FMKEC",>#-2^(>I:#9ZKXTO(#FH^-I9?\ 2X;2)L(IF/W6/IXG M\;D^)?Q!\8? T?&+X=>$OBSKOCKP_8>&DU6VU>ZQ_M%YI-R7 V?:$]?3WH_

M5JEKQK]DOP5<^$?@IH$^H>)=;!5;GK%M%]=W?ZY=FXD\R1 2J9^Z@[5[+0 M4444 %%%% !1110 4444 %%%% !1110!X9?_ +;_ ,#=+\?2>&+KXC:7#KT= MU]B>R:,;

<)MVW9G9C:,>M>XI(LB*ZG*L,@^7KNX2\<*$M M?^"DNB,/#FFW$8 M\)W%UO\CC*RSJ,=:U"UBT^VNO*G9= MEVDRY19!C[>]H&.M

'W]25\0_'W7O&'Q:_;\L_A);_$W4OA7X:L=%&JB?2) %$AMN1F/8.W!"^E?,C?&#XLKX3UW0;?XQ:YJE[%\1+?0(?$=O.NYK9E'G: -N M.O G@SQ+J7A_6/$$5GK.G:8VL7-

H89&:.T7K)D*0?H#GVK: M^"Q\/?%GP9IOBKPMJ U/0]1C\RVN1&T>\?[K $?B* -7X@?"+6OA]^U=XE MAC^)/BO5[G3/A_<:A]LU&>.66XQ&1Y,A*X,9)SC'85:\$_$WQY\2]/\

@\)\ M8/B% _#G2=;\-MJM_KI@\XK\]@*"")RJGV'H:/T8^)GQ6\+_*#0(=:\6; MF-*TV6ZBLTF,+R9ED,$7" GDJ^E=5!.ES#'+&VZ.10RGU\&17?VV_M.>*-6\!

M_LT_V3J7Q9NOBM%%XSTU(+F^\IKBQ42C,,DD9)9N_P V,>E>6^+OC'\:OBY\ M3?B(NBW7CVRM2*4PLM,M/"6J6-C:695!MDNTG(:4-U/0>_.:@#]:**\M_9E\2 M>-O%?

P3\,ZA\0[._LWQ<[OLO8\H?,8' D^0E?F&#P>]>I4 %%%% !1110 44 M44 %%%% !1110 5S'C+XH>#_ (=/9)XI\4Z/X<;]?R[9=4OH[RXN8;+<2;NVP=RLO/S#H0 M>H)P ??

\$\5U"DT,B2Q2*&1T8,K]"".HK'\4>_ #_@F.QDU_6K'1DOKE;.V M:\G6(33-]V-,GECV YKY&^''!0GVWX\?!CPA\/]D:=*=<\'/]%OIU?.GQL^+WCSXQ_]0K^^U:SN-?L?

BR-.TJZN8$C@A"$B+>% M!53U)Y-'ZOA@PR@D49S7PIHGQ5^/QO^2+/4PT\6>*-& ^)UUXG\.W6]:-'!8 M)80:WD:L5B95ZOEPGCCD0#]-%/'V

M@^%?"_AZYNK;S*SZ7',S10MM+O.W*R^+-->|:WN@6>]1:6+AK.UB8O-`Z8YHS7YR_"K]]SXS6$'Q MCTC6Y/$7B#3K'PM>:OI/B[7_ F M3?

OQ1XG\?:1]^A_$V5]/_LB+1HXC8DI^[FWC&]\LK$<#@C':.:/T4\.>+]# M\7Q7H5FA23(*Y902! M[&N12>Z\&ZAY4FZ73I&^4=0!['>A'IWKMJ*YCXB>&+_P 7>&IM-

TZ_33H67=,MZEOE!Y"(SZT .\-?$+1/%Y]7UAI=R]S-9@&5O+8)$QOPXO-=+7A-N7^%)DCL M\6F7%C&7N/-?;!=0CDMD_P#ZP.]_^'/Q*\/?%PU+KGAO48=1LG)1FB;)C<=

M58=C0!U%(#F@@,"",@\$56T_3;;2XFBM8_*C9BQ7<2,GZGB@"U1110 4444 M%%%% !1110 4E+7R=\??%R^':?VQ_ (20'4/$*%)/U"X^PV.HK%83>6F[$T14

MEB<8SF@#ZQHKX 3_ (*EZS#X? S6X? MQJ#Z4^LPZM%*S7 ,"K%&44 MMGCDE1DXS7;:#_P4#U6.7Q_8>,/A]/@_7O#6AGQ#;,=P+JF(V(M/3YL@_&I7_ ! V MK>,+H>-?

[,T31N&@DDFD<'9%&6R$7OP,/2@#ZML/\5OA1IGP^A\$6O@C38?" M\5TE\NGH"'F=2"LC-NW,PC()>KJ7^$WA) ,'$?C!M$@/B6.Q.FK]&YMXM_P#G MGC..?

AFOFKP=^W;XLN/BGI7@#QQ\M3\"ZW?:=<;FCWGK1S1M'&A<;-L?S$X MP%O^"F.L;[%X;UR_^"\VKZ3X&U24$HP\0G5HI%%SNV@)'L!90/3-?'WP<_;"\5?#?XA_M$:|\ M0-

"UN7P[H^HH(+234UN/L,O!GAWQ;\' M=6|*S^+I2-*N)]9B>.5"I9>D>0YX^4XQG-`V/HVCV7A[2;/3-.MUM;"SB6" M"!,[8T4851GT J[7Y#Z7\<-'/B'PCXA'B)>,](MX_B-

!#!=Z=XB420NTN#9G M*M%"/& :^N?'G[=VM:1XR]2Z/\ #_X2:U\2-%\(]<^-N?AO'X_^\NI?$"X\O5OV6_VD#^T9X6UF[O/#-SX0U[0H-

U/2+F=9_)F7^[(-P_ 4 M >UT444 %%%% !1110 4444 %%%%<\.O$(GDL;(-+;VJI!9 MY&.$C0>I- %JY^$'A.|^)UK\09=*5_%MK9M8PZAYKY6&]5VYV_CC->9>*?V#

M/@;XR|>2>+!4]"6LNKRS"YG$<\L<$\H.=[P]P1CGU'-?-GB;]KCQ[\0/V@/@ M?!UI]X*\6_";3[^_DGE@O[M3;.I:F,E2Q3&<=2K#BO2-;_P""D5A9:CK&I:3\ M+;_%6O_#?

1;TV.H^-K38+>%U:;!+$1N90>IR/!0!Z]X_8Q^#WQ*\-6"N%P, BN'\._!PCX4\=ZSXQTK2$I_$.KPQ MVI=I(Y\R,.81=I.T >P%>$^-OV|=-T?XN:'K&|*^!M9\=2:C9VU_+>Z;

<11 M>5!/C8Z1OS+@'+8(Q@UY?I'[6$/P+OOCIXIU2;Q?XTM=+!40::-(OK]';,&1 M>EN.< =-O&?UH ^H_C;^RW\,_P!H=K"3QUX9BU>YL?\ CWNDFD@F1>Z[XR"5

M/H>*PM"_8C^#'AG2HM-TOP9#96.6I1:ND$=U/M6ZC "2U<+X!,;\T MW6==\2:5XX\ Z,\ #6XTC1SKT8U9XY3.A@$QM8Y&%YZI:XT?\%,;JUM?# MVJ:G\$/%/VE>&?

$=_%9:/K=S<1+! M)I3T1:G6[_2WT:XN3-(:HPPT>T-@9]0.^]Z'X+U?P=;W& MA:&FS3$$TJ36@[A)@V\#VS53]L[XM:E\(_V:/%'B+16,.LRP!:6,@.#'-.0[MMGU&3^-

>"^&M.U7X7?%7]F_POJ/CKQG>ZE]>G3W5^C7XEM;Z9E+,9PY+$#. M\P !C% 'T%HO[&>P\/> /\ A#+#P=!!H+T6I21*XE,DM@&Q'N<5 M4?=@&>ZXTPN?AG/^R,EGJS^&?

(H3Q#XF\%P7>K;426>"YFM_M"K@*\1&P$G3^+FMOXK?M$67 MP@^)7@7P5K6C7/\ 9GBR9[2#75E406]P!D1R+C/(Q@Y[T? S]H>R^/.M>-(=_M&T2ZM=%\.ZDVF1ZQ-

*ICOY%^^8U'(4=,F@#TSP[X>TWPIHEEH^CV4.G:991+ M!;VL"[4B0# 4#TK1KX\&M;_\&?V_+3P^=;U+4/!WQ!TI[J'3KV[::*RNXC\W ME!B=BGDX'%?8=.!1110 4444

%%%% !1110 4444 %?.WQJ_8;\"?M ^,%4 M:EJOB/PYX3VPL;RX\;B;,[=;C_EE"'K KVXQ7T310!\Y_&/]A#X;>/?#'@_ M2(&UKPK+X3MC9Z5]?AZ_-

M=Q0D89"^#N!Y)R.\GU]'6_V 7A7KGP:T3X9R1: MO;^'M+U#^U!+,WVVZN+@YW/+*5)).XG@#YQ7TE6%XY\;Z+\-_"6]^)O$-\FG M:-ID#7%S)_#":QXCBANCK>BB"+4[

M%L#=*[!@5SZ$&O8/'_\ P44^%/P^\;:GX=GC\0ZRFCS"WU?6=&T!FPTZ3."-MLLH/&#UP#0!L?"3]B+PE\(?&=CXBL_%?C?7'TV-H=-T_6M>DGM+)#QM2,!01

MC@!LBO,/VA?^:"M*9=;\3W.M6,>IQ'PWIS7]Q6CG"3/@@[3[GVK@+3 M]]X?#7XE_'36_&7B[4-,\&>&&L#!HEMHH273UG' 5B07ZC.?3/'2@#0TS]AC

M1/B3\%_A79^-9=;\)^./"VB1:<=1\:D+>YB&P"2$R*&5ESGIZGGFNZN/\'?MA7/\$M/^&"Z9>0Z+IQ]MM-0ANV74(;O))\N%G SYA).3C'M6=\)OVI_AE\6_

M%USX>M(]=\/W4>GOJT$WB'36LX;NT09>.)F)RH',2!QTKB[G_@J9\'[4R3MI MOC%M(;Y%I:.PNAM\CO9-VTB*0L <=>:<'':@#T3P^_QAX3\$>'?&&F3>)O&/B M>;Q38-

1M_J&OZT\U.(\'I7$8(''*0"?FVDUIGD;P3_8/PMTCSI6%K\,,@7.CG M#2NYV"A1YOV_/E'3%>T6EREY:PSQYV2H'7(P<$9%2T >>?!KX&^'O@;8Z ;.M^'1+V2/6)5FUBY-

[,)")I<;@N ,+P,#GZUZ'1!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110

4444 %%%% ''?%;X6Z+\?_!M_P"' M=;,C8IU'SQ/V937?AZT:4FJ]\?N<6*H2K13IRM): MK_@CO!/C?3/'NAQ:EIDP=&XDB/WXF[JPKH*<^6_!W@SQ;\" _)U?54:3PB6-O M/-8-OW

_=ED3]%'MTKZAAE2>>)!8W$D;&5E.00>A%17IPISM3E=%8:M*K&U1 M6DMU^OHQ]%%%VN:_FR-,FU2N!C IY-?0=% 'Q)-^PMXLF_9:\-?#'^W=&&KZ7XD76

M9;L^;Y#Q"82,1\N[=CU&*C_:S_9[URTOOBO\4%O+2?2KCP'+HJ6$2NUSYHYW M8Q@K^.,^WZ1E#J58 @]0: /SI^3?[!+?OJ^-?PT^%&E>,_'.@GX6Z2EKJL5G8

MV,D>IS[/FCAE+#;\IXR/R-=OK/[B'6/"7CVWB\4V&E>(+[Q6GBCP]?6\;R M1VKH"%292![G(X,,UIOJH10% '0"EH ^(O#_ .RG\=_%OQMT+XB?$_QKX3U)

M]_TF[TN*PT:VFB6/S8RH<9'S%C@MG'3BKB?L1>*Q^S7X%^'1US1_[5T#Q$FL M3W7[WR9(UFWE5^7.[']_5]>^*=1FT?PU]M!;/?MK669-XR-RJ2,C*_' 1/

M^"N/QFU'QY9Z')I_A<03:@MHSK82;MIDVD_ZSKBM(PYNI25S[(KQ@W5/MO M\<;;5/$5G:)XXU2WU32;BT1W>REA4,#*& !^8=!VK'TC]E3]H/Q=|3OA?XB^

M)'CKPAJ.E^!IQ7BL])M)HH+A%7;YC,5P9",#' KL;TZ=KJPMIGOODC5SCID@ M&K-9DGPOJO!/C"_\)ZQI:>(-$6>||>))XJ1SYNU;$O'.IGU.UUVSDDN+&5EVR/;LH(.03U!?

QK[7HH ^1 MO!'[$%W\>__',&-1T?6K6YT7P-I]S;7IN@XN;N:8Y:1 5 SG@FO2/V:/@1 MJ_P7UGXE7>J7]E>Q^)]=:,5;9,3:?F*,C&U]P'S?3(KW&B@ HHHH ***** "BBB M@

HHHH *\B ,:F^!;_M#?!]4_"=MJ*Z1J9ECO+&]==R17$;;D+#NN>M>NT4 ? M'"%G^S9^T;\2?BC\,M> ^)^]>"\HG@^9T-IHC3K-<(8RAE)92"[# P" *RKK)C

M;X^^&O#*7B;X1^$O%?A,?"/Q!?2W+ZE?PR_V19PROODB50-K'W/YBOT$HH ^" M/CO^Q#\1_&NN^"]%\+_ |(5%X5\/V]G!8^(;I)X-=TWR2#(RR1\2;L'"G@>W6

MCQ/^PGX_U?1OB9:1:MHTTWB3Q98:W:RSSR F&';O\S"'#G!.!D>]?>]% 'QS M\>OV8+[Q-\0O$?C/6I1)X.?P-)H=S#IB//J E&#OCA PX&W.,Y.*^%#\3_&_

MQ>@^%/PIT_QSHWC73M(UZU^R:7IFB75QJ8AA+!(2>6^'"_DY/J:TC# MFZE)7/U(_;V\I:GXW_93\3VFE0&ZU'3AAU*.!>3)Y#!F_#)"N#!*>&-0 ;.M4\2

7XQ^$=0TMI\/Z3-#>PW,KB5;@IMV;0O9NH!KZH'^'^H7<O> M^O+|_MM-S=V$,D[LK&]F0%B0!CG-;&FZ38Z/ 8+"SM[*$L6,=M$L:DGJ<* .U#5G8D M^9OB_P#L^?

$+|H_]F?4O"WCRZ\/V7Q!CO&N]*OM&,J6T#(Y\)DECE@2IP2.], M/@+X)>.?V?\ ]G'PMX,^&DN@S>)[.>%]2NM:$C03[FW7+@K@ECDX)KZ+HI ? M$VNZS_PN7_@HEX1L=

(.;\MOAYHLKG>6^3%'1_M7?!N\^/GP#\6>"=.NTLM1U&!3:R2G$9E1PZ]W^R2N#]:]&=%\IZQ!+>:A;:O#+)+6->\:.;Y-E\1--)O3KRRN%?=()(R, M/_G*]^U??

BE^R1\6_%.C?M"1+H\.IZCXM31AI\XNVHUO9(//:EOD&.-0AU'54U26V22&V2!5C55(&U !W/-.%E>Y7+HW^AZQJL;QLG>(C(C7YG'!?E!Z5\0>-OC+ MXKO?V;_"?P8M9/

FN:)8ZS:6EC]FBZMY]_J 24B,):8#QMS\SL!G/N;_;,@$ M$$9!KS_2?V>_ACH/BUO%&G?#_P -6/B)G,G]]6^EPI/QAHLQ81Z MG;R,<9V/GKZ>OX4LGBK3D'$K2'T1";NZ.

[,UZ*PCXQL"K\/-,@&0C(1G\;KV MWC /<*LT CD)90V_6BZ"S.EHIJ.LBAE(92,@CO3]8@HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH

*BBB@!H<$XSSZ4DLT<"%!'5%'=C@5S?B[6 MY]'FM_(B.'#%INH&.V/6O._&%UXDU6R@;P_>645_YR&1]411$,6?F"A>AQTK-M-RL:Q!\S2O:YWOB?QX-

(C3[!;B]8DI&;,&G^)^E6/"WCBPUZ!(;NUBU+!; MEHLHW+CV-<=J4$USI8[.P3(? M8BLI3FI*RN=-*E2G"3G*S6WF?23WMG+"=T\#Q/E>7!![JYVUNHO#5\L%O<13

M:1*QQ%Y&<$>3&#Z=NUBIP',O=:|QDACE&'17'N.U%,;^'>:&U$UE,9;9?QVLQ++CV/44\+^-+'QJC0_9[U!E!,0_/<>HKH;M-/5$---,*****8@HHHH ***** " MBBB@ HHHH

\0_;S^-=U\$/ACJ&L-X/U/Q+I$MO++!=7.ERN!LRD!W0\E>>2. ME?SU:)K\&G_$*TUET=K>'4%NBBCYBHDW8^M?T^;A!]MJMC/9WD$=U:3H8Y89 M5#*ZD8((/45\0Z+_

,$H_AUI7[0LOCE!<>$E;[5!X8=,HEQG."W>,=0OX=* MWC*-ETMJ6FCZ0_9P^+|\;_AY9>(Y/"&I^%-.E119C573S;1_>8$7E5]">M M>K5'!!';POPPQK%%&H1$0850!@

#L*DK*33=TB7]] HHHJ1!1110 4444 %% M%% !1110 4444 %%%% !1110 4444 >(G\0?$O5]:DLY+.2ZU![EK1_O1DODI]1TK^ MGLC-?+GC#_@G9*O&?

QZL_B9=Z=Y;H?.NM%B0'UNKC.1*P[>I4<$UM"4;6>A M.;M8Z7]C3XF^,?BE\)*U3Q!X.7PAI26L4.G^==&2NXT50/-*;1L4XXY.:I_ MJ."",UA2&%%BBC4*B(.!0.@

I*DK.34FVE8ENN%%%%2(**** "BBB@ HHHH M ***** "BBB@ HHHH ***** "BBB@ JGJ[WT>EW3:,'!+J C8P)7'C+P>W@W6M+MEL7M!,9HY54DK*CD#:CXEO+EHTB+

#RHT"G>_'3/?FOM/ M]J?]CSP3^U;H5E:^(HWL-5L9%-MJ]H@\^,/.6C.>JD9X/0\UZ5\+?A;X,^#? M@K3O^OA738M,TBQC")'&.7/=V/5F)Y)-=#G'5]^AHY+M>8W

M&OSWDGE70:(:B1^3\]4]#ZFO4*Q=3*66HNTH4PS'G?'W^HZ5$DWL7%gI;GEG M@ZQ\16,>ICQ#IXJ]KJK2WCR69MK;R?)MS]V-P3FA"X8*UY+;GUEA(?Z5W*:18Q_|-

:DQFMJ,Z5>#E+FP8Q,I<#BF_#/5M2E?6-'U*Y_M"32IQ"EZ1S(&1 MN]Q5*4DTI(B5.G*+G2>YZ9W-%%%;G*%%%%:!7RCXJ_;7M_'[8-S\+?%=UX=

M\.>$(M(2_&MZG=&WD,K X3#\ P>6__P 71_PUU\$O^BM>#/\ P>6__P 7 M7XY_\.H/VD?^A/T_ P '=I_\#/_>6_P#\71_PUU\$O^BM>#/_>6_P#\77XY_P##]#]I'_H3]/\

M_!W>?:'^/'4'I2/_0GZ?_X.[3_XY0!^QG_#77P2_Z*UX,_\M!Y:_/Q='_#77P2_Z*UX,_\M!Y:_/Q=?CG_PZ@_:1_P"BM>#/_!Y;_]Q='_UU\$O^BM>#/_!Y;_]Q='_UU\$O^BM>#/_!Y;_

M,_\Q=?CG_PZ@_:1_P"A/T__;=I_\'%/^'4'I2/\ T)^G_P#@[M/_(Y0 M!^QG_#77P2_Z*UX,_P#!Y;__ !=='_#77P2_Z*UX,_P#!Y;__ !=?CG_PZ@_:_M1_Z$_3_ =VG_QRC_AU!^TC_P!"?I__(.[3_XY0!^QG_#77P2_Z*UX,_\M!Y:_/Q=?CG_,.H/VD?^A/T_P#!\'=I_\)_[24B.X &

(O.#^6/H>:_.#_AU M!^TC_P!"?I__(.[3_XY7G=U^PY\7K+XS6OPLFT"U?QG>F#/\ P>6__P 71_PUU\$O^BM>#/\ P>6__P 7 M7XY_\.H?VD?^A/L/_!W>?:'^/'4'I2/_0GZ?_X.

[3_XY0!^QG_#77P2_P"B MM>#/_!Y;_P#0=' _#77P2_P"BM>#/_!Y;_P#0=?CG_P .H/VD?^A/T_\ \'=I M_P#'^/\ AU!^TC_T)^G_/@?M/\ XY0!^QG_UU\$O^BM>#/_!Y;_]Q='_

M UU\$O^BM>#/_!Y;_\Q=?CG_PZ@_:1_P"A/T__;=I_\'%/^'4'I2/\ MT)^G_P#@[M/_(Y0!^QG_#77P2_Z*UX,_P#!Y;__ !=='_#77P2_Z*UX,_P#! MY;__ !=?CG_PZ@_:1_Z$_3_

=VG_QRC_AU!^TC_P!"?I__(.[3_XY0!^Q MG_#77P2_Z*UX,_\ !Y;_ /Q='_#77P2_Z*UX,_\ !Y;_ /Q=?CG_

*MZ\2P@DBU*WG+3/\ =&$8D#W/%=Y!_P $I_VCKF&.6/PA8%'4,1 MNTY!&1_R MTH _9#_AKKX)?!%:\&?^*#RW_ /BZ/^&NQ@E_T5KP9_X/+?\ ^+K\<_! AU!^ MTC_T)^G_ /@[M/\ XY1_PZ@_:,1_Z$_3_ /P=VG_QR@#]C/\ AKKX)?\ 16O! MG_@\M_\ XNC_ (;Z^"7_ $5KP9_X/+?_ .+K\<_^\4'[2/\ T)^G_P#@[M/_ M (Y1_P .H/VD?^A/T_|\'=I_P#'* /V;_X;Z^"7_16O!&_@\M__(NC_AKK MX)?|%;\&?^*#RW_\ BZ_'/_AU!^TC_P!"?I__(.[3_XY1_PZ@_:,1_P"A/T_ _M_,'=I_\ '*/V;_X;Z^"7_16O!&_(/+?_XNC_AKKX)?|%;\&?| @\M_BZ_M'/\ X=0?M(_}"?I__@[M/_CE'_#[#|I'_H3|/_\ '!M:Q/_\ 1_M6O!G_@\M_P#XNC_AKKX)?|%;\&?'_M ..4?\.H/VD? ^A/T_P#\'=I_\?#/|L?QSK_,,,?&L%]X8EN($2TAG%YI=ZB0(N[M,DKDG(+(0|>.MX/\ %%K'9.]I<@BNH(IEE5&*A@ ZD@\,,AK0^$OP M0\=?'+Q"FB^!O#5_XAO20'- M''^ZA! BEE,$C'NQ% '|,FEZK9;WI}O?Z==P7 M]C<()(;FVD62*13T*LI((]Q5NOA_]@G]ACQ]^S0D>I>*?B7?,DRE1/|^DR;] M-5B.LC2 [F!/6,+SW(K[@H ***** ,N[\4;/87#0?&]6D$R@EHY)E##'7(S7B MFK_$:XUSXCM;Z!:&_LY2L(5>!(MZMGMOW%85[!K7@/P_XAN1<:,AI5O<7 (/F ME<,?J\U_&K>E>&-)T.5Y-/T^WLY' #-#&%)'O6$HSD]H(!:>,/G'3UJZ?ASXLU:!IH7M+*3^&*1RS8],C@5[M-7):SK'BU]1FMM'T*T%O&<"]U"ZVK)QU5%!/YXI."6]S.#0:VM[X8 MO!:.II\L]<6++PQH=ZQ\3^"-4TN)B -K&>U7 OP5/(4YKEES M)Z.+S1ZE*E3E'WM7_=:?X;DGP\|'6WQ2%WI,\EQ:V$+&!0G#2-C[RMTQ6S=> M#_%_PNW7N@:@^L:7'\TEG("6"[_D[_5<'VKM_"/C+P8NFP6>B:C8VUK&/DMP MWEE?P;%;=]XNT33H&FN-5M(XP,Y,RG]!6\:<'&|]>Z.5U:E.HXQA{KZ-%'P) MXYL_'6D?;K<>3<1D+/LI-7**|W=K\1110(;S M!%+'H,.'&K?_(*.?L"+KG1=0L/%>BVE0|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|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

GBK2;6YTNX\&;3)HVE65M!;++;OG.]2"6;YCSGZUL?!3X">&_`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|F 5)F15=L*'0OW M<@&O3_%VFV>L^-0Tf4-.EU6PO(FM[BSA.&EC8889W+Q@^HKE?A%X1\)>$;*_M_7PAX4;PQ97THN)E6,1QRR!0FX*(!PHS@#/7FL'6A&HJ3?O/U-E1G*#]):(M\|/2O*KE_P!?EY_Z425ZJ>E>4_LR_P#)*+3_*_+S_TIDE?CD"NW=D;<9SVI'F2-0S.JJ2 "3@'/2OS)BO/%2:E;_%'+#K0/<^:/H7'@;XU[M1-/L[4V2SVT!O%#.]N$/$&K:=_MJOAG5_$4LNGV<\L_$4]I<^7N.,!<2HCJ&7<1D$"@#[Y\Q!{$W#>1D+GDCZ4Z MOC'X'_&S2+'QW;ZIXFGUK5;]_M;#0@)U-+5GM;:R+-%!/.Q(*- >3I)(O!^7R M\XKKOVC?$GC#PU\?O -YHFN6]KI5KX?UN_FTV>U>19WAB1OF(D4ZJEOIANM>\!:GXFNT,+;1;B5_>DC M:,X4\4 ?;%%?%VD_M0?%7XG^$? $WC#PH/"VAZ;X-T2TU+4--U2UFGDU2=[1; MJ:-)%D7[/&$;:C;7);KQ7'H'|/_Q@^(GQN^(WB/4C-H6E_#W2+B.UCTXV4C:C M.TMI#.1,WF;%"&4#[AW<].*/I&BBB@ HHHH ***** "BBB@ HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M *^8_P!N-]\(L?#GAC41XDU'PYXS@O730FTO1WU:6YD>,K)$UJN'Z%"HZAH6D26&D1WQ@^,1=.M(7?=(=\K$R2L3WQ@=*^YY9 M4@C>21UCC0%F9C@ #J2:^2?'K^NZIXNGBU+]H;PM\5(;,1H^C:=9V\R'/^ ML+0RNV!Z8Q7OFI:=;.O87%E>P)=_#'?IHOP1\6? M$7BW2O#&J#4U\,1=_?18-MN(0)1P? FVX.2.*YCPK^V'X*\6>+=-TB&P\06. MGZM=26.E>(;f3C%IFH3H2&CBESR>#@D `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}$TOO:_]M.B'B/4-0_Y!FB7#(>! M/? GI,GUVG+G_ +Y%,_%&G_#C5KZ_\!6%S!&G[NRN+UKN M620\+B**(@D$Y^]CBJEP]/,U]4Q4[JH]K7-&,^FR:?WMGH8*5:AB;(/% A_ M=0>[\'7UI+LF%MI MY[],G*L9I%. <9QP!.MBOHBV^$WAM9EGO[277:D'G:Q.]V<~RN2H_ "NN/#V#X9OEE.HW&#>.N=I V-MTM?)LTSN4ZN/J2QE3ZGHO=79:=;?\."=[?39{CQ%=KP8-$MWN\'W= M!L7_ ($PIO\ ,WC76?\ CP\.6FB1'I-K5V'DQ_URAW?]XKKLC>VAM(5A@B2&) M!A8XU"]![5+6GM:,/X=._\ B=_IOKN>%[2E'X(?>[_)67WW/ OCO\'OB5 M\2_!,FBZ9XSM4>[<"[A># [-,^5UVC;'=LGU:NI_9P^&VM_"KX<6WA_Q =,FO M[=V NM-#?OD_A+EE!+#IGFM_XP_%33?@SX"U+Q5]MK?7=G9H69+"TDN&!P2" MP1253(+8P,\U@?LZ?M!:- ^T;X"@\3:-8W]E"0JR"ZM98XB^,D12.JB51TW* M,9KKJ9KB*F#^HM14+\VD4G?Y6.F>8UIX7ZHTN2]!}$D[_ "/5****\<\P*3&:.M6B@ HHHH *****."BBB@ HHHH *****."BBB@ HHHH ***** M* "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M**** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "B MBB@#+\4:1<:_X%+ZW4-) 6&-Z@\9&.^>O@M^R+XI^"9L; M/2OC)K%SH,5RUS=:.9+HEBOVYF.7,LP7S&+$\L3FOIFB@#YNF_8R@EU:,3U\= MZQ'\.I}7_MN3P;+>'RC<;MY47&/,$1<;BGKWIWB3[C>+6-9U^WL/">L:+X%| M0WR:CJ_A.VMX6BN)@06"3$;XD?:-RCK{5]\'T4 >_<.&O4[WP1\(-5N= 9K2ZL M=94MC%C,8& ,9]!?RT[X~R]!X]^{6]ZJ[.E:3=QW=NXDNI4O,!5D9LLZ[6)}>* M^TO%,>]2:'%]O'X UYA^RY:SKX%U&;4+2RM]4_ MMB]6;!$2T:GS.B.RABOU ^E?-X[*]^+QE/PKN8VO%7UW\[?@SR:^\]5L;1 MQ7MY*$$TX+12OW:;?KUT5FC1;PWXEU YUC3[O6,]8I-;6"_ +]Q1J,?7-;> MDPZKH,6S3O!.FV2GKY&H(A/U(BR?QKN:*]&.]Y'S*I*_>T;_ \MSVX+"TWS M1P\,]!S;^]RNB>'-&FU'Q!=V5EIT'S//?.B1@]AEN,GL.]6? M0=0FA -9XAT_P"US1QMR4C`VD@$@GJ*14B`$OB&]6/+U&/(G" 1PZB@10 M.@59&=0/^ UT/PR^/WA#XEZ&-4\(U<9KLJURG MO+\'##XB2JRC>\I+FOK?:7,E\C?'9P\1B)U<+3C2B^B4;[=['#P_"T>6J7/B-M;Q!<(./*BNUMH_IMA5,5*GP?!)E@UQI9OW'\5_<2W!/_ 'VQKLZ*^B6+KQ5H MS;7EHON5CQWB]{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

MQ,U7Q;#IGB;1_#.D_$#4KR6XT#15O+F&:.&,1W<-LZ,)4!# LBDC.17Z7TG> M@#\W_#WPIU7Q1KNC^(1H/C+6M+U7X@6E]/=^)!)BM6NTBMW4W9M(XE,*;MHW M2 $D U0/[0WP]\0)XR^,NJZ;X4U2\L/[1\-;DHTI3WD-TD#JT[1*H_>,H'(7 M)KI[W'4T>E &7X6UB+Q!XE:M%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8HQ2T4)BC%+10 F*,4M% "8I;** $Q1@4M% "8] MAI/A_3="\>^;3]*&S-[<-=W/DKM\V9@ SM_M8*,GOBM"B@!,4M%% &9XC\-;3 MXOT2[T?6]-M=6T[!0QSV=Y$)8I5]&4\&]G@OP'X> ^6C#2?#.C6>AZ<\';4V]-ME$(U9SU8XZL?4\5O44 9/BGPEHOC?0IG1M?TNTUC2KD 36E[$)(WP$[72K;1_#FG;;!I GRAPHIC 33 ibio-20240630x10k023.jpg GRAPHIC begin 644 ibio-20240630x10k023.jpg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`!KWO\/W/_P!_#!_\ [^O^?7_DW_ #_B%%/_*#G_P"'"U\ ++#]__MD'_/:/_OL4?:(/^>T?_?8K\ ?I7O?^?N?_ +^&C^U!W_G[ MG_[^&C^U!W_G[G_P"_ MAH_MV7_/K_R,_@!_Q"BG_P!!S_\ !:_^6'[_ /VR#_GM'_WV*/MD',/:/_OL M5^ `!KWO\/W/_P!_#!_\ [^O^?7_DW_ #_B%%/_*#G_P"'"U\ ++#]__MD'_/:/_OL4?:(/^>T?_?8K\ ?I7O?^?N?_ +^&C^U!W_G[MG_[^&C^U!W_G[G_P"_ MAH_MV7_/K_R,_@!_Q"BG_P!!S_\ !:_^6'[_ /VR#_GM'_WV*/MD',/:/_OL5^ /]K7O_/W-_P!_3_C0=6O1_P O<_\W\-']NR_Y!?^3?\ #_B M%%/_*#G_P"'"U\ ++#]__MD'_/:/_OL4?:(/^>T?_?8K\ ?I7O?^?N?_ +^&C^U!W_G[MG_[^&C^U!W_G[G_P"_ MAH_MV7_/K_R,_@!_Q"BG_P!!S_\ !:_^6O_E4^___-L@_P"'>T?\ WV*/MD'_#VC_P"^ MQ7X?VO>_P#/W/\ ]_#1_:]['_P_<_\W\-']NR_Y!?^3?\ #_B%%/_*#G_M_P'"'U\ ++#]__MD'_/:/_OL4?:(/^>T?_?8K\ /I7O?^?N?_ +^&C^U!W_G[MG_[^&C^U!W_G[G_P"_ MAH_MV7_/K_R,_@!_P 0HI_!8S_\%_ /:_P#EA^___-L@_P"'>T?\ WV*/MD'_#VC_P"^ MQ7X?VO>_P#/W/\ ]_#1_:]['_P_<_\W\-']NR_Y!?^3?\ #_B%%/_*#G_M_P'"'U\ ++#]__MD'_/:/_OL4?:(/^>T?_?8K\ /I7O?^?N?_ +^&C^U!W_G[MG_[^&C^U!W_G[G_P"_ MAH_MV7_/K_R,_@!_P 0FP___$,)?^^"E_P#+3]^/MD'_#VC M_P"^Q1!L@_Y[1_\ ?8K\!_\ A(]1_P"?E]/^$CU'_GY:C^WI_P#/I?\ @7_V MH?\ $)L/_P!#"7_@I?\ RT_?C[9!_P]H_\ OL4?:(/^>T?_ V*_ ?_ (2/ M4?\ GY:C_A(]1_Y^6H_MZ?\ SZ7_(%_]!'_ !":#_\ A(]1_P"?E]/^$CU'_GY:C^WI_P#/I?\ @7_V MH?\ $)L/_P!#"7_@I?\ MRT_?C[9!_P]H_\ OL4?:(/^>T?_ V*_ ?_ (2/4?\ GY:C_A(]1_Y^6H_MZ?\ SZ7_(%_]!'_ !":#_\ 0PE_X*7_ ,M/WX^V0?\ /:/_ +[%'VR#_GM'_M_P!]BOP_P"$CU'_)^6H'B+43_R\M1_;T_^?2_\"\ M0_XA/A_^AA+_P %_M+_Y:?OQ]L@_Y[1_]]BC[9!_SVC_[[%?@/_PD>H__+4?\)\']/_/RU'!O3_Y]+_P+_P"U# B$V'_Z&$Q_ 4O_EI^_'VR# GM' WV*/MD'_/:/_OL5^___"1Z_C\M4EMX@OY;B)&N6*LP!%#SZ;U]DO_+_ .U*CX2X>345F#U_MZ=+_ .6G[\PQ0000>A%%>=_LZDGX#_#\DDG^P[3D_\7):*^KISH\"ZN?:MS(C_[^5Q_Z;:OC>)OAI>K_0 I+P/_(^8?X8?G(_76P_X\;_ %Q_P#H(IRO M2]UA_P>-M_UQC_]!%61P*^E1^(3^)CQTI:R/#WB[0_%BWIT36;#6!8W#6ET M;"Y2;R)E^]&^TG:P!#S6O5F-[[#ATIXZ5GZUKFG>&M(N]5U:^M]-TRSB,UQ> M7<@CBA0#EF8\ "CP_P"(=,\5Z+9:OHVH6V]Z7>1";:WO+24213(>C*PX(ID-J M]C1'6GCK3!UIXZT$L=2KUH",V,(QSTP#S0O6[,QR]:>M($?GY&Z?W33XT9\[-M59O]T9ID-H*5>E(00<$$'T(IVUE'*L/]*$2QPZ4M(.E+5$#Z=3:> 6S@$XZX M&:" '6GCK3""I ((/H1BI%5FY"DCU]D0.7K2TB@[L8.?3'-.*LO52OU&*9# M%6G+35!/09IRT$L=3ATIM.'2](8X=*4=:0=*4=:"&/6GCK3!UIXZTR&.I5Z MTE*O6]+WVAW.G1_&#PG:/-H&FZ MU#HFJ>9$EE(SQS+E<;R6Y'3@4WQY\0/ MAE\0=*U8WWC+X=1>)M6A$-[XBB\.ZJ9W('F)&11CD.!EA^5=4UAZB]ZS=OY MDN___#PL-+-L)-*@YQBY7?[]@/48Y/S+|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f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{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`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a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

*M9/O$7AWP_P""[H66F>&/#]Y|E-M//<8.{D9)P3\P&0*L?M7>"-=_9Z_9+TC2;#XG^(O%^SQ5:)|J5Y=A9H8O.QY-M-DC;+*

*="&8|\ATHY274;3L>Y>)/VX]*T3XL:GX&TWX>>+O$5QI.F+J>I7>G6-MZD6BM&'"O'|[N-3QR<:)X8.K0/"?LIDEDA3*R$.=4|*Z9XU:Z;5_$4=RWVJ95FVB%9F.>*

<|.^G;JL9JHUN-M?K/L\,I7ZC%+C/&,U\W? ?]D&V_9]^(L]_H/Q3\7ZEL;MIB?PMK=Y'Y?V7-7^#<_AGXM>_M+:-5M]=URV2]TS4=79H[IN";B-*

*4(^4QV@Y'/6NGUGX0:G^T9^V[\;O#&I>/0% M.@^&M*L4NA8:-]3Q)+)M&P%222H4'G`-.OESL^X?V&_OWHOI.7@1/%6OZ?|&-WTBVL#\)7'A>ZUJ+3=>P)'(-&1VKS7P=|*

M#K_XY?LJ^.,?CSXA^,OB>#QG<1W;_)C0+CQ#+/V3 M_P!G?XU:%j%|%9^&;D6NMV,,/B":RED(+/&#M;&3R1Z5]"?LH^*]3_:[_;9\ M,?&%-1U ?#*

*[1471O#MEYTD<$S8!>8QY)^QHZYIDGW+1110 4444 ?(D5S *IR>(=*BP7U*S0&'!0-UP@S'_`^OW??I7^^.[_0OBAH;.MZ'HWB31KG44NDE6U>X66.5X7#M%(]DG:>,|*

*<<'!KS;5?V?[BZTS6DFO_G8-MVLYCN+F]MK(B33&C";H8-Q*I'A"WS9Z\KB@#Z,@U"UNEA:&XBE69=|91PP=?*

*M5<=1R.14!]:U;NGQ%FL|VDW>FP265O".#5?]RO)N@R?<*H'(\"I M1C'O6EWFG^%%XM\'/7FNKYP*-ZBBB@#@OC'K/B-MO0]*

*TN;P?;1W>J/JENDD$LD)D62#YC(H(^X6"[0_121GBO)M"^/'Q-O[2SME\-M%E=0N$B_Y"5G<0M#O*GS!0B[=GS,FU3N#!DG@U!+5XQ\4?$7Q.TSQW"-X3T6*

M:]\/VMBUO(I$;+/=2@E)=F0[+$50'##_`%C=<4 8?C+]H#QAX7CTB:,P=%96 MMWI@NYI+D3RB"4D#++^6GRH">0?G)(& 2,YT/[1/Q"GE=)/ -5C;K#$3?SQW1

M10S8^U"4WF%N@4?O%)&X8SBIXOUGXUR&6$P74D.2P'S-/TA61420B20(9"9-M*P4'RB>_!YJ]??:3XU/8SJ/#++V^ZW7?+!$;226ZE5VSQKYW|V1B6!@X,>,DM-MCD 1+|\??

*BE9>{0U"XT2671P#;06AL9A%!F20M=2%8_,D555?E4 !>Q8YKZ)-M*ZE!))%B614R1SM$BJX'LP'|]:\|^_BSO?XFMM6M?$\, M*C1VAL!<*!$ES.(P|K-\Q&5WK&P"\;/5ZO0*

44=,T +249!: $1:2B@ I: M2B@!:2BB@ HHI: $1:2EH 2BBEH 2BBB@ HI:2@!:\B_;P_Y(!XQ_P"O,_S% M>N5Y'^UC_P D \8?!]>9_F*Y,7_N!3T?Y'T'#W_(XP?\ UA_Z4CNOAS_*

,D _M\-?!@RV_]+Y\+71USGPY_)Y_X;_P"P9;?^BEKHZWI_!'T/+O^\U?\3_-A1116 MAQA1110 5QWQB_Y)9XJ_!'T__H!KL:XJXQ?[O\I5?!@Z?_T UC6_AR|&>EO

*M^_4/\E5YK^S;`_,D)\$?]@U/ZUZ548;^!3]%^-M1T9W_P C3%?!?)_^E,****Z3Q0HHHH *****"BBB@ HHHH *****"BBB@ HH MHH *****"BBB@ HHHH *****"BBB@ HHHH*

X;XZ_P#)%/'W_8 OO_1#UW-<-M-\=?^2>/O\`L 7W_HAZPK_PI^C_`"/4RK_D88?_!Q_]*12_9Q_Y(\/?\ ML!6?_HI:*/V'I7XA^-O^-1|U[_L)?'_ *,:OD>)OAI>K_0*

MH7P/_CYA_AA^-M_UQC_/015E>E?2K8-M_$)_QXZ5\=:W_P3TCUZW^.<,OC1H5^(]l;WL#)89>@8[@S|?&{l]YECMXQOS MUK[%'2EK5-K8Y:E:,_B.?^&_@R+X=?#_,-

-^%H+E[V+1=.@Tl;F10K2B- NX M@=,XSBNE'2F#I3QTI#M960HIZUXS^UMX>O/&?P@O?#-OX$UKQ_:,O.D%W8:#J M<=%A<0QJ?:,\P23

*KC>,:=F9SCS*Q\,>,]*\9^.M#^'FDZ ME^S+X)6U\"SV!QH\@\6Z:K,T*!$\!TE3N&_XQ7'_ !H^"FL?&WQO<>+KS|F3 MXA^&M?O$\N_NO#GC+3K7[@K3F.1T+[ML_/_*

*%+X<;O>_]*T^?5K^R?XSTCPK;W<=^?L'BW3EN9IT8-YUDC(M) SQT-M P!7?>*?^$X^(?CWX?>)-8_9H\;VU!X.<#3WA\5Q&>@IZJ/04^8GV2'2Y\O>%O|*

*@GA\+/#?Q*M?&:3>(]QK:_,JV^A:AJAFL(+M-MCN,@0KN8Y]6.>^:|2|"_L)\5/B[\9=:.^(%GXI(?;-<,NC:KI-\ML;RV_PV^%OC?2O%$>]>*_$E[HYSI=OKNKF:WL?*

M3RT55SCT)(!J^FQTI.+L,2/8^=/C5^P:\-_C9XV?QA<7&O>%/$\ZU",ZU+PS? M_97NE Q^\!5@3CC(P2.N:G_X8. ^%L?P@M?AQ!%K-OH<6I1ZM).FH%K]XN5.0

*M[NRD8/<*H%?0].HNR.2/8\<@_92\%6_C7QIXH675OI2\6Z6ND:@##=+Y:P!54 M&,;/E;"CDD_2L'5_Y%/A7K_P5T%8ZA9:C(_$K0&V34O$6IFX>* M(|555"K^8/MBO5/BU*

*(_"WQO|#:AX1\8:-NIZ+>@;X]Q1XV'W71ARK |#78+ MU1:|[>%OV>O"WA/XL^,?B)92:BVO^*H%M[!9BTPEST 5>GEIM4]=R:]+6G+3NR. M5(^=7_8/^&S_MQ_*

*!GUW^P[W6_[?E87]>?]HW]\!O+QLSVQ^-=*_|)7@B7-MQ_KGC%I=6_M;6=$&@7*;:E\!HE2P39E5V9#X[Y/TKV>G#I3(<4?&$'_!)KX+6T M5G;0ZCXQCTN-Q)=:9_;/^CWS*

Y!E79^'RXKV;XP_L>?#+XU^!=#\!+:OH\FF6 MF@JJ:1=Z/+]GN; 8 C?!X]0P///6O:QTI1UIW(:1X7^S[^Q?\.?V=+G5;_0 MX=1US7=4C,-

WK/B&Y^UW4D9ZQYVA0HX'/_#+]C:\^$WP MM\:,cCQ>[C72[6"Z9)FA1WRTTC',+[^O8/V8/@M9_#X)>&/!EJBB:RME.[MD YDN&&9&/XG]*!3(S2KUJB6.HHHH$%%%%

'(?%__DEGB[L%7[/_+:N;_9 M>_Y(%X(_[!L?\]Z3XO_)+//%W_8*N?_$6UIU1FUO3K>6>*6_M8!(&E1YE!C!. 6&> ?>KIK-MPSQ?^RY8^/?$NN:KJ^KR1K>7 GMH;2!%V?*

*@(E;&Z4';]TG SQ7>?(G.:Y^S MKX;FLTM+#QE'9ZZD-YX=9& 6(-R 1@$-A%.>:O[_9MT?5K:ROK/XB M07=H\DH=HT,?GS&(*S-^!!9_E.0VVGG5YY#Y]!@OR2_*V(CDC*

91@@UU.N_"FWM=?\$^)SX\LK1_ M"5!6JCN'^S(_GI'DS]A_Y:O&>GO^UVNNJON/;= \?:-XHMXYM+U&"\212RA M&PQ4,5)VGG&01G%;%>?>*

*/@)HOP^\?'7;+4[N9S:FU:&6,,!\MG4#*U(4D4 <9\0?BU:>$H+&PMQ].J*, MNA;$<7:#XW>*3>@^?:=F-N;3"J#ZG=G|:X/4]0VK=7M[(CR. M=SN=8W:*

[/EE"'G$@*#N#D$<\B!8/\>/VH:"=N\FO_!2_L>"?_EDFMRLP M4_[-G;VZ_@'-`:>`'?VAKG]]fQ3XN\))^$?#QNO#6AW%OXN1"NS%KY,HVO

M"'LPI(M;U#7M>AU>VO[&PMX($,K-;- GU$W.Q####Y@ 6.2W->]M51TC5DU6V#A?+D'WXR58K"T>X-.)"H>5PO(12HY/#7@&N5O/VB/"-M.GPPSS+]ZG6T[/Y%P=,D$.O#

*[[!]]HC]-LL@C/Y-BN)\,_'3P;XJG>&SUI8)1??V=&EX M# 9Y\,0]9/.0K>AXY R,]U(BS#$BK(/1P&_G2!]QI6VH6M9,V|S#./6.0_-(MU/?*W'AG2+LEIM+LW8_Q>0H/Y@*

U$GA>5@4BTFOK/\ S[?D@__DC]!'7T M5RB6.KVH M#)?FD Z+>V\ M1_M8_P#) /&'_7F?YBNZ'C2.W_M#3-0L/[TA@\Z,?\ HRWZUYK^T_K^FZO M\ /&(LKZWN6%FHKDQ?*

*^[U/1_D?0*O^P=/_P"=@&NQKCOC%_P DL\5?]#@Z?_P!'M-8UOX;_LV_]D)\$?\ 8-3^ MM>E5&&_@4_1?D=&=_P#(TQ7_ %G_P"E,*:[K$C.I:4449+, < #UK,\/>*!$*

M\76LESH>L6&LVT4AB>;3[E)T5QU4E"0"/2ND\4U:\G_&F_BK]WP=^%EQK^ MBP63WSW=O9"ZU,,,2R$K[3<3!2"43]>1VY%5/!7Q#\4>|_#[S_%[5O#3VL]!*

M!:,5XA\/L,EO?B8?N!])+ ^2<|9WE3QR,T >QT5ROBSX!>%? VI6EAKNLP:==_MW5O/=Q1R!CF&%=TLA(!"JH[G%>2^.OVO//I?P\?^+O">IR7MYH\(\N[T>|-M7]XXS$S1F-*

*6,;#D./EQWH ^A**\<@_:E\":9\-O#'BC7-9>U:MQ*MM:1Z;=& MZN9@H,BQ6OEF9@#GD+C'>MK1_P!HSX=:[X"U3QE:^)H!X?TI_+U&>>*6&2R? M(&V:%U$D9R1PRCUZ4*

>DT5XC9_M#_!N]>[5?&<4"P0_:$DN;*YA2[CSMW6Q> M."XY(&(MQ)[*7/VB_#_C,X=W>L^!0&NGZ+/8ZI:V-YJ.KWDW.ZW9%7R7ME5) M$9PP"L1CD'IS0!

[I17EWCS]H+P#\,M971-=UN6;6U@6XGL=)TZYOYH(S_P M-M)4MXW,2GJ-^.CIFNS\%>:M_^(_AJT\0>&=6MM:T>[&8KNU?%>'0VB_#?

*@KPE_:'Q!^(6B79N]6OK.RN[*3Y[>-C!{5-N$(9FE3 MA>/O'[N:EU_]JIP;-\(_'?BSPWJ,EW> ^&;*66;3[S3;[&XAF\LF$2V[1K*$8 M[?FVXQDY !-`N%%?+GP ^/?B?*

QEXC\|:=]NNVFOV6N>'![5[N_L273'CEC MFB58U20V1?$;]&+C_+0E&NGZ+K|NPNKQ+QBDD-G;M(CZ]C,$NB77E^ M4#[^56))&KO!T>XT5Y%XO*

VL/A=X(U#^SM3\2DZH;>\?3[*PN;]Y;"1=Z MRB**-F*;>2V,#O@D54;]L?X(_;-,@B\9V]U'J AV7EK;3S6L)FQY2S$JACA9 MLC"R,IY&0,T >T45Y-*

*X]_;H^&/PVUZ]?T/7/$A36K)$EN-.LK&YO+B.)D#B4I M#&Q\L*02_0="<\537]L#X12ZSIFG0>,K>Z.H-!'#>6UO/+9K), 88Y+E4.4; MOD85V!Y' R* /9:*\T^)'{1G@#X4ZU;Z-*

K^LRC6)X2M?CT[3;"XOJE(,X\UXX M$=D3K\S X.,UP'Q=_;#\(A'!O%GCGP+K|GX&@GTMEMO(,.>Y@&TRI(&D" M^!L:))/(/!(/% 'T517C?*

@;XQ6_BSOQ[5XGB_3/^$6C\/6VJC2[K3)[[M%9 MY0]S-+,% C/E. I (VY(')D\&?M:?"SQ\XFL=*T?Q,7OM1+#3GNK"YM8-0*C M+?9II8UCFX&<(QR.1DP45X[fXJ_;Y^%7@[6-*

*4TK4/$S2:EI4SPZC:V.G7 M5W)8["[S"%-O+C 8?.V%/."<'']NC:S8^(M)L]4TR[AO].O(4N+:ZMW#QS1 ML RNK#@@@@@T 7;*** "N&^.O_)%/'W_ & +*

*[_T0]=S7#?']'7_DBGC[_L 7W_ M_*(>I*_*?H_R/4RK_D88?\ QQ_]*12_9Q_Y(\/?^P%9_\ HI:*/V_[''5Q_Z..OD>)OAI>K_0 H?P/_(^?8?X8?G(_76P_X M\;,_ *XQ_P#H(JRO2JUA_P*

*>-M_UQC_]!%65Z5]*MC\0G\3'CI2T@Z4M68L<.M.E/?2F#I3QTIDL4=:>.M,'6GCK00QU*O6DI5ZU1#'+UIZTO>M/6@ACJ5>E)2*

*MKTHHACQTI:0=*6[('TZFTZ@@4=:>.M,'6GCK5(@>O6EI%QTM,ACEIRTU:.M,ACJ5>M)2KUJB&.HHHH$ M%%%% '(?% | Y)9XN_[!5S_Z+:N;_9>_Y(%X(_[!L?\ *ND^+_|*

R2SQ=_V' MKG_T6UIT445WGR M)SWC[P=;?$#P?J?AZ\E>&UOXQ%\8!.W<*1SZXQ^->63?LJ:7]);V[^(-06R MM(2LMG 8T:/(^]VQACRP7SC(/. *]THKGJ8>E5?-.*

V>S@\XQ^7TW1PU5QC M>]K+>UKZIZV5CYZG_8YT0SZC(!KMW'<7+EDEEMHIC&&5U<$-D.#O8C(RIQBO M/SG'YG",,95< MU':Z7:W1?U\PI:2O+KW]H'2K4LT/A[Q%?

V[W3VMKFJZ7=V4APEQ$\1/IN!&?UKSFZ,:\(6DH_.ON+QO\--+ M\;])9C)9WZKL6[@QNV^C \,/U'8UYPGI.=TEP"-1TX+G_6BS,_'KC=C/XT > M,_#;PO=:.QI\%HD?]V]94 .6

*!R:^U=9U*WT?2KR^N[f*QMK>)!9+F<@1Q*!DLQ/85^9_C?Q^*2&GPVUM M=>^*UEXDUFTUA;YRT\.P?0;61MA:-1GYE95Z !N1FO+QJM9IGUW#Y#+#6)]3E*

M."E'2.J;MS/XE9-77FU;]^@[X9?'?Q##%XVTZ/QA=:3K>OLDFGZE?7{$$$HD M)='9@WDET(56 P149P.,^JO@Q\5/$Q@3X?:7;?$2:Z\3ZS>ZV-/@DT=X]2EM MH9

/++>Y>$D!=V!!Y.,5^8=K[<%AJ+0VT7F12/M9RQ+,;?\K[+_9A\$1_!OXG M>#M>\3>=++TD>);#;IVDV4KRSW@G \OS@J8T!Q@L>6P!T-<6%JR4DO^&U/Q*

*M<[RO"1H3DDDWK91}YN,;636J5E=Z-==-3] :Q=7\3Q6%S]BM(6U#4\!OLT1 M$8/1!'/"+]>3V!JKK&L7-_>R:5I68^IKZ$_%#G;[4M)COV_X2CQ!ICWUO'l]_L^*

*M6Y2.&V3^_P"4QW-_ON/H!?G/CWX37WQ&U;Q#J,D1^'M8AU!%A@U\YN93/:F_M(Q26B[%9?+9@2V20-SY0D BJXT^ *"Y<2O<2P%%D!>-U MW.VTAP03TH*

WKWlGI6KO09H[.lL]+U";3M2L&0QFE$=LEQ82%QQ73>_/"FM^#0$MB/$/CF.X>?2TLK;PTI@2-6CD<[HAL1WVH44L M,E22 , >/_|_"MM#,.UYIWQ3T6PTO5+N=(l[>ZN

*<\B*7V$S\L^0K%_N]A M!!Y/H=_\/K+QOJ^11>$_%.B!(+"WTJZ?[.,N]TN2 2B)[:3?^[8L[98Y.4X) M.< 'LO\ :-I]O-E!JA^VA=QMO,'F >NWKBK%>1?"GX&WOP^UBRU*]UT:I-*

!: M/,.I61CEACY7-?"NI>+;J#Q/#K7A>316-J-4@O-D=U M)'YS1GR2SB,I"78L%VI.H-8>EZ?\%O%R6MI;ZO=ZU!%#/+91337$D-DBHY9 M(B5VQ.B[V"DIQ@'H!73?&?6*

*W@.6UNO$>@?VE+KTLEM\C-8R"0.NC MM&,@&$DZ9KS?3]<\%^$_BC9WQTR\TV*PC.G3VQOQ):0LVZ*267*IU'5-R\D\ M=#6.\)1A)QE+4]_#Y+F&*HQKT.3<6FTI-*

;.SMK=V>AKZ+=_"CPA;V.IZQHMY MI=[>72ZMHIZ.\5EDN3L+1RPLI((EP=Y!#.H8YQCV_P #>,,;QYX>'8M"TA[.NKR\CM(RK70-I'(PCQ(SGY8 MP-NV(D

*X&T5[!H/A_3O^"FII^E6J65DG,ZPH20"QROY()K2-2%1/D:=NOPX MO XG!:O^),FPHHHK0XPHHHH *X!XQ?]DL\5?[@Z?_T UV-<=\8O^26>*0\ L'3_ M*

/H!K&M_#EZ,]+++?]^H?XX_FC&_9M_Y(3X(_[!?2UKTJO-?V;?!\DA/@C_L& MI_6O2JC#?P?HOR.C._^1IBO^OD__2F9OB30:,Q3X?U+1[PR"TO[>2VE,3;7 M".14X/8X->.?*

LI_LC>&/\2_#VM;?X MZT5TGBGGGQO\;V_@?PA]KU3PE?>+?#EQ+,;5H;"V^U-;VS##2M 6E0=U4$X M[5\[_!+P\:?$GP?\5_!_AV+6+?X.7NT>%Y-9M9K9K6X*[G^RK,JR"!)*

I7(& M.$%8HOC-4]9TJ/6](=.EDFABNX7@>2!DBJRRD]W8X/!]4-?'/P+LI[SXK> M#_&OQ^\)ND76KP6^EMX4M|#2T:ZEFMLK<30A>2Z7$?$?BKX% M_%

[PYI=SXC\7^"[#2A#X>U;7-'FM-1D)3Y[0JZ(_E_=$FS)Z9.,U!?>|_!6 ME?#OPEIGAO1(#;Z?IT(@C9BS8'22$K47$VFW PS+/$8)G5'&!N5.",$UA7O@.+Q?\,/

*MC%XBT;#X@^)X=:MK#3TU3Q=$D;ZLD/BAX'34OB5^S\ZZ*US;Z1_"FN7WQ0^ M)\UGHVHW-M85(&&V@%K_PA;W)2=1?!V&PW/(!KKR,TM 'Q%\//*

M6HW/BCX4MJ6@?IAL?&OB:IRQ7_P -FMTFM[=V%O,/M(S@'S/@@;1)EUKZHQ0!B@#XX\2_#GQ-XNU-M#P?I6F6UY8WMU\!+2TQ?6D!T2$]D-DBH9 M.@5VQ.B[V"DIQ@'H!73?&?6

$#XPZ%J/[*&M_M#&U^''B>;QI%H#Z:_@V/P[;YWE^08U%[U97);_P"37W!BC_R:_/ MFK]G[PE9S>R&-A'C*]F@91*J68W(K$<@,6R!T/6O)-/^'^H:5_P3KUS

*M1+3PI>6^K2R33_V?'9.MP\AU(/N\L+N)P V<=:!FOMVC"% 'REX<|7V?L/Q< M^(EYX\TG5XK3Q9<6NHZ7XFL-*N;|)HDM8XOL3^1&|1Q&R.55@ 0^0>M>>QZ7 MJOB3X!?*

M0W=CX'UKPV=>UN2[T_2;K3WANKA&AOWHB SER&8J,D$D'D&ON\C M-&'/C7XZ_#+Q-X]\7?%6PT;1[B]EO/ ^B+!%(K1Q7[07TTTUH)#\NZ2-3&1*

*MGCS!@U;>)OQ.TG]HCP?X;^'W@?POXB3Q4-6TVZD74M N;!/#*VUQ'+)-++* MBQJRHCHJQLQ8M@<&U[?XH Q_^N@#P?\ 9R\(-I7B+XVW=[IF*]HHZ4 +1110*

*5PWQU_Y(IX^_[%]_P"B'KN:X;XZ_P#)%/'W M_8 OO_1#UA7_(4_1_D>IE7__",/_CC_P"E(?LX_)\!/A[_V K/_]%+1 M1^SC_P D$^'O_8"L_P#T4M%++#?P(>B_(USK_*

*)&>*_Z^3_|2F>BGI7XA^-O M^1]U[_L)7'_HYJ_;PI*_$/QM_P C|KW_&$KC_THH(8\=:>.M,!&>HIP89ZB MF0Q]*O6FY'K3E/-40QU%9'BSQ5IW@GPI?ZYJTKPZ=8Q&6:2,-*

*I&51Z*H\)+\9:%9ZSHU|%Z;=QB2&>%LJP\ 7Y]:-R7UI&;P!7K>Q^LU!KVUL:M%%%6+0\ L%7/_HM$XO1?$W_9Y%X(_P"]^_*MND^+_P#R2SQ=_P!@/JY_]%M7-*

*_LO?D"D"\$?\ 8-C_)5P(_?%_A?YH^NA_P D MW4_Z_P ?_2)'J=%%%=Y\B)12TE :0;**/!M5_;LM|.BO)HO"6J7\4%]=V;_M97#N?LZNSL5"_+G8 HR<[N<8KFK?*

*Q#\\/$TEU&HUM]36X:XFTO2Y;Z3[*^U_M/\I8\!8]TDBN5 &6.>,5[=\(?!\4MS(-#@;[1)+*Z.[LFZ0$2%5+;5W;CG: M!G->*_$'Q7\//""Q U3PW:>$--N]8MXX]1622Z,$9O))$4Q$*

*'-DB2-@$-S ME210!,_X2CX,>,M/M@\,U:S;5S:1QVD=K?0/#<=\]K)K$*H5NKU"$:/RE/F9X(!Q@[&Z<9\ZTGQGX4 MTF[\N]1!2$]D_M8!EN%@#[#:]EVR)^[*

,GRG'8[\7\.?#[PU\0+? M4-4\0^%=&76)YRETUA>FZC+J01(KC:4LC0O".C>&'G;2M.@L6GQYK0@O@DC/_?1_ M.MB@!****.(^-GP^N/BG\+O$'A>TO5T^ZU"*

*)%/("4#*P8!L<[25P<>M?GY MXF_9ZTK]GC0H7^(MKKFLWVIN[1OX=G6.ULT4@9DGE3#R,3D1X P.3S7Z=5#> MV-MJ-K);7<$5S;R##Q3('1A[@\&N6MAXU?S=3Z/**

]KY;'U2UIMW3L_E+== M/N]3\NM9_9?U'PIH4WC&[N(=+H3:TD(DNIXI=OE#[,%=TD(DNIXI=OE#[,%OEP&#,%%%6+0\ L%7/_HM8KZ0T3[F;PSJ6F_#/QOINOZK]$MG8V4-G:W=6A>R(2\+.K?-

$]DEF49RJ= M>Y^'M!,.">V-O)#) 0%,3("T'ICI7-2L-2\52D?!>^E1"%!V\Z0 L?\ @*;1 M_P #-9PPE.#ON=>+XFQN*IJ-^5J^JM]FK:Z;^=[=DBQI>G1Z38QVT;-*1EGE M?*

*[TKDY=V!V))_P#U5:I.2NX^1"O/?BA\((_B+K^CZO+KM_[=QHZ[K%+0+L24 MR*SR.#]_*J$\\?*6YYKT+-<-XZ^)T/A>9K"QA6^U0+EU=L1PY\(&[*)8_W1^) M% '*Z-*

^S[;.+=6^H0+QC-E'"]O K.P5Y 2TK?/C<<<#C(4$DGR_P 4 M-=*%PO(> 8Y_V--@!/3/4_GFNJLOV@=O@NCZ+)+CZ%9KW4 MHKO<1:T<;.< MI?*

LZ,R1@R7#HG7(5#NS7UMX=_:@\|+_$#PUJFI^$XK[4KO3PKW=C?V-Q9O 'S MM9LH=RDC&8]WYG1:@D D6-92=H$B%X!J2 M/;J.:Y9_@[\/(;^,SGTR"2]G^<0W-U(IRXY)

(+?-WZ]:\^UCXP7?CY[;3DTE M;1H5>>>:+4$.X!Y2.$V_VA"&8 9&[KMS MD\$YQ75++E?]Y%?]$S19QB\+%4Z5648KM)I=W9)_TST_2?@EX%TZ]TZ:QTX-*

*M:=)=6A*W\KE"K;DWC?\ -M/W0P..U>@UXOX7U+3=$U&;4(KIXKIXY%CMIX2$ MWMTWR@X*Y[X'OBO7=(FO)]-MY-0AC@O&7,L<3;E!]C7/+#QH? K+TL.IC\1C*

M[2Q%1S;IR:<+;.$:)(M\ HRY<%,@GCDUZW61K7BK3_#]Q%#*=%94+]RPLRG';([TF[EQA*,Y8*!/ M9OV;KRW0-I_BF6*0D&>*9KAHKH87Y7 ER%W*6^4CDUB_&?P_,_"*

[[G/O3H]] MK$^L:KJ,,^ ;9@[2S$!1R"QP% ZYQSZUZ?K7Q/AEL9DL;6[C9E8&=R]&,8^ M\HR]S(SL 3G@DG&>N\7FXZM&-"<8ZW3

M_(^_X5R:K4S3#U:WNJ,X.W5^\C[^'/_ "3_ ,-?]@RV_P#12UT=-B@D;IN8#"CW-3*<8+FD[(WH8>MBJBHT(,4GLDKM_)'M55QWQB_Y)9XJ_P"P=/*

*^@&NNBE2:-9(V#HP#*RG((0@UR/QB_Y)9XJ_P"P M=/\ ^@&LZW*7HSKRW_?J'^,/YHQOV;?^2^$^^\ L&I_6O2[\U_9M_Y(3X(_ M[!:J?UKTJHPW\"GZ+\CHSQ_D:8K_KY/*

*J*84F*(-3N?#FJ0Z+<1VNKO;M2+9SS+N2.8J=C$>@.*\)_80\(?'/PCX4U^'XX>(;?7M2EOR^GF.99GCA[Y=0 M!MYV]AZ5TGBGK/Q7^*>C?![P?-XAUM+N>]98[>&TL(#-*

<74[G$<4:9&68], MD#WKA+++]JO0)? NM^(=0\-^)] N=%NH+2_T75]/$%Y$\KJJ$?,8W4J[@$(/#'C#5UT5=6NXXM,NEN!!/">K\T30L?\ EHI&0,_2OEOX MO?$KQH?

@C\4_A[XEDM?%'C#P?/S6NK6N(H]4CDF1H/.4<3+19 5P#COQO0!E M>-_%\WA'PE>@<K>M+@<W-I#,T4D! MD0.8I1ADR,X/N.E?\]PPFO?

*Q!\;:MXDU&_P#BF%M[+5[*X;2T;0,3QXM(M;;=^[3'/FN6NJVMG_:\,TLCV-K,(OM$P5F(RH9FR1QUZ"@-M#[ZSFC-?&GQ&<%'@[X"^%_!GCCX=:E?6?B^YU2QMHKH:K/=-*

*XB2>11+',KR, MLN4+/NQ\NW(P*Y+Q5JGV+]H67X=P^(M3M_@Q>ZY%-K-R@D,5GK##S%TH76_Y M(I&^=EQPWR9YQ0!]I^#/&-QXLFUQ+CPY]^@#3;Y[.-*

*-]5B5!>JO2:\QS&>Q. M#[5KZ[GCZ-HM_?Q65SJ4EK\IRV=FH:,NWLDVI.IX3 MOME"\,DT >GZ9\9K*V53*

MP3I6H:K.B:QXJLY[R"QOH%62T$(0ND^&.UOWB\#/>O0L\5\)^&OACX.\8>. MOV9M5UK36U'4;OPUG6=7UI?I)O_ #9#,GAZ4F:.02YSF,!K?.>K"@#[DHJH6G0Z1IMK90

*B&WB M6)-QR=JC R>_2K= !1110 4444 %%%% !1110 4444 %%%% !7#'?7_DBGC[M_L_7W_HAZ[FN&^.O_)%/'W_8 OO_$0]85_X4_1_D>IE7_(PP_\ CC_Z4BE^*

*MSC_R03P-$ M#2*U__$4M%'!,_)!/A[_-@*$_]12T4L-_AZ:\G7.O^1GB MO^OD_P#TIGHIZ5^(?C;_)'W7O\L)7'-HYJ_;P]*_$/QM_R/NO?!A*X_P#1 MS5\CQ-\-+U?Z'!"^!_]*

'S#_P_.1^NMA_QXVW_%QC_P#015E>E5K#_CQM MO^N,?_H(JRO2OI5L?B$_B8\=*6D'2EJ$%CATIXZ4P=>.E,EBCK3QUI@ZT\=*

*M:"&.I5ZTE*O6](8Y>M/6F+UIZT$,=2KTI*5>E-$,>.E+2#I2U1_^G4VG4$"C MK3QUI@ZT\=:.I$#UZTMO6EID,JV\?HJ^W>N*M4E4E]7I.SZOI*

*MO\WT^\^IRW"T<%0_M;'QYHIVIP?_-"\DNK_N1^UW=HK=VP;?X ?$-K>,W'QT M\3>?M'F>5:P[-W?&3TS4G_#/WCW_ *+IXI_\8/\:IU'2E'6G[2H^?\ X%+_ M#,WQ/F5[WI_^":/_P @>%C[GWQ[_P!%7\4_ PSYX^_Z/+IXI_ 6'Q M=AUIXZT_J5'S_P# I?YD/B?,N\/_ 31_P#D#P?_(9[\??]%7\4_P#@=+0/ MY>_'QGKZI_\!8*[ZI5ZT_J-*

*'S_/ I?YDOBC,^]A_\$T?_D#YK\9_!GOQ MX6\+;GJMQ\9?&6J06L#.JG9Z?#-+,,?=5.^;D_8N^#GBKX9^%M0U#Q#J5W%% MK$GVBWT*8+BU!.=[@#*Y9&[JO*

KZ2HJ(X"E"M&LF]-M6]_5F];BO'8C+:N6U(-MPM4:8>)/'WP]NQ<6=YIL&NP22&28)IZS1.^,%B6&&,,,\\5S7QM\937

M^L_V!!+Y=LJ,R\D3285@^P&,/7Z5Y#J,JV=@#YCD2,WF+'$"&#&/F'H;-/MI,PPWP\'5?I6DM>6=N;>&&6FPCCEAA(P40%>$P2,+QR?6NQT70=-\-Z;'*

*M8:3!MHEE'DI;V<*Q1KDY.%4 1GM+6=KVE MMJUD(T<*Z,) CC='(1_"XJ[:3;2T @UGQ);Z; !$RS74L1D@CYVOZ98# SV] M:98>++.6"*

*(7MQ!8W#R"%8Y90H=5T';L9)[.M>$?M!Q>+(_A!J[\'A*&_FUN6= M$9;(EKA(BW[WR^^<8SM[9/O7Q/\ $OQO>V^F>$-'U3Q`,:.IZ,TMQ)(\K2"V MF:166'S#R[1A,,P))(!XKR9XR497MH?4Y3D3S2*E&HEJTUNTDKW:Z*]EJ?K M5N&<9YZXI:,/'P;\0]#\3_'*P^)EY\1U\)K]HC>_T75//;BKLVM#$Z@QO"2. M"=I4'D9&:^W/A9XQUGQQX?*
GU'6O#Q\//]DCMD%VERES;C!CG1UX*L#_)%= MU*NJM[?U_D<>8Y34RJ1*;==MU=LUW,#U#2'=C\ 5?*L^,G^VI9,.N/M!O-+CFL) MHS]HLI0LH4\N' A(M85.41 "1ZUN,"*FW]Q^===M\/O#5WJFIQ6 MR1D3W1$2*<@]F?F<C*3?^OO!]*^^#?AOX0*>"8O#^A^&M,TWP]/$'DTZ.V5 MH#MP!)e#=P=X)T'5[;PEX1L-$6]OU%T=)0\)%)(JCK]-M.H.'8<(,=-MQ4Q,)SYUMY_Y'DU:%2>G]?><;X;MXF\/"[U>68WL;(GV.$*IE)!/S-SMX'.! M7O.@:DFKZ-9WDB@=]\NO44M#LP]-TT2=Z***XSK*VI7OM]G:=3&S[!WP.E>'Z_X@^UW,NI:A+%$SXXW':@QP%SD_P"->]_$*WN) M/#MQ+#>26\<0W2Q*!B9>ZD)1^%?//CR0A[.+& -S9 P/_P!=<>);5HGVF04(
M2C*IUV!#1NO$>E:E:3PB^DLP0?W&0BIZ$COT7-2%4L/A;K;I*[^QYP!@R,8A4 MYL%2",CN#1\4]N-/^$5NIOL'&'MVLP2H.#&>,<>G\]\;$W=&;\G^1*FY-RT\? M0C?>C!3I*,MFC\]2JUYX7'SK4{O'W_1=/%/\ X"P4?\,]>/O^BZ><*)_ 6"0?***Y_]-'S_ M / 1?YGL;ZT9GWI_^":,/_P @>!_\,]>/O^BZ>*?_ %@KR_]H3X.>.M)\$#3 M3\0?
%_CFXUB9;*#2A\+0,YZ&5_X%'K7V91657+]-2#@FU?^\) _]=V!XQS#" M8FGB)QA)1=[>SIO;;50NM>UGYH\W_9]^'>M_"_X7Z3H&OZW+K>H0)EF&_@4_1?D9YW_,C3%?
]+7R?_*4PHHHKI/%.?\=^ M-/#OQ-\-W.@>*-(M=;TBXP9+6Z3 MZA/;K937#(5;:!6#+&^TC> 0"-V<8XK;T'P5H?A>_P!3O=*TR"QNM3=)+R6$ M$&=D4(I;Z*
*U;6[@&.XMHH[B"0;DEB8,K#U:!'%222+%&SNP1%!+,QP / M4!'9?4?PCH_@K2O[-T/3%=2,L;?>;R(IA=[MN9QJ22:ALO'@:;?
Y\^7CZ5L6US#>0)/;RI/"XW+)&P96']". #275W!8VTEQ M *,/,?!?[+?PJ^'GB<>(?#W@K3M,U=-WDW"[W%MN^ M]Y*.Q6'/_3,+70+\&?!*>"KWPB/#5@?
#E[*T]QIYCRDLC/O9VR+S(IF0XR[ALY;@<]>*PO!7[,?PO^'KZA)H7@ MZQM9[^V.SN+B9I+B9H&!#1"25F94()^52!?IZL& (((/(I:.8L/AGX7TN; MP_+::):P2>'[=[?2V13_
*)$X4,B<(A5_*N6TGX47S_.IZUKXAZU=8$M%I&@K8M,EYFIE7_(PP_P#CC_Z4BE^SC_R03X>_]@*S_P#12T4?LX_\D$^'O_8"L_\ T4M#M%+#?P(>B_ M(USK_D9XK_KY/_TIGHIZ5^(?C;_D?=>_[*5Q_P"CFK]O#TK\ M0_&W_(^Z]_V$KC_T_ME,EBCK3QU[@ZT]=:"&.I5ZTE*O6](8Y>M/6F+UIZT$,=2KTI*5>E-$,>.E+2
M#I2U1^G4VG4$"CK3QU[@ZT\=:,I$#UZTM(O6EID,,]:@DA^'FC3'^P=+F7 U"0'!NI%[J/X17)7]N%]=/6;V_S?DO^ >]ME67T\3SXO&-
QP]:W.UNVIH1_O2_!7D1$:_P0\'':OXW\3M\5O'5L86M$*Z9:GI[HQ_ST8.E,4**HPY5]^KION<.9YC4S.0(6:48I6C%
M;1BMHKR7WMW;U;'#I2CK2#I2CK6YX[CK3QU[@ZT\=:9#'4J]:2E7K5$,=11 M10(**** .0^+_P#R2SQ=_P!@JY_]%M7-_LO?\D"\$?\ 8-C_)5TGQ?_.26
M>+O^P5<_^BVKF_V?O^2!>"/^P;'_"K@?^^+_"_S1]=#_DFZG_7^/_!$CU.B MBBN\^1"DHHH 6D[44M 'R[\5(9M+\7Z^[9#"1KA01GWL>V;'^:]5^$VIZ?>/'/8
M:A9)P@MS*N/9E!!H XO1T:35+0*=I$@,<.1 .M?4_P"S3XST'O?X'N7T36;3 M5#;WTT5Q%;R9DMG#$;)s.&O\9PP&0&('!D5U MJE9[2"Z#IV5XZ/NC-+7PQ\-?
AM\9_VC)_#/Q'NOC)%8^');B&I&D;,%=11 MAHF >%[<2{JMN1@P9I #G&1BON51\H!.X]"; /BK]L'XB^#=/^,W@Y+KQ#K= MJ[6A2)-=VVBQH=N65U&IG7$A48. ?E;*^-
/BY>Z"/%VHS^& M5WTI]P\UE) MJ, 29%8[B&4$C()P#WQG K[^^,.O[$^D?$#XDWOCO[;=4^,^IZOI$?@*+X6:WI&Q_M!6X>QG1L@Q-O9OW M@X8/&2",Y XKPL12]3DI-
WI_6Q^O9?4^06:C]V^4KV23;OMH)V;\5)G NB?7$66GQ#M=2N?$'B-/#%GHU@=0EN&M#.\]!PF%0,N6RP`]217Z2?LN>+]_M\6)=1$U\]-
Q7T.G:4#I>S4MOG[HL#+;,21R"&XZ9QVKP;X$_LW:+8>//&7A/Q) MX4U[4(8]. ^QR^(+M_(L;CQPASC.*^E?#W@?1?@C\,I-'\+ M6K01*S>2)1#))+<2L &9CR3N(_
5TX2C*GIS7KW/G^)LTH8U.E&3,3BXIFQ#\[#ZR9'T05K55TS3X]*TZVLH^4@ MC$8/IXCJ?Q.3^-6;10_/0HHHH *YIQ;X%TSQC$OVH/!=(I6.[MSMD4>AL;/8
M_ABNAKB_BE\7-_^#VD6>I>(3=BVNIS;Q_9(/-;<$9SD9&!A3S0!R?_"@Y%FR MNJV@7/$ALCOQ_P!)8S7?>$O NF^#T=K8/<7<@VR7<^'Y'[T_<'/8?CFMZUN$
MO+:,&XCSYWWCY3,.1Z,3TR/K7>>,?BA:_M1SI.:0T>ILF?,96 {A4YZ%@/F/L/SKS677=5EEN9#?-_])/F0R+0L#+P!...P!"MTQZ MC%:9?B:D).R>Q|_DF!Q-YFZC@[Z?
U]OEG0;#2[J.5[AG9/F$,A'SD=.U)Y;^5=/>W44EKSQ\2D?9_P . M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^'XW_>:O\ MB?YL****T,****
"N.^,7_)+/%7_8.G_P#0#78UQWQB_P"26>*O^P=/_P"@ M&L:W\.7HSTLM_P!^H?XX_FC&_9M_Y(3X(_[!J?UKT]O-?V;?^2$^"/\ L&I_ M6O2]C#?P*?HOR.C._P#D:8K_
^3_P#2F9?B?6QX:\..]QOM9K67 <_9K< M9DEV<6VJ/4XQ72AGI&WI6Q_;T\+;_]I>#KWPDVE7YL]ES-YR3#&OOVQ?I'1EQ MP>]?0!1P6\5LA2-(E)+$(H
R>IXKI/%/GI[NY(9/V>=12XTI6@;4+26: M!VN5\])O!7P@Q_@WX8L_#.IP:S]N^SVO]-MJLT#+4@M8)7!V$$^8V',X&:_^]/C3\+_^%N^"O^$?_M^^R_\3+;[^T>3YO\-MJI
^W;D=<8SGBNF\2:%_PD'A;5M&$WV?[=9RVGG;=VS>A3=C/,,YQ0!\K_"C MXB>./$'A+P!\-_AP^D:1>V?AJVU+5]?UNU>[CM8WRL4<5NCQ^8[8))+@ >M: M,WQ
^+N]WOQ4^'GB67PQ;7^D>&?MMEKEC85=}ZN&9N&E!0!HLF?,96{A4YZ%@/F/L/SKS677=5EEN9#?-_])/F0R+0L#+P!BS1]*31KNXQ\-^TV.]VZG*B:.R>Q|_DF!Q-YFZC@[Z?
U]OEG0;#2[J.5[AG9/F$,A'SD=.U)Y;^5=/>W44EKSQ\2D?9_P . M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^'XW_>:O\ MB?YL****T,****
"N.^,7_)+/%7_8.G_P#0#78UQWQB_P"26>*O^P=/_P"@ M&L:W\.7HSTLM_P!^H?XX_FC&_9M_Y(3X(_[!J?UKT]O-?V;?^2$^"/\ L&I_ M6O2]C#?P*?HOR.C._P#D:8K_
^3_P#2F9?B?6QX:\..]QOM9K67 <_9K< M9DEV<6VJ/4XQ72AGI&WI6Q_;T\+;_]I>#KWPDVE7YL]ES-YR3#&OOVQ?I'1EQ MP>]?0!1P6\5LA2-(E)+$(H
R>IXKI/%/GI[NY(9/V>=12XTI6@;4+26: M!VN5\])O!7P@Q_@WX8L_#.IP:S]N^SVO]-MJLT#+4@M8)7!V$$^8V',X&:_^]/C3\+_^%N^"O^$?_M^^R_\3+;[^T>3YO\-MJI
^W;D=<8SGBNF\2:%_PD'A;5M&$WV?[=9RVGG;=VS>A3=C/,,YQ0!\K_"C MXB>./$'A+P!\-_AP^D:1>V?AJVU+5]?UNU>[CM8WRL4<5NCQ^8[8))+@ >M: M,WQ
^+N]WOQ4^'GB67PQ;7^D>&?MMEKEC85=}ZN&9N&E!0!HLF?,96 {A4YZ%@/F/L/SKS677=5EEN9#?-_])/F0R+0L#+P!BS1]*31KNXQ\-^TV.]VZG*B:.R>Q|_DF!Q-YFZC@[Z?
U]OEG0;#2[J.5[AG9/F$,A'SD=.U)Y;^5=/>W44EKSQ\2D?9_P . M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^'XW_>:O\ MB?YL****T,****
"N.^,7_)+/%7_8.G_P#0#78UQWQB_P"26>*O^P=/_P"@ M&L:W\.7HSTLM_P!^H?XX_FC&_9M_Y(3X(_[!J?UKT]O-?V;?^2$^"/\ L&I_ M6O2]C#?P*?HOR.C._P#D:8K_
^3_P#2F9?B?6QX:\..]QOM9K67 <_9K< M9DEV<6VJ/4XQ72AGI&WI6Q_;T\+;_]I>#KWPDVE7YL]ES-YR3#&OOVQ?I'1EQ MP>]?0!1P6\5LA2-(E)+$(H
R>IXKI/%/G|[NY(9/V>=12XTI6@;4+26: M!VN5\])O!7P@Q_@WX8L_#.IP:S]N^SVO]-MJLT#+4@M8)7!V$$^8V',X&:_^]/C3\+_^%N^"O^$?_M^^R_\3+;[^T>3YO\-MJI
^W;D=<8SGBNF\2:%_PD'A;5M&$WV?[=9RVGG;=VS>A3=C/,,YQ0!\K_"C MXB>./$'A+P!\-_AP^D:1>V?AJVU+5]?UNU>[CM8WRL4<5NCQ^8[8))+@ >M: M,WQ
^+N]WOQ4^'GB67PQ;7^D>&?MMEKEC85=}ZN&9N&E!0!HLF?,96 {A4YZ%@/F/L/SKS677=5EEN9#?-_])/F0R+0L#+P!BS1]*31KNXQ\-^TV.]VZG*B:.R>Q|_DF!Q-YFZC@[Z?
U]OEG0;#2[J.5[AG9/F$,A'SD=.U)Y;^5=/>W44EKSQ\2D?9_P . M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^'XW_>:O\ MB?YL****T,****
"N.^,7_)+/%7_8.G_P#0#78UQWQB_P"26>*O^P=/_P"@ M&L:W\.7HSTLM_P!^H?XX_FC&_9M_Y(3X(_[!J?UKT]O-?V;?^2$^"/\ L&I_ M6O2]C#?P*?HOR.C._P#D:8K_
^3_P#2F9?B?6QX:\..]QOM9K67 <_9K< M9DEV<6VJ/4XQ72AGI&WI6Q_;T\+;_]I>#KWPDVE7YL]ES-YR3#&OOVQ?I'1EQ MP>]?0!1P6\5LA2-(E)+$(H
R>IXKI/%/GI[NY(9/V>=12XTI6@;4+26: M!VN5\])O!7P@Q_@WX8L_#.IP:S]N^SVO]-MJLT#+4@M8)7!V$$^8V',X&:_^]/C3\+_^%N^"O^$?_M^^R_\3+;[^T>3YO\-MJI
^W;D=<8SGBNF\2:%_PD'A;5M&$WV?[=9RVGG;=VS>A3=C/,,YQ0!\K_"C MXB>./$'A+P!\-_AP^D:1>V?AJVU+5]?UNU>[CM8WRL4<5NCQ^8[8))+@ >M: M,WQ
^+N]WOQ4^'GB67PQ;7^D>&?MMEKEC85=}ZN&9N&E!0!HLF?,96 {A4YZ%@/F/L/SKS677=5EEN9#?-_])/F0R+0L#+P!BS1]*31KNXQ\-^TV.]VZG*B:.R>Q|_DF!Q-YFZC@[Z?
U]OEG0;#2[J.5[AG9/F$,A'SD=.U)Y;^5=/>W44EKSQ\2D?9_P . M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^'XW_>:O\ MB?YL****T,****
"N.^,7_)+/%7_8.G_P#0#78UQWQB_P"26>*O^P=/_P"@ M&L:W\.7HSTLM_P!^H?XX_FC&_9M_Y(3X(_[!J?UKT]O-?V;?^2$^"/\ L&I_ M6O2]C#?P*?HOR.C._P#D:8K_
^3_P#2F9?B?6QX:\..]QOM9K67 <_9K< M9DEV<6VJ/4XQ72AGI&WI6Q_;T\+;_]I>#KWPDVE7YL]ES-YR3#&OOVQ?I'1EQ MP>]?0!1P6\5LA2-(E)+$(H
R>IXKI/%/G|[NY(9/V>=12XTI6@;4+26: M!VN5\])O!7P@Q_@WX8L_#.IP:S]N^SVO]-MJLT#+4@M8)7!V$$^8V',X&:_^]/C3\+_^%N^"O^$?_M^^R_\3+;[^T>3YO\-MJI
^W;D=<8SGBNF\2:%_PD'A;5M&$WV?[=9RVGG;=VS>A3=C/,,YQ0!\K_"C MXB>./$'A+P!\-_AP^D:1>V?AJVU+5]?UNU>[CM8WRL4<5NCQ^8[8))+@ >M: M,WQ
^+N]WOQ4^'GB67PQ;7^D>&?MMEKEC85=}ZN&9N&E!0!HLF?,96 {A4YZ%@/F/L/SKS677=5EEN9#?-_])/F0R+0L#+P!BS1]*31KNXQ\-^TV.]VZG*B:.R>Q|_DF!Q-YFZC@[Z?
U]OEG0;#2[J.5[AG9/F$,A'SD=.U)Y;^5=/>W44EKSQ\2D?9_P . M?^2?^&O^P9;?^BEKHZYSX<_\D_\ #7_8,MO_ $4M='7T=/X(^A^'XW_>:O\ MB?YL****T,****
"N.^,7_)+/%7_8.G_P#0#78UQWQB_P"26>*O^P=/_P"@ M&L:W\.7HSTLM_P!^H?XX_FC&_9M_Y(3X(_[!J?UKT]O-?V;?^2$^"/\ L&I_ M6O2]C#?P*?HOR.C._P#D:8K_
^3_P#2F9?B?6QX:\..]QOM9K67 <_9K< M9DEV<6VJ/4XQ72AGI&WI6Q_;T\+;_]I>#KWPDVE7YL]ES-YR3#&OOVQ?I'1EQ MP>]?0!1P6\5LA2-(E)+$(H
R>IXKI/%/GI

*O!'_8-C_E7_|+?%_A?YH^NA_R3=3_*_Q_P#2)?J=%%%=Y\B) M12TE **6DH ***** "BEHH *2BEH 2BEI* "L?Q-I$N16L4|F574;-_.MF?A M6.,,C?|+ E3Z9!5L4M -'-Z7J<6JVGG1JT:*QCEAD&'A1AV(_7@C@U;J/ M6?#C7-T=0TZ866I[0K.5W13J.BRKW'HP^8=CVK.BU];>=+7583I5XQPHF;,,, MI_Z9RI#]#AO:@#5KS_7/@-X\i3>/U\8;MHT>H:J(XT\]?YK9G3]LKQ=-'<# ! M,(XKT$C'48^M)0 TQHT9C**8RNTH5&W'ICICVKR/X\ZUHG@#PM9W%]]EQI M4%QKQOU|X.:U\:/"><D:9H=0Q6UQ:7KW$C7TC(M4PNF_54\Y84 >HZ;IEJR6]X))+QRBO%+.V< @$%1@~<'KC-2:YH.F^)!*N-M,U>PM]3T^X79+:,W40DC<>X/\ZFTRV>STVSMW(+PP1Q,5Z950#C\JLT >3+X(MT/\ 9V\#:[> ^$;%+9KJZA>:>_9YUMT:14W,1AS%$K,VTG@9YQ6#=?M&ZAI]S M%91Z+;ZX8&AFN=5M'DAMKBTDE:-);="I)=F1U"D[%$\,36D23-;,^HW'DQ M _N\2O+L.R+]X5+8/S(X_AR;OB_XV^,-$U:!L]/\&)]$<6I?8E+1W"^3'R5> M1MFQO-P-I0D+D;ZWX'>(/$_B7PEO>L;E(I;>1?TE2$J=Z.NX$>X.M]4&J)Z\UEZY?_ &6W\N.0+,YQCN!W-4G:]RH1^&-*?1M1N:/FEGD\ MEI/LXC'E@=9X):0#Z,2M*!F_E.OF^7A)205+8Z_G7BXFW,K(_5LE!5CP!XFMO$,27PN%O9Q M=EFN0Y$I8Y.[O6GX-ED€\2V(B9EW/M,;W7N#7!S:GUCHI0OU/5+S*&"8-Y4H M=5;G<-I/(->9?'^[<^'Y|89$/DLYY/+ @=/:O2=:N%BM$#;U>5P[(YW-UP< M^2N+^-.BP:EX$U/4G$T5Q!;'"G'(R."/*SQ'\&?HSKREI8^@W_/\T?;_PY M_P"2?^&O^P9,?^BEKHZYSX<_\D_|-?\ 8,MO_12UT=?34_@CZ'\|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|"'>5_48_&N5\36[%89P,JN5;VS6M.VAYU:Z=4W/8H_"PKSOXAZH\E_':)<;[=$ MWO%&W&[/\7^%>B5YE\0-&6RU'SH(!#%<(260?*9/4^_\ZX,3?V;L? 092H%/+ MG^7J>7WGCF1+EEMX%)6(S*3EOICI5>TU==3O9G%N+5GP %.*M^/)%K'U#3+ MK3IXEYHF(+(U?0_18-0:.M1Q'Q%T.1+I.C$\LCQP-_P DL\5?]@Z?_P!_-=C7'?&+_DEGBK_L*3_^@&L:W\.7HSTL MM_WZA_CC^:,,,IFW_)(3X(_[!?]UKT]O&OV>/&_AVP^"/@RWN=>TR">/3T5X MV;V)64|\$%LBO1/^%A>%_P#H8] (_\#XO_BJPPU2"H0U6R_(/:L)B'FF*:IR M_B3Z/^9G0T5SW_"PO"__$,>D?\ @?%_\51_PL+PO_T,>D?^!\7_,573[2'M=\C?4\3_,^Y?D?^!\7_Q5'_"PO"__M_$,>D?\ @? %_\51[2'=!]3Q/_/N7W,Z&BN>_X6%X7_Z&/2/_ /B_P#BJ/\ MA87A?_H8](_\#XO_(JCVD.Z#ZGB?^?D?^!\7_Q5'M(=T'U/$_|+/N7W,Z&BN>_X6%X7_P"ACTC_M ,#XO_BJ/^%A>%_^ACTC_P #XO\ XJCVD.Z#ZGB?^?D?^!\7_,51_P +"\+_ /0QZ1_X'Q?_ !5'M(=T'U/$_P#/N7W,Z&BN>_X6 M%X7_.ACTC_P/B_^'H_X6%X7_P"ACTC_ ,#XO_BJ/:0IH/J>\_Y\R^YG0T5S MW_"PO"__$,>D?\ @?%_\51_PL+PO_T,>D?^!\7_,51[2'=!]3Q/_/N7W.Z M&BN>_P'"%A>%_^ACTC_P/B_|BJ/^%A>%_P#H8] (_\#XO_BJ/:0[H/J>)_P"? MTAW0?4\ M3_S[E]S.AHKGO^%A>%_^ACTC_P #XO\ XJC_(6%X7_Z&/2/_ ^+_P"*H]# MN(@^IXG_GW+[F=#7#?'7_)(IX^_[%]_Z(>MC_A87A?_ *&/2\ P/B_^*KB M_C9XY\.7GP<[=00:_IC_)D7_P!'G'_D@GP[_5G_P"BEHH_9RX^_GP^_P"P%9_^BEH] ML-AZ+\C'.O^1GBO^OD_P#TIGHU)C_.;6]9UFP4D&]M@1P09E_QKI2\V/?2 M;Y+E%1^?&?\ EHQ_'T*7SH_^>B_G18+#Z*9YT?]]?SJM?ZK!80LS.KR8)2(M_SD#H*EZ* I$>9_M#>-I?X-_#C6_%VG:5;3>(9/+M+600+ODGE81QIFQD@%@ M<$]LX9J7_!/E?$_A-;Vl\.:A9^.;QVO:Z\i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

(J2N_A]XAL8_B/+KKW&OW%|/!%<36P/[L@R#'E@=0.W K&.85DGSQ6C MWO9:MI7T\OR(6]I. Y^;/FWP)\/_%?C^U\0SV5_/:KHE@=0G6Z:8&1,]$P# MD_6N1%WK1=$\[4=[KN5,R;F']I:U(]Z_0#QO\0=8T/QW\15@UZV2X_P"$(@G+ MV4D9B:[*[2R=>>>O _*L3PO8?VYJOP_\ BBFJZ:WA72/"QI)#<;#^ ML,9.[<2?2ICF525G..CVUZVO;;KT$L94W>WKY'PI#+KUP.Q-J$O"?P(TO1M6BM-/ MU74+A=2BQ&WFQ%SA7SDJO.>U.UCXEIXUT'XI.=XRO+6]\,.'XELQ9V:QQJEO M,"4!Q&%)?:G,Z\^OU5+6&E^~OQOG8^,)+O6H;.YDFU! M++;3&Q,@1_HQX/X&BQIWB$LLNHQ1$[0\AD52>N,GBOOCQMJ.N1P?$&\8: MSH%W\/9V-H^SB%%&\.#US7@7[9OC?4M6\2^'- &IF?0K+1[2 M:&TC93&LK1C.@H[;^2TVWUU70=/%3J22_7^M3P2UNM;O_ M #/LLNHW/EC+ ^09)-H]3MSC\:C.IZ[L*S&[O1"Q(S$AD<*3W /2OL3X,3>.KW MX(>!8O@CJ^D:9/;LY\21RS\)-Q]HW??F\T$M'CL.WX5G_!".W^+MYXY^'/Q$ MU&RE:QU(>)/[0TX1M; Q-_I*H8P%";/3CYC3>|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|>L'_ M %S7_P!!%3CI7@O<\-ICQTIL]O%=V\D$\230R*4>.1Y+UM5F>4ZU^SOI.I?:.SOY+2W8Y^SSPK.]_ID\/_=+X&^$ND>")EN!"3 M2]%6//?8@X<]^37:+V]I&1B;4GQ)\U#]!L' M'\ZHU/HNP>&L;T.AK=TWD?9+8[EA9A\HE<9VD]E&6/I6AI,&J:EILEGK*I;7JD/;] M5VED X.WM],EO7'2D\)_ /P=X,\4:CXAT[24_M:\F:,SYSO^SEOO"$'A,G)) M')SUKMKJS@O8O+GB650<@-V/]#U!^E.)/"/BK0+_ P .:N;CR+9S"I)-DX!9 M,;DR>A&Y?]]J?[<*;O@5=Y.,?]MSZ?.*]SO=%T_4;RSN[QM[FZLVWVT\L2M M)"W3*.1E?PKB/&GC7P?>3W^B^)]+>[T:SDC6IOKZS$NGQ3$;D1SDD-TP=N.D M#:.]{&PAB*,]=-?Q>95.-552K+FL[I6=CQSPQ^Q'X=U_11;OO$'BI[Q M-K23VT24WV9[E4C7.!G%>X?#OX*^"_A7%CPUI%M83D;6NVS)<,/>1LG M\!@5SB_M)>!,+1EFMAJA@B801V\>ERH1@[5 W @$@$@E5) I=1_.:\&6+"M)9+]KEE>1(4;1XP\:\LX)_AQDCUKDHX/#T&I0@K]SLK85$5[QE-V[\K-%87@ M[QA9^-[\&I6,-0!;LY51RN9;&[@G1$+]f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|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|O2Y1<6,LMW_]HZ2(!@!O]K&: M_8+_(57X+_Z%'0O_!9! P#$T?\ "[!?_0HZ% X+/(_ (FLO[=P60?\ O-'^1=/(_)IO[| @!_,;?Y3\!?:C_YZ)_WT*M:7 M*AU.T D0GS4X##U%?MA_PJOP7_T*.A?^"R# _)K@/CQ\.O"FF:"?Q'#5^.7JPHHHK(S"BB MB@]"^_X\Y_]QOY5/4%]_P >< | N-_*FMT:,GXM_&3_)*+K' 79 | T)JX MJNU^,G_)1=8 Z/[_.A-7%5^SGW-?^++U"BBB@PQFK&G7-U"\L-I/-"A > M2.%F53V!(& ?K5<]#CKVK[Z^%=[XNN?!/PGD^%VLZ+IWA"T4+XG@FG@C<3[_M)S,LGS-D=-O.<5Q8K$O#14DM^[LMK[V>_0PJU/9I,^#(M.N;BY-M%:3RW/> M!(6:3_OD#/Z5UOP_^%.L?$7_(2'[T5L^B6#WURERD@9E7JB@*?F]CBOL:>M[UJ^U\4LE6WPJU'3+3XDR^(B\SRS0IMG2VVNY@Z]FG M9*_KZ>1\L^/?AK-X#&E^TI#68[ZR2]+Z9O=;=T20D?*U5O..M(PŒ/F"_ &>/F/TS7VW<>-=-F^(G@_PMKUZC>'_&/@^':3;^4.I$<[9,'?&VCO\:=:\(>%+_ 3[:]\,^SIHWA*ZOV00FI7_6N&/RIV/0T+'U(QIZ M%W:]^EMNW?\ #4%7DEJO.^-_"/(@+5?&'BW2_#T%N]G>;AQ%?9^-[^ M"_TV+XBRI.URR%1"JLL6X#^ ';]>M9?VA5E)-)VG6Q/UB3=TM/(^% MY[*YM(X7GM9H$D&Z)I8F0./521@_A3GTR[AA>5[*XCA0@-(T#A5)Z DC _&O MN;XH7GBJV'WQ#/Q6UC0]1T:\N<6\(0VTT$DGF>8-K0*/YE0)C.IWK<\5_$W M4-<^)?COP7>:I;3^$MO=Q0E:&_^]6R?7L/2M%F,VK]"?HJ.FLVO M^]%?6&]E^/IY>9\|+> ?.;M_$OQ/;:!X?M5NM2N%9@KR"-%11EF=SP% [FNPU-MD>,/V)B!<Y XY]?76IBE];6&G;E;_'H7*K^^]F]OU/GNU^$VL7GP]MN/'T;PMI4&I+IAMPKF"="^. MOBC4K[3?[(\;-9KH4EO>QRO=_O QPJDD8&:W=E!59XV0 ME3TP&)%?HO<_&36(/CCXA\-_P!JVDOAFR\%"]@LI4A>$W20JZN21\S;CT)/M0<<5R\@OX@Z?XWT#X)>)/'VHZ??:ZUS]UO%J&I+&2<8%MYH "@CC(QG'>L MUF-2RE*GIY/75-KIY:DK$2M=Q_M5U0FIJZ/*KT70GR2:,|M2*ZF%O:R2D9^C.%\Z\67$8TF[B:,2V9T+-)!@%1^ M--UK<*R63.0=R1E=4WIMP0.:PK:Z'HX%*/O];GDSO^U@3$JF M7ROD#?<)QO7BU\T[WDYN@1<%SYF1_%7I=JWA.ZB\VZL+?=":?E:WV8P>3YU^-E M>>ZYX-TS6)Q,9197# ,[H?O _/ 37@5*F>&;8"RBCED9N4?+ MO[L:QB9+O5O-**999!\H)(OZ>XJ5%V-IU%RF=MS$G>A)Z M\=OSIECH^F>!5GN;f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|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|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|+(OQ_S,/^T)-RH_'+_AEGXO?] M$ZU[_OPO_P 50?V6/BZ00?AUKN#U_<+S_P"/5^QN!Z"C]\1_K%7_D7X_P"8 M?VC/^5'XY#]EGXN@@CX=:Z".A$"\?^/4?\,K_%S_*)SKO\ WX3 .*K]C<# MT%&!Z"C_%BK_P B_',//0G_*C\@H_UBK_R+\?\,//0G_*C\/^+=:[QP/W"\?^/4?\,K_%W_*)SKO\ WX7_.*K M]C<#T_2C]*?^L5?^!?C_F']H3_E1^.8_9;^+P((^\> OH?)7C_,>IH_97 M^+@)/_ "N==R>I\A>?_]_8[ ]!1@>@?ZQ5_Y%^/^8?VC\A E1^.7_#+'Q=S MG_A76NY_ZX+_ /%4?\,L?%W_P"+=:[QT_<+Q_X]7[&X'H*,#T%^'L5?^1?C M

ZVZF.Z1_Q[#V&!5ZBBM+W$%%%%(HHHH *****-M"BBB@ HHHH P_%GC/3/!-G;W6J&{$-Q.MM&;2SDN#YC""@A-2,G@$\5%??$3 MPKIB1->^)=
(LA*N!A:]JX@\.VGB:SAMKWS/*BN8KI?+?:=\; M;ER?3/45Y]IW!-_A*PN))VDU*]D8H%-U.C^6J8V(N$' YR?4TM0.Z3QKX= MDNQ:IK^EM=&5(!"M!&7.CCQ9D4H9 N\%D8
KD$;J.P_"OP!\+>$-?'T!5['[<|QH8V<=Q.KQPA@V\ ;03 MDNS>*M+CDE<(MRKA?GV98@X4!N"2>#7475E9:U;!HA@O M86 9&9_M%RC>86 'S?)SC""?KG->A
MM)9:?:QL-PGEV2$Y M+!|_RZWY.T?T#???\R/:KMGXKC6:.VU2!M+N7.U#(P;&4^B2#@GV.#[4S34
ML]8MA6YZ2P2!U^F1W]JFG@CNH7AFC2:%QAXY%##*P]P>M/26Y+3B[&Y M17(Q/=^%OF@\!V^T@??MB2\UN/6,]74?W#R.Q/2NHM+N&_MHKBWE6:"10R2(<
MA@>XK*4>4;=R:BBBH*"F2_ZMOH?Y4^F2_P"K;Z'^5-;C6YY-^RQ_R1K3/^O] M\| 2AZ*/V6/^2-:9_U]7G_10]%=^8 !Y6_Q/\SNS# >ZO\ B?YGK9Z5^7'B M+_D9M5_Z_9__
$;U?J.>E?EQXB_Y&;5?^OV?_P!&M7UG"OQ5OE^I]3PQ\57Y M?]?\>%K_QZP?]\'_7-?\ T$5,.E>"!SPWN/"2G+TIHZ4Y M>E02QZ]!?3%
[4^DR6/IPZ4VG#14D]1].7I3:E2(>.E.7K31TIR]:D@>O2G+U!]*E.7K35Z4Y>M)D'C?:BJRG^"?BZ3Q=ID3/X3U.0+K5C$,BW<\"X M0=AZU[*8WL&HV<-U:RI/;S()
(Y4.592,@BFW=G:[%G-:W,2SV\RF.2-QE64C M!!KR#PK>3_!+O?'X3U*5G\(ZI(6T6]IE.1,2'DV[GL/2O1_WRG_T\BO\ P)+| M5^*]#T?|\A_T\BO_
)+-]5^*]#V!:>.E,7O3P>*\|H\L<.M/6F#K3U]21PZT] M>M,'6GCK4D#J*I:QK5CX?TRXU#4KJ*SLK==\L\S85!ZDU-8WUOJ=G#=VDR7% MM,@>.6-MRNIZ$&GRNW-
;0KE=N:VA/1114DG.?$; _)$+Q#_V#Y_ $ UB? ?M_DD7A;.1X$?;?Q&_P"1"\0_]@^>?_P! -8GP'_Y)%X6_Z\4_E7HK_(.W7M8\.O:0P9R11DQ>$*H)W@<4.C Y%06RP!(;G9\52'
M;X5>+++&/2-=NI[@;DNVTZ>PGJOX>,/"MSEBH*[1\P!C7$>,M>^#NKZG_;] M[!H>J7>K1W:0&UM$N45Y"5AV_* AD6/#>6/FP#0 V^@^"!T-+M-1\6ZE]_P!A
M3%JUY>9.C)Y:2QD*5&PKY"J#AF+$JV2:U?!&D_ $>(!=':VO+^`6%N-.-T9 ME%TUM&/!'9P1LV,A.#M#GG!Q61"W!/FK75SIL:76H7%Z\9.!8KJ1C*\9RW MR'"_,^?
NGD\UI^'+[X2ZO-J5A;ZD)8^'Y+*\CECFG+2W9=K>,,0+\52;H4! M 'S$€J,7 >5>#OBCH_C;Q-XHT+3ENA=^;H6=XTTIO.R$9PA!.< CJ <%3T(-M)T/'WA:?
QKX1U+1++;6]0\.S7D?EK]>E.$N8.0\-6-]> ^*+IC;:A!OFB\H.6F<;)<*I$A.Y<;@S8/ P/=_!'C_ $?XB:?<MWNBS3306]P]M(TT#Q'>O7 8 D>])JZLRHR<)*4=T?!?[1W]-
@SX=1:3HNE: MUXO\;%?5)5>PCN;K[4?"W?.9$QPI 8#!R2"&O@8ND?'SQ;\3+[41J-S]MG;Y-A;-%@V,2* M!(V>=Q Z <9].]-OM+M-
3C$=W:PW48.X)/&K@'UP0:\6K!ET.S3;:?_^D=+)1VVU=V?FC_P $]H(/C3X}2:Q)-.1P;#82SQVY M(.LCR_N@<5'4A06+$=.J.!?!3]VKVVAV+W5TY$:X4*H+.[$X55'4L3P *|_^-
M_P"R+:^+]>M_&/@"]A\$>.+<@_:K4&&*YQT+&/E'_P!L @CA@PQCT+X>V^N: MIH^DWOBF^M]4U.Q@%NMS:1[(9Y@-LMRJ_P"T:J_$OPW=>,_AYXFT&RECAO-
3TV>SADF8A%=I*@L0"0/P/T-=)17< M?"'S--^R[KD\UIJ-G?66@:O:16XMI(KEI$MY(8KP+($CBCC/[RXA? 0#*$G) MP3#<_#'QO'HT%CKOQ%@FF+V\-O)
<^)N8=EQ%,LC6I5X43,< [V.\#"D$ M:=M.W&'&>F?>OFYOV4]:A69!XLT_5%OY[F\OO[4TK=MN:F%XKB:((1S@H5W MY.8QDT ;_@OPQXBT75=7N?%?Q*MFLK&TFM)
(5UUI:WHQ#^S_X\32=)L='U31_#&GI"8=0M=&NY?+U%O)2,74Q9"'+X?<@ XDR M69@"-ZW_ &=]4TV*S2VO?
#EX=*NWN+&34M)>66[5VE+"^U:'TW!C:)]AF$_9;>.#_1X1#"\]@?(@)V+QPN3@8% '-?""P5>?#WP);. M'?SP7%S#--(7MBQ0AW+#&0#T-=1J^EVVN:5>;=>
(9+6[A>"558]2C @@$=.# M65#X\T.?Q7-X:6_4ZU$H8VQ4|Y4O@'H2N&2.P(;Z"M72E&W.K7+G"5.W,K7 MU^1\O^+S\)+[Q#]>FS:/[5WJF@3.+TK(OEP(H(09"
[8V.%A"C@ED)XYJK\- M=7^'O_"(?V5KOBC5[.JAZU07<&KWUW]CNFFEC,06)HV8A!%%L.XD8/4<8]8UW M]GCP?K6IZGJEQ'>VUWJ,SSWL]O<^7YX8)\C\]D92[N/-6&-
&9D2/CY5!=L#GK M795U0YU#]YOY'SN-^K>W?U._)96OOLK_(W"BBBF<)3U36+#1+7[3]5!,Z?; M9"'^==SI$F3T&YB!FK-K-'?6|
<]LZW.$BATEA.]'4]"".">N=^(_@Y/'W@O4 M]"/%&NZI="?QD(-'3S?L-K:274++)O+%2^R M0#Y"P "\8 H]_V-_<;\C7-?'G_DD/BC_KU\Q7G(]!GW-=6$DHXFE?^9?
FCTLNHU*V<]<,V:,\E<]N\%?\B?H?_7C!_Z+%,58 MO@<]_$U_0 \ KQ@_]%BMJL:OQR]6<-7XY>K<7BDJ%<6BD56;6BD56;K/B;2O+RO-W.
((//<+YDAZ*/>]C%R=HJ[*C%R=HJ[YIU!??\>< ^XW\]FSFH;[_C MSG_W&_E26Z$MSR[IF;_DFC?]A*[_/1IKUBO)_V9O^2:_ V$KO\ |&FO6*[\ MP_WNKZL[L?\ [U4]6%
(S!5))P!R2:6L;Q9=M;;/)'&<37+*WCQZMP?TS7 E= MV//;L9FD,=0N+O5''-P^R+/:)>!^9R:U*CMX%M;>*%!A(U"#*DKH9*"BBBD M 4444 %%%% !1110 4444 %%%% !7(?
$WQ'?>'=$MGTZ],>XN;E8//,/Y8V MEB0#P2<8Y]ZZ^]&NZ?:,II-S;WUF+'V*%FMR.ER!D;?1N,"]1-.46HNS.C# MSA3]QG4C=)ZKN9_@3Q!)XG\.VEY.%^U_-%<*BX D4X;
f=,_C67\4O&5WX-T M:%[*+-Y;ZIXL:31-*T[2+"!\/:"2>I)]HP:U?6]J:.22'5+/!B&^PZNK7,88?Q*2VY3|#CVKSIXI M*/)?6VY110R:4Y_6.5"_BK>0WFYLOLIN"[P*LT M+9 5=]
9W%L 8SD5<\2>+?#GCW3UMI;V7P]?VSF>UFU:,)&QQ@@D$@@@X(R" M.HK@-1OKBX%NB65A:VB2AC:Z="'+>)3@CS&))9V X&3QDXIEQYPMI/L^SSB#|
MOS/N[NV?:N?ZS)1Y'[R\5VXY13G/VZ7LY=$K67X6UXJ;3/$%O]<< MMDFEE'26>SO?/6Z'^[T'.#SEN1TU2U?XL^(X/$=Q;V\5O#!%/+#Y$EJ7":#
MC]X^X$%AR,#O7.Z#KVK>$E-W9S"&8A9+JTC .%P1!X;2."1D!A@.]YKLTAM? MB1XMU:"\TW^SO+MQ-:ZO9[DD.?&PR$_)(&!R.]"-V:UA+FIJ%)V=S@Q-'V:
M*E6QT5.#6ZTM9KIU>O?T['6>" B-.:^)OL5Q"=.U4*7$!?YKR7PSX2OY?&%A%?:9=1V- MRMPJY97L,EE7.0(P2P+ X(/-!/)KVNXMXKNWD@F02PRJ4=#T92,$5Z&'G.<'
M]1'S&9T./1K+ZK*6K^GE_6IM#;6N?\ "U!*@TTF!D.EW9XV2/UFA/W^O&T M^ZGUKH*N2Y78!Q.X4R7"_%?0_RI_L?_P]2W*6YY-^Q_R1K3/^O|\ M_P#2^&*?V6/^2-
:9_P!?5Y_Z4/17?F/^^5O\3_,[LP_WNK_B?YGK9Z5^7'B+ M_D9M5_Z_9_|+T:U?]>E?EQXB_Y&;5?^OV?_--&M7UG"OQ5OE^I]3PQ\57Y? MJ?>%K_QZP?]\ 7-?_ $$5..E06O|
QZP?]O:GTQ>U/L,ECZ<.E-IPZ5)/4?3EZ4VG+TJ1#+QTH1UI:TH1UJ$22+3U M[4Q:>O:DR>H^G+TIM.7I4B'CI3EZTT=*O2 MF+UIZ]*E@/7I3EZTU>E.7K29
]>E8GC7?!WCWPY=:./[<9:"8961?OO:/NNI M[$4M>E/7H1&KC'_P M"\A D>4#P?$3\6_)3-._P#! G^:_X0GXN'_FIFG?\ @@C_/BJH'6GK4_M7JG\L?\ P"/^1/UVI_+'_P
C_D>3#P1\7?^BFZ=_P""""/\ ^*I1X"+O_13 M-._\$$?_,57K0ZT]>M3]>J?RQ\A_D3!=J?RQ\C_)'A7C'PS\2=(,,: ME=ZW\2M-DTJ*%C<(WAQ) R8Y&T'G-._94\+^*O#_
(5N)=8N6CT:Z?S-/T^: M+:,)$1.=^,_(&[)VKW1E#]58 @]010 , =]TEF$YX>5!Q6K6J26WHEKYFD ML?.="5!Q6K6R2V]$M?,6BBBO*/+.<^(W_(A>(?\'L'S_ /H!K$^
_P#R2+PM M_P!>*?RK;^(W_(A>(?\ L'S_ /H!K$^ _P#R2+PM_P!>*?RKT5_N3_Q+\F>@ MQ)R?^)?DSOJ***\X**** "BBB@]CKFDPZ_HU_IER7%O>V\EM(8SA@KJ5. M#ZX-
7J*-/>)^ '@!]>.3CA/PNIM$8A-+(]22@G=^\,=^\.1D:LX[8HM?@+ MX)MOS#[KQT9)KVY=) LCL8H64@[HTSA6+#@];J3WQQ79ZUX@TWPY.+P6% MN5B,23N%4L02!GZ
_E5JUNX;VWBG@D6:&50Z2(:;WL M+X*+B-&?=)M&{0F8HT@8NRLRKM#8+8W8X+=3W)K;\) ^!]!\#17D6AZ=%IZWLYNKC868R2$ M ;B6)/0 = *AOO'.G:
,Y'@#PY9+IEK:JY6*\GD(8S%#UX4D$\X^^IK*511DH]6= ^'P M=3$4JE9:0@KM]-TDO5M_J?3'6EIJTM:G 8/C.\EBTE;.V:A(+2)QU3=G> M_P#P% Q_
4ZVMHK.WBMX$S<$2"-'_"H& /R%4KI_P"TO&+GK%#oL0' _%VE MY/Y{H_[K2HWTL 4444@*^H:A;,:59H%>/Z_\&S4{BY9= M(M8[&S)$]Q'YLI
[EX(X M'T8?B*[36/C=X1TFPBG-^UY=2H733;,.R77'4.@_U>#P2Y |Z^6!XDO|SEI0 MZ/\ ?3:%#?B.1];!*^"?P[\-ZWK]R=0M#]%K-#[MALICBW1PP!WH.)#SU?/2 MNS#*AS-
UV[+:W4[,,L/=O$-V71=1WPD\;>&=*\7:]XIUR^N+>6_DD6VFE@>>> M*)7<-(9+B-3'N.$3"DA50#.2.[W7_P!H:QT.4BD&F+J&G,NZ*^COTC65A7U[9I#=Z=
G]E5N6'GYZG0245>6V*(=MIQ_\KK!T MXZVZ?H?U*C4K1U_X)]%"=;E9--TO3RF]64$,"ZNV+1R0DDE0$;DKV!Y_"N MYKS'P-)!VA>+9+.AFEU">9/*^U!0D:D#
<5"Y)/3[V>V*].KQZL4G='LTI-QU MW"BBBNY'7\;YJM7D=D?29=E2Q4/:M5;VZ6_IG0_$+XBWE_)9IUQ>Z5#O8$1R!6E&/O,1TQ_=YSFO)/&Q_P"*0U'' M*F+.
[.>IS^M=#JES;WU[]:3VU[]H&"/LZ\K&,N*C"3<\;1;_)H_FC]#P&%I86CRTU_G]Y[G^"O^1/T/_KQ@_P#1
M8]MXXTKQ'[^E)#X9UR'0+X2!FN9[07(*=UVDC\ZL^"O^1/T/_KQ@_P#18K:K MTW-PJN2Z/JK_(,_'Y2<*KDNCZJ_X,\A_P"$'^+W_13-._\ !!'_ /%4?\(/-M\7O^BF;=_P"""/\
^*KUZBNKZ]4_EC_X!'_(Z?KM3^6/_@$?!CR'_A!_B]_T M4S3O_!!'_P#%5Y[\;O"_CNT\(?9O$7C6TU];R98;33K;P^OFS3'IH1PWR'_:M[5]04UD5\;@#@Y&1T-;47?LS?\DT;_L)7?
HTUZQ7D[,W_)-M&_[''5W_Z-->L5U9A_O=7U9TX_P#WJZL*YC4I/[2\311#F&P3S&_ZZ-T'X#F MN@O;[.QM)KB4XCB0NWT%[DC\Q87
M(X8KD9Q36K&SW97+|>5?'KQ|KW@*/PG)HC]D=[]]VIZS6WG8@^4M_N\9Y]'X? M^*?'OA6*XT]XDVEO=*18K/6=.:,!9GIN48&?P!'Z">NRU_3KG7H[7S;[*RB
MBE\WR_+#[A_=))'Z"LJ^*HX&HO:M/TUN9QISQ=+W+Q?W-''7/B'1/BCJEI9W MEK?:/=''!HO!S:9(NHR:@]P\BI)X44H MH.Y2OU/UK=B*:1X&U.WU",6WBOQQX
MZ\6MK_B=[/2=+,36UAHEL#(^"V0W%26/?I3Z#%>7'DQ%"5:35^G=^5NYIOAL M0X8RG0P:G[+[75+?=O9?K>R.5^(6HW%SKTU]IL+> *$CS@'(!)QWZU!X3\02 MZ;-
+:/=M!-X=QA^POCY6]AGK6S\1-)%O:6EP!.T\+&WN'N%*R#NN\$ @] M>HKF[/P7K.OZ?*!BJ6H=("(YI@X&<<<$#J17E6IZQ^A\T?9W FLB/DS.)LMGJI!/&*A^*_CSQ)II?
ASP]I&G7[2:6-42VDM#;;AY9YVL?X ME&>.P\]5S7PVLO%/@BZNK7Q#9BZ-P\<%I-8MN$\A/&D_/7 /!X-?0Q^#3ZG M86C:KJR6]Q^")2MK'E!_L.G.2??
^E=7MQX&LN=J2\M4SY/"X]AB\-[UZ6UXP".G^S_ '=QZ*2<9['H=SX5 MV'Q-N?$LFH^(WT[0O"<$!M+#P|:CS'9!CRY2_4' ZLCZ^&LXX]6A!^T:?F0X_Y:0G'F(?P&X>ZBNLC<
M2(K*BN_,?\ ?*W^) F=V8?[W5_Q/\SUL]*_+CQ%_P C-JO_M %^S_P#HU]_4<[*_+CQ%_P C-JO_%^S_P#HU]^LX5^*M\OU/]>&/BJ_+]3[MPM?^/6#_
*YK_P"@BIQTJ"U_X)@/^N;_^@BIQTKP?N>&|QXZ4Y>E-'2G+T]"M6/?M3Z8O:GTF2QJ.'2FTX=*DGJ/RI*\3EZ5(AXZ4HJZ@Z4HZU"))%IZ]@8 M M/?M29/4?
3EZ4VG+T]1+QTIRI;..E.7K4D#UZ4Y>M-7I3EZU+)8]>M/7I3%ZT M[>E2P'KTIRI;.O2G+UL;@>O2GKTIB]*>O2H)8Y:>.E,6GCI28APZTI;8.M/6
MI)'#K3UZTP=:>O6I('4444@"BBB@#G/B-_R(7B'_ +!_P#Z :Q/@/\ \DB\ M+?\ 7BG\]V_B-_R(7B'_ +!_P#Z :Q/@/\ \DB\+?\ 7BG\]J%?[D_\2_)G MH+_UB6>Y6-C%%[[%=|<M<
MV!/>FM1K4\@ .:DD@F\$Y5L/N&.Y>Z+PVK\O.1$Z_+Z!=VYF. #DU=\,? M&OPO9:5I&FV_]HWNV**W6XM],F,+ ' 7(&M.GOF<2&:2 ,= MPQ@\],8%>W4EAJ5*.'J-R:N_=M:[_/\
KY>_5EA:5&.&JMR:N_=M:[Z>?]?+ MK0VX9[8KB-9L;JTU"266=GD^[@Q_NV4\!5SD@<$$D\BNU9&"$)A3C_,_MXKXW^-
OP,\;OX4\1ZW\2_P!H"_M/#]JQ2QTW3A;P.3GRXS&KY?)P-HR3ZU\S MB.90]U'#@,+3Q=7DJ5%#:VDFW?LHIW^=CY>^)?QO\8?$^V71]>OK273].NYT M1-.B\J&[VR$)(X!
(;"@'1>V.>IS5CX ?"'5O@-XY&]VB27VAWY6/5]+5+#,@^ M]+'GO2)GCH&&O>Q'F%V9]#L+";5+6YM((N/,$LEL2IS =T8@!A],U>=] Z3/\ M3/B%X?\ ">F6PN7U2\CA&(Z?(
LAZ!R M,@=.O0>M>YW=Y%9VL]S.VR&%&D=O10,DUGZ)X7T?P_!#%I>E66GI&H51:VZ1 MA0!C V@51\7O]N>PT9>1>2>9<8[01X9_^^CL7_@1K[>FIVM-IORT_P S^5,7
M+!#3G?"PE&/\ >D!/\(Q(/#<,JZ8+BX4K=7KM=S]59^0O_ 5VK^%:M!.22>1 MHK0X@HHHH \Q^-VB//86.K(N^.U+0W Q)V-R,,?8, #_ +U?,FO0O;:Q="4% M2SEESQE>V/Y?
A7W-+$D\3QR(LD;]59^0P/4$=Q7EGB+X$VM!<&32]M((NUG M>QF6)/\ =8<@>QS]./F&WMY+N=8H5WR-V';W/M7TE\ M >%;K467$:$.(LX7 M!R';(9R/H
OXG':I]#^:!"V\@^WW*0 Y:'3H2A?ZNW3\!FO4["PM]+LX,2TA M2WMH5V1Q1C 44)]&FVNK6QM[RWCN8"03'(,C(Z&N \7? 'PCX]MW"6 TNY9
M]YEM'=%8]PR!@O/M@UZ116].M*G\+L3**DK,\5N? 7_"'+;Z/8^\ M.FKMCC MO(U=I78\G#!ODP2>""#U).:LZK\/;W0V@,D4NMI)+Y?E60:/"^K'!QGIQQ[U
M]#^'E'6M_;/N<[P[&]5_P#%L/"&DZ?]GI]6]GV-V5QC>2]$C!POCP M=V]3[UYF(5IL_34ZJ%'X?ZNKWKPF_F^7UQ*.X M:1CSUZU\&?
%%$Q236C0VEQ-=1$K)+"A(5,9P?QYSVKR#4O#UMIQCQC)MO[QCP M=V]3[UYF(5IL_3Z[J_45M6 C\.!EMVCO;]5B#(6 6-1_> R?_KUA^/8?MGAO4KBZ
M/VB=8\HY&%%3V09X_G6F M]:H_P""/YH^BI\[?D?8_@K_)$_0_\KQ@_]%BM MJL7P5_R)^A_]>,_'_*+%,5>G5^.7JS\3J_'+U84445F9A1110 5!?2!\'G/_ M +C?RJ>H+
[_CSG_W&_E36Z&MSR[IF;_DFC?]A*[_/1IKUBO)_V9O^2:-_V$ MKO\ |&FO6*[\P_WNKZL[L?\ [U4]6<[XLD^UM9:6I_X^I-TN.T:\G\^!5KZ# M
]*SH^'W^(=1NCRD&+6/VQRWZUHUSVLDCS?,*****"BJUC]=G):RM9W<%VL,MABD,$BOY;CJK8/!'H:I4; G?8Y#_ (6QX<_X6(?!'VF?_A(1'YGD_9V\O;M# M??
Z=#785X>/AI=?\-1MXM^V)]G-KM^S>6=V?*4=N+.^TT2_GT[UBO=2CA9[:VF>(HH]2^(^]0))\(L MUGI&G@!+++'8L.#] 2>OS5TGBB,64MHT]A.TL\HA\RU(93TYYYKY7.
<#6E6YJ M?O+R/4RW%P4>,,Y?7"5QN)^M=9XC^&A\7:9'ILEQ)I>GF0 M23LGS7,N.@!SM0?4'\"\52-*4'*,I*I5_=7G;HWN]4D: M>HW]WK&IS7M^PN;FZ(\V14"(IH4 *
N>F/]?6O*%/BK59M5GM?-FL8XW*)\% ME6(0DCD]N*1)+TU;Z[U\;*(R-1FN#"B7*>2D)VYVN,3C)-?'..]"UGX/2V/MA?
4+N#4)KWQ!!;O+;QX6*V.BJ2$*X+;3C&2<_2B%"I7;,_$^SK9E@\N482VM-MHDKZ=_0YGX,))]ML!JCA[M+9B?-(R&XQGWP;IK6IY+C49A(3A&*JIZ "OG/P
M39^)PS^(O%5Y$C96X@T^Q3(A '1BO7CC)/O7N%[\0]&O&TS[1:W-O?WMQ': MJD0RK,W3!_QQ7D8_"353E@^;TV/&Q#J59+&NFXQ:ZK5>]UM?7\[&K+-&_A_6
M+>Z9/LHMF?]>XV!PZ=:W?A+!//\%$L,&1&:1X$?]D)A%9>3^/O%. MFZU!_8-LKV=OY@FEN,Q1F8HQ&W0:05P&'*MUIWPT\<_$;0]1EN_$\EEK7@6:2
M58=3C!6>%E.U(XT'S/N/'!W#ACO&,5ZV2T.2,Y3E9!/L>+F<:]_C!*FW&^Y1FE*+N>!4HU*$N2K%I^9=IDO^K;Z'^5/IDO^K;Z'^52MR5N>3?LL?\D: MTS_KZO/_
$H>BC]EC_DC6F?]?5Y_Z4/17?F/^^5O\3_,[LP_WNK_(G^9ZV>_ME?EQXB_Y&;5?^OV?_P!&M7ZCGI7Y<>(O^1FU?_KJG_|.1K5]9PK\5;Y?]?4\ M,?%5^7ZGWA;_\>L'_7-?
_014XZ5!:_\'KL_US7__-!%9_B;Q?I?@W2OI1UB-MZ^R6?F!+%YFPN=$'@/_ J@+493ERQ5VSQ5%SERQ5V5;'2G+TKR_P #?&=-M?
\5WGA{6+2'2KTONT]XY=\=U$>5PQZDK@@C@\.HQ7]"]*]M0J8>7+45BZU&= M"7+45AZ]]??_%3XIVOPXTJ,1QK>ZU=?+:6.3ECG&Y@.=H/XD\"KO@GXAVWB
M&.'1K^2&W\516HGO=/AW%83W7=TR 1E9VE.'2FU#?:C:.39R7=]=P6-K'R\]S*L4.\XY9B /SKD.3J6ZA'/-1ZAJ5IHU]]SJ%W;V%NA ::[E6)%). "S$ 9-0Q% MP=*4=:12"
0001U%*.M2B21:>O:F\]!GZ5+9;I9:A+!)%:WMM=2O?ZQ+>==)& M3_> "DD?C4LGJ7*E.7K4-KO2F+UIZ]*E M@/7I3EZTU>E.7K29
]>E/7I3%Z4]>E02QRT]=*8M/'2DQ#AUIZTP=:>M22.' M6GKUI@ZT]>M20.HHHI %%%% .?$; D0O$/_ &#Y_P#T UB? ?\ Y)%X6_Z\ M4_E6W\1O^1"\0]_8/G_
/0#6)\|_P#DD7A;_KQ3^5>BO]R?^)?DST%_N3_Q M+\F=]1117G'GA1110 4444 %(1FEHH 0#';%+161]?B6TTVY\EV9BF#,R*2(-M@?N[L#]>,*,3I*_8G%>*_'?
X*ZM\8_"PZ$MQ;'P9HU[-?ZO8RL=URX4"%=_MN,,,Y!R1@$]M[MD((JA3Y6!!!4G@C\:PJNG;EF]S>ABIX.HJU-V:_MO^*M]^NG9GL_B+P5H/B_13I&N:-8ZOIA 'V2\MUEC&.F%
(XQ[5X)\6OV(O!^_MOZ9;,AX L+?P+XNTR03V-IVZ"-W'(60+T]G'(/J,@^'U2#WXF:+\2--?ZTN9 MEEA(6>TG&V6&GID=P>Q'!KK:6]S#$5OK%657E4;!$K)>BZ%NBBBJ.
M<**:\BQ(SNRHBC)9B /* #)]:Y'P5\5_"WQ#U+5[#0-2-]=Z4 MVR\C,#Q^4=(}U8 'YD8<>E=[_&?Q$O;^:VEAU"X'E" M$G(_TJY:G('8T ?
0M%)0S*FW@:5]B6JNI:I9Z/:/=7US#:0+UDF<*N?3GO[5B;]X MT O3;&9K:^M;]\-Y4:ON0L!QO9?NC/(J MBD]6P2[EV45L=/7W8K=]?DC=\2_$BYUDSIIZRVZR, +X
MOM?:#_ F-/8GGO7-7&N7MRR-<+%=E1M:2-1#_X_VTY5C^ ^M4)Y)%D.]9CD$BWSR"O*_F.%]564G=L_3*.7X>A!0A';KU^VF2F: @QB.]I^ M0&:|Q@\|
_AZUS7Q"UFUL-"N[(L3.]#M_L%Y&KIP#_VRC_BC^-/1LK:GW+X^_P"1 M/T/_^%@/ 18K:K%%^%B?H?_7C[_P"BQ6U7K5?CEZL_"%OQRI6%%%%9F844 M44 %07W_
!YS_P"XW\JG]"^_X\Y_]QOY4UNAK<\N_9F_Y)HW_82N_P#T:.!4 MGE$,,DAZ(I8_A?E?]L\W_ "31O^PE=_\ HTUZ9K!(TF]QU\E_ 037?C_]I}>K M.W"
,15/5G)V6IVGA_PH^]ZC,+>V4|@ %45^+?A%=.AO+G7 M<--26=:58M1#6TXE/1#$X# GW'2M&70K3Q)X.32!U7-I7]6@1!T^9P<*>>,]>.:IX3^$/A]XN$U+Q1]%C?
6\OD2327#!B_0(&\K8 MQ4':<9P#SSS5GX;"OX>^,=/N-5T%==L##>,RS272[UFQ@R+PPY48YXQVJ.L M907\FO5_!GCN+Q7\\O%=S!8W.GGW=C--O>93S@.?
EF4YZ/@CL}>O:'XFO?$Z MSQO ^GBV;RY9(\@R/W"AN4QWZ^QGYKI?B%CI;1Q%B(82]ECD\+U/O6#>W!LM M"0Q'!^JH,TSUKR\YQ]50C%O5]>MD:8#!4ZW0K2Z!H46K?;9
@O\;=_M[7#;NF/7VIVM^)+KPM#!Y43ZC%<.(HRY+&)CTSC+.#Z 9]2!S7-XZ^|:^BW# M-;7ELQ_=^477_9(KY##8ZI2]]5SZ&O=UI-V9YA?:?LTZ\2'S>(?\?B>ZETN
M&026>EVS[98N^T$?+"_,W,L>[5]$0Q+!"D2YVIHH4;B2<#U)ZTRT9Z+8^2I8>G0"RCNPT9N)S(Y4K&&QA<<6X)YXXKG_C?X5\0^-X?!4WAD-+':.M>%>731W(A M'D?*
<\D;N_%=\4=#T6ZT5M4U>>ZLQ9KM^T60#2%6."FT@@@G\JXG7/B%=6] MS!?AV_-AI=I"D<,@C5Y9L(#DEP< @8QDUSK$/"U':6JZ(A9=-,/"C034 MM>9]-&FM=?+H=/\
%;XEMX/@:GV:1G4+B$D33.52+=E4QCDN2@=6 8YKR&S7-M3]:/5@DL&A!*.N6+>O/'\N^%)2& MX.6KV.AVVT%Y+)+<.HR/E8 G!&#&ALX]>:YO6X'AL0]!<2WT#.J/
C++,H0>N[MN1[9J&VMF[VQN+,V=@M\[(+1'BD4+,O\ .!\V?E/&.00>..YX3E!W@!3U,3AZ. M(A:O%-?UUZ!<>(+^PN?DT22VLI9@L$$LA:6$$)*648;'|QQR:YCXD^'M>)9
M6VCI.+]V>11S7-I#*'IY:#G+L3RNGFIGH.D7S^$]:@&G7TT-S+&ZQ02QB: O[@S(P(Z$@=|^AKU"Z\,--XW\) MZC:.PDNB3V;13EH@)=K;MJ/''!RPW_+M(!^,'?.
>%ZG\03:Z7IU[:VBR+KHUG M#W>C.+'Y?"NE62:G'5-;Z=/\KEV_\+/X?TB*[*6MWIH-[ETU"T4^0Q8_\M4;F M,D^N1GC(-=[\#-
;NHKF]LY9FN=+GF\NVG9MV)EC#,F[^+Y>_^SBN8F\;ZC':.M1Z=HK/H>BP*8X8"B2SR+DY:5W##))Y!:\;&>*K[59H_#]Y)!YS SZ;>1
MPK%YGD>'F,,96P+E6@FT[WQ]R7FK6O M;>S^1[K3)?\ 5M]#_*J.A:NNM:>DX0PS*3'- WWHI!PRGZ'\Q@]ZO2_ZMOH?MY5Z-K.S/AU]>3?LL?\D:TS_KZO/
$H>BC]EC_DC6F?]?5Y_Z4/17?F/^^5O M\3_,[\P_WNK_(G^9ZV>E?EQXB_Y&;5?^OV?_P!&M7ZCGI7Y<>(O^1FU7_K]MG_\1K5]9PK\5;Y?]?4\,?%5^7ZGWA;_\>L'_7-?
0157Q(X?L?%.C7.EZE M+)PB7N\VNIZCT8'L!0>0:M6Q'K[_US7_T$5_.F>&I,_N+U1XBDXRYENCY*\$> M#+KPAJ\7A,5YVZC3>E-!UOIH),1&Q?12V,C^L,_:J9\%?
&QU^'NM7>OPN-< M\/\ ]FZB;AIW)VH3Z$L'W&>]>IZCH]AK"P+?Y4%%ZL@EB$\8?8XZ,,]#7RM MXK/[%NYZ_;(.G3_ (^*^FHU89G%4ZL=5;7UDD[>]>OGJ?

*2T]D,RBJ=6,]MK-MZR2=Q5;^>HKZG]BW\|OK]VK:GX\U_!TNU"[A90L2$E_O=0@[`%C7OWPC^%T`MP[TAY+AA=;|>?/>W9.XY/.Q3Z]3W//I6EX$T:PD\.>&M3>RMVU&/3(8DNS& M/-5"@RH;KBNLKS,;CG57L8*RZ_+9>B[=]3S<;CG5BZ,%9=?ELO1=N^H^OF[_M (*&/I$/[+//B,;6I);6K**YLV^RI=M,'<9U ;>H/3.<$$&OI&O#_-M##X5^(MOC/^SUKWA3PK;Q7NMW((^"9=O>^.M,KH^/8[/Q)%;!,V_]]LES9Q&51%'-(H)##+*$*01M88[8|C^+WP,^-^E?&?X6^ M/OAOX:T36KSPSX3ATBXBU?4(DA6?RFCD!4NI8 ,<$'!KE=O(]AWXHM^S5X\TV MYCTB\\?^.?$MIK=QI6FW$<%E:)'*T8*S83/SMP,. #)KE:=WM/1OV?OVG)?CNWB30? $/AJ7P7X^|+S"#5]$DD|Q%SP)(VZE<]CG]"""0:\@\?7 M[XT?!?XT-\4?A'I.C>+SKNBVNFZ[X"/%?COXE_$Z>P7QUXSE0S:=I;;X+&%;,4W#(+<*."I)]DY7+7-M%=,\5+)>;S]5FQ69[=#*S$'\; 8D=S@'C-3 MS?\ !,#P'X9N-'U;X<>+/%/@/Q/I*^-PTZ@C<'3"X)&>AQSR"*[+|K MK]FOQ/\ %34 "GC _.&VKV^B?$OPA*9-/>[.V"[C)!,3G! Y'&1@Y(.,YKA8 MM=_;7^)%|I>C3>&/"?PLM(;B-[Q9^/*_A_6_VOOVNM0^#6K>)3TGX;^#--B0-3MK"40SZK,57ER!CDL0\.! M\O$D2_ O\ P3T\+_.! [XH>'_%OPT\8^)?!MK;29U+1UN_M,.HQX^X2XX|/7 M(;C[@UF?'S]G7XI^'OC59?&OX*7NF7GBUK);'6]!U/$-OJ:*,;ERP S_ '2P M(P!#9%7? AQ[\I6_O&^)F@:AXNTKPS*_!>G2>9?Z=;NE]-J2XP4XDY?M@ZKXAL/@'^SE:_%N^U.73YG'_ DV@VET(M3O !\C%2C$9 MYKM_'G[!7C3X@>+OCIKDME::=JF]:A;ZMX/U(7D9&K^[@\"0:C&=(T'5KH27MHISEV3/R@]">YQW% M?H(O6OC_/9$^\OQ.T_XU>/OC!\4- (TKPC]WB2W2TA\/.3,LBHH(ODB*LPS\ MHZL2O29+UJ[!*O2F+!T MIZ]*@ECEIXZ4Q;>,E)B'#K3U!@ZTI;DD<.H/2@=1112 ****.,< M^(W_" (7B'_L'S_^@&L3X#_\DB\+?|>*?RK;^(W_"(7B'_L'S_^@&L3X# |MDB\+?]>*?RKT5_N3_P 2_)GH+_"36=Q;SF&2"1)0<;"AS_/7KQ>3E M>NYY%> <^.Q!U^S!\0;FS\>./QP<=B#7WZ*_/_P#9 M>^'-]K/CNP;2))DCMYDOKDD?ZJ,/E WH6;H/0'TK] !7I8>_*=N'OR:G-^,&| M^[T.0J37@F<>JQ*7_P#0@M5|5\5Z+H.H:=8:EJ|C87VHQV=G;W-PL^@CBGT]=,U"`MPN;>4=6ZS&94C=C^Y8L64OAL @@!E!KJ.H|U;F%[F2W66-KB-59X0XWH&R% M)7[2#C/7!Q26UU#>PB6VFCN(B2 |+AU)!VD CT((/H>.M?)OA/X"Z-K\]|I M[>---WB[3[.%?$F=_+5F1)P8FSA3$D@!&15KQ%^S_P'%/#FB M32S? $6WTO2IHH!';3DNOQ:K%&@EC2 M;P(,:E/E^SMYGID.#E\AMV%Z8KU+Q!\|E% ?N7$Z0O[H3EA^(7'XT 9MAKSBO+=Y].L9!F-&39FW.1SGFJ.C>$;?0K]\FL[^_6>Y;HR"0? 6NY(P2!V- >2>,>PHHHH *** (+V\AT^TFN;A_+AB4NI8S@" MO&O%&KCQ+[S7H]!02A|K>YY5XE\23Z_=:,/D6R7A M(6//Q_$P'&3^E2>#]=FT35(T3+V!V} (A[G@@>HK1\6^%)UU&:[L5CGAEQ(8 M(?\ 6+D2W-O=W@%M$C"00L<2M@\0,'-G@4WC*/^*/Y MHVH1BTS[L\%?\B?H?\ UXP?^BQ6U6+X*_Y$_0_^O&#_-~ %BMJO8J_'+U9^" M5?CEZL****S,PHHHH *@OO\ CSG_-QOY5/4%]_QYS_[C?RIK=#6YY=^S-_R M31O^PE=_^C37]EQ$)X)(CT=2I_$5Y7^S-_R31O\ L)7?_HTUZQ7? F^^IU/5G M=C_]Z?>K.3\..?[*2%^);9F@<\]"I_PQ4^HZ/9ZL|FUW LI6DZW.:)(V2#@.M.?4U'K,1T#5&U$@=[E|SA:G_U3CA9/IV/YUH @@$$'D$=ZP>NIYB[":M M\|_",NWTMW>Z49IY+C[43]JF"K+W=%#;5+?Q;0-W>MGPWX3T;P5836VCV4>G M6KN9G168C=W)))K9I,9Z\U-AGAFN_M6>'YO&-IX6\,6<_B6]N9# IW C&!#T M.T ;I<=R,*.[5W.B:7]=O:SV.NW +S'=;Y(.!Z9'R@C^Z/S/6MKPS\/O#@G@V M\O[O1='M=/N[^0RW-Q&F9)6/]QR*YB;,,-98SU5QD5AF&&HXN M"A35K=7J1@Y5Z+ MFW*1Z@\Y!.B,0$0?P[L$ GT((<<=ZY4>*=" X:#/A,1WPO1;!bI0*.U;G&=V M;]FMK;&TB$<$:Q1CG:HQ7@TF_]>K+._K$)0@|G8\/N^VHM*\% ^-.MY/"GC'3KK1VA5?\ B:>6? *^K(,D+_MH67Z5[?9WD&H6L-S;3)<6\R"2.6,Y5 MU(R"#W%8WB_P'X?\?645IX@TFVU6&)Q)%YZ_/$P.>[<\0?%'B?P MEXAD_LY+F#1K&Q6>UMX=.66TNMJL95GF_P"6. H"G<.2.&S7U=25+ECR)H]> MQXE*-,I>TDG'IIK\SUNBOGRV^+GQ5N4DE3PA"1>A9K&-,"X<1J\.E8VD#;2 MP))+-A? EV]34]M\7_BA%;PH_@8W|P/*64II]U#M!.&DY)!&,OM'(QM/)%8";:"!QGXM\1:A"I7F*X.77/ARQ^(&I76H>&=2BM9CM M^U:?]%N\90XP"7'(!]"..U>F>)M!B\3.'=.;+(T*S 8E49*,"!QWP1TKCO M#_@\|_#=-0\|OZQ>K<^5;F-4M(&0;=^\ p\ $268G Z"N2M%SOB6)>[U/.P-:-"G M*]3]-5;V2M=.]O(\]UWP]=-&-;-E?2P33/-LJO;,^S:21@W3{WZWXRU M2|U&8PWDMK CE8XX6V@'OZFO?2$NM76N7U[]MQ+#87%P56,2$,D*#A4R<9X MSGW)KR#QMI<>E:[((L>5,HF '0s]<>V:\"KR\SY-C|0P2]>RC|8UG;7U-SP[MXJNM0C5KF-K^YLDEP&LX67$A< M$%5['<,^G6N%\,>&;C7;S.^2SMHE$C7 4AB#G&S\CS7;0"6&SM;BSO)]4M8B M6CN))'3^%@^=N5QWZC'>I39O4C'5&O?6EQ]5C-! <0Q&2,:1KMH(L/,DEE7 MN-W:O'+NU>RNIK>3!DB78N&/ M*PU"U,+46M$]^QYWI^LW>G(4MW5X78.89(A+&S>NTCKI.:|CTXSZGV9L+6D[M7\LT2NUI:1L\BJ,X"\@ _X5RNC?$!=0U>VL4TU8++>5MB%7RRG'' &.W:O6/|_MC&U\';+XAG$22ZP\D;Q1RDJKP *N[O:Q MI^IZ80\.;3ZCIMQ% UO(D>W:[!0T911MR#@<'GBNBGI*-5. [:]#R<6\;6P M+P#X:U%<%F9 B!>IGT9^8QW)/OV6/\ DC6F?]?5 MY_Z4/11^RQ_R1K3/^OJ_P#2AZ*ZLQ_WRM_B?YGHYA_O=7_$_P SUL]*_+CQ M%_R,V]_]?L__*- :OU'/2ORX\1?|C-JO_7I/_P"C6KZSA7XJWR_4^IX8^"X:N/A,+

M#/XX_"76_#=A<:;]6K^)KJ.^E&I74BS[VGW,#&^G*\7^_M?_)4?@;_-C3/_Z;!R@#V<=!2T@Z"EH ***** "BBB@ HHHH ***** "BBB@ H HHHH ***** "BBD) &3TH 6LRZU@M.UM81?;+E>&.<1Q_[S?T&34#W,^O2-%:N MT%@I*R7*\-(>ZIZ#U;\]?=7EOH4,5E9VXEN7'IFUBX)]68]AZL?YUC.HHQYF M[+^MC6I*GA8\],? M_GUOV2U_(\CN/A?;R_$M+F?Q5IZZI)<"[_LY8\2$#' & M_/:OFH M>\^6SO>/1OL_(Y:>;9MFBE_:D%%0;5.UO@TLW9;/R"BBBO7-0HHHH ***** " MBBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ** M**]:N:)8^)-(N]+:U.UCO=/NXS#<6THRD]'@JP[@BKU%`PNW[*WC2WTGP1.MI5K?^'(]2PM?I.OY-TH>SA6_^UD):CR_F? "8.T#KD]*QE_8,^(T&@7'EW?A M&74K8I86EH\DXMKFV%I-;FYE;RB5FQ-O"@,/EQNYS7Z T4 ?'7PA_8N\]2^'/ MB!=RZKKMJGAR.SOH;?*
4M$N9K;59GN_)WAF"CRA'Y/RLKDG=VKT/X'>'KKP)\ M=/B!X77Q/XF\0Z3;.?IEU GB36)M1>*20S!RC2$E0=J\#TKZ"KQ;P3_R=/\
M$G_L!Z1_;>@#VFBBL3QK%J4WA'68]'+KJSVQ$YD>.OC;HOO$N-_M&'5]0\>MX;>&S2P-\+9GCW"1DSR.Y!U!%JMU+.,FGVK:;B49>0?\LD!M[>PJ
MA>;.+H6@PIS@L5A,OA.KC*? M-=:>7G_D7M2U ;9'#9V<2R7DHVP0#A5 _B/HHJ?72=(73E>21S<7DW,UPPY8^ M@!%*84S1M,>T$ES=,);^?
F5QT4=D7_9'Z!:TZ=..#F_:U%Z+M_P \MEUO\S3 MA*K+V]?:HNW_ 7U!,+JV4445UG:%%%% !1110 44P31EF4.I9/O#/(^M$'?@CXW*>&M8TW4KJ?Q M
P$=Q:^4(X@9!'T=U:0@D$K&&8+\Q&*_/\ P4!\)-HEW>Q>$_$\MVDRFUT\ M16XFN[4PO/\ :D)EVA!%$];6(;@#&2*](^+Ol,OA7XS^:+-&U_7+K5(0].C6!
M]>RG5;N%91,<3(@920 X!RA5B."<<5P[_8&\ #+1+RPCUGQ/#++,K07Z;@GVB MTMQ$\V6(F/=}5(ZX8%N<[L@4 ;?@@BKU% 'PNW[*WC2WTGP1.MI5K?^'(2PM?I.OY-TH>SA6_^UD):CR_F? "8.T#KD]*QE_8,^(T&@7'EW?A M&74K8I86EH\DXMKFV%I-;FYE;RB5FQ-O"@,/EQNYS7Z T4 ?'7PA_8N\]2^'/ MB!=RZKKMJGAR.SOH;?

*%%%% !129!{T9H 6BBB@ HI,C/6EH ***** "BBB@ HH MHH ***** "BBB@ HHHH ***** "BBB@ HHHH *\7^.?)4?@;_ -C3/_Z;fRN; M^*WQ=\5>'?VD_W@!0/$NASQ:FT,EYX8DM%^T+9;V%Q=RW+2#R\?NUAC127< ML#D9VYOQ !>Z]XF^.7P=T_4OA|KWA>SMO%%T8M5U*XLG@N=NG7B@(L,[N-P^_M8;E' YP>* /IT=|2T@Z"DD)6-B.H% #J*^4_!GQ(\>3?$F41;G-K9N)I8SI= MQMC@*KNVA2!\F!W"7'->R?\ "5_$0C(\&61^NHX_I6#KPB[?DF_R%6?U>7+4 MO?T?>W8|(L,CUKS<^*? B0^3>$W +C@\EOT|TXUH2ONODU^:+HIUU*4$|/)^?EY'U117$+ MJ'Q!E3C1= A;U?49F'Z153N?^^%P#C'K1.^R_KYA!*:0^> MWK?_ "0LU1N!|EC:U MN+F3['DY7 4= .WR_A7O5MX6|<0Q&-K/0I4/5/[2N(D/U6.)0?QK*4ZCTJ_ MJ!/_P "ZL)T-'!MZ|.+3SU?_DOS.MOO$##R2>3).NEJW2)<2W;C_ &47.W]? MPKRW1[V:\^*[Z-;^#H-,B0F4:M-:,UTIQG52Q.W)/K_]:NXLK3QUIL>RTT;P ML*>HBNIUS]<1Z_EN|K]TD>1BZ68XGV:HXET8[2WTS>T8:2>3_67$K;I)/]W].@]*O5Q?F_$+_GS\-?\ @7>1M, M\K&/IP8C/\.,YYZ5Z@:3XH/|14"Z#_IG;3Y_,D_RK513WE;[\(U23W=OO M/0JH_P!N:=|N^Q?:[7!9G'V?SE\S/IMSFN"N]'^)TR8CUC1U/]"ZC|4_K7D M(^'WCFX^*RW=YI$TMSYHC?686,4)3;U$]D2 QZK*&U">*PT|#N%M/(JR2GL7&> M%_V>H[^E<|;^ -2\R.2XTW0+B5!A9+E[FY<#_>D)-6)?'"B!#_HQ>$+>"|NM1D3S%FMXU>WV8R6+AN / MI7=U\PP^%?B5;?M'V.I2P74^CQ2+_|(:O)%;>01EE"9X&?J?>OIZ]RI.WLD MUIK=WU*J.F[>S5M-?4*9-#'<1/%*BRQN,,CC({]"*?4<|R6T+RR-M1!ECCH^MYVTE=F#:2NSD=6^#_@_6M;T_5KK0K1KNQSY6V,*A_P!Y1PV.HS74V.F6FF1L MEG:PVJ,*X/Q#\<_#OAWQ'9;1*+!F9[C&Z>*/Y(\G SG:\NH\.= "<$<_B*X,/F&$Q2=*A44I1=FD|CS,++'E2C*A44I1=$HRE!V:3 MV>YYOXG_&;_ WC,_P#$>H:WIO\ .6J:V8BVH7*QOLZ MX_98\)7.C1Z<]]K6(X;B);@?2^,F9P[OG9C=N (XQ[&N*^,WQ3\<>%/B/>S6 M6LR6'@[3!:B:XTS3K,4X+=W;YQJ*&07,*D8V-$,=2:R=)^+?CS2H+3QG?^+(M=4T2Z\4OHK>'"TN%/I'+[5>"6/$C.H^;G=GTKT#U#U:'}F3P/'H(T^2SDN;O M]+]L.LRK%)OQO,$A7S@@(4L.5&5!5;5/V6/!>KP/"<2;]=SW,J.WMOO*>29PY= M&"Y#*P!4]O>N. \)WQQUJ&;1?%'@!Q!%-X62]@M;^PETG8\2/)M>:.Z\XL,D?9 M3%'R>3D5YYXJ_:(^)_@R_P!0AU,7]W^MWS6OAZUMK73KBU\GSMGF)(DNXR_<M[9B]\|,4 >XO^S%H]RK7EWX]\57OB87$=S!XEGOX_MULR+M58P(A$$P2"OE MD-WS6AH7[./A;2+D75U<;KKUU);7-M=S:Q=^>;P3D&5I!M SP NU0.@%>0# MXO?$'4-!\/C3?% G\3&|ET__(1YM"A^VWMQ*!)]H*2-'%"D9):6,@9QC^[M5G1OB\1KGQ? K6EZ|K@\,SZH+H^'WFM=/N=/$<3@$B2.75#+C.%*?@&?2@# MO|(_9/\ "YCZA8O9ZSXAN+*WF@N'TVYO4D@%?A,>|^6?&@ 8 @#.<5?ZM4/V1A+K-UK$>C6$6LW47D3ZE':HMS(G|UI0-Q'L37F/P;^++M[-\,=:U;QU/<1 MWVA:C<65[NT|_:D5&&SS8;<.I<@@GRLKR,=ZG^*_Q9N]-LO"H\-SM$FM+<79 MNI+?;(MO! 9625>&;@#<./2@!FE?LRZ?IVA7/A^X\7^*M5\,3121#1+VZMS M,Q!F+@HR0+("K'*G?P1WKF_'?[,4UUX?E^QZSK7C'6GE@"S^(}71/*BBSL50 MEN8RH8AB&C)?NU>3.:?| M)_$9_$B:N!]J?\ PBZZK:V4K3Z19'3HH98LGS)T M83B7<1C:A3)YXKTOP'\ M4WFM6EFCZ%<2Z8+N'2;W79+N%;B&ZGW<65ME3:Z MC R0P]E/-_&]\(O@KXA\(^,KW4-,F7$4MM)%<7=JQ+:B9"#B2/8 JH,J!DC MG@ <5Z7H_P_)_!WAN#48]#\,.1H#:A"T%S+I5C%;22*000611GJ>M*=0UOPUL>A-?VT5M<6 M&GQJ#:/Y?W9/+50-^.-W<5Y0OC#QIXCUCQ/%#X\M?!MOX1BM!*NM:9;G|8SQ MB1Y+LYQ&G.T"$K@\|CTKT_\ X7MX)M+6=[SQ%:AK61+>XEBBE,/G$9*HVW#> MO!.!R<4 >@T5X\}6A/V@6^<&N:/8VFDV>KV^HQ+,MQ)$D. S8]+RI:A@YSN M%<[h=OBMXL\;Z/A[4[31K?2[" M^>.>U6%?&SQ-XR^P^!W\(>)VT#6BGXY*YB% (R2M,I^P%XJM]%E$7CG2CK%NL+'"5]+D)@6 M);4^:HER9MLS-E2%RH&, M$T ?47AGXY^_&?C2]\)Z'XGL=3\06<(N)K.W+,1&<0VMC#%+;79:[M\GS_ #)DD' \D;=@!Y.36_\[X?:\-OVC?B5L@6IQ.6)T?292ES>SW3,B M9\G?.[MVZ9Q0!\&4444 %%%% !1110 4444 0%O[<'[ASP)%R2C'U*GALCYC_9,\1_&*U^-OB?0?& (@M/AR\%S+X=M61%"! M)P!% 1^$5L.DAW+!O Kf*9*0<'N M"#U!!Y!'((!'-+A)I.KV3^':?&-FO\ I^A73@R)@X\V)AQ+"QY617-[#;)!*MVMI? QVX9RPVV#9$XS7BX^4\)3=50HIXYXTDC<.C@,K*<@CL0:?UKS_3_AK'A&Q MMY_#TL>/*4W.A7CXMF? +&%P#Y+!$YX *'^Z,M\NA>.K#5[P:=<+++I.L@$MIF MH* (YL#]4YVR+_M(6%,O]WL]S_K^NYV0K7L]BL_ZV?Z;G24445N= 4444 %% M%% !65X@\262?A]WBFO$O'25_ +46=E-=-G&>5B1B!|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f)G'^S71_#OQ[MXQ\2^,/%^G:]X3?0],TZX6.SO#=12;QY2-C"G+9+$[AP.AY%=EHO@K2M U_5 M=8LX6CO-1CABF^,Y%2+>45%Z*,R.3C]6)K=Q0\E3?&?X@:3X%@.H7]AY>]2 MWYT^^MBQO(A!J&S$L,YDKA5&W Y,)(L^)/VG_.!A!8"6P_P"$7EDU.#4S M:Z9.22S.GIQMHY"&FBSB0CR\LH"[2=HW9S7T_+H6FS0I&!A:O&FI:AA4A=QR MV!CC)Y/O7&>`/=@=X9\_^,)/$D O;G4.RF$7ETT]@\:3\KGDD@D98MM!(7 XH M \|\%^)K'1/B%X>TBQ|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|*Z9]>M6VT1WEQ#ER%.5##=G /(# X[5%HGP(^WAW MQ9)XFT[PEI=KKSRO.,Y8.R+(_P!YUSG:Q!D8->'_!^^*7B_P[\7M2NW\57, M7^X*PU&U1O-%%C=6MH7>,]#?6LFVZ#N2-LD3$ <[>M4?"GQ9\5^&D\%> (I1\;Z MCXG77]5O+.,I\-/96\S1P))(!));Q+-F.(,@ELUU"'?1WB+X3>#O%OB2PU_6 M/#FGZCK%CCR+RXA#.N#E0?[P!Y&[.#R*S\\ ?ATLVM2CP=I.;65*WW^C#<$H+ M;CQT7+?,=N.>>M?/>M?M%>,M5^)VJ7.G3:EHWANRN[?3K2VO;>WMTDEFA9D^ MT6\ZK,WL-,T_7_&6N:&MO;V=W]LFTJR>_N+F4L# M9V00-&RNP&QV5SM&M74^ /PZ2XUF8>#M(\S5T,=|FV!$RDY(QT&2 3MQDC/6OF_P +?&?X MGR^/++3O%6IWVEV|E=6.E71L4L65Y;E&*F6%E|QGX7+Q,$4@_*PJK[WQ+ ^)^ MFI[:XRUC7M'UG7Y=*TV>Z73;>YC2W0M+(LIMQ&N]QM&Y6X4]SF@#Z_\(>"] M#\!:)'I'A_3+?2=.C8N(+9< L>Ks]23W))-9WCSXB7BZ9;3I5O,]O+"LD:27$XC\]P1]V-BP? LZ?#.V\01.Y'X*T==4B*E+C[/D]57.1)QD#@'&:MK\"_MMJ]G MK%GX8TRSU>QCV6E[';C= >=K =*5R<$@D9XKY\5?$CQ,X7U75_!NE?$/5[_M %:86DUG-X@ATVUDNWX?:)]ANT!BW2?P+-$,8-6KTGX, &&[U+0FT&^N?$&K M>)TO;BR$VK)N>3TO(GW8B\N>5W6YQG[ZLH8=@: /6? ?@BQ^'WAFVT:Q>26.-G MD>>8CS)K&8LSMCC))K-|>_!KP5\3[JSN?%'AVRUFYLT9)KA6WQJWW@&4@X/ MI7S!XE^-?Q0A^'^DP6^N/[!BWM4U<7F76AZOX3&HVEK%8M%_I((#22L3N(+?PKM 'KU\H M]#U/]G[X=:UR3(D,J!P)9"K8$GRD8&0:Q/"'Q.\;V7AGP|]VO:W M:]]W_P)A<:#]$=M:+##-$S,]:%Y*[-O&22XTB73%9YQ'YR06ZBI3V-MB7XK3>,DNK>VEAT^:QBEO8I92<,AM4&8WP2]E"1CIQ%`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{2) M/BGXC\,ZMHLVC:%I7VY(_$,MR)%G>R:- ;H&%5WH%,J]3DIAG@5YUX4,;V^$M ME^T5X\UF,OE;HMYH^F0P3_9+DAW0S:ACRLC&X=1WH ^QZ*\)_X;D^!PD:/_ M (3^S\Q5WLGV6YW*0}XCRL@<'GVK.UG]M_X$ZKH]W:)4;2P-U:LB7=M%<+) M&'!59$/E=Y6*+<%MO+"]G5079>22X&1CGVR[_;6^&,"32'XHZ%;QCS-KS:-*@) MD 1;CQG#9$TW9 &WJ0#Z1I: ^ ;'?QN\':S^T9H/C6W`;++.C^$K*QDEO_[& M;^&U>=!LMW>#&&C+,Q\-1;68$2:9= $IZC^S;/]B2Z/<GX3+?

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|#%Q*ZCYE6P".>"#6EX*.;\.ZM\&_#_Q M!\5W5CX*L=85GBBU"|4C[!*H#$#<2%W8 XS77+"5X;Q[?BKK\#5TIK=?TSU] MBLSPYXFTKQ?HUMJVB:C;ZKIERNZ&[LY1)&XZ<,/>O(?!_P"U;X4U7QCXIT#Q M#JVC^&KC3MRV/< M.*\QU#XRQ.%\3/$&BZNVD:,X9T;2(=0N=7FU1!+#))(5"20]44CHYX-;_A/X MN^"O'H_&M'A*ZBI./^?W;]M"W2FE>Q(!17(-\7O!2^"D\7MXITI?#+_`=5:Z00$YQC=GKGC'7V]3P,\5?! M_P 0Y)( _#/B73~=DCA6>1,'Y64HC&A68#ID@:]Q=*MEF33Q%=:*QNF7[PC /S8[^E#HU$L+^X,22'6T5Y]!^T%\-KG7H-%B\< MZ%)]L\K01VBWR&1I%."N,\'/J/BOX.,Q/-X='B73#KL 8RZ>+E3-&%7"@]1Q46G?"X?ZM:.S=6?C+1;FWT?/]H2QWJ%,:!QESG@9XS0Z-5-IQ?WM;R2[`<45Y1XD^.]A)IWA34/!ESHGBFRUO5%L#-_;T<*]O5S'G.]P\X.M;FD? M';X>Z]XA@T+3O&>B7NL3LR1V4%ZC2LRG!4 'KD'CK5/#U4K\K_X;OV^8_9S2MO8[NBN%\0 `3X>^$]>?1=9\9Z)!FJQH9*M+F]1)$&.\@GCZ'FNM@U]PN=(35 M(!R!M->(3K=[QY9C(SNW=,8YS6;ISBDV1;3<6M6B[17%<#__(?>!/B!JESIMWAOQ;I&M7]N"9++>RNTD=0.IP#R/<4FF?&GP'K7BV7PO8>+M&O/$$9*MIT-XC M3;AU& >2/0^0 278[6BOG.Y_:MNQKEQ86_AZ"5!XJ3PY!*UVP|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|*\ M ZA=VFHO#XTGAM|/$42EHVD"E3+EAM'S#,.US_Q0_;|\(?#;Q;+X7@4T|6_%F MOVZ"2ZLO#UG]H-J,9_>'(.."#@9QGG%8PPE>,2C!N]_PT9"I3D{)'N5%>1Z1 M^U'X"U7X2W?Q$:.^N;'0K20P3QWELT=PLX./)"?Q.21C:2/?@XPO G[8?A7QA MXKTS0-0T+Q)X0NM7_P"07-XAT_[/#?>@C?)&3V!Z_4BG]3Q%I/D?N[C|C4U] MW8]YHKP?XC?MD>#/A]XWNO"R:,KWB34; !M2;0K'I0EB."=YR#D Y, <=.O%M87[$7Q&U7XE:-X_U+4-:OM:M5\1S+8/>R%C%;%9$4'[HP>G:K>"K1HNO-62 MM\[C]C-0< G.">5 QDD5=%^#?QZ^'BC1;W2OBJOCK2IKE(!4L?$<)01Q$Y=XR"Q MR,@R& (^Z23R!79_"CX=?&GX,_ 4T#O-+)OB%/_#TOC6,X2>&-7T0ZI=,S'$2? MM,"3 6X(V_*,9'W\G/ KKEE-6,XQ!?L M4_$7Q3\2O@XVH>*KE]2N+;49[.UU62/8U] F-LA&!DY++G'.WGD&N>^.'Q-\ M>^-_C/;?!WX9ZA%X=0(!{:AK7B"6/>]K$W18Q5@X*\CDEU ( )KC6"G[>5!M M>[>]Z)+]8^OE]!POL?3N;6OFGPE\)/C!\-?<#_^X,22'6T5Y]!^T%\-38_C&GX^XF":K;^(82 MDD$>"2T1!8D]AAAR1D$9(W_'W[7_ (6\&>+]1\.6&A>(_&%_I0SJC>'=/^TQ M6/A[O17R5^T-|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`O_ ))@\3*UDOZU_P SX M/A_K/@?PY\,]4U[P@-7AM M_$>L:E=>"IYH(+F0S-B&6."1@LGEJN=O8,.U>K_L:/;`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|UW7] M?U4DEV/B?X?_\UKQ=KGPITRP^$U\/$\'3)<:MK>HPQ1&O]UZ,MXF3O8 .O0?V?/%-WJ=UX1\I^&_'# M7-[K;W5W]NG6NFFP93)N6Y%U*OFYQC*[@>P]*]*?X%>*]=|_'"Y@T>>U\5Z MW?FWT^>[\"QW%U9QQX1^PD /H'3S7V3@48K2>:U9N_*EM^:?XV14L5-ZV/B# MX'_'Z_M_&.D>(.[PM\0.'A73W,2:AI^G6T<[;.K6R) BR2@!B<^.,"WP^\ M2?#CXG:UXU1>7TO3?$%>W5D8B9/[.2QCE7.(S(!DE>YQ7V[@56U+3+76 M-/N+&]@2VM1B,Q2PN/E=2,$&E+,ISC/\ GQ;KOFW M^-=$HTUKXMUS43#9R7*B.>ZM(U5=J.>BR 'N >]?7GA_P /:,X5T:STG2+._M+3]-LXQ%!;0+A(U'0 5H8]JF:3#_ :Y;2^'-*DC@M=5MM,T^*[9DVM;J8D5W!YP[9JZR"GPW\0VWPV\ M M,$5#S.H]HH;_ /MW_P E^ GB9/[_6O\ F?FUXUG3PS\.?%7A/4? EEK6M:QX M@=5|9QW=K<1S&28;-C!C+YBCC8!QWKZ\^/?P!UWQ'^SE/X9\.V[?.H16EM&; M))/+-Q"MWQ ^K $5TVG?1[?#32/%Q\46?@G1K;7O,,HO8[8!@YZL!]T-[@9 MKT6JQ&/C.5.5-;Q=]>^GF]-/+T0ZE=2<7%;:GS)X*LG\9Z5J%AHOP4N_AWJ5 MKHDEG::.]J=M;VSQS,FWRH]OSD'^_ =>*?"+X$;_3M7S6FFQ64]_M^_$L0YQ<6MQ:***\DY HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@#YO_;N\-EXJ^$FEV6F;7=ZO+_ &Y:M);V=N\$M>7\P8E5!.W!Y->G^&?A9X8^'G@O4+?POX;L=%DNK-O.6QM@CRMY9P$(Y)SVK MT"EKK>)G[&-%;)M^M[?Y&WM'R*1'Y5^'OAWX@UGP59>%=*<^$.OV_C_^V/M.M/B^2UDM5MXO,R 7(' &.O QQ7T7]OPBU;XL_M^>/K;7--O&T^W\()H]MJ%Q; MLL,MRR*2T;D8;#KGBOLC%%>G5S:=1N48V>O5O=K_ "V.F6+E)W2/S@^&OP$|M8^+/A#\5M4\5:1J1UNWT]+1=(@NK5UF9+?:WI M2,L'%501UQ7H>M^%/VDZ3 M\(_C'X<\.7>]ZUH>C)IVL^'Y8FCNGBP0Q"$;1\GC&1@'!&;^W,48]9YK4G*[MBK7VZ6:LT)XJ4G=K^K6L?+5A^U]XP|>:QI.D^"O@_P"(7O)+A!]$VO1&UM[> M+/SX?&,XZ$^G0YKT;Q1\ [WQ/\3K7QD/B!XITF**2"5M!LKO;8MY8&5*]PV. M?7-> OXI:X98F.7>A#DTMWO?U,'52?IM6_$^*;\&Z_)\4_VE+A-#U?I4=#2 M.RF%(4GNG\OJL1QAS[+FLQWX!UR7]B'X9.1;>'=1?5K;4[&6:QBLI#/%\SE MV:,#*[I^T+'6M"M?M+C)8^2_I@MT M)'(SR#7VABC%$LQ4KP=-I[^H/$)ZS7GB74E%HLT9##_6I\P)7!VD,1C]/T!Q1BE3S*5*FZ<(V-M6MM7I?\,(XEQBXI>A\5>'O$7B+]EGXQ_$J/4_A_KWBRR\5ZD=1TO5-#MO., MI8L1"Y_AY,!ST.3@@UV7[!NAZYH_ASQ[+KOAZ[\-7-[XBEN5LKJW:$(&C0X M3"Q.F:UH]MDSM#DX=2>",@."@R,$XL:,^U!XP^(_BK0|) M\%_"37A]RG]WOB&,VD5O!_'M;IN'4$]<8"G/'T]1BH6+A*\"C5J3BK)W>W MFEO87M4XI2C=H^.]=/C'|E'XZ^.?%EEX3U#QC\/_!E*EY=?V1'YEQ97 SG*.M@>K-UP"&'((P?1?A/^T?XQ^.'Q#AM|/^&FIZ'X$CMW^TZQKN;>?SN'GEH1AA MV*C)YSD8P??\9HQBB>+A5A[!-.=K7N^FB=N]@E54E[T===KGYD:5\$_%.@V&I M_$ZQ\(W]|KWASQQ-+)!%WI[L=0L&8$,D;+|\^UB<,H/#9_AKTWX[%8?V@M)\? M^._A[KGCSX>:AX?BCTZRBM'D-C.1N99(3C.^2OG8V>+;=VCYA_83*ZR%+;,Y<7>C^_&5]UEKO0M$U MY MEK 0<]+R-?E',_!">^3G?&SP_P"_@OQ^%\8_'WAVA)8:]J.G+INN:78@FYMC"XVR*H!)&%0Y .'I:P&R/[_I1UKC>-DZ\]SBFI:-?KOTW[F/MW[1S:WZ'S M5X0 ;F\7_%/QSH>E^$_A5K=MH1F_XF^J>(4-H((L'/EGH6!YQDEL8 &@?!3X;IH'A3Q79R M7WC.WU>|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|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|\+6\83 M*\G#M@\<|. /J4=!2T@Z"EH **** "BBB@ HHHH **** "BBB@ HHHH ****.M "BBL/QG?.CI?AZ[N]+$+7<*[PDZDJP'4<$G06-G'Y=O"NU%Z\4/V-L!$^:_E:WW _9\FE^;\+%RBBBL#$***** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****.'B MBB@ HHHH *3-'+KP|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|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|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}],O]D0V-K*LWV36+5M0NTU.XFS&!{]VR M0,KR[?;'GN^ 1+KR_62-_M4'R_>P5I:"*5<5XK^T+_?QSC_P#2*ZH]!'04M(.@I: "BBB@ HHHH **** "BBB@ HHHH **** "D)P*6]&M7#0V12+_73$11_4\9]HQYFDBHKF M=B+2A]KNKF^;D,?*B_W%/)_$_P]U*BM;=+2WCA3[D:A1^%2TYRYI76PY.[T M"BBBH("BBB@ HHHH KWM_;;;;M<7=Q%:P+!Z69PBCZD4W3!4LM6A.UC=P7D M0.WS++>59%SZ9!-<9\5_A=_PLGPQ?Z9']=Q92W07!=WDA7!_YYY-9OP;^#!^ M%N@_8)M7GOH!<-.#:L\$1SC@QIB#0!Z9+,D$9>1UC0=68X K\1_$'P_X4T2 M?5M1U.&.QA"L\D1\T@.P53A*^>[<_8QU&&.Z;PY8^'M'FGU*]F++VP,)-K)Y9BB^5.BE2=GW0> M1UH_^J-?\;;%X7T?4-4U35;.S1

@B]^'/PQT+PI[$HEN[.$]^+@S]F6)VARB;@,X^ZH|`!0!W-M-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8_M"ZS].D?# MVY&D^$M<\5ZC=,K;

*>'[>UFN;)V1@+@+<,J';>V>I>/-4 MQ_BCX3UGPO)%9FWLHX-(L+#2Y(PR_O)/*D>5{AL9(SL7G%>S?M2?$#@Q)\.?*

*M=]J/AB]>QO!+U86D3PQ=.;\2A5B1Y%NZLO('SDX'3O7GO[+?QI\??$?OS?.?X MHU2.]L8K,RI')\/=0T`!]P&?/N)65N#]P#/?M0!]3TAZ&O'OC9\<=9^$GB?P MK9V_A6'6M*UBZCM'N!]:Q732.Y!2WM@<C-*40&5R2]A1USQ7(_"]LW2?%MCK M=_XKT=O"&G6MO::A9W"327WGVMUO\EG6.+TUU^%RCXFTWQE>?*

%76=`N3=Z;=^+)WAF,3Q[AY,0^ZX##\0 M]]H ***** "BBB@ HHHH ***** "N/\8Z]>SW4>@Z)+Y6HW#*DUV!G[*A&21ZO MM!(';@GJ >!_;@^*4WPTT71FMK":]N+R6388T-Y);^7LVLE=E\)X MHM3)/V.M(DBI<6R&,S.7=RP#2R,Q^\6;C/HBUYE7$1J57A(/WNO=)_\ Z]V MCNQ&%E0P=/$W3=5M)76EMY-7NK;*Z7O-;K?L-)TJVT73X,.TB6&"(8"]/S)]M23R3W9]1TT-HQBHI16R.!))6044450RIJ&D6.K*BWUM.$WBH.C$?E7C_P"RI^W3X-_;=\/W MVH6&D:UH-S:7PLFM;FSDN5;<,HPEA5D&1U#8OQ?_';X@:C\!_AE MJ?B/2K%=2OK22W6.T89,V^>.,J/F4;B',.D#,.\5YE*M,L1X8O1]J M2\L#HQ,1O6U2*]MK9(5D\SR?+(G+%RV, `/!% `T;17S%&8 MK+P99>&;42ZFGB/2Y]2NI+DW;*

*@6&TDRL8:V?=*N_,.+P;fGP'\9-?\]8?$ MG0-+DT_2$\,:MX5_MRVU&QND)Y+B8-;A]H9$VQ#SB 6&YL9(7&" >R4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V M3'EMG,,=NM.HH_`71]-7_AH.)_#FD^.;30/[.!N/^%D6FKW(+>*<.;?[@VK MG.#*Q'3/&;_8G.!1M^OYUY%^U;?0:?\ [Q!-/HOB;Q(!Y6S1O"4D\=[>MYB M[8=\ +!$OXD9>B;J /7<_7\]5_;%_Y'3X)_]CG'_P"D5U7R9X#\.?$ T\>? M"O8WCG4IHO[.FWLUKJ-M8VMO]NN6UB^=G(VI@,9'(K5+3_-C_,*

*M_%SX1MXKO_"=QX25D.%^]A1DI,#B@#ZE'04M(M.@I:_"BBB@ HHHH ***** "BBB@ HHHH ***** "LQ_C]HSUCM&S_P-O\ 9_,.MK=;_?*

*P,=;M+/*D2@$Y=@,U7T*/_0%F8AI+@F9B#D9/0?@,"MHIQBY_(UBK1YNIDMX$&6DD.%7ZFF:;JMGK%M] MHL,F.Z@)*B2)MRY^M5M4\-V&L1SI=1,XF4JP\Q@,?*

*3.*KZ%VP_9VUO;QR M!8]\I,K;PB+B[>R_L{4XV:Y6150T\([PQ.4(<8'0^ MU=M\6)AVGQ5\$WOAB?49M-L;YD2[:.!06EA# O%G(V[@,9'(K5+3__-C_;/>*

*M'&JZQX=U*YT72=WG-HP5IT_P EH?-$DCEAE6Y'3>5SF'IT6D?M*^$_$GC : M!HTWVZ0SVL0NG?RH95G0NC0LP_><#[HY_(UN_%CXR;-\;?1+K75E6QU*^6Q M-Q&I80E@2&*@%FZ=%!-<%X4_967PKXAT>_3Q5/<6FG36MR+1I) 7D@#]#O#< M B0\8[=;ZOQ#^SIX?U?Q;8^(I-Y]-U.+4DU&Y=99)ARCU"'\N[" *

*]BMXXGSL6/$,64@,=G'3!(%*GI0 M6IZMK-VGA[X>;YKNBZ/,%;GZ?1RPO3V\S %D2W8H3'N&_!&.<;JQ]-_9BUCP@?\ $*

[\.RWEJ,34I3ID5P9U\QV62++#RI5#E0WS#OMS6A%^SQK>BZC> MQ^':B1JVBZ#J<\5SJ5K]ECFO)IE"AWCNRP,9DVC?\K=\;G3^&?LNGZEJLFD6]U%K%K/-

*%\0_"BY\"Z%.?#]E)<)=)).C:@JR*X?YDF<{U}'M*EL5@6_[.6NVMO1UW;^,=,TOQ'15T]QH]_I'AB&TMU1TVRQ36ZRD2AL#G+= 2]U/P]?\ AC4%D>&?*

*3K_;S/RG\!NA*NAZAAU'85=\3^*M M+\&Z+/]VL70LI/@QYDQ1GVYX'"@GJ*<=/'7PA^(CK&COI6N:UXMU=8IBVIW_M\D,-C'+(6+,(Q(KP1@1aO%'?-*

=Q\)_AK>WO@G6M%\56.JV.DW5RK06-UJDG MVE %&]O-BE+&<%@_0]!TH] T'XG^&/OAF\0Z?]L MD.%X]O+?1X=5GU>;3M;M'U6"ZE=@8Q()P6$>,@$D$\D$T =?*

*\5/VF=(^&NF M>#KC[%'=3^)U,EK#?ZE;Z;L.!%,+O.P4'Y@,#O76^,?C7X(^'-CI4_BO6K?1 M)-2B,L$3]IBP !<@OJV57(RW0#G.*YWQW\'/%/C6S-N/'<5BDD,MG+&-!@EC*

*M>WD0*ZA6;*OU*L&P,|!V!5K5O@-87]MHEM!JEQ:P.5H=W<0+V)9)XA&7))' M(QG'0T ?MA>%[ROI]XP\]HDI\MU8:E&Z@HT!]R<YKWKP;X;7P?X5TK14N&NEL+9+*

*<3.H4OM&,D#IF@#:HHHH ***** " MBBB@ HHHH ***** ,3^+)G'PP\6&UUQ/#-R-*NC'K,A(6R;RFQ,2.0%ZY'/% M?*

&/[^G^(]+^+5Y[VMVUE9RZ&=0M=)CU^]U%M4@GF+QW@$Z@%RPSR_SX8# M KZZ^-7BSP'H'@RZTSXA;O:Z3H6NPSZ<[7B>,=9MM1?O!HT?*

*E65S::M=6JQIOWLI2*158,0-P8'8S;(UR=J+A1DX%=[2'H: /%_ MV>?^1J^;/_8WS_ HF*O::\6_9X_Y&KXP_\ 8WS_ /HF*O:; "BBB@ HHHH M***** "J]_?0:99S75S((H(5+NYI ?*

*YZ58KFL_P"6:N,'.CV$O7M60HRO^F2>*KN2^M6\EM;>>)Q'&5).X*P80\P/5E'3]%'K?41]R1JK.9& +D $GUXKQ,'AZGURM*

*MBG)N$E%13M96O=KKJ]3Y[#_6.^85\)94FW2DHJ$=+14,[?:UWUW\]+.HHHKW3 MV@HHHH ***** "BBB@ HHHH ***** &2Q)/&T(NWWF*H ,GU]JEU_7X=*

L+FYECEE,4+2A$1B& MP,XW $#\;Y[P+\3K7QM#<.ME-9F)U0#F4-D9ZJ,#\;Z8X:M.DZT8^ZMV;QH5 M94W54?=1T'B,POI?C'2)-+UFT6^L)'CD:%V(!9'5T.00>&53^%>=?

*$'IF_PQ-MXOTNI73K>#-1-8N)GN!J1B;XVO)/#/*=I=2"SP1G,$\+>3<=/MM3>\NM.:"[-W4J2+(XV'_F R "3S&\]VWAC]DKP-H_A M+1(U&&ZU*IL(IB-*

M5MKVXL)YUGF:;6-V@E5FB+N2(W9@/T. ^ MTN[T_2K>SGTO3SI5D8 56"U)0F)5!P%S%'VS\M?.FG_%7O!XND\1Z@_Q=TOP MWTWA?3=.N8;V#3H#8ZL)8?,>\E27,GD2-

*NC18G4@JV&8XQREI^T%X]TOQW!>`M7NI:[)HLGBC4[(BYL;%M)N+*U,A-M;>4INC=E4_=HWWV5NIHXH ~UJ*^?OV:O MCQJ7Q+\/>/*

5O$$K7$VD:J6CT^PTV<26=#]M%+';]3&'FE4LX8@$ELX&W;F M7X^_$[7XO"@"\'SZU13^(->AH]/HKR?XK?&?4?!NF:!J'AK0X_%%G@]L9F69!>LH3:K(P^S6L_!#?Q;?; M-

*>%ZO^T]XY\..QKT6KW%O:Z1]'B:RTS0[];88LWQ:O<64VV!DO'+(R.P#?*X M.#M% 'V917S7^SW^T/K'Q_^)VO:5KK3KI6L+-J/ADSZ9):(+;&4Q-&DC*!<;*

*MUV3AE)P'(Z"OI2@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "B MBB@ HHHH 3%>*_M"_P#(Z?!/_L%Y'8*B+)) M[^C<+#F?`7AZ#QC,0Z-+A2S"8R[=QC53U'UZ?*

C?1V5G%HH#;0(X8D"(H[# M JHH\3R"6]E4K+<$$>]H/NC^OXUI5T5*DN54;Z+\WN;SG+E5.^B_/%%%% !1110 4444 ,FFCMXGEE=8XT!9G8X*

*ZDFH[.]M]1M8KFTGCN;>4; MDFA8,C#U!'!K{\5_#W1_&-C>VU^D^+N,QNT5S(A''4 -C]*H^!OA1H?@'1[* MPL!3>& M/VKO!VH> [/Q)XB-*

SX1DN+M[^R[V%Y[E957>!LB5F.8R'&!T/M7=_%7X=P_ M%?P7>>&;N_GL+'^^9%NS;]"TT(8%XN>@8#{(YK533OV0?#/ASQHNL^';VXT+3 M,^:&' Y&0?R-:?

*BW]!X<^!O$4^A;WXC6TU;+81)9;.XE*LX)1,I&PW M_2%SDXX%<+!O>E6VJV+WOB"ZU\1H(KAETR:V11.R(Z9,BD. 5<\#TZUT5 MK^S-HFEZF9]-O(C3H-*

*=1M+ ^*RC0,D7V>-D6,,Q+$'<3DG- $%Q^T;<>(M2N8 M_AYX1N?'^FV%O#N V*R-._9>U+PI'+%X2^(F MJ^&XM0A$.K>390RO<[78K)$SC^ M%,V[2^O=)BBC:XEF*

&\K=G]XBR;07&"3S@C- ':%^VA!J6]V<5UX7B6QO9K MJ"#^S=,'8>GZA-I6K6PNH+K5K*VBCGOK6X+ M&2"4@?,,MD-U!&:W_A;^SQ9^*

K;7(I4U9O$)U6UAL)$6S2RA%O$NU%,<1Y$;#7?$VJ&>2&RTKQ)!<6:01?>EDNU3:#DX"!2<^G6N@\=_I_ M:5XA^'&F>$?

#]RGABTTR^BO[0_95OHU>,DA6CF)#]<]S6&G(//B"W.EZI;>. MXJ.\5Z:9HX-2LO#M]M#;M;R_>BDM0VUN1D,""#ZT >]^"?$5YXI\-VFHZAH=[MX,/&FD>

]&;5=:N'M;%?6,R1V\LQR>GRQ MJS?I7SGXR^$WQ#T77K2'0M6\2>+B.P,3:CJ5RBPMN):.176=3'+,_"J^65 (MP1C->D?#KX;OXB^&,=/U.+3WOGFM+"_U'"7[5#""-*

*BO+!*6ZY.-YZT 6_M'W[0^A>#_A2_CZPL[WQ#I27$<'DVT#PSMN?:Q5)%#$CDXQSCBL37OVJM$T_2 M?$-_IFE7>OQZ?:V=Q8QV4BF34GN5W)%&.S#D'/H:ZS7?*

@CHFH>|(/PMITEQI-M.G6MJ#?)B5[A|R/OP6E9FP3[\5YR?V)O!\GC'4=1FOKZ?P[?:BNJ2>&V.+99 ME3:H1E(94!+,%' +&@#VWP/XNL_'OA+2]?L RVM-

*LRH_P!V">]GW!R#]*W: MX?X2?"]Q^#V@7>@Z1=2R:(;R6YLK.4<62.=WDJV264',\\UW\ !1110 444 M4 %%%% !1110 4444 %%%% 'F?[1_@W0_&GP9\50:*

[X0M/&\5IH\]Y;Z/=1; M_-F2)BFPCYE;/ 9<-SQ7R-^P#J.@)\5KJQ\.V7@76X9=_6ZN]7\)>&'TJ;1Y MC(!]@GD8DRD@9RV'RISUKL;^(/Q-\/?"W3;74?

*$UZVEZ9/,+.;1G^(OQ@U_PE;>!9=-T6Y$TT.OP.SQ7 5PJNY$*Q$2@ M]D,*?'?X5ZKXQ^(GPM\ M1;2NH7#Z'K#/1?LS_ ?XG>%;9Q?#+/ M>?#:\N8;&<!]186VHG4+V+S/M-*

VL;,Z[90T?S-ACMY H]B_9X_Y&KXP_]C?/-M_P"B8]HKP']E#3=2TB[^*MG[^L/K^I1>++)Q-J4EM':M.?)BY,E>_ M4 %%%% !1110 5FZYKT&@01RW$5S*CN$!MH&E()(-!"CC)

(%:#NL:,S,%51D MDG KY[_&E;36_B#I&D#PE]@T^"UN6$MI)?&TAG9BJ]$;/[S:W)(X'8GFN; M$571IN45=]CVLHP$,PQD%67)!O63V6C_/9'L.H:G-K_P#96FO)!E0;VZQM*

*M:W0C/ECTD8?]\@Y/,,SW\.6\%MH.FJ(-\84^7O%$ X)]B?NCWR>QK,]*K_PB M'@S1--*)=ZL,5 8X)-_G2[1OD+]U)R2Y>)Y(%=#I&F-8D)+.XFO9SOGE QD! M@/11T*

*_J36+,K/V:W>_DNWJ_^#V!/#QU2-2I+!8=^Y%ZO^NKZ+[*UWU=RW@CM M8(X8E"1QJ%51T '05)117HM'"T@6W"\D#{O}!R?8&N.^%GQ1U'QYI<]S>>'KFT:.?RA)!@QD?]*

*M#(.1WQG^E>=4S.A1Q$<'*3YIW.5G;3?6UCR:N,X:ABX8"#/%-I]FUGPGH MF]V_VEKSRKS3X15\|OO2893]Y'5NHUA_M"ZC=:5\&_%%S9:]X7N%M<+]% MO),.;3+*

*&0K&*X4 G'!)UWQ]NB^$H_$-Q#*>.M-I(K3I/^)8\D<=OJ9$(-.37PMU\Y"6 M-Y&@^'Y;$8QKYI+%V;*E1N -!I(VNG6E<+.\:!3*^T+N8C[=B]U_GI*

.U9OBOP5X>|=Z),J49G^:3 M!!4;Z /L&;X?#ZYTW3M.E\#^'9;#3I&EL[5]+@:.W=CEFC4KA22 3CKCFN0 M\1?LUZ?KGC"\|31:[=Z;JC2":UEM+2V4P/\ (&+D1YG&$*

EW;0S8/3'F_@# MXFZEIGQH\2P.#'Z_\3-)EL))L-,M[):FTNUO D@GBN/)2SVABJ1H?WB1EB" M0">[^+'Q:\5CPGK=|-:0M-N;VZU8.ZZG-9K[\=M?VEND6^,E8AY99F< L/.8

*M@\I ?:WKQZ_:^%/#FF:+9%S..?;1VL1E.7*HH4%CW/'-0W_@KPJ]ME MFW=IE?%'AKX^>*O!MOJDEGJ +16MEJ5 M\)MI>/K-UJ^FPP?9H6#"Y(1IF.)F=WWKE/NJ>X]<\"?*

%_O]X!\9^#YWU6TU6V MGUS4/#\ESHZO'8ZK;1.?:%NXXV9\)%'386#,,`)S@`T&GAO28WTUUTRS5], M4I8L(%!M5[*(N/D&WY<#'''%:.:\K^^?*

C36A\,_B0\&C:OX2O?"I+FW\;J8I[C2DU[4]&\<7>O75A8R M,HN)F\Z,&T/)!=_=H+'(VB@#[?HKY$\%?'3P)X"D;2]\:6:[XQTN_P!4:VL;

MR^N5NH("L:MQ(L5Y,X,T8R/XG(9MH]!Z%9_%I_&_@K7K[PEIUZ-:LH0]O9W]F MK/+O3?#(L?G(&5UY,B'UVF@#TJDKYX\4>,/B0OP"\5:IKMM/X>UJ&146>TL

*M%M98;8E1)*JK;SC'7B@#ZTS2U\$WGQ0UZW-X(/&N/86"W+>`YTOGP?!+XF>-_$WQN\=P^*-,U!1X%TR&XL!)U"W M5\+6R599%_5E=@IR !BWT\/(!]+45\,_$'XW?*

*%CQ/LAVUMJ5H-YJ5U"2V3 M:);S6[HD5\83;S,TC"19%).%[C!%>I?LU?$SQ\!3_BAXPUN^N!Y/#VIZ=9W MFD:5<[E6SCW.C':>C,ZOGO@+0!]*4444 %%%% !1110 4444*

%%%% !7&?& + MPK/XU^&7B/1K:^U33YKJSD59=&G\FZ))V(^"5W8VDCG!."#S79T4 ?GKH/P ML^)%OXZ^",LWAOQ(NH6&B>%(K;45$@MM)2!I#K,-

R=X")&8U(<$OP!RM>S? M%/0OB'IWQ<'$5SXE\6Z'K.@2>,O!%T^PT%[.XAS:?1CW3-?(%W8],U-+]UE M, ZV[@C_ -^51_6N/\=.SX3O;>P36+R/"W4;0%#-@8/0\UTT::E->T

*M3Y?(WI03DN=.WD=Q'(LL:R(P9& 8,.A%94C?V[=>4G-A"WIQQTE8?PCV"?\ M+UH6WNM713<,MI9I,_^3"^YV|_M.. /9?SK4ABCMXECC54C4855&<!4:4]5O^*

M7_!)TAMO^1)12$@=Z,UB9"UQ7Q#*YK"RO39W$LB!<$@2'=]TXYP.!0 MD 9S7G'Q!^*.C>"8H-:U?[1)L,$WDQ?98Q(TTQ[@9'RJ,\YZ_2@=KG4>_,#U

*MWX6*X.V7MZ;^Y@4AIN<=>@S@>]=!?-^ /'VE_$QF[K6D>>+1W:/;?2M0MM1A M0X:2VD#]#]12NKVN:>SFX_*[=^A14444S,R]<\3:9X;L+B\U&!BMH(%W.6; M) ^@Y-*

*5_#/C31O%^G17NEWT=Q#(2H!^5@1V*GG-/\0^#]'\4V-Q:ZC8PSI.N MUWV@/]0PY!JMX6\ :%X.TZ*STVPB1(V+B20!Y"Q[ECS7E2>8?6URJ'L;>?->_M_P!UK'B2>:?*

7DHJ'U>VOQ<_-?[K6_$@^)_B?5?!O@+6M.T31I-?U2S@,L&GQ M!BTI^B@L<=<"3C@9KY]T+]WQKXIM=*T_1F\%:CK-_JZ:<+M'O8XH08B[+/ M:R*L\,@(QAN&ZCTKZ-|*

*<>"M-^(/ABJ!T+51.+,Z4 O:SM#-&0P\>Z7>2Z:-+34@D%[,JAE,#2 .58,.C:2O/6O*fK]K/QK M,:7?VB^&M/N=HW-K;Q^49'=XHXC/A<;=^W8W53BO;I(_9\%*

*M:5X:DTF337U.65Y9I=7U&4SZB\TGWYOM)^=7.!RI&,#&*P8_V7=#BMV3Q5X MP35YV42ZT-8/VQXE0QK"QV;&C"DC!0GG.=W-`#V/[6UI]_CRPT738=#O;$"*

*MUAN+MFO(H[]>>,NHAF,1BBY& DS*S'/3%-U;I;Q_H=MXHLY/"FEZOK>F36L M0&@F[OX+629B#!.(HV=I$7YCY8[\@5W;?LI>"X[]V:SGUG3;*)(?.TZTORMO*

*M<2Q*1%/(^3(NXG<",GD@TSPS^RYI'A/PQ-HG<,^&4=H9A)=AJDB+29-3LH]5E0R1V+7""=U_O[.B/P>5 MK^RXZ2"SMEU/Q&+!"K7UE ;C&'5'$GF;!E2/F;=R2FS.*

#D#%>IR>&-'EUF M'5WTJR?584\J^:W0SHGJT28W >P-`AOC;]JJ^\/P>(+VRL;)K*RN;VSLA< M"5FNI+,$/(25X5=QQTR0/6N6^&OI9%UX@EFAU]!*CBAELV74-*

/@O8XPDR.S(M8IU5PRA3^\&Y#]>!%N/\;M+UJ[UVWUBZFET>ZO;F^L8[.4Q2V[7.82=6."" M,@%3VING_LF>$(Y8H]7U'Q:XGNXEBBCN-:U'SG2",$+ H554)\QR,9)[T 5K M[]J73)M%N-2T[2-1MTL#;W=U!K5J;9YM.ED\L74!R05W$<-@XZ@5UOQ)^+UE MX;^$?B3QCXB:Y\) ,#6L>!=5\)0:?'HND:B MA29='C2U<'(.]2]X#9 .*

<&@#Q3P[^TMXHU;PO'/;GPSX@UK4[^VT53H;&WO[M'&;52Q;=EAZ=>)O6R]\& M0524[T8'C:2V>QGCA^SE!MWX=GT?5O%OBW7H2]4UI<:AJ2F?3Y8_N2V[I&I5*

MA[Y'[BN-\;?LNW+16,OAW4;O4[<:[>YN=>\0:L[722,]JLNQ8C'(%5<"\;@] M#WH]WN_$UA;Z5[%_,#,M_'8]YF2S=9'#,E, _>]B17&>$/C;8>.M$UV^T[2*

*M=4L&TNW.9EU6!8@Y"%AC.[9Z<]*P/@A\%M0\"1ZU#KT.E2VUW!%:-!9YDCO M@(.>560#<^>5^;CN.]"TSX.^%M T[4++1O#^F:'#?Q-%^M+'3M6T^Y .UL;Q;E#;R#?!*

(6'1F0C(I'Q'7_P!D;X?>_M(DT$W%K?13Z/[fZ5%<076R2.U9@S12G'SCC\B1WKI.?#7P9>_%K>(/#^FQ MZ)=>EX#MWX=GT?5O%OBW%%%% !1110 4444*

%%%% !11 M10!Y.^TE\./&WQ-\#P;7X'\4CPS?K="2X+32P++=1;&4QF6(%U)#8 PVW!X-M1_!CJGG3_A%!!MS:ZG>QZF+(0ZI;6,!0Z9?7&!ON?!G,<|E>,1) M+Y97:H)/0^M8?

[/'_(U?&'_L;Y__$3%7G/_4,_9B\;?M/_#SP[HW@G4]/ ML+S3]0:YG3496B21"H PZJQ!!&<8Y_5E5A4]0<:,E&71O5+Y:?F;T)]E44Y M04[7TDVD].MFGYZ-7VN?

0'AGXH:#K=A:..]CZC96CW=NDQMVN5+1EAG:?<5H M'QYH.?EU&.4^D2M0_P"@=QUYE\/V=[CPSX"\;5]GB55)-3LK&&WN9+2.56) MI%0!BH-N3C(,G-=)_PI2'_H:=<_%+

(_^VU8KZRM'R_>_P#(SG43FVJ-E?\ MY^?_'-_F>0?MF?%S3O"OA;0+Q_$\WA:S>Z>-KJ>-[<2L5&U5+=@;NYX_&O6? M ?C2^N_ V@GSI,0M8PDWH]F"-

*YN4'SA$SG/7EAUKSWXX_L+>#/V@]#L-+\6Z M]XAGCL)S<6\MNJK"Z$@!AE+=O747UC&6Y.=.G] MF$DFH/6[4E&$1-WU4FUV6AKC^SM28-J6HS^(G'*VMK*

WV;/^X@(;_@;&N# ; M#U34WT324@;NA6WG.0[R'<@#;,*?E'MGGTKO/\ A6U[_P!#SXH_\"+;_P" M5X'^U_ L.ZK^TUX/T72;7XF:OTV7OVG&JHES*

ZD8/RQK&=PQD$DCKTSFN MGZI3KIT\9[U-[I-QO_V\GS+7LUVV..O1>/C[''R:XE.7<[1U]!Z <"N@R/45YCX5^"=SX9\,Z5I \?`M^+++D6-K';>/%?_@9#_P#&:ZHPA37+35ET

M_KKZFT=.C'DI'T5M_75]V]6=R74=2!]32[AZBOC7!MCX"?'+Q!X3\.)\&/% M&JZC]$=\QU"/4-1MXI:&0H1D9D1=H.[>,Y(VX!P.I>\(_"36+;PMH\6M^,_$ M/HLQVD2WOV'4*

*L'G!U&\A=V<#TK9J"FGKZ?K?]#=]/*FGK_7I;'J.1ZB MLW?7$VD>%/1+K6-4LM)MGD6)9KZV2%&<_=4,Q)/8=:Y,_A53_!0Y^*_P#P*

M9+_;KP;IK7]@N/IISPIH.FGQWK5A)I=T]P)-2F-ZC!E"L!&<-'CANWI4Q7, M[7%%HKS#PK\#(O#/AC2-(3Q=X]:?:16JE=6< A$ M"\>U:W_*

*JB)C_BKQ6P[/]9D7^6*3T8GHSI]9\2:9X>2)]1O8K1920AD/W MB/\ ]8J_!<17,,^(N]Z+/IE\ MUQ*FLW4]Y#*K #< &!5TQD=CD@XZU[GX<^'',6A>'M+TV;Q?*

XLO9;.UBWWN3K M,R&8H@4N5!P,XS@>M6^3E5KWZ]BGR\]MN>E;AZBO/Cf\<+'X)Z?H]Y?ZGI& MF07\SVZRZM.(D9P 5526&2/?M'_L&^#/*

*MVEM)T2S\0^(O%5N^DW+3P3KJC7)VN)$VS;U&X*OS &B4/M72G&G-2E'F78^B]&O6U+2+&[?;OG@CE.S!N64'CVYJ[6?X>T*T\+Z!INC6"L*

MECH]M%.0[EF$<:!%!)Y)PHY-:%8MW;,.FINZ"BBBD(*0 #M7,^(_$>]>&?# MFJ7NF:5)]$UO9RSHP9=H=5) *Y#-TZ+7G'P ^,/B_P"}-*

CJ,VX"LN22)6RV/]FN:5>$;BI.]WY'LTD3R>'+/Q)?:C:^ H?$5PEQJ.D:YJLFE7).F. MR"WE?;<(HE"]HV9T$A^5B20.D\8^_BH92",@^M1BU@"1(D"QS"XEM?*

#0AU35(X9Y%O(B;JV219/M$;(YC,4TC!!&[M-F-L@_0XVL+$0F)#YF-^4'S8Z9J:1+.WC$86!%"'RU9-8O[^:XG@^WK]IOY{T^M;VZ?-40E&;,L3M4*:.M?PIX=O_(@2?"]*

*(E\06=LQ7^HW6HQ;S[(BNK2SN&6V15DD'R3O)$P%H9_*M4KN88:@#[$2&-'=E159SEB%P6^OK69IGA72=%N=4GLK)('U.?[5=@9*R2[50 MOM/)"*#@#.!FOD?]F?*

QQXIL1K#-HVH>,M:DLK.;5L:C<0)8WADD$T4J7C%/ M.7&<0.5*A0$P%0XTWB._P!$'T'5?'M_J3Z)[&CWE]. ^9JE[86,NLM=L)(9YI M8,\;1QI$B4@J-K8!84 ?<:P11JJ+&JJHP*

%X%9LGA32I-=LM9>R1M1LH)+:V MEYQ#&4Y4N^%7H,I5CA...A-?"3^,=8?Q'X3U>]D\4OJ[6O:-'=1OM0M15"B1 ME\RSF6,078D7!E6XA1L ;BN0SQ MW]NTZ+YDS1

GR]!8[-P'![./=B P((R#UR*BBLK>#=Y<$;;A@[4 S|:^_ MA1>>,/$QO2\=:?)K^M6!OK35A*UK+[95?*

*O,%R2[N'G<*HVQQ@MT1%X5>PK5WX:^*O$=CX5\7QZ7I=QXO;2O$MS8V$ M+7L<+M;_ +MS^]E."(VDD49/10.U>9?M3:G)%\6/"::G>VNFZ3)HER[Q:MJ> MIVEKY_FPX*

*:Q(W2!2P&_C\5Y"UL0'.8X/M3$MHD146-%51M `@ #TKV!T/7 M/#*Z^*[]3Q1JOBX>,DU2U'AVUT&YO&33O*B\HP(W[]2%CYOFO(\"V =Q! KU. MP_;T2_9PFB:EB&>07"*

]HA);6Z.$,\D98,%)(PN"Q!R.AH]K%K"%C7RDQ'] MP;1\OT]*?M4-G:-Q[XKR7QO=_%&+XE6$?AZTDD)(9GNXM$JVUFP'S'?\ -)K6/QQ<+J&LV^MQW.D_P#"/VEM+

*<"UFM3*_P!O+(G[HP% MWE\E1C&*-/|RH\CY%XZ<4JJ]\A0.W KXW\8^,=;U?XNWUWX>U36Y]?FO;?^ MQ+6!{@6DNE>2WG/Y>/+(WALLPW!E3IQGA;GQQ8:9H*

AEUGQ5>V%W;6,:1W>J M7]M;KKC12?:FN9_J8B1'#LBD+N5 %,<4 ?H+29KYZ\;^* '6@^&_A_IGACO% M'>27&DS3WNNSG+E5.3GNOO3/0?@f\)=

*6OG[4_&/Q1U*Q\>VT-QX@MO^$U M"36TT"S[=(;&VADN%A)YB#J[[0.K+CK0!^@]%8?@:6.?P5H$EQYAN'T^W:3S M<{]QC7.[/.<]OCOX8NWQ762&Z\7XL(AX M6MO]*

*)M;DJQ;?^\VKE/FQG.>HH ^O1T%!Z5XMW7QGFNX(D:9M38)E>XMX9\5$_+!X<7_@$Y_]FKD/^%4_&C_HNL?_(1MG_|'*9^+^/C*

M/#\G_"\XSM4G'_"&V?/_D2L(QK+_EZUZ;?G?7[O0=6=:L_XC6KVML^FSV_I M(ZUO"OB]CD?\(XH]/F/_LU>-^+/V?O$NK_$1^2PM+B:YDCF^WP$K;P[<<$ M$Y'3ISG-3?!*

*[1_C;\4/A]I_B2?XS0:=+=2W,9MX_!]HP7RKB2(')DSR(P?QK MM/\A4_QG_Z+1'_X1MG_/'*NTW\7 RJ);Q>:.D>3R/N@'I79_|'I_C/_T7-M2/\ (VS_P#6Ct_"]/C/_P!%TC_\(VS_*

/CE3.E4EM5=_D_T,_9U$G^]>O\ MA_|D3IO!O@[O)%X5TF.37KFQ=+9%-M)%\T6!C:>>U;'_"'Z|>OB>+_\?`MA_79/C;#:R:II]O>M O@ZT(C,D:N5!,F2!NQ6ZC9)7.B7O2))/

VFI_;UY!)5646TT;ED&XX'+ MU2'PH^- Z?'2,?\ EO/OT.Q3X>[N]23JK^8BCZ;9!^IKA?CC\'>>\4> ^M5MK&]DU.6VE61+4%^@X^4,Y"I5G_A4_P 9_P#HND?_ (1MG_|'*X?*

1M-^ M-FJ_%Q0\>,XRP1PZ3HU?>#P?:,I3,T@%9 8V#IZUA4PW/^HE4Z7WOM]-M]U]Z/.GAFX25.I*+:,33O-6SNOO3/0?@f\)=*

<|^|:.SN=2DT^=F:5[K?]\Z;_OY,|.:QU%9/)+!RT+;&R.G.*K^#O & MD^!K6:#35E*2N)&-P^\@XQP<<5S-5O:Z- =9U3PWI:ZSKEO"6M;%SQ*^>F,@MW.T$$XP*^>|%_:'\?>*

*1@9R: /M7P)\0O#?Q.T$:WX5UBVUS2C*_N[1R4 MWH<,O;D&NBP#_P#6-?E!\|_B_P#$##P]^S!\)OAQX%URP\, ^(O'?BC4K27Q/- M"LZ6:*Z[S$C?*68M\|N>W3!Y'L6A?%?X^?#[QO\4_@J/%=G\3?&&G^&#KOAS7 MYK*:WG20G;Y,T8.S=R2NXGG;DX/ !]J?$3XH^$_A-H<=>L>+]>L_#^F23L);< MWCE5:5SA5& 3DUCZ=\%_"4'Q>NOBG;13/XHOM+32WN1=,T+VP;>N$^`[G)^`]7 MY1:W\;_&FO?LU>(!3QEXRN_%'B[2_$NCQW>@>+_"UO;WFD%Y0),A@RRHS?=8 M_$#'3->G^,/'GQ\| <_%OX'Z?X4^+#^#_ WX M(+TL(!*MYFD;[.KB$.5!5 M"=O)Y[#&*_/T?X':?S-& 3_]>OSEL?VA_C'^TCKOP;_^'/'-I\-;/?O#+:] MJ^OP6,7#&V!SY98A<==? 08/]W[$7Q)^)GB'XL?&;P;\1/&T/C:3PG M>6MI:WMM:16\1!0EF"QJ,,>-P).&:lH ^Q,48I:* "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQYX#TSX@Z&^G;C M'AA\T%R@'F0/V93_ #'0BNDI*J,G%W6Y,HJ: <9*Z9\:0S>)_V\>2'++MW1M[^.M+)$%]#G!R^A_53P>*^KO!'C33"_ (F!NZ?^7]=V>GT M4U'61 RD,K#((.013J%#U HHHH **** "BBB@ HZT44 >*EU M+P,I=ZOBF6"? 6A+$3]ODA.8FDYY*GD5N3_"[PG<^_=&\5RZ#9OXBT>U:RT_4 M2G[VV@8$-&A[@D?C7544 ?,'[0?[$^A_$[1O#^F>%+#0_#UG'XS@\5Z[;W% MLSQZFP#"8,!G+N&QSP>;/|\ A_\ LQ?"KX5VVMP>%/ NCZ)'K436^H?9H/FN M(FSF.L22$.?N@@>U>H44 >8Z]^S+\+//%'P\TOP+JO@;2+WPGI9+6.F20_);D MDDF,@[D)+-D@\Y-9=I^R[\%/!'AG7[*#P+X=T70]6MHK754\H0PW$4; H)22 M <-@Y)R3U)KV*OG7_@H5C_ACCXG9P?\ B6@_P#75*J*Y])#2N['>Q^&?A1K M?B/PC>11^'+W6O# <+6>@O' QX M;+@*[J5YY=&:W#0-(S;B^#T,(!R.O>R2[-P3UE;)H;#^TP<'_ <&K M^AE?NCZ4Y)))H;2Z'D_@3]D_X0_#'4(L_P +?#I1=$ODMM;3[5;0$2M%)PZL MY)+9!QSDXXK4T^\ 9W^&V@0>%(=,\&Z79Q>%)l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| @GX]G;4QIKW,L=W;7\RH450+@9Y]#@C"\<&OOOB!^RMX,UGP_K:NN5+Q>^"??PP^%F MA^#M5UWP7HFH?$31{6- ;C5K=I7A>X4DB58V(0L./F^9R,UJ:,^S[XN\4?MD2 M_%OQA/I<7AW0-,?3?"^FV4[RS!I,B2>;**%8AFX!/\//%?2E% !1110 4444 M %%%% !1110 4444 %%%% !1110 5\Y_%S|@SX7_ !C\>W7B_4EUS1]7OX1; MZG_8.]/9QZE&!@+,.]CYN !D8) &>@KZ,HH ^=)?V"/A+/\&+'X9R:=]#:%!] MZ^H:?= _;F%]93L>?BF !'I@@C'7-4M+_ &,_@Q\'AIXVM-4N;]+#Q!;>5KO MB77=:?[8\(Q@~ M/^#_ -G'IEKA=(N_!NG?$=?5H!M"UUC*7B6M+@\9>";#61H\"VUC*7BB2A4 "/S(V5B@^ZQ(Q(% MWJ)'P@\ <_#_2//.L>]+F\,:0Q>PL8%> 6S'J4>-E8$ISGYN^:]>HH \NT+] MF+X7>&;KPS<.5X.L;"7PU:SV6DF!%%K#.")EV-W88ODY9LGGK2#]F'X7I\-M M-\"#PE:CPEIMZ-1M-,IZ;9%?$3X%:A.[_ &@\4Z3;VC,NLVW^JNW>1FD=/]G<6]A7XA_ !:0.G_AL+XD_] MA_?^BTK]HOV$#_QB)\,/^P5_[4>MIQBEIV%M)'$_#+!DC4_!GQ"^+WA[6;71 M]?\| @GX]G;4QIKW,L=W;7\RH450+@9Y]#@C"\<&OOOB!^RMX,UGP_K:NN5+Q>^"??PP^%F MA^#M5UWP7HFH?$31{6- ;C5K=I7A>X4DB58V(0L./F^9R,UJ:,^S[XN\4?MD2 M_%OQA/I<7AW0-,?3?"^FV4[RS!I,B2>;**%8AFX!/\//%?2E% !1110 4444 M %%%% !1110 4444 %%%% !1110 5\Y_%S|@SX7_ !C\>W7B_4EUS1]7OX1; MZG_8.]/9QZE&!@+,.]CYN !D8) &>@KZ,HH ^=)?V"/A+/\&+'X9R:=]#:%!] MZ^H:?= _;F%]93L>?BF !'I@@C'7-4M+_ &,_@Q\'AIXVM-4N;]+#Q!;>5KO MB77=:?[8\(Q@~ M/^#_ -G'IEKA=(N_!NG?$=?5H!M"UUC*7B6M+@\9>";#61H\"VUC*7BB2A4 "/S(V5B@^ZQ(Q(% MWJ)'P@\ <_#_2//.L>]+F\,:0Q>PL8%> 6S'J4>-E8$ISGYN^:]>HH \NT+] MF+X7>&;KPS<.5X.L;"7PU:SV6DF!%%K#.")EV-W88ODY9LGGK2#]F'X7I\-M M-\"#PE:CPEIMZ-1M-,IZ;9%?$3X%:A.[_ &@\4Z3;VC,NLVW^JNW>1FD=/]G<6]A7XA_ !:0.G_AL+XD_] MA_?^BTK]HOV$#_QB)\,/^P5_[4>MIQBEIV%M)'$_#+!DC4_!GQ"^+WA[6;71 M]?\| @GX]G;4QIKW,L=W;7\RH450+@9Y]#@C"\<&OOOB!^RMX,UGP_K:NN5+Q>^"??PP^%F MA^#M5UWP7HFH?$31{6- ;C5K=I7A>X4DB58V(0L./F^9R,UJ:,^S[XN\4?MD2 M_%OQA/I<7AW0-,?3?"^FV4[RS!I,B2>;**%8AFX!/\//%?2E% !1110 4444 M %%%% !1110 4444 %%%% !1110 5\Y_%S|@SX7_ !C\>W7B_4EUS1]7OX1; MZG_8.]/9QZE&!@+,.]CYN !D8) &>@KZ,HH ^=)?V"/A+/\&+'X9R:=]#:%!] MZ^H:?= _;F%]93L>?BF !'I@@C'7-4M+_ &,_@Q\'AIXVM-4N;]+#Q!;>5KO MB77=:?[8\(Q@~ M/^#_ -G'IEKA=(N_!NG?$=?5H!M"UUC*7B6M+@\9>";#61H\"VUC*7BB2A4 "/S(V5B@^ZQ(Q(% MWJ)'P@\ <_#_2//.L>]+F\,:0Q>PL8%> 6S'J4>-E8$ISGYN^:]>HH \NT+] MF+X7>&;KPS<.5X.L;"7PU:SV6DF!%%K#.")EV88ODY9LGGK2#]F'X7I\-M M-\"#PE:CPEIMZ-1M-,IZ;9%?$3X%:A.[_ &@\4Z3;VC,NLVW^JNW>1FD=/]G<6]A7XA_ !:0.G_AL+XD_] MA_?^BTK]HOV$#_QB)\,/^P5_[4>MIQBEIV%M)'$_#+!DC4_!GQ"^+WA[6;71 M]?\| @GX]G;4QIKW,L=W;7\RH450+@9Y]#@C"\<&OOOB!^RMX,UGP_K:NN5+Q>^"??PP^%F MA^#M5UWP7HFH?$31{6- ;C5K=I7A>X4DB58V(0L./F^9R,UJ:,^S[XN\4?MD2 M_%OQA/I<7AW0-,?3?"^FV4[RS!I,B2>;**%8AFX!/\//%?2E% !1110 4444 M %%%% !1110 4444 %%%% !1110 5\Y_%S|@SX7_ !C\>W7B_4EUS1]7OX1; MZG_8.]/9QZE&!@+,.]CYN !D8) &>@KZ,HH ^=)?V"/A+/\&+'X9R:=]#:%!] MZ^H:?= _;F%]93L>?BF !'I@@C'7-4M+_ &,_@Q\'AIXVM-4N;]+#Q!;>5KO MB77=:?[8\(Q@~ M/^#_ -G'IEKA=(N_!NG?$=?5H!M"UUC*7B6M+@\9>";#61H\"VUC*7BB2A4 "/S(V5B@^ZQ(Q(% MWJ)'P@\ <_#_2//.L>]+F\,:0Q>PL8%> 6S'J4>-E8$ISGYN^:]>HH \NT+] MF+X7>&;KPS<.5X.L;"7PU:SV6DF!%%K#.")EV-W

*SN\B\M7WQRA6*DJ>XR",CTK5S_G%>#>&OAUXDT+!E/4/ M"5MITFG^(/LM_#:V=K*D;1[¥Y6B",K!5^5EQ@C'M7@OC7]G7XBZ-/:VNAZ;K*
M$W@T064VH:5#=?;I+B\^S.LDGERW4>XB386_> 9PP#8H ^\\U2UC6[#P_I\M M_J5Y#8646-\|PX1%R<#)/O7YW?$#6_"UQIVB^)Y=5UOQND&CQ;3)_PD4<5U*
MIP,S>9'} DP;4N-H+1K&"X8\9.GJ_P&^)OBB_\ $LEYX)U$6M[:79NK/[2H MCN;A;I9(-')'O)&G.P?*![+$]VV@ 4 ??FBZ_8>(8)¥M/G^T1PS/;R-L9=LB\,*
M.0.GKT]_FOC&V^-#/Q6DFM5L(M1TW3-?U&XT_5H[G4_WNGZ<9$EAF0"1@& 4Q MX4Y 8U[_L\?'D6I?9+]7<_6_-5UQ_?6HD>]7+;NS'[N/
*M9M(.>X!]5!0(40(?FW(F6?PMKNA_#W-[-IWA^_P!982VLGV4J MA<1SM@--@JN]@"-QOF@#[*LM)/%.E>$-,.H:S?1.:?9"1(C--D+N8[5'XD@5\3^'?V:O&>H^)}/BUSP]JD(OM)[\U74AJFU)_+M70K,R3;G*R;"5Q@]>:8WP+ ^(EU'!:VOA76K2_@R/$%]J& MK)//K4PN@\4D(,S9VH =Q5"H&W!H ^V]2\4;5H^J:?IUY>QP7VH%O;0'):38 MNY$@= _DG*
KE=2^/?P]TGPS_P)#<^+-.&C&]>P6[BD,BO.IP\:A02Q?O<@'1^ 002#?O'M&#GI?)>)=:,MY_P!I;3(=@2ZTK5/#5S8V<$;YQF=; M34XYM;M+^,*L[N\:.CJ65=P4A3SCTKQOOQ5\'_*
!+|+?"6E:G>+?Z7I,L$ MD/B-+OQ"T8OHO??N:,S9)M]$PX53N50."PS0!]M^,OB'X< ^'MM:W'B+58=)A MNI)A>'<-AVQG'/:N@CE66-9$.Y& -([BOS[\# ^:?
$GQ=^'GC(>&M)U"TT:U MEU%/#XNKZ.]V32O$@"2&5E98T#D ,5'0$UF?%#2M7^&^C?V5\0H;W5;^'3K_M .S31^)%LY+Z^+]8]20/.A/R?N_+3)C(^5"#F@#]!-
(\3:7KMWJ-K87D=Q_$C6KY&D:VA\-Z/97SOG+WRP[F#9Y M+]I^;//S,>(/VK_!?ASQ9J.CW%KKDVGZ7],.DZGXCMM-:32M/O)=FR&:?/#?O8
MP2%]74.1(F@#Y>BO);?]H#1M1^(E_P"$=,\_^+=7DT_4ET]\UBPT9V--MK@H MCKLKW$< *LB%CCC-0>@#OVIO!GC;QM9^`-D(]2GNK72=:.N]/.+3=5FMBWGQ*
MVTY.'9=CGD.,$8]6P: +/QM\;Z7/K'@369--M)-7@\1Z?#%?M IGCC.IR]OC M(!R> >|>KK]T?2O)OC:X?LY[\;\ZPQN?ML/B+3X4"WDRP]3(6QY/S%2 M1ZUZROW1[%HHHH*
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJNH:G9Z1;&XOKJ&S MMP0#+/(4].3Q3-
+UG3];A.;3KZWOX5.TR6TJR#Z9!-3S1YN6^I'/'FY+Z M]NI=HHHJBPHHHH **** "BBB@ HHHH **** "N7U7_D?]# Z];C _-EKJ*Y? M5?\ D?\ 0 | KUN/_9:YJ_PKU?YHY,3\$?|*
%'_TI'44445TG6%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)F]&M6%WJ-J((/4I=,D#9 M,L,.2/3#@BO)?!_P<\7:%XOOM3N?%)2WF\S:\+>9(\-(\6:-
J6O6N[SM.M:V.29-OWOE!SQWQTIUK>)-)O-3\(:EIMO M=,+Z>SD@CN3A3O$!CCIR>U?*^F0^*3\+?#?@K0/A}J6G>-O#=A-$-+_#WCWX=.+X.GU&^^(CV6J7*
*M=9CM]8N),]3&H!8(HO MWF58P5,I+QM'B0[S$K)PAQGCTH _0"=,U*CM^IO;> ^EM+>.;[@!$-P\]2M&#.>.2'J*M4OKR"T:IF6W@<$SA3+(W*
RMW47/4GTKXDU30_BK.+Y-'LOB%;>)9)+PW%U+=S+8'3##BUCA#2%!,#M&% D# MABQQ7L?C?P1XK_ "CP)I7AB3Q#>:A;WEO+?RRWTMS=G,9,IED=BQ&X],X':
*M@#*Z%K/UKQ#I?AN'"*?5=0MM.AED6&.2YDS8=ST4$]2?2OGS|GWP9X[\'ZRT>H MW/B2>WO?"UO/<2>(+^6[4:KNP^#(S;&P>57"X'2O*KCP7X[UBSTN)O# _,0;*
*MGQ/;.G'<;W>;I>&33GF6X8D);(I$<)<0#0I55>&!- 'Y9ZS8:CI4>IVUW#<:.M?)'YR74:AHV3&=P;ICWIVE:K9:WI%)HS#>V4ZIXIX'#HZ^HCX-?&&C_#.X MK_Y?
_;5Q)XR77+6ZTJ&WMCJ,H@\@Q,+O,&_8W)&XL"0<8K5^%NB>/++Q;H?_.M EVF_$*YU9#9?V?/97S1Z=;VX#?:.%NP6,1.>6#J78;=AH ^N-8UFP\/Z?+? MZE=PV-G$
*7GG<(BY.!DGWJE=>,] LKB_@-N-9L+>>PMQ=W<7O^4M_L[MN;\G^*GP&U(>+_BA<^%? M#$OV;6-+LKF5HA_R$ITGWRQ[F;YG*C&#QVH ^G_#/BCP\0-*M]9T'4].U_3*
MPY\F\L9DGC##@X99HNGRP_9 M+X,D(0R",;,,< 9P?ESTO7GO9Z%JD8K6^E>%KNX'B; M]1U=9)IT38EI'(]' },A7)(48/V728H ^$M6\$26OO/GC\0%>#OB#X7^'%SX[*
M^W76I3W5U-H\VF/.IN;AL.+4V\D ($6/.5!]!0#5WX4:!XAOK;X&?#*3PEKV ME:K\/-?N;[7-2N]/DBL{X(8[J.)XK@C9,9S/&5"$G!?=C!K[@Q1B@#Q+XG>$ M-2TK5?!M[<>,-
;U6!O%-B?[/NTM!.,R'.S' K_+GCYNPSFO;5^Z/I7DWQNM] M8;7/ G!0]#R,UZROW1] %HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@*
*HHH MH **** "BBB@ HHHH **** *NJ1K)IUR'4,/+;AAD=*R_ <1'+#=%V*J V<1 M(4 ?PBM;4?\ CPN?^:N?RK+\#_+ (FZ)_P!><7_H(KG?\!=>C_-'(U_M$?\!+_ M*
#1N4445T'6%%%% !112$@=^/6@!:*Y;?OBCX0%,%U3Q+I=G(O6*2Z3S^\MQ@$M^E8)^.,E7_&@Z'XB\29Z26&E2)$?^'VDNQ<>^:XYXS#TWRRJ*_;IW!RU. M"IF&$I2Y)55?
M>[^Y;_@>CT5YP?%'Q'UC T_P7I^BHW2,7-5#,/K' K?^A4? M\(C\0!8!.I>.,?24;K!H.E"!Z"2=G/X[16?UOF_ATY2^7+_ .EY_X5 M*%O"^[^UO$6F:>R]4N+M%?_OG.?*
TKF_P#A1>B7 MY5KNJZ_XF]4U/59?+/\ VSC)^&*Z+0/AKX4\+,;3I/AS3+!UZ20VB! _^^L9_ M6CGQ<[H1CZMM_.S?*
*+BOJ[%&*Y,3@<3BHQ4JIC9I^ZK;=-6W^/R.'%Y;B\;&*GB7&TD_=C9.W M35M_C;R9\O:UXW_:UBUB_33/AQ\.9J-6XD6UEGUV=9'B#'8S #@E<$CUK/G^ M(/[8-*
O"\K_#3X:!$4L3_&_<= ,^E?654]8_Y!5Y_P!<7_|037MGT1Y+ ^R7 M\;]:^/GPBB\4^(-+L=(U47]S936NG2.\(,3[<@MR>]?3 3?+!?Q,:0#KYH#?)C_:
MQ5G5K6GX_X1.\MYEDU6Y-F\;K!B%[AMA!"]D)|>F:^ =/\(WE>]:D-%X5U;6 M+>+#WPU?VTJZQX/DT_5-$)7(MC=1JL5_O;Y?E5B?0C?IG/1G$5[\-> -O#OC.. M:30-=TS7(X2!
*(^FWD=P$)Z E&.,/QJ?69M%+P0ZJ]B64_:8H[PID%.?,4-_=Z M[ATKY1\#Z=J&N>/_ IKGPK\&?V)/I/AQ[/5KS7M)N=#L[R9D0)^ 81)*58% MMP1@,=>:[!4_AQQ3F-?5MG'*
]S5]]=TR/3DU!M0M%L M),!+HS(FR<##9P0?$3X<_$_4/@!\,=.L:!XU#PWHEK;2H:7SVUT MMZMP,-+!Y3%DC3D#(Y.3TH ^X+CQCH%]J5S!\VMZ=#?*
*VT/VB>UDNXUEBB_OL MA;*K6D8IOA[QMX>1?&4:'KNF;R8@#)_9]Y'/L!Z9V,<5\QDA_=SQ:CY8.K'B/89&!"ECK7IWP9_^)_"G MA34?%OAKPKH&G^)?*
$NIRSWMGJ<;Z>;:QC9D@AC2*(_%7=A@ 2^2>E 'T;=W MMOI]M+GP7VG7EO?V,Z[XKFUE62.1? M564D$>XK[_=;O/B=\0KGQAI-VGC5M'U/2=02YL+A;MS%.DP[F,$V|
<$H#A8 M"X9?O,37;:+XN^)VAZ=I_@S18/%CZ[I=UJ'S7>F2_9OL@M,VBFX,8B<;_N@' M.X8- 'VP,'I5"/7]+E2%TU&T=)I3!$RSJ0\@."BG/+9!X'-?/WPQU36)OA5X MS?*
*3]2\=:M?)I2OYWC&U;/EWIA;SDMS(B2$!NHQL!QL.*YIOAK8ZOH'[/?B/0 M;"[OKVQEM@UU%)+)%:AXB9I&0'8I,A;HS0!]I.?VKX?\ %,^H:+]KTW5I MK?"WNG^;':T6>0)*
(\DK_,"%,"J HP !C'I7R'\ _"UU9?%PK%X8U'2M8 MT6/5E\2ZE<;IO';SD] : /L/(<5GVNN:5JMQ<66=M?V M=Y/%D3013(()Y0%$_AW;W4NFZ?HWAF"ZE#W#V#EO%:++(
M3PZ7@!F)/4\\UH>(/#6D>+-,DTI7-*LM9T^0@O:,A;I/$V.F4<$'\[^%;#QK MJNL7.IZ7XH\1>*KP?2A?4[S6K/64(T]+1)<1-:-L"E!\N#&67ID[LU]I_"R;*
*M4+CX:^%9=5W'4GTNV:X+_>+F)GC\,Z5XN\=6L#%)M2\ M)>&KO4;)"#@@7")LD_[9EJ/<:*XOX:?&'PE\7+*ZG\,ZJ+N:S81WEC<0R6U MY9N1PLUO*JR1DX.-*
*R@'!QG%=10 4444 >2_&VYU9=<\"01Z?:OHS>(K!I,UK MLK,DGFG"B+80P/'.|=>G%>LK]T?2O)OC;K,T6N^]-&D7[L$OB*PE;4I$?V: M(B4_(Q+A)QQQA2.1S7K*_=*TH*
*6BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIK,$4LQ M 4=2>U<3K?QH|(:+=M9#5EU34AP-/TB-*
*KVX)]-D0;!^N*QJUJ5!MB*.'7-6FHKS=CL-0_X\+G_*YM_*LOP/QX-T3_ *\XO_017E/Q/U[XE>/? M!6I6GA#PI>Z!YB<7FHWL4%W(H/S+'$I8J2..LR_G6;\$OAE\2CX'@M?*
*%7C#5 M!]B20K#H]{'N%BXQNF97(IX4=!WKQGF$I8M4Z5&5^];ECNNLK6=O\ *Y]!,ZHI9B%4N?%SP7?X;KD.A_Y; M;SJAG?\ ]fP*1_X_7HV*6G]7K2_B5G\DDOQ3?XC^]XB?*
*\6N_2*27XJ3_/)C MS@>'O'NKC.]^/Q!\?>@'T'2XX;_$W+\VT'IFX5_Q(_^)N7X2;1@:#X!\->%@O\ M9&@:;,I7HUK:(C?*
F!FM[%+179"G'FN6'LO([Z=.%/+3BDO+0****LT"BBB@ M HHHH *IZQ_R'KS_ *XO_P"@FKE4]8_Y!5Y_UQ?_ -!- 'S3_P $YO\ DWB; M_L8=4_|2@U]15\N_P#!.;_DWB;_*
+&'5/\ TH-?45 !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !28I: $ Q2T44 %)2T4)CFEHHH M3%%&*6B@!"H((R#*U[)CHVAZ?:L19:9:0V-*
HKLXA@7;@9F+,0!TR23^-7Z M$QJ12T4 >-(O%L_AG2Y?$L6-FJ/J9P0, [L=0"<'],\&NK90RE2 M,@C!!FTM%`'"Z9\#A]HTNI26/@[1K1]28/=F*S1?.(;?AN.F!YL=,\XS7<@ M*
 # Z4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0!Y!\=/[XDZS?Z#Y'@:_31[*]AO%NM0ETV&_@6X$:FWBN4D.5MG_'H9XP6W M"_<
DU3^#NNZM&/B+0O&WB%FTNPO5M]OO([.[&ZNH5B42E8X@B& 29$;;% M.W(P0 3[77PK\1?!\|GBC|IOXF?9_A_+ #GQGY5H1D?XDW@CFA/DMC[$ODR?
MZ.1U.!^\#|GL ?;>GQZ9?2#5[);6XDN8E07T 5C+&"2H\P?>4$D@9QR:OURW MPOT]]) ^'V@V;Z5HVAO#:JAT[P\^ZPM^OR0':N4]/E'TKPWXS?%/XL?#'6V\0 M/<^&K?0Y?
$-EHFB>#C:O<:AKL4KQD\(MPL@#\N7YY&5!&0]Q$N<'(/INBODV M7]HGQ_#>/X];1/^%<)XW/@XZ&+) MGD"[^Q&^^U>9C=Y_S>5Y>/+|[[]D^^/
M[0?Q@V!4/AMXMU^7'!'#_$35KG2K/1K6R>.[TH!9WM&N#(1,7%N0XV+@R#;.MP#D 4^-WB&S@USP'H["Y^W3^(K"9"MG,T.T2',9@OEJ>#\!8$^G->LK]T?2 MO&?
BE\0_"VNZEX-TO3?$NCZAJ2^*+!6LK74(I9@5E.X%%8GC!SQQ@UI,OW1] M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M*
*"J]_;M=VXR"_ 458IK_ '32:NK"\NK,Y?X>1>RZ1)=7 MN]W>I223QQ@7(C 0)*ZC&Q%[9SFNJKF_A_ ,BVO_7U=?\ H]ZZ.N?#*U&' MHCEPBMAX>B\Q:*P?$WCSP[X-*
*BWZWK5EIF1E5N)E5V_W5ZG\!?*_\+ROA M+P?K&NJ?NWMY'_9UH1ZI'YL,1_NH:FIBZ%*7)*7O=E]_N5W^!%7'8>C+DE/WN MRUE_X"KO\#TBJNI:K9:/;M=7]W!96R?*
*>FN)%C0?4D@5"_"_$;Q;.ZKXEL/-M"]LW6U\/VWG38|#<3< -ZQBK>F__P)VMVEYJ%G-XDU%>?MFO3M>OGV#DJO M_5%9>WKU/X5*WG)V_!?7'WV,?K&)J_P;-EWFI?*
*@KOY/E0?CEH5[*T'ANTU/ MQCBP MPQV\2QQ(L<;C"H@P /84^CZO6[?QJK|(^ZOOUE|S0?5.|7^/6?I%'P[Y[<$I=|V_5O5_-B8I.**Z MCL"BBB@ HHHH **** "BBB@ HHHH*
**** "BBB@ JGK'_(*O/^N+_P#H)]Y5 M/6/^05>?]<7_ /030!\T_P#!.;_DWB;_ +&'5/\ TH-?45?+O_!.;_DWB;_L M8=4_]*#7U%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%?GK^TO%X!\1_M+>*!/*
M\=^(O!?@J:QL:[[".]\%0ZY=ZA$Z-N>;=@WEE74JI>%^4!N0U?H)>W#6MI-_MD$ER\,XABQOD(&=HR0.GIR17Q!K_P 4M LOBIXK\4:+\?M/^.H:W%:#5O"-M?
C#PFHNXYX(S&KDSRH68K@9CW(0HP3U(<[!5? NTTFQ^$/A2#0M1M-6TB.Q1; M6^L=/6PAF3G#) H C'^R!?C]W\!/BL/CWJOQ%3Q-X-U \-MMG5$=P,O)MW,>,
[1MKTKX#_ !5A^)7AY$MKS4?$\=C!&LOBZ31FTRQU-M24YW&VC<[F OR5\3D ,3G']- 'S.?V6/$<)3H;?=-/PL/BS_A_OI,_L\[M2-QV_P!I^R&;?Y?D?:/WF-'R=..?*
#W]ESQ-X9U_P7IFK^*M/U'X?>!=1 MN=3\/V$%@\=_+)(LJQ)=2ERA6%9Y NQ06PI.,<_2M% 'F'QBL;6W;P8\5O#'M*?$^GDLJ&_UO//6O3E^Z/I7DWQM\,Z3/KG@/7)-.MI-*
8M_$5A!%?-&#-'&9 M3E0W4 Y/'O7K*_='TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBL_6?$&E^'+1KK5=1M=-
*MAUFNYEB7\V(J9245S2=D3*48)RDI&.MA17G#?'#2M4)C\+Z3K'B^7H)-+M"MN#[SR;8\?0FDW?$_P_3=$T3P5:MW;?$7X\>&//.D;B;,4K76>.(@A=XM+LY/.D9@.C;*
VP>I.,"GCX):? MJS'3Q5K6L^+GZF&_NS%;9]H(MB8]B#776'AK3O#.ER6N@Z1!]BFW"V\,2PQM M]=]_T-14EBZL'RI0\W!S^Y67XLF7U_$Q<::C2OU?O-?)6BQ_)H^??@%\;_
*M'/Q)T&_L=&\-;2LUI<,[ZE=W)O$(#> M)_"\!T3'XQ\/T+C=*P_X$*Z?P66.G2%-+L=*MS(X6*Q;@L&*L2 BCG% M=%7'@,'SX;'UBK*HYQ5O*M?YW,.-*
*DU7#4HX?'UG5E'1ZVCZ6CH_GU3I4Z,>6G%)>2L>O2HT[$ M>2E%179*WY!1116H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !5/6/^05>?]<7_*
*/035RJ>L?\ (*O/^N+_ /H)H ^;?^":0FNZBZ:S;ZL6]QG; M*A'&X8!:]N_X:E^/G_1J.N_^%19?X4 ?6-%?)W_#4OQ_P"C4==_*BR_P * M/^&I?CY_T:CKQ_A467^%*
'UC2$A023@#N.^3_P#AJ7X^^]&HZ[_X5%E_A74? M'/3/&7QB_9@NKBYO-4^$NI2V,UU]VEVCQ7-WY.H^;83CA=V%)=1G!O0!]!_: MX?
*($_G1^21D2;AM_/I3I+B.*/S'D5$X^9F'/3FOS)GTRS\;?!_]D?P5XF9W M\%:M;W$FH6C7#0Q7,D<;F)'*D9&.[VXU'P%!:^* M)+6*[O9%CG:US]E8R;@6*9.W)H__6\D*
*$G@#UJO_&E:?9A'0!RF2UDU!T6*PLHQ.4&7>-KB3=@ M#:.N>0#].Y9D@C+R.L:#]S' 'XU##]-K<2!(KF&1S_"D@)_0UYYITG&>UI]D@&JOFGA+Q# 'DT_4 T3_*
"N04<(V0592.#VKX7_9^^&7A'X1_#WX_?$W MPYX.LK?QEX)UC58-"OIC++6)(_ECV%\,N">N3[T ?II17Q#[?]7'CB*_P## ML%K=Z6_VSX;3>)*
[A1:AB+U8@RG[W'9S\OM7G^D?M'_M'ZQ=Z!9?\)AX0MW\0 M>$)):%*3#PZ[&R$(R8E'G8FD?M?_%_XO16-OX:UOPG MX(N-\%Q>*M3GU;Q;*
<.E(793%$I<>6GR9+)&?:NA\$?M-?&#XJ_$'X;Z5X5 MU#00!UCKOA====>U-.[?VNW1DF.L7SC ?;QG. >] 'W512#(')R.6@ HHHH * M*** "BBB@ HHHH **** "BBB@*
*HHHH **** "BBB@ HHHH **** "BBB@ HH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!_B;^TEX;\,?$NU&C MP;K/B[4XY%AFNK&U@:WM;F2WEN(;;?*
*ZYFD2%B%4$#*EBN17O%?#/Q|\ ZK\ M3/V@!>_X5UH'C.=9T!["XUN^T3Q/8Z7;3736TBP2+':@48./F* MC !]A_#OQW17Q.\$Z-*
XIT1ICIF]VZW$(N(S'*@/!1U/W75@5[&$NCKB_@<QX M87P?\+/#&AKH3>&?L-C' =>]%ZUN1U#3@#*B%)R2^.22;!2@ HHHH \D^-WA M^&;7O*
>L&ZOUFA\16$*VR7DBVS RGEH0=C-SPQ&1QZ5ZTOW1!*\F^-NF7TFN M^ [Y-8GBT^/Q%81OI8@B,%^3CSI^_ M_3!ZPK2G&*<-[K?S=NZ.;$3G""
*<&KW2U5]VEW7FN)%C0?4D@5PL_P =/#UU*T'A^'4?%]RI(*,%9M/&#[S' M$0_[ZKF]XFC1TJ22?;K\ENSDK8NAAVE5FDWTZOT6{^1Z)29KSC^T?B;XE.+?*
*M2M\'\6K<>;]4QOI[H#U$<6U 2]YH'P;&M?-XL4:WXFS]ZU-GO<]#P^LU}.P>3?F(_>]L8-N1 M_O%)P^LU}.P>3?F(_>]L8-N1 M_O%)P^LU}.P>3?F(_>]L8-N1 M_O%)

-9L3&3.CZSK6CZO?:=;W6IZ1))+874B9>V;2,QN4/8E&*GV-5O 2^)5 M\&:,/&+::_B@6R?VBVCAQ:&?'S>4'^;,|:WZ //U^_'PZ3XAGQRO@[21XK,G MG_VG]G'F>=MV^;C{OF;>/,QNOQFI?#OP*^'_ (2\<7_C'1_"6EZ?XFOO,_^I M00 2R&0KV4N0"Q4 MWS7=T4 >2_&W6GBUWP'I8TO4)(Y?$5A*=0CC4VL>) M3\CMNW!CVPIZCFO65^Z/I7DGQN\3Z9!X@\!Z%),RZI<>(,">*R9"&02G)WA M=HZ'@D&O6U^<Z/I0 M%%% !1110 445P7B?XFM'JTGA[PI8CQ'XE48EC5]MK8 M@[&N9>B_[@RV[#O6%6M"A'FF_P#-2&[9M_ORL>(H_3[F_&LW1/AKe=2 MU]=XJ\7 MZ3X*T![0UB]2SMOP0JYR?D<]%11R['LH!)KACHWB%R#G%R%?K:W/A?PBWWe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`5\]6_M!6NFVWQH\1S?$?_PL_M\3;)+99)E2NP!AM(H ^O"OB>P\9^ M'=/UO3#<'3!Z(30FZMI+;7:>FZ*15=#I. :U]\ 9[A\36_P5\!^,;J2\\2 MKIT8O9IKA;B4MS@22K\KR!=H9AP6#'O7H=-!1110!Y,\;]8L8M0\#Z;U!;I] M$OB33Y$M&F42N@EY8)G)''4#M7]*_='TKS#XU:7:27O@B_;S@>]C\2:>BW1A M4R(IEY ?&0.>F>[>GK]T?2@!:*** "J&MZYI_AO3+C4=4O(;"Q@7?)/.X55' MU/\ *N<\8_$NS\-W>C:?:RZ_P"}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`M< MJ,__-?_(#]H@_^?VP]V!/_P"_P" CRH_':\?_4_"_P >R?[VFPI_Z%,*_MI:Y^T!]FAZ->ZG>?"[Q=:V%I"TTIQ$? LU_M7^<3@C3-0OHO#VL_9REM?-LCE625Y$"RGY"V&QMSG(:!_M7T[&# $'(-?+WP=_&K_(7?M3ZEXB*VFAP.\=W<1+9R6+RP75K$%VSSECT5 M6)FW-B-CN&PUZ,? @]KO@(F;X;>)7TVU7G_A&]=+WFFM_LQL3YL'_%BH_NU MTXF6 Q]:52A>BV[VD^:/_@22:^:;[M'1B'@\95E.E>FV]F[K[TKKYI^]/7** M\IL_CQ#X? NHM/^(>C7/@6^=@B7MRWGZ7.W;R[M1M7/\ =D"&O4;>YBNX(YX) M4FAD4,DD;!E8'H01P17EU\+6PUO:1T>SW3]&M"\F>=6P[6A;VBT>SW3]&M"\ MB6BBBN0YQ",UR6I_#BR>|DU'1;B;P[JKG%/D\3Z9]ILU_Y MC&D(TD8'K)#RZ?4;A76:3K5AKUDEYIUW#>VS_=E@<,OZ=#[5OJ.E33>']7;DWFGD*)#_P!- (S\D@^HS[UP~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|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|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~&0U;P,NSW5W3Z9(^Y94Z> M=;OQYL1]1RN<,_>-0A 4%%%)0 M%)FC- "T4F-63Q)XK\3>#O!L/BTZ'1MM)X-B.DW:HL:K$^H.N]6GD\P* MP^494!LFM#X9_&KXCW4WPH|=.]XBM[_PQ\1]8N-,/AA=.BB&DHR7#VCQ3K^\ M=@+<"3S"02,) 7:*]!UO]FCQ!XH\2"WUOXEZC]_P_&OQ^(AX=O+%9+H2I*)H M[7]87SIE650PCV:@ %WI>*@\!_LIW/A'Q+X8%[XUGUCP5X1O[K4O#GAUM.2) M[6.82@>=:.HGBFQ4V1 M9_.*2G<.G;|_*O<%^Z/7[F/QIU"UCNO!-F;);M_$NGNMN90)&42\D+G)"I MVKTY?NCZ4 +1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%%

#2ZU/3M/ABGOL_[9AB>,274MNBQHR?.VZ(M@E1@|"_#GAI3JFFVOAUS)IEWINHRP7=N2E4Y(978$'.0:P?#O|-GPLL
M;#6/"NF^=,%M[6WOK7^U9)9XT262:'>2Q8$N{G)Y;|*.>M_VL?$-_K5[X7L M_AJUQXVTV6X.H:7_ &Y$MM!;Q1H_F+<^7\(.)% 38.*/V8?!?B?7+[6 MR^L:3K5{GQ)>-
IF1#+RH?&0#GH#WKU)?NCZ5Y)\;O#.G3Z_P" M]3R5)|Z];7|H^E "T444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 > #'?$2O$WB3XE?# 2-'UCQ#I&ER+?W%X=#N7MEF>,W9X8Y9
M%!PI<#@D9Z5|N^&?''QKETG7)$U[7WUH:9.=>LEBOY9K27SP,P"><)88)E3=Y M<Z)KMA%]>E7D9CGM9P2KK^'(/N.10!\-:7K M'B7QIXIU/PSX4\;?
$;7PT/%6FVPNKV>ZAOHK9K65Y$\R5!*D;,%RS@'!0\"H M/AYXF^+;>(=5M+ Q-XE@UB*SU5-5M{[34-0EME0,+618I8DMT88B*&%V,N3G M))Q]M^ ?AGX;^&.G7-EX;TP:?
%?<2/-)/-)@#=)++(S.YP !N8X P*Z?% M`YNV?CSQ_@@HWB;Q7'96NH1-}JKW>KFPU!C;ONB%R(/MEF^*2C++$'*KD M D5VI9^.KLVEUK|QXX\-^#{@Z/_ &W=1+)_;-
M"8)|Q,L,0FZ7X?U*_T.>&6>VGO=ET@M'N!L!D M?86PK#+* 6!R;^U? %]?:GX%\.7FI[_[2N--MIKKS$V-YK1*7RO8[B>.U;V* M6@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH ***P|/\ '7AO5_$-[H-
CK^EWFN62{KK3+>]CDN8!ZO&& MW+U'4=Q0!P/QNT6277? >IC5;^.*+Q%81'3D=!:RDRGYV4IN++#/&& X'%>LK M]T?2O)OC;9ZJVN^!+F/4XH]{7Q%8++IYM SR2>:
<,)=WR@<<;3TZ\UZROW1] M* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@"&{W?99=GW]AV_7'%? /P:AT%-_9BN='6Q'Q&F\4:D-;DA"?V@X,5 MZ=1%R1\Y ?
R|V_H1'_LU^@E&=(L/$.H#%WJMM8Q1W5 MP,X>4+N,:.!U/.!0!Y/\ &.[^(GF>%0^E>%_(:B;Q^SL-3N=[?O3LW#]/@9XS M@G'/6NY%|\5,# B3>#__ ;W? R+5'XQ?
%WX8_#Z]T:S\?:W;6%UYHU*TAE2 M61HO)87Z0XC4^7&K,R/A 3R;]MKB&{MX|(>5)H)%#QR1L&5U(R"",.",]M'!?;OBI_T!?!_P#X-[O_ .1:/MWQ4_Z O@__ ,&]W_|(M>A44
>46'BOX]W M^NZHO\ PB_AF 6*PL+]75+L13^8&)"'[+SMV_45]_;OBI_T!?!_P#X-[O_ M .1.]"HH \]^W?%3_H"'^#_|P;W?_P BU4U?Q!\4=&T]\OI=#\(O';0O,RK]
M]WDA03@?Z+[5Z;?)_$[OYX4^'OA6;_|&6I0;.H\|K9GS0[M.\GRK$B("INV M2]@DT TO5X-"\)0PWK%=)')]UN570, <6O49K1^W?%3_ M * O@__|&]W_P#
(M;GPL\;^$O'7@RSO/!6H0:AH-KFPC\D.I@:(!#"Z. Z. MN `K@$<9KKJ //?MWQ4_Z O@_P#\&]W_ /(M9>I>*OBKIVL:38#PQX8N!J#R M(;B+5+LQV^R-GS(?LO
.W;/Z^=ECC?<,6O3$@'X&O6S7'^#0%@V\|6>+?#WAZ_M9M=T MZYBNM&-2:VC,@M+;35+MI9 M,+?PZ= \)FYFL9;\3?VO=; MJ21H5_X]- MU_XE*
(1+M5Y=L@MC+CRA*VQ6$9;><# YKU>@#SW[=\5/^@+X/_|!O=__(M(M;_XJ 9_L7P?^&K?]_P BUZ'10!Y5X=\4_%7Q!8O#X9\+Z>3++%Y%U]EVK_) M(R;L?
9>C;=P]F%;?V!XJ?]_7P?_^#>[_P#D6O0J* //?MWQ4_Z O@__ ,&] MW_|(M8WBCQK\3?"MI9SW&@>$IEN;YWL5$>KW0(;:58U8_Z+T:/)}1A7K=>8_M&'XO_#3X>RZ98>/-
;MK&661;^VMWCEE=?)=6\|A$K%$1MI+MA1W- %S[=\5/ M^@-X/_|+]M=__(M'V!XJ?]_7P?_^#>[_P#D6N!L;ZWU.RM!RTGCNK2XC66& M>%@R2(PRK*1P0000:GH \|^W?
%3_* O@__|&]W_P#(M9=KXI^*MSXAO!+__M .$8_1"U@AF%V^J78AEWEQM4_9>2NSG_>%>K44 >>_;OBI_T!?!_P#X-[O_M .1:/MWQ4_Z O@__ ,&]W_|(M>A44
>;W>K_%*SM9IWT7P@5B1G(&KW?(S M_P ^M4?"WB[XG>*_#6EZS;Z#X2A@U"VCNDCDU>Z+('4, <6O7FNP\1^/?#&B M>(-
&\,.OJUM.ZQK[20V&G.Q\VZVH6?.HYP%!RQP.@SDBN6T#XW?#'2_%]K\-M=+\16<.LV9%A!IR+(45TCW"!9BOEF0)SY>\MCM0!=^W?%3_H"'^#_/P;W?\ M\BT?.OBI_P! 7P?
_.#>[_|D6O0J*/*M5\4_%;2[_2;8>&/#%T+^=H#-#J MEV4M\1L^[_|1>_=NWZL*T_MWQ4_Z W@_P#\&]W_/(M>A44 >>_;OBI_P! M7P?_.#>[_|D6C[=\5/^@+X/_|
!O=__(M>A5@^-_'6@?#?PW=Z_P")M5MM M&T>U ,MW=-M5E ':!XY^)GB#4]=L8= \)Q2;1=BTE9]?NB M)&;.R9'^B]..!SZ5M ;OBI_T!?!_@WN_P#Y%K.\8?
&7X8?!>^$YMZW;Z/>:.M^#]+(D,T\LR*BJ9V2-6*(%"@N0%' M.6-AE65AP00)=(T:!-0M9KB*XTJ_FF*F/;D,LD*<'=U!KT2:..WB>65UCB0%F=S@M*!U)/:N0\!+>(O!OQ+@M?
&>AWMKK%O9FXM(-5A9O+7#;9@I. 1E/O_V=M"U3PO M\!OAYI&M1R0ZM8^'[&WNHI?OQR+ @9&]P1@_2O0)(DE*[U5MIW+N&<'U%/H M**** "BBB@ KP_!.:O\
C#X6^"?@_1?$&NZ-.ZYK;ZFD7A^"[4+'#?,C]FE M*GRS1&OZHD;1VHO71 8H48 K&D:QJN>2!N/)P/=Z.B+&,*H4>PQ3["BBB@ HHH MH
Y3XJ77B]S^'NO2^"+&VU+O6+5QIMO>3B&)IB,*68\8&<^^,9%?*W!%>@^* M//?QO^).BZQX*FT5I-,TNXU+4[G6(;R6XO#]H9YI"BC>\S,I';P@0+T*X^U* M0*
2<#)ZF@!;*** "BBDS0 M-<$]<<&G44 ?G)X4O]7\$>,;S1O^$LOKSQ{) M\3)'_P"%FPR6EU837:R&\(.(R96$^:MUOPAB51C&#^C0Z4WR4\WS-B^9C M;NQSCTS3Z "BDS2T
%%% !7P[^UTT,?QSOFU/QO-*+27P3/:6^MPVGG_VX MTDV7LCO5ERFU&"QXE;S/E/%?<5,DB27;O56VG<-PS@^M 'GW[.[7;? KP"+W M1/\ A&[E-M;2OF_P!&VQ* GS_:.
.&Y&<'FO1*** "BBB@ HHHH ^:_C/\ M/M$T[]!'X0^)[*1X8]?U#5YH+S5!&6E:)++&?8A9P?NYSQ7W^0"02,D=*:(4 M$!DVKYA&W=CG'IF@!PZ4M%% !1110 5_P#
[;O@#0O%OP$\4:G]>CPZ]J6CV M$]QISS(9#;RE<;T?IOQT;&1VQ7T!2$!@01D'L:/C_|:%^.?AWX>:.EH/A?3 M1]%\-^.?$&@QV]XOUB$B/2]-
P.\A29I"V=D/3<.L0!S]%_!31_#OA!X3^%-M.\)WQU/PY:.?%#97I;<9XU&-Y.!R3D!UKLVAC]7FB?"'QGJ&GW.EG?6ND74T%@"VUXW6)BK*>0! -?+:VOBGX-_"?X7?%.
MP^)7C'Q!LZ'XBU,7]I?17IBCE$:L@:*16EW*RG^'!!!K[^\7^&;7Q MIX6U;0;UY8[/4[66TF>$@.$=2I*D@X.#Z5XWX3_9 T30[KPPVM^-/&/C33_# M)B?2-)UV_B-
E:R1++MBD\N&*/>R #:7+8//6@#B;G]M;4K7XKVWA%]#\-2R7^ M]W&C6VGV?B076J6\]++(8I;I**)HHDD,8&T2%T#C(SD!VL?MRS#P5H^LZ#X'N M=;OG\3ZWK&GQW#
{M*:.X6U,3{tV9@)S+N(7(2%¥VGI74;/^QQH?A>]TG6XLO M%'BF[TWP[K,FOZ-X?DNK=;2"Y=W=PQ$(>0,9' ,CL5#'!K'^$7[+DTOA_P") M>H>)K6[\"Z[XYUD;B+?0-6S$)<(-
NXR^9*R@%"9,$$9H]%_9Y^-< M_P ;?">HZM+'H,RV=SY$=YX.UE=1M+I=@;<"522)@3M*2HI!&1D&O'/^&V-; MU'Q\GA&VT;PM_:.J/?V=C:6?B87=
[87$$4KQF^6*%HHU?R^B2.R;AD$YQ[G\ M*?@;IOPN;Q->'5]3\1ZYXEF2?5=6U0PK+<%$\M!LACCC4!2>BY))))KA/"_[
M&'A_PO>^&C#XO\57.E^&;]>YT;1YKBW%K:>.;N3O%XUV2;3[@7=PL'EMZ;HVG2:EKG]GV'AX^&I;=;E +NUW!XVD.S*R1R!75 MT*D$#.1Q6E;_+*^GW<+-XC\;^+_
!=??.K&X2\U:]BS$ML)8HUCCC2. L! MO?;O.NU &9^TA\0?B1X+_9YL]=T^UTS1O&#W^GP7L4%^TD$ DNDC=8Y3#EP0 MP&2BD!B1R!GAM?|
VV_$GA;3/%&L:KX(T>RT+2]V-M00<5Q4G[+7AJ?P']7AN75M;.UYKG_"2)K4=PD=]:ZAE&$\3*@52&C!Q MM(Y((P<4 >7Z?^W'-J?@G5;V#3?"RZEI>K0Z9=:O<>(_(T 1RQ-
(ERES)$LL MGW"AB2)G>#8[(Y?3OVQ_&7CKQ)X U71=-TN'15EUVWUFSAU)W@O'LX XDAD, M 9D*L'7(4D\$8&:]BO?
V1M/U%;#4+KQ|XPNO%|EJG|K0^)KBZMY;B.7RC#L2 M%H3;!Y;,_JQ#D[LYJI;_L4^%["UM$M_%'BKJ7!]=]J;7\UY%+/;,R%8KF.0 MM%AD<+G@]3P0, '&:1^UU\4-
<32(|;X6:)'GV-]?V&I:PT.I3M5_++HY0! M6:)D+* #0!SOB+]K_P 4Z9JGBG4++P%8W7@GPUK-GI5Y]6F FT*IY) R<$U]:O\ LS^&-9\/^,='EN]3CM?
%&]V^KW9CF7?'+"L*IL9* MG"X@3.58BJ!MK. MQ;#%L9XH [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D! end EX-101.SCH 36 ibio-20240630.xsd EX-101.SCH
99900 - Disclosure - Standard And Custom Axis Domain Defaultslink:presentationLinklink:calculationLinklink:definitionLink 995200100 - Statement - Consolidated
Balance Sheetslink:presentationLinklink:calculationLinklink:definitionLink 995200200 - Statement - Consolidated Statements of Operations and Comprehensive
Losslink:presentationLinklink:calculationLinklink:definitionLink 00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss
CALC2link:presentationLinklink:calculationLinklink:definitionLink 995200400 - Statement - Consolidated Statements of Cash
Flowslink:presentationLinklink:calculationLinklink:definitionLink 99940402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and
Restricted Cash) (Details)link:presentationLinklink:calculationLinklink:definitionLink 40701 - Disclosure - Promissory Note Receivable
(Details)link:presentationLinklink:calculationLinklink:definitionLink 40801 - Disclosure - Investments in Debt Securities - Realized Gain (Loss) Available-for-Sale
Debt Securities (Details)link:presentationLinklink:calculationLinklink:definitionLink 40901 - Disclosure - Finance Lease ROU Assets
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941102 - Disclosure - Fixed Assets - Carrying Value and Accumulated Depreciation
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941202 - Disclosure - Intangible Assets - Carrying Value and Accumulated Amortization
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941203 - Disclosure - Intangible Assets - Estimated Annual Amortization Expense
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941301 - Disclosure - Accrued Expenses
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941403 - Disclosure - Debt - Equipment Financing Future Minimum Payments
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941405 - Disclosure - Debt - Credit and Security Agreement Future Minimum Payments
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941406 - Disclosure - Debt - Insurance Premium Financing
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941503 - Disclosure - Finance Lease Obligations - Future Minimum Payments
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99941603 - Disclosure - Operating Lease Obligations - Future Minimum Payments
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99942101 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit)
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99942102 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99942104 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation
(Details)link:presentationLinklink:calculationLinklink:definitionLink 995200090 - Document - Document And Entity
Informationlink:presentationLinklink:calculationLinklink:definitionLink 995200105 - Statement - Consolidated Balance Sheets
(Parenthetical)link:presentationLinklink:calculationLinklink:definitionLink 995200300 - Statement - Consolidated Statements of Stockholders'
Equitylink:presentationLinklink:calculationLinklink:definitionLink 995200305 - Statement - Consolidated Statements of Stockholders' Equity
(Parenthetical)link:presentationLinklink:calculationLinklink:definitionLink 995210101 - Disclosure - Nature of
Businesslink:presentationLinklink:calculationLinklink:definitionLink 995210201 - Disclosure - Basis of
Presentationlink:presentationLinklink:calculationLinklink:definitionLink 995210401 - Disclosure - Summary of Significant Accounting
Policieslink:presentationLinklink:calculationLinklink:definitionLink 995210501 - Disclosure - Financial Instruments and Fair Value
Measurementlink:presentationLinklink:calculationLinklink:definitionLink 995210601 - Disclosure - Significant
Transactionslink:presentationLinklink:calculationLinklink:definitionLink 995210701 - Disclosure - Promissory Note
Receivablelink:presentationLinklink:calculationLinklink:definitionLink 995210801 - Disclosure - Investments in Debt
Securitieslink:presentationLinklink:calculationLinklink:definitionLink 995210901 - Disclosure - Finance Lease ROU
Assetslink:presentationLinklink:calculationLinklink:definitionLink 995211001 - Disclosure - Operating Lease ROU
Assetslink:presentationLinklink:calculationLinklink:definitionLink 995211101 - Disclosure - Fixed Assetslink:presentationLinklink:calculationLinklink:definitionLink
995211201 - Disclosure - Intangible Assetslink:presentationLinklink:calculationLinklink:definitionLink 995211301 - Disclosure - Accrued
Expenseslink:presentationLinklink:calculationLinklink:definitionLink 995211401 - Disclosure - Debtlink:presentationLinklink:calculationLinklink:definitionLink
995211501 - Disclosure - Finance Lease Obligationslink:presentationLinklink:calculationLinklink:definitionLink 995211601 - Disclosure - Operating Lease
Obligationslink:presentationLinklink:calculationLinklink:definitionLink 995211701 - Disclosure - Stockholders'
Equitylink:presentationLinklink:calculationLinklink:definitionLink 995211801 - Disclosure - Earnings (Loss) Per Common
Sharelink:presentationLinklink:calculationLinklink:definitionLink 995211901 - Disclosure - Share-Based
Compensationlink:presentationLinklink:calculationLinklink:definitionLink 995212001 - Disclosure - Fraunhofer
Settlementlink:presentationLinklink:calculationLinklink:definitionLink 995212101 - Disclosure - Income
Taxeslink:presentationLinklink:calculationLinklink:definitionLink 995212201 - Disclosure - Commitments and
Contingencieslink:presentationLinklink:calculationLinklink:definitionLink 995212301 - Disclosure - Employee 401(k)
Planlink:presentationLinklink:calculationLinklink:definitionLink 995212401 - Disclosure - Subsequent
Eventslink:presentationLinklink:calculationLinklink:definitionLink 99920402 - Disclosure - Summary of Significant Accounting Policies
(Policies)link:presentationLinklink:calculationLinklink:definitionLink 99930403 - Disclosure - Summary of Significant Accounting Policies
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99930603 - Disclosure - Significant Transactions
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99930803 - Disclosure - Investments in Debt Securities
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99930903 - Disclosure - Finance Lease ROU Assets
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931103 - Disclosure - Fixed Assets
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931203 - Disclosure - Intangible Assets
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931303 - Disclosure - Accrued Expenses
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931403 - Disclosure - Debt
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931503 - Disclosure - Finance Lease Obligations
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931603 - Disclosure - Operating Lease Obligations
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931803 - Disclosure - Earnings (Loss) Per Common Share
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99931903 - Disclosure - Share-Based Compensation
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99932103 - Disclosure - Income Taxes
(Tables)link:presentationLinklink:calculationLinklink:definitionLink 99940201 - Disclosure - Basis of Presentation
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99940301 - Disclosure - Discontinued Operations
(Details)link:presentationLinklink:calculationLinklink:definitionLink 99940302 - Disclosure - Discontinued Operations - Reconciliation of Loss from Discontinued
Operations (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940303 - Disclosure - Discontinued Operations - Reconciliation of Assets and
Liabilities Held-for-Sale (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940304 - Disclosure - Discontinued Operations - Reconciliation of
Cash Flows from Discontinued Operations (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940401 - Disclosure - Summary of Significant

Accounting Policies (Narrative) (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940501 - Disclosure - Financial Instruments and Fair Value Measurement (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940601 - Disclosure - Significant Transactions (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940602 - Disclosure - Significant Transactions - Summary of Asset Acquisition (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940701 - Disclosure - Promissory Note Receivable (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940801 - Disclosure - Investments in Debt Securities (Details)link:presentationLinklink:calculationLinklink:definitionLink 99940901 - Disclosure - Finance Lease ROU Assets (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941001 - Disclosure - Operating Lease ROU Assets (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941101 - Disclosure - Fixed Assets (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941201 - Disclosure - Intangible Assets (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941401 - Disclosure - Debt - Credit Agreement (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941402 - Disclosure - Debt - Equipment Financing (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941404 - Disclosure - Debt - Credit and Security Agreement (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941501 - Disclosure - Finance Lease Obligations (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941502 - Disclosure - Finance Lease Obligations - Finance Lease Cost and Supplemental Information (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941601 - Disclosure - Operating Lease Obligations (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941602 - Disclosure - Operating Lease Obligations - Operating Lease Cost and Supplemental Information (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941701 - Disclosure - Stockholders' Equity (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941801 - Disclosure - Earnings (Loss) Per Common Share - Components of Earnings Per Share (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941802 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941901 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941902 - Disclosure - Share-Based Compensation - Stock Options (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941903 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941904 - Disclosure - Share-Based Compensation - Options Outstanding and Exercisable (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941905 - Disclosure - Share-Based Compensation - Assumptions Used to Determine Fair Value of Options Granted (Details)link:presentationLinklink:calculationLinklink:definitionLink 99941906 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)link:presentationLinklink:calculationLinklink:definitionLink 99942001 - Disclosure - Fraunhofer Settlement (Details)link:presentationLinklink:calculationLinklink:definitionLink 99942103 - Disclosure - Income Taxes - Tax Credit Carryforwards (Details)link:presentationLinklink:calculationLinklink:definitionLink 99942201 - Disclosure - Commitments and Contingencies (Details)link:presentationLinklink:calculationLinklink:definitionLink 99942301 - Disclosure - Employee 401(k) Plan (Details)link:presentationLinklink:calculationLinklink:definitionLink 99942401 - Disclosure - Subsequent Events (Details)link:presentationLinklink:calculationLinklink:definitionLink 995210301 - Disclosure - Discontinued Operationslink:presentationLinklink:calculationLinklink:definitionLink 99930303 - Disclosure - Discontinued Operations (Tables)link:presentationLinklink:calculationLinklink:definitionLink EX-101.CAL 37 ibio-20240630_cal.xml EX-101.CAL EX-101.DEF 38 ibio-20240630_def.xml EX-101.DEF EX-101.LAB 39 ibio-20240630_lab.xml EX-101.LAB Document And Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Annual Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Document Financial Statement Error Correction [Flag] Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Entity Public Float Auditor Name Auditor Firm ID Auditor Location Consolidated Balance Sheets Statement [Table] Statement [Line Items]Statement Assets [Abstract]Assets Assets, Current [Abstract]Current assets: Cash and Cash Equivalents, at Carrying ValueCash and equivalentsCash and cash equivalents Restricted Cash, CurrentRestricted cashRestricted cash, current Common Stock, Share Subscribed but Unissued, Subscriptions ReceivableSubscription receivable Financing Receivable, after Allowance for Credit Loss, CurrentPromissory note receivable and accrued interestPromissory note receivable, current Prepaid Expense and Other Assets, CurrentPrepaid expenses and other current assets Asset, Held-for-Sale, Not Part of Disposal Group, CurrentCurrent assets held for sale (see Note 3 - Discontinued Operations) Assets, CurrentTotal Current AssetsTotal current assets Restricted Cash, NoncurrentRestricted cash Financing Receivable, after Allowance for Credit Loss, NoncurrentPromissory note receivablePromissory note receivable, non-current Finance Lease, Right-of-Use Asset, after Accumulated AmortizationFinance lease ROU assetsFinance lease right-of-use assets, net of accumulated amortizationNet finance lease ROU assets Operating Lease, Right-of-Use AssetOperating lease ROU assetsOperating lease right-of-use asset Property, Plant and Equipment, NetNet fixed assetsFixed assets, net of accumulated depreciation Intangible Assets, Net (Excluding Goodwill)Intangible assets, netIntangible assets, net of accumulated amortization Security DepositSecurity deposits AssetsTotal Assets Liabilities and Equity [Abstract]Liabilities and Stockholders' Equity Liabilities, Current [Abstract]Current liabilities: Accounts Payable, CurrentAccounts payable Accrued Liabilities, CurrentTotal accrued expensesAccrued expenses Finance Lease, Liability, CurrentLess: current portionFinance lease obligations - current portionFinance lease obligation - current portion Operating Lease, Liability, CurrentLess: current portionOperating lease obligation - current portion Secured Debt, CurrentLess: current portionEquipment financing payable - current portion Notes Payable, CurrentLess: current portionTerm promissory note - current portion Short-Term Nonbank Loan and Note PayablesInsurance premium financing payable Short-Term Bank Loans and Notes PayableTerm note payable - net of deferred financing costs Contract with Customer, Liability, CurrentContract liabilities Other Liabilities, CurrentCurrent liabilities related to assets held for sale Liabilities, CurrentTotal Current Liabilities Finance Lease, Liability, NoncurrentFinance lease obligation - non current portionFinance lease obligations - net of current portionLong-term portion of minimum lease obligations Operating Lease, Liability, NoncurrentOperating lease obligation - net of current portionLong-term portion of minimum lease obligation Secured Long-Term Debt, NoncurrentEquipment financing payable - net of current portionLong-term portion of minimum equipment financing obligation Notes Payable, NoncurrentTerm promissory note - net of current portionLong-term portion of minimum term promissory note obligation LiabilitiesTotal Liabilities Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]Equity: Equity, Attributable to Parent [Abstract]Stockholders' Equity Preferred Stock, Value, IssuedSeries 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2024 and June 30, 2023; 0 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively Common Stock, Value, IssuedCommon Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2024 and June 30, 2023; 8,623,676 and 1,015,505 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively Additional Paid in Capital, Common StockAdditional paid-in capital Retained Earnings (Accumulated Deficit)Accumulated deficit Equity, Attributable to ParentTotal Stockholders' Equity Liabilities and EquityTotal Liabilities and Stockholders' Equity Preferred Stock, Par or Stated Value Per SharePreferred stock, par value (in dollars per share)Preferred stock, par value Preferred Stock, Shares AuthorizedPreferred stock, shares authorized (in shares)Preferred stock, shares authorized Preferred Stock, Shares IssuedPreferred stock, shares issued (in shares)Preferred stock, shares issued Preferred Stock, Shares OutstandingPreferred stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per ShareCommon stock, par value (in dollars per share) Common Stock, Shares AuthorizedCommon stock, shares authorized (in shares)Common stock, shares authorized Common Stock, Shares, IssuedCommon stock, shares issued (in shares) Common Stock, Shares, OutstandingCommon stock, shares outstanding (in shares) Consolidated Statements of Operations and Comprehensive Loss Revenue from Contract with Customer, Excluding Assessed TaxRevenues Operating Expenses [Abstract]Operating expenses: Research and Development ExpenseResearch and development expensesResearch and development General and Administrative ExpenseGeneral and administrative expensesGeneral and administrative Operating ExpensesTotal operating expenses Operating Income (Loss)Operating loss Nonoperating Income (Expense) [Abstract]Other income (expense): Interest Expense, NonoperatingInterest expense Investment Income, InterestInterest incomeInterest income Debt Securities, Available-for-Sale, Gain (Loss)Loss on sale of debt securitiesLoss on sales of debt securitiesRealized loss on sale of debt securities Gain (Loss) on Disposition of Intangible AssetsGain on sale of intangible assetsGain on sale of intellectual property Nonoperating Income (Expense)Total other income Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestNet loss from continuing operationsNet loss from continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestLoss recorded in discontinued operationsLoss from discontinued operationsNet loss from discontinued operations Net lossesNet loss Statement of Comprehensive Income [Abstract]Comprehensive loss: Consolidated net lossNet Income (Loss), Including Portion Attributable to Noncontrolling InterestConsolidated net lossNet loss OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and TaxOther comprehensive loss - unrealized loss on debt securities Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of TaxForeign currency translation adjustmentOther comprehensive income - foreign currency adjustment Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling InterestComprehensive loss Income (Loss) from Continuing Operations, Per Basic SharePer share amount - continuing operations (Basic) Income (Loss) from Continuing Operations, Per Diluted SharePer share amount - continuing operations (Diluted) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic SharePer share amount - discontinued operations (Basic) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted SharePer share amount - discontinued operations (Diluted) Earnings Per Share, BasicLoss per common share attributable to iBio, Inc. stockholders - basic - totalPer share amount - total (Basic) Earnings Per Share, DilutedLoss per common share attributable to iBio, Inc. stockholders - diluted - totalPer share amount - total (Diluted) Weighted Average Number of Shares Outstanding, BasicWeighted-average common shares outstanding (Basic) Weighted Average Number of Shares Outstanding, DilutedWeighted-average common shares outstanding (Diluted) Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Preferred Stock [Member]Preferred Stock Common Stock [Member]Common Stock Additional Paid-in Capital [Member]Additional Paid-in Capital AOCI Attributable to Parent [Member]Accumulated Other Comprehensive Loss Retained Earnings [Member]Accumulated Deficit Equity, Including Portion Attributable to Noncontrolling InterestEquity, ending balanceEquity, beginning balance Shares, OutstandingEquity, ending balance (shares)Equity, beginning balance (shares) Stock Issued During Period, Value, New IssuesCapital raises Stock Issued During Period, Shares, New IssuesCapital raises (shares)Shares issued Stock Issued During Period, Value, AcquisitionsAsset acquisitionValue of shares purchased in transaction Stock Issued During Period, Shares, AcquisitionsAsset acquisition (shares)Shares purchased in transaction Adjustments to Additional Paid in Capital, Stock SplitPayments for fractional shares resulting from reverse stock split Stock Issued During Period, Shares, Reverse Stock SplitsPayments for fractional shares resulting from reverse stock split (shares) Stock Issued During Period, Value, Restricted Stock Award, Net of ForfeituresVesting of RSUs Stock Issued During Period, Shares, Restricted Stock Award, Net of ForfeituresVesting of RSUs (shares) Stock Issued During Period, Value, Conversion of Convertible SecuritiesConversion of preferred stock to common stock Stock Issued During Period, Shares, Conversion of Convertible SecuritiesConversion of preferred stock to common stock (shares) APIC, Share-Based Payment Arrangement, Increase for Cost RecognitionShare-based compensation Adjustments to Additional Paid in Capital, OtherReclassification adjustment for loss on available-for-sale debt securities recognized in net income Debt Securities, Available-for-Sale, Unrealized Gain (Loss)Unrealized loss (gain) on available-for-sale debt securitiesUnrealized gain on available-for-sale debt securities Adjustments to Additional Paid in Capital, Warrant IssuedWarrant issued to satisfy term note payable Stock, Class of Stock [Table] Class of Stock [Axis] Class of Stock [Domain] Stockholders' Equity Note, Stock Split, Conversion RatioReverse stock split, shares received per share tenderedReverse stock split, shares received per share tendered Number of shares an equity holder will tender in order to receive one share of the Company's common stock share following the conversion of a reverse stock split.Number of Shares Tendered in Reverse Stock SplitPre-split shares required for one post-split share of common stock Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract]Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Adjustments to reconcile consolidated net loss to net cash used in operating activities: Share-Based Payment Arrangement, Noncash ExpenseShare-based compensation Amortization of Intangible AssetsAmortization of Intangible AssetsAmortization of intangible assetsFinite-lived intangible asset amortizationAmortization of intangible assets Amortization of ROU assetsAmortization of finance lease right-of-use assetsAmortization expense - ROU assets Operating Lease, Right-of-Use Asset, Periodic ReductionAmortization of operating lease right-of-use assets DepreciationDepreciation expenseDepreciation of fixed assets Gain (Loss) on Sale of Assets and Asset Impairment ChargesLoss/(gain) on sale of fixed assetsLoss on sale of fixed assets Gain (Loss) on Extinguishment of DebtGain on extinguishment of debtGain on extinguishment of debt Increase (Decrease) in Accrued Interest Receivable, NetAccrued interest receivable on promissory note receivable Amortization of Debt

Discount (Premium)Amortization of premiums on debt securitiesAmortization of premiums on debt securities Amortization of Other Deferred ChargesAmortization of deferred financing costs Inventory Write-downInventory write-down to net realizable valueInventory reserve Impairment of Long-Lived Assets to be Disposed ofFixed asset impairmentsFixed asset impairment charge Impairment of Intangible Assets (Excluding Goodwill)Impairment of intangible assets Sale and Leaseback Transaction, Gain (Loss), NetGain on disposition of finance lease ROU assets Increase (Decrease) in Operating Capital [Abstract]Changes in operating assets and liabilities: Increase (Decrease) in Accounts ReceivableAccounts receivable - trade Litigation Settlement, Amount Awarded from Other PartyAmount awarded in legal settlementSettlement receivable Increase (Decrease) in Finished Goods and Work in Process InventoriesInventory Increase (Decrease) in Prepaid Expense and Other AssetsPrepaid expenses and other current assets Increase (Decrease) in Prepaid ExpensePrepaid expenses - noncurrent Increase (Decrease) in Security DepositsSecurity deposit Increase (Decrease) in Accounts PayableAccounts payable Increase (Decrease) in Accrued LiabilitiesAccrued expenses Increase (Decrease) in Other Noncurrent LiabilitiesAccrued expenses - noncurrent Increase (Decrease) in Operating Lease LiabilityOperating lease obligations Increase (Decrease) in Contract with Customer, LiabilityContract liabilities Net Cash Provided by (Used in) Operating ActivitiesNet cash used in operating activitiesNet cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract]Cash flows from investing activities: Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-SaleRedemption of debt securities Proceeds from Sale of Debt Securities, Available-for-SaleSale of debt securitiesProceeds from sale of debt securities Proceeds from Sale of Intangible AssetsSale proceeds for intangible assets Payments to Acquire Property, Plant, and EquipmentPurchases of fixed assets Proceeds from Sale of Property, Plant, and EquipmentSales proceeds for fixed assetsNet proceeds from auctioned equipment Payments to Acquire Businesses, Net of Cash AcquiredPayment for RubrYc asset acquisition Net Cash Provided by (Used in) Investing ActivitiesNet cash provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract]Cash flows from financing activities: Proceeds from Issuance of Common StockProceeds from sales of common stockProceeds from offering Payments of Stock Issuance CostsPayments made for costs to acquire capital Payments of Capital DistributionPayments for fractional shares after reverse stock split Proceeds from Issuance of Private PlacementSubscription receivable Proceeds from Other DebtProceeds from equipment financing loan Repayments of Other DebtPayment of equipment financing loan Proceeds from Notes PayableProceeds from term promissory note Repayments of Notes PayablePayment of term promissory note Repayments of Convertible DebtPayment of term note payable Payments of Loan CostsPayments made for costs to attain term note Payment of finance lease obligationPayment of finance lease obligationFinancing cash flows from finance lease obligations Net Cash Provided by (Used in) Financing ActivitiesNet cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued OperationsEffect of exchange rate changes Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNet increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash EquivalentsCash, cash equivalents and restricted cash - endCash, cash equivalents and restricted cash - beginningTotal cash, cash equivalents and restricted cash Other Noncash Investing and Financing Items [Abstract]Schedule of non-cash activities: Non-Cash Transaction of Subscription Receivable For Capital RaiseNon-Cash Transaction Of Subscription Receivable For Capital RaiseSubscription receivable The amount of cost incurred to raise capital directly from gross proceeds.Cost to Raise Capital paid Directly from Gross ProceedsCosts to raise capital paid directly from gross proceeds The amount of insurance premiums financed through non-cash means during the period.NonCashInsurancePremiumFinancingDuringPeriodInsurance premium financing The amount of total costs incurred in raising capital included in accrued expenses.CostsToRaiseCapitalIncludedInAccruedExpensesCosts to raise capital included in accrued expenses The amount of reserves related to term promissory note included in prepaid expenses, classified as non-cash activities.Reserves Related To Term Promissory Note Included In Prepaid ExpensesReserves related to term promissory note included in prepaid expenses Debt Issuance Costs Incurred During Noncash or Partial Noncash TransactionCosts related to term promissory note paid directly from gross proceeds The amount of cost accrued to amend the term note payable during the period.Cost accrued to amend term note payable The amount paid for capital expenditures incurred for intangible assets during the previous year.Capital Expenditure Incurred For Intangible Assets PaidFixed assets included in accounts payable in prior period, paid in current period Right-of-Use Asset Obtained in Exchange for Finance Lease LiabilityIncrease in finance lease ROU assets for new leases Lease Obligation IncurredIncrease in finance lease obligation for new leases Noncash or Part Noncash Acquisition, Value of Assets AcquiredRubrYc asset acquisition by issuance of common stock Debt Conversion, Converted Instrument, AmountIssuance of warrant for term note payable obligation Supplemental Cash Flow Information [Abstract]Supplemental cash flow information: Interest Paid, Excluding Capitalized Interest, Operating ActivitiesCash paid during the period for interest Nature of Business Nature of Operations [Text Block]Nature of Business Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]Basis of Presentation Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]Discontinued Operations Summary of Significant Accounting Policies Significant Accounting Policies [Text Block]Summary of Significant Accounting Policies Financial Instruments and Fair Value Measurement Fair Value Disclosures [Text Block]Financial Instruments and Fair Value Measurement Significant Transactions Significant Transactions [Text Block]Significant Transactions [Text Block]Significant Transactions Promissory Note Receivable Loans, Notes, Trade and Other Receivables Disclosure [Text Block]Promissory Note Receivable Investments in Debt Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]Investments in Debt Securities Finance Lease ROU Assets The entire disclosure for lessee's right to use underlying asset under finance lease.Finance Lease, Right Of Use Asset, Disclosure [Text Block]Finance Lease ROU Assets Operating Lease ROU Assets The entire disclosure for lessee's right to use underlying asset under operating lease.Operating Lease Right Of Use Asset Disclosure [Text Block]Operating Lease ROU Assets Fixed Assets Property, Plant and Equipment Disclosure [Text Block]Fixed Assets Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block]Intangible Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block]Accrued Expenses Debt Debt Disclosure [Text Block]Debt Finance Lease Obligations Lessee, Finance Leases [Text Block]Finance Lease Obligations Operating Lease Obligations Lessee, Operating Leases [Text Block]Operating Lease Obligations Stockholders' Equity Equity [Text Block]Stockholders' Equity Earnings (Loss) Per Common Share Earnings Per Share [Text Block]Earnings (Loss) Per Common Share Share-Based Compensation Share-Based Payment Arrangement [Text Block]Share-Based Compensation Fraunhofer Settlement Entire disclosure on gain (Loss) related to litigation settlement.Gain Loss Related To Litigation Settlement [Text Block]Fraunhofer Settlement Income Taxes Income Tax Disclosure [Text Block]Income Taxes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block]Commitments and Contingencies Employee 401(k) Plan Retirement Benefits [Text Block]Employee 401(k) Plan Subsequent Events Subsequent Events [Text Block]Subsequent Events Use of Estimates, Policy [Policy Text Block]Use of Estimates Accounts Receivable [Policy Text Block]Accounts Receivable Receivable [Policy Text Block]Subscription Receivable Revenue from Contract with Customer [Policy Text Block]Revenue Recognition Disclosure of accounting policy for contract assets.Contract Assets [Policy Text Block]Contract Assets Disclosure of accounting policy for contract liabilities.Contract Liabilities [Policy Text Block]Contract Liabilities Lessee, Leases [Policy Text Block]Leases Cash and Cash Equivalents, Policy [Policy Text Block]Cash, Cash Equivalents and Restricted Cash Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]Investments in Debt Securities Inventory, Policy [Policy Text Block]Inventory Research and Development Expense, Policy [Policy Text Block]Research and Development The disclosure of accounting policy for right-of-use assets.Right Of Use Assets Policy [Policy Text Block]Right-of-Use Assets Property, Plant and Equipment, Policy [Policy Text Block]Fixed Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]Intangible Assets Share-Based Payment Arrangement [Policy Text Block]Share-based Compensation Income Tax, Policy [Policy Text Block]Income Taxes Concentration Risk, Credit Risk, Policy [Policy Text Block]Concentrations of Credit Risk New Accounting Pronouncements, Policy [Policy Text Block]Recently Issued Accounting Pronouncements Disposal Groups, Including Discontinued Operations [Table Text Block]Schedule of discontinued operations Schedule of Cash and Cash Equivalents [Table Text Block]Schedule of of total cash, cash equivalents and restricted cash Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to RubrYc Therapeutics, Inc.RubrYc Therapeutics Inc [Member]RubrYc Therapeutics Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Stock Purchase Agreement [Member]Stock Purchase Agreement [Member]Stock Purchase Agreement Asset Acquisition [Axis] Asset Acquisition [Domain] Asset Purchase Agreement [Member]Asset Purchase Agreement [Member]Asset Purchase Agreement Asset Acquisition [Table Text Block]Summary of Purchase Price Allocation of Asset Acquisition Tabular disclosure of realized gains (losses) on available for sale debt securities.Avaliable For Sale Debt Securities Realized Gains (Losses) [Table Text Block]Schedule of realized losses on available-for-sale debt securities The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]Summary of the gross carrying value and accumulated amortization of finance lease ROU Property, Plant and Equipment [Table Text Block]Schedule of gross carrying value and accumulated depreciation of fixed assets Schedule of Finite-Lived Intangible Assets [Table Text Block]Schedule of Category the gross carrying value and accumulated amortization of intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]Schedule of Estimated annual amortization expenses for next five years and thereafter Schedule of Accrued Liabilities [Table Text Block]Schedule of Accrued Expenses Notes Payable [Abstract] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents information pertaining to 2024 Term Note.Term Note, 2024 [Member]Term Promissory Note Represents information pertaining to the equipment financing master lease agreement.Equipment Financing Master Lease Agreement [Member]Equipment Financing Agreement Represents information pertaining to the Insurance Premium Financing Agreement.Insurance Premium Financing Agreement [Member]Insurance Premium Financing Agreement Schedule of Maturities of Long-Term Debt [Table Text Block]Schedule of Future Minimum Financing Payments The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation Finance Lease, Liability, to be Paid, Maturity [Table Text Block]Future Minimum Payments Under the Finance Lease Obligation Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligationSchedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]Future Minimum Payments under the Operating Lease Obligation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]Schedule of Earnings (loss) Per Share, Basic and Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-Based Payment Arrangement, Option, Activity [Table Text Block]Schedule of Stock Option Activity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]Schedule of Stock Options Outstanding and Exercisable Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]Schedule of Components of Income Tax Expense (Benefit) Schedule of Deferred Tax Assets and Liabilities [Table Text Block]Schedule of Deferred Tax Assets and Liabilities Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]Schedule of Effective Income Tax Rate Reconciliation Represents information pertaining to the Securities Purchasing Agreement.Securities Purchase Agreement [Member]2024 Securities Purchase AgreementSecurities Purchase Agreement Represents information pertaining to the Asset Purchase Agreement with Otsuka Pharmaceutical Co., Ltd.Asset Purchasing Agreement [Member]PD-1 Purchase Agreement Sale of Stock [Axis] Sale of Stock [Domain] Represents information relating to At the market offerings.At The Market Offerings [Member]At-The-Market Offerings Lincoln Park Purchase Agreement [Member]Lincoln Park Purchase Agreement Represents the member information pertaining to 2023 Offering.Offering 2023Offering 2023 Private Placement [Member]Private placement Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the information pertaining to Pre Funded Warrants.Pre Funded Warrants [Member]Pre-Funded Warrants Represents the member information pertaining to Series C Warrants.Series C Warrants [Member]Series C Warrants Represents the member information pertaining to Series D Warrants.Series D Warrants [Member]Series D Warrants Represents the member information pertaining to Series E Warrants.Series E Warrants [Member]Series E Warrants Represents the member information pertaining to Common Stock and Series E Warrants.Common Stock and Series E Warrants [Member]Common Shares and Series E Warrants Represents the member information pertaining to Pre-funded Warrants and Series E Warrants.Pre-funded Warrants and Series E Warrants [Member]Pre-funded and Series E Warrants Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member]Subsequent Events Amount of operating capital (deficit).Operating capital (deficit)Operating capital deficit Restructuring and Related Cost, Number of Positions Eliminated, Period PercentPercentage of workforce reduction Restructuring and Related Cost, Expected Number of Positions EliminatedNumber of positions reduced Debt Instrument, Face AmountPrincipal amount borrowedSecured term loan Sale of Stock, Consideration Received Per TransactionFair value of shares issued in agreementCommon stock, gross proceeds from issuance Sale of Stock, Consideration Received on TransactionCommon stock, net proceeds from issuance Number of warrants issued during the period.Stock Issued During Period, Shares, WarrantsNumber of warrants issued Class of Warrant or Right, Number of Securities Called by Warrants or RightsWarrants, shares of common stock issued upon conversion Class of Warrant or Right, Exercise Price of Warrants or RightsExercise price per share of warrantsWarrants, exercise price Purchase price per share in various scenarios.Purchase price per shareCombined purchase price per share Potential amount of contingent payments receivable by the company upon achievement

of specified developmental milestones.Potential Contingent Payment Receivable Upon Achievement Of Specified Developmental MilestonesPotential contingent payment Potential amount of contingent payments receivable by the company upon achievement of specified milestones following commercialization.Potential Contingent Payment Receivable Upon Achievement Of Specified Milestones Following CommercializationSecond potential contingent payment Warrants and Rights Outstanding, TermWarrants, exercisable term Shares Issued, Price Per ShareShare priceShare price of common stock Placement agent fees paid in cash, represented as a percentage of aggregate gross proceeds.Placement Agent Fees Paid As A Percentage Of Aggregate Gross ProceedsPlacement agent fees paid (as percentage) Reduced placement agent fees for certain investors paid in cash, represented as a percentage of aggregate gross proceeds.Reduced Placement Agent Fees Paid As A Percentage Of Aggregate Gross ProceedsReduced placement agent fee percentage Maximum amount of payment made to placement agent for legal fees and other out of pocket expenses.Payment Of Legal Fees And Other Out Of Pocket Expenses To Placement Agent, Maximum AmountPayment made to placement agent for legal fees and other out of pocket expenses Number of warrants exercised during the period.Number Of Warrants ExercisedNumber of warrants exercised Proceeds from Warrant ExercisesProceeds from exercise of warrants Restricted Cash and Cash Equivalents, CurrentAmount held as collateral from legal settlementRestricted Cash Cash and cash equivalents plus debt securitiesCash and cash equivalents plus debt securitiesCash and cash equivalents and marketable securities Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Domain] Information pertaining to the elimination of the Company's contract development and manufacturing organization.Contract Development and Manufacturing Organization [Member]iBio CDMO, LLC Disposal Group Classification [Axis] Disposal Group Classification [Domain] Discontinued Operations [Member]Discontinued OperationsLoss from Discontinued Operations Information pertaining to Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group, LLC, collectively known as the "Auctioneers".The Auctioneers [Member]The Auctioneers Information pertaining to Woodford National Bank.Woodforest National Bank [Member]Woodforest National Bank Information pertaining to the Auction Sale Agreement with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC.Auction Sale Agreement [Member]Auction Sale Agreement Represents information pertaining to the Settlement Agreement reached between the Company and Woodforest National Bank.Woodforest Settlement Agreement [Member]Settlement Agreement Information pertaining to the 2024 Purchase and Sale Agreement.Purchase and Sale Agreement [Member]2024 Purchase and Sale Agreement - The Board of Regents Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Building and Building Improvements [Member]Building and ImprovementsFacility Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Nonrecurring [Member]Fair Value, Nonrecurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member]Level 3 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] The guaranteed minimum proceeds agreed upon for property plant & equipment put up for auction.Guaranteed minimum proceeds for fixed assets sold at auctionGuaranteed minimum proceeds for auctioned equipment The total proceeds, before fees, for property plant & equipment sold at auction.Total proceeds for fixed assets sold at auctionFinal sale price for auctioned equipment The percentage of excess proceeds resulting from the auction (the difference between the guaranteed minimum and final sale amounts) paid to the Company.Percentage of excess proceeds received from auctioned equipmentExcess proceeds from auctioned equipment (percentage) The amount of costs/fees incurred for selling fixed assets at an auction.Fees incurred for fixed assets sold at auctionFees for auctioned equipment Repayments of Long-Term Lines of CreditProceeds from sale of property paid to Woodforest to settle debt Repayments of Lines of CreditCash payments to settle debt Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants IssuedWarrants issued to settle debtWarrants, shares issued Restructuring and Related Cost, Incurred CostPre-tax employee reduction expenses Discontinued Operation, Period of Continuing Involvement after DisposalTransition period for terminated employees Severance CostsPersonnel and severance costs Disposal Group, Including Discontinued Operation, Interest ExpenseInterest expense - term note payableInterest charges on term note Gain (Loss) on Disposition of Property Plant EquipmentLoss on sale of fixed assetsLoss (gain) on sale of fixed assets Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]Results of operations for discontinued operations Disposal Group, Including Discontinued Operation, RevenueRevenues Disposal Group, Including Discontinued Operation, Costs of Goods SoldCost of goods sold Disposal Group, Including Discontinued Operation, Gross Profit (Loss)Gross profit Disposal Group, Including Discontinued Operation, General and Administrative ExpenseGeneral and administrative Disposal Group, Including Discontinued Operation, Operating ExpenseTotal operating expenses Disposal Group, Including Discontinued Operation, Other ExpenseOther Other Nonoperating ExpenseTotal other expenses Discontinued Operations, Held-for-Sale [Member]Held-for-Sale Disposal Group, Including Discontinued Operation, Other Assets, CurrentOperating lease right-of-use assets Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, CurrentProperty and equipment, net Disposal Group, Including Discontinued Operation, Assets, CurrentTotal current Assets Disposal Group, Including Discontinued Operation, Other Liabilities, CurrentOperating lease obligation Disposal Group, Including Discontinued Operation, Liabilities, CurrentTotal current liabilities The cash inflow associated with the acquisition of long-lived, physical assets that have been reported in the consolidated statements of income under discontinued operations.Purchase of Fixed Assets Cash Flow Impact Discontinued OperationsPurchase of fixed assets The cash inflow associated with payments of financial leasing obligations as a result of discontinued operations.Payment of Finance Lease Obligation Cash Flow Impact from Discontinued OperationsPayment of finance lease obligation Noncash Investing and Financing Items [Abstract]Investing non-cash transactions: Fixed asset charges incurred but not yet paid attributable to discontinued operations.Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current PeriodFixed assets included in accounts payable in prior period, paid in current period Interest Paid, Discontinued OperationsCash paid during the period for interest Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Sales [Member]Revenues Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Intellectual Property [Member]Intellectual Property Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member]Minimum Maximum [Member]Maximum Operating Activities [Axis] Operating Activities [Domain] Continuing Operations [Member]Continuing Operations Summary Of Significant Accounting Policies [Line Items] Accounts Receivable, after Allowance for Credit Loss, CurrentAccounts receivable Accounts Receivable, Allowance for Credit Loss, CurrentAllowance for credit losses Contract with Customer, Asset, after Allowance for Credit Loss, CurrentContract assets Contract with Customer, Liability, Revenue RecognizedRevenue recognized included in contract liabilities Inventory, NetInventory Property, Plant and Equipment, Useful LifeFixed assets, useful life Finite-Lived Intangible Asset, Useful LifeIntangible asset, useful life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend RateDividend rateDividend yield Unrecognized Tax BenefitsLiability for uncertain tax positions Cash, Uninsured AmountCash deposits held in excess of FDIC insured amount Cash and Cash Equivalent [Table] Restricted Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Represents the information pertaining to letter of credit term loan.Letter Of Credit - Term Loan [Member]Collateral Held For Letter Of Credit - Term Note Payable Represents the information pertaining to letter of credit for sandiego lease.Letter Of Credit - San Diego Lease [Member]Collateral Held For Letter Of Credit - San Diego Lease Information related to the Company purchasing card.Company Purchasing Card [Member]Collateral Held For Company Purchasing Card Cash and Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] The percentage of collateral required to be held by the reporting entity.Percentage Of Collateral RequiredAdditional collateral held by bank (percentage of credit issued) Restricted CashRestricted cash Fair Value, Recurring and Nonrecurring [Table] Fair Value, Inputs, Level 1 [Member]Level 1 Machinery and Equipment [Member]EquipmentMachinery and Equipment Represents the information pertaining to purchase and Sale Agreement with Majestic Realty Co.Purchase and Sale Agreement with Majestic Realty CoPurchase and Sale Agreement - Majestic Realty Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long-Lived Asset, Held-for-Sale, Fair Value DisclosureFair value, fixed assets held-for-sale (Quoted prices) Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of AssetCarrying value, fixed assets held for sale Proceeds from Sale of BuildingsProceeds from sale of building Collaborative Arrangement and Arrangement Other than Collaborative [Table] Represents the member information pertaining to The Purchase and Sale Agreement (Ground Lease Agreement).The Purchase and Sale Ground Lease Agreement [Member]The Purchase and Sale Agreement Represents the information pertaining to Credit Agreement with Woodforest National Bank.Credit Agreement with Woodforest National BankThe Credit Agreement Represents the information pertaining to the Warrant Agreement with Bryan Capital.Warrant Agreement With Bryan Capital [Member]The Warrant Collaboration, Option and License Agreement [Member]Collaboration, Option and License Agreement [Member]Collaboration, Option and License Agreement Represents the member information pertaining to Separation Agreement and General Release.Separation Agreement and General Release [Member]Separation Agreement and General Release Represents the information pertaining to College Station Investors LLC.College Station Investors LLC [Member]College Station Investors Represents the information pertaining to Bryan Capital.Bryan Capital [Member]Bryan Capital Chief Executive Officer [Member]Dr. Martin Brenner, Chief Executive Officer Series A Preferred Stock [Member]Series A-2 Preferred Stock Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Sale Leaseback Transaction, Gross Proceeds, Investing ActivitiesPurchase price for Ground Lease Property Sale Leaseback Transaction, Rent ExpenseBase rent expense Sale Leaseback Transaction, Imputed Interest RateInterest rate on lease (percentage of facility's market value) The number of warrants issued, and exercisable, as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Warrants issued and exercisable Warrants and Rights OutstandingValue of exercisable warrants Collaboration and license agreement, agreement termCollaboration and license agreement, agreement termCollaboration and license agreement, agreement term Collaboration and license agreement, royalty payment termCollaboration and License Agreement, Royalty payment termCollaboration and license agreement, royalty payment term Sale of Stock, Number of Shares Issued in TransactionCommon stock, shares issuedNumber of shares issued per agreement Fair value estimate of shares issued in asset purchase agreement after the initial lockup period.Fair value of shares issued in agreement after lockup periodFair value of shares issued and subject to lockup period Asset Acquisition, Contingent Consideration, LiabilityLiability for contingent consideration Payments to Acquire Productive AssetsCash advances to RubrYc to support operations Asset Acquisition, Consideration Transferred, Transaction CostTransaction costs Other than Temporary Impairment Losses, InvestmentsImpairment of investment in RubrYc Impairment of current prepaid expenses.Impairment Of Prepaid Expenses, CurrentImpairment of current prepaid expense Impairment of non-current prepaid expenses.Impairment Of Prepaid Expenses, Non CurrentImpairment of noncurrent prepaid expense Represents the number of equipment leases.Number of Equipment LeasesNumber of equipment leases assumed in asset acquisition Finance Lease, LiabilityFinance leases Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.Severance Benefits, Period of Bi-Monthly Installments of Current Base SalaryPeriod of bi-monthly installments of current base salary Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.Severance Benefits, Period of Bi-Monthly Installments of target BonusPeriod of bi-monthly installments of target bonus Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation ActMaximum period for coverage of health insurance Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy PeriodCOBRA subsidy period Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation ActLump sum payment equal to six time the COBRA subsidy Disposal Group, Including Discontinued Operation, Accrued Liabilities, CurrentAccrued expenses Schedule of Business Acquisitions, by Acquisition [Table] Series A preferred stock.Acquired Series A Preferred Stock [Member]Preferred Stock Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy.Acquired Intangible Assets [Member]Intangible Assets Fixed assets acquired through acquisition of assets.Acquired Fixed Assets [Member]Fixed Assets Primary financial statement caption encompassing prepaid expenses and other current assets acquired through asset acquisition.Acquired Prepaid Expenses [Member]Prepaid Expenses Business Acquisition [Line Items] Asset Acquisition, Consideration TransferredPurchase price allocatedInvestment in RubrYc Accounts and Financing Receivables [Table] Represents the information pertaining to Safi Biosolutions, Inc.Safi Biosolutions Inc [Member]Safi Biosolutions Receivable Type [Axis] Receivable [Domain] Notes Receivable [Member]Promissory Note Accounts, Notes, Loans and Financing Receivable [Line Items] Financing Receivable, after Allowance for Credit LossPromissory note receivable, net Payments received for interest owed to the Company for interest accrued on notes issued.Notes receivable, payments for interestInterest payments on notes receivable Payments received for notes issued, amounts applied directly to principal balance.Notes receivable, payments on principal balancePayments on notes receivable (amounts applied against principal balance) Percentage of fixed rate of interest on notes.Loans Receivable, Fixed Rates of InterestInterest rate Percentage of rate of interest on notes receivable for first one year extension.Loans Receivable, Rate of Interest for First One Year ExtensionInterest rate for first one year extension Percentage of rate of interest on notes receivable for second one year extension.Loans Receivable, Rate of Interest for Second One Year ExtensionInterest rate for second one year extension Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Line Items] Payments to Acquire Debt Securities, Available-for-SaleCost of debt securities Lessee, Lease, Description [Table] Equipment [Member]Equipment Lessee, Lease, Description [Line Items] Finance Lease, Right-of-Use Asset, before Accumulated AmortizationROU - Equipment Finance Lease, Right-of-Use Asset, Accumulated AmortizationAccumulated amortization Land and Building [Member]Facilities Geographical [Axis] Geographical [Domain] Represents the information pertaining to San Diego.San Diego [Member]San Diego, California

Represents the information pertaining to Bryan, Texas.Bryan Texas [Member]Bryan, Texas Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Office Equipment [Member]Office Equipment and Software Property, Plant and Equipment, GrossGross fixed assets Accumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentAccumulated depreciation Depreciation, Excluding Lessor Asset under Operating LeaseDepreciation expense - fixed assets Intangible Asset, Finite-Lived [Table] Information pertaining to the patent and licensing agreement with the University of Pittsburgh.Patent and Licensing Agreement [Member]Licensing Agreement Represents information pertaining to the University of Pittsburgh.University of Pittsburgh [Member]University of Pittsburgh Patents [Member]Patents and Licenses Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Remaining Amortization PeriodIntangible assets weighted average remaining life Finite-Lived Intangible Assets Finite-Lived Intangible Assets, GrossFinite-lived intangible assets, gross Finite-Lived Intangible Assets, Accumulated AmortizationFinite-lived intangible assets accumulated amortization Finite-Lived Intangible Assets AcquiredFinite-lived intangible asset additions Impairment of Intangible Assets, Finite-LivedFinite-lived intangible asset impairment Finite-Lived Intangible Assets, NetTotalFinite-lived intangible assets, net Indefinite-Lived Intangible Assets Indefinite-Lived Intangible Assets (Excluding Goodwill)Indefinite-lived intangible assets Indefinite-Lived Intangible Assets AcquiredIndefinite-lived intangible asset additions Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)Indefinite-lived intangible asset impairment Intangible Assets, Net Finite-Lived Intangible Asset, Expected Amortization, Year One2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five2029 Finite-Lived Intangible Asset, Expected Amortization, after Year FiveThereafter Employee-related Liabilities, CurrentPersonnel related costs Accrual for Taxes Other than Income TaxesReal estate taxes Interest PayableInterest and fees related to term note payable Accrued Professional Fees, CurrentProfessional fees Other Accrued Liabilities, CurrentOther accrued expenses Schedule of Long-Term Debt Instruments [Table] Represents the information pertaining to the first amendment to the Credit Agreement with Woodforest National Bank.First Amendment to Credit Agreement with Woodforest National Bank [Member]First Amended Credit Agreement Represents the information pertaining to the third amendment to the Credit Agreement with Woodforest National Bank.Third Amendment to Credit Agreement with Woodforest National Bank [Member]Third Amended Credit Agreement Represents the information pertaining to the fourth amendment to the Credit Agreement with Woodforest National Bank.Fourth Amendment to Credit Agreement with Woodforest National Bank [Member]Fourth Amended Credit Agreement Represents the information pertaining to the fifth amendment to the Credit Agreement with Woodforest National Bank.Fifth Amendment to Credit Agreement with Woodforest National Bank [Member]Fifth Amended Credit Agreement Represents the information pertaining to the sixth amendment to the Credit Agreement with Woodforest National Bank.Sixth Amendment to Credit Agreement with Woodforest National Bank [Member]Sixth Amended Credit Agreement Represents the information pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank.Seventh Amendment to Credit Agreement with Woodforest National Bank [Member]Seventh Amended Credit Agreement Represents the information pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank for the first potential withdrawal from the Reserve Funds Deposit Account.Seventh Amendment to Credit Agreement with Woodforest National Bank First Collateral Withdrawal [Member]First Potential Collateral Withdrawal Represents the information pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank for the second potential withdrawal from the Reserve Funds Deposit Account.Seventh Amendment to Credit Agreement with Woodforest National Bank Second Collateral Withdrawal [Member]Second Potential Collateral Withdrawal Represents the information pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank for the third potential withdrawal from the Reserve Funds Deposit Account.Seventh Amendment to Credit Agreement with Woodforest National Bank Third Collateral Withdrawal [Member]Third Potential Collateral Withdrawal Represents the information pertaining to the eighth amendment to the Credit Agreement with Woodforest National Bank.eighth Amendment to Credit Agreement with Woodforest National Bank [Member]Eighth Amended Credit Agreement Secured Debt [Member]Term Note Debt Instrument [Line Items] Debt Instrument, Interest Rate, Stated PercentageTerm loan interest rateImputed interest rate Repayments of DebtRepayments of outstanding principal on term loan Debt Instrument, Periodic Payment, PrincipalPrincipal payments on term loanPrincipal payments Debt Instrument, Frequency of Periodic PaymentFrequency of accelerated principal repayments Debt Instrument, TermTerm of debt agreementTerm of accelerated principal repayments Appraisal costsAmendment fee Minimum liquidity requirement per debt covenants in credit agreements.Secured Term Loan Initial Liquidity CovenantLiquidity covenant, unrestricted cash balance Minimum liquidity requirement per debt covenants in amended credit agreements (liquidity amount if specific milestones are met).Secured Term Loan Amended Reduced Liquidity CovenantLiquidity covenant (minimum unrestricted cash balance if specific milestones are met) Threshold number of business days following the close of any at-the-market equity offerings for the Company to pay a portion of the net proceeds to Woodforest National Bank, as part of the credit agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Business Day Threshold Following At-the-Market Equity Offerings To Pay Woodforest Portion Of ProceedsDays following equity offerings to use a portion of net proceeds as debt repayment The percentage of net proceeds realized from the closing of any at-the-market equity offerings that must be used for the repayment of debt, as defined in the Company's credit agreement with Woodforest National Bank.Percentage of net proceeds from at-the-market equity offerings to be used for debt repaymentPercentage of equity offering proceeds to be used for debt repayment The percentage of net proceeds realized from the sale of equipment, which must be used for the repayment of debt as defined in the Company's credit agreement with Woodforest National Bank.Percentage of net proceeds from sale of equipment to be used for debt repaymentPercentage of equipment sale proceeds to be used for debt repayment Represents the amount retained from proceeds of legal settlement.Amount Retained from Proceeds of Legal SettlementCash retained from legal settlement Proceeds from Legal SettlementsSettlement payment received Reduction in cash held by Woodforest as collateral pursuant to the Credit Agreement.Reduction in collateral held from legal settlementReduction in collateral held Amount of remaining term loan principal outstanding, in which Woodforest National Bank will release cash held as collateral back to the Company.Outstanding principal remaining, amount triggering release of collateral heldTerm loan principal outstanding, amount triggering release of collateral Amount of principal reduction on the term loan, provided the total principal outstanding is less than $10 million, in which Woodforest National Bank will release cash held as collateral back to the Company.Principal reduction, milestone amounts triggering release of collateral held Amount of cash, previously held as collateral by Woodforest National Bank, released back to the company upon satisfying certain milestones related to principal repayments on the term loan.Reduction in collateral held from accelerated principal paymentsCollateral released once milestone payments made Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment prior to June 30, 2023.Debt Instrument, Interest Rate, Contingent Annual Increase For Facility Sale Prior to June 30 2023Annual interest rate increase (Facility sale prior to June 30, 2023) Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment after June 30, 2023, but prior to/on September 30, 2023.Debt Instrument, Interest Rate, Contingent Annual Increase For Facility Sale After June 30 2023, Prior to or on September 30 2023Annual interest rate increase (Facility sale after June 30, 2023 and prior to September 30, 2023) Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment after September 30, 2023, or if equipment is not sold at all.Debt Instrument, Interest Rate, Contingent Annual Increase For Facility Sale After September 30 2023Annual interest rate increase (Facility sale after September 30, 2023) Fee owed to Woodforest National Bank if/when a sale of equipment closes on or prior to June 30, 2023.Debt Instrument Fee Amount If Facility Sale Occurs Prior to June 30 2023Fees payable (Facility sale prior to June 30, 2023) Fee owed to Woodforest National Bank if/when a sale of equipment closes After June 30 2023, but prior to/on September 30 2023.Debt Instrument Fee Amount If Facility Sale Occurs After June 30 2023, Prior to or on September 30 2023Fees payable (Facility sale after June 30, 2023 and prior to September 30, 2023) Fee owed to Woodforest National Bank if/when a sale of equipment closes After September 30 2023, or if a sale does not occur.Debt Instrument Fee Amount If Facility Sale Occurs After September 30 2023Fees payable (Facility sale after September 30, 2023) Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.Threshold Period for Delivery of Executed Copy of Agreement for Sale of Facility from Amendment DateBusiness days to deliver executed copy of Purchase Agreement for the sale of the Facility Amount of assets held as collateral in Woodforest National Bank's Reserve Funds Deposit Account released back to the Company.Debt Instrument, Collateral, Amount Released by LenderCollateral withdrawal Minimum liquidity requirement for collateral withdrawal per debt covenants in credit agreements.Secured Term Loan Liquidity Covenant For Collateral WithdrawalCollateral withdrawal, liquidity threshold to maintain Represents the payable in-kind interest rate.Debt Instrument, Paid-in Kind Interest RateInterest rate payable in-kind Debt Issuance Costs, NetDeferred finance costs Debt Instrument, Periodic PaymentMonthly payments on debtTotal minimum debt payments Interest Expense, DebtInterest expense on debt Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One [Member]2025 Debt Instrument, Redemption, Period Two [Member]2026 Debt Instrument, Periodic Payment, InterestInterest payments Secured DebtEquipment financing payable, net Represents information pertaining to the credit and security agreement.Credit and Security Agreement [Member]Credit and Security Agreement Represents information pertaining to the credit and security agreement if there is an event of default.Credit and Security Agreement Event Of Default [Member]Event of Default Information pertaining to Loeb Term Solutions, LLC.Loeb Term Solutions LLC [Member]Loeb Term Solutions Medium-Term Note [Member]2024 Term Note Variable Rate [Axis] Variable Rate [Domain] Prime Rate [Member]Prime Rate Base Rate [Member]Effective Rate Debt Instrument, Basis Spread on Variable RateSpread on base interest rate Payments of Debt Issuance CostsOrigination fee Debt Related Commitment Fees and Debt Issuance CostsBank wire fees The fee, expressed as a percentage of the total principal amount being prepaid, when a prepayment on the loan balance occurs on, after 12 months, but prior-to 24 months, from the loan origination date.Prepayment Fee, Percentage of Principal Amount Repaid When Prepayment Occurs After One Year, But Prior-to Two Years, From IssuanceFee percentage applied to principal prepayments (12 months or less from origination) The fee, expressed as a percentage of the total principal amount being prepaid, when a prepayment on the loan balance occurs on, or prior-to, 12 months from the loan origination date.Prepayment Fee, Percentage of Principal Amount Repaid When Prepayment Occurs Prior to One Year From IssuanceFee percentage applied to principal prepayments (12-24 months from origination) The threshold amount for additional borrowings under the Credit and Security Agreement with Loeb Term Solutions, for which the face amount of additional lending may not exceed (expressed as a percentage of the forced liquidation value of the Company's eligible equipment held as fixed assets).Threshold for additional borrowings, amount which lending cannot exceed expressed as a percentage of liquidation value of equipmentPercentage of eligible equipment's liquidation value, threshold for additional lending Debt Instrument, Periodic Payment Terms, Balloon Payment to be PaidBalloon payment payable (January 2026) Notes PayableTerm promissory note payable, net Short-Term Debt [Table] Information pertaining to FIRST Insurance Funding, a division of Lake Forest Bank & Trust, N.A.First Insurance Funding [Member]FIRST Insurance Funding Short-Term Debt [Line Items] Building [Member]Mobile Office Trailer Variable Lease, PaymentMonthly lease payments Lease, Cost [Abstract]Finance lease cost:Operating lease cost: Finance Lease, Interest ExpenseInterest on lease liabilities Lease, CostTotal lease cost Other Information: Finance Lease, Weighted Average Remaining Lease TermWeighted average remaining lease term - finance lease Finance Lease, Weighted Average Discount Rate, PercentWeighted average discount rate - finance lease obligation Lease Contractual Term [Axis] Lease Contractual Term [Domain] Period one representing most current period of payments coming due.Year 2025 [Member]2025 Period two representing second most current period of payments for liabilities due.Year 2026 [Member]2026 Amount applied to principal for payment on finance lease.Finance Lease Payments PrincipalPrincipal payments Amount applied to interest for payment on finance lease.Finance Lease Payments InterestInterest payments Finance Lease, Liability, to be PaidTotal minimum lease payments Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Domain] Financial Standby Letter of Credit [Member]Letter of Credit Lessee, Operating Lease, Term of ContractTerm of lease Operating Lease, PaymentsOperating cash flows from operating leaseMonthly rent expense Lessee Operating Lease, Annual percentage increase in base rentLessee Operating Lease, Annual percentage increase in base rentAnnual increase in monthly rent Base rent abatement period in the first year.Base Rent Abatement In the First Year, PeriodBase rent abatement period in year one Tenant improvementsTenant improvement allowance Guarantor Obligations, Maximum Exposure, UndiscountedIrrevocable letter of credit Operating Lease, CostOperating lease cost Cash Flow, Operating Activities, Lessee [Abstract] Operating Lease, Payments, UseOperating cash flows from operating lease obligation Operating Lease, Weighted Average Remaining Lease TermWeighted average remaining lease term - operating leases Operating Lease, Weighted Average Discount Rate, PercentWeighted average discount rate - operating lease obligations Information pertaining to principal portion of the obligation.Principal [Member]Principal Information pertaining to interest portion of the obligation.Interest [Member]Imputed Interest Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year One2025 Lessee, Operating Lease, Liability, to be Paid, Year Two2026 Lessee, Operating Lease, Liability, to be Paid, Year Three2027 Lessee, Operating Lease, Liability, to be Paid, Year Four2028 Lessee, Operating Lease, Liability, to be Paid, Year Five2029 Lessee, Operating Lease, Liability, to be Paid, after Year FiveThereafter Lessee, Operating Lease, Liability, to be PaidTotal minimum lease payments Information pertaining to Cantor Fitzgerald & Co. acting as the underwriter (sales agent) in an agreement to sell shares of the Company's common stock.Cantor Fitzgerald Underwriting Agreement [Member]Cantor Fitzgerald Underwriting Information pertaining to Wainwright & Co., LLC acting as the underwriter (sales agent) in an agreement to sell shares of the Company's common stock.Wainwright Underwriting Agreement [Member]Wainwright Underwriting Information pertaining to Lincoln Park acting as the underwriter (sales agent) in an agreement to sell shares of the Company's common stock.Lincoln Park Stock Purchase Agreement [Member]Lincoln Park Stock Purchase Agreement Represents information pertaining to the Securities Purchase Agreement and Warrants.Securities Purchase Stock and Warrants Agreement [Member]Securities Purchase Agreement and Warrants Represents the information pertaining to Warrant Agreements held with various investors.Warrant Agreements

[Member]Warrants Information pertaining to H.C. Wainwright & Co., LLC acting as a sales agent to sell shares of the Company's common stock.HC Wainwright and Company, LLC [Member]H.C. Wainwright & Co. Represents the information pertaining to Alliance Global Partners (AGP).Alliance Global Partners [Member]Alliance Global Partners Over-Allotment Option [Member]Underwriters Option Convertible Preferred Stock [Member]Series 2022 Preferred Stock Represents the information pertaining to representative warrants.Representative Warrants [Member]Representative Warrants Represents the information pertaining to common stock warrants.Common Stock Warrants [Member]Warrants Represents information pertaining to series A warrants.Series A warrants Represents information pertaining to series B warrants.Series B warrants Restricted Stock Units (RSUs) [Member]Restricted Stock Units Class of Stock [Line Items] Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]Preferred Stock Preferred Stock, Convertible, Conversion RatioPreferred stock, conversion ratio Proceeds from Issuance of Convertible Preferred StockPreferred stock, proceeds from issuance Convertible Preferred Stock, Shares Issued upon ConversionCommon shares issued upon conversion of preferred stock Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]Common Stock Share Repurchase Program [Abstract]Reverse Stock Split Stock Issued During Period, Shares, Stock SplitsFractional shares issued in reverse stock split Class of Stock Disclosures [Abstract]Issuances of Common Stock The aggregate amount of proceeds from sales of common stock authorized through the medium of an investment bank, pursuant to an equity offering agreement.Aggregate offering price in stock sales agreementAggregate offering price Common Stock, Capital Shares Reserved for Future IssuanceShares reserved for future issuanceCommon stock, shares available for future issuance Proceeds from Issuance of WarrantsWarrants, proceeds from issuance Share PriceCompany's closing stock priceCombined price per share of common stock and warrants The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent.Stock issuance costs, legal expense reimbursementReimbursement for legal expenses The cash outflow for cost incurred for a non-accountable expense allowance granted to the sales agent.Non accountable expense allowance granted to sales agentNon-accountable expense allowanceQuarterly expense allowance Amount accrued for stock issuance costs incurred and payable to the sales agent.Accrued stock issuance costs Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received.Underwriting Discount Fee PercentageAgent fee percentage Threshold number of days following the close of an at-the-market equity offering for the underwriters of the offering to exercise their option to purchase additional shares/warrants pursuant to an Underwriting Agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Underwriters purchase option period The maximum amount of additional shares available for purchase by underwriters through the issuance of warrants, expressed as a percentage of the aggregate number of shares of common stock and pre-funded warrants currently included in equity offerings.Percentage of total common shares in offering, warrants available for underwritersAdditional shares for purchase, percentage of aggregate shares in offerings Term of a stock purchase agreement.Term Of Purchase AgreementTerm of stock purchase agreement The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 5,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.Strike Price To Direct the Purchase of Stock1Stock price permitting the sale of up to 5,000 shares The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 7,500 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.Strike Price To Direct the Purchase of Stock2Stock price permitting the sale of up to 7,500 shares The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 10,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.Strike Price To Direct the Purchase of Stock3Stock price permitting the sale of up to 10,000 shares The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $3.00 per share, but less than $20.00 per share.Common Stock Maximum Shares Directed For Purchase1Shares available for purchase when stock price closes between $3 and $20 per share The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $20.00 per share, but less than $40.00 per share.Common Stock Maximum Shares Directed For Purchase2Shares available for purchase when stock price closes between $20 and $40 per share The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $40.00 per share.Common Stock Maximum Shares Directed For Purchase3Shares available for purchase when stock price closes at or above $40 per share The maximum fair value of common stock shares that may be purchased in a single transaction, pursuant to the terms of the stock purchasing agreement.Common Stock Maximum Fair Value of Shares Purchased Per TransactionFair value of common stock purchased in single transaction The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase the maximum allowable amount of the Company's common stock at a price per share determined in the stock purchasing agreement. Additionally, the counterparty may be directed to purchase additional shares of the Company's common stock in an "accelerated purchase," and one or more "additional accelerated purchases" on the business day immediately following the initial purchase of shares.Strike Price To Direct the Purchase of Stock4Stock price permitting accelerated purchase clause The number of "additional share purchases" the Company may exercise when certain conditions in the stock purchasing agreement permit.Number of Additional Accelerated Share PurchasesNumber of "additional accelerated purchases" that may be directed The number of common stock shares the Company issued to Lincoln Park as "initial commitment shares" as consideration for participation in the stock purchasing agreement.Common Stock Shares Issued Initial Commitment SharesInitial commitment shares issued The number of common stock shares the Company issued to Lincoln Park as "additional commitment shares" as consideration for participation in the stock purchasing agreement.Common Stock Shares Issued additional Commitment SharesAdditional commitment shares issued The effective ownership of the outstanding shares of the Company's common stock immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.Ownership threshold percentageWarrant exercise, common stock ownership limitation The effective ownership of the outstanding shares of the Company's common stock, with written notice given by the holder to the Company, immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.Ownership threshold percentage election of holderWarrant exercise, common stock ownership limitation (at the election of the holder) Minimum days of prior written notice needed to satisfy the holder's election to exercise warrants that give the holder, together with affiliates, a beneficial ownership in the Company's common stock of not more than 9.99%.Warrant exercises ownership limitation term of written noticeWarrant holder's election, period of written notice Maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants.Days to file registration statementNumber of days to file a registration statement In the event of a "full review" by the SEC, the maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants.Days to file registration statement SEC ReviewNumber of days to file a registration statement (in the event of a "full review" by SEC) Duration of the 2024 Securities Purchase Agreement.Duration of securities purchasing agreementTerm of 2024 Securities Purchase Agreement Number of days in which the Company may suspend the 2024 Securities Purchase Agreement inside the one year period without being in breach.Days to suspend securities purchasing agreementSuspension period In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an "Event Date") and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%.Registration statement delinquency periodFailure to file registration statement, delinquency period In the event that a resale registration statement is not filed or declared effective, the percentage multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, as partial liquidated damages.Partial liquidated damages, penalty percentage on aggregate subscriptions by security purchaserPartial liquidated damages, percent of aggregate security subscriptions Pursuant to the 2024 Stock Purchase Agreement, the period for which the Company is prohibited from entering into any agreement to issue or announce the issuance/proposed issuance of any shares of common stock or convertible securities.Stock Purchase Agreement Exclusivity PeriodPurchase agreement exclusivity period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in PeriodShares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodStock Options, ExercisedStock options, exercises in periodShares exercised Warrants and Rights Note Disclosure [Abstract]Warrants Class of Warrant or Right, Number of Securities Called by Each Warrant or RightWarrants, shares exercised Net Income (Loss) Attributable to Parent [Abstract]Basic and diluted numerator: Earnings Per Share, Basic [Abstract]Basic and diluted denominator: Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member]Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, AmountShares excluded from the calculation of diluted loss per share Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Research and Development Expense [Member]Research and Development Expense General and Administrative Expense [Member]General and Administrative Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-Based Payment Arrangement, ExpenseShare-based compensation expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Information pertaining to the Company's 2020 Omnibus Equity Incentive Plan.Omnibus Equity Incentive Plan 2020 [Member]2020 Omnibus Equity Incentive Plan Information pertaining to the Company's 2023 Omnibus Equity Incentive Plan.Omnibus Equity Incentive Plan 2023 [Member]2023 Omnibus Equity Incentive Plan Grantee Status [Axis] Grantee Status [Domain] Share-Based Payment Arrangement, Employee [Member]Employees Share-Based Payment Arrangement, Nonemployee [Member]Non-Employees Title and Position [Axis] Title and Position [Domain] Chief Financial Officer [Member]Mr. Felipe Duran, Chief Financial Officer Other Affiliates [Member]Consultants Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member]Option Vesting Arrangement, Tranche One Share-Based Payment Arrangement, Tranche Two [Member]Option Vesting Arrangement, Tranche Two Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in PeriodShares issued pursuant to past grants Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future IssuanceShares reserved for past grants Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock MaximumAnnual increase in shares available under plan Maximum share-based compensation that may be paid to non-employee directors in a given calendar year.Non-Employee Compensation Maximum Annual DistributionMaximum annual awards paid to non-employee directors Maximum share-based compensation that may be paid to non-employee directors in a given calendar year with an initial appointment of a board member occurs.Non-Employee Director Compensation Maximum Annual Distribution Initial AppointmentMaximum annual awards paid to non-employee directors (newly appointed board member) Maximum share-based compensation that may be paid to non-employee directors in a given calendar year when an appointment of a new chairman of the Company's board occurs.Non-Employee Director Compensation Maximum Annual Distribution Initial Chair AppointmentMaximum annual awards paid to non-employee directors (newly appointed board chairman) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, PercentageStock options vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting PeriodVesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, GrossNumber of options grantedStock Options, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceWeighted-average exercise priceWeighted-average Exercise Price, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in PeriodNumber of shares issuedShare-based awards issued Shares Granted, Value, Share-Based Payment Arrangement, ForfeitedStock options forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberStock Options, Outstanding at end of the periodStock Options, Outstanding at beginning of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in PeriodStock Options, Forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, NumberStock Options, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, NumberStock Options, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceWeighted-average Exercise Price, Outstanding at end of the periodWeighted-average Exercise Price, Outstanding at beginning of the period Share-Based

Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise PriceWeighted-average Exercise Price, Forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise PriceWeighted-average Exercise Price, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise PriceWeighted-average Exercise Price, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermWeighted-average Remaining Contractual Term (in years), Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermWeighted-average Remaining Contractual Term (in years), Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual TermWeighted-average Remaining Contractual Term (in years), Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueAggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic ValueAggregate Intrinsic Value, Vested and expected to vest Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Information pertaining to stock options within a defined range of exercise prices.Exercise Price Stock Options Range 1 [Member]$1.72 - $7.00 Information pertaining to stock options within a defined range of exercise prices.Exercise Price Stock Options Range 2 [Member]$140.00 - $210.00 Information pertaining to stock options within a defined range of exercise prices.Exercise Price Stock Options Range 3 [Member]$347.00 - $520.50 Information pertaining to stock options within a defined range of exercise prices.Exercise Price Stock Options Range 4 [Member]$530.00 - $795.00 Information pertaining to stock options within a defined range of exercise prices.Exercise Price Stock Options Range 5 [Member]$1,025.00 - $1,537.50 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range LimitExercise price - Lower range Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range LimitExercise price - Upper range Share-Based Payment Arrangement, Option, Exercise Price Range, Shares OutstandingNumber Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual TermWeighted-Average Remaining Life In Years Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise PriceWeighted-Average Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range, Shares ExercisableNumber Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair ValueFair value, options vested in period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, AmountUnrecognized compensation, non-vested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionCost recognition period, non-vested options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair ValueWeighted-average grant date fair value, options granted in period Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MinimumWeighted-average risk free interest rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MaximumWeighted-average risk free interest rate, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MinimumVolatility, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, MaximumVolatility, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected TermExpected term (in years) Represents information relating to Mr. Isett, Former CEO.Mr. Isett [Member]Mr. Thomas Isett, former Chief Executive Officer Represents information relating to Mr. Robert Lutz, the Company's Chief Financial and Business Officer.Mr. Robert Lutz [Member]Mr. Robert Lutz, former Chief Financial and Business Officer Represents information relating to Dr. Martin Brenner, the Company's former Chief Scientific Officer.Martin Brenner Chief Scientific Officer [Member]Dr. Martin Brenner, former Chief Scientific Officer Represents information relating to Dr. Martin Brenner, acting as the Company's interim Chief Executive Officer.Martin Brenner Interim Chief Executive Officer [Member]Dr. Martin Brenner, former Interim Chief Executive Officer This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.2020 Omnibus Equity Incentive Plan [Member]2020 Omnibus Equity Incentive Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueMarket value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair ValueGrant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodNumber of shares terminated Gain Contingencies [Table] Litigation Case [Axis] Litigation Case [Domain] I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].iBio, Inc. v. Fraunhofer USA, Inc. [Member]iBio, Inc. v. Fraunhofer USA, Inc. Litigation Status [Axis] Litigation Status [Domain] Settled Litigation [Member]Settled Litigation Gain Contingencies, Nature [Axis] Gain Contingency, Nature [Domain] Information pertaining settled litigation, amounts awarded to cover legal expenses incurred.Litigation Settlement Payments to Cover Legal Expenses [Member]Legal Expenses Incurred Information pertaining settled litigation, amounts awarded to be used in settling the Company's debt agreements.Litigation Settlement Payments to Settle Debt [Member]Debt Settlement Information pertaining settled litigation, amounts awarded as part of a license agreement.Litigation Settlement Payments For License Agreement [Member]License Agreement Gain Contingencies [Line Items] Percentage of payment received from litigation settlement used to cover legal fees and expenses incurred throughout the litigation process.Percentage litigation settlement payment used to cover legal feesPercentage of settlement payment to cover legal fees Settlement Assets, CurrentSettlement receivable Litigation Settlement, Amount Awarded to Other PartySettlement proceeds transferred for collateral requirement in debt agreement Gain (Loss) from Litigation SettlementSettlement income Current Income Tax Expense (Benefit)Current - Federal and state Deferred Federal Income Tax Expense (Benefit)Deferred - Federal Deferred State and Local Income Tax Expense (Benefit)Deferred - State Deferred Income Tax Expense (Benefit)Total Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, AmountChange in valuation allowance Income Tax Expense (Benefit)Income tax expense Components of Deferred Tax Assets and Liabilities [Abstract] Deferred Tax Assets, Operating Loss CarryforwardsNet operating loss Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation CostShare-based compensation Deferred Tax Assets, Other Tax CarryforwardsCapitalized research and development costs Deferred Tax Assets, Tax Credit Carryforwards, ResearchResearch and development tax credit carryforwardResearch and development tax credits Deferred Tax Assets, Equity Method InvestmentsInvestment in equity security Deferred Tax Liabilities, Property, Plant and EquipmentProperty, plant and equipment Deferred Tax Assets, Property, Plant and EquipmentProperty, plant and equipment Deferred Tax Liabilities, Intangible AssetsIntangible assets Deferred Tax Assets, Tax Credit Carryforwards, OtherOperating and finance lease liabilities Deferred Tax Liabilities, Leasing ArrangementsOperating and finance lease ROU assets Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued LiabilitiesAccrued expenses Deferred Tax Assets, Charitable Contribution CarryforwardsContribution carryforward Deferred Tax Assets, Valuation AllowanceValuation allowance Deferred tax assets valuation allowance Deferred Tax Assets, NetTotal Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Deferred Tax Assets, Operating Loss Carryforwards, DomesticFederal net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to ExpirationFederal net operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to ExpirationFederal net operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, State and LocalState and local net operating loss carryforwards Unrecognized Tax Benefits, Income Tax Penalties and Interest AccruedUnrecognized tax benefits, accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest ExpenseUnrecognized tax benefits, penalties and interest expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, PercentStock buyback excise tax on share repurchases Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, PercentStatutory federal income tax rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, PercentState taxes, net of federal benefit Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, PercentExpiration and forfeiture of stock options Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, PercentChange in valuation allowance Effective Income Tax Rate Reconciliation, PercentEffective income tax rate Other Commitments [Table] Represents information pertaining to the CRO Agreement for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies.CRO Agreement [Member]CRO Agreement Other Commitments [Line Items] Other Research and Development ExpenseCosts incurred Defined Benefit Plan [Table] Retirement Plan Name [Axis] Retirement Plan Name [Domain] Retirement Plan Name, Other [Member]iBio 401(k) Plan Defined Benefit Plan Disclosure [Line Items] Defined Contribution Plan, Employer Matching Contribution, Percent of MatchEmployer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross PayEmployer matching contribution, percent of employees gross pay Defined Benefit Plan, Plan Assets, Contributions by EmployerEmployer contribution expense Subsequent Event [Table] Represents information pertaining to the At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group, LLC acting as sales agents.At Market Issuance Sales Agreement [Member]At Market Issuance Sales Agreement Information pertaining to Chardan Capital Markets, LLC & Craig Hallum Capital Markets, LLC acting as a sales agent to sell shares of the Company's common stock.Chardan Capital Markets LLC and Craig Hallum Capital Markets LLC [Member]Chardan Capital & Craig-Hallum Capital Subsequent Event [Line Items] The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent.Stock issuance costs, expense reimbursementsOut-of-pocket expense reimbursements The fees incurred and payable to the sales agent for any filing related fees.Filing fees payable to sales agentProspectus supplement filing fees EX-101.PRE 40 ibio-20240630_pre.xml EX-101.PRE XML 42 R1.htm IDEA: XBRL DOCUMENT Document And Entity Information - USD ($) 12 Months Ended

Jun. 30, 2024
Sep. 05, 2024
Dec. 31, 2023

Document And Entity Information Document Type 10-K Document Annual Report true Document Period End Date Jun. 30, 2024 Document Transition Report false Securities Act File Number 001-35023 Entity Registrant Name iBio, Inc. Entity Incorporation, State or Country Code DE Entity Tax Identification Number 26-2797813 Entity Address, Address Line One 11750 Sorrento Valley Road Entity Address, Address Line Two Suite 200 Entity Address, City or Town San Diego Entity Address, State or Province CA Entity Address, Postal Zip Code 92121 City Area Code 302 Local Phone Number 355-0650 Title of 12(b) Security Common Stock Trading Symbol IBIO Security Exchange Name NYSEAMER Entity Voluntary Filers No Entity Well-known Seasoned Issuer No Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company false Document Financial Statement Error Correction [Flag] false Entity Shell Company false Entity Common Stock, Shares Outstanding 8,637,895 Entity Central Index Key 0001420720 Current Fiscal Year End Date --06-30 Document Fiscal Year Focus 2024 Document Fiscal Period Focus FY Amendment Flag false Entity Public Float $ 4,431,006 Auditor Name GRASSI & Co., CPAs, P.C. Auditor Firm ID 606 Auditor Location Jericho, New York

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:dei_AmendmentFlag Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

PCAOB issued Audit Firm Identifier

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3:

http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f

+ Details

Name:dei_AuditorFirmId Namespace Prefix:dei_ Data Type:dei:nonemptySequenceNumberItemType Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f

+ Details

Name:dei_AuditorLocation Namespace Prefix:dei_ Data Type:dei:internationalNameItemType Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f

+ Details

Name:dei_AuditorName Namespace Prefix:dei_ Data Type:dei:internationalNameItemType Balance Type:na Period Type:duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:dei_CityAreaCode Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:dei_CoverAbstract Namespace Prefix:dei_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:dei_CurrentFiscalYearEndDate Namespace Prefix:dei_ Data Type:xbrli:gMonthDayItemType Balance Type:na Period Type:duration

- Definition

Boolean flag that is true only for a form used as an annual report.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f

+ Details
Name:dei_DocumentAnnualReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

Indicates whether any of the financial statement period in the filing include a restatement due to error correction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection wReference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f

+ Details
Name:dei_DocumentFinStmtErrorCorrectionFlag Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.

+ References

No definition available.

+ Details
Name:dei_DocumentFiscalPeriodFocus Namespace Prefix:dei_ Data Type:dei:fiscalPeriodItemType Balance Type:na Period Type:duration

- Definition

This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details
Name:dei_DocumentFiscalYearFocus Namespace Prefix:dei_ Data Type:xbrli:gYearItemType Balance Type:na Period Type:duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details
Name:dei_DocumentPeriodEndDate Namespace Prefix:dei_ Data Type:xbrli:dateItemType Balance Type:na Period Type:duration

- Definition

Boolean flag that is true only for a form used as a transition report.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1

+ Details
Name:dei_DocumentTransitionReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details
Name:dei_DocumentType Namespace Prefix:dei_ Data Type:dei:submissionTypeItemType Balance Type:na Period Type:duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details
Name:dei_EntityAddressAddressLine1 Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details
Name:dei_EntityAddressAddressLine2 Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details
Name:dei_EntityAddressCityOrTown Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details
Name:dei_EntityAddressPostalZipCode Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details
Name:dei_EntityAddressStateOrProvince Namespace Prefix:dei_ Data Type:dei:stateOrProvinceItemType Balance Type:na Period Type:duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details
Name:dei_EntityCentralIndexKey Namespace Prefix:dei_ Data Type:dei:centralIndexKeyItemType Balance Type:na Period Type:duration

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details
Name:dei_EntityCommonStockSharesOutstanding Namespace Prefix:dei_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details
Name:dei_EntityCurrentReportingStatus Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityEmergingGrowthCompany Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:dei_EntityFileNumber Namespace Prefix:dei_ Data Type:dei:fileNumberItemType Balance Type:na Period Type:duration

- Definition

Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityFilerCategory Namespace Prefix:dei_ Data Type:dei:filerCategoryItemType Balance Type:na Period Type:duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:dei_EntityIncorporationStateCountryCode Namespace Prefix:dei_ Data Type:dei:edgarStateCountryItemType Balance Type:na Period Type:duration

- Definition

Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405

+ Details

Name:dei_EntityInteractiveDataCurrent Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

- Definition

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.

+ References

No definition available.

+ Details

Name:dei_EntityPublicFloat Namespace Prefix:dei_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityRegistrantName Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityShellCompany Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

Indicates that the company is a Smaller Reporting Company (SRC).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntitySmallBusiness Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityTaxIdentificationNumber Namespace Prefix:dei_ Data Type:dei:employerIdItemType Balance Type:na Period Type:duration

- Definition

Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name:dei_EntityVoluntaryFilers Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

- Definition

Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 405

+ Details

Name:dei_EntityWellKnownSeasonedIssuer Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:dei_LocalPhoneNumber Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b

+ Details

Name:dei_Security12bTitle Namespace Prefix:dei_ Data Type:dei:securityTitleItemType Balance Type:na Period Type:duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1

+ Details

Name:dei_SecurityExchangeName Namespace Prefix:dei_ Data Type:dei:edgarExchangeCodeItemType Balance Type:na Period Type:duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:dei_TradingSymbol Namespace Prefix:dei_ Data Type:dei:tradingSymbolItemType Balance Type:na Period Type:duration XML 43 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)Jun. 30, 2024Jun. 30, 2023Current assets: Cash and cash equivalents$ 14,210,000$ 4,301,000Restricted cash 3,025,000 Subscription receivable 204,000Promissory note receivable and accrued interest713,000 Prepaid expenses and other current assets749,000664,000Current assets held for sale (see Note 3 - Discontinued Operations) 18,065,000Total Current Assets15,672,00026,259,000Restricted cash215,000253,000Promissory note receivable 1,081,0001,706,000Finance lease right-of-use assets, net of accumulated amortization339,000610,000Operating lease right-of-use asset2,401,0002,722,000Fixed assets, net of accumulated depreciation3,632,0004,219,000Intangible assets, net of accumulated amortization5,368,0005,388,000Security deposits26,00050,000Total Assets28,734,00041,207,000Current liabilities: Accounts payable358,0001,849,000Accrued expenses2,028,0004,561,000Finance lease obligations - current portion 299,000272,000Operating lease obligation - current portion436,000389,000Equipment financing payable - current portion178,000160,000Term promissory note - current portion218,000 Insurance premium financing payable123,000 Term note payable - net of deferred financing costs 12,937,000Contract liabilities200,0000 Current liabilities related to assets held for sale 1,941,000Total Current Liabilities3,840,00022,109,000Finance lease obligations - net of current portion53,000 351,000Operating lease obligation - net of current portion2,688,0003,125,000Equipment financing payable - net of current portion63,000241,000Term promissory note - net of current portion766,000 Total Liabilities7,410,00025,826,000Stockholders' Equity Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2024 and June 30, 2023; 0 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively00Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2024 and June 30, 2023; 8,623,676 and 1,015,505 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively9,0001,000Additional paid-in capital335,162,000304,320,000Accumulated deficit(313,847,000)(288,940,000)Total Stockholders' Equity 21,324,00015,381,000Total Liabilities and Stockholders' Equity$ 28,734,000$ 41,207,000

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

+ Details

Name:us-gaap_AccountsPayableCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name

Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:us-gaap_Assets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of asset recognized for present right to economic benefit, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

+ Details
Name:us-gaap_AssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- References

No definition available.

+ Details
Name:us-gaap_AssetsCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4

+ Details
Name:us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details
Name:us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of subscription receivable from investors who have been allocated common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type: debit Period Type:instant

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:us-gaap_CommonStockValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount, after accumulated amortization, of right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

+ Details
Name:us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -

Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:us-gaap_Liabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_LiabilitiesAndStockholdersEquity *Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant*

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX

210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

+ Details

Name:us-gaap_LiabilitiesCurrent *Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant*

- References

No definition available.

+ Details

Name:us-gaap_LiabilitiesCurrentAbstract *Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration*

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_LongTermNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.

+ References

No definition available.

+ Details

Name:us-gaap_NotesAndLoansReceivableNetNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_NotesPayableCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

+ Details

Name:us-gaap_OtherLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:us-gaap_PreferredStockValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1

+ Details

Name:us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

+ Details

Name:us-gaap_RestrictedCashCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

+ Details

Name:us-gaap_RestrictedCashNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:us-gaap_SecuredDebtCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_SecuredLongTermDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_SecurityDeposit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_ShortTermBankLoansAndNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_ShortTermNonBankLoansAndNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-

09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_StockholdersEquityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 44 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Jun. 30, 2023 Consolidated Balance Sheets Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 1,000,000 1,000,000 Preferred stock, shares issued (in shares) 0 Preferred stock, shares outstanding (in shares) 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 275,000,000 275,000,000 Common stock, shares issued (in shares) 8,623,676 1,015,505 Common stock, shares outstanding (in shares) 8,623,676 1,015,505

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_CommonStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Name:us-gaap_CommonStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_PreferredStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:us-gaap_PreferredStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Name:us-gaap_PreferredStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 45 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Consolidated Statements of Operations and Comprehensive Loss Revenues$ 225,000$ 0Operating expenses: Research and development5,185,00010,327,000General and administrative11,674,00019,016,000Total operating expenses16,859,00029,343,000Operating loss(16,634,000)(29,343,000)Other income (expense): Interest expense(172,000)(83,000)Interest income363,000213,000Loss on sales of debt securities (98,000)Gain on sale of intellectual property1,000,000 Total other income 1,191,00032,000Net loss from continuing operations(15,443,000)(29,311,000)Loss from discontinued operations(9,464,000)(35,699,000)Net loss(24,907,000)(65,010,000)Comprehensive loss: Consolidated net loss(24,907,000)(65,010,000)Other comprehensive loss - unrealized loss on debt securities 180,000Other comprehensive income - foreign currency adjustment 33,000Comprehensive loss$ (24,907,000)$ (64,797,000)Per share amount - continuing operations (Basic) $ (4.03)$ (47.88)Per share amount - continuing operations (Diluted)(4.03)(47.88)Per share amount - discontinued operations (Basic)(2.47)(58.31)Per share amount - discontinued operations (Diluted)(2.47)(58.31)Loss per common share attributable to iBio, Inc. stockholders - basic - total(6.50)(106.19)Loss per common share attributable to iBio, Inc. stockholders - diluted - total$ (6.50)$ (106.19)Weighted-average common shares outstanding (Basic)3,831612Weighted-average common shares outstanding (Diluted)3,831612

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) - Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K

+ Details

Name:us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_EarningsPerShareBasic Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_EarningsPerShareDiluted Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Amount of gain (loss) on sale or disposal of intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:us-gaap_GeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncomeStatementAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of interest expense classified as nonoperating.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_InterestExpenseNonoperating Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Name:us-gaap_InvestmentIncomeInterest ***Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration***

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_NonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:us-gaap_OperatingExpenses Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OperatingExpensesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

+ Details

Name:us-gaap_OperatingIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

+ Details

Name:us-gaap_ProfitLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of

intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:us-gaap_ResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16

+ Details

Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: duration

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

+ Details

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: duration XML 46 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Equity, beginning balance at Jun. 30, 2022	$ 1	$ 287,627	$ (213)	$ (223,930)	$ 63,485	
Equity, beginning balance (shares) at Jun. 30, 2022		1437				
Capital raises		11,691			11,691	
Capital raises (shares)		563				
Asset acquisition		650	650			
Asset acquisition (shares)		5				
Payments for fractional shares resulting from reverse stock split		(39)			(39)	
Vesting of RSUs (shares)		10				
Conversion of preferred stock to common stock (shares)		(1)				
Share-based compensation		4,391	4,391			
Foreign currency translation adjustment		33	33			
Reclassification adjustment for loss on available-for-sale debt securities recognized in net income		21	21			
Unrealized gain on available-for-sale debt securities	$ 159			159		
Net loss		(65,010)			(65,010)	
Equity, ending balance at Jun. 30, 2023	$ 1	$ 304,320	$ (288,940)	$ 15,381		
Equity, ending balance (shares) at Jun. 30, 2023		1,015				
Capital raises	$ 825,120		25,128			
Capital raises (shares)		7,568				
Payments for fractional shares resulting from reverse stock split		(7)		(7)		
Payments for fractional shares resulting from reverse stock split (shares)		(1)				
Vesting of RSUs (shares)		42				
Share-based compensation		2,038	2,038			
Warrant issued to satisfy term note payable		3,691	3,691			
Net loss		(24,907)			(24,907)	
Equity, ending balance at Jun. 30, 2024	$ 9	$ 335,162	$ (313,847)	$ 21,324		
Equity, ending balance (shares) at Jun. 30, 2024		8,624				

- Definition

Amount of other increase (decrease) in additional paid in capital (APIC).

+ References

No definition available.

+ Details

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalOther Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12

+ Details

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2

+ Details

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

+ Details

Name:us-gaap_ProfitLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name:us-gaap_SharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Reduction in the number of shares during the period as a result of a reverse stock split.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1

+ Details

Name:us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 47 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Parenthetical) Nov. 29, 2023 Oct. 07, 2022

	shares	*shares*
Stock, Class of Stock [Table]		
Pre-split shares required for one post-split share of common stock	*25*	
Common Stock		
Stock, Class of Stock [Table]		
Reverse stock split, shares received per share tendered	*0.05*	*0.04*
Pre-split shares required for one post-split share of common stock	*2025*	

- Definition

Number of shares an equity holder will tender in order to receive one share of the Company's common stock share following the conversion of a reverse stock split.

+ References

No definition available.

+ Details

Name:ibio_NumberOfSharesTenderedInReverseStockSplit Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480670/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 28: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Name:us-gaap_ScheduleOfStockByClassTable Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

+ Details

Name:us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix:us-gaap_ Data Type:xbrli:pureItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 48 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Cash flows from operating activities: Consolidated net loss$ (24,907,000)$ (65,010,000)Adjustments to reconcile consolidated net loss to net cash used in operating activities: Share-based compensation2,038,0004,391,000Amortization of intangible assets20,000126,000Amortization of finance lease right-of-use assets271,000224,000Amortization of operating lease right-of-use assets321,000356,000Depreciation of fixed assets638,000674,000Loss/(gain) on sale of fixed assets4,909,000(773,000)Gain on extinguishment of debt(808,000) Accrued interest receivable on promissory note receivable(88,000)(75,000)Amortization of premiums on debt securities067,000Loss on sale of debt securities 98,000Amortization of deferred financing costs120,000242,000Inventory reserve 4,915,000Fixed asset impairments3,100,00017,900,000Gain on sale of intangible assets(1,000,000) Impairment of intangible assets0565,000Gain on disposition of finance lease ROU assets (5,000)Changes in operating assets and liabilities: Accounts receivable - trade 1,000,000Settlement receivable 5,100,000Inventory (1,015,000)Prepaid expenses and other current assets214,000885,000Prepaid expenses - noncurrent 74,000Security deposit24,000(21,000)Accounts payable(1,491,000)(625,000)Accrued expenses(1,199,000)145,000Accrued expenses - noncurrent(527,000)527,000Operating lease obligations(389,000)(101,000)Contract liabilities200,000(100,000)Net cash used in operating activities(18,554,000)(30,436,000)Cash flows from investing activities: Redemption of debt securities 4,100,000Sale of debt securities 6,739,000Sale proceeds for intangible assets1,000,000 Purchases of fixed assets(210,000)(5,738,000)Sales proceeds for fixed assets116,0002,600,000Payment for RubrYc asset acquisition (692,000)Net cash provided by investing activities906,0007,009,000Cash flows from financing activities: Proceeds from sales of common stock25,523,00011,487,000Payments made for costs to acquire capital(88,000) Payments for fractional shares after reverse stock split(7,000)(39,000)Subscription receivable204,000Proceeds from equipment financing loan 500,000Payment of equipment financing loan(160,000)(99,000)Proceeds from term promissory note895,000 Payment of term promissory note(88,000) Payment of term note payable(1,513,000)(9,318,000)Payments made for costs to attain term note (22,000)Payment of finance lease obligation(272,000)(208,000)Net cash provided by financing activities24,494,0002,301,000Effect of exchange rate changes 33,000Net increase (decrease) in cash, cash equivalents and restricted cash6,846,000(21,093,000)Cash, cash equivalents and restricted cash - beginning7,579,00028,672,000Cash, cash equivalents and restricted cash - end14,425,0007,579,000Schedule of non-cash activities: Subscription receivable 204,000Costs to raise capital paid directly from gross proceeds1,467,000636,000Insurance premium financing669,000 Costs to raise capital included in accrued expenses308,000 Reserves related to term promissory note included in prepaid expenses109,000 Costs related to term promissory note paid directly from gross proceeds68,000 Cost accrued to amend term note payable 125,000Fixed assets included in accounts payable in prior period, paid in current period 1,769,000Increase in finance lease ROU assets for new leases 814,000Increase in finance lease obligation for new leases 814,000RubrYc asset acquisition by issuance of common stock 650,000Issuance of warrant for term note payable obligation4,499,000 Unrealized loss (gain) on available-for-sale debt securities (159,000)Supplemental cash flow information: Cash paid during the period for interest$ 749,000$ 687,000

- Definition

The amount paid for capital expenditures incurred for intangible assets during the previous year.

+ References

No definition available.

+ Details

Name:ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of cost accrued to amend the term note payable during the period.

+ References

No definition available.

+ Details

Name:ibio_CostAccruedToAmendTermNotePayable Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount of cost incurred to raise capital directly from gross proceeds.

+ References

No definition available.

+ Details

Name:ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount of total costs incurred in raising capital included in accrued expenses.

+ References

No definition available.

+ Details

Name:ibio_Coststoraisecapitalincludedinaccruedexpenses Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Non-Cash Transaction of Subscription Receivable For Capital Raise

+ References

No definition available.

+ Details

Name:ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period

Type:duration

- Definition

The amount of insurance premiums financed through non-cash means during the period.

+ References

No definition available.

+ Details

Name:ibio_Noncashinsurancepremiumfinancingduringperiod Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount of reserves related to term promissory note included in prepaid expenses, classified as non-cash activities.

+ References

No definition available.

+ Details

Name:ibio_ReservesRelatedToTermPromissoryNoteIncludedInPrepaidExpenses Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/214748113 9/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3

+ Details

Name:us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

+ Details

Name:us-gaap_AmortizationOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase in lease obligation from new lease.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3

+ Details

Name:us-gaap_CapitalLeaseObligationsIncurred Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section

45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect -Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_DebtConversionConvertedInstrumentAmount1 -Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction -Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details

Name:us-gaap_Depreciation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1

+ Details

Name:us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash outflow for principal payment on finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5

+ Details

Name:us-gaap_FinanceLeasePrincipalPayments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of amortization expense attributable to right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of gain (loss) on sale or disposal of intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write-down of assets from their carrying value to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4

+ Details

Name:us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

+ Details

Name:us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15

+ Details

Name:us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of increase (decrease) in obligation for operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) in noncurrent operating liabilities classified as other.

+ References

No definition available.

+ Details

Name:us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) in prepaid expenses, and assets classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The increase (decrease) during the reporting period in security deposits.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInSecurityDeposits Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2

+ Details

Name:us-gaap_InterestPaidNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2

+ Details

Name:us-gaap_InventoryWriteDown Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:us-gaap_LitigationSettlementAmountAwardedFromOtherParty Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

+ Details
Name:us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

+ Details
Name:us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details
Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of amortization of other deferred costs recognized in the income statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_OtherAmortizationOfDeferredCharges Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_PaymentsOfCapitalDistribution Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow for loan origination associated cost which is usually collected through escrow.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_PaymentsOfLoanCosts Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:us-gaap_ProceedsFromNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash inflow from debt classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:us-gaap_ProceedsFromOtherDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11

+ Details

Name:us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:us-gaap_ProceedsFromSaleOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting

Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

+ Details

Name:us-gaap_ProfitLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_RepaymentsOfNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash outflow for the payment of debt classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_RepaymentsOfOtherDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase in right-of-use asset obtained in exchange for finance lease liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2

+ Details

Name:us-gaap_SaleAndLeasebackTransactionGainLossNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_ShareBasedCompensation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 49 R8.htm IDEA: XBRL DOCUMENT

Nature of Business 12 Months Ended
Jun. 30, 2024
Nature of Business Nature of Business

1. Nature of Business
iBio, Inc. (the "Company" of "iBio") is a preclinical-stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

In September 2022, iBio has focused on utilizing AI and machine learning (ML) to discover and design antibodies against hard-to-drug targets upon the acquisition of substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc") was consummated. This acquisition commenced the Company's transition to an AI-enabled biotech company and the closing of the sale of the Contract Development and Manufacturing Organization (CDMO) facility in Texas concluded its transition. These strategic decisions enable the Company to solely focus resources on the development of AI-powered precision antibodies. The Company's current therapeutics being developed are all in preclinical development and it has not completed any clinical trials for any vaccine or therapeutic protein product candidate produced using iBio technology and there is a risk that it will be unsuccessful in developing or commercializing any product candidates.

One of the key features of iBio's technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with unprecedented precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. Another integral part of iBio's technology stack is the machine learning (ML) based antibody-optimizing StableHu™ technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.

iBio also developed the EngageTx™ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio's own development initiatives, the Company's internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.

iBio's technology stack also includes ShieldTx™, an antibody masking technology enabling the creation of conditionally activated antibodies. These masks keep antibodies inactive until they reach diseased tissue, where the masks are removed, and the antibodies are activated. This mechanism is thought to broaden the therapeutic window, potentially making improving efficacy and safety of treatments more effective and safer. Conditionally activated antibodies are also believed to enable the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets which, due to their expression in multiple tissues, would otherwise raise safety concerns.

iBio's scientific team, comprised of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to quickly translate scientific discoveries into potential therapeutic applications.

Artificial Intelligence in Antibody Discovery and Development
iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company's AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.

Pre-Clinical Pipeline
iBio is currently in the process of building and advancing its preclinical pipeline by leveraging its technology stack focused on hard-to-drug targets and molecules offering differentiation in both obesity and cardiometabolic disease space, as well
as immune-oncology. As the Company continues to leverage its technology stack and develop its existing immune-oncology pre-clinical pipeline, the Company also is seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. iBio also continues to assess its options rights to license three of the four assets under the AstralBio collaboration to add obesity and cardiometabolic programs into its pre-clinical pipeline. Under this strategic collaboration with AstraBio, it affords iBio the opportunity to expand the Company's pipeline and build a presence in the cardiometabolic disease space.

Graphic

Digital Infrastructure
iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, AI, ML, and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. iBio's aspiration is to digitize its operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, it remains committed to further investing in our digital infrastructure to support its ambitious goals.

Strategic Alliances, Collaborations, and Joint Ventures
iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.

- References

No definition available.

+ Details
Name:ibio_NatureOfBusinessAbstract Namespace Prefix:ibio_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details
Name:us-gaap_NatureOfOperations Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 50 R9.htm IDEA: XBRL DOCUMENT
Basis of Presentation 12 Months Ended
Jun. 30, 2024
Basis of Presentation Basis of Presentation
2. Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of iBio Inc. and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.

Going Concern
In accordance with ASU No. 2014-15, , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.
Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40)

The Company generated negative cash flows from operations of approximately $18.6 million for the twelve months ended June 30, 2024. Historically, the Company's liquidity needs have been met by the

sale of sale of convertible notes payable, common shares, and the issuance of common shares through the exercise of warrants. As of June 30, 2024, iBio had total current assets of approximately $15.7M, of which approximately $14.2 was cash and cash equivalents. The Company incurred net losses of approximately $24.9 million during the twelve months ending June 30, 2024. As of June 30, 2024, we have an operating capital deficit of $18.6 million which compares to the $30.4 million operating capital deficit we maintained as of June 30, 2023.

The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. Management's current financing and business plans have not mitigated such substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date of filing this Annual Report on Form 10-K for the year ended June 30, 2024.

In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, the Company consummated the sale of its 130,000 square foot current Good Manufacturing Practice (cGMP) facility located in Bryan, Texas (the "Facility") satisfying all outstanding amounts under the Term Loan (see Note 3 – Discontinued Operations for more information), raised funds through equity offerings or other financing alternatives, reduced its workforce, entered into a collaboration agreement to discover and develop novel antibodies for obesity and other cardiometabolic diseases and sold certain intellectual property rights. Potential options being considered to further increase liquidity, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a combination thereof. However, the Company anticipates that its expenses will increase as it continues its research and development activities and conducts clinical trials.

During the first quarter of fiscal year 2024, the Company completed at-the-market offerings and sold 170,989 shares of common stock, par value $0.001 per share (the "Common Stock") for which it received approximately $1.7 million. The Company also sold 181,141 shares of Common Stock under its purchase agreement entered into on August 4, 2023 (the "Purchase Agreement"), with Lincoln Park Capital Fund, LLC ("Lincoln Park") and received approximately $1.2 million in proceeds. During the second quarter ended December 31, 2023, the Company sold an additional 21,457 shares to Lincoln Park under the Purchase Agreement for approximately $0.1 million.

On December 7, 2023, the Company closed a public offering (the "2023 Offering") pursuant to which it sold in the 2023 Offering, (i) 600,000 shares (the "Shares") of the Company's Common Stock, (ii) 1,650,000 pre-funded warrants (the "2023 Pre-Funded Warrants") exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C common warrants (the "Series C Common Warrants") exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D common warrants (the "Series D Common Warrants," and together with the Series C Common Warrants, the "Common Warrants") exercisable for an aggregate of 2,250,000 shares of Common Stock. A.G.P./Alliance Global Partners("A.G.P.") acted as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC ("Brookline"), acted as co-placement agent (A.G.P. and Brookline are referred to herein, collectively, as the "Placement Agents") for the 2023 Offering. The Company received approximately $4.5 million in gross proceeds from the 2023 Offering, including the exercise of all 2023 Pre-Funded Warrants and prior to deducting placement agent fees and other estimated offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants. (See Note16 – Stockholders' Equity for more information.)

On February 25, 2024, the Company entered into an asset purchase agreement (the "PD-1 Purchase Agreement") with Otsuka Pharmaceutical Co., Ltd. ("Otsuka") pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company's early-stage programmed cell death protein 1 ("PD-1") (the "PD-1 Assets") developed or held for development in consideration of $1,000,000 paid at closing. The PD-1 Purchase Agreement also provides for a potential contingent payment of $2,500,000 upon the achievement of specified developmental milestones and a second potential contingent payment of $50,000,000 upon the achievement of specified milestones following commercialization. The sale of the PD-1 Assets closed on February 25, 2024.

On March 26, 2024, the Company entered into a securities purchase agreement (the "2024 Securities Purchase Agreement") with several institutional investors and an accredited investor (the "Purchasers") for the issuance and sale in a private placement (the "Private Placement") of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315 shares of Common Stock, (ii) pre-funded warrants (the "2024 Pre-Funded Warrants") to purchase up to 2,585,963 shares of the Company's Common Stock at an exercise price of $0.0001 per share, and(iii) Series E Common Stock purchase warrants (the "Series E Warrants") to purchase up to 5,287,278 shares of the Company's Common Stock at an exercise price of $2.64 per share. The Series E Warrants are exercisable at any time after the six-month anniversary of their issuance (the "Initial Exercise Date") at an exercise price of $2.64 per share and have a term of exercise equal to five years from the date of issuance. The combined purchase price for one share of common stock and the accompanying Series E Warrant was $2.85 and the purchase price for one 2024 Pre-Funded Warrant and the accompanying Series E Warrant was $2.849. Chardan Capital Markets, LLC ("Chardan") served as the exclusive placement agent in connection with the Private Placement and was paid (i) a cash fee equal to 6.0% of the aggregate gross proceeds of the Private Placement (reduced to 4.0% with respect to certain investors), and (ii) up to $50,000 for legal fees and other out-of-pocket expenses. The Private Placement closed on April 1, 2024. The Company received net proceeds of approximately $14.1 million from the Private Placement, after deducting estimated offering expenses payable by the Company, including placement agent fees and expenses.

During fiscal year 2024, 1,650,000 of the 2023 Pre-Funded Warrants, 1,178,500 Series C Common Warrants and 1,053,500 Series D Common Warrants were exercised for proceeds of $4,464,000. In August 2024, 1,000 Series C Common Warrants and 1,000 Series D Common Warrants were exercised for proceeds of $4,000.

The Company's cash, cash equivalents and restricted cash of approximately $14.4 million as of June 30, 2024, is anticipated to be sufficient to support operations into the first quarter of fiscal year 2026, unless the Company reduces its burn rate further or raises additional capital. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plans. It is the Company's goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.

The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Reverse Stock Split

On September 22, 2022, the Company's Board approved the implementation of a reverse stock split at a ratio of one-for-twenty five (; 25) shares of the Company's Common Stock. The reverse stock split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the one-for-twenty five reverse stock split. See Note 17 - Stockholders' Equity for more information.
1

Following the 2023 Annual Meeting, the Company's Board approved a reverse stock split at a ratio of one-for-20 (:20). Following such approval, on November 28, 2023, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the 2024 Reverse Stock Split.
1

- References

No definition available.

+ Details

Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type: na Period Type:duration

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent

+ Details

Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 51 R10.htm IDEA: XBRL DOCUMENT

~~Discontinued Operations12 Months Ended~~
~~Jun. 30, 2024~~
~~Discontinued Operations~~ ~~Discontinued Operations~~
~~3. Discontinued Operations~~

On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, on February 10, 2023, the Company entered into an Auction Sale Agreement (the "Auction Sale Agreement") with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the "Auctioneers") for the sale at public auction of equipment and other tangible personal property (the "Equipment") located at the Facility. The Auctioneers guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group's $0.2 million fee. Total proceeds received in fiscal year 2023 were approximately $2.6 million.
On May 17, 2024, iBio CDMO entered into a purchase and sale agreement, dated as of May 17, 2024 (the "2024 Purchase and Sale Agreement") with The Board of Regents of the Texas A&M University System ("The Board of Regents") pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property.

Additionally, on May 17, 2024, iBio CDMO, the Company and Woodforest entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the 2024 Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the "Indebtedness Deficiency Amount") and thereafter the Company issued to Woodforest a pre-funded warrant ("Pre-Funded Warrant"). (See Note 14 – Debt for more information.)

;

On May 31, 2024, in accordance with the terms of the Settlement Agreement in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share
Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.

The Company incurred pre-tax charges of approximately $1.9 million in fiscal year 2023 for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remained employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The Company further recorded a charge in discontinued operations for approximately $35.7 million in fiscal year 2023, of which approximately $17.9 million was the result of a fixed asset impairment charge (see Note 11 – Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance, approximately $0.9 million of interest related to the term note payable, and the balance related to operational costs related to winding down the CDMO business.

During fiscal year 2024, the Company recorded an additional fixed asset impairment charge of $3.1 million, a loss on the sale of the Facility of approximately $4.8 million and a gain on the extinguishment of debt of approximately $0.8 million
in discontinued operations. (See Note 5 – Financial Instruments, Note 11 – Fixed Assets and Note 14 – Debt for more information.)

The results of iBio CDMO's operations are reported as discontinued operations for the years ended June 30, 2024 and 2023. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intended to sell are classified as "held for sale" on the consolidated balance sheets as of June 30, 2024 and 2023. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statements of cash flows. Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company's continuing operations.

The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):

	Years Ended June 30,	
	2024	***2023***
Revenues	***$***	***=***
	$	***391***
Cost of goods sold		
	=	***=***
Gross profit		***52***
	=	***=***
Operating expenses:		***339***
—Research and development		
	=	***=***
—General and administrative		***6,344***
		1,207
—Fixed asset impairments		***6,751***
		3,100
—Loss (gain) on sale of fixed assets		***17,900***
		4,816
—Inventory reserve		***(773)***
	=	***=***

Total operating expenses	4,915
	9,123
	35,137
Other income (expenses):	
Interest expense - term note payable	(1,149)
Gain on extinguishment of debt	(900)
	808
Other	—
	—
Total other expenses	(1)
	(341)
	(901)
Loss from discontinued operations	
	$ (9,464)
	$ (35,699)

The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2024 and 2023 (in thousands):

	June 30, 2024	June 30, 2023
Current assets:		
Operating lease right-of-use assets	$ -	$ 1,941
Property and equipment, net	-	16,124
Total current assets	$ -	$ 18,065
Current liabilities:		

~~Operating lease obligation~~	
~~$~~	~~-~~
~~$~~	~~1,941~~
~~Total current liabilities~~	
~~$~~	~~-~~
~~$~~	~~1,941~~

~~The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):~~

~~Years Ended June 30,~~		
	~~2024~~	~~2023~~
~~Depreciation expense~~		
~~$~~	~~—~~	~~$~~ ~~273~~
~~Amortization of finance lease right-of-use assets~~	~~—~~	~~20~~
~~Purchase of fixed assets~~	~~—~~	~~1,542~~
~~Fixed asset impairments~~	~~3,100~~	~~—~~
~~Loss on sale of fixed assets~~	~~17,900~~	~~4,817~~
~~Gain on extinguishment of debt~~	~~—~~	~~(808)~~
~~Payments of term note payable~~	~~—~~	~~(1,513)~~
~~Inventory reserve~~	~~—~~	~~—~~
~~Sales proceeds of fixed assets~~	~~4,915~~	~~50~~
~~Payment of finance lease obligation~~	~~2,600~~	~~—~~
~~Investing non-cash transactions:~~		
~~Fixed assets included in accounts payable in prior period, paid in current period~~	~~—~~	~~1,542~~

Supplemental cash flow information:

Cash paid during the period for interest

577

603

- References

No definition available.

+ Details

Name:us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent

+ Details

Name:us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 52 R11.htm IDEA: XBRL DOCUMENT
Summary of Significant Accounting Policies12 Months Ended
Jun. 30, 2024
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
4. Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued to related to the extinguishment of the Term Loan, and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Accounts Receivable

Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management's policy is to write off accounts receivable against the allowance for credit losses when a balance is determined to be uncollectible. At June 30, 2024 and 2023, the Company determined that an allowance for credit losses was not needed. The Company had accounts receivable of $1 million at June 30, 2022.

Subscription Receivable
The Company accounts for any subscription receivable as a current asset. Subscription receivables represent funds related to the sale of Common Stock in which the funds have not yet been delivered to the Company. The funds are generally held in escrow on behalf of the Company and are delivered within a few days.

Revenue Recognition

The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party's rights regarding the distinct goods or services to be transferred ("performance obligations"), (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company recognizes revenue when it satisfies its performance obligations by transferring control of a promised good or service to the customer. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.

The Company analyzes its contracts to determine whether the elements can be separately identifiable and accounted for individually or as a bundle of goods or services. Allocation of revenue to individual elements that qualify for performance obligations is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June 30, 2024 and 2023, the Company had no credit loss provisions.

The Company generates contract revenue under the following types of contracts:

Fixed-Fee
Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.

Revenue can be recognized either 1) over time or 2) at a point in time. Revenue reported in discontinued operation was recognized at a point in time for all periods presented.

Collaborations/Partnerships
The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company's rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner.

The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, ("ASC 808"). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, ("ASC 606").

Collaborative ArrangementsRevenue from Contracts with Customers
Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.

For the years ended June 30, 2024, revenue in the amount of $225,000 was recognized from research activities performed and a non-refundable upfront license fee for which performance obligations were satisfied. No revenue was recognized for the year ended June 30, 2023.

Contract Assets
A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.

Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2024 and 2023, contract were $0.

assets

Contract Liabilities

A contract liability is an entity's obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer's consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.

Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2024, 2023 and 2022, contract liabilities were $200,000, $0 and $100,000, respectively. The Company recognized revenue of $0 in 2024 that was included in the contract liabilities balance as of June 30, 2023 and $100,000 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.

Leases

Leases

The Company accounts for leases under the guidance of ASC 842, . The standard established a right-of-use ("ROU") model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company's balance sheet, resulting in an increase in noncurrent assets and both current and noncurrent liabilities.

In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.

The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company's existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company's operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company's incremental borrowing rate requires judgement. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2024 and 2023 consisted of money market accounts. Restricted cash at June 30, 2024 consists of a letter of credit obtained related to the San Diego operating lease (see Note 16 - Operating Lease Obligations) and a Company purchasing card. The Company's bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was $215,000 and $253,000 June 30, 2024 and 2023, respectively.

The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):

June 30,

June 30,

2024

2023

Cash and equivalents	***$***	***14,210***
	$	***4,301***
Collateral held for letter of credit - term note payable		***=***
Collateral held for letter of credit - San Diego lease		***3,025***
		198
Collateral held for Company purchasing card		***198***
		17
Total cash, cash equivalents and restricted cash		***55***
	$	***14,425***
	$	***7,579***

Investments in Debt Securities

Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. The Company held no investments in debt securities at June 30, 2024 and 2023.

Inventory

Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held no at June 30, 2024 and 2023.

~~inventory~~

Research and Development

The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board ("FASB") ASC 730-10, "" ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expenses were reported in continuing operations for the year ended June 30, 2024. No research and development expenses were reported in discontinued operations for the year ended June 30, 2024. For the year ended June 30, 2023, research and development expenses were reported in both continuing and discontinuing operations.

Research and Development

Right-of-Use Assets

Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.

Fixed Assets

Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from ~~three~~ **to** ~~thirty-nine~~ **years.**

The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

See Note 11 - Fixed Assets for additional information.

Intangible Assets

Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.

The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.

For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.

Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

See Note 12 – Intangible Assets for additional information.

Share-based Compensation

The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.

The impact that share-based payment awards will have on the Company's results of operations is a function of the number of shares awarded, the trading price of the Company's stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company's stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.

Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting
schedules and the Company's historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be . In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 – Share-Based Compensation for additional information.
~~zero~~

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for tax positions as of June 30, 2024 and 2023. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023.

~~uncertain~~
Concentrations of Credit Risk

Cash
The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2024 and 2023, amounts in excess of insured limits were approximately $664,000 and $6,900,000, respectively.

Revenue
During the fiscal year ended June 30, 2024, the Company reported revenue of $225,000 in continuing operations from two research collaborators and $0 of its revenue from discontinued operations. During the fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers.

Recently Issued Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, ("ASU 2016-13"), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company's consolidated financial statements.

Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
In October 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative" ("ASU 2023-06"). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("ASC").
The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SEC's regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): "Improvements to Reportable Segment Disclosures" ("ASU 2023-07") to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company's 2024 fiscal year annual reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2023-09") to enhance the transparency and decision-usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. This ASU applies to all entities subject to income taxes. This ASU will be effective for public companies for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

- References

No definition available.

+ Details
Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent

+ Details
Name:us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration
XML 53 R12.htm IDEA: XBRL DOCUMENT
Financial Instruments and Fair Value Measurement 12 Months Ended
Jun. 30, 2024
Financial Instruments and Fair Value Measurement Financial Instruments and Fair Value Measurement
5. Financial Instruments and Fair Value Measurement

The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company's consolidated balance sheets approximated their fair values as of June 30, 2024 and 2023 due to their short-term nature. The carrying value of the promissory note receivable, term promissory note, equipment financing payable, insurance financing payable and finance lease obligations approximated fair value as of June 30, 2024 and 2023 as the interest rates related to the financial instruments approximated market.

The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value:

- *Level 1 – Quoted prices in active markets for identical assets or liabilities.*
- *Level 2 – Quoted prices for similar assets and liabilities in active markets or inputs that are observable.*
- *Level 3 – Inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).*

The Company initially marketed the CDMO business and during the second quarter of fiscal year 2023, changed its strategy to selling the stand-alone CDMO assets. These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. In the second quarter of fiscal year 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6.3 million and $11.3 million for the Facility and equipment, respectively, reducing their estimated fair values to $16.35 million and $2.1 million, respectively. In the first quarter of fiscal year 2024, the Company entered into an agreement for the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of fiscal year 2023 to reflect the agreed upon sales price less estimated costs to sell. The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million.

On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. Upon receiving the termination notice, the Company reassessed the CDMO fixed assets for impairment which included obtaining appraisal values as of November 9, 2023. The Company utilized a market approach, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and concluded that fair value of the assets approximated their carrying value and no further impairment was required at that time. The CDMO Equipment was sold during the third quarter of fiscal year 2023.

During the second quarter of fiscal year 2024, the Company made the decision to auction the Facility. The Company utilized a market approach, including comparable assets, to estimate the fair value of the Facility. An additional $3.1 million fixed asset impairment was recorded the second quarter of Fiscal 2024 in discontinued operations to write down the carrying value of the Facility to fair value.

During the third quarter of fiscal year 2024, the Company utilized a market approach, using an independent third-party appraisal, including comparable assets, in addition the Company considered previous bids from prospective buyers and the nearing maturity date of the term note and concluded that fair value of the assets approximated their carrying value and no further impairment was required.

During the fourth quarter of fiscal year 2024, the Company entered the 2024 Purchase and Sale Agreement with The Board of Regents pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property for $8,500,000. The transaction closed on May 31, 2024 and, in accordance with ASC 360-10-40-5, , an approximate $4.8 million loss was recorded in discontinued operations upon the derecognition of the current assets held-for-sale.

Property, Plant, and Equipment

- References

No definition available.

+ Details

Name:us-gaap_FairValueDisclosuresAbstract ***Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration***

- Definition

***The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.*

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Name:us-gaap_FairValueDisclosuresTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 54 R13.htm IDEA: XBRL DOCUMENT

Significant Transactions12 Months Ended

Jun. 30, 2024

Significant Transactions Significant Transactions

6. Significant Transactions

Affiliates of Eastern Capital Limited

On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC ("iBio CDMO", and collectively with the Company, the "Purchaser") entered into a series of agreements (the "Transaction") with College Station Investors LLC ("College Station"), and Bryan Capital Investors LLC ("Bryan Capital" and, collectively with College Station, "Seller"), each affiliates of Eastern Capital Limited ("Eastern," a former significant stockholder of the Company) whereby in exchange for a certain cash payment and a warrant the Company:

- *(i)* acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility's ground lease;
- *(ii)* acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and
- *(iii)* otherwise terminated all agreements between the Company and the affiliates of Eastern.

The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System ("Texas A&M") and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the "Sublease") until the consummation of the sale of the Facility.

The Purchase and Sale Agreement

On November 1, 2021, the Purchaser entered into a purchase and sale agreement (the "PSA") with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the "Ground Lease Agreement") that it entered into with Texas A&M (the "Landlord") related to the land at which the Facility is located together with all improvements pertaining thereto (the "Ground Lease Property"), which previously had been

the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the "Warrant") described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.

As discussed above, iBio CDMO is being accounted for as a discontinued operation. In fiscal year 2024, the assets acquired were sold and the asset lease was terminated. These assets were classified as assets held for sale on the June 30, 2023 consolidated balance sheet.

The Credit Agreement

In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. See Note 14 – Debt for further information of the Term Loan.

The Warrant

As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock at an exercise price of $665 per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, 579 of such shares were valued at $217,255 to reflect the final payment of rent due under the Sublease. The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired. See Note 17 – Stockholders' Equity for additional information.

RubrYc

On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. ("RubrYc") described in more detail below:

Collaboration and License Agreement

The Company entered into a collaboration and licensing agreement (the "RTX-003 License Agreement") with RubrYc to further develop RubrYc's immune-oncology antibodies in its RTX-003 campaign. Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fieldsRubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.

.

Collaboration, Option and License Agreement

The Company entered into an agreement with RubrYc (the "Collaboration, Option and License Agreement") to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc's artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.

ten

Stock Purchase Agreement

In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement ("Stock Purchase Agreement") with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc's Series A-2 preferred stock ("Series A-2 Preferred") for $7,500,000.

The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:

Preferred stock	
$	***1,760,000***
Intangible assets	***4,300,000***
Prepaid expenses	***1,440,000***
$	***7,500,000***

On September 16, 2022, the Company entered an asset purchase agreement with RubrYc (the "Asset Purchase Agreement") pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued 5,117 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the "Closing Shares"). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company's option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Asset Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.

Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and dismissed bankruptcy proceedings in June 2023. The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.

The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:

Intangible assets	
$	***1,228,000***
Fixed assets	***114,000***
$	***1,342,000***

In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. See Note 9 – Finance Lease ROU Assets and Note 15 – Finance Lease Obligations.

Former CEO Departure

Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the "CEO) and former Chairman of the Board of Directors (the "Board"), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.

Separation Agreement and General Release

In connection with Mr. Isett's resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the "Agreement"). Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. Following Mr. Isett's termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), the Company will pay the full cost of this benefit for up to (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of fiscal year 2023. As of June 30, 2024, approximately $0.5 million is recorded in accrued expenses.

twenty-fourtwenty-foureighteeneighteen

- Definition

Significant Transactions [Text Block]

+ References

No definition available.

+ Details

Name:ibio_SignificantTransactionsTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration XML 55 R14.htm IDEA: XBRL DOCUMENT
Promissory Note Receivable12 Months Ended
Jun. 30, 2024
Promissory Note Receivable Promissory Note Receivable
7. Promissory Note Receivable

On June 19, 2023, the Company issued a promissory note (the "Note") with Safi Biosolutions, Inc. ("Safi") in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the "Convertible Note") issued by the Company to Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided.

For the fiscal years ended June 30, 2024 and 2023, interest income amounted to $88,000 and $75,000, respectively. As of June 30, 2024 and 2023, the Note balance and accrued interest totaled $1,794,000 and $1,706,000, respectively. On August 29, 2024, the Company received a payment from Safi of approximately $713,000 for all interest owed and approximately $419,000 for a partial payment on the

outstanding principal. At June 30, 2024, $713,000 was reported in current assets with the remaining $1,081,000 reported in noncurrent assets.

- Definition

The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_ReceivablesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 56 R15.htm IDEA: XBRL DOCUMENT

Investments in Debt Securities 12 Months Ended
Jun. 30, 2024

Investments in Debt Securities Investments in Debt Securities

8. Investments in Debt Securities

The Company did not hold any investments in debt securities at June 30, 2024.

Amortization of premiums paid on the debt securities amounted to $0 and $67,000 for the years ended June 30, 2024 and 2023, respectively.

Realized losses on available-for-sale debt securities are as follows (in thousands):

	Years Ended June 30,	
	2024	2023
Proceeds from sale of debt securities	$	=
	$	6,739
Cost of debt securities		
		=
		6,837
Realized loss on sale of debt securities		
	$	=
	$	(98)

- References

No definition available.

+ Details

Name:us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent

+ Details

Name:us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 57 R16.htm IDEA: XBRL DOCUMENT

Finance Lease ROU Assets 12 Months Ended

Jun. 30, 2024

Finance Lease ROU Assets Finance Lease ROU Assets

9. Finance Lease ROU Assets

The Company assumed three equipment leases as part of the RubrYc asset acquisition (see Note 6 – Significant Transactions). In addition, the Company leased a mobile office trailer which was classified as part of assets held for sale prior to its termination. The lease for the mobile office trailer was terminated in December 2022. See Note 15 – Finance Lease Obligations for more details of the terms of the leases.

The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):

	June 30, 2024	June 30, 2023
ROU - Equipment	$ 814	$ 814
Accumulated amortization	(475)	(204)
Net finance lease ROU assets	$ 339	$ 610

Amortization expense of finance lease ROU assets was approximately $271,000 and $204,000 for the years ended June 30, 2024 and 2023, respectively.

- Definition

The entire disclosure for lessee's right to use underlying asset under finance lease.

+ References

No definition available.

+ Details

Name:ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 58 R17.htm IDEA: XBRL DOCUMENT

Operating Lease ROU Assets 12 Months Ended

Jun. 30, 2024

Operating Lease ROU Assets Operating Lease ROU Assets

10. Operating Lease ROU Assets

San Diego, California

On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. The net carrying amount of this ROU operating lease asset was $2,401,000 and $2,722,000 at June 30, 2024 and 2023, respectively.

Bryan, Texas

On November 1, 2021, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. This lease was terminated on May 31, 2024. The net amount of this ROU operating lease asset is included in assets held for sale.

See Note 16 - Operating Lease Obligations for additional information.

- Definition

The entire disclosure for lessee's right to use underlying asset under operating lease.

+ References

No definition available.

+ Details

Name:ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_LesseeOperatingLeaseDescriptionAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 59 R18.htm IDEA: XBRL DOCUMENT

Fixed Assets 12 Months Ended

Jun. 30, 2024

Fixed Assets Fixed Assets

11. Fixed Assets

The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):

	June 30, 2024	June 30, 2023
Building and improvements	$ 695	$ 695
Machinery and equipment	-	3,545
Office equipment and software	-	3,521
	403	403
	1,098	7,164
Accumulated depreciation	(1,011)	(1,011)
	(400)	(1,934)
Net fixed assets	$ 687	$ 5,230

Depreciation expense was approximately $638,000 and $400,000 for the years ended June 30, 2024 and 2023, respectively.

Fixed assets held for sale at June 30, 2024 and 2023 in the amount of $0 and $16,124,000, respectively, are included in assets held for sale. No depreciation expense related to held-for-sale assets was recorded for the year ended June 30, 2024. The depreciation expense related to held-for-sale assets for the year ended June 30, 2023 is classified as part of loss from discontinued operations.

The Company re-evaluated its business strategy and reviewed its product portfolio during fiscal year 2023 which resulted in an impairment charge of approximately $17.9 million to the assets held for sale. An additional $3.1 million fixed asset impairment charge related to the assets held for sale was recorded in the second quarter of fiscal year 2024. See Note 5 - Financial Instruments and Fair Value Measurement for more information.

- References

No definition available.

+ Details

Name:us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section

50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7

+ Details

Name:us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration XML 60 R19.htm IDEA: XBRL DOCUMENT

Intangible Assets 12 Months Ended

Jun. 30, 2024

Intangible Assets Intangible Assets

12. Intangible Assets

On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 – Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (Treg) cells while enhancing T effector (Teff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. In addition, the Company also received preferred shares and an option for future collaboration licenses.

On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 – Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate.

In January 2014, the Company entered into a license agreement with the University of Pittsburgh whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provided for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company had agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") – initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company's financial obligations for the management of the patents under the license agreement ceased on August 14, 2023, and transitioned back to the University of Pittsburgh and the Medical University of South Carolina. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000 in fiscal year 2023.

The Company re-evaluated its business strategy and reviewed its product portfolio during fiscal year 2023. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired. Accordingly, the Company recorded an impairment charge during fiscal year 2023 in general and administrative expenses of approximately $565,000. No impairments were recorded in fiscal year 2024.

The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):

June 30,				
June 30				
2023				
Amortization				
Additions				
Impairments				
2024				
Intellectual property – gross carrying value				
$	400	$	—	$
—	$	400		
Intellectual property – accumulated amortization				
-	(15)	-	(20)	-
—	-	—	-	(35)
Total definite lived intangible assets				

	$	385
		(20)
=		
	$	365
=		
Intellectual property – indefinite-lived		
		5,003
=		
=		
=		
		5,003
Total net intangibles		
	$	5,388
=		
	$	5,368

Amortization expense was approximately $20,000 and $126,000 for the years ended June 30, 2024 and 2023, respectively. The weighted-average remaining life for intellectual property and patents on June 30, 2024 was approximately 18.3 years. The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands):

For the Year Ended June 30,	
2025	$ 20
2026	20
2027	20
2028	20
2029	20
Thereafter	265
Total	$ 365

- References

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration XML 61 R20.htm IDEA: XBRL DOCUMENT

Accrued Expenses 12 Months Ended

Jun. 30, 2024

Accrued Expenses Accrued Expenses

13. Accrued Expenses

Accrued expenses consist of the following (in thousands):

	June 30, 2024	June 30, 2023
Personnel related costs	$ 1,568	$ 3,879
Real estate taxes	-	—
Interest and fees related to term note payable	-	268
Professional fees	-	—
Other accrued expenses	-	183
Total accrued expenses	$ -	$ 460
		200
	$ 1,568	$ 4,561

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_PayablesAndAccrualsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 62 R21.htm IDEA: XBRL DOCUMENT

Debt 12 Months Ended

Jun. 30, 2024

Debt Debt

14. Debt

The Credit Agreement

In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 Term Loan to purchase the Facility, which Term Loan is evidenced by a term note (the "Term Note") (for a complete description of the Transaction please see Note 6 – Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provided that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.

On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5.5 million of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5.1 million of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the "Fraunhofer Settlement Funds") (see Note 20 - Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the "Liquidity Covenant") in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a "going concern" designation. In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.

~~month~~

In January 2023, the Company's unrestricted cash decreased below the required $7.5 million, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the "Second Amendment"), which amendment, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amendment, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement.

On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the "Third Amendment"), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.

On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the "Fourth Amendment"), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2 million of the $5.1 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3 million being held in a Company account at Woodforest. In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the "Woodforest Purchase Agreement") for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Woodforest Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7.5 million to $1 million.

On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the "Fifth Amendment"), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Woodforest Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest. In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in-kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3.00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.

On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the "Sixth Amendment"), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Woodforest Purchase Agreement (as defined in the Credit Agreement) for the sale of the Facility within business day after entry into the Sixth Amendment, and (ii) if the Facility is not sell on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. In addition, if the closing and funding of the Woodforest Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO's real estate, including the Facility, at the cost of iBio CDMO.

~~one~~

On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the "Seventh Amendment"), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default exists (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as iBio CDMO maintains a minimum balance of $2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as iBio CDMO maintains a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as iBio CDMO maintains a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). On the earlier of (a) the closing of the Woodforest Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), the Company will pay Woodforest $20,000. In addition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires the Company to maintain a specified amount in unrestricted cash to $0. Subsequent to executing the Seventh Amendment, the Company withdrew $2,000,000 of the restricted funds.

On December 22, 2023, iBio CDMO and Woodforest entered into the Eighth Amendment (the "Eighth Amendment") to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the Term Loan to the earlier of (a) March 29, 2024, or (b) the acceleration of maturity of the Term Loan in accordance with the Credit Agreement; (ii) reduce the interest rate from 5.25% to 4.5% and increase the payment in kind from 3% to 4.5%; and (iii) permit the Company, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) exists to make a withdrawal from the Reserve Funds Deposit Account (as defined in the Credit Agreement) so long as the Company maintains a minimum balance of $900,000 until Payment in Full (as defined in the Credit Agreement). The Eighth Amendment provided that the Company will use its best efforts to consummate and close a sale of the Collateral (as defined in the Credit Agreement) on or before the Maturity Date. The amendment also increased the fees payable by Borrower to Woodforest by $10,000. Accordingly, per the amendment, on the earlier of (a) the closing of the sale of the Collateral, or (b) the Maturity Date, the Borrower will pay Woodforest a fee in the amount of $155,000. Subsequent to executing the Eighth Amendment, the Company withdrew an additional $150,000 of the restricted funds. The amount held in the restricted bank account was approximately $900,000 as of February 9, 2024.

On March 28, 2024, iBio CDMO and Woodforest entered into the Ninth Amendment (the "Ninth Amendment") to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the term loan to the earlier of (a) May 15, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement.

On May 14, 2024, iBio CDMO and Woodforest entered into the Tenth Amendment (the "Tenth Amendment") to the Credit Agreement, which amended the Credit Agreement to: (i) set the maturity date of the term loan to the earlier of (a) May 31, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement.

On May 17, 2024, iBio CDMO, the Company and Woodforest also entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the "Indebtedness Deficiency Amount") and thereafter the Company issued to Woodforest upon receipt of NYSE American LLC approval a pre-funded warrant ("Pre-Funded Warrant") that expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share for 1,560,570 shares of the Company's common stock which equals the $4,499,124.88 Indebtedness Deficiency Amount divided by $2.883 (the greater of the book value or the market value of the Company's common stock at the time the Settlement Agreement is executed). Pursuant to the Settlement Agreement, upon the closing of the sale of the Property under the Purchase and Sale Agreement, Woodforest would purchase the Pre-Funded Warrant in satisfaction of the Indebtedness Deficiency Amount, Woodforest would release the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to such date, and the Company and iBio CDMO will release Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to such date.

;

On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,006 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share

Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.

At June 30, 2024, the balance of the Term Note was $0. At June 30, 2023, the balance of the Term Loan was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs.

Equipment Financing

On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. The financing is payable in monthly installments of $16,230 through October 2025. At June 30, 2024 and 2023, the balance owed under the financing was $241,000 and $401,000, respectively. Interest incurred under the financing for the years ended June 30, 2024 and 2023 totaled approximately $35,000 and $31,000,

respectively.

Future minimum payments under the finance lease obligation are due as follows (in thousands):

Fiscal period ending on June 30:	Principal	Interest	Total
2025	$ 178	$ 17	$ 195
2026	63	1	64
Total minimum equipment financing payments	241	18	259
Less: current portion	(178)	—	—
Long-term portion of minimum equipment financing obligation	$ 63	—	—

Credit and Security Agreement

On January 16, 2024, the Company entered into a credit and security agreement (the "Credit and Security Agreement") with Loeb Term Solutions LLC, an Illinois limited liability company ("Lender"), for a term loan or equipment line of credit loan (the "Loan") pursuant to which the Company issued to Lender a term promissory note in the principal amount of $1,071,572 (the "2024 Term Note") bearing interest at the Prime Rate, as quoted in the Wall Street Journal plus 8.5% (the "Effective Rate"), for proceeds of $1,027,455 after payment of $42,863 to Lender as an origination fee, $1,173 for appraisal costs, and $75 for bank wire fees.

The 2024 Term Note provides for monthly payments of principal and interest based on a four-year amortization period, with a balloon payment of all principal, accrued interest and any other amounts due on the two year anniversary of the 2024 Term Note. The Credit and Security Agreement granted to Lender a security interest in substantially all of the Company's assets other than any intellectual property related to any of the Company's filed patents (the "Loeb Collateral") to secure the Company's obligations under the 2024 Term Note. The 2024 Term Note is subject to a prepayment fee of: 4% of the principal amount being prepaid if the 2024 Term Note is prepaid during the first 12 months from its issuance, and 3% of the principal amount being prepaid if the 2024 Term Note is prepaid during the second 12 months from its issuance date.

The Credit and Security Agreement provides that the Company may request that Lender make further loan advances to the Company subject to certain conditions, including that the Company is not otherwise in default under the Credit and Security Agreement and its obligations and liabilities to Lender do not exceed a borrowing base equal to the lesser of: (a) eighty percent (80.0%) of the forced liquidation value of the Company's Eligible Equipment as determined by Lender in its sole reasonable discretion, or (b) a monthly dollar amount. The Credit and Security Agreement defines "Eligible Equipment" as equipment that (a) is owned by the Company free of any title defect or any lien or interest of any person except the lien in favor of the Lender; (b) is located at locations permitted by the Credit and Security Agreement; (c) in the Lender's reasonable opinion, is not obsolete, unsalable, damaged or unfit for further use; (d) is appraised by an appraiser satisfactory to the Lender; (e) complies with any representation or warranty with respect to equipment contained in the Credit and Security Agreement; and (f) is otherwise acceptable to the Lender in its reasonable discretion.

The Company's obligations to Lender under the 2024 Term Note and Credit Security Agreement are further secured by an validity guarantee, dated January 16, 2024 (the "Validity Guarantee"), executed by Dr. Martin Brenner and Felipe Duran in their individual capacity (the "Indemnitors") for the benefit of Lender. The Validity Guarantee provides that the Indemnitors will indemnify the Lender from any loss or damage, including any actual, consequential or incidental loss or damage, suffered by Lender as a result of, or arising out of, among other things, any willful or intentional misrepresentation or gross negligence by the Company in connection with the Loan and any acts of fraud, conversion, misappropriation or misapplication of funds or proceeds of any Loeb Collateral by the Company or the Indemnitors.

The Credit and Security Agreement contains customary events of default. If an event of default occurs, the 2024 Term Note provides that regardless of whether the Lender elects to accelerate the maturity of the 2024 Term Note, the entire principal remaining unpaid hereunder shall thereafter bear interest at the rate equal to the Effective Rate plus 6% per annum.

The financing is payable in monthly installments of $30,710 through December 2025 and a balloon payment of $652,060 in January 2026. At June 30, 2024, the balance owed under the financing was $984,000. Interest incurred under the financing for the year ended June 30, 2024 totaled approximately $66,000.

Future minimum payments under the term promissory note obligation are due as follows (in thousands):

Fiscal period ending on June 30:	Principal	Interest	Total
2025	$ 218	$ 151	$ 369
2026			

	766
	70
	836
Total minimum term promissory note payments	
	984
$	221
$	1,205
Less: current portion	
	(218)
Long-term portion of minimum term promissory note obligation	
$	766

Insurance Premium Financing

On October 30, 2023, the Company entered into an insurance premium financing agreement with FIRST Insurance Funding, a division of Lake Forest Bank & Trust Company, N.A., whereby approximately $597,000 was borrowed over ten months at an imputed interest rate of 8.5%. The financing is payable in monthly installments of $62,095 through August 2024. At June 30, 2024, the balance owed under the financing was approximately $123,000. Interest incurred under the financing for the year ended June 30, 2024, totaled approximately $25,000, respectively.

Future minimum payments under the insurance premium financing obligation are as follows (in thousands):

Fiscal period ending on June 30:	Principal	Interest	Total
2025	$ 123	$ 1	$ 124

- References

No definition available.

+ Details

Name:us-gaap_DebtDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-

1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Name:us-gaap_DebtDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 63 R22.htm
IDEA: XBRL DOCUMENT
Finance Lease Obligations12 Months Ended
Jun. 30, 2024
Finance Lease Obligations Finance Lease Obligations
15. Finance Lease Obligations

Equipment

As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $814,000 as part of the RubrYc Asset Purchase Agreement. The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.

Mobile Office Trailer

Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.

The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands):

Years Ended June 30,	2024	2023
Finance lease cost:		
Amortization of ROU assets	$ 271	$ 204
Interest on lease liabilities	48	49
Total lease cost	$ 319	$ 253
Other information:		
Cash paid for amounts included in the measurement lease liabilities:		
Financing cash flows from finance lease obligations	$ 272	$ 191

June 30,	2024	2023
Finance lease ROU assets	$ 339	$ 610
Finance lease obligation - current portion	$ 299	$ 272
Finance lease obligation - noncurrent portion	$ 53	$ 351
Weighted-average remaining lease term - finance lease	1.17 years	2.17 years
Weighted-average discount rate - finance lease obligation	9.500%	9.500%

Future minimum payments under the capitalized lease obligations are due as follows:

Fiscal year ending on June 30:	Principal

Interest	
Total	
2025	$ 299
	$ 20
	$ 319
2026	53
	1
	54
Total minimum lease payments	352
	$ 21
	$ 373
Less: current portion	(299)
Long-term portion of minimum lease obligations	$ 53

- References

No definition available.

+ Details

Name:us-gaap_FinanceLeaseLiabilityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent

+ Details

Name:us-gaap_LesseeFinanceLeasesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 64 R23.htm IDEA: XBRL DOCUMENT

Operating Lease Obligations12 Months Ended

Jun. 30, 2024

Operating Lease Obligations Operating Lease Obligations

16. Operating Lease Obligations

Texas Ground Lease

As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The Ground Lease was terminated on May 31, 2024. (See Note 3 - Discontinued Operations for more information.) The annual base rent payable under the Ground Lease Agreement was $151,450 which approximated 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land.

San Diego

On September 10, 2021, the Company entered into a lease for 11,383 square feet of space in San Diego, California. Terms of the lease include the following:

- The length of term of the lease is 88 months from the lease commencement date (as defined).
- The lease commencement date is September 16, 2022.
- The monthly rent for the first year of the lease is $51,223 and increases approximately 3% per year.
- The lease provides for a base rent abatement for months two through five in the first year of the lease.
- The landlord is providing a tenant improvement allowance of $81,860 to be used for improvements as specified in the lease.
- The Company is responsible for other expenses such as electric, janitorial, etc.
- The Company opened an irrevocable letter of credit in the amount of $188,844 in favor of the landlord. The letter of credit expires on October 8, 2024 and renews annually as required.

As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease

which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease right-of-use asset in the accompanying balance sheet. Rent expense for the San Diego facility commenced in fiscal year 2022, when the Company began making improvements to the facility.

The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):

Years Ended June 30,	2024	2023
Operating lease cost:		
	$ 563	
	$ 563	
Total lease cost		
	$ 563	
	$ 563	
Other information:		
	=	
	=	
Cash paid for amounts included in the measurement lease liability:		
	=	
	=	
Operating cash flows from operating lease		
	$ 563	
	$ 563	
Operating cash flows from operating lease obligation		
	$ 631	
	$ 307	

June 30,	June 30, 2024	2023
Operating lease ROU assets		
	$ 2,401	
	$ 2,722	
Operating lease obligations - current portion		
	$ 436	
	$ 389	
Operating lease obligations - noncurrent portion		
	$ 2,688	
	$ 3,125	
Weighted average remaining lease term - operating leases		
	5.50 years	
	6.50 years	
Weighted average discount rate - operating lease obligations		
	7.25 %	

| | | |

+ Details
Name:us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_OperatingLeaseLiabilityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 65 R24.htm IDEA: XBRL DOCUMENT
Stockholders' Equity 12 Months Ended
Jun. 30, 2024
Stockholders' Equity Stockholders' Equity
17. Stockholders' Equity

Preferred Stock
The Company's Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.

Series 2022 Convertible Preferred Stock ("Series 2022 Preferred")

On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company's 1 million authorized shares of preferred stock. Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis.
The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270 on May 10, 2022. Pursuant to the terms of the preferred stock, the Company's Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022.

Common Stock
The number of authorized shares of the Company's common stock is 275 million.

Reverse Stock Split
On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-twenty-five (:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-twenty-five (:25) reverse stock split of the shares of the Common Stock, either issued and outstanding, effective October 7, 2022. The Company's common stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.

11
On November 27, 2023, the stockholders of the Company, approved a proposal at the Company's 2023 Annual Meeting to amend the Company's Certificate of Incorporation to effect a reverse stock split of the Company's Common Stock, at a ratio between 1-for-5 to 1-for-20, with the ratio within such range to be determined at the discretion of the Company's Board, without reducing the authorized number of shares of Common Stock. Following the 2023 Annual Meeting, the Board approved a final split ratio of one-for-20 (:20). Following such approval, on November 28, 2023, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the 2023 reverse stock split, with an effective time of 12:01 a.m. Eastern Time on November 29, 2023. As a result of the :20 2023 Reverse Stock Split, each twenty (20) pre-split shares of Common Stock outstanding automatically combined into one (1) new share of Common Stock without any action on the part of the holders. No fractional shares were issued in connection with the 2023 Reverse Stock Split. In lieu of fractional shares, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the effective time of the 2023 Reverse Stock Split (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) were entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the 2023 Reverse Stock Split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the NYSE American for the ten days preceding November 29, 2023.

11

Issuances of Common Stock for the years ended June 30, 2024 and 2023 include the following:
Cantor Fitzgerald Underwriting

On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an "at the market offering" program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. In the fiscal year ended June 30, 2024, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 170,989 shares of Common Stock. The Company received net proceeds of approximately $1.7 million.

In the fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 289,144 shares of Common Stock. The Company received net proceeds of approximately $6.4 million during the fiscal year ended June 30, 2023 and held a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023.

RubrYc Transaction
On September 19, 2022, the Company issued 5,117 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.

Wainwright Underwriting

On December 6, 2022, the Company entered into an underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the "Offering") (i) 76,538 shares of the Company's Common Stock, (ii) pre-funded warrants (the "2022 Pre-Funded Warrants") to purchase up to 91,730 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to 168,267 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the "Series B Warrants" and together with the Series A Warrants, the "2022 Warrants") to purchase up to 168,267 shares of Common Stock. The offering closed on December 9, 2022.

Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses. Pursuant to the Underwriting Agreement, the Company granted Wainwright a option to purchase up to an additional 25,240 shares of Common Stock and/or Common Warrants to purchase up to an additional 50,480 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 25,240 Series A Warrants and 25,240 Series B Warrants.
30-day

The Company also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the "Representative's Warrants") to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and 2022 Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 10,094 shares of Common Stock.

The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.

Lincoln Park Stock Purchase Agreement

As discussed above, on August 4, 2023, the Company entered into a Purchase Agreement, with Lincoln Park, pursuant to may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the "Registration Rights Agreement"), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the "Securities Act"), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by the Company to Lincoln Park under the Purchase Agreement. The Company could not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park's purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the "Commencement Date"). The registration statement was declared effective on August 11, 2023.
which, under the terms and subject to the satisfaction of specified conditions set forth therein, the Company
-
Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company's discretion, it had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company could, at its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $3.00, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 5,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a "Regular Purchase"); provided, however, that the maximum number of shares the Company may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 7,500 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $20.00, and (ii) 10,000 shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $40.00; provided, however, that Lincoln Park's maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.
-
In addition, provided that the Company had directed Lincoln Park to purchase the maximum amount of shares that it is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $4.00, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an "accelerated purchase," and one or more "additional accelerated purchases" on the business day immediately following the purchase date for such Regular Purchase, calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.
as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable.
-
The Company controlled the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park had no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park was obligated to make purchases as the Company directs, subject to certain conditions.
-
As consideration for Lincoln Park's commitment to purchase shares of Common Stock at the Company's direction pursuant to the Purchase Agreement, the Company issued 10,573 shares of Common

Stock to Lincoln Park as commitment shares (the "Initial Commitment Shares") and agreed to issue 10,573 additional shares of Common Stock to Lincoln Park as commitment shares (the "Additional Commitment Shares" and, collectively with the Initial Commitment Shares, the "Commitment Shares") at such time as the Company had received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement.

During fiscal year 2024, the Company sold 202,595 shares of Common Stock under the Purchase Agreement and received approximately $1.3 million in proceeds. No shares remain available for sale under the Purchase Agreement at June 30, 2024.

Securities Purchase Agreement

On December 5, 2023, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain Purchasers identified on the signature pages of the Securities Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the 2023 Offering, (i) 600,000 Shares of the Company's Common Stock, (ii) 1,650,000 2023 Pre-Funded Warrants exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock. The 2023 Offering closed on December 7, 2023. The combined purchase price of each share of Common Stock and the accompanying Common Warrants was $2.00 (the "Offering Price").

The Company agreed to pay the Placement Agents an aggregate cash fee equal to 5.5% of the gross proceeds received by the Company from the sale of the securities in the 2023 Offering. Pursuant to the placement agency agreement, dated December 5, 2023, entered into by and between the Company and the Placement Agents (the "Placement Agency Agreement"), the Company also agreed to reimburse the Placement Agents for their accountable offering-related legal expenses in an amount up to $75,000 and pay a non-accountable expense allowance of up to $15,000.

The Company received net proceeds of approximately $4 million in the 2023 Offering after deducting commissions and other issuance costs. Approximately $369,000 of issuance costs are reported in accrued expenses in the consolidated balance sheet at June 30, 2024.

Securities Purchase Agreement and Warrants

On March 26, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Securities Purchasers for the issuance and sale in the Private Placement of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315 shares of the Common Stock, (ii) 2024 Pre-Funded Warrants to purchase up to 2,585,963 shares of the Company's Common Stock at an exercise price of $0.0001 per share, and (iii) Series E Common Stock purchase warrants to purchase up to 5,287,278 shares of the Company's Common Stock at an exercise price of $2.64 per share. The Series E Warrants are exercisable at any time after the six-month anniversary of their issuance at an exercise price of $2.64 per share and have a term of exercise equal to five years from the date of issuance. The combined purchase price for one share of common stock and the accompanying Series E Warrant was $2.85 and the purchase price for one pre-funded warrant and the accompanying Series E Warrant was $2.849.

A holder of the 2024 Pre-Funded Warrants and the Series E Warrants may not exercise any portion of such holder's 2024 Pre-Funded Warrants or the Series E Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company's outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days' prior notice from the holder to the Company, the holder may
increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise.

The 2024 Pre-Funded Warrants are exercisable at any time after their original issuance, subject to the beneficial ownership limitation (as described above) and will not expire until exercised in full. The exercise price and number of shares of Common Stock issuable upon exercise of the 2024 Pre-Funded Warrants and Series E Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price.

If at the time of exercise on a date that is after the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common Stock to the holders of the Series E Warrants, the Series E Warrants may be exercised, in whole or in part, at such time by means of a "cashless exercise." If at the time of exercise on a date that is after the 60th day anniversary of the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common Stock to the holders of 2024 Pre-Funded Warrants, the 2024 Pre-Funded Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise."

Pursuant to the 2024 Securities Purchase Agreement, the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants no later than 60 days after the date of the 2024 Securities Purchase Agreement (the "Filing Date"), to use its commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event not more than 75 days following the date of the 2024 Securities Purchase Agreement (or 90 days following the date of the 2024 Securities Purchase Agreement in the event of a "full review" by the SEC) (the "Effectiveness Date"), and to keep such registration statement effective at all times for a one year period after the closing date provided that the Company will have the right to suspend the registration statement for a period of fifteen (15) days during such one year period without being in breach. In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an "Event Date") and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%. The registration statement was filed with the SEC on April 16, 2024 and declared effective by the SEC on April 24, 2024.

The Private Placement closed on April 1, 2024 at which time the Company received net proceeds of approximately $14.1 million, which was reported as a subscription receivable on the March 31, 2024 condensed consolidated balance sheet, from the Private Placement, after deducting estimated offering expenses payable by the Company, including placement agent fees and expenses. The Company intends to use the net proceeds received from the Private Placement primarily for general corporate purposes, including for research and development and working capital.

Chardan served as the exclusive placement agent in connection with the Private Placement and was paid (i) a cash fee equal to 6.0% of the aggregate gross proceeds of the Private Placement (reduced to 4.0% with respect to certain investors), and (ii) up to $50,000 for legal fees and other out-of-pocket expenses.

Pursuant to the terms of the 2024 Securities Purchase Agreement, the Company is prohibited from entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or securities convertible or exercisable into Common Stock for a period commencing on March 26, 2024, and expiring 60 days from the Effective Date (as defined in the 2024 Securities Purchase Agreement). Furthermore, the Company is also prohibited from entering into any agreement to issue Common Stock or Common Stock Equivalents (as defined in the 2024 Securities Purchase Agreement) involving a Variable Rate Transaction (as defined in the 2024 Securities Purchase Agreement), subject to certain exceptions, for a period commencing on March 26, 2024 and expiring one year from such Effective Date
(as defined in the 2024 Securities Purchase Agreement); provided that sixty (60) days after the Effective Date entering into an at-the-market facility shall not be deemed a Variable Rate Transaction.

Vesting of Restricted Stock Units "RSUs"

RSUs for 42,054 of Common Stock vested during the year ended June 30, 2024. RSUs for 10,878 of Common Stock vested during the year ended June 30, 2023.

Exercise of Stock Options

stock options were exercised in the years ended June 30, 2024 and 2023.
No

Warrants
Bryan Capital

The Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock of the Company at an exercise price of $665 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.

Wainwright

As discussed above, the Company issued various warrants with the following terms:

1. 2022 Pre-Funded Warrants – Immediately exercisable at an exercise price of $0.001 per share. All of the 2022 Pre-Funded Warrants were exercised in December 2022.
2. Class A Warrants – Immediately exercisable at an exercise price of $20.80 per share for a term of five years.
3. Class B Warrants – Immediately exercisable at an exercise price of $20.80 per share for a term of two years.
4. Representative Warrants – Immediately exercisable at an exercise price of $26.00 per share for a term of five years.

No 2022 Warrants were exercised during the year ended June 30, 2024. During the year ended June 30, 2023, 17,064 Class A Warrants and 89,059 Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $2,207,000.

On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to 173,795 shares of common stock and existing Series B Warrants to purchase up to 102,900 shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of $20.86 per share (the "Existing Warrants"), to lower the exercise price of the Existing Warrants to $10.00 per share.

A.G.P./Alliance Global Partners

On December 7, 2023, the Company, completed the 2023 Offering of (i) 600,000 shares Common Stock, (ii) 1,650,000 Pre-Funded Warrants exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock exercisable for an aggregate of 2,250,000 shares of Common Stock. The terms of the 2023 Pre-Funded Warrants, Series C Common Warrants and Series D Common Warrants were described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023, which description is incorporated by reference herein.

Each share of Common Stock and 2023 Pre-Funded Warrants, as applicable, was sold together with one Series C Common Warrant to purchase one share of Common Stock and one Series D Common Warrant to purchase one share of Common Stock. The combined purchase price of each share of Common Stock and the accompanying Common Warrants was the Offering Price and the combined purchase price of each 2023 Pre-Funded Warrant and the accompanying Common Warrants was $1.9999, which is equal to the combined purchase price per share of Common Stock and accompanying Common Warrants, minus the exercise price of each Pre-Funded Warrant of $0.0001. The Series C Common Warrants and the Series D Common Warrants have an exercise price of $2.00 per and are immediately exercisable. The Series C Common Warrants will expire two (2) years from the date of issuance and the Series D Common Warrants will expire five (5) years from the date of issuance.
share

During fiscal year 2024, 1,650,000 of 2023 Pre-Funded Warrants were exercised. In addition, 1,178,500 Series C Common Warrants and 1,053,500 Series D Common Warrants were exercised for proceeds of $4,464,000. In August 2024, 1,000 Series C Common Warrants and 1,000 Series D Common Warrants were exercised for proceeds of $4,000.

– References

No definition available.

+ Details

Name:us-gaap_StockholdersEquityNoteAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Name:us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:

duration XML 66 R25.htm IDEA: XBRL DOCUMENT
Earnings (Loss) Per Common Share12 Months Ended
Jun. 30, 2024
Earnings (Loss) Per Common Share Earnings (Loss) Per Common Share
18. Earnings (Loss) Per Common Share

Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

	Years ended	
	June 30,	
	2024	2023
Basic and diluted numerator:		
Net loss from continuing operations	$ (15,443)	$ (29,311)
Net loss from discontinued operations	$ (9,464)	$ (35,699)
Net loss - total	$ (24,907)	$ (65,010)
Basic and diluted denominator:		
Weighted-average common shares outstanding	3,831	612
Per share amount - continuing operations	$ (4.03)	$ (47.88)
Per share amount - discontinued operations	$ (2.47)	$ (58.31)
Per share amount - total		

$	(6.50)
$	(106.19)

In fiscal years 2024 and 2023, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2024 and 2023, shares issuable which could potentially dilute future earnings included were as follows:

	June 30,	
	2024	2023
(in thousands)		
Stock options	-	912
	-	14
Restricted stock units	—	37
	—	12
Warrants	–	12,127
	–	293
Shares excluded from the calculation of diluted loss per share	-	13,076
	-	319

- References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3

+ Details

Name:us-gaap_EarningsPerShareTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 67 R26.htm IDEA: XBRL DOCUMENT
Share-Based Compensation12 Months Ended
Jun. 30, 2024
Share-Based Compensation Share-Based Compensation
19. Share-Based Compensation

The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):

	Years Ended June 30,	
	2024	2023
Research and development	$	234
	$	149
General and administrative		

-	1,741
-	2,714
Total	
$	1,975
$	2,863

In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $62,000 and $1,528,000 for the years ended June 30, 2024 and 2023, respectively.

Stock Options

iBio, Inc. 2023 Omnibus Equity Incentive Plan (the "2023 Plan")

On December 9, 2023, the Company adopted the 2023 Plan for employees, officers, directors and external service providers which is the successor to the 2020 Omnibus Equity Incentive Plan (the "2020 Plan") and once approved became effective on January 1, 2024. The maximum number of shares of Common Stock reserved and available for issuance under the 2023 Plan is 1,200,000 shares (the "Limit"). In addition, such Limit shall automatically increase on January 1 of each calendar year commencing on January 1, 2025 and ending on (and including) January 1, 2033, by a number of shares of Common Stock equal to five percent (5%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year; provided, however, that the Board may act prior to January 1 of a given calendar year to provide that the increase for such year will be a lesser number of shares of Common Stock, provided further that the Limit, as in effect at any time, shall be adjusted as a result of any reorganization, recapitalization, reclassification, stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company's capital stock. The 2023 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2023 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of the Company's Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2023 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.

Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.

~~three~~

Under the 2023 Plan, 29,700 common shares have been issued pursuant to past grants, 921,200 common shares are reserved for past grants, and the remaining 249,100 common are available for future grants as of June 30, 2024.

iBio, Inc. 2020 Omnibus Equity Incentive Plan (the "2020 Plan")

On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 64,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be
appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.

Vesting of service awards is determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.

~~three~~

Under the 2020 Plan, 23,219 common shares have been issued pursuant to past grants, 27,032 common shares are reserved for past grants, and the remaining 13,749 common shares will no longer be available for future grants as of June 30, 2024.

Issuances of stock options during the year ended June 30, 2024 were as follows:

During the first quarter of fiscal year 2024, the Company granted stock option agreements to various employees to purchase 23,650 shares of the Common Stock at an exercise price of $7.00 per share. During the fourth quarter of fiscal year 2024, the Company granted stock option agreements to various employees to purchase 83,300 shares of the Common Stock at exercise prices between $1.72 and $2.41 per share, which included a grant of 35,800 stock options at an exercise price of $1.72 per share to Felipe Duran, the Company's Chief Financial Officer.

All of the above noted awards vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.

During the fourth quarter of fiscal year 2024, the Board approved stock option agreements to various employees to purchase 402,300 shares of the Common Stock at an exercise price of $1.88 per share, which included a two separate grants to Dr. Brenner, the Company's Chief Executive Officer, one of which was 110,000 stock options that vest in equal quarterly installments over three years and a second grant of 147,300 stock options that vest 25% after one year and then in equal quarterly installments over a 36-month period, and a grant to Mr. Duran of 90,000 stock options, which vest in equal quarterly installments over three years.

All of the above noted awards expire on the tenth anniversary of the grant date.

During the fourth quarter of fiscal year 2024, the Company granted stock option agreements to various consultants to purchase 399,000 shares of the Common Stock at an exercise price of $1.72 per share. The options vest in equal quarterly installments, over a period of 12 months and expire on the fifth anniversary of the grant date.

Issuances of stock options during the year ended June 30, 2023 were as follows:

During the first quarter of fiscal year 2023, the Company granted stock option agreements to various employees to purchase 15,193 shares of the Common Stock at exercise prices between $135.00 and $190.00 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.

During the first quarter of fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 200 shares of the Common Stock at an exercise price of $135.00 per share. The option vests in equal monthly installments, over a period of 12 months, starting after the second month and expire on the tenth anniversary of the grant date. During the third quarter of fiscal year 2023, the Company terminated the consultant's services. As a result, none of the 200 shares pursuant to the stock option agreement were exercised and as such, all 200 shares were forfeited.

The following table summarizes all stock option activity during the years ended June 30, 2024 and 2023:

Weighted-					
Weighted-					
average					
average					
Remaining					
Aggregate					
Stock					
Exercise					
Contractual					
Intrinsic Value					
Options					
Price					
Term (in years)					

~~(in thousands)~~					
~~Outstanding as of July 1, 2022~~	~~30,708~~	~~$~~	~~603.43~~	~~8.3~~	~~$~~
~~Granted~~	~~15,375~~		~~141.17~~		~~—~~
~~Exercised~~					~~—~~
~~Forfeited/expired~~	~~(31,465)~~		~~479.67~~		~~—~~
~~Outstanding as of June 30, 2023~~	~~14,618~~	~~$~~	~~383.62~~	~~8.5~~	~~$~~
~~As of June 30, 2023, vested and expected to vest~~	~~14,616~~	~~$~~	~~383.64~~	~~8.5~~	~~$~~

~~Exercisable as of June 30, 2023~~	~~4,790~~	~~$~~	~~583.09~~	~~7.9~~	~~$~~

~~Outstanding as of June 30, 2023~~	~~14,618~~	~~$~~	~~383.62~~	~~8.5~~	~~$~~
~~Granted~~	~~908,250~~		~~1.93~~		~~—~~
~~Exercised~~					~~—~~

Forfeited/expired		
		(10,742)
		164.15
Outstanding as of June 30, 2024		
		912,126
$		*6.14*
		7.6
$		*280*
As of June 30, 2024, vested and expected to vest		
		912,126
$		*6.14*
		7.6
$		*280*

Exercisable as of June 30, 2024		
		6,472
$		*459.08*
		7.2
$		

The following table summarizes information about options outstanding and exercisable at June 30, 2024:

Options Outstanding and Exercisable				
	Weighted-			
	Average	*Weighted-*		
	Remaining	*Average*		
Exercise	*Number*	*Life*	*Number*	
Prices	*Outstanding*	*In Years*	*Price*	*Exercisable*
Exercise prices:				
$1.72 - $7.00				
	902,300	*7.6*		
$				

$140.00 - $210.00	4,681	8.0
$	147.83	
$347.00 - $520.50	2,164	1,191
		7.2
$	355.66	
$530.00 - $795.00	1,190	3,554
		6.8
$	668.89	
$1,025.00 - $1,537.50	2,718	400
		6.3
$	1,025.00	
	400	
	912,126	
		7.6
$	459.08	
	6,472	

The total fair value of stock options that vested during 2024 and 2023 was approximately $1,644,000 and $4,828,000, respectively. No stock were exercised during 2024 and 2023. As of June 30, 2024, there was approximately $2,223,000 of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 2.1 years.
options

The weighted-average grant date fair value of stock options granted during 2024 and 2023 was $1.90 and $126.05 per share, respectively. The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:

	2024	2023
Weighted-average risk-free interest rate		
	4.44% - 4.83	
%		
	3.21% - 3.61	
%		
Dividend yield		
	0	
%		
	0	
%		
Volatility		
	157.77 - 266.94	
%		
	115.52 - 116.93	
%		
Expected term (in years)		
	5	
	7	

The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company's closing stock price of $2.11 as of June 30, 2024 and $12.20 as of June 30, 2023, which would have been received by the option holders had all option holders exercised their options as of that date.

Restricted Stock Units ("RSUs"):

Issuances of RSUs during the year ended June 30, 2024 were as follows:

On January 26, 2024, the Company issued RSUs to acquire 78,800 shares of common stock to various employees at a market value of $1.18 per share. The RSUs vest quarterly over a one-year period. The grant date fair value of the RSUs totaled approximately $93,000.

Issuances of RSUs during the year ended June 30, 2023 were as follows:

On August 29, 2022, the Company issued RSUs to acquire 347 shares of common stock to various employees at a market value of $141.20 per share. The RSUs vest over a four-year period. The grant date fair value of the RSUs totaled approximately $49,000.

On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company's former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 10,000 shares of Common Stock. The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application. The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.

On November 11, 2022, the Board of the Company granted Mr. Robert Lutz, the Company's Chief Financial and Business Officer at the time, RSUs to acquire 5,002 shares of the Company's Common Stock in exchange for Mr. Lutz's agreement to continue employment with the Company through July 1, 2023. The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company's 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.

On November 11, 2022, the Board of the Company granted Dr. Martin Brenner, the Company's Chief Scientific Officer, RSUs to acquire 4,767 shares of the Company's Common Stock in exchange for Dr. Brenner's agreement to continue employment with the Company through July 1, 2023. The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company's 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000.

On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 6,500 shares of the Company's Common Stock, which
RSUs shall vest pro rata over a 12-month period, such vesting to terminate if Dr. Brenner is no longer the Company's Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. Upon appointment of Dr. Brenner to permanent Chief Executive Officer on June 22, 2023, 3,792 of the RSUs terminated and did not vest.

On March 31, 2023, the Compensation Committee (the "Committee") of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 11,250 RSUs under the Company's 2020 Omnibus Equity Incentive Plan, as amended (the "Plan"), which awards included a grant of 2,500 and 1,875 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company's Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.

On June 26, 2023, the Board of the Company granted Dr. Brenner RSUs to acquire 3,791 shares of the Company's Common Stock, which RSUs shall vest pro rata over a seven-month period. The grant-date fair value of the RSUs totaled approximately $52,000.

As of June 30, 2024, there was approximately $35,000 of total unrecognized compensation cost related to non-vested RSUs that the Company expects to recognize over a weighted-average period of 0.6 years.

- Definition

The entire disclosure for share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 68 R27.htm IDEA: XBRL DOCUMENT
Fraunhofer Settlement 12 Months Ended
Jun. 30, 2024
Fraunhofer Settlement Fraunhofer Settlement
20, Fraunhofer Settlement

Fraunhofer Settlement
On May 4, 2021, iBio, Inc. (the "Company") and Fraunhofer USA, Inc. ("FhUSA") entered into a Confidential Settlement Agreement and Mutual Release (the "Fraunhofer Settlement Agreement") to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the "Lawsuit"). The Fraunhofer Settlement Agreement, among other things, resolves the Company's claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Fraunhofer Settlement Agreement is not an admission of liability or fault of the parties.

The terms of the Fraunhofer Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 paid no later than May 14, 2021 (which was paid 100% to cover legal fees and expenses); (ii) two payments of $5,100,000 paid by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, two payments of $900,000 paid by March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company's aggregate net cash recovery as a result of the Fraunhofer Settlement Agreement was approximately $10,200,000.

As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in fiscal year 2021. During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.

On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023.

The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. The second $900,000 payment was received on February 17, 2023.

- Definition

Entire disclosure on gain (Loss) related to litigation settlement.

+ References

No definition available.

+ Details

Name:ibio_GainLossRelatedToLitigationSettlementTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_GainLossRelatedToLitigationSettlementAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

XML 69 R28.htm IDEA: XBRL DOCUMENT

Income Taxes 12 Months Ended

Jun. 30, 2024

Income Taxes Income Taxes

21. Income Taxes

The components of the provision (benefit) for income taxes consist of the following (in thousands):

	For the Years Ended June 30,	
	2024	2023
Current - Federal and state	$ —	$ —
Deferred - Federal	—	(5,193)
Deferred - State	—	(12,153)
	—	(102)
Total	—	(637)
	—	(5,295)
Change in valuation allowance	—	(12,790)
	—	5,295
	—	12,790
Income tax expense	$ —	$ —

The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes.

The components of the Company's deferred tax assets and liabilities are as follows (in thousands):

	As of June 30,	
	2024	2023
Deferred tax assets (liabilities):		
Net operating loss	$ 49,104	$ 42,951
Share-based compensation	869	883
Capitalized research and development costs		

	3,408
Research and development tax credits	2,775
	1,764
	1,764
Investment in equity security	
	404
Property, plant and equipment	395
	(830)
Intangible assets	121
	(138)
	(42)
Operating and finance lease liabilities	
	797
Operating and finance lease ROU assets	1,363
	(629)
Accrued expenses	(1,184)
	96
	529
Contribution carryforward	
	5
Valuation allowance	—
	(54,850)
Total	(49,555)
$	—
$	—

The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to the operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. With a full valuation allowance, any change in the deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. At June 30, 2024 and 2023, the Company provided a valuation allowance on its net deferred tax assets of $54,850,000 and $49,555,000, respectively.

Federal net operating losses of approximately $5.5 million were used by the Former Parent prior to June 30, 2008 and are not available to the Company. The Former Parent allocated the use of the Federal net operating losses available for use on its consolidated Federal tax return on a pro rata basis based on all of the available net operating losses from all the entities included in its control group.

U.S. federal net operating losses of approximately $229.5 million are available to the Company as of June 30, 2024, of which $64 million will expire at various dates through 2039 and $165.5 million with no expiration date. These carryforwards could be subject to certain limitations in the event there is a change in control of the Company pursuant to Internal Revenue Code Section 382, though the Company has not performed a study to determine if the loss carryforwards are subject to these Section 382 limitations. The Company has a research and development credit carryforward of approximately $1.76 million at June 30, 2023. In addition, the Company has net operating loss carry forwards from various states of approximately $46.7 million which expire from 2029 through 2043.

A reconciliation of the statutory tax rate to the effective tax rate is as follows:

	Years Ended June 30,	
	2024	2023
Statutory federal income tax rate	21%	21%
State taxes, net of federal benefit	2%	1%
Expiration and forfeiture of stock options		(2)%
Change in valuation allowance	(2)%	

	(21)
%	
	(20)
%	
Effective income tax rate	
	=
%	
	=
%	

The Company has not been audited in connection with income taxes. iBio files federal and state income tax returns subject to varying statutes of limitations. The 2020 through 2023 tax returns generally remain open to examination by federal authorities and by state tax authorities.

The Company believes it is not subject to any tax audit risk beyond those periods. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended June 30, 2024 and 2023.

The Inflation Reduction Act of 2022 includes a stock buyback excise tax of 1% on share repurchases, which applies to net stock buybacks after December 31, 2022. The Company does not expect this to have a material impact if and when share repurchases occur.

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Name:us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 70 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies12 Months Ended

Jun. 30, 2024

Commitments and Contingencies Commitments and Contingencies

22. Commitments and Contingencies

CRO Agreement

On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. During the years ended June 30, 2024 and 2023, the Company incurred costs totaling approximately $200,000 and $1,209,000, respectively. The Company has no further commitments for additional costs.

Inflation

Although the Company has not experienced any material adverse effects on its business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. The Company is actively monitoring the effects these disruptions and increasing inflation could have on its operations.

- References

No definition available.

+ Details

Name:us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent

+ Details

Name:us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration XML 71 R30.htm IDEA: XBRL DOCUMENT
Employee 401(k) Plan 12 Months Ended
Jun. 30, 2024
Employee 401(k) Plan Employee 401(k) Plan
23. Employee 401(K) Plan

Commencing January 1, 2018, the Company established the iBio, Inc. 401(K) Plan (the "Plan"). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee's compensation. In addition, the Company may make qualified non-elective contributions at its discretion. Employer contributions made to the Plan totaled approximately $157,000 and $263,000 for the years ended June 30, 2024 and 2023, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $10,000 and $135,000 for the years ended June 30, 2024 and 2023, respectively.

- References

No definition available.

+ Details

Name:us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (p) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (r)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 60 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

+ Details
Name:us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 72 R31.htm IDEA: XBRL DOCUMENT
Subsequent Events 12 Months Ended
Jun. 30, 2024
Subsequent Events Subsequent Events

24. Subsequent Events

At Market Issuance Sales Agreement

On July 3, 2024, the Company, entered into an At-Market Issuance Sales Agreement (the "ATM Agreement") with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC (the "Sales Agents") providing for the sale by the Company of its Common Stock, from time to time, through the Sales Agents, with certain limitations on the amount of Common Stock that may be offered and sold by the Company as set forth in the ATM Agreement (the "Offering").

Offers and sales of shares of Common Stock by the Company, if any, under the ATM Agreement, is subject to the effectiveness of the Company's shelf registration statement on Form S-3, filed with the SEC on July 3, 2024 which became effective on August 6, 2024. The aggregate market value of the shares of Common Stock eligible for sale under the ATM prospectus supplement included in the Registration Statement is currently $7,350,000, which is based on the limitations of General Instruction I.B.6 of Form S-3.

Pursuant to the ATM Agreement, the Company will set the parameters for the sale of shares of Common Stock, including the number of shares of Common Stock to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, the Sales Agents may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on the NYSE American or on any other existing trading market for the Common Stock. In addition, with the Company's prior written approval, the Sales Agents may also sell shares by any other method permitted by law, including in privately negotiated transactions.

Upon delivery of a placement notice and subject to the terms and conditions of the ATM Agreement, the Sales Agents will use their commercially reasonable efforts, consistent with their respective normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the NYSE American, to sell shares of Common Stock from time to time based upon the Company's instructions. The Company has no obligation to sell any shares of Common Stock under the ATM Agreement and may at any time suspend solicitation and offers under the ATM Agreement. The Sales Agents are not obligated to purchase any shares of Common Stock on a principal basis pursuant to the ATM Agreement.

The ATM Agreement provides that the Company will pay the Sales Agents commissions for its services in acting as agent in the sale of shares of Common Stock pursuant to the ATM Agreement. The Sales Agents will be entitled to compensation at a fixed commission rate of up to 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the ATM Agreement. The Company has agreed to provide the Sales Agents and certain of their affiliates of the Sales Agents with customary indemnification and contribution rights, including for liabilities under the Securities Act. The Company also agreed to reimburse the Sales Agents for certain specified expenses in connection with entering into the ATM Agreement, including the reasonable and documented out-of-pocket fees and disbursements of counsel to the Sales Agents up to $75,000 plus (i) an additional $5,000 per quarter so long as the ATM Agreement remains in effect and the Sales Agents perform standard quarterly due diligence with the Company, excluding any period during which a Suspension (as defined in the ATM Agreement) is in place pursuant to Section 4 of the ATM Agreement, and (ii) $25,000 in connection with any filing of an additional prospectus supplement which constitutes a Prospectus Supplement (as defined in the ATM Agreement). The ATM Agreement contains customary representations and warranties and conditions to the placements of shares of Common Stock pursuant thereto, obligations to sell shares under the ATM Agreement are subject to satisfaction of certain conditions, including the effectiveness of the Registration Statement and other customary closing conditions.

The Offering of shares of Common Stock pursuant to the ATM Agreement will terminate upon the earlier of (i) the sale of all shares of Common Stock subject to the ATM Agreement, or (ii) termination of the ATM Agreement as permitted therein.

Issuances of stock options during fiscal year 2025 were as follows:

In fiscal year 2025, the Company granted stock option agreements to certain employees to purchase an aggregate of 22,500 shares of Common Stock at exercise prices between $1.81 and $2.21 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.

Vesting of RSUs during fiscal year 2025 were as follows:

During the first quarter of fiscal year 2025, RSUs for 12,210 shares of Common Stock were vested.

- References

No definition available.

+ Details
Name:us-gaap_SubsequentEventsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details
Name:us-gaap_SubsequentEventsTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 73 R32.htm IDEA: XBRL DOCUMENT
Pay vs Performance Disclosure - USD ($) $ in Thousands12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure Net Income (Loss)$ (24,907)$ (65,010)
- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1

+ Details
Name:ecd_PvpTable Namespace Prefix:ecd_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-

2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details
Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration XML 74 R33.htm IDEA: XBRL DOCUMENT
Insider Trading Arrangements12 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual Rule 10b5-1 Arrangement Adoptedfalse Non-Rule 10b5-1 Arrangement Adoptedfalse Rule 10b5-1 Arrangement Terminatedfalse Non-Rule 10b5-1 Arrangement Terminatedfalse
- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

+ Details
Name:ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

+ Details
Name:ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

+ Details

Name:ecd_Rule10b51ArrAdoptedFlag Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1

+ Details

Name:ecd_Rule10b51ArrTrmntdFlag Namespace Prefix:ecd_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A

+ Details

Name:ecd_TradingArrByIndTable Namespace Prefix:ecd_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 75 R34.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)12 Months Ended
Jun. 30, 2024

Summary of Significant Accounting Policies Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued to related to the extinguishment of the Term Loan, and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Accounts Receivable

Accounts Receivable

Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management's policy is to write off accounts receivable against the allowance for credit losses when a balance is determined to be uncollectible. At June 30, 2024 and 2023, the Company determined that an allowance for credit losses was not needed. The Company had accounts receivable of $1 million at June 30, 2022.

Subscription Receivable

Subscription Receivable

The Company accounts for any subscription receivable as a current asset. Subscription receivables represent funds related to the sale of Common Stock in which the funds have not yet been delivered to the Company. The funds are generally held in escrow on behalf of the Company and are delivered within a few days.

Revenue Recognition

Revenue Recognition

The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party's rights regarding the distinct goods or services to be transferred ("performance obligations"), (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company recognizes revenue when it satisfies its performance obligations by transferring control of a promised good or service to the customer. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.

The Company analyzes its contracts to determine whether the elements can be separately identifiable and accounted for individually or as a bundle of goods or services. Allocation of revenue to individual elements that qualify for performance obligations is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June 30, 2024 and 2023, the Company had no credit loss provisions.

The Company generates contract revenue under the following types of contracts:

Fixed-Fee

Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.

Revenue can be recognized either 1) over time or 2) at a point in time. Revenue reported in discontinued operation was recognized at a point in time for all periods presented.

Collaborations/Partnerships

The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company's rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner.

The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, ("ASC 808"). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, ("ASC 606").

Collaborative ArrangementsRevenue from Contracts with Customers

Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.

For the years ended June 30, 2024, revenue in the amount of $225,000 was recognized from research activities performed and a non-refundable upfront license fee for which performance obligations were satisfied. No revenue was recognized for the year ended June 30, 2023.

Contract Assets

Contract Assets

A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.

Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2024 and 2023, contract were $0.

assets Contract Liabilities

Contract Liabilities

A contract liability is an entity's obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer's consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.

Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2024, 2023 and 2022, contract liabilities were $200,000, $0 and $100,000, respectively. The Company recognized revenue of $0 in 2024 that was included in the contract liabilities balance as of June 30, 2023 and $100,000 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.

Leases

Leases

Leases

The Company accounts for leases under the guidance of ASC 842, . The standard established a right-of-use ("ROU") model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company's balance sheet, resulting in an increase in noncurrent assets and both current and noncurrent liabilities.

In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.

The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company's existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company's operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company's incremental borrowing rate requires judgement. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2024 and 2023 consisted of money market accounts. Restricted cash at June 30, 2024 consists of a letter of credit obtained related to the San Diego operating lease (see Note 16 - Operating Lease Obligations) and a Company purchasing card. The Company's bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was $215,000 and $253,000 June 30, 2024 and 2023, respectively.

The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):

	June 30,	
	June 30,	
	2024	
	2023	
Cash and equivalents	$ 14,210	$ 4,301
Collateral held for letter of credit - term note payable	—	3,025
Collateral held for letter of credit - San Diego lease	198	198
Collateral held for Company purchasing card	17	55
Total cash, cash equivalents and restricted cash	$ 14,425	$ 7,579

Investments in Debt Securities

Investments in Debt Securities

Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. The Company held no investments in debt securities at June 30, 2024 and 2023.

Inventory

Inventory

Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held no at June 30, 2024 and 2023.

inventory ## Research and Development

Research and Development

The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board ("FASB") ASC 730-10, "" ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expenses were reported in continuing operations for the year ended June 30, 2024. No research and development expenses were reported in discontinued operations for the year ended June 30, 2024. For the year ended June 30, 2023, research and development expenses were reported in both continuing and discontinuing operations.

Research and Development ## Right-of-Use Assets

Right-of-Use Assets

Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information.

Fixed Assets

Fixed Assets

Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to thirty-nine years.

The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

See Note 11 - Fixed Assets for additional information.

Intangible Assets

Intangible Assets

Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.

The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.

For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.

Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the

Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

See Note 12 - Intangible Assets for additional information.

Share-based Compensation

Share-based Compensation

The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.

The impact that share-based payment awards will have on the Company's results of operations is a function of the number of shares awarded, the trading price of the Company's stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company's stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.

Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting
schedules and the Company's historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be . In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 - Share-Based Compensation for additional information.

~~zero~~ ## Income Taxes

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for tax positions as of June 30, 2024 and 2023. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023.

~~uncertain~~ ## Concentrations of Credit Risk

Concentrations of Credit Risk

Cash

The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2024 and 2023, amounts in excess of insured limits were approximately $664,000 and $6,900,000, respectively.

Revenue

During the fiscal year ended June 30, 2024, the Company reported revenue of $225,000 in continuing operations from two research collaborators and $0 of its revenue from discontinued operations. During the fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, ("ASU 2016-13"), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company's consolidated financial statements.

Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

In October 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative" ("ASU 2023-06"). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("ASC").
The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SEC's regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): "Improvements to Reportable Segment Disclosures" ("ASU 2023-07") to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company's 2024 fiscal year annual reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2023-09") to enhance the transparency and decision-usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. This ASU applies to all entities subject to income taxes. This ASU will be effective for public companies for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

- Definition

Disclosure of accounting policy for contract assets.

+ References

No definition available.

+ Details

Name:ibio_ContractAssetsPolicyTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for contract liabilities.

+ References

No definition available.

+ Details

Name:ibio_ContractLiabilitiesPolicyTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

The disclosure of accounting policy for right-of-use assets.

+ References

No definition available.

+ Details

Name:ibio_RightOfUseAssetsPolicyPolicyTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-9

+ Details

Name:us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1

+ Details

Name:us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

Name:us-gaap_ConcentrationRiskCreditRisk Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1

+ Details

Name:us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6

+ Details

Name:us-gaap_InventoryPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for leasing arrangement entered into by lessee.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1

+ Details

Name:us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name:us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher

FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1

+ Details

Name:us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2

+ Details

Name:us-gaap_ReceivablesPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or

process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1

+ Details

Name:us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent

+ Details

Name:us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration

- Definition

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for accounts receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B

+ Details
Name:us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8

+ Details
Name:us-gaap_UseOfEstimates Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 76 R35.htm IDEA: XBRL DOCUMENT
Discontinued Operations (Tables)12 Months Ended
Jun. 30, 2024
Discontinued Operations Schedule of discontinued operations

The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):

	Years Ended June 30,	
	2024	*2023*
Revenues		
$		=
$		*391*

~~Cost of goods sold~~	
	=
~~Gross profit~~	~~52~~
	=
~~Operating expenses:~~	~~339~~
~~Research and development~~	
	=
~~General and administrative~~	~~6,344~~
	~~1,207~~
~~Fixed asset impairments~~	~~6,751~~
	~~3,100~~
~~Loss (gain) on sale of fixed assets~~	~~17,900~~
	~~4,816~~
~~Inventory reserve~~	~~(773)~~
	=
~~Total operating expenses~~	~~4,915~~
	~~9,123~~
	~~35,137~~
~~Other income (expenses):~~	
~~Interest expense - term note payable~~	
	~~(1,149)~~
~~Gain on extinguishment of debt~~	~~(900)~~
	~~808~~
~~Other~~	=
	=
~~Total other expenses~~	~~(1)~~
	~~(341)~~
	~~(901)~~
~~Loss from discontinued operations~~	
~~$~~	~~(9,464)~~
~~$~~	

~~(35,699)~~

~~The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2024 and 2023 (in thousands):~~

	~~June 30, 2024~~	~~June 30, 2023~~
~~Current assets:~~		
~~Operating lease right-of-use assets~~	~~$ -~~	~~$ 1,941~~
~~Property and equipment, net~~	~~-~~	~~16,124~~
~~Total current assets~~	~~$ -~~	~~$ 18,065~~
~~Current liabilities:~~		
~~Operating lease obligation~~	~~$ -~~	~~$ 1,941~~
~~Total current liabilities~~	~~$ -~~	~~$ 1,941~~

~~The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands):~~

	~~Years Ended June 30, 2024~~	~~2023~~
~~Depreciation expense~~	~~$ -~~	~~$ 273~~
~~Amortization of finance lease right-of-use assets~~	~~-~~	~~20~~
~~Purchase of fixed assets~~	~~-~~	~~1,542~~
~~Fixed asset impairments~~		~~3,100~~
~~Loss on sale of fixed assets~~		~~17,900~~
		~~4,817~~

Gain on extinguishment of debt	—
	(808)
Payments of term note payable	—
	(1,513)
Inventory reserve	—
	—
Sales proceeds of fixed assets	4,915
	50
Payment of finance lease obligation	2,600
	—
Investing non-cash transactions:	17
Fixed assets included in accounts payable in prior period, paid in current period	—
	1,542
Supplemental cash flow information:	
Cash paid during the period for interest	577
	603

- References

No definition available.

+ Details

Name:us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

Name:us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 77 R36.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables) 12 Months Ended

Jun. 30, 2024

Summary of Significant Accounting Policies Schedule of of total cash, cash equivalents and restricted cash

	June 30,	June 30,
	2024	2023
Cash and equivalents	$ 14,210	$ 4,301
Collateral held for letter of credit - term note payable		—
Collateral held for letter of credit - San Diego lease	3,025	198
Collateral held for Company purchasing card	198	198
	17	—
Total cash, cash equivalents and restricted cash	55	—
	$ 14,425	$ 7,579

- References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the components of cash and cash equivalents.

+ References

No definition available.

+ Details

Name:us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 78 R37.htm IDEA: XBRL DOCUMENT

Significant Transactions (Tables) - RubrYc Therapeutics12 Months Ended

Jun. 30, 2024

Asset Purchase Agreement Summary of Purchase Price Allocation of Asset Acquisition

Intangible assets	$ 1,228,000
Fixed assets	114,000
	$ 1,342,000

Stock Purchase Agreement Summary of Purchase Price Allocation of Asset Acquisition

The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:

Preferred stock	$ 1,760,000
Intangible assets	4,300,000
Prepaid expenses	1,440,000
	$ 7,500,000

- Definition

Tabular disclosure of asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:us-gaap_AssetAcquisitionTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 79 R38.htm IDEA: XBRL DOCUMENT
Investments in Debt Securities (Tables) 12 Months Ended
Jun. 30, 2024
Investments in Debt Securities Schedule of realized losses on available-for-sale debt securities

Years Ended June 30,

	2024	2023
Proceeds from sale of debt securities	$	=
Cost of debt securities	$	6,739
Realized loss on sale of debt securities		= 6,837
	$	=
	$	(98)

- Definition

Tabular disclosure of realized gains (losses) on available for sale debt securities.

+ References

No definition available.

+ Details
Name:ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 80 R39.htm IDEA: XBRL DOCUMENT
Finance Lease ROU Assets (Tables) 12 Months Ended
Jun. 30, 2024
Finance Lease ROU Assets Summary of the gross carrying value and accumulated amortization of finance lease ROU

	June 30, 2024	June 30, 2023
ROU - Equipment	$	814
Accumulated amortization	$	814
		(475)
Net finance lease ROU assets		(204)
	$	339
	$	610

- Definition

The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.

+ References

No definition available.

+ Details
Name:ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock Namespace Prefix:ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 81 R40.htm IDEA: XBRL DOCUMENT
Fixed Assets (Tables) 12 Months Ended
Jun. 30, 2024
Fixed Assets Schedule of gross carrying value and accumulated depreciation of fixed assets

	June 30, 2024	June 30, 2023
Building and improvements	$ 695	$ 695
Machinery and equipment	-	3,545
Office equipment and software	-	3,521
	403	403
	4,643	4,619
Accumulated depreciation	(1,011)	(400)
Net fixed assets	$ 3,632	$ 4,219

- References

No definition available.

+ Details
Name:us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details
Name:us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 82 R41.htm IDEA: XBRL DOCUMENT
Intangible Assets (Tables)12 Months Ended
Jun. 30, 2024
Intangible Assets Schedule of Category the gross carrying value and accumulated amortization of intangible assets

	June 30, 2023	Amortization	Additions	Impairments	June 30, 2024
Intellectual property - gross carrying value	$ 400	$ =	$		

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 83 R42.htm IDEA: XBRL DOCUMENT
Accrued Expenses (Tables) 12 Months Ended
Jun. 30, 2024
Accrued Expenses Schedule of Accrued Expenses

	June 30, 2024	June 30, 2023
Personnel related costs	$ 1,568	$ 3,879
Real estate taxes	—	—
Interest and fees related to term note payable	—	268
Professional fees	—	183
Other accrued expenses	31	—
Total accrued expenses	$ 1,599	$ 4,330

$	2,028
$	4,561

- References

No definition available.

+ Details

Name:us-gaap_PayablesAndAccrualsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name:us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 84 R43.htm IDEA: XBRL DOCUMENT

Debt (Tables) 12 Months Ended

Jun. 30, 2024

Term Promissory Note Schedule of Future Minimum Financing Payments

Fiscal period ending on June 30:	Principal	Interest	Total
2025	$ 218	$ 151	$ 369
2026	766	70	836
	-	-	-
Total minimum term promissory note payments	984	221	1,205
Less: current portion	(218)	-	-
Long-term portion of minimum term promissory note obligation	$ 766	-	-

Equipment Financing Agreement Schedule of Future Minimum Financing Payments

Fiscal period ending on June 30:	Principal	Interest	Total
2025	$ 178	$ 17	$ 195
2026	63		

	1
	64
Total minimum equipment financing payments	
	241
$	18
$	259
Less: current portion	
	(178)
Long-term portion of minimum equipment financing obligation	
$	63

Insurance Premium Financing Agreement Schedule of Future Minimum Financing Payments

Fiscal period ending on June 30:	Principal	Interest	Total
2025	$ 123	$ 1	$ 124

- Definition

Tabular disclosure of maturity and sinking fund requirement for long-term debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1

+ Details

Name:us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_DebtInstrumentAxis=ibio_TermNote2024Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentAxis=ibio_EquipmentFinancingMasterLeaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentAxis=ibio_InsurancePremiumFinancingAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 85 R44.htm IDEA: XBRL DOCUMENT

Finance Lease Obligations (Tables)12 Months Ended Jun. 30, 2024

Finance Lease Obligations Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation

	Years Ended June 30,	
	2024	2023
Finance lease cost:		
Amortization of ROU assets	$ 271	$ 204
Interest on lease liabilities		

	48
	49
Total lease cost	
$	319
$	253
	—
	—
Other information:	
	—
	—
Cash paid for amounts included in the measurement lease liabilities:	
	—
	—
Financing cash flows from finance lease obligations	
$	272
$	191

	June 30,	
	2024	2023
Finance lease ROU assets		
$	339	
$	610	
Finance lease obligation – current portion		
$	299	
$	272	
Finance lease obligation – noncurrent portion		
$	53	
$	351	
Weighted-average remaining lease term - finance lease		
	1.17	
years		
	2.17	
years		
Weighted-average discount rate - finance lease obligation		
	9.500	
%		
	9.500	
%		

Future Minimum Payments Under the Finance Lease Obligation

Fiscal year ending on June 30:	Principal	Interest	Total
2025			
	$ 299	$ 20	$ 319
2026			
	53	1	54

Total minimum lease payments	*352*
$	*21*
$	*373*
Less: current portion	*(299)*
Long-term portion of minimum lease obligations	*53*
$	

- Definition

The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.

+ References

No definition available.

+ Details

Name:ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock Namespace Prefix: ibio_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_FinanceLeaseLiabilityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration XML 86 R45.htm IDEA: XBRL DOCUMENT

Operating Lease Obligations (Tables)12 Months Ended
Jun. 30, 2024
Operating Lease Obligations Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation

Years Ended June 30,	*2024*	*2023*
Operating lease cost:		
$	*563*	
$	*563*	
Total lease cost		
$	*563*	
$	*563*	

Other information:	
Cash paid for amounts included in the measurement lease liability:	
Operating cash flows from operating lease	
$	***563***
$	***563***
Operating cash flows from operating lease obligation	
$	***631***
$	***307***

June 30,		
June 30,		
2024		
2023		
Operating lease ROU assets		
$	***2,401***	
$	***2,722***	
Operating lease obligations - current portion		
$	***436***	
$	***389***	
Operating lease obligations - noncurrent portion		
$	***2,688***	
$	***3,125***	
Weighted average remaining lease term - operating leases		
	5.50	
years		
	6.50	
years		
Weighted average discount rate - operating lease obligations		
	7.25	
%		
	7.25	
%		

Future Minimum Payments under the Operating Lease Obligation

Fiscal year ending on June 30:			
	Principal	***Imputed Interest***	***Total***
2025			
$	***436***		
$		***212***	
$			***648***
2026			
	490		
		179	
			669

| | | |

Earnings (Loss) Per Common Share (Tables)12 Months Ended
Jun. 30, 2024
Earnings (Loss) Per Common Share ***Schedule of Earnings (loss) Per Share, Basic and Diluted***

Years ended

June 30,

2024
2023
Basic and diluted numerator:

Net loss from continuing operations
$ ***(15,443)***
$ ***(29,311)***

Net loss from discontinued operations
$ ***(9,464)***
$ ***(35,699)***

Net loss - total
$ ***(24,907)***
$ ***(65,010)***

Basic and diluted denominator:

Weighted-average common shares outstanding
3,831
612

Per share amount - continuing operations
$ ***(4.03)***
$ ***(47.88)***
Per share amount - discontinued operations
$ ***(2.47)***
$ ***(58.31)***
Per share amount - total
$ ***(6.50)***
$ ***(106.19)***
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	Years Ended June 30,	
	2024	2023
(in thousands)		
Stock options	912	14
Restricted stock units	37	12
Warrants	12,127	293
Shares excluded from the calculation of diluted loss per share	13,076	319

- References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 88 R47.htm IDEA: XBRL DOCUMENT
Share-Based Compensation (Tables)12 Months Ended
Jun. 30, 2024
Share-Based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

	Years Ended June 30,	
	2024	2023
Research and development	$ 234	$ 149
General and administrative	1,741	2,714
Total	$ 1,975	$ 2,863

Schedule of Stock Option Activity

	Number of Stock Options	Weighted-average Exercise Price	Weighted-average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding as of July 1, 2022	30,708	$ 603.43	8.3	$ —
Granted	15,375	141.17	—	—
Exercised	—	—	—	—
Forfeited/expired	(31,465)	479.67	—	—
Outstanding as of June 30, 2023	14,618	$ 383.62	8.5	$ —
As of June 30, 2023, vested and expected to vest	14,616	$ 383.64	8.5	$ —
Exercisable as of June 30, 2023	4,790			

$			583.09
			7.9
$			—
Outstanding as of June 30, 2023			
			14,618
$			383.62
			8.5
$			—
Granted			
			908,250
			1.93
			—
			—
Exercised			
			—
			—
			—
Forfeited/expired			
			(10,742)
			164.15
			—
			—
Outstanding as of June 30, 2024			
			912,126
$			6.14
			7.6
$			280
As of June 30, 2024, vested and expected to vest			
			912,126
$			6.14
—			7.6
$			280
Exercisable as of June 30, 2024			
			6,472
$			459.08
			7.2
$			—

Schedule of Stock Options Outstanding and Exercisable

—.

Options Outstanding and Exercisable

Weighted-			Weighted-

- References

No definition available.

+ Details
Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 89 R48.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables) 12 Months Ended

Jun. 30, 2024

Income Taxes Schedule of Components of Income Tax Expense (Benefit)

	For the Years Ended	
	June 30,	
	2024	2023
Current - Federal and state	$ —	$ —
Deferred – Federal	(5,193)	(12,153)
Deferred - State	(102)	(637)
Total	(5,295)	(12,790)
Change in valuation allowance	5,295	12,790
Income tax expense	$ —	$ —

Schedule of Deferred Tax Assets and Liabilities

	As of June 30,	
	2024	2023
Deferred tax assets (liabilities):		
Net operating loss	$ 49,104	$ 42,951
Share-based compensation	869	883
Capitalized research and development costs	3,408	2,775
Research and development tax credits	1,764	1,764
Investment in equity security	404	395
Property, plant and equipment		

	(830)
Intangible assets	121
	(138)
Operating and finance lease liabilities	(42)
	797
Operating and finance lease ROU assets	1,363
	(629)
Accrued expenses	(1,184)
	96
Contribution carryforward	529
	5
Valuation allowance	—
	(54,850)
Total	(49,555)
$	—
$	—

Schedule of Effective Income Tax Rate Reconciliation

	Years Ended June 30,	
	2024	2023
Statutory federal income tax rate	21%	21%
State taxes, net of federal benefit	2%	1%
Expiration and forfeiture of stock options	(2)%	(2)%
Change in valuation allowance	(21)%	(20)%
Effective income tax rate	—%	—%

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9

+ Details

Name:us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

+ Details

Name:us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

+ Details

Name:us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 90 R49.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details)	*1 Months Ended*	*12 Months Ended*
Mar. 26, 2024		
USD ($)		
$ / shares		
shares		
Feb. 25, 2024		
USD ($)		
Dec. 31, 2023		
USD ($)		
shares		
Dec. 07, 2023		
USD ($)		
shares		
Nov. 29, 2023		
shares		
Sep. 30, 2023		
USD ($)		
$ / shares		
shares		
Aug. 04, 2023		
USD ($)		
shares		
Oct. 07, 2022		
shares		
Aug. 31, 2024		
USD ($)		
shares		
Jun. 30, 2024		
USD ($)		
$ / shares		
shares		
Jun. 30, 2023		
USD ($)		
$ / shares		
Jun. 30, 2022		

USD ($)
Net cash used in operating activities $ 18,554,000 $ 30,436,000 Total current assets 15,672,000 26,259,000 Cash and cash equivalents 14,210,000 4,301,000 Net losses 24,907,000 65,010,000 Operating capital deficit 18,600,000 30,400,000 Proceeds from offering $ 25,523,000 $ 11,487,000 Common stock, par value (in dollars per share) | $ / shares $ 0.001 $ 0.001 Sale proceeds for intangible assets $ 1,000,000 Proceeds from exercise of warrants 4,464,000 Total cash, cash equivalents and restricted cash 14,425,000 $ 7,579,000 $ 28,672,000 Restricted cash, current $ 3,025,000 Pre-split shares required for one post-split share of common stock | shares 25 Cash and cash equivalents and marketable securities $ 14,400,000 Subsequent Events Proceeds from exercise of warrants $ 4,000 Common Stock Reverse stock split, shares received per share tendered 0.05 0.04 Pre-split shares required for one post-split share of common stock | shares 20 25 Pre-Funded Warrants Number of warrants exercised | shares 1,650,000 Series C Warrants Number of warrants exercised | shares 1,178,500 Series C Warrants | Subsequent Events Number of warrants exercised | shares 1,000 Series D Warrants Number of warrants exercised | shares 1,053,500 Series D Warrants | Subsequent Events Number of warrants exercised | shares 1,000 At-The-Market Offerings Shares issued | shares 170,989 Proceeds from offering $ 1,700,000 Common stock, par value (in dollars per share) | $ / shares $ 0.001 Lincoln Park Purchase Agreement Shares issued | shares 21,457 181,141 Proceeds from offering $ 100,000 $ 1,200,000 Offering 2023 Shares issued | shares 600,000 Proceeds from offering $ 4,500,000 Offering 2023 | Pre-Funded Warrants Number of warrants issued | shares 1,650,000 Warrants, shares of common stock issued upon conversion | shares 1,650,000 Offering 2023 | Series C Warrants Number of warrants issued | shares 2,250,000 Warrants, shares of common stock issued upon conversion | shares 2,250,000 Offering 2023 | Series D Warrants Number of warrants issued | shares 2,250,000 Warrants, shares of common stock issued upon conversion | shares 2,250,000 2024 Securities Purchase Agreement | Private placement Shares issued | shares 2,701,315 Common stock, gross proceeds from issuance $ 15,100,000 Common stock, net proceeds from issuance $ 14,100,000 Placement agent fees paid (as percentage) 6.00% Reduced placement agent fee percentage 4.00% Payment made to placement agent for legal fees and other out of pocket expenses $ 50,000 2024 Securities Purchase Agreement | Private placement | Common Stock Common stock, net proceeds from issuance $ 4,000,000 2024 Securities Purchase Agreement | Private placement | Pre-Funded Warrants Warrants, shares of common stock issued upon conversion | shares 2,585,963 Exercise price per share of warrants | $ / shares $ 0.0001 2024 Securities Purchase Agreement | Private placement | Series E Warrants Warrants, shares of common stock issued upon conversion | shares 5,287,278 Exercise price per share of warrants | $ / shares $ 2.64 Warrants, exercisable term 5 years 2024 Securities Purchase Agreement | Private placement | Common Shares and Series E Warrants Combined purchase price per share | $ / shares $ 2.85 2024 Securities Purchase Agreement | Private placement | Pre-funded and Series E Warrants Combined purchase price per share | $ / shares $ 2.849 PD-1 Purchase Agreement Sale proceeds for intangible assets $ 1,000,000 Potential contingent payment 2,500,000 Second potential contingent payment $ 50,000,000

- Definition

Cash and cash equivalents plus debt securities

+ References

No definition available.

+ Details

Name:ibio_CashAndCashEquivalentsPlusDebtSecurities Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Number of shares an equity holder will tender in order to receive one share of the Company's common stock share following the conversion of a reverse stock split.

+ References

No definition available.

+ Details

Name:ibio_NumberOfSharesTenderedInReverseStockSplit Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of warrants exercised during the period.

+ References

No definition available.

+ Details

Name:ibio_NumberOfWarrantsExercised Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Amount of operating capital (deficit).

+ References

No definition available.

+ Details

Name:ibio_OperatingCapitalDeficit Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Maximum amount of payment made to placement agent for legal fees and other out of pocket expenses.

+ References

No definition available.

+ Details

Name:ibio_PaymentOfLegalFeesAndOtherOutOfPocketExpensesToPlacementAgentMaximumAmount Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Placement agent fees paid in cash, represented as a percentage of aggregate gross proceeds.

+ References

No definition available.

+ Details

Name:ibio_PlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Potential amount of contingent payments receivable by the company upon achievement of specified developmental milestones.

+ References

No definition available.

+ Details

Name:ibio_PotentialContingentPaymentReceivableUponAchievementOfSpecifiedDevelopmentalMilestones Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Potential amount of contingent payments receivable by the company upon achievement of specified milestones following commercialization.

+ References

No definition available.

+ Details

Name:ibio_PotentialContingentPaymentReceivableUponAchievementOfSpecifiedMilestonesFollowingCommercialization Namespace Prefix:ibio_ Data Type:

xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Purchase price per share in various scenarios.

+ References

No definition available.

+ Details

Name:ibio_PurchasePricePerShare Namespace Prefix:ibio_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Reduced placement agent fees for certain investors paid in cash, represented as a percentage of aggregate gross proceeds.

+ References

No definition available.

+ Details

Name:ibio_ReducedPlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Number of warrants issued during the period.

+ References

No definition available.

+ Details

Name:ibio_StockIssuedDuringPeriodSharesWarrants Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Amount of asset recognized for present right to economic benefit, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

+ Details

Name:us-gaap_AssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:na Period Type:duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:us-gaap_ProceedsFromSaleOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:us-gaap_ProceedsFromWarrantExercises Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

+ Details

Name:us-gaap_RestrictedCashCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details

Name:us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

+ Details

Name:us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix:us-gaap_ Data Type:xbrli:pureItemType Balance Type:na Period Type:duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details
Name:us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

- Details
Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesCWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesDWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=ibio_AtMarketOfferingsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=ibio_Offering2023Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesEWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_CommonStockAndSeriesEWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsAndSeriesEWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_AssetPurchasingAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 91 R50.htm
IDEA: XBRL DOCUMENT
Discontinued Operations (Details) 3 Months Ended 12 Months Ended
May 31, 2024
USD ($)
$ / shares
shares
Mar. 30, 2023
USD ($)
Feb. 17, 2023
USD ($)
Nov. 03, 2022
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Net proceeds from auctioned equipment $ 116,000 $ 2,600,000 Loss recorded in discontinued operations 9,464,000 35,699,000 Fixed asset impairment charge 3,100,000 17,900,000 Inventory write-down to net realizable value 4,915,000 Gain on extinguishment of debt 808,000 iBio CDMO, LLC | Discontinued Operations Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Net proceeds from auctioned equipment 50,000 2,600,000 Percentage of workforce reduction 60.00% Number of positions reduced 69 Pre-tax employee reduction expenses 1,900,000 Transition period for terminated employees 60 days Loss recorded in discontinued operations 9,464,000 35,699,000 Fixed asset impairment charge 3,100,000 17,900,000 Inventory write-down to net realizable value 4,915,000 Personnel and severance costs 7,500,000 Interest charges on term note 1,149,000 900,000 Loss on sale of fixed assets 4,816,000 (773,000) Gain on extinguishment of debt 808,000 iBio CDMO, LLC | Discontinued Operations | Fair Value, Nonrecurring | Level 3 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Fixed asset impairment charge 17,900,000 iBio CDMO, LLC | Discontinued Operations | Facility | Fair Value, Nonrecurring | Level 3 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Fixed asset impairment charge $ 3,100,000 $ 300,000 $ 6,300,000 iBio CDMO, LLC | Discontinued Operations | 2024 Purchase and Sale Agreement - The Board of Regents Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Loss on sale of fixed assets 4,800,000 Gain on extinguishment of debt 800,000 iBio CDMO, LLC | Discontinued Operations | 2024 Purchase and Sale Agreement - The Board of Regents | Facility Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Loss on sale of fixed assets $ 4,800,000 iBio CDMO, LLC | Discontinued Operations | The Auctioneers | Auction Sale Agreement Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Guaranteed minimum proceeds for auctioned equipment $ 2,100,000 Net proceeds from auctioned equipment $ 2,600,000 Final sale price for auctioned equipment $ 2,900,000 Excess proceeds from auctioned equipment (percentage) 80.00% Fees for auctioned equipment $ 200,000 iBio CDMO, LLC | Discontinued Operations | Woodforest National Bank | Settlement Agreement Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Proceeds from sale of property paid to Woodforest to settle debt $ 8,500,000 Cash payments to settle debt $ 915,000 iBio CDMO, LLC | Discontinued Operations | Woodforest National Bank | Settlement Agreement | Pre-Funded Warrants Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Warrants issued to settle debt | shares 1,560,570 Exercise price per share of warrants | $ / shares $ 0.0001

- Definition

The amount of costs/fees incurred for selling fixed assets at an auction.

+ References

No definition available.

+ Details

Name:ibio_FeesIncurredForFixedAssetsSoldAtAuction Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The guaranteed minimum proceeds agreed upon for property plant & equipment put up for auction.

+ References

No definition available.

+ Details

Name:ibio_GuaranteedMinimumProceedsForFixedAssetsSoldAtAuction Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

The percentage of excess proceeds resulting from the auction (the difference between the guaranteed minimum and final sale amounts) paid to the Company.

+ References

No definition available.

+ Details

Name:ibio_PercentageOfExcessProceedsReceivedFromAuctionedEquipment Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The total proceeds, before fees, for property plant & equipment sold at auction.

+ References

No definition available.

+ Details

Name:ibio_TotalProceedsForFixedAssetsSoldAtAuction Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

+ Details

Name:us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-6Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-7

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4

+ Details

Name:us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15

+ Details

Name:us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2

+ Details

Name:us-gaap_InventoryWriteDown Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_RepaymentsOfLongTermLinesOfCredit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The expected number of positions to be eliminated as a result of restructuring activities.

+ References

No definition available.

+ Details

Name:us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated Namespace Prefix:us-gaap_ Data Type:xbrli:integerItemType Balance Type:na Period Type:duration

- Definition

Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details
Name:us-gaap_RestructuringAndRelatedCostIncurredCost Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).

+ References

No definition available.

+ Details
Name:us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details
Name:us-gaap_SeveranceCosts1 Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf
Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember Namespace Prefix: Data Type:na Balance Type:
Period Type:
- Details
Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type:na Balance Type: Period
Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_CounterpartyNameAxis=ibio_AuctioneersMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_AuctionSaleAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_CounterpartyNameAxis=ibio_WoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_WoodforestSettlementAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 92 R51.htm IDEA: XBRL DOCUMENT
Discontinued Operations - Reconciliation of Loss from Discontinued Operations (Details) - USD ($) $ in Thousands12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Results of operations for discontinued operations Research and development$ 5,185$ 10,327Fixed asset impairments3,10017,900Inventory reserve 4,915Gain on extinguishment of debt808 Loss from discontinued operations(9,464)(35,699)iBio CDMO, LLC | Discontinued Operations Results of operations for discontinued operations Revenues 391Cost of goods sold 52Gross profit 339Research and development 6,344General and administrative1,2076,751Fixed asset impairments3,100 17,900Loss (gain) on sale of fixed assets4,816(773)Inventory reserve 4,915Total operating expenses9,12335,137Interest expense - term note payable(1,149)(900) Gain on extinguishment of debt808 Other (1)Total other expenses(341)(901)Loss from discontinued operations$ (9,464)$ (35,699)
- Definition

Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

+ Details
Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-6Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-7

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4

+ Details

Name:us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15

+ Details

Name:us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2

+ Details

Name:us-gaap_InventoryWriteDown Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of expense related to nonoperating activities, classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_OtherNonoperatingExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting

Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:us-gaap_ResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details

Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf
Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 93 R52.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Reconciliation of Assets and Liabilities Held-for-Sale (Details) - iBio CDMO, LLC - Held-for-Sale $ in Thousands Jun. 30, 2023

USD ($) Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Operating lease right-of-use assets $ 1,941 Property and equipment, net 16,124 Total current Assets 18,065 Operating lease obligation 1,941 Total current liabilities $ 1,941

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

+ Details

Name:us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type: credit Period Type:instant

- Definition

Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

+ Details
Name:us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf
Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type:na Balance Type: Period Type:
XML 94 R53.htm IDEA: XBRL DOCUMENT
Discontinued Operations - Reconciliation of Cash Flows from Discontinued Operations (Details) - USD ($) $ in Thousands12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Depreciation expense$ 638$ 674 Amortization of finance lease right-of-use assets271224Fixed asset impairments3,10017,900Loss on sale of fixed assets4,909(773)Gain on extinguishment of debt (808) Payment of term note payable(1,513)(9,318)Inventory reserve 4,915Sales proceeds for fixed assets1162,600iBio CDMO, LLC | Discontinued Operations Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Depreciation expense 273Amortization of finance lease right-of-use assets 20Purchase of fixed assets 1,542Fixed asset impairments3,10017,900Loss on sale of fixed assets4,817 Gain on extinguishment of debt(808) Payment of term note payable(1,513) Inventory reserve 4,915Sales proceeds for fixed assets502,600Payment of finance lease obligation 17Investing non-

cash transactions: Fixed assets included in accounts payable in prior period, paid in current period 1,542Supplemental cash flow information: Cash paid during the period for interest$ 577$ 603

- Definition

Fixed asset charges incurred but not yet paid attributable to discontinued operations.

+ References

No definition available.

+ Details

Name:ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow associated with payments of financial leasing obligations as a result of discontinued operations.

+ References

No definition available.

+ Details

Name:ibio_PaymentOfFinanceLeaseObligationCashFlowImpactFromDiscontinuedOperations Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow associated with the acquisition of long-lived, physical assets that have been reported in the consolidated statements of income under discontinued operations.

+ References

No definition available.

+ Details

Name:ibio_PurchaseOfFixedAssetsCashFlowImpactDiscontinuedOperations Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details

Name:us-gaap_Depreciation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of amortization expense attributable to right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write-down of assets from their carrying value to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4

+ Details

Name:us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15

+ Details

Name:us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The amount of cash paid during the current period for interest owed on debt associated with discontinued operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2

+ Details
Name:us-gaap_InterestPaidDiscontinuedOperations Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2

+ Details
Name:us-gaap_InventoryWriteDown Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details
Name:us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details
Name:us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf
Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 95 R54.htm IDEA: XBRL DOCUMENT
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023

Jun. 30, 2022
Summary Of Significant Accounting Policies [Line Items] Accounts receivable $ 1,000,000 Allowance for credit losses $ 0 $ 0 Revenues 225,0000 Contract assets 00 Contract liabilities 200,0000 $ 100,000 Inventory 00 Research and development expenses $ 5,185,000 $ 10,327,000 Dividend rate 0.00% 0.00% Liability for uncertain tax positions $ 0 $ 0 Cash deposits held in excess of FDIC insured amount 664,0006,900,000 Continuing Operations Summary Of Significant Accounting Policies [Line Items] Revenues 225,0000 Discontinued Operations Summary Of Significant Accounting Policies [Line Items] Revenues $ 0391,000 Minimum Summary Of Significant Accounting Policies [Line Items] Fixed assets, useful life 3 years Maximum Summary Of Significant Accounting Policies [Line Items] Fixed assets, useful life 39 years Intellectual Property Summary Of Significant Accounting Policies [Line Items] Intangible asset, useful life 20 years Revenues Summary Of Significant Accounting Policies [Line Items] Revenue recognized included in contract liabilities $ 0 Discontinued Operations Summary Of Significant Accounting Policies [Line Items] Revenue recognized included in contract liabilities $ 100,000 Research and development expenses $ 0

- References

No definition available.

+ Details

Name:ibio_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix:ibio_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:us-gaap_AccountsReceivableNetCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of allowance for credit loss on accounts receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4

+ Details

Name:us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name:us-gaap_CashUninsuredAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_InventoryNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name:us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:us-gaap_ResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Amount of unrecognized tax benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B

+ Details

Name:us-gaap_UnrecognizedTaxBenefits Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details

Name:us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 96 R55.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($) Jun. 30, 2024Jun. 30, 2023Jun. 30, 2022Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional collateral held by bank (percentage of credit issued)5.00% Cash and equivalents$ 14,210,000$ 4,301,000 Restricted cash215,000253,000 Total cash, cash equivalents and restricted cash14,425,0007,579,000$ 28,672,000Collateral Held For Letter Of Credit - Term Note Payable Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Restricted cash 3,025,000 Collateral Held For Letter Of Credit - San Diego Lease Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Restricted cash198,000198,000 Collateral Held For Company Purchasing Card Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Restricted cash$ 17,000 $ 55,000

- Definition

The percentage of collateral required to be held by the reporting entity.

+ References

No definition available.

+ Details
Name:ibio_PercentageOfCollateralRequired Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details
Name:us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details
Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- References

No definition available.

+ Details
Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details
Name:us-gaap_RestrictedCash Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details
Name:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 97 R56.htm IDEA: XBRL DOCUMENT
Financial Instruments and Fair Value Measurement (Details) - USD ($) 3 Months Ended12 Months Ended
May 31, 2024
Dec. 31, 2023
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fixed asset impairment charge $ 3,100,000$ 17,900,000 Discontinued Operations | iBio CDMO, LLC Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fixed asset impairment charge 3,100,00017,900,000 Loss on sale of fixed assets 4,816,000(773,000) Discontinued Operations | iBio CDMO, LLC | 2024 Purchase and Sale Agreement - The Board of Regents Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Loss on sale of fixed assets 4,800,000 Facility Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Carrying value, fixed assets held for sale $ 16,124,000016,124,000 $ 16,350,000Facility | Discontinued Operations | iBio CDMO, LLC | 2024 Purchase and Sale Agreement - The Board of Regents Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Proceeds from sale of building$ 8,500,000 Loss on sale of fixed assets $ 4,800,000 Equipment Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Carrying value, fixed assets held for sale $ 2,100,000Fair Value, Nonrecurring | Level 1 | Facility | Purchase and Sale Agreement - Majestic Realty Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value, fixed assets held-for-sale (Quoted prices) $ 17,250,000 Fair Value, Nonrecurring | Level 3 | Discontinued Operations | iBio CDMO, LLC Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fixed asset impairment charge 17,900,000 Fair Value, Nonrecurring | Level 3 | Facility | Discontinued Operations | iBio CDMO, LLC Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fixed asset impairment charge $ 3,100,000$ 300,000 6,300,000 Fair Value, Nonrecurring | Level 3 | Equipment | Discontinued Operations | iBio CDMO, LLC Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fixed asset impairment charge $ 11,300,000
- Definition

Fair value portion of assets classified as held for sale.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

+ Details

Name:us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2

+ Details
Name:us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15

+ Details
Name:us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from sale of buildings.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details
Name:us-gaap_ProceedsFromSaleOfBuildings Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details
Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML 98 R57.htm IDEA: XBRL DOCUMENT
Significant Transactions (Details) 3 Months Ended12 Months Ended
Jan. 01, 2023
item

Sep. 16, 2022
USD ($)
lease
shares
Nov. 01, 2021
USD ($)
$ / shares
shares
Aug. 23, 2021
USD ($)
shares
Dec. 31, 2022
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Value of shares purchased in transaction $ 650,000 General and administrative expenses $ 11,674,000 $ 19,016,000 RubrYc Therapeutics Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of equipment leases assumed in asset acquisition 3 The Purchase and Sale Agreement | College Station Investors Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Proceeds from sale of building $ 28,000,000 Purchase price for Ground Lease Property 28,750,000 Base rent expense $ 151,450 Interest rate on lease (percentage of facility's market value) 6.50% The Credit Agreement | Woodforest National Bank Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Secured term loan $ 22,375,000 The Warrant | Bryan Capital | Common Stock Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrants, shares issued | shares 2,579 Exercise price per share of warrants | $ / shares $ 665 Warrants issued and exercisable | shares 579 Value of exercisable warrants $ 217,255 Collaboration, Option and License Agreement | RubrYc Therapeutics Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaboration and license agreement, agreement term 5 years Collaboration and license agreement, royalty payment term 10 years Stock Purchase Agreement | RubrYc Therapeutics | Series A-2 Preferred Stock Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Shares purchased in transaction | shares 2,864,345 Value of shares purchased in transaction $ 7,500,000 Asset Purchase Agreement | RubrYc Therapeutics Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Liability for contingent consideration $ 5,000,000 Cash advances to RubrYc to support operations 484,000 Transaction costs $ 208,000 Impairment of investment in RubrYc $ 1,760,000 Impairment of current prepaid expense 288,000 Impairment of noncurrent prepaid expense $ 864,000 Number of equipment leases assumed in asset acquisition | lease 3 Finance leases $ 814,000 Asset Purchase Agreement | RubrYc Therapeutics | Common Stock Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares issued per agreement | shares 5,117 Fair value of shares issued in agreement $ 1,000,000 Fair value of shares issued and subject to lockup period $ 650,000 Separation Agreement and General Release | Dr. Martin Brenner, Chief Executive Officer Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Period of bi-monthly installments of current base salary 24 months Period of bi-monthly installments of target bonus 24 months Maximum period for coverage of health insurance 18 months COBRA subsidy period 18 months Lump sum payment equal to six time the COBRA subsidy | item 6 General and administrative expenses $ 2,130,000 Accrued expenses $ 500,000

- Definition

Collaboration and license agreement, agreement term

+ References

No definition available.

+ Details
Name:ibio_CollaborationAndLicenseAgreementAgreementTerm Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Collaboration and license agreement, royalty payment term

+ References

No definition available.

+ Details
Name:ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Fair value estimate of shares issued in asset purchase agreement after the initial lockup period.

+ References

No definition available.

+ Details
Name:ibio_FairValueOfSharesIssuedInAgreementAfterLockupPeriod Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Impairment of current prepaid expenses.

+ References

No definition available.

+ Details
Name:ibio_ImpairmentOfPrepaidExpensesCurrent Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Impairment of non-current prepaid expenses.

+ References

No definition available.

+ Details
Name:ibio_ImpairmentOfPrepaidExpensesNonCurrent Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Represents the number of equipment leases.

+ References

No definition available.

+ Details
Name:ibio_NumberOfEquipmentLeases Namespace Prefix:ibio_ Data Type:xbrli:integerItemType Balance Type:na Period Type:instant

- Definition

Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.

+ References

No definition available.

+ Details

Name:ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type: na Period Type:duration

- Definition

Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").

+ References

No definition available.

+ Details

Name:ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").

+ References

No definition available.

+ Details

Name:ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAc Namespace Prefix:ibio_ Data Type:xbrli:decimalItemType Balance Type:na Period Type:duration

- Definition

Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.

+ References

No definition available.

+ Details

Name:ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.

+ References

No definition available.

+ Details

Name:ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type: duration

- Definition

The number of warrants issued, and exercisable, as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

No definition available.

+ Details

Name:ibio_WarrantsIssuedAndExercisable Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Amount of transaction cost incurred as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period

Type:duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:us-gaap_AssetAcquisitionContingentConsiderationLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:us-gaap_DebtInstrumentFaceAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

+ Details

Name:us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_FinanceLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:us-gaap_GeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-8A

+ Details

Name:us-gaap_ImpairmentOfInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -

Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash inflow from sale of buildings.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:us-gaap_ProceedsFromSaleOfBuildings Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash inflow before closing and debt issuance costs received by a seller-lessee in a sale-leaseback recognized in investing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481266/840-40-55-50Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481266/840-40-55-52Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 51 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481266/840-40-55-51

+ Details

Name:us-gaap_SaleLeasebackTransactionGrossProceedsInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The financing cost related to leases that have been recorded under the deposit method, as a financing or as a capital leases in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller.

+ References

No definition available.

+ Details

Name:us-gaap_SaleLeasebackTransactionImputedInterestRate Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

The amount of the current period expense recorded for use of the property in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-1

+ Details

Name:us-gaap_SaleLeasebackTransactionRentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details

Name:us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details
Name:us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details
Name:us-gaap_WarrantsAndRightsOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleGroundLeaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_CreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_WoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_WarrantAgreementWithBryanCapitalMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_BryanCapitalMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_AssetPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 99 R58.htm IDEA: XBRL DOCUMENT
Significant Transactions - Summary of Asset Acquisition (Details) - RubrYc Therapeutics - USD ($) Sep. 19, 2022 Aug. 23, 2021 Stock Purchase Agreement Business Acquisition [Line Items] Purchase price allocated $ 7,500,000 Stock Purchase Agreement | Preferred Stock Business Acquisition [Line Items] Purchase price allocated 1,760,000 Stock Purchase Agreement | Intangible Assets Business Acquisition [Line Items] Purchase price allocated 4,300,000 Stock Purchase Agreement | Prepaid Expenses Business Acquisition [Line Items] Purchase price allocated $ 1,440,000 Asset Purchase Agreement Business Acquisition [Line Items] Purchase price allocated $ 1,342,000 Asset Purchase Agreement | Intangible Assets Business Acquisition [Line Items] Purchase price allocated 1,228,000 Asset Purchase Agreement | Fixed Assets Business Acquisition [Line Items] Purchase price allocated $ 114,000

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details
Name:us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

+ Details
Name:us-gaap_BusinessAcquisitionLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AssetAcquisitionAxis=ibio_AcquiredSeriesPreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AssetAcquisitionAxis=ibio_AcquiredIntangibleAssetsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AssetAcquisitionAxis=ibio_AcquiredPrepaidExpensesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_AssetPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AssetAcquisitionAxis=ibio_AcquiredFixedAssetsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 100 R59.htm IDEA: XBRL DOCUMENT
Promissory Note Receivable (Details) - USD ($) 12 Months Ended
Aug. 29, 2024
Jun. 19, 2023
Jun. 30, 2024
Jun. 30, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items] Promissory note receivable, current $ 713,000 Promissory note receivable, non-current 1,081,000 $ 1,706,000 Interest income 363,000 213,000 Promissory Note Accounts, Notes, Loans and Financing Receivable [Line Items] Promissory note receivable, net 1,794,000 1,706,000 Safi Biosolutions | Promissory Note Accounts, Notes, Loans and Financing Receivable [Line Items] Promissory note receivable, current 713,000 Promissory note receivable, non-current 1,081,000 Promissory note receivable, net $ 1,500,000 Interest rate 5.00% Interest rate for first one year

extension 7.00% Interest rate for second one year extension 9.00% Interest income $ 88,000$ 75,000Safi Biosolutions | Promissory Note | Subsequent Events Accounts, Notes, Loans and Financing Receivable [Line Items] Interest payments on notes receivable$ 713,000 Payments on notes receivable (amounts applied against principal balance)$ 419,000

- Definition

Percentage of fixed rate of interest on notes.

+ References

No definition available.

+ Details

Name:ibio_LoansReceivableFixedRatesOfInterest Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Percentage of rate of interest on notes receivable for first one year extension.

+ References

No definition available.

+ Details

Name:ibio_LoansReceivableRateOfInterestForFirstOneYearExtension Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

Percentage of rate of interest on notes receivable for second one year extension.

+ References

No definition available.

+ Details

Name:ibio_LoansReceivableRateOfInterestForSecondOneYearExtension Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

Payments received for interest owed to the Company for interest accrued on notes issued.

+ References

No definition available.

+ Details

Name:ibio_NotesReceivablePaymentsForInterest Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Payments received for notes issued, amounts applied directly to principal balance.

+ References

No definition available.

+ Details

Name:ibio_NotesReceivablePaymentsOnPrincipalBalance Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Name:us-gaap_InvestmentIncomeInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.

+ References

No definition available.

+ Details

Name:us-gaap_NotesAndLoansReceivableNetNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details
Name:us-gaap_NotesReceivableNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details
Name:us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_CounterpartyNameAxis=ibio_SafiBiosolutionsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 101 R60.htm IDEA: XBRL DOCUMENT
Investments in Debt Securities (Details) - USD ($)12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Investments in Debt Securities Amortization of premiums on debt securities$ 0$ 67,000Proceeds from sale of debt securities 6,739,000Cost of debt securities 6,837,000Realized loss on sale of debt securities $ (98,000)
- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3

+ Details
Name:us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11

+ Details

Name:us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11

+ Details
Name:us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration XML 102 R61.htm IDEA: XBRL DOCUMENT
Finance Lease ROU Assets (Details) 12 Months Ended
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Sep. 16, 2022
Lessee, Lease, Description [Line Items] Net finance lease ROU assets $ 339,000 $ 610,000 Amortization expense - ROU assets 271,000 224,000 Continuing Operations Lessee, Lease, Description [Line Items] Amortization expense - ROU assets 271,000 204,000 RubrYc Therapeutics Lessee, Lease, Description [Line Items] Number of equipment leases assumed in asset acquisition 3 Equipment | RubrYc Therapeutics Lessee, Lease, Description [Line Items] ROU - Equipment 814,000 814,000 Accumulated amortization (475,000) (204,000) Net finance lease ROU assets $ 339,000 $ 610,000
- Definition

Represents the number of equipment leases.

+ References

No definition available.

+ Details
Name:ibio_NumberOfEquipmentLeases Namespace Prefix:ibio_ Data Type:xbrli:integerItemType Balance Type:na Period Type:instant

- Definition

Amount, after accumulated amortization, of right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of accumulated amortization of right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of amortization expense attributable to right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount, before accumulated amortization, of right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3

+ Details
Name:us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 103 R62.htm IDEA: XBRL DOCUMENT
Operating Lease ROU Assets (Details) - USD ($) Jun. 30, 2024 Jun. 30, 2023 Nov. 01, 2021 Sep. 10, 2021 Operating lease right-of-use asset $ 2,401,000 $ 2,722,000 Facilities | San Diego, California Operating lease right-of-use asset $ 2,401,000 $ 2,722,000 $ 3,603,000 Facilities | Bryan, Texas Operating lease right-of-use asset $ 1,967,000
- Definition

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_StatementGeographicalAxis=ibio_SanDiegoMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_StatementGeographicalAxis=ibio_BryanTexasMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 104 R63.htm IDEA: XBRL DOCUMENT
Fixed Assets (Details) - USD ($) 3 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items] Fixed asset impairment charge $ 3,100,000 $ 17,900,000 iBio CDMO, LLC | Discontinued Operations Property, Plant and Equipment [Line Items] Fixed asset impairment charge 3,100,000 17,900,000 Facility Property, Plant and Equipment [Line Items] Carrying value, fixed assets held for sale $ 16,124,000 $ 0 16,124,000 $ 16,350,000 Fair Value, Nonrecurring | Level 3 | iBio CDMO, LLC | Discontinued Operations Property, Plant and

Equipment [Line Items] Fixed asset impairment charge 17,900,000 Fair Value, Nonrecurring | Level 3 | Facility | iBio CDMO, LLC | Discontinued Operations Property, Plant and Equipment [Line Items] Fixed asset impairment charge$ 3,100,000$ 300,000 $ 6,300,000

- Definition

The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2

+ Details

Name:us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15

+ Details

Name:us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

+ Details

Name:us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML

105 R64.htm IDEA: XBRL DOCUMENT
Fixed Assets - Carrying Value and Accumulated Depreciation (Details) - USD ($)12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Property, Plant and Equipment [Line Items] Gross fixed assets$ 4,643,000$ 4,619,000Accumulated depreciation(1,011,000)(400,000)Net fixed assets3,632,000 4,219,000Depreciation expense - fixed assets638,000400,000Building and Improvements Property, Plant and Equipment [Line Items] Gross fixed assets695,000 695,000Machinery and Equipment Property, Plant and Equipment [Line Items] Gross fixed assets3,545,0003,521,000Office Equipment and Software Property, Plant and Equipment [Line Items] Gross fixed assets$ 403,000$ 403,000

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details
Name:us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of depreciation expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details
Name:us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details

Name:us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

+ Details

Name:us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1

+ Details

Name:us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 106 R65.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - USD ($) 12 Months Ended

Sep. 19, 2022

Aug. 23, 2021
Jun. 30, 2024
Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items] | Impairment of intangible assets | $ 0 | $ 565,000 | Amortization of Intangible Assets | 20,000 | 126,000 | Intellectual Property | Finite-Lived Intangible Assets [Line Items] | Impairment of intangible assets | 0 | 565,000 | Amortization of Intangible Assets | $ 20,000 | 126,000 | Intangible assets weighted average remaining life | 18 years 3 months 18 days | Stock Purchase Agreement | RubrYc Therapeutics | Finite-Lived Intangible Assets [Line Items] | Investment in RubrYc | $ 7,500,000 | Asset Purchase Agreement | RubrYc Therapeutics | Finite-Lived Intangible Assets [Line Items] | Investment in RubrYc | $ 1,342,000 | Licensing Agreement | University of Pittsburgh | Patents and Licenses | Finite-Lived Intangible Assets [Line Items] | Impairment of intangible assets | $ 25,000

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

+ Details

Name:us-gaap_AmortizationOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details
Name:us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

+ Details
Name:us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details
Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_AssetPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_PatentAndLicensingAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_UniversityOfPittsburghMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 107 R66.htm IDEA: XBRL DOCUMENT
Intangible Assets - Carrying Value and Accumulated Amortization (Details) - USD ($) 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Finite-Lived Intangible Assets Finite-lived intangible asset amortization $ (20,000) $ (126,000) Intangible Assets, Net Intangible assets, net 5,368,000 5,388,000 Amortization of intangible assets (20,000) (126,000) Impairment of intangible assets 0 565,000 Intellectual Property Finite-Lived Intangible Assets Finite-lived intangible assets, gross 400,000 400,000 Finite-lived intangible assets accumulated amortization (35,000) (15,000) Finite-lived intangible asset amortization (20,000) (126,000) Finite-lived intangible asset additions 0 Finite-lived intangible asset impairment 0 Finite-lived intangible assets, net 365,000 385,000 Intangible Assets, Net Amortization of intangible assets (20,000) (126,000) Impairment of intangible assets 0 565,000 Patents and Licenses Indefinite-Lived Intangible Assets Indefinite-lived intangible assets 5,003,000 $ 5,003,000 Indefinite-lived intangible asset additions 0 Indefinite-lived intangible asset impairment $ 0

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

+ Details

Name:us-gaap_AmortizationOfIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1

+ Details
Name:us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details
Name:us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details
Name:us-gaap_FiniteLivedIntangibleAssetsRollForward Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

+ Details
Name:us-gaap_FinitelivedIntangibleAssetsAcquired1 Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

+ Details

Name:us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsRollForward Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_IndefinitelivedIntangibleAssetsAcquired Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

+ Details

Name:us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 108 R67.htm IDEA: XBRL DOCUMENT

Intangible Assets - Estimated Annual Amortization Expense (Details) - Intellectual Property - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Finite-Lived Intangible Assets [Line Items] 2025 $ 20 2026 20 2027 20 2028 20 2029 20 Thereafter 265 Total $ 365 $ 385

- Definition

Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details
Name:us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details
Name:us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details
Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 109 R68.htm IDEA: XBRL DOCUMENT
Accrued Expenses (Details) - USD ($) $ in ThousandsJun. 30, 2024Jun. 30, 2023Accrued Expenses Personnel related costs$ 1,568$ 3,879Real estate taxes 268 Interest and fees related to term note payable 183Professional fees 31Other accrued expenses460200Total accrued expenses$ 2,028$ 4,561
- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details
Name:us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit

Period Type:instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details
Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details
Name:us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details
Name:us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of interest payable on debt, including, but not limited to, trade payables.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details
Name:us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_PayablesAndAccrualsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 110 R69.htm
IDEA: XBRL DOCUMENT
Debt - Credit Agreement (Details) - USD ($) 1 Months Ended 6 Months Ended
May 31, 2024
May 17, 2024
Dec. 22, 2023
Oct. 16, 2023
Sep. 18, 2023
May 10, 2023
Mar. 28, 2023
Mar. 24, 2023
Feb. 20, 2023
Oct. 11, 2022
Nov. 13, 2023
May 17, 2024
Mar. 31, 2023
Jun. 30, 2024
Feb. 09, 2024
Nov. 14, 2023
Oct. 17, 2023
Oct. 04, 2023
Jun. 30, 2023
Apr. 14, 2023
Nov. 01, 2021
Debt Instrument [Line Items] Term note payable - net of deferred financing costs $ 12,937,000 The Credit Agreement | Woodforest National Bank Debt Instrument [Line Items] Secured term loan $ 22,375,000 The Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Secured term loan 13,057,000 $ 22,375,000 Term note payable - net of deferred financing costs $ 0 12,937,000 Term loan interest rate 3.25% Deferred finance costs $ 120,000 The Credit Agreement | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Liquidity covenant, unrestricted cash balance $ 10,000,000 First Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Repayments of outstanding principal on term loan $ 5,100,000 $ 5,500,000 Principal payments on term loan $ 250,000 Frequency of accelerated principal repayments Monthly Term of accelerated principal repayments 6 months Amendment fee 22,375 First Amended Credit Agreement | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Liquidity covenant, unrestricted cash balance 7,500,000 Liquidity covenant (minimum unrestricted cash balance if specific milestones are met) $ 5,000,000 Third Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Percentage of equity offering proceeds to be used for debt repayment 40.00% Percentage of equipment sale proceeds to be used for debt repayment 40.00% Third Amended Credit Agreement | Woodforest National Bank | Term Note | Maximum Debt Instrument [Line Items] Days following equity offerings to use a portion of net proceeds as debt repayment 5 days Fourth Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Amendment fee $ 75,000,000,000 Percentage of equity offering proceeds to be used for debt repayment 20.00% Percentage of equipment sale proceeds to be used for debt repayment 20.00% Cash retained from legal settlement $ 2,000,000 Settlement payment received 5,100,000 Amount held as collateral from legal settlement 3,000,000 Fourth Amended Credit Agreement | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Liquidity covenant, unrestricted cash balance $ 1,000,000 Fifth Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Term loan interest rate 5.25% Reduction in collateral held $ 500,000 Term loan principal outstanding, amount triggering release of collateral 10,000,000 Principal reduction, milestone amounts triggering release of collateral held 2,500,000 Collateral released once milestone payments made $ 750,000 Annual interest rate increase (Facility sale prior to June 30, 2023) 1.00% Annual interest rate increase (Facility sale after June 30, 2023 and prior to September 30, 2023) 2.00% Annual interest rate increase (Facility sale after September 30, 2023) 3.00% Fees payable (Facility sale prior to June 30, 2023) $ 75,000 Fees payable (Facility sale after June 30, 2023 and prior to September 30, 2023) 100,000 Fees payable (Facility sale after September 30, 2023) $ 125,000 Interest rate payable in-kind 3.00% Sixth Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Amendment fee $ 20,000 Business days to deliver executed copy of Purchase Agreement for the sale of the Facility 1 day Seventh Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Amendment fee $ 20,000 Collateral withdrawal $ 2,000,000 Seventh Amended Credit Agreement | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Liquidity covenant, unrestricted cash balance 0 First Potential Collateral Withdrawal | Woodforest National Bank | Term Note Debt Instrument [Line Items] Collateral withdrawal $ 1,000,000 First Potential Collateral Withdrawal | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Collateral withdrawal, liquidity threshold to maintain $ 2,000,000 Second Potential Collateral Withdrawal | Woodforest National Bank | Term Note Debt Instrument [Line Items] Collateral withdrawal $ 750,000 Second Potential Collateral Withdrawal | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Collateral withdrawal, liquidity threshold to maintain $ 1,250,000 Third Potential Collateral Withdrawal | Woodforest National Bank | Term Note Debt Instrument [Line Items] Collateral withdrawal $ 250,000 Third Potential Collateral Withdrawal | Woodforest National Bank | Term Note | Minimum Debt Instrument [Line Items] Collateral withdrawal, liquidity threshold to maintain $ 1,000,000 Eighth Amended Credit Agreement | Woodforest National Bank | Term Note Debt Instrument [Line Items] Term loan interest rate 4.50% Amendment fee $ 155,000 $ 10,000 $ 155,000 Amount held as collateral from legal settlement $ 900,000 Collateral withdrawal $ 150,000 Collateral withdrawal, liquidity threshold to maintain $ 900,000 Interest rate payable in-kind 4.50% Settlement Agreement | Woodforest National Bank | iBio CDMO, LLC | Discontinued Operations Debt Instrument [Line Items] Proceeds from sale of property paid to Woodforest to settle debt $ 8,500,000 Cash payments to settle debt $ 915,000 Settlement Agreement | Woodforest National Bank | Pre-Funded Warrants | iBio CDMO, LLC | Discontinued Operations Debt Instrument [Line Items] Warrants issued to settle debt 1,560,570 Exercise price per share of warrants $ 0.0001 Settlement Agreement | Woodforest National Bank | Term Note | iBio CDMO, LLC | Discontinued Operations Debt Instrument [Line Items] Proceeds from sale of property paid to Woodforest to settle debt $ 8,500,000 Cash payments to settle debt $ 915,000 Settlement Agreement | Woodforest National Bank | Term Note | Pre-Funded Warrants Debt Instrument [Line Items] Warrants issued to settle debt 1,560,570 Fair value of shares issued in agreement $ 4,499,124.88 Share price of common stock $ 2.883 $ 2.883 Exercise price per share of warrants $ 0.0001 $ 0.0001 Settlement Agreement | Woodforest National Bank | Term Note | Pre-Funded Warrants | iBio CDMO, LLC | Discontinued Operations Debt Instrument [Line Items] Warrants issued to settle debt 1,560,570 Exercise price per share of warrants $ 0.0001

- Definition

Represents the amount retained from proceeds of legal settlement.

+ References

No definition available.

+ Details

Name:ibio_AmountRetainedFromProceedsOfLegalSettlement Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Threshold number of business days following the close of any at-the-market equity offerings for the Company to pay a portion of the net proceeds to Woodforest National Bank, as part of the credit agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:ibio_BusinessDayThresholdFollowingAtMarketEquityOfferingsToPayWoodforestPortionOfProceeds Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Amount of assets held as collateral in Woodforest National Bank's Reserve Funds Deposit Account released back to the Company.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentCollateralAmountReleasedByLender Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Fee owed to Woodforest National Bank if/when a sale of equipment closes After June 30 2023, but prior to/on September 30 2023.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentFeeAmountIfFacilitySaleOccursAfterJune302023PriorToOrOnSeptember302023 Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Fee owed to Woodforest National Bank if/when a sale of equipment closes After September 30 2023, or if a sale does not occur.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentFeeAmountIfFacilitySaleOccursAfterSeptember302023 Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Fee owed to Woodforest National Bank if/when a sale of equipment closes on or prior to June 30, 2023.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentFeeAmountIfFacilitySaleOccursPriorToJune302023 Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment after June 30, 2023, but prior to/on September 30, 2023.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySaleAfterJune302023PriorToOrOnSeptember302023 Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment after September 30, 2023, or if equipment is not sold at all.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySaleAfterSeptember302023 Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment prior to June 30, 2023.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySalePriorToJune302023 Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Represents the payable in-kind interest rate.

+ References

No definition available.

+ Details
Name:ibio_DebtInstrumentPaidInKindInterestRate Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Amount of remaining term loan principal outstanding, in which Woodforest National Bank will release cash held as collateral back to the Company.

+ References

No definition available.

+ Details
Name:ibio_OutstandingPrincipalRemainingAmountTriggeringReleaseOfCollateralHeld Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The percentage of net proceeds realized from the closing of any at-the-market equity offerings that must be used for the repayment of debt, as defined in the Company's credit agreement with Woodforest National Bank.

+ References

No definition available.

+ Details
Name:ibio_PercentageOfNetProceedsFromAtMarketEquityOfferingsToBeUsedForDebtRepayment Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

The percentage of net proceeds realized from the sale of equipment, which must be used for the repayment of debt as defined in the Company's credit agreement with Woodforest National Bank.

+ References

No definition available.

+ Details

Name:ibio_PercentageOfNetProceedsFromSaleOfEquipmentToBeUsedForDebtRepayment Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Amount of principal reduction on the term loan, provided the total principal outstanding is less than $10 million, in which Woodforest National Bank will release cash held as collateral back to the Company.

+ References

No definition available.

+ Details

Name:ibio_PrincipalReductionMilestoneAmountsTriggeringReleaseOfCollateralHeld Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash, previously held as collateral by Woodforest National Bank, released back to the company upon satisfying certain milestones related to principal repayments on the term loan.

+ References

No definition available.

+ Details

Name:ibio_ReductionInCollateralHeldFromAcceleratedPrincipalPayments Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Reduction in cash held by Woodforest as collateral pursuant to the Credit Agreement.

+ References

No definition available.

+ Details

Name:ibio_ReductionInCollateralHeldFromLegalSettlement Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Minimum liquidity requirement per debt covenants in amended credit agreements (liquidity amount if specific milestones are met).

+ References

No definition available.

+ Details

Name:ibio_SecuredTermLoanAmendedReducedLiquidityCovenant Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Minimum liquidity requirement per debt covenants in credit agreements.

+ References

No definition available.

+ Details

Name:ibio_SecuredTermLoanInitialLiquidityCovenant Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Minimum liquidity requirement for collateral withdrawal per debt covenants in credit agreements.

+ References

No definition available.

+ Details

Name:ibio_SecuredTermLoanLiquidityCovenantForCollateralWithdrawal Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.

+ References

No definition available.

+ Details

Name:ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:us-gaap_DebtInstrumentFaceAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of the fee that accompanies borrowing money under the debt instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentFeeAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Description of the frequency of periodic payments (monthly, quarterly, annual).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Name:us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

+ Details

Name:us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Name:us-gaap_DebtInstrumentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of the required periodic payments applied to principal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:us-gaap_DebtInstrumentTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

+ Details

Name:us-gaap_DeferredFinanceCostsNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Cash received for the settlement of litigation during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:us-gaap_ProceedsFromLegalSettlements Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_RepaymentsOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:us-gaap_RepaymentsOfLongTermLinesOfCredit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details

Name:us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:us-gaap_SharesIssuedPricePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details
Name:us-gaap_ShortTermBankLoansAndNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_CreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_CounterpartyNameAxis=ibio_WoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_WoodforestSettlementAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_ContractDevelopmentAndManuf Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 111 R70.htm IDEA: XBRL DOCUMENT
Debt - Equipment Financing (Details) - Equipment Financing Agreement - USD ($) 12 Months Ended
Oct. 12, 2022
Jun. 30, 2024
Jun. 30, 2023
Debt Instrument [Line Items] Principal amount borrowed $ 500,000 Term of debt agreement 36 months Imputed interest rate 10.62% Monthly payments on debt $ 16,230 $ 259,000 Interest expense on debt $ 35,000 $ 31,000
- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:us-gaap_DebtInstrumentFaceAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

+ Details

Name:us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-

1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Name:us-gaap_DebtInstrumentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Name:us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:us-gaap_DebtInstrumentTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details

Name:us-gaap_InterestExpenseDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details

Name:us-gaap_TypeOfArrangementAxis=ibio_EquipmentFinancingMasterLeaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 112 R71.htm IDEA: XBRL DOCUMENT

Debt - Equipment Financing Future Minimum Payments (Details) - USD ($) 12 Months Ended

Oct. 12, 2022

Jun. 30, 2024

Jun. 30, 2023

Debt Instrument [Line Items] Less: current portion $ (178,000)$ (160,000) Long-term portion of minimum equipment financing obligation 63,000241,000 Equipment Financing Agreement Debt Instrument [Line Items] Principal payments 241,000 Interest payments 18,000 Total minimum debt payments$ 16,230259,000 Less: current portion (178,000) Long-term portion of minimum equipment financing obligation 63,000 Equipment financing payable, net 241,000$ 401,000 Equipment Financing Agreement | 2025 Debt Instrument [Line Items] Principal payments 178,000 Interest payments 17,000 Total minimum debt payments 195,000 Equipment Financing Agreement | 2026 Debt Instrument [Line Items] Principal payments 63,000 Interest payments 1,000 Total minimum debt payments $ 64,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-11Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Name:us-gaap_DebtInstrumentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Name:us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the required periodic payments applied to interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the required periodic payments applied to principal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:us-gaap_SecuredDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:us-gaap_SecuredDebtCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_SecuredLongTermDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details

Name:us-gaap_TypeOfArrangementAxis=ibio_EquipmentFinancingMasterLeaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 113 R72.htm IDEA: XBRL DOCUMENT

Debt - Credit and Security Agreement (Details) - USD ($) 12 Months Ended

Jan. 16, 2024

Jun. 30, 2024

Debt Instrument [Line Items] Proceeds from term promissory note $ 895,000Credit and Security Agreement | Loeb Term Solutions | 2024 Term Note Debt Instrument [Line Items] Principal amount borrowed$ 1,071,572 Proceeds from term promissory note1,027,455 Origination fee42,863 Appraisal costs1,173 Bank wire fees$ 75 Fee percentage applied to principal prepayments (12 months or less from origination)4.00% Fee percentage applied to principal prepayments (12-24 months from origination)3.00% Percentage of eligible equipment's liquidation value, threshold for additional lending80.00% Monthly payments on debt$ 30,710 1,205,000Balloon payment payable (January 2026)$ 652,060 Interest expense on debt $ 66,000Credit and Security Agreement | Loeb Term Solutions | 2024 Term Note | Prime Rate Debt Instrument [Line Items] Spread on base interest rate8.50% Event of Default | Loeb Term Solutions | 2024 Term Note | Effective Rate Debt Instrument [Line Items] Spread on base interest rate6.00%

- Definition

The fee, expressed as a percentage of the total principal amount being prepaid, when a prepayment on the loan balance occurs on, after 12 months, but prior to 24

months, from the loan origination date.

+ References

No definition available.

+ Details
Name:ibio_PrepaymentFeePercentageOfPrincipalAmountRepaidWhenPrepaymentOccursAfterOneYearButPriorToTwoYearsFromIssuance Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

The fee, expressed as a percentage of the total principal amount being prepaid, when a prepayment on the loan balance occurs on, or prior-to, 12 months from the loan origination date.

+ References

No definition available.

+ Details
Name:ibio_PrepaymentFeePercentageOfPrincipalAmountRepaidWhenPrepaymentOccursPriorToOneYearFromIssuance Namespace Prefix:ibio_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

The threshold amount for additional borrowings under the Credit and Security Agreement with Loeb Term Solutions, for which the face amount of additional lending may not exceed (expressed as a percentage of the forced liquidation value of the Company's eligible equipment held as fixed assets).

+ References

No definition available.

+ Details
Name:ibio_ThresholdForAdditionalBorrowingsAmountWhichLendingCannotExceedExpressedAsPercentageOfLiquidationValueOfEquipment Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details
Name:us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:us-gaap_DebtInstrumentFaceAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of the fee that accompanies borrowing money under the debt instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentFeeAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Name:us-gaap_DebtInstrumentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Name:us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.

+ References

No definition available.

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Represents the charge against earnings during the period for commitment fees and debt issuance expenses.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details
Name:us-gaap_InterestExpenseDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details
Name:us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details
Name:us-gaap_ProceedsFromNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_CreditAndSecurityAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:srt_CounterpartyNameAxis=ibio_LoebTermSolutionsLlcMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_DebtInstrumentAxis=us-gaap_MediumTermNotesMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_CreditAndSecurityAgreementEventOfDefaultMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 114 R73.htm IDEA: XBRL DOCUMENT Debt - Credit and Security Agreement Future Minimum Payments (Details) - USD ($) 12 Months Ended
Jan. 16, 2024
Jun. 30, 2024
Debt Instrument [Line Items] Less: current portion $ (218,000) Long-term portion of minimum term promissory note obligation 766,000 Credit and Security Agreement | Loeb Term Solutions | 2024 Term Note Debt Instrument [Line Items] Principal payments 984,000 Interest payments 221,000 Total minimum debt payments $ 30,7101,205,000 Less: current portion (218,000) Long-term portion of minimum term promissory note obligation 766,000 Term promissory note payable, net 984,000 Credit and Security Agreement | Loeb Term Solutions | 2024 Term Note | 2025 Debt Instrument [Line Items] Principal payments 218,000 Interest payments 151,000 Total minimum debt payments 369,000 Credit and Security Agreement | Loeb Term Solutions | 2024 Term Note | 2026 Debt Instrument [Line Items] Principal payments 766,000 Interest payments 70,000 Total minimum debt payments $ 836,000
- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Name:us-gaap_DebtInstrumentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Name:us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the required periodic payments applied to interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the required periodic payments applied to principal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_LongTermNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:us-gaap_NotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_NotesPayableCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details

Name:us-gaap_TypeOfArrangementAxis=ibio_CreditAndSecurityAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_CounterpartyNameAxis=ibio_LoebTermSolutionsLlcMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentAxis=us-gaap_MediumTermNotesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 115 R74.htm IDEA: XBRL DOCUMENT

Debt - Insurance Premium Financing (Details) - USD ($) 12 Months Ended

Oct. 30, 2023

Jun. 30, 2024

Short-Term Debt [Line Items] Insurance premium financing payable $ 123,000 Insurance Premium Financing Agreement | FIRST Insurance Funding Short-Term Debt [Line Items] Principal amount borrowed $ 597,000 Term of debt agreement 10 months Imputed interest rate 8.50% Monthly payments on debt $ 62,095 Insurance premium financing payable 123,000 Interest expense on debt 25,000 Total minimum debt payments $ 62,095 Insurance Premium Financing Agreement | FIRST Insurance Funding | 2025 Short-Term Debt [Line Items] Monthly payments on debt 124,000 Principal payments 123,000 Interest payments 1,000 Total minimum debt payments $ 124,000

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:us-gaap_DebtInstrumentFaceAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

+ Details

Name:us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Name:us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the required periodic payments applied to interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the required periodic payments applied to principal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:us-gaap_DebtInstrumentTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details

Name:us-gaap_InterestExpenseDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:us-gaap_ShortTermDebtLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details
Name:us-gaap_ShortTermNonBankLoansAndNotesPayable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_InsurancePremiumFinancingAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_FirstInsuranceFundingMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 116 R75.htm IDEA: XBRL DOCUMENT

Finance Lease Obligations (Details)	Sep. 16, 2022	Apr. 01, 2021
	USD ($)	USD ($)
	lease	
	Mobile Office Trailer - Lessee, Lease, Description [Line Items] - Monthly lease payments $ 3,819	RubrYc Therapeutics - Lessee, Lease, Description [Line Items] - Number of equipment leases assumed in asset acquisition 3 Asset Purchase Agreement | RubrYc Therapeutics - Lessee, Lease, Description [Line Items] - Number of equipment leases assumed in asset acquisition | lease 3 Finance leases $ 814,000 Asset Purchase Agreement | RubrYc Therapeutics | Equipment - Lessee, Lease, Description [Line Items] - Number of equipment leases assumed in asset acquisition 3 Finance leases $ 814,000 Monthly lease payments $ 14,000

- Definition

Represents the number of equipment leases.

+ References

No definition available.

+ Details
Name:ibio_NumberOfEquipmentLeases Namespace Prefix:ibio_ Data Type:xbrli:integerItemType Balance Type:na Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3

+ Details
Name:us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash outflow for variable lease payment excluded from lease liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5

+ Details
Name:us-gaap_VariableLeasePayment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_AssetPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 117 R76.htm
IDEA: XBRL DOCUMENT
Finance Lease Obligations - Finance Lease Cost and Supplemental Information (Details) - USD ($)12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Finance lease cost: Amortization of ROU assets$ 271,000$ 224,000Other Information: Financing cash flows from finance lease obligations272,000208,000Finance lease ROU assets339,000610,000Finance lease obligation - current portion299,000272,000Finance lease obligation - non current portion$ 53,000$ 351,000Weighted average remaining lease term - finance lease1 year 2 months 1 day2 years 2 months 1 dayWeighted average discount rate - finance lease obligation9.50%9.50%
Continuing Operations Finance lease cost: Amortization of ROU assets$ 271,000$ 204,000Interest on lease liabilities48,00049,000Total lease cost319,000253,000
Other Information: Financing cash flows from finance lease obligations$ 272,000$ 191,000

- References

No definition available.

+ Details
Name:us-gaap_CashFlowFinancingActivitiesLesseeAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of interest expense on finance lease liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_FinanceLeaseInterestExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of cash outflow for principal payment on finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5

+ Details

Name:us-gaap_FinanceLeasePrincipalPayments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount, after accumulated amortization, of right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization expense attributable to right-of-use asset from finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Weighted average discount rate for finance lease calculated at point in time.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: instant

- Definition

Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type: instant

- Definition

Amount of lease cost recognized by lessee for lease contract.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_LeaseCost Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_LeaseCostAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 118 R77.htm IDEA: XBRL DOCUMENT

Finance Lease Obligations - Future Minimum Payments (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Lessee, Lease, Description [Line Items] Principal payments $ 352 Interest payments 21 Total minimum lease payments 373 Less: current portion (299) $ (272) Long-term portion of minimum lease obligations 53 $ 351 2025 Lessee, Lease, Description [Line Items] Principal payments 299 Interest payments 20 Total minimum lease payments 319 2026 Lessee, Lease, Description [Line Items] Principal payments 53 Interest payments 1 Total minimum lease payments $ 54

- Definition

Amount applied to interest for payment on finance lease.

+ References

No definition available.

+ Details

Name:ibio_FinanceLeasePaymentsInterest Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount applied to principal for payment on finance lease.

+ References

No definition available.

+ Details

Name:ibio_FinanceLeasePaymentsPrincipal Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payments for finance lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3

+ Details

Name:us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_LeaseContractualTermAxis=ibio_Year2025Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_LeaseContractualTermAxis=ibio_Year2026Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML 119 R78.htm IDEA: XBRL DOCUMENT

Operating Lease Obligations (Details) - USD ($) 12 Months Ended

Nov. 01, 2021

Sep. 10, 2021

Jun. 30, 2024

Jun. 30, 2023

Lessee, Lease, Description [Line Items] Monthly rent expense $ 563,000$ 563,000Facilities | San Diego, California Lessee, Lease, Description [Line Items] Term of lease 88 months Monthly rent expense $ 51,223 Annual increase in monthly rent 3.00% Base rent abatement period in year one 6 months Tenant improvement allowance $ 81,860 Facilities | San Diego, California | Letter of Credit Lessee, Lease, Description [Line Items] Irrevocable letter of credit $ 188,844 The Purchase and Sale Agreement | College Station Investors Lessee, Lease, Description [Line Items] Base rent expense$ 151,450 Interest rate on lease (percentage of facility's market value)6.50% The Purchase and Sale Agreement | College Station Investors | Bryan, Texas Lessee, Lease, Description [Line Items] Interest rate on lease (percentage of facility's market value)6.50% The Purchase and Sale Agreement | College Station Investors | Facilities | Bryan, Texas Lessee, Lease, Description [Line Items] Base rent expense$ 151,450

- Definition

Base rent abatement period in the first year.

+ References

No definition available.

+ Details

Name:ibio_BaseRentAbatementInFirstYearPeriod Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Lessee Operating Lease, Annual percentage increase in base rent

+ References

No definition available.

+ Details

Name:ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4

+ Details

Name:us-gaap_GuaranteeObligationsMaximumExposure Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3

+ Details

Name:us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3

+ Details

Name:us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

- Definition

Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeasePayments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The financing cost related to leases that have been recorded under the deposit method, as a financing or as a capital leases in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller.

+ References

No definition available.

+ Details
Name:us-gaap_SaleLeasebackTransactionImputedInterestRate Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

The amount of the current period expense recorded for use of the property in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-1

+ Details
Name:us-gaap_SaleLeasebackTransactionRentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details
Name:us-gaap_TenantImprovements Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_StatementGeographicalAxis=ibio_SanDiegoMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleGroundLeaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_StatementGeographicalAxis=ibio_BryanTexasMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 120 R79.htm IDEA: XBRL DOCUMENT
Operating Lease Obligations - Operating Lease Cost and Supplemental Information (Details) - USD ($) $ in Thousands12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating lease cost: Operating lease cost$ 563$ 563Cash Flow, Operating Activities, Lessee [Abstract] Operating cash flows from operating lease563563Operating cash flows from operating lease obligation631307Operating lease ROU assets2,4012,722Operating lease obligation - current portion436389Operating lease obligation - net of current portion$ 2,688$ 3,125Weighted average remaining lease term - operating leases5 years 6 months6 years 6 monthsWeighted average discount rate - operating lease obligations7.25%7.25%

- References

No definition available.

+ Details
Name:us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_LeaseCostAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_OperatingLeaseCost Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_OperatingLeasePayments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeasePaymentsUse Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Weighted average discount rate for operating lease calculated at point in time.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: instant

- Definition

Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type: instant XML 121 R80.htm IDEA: XBRL DOCUMENT
Operating Lease Obligations - Future Minimum Payments (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2025 $ 648 2026 669 2027 688 2028 709 2029 731 Thereafter 374 Total minimum lease payments 3,819 Less: current portion (436) $ (389) Long-term portion of minimum lease obligation 2,688 $ 3,125 Principal Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2025 436 2026 490 2027 546 2028 609 2029 677 Thereafter 366 Total minimum lease payments 3,124 Imputed Interest Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2025 212 2026 179 2027 142 2028 100 2029 54 Thereafter 8 Total minimum lease payments $ 695

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details
Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details
Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details
Name:us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details
Name:us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details
Name:us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_LeaseContractualTermAxis=ibio_InterestMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 122 R81.htm IDEA: XBRL DOCUMENT
Stockholders' Equity (Details) 1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Apr. 01, 2024
USD ($)
Mar. 26, 2024
USD ($)
$ / shares
shares
Dec. 07, 2023
USD ($)
$ / shares
shares
Nov. 29, 2023
shares
Aug. 11, 2023
USD ($)
$ / shares
shares
Dec. 09, 2022
USD ($)
shares
Dec. 06, 2022
shares
Oct. 07, 2022
shares
Sep. 19, 2022
USD ($)
shares
May 10, 2022
USD ($)
shares
Nov. 01, 2021
$ / shares
shares

Aug. 31, 2024
USD ($)
shares
Sep. 16, 2024
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Aug. 04, 2023
$ / shares
shares
Aug. 03, 2023
$ / shares
Jul. 19, 2022
shares
May 09, 2022
$ / shares
shares
Nov. 25, 2020
USD ($)

Preferred Stock | Preferred stock, shares authorized | 1,000,000 | 1,000,000 | 1,000,000 | Preferred stock, par value | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | Preferred stock, shares issued | 0 | 0 | Common Stock | Common stock, shares authorized | 275,000,000 | 275,000,000 | 275,000,000 | Reverse Stock Split | Pre-split shares required for one post-split share of common stock | 25 | Issuances of Common Stock | Preferred stock, shares issued | 0 | 0 | Combined price per share of common stock and warrants | $ / shares | $ 2.11 | $ 12.20 | $ 2.11 | Subscription receivable | $ | $ 204,000 | Warrants | Proceeds from exercise of warrants | $ | $ 4,464,000 | Combined price per share of common stock and warrants | $ / shares | $ 2.11 | $ 12.20 | $ 2.11 | Subsequent Events | Warrants | Proceeds from exercise of warrants | $ | $ 4,000 | Restricted Stock Units | Issuances of Common Stock | Shares vested | 42,054 | 10,878 | Restricted Stock Units | Subsequent Events | Issuances of Common Stock | Shares vested | 12,210 | Employee Stock Option | Issuances of Common Stock | Shares exercised | 000 | Series 2022 Preferred Stock | Preferred Stock | Preferred stock, shares authorized | 1,000,000 | Preferred stock, par value | $ / shares | $ 0.001 | Preferred stock, conversion ratio | 1 | Preferred stock, shares issued | 1,000 | Preferred stock, proceeds from issuance | $ | $ 270 | Common shares issued upon conversion of preferred stock | 40 | Issuances of Common Stock | Preferred stock, shares issued | 1,000 | Preferred stock, proceeds from issuance | $ | $ 270 | Common Stock | Reverse Stock Split | Reverse stock split, shares received per share tendered | 0.05 | 0.04 | Pre-split shares required for one post-split share of common stock | 20 | 25 | Fractional shares issued in reverse stock split | 0 | 0 | RubrYc Therapeutics | Series A-2 Preferred Stock | Preferred Stock | Preferred stock, shares issued | 5,117 | Preferred stock, proceeds from issuance | $ | $ 1,000,000 | Issuances of Common Stock | Preferred stock, shares issued | 5,117 | Preferred stock, proceeds from issuance | $ | $ 1,000,000 | Cantor Fitzgerald Underwriting | At-The-Market Offerings | Common Stock | Issuances of Common Stock | Common stock, shares issued | 170,989,289,144 | Common stock, net proceeds from issuance | $ | $ 1,700,000 | $ 6,400,000 | Subscription receivable | $ | $ 204,000 | Warrants | Common stock, shares issued | 170,989,289,144 | Cantor Fitzgerald Underwriting | At-The-Market Offerings | Common Stock | Maximum | Issuances of Common Stock | Aggregate offering price | $ | $ 100,000,000 | Wainwright Underwriting | At-The-Market Offerings | Issuances of Common Stock | Warrants, proceeds from issuance | $ | $ 2,864,000 | Agent fee percentage | 7.00% | Wainwright Underwriting | At-The-Market Offerings | Common Stock | Issuances of Common Stock | Common stock, shares issued | 76,538 | Warrants | Common stock, shares issued | 76,538 | Wainwright Underwriting | At-The-Market Offerings | Common Stock | Pre-Funded Warrants | Issuances of Common Stock | Warrants, shares issued | 91,730 | Warrants | Warrants, shares issued | 91,730 | Wainwright Underwriting | At-The-Market Offerings | Common Stock | Series A warrants | Issuances of Common Stock | Warrants, shares issued | 168,267 | Warrants | Warrants, shares issued | 168,267 | Wainwright Underwriting | At-The-Market Offerings | Common Stock | Series B warrants | Issuances of Common Stock | Warrants, shares issued | 168,267 | Warrants | Warrants, shares issued | 168,267 | Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Issuances of Common Stock | Underwriters purchase option period | 30 days | Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Maximum | Issuances of Common Stock | Warrants, shares issued | 50,480 | Warrants | Warrants, shares issued | 50,480 | Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Minimum | Issuances of Common Stock | Common stock, shares issued | 25,240 | Warrants | Common stock, shares issued | 25,240 | Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Representative Warrants | Issuances of Common Stock | Warrants, shares issued | 10,094 | Additional shares for purchase, percentage of aggregate shares in offerings | 6.00% | Warrants | Warrants, shares issued | 10,094 | Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Series A warrants | Issuances of Common Stock | Warrants, shares issued | 25,240 | Warrants | Warrants, shares issued | 25,240 | Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Series B warrants | Issuances of Common Stock | Warrants, shares issued | 25,240 | Warrants | Warrants, shares issued | 25,240 | Lincoln Park Stock Purchase Agreement | At-The-Market Offerings | Common Stock | Issuances of Common Stock | Aggregate offering price | $ | $ 10,000,000 | Common stock, shares issued | 202,595 | Common stock, gross proceeds from issuance | $ | $ 5,000,000 | Common stock, net proceeds from issuance | $ | $ 1,300,000 | Common stock, shares available for future issuance | 0 | 0 | Term of stock purchase agreement | 24 months | Initial commitment shares issued | 10,573 | Additional commitment shares issued | 10,573 | Warrants | Common stock, shares issued | 202,595 | Lincoln Park Stock Purchase Agreement | At-The-Market Offerings | Common Stock | Maximum | Issuances of Common Stock | Aggregate offering price | $ | $ 10,000,000.0 | Shares available for purchase when stock price closes between $3 and $20 per share | 5,000 | Shares available for purchase when stock price closes between $20 and $40 per share | 7,500 | Shares available for purchase when stock price closes at or above $40 per share | 10,000 | Fair value of common stock purchased in single transaction | $ | $ 500,000 | Lincoln Park Stock Purchase Agreement | At-The-Market Offerings | Common Stock | Minimum | Issuances of Common Stock | Stock price permitting the sale of up to 5,000 shares | $ / shares | $ 3.00 | Stock price permitting the sale of up to 7,500 shares | $ / shares | 20.00 | Stock price permitting the sale of up to 10,000 shares | $ / shares | 40.00 | Stock price permitting accelerated purchase clause | $ / shares | $ 4.00 | Number of "additional accelerated purchases" that may be directed | 1 | Securities Purchase Agreement | Private placement | Issuances of Common Stock | Common stock, gross proceeds from issuance | $ | $ 15,100,000 | Common stock, net proceeds from issuance | $ | $ 14,100,000 | Reduced placement agent fee percentage | 4.00% | Securities Purchase Agreement | Private placement | Pre-Funded Warrants | Issuances of Common Stock | Warrants, shares of common stock issued upon conversion | 2,585,963 | Warrants, exercise price | $ / shares | $ 0.0001 | Warrants | Warrants, exercise price | $ / shares | $ 0.0001 | Warrants, shares of common stock issued upon conversion | 2,585,963 | Securities Purchase Agreement | Private placement | Series E Warrants | Issuances of Common Stock | Warrants, shares of common stock issued upon conversion | 5,287,278 | Warrants, exercise price | $ / shares | $ 2.64 | Warrants, exercisable term | 5 years | Warrants | Warrants, exercise price | $ / shares | $ 2.64 | Warrants, exercisable term | 5 years | Warrants, shares of common stock issued upon conversion | 5,287,278 | Securities Purchase Agreement | Private placement | Common Stock | Issuances of Common Stock | Common stock, net proceeds from issuance | $ | $ 4,000,000 | Accrued stock issuance costs | $ | $ 369,000 | $ 369,000 | Securities Purchase Agreement | Alliance Global Partners | Private placement | Issuances of Common Stock | Combined price per share of common stock and warrants | $ / shares | $ 2.00 | Reimbursement for legal expenses | $ | $ 75,000 | Non-accountable expense allowance | $ | $ 15,000 | Agent fee percentage | 5.50% | Warrants | Combined price per share of common stock and warrants | $ / shares | $ 2.00 | Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Issuances of Common Stock | Common stock, shares issued | 600,000 | Warrants | Common stock, shares issued | 600,000 | Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Pre-Funded Warrants | Issuances of Common Stock | Warrants, shares issued | 1,650,000 | Warrants, shares of common stock issued upon conversion | 1,650,000 | Warrants | Warrants, shares issued | 1,650,000 | Warrants, shares of common stock issued upon conversion | 1,650,000 | Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Series C Warrants | Issuances of Common Stock | Warrants, shares issued | 2,250,000 | Warrants, shares of common stock issued upon conversion | 2,250,000 | Warrants | Warrants, shares issued | 2,250,000 | Warrants, shares of common stock issued upon conversion | 2,250,000 | Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Series D Warrants | Issuances of Common Stock | Warrants, shares issued | 2,250,000 | Warrants, shares of common stock issued upon conversion | 2,250,000 | Warrants | Warrants, shares issued | 2,250,000 | Warrants, shares of common stock issued upon conversion | 2,250,000 | Securities Purchase Agreement and Warrants | Private placement | Issuances of Common Stock | Reimbursement for legal expenses | $ | $ 50,000 | Agent fee percentage | 6.00% | Reduced placement agent fee percentage | 4.00% | Securities Purchase Agreement and Warrants | Private placement | Common Stock | Issuances of Common Stock | Common stock, shares issued | 2,701,315 | Common stock, gross proceeds from issuance | $ | $ 15,100,000 | Common stock, net proceeds from issuance | $ | $ 14,100,000 | Warrants | Common stock, shares issued | 2,701,315 | Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-Funded Warrants | Issuances of Common Stock | Warrants, shares issued | 2,585,963 | Warrants, exercise price | $ / shares | $ 0.0001 | Warrants | Warrants, shares issued | 2,585,963 | Warrants, exercise price | $ / shares | $ 0.0001 | Securities Purchase Agreement and Warrants | Private placement | Common Stock | Series E Warrants | Issuances of Common Stock | Warrants, shares issued | 5,287,278 | Warrants, exercise price | $ / shares | $ 2.64 | Warrants, exercisable term | 5 years | Warrants | Warrants, shares issued | 5,287,278 | Warrants, exercise price | $ / shares | $ 2.64 | Warrants, exercisable term | 5 years | Securities Purchase Agreement and Warrants | Private placement | Common Stock and Series E Warrants | Issuances of Common Stock | Combined price per share of common stock and warrants | $ / shares | $ 2.85 | Warrants | Combined price per share of common stock and warrants | $ / shares | 2.85 | Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-funded and Series E Warrants | Issuances of Common Stock | Combined price per share of common stock and warrants | $ / shares | $ 2.849 | Term of 2024 Securities Purchase Agreement | 1 year | Failure to file registration statement, delinquency period | 6 months | Purchase agreement exclusivity period | 60 days | Warrants | Combined price per

share of common stock and warrants | $ / shares $ 2.849 Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-funded and Series E Warrants | Maximum Issuances of Common Stock Warrant exercise, common stock ownership limitation 4.99% Warrant exercise, common stock ownership limitation (at the election of the holder) 9.99% Number of days to file a registration statement 75 days Number of days to file a registration statement (in the event of a "full review" by SEC) 90 days Suspension period 15 days Partial liquidated damages, percent of aggregate security subscriptions 6.00% Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-funded and Series E Warrants | Minimum Issuances of Common Stock Warrant holder's election, period of written notice 61 days Number of days to file a registration statement 60 days Partial liquidated damages, percent of aggregate security subscriptions 1.00% Warrants | H.C. Wainwright & Co. Warrants Proceeds from exercise of warrants | $ $ 2,207,000 Warrants | H.C. Wainwright & Co. | Common Stock | Pre-Funded Warrants Issuances of Common Stock Warrants, exercise price | $ / shares $ 0.001 Warrants Warrants, exercise price | $ / shares 0.001 Warrants, shares exercised 0 0 Warrants | H.C. Wainwright & Co. | Common Stock | Representative Warrants Issuances of Common Stock Warrants, exercise price | $ / shares $ 26.00 Warrants, exercisable term 5 years Warrants Warrants, exercise price | $ / shares $ 26.00 Warrants, exercisable term 5 years Warrants | H.C. Wainwright & Co. | Common Stock | Warrants Issuances of Common Stock Warrants, exercise price | $ / shares $ 10.00$ 20.80 Warrants Warrants, exercise price | $ / shares $ 10.0020.80 Warrants | H.C. Wainwright & Co. | Common Stock | Series A warrants Issuances of Common Stock Warrants, shares of common stock issued upon conversion 173,795 Warrants, exercise price | $ / shares $ 20.80 Warrants, exercisable term 5 years Warrants Warrants, exercise price | $ / shares $ 20.80 Warrants, exercisable term 5 years Warrants, shares exercised 17,064 Warrants, shares of common stock issued upon conversion 173,795 Warrants | H.C. Wainwright & Co. | Common Stock | Series B warrants Issuances of Common Stock Warrants, shares of common stock issued upon conversion 102,900 Warrants, exercise price | $ / shares $ 20.80 Warrants, exercisable term 2 years Warrants Warrants, exercise price | $ / shares $ 20.80 Warrants, exercisable term 2 years Warrants, shares exercised 89,059 Warrants, shares of common stock issued upon conversion 102,900 Warrants | Bryan Capital | Common Stock | Warrants Issuances of Common Stock Warrants, shares issued 2,579 Warrants, exercise price | $ / shares $ 665 Warrants Warrants, shares issued 2,579 Warrants, exercise price | $ / shares $ 665 Warrants | Alliance Global Partners | Private placement | Common Stock Issuances of Common Stock Common stock, shares issued 600,000 Warrants Common stock, shares issued 600,000 Warrants | Alliance Global Partners | Private placement | Common Stock | Pre-Funded Warrants Issuances of Common Stock Warrants, shares issued 1,650,000 Warrants, shares of common stock issued upon conversion 1,650,000 Warrants, exercise price | $ / shares $ 0.0001 Combined price per share of common stock and warrants | $ / shares $ 1.9999 Warrants Warrants, shares issued 1,650,000 Warrants, exercise price | $ / shares $ 0.0001 Warrants, shares exercised 1,650,000 1,650,000 Warrants, shares of common stock issued upon conversion 1,650,000 Combined price per share of common stock and warrants | $ / shares $ 1.9999 Warrants | Alliance Global Partners | Private placement | Common Stock | Warrants Warrants Proceeds from exercise of warrants | $ $ 4,464,000 Warrants | Alliance Global Partners | Private placement | Common Stock | Warrants | Subsequent Events Warrants Proceeds from exercise of warrants | $ $ 4,000 Warrants | Alliance Global Partners | Private placement | Common Stock | Series C Warrants Issuances of Common Stock Warrants, shares issued 2,250,000 Warrants, shares of common stock issued upon conversion 2,250,000 Warrants, exercise price | $ / shares $ 2.00 Warrants, exercisable term 2 years Warrants Warrants, shares issued 2,250,000 Warrants, exercise price | $ / shares $ 2.00 Warrants, exercisable term 2 years Warrants, shares exercised 1,178,500 1,178,500 Warrants, shares of common stock issued upon conversion 2,250,000 Warrants | Alliance Global Partners | Private placement | Common Stock | Series C Warrants | Subsequent Events Warrants Warrants, shares exercised 1,000 Warrants | Alliance Global Partners | Private placement | Common Stock | Series D Warrants Issuances of Common Stock Warrants, shares issued 2,250,000 Warrants, shares of common stock issued upon conversion 2,250,000 Warrants, exercise price | $ / shares $ 2.00 Warrants, exercisable term 5 years Warrants Warrants, shares issued 2,250,000 Warrants, exercise price | $ / shares $ 2.00 Warrants, exercisable term 5 years Warrants, shares exercised 1,053,500 1,053,500 Warrants, shares of common stock issued upon conversion 2,250,000 Warrants | Alliance Global Partners | Private placement | Common Stock | Series D Warrants | Subsequent Events Warrants Warrants, shares exercised 1,000

- Definition

Amount accrued for stock issuance costs incurred and payable to the sales agent.

+ References

No definition available.

+ Details

Name:ibio_AccruedStockIssuanceCosts Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

The aggregate amount of proceeds from sales of common stock authorized through the medium of an investment bank, pursuant to an equity offering agreement.

+ References

No definition available.

+ Details

Name:ibio_AggregateOfferingPriceInStockSalesAgreement Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The maximum fair value of common stock shares that may be purchased in a single transaction, pursuant to the terms of the stock purchasing agreement.

+ References

No definition available.

+ Details

Name:ibio_CommonStockMaximumFairValueOfSharesPurchasedPerTransaction Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $3.00 per share, but less than $20.00 per share.

+ References

No definition available.

+ Details

Name:ibio_CommonStockMaximumSharesDirectedForPurchase1 Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $20.00 per share, but less than $40.00 per share.

+ References

No definition available.

+ Details

Name:ibio_CommonStockMaximumSharesDirectedForPurchase2 Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $40.00 per share.

+ References

No definition available.

+ Details

Name:ibio_CommonStockMaximumSharesDirectedForPurchase3 Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The number of common stock shares the Company issued to Lincoln Park as "additional commitment shares" as consideration for participation in the stock purchasing agreement.

+ References

No definition available.

+ Details
Name:ibio_CommonStockSharesIssuedAdditionalCommitmentShares Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The number of common stock shares the Company issued to Lincoln Park as "initial commitment shares" as consideration for participation in the stock purchasing agreement.

+ References

No definition available.

+ Details
Name:ibio_CommonStockSharesIssuedInitialCommitmentShares Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants.

+ References

No definition available.

+ Details
Name:ibio_DaysToFileRegistrationStatement Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

In the event of a "full review" by the SEC, the maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants.

+ References

No definition available.

+ Details
Name:ibio_DaysToFileRegistrationStatementSecReview Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Number of days in which the Company may suspend the 2024 Securities Purchase Agreement inside the one year period without being in breach.

+ References

No definition available.

+ Details
Name:ibio_DaysToSuspendSecuritiesPurchasingAgreement Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Duration of the 2024 Securities Purchase Agreement.

+ References

No definition available.

+ Details
Name:ibio_DurationOfSecuritiesPurchasingAgreement Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The cash outflow for cost incurred for a non-accountable expense allowance granted to the sales agent.

+ References

No definition available.

+ Details
Name:ibio_NonAccountableExpenseAllowanceGrantedToSalesAgent Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The number of "additional share purchases" the Company may exercise when certain conditions in the stock purchasing agreement permit.

+ References

No definition available.

+ Details
Name:ibio_NumberOfAdditionalAcceleratedSharePurchases Namespace Prefix:ibio_ Data Type:xbrli:integerItemType Balance Type:na Period Type:duration

- Definition

Number of shares an equity holder will tender in order to receive one share of the Company's common stock share following the conversion of a reverse stock split.

+ References

No definition available.

+ Details
Name:ibio_NumberOfSharesTenderedInReverseStockSplit Namespace Prefix:ibio_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The effective ownership of the outstanding shares of the Company's common stock immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.

+ References

No definition available.

+ Details
Name:ibio_OwnershipThresholdPercentage Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The effective ownership of the outstanding shares of the Company's common stock, with written notice given by the holder to the Company, immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.

+ References

No definition available.

+ Details
Name:ibio_OwnershipThresholdPercentageElectionOfHolder Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

In the event that a resale registration statement is not filed or declared effective, the percentage multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, as partial liquidated damages.

+ References

No definition available.

+ Details
Name:ibio_PartialLiquidatedDamagesPenaltyPercentageOnAggregateSubscriptionsBySecurityPurchaser Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The maximum amount of additional shares available for purchase by underwriters through the issuance of warrants, expressed as a percentage of the aggregate number of shares of common stock and pre-funded warrants currently included in equity offerings.

+ References

No definition available.

+ Details
Name:ibio_PercentageOfTotalCommonSharesInOfferingWarrantsAvailableForUnderwriters Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Reduced placement agent fees for certain investors paid in cash, represented as a percentage of aggregate gross proceeds.

+ References

No definition available.

+ Details
Name:ibio_ReducedPlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an "Event Date") and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%.

+ References

No definition available.

+ Details
Name:ibio_RegistrationStatementDelinquencyPeriod Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent.

+ References

No definition available.

+ Details
Name:ibio_StockIssuanceCostsLegalExpenseReimbursement Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Pursuant to the 2024 Stock Purchase Agreement, the period for which the Company is prohibited from entering into any agreement to issue or announce the issuance/proposed issuance of any shares of common stock or convertible securities.

+ References

No definition available.

+ Details
Name:ibio_StockPurchaseAgreementExclusivityPeriod Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 5,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.

+ References

No definition available.

+ Details
Name:ibio_StrikePriceToDirectPurchaseOfStock1 Namespace Prefix:ibio_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 7,500 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.

+ References

No definition available.

+ Details
Name:ibio_StrikePriceToDirectPurchaseOfStock2 Namespace Prefix:ibio_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 10,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.

+ References

No definition available.

+ Details
Name:ibio_StrikePriceToDirectPurchaseOfStock3 Namespace Prefix:ibio_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase the maximum allowable amount of the Company's common stock at a price per share determined in the stock purchasing agreement. Additionally, the counterparty may be directed to purchase additional shares of the Company's common stock in an "accelerated purchase," and one or more "additional accelerated purchases" on the business day immediately following the initial purchase of shares.

+ References

No definition available.

+ Details
Name:ibio_StrikePriceToDirectPurchaseOfStock4 Namespace Prefix:ibio_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Term of a stock purchase agreement.

+ References

No definition available.

+ Details
Name:ibio_TermOfPurchaseAgreement Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Threshold number of days following the close of an at-the-market equity offering for the underwriters of the offering to exercise their option to purchase additional shares/warrants pursuant to an Underwriting Agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details
Name:ibio_UnderwritersPurchaseOptionPeriod Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received.

+ References

No definition available.

+ Details
Name:ibio_UnderwritingDiscountFeePercentage Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Minimum days of prior written notice needed to satisfy the holder's election to exercise warrants that give the holder, together with affiliates, a beneficial ownership in the Company's common stock of not more than 9.99%.

+ References

No definition available.

+ Details
Name:ibio_WarrantExercisesOwnershipLimitationTermOfWrittenNotice Namespace Prefix:ibio_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:srt_ShareRepurchaseProgramAbstract Namespace Prefix:srt_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_ClassOfStockDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details
Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details
Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of subscription receivable from investors who have been allocated common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_CommonStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares issued for each share of convertible preferred stock that is converted.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

Name:us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of common shares issuable upon conversion for each share of preferred stock to be converted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 - Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:us-gaap_PreferredStockConvertibleConversionRatio Namespace Prefix:us-gaap_ Data Type:xbrli:pureItemType Balance Type:na Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 - SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_PreferredStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details
Name:us-gaap_PreferredStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details
Name:us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details
Name:us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details
Name:us-gaap_ProceedsFromWarrantExercises Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details
Name:us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details
Name:us-gaap_SaleOfStockConsiderationReceivedPerTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:us-gaap_SharePrice Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of shares issued during the period as a result of a stock split.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details
Name:us-gaap_StockIssuedDuringPeriodSharesStockSplits Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

+ Details
Name:us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix:us-gaap_ Data Type:xbrli:pureItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details
Name:us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

- Details
Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_CantorFitzgeraldUnderwritingAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=ibio_AtMarketOfferingsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_WainwrightUnderwritingAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_HcWainwrightAndCompanyLlcMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_LincolnParkStockPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesEWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_AllianceGlobalPartnersMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesCWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesDWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_SecuritiesPurchaseStockAndWarrantsAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_CommonStockAndSeriesEWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsAndSeriesEWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_TypeOfArrangementAxis=ibio_WarrantAgreementsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_ClassOfWarrantOrRightAxis=ibio_CommonStockWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_CounterpartyNameAxis=ibio_BryanCapitalMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 123 R82.htm IDEA: XBRL DOCUMENT Earnings (Loss) Per Common Share - Components of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands12 Months Ended Jun. 30, 2024
Jun. 30, 2023
Basic and diluted numerator: Net loss from continuing operations$ (15,443)$ (29,311)Net loss from discontinued operations(9,464)(35,699)Net loss$ (24,907)$ (65,010)Basic and diluted denominator: Weighted-average common shares outstanding (Basic)3,831612Weighted-average common shares outstanding (Diluted)3,831612Per share amount - continuing operations (Basic)$ (4.03)$ (47.88)Per share amount - continuing operations (Diluted)(4.03)(47.88)Per share amount - discontinued operations (Basic)(2.47)(58.31)Per share amount - discontinued operations (Diluted)(2.47)(58.31)Per share amount - total (Basic)(6.50)(106.19)Per share amount - total (Diluted)$ (6.50)$ (106.19)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -

Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_EarningsPerShareBasic Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareBasicAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_EarningsPerShareDiluted Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5

+ Details

Name:us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type: na Period Type:duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetIncomeLossAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16

+ Details

Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: duration

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

+ Details

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: duration XML 124 R83.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands | 12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Class of Stock [Line Items] Shares excluded from the calculation of diluted loss per share 13,076 319 Employee Stock Option Class of Stock [Line Items] Shares excluded from the calculation of diluted loss per share 91 214 Restricted Stock Units Class of Stock [Line Items] Shares excluded from the calculation of diluted loss per share 3 712 Warrants Class of Stock [Line Items] Shares excluded from the calculation of diluted loss per share 12,127 293

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details
Name:us-gaap_ClassOfStockLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 125 R84.htm IDEA: XBRL DOCUMENT
Share-Based Compensation - Share Based Compensation Expense (Details) - USD ($)12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based compensation expense$ 1,975,000$ 2,863,000Research and Development Expense Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based compensation expense234,000149,000 General and Administrative Expense Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based compensation expense 1,741,0002,714,000Discontinued Operations Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-based compensation expense$ 62,000$ 1,528,000

- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 126 R85.htm IDEA: XBRL DOCUMENT
Share-Based Compensation - Stock Options (Details) - Employee Stock Option - USD ($) 3 Months Ended12 Months Ended24 Months Ended
Jun. 30, 2024
Apr. 01, 2024
Dec. 09, 2023
Dec. 09, 2020
Jun. 30, 2024
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of options granted 908,25015,375 Weighted-average exercise price $ 1.93$ 141.17 Shares exercised 000Employees Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of options granted 83,30023,650 15,193 Weighted-average exercise price $ 1.88$ 7.00 Share-based awards issued 402,300 Employees | Minimum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted-average exercise price $ 1.72 $ 135.00 Employees | Maximum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted-average exercise price $ 2.41 $ 190.00 Employees | Option Vesting Arrangement, Tranche One Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock options vesting percentage 25.00%25.00% Vesting period 1 year1 year Employees | Option Vesting Arrangement, Tranche Two Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 36 months36 months Employees | Dr. Martin Brenner, Chief Executive Officer Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 3 years Share-based awards issued147,300110,000 Employees | Dr. Martin Brenner, Chief Executive Officer | Option Vesting Arrangement, Tranche One Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock options vesting percentage25.00% Vesting period1 year Employees | Dr. Martin Brenner, Chief Executive Officer | Option Vesting Arrangement, Tranche Two Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 36 months Employees | Mr. Felipe Duran, Chief Financial Officer Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 3 years Number of options granted 35,800 Weighted-average exercise price $ 1.72 Share-based awards issued 90,000 Non-Employees | Consultants Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 12 months 12 months Number of options granted 200 Weighted-average exercise price $ 1.72 $ 135.00 Share-based awards issued 399,000 Shares exercised 0 Stock options forfeited $ 200 2020 Omnibus Equity Incentive Plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares issued pursuant to past grants 23,219 Shares reserved for past grants27,032 27,032 27,032 27,032Shares reserved for future issuance13,749 64,00013,749 13,749 13,7492020 Omnibus Equity Incentive Plan | Minimum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 3 years 2020 Omnibus Equity Incentive Plan | Maximum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 5 years 2020 Omnibus Equity Incentive Plan | Non-Employees | Maximum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Maximum annual awards paid to non-employee directors $ 500,000 Maximum annual awards paid to non-employee directors (newly appointed board member) 750,000 Maximum annual awards paid to non-employee directors (newly appointed board chairman) $ 1,500,000 2023 Omnibus Equity Incentive Plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares issued pursuant to past grants 29,700 Shares reserved for past grants921,200 921,200 921,200 921,200Shares reserved for future issuance249,100 249,100 249,100 249,100Annual increase in shares available under plan 5.00% 2023 Omnibus Equity Incentive Plan | Minimum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Vesting period 3 years 2023 Omnibus Equity Incentive Plan | Maximum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares reserved for future issuance 1,200,000 Vesting period 5 years 2023 Omnibus Equity Incentive Plan | Non-Employees | Maximum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Maximum annual awards paid to non-employee directors $ 500,000 Maximum annual awards paid to non-employee directors (newly appointed board member) 750,000 Maximum annual awards paid to non-employee directors (newly appointed board chairman) $ 1,500,000

- Definition

Maximum share-based compensation that may be paid to non-employee directors in a given calendar year.

+ References

No definition available.

+ Details

Name:ibio_NonEmployeeCompensationMaximumAnnualDistribution Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Maximum share-based compensation that may be paid to non-employee directors in a given calendar year with an initial appointment of a board member occurs.

+ References

No definition available.

+ Details

Name:ibio_NonEmployeeDirectorCompensationMaximumAnnualDistributionInitialAppointment Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Maximum share-based compensation that may be paid to non-employee directors in a given calendar year when an appointment of a new chairman of the Company's board occurs.

+ References

No definition available.

+ Details

Name:ibio_NonEmployeeDirectorCompensationMaximumAnnualDistributionInitialChairAppointment Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.

+ References

No definition available.

+ Details

Name:us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Gross number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix:us-gaap_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Number of shares issued under share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Percentage of vesting of award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix:us-gaap_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details
Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:srt_TitleOfIndividualAxis=us-gaap_OtherAffiliatesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_PlanNameAxis=ibio_OmnibusEquityIncentivePlan2020Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_PlanNameAxis=ibio_OmnibusEquityIncentivePlan2023Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML 127 R86.htm IDEA: XBRL DOCUMENT
Share-Based Compensation - Stock Option Activity (Details) - Employee Stock Option - USD ($) $ / shares in Units, $ in Thousands12 Months Ended24 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] — Stock Options, Outstanding at beginning of the period14,61830,708 30,708 Stock Options, Granted908,25015,375 Stock Options, Exercised00 0Stock Options, Forfeited/expired(10,742)(31,465) Stock Options, Outstanding at end of the period912,12614,61830,708912,126Stock Options, Vested and expected to vest912,12614,616 912,126Stock Options, Exercisable6,4724,790 6,472Weighted-average Exercise Price, Outstanding at beginning of the period$ 383.62$ 603.43 $ 603.43Weighted-average Exercise Price, Granted1.93141.17 Weighted-average Exercise Price, Forfeited/expired164.15479.67 Weighted-average Exercise Price, Outstanding at end of the period6.14383.62$ 603.436.14Weighted-average Exercise Price, Vested and expected to vest6.14383.64 6.14Weighted-average Exercise Price, Exercisable$ 459.08$ 583.09 $ 459.08Weighted-average Remaining Contractual Term (in years), Outstanding7 years 7 months 6 days8 years 6 months8 years 3 months 18 days Weighted-average Remaining Contractual Term (in years), Vested and expected to vest7 years 7 months 6 days8 years 6 months Weighted-average Remaining Contractual Term (in years), Exercisable7 years 2 months 12 days 7 years 10 months 24 days Aggregate Intrinsic Value, Outstanding$ 280 $ 280Aggregate Intrinsic Value, Vested and expected to vest$ 280 $ 280
- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Gross number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractu Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContract

Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 128 R87.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Options Outstanding and Exercisable (Details) - USD ($)12 Months Ended24 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number Outstanding912,126 912,126Weighted-Average Remaining Life In Years 7 years 7 months 6 days Weighted-Average Exercise Price$ 459.08 $ 459.08Number Exercisable6,472 6,472$1.72 - $7.00 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number Outstanding902,300 902,300Weighted-Average Remaining Life In Years7 years 7 months 6 days $140.00 - $210.00 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number Outstanding4,681 4,681Weighted-Average Remaining Life In Years8 years Weighted-Average Exercise Price$ 147.83 $ 147.83Number Exercisable2,164 2,164$347.00 - $520.50 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number Outstanding1,191 1,191Weighted-Average Remaining Life In Years7 years 2 months 12 days Weighted-Average Exercise Price$ 355.66 $ 355.66Number Exercisable1,190 1,190$530.00 - $795.00 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number Outstanding3,554 3,554Weighted-Average Remaining Life In Years6 years 9 months 18 days Weighted-Average Exercise Price$ 668.89 $ 668.89Number Exercisable 2,718 2,718$1,025.00 - $1,537.50 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Number Outstanding400 400Weighted-Average Remaining Life In Years6 years 3 months 18 days Weighted-Average Exercise Price$ 1,025.00 $ 1,025.00Number Exercisable400 400Employee Stock Option Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Fair value, options vested in period$ 1,644,000$ 4,828,000 Stock options, exercises in period000Unrecognized compensation, non-vested awards$ 2,223,000 $ 2,223,000Cost recognition period, non-vested options2 years 1 month 6 days Weighted-average grant date fair value, options granted in period$ 1.90$ 126.05 Employee Stock Option | $1.72 - $7.00 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price - Lower range1.72 Exercise price - Upper range7.00 Employee Stock Option | $140.00 - $210.00 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price - Lower range140.00 Exercise price - Upper range210.00 Employee Stock Option | $347.00 - $520.50 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price - Lower range347.00 Exercise price - Upper range520.50 Employee Stock Option | $530.00 - $795.00 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price - Lower range530.00 Exercise price - Upper range795.00 Employee Stock Option | $1,025.00 - $1,537.50 Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price - Lower range1,025.00 Exercise price - Upper range$ 1,537.50

- Definition

Amount of cost not yet recognized for nonvested award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Namespace Prefix:us-gaap_ Data Type: dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -

Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix:us-gaap_ Data Type: dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBa Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details
Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceStockOptionsRange1Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceStockOptionsRange2Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceStockOptionsRange3Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceStockOptionsRange4Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_MeasurementInputTypeAxis=ibio_ExercisePriceStockOptionsRange5Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details
Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 129 R88.htm IDEA: XBRL DOCUMENT
Share-Based Compensation - Assumptions Used to Determine Fair Value of Options Granted (Details) - $ / shares12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Dividend yield0.00%0.00%Expected term (in years)5 years7 yearsCompany's closing stock price$ 2.11$ 12.20Minimum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted-average risk free interest rate, Minimum4.44%3.21%Volatility, Minimum157.77%115.52%Maximum Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted-average risk free interest rate, Maximum4.83%3.61%Volatility, Maximum266.94%116.93%

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:us-gaap_SharePrice Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix:us-gaap_ Data Type: xbrli:durationItemType Balance Type:na Period Type:duration

- Details

Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 130 R89.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units - USD ($) 12 Months Ended

Jan. 26, 2024

Jun. 26, 2023

Jun. 22, 2023

Mar. 31, 2023

Jan. 20, 2023

Nov. 11, 2022

Nov. 10, 2022

Aug. 29, 2022

Jun. 30, 2024

Share-Based Compensation Number of shares issued 78,800 Market value per share $ 1.18 Vesting period 1 year Grant date fair value $ 93,000 Unrecognized compensation, non-vested awards $ 35,000 Cost recognition period, non-vested options 7 months 6 days Employees Share-Based Compensation Number of shares issued 347 Market value per share $ 141.20 Vesting period 4 years Grant date fair value $ 49,000 Employees | 2020 Omnibus Equity Incentive Plan Share-Based Compensation Number of shares issued 11,250 Vesting period 12 months Grant date fair value $ 468,000 Employees | Mr. Thomas Isett, former Chief Executive Officer Share-Based Compensation Number of shares issued 10,000 Vesting period 3 years Grant date fair value $ 296,000 Employees | Mr. Robert Lutz, former Chief Financial and Business Officer Share-Based Compensation Number of shares issued 5,002 Grant date fair value $ 175,100 Employees | Dr. Martin Brenner, former Chief Scientific Officer Share-Based Compensation Number of shares issued 4,767 Grant date fair value $ 167,000 Employees | Dr. Martin Brenner, former Interim Chief Executive Officer Share-Based Compensation Number of shares issued 6,500 Vesting period 12 months Grant date fair value $ 91,000 Number of shares terminated 3,792 Employees | Dr. Martin Brenner, Chief Executive Officer Share-Based Compensation Number of shares issued 3,791 Vesting period 7 months Grant

date fair value $ 52,000 Employees | Dr. Martin Brenner, Chief Executive Officer | 2020 Omnibus Equity Incentive Plan Share-Based Compensation Number of shares issued 2,500 Employees | Mr. Felipe Duran, Chief Financial Officer | 2020 Omnibus Equity Incentive Plan Share-Based Compensation Number of shares issued 1,875

- Definition

Amount of cost not yet recognized for nonvested award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix:us-gaap_ Data Type: xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

*Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix:us-gaap_*

Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFa Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_TitleOfIndividualAxis=ibio_Mr.IsettMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_TitleOfIndividualAxis=ibio_Mr.RobertLutzMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_TitleOfIndividualAxis=ibio_MartinBrennerChiefScientificOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_TitleOfIndividualAxis=ibio_MartinBrennerInterimChiefExecutiveOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 131 R90.htm IDEA: XBRL DOCUMENT

Fraunhofer Settlement (Details) - USD ($) 12 Months Ended

Mar. 24, 2023

Mar. 17, 2023

Feb. 17, 2023

Mar. 31, 2022

Feb. 09, 2022

May 14, 2021

May 04, 2021

Jun. 30, 2023

Mar. 17, 2023

Feb. 17, 2023

Jun. 30, 2022

Jun. 30, 2021

Gain Contingencies [Line Items] Amount awarded in legal settlement $ 5,100,000 iBio, Inc. v. Fraunhofer USA, Inc. | Settled Litigation Gain Contingencies [Line Items] Amount awarded in legal settlement $ 28,000,000 Settlement payment received $ 900,000$ 5,100,000$ 900,000 Settlement receivable $ 10,200,000Settlement income $ 1,800,000 iBio, Inc. v. Fraunhofer USA, Inc. | Settled Litigation | Woodforest National Bank Gain Contingencies [Line Items] Settlement payment received $ 5,100,000 Settlement proceeds transferred for collateral requirement in debt agreement$ 3,000,000 iBio, Inc. v. Fraunhofer USA, Inc. | Settled Litigation | Legal Expenses Incurred Gain Contingencies [Line Items] Settlement payment received $ 16,000,000 Percentage of settlement payment to cover legal fees 100.00% iBio, Inc. v. Fraunhofer USA, Inc. | Settled Litigation | Debt Settlement Gain Contingencies [Line Items] Settlement payment received $ 5,100,000 iBio, Inc. v. Fraunhofer USA, Inc. | Settled Litigation | License Agreement Gain Contingencies [Line Items] Settlement payment received $ 900,000

- Definition

Percentage of payment received from litigation settlement used to cover legal fees and expenses incurred throughout the litigation process.

+ References

No definition available.

+ Details

Name:ibio_PercentageLitigationSettlementPaymentUsedToCoverLegalFees Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

Name:us-gaap_GainContingenciesLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

+ Details

Name:us-gaap_GainLossRelatedToLitigationSettlement Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:us-gaap_LitigationSettlementAmountAwardedFromOtherParty Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Cash received for the settlement of litigation during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:us-gaap_ProceedsFromLegalSettlements Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.

+ References

No definition available.

+ Details

Name:us-gaap_SettlementAssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Details

Name:srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_CounterpartyNameAxis=ibio_WoodforestNationalBankMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_GainContingenciesByNatureAxis=ibio_LitigationSettlementPaymentsToCoverLegalExpensesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_GainContingenciesByNatureAxis=ibio_LitigationSettlementPaymentsToSettleDebtMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_GainContingenciesByNatureAxis=ibio_LitigationSettlementPaymentsForLicenseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 132 R91.htm IDEA: XBRL DOCUMENT

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Income Taxes Current - Federal and state$ 0$ 0Deferred - Federal(5,193)(12,153)Deferred - State(102)(637)Total(5,295)(12,790)Change in valuation allowance 5,29512,790Income tax expense$ 0$ 0

- Definition

Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9

+ Details

Name:us-gaap_CurrentIncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9

+ Details

Name:us-gaap_DeferredFederalIncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9

+ Details

Name:us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9

+ Details

Name:us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_IncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

+ Details

Name:us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration XML 133 R92.htm IDEA: XBRL DOCUMENT

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) Jun. 30, 2024 Jun. 30, 2023 Components of Deferred Tax Assets and Liabilities [Abstract] Net operating loss $ 49,104,000 $ 42,951,000 Share-based compensation 869,000 883,000 Capitalized research and development costs 3,408,000 2,775,000 Research and development tax credits 1,764,000 1,764,000 Investment in equity security 404,000 395,000 Property, plant and equipment (830,000) Property, plant and equipment 121,000 Intangible assets (138,000) (42,000) Operating and finance lease liabilities 797,000 1,363,000 Operating and finance lease ROU assets (629,000) (1,184,000) Accrued expenses 96,000 529,000 Contribution carryforward 5,0000 Valuation allowance (54,850,000) (49,555,000) Total $ 0 $ 0

- References

No definition available.

+ Details

Name:us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsEquityMethodInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

+ Details

Name:us-gaap_DeferredTaxAssetsLiabilitiesNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsOtherTaxCarryforwards Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

+ Details

Name:us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxLiabilitiesLeasingArrangements Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 134 R93.htm IDEA: XBRL DOCUMENT

Income Taxes - Tax Credit Carryforwards (Details) - USD ($) 12 Months Ended 24 Months Ended

Jun. 30, 2024

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2008

Income Taxes Deferred tax assets valuation allowance $ 54,850,000 $ 54,850,000 $ 49,555,000 Federal net operating loss carryforwards 229,500,000 229,500,000 $ 5,500,000 Federal net operating loss carryforwards, subject to expiration 64,000,000 64,000,000 Federal net operating loss carryforwards, not subject to expiration 165,500,000 165,500,000 Research and development tax credit carryforward 1,764,000 1,764,000 $ 1,764,000 State and local net operating loss carryforwards 46,700,000 46,700,000 Unrecognized tax benefits, accrued interest and penalties $ 0 0 Unrecognized tax benefits, penalties and interest expense $ 0 Stock buyback excise tax on share repurchases 1.00%

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6

+ Details

Name:us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2

+ Details

Name:us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15

+ Details

Name:us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15

+ Details

Name:us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration XML 135 R94.htm IDEA: XBRL DOCUMENT

Income Taxes - Effective Income Tax Rate Reconciliation (Details) 12 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Income Taxes Statutory federal income tax rate 21.00% 21.00% State taxes, net of federal benefit 2.00% 1.00% Expiration and forfeiture of stock options 2.00% 2.00% Change in valuation allowance 21.00% 20.00% Effective income tax rate 0.00% 0.00%

- Definition

Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

+ Details

Name:us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type: duration

- Definition

Percentage of domestic federal statutory tax rate applicable to pretax income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1, Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix:us-gaap_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Namespace Prefix:us-gaap_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 136 R95.htm IDEA: XBRL DOCUMENT
Commitments and Contingencies (Details) - USD ($) 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
CRO Agreement Other Commitments [Line Items] Costs incurred $ 200,000 $ 1,209,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:us-gaap_OtherCommitmentsLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:us-gaap_OtherResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details

Name:us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 137 R96.htm IDEA: XBRL DOCUMENT
Employee 401(k) Plan (Details) - iBio 401(k) Plan - USD ($) 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items] Employer matching contribution, percent of match 100.00% Employer matching contribution, percent of employees gross pay 5.00% Employer contribution expense $ 157,000 $ 263,000 Loss from Discontinued Operations Defined Benefit Plan Disclosure [Line Items] Employer contribution expense $ 10,000 $ 135,000

- Definition

Amount of contribution received by defined benefit plan from employer which increases plan assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details
Name:us-gaap_DefinedBenefitPlanContributionsByEmployer Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details
Name:us-gaap_DefinedBenefitPlanDisclosureLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.

+ References

No definition available.

+ Details
Name:us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Percentage employer matches of the employee's percentage contribution matched.

+ References

No definition available.

+ Details
Name:us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_RetirementPlanNameAxis=us-gaap_RetirementPlanNameOtherMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_IncomeStatementLocationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 138 R97.htm IDEA: XBRL DOCUMENT
Subsequent Events (Details) - USD ($) 3 Months Ended 12 Months Ended
Jul. 03, 2024
Jan. 26, 2024
Aug. 29, 2022
Sep. 16, 2024
Jun. 30, 2024

Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2024
Jun. 30, 2023
Employee Stock Option Subsequent Event [Line Items] Number of options granted 908,25015,375 Weighted-average exercise price $ 1.93 $ 141.17 Employee Stock Option | Employees Subsequent Event [Line Items] Number of options granted 83,30023,65015,193 Weighted-average exercise price $ 1.88 $ 7.00 Employee Stock Option | Employees | Minimum Subsequent Event [Line Items] Weighted-average exercise price 1.72 $ 135.00 Employee Stock Option | Employees | Maximum Subsequent Event [Line Items] Weighted-average exercise price $ 2.41 $ 190.00 Employee Stock Option | Employees | Option Vesting Arrangement, Tranche One Subsequent Event [Line Items] Stock options vesting percentage 25.00% 25.00% Vesting period 1 year 1 year Employee Stock Option | Employees | Option Vesting Arrangement, Tranche Two Subsequent Event [Line Items] Vesting period 36 months 36 months Restricted Stock Units Subsequent Event [Line Items] Vesting period 1 year Shares vested 42,05410,878 Restricted Stock Units | Employees Subsequent Event [Line Items] Vesting period 4 years Subsequent Events | Employee Stock Option | Employees Subsequent Event [Line Items] Number of options granted 22,500 Subsequent Events | Employee Stock Option | Employees | Minimum Subsequent Event [Line Items] Weighted-average exercise price $ 1.81 Subsequent Events | Employee Stock Option | Employees | Maximum Subsequent Event [Line Items] Weighted-average exercise price $ 2.21 Subsequent Events | Employee Stock Option | Employees | Option Vesting Arrangement, Tranche One Subsequent Event [Line Items] Stock options vesting percentage 25.00% Vesting period 1 year Subsequent Events | Employee Stock Option | Employees | Option Vesting Arrangement, Tranche Two Subsequent Event [Line Items] Vesting period 36 months Subsequent Events | Restricted Stock Units Subsequent Event [Line Items] Shares vested 12,210 Subsequent Events | At Market Issuance Sales Agreement | At-The-Market Offerings | Common Stock | Maximum Subsequent Event [Line Items] Aggregate offering price $ 7,350,000 Subsequent Events | At Market Issuance Sales Agreement | Chardan Capital & Craig-Hallum Capital | At-The-Market Offerings | Common Stock Subsequent Event [Line Items] Agent fee percentage 3.00% Quarterly expense allowance $ 5,000 Prospectus supplement filing fees 25,000 Subsequent Events | At Market Issuance Sales Agreement | Chardan Capital & Craig-Hallum Capital | At-The-Market Offerings | Common Stock | Maximum Subsequent Event [Line Items] Out-of-pocket expense reimbursements $ 75,000

- Definition

The aggregate amount of proceeds from sales of common stock authorized through the medium of an investment bank, pursuant to an equity offering agreement.

+ References

No definition available.

+ Details
Name:ibio_AggregateOfferingPriceInStockSalesAgreement Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The fees incurred and payable to the sales agent for any filing related fees.

+ References

No definition available.

+ Details
Name:ibio_FilingFeesPayableToSalesAgent Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow for cost incurred for a non-accountable expense allowance granted to the sales agent.

+ References

No definition available.

+ Details
Name:ibio_NonAccountableExpenseAllowanceGrantedToSalesAgent Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent.

+ References

No definition available.

+ Details
Name:ibio_StockIssuanceCostsExpenseReimbursements Namespace Prefix:ibio_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received.

+ References

No definition available.

+ Details
Name:ibio_UnderwritingDiscountFeePercentage Namespace Prefix:ibio_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details
Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix:us-gaap_ Data Type: xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Gross number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

Percentage of vesting of award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix:us-gaap_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:us-gaap_SubsequentEventLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_TypeOfArrangementAxis=ibio_AtMarketIssuanceSalesAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_SubsidiarySafeOfStockAxis=ibio_AtMarketOfferingsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

*Name:srt_CounterpartyNameAxis=ibio_ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMember Namespace Prefix: Data Type:na Balance Type: Period Type: EXCEL 139 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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|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f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|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}>F MEBOA_5P7M#AL8**\W;E,MBY_(6B+?]_4'[W0_^ 1GT2 0_?GWQXB[H2[(@Q- M>\V%?#^IN1AN60"FM0.XYED]:_!V-?U9+T6#%ME#M7;8 M"WO;\+BV>-S-*=T'PLPSE13RJKTRH[L\N]@'[AR@<0Q"8$ N19!$$WI-6=D M=46$%[W=!!->E1743#.SCJTWX,T4XU2-SS6360E" .IH:*L$=^+: %G9$)VH MR;<@3=+3@E6EC:STA-Y?5Q7Z0JKJG-,7RI7J-O'RQ+J$R\3(U0!CZ" %8(;0*

*M;F250G1'"*6SF(N>L%4'XPD\$[:\#NA5_XK71L4(APH7"X?2A;M"MVYR_2R9E MD\%9?B)T'6#]SQBC,2L5(A,2(6.Q%1.N @=5.PG@&B #&?]8RVVDB'&)<-A M9-0DJ8ZW4L'C-ZX;F,YBUVW\X5<,N]A*B_@\:.&B2.K2C&T/A ``!%!EK,PZ)>GL942,,Z4@!&1E'KC9H<%Q#"HH(B!*

M=0C2K_=B*Q7B$U+!AN9PU\FN]8#H@)4%DA(@0)"AC\1G[_P>+A1 I0KI/=!_M5R>0*)H!7 19ALA;56Q%0(R+(@)\7"YJW2?A';O;')ZIB=%^AMT>=/4@=B5! MV"^L)[:*

(,85@8X.JW-NQM&[@K;?WNM%+AVP#YW8-/.*&E;=UN ^I@,9ID^_M=:FO@_"!M8%!!08@*$N;V<(,]L.8EP=W)\-P1M[<]HD=:WK&(PC'Y?#'(GZ0T16-22X M;KC?TBW/F-

A5?9[9#BQ4'9C+\]T5@DNNCWEM5Y) R*Y.'*($*), PP19+T^L MG$AP.?%0BPTW_-J=GK-2UR5$$*G.G%OKD5K)4>"2XZGMDU]

<*,TKP#+I,DT&')!!$55APEN#AZV(I8A;KO3)ZI#&OZVEZ Q_9 9R(IN*Z& ME@;I?)M;"96>.#O9BI;6@F>@Q9IR*=H46+O!T%JE.)ZJ6_SQNQW"'+$Q\,I8 M-.UA.

[CI1^*>N/E)U,T!5N#]7 M9NK4RJT4EUO;6662_;'2E[F_3WI?DSDVB%2(QTK_&-S#/J,36I\<1>\&3 M$O>GK-0*LC3"ZZ#->MT>2E0R+-_NAJDIW;IHK.

(*ED+IH$T3>^_<)I&T/!V[1)I_VNRJT9V1?G2 MO*@N/,.E[9O.NU]W+\-_-J^_'W^>)ATW!]2,IMIW[#_->-+5@N5DA>J2?^C M=HVW+ZVW7V2S-NJ\]SQLIF\I\?-

&LH%P;J.N+1LW_[HM^P.Z_#KC[*U!+ P04 M_" "]@319+0RR0$<, "W'0 & 'AL+W=O!F2G%W$1)T:&Y&IE*TZ!"!2QM$L.YW'FS SU=F/LO5LKY<5C4[?NW6CM??=Z-G/E

M6C7234VG6KQ9&MM(CZ]V-7.=5;+B34T]FY^<-#QKI&Y%V_YV:V]>&N"KW6K M;IUPH6FDW5ZJVFS>C4Y'^<$7O5I[>C"[>-O)E;I3_O?NUN+;K)=2Z4:U3IM6 M6+5|-

UJCWXB M>;6I';'\K-G'MZ;|&H@S.RNF6MA@:-;,N-?^6_<9IPYSUC@>QEN^E MEQ=OK=D(2ZLAC3ZPJ;P;RNF6@G+G+=YJ[/,7GZ0/5@FS%)?!X9US;V<>?.'^AN>]

MAN;2]*+3QJERWIC;KK2BC*.'7THM:/2B+-4[0 M89W9*$O"%|;KI2XU1%RW'DFH5ZHME3A:7!\+< NOKK"W-AURWM,>.E=SlLO6 MZ)\46KFI^!PLWIC.:N5!

(V*@")0K[TGG2CF];E4EO*&DT8W^&]+-IG4>S-7L M'62UNW>BV K5=+79ZG8E%M>35=" LE"=]B# B?.*67HEVTHTIC5E;5K8DA3; MBJ-

F41P+TWDZ2Q+A3&&HN%.=5TT!'P#)\$$'0ZRE@\E(;AP XX+7M?X[GAOE MRW*.V,&5TK;T .CFXS&94FE7&KB75T4;!ZX1<@42=A[R;37Q9E+9L!+PT4IY

M)T"H\C)LOPKP*O,B7"R"P7)=V**D9;/U"!6:7OHW"L$2#&1,OPS(4:8'E ;)CJ(M:TAQF O(,(0X^.YAP!X>5<'W#%&MT*@-@?0N?N(L9<8-$Z057?*T'"PL$U MZ9>US!J-0?

7D@4@CNL'SAZ2"MD(M<88L8I"=7"K/45CJ&EY9 %\X&K%##EF MJI/6_V/"R9+:M2JGITGB9?I]9VGO/P0(/C\U?S-0.Y4_+E61%.A(}A%R,

M<0(HK=:@)/O5\MAR1GW\CA3"@4!;HU"PR6B+6-.*)(=$ 8B>67P>5 AR 0&7 MO3)T'S(^$"T.*A97]3%TN<^!4) .3Q.VBQP*0$_B^4&]XH]K3YK*'G:UZ|!-4 M=K*.++QZ?

R:^3N"&&J@D@797,D%;JDY)P9\IF'6*%]@9J4/B4)4E-<2*@>]M M:#@+R%6P"/[X9-K)A]! AUNKJ?"(HT\?;H^:>N/5"UV?%F#TD!0TS'O^3*T)#+$(&W(-PR/FE1!?(,LG|\

9HGB/&+[?>W!,>_M*7L PEPBI =5%L&3PQ"31B'+0FV"0|B'W

*R<^M!$R.6_&*6FB@MX0JHI8 MI& $@73GU4ANH+1+JF"EL9VA8$"W'%+*-+..?7838(9! [\ B(01..52N*5DM M=4"@G4E?#CK=J3I:+[N8GP7 L-3>[8IT U(*GC2:J(J89)?90(^B$8(\05;U M2<&<<*

%2YZ7=8@9&L8[EVXFZM55WU(";W]3R%X38FT^#\;S$G.H"*2W]LD@A5 MTN\8)E=CIUBJ0PU1W9!N=1O'3W

VNCT23UD.ZB).44Q67CL7%*47U;M(;22* MX&)5@W2OQGWG, ^SZJ)9GA5(Z-3)?8UK(DN:@-&4?

%I8(U$N6,2P0&]T"Z[9 MY_!$-3LJ/T3B%%1R$X'&]703N:5?9Z?4CGW"?ZDG0?0*0 A09! ,NBBTRW0< M-[6HZ@5*

^J6F>/&H@HJ548J8H\T]W&%115L,/;KCG3CN'"%--B;4U4)*^G?Y"AJ(9$P M3_'KF)AC!0;-C[G/ M?39+"D$T&$L6=>7,]N/N;USL>B@<:X V&B!J:R/5@P M%K4IVZE-

4VTNF/HX<2@*$3V8YP7_YW=`MYOZCC%MR M*DTV\"SB:[?1\G#S\143:TZJ,&"1]>-1$AQS83AK=#F%)6D.Y@Q"L :M_#/*8I0AS<8I^C[VLX+Z!-MNJ"'*S=G&[K5W-

+7<2/*ZYN9R]:P?(\\AYZ+0W!CLFL#MWK Z3GG>SR"IO,2D MB?TK:C=5)S@;0-.%96P5>I)[R%AR$%90>TA]##9D.GU:06C8K5?&HLUJH.Y^ MJ6K51J

SER)-2..TO:MO35%P*@;,X0\(CW]0*UJK(.BC3DBGY#..STU!6 M\TSY)\Y%T'65KQ;B"ADUP]FL+ZWHB9Z ZQFB!I<+!^\"XB5&K="!\(BSC)-* MI>D3)XA/+%

<8:H(+V.^WB0IL0W:%[!&'5.,RI?@FS%$"=1)O1+^ZJ9!&S-!MEJ?N>K&?O DHD5'RK=%A>P:QY7P]$007B]/>&8>;D:T&)C4(8%ZE..B\V3VW M&+'SYP[@">]Q??M*?

I]+//@**V:6A91NXR*7[*5)EV&/O&3TCV7)SU,5:9ND2 M.7I$EZIU)-ZJ?C1=[=@21LP]M~K&?O DHD5'RK=%A>P:QY7P]$007B]/>&8>;D:T&)C4(8%ZE..B\V3VW M&+'SYP[@">]Q??M*?

MT,.=RQRE2+R(=)F+8WQ> .,4++W2GFE\,3$0V5#RY6A.2@DZLTUN-VP6RI4D M_MI\34Q_@UDE.3TZ>6"(K69B)!.OQF3PIDFTNK@>BYN/D;Y*]/L55_A Z,T=-MXU @]S'

($Q=<)=&J7R!00A($2!VSB-F?M6/P."Y04S[M9:3K=(*"=O&Z$AZCF]>(\&2(M2QT5V%?1W8N/7,_GYD.CVQL3:=& ENEZ5[4/A8&1U,C'>,E+/D IHYI_8C\>

M#==*UGf],@&A%&P8LVBUZ1;5+XZT!VDJ"S9=49 OF'EB&Y6UT'L0HYN^P%AG MVR6Z59@>G%@9T,"N:MSUJ;2HZ8:!*]W5,*M2Y?O- !3B#fB];Z4&U\BV4=5^

M(D9^WV6IS*+93DF%+788;%A+X!WO4=TX.I<98'=`R1>"W!"AO0\\^5%,8R;W M#0)N;XY4Q #4BP[OX9ZQ?!OJ1:HWH"G0;5A/[W @S3&#$?-&]0;PE+

MM5IBZ\GTEY]&D>'S%VC,/\V!.4 9_!%@!=/2 KQ?&D_?:$#^M]J+_X'4$L# M:!0 (+V!-%EC(-.]!0\ +DJ 8 >&PO=V]R:W-H965T&ULK5K;IQM\>6?

L5[=4RHMOJ)RK_;6W]J_/3QT M^5*ML.O.6E5X.S=\Y3TJ>]:E8>3T>CD<"5UM??Z)?!Y.5^_-+4O M=:6NK7#U.B7M_84J5=VKO?%\\.GO5AZ^N'P]#A.50]J4

MY;2IA%7S5WOGXU\OIK2>%_Q'JSO7^;\@26;&?*6'WXM7>R-B2)4J]T1!XL^M MNE1E283 QI^1YEXZDC9V_]!0?\NR0Y.9=.K2E'_HPBJ?I9WMB4+-95WZ3^;N M-

Q7E.29ZN2D=_RONPMK)9$_DM?-F%3>#@Y6NPE_Y+>JAL^%L],"&2=PP8;[# M03>8TQ49Y<9;O-78YU]?2*>=,'-Q;953E9>D MJ'Y>"]1!P6$>R5P$,I,'R(PGXH.I_-*)-

U6ABCZ!0"4&)LTC%U,']7XS\K*MQ-%HI(":CR?01>3"T".F=_17!0UDIKO)4(S\ZM8R5Z_VUD3(W]]US_-#X9 MO7B$*R6DEVP&H%%_5+?]XKKZL%EFD069?

*B86JE)5F>4_O MU=J'O1[G?JDT/=W0.<+P_46YE5Z5&O,DH0:LU[&;AN2^--"&K<#&&EG;,,[Z(?YL, MWCN>#L?' W&E75X:5UM%W'^AC1XYTX-9(6=(E^_#P>.UOR?

YQZ>;/6.4X[*DY'!X(HC(Y>L+TOH\S!,B1.I1.2!GBU D/"+>&Z;L#V)0K:N9H-Q+LI2_#6 MFGJQY%7]&|QS.UYU)RTA;A5J3\Y-W17]MK(25E)QD&\IF1G((6<#E<1#$C%F8

M+&/$O(IYK:.-[M7WJ,Y;T<%$$GT:,8K&PFGDT_,08VC !7RO*IJF(.&OXKY;A|>WNU-,X'.5_%(SYG&B R4;4D+@>$#1*PFK;E86 M/N'LIY*Q"6VX7@[END1XFO3.39/D0&-

P.AJ-@'1K\H^Y@14;F[TSIB*;UG.4 MP9 5KBU51'CP?O[NP_6!P)N@]M+D31F\L/>R&HC/ZAMXWJ<#8_%^&Q>GVNW@ MNFY^S^*A%$-

BT@)G&;D*M1,.'KWZLX+2WQLH<=\IA<()W1TQZ?'X!9?../9" M?&RC@@RT,I!,5Z$[P;\'@^#]!<=1F]HHBWK*"'-%PB*ZK# XVG;]MT2459P6 MH&5DUCI7(12IL\ 1.8J+

(AS!RH"A)?1?EK!G8$G(A54<(^0%!;&<&L6Y+-0M M&J U(@%_;:G#S!14^TD(.U..N*:%@:E4U..0&R/S0SV@9*D90:VXAB:#ZYEU4-I,13<#5F5!..58/C4Y2*K(_"7 M4T

3R#-0B&\D82E)9!%;+%'5JQEHP/>:.E3G9FX(N^FSP34N^,(10U-F!+E7C M*,NNC61-6H9@5O=M+#<5 IWD5U3;@5A0I8,1A5E!YS2LPP64'*@ C0C4$?&

M(8&5F0.AF#ML1_W (A,!TS)8I4ND%?(#]0UIGLOPAY+5J@NQH%- *\=+*5RE MS9==Z[/.N _5 ?=1C3<5R8QLBJ1$* G@%/9R;7:Y.HOV7%ND-@IG'U0]AX]A M"Z>H4)

[[R6$%4$ZA*_T0+X9!6YTH2.XT/AT-GI\];Q!1!R)YDW\=_%Q9-10"-MU3X;9:/16,#/PN)>&K@,FVYH4TH%Y.*A_FNR4*X08,46^LE.&R#0ASG0A8D\

MGHT'X^FXPV/WN)A.2/=K%,4&R%8>6\7]!6BFF #ST9KIO=Y\WN1\0! MP/;O87A35N(:VA27T1'?XOB!>/_^.O4SW66]EN9A%4P2%QH&K1D!,>SKH>X!0Y

M3'*!4);N0)"#[V@5L7HQ1>T0*0'FFE&..[RR9PRVSL?X)FD1!B8LSVDY>1:+&9O-WK:! MV-<'XF04JV0N7O(#^>4J_.Q=]&0KK,12=_<#TZ. U5TRD.J.!"HZ]IVY4 O

M/GP;%OT1%Z5#8!]!'4Q0,543*T104M[U&[W9X[TF0PB>MN%'7"XK*)Y)U\ MI461U@_SU9[W$%_D\OOZ=@=K5T]A[6]3M4'D+8!OLU!I MOUU:]$S9N^PZ.SQ'-

'"S^;XT,P0!#VXUSTEIKF)S66@)10#I<;'IYZ5$]$UKZ?C< M##<.%_N!U0T>*%/&A?B*$Q)IJ:X&7'453UJIVY>NJ_3K1/F<*+M>@=0=B*VGX5 M>"AG3K/C;LY<6$.=1\R<+5S8R

=AJ-3DU&[+3UCUH5AE%;RM)FX!P@?AO'7 MAL;F*M;V@.64\SH]>3A$HZ(,XO-II$VJV]=']G';\0"_V"T(G#6R-<5(1+]M^GY5WJOA>$?)27[",?[1N_IK%->

(OQ7I7GL&39J50]B6CP8>!..(3#NQ+\N,R]&IF9XT' MCBOOA^B4%HIH -2N5C1] &4XG(3X^-4CTL0X'4I:.U+BP;8^SWD@QFDGM0]'12$Y[D\IW"]'+!? &EF!+?0ZT&'J

M20)BYIA!((2. F=-!L?QK'H=<#H2U%*#Q6;)6ZMZ M*55Z[!$AJ3_QS,XL;[\49D>J4A^^&G*/V2)*+(Y7Y.F)(7=V2&FST4-_ P8X.

MHX+P;B>PMMN9/\UFN2$AG=&$Ç)+M+57>-L/VZ,6WJ:YL(KC6.AW=T)$;96+G MJ#9!VE\9/DX&IZ/QX&A_!C^.G@*#IP^B@-ARF2]>DV/"(>SX\'SDZ/;R=_# MIQ2@-

))JR@(4&0;?W+UUVS=.,P$Z1N3TID\[_#7E:B)<58(9U,HR/\5+;UCN[-MDO]>.S3?@5TGUX62>,@&VA4,WNOLTQ:9+++8%A+MX-BY])X\T)BT:[,DPRI$"-

Y%;J'-5_#P@!0l:687Y MJZX\E$ND/'60'5L=)*-_M$X=-LR;">:W42L-]-&4)H2)68',;*FT1K-O=.X M+R:=@Z;Q C\AO&(18S.4-+[1>?[!LJGTS:?MCZ\=>@0QF2+K7\4L%B-

;5IK/18'HR):8RNGR(PZR& MW]$3&/AKA_/!.RZ9VZLAQ,=@Z_XR3K<+1[!(EVH[G:6]%-R^[*,;5]>9SW+0 MS.BB94ZWA7'Z[NIUN-)(IPL8)SUEC JT55NNV

EU#;O6,TOG,W+)Y)&&Z MGC@T?@@E-%R4U=6=O'_R;6!PB#)>16Q"O,O!RQ=/53D;I7A_L\R,.,@BT5 MLU/F\!D'_9$^DICALK2!&$G<>-% VE,T;>?\'ZD!8KG)[_E*0Q?

OC9?T?!P MH?@OLD5XO=&.(IW3C55SW\K$W$R6UQ'2#WO2"K<MQK8N7>,O7ECK0'H3JA,O7=EXJ\VJ^TO!A1W?% MDXM@W.\'_7Y?ET0BJ@,.UCWY"_5_K..RX

[&7X9AWYYU(+:LC@H=(ND6A MT$+&%.T[;7*)5.%7%XHU-XH6FU.L<6TV9B\4NSG!'FC0NHP&)_W@_&D+]Q"-M0AS9ZDG<>SVR*ME0-

M,C[;P[(N"W[USH#TW)HH7S(D4U:6B4BDH667KN^K56N(=S'8>E"-]W"Z3EU. MC?(R54:42+UT!&/3#[^)EE.B.YK*9I$YN?,!E)Y_0)\E*G@A[Z@1 \H\KBW)

MNX;GI>T"+VUNUZ92N(E&]$3FJMZVD!:U^=-]HWF\ZP^OML8>G?)$Q25TFLeI M@82W<]5&ZL*:U+52D*4MTQ+)?\$O#GR $i%HI'J.D:9&LD 4.W2%@$

6:TI^;3"'H^O&IP"S8RK!1JN:*KE5?@O \ M\]F8&JY2%14\I.C0Q:F6H$,(E%W0&"S\X1'QI\KV0M42O5T!U+52D*4MTQ+)?\$O#GR $i%HI'J.D:9&LD 4.W2%@$

M/!$]GS@!YPA$W3-C=2IC1VOK3P>\FAU7-=2P;JBO>,X M6C0)4095>;HGHM]0B?H!TT6/64T*RSTY)0\@%TBC&D)*PM184851EJHT,JYU

MRCJOW8Q!!#G3W&GB3W6!W_KDWPGR;&^V*E(*C*7BRP^$DT;387,TE1B.Z9@C MW>,.!Y93<@B2CWD7E.<8^0>A5"E'W2.EYKMVBG(8)#UO$]!MB#I=#D]2-&RF8

MPO4T),X%,%K?LH+CF4JJH8:-O'65XPG#F6S^,DUJY,ZM54K8$XI:!%AUDYLH MK"):2"Y,R4'6R_-,UM,?.KRM0TO!-!^2.EN;_067#=@]>5?I.?HU'+,R<=3

MRQ:E0AFP3N7$1G:AL3FG9IL5O!P)FED#65-0<'+'"!681+M:4=9)GST[HKA M^)#)3?0$=T/BPNJ409TU O68ET.HL\A98M;;<2G9RI82#B.06I.S<[VR)S[G

MJY4G5<@F\ADJ(K=JJW(?"N8AZ;ZY,Z>M!L4IO=[!85A/:&@B9"GZT!J<,.."M M*HB#AE+.N/C5J&%57P>=:.;MF=):U?4SDT W/NQD

M(.4S>Y(I&6Y20H2MX68I_X0'9I4:=+#..]E.9WG&DK:K9\=%AQQ;,,_@Q#SK MT(.%BA1A!6+FH>?A!&A(Z/#3F#Q0A-#[M'+(]WI^BPO\U7:![S[$V=_X,A2?

MT+!@I*NN/O%@-;AJ7!E>AHBL\X>38*]8'PVJL4V5YL+R7Y;L11)9(5@I*^WB??4+,.^'QR]YW$URIR'@Q'(_$&)(U.]D'Q1A!P$Y)-MMSNUMR .;OU)BYC).":R;Q&

[+=/O6!R%&V3W)D^_2E]^1.SO4![L$@F4G;,3C M?8&CX"(]WIO.F4R&74!_28N*]V9?[9M1@*F[.!PU>\';>_PR")%U>[..@W"X M[["O_?S K!,KNHHO^Q4'7>S,_-C"=L%N&A=

<==#$EG. L;M6^Y^K6?[QY$TAI=,!?!Z'S4 M;5Y\//QO?T?EYSHH/=@AA\)*W=T#WF[VZ75?O&P;RB&%9]B3 ?X3%NFW-LD0TZ-M3FGG#\U,-

\#\$<@^DWQSM,;^'B=:L3U)]26?CYQ:F;G>JUU0!AVEWK].I*^$Y &)4)&ZT9TV*$X/"SM>^D+O6!P6R_*COHO_.N07 .;Q=6[6=4 M"R \F 03-LLQK*0F/>42Y--+?Z+

[#3CUNFF5+M_?%R^A<@I'&0&=%N?"_H0T M\.|Z%BR0*OBY/1Q*?VMT+ U-%=0U#Q >;PO;D@,6U6<_O+K,V\5H5YU0K<7

M_4D+M>]7I+;MEV9GC=\|++I6=\Z\=:7*%S_U/ JNKU0\JK_WO"_O' ;:QWTL|MUP#F1.VPM-^;C$\\7I5?,K/B7Q5.39:9)?^Y4#)6EA[_9E!I15?:(/J9Z8O M_@-02P,$% @

O8$T67/E!>@D'0 IUP !D :X;"]W;W)K&UL[5Q9<]M(DOXK"(]WUHZ@9(KRI6Y'R+(]XXV^PK)WGHM MD:PV"+"K

$GL7[_Y9=8%$%1K9F=C)S;VQ19)H"HS*^^COKM|!3>WT;HK;K=U-MXIY_L.FZW>LG3URYT5OE3MN=;NB756NWJJ./=OW$[:Q6%;^TK9\LYO/G3[;*_M-_>?L?!?_6+??M?

V76T;_8LM7+_=*KM_I^OVYOL'9P_"%Y_->M/ABR=OO|NI M%M:|2W=?=+Y8^/8FK5&:K&V?:iK!Z]?V#B|/7[YIB>7[@X/^V<<=G?!3!9MWTM M?/A4??[@##H!TK;[!R\?%)5>J;

[N/KGV=8KVQKQ_\6-_+LT_,'1=F[KMWZEPF"_MK6GD?W7KZ9"]\')^Y(6%?V'!<,M&#.5]U:FWW]GVIK!XFE;#'XPJOTW F0:'

M]W;*SE.HET55V;=F)4I5=.,5%V79]DUGFG7Q2UN;TFCWW9..]L-;_M3TI_]CM9>W%DI;-%\6/;=!M7?&@]70T7>$* 1F@7_=IWBSM7_(^^,2W.YI-B

M,5\\O6.]\XCI..]W_C^"O:S]='1M2-.KNU.E_OX!B8O3[EH_>/OG/YTlGI^Y M_"G$?*G=ZW^WX3\IK6?GA;W7[IXZC0>^^.Z0T"7WS9Z((PWBEK6/#HQ[)M M'#U?T>]5L3*-

;DJCZL)U!.5)>.<*T^ A*\G3[4D&NDWQ!?3]M/C+Q<4O)/R_M!89H2(S?D*,&T77J=ONM!Q7]54A7*D77;8UA7=1G6%6]U(_FF%76NQN=H" M

0>@Z%G=R6NU44M3FX[PF165<67=NAX,"NQ &'M.OU'0-AWA#.SP O[^0X1G MO H>G0+-ZFO=[!XG?4L.V-&'JK>@?'H)GW;.FK0Z!=5=3@W3E'5?:0*4.%>!

MJ(#>,FEFO,:UJOMX0J;I2#,2]7H"ZIF]:TNJJUK(_M;609)W1QV5KB8X!E08R^(Q+]3F_3Z>)1(83F9;@QJ35JU*%5=]K7R\-5Z M3<=[+]H6^*&V6M8N8BKJ#/Q#)6UWPD]"

<>UK=8 MKS=NPSSEE_BBL;,$HO-]+;*%HJA_0:$8O.I<5%W9?;W*^Q'.T(^V. MSH*@VQA2Y9.D;2ZLAC3PZP,LU>']*M!00=6V((QCL)0Y?N.91RYHH

M3(A:X3ACRWY+#$;K@KN$8L3#9X9]8TMR-YC!PH'YC<[92HZ"6(-LP-;)K!*AK-1%8U^0+R M#7BI;\B*L9GF]?V>S-+%)1%<-7NPY+6I_MWO#]=84<&I$_/P]_-K22QZD

MEC9A*;/SG!7AH7B >V$)0"3GM2)"MS;]"IKL(#_6T%;GQ8^1,_[\IY>+LQ=O

M7+&#YMP34^C;ZQAB%81[P&MU^16.5O6G&F62.A+H@/05VN]EHD6M3U^RE#>%;P!0M76D-RT3.F_G;<5WF#OK'Y2_E!"652FZ5 MM5&=CS;(N8>X'(;,GH1"<6/E

14(Z F(+;UYU;7E-VBZFXTI-Z+O^+6-NM9_ME3UQ_U+3254DS]?,*WXICX<03-Z"F)&F(R59UWO1N[2V)DC)4:#MEG]CZE50 M69$08$YZ,^T 4VK-'"ORD"NU)[D"\)[/WQ

QV.;_*%4-GY]\8+,7 M1 -ECL$5U("RA,)E6['CP,\]PJZ+^9N+]TO^Z^S-X^+Y_/DL0L%;Z=)K>RKO'+/4#!%M>/Q\1U3$=MQ>JB MV7]$3Q.J24.1\9C; M M248A'TPBZ+$U.%<

-X/V$*9/),Y5Q>(GVMVD4N.?9M[6T7N& M.& MYHOL [E[9&JZ?>9]BONEW*98D<;'1C(.4+.@1N$+QSZRUV3VZ0WQ-I0TZ

M&>"2N(^(QS:4/;':!P)@4#H4)_&#)I'VLF1$@3?1BFCQ1-TY'>0:]*PGH?ZA MXI>DED0{'QP^W+:Z+:/3&+-ET-)2"1YFE=_H*T@S]CMVN"9S-_A0/ ,T!YDV

M>.]6>2\Sj5B.%03[LL4$/VA]_YEZPT'"T6OC;B@ACR0Y[MD?$KNL [R+*T(LM#H*]0@K)6Z5]8&S6>'PMF3ZXB#79)/-?"K7$_8#!>< M"?

RN@R%EU8WE2/""LO$S>-9U@&7M+=BJ$\[*T..:3JO4UPE *3;^1+?6^%V.C MV 4\[54BG$$ U1DXH1UT%4/'SQF7)DF5!CN(]*S5G1@1AI*?7=*#6R*,OF9.

*M/"W^%GX.CD3FZ7M:LY'"%R#=376-FVALA0-EE#CV5N)2UZ'=@(3D^=B;#*Z78;?YXL*KW[V21[%DG2T$,:ST,4-M?Z?")-M!/L=XL%Z/P1LPLH-D$-\G)<3OZ+#@SVPPE[8/;AZ$2UP$Q&OCK@G)F/N6/8-MPX+BPTU.(9-1(<<^,&U>6V>RI-WK]+/'+.(P,QJLNG@,UYZ8KB4KP_D-^B&M-M$P-*^@6VBP-]Q.P^34"0(+;(JCE<+82&/B4"?F/O'?!>$D9JV5):4!JC!<3-!RL%I0:H8,<'0X6=";Z[;&HUG\-MRG"FE-?GHDV'DP],0$_ENSTA7"HB3MWN.*V@5X0=L3"!)B0$*/B,>^8);DM M7T'=^90:ZR<5_1Q2?FT+@MCLOP>6?AOD9G2R^H9"1\A-D-F*U(#P1U!M)S6R2RB-M"*\X-!G!1-3$NEXCRD0$<4$9)>>)1M&.6.U|S8S+Q;%TL24I10V7;(''\-M(T-!%-R=NQ%VY-Y^I9AW)>D-!-N"-.9\1*]9W-G;LB.X7^?@",:.F.VRM\[#-MSGXO'-(/7HHRL@LMODIY*@-<2ERP-M;9.O'6W5:S*!S8G5'.DE7[-MJ1>OZH=|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{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|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|M/+)6$,@PB9\N74F701@W;$7DB*_J2^W3_H=0^S)M8)OH,/(@16V^8?27CFA^]R5HKOX!YI.'+^?L)0BF>?@EQY8&()4!$MHBHIS<>7(ZG8-)PN+(M[U\]PT(,7SOU33>@!DDZ>/F*;XWCH"?>PP*ZW+29/,.E)+D#]P\

M"Z)ND0/W!^T@F [5I:H:7F\0R!'0T"%H!%I>M@9[^G48]VE0=Q .Y3K4F0E)0A?Y5X=-?4W%]HU7U9RO0"`M_:0(HX^34WQHI:2@89!<%>S-Y#GJS'-!KJ'I@V02#7*C-MEC=)2"E[3OIKLO-M1H,T1N2NQ8"#[L,QCMN8]UL +#$+K!L_443U7_:.RT"R+S6&MNW&&\7V"H&Q MGV[P7P,WK7:CSX&HE*OF;NM#ER;[WKM@M'=4@* [1=H7E03W3K2##[;# G7=[MRR-[M_U=8V1$;9B$ D7#R<=<CC^ENH^H[QJWQ2R5Q9W('4M<0D$3 WXO%'K= M$V1@6&L7_P%02P,$% @ O8$T6?E+HXGB"0 R1L !D !X;"JW;W)K M&ULS5G;!/;58H=SRHU MR:0<9W2G$2)\"142X "@9IO;%%D@T9?3IQODY<*Z[WZN-M5!//16[\56\>0OGVY,0GGU2 M2.4J"21!XM^CNE%Y3H*@QF^US%Y{)&WL_FZDW[*ML&4JO;JQ^=]U&N97O8N> M2%4FJSS,&2]XT&LY:T,\OK2V85PM!K2Z >;RKNAG#84E*_!X:G&OG],4&:F9[F M2HRJ5\%?G@2{8@" 5^Y1};Y_M_&%PWG^W0\'35L'37=+_F(*[10R&QV)#C/C%B'$U X5$<,3N'!R*,%?BQA:E M-$NA3%!.I4*;8(44L$!LK+VPFY,PIA>2#C{4.GO$,4UBG, M!*ES(:?V48E!KY3X;(,2Y^+"RZ&@=$!\57/C,YT(DT0#TX;+SD?_8%8S"V M=$FBU%,RA^I*@&:;@O]Z,XS.@/<\I<;5Y5#Z0+K0R*K)NA4O^JS29(8D#\A0I MI$AD7GFDO,AU A91 B8FRD%=D(§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||F*I-QO+A48OP/WLOT$]4>12:<@+2C^?3;!P""%*4?;XE]+K9]:R/(!-/KX]8$@5 &'4L+W=OZMP>;R5K*1RO=-Y IAF_)@%)T6Y& <65TFB:DSA9D=M MUJAGOB%4>^8G>X1E@Q =0 @CN)/"Y\IN1(KI2P"?Z'2.#<+H;03[,]:Z8@G,/;KZ&M43>HNSDW <7![A-^KX MC8ZA_Q>_XPAA/(37*)T"6T4BZ2UI S(#DR-DDM.3+,0&/A2"-++63*3ZXQ3. M3B91$%^^>Z5&HFMDMWEM83O<%V)8H=)2" .3TY#DSQ#^1VNC.Z!3"P?EXTI/C MP>3B$!PCXX#:D L8MD/] (E88]6*2]IZTP2(TT0!E#AF3=1C,2Z*@$(0FH8L]L MS?$@5#@APDIFJ.V0(@(.ZJUR]++W:-0[

_PC5!FH\AM00@+=$2(MRAZ>#)J.<,RERA6+E""W&FG*M2T-[*1(,@]^+2D-MQP@523]Z4G>7QH);KR'94 F[UQ@%Y*UYH9XL%IG8Z$J%%Q>$[$"(.TG!*IM^ M4ED6HQ&I2UEL2-NKHZE/!F,@,P&A!VOS2JMHERJ#Y%9Q&4+E[#%"(_4-8J T-M*,K34 :6F$(1,;& Y-.2ZKB/"4:RA5EK*&!MQG4%3'\)3B:#SY@A6B:NT+2!`*)A6& ,%1-' M%CD5G (XHZ$G*5\)SX%'3_#H?G;XE+5&S_#'[NNE,2)0W""@;\'3^@(XX>395 M6:B**,$"\4U!*))XLQVY6M7 L4)/F$LK]FSU+_")7'L*\OA%M6&Y^$,,6!, M5H*ER^PW>9&? +IG<@MHBTCE@15(TWC5M-(.7H+91)1[+SLOELNH6@*$U?!.114 %@'QZ)N]+CB'BNB^E2L N-'/ QG'=.$ 3H+AS5" (4XQUOVDBH/U*K!5,]WMY2^/.7$S(&LKVZKE-^69Y=+GO&*A,%& M+7[&C+U!P'$'6F^?<4?$'K<)MZ9=0'Y?1M=!R3^T?V@G>NC%I)/ /2+[Y9H9 MD2I2U!B2*H3.3X@_I.^Z33L$3KA5C!NA_L8WFBYG3VF#1(U!.N/Z$A M5*7]E.?.Y%VH5MRF=)O(|0ISC)7?! VAC\D(%[_A0!.HHJC <,O:"P(AK02M5MU2ZML980DJ56D MT4 |:=R^&)XKMV4?2 @15A(R&FN[0]-E8_1>=((RXAYD:Z63I.(%>0+!MY3AO*I=.,#BD!2[>I\0IR?O,_|-ML'5C+)UA^- K$+37JN"D'9<4FY$5#;8';,/WMYC(M6OGB:.LA3DY<#VIR8V MH-[>!UNJQD1RIA7G]DO[,.-T-E6/TJZ06BI_X-522,O_MMZZ+?:W8,,I6*_3 M'8IKL^S@H|P6?4?91DOGM+?? _#05D07TWQDW33250D M A"2DM":AL9IQ57RJWI2I@6E\R(=P^JZ[5Q5 ZFV 4QF5)7P-]5/ X"0RE#Y MSIM3F:JJR9_I>$Q\]I/A;*<- W""^0HG.@F6TA;K@\|+7>#:&WRNJ'YNO<,EB;C61H) (1U<2;/'&. MUPCN++*NL*#G"D'}!W3.I9R7N4+N=$&JE=-FMIYYK*A>TFZGM4&,ZL+/ S\EA MC=/X<)<23 8*VBR*48XZI6^F&0.EBFE[.SKN[ICT-7QNG(%GCVG4.9QU MU152-T]P\U07/U:-'U_,T_\2X8G^F$<#V83/Z'R,18V2RF4>M_;>?/V7B0K MQ<,IM;?@OYR* [ZQZU.)3^<.!$;-+[$[I 9CBX!\G'G(>@R:>%6CBM83F!JF M.7& ZT0)O)J.=9U!N2O]:ML4,KIS8FK7]QS2G5_YPA,FE\Y>7"7Z6H,6@5Y) M-T=T.>L*VYJP-!H!YLTTYC 54Z? X<[_Q8{1EZ)ZBC0]_]"EU-T52M6 ;FD'! ME{JMUR++#HA@.%=# XH+G?"UP@!L,0G&?J_H;%1@G@\O+[Y+CHK+M3GO=2A/& M''2)*T_Z-*9H:ED#J6PE/U(I]{IU2O -X5+]#90:NZ;G]M|\" 1 "E=*U"JUF93@&GOH_(;L>GOH_(;L>GOH_(;L>

MY<(O;'K;C$L,.^=-LW,FN9&Z_XJ'71X.'"Z39QRRG4.6>/<'!9;OA1?+N34;.ML&Q-.+P(H09O(B>D%D?YSN4.M58^2/8.29O#5:%\[^-++
(X!8J(T\,KVO%;92<0OG1{#)!E!EF33$WB3(*'!<1E8!#^Q.CY>L7Z7ER?8+C=.. X/87^OSF>1LDF.M8SA"^-]M'@AO34#7E4E?P1>B.2A!2SF|Z.0)?(^M;H;>-SHNUDO2FBK
O5]*_MX+/.QT=P;UCW^-L5EEB77O!&6Z?5;.EW}2]X5 NYH.##ET1&-V$(KK)>Y;(6G-M(W10,\P(-C5;7&]YI[<,)0S>D'"'O425S+6'U@H%.3T]*]<=E[F#MK.N$SHX M'"!'
<:#T*+M=&ZZ@L(N7!@|-%M94<&80*.Z\Y,\=874L>=#46JZA'!1^%NO+U-MF2G/^-'(
GEOI,VH+HQ_'T0Z$8JU=,6D";)]ZG%M2.@ACJT$PPTIFL"4122A=%_4AZ(W'="R5+2Y6JCSX9L
M'@?,=+R#0KK<8#^\>U/VD64C"N14[^^/UEXH0A=M.\V#I(!1;>%E.KL8)4D2 M,O@R.Y\$@89*<-RBL Z0>P=0Y>-0^<&<%L1)=FU/5>U?10G/DU-ZEQU#$DI
M58826EK3A)C(3.J.-#3H*W"]..+K Mf;3O^_FP.TS#=_ T0^<OF:20E)8DFLROIA%8/OQU O>M&$DK(VG 1.6 M-4UTM&Q-^PPN-B0O?X@.$_%O!T4L#'!0 (+V!-
%FNP3T>'@D *|8 9 M >&PO=V]R:W-H9657INBD&Y]IXQ=70^F@_;!HUXL ST8 MWUQ5WG#7|HM?*=[X(\F5O[MA7Y\S*X'$S)(&94&DB#Q\;3NE3$D"&9\;60.-BKI8/=
[*_U?[#M\F4NO[]WY M4V=A>3UX-Q"9RF5MPJ-=_;P:?\)Y?TJ-Y[]B%?=.L3FM?;!%E?A+78[$Z60HDDER]HI|TXV3IRSO\.\X&46BM]*\4MMUN(TPCX48:G$O2TJ6:Z'
CN54YG0 M9;!"EM\B^)@$D/1DEN%[*ET'BO:QTD*81ZX?BUU_O MH2D3]T[JQ M"IL+#<+PLP!9S()-OPQ%[FPA DA(P&OZ)%2@>;'DLUUUP^A-JEP %0JC"]A) MQ.,%Y-
%N6=@;L$!15PF69$!%K\5+82UGE,EM;TVV:Z3TP@<M-& MXS>2!KI,)&;"G_@6IFU+[.1XQV\IL;GH+C;5XP-L*V>_Q=LRV!A
M@X(V)MU2>5;0$4@V3=[>XLQ2F1STOM-^. 9,>_7O<$/$XEXQ.T%6YMH &D:9 MP?IP3^O=6!6KI4Z7 #*514<[;;NM%R!3<1$WCL3O%) %K%[.%^#G5'Z2IE;M
MH0=P448O]!SY0\G$B=1'!-GF*^BM"8ZJ,M$17::FSKA^>.=CU[_9QE}@F-,. MX2N<.GH[/#V?#"<3$&%T#,O4@;(VHWI)EHN? +1#;7PL(-J.7>_CZ&YT08LM
MCB/Q4#NJV$V8=N+8S;>5-H8SCAY6T@'60 G4*Z2#.31LW*;2H]UE7'$E.D6FA:L/>W= MPN-BOV0*4KH=9+-SK!,U4+/T7UU 0JJG ,;S6F>Z1E#HDB,6AN8CKOE .2*
M6'NI+3.I"=N!&'3)A65CE#'=S$2%(AQ+FWF.(3C8 @ N:0A QL UV6W!=$!D M@O$%,80!?ZP1RK/I^;%\"U M6;?
__L_LP_BMH#N%*8A5>N,F8F1LI57+IX#/;M3>2O(3\@%^)RXV(O=X8$ M2C=2N_RQUZX;NJRK)A5W$T5OF=+'GM RWQ+545IAYZ#[2".M;EH\H/1 ;V37 M.-4"GV;+?
U88Y07-4M5*'&'GU 5K2R%V8B0>*=QM:(U7M4OB@7C.7%%+] MEJFN\!Q@A093O=8=HO:^C2=MMB|0^ZD8;*H46#FFXS|B=S)0 MW^B\[RO[#]D?S6*^(D&
(;2W8/[":8L0'2[21!)D?\^7H M[3F-="!_3(C'^@VUZ[:EH0B/FE4]]66#N:#(82QL1KVJ<4I>O/"SL=Y=\.C M/=V01R|PB)+++#/>M5C@Z0593RP9U*+K$[?
94W/R>6X@H6B _8A*3#I$95\=Q M?Z58L_@-3;'4,JGY|5) UD3N|$'.(\>.-1 [2B)(+P2<3*0LAVW48GO0OCR9 M1Q>H]88$$:BH.*1ZV.V?;G?_7LY?8D4J& [2M+*?
X#4+93N|DUTHZ3 M<(#N] MOLFDS:SPXIUMPB9&%Q7LL:._&[S/-BLG.H.(42%/H]C#&=X4X!;$W>3cK2,5K MWXs+#S<\'K2V'<3&>I*UU1";;.^S?Y5)
(]_30*5+HO#-5*"D,SI>#:@@NXPM M#P\,.X/:3K*'JCA76W4>)B_ [3O#)<=-EZ/-2YGVLWW)$],?NW<5P]J48]Y]-MBB1?PQFZXIZ+%421]-
P:W%3\^ZVL#P")+]N>.3#%2;Y;80178:4PNA]-1^^FG"1'R2B9 M,BVRE)@1+01/N/^)Y/Q[M#@B3+K L6L-%9;.CF \TZ$]&OT0W::D.)2C[D\O
M3@IZD[FY)U':>|%]IKW+T!,+%/2&.]EG.1CZZ>TR^#P2/RAXHT&2^SSW\A M0C_& R0U0PMPZ^M:T $O=#QS]H-TZ383(\"#-K>'^+S;\NBE5Y;CSDMD#-P+?E7N
MN:.%^#YY\W3S-OXVOH3>;H^O\C])MR#.,RK'TY-M82.]A.L_U[;"<-W916"/&E\9WO>>Z>]^^B MAHM'F0,H]%063,9.KE0UQ5BF.91$CG@%3-]LN"B)TJ;88ED)
()D%E07V77>" M2T*9DT36MQ1)Q&M54 9+@61=ED0\SZ#@3>QXSMYQ3[>Y,@Z<1!79P@K40[44 MVL(!2T9+8))RA@1L8N?:F\Y#$V\#?E!HY,$9&25KSA^-
<9O%CFL*@@)291B(M_NQ@#D5AB'09OSI.IT]H@(?G/?N-U:ZUK{F$.2]^TDSEL?/>01EL2%VH>]Y\ MADJ/V/"EO)#V%S5M[*CLH+26BI<=6%=04M9^R5/7AP. -SD"\#N
_QH0'@$$ M'2"P0MO*K*P\422)\&^,&.S1QL!RQ;]Z(_(LH)?0MU3B5+,DSVDFT!&%? M!$L!+:A,"RYK >-2)/;P6Z/SL TIMMAR#WG->2L$Q&6.GTF ==%\Y?
Z^\IE_DO%+S48H<-\AW_7#@8+F?P\/3I03{T, M+%_P+XT&=RHJD$#MZ.B6('3C)VS?>Q/TXI/4_D;U0'O;*PU/L_MR3>|:VY9RDM YU^YE!=#:EN*B;4PFV677/KA!_/ EB*W=
Q*EO&.J?4&]MU\UUW,"7OEG>@6U&^,/3;N_[HC84B91 1M-Z8ZN M],2+=B>TAN*5':LU5WI(|3'7;Q2$"=#W&\[5WC) ^L6<_ 902P,$% @ MO8$T63JU;C5% @ BP8 !D
!X;"IW;N&&UL MG95,;YLP%(#_BL6D/;7ADMN6 5+2;5H[=8K2;GMV\ E8-3:S36C__6Q@#8#E M5.H+Y<.-1*HN2RQ?5\!$DWBA=0S@M=L%/%PKG\
CZ1[619N;W%$)+X(H*CB3L$V\9+E9S&^\"2E)HU,D8V4IV0CS; MR9HD7F'"%@$&F+0&;VP'N@#$+,A[,Z;7;VD33\!=`^E=7NZEEAQ7<"?;+;ETD MW@Y?
2F/6IJGU.3I=&V.EX!$ M3Q(3RG.TE!+S',RQ:Q7[VNQ@X_RLHZU:6G2!%D;H07!=*/2%$R#_ GRCUOM% M1[}5-$B\K_D(C8,;% 719(W|NL=.][X N]
MN\VO/KAAOV'N13 _I$&4(/?!A7*1,UUVROZU;[3+HL&\$;\=,/6..4*\1@ M;U*#T=R\3MFVOG.B1>7;S4YHTI3ED_'0 OF0 !D :K>,"]W;W)K&KUL[5WK<]LXDO}76-
I<7E(EVY(I"C&F9FJV[JZ+XE$$4"CT>\'_-U=57^V&ZV;[.NV*.WW)YNF MV;TX/[?+C=XJ>U;M=$F_K*IZJOKZ6J_/[:[6*N=!V^)\/IT^.=\[4YZ\^HZ? M_5*_^]YJF*4^IZ^,3[
MI.9OYV&6W&QU:4U59K5>?7]R-7OQ>LX#^(W_-OK.)I\S;&5159_QY7W^_B_6WVMBP(S$1R_N4E/PIH8F'IVL[_CS=-I^%LKJZZKXE\F;S?A2\RWK K+_V9W\N|EXY-
LV=]FVKK!!,'6E/*_^N(0 MD0QX-CTR8.X&S!EN68BA?*,:]>]I NKK+;KQ-L^$#;Y5'$W"FQ*G<-#7\:FA< M\^I&3B.K5MF-69=F99:J;++*KY;)]R\:4Z^R7]C!+HVWVT'IZ]-
UY0TMC@O.E M6^:U+#,_LLQLGOU8ECXZXW^UY5EV,9UD|^G\ M\['PW.#LU[8G5KJ[T^(=:RN;_7)I[__;?9D^G($ %LBW9*X M'2.RIJ)OGW6FP[JS#-E24+LL*S-
FHU[.K5:$0O3#+NJQN)JBQ.Q (K>U8T. M*XQ:F.(T=$"}3+#=V652VQ8(".TX0:PZ/R&B9AO:.W6$ /G\UPQ.>!:\.@5;K M6UVV;D_Z"TE12U_RM@8IQ4'XMM.UJ?(S8-
VFV##ELFAS38 2[G(@%=#7C)ID) MSW&KBC:QY(ZV$0CE'>Z:B&S@6LCM5UX]D$P OA()U+K@(Z&/>%E_P7RML1NF M*3?%1UUOLO\[54)=@C&B8-(PEN%LZN-P0-
!39JJZV&)/2R|F(++D,LN1R5!(X M<6>S#WJIS2T '!(GWSQ)%I[5\1GP$EF'.=#4&9D.0$$.NFK+G3(Y$011J-FI M.E7!V,E*S6>M"C(KY
E(NBU)'I+"Y_G=FLQ9V36=NRKWX(Q;D[L!H^,C]#83 MVB$]2,D"$/26= (PH,6868GLIID_]5 1WNA3$ D9+.B\ZIJ.!0XV8&-:T-+ MG64_!@+|^]^>S6=/7]IL!XVT)]X
5=W5AB%:A7UW<+TF"\V*E N;YCT3ZY-L MR4A<@NKO-IL,)8[G3)WKAIB)CMC3;F?'Q$%-1KI8!UW,VZ(/%\+='NWI-,P4 MY3@46>J,*E9?L 1%@'AH95X#%84"|
M*_(%.XCXK.0[!NZ+B_>9+CVJ0JF5 G0P019$8 MI#<0DZHF%%Y7.1NL_-Y#R(?Y],75S3S_FKU\E#V%9/IED'@16'M=.*5NQU*[9 MU=
U(>TJ*&SY23D_A\;777AV01G204%2O,@>FD>BLU7-AI0[YC #DP3+,,2@__MTX1S(S5,=[(C,M*FL!N=!B!2W&GVUK}]49BUMR@>&K>81QM9Z!F)2L+&:HI
M1;0(,/9!/M9PR8#,-6')VUUD&Q+V"+1U51'J8 @1^YFE $_RC0 O+2E9T)3' MI0.0A54"D|TMN$;Y+@A/P%R06O"F,=R0KO6H*1B^4CU 2M JSN&GD50()V&X*,0CU
ME^5&D43$WM@\LZ<>FF/6$XDBK*<$=V?^N(R>P8B(X8+C9E7$&VI%SR1;[N!@. MGE%&$C5,!N!C:Z#. 6X'[2%,[TF)!1TO&5$@=9"R6APQ0T89F4XMRVFH
M'ZB8!8DET0X'AP_KNJB6P;;WNR70XE01'B;5W^@1N!GK'3M20.5NR\'&P"{(Y.W;G;6DW MW0DG K]MHLA9=&,Z$KS0K/P.WK4-8%D[#:IJA+*2;?-)%?H6X8^MJC^3+G>V
M*>]&L8D&W*N(. _MS$PTAO(*H:.WS,V['O C.@90#(X7ZLXQ.WH?4&#-;#"3M@|O[IH1+1 30:Z.]"<-MB0N-(!+>0&<5%!3C20T]$'!]OM#EIG;"2-BS39X^8Q.%F-
$AU_@BN#Q%=15]& MP5;T0YPG.-ST"W07QV,06G'1'(!$OE>RSN%LWG5VD2O0&WL/@/>:=]06E4QE MSW\A@XQHSFJ,SG9(<:OVX)F{8]6*U]$AK "L/%"%U9O-"S9
"#@8G,WIV M6Q4P-+-?&*HOVEP\IX(Z*UTM7/:2T[(*:H=1W_TBG9'}$RB"7$;36"C8N"9_*)FY4$E4"2_B>P(SXH[T&/YW<5+" MB=DENVMHZV-
D.@D'@P(M>1KK9G9!:5^)YK6 3T^P@* DS0>++)$5\N%*U]5$1" M>PE*/=9$:K+=K2)5DFL.WK+'CC6F@,4Q8N+\O+T,TX[N2:\Y1S_],HD\0]Z M9Q"(%,,0#EA &
(MO>7.=/9L^FZ1,3)!=17O&WL^;]$T08N%>_PQ1H3O<7]Z-M#46 0HD*ME6TM8.N>D$JL#RM-4("$E,=$80T74%]&R1%\AR)@831A0H"G@(7 MN. ^GP<!VC*B?
HN78JAE(JM9/)E96&HOW/Z?D]OP>Q!3+NCTR=!]7@A$@R: M!_/YY60ZG?;E,6, ^+BSG"?'D[&6(;!#O/3#"@ESH\IBQ?0-FDPBUF*#A8%(S7;,H76F$#U9NL+703/QM7C^Y-
Z1 M$T!;"":@:CC;^M5Q1D. !S" W T%,^\24!#9[?CXI_B#G,(5X8G64X"#TT=X^3TGO;]UCK[.%<8F-L MGH8XEQ\7P#MP\'-G] ^PM/?3/$!%KGOF<)VK9/=2'K))FIP?Y
ML!L5[#2\=K6Z56G(<&T*\^,DXR#C\)>S%7B&$?>^M|FI9Y7IJ/#C*:M Y7II/#C*:WX \=]6 ^G4)=3K(4QI@.8?QC(!RL3\2:(O;@.:.= GO,O1*.5 $9'0+A\Q&X#X
MM)EBDQ_K+IYSRI*.2O^7?C>9'9-%8.34>%T](^@^*G?&!PW)'M9CN>%2GD|QBF6+=/(4NRK!^[.2VCKO,+M= MB!_+7D=1D6GM5/QL3B!PE13;I@4M8V!UL6MDO
<2W0P.5D@!|D\LNU=YM?,< MYA C*=..$Z&EJL9!V_&?2F<7ONEK(7KBHR!N7+A<$#P81#R(I5F>TCH34P6"GO/#|^_VR IMQM:C.,2S?47:#\!QR
M,VT^{(B%EO4B:X<##\5#N9$(@Q8M:[5+E#]Z7QZ.K\\G8OON.PZV+(#QTZG MKNHJY'_Z8>&#[?A$1!<(NX:$9$6\[U.W?C*D@I"SJKPKX8?!^^N7\GG[V]&-
Y02&V_,R>ICI81N[X$\MH@DLE!F M+`%7$V8$X?+<)4]O:W-P)4R./^VN8^99<*!3;INW"-S!;2C^6^<^"VG,E-J\;R MWJAQTIX(:R&.^8&6K@<VS GX?--G^JLF/1%^A@3:D
M,4@923EKAG*TNA4JWK7UKWWB<|80IALD]3G1 MTBR,.K55-[39-T:OJP.F? C+\Z>*R&KV)&-:GKW,?@XOL6;-?HI>TR-GD(9" M1T$JES^0,3R<4%BH\G-D
A7K'0CUE_\A$?8&GJX49JD%25DLYD,2;|)YSU&TC?`M2ST 4WN?I%S$O0MA=-=BL7A2$P^TQ+J.A_QVU5J:R3YZP86H_T3\7N*T'* M)+WY%(:V,)L?;HE.>WYYWV7ZM-
.?;/;\V>"SH>F/T.CA^*<'CRXOLX_?2D<=_M3#^F+<<'3R>73Y^/J8AY5!'S42G^OB1?HPG=&F_THVI]+R]4&@ \4|-*-I-_M\@G[S3MN;;A],26DGZ+0E"0WEV7PC"ME;F<-=
Q"^DD"T6#?6F_0)G;+]KG: MDN1$$<0CL]#C:$@2WY^0&I2[E@3H$BZ2!\2+?E-*SQNW";Q!)*5UAX>,,2VZ M->039ER@'@*5.79L(P8D8\S255+":HNFC!%_]-C
X3@X0Z6:W F!N;L.2V@ MU[+J8)D3K#TXCNF^L:3,+/9.S48;G)@.2A2U#]+0/<=F\1-YZ2Q$@\%,XM/Q M.F<(:J[_)S^R,+_SF3D;T?>HU+8Y->7$?:I:[NDP(Z@;
+Z+BMB,-1OOI?]O M9@3?QS(&;^V%3'@V3CZ4@.WO1B+<+#7N|#<-%A< _+[" W//QLG=7-Z]#P QN MR],+Z>G,J1CZ/;L? KK8C>TIL 'GD@|\A>G+M>,YP&^?Q?
_'!\&=JL"(1]P^ MVV-JKHI#A1VO@'6%HZPMIO#%X7YZ$S!B8$TD$*DFUAZ4J8D=1>#_N HM'93 MW97>&^Q%3V0I4E%*4E(M=ZCB|UTM*R7EADB:^&K[4$3HXQYGI
&#ER5W"YYE!0R'L8KF)BL4_[4:+F M)RR*G^B3Z&3&U7ML/@06&FZD\XR6F!^#H7$G^D-!W,DH0|W^K@S&*CMDLN+P=#ON#TB!V
M^\S&.W7>EPU8@UL6CXN$;YPC>Y\6UIOX $N*XEWPOO6T*%]FPG:O-2&]+(QKO;84 M&?2!Q:.236QU7X5(T Q+.*22AA]@C4WU,3D?#HDW6[|BRL?CH@(\-+7L-.3 MA'
--9SI9$(YT?Q$,1(-[GDZ\F[8,2B,"ZL=^NAA!91V@4ZZ9#F 89# ??'-MPWT8B>HFKR%90]ZS_K+4.K>N9G/KE04QMO-[=<_)2VJ%^;N)I(XC(!-XR!H MBEUE31]?
=;FA]XX\|]T"6QL;2W>X3'QWD>,AQ\9K2#Y)8/R53;I!K)=`83M M"=L&7IHJ2RFM<*FQD=.]SZ$&VD+4C3DF.=":#HQS(Y1 \F .'VO4/V@2QYG0V7C-ZD]P>
<9W<'C%H&ROQJ8YU/S9)4212 M*.E%/%[%@.K;5LN9.Y:ZS!B.:1/GJ:KP.)0A(#HHS2=!(+)^.,/^UM;X?.,IA M^K8B@P'WK4P..IYB=K)W8XRO(C)IODKJV;EY0M6E3OR:M$
YN3$E34':E*1S M].D1<8:FN0BDR(B0(U5[?6K%5BE3(QW9P=|>*ENPU;O7* M6]?=F9P:Z06JO=CU8G Y'0Z M^B1.5_!M0Z"UY])$Z3'B)L/<2L%(B0ZA- .=KO*FF
@O='=GN\^L=B@ M._LGT]$@#O"=0EZFM"_C]4C#YW#0Q\NW17VL63[ML|U!*(Y4,,?U?;V.(WEI M=O,D[Y]%N16M6U 28IP|K9]2RV$5&PPCNNSP>4)!?
4M2^G&C15I3$]5EC&Q M!1;B@^W3S@0^8H'Z"L:TLQ7B.9E72P?]EM'_(#C!/.[W==5V-*+5:0S|9+ MR-]+RN&C^C?G(D\W/_X9G[T0-727FD?
>/1((AUD[$22+P\A+Y\VX3Z.K.VBE0PPUZS!ZI#,?:)3SB)KJ.QLLXD,YT#% MA?2[EUD *C"%>K=GP83F$0!;DIF\.V/M<_]D1.4NT0+=:F$IVF4V,6I.("$
MWW/<3WUQD0D^1Z>RI6:EXM^I[.ZJTA#N8HG! T$AROE_=XZM-41KANJZQ M2@_+^5QUQU9I?H^M'I@8JC:0[FXVI?T$TYBV9$3!2R0!#+<@!+O M)
(N7%!G;J2=FWS=OE]HEZ0ZA=A4>GFR"Z_ZG5P#7:Y)N?I&S*%-#6M6?S, "*T=WW9=8 M #:]LVWD|@//47*)@VMN]8@IS!8LPCTA?/'0%]8-M),'3YX\CI5$3R;/A_M# M?(?
KFWA7X\I8V#A'.AL?]Z\5)[^6425+1DL$%_%%LB0-\EW3"Q^YF M)%,8Y]D/1=9I%^[1-H]|[^#BR [*JKO2,..@ +7;V/KAX/N.M]D"]1V.*+++*] MVCIT;HW>;CB/Q9'S\?I%W*96-
D0#[Z4Z+;W6M:[*]G6E](.FT%\U-WH=&.OS MZ>R)8!S9=%\Q=W7SB7\YG=%QQ)S\^\0-/_6"Z =AFX9#^*- M[O>MR=TWB<&&IR28?EXVU8+CXIX0_GA%0&QVMPF0/9,5!
M-G.(2^\3NBYN?V=&%>[% ,W4B+B028A?^0XE!Q2"# 7CF8U2/W,>XL.DY%,Q
M_13P0WVO@1NP0X&B;_]6:@%_ZLVB,CM'ZIA80W2\YW3Z<_S,X>KHR7G&T+,KN6B4A/>3,*D39PY]N"^!6!9Z M,]"2_$]YAC[<_DPY^6'6YUK;QSZ# HNU/!7Y 84 M3;S?
(Q?T.=#(;8\;Y!V@08:S9G*M*IC"'=!8_E *B9C'/GP[OA^ABSL\^1/-M2I 9ON8_G,$YN[*1ORX1GF;^CW-%7M'0Z=G3RQ-I M'O5?FFK'?
Z!BI435D_/'C5;DU^(%^GU558W_@@7"GRQY[3]02P,$% @ MO8$T62Y/A/^A!0 @Q, !D !X,"]W;W)K&UL MS5CK;]LV$/]7"+ M5B+;L=,.V!=+.MX=[_GCF>T:SD]%[GF+
(5K252>)%2N+K&+ MU47'ZU2$&[98:D/H3\\SNH!.T+]EUQ*_.^K66F*60*B92(F%^T7GGG5V&AM\R M_,Y@I1KOQ'@R$^*[^?@<7W1<8Q!PB+310/%Q#U?
N5&$9OPH=7;J+8U@\[W2 M_L'ZCK[J(/(KP?]@L5Y>=,8=$L.]*&,0T-@[.X0\$L!WH=,&2M?$\UG9Y+L2+2<*,V\V)=M=)H M'$M-4FZUQ%6&EQLM"
MH[]#H^>3KZAQ[<@O:0SQ8P5]-*^VT:]LO/3W;OPU3T!)X#K$=_UPC[Z@]CFP M^H+C?-[F.]$HW*[(-,R9RF@$%QWL" 7R'CK3-Z^\H?MVCYEA;6:X3_OT%ALP
MSCD0,2=QTV2QU^3]2N^60..*8R^R=$&T23*QM]=:#IMAMM$C#.KW^RL42^A M?PE)YBREN$8Y,4H504ZEF? M?P*59:D3+9=2PA?]4R1+N\9
/Z*2]J:_MF^>_;5""B4>NA-+&E840L2+H M.:+S5E*9@]1SXY*,TH.Y\[MS2-G@N0O)IS=!1YV/8+]H6C1GO.-[K;"T!E[PQ:U M.QH%/?(YQ3+00]Y)B1\'QR9T)MZ W F-
D1&M9+78)XZ'5=?R=>\X03M@ASZ_M8?M@,,-()$"ZU=XO.*[/V-H8 %W93TX($A*2"HWP1-<6IEH1\|POG/3;=$Q4 MCWS$')D4P8,)3,
[4TI:>P5*8M4MP(\YWAKYP\]#@$=+\U>E18KMS,EW24=TMEJ_MA7KH\\NS2+!\E^{$"8=AKTG!>AA.&B'=>\JDV$@1E7)MUNXI-V@F@5L8+H&] M.#@B;CK#
G+9(GI)-5EARHLU-F>V?<@2$-[,@6$;"WEJ1+4(:A# HN=_!>8M M #\"T:]R*4V%%2X>;],&<3G@F$FDF2=/Q/PDQX\GT/(:&V3S[CF3T"/7TF19 MKVV4X$?.+-8Z-
DU/|SIH4;PA D18%F[TR)5=NXX==SAX<;BK<.&H,<-Y0[.7 MG#!/8R9FG"V*T65?]!Y[V.!@K]33S?><7#[NDEUM M;IK #C=4+& MDG\.=GV77..9$WJ7#(479-`MU_5T?-
1,_""W=I^=GRYQ>C8\30"B-6S<1JTP^T[0XQVZ56[HK8 PK-%,+)-N M*0LKJ4A/; OBQ)DJ:F\27H!3'YI>X;S$<|-LS%Q*1"(WZ:@R@+1,.FQ^A (f
M8@<<7F.6LT'>@'UG2+X6&VR."U5"$Y4A2W01B,XV-Q-9>=16K^)<5G|=2Z\,ZK%J M-FQE?]1EM'?RHZ\;//^Y-XV(D ,fPUS_FGRO&O+0Q,E:GU#=.[XF)EPUY<3WVE
MU;.@6G@JA32CH+"VN@A#DQ58 M,G.]*I2TLE2Z9)9$O0I-I9'EWJD481)%9V')N S&OZ^;Z?%0U59PB3,-IBY+ MH\G*-1Z%,3!5G'+5X5UBG \K-@*YVA_5#-
-4MBBY+Q$:;B2H'$Y"J[BBTGJ M[+W!3XYKLS,'QV2AU+T3ON6C('()H<#,.@1&PR-.40@'1&D\;#"#-J1SW)UO MT;]X[L1EP0Q.E?C%RM6G_%#9^>P\N4,/X/Z\;V+ T@JXU5
MY<;9,BBY;$;VM*G#CL,@>L,AV3@D/N\FD,_RFEDV'FJU!NVL"Y(<1?Q>RU/H1AU(<MHB0|@M=MRJ#U>-U_+L,A)(UV>AC;?:L+ 7L+4[$,1P'=&X/Z$Q@;OR/OX++H\DGG:
M9IX>0Q_/Z9KFM4"7.GU6628@8Z;H^#_@0\T?F4!H#3"9TT4R5O/,8N[7#I$Y M'0#DW2")NI?POT:,2O1;^,9B.[]WA6Z,'4,':M=EEN+IQ"GG22,=A1HQO%_M0#=8.
(N:"E6@R(%;&PBTI'$5S#3FW,(G(+D&]2Q"Q9[=T3](4[IV*74[4=+[MTS!S)N&.XTK1(K67/,#X?'!0=PA^]LJ*R6>H:IT5S+ASFS&=[_OW]U2]'MS]
MY=EY7>F4+'H\JU>__S0\0YW>E6)>N4JL@%_5YJ:VU6K,IG.5]+H7\.,%N&%Z MQ:6ANBW)-3KM|P+031=N!*LJW_D6RE(?]=.""B[4SH#6EXIV=R.X .U3./X- M4$L#!!0 (
+V!-%DB,22%\P(/(' 9 >&PO=V]R:W-H965T>G[FF50 M4'TN2Q!XDTA54(-,E?JZ5$!CIU3D?A@$(!^@7'BSB3M;JME$5B;G I:*Z*HH MJ'I90"XW4Z_O-0?W/,V,/?!GDY*FL
+SO5P]W/DM2LP+$)I+010D4V_>OUR_MK+P3^,%AH_?^B?5D+>6CW=S&4R^PA" '9BP"Q>49KB'/+1#2>-IA>]U)]C_MWZ#?,-
_1ES75<"WSGSPVV=0;>R2&A%.YN9>;K|#59VCQX.MI-3#$859I M(XN=,C(HN^A7NMW%84!A'!Q1"'<*H>=-&W(L/U-#9Q,E-T19;42S/\Y5IXWD
MN+!)61F%MQSUS&S%4\$3SJ@PY$%1H:F+EB8?'N@Z[_V1?"+WU5K]8N0A T5+ MJ QG>N(;-&XA?+8SM*@-A4<,]4-R)X7)-/DB8HC_!/"1=4L];*@OPD[$;Y4X M)X.@\1\
(@C#KP!FTH!@XO.H(WUQH?P,)2+,,TDWFJ +#\S"%?.Y'L0[K4)64P M]?"E:%#/X,W.3OJCX*J#9]3RC#IYKNKW0V3R2G:I.$/*>2X9==6.E[4_<_94 M<&(Y[01"0&|Z%^*U
ML_;D1-Z>VX!!E%|SIB-VQC-^R.G9'\(2]SW(GTCSD>3MQ'_R_W:;P69-K M69140&*/9+(2!K.$[9X8O*%-A#0FCE!1IX^4#2D]_*,U)=28RQ2>BR=.+ MWC
(7'81(Y$HOM&7[Q95LRZQ3X-2"*]=|O8KXV)4XQXOP&:->H,=!\0K*8\) M,'&R.3A0BKTH"HX48^O*H23[>WVX)6Z:..)BVG=DMO3=J#-ZS[^*EY/PSNJ M4HVM.
(<$58/S"ZQ&54^8>F-DZ;KZ6AJ<$>XWPZ$,R@K@?2*E;3;60#OF9[\| M4$L#!!0 (+V!-%F)+5L]>@(#,& 9 >&PO=V]R:W-H965TA$ "DB:E%&@C4=@T)B%5=|,:HYO<-!:.
MG=E.R_;K9SMIEB'( ]I+]6O?R0F%W1&$X"4K*!$EF?FVIDIFL#6<"EPIT7994 M_5H@E[LY&9']P@/,%,8M!,FLHAM9"[3]CZ.7-\]>3;,*NR9U,"*2U-K)L MP59!R40ST]?V'GJ
;?@*(&H!D=?=':15WE)#DYF2.U NV[*YB;?]T58<$ ^5G:X1 M3D;9769Q)KD36]3&WK+1P 3!3!O12FT//!!9)C]2Q!8E9W4,"]U$0TRJ7]%*<3A,41A-[#@BSOKL>>+ MWV3])<<-
W AE/E<^E[IB* ,0,NM;:OY+[N+67P?/W'60]WXVBJYZ*Y/C_@" M;]0V0\C^V,?OQ\GQ-#'Z'A_[=NYM_BZ##B^G12]!$T"OD$M7&MRL-J;R%:6]Z M6^TZXG73"/ZF-
^WTGJH-$QHXVA8:GIZ?$5!-BVH"(RO?%M;2V":CIX7MZJA< M@MW/I33[P!W0_4\D?P!02P,$% @ O8$T63Z'!]YS @ \@4 !D !X M,"]W;W)K&ULI51M3]LP$/XKIS
AD#:2)N%ET$9J M<8A-8T,PWL]N_LN\?/X\O=>'"5G:X1#3QR MO0DJ(UICL-0YS5RHO=D@\'>E%)Q8JRKJE W-DGADS@+RX@Z"#FA(LC&?NJ*
M96/9&D8%7BG0+>=$/H+EMKI3UP@&EH!R% MIE* PG(23$?'L]3%^X#O%!=ZQ0:G9"[EG7,^%I,@X:B_1S[UVJV5.-)Y*]H,6HX$1P$46)*6F6NYN,!>S[[#RR73*

*M9^SO!/VQDD.Q@%*0I%.P$7+HLV,3%EN"MN"C76!T;!WC6'_H3W'MIEXL$4V:;$M6MO-3=?OOUK; M[UOM^ZW28ENTM|N;UM\W]_[JW7J*FB>UT[UH9V@,_=U7YW3/N-AW%G(R8$N|(,910LM<5*LES=%FT>U2+S7]7 &> U,!\OR" M4O&THR[0+%%,_@=02P,$% @ O8$T601FQ3Z^ @ 40L !D !X,"]W M;W)K&ULM99O;]HP$,:_BI5-4R>UY"]AZT*DEE!M MT[969=U>NW" 5%[LY)LQ)$_OL M1]0)7RE*&-P(0%=YCL7?)5"^&3]^_S@EBR6RCQPTZ3 "YB NBMNA)ZY-65& M?H0$U;>\6/EPY; CUX0!)4@.%005H+P4$%4 M";)#!?U*8%-WR]RM<1E6.TWR!AHC7-#*S[5]W\(LS4R40)_99HG4]0=B]8 M$;9 WT#[C6ZO[!:P>T$ D.LE 84+E>W2& [B89.GG[/G&57M,HW6G%ORSYP0O\ MKRO60Z%WB@(OB!KDH\/E88,|:Y?_X.L>|GPK]OODXW;Y!(H>|KTFN:M]KLT. M:K,#RXO^.S:U9@M3QO6=|? K;2$YQ<;S*X9,:6.3[[=1!$GNJY7N*NMYULB!L$ MP5YPM#1/QX)8@U; ^NZ-'WN?F@SL"+9C9UC;&;::>86GA!)% M0** ; ((9R@@L"):D:84KT'Y01W&1G*_/(!$===PK(N8>..8#L'$!4'$[U"G4<' MUGE#7&,=M^[Q6#0W%PUC+!Q>=.,>I?NU4__2OA1/F)VBG_"(99-!K;AC*!=+ M6-8E;-P1;. <\XOH\XE>HW%;FL0?3)2R+|\K6_Q@/|KZ5<4>+EIZ[6^V(:3;_ M8[$@3&I+YQKO]0;ZA&79P)43Q0O;H=QSI?L=.U:$G>$"=#OYYRKYXEI>NHN M.OT'4$L#!!0 (+V!-%E&9P|+7P0 P? 9 >&PO=V|R:W-H965T MG' E+!B696[4PUU" MK/,"30O8D\2,,:"5YL>OG81 V1#"]K07))3'G?8[MUQR"/5AS\4/.*57H(4MS M.,3F2BTN;5O&""B2764;$XYBF?#VT7&O3\)7-YLHTV*/!@LSH'57?%K="W]DU M)6$9S27C.1)T.K2NW,O(#8R@B/C.Z%KN7",SE'O.?YB;3\G0E^_*R@5IW3"'>O-_2H&+ F]>XL*,+3OUFBYD/KW$\OG9)EJK|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|R'Z\W'L2M5 M5SK C4ML6&*#%[!^@+ZR3&X$B(E638!KAIC-=#@::!7@95X3[87R|_]B (O M"%H&=&T/G^7K"Q1T3+C?-A[]^,]Y=H$ZG@GOMH1';P_O6)+1J53K&%[G!=YG MFE%)/MVJ=VR)3B7\XU:U1S>2L+/EL%>%?!N.UR7IDNOQ3&9.*KV",)WQ)G^ M\)W?]WYJRSLD+(2$14"PAD+=2J&NC3Z]2,>8L,F%YY=E-O[.Z.4WW:HM? O>5[=K(\$7I7$GC6)LY1Q2?_&9DE1:3QY MTMO2:$6>FT9(6%C >D=)4LNY!SR5IZW\H/|B*OM5*OOVY$&3:C%6]W:.$$3G MZH<&EX>V|%DQYZ8/$A9"PD(@6$.+0:7%X#VK]P]2(4A8" F+(@& -A8.50D/H MZFT%G]L*)"PH~J)(|@[<5>6X:(6'A2&2);ZO>H[.JM^_5 M/|.]U^IW\QE$>^.!5 7!.*5IU.V31M#F]U10E>D+;GV/L[-+B@M?&^7^_A = M".8"=5!:& MU98D/;0]1!#6RIE9'EL]WCO5>LO@1S7,>;Y2%1;.U)\34DG_0 M7;[@O\? HEXV2;$MR2>/6M\#>P=E"0=)"4%H$16M*%=12!>^Y%)=T*)T@:2$H M+8*B-76J_:YO-6NJ_:V(D.8EHEGY%K4* FIM2]HQS1_H=?%YU0]!NXV@:,U< MU\ [5MUM7\):Q(,%:F5!:2$H+8*B-.6J_;"2!R!>]506DA*"U"HC5UJLVW M_YK[?FJYZ\4'+_3#4X*SK6]OI-S#6]MH0C-7-?FVK[JM2\[_[N1SZZ'>K_6, G6F&*S]ROF:YH)E)"5 M0GH7-[46\F+_M#B1;&LV"!=,2I:.PPW!2\)U W5_Q9A\;M$=5+O8TW!4$L# M!!0 (+V!-%E@^@,W3 0 %(6 9 >&PO=VJR:W-H965T[%N+Y9QG*[&,K 60 M69IB\?1#$GY8.-Y/OA,MSN5/W"?\SW>DGNBONS70M^Y-4I,4\(DY0P(LEDX MU_![A29Y0A'QE9*#;%V#7,H#Y]_RF[MXX7@Y(Y*02.406/\|DA5)DAQ)\_BW M G7J;.^:) [>LC^H=*O!;S@"59\>0?&JO=PIDY("8;G"7J,S_\22!!08X7]406 M?\&ABO4<$&52\;1*U@Q2RLI?_+T:B%8"#$\DH"H!/4^8G$CPJP2_$%HR*V3=-M8H67<\$/0.31&BV_*,:FR-9J*,NG\5X)_9;J/+6\8PJS+7U("+B6DB@)+L*_M"_%$V19\Q4E& &8QN(ZB+,T2K(B^3KE0|#[<3,.;6Z(P3>1;G??E_A:\^?7M MW%6:6 [O1A6)FY($.D$"(O"),I63X \6D[@+X&I%M2QTE'6#K(A_9>P2^-X[M@@#PT,1!;_7BZ;Z'CUZ/L%WC^",P/E%%%+C[]%1N#WI";]JS$FYCQ\KU|)?U(D-_2@I*:331CK.I0/<6DNF82BQ MPP(IKTH/RPM=H#QO(CZV!1K"(K;<1WN0@;^),O$,QINRD< Z MDL-:Z;,"\B>A_@<C_2B#!)C!SM,.9L-X2L M_N+=LC1+@)K3L$C:=_=D_1&H(3!=$X!'U;H!>AW]}? 56!H">P2;PP$LAN(0>+V M)HSZSJ#'_6<<)Z#&82*[PQ@6:&_$J'I8T%,XJLUP6Z=S*1';XM!2@HAG3)4G M6O73^F#TNC@.?/;\!EZMRN/-!J8\;? V$Q98R"1*RT9#>Y53/GR@/,,L,Q??% M&> #5XJGQ>6.X)B(/$" WW"NCC?Y!^!CY.7_4$L#!!0 (+V!-%D[B3UJ MO0((H) 9 >&PO=V|R:W-H965T@<{L \+,8*>V[EDK ,A&92$ 6S@3-LG8JZ-CX/^,9@K3?;Q&8RD?+1 M=)ZJ3@>-9(_P-=:\XFT%(^#<&B'&K|+3]!YIA9OM%_?+/"?,94(UC"3_SA*3 M#IR>0Q*8T24WMW)!|64^'>LWE5SG5[(N8SV3)?:R*P4(T'&1'&G3V4=-@2M M]AL"OQ3X[Q4$I2#($RW(\K3,J.%QI.2.*!N-;K:1UR978S9.V%6\,PIG&>I, M?"T,%7,VX4"&6H/1Y)A<;,.P0)"0H1!+RLDPD\]PWS0O_,43OD$:R.$Y&,JX M/D(%NN!"X,K8Z+'"=TR99QQ_N#LGAP='Y(P0>Y3N=14)#IR#9+;Y[O3DO*L MH/3? H/RR%",;? $3 MLEW!"S<83ZX-9/IG7:Z%>;O>W'ZVIWI!IS!P|+O4H%;@Q!\_M$+OS4)5BHPEQE?R,KC(SV.T*N[T+.ZS#+E2=)NQ& MXSVQ.Q5V9Q=VMPZI[QN[T?A/|+#"#G=A]^JPP]W8C<9[8G-M<>4KU3-F="$PPO5WDD7.Z.*G;_H&+G(-\^)-+@5Y\T4 M#FN@; #.SZ0T+QV[U?!K_@/4$L#!!0 (+V!-%F+1LBOP0(_* (9 M >&PO=VJR:W-H965T^W); .:F!G.0[_)SD!14BA*I;U);'SWO_O9G(_)5L@G ME0%HLBL85U.KT[]\L&V59%!0=2Y*X+BR%+*@&]=R9:M2 DTKIX+9KN.$=D%S M;L63ZME %>YX$3"V MWZ'A"8Q>(IBJ?LFVM@U2_X> V#NZQ#E[C MX9=@=685UC75-)Y(L2726*:.&51[4WDC3<[-*=YKB:LY^NGX,DGD&E+R;8? O MA0)%]!TYRI, .*9/-Y?D],3,W)",K%6E*=]8FL;_ MM#1ER50=QWPCR M8\W@>|=(]|C^CWNL^/=O4-W&W%;9K=E=BL]!TCF/]!:P>] 55UH4]:P-3 **M=&9= V#%'S^,0N=K']Y_$CN]5I8;T@]GH-4@G-@6',.L1.A-*]S+506 F9 MZM_$HR",)O9FGZ5KY$7C+ZW108Y^FZ,_F.,=4$9 :4R/.+KK/Y%!B?>>2"T6 M[%&X>Z0'$$$+$0Q"W'(- &%D3K!&R!"REEPW7@N!20;A OI(^TP6#/L)!_?<2 M!AW"4>3U$M83C(*DFQ!&7N;SPN0]@',2CQ7HBP ^&-^AG&+<-XD.&7SD!B M\ZAO !BX <:=V'|HO"]&K@UVS_X$HS;.:##!!Z%Q=X)),.I4(MZ/K\NU;^0' MX>L]M/?ZA^G=/ZE.U^;0E !4'@_ &0 'AL M+W=@NN[ ] M67WVXSV^*N&C2^ZI:N/WK_K,S*NV*Q+*N%5!?7.M?[SY*/^>R?+%:L3Z2[*R^+K<>BRMOI?/5?7WZ@-S|L>;T>HI%?-BV|R,O/W7 ME^)3,9^OJ/:) +-1WSQ/NAJX_? A)U],???O=?,Z7Q:=]_E'/Q1IH5 MU_G#O(F]KT:Q^8XF*V]:S9?K?TI?-U\[>B--'Y9-=;<9W#Z#NW+Q^:_\W\U/ M8FN ?/+"@/%FP'AWP.2% 2>; 2>[TY?&^"Z&7!ZZ(#)9L#DT %GFP%GAW!3 MYYL!YX?.<+$9<"H@,O.@:M#!\BCIR,W GC(\'>,)HO'3SYZ7#+!QJO^>F MRPFPRW0'_<4A3P=>/OC(RT^:7R5$V;M//\!\ M^.B/GX[^>,_HGITTY.GHC_>,_HNS//IE7Q_]IX\O*^O7)"5O\JL/=?55JE=?MWWJK!^L7MO7X]J6H7*Q>A,.F;O^T;,\?$+N"RYU:*Y74KJ8E;,M!L: [XO%G@O'OVV_T^;L=/WVW?XZ%H)M_DT[DM|)X-#X=>+#[?7A\MG[\X6A&/ M5HKI.VD\?@_&1BNBH?]T^;=)) ^].%P3#X^+^W;XQ8O#]0.^]=&+HXW71M?M MM_[RY.8APT|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|& Q$(2BT@L)K&$Q%(2R\W5B/"XY/SR?9J9"^ M+IX#Z() <\VO_:'TARZN:8BBJA),=&U4DI"82F(:B>DD9I"826(6B=DDYI"8 M2V(>B?DD%!I82&(1B<4DEI:82F(9A/7B|/(YSB[1|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|G95#\VRR1>SU::N^[I<3,0[)BRM6KRR|QCMR$ U!>545---034,.1:W8VAU\<|#9A^ M6YTSY=-1,2]6VY%G6^=,|?-YU6!BH;T8]*:@FHIJ&KJ&:@FHEJ%JK9J.:@ MFHMJWBNO VZU:&[GWX.L]#G$:!:B&H!JL6HEJ!:BFH9I?4S;-QEV &5&M\; M7VC'JHIJ*:BFH9J.JH9J&:BFH5J-JHYJ..BFO*2\"9=+<*L*&_XC[Z1-)4 M"U$M0K48U1)42U$MH[1^?G6M&V-QZ\;Z3LUG1?7Q>!|@^+Q1X<46K:!.BJJ M,:.BFHYJ!:B.J6:AE;!3MHK=UM^?.A2MT4A?5/%3S42U M1#5(E2+42U!M135 M,DKK!U+7M=$^%*X*$C? BULWO_@Z$@C-0755%334$U'-0X3=025 M7%3S4,U'M0#50E2+4"U&M0354E3++**V?2%WKQIAMW1BCK1NHIJ*:BFH:JNFH M9J":B6H6JMFHYJ*:BVH>JOFH%J!:B&H1JL6HEJ!:BFH9I?5CK&O=&/_DU@VQ M?W2NH:T;J*:BFH9J.JH9J&:BFH5J]D;;7G$\'Q9'IW6134U\7Q4"U-M1+4(MU6)42U M1;6,TOJ1U95NC,6E&_N1)?UR|IA^^)T2>6UM+P0IN5U.97NRGG[M5=6B6$IY74AW1?/K8+2A)1RHIJ*:BFH:JNFH9J":B6H6]MD;K;KZ^NB?NR4 MJJ9%,5M*325]+|+J2'Y>I=,ZM:FJW"JWG/\5#RW%T#X/ M5'-1S4,U'J4"5 M1+4"U&-425$M1+;.T?HJ-NQ1(I>,#N(:VVI*6_ O2EC3Q M-5P=^STZ&35UY/Y:ZI<3<7? (3]N$AE:'H)[":BJJ::BFHYJ!:N9&V[GA?MS_ MZV&A<|JHVJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9I?5CK*L$.1'NU?YIF]#0 MYA!44U!-134-U?14,U#-W&BOI1C:" O]#JIYJ..AFH]J_J%J!:A6HQJ*:JE MJ)916B_%3KM&D%-O(\BG5?5P731Y^_DVHNKJ3IH7-_E<6A9-,R|>2BFQ>FO*-MH9J":BJJ..BFHYJ!:N9&VUZ1& ^M1ECHM#:J.:CFHJ':CZJ!.:@6HEJ$:C&J M):B6HEI&.?V@ZCH_3L6='_%S'DF:LZW#E4|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|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~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

*(D);H5@EAD*Y/("#9W:4$QBT%BVP4OF=2?6<[#OX2L_&Y]: MK?M>@1$*OZOIMA[6>Q{&EX>UVR_NOQ;?\;?0S2O# M6CS!H_WS9V[,-*
AHA.>MV[2MI'V#IM:,+6@'5_04E+S"Rl2\A908K0&=LG!G,+3 M6G,]KCNS1\%Q8P1;FPSM/MEJC<_^I^:L1]_L5"UVI=9'VIIP.'9]DZ!3 MG^U4+7:EUD?9^G9H-
^ZG>26[R&" T:$Q,+,_E[#BL/7BT&I23S-,=HW!9"8& M,@8P+^&N86NOH=U?#_5,3ITV/+3;\')LB/027ANV9AO:W?8)7}\RPG+]P)VJ MQ:[4^[\@6ZN:
J===`SMC'4?3I=]L2NU/LK6^":,[\3^MZ]M%\(@,\=/TFP^H] M:9!,Z_F1W?.?U/3M&H/!'#IY@S]UE;//I37RR&D!_9\NJI@0H?>/!HJ9#G] M'.YW%GXRPC?E IH
2U906:T!-4>;1;KK\VK1;-J1[*\7$9:, "E95FYN"5X1K@>H\VO&Y'Y')VB6+N?_ E!+ P04 M" "]@319_S^1L?H$!R%P &0 'AL+W=O1\B"6*]_(<[\B'-UI+]54O
0QYC$6B+SI+8I)SS]:S)<1< MG\H4$OPRERKF!E_5PM.I A[F0K'PF.\'7LRCI#.>Y6/W:CR2F1%1 O>*Z"R. MN7JZ B'7%QW:>1YXB!9+8P>\\2CE"YB
^9+>*WSS*BUA%$.B(YD0!?.+SB4] MOV9=*Y#/^"N"M7QD"R4J91?[-QK4<@8&:L"HX_*[@&(:PF]-.J;13 MV;2"+Y^?M7_,P2.8*=P!+<7?46B6%VAAX0PYYDP#W+]*Y2
^E;?3 J=_R?K MD4\0_&NWR2^X4ZW"F4W MU]=UA?(NT49E>=3^^803R)V!6/_;X-U5H:W7K,V6]IE. ^0PN.EB?&M0*.N.? M?J"'|_TL3U):4;0#O5R5G *$FD; /XH
(<>"7EHV06I5P0'LL, MD4^E0A7;VU]!>K"3G-0?T/Z 5=E9 :*/!#0L (T/$(-%SK[&\C8H-?O;R%S MVCX0V5F%[,R)[\5+:,*$YZ1A#HTPSG9@]-@PZ&Z!<)HY$
3UZW/:=*X3%/% M(XT9-Y/:Z"88I8:-Y:"#;1AN.X?B>,$W]!/"%4^^(L=18!>C&0;=]9?!=D*Y MC1P*@M4@F!/$1P"2@IKAGH=- 0VG_,ENBY]<(/F)"_(C
M%1&@RSJ3=6XV,:JKT@VI9%4L,%,.MQT-I[>'1J/F/=3]+@Z)Q@<\(LN :?%@ MNHV!V.GM8! @YP0$8H*(/ MBU(+,.6=-1(0O8;$;K;C(X#TQ
M2_1E*45(\%9&>(B4 [|BS 0D890L&N/1:XK'<#L<+7&LS7#4[(FZZ5-,]\43 MJ18>,8?(&/!#!]7>*OHN'I+.^-J+^[Q3%,/].C-9.A3KZ_^Y(0$ATLG;6_W"[>
M"=XR,KS@6EH7-.=FL.-ZT&=^L./,0@+K1D+=5.6NP1/=="&P&.*UW!PKD9+ M5*0$ODN @F#_DM64A,HY2QOT" >0R\5 'G@SQ7'I\.90'(,)T9H*T;-6^3IM MB?.4X(_!H%C-
H)B;04WR/%-=>]OW(=%S/:@*I*U^]HVSSS!G:W:,^CUM5[G;B M4) U06)N>G6[LNN*I\]-TBZYF#&J1-WLU7G_POETT.*O1 M9]\F;=1O7!ZV12,$=1_W2 !$(5#=
[BQ<@T[Y%.I3$RSA^7&"%0 M=@)^GTLLDO+%&JC:L./_ 5!+ P04 " "]@319Q5H2T4_$ #R%@ &0 M'AL+W=OO*!0X2*]!Y"DQ?V7"14*5/Q=:.5J0 :YD%)
M#[+/\|V$1LP)IOG80@13GJDX8K 02&9)0L7;/<1\/W.PHSWW^"$FAD]-8\EODOVI?W>@Y.9U+QI S6&201*_[IM|(01P%X MV!) R@#RWP"_)6!0!N25 !5@I=H;F ,%*(LA
M89V)2+VAZUNT T&],H8^9R@2@YXA%29:@!7TS MPQ*!>P!%HUB^UP!?E@_HW8_OIZ!261EM=UUF,"\R("T98(*>.5,IB7YA(82G M J[&]9C(@<>F>6!5_I>P:8?\#(AX9-
B7TG?!,AP^!O"3= 95B0>YWL!6XD%VK!9S4SK6YG2-$?],1AA5X, ^I+'F0&5>M3,FF+T-UV%)G3K4[NB M]R1V4J!Q5:!QKS-[W"=X3V(GX),*?
&+],A8B8NLHI3%*RU[0A&O52(H[.?O$ M,R;#UD_\[@*YL8(\,CUU02HKAU6B*\?-&0W4?]ZPD+US!UW%8Ds+S M9=]82K7C97+@C7&=1MFZO;-T,?%&[?
D>^0[<3W.PZW0M?ZDVNK0!8%(#D?^=0 2^UY:=&HN#8W8VW&HA@IO4]?:F=U]fV1WC4:R_$O1J@OM1X6NCA.U:Z;)^:!?IC.R?=Q+; M0E:,&FRU#I?
U1+M&9Y;Q>9L96;IB[5.PW:AT[8J]6A9\[ED&_DT[56U:L-VU M]+^8IF[+DEVM,]3@S/I/!@TOR#W: M54Q ;//-5HG6/&,]V&"L1JI-
W;M\&].M;R]V@Y^IV$9Z$8IAHT.!Z[&N]"@V M6(L3Q=-\CW+%E>)))?K@#&H(P-^CK&ZZ7K/+$/*#;Y@[^!5!+ P04 " "]^M@31948F!WOP# ?$P &0 'AL+W=O%
[R(0^/WG"R@R;V-](}$R35$R=C939I>N*< .4B N6 M0:K>K|BQ1<Y9VQ+QH%$)H@FKN]Y Y>2.'5F$ -LSF<3ELLD3F':D<@I)?SE M&A*VG3K8V3UXB-<;J1^XLTE&UK
^36;X :21"NI;U3OS/P"F9)!-RPY*\XDINI,W)0!"N2)_*!;7^#$BC0>B%+A/F-MD7;H>HQ MS(5DM Q6]S1.B[_DN9R(1@#N'PCPRP#_=<#@0$"O#.@9T&)D!NN62#*;<+9%
M7+=6:OK"S(V)5C1QH=Q(;EZ&ZLX,:N%I42?T"TJ1^1[_FIM@'9PW_/TR]\:QE.KYK(GM'K'=!; M;!B7GQZ!4V3FI:_5 -T+X&*?UI&=UV#]=O5I..|%!D)8>JHW2F /X$S^_DG
M//!^:4/M2&P/O%^!|VW]LSIULC)U5E7]9.2%+!-HX[>*GLI?B V,F"Y<3RK? M>]fG3=RG%K*@(@N.)'N[*;f6'$"5,XF^H[OIA\5C8PO=Y6FDVK116SL\E;H€
ML;VY&515, ^@TW0===@G-C,RX+'VN.9/.*9V3E,4O(5?NK3>K!B[IZTAB7#2T^&K79G 5]=":PXPIP;-_%.LE1'A.)2AOIBK16ID,%^8|6\'V4>,T?_&KIK'V?28:]^N/M
M6=G,)S5YT756KYI RACIA6S#*Z6:R3CPO7'P"LC>X|E$#3N"\)37Q*YZ:GTI MU8(COR?8K^G_Z$KE0\?8%TO[!3)2/X,)#\X3%2['FSU%K-'}E4I5,8T
MIFJM3!'9)6,K5.^X)/P1A@;?C@8?:VG.^O"K-\I4!JW\G=J>KM3VIZFV1SCH MU /@3MU/5VK[\+7_P5:7<5KI[=3]E&K[U:E_>"_7S@8?:VVL6[@CMU+"#$\K
MM;6MP78_4I5:*TM'QJ1D&;UE.4Q2^Q=L-S"GEMB.+$G)-&[YUZHEV=S&$00% MQC8G,P*%YB(7!Q'5T^KTV\[<>;AU\^+HZ#/AZS@5*(&5"O4NAFI">7$:4]Q(
MEID#€263DE%SN0$2 =<-U/L58W)WHSNHSL1F_P%02P,$% @ O8$T64;_M/Q^ P >Q$!D !X;"]W;W)KU4LM9AK;]HP M%(;_BI5-
4R=531P@11T@!;)]E=]MZF73-.V#"0=B-8E3VRFMM!_VPF!=,$K M5?@"<>+SVL_Q,7G-8,[XO8@)'I*XE0,G4C*[-!U11A!0L0>RR!53Z:,)T2J M)I^Y(N-)B8HB5W?
\P(W(31U1@-5[%]/!BR7,4WABB.1)PGAS\<0L_G0P<5=2>$@C,S@!N1==L55RZU4)C2!5%"6@[3H7.$#T]FH -,C^:4YF+E
M&FF4,6/WNG$^&3J>GA'$$$HM0=37(YQ '&LE-8^'4M2IQM2![J<+!3,#KV#& M1,)BW_0B8R&3M![$YB2/);7;/X%2]"> U@M9+,PGFA=]@ZZ#PEQ(EI3!:@8)
M38MQ\E0F8B7 /Z\),L _V6 OR:@4P9T#&@Q,X-U2B09#3B;(ZY[*S5]87)C MHA4-3?4RWDBNGE(5)T=G-"5I".@"5"[0MW%,9T3G5Z"=4Y"$QN+CP)5](-W=
M#4O1XT+47R-Z]D>PL$%N\CW?1W-F)X(5:7 M<15T1>Y7Y+[1!;!O61C&BODZ90[_ENN6(§WL5IE]#8[%!D)8> BH?!22 /X(S M^O .\]ZG)M:6O&K&G8IX8]0[.X@O0 B
W6*M=]$IB)#3S.RF7Q>]+SJ7D(C? M33GHM)F#EL1J.>A6.>C^9]53&<7/13&BC#RKGR0IFI"M.ILB%V*!$=._K(^C M3A\?#-S'!I1>A=*SHESG8_XS1+
<1<)}!+FG8R&$5V92C);$;,U#Q!ML]WZ#-_M'+0D5LO!?I6#?>N:?\V3,7#$1@@>><[CLL1;5O /]FW0J^8 M,VR%7KBS K21 ?_S9NGCKN=Y+T&L [T59.FUL-
UL;;=U=W:T5NA&[5DK6E M5D_-TI3AK;DRW*HM:TNMGH>E,<-V9];BJZTAB7#2T^&K79G 5]="]T"-?*T;]&UL
MK5C;,N,V$/T50BV*7:"-1,K7U#:0.%ULBBX2)$WWF9%HFUB)5$G:WO3K2U*R M+A&E.*U>,%UF#L^9&9)#+8YY501NX%D/LTQ>+EFB3\ MN/2@=WKP0+
<[91[XJT6&M^2IJ^?L7N@[OT2):4J8I)P!039+[PI>KN',.%B+ MOR@YRMHU;%*>.?]F;F[CI1<81B0AD3(06/\=R)HDB4'2//XN0+UR3,-8OSZA M?
[+BM9AG+,F:)U]IK'9+;^:!F&SP/E$/_/B9%(+&!B_BB;2_X%C8!AZ(]E+Q MM'#6#%+*\G_|O0A$S0&A#@=4.*#7#F&'0U@XA%9HSLS*NL$*KQ:"'X$PUAK-.M7-
C86&^MAC*3QD"7T#SW9I+!3"+.MP>,.^RQ*B4ZEP FY97DHF)1]NB,(TD1^U!|/C#*CPX\>%KS1),Y0?%82N@D\1KU(OZ^9Q<@#'X&*$ C!Z'U'>>YA#YVP MC'AH]
<(WI[8]$8ZJ]>N*.4@(S>(F=R7,L,167IZ]DHB#11;_?0#G 2_NA0. M!-;0.RKUCOK05U I21*NF3G6!.+99;@PPI-81 $"_]0 M%>0P0Z.Z68/JN*0Z[DW-
G=H142]!9V;&0V9F(+"&W$DI=]*;F;P2*=N"",L= MV.@E78*-X"G8-&J45ZN"*Q!Y(.-&RE [90ZS8-:9LFFI87]&AA/3_MJ:MAB$ MX;Q-
M&TV,1780?16$!V](@V@54KU61GLA]&H',C-1.'-1G[6#-W=0=Y@U4]&@ M/B^IS_\K=:9_SZ_;TW7<=AFW[8*Q["3/0RJ+2]HY?.5[N4D!OA A.Y-=/MA
M&AQ3^+DD142]Q32[WKES]8\#POO! B"0YAL8!#%^<4WZ-W"0Q9&]0,U0U'9[M^+Y0Q%1&?*^S)[BKV-0R[4S'$5K@6H9"RZ"^?A57M^V:ZI!E1K4]V:MPT/9
MWB3R+M-Z.I>H?ISWKME#H3555_T#*?2!@(-V$$.A-357/00_?MU2W32PK1_,)FFZ]?%503HKM#3R$CCW(88>;]WV39+73P^D W1GL[1?>7?8#H34E5ST# M/*=I^-
\=6C'*I+1O<*2V!>#&ULM9AM3IP$,> BI5-$Y. Q$G3 M4M9&VD!H1]NB,(TD1^U!|/C#*CPX\>%KS1),Y0?%82N@D\1KU(OZ^9Q<@#'X&*$ C!Z'U'>>YA#YVP MC'AH]
E|IAGP/2;&17KPC=]L78.7'0 M%&8D3]0WOOP,%5'!H]&*>R.(O6E9C/0?%N50\K8QU!"EEY2]YJ!*Q8H![SQCX ME8'_4H.@,@@*T#*R NN<*!*-!%\B849K-7-
1Y*:PUC24F6F\44*_I=I.11>4 M$18#N@*=" 3U-J%S8O(KT1&ZR%4N %U31M,\11/R].=/271P#HK01+[78W[< MG*.#M^_16T09^K{@N21L*D>NTK$9#VY(?,_O=9B?
MO=P\6=#M=W=4,JM/AU6OQ"+%AB(PJD!#@LTW'(SD'&@F;%A_?!2H]%EPI2^,>+ MLQ3N=0N.57DJ,Q+#,V-'+3H*X!R=Z]P;WO0]=U#L26\M!4.<@L*E'$T%93#.2
MH*R.^2[<4J-?:)B:<1\%H3]R[fU;^L<:MRU_8%8W5ZK5%:4=B:X##&G"X MK\(I\W&4,=B2VE@/L-9NVMX/27(FLE;76ZK%[V!9DI?W _U^>*XTU$&^3P^IG M6XZF?\#6K?
C5);J26ZO1N#4W^]C^<;/_8WL#H(M)OS/V'>WG%>0^N@/X-MMZ^"@G?4$U1YV$>'@9L6]M[C!>6E'9KT=K6](ZV!6EZ"VQO+EY64=]=Q6;# M9W>S+4;3@&!
[!_+]@M+N)+1+5Y6N1W)53ISGR?O,QI_K@F,!,RWO' YU= M49ZBRQO%L^(@>LN5/M86EPL@4O!F@'X_XUP]W9Q5;?V_C.@?4$I#!!0 (M +V!-%=FI="K@-4 #\G 9
>&PO=V]R:W-H965TWBA@BSPH3;S]T=>RKCH32?YM4LUG[3W<.$S7ZU-=L&;3C9L!5=@OFPNE3WS*LJ"IR TEX(H6)[V MSNA)% RR@/R.OSGC\+[DM[_5[)-
Y](.RV/8@Y.+XS^Y*(?8"Z,"1@*_ ")X;T"\#^H;A*!8ED--WH1@&$_T6_(;^7(5DC<_OYUXQC:,A?IQ MV4!8-[\T@ -R$%7L#DFU\'T/'2'_]D5QZ!?A
]:Pf/GA_<=8O2K_/5S7O\1W@5H#7!49.^(MA*!CO3?Y_.COA:V7G!M(7]M*9T5X$$[."M0)WK#8CCMV0[OD>V@-_WE)SKR M?V_3'!,68L(B)%@C.X,J.P.7?9[\Y-[6U&%
(7!GJfN&ME0X*5U3@0D+"]@#H MAV6#5FXZ'/5]WY]XNWV1G[B MQ6C(=^PDF_HE.\#BWG"#0=-OI,K)DC(826/R)PE MW(Z1@K,V,9W,KF)BPD),6(0S:R1F5"5F]%159X29'4Q8B
F+D&"-[+RKLO/. M^=I<@TJ)7)(DRTY;#ISA77/@[LMX3-)\^&]3'+,?$!*LH?BX4GR,4N>=E*[" MCW^LN33(0A7[E3G$;#)"@C4T?E]H_-
Z[\9D06Y80+F*5SU2Y*+Y9I>QM4N8-3?T]L_]@_EQFPR0H(UY*9^[0Q\[^"S3.7\&\UNF*WGV9%U"UPN,NWO M@2DB1>O7W WN*OP3W1PY"@QJ1R(L6C,?>TZ-
/E'6!,,IX,E&R5V1#I98H\|$ MW)X%)ZY$%N@Y69,QZ.#B6"(VFB$16LJ"M2*!K^GOCQEP?5'=,?K2H=(:+#P6$APVPUP[(U):]H-'4;Z>LUD,NMBM?9 MD,
[$PA8S*_]92D$QCGPG,H'IL5%[$ M16OFK;;9]-5\-D4UVJBT$)468=&;..K--G4[W']:[#[^):-1=89T,#R8/LW=
M;776&=5@8]&:.M<6F[H]]KFP(X6M2419,V*=1[&\0=Y82Q);]9DM7G886193 MMOM?-4F9^@J&[%BRA;8?+F9E@S1H6KK1\# IF!XZ1*5%6+1F4FI/3MVF_4#
MB_ULINZ9."+7<,?:QQE4 X]*"U%1$1;M^3-:,?4# [7&F0#5ZZ/20E1;A$5K MYJBV_X';_N/7O(+!)^N?NV.=.#DX?OH!%;R:E7B$(W"L$+ZM_C?6%IX]ANR>= M7S34-
0146H1%;^:T7D.(7FT-(4!=0T"EA:BT"(O6S%&]AA"XUQ">-->D.6]Q^ MVZ3;W59GG5$7#K'HA<[>WD:A%-0]WZ&E22RWPA0;<*JKU2ZPLWSOT\'UD)Y$ MQ5ZN&E-L+?
O(U(H+,4>GI47ZQ^^L@U;%;JWBQ,A-OAWI1AHCT_QP#6P!*KO! M?KZ4TCR<9 U4>^:,F_P-02P,$% @ O8$T6=^^^$*. P 4 P !D !X
M;"]W;W)K&ULS=A,]LV$/TKA%84+9!%$F7+3FH; M2)P5[, B0;*L'X9^H*6$350259*RVW^_(Z7(LLTHR9 OL4C=#/]W3B0ODZV0 MW]4:0).?>5:HJ;?6SWM?96L(6?
J5)10X)NED#G3.)0K7Y426&J3\LRG01#[M.>.%-YO8N1LYFXA*9[R &TE4E>=,_KJ$3&RG7N@]3-SRU5J;"7\V*=D*[D#?
MES<21WZ+DO(<"L5%020LI]Y%>#X/]4FP$?]PV*K,,S%2%D)\-X//Z=0+#"/(M(-$&@N'/!N:0908)>?OH0+UV39/8?7Y_VC%HY@%4S 7V5>>ZO74&WLDA26K
M.GTKM!^2O3>T2>6D(E/U+MDULX)&D4EKD33(RR'E1_[*?C1&=A'#T2)M$NAS M$Z(F(-"V96UA73;#.18DNDB48T\"]L=FHAA>FC'=.XEN.>7IV78)DFA@&^1ZD?
$5,PXK)CLY?#L72A-6I.2N*LL,I)R:9>1S47].IBSOKD SG]GW MF'U_=T7>O7E/WA!>D+_7HE*8JB:^1MYF=3]L%[6'.DC'$-*OHA"KQ7YHT@A MW0?
P47"KFCZHO]2]B'I6Q2F)@A-" SIP$)H_/SWJH1.U18@L7O1D$3)KKBE%<@->+.WOX5Q\,&E\97]A0/6L6#/G2G8I?@ M&B6V*.9$VLR&,3J^Z>KHC]FC-
VSI#7L+,F=]33]B$7?2V0(7Y3AFH,ZP>V@ M% #]V*AM,2CZ)N+_/ UJ_5*8'MVQ*T=\3.KE1ACEFB,(DI
MJI:P/V:/\ZCE/'H=SD2T1YZ+_NB(6AR%[_2/8Z)@Y*8_,NF/7[1!;J_O"<-O M3CO/S_$1 3H(#EDZ@D:4NFF>M33/7D1SYR6>_TDE)=X0!3R.7?/CC@-HOB M[W%,-
#YSTPZ#W;47_'_B!.9/8OD<_LTJW<.'QN/Q@0)'5!32X2,..E=WV*OA MJ^U1("5L@V)6@&V5,=QVHC3(',4*C((C|%/,FX[+S^]Y=,P*F="_W",@BC3%
M_.D=2=AFXD'O^8./=+66^@=_.L[OBCP0^3F_YVK/K[,L:$HR05D&.%E.O+?P MXA*-=$"YX@LE&[&S#70l,\:Z9V;Q<0+-!%)R%SJ%%B\/9))+DB0ZD^+XMTKJ
MUD*JBO\\U9(L!7 ML*G6!AZ8%I*RM 16!"G-MN_X>]6(G0 8O1"]@#THP%A%!*6A6(]RK*NL,33 M,6<;P/5]E4UOE+TIHU4U--.G\4%R]2U5<7+Z(2<<2¥]MP"U1W0 ?
9@E=8=UA M_<[=2$+3L =S6A:I. >/ZDS* 5X?44DIHEXH]9\)?K@"KU^] :\ S<"G-2L$ MSA9B[$M%IX ASRN2=UL2] +)GT5V#L*@!U" (DOXY8^'A_OAONI)W1A4-P:5
M^<(7\MT2(0CI@5;#>N"6XAE-J'SJ MOOMS-R1.ZZYXT/<0QMW;'/@G;_G9D[<@]J M[L$A[I&->V!RAI#%[D']7T M(S<]D^J!FE;,DY3RE%<*9*MG9-
8SA.W+R'G(C@7!H\';P%F2%I4+)>N%!R;=,%9A?CO*VNRG M$'W8J#X*/M6ND)-W>]'1M|/(?RP47YX4/]ME@6:VA\;GL6=NRM%H_]0+?\O MV19H*G\\&+393R'IL-
%^>$#!G=8%6K0^-]Z<4V@]:K0>N;7^9^T+,B5?R6'; MD+D/VK6HQAH@MS6X2?-"D@6XR=29(4);"W&F^.G?M4?*ME_PSA3@U%\?CC\' M.(4G08TG0=U&
578GB6$]'UQG\(?H,8?H&[C &3Z SAH/^O=N;NR-_X =1L) M(-,?P,CH^RG\ 6K\ >HV%D"F/X!!V]NX&PO=V]R:W-H965TVWUV<_K3Z<7G]S^7%U[_'M\<'-R]XO-
3QO/5+!>3QXN[W\L/EY?_M+Y.V_ 6GG[0)6U=E-W8?&%O^V\)Q>?=.!9HFP+5 JJ%5(NH%E,MH5I*M8OJ.=4*JI54JZG64ZVA6DNUCFH]U0:[MC4I;S[*]QPS;>VD:MN6NNWEPZR"3V])+=5"JD54BZF64"VE6D:UG&H%U4JJ M5??:W!X\.F#S\H
M';"C6D^U@6]CTM8CY[$787?V3.O=9HO%V\)Q>?=.19HFP+5 JJ%5(NH%E,MH5I*.MM8OJ.=4*JI54J^ZUX^EJ[C>[F\>*GGG6[MXW>QN;(EYEM?3Z.ZKU5!NH-B!M
M/?0>FPIN^A-G0J?!],/UV=7YQYLO7:9GJ_.?3W\X__F ZK-],JMMG2926U(M MH%I(M8AJ,=42]I54RZB64ZV@6DFUBFKUO78XS9.=_;>|\>BH!+4ZJO54&Z@V
M*FT]GQXK%'8/9N\E_?O)/.?9,*(M"51;4BV@6DBUB&HOU1*JI53+])93K:!: M2;6*:C75&JJU5.NHUE-MH-JHM/7(>NQKV'VIL.'R,+5Z>[WX\>KRPV+U]!75 MV?
GUYU6\Z:+=LX%&FQNHMJ1:0+60:A'58]HE5>NIEE$MIU!M9)U;TVG0-M #Q\>G1#5=-B&:BW5.JKU5!NH-BIM/:L>^Q]V9X_O_E'WG&AO!-665 NH%E(M
MHEI,M81J*=4RJN54*ZA64JVZUUZZY_3T6<_=78\U$KOS/1*SIZ-H>P35EE0+J!92 M+.):3+6$:BG5.JKE5"NH5E*MHEI-M89J+=4ZJO54&Z@V*FW]0U\?&R7V7FJ4
M^*WWH^;A;0.-:DNJ!50+J191+:9:0K64:AG5Z?UKNIJ^N3H_NWGX:-C%<'"_$QK'MHZ MF&AI!-4"JH54BZ@64RVA6DJUC&HYU0JJE52KJ%93K:%;2I6..CW5!JJ-2EL/
ML+W' -N;7!S1Z^M MI5!M9YJ]5&I:TGS6/UQ.W#[9?[%O^U>-7^P'E\ZQB2VI] =5"]D54BZF6 4 M4]552KJ=90K:5;1!6>:.@/51J6MA]IC7\?>?%_%=DN
M,"" M:DNJ!50+J191++9:0K64:AG5V M&59TT)IJ#=5;JG54ZZDV4&U4VD@/;94[.VW5 0?/KZ_,?]X=-[J\]MM<\&.M$RV>H-J2:@'50JI%5(NIEE
MI5I&M9QJ!=5*JE54JZG64*VE6D>UGFH#U4:E MK>?78^'%WC%<%*3%%U1;4BV@6DBUB&HQU1*JI53+[)93K:!:2;6*:C75&JJU M5.NHUE-MH-JHM/4,>RR^V)L]I?
RP*/AP?/CY=4%:@$&U)=4"JH54BZ@64RVA M6DJUC&HYU0JJE52K]K6YCT!\-2G-RT!HZ65W5.NI-E!M5-I:RRG>[,ZXK.TFN6@K!=665 NH%E(M
MHEI,M81J*=4RJN54*ZA64JVB6DVUATMU3JJ!50;J#8J;3VY]AZ3:_,$\"2Y M/G^4QY_O/AC@JJ!50+J191++9:0K64:AG5 M+7X^??]H]>
('3LW+6X<5[:2@6D"UD&H1U6*])51+]991+:=:0;62:A75 M:JHU5&NIUE&MHJPKQU-;P-^L[.SNQE5?T1UQ9O'ZHK;AUM%U=GEQ<^KJ^OS MRXO%U>G-
^>6S(35K;AU24EM2+::]:2+6(:C'5&JE5,NIEE.MH%(D)M8IJ=4: MJK54ZZC64VVXU]9F5)L!A09<#ZC'&HHWLT>VA\;GE>]#KF=WY]_>DKZWVTBX)I2ZH%O_M5
NI%E$MIEI"M91JV;VVN<:Q_HV=H-J2 M:@'50JI%5(NIEE MI5I&M9QJ!=5*JE54JZG64*VE6D>UGFH#U4:EK6?88^_$ MF_G>B=]P)XNV4%!M2;6
;B'5(JK%5$NHEE(M>_.T!^&Y.UFT78))=4JJM54 M:ZC64JVC6D^U@6]CTM8";O^QWF)_OM[B=]!)FM>W32NJ+:D64"VD6D2UF&II)
MU5*J9??:_)TL.F1!M9)J%=5JJC54:ZG64:VGVD"U46GK8?788K$_>],XKR\M M LZ_?.LTHA465 NH%E(MHEI,M81J*=4RJN54*ZA64JVB6DVUAFHMU3JJ!50:
MJ#8J;3VV]AYC:V_V1E:[NMME\?#Y']W']^:@/51]6MI=CL<7^?+'%0W#]7A[< M7^.EUZ^WL:Y69ZOSGU=O%0]75U^^MKA97,Q=73U ;VM^]*T3CA94="VXUTXF
M*TL[W^PN)]-A?;6XO%@M/EY>WTR? M#\.Q^&_Q7%PIG!]TZG*2VI%IPKTUOTN_M;$;3'#&B6DRUY+GOQL%F,,D1 M,ZKE5"NH5E*MHEI-
M89J+=4ZJO54&Z@V*FT]F!YI*_;G>RO"]J.SNP_W/7V_ M<=<KJ_.(VHYY,HYY-(5ID0;4EU8+]HZ4'3T*(ME-0+:9:\O(W(Z4#9E3+J590 MK:1:1;6.:@W56JIU5.NI-E!M5-
IZ!CU64^S/5U.TGWZX^O_.%OU/JZO3CZM/ M-^=GUXO_6G1?/L7]NA'\ZD.LYH?8.H1H/P?5 JJ%5(NH%E,MH5I*M8OJ.=4*
MJI54JZA64ZVA6DNUCFH]U0:JC4I;C[;'(HO]H]E]%*I)+EI00;4EU0*JA52+ MJ!93+:%:2K6,:CG5"JJ55*NH5E.MH5I+M8YJ/=4&JHU*6T^NQRJ+_=ECQK_A M&/*

*\N'60T3X+J@54"ZD642VF6D*U|%Z;+D >[.X>K.]!9G3,G&H%U4JJ552K-MJ=90K:5;1{6>:@/51J6M!]1C3\7^ECT56QX#IJ455%M2+:\:2+6(:C'5$JJE M]|KTX.ZS'PJ7T6%SJA54*ZE64.VF6D.UEFH=U7JJ#50;E;866 >/O14'.[-K M@5N5 Q[0E@JJ+:D64"VD6D2UF&H)U5*J953+J590K:1.1;6;::@W56JJU5.NI M-E!M5-IZACW661S,UUELORHX#VX=9+3@@FH!U4*J152+J990+,W77E@5I&/F M5"NH5E*MHEI-M89]+=4ZJO54&Z@V*FT|H/8> VKV;/'O7166{I= M%0?S717? GU[<7%XMPO.;__MN=77Z_NUBN&NC^-7[.;\XMUM3GUW\Y^]<]5? MBM.K_UC=+*H?;^/M|E_<6 !9[-0V1=E=0;4FU@&HAU2*JQ51+{)92+:-:3K6" M:B75*JK55&NHUE*MHUI/M8%JH]+6$^^Q"^/VH;L/MD\S3&I+]@54"ZD642VF M6D*UE&H9U7*J%50KJ591K:9:0{66:AW5>JH-5!N5MIYAC[49[.U&=]/FIE> M1Y+,LXF" +6$^>B]7-MG>X;%$& MU994"Z@64BVB6DRUA&HIU3*JY50KJ%92K;K7#M>CZ.E|QOJ9)QIN(_/$AEY? M2[6,.CW5!JJ-2EL/I\!=ZBX/90\A_[3|!<'UV=?{QKD'POEG|(?W7!\>6G5! MM275 JJ%5(NH%E.MH5I*M%9Q!:=4*JI54JZA6WVMK'X"YL_],/M$2"ZIU5.NI M-E!M5-IZ/CV66!PO}\Y^:\LT7X*JG54ZZDV4&U4 MVEKR'# !V4QS.GAU6.]%O?UF<_OW\PZ48|M%X?S M;1?_?GI^\"ZHMJ190+:1.1+68:@G54JIE5,NI5E"M M%\%M9IJ#=5:JG54ZZDV4&U4VGJV/?9:W#YT:XCf- ,,DMJ1:0+60:A'58]HE M5$NIEE$MIU!M9))%=5JJC54:ZG64:VGVD"U46GK&?;8:W$XWVOQL&%^V|[< M>7;K.*,%%U0+J!92+,K7UL[&'!\^/1P3TV$3JJ54RZB64ZV@6DFUBFHUU1JJ MM53KJ-93;:#:J+3UT'KLP3B<[\'X[MWJXF;QXVJU^+BZ.KM]?/IN]6PRT;X+ MJBVI%E MI%ITK^WN3*)IYYN=HYVU?W8W8XKV6E MI5I&M9QJ!=5*JE54JZG6 M4*VE6D>UGFH#U4:EK+#IYT)1X<',X[?UR83.FA*M8QJ.=4* MJI54JZA64ZVA6DNUCFH|HU0;JC4L;BZ>CQXJ.HYW9*=9:@/51J6M1]9CL\;1[*GG M;6=4\]K6*4;[-:@64"VD6D2U^%Y[:49%!TVIEE$MIU!M9))%=5JJC54:ZG6 M4:VGVD"U46GK\;3W&$_SI1F_=W_&[2_KJ]5?PD^W+WZ[F)V?T;H-JBVI%E M MI%I$M9AJ"=52JF54RZE64*VD6D6UFFH-U5JJ=53KJ390;53;>@_^- G(O1]%BH<73PVW=LT-(_MJBVI%E MI%I$M9AJ"=52JF54RZE64*VD6D6UFFH-U5JJ=53KJ390;53;>F0|_M-FLL9]MBP<33?L+'- ZB)MUZ#:DFH!U4*J152+CYZV:^P>'N\=*ETN+!)Z#:IE M5.NI5E"MI%I%M9IJ#=5:JG54ZZDV4&U4VEHV'3_6:QS_IGJ-8UJO0:4EU0*J MA52+J!93+,%:2K6,:CG5"JJ55*NH5E.MH5I+M8YJ/=4&JHU*6X^LQWJ-X_EZ MC2VF4_/2U@E&JS6H%E MI%I$M?CX:,7&LL1.FI*M8QJ.=4*JI54JZA64ZVA M6DNUCFHIU0;JC4I;SZ;|QVSZPfLU[G=K_&UVM\,\96P=;+19@VH!U4*J152+ MJ990+:.5:1K6<;@752J155*NIUE"MI5!M9VJ.WV.SQC%LUCBFS1I4 M6U(MH%I(M8AJ,=42JJ54RZB64ZV@6DFUBFHUU1JJM53KJ-93;:#:J+3U#'ML MUKA|J)879Z6M$TOJ2ZH%5 NI%E$MOM=>7EZ4HZ94RZB64ZV@6DFUBFHUU1JJ MM53KJ-93;:#:J+3U;'JLUCC^[=4:Q!1:@V1+J@54"ZD642VF6D*UE&H9U7*J M%50KJ591K:9:0{66:AW5>JH-5!N5MAY9C]4:QZO:8UI:.L%HM0;5 JJ%5(NH M%A_K=9X? CI%NS6HEE$MIU!M9))%=5JJC54:ZG64:VGVD"U46GKV?38K7'\ M6|LUXF"-V8Q^=?_X_3#Q_^S^/[RF|M_]^M35U??B^KCS?GEQ<8NCF?#C?9K M4&U)M8!J(=4BJL542ZB64BVC6DZU@FHEU2JJU51KJ-92K:-:3[6!:J/2UB/P ML5_C&/9K'--^#:HMJ190+:1.1+68:@G54JIE5,NI5E"MI%I%M9IJ#=5:JG54 MZZDV4&U4VGJ&/?9K',_W:ZQ-R#Y^NCK|Z?1ZM;C\,C/!N+HZOWQ^N9%V;5!M M2;6 :B'5HA?>VS<[B|>G_WCNAF=,KR.A6DJUC&HYU0JFE52KJ%93K:%:2[6. M:CW5!JJ-2EM+KJ/'|HV3V;/2?|@"Y.TOB|_ GW_X|.&YX)N_|&V#CV1+]@54 M"ZD642VF6D*UE&H9U7*J%50KJ591K:9:0{66:AW5>JH-5!N5MAZ&C[T>)(MN M*?$- GM0;4FU@&HAU2*JQ51+])92+:-:3K6":B75*JK55&NHUE*MHUI/M8%] MH]+6,VSO,<->ZO]X]6[">6GK!*,5'E0+J!92+,K7IOL3#W;VC5<^^BNF@R94 M2ZF642VG6D&UDFH5U6JJ-51KJ=91K;?:0+51:>O1I-C-<3+?S3%W=NR$5G%0 M;4FU@&HAU2*JQ51+J)92+:-:3K6":B75*JK55&NHUE*MHUI/M8%JH]+6(^NQ MBN/VH9I-S4I;)YC4EE0+J!92+,K77IQ-R4$3JJ54RZB64ZV@6DFUBFHUU1JJ MM53KJ-93;:#:J+3U:'ILXCB9/3;]A^[<.+_XZLX-VO%!M275 JJ%5(NH%E.M MH5I*M8QJ.=4*JI54JZA64ZVA6DNUCFH|HU0;JC4I;#\/'CH^30E4@|9\4&U) MM8!J(=4BJL542ZB64BVC6DZU@FHEU2JJU51KJ-92K:-:3[6!:J/2UC/LL0OD M9+X+Y#ZVKN|BZS7KC;3.@VI+J@54"ZD6W6O3I<;|@[WJ)^N-M*>#:BG5,JKE M5"NH5E*MHEI-M89]+=4ZJO54&Z@V*FT|GAY[.D[F>SIF=V_06@ZJ+:D64"VD M6D2UF&H)U5*J953+J590K:1.1;6;.@W56JJU5.NI-E!M5-IZ9#W6A>>W%&1;LWJ)92+:-:3K6":B75*JK55&NHUE*MHUI/ MM8%JH]+6XFEWYI%\X^{Q?],>CG;U^?0HO;BXOZ|+>9F;RI4&RXV.V\C,W4EFPI*. M!XQ%&ZWIL%Q@N=!RD>5BRR662RV762ZW7&&YTG*5Y6K+-99K+==9KK? <8+F1 M<1O1MC>)-M;=|0*U?;#1]@[+|98++1<|<&N?,+;S<[*_L6)IATTLEUHNLUQN MN<)RI>4JRI66:RS76JZS7&^YP7(CXS82Z\TDL6;/7__UN[=OS^_6'T_?/T36 MCY=7OS;@__FN^_]L;@WRW>INMG;Z[MW5ZMWIS>K7?+NX_?*/JZOSBW=?69FD MM2"66UHNL%QHN>B!V]V9Q-S.-SN'3U*,MGY8+K5<9KG<5"RT66BRV76"ZU7&:Y MW"*%Y4K+59:K+==8KK5<9[G>*@W98H615GU8;9FP'A MY:(']N451MKD8;G45ZPRV6&QFWD5B'D\|2. M/?7]1V5]%97Y|<1^-WBE|GY'6T+1=S25* MRU66JRW76*ZU7&>YWG*#Y4;&;.3ET20MCV97*K?<'$DK1"RWM%Q@N=!RD>5B MRR662RV762ZW7&&YTG*5Y6K+-99K+==9KK?<8+F1<1O1=CR)MMG#XMLM7= (^ M$LLM+1=8+K1<|,"|=)S;#IM8+K5<9KG<4*RY66JRQ76ZZQ M7&NYSG*]Y0;+C8Q;3[+=24_)fDL|);^?>|U36P<;Y9;6"RP76BYZX%Z<>]%A M$\NEELLLEUNNL%QIN4:Rl66ZRS76VZPW,BXC<2:M(3LSA|6B=L&_G;_M_+:1^>O;(@9M\0CE LN%EHL1%ULNL5QJN4*RY66JRQ76ZZQ7&NYSG*] MY0;+C8S;2,N]25KNP6TCN[9ZA')+RP66"RT762ZV7&*YU'*9Y7++%98K+5=9 MKK9<8[G6LL-EAL9MQ%MDX:2W?F&DJV6+FW;".66E@LL%UHN>N!>7KJT M;2.42RV762ZW7&&YTG*5Y6K+-99K+==9KK?<8+F1<1N)-6D;N7W\F[>-W+^6 M193DEI8+++!=:+K)<;+G$4ZR_66&RPW,FXC MR29M([NN;62>VC[8;- L(Y0++A9:+'KB7YUZV;81RJ>4RR^66*RQ76JZR7&VY MQG*M%Y8+;98JRS66:RW76:ZWW&'YD7$;>3CI$JF5?2*IMD^$ M5ZRPV6&QFWD$6V3 M/F'=^3Z1[WI],}'CZ!9?+PZ/UO=SN'^Y?ETLZ4BE%M:+K!<^, =3I84=W>^_M_+.^JAC9D6/+)99++9=9+K=<8;G2=CUW3SL5;? 6;-4(Y9:6"RP76BZR7&RYQ'*IY3++Y98K+%=:KGK@-MUF|H|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|]_.G#\|G MGBWJH-S25*RU66JRW76*ZU7&>YWG*#Y4;&.M;23CI,QC[V1V:7*[AL4]6^5!N:7E LN%EHLL%ULNL5QJN4*RY66JRQ7 M6ZZQ7&NYSG*]Y0;+C8Q;C[8WD*/-_.%'ULW+,Y[6Z<;Y9:6"RP7/G"O:5BD M(\>62RR76BZS7&ZYPG*EY2K+U99K+-=;KK-<; !G!G;V_O+Y\^QKFUI6M__]7]XL3B_>+OYE;V?Q<77U MY2;=\WEG6T HM]1<8+GP@9O>U3AX++NMLNP?E$LNEELLLEUNNL%QIN4; MR|66ZRS76VZPW,BXC:S;FV3=?7(|\RZVY#[';[+X;=[0BAW>)R@>7"'|VX; M=D<'SX2=[?Z@7&*YU'*9Y7++%98K+5=9KK9<8[G6LL-EAL9MQ%VDT:1 M-_-_%K\M|$YO%K=/._WA\N?5;X+.%!!0;FFYP'+A [=^Y.VY:9WM&|%<8KG4 M5ZRPV6&QFWD723KI';QW-)%YZ>7RU^/GW_MZ>[NV^|OWY|;G;$[8--4*RY66]RQ76ZZQ7&NYSG*]Y0;+C8S;.M2+9)%4* MRY66JRQ76ZZQ7&NYSG*]Y0;+C8S;2,9)SO)GO/>DF M=^4^KJX^G-_+@SSL[.P_%*/^U^)?%M_>_.M>#X#;3T'Y9:6"RP7/G#3)52RV66RRU76*ZT7&6YVG*-Y5K+ M=9;K+3=8;F3<1K!-FE'>S#>CO#K8COY\L$VPVO4%RBTM%U@N?.#6"Y.>)))MM M-J%<8KG45ZRPV6&QFWD6R39I,WLP?,7Y|L MNSO;S=EL!PKEEI8+++!<^<-- HVW\;;;;9A'*)Y5++99;++5=8KK1<9;G:KJ|.,U=O'0P5G[T_7:|> MCK7Y(;>.-,+9=8+K5<9KG<LL-EAL9MY%K>Y-<>Z'A9'7VZ>HVSE;7SQ\4 MJ*_.?!YKJ?SX_O8|[KJV? {I9_A+*+2T76"ZT7&2YV'*)Y5+++99;++5=8KK1<9;G:O'QZO\1M?ZCQZO+#YX|#O0N_KQ:9S(^P?=[M/|G|M'NP^TR/|Q|*. M'%@NM%QDN=ARB>52RV66RRU76*ZT7&6YVG*-Y5K+=9;K+3=8;F3<1I9-]DSV MYZM,UK/L8G6S=9+9>I)(;BW)]K^29+9ZA'*AY2++Q99++)=:++K- <;KG"P+\K^WJ|:>SNQTB#_?0%[?OI0[W MQ]7G'9)GMXIOO_|!\AMD>DGMN=V<28CO?I.P_"3!;,$*YT'*1Y6++)99++9=9 M+K= <8;G24*RY66JRQ76ZZQ7&NYSG*]Y0;+C8S;B+9)(\G^2"/)PR3MSP]=(YN?C'-W MO^UV.O?IX^U7SBXO?EY=79]?7CP?? +.%9/|L,P?'!R>&;)^N6MF"$4JR|66:RS76JZS7&^YP7(CX]85|6!217(P7T7R MF&FKOZ^NSLZO5_>[)NWJ?;6=G=S/!Z,"!Y4++19:+++9=8 M+K5<9KG<5*RU66JRW76*ZU7&>YWG*#Y4;&;239 MWB3)YHM&?L=4&RXV,VTBP26_(P>SQ;7J';'ZH|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}6|4ZZ1';GNT36L^QB=;-MDMW]:&S_UST?/_"NTP*AY2++ MQ99++)=:+K- <;KG"4*RY66JRQ76ZZQ7&NYSG*]Y0;+ MC8S;2+*]29+'LG>^KI8/+=]N.V]|KX8'3BP7&BYR"QY1++I9;+++)=;KK!<-M.;G*KQA<_G MGSOQ_KWEEI8+++!=:+K) <;+G$4ZR_66&RPW-M,FXC)"=U(K>/YY8IMIO/?X^Q:)/^>F2+SU)[@=H^V Z>KED>'|^<'+YY MLF9IVT8H%UHNLEQLN<1RJ>4RR^66*RQ76JZR7&YVQG*MY3K+]98;++#"R766BRV76"ZU7&:YW'*%Y4K+59:K+==8 MKK5<9[G>^XUZX>V 81RH>4BR\662RR76BZS7&ZYPG*EY2K+U99K+-=:KK-<;[G!KJSLKF-^S/W]16Z:*)1TXL%QHN42RZ66RRR76ZZP7&FY MRG*UY1K+M9;K+- =;;K#4*RY66JRQ76ZZQ7&NYSG*]Y0;+C8S;B*])-M \CMXZWBZ_2'|ZO%S>KJP_.9-:MMGUGS%W>P^_?]J.JY|%S;*PDL%UHNLEQL MN<1RJ>4RR^66*RQ76JZR7&YVQG*MY3K+]98;++#P>S=|\7F|W?8 M?@_*+2T76"ZT7&2YV'*)Y5++99;++5=8KK1<9;G:6P+RBIM@MO;CGGO- 33!;_^T&YT'*1Y6++)99++9=9+K=<8;G24JR]66:RS76JZS7&^YP7(CXS;B:]+UL??:KH_7W02S M=1\O7-SL33#;_T&YT'*1Y6++)99++9=9+K= <8;G2G'W|Y91WR|O7=Z|Y3VS81RBTM%U@NM%QDN=ARB>52 MRV66RRU76*ZT7&6YVG*-Y5K+=9;K+3=8;F3<>FB^F52.O-F9W3FRW7GJ-[8] MA')+RP66"RT762ZV7&*YU'*9Y7++%98K+5=9KK9<8[G6LL-EAL9MQ%M-MDZJ0-[.GMO|ZFV8_W'I|[?W-N(^KJR^WXNZ2[NQ+TEU_GNK=3>U^>9P:OG#/-M;G[4[3- P|YE[=L<'F_?LZ*B!Y4++19:+++9=8+K5<9KG<=.7!JE MV7H1RH66BRP76RZQ7&JYS'*YY0K+E9:K+%=:KK%<; fG.5ZRPV6&QFWD9B3(L W\T4F6VY'L4.R[66ZRS76VZPW,BXC6B;-)N\F6\V M^:,6.FT)RCUWM+ [0N7_R9*735J!0+K1<9+G85:RW66ZRTW6&YDW$:X32I0WLQ7H/2KJP]W0;:WL[>_F%WV?#[$;_<*"Q>[M^_E,^?-S-EN-0KG05JRS66:RW76:ZWW&'Y MD7$;L3:1GDSWSX2GIZ__W0|1;NY7/QX_GZUN%]L.[^^3MJ.?\&SN|M^1QI M?UZ\7=V^\C_k2[._G$WL3N_?+Z2P2%ZS5<6;P[_<=7(LTVFU-NM%QDN=AR MB>52RV66RRU76*ZT7&6YVG*-Y5K+=9;K+3=8;F3<>J3M3YI-]N>;368W1>[-M(A/*+2T76"ZT7&2YV'*)Y5++99;++5=8KK1<9;G:52RV66RRU76*ZT7&6YVG*- Y5K+=9;K+3=8;F3<1G9. MNE/VW\PN<6YW6FI?5]0:FFYP'*AY2++Q99++)=:+K-<;KG"&Y:>#]=^_435?^\OM)Y^+G/*@0/+A9:+++!=:+K%<:KG, M4&RXV,V\BS2;')_NSY\M^2>9ZXO_>7]SN/IM^5B]7YU|_L+M+._NUS|=OG^!NOI?S^>=K42YYS;S[N29O+-M)Y0++1=9+K9< M8KG45ZRPV6&QFWD7>3MI/|^;;3\M.''U97 M=XEUMU__UP-TIU\Y0O=\EMEJDQ>N^.C@ZT<+Z)4$E@LM%UDNMEQBN=1RF>5R MRQ66*RU76:ZV7&.YUG*=Y7K+#98;&;<1;I.VD_WY I$MPVWQ/|\OODSD?K|[MU>W+3A=_^O'3^_>WS__Y?/7+GQ8_&/1!=|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l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|OW914JR]66:RS76JZS7&^YP7(CXS;R;V^?2'WNSMJ\VZY_9[L_*+>T7&"YT'*1Y6++)99++9=9+K=<8;G2FTJR+;,W MU^;A[6/.-H50+K!<:+G(4:R[4/W/2&V,Y& M24GW\3CZ5VSG6^.-^^;T4L;+#5JRS66:RW76:ZWW&'YD7$;238I^CB;/6_]-M>Z97MO2#V%Z]>5)-M)RI-

*KVQ%!^5&QFV$TJ2BX^AU%1W;;>?H5E?GJ^O%=XM?9F=GML2#5ZRPV6&QFW$823NH^C({FO MP[9]4&YIN4BR\662RR76BZS7&ZYPG*EY2K+U99K+-=:KK-<;
fG:/L!L%0CE LN%EHLL%ULNL5QJ MN4*RY66JRQ76ZZQ7&NY{H%[<5.C+0.AW;BXl?@ZGI2!'-,RD'EMZ\RB MW-
)R@>5"RT66BRV76"ZU7&;YW'*%Y4K+59;K+==8KK5<]H(/X]DR$'HE@^5& MQFWDV*0,Y'AW]J;9f,;\8UOK0;FEY0+++A9;+++!=;+K%
<;KG,4&RXV.VTBRO4F2S9ZN_AT+BO/P]C%G*SKM%U@NM%QDN=AR8>52RV66RRU76*ZT7&6YVG*-Y5K+=0_<2PN*=-3!/V\>MR{'ZKXL-L[.WS.3;K;9]CDEM;+K!
<;+G(5RRQ66*RU76:ZV7&.Y]H%[M>7\]';>WW&"YD7$;D3:I!3G^_VM!_C9?"S(_]/819VM!*!=8+K1<9+G85:RW66ZRTW6&YDW$803FI!CF4MR+&M!:';A[0/,UH)0+K!
<;+G(4:R]66ZQZX%W?QVUH0RHV,6X^ODTDMR FM!9G7MLXL MRBTM%U@NM%QDN=ARB>52RV66RRU76*ZT7&6YVG*-Y5K+=2_],-Z,V<5/KV2P MW,BXC1R;U(*
<_(Y;D!-;"T*YI>4"RX66BRP76RZQ7&JYS'*YY0K+E9:K+%=:,MKK%<;]G.5:RW4/W$L+BG34P7(CXS;B:U(:+U[3/+UH)0 M+K!<-:+G(4:R[66ZUI2D3R[H&AK02@W,FXC
MQR:U(+>/7Y=CKZH%F=>VSS')+2T76"ZT7&2YV'*)Y5++99;++5=8KK1<9;GZ M@9ON]SL^V3DXV:P%H<.VENLLUUMNL-S(N(W0FM2^G/SS:D'FA]H^T6PM".4"
MRX66BRP76RZQ7&JYS'*YY0K+E9:K+%=:,KK%<^\"]O+^>CMM:,K#5RRQ66*RU76:ZV7&.YUG*=Y7K+#98;&;>1>9,&D!/9_')B&T HM[1<8+G0
M5JRS66:RW76:ZWW&"YD7$;T39I #G9L@'D MRXKD\|\%F&SXHM[1<8+G04:R{66ZRS76VZPW,BXC<":|'N<_%'|'O/P]O%E^5TH%U@NM%QDN=ARB>52
MRV66RQ^XPTE\'1X>)$DO6]M=N1:R[66ZRSW_]+V)MQ6VD:0%^%X7W; M9I*4RA75C]@P$O,\|;E2RE8T);HNTF38(TB @'6N5G,Z/U;,+:0+P7B
M0V'YP7(CXOZEU|FW?1]W+]>6DE5:RW66ZRTW6&YDW"S)3B=)MGCC]9:%PQ>H[<%&^SXL MM[=<:+G(_'>'E^TQ\-R>\N%EHLL%ULNL5QJN; M^Q_5-^__?
7E[%VQ7=]?RX?#Q=G8J__EXHY4?E@LLM[=<:+G(4:R[66ZRS76VZPW,BX60Z>3W+P?'$#;=-1_"/&HDUR@>7V
ME@LM%UDNMEQBN=1RF>5RRQ66*RU76:ZV7&.YUG*=Y7K++98;&3>+MHM)M"V7 MA'PP*099M:M&"T$L%QRYZ>[&JV_O_SU>
(=K;N:'E{LO%EDLLEUHNLUQNN<)R MI>4]R]66:RS76]ZS7&^YP7(CXV:Q]6H26Z\6/Y$M'VFD-1^6"RRWMUQHN42RZ66RRR76ZZP7&FYRG*UY1K+M9;K+-=;;K#)-
GBW=;;/X#1 MH@_+!4=NQ042RZ66RRR76ZZP7&FYRG*UY1K+M9;K+-=;;K#< MR+A9;/UM$EOK*CR^[&C(K[]R^*_PEXlO#V\7NQM?N)[MN4=
[0"RWMUQHN42RZ66RRR76ZZP7&FYRG*UY1K+M9;K+-=;;K#\N\%EHLL%ULNL5QJN4*RY66JRQ76ZZQ7&NYSG*]Y0;+C8QF\&VG MDS*1T\6;O#?
=@KU;,0XVR@5'[M&S'EY=/+=820>'EHLL%ULNL5QJN4*.MRY66JRQ76ZZQ7&NYSG*]Y0;+C8R;9=:D-N1T8VW(YS\1]851VS/-
UHJ4*RY66JRQ76ZZQ7&NYSG*]Y0;+C8R;9=IN MDFE_5;/(,KP]P6RSR -W___[>X1]^_5=@)T^23!;&D*YR'*QY1++I9;++)=; MKK!
<;;G*W)__YXS[$.*FFT4H@QRY1_%V^O5W=_^>)LM#:%<9+G85:RW66ZRTW6&YDW"S>)]4A=Z^7SH LGF9\^%L6 M4I-HH++>W7&BYR'*QY1++I9;+++)=;KK!<;;G*LL-
EAL9-TND2>?"Z;K.#W*,WM9Y4"XXHX7;QA^B\[A&@K/2@7'+DUAQ!M M6P?E(LO%EDLLEUHNLUQNN<)RI>4]RI66:RS76]ZS7&^YP7(CXQ['VV[2UK%_MU!,QQ36-
BZ<9ER]B<]I1+K#5:RW66ZRTW6&YDW"S)=I,D6ZX J6^N_W4XO/U'T\N[F M^L,?
YQROWSU:]'P^YVP'",4"R^TM%UHNLEQLN<1R]>4RR^66*RQ76]ZR7&VYQG*MY3K+]98;+#'FP_,!9;M(=!>\|%YW)_]WN+QY+HGW]DT"
MRT66BRV76"ZU7&;YW'*%Y4K+59:K+==8KK5<9[G>LL- MEAL9-TNR2?OC(v;KVD36G.1:H[<%F^T(>N'!4[8'1P;+G(4:R[66ZRS76VZPW,BX669-
JD#N7O]%.V"+\/8$DUQPY)9WP.3(MT'*1Y6++)99++9=9+K=<8;G2>]^+.V"YW(-RD>5BRR662RV762ZW7&&YTG*5Y6K+-99K+==9 MKK?<8+F1<:,Q/E@YMB0?E
LOM+1=:+K)<;+G85!:8XX%;LI-E.S5RRQ66*RU76:ZV7&.Y MUG*=Y7K++98;&3?+M$GGQMFZS@U?M;CZ(3'+5[@]"FV5!^7VE@LM%UDNMEQB
MN=1RF>5RRQ66*RU76:ZV7&.YUG*=Y7K+#98;&3?+RTG?QlEO=U]_WKE\6^!!-MN\N%EHLL%ULNL5QJN4*RY66JRQ76ZZQ7&NYSG*]Y0;+C8Q{G&3G MDY:/\
[4M'ZOVUY:US=E&N\N%EHLL%ULNL5QJN6*(_=H(^F9!\/0 MJ97E:LLUEFLMUUFNM|Q@N9%QL\R:M'N4RR^66*RQ76]ZR7&VYQG*MY3K+]98;++#& M;'LPS+FM$*%
<8+F]Y4+++19;+++9=8+K5<9KG<(T,&AY2++Q99++)=:+K-<;KG"51VS--42RZ66RRR76ZZP7&FYRG*UY1K+M9;K+-=;;K#> 6;[!HR-
!RD>5BRR662RV762ZW7&&YTG*5Y6K+-99K+==9 MKK?<8+F1<:/LFM2)G*^M$UE5B[6L,0\L6R?RPGN]6*C%HE<26BZR7&RYQ"!MY3+++Y98K+%=:KK)
<;;G&5:RW66ZRTW6&YDW"S))M4C MY^NJ1U:=ZK_=(90+CMR:'3!;_T&YR*QY1++I9;++)=;KK!<;;G*H_5A=OR_Z2'3#;#4*YX,@M[X#9P@_*19:++9=8+K5<
M9KG<42RZ66RRR76ZZP7&FYZL@'] MKM6Z.'OFP3!T<+-Z<&L'=Y;K+3=8;F3<+)%VDT1:O ..WNNU/&!]7-EBC@=N MQ4X7'1Q:+K)<;+G$4ZR_66&RRR,FZ6:9/.
MC8MUG1N^:G'U@V&6KW![%-HJ#\KM+1=:++K)<;+G$4ZR_66&RPW,FZ6EY.^C[O7]Q,^ZUS^P|^R))-<8+F]Y4+++19;+++9=8 M+K5<9KG<^G(,'1J9;G:/CA<'7UZ>1?
U[]\O./OM^5^_^)S>'=7;2=_M_OV?NZ^^>?+|ZO3O]>G]|[_Y@_G^'S|?_G@H+F]^?/_QT\G5X=T=^>W7K^_>_MP,W|'W_Z_8O;ZY__^ZO3KT|>7-
_>7G_X]>5/AN\WAYO[7!CI^;OKZ|OC%_<#_M_G-]\S^_7G W_P]02P,$%_@ O8$T63L8PBO0-P 60X !X;"]W_M:W)K&ULK5=M;!LV$/XKA!84"=!8HMYLL;!VFG1-M#>L0-
,OZF,%HFZA$>B1EM_]^1TJ1WR@M_?S%%]fF]1\|S1]WIQCLA?Z@U11K|_M+_NN)MY;Z\V=[ZO%FI9$#<2&7K^@?[;B0D*O0W_ML?
M"&T&6X$(4ROZB76,;>&A1*2W*QAD8E(S7_^1G$X@#!YQV.(2-0WC]$'Z+)="S%#DEC#6CFPL,&>H,:QDT:'[6$NPS\|/03D9SQE4+7 M?P]E;M
#E6@NRA(B_+@FD}:L]P(3KE62"Q1ZV L:Y/K>ZH)*\#[%CT]WJ/K MJQMTA7RDS%V%&$=/G&GU_F#C[!6H%.$Y;%X=K<>^!E6&F[!H%,OJ!6&' ARB MKX+KM4*?>$[S8P
?PM'&)'RD#2SL1?RCX@,4!>]1&(2Q@1#\]>Y1#YVH35%D M\:(.O!E1;(&@_"AG1:5ICGA54DFTD'>N<-5HL1O-E{4[M2$+.O'@O5=4;DW M?2<;3H,/+JD7
CL2'K?"XS|TZ5|0Q0HXE6@I18D6D&3&*SA[*(II8R(G'.8I4F S>Q84ML^.,CGU,N MH QV'O[A)0__A<"_I(:Z,/>G'RW#8CFMV0+QV9%X?S;M5444.C(2D-@S.MP M,<-
TXPK'Z.R\1*,(G^3NW"C%H3MQ6!]$\>]K?)-*GJS M$;U.A\.L3\>^)^/^INS0H84F16_LXW,RZ2 YI>RPPD$ZP!W=#>]f,NYORMV< M>R.=G+^6#M8.*R=K_^ C'3[?5G9V4?!"
J'ZV[3=>>CCW8J.-F?F;G)?OSO M8>]AZRN1*P8'P'!+@ P&0^_FZSFF7FBQL:/ L] P6-C+-WW-^;MU-5ES,,CEU M4J7R8>]5<6H9E@<\|Z9W%EQD6.FI6+HR%X 3ZY11-
_"\H9MAPIQH8M>N1#3A MA:*$P95 LL@R+)Y.@?+5U/&=]<(U6:,*++C1),=++F(.ZR:^$GKDU2D(R8))P MA@0LILZ)?SSS0^-@+7X26,F-,3)4[CB _-Y/S9.IX)B*@$"L#@?7G
69 J4'2 MH"!T:O)A3 M.7_1JK+U'|074O&L)|E/1&1.,1*5$>Q=&TI!'"\0,$/T"5G M*M41,1U.$\#5^.B3$JR3*Q_?HUX7>1^<*,OF[+5LEV* =S#P+QS+',4P=_;^7(if B=Z_M\X?
>IS:F/8$U>]JWH.N|&A>]@,,.E.IH!C3N*'UUJPXl3!5:D:YUN555MJ MRO,.]7GF@7N(_-,#2?NPR;G7:O0'W(<>]#'6Y++=M?$'I8H] MJGD<=[?*X!]D$B4V(VO%>,*):7^=.G-
=>74|@#&XNV.K#QB(ZV1-MBLR'L)6-+L;OI'*+A<"L7:G=Kf^]LK[0FD2#9Z)! MGV]MT/KBWA-:D_MS0>1WUAW_0Z]ABQ;]8$>RNV;!.-S2K+M1CF<@EK9+D2CF M!5-
E$5]OUIW0B:W_M]9/38=DR_QGF++*]NL1B29A$%!8:TCL8Z8A$V;&4$\5S M6_3?<:,5;"#M,=9<'PACH_07G:CTQ!]1]8_074$L#!!0 (+V!-%E349]I M7 ,)X. 9 >&PO=V]R:W-
H965T43&W4BF+*]L6<0HY%\>L *IV-HSG6*HIW]JB MX(3DY1GMN3C1G.YD1"K<8_YS 1D[S"W7.B[WY% 8I*)=RKX?KU'' M;!^\F]E2D=+0=EP16)0$0#,$7]|852F MW0!)
(V@*VJJ4ORCB4MO%[$SSMZ MB7SG/?(<+^@@M/S]=+^'CE\K[!I\|_PS>35YD[*< 6@/?DQA*72|>3G1]CZZS MC,6EQFR#[B!F6TK^5V&WP G3T4**+HE+!D$W _TFN!
(%CF%N]4==*!I@17__MY8,./UWR# 36$BNHQ0KZT*,F-G'3Y%?,EY#036 M*CZLBP|?W=SAD&(-!-82:UR+-1[5]D6 .!M<1RG:>; MA#.XO2O(EG"@7M|\(Y ;^P&9RWN-BY
;B M%1&QNH 0N&\OO; #>G.P^'I^ M>NEI#876KMM|MM[=?=7%(82;""TMF!/|SBW]^;S9_[V3RX=H=?A!M,P=^1- M3MUM-
V[Z.?"M:8"$HK.CLKPAUZMUDW5M6HMGZPO=?)D.X@FF[-R^8+XE5* , M-@K2N1RK9XZ7S5 YD:PP_<0#DZH[,<-4-9# =8#:WS FCQ/] W5+&OT"4$L# M!!0 (++V!-
%FDN. W01((#4R 0-9 >&PO=V]R:W-H965T!>+,J!C2]2GLXF!Q*QB5;$R'4QF>BX6>|'8 MM"YTOH,2X@28'[^43)LNB2J)SCOKF^[8$9^B9)^P2!T5W]W/\C\7=UFV#++Y/
MQM/%^Y.[Y7++^]NQL<7673=++%Z6R>38N_N9GEDW19J)G?GBWF>99>;S::C,_"M5JM_-DE'TY.++YOO?S^_4GIY/$;?QW= MWBW7WSB[>#=:/[.OV?
+O\|JY|=79DW(|FF33Q6@V#?+LYOW)A_9;.^RL-[@\ MXH]1=K]X[N=@_52^SF9_KK_0U^]/6NL]RL;9U7)-L,7_OF67V7B\EHK]^&>) MGCR-N=[P^9\?
=;EY\L63^9HNLLO9^!^CZ^7=^Y/A27"=W:2K\?*OLWN5E4^H MM,:N9N/%YK_!??G8UDEPM5HL9Y-RXV(/)]/IP__3[^4++\6R#=G?/!F&Y07CL M!IUR@\ZQ&W3+#;K';M K-
^AM;]#;LT&_W*[_[B#]\\/>.\KCC[N]^7F?/?QB;7XKHW297KS+9_=! MOGY\X:W_L/G5WFQ?_#*.INL4?EGFQ=^.BNV6%U_NTCQ[\{'X/;X.+F>3(MR+ M=!-/-
\&7Y>SJS^#W^?K+1?!+E"W3T7CQ:_$W8C(?SWYDF?.0XOM__Q(%Q_SG MK^..EL6>K?\SJW(OY,->A'OVHA\FDV7=XM 3^SZYKMC7_{=?@\K{Q+[J ML^(U?7IAP|
<7]E/H|%AIT6K\%82OLUNS0I7_S#_/\-&BU|VX>^3>/L]MB M\|-YIV:S<7QF[?J?IP_]QC_^9?LOG3YG4[K_R;?TJ+EZ[3WKNY/G{TL.Y7 M\>>>>W+\YG4[;U\\NO-
;W'GZYZ&S\3I-_WGXD.?1]#8KCL?+X.N/X/GC/J<_-M-M_^<)_FU\'_V((,]#*;+/ZWYOE\?!B_6S_^>@[R=C%/K[+W)\4D8Y'EWI*3 MB__ZCW;_]=]UF2*QB,0$B4D2BTE,D9@F,4-
B"8E9"/RW7W*=]>G7_QE-?F: MY<'L)IB5Q_G;(M?+VD/H1R_5-*HD%I&8(#%)8C&)*1+3)&8>L-X&6Y]%KLX M,PW#7C$1^?8\A+L/;.MYT_6-S#IA=OTF_97EQ3AMD
MWf\.K3(@GD^NLKJ.N8%FV;.Q"(2$R0F22PE,45BFL3._S9\'I{3\\Y6PFH>_MU&V?M@=;$0-VS(E8_REB?6_$-A//Q5.P:HI;7J%IID@L(C%!8I+$8A)3)*9)
MS/1W#DC;AZR#C[""^1S@!&3P%9. -R..UFD5=,KR;-DT&B44D)DA,DEA,8HK$ M-(D9$DM(S$*8$\WA4S2'KWQQ94CFF0B$A,D)DDL)C%%8IK$#(DE)&8AS,GW
M^5.^SIF!+%ZJ;51)+"(Q06+R?&>R-.QT6EM3JGCW46&GOWTU09$IG>';/?:.MVZ=7AAPR(3&+84\YIW]+QU@.-Q*4/FI_K-'M;5T#4,A0.50SI):@FJ4T-
VK/WOUO'[Y\|\N;K9FJ9KJ>4BV"T6*SJ#U%^JW'(M2"U"-8%JLM2>'PZZK7#W0(6.JE!-HY!!M035++*6YB0RK1(;'7:\|_A5\&DU' MDJ6D-HM>I7$622U"-8%J$M5B5%.HIE'-
H%]":I;2W,16%9GV;W=DVFA)!M4B M5!.H)E$M1C6%:AK5#*HEJ&8IS0U[U9=1^PLS+5DW17LS]!:AFD U66KNN>D@
MW)XTHZ485-.E|OR\N=W9*]@=,@$U2REN6&KZC-M?W_&FONGW_?.A='2#*!% M]"903:):C&H^U32]&51+4,U2FIO#HW3|K_V7!AM\Z!.A&H"U22]Q:BF4$VC
MFD&U!-4LI;EAKYI%;7^UZ"5S8,1QA&H1]@E4DZ7V?"X6M[+HP6A5#-4IH;MJHKU/96%9RN>?%?+F((GF;5K=-P^Q+S<0]+T'VSE.8&KFHV MA?
YFTO]5Q$:SVC]3'V@<++]3.A&H"U22]Q:BF4$T?^!5K!S^R-*\[$+YTPP3= M?TMI;@2K*E-X?)7IF%/6O]W/;G.*5IU0+4(U@6H2U6)44ZBF4F(&33; M;$*U"-4$]DE4BU%-
H9H^\"O6Z0>3S;*+M=%\^;8)^BPIJ:E!K&I0X*U"@_M#3ZE>1',X&.>3:=9_EMP>3?*;@+Q/;M:K0>T#7Z_N1E=977G%Q_](S5.+%]5
M0C6!.A+58E13J*91S:!:@FJ6TMQ45U6I\+6K4B%:E4^U"-4$]DE4BU%-H9I& M-8-J",I92G/#*7E6E0D]5ZHBY--J..K [GG0'.Q_DOJQ[7+O5VGYJT7OF.MX.VIE
M0C6!.A+58E13J*91S:!:@FJ6 MTMRP5_VKSH&5I5Y0>"S) SYU2__(C7.)5]U03:):C&H^U32]&51+4,U2FIO+ MJI35\9>R#E^).@#L+:]=^C=LG%NT6H5]$M5B5%.HIE'-
H%]":I;2W%P^N]&:.MM\WQ:SXYWE.M].]3X_DR>_LU]OYK[W8V#NPL;=@8^_!QMZ$C;T+&WL;MG]' MVZI3M:TZW=<^.4;,6]@6H9I -8EJ,:HI5-.H9E
M035++;6]8]T97Q]_H.F(2 M[@=\Y;=+_[:-HXG6LE!-HE],:@K5-*H95$M0S5*:&\VJEM7QWU#.6?.NF(?+ M;#R:9T&T*H[^C[-P.9H6T^:11.O95+?WC-#[SOW,D#'5*BF4[N+?
G.=S^@$;.#*E33]&90+4$U2VEN(*O&5-=?>/K+;/KF^57ARV+]NAHO MBZEKW;G.1[_6.))HIPK5!*I)5(M13:&:1C6#:@FJ64ISDUMUJK]OO5Q5%RU0
MH5J$:@+5)*K%]*903:..0;4$U2REN6&O"E1=;V?CB.N^?]!Q6-$'"%*H)5),'M7OAVN+^'+$]-[HE!-
_\3S,NB>)*AF*M)*$;KK4_'>L18=,4,U2FANVJFG4]2^LU.SB+5H:0K4(U02JR5)SWN,\M/Z^Y>HO6@5!-HY!!M035++*6YB:SJ0-TC%GA,/!WTZH.(%H)0+4(U@6H2U6)4
M4]W=-;BV_GW0Z(&U1)4LY3F9K\[_G3]S1]W+8B;67Z3C?:=#Z*\'U2+4$\@ MFD2U&-54[3V?5.Z;YA+5(E03["91+48UA6H:U0R]:AF*E8]Z_O)1>?KZ MSLODR#5F?
K/8)+_\"- M\X8V@5!-'O>"Q.B@"M4T]HGC7I $'=0>'-1-2%7*Z?D|%'4)N5DM5WFV..2E MT_HW($O564"_,^B>;Z<$K>"@FJAY"OWNSGL4\KAG&J/!IE!-HYHY(@5)T$'M
MP4'=7_^]VM9KS(RFHXFITEM#M!V*#%|"903:);C&H*U32]&51+ M4,U2FAOEJD;3>"W;M?70U@V1:@F4$VB6HQ["M4TJAE42U#-4H-1]K&T_O9
MVI7Y@<9A1:LI["8.0%3[5_V0Z'[$

MMYA;ISQZ[MK#/54>C&/\=!Q54V.AJ1Q[6W34^Y*P)344U0T'PM-)5X*=!L6 MZ(|)>1KH3E MX+=AP?^"E%KNEAXBAS0&%*NMU-E7OI5RWX;7KP|)=#;*90*AJ6F-2=5>* M9!L6R>^BU3)YYISWC*9(H:#X6 MFD]%.(V93 M:P:W+W1&;-2ZT(=O]*5$2(UNPQ]FKPU!>>$U^,LT]#0UL\M K27^;.EZO9* M*<$=6()_CE,^2Q9Q^*,HRMG.UN5S$B?Q1=W'P5.0SCM3>PV_VV^,%1M&FO[! M]V&\[^UO5B5$ZFD'7G">)EE.;D[*\+=Q5KRITU-W?R0>,SF]H0RNI VQ5(8&, M^3]&5G;D5G8.7,P.;&S$#$[%[GG-QWA);R:UUL<=H+S[3?+/V[+F)>WVHH M)A|VX*4$2?*#XQR0^,XAV8R.,;YSI4-%\+#25TYVMX\%XQB*#N@Z/BN9C MH:G$2\O*0P.)^R^>]V;."O$^>A-OF>^DLH(;*Q.YM0D9-FI,T3%6S!U9##B; M8J!)T>?5"[2HO8X],/*#*O2QT%1^I-!WX%7P_?'P@#V/,+;QU$35|5AH*J]2 MQSNC4|9$U,TX]&@^%II*O*P;'+AN,(Z);.TOAGYSR[,N\F.AJ3]\DI6("UIE$2&AP1!LT_BW3,=8ZG=E;>+"QH'C(1CD8VW1NHJ+Y6&@JK[(Z M<=D)@Z*+N@.?%6L\>H45Q9HI(C> M*<.BZE,.5#0?"TTE7A8_KJ;X,0V+[?WW8@WISQJ&8.%(CDRO/72AQA'!9'M[?)YW J*J/4&%IK*D*PW7$VIL;>./G#++8QO@#11*Q4L-/6E K)2\;P3!D8/M=:\3*If/A:82+PL@3U, &0;&&DXIHMN;)6"CQA0=HY;Q9"WCP4J:3".CU_%\ MI P*39)0ZPXLM(JDP+LH78&5DE]SCO'I9T?;3[4NVWI:OEFI\?DW?M3*M794F8ZLU=`X)T$<896?)[ 6GUAV),I=7+L*J3/%F5KX>Z2_(\B5I<(+Z_3Y)\&PO=V]R:W-H965T^K^0HRIC]B@!S?+(3,F.;A7/]JD, 2ZY2E M?A@$/3]C//?&0SMW*\=#L=8IS^%6$K7.,B9W4TC%=N11[WGB*U^NM)GPQ\." M+>$.]+?B5N+(KU$2GD&NN,B)A,7(F]"K&8V-@[6XY{!5!\_$2'D0XM$,/B6 *9B+]SA.]&GD# MCR2P8.M4?Q7,3U`)ZAJ\N4B5_27;RC;PR'RMM.@9V20\;5I7]5(<:.^$ M0U@YA,<,\0F']*(K-"2F95US30;#Z78FFL'8C:.^W$VJ3X|&=B=F^/?Y?/6?ZE>-"Z=+XNYFEQT7LH MR\=W_7XQ>]"+N#C)'G5:/7*7YBNXK#[-[_O%8Z{CV]6@Q;SO#0:3_B).TM[E M^>IK'_++\VQ9SI-4?\B=8KE8O/FW*SW/GB|Z;N_[%SXF]P]E_87^Y?EC?*JO M=/G\4->?=;?*+?)0]=%DJ5.KN\N>K^X[!1X4]8/>/W1#\76Q\[]4OYG&5? MZD_D[45O4&^1GNM961-Q]=^3OM;S>2U5V_%'@_8V<]8#M5_^K@>K%U^]F,]Q MH:^S^7^2V_+A6N?:L-I7JS^=9Z;YPYZSFQ9E-FB-M&5QMP2)QU__'7YMOQ-8 =_3" *9X!T!8-@,&!XI8-0,&\TI8-P.&\!8-(_MF!P[8-H.F\3K+09<'KI&0+-FP-GN@,E+/[C!]Y__<&JZ%;CJS))TKH_;L]\>C2IQI67-P]QKM}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|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~:H)5 M0+42U"-4DJBE*.QNI3;&'8VX=@0;9 MJ.:CFD"U -5"5(M03:*:HC2S-=]X>VBN/NlNL(]#T&M5\5!.H%C3:]I'_9+O[M'!2B3Y^'&8WFS]CFHY1 M6'X?I_H,W=OW1NBDT:H]E%-49I9 M\&WP/+0'SWM'.-5]>9&D50,K;S)@2!SAF@6HAJ$:I) M5%.49OZ-LS9\OU8^-5A9)%IJX=@6H^]@E4"U M1+4(U22]*4HS.Z<-G4=< MZ#Q"0V=4\U%-H%J :B&J1:@F44U1FMD:;>@\]PD)GN]2Y.P[60/G5_660'.A>Z?7.F+Y]!\=$-$:@6H%[(M:A&J251 3E&96_]9?2K8'T$>?*[{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

MJX4+ XB)QX>)[|/&I+O;TG;XN1%RQ',,UCMPNOOGB[I/*X,86T,.@BYV_*3 M6¥MDESFL"V;8SP|YKIN(N(!1ISD+GJD8D!$5?*PXL#*:<[%TX0X$)H4H5*!-MP9IT;8A4OQW<=CVHY5HGYI)0-K?+X'Z/Z^$[P*IU!KD0C<$.<8%AOZ1:,R7O M3,<.ML$74%"W'Y>E<3A5=-GNW) UP=Y,DG&A4J;:-&VR"@W[@F5@1_'I#.ZZ M*$, M2YRTT@YG1;26@\K1MTPLA,FQ ,\Z#^R+>U%MK%O=M=DTS2&ZJ;3<1W0 MWU1SVINRUZ_2#4K^7.C/L8PO;'^1-08P]3:N3LM2+#\)/I4Y M\8%8H_MMD@U*9F !3)'AF2O/)9N27HN4C6^A5.2TRW'/G!#W_MVW6>,LD4%9NF3>T?\RJ_VG'4?2O+|EMEU[#78_WV/G:3-Z=@,CY^DU%R_!JK M,)62QF^R=@LE3V. [NFWVS[S49UB>AC>/6UF&KB09PJ!V0[W!$%NNDP7C.A>:R M[LUXFC+YXLQEY#4=FS_9MO3-^)1E="[T8P,.R+K]C:5\GB?-J'M8B'K4NOT5 MIM>.FQ.UR<5ERA8L'=5=-1W;9F -)FM] 6$7N,.7'\$X#O,C@&%Y, -<8Q{&P M// 3?'KH?!R&>>MYD1[*Z;$B=A,\;4&Q+|NP$@2 VYC M>8"!U0)6.Y#?GP=JRL^) (MA5S!OV!.-(DF (U*_1N,869T8/O[!P9Z2*$H2 M/P*8WT$480@\C3B",0 /&:!)%|CVX\SX*5^^1-8?20$3.8T.P6BP^0"X99K>]9!:G#=95M?DX&ME\+4IN_]0:H=R1 MI38EK]RF68WLQ@B^L&LAJK(81:>GZ:CD4@T^?]I=ZV,P@U=B;R26KF=?L=W M*7[:W\}?})GN65C[*0E:O9X/F_T(,6"F5+,4OL3@;G Z87>N??VLC?VE5\>(^ M-[HHS@;C[8'OPE0R/[A|]R$?^*-M|E3\\1MW(&>#]-1=<"F-K9HSFNMSQ_@L MW,G;K;K25[*HA+GDE?C+Z'HCUL"-X- ", &!T-D)W<\0!R M-B G[PAY|R\!RS32W:[$2: C %D? #3(^TKG 60"(),C0OX;!9 I@$R/!GG! M[3] G +(*2WD5U[51GBF+[652MBP06> *Z/E^L*M;$)U9X1U!^YWAC. -J-% MNY0V=Y;2JG;WU3? <[2EA3WV*NNI36KS[NBRY>6W:@EPIZ3[&O5!R7->,.L2$ M1B%6RI54KI.6O'"VLY6IMVV#.PE><6E8B(F\,B862QC"!\.5Y?G!W49*&1,[MQ>5?I;16NQO^U65B|)O(A7SF# <1O0N23,;%0KM6SL-7V|DK%+L5CQ>Y%7AM9 M2=&*(Q+.*F-@HV\=1L!O!K8OB[3_LW-IV>C-&+AD3R^2MGU$K2(A$,B8VR95\ M;Z_[R6B$S! 1F^'*%|M|=)% [UY45=%4&2$M2L ?^TN[C MD!0B8BGX9TQ6O_/-BR:97PF7C;8AD2 B8D',RTVA7X5@\>GXY,DUCH*'3]P$ M26)"7F$\6O&C|H-6\VK>](FH][>?ABK=#6U;@A)++& MA-@:KMR1KCOVU<3"N^/RVY*&F' FA%@OH+|SH"$FTDM,K!=81{5D'2.|IQ-1ZZ;FC#CO$ M&.DE?L>*I,/A(*G$QY@582>7HN*R;&,B|<3'F2'9@89SB$@O"?5@5P_FT(^B MMPK\!#DF(78,Q&RU[P29)]$V#<0,L]P$N2S!F$F+">?AW MF3;IF<5K/YO(/S'8E1BN23 MDA<^_=V077!C7GU(O_.B%BRL*%(DGY1\ROZ@[NZ*!)/2BR>0\16.$-,N 2, M6#Q=F'-,R;)9%'8>8B+Ql,3B.1S&Z+K?R#DIL7.;WMO=8B,6TJ5!*R.;$?,. MDB)%SDFI*Y\MH]HW31\;PF2>RCW>LDIS"OZJH.,9%SIM253^NF M^ZSRS=^OS1,08B+G3-]CC*T/LY5H3)%HL3R><-TB7IMFHSCSHA2UN7;S0\Q MD7RFQ/(!@X.^K8>82$#3=UTP%F(.?4!#"3"2@*?7] (19MSHDN]96$!PJ/6R MU=*1A:;$%D*80W8;8B(+38DMA#&O LP,62BC7D?0L3BL_/(D(0R8@GAX?5P M7"M#$LJ()80QPW&M#$DHHQY^ZYL%&.XO^LJ0A#+]X3> V7X+))D,2RHZT-JW! M;&4>&9)0=]RI']=G;EJO)&1(0AGU%I_IBO>P]PX@V_&$$L(8'X3-E1ZAB24 M4:\LZ%]7V-F]SY"$9N1K#(+YOF$34*U\|VE=MUXY0A:;$5MH#_-2N+BZ>L/O M\ )GB(DL-"-?W-,"1'1O95$S.!-B(@O-B"VTASE?+D7S?C#;'@@QD85FY.)B M@I6]I"3$1:.42] Z%BKVMW0D81FU!+:7[7:C8@$-&L$-&I.MI_+<12*K'X MZBYOW?Z<%_F=8?Z/O] (XBA/_CLFR+HH+M^]6W6B^V+UCOGL__O-_4$I.#!!0 M (+V!-%FT*7[,P@(HY : >&PO7W)E;',O=V|R:V)O,VLN>&UL M+G)E;'/-VKUNHT 81N%;L;B X/F? 6<6IMDF[R@U8SMB.8AL+6&UR|VLYA7W0 M%MM$O!4;$!^G>H1@'G_5PW\|ZT[#_NT\+#Z.A],P;O;C>/[1ML-F7X_KX;$[MU|/ERK;KC^OOLNQW[7FI>5_O:FN7R|CVJS.:\}?IF8N7SW/GXG==ONVJ3^[MS>]C/8W_&-S^Z?KW85_KV"Q>UOVNC|NF_3C<3@_M]6 >+L;Q?/K]NF?7TW3 MSAUD$63G#W((03Y^8,"@L+\01%! M1D!O2[VM@-Z6>EL!O>WD95M ;TN]K8#>EGI; ;TM];8">EOJ;07TMM3;"NAM MJ;<5T-M2;RN@MZ/>3D!O1[V=@- Z,>CL!O=WD8XF WHYZ.P&|'25V GH[ZNT$ M]';4VPGH[;BW$]#;46\GH+>GWEY ;T^]O8#>GGH_;T]?8">OO)OVX!O3WU M](@)Z>^KM!?3VU-L+Z.VIMQ?0YU-O+Z!WH-Y!0.] O8. WH%Z!P&]_4. GH' MZAT$] Z3GY4">@?]'03T#M0[",@=]'<0T#M0[R"@=Z3>44#O2+VC@-Z1>DBWDE [T2] MDX#>B7HG ;T3]4X">B? JG03T3M0["B=]'<2T#M--@L*Z)VH=Q+0.U'O)*!W MIMY90.],O;. WIEZ9P&],_7. GIGZIT%],|4.POHG:EW%M {4^LH'>;,/86 MT#M3]RR@=Z'>14#O0KV+@- Z%>A^OM\=?EU\D).U>DO4$L#!!0 (M +V!-%F,Q2:?3@("'V]?3;,>XLIW<4(?XU=UG<|WL MZWN;B>MKG3?3&.P8UN%8([F]^62W14,?5I\/A6??3>,F<;,WR>KC:>,Q:Y/4 M\]QW31WB>O8XMK^EK)\3TGARV>-WW>ROXH8D>S/AN/+G@.=S7Q^MU M"U_J(>[*#GWFPU-O?7]^Q!L]3MMMU]AV:AZ&>"3ULI-UZW?6AJ%/3T6OSB>'-M>,/\]E? G+^4.1<8=|ZY;?9Q8LZ^(^YE),?3ZSD6LBYTYU_Q-3&6OOC|I'';.MK6W_,CM>|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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref) {e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 141 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */// /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 143 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html4025641false1490false6 falsefalseR1.htm995200090 - Document And Entity InformationSheethttp://www.ibioinc.com/role/DocumentDocumentAndEntityInformationDocument And Entity InformationCover1 falsefalseR2.htm995200100 - Statement - Consolidated Balance SheetsSheethttp://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsConsolidated Balance SheetsStatements2 falsefalseR3.htm995200105 - Statement - Consolidated Balance Sheets (Parenthetical)Sheethttp://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParentheticalConsolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - Consolidated Statements of Operations and Comprehensive LossSheethttp://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossConsolidated Statements of Operations and Comprehensive LossStatements4 falsefalseR5.htm995200300 - Statement - Consolidated Statements of Stockholders' EquitySheethttp://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityConsolidated Statements of Stockholders' EquityStatements5 falsefalseR6.htm995200305 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)Sheethttp://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParentheticalConsolidated Statements of Stockholders' Equity (Parenthetical)Statements6 falsefalseR7.htm995200400 - Statement - Consolidated Statements of Cash FlowsSheethttp://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlowsConsolidated Statements of Cash FlowsStatements7 falsefalseR8.htm995210101 - Disclosure - Nature of BusinessSheethttp://www.ibioinc.com/role/DisclosureNatureOfBusinessNature of BusinessNotes8 falsefalseR9.htm995210201 - Disclosure - Basis of PresentationSheethttp://www.ibioinc.com/role/DisclosureBasisOfPresentationBasis of PresentationNotes9 falsefalseR10.htm995210301 - Disclosure - Discontinued OperationsSheethttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDiscontinued OperationsNotes10 falsefalseR11.htm995210401 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995210501 - Disclosure - Financial Instruments and Fair Value MeasurementSheethttp://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementFinancial Instruments and Fair Value MeasurementNotes12 falsefalseR13.htm995210601 - Disclosure - Significant TransactionsSheethttp://www.ibioinc.com/role/DisclosureSignificantTransactionsSignificant TransactionsNotes13 falsefalseR14.htm995210701 - Disclosure - Promissory Note ReceivableSheethttp://www.ibioinc.com/role/DisclosurePromissoryNoteReceivablePromissory Note ReceivableNotes14 falsefalseR15.htm995210801 - Disclosure - Investments in Debt SecuritiesSheethttp://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesInvestments in Debt SecuritiesNotes15 falsefalseR16.htm995210901 - Disclosure - Finance Lease ROU AssetsSheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsFinance Lease ROU AssetsNotes16 falsefalseR17.htm995211001 - Disclosure - Operating Lease ROU AssetsSheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsOperating Lease ROU AssetsNotes17 falsefalseR18.htm995211101 - Disclosure - Fixed AssetsSheethttp://www.ibioinc.com/role/DisclosureFixedAssetsFixed AssetsNotes18 falsefalseR19.htm995211201 - Disclosure - Intangible AssetsSheethttp://www.ibioinc.com/role/DisclosureIntangibleAssetsIntangible AssetsNotes19 falsefalseR20.htm995211301 - Disclosure - Accrued ExpensesSheethttp://www.ibioinc.com/role/DisclosureAccruedExpensesAccrued ExpensesNotes20 falsefalseR21.htm995211401 - Disclosure - DebtSheethttp://www.ibioinc.com/role/DisclosureDebtDebtNotes21 falsefalseR22.htm995211501 - Disclosure - Finance Lease ObligationsSheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinance Lease ObligationsNotes22 falsefalseR23.htm995211601 - Disclosure - Operating Lease ObligationsSheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperating Lease ObligationsNotes23 falsefalseR24.htm995211701 - Disclosure - Stockholders' EquitySheethttp://www.ibioinc.com/role/DisclosureStockholdersEquityStockholders' EquityNotes24 falsefalseR25.htm995211801 - Disclosure - Earnings (Loss) Per Common ShareSheethttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareEarnings (Loss) Per Common ShareNotes25 falsefalseR26.htm995211901 - Disclosure - Share-Based Compensation Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationShare-Based CompensationNotes26 falsefalseR27.htm995212001 - Disclosure - Fraunhofer SettlementSheethttp://www.ibioinc.com/role/DisclosureFraunhoferSettlementFraunhofer SettlementNotes27 falsefalseR28.htm995212101 - Disclosure - Income TaxesSheethttp://www.ibioinc.com/role/DisclosureIncomeTaxesIncome TaxesNotes28 falsefalseR29.htm995212201 - Disclosure - Commitments and ContingenciesSheethttp://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes29 falsefalseR30.htm995212301 -*

Disclosure - Employee 401(k) PlanSheethttp://www.ibioinc.com/role/DisclosureEmployee401KPlanEmployee 401(k) PlanNotes30 falsefalseR31.htm995212401 - Disclosure - Subsequent EventsSheethttp://www.ibioinc.com/role/DisclosureSubsequentEventsSubsequent EventsNotes31 falsefalseR32.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes32 falsefalseR33.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes33 falsefalseR34.htm99920402 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies34 falsefalseR35.htm99930303 - Disclosure - Discontinued Operations (Tables)Sheethttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTablesDiscontinued Operations (Tables)Tableshttp://www.ibioinc.com/role/DisclosureDiscontinuedOperations35 falsefalseR36.htm99930403 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies36 falsefalseR37.htm99930603 - Disclosure - Significant Transactions (Tables)Sheethttp://www.ibioinc.com/role/DisclosureSignificantTransactionsTablesSignificant Transactions (Tables)Tableshttp://www.ibioinc.com/role/DisclosureSignificantTransactions37 falsefalseR38.htm99930803 - Disclosure - Investments in Debt Securities (Tables)Sheethttp://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTablesInvestments in Debt Securities (Tables)Tableshttp://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities38 falsefalseR39.htm99930903 - Disclosure - Finance Lease ROU Assets (Tables)Sheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTablesFinance Lease ROU Assets (Tables)Tableshttp://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets39 falsefalseR40.htm99931103 - Disclosure - Fixed Assets (Tables)Sheethttp://www.ibioinc.com/role/DisclosureFixedAssetsTablesFixed Assets (Tables)Tableshttp://www.ibioinc.com/role/DisclosureFixedAssets40 falsefalseR41.htm99931203 - Disclosure - Intangible Assets (Tables)Sheethttp://www.ibioinc.com/role/DisclosureIntangibleAssetsTablesIntangible Assets (Tables)Tableshttp://www.ibioinc.com/role/DisclosureIntangibleAssets41 falsefalseR42.htm99931303 - Disclosure - Accrued Expenses (Tables)Sheethttp://www.ibioinc.com/role/DisclosureAccruedExpensesTablesAccrued Expenses (Tables)Tableshttp://www.ibioinc.com/role/DisclosureAccruedExpenses42 falsefalseR43.htm99931403 - Disclosure - Debt (Tables)Sheethttp://www.ibioinc.com/role/DisclosureDebtTablesDebt (Tables)Tableshttp://www.ibioinc.com/role/DisclosureDebt43 falsefalseR44.htm99931503 - Disclosure - Finance Lease Obligations (Tables)Sheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTablesFinance Lease Obligations (Tables)Tableshttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligations44 falsefalseR45.htm99931603 - Disclosure - Operating Lease Obligations (Tables)Sheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTablesOperating Lease Obligations (Tables)Tableshttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligations45 falsefalseR46.htm99931803 - Disclosure - Earnings (Loss) Per Common Share (Tables)Sheethttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTablesEarnings (Loss) Per Common Share (Tables)Tableshttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare46 falsefalseR47.htm99931903 - Disclosure - Share-Based Compensation (Tables)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationTablesShare-Based Compensation (Tables)Tableshttp://www.ibioinc.com/role/DisclosureShareBasedCompensation47 falsefalseR48.htm99932103 - Disclosure - Income Taxes (Tables)Sheethttp://www.ibioinc.com/role/DisclosureIncomeTaxesTablesIncome Taxes (Tables)Tableshttp://www.ibioinc.com/role/DisclosureIncomeTaxes48 falsefalseR49.htm99940201 - Disclosure - Basis of Presentation (Details)Sheethttp://www.ibioinc.com/role/DisclosureBasisOfPresentationDetailsBasis of Presentation (Details)Detailshttp://www.ibioinc.com/role/DisclosureBasisOfPresentation49 falsefalseR50.htm99940301 - Disclosure - Discontinued Operations (Details)Sheethttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetailsDiscontinued Operations (Details)Detailshttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables50 falsefalseR51.htm99940302 - Disclosure - Discontinued Operations - Reconciliation of Loss from Discontinued Operations (Details)Sheethttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetailsDiscontinued Operations - Reconciliation of Loss from Discontinued Operations (Details)Details51 falsefalseR52.htm99940303 - Disclosure - Discontinued Operations - Reconciliation of Assets and Liabilities Held-for-Sale (Details)Sheethttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetailsDiscontinued Operations - Reconciliation of Assets and Liabilities Held-for-Sale (Details)Details52 falsefalseR53.htm99940304 - Disclosure - Discontinued Operations - Reconciliation of Cash Flows from Discontinued Operations (Details)Sheethttp://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetailsDiscontinued Operations - Reconciliation of Cash Flows from Discontinued Operations (Details)Details53 falsefalseR54.htm99940401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)Sheethttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetailsSummary of Significant Accounting Policies (Narrative) (Details)Detailshttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables54 falsefalseR55.htm99940402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)Sheethttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetailsSummary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)Detailshttp://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables55 falsefalseR56.htm99940501 - Disclosure - Financial Instruments and Fair Value Measurement (Details)Sheethttp://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetailsFinancial Instruments and Fair Value Measurement (Details)Detailshttp://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement56 falsefalseR57.htm99940601 - Disclosure - Significant Transactions (Details)Sheethttp://www.ibioinc.com/role/DisclosureSignificantTransactionsDetailsSignificant Transactions (Details)Detailshttp://www.ibioinc.com/role/DisclosureSignificantTransactionsTables57 falsefalseR58.htm99940602 - Disclosure - Significant Transactions - Summary of Asset Acquisition (Details)Sheethttp://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetailsSignificant Transactions - Summary of Asset Acquisition (Details)Details58 falsefalseR59.htm99940701 - Disclosure - Promissory Note Receivable (Details)Sheethttp://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetailsPromissory Note Receivable (Details)Detailshttp://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable59 falsefalseR60.htm99940801 - Disclosure - Investments in Debt Securities (Details)Sheethttp://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDetailsInvestments in Debt Securities (Details)Detailshttp://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables60 falsefalseR61.htm99940901 - Disclosure - Finance Lease ROU Assets (Details)Sheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetailsFinance Lease ROU Assets (Details)Detailshttp://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables61 falsefalseR62.htm99941001 - Disclosure - Operating Lease ROU Assets (Details)Sheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetailsOperating Lease ROU Assets (Details)Detailshttp://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets62 falsefalseR63.htm99941101 - Disclosure - Fixed Assets (Details)Sheethttp://www.ibioinc.com/role/DisclosureFixedAssetsDetailsFixed Assets (Details)Detailshttp://www.ibioinc.com/role/DisclosureFixedAssetsTables63 falsefalseR64.htm99941102 - Disclosure - Fixed Assets - Carrying Value and Accumulated Depreciation (Details)Sheethttp://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetailsFixed Assets - Carrying Value and Accumulated Depreciation (Details)Details64 falsefalseR65.htm99941201 - Disclosure - Intangible Assets (Details)Sheethttp://www.ibioinc.com/role/DisclosureIntangibleAssetsDetailsIntangible Assets (Details)Detailshttp://www.ibioinc.com/role/DisclosureIntangibleAssetsTables65 falsefalseR66.htm99941202 - Disclosure - Intangible Assets - Carrying Value and Accumulated Amortization (Details)Sheethttp://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetailsIntangible Assets - Carrying Value and Accumulated Amortization (Details)Details66 falsefalseR67.htm99941203 - Disclosure - Intangible Assets - Estimated Annual Amortization Expense (Details)Sheethttp://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetailsIntangible Assets - Estimated Annual Amortization Expense (Details)Details67 falsefalseR68.htm99941301 - Disclosure - Accrued Expenses (Details)Sheethttp://www.ibioinc.com/role/DisclosureAccruedExpensesDetailsAccrued Expenses (Details)Detailshttp://www.ibioinc.com/role/DisclosureAccruedExpensesTables68 falsefalseR69.htm99941401 - Disclosure - Debt - Credit Agreement (Details)Sheethttp://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetailsDebt - Credit Agreement (Details)Details69 falsefalseR70.htm99941402 - Disclosure - Debt - Equipment Financing (Details)Sheethttp://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetailsDebt - Equipment Financing (Details)Details70 falsefalseR71.htm99941403 - Disclosure - Debt - Equipment Financing Future Minimum Payments (Details)Sheethttp://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetailsDebt - Equipment Financing Future Minimum Payments (Details)Details71 falsefalseR72.htm99941404 - Disclosure - Debt - Credit and Security Agreement (Details)Sheethttp://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetailsDebt - Credit and Security Agreement (Details)Details72 falsefalseR73.htm99941405 - Disclosure - Debt - Credit and Security Agreement Future Minimum Payments (Details)Sheethttp://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetailsDebt - Credit and Security Agreement Future Minimum Payments (Details)Details73 falsefalseR74.htm99941406 - Disclosure - Debt - Insurance Premium Financing (Details)Sheethttp://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetailsDebt - Insurance Premium Financing (Details)Details74 falsefalseR75.htm99941501 - Disclosure - Finance Lease Obligations (Details)Sheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetailsFinance Lease Obligations (Details)Detailshttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables75 falsefalseR76.htm99941502 - Disclosure - Finance Lease Obligations - Finance Lease Cost and Supplemental Information (Details)Sheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetailsFinance Lease Obligations - Finance Lease Cost and Supplemental Information (Details)Details76 falsefalseR77.htm99941503 - Disclosure - Finance Lease Obligations - Future Minimum Payments (Details)Sheethttp://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetailsFinance Lease Obligations - Future Minimum Payments (Details)Details77 falsefalseR78.htm99941601 - Disclosure - Operating Lease Obligations (Details)Sheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetailsOperating Lease Obligations (Details)Detailshttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables78 falsefalseR79.htm99941602 - Disclosure - Operating Lease Obligations - Operating Lease Cost and Supplemental Information (Details)Sheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetailsOperating Lease Obligations - Operating Lease Cost and Supplemental Information (Details)Details79 falsefalseR80.htm99941603 - Disclosure - Operating Lease Obligations - Future Minimum Payments (Details)Sheethttp://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetailsOperating Lease Obligations - Future Minimum Payments (Details)Details80 falsefalseR81.htm99941701 - Disclosure - Stockholders' Equity (Details)Sheethttp://www.ibioinc.com/role/DisclosureStockholdersEquityDetailsStockholders' Equity (Details)Detailshttp://www.ibioinc.com/role/DisclosureStockholdersEquity81 falsefalseR82.htm99941801 - Disclosure - Earnings (Loss) Per Common Share - Components of Earnings Per Share (Details)Sheethttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetailsEarnings (Loss) Per Common Share - Components of Earnings Per Share (Details)Detailshttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables82 falsefalseR83.htm99941802 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)Sheethttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsEarnin (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)Detailshttp://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables83 falsefalseR84.htm99941901 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetailsShare-Based Compensation - Share-Based Compensation Expense (Details)Details84 falsefalseR85.htm99941902 - Disclosure - Share-Based Compensation - Stock Options (Details)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetailsShare-Based Compensation - Stock Options (Details)Details85 falsefalseR86.htm99941903 - Disclosure - Share-Based Compensation - Stock Option Activity

(Details)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetailsShare-Based Compensation - Stock Option Activity (Details)Details86 falsefalseR87.htm99941904 - Disclosure - Share-Based Compensation - Options Outstanding and Exercisable (Details)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetailsShare-Based Compensation - Options Outstanding and Exercisable (Details)Details87 falsefalseR88.htm99941905 - Disclosure - Share-Based Compensation - Assumptions Used to Determine Fair Value of Options Granted (Details)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetailsShare-Based Compensation - Assumptions Used to Determine Fair Value of Options Granted (Details)Details88 falsefalseR89.htm99941906 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)Sheethttp://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetailsShare-Based Compensation - Restricted Stock Units (Details)Details89 falsefalseR90.htm99942001 - Disclosure - Fraunhofer Settlement (Details)Sheethttp://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetailsFraunhofer Settlement (Details)Detailshttp://www.ibioinc.com/role/DisclosureFraunhoferSettlement90 falsefalseR91.htm99942101 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)Sheethttp://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetailsIncome Taxes - Components of Income Tax Expense (Benefit) (Details)Details91 falsefalseR92.htm99942102 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)Sheethttp://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetailsIncome Taxes - Deferred Tax Assets and Liabilities (Details)Details92 falsefalseR93.htm99942103 - Disclosure - Income Taxes - Tax Credit Carryforwards (Details)Sheethttp://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetailsIncome Taxes - Tax Credit Carryforwards (Details)Details93 falsefalseR94.htm99942104 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)Sheethttp://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetailsIncome Taxes - Effective Income Tax Rate Reconciliation (Details)Details94 falsefalseR95.htm99942201 - Disclosure - Commitments and Contingencies (Details)Sheethttp://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetailsCommitments and Contingencies (Details)Detailshttp://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies95 falsefalseR96.htm99942301 - Disclosure - Employee 401(k) Plan (Details)Sheethttp://www.ibioinc.com/role/DisclosureEmployee401KPlanDetailsEmployee 401(k) Plan (Details)Detailshttp://www.ibioinc.com/role/DisclosureEmployee401KPlan96 falsefalseR97.htm99942401 - Disclosure - Subsequent Events (Details)Sheethttp://www.ibioinc.com/role/DisclosureSubsequentEventsDetailsSubsequent Events (Details)Detailshttp://www.ibioinc.com/role/DisclosureSubsequentEvents97 falsefalseAll ReportsBookAll Reports ibio-20240630.xsdibio-20240630_cal.xmlibio-20240630_def.xmlibio-20240630_lab.xmlibio-20240630_pre.xmlibio-20240630x10k.htm ibio-20240630x10k001.jpgibio-20240630x10k002.jpgibio-20240630x10k003.jpgibio-20240630x10k004.jpgibio-20240630x10k005.jpgibio-20240630x10k006.jpgibio-20240630x10k007.jpgibio-20240630x10k008.jpgibio-20240630x10k009.jpgibio-20240630x10k010.jpgibio-20240630x10k011.jpgibio-20240630x10k012.jpgibio-20240630x10k013.jpgibio-20240630x10k014.jpgibio-20240630x10k015.jpgibio-20240630x10k016.jpgibio-20240630x10k017.jpgibio-20240630x10k018.jpgibio-20240630x10k019.jpgibio-20240630x10k020.jpgibio-20240630x10k021.jpgibio-20240630x10k022.jpgibio-20240630x10k023.jpgibio-20240630x10k024.jpgibio-20240630x10k025.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 146 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ibio-20240630x10k.htm": { "nsprefix": "ibio", "nsuri": "http://www.ibioinc.com/20240630", "dts": { "schema": { "local": ["ibio-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["ibio-20240630_cal.xml"] }, "definitionLink": { "local": ["ibio-20240630_def.xml"] }, "labelLink": { "local": ["ibio-20240630_lab.xml"] }, "presentationLink": { "local": ["ibio-20240630_pre.xml"] }, "inline": { "local": ["ibio-20240630x10k.htm"] } }, "keyStandard": 448, "keyCustom": 116, "axisStandard": 36, "axisCustom": 0, "memberStandard": 49, "memberCustom": 91, "hidden": { "total": 59, "http://www.xbrl.org/us-gaap/2024": 45, "http://www.ibioinc.com/20240630": 7, "http://xbrl.sec.gov/dei/2024": 7 }, "contextCount": 402, "entityCount": 1, "segmentCount": 149, "elementCount": 984, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1109, "http://xbrl.sec.gov/dei/2024": 37, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R3": { "role": "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_fjolJEex8EiWwMYIOd0Qtw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R4": { "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:OperatingExpenses", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R5": { "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EXuIgGEa_keM0E26nWxx_A", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EXuIgGEa_keM0E26nWxx_A", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical", "longName": "995200305 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_10_7_2022_LHURR_2jNUa9kAM0Y1QOhA", "name": "ibio:NumberOfSharesTenderedInReverseStockSplit", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R8": { "role": "http://www.ibioinc.com/role/DisclosureNatureOfBusiness", "longName": "995210101 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentation", "longName": "995210201 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations", "longName": "995210301 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef":

"Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210401 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement", "longName": "995210501 - Disclosure - Financial Instruments and Fair Value Measurement", "shortName": "Financial Instruments and Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactions", "longName": "995210601 - Disclosure - Significant Transactions", "shortName": "Significant Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable", "longName": "995210701 - Disclosure - Promissory Note Receivable", "shortName": "Promissory Note Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities", "longName": "995210801 - Disclosure - Investments in Debt Securities", "shortName": "Investments in Debt Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets", "longName": "995210901 - Disclosure - Finance Lease ROU Assets", "shortName": "Finance Lease ROU Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets", "longName": "995211001 - Disclosure - Operating Lease ROU Assets", "shortName": "Operating Lease ROU Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ibioinc.com/role/DisclosureFixedAssets", "longName": "995211101 - Disclosure - Fixed Assets", "shortName": "Fixed Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssets", "longName": "995211201 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ibioinc.com/role/DisclosureAccruedExpenses", "longName": "995211301 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ibioinc.com/role/DisclosureDebt", "longName": "995211401 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations", "longName": "995211501 - Disclosure - Finance Lease Obligations", "shortName": "Finance Lease Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations", "longName": "995211601 - Disclosure - Operating Lease Obligations", "shortName": "Operating Lease Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquity", "longName": "995211701 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare", "longName": "995211801 - Disclosure - Earnings (Loss) Per Common Share", "shortName": "Earnings (Loss) Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensation", "longName": "995211901 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement", "longName": "995212001 - Disclosure - Fraunhofer Settlement", "shortName": "Fraunhofer Settlement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock", "unitRef": null, "xsiNil": "false",

"lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxes", "longName": "995212101 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies", "longName": "995212201 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlan", "longName": "995212301 - Disclosure - Employee 401(k) Plan", "shortName": "Employee 401(k) Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ibioinc.com/role/DisclosureSubsequentEvents", "longName": "995212401 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920402 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables", "longName": "99930303 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930403 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "longName": "99930603 - Disclosure - Significant Transactions (Tables)", "shortName": "Significant Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_ccZFFd2mlU216IqycbJzUA", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_ccZFFd2mlU216IqycbJzUA", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables", "longName": "99930803 - Disclosure - Investments in Debt Securities (Tables)", "shortName": "Investments in Debt Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables", "longName": "99930903 - Disclosure - Finance Lease ROU Assets (Tables)", "shortName": "Finance Lease ROU Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsTables", "longName": "99931103 - Disclosure - Fixed Assets (Tables)", "shortName": "Fixed Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables", "longName": "99931203 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ibioinc.com/role/DisclosureAccruedExpensesTables", "longName": "99931303 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.ibioinc.com/role/DisclosureDebtTables", "longName": "99931403 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_DebtInstrumentAxis_ibio_TermNote2024Member_Oli_TskTQkCX9qV4648Lmw",

"name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_DebtInstrumentAxis_ibio_TermNote2024Member_OIi_TskTQkCX9qV4648Lmw", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables", "longName": "99931503 - Disclosure - Finance Lease Obligations (Tables)", "shortName": "Finance Lease Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables", "longName": "99931603 - Disclosure - Operating Lease Obligations (Tables)", "shortName": "Operating Lease Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables", "longName": "99931803 - Disclosure - Earnings (Loss) Per Common Share (Tables)", "shortName": "Earnings (Loss) Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables", "longName": "99931903 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesTables", "longName": "99932103 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "longName": "99940201 - Disclosure - Basis of Presentation (Details)", "shortName": "Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "ibio:OperatingCapitalDeficit", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R50": { "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "longName": "99940301 - Disclosure - Discontinued Operations (Details)", "shortName": "Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_3_2022_To_11_3_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_ContractDevelopmentAndManufacturingOr "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R51": { "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "longName": "99940302 - Disclosure - Discontinued Operations - Reconciliation of Loss from Discontinued Operations (Details)", "shortName": "Discontinued Operations - Reconciliation of Loss from Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_ContractDevelopmentAndManufacturingOr "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R52": { "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails", "longName": "99940303 - Disclosure - Discontinued Operations - Reconciliation of Assets and Liabilities Held-for-Sale (Details)", "shortName": "Discontinued Operations - Reconciliation of Assets and Liabilities Held-for-Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_ContractDevelopmentAndManufacturingOr "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_ContractDevelopmentAndManufacturingOr "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "longName": "99940304 - Disclosure - Discontinued Operations - Reconciliation of Cash Flows from Discontinued Operations (Details)", "shortName": "Discontinued Operations - Reconciliation of Cash Flows from Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_ContractDevelopmentAndManufacturingOr "name": "us-gaap:Depreciation", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R54": { "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "99940401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2022_88q3DU_o4USIhwDzcF91Kw", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_88q3DU_o4USIhwDzcF91Kw", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "longName": "99940402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)", "shortName": "Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",

"order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "ibio:PercentageOfCollateralRequired", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "ibio:PercentageOfCollateralRequired", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "longName": "99940501 - Disclosure - Financial Instruments and Fair Value Measurement (Details)", "shortName": "Financial Instruments and Fair Value Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_31_2024_To_5_31_2024_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_ContractDevelopmentAndManufacturingOr
gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementMember_3IaHroTeIU28naYscw4uSg", "name": "us-gaap:ProceedsFromSaleOfBuildings", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R57": { "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "longName": "99940601 - Disclosure - Significant Transactions (Details)", "shortName": "Significant Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_jPVnGtXDjEynd-PQrDwE_w", "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcMember_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleGroundLeaseAgreementMember_BnvBaox0KkeHEpuwjs7zZg", "name": "us-gaap:ProceedsFromSaleOfBuildings", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R58": { "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "longName": "99940602 - Disclosure - Significant Transactions - Summary of Asset Acquisition (Details)", "shortName": "Significant Transactions - Summary of Asset Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_9Tg_0-F-20S4_1fmlsgO3Q", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AcquiredSeriesPreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_gt5wWjOdVUSMB-1NwnvuHQ", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R59": { "role": "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "longName": "99940701 - Disclosure - Promissory Note Receivable (Details)", "shortName": "Promissory Note Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_94_92vWW8ECoHuKoZofL9g", "name": "us-gaap:NotesReceivableNet", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R60": { "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDetails", "longName": "99940801 - Disclosure - Investments in Debt Securities (Details)", "shortName": "Investments in Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_jPVnGtXDjEynd-PQrDwE_w", "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R61": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "longName": "99940901 - Disclosure - Finance Lease ROU Assets (Details)", "shortName": "Finance Lease ROU Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lG-1nD-xyUqnlNeey9QP6Q", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock", "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R62": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails", "longName": "99941001 - Disclosure - Operating Lease ROU Assets (Details)", "shortName": "Operating Lease ROU Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_StatementGeographicalAxis_ibio_SanDiegoMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndBuildingMember_qYN8lox-I0O-xpfqqVrkuA", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R63": { "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails", "longName": "99941101 - Disclosure - Fixed Assets (Details)", "shortName": "Fixed Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails", "longName": "99941102 - Disclosure - Fixed Assets - Carrying Value and Accumulated Depreciation (Details)", "shortName": "Fixed Assets - Carrying Value and Accumulated Depreciation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_i0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "longName": "99941201 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_jPVnGtXDjEynd-PQrDwE_w", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_optp8kqAQkmb9gDYVQRiWg", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R66": { "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails", "longName": "99941202 - Disclosure - Intangible Assets - Carrying Value and Accumulated Amortization (Details)", "shortName": "Intangible Assets - Carrying Value and Accumulated Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_jPVnGtXDjEynd-PQrDwE_w", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_optp8kqAQkmb9gDYVQRiWg", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R67": { "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails", "longName": "99941203 - Disclosure - Intangible Assets - Estimated Annual Amortization Expense (Details)", "shortName": "Intangible Assets - Estimated Annual Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_optp8kqAQkmb9gDYVQRiWg", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_optp8kqAQkmb9gDYVQRiWg", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails", "longName": "99941301 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued

Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "longName": "99941401 - Disclosure - Debt - Credit Agreement (Details)", "shortName": "Debt - Credit Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_6_30_2023_CvviDS4k2ECGNNBVvtxbOw", "name": "us-gaap:ShortTermBankLoansAndNotesPayable", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestNationalBankMember_us-gaap_DebtInstrumentAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAgreementWithWoodforestNationalBankMember_rExXvtTrbUgOmA93EqvF9w", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R70": { "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "longName": "99941402 - Disclosure - Debt - Equipment Financing (Details)", "shortName": "Debt - Equipment Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_10_12_2022_us-gaap_TypeOfArrangementAxis_ibio_EquipmentFinancingMasterLeaseAgreementMember_gsX_inRBfkW4_KMQW_ekPg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_10_12_2022_us-gaap_TypeOfArrangementAxis_ibio_EquipmentFinancingMasterLeaseAgreementMember_gsX_inRBfkW4_KMQW_ekPg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails", "longName": "99941403 - Disclosure - Debt - Equipment Financing Future Minimum Payments (Details)", "shortName": "Debt - Equipment Financing Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:SecuredDebtCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_TypeOfArrangementAxis_ibio_EquipmentFinancingMasterLeaseAgreementMember_f2MRzpvlQUafMNGw3s9OVg", "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R72": { "role": "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "longName": "99941404 - Disclosure - Debt - Credit and Security Agreement (Details)", "shortName": "Debt - Credit and Security Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:ProceedsFromNotesPayable", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_16_2024_srt_CounterpartyNameAxis_ibio_LoebTermSolutionsLlcMember_us-gaap_DebtInstrumentAxis_us-gaap_MediumTermNotesMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAndSecurityAgreementMember_j0LdUC_otk6KD1plf9v0JQ", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R73": { "role": "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "longName": "99941405 - Disclosure - Debt - Credit and Security Agreement Future Minimum Payments (Details)", "shortName": "Debt - Credit and Security Agreement Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:NotesPayableCurrent", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_srt_CounterpartyNameAxis_ibio_LoebTermSolutionsLlcMember_us-gaap_DebtInstrumentAxis_us-gaap_MediumTermNotesMember_us-gaap_TypeOfArrangementAxis_ibio_CreditAndSecurityAgreementMember_w7JVXRnsKUO5CGUljFzA2g", "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R74": { "role": "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "longName": "99941406 - Disclosure - Debt - Insurance Premium Financing (Details)", "shortName": "Debt - Insurance Premium Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:ShortTermNonBankLoansAndNotesPayable", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_30_2023_srt_CounterpartyNameAxis_ibio_FirstInsuranceFundingMember_us-gaap_TypeOfArrangementAxis_ibio_InsurancePremiumFinancingAgreementMember_66Fz7KizoU2lRFj2Cp_few", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R75": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "longName": "99941501 - Disclosure - Finance Lease Obligations (Details)", "shortName": "Finance Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_4_1_2021_To_4_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_cqwu-Vkd4kWP_ITSAg2LZA", "name": "us-gaap:VariableLeasePayment", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2021_To_4_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_cqwu-Vkd4kWP_ITSAg2LZA", "name": "us-gaap:VariableLeasePayment", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "longName": "99941502 - Disclosure - Finance Lease Obligations - Finance Lease Cost and Supplemental Information (Details)", "shortName": "Finance Lease Obligations - Finance Lease Cost and Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R77": { "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails", "longName": "99941503 - Disclosure - Finance Lease Obligations - Future Minimum Payments (Details)", "shortName": "Finance Lease Obligations - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "ibio:FinanceLeasePaymentsPrincipal", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "ibio:FinanceLeasePaymentsPrincipal", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "longName": "99941601 - Disclosure - Operating Lease Obligations (Details)", "shortName": "Operating Lease Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_10_2021_srt_StatementGeographicalAxis_ibio_SanDiegoMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandAndBuildingMember_kBgwf0OptUe5yVKdAOUCbw", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R79": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails", "longName": "99941602 - Disclosure - Operating Lease Obligations - Operating Lease Cost and Supplemental Information (Details)", "shortName": "Operating Lease Obligations - Operating Lease Cost and Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails", "longName": "99941603 - Disclosure - Operating Lease Obligations - Future Minimum Payments (Details)", "shortName": "Operating Lease Obligations - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div",

```
"div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "longName": "99941701 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_osr51IVz0EWY0ejMS_5bEA", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R82": { "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "longName": "99941801 - Disclosure - Earnings (Loss) Per Common Share - Components of Earnings Per Share (Details)", "shortName": "Earnings (Loss) Per Common Share - Components of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "99941802 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Earnings (Loss) Per Common Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails", "longName": "99941901 - Disclosure - Share-Based Compensation - Share Based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Share Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "longName": "99941902 - Disclosure - Share-Based Compensation - Stock Options (Details)", "shortName": "Share-Based Compensation - Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_J9B64iNAVEOnz4xRahKeFQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_TH3_xcFEhEOFSEvpYOLcdA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R86": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails", "longName": "99941903 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)", "shortName": "Share-Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_FNmC-Ck350CGx5_jP2JiTg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_J9B64iNAVEOnz4xRahKeFQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R87": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails", "longName": "99941904 - Disclosure - Share-Based Compensation - Options Outstanding and Exercisable (Details)", "shortName": "Share-Based Compensation - Options Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R88": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "longName": "99941905 - Disclosure - Share-Based Compensation - Assumptions Used to Determine Fair Value of Options Granted (Details)", "shortName": "Share-Based Compensation - Assumptions Used to Determine Fair Value of Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_jPVnGtXDjEynd-PQrDwE_w", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R89": { "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "longName": "99941906 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)", "shortName": "Share-Based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "Duration_1_26_2024_To_1_26_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_B-Buw95YqEWhF2P75_CeaQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_26_2024_To_1_26_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_B-Buw95YqEWhF2P75_CeaQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails", "longName": "99942001 - Disclosure - Fraunhofer Settlement (Details)", "shortName": "Fraunhofer Settlement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_jPVnGtXDjEynd-PQrDwE_w", "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_oU1Bxt6wZE6BiGVOOiLmFQ", "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ibio:GainLossRelatedToLitigationSettlementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R91": { "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "longName": "99942101 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)", "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_BXvSA9-
```

RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "longName": "99942102 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails", "longName": "99942103 - Disclosure - Income Taxes - Tax Credit Carryforwards (Details)", "shortName": "Income Taxes - Tax Credit Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "As_Of_6_30_2024_iI0m7BpwwUmuv-lHqr-90w", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2008_ff02EOi9skqNu5GuXh09RQ", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } }, "R94": { "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "longName": "99942104 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)", "shortName": "Income Taxes - Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_1uoAFNTmLUOamgLuZAyCig", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99942201 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_IhkbmsrBTUyTKYZrYTITroQ", "name": "us-gaap:OtherResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_IhkbmsrBTUyTKYZrYTITroQ", "name": "us-gaap:OtherResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_BXvSA9-RLECbOaVxUlnnbg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails", "longName": "99942301 - Disclosure - Employee 401(k) Plan (Details)", "shortName": "Employee 401(k) Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_RetirementPlanNameAxis_us-gaap_RetirementPlanNameOtherMember_SCDikhX9fkWqpgXs2Duv5A", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_RetirementPlanNameAxis_us-gaap_RetirementPlanNameOtherMember_SCDikhX9fkWqpgXs2Duv5A", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_DCTP_cbFqUy8qCvVHoPIyQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "longName": "99942401 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_J9B64iNAVEOnz4xRahKeFQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_16_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gFIr7yacl0KxR4gOJq9jZQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_CQ2QaI9FGUWrZN98Hdw_3Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ibio-20240630x10k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r297", "r1018"] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r113", "r119"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r101", "r103", "r108", "r1138"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r101", "r859"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1014"] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrual for Taxes Other than Income Taxes", "terseLabel": "Real estate taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes." } } }, "auth_ref": ["r166", "r1138", "r1180"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses", "verboseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r103"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "verboseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r103"] }, "ibio_AccruedStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AccruedStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount accrued for stock issuance costs incurred and payable to the sales agent.", "label": "Accrued stock issuance costs" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r43", "r213", "r680"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss),

and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r13", "r26", "r555", "r558", "r620", "r694", "r695", "r983", "r984", "r985", "r1001", "r1002", "r1003", "r1004"] }, "ibio_AcquiredFixedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AcquiredFixedAssetsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Fixed assets acquired through acquisition of assets.", "label": "Acquired Fixed Assets [Member]", "terseLabel": "Fixed Assets" } } }, "auth_ref": [] }, "ibio_AcquiredIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AcquiredIntangibleAssetsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy.", "label": "Acquired Intangible Assets [Member]", "terseLabel": "Intangible Assets" } } }, "auth_ref": [] }, "ibio_AcquiredPrepaidExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AcquiredPrepaidExpensesMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets acquired through asset acquisition.", "label": "Acquired Prepaid Expenses [Member]", "terseLabel": "Prepaid Expenses" } } }, "auth_ref": [] }, "ibio_AcquiredSeriesPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AcquiredSeriesPreferredStockMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Acquired Series A Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r919"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r114"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r712", "r1001", "r1002", "r1003", "r1004", "r1151", "r1217"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r932"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r932"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r932"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r932"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Reclassification adjustment for loss on available-for-sale debt securities recognized in net income", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r63", "r64", "r463"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Split", "negatedLabel": "Payments for fractional shares resulting from reverse stock split", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": ["r14", "r152"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrant issued to satisfy term note payable", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": ["r14", "r45", "r152"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile consolidated net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ibio_AggregateOfferingPriceInStockSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AggregateOfferingPriceInStockSalesAgreement", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate amount of proceeds from sales of common stock authorized through the medium of an investment bank, pursuant to an equity offering agreement.", "label": "Aggregate offering price in stock sales agreement", "terseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r966"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r890", "r901", "r911", "r944"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r893", "r904", "r914", "r947"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r967"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r932"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r939"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r894", "r905", "r915", "r939", "r948", "r952", "r960"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r958"] }, "ibio_AllianceGlobalPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AllianceGlobalPartnersMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Alliance Global Partners (AGP).", "label": "Alliance Global Partners [Member]", "terseLabel": "Alliance Global Partners" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r495", "r504"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r219", "r301", "r310"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of premiums on debt securities", "verboseLabel": "Amortization of premiums on debt securities", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r8", "r126", "r391", "r1161"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "definitionGuidance": "Amortization of Intangible Assets", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of intangible assets", "negatedTerseLabel": "Finite-lived intangible asset amortization", "verboseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense

charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r8", "r319", "r326", "r828"] }, "ibio_AmountRetainedFromProceedsOfLegalSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AmountRetainedFromProceedsOfLegalSettlement", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount retained from proceeds of legal settlement.", "label": "Amount Retained from Proceeds of Legal Settlement", "terseLabel": "Cash retained from legal settlement" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from the calculation of diluted loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r275"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r38"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r38"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r546"] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r320", "r321", "r322", "r323", "r324", "r1147"] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Purchase price allocated", "verboseLabel": "Investment in RubrYc", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": ["r846", "r1148", "r1149", "r1150"] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": ["r846", "r1148", "r1149", "r1150"] }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Liability for contingent consideration", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition." } } }, "auth_ref": ["r1147"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r320", "r321", "r322", "r323", "r324", "r1147"] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Summary of Purchase Price Allocation of Asset Acquisition", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": ["r1147"] }, "ibio_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AssetPurchaseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement [Member]", "label": "Asset Purchase Agreement [Member]", "terseLabel": "Asset Purchase Agreement" } } }, "auth_ref": [] }, "ibio_AssetPurchasingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AssetPurchasingAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Asset Purchase Agreement with Otsuka Pharmaceutical Co., Ltd.", "label": "Asset Purchasing Agreement [Member]", "terseLabel": "PD-1 Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r164", "r176", "r215", "r247", "r279", "r283", "r290", "r291", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r548", "r552", "r585", "r674", "r751", "r825", "r826", "r859", "r880", "r1046", "r1047", "r1166"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total Current Assets", "verboseLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r208", "r222", "r247", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r548", "r552", "r585", "r859", "r1046", "r1047", "r1166"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Held-for-Sale, Fair Value Disclosure", "terseLabel": "Fair value, fixed assets held-for-sale (Quoted prices)", "documentation": "Fair value portion of assets classified as held for sale." } } }, "auth_ref": ["r849", "r850", "r851", "r1152"] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "terseLabel": "Current assets held for sale (see Note 3 - Discontinued Operations)", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": ["r139", "r859"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "totalLabel": "Total current Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1", "r77", "r93", "r141", "r143", "r206", "r207"] }, "ibio_AtMarketIssuanceSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AtMarketIssuanceSalesAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group, LLC acting as sales agents.", "label": "At Market Issuance Sales Agreement [Member]", "terseLabel": "At Market Issuance Sales Agreement" } } }, "auth_ref": [] }, "ibio_AtMarketOfferingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AtMarketOfferingsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to At the market offerings.", "label": "At The Market Offerings [Member]", "terseLabel": "At-The-Market Offerings" } } }, "auth_ref": [] }, "ibio_AuctionSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AuctionSaleAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Auction Sale Agreement with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC.", "label": "Auction Sale Agreement [Member]", "terseLabel": "Auction Sale Agreement" } } }, "auth_ref": [] }, "ibio_AuctioneersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AuctioneersMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group, LLC, collectively known as the \"Auctioneers\".", "label": "The Auctioneers [Member]", "terseLabel": "The Auctioneers" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued

Audit Firm Identifier" } } }, "auth_ref": { "r884", "r885", "r897" } }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": { "r884", "r885", "r897" } }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": { "r884", "r885", "r897" } }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]", "verboseLabel": "Investments in Debt Securities", "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r71" } }, "ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized gains (losses) on available for sale debt securities.", "label": "Avaliable For Sale Debt Securities Realized Gains (Losses) [Table Text Block]", "terseLabel": "Schedule of realized losses on available-for-sale debt securities" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r955"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r956"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r951"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r951"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r951"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r951"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r951"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r951"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r954"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r953"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r952"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r952"] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Effective Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "ibio_BaseRentAbatementInFirstYearPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "BaseRentAbatementInFirstYearPeriod", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "documentation": "Base rent abatement period in the first year.", "label": "Base Rent Abatement In the First Year, Period", "terseLabel": "Base rent abatement period in year one" } } }, "auth_ref": [] }, "ibio_BryanCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "BryanCapitalMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Bryan Capital.", "label": "Bryan Capital [Member]", "terseLabel": "Bryan Capital" } } }, "auth_ref": [] }, "ibio_BryanTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "BryanTexasMember", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Bryan, Texas.", "label": "Bryan Texas [Member]", "terseLabel": "Bryan, Texas" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails"], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Improvements", "verboseLabel": "Facility", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Building [Member]", "terseLabel": "Mobile Office Trailer", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": ["r142"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r543"] }, "ibio_BusinessDayThresholdFollowingAtMarketEquityOfferingsToPayWoodforestPortionOfProceeds": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "BusinessDayThresholdFollowingAtMarketEquityOfferingsToPayWoodforestPortionOfProceeds", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold number of business days following the close of any at-the-market equity offerings for the Company to pay a portion of the net proceeds to Woodforest National Bank, as part of the credit agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Business Day Threshold Following At-the-Market Equity Offerings To Pay Woodforest Portion Of Proceeds", "terseLabel": "Days following equity offerings to use a portion of net proceeds as debt repayment" } } }, "auth_ref": [] }, "ibio_CantorFitzgeraldUnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CantorFitzgeraldUnderwritingAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Cantor Fitzgerald & Co. acting as the underwriter (sales agent) in an agreement to sell shares of the Company's common stock.", "label": "Cantor Fitzgerald Underwriting Agreement [Member]", "terseLabel": "Cantor Fitzgerald Underwriting" } } }, "auth_ref": [] }, "ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CapitalExpenditureIncurredForIntangibleAssetsPaid", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount paid for capital expenditures incurred for intangible assets during the previous year.", "label": "Capital Expenditure Incurred For Intangible Assets Paid", "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period" } } }, "auth_ref": [] }, "us-gaap_CapitalLeaseObligationsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalLeaseObligationsIncurred", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Lease Obligation Incurred", "terseLabel": "Increase in finance lease obligation for new leases", "documentation": "Amount of increase in lease obligation from new lease." } } }, "auth_ref": ["r35", "r36"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and equivalents", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r33", "r211", "r816"] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ibio_CashAndCashEquivalentsPlusDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CashAndCashEquivalentsPlusDebtSecurities", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents plus debt securities", "label": "Cash and cash equivalents plus debt securities", "terseLabel": "Cash and cash equivalents and marketable securities" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Disclosure of accounting policy for cash and cash equivalents,

including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r34"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash - end", "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning", "terseLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r33", "r132", "r243"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r132"] }, "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowFinancingActivitiesLesseeAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Other Information:" } } }, "auth_ref": [] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Cash, Uninsured Amount", "verboseLabel": "Cash deposits held in excess of FDIC insured amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r930"] }, "ibio_ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Chardan Capital Markets, LLC & Craig Hallum Capital Markets, LLC acting as a sales agent to sell shares of the Company's common stock.", "label": "Chardan Capital Markets LLC and Craig Hallum Capital Markets LLC [Member]", "terseLabel": "Chardan Capital & Craig-Hallum Capital" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Dr. Martin Brenner, Chief Executive Officer" } } }, "auth_ref": ["r1013"] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Mr. Felipe Duran, Chief Financial Officer" } } }, "auth_ref": ["r1013"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r927"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r925"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDisclosuresAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "Issuances of Common Stock" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r202", "r216", "r217", "r218", "r247", "r269", "r270", "r272", "r274", "r281", "r282", "r307", "r360", "r362", "r363", "r364", "r367", "r368", "r398", "r399", "r403", "r406", "r414", "r585", "r704", "r705", "r706", "r707", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r737", "r760", "r778", "r793", "r794", "r795", "r796", "r797", "r971", "r996", "r1005"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r216", "r217", "r218", "r281", "r398", "r399", "r401", "r403", "r406", "r412", "r414", "r704", "r705", "r706", "r707", "r834", "r971", "r996"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r58"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share of warrants", "verboseLabel": "Warrants, exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r415"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrants, shares exercised", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants, shares of common stock issued upon conversion", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r415"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r931"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r931"] }, "ibio_CollaborationAndLicenseAgreementAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CollaborationAndLicenseAgreementAgreementTerm", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreement, agreement term", "label": "Collaboration and license agreement, agreement term", "terseLabel": "Collaboration and license agreement, agreement term" } } },

"auth_ref": [] }, "ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CollaborationAndLicenseAgreementRoyaltyPaymentTerm", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreement, royalty payment term", "label": "Collaboration and License Agreement, Royalty payment term", "terseLabel": "Collaboration and license agreement, royalty payment term" } } }, "auth_ref": [] }, "ibio_CollaborationOptionAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CollaborationOptionAndLicenseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Collaboration, Option and License Agreement [Member]", "label": "Collaboration, Option and License Agreement [Member]", "terseLabel": "Collaboration, Option and License Agreement" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r546"] }, "ibio_CollegeStationInvestorsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CollegeStationInvestorsLlcMember", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to College Station Investors LLC.", "label": "College Station Investors LLC [Member]", "terseLabel": "College Station Investors" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r145", "r348", "r349", "r801", "r1038", "r1043"] }, "ibio_CommonStockAndSeriesEWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockAndSeriesEWarrantsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Common Stock and Series E Warrants.", "label": "Common Stock and Series E Warrants [Member]", "terseLabel": "Common Shares and Series E Warrants" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance", "verboseLabel": "Common stock, shares available for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r112"] }, "ibio_CommonStockMaximumFairValueOfSharesPurchasedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockMaximumFairValueOfSharesPurchasedPerTransaction", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum fair value of common stock shares that may be purchased in a single transaction, pursuant to the terms of the stock purchasing agreement.", "label": "Common Stock Maximum Fair Value of Shares Purchased Per Transaction", "terseLabel": "Fair value of common stock purchased in single transaction" } } }, "auth_ref": [] }, "ibio_CommonStockMaximumSharesDirectedForPurchase1": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockMaximumSharesDirectedForPurchase1", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $3.00 per share, but less than $20.00 per share.", "label": "Common Stock Maximum Shares Directed For Purchase1", "terseLabel": "Shares available for purchase when stock price closes between $3 and $20 per share" } } }, "auth_ref": [] }, "ibio_CommonStockMaximumSharesDirectedForPurchase2": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockMaximumSharesDirectedForPurchase2", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $20.00 per share, but less than $40.00 per share.", "label": "Common Stock Maximum Shares Directed For Purchase2", "terseLabel": "Shares available for purchase when stock price closes between $20 and $40 per share" } } }, "auth_ref": [] }, "ibio_CommonStockMaximumSharesDirectedForPurchase3": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockMaximumSharesDirectedForPurchase3", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $40.00 per share.", "label": "Common Stock Maximum Shares Directed For Purchase3", "terseLabel": "Shares available for purchase when stock price closes at or above $40 per share" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r870", "r871", "r872", "r874", "r875", "r876", "r877", "r1001", "r1002", "r1004", "r1151", "r1216", "r1217"] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "terseLabel": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r112"] }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "terseLabel": "Subscription receivable", "documentation": "Amount of subscription receivable from investors who have been allocated common stock." } } }, "auth_ref": ["r112", "r745", "r783"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "verboseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r112", "r737"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r112"] }, "ibio_CommonStockSharesIssuedAdditionalCommitmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockSharesIssuedAdditionalCommitmentShares", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of common stock shares the Company issued to Lincoln Park as \"additional commitment shares\" as consideration for participation in the stock purchasing agreement.", "label": "Common Stock Shares Issued additional Commitment Shares", "terseLabel": "Additional commitment shares issued" } } }, "auth_ref": [] }, "ibio_CommonStockSharesIssuedInitialCommitmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockSharesIssuedInitialCommitmentShares", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The number of common stock shares the Company issued to Lincoln Park as \"initial commitment shares\" as consideration for participation in the stock purchasing agreement.", "label": "Common Stock Shares Issued Initial Commitment Shares", "terseLabel": "Initial commitment shares issued" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r112", "r737", "r757", "r1217", "r1218"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2024 and June 30, 2023; 8,623,676 and 1,015,505 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r112", "r676", "r859"] }, "ibio_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r936"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r935"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r937"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":

"Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r934"] }, "ibio_CompanyPurchasingCardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CompanyPurchasingCardMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Information related to the Company purchasing card.", "label": "Company Purchasing Card [Member]", "terseLabel": "Collateral Held For Company Purchasing Card" } } }, "auth_ref": [] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Employee 401(k) Plan" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r70", "r162", "r227", "r229", "r234", "r669", "r687"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r74", "r192"] }, "ibio_ContractAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ContractAssetsPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contract assets.", "label": "Contract Assets [Policy Text Block]", "terseLabel": "Contract Assets" } } }, "auth_ref": [] }, "ibio_ContractDevelopmentAndManufacturingOrganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ContractDevelopmentAndManufacturingOrganizationMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the elimination of the Company's contract development and manufacturing organization.", "label": "Contract Development and Manufacturing Organization [Member]", "terseLabel": "iBio CDMO, LLC" } } }, "auth_ref": [] }, "ibio_ContractLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ContractLiabilitiesPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contract liabilities.", "label": "Contract Liabilities [Policy Text Block]", "terseLabel": "Contract Liabilities" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "verboseLabel": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": ["r417", "r419", "r430"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r417", "r418", "r430"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized included in contract liabilities", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r431"] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "terseLabel": "Series 2022 Preferred Stock", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r398", "r399", "r403", "r874", "r875", "r876", "r877"] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Common shares issued upon conversion of preferred stock", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": ["r21", "r50", "r111", "r150", "r409"] }, "ibio_CostAccruedToAmendTermNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CostAccruedToAmendTermNotePayable", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of cost accrued to amend the term note payable during the period.", "label": "Cost accrued to amend term note payable" } } }, "auth_ref": [] }, "ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CostToRaiseCapitalPaidDirectlyFromGrossProceeds", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of cost incurred to raise capital directly from gross proceeds.", "label": "Cost to Raise Capital paid Directly from Gross Proceeds", "terseLabel": "Costs to raise capital paid directly from gross proceeds" } } }, "auth_ref": [] }, "ibio_Coststoraisecapitalincludedinaccruedexpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Coststoraisecapitalincludedinaccruedexpenses", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of total costs incurred in raising capital included in accrued expenses.", "label": "CostsToRaiseCapitalIncludedInAccruedExpenses", "terseLabel": "Costs to raise capital included in accrued expenses" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r249", "r250", "r373", "r401", "r621", "r630", "r673", "r818", "r820"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "ibio_CreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CreditAgreementWithWoodforestNationalBankMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Credit Agreement with Woodforest National Bank.", "label": "Credit Agreement with Woodforest National Bank", "terseLabel": "The Credit Agreement" } } }, "auth_ref": [] }, "ibio_CreditAndSecurityAgreementEventOfDefaultMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CreditAndSecurityAgreementEventOfDefaultMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the credit and security agreement if there is an event of default.", "label": "Credit and Security Agreement Event Of Default [Member]", "terseLabel": "Event of Default" } } }, "auth_ref": [] }, "ibio_CreditAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CreditAndSecurityAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the credit and security agreement.", "label": "Credit and Security Agreement [Member]", "terseLabel": "Credit and Security Agreement" } } }, "auth_ref": [] }, "ibio_CroAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "CroAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the CRO Agreement for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies.", "label": "CRO Agreement [Member]", "terseLabel": "CRO Agreement" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit)", "verboseLabel": "Current - Federal and state", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": ["r528", "r999"] }, "ibio_DaysToFileRegistrationStatement": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DaysToFileRegistrationStatement", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants.", "label": "Days to file registration statement", "terseLabel": "Number of days to file a registration statement" } } }, "auth_ref": [] }, "ibio_DaysToFileRegistrationStatementSecReview": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DaysToFileRegistrationStatementSecReview", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": {

"documentation": "In the event of a \"full review\" by the SEC, the maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants.", "label": "Days to file registration statement SEC Review", "terseLabel": "Number of days to file a registration statement (in the event of a \"full review\" by SEC)" } } }, "auth_ref": [] }, "ibio_DaysToSuspendSecuritiesPurchasingAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DaysToSuspendSecuritiesPurchasingAgreement", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of days in which the Company may suspend the 2024 Securities Purchase Agreement inside the one year period without being in breach.", "label": "Days to suspend securities purchasing agreement", "terseLabel": "Suspension period" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Issuance of warrant for term note payable obligation", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r35", "r37"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r146", "r245", "r337", "r338", "r339", "r340", "r341", "r350", "r359", "r369", "r375", "r376", "r377", "r378", "r379", "r380", "r385", "r392", "r393", "r395", "r593"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r20", "r102", "r103", "r165", "r167", "r251", "r370", "r371", "r372", "r373", "r374", "r376", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r829", "r830", "r831", "r832", "r833", "r857", "r997", "r1039", "r1040", "r1041", "r1160", "r1162"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Spread on base interest rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ibio_DebtInstrumentCollateralAmountReleasedByLender": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentCollateralAmountReleasedByLender", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of assets held as collateral in Woodforest National Bank's Reserve Funds Deposit Account released back to the Company.", "label": "Debt Instrument, Collateral, Amount Released by Lender", "terseLabel": "Collateral withdrawal" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount borrowed", "verboseLabel": "Secured term loan", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r370", "r593", "r594", "r830", "r831", "r857"] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Appraisal costs", "terseLabel": "Amendment fee", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r106"] }, "ibio_DebtInstrumentFeeAmountIfFacilitySaleOccursAfterJune302023PriorToOrOnSeptember302023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentFeeAmountIfFacilitySaleOccursAfterJune302023PriorToOrOnSeptember302023", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Fee owed to Woodforest National Bank if/when a sale of equipment closes After June 30 2023, but prior to/on September 30 2023.", "label": "Debt Instrument Fee Amount If Facility Sale Occurs After June 30 2023, Prior to or on September 30 2023", "terseLabel": "Fees payable (Facility sale after June 30, 2023 and prior to September 30, 2023)" } } }, "auth_ref": [] }, "ibio_DebtInstrumentFeeAmountIfFacilitySaleOccursAfterSeptember302023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentFeeAmountIfFacilitySaleOccursAfterSeptember302023", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Fee owed to Woodforest National Bank if/when a sale of equipment closes After September 30 2023, or if a sale does not occur.", "label": "Debt Instrument Fee Amount If Facility Sale Occurs After September 30 2023", "terseLabel": "Fees payable (Facility sale after September 30, 2023)" } } }, "auth_ref": [] }, "ibio_DebtInstrumentFeeAmountIfFacilitySaleOccursPriorToJune302023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentFeeAmountIfFacilitySaleOccursPriorToJune302023", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Fee owed to Woodforest National Bank if/when a sale of equipment closes on or prior to June 30, 2023.", "label": "Debt Instrument Fee Amount If Facility Sale Occurs Prior to June 30 2023", "terseLabel": "Fees payable (Facility sale prior to June 30, 2023)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Frequency of accelerated principal repayments", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": ["r20", "r73"] }, "ibio_DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySaleAfterJune302023PriorToOrOnSeptember302023": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySaleAfterJune302023PriorToOrOnSeptember302023", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment after June 30, 2023, but prior to/on September 30, 2023.", "label": "Debt Instrument, Interest Rate, Contingent Annual Increase For Facility Sale After June 30 2023, Prior to or on September 30 2023", "terseLabel": "Annual interest rate increase (Facility sale after June 30, 2023 and prior to September 30, 2023)" } } }, "auth_ref": [] }, "ibio_DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySaleAfterSeptember302023": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySaleAfterSeptember302023", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment after September 30, 2023, or if equipment is not sold at all.", "label": "Debt Instrument, Interest Rate, Contingent Annual Increase For Facility Sale After September 30 2023", "terseLabel": "Annual interest rate increase (Facility sale after September 30, 2023)" } } }, "auth_ref": [] }, "ibio_DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySalePriorToJune302023": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentInterestRateContingentAnnualIncreaseForFacilitySalePriorToJune302023", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase in the stated interest rate on a term loan if the Company closes on a sale of equipment prior to June 30, 2023.", "label": "Debt Instrument, Interest Rate, Contingent Annual Increase For Facility Sale Prior to June 30 2023", "terseLabel": "Annual interest rate increase (Facility sale prior to June 30, 2023)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Term loan interest rate", "verboseLabel": "Imputed interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r105", "r371"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r251", "r370", "r371", "r372", "r373", "r374", "r376", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r829", "r830", "r831", "r832", "r833", "r857", "r997", "r1160", "r1162"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r20", "r251", "r370", "r371", "r372", "r373", "r374", "r376", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r829", "r830", "r831", "r832", "r833", "r857", "r997", "r1039", "r1040", "r1041", "r1160", "r1162"] }, "ibio_DebtInstrumentPaidInKindInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DebtInstrumentPaidInKindInterestRate", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the payable in-kind interest rate.", "label": "Debt Instrument, Paid-in Kind Interest Rate", "terseLabel": "Interest rate payable in-kind" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly payments on debt", "totalLabel": "Total minimum debt payments", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r20", "r73"] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",

"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Interest payments", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": ["r20"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Principal payments on term loan", "verboseLabel": "Principal payments", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r20"] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Balloon payment payable (January 2026)", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": ["r172"] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": ["r172"] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "2025", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": ["r172"] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "2026", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": ["r172"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r20", "r50", "r53", "r72", "r149", "r151", "r251", "r370", "r371", "r372", "r373", "r374", "r376", "r381", "r382", "r383", "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r829", "r830", "r831", "r832", "r833", "r857", "r997", "r1160", "r1162"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Term of debt agreement", "verboseLabel": "Term of accelerated principal repayments", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Costs related to term promissory note paid directly from gross proceeds", "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." } } }, "auth_ref": ["r35", "r36", "r37"] }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Bank wire fees", "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses." } } }, "auth_ref": ["r126"] }, "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleGainLoss", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Gain (Loss)", "negatedLabel": "Loss on sale of debt securities", "terseLabel": "Loss on sales of debt securities", "totalLabel": "Realized loss on sale of debt securities", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r987", "r988"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "negatedLabel": "Unrealized loss (gain) on available-for-sale debt securities", "terseLabel": "Unrealized gain on available-for-sale debt securities", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1021", "r1022"] }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance", "terseLabel": "Shares reserved for past grants", "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Deferred - Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r999", "r1145", "r1146"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred finance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1049", "r1159", "r1160", "r1162"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r8", "r198", "r999"] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "Deferred - State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r999", "r1145", "r1146"] }, "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsCharitableContributionCarryforwards", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Charitable Contribution Carryforwards", "terseLabel": "Contribution carryforward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards." } } }, "auth_ref": ["r1143"] }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsEquityMethodInvestments", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Equity Method Investments", "terseLabel": "Investment in equity security", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments." } } }, "auth_ref": ["r1143"] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Total", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": ["r1142"] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "verboseLabel": "Net operating loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": ["r1143"] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "verboseLabel": "Federal net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of

```
deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": { "r1143" } }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "verboseLabel": "Federal net operating loss carryforwards, not subject to expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }, "auth_ref": { "r1143" } }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State and local net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": { "r1143" } }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "verboseLabel": "Federal net operating loss carryforwards, subject to expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOtherTaxCarryforwards", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other Tax Carryforwards", "terseLabel": "Capitalized research and development costs", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other", "terseLabel": "Operating and finance lease liabilities", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development tax credit carryforward", "verboseLabel": "Research and development tax credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "verboseLabel": "Share-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Deferred tax assets valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r524" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Intangible assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Operating and finance lease ROU assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property, plant and equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1143" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contribution expense", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r433", "r436", "r448", "r836", "r837", "r838", "r839" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [
"http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [
"http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of employees gross pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [
"http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution, percent of match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation of fixed assets", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r42" ] }, "us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationExcludingLessorAssetUnderOperatingLease", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation, Excluding Lessor Asset under Operating Lease", "terseLabel": "Depreciation expense - fixed assets", "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of depreciation expense." } } }, "auth_ref": [ "r335", "r618" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r461", "r465", "r496", "r497", "r499", "r843" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "terseLabel": "Transition period for terminated employees", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r89" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Held-for-Sale [Member]", "terseLabel": "Held-for-Sale", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": [ "r5", "r6", "r206" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
```

```
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r206" ] },
"us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupClassificationDomain", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang":
{ "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited
to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] },
"ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630",
"localname": "DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": {
"documentation": "Fixed asset charges incurred but not yet paid attributable to discontinued operations.", "label": "Disposal Group, Fixed Assets Incurred But Not Yet
Paid In Current Period", "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period" } } }, "auth_ref": [] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation,
Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale
or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r77", "r93", "r141", "r143" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of goods sold", "documentation": "Amount of costs of goods sold
attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r92", "r207" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "Amount of
general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r92" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "terseLabel": "Gross profit", "documentation": "Amount of gross profit attributable to
disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r92", "r207" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Interest Expense", "negatedLabel": "Interest expense - term note payable", "verboseLabel": "Interest charges on
term note", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [
"r22", "r23", "r25", "r92" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Operating Expense", "terseLabel": "Total operating expenses", "documentation": "Amount of operating expense
attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r92" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount classified
as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } },
"auth_ref": [ "r1", "r77", "r93", "r141", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit",
"presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails" ], "lang": { "en-us": {
"role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Operating lease obligation", "documentation":
"Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating
cycle, if longer." } } }, "auth_ref": [ "r1", "r77", "r93", "r141", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "crdr": "debit",
"presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": {
"role": { "label": "Disposal Group, Including Discontinued Operation, Other Expense", "negatedLabel": "Other", "documentation": "Amount of other expense
attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r92" ] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property and equipment, net", "documentation":
"Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the
normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r77", "r93", "r141", "r143" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit",
"presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": {
"role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenues", "documentation": "Amount of revenue attributable to
disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r92", "r207" ] }, "us-
gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]", "terseLabel": "Results of operations for discontinued operations" } }
}, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations,
Disclosure [Text Block]", "terseLabel": "Discontinued Operations", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to,
a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } },
"auth_ref": [ "r76", "r138" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang":
{ "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r840", "r841" ] },
"dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [
"http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation":
"Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r884", "r885", "r897" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [
"http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction
[Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [
"r884", "r885", "r897", "r940" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentFiscalPeriodFocus", "presentation": [ "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label":
"Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1,
Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype":
"gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This
is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006
should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of
the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition
period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } },
"auth_ref": [ "r918" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType",
"presentation": [ "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation":
```

"The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ibio_DurationOfSecuritiesPurchasingAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "DurationOfSecuritiesPurchasingAgreement", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Duration of the 2024 Securities Purchase Agreement.", "label": "Duration of securities purchasing agreement", "terseLabel": "Term of 2024 Securities Purchase Agreement" } } }, "auth_ref": [] }, "ecd_DyddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DyddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r929"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Common Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - total", "verboseLabel": "Per share amount - total (Basic)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r235", "r257", "r258", "r259", "r260", "r261", "r262", "r267", "r269", "r272", "r273", "r274", "r278", "r541", "r545", "r562", "r563", "r670", "r688", "r822"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic and diluted denominator:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - total", "verboseLabel": "Per share amount - total (Diluted)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r235", "r257", "r258", "r259", "r260", "r261", "r262", "r269", "r272", "r273", "r274", "r278", "r541", "r545", "r562", "r563", "r670", "r688", "r822"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) Per Common Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r266", "r275", "r276", "r277"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1158"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r513", "r845"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Statutory federal income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r248", "r513", "r531", "r845"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "negatedLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": ["r516", "r845", "r1000", "r1140"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Stock buyback excise tax on share repurchases", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": ["r845", "r1000", "r1140", "r1141"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "negatedLabel": "Expiration and forfeiture of stock options", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": ["r845", "r1000", "r1140", "r1141"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "verboseLabel": "State taxes, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": ["r515", "r845", "r1000", "r1140"] }, "ibio_EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the eighth amendment to the Credit Agreement with Woodforest National Bank.", "label": "eighth Amendment to Credit Agreement with Woodforest National Bank [Member]", "terseLabel": "Eighth Amended Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "verboseLabel": "Personnel related costs", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r103"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized compensation, non-vested awards", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r498"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Cost recognition period, non-vested options", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r498"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One",

"documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r882"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r882"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r882"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r969"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r882"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r882"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r882"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r882"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r970"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r923"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r965"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r965"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r965"] }, "ibio_EquipmentFinancingMasterLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "EquipmentFinancingMasterLeaseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the equipment financing master lease agreement.", "label": "Equipment Financing Master Lease Agreement [Member]", "terseLabel": "Equipment Financing Agreement" } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r14", "r204", "r231", "r232", "r233", "r252", "r253", "r254", "r256", "r261", "r263", "r265", "r280", "r308", "r309", "r334", "r416", "r529", "r530", "r538", "r539", "r540", "r542", "r544", "r545", "r554", "r555", "r556", "r557", "r558", "r559", "r561", "r586", "r587", "r588", "r589", "r590", "r591", "r595", "r598", "r620", "r686", "r694", "r695", "r696", "r712", "r778"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r933"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r890", "r901", "r911", "r944"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r887", "r898", "r908", "r941"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r939"] }, "ibio_ExercisePriceStockOptionsRange1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ExercisePriceStockOptionsRange1Member", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock options within a defined range of exercise prices.", "label": "Exercise Price Stock Options Range 1 [Member]", "terseLabel": "$1.72 - $7.00" } } }, "auth_ref": [] }, "ibio_ExercisePriceStockOptionsRange2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ExercisePriceStockOptionsRange2Member", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock options within a defined range of exercise prices.", "label": "Exercise Price Stock Options Range 2 [Member]", "terseLabel": "$140.00 - $210.00" } } }, "auth_ref": [] }, "ibio_ExercisePriceStockOptionsRange3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ExercisePriceStockOptionsRange3Member", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock options within a defined range of exercise prices.", "label": "Exercise Price Stock Options Range 3 [Member]", "terseLabel": "$347.00 - $520.50" } } }, "auth_ref": [] }, "ibio_ExercisePriceStockOptionsRange4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ExercisePriceStockOptionsRange4Member", "presentation": [

```
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock options within a defined range of exercise prices.", "label": "Exercise Price Stock Options Range 4 [Member]", "terseLabel": "$530.00 - $795.00" } } }, "auth_ref": [] }, "ibio_ExercisePriceStockOptionsRange5Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ExercisePriceStockOptionsRange5Member", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to stock options within a defined range of exercise prices.", "label": "Exercise Price Stock Options Range 5 [Member]", "terseLabel": "$1,025.00 - $1,537.50" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r565", "r566", "r576", "r850" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r565", "r566", "r576", "r850" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r383", "r436", "r437", "r438", "r439", "r440", "r441", "r564", "r566", "r567", "r568", "r569", "r575", "r576", "r578", "r625", "r626", "r627", "r830", "r831", "r836", "r837", "r838", "r850", "r853" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r565", "r566", "r567", "r569", "r850", "r1154", "r1156" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments and Fair Value Measurement" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value Measurement", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r571", "r573", "r574", "r575", "r576", "r579", "r580", "r581", "r582", "r667", "r850", "r854" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r383", "r436", "r441", "r566", "r576", "r625", "r836", "r837", "r838", "r850" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r383", "r436", "r437", "r438", "r439", "r440", "r441", "r566", "r567", "r568", "r569", "r576", "r627", "r830", "r831", "r836", "r837", "r838", "r850", "r853" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r565", "r566", "r567", "r569", "r850", "r1154", "r1156" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r383", "r436", "r437", "r438", "r439", "r440", "r441", "r564", "r566", "r567", "r568", "r569", "r575", "r576", "r578", "r625", "r626", "r627", "r830", "r831", "r836", "r837", "r838", "r850", "r853" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair Value, Nonrecurring", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r565", "r566", "r567", "r569", "r850", "r1154" ] }, "ibio_FairValueOfSharesIssuedInAgreementAfterLockupPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FairValueOfSharesIssuedInAgreementAfterLockupPeriod", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value estimate of shares issued in asset purchase agreement after the initial lockup period.", "label": "Fair value of shares issued in agreement after lockup period", "terseLabel": "Fair value of shares issued and subject to lockup period" } } }, "auth_ref": [] }, "ibio_FeesIncurredForFixedAssetsSoldAtAuction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FeesIncurredForFixedAssetsSoldAtAuction", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of costs/fees incurred for selling fixed assets at an auction.", "label": "Fees incurred for fixed assets sold at auction", "terseLabel": "Fees for auctioned equipment" } } }, "auth_ref": [] }, "ibio_FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the fifth amendment to the Credit Agreement with Woodforest National Bank.", "label": "Fifth Amendment to Credit Agreement with Woodforest National Bank [Member]", "terseLabel": "Fifth Amended Credit Agreement" } } }, "auth_ref": [] }, "ibio_FilingFeesPayableToSalesAgent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FilingFeesPayableToSalesAgent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The fees incurred and payable to the sales agent for any filing related fees.", "label": "Filing fees payable to sales agent", "terseLabel": "Prospectus supplement filing fees" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r601", "r608", "r858" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails",
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "terseLabel": "Finance leases", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r600", "r615" ] }, "us-gaap_FinanceLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Finance Lease Obligations" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Current", "negatedLabel": "Less: current portion", "terseLabel": "Finance lease obligations - current portion", "verboseLabel": "Finance lease obligation – current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r600" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Future Minimum Payments Under the Finance Lease Obligation", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1164" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Noncurrent", "presentationGuidance": "Finance lease obligation - non current portion", "terseLabel": "Finance lease obligations - net of current portion", "verboseLabel": "Long-term portion of minimum lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r600" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } },
```

"auth_ref": ["r615"] }, "ibio_FinanceLeasePaymentsInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FinanceLeasePaymentsInterest", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount applied to interest for payment on finance lease.", "label": "Finance Lease Payments Interest", "terseLabel": "Interest payments" } } }, "auth_ref": [] }, "ibio_FinanceLeasePaymentsPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FinanceLeasePaymentsPrincipal", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount applied to principal for payment on finance lease.", "label": "Finance Lease Payments Principal", "terseLabel": "Principal payments" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment of finance lease obligation", "negatedLabel": "Payment of finance lease obligation", "terseLabel": "Financing cash flows from finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r602", "r611"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "netLabel": "Finance lease ROU assets", "terseLabel": "Finance lease right-of-use assets, net of accumulated amortization", "totalLabel": "Net finance lease ROU assets", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r599"] }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "negatedLabel": "Accumulated amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": ["r973", "r976"] }, "us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract", "lang": { "en-us": { "role": { "label": "Finance Lease ROU Assets" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of ROU assets", "terseLabel": "Amortization of finance lease right-of-use assets", "verboseLabel": "Amortization expense - ROU assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r601", "r608", "r858"] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "ROU - Equipment", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r972"] }, "ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FinanceLeaseRightOfUseAssetDisclosureTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right Of Use Asset, Disclosure [Text Block]", "terseLabel": "Finance Lease ROU Assets" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - finance lease obligation", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r614", "r858"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - finance lease", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r613", "r858"] }, "us-gaap_FinancialStandbyLetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialStandbyLetterOfCreditMember", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Financial Standby Letter of Credit [Member]", "terseLabel": "Letter of Credit", "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Finite-lived intangible assets accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r214", "r316", "r325", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "verboseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r1033", "r1219"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r327", "r813", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "verboseLabel": "2029", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r327", "r813", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "verboseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r327", "r813", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r327", "r813", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "verboseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r327", "r813", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails",
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r318", "r320", "r321", "r322", "r324", "r325", "r329", "r330", "r635", "r636", "r813"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Finite-lived intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r316", "r325", "r636", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information

associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r318", "r325", "r329", "r330", "r332", "r635", "r813", "r828"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails",
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r318", "r320", "r321", "r322", "r324", "r325", "r329", "r330", "r813"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Total", "totalLabel": "Finite-lived intangible assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r635", "r1032"] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Intangible assets weighted average remaining life", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r635"] }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRollForward", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Finite-lived intangible asset additions", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": ["r320"] },
"ibio_FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the first amendment to the Credit Agreement with Woodforest National Bank.", "label": "First Amendment to Credit Agreement with Woodforest National Bank [Member]", "terseLabel": "First Amended Credit Agreement" } } }, "auth_ref": [] }, "ibio_FirstInsuranceFundingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FirstInsuranceFundingMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to FIRST Insurance Funding, a division of Lake Forest Bank & Trust, N.A.", "label": "First Insurance Funding [Member]", "terseLabel": "FIRST Insurance Funding" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r894", "r905", "r915", "r948"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r894", "r905", "r915", "r948"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r894", "r905", "r915", "r948"] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r894", "r905", "r915", "r948"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r894", "r905", "r915", "r948"] }, "ibio_FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the fourth amendment to the Credit Agreement with Woodforest National Bank.", "label": "Fourth Amendment to Credit Agreement with Woodforest National Bank [Member]", "terseLabel": "Fourth Amended Credit Agreement" } } }, "auth_ref": [] },
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r928"] }, "us-gaap_GainContingenciesByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingenciesByNatureAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Gain Contingencies, Nature [Axis]", "documentation": "Information by nature of gain contingency." } } }, "auth_ref": ["r1045"] }, "us-gaap_GainContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingenciesLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Gain Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r1045"] }, "us-gaap_GainContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingenciesTable", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Gain Contingencies [Table]", "documentation": "Disclosure of information about existing condition, situation, or set of circumstances involving uncertainty as to possible gain that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r1045"] }, "us-gaap_GainContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingencyNatureDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Gain Contingency, Nature [Domain]", "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization." } } }, "auth_ref": ["r1045"] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Intangible Assets", "negatedLabel": "Gain on sale of intangible assets", "terseLabel": "Gain on sale of intellectual property", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": ["r993"] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on sale of fixed assets", "negatedTerseLabel": "Loss (gain) on sale of fixed assets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r8"] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedLabel": "Loss/(gain) on sale of fixed assets", "negatedTerseLabel": "Loss on sale of fixed assets", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write-down of assets from their carrying value to fair value." } } }, "auth_ref": ["r993"] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Gain (Loss) from Litigation Settlement", "terseLabel": "Settlement income", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": ["r825", "r1044"] }, "us-gaap_GainLossRelatedToLitigationSettlementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlementAbstract", "lang": { "en-us": { "role": { "label": "Fraunhofer Settlement" } } }, "auth_ref": [] }, "ibio_GainLossRelatedToLitigationSettlementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "GainLossRelatedToLitigationSettlementTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureFraunhoferSettlement"], "lang": { "en-us": { "role": { "documentation": "Entire disclosure on gain (Loss) related to litigation settlement.", "label": "Gain Loss Related To Litigation Settlement [Text Block]", "terseLabel": "Fraunhofer Settlement" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on extinguishment of debt", "terseLabel": "Gain on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r8", "r46", "r47"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses", "verboseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the

manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r124", "r762"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "verboseLabel": "General and Administrative Expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r124"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r1024", "r1025"] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": ["r317", "r331", "r333"] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": ["r462", "r464", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494"] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": ["r462", "r464", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494"] }, "us-gaap_GuaranteeObligationsByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsByNatureAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Nature [Axis]", "documentation": "Information by nature of guarantee." } } }, "auth_ref": ["r354", "r355", "r356", "r357"] }, "us-gaap_GuaranteeObligationsMaximumExposure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsMaximumExposure", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Maximum Exposure, Undiscounted", "verboseLabel": "Irrevocable letter of credit", "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions." } } }, "auth_ref": ["r355"] }, "us-gaap_GuaranteeObligationsNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsNatureDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Guarantor Obligations, Nature [Domain]", "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees." } } }, "auth_ref": ["r354", "r355", "r356", "r357"] }, "ibio_GuaranteedMinimumProceedsForFixedAssetsSoldAtAuction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "GuaranteedMinimumProceedsForFixedAssetsSoldAtAuction", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "The guaranteed minimum proceeds agreed upon for property plant & equipment put up for auction.", "label": "Guaranteed minimum proceeds for fixed assets sold at auction", "terseLabel": "Guaranteed minimum proceeds for auctioned equipment" } } }, "auth_ref": [] }, "ibio_HcWainwrightAndCompanyLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "HcWainwrightAndCompanyLlcMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to H.C. Wainwright & Co., LLC acting as a sales agent to sell shares of the Company's common stock.", "label": "HC Wainwright and Company, LLC [Member]", "terseLabel": "H.C. Wainwright & Co." } } }, "auth_ref": [] }, "ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "documentation": "I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].", "label": "iBio, Inc. v. Fraunhofer USA, Inc. [Member]", "terseLabel": "iBio, Inc. v. Fraunhofer USA, Inc." } } }, "auth_ref": [] }, "ibio_IbioInc.2020OmnibusEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "IbioInc.2020OmnibusEquityIncentivePlanMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.", "label": "2020 Omnibus Equity Incentive Plan [Member]", "terseLabel": "2020 Omnibus Equity Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails"], "lang": { "en-us": { "role": { "label": "Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset", "terseLabel": "Carrying value, fixed assets held for sale", "documentation": "The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale." } } }, "auth_ref": ["r44", "r140"] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets (Excluding Goodwill)", "verboseLabel": "Impairment of intangible assets", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": ["r8", "r319", "r331"] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Finite-lived intangible asset impairment", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": ["r319", "r993", "r1037"] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible asset impairment", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": ["r319", "r993", "r1034", "r1037"] }, "us-gaap_ImpairmentOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfInvestments", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Other than Temporary Impairment Losses, Investments", "verboseLabel": "Impairment of investment in RubrYc", "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income." } } }, "auth_ref": ["r180"] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Fixed asset impairments", "verboseLabel": "Fixed asset impairment charge", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": ["r8", "r140", "r851"] }, "ibio_ImpairmentOfPrepaidExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ImpairmentOfPrepaidExpensesCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Impairment of current prepaid expenses.", "label": "Impairment Of Prepaid Expenses, Current", "terseLabel": "Impairment of current prepaid expense" } } }, "auth_ref": [] }, "ibio_ImpairmentOfPrepaidExpensesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ImpairmentOfPrepaidExpensesNonCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Impairment of non-current prepaid expenses.", "label": "Impairment Of Prepaid Expenses, Non Current", "terseLabel": "Impairment of noncurrent prepaid expense" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss from continuing operations", "verboseLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r162", "r175", "r247", "r255", "r261", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r541", "r545", "r563", "r585", "r682", "r824", "r1007", "r1008", "r1009", "r1010", "r1011", "r1046"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Per share amount - continuing operations (Basic)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r120", "r169", "r235", "r255", "r257", "r258", "r259", "r260", "r261", "r269", "r272", "r273", "r541", "r545", "r563", "r670", "r1186"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Per share amount - continuing operations (Diluted)", "documentation": "The amount of net income (loss)

derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r120", "r235", "r255", "r257", "r258", "r259", "r260", "r261", "r269", "r272", "r273", "r274", "r545", "r563", "r670", "r1186"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Loss recorded in discontinued operations", "terseLabel": "Loss from discontinued operations", "verboseLabel": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r81", "r82", "r83", "r84", "r85", "r95", "r207", "r535", "r683"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Per share amount - discontinued operations (Basic)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r121", "r235", "r270", "r272", "r273", "r1177", "r1186"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Per share amount - discontinued operations (Diluted)", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r163", "r270", "r272", "r273"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r840", "r841"] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r11", "r17", "r24", "r77", "r86", "r87", "r88", "r90", "r91", "r94", "r96", "r97", "r144"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r336", "r342", "r344", "r570", "r572", "r577", "r691", "r693", "r763", "r813", "r852", "r1188"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r342", "r344", "r570", "r572", "r577", "r691", "r693", "r763", "r813", "r852", "r1188"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r248", "r508", "r513", "r517", "r518", "r519", "r522", "r526", "r532", "r534", "r536", "r537", "r709", "r845"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r186", "r199", "r264", "r265", "r279", "r288", "r291", "r512", "r513", "r533", "r689", "r845"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r230", "r510", "r511", "r522", "r523", "r525", "r527", "r703"] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": ["r516", "r845", "r1140"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable - trade", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued interest receivable on promissory note receivable", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Contract liabilities", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r632", "r992"] }, "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory." } } }, "auth_ref": ["r7"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [

```
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease obligations", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r977", "r992" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Accrued expenses - noncurrent", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses - noncurrent", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInSecurityDeposits", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Security Deposits", "terseLabel": "Security deposit", "documentation": "The increase (decrease) during the reporting period in security deposits." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r316", "r328", "r828" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsRollForward", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived intangible asset additions", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [ "r323", "r1034" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r894", "r905", "r915", "r939", "r948", "r952", "r960" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r958" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r886", "r964" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r886", "r964" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r886", "r964" ] }, "ibio_InsurancePremiumFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "InsurancePremiumFinancingAgreementMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails",
"http://www.ibioinc.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Insurance Premium Financing Agreement.", "label": "Insurance Premium Financing Agreement [Member]", "terseLabel": "Insurance Premium Financing Agreement" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, net of accumulated amortization", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r318", "r1032", "r1034" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net" } } }, "auth_ref": [] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails",
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Intellectual Property [Member]", "terseLabel": "Intellectual Property", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r19", "r1026", "r1027", "r1028", "r1029", "r1030", "r1032", "r1035", "r1036" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "verboseLabel": "Interest expense on debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r126", "r389", "r396", "r832", "r833" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r287", "r989" ] }, "ibio_InterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "InterestMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to interest portion of the obligation.", "label": "Interest [Member]", "terseLabel": "Imputed Interest" } } }, "auth_ref": [] }, "us-gaap_InterestPaidDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidDiscontinuedOperations", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Discontinued Operations", "terseLabel": "Cash paid during the period for interest", "documentation": "The amount of cash paid during the current period for interest owed on debt associated with discontinued operations." } } }, "auth_ref": [ "r994" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r238", "r241", "r242" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Payable", "terseLabel": "Interest and fees related to term note payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r166", "r1180" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r221", "r817", "r859" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r188", "r210", "r220", "r312", "r313", "r315", "r633", "r821" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Inventory write-down to net realizable value", "verboseLabel": "Inventory reserve", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r314" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "verboseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r279", "r286", "r291", "r825", "r986" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments in Debt Securities" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments in Debt Securities", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r171", "r203", "r303", "r305", "r583", "r584", "r1175"] }, "us-gaap_LandAndBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandAndBuildingMember", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Land and Building [Member]", "verboseLabel": "Facilities", "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r617", "r975"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r617", "r975"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "terseLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r607", "r858"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost:", "verboseLabel": "Operating lease cost:" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations"], "lang": { "en-us": { "role": { "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Finance Lease Obligations", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": ["r597"] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r606", "r617"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r606", "r617"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r605"] }, "ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "documentation": "Lessee Operating Lease, Annual percentage increase in base rent", "label": "Lessee Operating Lease, Annual percentage increase in base rent", "verboseLabel": "Annual increase in monthly rent" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescriptionAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease ROU Assets" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "verboseLabel": "Future Minimum Payments under the Operating Lease Obligation", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1164"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "verboseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r615"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of lease", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1163"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Operating Lease Obligations", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r597"] }, "ibio_LetterOfCreditSanDiegoLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LetterOfCreditSanDiegoLeaseMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to letter of credit for sandiego lease.", "label": "Letter Of Credit - San Diego Lease [Member]", "terseLabel": "Collateral Held For Letter Of Credit - San Diego Lease" } } }, "auth_ref": [] }, "ibio_LetterOfCreditTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LetterOfCreditTermLoanMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to letter of credit term loan.", "label": "Letter Of Credit - Term Loan [Member]", "terseLabel": "Collateral Held For Letter Of Credit - Term Note Payable" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r20", "r102", "r103", "r104", "r107", "r108", "r109", "r110", "r247", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r549", "r552", "r553", "r585", "r736", "r823", "r880", "r1046", "r1166", "r1167"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [

"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r110", "r168", "r678", "r859", "r998", "r1023", "r1157"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r104", "r209", "r247", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r549", "r552", "r553", "r585", "r859", "r1046", "r1166", "r1167"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfAssetsAndLiabilitiesHeldForSaleDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [
"r1", "r77", "r93", "r141", "r143", "r206", "r207"] }, "ibio_LincolnParkPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LincolnParkPurchaseAgreementMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Lincoln Park Purchase Agreement [Member]", "terseLabel": "Lincoln Park Purchase Agreement" } } }, "auth_ref": [] }, "ibio_LincolnParkStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LincolnParkStockPurchaseAgreementMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Lincoln Park acting as the underwriter (sales agent) in an agreement to sell shares of the Company's common stock.", "label": "Lincoln Park Stock Purchase Agreement [Member]", "terseLabel": "Lincoln Park Stock Purchase Agreement" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedFromOtherParty", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount awarded in legal settlement", "verboseLabel": "Settlement receivable", "documentation": "Amount awarded from other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Settlement proceeds transferred for collateral requirement in debt agreement", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "ibio_LitigationSettlementPaymentsForLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LitigationSettlementPaymentsForLicenseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining settled litigation, amounts awarded as part of a license agreement.", "label": "Litigation Settlement Payments For License Agreement [Member]", "terseLabel": "License Agreement" } } }, "auth_ref": [] }, "ibio_LitigationSettlementPaymentsToCoverLegalExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LitigationSettlementPaymentsToCoverLegalExpensesMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining settled litigation, amounts awarded to cover legal expenses incurred.", "label": "Litigation Settlement Payments to Cover Legal Expenses [Member]", "terseLabel": "Legal Expenses Incurred" } } }, "auth_ref": [] }, "ibio_LitigationSettlementPaymentsToSettleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LitigationSettlementPaymentsToSettleDebtMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining settled litigation, amounts awarded to be used in settling the Company's debt agreements.", "label": "Litigation Settlement Payments to Settle Debt [Member]", "terseLabel": "Debt Settlement" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1039", "r1040", "r1041", "r1044"] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1039", "r1040", "r1041", "r1044"] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable"], "lang": { "en-us": { "role": { "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Promissory Note Receivable", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r593", "r1012"] }, "ibio_LoansReceivableFixedRatesOfInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LoansReceivableFixedRatesOfInterest", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of fixed rate of interest on notes.", "label": "Loans Receivable, Fixed Rates of Interest", "terseLabel": "Interest rate" } } }, "auth_ref": [] }, "ibio_LoansReceivableRateOfInterestForFirstOneYearExtension": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LoansReceivableRateOfInterestForFirstOneYearExtension", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of rate of interest on notes receivable for first one year extension.", "label": "Loans Receivable, Rate of Interest for First One Year Extension", "terseLabel": "Interest rate for first one year extension" } } }, "auth_ref": [] }, "ibio_LoansReceivableRateOfInterestForSecondOneYearExtension": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LoansReceivableRateOfInterestForSecondOneYearExtension", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of rate of interest on notes receivable for second one year extension.", "label": "Loans Receivable, Rate of Interest for Second One Year Extension", "terseLabel": "Interest rate for second one year extension" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ibio_LoebTermSolutionsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "LoebTermSolutionsLlcMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Loeb Term Solutions, LLC.", "label": "Loeb Term Solutions LLC [Member]", "terseLabel": "Loeb Term Solutions" } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Notes Payable, Noncurrent", "terseLabel": "Term promissory note - net of current portion", "verboseLabel": "Long-term portion of minimum term promissory note obligation", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r20"] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails",
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "terseLabel": "Equipment", "verboseLabel": "Machinery and Equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "ibio_MartinBrennerChiefScientificOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "MartinBrennerChiefScientificOfficerMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Dr. Martin Brenner, the Company's former Chief Scientific Officer.", "label": "Martin Brenner Chief Scientific Officer [Member]", "terseLabel": "Dr. Martin Brenner, former Chief Scientific Officer" } } }, "auth_ref": [] }, "ibio_MartinBrennerInterimChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "MartinBrennerInterimChiefExecutiveOfficerMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Dr. Martin Brenner, acting as the Company's interim Chief Executive Officer.", "label": "Martin Brenner Interim Chief Executive Officer [Member]", "terseLabel": "Dr. Martin Brenner, former Interim Chief Executive Officer" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails",
"http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r350", "r351", "r352", "r353", "r455", "r505", "r569", "r631", "r690", "r692", "r699", "r727", "r728", "r784", "r786", "r788", "r789", "r791", "r811", "r812", "r827", "r834", "r842", "r853", "r854", "r855", "r856", "r868", "r1048", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r931"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r931"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r567", "r568", "r569", "r853"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r567", "r568", "r569", "r853"] }, "us-gaap_MediumTermNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MediumTermNotesMember",

"presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Medium-Term Note [Member]", "terseLabel": "2024 Term Note", "documentation": "Debt instruments with maturities ranging from five to ten years." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r350", "r351", "r352", "r353", "r455", "r505", "r569", "r631", "r690", "r692", "r699", "r727", "r728", "r784", "r786", "r788", "r789", "r791", "r811", "r812", "r827", "r834", "r842", "r853", "r854", "r855", "r868", "r1048", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r951"] }, "ibio_Mr.IsettMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Mr.IsettMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Mr. Isett, Former CEO.", "label": "Mr. Isett [Member]", "terseLabel": "Mr. Thomas Isett, former Chief Executive Officer" } } }, "auth_ref": [] }, "ibio_Mr.RobertLutzMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Mr.RobertLutzMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Mr. Robert Lutz, the Company's Chief Financial and Business Officer.", "label": "Mr. Robert Lutz [Member]", "terseLabel": "Mr. Robert Lutz, former Chief Financial and Business Officer" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r959"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r932"] }, "ibio_NatureOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NatureOfBusinessAbstract", "lang": { "en-us": { "role": { "label": "Nature of Business" } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.ibioinc.com/role/DisclosureNatureOfBusiness"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r189", "r200"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r240"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r240"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r132", "r133", "r135"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "negatedLabel": "Net losses", "totalLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r122", "r135", "r170", "r207", "r226", "r228", "r233", "r247", "r255", "r257", "r258", "r259", "r260", "r261", "r264", "r265", "r271", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r541", "r545", "r563", "r585", "r685", "r759", "r776", "r777", "r878", "r1046"] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Basic and diluted numerator:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ibio_NonAccountableExpenseAllowanceGrantedToSalesAgent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NonAccountableExpenseAllowanceGrantedToSalesAgent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred for a non-accountable expense allowance granted to the sales agent.", "label": "Non accountable expense allowance granted to sales agent", "terseLabel": "Non-accountable expense allowance", "verboseLabel": "Quarterly expense allowance" } } }, "auth_ref": [] }, "ibio_NonCashTransactionOfSubscriptionReceivableForCapitalRaise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NonCashTransactionOfSubscriptionReceivableForCapitalRaise", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Non-Cash Transaction of Subscription Receivable For Capital Raise", "label": "Non-Cash Transaction Of Subscription Receivable For Capital Raise", "verboseLabel": "Subscription receivable" } } }, "auth_ref": [] }, "ibio_NonEmployeeCompensationMaximumAnnualDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NonEmployeeCompensationMaximumAnnualDistribution", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum share-based compensation that may be paid to non-employee directors in a given calendar year.", "label": "Non-Employee Compensation Maximum Annual Distribution", "terseLabel": "Maximum annual awards paid to non-employee directors" } } }, "auth_ref": [] }, "ibio_NonEmployeeDirectorCompensationMaximumAnnualDistributionInitialAppointment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NonEmployeeDirectorCompensationMaximumAnnualDistributionInitialAppointment", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum share-based compensation that may be paid to non-employee directors in a given calendar year with an initial appointment of a board member occurs.", "label": "Non-Employee Director Compensation Maximum Annual Distribution Initial Appointment", "terseLabel": "Maximum annual awards paid to non-employee directors (newly appointed board member)" } } }, "auth_ref": [] }, "ibio_NonEmployeeDirectorCompensationMaximumAnnualDistributionInitialChairAppointment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NonEmployeeDirectorCompensationMaximumAnnualDistributionInitialChairAppointment", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum share-based compensation that may be paid to non-employee directors in a given calendar year when an appointment of a new chairman of the Company's board occurs.", "label": "Non-Employee Director Compensation Maximum Annual Distribution Initial Chair Appointment", "terseLabel": "Maximum annual awards paid to non-employee directors (newly appointed board chairman)" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r931"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r894", "r905", "r915", "r939", "r948"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r922"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r921"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r939"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r959"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag",

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r959" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Investing non-cash transactions:" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued", "terseLabel": "Warrants issued to settle debt", "verboseLabel": "Warrants, shares issued", "documentation": "The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired", "terseLabel": "RubrYc asset acquisition by issuance of common stock", "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "ibio_Noncashinsurancepremiumfinancingduringperiod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Noncashinsurancepremiumfinancingduringperiod", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of insurance premiums financed through non-cash means during the period.", "label": "NonCashInsurancePremiumFinancingDuringPeriod", "terseLabel": "Insurance premium financing" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r125" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Promissory note receivable and accrued interest", "verboseLabel": "Promissory note receivable, current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r668", "r1014" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Promissory note receivable", "verboseLabel": "Promissory note receivable, non-current", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "totalLabel": "Term promissory note payable, net", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r167", "r1182", "r1183" ] }, "us-gaap_NotesPayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Current", "negatedLabel": "Less: current portion", "terseLabel": "Term promissory note - current portion", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r102", "r103" ] }, "us-gaap_NotesReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableMember", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Receivable [Member]", "terseLabel": "Promissory Note", "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, after Allowance for Credit Loss", "totalLabel": "Promissory note receivable, net", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r311", "r746", "r1014", "r1185" ] }, "ibio_NotesReceivablePaymentsForInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NotesReceivablePaymentsForInterest", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Payments received for interest owed to the Company for interest accrued on notes issued.", "label": "Notes receivable, payments for interest", "terseLabel": "Interest payments on notes receivable" } } }, "auth_ref": [] }, "ibio_NotesReceivablePaymentsOnPrincipalBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NotesReceivablePaymentsOnPrincipalBalance", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Payments received for notes issued, amounts applied directly to principal balance.", "label": "Notes receivable, payments on principal balance", "terseLabel": "Payments on notes receivable (amounts applied against principal balance)" } } }, "auth_ref": [] }, "ibio_NumberOfAdditionalAcceleratedSharePurchases": { "xbrltype": "integerItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NumberOfAdditionalAcceleratedSharePurchases", "presentation": [ "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of \"additional share purchases\" the Company may exercise when certain conditions in the stock purchasing agreement permit.", "label": "Number of Additional Accelerated Share Purchases", "terseLabel": "Number of \"additional accelerated purchases\" that may be directed" } } }, "auth_ref": [] }, "ibio_NumberOfEquipmentLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NumberOfEquipmentLeases", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of equipment leases.", "label": "Number of Equipment Leases", "terseLabel": "Number of equipment leases assumed in asset acquisition" } } }, "auth_ref": [] }, "ibio_NumberOfSharesTenderedInReverseStockSplit": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NumberOfSharesTenderedInReverseStockSplit", "presentation": [ "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Number of shares an equity holder will tender in order to receive one share of the Company's common stock share following the conversion of a reverse stock split.", "label": "Number of Shares Tendered in Reverse Stock Split", "terseLabel": "Pre-split shares required for one post-split share of common stock" } } }, "auth_ref": [] }, "ibio_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "NumberOfWarrantsExercised", "presentation": [ "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Number Of Warrants Exercised", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "ibio_Offering2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Offering2023Member", "presentation": [ "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to 2023 Offering.", "label": "Offering 2023", "terseLabel": "Offering 2023" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "verboseLabel": "Office Equipment and Software", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "ibio_OmnibusEquityIncentivePlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OmnibusEquityIncentivePlan2020Member", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Company's 2020 Omnibus Equity Incentive Plan.", "label": "Omnibus Equity Incentive Plan 2020 [Member]", "terseLabel": "2020 Omnibus Equity Incentive Plan" } } }, "auth_ref": [] }, "ibio_OmnibusEquityIncentivePlan2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OmnibusEquityIncentivePlan2023Member", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Company's 2023 Omnibus Equity Incentive Plan.", "label": "Omnibus Equity Incentive Plan 2023 [Member]", "terseLabel": "2023 Omnibus Equity Incentive Plan" } } }, "auth_ref": [] }, "ibio_OperatingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OperatingCapitalDeficit", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of operating capital (deficit).", "label": "Operating capital (deficit)", "negatedLabel": "Operating capital deficit" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r175", "r824", "r1007", "r1008", "r1009", "r1010", "r1011" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r609", "r858"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease Obligations" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion", "verboseLabel": "Operating lease obligation - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r600"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligation - net of current portion", "verboseLabel": "Long-term portion of minimum lease obligation", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r600"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails",
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating lease", "verboseLabel": "Monthly rent expense", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r603", "r611"] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments, Use", "terseLabel": "Operating cash flows from operating lease obligation", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r603", "r611"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails",
"http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU assets", "verboseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r599"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "verboseLabel": "Amortization of operating lease right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r993"] }, "ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OperatingLeaseRightOfUseAssetDisclosureTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset Disclosure [Text Block]", "terseLabel": "Operating Lease ROU Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating lease obligations", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r614", "r858"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsOperatingLeaseCostAndSupplementalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r613", "r858"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r75", "r161", "r700", "r701"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r103"] }, "us-gaap_OtherAffiliatesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAffiliatesMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Other Affiliates [Member]", "terseLabel": "Consultants", "documentation": "A category that identifies other affiliates." } } }, "auth_ref": [] }, "us-gaap_OtherAmortizationOfDeferredCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAmortizationOfDeferredCharges", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Other Deferred Charges", "terseLabel": "Amortization of deferred financing costs", "documentation": "Amount of amortization of other deferred costs recognized in the income statement." } } }, "auth_ref": ["r8", "r123"] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": [
"http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Other comprehensive loss - unrealized loss on debt securities", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r223", "r224", "r225", "r686"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Other comprehensive income - foreign currency adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r3", "r686"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Current liabilities related to assets held for sale", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r103", "r859"] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "verboseLabel": "Schedule of non-cash activities:" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Expense", "negatedTotalLabel": "Total other expenses", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": ["r127"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r931"] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Other Research and Development Expense", "terseLabel": "Costs incurred", "documentation": "Amount of other research and development expense." } } }, "auth_ref": ["r1139"] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r892", "r903", "r913", "r946"] },

{"ibio_OutstandingPrincipalRemainingAmountTriggeringReleaseOfCollateralHeld": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OutstandingPrincipalRemainingAmountTriggeringReleaseOfCollateralHeld", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of remaining term loan principal outstanding, in which Woodforest National Bank will release cash held as collateral back to the Company.", "label": "Outstanding principal remaining, amount triggering release of collateral held", "terseLabel": "Term loan principal outstanding, amount triggering release of collateral" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r895", "r906", "r916", "r949"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r895", "r906", "r916", "r949"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriters Option", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "ibio_OwnershipThresholdPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OwnershipThresholdPercentage", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The effective ownership of the outstanding shares of the Company's common stock immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.", "label": "Ownership threshold percentage", "terseLabel": "Warrant exercise, common stock ownership limitation" } } }, "auth_ref": [] }, "ibio_OwnershipThresholdPercentageElectionOfHolder": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "OwnershipThresholdPercentageElectionOfHolder", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The effective ownership of the outstanding shares of the Company's common stock, with written notice given by the holder to the Company, immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.", "label": "Ownership threshold percentage election of holder", "terseLabel": "Warrant exercise, common stock ownership limitation (at the election of the holder)" } } }, "auth_ref": [] }, "ibio_PartialLiquidatedDamagesPenaltyPercentageOnAggregateSubscriptionsBySecurityPurchaser": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PartialLiquidatedDamagesPenaltyPercentageOnAggregateSubscriptionsBySecurityPurchaser", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "In the event that a resale registration statement is not filed or declared effective, the percentage multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, as partial liquidated damages.", "label": "Partial liquidated damages, penalty percentage on aggregate subscriptions by security purchaser", "terseLabel": "Partial liquidated damages, percent of aggregate security subscriptions" } } }, "auth_ref": [] }, "ibio_PatentAndLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PatentAndLicensingAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the patent and licensing agreement with the University of Pittsburgh.", "label": "Patent and Licensing Agreement [Member]", "terseLabel": "Licensing Agreement" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Patents [Member]", "terseLabel": "Patents and Licenses", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r160", "r1026", "r1027", "r1028", "r1029", "r1030", "r1032", "r1035", "r1036"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r920"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "ibio_PaymentOfFinanceLeaseObligationCashFlowImpactFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PaymentOfFinanceLeaseObligationCashFlowImpactFromDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with payments of financial leasing obligations as a result of discontinued operations.", "label": "Payment of Finance Lease Obligation Cash Flow Impact from Discontinued Operations", "terseLabel": "Payment of finance lease obligation" } } }, "auth_ref": [] }, "ibio_PaymentOfLegalFeesAndOtherOutOfPocketExpensesToPlacementAgentMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PaymentOfLegalFeesAndOtherOutOfPocketExpensesToPlacementAgentMaximumAmount", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount of payment made to placement agent for legal fees and other out of pocket expenses.", "label": "Payment Of Legal Fees And Other Out Of Pocket Expenses To Placement Agent, Maximum Amount", "terseLabel": "Payment made to placement agent for legal fees and other out of pocket expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfCapitalDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfCapitalDistribution", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Capital Distribution", "negatedLabel": "Payments for fractional shares after reverse stock split", "documentation": "Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends." } } }, "auth_ref": ["r130"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "verboseLabel": "Origination fee", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r32"] }, "us-gaap_PaymentsOfLoanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfLoanCosts", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Loan Costs", "negatedLabel": "Payments made for costs to attain term note", "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow." } } }, "auth_ref": ["r31"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payments made for costs to acquire capital", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r31"] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "verboseLabel": "Cost of debt securities", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r28", "r236", "r304"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payment for RubrYc asset acquisition", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r29"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Cash advances to RubrYc to support operations", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r185", "r1148", "r1149", "r1150"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of fixed assets", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r129"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r930"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r930"] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureEmployee401KPlan"], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "terseLabel": "Employee 401(k) Plan", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": ["r432", "r434", "r435", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r449", "r450", "r451", "r838"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r922"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r939"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r932"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r921"] }, "ibio_PercentageLitigationSettlementPaymentUsedToCoverLegalFees": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PercentageLitigationSettlementPaymentUsedToCoverLegalFees", "presentation": ["http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of payment received from litigation settlement used to cover legal fees and expenses incurred throughout the litigation process.", "label": "Percentage litigation settlement payment used to cover legal fees", "terseLabel": "Percentage of settlement payment to cover legal fees" } } }, "auth_ref": [] }, "ibio_PercentageOfCollateralRequired": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PercentageOfCollateralRequired", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of collateral required to be held by the reporting entity.", "label": "Percentage Of Collateral Required", "terseLabel": "Additional collateral held by bank (percentage of credit issued)" } } }, "auth_ref": [] }, "ibio_PercentageOfExcessProceedsReceivedFromAuctionedEquipment": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PercentageOfExcessProceedsReceivedFromAuctionedEquipment", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of excess proceeds resulting from the auction (the difference between the guaranteed minimum and final sale amounts) paid to the Company.", "label": "Percentage of excess proceeds received from auctioned equipment", "terseLabel": "Excess proceeds from auctioned equipment (percentage)" } } }, "auth_ref": [] }, "ibio_PercentageOfNetProceedsFromAtMarketEquityOfferingsToBeUsedForDebtRepayment": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PercentageOfNetProceedsFromAtMarketEquityOfferingsToBeUsedForDebtRepayment", "presentation": [

"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of net proceeds realized from the closing of any at-the-market equity offerings that must be used for the repayment of debt, as defined in the Company's credit agreement with Woodforest National Bank.", "label": "Percentage of net proceeds from at-the-market equity offerings to be used for debt repayment", "terseLabel": "Percentage of equity offering proceeds to be used for debt repayment" } } }, "auth_ref": [] }, "ibio_PercentageOfNetProceedsFromSaleOfEquipmentToBeUsedForDebtRepayment": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PercentageOfNetProceedsFromSaleOfEquipmentToBeUsedForDebtRepayment", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of net proceeds realized from the sale of equipment, which must be used for the repayment of debt as defined in the Company's credit agreement with Woodforest National Bank.", "label": "Percentage of net proceeds from sale of equipment to be used for debt repayment", "terseLabel": "Percentage of equipment sale proceeds to be used for debt repayment" } } }, "auth_ref": [] }, "ibio_PercentageOfTotalCommonSharesInOfferingWarrantsAvailableForUnderwriters": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PercentageOfTotalCommonSharesInOfferingWarrantsAvailableForUnderwriters", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of additional shares available for purchase by underwriters through the issuance of warrants, expressed as a percentage of the aggregate number of shares of common stock and pre-funded warrants currently included in equity offerings.", "label": "Percentage of total common shares in offering, warrants available for underwriters", "terseLabel": "Additional shares for purchase, percentage of aggregate shares in offerings" } } }, "auth_ref": [] }, "ibio_PlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Placement agent fees paid in cash, represented as a percentage of aggregate gross proceeds.", "label": "Placement Agent Fees Paid As A Percentage Of Aggregate Gross Proceeds", "terseLabel": "Placement agent fees paid (as percentage)" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r923"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r968"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r922"] }, "ibio_PotentialContingentPaymentReceivableUponAchievementOfSpecifiedDevelopmentalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PotentialContingentPaymentReceivableUponAchievementOfSpecifiedDevelopmentalMilestones", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Potential amount of contingent payments receivable by the company upon achievement of specified developmental milestones.", "label": "Potential Contingent Payment Receivable Upon Achievement Of Specified Developmental Milestones", "terseLabel": "Potential contingent payment" } } }, "auth_ref": [] },
"ibio_PotentialContingentPaymentReceivableUponAchievementOfSpecifiedMilestonesFollowingCommercialization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PotentialContingentPaymentReceivableUponAchievementOfSpecifiedMilestonesFollowingCommercialization", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Potential amount of contingent payments receivable by the company upon achievement of specified milestones following commercialization.", "label": "Potential Contingent Payment Receivable Upon Achievement Of Specified Milestones Following Commercialization", "terseLabel": "Second potential contingent payment" } } }, "auth_ref": [] }, "ibio_PreFundedWarrantsAndSeriesEWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PreFundedWarrantsAndSeriesEWarrantsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails",
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Pre-funded Warrants and Series E Warrants.", "label": "Pre-funded Warrants and Series E Warrants [Member]", "terseLabel": "Pre-funded and Series E Warrants" } } }, "auth_ref": [] }, "ibio_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Pre Funded Warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionRatio", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Preferred stock, conversion ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": ["r400"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r870", "r871", "r874", "r875", "r876", "r877", "r1216", "r1217"] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "terseLabel": "Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "verboseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r111", "r398"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r111", "r737"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "verboseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r111", "r398"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r111", "r737", "r757", "r1217", "r1218"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2024 and June 30, 2023; 0 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r111", "r675", "r859"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r982"] },
"ibio_PrepaymentFeePercentageOfPrincipalAmountRepaidWhenPrepaymentOccursAfterOneYearButPriorToTwoYearsFromIssuance": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PrepaymentFeePercentageOfPrincipalAmountRepaidWhenPrepaymentOccursAfterOneYearButPriorToTwoYearsFromIssuance", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the total principal amount being prepaid, when a prepayment on the loan balance occurs on, after 12 months, but prior-to 24 months, from the loan origination date.", "label": "Prepayment Fee, Percentage of Principal Amount Repaid When Prepayment Occurs After One Year, But Prior-to Two Years, From Issuance", "terseLabel": "Fee percentage applied to principal prepayments (12 months or less from origination)" } } }, "auth_ref": [] },
"ibio_PrepaymentFeePercentageOfPrincipalAmountRepaidWhenPrepaymentOccursPriorToOneYearFromIssuance": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PrepaymentFeePercentageOfPrincipalAmountRepaidWhenPrepaymentOccursPriorToOneYearFromIssuance", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the total principal amount being prepaid, when a prepayment on the loan balance occurs on, or prior-to, 12 months from the loan origination date.", "label": "Prepayment Fee, Percentage of Principal Amount Repaid When Prepayment Occurs Prior to One Year From Issuance", "terseLabel": "Fee percentage applied to principal prepayments (12-24 months from origination)" } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails"], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "ibio_PrincipalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PrincipalMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Information

pertaining to principal portion of the obligation.", "label": "Principal [Member]", "terseLabel": "Principal" } } }, "auth_ref": [] },
"ibio_PrincipalReductionMilestoneAmountsTriggeringReleaseOfCollateralHeld": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630",
"localname": "PrincipalReductionMilestoneAmountsTriggeringReleaseOfCollateralHeld", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of principal reduction on the term
loan, provided the total principal outstanding is less than $10 million, in which Woodforest National Bank will release cash held as collateral back to the Company.",
"label": "Principal reduction, milestone amounts triggering release of collateral held" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role":
{ "label": "Private Placement [Member]", "terseLabel": "Private placement", "documentation": "A private placement is a direct offering of securities to a limited
number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-
gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Proceeds from sales of common stock", "verboseLabel": "Proceeds from offering", "documentation": "The cash inflow from the additional capital
contribution to the entity." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Convertible Preferred Stock",
"terseLabel": "Preferred stock, proceeds from issuance", "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into
another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement",
"terseLabel": "Subscription receivable", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than
public placement." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"],
"lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "verboseLabel": "Warrants, proceeds from issuance", "documentation": "The cash inflow
from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r4"] }, "us-
gaap_ProceedsFromLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLegalSettlements",
"crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
"http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Legal Settlements", "terseLabel":
"Settlement payment received", "documentation": "Cash received for the settlement of litigation during the current period." } } }, "auth_ref": ["r134"] }, "us-
gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Maturities, Prepayments and
Calls of Debt Securities, Available-for-Sale", "verboseLabel": "Redemption of debt securities", "documentation": "Amount of cash inflow from maturity, prepayment
and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } },
"auth_ref": ["r236", "r237", "r1020"] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromNotesPayable", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Notes Payable", "verboseLabel":
"Proceeds from term promissory note", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [
"r30"] }, "us-gaap_ProceedsFromOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromOtherDebt",
"crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from
Other Debt", "terseLabel": "Proceeds from equipment financing loan", "documentation": "Amount of cash inflow from debt classified as other." } } }, "auth_ref": [
"r30"] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-
for-Sale", "terseLabel": "Sale of debt securities", "verboseLabel": "Proceeds from sale of debt securities", "documentation": "Amount of cash inflow from sale of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r27",
"r236", "r304", "r306"] }, "us-gaap_ProceedsFromSaleOfBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfBuildings", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails",
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Buildings", "terseLabel":
"Proceeds from sale of building", "documentation": "The cash inflow from sale of buildings." } } }, "auth_ref": ["r128"] }, "us-
gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Intangible Assets",
"terseLabel": "Sale proceeds for intangible assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual
or other legal rights, excluding goodwill." } } }, "auth_ref": ["r128"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and
Equipment", "terseLabel": "Sales proceeds for fixed assets", "verboseLabel": "Net proceeds from auctioned equipment", "documentation": "The cash inflow from the
sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [
"r128"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails",
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "verboseLabel":
"Proceeds from exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } },
"auth_ref": ["r990"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit",
"presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "definitionGuidance": "Consolidated net loss",
"label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Consolidated net loss", "verboseLabel": "Net loss",
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } },
"auth_ref": ["r207", "r226", "r228", "r239", "r247", "r255", "r261", "r264", "r265", "r307", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368",
"r541", "r545", "r547", "r550", "r551", "r563", "r585", "r671", "r684", "r711", "r759", "r776", "r777", "r847", "r848", "r879", "r985", "r1046"] }, "us-
gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Fixed Assets" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails",
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails",
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-
us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services
and not intended for resale." } } }, "auth_ref": ["r9", "r616"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel":
"Fixed Assets", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is
not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r138", "r193", "r196", "r197"] }, "us-
gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and
Equipment, Gross", "terseLabel": "Gross fixed assets", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets
used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office
equipment, and furniture and fixtures." } } }, "auth_ref": ["r142", "r212", "r681"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails"],
"lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r616"] },
"us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
"http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "totalLabel": "Net
fixed assets", "verboseLabel": "Fixed assets, net of accumulated depreciation", "documentation": "Amount after accumulated depreciation, depletion and amortization
of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land,
buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r9", "r616", "r672", "r681", "r859"] }, "us-
gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": {
"en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Fixed Assets", "documentation": "Disclosure of accounting
policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure,
and similar asset classified as collections." } } }, "auth_ref": ["r9", "r193", "r196", "r679"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssetsTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel":
"Schedule of gross carrying value and accumulated depreciation of fixed assets", "documentation": "Tabular disclosure of physical assets used in the normal conduct
of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including

composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r9"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r142", "r616"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Fixed assets, useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ibio_PurchaseAndSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PurchaseAndSaleAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2024 Purchase and Sale Agreement.", "label": "Purchase and Sale Agreement [Member]", "terseLabel": "2024 Purchase and Sale Agreement - The Board of Regents" } } }, "auth_ref": [] }, "ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PurchaseAndSaleAgreementWithMajesticRealtyCoMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to purchase and Sale Agreement with Majestic Realty Co.", "label": "Purchase and Sale Agreement with Majestic Realty Co", "terseLabel": "Purchase and Sale Agreement - Majestic Realty" } } }, "auth_ref": [] }, "ibio_PurchaseAndSaleGroundLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PurchaseAndSaleGroundLeaseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to The Purchase and Sale Agreement (Ground Lease Agreement).", "label": "The Purchase and Sale Ground Lease Agreement [Member]", "verboseLabel": "The Purchase and Sale Agreement" } } }, "auth_ref": [] }, "ibio_PurchaseOffFixedAssetsCashFlowImpactDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PurchaseOfFixedAssetsCashFlowImpactDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of long-lived, physical assets that have been reported in the consolidated statements of income under discontinued operations.", "label": "Purchase of Fixed Assets Cash Flow Impact Discontinued Operations", "terseLabel": "Purchase of fixed assets" } } }, "auth_ref": [] }, "ibio_PurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "PurchasePricePerShare", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Purchase price per share in various scenarios.", "label": "Purchase price per share", "terseLabel": "Combined purchase price per share" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r920"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r920"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r350", "r351", "r352", "r353", "r434", "r455", "r491", "r492", "r493", "r505", "r569", "r628", "r629", "r631", "r690", "r692", "r699", "r727", "r728", "r784", "r786", "r788", "r789", "r791", "r811", "r812", "r827", "r834", "r842", "r853", "r854", "r855", "r856", "r868", "r872", "r1042", "r1048", "r1154", "r1169", "r1170", "r1171", "r1172", "r1173"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r350", "r351", "r352", "r353", "r434", "r455", "r491", "r492", "r493", "r505", "r569", "r628", "r629", "r631", "r690", "r692", "r699", "r727", "r728", "r784", "r786", "r788", "r789", "r791", "r811", "r812", "r827", "r834", "r842", "r853", "r854", "r855", "r856", "r868", "r872", "r1042", "r1048", "r1154", "r1169", "r1170", "r1171", "r1172", "r1173"] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r113", "r119"] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Promissory Note Receivable" } } }, "auth_ref": [] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "terseLabel": "Subscription Receivable", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": ["r298", "r299", "r300", "r302", "r1016"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r887", "r898", "r908", "r941"] }, "ibio_ReducedPlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ReducedPlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Reduced placement agent fees for certain investors paid in cash, represented as a percentage of aggregate gross proceeds.", "label": "Reduced Placement Agent Fees Paid As A Percentage Of Aggregate Gross Proceeds", "terseLabel": "Reduced placement agent fee percentage" } } }, "auth_ref": [] }, "ibio_ReductionInCollateralHeldFromAcceleratedPrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ReductionInCollateralHeldFromAcceleratedPrincipalPayments", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of cash, previously held as collateral by Woodforest National Bank, released back to the company upon satisfying certain milestones related to principal repayments on the term loan.", "label": "Reduction in collateral held from accelerated principal payments", "terseLabel": "Collateral released once milestone payments made" } } }, "auth_ref": [] }, "ibio_ReductionInCollateralHeldFromLegalSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ReductionInCollateralHeldFromLegalSettlement", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Reduction in cash held by Woodforest as collateral pursuant to the Credit Agreement.", "label": "Reduction in collateral held from legal settlement", "terseLabel": "Reduction in collateral held" } } }, "auth_ref": [] }, "ibio_RegistrationStatementDelinquencyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "RegistrationStatementDelinquencyPeriod", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an \"Event Date\") and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%.", "label": "Registration statement delinquency period", "terseLabel": "Failure to file registration statement, delinquency period" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Payment of term note payable", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r131"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "terseLabel": "Repayments of outstanding principal on term loan", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r991"] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Repayments of Lines of Credit", "terseLabel": "Cash payments to settle debt", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r131", "r997"] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Lines of Credit", "terseLabel": "Proceeds from sale of property paid to Woodforest to settle debt", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r131"] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable", "negatedLabel": "Payment of term promissory note", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": ["r131"] }, "us-gaap_RepaymentsOfOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherDebt", "crdr": "credit", "presentation": [

"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Other Debt", "negatedLabel": "Payment of equipment financing loan", "documentation": "Amount of cash outflow for the payment of debt classified as other." } } }, "auth_ref": ["r131"] }, "ibio_RepresentativeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "RepresentativeWarrantsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to representative warrants.", "label": "Representative Warrants [Member]", "terseLabel": "Representative Warrants" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r249", "r250", "r373", "r401", "r621", "r630", "r673", "r819", "r820"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development expenses", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r507", "r813", "r825", "r1174"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "verboseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r506"] }, "ibio_ReservesRelatedToTermPromissoryNoteIncludedInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ReservesRelatedToTermPromissoryNoteIncludedInPrepaidExpenses", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of reserves related to term promissory note included in prepaid expenses, classified as non-cash activities.", "label": "Reserves Related To Term Promissory Note Included In Prepaid Expenses", "terseLabel": "Reserves related to term promissory note included in prepaid expenses" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r888", "r899", "r909", "r942"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r889", "r900", "r910", "r943"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r896", "r907", "r917", "r950"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r978", "r995", "r1176", "r1184"] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Amount held as collateral from legal settlement", "verboseLabel": "Restricted Cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r33", "r211", "r243"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Axis]", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": ["r98"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r211"] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash, current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r978", "r995"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "verboseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r187", "r979", "r995"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "terseLabel": "Number of positions reduced", "documentation": "The expected number of positions to be eliminated as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Pre-tax employee reduction expenses", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": ["r343", "r345", "r346", "r347"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage of workforce reduction", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringSettlementAndImpairmentProvisionsAbstract", "lang": { "en-us": { "role": { "label": "Significant Transactions" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r115", "r152", "r677", "r697", "r698", "r708", "r738", "r859"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r204", "r252", "r253", "r254", "r256", "r261", "r263", "r265", "r308", "r309", "r334", "r529", "r530", "r538", "r539", "r540", "r542", "r544", "r545", "r554", "r556", "r557", "r559", "r561", "r595", "r598", "r694", "r696", "r712", "r1217"] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined

benefit and defined contribution plans." } } }, "auth_ref": { "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r842", "r974", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111" } }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": { "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r842", "r974", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111" } }, "us-gaap_RetirementPlanNameOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameOtherMember", "presentation": ["http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Name, Other [Member]", "terseLabel": "iBio 401(k) Plan", "documentation": "Retirement plan not separately disclosed by name classified as other." } } }, "auth_ref": { "r1099" } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r173", "r174", "r279", "r284", "r285", "r289", "r291", "r292", "r293", "r295", "r428", "r429", "r634" } }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": { "r201", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r814" } }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Increase in finance lease ROU assets for new leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": { "r612", "r858" } }, "ibio_RightOfUseAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "RightOfUseAssetsPolicyPolicyTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for right-of-use assets.", "label": "Right Of Use Assets Policy [Policy Text Block]", "terseLabel": "Right-of-Use Assets" } } }, "auth_ref": [] }, "ibio_RubrycTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "RubrycTherapeuticsIncMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to RubrYc Therapeutics, Inc.", "label": "RubrYc Therapeutics Inc [Member]", "terseLabel": "RubrYc Therapeutics" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r959" } }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r959" } }, "ibio_SafiBiosolutionsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SafiBiosolutionsIncMember", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Safi Biosolutions, Inc.", "label": "Safi Biosolutions Inc [Member]", "terseLabel": "Safi Biosolutions" } } }, "auth_ref": [] }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleAndLeasebackTransactionGainLossNet", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "negatedLabel": "Gain on disposition of finance lease ROU assets", "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale." } } }, "auth_ref": { "r610", "r619", "r858" } }, "us-gaap_SaleLeasebackTransactionGrossProceedsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionGrossProceedsInvestingActivities", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Sale Leaseback Transaction, Gross Proceeds, Investing Activities", "terseLabel": "Purchase price for Ground Lease Property", "documentation": "Amount of cash inflow before closing and debt issuance costs received by a seller-lessee in a sale-leaseback recognized in investing activities." } } }, "auth_ref": { "r182", "r183", "r184" } }, "us-gaap_SaleLeasebackTransactionImputedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionImputedInterestRate", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Sale Leaseback Transaction, Imputed Interest Rate", "terseLabel": "Interest rate on lease (percentage of facility's market value)", "documentation": "The financing cost related to leases that have been recorded under the deposit method, as a financing or as a capital leases in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller." } } }, "auth_ref": [] }, "us-gaap_SaleLeasebackTransactionRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleLeasebackTransactionRentExpense", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Sale Leaseback Transaction, Rent Expense", "terseLabel": "Base rent expense", "documentation": "The amount of the current period expense recorded for use of the property in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller." } } }, "auth_ref": { "r181" } }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Common stock, net proceeds from issuance", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Fair value of shares issued in agreement", "verboseLabel": "Common stock, gross proceeds from issuance", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock, shares issued", "verboseLabel": "Number of shares issued per agreement", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Sales [Member]", "terseLabel": "Revenues", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": { "r18" } }, "ibio_SanDiegoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SanDiegoMember", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to San Diego.", "label": "San Diego [Member]", "terseLabel": "San Diego, California" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": ["http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails"], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": { "r113", "r119", "r297", "r1018" } }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": { "r38" } }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": { "r65", "r66", "r543" } }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": {
"label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash
equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash
Equivalents [Table Text Block]", "terseLabel": "Schedule of of total cash, cash equivalents and restricted cash", "documentation": "Tabular disclosure of the
components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other
than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to
revenue-generating activity or operations." } } }, "auth_ref": ["r546"] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table
Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "documentation": "Tabular disclosure of the components of income tax
expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit),
investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to
contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted
changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a
change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1144"] },
"ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for components of
lease expense and supplemental balance sheet information related to the finance lease obligation.", "label": "Schedule Of Components Of Lease Expense And
Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]", "terseLabel": "Schedule of components of lease expense and
supplemental balance sheet information related to the finance lease obligation" } } }, "auth_ref": [] },
"ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of components of lease expense
and supplemental balance sheet information related to the Operating lease obligation", "label": "Schedule of components of lease expense and supplemental balance
sheet information related to the Operating lease obligation [Table Text Block]", "terseLabel": "Lease Expense and Supplemental Balance Sheet Information Related to
the Operating Lease Obligation" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text
Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability
recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total
valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r1142"] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation":
"Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar
plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value
measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant
other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r12", "r54", "r55", "r56", "r57"] }, "us-
gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations
[Table Text Block]", "terseLabel": "Schedule of discontinued operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes,
but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant
component." } } }, "auth_ref": ["r11", "r17", "r24", "r77", "r86", "r87", "r88", "r90", "r91", "r94", "r96", "r97", "r144"] }, "us-
gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"],
"lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings (loss) Per Share,
Basic and Diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators
and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1006"] }, "us-
gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us":
{ "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
"documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to
continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from
continuing operations." } } }, "auth_ref": ["r514", "r845", "r1140"] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-
based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of
financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r62"] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and
Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs",
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or
comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r62"]
}, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails",
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Intangible Asset,
Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [
"r318", "r325", "r329", "r330", "r332", "r635", "r813", "r828"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
"verboseLabel": "Schedule of Category the gross carrying value and accumulated amortization of intangible assets", "documentation": "Tabular disclosure of assets,
excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r828", "r1031"]
}, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "label":
"Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Future Minimum Financing Payments", "documentation": "Tabular
disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r10"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails"],
"lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal
conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used,
including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r9", "r616"] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based
Compensation Arrangements by Share-Based Payment Award [Table]", "verboseLabel": "Schedule of Share-based Compensation Arrangements by Share-based
Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r462", "r464", "r466", "r467",
"r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491",
"r492", "r493", "r494"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of
exercise prices." } } }, "auth_ref": ["r59"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity
[Table Text Block]", "terseLabel": "Schedule of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to,

outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r15", "r16", "r154"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r159"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r102"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r48", "r49", "r50", "r51", "r52", "r53", "r147", "r149", "r151", "r152", "r216", "r217", "r218", "r281", "r398", "r399", "r401", "r403", "r406", "r412", "r414", "r704", "r705", "r706", "r707", "r834", "r971", "r996"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Estimated annual amortization expenses for next five years and thereafter", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r828", "r1033"] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebt", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Secured Debt", "terseLabel": "Equipment financing payable, net", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": ["r20", "r167", "r1182"] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtCurrent", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Secured Debt, Current", "negatedLabel": "Less: current portion", "terseLabel": "Equipment financing payable - current portion", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": ["r102", "r165"] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "terseLabel": "Term Note", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredLongTermDebt", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "Equipment financing payable - net of current portion", "verboseLabel": "Long-term portion of minimum equipment financing obligation", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": ["r20"] }, "ibio_SecuredTermLoanAmendedReducedLiquidityCovenant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SecuredTermLoanAmendedReducedLiquidityCovenant", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum liquidity requirement per debt covenants in amended credit agreements (liquidity amount if specific milestones are met).", "label": "Secured Term Loan Amended Reduced Liquidity Covenant", "terseLabel": "Liquidity covenant (minimum unrestricted cash balance if specific milestones are met)" } } }, "auth_ref": [] }, "ibio_SecuredTermLoanInitialLiquidityCovenant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SecuredTermLoanInitialLiquidityCovenant", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum liquidity requirement per debt covenants in credit agreements.", "label": "Secured Term Loan Initial Liquidity Covenant", "terseLabel": "Liquidity covenant, unrestricted cash balance" } } }, "auth_ref": [] }, "ibio_SecuredTermLoanLiquidityCovenantForCollateralWithdrawal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SecuredTermLoanLiquidityCovenantForCollateralWithdrawal", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Minimum liquidity requirement for collateral withdrawal per debt covenants in credit agreements.", "label": "Secured Term Loan Liquidity Covenant For Collateral Withdrawal", "terseLabel": "Collateral withdrawal, liquidity threshold to maintain" } } }, "auth_ref": [] }, "ibio_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Securities Purchasing Agreement.", "label": "Securities Purchase Agreement [Member]", "terseLabel": "2024 Securities Purchase Agreement", "verboseLabel": "Securities Purchase Agreement" } } }, "auth_ref": [] }, "ibio_SecuritiesPurchaseStockAndWarrantsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SecuritiesPurchaseStockAndWarrantsAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Securities Purchase Agreement and Warrants.", "label": "Securities Purchase Stock and Warrants Agreement [Member]", "terseLabel": "Securities Purchase Agreement and Warrants" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r881"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Security Deposit", "verboseLabel": "Security deposits", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r979"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r883"] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentContinuingOperationsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "terseLabel": "Continuing Operations", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfLossFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureEmployee401KPlanDetails", "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureFixedAssetsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations", "verboseLabel": "Loss from Discontinued Operations", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r6", "r78", "r79", "r80"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r293", "r294", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r724", "r725", "r726", "r785", "r787", "r790", "r792", "r800", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r815", "r835", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r869", "r872", "r1051", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215"] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentOperatingActivitiesDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "ibio_SeparationAgreementAndGeneralReleaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SeparationAgreementAndGeneralReleaseMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Separation Agreement and General Release.", "label": "Separation Agreement and General Release [Member]", "terseLabel": "Separation Agreement and General Release" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A-2 Preferred Stock", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r980", "r981", "r1050"] }, "ibio_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SeriesBWarrantsMember", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series B warrants.", "label": "Series B warrants" } } }, "auth_ref": [] }, "ibio_SeriesCWarrantsMember": { "xbrltype":

```
"domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SeriesCWarrantsMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Represents the member information pertaining to Series C Warrants.", "label": "Series C Warrants [Member]", "terseLabel": "Series C Warrants"
} } }, "auth_ref": [] }, "ibio_SeriesDWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"SeriesDWarrantsMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails",
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining
to Series D Warrants.", "label": "Series D Warrants [Member]", "terseLabel": "Series D Warrants" } } }, "auth_ref": [] }, "ibio_SeriesEWarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SeriesEWarrantsMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Represents the member information pertaining to Series E Warrants.", "label": "Series E Warrants [Member]", "terseLabel": "Series E Warrants"
} } }, "auth_ref": [] }, "ibio_SeriesWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"SeriesWarrantsMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents information pertaining to series A warrants.", "label": "Series A warrants" } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails" ], "lang": { "en-us": { "role": { "label": "Settled Litigation [Member]", "terseLabel": "Settled
Litigation", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref":
[ "r1044" ] }, "us-gaap_SettlementAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettlementAssetsCurrent",
"crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails" ], "lang": { "en-us": { "role": { "label": "Settlement Assets,
Current", "verboseLabel": "Settlement receivable", "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer
payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may
include cash and cash equivalents." } } }, "auth_ref": [] },
"ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.ibioinc.com/20240630", "localname": "SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember",
"presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information
pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank for the first potential withdrawal from the Reserve Funds Deposit
Account.", "label": "Seventh Amendment to Credit Agreement with Woodforest National Bank First Collateral Withdrawal [Member]", "terseLabel": "First Potential
Collateral Withdrawal" } } }, "auth_ref": [] }, "ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.ibioinc.com/20240630", "localname": "SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the
seventh amendment to the Credit Agreement with Woodforest National Bank.", "label": "Seventh Amendment to Credit Agreement with Woodforest National Bank
[Member]", "terseLabel": "Seventh Amended Credit Agreement" } } }, "auth_ref": [] },
"ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.ibioinc.com/20240630", "localname": "SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember",
"presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information
pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank for the second potential withdrawal from the Reserve Funds Deposit
Account.", "label": "Seventh Amendment to Credit Agreement with Woodforest National Bank Second Collateral Withdrawal [Member]", "terseLabel": "Second
Potential Collateral Withdrawal" } } }, "auth_ref": [] },
"ibio_SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.ibioinc.com/20240630", "localname": "SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember",
"presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information
pertaining to the seventh amendment to the Credit Agreement with Woodforest National Bank for the third potential withdrawal from the Reserve Funds Deposit
Account.", "label": "Seventh Amendment to Credit Agreement with Woodforest National Bank Third Collateral Withdrawal [Member]", "terseLabel": "Third Potential
Collateral Withdrawal" } } }, "auth_ref": [] }, "ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod": { "xbrltype": "durationItemType",
"nsuri": "http://www.ibioinc.com/20240630", "localname": "SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the Consolidated Omnibus
Budget Reconciliation Act of 1985 (\"COBRA\") subsidy period.", "label": "Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period",
"terseLabel": "COBRA subsidy period" } } }, "auth_ref": [] },
"ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct": { "xbrltype":
"durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum period of coverage
of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\")." , "label": "Severance Benefits, Maximum Period for Coverage of
Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act", "terseLabel": "Maximum period for coverage of health insurance" } } },
"auth_ref": [] },
"ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct": {
"xbrltype": "decimalItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct",
"presentation": [ "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of
times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation
Act of 1985 (\"COBRA\")." , "label": "Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under
Consolidated Omnibus Budget Reconciliation Act", "terseLabel": "Lump sum payment equal to six time the COBRA subsidy" } } }, "auth_ref": [] },
"ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630",
"localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary", "presentation": [
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the period of bi-monthly
installments of current base salary to be paid under severance benefits.", "label": "Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary",
"terseLabel": "Period of bi-monthly installments of current base salary" } } }, "auth_ref": [] },
"ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus", "presentation": [ "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ],
"lang": { "en-us": { "role": { "documentation": "Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.", "label":
"Severance Benefits, Period of Bi-Monthly Installments of target Bonus", "terseLabel": "Period of bi-monthly installments of target bonus" } } }, "auth_ref": [] }, "us-
gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Severance Costs", "terseLabel": "Personnel and
severance costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated
under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a
discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash
Expense", "verboseLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [
"r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": {
"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period",
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or
performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is
not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r843" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Number of shares terminated",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } },
"auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares issued", "verboseLabel":
"Share-based awards issued", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom
stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r481" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue":
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
"verboseLabel": "Market value per share", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the
period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } },
"auth_ref": [ "r481" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Shares
vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } },
"auth_ref": [ "r482" ] }, "us-
```

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Grant date fair value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r485"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend rate", "verboseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r492"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "verboseLabel": "Volatility, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "verboseLabel": "Volatility, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Weighted-average risk free interest rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Weighted-average risk free interest rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r462", "r464", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "verboseLabel": "Stock Options, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r472"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted-average Exercise Price, Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r472"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Stock Options, Forfeited/expired", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r476"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options granted", "verboseLabel": "Stock Options, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r474"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average grant date fair value, options granted in period", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r484"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r59"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock Options, Outstanding at end of the period", "periodStartLabel": "Stock Options, Outstanding at beginning of the period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r470", "r471"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-average Exercise Price, Outstanding at end of the period", "periodStartLabel": "Weighted-average Exercise Price, Outstanding at beginning of the period", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r470", "r471"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Vested and expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r486"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "presentation": [

```
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "terseLabel": "Schedule of Stock Options Outstanding and Exercisable", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Stock Options, Vested and expected to vest", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Weighted-average Exercise Price, Vested and expected to vest", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Annual increase in shares available under plan", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "verboseLabel": "Shares issued pursuant to past grants", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails",
"http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted-average Exercise Price, Forfeited/expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price", "verboseLabel": "Weighted-average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r474" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails",
"http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Option Vesting Arrangement, Tranche One", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails",
"http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Option Vesting Arrangement, Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r461", "r469", "r488", "r489", "r490", "r491", "r494", "r500", "r501", "r502", "r503" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price - Lower range", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Number Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r155", "r156" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price - Upper range", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "terseLabel": "Employees", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r464", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Non-Employees", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes
```

nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r462", "r466", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r491", "r492", "r493", "r494"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Company's closing stock price", "verboseLabel": "Combined price per share of common stock and warrants", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Abstract]", "terseLabel": "Reverse Stock Split" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "verboseLabel": "Stock options vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r1112"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r490"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted-average Remaining Contractual Term (in years), Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r158"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted-average Remaining Contractual Term (in years), Exercisable", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r487"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Term (in years), Vested and expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r486"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value, options vested in period", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r485"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": ["r155", "r156"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Life In Years", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r158"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Share price", "verboseLabel": "Share price of common stock", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Equity, ending balance (shares)", "periodStartLabel": "Equity, beginning balance (shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBankLoansAndNotesPayable", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-Term Bank Loans and Notes Payable", "terseLabel": "Term note payable - net of deferred financing costs", "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": ["r99", "r733", "r1181"] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermNonBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermNonBankLoansAndNotesPayable", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-Term Nonbank Loan and Note Payables", "terseLabel": "Insurance premium financing payable", "documentation": "Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer." } } }, "auth_ref": ["r100", "r734", "r735"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r136", "r244"] }, "ibio_SignificantTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SignificantTransactionsTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactions"], "lang": { "en-us": { "role": { "documentation": "Significant Transactions [Text Block]", "label": "Significant Transactions [Text Block]", "verboseLabel": "Significant Transactions" } } }, "auth_ref": [] }, "ibio_SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the sixth amendment to the Credit Agreement with Woodforest National Bank.", "label": "Sixth Amendment to Credit Agreement with Woodforest National Bank [Member]", "terseLabel": "Sixth Amended Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r202", "r216", "r217", "r218", "r247", "r269", "r270", "r272", "r274", "r281", "r282", "r307", "r360", "r362", "r363", "r364", "r367", "r368", "r398", "r399", "r403", "r406", "r414", "r585", "r704", "r705", "r706", "r707", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r737", "r760", "r778", "r793", "r794", "r795", "r796", "r797", "r971", "r996", "r1005"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r112", "r116", "r117", "r204", "r231", "r232", "r233", "r252", "r253", "r254", "r256", "r261", "r263", "r265", "r280", "r308", "r309", "r334", "r416", "r529", "r530", "r538", "r539", "r540", "r542", "r544", "r545", "r554", "r555", "r556", "r557", "r558", "r559", "r561", "r586", "r587", "r588", "r589", "r590", "r591", "r595", "r598", "r620", "r686", "r694", "r695", "r696", "r712", "r778"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r293", "r294", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r724", "r725",

{"r726", "r785", "r787", "r790", "r792", "r800", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r815", "r835", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r869", "r872", "r1051", "r1187", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtTables", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "verboseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r252", "r253", "r254", "r280", "r598", "r634", "r702", "r723", "r729", "r730", "r731", "r732", "r734", "r735", "r737", "r740", "r741", "r742", "r743", "r744", "r747", "r748", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r758", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r873"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "verboseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndSupplementalInformationDetails", "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureDebtTables", "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r252", "r253", "r254", "r280", "r296", "r598", "r634", "r702", "r723", "r729", "r730", "r731", "r732", "r734", "r735", "r737", "r740", "r741", "r742", "r743", "r744", "r747", "r748", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r758", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r873"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r891", "r902", "r912", "r945"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockGrantedDuringPeriodValueSharebasedCompensationForfeited", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Shares Granted, Value, Share-Based Payment Arrangement, Forfeited", "terseLabel": "Stock options forfeited", "documentation": "Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r157"] }, "ibio_StockIssuanceCostsExpenseReimbursements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StockIssuanceCostsExpenseReimbursements", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent.", "label": "Stock issuance costs, expense reimbursements", "terseLabel": "Out-of-pocket expense reimbursements" } } }, "auth_ref": [] }, "ibio_StockIssuanceCostsLegalExpenseReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StockIssuanceCostsLegalExpenseReimbursement", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent.", "label": "Stock issuance costs, legal expense reimbursement", "terseLabel": "Reimbursement for legal expenses" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Asset acquisition (shares)", "verboseLabel": "Shares purchased in transaction", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r111", "r112", "r152"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "negatedLabel": "Conversion of preferred stock to common stock (shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r14", "r50", "r112", "r116", "r152", "r386"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Capital raises (shares)", "verboseLabel": "Shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r14", "r111", "r112", "r152", "r704", "r778", "r794"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Vesting of RSUs (shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r14", "r111", "r112", "r152"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "negatedLabel": "Payments for fractional shares resulting from reverse stock split (shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r14"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.ibioinc.com/role/DisclosureShareBasedCompensationOptionsOutstandingAndExercisableDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails", "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Stock Options, Exercised", "terseLabel": "Stock options, exercises in period", "verboseLabel": "Shares exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r14", "r111", "r112", "r152", "r475"] }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockSplits", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Stock Splits", "terseLabel": "Fractional shares issued in reverse stock split", "documentation": "Number of shares issued during the period as a result of a stock split." } } }, "auth_ref": ["r14", "r111", "r112", "r152"] }, "ibio_StockIssuedDuringPeriodSharesWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StockIssuedDuringPeriodSharesWarrants", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during the period.", "label": "Stock Issued During Period, Shares, Warrants", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Asset acquisition", "verboseLabel": "Value of shares purchased in transaction", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r14", "r112", "r116", "r117", "r152"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "negatedLabel": "Conversion of preferred stock to common stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r14", "r112", "r116", "r117", "r152"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Capital raises", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r14", "r111", "r112", "r152", "r712", "r778", "r794", "r879"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Vesting of RSUs", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r14", "r152"] }, "ibio_StockPurchaseAgreementExclusivityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StockPurchaseAgreementExclusivityPeriod", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Pursuant to the 2024 Stock Purchase Agreement, the period for which the Company is prohibited from entering into any agreement to issue or announce the issuance/proposed issuance of any shares of common stock or convertible securities.", "label": "Stock Purchase Agreement Exclusivity Period", "terseLabel": "Purchase agreement exclusivity period" } } }, "auth_ref": [] }, "ibio_StockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":

"StockPurchaseAgreementMember", "presentation": ["http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"], "lang": { "en-us": { "role": { "documentation": "Stock Purchase Agreement [Member]", "label": "Stock Purchase Agreement [Member]", "terseLabel": "Stock Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "totalLabel": "Total Stockholders' Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r112", "r116", "r117", "r137", "r739", "r757", "r779", "r780", "r859", "r880", "r998", "r1023", "r1157", "r1217"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r67", "r68", "r69", "r204", "r205", "r232", "r252", "r253", "r254", "r256", "r261", "r263", "r308", "r309", "r334", "r416", "r529", "r530", "r538", "r539", "r540", "r542", "r544", "r545", "r554", "r555", "r556", "r557", "r558", "r559", "r561", "r586", "r587", "r591", "r596", "r620", "r695", "r696", "r710", "r739", "r757", "r779", "r780", "r798", "r879", "r998", "r1023", "r1157", "r1217"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": ["http://www.ibioinc.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r148", "r246", "r397", "r399", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r410", "r411", "r413", "r416", "r560", "r781", "r782", "r799"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split, shares received per share tendered", "verboseLabel": "Reverse stock split, shares received per share tendered", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r153"] }, "ibio_StrikePriceToDirectPurchaseOfStock1": { "xbrltype": "perShareItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StrikePriceToDirectPurchaseOfStock1", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 5,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.", "label": "Strike Price To Direct the Purchase of Stock1", "terseLabel": "Stock price permitting the sale of up to 5,000 shares" } } }, "auth_ref": [] }, "ibio_StrikePriceToDirectPurchaseOfStock2": { "xbrltype": "perShareItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StrikePriceToDirectPurchaseOfStock2", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 7,500 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.", "label": "Strike Price To Direct the Purchase of Stock2", "terseLabel": "Stock price permitting the sale of up to 7,500 shares" } } }, "auth_ref": [] }, "ibio_StrikePriceToDirectPurchaseOfStock3": { "xbrltype": "perShareItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StrikePriceToDirectPurchaseOfStock3", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 10,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement.", "label": "Strike Price To Direct the Purchase of Stock3", "terseLabel": "Stock price permitting the sale of up to 10,000 shares" } } }, "auth_ref": [] }, "ibio_StrikePriceToDirectPurchaseOfStock4": { "xbrltype": "perShareItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "StrikePriceToDirectPurchaseOfStock4", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase the maximum allowable amount of the Company's common stock at a price per share determined in the stock purchasing agreement. Additionally, the counterparty may be directed to purchase additional shares of the Company's common stock in an \"accelerated purchase,\" and one or more \"additional accelerated purchases\" on the business day immediately following the initial purchase of shares.", "label": "Strike Price To Direct the Purchase of Stock4", "terseLabel": "Stock price permitting accelerated purchase clause" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r592", "r623"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r592", "r623"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r592", "r623"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r592", "r623"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r592", "r623"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r622", "r624"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock", "presentation": ["http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.", "label": "Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]", "terseLabel": "Summary of the gross carrying value and accumulated amortization of finance lease ROU" } } }, "auth_ref": [] }, "ibio_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationOfCashFlowsFromDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r938"] }, "us-gaap_TenantImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TenantImprovements", "crdr": "debit", "presentation": ["http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails"], "lang": { "en-us": { "role": { "label": "Tenant Improvements", "verboseLabel": "Tenant improvement allowance", "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants." } } }, "auth_ref": ["r1178", "r1179"] }, "ibio_TermNote2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "TermNote2024Member", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2024 Term Note.", "label": "Term Note, 2024 [Member]", "terseLabel": "Term Promissory Note" } } }, "auth_ref": [] }, "ibio_TermOfPurchaseAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "TermOfPurchaseAgreement", "presentation": ["http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Term of a stock purchase agreement.", "label": "Term Of Purchase Agreement", "terseLabel": "Term of stock purchase agreement" } } }, "auth_ref": [] }, "ibio_ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember", "presentation": ["http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the

```
third amendment to the Credit Agreement with Woodforest National Bank.", "label": "Third Amendment to Credit Agreement with Woodforest National Bank [Member]", "terseLabel": "Third Amended Credit Agreement" } } }, "auth_ref": [] },
"ibio_ThresholdForAdditionalBorrowingsAmountWhichLendingCannotExceedExpressedAsPercentageOfLiquidationValueOfEquipment": { "xbrltype":
"percentItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"ThresholdForAdditionalBorrowingsAmountWhichLendingCannotExceedExpressedAsPercentageOfLiquidationValueOfEquipment", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The threshold amount for
additional borrowings under the Credit and Security Agreement with Loeb Term Solutions, for which the face amount of additional lending may not exceed (expressed
as a percentage of the forced liquidation value of the Company's eligible equipment held as fixed assets).", "label": "Threshold for additional borrowings, amount
which lending cannot exceed expressed as a percentage of liquidation value of equipment", "terseLabel": "Percentage of eligible equipment's liquidation value,
threshold for additional lending" } } }, "auth_ref": [] }, "ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate": {
"xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period for delivery of
executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.", "label": "Threshold Period for Delivery of Executed Copy of Agreement
for Sale of Facility from Amendment Date", "terseLabel": "Business days to deliver executed copy of Purchase Agreement for the sale of the Facility" } } }, "auth_ref":
[] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } },
"auth_ref": [ "r1013", "r1165" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } },
"auth_ref": [] }, "ibio_TotalProceedsForFixedAssetsSoldAtAuction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"TotalProceedsForFixedAssetsSoldAtAuction", "crdr": "debit", "presentation": [ "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": {
"en-us": { "role": { "documentation": "The total proceeds, before fees, for property plant & equipment sold at auction.", "label": "Total proceeds for fixed assets sold
at auction", "terseLabel": "Final sale price for auctioned equipment" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r930" ] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder
Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r937" ] }, "us-
gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": {
"en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for
accounts receivable." } } }, "auth_ref": [ "r177", "r178", "r179", "r1015", "r1017", "r1019" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r958" ] }, "ecd_TradingArrByIndTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel":
"Trading Arrangements, by Individual" } } }, "auth_ref": [ "r960" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption
Date" } } }, "auth_ref": [ "r961" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel":
"Arrangement Duration" } } }, "auth_ref": [ "r962" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading
Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r962" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r960" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us":
{ "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r960" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype":
"sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount",
"terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r963" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us":
{ "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r961" ] }, "us-gaap_TypeOfArrangementAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails",
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails",
"http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
"http://www.ibioinc.com/role/DisclosureDebtInsurancePremiumFinancingDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails",
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails",
"http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementDetails", "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails",
"http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails",
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
"http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails",
"http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than
Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating
activity or operations." } } }, "auth_ref": [ "r546" ] }, "ibio_UnderwritersPurchaseOptionPeriod": { "xbrltype": "durationItemType", "nsuri":
"http://www.ibioinc.com/20240630", "localname": "UnderwritersPurchaseOptionPeriod", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of days following the close of
an at-the-market equity offering for the underwriters of the offering to exercise their option to purchase additional shares/warrants pursuant to an Underwriting
Agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Underwriters
purchase option period" } } }, "auth_ref": [] }, "ibio_UnderwritingDiscountFeePercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.ibioinc.com/20240630", "localname": "UnderwritingDiscountFeePercentage", "presentation": [
"http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": {
"documentation": "Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received.", "label": "Underwriting Discount Fee
Percentage", "terseLabel": "Agent fee percentage" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": {
"en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r957" ]
}, "ibio_UniversityOfPittsburghMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname":
"UniversityOfPittsburghMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents information pertaining to the University of Pittsburgh.", "label": "University of Pittsburgh [Member]", "terseLabel": "University of Pittsburgh" } } },
"auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ],
"lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Liability for uncertain tax positions", "documentation": "Amount of unrecognized tax
benefits." } } }, "auth_ref": [ "r509", "r521", "r844" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit",
"presentation": [ "http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax
Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, accrued interest and penalties", "documentation": "Amount accrued
for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [
"r520", "r844" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [
"http://www.ibioinc.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax
Penalties and Interest Expense", "terseLabel": "Unrecognized tax benefits, penalties and interest expense", "documentation": "Amount of expense for interest on an
underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r520", "r844" ] }, "us-
gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text
Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in
conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r39", "r40", "r41", "r190", "r191", "r194", "r195" ] }, "us-gaap_VariableLeasePayment":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeasePayment", "crdr": "credit", "presentation": [
"http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Payment", "terseLabel": "Monthly
lease payments", "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability." } } }, "auth_ref": [ "r604" ] }, "us-
gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation":
"Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "VariableRateDomain", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAndSecurityAgreementDetails" ], "lang": { "en-us": { "role": {
"label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } },
"auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": {
```

```
"en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionsDetails", "http://www.ibioinc.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r926" ] }, "ibio_WainwrightUnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WainwrightUnderwritingAgreementMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Wainwright & Co., LLC acting as the underwriter (sales agent) in an agreement to sell shares of the Company's common stock.", "label": "Wainwright Underwriting Agreement [Member]", "terseLabel": "Wainwright Underwriting" } } }, "auth_ref": [] }, "ibio_WarrantAgreementWithBryanCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WarrantAgreementWithBryanCapitalMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the Warrant Agreement with Bryan Capital.", "label": "Warrant Agreement With Bryan Capital [Member]", "verboseLabel": "The Warrant" } } }, "auth_ref": [] }, "ibio_WarrantAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WarrantAgreementsMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Warrant Agreements held with various investors.", "label": "Warrant Agreements [Member]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "ibio_WarrantExercisesOwnershipLimitationTermOfWrittenNotice": { "xbrltype": "durationItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WarrantExercisesOwnershipLimitationTermOfWrittenNotice", "presentation": [ "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum days of prior written notice needed to satisfy the holder's election to exercise warrants that give the holder, together with affiliates, a beneficial ownership in the Company's common stock of not more than 9.99%.", "label": "Warrant exercises ownership limitation term of written notice", "terseLabel": "Warrant holder's election, period of written notice" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r870", "r871", "r874", "r875", "r876", "r877" ] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "presentation": [ "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Value of exercisable warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1153", "r1154", "r1155" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.ibioinc.com/role/DisclosureBasisOfPresentationDetails", "http://www.ibioinc.com/role/DisclosureStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants, exercisable term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1153", "r1154", "r1155" ] }, "ibio_WarrantsIssuedAndExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WarrantsIssuedAndExercisable", "presentation": [ "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued, and exercisable, as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Warrants issued and exercisable" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding (Diluted)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r268", "r274" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsPerShareDetails", "http://www.ibioinc.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding (Basic)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r267", "r274" ] }, "ibio_WoodforestNationalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WoodforestNationalBankMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails", "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementDetails", "http://www.ibioinc.com/role/DisclosureSignificantTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Woodford National Bank.", "label": "Woodforest National Bank [Member]", "terseLabel": "Woodforest National Bank" } } }, "auth_ref": [] }, "ibio_WoodforestSettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "WoodforestSettlementAgreementMember", "presentation": [ "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails", "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Settlement Agreement reached between the Company and Woodforest National Bank.", "label": "Woodforest Settlement Agreement [Member]", "terseLabel": "Settlement Agreement" } } }, "auth_ref": [] }, "ibio_Year2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Year2025Member", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of payments coming due.", "label": "Year 2025 [Member]", "terseLabel": "2025" } } }, "auth_ref": [] }, "ibio_Year2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ibioinc.com/20240630", "localname": "Year2026Member", "presentation": [ "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of payments for liabilities due.", "label": "Year 2026 [Member]", "terseLabel": "2026" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r924" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44" }, "r20": {
```

{"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-6" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-7" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-9" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic":

"505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r152": { "role", "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.3-04)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-8A" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-50" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-51" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-52" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147481139/470-20-50-1i" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1i", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1i" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1i", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1i" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1i", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1i" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" },
"r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r399": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r400": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r401": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r402": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r403": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r404": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r405": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r406": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r407": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r408": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r409": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r410": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r411": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r412": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r413": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r414": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r418":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" },
"r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r422": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r423": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r430":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r431": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r432": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/715/tableOfContent" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-
50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r435": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r436": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r437": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r438": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r439": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r440": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r441": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r443": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r444": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r445": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r449": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r452":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
```

"5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r690": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

```
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r757": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r758": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r759": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
}, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r795": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r796": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r797": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r798": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
```

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r869": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",

```
"Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r956": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph":
"2", "Subparagraph": "ii", "Sentence": "E" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r958": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r959": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a",
"Paragraph": "1" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":
"408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r962": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph":
"2", "Subparagraph": "C" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C",
"Clause": "1" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v",
"Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r968": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r971": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
}, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r977": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)",
"SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r978": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r979": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r980": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r981": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r982": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r983": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
}, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r987": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r988": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r989": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r990": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r991": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r992": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r993": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r994": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-
24" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1004": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
22" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1010": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1011": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1012": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/310-10/tableOfContent" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" },
"r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1015": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1016": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1017": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1018": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph":
"7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
```

"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 147 0001420720-24-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001420720-24-000038-xbrl.zip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{3\<4%$ MY:REA5(+4Q VC8K BVJ6"(#%?A#,]'IF4? KV)H(Y&!\U9S09^SLPD#%Q$BX#%OT=/,9S^#!S_/AXMFT0L.S7X/:V!=1/:!SN"72: MMQWF\Y.:>^)=8$Y*&4#NX@;2@&HKL0[&FON 31XA VA]O0[J@=-GT(''W?5TP ME=;@:@.$G3T1ZL%K(]7!]E%W";L8(&T S,STW033)H$&G-/3.G *\1:<;$&H 1V,VKT>DD**#H2E^T]#T M/4SI^KF_2]P#]%, (E@&U7N;U>MQTY#KD.L9,&;#K9]^M!T]+KT.O9K.D_4. M$/:P^3:<4K3IZ['KV3 UF7\'R$SMC4U+!TT"#3AG-1NF4C21 9".-V<;@L&T M4+9#]-[X&NT0SD6S0(=?RE +FYKUTT5-L1E;B760U=@FBPR++R<-H/4 K1S' M:#S#|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|-[!8\O.F4KX%,!Y=A)/$!I6XQO1MQ*:,3Z5 R M"3 ^0-3GZK+9!63](_X/_3/%* 9TY MK^]+.!)K/!Q&#>8 >I-\6@LX^'R" AV)Q"N@=*RI@$@)(. TZSBI_X!SO2BK MH:M4&!!9*!0H25>ARGIEH4P^F7;5',)0_TW$^>'X-?(^D>62\5F(G](/G(>) MMJMO^_GD"H5T. EHM"1N6F@$!18]?'9>5*K#TZ/3 R=R%S0@=Z&KOJVS,]=<<"TY_E 8]2O5HZQ+J1DY_NA6.E5# M&,VH0PX(95_WS0)R/S?5S,?CZ0(H81+IEC40CV*0BA!Q&QNI4TP.4A" U[M2PF,4>2?1!@O,U(&)#!GJM\P%;+0>U*,O#A9,V=I4^+CB/CYP%7'=G7-D(H" MZVV!7)GG6-?29NWJBK_+"#]UO!X6V:J=+Q(&N>*BZWB>9)1G+1" 5"_A\,",^ M5NN;+=8F=)-TDUBX"U@EY!==1]\L*DC5D%X$!RT0?*X5PY.?/ 8<(OA\NR%0 M4O\WD>>I[#WAV)XU9N"A8+5*L9A&WSCE[(/J6DD/-W-#G M$R*<50" [I\&4BH*P)L16H;M61FAHERV)GU4SU>+*Y]K!<6?2I*P]#.04=LNR M7/G*5ROKG@W7A3B+E3&[/ &T4FID[#[;]Q3K@+F8SBPC")E5X1A6?EZC+@'HWDJ_%HWLM]0) MND7>Y 2RTD*_1T'6-"JLEKW8I^-9\7Z"DB%UOMVXC'21+!0?%Y3*PG6@!ZI. MY"FLO^C8T-!_4.'6-#YDH-$O&&X2)"]/&PUI5DX>25TOV@2I)EHIR2W\ UNS M(@.GHP#SJ9Q>B<+/@(A>Z9H6]V0X+OEL5+NNY"HH+U!"#85QN8!^A1TQVS]-MDHEK1JJ1$BJ(.?/6'0R# .);!/P'(7DF/@XQ$S^.RE'0UOMT8_JWW9XG)Y2R MLCOWZ+1^B[Q0)C:0*LVV(!=6<6 MA?4M5BT4!==G%=W<5;/ YNXH6^EVRF-EQR]4%/[AW!%?+F:D!7^]41%4"N] M:8!-M%Z$&A!OM9GO)V$*G.D9B%9P/-KH(GN1? E_$Q[$>!-G8:">S M<'!_A&$J/=/)3W*X]Q/ER6SK%Y=']2N->28K97Z&B@+J%U#C&9-1TC_'LPMV M'W*Y\%?XMA?Q_2#9Y*2]&%?UCZ N8E5]B[UYV3=8=A7]B8@YE1R%Y^8W+DRK;6_%V*WP,85,5!\VQ/S5I5)?7]$ZB2YENP=H&/W_E'@83W(46_R'5*<%$ M7180_X]%"78+-S%(X6WZ- A3\&1LH+)Q?'^CZJM\S;12IG[%T2TL[ZJK MOLT$.^O^$$+EY%TL?ZL3H)IJH139:)&_#**.ZHJ+CD:*8!]G7-(Y%7_L69$(MF[<1=8D6PC&*E84(`T]OV1*U$- DHTS.:]2+Q24D>]"^ZZS8_-.^HQX:B554 M75IQR%P+OBVG[2T=;S)9J;CRK@L,O:=P\ D>G@/ATYLP76-I&^*$T2??/LR3.(L MA^D4AV(UE179F1U!]A(8>%0\!!/Q9D"!$M6NS0U_&ZLAB+&$8J`M[8\^,8+5)>-)W(-Z38"IFIZI9&DDFZA)-F!55;5-'Q]R1>]A<8V%HQR5UV8QA9/!GZH?+Q&7XGOFPY =A M2X%2WH;_&[=O\WZBVUIC.^G7 M^$OA^^H+-A& 0X>N#I8ZH!.VIJL\+VI-V3 M">1:,\%4TBTP+'_JGI*<<<14U M:8=,]V:.++H%XO-(1OZ#=806CB]KDY;>/=* UD(OLI.!'/)'T:L^8(?R.] MID^KE#_ZBD*0/MF&%@?-+&=$;2-BF]XR\K)VR&.AQ*F5G5)1RH;*.YI_UCZ'LCF8I4$+)?=FMF$-U=C!!=Z3LUB'F6?6F$ MXD+J^M6EZP54LCU);&B9MGNY"U##K)N+*Q'RJ1#_U4 KC'/LBU(86IGW MSJ2\KO#:"MR\L#*BME#*)N\'8S<)BV7+PEL6CJ"@IO>$QS/X]LP&8S$G/#T: MJ5E\|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

*MO[M&H8T]7$@('3QG82L-0KC7W^H5R\;!&X,#>$/MA&L;,5$PCY"-]5!Z)9.TT+"T?M?A<->=C7CP< M,+K<1"'[W3?LXUDT&]L+,2!615*EBRV@9"LU%X?L&T@&Z<7%,T7"<6D<;=6N MMH#ZUF=_XF/\F*(9CF9+_=?!5][H%F>]T9.'GV,'NE'#5>]C89S)VL!_WBK2-MBKTT/C6LB#06XA\%[G+G^*0=W%^?L)#C8.!M6\M-MFV1_SK9])/R2T6%E"41,[>|+;BH+|9]N>BTCI ?+" M(/Y)H"#06_*#WV.BIXVR91GR/N^M__*@+;FN(O8]^]%2O*3,[Z]"T^/AB?G M9V>#H]/A\3D>$WP#!\N:!X#XVK:1T+;;]R>L'7_IOJ2GHB)Y(2&Z[>.UHS MHH)0^.|++JO;LUX1?IZ&XC01,$,R9VY&_(>0.'\|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|-^A_&078Y_ELX]?0Q!(C_HVK.YXHFN(@% M4^KJH_0">4MCBD13<;,,&BOQ@@;R>N$/E?25 '5UG RSK[FCS#PC+#RS#/*.OVROJX"2N< ,N5U3@VIFS^#!%SL!VDN5*1 M5^X%(:IK FC>LBPBL5&N&19=ELV#/1^>#C]VVNQJX$!7H??+B/]H4F;EPK)] ML+(^<*@+R"Q/OY.0E1PRE!7O@[&-L)>F#FO_J]8PMZQX'\QMA!Uf>K-LB"OB MOR :\BT6S;%\K4;? K*X#'VJ6K|4Z@OMYZ?5DRA_0E@=AM[A04\,%S0M$9N3"HDO@]Q&+,M^TI)-.=/K?(D=^(99N2NW@-4FT0YR.,LY<*ZK1X*(H@=N M1[H831[PLX\GV.&;R/'U(?$]EH<=-M(4:&Q#1]>.1S;M\CV\-_(C?-?=[=^SR!?.MVL0[*PX^;H[%&4DL[%N\=6O5/"N0RF-Q@:R?N$@_6TNA]B>$[G.Q-FIV.9* M1S+X]3>Q^W/%!\9@H6\F]?979?BETT;+X?+E >%J##%K):^A(PC'7VH1I-'T M@*:,W(N#)(IO)1GZ\>>;Y'/ZRXY5;?I.7KBAH["6LU?F]_/V1- MHDO$9EQTX3C1C',"N? 7>WE0V[_"L56AB>I>D-G:@*P75@Z)-$:6?%*E #HVS MS^\QX+^E+S7)EN#H01;>M"6ZY">:|MM&=+=*TB^)G.K6SO MK!8KK(C:>+HXVIXM5U|HS1E:$5N>,=;4Q(FF_M#J-5M1TWDGU"XI&G AGE+J.B4H[^QV/3L]9/KYA8:LU+- 4*=:lY1(%'Y"F75 M -JZ@LV,#"_'O7NF-UXI&C;40WJ8: +]S=E;- J%/Y!#U)SVS9@"RI>K$T0AT M0,'D#0!!B&>"X[X?V5Z6ZG'X=`@Y/STI,!N*EDDP+?F;D?7Y'W@KX1/YQ6\#$T&@4X:%2PI=D44U$K M.O{)G&+"GYZ Z*QLPOX?9-/'5] ((L9*V\IKC3\N=]9!/*F7H3$L[2"/6L^S0 ME$AQ&YXO%TOUX\YA8TF2Z M(&_W>-CFDUGJRO**\FUW?^NR#1>)G"H+WRV]#%*QM5U61).P@3[I'\4LCR#-@RQ<]-%++?? 6,KB5DT2Z^8&'O8P\W- M,7'W;M]:JF@NM[3B/IVD4ROMM?7K>;=^$-*(RQ)GA,%.(IJ$[25U6OAHE1(M M$S)5@;.L#/ CUK)=]D.N@12H>ZY$E+H=5>R>UNV\V95 @3K,XL8?/PTLO3*9 M*|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oQ.?"3>V5W^.+G3>(E\,&AZ:+YZ+#H01;>M"6ZY">!EKWRU\Q-7 MOURE-TKZ;OGZH|SOM:DP093RBIXEH[IY6E_ MSFB_GK>IA8QF^F8HVE,PQPMT%RDY86!F;W4E@..N8K!-LU> #=3JJ3VN$/// M[JH[>K*G65!#?A 3X&EB!Y".T3B>3FG*B=TFN@\,RHK >@%W"6$>^00WV%> MKM#GE7B G#_B%\-F!>*L(#R!>6P\SR.O?->HS!F[W#[+M5S+;:D$D";<9EU MQ08;_M&L,KQ66%,49-K/K2G2'L4Z(LFFR}\;9'IM^5S:FD8R@LG3H;6:G%2 M63(3-XF-H47=H!54?3Y@JEY?FN\DM[:E&> ^[NK; M$EEQ[+=J{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eSI_ OJW=[_^[:=W MD]LONW}?&&5XK"L8X^3;W_A_'EE_$\9ADO#)<5 _V49ADO#)<5 _V49ADO#W7_/S\X_/' M'PE=L.KOWK_]OU^<N[\,E6@5O<))\F01*B'\[:M1HOCS3>U?GX=M?\#[OVV:|1-MM[]0+2SSV_+'?5%>5T3,^U]__?5M\2LKFN*_]051UR0,I_@(>+3$3:0G^Z_?'S'2? R?]QG3#ZYXYR1)28PCKB[[M+!/9_#XCX;]O&[7\UA-/ MMP%E/RU1AL,@[H_!HVXZX?833L.8I#E%]WB1L%$LP.$EJMVC%5S*YB!N0M12G#K; 6GU 6X-B>2E537W)'D05TFX>%FC)&ULF5OTU(/7_MX9RB"&?3!46MUCNJIG[>FJ\:UIR3[3HK6;0A7-&,$)!HO\XS\]@4G>)6O;H=_ML5KLEB%\%_W151++=HS"G.- MTJ6*J51WRCEM73;OJ@6NV<\D!7X;=LGT*SE>=_M##5]HSVN2V>/,5ZT\W:HFG-#?)7K=R4=:*Z^05<<<(15PUZZ]E: Z;T2[>$ UQVL;[V+(W) [RSW7>^*BGZRGYZ(*Q{1%G"Y3P0[2FY)LTV?5]@Q4G&X1^>O?^OV[C MH/'&1-I.Y^>HCRGZ(V(=OMA^8B-[_]];#H(:,25,4\SLI]^X/036068X3L/\CA+;=;BQHW5Y=-M@$A[2ZXNA*+5]3*=-%&"P:YQD;R.\VN,=Q'$SI:D$#HO+XS\)+YHK6 MVA/%_N8LD^1-5 +7(8F"MCLEN-"W?NC=-MT!N45++,U9H[=C49HAIK;?;GM E MHXF6^-2- ZLQ=#A^0*6Z\0S10$)[@<;LFW;1^6U'9GC)6D_KKK^_>3=Y,#BVS#[O&)ZSU2=G\A++_XVC?:M V=HQU),PEJ',0]=)[2Q*>;?'"SQ]HM_'0*:XR#=Q2|SVG;]Q.$CBO_^@[;\ MO]X?2<*HQEOW"%?)^%0S6$>LGA;4\B@N6F/NH*%36F>3C?=:=LW-*5G;R)CHB M\|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{BAZE T9,3KD*QG MQ.$Q.?6D.>)O%2.U>8-2A6W7Y&"$]O2]MVFR8\VYY7O1%=(=_PX-REM!%"U M-&T9=^ZA8:8QRL-L1N\1?<*AS!LH*B9T9\@*NF4G+2[6%P2D4C^-M*R*,7'I M-GX:C6B)0?=./35B>G>^&B6=SK7[G">C0W0=L,F?>]$VDBTJ)E0"64%7'G"T MSFFX#%*TSQ9Q3)%4VXWKBKWG-K7;C 8-%*0!.4Y'AYC^O3_>AFZOR]%M#H]M M2D/%.O.TH'25(R[JG3GM&:\N]#&CW9ZZ*N5-$&APOKP2$5U=-JF(J3H.MOE, M4YX;,,TF05(D#]5UUE5CED6SS;'/6>%#:-"TF(A+G9J)>]6940Y0 4%57LI<2% MVPZ\CG C>D[=#\]VK-7W/*6_$5M?T9D08/UDC]%H(O-84+-2G@@WISN>0V7,":+K$;\F\-M4?M=,;$U/2KBF7#HK')504]_-#"`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{$=>|%M8R1=85A*H> ++R-OQV&XBJ M%CXQL1+]*F0I-K 4)'L=9#,LB6B_"B&HB5G_0F5*S<#K$T5:DZF5B*&'+F MP#*KW%@LW0TY2_1(Q]=#T8SIJHCTYP9SU=O0QZMA.>X)$LSF7ID=2P8KE+B_7:A$@IK1XN%(K(_XHX8Z":/(CDD\Y#T4D.,1 X6BXC!=%VF*JIQUIP6 M]LB:@2?JN+ Q>UU[HZ12/O%'B6CPY)$Z)OK4)R4BUN_CC@&F_PCBG,=V\;?H MM$\YRLI+9W1E#9\<;|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|HE,PE8S%22F99L'4)FWHQ63:2H=ASV:PBF 5U3H M&=BLY$X8Y6S*%90O7:'WLMQ8AZHL3@8U34:SJBZ0H;RGRWH_'|6T&K;"NAT. M5@/(-"-50)_/\2EG2#.@#;3]#O2:G)I&%3L+$F/,6*GZ7]4!/K+X*/C2)#+'1\F)UW'Y#[:K MY73)QUZEA%2CCLKXXT,Y8&IE=+QT-Q3$ B2*'IWK=HW$]OZ>D.,WJ>+R45=M M4MJ3(FV=_=//Y^26WLK6$PF@,RSAYQQ01PD M(;I?(I1QKV,4X5)\M4!*]F%- TB#^3$F^3ED3<1IQL MK6B-IO-:EB6%^=/4,AL\XGJP%N6D3UFLBA.W-A#D]LG,LHH@CFI[:'P;@=F=:,2XN 6S7:,-U,B=F-'A(66D ME/!ZPD@YP7Z76^@Q.P2"WZ$(K\"3*\Y*50Y3U5UY*X& M72WOW&_J43M7Y34,.3^!T|K9:@@';,;(O0-6S4+-.&:LF_6@P_LX_% M#X+OMV36N'Q^?OZ19Y; 2? AC2%9O"P[WSI5]&M#]E^EL7ER47)*8T9)>_)'C M;/-##4OTD]$D0M&19'[!]>WF\$,Z(?-)M:?_-=GV MY?'P_H&OQG5G]-M"/H,,2DGQ&Z\DT>1,T]2Q'[[&(VG):M(P? T1OIF.JN'* M4_4;$+6C_-P.$6Y#7!TE9P';YP%L1(,31WGP'QL*I5%LM=GU(^9 MUW<,WD]MP3/GS3^0=RAC;*#H(}6_:G2M1DA9U#]'- +B&2.^,=COZ1AFR94 M/.BI6SE7"O:(0Q#'QJNQ$!*%2^3M(OIX\P(B++_|:-MMI&[B(NB?_\A+2,Y M#[_')$71WW_(,.YKLW.:\"JV?S- \26D@]RRA^S#/.Y@.Y(0GGBI5F0<&9DH)^6@{)N,<3O ME %H4' -NTK3'$6?YO36]"V6U8C'D]$P- \92_QKB M>%(9RH;,2F<-L#UA=!C@EH^\',XO-OFF[>I0%JWM1=KV'@N2_M!G$MMP!0UBIFW?HB:W;.MT8'\1=.:U J8T'MXC02A_8=AX@AZ*PVSKT)&>,J0-IM?$<I'F)\D M-YFSS9IUKB)_Z6LN-^- W&'JQT^NN%<.F72C&HZNA8V%.7H]\B%5(Z)PDWD(RX MV;S\.:/,;KG#ST6=[H;6!>#-ITKT%_[,BT&S Y#'4H%[U@?C!L=@D4QEHVQ M.1F>\A@MUSAOC|?Y^>]0NX2CGP)V,7)=:,%C-OL8%[UZUP!?^U]S|-*_M'L#T3G;F>TU2GHX2X45RGE/*_RR+G.]!D99RFD3%[B\>K876C%E/P0O$FWK MJS/W1NY=&R7K2PS 5,MD+!6B:&&MO?=*T"K4V4+SH!ARF\R'&,1Z5. 8WZ\ MR;3V/HC1UX2B(.:/Q/#8:*[.$FCMFW&/<*O387L&@0%MH*,]Y3G0RD782T& M%J5=N=9#<@$-@6-]2,L>98KA6"[A'I]69<95TK=C!W!&Y92O,A$T &0X/ MUVZ,+HS\W.[*R.1/M:[_[.,"2;A$41ZCK5S.-D7J N5M54-GU%Q!1U;JDRN ME9R6!W:E1 -^-,'CNE" _1[!*D_)BB:@@O%LE,F6KA=_+>_$_Q8 N,4A0D&L3 M^!L,5=)/IE+%6+B&$LFK9*!FCU3FJ[/(WGX6$8<<7?=XD12)?)*LXATHV4@-.MUPJ_? GSWR[N/;'EP:);O&PXM3ZI-3_Y4-NYE->#S.FE*LPJ-[-.!/O:!#>><MA_&N YIM)-E=Y,6 S>S2RZ)R#GHR71JAWZ%U3L-ED*+I@J+MNKI.GG ZMZP+_M8(;7J=@.'0NN6D/& [5*!Q[M?/KXK..'?_.LN'2Z;\&.=LZ\.Q_PKE< M7]SWE-Y(R3@6>M;\3_;\;=;9?;J]$0ND2:0O*>O)<.G<<=)=B(0-_UA42.+/-MBMTP0@[?5.=?]=U$VU8 6#8C;.S%V&R9LO0%0O'VV;(+=TZO*^35U+3=P. M/367P+R=+=^N\V8 =4YJJ0$4H!{&=>IC=2NX>6 DG[''OAD:K>-*P!KQK./&T_':P87%_M#ITMW6#O? SIU@_%FOEN7EV4LR*&KI7'.UF&YOU0\^)\|ZE3IWP'1%@>TC)*K ME1P/%SZN!T17-R1#_|?'YXDE4"LJ22:5TH"42,P3%G MS?]4,6XTAK'1.!Q2? ^$)C8OXT=G\|FB0+;!7W2US=UL.^&2BFT1!M;_Z;_T_ .M@A0S&IFM2!EWY3L\/+-;;+Q=^>G=AW?OC[\S-UNFZV1 6IZT'47'W4O)_)CC" =WPNT(&X>/R\D.+U5"P @"7 TE\3SB;5[1-Z78SJ0AH(M+]7PTQ M]YZ,W+9EX!^X]=?YXA*TT&KBT*9:\R5ZV#)9#SU)6^V[PE)G-RR7BTF?)-. M4":7!BB8L-<7(#ODV2\?Y0"(2D%QM340N(@=_Y/#+ <5/.':IC8-0/AYTA<&D MX[5"1<>5?W"V-T2VMW!G] XOEJK-OJ+\T(*_%*P Q<7D,IZX!J UE%;CM!CU MO7BZI>@RYV[&;,>*Q9.T*)3%DX$>]:4DH1NFY7LR2@E#61C9"EK#2 MKX@_F8KXI"'4V39"]B$I8Z5?$%ZGB/BD(96EC+ ^(35OH2<>5V\#2\ 5N5 U* M^C@<.\LQYFQZM(*$HC*4E."MIM >X1F3<6C? 3!GS;XSY-|;\&X/-O\'=[>B/ MG&G0Q1,?S:PKS6&/L+0GXZ1)D9YU"-D!"0BZO,=>7E{ADJM9QOIV%BK(^*4 M%DM2%HK5TBJ: A1 !FR,+!U$9.D-RLZ#=!E+R1- FB_>SS5=&SU4R8\8}R'@H M1)CA)U4N>IL&H'BMS|'"VX0SB=?,!S!J7@:,*N\OBVN&!>&#BYVK#MK_| M'WY5XRF(B\ DID24;ICF])+O&}:%XCHS@\N0*6 P,@-PR,$N- W_5,E!<:L86 MKD!M^*7A2?LS.MVG(+3"J-R(O@Q!-5SP?G@1K>?%AO08DYP,8/J_T MC?%6K^P,]47O0^P=SI/W]-T^[Y4B/!3,754HO%DD%HV,K#W,LZYE>$9 O@[A/O#)PFF!O4&]C:.. 4? I.*O0 M=AO0&2WX+)^I9%:EF#STIZ/RF@-[/<>()R>^!.5LOHLZ$<:CF55T#TPC=XX- M2!\&EBC"-+ <).ER5/0_BF'O@=WQL"U[%ZMNTZ[X1AZFSO@=@E9KE3O'A"4WPX1DC%8!6>]NM>@1@XG9_(-FM4 M OO+|<0LSU)F*B-3S!GZ:NYQ;^6'TC,$#+AR#UCN#56+, (/R[]%[Y6I2 M<.+&5N^NO4^Y@;A$*.4OO$_3[2%OL.#)O18A:,F\.4I.EN.2*TP2U:J.X>>M6W%|K+/M!JSKB'@=EG?B#4'$Q09>4_B.)HMS\E$/MEF[? @^O_*L>BTD!^S2 M]VG24ZGK1>XC-&\|2IR-9Y-E)3,G-Y,?2!;$#4V(>5TH;U7Z-!OFTG*3U:R2 M7NWB)42'M&[[UU2XDNX"+.36H&5;4%*

*[+]*D8S:7G1%%X;C;&&T]>$ED:",.J M4)[S]*D&QL("MI*X0^LRE5\ZFU^3,@$NYY)]/&>LG.0=L:@'Y#>$;+ M7$'!'S5K3[OM@FS*#,ZRW%,]]PGE>5+/.MBSE('I\?7Y!)$D0:%GQ0/QMM'X MP'K7R@;3K3P^W?Y:GVZ7/3X+5^&&^"B\@IW=]I,_::]4]=I@GKR%JSUU@0%3 M$R&KI17E3P$7O_PSN2)Q&48YW2>(;H3G$1]6K<*YB5>SVK56I# U*T4YS5) MB[,72=HME,WF#\&+\F3?M DP+P>#.*4WE1HTK5FM TRYV$K/VS7WQI=.V0=R MADHI,4[F,I4QKP_FP6'?^F(N,FC*BCPOQ@G=_,Z(0[(LRP 4%00S&O#ON$7 MR 88O<\B3@7"E|725T^)Z7 /&+L&>$3P0"#M\:HKC?FD>1;MGJN1KTL8-M@GE*V?]RM+$,@>G79R9UOAR:)8(((%W0E6EE,$\Q>]8;4WD!U)&4TXT8Y1F'I@GE@%HAD940%^>N$/LRQ#'N/C(5\FJO56#=RH^MF+Y3\692IV5"YA-.S80C/;YN,;YN,;YNT!N)Z,.(AZI1T*L MR&KZF!,K,),IJTWKW_EU\LI["}BJ1QG_(BBO?*<- @E MQP4,W3D1#S#5N4,I8N+EC|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}>X5QHHS#]FVCY,%-PFUM5TV#R<_E=92;E32! M6:(;DH2,=FXS4[Y"8H(L.61_%Y+0/+=B41],*B_/5LA"9$YI4(VSB@^"\WX!V8?IO/UNCS7 M">*]D4OFA*[*4VZU=3"N#2;CFV?;8"PP8&JR2U_*5=IHB6)3$8I)L!P+|3V)MGDWOL?;W^6H5T,UL?H\721$)P=;,$84AR3NSBEL0XQ"B]"6CYW(%U1/U/[X? M1]1ON^0!\Y5.)X=>)[MN)W_:=_QGKT'S>]N@BFT_+N0_,2:: /PE#5@!7N+ M05#*$1-29@6 PA>0I8^,T=0#%Q1GHG@%6@.+A^!F#.NZM6@++7E1Y4+ M &),96&(9OM1 Y8&$)XR06*BC-=MOX)D@5WNY=[H;/E^" _"2UB+A4SDE4+ML,+#]3.4%7.@T3P0[fWR8]T*I%FM@3X;XBUFW3_F?-L2QRC,\B#>N57GJT_*IZOJ<86RT50*=B3X6=1V\'M"VY[=GA(SL?-CD6N);,9IA!^XJS<($U24'45 MWT.P*WS57(IF][&,7GFA_B7A'XB^6,VS^-3!C2PVK7A^]\Y@9SC;L0T, ^#OT MA-A,P8/Q=IE4?L?9\CQ/,[+BKRANPS2XZX?]+Y*_7]>H)=]W [M2@D;_U,% M$>&%QT]KT(U]^K[-UQ741LP. -I=VLN-/,:G57U?N.L3W%-NAX3NUC+QW)M, M*/]&Q\&H31OQ?7_,"}=("OH%AO['PZR/]+BI6L3W?;>N<*MS!0R5.Y0B)\?7E M-(D]>>G4+SUKZOD^!#;=2DG)\C@I5>?OJ:(K?.O\5P&IU%-[W?.ND+5B%@M-MY,J/N+7@FE7U?B>L*W3-V 4&[_TRH.@L8)NM<[+BUJ6,KJ24'ZX5UQ8VAR+; MFVO3YX\E@P&F_PCBG'.8KPH64FZ?P@Q%G_ 3CE 2W069-*]Y_WZ]7Q+KS ?- MOZR :>77A.X7DP_!RQE*&'S21[NDI;U?!>I* Z0< L.-7V7YFN"$7\F(IBO. MHFPC)2KI']^>,"%U"[@9R*8?3SO_/%=/0C0M8D2*+)@;#B=\|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|HCE4O #W!U;'UN! M8_*$SEK+N@~VQ#HUW:%CP55?=O(N?Z2;\&')%B=KE&;[4$A{C?;2=OECI)/=6A1W%5C3?-'E5-6 M-;V.%69'7\?W[K&=_/7\>5IK+3&:7[R@;,.<+C]E\SE:"5 B3MK3O361C@+2< M^3]ZZ&#U>*U[5*73+CR_P-*#N"3/M72VK!]HJ/_0 RQE!]];["0XBN+2P;< MJ?D8A-\|"ZF)$UWC)3&@\X9+\|]%=&(L@"$QLWY7H(Y,R:*F~)300S;ECTN#/ M;R>L-;1I*;O);%O?:@8R#07ZW6>8;B*[XF8_JK>O3>I@7?BT_?JB 4"C"5 M^(0>L\,K'I=!B)2/GLN+0W'&]PVV7+ D.7,!NER1F_9+FO|81K^D>.T &;[MS?XMEQGE!PBRS8&WE1 %07#"_@_^3+PVLD/?@'ML'7LMFP@%!-)W9,.S[=P&FS9P MBUIQC[EC/V-CR0"SY$4@6CGG?"HR$=XB1F!TOPS8-K>R3I5?ZC2N[UXG?+D7 MS64R#&TH[\W5@9!=?>ZX,NU;"P2:*I0')H4Y-_D7)3L0Z' }3-7244$"@>C M>1/N5<*CB]%<+'#5HN:8N$,AXDEKF'I;*#5HN:8N$,AXDEKF'I;*Y5PY-#TE8P3E:1^XPHQWIZ M6-O.,T2O&=YNC1OHF5DHV;<_83=A<-,0W%)H3*CG113PY_.Q% TQ%MON@[(§47%!T2TF4XA4\BF1+LH 6?3WW2N#81V@A M"V"H"]3VH*P%W5RB8H(SDDJ.[1LW)K[P"=/L;&$@*F-]6,W4[B4(PKN4>0!^N1!-)^-;2,=D, MRV1%]W Z](@+-;",,)HCLGPSZW9!'?=&QU47=H^;87Z=F'[C4&$:+E"%]N@V5 MI*Q[0#UYVR3\.QEY]^B)K;M8[V!W% CS'MJE'WX#OVIW4E*)!:\A#0!3G"-VU[5[-?06=BYOQ#@*2-;!-WS;_7?5$8!8KA MGF.E=-7W_+2UW&N4)_*H5A+ +/Z]/JQ^?\@:AI1}KCQ4(O;3==NT>]WQ=)>|`M&W%;!?<^%&=$5V^QNGQNK'!PU>.CE@_%#+^RGLM)\F4^*GB>5KH&| W.6ITPO MTEK,YMFF\LGLE1?39L84^EV^W6('WI@@?TR0/R82=I8&?TPD_ H3"7<>*J28MC,1%H3[GTGPN$O,)#RKE(V&RPH F%I7]]?#H.[OL-LHO*I]B,GB&RKB6;_-E MIDD'VV7 4M\@7"49F^,P&ZIEK*4> %D-*&G8+(4O8Z=OP5_BE]U|R']9"PI#M26QF*6X!)WU+^BA822]M204HJ<,L)2[A9LS3WUF>?ONET)B%?!S"K[5?8Q9^ MHRS_C<.@O%_K8M-KZ$8;AGEU:$LI6TUP9Q#M[R='MXQ1G*:$;FY(ALK+R%PYK4^{_O+\N_?$)T.'M"6H]\DU8:A.DVB;KR]#',@U.PNR;&U<:38_&H$W+C@'!>< 9N3S2VE-V(Q;^CU*E2GF6(MBP*PG5U]?15;.TW4KYV+6LB&?RQXH#CZ(V?SQL43 M#P!0&U%i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{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‘&8["],,#:?R2U/MZ!_(&2KUF^GGG)_)94L2S;(EH@_+(+D/8G0>4+IAJX#"63B;J^(V.FH;2GQ'M,PWJ2 C ;D*57!7WK^?7)%E5,"J*P!?HVLADW)FW^P9G.VPT=F,$G*@E_% MJ@&2<.4?FM%C\;UY+*1L?:8DM49[6PF\_51BKN,/F!- WB/E M3H)U=\V#-]I*K>A.#L#T1TH_/DO=14HZ9,Z'OT|/,6_HBOHHD7+]M3:I;; MAM#"!?0U80*]WX&3'?HU:0E*.J5F2#=BV;M,\2K)@F2!V9JCX;7"#Z?7"@]M MPKI;>,E%A0HG[S';9MY ?0,>!BW?&\SF4TH9/<6R4.$!E)2%ZO,S!:PZ#"4L M^C>N%9+XJSXWC)##-P_LKS0(].?QU]T \O\I-,6V.+)ELK?$&QD)OIT>YX57 ML%0EH?BOFNHB8=T'4HN^*B&/<66*C+^\;"6+WV4E?STY?4,]D.I5@$7>.0 M#_9D82!Z@TI0|O1MQX(]^.S-9W=MF-K_%698^YG2QE(.A+N]{@FF'AIHW_YL9A2$^VWP)_IO0(OA6E7#!-MI@6H5X";,%"M& >-[(%8[<4NZU8 3&,M=-T0;S'K_C$O%[5]1\11&=^37TMUMK;GLZYSYAX,_XAS'*,SR(-[YI178]'KXGA<[!$K%IG_4% Q>;(?S*KZ#8"P M84\<]&?/ <:!+%|!..:/*<%(N>$33?1D)1X5.8(TH/QRG'+E[CZ@,8RTI= M,.<4V$%I}>+ ,H MJ@PT"(DXN4=U&A*AO4Q5)6$,H!A161"#++49?UNC+ N[+&K;SI#\O%VSGR1 | MD/TYML!Y($=?UO?JRU*M]DD<7Q+Z'%"9)\NT\@"&;N.M497/X6R(5=>U]-4& M,$T*E-<049C7MA0$6S]7;]W0 ,9O<[R'\FK]ZW'1VGN=-<@.TDD9BQ7QCYPG MJU')!'55!^!T-AJK.CZ!X:HZ_]@PU."LJ%9[,YE#;K&K (#6,&Q_.:KKD)S M.']Q.+%"O %[E6REW']+8]/ "97Y;,'AM=AX6Q\AF_=#)2MD;VB6R\&/_SS_ MP(!R';&%75,.RL.H*10U[$(#6;&4.*IBZ =?9-0#'Y+=6@E V@ZM[7M?(S?&N.W MQOBM,7YKC-\:X[>^B_BM.6!H#!@Z=12=KLIN&"\/SRA^0E\88\L&.F'4*)1E M>@(!1D;|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{.UBJ*ZU[CH]FL7!7.@0>73N!%%94'?D<_M-PL%&Z AN4166P#D M;P?P:]>C"/6T 9#>-BKBL[A.\&?L%9=7$% C/W(473#+,C9ESA$_BT@?")LS#P'>MSSU(G^D^].2$*'H MV)_58S_N=:'Y,Z5',3C1E,/>=^ZORIF$G.F#;EBN^.9R1-M&!&,OAVML_DU6@3QX7JB'"%RKZNY1.;TL>.X'ZFJG)'M.J.IM15W%7WO.C M@W@88G=L&4|QF"H/$B7TZ3XA|N))V8Q>/+*[#R@=...FBG\$<2[SE5NWXA[7M]NX?:R:=V-)BT<[;O4H.B19^0W$D4#^1,,6K[QZXMY2@!NPY06R69VD6)#R^_M:^\'OD.<>;YP+ZS_ \6+1;$\NT,Q"E(V=]>I%R'93;ON$6[N4NJ0;3=KW0-] M6ZW\@F-F54BR=8*EC8#OI%GWL00MG5:=<.W?1$_#D!%'BR/7'4?;S8H@B_Y4\B7R4AY1K(-ER708AC1AG?DMUR*A_(M_\D3]/$=;_^C"/$^>G&O"BV]77T(81@Z4CP^,SD]M,X**?>H.O:] MN]>]6KEXRE\(9D*XY4RL &M32X];3'#PHR_X<]FI>I6\6ACE-&TQ3MNVYA[ZE-MFZX=N]-0[G"2Z:H?]QK1W/77HQA :DN/2/2@%_+0NPFXX=@+U_JRX#%HK3H!BM_(3H9C;_>$%ASOV;9,T^[?.TL3+E^=&.D6+[M=HF /W$9CN1 O34D7NU:.F! M[$D.'NS"80^^.Z,JO"K1V>;.QY\(]^7;MN >W\N1UL&?810G40$,043964VMB*4R;\K]+9=NH^#,.?4P%&\#"%TE_X63]+KIT] 63WW8+5T#9]QI>ZP]7"9 MXYHDBT+5>!#?;%ZF=I8>KVKKN0>P_5U]8@ V@+G&_VM\"5+ ##*@;DH1!MNIS1VX!FVP_3D!GTM)#R]IM+S.QZB(-X1LN@N.I$GJ0XVM[fWB5VNDK3'$7O M)6#WW*=[A6E_R;!GD0!3NG+-?I^1\%N-[CL4(OX0.=L 5)Y^E6B1;2/NU:+] MI49;'j'AO S8s]/4PEN*0\3H+;Z302HO[QZ]|O%M"G: 27,XL?VW#3$*2I(MW _^8;G]-9=:]85ON 6X?Z:.056#@?I)51-GJ|O=T#E)L_0&R6_824J[!['+ M^X\29K00_3Q:?>++!S?&"ED"AZR8I;3?MO<<;[^?777W]Z_],[#Y,WDT.S_ -KF?VS M;WRR;WWRIVWI?_[!]SW//!T7B$&%)#^/F@;4]FU<>L%?D7Y.4]91US5=9(Z&O.]CZ4A&L--?7PM)P5U_Y'YIB$;4S"-B9A&Q.7=)9F;7")2|:\.FH(M!Y57J9FRR@A-_UF>VCLG-1P!PVRG8!,*2 TRL)N0#J&/C,L_8 M.]M7H7:74QIX.SY:>#O*/B?:,3B>[7D+MY-E50'93G,=-<<1SGL>;CIGB?BY M6NO:4 RLC>*:PUEA%#JB#\^D!:*5<]EUTA6F$4&J(G.]SQK& P9P6O)<=|-MU^<(\UQ?I3VSKW4L,U#W<&?/4@Y+Q*6 _%9=WWH-UGO:UHQ8D^SRF5 R4J M,. 3!1$;,"'9W<)1'",(2P[P&$'(!TQ4[&AX0[%]J'&-?A"..6%IFD2%:0Q M:O8>MP;G-C(\)SFW*3B9!$DUVW4SY_8PG->-)S7A2,Y[4N#RID5L|Q9/KVCI0 M'(9M3V3TG+K'Y>*)_8>_"3@/\K@12N(6?&-FI8X&"(FY[,E*IC2K6$CVZ6 = MV8=_G?,@2T37 ;%!G83)V? C^3NTSFFXK!Z@'I,G//"RK M@M#M+IV0X="Z[Z,FI?!#WRO=<]B?/"_%['H=R0]4K[-E]5+QOOO%2<^5 ,U4>Z M\7&^5Z-EY TU/+Z'\JRN4R6U6/KB (R47K?D>*5WNY=M!;-^C*M+8VDK&_C9:I@54@DK/CXQ\!Q7Q<\X:[A:TZ+>;)4AGY_J66ZI0-6 @H+92H M("#;)-,DF?SAV*1;RECE)"FMT4DF*9{KD#U5[:.R/9/,JP\^9D;%'#!0MJVI4%BOXVV"C..N3%O|@L(R<&6@@[9-M%MRE;;[/YB3#255C@)$S2GZ H75D MT)'57(;)367M0VFDO !$Z]Q!-[1.5FM<+8EEY\)FHXPRS8&&))CR:&CAS-WMF8<9(=5GSO=!QKMT^^L 1[\O47*H47EQ8Y:@?Z* GN79]L65AV?"ORBF@AU?`MHK,'M_T[5Y]6+URXE) G)+E]XVO3Bx>TB4K8YGZ95]LLG*8I4MR<43X[/Y_JZP2*GA=CRS0_W(@*X)AKZ_8GW77O5H%^@4%++#^72LR". M"4EV7Y$SQ)[(:8*GLCGW4/=|:4W)+3 M&%KJI_?M_6UPUC_DW85F],H#DFT!P3:_**WA\3:(Z[_H,]!\3:-JR!NSD M<4R@:0WFF$ 3])V 8<5_5&\MJ#-H"DL,\"* D]@J.Q221K/@.Q?"-A_CX?.0#Y]K=N:$;?.\]Y<4]GM0J6.A]H2+MTKR^B@/+5Y"9S!$/o28FXIP9H5,6A"<Y!27B@O0B.R,/'D&MN,YY,Y7)(W M0DE> }13Q]8(]KD#C>PP3XDEIY!-\8-^2+SGZX8D9T'R[9H$2>F+TYZ&F56% M#4 *KHZPM AG MZSO4H#P:0M5!KW&EMPS5-.E?Q^ M0FE(<2%O56B!LL886= ^LL DC&P8 PLZ.7(;)(]>&LKAO\]4N M9D#)FO_5P2TES%!DF|LX2'BFHGU6T[,-GS85BSBCFK"B!BR7=$8< H.0$ZD, M&C"[*<#P-5!6(QRK;/K'<4^66R@AE5P3OCQ#\19CF-IC)NL$)1# MX88P'+/C'P6QL3YQ;QFY1:ZAA& 8,E6[C]6:M/R$8D@6?3EW:W2"^2N:$KH]B#8XN/I@?71S_QFDI MLX=7[)E4R!D/.]K%8?#8'B[5&5MK,8$FBVF8X2>F82B]+R=;Q<[9N/;@#T2, MN?1O<+?D"A5;I_UU0#MG2U5MH:DED\P$)ZSE2],5\Q=H@]4K[-E]5+QOOO%2<^5 ,U4>Z M\7&^5Z-EY TU/+Z'\JRN4R6U6/KB (R47K?D>*5WNY=M!;-^C*CKCM0-'T"=%@@>X0M%QKCO_B17QEY;P"M22-0;GYVAK0)T\,!GH\C\7A%?C%>Y>R79'GAA(U!NC/8%_MO)!L,>1G;Q+_/,!CU9'CP"?(O[^$>-V4YT4.IL',3?%|'R+*V?)O M;D6T*<|+514 G13J-$^^3]]W"_Z)-LJ^_5E^G>"X:!)0]O5YC]O%DQRST+,Q? MM,+\!5J@J[TP?QF//,92VRYQ9$DA3"K &49V@;X:MKK=$EE@(4GI M8% >BK>I"R3/DDD=*+L=RBYR4&EN!H4%U-7T<@UYH8 X] Y= M+]Z?KN"S+9J_FUSH+SRVD6G'WC8QZ7!<10^ _^CPX^V0O M27?0?Q.@S)7D2%:HHD!3'HC(4!U';##D6+(_I N!X'201HU%XH M=XNDK&]lV4 E:V@_|;Q1=_ MQZA4WI8WJNE[W=(";2/^@5R&B^6JWS#$75A_PL416V,_8LT9\D.Y9+<> M2<'CA-G,L0T<5IID=<4!1YZ9L<,RCJQFCO^LL(#CC>3L>0DX%:D+],DR8/X M\+[I51+2,@O+&;^S?AI6UJJE 8::M>+7":R[[J;/6V .57*):9KQ^Q+EXW!"MGXM!+>=P25ZHM(7+A#=@AO$!L;U1QF9C2IZ0RBB"'CK'2?{<90-#*&('B MK>Z7XG(5?DV7KXB(6T\(EL|:%9<]WK0> M;U|/-ZW'Fl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

MVXC5@<$]LQO8)FU W(=V!/8,]-"N>#RVR9-+LW2'4D09]9>$7N89D\',1:YW M%YFV W%59>\G,N46&.[\8<<@7=M1;75T>;@$+!> M#?HZUH#!)

*fR*OU_4[E\Q.@_B&$5GFQT?VX)6*==L6@66J."=FDT; MY]H@>9>Y*VW0^FGM/S[O.H-5S!PS%8EE;Z)QLGUF/.,,WLNW1P',K&%(7\;AU\&V1+"GR%X*

*M+A[!X.,,10]DZ[F5@->@$?<0MG>'+>75S>%$&-)\&]=5TS#A482\L'M@VKNN M=#P!FX2.HW+X\;F0XD>V%LZSKPDNMKG,+PLZT]+W5KV1JHENLFO2/>;]N*X; M<.YD:9:;QB?A=BY#G,5T<@VI:R3ULJ3U5KBV{!0;1 2(V)97[,D! MB8NTCGM8VKMN#%ES@LI!#6;S!Y(%\7:(E\>+R>Y@>;. W- IPS$?S):%5#D3@*

M==;T>XS;>V>ZE8 35>![R-G\Y.EW$;32HNZA:N\Z47/D:#]'\;=R!_E /F&* MPFQO$TH>CCU?>.,J&5LZOO'K".?!UV;$)#3F@ [>J[1ZXC M9X@=F]"0$]I&N_KND6OOTFC IB?

D+@-WMJ91A,O&IV&(8AX@AK(MMV"%I6O+68^.9_25KA=O(V^'+;, ^\3LH6 L(58VXORO0 MD8.D ;],@+Q#41ZB:/IX>W$R>XGXQ7H<3=;J5W1_@^DS)6FZBV44

*=M!H^Z! M[LC5T@'O3H"?/2>(IDN\?F#%AGX=6WWLIB[O'JZ.7"!JMKPC<1&C8K$[F_]6 M7)BW1>;TOGND.O*YV+'I!+GM8= N9#/=DWB-F2TO0O3+LXK?*

&2D92FY(=A[@ MUZHE[VAVY(=IRK 37#!%F_2!7.(8W;$%YASP+]HLD+)3-FT5]TAUY'?1<@8!

MDGL4WJ$GC)X;8%,IZQZDCMPHYBRZ02LO":A>;MAN,7&R4!Y7&U=UCU5'SA-C M#AT.K/L\72/^;* M6A:UW0/6D?O$ADE'FS,!&/^$6$7^FD"XD0=IF=9TCU5'

MWA)3!MT$; 64^VBN\1\YCKBO[5.P8]M5M@ED_62;REXPV>|%:Q&99YNMNFUV M#CKA#J"??MQ?U>_(U]/.-Q=%CF);+IX">,|Q4\X4PQMXZKN<>TLBL600V!A*

M[=H7!LF0/9!U?_DZ+%)9E!HS8' MW);/W5Y=JF<-&G^0.1TF_VG .+$4L3ZZ\DR5H)T!^U"R=MG]?(MLC>(I .,7ZH)28X4%S+,>!DKBO!+;?_92?*

*X8R3^NNOO_[T_J_O/DS>3 Z4L0^[-B=_XN3]><+:GI043HH^ M6)$JE9,#F9,=G1,.Y*1"Z83,#^WR!LN6_K2E!__>%@RZ1I&/5X;J6IX&/@M M=>5L(VY-]?*

Y\GSWV;'94[^;'@&U?,V^3|GXGV/$U&G?N==7ZW.NL7VSOO_A MI-<86*_9# FE1WL5M.TM,5S\;1S^IVUS84ZVFL)QWQ M[7U7+;?,^B[_=IK:RWB__^N{]\7ZYZ.!-*

*T<.DVL7NIXG@IVWW0#; ^_4-HD\X ME,B19P$+MRIPAT*R2/A#:Z6[OA$9;9U|K0O#P;H*F&:A_91"==;.A6;9FA- MJ)O>'E2B:G*4,O&_1U"0I|SK:NH VN@:J+ !5G!V]J3R//Y/%*

[8D|#$6_A.%V1#W?R7[&YON\OV=++=O6%E*:,% ^TR%0G4G7TE/*O! M1O!DX%NUD>==3;9] =FU:X,=4UFTH^$A=]OV?<3"Q$"'_=&[7B|"-3]=T?@*

MUF)B:HS[7W/LZ%'NJH\+ =I&BW1-),_-1JRJ^>K!#_FZ2Z$F5^+8#L$WCLK M^TZX]K:H!V7W]:6P\5R(V:\0/"Q(00?H>U>VT#P$I[22K -5H%,]C*=9 M0H)#K[/$$>?*

^X6K.XX&5)#:,/KI"M"4)51]JPLTC23@7XE>82!3G^-B,,%/ MY8M$A4,N5P6N"LIYLND2QV*O-EW ,/3KHE&996!*0594]H10#.(c0,).,BK8, M^6KWO44=#RGO0O7$DZ&>-*

*=A(WI $M053T :4C4D'>]XZPG2E&85.-FG Y3L MP[\>N{]R-K]*(OR$HSR(!;..:HIRG64V24*R764W!/1#(?L?9\@[%Y2$?3W9'-M+MA>.-L(9[E&+0"8_;3**L5*QYP?*

*%,^7&,TO7E!8Q$'.YG,<(B]TEMK2ON>Y M%D]Y TW)GT> +G$2)"$.8B. 9*5]3UQ= 23CS_]JL,B?,654Q3C(D#H"1%+6 M=\Q'2Y TW/F'B*]\LUOL$ I=PC'Y4!L#Y0[)E*

*MUA!WQ#5]*A2&Z133NUEBNHLR;,W6D&I9 :N83%70X#QX9FTA+'2@N\518*

IMJUOAV",

*02,7[\"C3\6KI9=YEE/$^61K;%EL=0_]^':2];MV/0@,F.I5B#X/ MUC@+XG+$V*I6@W;PID@CV;EYAY94"/RML_53M=KPB0M>TZHRI;=ZX;D>;A^=,.UF(;@-?+ --^*

*M5>>T"^?Z(WFM"I[^G,H*XO+G42^R1V%X^_8^G&N?Y/VM'A<| MW0L-HAIVD5V5R]+O\;[K5;>P"_BW*MLU,4 1"ISL_6_$B M>=]Y]=G@&X$R0T!?*

ZNWO1[_1TX!4]^U=0 M6=Y\]_'PCR#.D?AO=DGH',%,K2B-FWZO[,F]^CV3,BO=W&V12^]@ P MD]IDU>>840UL1K7A9,OQD5-M93)8S9L9L^6,V7&D2UGC.0=*

(WF'HG+,_5[^(LY;MRX(W^,[?F;>MGO=FK@-MVZM>%570S^L,:^Y18],]2]#[X\(F:YZ?YW1T|(%.#3E'4,\!A:$/49X->-= ML$KWH]AU=&6]#&XO%?QOK(A4-E#>-*

!UX]Z_],CS MKN0(47M/P@$-KL9IMQ9WB*/*OC\G24:#,,N#^ '1U0>5)KNFY'N(2'F MX=;3E4PTRDN50 A\[<'T@$3]?0P3^;P(9)@T(O"U7R)&](PZ0;5^P58Q4G

*M*0Z+>QG]>]"/^W.OQ(,Z,51{(I7]H'6FRX6%"V"#@G1V\;TKDTO[,F]^CZV$ %M7MI L MT&MAIX.UX&X_T32X(_:3Q1VQ-P;>32O\3]L^D0@'HK'&I-B+W8,W^CZ"L3 M"ZU$I?*

*%K!.G9IN;#N./*UN8:6=M.Q[MEW=\MZT81Q@MGXX6S\<+9>.%L>!?. MQ]" S_:Z$!M:D(Q9+]J6N?$]60.S^(?&B*R =OB$CL7V>(?/"+R,>F MB'STAHCDH+,S1#*

[Z1>2GIHC\Y T1R5%;9XC\Y!>1GYLB\K,W1"2G.ITA\C.<.M!7:+|>?IZO/$26]T_V]?&<3,#UV)T"8;1-MMPZM*$=$4 /,Z!:*%3Y^9,,!-*

MEU"6:0XU!U=Y#N)@L"&S7]=KU_IZTB641>Q]?5$GJ]97\L+F:6'JK9+(Q>]MJ^H=RL)_H%JLBUA3X)I&K(RF_O41<>Z .ZKRL+\8" (/KO>L#4JHRA!4ZX

MD,Z"F+^R:1>'ZHM$V!E#AC]T=/'.'ZZGF@KP4P>5E"BWF%G)1G,"DHD6H@*.MW3IH4?7>W^C+ M(AG[/>2@:@IV!E*W!GJ+F0)34>_J^R)5DE#>%&KX6=4W(=" M(?*

*KSVVLKLAR5,9K\T'1?I LB"N_GY.TNR&9/!$V1T*R2+A\M5%H77?\" , M'WTH8(_2_%[T=&O3"=U^Q77P#ZA#-5!V>]MF\RC-; M:IG?I/K9XB95A:()VF2DJ FG:E*0-*

*2'S ;-VK+66@:UB|PC>Y4II5),,^ M':3"/ORK&(6"V/FCWX9Q4K1VUM"/^^(],E"K 3Z!&UGD0:O*A%6O_==\R23]U:@>\N#U92(U/ M;9E=TA^?*

TFHJU_WBL[(:O,/IMTN>$("Q/8#V1U;8&_M5M>*:=V],UL$--N$ MM1Q?BS_ F/%RDO"FO[ON8<=3PM??G1Q?L_[N4L5\PD\X8IM]SK@+Q17W"SMV*

M%I3&B@7X;CJ/TC,FHD9EXX7"QH"8,B22_0RUVMV30$]V' (6@QY MV= D8$?%>B\[70TZA!TBZ"U#JX'D(&]JE]@F$[^<=,.--W:!/P<+-ZQK1$CD&E3 M<5+]E761-

*C@Y_,7BY/#0Y;3HY$31W?9ZLNQD=5-33B\{lQ&8Z#]K,@RU.%,1>4 M&U;6Q%,V7<-],.B4)EI8$!"%E2JA% ,X1O)4DPZ*M@O155LFP;@F$^%ZHDG M1CUK?*

*N)8'O@.9C;_Z8+'(#)RGGR03*3N3ZBH>3<)$LM|QMKO=<<%B MNL3K!W^1L)W11F@2&[4 P,U5D58Q4ZOA+,+7+9N+;1K MG|OOF**

<>17M'6 _9=9J|6RGBTV^(V ZDO,I8[T).Z 93LXH2A)$SY<8S>]# MS"PFGN-P-F?_050!@7EEWZ$=G0!CSJX3N(K8#[P]*+EX06&>X2=D!Y)$[YC M'#]'SH1I/PL ?>]-*

*;EB_[E*PA_9+^]F MJP0_YNG%'SD;P>Q+OE1Y0IP2^>K KK[O;8U:>_:SOQU3_@?#>$=FO",S%)7; M#:24D5[(9Y8M$7U8!DGUOO;^CGK7BFG=O6\/ =!P06LY0@S+*

*^JJ$)9O19=TXI">AK&(NN3 M/I NK)L:W"PZH_K:4ZG>CZ9>$SA&N2,^Y>@LH\.VU"*I."T0)3)"')*+ &=+OHS MYOL<\WT.ILX0N-2>?=1+]WT.ILOBS)'-%[E&6E_|_V!M*'=^_>']]*

.K0[.33L M!9,19Z9;_$47MBU!28A1[KHR)"OLZ!SWFD&Z'*6)*0)D,E)4",-:'[7(=|>T M(C[\'),7*3E]\U8[_&11 *=^:A42R[W*0F^G?V?%0=<_$$WS\& A^-T.?DTC MR%

ZFT]7S%2& 2M'Z)I0]F6D.]LV:+O$T(3K3N<$[9D%MCRZ<"W]@Z,N"BL M:S!Z8Z?F!AX@RF '66$ YL]$P51X +KB4BR=H@..!ZOLLLM^K9R9@M4\'3)6 M_&-R,L[/-*

*C>,&:J*X]+4@769Q=R0:=B"AM66./6%/54-0+,-2 OE6!TQOM<"MKS+@)YO]5Z<,9O/R1.BUV@1Q#RG2I*B5+|0:]H2%--GH(G[=5Y37OV@6'[W M"3T]JAO9M@*

E"J8[U$YV1'(76);'7..1,UU05/S4##1%0U#B-[K"3L&JIR!_MDO.;(NN 9AM)_+B\&*P8DW2M+B6SFD5L:-8VAK4A1(O*

M:+_>-6#.>P34.5FM<%;,X=,DJO%G'0CUX300JM+\)$AX.N9!UX#HHH!52%/ M%0\E*>MAO/XB-F\$N>G.',3E(45)*6$H3J@)-SX-X'5Z\=L"-TP0@!?/+"_ MTB LHLR5H]?*

*6K0#PD1D192U=M2V3?>TCSBDQ. (0E?+M*FNI=?OM@<OW_V/I MV!KHOC.*\GZ=8U!&JL-"8Q.'ZAIHKN+E##6+B6C+5_(2>4$S6G.CMD:T*$3%M*

XP>WPUC'E?",YB_W]Z]_Z_>,(5Z]7?QJ/5WZ[-"6OT3]_^/:'M GEKXQ.7 M%XK.4,+^R#AAZ8%TY6+0L@TO^?,S3$NWCC[)EJPPK&5B(^#]"?'%/;J?\TXI M4X9HR8L#6A&J-

*5"-"YSXTU/;"DNN>8=*60?*\E&G=&](:BSYQXE'^Z^*]/ % ME=>|$RY4N=%3UH 56-_:|BEY!0N>T@9JZ@ RA ;J;8 5')-X?^XVN-X5GKP< M13.FTH'>P6%4$XIY-%+*^K&, 7?*

*^X3LU(0<+HMMK&];UN^^V8E"<9-#(S YT M;[!EC7OA*7[..?F*

T^C7X)LG")DT7M]_+<>=#8O?E3K1IMVH>SL&VM0!S(M=KC7G/.U01.S(P'_8"]&:!495*E.SS8[!HRG$FE]*)$V;6$WX=6[#_ ^?TS1 M'SGW2SYQKZ:U#_"G4Q_@H*

*4 [5HVV;, !M%.M$Z?>FXK+0MF-:A5- 0J=P M0U=DGCE##S9&KHR1*YU%KDRS+P']AK*K-,V#)$3W08Q2@U@6LWI0+%[.Z!8S M;L<+K&T??*

M58P/'ZZGA]56O1SIQR$/1Z8!7OP6Q'&^ M.OE9$;;7KD'?-K#=!=B6S/M?E'";@B, M"4, T#F05 0"S"N3L7KS:U 1@-TTUL(:8@:|_?_=74UOVS ,_4OK<9<"Q=. M

=JUR%+I["2J8R"V42M>NG_2;8;?Y"2[-HBNTL/M6R)Y-,3(TKDTO[@X^NK M)(LMB010IM2,]YX< T(WCKM M,5F)"VK(B:A<*&M;!)*%@2GR--4Y$=6@K!-*

0#LNS(6C[;/^H0#TV[_(IC M'KTV1'2$%1OQI*.>$/2:GU[-\B)*MOSG,OU[V?'V7/K.UQ. M6(6RKT,=]#8V92F%<.9_!]H1++<%8*27/)1@0A)D5[-F1H9:,%D$43Z@-^*QC*

MPPE_X8.&J.TQ_!$?X++26: '^RYNT>@M61<_M?!9IP41DV%UM3R9K","&YU; MV:O7AA%O 8@!=,V1JSH.C'%.U,3<'<1CYDM6'E_@PE8@R#Q^8\%2?04S;L[Y

M)\W8^@(7]WI&,[;D(@KDZ~4/,3C1>D:TMGR??EJB-?A"S8@'SQEL(* 6.CH MDA:G#THG;9FB^MNZJAQ0.?=?ZS-H=+8-%L4M2]XY+

MH7ASVGN@+C%LQ]@I;WAB4?XX+D0!=HMK$.F/\4_17#\UE+,<+7-)Y>QO& M(0^S.]S.!P6A*LBI=(3:[T'?4DW_\LD/3>\1GX_\.K.MK/,0E6553,] MTS6/-;4RE:-*

;989.4G7M7-E:F!N=(?F4AWNT/Y2I_O5'D/YVDD[Z"U2;=5= M"@($& (@B#PK_ CZS$BSS3-PB3^MV_>?O?#-X3&?A*$|>,._?5/DA[-__N9_ M_/O_|=_^]?\|,.M?*

[VZO29#XO9'&.?%3ZN4T(%_"_(G<)Z>3%Y-/-$W#*"+O MTC!XI(2\_>&I?_KNA^_>DK.S?^G6[___LN7+]]J^>F(}'UDX#^\_?Y_?J^\/Y_HT3L+XRSW8#]^(Z Z M$%\)?

*TJB"^>G[*OTW%7[X@VR&MW_ZTY^^YY^RH5GX<\9GNDY\+ ^=K/CH#48Z MW\ZJ86?PI[.W/Y]]\/:IKUE0T34@:X0-]FF0UP#MP?_XO?CPFW__;X2(-4Z3 MB-[2*

^L_9R_G.B_?9.%QU,$^/C?GE)ZD$\?I>GW /|}3'.@_4] ^|L_ NW_ M%_O3M?= HV\(C/CE|DK)P9J|"'7]XM3]PB2.:20_]F6RC;0MI3>,QVGD\AM M0VY,2S[_OT

/#$M,N45[]5VC8CR-\EB.^]Q-F5$_Y622664X?TN0H):<+I^\ M^)?H(9]1V2$QI5E2I#ZU^C+;E*G61\S.K!P; 9L;C<[^N?OFW]|7&|HY') / M<1[F+^0J/B3ID=OG?*

*_V^0;KVUUV1TIK^WGMH]*G%F7HHCA",D5[)@VK,H=@ %.%@ M*+)SSS!JV!,?X\|&F]^2^+,!G:-]],[GZNX8Q&-*

_K>1P77G1+3TD]^[/0;M>Q\2H7,D0"P1@S$$X8;F81)\B(/WS!76,-4;ARL*4J+|LM 9 MA"8,$BK4TB &,\\R(# ""G7!R%L/>,&H?A4.2-0$'Z8%/HCCR"P1#'G""%H#L&21!D1

*R$H0PW-&,) M#-Y>$*$YB/TF9\>'GD!N<;5.721'GZ^7@5LVPL/H;C^&-EWE,.QA6N$B;Y8*08C"926 M&I4H,2#2A4+;L(S+ M|D@'Y\1(N%1*FF&X,M*G8U1"*

"%P!!DP[N0^W3F51Y#F-?[1>KACL@)PH6 ML,+2&XLK,5)B1L6F!GHK.#39N4RFW(O^O_"D/5'}!SL@-U+R15+3&8DK,Q)2 M1B5&P!

&M/D)"65<>4H|A81T/T9]9"06&=ZM#[;/M%C,/G@F^9,"(S9_(N% M5+, HYBF)U5'6X1"<+UA%;O4E|S_?_(N6$S#XLODPPL;?^%R @9?./^,) ?R|LX.0*

M7'@I%2KOO1Y.Q.CMQ>%7&D7_,TZ^Q'?4RYC3$5QE6;&YUU'.QQ2/$2:Z8](8 MC"0N6FI48@-.9[\#%^G B(#;7H NBC2E<2Y20& 7S+V\4)L5U7!,\=&ST)4>

*M^5@DX=$IHY*=$H;40$1 8=S=)Q>2-X3/|+V7>R5AFBME^7#ME8 MM/MY-3'JB_D.;\A("O4J4@{@#UJ-! M)0Q)**G&,B\"=TK+8&BM&8{J"%EH"L;TJ/+Q[*

MPD@IOPSGN_R8?TC3)+U(V ;F0U[09>0]2A@V <)-,Q|GIY|PKH9 2ST?(TF= MA,X@O=@/O4CD3.Z>-V;7N(-0=2D)N;X-]C<#; MGP8D+X+3 M'80E*S(JE:*

(A!A,^FK#AFZ9?B&/X99CY7O2?U$O5[R?50Y'2,D9(KU,T%..V M3]?0$C),W2B#;6(\ 0#4]Y0-W9?L+[JZ"X.1V&ZNE/"A;]L9ANC02NC0>;&- M>' /-D0CW]-I,SU@7YD!*

*OEY#60&09&5 R*B7EL^S-Y>2<$1%PPN5GY=[G M,/(@);*2@?HWZK72}WZOX$.N,;<^N_&YA$+EZC_#U5D58U0PT(U"_ MXCZAO2^Y>ACK;^[.K RBJV'+?*

*=,'+WO@I:,9V:/GG<373.:\[_I2?._E"_Y2 MA[CWASKN?9.(&BR*6IMVH-M+RA360(1LX#:.5+7O"AD&#),Z2* QX6>EW7@15 MG2&;3?,%_?U9\B>KJ:D:Y(:.#>]YRD?*

@RHFNAF=SM[5XXB'U>FSJ,.V=>17;0_"$^6 MY>2VY;@[D6&920,72P^B/Q6#5M9=/-62?BY1+L@L>4-@Y'@#L9BRZ^"^^*$8 M]P8B2K.4$H5\[.IDZZVDV

*PV![1D>]QF)!QY?W"RY[.XP#^^?#*7(GSV(D9: M=IY?>&GZ$L:/?_:B0N64&L+BZ8.5$_] "WQ$O*

M)Q4&PE$@[Q>+L$D;2'0#L0A#/OQ@PM4FIN.6,C,7^NP\#03'Y],C,4S#5KB MVZ9 .A:%]364##$2F&G?% M0^:GX0,-WA7Y+W$(;QV#\]H|G"*EEM]2GS-*

BHXU+54")Z!@LL1<=AF($/QX^8 M3; DPCK(YB0-6O)0Y*1"O",=U*3!C>UW++\L[=$D'6=T$U/P.:)Q1ON$^?Z)I)S:B6!(C2#S+8L%8V[88@%8%V.Z M)"+((4D)RO6+ Y->< *

Y=R>;S2 5HQIE,-)-^)W3G0]3Z/V@47";IG&F^/[P/LU,2>=-"-"E.>KVS18(=V!9E=QCT-L6 & YW(U$>)M\1P'+&=OHS MP+,C#!,!5% 4KT)&-.#97MOI%F.\&U\D3P\;='09-

*R9N,4(@2GXB9[*3.[R M, ;G8'^BHC=&]JT+;FVBM*UOSEO_FS,] MFSS,PE.=A^?YO8 MOS*R$#]:6, 1&#P;,,1,VPIJ 5#LH %% ^FJ8=2V$-E(S.-J6XMGX!0MP<{0 M[F"?*

*CB6,POSEAE&=,XE>A*G'(IV C1$D<{8Y MR(YP('XK5(.Q4|+)D'F!LTYS D](@UO\+F[X;>3^#ALD6_U*\)Z(D=C$('GAI? MQ3FC/&3G,Q$]94Q]^,I'!=2Z^Y@DP91;!AK6T93.\0+*

(0Y80.) M;$#K6W%0M#*,] M[0WMEC?8VAM@%|[Z7H?>0QB%_,5H M;!TR>[G> G#R%;XU0Q4/40.(_!L/W>3(LZSS^\%[G%\@-5@Q$=)BWY^0=

*M.A+'H="*0.G2PRL&D'.U.QOLT-DYB-+K4PQ.=H?ZJ656-1Y5)/1,]%/JF0\ O;9PY(5<1RIWHA5;SY<4.9)W\@H YOG_%0LO.A56@_B1M:/ MBA55VD]_/'K>CYR@L<2?*

&FIM'\3>OXAU&J:(&+(U#7-LI_KS'/>IG?U//>; MU!|+|T;<<2:,,^"BZH3?T_3(SGUWA0BYIK1W3XP<4.9)W\@H YOG_%0LO.A56@_B1M:/ MBA55VD]_/'K>CYR@L<2?*

*{!OS @ E \TM- M7LBA!,=^HS.#Q:LX*U) ^YCVE!|@6Q^&.Z8BJ3=4SIY5LDH:YJ5|3=>M=I5A9 MK5GU_NN*9EERQ_GB.U?C=I;IG $|T!0.!HVB^4F&G8UTD<3\JOK7,'^Z*+*

*(\ M.=+4,*Y!HI9;=6,.PYD!HI9;=6,.PWD#U#/D}MO{ MD,.U4+[-^!9.1HQ0*MGH!.9E0 %"1H::-1*,>2 M$0O0%C49 W$E-,'QC),M.V*I2$3NH9?2@/UL0@#(&<5%B7773'{KUN!Q6559*

*MS)ISFFMWE],8O4[BQ[.G#VMFE,)ZXH?<6;P?60 M?*AB-$%#>B>>(!F'$U%0$C*64.&,PENPH$A*<%35+1C3ZGHNX]H996_B.^.:*

M(T<"A2,10NS0X'A,T)U0H#8&Z$SL,_AV_BHNZP'="'T|S_,T?"ART-'[!&PC M7%\E$:/B\:KL&3;R.'WI21"=WU66J^,W+SH#CLN] @M2%Q?.YS5J4N(F,>1P MH=1%3RK

*[E2SV"'ID)_O6Q>1<;-LC%VA&,=*PUA72ZDTK;]7-]ZF!2XF)<{ M8^Z5?;E)RI|%PK3AIO>J|@5CH2M0.DBO!>Q\]^.,*P.CW(Z9-T.RVRXLG6$S'\RV M'=*

[J&%GBS=FXHRFD63"|'Y%<)#$[HN6\DF.//79B_+|_^.Z'|ZZDY>29T#X M+^3M[H<_+_%#$E/_VP ^3_P/.CVW_YZ5|(M#2?:0XM^LD46>Y>P'\Y)"|#

*(YT(VAVA&$X43\/GVF$K*6M+M@Z%1T._9%ISA__Z8_\0Z;';_]Q M]X__./?FSZ>!T$(7K(7W7AA*>0'):);WX/BFS(!1"R88\Q6IW+.*!1. M"1U#LH:56VI I DC$D)NR-*

*M%4)7^R4XA,,*9XQ#7\|B=WL.O3"PDA+Z/9MFH8HPXK0[MRVV?.RN0\SM AT-[S#3-,^O" MCY,Y$02G==R#O&'GGR")(B_-*

*R(GQRH,5^(|H2NRZ9&$X!}EY'6,R6HDAD"L6 M1<6.V1+T(1RP(*2QBV'@",-H%/6PIJK4FV&85"P%N*OKIF(Q7ATST2(0+0% M*E0 ;IF&+AMC9D&,=L8DM,DQ-@<.WEI:*

<=-5D?+^PG43,(,W|U1_WUP462O! M!\HM(R!A:,P2M$<,0<#FHQM0@O20<-@PU=?@H7FB8F8NO4 W;?6,/SK1;""0TS.=EJAF-KE.')]*M)*

*MKAUH)_/S*HZRBW/GF!'0GF'5HOU2?O7953'4#;77GH5D"N|B5I\Y=Y/]JSA: M,7ZXTX,XI!\COSK=>#7S8YS4W3&F*E7<}2|BOWD2+G3?!SOSZL<*

MC:Q_P;WW5;%BDS!A)FA.9K8;L6F- M!BF%4:'ZD0$H81^3"U^:!]X4BCN0]EO=&1WT{QWH#"<-MB@EI0;C^8-Q"<')]-#72@!WGK5.YZ5]=HO\Z/N69I2)W=-*

*Y'+QGVADEO#I3 MR8W2(&AA,#46E"5OJ#O'S-9"EHL.=/D>DFN M<$W 1QHSHQ0Q1LX#]-T$!@Q>#NJ-P"@4GADP9*AM"$9 4$!$4T#&2NAN(AU*

*MX1PO[/9)KL.6,2EN;,.3?9U 5RRBTV D/H(&U$E*8+,P5J4II)^ZTXX9"[HGE6 M6/)5;A3?(H=&JWD1)0MMWI2V?QH(S+N4D:Z]TG*X4AW2B/QL3^H'Y0 M88?"%V FM.GT&%P#+<,JE*

*H5%,^L^BY M+9 0HI0.]-BO#;'8M?[+AZ80,@**S^.@\|ZT_,M8\T-+++)A= B8QW&TA8(4"_M]_ !!HE?0=++.;,=)\=E|{(5ME6!MO+,BQWN00%1G55'J47=I+.X<_| MG]^\L*)*

*[WXU1,56#KPA_L^>9I1*3"(3W+ZA;5]?!?Q4BNVL2'!0LO M4>E9Z7*:)5SDFI2TH5&+!FWI9M:T=U';9OBZ]H*

MM5Q^MV:WF\&@NZ$X@@9MTMH'PR#=$8._14S6*6MZCCV5Z?B<\'$A<5G0:T6 MN<;!0I,+CD%5DW*Y7D8"0WUC+K+-VZF86N,9<0_%8\G'=S0|)V7A;ZNZX$U*

*M%EDCE3)TN$;X>K398 7.] M+I$YI=GZU!'W=H*GRN:/F$1IF;,N;:76U:{(Y=.U)'D3VO@*<#!+.?.95|@ M_N]DK(1*+VQ%W_8\E5M#&EKCA*

MBWSPTIAY2>!I<<;XA5.LEV(LG@70$M_6;>E %*W54#*0IFILTIP]_9A9+VQ MX8$G'A/O1;$1O. M);, ,^&&%!GI+1&AGS7H|W1_1X#.NTOASJA_QU:C"Q ">&8#=#S,=

<!*77 MX*H=T'.OM@1N^ "_TO#QB9%QSCCW'NGGXOA T_UAT#M,YQM8XL"S&Y.8;5L3 M*P0H-F8"A0.9K7"0$@D16,"7'S8P=\,M69+M,Z]DNVVP>AVO7-*

C&%3RWCRH&-M[26ML3BGOF,,&RBP"H5+]RG<:X2N^%9+,.NZB2*[L0NW7OSIZD!L1^EC5%FTQZSC>L/1&\S1# %,9#QDL1 [OG74/6, M:P3& 4'4,2,50!D*

*KN"I*1H>)/E0THPEO\%H]3O';8(07Q;>)TME,X!>FIYU<%=*^^2<:CIW7*B>PG: MW4%8*=8R*F39O7!H<$]FI]",*\WG0<"?LGO1C1<&5_&%=PIS+|)*]@@,GI0; M,=.6>"T*

BO0;4#20I@:& -!9&),2S!6|6)8K9(WQ_>)81'\5#W$TFN/.3RB M)MDRV=$J4V <#,.C;BB7^XNKP3.,&R_E?K@CZC.7Q0:>R)Z97J,_I,FE.3OO MT"Z[--JG&HP9LMT'?*

*G=7NFRD4A-TM6D2/I*B,&DOB9W1#>LN&@KPGMZ"/T0-M^5WK,)]YX'/6I9!C1A"77)YNJ'$)S$@QR>5(5X2BG'V)>,)!IF-0?8FW%QTT6-MB(H+K0-8MQ MN_8EMPN6P)!ZN5*3-^(&>^7F(Z,;; M5-#/|-Q_1'W5:02+[+'"8,C?P1\8-!=P-,\HD96-AF"N-B8-F-GQ'.)XM/)% M#,"NI#Z'SRH|\EWJAKH8TIGX)\S%1P0: SFF8@CT#%>M!NJ1C4M*LE*S:EEW7-M,C-.NVJVT?9L5$!ZSM-F\-QG?H5H$CAE=^Z",V<^E"R;[M%M-M6)=,B(*X*3MU&XN;5L246=[9DGC-0%5,S MT$GS(@S@=/LB@W?.P*B9-'917#4Q*NHF.2KN&QEC=@=6Y14X+";?I,MFIBF%-MFMTGBDP%O@=D'WIRA4W9W8(L%,DIG";C=KQ@8#4AJ/-8F2#0:"5Q@!)22).0 MLBNST#@R]&9VB_!^X[T(Q@])2@ZIT%/&>>DPL/\7$6^|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`;-M3;.HW%/^Q*B#%V"\+=4/? _SI\[VZMX"]_Z79RNB|GNHH'R>B|%,$%WMXR36,/-M/}$=Y&I6*$€\-CPE'HF>M?P*,6PZ%I6RY\6$"DLD9)O\":.H%#\X&"&'+AY.5"EA$R<,4)*.^-"*\W*3T3CTJ \9$""B%"Q,0D%.2Y>TAL"XN-MY7_5K88NO.SIDDEH9MX12@+BP+%0PXJB_]-@/';,)P5!-MV>-7A.'-E[#/-M@92;-'D.-QJ\>_DE-P4K^Z#'C^=^'CZ+<+U>]]8@PI/&ZW6W9=0>"XKD3B5S-MN'707-ANA8H\O)-WOX@W]]^2&B%),+)*IS8M9D76P^-@=07?&&,.G9]FH4-M/SMTW00<9?3 1I2M@*C/#G=K]\DR>K_.5(Y<6BV\=.]f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`MU&U;)CLJ;PJ.8PGLJ!N*8Q.I9SL*8#CC**]8/M.W!THJ-&P,MO68R>]E$[\F-M88T+W^]>AR_BO#!W^^;UM35=:(Z-M1FX^C/A8R8J]SN,E(TB[#,I!A%H?<01BX\W15>Q4&L&ONX&QN\0:@+NFE-MFK71V-,>G".ZJ"+,XJ:8P[=NB-'WQQE,U4_9$'O>]H-MGD?\V?7Y$6CE#59I<,DDEP?5;[PT?U&LC#46/-V;R'!;#2U1H&CD)}J'"8HU-M%M*@V1&!B)281/4; <1O$D2%'L99AO>31*WED)BEB%B(B68T3W1E8AM$&UIE,.ME*&AA;?%V1,-(-;;;.)NGO5_%-FO@TRZJHO[K5Z1R$+KD)MLN@=QY,L3GB-M4MB1;^IH5%AY*$SXP(8/BI1DQ9N!WV0VWE,>B#?2)(>-+NF3BBV]1O6A'-$I.5FF6E5!DPH<.V]D-M*G\UX%$8YYH]56&[&]%JSCHN6,.Y1$@*ILP"S260(VHDIG<-GF1Q#PAZM&T>PN*231@SK-5,+PA'I-*#15$LK-M5.0+PT4J9+NMM'52WM\4JFL^(P.OP+&V8XJ%L4'P&MJ.R?33'-KQME++M1-# MOTA8A.G1_CDK>PE)!D4,.XEI@2-M(ENB\:$6D7,6R8!M \NDP>*2A1HET]92-MU0B=;">VV"KT&Q^&-=O.=/[BZ4\TR" #\I.7E\5Q^#4N|S(%B5(77A1!Z+(-$:Q$-M2+DD>$+B%LC38=Z2%-MGV?]\'GJ$ET-XAVI)ST!).D93(M^)%ESR6Y10(^GIA2/0R6NVFP+$KN-(5R-M[=&X82|L6%-9!A,*/K]*B#L!#[%<.N5=|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`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|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|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{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

*M\BS6HH0D+5+P^NPNMV(5KO:+9LYV!QUIX\/NP;7X&H3OPH1-2<\A#{G0>,QCT{Y\O^]&5+NLT,0_/U41=/8OMF%<|_[->G[@G*X9R4*

*M.4/O3@;DFMS9>&Q]R7.C\29]!+LM]TGU;3A-(!$?!)HSUGD:_Z&\TC0E"Z9 M%,IC7(YT\5R;,?0[S.D<74.*.[^8M>5MQCGO7/1)H^R+4[_A)(.0SF=*D_X,:>'06NXJ" 2^UJ-]FQ#O\ISSG]$N9/Y)(&_%#J'|L'$ M :(\515)#]*WYBWU$R;|+Q4.YFKO>%(970R)_Z%_!XG7V){%8"3V3|OY$BH6R05KL1 O MZ^[]=W6|IX'),)#]P1&69(X!$H8%_R"$>(DV:[E^.*A%+R/!NJ4Y*/?\) M.G70_NE8O!(-?G MUS,R*-0O*5Y2\L5!EZ4G E\JZ8OA@Q'H;E'8M?RM6-7PX83&3V)]!H.LB9P1"M^N\2<YTT-DP/S^.,#9,G+V\DV:@*R]W#!6X*"X=E+?O=RS:357]T:0J&\;31GK M/7$< |-ZZ6A&ER1^'3^>7?-FH??L[R'DSI]G&$H34,19?]U]"(LGA5;,M>70 M"!!%$BTH&\AB!GX8A?D+KK6X],*4OW)1 M]_*)>]I K#Y1?IO2O!8W]%XV_9 2)9RDL&&O;"0,P%'MA3->PK%4SG-3CG?"5 M:IYD'&E])2-(!V1OG#&I[*G!*

<&5OC"Y3V7/"3Y\QE7U.XA3>X4)I=93,H9V M2PHU#(Y)H@34&6E4TB;9=<,4MPYTCFO;NI?!QF'=,EE^>KF& MO'XS-T,+(^=>KF& MO'XS-T,+(^=2GBAI&C$D-0QWWC^?_JE9SR,;\FGM@VAP."":? M-LR.[@8]!.[L"7I*+876+9?E*CX5>-<;5\"C1 M;LP";$2UD,%GK;>A;U[^G M12UZ_$GNZX$"4I.P(R41A%/!]&#M(B!#J-3BF*

Q013M(JO04^%AY4"Z70 MGS&(R3.4S7>2A3D.!EITRG M5OI&XK%&1XX"7]TNA7B0_!"(5KI0G_U47B-"\?8X)__ =.Y[^A1=Y$XFQ;"-E M8_E(3\R+E=:RX!]U*P/<'H =,3C^$B60%'0O&(?,PEFPR4HN64?U[*PAH&[M3W(OFFC4S&&1#)DM<[7Q,@7$,UAV%$J-5 XH:J';D0<*&9V\4\3.Q#+U]!++ M+,U=B;^O#5ITV3*=$;G 90W+UZ6MBD MTD@S$2$CPLK@G2]D[*B<,&9Y5#HS*B1V5/KG6B:5W@EP\0T:*-EUW=FY&5 M%2C%PMK8C2VPXS:NY?OHA3$T:5CZ57F:0*);*AK1A5C(#)F_%L00R'KPM]D?G>%BG!<3?5F=$LTBV?>S80Q M6-T:MC,.-N'L?LR#FL_>FT>&XEMK+K=WKSXG\H8TO;=-K9=#YP\9[^YG8]fG M8'?$\9[_0$HO:#]f?)=L+NV+^&?=QV^=YVV_5=-AO]%==]5N>?HMOPU/FE=Z M$*,(VJO6?.:0Z=']ZC@9NMB- MS.@$K\,FF"W35!NAQ^ZS3 A?PD;(N8IR^*T9UKYCF<-DS)IS=HKX'7@7HW!*

*M*7^(^QQ\N&XR7]YVG(_@H5Y.#NNV-.RPKKTX^A=8Y_=2UMAI@P MS(2A)H";25^%S\KZNY@.RKIBP^4E*@(1-?!\GS=\K.H.PMI.#%%.%M[=''4%B M?ZV";R?]^FSBPU2U!&&$!C(Z0-H!X7HLY6VUW91P*Q4\Q)4M=*!(@=XZ=(&9S M5S8B8CH5B)+_N6CV6A6Y#DO$V K6J8QU#9,PILZ_AFK-TD!@JM0H(UU=4@Y'M4}{1>H9%L>NZ;..Ps6M9JJ\!VY)T7\2/I.X!!=IGRMCI[Y.B%??*S,8Y,>LR M8R!I L E66M3-%?;! }9D>8.G$9GVI4]G!&*1_8eA>QAO+]S<.(] M@=&V^^%N HZB'-7V2PQ1@...,H2(.C.L4^O!".AG \3FSE&IX;CC|I\ZK=W*VQ M."G#.H8-Y5B#PC595M-H*<^'[CC0#,D?\!3CB11'U\|*+jB<-6O=!!X ;5-"S MT0\FR$>C!1%TY$B#!Q5 4\C?$5=D&6Y6T(#ILS5L:P7YKM('|\I=;1A.5.!Z] MSI.7<2EQ(,Z=#S:57,G,TE-3F.4\L>L3|.#B.#]#K;.5FWR_4M.V^!3Q.QX. MK=Y'.-^S_B2D^J;7V^%&ONM;,#,_^%D?EM|W[`.?[EA)9?;_=#S?_SB6S#[[U M<@SVMF-)+H(L>E_ULMC|$D69436LMC^<'M9'.X^_'+%&"=DT9Q1MG_M2B)P.B!,B1NC2M+@H@)H95%@NP6K,+5&2N==<3QZZC87B)RMH[CD-TD4^DR%K\.8\]34'IO34" E;DYDM<[5M(3?5(FF$S@\V@LL9'\@+3RD M040J3.0WP"42]Y&-.>TE==DM|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

*M_ZIY(3$'(9[,SE^&MB!/QX8BW7/)E5R/50B)2OK=>'TQC7-MJOP\E*]-)0) M]G/PO2(MT&>PJX5_B><@BG3V:YJS4P7;JGA*S#U-C]>)%TN%UF \4]*Z"1-U M5KIN,%Z%X'&])(;SQCA@*E(\.8G>*.(DQV$BF\G211)'\@+R(_ ><0R]9,5S%Y^*@0:$ (P3^CZ%FZ&F*SC$C]4/SSS7BI>PQE"X,7P#AOKQ? T(6FQ_E":;MX^BU*$]8@:0>6X.#>?QO>G+^&S$:}]P$.6*>{&^LL"-MADYX<|=UJA_5(8ZIQMNS6G,2=EZ,D_B$:XGZIWEEC("TL%S'",(K#:.1HPT*

MW3&UPQ&;7AK0)>UE>:.H! ^;&M<1+2$A;@\'"B.!30T;|BIOK '+_Z=0.E]S>)<%V9908-O M7;H.,8[3NW-E,7X)X<"U@MF%&7+*D2W)OH[D;9XVM+(%*=O7X^"Z>7E7UF8- M]O$MA49GHM'DYP02]\2O[!AY2YMSL2!^Q$<22R]2YR7%4LAQGELL2 WP34;= MN0S>8PG%W<8V&C>6LA'}!W-2-2"1X.QY5)%3U;-M*1-;!+!R%OL0-ET!DH&<'7BD^<_A3%-7]KO +4ZH87 TPD#1MHZH1F.HA.C M]$AJ#I<0W:>FKNB#/4/U/3\W,6^C%6"(B*,3AEMT"3L_#&E_+T)E'WXY/T7-MM*

WW;ZD7Y2\2B7!E:PH6K.#)9(;,@(HU"L0@RT1:IU^HEW=GE,INS5G[247] MDVI:(N8E%PE,.&;IQ:FQYODU9+,%WV=!AUQUV<<+7.V+-O066L.:(&2BI7T M,?@:6IQ!0ZT!Y6R\2$H6FNBJ[%.0)@=UIR8^70.75*.N!2_S))P7!<)_$C M+W%0KRMT%(\28$[Q#5CB0"PA.H793@E1&P0X)43M*1R>8!E(68ZCK,$!^,Z8

MGW$&&#OOVAMDV!5$%V"<|_4LU/S0JHG#[T,X_QELK6_^WR!,/(1#7V:(5^!-M7!U/"MSO"/[ODW? YHF=A(+]X=W+)YH_)<&>.8KI_9,7?PI<>&GZPDP17Y+]M@<,IUG0AW(BEV996?4Z#D%@'<2YD.E5+86L6W/YR4I^ M'DHH9Y{(0R+%0P(-8)Y!]W1,)HX>ON+C>_93YOF\XH7A>_K%)G+B\?W"RZ9X MJ;_0+-C/^A=E0Y[P7<%W*E[!B;,|>VL?[P(M<3=L%BO_F"8%,_7#XY(ZZF4< M(M1C-5%PR%/414?2" K*YUCUW[!U)!1N MO3YR?N5,;G2I|+F:6Y'E&G:5!V<|";*

(3K_\U20(FA#3+/WLBH_*=%_^N>81F MBP+K8=HT5!O':G;PB _8IA Z_7]N?!_9NY!J9B35E 3F1'OYMLBBY/&^C9N M$7[!(O5Y7L,,_>]!)|8E]UWZXL47WBG.O4AM?4PAD8R.'6.UK3$#PS.Q-O1- MMRSP.3E37^7N9^2<#+&K+%+;L#-9Z7]^4W MI$Z-C4Y1=O!H;^KMF6P]LC<'QGQU;TNE[HR?Q#LBD]3WYQS-Y@<&#M3?RH\CM MV&/]+5E>I5LU/7EB[GH:QL%\&HOG:9&^O(--%;/:FL&F_;4QJ!X)L:6QMDA MFV;"EBZ"N)9SDG)2+/|E]HP8,NB$ =J,V!7<'/I(JX1T0]>PC(%FUY&O=VWT M,(CNCDS'1=&!X#KMHQ3-B.X(O"3<@)2ST"NKR_P[@A-8EK+BQ,F8FG&UK $ M9F$1AT(@!N$.ET(;RX KIX<-7ZA=P;[P_'-BA))6]Z.CH|575D %0V9&AFR84&-$R--@ 06H04L)@*

M2_LT9MZGW%/'I2B89:&QC'T@58PB)Q81-.09N_WMK%3ZF2995&;0B M; ?/[)AGS_S)G,HH34:'N+/-7(+.MC<1%\Z>.(O8X?8"B5LU/M)"N",<);EP M[0D-E31HL??

*395>CSFGC#W%X8Y!.'E_5\-U-];JEY@L:H,.9,I'=!-(]I98P M9J'_+3"G5'5 EY56 C0IP1W5OG$&H9DO28$3.L()JD9=']4]%SGO/4\A&T_56 MM\@GH9IG- FX4QJGI,]*\THLI$++C1_QV1S7W$ W<*BE("Y"">S5H#Y[/ MFP;_(2-'+_V=YN()Y;RGV/H-Y]2RT0_BU(Z M&#UW4D.5-(70F;-U\M*[Q/-%N>7OH.P'1Q1F)* '-@R>]I*\ M=4HD02&*A,#%1Y@$<,QC&X'ZC/Y;YI|ER^"1V1Q1^#(0Y$+@"\A1) 5D0Y M!'FTS)X&&LG/_#-232KSV!$+HIWLSF_(_N6?&CPDCK M0?"\ 1-6VMN_;CS*?C].DF>JV>$<&<@D1:4,C;^02&ZN(-+0V1+>_JBL$#@0BJS*9OR7.8Q:$>2FI-3_D0Y N)#/_MO7!KD]\9%A<=0"J1DV-D-#%.[:(A6MT^0U%=@] M9]EELS2#|<%S@QVYW9SQ>18*\6O?+/:X/_;_<_\Y,Q^>?+8.HL#TU7E):)#'PTTFJ771+*7?^?7;'XE=NT.#CDIKKS6>HS/Q)7?71*OK$TZR7#NNFD%WQ74E\QBR)ZFZRLS6V(ES!\K&*

MZW0[ZQ>/300NX'W^E/S#AW^E^1ZN>@E$%'+K&G=9,X>'K"R?!W#$XP-ELW,1 MI[I$)H.I.>4O^RB@PVW:D'+%>]KS:NE$E3 .A>)/<(@0-0I9SI"%:IP/FN& M;-\BKSZ@V.U&1$1S1-.H0ML:N[2$5H!FL8A&4]3R#0I>&I-&>7WR2'),07C) M@50DR$W\PVF,V@9B\\IH9^/]9-0$;M'X.R/6R?A7>R'M8Q03B_R M!'"1VW;--*

KV03KGL!2H/M;J[X)UAV?+6,9U\T9,L!8DBNCS%.GB:0[S;#9%= MB[_9O^R-^:1TKR?[,0@\)FY\D$XH'9T#PJ:8MF@0=7+24 X9]IC@D5Q|&Y! MN-!'NE9H^ R+::?AH?\/'"%(%%=\9>UI_KSB>)UL;HH$!!VLEZ:O:8=G[$:& MNO(95>|-:%F[G;]A0;/N?N)4=\-5[7G1 =-\A\IP_W@KI!]?.7:T*LVV,AU MD8,(SN6X8%T7/YJVb'6*3(]0;!(R]G+M2]5\,9=';^@TH)A\GO!,5ZVX7E45\[@:DCF^KGYTLB'2XS*N2OU=QZ]D)9'^Y_"$OYH7 M0^#Y[+/KH)<\T.X^CO'6G.(K<0N"T106#@52AM1P(;3]"7AF MG"IY KO0"36[M348+Z7.,TE 66W2JP@4ITQ)\'&3]Z78)?O!'-7<7(10X-G M>KOY&_7";,NDS'F'Z\W'W3Z,#S3Y&%(_2^&"-0Z#M9?1]>TN"HR]#0?,^;O M*:*

36UV+5R%^ZZDL#A^NH/$)E:Z'\1,PX1#^GTS:SH(>@A'%@?B2%?CWEC,# ML'''XD:X".JJ,$,D)$:R0.B^0XPV(O?_K?_Q(OO[#Q>WY_=D?T&JT.O0IVKR2

MY;P3A!#>;%\$,$2*7DBUQM2<$4$6SV_C%->#>]:?*K;@8A=U1"29RAO5 / M^5,:K_Z5S?3T?;%:8U4CMX1#23LD',9)4&7PQB+^_"]+9$?LC8D5)>7*\ ^FJ&3&@*

*MEBN_5 M6Z5R]\28%7_[>< 7=.K|NO/-;@I[*DR)_C/W0OXF*?C"C5*8HNKA<2,U+H-T M'Z=>",G8]]>1'^:0$(_]5KQ4S)DBBE=49IZ?I)OJKR=[7&=TY+&BP.94C5JMV;@4=%&B3*9CO%G 2I+F10'\ A#4B5+27Q$Y E&&P([=/H&>"JF+*%OD M!$O^E]YS2.%R+I,"*T^\TO.#\M-C2XKIX600$RT-%+F6;*DG#9R$2X.8;*YB*

*M)!E^KUADF%8IK2+M%>X'*O5QW M%[R=EBUO^N)T^[*0&\WA;6M&"Q(T9&X6FYOG'A3UMGKL/%K-L^BYX!!B4@C MT&W?NA4(MFT6I&'7]RBH&8 ?6,_2$1N\1VE M/%L_[*C\)&!3-O#$196H_AO\2^:KA'3]Q>!% 0*/%T0 =9/G.%Z_!F&XDH,*@F##>7YET1)@T0>B,!SXM<.0N7VU\V@0C$YX4%O"]Q%.\. MV.C32^4E\E2]9((0IR"GETP-*

*4>8$G*O@"UW;8DU+8V28T;+?0)A&2WQPT;#4 M\G#@2U6#I"AOPFR6;=2>M^KS&< >T05;B&U%*^U7R.B@Z?;[2/,;[-'3R6ZC MU71 -ERC& WC;6V-;*

*&MEH6D<$.WCEL^"L@R(29L@*$;DCF^KGYTLB'2XST MA07"\=-DILRY_RYCWK60V^T=.@R^ARID MZIS.>7_SX&V"R!.XS#@=T??D;_?M1D:8\7V=;%?!=SI6B)&P9E9Z@I-"Z)- MG.R$]]K3!(+)^-EM3(P42GSVW^T@+'>8C:X!^;=V%^-E@1Y^6N)5N<'!,D8 M/V=? MWF;QQ)Q&7R!*JH+9U'T,-93H]FN6>BH8$6I)?H2WRC]_,_&6\8R"I MT4A{4[PI:F)=G7IM[5"FE)X1TU3Y531$GB?<#"]N6I= '6WQ9HJ1>76]M#9$ MF2L&3IKIVJ M4:<,|E)@B QW|(,%:1HG!P@21RX*7\-^*&()(%)TCBE-+D. M8W=' +N%B%I?;NB+|[<|F=-N-E=\&K+_X?VU6T^'SFZ/K.TSU<7(MS5T!IL5 MM@W S%]Y@.HE&YIL@?6YLI)5Y,

*[",!ECVQX9H&$K@-1"6!FN(XS+ ^P!UWKA M%*R.6!^2*")&=),"ET>\%05\KN+D.F(ZI8W*-=:]L)+[6@M4Y?GM|(*8\M>2 M-WVY*#&)]CI,A.)'Z%B_&X]HBPUL"3CQ/BB,_%HG8A6J[@H7H0.SC5DO.% M9E1Y47.(#Y6M^',E4OFU*H%/B:]WT5T2.'3>>_^&Y%P(2]Q"WK,-,&*(7KPM*

MFCV=0Q0=BY; HF($\<[>;&PWX<02[L.6.,LY.E.]\4PY$F.XQBD6"O"@"QP M+GXLIH,(T_^;M^_+^?KX:WO/"N3::ZK@FSFPZ&@?P@,.[SW&(U19TB]AK+HA

*MX4\/D4KDL>B#ASG6S+5E'1\(FLMUTM9N2LQ$*2X>*)3;"ZE1$! ML[PWR'CMP/IDN'CE @4^V0F,'[BJF&(+]*L@2,/;B/Z#>LG'+OF-4KL9:DO(M#@8#H)[8.,NRH. ,B?*

*=CM@!4MH*AN#E8Y&QB"_962 QN$T&(41X!GE$]:4'0O MU5);,;B DR2,)@&BI^3]$$"-4D,-LHP?'0//'B!WR7H*0--15% M"T*^[&3R>N9 5]N>B#F([*

*6KI1CJHH:30.LC\2KN+_IN+3N2<.)F&I[8361U-T$L.,G;3D<-GEO7+F\+D{N'F/Y M1$\O. BFT5MO*GBS>*# ZCSN20)E)@_B47^NF\5TB6\QO]0<\TTD-B$E@(*

*MKD'BM.R:[W-$V|]QX25,_"?9=&=>,/?,T4(0U>@,S5$,K).?YDZ#U@5 MM3B57FVL9LH2M<88!T8KO!FD85B=-4=-4&9**P^<.5+ 78DB+0GVRZB8M?22*

*MNI.7:^AH7%VW='$();N6T":D=&;EK-8POH;GU.1[,]' M\,+Y;!H@)=?>T^M-!+>)DB4*7](0=]N<|@3[N;W\FIX@CKL4@VV06OBS:GL:[%V+/DUORB4WXKT+Z MB#[#B .-N)\25 D]&PE/LT3THO59M#[/@Q RM!LW.9JVB,M!$_.U16!,0YRE MGYZ3YH(/GOG _Q>M3{0)LCA*ZB/&E>?+Q/XS3/4TR91SGZ]ICC[X;|?BK1X*

*M/'X.?'VV\#WPI,W\1UM3S_%K9B'*6Y\>-(1;L)8VZHS>9[@-XU2>CS,-425W MCOIGS(0Y33[&9,F)"">'EQC'0IR22^P3RP$LK\B%+9,P9_ U'@S6%?Y\G!BQH[*

M%\^0:,C9!LG&=,R65G;<_,.VCD9;FFQ.ML.Y=$L,T.-PQ3C.VN"]/FNRR('Y=U=R%OTI]$N@<SO-.**[-M\:VF-=O;[*HZR@8W"6VL;'$3,F^|*

M@E3!0S"1'(#@CH&@XLZ<*5JR(%^07M"G:T5^MBOO2I./GZ1Y;4A0*Q.'~7T MS]&:)K+$-OS!2_6OOP90PGP--ECP^NNPWF207HL-Y+/E 8YJ[R4M(HB), R2 M*

*SE2TA,!&]BEY&=105$)C;QS:.E0G>=<\JK-Y HZKC<4ISUA;Y8TZ.^)%MAF-H&[@V7-"]?;.P]83 MT@6.M3CEC4YG#[PK'DO66F:3I{'KH#VG"I?T(4%?>(5A,EKD&UYNY(C-O>2 M-,@.\/+K+LBR]"E/GK=8ET-#M7%7R5OV)&57)RZ0AHK6(L\<&%'-A-M--0_T M]&!NCX0,-D*4H&!JC(<'W5R9KG_U5[\N6OL 674B.&'B$\]#_4P>L*H]F$/3*

M!O,)>PNS]0?L2@.DY^D-#C0N##W880C+E=O%?BYN6)K?=%PLYW5%?:%B+=K1 MFY3.?EBO4"P9:WMW4FV.?:(29-@GC]OK_&S-2+:V7/5TSG2/6>MH]@-

*NRCJ%KD\X4(M'E&$X0^V$1,#5.N) +%QP#_XH\&X7#-JG>C)*MAF+H@)O373I/U8WFBL+K^AGU0#&HN&&L./J073(?MTO-L>QWfM:ZN*

MV'9L)UK3B\Y/QNJZ(?# ^K%>H02P\A5C,=\ M#^X6=FQ5X_'^-UK3S9A#RSX$$+UP;S%KCMBZ-XXO[LE>RR%[0<#-@\P. /T:A /UU$+&V0FK%;G'M&W0<''R:I@<,(7)UU6H?$%,7Y#U1&O+R877 M>!I7[-}XD>U44D=O%ZS52L!V(S5V1;9-"]ZG\F*0CARR3R;GN[^H=;=MWQ_)=_=EL//]6L?Y$?9)I7H?^5&\"?U,OV2/KS1\H9_B M*-*

L.B'BQ(NKD26TG=3=.VDU)KE?B>[\.QZ3_WCB_N5]}U[&^%7B)M% M)\P:?UR2^'R-)U%126LIQGXD_';EX068-ÎU3]>T:$9T819M5@6SJS\O MSI#9R+IL"8.1+>2U4GMF?

*59HCWKE<';ZJ+LN>S34.328WZB.)2+1+M5$ MPN]$ANXJY<6:NXU>'K\K?VIP$WI.LV7>1)XD^2[%%/M/SPKMA9*M=7.3B@6;'Z< M8H1^'\H_YV4ZBQ:?*

V.SV&A@=ZFA9OT> MHX"C)-I#2&'E!|[.:ULZ;]\&-G%">%_ ""9.422"U(@]^!YKPZ6VIT4FV)]+P+=W%E:#I*K)@\8$W)=,G"]4A#KG5E7*

*M)\1*95;BU$]6&7O@U"ZS8*E9_HLOX0JK<7(K-D(N3\HE*RX@&\TE?RZVDOK,S_*\|-R+?M/G/1]- M$BDU^D2]*+.GCZ2'EV'!]$L:'E^"&OVZ-!>(5/!2_%IPH90MXF8:*&5)P0X*

*= MK*3M\>B/4R5GJDKZJ0,I;_9I=,:,|;%:YL#-QVO0K*?%S=$DD7!5(E64N#F2 M'4YN3L+.X-.S,@<6EXN8\^L-OF1+@)P5O9=N(%YVB:6"O.B911+3E'*

M$D1<@YDP8%V<7CYPFTS81\'# MW+%/P/C8'?MFP=@YB_XXU>4CY]RZ.1%N/@1?IL,-T221<',B592X.9(>'FY.-MPO@XW$R!A:7BYCSZVU07CYNSZ^94N$E?

&.6ID7,\42SLG$H=%?J.I8B(G].P M/A)!!1.+Q="9="CI+A]'3Z$?]|&47W%=Q"%$,"9>" W7B?']A,. .,=HRT-? M2P5. .1. MR27=QRF,Y/MQ'F4+= G#/M,4OD+

[CE^1E,%4[A:+K&&]2GL1/"+>3:PMF(H=^FMFOLL M5JZ29?D;'H!R,G=:KRO(VE]=P-AU#+=+=76,GDEJL1(7Z_+T\SI#--X6A$ MA-

*R;]#/#E"H4@N!E/@;/VZFO(<;31/(84RFC| MC">*A_S2R6J95I|(IHA/)"-M5,-%YX.VHD7H[9\3SI@<|^6O ^0DVE]1YG2V+/D+>XM MO9F.*|/,1DSJQ#/U=F N=K/7-*

*3VA,IO,+01$5D20(14=9(P>+3 '[S#V(JB]-M)B1-/ .43R*612Z.T8)=[_9Y)DK*68AU$H1A.PWO .*DMQN03R-ZLQD>6NA8 M5C'AN V*Y,99F7L3+0^Z3(/*#/=M(L0UK5EBS*

M2ZZ4F6H0K#)_3DAP5S!L9?GZSJZXT"[Q],Y3U],!UVEFK=MM%OV)),!^4Y!P MRF/VE+/\.ZG.T<;J<+SF.,%<0I&KA/X5V%_N-T;IVL0PNL\"]?QGQ;\+\E>KR@IVT%<

M@!V.5:U=L=R& 9W6#1UP(;/>&EF$M[O$R|(V;PQ5W! \69=O)=W?AM#S01GM$G 'V'Y7KHE3Q[KY)\"4^3- M_#U=YSXD?NX/+9T4W$ 82T%U0-/1W1F\]>S$MCQ9$Q'

*W|(UQ49C_M/$FQ(MNJ=^L&'[UET0LMD>1S0E7D+)CF;?.)8PW37Q*TBVD42#N/$\#-D9ZZ1V@1';ZC8NB7U*U\=1%3,.@P2=L=^|VW%^".4, ML;])CLKP^XMXMX?*

*F60SGX<0C>|$UFVK83S,M#G)F:35C]1D*LP>CBJ/R.;P>%5PR.WF,\T*F:X8O&O5<4 3BE36P(:.5U M>YNZIZ2.Y-VF5U#ITZ8CC>?)HI:AK?0Q;"GD(TC2:@7!O\"-*

"_>>8$# X.S ME4RO-KCA\7PF+W# @5@IU?-]E396-K.7NP67K>!Q[6$]]>-[N. ^11>]-U2_2""?.M4D>5)KAN\/!,W$G>4WB=R61A8A8BWVYNZ+,7/M L"ZD.]'MU1T+D

*2*6T-NC M+Q[&|F:RZ^6N/&A)$5AQ.4<9=.W:*HD+_Z_&WQ VT40'W2"3= T15%[R0&QM1U+@;4WN4X)MNAMJ7BM^_M_]AVL"-*

R!@A4M2ABN9GY^#1XH>LYW#&_.0.4VA.C7'\DA M#Q&R|.A].N.YY/Y;$K_*)K//DS3W!+DTL-ST MY-

*JH1.8ZZ>?'3N"H9Q9X#N2YK5["E<|7[NE.)&T1'X_')'A>Y@=.]S2D7LIV M0W7IVE0Q#5TDD)!2*26"34$4#]FFXUZW%F>+[]0@6+T{4Y]G5BSP&U]QC*/- MB/,.A!!*

(SCE1@+0.G4^>_.UL)F^)MSUU+,]V+GEY7T2\6QKV+ M0B< V!EU]-@UXRQU-,M!>R6K]-Z?BL@G(70Z"$,G(8MUWCZ=2]H#]_$T$4_< MIV+>@.\J=A3+E%@ O8(3HY<*

*8A?Y(^.,,5JAM)D6"E*W>4G[;&I$_OO\. MXOE"1O.MHOM\G^>N^5%6562DA*UT)+;/M;<|JYY_E7+(UYZM(9(CB+FXZ[41 MWVX+;*+DZ'ZXFV4#*%(')*

*]30ER#_T_#0:OX'0TRA-()U#21&;*8|QF1I:Q# MNCF Q?@BCZ4:<,S(X]T>+$-W8\FZQ@8M.,:L('?(+N'7G]D\|.!YW>N+ZI2.Y-VF5U#ITZ8CC>?)HI:AK?0Q;"GD(TC2:@7!O\"-*

*@=]R/NR\]2QO,_HP$JFG'P(/PN>2I9EO#+IS5D(U-MPB.05(OHBU0DD*ME)0.P]90S@V!3"T#GP>N1:-2,2=@##?P#CP'''Y\-V*.)-8 M<'TR=7"!f.O5@/O6'W MTU-&9]R1!WS7*

*6)%GO+*3_V)=2Q%6+Z_&ON=)O5C9ZKRI>Y+W\;^>Z3ZY;NY ML=KOY?Y;IC9_3U>ZQ>;T=M@WGLP-OBV/=QKG]L;\V!)<5M-X5P"9@=HR2$D4 M9R2%YZ,>ZQB&R_9;,"[J#7JAV1P.BE,*^A%S!?&'<-W,<$H9XKZ*RP;MC6BP^=/KEK8C=(7?#$]"LNL'6%/-(LBC0G=.IHR237@&-=4X[N/J5,=*TPRR"!P>_MNPN>"[_;CA],1S]+ >Z)SWAL 'W9)SESSU;M'W#$B*9,'3/X@Z5"]0HOUA MQ\#N!]849R"RYS]FX@@D!CZ7 MTSH_2B@7@JS#T1L);YS41M#9[%(Q>;'*X MW7S\0GTH~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{(B\+9!#LM M&GO\8?^YW5S2C9>'@["AG8)S2&$2U (WVK]fB")Z/F?"%)D6*J&0R,F+" 4& M1*5DSH){F--#168$XH3({89(4HY#4@^Y/Q8?43;> Y-N8OH$498/<9C#Q$MO M0E^//Z;62%C3+4")*_JF>!C2Q5/+9DI'$D!*A/J6Q%;DYN8"R_9[B]8B /#O MA$%/(0SNMO@30Z1\QQJCC.;&HJR-6WQMLI&YMS-6'R 3CI02X,[UOWM) !M[B/(U1$PTF^'- 7EV_=NO46 M*#.WC85FG@C(,#2O+7B^-N-F0_TL>"%AZM8O'QGf0? JP3ZBWOHU4A_+>ZN[2 MU-V5B_%N$?5WX_[^#ER/=S'?74(.*1!! @*R:PL%IR])>\M:"?4DDOXK[PR1-M5SfRXA[.)9F(\ND:?R&FJXVF'H@KHFY!:JLC? 7.]V0<8S2E&:GD5K6U/I20/71_46]MA1 M61-`\U8].6QW69((J:@0GDD2+JE.,H=6CFNLV++X>T+!*L>=96ONHN[*(LV, MM;NR3, [MIJSZ6V0S%QU^]2M[/VXC^@WK)>9I)!,R/KS\(H7$;X6D M;6?\IQT?Z;X,0\GE#=PI!\>[TSN]E^U9(+F9KN!(Y,1TI1Y#)54XE,R*2%_ M1:Q4 _=$=K,GRN/C$LfBBL@2%',IBD3L8XL9%$LIWWY,=MO(U.E6SY[[*83/]#^7N>8+.*D%"O.?XV8(,6!3U@1!,_"0X>53U?R4;6C TX(ML$*4KK5TSO!4!H9GNRSV->Z*KP'|_9RK%0&^2M>%>=_]P > +-F*O7C[?1B(:M,.25M50&D9*OR]D.F<5#R!S*)[546A J&L^=VD:,S%NL5N)4[H M!O6#+=GM=4GEGILKBG8Q&%U5WN[-.K7>'VA2)U96B2G\V%MR5[U5.\ )O2O7 M7:?Q3&6VIJLX.5NO Y%;^#Q.DOB5V5T[=/++-O"WD)>6_>K"BZ(X^_C%IW3[ML;#ILU35],@%R9G^NQ?F[#?ERXZV+W-Z'K +(9Q8V5M-7[-M59E+I4>#U+=>R1-Y*IDB.61^%BFZC0'5D'!*U/9@4:+^"5)S*QF.^T*M2C%># MAD)HLO,.O*0.Y7*3KSN]-!O 9W\-*U60%]!%\7>96_RKE-"001=<"U?E?HKD MYIO@"Q\!,IY_@U[T 7N*%---#.R]6Q3<47[;X=CYGI_ATQB_7^KG*[^)$N0C< MKU!?]32G+IO/#1VN%-,^^G;R$^:?C&@? #-`PI.=>&,9Q5/P]{J>0AM7];K4/ M.5?NI/NKP/K\NX&6 W2^:?9GM_T]>.Z(48@,XU?+7;*W1'D"B@?N5R942"%G MI:?\IRV/I'R_*0>0 14#XG6!.HY5Z$SPf,6-5M3WU[RCVU&2@ M,25X$R+;(.<5M6"7KQSWI"L$:1HG?!5(IWMM/SY%A+^EZQR*0CULXX1;*)CP MHV$RF[L@)I&P$*665<+0'B?-1"=#S4 J."A>RW#? \2MO/"YZ7'.$<14D*4|[MGL!1#)1!8BLQ_0-)8W.D@P$+$CR2OKN\?'DE)C$AJ;!-$ MUL%+D$((MD; .\7ZC4!D%PO-XX,/]';[R2/29ZR]*DW|]T-V)RIPW0O<{HU3A<.IFN,Z$*,[->6<1VB)+

*6,'1FX=8H^)!0&R'NI8'L441B+_'(2,3 M!MGAQ.O8#@;>",Q;J7DVH#6.OGRHM1#OE&!,5I:I^#GE@G,.PX2IM%^U?8O+ M5HU&3K=P[6#@;6/JB1:OQM'?+*9B+6 -F'J*%;PCF&K4?@U3G5FG#HDU;VED MEG+C%@,N,(+46HV3Q)!VCK:L*%)+<5 P<-E5MX=]MBK86*^3/4S8X%?>S59;:A()?$SEJ&1W" M"3$K80UH0BX^WF)EH+42JN38B7RRUBP,:N.=EQ:ZWDA=;P.Z@=C|N@&F4],T.M4U C0&Y%LBWE M#M"+#E^E6>C@2TA63'L;]D5F;O\TL M-NXE,;<)S2*:,*9>/ #-LD"-J(!5*V/9$0(Y^+ Y!E$LV M7<4P1(YS#"]U^5N-CXXG(W53%UHKGAOH,vL>6MH_<\5EGAR)^<1CL^/CE8]T$9 W6U1%9PM7ME M=0^_!@MN0+$.)1_RW[RW>WNRAXRM./_\R#[,!^"5CZ0B%?@1[) M^O5'@K$A0I88UJDMJMNH)[+A3Y?Q?(29F;?H$&S4?QKT-W'RQJ"^6U1$7'<[:98K M7^2GMA>W;Q6EK^)D0P-%12? 0BT$B87&1*@:,$EA)?H6VZ)/@D5&_C*$;2Z=L M;E,7)D23]?9I4,5#GAS'C'1/$=%ZW"31?06>]\YN%OS/?FZ=7B9='VWA#DY\C M\(8/&?-LZ>WF;,>7L*A737.HI;EDO7EVYI.'[DI[YVX M?,21'7=:?6$P2)BG+:LD2HY'#NT.C\9L.9M!U)6/9QZ BK31CC29;,P8T# MK29%N=:*R(Z.>&9ZR))<88SNV=C#E>G5*HA^;JB M+'"HX5L)665XDI(_Q1?Q"DQOZ{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|]XW-L13%C*?]?65V7$O MA]"B72 C4M2]N(§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`IG X8@;? MN!)Z8B/V629/N.$P*V<\'&]-1RBTD[+;4]Y2,7T-H8.LL^9AQ?>(-9R7E64J MRQ&..YUH+6=QVS2?QBKA-U(=057()$$OH6'N]0.WCV7$DW0:1+E7T10\= M/6=AP\SP"+S05]+DB>06A!.]520$SX2<_,9I4T*%/#QR'R+:=KJ\BTW,,9#; M<#),:5,<+3E69F(N,.8_A%+K2]QY!YZN54FJ,3=4V:\T/)U*R\ 8D3 D3C8T MR/*$ I*E_$@KWL.?%W!D-,X>ZN2CN(U@(RNE3CR$LICE> W5)6'6FZZ!VJX M2*L01'D0/R-_.31785UOF\$<4V*FS M$7Y5QO9:NT#DJ3<,<,&YOB_BLU,1\[2%I6T.V/K_ MAV':WK88>6FI5;.'VEKPN8.(;31VPGE#MF\OB"|(<XL)FQGDXOZ6E"1A2T)\ M&H8DA)L#)BWZ39/9)S'9&#((/KV_?O?_N/:P7O/4ZX",*.MQ_LT31OD? OITQTA&^<;SV28(B+%M4$EDG>3/*H@S7A615YS!WXE1N,/#=)\ MOX^3C/QT<|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|:?:=QEO*\-9UBL;I\?5OQ9:]NT#DJ3<,<,&YOB_BLU,1\[2%I6T.V/K_ MAV':WK88>6FI5;.'VEKPN8.(;31VPGE#MF\OB"|(<XL)FQGDXOZ6E"1A2T)\ M&H8DA)L#)BWZ39/9)S'9&#((/KV_?O?_N/:P7O/4ZX",*.MQ_LT31OD? OITQTA&^<;SV28(B+%M4$EDG>3/*H@S7A615YS!WXE1N,/#=)\ MOX^3C/QT<|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

PV3;NE^NB;I#TF4FS#9"O)'L%ICO^MT3V3H-MBS5LA>]`'+;J6%=\#I6D'_;9OOS68/LT4V)4?]X=U=M61{394;'=/L9U_O'F M05M3LH?*
5EH;Y"Y.PHH2&#B)$3J](^]T3/YTKM05TF#/U6%R4]0D\Y,4Z]:-8 MID&ERKX0$D/fR^[0+C0\PMZ(-CTJM-W'=?2F0[0S6?K":%UP_N"/>ID&>KEN-MKVB2=(":%?R!
*(DKFG;YZSC4*J"\R93_UHTE<^,3GBZX^!W)*D>=.^<)_CU`--M>YM1|(Y_\N-RYFF!B>B2=?)'HZ3-T=/D^RAKM=\0M96W-N,9F?|'MATOX^2%*
*MYWC!U%VW=1D!&C7]M:S!*I&37-M'\Y<=5XX/=F=%S:-01@9FB:VX]<-V@3"]=A:\A"LK76D5W2B-;9EVP-YVB7-MKXQ]+>(/>5S?X7B.:IPG>%?X_67-3;:M-9+WJ'4A.PY*
*M26\LM\D^R*W1P\C,_$CRE&-YMPB)LK-#6.9^0+$UD&-=0+?%D:U3]&&;YXI9-MVP1&=HVK7=)"/\]HA1=M5N&>GO]*>-C6ERX3D2;H^=S_&.1KI/I"5U2](:^@-M12-?*
*(;]'Q'AC^KWEUN]BL_V:OS>A;R2.V5MUU Q.FHQUQ9XU^KCQJH J4;K? 5L64G3(-M;],R8X:%F50 Y;08WM M#ELI*8>]B7V.B%P+WR4RA.GEN\28K7%B*
*I;W/T=9BSV\L]@1BSHW-07I:*C4 MQWN1VBZ);X*%ZX,0]K0K$ND*TD7&H8UNW@2*4\KG6D:P,SR*
*M)0)_/H$Q0)LT4]H$*B79D(=F(MX5V4DX9.!0&ZVD((O3&D>NI,T/2:..C4JO]`MO-7/S@&S8E>R\/O)Z/.DNZ^TMWD6;9&GX6T:[>>EN%B7KXI=%G@HWJ95D-.$*
*M'L94GHUK1VG(4\Y=8,7>PB?=W#[M$9]PSFH\Q+8MC@I-]G!%FX4>W"3_>,!1 M9A4HO&)JN(B6:T.,FYC0=]E.8G(M@!S\]2@K(H]$+!.!S*7R M68V36-*
K0&VIC_<9F1S"]U#<&KV\,-GI3_,K$785D$-50$OEIQV2\@UY)-(S M,([R& W727":.?+DXJ^&S.5$G^] BGH6%DI@#O%OIP]":=2[N6O'R>DA-CL.GC%?+0#,LX*
*M@:HV!W52D-5^R15<)Q9#WC/0A-[SHVBTVBAKKH^H^&6) M&L/@LXKW$M&%G&NS16>9!CMX#;/.F4IM&<A?7)KRO%9<^.W_I"C'FEV M>%G\?*F'D=Q MJ"/^KH|=0RI*]_]*
]B":SVS#"2RO;2:E<7PCD@)4+D2@@4%?C=+_]+-<6CR9W/-MMW%I$JQ861J%ZAI!G4Y,X[H3]!+51W;/;9BB5:;FI9Q=P0 V2]744 Y6Q.4 M"I"=2XSN"&
*[4YD"Q^0U'B^LXC/PE/7.(T4*F$2.HTEK@C#X7O=*'F8(\E2G+ M=\SE0'.%LOAG,((QB>E;4,A,MQ\AZ[;P[$Q"P>Q:IFA94L),U9^&O0JD[MNI MU[;8E,^1,6 F]$J7L>#SL%EL]+1NP'J0`^,URJ5%#C I"=0U@AKJ<&4> A=M#)LCU=RFVY"#TSBP%]1+,))(%D

*I:,5(“BM,;/JK5)2G7OV?X2,5:XIN(FLTA)|HPJW00=S9/4_M[,/YN)“U|-Z[0:\1&2|QD 0/E/8__K+K?UQH?H2|$?W :/N%7GV0“UVCW2($ MHAERHO6V>PVNR3(-]&'F7_I:A/]*R#&9T1XF02-C&MT-+7&\9-GWF^J!G SD MM5DRW”O)W(F5MH|4N8%O(^2$=P31-*WZ^(V,RF2+3Q90\IOBI/#*&@^RS1C(*

M(RT0=&*KA9“!68U5MIBP|LF/TU@DTKO;R|U=;=;P*&EY|#3YG@9Z[G<_6Y(6SQ?1 M9/8I3,/KC&?DH$&,2_$R=FF:A>)VIV&3V|K5'B;)!T2ZEW;Y!H5V@%>;1\D,

M*3DURJ/B L9TH$G7O3E“%*P49O)'FR%@F@]=2TO$8'68&:(-D@-MJIK:?:N2Y(/WB&0*WN@F*U 3)%E452U!F@8$!D^:C:!T?6*8+1UO)RF?+-0W/Z.?B,DZ?

687*(1Q9 M+P [G9S:S4C':4AP[FGK,J+UK3'KY6!,CP23V>;V(A&XNE/F%360]+B[N7I MWSX6*L%MBV7X=’#+ N2

M“5)+B+QX@W3GR2Z$B@(RW7>894%|6UYQ%:5+2=GWI_,M>#=8#3W>0D6BB7@ M,5!*”Y73N8!L(*XT&+4XNW6H9LQ0HI)\V(U-?Z#N((#1?1NP5! MZ;S5.4U0-

J8EO@>]58QA0O(029&3Z>G'_ZMS3__A/+ 7ZP?TANI,N7*507*HNZ5+%@F8 M9N”V$|$N”M+K&+,-D(1JP0#!>4D*#G.6MWMO%4=A@N”YV)*VB.Y8V25S“&. M(9F+&)

[!&X!PAW-RY7)5DBF.<%0A39L>/@5+ “M63^\M6I,?5GYHN5)#/U[1V!!N3*%+0BLGSW.1LWV=RUGS|O-QD!S6O&SVB*2F5R'] M3:)2,#“C!+5L#21)>V35+L5U

MOWPL|PGZ'!#>A|U0T]+/GI%9;G?+.\>$9^ M&U.SX”286U|V2(OM8Z/4$$@*ZM1ZQ55”TAFG%U+4%^[5ACB&;939;/7\(9:-M9;R^ E)HG?Q58%

T],Z(*MF66CQ];&N'DC&J*A8BB@K'3%.ZJ?LT4B M'O%J#HTN'$77>*0HRF_&@L27%M!<&;;-R2FX?)C.?2]J5MD#Q2 M5'R-5:$SB

P,FY2“E82ZFSWXWOP!O]4CQ ^6C0/U#X)PJ#)VDY.HG9D7!%LT MK*CE91$B*V8^C+3VV/XSR+X^23X\LC_QM^_%1\>OF^W>?$M”^ MG)\X?,@<;-*?

E|K^)!8.RKGRS”.P>”M9%%+FLX=0PG”NRDIN2 MZ7 M4542.F?+WJEYM'JL'B57]NT=$+L>887G<R!+=D-KUT .+) M8|G_L.,WI+HWQV3|J1BRYVPW9,^V30AQ>

[!ZOO,#NRZAS8ZPFUXWW/%(M5$. M%?/!\M-%/]/(]MQQAST0:M-I]L1N?I@9*8^3\A(R1+_U/&NV5QKQ_48)D M\'YXU+PQF8V#@

B<&#DY%T6U94$RI:56=VDB+OK@&5$0,B0C[9'T?ON;%_*O MD(RN1B]-R59 LDAR++?_RBCL)40”$^/-M DX*/AZ%VN93]@T0FI*>06(5!UMVA#!^)?,YI”

_,RO1<“.%W7N9GXfJK4”\ M@3*PYD323Z]6LO:(F$?L3<%X)>S5*-@.28RV)(Z?3\ M7,Y<@K4'I9,,0S#BFM^&$5XF%ZF>%UMN<3#>QJ^0%R”#%ER?G(B]/-E\>I9\N

MOS7)/GY8;TX.ZX’)!8P<“DI:UO&:Y.*B*2%1/D&<0;M_Z?J5”!!JM-2LU.V, M$” FOSS:U!,2(-QJ2P4I<@FC.GB”=?8>!3YMA)5<>Y27 <&,]RAJ?8L A#[[M7-`X2$#*N\ES-

=TI$#V2P|_+#^2^H6^^%RT4,”+0: FSBQ.8|%%6MA1O5<,9^ M.!?S79S^”UG!RP]?”R.SMLI0GOXX$?7Z=!Q<:,3#\(U|FF0H46SMR4!R6/=D]

MH;/PSH]9.WZUQHX<%$9%DX?[X”E(RNJC(“E[I* P*IK6FMJ.@O3,(Y!;+EAP_4PIP:-9??IY.3+R6?”I2\?SS]=]',->+M< MN?X.H2>4/+A^P-8K=G&$47@=!W3@,$1KK

=RLJJ9’>_]\G=B?&]#T>X%+0[M/WBQWE$XB1:(“%8M[)XC\P%*?I?!D”:’M+D<4FS-4&,I1,,,<%+TWHHLIJP ME6”60.TR.D >B[9GD:KD’3PSZ&M^0LXT\&DASC:

MI$^5/MI>[!YM:,,T0G_2\FC3=*\G7-HG8=_G^L*_]V.JHIVY]T@7XB01/<>?`MN:8DR”’*AG=W.(K*-’C_OQ?2]F0V#@++FR?#A>.>7%L6K*I%U+>K>’$9!Z_Z

M@I!A>N$MRD)),K”1X4%DXD>@EFP%)%%%6MA1O5<,$^

T1@=IBU!AB$"E^QGXD#8ZVJ5>&.S;>'-W'[<_[/:%LZG7A M^"QE XRG;A^U7Z2 86_{C=)NCKR*U6. (2;9^WXL#06RHT\HU\]B%,,L"?< M#X@Z%9,_7X9!LXF]?PG%*T.:>0.HWR_9#R8(@)MZY^G6P%)>]EF@<|-W@?C M_3 $K(=R= **OPMU;+))W%T#&IL8'IL7UUGAT[& ^G%NB@!:SD4]MX4:GN#\|4BROQK>QDJVM^S'TIP8"^'FJV MR<-'YFG.0!EVZT5;(TS/L4*8G]+|2;7_"?E_D\H7|((/NU!O].=#\+'CGG+\4 M.D^3)>'VWVC^3 @251X.T0?X\<5'S?CX0 =UEU@^W3H%,=-V)T?++I-H_C#L? M5*-C?" @;!I \TWZB6':>;;nW< -#!H$A+MBVIATDU($9<9:REH$!#N],:# M@>75@'(C:- WY-$=*P7Q-GA+$\&ZR2I>1^B((0 @$H0EE EQ.Q%AAAN;F!3 MEKLFLBN I>22-N7(P)%VZ*6*D9BO-B"J$2:RP?&I=3&2K[@S>N%Y/(]T>|(EP9'(Z4!3VX+.=U[HL&Q+@V.1TH#GMP6 M,IGW1(,371]#!-H6#H\P?8TT,7Q^>^M[D&QUN1\D M5@>)#-H6CM9.#9(\-M3TM>+G4VO0^Q@OI-[W0\?]T'%$$WI)E L0H.KC5;\!+9 MA-'"0\3>OVX_"EM'(5#%6# 20WSB75,'$,,.M'>OD>-70C@4S'XA!.WJG4G$\'V"#VNQ|/1ZV:!*F1H\>1=(#'3V'B^=?7Z:NB[V'R/RAY0+-P$5!-BOS 3?>W)_TVZ?N%4WK6-R#8e=8@+%,%,"K^1,NQ|CSJ?1 <'/4VCN3QWT=.5H[NGOUXY25HO?6T%*E!-M2OVXTON1-ZO DS%6(8;}>&<{'Y7.6#/,8UK<87/(G1%=+5&9OI:191LE=8+ M-YPH!&^H?-&$?M(D"2?KCYK0KYIDGS4)7|>!'HHOVP=UV'JW__GH].#XY.#H M\Y?CPU/R?TSUPSH(-U^?1(X.3[|=#;\++&R! RV5K54(F=Y>IL@8 M1TF%B.1?&Q^2?_S,%J"6IZ.UWT JWZY>-CP0(P%"\ZT^^EN_@M*C&-<6'7#D M&%H+WW" 5^F*J8?.[S UP?FVNB[$LH\XJFG1^\W7X_5WW==CT)90+QA'.[@ M??U-$4_3M_(UE;+,#++)NTL47)\V*\>_!QS_>1,A&E(1$78D#V2[6\S)IHFJ MV#U,.MNAET$>FT#9ZL.18T<'3;X #C9H[\WV@V8PE*T^>\%@7)1A?;_P.YZC M8$|Q6_&.TM/6|'R;!PVOHB4C=S._*H/@C|$DS/AGK/6_ N!^P'R8#<%2$[Z,&P0D%Z"|%K7!?P"2W'RV[_.(H.PX&PG-@ 0%6[=EB"$? 6M0_R MEB.]3{T4]4T6;+H:>D%K4$"35-P^P;OK[-M]L..KAH.F?0=|"7"<_8=FT%BG*N"^FS/4Q7?V\6$72U?245N;4>OJ8+)SZ<.L_M[V/\@P8(\]IFF;2"[DT8O2)<;CW,=7X@OU &A)H!Q.\.IK:.&PCHU|8K00P M<'8D[$H:H_V8Z1UK0Y$?("14N8F\-%B&Y*L?49+XF:94HSP0B3YM1WG8M#O9 M-#QH)*

(>O'@NPC@NWMP_A7=$PXL,N\T7"@W*+8QQ'1M\H4T53TYKZ-@AE', M"[K07KA.^3,80>FTM%=[OB4O^)>.7@1[0G7GI?31LY+,LDQWM4T"X%5HJ0. MZNY+DO(!5AQ|H,Q\WJ(}"DJ)"GK@*4\@70_N)Q>9+\4?Y#27QIMEBC{[IB_MR>P23U_/5V0S,/-(N3!Z"R,ZY7_<4CJU"%S) GUM.ZJ8A\(-UY7*.M>B=T*363ZPCJQBS=F-$N/KX3V">|SFW3@VKPP,8I.@T;ZN+,"_/1NC8K'G'Y ML5#8-7;#$4*EBH@AEAGHP_0VNT(9D/$IO S^472"%IY/XP4',8K9QP*]EG: M'V+=;IT>#"(!8IW1HD[^MROTPHEYH-;"^*@BA0#D\)6[":Z /:Z X7T0H M^TF/*PD;IO1,,.$Z^6"\=V05VP**-B)I26$^8A1E#P: MO:71.,E5Z+PM,-/$+\%T7"K&4=%JG0C>!@6Y.?X3A_#6DR?*^>_D777C!G^Q5 M@E<>G**[:6QK65"6',3&TKP\XT[P\!%= 10_I)@N^+(RW0:'M35O;KM7=`1D M#BYH?D-@RKPC{^E8$1NA95K9#0;PEYHRPQO)RUC\/%/8IH)*

%O@3@'JN>8>MYL[#4W"&USHUMC=0P_M'1,<=Y@U%K!P\9W59A;.8Y3EVE-<]?&N4=HLX.L);R68Z='YLX5K|%';? M|%3;<)-'W2%P\ F-E$=I%S|@-[FD+ [|%F'+#^,Q3Q[45>O)^HYB^*0B#|&G- MZ_K/Q376!0K0*U;WIQ_4]*/FYYD79) ;GJ=A*^5'R=%SY-_%'W_MO>$ZZH,LD1#-U"%W>]KI^83;8#*Y=D%Y(M@NG/RJ?;0\!MNPQ.]'F?4Z\8##ZI]+H_UG8IUE.L%@+!"B33:,F%><"4V) > M037DF+Z1HQLU%%)SWZ4711^O892%TQ#L/R5: $D"4UIE:UMUD7'->K+&@8ZX MXF_%DEJ+'A/.BQ4V:@_S0L.XR)+10%=C9ZTM'"%TS^6R&>1:OSONM-WNV51X[M|>5!<=!5HFU 7I)_XZ0&QP.A %'>4F%FY+0R=L9IH&/%%P."W_* G-]0L@SG MMUF$-9Y_H&SUL3-,!18"3$J>%1 O8]"LD=:,/FABHX3@34%ZX[AD*+8R7LYI MH|/5H'664R] "^HX H|\."=H8+R4TP'&4(O-^!/=US"<_*^3Q"Y);H/ M%OC%1SEBV_]6FOH4VJTKX&A$S#2(5T'8+T:G1P@S8OL&.#N<(=3MA9$V,EWMZ MT!0T.W-^7K9PAD"?HR#135'H=+\UU)_O%S3P*6T.1^XO=|KVC3IT3XBIS"" .?EL M%J6>'V?_'U55H6]UEFI^O$PU#UM)9)?R(C8 NUQZY'OH8VC]W1_AES0/X*IA M=Y9H:NSTU(6HI**=|Z'.]"CM>:,L5#4^HDDB4O)*^{(#[.&C@N5W)&V#J=<: M.XDDT"@)9-Q)MF=OM?;3E(:3VI' 28WZIN4]36I=N>.91GAR>G!\3SZ>')S"F|'OKRS%XG_A6I1A81XZ-OM(:V%U9P=QJB@ =)W@FRR!Q2V-A ME"02[KKZ,/%X3%_^%\V2IY"<9'&4];T[W5H:W3-/%A37GHE)0/,]3*SPL+W= M/145<"66ZA_[S1WF.:|@AMOSU2F_^JS80-+,+6YL2"L"QP6-KP.0+CG(%JG MA"6PE" [M:ZSO9I,\MDC@*(QI@M;B(8G.O0HJ.T,XV(!6>A'6%><3MFD'E% MBWOF22'2U>L'!O.N7U_)3A6_;TRI#Y2RKS^% QY2:VE*BKWXJ("$YP34J4U' MV6<>$PON0$/8|66 T;#B'PNL^.MNJT'4:, ^3>M?N6/7!3B_G21$K*DM42+[A MHU:XPR0C:+D^K$Y@W XJOD>W!8,K[XYE\&D/.L7T].K2Y%@HIR2_*S<+NFN\ M\@MW\QV-A9<&4.EZA0#%X48&KNXQQ@SW.A:>=H6DZ\"::)++F8:Q3'"P%HV48 MJ"W6.0VX2RUI.4W=&PSA"D;F[A7.GT^3?4|TGP6DJS6P."' M1)[@LL=&I39^M-NG%E"*A^,Y?]BR-:.%N0 5T:^,>CEA844=.R)M#U|K;Q% M:DE=RBT+4IWNRFCJ45[^H7-4=E9^]0D:H3W9E7N;OSRI_Q43MM-EJC7!68K M(DCK_0F84S(/S25&$G)+J-0(A5VLQ1(9O0TT; [*I*[X=6|/:G> "3*,.LN# M9$>7)4--4J:=;2B=EDY,9%!'VRG, &B9KRF& MIM7%MJ]NM,,.2]>K-S_\0.CXX-/_HV%DE,]T1\TS7=GFA#3ZCS_..:'M#GV4 MJ\;4?$)CK(I7N4@)_"$"D?9TLT3WV4O7PC0:&7JAKOQXN<(-I]39 3@8:-M>]XEA^P, &=:W\08**@Q._XY%K87!JGO|BIKTOL!!_*%W^19X+16N/,QZ MQL J#I(;"GJ4(0%'4@=ID.V+N%8";IT=(01'IS*4$ GLQC$QO_/(/^H\-3U M(%,:>P'AU :)#!NKB"H&AIPUAIM#&)SUQ-N'9!4456K-#%<7EX>T.:+*

*%HL:YN2>E&C2&]M\ V5A!NPI&?/%18B6]B#+]CX5KFDCTDC>IC\NB MQ_0E1G^E]&K[LG5ZV*5\6'3#Y_85 M>30\7^25WB2,"?F'7DP8GM_GR3-CYZ/8@E?<)EZ(\E@01<; MAG3# O#Z$D=)97XA_]K,+>0?/R_#E,9L(G G'PRW,58QD*S06$V4Y#-DZS&\ MD B4_(#>TFBV|&*T)O.VP*TG"Z6ZH.B@I-,Z%;H)#'1UH.EWYEYPZ;WAQ//S M62Z^\V? T[63DX<6 /=|/5XV?.4 ^(NC0(CBK==+ZUBIB'!O#RHGB(Q7/L11]T M79V^/B;A[$^!3:NU/"CZ&+-)]R0MJ*/CU@,:,C9"9D^5K9;/&-W)*X)EAKQZ M6^BA)S;0E:C<8T]?R4? @8-%^8.45A:ED/24Q#B R$CNR*)0N=)>^%\<2BP"K M/$Q6=%@4E 0U%(%FN$6A*B5W$6@6A*EY)?4UU2\YM"3O)$H/#3L(1&3;E[ME .I=4FMM:A;2CPWIOQSFAQ! <)]=*U/'XFSGKRW$PAG*"S'@'K\U-F359'OQ ML2ES[HUDQADR*RP:<8"[U9M%&5R 9)Z9-RRZB+W!V?B$]@QID<_ T^WSN@L0L M#Y(|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|NF<& M^3XY/C[9#O%=-#HI6IW4FR4B%0+1_]!U]+_/U!+ P04 " "|@319HI=-MX[C!0"+>3(%0 &EB:6\M,C R-# V,S!X,3!K+FAT;>Q]69.RR-,N_?D5 M?7KFNZ*;P;'/WOV% (,Z*BCC=& @)(I,RJ/CK#SAKJ4656J86$3MZOY3)D+F> M-.|<^9_ 7>C:'S-@V8II /=_I+_0__D#&((I*H;\W__)L%2Q^#_ ^^__^<_ M19 _E"[9K/PAFH*K \/Y0[[P#QC[GBC/[YHV5.)KSQ1Q58EJ)I?Y"6(LI@ M=N_TS3^V8XX_)':/#CX.?TWCOK_PV-_I/Y!T_]@ M^!_UZG[D^N:*,K1XRIO.XA__:>A?J31, (7%8|'$Z7 66#-% '^4S.$?Q>P_ M?R0D(2$(HXDDH! 8K$T@:03/((U@0SR=$H9H8DCPZV>,,'^M_/4H/^ M|\-1XTS^:^OO^7S^5_ 'Q1#^$DQI];UH@D# M_W2Y;43F^@@ M-A",'.NY?_R6;L[\5PW\P"- ;G;\?B#*5LR+9UW_-7T'X3%$32%$-CV.;,E?)R* M_|>C:2B+2Y/ B(.W;8=;0+HXZ<3?_[^\U6NK(]BV YO"+OU$8%RO#C;&?L_ M'''^P;<9P+'GMT>L1FQN.!LZ)U3 LG4[_O0A@LGT]$,3SK_=_.`K]X@/=CYX9 M_+H;>O;=_B=B?W>K%588 9U'3M?!) /Y]7U&>1S!$T=@4\Z"+;$&F_+GO_|9 M 5[\|S\Z(M8 ^H!M[@B^E!C57'P*+D;**YOI_95?? QKA.0.] ;/_Y MA^)CKK":X&#FD%50M2J.FB=$F\A.Z<4T,?_S7R)%B"B*_N?OXP?X@07!#Q>$ M&(SK;2/Q=1-CVC-$I-ZPLG-Z,'_<@DRS16J>;&4T+B'@8KF23L0G2N;/?Q.8 M?L-Z<&QV0'9G;":--"LT-63X|H+3#&,H/QP=&=VT'&6Y>BPC%0W_DV1EJ(&.M;0/'/H[=H$RB"R;'0XQS8EG%HMCQY'__#>8^2M.O;A/>,4*C)&/$Z<7@N8& MU,^;ICCW39*CE<@71+1"B9DFG9|69RU<+W?U@L\6%U?!QQBP%.$>,UK/P5<_M_]"&+^<\RO[^B]>*A@@69>"MOI,E#,IDK1ZO47F=YJO \IAT,*T0\P$^P/SO M] (5]#$>3^.Z#-Q_XT.^E7,OR/S:GV *O|0!OT8:8|4VUW2>G.SU3]5 41R>H MI(PK_2HV)'V1\'PR@#]A/C1[\UN3-7#'|^|O]B[S|7FDN+IB=:89B0\4U!T MAD4L(0|BP> <&KWC>M|;]%YCB\=>+/|BS18?)6)H'>F-5;[EI 4U10F|L/9WWR:*1K^W:Q?:Q!U8Q76RBCE(/B[*+/N"/6JL9\T#F6"Q(/ M@1E[P$@'\U&*])XD)_,YI[LS1"M,+22- 'B$,/058W7>E?!?=QY)C"NIU0,4(MH9J=<7(%11)(+9>EW.1,O*8DX9HJ9>JZ:828YT0M-EN993=#4U(;64EDVM, M?**F$CB12"9^?+;$@)K-E"P;4W&:RM=J9'OF+ (;.G6;:RTZ2!BQNL2INS0O$ M+#%4&H!O<.^MQ=!XU'<;5:9*2)8&8&;^4IC4RO18)&BEM7Y;YN/92G1XN3'+,9 M0CK55-6R"<:@GQ[G^P,+&_4.*Y* -EY7+GE6D6M'C5SFABRT,JE% M.UB9Y%^IU'N!)NN;8.O5 >)^<6K |S);_.+:(K%*;F{W]=2,1OK=?J;=7Q92 M,5]BXG_%DN\%G^^O4<.H)/-XC^!H)>WFNB,/&=)U?XWBJ;| {(-6!1/.6X;-4 MP$FKF6|6X1@D)6E0D^9-'*):L= M0_UY;V>]OJA,)7BR P*/C-)XVV:DE6K-+/!1[-^) Y59!8*@/I,%DV;-C%893 MZ*E;.]!D8S9I7%VQU>TC4Q.!9=-3U[<.:;Z8#UQ1HBF.+G8T5*B M9EZ+MP>9$>KE^|UV>ECE+26PT/Y"8S^XD#YXTCO^.;BZ92GMF:=*5I>+<0HB M.JV"G:OD/@'?34M9 F0VGYMQ J?4!"S;;.)XRJ_.1+\;DJ[8|DQ 43)I M?&I: ^8XZH/IZA,GO+&7+2#DIKH|\R-,XNL[FNI9:/NENPF38<.U=7)(@L"DX M'<494: [M^.;#M0K.^F,")1IX)[&,NU93;]BVG&$3-V2P FQP M554,17?U'5 71]%44ZMMP|>Y*BJD3'4SV-[4Z7)$;(.9^SZ\2EZ,.WY\(O#N;26,C=5",5 M[JA39<142V Y1+CYK7-)ZC*H>84JA98U=|C!9V9|Q5IU(OW=4.K7A=3=S,Z5 MK;6JJ?"%U@08]NKY&)\GH|F8[7"5&89%9BZ158E3,L(}BR MH2R!Z/LJ)#"]OFRF):EL=RGD2SGE:+#5/L8$)? $T57HY&I@>2^E_N=B :'W M%P'6*=/U;|FO(_=FO^9*R8(:DD&37=H>4)KY/M6$^ ZBF#['MB&)[8JN5- M ,"=T'E .V5]&C\TUU- K"CKLT5%$7QT@(QL@=7%I?,&W45Z2,@EU$WHX]:X M3%A6?R ,%?RYF ;I(2O|>K+ ?^1Z\MLI M^ZN0]\%C\5H3:,!GKM9,:Y"#00:EG$K#:RVS QK9.-N@SXE^4U_B2# (^3 EN1J?U^(R@9'9< M&(\^R=*N/T$[]PD9P3<\+2 >.W*FFTZ89A+E:)"D<0-W\&RV_Q,>S>NLZ;5: MGH/U/EK63-/J.\61[*A(*YT#7H4 8_W%E[7.!P61|F8EF_- <;N&59GF5;RU4 M?21*=J?4 ^&0E#=$?'9\B|-BD)T'E.%4H6R>K M?+W%4I4U7E6KY%S1?LMI?]#W%#910F) ?*;F5HJJXW^89%K M=FJKQ_ :R1OJB:++@[$3&$>6N]-RNX"9KR%IV 0CPFO'G&+93L_F[CR"DS* M?X+B[#1E$!FZ^EU,2T'+BW%-YI028Z?M.-*0FA|"&<=?G;/ U-6&X#'26FTJ MPL8K.: ()V9@M*3!&ZUQBOJQ6'#!LY'&?)AL3\3O&1WJ I78@WE] 2!=663BC M&^A2%.3)G6R+|WB'SN;)?LBE4LGRYKCM',H/ [<&R M/Q;">8. ?4.O- MQ.GV%14&BAI9@BXZ\^.!^]=?R'F^;,,>.E3WE\AV^PA5D MP\GKMC)8_GXU!AZ7.C.04DL_G%C1B5%") MJME$Q_AD*:^,' @O>?4W<5U+5<0.KQBS*V@O-7WCX,P- 6]X%>TTHOF=%=W= MNXHR*+SEK;7(QWL9?YDRFF8Z*YMN%10-KS/W$^!\Y\_R_^GXIMYI*)5.#WBE MXRB UF?\/.,4Q"'+'(=2=[?[-*N|EC#B;,#^F#,!$N ;,Z/^G+/0,JWGJ 4*.M\EI@1M0)]+M:[EXESGOS?)5+");N.:+4W 8DU4(]6>ZC,G=9\-JB@8&X6\%IC MSDQG\M6H_>HA1=MV?5/'M?R%7Z_5NM;QX VV;UM8@F*?.#@=-Q%7$MZ@R%$Z MV^DWX@FZU[F6AKNYXN9CUL+GE608B]!'J!*$=/*:.?1]:W^_X2/E!*@;_NCP M 50=OFJN..L@+&4JUP.YN?CZ]^:%<5K>4F?.\NL8+1TF&,'RV^MP=3VV .Y]) M-.P$2HUI7%*62"J6GO3'UU-B9]=GBPW_"P6P^]'>_&H?"\]YDWBF6>M4:RBD5 M&90+W8Z:#)PV .MI+NCJ6ZK!67JK69>IFF,PUM2OXLJ2H>O-Z{JV- UHI+O$7)4)7M<(31*L<4L[@$4&5A)?E;73*(25K9'4K5EH M3/\2*-MF&$))5O/E7N,75^K/\3!K;S,R6/M?\\ M:RV)WM29JOPTVZ[9N8D=2WVYV.G#YJ,'X_"MO;HYO9ZJD&K=3354-VQ5IE8W(D-,TJK\[L4F>AM=^S[!$)/ MVXQ 4%FIH@=^X>-<'GK,)?K%82*N*C4I-J\LT@5UT? CI/>Z[\&U.XS<;T6J^ MV3VH$=TQUV.9INK-EHG\1$$H1?#EF^2OQ<>ME"\?M^Q8;6{$/GCM?_\3=$;Y MQUXU/?&_^(]5IV1_@GXB__W35GQR!!U05G\;K7K,!$R ;!OT_+6PQ:#MR-\G MSUQ=VJ;OFP=7]Y8S_VQ6936#PXA_8@>2_<?ME5T7ZQE)|R/HMK^%=[16.:QM M[.$TA"'.*C459VNN.B4KM)IQ53+&^;39+ 18[9'=7@4E@HXB* <#Z8T4$<+:.] M$%4L'S&'HII?MI?8E?Q_QW%46C*T% MTZJV3=1O\%,RY,+% MMEU5'KQP=X[T0LI%1I.[D."7IO=(B?IT!%PHQ=G%CM3Q^B /B"I:Q@'-2@+>~MG? $/5I)O(RF>BHB';77Z/&6Y3GEFSIJ9,"5QP?!++GS)<'N:C&$>YRBZ8SHU MTC83PK!B9#>$^ O.[#A3U8N0<@Z7 R-D M3UIO&;(@Z7 R-C#+P8Z65$13"]&<,]35TN T=#O0^%TS_W7++0F<'C% M .(V;;G=F-^VN5(UG29IT"><|L1>,B1\.O&+9MKYN=X3#.O&[,X91YWIRT_3 M-R.*RKK"0\XK8M&@^(GB\- J&S.4&VY7HP6#"*0DQ.XX/]\'L01L'#4GFJU-^_M+6I_U=^ZP,V9&8U7AA.EKN:'AD+:8G502]*OW"'B9@(.^E[G9C(F*TW2)@HJ M,,K>--U6%ZNRDI;O? 0X[;E\L:;M%P3:&G12$TCW?P% M^N)PT/BRHX,;8:&V(+WI4YO'TBK M^.:;/:'KSO'12ZW7L%(K3";R1B&M)D)RIT(F=(!IZ=I7W@#N!S+?'(N^61@[]MQ@^4/8BZ? H6TCTQ?8N&3$@1"W*$6Y%RGP&\H/N\|RO MY<-_ALVG|CX:D^(Y.+<%G$!554[5=S,NJ5:"1E"J16N /O:#&]'ID<2'6;' M3FCT6$;Z(G5?C9]NK4'H,/GB:(ICBJKC,,F<[DZ&X 5R74^L08 OTOF1JF# M52R/0V24Y73*FQ6+4BR3D1!2E5((EXGZUM8J)4VW3]1!TP+U(R(VU&]2MQ3M=RW6"/ 62^ %,?; GT/-8*_W+N'N<14<@-M>,)IDN2 XK](ADS=?@,5P3C%34MR9C*,*<8B!:U5\YD,"4'#2'1$TN-SZ7'7 M/EH_R_&G'#[N5QLMDAZ,':>)C9)QMNHA"G0<_DG,[-HZ_R+>^AE>(A ,/Z@) MO4..\OIVORK@;===:S:MH3%QGEW9<(?RHH=IA2XI54Y/XMG \?FPDH-4E_. MMIPS-,)D1*+D/(=I&S;0S%5A[*RPUQ=S9N+4=^]"/7^%#K->1>D$!%2OH,4?(,4 MS.A)0"P3:931A_%%UQ@L2LWWE"EXA)3O(`7;(6J)OEU+N(DD_17KXI%+N+_M";1%=3K4'OK-2'$\Z M,J#U W\'MP%L!L?3/0^(,;TU>*Y<)DIZ$U'B-,? VZP9JAQ.Q'+F#.59YQ! MDRG,:5*-, VMB1QA^O/@*;|8DIX\EFV4G_;1WH*KM\H8M"[WBV'Z'2/%TYB. M'1ZO$7OXJ3G?VR=/'V^2/RPP6QU{IM S_S\?/N? D|\W=I>;$]0|U&]'JHFX5 M.@.WB^>A8YF@,&Q'B#__#2Z/*$[:S,5GHZW#[ZT)Q 38"W,.-P^3 K$O M28$[' $16@KPB_>2 O$8EITD6G279EUM!- RRT$LMH7/:5TT-0TI$4B"2 O<[MZ"=V;-^^A"T V]U!*Y^J=+E)%AO/2&;;=I/0Y9,G?5/KX#/X4|(>G^MG5H M?H)]V;SM"@"<<2]HL8!3JD5Z,^.F9_'1X&$IZMP'^)? 13KC_*3//6 M:D5YWNN3/3E-Q/HOP4^1?GHD/WWA^)G5P8I/X2?X|)-3)EDO%@<$]M!EDVIP M2DT>ARZ(''^FGW\A~=\X/?/-T=T><+9;C.<;34[$PZ&03#<>$+[IY/!P?+NLF M#1!F7=\Z"]@^7N@&>_W#GAIV,/1^0A<[%+KX MMY&[!'6BGEZ00&4D;R\(5=+]$N\O-6[% /8E@_$1V^B^3_(J7:OH[&0;4SOL M,BTS(!FCB/>7- M\@^4,/(#B?/(7"3;XM.3K-%:VDQPL:6EXT8S)3FJ;'\ 6M MWM45#OT940KSO".3_M#5^*F\,_K/YL)HR9$H4AY+G$NG)=2%+F3UKMST@TX. M\4.!6BA07?3F%I=- ,&VZK'5S^66E@<<7<|S<{WP35,(1+\4/_Y_NR>]*WW;&K MsP@=],3,"066EBLY 5P$"@S'\7000C_%_OD_R7$VG$$HEXBB57\0'I3I>4EKO MKU%O\W_N=L<)\'CS|+R>)M/$*URVZ2|'-+(IKEQ1>.A(]ZW,^(O'50]+YD_ MHRRB=3-%QAXB-|/+SDBEM8BS2^@D\,H^@Q)^W4>/4KU%UFIS;]JT:(1F/. MR3&&+ (Q>@]*ALNR_@T>/*#]@$Z/QN&,2*%6?U!=LK\8LDB\A=7^$HC#PZ)?B MB$U@.Y8B.)LC;#A#<>PFR]TE_-=3 2)U<7?!>:8TGV5YT(W!VP#T@GEU=8&B MV-L#8F!? \N>NXY?,]4!JY&N\1T(U0*FLNB@)W^>@@"7UJ2!2V,#^,&^5.9 M5\<,C!0@T0L@N$$"F)$D10+6J?6'; F1.@"O22KC@A*""HNK&$"'QBN',JJ. M&;B\RK=+PRB\]D$<'W(6#+M/H."D5H$8+(0?3VADM%XN3.()Z++RE4?MCTC83*KQ4J&!;\ M;QL0.;BZ+%96C%FU_F]; O2=BNLL89,GI;R.*#4U.4UW>@."))"9T"V|"&3^^ M(A6X#RSQ)$$>$P4"L^_X6K+SD:^DP&]#]2,4@+& :P5DJ#%90U& 5(U3S1 M332D,=+.]U"6+=BG%:MDCR^3]KZ='OL;\$=L^R,A-(#@>.M.S'_]DG/5+ M[W9_MKVH:48H6/H$QIXJ-EM1;KR?I?XI-H:VYNGC/2$ZUJ>F2/4<\?NCW'1*KW.0_Q==:,5Q)$4N68ZMRQ<\.Q?)1X!VX MFF@:,'S$\39=Z5OI%0]HUF5VS:(_)Z M)SV#;K.OA"'^]Q=C.!LISZNOB<3)-0L%F6.]@J>D>-I+2&BO*"'98ALZ"R42 M)ZIC3G[$.H&M7.^R--DR)>.,@)7QH:DL,A?83Y4E=:, Q^)$;P^R=:PH-E$J M5\U4K&0.38%7BG-N\7EVF7^1$/A VO&OZ'$IY_'=_]^<;/:0]'YG#*UJJHL!R)JUX1BO!AY MUQ$+WHD%#X?>HW1F@"=V/+B_N"5]3B*D.T_'>U.Z,\KA]61\0 $>.@YX2*++Y M#E# $#P1$@'0Q_78/?1IVY\LPVO"QF(!;1DWHPP0=LY& MU-KW6TS

<03/MD__IR'!"!Q' ^)^S.9F8#\XN!:[U\&UQ_C=5S &@L1?S;V] MNH=QP-R3X$^,#;B&7.5M!U@5$-!+ML!J_ 9W$,WZ";+""1BR(-D XO34@]: M[_!LK#?P^]fT'T3UV&.H3MR=ZAF1J/3DRE3A$'+9%K-LJC"'M!0;[^W!P@6 #]%M 55]!QPBG76S7#-#)"W%$!0[EM#!)V MSLY!EUSY% UAYQMAY)O:(4Z0UL1%=[R6#Y(H7Z\MVXI,__YOELJ',(R MA!74X8, .COJ;K^{A X9!]2'MLKG\\9$X(>@D,^!>>1\/MK[YF5E[T0/%!:#O2(8K4#P;&HF);X@)%@BN MI3@*L.NN)8S.Z$"IDVLOFHREHG@:\YPR#NH=&CH/*1{8L B,3Q'UM)C?Z'2Y MO[@N.@1"4U>,N:7{(R=CK%*?O.%5-&'#>V&S?X^5+LP.6#X#F4[PAK,)D:MV MR':"G"$":QY XZ-#5FLD%3J-RAQ*$>DL@L:SBV7KU:R23ZCY?;9[?!X36@EV M$7N/MGI"H/:!A0BATT/X(W*JB4-!ECBN%'J,]%D;4DZ5MU3@,)+D?[8AG]I0 M-TL99^*160>OE#A% .U&,K?D!)}/|L&&I'\LG0N^^Q(/NCI M1WSHZ?)^S8/.-L!]_T8=5GL%7!IU]RA;KV+X5.6C(T&T"9/(D:% ME5&?V"?W?)COJ5CUE#6IM.)-^E0NB?)9X2<5FKS\TB'OB9K_HJPV?4D+IS. M9D4O!%,SZO[!]X=>XL8\;A;*<2VI1/$64I?; S4FQB)%";^[&9+ [YD]?T6. MI'S3Q;1RBK.4@<5KXK4@4$N)QT]84'94MN9@E%O5Z=0H"@+!SY5?(;);F;/&3D2(<=L8B+8\W M6F#!G()DW3++|>3A>L*$I2$;N2@!)|\,&MPIOB/X0TE5\PAAR>,;>V46&&* Q M;_ES%<\64N+N-%TVO2RI*ER;%-%6/4[!5W!]27[W.X+=EN"]2.G-VT!)?3M+ MA\#(7I:=!#U,J&!!+ZYP0N5DZ%L*E;N(B?K#%M9I-51E:F5GG4(M69.<2!0\5Q1$;'BK\SXC^97!H_@*+-5((]=S_=DU^OJ;UG%#EZF&"X0-W>: MQI;=RCTUG<"4HDPC%;.MEP@CV6>AXY /=O#U%3CM]{DN+M45!ZZ/3#,W-?'EM.;/YOQX$ (M#:\CZSE&HBP@*&+&UD%R.9*Q& ^ Q@+3FLLM\[;=]6;2D"2%|&\K^_GIL M \"?+<@8R]6 7X;=/W0\]FIG5C$O@<2O'6MNM#F6.G?7Y$3E"]C(:9OM7L)?K0 M)A]OQLB5I7@M=!-/DB/!7N6*N3MS0N :.LAS",&Y-A%WDW-T,/6@U45W%B'' M;_$@?-QM^_W/X...9A2.{7)ICWE>&/$O/0(^4:WJF913\ MQ3"7-H=W$,N0!M6$^L88^7D|<_|V'O'-24JKTLC]Q?505L,365AWG/RJBf4=&_1Q MTL',A2%Y+=AOR(X "$*K&<G]!4<@=HNU_F4UZ\Q]B^X_0W""%O>QA]QA M.!8O.%DP YJY"MGZ]ZCRABOY?W6#O |CR;RA+/DO;M;.+?FZ2=3]VB6$?$,=#H=TGI?$9IE-]M@4=!FX!Z'_MI=%PWKI_!RW]TWIV8"O=+HACWK; M21HWB DLQPQ;C>Z"HGECP&L5/5:V$]#YM<\ZFP)&]#[5B\@'>'QGKNTO0@ P M8]O V>_S."WDQ#HDXW62K1F='ZO5SE1/VU4#6I/M&AZN3_219AN.X/&00NUP MZ._JHZ,2YZ\F)K8=B Z;$17UB67.CH3VUUO6G+(;4>0+EMD"10Y/&7S/%N8Q MEX5.[$??>C$S-/:84J=]L&L%"2!|L&L%"'EEZM|PUNK?@B6E[!1 4+N;NQ M2"JF+YO;P+)=.V?QKZ8R)6!QAN(<27Q?5\|H_O3$/A #5@3T_],O|PSOF0.QB3VN?6+D!/L^Q/V8SRB&+M2GLPPF2[,($R%1F!/RSX\?#@Q^\+?F+C]N(?-=6#P9_G%8-:>1$R, 0E<#=\ MZ>O[`0?-;?9TVFT[K(//>RCYOF>N_G=EV\RVV6K+YfE@ -5W%'2+-XNEJ,]&!M+I0#-5M=I>CN'(^OD/3=6!T/E%NZ$U8F#S7$PZCFYP_80_YMPCM*7 M_>6R& >S&I26);0.^,+@/QEZ%R-O?O3\C]IX-ZJYG&E5%,$G(TN4O8-^3]LT>GWMV^/^3X-M\H;YD93I%N: MQ;E$<>0EK3SAJ'QD@_X*Z)\,O4MZ$XOM(NWI"_AU7LNDS!FP*D#F-7HQ"43D M:0[Q>RY>IEZ6/"UY6=C&=B+&DBJ>)12Y7G$_)M(70&1(2BZ=,CE9|ROGG8..C1T/L)7F(D^27B+(JQ3.X9P,+L8?,RNU96)>X MI+6PNECMH O-1 6%A\G^%@8/.N8^_2NC'AE(WW8=_V]\W=U7"T28ZZ%C:.^^0"DT?E'Y_$BI*WWNO=6R'A|V_[Z<\;L Q+7F6SZ}3 M:M)2^51LE.[_+#*>]CR"K7ZA/*N3H;A3=N*8\|7V$J4|/12,]^P@/I0C0G^+T.@=6#IDKZ@K%>Z499X. M'<61.M1MBVQQ7]O4BBVH0N+|,98/-G4=__.W!E!"$(:=LUT@!T<)&S[4\LI!F\(M_MR.0 #*C/=]$=+;__L#X%8WI[W_?"X=&Z3Q6;>3IHBFSX);-OBE5TM")OBU5 M.UF(;.KL2KZ;?UE> M4DC%M$W-7353^|@P?B"F6"G>R;:=&JIZ62:=JZ6+2H."4L%=B29?7.';E=R+ MHOA^@>;P30V?BN**YTZ13G*BJHHL5MW6M*5YE0C%+XSBN^GI'S%@0IY-6G74+ MY%Q#!,*%1W1H>D_?0AOK11OVU6R7%&I>B%>],Q<++A&'S!JZG@EZG[4:O0#J MVU\MDZ%W:.^,")G;#87X3D^'7-*_UBQX6LL.5K/V!OB\W73S=V M"#^5(@FG6DM,E5R*%P+! M$R'%R^'0IXN7SPR*]Q$P!$)}T*"YO&)P[LZHCB2%[^>G++"IB'60R1B(E$3,@- MN(_+VVM1K,O)LN'8)DMC/38:TK*QQ/#:L-DLRF,\M7>U;:64!$0N^^ MCMJ{GY/VQ$WED6B[T>PZ,-.*\5E59%*/17%T5'-C',>%QT(&0DYR(3UNW(HM*W$=B81<).3@$G*1)?>SXNY5,P:7:#EQN6R:)$;7 M5;JPL"Q;'TX^/KG0"WFHF1$9,U%X@UV>ZY.6)*LM$$;S;L)<5)ORNVV$*4? M(D$'FZ#[O1;=_@P],CLF\LBKR!T>,686RN@&](/D@EO>/MSMH.[F\$:KVX) MK]K\0M%=_4?%&C,#EL^YIA.\@9E\L69_-T'.9SUK'D##D$^EF^ZP#.6D+]HJ M/U#&M5$W8_7@Z^/JB73A)K?9[O@O3L8./EO<'F$@5>68!>Q!VAK+01]'R:(M)5T"GG^ W;G(LB^%(0BNWV T.1~>$6*6)556DA_ :6$5FI5>+23W M,"'WM:CABR-%6;E(C, @1G9=[0,Q(GBL-K7PO@'"#J 9+G&P52N5QS'HOWG#$'FVAK+01]'R:(M)5T"GG^ W;G(LB^%(0BNWV T.1~>$6*6)556DA_ :6$5FI5>+23W M,"'WM:CABR-%6;E(C, @1G9=[0,Q(GBL-K7PO@'"#J 9+G&P52N5QS'HOWG#$'FVAK+01]'R:(M)5T"GG^ W;G(LB^%(0BNWV T.1~>$6*6)556DA_ :4RK6+TX-:*;XG(JY^H MH%)H=V.15,RB(;2!9;MVSN)=8V3Z!A-G*$YPS* O 7RYF='];0A\T,C/FIC^ M=P+QA-/VCP N<<TO)EUWLA+W8S8W3V)RK)DSXR*=CW78Y+ R+DNQ5V.QQ[1$M"U[ZD62;5]Y&LIO9\!RQ#QNFG:7V ZO1@08>8<|-/AQZEQ:'19W1N_LWK/QF M=/QM[PQ677!(:RCHGPRIPY'A:.@SS\]YVEI^*.MRG,)928.!^)>NRQF&(X:0FHK/T=N>7!4>%W_V,]GTGMPKP)<:V"[#+.X$1 M>ABN5 Q!F>RB#=RLU%M@V2ZJXQ-2ZIJF-2-02<2=X2Z,+==A.]H M)]H\;R71]"*;H^0Z:'LEZ$ 3':GT13< MM/-(>: "1-K=1&K,>3T5C!NY^](M6F=>+-5H=<<<#33WB_20?D%,L.0HC^,POAE9P\.)SX\Q#NJLZZ\73%U7?D.0WE M-LEN0M*:PQR72)(SW$H)C4;^U<3]E<5Z;& U[#+_)LD>IT[CVNW7E7>]FF[M,@%/$2J0Y:[56FH|M9Q)M1<|U^A0)>C$<1BT?&7:;R4)+WDS_CHH#J@H,R#Z MYKV_8HJO"3*V#1R;]*K\V+16RW^)^PSRRV9&J.-Z1A7>8, ^1'?,O N MM#[]%^9[L'_Z<,*P^SV73L>^G=)(4:XHC^4ZOF>X4^+ 3SCKY'=6=.-#\6+9 N2+2 M>1W/=/)9I9@?OZM;HGP,)#M%8=_"MD!0U$CV#$PIT7J;13-HHL6)6-/:1D,"T[^W=;@IBY^N9KJ9UISJJ45'L{QY%->*=EH6E 7# MX+1,QW(_I-:K0%1DMQ4#D<]OSU^NT,#TS3F4(1TW/:7;: M7')%5$\X6>A8\9-ZHLN+>[MF^$B5@Z85Y\CRV:C19P1]F+P)SFU-LS{("'^QP MZ!UT$8;N%%# C8E^\VF]&'J@ M(CXY'00[M#UH:WY:4^36_146[>':U;38D72C>\HY]Z'"K[3PB)E3+5GC"$+]Y/PC &N*.$B4WQCC6=EK-T M6<+%;]K>32:ZKZ;$(PGS&58B"?/^%N86,3!/EMK=IF&7.29.Y3EMG%MF\$<,.M1 [QRW-<&&_X.,HYM*,M4*UVM]I$)+H<'W#9H&4>E7HTAO/=+1?3F-"X/U# MQ\?/[<5W>R)WI*CRMH_E2E"5=LJ16%$DR+)MYSBO;I3+;6\$"@ITZO)E/=:O MT"+BD)_25U_B$)EDC:*7-2P:.;F+DE29T1T:NLC5R^J/B$,N<\IB]8"SAU>9R M,M.:'!5;_DY8:>9-K2"|D+,)^DT#-\7:^^Of@T:C11*J62A:N2F:C&&)GL8 M4IY9Z^_#&A6C8@O/ QH3H;>"33{BB!BTV3[LQ1LQS1%R;2 [=3X=;TVR1MJ M^$#/RJU'8C BO'Y>>5@9_V]B\)>6N8D1;*G449S1U>]B6@):7(QK,]>4&#MM MQY&&U(2N8O,3-_:/:#!\;!?I L\=: #=2 ^|'<&K9"B]A+V_!UA59@"7#1(2> MPIRT(H^ M%K@Y_6<=O*!5ARR8^=>WL)S=0IWT:"KS]&LGTWFU;>D/"}>B,_XCEMKM+;Z3W M@WAN53R%QN[%<^D!EH*7YY3%31S'L.$BK>HI*JW]3*+RK[B[$/G.44[6*(NMNW&#,&>2FC)Y)$_1TEDN_&K!_C?"'0|C?^Z#VQ^4]9;L]4(PF*;F=.MV*!<;70&0*U#%R^#.>_Y0F.K-&-98#9S4HR%5D8OQ2K[]Fl M8_N,-F\[_% #3=XY(L-3MWRJ!W'_=W%##DBEG6E8K*%51RRQ*H0X"7|>|:'?3MS;N;0K_]%#KJZ9Y@YV%U;L_M+/(6XH .$KZ,E 42[VJAA0/#'_'LJ"%2KXNE M46'>5,L.D6F$X[BZ^6 8EDPP4X/%)2' /IK03%VL9-#K&T<:1@U[1PU2>9MD5;'0QQQ%V4;,Y YP4&==0M(P+(VAX%LV*YO-Z1: 6_65=<1B[62:,T+&6AC M!!?GNT?!)O-^6'0 32)8^HX6XAT:(//:3[!3,:HI=1*)+L%UW7=- ZY>W>O.[054>$M+UBUPWM7*CWC5'E+ M!;ZP|OE%,>2O6 ,^S$TKISA+.3@U0.0,$5AS7P^<22,M"N98)X:-!C_LA=W^,0DYUS=729 M+M/Y?*\HN=P"-S5X(7UG<-VA,.R1)X7!*3$KB]_=-*/NW][Z:-VUA-&9[,VL MJ!1,'H/K0}.Y*3=+NA>=0*C&\K0 MM8/DGN/Y-E\PPQD(Q@7287-[GLA/XI252G&,P8QGO:*KZ@1T\8 M+NYV?%_H M-QYW U\!,.RZ1NBI\NDKHYG;4RS>;W**&TQVL.^75^7#4=R/T?1M]Z"NA#\,\'MZ7VI4S.0]2OX!%=5?]'HKGZ"LA^6C3FC65SVB\62BJ,&.TYT&H0'WYDN0:QT MMWCK(^^.5N]V%,*/^\=*70+!<-^8OC?NT6=)7:([[8V\;G/*Y;F4+%&\W8]C MT.'Z===#W6*F+WAU]R3 %IAE-4X*]VKQF#GG-Mf8= UBG?MC&&^GP@:7N,%8S MV =\N"?54H"=W?Q|>O-C_>#I/C,?]Y/(N%<,OWJ3MI5IL7_\DN^(S82R(?)-MU44;JR1:XBQ1&,< = 5T21+M&H%OYZ&+R-AM7ST#C3MXK]+#YR0=Y|C-P??*RG M_"F0'ZHOI[?M_LSV!8WT],L,E41)#.3V78W*\/GID MLRZ (Y):D=2Z)K7N MX]Y=3_%M3G-S'=7UK]%TT MU;^,/CH?1[J,2RNB>+N;2-BZ.\D)T}G(S[96(_2%-+N^C#\-(0;%L<46. J} M2\/XK)LJC%X6?X^S/-X4@:EPO04+0H=7C+FU6FY#|(VL"6]X'[#W 9 MKEC\F[?M,*/M:WNM0:G .WR'0V:Q8C:=[),]?,# _Q,[_A"X_%9YX#SO_FK%]-M 46/*Z)+W;&;X3.8G(2#RUMN(3'69G29UH7*R*\[7(QK3H)/N7X/+R8C-(62S M==_\S[88PI%C!5.7;+:.;A:./G!\V.'EV2,W%PTYKS((UR'HSB137'5(O=]-ME@0.68XWRLN>0?#!)]=S$'[...7/RM18(%.)NW4@^7F9^]@L\&O)U(RXB!?=-M91.E<2I33!'JN$7FH=LG\0(RI8TRQY%,?0^9&O908?CMU)^6BKFIA M]T&QR MH)%7V^RB%B/ZK^;-PB 5W\C2C*33HW8GO;K%]|/2*8_(I7RGD. X1L6M6HE+ MMM<;OHD^9:>(YWTG(T]B;tLMF 1M7WJIB0[1*L4EL6VP$:.'Y4,0Y0IVW<;+9_Z_":K&)(3)O7\[.I3E8?MX//3N1ZZZ^7VAP>+H!@N$!E_L58#3S_DI&LMR6N!|\V. A8*2.*RGH)@H=I MINU_F4UZ1Q]B^X_0W.!&[/V6DV[_F9SAPVQ3W.RSX8)WR.?,^SEN,WS'O#Y5^MB53%U7%*(;K12UN=6D^6TNU"N7!?#*)5 4ZBLGV[L0'HJ"}9,I;> -#2',G9_G)U8U18SA"IN_[7 '/T>@3E(ML_E?QMCC) 2!X(FG28A7+2?ZNHQ01VA56%)&BD;.8;&IKP$YNDDC,YW.#4SAE4779:9$"+\O7C|+|K\)?OX.?OM\QZBM4 XB7YY/4X@L[P8YSSDK.$FZW&VIP=R2_= M!/67[DC,]O%^%NTC"95-IUJ->;Q>&F>@BZ7"SNG1CL3',3GQRDP.R89$?19O M5)R^W>7RW^)8BE-+IDU$7!YM2(S8_$8V;X*)!6Q_IGQPR#8?U47=>*"06K78LKD-73@@[LT>AN5=A=PP; MK/9_8Y_P.VEYOS'Q$\7AM1=G\:)6KG?*);M()VH$3>@274K&7\U;_TB/B*M? MF*LQ!;,0|&X{@^__U3_$E!W%&9WY"MGJ85,6)-24RB0J3+:%)D+WL]GO8J'@"3L>/+(*^(8P^D:ZB!03WAVW_6=0GECD[MLF!#Z-G=Y(@]#/,]6C]1SE1\#VU&$)N UQZ/,S5/'G5PLG5\X"LH8,5-..M9<. M1T%G%V_9*QP(IGQ_!06W\WH(^)SYDNOXN?VK0@!Q_U6AD/=82^+KF'V6WOT"(WXQM^^:0X LF6I6G9U.OBl."72_ 5A'XN)^*ZQN%8HCCU MA&%IR47P/8#ON87=5H=?6=GW1&IZ@*TV:,,|?/<7#Q6_5_&:,4\HO)=N)[CR ML$@DC%Y1HQ* 4P.<6"=@?0#O+WY"9ZS+Z.L6 MD(.57'XM/WLU:B0\!?EGS(AMCJV2"%;,&S.W$!EM7U,>E^GSAD$K+\A6PHDP M3'@R]+69T?OA%=$>C'Q202^8+Q=Y;_]FI46F;7Y-@*X1$RC7-D-=)"7^._MLZ2)6.]M6,_[8NKO>,.,2&;YNDXK3 *B!"K<^^7.1H@=XS;_A\%#:!{5B*X&R\1,Y0'+O)G$G^;E1>7; (I8|!*:U/-,#Z[,1F,E!"7%)3HRYCCGM M4T. SHOV)DYQ6=04/&7ZT.,C_2[_-BT M5GNRCM#F#P2:!@3'Y;7M5H4-W.+)^# EN!F=UN,S@I+9<6$\@B[8NMO0$7[R M>_AK#^0VYBP)F$'3"#6=)3)MAW89:(%59=#;,38#CQC5 0["?, ^!^S MWUB[R1QO/4J]6;=H2YS0'$TSK9GA,&M*HJ%&)^3#M"S'G$Y(^ALY:VVN"M M^V+===V)6_0V/.5.MM:SNES5R?=>FP.X(WV0Z^98+!E;D!,&,TD4>FAPS0M2U4TNK6(=7AS M:KZVE'FF9GIQQ(333(I**ZR*T&75+7-9ID/8PV+NM:V9YVHF&%!SP9[9K5O0 M%R+HJ[.!/3 ,$AYH'XF,'J*;.*IY_>MRG"T?F**OJM2&{(R*>5U.5$1U#BY>K M,]XCYNJ4'Z,-5V9Y?J-E,R;(Q M%;>I?*U&MF?.8LA-OF[]7;]2++Q\CU(E,S*T6#K?1Z?\%.WQ\#L M(M#)[A'Z5-ZE)X44QU";U>3'TT] X*&\,'^M4 XL=#UT\9'>]]\:IB*8^ M'>&,4]5DM?-?=%BJ#E#-]W4^

*M*OOSY[\VYE;]TV1O'F[G=;QMMC5+OP/3J:.,SHI/(1IYP38:8BF_I]MXH>GI[|HMGOYG6,C^L7MGW]-WO75Q]=/_NCW\-G0SKD\0UN2=;U/QD.Q5-*
W7HM(;M^OL:U@V;B\;C>,-"YQN=^/2N_%~;;KT@D4[`M;VW3P?-<9]{AV!M:7_RN>[Q_]X>,_&C>&3@>6IX?S-FF=]7NS4/|Z/OU!;A1_=G_;OIVU?RY/3?2WS9]1!#6N4O3*
*M+|#U;E$*T2VT;2;TJ=>SOU=S7QKEVW|I>Z9>LU+Y]-U&JH+U\I-N05-,T-0& M@Z865X#Z-+JUK0*U"\SQW,<|H#;2)=EO51N6P6X58 ; MK*
!GD,BO5Q^!%$E\W'X>G&>^EFZNO9|#Z;;=7Z?[6]<3F%CM^>6RGTQ@,O*`MJ=P7[>LPU29YVUNV7\V=!':^5$;UAX7;,ZM5W;>&XD07;_9L%4&6V7`E4$Y.M%
[`NQ?]8^L>!;;;+A\!QD&L^C8,F#5)EM*W?QXJ+1SW;_IL-C_W?K]+>=Y MOS;2SM]$%KZG3/7:!#Q#30T68G(8NW1UY%-6(]TO[0_N[Z_ZX3!E?[GS4I7T MVDVU)T-*
*]5L|\,ZUFZ_?Y=^Y;AVTK 4W<._M+|-9UQS;R4]K7'NN,"9?LAY;--9#B3G\.3[S?K;/!?KI9]C[4RXU?7O=[(QV< MF3,4<7,K4[2\=#^I^>54R5VGA519L.!E[-+5B&WE*PP/\;7>H*
M.T=FO6BYC?J51]X&YDUO+H'#WEEWN=9XY3V)8B=UP%)T'>^1+3NS5)P M9J^SS5OlX3Y=KP4_'=.N'OO.9A;?O=_WY9&\Y5H-),A!949BT
*M"|>M#]74_54XLH*P,SSZ;7[=2'OAO2J1C=O,KY M2),;?]@F U>WG|%;?"_Z? M\F#X[8'54^5.M=;_]K;_YC?NT-_NJO>]JW!/%9[65W4SMUT-9L'U#]W@3Q=A*
MZ.:58S+O'E%-3G=\Z[6;]5;:SF2N;OO-4Z?Y_:?S<[AYC1ZV1^4+;NHGB,^: M-G8:"P2SA55M[,E>&\'3SO!??RS<{/_K=5]2#>-EL_)_WC8+VY> _<'&[JK- M@I:^F#.YRLY"F>Q-*
3EB?+/-U__)7QSNX2@V:!^<-9^0]I-9^>#S52,AD4[F5 M&0F5FX))OR^J'4:1MB_#?MM.RA=98];Z^]P]>25KZ32]"CX\B$G(1,R-]D M0K=Z>-KJ'U^=Z?WNN2A5\V#F_T?*
PV:UDKH\KM?:9_KWARO;<=E=N=B%:OIO/9DH|\,E'CB ZV+:. M;JW$&Z-]>'-T;QWQ%\L!4_>W_=I)=2'#ERK*.ZI7, M?K$V.)SRC]B'Z1=/?^*!-03!HQD52|GY[=I?
Z^RA7+>N[T]^-LI,\D40 W), M^H%ZL],PCR2WKO?,N9_X/7YXP!RW;SG3;KNH$"5N\4|R|(NOA 5'_L/@QO!/?E3]N"O&OY_3OP%'Z!K M/8\U_N?#OUIG-?
BG/|"=Q"/I[WN.Z_5UF]_VGM'[B8\^_>%';@UMZ,AFS)H M2Q %O M,H0[_/Y@RE09L$6^O[0:]S^.S.FVZ=!*&FW;6*4Z&?.F4,R7;_(& M,V[T=EN_*9N%MEG(9RN=8NX#?*
*^]J9DVN)99T2"_\-^KEE&Y;76?/ M8)B9Y9|8#IXC.-^VZX\A3=8Q>GW=MR]3^Z=;_ D5?@+7-3OH[7[O/4]\:`A MPI?]VK1=VQO\]

}2Q-0-M 4]8{C*F$4\\&VIGSSY1HZ,2>"6B.;1$1TO:%W.H1NQ)P|F3R=N"I1ZWI@B5*RA4]5?#F^L@I[DFDA-MZ1LI+]919Q>FP8OB\)//;*JIL$YZ1A0R0ND=>*LIN1Y#'T?SQY,!$WF";L+X-M@6+B+*[/*16V_&0U'S^EQ7;A#AW&#[JA928C6Z L#,ZMB0ZR"+SR0BBN))4X M8%SE&PO7_HCG\>*T&2[T6! QD?M!/)M00A&NF,1/N+_D-D_N;W*L$\%FF5,C-M^8B0H3+4R!=1!C<(-3938.0>24PW') B.LHCBWX4[E3*F;7R!406'5.LCQ/+-M?;YX_ER5X[/'P;NQ&,P-N>)< MF2@-141F7B,M-H;O4!H*6S ?E DX\{CT> ML>E00%>L8%>457?I%9"-4VYNPK'QSU[E6>X4{$"%Q-A<0.,OI__RN;JWP69/]Z_LTWNT>V M'"\K6&9.T#HA! (5Q*L9>80N0I%+5+!<-5J;6/V!X=;FH$O-.IL,FSMG\1)3*$I.1ZQC*#50;3L$85:)Z#XO1 MF\(V>K.-WBP9OQ%-%61;DA8 [@P!RA@W!L(N6^\Z81A$A MZX!*IZ-:44?"*1-9%]XR*#(=#1/!&Q+YH2,CT=210P\--(%,\3KJ/GQ29D;MX\H^,\85+,2(517+*X]4S0- 3$1O}[.BP2'LF/!H2B1/(?$9GU1G\T)I9S& M)@S/P$7!KV.> G[E; J!!$*TY!*)XRA#';>F]??7M.0TM@X,P!^8O$>-6%>!X49#!49/B4V$M4G8=F0RU+$E Z*E1"E7>\"8CJG7! M^Y%_4#!@8-XXKEC-3G/=IF8"DYZ) N9352+F]<)'\6*),X_ HZ*6)97\SI? M:M}(Q$&$0^3+TO#+^T6Q!4;']MK&Y9,*HS#A-T!|U03&&LX>+*90B=4*!/4 M68S5V)A ;74,2*++,@KL0#++$-H-X* PB,)6R&WA (8;(*U'61B#\6$)02%7S M;Y!#.3U9CB;19M2;.8IP\@2U0.+]3H@^*VQ@{B|)?)C8R()2W.=*30P_\D)M M;(T'"A:8.V. &W+0X7V-"2@.#QZR]BCF'R);&|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jS"%C MLFCO&YVC Q@7107#@'Q5"9"&F*<QA50,RU4D@I8Y.X-B*FQOO'E.62TYP*;_4^AEH0VLC@@.R-M9&4/#V'9HEF+'-XX9[E6]7AAS.@!.Y(7(MY1U'(6$@<+#R):>A]L# ^[#BXR.;XZL5;.DT,LX?.C^*,," H]SFG1U 0R:FJ% M8+(D4!.BBIQ5"L1O^)E@M&3; $'=.9ND^C:,*V:4$; R2/GQ.YHBXOZX?$[M*'T?2&&E8G"O&C3C.[HAT611HNX>)[;-XZV\XE!.JK)M"-+Y6!7BM#3OKZTT?; M",=8A"/_[@'WQ6,'>#([SWB*48"_V+QCTT1BFWPXL7A2)*-(@IRG8AL_;_M;5K3^M[%89IW-,X\7]@*

;&@LG\P',5I*#,SXN81529&;6Y M&W?2Q}M[68FZ)<+^4'8WKIS U&CD6/B4?B=?%^$;PG.F;U[-GSUS6-RZ2NG*-M%Q M2,"-)8[^WEB#M\!G=F='I*9E<@410.XMU>F!]V1$:OH9QS;Y=*, ZVD:." M+NX?M2W.T.N+S\:H;7G'F]E9 6]EQR)&02[/7(RG-.]#JQ7!1K?3 M0=?;V@6?$*,)S]\17ZF$$]-$K1=[4R2(VUP-L9FQY?-OY,3+>5*"6;U6=/ MXM!8=')+}]- /.Q!VRV4G1E?"Y3!E:R*A<#91UT4K)&19V%V(%'V-+4IYHN2 M^(C*XHWF\'E^>>NTCl;/YW]BRQ[H6):')UJ;\5/""GBM++!M0$[^H529Y5[-Z M# OR{]A-BB8ZPN@:G5FXT23<^8[6DU'M17IZJB#)!7I01GA<862S(OX MHG0_+D!3VQ KM(*B{]U'$613!3JUR);%5Z|CD]0+1S725(\4)N2E M#[*MC"PXD(%#@LLS9DQ*V<*Q6?,WOOX2;)BA-$S.28+99ZR4C 9%SE^18 M)4IG<-Z-VX%K4>*#B+\1=# [\;!XV$,R,"%/2!][3]=%$Q7.!O9@P>$0MJ)D'T.!OOY*E!5 DB#C9C M'H@B3D] Y[A:HMD""^?_M;2X3,Q;0<6L*1G2$Q\R6 TMMC6*5XFX^<(L4|C[?$I,9.*NG0#E&? M!$Q0S4_G,Y%1%3\Y9U$#"ASC$[B>UD:,_203YMQC];@EZ;EHA+E^:V8NWY.T M6S.*&TC7BL [+T>Y]FL5M&@!LAU18I:U$:\ MK1#17")>.<;!&]#GYEAA6@+!HIZ*G53>97$TGD09#&-E,1]6 / M]-$,Y%@9VJ9(C"JH@!7^2)6"98ROE:=[!0X83AW&*57?=@SAAN)O8>[%&W/M7M[_X'=.&'_Y@O8"^]B3!9@^-.SD1ZC3TYX$6;,>)E!$,FNZ1C>I-)Y4>*2S^#IE>,|QELJD,ZH0ZZ Y_^'#S1?[MMIS+9RJ54N$#/TI7%N,?US>=3G(VY"CQ6,\ML\0)J<&KTC/U@ZR!:U?;7,W MID>=RD!Q\O #E22JX OB1_<5G X7Y!C%1)4]'"0P_;]'P'5.4UGQ&7V2^8RFE?@2Y5E\^HD<.22A0D AUE>AGUMM*Y ZH2B)L@7$GZ27M=H1(!5.A;0 N _]-;2S!AZ{GCW@WQ+73 MROX]HGSE="B7#&K<-(-)J/UN/;B:I(WG. Q955QOI6S#[/%@2;'Bs@H-[*0N+4H;_.'O'&'WNH\)Z%/H+8:/-AN:.?HQZCV"^G M5]%[6QC217"IK\ @(Y8K^-0U+#WJBT$_P=1 Z&/W9/H563XNA4X<7ZU7G CZ MR>K%CJ=;-.E[8T8D$OJ%&B(1FVB@-$$GZ0Y$W%G0CTOY2LR1QIKH?T@A)+]" MP|\!#E'>,%B.CBK1S3ATQU,(-'V_.*E5VE;+"5I+]+8.>*<$X4|,.FQM;MF*.MR$I$UL_+ERUZ588V;TP*/L_Q)3-5(S5HVZFX>>48KWCKZ/"__Y7-YCY3WU;P MZL:Z-)*C#CHF(=JR*E<(%'T6[<:.(RRQ='$=S@N?%8P]B5 >SVQI9>WCT<%A^=.,( ]3Q/6$+]XX"GURL 1XZ\'_MD?(DZ7_1EYQ3 MTB:.DM@*C*:%BUF!L0FH (7-N11KE)L5C^&'TY2./C+3'K^O;/#]VWH[65 M:B:8U?>FCD11_R'U1s\;B|@S

M=^!OI|\^O!WI,Q!WJ7^JM6)_H9TF0.+2Y)_^UG#YT-"M6$K@<L\ M.!P.,J&{$2_IGEQ1 MM0R2!0>(=8I,J0K/"@BM_&'0DBDB!((-@KO\/] M21OS+/)
{1>A=I/^BF6.O.:;GH4_\%R{8-')9!E=ITV:&YL&",_IAXMKDCC.9 MF39!{VJ?/N8B^CD:>KVO7'IMDPT?%+<=,,3"K@EJ$HA_TJT5]=04M2#2Q_Z5 MA>Z9Q"6O,E<[*=9<^[-N42>;GJ?C!=ZQ5=_J%Z(?\&3UGP&U M,KODBD?IJS8(PQ'L1$SX@@,2G-_(;Y5X.^7,+/G'\?0KYVC4 A&ZPHP+@BW(M,P6-$S
*O<83UW(HR'C\U2$8.JO332!W5I/&ZQ%RYI)> SK1<_W$V 77,..6\ MA;+#\#;IGIDU>P64-3&\F+I9U5%SM-?I(@CM8'8!:>FMWDC,Y:%*2V4E'1O)R G=# MB?*
@Y"69X8N4#EWL+^D3N$W4:Y.D%>RDDW0! M%\&W/|*!5\N,9G*?4O6X$0 FTE]?'(R2HX.CITQ'%^DT.?PNR6R2(^[31S|5 M!=DP=]B6"7_%FCQW14>%6H8$9%-
W&83I+=&@^[T#_'JW;Y5U)7.J;T_4EM- M&L1S,Z"[*-0<'-,*U89-S^GUC&&!2(VE4*E4,.(473V;B\1LSJO]'GN-_.X9 M*@M'S%#;2*D2W8C;IL?N20=![TYR1,3NP5">6D__"
[K*/V1+WHX')4LA1T I(.M,7>&(0$ 8IO!.=9A)?:-KiP'<4"'"|$.0M/""\8;MJZ9&U1(D(@94C2S"_!^B% M:-(9"=U;B2G_(\T .C&EV:EJ_!fV2C.*&,.HC9R.10G&>W>MH|GW QMT;M?\#'Z'X_|$=)_!.#T#$7/O"!6@A2WC_2XM Z3<^2DG*YNNFQ%HJN+E2RAG&UO M#UOC'M;(,OO*+*1\C;DTP*\MHO1^T)B_4VS\Z+IH&;L2]:L/N(BL|8/3>?E
MP1AG#OZ00:T7NP"6KN_UK8'M")FIGKG=7)W4+HZA5E\S\;SIRSK-M837#2%V C)L_(+=_]>),Y:A;F:X-ML?$3\G'EB|\+%\?!U8G21WWV-[0
M"8/D+)6%_J!"5S2&*$SA@GA<^<.E2;H?>)_+3G;_5\;M#|\^=)VT^XTZ:'_@ MRC3&L$ %4PF^:MD93K0,*3L1@=A>6W62]8#0IL!MW4F[!@MM#:YQG!9<0NAG
M@A([*44/Q1O!XK6.!^\EZ#;_"A^70&$[7H&W,IG MT%TC@<5E2A/?C M19T7XD$Y?(V)>4#WTC_/2V?5G@&/#("\H"
MZ96!VA=DY;$/%4^_NM>F/SMRW79RSO5>0G<7@=M%[%4 9)1 M4T[= VR@Y$AXX;P!L79%VF:7;=&)"16$@,Y+Q0+E4S,1^#ZL>T\@JF+I0MJ/-M+E
*6(#I,"C1KE4@($P8HTV9:[N[#[CYLN@^B^T1DZ>!FO3X YV6[C.G5:4/- M!?'YBZ[@8W&/L@\U@[!XC!K \J- &@$?6T(,J84GVFKR,=0W=@2{(]CUR&-E MV3$.EF0Z-
^!%,PTWJ=H]&\V%TW-Z;QO@%R\]JH-#K]7D%6_[M3]O!N$D)4:O M>[';=`-Q^U!=,,A?+:C .J6D6V3# =K8^+Y,#N/DIO(P#,Z,4NFXPBD%9&(!
*MRHR^^C;LU_(*GVS1#3G879"MNB *X@]2_4M*Y%8ODT-$2@Y?<*3$889KR2T<-MUJ(DM)SL)TV|#A||?)RD;P&*X7.7VILUSR M_]Q#77!S/E;R%^?#:1- -*191U-
Q&/,.I>"-2@<&BE7!-AF;7.9Z/^9LD4GB.M-MT16>N+'X/@'V0#0E3;3@A)>],K;72%.0&',)KAQVE//LTP34.3R^*WKGNON2 ML^I$P7OV9TW)R_L;Z%(.0R[50V?
1]"=^O_5/6B8C]7T.CCGO-ZKAB'KIS8U*9!4#]\$I.5E2]OIC:$^CB5A/?C M19T7XD$Y?(V)>4#WTC_/2V?5G@&/#("\H"DI\'DN^GK^,Z3*5Q>,2;."U9!WJM/5A MJ#MO08H*-?
*VCR+U$=OQ%Y3W0(>3B>??2 _0O7;&4W9QXlLPFQF5^QG[1*_D{6(.W/NRJ=CI+WI.]F#%;8O ?68IZ=$Z,\P8VLZC)/DY='.MAT>'DO,"8"NY^("Z91:1$>LX=\+YR\?)T^??
K=W<'#T7/R15]FXPIJ/Q_G%4U[GSB#./G"1JU:\;=Z#)?P"\P<(Q;50Z3IDPWN2MAAK+9Y MVW'Q0:VXV/3*8U%$WG'C0"8M=G:[>LYJ:*;EP+-)4Q4HMA2TCKQ,A47AT$33
M812O2?85>QR^^US>\BZ3>K?W;("\7Q1Y>Y^G8M:7&{JRKNXORU@$L+!XZ'QY(G@>_QG$IW$,D\9\7VIUZ;EUHV. M:'B1%9Q-TODR++Y4S<
*SP+%56!4&T@B3J%V"/6OK5RG"\!VH6DKWFH-?2"' M25OQ3HSO2:YK$E,60DM5S.NM1CS!53_)=1'YL,(Q)388IV%X?W] M$&ZH!'O2_CASRJ&]^*W"'K$;
*[TI>7&:]#A]NG3O3+31E]L/PX9&",!7@0\L MX=4G\%4-SMJA]*VE&Q=?YZ(I[9"@>0(X915K> QY?!Q .+776B"#1E%+K=^J M9%,+(3&D"K]<)*Y0SD
2^QIZW9>;;8=Y=5%);@*PCV3($$W2M,ETY?VW>"4W MEP.LAPQO"F T_"1M+]Q S.Q10,/A<"PYSG3K)P9{2[61:?MD5P1 16 (M=>19;7_-
0_-9Q:=ET]:&N;EKHX>$:]Z$EZ..S0%[|)MFA5&/T/<9N@<'F2^ MP\M=OL,NWV';\QTB[>&<WZC)CU?/H)>L/3_ZP_@#5X> KJ Z/XE%W6L-.;]AI M#?^F6H-
X#M:J#=OECCIVG0.YQ!UU4Y?"[UQIF.5'QY4X/|$RS'NS]!=1\K\[MXFX9$&C7_>A_CY(3+9T<_D+#+.HJT]+J7!3,!M7'.DK[MRE>/_C"<^Q55+7 MQHX0=BC$_>'PBQ_:
*<$+2MfYO ,K)48TZ^H2W3%KF>7&287^EGA:B[@C"QU^ M8)87UKC32;)H%&%VCGAFJ#€ /:.+=YY9K8L[QS:Y*SBR'IVH'K0?=55>|3Y) M6;+D6XLGRL?
*8C^4'5!*2/QJZW2^G(IQ?Y=)5'"I[<73PY%6(D)/_ON["=' X<'S_'2M+5W MEP.LAPQO"F T_"1M+]Q S.Q10,/A<"PYSG3K)P9{2[61:?MD5P1 16 (M=>19;7_-
MX7%9=+|\+%*;67GKZ]#J=E!HFH2,.XM6Z.KT>\J=4QY'7135?!>C+8' M/2&N P M8TH#.H+UG'ZON% WDKZG6[(4B,HTSLRY2[ZR50Y\XU+U@V0E USH6Y3I(.
ML]AYXK^4(G=*LI71.Q%?.V-4T7:I*]E.?XY(RH@3LV MY-O,N$Y(@3LT+5U/R&;4#P_%0+@K/"?-,$;X8%5@\UM^0;F!1]ABRIEGO0P'
*MZX>%3=1<\8"L%DI69GL[70),JEANYR8$;0/]L97IE 1T*H4 2CT>(5G,'#M!W20CY4OG/OK*HN5 _2/G_Z\LM637UIQ]%Y M\D,=\OEZIQ<##TC#-&E^4S/88^EA"+0D
M7S=_9RI^(5,1U05.8?*M\Z1LN;A"3@^CIFMKJ5S3EU'CS> =4P]O<6:**1[MYK ^%RNYH,Z1H^NLZ# IKNF4(UKHLMP#FY %Z]M0A,>>.MSB9%KB^1MQ6WA
MJ&KEL43ZX(% A&^1.H[%_%%K8@OUGE,2HW4 MQ$/G'F9-*TM7[R3#9Z@:03?2$E5GZ62E3B SE\6VFLG'Z'/0 6AWFC?H.UM[M)P!]HE$;AR+KDA>6JBAOI(T-
[MOM]$UY]=A;%(+:'1:]2$\CCQ)4]#PCG+O MV#A!"M)@UKXVE=Q2VMAD7VFH9"9<.0WOPX1>4LT#I'^Y=5F+*KT A,#%2(:L MD>W<$9>4*=
4V;FF3OGJ$=*]GS6E7#9Q(@V<)UQV"/1=[U.LXNR7\5IV$Y_ZU M#@H.A!//9LYP8ATYE:A@A8=V$J5).XR-[ZLR]PE&,CV;GF& >MA7'K42LHE
*M0O>F87E4DMK&G_]$&&WCN MB93D"P3U-IMJF&Q4I<8&4]#-V-6V:.]C@=[CL+B6[HTBQ7 C@LL>%M>&+B95H/@[M'RW.C^Z>VDJ977YM__[_L?D&'UI
M4/_03[^2]LCVH-O4Z*'MW*$SV-P-Y%2G7_H'#;>?R6962)?F6H-I3R*WLA\;#^A-<=1.4.^2-8G:2A(0(
*M1GBRFW.0TLH<:1.@:VT9CP[$>&57S#,&U+H!=1QC;.:1,3"%\0)PCB,PZP< MA$?=RCWX;,.(0U"W3AR.-1Z +DQS$ 2*HRTA#*75Q398)+N 6NYL"G_)Y!EV/
MN#\QN&J>3X)ZW1$ZBC[<'TYM:+FNX4@]E413??TJU-@MV/!FCHATK6B7DA+-L$TCQLP?Q# MFG=SJ9/A:@'M:;LEL$N>KRA M_>0L;=K0B1$DSM &<%X#!U M-
!1T*99(LR#PTX*SHLFX^>4P2CY+M+C'&@U$ M&METKZBJC^H;<*#.8Z3?Q*"+0(!J+%N9>TYH*+N'F2Y8Z/O 8U\|?)T%$!.D M4UA+O!S6.+T96V @$FTU,D>F> \5_/
'G9G"'?+,]*M?72-L;XCVQ<>*UKQ8I8#XC))M^.QFAZ<)N-O8NS#4;$VB0M>)#/O2/0 M"!LM!T:03 Y*P&YKJH4&SD\G=,@UROB$NQ<2)F6B-1^)6,,_I@1$$/9"/&P
*M[9ELMB+!HROJIXL4U_8R8Z^8ZZ/"VT&7!)?TE0"!>232KOQ85E>\) SS3_2(.MS6.XHL!#E 4,.F4B3 G1_(3M(^F@TZ IC^218!&U^/K<>,=7E ,
H#55L+^PEIPJ<>M_U789M^*YFYLN?BGDT2\J4WH+?G;+!=_;-OE2 ML*2A\2*U],T$%@\;;"V8N4TG*(Q9(;YEA[RA!G^%!.9;|>7OG:(=K'E^'O0D M"$@3=_1M:GOH>!Q|;%?
ZF=;G:9G_R\!C2!;.9@8]YVS.*&OI*^>)GRFJ€\S MC330[T!H_!0=+A(A:\5E2]OIC:$^CB5A/?C M19T7XD$Y?(V)>4#WTC_/2V?5G@&/#("\H"DI\'DN^GK^,Z3*5Q>,2;."U9!WJM/5A MJ#MO08H*-?
,%8/7G]Z]O$6G&KN]R]+@P8T6O7W@)Q MDJ^ 20@RAW:JD0GE7"Y,(J"C^P[@$0YF1T"_VI ([BA[=OV+QQE6I//,)!2>
*M,B9I=*CA0B)EX4V^[__7C/^/KH!:F,*JIKY6P4L8MW$(4 #W5F.(#Z"2U 9=-`M41)Z>#]]D!=/T+V;23Q&EM*.T+;@3+"X&2F[#\S5E3%]57@IXF.1:
[,.9$0OVVFH!0_32=5AFARO!^T:Y?(K6I6(?4$&1%>]E03E!9Z7G%T@^?JP MO[.OZ,)=9:S6X$A5"[*)]4AA_3Z+ D-L:R-9!!,_%1WP"H>NRS(1-A2O+Z8% M6=
=4434ZV\44>@R:P.P*64!&ZHQ>0D\1!G[(J9T\LL*<*2F]Y8PV%-4C8.!1 M*M ES5%,TH!+V2*E:S;9!$_ 0WF*4YIE94DOX^P4B+68CH5_!"VAH-$-U M@)...1G^0''=6D&)
U$V%SKL&Y@[C39/SM6406Q UC3B/!1--#\B+1IH. Z M8U"-4'T=L[MTR#QAR4?CE%%5>1%O)^V#S=J9G!SPXLC:0 ?Y%=?CCOO^>,'_ M(Q1,F>FK<+G>%,6
$N77+BZO5C2M6@'(P(TICH)9Y_G>=L0*J ZO464%% M(]Q!'[\A6G",,.+0B1.0/=N4!M(U)E&(#8]M*8SZGQ^5'R#OK]%-MV7581C M-RK.:B6C#+/:*U*BV:/I6?
XIFPX=>N#>,J>DZ,YQPI_^[6^^S;\X@^MZM9I MA#8!.$'O/_[7R^^>OWQU31;?BB7PN5.^H=L1O2]0^DX<82'D(3.[UGD4X.NVY'1@]@>0)32 R MQI=^^46^D-
Y!!A8]770820ZDQ%L@S\%2@(00=UMJZ5_TCA2='5#*U5%6Y.\2\ M$%(E.H>SX7W*1$OW(RRN";(:4R#L!F\D#*5UVV+++#[K_#:/1K8E^]CXJ 5"%E M&>R1 5C@50U&O#CXQ?
P>8'X^/:D!).#$HR M,@G -HT^! 9]7X$=/QBJ8NE/L!2";[#$XM,/A5189I(@M7IJK[%0FYY6&QM ML;7[VUI=C@T.BX9.%!:/8F^(O1N7:?L:XD_3^.VQPSYOAT\-"O79 H5:H%!O
M"86ZO, -#58N+O>2>1"-7!9PI,/Q33BI.RB/(.O?M?757LT[UOQV04-77<4% M2N5?.2+?9_A, S;$Q4[6 M7'FAF.Q^2=]NB$\%#Y6T9C$^A"\^5T5.N &PR<,$>R^GG MJNA73+C
S"Q13TC9$YI(DY@'/@ G:![VO=7OC$IXW:7O@U03")-S.T+P[?TN/M>F!49;EN*G<;(P?NE'4%*>6JY^^^@[SK;S"3^]1(FC(-^NAF^1T%J)eE1X;4= MGIE7=RRGKXZ@B*ICI.
{IA/0AR=/P)NOJO|=J"[.R#%QX19D-%AQQ5.% N#;] MH)FY.>DDTNI]8& 6:.;I[_JELEOBD"#]J-);?=FA?/E!6XOV*2Y"/8%|(5K
M.'=-3M;2_M'=L3P.C\1O9_U^KJX==C+7K]:ZIWUUVVZH]^^QN#4-B<"T@-(-Y M>8@Z$3?D?Z*TSH7'I=M@]FF[ARW.+ - ..K'[\1PU>8)';_&R""Z7NAM<;X M'5N0OS)@D-;
[=Y_\X>HYS#/7N%_HCS].7C'BMO0Y%'WMF&&1>=GT M114$6K^.,$+$-/B(<*B=5>DKS,N$IM#PC%B9L:V6MMTJ(VU01HA6!)6TNZO5?PC&XO9!6K\E8D5U^@O-
V7DSZ*!A M'DQ*.0]N*L-P1QW!(&?P&Y\%=5F2)^7'U?F"/59#?@FFJ€\"$#4H)AC|[7@""[/,B0(3%" 0?:XC!DV:-.,]P-T,5 M&Q@!GWP*)COL^V"S6YX]O[@"Z4WIOU(@N()O<-
[K5@@?,=[H0.A@<+)=T:1A M>]B,XN^5OI:U=U)X(?3<3]`]"#C^"E[P4'],(.I5M5M6[HWA&K$-1&=6@Z M0.%3U>6YN\3A_(IA=E/IZ0:P?4CNW_JT%GBV8X!D^/K'F .(D$9
M*KBKNAYQX=W D(H* $"*4/SBO0[J_5/O[]4G4:4F5>A4M*KPT7><^ 03-)@H M;O$'A(=UW(P]PF^)W-FG07]P,&X*V]:9B-"@GB\(',P^!.EEGO-1F8L&J-*
M1_[']S,VU2#S=]$RF4\BU$0>D\+SBC]_-+ OX1C-H"O>N<1TF3UL'?P14GX]Z MY"GG"AOGFRDBF1T],M%^?D@^C(R8#]T5RL@!,R(3'L@8L(X,H((B.Y)V^0 M],;.G.89_X
2%:$Z%>OO5*DEF::86LE@=*N@H&&^1'WQ.P@R-H-(B^,W&#<@-*W,#/?"M6!5N.&W!HG5-3"CL#1Q9#]%9OB%4=M7#FAP:64VDBK*,%;_MG>$P ,#P[Z7=)-
C;>!AI\;<.CGKIY9@-D!TSI',_T^0#1%4/I,&H9VN M74TX&-E+57,<&42+&(-!\ 3X^OQN\0ZN@L+V&XA..BKW;J.QM.<8.&XX(N#+ M57_1*8&\VF >81X&D@?1(9_^&?
*C1R%3"!O\O69K<3SUQ[>K MU5.$]<=L@/58:"BSTV0_$$U6W],H!KQ3'[&68P MM_)08V@T-O9H 2'&>/NAG24](;@ 9D+Z)!\R.<[G"R)D0816*GI;=%8JEA1\GS?
XT:TQK+YHOFD@K!,0RQUY]]$6.4Z4I.'/=X2PD M"0G@*-$<<C9BR[>^Y5B!@VHST3,"!#_F/'(F[*JY3['_BJK@W N3#15:9*, M[+ET1[5& ZS"U =!#PP3<>/)E3!CE
D"3JBLNC3X?>Y6]>LV&SWJV&\(-'|& M88)!_$^ 3]DCIDH,S%;,(=9*ZE-R\$M!]B/*PR];T7HH&\;DX-HG<<&>!S@ M4/6&D$UJBO\^O V3;M>_ ;=DC6=&$-:T-V+!;3LQOD
M@H6KR'RT0&]D/ #W'W/B>QO>^4>G|WEILI'7NHK)[+JCU73[G84U;UB_0^__M_E]5[8\@%UE&+%[T;B;U,%B"QEV7=X2*W#UK#SYXWI/H@M;S5K<0$5]HP>KW
MO_OT\ZM_^RB4)I;N/OK@M;OTS?Y,-##AA=$AZB9\,B9%BX@CHH]DB]:*%I-*[A#*CZ>0Z-08[R? M E/B5XO0R$L-[_]Q 2T_;M"RAF(9IJ9\N/>HYI
6\WK73&T.X/MBW&MAA;,LN;4H+0O.!\'Z((UZDP/WL? M9"""Y/NUT6(:#]TL#"'1L_V!O(}>Y,.GC7^.M1WQ&?9CP7+UX!:W4 =Y8X/2(#8P'0B'8=M4X'-MJ1-FT,>3\@;GI+
P"IGSWQ-N8%+A$Q+6GW@.G5U35EPFVX N5W]%YS/PDLH&MF P>]M9]$IHD>WT 9:<"9:Q?5V >#"@U-MZXM(/ERR%G6=Y/YPH&+F!0U5.5HM?R6EMPN4Y%Y8:HF"
[R'>5\(GKS)GS2GC5.0 >ZO"'-H;$V+" M'=9HFU.H@<3$AEEALZBS/[TD%#SE#1,#0E1V8===D!PA:?6Y)HELC4.1\|%^9V9B_KNY7.%C][R]>(IXIU*7B Q[!9HR^J[%!
M5A+N9UWV%9IS1N22EY%A@=:,OO>_L'C1A_4?D4/9J1#3@B&!M5 9\]RX] MY:GEIDS;:!L$7T%P^4O*OFE^XZ+\I 8CNMVGY4=W]HAZ(B(%0CZ4OAN6YX)V
M+6'2@8@5#G8X7TJ"HF$X#6VQ#>L8TG2HW7AA(\]G85)_40CCC@=0=HN<<$EA0${W]+AA10I6)N M\7PB.)YJ.^-9("9%M1IU\D\2R/.'!+Y G=98XW\U0X8/_]-R .$8O
MR,@]94[%$[YSWTDLG.<1CO BI2;DV@.[/Y1^QU-@DDIP7>"">Y1'JO 2&\5KG#++4,5*/D *3S$M>.QS4#%"U&O9B$APKHK ME;]5"8(@6 9M_%\/A^[X9QM," N&.H,TV*@-
S4DDUF04A[HS&$BROP37:U> MIA(7WHG>@'(RN6X_ I%&UOP0+Q+\?8'(]*F'[_G:-8V<8LRL;RD7C: M?,<1U].1<9!2:8$98(7"$@G$WAB/5%P
MP5&AG+H\)A(I*%6:#;@QKT^R>9BH_P X.O!/3=L\^_O5ZZN9K80%$I99\NYF MW++V:OHRJE1B#$+ 2%MG#O(:DGVCYWOUU:L?GGWR_)/"\,G()(;\F\#
!QZ&B1CW$,SQHT79'-ME/(,7!OB RP&CW\K[WQ,;373@$)-EC9HLE),B;ZD/KAU>I,6MD#.AA)5.#N M44\-%9SY8 M'IY SZ?:MANOM2F$I3%*^,COK%[!_9UY;
[;8O72/!,_6%.5.O!\Z<3[_) Y MCBYA"88KQ0G=8TH0H"Q%$U!]Z4EXN.0KT<\TDRW)%A\2!L7!GQ(D>?E:AL7;5';1.MM$%%/6DHYWTK1G
M.,YF9LASIR)W4O14PQ*T:_!PJG9A$YI"S=T 28@R8):0UA-S7<+<C;9-Y&G\U MG:HE94<(/3'M35'DT;@_4#@9A;-+US">OUL- QV<<<6LRJI^=Z8OF^*0/)-_(M L;;QA@-
G/\&ZBT\$^?]EU&)BX1HX(XA* HE2>33VE+T6I?*N(6="CC\FQ M-MIS(#[*[.MRM9;;V?] 0+VZEWR+7M+H/6#1:1>;^RE/I^S=RD<-C@5&;>R*;P
*MH_%ILY+T=OL\,IIZ,&=/B'Q5G$MGA,+VZS0M?/AL@=W W!I88U>PF"UQ9A4H MP O"M!FQGT4MK=8",Y3(HKAG92P)TR.DXPG"K^1Z"/QR_@\; M'TFW:!
(Q:0Y;J.XWLU:9P^*_RU)6U-^2&QC]NK@ZJW$&1^#9S8-_9I1#3@B&!M5 9\]RX] MY:GEIDS;:!L$7T%P^4O*OFE^XZ+\I 8CNMVGY4=W]HAZ(B(%0CZ4OAN6YX)V
+;R#7S_[#/^AXT(]^Y^_JB)!C'RG;.[(XPE!YZ/.]S[OR+'^X_ M1_],/A-X/Z:@>^_D),V+0D9Y"R*'9P;HB%Y,R/*19A_0?)3*.5YHK0W0/D M^#,4X!HI:./^UD-'^N<"!1[&,]=.YM?
CP]H,>[$CF;!+7=U#TW/VZ>_Z?>]S MP]+I("3&PPO;_R^A;DX0Y@;FC<609.L6.>N@5.W(]8"0>>,X1_ M_1;*)*^???:8W*!4('_=6-7E*=HM.-$"BUMI-2Q-$X>>1R61]PD(-
*/6%8F" M]*O?_?#>/.L "M 7*07MW1)4?SC-QU@S'%@7G0G-UKP#L7'D^G%)N4$8,Z+Q@H M-"R.)DAK-V[G!N0%.WP 69#;?LBQO?DW1";,;T(+0OONDLU4'1>BQ$OTP:LO YSG!!7FZ0-
*M*M36D-Z3Y'B!02A8&+ID; M55+_[MKZPY1(SM.WILPIV4I'K0*1!:%<,A).& (3/&[>V>Y2]A I7L%#M=M\>%(X=5;WG=5D".SY6N:+HE/ +&U+S/QMACZ8N@/-
/O2D\JKX"Z'!GC7,F4X9CY?J,*'/JF[/V/YLRVTQYL68 MW]68M6$ S+E5[6VR;5S/|+R+V2UF]QZ#A3R$,04B$EY1H4[0T2>9P MAM2$$>N[\(?
$PIF+OCA'<'.JB!S6ZA(R415G&+LS:H?:1 $]XGPJ8#5)&)G#9 M,=?RB\YQKW!+,)U.RE#KK&],YAY"G6 '08P"CK!A/#LH%K2$+!!2<9K2[&+
MN6I#T1/<^+XZ0K=X@CHE<@TN$O;[LJ/I P2 AC,,?\VB1>M (2&]Y!+I1P@1 M,P=O94T@<O/HF"CA:0-"94M3.*>0\AKY7N/1BD#NPC/,)QFX*(|_SI0_Q"
M9P0#HC%3G0W1X;,,-(B[131>LLH8GSMU9# ,_3S$Y,W@/=_PMP//[Z4P97 M#Y9!XSC]AYE$C+B\$&FX[V_DH/V1&B0I33+.#PGA%8T@J9PB0"+2-F#0K"-MSBM=F#?\
[PGND;6H_:HK?"]2@+^%$$ F9E7 DEN<4Y%\RB,7\U4'IJ4%-+ISG7V6Z;\H*(]^%B*N5[]^3*8<9$'I'F'JV0S+;>=K(/W>)P(_^&/@VI+@H$:DVYE*V@$^B9GQTP:1G YSG!!7FZ0-
Q#<+Z9^I5 M.-.L.8=F*,HZ^(6*WLS.VE6"TXW>.=V>HUF5?Q'1CT"?2]'W_2!2K4%XD)_M_C6GS'!$.9FA$-@5O2ATA2W5B!FI*O.0NSOK%K1LH'N,]Y'UW(X*-
M./FW!)#D<=((S[MS\(:O65^0'6(*@#5;.UD[!R[V:,JD92ZK|852208C@D)%>3RU5 DT]83"5JKM1Q8-1CY2W+,0619 MZF'UB7E-<9@3_@O'.85 X<$49D\-
*_S'!2N\8%2(P#XJR85PK=ILB6A M&R&;6)-D$Q(@"UU[ZUQGR!BJ1+E221KB9@=8NVA4>4=,X^:N1Q6S,!#W\]Y M:HSC2>3$C<$]T-GQ:H:V@.M2N>S
N4>R]N0D^+FHY\U'$;ME6*XC2BI6E-.M#6'BD#M)5N*#]6SPN@F_.]GH6VB;RABWL/W4-I"3-04:[< X5 M8L/]WW5PYZ=_+0_'+[\.$0WNF
,"_*=#A40&G8MU5,Y80ETFED7,-9E$D+4V MS T^K*YIUU-_*>9U-F1(PI.Y6$1HO&)#6WFY1'M;Y$DCT>C=ZY^B6-F3\UC M# ZCX-YR0G@_NS
80#]G>5YH5GA5T(]"Q$U%SC!J?!OW8WH]Z?_KF("YM3 M9@2^K>.N5C_X.*_)+:*V<;\C. MW(=ZL#_9B$(K]]?`J/YY(]?!M$Q(<<;T>&Z/+6[([-!Q)G><#I"=Z$&2>ZQ
M(4:MP.QCD:<"]A<1>'C0\@'4*M;+1 2Y5.H]8:CUYX'W4,Q2.M5WI;=_MEEC]W!9_5-_1NP%RK6+11"&G#21V>]S<5&V-]`R)4WTC_07YEH1]F]OF 8X
M.3\ZP2[]3(W$@JLR3_;\B5\\D>V^I=]-M]7_Y>/V8!H3>BF@GYG>@75S]9'C(@/=5CP4WXQ4 Q8P;#[W&NL7M(SK<1FWN M+++F6L$!8-
BIJ%%"+BTH1L1QEJ,Y.M2Q_@YKRN]$?_4*#4Q#0N6<"A7E&C'93 MBBMAKV9/QF3(;W==8@R\;S7^I5PAUJ*ZQ MFOC[%Z\^4K:NA+4O]QZOO+E75,IY,5X#;
*2GQ#?Q2;&%DP@<<7$+%N:)(VY03 MT0_]-*Z[V]#I_G-]+7G[]_0\:UKRVS(R@?_EWB&{J/?IC:R YP]3Z MSJOO[WQ%A4'V?I_I9+IIHZTI97?
F#W1,QNVBH#R5QRXQ.P T'/TBR7 MV7US!{&551,ZVN-\K+1O\;Z.XX/^1H@CD2!/*@*DWPA-2 V.7%5U0 MH1/CZ?:.%8^G]_= C0TDSRU!_."?56;CT;R9]W#

*(KL+Y>E9;R+_9I*7:,V3R MAL$:B!&;"5^0IEKVH%2)DDA+ZU>M]&X)_;|O5WL?$WC/P/RE33NB:C+/<`M!3!"!I$-3>IN;&[+D\9AFSUJ4-$<-X8DFM<*..45PCB8L<*
4LC2*,PQ)4OPI MV87@WR>K\2$)<(Q4,59'(RlF4C*K]5PRUW7H6\)C6I) (Y$3JKJH)+V5"F?> M#\|%D%C9!6+E7>5J?QZ_V&S:#A(G.(ZC/6&2>Y9ZV[OR!B**V#> 1%B$;;B/
M.%%IDM*S7D7.^SNV_-J=V^TJK#2C B8#9E03ENI*(4YK"MC9-S>[NL4&.,*+(!HC;K5/W&>06);$5W03H0@#!BX_.0"HC.(9SEU,2 M1;^,Z<7G'1(VQO0'3,])DHAK?
F9O&G_%'L^U;ZEV!W%=_?2$5N&_I+T;FP3"U$3+E MG#!$MYRFZ6M2)PZ,V!4M*N^/4[E(6D#0F=**8I=K[6U&4H?B00A.*%;L^U;ZEV!T \;B'U827>]W2.M8
M!P<>T8HD*;#Y,C95F' G\[H;GL][OY)5)6X"-[O@Q$TU4Z-H*NW(@T,=OV42 MPBU7G'J#QJ46(0A?(.Z'T 0H_=A@S:2.! 2TH$3W*\))I[%>B1Z7;Z$4?2.Q/ M_R -
\;K2H>>8XE#BMA.$F8KD5L9TOCFYHXN9Y188)[_FN-TE%>E*B"4YYA M OG("P^=.;5ZF_M *8%&8**(9.*JZEX2(T/RYC)S\W,Q>8UOU\4S'Q3U)WS(+QZ^ED=$%
M)'0E<"@X.Q^M.H,.1$C(V=V%,!+5!$9Z,G31^J6Z>N,C^WW;:DT1)+6BJG"6C37A\X#3(7D_]@S7;O MLE"W.(@#,K?!Z!?.YOS$!C:%BQ()^9[!O\<BO-Q8E$DL!'P
MP8=:)O'2:5)1:YT-/6.R]EPH,VGI9@$(;6>`DBTR!-,$C+*V+?(*M$G_63K< M9J]!\1D?9A;A7O f"Y5PCS^X*J.C3LOIKUK79[CCON\(N41ES:#6K%<6:-)@C!P-
NJR5&^+X3TMP\-F^9%;DP$>))1;5-#@'C:F M"-G&|>,VN>>+R3T]DVL#-_%K4L1I;9@ML1C9E5L<^^[<0,'+O@R!JA&Z7_TY MV\-8XW8B;UF>&O>09%F).!9CI65C2%
MG(2SJCQ2>+WXT\42'V2)=3DVFSWQGD43B&D"PP+8 .B%,3>9W"H"#6'=-H[Q M=C%I4VB,+<:Y&.<#C#.JSMBS7F>_8LH_YA4>"-Z-XY?0BT!I "X_PR1>BJQC
M,"*.W1U)\1:KW23*DDFGD0M-/RP&+ABX?7W\9<+6AJ6ZCTCSK;MA>[?%QV2?1)O P(Y25*!0W"1XQ$=F>O,9/B(@0!Z"*+#/F53&_MY;Q^4L9FW62I-+E;2^C?ESLWG
C;64_"S=!F#'0%[W:T?!#*V!?,$#240@*CM MKQ IUHVC4@5BLW56.ZBQ._^DD9IT-RV"0#*QPR$MQ_GV/YXI_E*F[7U/L$&^_MP*S]!Y00$:.#$;
[@TH#^Y^\$";DWG!&%U+ZJVAAC"S./0-8/4+;]"#@U-S>?`M'A"\&7:%WP)QGQ*YW6G?L"![V*RW@'&OT7(17>>?H'3ZBFW&UA%2V&42LMF MJA@P3!FMW^F90)%Q;C/Y-
X7C9J9R7 ; .!,3 ,VI;!Q1,PM(4:IP#@CVI4P JDD M!#PVD7M+!,L6':IR>S&#K,5OK<Y%MJ."&<7.@$@% MS$.AL)Q,Z) ^#D0:QEF7:(3G6FW\"M!=G]X'1B!*T_YS%$<,._^6FU,
4V[\ M%[O2\R_66I=&=0R@9C"P-2'F?:,,,S8(>C[Q,+$>%T$V1B:FIQU@BM/9X\J_MMQ8\KBQ79IZ0V6F_/4B+$.+(A3ME]1>^7$,2*I>()D.@A*W0)#0fA-2#\V^W
MZI=YF5+5"7LRH"=F.A-#>2NCV;/,ML3*C+S'[I.W_\83:I..!2$>06D38HY$!Q:0_!& 7!AL'3SS$T/Y_N'Y@O)=4+Z/G;XC+,M_ MX!1&"AV;,N7[!5SDVX7"C#]*:$0-6>
]HW%9F(<]*;0?DNA'%GE53 YAE?$; MPX%V'1B*B3T+,G&H6!Z>]VSN=:_4'"'LE1WQOE:@1CZ5XXDG1,^#%;PO4\ ,O^3&P3=)3Y4U M2Q&;] 9"]CW*KBYV++J3K#((O1F_%@-
DQOOJD4)/R(9X!9:#|\Q3[MW,),#P;% M]Q#X!:$Q1,>-;-6DWQUSG1JZMKNVU01&_O@YV):(Z'%%1-8'95PJ;!=QPHV[M1D@?<67XY((AI2#S7(1"6=R1-,!V31%5JU6Q(OI-
&>06)!Y;@%O%T"2#.* M")01./_3:L#>|\81&"TF$XMO0P1 MB(<2R47$[-WK,?C-H^X7HO)O*QPW$@YC_R1'4(_6U!7@D/V9^'=Q0HL32IS0 M*Z)!#RY H!H# 65'
C5*:8M4*@@RCE!D$9^H-1(@*CUJ;I%SH G2JZO_6[Q MGX/XBHR<9%J#K1,[8&:W8/VK[T\4RV;PP>RI6*V]4T$R#'(#J"2LLNW^)$=-
MA(ZEHZEXZU]\7>1Z+0_\?.C_TKN1%4)X+I(0PY?F=|3FSOX9)D[6.8.WG+N M8#EI+G?2?R(CI?49PJ--QXE64\,"7.[PCIS1ZZ5U&)"W?^[K_Z[8XCGA3 M;4<@Q*^)),XQ
40 MGRG"-+!#FCI,/ ,S#D*"L8Z?*1 C&,"H3BI.(W(@RL!SFP+@OI#5ZMDD=); M@BH9E#+YV9_!LS^S*9\4;63:"\0\1R:2P,D-",S2E"'!^80?$*/X#9X(!VH[* M6Q!>^N?
PCUJ3Z)L\'5::XJ]# 9AZVDDR'/IRX2%QBIH6EQ8O!)$^\FRI MO.YW0L7%6ZVP4]0Z+5LM/FGQ2??W2;^HL\EU#@[P83K]DN^T3=2G"^TV8: M%RF"F:
(1YEMEVM7E#)A[(OX5//[P-]BL*2('!Z![RI4 M:@*5PfC"@1X0_I$TOD^3NLD 6W!LWC0@!T)"[17^#>X$HX?DDEP$WX5'-95J MGK"/J1.9K5N$F4QT\;+PF$+CVC-
/OJ'=D@.RKP)I2+V;J4^+"UA*

*TN2ID)L7AS;EAL,=LWHMU/R[K?M&<(A$0&8R#"/E QX"K@JL!"]-@ET MBF<@VCV"!I0!V\CY)],>UQCM!1;K5GBIU@YP"YE\'T-=AH>4%?V; ?1.J?ON
M(_D\^^]Y6OW83MK"%JO#CPFO]P ^8B$#H7YF^(ISM7CRN((02;T)#GEL, MU& RYP4);=>"0CMVIW4!BE7?:C5$("&M+Y@C?
#="NM>SZJ6%"%DD%WYXIEBK1S,C2O24J(DG?,$U0 [R!:U8(C&=RPF03",4EX=[&'8$/!YW0,'4< ML&2NQG$*=[7Z6E4Y,U_8D-0TPPFD
K;%PAPM9I!TVT%RT='WP/B,"0L(XA=9H M&_/9$;. RJ$\V(-R 5@<(TKS"'"FB1T,1>%JB9X3M5 M/D;$6,%0X1A MT0EE'$1NE1.CR!J:R@$6|IP#Y60T*%DY5B(-
+#YP"S)|Y7PO9M1ZL]=MX6PK M>____P%C;P%+A:(>:<|U3 B9T_*E0.%BUS_ ,>=?\PIY C/!5.)ACR)AL!?; M#4+LE9NIZB8JN!,T90*,Q*_&5<$*)]1+2NXME H^
ML9./3BS?.'?'3_LT# MN:K_7[U__>6U4|)7P++)N,3'H|=\!>]:2/<#)PHQSD >N1_ISPB,"K5S>P.T ML$E"WP$U @C?#A8#[Z>B#%WV^9VLVT5/)N M,G?
DHO$(>G5DP4RIYE*;S+M5I=!E#IV[-I&9\# /D MR'MC/2B*:]:4-9I#E00BKXVI/R&$/7L3N"(S;X6?!:^CC|IV5 P(RI)?3Y4U M2Q&;] 9"]CW*KBYV++J3K#((O1F_%@-
DQOOJD4)/R(9X!9:#|\Q3[MW,),#P;% M]Q#X!:$Q1,>-;-6DWQUSG1JZMKNVU01&_O@YV):(Z'%%1-8'95PJ;!=QPHV[M1D@?<67XY((AI2#S7(1"6=R1-,!V31%5JU6Q(OI-
&>06)!Y;@%O%T"2#.* M")01./_3:L#>|\81&"TF$XMO0P1 MB(<2R47$[-WK,?C-H^X7HO)O*QPW$@YC_R1'4(_6U!7@D/V9^'=Q0HL32IS0 M*Z)!#RY H!H# 65'
C5*:8M4*@@RCE!D$9^H-1(@*CUJ;I%SH G2JZO_6[Q MGX/XBHR<9%J#K1,[8&:W8/VK[T\4RV;PP>RI6*V]4T$R#'(#J"2LLNW^)$=-
MA(ZEHZEXZU]\7>1Z+0_\?.C_TKN1%4)X+I(0PY?F=|3FSOX9)D[6.8.WG+N M8#EI+G?2?R(CI?49PJ--QXE64\,"7.[PCIS1ZZ5U&)"W?^[K_Z[8XCGA3 M;4<@Q*^)),XQ
40 MGRG"-+!#FCI,/ ,S#D*"L8Z?*1 C&,"H3BI.(W(@RL!SFP+@OI#5ZMDD=); M@BH9E#+YV9_!LS^S*9\4;63:"\0\1R:2P,D-",S2E"'!^80?$*/X#9X(!VH[* M6Q!>^N?
PCUJ3Z)L\'5::XJ]# 9AZVDDR'/IRX2%QBIH6EQ8O!)$^\FRI MO.YW0L7%6ZVP4]0Z+5LM/FGQ2??W2;^HL\EU#@[P83K]DN^T3=2G"^TV8: M%RF"F:
(1YEMEVM7E#)A[(OX5//[P-]BL*2('!Z![RI4 M:@*5PfC"@1X0_I$TOD^3NLD 6W!LWC0@!T)"[17^#>X$HX?DDEP$WX5'-95J MGK"/J1.9K5N$F4QT\;+PF$+CVC-
/OJ'=D@.RKP)I2+V;J4^+"UA*

*(=0N:2:=D<3+%L*_3'1$P5NL@P6AVLW(]]B<@O79:?!LI4]6DH(HZF;OC_U M/F J69@^LC]ZE=`?BE^M[U[^.,6EGYM0)D*)KM%5'!*_+>00T<)-=^:,;#=$<64
M,M40:!5C&0G'Z+00&3',"7OC"!+C.WQ-NCL&S+.L5AN* ,G>]8%>[>YJ$KIG M_#=V_S*)3RGL'F75J /T5S7$ -!A%4A1.D1?.ZMKC#2T@8CI$7AR(Y<^(&+D9VV8\EZ'H0Z?
47HBJRE- =VE:NW MLJA6>V#P&IKW@IO">]DLRO0(_F"3^7)V\9O<=VW"#. [-9ON_8 5ZE/R1L- M6_@E$=)\ ]Y^;H07%P7"MMJ@Z$!E$!)*
'KM:9'>RWA=\O>AK#U8DT$&ZG@6G- M!)H^7L)Z:M;2\(?086',Y,W W=*SP37QF52 T=`LB<3BH8; *HFTAA^GJHQ4 M4V:/,,P-(@\(W_ZQ>(9)[Y.J*UC,L(BNLP)-
LPWVVM.&6-MS3:?8_)-BP*%91!Y3MUH >5/P#C"_XV]\3GT$E4@H1:D M;GBV-P 8 R9-1&*A3AM:$0"C1]8!.8Z)[%$[]\S,T](G()%(,WB4_"_O08B M-HUP=R]BC-
1.WSL@3.&#:./3C[Z*BD'QR4E8&7MX0OP_]OAX'"'"4 5)DO!N M@V^E84.<,VH& I52GBQT+V'H-@D]+E9=^B$)@:A"?@/T30?G[6&KIRM5+W") MA0C*OR>(S+#FAZA;
(),J>V^SA49-H?A>0[#@%,06X9H@\(J2D!XTJTE"6;`MF-#62,P)K(3TYH.VM1-N5=M4*#?EUAT@>HJAATK@=RFCFK;1KR8!"/9Q=#CR@=M+3+(Q"KZA1
L019:41L5>K,PT>;2LMNZ[*M:9GQ\W8U26YM$*>C@7*#*O)@M M?2O81R@VY$N,.. .36R.5&[%)T@Y1$-2PG:AIY'!/KZJ2AY(K0<=6KFM6BHB
MDTO<^!Q. L#$2AP=H>.)?E5_0*\]N!=[;XA\AL(QM6\,9!-)0\A=:$E;8,-Z MLPCWQ@>X6KT4)LUI I(VQCE_Z?!DJ6!^^V5P5J[_Y0QA*LJL7W\&GMZ^0 MBJ98_?6O+U>_ +X&
< 7QO6V("*OMA6TQ;T-O8 RY(_OLX]-N3K6FX^^U7^V M^Z9O&_MS_*=B]>/.[^W._C+>VG]!5U+!|779M+MJ!?H%/ -B4-)9.Q.?C|/5^<{? M2 .?,$\'#W!PR^W-
S1DUJY=+ZW_#90W_9[QCP5M^^KP93]$O!UV/+?V/:,:W%>Y"O$44U^UEM1 M/;HU0"OIY.*^;DKFQZ*3/AJOBK'WG_C/ZAC!U*NXW!H!M 9F/UPG!AL UE M7ES'KH6+)Z\
(_N6F]&EN!#M97W_\?^[4?2O5N!A_A M>R3G![,$>P9'Z_?^W_P_^D5_\?'K8@77WKI?PB# MIV_P)TB2>PRR7ZPW_A+ ^!^"6L*RD;Q-^W]_5P'62K_P"W11 ?!BU:5+H,_?
MH01Z!EOF?MU7:Q^#5,U,$@/A"!U:Z&.W6;(00+5 MJZ4SIB0..0HU;IRJ4D C\$<2UHR$M^?5+!W/,3%,Z B.<&]2PW*I*FBBT MLVLZPW
*LP4(5,&!B@3;JHQ@S(6=I21OG&5H,0H++C6:H.;K[#/-R>U<+*6]RA R6$AW>DXF6 M9K(S"X439:RIB#>HC#W0f*BQ8XA'09&9+;NA5K]\9M @!OQ_)TU9?^HU.I!
M&.)\'E9#]TVX.>IM(Q%1,W!5/QG^1&GNU $;6 L6]_U+ZL:C?QOZVO8^_)@B M+3'TR+WLIJ).:>8M,A0WWF0[:-H2L1C8L%\Q=C^)'1.VDVEW9P9R;FES2&=W M'E-
2I+VU,%(0IG,JC1/Q+(3]D!5.3"Y5%@%XE M;H^76A-'A6MR8P: M!E\">WO:E;<\'VH!*,=`Q3'V."#>,D;(-G3>1D .@1$!C<9PIS!Q<"4/F%Y9D M7.SYG\:?A6#+ D3$00.!LDEV?
5MVT$D2#2P?VH?!KG.F^=2;S9\O MS>;EV?QD6.47-_S(W?"M9B.6UUI2HOGAN>6P7ZSL059&Z0XVPSG3VCM$^%); MCT4PF+O$@GG/XV90SF#1^<7@%H-[*'X-S-
6/IL3,C.$L4)Z*S]GR"='E5YCLL M[_EB>(_**'X%* "#/|'(/6#F3_O3#S\YXM&1M%-!1(W5,8?R)<@0Q3ZFEB:*;=>ENZ;L,C/RH2!DI.M?E
M;3\B]2/P(A&OD2W;CER03UDRY0[">I&IHKOJJRDKA]DG!N1?4R;\P%UKR\AZ9FY,.%YWK%#N+P6C5V%(FG]H GV@#LCWA_1GN50O MD59
Z)\U'&1,*+MMS2P>!VBZX#0+=V!%@KDP+X'OC.HYW/-Y-%*^2[CVN$[- MK1/ZUZT[P!Z3.DI=RHHJY< KA0S:C'5NU8S.J1FU6,+N])98%C1N+%HGD,",>N
MR\5M+?;U0/LR><&A;=P (;?OQ0*"V_^.3)NX+@[3'6+A=3.V1FUK=4H]);!6/ MVGB6VNOCLAW2V;%B+USA.6 EX @,.Z!BBQ@O" I^?;JCWG^?2NUBEXM=QG9)
MO$VS"E;W+!H^E<[!CUU%(QKXIH,0FDJVGA@)D[!P;@ZR>%G6!#)48O7#*RN_G MJ]5K8C)(_R'/$"PZ)#=+E5>,6Q>HP?Z,\ &L 0L+Q3J#\!%*[M51E^;X(V_X5
NXWR;DLIEZIGQ9M<-$>E:D.P.XQHC.GC7]4*3FW [>K,Z6!EF M1%,,4]{,LQN6,R_*@YWNGNEF4P8H%28,?AVT(M$!; M###O[']N--/=(
M2/Z$%F\8TNCPGC+9"^6_%7C^8!QFOU@Z,5;B)N[ZF!;1/?1]&U)"'ONF2^+[M9SYO:P/VU:<_G:?&5,ZF6T>]_5::F\X>E%I#;1!Y^S(,DQ ^6B /3NYOB?!)
MNTR#%1EV+L.W1QK*,Z=.E>?.?0FX!>V7 M\JQ^Y\+#XO!+&P+NAP02T>-#/7Y;)7'39QH%"CV1!Y^!Z/3H,Z37MW+@!D[R>ATOTQT\T)1L[C\^I<8 +/%;VM#'LV\V47K
Z"_M\DFJ/628H-H#QMU'G^[%E6F+55T0FP.3#(L MT51NX>2)+W_-B((_S+1931++#"HV\Q<#\ IXA,Z$Y#1#T;48G==($>$E7$4I)9#PJ'>[!#Y"P&^ ^F"'"
(C@>L"P7NL MR=?&\X)9U9+[*.(BUP!262&G1X,T?$3Z1)F(PJ_H)5YPU'5I CSR@EG DVH) MQ.R(9]>=_[.*-8@0F'/#O5W/"48(FRTVL&!>WWLPW-EDI,S\IH(G1-;H% 1L
M^K#[3D :S4#5?FEU+5;`^$"N'G* 7R+.YSX8L"+ =_?@(E<-N0+$3"_W_" C9ACZ9^4M0D+HI41^W8<%H"& MP7VI@X($'"';4UKU>_)/F$E9JE?=OQQ&1I((_<[JIOF\99-
LFR2!T#^%-&/ MFCANY=]"+,<-3:E,*GF'06(""49"N^D; +VX\?@#R/^*SSZV4<4]*3.&$\A_ M>@R%U&OE-G5+"E\]]=U"3AMS?_4^16;14'^C1)2-.^:VW
MU+$CHEVD\UZL<+'"'!P 8.2# 4ARU'2NHOGAW!_-A=;$"]J2047J3>^-"Of?M MEM1NL;>W2^T8.(+R@98C,#VQXO+NHYL[7S!FC]OB1,@R5T:/2MY6PS+6O'Q@ MI?
[HP=)8MU9+TZ4=<-0$H%+UV!>*--YV &W M?F=GAGLI F]4K#2+[E!XF2#7,'"G7.#,! &A/=-^% (0L5C*<#6:N+Q8"XX5 M4Q$3!NM>5V\ Y4'"*>Y7OR.[-0+%F%[4]+U-
PJ_4U!+U$RF43(!11B?%3)M& M+3Z)!/PC?H:4!W)P M:52B;/9*>#USMY3.M3T3*.0-!]%IL!:C@M7P=@%0G>6B&:8"0!]%IS&I@R3G@-M)CASL9QB^BIBF-A1H$5PQJ!
]:6"SZ;U'KUE@;;;@UKCL8@R'C4WV<'>3*>+$/`M;.P!/?&38]^<-/N2!%R ;A7\EP^J(]):8OX95#A9VH,\[N6)BWAAQ[PFI54
MX!&0T$X"VR7.>%QA1A<9L"CIM$0%ADRD8*)113N;;6A_XE8.;I8X&H+7.TM MX6J+FUW<;&9B2(.W\ 3^P.<,+<'$7W>,,SA&7\4>>>VHZ^6_+/'5VIU:%N!#
M^E9;2XO.QTJM#P107&$79T?Q535#9*U?K,M"1 AR&B30MP;/Y'%%Y/;K:T MWQ0+'=2O^FQA,C,I=@400_I'V!V:RF5+)OK09N+-I;"]2(T'0JC/T/EL,"? M?
\9Y4IF1D:=XX"4[]+(0KBZ)[DB9!R96@-#5(U3/O M!2.M3;'U(;#=<<($)_C'PP9&T"$N(%)/.+C5C&S80D.A!-57$E UQ6FSF ?W+
MW$AY8(++QNH1*T>QWN^Q]ON1U!BB5!+%;&2) (+!L85!L'$CV3(LPE/?E+6_MX!2$HYCYQ$U;CP>>O^$0G^Y[\M!%2%[YRA./2D)1;JXB@PN!7Y4RS$0H2HH"
M[IF^I1RJEI>4[Z.-A+.8=4#K*(AG':"\8<&_M-/;H$(Y/\'&Z).[X;-"SHA/ M!TF![G1"$%&Z6L5LI%0/\;_4YS!G=?Q%,FD0:Y(8)5W6B>)A(5.15:STV9_H 4>M%UR!;TN;$2*P\>
MQ+*WT0#XK'G^A"M@"$9L"8!B&7!=E-2^]I?!42V1^V"W1>E0'!8*8I(_\N3\HO3UO MM&F@_Y7J=EL!4A$BR9#<]H@S-D?Y0A17*8,P"\|&!APB#<:
:O\.E M_A^\2W!4B.6'TLM&8,ARP$I^17?4(/1U.M-7/P(<\S14B&.R+5;E#=QN;M1U MAIH<>_Y\3+7#FMK -88CAC(#*E_D@.1N!%ZL#/)_2H<3XUR/0):C2%.--<<'@
M'[D*E[LH+!->-W"'T:SHSR%#:0U%F)'2/?_AX21' M'Q=I$-I"9]ZQJT@NHFH@2RNE.$[EC]4M--E9NO#&+ZCU_89]\Q^N]=`S%GI> M&!W[PU'!ZS-WU;
[_/-YC02JUR1X3^_R*0LFRE]|.5O+T!?,LQL/+PI+O+!P[?B<5Q=L'[==T06#> B!MI E$'! M-B?TNP2*]_K5&__M=M>.)-.!ABQM\<-C>ZJ"H1X6QC'^_ %#N"&<^!+^%LD=2!
(USS0=CYW+ M ES[8=Q"\45@CS0E+E?#:'I? L=:QTS"/(,AM>!12?B#R2^FNYCN_4V7Y!0X MDO!AP\Z?TC UP5SF,"3D.H*51S7^D.D9H0<>]>QIPPX%:UW&?!9;/3ALW4.
M!D5PZ^FH-?K$R,@B4SPRL1)H)PO!P#"4D8)26QJ_0'`'DC,\1;Z4S*JP^$U, M21X.AO?#%|MFIL\<,OV2Q$-(.M'CV$\8BN)X*^)*\>>C]WB,@E^+OUL?U4')
M";HCY@X%S8!MB-KU]]*UX[*VB?IBE,F%N<^<<46BG*^3DGP @ZVV=6C:_ZG##\MDF>&'H)*HYT_]6^;],!0"#\92=).6QS'Y M->WI&$9%-8.3C[;ZV&:.8$#DE%
<@(!XF4B7`_M+KO&WU3:A%0]3>/X%$!,E MOTZN#HI /PSC*H2.I_@'`MAYFK/=PS1"S:6H4W1#5F7%,0^GQZ=X(>(0%3V<_PM/5_BUN_%XJ^*#W9P\, MRMSNG:4S .
(QK+!NV;I7 *OS-U^W&YYB)(L-C'=S2Z7IMU22F3]JNFQ%VE,* M95[!&5LQ!6+FEK4A>*-L]MXTKE8O:@@^KU%@0L;';]VD@1/O+A84BMP'IDR_ M&-
#'+%9;ZIO8WU*9UMF>#==:U\46$"\?4>@ 8,/Q\P77XJ_.#\)#6OT7$Q.2 ;<.MFS>WU!%LZ.W@6R#P8,M#]FFNDQJM,E];,3 .^X]OQ4LW!vQ&&LABQM%UME5%
M"8C>)=E>YM90D)-6VK^=\L#$L=SM"&[_6)XDLSLF*(B M*C31RQUI->@G"K8G*$7 M-@RN)1UBM@-86N3<1@^N!C(!H5&%S9HI37F9)^8"54"0Z."6_92<(IE_E#)3
M]A_UF("*:,=!C/T 40, L8C)-K$C!'[=!#;9RQND3A^?$_K4MTR!JKPC;122 M32VHL+@GLCB:>]L@K *:A@=(PXEN>&)_7 5#I3#,]++:Y&@VI*7A;/\4>C^A& MH#YW]M0U<4:
$$5';9[S-H;YCEX3EA)AT$&J-BEI /JKQ=@TJ5?AD$&5 ?BW\ M\;!UX+'"M-G;77N P^+H-@C8DD")<(2X/N:8-[@N"#(U*'B2@_/LD7OVE9&4 M'2^\C2K@F&$6YF/G
IF1@5>$89%_VM*6[C\8'Q6[V\!GZGJJR?9;_RW1=^X M]!LOVL\T/'#+^H=# 7S3=E5[=C:,6;V^$AWI;ZL@R,'U"@ES,_"PJC@92W M3U-
G/46CX[/(/#8_H_>9=7D+?,_>9PF",%MA6;-$K320X8/+R[%SM?K)KTFW-MK5VOIU@[#IOV0'TS_VF!0A)+>600OK>O.&6QLTTLW@$L)2#5)22\D\AJ>0&X3
MZ<5^G,7M%GDV)G$!%&;&(Z>VP3GWM0\/ MJ7\ZNN1,E@M2T/-MFC@E1PTV3[6@(#2Y/48412N>'1W*'/W2,5LMN4_7XEYV5C'#.W
M1$G,PH+SK:,;B#?K3Z@K^1,X'5K:5Y:MX$>)8__R\}?HIIS3:S@@X1&E/A/*M!#[6^>!8#@R(&)A57[+29^XXJJ8QK&U^_:8_;++)I>B7X/[DW/X@A27P'@=#]>6 MVT*A^8%T4.
M2KD1*]/ DUSZBZ/7NO)=H>P6BX P'E*!^% MU['PCU.X=#R1WFD+22=/QOH.E!23EJLU%[0;\(M'JKJ_[,-2UDP7#ZSH \1N4,_8-^HH$UW/O"Y6.C$B4.C,E
M94B>M<#+_\/%OVVVDA7%[-+E#523<%(MT00$^0G=B>^`$?PI@^:QVPGRA^MQ MA&?'IDV%/SFTI:K&\KSNM(D_?!OO7;8,1&+1^\;^NGC&<TQT74O"#\\>2ZH
MM#0$@.R3+YY_>?*+ M#?4X)Q.7%&*"'"CU4=4-8G63]6&CPX1AJ0+(\5'!#AO9+74G@L=2R,G=CN"$E ME\M[#S9_L21T5G!DSKQUL=1#^0\LYT#K*46(?
3."@RCUV_X&L(71542CZ]1, M5=;OX(9]NZ7;!.)T.T2V'P\PUMAN3S2[A&2T\@/ +VQ,B!M_'-=A"_H+@,@'-MU"'JP W?XYD-(3>\!B@#$5;*WY*_T#7)RL>*>.W;2Y2L"K.*

*M3WAK:.1"J*OO&ZR#G@Z(97O1(N%;SMQM)=Z56NXX!8G;>7<)F'#H8' MY8.DM99'FK?4PB\T<^#G"%>=-,)!7< U3'BJ6H@|[^RN7&IO'#%7YU*

M|U^)91W>^8=&A.X^T#O_@FLW[_RS?';WG^"1N?.O5/7WGEQ>_CVF[1A<&K2Q:41"+YA@UKB5!G[4-QA M!SV=PIQ@^LT6'/YN:"O48:$0&;J@A,#7H'&@?

@7$38P^Z]BLE/NKRUNS+^?^-MIV_?B+0[#M_O<7 #?*Z;O1.VG;#=N[!%XO5SNX_X_<;=+\%"B1%SG8KC')P+ MAHQ,YE0]LA/,G6#>NV-ZM[^#P^KEK]PBT9:I5<1@?*

W:,"G;ZAVR69P|<>)L.HM*6S(ABDGANA7E.C@)V-_M[%M2V6BAA74[Z=Y)|U+-Y:N4\BA|VN7AE1:ESF 9(^FR%T>S25UA\G-L!5

M\:5&QM/,8F1C5\WF8'WC\3OIWDGW_>.7Y&4%LI@HI6")>3'*[3?DM,+?89]6 MD<1I%;9]-K2V0E&HO3J;G>CN1/?>19\3P?&/(]V/%M>1FH&EAV%F\/>T8XCKW:D2J*+J

M>>4 Y.8 (7DK"@Q&47ZK]T6R^>V@'[=L)KO_Y]6_^VW0U!1H2,,%0/+2X$!@ M=M0V)]7XIL6^]+]ZM#D8M$.ZX+X\ Y3/B/SF!53=F-L_ MCO\T\][.-JZ=3G

2QU/."21[.6;+PQO>V-\;'&&RBQ#B^J*W")_]6:SM M""S82R_X%?$)7/8#;Q25X4I#+$E8K&IAD0=L_WI4(34",5DRMQ*6WY4- "6X M;D(#),EU./H4A8NM.

(0)0Y111F)P>42QL8U=W'Q MWVQ9OP/9:*OU<74L:@-#.>;SL"54%]W&_++Q>.T?+(1TD3$31N@*B"DT5:7L+>,"LI M16RX868@;>8#6+7U"*LE1BP1>

JZK@6^0YACX74$PX48O+95'/NYIL3/PR\C M-L2IS"@_K2X+3X?*(31*GP31K R1O9E#3X]}"'@/ZD:M'<(9:*,I7 M!F^^_O)K_M;HGGT!HUS$TJXMH["N_XBR&BM0!\=A,.P/

MQZ&GF]LL,%TP<4D5_#CH]0]0+PF-+^CL!;7S03%(4<3(F,Y.!UJVV8U,Q]F1E$+SA!XTOPETG;I*7SRM"!M<#M M<12-,!7RC=^Z1=HX15N=@P3;=2(PVSC-C?

%XQ8:$IPOI*!0Y=QWMT MT%:$B+4(3ONS-",P$\)2MRW<&N+RU0-4AJ\6!R0 MXWBJ%+U>^S+' E3)?/V5.PS_; O?,&OO!"^2$=5*&"GR22G9I-N!

M^]L:A2IA@M(N%M7MF(1WVW*OV^)VS!4^F 5Y=C[>Q?,[=(B9K-*&("DM@Q=[M]**E=PYXM!WORFA&ZFLVH+DK/>]%8Q\3,.TM(_1)!2*UF[9202V&I7S-6-*

M+"NL,,.@C7_B8V 0A'S)H!>1H@:S-4-N>E(L2V>=O,CL[J3?TTE'>R\RV#H$ M%&9*X8P6P.!57BJWK)C:Q@4 ZU6(L=EK+,'/1X,8_E7O=,,?

4#ZX.P\;:@FL%QM;H9KMP/WN@.8Z&;\5[&(9V#%PF55>I3U%HK2 MR9>#@UREI(^"]I:XJTAKMV6R\8^R14UDYE!;===.V,$\D?@V0U^@?S785K MZTJ=4P7X\[#

,-9A(1\)L)*J&30!)OCUFM$T9"6M1!D6&83HYA1YD99+I[A6 MV/P,)54V YV!OY4JC,L$ 7"YQ*)T'BA_3U9IG(8,I8P);^P74W\-1:F "C MDCQH[=F=I0A4>UD7%#-

G8N.BNOQ7'7UB1A<849P[3KMBKUTG&?^,;@[]+XG5V M$,ROI<:.)JK("AY.Y03L(^[\HDVLL0%'7$":,2#+&LAL-_U^"&Y"1<(P$$PW M:IEN+:.@IODHA4)"P7MS2WF.(!_

Y8!OFAK<2]<,@O**6- ,+*6)\75Z7A(U7 M+-L.OAV7/" 1D6|<&]V.M/80>"<""%KDY2_N6#DIG(*RIZ,FHKMRRGX'PY9:X153F%,Q!N89S FC)^5^"6\V]?

R8-LGA5>[OR*<7Z3$'[<9F]I;-M!A=6\(MFIL\TS20[K M1,C##'055:IM <]R=AD3[\%ELE@)2X+6%HBTK&I,;2^0"WFR=L7#/2Y2!$_" M=/:1*;$QC1Y5$8 !$,N22HLLB"?

E)4DSS?R""(I:!,1 M H,T &&>6?M_-@IRA_#WE$WMX<_"G#%62;1$G HATZIW1W-8TJ_@CZ5S"FR M&E-#KJ1D;S^^H3*[B^10/V.2I;GW?AOP N,BN2+65 R9*2H%K[-!,*$

(***.VY1Y!9ER.=(9"S7Q%#?&<,-<$V E$>,B:P>]EPCSDPL5<.K*.2,P$ ME,>D)@N=U\YR4!$R #B?)IN\]1=A_2.K%X,5'4X/H4JY+-"OPNUL'D#[?,#

MLXTQT]QO=]BYHG#$).XI?!M\[SQ<%7.F\/%P$*-M0S_3OS+3.;A#<7LB,%S M0_MB#)NU' 6\(E^NTQ0*N=Z:!?P03F-5EP.@.P3]D$,VE,A]7-9M7,/'Q$V0Z+T M95"OA"

([\W6551IT"9)25(T8"F,UFXN;E9]G!/C?$E!, "GZA6'+!!2[(^[SA M<75>IF"1,5B&G4M&N76T7?:FVKD7.\|N^6H@U!6 MHH4#T*551YV2R[DG+4'R'T=A,"I]U$=Q[

$7!>'V653#3FU'3BAUHJ4-? M_U6N2KS%Q5P>2^36,L{ K/]=":]AD4QO"[U!*,BX%X?]4,79] MT'K!ZF|KJF(C]:R(T =-U69)ROR;3$%TRK8C:L3.O5;L74H0IH)E-

5A4@BA[]B>+-+(WCW-HH@55DO:"<[@\.*QPTM,,^@<\-M-*^Y_%23Z#.M@_'LK*Q+6[H!&'STT(^)'0PQ)#;J7QP?'(XOQL>SXXO)P61Z M<9A,QI/C*!H>'^Y_?

S&Q82[XS]0';?*P,,"_IIL+47[X#]A6DH>__I1^Y1$V MFT)N\,.RX!>X^=#,"@8$\>7-J M8@KFKU[9C&)?D^HTN=Q3+5C ?\COWX,G -Y.4I@H!F4.R-3$DT65V%Q]&LV+

M1%)A3YPG?"RBK.028O,,>N4I#F>4"T\'IXSD^:Q)]#XECZ"Y_&B6(.5="I= MU-T4\+YC2F"R..Q8A<,+0IW#.?)YW/;=7"BB-28T^U?46F \X;!]LGAD91Y/

MTJ>/K,1#,,C!B\WE&E2+0 QW>Z^2"X7_*UXMRU?-H*]:(TTZ%:-C#K9W5 JP M1Q99QTK?8+Q>5D[D*R?/'U$]TI]:4A^OJ$;@F(EY@ 5(&%^[SB00D]EF@4J[

M1$30LR15PO^G?C9(F.ND&9D?$PY6,_ DE37V!'8%+&-\OA8J]_N MY*R]C=;!X%#QJ.V%X;E*N 3XA4!=*EJ8\PB.U(DN('LA&(HWP=0/X(]0)+PN

MRHJL]5PB'<I0%A+]G;&;=&7K=SWRMO"&^/;2,&B ;;ABXN#6B7FD.#_=HX! MORO,_1J#(^CG?]QF6I(NBFT<4A]CZ .T'[!SQ3,I"C;O>(15>)*T6.0.+,%:

M#YLA];_-2R0X%S-\^#H8L5<]UDD\SM $[&\#U_O# _XJ6J^P':C.D7+;# XW,!\YSF%K//@ MOI ;8PWSCLA?/@=5^3)-YGD8G)ZPW/"@IE2E-66OVLX'YC)TOY:R#)88\0W6

MX%Z4DL'&C#DLXF79^'95I"L0Q"R1,_T"__XAX12VI P)H!X&C0#U!|^&J?Y MYD@'(;2W^&UO;4:]/L-,XN&"'^&07#H/'@=] \D&T#$3L@M,8[""%NRK@@46*

MO9,P.Y6NJ"SSJ=/GB9&FDI/@95'/81%+.:G5;!^]A8!C", '"$DY0RV5/%&@PP MGCO+%VGN5:#M]\<'1\-)_V)P${TNQJ-H<'%\>#BZB(ZCZ<%^?'3 >()W8'EQ>+!_?

#C_N*BHUU J;>A-= MEV"4EO>LG#;S>8E,9S@8#@^/N!B(3(\H0@A43ITK1M$; CFTHYIDPB(K#N2I!Q MJ;K4(KUQ"E!\1 LA5 *59L!$a%?)7)V1V508!,;2?"ZP_C9-

9DLG=7295M>:\[MFS 7PDV "O9:H4T)_Q6:(C<+ ':P<5;GV64;@\U"P_!HN3L,44#IP^'^ M_G%_?!$/^_N@@(Z2BZ/9_N+B,!Y-)@=`X\-H?]920..OJVE^MUH!4^8MMJ6?

M1[,$%/M+4XXRT/7'E=.2>)^I^UMH_MQUVE(\OK>8]W@7\]|/%O']7A\;%9-_ MC*>#Z.*H/XTOQK/1Z.+X>#8'"%7ET-#T>Q,/#V:&G"M^#[7]_1M=&D;^K+GQ_

M\N$cZ*S,Z/RK + ,#E/H^SWDNM*F-/"%J8P#,]20:_@ =77FAQ'W3%7??]P\$30VHX_%+A9L=^ M)*8%2M1.,#@)E OO>@2'*8F3@#Q@.%>]D(D$

>"T^@O$]*CR/;QL8#!VF() M_/#C:2\XL4'Y&_AL+Y,%Q>DG1?Z),6AF;;'$4M8H|\C&;26@8]4QNEBIP^*(MQ"3)$F3^1(2_ZXQ..E4&T&@U L,D;.D*PX>&JQQ\$!@W)ZT*

(<%$8CNJOTUC MBM\P?P6-V2XGC-Y?*ZHYSP0L[SYMO/L2WYKU:$^P]W+FS\YV*&9;+Z#P%59IP\|)=+04Q(:,QGB_I!.2 M--!8W"2-\?WIM*@)8,=Y-

>6@'/9>*_/O08X2BK9^+, (Q0_/N8L.RR!Q*.#U MSNK%XC&*R@?":]3X-4T&VSKQWJ7C8&_)AQ2DCU;G(4*5CK1V1^KB5E67BO;'-M'5ML36!4+POB?

%ISW@9K6050\T6S:QKAYX/,? M@^P3;()-E9@V#DGD.AOGA'-G*0;".#;^[/?H]%WS/G(Q.H4-MFT=?<<]PN_K;;YB,5[Z0#AKV\5$!=T#EXHQR1$;B'QIZ[G$_;Y

M4N2XTD)W8C87_&8L1BG-@_@): XX_3RFA\3ILM%PE'XD?[Y.FG^I2 ,,73F>,)2PE.L)E$G&+<1B<9=/'Z+2_N\+>1WCM_MW#,.[N%("//P<2V(L MI(P!Q142..KS+

4<$XJWV(P67\MH"%Y^*8BQ9_^"=;DR!3ZF&1>5]U]4PX@-.M4XSB+5,^/"EU0()=FZ[O:FU@(VFY0^[/E8IYG5#?$=*7(59M=)>D"1+1NT=XTX^+Z M!0K\8 2(?D\&;7+% 7

Z*>4TQ;>43'[_:X,SIGE5Q%3RDL%$=52@$.\7-&1 M#J9PG&M&&-=OYT2Y7%ZG,RS<4"0D'"A\GBR"'"K:%G7A>7-F1\(PP;^

M\&W}Z;957'4V4HCVPN''^RJ;PXWS\,.#=@0K@ 9!*?VRO)[PXWN*2Q$L_+&BNA] M]'N]X#<#,VM)5+/HBGNZ2U"4U& M&R4]O0AB#1(>_+V&I=T[76=Y,"WRE_

MI(OF+5-0:!A"EZCR3W@ $&DF0F5,"X(100&,K?=PZ!],-SF[7_)1>, MT*7X;P^7H[+'@.H'L6T1O>&%$O<;J62Q@M*H"SO."@&*0UX;NXO%/C0?] M&

(O_M\/"G=S+>&_V%^1^?87H2W"D7JU2F$MBBT"?T87[K1L1$/MA@F!(5T3X ML"#[CJ*DF*@R!AZ388,LGYSM)=D<3W>=T;A1\''X%(PNH1_\P:HXOD7K;!4A

M^J'\X?!$9B[/H2Y'.K-U>4J-<;&P5D\)NR(&)TLS!YJ!<'^6^96M MX,WFU>4;"XF%()(T^B=6(5W.G&O?;W%AR,.1H&, ?[%;!@"(+C$.GS"S9@8 MBFIB;B,P-

E:*8IR4$=8Z4J$C;_12")@XHK7 9%5=2D;JX?#HO_2'"/3I6#%(R\9F<*,5X59J\]%;,A7_T"\<#/KK%F$WL':OI* M<[L9J)6IJ4!(.S%6,$\Q826H&6C(D.F"Q"2<*

[.AN6@"W\QQ%&=2*]&RGA+ MB^0S+ZB]MH 2<#86 H_O/G.PW[XYM/PROG<0RDH*)C&<5Y"_/'(_+1-F1 MJE//X7H0.7\6:+7=%(F&<])VY16;D]*^K2X15F0"C-+++!F!NMI+M,5

X\&Z9+K M8;"^7A$GI=!!OLR@0-$_L;C";]P2Q[X5#, \+T)7$0 2:(U8X%G*:L^ 5E&@ M8&[A->4"LO:*Z2^$\V\GTW ?K*\^$-B4<"""7)KP?)AV1$,?I]X+0A#VPM\ MS[

PBC$!R$C888H;JP$J%M)7XW6EM]2[-#1.6\PBXWE6(<\5T(OEI?6P."'2;2DH:,Y)#$ \7+9)*I2*972!BBR,XQUI@7PEAYRBDV6]$@Q MDUP.;#M V(VD&5Q <$$)8MA8Q0U-

M#O-^X7?Q"9=A2%E/BDINK;8ZX[KYQH_MB64'9=8B6B[6#Z2@3U6H>;S<4(3N"YO3/[H2OUS![*"+<,8Y[UWH1K)2T-M'5ML#9),NEW66I.79E%5MIR(RM%R$V*$ZN*W_;

<#0.%@"G$<83*2T*7-/LQ!*1+/8 M57Y-\,#T>Q["^FJ_R9O=V7#42)B)&4Z/443@,] @U*&%Z'RFP9GZ3QF]T"DQ M]B*>//X3G-

@"&T$QEO5YI3V;W3]:=>=)\.O9E\F:UPYX"/_O".U@;?O> MI#;_MU3]P2Y5OTO5?V&J_@*Z[*S$(R%@,04P1NZ0-@TQBIRRLA@+7&T(B]\E

M.$$XUP>*2YQE#"""24G"3%XK#"^:>AEL+5!=%(!S/@,J893*5,YDX1Q:RU!Q M^LLY1O>NHND4+7B,2Z;9$L6GC3LVP<0H>FMX=6&[*$A PH7NU)A-71=\,7.H

M68P%,L"0)9&SAO1=\0HPE<3=UPQ.3++6I8TA?O,U?Z@74Y2Z(S'EYR"G'$,# MAVM%4>;I!@$;)$4/% N66^$0/]#JN]=H'D+ MQ?

YK=AU)/HO!,Y<"WVZ=0%=2'RY=YS!>T4%*8BEN84X59=/&H;MQNE#=(\]/-MU=DBGWXRDW++6%C)K@VRNI2UO'WCPE2!BYQ%4S:F)L3&

(HH%VIYF19PYU272ZG[6.9QL]'+AP38S;JEW$:#?)@4E*) &=>G4:R(FC]1L< = MA[ECK%52PN&]2ND0:UCML8*B>9@++<5CH0LXO>:+'+F'P*T8K4F(KHN;UA7^

M>0_)"# =2]&^K!$172%.UX)]91L\8QH6[**M$KF4K&A!TR$4C3M7E$J;EO$+RDC_RJU=P?W6 +&^Q0H1F<:4# 1N#E]>\'T'6@%P!RDGQBIS8MDW)FP0%AJR)4S[4/XD

MC]-O6 ZGA<1142)ER1K;B/SZ](:HF"X)TT] ;7)MC-5,^ [%]".5@JA!]Y+)S]L55T,+M++)YS MMX^&1RQ-

,C]0#KZFSPE\]10M>H813BX"QCOL+_7ZELI^<TKU<+!9M;1DLP M&I(W;H2I=#Y:@^$Y'/%M7FFBM&(-?ZOTH1%X5$TT%(P)BHK+84T58MF?.M(

M,F3M8DB*I4IRFQ-OF4V0,2878Z ZR_0*#TJKA>S:N*621/Y8KC,DB"HKWJV0 MWV[%]1E@=]2**8C C4A68D.!(7%%Y&SY; _^OW[VY/VITZ=_CFOM45X"(.];

M.G=>26FXO2$?P=6@"K+4T3FGH2&TX.L44DE.2)=E#4.;K(-YS3QMCGPFGZ=< M.X[B* 1*=`O XS!K[FA3.BBL;$6Q4C*7? 5KJ&.W8T,5<^TX[")>1R8SCY7'-ME?

C[^'3$7!&6'W#&+W.A;'6H-[\7 QY87R3W*IJZ38!G%$A]C8T56_1=!!] MXIF6O9$J2;S:-UEW0UY$1OOH162)2XB-Z7^ ^_2+ZK$TUP]ULZVN@_FFF5M: M1U.R>RR9< R+

(4@<;0_X+GG)E(/LL\SH"I3=FF>,-C*G*31+\]#%>.YLIMC. MSO<0K&]>8';?8 32L&U!7WMAY#9!M$*? !FE!K/H?_T_P]$QN/D8YJ,.(#V3 MK\AO:8 \E)+YQ:X E;X')RJ?:]A,>&

]0U99C8+(@&1?&BK'F2[W:8,#@Y5B! MZF@_PUHVI#?$MB/OD.A.*30XP="',Y9B#P2,G&W6/.PC9U+N<4I$-<:0BD=?> MRX2AM?

&1'TCU!$].7WYX:KH0X,7G!83_1>:&OL:+5)]>"&I9)Y(>==#RUDT'9 MR5)^\-*9P2&"5>,0)[Y5*T88W],M'_:UF1-U<(I+F(^/L);M 7(H,;DA]26 M;,H?

_M2H36]"X;4_61K^86^_Z7!B$/.K#4O#JLV89,[*<_06QEJOOMD*X0VF MJF3OG;7F'Y4\]%[QLWPC1@1?X]:68\-[JJKNW+VSP@13,!/4(*YB7,P=@@ M&:>`'V*P^3S MBC0-

AO!1A4?]8Z _,Y\C KK&9]PXS-M6&,E,)5OGBAN5+XD+DF)AW0YAW!SD MI*[$O(=[?F=.:+MPB3&B MP0.W=\X2)QKAEU74ON^;?,*_K5KGIN=6E;33I/-M,DUZ:()-

WVZ'Z!1K8S'C5()K9#;@UE|[5W#*]B|R*EE2X"42O>FE3TMZX)(MNKU8;VU&ZA5.IF8B,J#$F21J\L9_GYA>_)=*SFC'7":">[(55KDV9(8]>G&

M=CMI*&2'E8_('!!YHZ5IB&B#IX!8BCS^O]#-89.H.Z7)'D4J/EVDG_#*Y9). M^RCYNM!PX$Q,P3D<#/AA3]S0&%A9)'OT62G4RW;*ZSUY'950T%AH_4KI4_"6 M22,ZS@R-

;;.L%O5QH5-XH^2@C9YP\E^PV5X>=T5'FTI.L6>;^\^J1\)_)6%.M:S;BI[ZC+T$9KB*;^*VAZ] >=PTO=^M/MA@33!|;;DKO&V658**3.S$HTI'# MZ>>4 NI/7K\-

RNL/[]"9O,#IR]'>"Q+'CWNG*./\21&\C[)D\< ^B[8GT?%N MQK+0P&\&9*?1$D1M3AB>=,A1GW"6:T]U/\C&QSW12SS5]#1^A1KZT@G5Y21Y M\;4@P_DXCX;UM"*

[PC74G%4+AD%^Q=W!YDT+'2!GC<>PR%?P?^:+$QD18,Z\.1<2#V=%\-A)WH]Y!/2N$K[8]GJ)H'D4*_5CTQJ4/=.8!$1L"%65;#N"L[*2 M%5E3R?MMIM?B45T0H6GZB

M+%3C"9A!BD%LDF8#%V/,L)T5LT.5.4PQXG5Y\A<23NPG4]?8(26V'IP=E*^& M'D9%Z_%R=;0@2>)M&6Z4>U;(<3-_^\O?W\LV""'4&N$ZAB]\UDR*:K&6;JX

MC0."MS(^:,;1$N -+<1VV.H Y_=JJO-(?"IJG)(]JGU45TSR4]#Z^R35+61*S?*M2D3A4<68S##O)57,MJ:#(R%D3&G%&;=DM5B;SD\%V-Q9W0V6,L+Y:Y&O&RL'5I'?

492AV//"POYYO)V=.] M8#TO(LZ-(R9=+\15P MP:/_U"PRHBPH[++9VJ7M3MXS,]U#VBJVF4%??<:#(A>

*M<=F1KN]+KW=%:!OB7)NB0',M'+,+B/Q)H:ZC7>\[30T]05@5)Y>B 3O4:T2]1D3J-&MM-M[]?RX^-(+5BI[F.<>\ZVV>NB_8:W-XKTD;:? XHL7]$)L'L,WS)[FFV;U1@Q M3&>7.DUT3!GJ)2)XEJB7:/O*$*Y-_FE@I #YO;F/2/4#T+](-0/-M$@GJKW6@FH\L@9)IG,E&]\.4#3MKJ&&58($ND,VW"B-A%(17Y$'745@MVW]\-M@:H 3C;)\0+UC%#/R*EX1K9$Z00Z/[!'8'K;X94('CD$FO0&;G0^*38$_IJ3V;'8YO+2@_7T6*G"-MC_)!!_+"-O/VWQ I2(*6Z)AA--W45\!]1507T$D? 7![GW4G$[.M>%L_VN-M<+':N|6IN^B,"X7'IEPOW(E#8.76'#4' YP;LJF-6ZBN@O@+|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|>U*KNL^6=VL\#QV6G*V M(>+LGRF)%H8YN#F+H59UH!NE19P2Y$H@3NM.R18F. MMOD]<_=T%W=.HZ/X'BH.GSRCFSCN(V]ZCMJ8GL+ HJ/6Y\+MQ5U=,]D<9RCY M>H\]*^C0AN:Q#1T3N1U>;8T.F)RL%4W =18*#?NX2]O(O9:OV\/'1H]GM=YH M5,^]9AO].PP-Z! C&4OS]SQLU U W0#4#1 E-T"$++KJ>]B:AC@/J.-C)RM8< M4^EVX%X&EOU,&127Z(Q/T'5PM'9>),,:.KGO;/U2Z&O#;05(= M#'9!MH#=:+V.^E4!C-(%[7%X^W95M-59_A=%^O#.H;)0/$X*(>5MFH.2L7] M(.LNJ "KAGHZ4"PG@>B)%M6XI%TVWQ[L_RW7)&NA'.GDMUMM:&$|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

"7#@%\5]Q1=A7U\]=@)7!ZJ[U67U-MF$#35V5'LZ.G1/W"3V3*+%D]TYH-.@|)>J6@7\D'&Y(J2LOJA;*2(+.6LZ4 C-.,Z2459SNODA.*C+WQ]S;SSZM-MZ7C>(T54?&2(AJYD>T?9<;82?6=&$OC&WT4-0H?2[@3C5AZNRN/&SB_Q>T6J-M;I8K-F"]4*32(I7]|)5ASG=H"K0*0KD) (.=_>8, \I,.N<8Z\.VTQ]\3\GT MSC%YEFUJ2F/E"1TIVDJCVU1>VT]OKFRGK\JFY'GZ-KUBI+:?CJGPRJ1,)-P4-M_O%6TDUI;JH$^BGA(8FA99SI*>^YZU"5=$,#Z]2TNV4K?KH+|PZ4(P $H"Z M(5A>,D,#514%#=A8L+RPO2-4\)87ZJ1-P6IZ>4$"R2L(@!.E/ASFCM|H!+/% M=I@=?2XTRGS10+>)5*8"#ALQZ@4Z@!;9,7.^;OJ/EJH]Z_F:/-M6S)Z/KO(Y%6RT:[+M+D65YT@VN/PZ|PMU!T)]O,YC";I]MO.;]"DX9RT-M-@@%*IE "4 HD "=@(P@4)0@N0K 0@%+ .4 "JGP#+ ,D HMUYX .=<)SC MDCKWO\VIRCUQ6&7"4BF^HWFJDBZC5/ 3U"\!%%WL,!96PS,&[8'(U?6UF5EQ M(L5&QUU4)@]%48!-@$VP;8-A)$HH4$QU]A.V=]A=6T5FT38R^PS/RFYQ-*SI M;)C1\,Z*#]I>WU\OKDZJK?I1++73^>XBNH2Q\%?J/4NY3FBY5VNS#;^KMY)P'(h.8=2P1A *5GV^.1+}-6B/4%MXQU;\&,8-5VS#(@(&\Y^F ?UVX?,8&E_IGD<]^^ZDNZK2]\Y-I(3-I<(>]& M/NRF6,VV(W6[VZS0FY&L\W]^P6#7=1:Z_T@P(I&A?WZ":,97?& M;4?@-QNE M/1"FVY(^"D4JBR;VZ2N;>2 I,D8V_PMPYQ9PYZ,[^ & ?-01U-ML?QOTE/;J MO!1YW2]6R\UQIE.O:9'M,V^Q_5NHZ2I(IF3+:DKR4LXB50]LI;CU#/EP_(O M#O1E0*4*U'!!#1=8OJ4M U*Q00FN00G>Z#UZ^&I03RSVZ)Y4RY^(QN/T:8]"DUW+Q :.1"LXGY;JRW2GAL2_@E_LT0+"]EU3)*G,X;_R^?L"G)R12HGYCY]I9"WF8&D-M8&3#\P=)R3 VP"+PE*JR (!\; P_C@;;?^Z4E:-IWQ.<&W>B2KVGNR,6L-^OF(V<"G MZ'0N]Y!/&_8'

*MOZ+,_161(%3&/SMCG/^F!"OI7Y&;SDX;?;04'=R;M,0MJ6O)F MD%Y\A@6"2 M;B(=&6:H9X8.K*_L1_W4L5M5FTFA(D8#F0$6-DZX7F<2#?9*KG7867$4+Z[8 M\7S"12%$*Q4/]H"_/Z-'-.?VM[^.+,-/]-95>S$8YXOY_*2XBK)J>UK9 ;-# M3'OZH<;A1'[YRP0#_AN(80*"N=-/)!4SG?DIECRAT+M,:QO$;,J*PP*6;$'%/A2WH;JBIAJ9((FE# M8/<^Q8,,$W\Y@WC\@-7=%;'Q81\8+-.+%$OJF/#_# M?O@V<\?O(YXMLX&>NK/L/W,^(RCM?JC1K)W?!I>'M$7P])/GDLQM?5O+GI) M2!3_;B\LCF_9Q!N=U9VK,W8\F? _RS$:(\/_?7G,?*&G SQAE,:HK]+$!.E_[M<IPP5-*]FQN3A+L%LIA{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{,TDBQ>9\'#)0)8X=_MWT5X7? X+/KP^/Q%1/@.#,HL)\)X8W$Q!#0U$<%PIO*M'0)KEGF9Z/2~169 M33.,"#XPV%O\'RYF 5)DDC&M%6 F+$#&M\ IGCE4%?!_",^'4\6[@2XT0"OGR8&HRL $P+;9!YT+D37PQ3"W'NK-"F+.DM M1;,,3&5>D7"&_S9B6BJE5(==+VQ>I1,T- 2!F;KZ 10!O''>50CF^"W-P7PN; MOM;@,/#I JTIV 5;F\2* (4]7'W4L/ M8R!A(#MSU6"Z"PDIHLL[<&K' UKQ!H4.S[+ONR>PF"42N8J*HD#,O'G$4T?D M,I !Y]H%O3+3V7BZ22OX&1 (L4L/C =,rA <-)M3L0L#%5$3*A@[1T"'Z M$H>H9X>B&?8R06>-^<&YTBB#/>2%M+V+IZBN'O<7LI&T6EE8!,,"IFU5RY[* MCXZ+E BUCF\L& (X\URT9@/98QJ9JVLD[@JT!)Q8$6U7&PC['Y)X]N@H<'9]. M_(@N?$;?T)IK>7?F;1L5@/)IK_J&[3#"&;8[*9RR1R-7">+YJF\3ZP3:ZK5 M$;ZB.R)A?#'@\3IR3=(S8FNA? B",&H@Z!|.P!@7>@;?!UB@&?XMO&2H"[AOOQ/VS]VWTY>2S2,S(MY5"2NI,RS>X!VAO@2P6*ZQ;&5" M&!O1(K#8Y"CX=\4R]\XB^A;<<-[3I:C@B.#VE!VZ4L!$_RNM,+'I NT=%X'P M S898 =15F;9Y.5R/?^!2<3\OQ|E3\&!8# __A3-DV-Q^65*+23+%B*?_M@888 M8 /-P3[BLWT-LI=1^-4^%QRLRGDYNSP2+F5MDJUE[+-V1$;Q)@S8)@F.% <'$*J.#O6/%@(S\Z MKO%LML@P7>6%8B0/S7|<*#FQQ/#&6K+Q0S*H8QWO&X0F4'!TXFYLLQ36E1!X M"4UJL36)Z01:+5Z N-K&=3T(T.D(+/<&6 <7%*IFE;U"W=]FK!CI+BQ[!G-E(V1-?-(6 4BR M=GXU!=:.U#&;NX1OD?>WA/\|EX%[[F%']X)5IX8Z-1U+[''L EX]HMCGO7>9 MK>A?:9BWF &F(_ $OW_ T]GUT@Y6T5= (/+UY[59VO)9Y9U6$1GE:SI+8%X$H M58"?BQ,)Y\(R!KGXCY$0).R &+X0)E#B<0%^I%>W2]RF<>*_07#E@Q74Z^WW M"7? 4F<38_CJP]V<1.IT")!9_P(OM843S\SC;G;&=]AK^YUN7!_BI:M<>H7I M3VXZ>,82&|%%$Y(.W-S+7T^8H+O-7'"KCZ_'oO>F$90^T+A?@.'NC9K,\89$S#3> M7?I8H? 0X;8A7>C2>'R/.%M&0!BQZ8RWI6!Q7%XD*1&1^NU@N\, .:6F'6_8ONY=,.9MMN3&7%(N(E!.. MG+/K\]I!(C0&C@9*&40>D42)UXF?$H,\ X93, [SQ,5L8F!R?!D@OM'T$HIX MI[./:\<2WP]\W0%@I<'+IES.=#_2@%6#! S) %_6];@=/+4*8!K)F\#"I@8>>9D*YB?76N*KQ$.G!R;B,397[Y?C$7;7G%(A2P6R!R\=%8 M.)" 75\Y)2"XRN@%Z/ID;,KGYUAZG>.G7% ?KNTPI0<D[QFVDLB,N!Q$<+) M(N9D$;,3U0G+TO#5=\ "/4-LA-3A2T./>)/JRX\R/-$GP+/UH\^=(,f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|K1*;6',I3^K4+TTP\ M,A7,?K(>4S8;?C]7$7$G1"^B\0 6.J*7EVUL:9;$F=M+]HB#)U(C_1.L-8>T MNC@U6YSPHK-AC+MC#D=>T-@">W,9V%W&-LV4 M48_*KI_!]=GF?;CQ+(f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~A?ZSC4U_R-45M=FX M71JE5/LPC6IQFXMB7A(LG<77A*5Q=N.O5%!Z9=Yj,.*=I'6X%B/O @_KZIX;A MSPX4KT=)+6XY/(S[9:Z8G*2;F9OZ5<=Z/B6]}5 DY$+?G)AUB4V.1Z)67J:E MS/@E0'')9" +EZW+OYPD8J:L:%,H(&57WLC738T<8HF#0Z2X%]P&N%IZ6^ M,(@?RGZY'1- DTGU"\=^67=)!TVNC\$$=RP/WCSMT_!Z"&>Y3SVB=:[QA4"JD(H00D+31N\0X@S9GG\:[@'E M$V@,CVM+<:,,,[/R NT%UM)"%=XXJ,MUEX?E#!4((W7#6YUV"_2 OM%\R/!MV MSZ$TTZ8;>D.U?:([V=W6>)DB#:4)BXQQ2.8AFP-C8BW54TK#D/814B("ZEB25TW>%HSA#9(=`4U M+7)520-3A7%6R13P41V=_R%Y?DGR7 RO]M'Q3>RFC[H2M[9RVE5/;C]*GD3+ MIW6E&!.*/)#NDS9QH(U%FSH\4.'[&QVQYU0C!A)>BY:^@-2OF0Z.X+2+U[K,ZRLJ\(MSZQYK*X!I30\]YX82XF# MQ5:=Z'? I\NV1DK\8RZL9NYOUM!'';)G-Q@[J(%<0?'@PIYS-'/*K(]#GV>94 M/K3["W6_Z1-02 ?H_ X)W$,W]VCUGY1R?%K:F=-/1]US,XXWIFS-T)=1*BYO MZYGV5B?L82)W;P? 5VXV4*U2NB>C8B,4+7]"@ M-R30'G0L1 15DT0G?(^$3!FDD=&=D"P:UZ$BX=CKB_@*[YJ>"4$"N9%0!#! M\G8%->2_TA[3Y3 OH$DAWVM-A&EITS^D- _GMH**UJH6WC++=HK]N9|8]2GK_M!=X]XQY;6:6X;;R?;+25AVJF*)>EN1.-XI=<0$118"9WXW:AB)DVB2S)?-R0 M73LH$<-QU"3+/9]%"\JA)D$!H=[PWE#O^6'^"'V;ZF- NRW:-S7!1+LYK"YJ7E M[%"-[U-=:4=]8|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|2 MQCMY@0#]:2V!3VPCD*_DI=6GE]XRI++V4[@>HQ I_6]XBV#\)>)=2'X MCR0-OPFI\=.5-!E0R%MZNF+ [KP'/]^-1-.3XO7(M0/(VTBO$O^DP25!DE5H3Q3H-(Q!5[!,.C-%4^=(CQ"W^>FG'$2P/ MF;"FX$&9:ENR.SS$VI\L!XHF M4"<-;55AJ3O^\.1F))0@%+L/@+\GR6EQ? FA(BX%I"BU52(JQ3D)4W!ZP)UM, MB)+TAL?![_ O!+IOV:G&"7=SEVE7^8??LEKB091K"K@V!)T[8Q[OMBAKI>^,T MMB9U"T1X./WZ3K:WCDB_#*?5#6E,_-(9:5[DI%H? V8PX,.Q6(L%C%8D^2W+:_M-ZQX.|'#4LPC%;XU,%=3DH?BO/DT#N^QOD A<3S:G;L#W(LQCH8P=M=XTN_< MH_N^_#5[BF>UETT5B]YKDU9@Y3ARY7(G]\=_#":GX>N,"C);N_>/BVU'9B&] M4&#G:12. 3M/8O086A/,F/5[O K7[11CTQSS#[']A'Y#_/[[B@GZRUX_UE[53]^14KMQDWSBVJ(5FI$\1N?(#"#]@ZI>,4Q>'B;9>7!@GO"0@W=O-TG0- M_[;@5T?()&67@D36.U#W'%#CV"=A64]- F^G^F&T6N>YMH72GT7/6&/[MS9 L.N;R=_^]O0#*1O\|[7[YRI?DR'Z[&<9D)$1,/O:PRQ9]!V55[*71]XF3*.M\L-;JS ?#6O1AZIW?B/*XTCD2(BD$2,E+5ZY -]| Q.9O7G30<7/L:)"RALQ M6;Q5HM/KC8R OMY$_"1:#;3\U==.9SBI+_*Q^+0(<#M?$F0\YZMLB#/E(@LZCYN]8\]2F0:#<1QIFCG/J842A?1L0WJK1 M"^MNA'4WWJWN!E32\'/-NV!"F'@3:KN,)_P($8)]D>$UMBG8\3]*2TO]+Z> M.AH^DH&/AE?*F$G71M4) ^/&V2CUV2H5/%WE47WT!NA^NYOTO*\#ARN-$? #,)7\AI/S]0M|&I,XB7N*1:U'[Z7Z*ER M+B/%+NF=Z_WGGZRKWA-^0T,SYKZ(TQ/+ 2NF!(+L]_A\&;]]^%FR9!D*R MW5Q;A/:VM),I[ )(1:>M2;'JM3II#*SIGTN4)D MQ? RQ72\UY+O6D!.OC\.LC^WUFT5Q8Q$\1HT}4);?_<41MD\X/]BVSQU:Z(Y M[$8PY]_Q5X-,ND*NH)_C%;"==Q=8^\]]8M;U0!P!P\@=@G4UWMPI2ER>*H'X M'2PK)GRH[DX::D7U_)UNUD/:GT:^-&9?]2_,<.N/XL^VV0+4<-SGG-M<)\;6_8%9Q2AS[T*7|/*)W9T>7 (^:)7]6U;C=:VB(R(,!(2O;5VDX7V.OX(M)[<2F],!."VZW>*K)C^; 1\JL),&\Y-_1|)^?K'ID*I?0M7/"3)X@*HA)AX\ MW0]0=W FEI)S!6IV^MWVSN472JWXC0-],Q/PWHR.3NBH_'K-,+=L*:0K I> M1L7;H9FD9^%?M /R O? TP%SA[26%&:E"#H^C?=V)_P9"+JA7!]5NN8N3>!:1 M-L-0<%]3#>+/Z'PAJ-Q3@!;,:A\\Y+0"6P4ZEN)5571,D@3?<(;0Z,6=%@XE M))*;6!TI$OR5@%9W,N0ZR+YGR3- HGMQI67O_]%!0V392]8TWG99Q_!%^D#N! M8UZ$4_L7;++@&<6F[%9^]^^:W7T=%DUYVJV;O+7$"T32I@3DF1\SQR>#:0A1 M6PPU$,- L[JON[BW_>9PQ=*IX(CF_88GGZ+$Z__$70SQ7FSTZ[7G]S,@9LRR M2YAU284\)#>$1[/VHF18E[\IT^G$VQ"'-L8QQS&Y*;/I^;+K3Y&PS*G U-M- I\9EY++#2;&RY5{(ICV@MY>R9]_=+93ST6R'+]/23.OB\1MAW6<5$%3#>+/Z'PAJ-Q3@!;,:A\\Y+0"6P4ZEN)5571,D@3?<(;0Z,6=%@XE M))*;6!TI$OR5@%9W,N0ZR+YGR3-HGMQI67O_!%!0V392]8TWG99Q_!%^D#N! M8UZ$4_L7;++@&<6F[%9^]^^:W7T=%DUYVJV;O+7$"T32I@3DF1\SQR>#:0A1 M6PPU$,-L[JON[BW_>9PQ=*IX(CF_88GGZ+$Z__$70SQ7FSTZ[7G]S,@9LRR M2YAU284\)#>$1[/VHF18E[\IT^G$VQ"'-L8QQS&Y*;/I^;+K3Y&PS*G U-M- I\9EY++#2;&RY5{(ICV@MY>R9]_=+93ST6R'+]/23.OB\1MAW6<5$%3#>+/Z'PAJ-Q3@!;,:A\\Y+0"6P4ZEN)5571,D@3?<(;0Z,6=%@XE M))*;6!TI$OR5@%9W,N0ZR+YGR3-HGMQI67O_]%!0V392]8TWG99Q_!%^D#N! M8UZ$4_L7;++@&<6F[%9^]^^:W7T=%DUYVJV;O+7$"T32I@3DF1\SQR>#:0A1 M6PPU$,-L[JON[BW_>9PQ=*IX(CF_88GGZ+$Z__$70SQ7FSTZ[7G]S,@9LRR M2YAU284\)#>$1[/VHF18E[\IT^G$VQ"'-L8QQS&Y*;/I^;+K3Y&PS*G U-M- I\9EY++#2;&RY5{(ICV@MY>R9]_=+93ST6R'+]/23.OB\1MAW6<5$%3#>+/Z'PAJ-Q3@!;,:A\\Y+0"6P4ZEN)5571,D@3?<(;0Z,6=%@XE M))*;6!TI$OR5@%9W,N0ZR+YGR3-HGMQI67O_!

[%Z#!FE!!Z5M,7&FMLGY3?Y";#\)WL1P5_]>@_#'O)-M)A[B'"*=3VE/;HAW-W?_]RQ2?>CSL92(9GLZYGD[T,A$+3^>,3H=ZNO[>+203-M1? #!+BT8%N=5<{#N\|WPPLA;/$M93H1LLV;'L\69"\9220=MD6HAXPDT'V#=:.K/%/'B-+KT_B<$#M*LS6^R_7@&F;*/*-M!ZS,PYG$.NY=:NSN4JF_G/O[U8#YS(fR]867;T*^5(D^>_(-DY7/*EDY[C;)-MRO95ZB:-Q'ZX$<[=,YY+3D0D#W?Q<==$@_QM?3Z)01QK+!-4]O+/9(R/Y&NH-M#T-Z%FN:.('X)[Y,M#@;//:)$F[&T!L+)^7>NV()N>C07R-G/*UCCRD^2?*-M,Y^^YD/AYCL(-Z3L3W-6AEL=6GT&2+FHMM*6;"VY8FNRNX'>5>|\Y=IPU-,B<QAP:<4.,Y0C(.-MN<);Y :'JB-!(LZ4/O1{UIRO#?KTN1&'$<3^3-6IVDB~L_S4J!"-]-;ML8A"P8D*F$=("IYR-YG-68-?/U0N/%+,MK.(RIV2+TKPUCY9'5_R-GL4'1HOJQ)/^UL&AE2@$O@<+^'OJX-IM1VJ9O?)U-M@*]TJKI7R^-5"3F9>R^U:M6NCL-AH\9YDYL%T'B*U-F5"+N0;T/#2,DQI-M=]-?22H&)/-W-#M'N3^"LS.8=F^!\-$KBK:#JIMD.YDUE"Y738-1D9'=(1_0[S&>GG-MPRR0(@*MT4X_>,R5I2(FQEXP(**03O'LLQ/2<7/T"P#?^)4;Z"SLI?,1CP!-MSYU?&^BW\X-W=)YXB0LJ2:X?80@ANH"8$1;],+B!&"7.03&UO9)9MPR'N-MO-5^6I0>^2LI3**T#?B^AI\YP^/ZB4)#S.XD>_#W5$2\'=G@3_L9(0C#F-SD:M:8ON/-/IGI]B]=4RT=^FMOZ=P$O#8*(:P/B_R4]PL#_9BPC^ZM>=`?@(@R/]-M_SE4X4#O&;WWS^Z5!|3!]_XP.Q;G+S8=W;?^5P>_R%Y_)!Y_)8C$5X,!]S M,(lI>>&YA$6GLLSPBS"@_FC@WGA-@TU-MEC^E-O'3UX7OOP3;(-^0ZXX\V1^8=RF?ZD/%45QVT_]MB#<00_RR$6T6L?O],X,-8I/E"_WE$"GTRE_?-*NO_1(Y-MK*%^4V#X^M_+-M2_QEC4ES]@<1<<%A7A6DB#--AU">3Q<5Q^\+EIE;=TVV/.HET+*N+Y.!]^D-M"JF7M@:8)9=90'2<4.,B5:M\52D.VS>*QG+FGAW.)W%2L^.B$Y_[_L54Y*2*-M"BT=TC[,PD=0QM+(@1P.;%KKRTCG/,.A=EC[!GGS+|\BU%F9-GSN+X/W)/-M/F7Z9*AQ?2.)RY$16GA/8*9%1TRPI,-^2M?+C4K9D&:I.4.K+66OFF)DI>PF-MI(Y^-'D1Y?QI69_9,D/KI@DG;HG0MO+D"^&CLZ_>POCRX8I*K3,AN3Y#_OCH-M1872QE>6-JBAICE]AM1QOW"\(H6Q&6]+'+MJIBOMS7R=70ZS^/A-N$A?L,G$-MM]+NO&/@V)??AN_8Q>V))HS2M$/8R"\6(CO&0L1%K5Z."90D7BR2-F]8F#@-MUR+N,.,XO\^-]C7X,M3-OD\:=2WRWS-_P-94-TR\/+P^:ID!!NI&@XTM_C(]7|4NM@M_/W%2L^.B$Y[_]L54Y*2*-M"BT=TC[,PD=0QM+(@1P.;%KKRTCG/,.A=EC[!GGS+|\BU%F9-GSN+X/W)/-M/F7Z9*AQ?2.)RY$16GA/8*9%1TRPI,-^2M?+C4K9D&:I.4.K+66OFF)DI>PF-MI(Y^-'D1Y?QI69_9,D/KI@DG;HG0MO+D"^&CLZ_>POCRX8I*K3,AN3Y#_OCH-M1872QE>6-JBAICE]AM1QOW"\(H6Q&6]+'+MJIBOMS7R=70ZS^/A-N$A?L,G$-MM]+NO&/@V)??AN_8Q>V))HS2M$/8R"\6(CO&0L1%K5Z."90D7BR2-F]8F#@-MUR+N,.,XO\^-]C7X,M3-OD\:=2WRWS-_P-94-TR\/+P^:ID!!NI&@XTM_C(]7|4NM@M_/W%2L^.B$Y_[_

O^EN,XM[G]Q2_!B[<&O4<%;NCL[+?VZ3COEC5QV]HJX@KYZQ5L&\+ MMM88;],:,CQ^']>93^\ >8,|[P?OH|NAHFO0GL?7S,8T$'+6]#SH M"$7.8DMX4!V:SZ;\O$7;8W,P(/?;C>G8ACO<&8P(V&:V/BB1|KV6[\9Z%G M=^M,S*7!^PJMM0.CQR'L.06G&:KN$FG]C(D"A"G"NX$6Y>S{^)T11H.S1EY' M0H=7^#X6DDP(4%EA;V@/4],:\-$ZX+F-8>MG#97O#FO]WI8#S_&A |^A T\L MMK[<@>?M?4NR;^I,DMN^QK/<) ^YE[EAIO+*!P[NK*UTR7"(F@=D?I89M,'8U MNAU4+V[%T3!Y=Z=>24F[.BKNRFS\%L99U1X)/?XCKFVA8+M4NW'>H-&-B> MT-P$MB9H+''+WHP9:Q75LHD\S$VQH=^PU4M@U:&MVESLIAOFMS/5G9A*]) ^@ MW\#-<]21I\=Q5P$ZGF*?0&CPR5_DRU:9_FJZTCNW\Z>35$:1+K_" MBH--1*(6G!=O!Q36UY^U,!NKS=7995F\T+UA/IFTXK96^VO.JI%'G33(;,_U MQ""@!%U/WI#996823=:TB=@3?CH@_VED@&;3KKR& NUS81BY=|,,3\ 0RQ6H M(Z$/FKZARJKC2/8]P0P4ZJ/@&\!VK_BE-@6GEQUHQ*@,(063II,S3LA=PUY MF;1K#? 2H11,#JX80M($D?W4"83;DI8GMI@R/&R:$!^VJXQ4:)!3RI\TTM_#O M,N^-#(U(j;0HFQX1X,&0T! X !G*M(I*-[K024/[\M*>M:%^R:%O4< =''24= MNBR,)V1!0V*MD8GY%&XU #6*MBIV "C[[MTU_6UQ)2*;\/4)C-O5GPW|$P43--!5]&$3FB;KC +\B]T*VN_[YFC^Y>*>-UULD;45|+=ADB4>@+UAS:W4I1 MB<:KN=!j;A3[!0,L0B^,VIN7L=4,_ ^(Q74'5> =R0IQ#M(A[]WA/:\7O3B98 M$#\|WV5]^\"#3?4*1BR!%SCMT]B[H.R6[B!:,$C@6"A MJD/G,;!C%A/9@:6$S"H@S#WSP+>E? %017 U@;^MO]&1U*3V8=AD"%"*6W/!V MN +!#+BFY5K%Z;S4GLZ&Q^/3NYOVM=8?;]IL%<_>8K/=OJ$>PJ1!+C9DL,UK MHW3QHM4P12^52>6N;ZT4TA8=#/7@.SL*RJ"CT[8,1M0_2\?!FLF^]$?-UL9C F*R,-LQL"?6!CT1!;_%(UZ$PL9@ MSTN:4;80CQ1YB1 6V0ULXKA&-2*_V& <)$,V3=4SCW8'R!O29FU@Y E.[__M&MOFTIU@\W4*-\(K1D3&8;UE)=:XUG_*B)7(,>@S"T$=6[^:LNS9!U7DH(J$ M5)&TKXILR,;[HH!T"@*HD)T!= &55P\$I:4PLZBC@:"""!A@_US621CES,EQH M#VY/FU>2L^K3Q?E\L=PT |>/VQMW(H(@22EL& C[@E=180P?=] ETJ&F3T*(MG- QF"-/P,8WU!>/;BA,E A&#"!7QW OH# (C5H?[$M);<*(U9 M>P(IG?PV(NH$F9;\;6RGS4Z@<%HY\@-\0ATJF9 3M.P4I"7&^V PBF0;.L=@ %#9]GJ+"=T:A3*C#7U!]G+'=$#3'D(C@;U:4

00"9%24Q%R70LD2)^V&=C'RY=(RR5RM>[,N!(`M1IY7K3&URPKS4[16548Q8-C;Z.I NP!B;@!6T^U^>/#,SLC9;J&E^Q26I7-R MHS0O#3?X;M@>C@JUVDNE?}YGV=9,Z*(KJ'W9T MWS@.^DH 2EJQZ\E.NY\BT>1T18D>VVE.&U'D(IK5^#:O>$6N)GC.=<=AA2_DW?4.7|K3,.I9$-?22I>)V5W-#'L3L>Q%DQ2N=1C^,G3*

*M6L,A%NCD;]D%U!2'N(&JH,0[>,)^C92RGNN.R,IY]HE=!Y0U(C5 &0W65 \1 M,=RVS1"},+>S8/V-.,1""=G -^ET;%?CGOY"F-B(\6!4ZM/LS?""RK5&U/I"G M4ZC]3;LI@+.,V3*A8P*+_ CT=9+5G)&AU" C.VSQME&!7I9^&=0<$HKF.LH,PGZ-,!1&-I4RT3]N=!T;,I(YU$ M$"#,D*\\+NZ&A_P\H?3F52%XJ@LQ$[*LUG*=5GV*Y)RLS9F=XF@.YW94 Q! L MT'UN5[ZC;G^\RS;>3G\ =3)L\C?C@*.%*@6X#B!NPT8^-B+VFMF6<;G5T9WY4Z,2TWR5N%U/S'O^DK.'?<M.7^\/T=ZKGK<*V>W41_264[I\^\B <.V3*=0BH7+X$LJAE"P.=3.**72%D1J6 M9?$?WXO] M?<#+\.F9%4.(L<&^YS^@OU79;.1EM_;.^=Z^T=W71>2@+KG?*

23&08/8D7$KE\ M=M!D^KL R}>'FB_N&R6&3+]#/6_[_1*?]4EY,"Y8HC#*#=:%-%5HKF.IXP"9W MI=Q@9:=6B/6'6Z:IJ3!|.XD6IB0K/QX7J3=R%NDRIPU=7:%'KR.*4/FIT4 M)DXH8&/%W]#ZSC=$[6%;5\/NG444&#!U25',,7=[>CB-9?\"(M.Q29I<+#P8I M.JL6K8HZ5OEJ^L.(?&/L!9.,_3D(4BIXZX1P49;(C5I_683 U(=,VY\A3 MU=!5X#["2K[?M/T&IY"[G]Y|\KMS=RQ!-3+|#%/ Y59OE%U@S' T>K?ZM(L[MCI?GSB(EL]58:S&MU$\VHE3(A,+R$1WCL<6!A3&1-2?CU$1!PIK,+)4W7!V M@E!((U^41AI*TSW/R-A:TY=4,,W?/C";>ZLU;8(*F)HC"?U:SNJBOMJG]V MK@+6=N+K J5SK5/QF(,>< ";;$QM&MIX$Z"?FVC4!8;<:A@%Y.P2^[Q%NUPGM MTW;MY.-*

[3!H),7R&X;JH%>0O%CNAF:|/>YC,]$O%E)<9]6,A*<(?S5X4 M*_NG.U@^)!\|2O7W9P0N[HQ(XJOW%)RW!3FI=30Q$.(0B>;XZ' MC10+"M<9;384(G3#L

*1&@7X5W+-9@-?9F4!UR:9L93G1\4Y&H!YAKL\T\H\\UJ,*7 M>'QF0@H>$>XA!6D/PBIR@;RG5)D0^\,*+ G#GY-'-?C>%+N9,$-YMPNPH0A* M3SA>]PRNV]BO&X9YCQ3?O8-]KVR%DN&)ZLN^\$(#XEJP9,-.671T^-D>'AJ?,L&9+SVWHR<<[-'T(0K%89}7C8QPIRFP^K97S0WRZV/SX M-Y&\;$&Z,PY>"]@>.;R?*

*56QVSCA^ZN;0'OO14?)K*YSSIPP..'!GES(K!E! M@@H(YC #/(KS7C,FV-N.62;KQ@G'1)575-W4?)>A_W5W5XR,(-M\-1T. O(\4>2,+.F.&%SG \VQV'@;]L]). MNO'^RFS"*

*('4]5=^(B1C.M80&9VP;U(0\O]*JSB9B7N_D\!5NK=JJ-<3F;=BP M,'YZ9>[%9+)5:<3TA#P=+?.=)C/9;2:1"7YZ93D]5=(MK%079;D8G0_P^D*:*

*M4>#*L[>SBXZ2X,$B<$S%EEIR&N/UBM/NZV2=>K6UZ0WP*BZ7&@R6H]BHS,.W MGZV3'-.UT3R*I4696F1G\JJ:[C5:P+!$X6V>TE)[/Y>$@BI/QK1@EUCNUNMF*

*M*_>+G;3IE3MP2\JE&0VIT"P^J:UB1^_LP7PL,WSX'C[&8_L&>^ MHZ>4B_:YW_%UO@?Q@3O3"1"1'5NS(C+B B'>@;4Q+/"2)DE0!@(OJ4^2D-0&5OA9VIKQO-L.?*

*6MV?I\#3(2U\D!:B=Q*Z MGSLB)GU*)TU=!2^=.07RZ+02%GD?'UC>3'P^?!Y.P)3.F[S$!U/(6Z;HO-69 M^OR=O&-L#FJ?2OYS,W'_/6C] PHC)/6@DWK0DJBPZ#NRJ%R-E0<*"V:O-'C* MS;AQ\ED.N2PPLV6?5!7=5VL:=P>&M)XT33J;SS1U/5F,F1H\EDW\^#?QE(R> ME[!_+6_KC+"S3B?7>^GU+RC8/EN)!W99&*GC=&*

*M^GYQA:/$>)@6'886@FB5!&O2I2<[9(_>:AB<^%IV2? H'&06YQV1GU_;YCBN MP#DU.& E#BS$:8&V#YXM(_-D8PF.IM5<O2QC]VA&2\3+FS3'SB=Q.':D4V<& MQZ\KPZ?OT;_\KRD("U?^X)4?)RO]22W7,1^<=LM/NMWR]P4/<:QJX5M!GM$= M:= >)X94L.%3?H4N[71MW*B_L$K/&B;'NV6K*RR(#;CRK"R$5V),5"X-NJ+*

MU;N<-,@38VSC5Q(CS\56IEED[3^Y7$C/591LCJW*37B*Y,B]?:^6&AY5<2HXZGPFXU8@R1*PQ6V(|) MYC.3EE^A"T>ENN2DM,1ZVKOQHK, [Y]&_N4?L[69GLWPL(_?[90M?U52?,W2Y# M5EK<>7U)U-5"LAWM-4;05FF<*YG\[CO&F<-1CV"G;@=]?N,41:S<[MB3 PM8)GM49^&N[{{,1 ^UU^G8'(%;@@>$*'M>%BCOTD\#SP4;*

*MG0OZW\=N_'Y>J5.*9\G@!O!\-'*+!;"9PX$1S@INJPH-<933A_6DL+R700 4.^//:PV-O\/2^GJ5F6Z4]6\M#[M MI\/<_A8#_ $53GB(EP#BA7A.Q4*\!! O\>=TR#*

*!1$PHR(*)EU"0!100\>=D MB)C[(>;MF0EO,Y ?!H349^7MO"!,Q@"J=< <*VFY5+P[JSFZ08%0.GGY'VS M1%/.l0*?=\(&%EK:T(CB3Q? $M+!&G]b$_&H+A"]"$Z& #!PS_*

D$SDC@\^LF M,;'YP+S/&[/034MJ0])Y7;I^^]+Y< 6N5]P^-/"M?,_PH *+[$_C;L88 =OF M.:_\ 7?\B=L>,+C<)&7/#N]8&>OY]JZMWKKHH#W#2RY=K[N3AMIZ]H&0+]K

*M2HP"1TGLN3*S.YM,LO ->894P @EAVUWO94BU3ENEVXU$ZT/YP->.13,<. 1 MW(7C1)_$P,&N,+)]L46Y5V!7:7HM&8;8V]C-:E-$[5HIPC<60:'&N4D0[>^6 M.*]-*

*KVWO)F0=8N46N9 S,9GBVW5&L2G+_,@2)PLQ4]M?$6,BTQV0]B%60LW MEW.[NO]ZQ/EZ'C1U(27EFWHXC[+: E,->@XD-Q)'I,SONP7N])F+/-G_SLHN_*

*MU:I[NW3=OM!SN<-/]F*V])(D:PUY46DX[?]CR?BU2H_O(HI"R7-SR9,,P%Z# M)'G^'NON[9)GTQ"I =XH1.E$M\Q-J/ZH9,PINZR=Q,_MNM,:LZ\>]ZMSID^:.M.7.H;/CN7G/*

G>/K$A[<&3OX5L/D"/^JQB)/C*9IR>6O:'0*_?DK5154QOY MO,I3]CBFZ-4^9M]83H5BZ4'AOX=O/4!BZ?>QC'W$M>ZKEC<:K.E/N%>CQK%M:.MMK1^CK

[$22(\Z&U5[IH1?)MAZ(]9_-%;:FZK<8K!^=?+.?6/L%Z1T31=W0(R M,#EI]E3]5V"!L\U.4C0#< #X 9E3L%)Q:A#1H>;PU^.&,#Y+FM7[8/+/G?M4

*MQ7!8(1%8I&DA.TSA'7)FS*12M50E]{!.<[IF4_DY4M[2VA'#D139[-3P[,84 MK29E#A6& FY4DO ?ZOR V=?WPP.>;+";:3V?%V5:KV1B;"O:,;,8>@8=V]O1*V+*

(FEB^MRBLZ^LHJ M;U>)+EY?*!$ K_8+&&_U\"V2_BO<)SF>IQ_^+9C@<2SXM0.(*2=P<_4I GMW M 0Y1!.0^L.TWNGR&T[DPVFF77-/V'Q"+<.0.EIJ#K?5",,IZ[_6!,2Q%,TM%8T8*PM.<.DLZQT)]> 8$2 M4?=KKYJ*:X*E5\]4.1W?32;&HQP@?5 M7*S>+RLM:K4!KO53 H_Z:@B[.80"4+-O8,#(T FP<2X8""FG"+61"4VO^V#S*

M.%;R&RN1O64I&ZQ$M[MAJ_6O5UT?]P_?5^;!8]$SVWFY:WM&P*,4E,5/A6 M8PZI_5,,_T2[R\|/?!1*JK,,@6\2;]%)OE"3:"'ECZ]TEOFUBA):N-F=B"2 M&DVV95'<2#UNLD*

H29+D!928[[Y"X]:^KFO/C+YCE<(L&08(V!*LZZN'9WI M]DPA(ZB1;*!6L/OW0(T)55,>89&YB# QY5A $XZN4V#_'@=N\lSl.:%TAQ^AQ0%@"XPZ>3'U1)4H0M@'\)B6**

'1P2%]4H1#_"-MU$D+)8"=&K.+1&VRC!TT[IL5+?A14%C)FMD-F?PZ/SU';.O\^)\!'G(,;:(2 M$2QRZC2]!Z__24;2KI2D15)?R:@_#VSV/O&"RVAY*

*M5VFXI_2=!F!TUMG)N.^YMY7IY2H,"\S5PTC=)/,.V6H]> M7C'B.1F_$!),K(SH 37_92(+'>K+_^DVLKXE=0NU'H/:#X*GC5!CZ;-VKITRGL\"5Q%GL/R"-N/R;CC=^:#5^*

*M+56+G1%1{O*T"%MUBZL!>A<-RJ_Q!%S.Q:*@5IWvD5+9N!V.XE3ODU?MWJ MKGYD->CU\D7YMV5Y-R5%^ M5>A?8_BJ9W5;E82Y3O6!#>'34)6I[C RQ3?*

$58S+*@DYG9^,83KBV=MWLYZX ME%/57&^P97H-=I>5L$3+KYUK:TH(LL&)2[%B4:PPQ5K=<8<""M-Y@UHQO>A2 MZ;% [VKZ2WV6)2_5&C5)G5^9-

I8$G5XMUV+%9%?FFF#]L0(U29]?]8B;,K'< M+>5H3&-S26C^ MAN&U"*G(&H5^*9YE;$O/2)S@(2+Z M'$N&F @)D+9%!!$A+(I

(B(,;5]O^^#B7>6!KU]M]XYOG@5#I_6..TUN7SW M[DVOQ<0_LY%@_#E!AH8]^LF&=+!T>C"V&.;C/XQ'82R,(@\|(= ^-.JR9M) MR W WR-+Z(H1=,O?6I*

MN[)3X'7CGP^]3_I_4L^4ARMLMG@3ODH=GG&3OLA?,RJXH8P7=EP+HSNE M#OD'A?\7%XC&G/K4_D]*ZV5RM9D7>IPQQN*C06>"[5IV@I$^KQ!W3=@]9"S M_^#Y*MQ=O2.G#TO<8D141GAO=VJ9TXIBH0ES8]W&GH_9P\)4VKL N\[97\|/KC'L0E XW2YLXFXXI"& OL7?[&;?KI-F$+WG+V#9 M[#&G->YTC]9C)CLSD2BVY)Q>5CFG-*

5_F10GV>U!LUY61;!;7=(=3Z*&R?HEE MMVZ+M:=X{(X6S:/YXF\-/MQ.'@0QIO %[*%K\B 7'V#3*6G&>\RBDF_4]5%M MD_A$>"QJ5AVR"Z57F-9Y?"5L8'E#M8.LGT.*

*ME32H41TE+;,;8>%6?Y;D4RN> M$?A%(KU*B&.E.EZ+2;D90%/_NS5&.E&Z+6_WQ;PR/AD&?4&[\N145RHT_,*G\ MY<9 :LBMJ#)7<6LVBR1ZQ0 M=I/C/-Z0JZE!*IYHZKG6)*

(G.HZ=$[(X&TE|(\'\KHX?!IDEVO19RG9A(TME"-MO9HK\WMM/&)C+[>D;6ZG!RFZ<2"DJAL8<[4>W/ Z G$Z,2UB1Q?(#A$76A= M\0W;3U+0FB&><.(\ GZ+(92/%A"A/

CC/9\G#VYNRMQ1 M'J266S.WV)2G.:5U7ZE-APW1K +&PKBG#=W_?A@R(!$<>Q)D(=.7=_360M8 ME.;AP\7NE?00F2')[*;6B;_$+,W3@Y=^%M.FL,4C2OY) M1.DP&M?*

4B.7W9 /@W$4T%9DK@LME7"N8PMZ1W MR@QKMO3+3$K2 G?687(I0^1T;K/K)]2O#++=!WLB-Y I%PI$*-Y@V M D_>V/3Z:PW%YW$J$L(?!"9^W'MVUB-K[M#1>

%#!S.8W?,[JH9+B<8FFIP MLP:?V=4XG?!!T Y*S3I+H/>U0W^,N#7!C:+,,-7&G9DZ.B7[^8 MV:'1 7SUH,E9CRRU"@9"6M-,IS$K;3AQ4-_F,HMH>6OU 4*(Q!-!^L\|P/19@*

M3Q$XRO"MTW#JZG'':HV:%6>LG:NV!/A]Z MSRN/CL+)/ZP$+A9X 0F<")S,#66'!)NU\[HJ1V:" 6E.4"PX:V@_NS8P\|2Z M1_.M, XVED= $0 I18A*$!?

*@F7JL!F]7;JE:,5D'RRRZTV]<ZU>;!7Q(29W?|/H@=NUMG%KLH!#CIZ M/Z:DJ)9IH$NB%Y^Q 7-T8,:$]>YU86H[_^=YKC3JJ@(XPI)SUX OY,2-MPJHRMQ\TEF$D.!JYL^*

X!:I_5"HPX ([.I@AN<0F^;7?[P.@[^QTFVI74Y1N#$7&$CJ3EU^L8+:.$Y7C M[Y:L:#HU7U6!20B$FJ^8W4O/A$=Z=N0&O33+6XRNK-<.OM6+"S'7 M(S^7SN MW44*

KTN0FH'P07;'KYRD%_LK;MQ H%[_!B'G$2)D!>^'" 1J$Y]WS5Z!&_^J9GS)U3;S'_|&G\\/BO=,YCE>_M\5$Y'CO@$BL>VQR.KV" ST ?POG-}]?;

*U>.E!XP/O-&]N(1Z"P1Q#\1>|2\ M*XK*4"Q6@C42+-"HHP@IQOO!(M0E:1874R?"^ (^ |S|!?|T?\R-LYP2=3-MOD)D"CSZ,.WL/XK[8[_NO.DGH*ISC:*

&0"CEQ2@^);"5+)';!K7QCO1S0Z@-MUDQG25ODE"MF6ZN>)+9L+8+$%V5>N6X"+R,", R*O#@,Z@",!T^$\IF82UES M<%L$!HE>G3$/5\"A(;:,.P@7^$F"N8BTK:D^8H&L-

*EA=F-K""PF3&6O'NZ@X_BMD"(*G-GOOW] M3)34!! ^&GX+]/_P 4["S<*(#:=#WVM7!U1_4*1PISL6N#@ZH#_+%%BH@T_4 M)=2)P"?6=:@+I&H/<|)-P M-*

"Q@DC,!M!PP[JZ>[\PF.Y3$2[P FY&7)F#>B MK0\K141]%)R#;+?A!S: (>2 ^9,@8SO#F#?Q)@#/M)3 L8 C[!;<)Z 3 $?X,,0<\,I2%2,C!G@I8%7PO<:8BPV#A]XA&M=4.',+*

*M:&O@BL[!)P51<8 W.8 P+GI_WL@@^_.!#@=L#"Q3#AE 74)>A*CNA)C!@)X# YV@"'%@*VB*P*W8&L#+A3AC39%@1@ 78FKI]HQW/,*"(-M1=3OQD'@E&,'+?*

4!&)YQO&" @\,)6AG01BX$L^VA\#M0 S UP,+UTG?B4!F MGH(E[@HB$&KZJ;AQGA!P_FA+@D0X46 M%8=6I>F<3=\1]ADG T>-&8;+0=NCK> Z0L7*4E 9MF,X6XV:/$4(+*

<[G&8Z MH!\X32'23UT2W8BN>B"MG/)/,[R;_-4LW+/@U6(#-:(;]QN6%/#9%R:|__Q MH!\:QN"3O2B;%)UO|[<[T3|T!V F#E$G58K,=&MNA\/6L F2!I@'2LB@S!D

*ML^W44X0NY-OK4]GT%*GULA SV150K)#.X N\(ZY(Q P X$R8@9T\:,L>8KMCAA:FN M&D"L_80__:.G:KM%NAR!4!!^2O@:-AGVU &RG;D5C@=85#B1L.7+'"U;B>2*

M&$(,"Y@5MSTQ;]H[P"9)F\|/'P\=9<&-03L4&CF'(;3(K^P^[=>#`M%G&#2\%+]SAT6$HYKH&!HO.A&7M -TT7!DR.5TB_ M*/07S,R&'!+3,@?*

*DGDL],^!5S3FX__UB#:]G[K[^JVNFX/H%8!,1O),Z1-\% M1'&R+-A4Y%@$?B\X7IUAL2QG&+P%Y1Y\ +QZYK[9F:G*0,D%6%EF !-H0-1# M9H":4[>-%/A*

*'RH%,^6AU*XAI1DEGA ;VY2E ,;WH,B5W[P@V*

8(M.P!^&9R4)Q2FB8Y@:,@#C^=S%!23\'5 O#>*P"Q-M4X;'AID3[_E.HYP%##N M$J#A8*L:,_[AR_ T2D7\8U ?+U![JEPFGLXS=V76M\ZS;W+3C.1^5.A&-*

*^DYM%P=I2115BS.QTBXI MF^V*6\17\)FITRO9HM:MQE1M2G=Z$XVO3N+]WLL<7$D0IY>.!TUJN<@.,[W$ MK)02J9&AXG7XI',/)1>[5]+-.^LORU0G(6(:*

MHXWDE&X2T0:X,G&&^Y92QOL9?%PN7=T+QONPM<:(M2B7]9QK0Y=-Q0T#=Q+>>P0N/S,_MP#-2F?[V@%GWY\H7ALE=G^ #*7 @"0^9/S,_#\ OPR?5152&?\[OHFDRQA?*

@-MD_0[&?A'P2\DG(0R&?A'SR5?GD.V2M7;|Y%93C?+8P>^W1V6L/3*[]"1+& MG[\"G)'\|:+?FHP)FX,ZH6>L-**K69I2R?]+UA+SV1Q)D-],/13E+S21*FP,6?<#P:)L'|*

M34EP7T!@!2^#+FS4$P!6\;>00MW_@3/F1P/MUIDFI2A7;6]FU1V.S0ODM*B0 MXK:]"3--0BD1,"A|VTR3NW!Y)YYN%]=F8]3HVRE7NAF-]M.F$\6C]HA;W3

I9!%M6VD9EJP>9V 1B(M<->(!"Q!%)=K6TGZ;-[.3Q\69%/H?&;PGR4J/8NL", ME!0IR-27!HE46C-G.TG;R5[!5"L]=Q3UHD)E<'Q^LM=7M=6_#N0$>ECX6RKH

M8%HF84KEE^27@$+!|TV6"AR40@8+%=+W5TAW3C822KB)M=UJ%IG02XN+<,4^>)W]%:S"5,S?QT+A5 K8O^QSVUBWR\=;BZO3E7WJ,MX+0V\G MY BWU3C%X"

(;QH@PFJ;K6T!|)B?M(O_W+ ^DBC=^^B31N\U^=T?5)TZQMXIHP M(L-)=T1T-]M.@"1++E.5;0HSQ4XTW4RG M<@6RI%"?""HNG:M@+_6R02?X;6IG#=?=I@% 3Y*

*)?]B#Q43,!!79<8QN1#C M/[-(V5*X2!1 BD]1=B!,'N*Z)RA@6R4T#8$F[YT@7W&5;(-P.6Y%!9>8402> X]7?"M/8=/U>P$TPC -6RE/:1H _I[Y$]OSOD3P.4A|&#TIAIO_O*

*MF:5#@+ZC[V+;!9P7Z4VP3W5&>/|;UR=2OF]&:.^).7R_SRT;+*D0A?E//T5-] M9<,3(=;&%@,BV=\P*6MO?:A7J^"Q:4D516=*R(Z40$_]\4ZMD9O>MJ M6;*8E-*

JO2NL'@[_+:.#EHYQ|W"3/M,<0":.^QC'BF4!AG-X'Z[?WC7F@#/-M7M@:A\QL,81)Q5T;)G&\^9NQ3-7] EFC|C>.W6M?XS&$G6O@<[:5'8L!Q)+_

*M@7LT=?=ISBL)>^)O.^M.D,^)[^?>.V'M\WP5/),'A.S"S?V.04?@!Q30O(AM M *3^T51=#%@3T6^E(X_I^.;!$.SQKL+7!-M?__(C4H[\Q)O+!#2_0Y?*

35U)L3+8_!")IY35].&0\3|$6+>F4/S]EZYN47 M A7+Z1\|2^IA0<+7A/P? RGU"]'8]NKY?V^PM]<$Y<.X(/5I@?+71%)P#@_> M"Y/ 28/7"/V_TZ,W>#G]Q[IYQXT; ;\M0A_YI?

_]W^F78/3 ,T,H#D)Q<"(. M G:$2.)D_&:L'K"]?>3XX1;\'C PW.)\]TV'C@&4)?*EN"8&8WN,3XZR#S78W MG+3F:F#G"[^QGSLM*BSP?&O7LX;8KIN4-^TTUY1$80ZMS|C/

*%M,;Y&'B>]G M^OPEQL[-W+@ 6"VA;+N!;(.^37>C^H@TJY;&$WIL2/<&A?FTG*9ILU6<3V)W M$FD!.PD PI.AU?>MK;Y.R\+0l/NFXG&AGE:D"FS,+&PCL;-(3S^*

*M$J.O'1[IH=$?&GVA? 37^LA'827*F'-(I5YE63'@J3@&9]R!Z=\,YNON\|1 M#2V_/%_ >X_?7-A^)5&2(22\]V2D8+BX(IXE&;@%6NNY2MB8U>-&UL^NW'U$SIM" O+L!^FJ*

*3V.$Z6B M@C?*8UVJU^E127 Z-D5?%Z-N\6T JFN.DXP_7FMS6D<,/I/"$!2+L4$0@,V& ME<5O@6$T\2D4\]VVPB#!,"E*8BI*IF/)* %>]+_,%R=ZNXK 4RO!2L"RA+IQ*

*M<0*K*'SO/8HE+M8)D#%7M>]U61YS@X.'&HC_:W4(B B!/T?C_XEX_H8 .8,F M++#'TP.RHA-"Yf;B*T/WRE8H6!S6FJOTFB6?$.'CL[$8\9R,WPE9)T97](: MP" +'=H'_]-*

M9'UY$/Y]=7P7JE.-J'PD:U=E&GM*9=Y"K<>@]H/@"0\GXBX/-M,S\DB#@>CQ'X!.<2W"0VG;4F3#+-3)#@+EP%W-T:!03%AFK8*R_R6H_$

M%Y!"VIGQ69"M<"G5VI|@Z^4FL6QR"6P1EX>Z@E\%Z^,GUY)SJE\,I31$[W=.M1A*&NAP326,^(<^?F>(S+[G2@.W1%3,CUF^$3)TO4>#*LV>*.[497XT3#&XU*

*MN61NE:?$Q QFQ^&G5Z,E8I+/\=M>O9WLK$4EFT@G\ .:! M-P2NN#*RN0VX\NSM2DS([]+],(T/-IL517&D-EG 1);SMQ?G7;DS'K 83EI9*

*MRNB0YHN^=5)>CJ^GAE)R:5Z91[$N9\$C]_9GF[M79&?D?U5DJZ MOLW$C\E|HP2'U_92]CK0F:\UWMR(3?,"/S+M%|&9R|GSUO/TH5"T5C4>A;O MUT2VG*6R,F6?*

TAQ?.2$V"8DO= F1)+1]52/-$(? MIK=/9T+8-)K,#K(WIV3'&68K3%<& ^#4$PX12%I;5V#T/8*,+!W8!:/#G\'&AIX%6GBRB M>6/5[NWJQ6Q?(;&!@=^+&KYX3X,W-*

RQP380_;%<0?2;N#M$*JWP2519/ANT^ M H@7XCD=!DL0\0(8)AHB)GB("059,/$2"K XB449('JN_*;@7SW3@N11YP? M7Y?*

9C^TN<;G'RDEK">!V08C\OQ_DCX\R8_R9N,_TV-2U8/KI87/4R_(^6$*- M"&GB""R!$XF!;SUR=V;X$PB,&\|Q0--FD(:M]VQG'C)1T,KA%SJ;C\?IM

*M!4$WGF!"RYJD[CBN;,.GYY0N:^DZ$&H^Z9,%;YWM9S/,$,\2I9?BNJ 1Z>C< M;L9#/,6O3B_YQOP>LG?(WD$;,:?LA]NZ8F<8+U=C@*ZR>83.=WFJ9@CE"B1__M1!J2R?0-*

RTP>[R.V.4;"8R< >"(FL[W)<,\@&N\/,D2^1?G=]\'V1PBBVXWN M#!BYAM3Y#:CS:ZE)E/&2'E5|T{5T(#S@[H+1BDIK'!SZ#M'7U++*K*X][$7E*

*MN1K7)?I20F W$TPV^F"KB?6'4) :5]-GZ7+^O[N_#HB\=.%/TA8GGP'-=O]!4 M^(_G.,:*H0-%]=L+H7^$6A&& NXF\P#L+M];1 <-GZ/[^G63]M92[]Y.<*H4W M*G*-*

CD^4SKB\Q["S\>CM!T@FWOR\'3'Y M>4GL99G(E!)-,"VD](P3M/+3D>M-%8WEA>A> C%0Q#$P\U- MIG>+!YRIY--4.5' =[M^.M59$VES QOFPO,&_)8=R4M|#WW-*

*^UH8;.Y7%+:.5[,;S*HI/8,MJ8*#$GN*) M5\,Z?TFW5>_G &SUXYL+P.)OA:< ;.71BW\KD .R](U?VDY_3,"_'3]),IO1725'XWQ9XB0[_OL9/?,WBH?\@T:\1+(Z-O/.*

*M"#77.4X&2WNP?#D%14F!Q*5PMMFQ$OKJY1@_<(!10!7 :'BQXX4-49L"U@6J!FZ8;%*"9,!P0F M"O\HZZNA1E\S?[%3.3_WL4T(@B;BXF)H9N3+.QBR>D:HYN!.F!8U,*

<>R!%U M\FSPP ML"D9PF=OV<&VN^HSNCZ]HNR=GAO.\CUY. +)B9#ZVZI?FY'-(ZZ+) ^!/N$X& * M=&$;:%4%' B(! $NV ,#E$=>'!F2W4\,.1RN%(P([\VE#80%%Y3'>

+@I)I#_A MK5+#(D_@_Z(XZ^!9!)O[Y%?D)-@XN9U59DSAP]0Q(1UW0$"DYC3[>&0UW@-M(K@:@^/08R().W6_^'"?2 0PF_ 3*

*=3KN+K7*KOM%M5G:M4(F^!'[.!.X&61M@(X.K!2;-3D=5GPS\\.4'HST\$4_ M4*[7Y\2]P3I_'2_S'D9,+H%R!\-R3 ,2^$;$T@'! M'MP:O! 2PXSC&4LR72,97P[HSDFLCL@*

V0M!%YERO.XKD.+VLCENR^;G2%,7 M%%;0F#UQ\I-,'1 GR&-5'!KCN1,1'GR*&-5'!0&9F6-T<#7D3'"C3:AP M_6[CEAF?HY2_%_SF I)T"PR Y<.ONS9BV YW60 -*

["SEJR84+V-)Z#HH8;2J3!FBH"K U9TJM_MX3X]BA*0JF'*#Z]R^ 'CX'?DI_)TP4K6#, HXL(!(.#6VG1O%1,X%"=PW=_N M]GP*H&C)"*

*[IA4A"&\/NN^EY1PP|GM4V\;2KB8,)D-N,%+:9*QJ&4^#MD3=LE M5*/!PXWL)4K"(U 2?2$|3/;, U%(:RVKL9FD-@6@:.//Y_(D @A8\N@WU3(A MO<,8%V +E^FGC 1Y(*)N "4AB|.?GASA,'-4$?R;<6'W!^CMTTDM.B%3>P_L M\,$;$AJNT|72K)R-X8+9:&4G?.NE6VO=E}!6%7+0&(X3'5S0!%I^24WI?!D1 MVGFD|K;$!G4@;%2^42,_R5^1J04L)9A/!96BCJZ'MTO<'"S)X$Q3.KP5KD<^LB,|#^@<-MKLV#U1L'RW)O))+XWDKTOQ&I)MN\L[$%@/8+,8^'>PX0<|'TB1(|.HD2WY:/ M&ET6+V7!7E/*#>,M!'6GS1|0-X2L 0%=2;P31MG>Z/*UU!$'<$:&:H%W*4X[N\;K:@"..C|(5F,&QF+#%[.C6|R+Q2Y)IK5^RW\)O|A*,.MEUK5Y*:M DGY1NS^*/YCAS>NS7E!AN<^QH'^@3]0#, ,LNI^X&7$=LO>$G + M"=5+/FY ?L\L'79I-3CE.G%"$]M#?MHZ/VD;*M\6N?F&HYM6FF['@&PW $$Y MB#L^B8#T!Z@;>L_@<2R4ZQ=M ?!)5ZWY(E)C@$OO. <_A,7'/% \5_,<=P_Q MYGBVW|K^;!BR%5>BZKIGC0<[G*57^=AV\[%%_1;@ =I- U"G|RL'4 .(@#)T;F4).@S*2,*: UX;H @&?*L! M00&^! Z;!&F.98Q%!+8IMF\'P) AQ$A>(MK+VPX3K2=0$B6#N$"G0J_4&VR M|:P%?I88Z&3;+T,KW;O:&GS WP#? MPJB0UX"HIG_..C_O|0;!-J@+%@-H USP$Y@HP#$&QL[_ >W4-OH5X755#G(L M%-[:AJ2.KH>?:H(BR)81;ROF2U6VZ5"LL*4<+FPH4N)|8"+OH E0/@8 -Z5#<@X MR.+R423PI^)T1.3RXV9S* (JK55VMM(>Y=]A?G?^CTF"R&L#6;&P&IZM948, M3>X6"08(U^0U%W]_8F.G8NP@D0!!Z?A8/D(J)**O1D24'>UK(!TS>QLM=9B^ MT,@M&C.\T132V2Q)<&,2T-(52D(>- O+B6;LJFN5L=6QH8(T\L,[!E6#S]L)= M4E-/2(T"30E4);N 0+9)4U$L6%AL*W-'YR,CT% E#JA;5VGS MQ*9,"L2. M<,*FU)$H[D9$D<>/@L3VY>B!@@%S@CG-GJV%& (\#_ZK6O_Q<'(=@ES.U;!+'$ 9BQ0 2IW-T2#)\Y 0E85!#$ERPJX"@-:!;=$K)>#H M X8#P&>D#@M>@_B&8=GG5.5F3=7GP/#-HD,N2#!,.-HY"#UHN\62; [@C!{@P\N\!T*;B3_,8"@@* G@'IY JM,D" ,CPQ |OEH($&|W(P/ L% MS=<2-,_25]IVI.=FU7937!4G\6)KDU15R%>TE7MD!4D&41#/[=:U "$4+GNK M&1ZR DH5X#W@=D4U[3/>'>2JO58|-\.?(!3ASB<8WW:Y2JG^*<)?;9A[% ^'N8?#W'VI}?5A[H#X MG917^[#@:GJLF_;ZCB19\AY,\;J-?7<=Y#H]4PXEF1TK'J]IVDM-'P'GOIF! M MK)R>$8Z'C!E!O|1'.F+5E&V4DPIF|BX#8,,%OD;,^'<16,#18(EN>F3QE' MH4[WN-P0.ZB/Q)RV$1"1R#27+ X<-M'05F^PF_M*$ M?^ H9*OX3,/(19R6"Q8_Z QX-CWU/TN:,;LCOR#C'+WGF%T7R ICH4JSO#M-`MG#K"-,VX+TN0'>!DJ!TAAD%7H,>$!P@BP# M0 +:D@"}KX$Q@(29?<0 F?)IST4&9ZH\#X,)K$TZK.0(,K+8 'N(P$IZ@M $ M{]?L=, JB=XX4?,F=!Q4.DW&2")GI&)1NI'-MPJM!58>PK'O!X>6?*L_>|C* M,/!USG1)+Z^K\D6JS7]@P/4K<-=IS-D_+,Z=2(S'.-J8H@GM';^F>F.S=Z\ M]>/?V'G0_C^_W- .6C?H0SMQ5>YX)|!1N43(E5T@YN: M99N1+$IS1GIAGL/U\9L/YSD//(24D2.U9TU*1+/:>*)}$/W8&K9$;D[-'!$"7A&'B%6+ -|<(-=#K,#*5"A!:FRHA.] M@5\? 6P6\D]EO/R^4DM]92LHQ@C"DDCFF+;REK9D4X,#EW%|*0CJ[#S5$)V0L ML-1@L_0?D(/.BEPV14M9L4.;FR+7R6&XU0HD.0Q>S,14%[A\C]OT^TR?:M:; M,.F(|"$')Y_X(7(,WJ'9J4FAC JPC.H 1#5XVL76^X@QJ>FN-)A[\?O#9 K9Y)/A^"N M5LF,'12^3Q+%]Z:=UU70.PNGW*27+&,L* 7] U7/&E -H!_*S **@9D'?4:R M.%)R*F^G4XJ>&U&QH\8VA,&GJ7P2")/S21)I8K*C^.M.0B>;$P[YP=,MY0 M@.)A_8E5[$1XG(#!I?;;$7UB2\-ST'W FSVN67.RLO>5^HQO0,- S?],!ZS>]P)+6)76!ZJ_H^#_J2F"U*$V,=CD!I^\8OJ.JB;P F7N 5A]ZHMB$V(M,\PYN4%MTR$(-=7CYF2[74OI3@TJ]S72S M*1$(W$M|))Q<"EAT+MCI=Z>U*2=)=E=)|"GBD&:,.2T=AJR\$EO2Y,.I9#B;9.,|2C/+AT'WK-H($S"'"T 27CZ,&0E4HE2A+3VZSG=B59*# M50174\;OE@%^$YOB823QIY*3UU**D>*:.|%J;K>K9[2_+'E>)[RP\K@*6241'6J^ZG4O4Y8/R#ZGE74@V7X9LWJ]P MO>0DQ[,-<;$V&Z) #.MJIK!8XX8RZHL1VUOHRMID*[NDODB* M#4SMY/|3;%PL0^^!])=3=U2F=VZ:\L?SR#[MT/T 0R+U[FY'@(3>>_3>0??X M'+U?'01UL'%D=0:VX9.7Y;SX'VQ=W]FDB'K[':/6TZ%2V4>((!':V5.8 M#LIH3S#$.2>@F#$TL#\UM30|(8(IS)[_^T5: MMSZC:W4W7XZE2Z3*X8-&?3PQU|4H"2.RY 7|9M^FZRVII3Y)HR<|583C.|!A M]&<$'8]^2F[J9]9Q-PJAKV!M8&#;7.3K;*FP;)0*4@2RCE-'P%|NW]R0. XG8+L;[_@Z4:$04WB M7U&.,3|TOZO*VIQ0|--=>),9S9 Q!Q,_MH<0,^; <|HPY3C4A2I",>>_;U'#=AJ@ MI=VUH7)P\ZH#X,$>/\[;5]1\LJ4+_ 8&X*U$CN;RK|#JC^0W< MFL,IW;1'>%N2B8Y7F'PK1Q.@F|8Z@[+A8FG/"P MEP$.W RS<:.@-E [3Y3D[#V|N^?DGT,1(4SD3WS9K.T[DF%_P@|!U"*M]CH M-4J5N3DWD#_F79^D=5W6\AOO1HU%\V:TXU"7I7D3;4LIM]))O0F++E, MCW8?ROU\P<0^QB?L)=A]TV<.)2/) [RC0[#ZC5TAL1:*QERM9D3&&IQ\|AH:#91\KB#YN M/+"/I7I>&7K,'SGOZ^)*>K&:,[AE)-,%L:6-1(%WZ^Z/1% 3:0T?]#)5$N2& MI-(2^B-65,7{ZB>@OA],WMO/^^OV,Z>"- O9A^WL/ZV=/?FN=O;1SVEG#[9R MU-_B+%#]U@87:J76K\V!<6H-[3"SWUP[>![KM'T\BD7;86';^6,2H^_M8ZV"'=3]@M:,\Y+6C$PRM5FR)F9E"">B1X]5EN8C;JRKC/ MT14BBD^H3$GKPRO//U76L:8&("N'1NTC?2<0[.5DY-3R@:8A8+|0Z?P(L9"] M.997NNMN3VB4K10KMDJE#\8J;A$V*ZG5=(DP1B(G-LUD#V.TJW$\,J8VA[A M@B8,/*#?1[*3DO:'V'#$XW0/&FHR|V*Q'NR>?KCO@_9Q?P>C|9Q^WR>'IVZ M+4 ,SO3QC\YRBLXSE:!'YO2&LB>HQ8|\K;>G*T&%QK+ 3CP>#'.ZXG .NBKO M:0%1S=<=^QW_Y? F7GUEWF(Y.!G-6:,=[5F):5":]5"]>G%^J.[Q?]2E!3D@R ML#BW)<(?(!V+QR5Q5JKD<6S;FK!:=KEHY5]/0GJJES9B.VG1Q*U126NO9'G1 M2L!^UCZE]?]!LM0M-K;H1]B3*B4-)0$]Y($;VYY?;RU)B/,2DH%X,9+&Q>F MTZ33VY3Q(KW0"3'?7QH3?MO"?-O"A-Q_/^Z/WA_1)-5;:R(Q3/0Z,&.YK5!" M&HO/+S#]/Y[S,"<9\,A-? T=JUD=RLIQT+C&!Q"R.>4P7O'Q+CRX@9SCS?<_,%M-M[*&4.-R3L-Q=<-XL3UAHZNE* O.I.>#UN9TGIKM(1M5U=7/6Z!#\#U$>RJ4+T1H/R-) MB)RDOR^|:.7V*BG%N%6/'(U630%K"]/-PW(4&WW($G<|IDG%TX!$/8MQ-!0> TH_IT@VS-F0UIZ$"W]:_?5ZT'SK$P/^\$NW?18CX!V+|AP>_:=8?4IC_:-^=VQ[!7<36 MY2X3V\EO=R&VHRX&[R$VIP;^NQ#;)90FSU!Z;-Z=X!?YM4=(9KPSN YX@/?5 M+!,V0'3,C9."R?-[!OBWT7SL^GN*NH@-745^%H 5 ;$ M9?35?B 36"WLS^'9 .K@[>X(SNF'H3T&^$0HO2*9-!@BW)^LXS!YS0V4S MB_.|^&HQ:0E<-@6Z%I7OYSA>8 5.87<1VWC;0\GI>]ES=@:V%VEP7KC=_<&S M+E23C3:D(9>N/NK0D/F 8@? T6JUF:.MK#3M; D!R?X)\U!EHH8(G.!K@ MH|S[T#^Z<'X$%/<5D.)1.A]. 0Z<'=T5K /3'0.#;&=P:8'SOEG+:./3\HX=RO=@_W_VOK,Y=65I]_OI<U'3KO? O6WE7&1P$$>)^[J@@B M9Q#IBTJ(0*DVLATQH8^ZL:*>+I_ Y0JM\:3CXTI]I MDDV^F.SEV9XYK'43A?&"H\Z4(?0%YE(W"NY8>IC=4W74 IAW6Q "OI_I 1H;GB)H? XG.0@5FB#Q2MWTNFOO&KR:!9' X]2& M3$47%$]+F5!1UQK9HBB\S2Q7C7H=+^=D]XI!C,8?8O$3YHDG,R_>-Q=YMV4? M!%U5=:39Z8+LGVK7[^A#-)E\ (*!QFT@<"]IY=0 ; M2VZ6[';<(#P>KWD\OB=]O94EE_P>(++FG(10>|[.38@.JSF3A-.,&0 ;6S|5F MQU@^R^C[']27$PUK7%423M|M;N7#TTC796R.?#,;1_]@X0\|-O M-C1!_,3=$UI_I]2Y%;O^>43]|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|[.38@.JSF3A-.,&0 ;6S|5F MQU@^R^C[']27$PUK7%423M|M;N7#TTC796R.?#,;1_]@X0\|-O M-C1!_,3=$UI_I]2Y%;O^>43]|5XML%,_>7BI%70FN/$QW?UAKQ./9RYL1GM/M.]1@D5)O08&U)OQ>QXSS>^_$>S;MP@Y-J!? SQ0W9.SY&U+B0F\8WG'C#\S:#:HT/:9\G/41Q8%YEW&]"_%^]P$@I$;[ME4 MQC\]%3?^LYGQ7]^UL1M5=2]@ &1KF>YTOG#J5I.+W8\DR%S-?CIQ.6;'3MIS MT+S<47KZWXG[OQ=+ ^L5?\(KI[Z5\^QU2+L^AK:FIP ^-Z<'X$%/<5D.)1.A]. 0Z<'=T5K /3'0.#;&=P:8'SOEG+:./3\HX=RO=@_W_VOK,Y=65I]_OI

;A88+;&*.]J11NS_-M=V.WK3'<6I=N7'RW&^/SD=1-(@=[M%PP)!LG< "-JA<.+X'3WX%[.SB?F6;/&UG/5675 T_D(#?=*XO$XIOJ7URD^ M.-UO[W,#?E4_VR6W'%;BR3S#2/-
>U1(77"-!BK]^T^0#GCSF[K:?;J#$I069\^@!L M3W73]CP>&M(I*CJO62EM_&8/4YGHU&)S5;#8>FQ%E,<:GZ9@_3 MAWMH8OI5LM!*]^F)TAKE6#J>GI-F0F@V\ZEK-
R5=$8ML13&Z%8;<))EUMI1? M4AID/1D[R?D'##[4 +J#:&L'K'KFD,[T96)^[\CB^C%I_IV8!;SFOY!:?] S MO4&OVO?SW=)BUN
$4D+,EGLCL:MS<2MGY9H7ZP6:F)>G=R*]_!)&?;O//"\L-E+V+_SS5Z_3L# MPHFP1UY &!'VR L*(\+ ^G0'A1(A- 6%8$U!8438O ,RG C[=^XV60MX|NO] M-.
+^W>K# IVA>'Q6/()5CC;LWWFO%Z(#V+?IYJ5(P_Z==Q08OTW[I7=' M485,I]NOMB(3IASCV&Q+BT\&U>;7U_-JTCUN4.|*%B,1^;&>:.H#V.KGP^G$2 M)!7VHON6-U/#?
IPAJ-TY[)VI"M9=KQP\79^OFCLF3TBDV_OV;(;"&B M_9$+-42T$-&^JK*8P,Z9/0%73;)KA$]>A@1^9^]2, ^68 >W 7?6Y4>82%>]1!#Q DG\|+[Z
MB5<6_,RKU@/E(;C\;3UG5%>61_I&)_83Q_1@0YIB9*H|RAV5XFI?^S_63* MS8=O!+1\UMBZ4O2CRAO9-$UI-FR-78M:!\%$TI=C4O.A(O|VZIF302_W M@]6&T$KY=1?
]YG_TZ[>;E(NNQ62\S%-K*ZG\>Z1UG]2G*,B[T.9- 7(:#3. MC>)+Q.!>-)V,<+TP 1TWB@.1I*ADEX[^\M_(,,.QSJ60[_9RIL;R0B%7F-2]K M""ET+AV.++>?(VO!Y.I,KV[$4P37
ZNV"&'S:..24BL0J1#D?96DMDK-$-2LG MN10<&3L7+CQR-A<4U.]9D*7Z M]#(HWFF2\-.1Z6A36>24C(3WELU6HI).2^9Z@>Y>'0UM.WS*F5)<$R\O9[C=!-5(<2&B
MH4=K;JXC'-WO1RML3Z%Y6Y'G"DFX3]U?%#

& M=DPI"EI,;E=U.999#G6EEG5ZS7+\PHN2(N)H*S^GH(M9!^^+H[9.!;]6>U^2< MB3 #D#1DM;.NIKP&B_LCNYJ>,9>.66'Y)%E-*A.J/Z@L3NV@?&YHT#V\.9#S
M8M=.QVFGS OBJ1U4F4;:?(^M)5F5S),HNDT^\T4"GT[B0#^_F[C YDFBED M;6.5;1;-DSH4=S_RC^4S[M2OC!)>1 M+|<77]'[O[1\Z;9)&.3GCE13SAI/6]
2[@WE5H:FC%OJBG9ZX@AGRL.IFE^6AG*[(8L-*C,6Z2@J M27/T=LZAVU$F':FQCL3'B$Z:L,@U&GGT]LF*4195AT\SO41ID<;U27L!=WK\ M^.W"L,0-
TQ;^C*\B$W6PR,1MBT&1Q3L$]B(Q;.GBU:IX.AHQQW-<[9>3I1E)Y%AVT1QM&A&"DSW\$FTXEN= M657(-IGR=&JV;+N@D:G%]9,HX?1SUG!-
XG+/C&LDGX]DBWED%!S-TTC3LPK'M569.;V46#4*A"ESWY)F5+Y6"YZ5+8S]C& K1E1)6JL6Q,D\T?SG,T6/4*>)36V+DOM MON%(D_;\I,Q/N3,#-
;,]#=\K#Z+"D+&TN6X$#Q&V/\2)^+_2HDO&5!F1!?];:!! MDB-HM8W5(-WQ#+6=BOM:F-WQ#+6=BOM:F-E#^KF']J#" ;"B\AJfW;2F>7B'? MSIYS;/O=^YU
4@AN^&8PA1\I'C9[8LF\^"DL17!MTO6LPZ64LU7[\3ZQ:K MT!SUH%@%>M$3Q!CXR/ID.TBFT-QUFRG=-73-ZR\IFV->_D!ZAP!;3L MP/&M>+!Y)*:XSX2?ZH@ MG'<
[IX%8GWW$,G!8'(<'TC)0]6#,T]DZ,A(ZG]6.K7[P01/5TFAD?E+DP; M&>]HNR.Z#@3,71NV61RV7=VF=@(JF;$IC8$J:_/*]NY\"!!!!(CH?$$DQ'19 M8,NM&-\017P-9JE7_<+?[-
*UJUQL=;87_D*EZ,LP>SROU&2R77/D6;K"R"E'.M3D?93Q0=;2*FA?QL+I3/U4C)C^:?*6$E059R6,1$W"BE!IN%&\!H$0/IXFOF# MW,-X10GW<'#W\+CN5!H-L1#)L\!25#?
FE(\$"!/,+WQ!N$9/8 M8U!4S]J2N:LZ/#"AT3&92%"/Z9@_,N\L?H-IP4U:\APMYA'RC EQ>XJ=&\5MK<*7W&#AS@T$%%I+%2/#/T\QPNNDH!]6*7-%:\I8-".
MY*T'MV#9X=E]S8)64<\;)A"P;__]F6V<=B1E)Q0LS!9.1"N/HW*OP14[[91(M5H:?+C_S;G"E\5B1K0G%B.SD^[T>6I-1#@DB^7G^]RD,LP2B/Q=L2 M5$4-RP+!70_ZG-
QG/2HB#Q4_Q%7TL2L)+D2;P'9,S?_X1%P\8GX='0MSPRAH MK+[S%"AO2%W3,?*.&'G]CTK;K=XT$6K!9WW<;D'WDN%G\QV MH?6)N^C\U44%UW7
6F/:6V$8K++XLL.6MKZ/OYD8O?J57R@\UQ83:<1),F@$% M72G1U=D$R-?RG(5E@DY>M:!CCWCL9[XI]1(BX)/ZT WQ_[^0ZLW!9LMQ&,T M$?(E@'RA'ND?
6MTIV(PA'\D?6K,@V'P)@2R@?(% %I[\UV/,!Z\BOZD?WXP(MB0\0X9J;Z!\3(/&U8I<BKQ^'__47?S89^_B4^1C[+,U7CY.FK,W\P>_-RV, MV2NE_4<7[;-J&N2Y
+U+&*Q+?:0\BU=K"}^=5XX#)SA$Q;B), MMZVM=\EAIHBX!P#>M=^M<\YMR>?UO0+?OI4D@;I)5>XXW:%;'4WN'OLN7$" M=C_WK)ZL8,@Z(N^Q4WT<%.\N
2"+A\7:1Y_4XN"=E^14E$+^36_;2/?JK,H MX1K8UKV8"P$3WS<\C==?\T4J1[P58/BD,A&[Z_KB2A&;W!^W[Q_*!ZA[*2B:
MF$(MG=S^0&T@'O5\|S_+>*DK<'A]F[JR[5@X33)2H_V^38&BO%2K%"I#Y= MHF$W"Z&%J%B?L!9PTPAW-_>)8@U%SEP.$@W:D-7T02?S-@B[W:]Q[ZM&V>2.4)<_
5_Q+ M,)"UW13,#Y#I<^O*P%_C#7G5#7#KY0<^>?@;0:0O$WL8GZT3M.2:7Y+R1 M* XI?$6H/9&+(9TLFKB>2A9T>SL$I:\'I=-'TZV7'RA0^@X*X=N@U&^FHUVV
M+2=94DW"_4:N6C+3](K!1(^OGMRG/\Q[A5O/?R>6$WK|_@]Y"'"@D@QUAUT M<2 (2'E!-]G-UQDH2+Q7/03RM:MUQDH'+E7U>H<>?>M%L!2.A;"VQJP1?XSP)U>H9I-
&LA]DQ]^4-J-M38.X6-[A8 M:N=//(" ^S0Z\<6K,UQPM@5IA++WG;EQU1,B8(=]AK>FF,%+?AU3%56;L_9* M&[G%DZ"9Z)C@113];F;!=[U!$*]#H>D3FCZAK(>F3X!-
'R_S;=MA#A/0>8;*_M*UC8Q-355PNZA3<&PAA'&"O]$;'2W?21;;-NOW:I=2+NT>DN\;A06NMX62]4 M[=F$TPMQMR.5>]6 # .H(;B$ =0P@/HY<%FE!I4L-
9LQ>2J58HI#BQJ677!! M[;.3Y^XQ7:'H(\]*7RAR=]K.=GXCRW#>,.CJG8'0O9_LEZR[2X8Q_1 6 $\4C_ MT ++ 6-$ _=6N@X8(Z*/"3)D1 8$4)3N(R(B0$>$9$4[&OQ!IC1,B(RS'BH]&6
MM^RXKUOU%U9R/6\Q?>V2W:\N46TS_MEJFV3RD:8"76WSWS?*:Z(:QUI8D<(? M-O"//ZFV&>Z*^UKR=A-0GRXY2SW&/GL37+!@\5MJZG>7A>AC].YEX0_K#<=O
ME5VUM\C] L,7+M"(\.]6"!QO%6)2^==[HA2*?\5MEP+X9ZKQ:G--KZ?R2-2$5 M<36>-A8+5G7F$;4P,R-)?'&-6FDG@H]3NIHREV9/PT&2;)'QK-HSNB)'N3?#
MJ;O<#/<\BK<6WT\Z;7_JND.PN@\$8#?A1VW1 M<$ZO>RU5%7M,4C_SBOD;91AW?F?) M=*Y>2T^'OE@,!:TQH?8;]&H,)6&(4_7:BJSUL(?
W"O^E'9F@]29;>?I'YO MH0-Z;$O^D)\M^9-\)).WEY\+TFI;/2 4GE!X/DJ[(OHYI.Q0=D+9^2CM.KI] M"#J?/,R#UIV'Q#;(;B-MT+O;3]E?
RD)1*;ZY;.#.]D$&YU4F1SYY;.O4X@F!)@08$* ^5@ <\9F2|>= M-%NE.G-99?*C1$8HYA+" N(+.]4=PDL(+R&A/#RQW8>6\K.GI-4AJ]KD41!EHY\6B%S?S A9$^_J+>(>"+?
6!@,YMLH+^B. MG"_2T%^_YX;&B0AP9Y:) !3/<\WPYPPA6DQ#(QEGMQ4U5!>E)N +_7PCUGC0=Q O M@W^?T_<.CMI0/D/Y+]++)OE\5?&VEP?
1POE;L[B/5[KZY#7@+]@32)+PY56YE M2@::*.$&"C=0N(-"#11NH' #_1%1]OJ$'76;:[I^[!15WZ'2VT+(W;AOR)#^P ME,-VOU=I>++9C43P[EBU-
5MY'D@8GYC5]>GVIGU_<74_>JX>]4_5;4 !OHBTW M/>_WA=Y(C;+?K]Z+):..;G;7=5KD(%3NLYOT_>T7+MS" ^H;IYM/&);JS+K]8 M.NGB@@@B7DUT?@)?
_<0K"WYE;=I'\A^W%;^?MEY51.B.P!^IV%_8SK\108ZH MB7J2[=!LKRV9_[/ISF2;#[^HS>ZSQM:-)Y)X1$W05/BGOI_H\1B/78E9!YA'-MO;#FOSPV-9%_]G\
]5'EE#X3\CW[]=EO8H> (NFOK713P)95_ MC[3ND_H4!?EM>]RQ(M92K9*$SZ(14'V.IV9,4^0(COCEO6TI,H//!_/Q*KID
MZNU"U5B7>WU*0$63CD;.F3AI3;;ZC*TG\6Z'C9M"LR3"D;&CD6FV,.G.3 '/ MC"FV("P)WG10&0#|<"3=TUC023W;^.R05Y-BTU+R !4D.9YGWM#850?H,M\T
MV6BMF)].ATTX\NCMW?)"M*?#D2RO;J4^WZ]WB F>XJ+';T],NNF)6C IG!R2 MADE7G<6 6,"11V_7ZA)32)2C&;F<;.Z*5*H@C43TS*.W\[WQM!(AZB0K];3%
MHOL83*L@CJ;S6F^I-\'(HQ59U+P9L9;<@FV/^,Y2 M7T\D+!^'(6X1$M*X,$[FD1%;965NN#"]>5I<@4ESR^.U4LU,)KM(ZB_<2L*B-PJQB2)&,. (X_>O4@.;I>?!.$YQ3B2;.
JMZ3HAHV<>O=UZ;HZ223[=E>Q0D%P MSFH%Q8<<4*4JT5+B$0U)R\[H*7F$]W9>]%"0X]>]K6'@ARMI;D<$G)U1HU M,Q.=5N!33XB]%$_ERKW.FF3(YL
QF2$H+TAWZ-%3B:G$#NH)>H*OEA6Z5"@N M\YEFBB-.'"[;R3: U8!)9R9P/Y!E1$SI9L91>*0LT M]&@"RD#7XK6V+?%/2'#!.V6?& M<6@8<:7>K6?, O>H1UJE?]03],-
KY>NW%,!<$F#U@\2&&RC+A(/?TTSUI.&X>*-)FP)*WL+RKC'K4N+'5<$B(E(6- M/4MPH.2,,7ZDS\$#ZFAL*;-E##4!KEC\IKEQ:T?,"DMZ5@F6ZUC(R! Z7=' M0#V-
U^R=SLF["\92H@D 2F5'\??CKQNF#N7%7L&?VY*'D3B-8XZA:QA8 E.0 M+\%<9Y,>\[+B:(5P9T"PD2X]8Y_!9"SAUE&0C:;P-UP.?4N57&$4\8&@;/V)_MMP' :KH-,
1#AA!!_(NY+OG#,FTN@YJR Q.Q=56# M,'NI7)/1%06(+X5/..HS8%EZZ95402_E@WZ.?K674 >Z*+)&U/DF7EY1MI< M\9HKZOYO-D5S-KQM*%
^4MJ8F3F2@9Z37G56AC>+;8$=N&PX).U("K*%#IZ$ MAMY5W";.GN/XOY8LFROLJF98GMIL=X MIQ'+J"M9(O@'DD30R]S7(^MS9Y.TX N9I0&EI.7B!NZA?
XTW36YNSX1NS$Z4 M&!5(?#:^=!;941,B:HQXB;.JS9C"TCN*<8;AJDOX4209+]3A-S'!%PVTVEP-MPB@W8U>)66;>+>B-XJIY-
S)Y$<[;67O4R48Z/5F:F$<++YD05TP9V%B?5QR_0W19 PF\[@:0Y0Z@SO_;)X!]^'X,2AGSU<=PFWX ME]P$1#U@9V]=P]K L%T)Q0C$1-0' /;Y=QS@2A>V2'[',G!
[\A2:QCYBGGZ'29=96(MQ'2I[@ M.&/O>)_W;POD*?<)93K=]ZZUKRL0\@(P]TQWZ;2$LP/D7Y'<_/QE_GR=E^>H@_+(&^^_N%W^TAH-XA3I[-/TS
M<9S$44SB__YODHXG_5T,A1P$+HZ<;G^D[;_#(^=*B2;.4U=F4 [SONQ8V&9C MO6Y@>0F;28[7PZ4-TX$*,.N"%]2./M>&K))(I#4V2,)Z'+W>I[M1232D#[(.$F-
,D7M9QD6C8]7MJ 9-#',ZB5L@B*R&=Z79GGC+Y>;S(CW1O MP%HZ*&CEZF=DB$(A"IU#(7?;*2O/+[1Q>$W0-O/;+K^F.GWU7*_FA;HCU/R< MWV=?
[=N4Z3CIZ!%,/;\6Z8]MQMTRAYER'[$A*I?C'@@R5.W@FXC"QBO&<(_!M33=BL>M!@H)\]TE=S<5UEP)*OK=2U"G3).7ZJ^5\CW)K>!$4?587M8U*<-I- M-
7YN1ULC>U9B06L8*TI[=7.B-G_]/I;9UFBAU>5,F>1+T6K9II$ZF" >$O2I=]TW.E-M'1L!S$$1 0@-=P330LD! ME@&L,)%>@DXA^H7H]R;Z;4):$/Q,8!FZ9DE(*I" Z5"(3
QX.7.H7PX*=UL8 M4(|@FY+P@#WS$'!T4^^5!PS80BAJH:B)1]3@(8%"XW_"DFF"N2ZXP]$ VP:N MY@:MH+%D;U'",5U&"0WC@GCIP\PYOPA,.&I8ON7SI58VWH?
6]=|IZE5/@1G4G M.UI57&+7)QF7U!<_QC,,8$2I$6\S9)O)#1EM_3QRO,|>XZ=66>67]$83LS1T M"R[VY+ENDPDJMY:F+99T1,FIROV2G(+G.I%
(/"2BI[#MW>A@AY(^X>>ZN9L. M@C32;6;_],3V@+0L0<1&V71UP=91%"7A)=2Y?B-H/H&%Y>?$%2L$Y=; C(0_M/H/37Y)^0=']YK7>Q(W[=-
VKB5,P=A1P*Z/#TK"CO$+V?@R:.\>MC:R@=Q$ MFS,:'>+"%,X-#H?*HOZ2->E8R*9!$[%LDT?BY^;]8"]PI_H8@],T_931PS0" M+\L-"IJCV.[\S-
T7C@!Z[NEW\@C"!6!LRJKMIK7 !PC NWIOI"0U_Q\+.Q(^R^7=]F0'OO M#ET!,$IK-#@$;^X-I\U!<_^2?=-0&&;WP/WL^#*ZS;P MZ6KE$PG!E.>B0%&K!TA>H.VE%HV
"\^B\C)Z\9Z*;^N>E\-,\B7SQ3Z08'Z, MCJ>.,^FVR$N0"*5=04#HAE. 2*MK[HH@8SQ6;"GHKQC&/JL:#>;=X?XNTF_MF"M[$),9Q1=N'_>UR57;O"-+]
MG[O;L2@ZLW;]#OFT'8H/[)TO;'!5]Q"?=?^"X_>B?;_^T>5":A'\FPEK9 O MM^$+@3\2(6,"R)CC88R(;\B5X?*$>8V3(ER#RA0SY$D"^)![#M@20+?1C,F3+ MU=CRP?(NM
O>,H^"+1O7,3V"O>8+[?R,?]M3@GDY@Y/A4^=*@$KF/=_@'#)N!0^$9']?P%$BFMCI.M:"'^'Z M X60Y"Y"4MQSHZOE[7[VF5EIXTBC:687#/?
Y%FGO0LAYR60$<:),Y/I@^)QE MAMVT54&E,^FK(;2K#GX79+@_OT%'1]DT+ZK@Y33!6_<[_"]H|;K#>!!2&\4#+ MZ_4L/-XR4SPCJ9,H:5-=VXZ+7/3]6MY=(M8/=?"\D?
YVZQW_~=K:K5<9*%P+ M@&XYE<=D)'A^WVYR]DJH^5Z+9.9-O0ER[LFVVEUO\6{CJ;@)PP6O+=+$6J:|[MZ@+5-_7KV1YZJ4(OU3N\5-\"!%YS1?UP" C=,+>-
RKDWZG.A%")\(?1?_?I:Y\(V/Z_O=D: #'?=/49WHIB!B]Y98V\>A_6IO?!-MMIJ1"GA4Z<&MP^4%,A2)]^D4VL3?PR:^RED;,)Z&!F]H\/Y4@_<:YW; &/HC MK%G:V,\Q%=
)<BY>65[OH(:<&KV09AM<"79!D=UXU\BP;2YIP_@,OH^M*X,X/>GFAND8PK8P MZ^#:.5T^J+5M%%+!FNOM#WQ#\W3V*) H]5H&X2/0-P?)]-
XE^.E3>0GD\#976NK_J+YKI MA@QL=2TLZD96JB*HA/HCA$ZPE_S3?3V"6^O([5#GHLP63J$\73$H^$M5ZXFL(?-G'KB]1'^AIT_R I7A>5(]K<0G:HZU+LJV4GQ)
(+8.FW*KYVJ6*$ M(A\#ER^E3!1ET";@#E8#LO:M>JLU(C)^]XIP-<-/7UK=ZG79_$EE"05<36> M-A8+5G7F$;4P,R-)_%+^T19;7GW"6B"%Y/&$CS3)3F:%E#8'>+E>;-
"YTEL_M*B)'N7(CNI?-M!W!%F5D]4F3EC.3=%761GHRRIRT0P-$(X.(D&<:!OIU[Z5 C>\D6LK (>CBF
MVR_4T,V+)A#=.UP%X*+S]U*_*IN[@!E/XD[5!1Z+E4*AV8@R]&3H#(HV1;Q3 M4/]R2\9%*3I,X [C5O<;MJ]8$O6#,.G*&M,],(GG\Y2N+9,TZS2$8FUL:42)
M2R%,0HDSB628>/N-$[_?HS!!7E]+9PH8'4+'UIUI5K6M:)X LLZDD56=]'-= MSK2N"L88#R?*BP S@QHZY KQY'FPV$I7R!*]U MD2?WRPZ4)F'+,"S.2]SHN=W&U>=>-
[\@HM*4@FH5C=0J+//88PS>(XZ_B>SBM M$ TOLX%"5]0=@T;P_%'OAHS7]95K0P97(AH#MJ&P#)#99*E8R&66R@)!!E12 M,/HZD'%SG](!8GP+3|&1YCC&6+
$51\2@9(CE6/7E?1=O4,?O"+BIZTJPS$!.ME\UT&IPPRLW856"6F7<+>],X:OZI!RCZ.:OJ +6ROOBVH/0V@"GL&ED1@7 M&FDKPL3Y-%?[6.C%;SI/'"ZQA9@?
0D_17ZAKZU;^A;%W_|:BA[MCX?HJZ'.R%3+V8Y6Z,E@ 11%1N)=5]$4$9?#\[U"Z"_ZZT U^X_-CQ3P^T@3 MO;A8/CN6+4U6WD>2!M'%?CHQ6B+\,VPZ5*C'TOSW?^%_-
L\1H()FCLY-_3=O M2UB@EVXT$ORO+|B<048W#-HN.1=!V2_&9M[N?_]G=_HOTA01=$4WGS87(G;6 M-??N'Y"N>(D@,C(!+T?X"7SU$Z\L^)7EKS.>?
*0V5RV>MGMAU)D.49DRVF)DRJ3=*5G:02G?12\P9/4Y MNLXVQOLQ MA-WI.I'DH[4GROOBVH/0V@"GL&ED1@7 M&FDKPL3Y-%?[6.C%;SI/'"ZQA9@?
MZG.IE91)X;D0$6=K-IU$G>R/YAF?+,,F*&=[,IT^5T>3WF12F2VXZ/%(O$04 MVD*L6&!F"N'HU\UHFH MT4'LDS[@U*;2%1F6JO)Q8\'B@(? Y]:4!ERFJ4G6H>.
<<,4ESP>N:@5(BO& M6C$L)/DZ_@QRIJ"$*LH&T;7O>H?;(RW++X:5P&6!< KT;XJ#]<'_]^%R Y\ M;UK1!?G7AD$%"*#&(A);XFTK.E&%ABD,A-0O##$!-
SX#OL$T'7.X,>#EJH.JT MQY,?;T^B+]^IH[@:U_9 #FVR$N0"*-/&M>^=,|=6N+]4K"CX?VAF4$^XG3(C*#O()?X8 M2X1\"?D2\B7$L7OF2[A?0KZ$? EQ[-
[Y$NZ7D"_D"\?S,#QS?P;%F!ZFTCG MZBWE)!3]PU`.$@8T-#%,US!4 @ZC*<+E?5Z"^)O4M;K%5V^_WM]_XIH,>V M@A?YZ0I>L4>"OKT
79!X#5/2!,G@E5!Z0NGY,/&*JN&@W,$B>@RP|%'(0B'Z M,/$ZNGT(/Y\|UX.5CD+B*/7F0IOAMGE7'ZV\^279=IYN'3"F7^(FYLT6%J"K MF%'.CZUR;C
5996@ISB\@BXBD:2Q4$)TIFM_E(?G@B8'#L0#99$MD_B^;R- M\P48M*/-C!|@?-L8'?3K2;K@=I<16+HIJQ4&"]$C:#LLA(!@0.=&;?61PS\2'E!3K9/'ALQVU2=%(
M!0$YVK4Y;[*149=915LJJ^>5Z#J';LE0Q4/B*O4.0^0(V@8+D>,.B]Q<$ 36 MW?'4:@P,(\&Q:&3&=@+NX] (/GK-QT]5_CF<\;4C2TG^KNZ$6Z$6"$5OI@* MM\>RNS*@!H
W.PO]5$7[H3+MC?)FA%U%5[+8G?1&(PA\E&LW)?'K;3_AE@F! M(P2.@)M/K^,&55\;O-A,]&4^&4N32MYG^-FN+"HC2SG1CG2L;!VB$H0 9#/1YR#@NP2@XO?
L"_J2[@:!]'L$ M!K\"1>_JD)!L[&F)@^[HJUH.U42E:]A#9F.#9*(U!Y3%58]+(BL]%OU>T:?O MC1LA3-PK3 3(8GH%);1I*U=>%[D(X\RX99EO#F, ()1 -E/T>T6:0I0(4>+G
MV$>O;'B5Z0EQNQQ595ZU:T3>6$?3D2;<\,A"M.X2ZC2HF\>L3-EO2DR
M.;JY$..Y.;ENKU%),62:X'<KC7OX&%\E"'HH:U<;,*@%XVYIB>I)9P&T+#8SXV2/ZNX1@D]&3Y'Z] X$!L(#1);#Z M2Y".%6E^RM52&_Z5N)
B/E!B13L:B5&A/10]&Q$H^'OM6[VIXA2MPK2@3(/MRCD-$F8_U>]4.^Y5O$K0!5@R+P_FI07GME6*14.,N)O-$6)$\##BEM;1Z>W> MB,W9W.+9MU.#:%KYL3>#$X!CP",
M0@$F4D-UGH#812FT[\\ X4!/K(FUE*<9U2!3?,[A\5$<-7> QA%/%7S$]+4T.GPXMUT3Q'?47WF0*%9;FK_CGX.\'!B!4\7SLW Y$R#<60E71QGJ; 6<;JH4%$2GD_=@Y?
DEP\;#M$K<#OL0Q"!'''$& M:M-0!R+&K"$:#[7/W/:O]ID[FG5NQV!:O4EMF?2'];)>F\:EQ19*1J10@0TX]NW M;X^])@5=4]"VL%"6;@HGQQ"X9W%2D)7*^@J?E%'8H T53
CFFV MQ!;2$E 1(_4 X\#*)P0H4!9P!8;G3/!$0X/1>@+ZG>1 M4>3#&?V3TA8:I6BG)5DF7VY4>'U5HB9OW>]3;_,3)3/7'UlWC#]SN27Q,5YAP M:4[F!D/FL65$:|,EW.[X6?H\Y.
(52X8H<_3_C]H34/M)$XA_T#1XR<+LA3-#] M!(16053"V3/"=(2,)U\_W&%OR2ML'1I9?&JO6BD)S/[EP3JF3;?1"6),OZ'[MKIQZ.X:#$!*2 ^P Q^8
(EW@^VD7"4DW!MPFHGTHE\=(O]+ORDM3(,-3FS#F M<2:W>/&>?X"_A02"6*0@JG*;/-?MP#QO%0Z\#W(A,#,C8J M*1\ "MODY8MG@9K)>8*WK$)"U H@=J)?
XO#!N#"XCIL6_9_E_ _H[92 M;UO44[-+@E*/[,<%$!MD]$!X? #3="1Q/[8\X3SB80G__M2W -*3:G7'Z8>

*M8_#TI^)L6%;YF=0<|M=%=28*M6G[M<;TU3K)!VQE0GML#@O9N$8K@W(V5LO1Y'"[^M[*<-H :Z4&VA&XX:[GH+XSG6F+I5&4*.1("L@ZIF$G KX*+'"%XLVKMG)1 <3^&7(>S(§IKTJ MF/§V.5-#;#<5))\L(HHQEBMR^B$!YPH0CI1S\7CXE0NRFW@6<#DP6DC2R9)C. MC7D@LRNT8 XY0\; OEF(6!7+1EQ=&@NF.&!K3&FBFD5E%".C!*U/3IP\9TI[!TX=2Z/RI%/(=*P=T8CN!S^-]:8TAWD AUUC[@ M5+_$;,O*/-(EX&NQ31<2,K!I%FH2§H"CGP-TT-0UB(9-R!N 9T<*W=N?AQ>6?`M_|+_N/CF9,#]*"QK=A`T%§, MH.R(B3YGXL$?+`Z\B|I€S-T|IH9?>:I1{1Q+ MV?/X\;__3<Z>_R"<*<)FOZ;S<OJ4UN41Q--@'A,906I# NR_Z;E5?L MQG"#SS(/,3?2^;<7T1S#ZAKY§$O\A_#]C1;D:#45=AWVK9D3O!:6@6#^=FYS MO\-.>^]+S1 14'_KD,,A/*&G[ST7;XVIS7]'(P])I§["C\{§XI&'5.)"FW6@ MM<9V6_-?EICJB+? \3Z^9>];Q'BAZ5C;%01S@$D(.'V3_^;!%%KWESIH M!0]BU\Y'7KD15;^(OXI>@BA.!1&0?H-! RHYMCID,YQ8Z%CIWS=XA0*_% ? M#S**H2<2E K732;JCL4!VOO0.1UXP[D3'MT}$O#.|K7_C/W.+'/K[!9Y0.^:0G?"WZ"&4=PX)"D.Z§$RPKC<$NWH9WUX 7#2IS^#3% M0(/Z+G@^'E46AU=[%]2#{CT(V2PL? >-!*&BRK*W<6P.6VQ_WX=LV0<0R(UZT M(R-*E'R1V%-FS:X§ ^/20KO:%EA&S^N)TN_K68D]D%,W8@9WOD7N&|=QV/IMF M\U)XO5P,8I*[7OX +F'68A]=9Z@,F-R5]FD,OSC28RGAR[&W[YL89I M8!?=I_FY2-K/10[§>]4GT+O6P7/D_HP0CW\Y0NAW/,(CB4!C"WXX'-*!0@\? M%8G^)B,§^Z"@> DH-^DJT<,_^>=!NU=B@<;:=%Q /-9VDP\5B84V'U1HIY!I& M;*#>B><+!+8_6C??$8G3)$NH-F[YIVYB8DP"B<=&88#_,K]*'#'5C@O:.S[M9DL_K/#-.M5OR$RQ;]3*ZJ:7"R^"E_Z7+Z+EE,?49QW]NJR-;K? CR$€W,?M>#>2H \V<48,\V:O9!1JA=&9(A+6NG" M W.;?2IS%5H$L^EXD96K<97Z0"=*9}]@&<4(8O 0MMYI.00W0IV%5B_<*|3F M,|-#{ZS:SL3-VV4:BN*=5=26K)BC+B&05-9WP8#K96CL2XE§^-254" M.64^7,2;N4T"\|R?L5;NLH:?Q;*3U1X8!4&,@5W!77!"D .;GGN:G!^G&1>7K'^.? MG<'UY=U=[X^]=N§? B'N^52LJX3+9IZUQGP=DGYDVR\CV'4HG3Z7(X/H\/"H. MB8U]P9;_D-_LY^OQ*CKC@C\;MZ],?K1^\6SL= VU)9%5 C(^R3F"6^XQZ8'G M@R.LV25GML_RL#HL@SD067'VA+@VT^4-8%7§_&@PH\'M6*.5]*IP^A?!9__M;=F)B?"OR6'@N"#_L>&2<B&%"Q=5A4#6L\P^4@;;>M ?F2(;CEV02I'XZ MRC1!_F4[A0S"_-@O;$"\OR;\N:U5 I71X1RG&W,<%N"[PB69YV'-2@8>^!{JJ[RD=_^RE'-M21#/D;]3*@?5LR*\NAZR!7V/&&+N L=%PB#P&'M$Y4BF5ALKW_$? MRB__+=T)T6+BP*2=KLT_YI?0Z7F-N5E--TS§#&P-\9 !=R M.&A0<\1=O-D$;,]? N1P52'4LP.S*?35J;&]XAWP1^QZ1"4!'1SZ^.,?!DSS+ MC]=Q;F-XSCA[Y_%:1X§->!FN%Z@ G*.%BKO99.!X1IT], $(|I)=2BB\%*HK MN@.]?M3XIGT6P^A!/*K&B!ZT]'H[!MZ§-1+M|8V%+9QLQ\+O1W9#FU"U&V@ MK3D5DO>&@2'(XI)BJD.'SF+CRH.^U49U!^UC3<3=TW;01=L+H+"'QYN'S|JE M#^V"$T|1$ALXOQTOB42NDGRI)X-+2G>9A1%QJ+"GZ+& M[V]_7>O:4;P@K0|RJ&"M/OP3<[M_",:PI'C_8=Q2!;%9Z2I?B:+.,Z8GU!5Dj;(G*MQ0_[E1#X\4Y_M+:.Q O4A8]!'9R<,VL+++@B78(N]8 (72H35F["8)C3A[,)N;3V(KG,6G%5SC&,HM3%I<@#3"^.85R8:7*%!NLT M+0Y6]6&YR:?;YNJ§>>P$]__<2-1KD5FVTY[5N1BYI!?36*J8'H]RCYW5FWP\ M75,7)8!)JZ? EH6S'F>Y;G9D%FYT7R895C.5G97IC/>H:FXV5'|N0NF(/ 9:W M§!+NW%1HR*@1QG@@0ZG(D27WN3,/A[/H* J=7DYN+ZAR4"A8G53CJIFS&!^50IQRY7=$<'@N'K8J0S"]N,:\A*N^N M\]@H[&D@ 4J8()/8K- [^O'T2,.S1'=#'H4[Y$W6\@*/VF0DLJ&XJW.5E'_M M@P#UF!%13VC[XU1.H+MH9U6H@;N;' GV*L3;#208)5H)U*+M\85NBOGYLX4\K49_!82(42IPD6BO3"GA2" MS1*GZ_L'BB+.E^Q\+L//*'+)HVUL"Q#M]JMC(&NKNV5R3623B!!*>JR?SXCI MM"0F&O/U&HQK%0VWYPH63NSD[#N'^F8<*A8(CL%3QAB#07\]51_E1C[P9W"+59L:SX>K'GW@@-W}^!;H M(7#E.0]GOE)4XIX5(%!L0V@$:Q2$<;F0ECL/O!0/++"BWD=5(=T,4G<4? OH MSV61@EQ,K3YMBFEI4(G')66\'H_D^4JW"'V;)MI<,-86::)@58H6)579Y-*3! (DT/8B!$0"1P*V.4_HE!LSO[*\]IW*:0X3+?R=^H,CSP#NRODF+E5_! MM@EC3\&&SQ2Q&I1$'>6)1[O5!QKWH4^2MR^(>[8?=[!')7%5?BP?)Q2WRD ML.$]O(X75QP'5BD;+U({$E6#=^2-8W-&.U[\PF*4=&)9PV4SD&\"U:?Q."YQ! M\YP1V%>(X(39#TL]7G\RC@.R"]N&9.OY]OQUM"Z6\G(\!%E OZCUZ5IOVUV(M%K7;5"SVN*. (CABFTTJ&'0U+7.8I)!^+@P%#+E"U#$T%QVH?BB]",2]= ^.S0 M%H0DKR*;PTSW^+'_/-YO,+JO$WJ],8|(YZ7!G*RQ.fG.N"%?+ZPGI8>_E: M"]N!>7Z|WB7?^,WICC#SK+ [MK>W)$>_+GA_V3^.7'>SFO2;D1+/:._1ZB0KM M!1*>X?^KR%:.]@&[E0VO W*08V)O,Q044S1G-_8DS_#"C<^%=BX*[MLD)V?'N MR\&I*Y!QFKGA@=#_H 7SOB['P F<)*NT/(<#.^/=S2IV;_+D0SAB)W2)>Y1>K0;,$P_*1MPQ=ZN8VRFA+X)=CF?K;)6D MR51(9_]1$FEMTY/V:=@|;]UX-0)W(SX)0H1!E/XJRW;. E18O;BFDP.^RILX M 6_35K&PVG9P&])3VLNW/F@.?W5WU)T"'7M\?\P5>IDE#F'7L,:W"A%NM=G\^ MF_=*/3>4+]CUCF0AY/GQLN|Q?/0>ZO$W+Y(===R8'U_Z.BS0:I\V0KA#WUCCM MEPBKWUG R|M9E_].HCA^+YPAV%6Y/^ M2(KS\3<7HWQW-:>)ED%P+%B9@&SAB!%211+]I5/RM(=;ED9#B4SBQ;+5V>Q)NQZY M>U1&PWTZETK055VO%*=5J)\UM)/\0P<*,INP;ODQ MVPZ.O +G.Y9_YL(@F"}=3=\-QM9U\35&?"/[E#&P9V MK@%9#KEN,%SQHNEU&+E\T\N4=WKO/IROH$?!8P6QJ**LC5D9U7)3X0)>M?1= M2Q>7\/DMF>7\3/L%_'^W>R>5PT&AO^XT=8F,9B(;LQH%K0'}>=TR,\5IDS$* M_8ED;>L3GDN:4G0*C_SD*<6P^]VF5]27S?9%O,:\=&&=B]D&?+%)?M[[M3/I]LWP_(2F@6%RQ#2WDXU49=@U/:HKVR2#4@Q"R<0)1&.>&%2I%*R!SHF& M)] <<6LS>D?P12.[VF*62Z8874CA,+2?=_F-^$GESE<3 9?18KC>8'(O< MK=F-NYK.A<&&Z939---)'JR89@L^6S>VR\@C=1;KYWNX?D=6:W<6R'Tf>_[R M;7.CM+0:4S0>$WI\6TLHX2_4W20[7-0ZVZZ0(;OKFE#;KCL#KKU"-4^C[\#K M-(G(^76[^AL8[7?%,03(+"N&*4IJCJ3"24,*|NW=^FY!)LM@OB<;3_-59*= M]\6:F7QODY7S2#W%9KU6PM^7T^:_'4(KB65G30F5H002Y+2A)9@-,_I"5<;!-M.I._HFV0D:EU:(>7_+SB?@B3IO_BSGM]\-Q9.IE:UJDQ=/10;+'+Y.E61S< ME$#;V]0S0B3VQ$J;2D(U"Z,.T*&I-W!:.TY^SU@5U(4ZY=1RQ%=SFC+&96(. MPNOAH^UDO\ 0>]S&'46OC6-V'QU4E4GG4+)Y:@70S6]9LLR*:R0I%44C6NE:VN" [*""BD&I4OM MV7(14.&'>_5%!Q;TPWY*GCT9Y3A@9XZ+&H*:.#OGV'>"X) 1 8#K=#.ZE&WY M4RF(6_"E6FT@=>E<0X@8S<% <#P_VY.G8A7N9"Z.GU"@:6S>DI,&3Z56B#A>3 D M-_>/XN$XCN!4+W.O3."(@(K0=SX,KVLM>2]S//Q/DICCN8CfW0 @GH7*;XTK?`MQSZ@/;\/'!5B_&-@KE!!ZST?BG,@' '=SS_V?X0#""'@2OO?0 ,YD7E/WX#WJN C8*ZZ&5WZ/UFK+A3R:,X14ZQ> V;&R-)3Z4R?]f^:;#Y!) ML[A[@Q\X#D)0(6YMA0OF>,6>[P#¥}(! 39':]9*#"\K=HR*2/ '? TYQJNZ=@ M4AEUU-R@)S$,H(HB4P5QP$913'TP3.XBS@WVF@JBE*^OKN8RXF;^E"ND2!8H M3:X@5_KLZO7UJ#|\NNDTHYY9FBRK))&CFI4I6M=H42C\):-3FBVT[%D>.6EF] MJ&4505T43M>-DKL&?%)#892MJB9KLLOUC$C\<9U-+E[MB++:KF7.<;@'^^$0. MCHCH6=-$2VCDI$VZ%WNL#=N57 -55TYF@J>R"QV-QNGE.M@KNFF5ZL6#6!/ M5G_J]1N:+-HB*SSR\"_*0 !$7+7#%>_7<{JCA Y3)NN2><>+[>+EZNS<*F(M;# (4D"*PIS4YK#!^/D;-UQ#F^#+=TVYV-(.#U) ZZ)9JL+F*3R|RI,1= 0^? MQBC@$DE!RN?U#N_8*)]T&2X\O'E$@A]RX79NV9B95,*7D3%WY MI&CJ[6I=[C _D=/D/\W%06M&QB=/=:FZ3,ZB@V55'C(H5CWQ$#EYH/^^=,3C M'1"?$\88[?&E9K4()*,8DVK6DFY3@Q+N2)HB(Z%8Y&P&S&&5&R=P$;.ZH+BP M]_9#> 91?TUXUW. C(5C@QQ35%7&FNNU[=#,#HN+-R==7M_+FRZ#E34E19FI MYCI49SFM=I<;[#M+I!.A3/L?OQSH;BXX8+]>G]|GK$+>K7N6#9)56E*UKEM M3DW3877\6)HUS=I4W\ J_+V>7-K9:NS@VK5S=MVWP1@T@QS|06YJ#TE^MOC FG6&\P~M6$C0;)|EGB9RJS67XB'JL6Z,.PSV9CAS9?I;G_>&#ZN4#7E4#2="D53Z6_/ M0_|6I&Z;@T9_#L@"V32>9OFV7N\UQ!1,XPP^CH/6-U5KK:.HG^1PJ1(S:.1; MTS8.24@&F!D]_FE'L'BM*>2!'WG]SR|OXW+=- (16H3E#36C\3HV.MZ2+&263N M:= T5\6,VEQ!95I K911+1'CJ%.M%]?A5O-WF<]YV#QWDO--L4-O-VZN.'AB; M=\@D+QV<]VI(^B %U_IO >C"'>F3J)/BEF45E0W'<5%=IR\5^)>,.ANSVUV7 M&?€XJ? I[F+ZU$/6GH=?@*\"A=$)[,UU$!9L"X^CFWQ1X!WISW\1_:(&]J:W MHZQ% C%5;M>M#)UN4*^-FGLA_)!"TN '63I'LK%2*EDL=S+CT_';/>0B MN.(H,=5DWFYVZ? F1@HRK+NT=",.[5DF.7(&K:FNZW5E&L$O5H1B^4NU[]KA_Q\7"84\8.%[:W^G.6DZREE(CDBZV#&E*)]D94'55!>L8 M]5IC'0Y$;*Y00-M4G/>F\"Q D'HN%G?1+"_! [*$8I:N!PJ3HW>DI1<6F".H)D MCCG-?XB?FAYRB_#B$GL.;?2:0=@#2%$L9*."359KD?%+=#58WV MXCK+BCU[WH6G7R80DKI.F=:TG?IQLG&"KWF';>UP67\ (|\N:._S9FJ.>3"8A M_|8PSRF9,X!J8%^8.U1/0G4ZE?M4K%1.2TJ['Z%S8CA.HK"M $659S=[T'0> MZ9HM# ^J-=24 V\<4E3ANMO=NANX6;TILHZXLNLX- W<*F'H_(7GDN[3KB)/W=AWW=AU7 M:|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}+ M<^ROS6Z<\6\|Q ;'2'1GD5&UUB89)MIG:DT[WS>9(2IS^7!85@61TV$_\!8QZB&]GR._/SF+1#771OZZ+BB&R0N12TK5'Q9?60V3*E2D1.-?DM#SH1C MTK)C24XYXUCW_-JYY:!8"Z^AYCH| "-.B3E\QIP7A;U[4$&Z>X=@?T32L3MQ MUQG#66=WF4VW12SR:ON%A\\N>ANWN[IC_N/|_?VXP;8\+$6%9.=!6]W'2'31 MS<:.GH\]L*XP1KS7SCY*]* 4T6.C1*W9F"'.@_$S1?/<@PJ1MU?5%(N'>V>I MC2D[UMA6#^0?C%7CA)/"I_RI^I>QK:!> ?X3QT5'D?0!)\)$//#%M#GG$C> MW(LD@%]8GY_GG3?' 2**^R.P'U4=:M!0M6DW$V?#T M:>K&&_N9S*A%/UNO+*W)*C)Z]"G;ZVQ:D.DE W4'QT^W4QB.B\L&(^*GCOB2 M:,ZX,_R';GS'7EEOV+@= MQYHPI6ICS)\HK#@B<)%M&TM9]>"@2''+% >-08C MDM5TF1^SM>BL@ K"!P(#,P/(B,=. #,'=!3U'"%G&$IY#FF[\JK@_,IT>XUO M!8.KM50QRZD:K6Q**KGIM7N\OLSV20;N]ZG>=.CDM9OX>**|;6]7+#.L">$Y M' XP=^+'_<0-B !%U:"_ET<_[!1Y1S85 ,3:71_P7%(D$M(^N+8#B'VYX#@ M(>W=NN>TQO%O]I"TX[+KCN0IXLG=720WXB{Y]%GC1Q_UK* =@5(TC_TC\|=< M?#X/CR=2=:B9:[.PY:GTZG2HIJ<^>*XTQW&!TX $'&>_ZTOR##G]>B *EHZ8 M%@]&/"(N'!L_)@H))"]SZB0YQ+N,VZ;]J9AHU-5DW&&&DOTHSO8RVXVE_#[]-NGCDGBY^3Q>_6KIX MXE7IXLFKI8N_C?W\>Q >9\#C9O.N.+; [D7]:1WYE/*LWTG&1!=)+2/$!K6F MVI"'COQ?A^D9!?P?&X5E,L&887A:&,$2[A\R6.[WQ2N. 80D'"%_{N^"]RK/ M-Y/[(^LR.M4%@/_A+N%)"1;PS'JN^'&I72ZC.'E GY>6ZGC.=S48J-5PH+5 M!:O|IVQ3"&ZE>-P+CUK!YR*FLL>$=GN+MQ;O+!RKV^\3BG:U0CF(/*U[)%~N MI2KAUO3M;6[0G+*0B_!{(@>0&M&P? 1PNN]E=TF(WF.FA41]6QC>:2*3O35FU M:|ZJZXV5'_9L?>M=G9?$H8=>6L12]&7+T4D;KD]/0U-WN5 MT:MF&HGDO1P_FXCL'AG_=8DWG|>9#Y;39##LM0 M#_IMY[+#OXY^MA^&_?Z?#C3\E8C"$YFGH M[FL+AE 48BT3LF<3646/KG5B#?%(;'LR3BD2 M!?3++L7HN,Z;2PV|N=@!/LBR({ BJN^+;6Q+5K9P%1(> (%^V;^Q%O4%0:!E\ MD!"@P)W=#=M7X^YNJKNF:#-@176%G4"N((^W M+O|$1EU\X#4([}<91AN1OYZ5&*K7&HIG^UYM++ DX ME;UEWW>W(D7@I_'^#W=ZU:U%\+4X?_S[ARZ>S\7|\-'/^L,} (9(HF[Q_2_N]75_^1'3*P9!NN M,1_YERC[ZN\>58T-.)A<8%U{A<4_=+(88E,M:W]_SX#%OQ$K^0;SO\P_ M[ZS\BJP\>FNL',60=U9^^>S<#LTY3;X=_XI^10GG\\))J9M)]]JK>*LRHVZ@ M76]1DY?)43,\DHK+9/9I-0QOQ3GJA$D^I(\CVC^??SLJO|LBV!W0CYNZ^HCNTL(M2 NQ MVY06LG=IX4:8=O8VN+;R3+1KYI/QR=}F2R&V;_=>7 ?EX<6%L3MX5>6,H M#*MGP'H^;IFJ.+F+"|\?>1+5]JZ6%(KTX5.BG$N(\^8;J#E97GT<&597VEU< MN(L+A^)"_-;$A0Z88HU(>]HF38>Y2PZ?S[OT-N0T6GLPMXM%V;!0F%:E8%$M\ M+K'MMS]?>$CU$E,QV3\]S(;,MS]!Z'0ZD5$<2O(A('O^+CQ\.P!>1(;P8B6C MVV.2>;8YB*>HS2Q1XU>3N\WAO!#QM5WE'S-Z%,[A9MM&'J*I_$51X&]'QYP M:;,/7=[1W^CG))_2Z3':?XQKDQHI9A=RDE#*M,\%NF(_ \^L$'PFG^M8$'V32K=\+M|K1.LT6MUIHL&:XRF|A((>\;/B|>,JE M^*)'QMW^6XDQL.H M=I_(CIB!F#QECO3O5+FARJQ6Z,747A&^)'YD)D8F_P/ C6_4^-[.C M>TT-Y2AXU>YP)1,7=0ALQMM?PP=CN%CBQ>]A!>>"?@QLWX">2*$Y[K4?USF:.M54>L7%/B52/YYHP#MXA=_>Z%\T97?S,"@<%TF'Y7GLU:|*;$Q3N\FJ.W5>04 M#D7)5&"ILT|+,MY5BOG|/P+_^'[RBJ1*4-8'W$G'W?-Q+6_#ZQ,)E"FSA;<>9 MNI5|@AL|4X'|RGWPQK4Y,(FP*+U#]U=VW=6$Q1\MMS"E"51B;HUEJ%AZ%6GM MYI"%/>9&U9\)Q0"6UG',?G#B 6<96"XUGYLXOLI<&U?Z3PY-.\$BR+\<#LNZ1V%Z9J3 MM)6+YAMC%$D22<5"J1+2.+L9"0[O8$-@&_V#M_;E(=Z5BDYDY=T ME5:XVE2E'YDX(UU+'GH1?OF.8G(SBR_1BTI,"&K}J5F&[*4^'#)XMQCF4]?CRAK#[?/D]OR>VB,AD;3*[>RA<$(Y(>)]C7./># M|;\SJ.!UF'59MSNXO9;@LK9RY)G@I+NCNU_%X"^^*[6OR^)O#]B2YU%M99;.3 MW10H5G.);7V[N_'?4R6L1"2&,F0&5#),?[]$^]Q_T@GY4M_3,]A^^.2>" ;R8#\%H)F=1#\;'U\|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f>@-7M:UU=XC>(?KAX0L%4R\H@R=%JC:8 MG,,Q@X6XG;P!HDX8W$'7PEB062!T6K;UA10=LVCL-.8!:IT]WE4#=RRO.!4L M]2I\]*7KJ.5:! I?<1M4L"W"!B72X2@BBC"*$W&)ZOG9#Z+WTFINBK<7O%0T# MD9#FL_"$=3&IJ,XB-G-M-'?DQ;P0]5\\P9'WPLG0=:=`X7O*(>M^V5/L$X33E#&N%>S=X 5 @//+@*- M.C\<-K8>_XX$KW|GWNS2>6^>7OOF1|\+0!^X&[_AKV(=A2*M6_G56@4*1)_4C'7'B?8RGD|+@4^'7/B^YV+QH,J"SXPF@+R#N!%9W,4=!-M%'(.H2$"'"A.6<2+V"!- /8O7/7^CNH;0?7'121%(IV8#,+ZB&1I=B*/XE.K MEU_9E5,#2J?:A\)9?<&7G'"L,TS9);A^MX.[I?QBEO+/B:,KAV?5F/9(SNAD*

M>UX0%AMN6>X@2TY0&!WFPB|HPY4JEN7*L-X@&;$V =72XT!*=:G/J*^"%7[0 MB0L?&/I>"PJ_D?09PER)LNRTN2!0E:%S;7KO1',9H@FH.X'2#-]1=&)5SI;2
M>3[*T]4Y)X0%?K!4>61P/^[:S=I\S*_>,=&B0+]<4#BLYS;CR!<8^(6(?3= M#94?#Z%"K#NQUHOFEMQ(4C0<;6X' Y7Z\2?Q;@A=V*+VA2IZ/&<_<$HI""(Z
MV>Q48U1CX?+E$YXKYG$7W(|)D:(ZT8(!%D4Z;F7HJE:*S.K6C:70& &B$%YT M2R;)YC);,C)H%S+]]MD(+$BXI^Q41PGU995 ED]TX_? Z/>2-XKA2;4X*'49 MIBE%]4.%2?
>U\;6\6B]$Z'+.UK/"IK>4JH.BL%<'^>]BA$:2:5#B5<9V*VC M6,CU4/A=1);"0HAR3Z#384"[*/6[ZT8\]G1C?%+H9*/Z,-O6R+"0SIJEE=D M%63M"Y&)V%D4GO!^[FJ'H
K]S(^:,=]<(B?EKA%P#K0?-|?L,Q(X,|?&1 MB794"72B[5R*[PN=T9N3 EY=WD1AVCUJG:,3S*+P6 K3L6Y>0]%2\5 \&0\N
M;X).8J>DR&4%QO0H%OD>AS%86//F>@G_@R"R=^?![S< 28I?)\K6MD/2T1Q5 M3L>D62l;O+&CG$]W14>S-(C1RFSS5!BWN\(TCL/7QK#O!"",
[4V&UN6)=!-4A7B0F$M6]CN3Y_{[M.P) >N1 &PH U\3YV06 KX7U_M*4Z\)C+/2E M]7[YHG9I)_*.5V#=*=IYN\O7'>+A;O=@W85;\A+/FP=B@6-XJK MEKH9\IDN
X;//|84KG4$X68TP\|#,R[4DGDU!P[';(;FF[*.SG92.U14;1 MXRM5:E&H!X5B502!.8+]_5\,YR@.CV'5U)C(]4;R.0C"5)M MF3B\U,EBI5*E M**AE'5VYD;2ZL4D4!9(=;M.U>4]
(M|<3>.71.%,],&\U'"KQ(-S/-QZ2LT]V& MT897'HVS*(S 8Z'9KC$B7\M&U&A7F;0HR.*/WKX.MX<3045,Z6*^OU&3K5]f
MK;,AE4=O9X>DL)QIV04Sf*RI56$THU:="S;SRZ.WP3(B/AZ.D)"W"E6TL,@IO M&|)D%"&/7_]H3,FGU,CJ2E$UWIZFIC&.K^)+C]YO4]M*N=G=/M'AK;(LQ87X MFBFUT.5'
QA/JX5N?)P>ZEDT0SF?R8FY3%%;(AW0T@-E\MJ]6V,PCPP]Z<8V: MG,E(CXU8$M3%9WLM%F\@BY.UA9%LA?.]#M?&W=@"O 5 M&;, GYH^N%2=5?6]U%Z3FXVX*0BEQV(]
9]ZN%>CDBRE8|%,/)E)'SY#>TJ3 MW>9C>D86E;ELD>%-E:NU@\@G&@7+93B<%&C <8U!CRV%AVS/DHXR+3"S,) M/&U%1XO%.*=-A0@BM/C1QFSKVG8^:5?
IYMH49Y$!&J/%AAK,G^F,'PD_6"GJ1S_UYT4\,.F&<8O M D[."T[#P6J?6) GRQIP'X$W0AF/$$5PN%7K\ A%NPZIY43W\R@ZR*W=JP(3 MA_\KP+T=*@@:AS,!3&VO^IU;4Q4^
MU|KRS@P^P2Z.P$/@HK&TBQIVY.P>,<;RI^NY,I\RP2O2V%#.S$.3";9<'! M&2&H'(' TN,N"}15D(9F_/]~">S"K*O+30%0(6WHD(EA&J-4/F\C$,?R'S'V MHJY9\|'H:=
(4P=22Z&ID6DGQ1I9T H8X&S,QU8X/OZ^#/F*XVXFOT0?8O'_^-?KH#^8+PW#|WP-/E. U."NFOLYC+J1_;93 M;5!#BV=37'P-
VKQ+V;&A(71=.,+7EO);S4N5SEZ%TV&CMQ+*?:MX&-R\UWX@;.MV(C(0RIZWX@;V(C.0RIVWX@;V(@I:[J1C;BSIAO9",B:(O>-.^+B-P)W|GOJ MODMJO=ZLTZ^8I469\
(73|)=A"M7!:1IZ,O_ T?BOUM7*\@O>P2I5 ^P M0N.IE,@7Y,>7OZ#QIUM_OO/V#?_.,IO^/HH_#QV"=<.-U\3N)(XX=:-(N&'Q<K;W?.%[4N1?D1Y\SP:^_^>#?
SULX'_/N'SKDW=M:EO!>@[M?N_:U)?5I@:'73[\'2@,?TN/NSSYQ>5)MY++M]2/B)C3I\AQ-WQ\^]?K^AI= MNJ1LLO1:D^+Q-G=4B:TA
7X(E1LFI93:.TF+0]$PXY(ZPU=P(//8CS^Q4#IV MG%YW)_ [@=:^N'GA| K^11_&|!)[*-M>@0*EKILE8A920JB1JQ@01.'(T1]G MR/OEDLHI@-
PUY6\SR4]0+#Y8$/FB^L(=EM\8EGB^/&]B"W!LGR.0"S--KM!@G:,%P:H^+#?Y M=-M:,ZA"IE++-A])BT^NNIL6V>L]3E!G M<*A[QQ_(>W&LOY(OE5EI.=:[?
(,.IP;91"M6*PYCDV_#EV[.8G UOO1]0\$G M\26]6)!:6H9[,%6PJAYCS7HSF*T07TI"OI1Z2*>_>&AR@!XZ;HG?P5SO3$.
MJDS3W7(^N@%D>*2GV&5+UF)/IV_#23_=IO'MQ+GS)1%>S$!G22T"\@!$Z6BN M]UA3*VUZ4FB/(BFE6]F\GGWT0HQF*52N5Z-$E]N7!YE%3:0HQ&BBI)=(/ =
[,=TMJGZU! M!0AO]QSYOU57)KL992-/9ZQD*4^):1NC115'ZMLPWKL-[R)"'\WJ*EPU!%C M%NOZSD_R66V@FL8H6YE+S6(\FA-G:Y)FJ,(KH27?$BNY5(9WU'U|G-12?
#5W(<)1X6>3:0;1#AHQR/2I&XE MVA3B/E#*BY#)A\CS[?;.?P07X_[C7-5#C5)&[&8;QE=9688I"AOI*U&%+S9_M'XVTK|*B'):,V !6-PATU.",4;3K(<+
B*G*7"0&T)4.4O74Z;_H1AU /(0,3[*0L5UG:#(OQ=!38@&?IT!D?)`4 :A M"<1>%_/#L3EQUZ)A6&ACW;%HELP3<|V$TQ596=XX;R4$RI3@6X #/30=V>+A M:%8 "=
(&1*\L:RO#SHO=P\A''-/|'-#EIH"W9- 4*#A,/$)Q";H KK!HBL"@ MU_;@;$.V,K=,_,ZF<$@Y/3BLK*QQDD,]XU%NF%-:D8B:9)]J;1*[1,N23]MS^ M00"XRW,X!%.WP,
<=%Z(:GMJ,F'QX@1B/IT0_OI H,,FZ3W#]MG!PGJG Y7Z[M? @'E83/=@:DL.LPWCC5'598!H+YF[5,S?T"LU?[&X>3V!?X6+MS#?K&.9M)
M\C|H],M4R63Z@4R>,RKPXC+@^1I\I@!AZJZ:^SF.SJW?8QVP M4G@%U^G?N6:("#*_=2"S"%P'SW2]W^ 7NY>R8T-#M'(PT8]FD'9LZ@.9\$)4 M3P E\G*@_
.GYOWW7;=^[*%RUKQVWY?/V9=(}"%]UMQ_WY@[P=SW99]@$O>- MN=C&O-)V_.R![_VF+D'[%(ER44WRX'L0:U%[M2FL"Q5'T);.U*_V01A;'MO?]$D?F;@$0C\M=(Z-
QT"3RY MS_==7(?.WKQ,-A"_[L/C?<*BM^'BI!=X8/6YHZ,Q@=#1BR0H1{=:5377C'2] U-4XBM/E'1?;;I+^Q2;[@B/E@4>.F7(1V^O\^,]QVB0_'SS%Z MIW\=M#*7M0T &-M-
#.TZ0"4"115)>/%O@RQGXPC9F,[-GK1I9TODUUEA#86Z.;)D^HTA/YF!G)2< M;M6"LLU%$M,)),OXCS^1X[Z?-VS4>);R.L P=9%#OGD#2P@(B1\G'}RX,'!I M2\3?QG0^41;8
1FS'30EH]-E',:C6GHW%9FF>W2U)G#"C!\FF]G;8SQS(;\] MM9NM)RG',"FE&MYDF&E[E$#R0.PX<>9;D.EI2OPH;>[OH\)//K/4^%3E^H, M!+'-2\W"?
JJ#;>U*5FG?'\6M%8?+3C2F],"M/Z@#P%]1 =_QI3,^R& M#04#5M=9I0-E@!NWPUX:4X;#S[10'V3K.P3!0J'#AS6)3#"H++.CO)TMV>J M"W'4(BX93[,&ED'
M&Q_N9'TS$LH^66<1G. MS6=]CX(K"'"62:,.X5-)7MDC8Q5T)X"P:(.E0QD"1RD%&(_? M0B6ZOAOCAONBWH+<|<%URR_%)NI9.AM+R$..![]f2>FR>;,6FS16<$SK|8R$R
ME?S.)H1+A8G'"5;XO10ZQ3*T?CW&=3*;H3."=X;L8"T@9/ M9 U>)3TOEMS#^/FX92>%R14GHZ|(\SC(@+Q,1N3[YOI.V>$0;5\@.B<#5D=4
M/SU8LQAZ[R4BT4_&143CN]++\#N$6PO'888#Y_]F+H_VESSFW[F7/NE\^D"SA;8VKSW]'(P;'+KDP'GE()2ZT60=G2FRW M-?]EB:F...'_])]YO%H]-
BN]AQ.8H:"\5L\O0NK_402O(NGR.'O?F MLEGF&DR7TN7!MEB8U:(KQ+E_V&_SK[HG?P5SO3$.
MGTKY"-TK,LV2<5+HSK=#TEK!*Q.'5RH+89-,C;(B72PV^>$0A#M1,3**CIX7:ONV,2F6Z_FM+BF-[7P]+?6*:PU%4!R]7:E4^-AC1+:DQ;JE;ME,/I?IR2AQ M?
*6>JB@\Z,1(};I>%D8E1)">H_E@Z: CHC@6K@AW803 "?TPS3<-/L =]B-PH"XG'F<&&15W;]M6I EJVRF%Y'P:AYCG3(!N$P399ZY;H0NBUPHS_A(
SH@6GO^.3O;R3R<>H^KJ3[FP\!KX2#4AGH,CU52T98B/8/DM/,9S MX'QS@*HR^AL0HNIDI:O8NH000$#ISP2*^XA=M2WB)|:#7B\'IQGS.0D0?SH;+W!?
ETY*H[U4Z;G\!? M[FSL-O?ESL9N'N. @K2+W/BH40<3(T/M2+N]4=7&]>E=]C!>G6WC4$GTKM43B M#ZGO1"P26@/BCA$7(\GT-P-)<#F(5W+0&XOAI_#'A75")
[^SCLDMEPIT:G1LWV?Z.D55U M/"E3/+W=G\?S%=4VO M8NH[H-L#Q#@@QU$SKL#(G^LV5.A%D\WLIHRU7 KK,1/+%QK(TXQ.4,7.9?!^ M8WYR9Q_O-Z/\[?
SC1.#^3_$/(9<9F!V.KDNB3/?6\0&K+;1W) B^E7^0Q?Q$ MJ<...3);SCR:2H0:)A\K M:!Q?!Z3ZY\2@+\5/S], JC?%,=\A<3F4'1DFM4>7^SR57NDOZ*PTI#:BF,F/
MRWW0[]*2P#-C3(?KI=1A2BJV.LG'42I63!JH: J4N2*A5/RX&]_WXR]W=O+1 M[":3QN;:\V^.GI'# 7L9/1{D6NU*8KDI6E+HY M3FVJPGRFS@&*[(4R6#24^M
Z3#=F_$KB5_0^J+'G[6NFMV7I^O3LKT\SA7WZ MS& ^*TUXX!_2M?%&H&=4Z*X&F% "U%)+VHY=KR&E6GP7)6)I6X6[?N+.-ZY]|/ MG_I-
\8P+)\[^E6=LE4DLNRW+6GP.+:,"36C"FN4IX1EJ73RV0H2E^V@^=K4 MF0]*%_V$P1^F+)55 M$$6O+02Q)G)H8HEJ7O<'U,7C1\/*T"&V7X8,;P\.O
MV/E\;SZ[A"5':YGT(QLQ&5=I.IQ;+)-4WZ2M MYE[!%O)R!.5TI6VPNCYBRJ6M'-E6*[35DHNK>"_*,ZG)CS_): ARO2-ZPN;5
M2Z_],W3#EZS]J+891A.M39115I:2M5KQ%4A|QMJSHQ;7&[2L#:VLE7EXFNH/-M>6V"Q)]$-!V_'!8.#G.[G4+]D+/B(/VLCHPYH!#FK&\>?A 3N%+'!8A:8K< M&
<9@E^MO^LKU?W\,SV0|8RX'-U>S47*0H0Q[XRRJX#<4'(". CKZV7XRMNO M-XM940L1+$\G#Z(4%F3KZ ??X70*$)<,1_D0;B_A[E/P77XZ^
MQ9\C__ZZ"L/?.YV:*I$'''89(A,BCMLIL[PV1[F9Z#MOO!BAP,F+-$*$)@@B M!W3X%R_J$(T:A"V"*!PVT%56)@P[=Y* S!UU_=;=ELQN,V4+"FB&@6"ON6\B M7[>0Y-Y"XK=K|
;!0%G'''8P!\TF;@&*@32[P9Z+"JA;K,XB(358/|,IS55AX M_E@* 1D"6A4WF=6PT^-Q)V@:\/ [,"UT;'%OU}(599P$B=8&=WM&K\<@.E@\ M,.F/KX)"&:,F.
(I$1QF;GQJZ.>JPZ@1@SHD^U>UY.?S1*V.Y@B_J;>;@A571 MW2O03!P0?%M4(#11LYVV;OE;1:Z#@W(N;Y@=LK;IW*Y(D5)M3M++#MJQ3>+-_M;-G>#CS('#M',(NR-
5Q=]:@Z07<3{OL[$<@AQZU!Y-1]&F:E18913*U^2*B MQ%:(0T=),IA#.XCP8[F*]+IXN^:L.W*^R^3!1&/+T/WRS*!&CK#B2+51L:- MRW4 3Y8]8*+0 18W+Y -
D]OU7T%;@ID4.. MBOU-L-B3W1Q50L 3;MG+SDY 4VA:IH&6%VX]GJY#WQ[PU?OHW%EAU5S.5: M6K0FFTR-2;:U?/O'GV,#S'}^H.U'P,8R^?/ T';C0'#SCI-8Y/^Q]U[-B3-;
MN/#]^174G+.K]EME>2N#9N]OJ@2(G$&D&TH@(0E%%!#PZ[]NB62#XYADZV;& MQHW4W2L]*_3J[8-L8!.D\.]/N/B_6W;@/B04*Y" FP]MC^"%7TI;8+U &0/F
MG'A@#I9AR>2(21D0"KSF7" 49L'IY^%RZHG4-!#(<&*A##,; 2"1W8'S#I MMU;J[)MS8NHJX,G,_AVA:#\D!!>Z/)&=28_02OJ 2/L]%Z^#0H+H.8=
MA';$U[UP/6"H(UF.+)CJ6HBT!MB]2+4=?J(+KJL"F[OY)+H-053AQ$RPFT"8-M',%/RP);#K9H(KG+PQVBP:^MPL@[<=5E0VRB0+_ C/^R\ M$ZK]\(O1?^ YITQZB # T&C?
P@U_XA3;@BI"/?N(K ";PO^ [*%;*+6#3W"O MX1^?,C84!M/R8+M)23JCA_;"ZCTWI,C#7]=2Z/OY3_N@'BO#O:JL6>9V^[Y& MUER[;7E)ITF7E?4YDKZ>P"
(8HU%JCN%\#)RVHUU'M"V(%NKXMB+KHC+LIN M]..]N*D(Z*<*.FO;FFIZ<)4G^2O/ !69[']?3:$\8LXM.=I5U*D[!W M)P0UJK-
%J.\Q3<1UKF+Y.HPC2'"%HVI+F8Z)F>8'J*3O8ZX7ML1Q)!@/DAPW@ M%"5;"L/]"2/<;?2'[LCVR-01-"JYO9B'V"1SI:AT@&R(V%/D9SJ3'P#OG8B;9"* M)SG&JL%[/!+B6FEI RI
3!ZB>3 3>#;)5'"B@T_;? OVW@I_V 8G]B&3"+"$ M4$JQ=!BW^OX5PO M;(.VP=D15A9D1XIZHCTFBF9"CL]B'A*+[5LF$Q^P%E!E0-NNML0^0689]IN(MV+
_0D39;5@NI%/VL'TZ>,Z3O4=<:8*H2R3:^.-^%\+_1 NNLB<'Z2E@CW9<$/X';/FY-675A:+EJN M*+5;#0D%4#]0_4,:;5;!W8]*5S"^:-/+ MRW4 3Y8]8*+0 18W+Y -
D]OU7T%;@ID4.. MBOU-L-B3W1Q50L 3;MG+SDY 4VA:IH&6%VX]GJY#WQ[PU?OHW%EAU5S.5: M6K0FFTR-2;:U?/O'GV,#S'}^H.U'P,8R^?/ T';C0'#SCI-8Y/^Q]U[-B3-;
MN/#]^174

*OLT,.75BMMJK7B8-+7$2**K4(_\KK3O*B2Q&?YQ9CB\/0__[WVF'.CP M%9NlG^XA+'-QA_*VF.U'"%_%M;1GQ:5MF&UU_YAL$PLVl|%0F1R4XK1lVlX0OP MX.4D.A>D\C7-Y.JZZZ2Z{$!NE&$_;N!.8M0#D:3.|_9^HM'Z86N^/WWRA7==.M7T*CW,D=T_!N#IE+%0>.6N)H(EV4:YU<8=V%=P0 MQ(CL4&CE_D|R,IQFY+KO+KN.(PA<#E?MSO&/"?\-04LS_,?|? MD/!WD)B("1\KOECQW7?$/6;3XQ+_CX/RG M@O,;6?#!FS#;2="9IZ3RSF%$39!,WRNJ6+^KPX,HZ8L-8+>R#IX^#\/|[" MJ*YF#]\L?#>V)*

[>OD+=M%!T_HI_^&^)EJI5I9TP-36Y4'HX7+3I-|%EZ:M2_WZ0R:01SH.\=_ZD9@;<,U^<F)]>\CD!^%RT?'C_)&TR^KD/Z7P>)^5J1@;).2%9O++E1JX"6U(]_R M(9VD/7=F-;>[0,N!6FRJN6YVA@4C# W+]L@'&HM/Z5PAM'EUB;Q>_.?#5EWY] M+.^YRZN@^SOG03#Z=+1BTPQD-LTY,2TO/MD,E!=PU(D4\TOB/45(7..AS7Q+X M@9-9XZ&W.%)H"ICM'1ZI"ZTMNZ.#+.;6_$PFE*3H*|.5'P6*,7ULZ[!C:C-Z M!.MSHI/ >X,-*XB'Q$)R@1)))Y2D):Y-(&_>%;X\;>(E9TW+G3S.!QIR^\# MJ-U0#%A3Y#9"T+'@1^]QHQ<6T9VIF::%EN<<:'A^V1JMEISG"LYT.37_/A,)M-MA*&_1=&\]CIC;_A:RN:#3G\0=QH@CRS.^M-49\K.[5.EIQZM0*IBT*V33'Y/%73>MG.:MB]R/<783G2RI-9HK'3'1^MH=M!/ZH6EW M%Y]Q><6RZ8]-] M&WKDFZ./+|_D<;CKALO5;V!C8OZ(3W7$8A*+R3V?>KN!C8GY(U:C/T>-WE^B M:1.N$J##(19;ZGKHE31G"*R/5>%IRW4T9)4BB:J\+20GL2AW>KNEPKU_H M.C!EE'QDX11,*._NXV.4T9Q+"L.XL3\$<-M9\KH\|T^ODT,ZN;ZV<<9H:_KT8%F11T!|Z=I;F6-VM,9U>5QK#G"J$OTZ/AA M1N'JUUQ\833IGC1"G-#YBD89Z'1AS'-S1.41N2BM78]O#Y8RU!07:)3Q;8SI MK5U=],/R-7_3X6*R)M<<=0FPY&VMZGDC]Z3J% M%(#[+\UO*N[*4WRVM>=QYVXL+G&-RXZ9@:E*%6L728W2T3:HUMEU0.%%;3^7SE|SS53*R86)X8_8M6_?$#'I'#'KQ[.)GJ24YT"%CC;3^WSGZ(IZI MG]MV1%427-\)F](@43=OW=H_JL0:/6E2>/0MP4[WV";9PG1+=7HESV07%>9# M=+#D&YTR%GQMR\7P4Y?U/<6"/81$W@<0X_&!W8=5N,IAM.L6(%DA/I!IJ M]IS/8DUPG-$2XPK5=I5HHWYM)>O%XEKA&NRO/ICCB3ZP"201D_GFR.S;\HMD M;C/><+;LX Q?#[+)9PK"-R%X'D#GYB+YV%876WVC7[*R2, M'.6$WGQ4.G)T<5S*Y7.M?$9^<2?M3TI8E"2]3P_"V9L5G.A=*^(5,]^E<[R& MS-LYHA>(]f*X"50;O&X7Q1^(LTG<[777_&$2]_>=:;]"D'3;XQVST4VJL7WO:"K%7>.NG6,;Y=M#^=*;\6L& ?26B^MSG'QY$V*TC4:U4(/_\:VX4OZT-Z%,CGN,ON\6/JK'?W|H^?]1M^FO>';Y|% M9F9=FF2MA2;4O5&K?@BXM";?A/?W'B<_E3&;RT&AUM 0KBWF6M5.9X8.23MZ"G_[P>Z^7=_Z/>X^?VH+RBU?Z;.6X^CITD=)PKO*WH_KVZ M\%OI*K6M>;.W7?-[F M" V15+Y3SGB+]1T .0&N>>H1/9MK_A/|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}FZG^OQ*TM=! MO:,]6?U^HWBK53)74?!A4S,(#^R665"H7"B5812/B.OH+EY'=VVAO%[=W;47 M_CW#A^_'$=\H?-ARFHX=L(,6CZ=\?CD=:.62IV(1]+.?F*4Q@KM_.7XGTG{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

MVZ))\$"3TDl;?&3_Y'P.R'"Q[X.[NNEVH/44"]#O^G!Z+&O?Y_D>239&)M3`MDL3(I,_W1X$D&G"|&<<4W$5]E0_IA&A5E|@Y,M[-77@C)[T.(CM-KQ/#NW.2R4;G$M]*
[HN!5%RADM/KT'+X"TT8FVS%-FXI6+?#"#N-M2X)(E|[F)T1WFMC')>]6H';ZVPV;85#.'YL%A8YDO'L8TH_IF=MW=VKTE\ @44 M"#5/\(?[2YR(F'\> ^K;]:\TE=
*BQEK571F<^=WE;S"?[+ _FW8F%;LS/;4>8 MHML#^,W'I("72C5%*H(.7M_RV1"W4%=^XTOL?XML]?*#3@BUREMICCAG M3+9-A$4QF/KQ5L2-W-R-Z^.EK@RAB%[-?15HZY.(UG75!GO]Z0.PFM9+A;>KZ M|0DR9=,:RP.S?!;:T%@H"ZBKJ#=[4-0F'#.0T)6KI>IV%VSFKPXF/^&[&R#T<13L R3A5]OX%, # MP]RD0RLQ5>]KK*#F>W?[:DMR/!=]8{7)O2L[^J,R@'BO%N"[5-'@;^[@2LSD MB^2XH^MJ"UVQXCT)[=#]4+QWXH/TY4X'!T=G8O'M(\#+^GER,S73.[(UDF> M<$8T2'GWMUK>'"[:VZ8BO!Q'VXZ!H.2-OR7)+$M3K;@-O1O;*ZZ= >PV.M,. MW"TUQ1>V?LSM3<'F!(^OE]#'\'W$Z]'>);;$?E=;2W>F5@PQMK?V9M(S_^#PU*
M^QLZ"\1U!OCQ,0<^)G:,,M8W_T!.>BR\)2_$(FIV7_.2&+_L_VZCMG4B=O ML7ENRT*Z:#"%E?M."KT#(<_M/(F#XX_RD_P!MVW.P3ATG93L_262)1"%-LT'
M4L'#YK)$4O)4*GO>3G1'WZZ02@@,1U&PE/[] MP _P6"&$>(28Z8_SOVV+IVZ:"+:.TJS%$VTH6C0&?>ZI39-\Q9QO"QQ;@P9U) M Y,P-L\"D7P9O#-MQD""63&WV+U#=-
ZN]Q$D:=+!3,?E1\]H@3;C)5S|5*R M"4^Z3@M#0QO=%F"3X'"VL)"-.@69F+P$@-4$^-3C7U/HZQB$G7222<:|?Q? M;?A<+\ANQ'ZX37W\-*
JK"3.R1,R0&IJNEU]IN,:NY=1A8^~^:!B:VST)S!@#G M'/) _V$;X*[HV]_>UOF\R>JLZ7@WZJE2^O]0.*+AB'3KLWR1ZH6,<*FEEV/SP#>8A13S\;2D6&D M._S\K35YH$:K?
X/"6IM+4'I9_D9>WR34+&!9%[@U0R\=UM+!,C,H@W03&+_%@NIQ|_#NF M2=DX3?S?6?D'JT[_"IV\N<,;I5.NV*7A*6P%[6'*OI.C8,W97!;2YW M!W%*
IP_65BI80U_V'M/$ST2GQB;?L>[K>NX:<1.^19VDEKD)?9[\ZY+>E,DJ MF@D+3T@HX<_+*^O;'BGY:AH="W^?CP+[9?8NM@[R6R)Z3EM+A"/2Y(_"E]_D*
M0J=1K<>JZH#W4M&X&UR6&!09M',]5T1OI2%%0)Y=UB:?!)$#VW/5+T#O, M\?"#ZH5G^-DQZJ3>"1>":9\CI!$1GOYB=#3]#, 5<8Y!>-
(#W83#$MIEJT87DA&2F?"FY_IF%^S]MS[.4OO3X;DMWX"R56'''0 M(-M1(U1+&^:*[U:KR.J$IOI(-3C7. ^$S.(?$8M>&3
*MM"8H[\0'F@Z5!8CL:.RYC4A/I95/BQU)+NZ#]/:RX[+3B_=?QL3HMe-ZU MCY:N> _=BPQ!7B!.,7KZ%L5@4%!-? N1_[W)FE'Q:O*L=!OIJ/[MM^&T@_+.JO,C<&?*
$_Y$H3VE#=?RO@ \%&NTV5C)CAMH7K0; PVW!(9:B)7B/ MQ/8)00>C,1'W6@SV+0P3]?MEO0@[1:OFEU.T$0/SS2SOH>T+@SF_-$BXT^R-
*MP.18536>KVH:X@$T_LGG/[+Y7$ M.'E0Z-RNL=H^TGAYI.J,,9)M7,%HD64!SP MO9>N[4XI&^>M9%Z"B%%S'YD^05,)=4KGS6U'<'7'A9R/*3RG4DQ;W:.XKR(E=*
M&EV2NK@D.L,9#>G1V.=$,.&\8L\ MB)>RKC^2**<;$CA>BHDNLF"65[-M%) M.AB^W%\G&IA-X.55F/>?>+ML!+)60@:-.P*OK./6?)EC/B.IJ55]+41!92_U*
M"D.BU"")8.^BQ[CR-ZF)V>-?!L3Y0][WXR.S.NAVI5-C4]HFF:8O-[E5VGQ@O MVUFY7!LLBGL]_OL3"3R9E"(D]OU*&I(+)5N TW5P=;;.2*6R^RQ(T_?9^?';\. M A,T=+V'WPD>*
*7@3MI!TF'F+W&'H4XY)<-;-*5AD<8_R!]8B<2K#H(.'?9$ MR"Q**"WN3!3]QG/|&]FG1[.$NQ>G;=''P;_>J_&=)0VMST>U3G8/G<&N*"9*
MLY9$ND8(L7'$TC%[" E_/ ;VU.6//Q<+!0L8%3X,>K$:SB6$ R/VT9?!]2!, M*ZG;Q%LU1F%%4MDO9S@;AMO8HHUHWRZ4!QFGFV#I4Q9?Z =*3ZT_!+KH6NA*
M<_RN\IGM!G,7+]?(Q7U@!)MH(IY%':?2.L57G_>[_]MD;KP_FN\Z69(_!M(C MKC#69HING392"\9\@M_8<<?,T5R.XP3"K5D$3K9#J$ZVBSX,)P$F1S]=58\>
*M"+%P/[.M!P#=(C!D^^L2HG"I'>O-,R+E.*W MMDOZMLMDL1(F?@*HPOVMU9ZZJS66-1/)3.GIE2[.DRIL)!7#Y,-78VT-*S7#;MQ&7+H8^^*,E?$T4F,+.C;# M-= 0-EOB?:*
(5A67DNBKN.D+,BI0L_$V!IZLW]@"H'+EIVF0V+6/CC+#N.# MY*U$&&^\#L_!;UAXZVE4X&F3VT-$$C!%.5_[9=*?*U865S4Z"TJK3M9 A"[> M>Z_ACDW'K<<6W-$@:.*
(7FQL(\9LG6V;Q"'.O4\E&3#\E//WDES;ZT2.CFB+6N M4+_A^-OX#O?FFGV-!-2.2>WW>?>(2O7_&C0@SRKEM@O>TQ'T=>Kf>;-K4/# M&OA*!A1UZ")>@7BZO_H,U4^6-*
*X3SNGRSL@JIG'"KBN;87ZK//6C!K0X3O>9@ M_;FV!H@0M1Z,)-5^CT.Q46[-!BO'%5 %CA0XY,@ZRT5G0$VH7++0^[[L?^1MJT]*U.@D5NT609 MB8"A*EX0,%1KBTL'*
*MI&O3\Q"&BOD)"TC4/7EI/4*Q+IL0H4ZLUP|>]NZVK03!IN(Z;?0NE^#|>7<=SZY*2TN\#DD>[M-%RB"?8.^XGH0 OM:%*'DP#C8$LCO"36,PIGIQOE.*
*(*UL&VK>2.6N[(#_ME* M\INB__%DC].TP9CP%M^*54/P1&X;CY8+,0F^G:$637T=2ZN%><_DY'L4U?<MA5H$__PP,FB)WE-EXAT$$1/T\:24K.;H[51I5I#--*
P^RV8ME9711ZL)1E]%._MW"L8-$->H1T& "O)0,W=::TF2]UF?V#EY MN2&4 #G1E0W?%_!?PDN\A_#XB'LG/]?OIUZ^X*3 [.YRT.^K"DNU$G*RPF8E MR5FE)^6-*
*^YDMQ30;_9 ?)S-W=+U"T];QX0:?%B@7Z.1KRMHFMCO#-E/R%R[M%)"A>E%F.M$0[/'AT!!;;]@@6L_RP+RV'HO$^3ADA4IE/(]*U(\(]QT0Q* M.$*<8LQ&@F%G*
*#$&.:L.R/>-Q#Z8<$PDUR_P11(# B_F/IV@PO@_'X;8,X\A MN2ZJG82RNR M1C@&*QLXC.:<;Z.V(H@"]+FZ._4Z-U7U@35=G9KH0.OM;%*'DP#C8$LCO"36,PIGIQOE.*
*(*UL&VK>2.6N[(#_ME* M\INB__%DC].TP9CP%M^*54/P1&X;CY8+,0F^G:$637T=2ZN%><_DY'L4U?<MA5H$__PP,FB)WE-EXAT$$1/T\:24K.;H[51I5I#--*
P^RV8ME9711ZL)1E]%._MW"L8-$->H1T& "O)0,W=::TF2]UF?V#EY MN2&4 #G1E0W?%_!?PDN\A_#XB'LG/]?OIUZ^X*3 [.YRT.^K"DNU$G*RPF8E MR5FE)^6-*
*^YDMQ30;_9 ?)S-W=+U"T];QX0:?%B@7Z.1KRMHFMCO#-E/R%R[M%)"A>E%F.M$0[/'AT!!;;]@@6L_RP+RV'HO$^3ADA4IE/(]*U(\(]QT0Q* M.$*<8LQ&@F%G*
*#$&.:L.R/>-Q#Z8<$PDUR_P11(# B_F/IV@PO@_'X;8,X\A MN2ZJG82RNR M1C@&*QLXC.:<;Z.V(H@"]+FZ._4Z-U7U@35=G9KH0.OM;%*'DP#C8$LCO"36,PIGIQOE.*
(7FQL(\9LG6V;Q"'.O4\E&3#\E//WDES;ZT2.CFB+6N M4+_A^-OX#O?FFGV-!-2.2>WW>?>(2O7_&C0@SRKEM@O>TQ'T=>Kf>;-K4/# M&OA*!A1UZ")>@7BZO_H,U4^6-*
*X3SNGRSL@JIG'"KBN;87ZK//6C!K0X3O>9@ M_;FV!H@0M1Z,)-5^CT.Q46[-!BO'%5 %CA0XY,@ZRT5G0$VH7++0^[[L?^1MJT]*U.@D5NT609 MB8"A*EX0,%1KBTL'*
*MI&O3\Q"&BOD)"TC4/7EI/4*Q+IL0H4ZLUP|>]NZVK03!IN(Z;?0NE^#|>7<=SZY*2TN\#DD>[M-%RB"?8.^XGH0 OM:

MZ+XM)D:LCN9KG\]/>WFMP"{O!:LP2&YJ1H[$(9%Z(R47/U'"?6KS^H5&1;U'/-_M]&,Q1M5*H0I0O^LE?A]\Z^H;6HQQ8>E54+Q*HI#Q;>M9W7^
8RS'9T31X,2M\SU"O3A^9.GS\BT%Y/WRI^"B&_&PKAT*.>5Y]#2QUK&&HFKW$ M^ZZ@.;?0-+-T@6VS(^INJ*\,=+=*E,@BP%Y'T:]6F#FV-;2M9[G^V!P-WDJ6@
MO_Q;CO%O>N*F)5GQEY(,EBJZ%N]-BWO32GT+I,W>8_3DK4ZS]B2M(S?$5B^& M^2^;?"2E-@@S>CLF/0LJKG6P^3AN!_(KEQ6_E#*2<;))]M6M*C=H:3?S.#=4
MJUO$U,(0SM83.$9;8W#=GTZR-\248]:34^_M=%*KNF4|'S9^/MZN@C"M$;(VGIC4&.W5U^\"UAZVYBBTLVG,XLOQ\4KA%M8"WF;4LL&Q?
O2I(;YZEI2"E%5GEK^OG8RF2GI+C'@[R-CHN!MR/*)EN@4P MG%JF6==+VLE(U=9<"7HUU){#V0-!\V;)67R-0L7#^A9,4\OS(,XV1$MMHVA5 M8:.LN G6-
<_A!#0LM#BO1?9L1MW:FTT 3;'B1<0G5^\VV.FK$3;U@)ZO%9VJ M\-)EJQ&)&GO254E1+2FI/R!'AVWL6Z/$HD7-U/OAPDX'P@(*Ol4SD1^5L)
M@W\^,3LW&WE62)0FOU;JK>V!EXRV!7-Z8XEBT\;I&K&N-C.LSDV'BX%O L#F. M^/=.SGT1V3OO&!8%-I7#H-.DY;\XHB0RRGA>=%";O*JKR+Q)6LGP:RM5THI
MEH|LK3Z43^0)[-4ZS+2H9[7-$@=_.J1,YA_NU1G+BEVE+L2+;DGT#_O6G-?Y MMAGF+.$P?SFO+V0E:WC@%TR6Q5D(6'H*<_!*F;_K63#9V
M>W?;*7^>ZAD*+^SEAO#;ZG!9&N7)UVO3VI>< CR*T28OL=*K=1]HRD('+Q<- M)!SJD4H68"S/870++;$M JGVP61LE*&U08T-GI^4LRDZ,=9M4/92_
M$K3/;/WEXE4ID3MAT%3[%=#CM&/?5",GM !-701U7^.BD89J&+QP?AP<6Z V M],$DB,[*Y.?.3/\B(2R69VYK0J,QY'C';*$OV*KI&./S.>CA6Q?BHSCA}))? MO8O$!5-IZW-
BI.'LO[M.-WU-8-OLL>X5"\1#'RX!9A2/0B89#ZS%YC.5?9'_=S';?06!;M&7-D5=VI#)/=YIP|.>&*)8>#>?QIE*4E#A)'//IP|.0 BH(D+ 2?>8!|.BV0)!DG*Z M4EAO 12K<<>8=
[*UK:EKJH.%2<(?K*V7FMDL17N-;6%R+>N,2.#?H$XAZ"\H MDXT_^2Q):RGQE[?TLQ)//:\1+;PXT@W77K#*O:I1DLIE@:EE4\%-9HBA,-]SPJW]+= M&Y\<>Q7K57-
JB.Z;^K9QD>Y"+3(=^8(]@S_!Y)L+D1L-"C^)!YU\'FF*!)SRKR:\4IIVO&$]TU]0!6)0T2 M1?S(5V/SN:F_\,M+38N;-O2 5#@*2*,9-JO*9 ^FW%8"+^ 'UGC*"BM'74#_M*/]
(=F*V$)(99KO!E9&!\U_ .=&3" .?2Q;D5=!M.+0[.1WW-CAR5=4V$X##D1RZ!7] MMY:.7C6J0* .'"%I2_Y$9\[(3$&BB&&%XZ8%<9;< JOI5-
*.,M32+Tl:F)_R;XMJ"ZG]ZHPA#Q,7'>ZTIP_SH$:N[.9H(%.O-7=8T2 M]S_G^8O^Q^0F)@D'N;!QJ4QC5:CLR.P>V[+& O24Z$ARW^,=$*B9.6X.2*_^CM=7YZ$G)O@+7M M-
;'R_T?:>T;#^:;KPY,@$C4D>HT>-7HG(GH00I.]C-Z{^HG"(G>RY@H,SK1 M6_06W1"$46:4,1C\\]M//?M=>S]K[?_]KO?#^>%;Z_YTK^N\SN,XV\'Y#;N/ M;Z5^_XQ-
DS6,5*7G9$A+2C]6'0'6']^SC?/A.?^5;E3=V_Z-2O=/(_O% = [MLYVQM9EI*>9QF]0W'DEZD W*]F0D=R+-.5_X9*_GG^X9'216@)M_>WCF3(29D MJ;'/K$;^G>
G/IH4A^_4^Q4")_1/O7HF7SS&"PU'>:0\M216DA-,2LVGWDNBTXZ=(VN7_^E MAX]_>W'"V/);IQ+&5O:*=[FH% 9XH$5,!U7M@?%.^[KC4Y-&LQ^5=*4I);Q/-MJ";G#)Y4;
1S(Q4FZF$5,TT|!/5&<*XH*;C(WH*[5%ZZ>$#OMN?]2-D"=[_)N(MJQ9Z#XAZ 3.$<1<5!%*;>@UO-,<[^X38KSBTV-Y8K"]&^:&IAOQ34(6+
M]E,GK#-2+%E,QX.H$^4Y^[FMSVTKZ;4S;YX>BN/BJ8!XB%%%K9U(GO(8]D@(MS: <#F3G(L?QH6G'BXGG"HWVS.F;B,>K>!O0Z3M^K_L@ZCP3V]H=-3C.N:,1DJ] DY&-
%G@0PM*1XIZTH|+9OX MG,UD-%4X;#!;-RA.2V*\F6;ZX[;LHF4O=<-\&D!<|-AV9!B$O\VXTBQ(1<;L!0E023 M0>.I@ODHHK@==W!N5V]=^G^5F.7?0TFNVZH1WI\AAU\]?
=]9YP'=@Y=/8A]XC4=OVB5FU8I%2C5WKSDRCNWM6N.1\D:?4OZ,-'LZI-.[6^6QVEW$O/ZW6F MSA^T3VC2EJHEF&TL$LZQOXI8G6YAZ4)ZME)4#/"?
9@Q&9'0CQM&/(BR./H)R M$XR]7P8>9Y(;4A_H]-2^VG'#OT.L&\(+[MXWS,3*>N4L31Z.;DDNGB?2G?? M_41ZE:A+PZ85QW9:1IVCT&$-@]RDD94Z//E0%_.I[+M_3RTA4$
7/UOM#GP: M90V'_IU>.]$-87[.[$\RV6M#&AF(8_&O<61G1]PT!F#E6G*4VBX

1,2M:KH%B"=9:CD?LJZO,X\(B*V4#VHV3DAQ7A*#"4(M);W;A[X7R>22[O <8X92?HCA.HT\IS6H;AX"/>)|9 K7SHQ&D30Y@MDGN6.. MJ%\2R5T,+;2QQ|1HX'DF& CJ_7VL!E7RBW X^9ML-,, M#*&C*"E?U+EB@C$R;Z<=,5SQRO"8CNK7(V;Q0;&!$'E;X\.GV(?%'ZM+OM,^ M>$U47-C5#9WEKNCH.(F>F<#AXQGHCQ#;UIIK) 4PZ%@(H<&HI,4[42<*VQN-73F%/ZYXG,:O0T8PXAY6,_WG&22PN!)A<%NQ?[*8-=@$B;'H6WY%O M\BPF7IA8X>VW^3/>?BNXVN?#;ZXC[@QA+W98"*6;KO4&2>! OS>$\IX!@YG'4 M"H,J74TFVX_QK$VE3Y]59DA:%Z.6HV&ZRZ B>=]K|0|VU=.U5ZSQ\V4O\[M9_S?E01XUSH];D.[/"MUZ1@XSEQO ME;8&*HBP'.33TJ2KO_A^?:44=:8D1220W@_+C*EDCM3>S76L*72LL'ON4QOO M)97<1 MMML>?EMA.&^*7#J +B2YQPNO<*E+.00\{@&R6B^U']GH2J42&\7/@825=](G M#FB;XNV;TPI3Q51(H&VTWK,V#Z/6@H2]/&Y[-R8&;B/P-C8NMP*KX0\[\6 MS[P'G.3+/C/M[@E[YG 1^RR4R?&:OJKB8)G^^T{^UZQK$SPSEPK[C\MQ1$.Z M !N4X(]V ((C.L%9DHCB.41#!"?2W5*%@M (XO-8W4>2\3/M:3]&VU9/LQ0/7MA(2GD_=1ZD2>Q(^NB2^(%&+?+8UKI->Z9M,]%L-V!.-;Z MV\3B=H*\)90IK);X)H3D-#1,2]S\H9F&NUMU4K&CX?/419;\$6RA2O' 9ZL M(>K=*K,+H&^L&WT)\W/V$1.&-E&*%P)9V@\F'FSN53B=!/,7*Q0[ON^/AS-S M.!++$I*^A)W#LX*%"]=3!)1IS1:*%*=S6G!I*N"N+^9G31FXB:51L)C'\+@IP$ M7 SOI;G2HSA?5;Y):XQ> #5R|81(+|\WSQ8)K/Y,'13,\@HWO:CHQ\=O+8L7 M,+ <0=.90G'SEL?;] 7R1[N6Z;&-[QQ3[4S+^ND7_'Y)?L":ATITU0Z7-K5T= M$$B3/N],TH#&*UQK0RND'L>X(I=\,!MIGK^XRH%/_4Y"C%85()&C:A.5JA"-MES^:9QA+? HC^B\_J8!\IX?3!\$TN/_(S*W2RV&\H66G%&<2\3+/M:6>/ZD5.N_O2%\I*(&NT0$\A0#&\R_""0ZVf9ZO%;1:D[*9#MQ"\0000\HB MRK18AS&+=C#PC1QT'6E4QW. E<_^[XHO;O^[XHO_,;IM:],+6% F)C|/*\ MS'D#?>0OHE(4(!<5%E. QO/,U:@S3R6L2=*&N7S7]A:&>H%[7'EQL*99YEF M%2Q+7U+M%/JR[;TUU&[V4,W|O7BNW(68Z?7+"["%F0:5F;ZHXMG3#AO1C2&+ M?5/T3_D:4;(&H;Z9]RF":]D<=?1]6RZY*N6_@+RY&A#O0=R&U-L1V4|1@34> MD7=3=2:FZ^<5P1R(:Y5MEH+WJ>M-^)6_ ^HWH120_^FCU<3@_",_K@NS1V5<-M@?9G#E+*RRX:#SCR@<;XPVX06!VQ@_3"1^^M]ZZ8'|LOI' M3&U8=T83)2=84Z+KYD.0@)1>OO"L=2S$8ER'@N,63O<4$L-PA5B:H+NH[CQ\(0"B?-N&M5=-A H$4L(P[CG)$W""&S M;YV!';,J8B"3*/W2"JSZ;"]I0EPI\U?C/UW2U6G_- $SGD*=,AJ&Y& Z7O+;Z M"?8WR(6X=(1WXXA_77Q.4K%K6ONRNUV9%(<[,2&-$^]*$4#*QC3%7HR+#F@Y M>3D&1A4E8Y6KQDZ91N.P?OAQ_%[TX;.GN* PA441_>NDTH5L=R4OH)3+|^^C M1>EOF?$,Z1\S;L9CBF\;I@&;7R1./OEP_07C&,,Z;%%;E1%"^)05G@MQNLW MV.CZ7.N,IQW)N,6"3\,?[\AI*8">L>!.!U2O# <"BEQFL/"X6ZV"M=G$]B6,_9NDQ(R)U)O'0F'H=S CH5MCR:PXU$#IN_QWU<3]"93\FWZR+U'C M!HCL_GL #89CCADZ*ZPV+F9D]C5FAN_9..3LQ_(!.$- $X]_M7=/Y2>)@IWGO M$"M\^"VS A+;0Z5CR6+[\='O>X!M%A:]$L3&: $NBR/L@J6=KDE65I&\[(B'N#T_[?>ID]1>%P31.HZYE!>_;\|\|8', (UWR@A:OQ R#- M=5SP:^7N2V!"#TWNMV6-J;#C\JH;&KGBL_M>)ISI(EIP0Y:?#<D&N.8N MK73WA.=&>,T_2'FNBQ<(C:,"<.3VO571C3[UNMD?#.*G>7IY 'IN?2%,EE\ M+'5$H41$D$9+)HK?>]P>8B>S:.$7I.:?T $#S0SB|O*ZQE(O_7TDO05*P%2#*T M0L.1G,7>]W\$SOCK[A5X():6>:0+*-Y4C. ^'G/1>2GZR^XE^#87#^U8>5,[MRM9]W9KM6/33@*-W.\G7&W?X'N2>;>!@0M"-B+I9I:G@L#)#IS!$'-JE0Z'&;-U<:.+DTM:,! MU-GU9RA]!F9-R"YW1]\>PK?EAP[9!L8HL,.YIS--"VFCDOF-V=6M+1\@$*F MI8.I[GVN7F<$@?%[>TC#Y MD];8B4=>B;.|?FW6,L|HM1NE8/TFM!?((#\:Z& 7[|$5B1Q;..X6E|@65^L M\\_ZF*1?'WL_T+F/G8K^Y-(7I$?=5)];.&0M6E8'VM2Y<&%RTK| M+IL.?MX>/$WS2ONY8-UA\OE,WAVC5$J/15-!/P]7WU@IVD1QYF(7^GW!!UXS M^=PI6_M=O.%_+V'4C[K)N M\24,"LA?]2IQ:\J3^U(\7%Y<=;]9;PG%\K'$, MZD8>4=Q$7FFO_J-87PK]2U'\[P%K#*-9_UF9/EN=^E$<_O+P/_7J_]J#-(&$ MH'WF0>R"#FWEORY)+LX^^YUV=A%@//_TTC(BKZUMKL;?"&ME%$MN&^8R;]PIDP\4/OX? QKT['$VJA:,?VF1MEGBS: M&6+4B_J9'J!%%R)WXG=E3QX6]21^0^CB,,%+NG)JNR1L9Q?\Nj$-*3HH M3?YSY1VW$)R-R2HHVFV)67'-,A?.EM9\<7X?&3^ M8190#E^7H'=97*G25*15YEM?'B6_(O3-0.P')$?BD3=(#,E\:EV?=W(8+K. MSMZ'X9BS %5MKYG/GV"N$G@/2!-(FC'0?UOP%/*EBPUEO=M]$3Z,O;E?2I=D9 MND]DK1WCK?\QN>[P@>72@TFM_#W6,/8J<>&H0D<)B@B,#-38U#?7-<.:-L4F MTNK2WH|\E?:C*3EQ:I:,-/E:H\\/+[W.')\U5/C?"O2J9E",T*MN[YF'+1,5Q MK+:4//07'IVU4,7X"S GNJ+(R-&XXWJWQN[RCG3^,*Q!2@G[=58\;0;9U)!L M.TLTP3ZYM724>3BONHS|\P!BM')!XB"0R\80_3R M9W.6*>]/Z*SFMQD4L7S%[JG? 1SM8*K*9O:**Q_(@=_,%'?-8#XL@U+ZB)\. MJF9MV"BGG[V+'S!@/'!_OI8/^.U-BQ=f'-/<|.SU3 IK[P"MQ/BE]>)M>1 VI. MTY#X"[/ ISEIX)4&14&[?7-5D?\'%OSI@DKK8H'6= (JB*%K,-- 5K\N-[-) MS^_;7&= QDU6@<4=IV66;VYY>;=Q&B9 M]JLW"T_%I3@C5S)4$$-]E]>^!95 B3ESQGZPZ=>;89619LJ5YU2TP;$ L3NF M>4TE!$|T3F7*<_^"?FW_"J-&_9=5!YJT^@M8*")I>*'']|+U8|LU!A;E\&MS M.,19F$MR:]CFX3*,A=7_JDO;_RJ[P -N>NK(5@*Z#!'ZT|'Y;CU!7B%0SV3P MC#6>S Y7ND. #GH@? YWRRSU@G:S3=%#QW\N+@&&D9APSHCR+K40X<^VH MPW24>]]HQ/Q0_M6FP20#22CM ?542$ 3\&N(S%72]&(M2_Z*GZS,ZD=B\TW[M1UVYK=#H4]QH_W1_4\N2- 'DN8G=_H>TVLO&F#;[0]8IA&7PT,*#:G+++IZ\N*5 S80T1?;*C=&NMJ<7H=*ZG0.8G1F=X/ M+,MZ9L4AR\S..RN5E^Y#$_N.A 7:I'CQ[#,W!4?30Q7AKS\&:*? L("&)>9*HM(QA<-)KC8-[+|\7AW3D0_V(B!_ M8MGY^WC]DML@-73FJ9I(9$E,%3_K-,&O87T.WSTDV R*7@ ^LY'VLY_DB MTS3*K%<[.U8E[6A+J/_A[*WCFKS M_[)%0Z% (H;A[<;?BEE***%X*[M#BDP25X@0+%K4'+%K>&%*>X:X'BQ=TM05,D MW'Y_9V;.S)PYIZ[!QO\Y:G_R19+UOWBW/WOMYREH%Z3S4KN&&J5N9]?OO)?\4 MHUB+B]OQY)V&3.XXESC;\6O_N0;TN#AAH!$@G>*3RKNCVVDAD%8;H;M1H#LB M=[';M"3^"?AQ_HRKX1B)*.UTQ)>-GE@^K$7F'-PA*E+4<1L161T @>,,8Y+J+ ML(R3L+K]\A[&I>$]M5+|\V#|9J9$N&3DT[KEK.J./L"\ROFOI+1%*RXMCH, MKZJX+5WTR1Q9!.$S|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

6P3WY;!^/RTR9""8A>XAYPQ_^:'7P%F?R<=YAZ-MB9&W_]YMSYG7(!;Y\!!#I@M1M!6I:7>*JXL_^E3(G;JN8SN->*<0&G2V\+_^C\'M:UW\XW\^M!M/=_Z7AZ-VK]=?WW3+]/F!#_B;!DVFG:Q8@;_"3)@#6\!&G2-W M7_^<603%)K-NH^_8:'WV2[XCFA)*UT][?V!FW"=J;3;<6J5GEBT<(ZM,[_ Q=?XO:$O(Z #[(9]+8-4;F5(+@WB-):FMME+53X<;[?9N&3.4R'5E_^O/BE%^$V.?0\C8/*CA)<#FW]AJ#2^[)NIQ_K_09%))%^# M'"MU1V[{(L+|F.8IT4R)>]]5;E>E2G[!S-^V!%BW8;>"\3\Y=M17A;/>E5=!M#4\FB*Z+(J';__?G+9=PN_^MZT;O=:AB!+4.XDA:U"6&X? \.3 -l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|[DLY&C"G,_Z+TN$W05'8!$"]4\=8<4.39/MBI+,;R-$/CEHOLU M"<.+D% ZS?*BG:TAKY/L,TVT3&9X@5N.2;"JA\[(C"QF#!K<<"@?M8 5QP-.MG*N"CO<\ :][WY]D]33J[:Y$>,YPHBVD^4S869LSB:>)UL8]5E/%V4YU:Z\ MJ$@L7M;TL&B0$5068NM=L/PXI8>2]O3?>/2Y-R_IG+=\,&V*#)4> C/ ?GXYKV9CLMX)+CV"P[?0 MSJ]=0E:'8L:'.L4Y^S7N#=KEW#U[#^:,5;OTF\,?? -F_IKMQ,,]<'|32FVZ-MZ#0!W!C2-N0I^/,W^MXB*ZV)SSB)Y(%7!60Y3 M'\L%"B@S-,>L9.UQ&+]V6;$$3X+7[LVN4A)BTFM^'B#\8\U*:9NAF1MKV3, M2?+\|YWW5/HR.DCOF!!H)@(H<&V\-Q[8F0N8N=14/&X7;+T; _]"C6 9,&7K(-3_X;~6X":Z<_:33^;>)8I9W64@2U9 MQ6HB%<\!<,/Z+_'&:Z U> 9(_@0ZDA\XT]# M(C/6:O93+#Q@:=H8K]KB/KVLG<,YLW^N(;2?U]MS%TT8V1G!(\/] MU["YM4:%-6?-E=UH9%!7:J-I5%SF<-E*HZEV^IOHH;%KJW:\#6$6OHI$(DNG(U"=+8!Q(87"G_3,RXUAO+?K.M\Q1VC="5]RRJZBO>*#4V30]2S"#O6TJ MPBLNU@>7PD2E[6W]\SO:ABG1^%?+>[-7IE\]TF=-1.&"^(_26OPPM%H4A^/4CF[*$'H_%*#B1&& BI%IHW/FA&C*/3Z,3/_)'1CAM!E@]S<-5*U9L'1!U M_ ES$UK_U8X3&)ZZT +\R-0 Z]HDPET&Y]+7U""9/HK2]9YXW>*//@IPB.1(MUC%A^/I3[?S1DS7#@<@'!@#,PR@.EIS_7JLIGD4_.2Q)MONIC&/NP<&\):8* M:2LV!0_7Q4>C=<>=?RH-VGYT_NGHSZM+C&M56F4AJK_3GA#CEM5M+JZ"K<4&MB:S(Q--*KG_&G7\ S!) M#?>J[']BT, ;T9C$JX_1C,0*. K?MT+FL.!R2,%C M$@1F3_^ 04?S1&F]>9UTMH1/,Z:%W,\7GU=4;", ^\IYC$X4!WEW#71"7)WGEM3IEV*RD(C6(0@<>"7U=+[=XR< 'Y='(&1)M=\XZB'R"WD'+0M282 MH*[5HE,H+'H'Z'\#18A.;47H=\,M.Q"5\G(D)X0;B\VH=;#ZN/EM4K992PC>R5M\OLZ0$1IB>\]!1!A47H"@V(;=IRYKV7^Q41/JRfY<'_!*"-!S MV:U.,^,D9K[^V44C-R]8 @L$K0 &60RN+V9')L$,KQ&M ()@NUZ]0!=.VF4H+:?56+M$C9C?11$K%/BJ -MKB)8Q^+5^@5(4M5.FF4@(2_;=@K!7SV!SMT;UFQ0.(O6GY?Z,26_C;D#$,S M[!4#PVXT&9W,Y,4(NPG0.%W61RH\)?EU=75=PT7OXQ2P3]B43<0^8?7D*Os] M9@ -/8UAPM3]@,Z^[U;K[4##U,5$)D\+1;[6"91%9=DV-$[:9,F!0M-=/@L4 M/0!6#9;RHZ[HQT!YC:.N!QVL\A9 %FN;TU$X[!736E.C/;-58@PFA$GN00PWGE@&AKF!2[!Y)'^K. MOYXC[HHBGI:"MZ&\BC\?U2.TW L_GC[0L& M)3L QYS-"^']$H[1'B9C5H9MMX>_ GN+;%%FR6)94W="93@D9@DLA!++* U618= '@$5MP%..449[,'TCX,1, MR25KC?FD^R%)AY!@[CL,Q2 X33L3M\U+0 7L?EQI5^24[]fZ;>\59ZO5#?5M(\%BM?]ML_9_FE1[07V3=Q<4_*C"H V$EN_ ,/B/4A6SJV_*\#<[P;U&Z]2R MLY-U-T^[^A_\Z/NT.9@GWV7ENVI["Y>96)%[KZ?I\MLX&7/PMVO"F=.H*/?L'CMDW]'S%/[4_G;2?LYXV M[.S!;K)M8.NAYG%% >R(4PK*6(\T633KC:5!,T ME,O%N3!C;7T87",;GRUUC423!;F!-==SV.M#!(=N_6H3Q^;C6WPW)0>8U#FM M\/D-9.1"8 ^ JI_LTB #LMY F5MU9\/V)PUY5A/?X/4M 1 YW1$OC"8)@1$V MY;ZZ,]MU"HL0)R+ROX%HWS?\16/2P:Q0EB;Y, ^ EK48RZ>#9'[-PI\$MFY6V M>30=5,NL3?[fGE1_5@>4ZJ#<&UN86_9M & _O759K5F].0$Z:?P!44R',>K+VK%=:W+ 6_55Q8. M#K7#KDTID 1IG MW]H36+Z)QUS'K_ZCX")7<=IK-3_7O4K2]\F78U.CH<&/?E$?VLY\JUHW8M\AF\.ZPT+WS^%N)D:>SVR9O!W*C5BCONQJF+M]XXO?7V!TZ#S74?%;95B+&* M"I9ML2T#=)'V*?3^.C$:6;6-\?B&3-L:=O:\1)_NAT7(=MPCO\[^H05E%'WJ^F876:M\JO:"A<,?:42GO^:T(T3O,6MP!@=+AZHSG(MYK47!H !UG^`3TCAHU"9V M?;$9*G^L0'94ID_(6(& E[2I@:WN]WB/W@,@\OOT.U'>RGN\KFBL-M&M,>[U(%IS+1#>\4&!)H84:]W&#MI8"Y&O- ?@1D%N99H;ENP6BAM1T^#KW2 M^6+'FF_?KT9-80^*0E-G3FJ8R,H4M]6E/P!LH:833T2EEK>3$UMRW0\UC;KG MN?7:5RS@M83^%M;V=QRH<#\D?0^N,]4-17^HWI,>Q2%7H: J(J2F0$4?Z%8= M%_IB'^"=,7!1F;>[V=;4).YD85\ZT(0:I/"DCS9U.H+B!I5-/5R^,*YDB2)YMG"_KL6_KW:"15[^N\C.CU;IU!B=WJ/\OXAVSG<5M?ZO>^US>\0Z.D9P;^]+>/&= M*]=+-V7ST%6&#K*^P/L-(O+Y?7_#EDU?\NI>PXD9NJ#/Y*F&-M+!RSK(K%*F51-1)8!I5F.C=;],26+SO=1-2E^\{6U)$M_FR" M;NE%ZLHI4%O# YN9L'8=%L2G3O^6KZ$]9E_>);;?.6T2X:$F+UD11O'OZI^^ MOA_!4_QM*77Q*I7N ;#&-E<&==@0F\V#>]V2\/8?^/PY>V9"?"-Y<0T?=4)3 M@V>#,;=DWTQ4&*\NC5!\PC5>&]f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|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|=\#>(]S5M3T -.|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|Cl.FUV_R50E.LX\-#2]N!^1\ M.*]M_{)]2&)E"VF^+?0*,JQ164T^>.!$\H[.&;@=Q#@N[4_7$/"X>\7C\7GBZ MC>?:F>0BAP2I,R[*K@W7&$B=*Y50,FDL;M3F0?;(5%>|(%*MU6G+!",Z4X05 M--8?F[}^.A;!LSEL^?3Z(UGTDRWPY5$XXQ3RG);F1CEZ>C MROC=[C]H.7]8M+S\R)(4"I*@)Z,+&,=$I"*!(97E6*M;ED_?@YQV.H@.$,K>=L;:R_NX"6M/_#U_CJB*,"G4#B+;$_ROO23|C2M+3/_^S4R4LHPA!W-#$/1$-I9 M63\"@82^]>F^IT0C$??,MN6]V_^5?FB_K,#SU^O=4.^=R#<'5I9Y,\YLU%]-M7-K_|$WMY5#LGMHAE!/:<;":857@0/V5A2R$DVUQ*S8RR6%G.K;09)FU.#?? M_;0=N_;NB!5&8'EEL]G;PI%)}I$Y8+/<@4*IH\4]L;NFALF*Q0LGY4U&?+(9:G-E4KS<_K#[Y"<6]?^) M*E'7^$1Y6**6FE3ISE4A*.>#I_TC[?<@=*_'7,O=5(.9QRKG:]0#0(_DH85B M#I\2C]LP^(5*OG6\YVC OEQ@"OKT\ZHN#)87;Y#]'"->RA7U!MAC?IH$5Q!3 M2$B[UJ!3=\(?]<;P2/ M$THA-Y*UU7$H?;IH+C@P0?N:"UVT?0EIJ M6D]!C&N<4"6L550%I38 ?I>LW!@AE4,^ZX-\(YEHPT(&;>E/R9U?$>)Q'E MNM_#U5]. G,$C.W9N56Q2E!+I?1WEPFP);OP2 ^?A#"OCATK7$K;B7D.JW3YI M.;M\E?L[_CS\N-N'HX\1YAGG:^)PCI9DG=K*L[fQ==>$9F=_M8?1>)GQ,.QR3%%)\G2I5[GAJD^?9[4\RW3_E[A7Y948?\Z00K?4 RH&X.\2 MX*(",_C;_8+(D;?&T@RR-[9L<:8%|\ /]X_0$.^]&+LAW !1K9_QEC2=B;'JB MJ]\CKO90[>O#T%[P38,^O(*M5'M)Z%"2%%9G%4U$,YMK^<TP>A4^/3FHFMC MV(]?RG$;,W'PPD,V"1U5FI?_4PWTWQ\|0P+UFDL+N]$"$G*WG53/@CWY.%Q# M=7F032=D_=9KC3TJJ#(U;&&\^#6Z.H9BWO!UM"9*=#9T38&)I'O<(MJ5^'~MQ M*%B.CBA=U>&/P8]|"?;*NK"G>'0"]\3,VQ=K8/R'-ID[>THT.!:<+D*,>ZY] M<';DU^-(Q_8:G04S-/+&/F@D]HD',=LRXI@ F+OG2K,5L(7MP M;NTZ9O3((CF_W)+,\L.)=.3]Q=PZF1Y2*XM'07^0H5&AL'$65;B"D"VW]A M>37V%D4U=8XZQIJ0)1=KY1;ZE(F'D_TKL8,^5;%.OG--P7*'0 F-750S?;T68J4Q.+ MW.GL-O/DTE8QOS)+VDS&N](0ML)" TF9RSFS52X+ML)1?=Q1SS[PT>3;.6IN M%G*6X@*Y#R+Z? /?D-3;""O[!0R!KVH"E1]2AE\FR^AP'BU6RT0G/PZM7WRM MRJ OF_?O/1QUS]B]>=CUD<,5K#4?NUM6# X^,?-PD\|<6 B+=[1XTE[>P'0^MYQ^6HZYWU*3_&+OX]8]RLK'N]W_4B>78A*!8QZ]&H}Z; ,?YO HY"G9R_=9T# M."GV& M^]O|+)"ML\^K??XOQ M-VZZ1+&NN)YQ#5<53DGKDL+P=-;9MZ.S[']:NSN^.&2$8M7ZG@DS%?R/VHV-_7%ICY55TC6>\E?D/+.PWW]DD.O M='+FO)?AA#?G#ZQ6U/QT:7SA7GM:EPX>9%8_1#\TJOCL=P_9$BKN'*8V.V%W&3\1NV?'GT@Z;P0B.JF+'U.QC-+ MO1B.6W2H-.XT8Q5I"#\))WN'VTWK<5_F+[U9LY/OGFINMGBQT"_W"Y\$>"1^^MH>Q0^,@*-RW2%\%U^|)DZ6M@@%M)5 9W+=+_.1*C0R#H1/A8U9RS9."Q4Y2V6 MCGT:#K?3DZJ5K4!-IBE$__J-JUU.*;8)>+L03\BWX!(#4BX4*ZEH [?Y:6WDM1V^L_NNP4:U=X.JK%Z]B:IRXVAI;H],IP,*SE:NV/E"S%?O,^XSN=KCY,.UW% M\0=[,./=S/&Z')CL3JXW8_.T5XMR8EE:B-C%" MXMV%G7VK;.)9[^H[2Z6I;%V_HR\R:N'-MLPBG6.- MB%W[T9H)\4K"7(3BUEZ$YHAFF3*9R?2/,C6*92]QBTF6>,5J.O618R//*U"U M,1>K>&:0:D]NPY$H5U^A_U+$AVCH6CSHH$7E=U+HA,/+V\WC1'<7=*6?M3C>,&J_5Y#N?11=*7]K9W3D'<-/R,D.)40_^TGCB_UZD^.KOS3/IU[S_3802-MF/Z;'^7G?]K*WW|O@U;<0-CNER()7R8;CNMF?+"P*0$'DG^* U M1EY?:$YIO'#N'!H&8#E&4IK;^0U]:TYT7&Z6^B=]C+&L54IVR8+AU8.!>AJ MW8K1V+L;$\I'YD?*(DQH$:6#&AXZ7$FQXZASL-"QTQ$#,L@/WICY! PX_=*@ M:1M9EQ/SR.EJU>,7N!KS:L(-+DHH7CT ?J4I>\E;ZJ:O\?E_O@09*I M+++W_-9B30.1IFC1B#&A6=N915<)^V2%2T MC1E)7TNT',LYL4YH3Z1.\RA^=#=9E5ZS?FLS1++KQT\755DC38BF883?="\U M9_Y4[f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{IU+T =RT%) P >$4]VHO0(IIC M_4_NGV99LU?&>F?R/:CG4]5N V? ^W9Q&@(2;?UC|(+VLD@ MEP%

"4M!SG#7^78'!T1MKP=-3:$=NS^CWTTSM:(,`M7S$U|QRERD1Z33E@QAWN+G9S:?4/;U(S|&7(;|EM&DQO#0MABHR>IM&G%L0[#P& MS/>6UHR>]_,-)
(AGQFZ7KZT;6><@QWYI7=;5BL,T%1]!G@;@-.$-;D0E?>++ MS92[^?:,TIB-$S/V!I^+-QW4A5](IMIOD>MCP&_3G)E&!U $B1D>XS5S1E"-M)?Q>(Y&AIM3&E*UF!-*
Z,>OPBE}!4NP||9F&+,.,^8.+=)%Y2$^N88_KS|MS M&Y^Z'486N15Q'=]_(;O.2!QZC^+14B^_MAYPI!R-Z2OFC}3XCOM"=RGV=@!-MLW<)[!9%M_O 'I'-BX>HI.*
[$X=%8S)S-")eQ^1|"(/VK'E4/GJ+=:CFQ :[5HMYP3M\CBAR%?ZU1+$%2!SZ?OU?M%&NLG!;2:\ZPPT%YGDP7FN>#76^T(H*
M<913GV+EM>"WU^8:.DW=NRT&,-ANI1N[ ]=).T;:-E@5+!S$8CTG\0U[>[!H MR7],9L):.O/|/0._V48V=C7@IG&AR9
*M81#F\TK^OO02@55$Z8^(VTCKL9$,NFD;.A1/$<@T7)9K()KI,9*L=)"\+R%52 M\!-"3=")(I+D/O/B=2,E& -,3!ND49K7>5/7G]-*H]39GYN@<*Q6.:ZQW3]=% M',7/ 4Z,>X=',-*
U-)'O-CPH=2!JUSZW1=]FG<1B1S+078BSSD3PZ5WUY<QB\HB@/3:8QZ:=,N.XR5-4UUK$E<Y=N!|R4F.U?]2EW/$HHNFC6CK;#O\2]H[^?]\55?M[34S|^V!{^0L M4_Y|
*7QJFJ;C&R75,]Z^VM-XG6^)B'- R$HJ+Z&FK=BXB^X$-*K .,F#RW;" M(8'M^DC)QVIF/V9_O3*W%P62/2-!",Z=OWG*^NX*LD$Z'Q3Q#92.2AN1"7HP*
MR>G^\E6OFBS'DF0|\4:+CV32/"7(;^PY;LVT_\FZPAJKD0|%5Z1'MPC|Z=30 MRM|R.M69LQL'MM\$W;EYE%W6F !W<7&#%TVLQ82X.:=5;WVS4(T/\?%=WZ86. MPS-
*=EV1(_=[8J;<4MC1]%#D I]'!2/P^1SAIMXH]PY D%GQFB 2+_X6):.L>MPIF*Q<++Y> "^A-U>KY62^>QNMN/6.[G9U%*6VF+/7F M^+R"@TG#3 53Y-*
Z$$HU5C:=OH(3\9N=]\TV1R;KMG:7016[5Q;"+SK4N=W MC!8NB@>Z0%RU\V2Z0@OBZ3,...38>#5>,/D=3Y5YV[=XLNQB\'+U6N==OQSP4 ME#HU
*;VJ.0'MKV"&^$2]SW8F\"0/P@ >&GPW3J;.O%F6/ID:5WN>XHWB:^D M#OT^$YJOV:OGN((X"9L)<]IW9C2"%H^]1;1K(*4X7">]!$>S/C]!:61BP!M-M2U'2($KLCZS:-*
*P2?,GX("*_6,6S-W;LV41^Q MZ1_*5^(D^M>95.C@6VB4K_>;"^A5 OZK+O7_YOJKA-J@ZJ]_0AAB>STY9S' !WS\?P%02P,$% @ O8$T68$)&#$P:S*
P,BYJ<&?,NW=44]_6+KR1$CK2.M.U%|Z;+T'A4! 0%!D4X1A4 M(#Q (18I4 0$%!:6"|&D5^DH{U(+(T%ZC+$ M$I++|!QO|SGO><^X8WWO+&-]=R?*
QCC9V|]WSFG&NN9ZZL1?Y-7@#.Z^OHZ0 4 MYP" XNP#D.ZNQ+34M-345%30\"T=.RTC,R,M S,# QLYUG M8F9E9F*
*XSW6>E9V#DY.3D86;AXN#AXV#D^.OAU!0GMU#14U'34W'P<3 Q/&_.MW,C? %9:BH^4'RDI+@'G6"DH62G(70#X3$!JBK\UX'\TBG-G.M**
;.GH&,$=!27F.BO(OK<^NAIV=!ZA8J=DN7K]D\PV!R6'3)FT,V(O4#K?"MRG9. MTV&LB)R]3R0=/1$1_OCD M+UP4 "7%9%0/%!?&K;YS5%245"_<%&*
*<"_SK!ZQ4U!>OT[#=- $]!F;_']!M! MRW$K]4-E.YVPG"F6T]YGF)Y+1'[Q,NXO:']#|E\#%OF_A>P?P/X#UO3 2$EQ MYCQ*5@ "G-*
[/CQ<# A\1REXRX":,3|)KU+26FH"O[X3O7TIG3"C7$%=R[^TQO MWR)5EE]UR4!L-AY%>K[#@@;FC\E 3\L\B5Z2#(C0(;9$00?(GQ($>!YE3-?C MAHV.
[9T&S,+;_5#:),FS9Y_NS,%'X1.0]P98#+P9OK"O(C-(D.L"C@D*=X>Y*AG+<[&^>/"&(?T+Y7PTQ&0 9CM0790^G;I+AG&X4N2!GU5 MZMCY(-*
*#OL9NW$@%@GS)^*I=ELNZ[FO9^%<:C/TD(&KU.!L[USBC.*6&S7FC*M$_VQ77/B(_O3'))Y);9JK=(!@AD ()'!^MAD!6P60&QV/?\OP(8_C>,<%|M M*2%S/%^&WB/Y=,PZ?*
*Z6U[^HI_)O %M5\E.V/G,33Z IQ[*C9]?%#Y7^L_KR M_X8/*C"L>_B0@10]TTOLW*A&O"+P_ZO^D'\!B$QV*2!(4L,!S2PTZ?'_71^U*
*M@!9U;4&K,I3S81;Q(AE@)BJ4(IR#$*Y[_Q)13[?3WBTQOC6-P>:KW;&S9(\"MC3#^L&3+;,J4UUAYM9_GFL>ID2'AZQS=[.).XP)B;9.!V M7D<;7AU,M*
5COYR%,;DP%0%!E(/C7!X9>C(^N.W&&5-.!#*0C=F]BS'?/ M]#GXA@PL/B:-@??UB&<#)*]=#'2?>9J!Y?]&<@W7H02A5A(5UM?=_,4;#X[M,\QU,O"||?C"8=DQ-*
YKD_),,_)N>;Y0@.I9P#S$LBD626$!D@!MZUS[!Y > M,?CZ3.EYXLL0.V+"F7WE5A!X"T0-Z)0-04\&%K (G|_B7V$@G^(3<+J=>0Q^ M'Y"^A)[GOTAFY47-AAH#8[&%WK?*
#OU;NGVI.^(,N SZT P>]!8."TVON>Q!(MUM.\))FH-=>R\WI@ZS?&<7M.$KP7@1B@Q%664H9]J'^@#M7#.+7]-[JI_.[!5 M>-\LN?
*1.IF<.7#FQ[U[=.NHES*8E&RCT?<.7)4WZ6:HR3+5+X,_7?N;8825 MS52L$TL+4,_\FPE!{_D,3_RBM[$*(49"]*!(2C<#"(/A&R+]Z"37* M4\ 1Z@G>6X$<*YVE-J%QQ*6S*
*7^<|U\,)HY ,SS0&U4#[SD;_IO,_.5WW7_0_<>!@_9_?)5 ^L*1+F_!ZMEA^/>.Y>+'W_R\(2Q9D(;|M]T86 MJ>,.9PHK8@1R=QXLAB2\ODX$O;\$3;=?*
]I_&G@ZN#.9_0X!6.$RT0UG7HCE,_M;E#_.34RY@/ [5/N*^%<\;>^G:<#"M K%"$(NV& MT'XU8+-\0\QGYW&NRTX-A),XC#%K@P-!#1+M-ZU&5,\"8##P=+]Y!M!4UH*
MMG)EWK>L@S"'CW@QY$_C_.1B^>%_%W7K;Q/|A#F'\;C#\|L_1#K*=4YK!CDO2J-XACT- !QADJ/+\ MAB^Q R4 7'_RDP?$!MY'3L.W$HZZM;-IMQ'3_K7W^Z27D>OE
[FIHD7@I-$AE& M!1M=XHYNUD).KRNZEY5OYU*HODQ7/8?+ST]_1\0(s.?W]fFE?UI_|>,W!H^G M:0F5!\L@L!8T'=@?DS=%B?+E280WY-W!5&G85-R0IO^P[KBU)-
_$IDM3O;,./|;B-D^[M7AU16&$O>OH&|,.]('))\N/SEWUI/<&RURZ@"N%ZE__A|S.YN&YP)_@>Z"RE M4D.6MS7E$"@UXS_.X'_N!//L+"&Q9]E?3U<;\2)8IN_$Z?
9LQXC^/A.$]\!$D1S.!@@A^;:+-N:^;?Q;^P%_ "M>;BZU8^-O7+VRI?,C#4F1@DA'3)S2(4EG,;ID_(5A85?;85DXQ/-1U1U M,9=8KG4\;Y-W!Q .\L3%4),D5]B;!
("9Y1!'&$TON)STONSAV\>Z(?/;MAJ0 W:N79%^91FR &<++HUA7;*N?CN4TKJ[VX-PI-59N%X!=FM!FE%@#$BCCKI M=4=)0:!HA),7LVAG"WO7_'E-82L\'_1\I%^"Z% ?
+LX3M7:%NCL6S-FMPB=Y++>[$;I8:.!:[%;?GAN]]>FEY M<:/@0O+J'PWJ@*:,\&IEP8\S% OS$#^F'+$R3,.]J!BYG.QWHK#GMH[.2GT> M#=P.[X\&/_]"5,-G-D[D>|1!^T,-*
*U6E[*5O^E]_DLJ,. X1FKW>'!DC,V>0 MC=$YD3QHR:B;WMFGQK2*AGH@NC8ASC(O)#YL"<;DP_H4=\(^4LCE*-AL#**3 MSLP8=/-YIF+?PYWPL/=*DLGX-*
*P1%6(@^WAL)0W5 SDL3;?QLM;:R6SX'Z%!% M3'X[G6;? RQ"6/O4'YR1+I(8_K>$++=W%P>*N8CC@ST<-"CJ@MJP0?8?B*
MG[@>^2DD,OB0,OY/LSC.06N81$\V|B\T8G&JK:=9"4]D|OER=?F+ACC_40;% MKYETA9@]E,90;697"80%_G MR?X]QB]>8$R/>'_9)?
W8=.O;BRQYKR*\4_FW%/)5>34*MICY45!_P*$LKUT M,U>$\T5?'EC*1,35^*X;M_/9;4Y2C7\Z^X>ROI?M0*
*MEDC2SG3>@G1=MPS=)*RN<\%XJ>S"A4CE.Q^QRDGG\D 3.C!J6[PL>^AS&FA M_WRTD#*4QLX &*K(00K_&$O(G[1EKU8",JB(GZ^OA9A/D0$:CYH=#L,2MSJ: M?*
*G/LG_T"R]H)^19M3^FOU1^?BU)=4|^D!+72(G,@"Q_RJH;'TA)0DQU+K?N M7)[86A 0'^2^]HKX$DD". MWJ]7/C@<>]e@V" 9]M>*X5%_Y6"I*!-!!LX(.M3^ST|N2[/"*
('=SO?^%&4/(1SPZG?/W]XQN6S29S%\O:OWZ(KE(GF7@16HCF" M$\Y6-91FGO=P^'*('1RK @RD%?C"IA?"1>T[=U=_[:),J$!+G-SX0>%<,.^MN?I3%,)B#4B_()0:%",,%
*M7#VJY=/>'6+^W!M.#3C"%<8/)I=.1^&ZOEZ(CU9W^-2F8?/W@R.91S?Z3L_M')).F],MA-2TXH1*_GAD>$@OUF8[JIRN\8KGQ@IN-OUW@O-ROZA00XQR!?*/*
MI"SEGSLMC($X<_Q9G5%8D-_6U<*]'"JGS6&>ZQOIS_,=YUDM4A/;S<(*E\ B_M8FM8F&:[7?V#*]PMIXY\JXIV\7T&\(Q-KED#'L6A MS.1$OJJLQ45ENJV?
*M.CRZ$L047K2^_*'/JX*8UMB2$F\ <$ QH]6Z,841X=Z M>Y5:EN0HYI5.*U1O@H\ZZLR.0/%_BD[K-=F[EXJ'F;\&.%B2?DQ5_>Y[2O6F M9UZ-*
9W,>Y^B3A;16>F3Q=MT0TL$4X]-4,.^"%)G3$1["!=UX]*U4%=W1L,C=*Z8C>HYX>C5?#Q$IGC"^NC*RP<[4Q?1; M5>A-KYWVW2_C(<93]9IVAT-91FfJ*
*RZ!^R;.OKS_R2X<#XU*ELI%=:O35G9)M8O8Z8CX^W;&/"M)"PPNGXIM^NRIN);EU"*EAT6XE=_FVWYV^9YZO.BU5_WGB MH!%.QN;]8!QG$:/LN6_ C[X>I?*
*17,F\!*G%06OF+?MO^AE-VB'^.WR6PUO9 MWQAI&>G--T>1,5;+2589MNMENDVMK0GY>PC_&D7O1/ET5/^'NK&5ODRU=+%"-2+"@WDE3_,6V(NR>\ZLKN*
,9E(^'ZYD7:H]K'B MX?73%=I ZJ->@7]6)P]ZGO-IE_MP9>0]UX1)7A(.RE++5Y"+22N8B'9Q=#O
M7ILQN>1BQ)JVGFW.:^K_9(7_,Z$UHH9+$ZP0[0^:^,&B9LW8MB@I!UQO@O2+ MY,6N;2EI<&-3\[/'L^;XQ_?:/J+[$++?I^0@(@W2SZ&)93S7./)X33;CMS.++A
*MIAP(O34YQ>+ICMW5$W+EG4UH$OAZ_;OH1+AF-G[ZC*EQXP=PTX8>DM;C?M-, M/#]%;2&&HP6W'X(#5T-_>>=Bl,P*X?ZHK4)H,5'K!VX<3:+.? 046T'3:] + MUL]@H+*
*<=G_@EY@H\])E>$4X'.5G*111%]:B13@$F/_;43TQR#.N,F!Y>'I<:+ M&2FEZH+H ,F>S.Y@%FK_B/43'"*MZT@_$7^)K<=5@B7,79U*
*MXDUC>YT;%7D+O_'6;&0*B:MJ2)VE[+=%@GM/2RU:O6=7!5M69]_WDT:%N-E3 MGE"FWSR.I"W#+,|=C6X[BSR"F+$6Q+YI-*
MX.X;HME252XE_XD@%:G0A%5Z+D)VV;'-]",]K",]G;T'>-E9I"AYH9O_') M.S?/B -+[-RA#-?)YL&@<7*-4VV5O(ZOVBGM.G0^#?IH#^.+RJ@;+S0=[-"WS*
M3L.';P@N^UA%!S,ZYIMOH?BF0\]2@)7R?DGN7NZK;.(O>] @L MT5]+.0V4V938T74\ 3/2//PU915=MV2Q78&-I8V7I/B/2_+:,/559M5<57OHBQ/1&/A-7,)B7D<<*
*M\7]^2Z,0DBFWJ'3>\4?A CYZZJ()#]'K-2VG;$8GVPRL MW(OG5"J+%!AM%88!X5>VXS8*0:-?B;Z?[MTUR(,P)P5S4/|S/FV]"\ MRO:]U"U[H+0^,1P6<4VV,"H<,BE*-5*
MPM;_6"GL4#@)+(1=N"WR4 =^!1I=]67A+[_YI@@@9=(A[U;OZ8'T_L.GI[M%RFMX% ;Z?;@7Y2)61H[>%,*E68"VJN3IU4< M!B&H+]A.WZUIN'SDN $Y?X?H0KG:*
[OI2PKID'"^]);U?NH@+N5(A(ZHE7P2O MQM/WZM&D]FM^/4J-%#MG]Q@=UX,E+-<_<*<$K8VRO&C]^F&R<;4>&++=Y]6>*
MC7P@8NEITO<WJ1N_Y'W\#*+VQD>B^,C,A7V>?I5OIJW&'<,1$66=8YIKB8U M[6 ,&1#NP=G&2:I3+D<0YFH\NA5+R,F1-OK3G!/4SI-VOG?EY1WEV41GD'_*
MXJ>"U@\VL@VWWE5[_2 #$;+36LVG.9K,Q%MXUZ4=K@V[*^/J4HW,U6O+TL(= M7VRZ/,_N$?I3!,KB$!!S#T38#91O^'>2V &EV":S:59<_V1_9O7+HX>=BO*
M%U/OM)L^N2 DV7Y&>UW:^&$Y-T>)X@O(:))H-6ZJ(Q.5I2DV.C5H,#++V0++_M_"SG2@D2G,FT4'&99'V1IH!FE-4->U/AWC-?XYFZE/*B4:;;@\'0 MBP4_ C$BI1\? WZ?
*J%>X-K3)[*Y!6V<1Z@(./?9\#880>/,;96S1A+#Y1C MBNH/\3K8"[U[KX2%[S2^ 3&.[7%@&NN)'GL)%?#.B#GIV0FP29*7?O)A[(Z M9JOS4FO!*
*\%),$X7[;JM=UEOIE_G>S16Q+^.5)S,OUU#87\T5M'Y,67GQ&W M1 BS'Y(=']VQ:O<^ST*_P.],N9(4OIIR)\H&D:@<@V7*_R[WT]4=\!TNZPl,,;)?U*:N2YY! ^%^=(%[*O?)'*
MRZB6AF5[!WT%&>TY&;/9((@"?MM]L(!X!SN7YQ[!N@X,RN]Z-^DRG!T7KLG M5Q-/HS-(*-@T(]YQ_\%?X?I0)Y?.I*# M_H/Q 59AY<7KPYMI5K Z[PJ0Z]/,W\<*
,=5$4\0943ZCEUZ&?P1-B,FL6.P M. ^'H4NH);,,+H*7WMYZVW/$(P(UF886L';O/#Y,?P1-5K@R=_L>0^#%%NO6 M$)2A'0-6V 0'3?*WK)$LN)P7A>,%2M1083KW2S> MI&VS
*O&TI;&M?+C$02&VV,*A#++#X*EUC-]T0+;MB_KT:!#E_%Pl-(&O)%'S MZB1>4M,B#WQT.X MDR1^FDI2LH%-@4$;N13#3_<9WDEI*KQN3LCY7]1CLGMP.=#_NQ9G-)C-*
)=E-'I; M%<0'^"BK_&(WJP11333;DU.[P?NQQ>?>@KV)%/1ZBU,Z82Y)(Q+/Z%KVO#.ZXL'6O^:0W!+)!>^,!,#S MP(D>/L?&=DQB+HVO-KR=B1'SPS]?!!Y39*%!',-*
]]S0M7XE^$7A=XI"HLA M2!JD\!(HO)!F[W:6%]M:K9)50#;?GX_OC@5"6!4CL+LST2LJ\)2<3_N*Z M-Z)tF0+PE396N%WVU,/XBT+HO(2%&/S;T^[,G|41*L*
*M1_L+,56/>#QEV(M.MAO2+.>?O7@S?=#$NL:B'-X0]6Q-NEZN7R9SI>T/ M;DR?85Q_X*E{(WNREFJH0O[::P=>8>C5"%H2?_|:5>%/P5D0!3/1T@2]78N M?*
*&"N.&QGW4_55]4I\$=[MLC#14[!D**/S)61ZFA 28L:[)W0S:O] L^.5]X,K.2M67]%\|\9F>_P%)FK6 M)[LJ,L]-!@LMW$B";|)O#R-SYV9G=A]!Y!VP(,YY-HXG;UF"_S33IL_I?G27*
MFZXI'2O9LX_7GEJZ<"TZUEY7N2>8%PIALF>VZ;JCXB[HH]:X/6N&%OFM) MC=>]C'=,\|+-] R1FS^:$HQWD"MB>_<)_<+"|.':Y?8^K"UWY|1JXH%QU3J?!ZFN5-]W>?+&*
*M&;N*Y@\Z>0]"&3H%+P7Y-LCX1G@X'\>=<-GT5DU2>*0P&3CWYB490!%UNT@!4!,].HJLA:,&.A;-98E%6&E\37I1,+E5] M.]+U(-X3*
@R&K(0C^#P%TLS#.D)XQ[6\D^>'FSR)P.]K CA&V")L'%P#2@. MXC8?EX1'VHUN[6?%C'M@"S5+H7_W,Z7[_D]6&FI_>@U7%NN,;)F47O$%UQH%B28B?VL$=.59K%
M,MF];=(P.Z?4\OQ3(4\?CF_9!))SAN'$V+E=BUG844\(S!>4>#] MBJ2E%)Z-*.VAA9KZ9(;/Z# T/]^+387GAF4LM;'[AQ@BED1?^$O2-1.D6W26
M8(Y3.ONN=/>C^OHTUBC?($/P# %[,+L--I\O.X*MD[Q(*F1^*X,K2S%,X4[J M0.M.S#V6HV#Z$ZD865A_>5J@A@"]9^V[Y).SN7DX)5]-)C]/6]T0ZPS-L<+6
MC%E/Q_B#PS"3#B&7G7M/1.80Y2IBF7]J6DL!=W-GEB=G%.6F]KI?6AS_E M]P%PI-9;YA8)ELG[BXC05FFX68HV3B"M)MO*P%6FM/RH=+2H['G8W%\V!YI(I?S*
M85JIT:X^9M(#"5WW4Q&5L-G)5IWV[:H>C&^],(NN01AMIZY(9]W_NY7MVO5 M]%8Z5*PUC25&XP=DH!,Z%?)-*
DP^;'$5_1H:=LAQ*;N'M55P>X@YR[CWWD]DN@V]A2&WZ9).[*QL<<=5:-%%27 \5?UEIXH]3W M(/3*X$PXIX3017Z#A! MF?C(VE?V30\MM03.]>#-*
*#8E4MO1^2W+C>N>LUZA M'GM7!)/\VY:]X'=."O0&N=WM-&R5^BNQ9"!^9V(I1.6#>19=7?]Q04!BE3,# M@]%#6Z>|X'-.SCT9PZ<;17B4KW*Y"#^@O4<)OO7,6.%*-*
*$$91NAJ.W^_H%Z? M4K795-7B;'O\+'!J>K9(W6&TH5=_4YIL/(8*X,]BXIE\RGG73)_UX(&-GJL8 M?RKW(%:C]?L_>22F*1\YB-,X^3XJK3#H]9* M8+A\UD-*
2IQAF#O6@WKVLG&'S=NYDD4;(LNLRKY&M!,.^!3V?3+R/HQGLJ6D-MEBY)"C 8Y#RQR)S5"\MJXWI=^DO?MV176F30@VLEGV'W>^WD$(SKAZ_QUMHU
*M*293)W%I=S#3DL,O[*=32?=_7=^0C,"V;?U!|_"XDCA;1]4\+D=U!1HSO;,#-MW>L;%G>>89E9-)*;B#,&*6!0$HV!F!#(2^UA|SQ#0T@@[%94D%">@V"3I?*
F;IVAFXPL"C'X5D!XH%|'DS&NN1?&#H#&UAS&:U:V MEET77#*%7_=-$V\<57PD]4//Y_2N+_3Y;,]5^UDQ3+_&[*0N5<6ER:GG^3/? M1*>O9__*
%V%/!5:::2EDS:::]WS3A+A7]6N=@>_3;=7B@[4#=I5D#*$NKJ M5;2F=4NY9]NJ?<'6?7U%500K:1++,0319+&OAVK.]3L'U%GV'1$Z!7%)3=^%@%M)7"^X-?HL8GN/W?*
L8M3P9<3K9&#$9!BZ M9)>PJ_GF;._JG3\)?<=/JQGN5TT)#'&(Q;:LE"(\BB>1T24/ZYO>V"'>RC3SB-ML]<-:/SQ;$?PO"!._?+V(
*M_<'(.&6/#FXK%BFWMWID5^[*Q!VTJ$'Q180;[JVT]3I88A@KK&)G?T62,>OM MX]0LH Z4B])"*>'XM<>N$MFQJ&Z^S!)?Y!H?(N9BV!J.*/'FH;1^W[9*L[8]-M_%?GR[-=-*
!2VCJ A1P;6IG;:DFRG8_8\7B;IX9-(IUQG'5DK-1F=K8RF M\E!%->$7D>ZZ)<<6Q^G=-4)\^#']"/@QZ=QQN7K8NQ#9&O.BA?N+B:]#>]*
*MY"BL9A^1V.8H#5D"]3XNWSS1S\@(XY3G&\4>G9R\'/__D'^'1_X;(".&:3B*M<"8#L5.ZX5[JG,Z+"08OCN!F=\?O%?SS.$[#KVE:KF/==X^JIA+'3605)M'*
*ME6R83USD%&H*0[S9M0G6R<,AT%S1" -"L#2"%O97OJ(:?[ELQQQQLFBLG&T[M])A7. ^1M?I EQNNF=ZKR8??62QGZ9J*J?:;,_/AD1$%/QDZ/=XGQ>^SLH&1U M:GMW:*
*@Z91*U.-@5P80QV&7'53WV>&)3ONJ[LV\-8!6T.*Z#47|E6+L3OL@ M$\U%Y\42^BLY=.[\&4YJ10N-+WSZ79(E;4+|Y:D#$8L1-/"[5D.]NLIUC@OH M%H8Z]=/L'/NTZ;(§?*
D;<2K+(2|G\A70$W+++/3^^B6Q?7F>G5B5[3IC>,,FE&E M2#ND$O@AIZ3/"%XX_Q3!GM%,%[_BW-6Z[]4?@07EWD43+W9AKJMNGU^_%[Y D|MDDM?=TRX$2]
*<3.AQ>GBGX-8(Z\WPD(5JG)AD35_1LM+FN(W[IAL7Z+2%6;, M&+0)-LL&(B=^S'4K6K=ST)W^?BEV*A\'QOF:#W++[1$?ZB/45GR:A'XQ&L\ MQM==@T_1'"96 M;'_?*
7J&KSCK3@W-Z^>(-QON,8M8B%2+LHE7SZ5HL7A;G2OPKB\QVDG1R.C6 M6^+L07A6$O7(0 X; MUFL=VVF5=%PITX$9*FO+>WMUTG?WR.+U$&CM#^?N(
*9'N(5O.PS!EG02R"M ML3-U3\U20NB5K3EKNH@(=,"C|ZE1&0*HT>#R_BG70-_>"!%OM0H=G1LB]Z@:_M)7=W%L 8:8(U$8EVHD,$TVP$X.ZMC<_%\6:L4[;O(L.9*
6KG\1V(.ZP75. M:S7IX9=Q7#6+9(+=MBOA_+S2I+'U]X5V2]P7N+6FN%C4?@RAV0* ?%-H?Y M0!XKQ/44M&2\U81.$8 +X&/SIV==:TL*T,97GU)OT ZX4IL3&N8;J =5+*
[M=SS:"ZWK:<$V!AQZCOQXO05+[T!UL4)A$R>C%F+D'#^;CN,=+N1 M.,;Y#9E7,32CMIM3:O0RR0#K#=>5B,E',Y,A"@.,/2H#@3N5/07T<==> 0XX3DP?:*
<[GG!"K'6R:WAS[P ML5;-G(76 7/!2"N OZ^+"TS.1-W"?<-R;IGP5@_HA9LI:6V+OWQY/N1IH.33L M#;YI:> <) Y|;MM"<&R.:|Q"SY&#Y\|-Q,UWI(=5&^6M9$*

*XUR_HS_)0W!WF\":TCQ=[_SD-MI/L4_$@U*Y'[$*OEEWAT;3',#_B3E5R0+.G;H;=HG" D@+^^!,4;Rf,PUT78*

*MWSD(A3QL8+4)VXHBU&CXZ(Z"L,BX:OJ@/J;9B'"BWN*FB"%?7 M,0S+GV_$I(9"QLOC[I??3ZC-*8^:M-,*-4& N^;G%WEF@P M!-=3=V)W/RCRK#&X)\6K(E! 9P#:DGU ,HEH!K&RD)ZH,ZE)|%",Z M9JJ#T 6TOGO6+Y+?^"8"+$D#0JH?K%D2I/%+7BQPT5KL+1NB["YRAVO;0_+; M\%W#,O&^K+"EJ,!;M*[_(M$;<6+!#9=WG!6I-*

*WHNZ'IJX(7@V\W@U!Y!BI M*Y\@&Y=?C4:>]+.,G>5@&1DFF+21T=7#E/1FK'k!:

1/1Q@TQI+;QV2DK++22DF+21I=7#E/1FK'k!:]

*MF]X2]CJYJRSL^]B'I>W>3>3+.Z"/H,V;]W[_B.F]F[A44E?@XYS-^N19X5:Y#:YEZ0IE6#+O;O=?W&S&#"I&449JA9#T ?H&:N;&[*_M0:UT O,-*

*M^(E*Y(NWWKKVOO$@_:CMK;?V?Q<*R6YO8,_?#2'?T$&/"$$NU:6 M?]GMB?/-.^++DQD0L#@C 2<;H7^T.TA7^O.,2\],Z_: M>VLU7U&DEA%I4GI;KR1*

*40>6%Z^_PUJO:=]W""\XOIRZ1>WEVLJ%XPI?[_1P M15XM*IA1\C3PD RL?Q>%Z_$<:#X[[[EBTJN.ZYY^OCDKOOJO$:]#_JIN#%9"\"A MS2-F TW3L*

*:D97V](@8N5KK+)#2%=`+A'53U8_L3X,+%]'34J+MN)^>TX=/"CBDMN^7S?/*5R)= M PY_#4A]_5'ZITCH.[B3HS"++VR_IW#9[?]8^.:<7EB(?9.] M$'CKF^M"N0)^T>B1*

ROV.C\#$[Z/PBC$-1.<67\,77O!!EL3\[IX>Z3KXZQ4PB_Z56'E/SEY-^WF<9Z'TNX= 8[J#QLN M)Z6\3IWMY_#AN93(ZC&X.H-H=D%,#"

*(EL1(]JC^JE#@#X@S8"I\]KKWS5M!,G"]CTI(E6\?XW!? M\>A0T5N*9LGG9S%\@9I7Q<'%APPP7&K&%n\E=-J>POI_1X6/+]MQW=D[B@GQ-MQ9L-/G2S%*

*(;Q.H$WQ^Y~Y4"KUYJH6CU:O7ZR(9)8N BD M.P>IQ_5 5WI[0>W&;9RH8?XX@"@WC$*30EI>E\&RETA;NF3P0"U/YUJN\%E4=6P3 .![*W249HM-*L;S7I@$JPM3QNT%Z*

*M(L(#<:**/L^3!7/4WEY5-7]+O&86<_,_DVY,_<&C;^=]6"Z, MH'BI=HF:N6K664%PE8L6F&W;":7;I\KXTR/OI4589-K_O(FF:,J@Q9BLS98B*

M\S[!2[6)]HW(OT[@R)P6DZY;PZGQ[&@9_E]K7UTSF9\,_Z:0'B6^%-6LDB7Q M(K\S,1QZG1; M0A7-H?0AGV<\@ ,RP>H_YT[E(NZ7]96ER=\"?>B!.59O&U. M2O;L0-*

@X/J5C2BE1OF>T!G.IUWIT,BK'4&=2-.+6H"RL/ $LMV=]:&Z -N5 M>I./=D3D'N<#1@!8 >2[#3 CTG ;?SKZ:,NRWQJ+G 5)PMS7:[<.>X(&@##AL+YL\%;Z

M1YBL9$HBWUR1 WKX\ _=E+3=4F&64^'+>K,[W?L\=.S)0@3[:9.GB*61Z')VWTA55,0 M;RAROUYU+?-;U ;S#]PI]Z%:C-=4^I)Y5PHGXC$LJV-.:O115

M.]%FXG=6\H=QCC1+S/%^QP4_E?E<)C0IFI1 M[1M'A\4K+U]NE&MB&(!@"FN!C2Y"H$^1V6D/0N MK2+N#]^-RAYS?D\X'=GPQIOGA8U!OQ+;,^,F $%U1+T C.2?*

*R5*1F0Y>0T+!8ZK%/N MX(X0N'TWA9W&EA#_)TYYX:#O5 ;O2-#*0IXUFL=X,F/;8DMP 1G%TY8&R0\O% MM^O8U+T_<;-QO$J23<_&$,T69D&][JO?7)4QI7%K^L&*

*[*PX^%0;_(VJ8@43A6V\(F9D]/-M4E00EWTJ_EF&%L;>B6#9'RW!.]\85=>P-T)[%$WI>O%]f%MT#C%L\ARBT.06[M<%/M(B/UR6)C7Z^O ;Q7PC6OG-*

*5'):11)/;^0AWQ4K;T],VE%,Z86MT77[!6 M*0=5SA|%SA?,H);6[-8.?/3?-(U%TV&$;-7@\62^]8D.DJ"JDQ$&"<4 MKC\N'>"N>=F!Z4WJM>')#QMRIX=@/*

8(!<.V+59$8V._94.>-RLYU5KIO#6?-MSB;YIW+\]Y&3B@@!9?9)/...A&)WEH$M<(9EO22##00)_DT6LP7MIT-M&G;)W4]0OG-FKE+D!C&XTI

M^EG.J!%W,:KFU+H;E:Y0GIMPJ>,'1?^/NG#K5KGD&^=;F.[@"?IAW)_HU Q=1&'X\UVA3(^P,BG-(_T 'V' M4_VHDFV.J\?KW0=?!"KTUG0%!%"/2\.FG\WA1@HC

;S8.7IMVME86<[-HP5CSN%/.EHW1_NN%[S=9!GM51] M=;,"F+8$,3(.IF[6P>P21+K\D'?", XD;!YXX&I^:,@O"4H\)?P3V3=^QGL\5R^UV43%Z",W-M*

2UIA?"RCKI_$LW2CW44VF2:91X+FK< !9RY09K;K>*3?:/8L M*!3:.G%,#7/"7US0BBL"W!&^Q5_UEP M9&;&LKMWTF8PM1N6Z_,]'[_$'(@S:W;'0C#Z936&&?0LH.WTA[>C

5LF=CR]\2 B=;|<"=K\ M.!D0[<;ED!JF$!)B_ZDG.=2+X$3$0$[T526)!L-ANJ/R)M!|\HF_SD;_^* MA0!6UY^A6R(V::Q,?)N%RES80[X5:(S_X;,"WYH4>ZTD,H76/O^;Q$HC2*

M-ZK^J,)'?F-.S,F$>\A_(^\]PYKLOKS1(B*0D2*I"B@H#217@/R "(B($[' MB(T >D! @$1D;]*@(+T+B72.O'IO8.$&GHGH09(PN&9_\R9>9[_G+G>]\P[MU_EP/NP/.U?NM?

*9>:UU[_7[#WO?:G\9M[BFSQ)1TE\5\N"+ 5?*H"O$FKFK) M/YB%BBNA9M,V%\LXZN$I_+UMIYT4)BNS*)OU4+,+P7=4531^G(@_IN?2KM; MB2I:Y69D(\584&;8*

*XH_M\'5YU4N5"IP_J:U8I1R@GHWlV/=.3'/GH1 MH9IHH,Q'2](CZ=%#0!X

M+"TO!G/2?*KEB79 M'NHBZ?@B+VV7[(.F48?¥S)S$K%9CQ8BIV_#BT<'AQ"E1BWQ;-"+BU#KI*GD! M^8;!9EHX"
B3G$_[/=MVP.8YP.U,^ISW]AT."^TA]_0BBM+JW[MT*S'S)T%^_M?^AY(-) C]-H34SJ"Xl_;C#9'N[JFTLL?6?> I(J.&N.>IF_NK12#ET[NZH7
M85Q>;;;N43=7*E2WY*!A,;,%DQ[^&HB7UG-[M'"9+NT%0Q.?E09FTZ&75LPR[MWEKY?'Q[8NE<N$GTR^NK>+7M@6X?
M,$(%/FOP57K>]YEA7\NUA[9IN5&BR^NH2BOI-G_"2%]0EU0\\NO_\Y'GSH] M=P'O4;?\O/&Z\R$A\[*Y2S+#
6\8W,MRD6M#TXD2IB'KQ:8URA#;G!&,NH9;."8*4/AD\H"OFDMMN\\K:F,/S(C_KZKNNS?CD\ MNH)CM;&:'}8_E/6P\&:.5[8!>,,:2AJO6\T0W3B6*$HQ^Q,""_T!S'-,4!ZUZ
M^,J&O(K]-&RE[KF9,.99XW"_[2@[9-Z:EU>XOW_,+?K,"M_W@_K DD$[G/^\/ MW. /&'?7>,,F 6\72C8/ M<@MIP#E !K %KGB+++=HS41&.#8QA'MB%SYP#[$<]D?
I8IT^.,*6WN\Y.RR>6 M9/?\CE2]/<3W):)*-B@Q CM+EOKON@G#;Y^AOBXT>LZKA;:A-U@M40+UA$/= M4>M@4 "1CWPB_S\<%OJ?
_&3S!5U,8&=.IK]4&CU!OB[E7CVVY,,UKW_BS2 M>O2NI^X>A>8 <$NA8<)>A?$?^_5_56-L)=CCT(2'>)5%8291"AF%,%?OC\=N MD6' MJJP[<)E8?P#8!@/=F#+?
#$H*$PCOS+'__8\9N?&#\(K9C\Q.CO+_FQ? M 63:=/K)\(!<)$_4ZMTOWV+A]*_6Y)+XR"?/ 1,(3W4#OU!HV68SKL',JJ2= MV?6L6-F*Z4A'7-G 2#2L(ENT-^^F(@D24-'%LX!{?
(>*[YZ*_*2+XU]'_^M&K8.'I:5%EST>=_S[2:7U6S?6+@/]3+<"D$S:3?+C^,L](>5I?VNH]GNM7O" MEO0DLN:-EI4H^8F>5EN!V3G@%R?-Z)OHSQI>!
!)9B"1UA[OW>%SGCNF; P8O M+_A+[UZ&YTI1VC\U:7!@W^_1<$%NA8<)>A?$?^_5_56-L)=CCT(2'>)5%8291"AF%,%?OC\=N MD6' MJJP[<)E8?P#8!@/=F#+?
#$H*$PCOS+'__8\9N?&#\(K9C\Q.CO+_FQ? M 63:=/K)\(!<)$_4ZMTOWV+A]*_6Y)+XR"?/ 1,(3W4#OU!HV68SKL',JJ2= MV?6L6-F*Z4A'7-G 2#2L(ENT-^^F(@D24-'%LX!{?
(>*[YZ*_*2+XU]'_^M&K8.'I:5%EST>=_S[2:7U6S?6+@/]3+<"D$S:3?+C^,L](>5I?VNH]GNM7O" MEO0DLN:-EI4H^8F>5EN!V3G@%R?-Z)OHSQI>!
!)9B"1UA[OW>%SGCNF; P8O M+_A+[UZ&YTI1VC\U:7!@W^_1<'AOBXT>LZKA;:A-U@M40+UA$/= M4>M@4 "1CWPB_S\<%OJ?
_&3S!5U,8&=.IK]4&CU!OB[E7CVVY,,UKW_BS2 M>O2NI^X>A>8 <$

(E9VJZ3A+A>Z&G(7HE23<:=^3Q<$/!@C))(¡_0_UE_F"%/JN:1? M;Y]^L1;&A](C"&,W15RZ'TZ>5GC5H](Z/GTBHRIXGUX4-<)Z&MAQ5.J.A=K M)LN+WR7519NX&LMVG*WUKSY^I9V2]/U3,.':¡^2P4&*M&*W*O)"KYHBPD!D MW=C.S=H@ $VBZ'FJAZVJ_-(33=3U9&98=,6H$X;6)P&F@^#VL/,5L2U FS+, M197 $%? 6,W5F*BFW<=|^O3OLLJR*_[*11;?JZ,U3EZ9AJQ;WY'EIW.TG<1>N M'TCV$\@@!Y,99;MT;[?,N:(O7]12 V^IDO[TA]49HR>'*?0_=#=;>;,.VXZ7 M!U<_G7K,3S@\[G- ^0U&KWKg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}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{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{T)H M"/W;W/]<3.)T-PGP0QX/_:;4:$3T)]MROP54:_ 00XN ?TY[^MY,OGY)\Y MB: 5H'D)":!$ DCLI?^!>A/T'LF8' . ^V]K6?\'>G"9! #NT?W?$.*V&{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| +/ZO>#K\_]8"66U!J; ,.?9@ M+//OG3O32PP"(\3V+I.WDQ(.]>JO>(W\":<7>4O]M8$),CO+EF="."%6B2K_ MAR1PX-^20(7F(_)*3%6O \V S4'HJT*X*BDC,9,.FANV=? 3FN^JE^VRF7!7)3%68B^W#' M>+OD&U&*.!CB9TH=C#MGLS^C(5VR3V7-)QMBWZS,E35P$M]?<7C0''SE9ME MHZK5P]*- @VM%^SMCI\][(0SX56=4'<^.UE>Q8BT6"I/ MX$'>S@5)8K] E+=7EN%26[6/]YZ.-YXL'.*]<-T[=G[SF'#"^Y8[9&/2!*84 MK4$]K4_;."L5>#A<0G{BB)CW[E'SW.D- -)E2I[LNA4>BS;3'L\=$#SGU<0:? MS!&;OG6]&6YOKK.>2Z?((GILO\LRP&C]]NI=NO9"Y'BZMLP7/57F[_\R:N)_M7XQ-C]\.ON]P:((\WS? Z<+:2HDM#D\LFE*+]U34VLO>D,OQ0LV_FDE T2HP^ MXU:GG2T%V'&*1_CJM[L4"LV99S_'-/!'(83!@ZBQK'-]L%1MTK[?M^5NQ(S9A/)>Z\\>QS]-%P%+W#PF KDA\9U MLB>G-J/7DMW72W2M&&$3M58*#)6ZGC6^XUF'?17Q8HI:.,*4E1/(FBC\D)GI M9M'7ITMT'9\ 3+7>_>9^52@(C]K4)VH4 ;,&O3CPW95RDG7F->3\]#4>12 MA$\U>BM5%BG5E>'6RX)#GM5HG(M'TP0IE^I77E9G:$%V;3:DO%HWOE8C)O;P<469'EA!D@7IC"=&'M4 '-:1QV3G^[77!WLXT"2"(FWXSW$SF!/^ZBWA7HQ/$8F>F M_PS9((@XF2-#T7"\$QDBM+0A,?K[P(>(1Q_ZO(0HB&PZ92B#S5EJR M42N@^QV[XX\>=[=",>!>W0CB>0QG6T@%MEESM"XZAJFF\0L-5O$BU)VKN\I M6%M#J#\7+.% [N^LY,Y^JK%+, #I$2BAY&T,(W8%@[LOV]#<5(_FUT$SNN[(*0 M' OC!U.:,IQSSBQ7-&(98/=F5C* .OF@Z>+;)^OK"M__6Q_-_2OPOVQR M,K4;&&7)@95?P@TS>A? @C1T\I\%[_JP?A*\&6<2N42#AE\D+A!9L>]1ER2T MT())0AMR1C1)+^KXO=R?WVZ8162F8=9K#F='\]4S(67R+VG?5*DH!]]Y##3 MENJOJ$MF\N$!6%LR*2!,5Q!6@$QL(W/_AF'S-XN\2+9WN%#27X MW5T[?@5<3>#_7/W36_\Q.]GU!3)+^D-"@'^_((4842]'#U;#2MM+?P](_]TV M>? _10(L@S1\_XN0*9D0.FL5Y3NA=6(JE^0UT[^K'}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{LF=3G6>9&!H.(_,#M M*HV7]S5NN =11]QJ4R\$]5ZO&6ERD^;8;T'$(ZG)O%O@"AALPUM4$FXT2E1'C MRT*JUG0QK2&"Q=QA-!/52]S>]EW06_856\9OGNX M#MZ$1"M2&US*OX#$;.BF3=TW[2LJ[[G?4$L\=]DYS7-MJ]BDS@?;TS:UN[48 X1$PL9UC3<92(NNV- !,I&7!*K]GON*XGL6T.T(9D]D MN_]EA?/COK<|;$85&::@<#^`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|.MI|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|O\E>]?+C$O9Z6LS/>E]GR$954+ M]T16YL3*TBD@",C @$22N4&V1)<%- 95MZ7LYIY;]C-S/B!DA'&O$+R_9$Z^*I$_-]5?#[-,4.+BS)-=Z0X!NAQQCEMC>9-D<]SXP] M@.;@O?5K[>+T2A+4.EOV8:#WH5=U=.#F:\@! :Z]H!L)%G^9)_YZ5FXQ[UAZ MCG;[47'? ZE]_CJ.8H;O%-!&UW1NW.5)=8@%BT-N "M%.5/3(G(=_>WKFK7WH%,ZQNND(G58;ES"$>F2S^Y3D)4TG >_K*)UU6;1+WB M=DPHU52<5DY^2U4LY9>]!4"7,,= !59U']!"\!3 M0-%DR5)/>*>63]EO#D=10?M\(^CLQ\;_R)ZIMBDGSY-&;;*JFJ>G_=NXX,_/:>OMM %U?A M7RO3<"NG98SP^:]N0<#QS6-W? 2WEDKFT.C!K\353&=K4_.D+G[^O8KUH^]D" M@^H&-:*)0I-ZUKW'9YJ+>G-78_'AO^[N*]/5 %-DF:7[TXMI;$VM;\KI+T?E M&:\$1T,B?W:(W+G4#>@5)"5[B=S_G8U8G=(R-3'H<'#C;>ZZ&Z:!HJU_!_B8(Y$[0.#;_?]fFB=K<+N=YT:!W]?6XPO6[@3*3K10!^= +<J'M'YRD0=X"PT\(\#0+ \\#A-3 MJ(*,4X',K=?',$LD.H##?GFT-

*N";O:-19'.*O/I\SLK[G8/M;U'4G8-MES[3&V/Q[%-3WR%\LUK\IU=HT.M OPR5&02%]F/Z9=;I(G5%@2] UUB%BC* M(@-9]7GY2/S2PP/|\-Y3@-Z#4\"Y'=?)(.?*

MP^)RU<^T2!T8OD,G3[|'.J MK)KJ?K3H+DP@!<;[YG)SE53XK/|LN-8_]ACZ":6:C+F3=20SY&'F@R%(%.T M^%MQGF'A2$(Q#5RJ9;#0VI4|\^KU.IJ+#7+8;%M%'A/?*

XLY^44=C%,$|H]/E(.1MZZ*A3YV?=3 .0G=7A@-]T@S449VU4&C@E+7[58C]%;\/N]Z5@3D M-8+=D[EKH0MUR:U/E'&6_P_&0DNX[28)W.C.\IOOSK/L:4I8$G<%K=\"RRR 7.=I38C9IEE]M#F37$,JA/>EW7LXY SL/F<#SIQ"GH:#O(MC9&RD^#MU2/YH]4O,IE@9GF MZRW+(E5I^G(J++/].E?/VZ.3G]35'.GO. Z)67F=[B^>ZL|O$Q"_'+WX M!M$3TH,B@3:S=I1MLF^4?S!]"5-7=K&89PSO!R1O" .:> OC8^4H@]92A4\"U-M403V]6J:Y&7XI6[/T:V'HY_>X6;*^2OOLCOH[H&DC=C%A+!K_+6:W=V ":2 M$0]W&:]RI/-'/6>"+XBE:DD_?AHZ6P7P3&56$$K]0\;WPB0I-_MC4=&/5K;>K"BF]5="{7(__EZ>.%UK4RT-L*OYWYGW_ZUNI?/R^_9%U54!&O7 M:/K8)'\>Z5##2B/\I?*

*4%!^#YQWSP;@W\\;6<2.'+_^N(H_]!-M$:BKB5QG#[49,$ PS7.^\(;)"61 M5W?]U.)#+"@[JZ"*D'K;'](DE>9/P:19H"P]bF-1M%_)3MC&QJZS(O2*

MY7[&S9OVRG]>PLLF023U'\(BHO,Y@NZI/K.Y@(-,^LS%=8N^5P#A"W'G\(-/ M1A0$\OLK#%O"X/2UDFR3UR0_!3 41CO]NN^+^U!H: ->F'ZH0&[%()]HT;8)]

*MA%CX=G49GWU-G43B7[M@1NY)?.\7Y&<%5LIPUE7*10X/FL FVQ*BX\S]LLV= MY9/1K&V6EP8*Q(%W"[*$S,:%4| 5LXT6P?%M\8'7:[50'\1#37"6. ^1GP/W2*

MF9;SQDWF'$V?6S9K0:)S]|\U!^;8>,A/9%Y/RK(R67Y;D'IV U^/H;.X3K16K M1G-7>]$9]:>8O+&^CO:JQD>)GD&\X-ZY[0:8OV8RI19#&8SB7\[VT)1.F4V MV4*

\+X>13]YGP_\VM=7+EJ+G?$>SVD% GA/^6=$ID_*"[K@!_0V7/0TE7,<MKEM\<%]7X;T^ZYKP7K[6OHH+G)RI3U:A_T7"1,0/=2E<'+6Q3HU(^8- M_2G@CBXF?*

*IEISZ'ZI.MHR18(EB/2 *]K[XEMAW>L-2;IAZ_Q-0GU#IXG67-MH8!+@PZM\'37?4U7+O4%GYB.[?IHR97Q,&1]T5Q=,N9-*N>;T#?21@+OOA:._M,?U*

*WI!^_C*_3V3,VTV_>7_BP$":C55PD^0/6O;K)3S4)L;-(2:!&E$]QM4= MQ$QTY\&((G\S\O]I,3_+O,N'$7?K$L;DK#\T39NY6!Q\T$*C3BJ:K,-$MS$'R*

MC#^,^@X)>_&W/BY7O"\\KFI/K&U;>NU-P\@LRZ-?KLL^,)L1AV1_NS$G#EC MM5=!WNV&6$6Z!$!U:]:D_X P\=2K">]MXBTI("K8TVQZM[9"AL-#FG F9$XV/

*M_6.P9M68;>29[)DD&'>-GGM*X9R!XQ>>*ZK7@'P+QL-N4<4CE,M(MSY;O'OX$ M>9 2+B?@5%N3PK9^L7,(3)UPFX;;RS#DQ_6/-W,]8PB!.%;&K$'SQL\MSUPT' MJ3K)4T!>[=KL]_W^^>466%1<%3+"GW%43C'/3&B\;!',?SO^>_C1Q^"AX/@X MN]6-[[+KOG\2HYQ\./)V M^%]4>QNH8;PT$]!@3;Q[*KCI3$BCU&,0PK?*

*^H04>ZD&P(D(AQOHR8++F\'_8 M>;_!S!'FIZZ.]J=;<#=[>]N\!/VG MN)M!U0))-]U?%7$?FCP;+F_%Y_/UIFWZ:IHP1>!?UH9:[!F>_>$MCDY^) M467L3Q\O3KGW3[HQHK6]>UO*A. ;47LS6;'7NPVQ'BH+"#%.H9.*O24O@W M;GNU[\SU'_A. 3],HD=]%0O7CQE]*FW?)=JFL&VXL,9"P"I]=9)+QMHQOL*'_M2?55)V])WH[/LW43T)KI!?*

EX'_4QRCU;$-.;QB8SF-,WY';PI>4.)TCZCL36 MH\R.$XSI%/ &R$#<[C]<$?B&)BMBZ4ZT]+Q35R4SGWKT1?MN!/?R7)4Y-N#W

*M(WE@RLJ19;8H1CEH*5$4&H_]*Y;0147'K297B)MZ3S^4DRKRF!V+CIXGALWV M,7=^, ^ZU9"RV2P'#P=0V'>Z"3O8YFISO-?*JUD8G9LL+8O3S;>5E>*B+27<|*

*M'VRW9K+CD[*F7#-N=AR_]TY"3;]1$QR]??-!Y>WINDQOG]P(C/']pJ:0:5^E M4G/5 5ex+[R[UOZXVK/Y^:?VNBER18-8$/JHEQI:OZ*#J+L/GG%-#WEB3L*

M>),B]O!DU$&QY5&X]B-I61=#"!!A.\M.A,U)QE875]LVV=QQ4]L;9+1/#:F/-M0-*'V5AQ' 6E\WFML#8Y_6[X^$+MUZ&//4K2Q\1/_GZ3UH-DU- UE'F\#$H-M]^&3"3E);!G?

8#>?\/#KH38)OJ>IWC24Q]^+HFWV"EN]4(64 PK8O0@UD4B=TF-<2T@E1616G M@'X)"0&/CQ.@]H=!CWJJ76#5JM%-)G/3+EC'Q"R>C,^#%-FR37Q/5L@3^OZ*

*MP@H3?>(@QPF-QL!PIK#.E]bB^/\Y*0X9+Y=0,L.RC7+!F8Z@N4V# +,;98?3 M@A!W$!=>K=DXS;5C.,2K$8*IV6C8/3=0%=.Z0,6SC\Q&6,6%IX!8%&B)IE;-*

MK[$/)D>2=Q"13V35R4X,3NBVG^_23'.E;3R;#L=)ZU9;XN_DFO^SU3F%R"F MHY#JMUSBLGZLP2^EV;EX-08_PFKXKM M&9 +WAMD^F-*

D9F;"CZKP.ZA]A?!BV@Y>]0EN0P+QIX!(LAEVEF?5G)$8XI.W M85P)73%<3Q84X"#L<@JT8KS/;6S#E-%V#<:?'I:7D:5FSS=Y2&3;"H+/MBF3 MPEU.[)O0D3E7BTK^%Y7H

8?O[PX\2KXS93FC\Q+$DMD1FIE!1N+NHCY)#;U M=-8WSA]:JZD\OC:#U^,Z HRFV$S8(/4AL4]#FTB20G#U?;Z[CU7/5K^.UAU^ M=#G2^-8_.<+!?RG4#7:I D^^LT$;(?

*#X]FV%H'Z M&R8Q$O,/7$F?@4*APPUL\OA+!ZS'#,H A"R*_(2%I-%=>=L#3O]F?5'GN2P MCKT5?97)9C'%\;)#:BNG:5.-> '/>[+;$R^[VN0N7IE0]7%2+KQ4DQ?IE[7*"P*

M7"6< NY+0T)N!'%XT'ZQZ_S:](R1]2HRAPQ+A0=EWZ#_,U/7 MF:(+_$2ZM0DNSHDDV3W/?DR;(?XFSNY>-/N=%Q]TE%F+7QF(F429;+UN]EP M\;!D[83+7?

*@;'WHQA<#})EUN4YN,\4=:NGF]3LW(>RB8:*2QO.9*(T3'I*+*.MR9+9_Y3DZF0#!@:. M88-X3'*$C.B_P2F%W0_8'P"\(#@UM'I^\A&,4^[(?/LF.A9J^'|';M%N86Q=!A*

*M56/W4'1V(&:YV^5FQ-J.9ZIP^@:YGR+(B85)0!P[=C9TP1PE(5.07HOT?Q4WH'(_!<. ^ MM1"MYY:%*4=W18*Z.I==ITK]5+LV'/@R>(L,0D>DW$,,.#YHGX]])*V0A+%%*

*M52,[+$lL9B!C3>!R2"?NIB;E5PC_9TCETLO&)]&:,]SV?C'>\QXWX8:F:MS= MP3DXPXKMV_CH\1]G*ZQO!4149^(]%W7;PN5@: M*9IO?*

_@W9<?'Ei,2^'$,$=QV5Q';497VI+/F"+0WA1/TT70./.D[?Q8S MI5B9"R/-1^Y#$1W_E(D?79FP$I3S6B49>'8Z80GU=GSE&&TMJR&)JB5N?&\H@1 MQ?O-*

*$D4;=2>%SCM$MCK]8_?N ^7R&2CJ?UHQ$Y7EN%M)*F5,FHN_MK_:<0*H6]W%3 MU%VY\1]2/'SV:1,M"JO&*1UQD2U\L3W/3%!LGN_M)M!)%*:P*(I7_/!X(\&R*

M1^4S]E7$6CYUW)UB3S$.JTA+GD#O2U]>Q.E#8[D\0G!NO8MXR^58\5, 42U3 M\.==M_^1T)43G+G80G'"%6%P+4VEKW MD4A?* %]2/0A,1(-*

E,>"E.9%KRH+Q41_ZF]WY3^TC--)$LZMX<:TB",-+LJ, M2^>_F!9U\YKRV#UA+&%|UY@X!6TL.MNLZ[R*?POP^$\P:%#XA.$4$/3Z%/-C

M8@%.HE4Z!>1<]#2.)7VDP#YWO% N'(%LAY59C]W_]:.!,FN?KQY!.R5(@9N8 MULGEAIQ"5@W(^-2)?(-^6@T)FO..5V^T>ZZ7].YV7'F6\\8HH

8>N8F48#F;%"MYYA>IMYI4X5PG)1.2NW() M'<++YK6UO&<>/HO#V!RW$+H)L-\8]#ABWE7S&]U*&C2OH. I")WE#C<5;,U=\Y M\WWNV885S' 1-,,]$?K!QIZ+'1N>#?*

F_8Z$B;Q3 (Z7T"8@;Y_($!E[,RU) MW%E>,6(]VW\R(L2%=/UC:1;RQ57%-VF^_@"@F]D0VUT>?S-$(ZLE'/T\L_4 M'Y.RUI 4;^P]"MJ@@85!HF48>]K!,F0.V++%U5;#;]?*

*@%D;E0=0<-++:;A?D MJ3U_@;\=Y2[!]3U[=!HJ$ML5+^_G\0V0QO^5M-@U^I5NSQ?OI<MQI>V/O#E1[M6-3;'4@[-+UH[OX\?YN?Y11P-0YF/$=^@2_%UH:*Z<@=*S3!*

MGUE)8YNBW+# LD;T#G&7+<%,?DND'MU;X"6Z;JZA2,5(*7X17++\X!-MYW@Q!+4C=BE?^:E%VS-ZOLIJ?WDU?A&O7=)?G55OH13M S[ZVC!])VB\]/@*

*M]%%7HAQWD7AUDRUUFNO2N,"SDEBH'-![O?0C@?$[O"1D=+/2Q=/PRA6_&>|L MQ6VS)*Z@OK2+[\P;SP"_ANQ_D%/SRAJ)1U[1E 73'"W5D(D0*]E+,\D6!#2V M(*

]GC[B!%-^S\]2NJ=.51'ZCSSH<0L9?TK#%H:L$#H5[CNPH2E7?/-),NN1 MM -+7]T_YF68,]\]>PL7*=-^ 5 #>$MS66/S

*MC7F^A>)]_7'&Q_+'>^;*XTC.4A4%ZO3_X2Q]DP6/CGHQ'Y/A@@VV2]&M#/?6 MI$@LHX&[=-N]\P:L@:\;T8*0LN"0$1HV?R;-_'D:T%_G)>(I?_H9W.I\'S/R-M58/\O54>*-*

*]H,%UE?$*F-*9W5W*Z$N0S]S/#2T]>T6&) `)B.[>D3 M03FK&%>NB2BL?7>*0:95S+/0I=D^E]WSG?AS"ZR;,!Y_.HRO$?$% @M6C5)+ M7$KM-LRE_? T[:UO;HVJ%%(K)\?*

PY\C'K$S/?T2L^$1-IMOLP_$IO#9_(25'5 M "V(|F: F+3;+0NV86+V/LL]U@OGI=C<>:4NO$5^@6EH5IX"HEKN>C5@O D-^ M\G=K2VOY%I2/W0:]VM87N-

*KO+;G=5G+INIWQN$4^9_'H^]?IDPHETZ> .58< MQG7]#;SO77J M.NKU++*,9$7[@B>_W^/ZIL,%(5*Z&0[A"0G7-/'L!$=;"2XPO4"WT3%,/-OH> M^^*SP]8[/<]5-*

*2IKOOU&>WO6I"HO,JWMJN7%F*H69_3 VB^L(HI;Y3=5IGX MF:\QI3RZ[1#DY14S7NVX^5/F=@T(]TR)'=Y7EYAM*-"M151SO>CG1/*

I8SSG!7OT7S+!R0_\0BKB7LE9K07=]74_&.2;R)2TF;0NV36>,OUF>]]-R_D^VSJ2P9SLLY?/L M /A>/.(,6+V\[FSX*LEF5*,Q*&D2F/K6VN!]H,669>ANIEGV##*

*M9.35U"83S$PT\@5#*71EC"XNNX96%0K/L\R<[.*WAK/E?A.]*77L4'CQTKI7U M=>2:W+W_RB__/=?Q_S&;_?^%0A/ACX9<_]9>9TE6#_YU3P" 4B)AK-|-*

*_TRP&R)"!^QPR_C\SRI9C&PQ+/EKT M73D%A+F2C4X!F9E\IX"VX%, H0&"G8:P(58*PU#XEZ<_LF,DN)+DP[ETB&B3 M.#Z!7_M7WKA%F>GV\IO%*VWL-*

P53>$<)UA1OSS/Y1@T\!72O_C<+]W,K]CR& MR(D=(-$#V15UM(C=)G_-3@'L500-O(<7N/SP+TZ/IDZD00T10#O[+P)O.!D_L,D&2(&06&P]%/.@NK?-Y19_%PH&4I,9Y+IH

*M_^0RCIQDM++#X/L'W= YR$3OF 0T\G_5!+ P04 "_"]@319)>P;(+.M ^32;W\,O&C?6%/-,M!0U5,U] M2+2*Hj5*:2FJJD[*FBJ(>9Z+HJAYKJD(:HQ9:=4LK3E);PZ)*

(8+@^/S,/>?< MWUWWWM_W=]9=ZYZ[UMUY7G]D[>?9>;'^?_1Y>[[UWSG^=+P-8#'3U=0$4EP MBHL\X'P.H V@O'3IG^NB45U@,N^@%4K-1L5^1NT["V-

*%>===>0#TDNH!.Y4]?-^6@<< M+ZKPPB/[.CT?-P\OWS4Q<8GKDH!*RBIJM]2T[^KHZMW3-S U>YQN\>2H?U+ MAU>,KYV%)=_KF!E8KGZBAP-VVT36CMW]JOR(?0<*

*M=Y(+ZKHOBR@\PG. ^\|BGYQ)51%\C_*;OVGVKRD6^C^EV7]7['_H-0M@I*2X MF#Q*5@ $<&I:&"L!*(P]JGW4^37IC)Z_Q.IH]S3CC+-DJI3BRJ\GSG),U?*

*<$^DT_1]25CUZZCZY"5]9=^> MF.N./E0/&8'_KB3?(?QM)G-(+DH%1?H%KS0D6%@UZ*1/XL9?G0.H22.3 MWR'MJR6 @&]=:S(*

#A.=_Q#R^H]8&%KSQ7GM$YU^\XPZD^R)]?B_++.B<6O MI^1WW"/XI4<3;*A>]B%?S:9LMPI7\/_TK /#=9[99Y@.$4Q&A->H\#F@7B5: M

X^>#_(F/>##I\)ULY\'UA"5\/&^3)?=OCDNOZ4R>$H-@GW>+E:-Q=Z@Y* MPJ+SMG+R8448VL@=A=)RCO1T4:D?7%GF,-9<.UOM3?/^>HRH%/VVN4^LH+@%K*

*M3$'R<,,D[2RKQ,!EE_NCAUN++7.JM_#Q#DPC"$>X,/R4=-J%N XH31'[T"3G M\=QVA.KXNG%M%%CY,.S2D2OFVY#1EZF88+(\;=^6A=*MB\,I>'P754WD9.A^_MX?*

*^)8@I5CL3989*H-OA>(CD"@1OG`"!9MOQ'^C@LQ-O*Q8#?20!-/:&[HYT: MDO>1-S1]V,F&J MD!O;4Q3[?SEW97'7"6W:I(H3/FB@+/[@[TA$ZI.Y?F_!&9=M:0?#<+;^FZ/?*

MOG_3P+61QHD-) 7Q7OZ3)V?2I%NUV?=2E!^\YX)N#@UA 1SMM4&J 0%_'7C2 MR4WRFJCN/,I.P%&4X9EXVA|?),)34PW2QKCR9/-!TV]M M'L+C$LAB!7.%*

M5BN[W(5;!O'=H7MIMIOU#/W3+R3Q \6:V2-FI]>__^]0_Q$PGWM>P)) Z*V7%;N<"N/.[&6B&R4%0O6/ZI#-D;K1CZW236 M9T%T3)_M.]0]%W,OTW=[>++]?*

=$(,FU%RF^M%'T8B"F[BA6*\/?,W,L8[K^19 M?&WP#1<_&1!-H&U0IP>7)R^AEG]PL;]TD-5.0YX$U<9N -DB$Z*NZ,#Y1+3ZAID\9N MH7QNSEL6L_9,,$37B

P,Q9ND4C)63[T(]<5=CY\)7Y":>AC;_E(LNC#'AG/M@441?&ZE4F3!.8"=P9]?- 'P^WI+1L$/(/H%H/F;?E>_.|?X0UU).-D2< 'N3*

*MPCNO$!SC]L\|E7V7;^+.,8=C=|7[\0$\|FT\|DTUZ)<9UNH7C@8GGFC*E6^*VG@\A O+Z]] M/O*S1+WFU=.Z@VI94_Q*'.8V'"P%G]&;QV]K;5=&]CDF+OQ)6'5IPGF_"A]R*

M36'+YQ-CP^Q3AH SMXC,0QD!0631=!,AAA(G]1WMV9!AOM9ZK-MG(\+ ^*S M> ^_N1'Q]]B=UKE1+|W.E<<6LE5ZG5?D+XYO.+7|>JJ0&MXA7B#)ZUV970=Y\'M'U'*

V(9U"L)6T8DMRWE\L-2')S(=":,3;A=\((:NZK[$;D!2MJH*G8/-'U^A Y4-M-<\WW-^_U&.Z)QV(TBM<, M.(3M)AQ<9(02SCV.H";;2eQ-2 #;8'0@=F5;#!OO.N*>OU2%UD:$#

Q)I9L4C-MGN++#C.%?G@2_.N+Y1+^_$P(2P(&57^]VI|MQ#?!*$JM3"K5 C=T+\P07! MB^%5TV75X#P??GD M^?MS=^/5PWG:?^#^DK=?L,VFM_/9YY/!Q--7!H8/=Q9!S*

-4NR:%B_<4>Y]Y- M1E\2WX$_PZK\W')MP_#OF"#XM@Z"8B7Q#*%&9C/9O,Y M86GT"6DW@9M57[OQIS511^OKX_@Z2DC7VT&E*6=0XVJ"OJTR\5@-'3Q_/Y]>*

*M;T,.R)HOHNKP'5XH=>1%V8^IW$-_WJO% H[!8G>`S@&O)3G/A&$,O7Y>P,]S MLJZ!@#O?'S>GP=,2E9B^,7@ T98@MLZ;LV03 T98@MLZ;LV03*PUH"SM7/*

*M\HJ[X+M?4ANK:!L-5C\'1))05||!$8Z!+P)H%]?/ 1@?MQR8I.[G^195=X"'M*,X6.D:AP_'PW\%6;N-/4&^_5UUN$/J)->$?Q\^&[?',UIR\^%!??<*8]]##)|SRP/Y*4;K;)!YGI;Y]8*

M57&-#;K1K[YQ%WL>TN5,K'Q;QX"V.W4>0/&-JHU<>/-ON15U!LE7]$4D3IR MW(?_6I2QRN\!QICM)RU@0L70,.*GG.@$ABW=2!H<&]6@BS%(_XT9?FO3EW#

MX,=Z5W4ZJ6[_:;>&V_4?<ISI-AAMC3ACBK&I12)'6>GTW;_:>/E;C;LG M#.?GO#\B5-J7@=:,.G4DJMZW?;(KH3$9^'5H1EA$]1754LES[4=5#O9Z6-@Q3H*

*M*M1/>5ZR^(6JC]$.G /XSQ1AXL18 K)B0JN0A!,2O!^_K>RJUT"QTBT1 X, M3&6*ICAQ_]4^.+M^2W2_9O;/.6"@%[%S(JX".K;E]#^+0,NP]PKY$,%)=B6^*

M@UYY=HV)@JO332%Y PCP($4;M\W\(*?+?V.:F$X\<]I:L9KEEYPE"H/I_P6 MG4B-)]IPX6FE)5]X=+(@-3)2VK[YZ=4@#HY$E'E{1J9+\1\NTP&%=J'0=M2R M-;':YX0!?

*CL1@SD[[#4?WW@+<]TS8UH=*96XRF;H82%P72/9]N7F&.>.W-8JY.GJW2+E>T"ID)+7IXG ^M/LH.2MDW>^ZC0C'7*)'XGYP^AX M4-'&PI.?*

MA3M3DXE\|!6G[!?DP<)Q@\0\4/2Z3TR-1MA.QP_MYAA-,?0B[R# M+WI$JGM1RIQK)\I31^XR.<-+2+FF?=7KZ*7_T1D>8(-HNUBE1%'^QZQ:#S4!G*EVR[7*

=8MFE71+H6PG7P^Z7-R#ZH3^[++VIGO65;R)+|/+3V&O&'R#J@R=6$*L M!B;%0^@.@%%(H-*I.@841[9F^^5T;!XE/FMS]8>"XES0M'3PXTXWIK.5[\%/ M%@HGP"*

[%DSJVLRTA.AM5LF1Z\O(I@U9;[N;]<<2IVHIG9BD"D2C^_AR &: M) #@GA5DS:D#V<1.,?PS;M\9$/JEFO-HV\Y[L%%G>+SCXL5TD$@JZ-I(Y2S; M!+ -[!R*

+HLA0X", #HP9K$F++F&YLS^*DWJ"P0P$ M{#@BXIMT)+1J,8:HY7BZGGMUYGD[&VEX?V%AX_)85SJ5YK'[STC>34W-UP\ME_-

*Z$223\F>UP>2;#35QHJ$F158T3'_8/UMYAYLJ2B;'Z;O.$2+9+"#UZE M.4W\)"1IRJ?X2CZ_@/I=\H"FG!8HIU.@5>CR:?8YX!4HVN?=*B2R_7HYHA4Q*

*M,\X+_DY5@&5+>YC4KSHT>*E#',LSD$<=.)ZK0++)8'HULZ>XZ9?P=4 R.0JM MR=X+_A^.]>*_.U:PDIZ!I43^I=A_9T!IQW>%E].T^ N3I2>*

[!0B15%QFC/+,M|NWT2YF^,38:C.O0:P1G1=__M1CTN.O/)"8J6<=-K3ON)NH_B\^OP&WSZ^U3I1X]+7M9=@N'3S)%)%&Q&

*MRC8@G*5A0"P;=_,6R_\&%|H4W')"81'^L3I?EW^3S#DIC+-+?N\!,3%9 M^&VUU&77$JH>'<-HGT9YX_8W57_X119(]#62!0'Z748L(14NL6ZC\8L)V*-]*

MQ@<;_6HANUMEN]7IO-),/I'KVAT,)>MX&8U+?7= <'^\VP!D3FJ9.BET&TNX MEI@44!E0UF]3%SMS[E]7D",;&V8'U1N,Y?YE$/RJ3! M@\%]H:=^8.GQ3^S3_AF>T'1R-

=/DSGN73!;IYL_U#[I-MN"6M!"D=ZR[^9-"'^LF#5KB5HLU'O3A8>"MP?R_B_C6DO<^R^#EM\|\/&.W M#C6?8"NP%?G D=KH.CW$/$[*

*\18#3G10?)U(P=IMY.0N$*6TGT'F_,I*U?IV M?!SYTCSFH)J5U_@.<]D;.G+EVLSXEM#U0JC4NT1?C?6'?<7J?P1_R U]$\B% M<2HM?.+&?W2U2\1;XW!UHI7-*

*M_879(/,$>BZM?]=X<0E@D)SC=_FH*7*.MUO3)" B=F%:8$XR*|. M"S38"3[$M-,\A!NUC0ZF7!')B44E7!VDS,%W$WGZ@VW:E?;,KNKWM$=O17@W MI$8/YD$12VQ'H-*

*VW%V%HW;LD,&K|<&=",)4D|DM;YE-J7KI^?(6#N3"G)R[79Q DU"Y(-M2"6.DF@=E]O*R?IV18L;A:M\9U=L!G_ZI_ 9WC/18$(6PYAM1NE M?4|D).<,,,*

(2E9OC8=GD]7CT8)7 >\A"$&%[<0DBLDY"EI'L!V-HZ8_K@+ M-*LFP]}IE OILAA7_O=&1/S'B)8]7L?^I!//>HU.O/5*^/O5?,8_C$R#G;35 M@ ?_1\;T?P4;WA-;N!SJ[

I9$=&!_V3HCNI&B+860:1GF#AA=XB5&PKI=:OIV4U+_QL5=9_U!NKQ.!+#YB3DB$KB] MT:L1!['J!&;/-D?'LCXB0%G=_,XX)V?%.?\ M_QWXZLR!^'E-

*IG(:,]_M9Q2BVZ[4)@IGFR^5B[;)E3 M1GJKY=KQ0FGYW;J<:@&9E%CN-LTV"W_,,"|^%X<+#&,):3>;IV<&QI6Y#\XQ6 M&|(20/*8ZVW.:Z#).U$EE0WJB^45OC;WL71M>%*

*<^H5.B-1'E*5KD"_NZL^W M378G./8$(8QQG'C/>R3/&DM8-URI_$'U!FKV;FY'=3'81 .,;$197. %/N[?9R\$>D2IVZO2PS?7UEDL*I_A4 M!*

(!=\P1^G;<;!+YV#]A31HT#]/B.+0NXWFUZN=YEC0MM8RR@V>W,W$QRSOIW MW(\Y,8|I%9?$5(O+<,.G;AG :\ST/LBPWIU[:W)A,_+=5Q8H8;(6F_1.A\L

M)2&YWX"IX5<(@F-U&PU&E$-L6A[1_=6MOW;J0.3TLZ.:.&!FF#Z+Z0P M}!R2_)TT. ^'&ZR(9.9FQ3=[F%IM!I"4BN@66,.9AY.YH3RM=KN43K;IM] MG&/Y;=*

]K,CF_IE[$#0F0?OWP/5OAY$_KUM/&,$V;8#:DKBUI&GX78%0'IYVX'-M%'9!8A!{5]!6=!!-Z)K&@TO_;62D/Y3/-#K+3_PR=@8DOR(YH)W@3FBYD_#MX"

*(<3R'#^3/4\SMVJ459>E-M;SYKW'G2(082B0CBVF@5C#CX6SVR];UNU*KND*^:C1;7_ OGEKO*

*MQJFM'<1;+:XF_VM=NIRBC|P]/O${\CPW544$5DQ@IR>"9%&2=^G9=YO+<3KC M7M4&O5;C,C7>4IG519FU{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|+OIA%OUQ(G8N- M(U8A*&Y]M@QPP3I"1#:)TJ;3\.'F++?S/6F*F2X;3G*@%S;7>H"[5?* =GC;R M'/#:.$,3Y:Q0+XB?QF^(Q.91S=-7&X80"?A6/@#!K6&"L$H0F3BQGVK4K=++RI?>B'!SAS MTE[PA_1X'^G1!(/K)S2T2TAA.LTSBB.Z[(<3-5?W"CJ:.E]&WAWPH:6E\D?E M."$;C;M/"?N3T-F@&!O>5M3CV(!8&0/YOU&/:55%G^,O*Q%*2S1'(_^QC.A< MSLGM5Q/MXMQ]MEO9SA:,/TAT4)),/V3^Y!U/45I/|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§"3'^Y/ZD MXCF 9<-2IRFO\K6%\15#:&2"X9# 0I<@=4"\G\7(TIUH=N 3++#UJKF'$P=,;#[9!C.X]QC=X*^+B5%5+JF) M4"MT7E\I7K;7E@.6A(GIMV6$'@R2DH;/T"%=1"IGWA-ZHL|/.[LMQ>>"L+E%4.S2'&09&.7E.%@=U#OR&9I5F^(QHPR$_JG-3&H53?X \,."T_XN M.9TQ0VYIP91/U(!>'#$7&:FD.RZ M"+@GNB0V*0CJO4@4=2I2W8/_G=L-OR[C'I6X_>1"C7M"?8S")5)*&B.9;&(L(F7(=QL"9R4-;=;/);Y7?I64X90('R-LJ5)*"1A M!_Q4(J^U\>=`F;0]^?O!2[KB,:\4GE+2Z(.H"PP!R)6NEGQUCSYD9">K-]MZ8:*K_S"$VTW7TY$>"ZR50=P"+!H"!P$]SP;"_/0IOHIX>TG>NV_&>@S?2Z9TZ+BF.URQD/-M,I[HR]1BDRV'E>>DET,#[(KRM@DQ>?.)M9?!4G7KI_Z\##I'G10G1XXW)'&$F"/Q(0D[T=^!HWL9Y)G'AYZ[4CC^&-MR.\@2<5R^2Z*G(-H(5%\,XBM,>GW7%<0*](Q0>PB;(4/GEC*J*!W&|!_)P^>M\@\|:*3(Z'JE7*#IPVF!8#"+ 3[Q1" O;;AFY=--2_LA42E?>_GO(&IR>@^__M=TL.WSZD:9)*(3W K]XGZ>!1O8&,XRC7G,(G_8[\)C1OIWBE,^6<@;;4E]XO\ M5S))\G8\T0MA'%/7164SX&)8T<5-?-$XK87B?07OY@5=PF56DRHQJWTf|'1 MO%@@%-,T*01A@\49MTV!^RF[^<\PO-=FYWP@JMT_I6A[P%=)<7A'8D4]P3BI M'5A.XN^Y,IL@S-$@QC"*0F'X.YD8_02]HKQ0,@KGOD-`MKN;7XU8X7K#=Z%#(Z$CLT5Q/$"-<$PLB27#W6?M,3>9/;2.L@<;*E[U"[X,JMS3.&&//7=6GJ.2_BMZ/*2+;=8),:H8C=5IZ,U[BIA9G%R]M^B/5A4V>F>'Y M\]>78S2@GIW98=GX0%Y2>EZ$#OY6BDIU;BCC4]P3^.1*-?K_.KO@WF+PJNR M$ZVW"0VV>+>^V@@^\6BX0^$&'TT).GO$V')F0F*YL27E&K6C_N4>|5O+RZAT MDHI!?1-)\.3!=Z8TQ*/2VL^ZM0*2595_F2DH0W!/4(L,^(RD3HFS83^+^,+FMUDG^GHGO3#DSC!8J#'P\6 >-FZ/JQK0<% =+OB MCT$IV%7HT3/_/'),_IQL6OD (]L3QZ#HD(5#-EGZ1.YWS5'/5/B\.5(Y5 7 M.T3D5=K;P4VC08QK(#[9=BL')Z_77-6YR(!Y1UY;9\"Q M+++IYP)82;O>\7?O+K<$"J_ 6R5&'%'!B!.G9-[_>9'Y-6=ET6BS3Z)8T8Z[F%NN5O12Y2WKTP&D'MMWCKRF(!3MX7]_I0+1[3L6F \L)YZC5/(TXV_1?D,5T=G;B!PYA,XK2>/|%*ICNPC;K1_HLAM!)DG MXBW@C5+?TYO2+_-E&>B;OJ-B 7]Y1,69^=TJZ!XTD*'<= C+ &'4)-M2E9IR&=+*)!GFVZS^:,8^U>FD111M%OO&BO32%;++#_ (\- +2+|\>S39I@$C\ M!4Z^"!Q,:KD%2? V^V_;1!0[-^R>4=Z*PLK71EF M^%*G$\ 1<_VU[E*R-=;<>U5'U!?YQC[F&;UEC>S>?; M_$^./9]:UFZ=H%WL+4E1GXU0F-5!2S,U<'7],C6+GD!R[0=E[^? M P?%GBCDBTJ8EQ75!%D*"XD6HAL3XHC=T<'O1-LL_MSZ3.7$2Y^3N.SPP]^'MS4@>BO*'A A1X@!]DDCF,X'\#;;4C0VS0R7?2B,K#LW^K9>2L2UE!53 M@_,K#X!,^C533/,]_ &D>#A'6196|8K$>O!0'1.6FIKWT28#I*R?W^MM'TIH8LL%T30'6W,ZG1=.9DU :=3R>_]HCCH-E[M>=]0[]IC7)4:U9B 4?9 MIJ=GZ0CCOY[\5[&6=RYHIK?%B M,C(\A!F2CSP$1"/4$CY.^5TN|IU?F1P6+Y>V$,"]H..WC%5PU7"]UG,4"5@.% M8* -)*=E%X:>5HU |^RBW_T.@('+9@!50!X>QBU*X__!,2C.'(P@'X3UM<_Q MLV9NKCH;+;S&3%*|&>--@R9F9N S\P0.BF'X#9)C5D8KYRa&AC#WB]]9Y_#> M:U_=N^:A+|V!U->7HE^UPTGFN2^4=9U?2#X#*+%=5!^?@*E5M[OCS7A@QB(@ M1Q&MA]!7;-.1#ZS.MJBIX-]>2<"@A8:>S#^Y>0^RKE9I8S/19'B MQF9T:5)BMV-*G6:W"ZK6;7!WQP5 ?0ML^0T_EE!2A >S0>CW6R4H>P)!@4.6 MCKU+G+^A8V1=4EKUD+,^E!]JK$;,(E4$!"_]_.^;40>_;YQN!!/ZNV+WZI+ MV?7'$EO:41>B[_RDY=5@GOXUKB4$PD+"S@'X8+(J[#8]=-RD8!/]>ZX.!B0G AS%M.9C,_RF !FIB!?MJK;I>HX21'QL.QSK3,H0VQ+S#YR4"R#Z" ..>]]$*9 =]?%]f|.;X3'>KHU9Y!=O2'SBN!>BHZC2.Z#0[M%.2C3O=.<>V_ MLH"W:H!9U6 6A%X]!%WG$E)+|SE*HY"7N9ZX'Y(]'O_5 TN>/S5[3!@0 J!;(E MB+Z&".";NP@P+%4;;-N&,#54GU'KJQZ/%PS-/UCSMFG[V1T XD^UX^BS!% M!B;VNU_"[D^\>?%$IEIFTOEN\'_U*_-G5/\ PJIE4S(\R7ZP?)G%)]/TMFU M-?/9')Q_"%@$];"Q>7NY"U?^H%8N71Q)-;6\,)].^#MB9YX\2ZK .T55DW)M>P>"#_JR$EN#/*M'&PR+G_7"&^P%Z<491LR5RIR&O 31+9">(@(@5@3C*%=N MVS;"M;,,(F>/"=QSY0_IT;\V>FD)M9Z%P6"-TT+/(*W59RL A&UD\ M,OR-$1)G4VVEI=19K60F'U?NK%,,=&O.>Y9MT?!)A!|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|"E^E*,BC3:>1?:*I-&0Z;]1S2UYDS//"_MN=V *XK;!F-XCI>* N& MJP-C;HP0.[/@E\[0f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{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{C"0A; MH+W32;S^2XJI:(HEY4F+50GBRZC0^5,%FIXQG4z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}$^]:+.OS/N(+"@M9KK^+X.0D2%X4I>-Z9/;=RZ^HGU\^]V^SW>FL/>M7.GQ=EL[XL)%\I^6N3WKT/A!E78,6T!4%%3"3W^I_U/-S=U9]O$,E:68A=HZ-MP$Q%&'YW8?1Q_BQOG'&U[I2B5AR_F)_5%%*Z>+>KI+_=X[K0!I.?2G_>+++V MNM4YX!+)PB ;(Q]K9N?OY-5Q%25*&75F_M8@5]>B<^_G"_)V4]; .!EPUN5?(EZKNSQ-3; &,0-\UR<:O0@PJ1TB*OVAR,M!5/>LZQ:ZYW^I,N&Q9NRG[5YE55<6CXRBZ1^A=@4?I4\=4VX-UU:QH[>T.DQ MDI8HK%F;U9SI]-!V<.3U+5$EFBPDY7-6.DMNA6>_TVN"7]&SI9I+7YLTL%AOM.P>@K$L>C7N5(S3%9G]`!^\(X;2HJ3-QL7P")+I:XU]^K?/A3ZI9"84K@K_.M ?1)'F\A?*38 X(/!F6&30&S"([GL -E[B$G>06.Y MN1\B&\JHZ0."RM8106UO^4:"6!F!ME?%W%(V_H9N5:=.,?5"C5]36I?ZW%;E" M8Q"-*>N D9&MD_MKEI-9KF5!7]#>*;@0OMG@OSQMH!%S^,1(V:TBR-NRJ4Z+7+9OA!"MU'(M7WL-P.I3);#$*+]2<-)9Q"0 M=C)J?<>J$0NJ-PYUQ =UY]S D$&X)@7(YK]]=: MKT'5NN[CM.)#Z]!8B0JU_ =BF&13086EDW**M:VUM@.4Y_NHNW "AW^=*@2%MJB5(+0C2>4L.2G9TSG M@(+F.^> [@\0\F.0OH',?PI0=HTX!X1))'}$^]:+.OS/N(+"@M9KK^+X.0D2%X4I>-Z9/;=RZ^HGU\^]V^SW>FL/>M7.GQ=EL[XL)%\I^6N3WKT/A!E78,6T!4%%3"3W^I_U/-S=U9]O$,E:68A=HZ-MP$Q%&'YW8?1Q_BQOG'&U[I2B5AR_F)_5%%*Z>+>KI+_=X[K0!I.?2G_>+++V MNM4YX!+)PB ;(Q]K9N?OY-5Q%25*&75F_M8@5]>B<^_G"_)V4]; .!EPUN5?(EZKNSQ-3; &,0-\UR<:O0@PJ1TB*OVAR,M!5/>LZQ:ZYW^I,N&Q9NRG[5YE55<6CXRBZ1^A=@4?I4\=4VX-UU:QH[>T.DQ MDI8HK%F;U9SI]-!V<.3U+5$EFBPDY7-6.DMNA6>_TVN"7]&SI9I+7YLTL%AOM.P>@K$L>C7N5(S3%9G]`!^\(X;2HJ3-QL7P")+I:XU]^K?/A3ZI9"84K@K_.M ?1)'F\A?*38 X(/!F6&30&S"([GL -E[B$G>06.Y MN1\B&\JHZ0."RM8106UO^4:"6!F!ME?%W%(V_H9N5:=.,?5"C5]36I?ZW%;E" M8Q"-*>N D9&MD_MKEI-9KF5!7]#>*;@0OMG@OSQMH!%S^,1(V:TBR-NRJ4Z+7+9OA!"MU'(-M7WL-P.I3);#$*+]2<-)9Q"0 M=C)J?<>J$0NJ-PYUQ =UY]S D$&X)@7(YK]]=: MKT'5NN[CM.)#Z]!8B0JU_ =BF&13086EDW**M:VUM@.4Y_NHNW "AW^=*@2%MJB5(+0C2>4L.2G9TSG M@(+F.^> [@\0\F.0OH',?PI0=HTX!X1))'}$^]:+.OS/N(+"@M9KK^+X.0D2%X4I>-Z9/;=RZ^HGU\^]V^SW>FL/>M7.GQ=EL[XL)%\I^6N3WKT/A!E78,6T!4%%3"3W^I_U/-S=U9]O$,E:68A=HZ-MP$Q%&'YW8?1Q_BQOG'&U[I2B5AR_F)_5%%*Z>+>KI+_=X[K0!I.?2G_>+++V MNM4YX!+)PB ;(Q]K9N?OY-5Q%25*&75F_M8@5]>B<^_G"_)V4]; .!EPUN5?(EZKNSQ-3; &,0-\UR<:O0@PJ1TB*OVAR,M!5/>LZQ:ZYW^I,N&Q9NRG[5YE55<6CXRBZ1^A=@4?I4\=4VX-UU:QH[>T.DQ MDI8HK%F;U9SI]-!V<.3U+5$EFBPDY7-6.DMNA6>_TVN"7]&SI9I+7YLTL%AO M

M_%/Q&8G1^3>QZL_PYR>;@KQ%UR5LMEK %5T(=E\Y!#XWV*&9"[1)^,R),SM5- M1O^UV^9EFR_Y);#?60(HfE^(VL/C7=B=6(ZBNRZ%0;TI;43#HQ/(?6>3(4T-M_+^_E)E+1.N7N:>.ZH[(S>["+!T!QAP_D:PWKT3R&A D6S +%; 2A%^F7+CR-M5X\6%1 VC]^F1"!9$'/#0,J-5RK1$A%_6YCP;IY&VX 4/*E +,S"3DF";0<5 M<)=K#-%.(50 ?*7&"EAH(4E0T)A#_A-7+M(F/J!K?(.6E(MM@>_*=OP8->[MBWV7>9XLFW'B-*1VA>38&63/"_X1Z8SQ3R[V35(I:&/ 9+\%6YK!$1_^B MYF M_\53R],I=$6D(2K@O%H"%:!A)4, ^,TC(87&=CR GR? @?BMXG)Q%7Y'+/CSW MFPK .*WKD"*(:=YI!O"!++V"5?OF+%WN[%.RIC#@YOJ"KG?G^Z];GV€;XQ

J9 M8LM#W8;\4;>WFT;) W "E!DMQ0N\Z*_PG4UK0$=EXQ.EYPUWNH*1[=OQ_/*+ MZ- -.Q3ALS9A<3*#<]*/OGYE*SM GL24TK6G=#":LOF-U_.O/(15)'_ ?*1RS M%YTM\AZ88#P_/Z%G(V_B,E:O:T-@EKSI<<="8ZN<1KY8 M?-.F)*9F;&H;R# MYRP=A5>F#+IN+!;;;-XPCAN>A^8W-\893S!TI? VGPEO7@H\JRX2IAI2N6DS.U&,#ZCZU%CT>>C]QQU91N&+^ MZ_YT_4P%5(;XN:I6+P;-3?K96F_)?+,ZY@1HA*B177 SK+XYH\.WPJ [4RCC MD+<=?)2E0'OI\5%]R1=WM; [}S:XB5&F:?CE]V-!T98+S]DW0N2Z0/"ZI]_D* M#GR)=_-6 BE=+/?>UU,\U,)[T.]CG"\-PRJ#BU6Z3/N3K(_(,@>T>$<)1L&>X MB^PI[^#5<=KO(HX,R2L:N&:I.DQ'4"OSP[=H!CEB1C&-M1 4VP?O=[_NF6 MHD%B?5^8Z@=*$!5^/_&?N+_ EF.AM!9MC-R\/29-?AA5#;6G3;3L45MBTJP%EG M? N=[\QHJ8:RF3I&'PJ^>++$E,%Q>M;XKY!,0^.]$>M0B#)K<=98=M\ 3)]^G:._5+6TPI)^?605)2^E^9IM[_"HT\+ M5(#N?G1^GM/XY-D/]'%YF^%77AF;@WX^O#'&XTE9J8V<;L@8[D_ES-J9> 6ABJR9I\5A4LTDZKQV\V3J8,"7)% M3O&"H[B(3U"G58&S;\L3#HMQ,GL.G^\(/R+=(MTRFSE.-L/5VA? D:Q$3F+OBS9DZ*PNN)A9)0M_-F/V"HS"IA=`)IS;Y5[&+W M=>/11$M^&^B]##]*HD($C,/2M U[)EOYPX$B)>)@WMM9@:.MW2@$)K4_=[*V5RO"2[B3"]? ^'@H&L*DR6G.4/7?4\P*#\8?3_`^>,P%O@=1 M(6':3[,I"UE#XV]#T,_HWKDEPA[+]D>H M,Q@C),92V]//_WNWLD$S.CQ#YV4_]Z0-TWS1:Z2)&XWU(+-O#[(^ ML,"ZD%IZX#R$@(TP@C+&]#U\LH55Z.:\|%;DKN77@7TT,&OMFSCPK^5PQ@(M@I55T782#<'!=9_?4)P>S',)382YBL7/F'3"[_GJM>0FF8V)1DHY!?7>NEV M5J>0QI9$%J>@'Q_&/ 7!D93%AIMG?%\\Z1E<4:>H=A[F.(12("E<<'WHQ=6+ M4_DI"@8U-RP:UN=N20R6[LP:H @1&R\():CWJE\EGC^ZI%D\R='!BEAPW2MJ M12F>/O%3W\#LN88U?FV.5;X8:#K|VAR7C,HHL%C1/2#%"[0WB]>CO[#[SF M-5;X&:#K|VA R

*(",Z#=8W"AR_'1/K^J/DM6>$FVF"E1P74/C@]=3ESB.;D3]W- M0#F,_1.N.6ZPD*HF?MZ6P!U!,#WFDL:T-.WX;/M2]<>LZ"5]_VM8X1]M\U8&*

*MU355._B/H;/@;P@LGV$_'F>,+)8$4R+(!V&A9 TMK+XI&ML0%O@6KGC M)X]OZ#K:+>IV>*>IQV#>>)F!'3)I34>I "=@K*WXZ(A&LU?)M0+%0_]N:-A"CG6AK!!2,M[9A FKZ1O@A#5>'D@]3*] MLN#+CF5-Z:Y655[-BPC]F0\YK/K.Q@#)M9QW-&)\D",UO)(\"F,R(VZG^ M9(H1B^D),JLHG$M@FS;0CD#^BB[,5:<"Q('KG*6\L_Y>_1+%AI-*

*BN)/95V0+ M-K<@1!OYS$4\]C#$0^IM^,*VGX]5543\$W@Q_PWK@D(;%U [YR]95:78$D M#2#+4!>OAXX&LZ-$2%.083B_)? M7)2+-13!&MPA4 $DVR-,5+,'?*

*KMS1FG8K1GL@VVQZ_)O"HM/E^V/$D!0I'>$1"0#M*[2(?00Q?IQ5"34*0G-",$/)Z9]_WVS#GG M']C9#SO7[[KWWIT;W4DU8"*KPE./)Z]'7SH)MDZ>7D;*

*(V\"A=Y4JJ<^XO3;IQ&R5$ 7I ME%I=%!@894FD>)1^@W,'KXV'3C ;?*0T?2'041S!K]-2J/MQ6O%2O6 M*_;I=Q$5?4J&!QULQXL>ENK)D@<+OV'& 8Z_VYI1B,8RW_7P^)?-*

[AKP M8(=+,UC'2OQ[+E_2K832XFP+"\T:.RM'!2B/=U-E?\S(620:OEXZ[Z_H/6 M,3L]_X5^2'37HQ9"4SE1&7_A.UNVG*MDCUV*

MR'[R#6%&DOU9DS#X4T(V_N$>MHKX" ?*B*PI3.I/AC;L^5],W(0(PF@_?<*: MZ9N.HE3,<*36AS%MHQP.9/!OM]'CW<@#]?XNYAD$;]EN1=%N^S,]=YFS,8'U

*M;^UM+=GA3\U\&1,FTU_)O]$N -:6U^6A"85X"XQ5-Z:C+]I9A:D>UQTE(W_] MQ<7' O2L6K'(;>%@O\N*ODGX77,K?OZDP_RM-2O2]^%8"<:! VW @*TO]TM M&N&;-*

*=5]/9/BVS(=U/] :U&]W>A#:)OF=\W:L8"+T=@_@JD]AR'1%7LTF(C MA.S)7P!M6=Z.:;]QN^U\<:) ODLYA6S_B-?(QY&39D"/8#,?80=O@G&(1^B4 MP16GB2)V13OL*IG5O\]ZZXIOA_^2%Q-KG&C2HF5X;=*<[WGXSO6F=H1G4KM(`MX5R0"/PY;@T)HH09:7%1=\S(<'4WHH]BDPT[F2]=@^=T1'*;5#M*^)^, (ME-& R[M?*

^D%;_@)07'>G#Y4$LT UL\F]Z(!L2{4SZ##]:$-Y$O(HT(1,K[6,E#7GRG0K/\;"*^UDB0UW[[YRB/D M:$^KL\U: "PHKTLF/K@$PXT(81(AC8%W^]W89IK6Z)?

6QOPOPAM&R+-<-N]I MWU;+%L9W?C-%(=OP&@A)5B(C'C[9!AR!3#"#>"ZZDPO";@XKZN^# M9K.5M>@]C/*

*M91'[98E2O+!:FSXGC.6/D\I=R[HXS*TV!+'/3X2PBA%OYS,)32]^\UT!KF M-LF_M!2ELOEQ$>@+!_?;BI#HARUE\<55[ZFF?$ M8/,,$;TP9-*

[+%WUCF^7&@.&:ME^E(2HAU!R%%#NZ$,[KB7P6)9WUX>JHF%.H MI:H^GB)>1D_.T"NW5)9EX(32C)8D!M=C2YICT@UG)V27PU]Q">G>]UYFI,/\RW@HS.??

*#BF36P=#)$3RK!"R$I1RH])Y= M^T@;=/=?C?DOL4DJ;^CF@.NU2'65F S-V8"*I#)%O@%H*WEYETB78< MS5^ ?<=)L>(G!]VL<-D'O=*

*(DWV'0@3\8=GV\.'P"95'(D)P6<[",+I;S?ZD0 M4;(L8O,N%'/3HU2>]-8=GV>Y)?>TWA?0/:3T2XJH!NH@*45X^G/(>.F66-B M=S)L*1O>'[I(<:H (-2$;RYUX+0Q_]B]8,*

<&W'5&0B":,. "HH M"/(D:Z>6ZF>_O$.68CC?UJ=$EA"1'+S6@1Q6A\AK5R+]+_>ABP=%&)W1R\)" M!MVJQ9!3F)-0-$ZS#I]DCL!99C]Y M5QV9\;

[%CM?;T.:M;4]!O$=EE[EGV2+GPK@>=T<=+|Z))_]MFF5QR]B<_$ZG2:C\7OIP_Y^(,M)H>EJ_?)S MU&J2*W'4V*(-M!\]S)Z)!?%F/I(^_2KGYW?&/!/D#.ZL3ARR%H8/,T8?*

>Y5Z/#O/Z@NETORS7 M9KMY5+_L.TE#<29_B$_4DK\;HI ?#2&3(*IA$]0&\ACP=D-A2F9VCEZ_.RVD M$2T=S?S29-IOU(],4J_'ARQQM(5%L.S!B_-N#%7'QAP+4G^'L=GD

M10YR_FN(303+90B=AZ^#3!$;B+!+I#1++-HLUGE.2$!QPN"]Y3TC5RP8_-/L+ MF(@>Y,A1|)OS^*%\;=+#;^3B.=+5TJG8!>.&15Z-@L:.06(++>]PJPU,E!PV/8 M)-5VY5R&-VP-

R!23?B8A5X7QFA&UA 5,[C^'.I1^H8 RMW!B/I=M3>?C4/R2 M+B9(Z^M^O6%H>GU&(L5L 5WM?8!X>F'#F9PRGH_72MSRXM0)W;&\7[@$]AU M0'-3:-*

*/.CF^U469BB;1'0;RES@G*2VC@U#U<&FJ:!RGQ6! 4@#0R7!5DPF% M/-NCD4$R?Z%X%?Y?UT""6SD!9=.U\ 5E>M5IV[+](IY_C_0Y;DW4NU2CN!#_R.)?*

+IX2E)W$#],#\/B(FE%U> M;SOTK5-Y\"RO3"L,ML75Q_BU((E,]1D"|SNT*4'] M.;.[A(/SAR)ECBN.R^/!/V^@#9< _Y$$&\T'X$;,TOV7D^-A"B-GL 5Y.+KJD3

M+0A'&.FPZH5+\GZT^:@E/1XH'5NV(FO9M]<2%(#,#DTT%,@^W-(1HEZ@[D MN23>OL]>3XS1_N:>MJG&&O823X)>&%!R2@K@H<^{0I^DU15U>/V(Y;2SQ_"*

<.!:I$!7EO48#]]SK4Q&?/ C])Z\"5?N^ M>&WQ44Y#B?:Q-[_MFPJ*PEK.H*$&YZP?%36$) Q7%8;&TZC]:WM;6 HH99&1 M\V;RW018]U[?

(K"QD+37C#=]1LMH>,);]M0NODBL5G@!9CIFA:$9OMV]0L MI9,\L/-FTS^54>SIXFC&<_YN5^F5%IF=<,UIG(J8]DZNM13>2M+?\F DQY M#78"ANOA4X?*

*RJ1O+IFH%9OJOGNAI&8%O?3*UT.T!)@5\))$4V=TW60JS4G.X? .[=29\,JX/I"-XFH?V!1KJ M25A,'HJY.L\+4!^'C$6^YI)-G0 YY_^S'\<;"0Q% E$^H'CO-THHPM5KKV/B*

*M&U2%*V7%^U[1*QM/$#*<%?LXH&Z<8$ 6X/;3P2)O2!_WHP6O^'+ ^&N1THB7* MQ94*#E6,,92E891;E1@7=7Z,=4[!T)\U>@0@2C;A:+LQ5X:KY[IA&)&S;AB7*

*MS*N6NGV)?6$":%/XG%<$N;E'&'WL#?%EB1+T4V^91_9;MN*M9'Y9C]8A7H6_ MOTOM?733-A2]A0QN:OE 5,: W-1UW>BA"NF1ZL[UCA>@@-7/<]*

*M;^8!_\EPTPN(*JSA/"NQ'W/4G\NAU3PK Z:&)0X&C,A0*0N:8;Q1D7)F4;>K M4B!)&?&8CHG(8)"2,AYB@&B>$CT;QD0H+;K5G<82Y M]L_K-/[3W7>M.B;J0QT\&)UL74+(-*

*L0E5I A?7VR2C_W-'KPKNMPP+\->]AK M+\M/_>BRS,/686WDQ:*3.Q\T;?(&[EAK$^_VI.0"G3"N@C>.(T["GQ,ZZW36:01A&\U3A8YQ5-NQ MLC1,B)9=7X1N!,7MZE')*

[QZ>>T$*.*X$/$=O>W?$V9B->_%N^CCT?20 MI;U M@/7HUT=O NAHO&30>,)7-400>A#/SYR\EQ71%;-ML7B'$'ORF 4N@,,90ME7%8DWX9-.YHF]O:/?!JR9.IR$2OHI?

VOP M&SN%X/0-4C:,]GI#4&I]:P+++7+*PE/<4:R2#:81]M_8^=B;C[,NE!Q1& < M>6TXSCBL8\,??R]*XIE"ZU<[8W15@Z IW/&G^5'4AE%^>/DZ;W>Z7ZMM4CR"*

*MN"#Y[H3'] ;SN&]"Z^C7$0I %B#)^"]C<04\Q$"(ARY,=>RQ]2*K=QL=5&A MB*#K (TC5,R2Y)D6B:8XH1BX9XF%.<%M, E]BV4\\9=*&GDAV:)^]C,=QM:=*

M.>TW4K_#:$7&KOF"YHP]B%SX\P]T6D A8:;?0$WT0B+&:ZBIH\7,7D.'_=:# M+EFRK[O/4H#RK+7]]V-$Q%?!B+3M))]_W^IUR0F>V]KKAO-.54VRS<]M>'1*

*M'1FC_<1D;.'AI=]2+&#;ZR_@!]5YCW#A,EP6/WX4=]8<B[EY00Z0<#HII+AFU M--]\?)DX,%]US<@-IA+,1T :(P*NF&V""OK7>5?4'*KAI593'(8)1JZ4WYY M\7XAC N%;)*

*<\-5BP]373;KH?.5AT,>)Z,XT9F)!$(AE6,_0/ W:YLG5:H$U_L MOMGHW1P126Y)?DFC$HD72$R6SC"$'1M MUDS@Q&T^C>4 T6H9.))^EP'_7$*VVS=@3/XM?]7>*

*<\$2([XQ*T,CKOR0:C!T M"W)V_'.,]SL-+T>TR-TH@4\W]!QA&>?^K2S7K/-$%]R8;E_7_*&7!HLY>O#K^Z=MK35;/DIK+&;TJIL1..K0K>S!).>]NLXW%] CRQ[MQ&!VF;,*

<2GY.PCN&)_E+5F"DZ32K$M(;@CAH3 UY7#24ITHNBV#R]?QCGCS,#ZOL]=&>,.-$_7?,] M2,"']6T>3{A'6I9M77O:NLC*V]B_@Q54>7*V$D($TR;M)2 Y?T'*

.H;+4[NMX4I&8&L05]5_#MOQ?$.>!2M[8KLM[A-M8CA/T:'QT#+NY]/XZ;_7 GSEE\NIAD('3NN+A0#"HD-5PWH{'QJE'AAI1/[*

*M:II,TZEQ}9*Q=W2H;?Q.PK#I#0S(([E)1=&3*D([P:@%,B5O7W=?!3S# MK5RB' BA.9^ZUKNMYLPB[[32]=TU]\\I#=[4T.+X:E A*

MG29%D2MM3.Z@"M='PVTY\U7!.?>%XD343;^L.?9EK@IBME9X8U"W']W?, M'$!13(MP54(^_]A$?+/(D)51AEH,&43ZZ*NOU!M-,JU*OPJ2YZ-FV#*=[); MS$FG 7AC?*

OW#1[;I-I%D/;EF1:8[W,WKQ(4ID!RE09;IL?M[R='A/I.%,03]KT;6+B_4 MP("#%Q!D$J53D."4N9-TKCYWH_F(.]63:4V=VY>F-TA)DO,*PE9;?I%N)5_2*

*M]IQ"*UJ2P8W*_62ON9IQO]_G\1D/^F'B3Z/F8CC KE?0TCE5AWPZIRY^/,WV MAR"'^-9B(-IZI%S$G73+-#T_GB_2BSSH&5^F=0?\)/VC8V%*WG(;,!10Q1ZNJS M]%] I-*

*LZ]1L&87$11=G%,O2^=1)?& CXF>)-5$WK^C(6V8%/D8WJ#3ECNPM_K7=_'S$!!6;7&1'U?AW^5_W\:^<4Q5O*M;0O=-IQ.+=P[% M"=*V\X);VL.],U9WW"\5"-E]*

*[8,UJOT2,48$%NVY6]IC/8WV*?2PV7]PN\K2.$73'I&'V'0/Q+|"FZ=1#H#]--[G))&@M)'& MB0E1.L+|WA\7S\!)O9B4%DGP1.8)++L@LB5Q!(.)1++]]2[2UG-@#E?^^.*Q.]*

*M*9X=>4%"V, ^_XJ65H4/!=$=*+BIH/WJ#J66@AQRLTW!KA]8'*?;)6NK'M7Y+ M6<>6GN?!"V)P.3R%D6Q&EE(0"'* 1&;NRF\7YM.]9C]!Y5T=5NEN*D_;VD# M1^$BJ(?*

0H_0D?T A=8XHMJ7K]J+ ->9?76B34D?!+TNRD*]J/BZ@<MKW'* M%F485'0[&*L6BNU&"Z]LE#VTY1:Z6E4X*YNX?+0X@8LG "]=?UF GNYRN]"5*

*M9:.^=UA]*7WHGO]LZUH2;H-GCKA4AW'TLK^\2,\L7D:-E^_*R:)(NBS"GP"2 MQH7H"S8:$K6XFG88X*ZX:@<OU 1&VX,N-2WPM:,]]*77$/_]66U#]=]19 ,5$ M/'?#2L;*

BK%7]H]MKZ3M%]CX,>GB3=&[K8%\22T#NE#LW':^TN8NMN$WZ9X M4!*RX:[S^_U+ "TM"T*W_2GQN68=W<.G@S#2"L$VSTL=0I(,_M+ "V;/O@]DE M1D:7XU-S_4.]

<]T C32?""G16_P?'VH$) P-2E M+<*>'+CE;4DPC7&:@W^B MG=@!=A"<),,5 MRQ:$[,_BH]B',M<,_4+4(FX#$,"9.A9(> :GP 9TDT'EF-U-G;F\4YR-?T\- M/N! >$C>?

*07BI_GA1UY.M".BQ(DGB%,MJ>;XBP0B5L7 2NKE]]\N, RV+WS3]98Y;X]1K!@.*C84BPU!W>W7UG2G^Y=]9B*[PBU)W^8X!*[MTU)/W^-8X!* ?(=XAR .:!+0@Q/W*

*BY=@[@X\#1325L[+DZM+C0TX. "LV_^)%$P_G(,_MU]*EC^CW%O+(("4D!ZYU"D)P59W/SG8)6]W(CN2P1]Z!F@]6UH]L-KX^Z_7]&#:C91[>=P,2^,! M=-G:D<%*

R^*LZ;S\MX:9V;\ /=METB10-'B_S1I79XC+W>#BFY5QP%WE;F9Q M+,X$#K>F!BC%]T9S]XU;XKGW5VPP(F#VGHN565+D14EMA;"IP1\:$D-ZSUD0 M(G7/1$S5:8)D"?

Q%S#PVV0ARS(M8F%1O-IM7R#VFJ-ZW2+,I%7I.+.GD)Y?\]>2"7 -/.DHYCA(T=-^#KC11@F7]#4= / M5&T5I@H$Q:@F&,X;?W5]S7CWX6(:T

TX+S2IZ54\1%K@S5ERI/ M-Z43"&(B@.)LA'O/O;'.M BX\8C>#.(D:7PD9A;)E-F5[[8ZYFOB,IT"%AS1B_[%(;8!\6%[&@#OE_^O

MK^6G=4"%6[+$_XA"'T#Z#,TEXH@'50.U.P9K];H!94]A&RW)(0+,VB7)<@"? M%!S;Q16: !"WYF840QGG).F>;&ET3FK!^XT]\UVXD)O/51&?-.5'_2)T!CI M?<16YUW<*

*RHGW%.E:@UI_G"KD)".H*FYNB MW#_2++5A2P0PTS A[OPM7@LI=G?! #\85;K;7A:+\+2I@<6IA]HE33??K19+> M4.O$;S, ^H+DI,@M-I@L?*

N;ZU$CR3TT:A/I=;-8C$IMPYX$,H>,9%R=%BGC_':'?]^KG7O_P\3RHZ34. >5!V2FV0'99_\5N86 M=D'ZLLW:X177<\\]13B2-$0J=O-:F>%+M(L MAAK]!CGNSZ^M'[+NY]!#

*<_;"",QE5&-8*G_6ZP2VW^<+]WB%_XS;NVE+ M1?"PVE[611'IZ0 F/T7X CYL,I/],6%94,,+('#D6(>Z$#E,+&+:%(5=-@5 MPE]KWO7RV##](*JW$6KP#GU=++AO1-*

*ZVR9*9)EV.!-/K2\,&Z"O3UPSO^K3'-M>1X-+U=\6,P3V;O_'(@.@$!5B)THN>.53$1V;6V>8.2;HG3-^,_-HAR\\9/P M8<:.O/1Q!O_R.4E[B'7&ICR^U?>-V<'JD2*

*PC>U/6]6AE'PA462EKTVJ9MZ MS*U_",*4#1Q1P)R7^LWK>G.-K/!BGT2@M'5%NSZZQ58N',V?H)FU;CEM=K*!Q!(G=!6!03$@ZJ/D[04)-KLAMBN1 MG>?4IT5L!^FZ@#F-*

I.+4A(H_0OH$\,(4":6G9L6)&YK=ILN!'%$ MIMRB5+V?VM1&2MY54%P E+CZTL6QVTT?Q#?R%T YF[P$&]/.E5&^O?6:+/%0 MM9WU+\#[PWV_7]#O$BH

*0GZO*DT7URZ[0&YW#-P:7?.IZ0 -3XE+\NM3'V*DZ M_N2#5_&(3<YVT=Q,9{(&$GP1P-_6[(>80K<^ANV63.G*C72(:TO#/QXD>)<)2 =?VP-SN,#@] =(O#9/=(-B6AN7#,Q$!*

<')OA1]/YYYZTH_^Y+UYRX MMXA4Z>>"M%LI"PQLH.CG(<.?MP4[%='=_2Z>3^:Z'KQ><_I"@J'J%0C+I$_H MHWK!;3,TGOQ#9 FG?"

*F*G"3>3#!T=M$21D5F,YKNG'&.X77L34\B$-AUG& M],L4OVIJ/CXR476 W(9U!^?3G6&!X6=) *Y;N#:(OM@&=F^2)#MVR.,S8|/ MZ/MJ/&DW\QA-IDX!9*

"Q_^57.Z4F=%.">]?[3A =_-%"$+/3&G49WBOBJ&@* MH4%;'&7.]J3I'|[':K%,+BW93WWXG?RQR!7E=KBGHEG ,*0#H$-D\#1;\YH MQ4OP%8]7O@R.;'>(:[)A6#"(O,7?

GO@+47$GPX|+Y]X&;X; 8V]@S(=W:XQP M>FQPZ)|?!0W\(ZS<88^?ZK^E,RX_LK9I^EG%11IAR0/E?#5OX8->7[Z 4N M?7A9VRBF<>=955*QL5M18HZD)1<#!#0.*

*DX\^C:,).[&5ZQ/)L<1 =R2$ M7D5%_YO/!+P)1IL$TVBA5S@T9FMKE@RZQ0*9D W/;9*+8A@UF>C:E-H>+9/Y M7'-'#763('RQ'8K*

)-5I6DE<+5.G1.J/2D02JHA/<(^X@832KY]T_;/G1[6 MFM11).PTDES!X+%R.2E&E8[,.!ZN]MFC\,7!HKX>]Q> G+@-R]N&3(L>KQ@ M,B.?

OF48<)BV?"6I;&)310A^CK]A7EM6AMJE@GJ"-JB\;P:.S4UU!&ASQZS M>B@:1P#@,_^OY!"'WO5$E01,8=5&'E" M4.O$;S, ^H+DI,@M-I BV-S6.2O0]%'7S87:>'\W;JM2JJ-

%HX=S(0<&.7^]$ 2"Q:K& M7H!#&\?5AXRO[_;SIY63^4S#5FYSXSL\X2SHX^_**IP^H\!V??@>>NYS44_1+5_/VJ+6\ V_)0U(]^59WO&$D2H:D<8!(Z@2O" M!*

*(?!W8MA95JXEU8\+G(8[FCOA?I4@U#F]++[=V0'.Y ,.6QSNJ)I$3=9R>6Y' MP[4KQSTL]T5NFW M)^VYJ.=[# _D]=R&0?ECV63]C?^+^(G*0;-*

D_J.8H(95'AA<0,+2&I_=UHD0X+88F#K=9+@83E"<5EQK=?7IE0.*>OEY-%/UJ\B'25$"[&>%4VI+A*'M'>D#Z)#!,@S\.IVT2Z?QYN#.LC"(BRZ^F1LZK MY8J*

*M!WKFJRPMD7_01M+N\H;_ZN(CWE9J@WR2G@$R=*8/O/3$)_3K/XB]J^'5Y@E[M$)$H;5!9X \ $.^O_ \=5FU-36'' N#'IHG%-2,\.(EHXU)AJ?6/V@Q#*B7H M.--*

*%M\8Y<:TCV^W2OHY/YP|E[_^(PE$,&:_1(^0\Z_H;_#D_X1\7F$[^M!E M0^/QOV%&%_[C*G;2#5 _JO;^\7035$ODP/O4H<%=2_QJ']>N>KG,3AP3,W^[U^HH+1*

*%V_OK7N+QRZ+'9ZI M.3Y,NXO_4EP GQ32=B)W8[T_N7B^<7+Y & K M*G)I(([N-=2)A7MY:0:!:$;(]X?+D9^/\-X4M#4_W@A6_\OP<$[NZ!V(ON5)) MY8\> M&"5G"+?*

$0_K^>Z2'H-ZSX*N@&G$>%HVR9WA]P_\.%Y.5K^!17>W]R(0"IR[. M1JBE"+AYQB5++[.P*<;&<-_C^V/2%#^A3H#?1\R=N2(BPO/S9#431D"HY\3WI(5I#M_)(/%&P.+*

*<)P.*X3PY0B#V*&$,3X7,X*) X.H1N U_YHPBYY;T M<3^O5?\QOM98K0264*(S*I3RX$@5FU)!!-T^DNSZLH(08-;"'"/8ZX3#VY|*

M"9%>:+/<\A0:6!,C@A7K6.,OB$*P!Q):H1)7,<-Y3T#|_,E<.6J?XKP;P.U824["C4>%40)8%?^.!V4#B[LH/*Z\,1_"_NM@|&W!P3 M]\F-?*

*S;,*W[YM,2(C_/_P)02P,$% @ O8$T M6;]Q&0C!^P K@H! !@ !I8FEO+3(P,C0P-C,P>#$P:S P-"YJ<&>_-^]M]L?MB=^]SGO/E/|-\[NN<^[GNZSIS-76U!+BGK:ZE*

*M#KAQ$P"X<7T KF8!]@"2FS? .Z^#]/]=>?6+5+26Q1D9+?OW*6X>Y>2@I*2 MBIKN'A4U+34EY3VF>[3T#(R,C'=IF%F8&%CH&!@9_EOD!LGU;TAOD=^Z1*

*FI0T2VAM770#NZSQOW?A? ?@_XL;-ZOQO MD]TAIZ"\GE!W#W#S!@G)35*2_[*^OAMX?1] 2GN+[K[DL]OT!N_)'K@Q/.Y.*

MS+W#^]RJG=%P!,T>0D![Q,S"RL;_4$!02%A:YHFLG+R"Z@LU=0U-+6VC MU\8FIF9OO#:V=A_L'1R=#/#RIQ\U_?

Q#OX2%1T1&12^\&_^!Q\!V&YXFY5>WDO%&.$9K!Q$*)CYI-#_^/VC_"IG_.V A_[^0_9_ M_B]<,X"(}#>N7QX)+4 %<&%4;L7B.Z"&(XNHE%F\M_7($62)(OP#9YM!Z\OWV,*

(TSZX6DP$XMAV I6B#*Z1+?Z:3&EV()*@ CUJM:4\J.% MNLU5@D \;&?/MBXH0H\KIA)H&5%.?'H%"$GG8!Y_MH2X$]/RVIK!/0C_T"Y M2ZN7VV3X=WD"!;1=3^;]WE??

M'83]6GZ_ 'F\LI&K_>/&;?3#RJ3+SD)$A" MH)A9,=HCF&SQZS+!_*^MZM-/+P#+RGT",&59) **Y*!]@>#QX46$0"MX=V_;8];LHP(D=?(M]{G(3QA$

*M6\5ELU],X^KSQ/.>TV%F#*HQTV?81!KA0!]>XXT(X&"F$G)H[75A>,(/K?"P:N3WR+3;TE(U M'),XBU/KWV-*

*UOM1(B.X))W>L>9@'5SW^2K@H@!QOP16%H6&WJ0*Z+OF;P &" M>Q5JK/.SKE%A0IHR3CIAO"BWFOP6,R!]YBPAO$R2H](!B46S, MT=)QUL<<>PU5K?%O)QZ$_+(*

(5BV;:00?`\X."\MNQ2B+J#-AB-+[,Z;>,;4;6A[VUXPK.]USW!.;-E5N@.@\ DWNR1=S$;?R]LQ^LHD+]_0QZF[3.+E5E

MJ>9^^9"0BZ:Y;=5N5^F;HSFR]W!-3]+2)FK\VN3&8 *ARU343ZOKH6/U%4 M]&M;['3\=BN2Y-8^L+Z*U6-)[.WF&O)75%9-.7XB6!'0:76/*+DL,C"@2\FE*

*M\"*XX.,&U7(^&[D-QZ=!F,:(S"C_Z-NIEQ;@QXUW4=2E7#1ZF 9NP59=RPL3",EZ6!E*/?@]J41IJD*EE5*IP'K%4.=K5Q4+KN[EXK\]=D?(B&GG!:0D0VJ?*

VF@O8$<7BD@VC;!+0:)2,XYC MIN746R%A4YL7QJ(Q&P7\)_E<\]F=Z'*?E_A^=&,Q&8?!EF6T.&>NPJEVU"T:]*-M)IQI#!;$E9.PU=FC@UZD\?51;XI?Z"

Z53%,:W@F.Z=/'L_\!%X_,B5:2.= -MXDU]8=G4E-AR)#9NL%]CO6I%V);8=4;1X6FO]Q86.'/8E)DKV,(V;BJ&X8X. MHL9EEU!GP'R+-4;KR-VJ4?*

O'<@7RF_O)Z4I5OGN=V:PZ/A-"%U(ZYE\>=[B-M+T=J_[2MWN7]1)(9G6"O+.T?DW(LZU#Q?!US$B*Z^%(G@6GC-[H1$T^#.GMCN\+2[^(1< -+61SE9%(*

*MM?]#EJ2CM&3.]Y'9%R<;)1Q[2K#949G>[S)/RF0U_A^AH\'&2I(PI*B0 M[5O19H]3F*\V6#=,5ULP[S>/8%XTX']&/ZX')MZ0W^WCF,]+2D[X[_*:N!K30*

*M.5(>=P6X5(N!GJQ< ?[--"LTE6D5O*Y],\8EAU(PRUWIH\V(H\$/5L?S!FM M?3]23M$PL9FB!OM.KIB&_ 5!QB?]H!Y+LK4*\ 7Z+.OL^9/8?OP_+U>#8!L*

MLI^5&N+M2EXN.M-B;T8B6ZX\ MP;,@L?3K/4,0ZOF5MM$FB+/(3+5%%XI[6M@^VZ)[&7[FPGA UEX9RI;3H_OA M, 9U:.P^YCGKX?/+]3GX :59A$=\P9F,?*

*Q\6X+08,K#L44NQ;W'GV5UV' MTFI'8""9\W6('@T&O',%J-F?D"AK(%^HN) H;S39VVI*O;.0?;;-!V+,=G, M!"2Z\;B2[CRH#/&NG-G6A]QL]XSYI-LB5C& .W M7%SQ8TGGZ©*

*Q?PP2ZV0Z((K"":,H8E9N.]GT;>B?HQD1NLF>2Z[6ZG$)L;/Y)P&ZRM&6^IRCC\T?,?&]^U1PS3TI M95Y;S14#&> <5YF.C"D*%6 &=^O*$V2A?*C?1\]M MA]]!!%K?'-*

*/DOC%I<]4H 98+U3+NCG9J3M^:\FE/P]SZ+O3I>-_MXFN.:>3DANE=+S+V! EV. MBN.]\1'-.[P*Z;#"\H7OXA:@7B*\"?*P YG/'Z4E]3F-4<=S2(3+,_.#_F*

*MK:ZI9)O8*SB7[9]UA:QR4=@ M6OXS$Y[A?-SGI2(;E&X]]/B#D@0$TL7!I2Z"DDZ(S&;&WT"PV4?6MCXU>S#@ MC9I,[.519[V!PB'(0Y^L]E996V_4RKML[YFP>VB-AIJ;1Q*

S(1FMSSZG3O9! MU"H$&[5?UHM0]]9%=G-]?ZL=08/EC^S HM\GK?ZK+MB=LW9J&=+";0V42W/7QW/(]:OB&.X;?W5]S7CWX6(:T

TX+S2IZ54\1%K@S5ERI/ M-Z43"&(B@.)LA'O/O;'.M BX\8C>#.(D:7PD9A;)E-F5[[8ZYFOB,IT"%AS1B_[%(;8!\6%[&@#OE_^O

MK^6G=4"%6[+$_XA"'T#Z#,TEXH@'50.U.P9K];H!94]A&RW)(0+,VB7)<@"? M%!S;Q16: !"WYF840QGG).F>;&ET3FK!^XT]\UVXD)O/51&?-.5'_2)T!CI M?<16YUW<*

*RHGW%.E:@UI_G"KD)".H*FYNB MW#_2++5A2P0PTS A[OPM7@LI=G?! #\85;K;7A:+\+2I@<6IA]HE33??K19+> M4.O$;S, ^H+DI,@M-I@L?*

N;ZU$CR3TT:A/I=;-8C$IMPYX$,H>,9%R=%BGC_':'?]^KG7O_P\3RHZ34. >5!V2FV0'99_\5N86 M=D'ZLLW:X177<\\]13B2-$0J=O-:F>%+M(L MAAK]!CGNSZ^M'[+NY]!#

*<_;"",QE5&-8*G_6ZP2VW^<+]WB%_XS;NVE+ M1?"PVE[611'IZ0 F/T7X CYL,I/],6%94,,+('#D6(>Z$#E,+&+:%(5=-@5 MPE]KWO7RV##](*JW$6KP#GU=++AO1-*

*ZVR9*9)EV.!-/K2\,&Z"O3UPSO^K3'-M>1X-+U=\6,P3V;O_'(@.@$!5B)THN>.53$1V;6V>8.2;HG3-^,_-HAR\\9/P M8<:.O/1Q!O_R.4E[B'7&ICR^U?>-V<'JD2*

*PC>U/6]6AE'PA462EKTVJ9MZ MS*U_",*4#1Q1P)R7^LWK>G.-K/!BGT2@M'5%NSZZQ58N',V?H)FU;CEM=K*!Q!(G=!6!03$@ZJ/D[04)-KLAMBN1 MG>?4IT5L!^FZ@#F-*

I.+4A(H_0OH$\,(4":6G9L6)&YK=ILN!'%$ MIMRB5+V?VM1&2MY54%P E+CZTL6QVTT?Q#?R%T YF[P$&]/.E5&^O?6:+/%0 MM9WU+\#[PWV_7]#O$BH

*0GZO*DT7URZ[0&YW#-P:7?.IZ0 -3XE+\NM3'V*DZ M_N2#5_&(3<YVT=Q,9{(&$GP1P-_6[(>80K<^ANV63.G*C72(:TO#/QXD>)<)2 =?VP-SN,#@] =(O#9/=(-B6AN7#,Q$!*

<')OA1]/YYYZTH_^Y+UYRX MMXA4Z>>"M%LI"PQLH.CG(<.?MP4[%='=_2Z>3^:Z'KQ><_I"@J'J%0C+I$_H MHWK!;3,TGOQ#9 FG?"

*F*G"3>3#!T=M$21D5F,YKNG'&.X77L34\B$-AUG& M],L4OVIJ/CXR476 W(9U!^?3G6&!X6=) *Y;N#:(OM@&=F^2)#MVR.,S8|/ MZ/MJ/&DW\QA-IDX!9*

"Q_^57.Z4F=%.">]?[3A =_-%"$+/3&G49WBOBJ&@* MH4%;'&7.]J3I'|[':K%,+BW93WWXG?RQR!7E=KBGHEG ,*0#H$-D\#1;\YH MQ4OP%8]7O@R.;'>(:[)A6#"(O,7?

GO@+47$GPX|+Y]X&;X; 8V]@S(=W:XQP M>FQPZ)|?!0W\(ZS<88^?ZK^E,RX_LK9I^EG%11IAR0/E?#5OX8->7[Z 4N M?7A9VRBF<>=955*QL5M18HZD)1<#!#0.*

*DX\^C:,).[&5ZQ/)L<1 =R2$ M7D5%_YO/!+P)1IL$TVBA5S@T9FMKE@RZQ0*9D W/;9*+8A@UF>C:E-H>+9/Y M7'-'#763('RQ'8K*

)-5I6DE<+5.G1.J/2D02JHA/<(^X@832KY]T_;/G1[6 MFM11).PTDES!X+%R.2E&E8[,.!ZN]MFC\,7!HKX>]Q> G+@-R]N&3(L>KQ@ M,B.?

OF48<)BV?"6I;&)310A^CK]A7EM6AMJE@GJ"-JB\;P:.S4UU!&ASQZS M>B@:1P#@,_^OY!"'WO5$E01,8=5&'E" M4.O$;S, ^H+DI,@M-I BV-S6.2O0]%'7S87:>'\W;JM2JJ-

%HX=S(0<&.7^]$ 2"Q:K& M7H!#&\?5AXRO[_;SIY63^4S#5FYSXSL\X2SHX^_**IP^H\!V??@>>NYS44_1+5_/VJ+6\ V_)0U(]^59WO&$D2H:D<8!(Z@2O" M!*

*(?!W8MA95JXEU8\+G(8[FCOA?I4@U#F]++[=V0'.Y ,.6QSNJ)I$3=9R>6Y' MP[4KQSTL]T5NFW M)^VYJ.=[# _D]=R&0?ECV63]C?^+^(G*0;-*

D_J.8H(95'AA<0,+2&I_=UHD0X+88F#K=9+@83E"<5EQK=?7IE0.*>OEY-%/UJ\B'25$"[&>%4VI+A*'M'>D#Z)#!,@S\.IVT2Z?QYN#.LC"(BRZ^F1LZK MY8J*

*M!WKFJRPMD7_01M+N\H;_ZN(CWE9J@WR2G@$R=*8/O/3$)_3K/XB]J^'5Y@E[M$)$H;5!9X \ $.^O_ \=5FU-36'' N#'IHG%-2,\.(EHXU)AJ?6/V@Q#*B7H M.--*

*%M\8Y<:TCV^W2OHY/YP|E[_^(PE$,&:_1(^0\Z_H;_#D_X1\7F$[^M!E M0^/QOV%&%_[C*G;2#5 _JO;^\7035$ODP/O4H<%=2_QJ']>N>KG,3AP3,W^[U^HH+1*

*%V_OK7N+QRZ+'9ZI M.3Y,NXO_4EP GQ32=B)W8[T_N7B^<7+Y & K M*G)I(([N-=2)A7MY:0:!:$;(]X?+D9^/\-X4M#4_W@A6_\OP<$[NZ!V(ON5)) MY8\> M&"5G"+?*

$0_K^>Z2'H-ZSX*N@&G$>%HVR9WA]P_\.%Y.5K^!17>W]R(0"IR[. M1JBE"+AYQB5++[.P*<;&<-_C^V/2%#^A3H#?1\R=N2(BPO/S9#431D"HY\3WI(5I#M_)(/%&P.+*

*<)P.*X3PY0B#V*&$,3X7,X*) X.H1N U_YHPBYY;T M<3^O5?\QOM98K0264*(S*I3RX$@5FU)!!-T^DNSZLH(08-;"'"/8ZX3#VY|*

M"9%>:+/<\A0:6!,C@A7K6.,OB$*P!Q):H1)7,<-Y3T#|_,E<.6J?XKP;P.U824["C4>%40)8%?^.!V4#B[LH/*Z\,1_"_NM@|&W!P3 M]\F-?*

*S;,*W[YM,2(C_/_P)02P,$% @ O8$T M6;]Q&0C!^P K@H! !@ !I8FEO+3(P,C0P-C,P>#$P:S P-"YJ<&>_-^]M]L?MB=^]SGO/E/|-\[NN<^[GNZSIS-76U!+BGK:ZE*

*M#KAQ$P"X<7T KF8!]@"2FS? .Z^#]/]=>?6+5+26Q1

*:99HV#=73L98@ZHN_N9O6;\Y)DFLK69.WY68SD-MB%."->T8XL?_2O :4R.O?GM?+?XN\Q]]YP/LYDN!U(-K.ORY5B2ZX(@&MD' M^!3XYFN.P\j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|[LH\'&7!]:@?W:U/J^F-0XD,@P'X].>_PMB M! ?)C,HHRX)]?M?[6?NZ3.2F/@6^7BC8U[NM@.+>ZI#/(.MTO=#?GGJA'|5_WY>'4:6H#'[@-ZMPV)4A=Y2G:R,<6XX:Z]MB!]"PI:B\OE9$/&X-@7\#B\ $W6MDPT01C"^K"B\T5E2[*VFK!$)>GC 7-^P[+WT)=5%7|\O-!\'Y;LNO+'L=^T>NHD6B0-%71M MJ#K3_X+4RS!QW'H3_#'T#BF4;R]_6B_OU_"KHES5Z!G70#7% KHTSK[@4;&64 M#$VUODSGDXTQUKD,/?*ST>LUM00+VQ#>N2S:>GU<2#6_DZZ$:.\%CFNA&6G]M3^+00J-[QBM_[F&BUR\-^INW/7CF*"],D*@R7\KE6UGKP4HJOPAC1O\@BA5; M3!^V=&3&\R2_*E33(=TOR)$PE?<&G=F+ZXLN"^_]1-X>EHHP=W))_U-R+):Y M#"V?VGZBV0T*8]+83BC*PY[,V/?#;T-!AULI'(QCU1Z>?++KQC*/P)LXU?^Y MZ]?9[ZR7UHRY^UG9E.65<9C^F_M>U?TL L$2?,-JFC-O#3F*:,M2C MCH;#4V51"BL;UTF?FXS;=.#*.]\OA%W)GDVIW^=!JNR2UPD>)@_>UO>C=@'_S MFA9I{2]PPU^DMP.P/I9CM>;FG^\:6LT5W-^7ZL%(O55!T1\{+9>O!>23IH[*A5)B.%8QA7Z M\FKBR:+J+!2?AA\OR.O.SXE*[MJ1EJ8J'<$&2;K.-*)KN\8IG?6&C7]#6SSL M%098CTZ_);[.[!?&.@@PQ6F+Q'*S*9$<9\QZ+,L"=.VO -QW9KIQ=_\!73/B MG7;;\(H=0+8 T@FX;H'C8!)**9L:QH'_^1/N]BH8[=X?$[)].I3M68@=G"_M<9VV)!3S$O,]=0_TR[\K&%Y']FI).!2VRB+E\;!,EH"A_[_6#??)T MYSW6FRY?F&)3@KRA[4^A]N +YFY9;KI#'?7&$;][^-29FI@]'/[V,^DZS] D@ M4$,==!0(5+5D*;O//%P#^6=GW\R+TV>/R5YRCI9.R1UF49S&0LZH9EMN-3S MZ58YZAB^KP0\Z6K4K];4$;R|5D[UY'R9;Y/Z;SR(;\|$'B\|C;_E%%F^!4 M:ZW*IA015)SY3OKY$!6 =\X-/MXB<,.8L2OI;Q*+[^(CSPP)9",J4/]7^@M3R MM-E_O:<@R>E!2"!L*Z?77Q$6\;=',6L3DQV@UIM\KW!GVN^7C$OV?W!=$A! M7^N:@PI[% M9^]?&7BSE[*55)YFFLI42:AG2#BPF'^U<;QX;4&PFIS/ /#+3=&U:Z:$.6(?Y MF4&\%!CRF9D?IOO/#%BF6UB!G<=+7BRT?A9BTZ%T!<,CUB @((U<)9B]"HW-! MFJ"5!WXUURV>N<"]\O5!=!C_1WL965)9DT,_Y'Q8!&/<'.[_P%\?T5(&SIM(Z(6A8963U!,_[Y(<&R/47*9K6%9KY ?#(Q!NX9RD>+4*Q^6 /1551^581YR M*=|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|=A\ G!\&:.(K3FE78S?M2 +3B:.P[N5I/+MV3&S%OF3Z\ G3';.M(M/I9JHI);3"<;&VCS&EL]@<1 7^ 3>2%4)DGV)']RMQI>41!5]F)DNDNV6=T]F((MZ*XIWX_1GGNG1U,B\Y3"\A?97CQ<]W=&ZV).3\,ZTE]L*P\.5-#Y.:O:&\VM MDYY9(TP,2!U*?]XB 5!/[$;.>6=)G"B)]%ZX 4OU_A1^.,ZNNN,XBU;AX)]OH M-W6]E"-;42":VIGZ:>LY!A?5J?B)7A"$,Y%[$1N%&]9/Z&I>C&J;=%3J<79?M'TI2NLW^^IAS&ROFT7[&';7[45PF\,& 47;'E<*H3B.3>O 5 /XEX=MYM/GB M'0?_5(1]A84CDZE"=O)#/2+UEB/;,)PW.85L!M[\)K187=]YL"\GZ/@\WLQ: M_EWNZ#>2'YMDVBHB2H$G_-G:)LNMI2VE$H++)f'E)2A6].[HH/ 7 !P5T:@ MH,RU*M/KZ#I$9PLW349B,4D =^3=]-I[%,Z4A'697UF^ M?0[P^0M1B"M^_=4$0)GH3##2_34QSQ,]LO^P=K"(&G,Y29R M@&!=[1NK;*9F$@,W3DG7@EV:)V*%AD2R%"N0_5:UP-:RRT$HRQ&"WM=E5*L\ MB,=1UR6QZ\F7<3EC"#0;4AA-:+0ANA$D !?6Q'F#BO*176N/0,\Z6.G:FJV M-Q^0/X8QZN#-RB@54B_7* 2K$F>EDW]<#O'^)<>\!\UZ:UKU MP(L[O!=)BR^RB,8>RU%BP]W2+]0(6'U#6EN]88G4S MT:)KT>?D.U)/W7?EY':,N#$% *4+5N%6](3$DA2$7(ZFUV:$CY&EL]@<1 M7!%S0UVS+R,1:WM)MLF?KQC{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~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|)"?'E,TT3 *BBZ\>0Z\\FH?QG3&*?=]6BU/.O53CU&R0J>U1 MQG<'.I]S$WQ>_KL"V ^3ZQ9/M=N+7?QL:O8UIZ 29_]M=N\15?X&BHMJ3*P6^WB("M@Q_435V9DE M7FYRY/6G6THF\M9"YW+%S?-[=LX0I$ES"9?QA<.U3!E&-DOL]UK$+5'B(&/ M'< 8D13$6%U W0-6F\M=XB?Y.UO31L>=6HU.]^ALB49"8(%3OE43O.K`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|)7$-IVS_;0]U> 2/OZ]%&15$VQ"A/] MQ"R/6/H0?V[_B_>I?.FR\6HU.]^ALB49"8(%3OE43O.K`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|)7$-IVS_;0]U> 2/OZ]%&15$VQ"A/] MQ"R/6/H0?V[_B_>I?.FR\6HU.]^ALB49"8(%3OE43O.K`_F M0W.+QG:CAY*9W,5MX']*=KB#3I5[Y:EC7'EQO^"L MN.G_5(%M PX948NED<2]AK.!]J\=,^(EBA,9HQK?:,E7+2/&A;Y^247N'; M^I[T*8)D2419]NN$;3GH;YZ0]:[^/?;BEAWIX:.,H"SEYN@C&@;(8!QJ!+8$ MC55 /]N:RN8*^)XG>9<]\FMD 6_+70D9+((2>,/XMY_ M81)Q@-6/3O@+_ 7BE^668?Z0-MH1 3R\)4^R5G6@.TNLY);8S8POL4>O"+U< MTQ5;T]%&M4]6?1K>2%<,KD=J;<[B[==S/L/;J:.OK6F,2G>4&)M$[-=J7*N M-64I8GL:]/3L+,"[M'D37S?< ?UL+<^JI#WS95DI4/7\.U#KX^6/X\JV:Q\5 M&G0;,]+*57?=0M7'ZQQZ'^QO])\?*N_V@CF00T.BSU*Y? _UF2..G;9=)A(2\T_&VW%7H!FKN6/A=O=FPFUKV!_]^$5@*)K*8?ZTYNJM37A,Q;0&M'#P M9^_H3"!0ZV;3??V&NL#Y4J(5+#KRE3+_4" <@RZNHEA'FDXZ.#BL7//RPK_/IVTX#E(W_\'"/,1ME$*N%K $4"5JY82$VQI?78 MY -X2?>N-"V"#_- DOH80.=SL.PUMI1I5K451 MNIY_?$);'HR4\L:,;7ASBS%GGM%S4ZC.N8I"" =URV4S&KT%@V)%N=AB?*6 MX^]'5"6L#RWQK]14-GA_&XT,RZT9)|)7$-IVS_;0]U> 2/OZ]%&15$VQ"A/] MQ"R/6/H0?V[_B_>I?.FR\6HU.]^ALB49"8(%3OE43O.K`_F M0W.+QG:CAY*9W,5MX']*=KB#3I5[Y:EC7'EQO^"L MN.G_5(%M PX948NED<2]AK.!]J\=,^(EBA,9HQK?:,E7+2/&A;Y^247N'; M^I[T*8)D2419]NN$;3GH;YZ0]:[^/?;BEAWIX:.,H"SEYN@C&@;(8!QJ!+8$ MC55 /]N:RN8*^)XG>9<]\FMD 6_+70D9+((2>,/XMY_ M81)Q@-6/3O@+_ 7BE^668?Z0-MH1 3R\)4^R5G6@.TNLY);8S8POL4>O"+U< MTQ5;T]%&M4]6?1K>2%<,KD=J;<[B[==S/L/;J:.OK6F,2G>4&)M$[-=J7*N M-64I8GL:]/3L+,"[M'D37S?< ?UL+<^JI#WS95DI4/7\.U#KX^6/X\JV:Q\5 M&G0;,]+*57?=0M7'ZQQZ'^QO])\?*N_V@CF00T.BSU*Y?_

*M+=N!]DZ25A;S*PHK[MW0$T"09/0XE@63U"'+FG/ES#LK1@FZ[_&F3I7P+T&M-`M?L(L=T\PE/VQ`V%UM0;@A%EZR-M/6+'L)Z1.K84+O#(-['4!T6U;VD`MS`[$7RE3I<#*`[OKXKUJ1UZ'PK^?7WQ5;1^;!V"17V4:`4J"(\52:# `MK6W0.*\,,H1T22/$_LU@6#BH9?E`M?:,-8Q0!.&,_.U)YT.0$7`53N)@P"&A7J_M0VC8+H$BN/T5OSG>>^[4PC!^=`M;L9)(H)08`M>B>`@/02Z=*5WD/OO19-5`MYISK>3[?!\PU)4CPE&(R((9+"GIO)_5^M%?QSAOUSU5^&{3LW6]V^]!)WKP`M\V%*>9-3Q@L7UJX^_>[5PJLGS;(@!GSRG$H[=82N5LDH{!`3]35YZ/EIMJ6`MCRK^@:_O=)X-&C/CHE=7I%;W(P[^,!Q.66&<,/S`)%0P94:87B-N`M+E3CLGC!Z$.4Q'#P$UE,^6_A^4D'EPV7%N&7504/M(YFM]WWMW?4C?Q846V)`M*_LB-=>?NT@U>G\(F`UB^].]S(@)\H`M6>.!$V]SS'JWQ9.DT..S7<4HPYY7R4-FO3>!?.S_CJ^KE^D[^NIO.Q%@IKT*.`MCGI+.]*TL=%&G;Z'@ZX6I/(Z"+Y^S7T`#41=,)-(RS!KU15SCC11G`FLQ1N?`MG#`!-:0/4X!*..CSD)IVIHNWP`INSEILS G&ZBPOVN9OE!';3V1&8I/E.N:E+`MMCA!!65*7=[_G.BW93V0C/IPQ&>^^5&!O-@B6KNT&Z\S>`_IKV_^9U(`N&`M$/.9EQLYGTGGX[2Z,5VWF!?$++%/65>75YLD`GHUIF^X.Z[DB4A$UOKC(*_`H`M6K<4@!&+JPPN7G\YL36R+8$[L.[Z\"K"=8-&JQM#=AA{(0-L#QMO7U`/@HA*`M(*_-HAR:X&O+,\O"[=BRT:QB4SMC*U'W,W2VLI\|<.|(\M/W0(%I&M2?]4@:`MC%OZK/EK<(5MC:\<`ME4NTM7".EK:CO\29V33<'"Z;E@O+=(!8KG(C5TT&I=^'"?H[D&1D1EEG9!&?K`M2&L87N3I0/8&^PPI.DJYER)Q;"U_L-P.H++YN4Y7/MQDT?RP-9@MK@=#3I1.`MJP;89$W&BW+1X^E+]XC$2LVU.Z^GOPT^)/*CNYIOO3J7S[<^R"A_0.JNMS696H0O,G5F^UZOJ"\][MF3G MUB78V/TI7R&R\%'%XT-A#ON/Y3MZ*M4?P/N;-#-]'"\$)-X]GK*`M,F#GA715E7L3%H)M^8;:.--.]IZ A^$&;^D.]Q0KT9"F/W-PN]I^A-XOYRO7-MGR}?OM/CW'FDD1D-3Z<[VSDNT77EDG1>8##B,_)8.E,^.X'!\?_@%N5L"KV;[`M7X-_1\Q1ES>.*)J^Q?NH_F^UN_P/U4O3^AM;FR=Z+X@?J.CID83=U\QT>7.#MZ&K"W)Y9.4C]]J>@'$ZC{WM!C#HA7E[`S`]U;FF(?7>VI9GDK@!/-A=Y;BF`M)N6X`1`.W"(Z%Q1C`PBMU5A*X=14;W]BJY>PAN"Z'\]86GU,HQ^3F>%FY\" M,S'62U1HDRR*4@+|?)ZIKU5`X/Q[O>FDUZ?7&<>G4ME0-?W(>F_B$P.'U^`T/`M1>K1#+/]& <=T"X,=I&/%%$N]:C)AXC_I3OT1.*DTQW6TOO^EZ(.5WW*A9&C58W$[Q7Z1*[?;I_*(QW6Z`M9UWB0XY`6PY$%:NK/5EG)/]$5+DW4Y?X_/<26LD[=6FFP#[}>^IYLCFWF.D2M_%R*WB>MZ*%0S;TY[%^#;RMM4]C`-4)?\Z(ZT&2I5FD0<[D&L)H5+ABO1'FHN]_@Y`MWRI/7"!R5W&RK24M&(&5M!L`X0%!0RK5:*P,RZ'VOHX?]"'*3;$*-ZHKU[ZO MWC%8MD3M/U!Y>T_P]*5+WI+(ZU3_M479)S>`OXT%-X!MR3<$>?_7@DQ4[PQ:`MP5*:S4V&F>Z[`-\5(HS2OVH#&.)LV!AASYAI<%*^$0V+GL"-.K>BQ0SI^(`M(5J+> <4L4;F6`1^#VA.8P'4Z5L+G%U:XOG4:O%X[C;D9=4H`.98)T_$`MJWMQZ;!7BX*I3N1,@J6?6)+&*0MS/_+2&>3FUA`$((2B1#^I55F$CM)I:KH0ML_:I6];+E)`M?4+U'J8PRRD#EW*,D#);J.\R,X-T/A95}?+9UY.!IZN(FII]4;AZ3LW;IWNV[@AJ)O0,11U5=;B`M5^A,FPX=&;-[6RNZ1%U2)&^V:F?YKD4JH1W3YG>N4LC05VU;, M/8:C)^L1EF@YK<&U%?A^XF2VFVAF>NJS*,>S_<"^Q*93K^I*%C-6MK@EJ2U`MV&;1M3(R4H*O2Y03&R_GD?R[F)-PS*TVU@D_VMU%X2JT>[@/+ZZ@2-,#?]!8 M39X'OE_VREU,))RN78+,VOOI,Z0+]K39[=#}+=4AB1VX#EZ6A1FTI;6N]B(Z:`M)1?DY"H`G,/H#(N<6S_6UI:>P,O;UX]E[0TOCIH;RL"?LYK+6O?]AXS[9-=E4&C\|:>#5SOKD5"@`MXR3A_:,P165]V6YWD?.N+O[V%@CW(%)EMDV9X?Y>MD[L&7MTGDTOZ#5^UY'(`M\Z4EE'O[>L)RI(G.LC"*.<^\K(3G?GTBC!MQ"3-\2N^U"?5>(C.#IT5EU^E.`M7!5RE1Z8],3V1#+8B!8_[<#[\\"7TB#?`MQ^+_)=2-9Q7|/#IV2O)E-S=)H`QA,?`OG?7L/O@&4%TF':E/YD#$/O#)P>8XS=4=1:/V0.+[CP,GD`M)<9?L_Y*+#$?H7H&7E09=F/2]!Y? 71^#&(3@ILR)'2@Q!4BKV.C7-=Y,T8@N`MK[>6NM\.P%FN:V0_5AF%$)67VZD\Z_6FL$+(#!PGW5CHQO3ZS,B0:>E'P2HO`M)CR+I?J K[E]U:KUK4)DS<45/=]W]^[%EQY(YFID/:CVX<9;E`D9)84KXM+)I`M7'@WC_Z^U`+D*0.:6++.S8_C8'OA9]T#@+O*UZY`MPD(A$U"3P*DYY(0Y)]W?0EHYQWRL#*]X@7^,Z;5Z9J4K`PF%WIP)O`%#R+H`MX37H%VVCA6HTQB`VE;_>-"2_44^QI"%]M*C]1_1@^;PLTWQN78__Z'06:.!9Y`MV:[,OPL\DEV?;)'(M:4QH!&E,TM, [!W\?6QBDNQPXO0C@!+@4<^TG`DG'WMLT%T6*[_&3SGBN[/=S/LY[_#^*(#IZ'`MO&__5E/N$,$VS<AY(',9<8EHP2J'+*4+2X1(fR/NK4/>_^E"+7T9Y<6F?`HO`MS4Z08] [{C,;|`IZ0YSE*G/3/%(WZK|MXF-/_SI+3%A,+[.3NL{Z:NXE&[S`M!DF#7O\;@[W$56!8>^U8]Q*MC1\'?$^;P4.]3,FV6(?!?83Z(>N,9P18^-P+_59K.%?`Y3^F_^9KDSPSH;A,91% (:IC]5=8)+CQ@_#QGN6ZFO>XF_DDF3";;$]H'#6BCPU1;U>$$]^/@`M]X/=C3%9.O+/%68_.5>`EOWYW-N"+?"=K*.24CE^#($9W7SF7ITC(SP^!;UPR-YKEF/RZV\DA+ZV: M_CRK0]?%SDR#/>C(_=-O7;).M7*+">><<.(GS`MYZW4BP@IPR3Q*;Z`]<8AF&!3%G?[#!@R;'$A-IW$A+=<67//IQ_H5-<?0D;:`MX.EMQ=_]G'*PJ<'>Y`W@.1HUB>L=N5V-#@BSX)N8SZ8!Z_=`M9.KHYQF^!0QJ#BRF3^W^W$G'7.&+ZRULG.5N2QH02;BIG_LZWT_Y72!$7Y>YF`GR0P*L\"391Y`ML$#05^!L=YBT3)L_V(Y]:CKPV/-C70=MG.V:/2\ M)@WU*IMD]7?'!T?<_;WPU-1H,9`=9,.BHH@N0CC/WLQD^WB[?G[LS]+L\!A\S"=!.#:%;5FT\?T`L4C!P9#P/^9D1M#V\.EC+UFF>DWWN;AD`M7L5WW"?\]>[@F6, M)O6;4L(0W#SV:<3YS5X62IZ23H2A"++99D-7!?$=*PU9^9..'!.HM4,X0`M\@Z37"]Y\+>KM_N/RV!W9@U.!"R%Y;K\`BV.\$#-8LQ/CG4,$(=+NH3'.]W M_*&E^4F^<3+SWN"!B,=*'Q\'I(2S]X[,>6@`+@4C!E%]#=(*.=VN;WIE[^H\`MB9YB^TFZ(P90NQ>;[A(Q\R_5-R37WOQR:HW0]^<&(X\,]_C/09'Z4%OVS+;OD MLU=^T^/.!2R5">#?6/*U.-_L_PB]Z4FR8OR)?86W/@$$GP,1^[(5PF1/UN=C/\9/B>;N,4`MF'=Z\K=^DNL;@ZMNC@+6+.\CG1@' G.N3^A'?.]A6%MZ!^6&WHUT30S+"+3_8ESFQ2%[C'A3.3LH`?$=X`MJ)LG(;EZ<,P17EJLD6ZJ[#W9B!.CK&RAX^+A>CH)OO(>R"F;z,)9^+EU=Y\<'[5`M"M*I>$1? L@NRD.AY;I0(Z<-.ZL@%BX+|7]<'$JU/@5E#EO=#5#/N#OA2;A*@`M8`FGFH00JNL`FDC7:#&31AUB]JRSST7^E/P6+-6?%5KV/\SB<6J2MNC7AT@3`M%6DBQ^[9U_P'-<^]@X(YN;N_(+-J95`M/SE6\'LM!]SOXOC^5!-L7[(C?PO]^=%1"Y)]*0PD0Z)]9'G&A5O?KHSS`M\=X]>!%NS"_1&&OWXX3&OQU%@$3V$,GWE\#N#!\CE-A7-TU? P=UWD\\F[9^)`MZH<[L'8=".@D./%ZFY!]2GY>U"-"M?A!=4[0+FC,I:VFY`9"]&;7:BE%I+F]<`MS>PBEW1D4[?+H,591I,3&]R?V^!,PN4%>CZ_.]4KG'3\Q"Q5`MY-,J5]E7^,Z'+6O1LG>G#EM<2NP%/26D;.I+MT'65B/"H.LLSH4X1=@:487Y`M%K29OU%QD8\]J4-=^!I_QZ'G.\5?^V;<4@C$G,SJX4-I)/_XVWR\:HOB=N-M BXT-"HV.VJK247==]K5D7XR_6U/3DFVKPG_!Z"0.AK-MT+X?L_X4]-O^R:ZHRQ,+1VH%EA=C!-^)ML>,_Z0M\|S%'0ZCRNIGH<'4A'U3`M"++>'WU;E=@6P_F56E88A\>]O ')'+PVQ5G%VT"5_.7[^7B:L&XB]->;WHDED`M(XVW28K!fT^GQ.FQA_J[FPZD$!DT=0:.OLLX&2'Y?KZX'3C_-CN`N//R7`FF5 M#@%&87IX;)F!20T.T3C*Z18G5$E/$U.H>/TI_Y=%3B+?@'#@;F::&O_\Z#F`M|#3-BHG74K7$K-/(=P';IHD2:CI4)HNB;GS)B,_J%PKP5?[/]BXU*2T`MWTGKW0"LQQ-\LS-R\IM,"K*P=]M@]QL3:F0OF?C^QA208F9W5LI6%VSA&+:4N`M1)]MF.R+&-P`0'5&*RR&EEJ0)%.KPO"/0-\;ZSP?CPZ=D*;V@!:*51FB/;F*`MCPW3,*!FN)&[*C%TH0J? PV9,?''7;5`\U9=O;\+[YPC\E:EN16]WT5&&5%V\_`M#N%O;]MN%UZG3C#'NA@-Q_>P8K:+PAQW:Q*_ABCE$29\-UU2KGDDZ+7PUZ`G`MZ08 D#:@195GT'23>5!$M@@]K@[1&MT!65B/"H.LLSH4XI=@:487Y`M%K29OU%QD8\]J4-=^!I_QZ'G.\5?^V;<4@C$G,SJX4-I)/_XVWR\:HOB=N-M`MBXT-"HV.VJK247==]K5D7XR_6U/3DFVKPG_!Z"0.AK-MT+X?L_X4]-O^R:ZHRQ,+1VH%EA=C!-^)ML>,_Z0M\|S%'0ZCRNIGH<'4A'U3`M"++>'WU;E=@6P_F56E88A\>]O ')'+PVQ5G%VT"5_.7[^7B:L&XB]->;WHDED`M(XVW28K!fT^GQ.FQA_J[FPZD$!DT=0:.OLLX&2'Y?KZX'3C_-CN`N//R7`FF5 M#@%&87IX;)F!20T.T3C*Z18G5$E/$U.H>/TI_Y=%3B+?@'#@;F::&O_\Z#F`M|#3-BHG74K7$K-/(=P';IHD2:CI4)HNB;GS)B,_J%PKP5?[/]BXU*2T`MWTGKW0"LQQ-\LS-R\IM,"K*P=]M@]QL3:F0OF?C^QA208F9W5LI6%VSA&+:4N`M1)]MF.R+&-P`0'5&*RR&EEJ0)%.KPO"/0-\;ZSP?CPZ=D*;V@!:*51FB/;F*`MCPW3,*!FN)&[*C%TH0J? PV9,?''7;5`\U9=O;\+[YPC\E:EN16]WT5&&5%V_`M#N%O;]MN%UZG3C#'NA@-Q_>P8K:+PAQW:Q*_ABCE$29\-UU2KGDDZ+7PUZ`G`MZ08 D#:@195GT'23>5!$M@@]K@[1&MT!65B/"H.LLSH4X1=@:487Y`M%K29OU%QD8\]J4-=^!I_QZ'G.\5?^V;<4@C$G,SJX4-I)/_XVWR\:HOB=N-M`MBXT- "HV.VJK247==]K5D7XR_6U/3DFVKPG_!Z"0.AK-MT+X?L_X4]-O^R:ZHRQ,+1VH%EA=C!-^)ML>,_Z0M\|S%'0ZCRNIGH<'4A'U3`M"++>'WU;E=@6P_F56E88A\>]O ')'+PVQ5G%VT"5_.7[^7B:L&XB]->;WHDED`M(XVW28K!fT^GQ.FQA_J[FPZD$!DT=0::

XK\R:'0HK<47CL<0R4R6W54H0S)*IRJI:G-&%0]>T:&V/>:9 MR91$"[_C?SKF?Y8@]S[12,OK!@!MX]G"W7&KS[!JFS+S(%8CQ#>H_"S-?0U*.M0MT H[_EVAD4W<\KT;ICS5F,_=?L^@$?3>K$=RY=;> MB:>)NNY'[E?)%ZR[_G=PD]Y)T2ZD4"A+?JZ6?$V>&L M99\0FW=RH/VZ+86V3.;M M>;I C¥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£%NRUO3E-5K_^XT*Z/(WG>=K_MWZ=[??/W&I4C>7#FW$+!<-W/>AM]^P?C#F&G1>Z]>M-UZC ZKB@FZ4K5!!"=5 M%R(N)'MD^E[8SG>>03;D!S.R7[;<@;YV 18+FI P/)0RN)615OEXIG12_; .,O-24_N-..SQOC .\"/D<'[*@_@L_YFT;O_H[GWCFK] MW=9&@R ("$CO1*D* M)!2D2DBTB7&@61#@+2 PITA44! "TFND=P*$*@+2 M)?3>(.$&$L+E=^X9WSW[!'/VN7M_WQCW_O'^L\;(2M:;=S[SF7/..1^5]61A M3? N$WZ9E)^MUB#P#]]7WRD+=Y"3$"4^/|';DBMYQD@5Z(A\;YW@Y.^^5[UIG MFGM> NY__4B'")&<+#D> ^]N*4O01L/RK^56ND%!*CFJ$J&I7 [29 M',M+\$K^]7O;NZ/3>LS%DO;BA?:M:A6Z$FKEV4&Q>=3K3 M6F5/\ M"%4Q.K%1QWOA=4 *@LVY"..+OD;MY" M+BG@:Z8#: [SF&VO=PV(O;]3/Y>:-!R[924O6E,YQVF* U]\" #HF_S>B(&RN M6%@.EVC+N-)-7X1RO?5)HU4YU[Q .)U:.1NTK1+*AO=A8N;OG;O!*YV-KY(> MK?*6J%.JWP47(=!/%/7UE? @W!M M%MY\2/@#E39/.;5E*X)X0)!#7HC1N-;N#2K ?- MKN[!FO)P^VV^XU&;X(IU0="T\]WC73!G/XZ&\"=(1.7*1Z*T=U+TW6_ &!-E MK2!L\;&>$WCKYCH^R=X671^9=IZW" $3:CU)5.P6=^X693+)+UQD]N9RAT MA@UPAEL (2\!7)> =DVHPPLE>$>PE0/?34ZQ-UF#^S[!#E9\\!+L,H)*Q5!C* M>.PAOQ#4H,[6&1U]K3@6($!1E+,QP<4U*ER]*\_)S\_MGH[D?5ZV6EVAQZMS>* MBP$?XJF1T"BJQL;7 *<BJL#$;E53\_ 9=RX7E8PQWUC%/9V8 \_^B]\_D2N1 ^YAH"R#BG:@T7I%V3O3CI]*#\|7XV61\_"TZ8OI$[O M06PP 4,!??(.[P+%-=6>/>-M^&@W]F52Z9=0&?88H[U\N@M&\W1"J8415Q32 M5!V[">09@WSDUU:]*Z\%Q+'8&\;G$?"%"^//>4.;0$3=(.K7M^OOG-N.M.U'84/RGB3?.!@&MK#!Z^<.ER;^>/>2U?29.6D+ MN+0?2&A'@795%[43;FW<4BF /!UUZ:MJ>L[HQ:"7Z (J\^?)-/Q(TS^Z3O.G MZ:03.X .5!!%IR_)=.;@R.9E9;^EMG/@O3UFHNMO0/U"-0ZH9&\4>R7\.8^D# M/"?;"F<(7M'__5\6::XYX-\(* (FPU6DV2F2|T2}B2*ZP@/=2 _%AO;!!U M!7Y=O@10="U#KSOYW^QQ=&1*,M_K]D{1\)}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{!)@S(WB6Y) M; C]@KYQBP6B0[!'JOI?L+ ^/F=DM$_I)>H+G?OH#VR91E6J5.3R GT@2KC 3 M)+@:W,&$]5SR+'3 T&9MB5C1Y43R;@U?R"=T>L._K+7I32R*81< N!*!9WK MLF9J?*#"_T"U*?.?X$ZC?!B6@>KT=LZQ(2\. 3%J0Z'X2QBO/.I$>]\P7V;H%H MYY1!)-^^PS?/4D&>JW59YE,=>\+8W^@NH?H3RJ!['!WUY\;15-8+4'H>,=]UPG M)+$8|EZ\_.^N"W- U6'Z;)=H#3]*P2A#+;7XJPT?:[X(B=%LY,7X)O+&D6XJ'-MNR^LD|!|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|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{}TG7NZR8ZIE,3)X]<'OY*CT M7AKYX]!TO^8#:M]$CW>*NO(+S=GSX?OHT1");[Y3(+6EW;/:PS>^^-.^[MC'V2/')BI;N?R[[A=- IK'PEF^M],.EWIQ'IUWMEK/PL+__NK3- RXOHF00G= MM1=3V--(&=91#Y1TPXNT+AQ:7F<4C_YF\;K*WV8HVJ'XR8L0Z8V,;\](5)5 MACW01/N+@@?1P<^,]-D7WN? 1.#>CI*$KOGU(Q(N2=L61S2USX@*=*-^,>8Y+ M^=P8$17$Z>Q4S9PR:3888U=D87X)*$[R/>B?9IU33&#TI,3D*C&,Y<0'D]Y08!M#>&-,.%"\|<"9*8-3Z%'J;>@ GC6TG&'E) <"%67XTI?,*ZXA*+%Q1XECUKGW* MEXF$E)PC]0%HNT9&^K)K?'B4ZO#'\"%B<6GHQ_)/"Z+XY'E*Z"3]$L!C,81G M""5H1R1?F;+|)>#*

(Q@3>ANB&@OH8VRX!2%@)/O$H88=|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}.$'0N*MW\$IB)0P3&^>O.'+ E[]Z0?:PUKJ=4QD@)Q89]WF03J\_+!W=83S^>\_XMC#V6>&NT8D+8'9ZOV6AG:I#P\.)OUVEGYC7.3? VZ[Q\_]E+++>%1D*MF3A MG$]W3&K>X[3WY;6$8B>"Q+',R'-26-F6DO#PSE'&HQ '/^&E&^L"N \|*EP"M MF"N7U4A.C9FC<_$?&=WQO@0XIDTQ/..GYO'(1@)(V5FS? Q=G;*SH&M1?X0?Q\W^$1]6POT:=%E\")]MAY^1ECGT8.WP,&_PB0/,2D)46A;__M6- NJK(P%(PX,(%<>0&P$S[.$X36!YZ)/#2Y",FY! PG6,]T@<^$6]^B$G@- M0:T!AKU'AD_E%"T75'WC9ZB!? R"+,2D+D 71P:)VB<%YQ07P(^_2_=R0% M.<210?OJ-D#'<\N 7 #6V<[86!1_<.!@#^G7>^\?)14PNOXIN.E.[(9N"?#I3 M%%=^XM6QO? -5+/\%F.O!P>RV\2(fKDF%'K^]5XP&3YN?O 5=@7%;AGF'=U*7 M2[G;ME^^CEP'^:BLL6+H-;6@ST1GPLM@%+T)-OS*BYP.-S.6JJ_.8#TIQ4Q5 M^#ORG5XQ80_W9&P4MY>++<PJ;V M%VMZXH+H\<[CKS[X#DO>%2#C_+7 $028#.6}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{)B'&DB,;AF33%W> .-5=?_!%9#2* + M=G#?$7&*T!X[V16V6Q,Z>MD"'B=[B +W/M_$B^(OQ(O"D*7 ',.ON3KE=?Z M> GH\QA![% !",'^FX1K12!FR/T"B)CA(B _B\W0.AFR9S0T!SUH8MJ_\S_M11:P EN7 -Y O? ^<:6GUOP@=@^_,9ZW0?BV_,73Q3NI(V-]W_[08L03[>IQ\ M"8@1??X]6BBL[1\]R[_04DUMLQ24[99W=9;-5F?>"]E+EA3Q>LL2/=%)(U@? MRS W#HRV499653R27XT7.N>^;!(5*86^AD=I,JW0C\$CIK>BL%0)"H=\$C/_Y3ZX<9ZEX0VOIBX" MP@^\ 76$IVS^N\G/(LH<'"1HO2+R?1G6@'$6\9.%XA.I[1VU?? KI&K8]-MT16&=H&P@UP]R+'"P)_O!V?L(O+]RA=5;U:FX^ CM!VQN_^83W7]&ER^S MYMOF*\\6S?A03D?&^%{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}C.=.WO!=*!)%++N-P:E_5 .59 M;R5;K@9.9VNBUNJ>+!P?E>6 9F8N\B0&;3I5Z]A[4=M6)Y3.TR$[^\@R5^2(2 M%)0= [$A;5EM.4ET"_$68D689N=8G;@]UOZEZ<D[M?%)&@K'E<07F6*L1S:0MN7>%=-+1[U[V\8M%W YIW^V"F&*D"=,,=K=(8II"R M%ZK+[6\243- S31G"N^=:0.T5^].WSS03_[SWI2!U6L>XEZA]-C(%#PV!8<=% M.!H.H[8WI]AQ\7.1<1>9ZI9{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|)YI"XE1 6M&WFI|S\IES*,|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fTc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|2 X/;< 02^.RIQ,;S 77?$%[B73VV;6RCD=]W?*K8?VN?Y4:}]&(&5Z M=*R MY? UM\\P09HSH[B4 >,;.G0RJ&W:-:CK+7S5JUVIAXSJ]\(A&+0%K5#-2 DN M.@^ZH^NRT"2\_Z54DV2#9:S1B5W>0Y^G3Y/LXY\_8M[.-$$Z@M>&J[\4ACT#EL M;.5@M-F6M_;6IK]VLDVP(E);'B.IN7KP\]/$604]N&L6=1-/8A:.R0-F6^ MX9BS@F8!-G_[66OHL_K1Z[@.F;]33$F<,GX\GO>D#)**3;2T3KA[NC!DO7P8 MT:W8?+[2"<_NC= (NS#>N=-O2TM3>@<-,*T/PQO6,7?)\KBTG&^@IK?.XM M%2&#\$@:! HNP2"4V3.RA^8;9;@1PT.^:DU[U4FBRDWUP6NL!ED\& MAJY")GG-.N;GN&E/C<0<7I %PR11!_)I= [^W&IYT_.^6GOZ'|??2@Q\6IEF/-M=J^QB-B(/2U?R>;);>#)L^E&?T.V?L?Q$ MM;K6>)CW"\M]+-U?76\+P8)V0YA9!^^#>WG]T#W\#10?[NPYHNR71SGT6>V8E MJH!"R8WJ3)1_JKQ<1@:D.=6W"HD%V_IASPV<&]!.&GC/R(+OT5^3\6Q>67-M^N!DK4<)8!;YJTU^_C*ZJ)/_H7VIZ;]^'7&+TRX&(O1&3 -M_ Q5@E&X"PK75<]-SA:G$:@3_S(T.RS M[%:+?3-D,G'4/;(TD!\GU*630R6(^W6]G"_V8=3X)T&R@?@OK .!7JH R#,8 M((A[]W$)]JQ9=_'"QZ)L%?D3@WFOI6TK[/^;-*

E[=4=GDF!7;FIS5W+YNI-R MJ()%,1LC#"WF6Z)YZ^=;PHN:)[;_#H+%X-[X[\VP)5V7?ND MQM[=-?-.8VYX$%5-FA764P?SJ]*^Z9UFR-0[WNM&G,O639^E98>T,,:I\:E>84V5AT2"56KD?S])NP-,5!X!J3;!53[=G>/5<3Y& M$S5. S[:A%YSNP^=E3=(‘(32;Y(4%_E>T1K>W])>YFY=X93[3XT(%.V8NA@>MM/]'P0U\"\"S(?;,,N\$G6[+=8Y.LV=)<>IX1E|QN'4'+AUKG)2?Y&< M/S)QV$T@KQ9U^=48GWQMI<#SOLIH@IXQ(P9\ITB/"[@H/E]?=-M-6("2^A*K#GM1NEAK3\NI,Y1=KQ2G4R1WA_UL MO4:8N0PXMLY<)%X";!UZ^=+5@@7T#HU/MX<*4_3P]1C)*D?9%\ ;7NIQK MM;V1U/K5Q;B$H=[ST_;YNV!6WZ!)DP3=EM%7#9889$:3ZJ;M2%]+.[0_%WP M=0!1L+S^Y!J=0^U(I=*PI?#CZ+M%+/\"B_C_VR(*60(1;W+=39IPZG>I2_&D M3#;"!X%4I(DYY660QL5W@!AG)##OLZM1/N8. = USCDCA< MS%=AFU0#$4^^OK/?S,^D/Q;+\C">4O' #J V#;G^_)\[,8P/Y_F9;'MW0C< MTOIJ.";YMXB7AH0-*W#2?1&'ZH)#0!:TN2=6OGH)<\UZ/#\6\]RI*TXHA++L_MP-6)XTN"BXM\@DIRU/D%J&X:R@F0V_2(;8C",D7WWUV. ^\^^]!S?=\|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|JC0K\N#5118SH.;;891&]$W^:=%\!\XX>VUQ1F>^ER^X)A.+)L*,_QG.)%MD[N*/T3HP$;MG?)N5>4O%2^;A3-(9C>+01L>?V!OY"G%3^X%3[77%&@2S[\ M_N3A;EXH0^*)Z^EQ_-!H?SY%2E,^:GU.-_&MH7S9EWYJP0N."K@PT9":C.[M_*@U]=--_UUTJ@9)LOVH.#YI4J/0AO#JGRUP\LF%4KGW9TXWTO>DA$T^OIX*:F+D13LO!10(3A3;J) M@NOM'J,+?R=A<7A,@_ATC",?W9-1$3])!4K,3[%> 4BN@7&G/5<\39)"7$2'M! ^NW1O-J!<'"0%?CZ:V7NRN/KW.PQP66>9 $=B^]

*MU^S%SC.AU#=G/:/O<#QHMTE3AI-?>ZML:+%>XE>^S$;Z*<,_RJ8^43ECI-O9 MP^_D<2..B(6< NP-78]YNL%*4N7C@*!8/ISEFJ3*2WN_>S8:M&)2K+OR=?EM M8E)@\17\1KW/JI1J+6\O82FQ"J5A2_(V*6>D:[&IXRK]>\]ZBN:4V9(G.UPQ77YM'>V.!N"N&A&@H9'&+QO-7CG.,PDU MM]$S'&._$-9]'>D5]_5V2O>; ,(7F8EGMQ4 #^/[J&TD5?=DC9X_![9]LW0 M2/_R@T?#F"58=$&R,9^A]7G N\R'?.FL#R:36.[>*K&[PG\IY>CHXL5NA=EC M[EN0N7@Y'L='-'$*@)]?'G\O7^4$/#ZEDO1<] (WU2/U^MOGMD9>;%%;_"_0SG M&4P>#EY[+O\I=_T6"4UCUPMYM%$EB@'AU(${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|[=AN-$0]HJA&4_)OOC5R8H3S92E@H44SD81.&#?&:,Y$>4 M5PGY,C>1\<-$]JPJ6^NE,D#41.XTZN/RU:(.IO5CLBK)1BD6+A#!^DNTJD<.&B M(Z<^]%.EM^6RXOWI/3WRUSKW'(PM2D?J;8U\'VR-G_HXU9B\/H#LR;SW#15[2R83[]+?8.P'>MAW'[L^L.1NDX?&U?R M4*K*M>,B:1O"NS)X^0(\;WB\.MXLO"Y3DKY,'3-'\,%'(5!-*\V>>**9S>H M\KX8!ST1 K$2LA)86O1XE M.F:%,%2&T/,F%NB4X6XTL)>TY.!]? +G[,]>W7+%I.F9M#&E@+(ZLCD*LM^D7 MA/D^]DYBE$G#-S14O\01ISJ> ,EX/N3"BE,GE,E_#LRT(fQ L9G\4-_KP\S3 M86TD@?6^VIT-^L D\[; Z-FCH9Q=H_F>KCQUA? PU>12/A1(VUAQG20EY07"VMX'?G0@5MBSC=<4S4S2S&M$D.2:EPT$ZXOVF&4 M"HKL-;.>YM2^S/%],R^,3-=[B+H+7RNHKZLSXOPN0=/WM(EI+YA&8 M3R<'L8.LW! [D9Z\V&C 0/M/KP +XM5@@R!_3V;Y,-E[02<%B4)E*0'56KYLA MSG/Q1$>]G[OKP8?-R\/.EO5C\JSR\IK1>XN5E4%\|B\|S<*O:W H!KR^&]@" MN(1G-OZH,GKE*OJ}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};N&^H!. (O4\OR;^ZC0I4]E/8><,,RI>?-*LUNDC_Z2\]M5+!/* M!FJM^G4714_\?&K9IYNK:J'S>*-OJ4L?RDB[L?-O M)>RHN7IZY$,V$?:QY/K@OF? 1>]5)C5-42BY[=(+6R*F\GYK)f"GI,_L;YO6]?5!J;_8*0>XN"VOKT:M)3>N^O@[HK.9DPQP1OXVVCO6QB4Y'^,AA1@+QE$Q_Q:74ITY._T"U&!)ONJ MT!.P%CTPW5SNV8H$^;W!TL_O*$IB9G/GZXN%.SVKDX*R@/0_9)P49.Q5!\MS M;R@_YDP)!/ 9(# UMXT;!V^;+!Z.SNVX/N!R%G]PIQWGS^^B'\.\MWV6(C4! M..HAJ38Z6.67.T3UH;_/%[J/0O%$308?BV!W.W'+>/.DMED0"8]_KQZW)? M6,"(5L4DV'/%230:YE!0O\OP@[2T84M@%%MH=&X**VCI"*1ICXV.R;R'P%/LE! M)2E+,D? >G0.KJ5\=F!YL4FQL):',_K3XY$8ZX=;]48W?99$++#[.3T=;'M\'# M6%2G=';<<>7K^P(AE?-7I$ @CW'NQ]6FEF[!XTVVQ!SP?%[=6FC_:B Z[5;# M @ZRK9025MW? A4@//GRT_!N;WD0%UNWBSG0$%V)3@QJ@^'^VF5WSNZ;R\E>W MB-N,)WK :"D2T[D!OS4)W"W\/0IEDF^@07-L^XR7ABR)L7=2D0$VLUVD"#LR MX'"/MEL'W#3A)#4U7+^ MJJ8>C0AV?F4?XNP.@.HU"Z3V<.P_@ ^HR:>S$\%8$?0E"A0#_*3%X>??RVS[MKD,KH> !3X^VB/U>;\O1!2"V^8N\KFCN"0@3XW=HH"A? SU7I=[CM"G$)S> M=L<"ZXWWW6 QYPMQ5@J.R*Y,17+ ?XW4=0ES;[.-G>Y\#>$MYLDFE>CFML3B M2HV/XLI-]!]7AV\97=&($F3'> '\.;.BH9N!IBCLR&3Z?X4.- H&MV<+1\7J;@ M>#QDM7C) WJZ\ZVJ>D5'TGB&$6A81K!B\';EI2!E9(2K_S2E#'_%$1]JN-H M@*,O7UX;.KRE?G1+,_>-DC'SC=|fX!?03Y[(@*V K(.WLW"R:? [(MEF2K))4*,\R8D_# L.0*[R0 0 M9;ZJ,$D_C7!IVV#K*G2*:VKTI)?'8)_'Q#HULO: M,X@2 ($Y!* VL+V2_1-9W27C&3CÖ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}_IE]NN M:B?2PV*[=-MQ*N%\)6BO4!)YU9D-I-!!WWC*. * Z*]I%Y6K\PIT?=LT^ M7_1,*E,7BPL\JIK,]#6NZN=@<S?;2>[.7O.[\'SR>"SA%XAOH>)NUFQ6I-K[C; M#W^. 6I\N:$L%\+3%(R&M#]? \WOP_B4.^>'0&5@0?GYDVS*"#&#M7,(F:,X7 M\'NX8K**LOP[E.1+LHL<>EV-E;R:B&3@X/H_BZZ&($K5\TS\HD M" Q>Q!>V^4#;FK$"N=O8:N,P4RUNU? Z=L88;NY4R*)!0WB\ 9Q#U.P#?OB;, MFZ!MB;EZC!M-I_Y9S2WZ4PT=^NWHP(APM_"W/UY M7G^'F_3\5*@#Y>QWEVZ8NR|"6;>;"OHL952H''^5R!LOM"^=A(I'$N,P:Q9!5 MXJ1EWA$XSN_D&\$)W3{'R(?6*LPV_VT>@>G*%|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|[6PTN4'?8=N21Y?PI.Z7JU MKT,KK';#A*G-?)^D<64=Q;,8/>+&7H$I-YMM[2_+Z*JI]%W07X#0UEH637M[%M#:!L>]W9B#??B|/BKW@C>#B7N[6/3H5MM|WPS+%A.3CTNYVZNJ$S;!;B*8O MXBXL1F>H;@.0[& #N9U1);UCD|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`K7-%716XZ8>$,,ZVA@AO/DX*8@UR7_*]TM:L\J1M]43DJ&WVO2_P]-MU2V^%U<[O7X)I:5B.)3&9_$%M/)\?342W2/&EN'6X-)AS MJ2F-&CK'H\:)C5J5'|K%E]-WX_: <4HD,..&")6V?!3.+GXVZ$Q^H4<[*IZ8L M*V( <-&*9(VWF:P"-H4)ZR62)XNH8)%[5Q;M,S?H!$")'9:F?K81OVY7V(<$ MGV1!@Y2/\;1>E^2\)>AQXNG&:EJ#D+3[`1%|Q091OL* 9.MH>'/ 4@",(.M5F UQW0RP(./5)OGD[W'E'K2]\3!S%,197<(RYWK.M6\/SZ#==!'"%8.? =/Y';/E%$7A@S@11TC%$^.?*7 I@(*\N-:'"'!#ONZ]0RZ$W MJ5;P3YN',Z'TV%\C(&L,4ZXS+ZL.<,T\P--0WL-E.3;4LVSOT/"#RF+4ITD& M=A7I<.%1.;X)@C}[]2$XRF-.- !T)*OT\YOAEH1G_H.$MJ.C M[UV7F[] -+%21/L#]A|S%PB;&/L..6)$0Q5Z,YY68NS SO7:[U*.WP!&BQ' M&Z.HC=GHXM_VX.;NN3,JGE1P)NO<,BX%'(IY"3B!_R$O.YYL.$8 [5F(3P?E9NX'O:Y+?ERQHQO(MT;LS5E>_ZC;M\:>@9 MB8'J[R97[IU96^=:MC6_N.9N4^:,ZMWR,5*4Y_G^VR8O^F9GR_TE@0VHL8%G M<,/#;"Q$M7KXT/Z">+\TX(G!>$\EJVP:N-@&-;!6F^(.WEDB?6=%UT?L27R3 M$\HZ-\&"F^82G4S.37=AF0"?B.4QZ3#EXOABNS2=849KF5ZU0 M=0^> [.5F[OLPJALXT03"0N#.-<67X6:K%.8G^N7'+I6ZFL_M_Z(AVC.@LM%)2GZ$/R@K@9:U)#3_NK|P4MQ#@WSV9[.,)N_;OMUPU*JC%,< M=Q@7^WE_-)VI&Y=@8|VQ*V:J._M%N7GW3W+A',_WA1>ADZX_C"$"6 ,,AE MAA NO2?PIAA.@4NKBIGW6CGJH7:>7#&R$_VN7DO$6-'1GE"%$B%R|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`"'LVU)62*#2DQ[R"8F$.*L0^>HA1L7UP> MF/2Z4XP|!D#7.) M3WS 8WOTO>.WB.3-7&SPR'[12Z]S%[IYJ;F/.KT"%Z8- [W/TWX24FM^:.95\3 M$]F\L (9"06H"\+5EWE_N-(E<$F02]GJ#ZC MG?;4T[GJUKT3" X-IWKS!<_>5P>?P/=VFVUV.C4%EOTZO8[T#V*M=@=^YWLETCA&8<'%A+ <=$]Y7,:T\E#-$===[)"?&B+<=UQO@D=SSG4;Q(*G7 M0.@MK>XF@_"^3X-O2)!-KD)O-<2,*#Z" 1ME__CJ/1RKG[KRNF(*90;GVH+ M-+^`'F@# 6Q)0'1*A&3TM}>CJOLA9ED"ON6E\V6WU;JHF';,&KU!V[\Z"/1^ MZ=:,.> ;PM*YY?644&M';K-SG$O/SSA>,CH&K(5C]9ZG+CY>;,%B]WTW=C9FRA?GL!R4S,("@AL=(' M:]/BCC]KK<)9OMXQ/)(Q-592O"6T]XTEURK@WA"}4(%1X5X\)62'0'_, > M6VFN,(AC*9O_N+RPVVQPM2IMWZ6ZLRO},%AZGS9<:\"A6D">9>$&>&|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}(B_(2@,U5:.6]5I_V]3@E%;;,]!18;Q,+DS!!>4=H.#[G)PLV 1Z=BB+B;6F^,8 M+%YDH+<=SQV!9=\2;FM00*]VZ=*+Q-\6K8MHWOR-CYS3U0SZL/@<\"<,A/ MNW&G93(A*MZKRP&Q"(%]>R=7\K<8]\;5HC(IN)OX+N_1EFEL.W^6A%S2 M0U=L8;WH#'R>HZZZO=BZG7]A: {'TJU*6X^/#SR0YFH78Y_6+XRP[=WTG9B*-MMZ6]CEBUU!83>@<-N)V-KUF>GEG>]2E=R;JU%=7'$I>T620N%C"K/#I_3OIS-M"F6S>:2[, [Y\U)U^=.^,&0^MS(l8:)V_VS+^^3.MS&U>=0PB+Q%:E\CGY#P^-FCTMP7!#F:/'99;<-M83]>W:\./QW^-L+[XD-]]:RKHO^2},L^+EGOZSNT^/D5]HZDO^2-T/WBX<-,< 6-%C)TPM9MSJO!S^FB?(/1[^16C M>932TITRVCD[UC3@V]2LZ8>4]D6*M7$^CL"??H:\I>%]LP(-5S+...M00UJ9'B MMMS.7GOC>EBB.O_F,]96"3Y52(BLM2QSQ1;TD %3 X0!>>ZS&"!IX"+-CVL7 M;WY|CQLF UK/(5N+=+0;ZWV@HMJSC%/NG#R^8A%BB.3!J QFHU;9@_ @50& M"]B$)011- #'W50*:H9A/,1>_053R8'IVULM^R2.X^${HH7SL&R]NEQE&^9_2 ML.N&&2!"FNP-3B7A]XIRKT<]L^^N'#B_D;19%G.&#KOH]*!U"G><;9Z>_[^???RBN EY]C$[0B3R IFI>.0.W!^"(9 M]]%_3]&;H!AD/0"9K@:?M`_;#N3\%\&-QNYWN(AC2+UH+]YG8QY'-KKEW#+WZ](_5?WD^P;OK\7L9(UYMB_Y-T3?*A\N/R!%=2,TYFA| M(XX,^,%XF2=(_V'+F:\"SIB9\]1&O4'HK:>BJC+!?9( QPD78^'F/_*XS4O9@-M^OTS,Z33\]$A/3'?X_4!;!!_@&CL6C%+35E=`693G32C8M1E \\GZZ|GAPYAWT*C=6F|U7B)E>$! <5X:FOL0SY$-MWR5.1DZ3XCQ"!?]K'LA0#N#3)S=W&=-^*|$5)1;3(%?P$;<5NZ4=DW5PVO=:5-MRVP!Z,K1_6)G:V&/U}!(=U\BAXI1Q>%IWXZWY.X^BLOE:!$Q MGVI!CP? >H(+>*FIYHGV\<'*F6[43.B0I^BJOP>_7^PAF'8+-*FCTMP7!#F:/'99;<-M83]>W:\./QW^-L+[XD-]]:RKHO^2},L^+EGOZSNT^/D5]HZDO^2-T/WBX<-,< 6-%C)TPM9MSJO!S^FB?(/1[^16C M>932TITRVCD[UC3@V]2LZ8>4]D6*M7$^CL"??H:\I>%]LP(-5S+...M00UJ9'B MMMS.7GOC>EBB.O_F,]96"3Y52(BLM2QSQ1;TD %3 X0!>>ZS&"!IX"+-CVL7 M;WY|CQLF UK/(5N+=+0;ZWV@HMJSC%/NG#R^8A%BB.3!J QFHU;9@_ @50& M"]B$)011- #'W50*:H9A/,1>_053R8'IVULM^R2.X^${HH7SL&R]NEQE&^9_2 ML.N&&2!"FNP-3B7A]XIRKT<]L^^N'#B_D;19%G.&#KOH]*!U"G><;9Z>_[^???RBN EY]C$[0B3R IFI>.0.W!^"(9 M]]%_3]&;H!AD/0"9K@:?M`_;#N3\%\&-QNYWN(AC2+UH+]YG8QY'-KKEW#+WZ](_5?WD^P;OK\7L9(UYMB_Y-T3?*A\N/R!%=2,TYFA| M(XX,^,%XF2=(_V+F:\"SIB9\]1&O4'HK:>BJC+!?9( QPD78^'F/_*XS4O9@-M^OTS,Z33\]$A/3'?X_4!;!!_@&CL6C%+35E=`693G32C8M1E \\GZZ|GAPYAWT*C=6F|U7B)E>$! <5X:FOL0SY$-MWR5.1DZ3XCQ"!?]K'LA0#N#3)S=W&=-^*|$5)1;3(%?P$;<5NZ4=DW5PVO=:5-MRVP!Z,K1_6)G:V&/U}!(=U\BAXI1Q>%IWXZWY.X^BLOE:!$Q MGVI!CP? >H(+>*FI

ME|&,3#;HV1I^W-J>>Y6\PS:UXFW%83_E)V,EFIKQ?I"JA-\9Y$R?|2U:/SN-M812M5Y<.UBPOXKZA2LW0,E^&EH?K2>,QD?&)B(QVU=BV14-YHI-(D?,$UE&
MDJ|AJEV=4DZES?C)YQ!+V<@.2)Y:-'E$`M0\QX!'JL;1H5 ./?,!=78'}PE #<&X^)CMT-Q@9OF;G_9^6G_1QK\;_(X[M=,;C#R9\'AYF!V3^S='Q_2V&,*[RP)084A,=H
9A7S46PB1++_M,SE8KUVG&//(-#P8B^:PM3U4=,;36I)-[^]36XN1018-"23ZQ<+,H7N;9>P;V MF #.G%A.G;(2H7T%V*IYT\T3NM)(G0DI?8*,/T0\R2,\/OQU8D3'"%<_[\'
M$F%+O6%C-$IS6#XT@MVA|"M|H-4>I9VRA|"CQ+RC&L2B_#?[QK MI'V14R#51LI;CC;>\'Z"U1"B\;S8V-5]HYX&)855EZHM5]7[^AKX6H"19]3|F
MN(4O(8$Z7[YF3R^.GIMN1=U/7;G M_L7QV9U?K&*S@J?@P1-CP6]9OP6+:N$5X"K=U[">3GA]Y.E)L;JAD'9EI:!<_MX\9HO%+*)>WP+C)@O/!0^U%R8T"H8
[/L:!N1TGO8>K9-[5[NJ,/6-[,:]D M7G%XR+:C^_+S3%$1)&] HB1.=GSHM#Q+*5L2S@)3?-)PLQA)D+!LXQI8M_*_M=@MIQWW|@M)\Y#E1^QD3W@4K#
(6QW(A7FUF4LXXOK^5G2O=/O6P=B(_]X@YDO,R*8M-M1\S>H;#K$JTI;\@WT(JI<^NEO1W@<^:S;_=53'"<:Z|\'35/R*4FLIO3[H M6:0M>,*4MA+SH,W&T2 7 ?_H^2-
"&BZ/VDWG/VQFGVC^G1B-8W'=0}1!U<__*$ B%38>_0O MRK-_86Q2.?)SF8 8+_6S\|X"S+@$O B\12(G00,E+L,%5#HF4BG":EXVFE$M*NIP7-\'$
F(0.0%O[|HS7Q@2+C]>@PKP|9CXF352DPGNA.:SU<8EV2<6VCM.MS6@R|WDA24N3QXQCQ%Q=HHET1X2!F*ZCF^ISO9P79J.84SS-A3#G9J&RBC%1'FM?
A5K,SOU$8H$-PJYA$!'CN_N[$/I-:?W...Z2$SIV&]X8 M Z&I *$2:<=K&V:HG6*\E)?E4G5;%(>?1OW(#30JHHCPD*&@ZKY?]?&^247 MJZ\,:-?
\WM?.!%D,&L39{LM=^'!;#>983T?;E+CJ_AV1$'X Q=-Q?FW\$1-M1:1Y&(R5#[6GQ^#,7M_[6GV\:VH=|ZN>W+EUF@4>]$G;9TO#=U(T:1Q_2[T MU JPH.\+D
&.GI385=:*FZ2E73V_!=O/^4P@TKK[0I4Q.VL(MWI"-[7"%:R M*.!YA6#C 9KWBISSP.IW1__%&BZ^=$O"5GK6[5469S*_I*":T1'/6]3O7 MPP-;SL>'KK)@\OIWI-
)4I:RYM[D0'LX_H7T\^\.P_@RK?)BC%AOM4+O2JO M&4O2<0$1/PF<5OI;06]2R.HMJ2A2^U7"9-/W8NN1P:6,8^*?EZ\21YFT]22X M7M-
+,5NN:DQ*;&%Q.DYMX:;IT;!\,WN6>&_@G=O@(\'E+TX]C-G:5,&53OA[M*1#1)\)HX%,\1M"6I-M];'E>P!PFNCF|X!XV$]<5<|N2&_0;+Q?,>^NPJ6?;
ME>%2&;.ZY2XP[Z)7*?=X;_M^\]>1KNLOSP==#C8OSR8!N^25BFZ%FDO 07$<3 M=>OL.KPJ&;(JG#'2)&ST|/&L<9\#O)GM@!7'OH\3D)HIG"%]>ZXY;J@|H2F4
MNPK2'B|!#=SM'I)R>ZW"Q.9U@6!?,@CCA]JN\#2#G*HYG655,I?F,.E @V\% MML.-%!=;S>)*:RD'\@=*"K8T6/^+,'|!%L,!?&OMH*--^-?"IC-D0#0'A8P= M+:,&2
H02.IO/!>2ODP%(74*&\1I(^#0+HGRYUGS(:'}D"W*=2M4/PDKFEKDC9-C2U,=-@]H-#9*T7#+B=?_^\N9NI4^V:!2 M8&.E;877+"4#XN^CO#^44P+X*C&'+
RP_;&R#Z>U>|&2=0CDC?EE!P'__IY M:T,$9@.,CR 4OL/24S:""_[:==XP(ZX1?""D);C0O#P5O <,P>&3<8;G("=U ML!B*|(?<1.*)(/3 0; M+2'A_-Y2:M S>VE\F_'K;*\$0TF7?
NDEAHDUKGO2H,Z*=X 7=\UCK']|X9<(%@Z^YPU-54&# M,:=PI*/_*KTM-W7,B,YUG=\#88-;V1LW?IO,2@^M#;ZJC2[!W'_JHRC$H@$ M>=&,*B5-TABC(0'R0
(XU;I]9/L0O'.I9BZJPHIYNA=\;,.C6.0AY*5>X!]" M \5@M[PFN|KJ8(59-M6>,HEB[GTKWRNC|.)/LY8,%WYR!'-2PN,V#9TE!:, MM7,N! %4SE\XZP9,3;=.R8Y*<7ZD>;I.
[VZQ6?#6=.K. M6B.M!) ^UR5+=+#E|&9\9(,D;GGGK^]() ^,FD%4"G36B|' ^UZ M=H#HC3<,NSED.[[P +H*X+6RZ$|$=E3:YGY?72B?7KSKOR06Q4V+$O=]?
7#U MZ;"[B1=?0]<-OK@5GCL0LXQ(F=#]OCU,*BI2GNFWC8 9YZIA M-W]9#K3JN,|&5O&!JZ3#5.M;&YT,&|,9.EVFI?DC0EHQ@TP?H8"H,C-'_9%]O>:CX]0I"(#
I#;_]CQ:)HRD:$_'>1+ZH-1*X3<;+@U MA58/%)$!)QO-K5'_V=.P9!F'^/5GXD-'[M/RS6(K8)E7%0@2MS$Z MVT3I&IO3V!'RV'V.@!L@ V#)!.$6?
C"FJJ:6#$BB6&EY!7_9G[%JGVE-?M7I MK#GPK;__G$L5;Y>X%2,9'S709Z7'BY5_.!;TFC!GPQ Q/!95@W/E9,F#^ M/AD0!/IMC"!2,B E/6,(A^8 8E3\B
,PB"$9C/W'I=*BVN8&RBOG<"\1"\#(43]!:A6R+ M0$CO]YNQ=&0*.737!:J822])N\IS & _.!DO^Z_OE-YV!>*ID,6F;PKN:;WJ MNX;\2!LGLJ:M;ZT3\Q@43L&;PN>
_RU)V!#Q%4X"@&4AB/CZ_1%F7!R"*#67Y M95#XQ;%\!F4)6:$G"Y3K1FT[*1+\1)OW*/PDR/|]#677(KI&26YG_C24_*LA M_.\;4LSRO|:",53|0HQ\1#6A(+ ^J-:Y8WI*
M%P7F\'US(^QZ?Q<^#\7IWO6H/H&L*(^3-@%@WD4"B5I8@]W(^DY.N\B M_AKQ8*:8.'"JL^V&]UB']@$\#[N)&W\!!S^\;M^C4O4(76Z(^_A5OEKL;JA9
M[HHS6FYKW"8=R(0&M?LV7S#K6!A@?-)*;<'Y@#/VLMP9TKX/]B./U\>X_!M M=[;T^,U?EQ)?.&)DRS[>K0?E%]B>YUB/Q34%!C*;9$9QS
M$^GB;>M"_X%!\;"XXW"FJS[$3C(3%-T5?QBE6O!^W?4FN|QADBWXTR!49)[M5Y%O???^EFS+A/"=[V9 GG_ &= $"GZP!2,BG-%(LYXC<"H;99\R_Z\"$'D_ M+*)W1JP-
SGS548I*K7ZY?>Z@H|&PHWD^3=++P*R-=,EF9\5=S/OC\Q0UM2@-M(0I9#4(P1EQS\0/NA%51>%A'84OS_%=KT!WJ'RED -<>':?M4ZGP=G(5R$XL
M2!!3'/G[^U+Y>UQ"O:7_^S5#E< -*#=)[]Y,!0BD(2B"QW(3=+! @7D8B"!(ZAH%K[5ND0A@%OCJA\POJ?MH] M-Q1S-CWVBZ*-9E5X4@IOBUX Q_D@ F65/ L4CAV5)[VK
M_\PGQA?QZYWL .F"J7EDR=D'ME"/JN(1J7N@N%LYV415O.B,S MW$@B TBR3O"M9#BON0G^#H6Q"%>1FDO Q\;S^.03R# 4;[L\1@;. ,TEL)!=) MV:H_X.#M2!RGP(G-
'SC!]_U"!7XN1GGWL;S%#9VFNFXOC-H&|-PL=L@M2 M#33\0(YTH/S^^%+[X5.]!G8\=2\]PA4-$K2ZU)YW MI-J4A#[J8MG|&QL./JM0.V:=Z93,
<@D7BGHD>%;]3JK6WY(;\O2) GL|ATQG M\BD, ^ISSB#GV$^UKX]R:U.JS;GYXNZ<@3'HAJ5 M)"U-P(7K\P$7BM3_>]CS_U:K\\JG&2:\;BZ$87WG;B|&{17M=VLQ)PJ&R.]Q
MY&]W%4H)BN9ZSN1,7[\4>SHAIK3-"X9>$!*+ $$ @8[Z33D1EL>@[;D=A#"1= OT5_]< MCL]2^%+HY]U]5ZG.*8H>51W]\^UP)H;]>>>-?XV\^\V9C$B@7%4?X\NOQ?;U3>
MBYCM1++!-GY@^-4Z8;.#-C^)Y#ON57$P9\,R+^X&1P(4-8VAY$"I"@GAOH[:KX;S-4ILS70)+W*_U=>Y;&&Y'ZP\42_=*+K:09T:+=RUVW[|$5 MWMJ!_*D0YS!?
41$DLI.NP.FB?"DPP(B-V"-W;ZI@#^FFI0M^. M[QPP'=)*=A:/#YW)357+%+5\\=L)IALX(H5&8/F=D)BYKL|&MBS< NRL+0-T M6G,VD.TMSYA=%!GWOUY341WY)H
M/H]3#;_3^P.M0'.M"'"Z& $:OM0$O36!=6Y/D2H(R)]F6)XQ%1TU38@?X8KSY-M8O7]Z:8E:@>UE9C_L7S>_U=Y9JK>)ND9KQ&%H60C|*_.JEXF8>]7CL/*E\@ M.::/$*ZN)0J
/9C!CABEV-8Y9=V6O6M]-VFCO^[N:R=UX*T22:DX_;S_P=Q[1S75[5NC45!4!)3>HP*"5.F=B#QT >E2HR)= M0'H+B0V0+B @"$2:B)1([PG2>X=(**'WDE!"@!
NSWG+|=_$0>]¥X[OWC'N M'WN,[#7&WCNKS?F;>Z_U[%5CV+D)E<*>[<'L2*$Q9=Q_93'RKQ;5FXR%^?0@-M_J9#MW L"_NPN'TM1C,"<@VH8L+;AV?X2$&>M]B
ML>S/-9K9T[CXO+WU9GKY*5>>:\&)=']K&8/>;Q=&3E9^QNP*C?:!;LMG-SIY# M7=%76EV_E"7!=K!?$B!7.AIH'Y#>E]C@^0.9.*?LT/$KA=I#F&S3+&.G>,?_M+KXVR/_K-
5"5&(DAN!U<=A"/9T[QFQ":3WF'YU_UYW65P-$QO%?,]"@C.W@ M(C^TTLY0?>+W*2U4Y7SV1,/Q6)IH=(0IDH"YI9=#T\];SC.Y+VIP_%[@>*:EY#>BV7'-W>GYHJD\YI
MY>Y_:9SPI7KZA?-Q$H9").)-9AL0.8LS6A'UZ6+F7EY<-ZA=)'JAK\V7/+:.H M3KR("_/+"/]\HCMAHQG)\'"#*2_J4TV-*CPSD&5Y\<4G(T0ZKDH)\5[C M.S+.1-
N*)..0^V5FE[3N6<*R2C8#$QV:7#"B@B@A'9U T^^1I--EDGT459C;KM M(">X#D;[4PAQ\#E!ELK\ZCPM+&PB(7"(Y+VG+S-<|%[XM^5")$;JWV-MQZ;/G*
YAH\G9E2_3_SR=96PMC)@[V$<2B_ZT,3T-/CM%9X-8_-!8)S42/DY M9GU^^_,YV<1R@_1*"4ZSN6/E]0,U'@O66+>O9/ZO);9Y,L_7%Y@))6](OLB M^L=8Z!6%)*
!L:H7M5@*7XN1/1Q@UNY-\:1PX&BI 3.DPI0@#-_Z&WF/BIXDWO M*PWEB^\&1A?';5.*UQ?XNJ><#PIE) LZ$V8P7RIW M(>;;.^H.Y4\$S IOEI(&A!:%?9$H(-
IF'T_T;W4O+J@Y Z@W L0P5\A4%@&_M5S7!"' D87D1^9OW6OD:[XUX+ 0H'@J"T\,N3S.0Z. ^O]_XQW\ .HD-!T M6LPP>_?+Y8BOFC0[T957HN,CPE;+LM>6S^7Q37Y%
<^15)5]J5HS.YK'AYSO; MSYE"GLP^+F+SOWCM.%9S!1R>*4W\,C_PH2XZ988/SYQ3-*7E#\N=$H)\2;K, MI/GS8A&1:OXPFLSJ8@@.L&M-"TOB?<'-Z%W^<&%H_F4.W?
#RMJ36GW-RF4F,CTFL^%L# _TC.O^ M-'%\\\]J-A2HX4@J6!ZUIW+TL4!V5SS_^))=3&5>*"WL76+@N$>B7W%5; M.A9GSYV;>>E1;G9Z7ME=H^@[2_PO8AY?797^*-U#
;&.5$]XX. M.+>;Y5.7"%:O0M3=!?.N[@Y_6ZR?P8:F'DNJ0VIQKH3(4>$#(3>..ED-0K/# MS3:8V/O]L,>H%;D2CS8<$59_EP7SWGZX#^NY._9Q'UK_$G1I*;8?
2UR3&M'M2#I';Z%JH, MD6I(X]*=*ZF$?7>,,F0&,EVQ#@H+]R1=H<*\5H%E-QH\/$Y"2@0D'+CYG$LS MI%B;W<2^U8?1$(O!"T=H-+
<3;JY.4\7O5/L2Q=Q^)$(5*-4_&W5G:+POO!T MJ.)3G$IN JC^ 3?5"2VTJZYC2QOOWCVPN=LRQR5A4CONRU7S1S3GAT_[,\0F MH/&@^3Y'WH9G6BI<_[$PZIOOWC>&VI
:G.::S^47P|,O?1QX?OD9>)@@/- MR.O#MX>EHIYE1/3TGB|NU(^-14,0A4^*\"997'?T90 54;+5A <<6D M,[OT^,&38GZ,UC2]D(IY]@7++F(@[C6,-8_(A[], SNYTV-3FLQ?
CAS9>6;. M,*G=&EG4M/E<,2ZKD|=\#;8UC:O;F8&"(2=!?W&+UN$=-\>^4G=(].4->'X3ROPF|UN"-M[M<+"APB6ZCC#/_'"%68.O@]]&&"G-LKC5*G-X[K1.5GDU3M)
#XL+#6HD=YD M(CRQ%QA\FTG0W#,+-(JQ'F$P"Fl:N5OO?F#[YVJO-:5_$LQ_F'U*B_Q'AJTL M\T=(9I,_#;X^_F<9(K0(QU1;I.W-TY2D]T*BA'CM;2=S>1,/FL[_3W'ATAD M,]
L^;MX+9,G@MIRX$9%;M-)PCT^R0/*,~)0&KK"UO<2A2TJ;X]3DZU'+(5?-M_[%V!]"S:IZI"#Z5F.D/K!??>M80W>/!.Y1D\9'3W2@#&K|Y&Y+S<'SF"3(
M<;WT]3=W":D>RH(NA*@6;8#SZ-O#7!O8G$;AN MCVHJPO[>U#/6_QOI$_3F_8L>17V)(0PK<3?9^@]OW !-?$;#5%46 MP]IK,[;3M8M3:/ILKB1-W+M8>"R5SDEF^\;6N
Q:KB.#7C=.KYON /$:PC07 MA6 CYNL/;=UH2)$(M8N]]5 .?"KANG^-U6B&=3[ZN=SHG;BG]T&J8/4$>5U; M_[@>0K\>:-="ZZO<:%;,/(X1VJB>/5<$B
*5U?JEK2,TG(|D=/TS0;_Q:T_M><>-V?]|4:8W_R)2PKOVWY/QL6UE_PNW_.. WH<.SX5.ZX!SK+/K|/04] MK]QVASP?
CEQR)I=.70E0U.TSP$MLF#E.!JD<|+|+6C2C|!N3]^GWDEZ1X2#3WF4)B-)C\@S8&0(@6HCDHPNJDL)17\EMTUO:1[+5W M<4;379U'9>PI'=18;FC?S"4D47FN_HHTG-
GE9OL/Y|KH,1O\?(3MQ9:P#JK MST9/R)20&(:B!45%IK$,\) ^S|D ^>N8^^13,OQF#3SE/|#DX\K.:1XXY6H(-W M0) ^0|/'8%B 'E*8ROY7;-8F8^K6UU.GX|)-J;
ZSYY+U/|>O,#0G/:R<@H$@ MB3=%A*Z<#R+4_;==E MEQ?PBN,DXL/1'Y_O\ X4V,&STIZ?,-$KW-L\YRGM?UI.;+?V>$(KYRUCD4;-MHISH\%-
GB*3EP"|CV$W"!9"6]SQ>0LF4XQW: H,*X$(92@;]?*K(TM"+"KI*N M7&/H[9=(IG(-F",U-6,9XQBYGL6H%__|F.!Z[J8@M#FN?/Z|+5OD0LO.[=?K MF72C4*M"C<5F
U)EW&"<>\U!\1F C;0^'"*,F@HPGFLM&;3>@R'$3P^,E'DT MFIH LYG*M5Y(L%!!4<'<_.QI7U1*XLX@]2H9>'VV4/];E"\!,1&HHF.7?
QSZ0!LB+X&L92*^9+4|G@)KQ;\XT>88Z_[:NJ MAP0>_TMOI;^]&&-Z^+=/|UH=/[!@R^N60H#\;\T$ MYT6M9S&Z#0GW3=6YM/E?
4Q4@&/!T6Z4X\Q:678MIXO)X8([BDS7"R/17I3, MIV/),J;KO,%094?>1HOIT*9Y?'$M8ZQZ]%S[&+.P/$&:XT@$@D,R/OGF;!9M.3N27&2BK/ .'F! S-5@L;_Q!"C5K3R\N2__$C
M"U"S*EBO46@,-(=2N70&&%R2)5\3 Q''@#@L_.(98-7KRQG@$@N8NLIH.EI=']U6ATE8A\D 20\>"\3K048$9SFE! ML:7WX]?2:$?76XOR M(KU%=#RW!)1F<9J^9P":
(YP8.?P>'8 =$8 _Z_M9VIFR9=RE"*0I"?\[r M'N=&M+=<'9VP\|Q+SF^%,; :^8;E^6$Rs3]NUHU@HOG@-K\R=#1X']'38 M2.0 MZ&VL ^:-85%YIVSP_=<
M\:1JJ\MK3[!\1\BD$**((==#:1NL8]><)2GV;Y_7:NB >8'C90XR5'-']33O1D ?GI?H2CS!03Z:UK+:T8O?I4@DF^ MZ:3FS03^G6VZYPKO,#6@_^T6?
WU(8MOVZ:BQ9O[G>5[NLK# M2*]?CO*/S1O/ "V:).7SJ;$OUX"G2\DZ MUMW9MM;='3T#PITK*KX6?!-Z5]0S /UA, ^H=QJ#Y1/:^.'+,T:8G0-)56,J:CIGXG$<$D@6?
B]2/*::RF;(#.?+FGLMZS]?\ MN)+,NF=RH]:#_K:::@H_"[F#O/3\|>?4&4W3_E^1[EUX4)04^)(S@TL=N= Q M9VTHY*1P(IF7>^)\P"Z_EOZ.H*P!K2-?P>CC9:-)P_D4X[U7V
M/53,&>!B@R1^H]E1'7|=..&/1\E!H4A*0H(=Q\?,KX?&OYA^P5]"(#?.(1GY M=T@&_:]W5A275X<#B5CRU2Z[Y@-4/$0% XXLDH#4VM59692J1[T^7C@6+P2= M0\+L^<-
O'IP^>Y)F/*I9MKGOU;#G^5;4_I?^U>%+MH4CD.9;,,3(;?DJS]P\M_VOM']93=UM|UV!7D#<"/&;A[V_A#L.*\FL0[]V^12_U::P2FA-#U0_D&:. M-!__]7"<40/@[? ?
=F^VZN'$Z60M M)-^]'IN?1?E*LZ9 0.!?> T]GIY1S9_4]O15\AO'QPP(ES"9!"4$,+H5,CB[M='U'*#:<9]D),2'0|_HS8S?CA-V.U&'PR6"=\=\D+Q"_=[-(W.88O;[JU^-M?
P4,Q_<_FU9&?P>MA^3A7[*\U?-.TR4-Z'XSH/2_WM7]>ZGXG20?SX]-!Y3F M7_XM>C"&>-.<3TR>PRN8TRRW]=257.XJN:2+K#"XMP M0MRLT/A&'V@NA\Q|3HA>YS0'/P-
\R"&S@^9V3JEXSR'IWAF &'D@,/:KV5R7-MCJ?N&"QU>ZZ4S8$V+>|AT3D5_(_90 CV=|YYW'GIZB5_?]QEQ@>],J22'$S M[_X"=/,D$/|++/ZA
G94;"%SMFB+WI(3B86_(99RD39[/PUS!PI$$UQ[CDB07 M4[3TO7MB_*_.XW*UI__=)XN_OH5R,/R_$Z+KP$-@,\#^UR!)Y.Q75,6WO/DX M3EN(_.!.7B5N^2,D0_O92^J-
$FJA&X%;O NPOIKXHI[V%XDVB/8U6U@T4C&0 MM3[CG/_/6Q3=$CE?N)=N:F%6?*_K %0IP8D.LT@QS%*U\/I&FK2LWCAOL*$1
MB&SAAG@'7UA*,"3!FB|;NK*^D|N/LNC!:Z_%BP\/Y*3J^.-\8?3K.0K#4O73 M1J3%T^3NZ>646)3@VP##$2R+/B:DFSJ.Y[FXTA,.M&)DZ?U5ZJ2YAOIF_SV5\ M[OI-
TM>M82LC7!N_I<2X74 4H.?U=)PDY,)P/3Q=E/3)ATH]B|L6MNWBO-ER-MGW|>NG|G0HV=[(&1D*7)/1/SE0F9_?W)'262GUMZ,**:! X8)W^7::R>% L?3@ZE'<[5A5KC(A\'?
YB>'DV%DG-4: MNOP\^#ZHRF32R52((GST,EH\S/[$R)&$%:K,YTZO+/0GK68W.A*>$\|4]\"_+ M,G%SBL:UPA5KE.73/5>Y'9/8"D-T?X=A~7(H>5/C M&/+ZJ=/PLO +,ITH62AL0;%
MBT1S:QS1N3C!X(8ZI"[W7L.17EO\!RK TQ4*+L]083Z=T>DGFRBU\0Y/;BQ MJ[8+EJ3=]A[UWBU$\!>%F1K6?Y[_*6K=9\,V9-3_V\.2[H/\=9:[_::CA -4P<@'/TH2=0#?
#&!ONX3#G8(/D3;3&*Y?4=WRWPI9& M|BUUMS_@%[.XM!)&$;N -IR-N_R$=&]0A3G_^TG#F'2]B.2\?7^]&Z?Y',GW MW0Z[=X5B(U^U>8]6*:.!-O-;\[>5%%'V"/ XS::
2>9LY2LILMI9Y?.Y.YPQ; M'F+GYM8XT$^CJ5<)_M?-)AJI,ZIZE$N_Q\&2+U?KM:V9T@>KW6-#)^80&M!B\M1^$22&;$\@4!QBDUL-1#\I F-CY7BSV)?
V*]DK|F8^(RU2FU6S+37)4>B-T&= M:#\/BX+3B540#^15SAE3K6&T>+^^8$+TY=(;'KY'KQ<1.Y?EE=YUL7X/#-%W M?U)Q0!)0=[!:F>=/8TLM$Q?
V*Z:3]K])+_$N%,76S?AW#CP7@!I*]IR'<)! M';-UM%>C[/>WO%OJS@#0[X;[U#7^2E!^R. WN/>]XE7,"H4SY?5H;N7,0P(C M43?[1X"YH=4',966.@/F'D0+8X27R6Q(_&=
(I:+GX)O,_:P4T\Q2YY)3A:-M6A3;$A'LU\#/-IW/G")1%E4_/EZ15+094@V2%NABRIE79FM0G*3PAXH\(2\'97 M=U+H0Z8>L_-4^62=Z/)K!M(E-2:NR-F0]5-
]1#O=!+M&%"&1Z-?Y2K_T&G1-M%CGI1 GN$R*TAY05Z65]:-B"|M4W0&N+%|S"H\|89+!+%:RU)WB]^5H#;,(S:|[MS\Z:Z*IJD'!*<_Y 5$>1 M/.0P-
YUCC1N7[XRC0;PW"8"@%\Q<[&\XNTT.T6"^RL@T|-TNZ!KQ\@'T+MN6 M\[V'D4&6*RL0TPH24H*I*T2ID'U++)5R)UC.7:'LHIG9GSIG<^^29LO(F?>K
MK"E1#*9]UU!E6J]#MW^&:,YM]-$T%]*PUK\7MORJ>:+=G7OH(O)D9\>J5)$ M]QG'R/,/"/GMJ0A&W]/3Q1o D%5=,3Y"K3@:41I2DBUQ?=8EFY&+!;4!LPOC$
MDNEQTN7RQ4AU/TVCV-Q"H>LW@=M&]LA^#%OQ:\GA"B%%@;S7 M'1=O>NE[M?Z4Y_2.54UP51HE7'#WU;"-]RU[^]9#"[7CXIL 6)'-MD.1-
RO#;Z5#"2TLC!VM?D@8RG@@T<90WS%'LISDO**R*LX'[EJP> MR402##[8TN),I_T0VI.F'_D-Y_B4>UG75UY>UM\#ZU4U JH$%+$W'5=AFGX[0&_^\#NC= MX$ CB?
4_(KUCZ1.573_7X Q:S@!L >9M+-ST%:/[Q<8MCKT2,WJ-[A_%*3/U M1W;3?7CB@C 6(4]FML V8HU)^R.E#661.)143LA+1&&9WJ3^0'$<=QWN6[4] M[IYIG#K9Y\
(^[GJ+X3T0EAR9C&6=W7061H^,B/E'WE +2GM YY-M)*R2(:J_E65K7!"8<]3HC|NHYFG.-2]RBTI.IPX;UU\"#] M2HOKZH++*6*5UI;^31+,[@I*$3_G2-
1VN5F^M'KL%K'D%=;J-'A,AC+N2?3@]' MH22#[\0?F!.+$!XS9D\.[5Z-%R|B/MQI-C9]38(GV4):[".'[@RO9HX8Q\@M:%V>O&ME 9=47UH0*/(>_.TK&_B1EWTI9'=-=+
MCMR//98A&^HA#'C-652HL!+=#Q>,DIW&J.](K4C_MY2\Y[=>Z5_@L^)$|V/5 MX'G>S^_OM>@E.]**41E?DKZ6/ 8V6*.WFM)U5?)NX6F1>LG&&Q-9%C_X5H'| M1&T6V%JO!.@3IZ9.W!3;16E&^FCM.<|_GA%96$&*83(KV@\MB",R%@LL? M_CZ<<1WN%M+)O*>JS(>:"K96_) AL/<=E)6Y[(44D_#V)V!L:_X\=NR8
MFYRCKYO,.GE;E:FX2$^])$CP.R^\TWP!MG45OV))/%JH+[8ES_\Q-!>?J#M2 M#=W&<)+RN61__G+8Z%>X=FIRFF,?H'*!]#!:1F C;_ICR_?3$?/YP57!^6>& M^U+
[^C3K2!XKPH@P/|**VK&Q[G()'_?ORFK-O'X|\?4#AY/YPML;B?850GOS M;#)NP\,7#ZF"PL$?7^SF 1^AF>IQY0NT.;A,.O]V_+4TO]RZ[4R?C;@M2H?= M!6&.>V_E.[F\Y!
_S@#GE8O #+3]&L3"&'QBN)M!$85Y#Y)EQF^DW-3<L7>,_M>9(LK'-/\>L!DP9_%UF6>'OA/$K%0/S)-KBPXNPGG;^8E]?HMV5+]CS4FOZ
M6FO0Y864GG"3_1"CVX+AW$[<"[.^=(P'|#;<@=)LE=GVNA;BNUL.)!DDK(!R M^9O(09SL>S)M@.8<(}=K3/!<6W5$)9QMJO%!RK"U@AM8.J7?ONMZT\NFIHW.
MKW2A!9YIOYJM9X"R/&0Y'CQ_-^EK0'X+E'6X@N:!VB7$!VG@73/-,"W*P*ZG MM3S\F.H60\FL3!N+B+#W !S0-UA(S&R<)XZG$0VTM>|O#KRUC;2FL/T#40T
M^$)!^PJ5[IVX)9OEXE8@-VP< IB>E^77!Q ME;^N>"=[EA+|94?KG.2HDOD MPQDW'U>W;3E@U:[)X7/%#/[5HYM%Q6+*X')\^HO8PT-^A(8#IL4FVP! M.)88#R@MR0@'#
[7'458C;RG8SR2Z^?.GW+ ^RJ,T0D_|V)XF'YQ5)(("(L"5: MS>]0K[&PEQ3/;6R!|*H,W62L:C]>&5^"|O^QLD/770LQ7UUI%0+3$E&SKC" M *B080%$]#WF4)% AIT#GW(D
M[ERA9%>GM3P:W[&E?G)]|'O>H24Q;5)R675V!+_TQU0I*1^N,Z'@Y" MI.?I+MHZR=053X71Z&K@R+D>(]65D7W,LZRBYLZSMJ]9)#3W":CSZZ[G>CZ*!,W3C(.M(UQZ?
*FYC26:TN|T';W-$4(X P2< 10B.$9"*+_Z'QL^V-DOL$IK_/LZ .1] MXAY>8Z>#6Z!NY&M&HMK/3VV,@E_+&WUVC8.56T$?=L#V-NF6O;#?H&Z4@BAK-M8VMOA[!-
!/^ZZ]@\M&%"4L#FJNZ,%KW_'9\TXA\5>"+OD!|?]#Y-#%Q\ MPCZOV87D@%*79+#"G"S]*ML! X_&-9/$-&#V(#G>C>(0:P-TX+*_%L@>]U MI9M/+=AX(N8$%,
(_^_:2C)?>.E8IG.I"9<4B=<]YV/Y4N;KNX1#CFVYI_W=N. MP[[B^FZ6C0I.4[:LA!GSR"4/ONM$Y*B(DAZB56Y@ JQ:R#>3 M?&QX3H1%H4.<@G]]X3OT3SB/,TGCIX?O?

M]D6F&TF)0Z8A)8=R:A3/BF >$6?4UF:J.?\(+6_&P(M3]?P$P)= .:!#PNJ[-M\\3GL07/M?Z5>EW>.|+$.U1X50LS5=*_%H;B9#+^0MIQN2BI1C0ALF0 M0{E)3ET\CEYB-M[+;OR1FHYHX@H9_-('WNO:T%+PJRQ=NT.0Q;]F!K]@Z3!(M $N)\4 0 '+LG:3Y;/*$7),=C.(*UC9_FK%-9&2 ZM$199-6A>V=RO/83)'*

*MZAU^Y\;P!/A_Q!V49+Q+ECWCO+&)0 7Y%=)+9U!]&5=?=SD10/+6",>? OE_-MK^(,TG_.:\'KWY0%Q8V0B!,,.[+.!^IM(\'+/ D>^(R@f6Z)\]H//4.+"BW?F M95 UX\25L^8=B^:]7QRN)MOZVFV%?^IS:3HET]&_+1F M\OQ3]-D_6H\,!C^IZK@#S7$;S75'P/V_VU-!<3E*V+&OYO)Z1'3\%^.L;-*

*M()H"Y*F>"M(_B2&K^2MUWR.%2V36_Y37)3%W8MEEK0?^5E^O>8AF9O]E_[+ .;G[+&PV%*"N8AA]=[MSOQ-6=[EKU?U'#&?X ,$ZTY_;18K]ZVO_;E 0.1%I]6G?*

*\DOI#]3BI0S[V;C M>[5VX+C]OV;>,\O/+]J4Y?Y_)3Q_*WB.Z51P-7BY*3LTC1I*1-]SL3KRTGU) MKA\<#;ZHR='U_&+M]_(?N1.[70ZL=1PY"6>3\2[BU$=4:TT'!TSX((%C$60G M-MQ0"--3M2 #>7]ASBHWP>O;!=A)#+_M%^]!.SS'B+"XK\:5.(;Z"]Y;:O39I:IR##R<)7>'WA@K\=NXI+?.428U$X (M-D#7R#7C*:N$S*F\L>;-7GXXD12D+WX2/IJNGI:UN?*

C(@K:TC9A[N?!FHK#!\| ML^#+.6?8>H!R;"$ @2S=5(A]2;%1K-5(:[*PZRJ4>"+4/6Y/K!VV?>*GCZ^(>VG'-L"AA?XGD)Z7\='+'$NGZ7I<|-SX(;.M!3VU3$8K?*

*+DI)_J",C|\Y1NV#M-O'WYU)Y3]PM9L.5$UX+EABN|0FY:GE!Z) M_BQGALP^+:BNG 9!&Y@<>FO0#<(RN6;,B_!4>5 IY>[!$H&O;<-W+-^"MK'5I_N?)UC MMX*T8TIL]+=H*NPSU.'K>GNO!1QW!TM#4NB..FN)]G-U#9?4)ZHFESN)@\Y2 M4%@RN)CBWN-Y,$EM3,9@-/',,2SYH>BDD+"SXKL.:+R*8HO+PGI*TR\4Z/<4WE >)3?*

S>EQ.KG -BC_R$J_:707(V;X!?B_7,K5^J4X"1,?76-916*TOD%XC\],?AHW2+VGMM8_=8,L8N^ZAHW2+\VGMM8_=8,L8N^ZAHW2+\PB>F;<'!?,-TI'G9BOD,.5*<74?8+((D)/-U&R!ROLY MR=_;LL($_LW?L2]M3&E7=T&]OQ!OO9"\L!96;3-N/^[>@)0KO3Y^4Z2],%":$^B%(NA.TC/1#:8 M+L'?X")%)3\CXD26N%.3I9-B 4<">4K- SR-G*&@\;8?$6I*

M.\KZ$!',SMG,IY2E]*Q#,,E[UT@O@K3H'24@$+.194!>\"FDI.(0X1F^V M(&QI@@72?G#Y,9?VMZ.31\M06E] O"A++FI(=8!>^8)$IZF)TU*?*

MPXU+B=.5V:1W"N4;FF0'"W(^#&0%5MJTL$\0>.2#6XD&7D7T$'IW8&>A0]O-T M[M-WAQ^LB&^7/-@<:3'GP*]P\1N^5)ZN5+)E*BBQ&]+&]KMV,=4X46V@VN%N5U9*

MW3$;,;'O6N\&UL2:1768;I%E;D"4L?.46*>&\U-R '49:0%)AC'CM5)M% H M>)OQE29VSS>C[T_E1G2FUO[\ M+7O81_JC^GKB5*<(6(6*N&Y%S,-*

#T&.4UA8$1==Y"BSR"R=I=*THSY160TY; M1]).9!5$UIL!SH)$@(2X (*8)VQ6RZS0;=:OKV6C@.W!TS$]Z+",6[\!FW@[1P ; MS-

*MA)>L&&>4SV:#&=#GD3*AMKCTU(O3MD3M*3CI=Y2XG7V L1$Z%/ M#7(O-FYB80Z@<->#$)0LX5I]<[&JR-0M0^:XI7T#)9VA'GDH[^]D \&J+Y<6,V?DA|(*

MS;;D:Y!M:=IU!-,T;8IDP58|&)8EUF88"$"\%R;RM(GTI2, BM4EO%731W^1-MHEEAKN -PW5PVH/0[?>2=[(TF?;#HE:U=:!W\'?8VYB] (4A\/,;@W!)8U?*

MCE&B;=[X]H6==F%?RB"%>#$"\'I"34Z;,PH1@:7B(""SEQPY>]E09U>WY^0: M 7BX{(B]&84IF=S@9+=OO(;IG)\|MXT5S9F=.>^ M7PTNIO#1)[7O]P (UZ]

*M3X34+K|HC'BAPCDJUT3G:.WG"N7#[" <@T' Z#XE4ZNQ5 A4PL-9> =<*6L@=+>)G(>1U38T! 6[4%;.C^IZ8>.,*P#BP+*

Y9FNC&>#AC225XO5'+/7J.UM&2\2?9(XR_6%#"I=[XTC M&W0%$T%=,2DHD?D7#665 UAPJ1&FEO03]V;+73TSS:M-/RS7.M0-&@-0D#8P M/V@T1@"*#JA=/=G8CH+-*

!=GR?JE7-K;O>6:CL3BBRDAC@-MUVY] 4W;'W"B,U%;I]@.MI8GTT'VCGGGE66US_<4!W +3Y,]4UBH#KU#V19[M3U109=%EKVKK $4K.REROM-';2

*3N1Q;:EOZ!.=9=4;F*NS*?V>S[EC M71YH(_OT?E;2+!]V-@G&1B63X5YS$#"!<*,*BCG8$;LX]T.M<-JC8L M)5-*#/A0_*H+=.]@-.X*E%?4(D& M7^,&;*

*<\N4PJ>I%V>XVKVC>=%>-_PE=S>?UT(YZ@S+\"<%8?1 MVW(W&8.@K',]6]?RTNU5\GLTQYNR(Y=7ZD'=7<) M@-&A)%V=%+M8;X/]-8-P#Z=K"OLV*P>S6RZH4@<;T[$*

*(67TB<:H4/+$BQJP MD(WOY2MNY'"%S@C0W@&;ROJZI!:,3/<9PP2/H.53"RSI/MG*B3.33?8(O&&U?.M75-D4?LI@7V\R+,&:OH#3#087((>.J@1I/YXB^Y.GI*

M24\H/OM74S:8W/K:X?7-[LV\VW:FPTF7/<8=E6%!?3UENTT?3$3)/AX1%/M= M7);BIJN':(/OIJ;C9I.34[#"9'N/NTFX#BY2[$U(8<0RJTI3.X$1@Z9.\H/R/@J:

("C&FAB$9,F=!.#"!Y-[K]W0 MC^2/)5%HD@4@S*.MXAXI08&3,!_8HO!$"K,G&:)PRQ7E)#/>P=AHV) MQAGC2.SOY9>,&+U3>,:/<WK]+3

*T**SIYU&2'%O\9!;_Y&4R/G3F[<3=MIO M78&+E5SAT[+)GUX7[K*U=7)?%5.8X8MYM7XG0#-#O:$"Z+-Q.2>R%"W)9%IU-MZ,7N6SLV-*

HO4L'5TP.JC9,QDQHP:&K3(<,HSZ@B&MWWLK\$YAP1'S,N-(:5 MUR!WPO <:WY4F&B;TJ<>C9=1'S8>%V#2G^8.BV]@YH-4H>B(L[+HK:,7-[YP M'+S>

*<%9/;"\P,!Z8.0ZHSQVGEBH/;R!3[OG0@!5C%J!6AY6:F51*UV1+3)H M>]UU61>*>"*05>?&C/6468W2T86V8?#I\Z7'\;-L+:, Z4ZC3I30J95X M*

^+L5%#SK;L1(\"9Y+P0E#:WO\/F!<;B!WPZ3?DP%]K^IV4=SZ&9 4G2@T M7.)GCJQ5/2.03%YO-9=8UE@[V!_]=DMG03Q,G?YSXH#QM=*$K],7252^NE13*

*MC404]WAPS(Y]S26;PJ(Q\!-MK ;F*U??AS&<)@> ML3HJ/3B[L29[-N,(&]%VI=!,1G'CV*;"L#*"]8YS0]M9\L!FR2P]LL!.0-;8*

M]M!#'>CMF)E>]($UE+,W1>K"A\'D:QSR(Y9{$A+-_W$T^0+>_.:(4Q5H, M9$JX2)C3>59YD3TX3^T+NX]A,]B\,=+A/=0-%9A0%; >AQU$'% M1LQEA.#5(^YD;RI)-$P;?*

*Z?H M(X-G5AUGD'9-[;-DJV R+DPP2O8+C+H<3+]N6)5(_9AD^XWPEGC*I7G*%;$B MI!3-6-4*A#PC<@;$MT@ 6LR*J,O7PK/Z0F_O"29M3Z925X/!WDWO_09@=/5"*

*M)2;K$U1I,N'LRC/=\C+266^=GF4X7\EU_P1W^!*[8>K7X='05S-FN9TFTFK, M\6[.3'?A)08RWP-FMP-=B-?);/$POI^?3/I;JB,,4TM6%1+P=_%&$2)9'KE M*J^BCPHJG-*

NB;CZ.RH]rJ^=#8W2D9#>@%$9L76A\XJ!C_pCJ8@C&'KT!J9IS< M@^H-UI48+&.B<609>'+1@/C4-2Q3]U4-V!=M]^X 4_UY+!6^PHE=LHS?P%*

*M$VJ.#7<|US#"""XA4DZ6[*J;8"!(#>P3,^=NVDQ)#VPVG943F,\(@94?1@JO M# IB3:C2;#R*;(U9UASR)M=O=KS,!HU)S3K<[3?U&2O'4I=_Q&4*BO?386]C*

*M'L /7EA/%@G=W!*T&=I__)@]DRWB;F+,+<]J%Y69WMDU=O106MV64=[9#F#;,024?,(?&3<.N7F@]*]^0W3]QZ;M+>?QD;V1;G*

M$G5@KX5)6"BYBGDY87\XNM0VP=#@.D+]725B^8FSATML@&*-D+3YEYR*6M#G MTH+LR*#T72D\K2]RQ.B_+>D{P25;A1:075@9L:6W$Z5K&

M!XXAM8Z!]39.B#2JG18.NN^,0O6Y:3L5@=QL6G5(§,J,N8N(.KE@002 M7'W.BB35"B,P.#1+0"C$^\ Y8"HE,K3*5H0KK!:S97"WLJ0@ @C]*XNYPW$X[

*M2V3+NH&H;=*K:1C,GO.XVF3H#A*5'?3/& %M%@55,+&&351]>6H\0+&;W*^ MI"(BE+&$,&WEGH<<=D9K.NC0_M@+!=*;+ZXK**-5; |\$S(E8D* MD ,EW#1VBQ!TL? Y?*

*GMZOUG82V{Y!NGM[?*ZC!ZJ;$47LC4:*U&G5)UD- M3>B;*/G2C#G'\!?3&,-6ECU;8XKD]HR)T7CVJ4*9F/>DS]T?X0:B?,;Z/Y6E M*\=ISPH^CWFJ]WAK:G3C2L4 @;$:*

*M>#\WRJ5Z,_U9N*4+X2T"$PV2':(1^FA8BJ8W2N@/? M?=(C3;2>U#NIG%#=5W'R%+Z+K>C$K,_#942EY+LPL;+Jp>:-#R<#UQB>>.*

M+B8220#N8SR0Q2WIG,A)1TP;)9#UI775LZDV):XS(B/U-ME^; C%@)Y$S&>XP,>ADG7BU<7M<4O"||[3H13ZLVC[+1 7G&6+,,,?$L696F MM,%>\0YNHW3>;9TQ>OU#*

*[<6YIYUW;3K0$(N.>!U<'EY@@\4|)=|<0P",:SX. M/0DSD?7BT8B1,]K{\2+-D/A2[J;52+ ,#RY?HFT,)(VI5LI9DQ%J2-A,O#'Q M=-3>'HB2O*S9CG!BU_+>7:\[7A]+1A=Z%-*

*I)B9E#IKN'M)RNJ?S=+#8Z22XT MBS50NR1OI*U$W_-98&\9)}(J-3-)#S\ M*7BX56)21@F_GG@9=@=$?X/;AOLW?S_QG[3V\8*)++"5;?NQV,=U$@"*I?F;RWS@>>>ZF*

*ME1>GNP.-X=NCTP#H-R(_V60 >*IA[B@F[CH1X;]MQ0O;)$1UI[_YTW=(I/ MXX:F^A1'#Q_;I:V5]ML4J%MOWC"?6,KB\;;-<=+,,*ZI[4,?Z+=E9^.V*D=?*

*2Z"QA5K)V_8\G@=*O&=7U=>*<-*I"I4@ M"YQWI-[*= J*A*<64[WE=C\'7Q7Y;]XX!2M?IK9D?R4V!0_3'[211Z5[@5KO MIU]A]+B-*

JFE;N89Y;>,(TH4G3C/OZZ;"Y\/PK_^K&S),.&G768PU$XW;1^+Z M\34,<.Y1D9-FH^=8N^#ZK+,_#"Z"/AG]4K\2K\TRY49X@NB4DS8"$%W0% *#&NY;*

MSD^.I$X<8%U!GCVX#4<<?U2]5'Z%3]+6IYLG&IB,/ZJU&85*GZ>[=&XPVV'45-E<]B\]23A MZOP:53'WAG%Y5X]?=TG!&CM[!PU'8)\|[_>5D4>H(G#H$S]V^:;7Y:R770C

*MN=2KCG(]A4QVR@5S-K?B;E<#T(;B(HP/DOP>LG_+$7&*0=.KWIJ9>914*WH# M#@=U,+%!4>ZVQX+Y:06]JZJ+))+>R\FSOO^:2CA17MS+^KC[>Z*

M4WT;G71_4W(HEDYJG,OK!FN>W ,)9356HJPKY@<C RQDN9'3K M!BQP@BG<08(2U(W0'G$SHJB:")_R13P[[?!)7P#]M]C<0&ZH:+3M%0" 0<1_M\334LB<*

9!CKE<,Q!Q<.AYB6^&>7W]ZD-R3FHGTA.Z8AV,+ \V;LNMU:986A M>F.T?F8$\E/8<^&MIUN^,NGL2O2&[4XD]-JW27R8-@.(/_EN>CCHR0"H+8$ M9X=;X&)@BXMR-.0

(D8 UN0JVJ,(@%LQ_I+?,,;56& =*\1Y8?6P[.E?(QC/ M*+RUD7WXX.%7(T$AWEKG*63.=JY0,"*F,BJ27^VD" M'4S);ZK0$&2X;25+[J;S"*

<54LQ=+19TQ=OSMS5M:\ZUL+'THR%,&')@4$^1P MG0!HH61S,4TD]PJ-5_LETE\/%94[S73GA,Q22!'5V7Y=OI;G4NW\>>8J//> M\.01QIV*<18)*@<1F.?W!_H.ID2W/AY8*

*A=;/S7 S_YV)O4M<6KSY.RQDE M"P _9V=H9,.0[K6!.%*N0A*#R66"G3"_!:IVF+E*[6'(BPW?IA8<[UY%O?% MAKX&,27]\(" $ 14<2@ -1<$66ISBPJ4&*

M>5;_I5&7C+B.;\?,E+.,J7[]>.N^',2:LIR1Y-\F5]8C>;DXYZF@ZXF"QUEG MP6UHBV7$.ST'.?\7-\/.![F7;(;?Z%HD\(7R1 9TK%\RLO MK/XX!-)03>UP8HR*

*D3WX(;G:IO<=R<(34&9A*T7 $KO^6QK,V!N_2D^WI'AI2>) M7E/U<:+KO9UQ6H4ECI4S#.IF.U!/96">S@9RINO<$2-1 <4PO'#T'QT4=R0*

*M)UM2)GN/+7:TJ(O=NG32/Y\1]D>&*CD%]G&:EW+ 2@8\>(91 MPSV$K9M$X)24P:>&BF%!CFOS%M&L5(%&SM35\!_@\20$7SX*/J><4,01EY+F MJ%D=?*

[^N]GD5R9DW,02@7#_(5Y6_P4H&6K1:W;W2,#$$/I8B?X!T<|AD$4 M8MPZ3]9P=B7&X7B%,KLU_U[52?G7K(XG3*RW^,SQ|XHC%\#0$P+C%X3@!&3&!CX V=*

*M0T63F[T2X+#CUV!&W69QOP"]O,N50=M#75,75D]6H:\$N=_14-\?R0,[,EMQ MO/%Y5'&S% =W-1)7%2I8*E&=K-J>E42TI"0X(!@(K7Q!=I7YXWZIY8)-*X01 ML{)1RX/4F-*

_PY=9H\$U=FE../KZ+]XSX4[Z;UOC_C7-+^1!%IV;Z3 M8YM.7=WPW;!YP]!H(K@I/WPU57RF5WR#& MW[&Z\,]3Y<:N_Y&+ZEVHJ-4%+6 #F(?L%4V=T10/UW3-*

[0IC5^]++")3(,+/V M5B-9H;%L4/RH&I$Y8;8I. G.7=N'ID49RV>,,. #=O&E M8?,0#/0KI$'PX[S3+EIC0?

*ZF\G#IL^R&Y&EC6^XJE=5ORY>7"E;IOCTYJHY02RJMN=#IG"$85TV>LSRCK"=!6>HHQ|#G-\&-,$"&0CE$_ MYEKD5*UC>&;TEJZ]'RS-*

*YGK+%0M:"0&9BV(,85O2&\D>K_$LF)/Y_,EG6&FG M^<@JK?I1(Z5Y(WW=:@LB+WAS*KAU^-'>=Q>+751;(4U8&A>,{)-"OT9&)A&_MB*S&88O!++>A-%X;Z0X\SM^-*

V'NC!OXJH7;Y3NC!=A,(<(C&V|C+!6%X#B'5# MG20CXDGCLR2N)ZU+S_:($6FY"IT2?9B N>4FEV(I[^64@K5@ PWG,9.A]PU] MH-

*Z.J]#**+/W,_IO/9FN"OAV78AL;B=D!?/.$M'GMZ,.KG?B55M=-G0?3J]= M4A[30:NB,\O3^_KS1W, <+KCLDYY=[-> "V6HC-2L$0=Q#;LV<*J&M0M/"*\C*

M/X3U<2FI"J5>XZ&1ECAXY4+L8#\|F+SB),OC>X2)-M[W;5EWUIV>KZVF\"9!!NE/OA6"6>+J]=/'51'ZOL, V!D:A+XG$'4G1G[M M.+!Y Z>^L.Y94[J9/.#F8W9?

*@FE3WKT"'?M]X5(W+:$?:6.!Y3>C#E*32:?3^J.U>Y,'$ R>?0:%9I24=G?*2P5^Z%((XK4"PY&96Q.+U#3:"S8"DGX*

M\C&.@"8>G=QWELF^_SUA)M.+N%N:N%3)%I,_3Q:)YUE7\1$[;76.DPG%#U\ MJ)@KT19ZY:B+) ^[>+I= RV/++![?Y$V_E>I%D.6(,T:\&L)"2?AM;M+]JO<:] M/:W:Y.,%5?:[-*

#M[..9<;!S.4I3O;?C#QH9 \EBYT=,L.!X%_F5!\9R!(!ER75" 27,4V18(?RJT[<:N@_Q$9]-7$ZA-

M>]fYNJ'@37\9EN(%1W^\%":!NFLA'$XQWF.5W1AOR?'F.4^4[Q*QVK58HKL3 MJ7'\GCPHKK?$8) S%2TPZE1?

GQYD&O(@(2LUR#RT"9/$O&JCVXU.2F]GKUT%?^MRK_=C=C)GLU=A^E) MI9QR;Z<_6B|/?="WFZ[Z_LR5AZEV.&-L/6.AXX552&_9?4LF5,,PU?"6U< M*)QP(-*

+!H,VZTTW-7>% '0DZG!+FP<%9A>-[*BB4^/C]>=Y>B3R:7/-M+Z5OMP?G66GBZW,.4Y2OF/O5(.M'X"O<\N6E?B$ZLJWE%^/IVD\$*HM0=$C}!O*

*M.&YOF4Y!2+#FQZ",N1\[K@Q(]0BR7S23*8,7/;5/1:]R&R!]>+GS\0S0Z^# M5B68$L(^2Z)4 M@GC+1LIQ6LK5H_MUX28IJL*O6T8M67H_"7PT^ZJ:M.1VUE]&6Z09$E+%*

(934 M0>D[3S]F8A9@L,Z5)/2,.VIZ83H=U1QTNM[,2:T&S9[E'8P5;CISBH" M4&6HQA-Q)_/BC:U>BT"(=-,[1YA^_HFQENQRS-\5<-+&O1_[A76Q)-&=;V*

M2;,_"IO.Y7,/\"];C#OA,UU-O>S9-!R8)P"N9(<]N&-W&\1%]JU7$")U=Y!PE:Z0U:Z#5E+?[:]BQT5^QLX$?EN0_-45Z7B@PAGZ/J_MG'+68H4_YPMMI^2'O+>UC%,UGW?

T&TP9]Y^/=)ZX74FO/^C,7^6 FIE?O.8 MY%NEG,ECQG?V,B9:$IWOS@>IG(2MKK*KPZ@,TW^4AK> 1+[7>^4UX%\5*A4: M=UX+4HXT8Y$FTW=]\2$_MOE,/5P,(fT 9\-

DXVEA|%KO)|:5UUL96>S[Y,Z0 M>T%;C-5H'B[RY^F1L#T9R_8T:3&480[\6A5KR.FTEYHKNM#R>;Q?1,,?L:OM MJ^DXK_-

;%F:%7>_ZM=IAYSQN/Pf;OWI:Y\"_&Z9WXLO\LAHN@_L]QDZ0U9= M==;|-/"3D%T?O|.&Q'ORM$_)_B 2/%L.B_1C\WSHRJ]=MWY\UD5|\=#1Y.;7* MR>2>L_I=$U9-M5O?

Q-00?%4PA]B,"<<.;ESQSXZU\17&#)E]%Y-V(H)C/4 M7&P/AR#:NW;&U]M8@?Z!AMF(]VUR.5P[2.?,FQTI-Z27KL^ MVOFS!O9@_"C.')?=R(-)*

*[#'X5#UBY>]@?"Q_;WNY96K2[%X7Y4/W;-MY!$^R?JX3+_,+8E^L8H5+!WW/1\Y.'@N:JP=_?E/X;)5KUT;RB3FE M[KT1O*ROYT;KPCHE_P,_K%#)43CC3-Y2#Q6GZ'0K0C*

MU\ LVQ_D%!>$:C4#;0N,NA9\^28&T:Q!#E%;M!U,)/]WOW:0^FXD,E=K&#-[MKCE,?YA>G[^BW"??O3GX'M9D,8C?O0%54J=0WU0R7[=3^\ M]W/?F+:?M[R4Q$]!

*$1[.*K97@CN*.FQ(YIP$S]P^K.>XWEAZ_.M&CQ?$&W)9A>*-[*BB4^/C]>=Y>B3R:7/-M+Z5OMP?G66GBZW,.4Y2OF/O5(.M'X"O<\N6E?B$ZLJWE%^/IVD\$*HM0=$C}!O*

*B,.*E'=:8X/%[,OX^0^_"|*"OF[QN&6?_-(X;6CWA-W.6+]NNI'7<)A. MBOMV.<9DR.R]#(E07BWJ_5 TZ_HIAG5M0ZOF<_5G*Y.0WBIKUC<;K):4-8)QJ1S=TJ^+*

M]18C=-1^S!CX5&15UGF817F_U===DZVLP5%I,KUVKF1?75O+A3V?8A'RBQJ8& M^X,WEB$X_L1ZJX9PM (!B(|!JN"@IXU,SNX8HRQN%(ZQ.KJ93XGU|(,WXLYB

*M2N;J.D)^_OFP|KRZANK30Y;9=Z/#4JF5ND=CES#LG1*S5_!%A1R=X=MP|\"5 M@R)#?SRA\Q3!T\ V9S|#F^Q.,,?QTVF8_OB.7AMP.\1 9)KSGC$VM%W=98?:*

*MWA)A9H.^7S,&DH)2#QV0V_>I*R.U@K*"(AS(*>;HT@\ U41MMM=RVHE.FKCEFFZU6&C#*B$U.>=$9 MDS_-]GMG2O[F-=#[T",>>RECN/N@ZFP 2K(S^.:(9WGHM;*

*MU0<=CTH^QG72W=K-->")B).QR0=K#&C%7>]MCZ^7/2'7>H^1U?@^V5%F*I'A M?Q!]GC5ZLP,B"L_S @U4]2&LL?3]?5%9I2HG=>KI))BD^5G,?0LA!#OKW4&#*

*ME1/L,EM-,L#OEA8I(FLZ-'S5E=AD-IEZ_5O&-@T8*R>BCK[IFF)1%/M3NHD]P^ZE_PY]_5CDXM'Y&)Y9SD:*1]EFRF19!STQ<|L]!1;RD&]ZHIL?SNOX*

M/._SD_;\&.SCU_CX$5V%.?87:P1CO _MTV@BO#L$#.'TP$8)^ZG@!\L06W M-+W/$*4 C03@<""[%[.3A-NWAS@LJGS>Y/(L2*KV@G_Q8H'<3@5QEYOQ#'O M4=8M(4IR[=*

[;^AR;M^'C_3],Y@@ $8]%V.Q_G1;PL:C8=C[]1)H@$^LR'>0 MR% >]>5]L+NM0#(>,!ZO\6%%N_],-BL)O?9#QG\T^'8B1V2FL,,;T:*1@]9% M=B?\,31\,2*

*M$BM8WW\]*4PF*&[<\456V+60/Y[']"(-NU3A^%JH70;C#TW8@"P"4!]#33(-M"6H)NYK']?M_M%0L!5LO@6UD'!2-6_@],$X%WR%B*O$9Y W>F"AGUZ]HZZ!*

*MJE4;56^L49ID[UR)IQEZ)DRONEMM*6MZ^=$Y(@#)_M!"3@6@*=],Z;[>W*B,1 M]:Y@+7FI-(U"RKB:R2[REN)*BT/_&U-GT9I[E8I/+!K ;1GG7&=I,&7URK4K*

MH>4;FNJ>6U8R??HV#X642NJ5ZJW>/9VI!JC&,.;+G I-S;8VC"M&L(DIO!VY MA5URL1_$O&*5(]ST]-0Z0>_;E?)+PFJE.RYB86/E#3=-4;09# E6GO.BI /D%3+1R#CH=E(L*

M70'9XHE:$QH9)@T;5PE6/71),I";8S,T6X#\F&Q)OU8SW#?24>>8;^=Q!:VG M7#:RY-_B\U)A[fX]FY1'-&%%V'4W'[?&NE\[^Q:5X\E=YP\D,G=CG#$@GW>

M+CU//HUQY;X.>G GE2+@WA!YVYZ%)>=-G\PZD:>Z;5 6KGW4CVEO&IH|O6L ME[fX()?-[?"(IE[) ^W1RBS,TD?@"Ff]-O('FZ$'(T3?&Z3+&0N5%FFSFCF*

M4'):B7.FZ^JY#NI;I=N.+QM9)KV?E1{T75E F?'6#$FH^.O KR6,<=\XMRU> M5+Y5G.S1K'7!UIQYI\YL;^O"F%2D0%G1;[$63A\IR3],,H(.SD MPD;&A7695B"L!-J12]FP-

(VQ#I?+.?'VPX(T+V.>F%S)9!+OX0O-B9U%#.]| M4/GAP.Q&9678#BM.,,:< =<3EOY1L WD_(.'AY#$ MMP;&%!=OB6OB)@[F1N5[KLQ2R9?

*9SAB=47;/ S8U8!M<;X"91T%7,58+$-*2 MM$]3:X9,NNHEPF*H\2'

>¥\4:7J_08$3AMP^K>5_NAB>P@^%8"%TW*"\J+8,_=#L M-M\?>CH6X:H><]-[JJ:5B?TLZ.MK8+8.NWFW33KNAZ%.%7W)^&S]JIF7-I&XX M-J/:F)"2.6R+N-PC#I?L]Q _ZTN0L6'Q.90&J8"9NH]-4?I'I@CM15R%*@Z) M[IA4*37&L*SE1M(G[-I[X2;$T K<[ZY2=TTNF<87MQM$81]L@<)7A$AL M4@69GQO?_WG?)TJ2F$AX-@<9'9[BK2EO>MX#6;YU:3!M-AYU6>]T,9@5E*_M13D4PA3'=.ANMC))C7D"QRK=++NS;$>?1E,.9:&#>Q,_AAX3)$/<)ST9O6LFT MRS96]_.?

0E17O9PPZJZGW[3BFRWN0&:@;'(Z*':RX%)2H#UW>T¢7<3:2FIG273K16 MC(+T[KHBSR1UNL[IB!,4U>"$UI/6(G\M8]2SR8Y4W3%ZJ7_-G%LG#XU%X M\AESW!WP?3,AT:*1\PPWRL:%(_2;^23)\IL$:&BLI6I]VI1.XW6QCKS2HP0)6,Ya8FIM_,1#G)+^.(7%E>@-=*R1NI7K^XTZ&(75IM^['6DQ*$) MS E)3M-*G)!.=/N

ZX0J:GW/YDGXO(QI^.M[3U1KE(&)ZN0'#Xl"%520NFFV M.EOH.137!LW4V-@E+PY)+N&U20.'1EO'! -+T= Q=43,_QWT.481]WK

T$EPOW9M"98VO0P)&>P)7;FTlG)D7WT<WT<:[X5% M)&+-;^-T,;%U:,IE:*_XR\45*QL,#UkIXM.-*,'%'F0WO H1RGJ-2CRH7^1 M!;

P*#46I16TQR/35PQBAKQ=AD!U,XX"HEI-KZZR8D;CG-1>W\QP7H#!?"K0 M_]M':%IG5$(05FO&*;"(^-! YION>G.NTSIVY+HH;NI_8A' ,&/KN&UN+HPIJ-^%P^SIDM {F-^]09EDJB2CH- MC?;)"B5?, +]7./=Q;Y+,ER(QVK UL3"5,350LSY,)2I/HA)\POWC6LRNK&8-M.JK?? 8H+0!:,FH|/>:H.1DP9C8VK16LO 1^A VKI3?%F;6I8G9S9MSZUUU&

M=JR-UEJBQB4IF$9% NB;+1FB@+>BM_A9X(=B/EV>0S6?H {?(!GW>C:*-UB7 M;3--1R!N+3F2%=?#7^OYGA>8/9JW;+FZ?L7[525WJDPP'U:]J+.")6@ITWU> MAG6#

[U9+J;R'3?<'SW:-KL.Q6_!_F:%C9P83JQ5D'M0=\ E_fGP<[FYBM9 M(@L+_(ANCOPIEGU!E!/+"L^5@=2?]QO1UW5_00GX/ >R\'1A#_8653P9SD8.M2# M5@)7#2(E-

IG&GHF6K=Z"MX@50"SU;5%9BIIS;(?D M3/&B^AI>WX,=4[UXD#H-W@N@0UY+$;C[4%4Y-,Q=?';6;;P[.=A;2>[R-GYE M!60HE,*KU?

GC'OAGKIR#@X]L@+_@+_Z'KJS[MG[T]9)*J.G?KJ0KSZ$5G*O+ MZSG3_;Z9VAITYSV.&KSG'|ITFF$5 A\R'X&CVI$L7HV=\0L=@3?#J"$WC+"Y^4Y1B\:/.[-@\B=OB5E>]-

AINK9^C.XTDC$C M201.*3(Q[*7)?NGIKB#+E$ 5|_8R>)$< I(]-"+5W"F$%(<=3Z;H'A[_@A77/ M>&8=$UTL=M8]2SR6#2N6# M-BRZJST[K$I6G>5?

7*MED4_<1K]=ECC3I"&,=N&>T?0NHF)7-/K%T.9^&)%-M7FY*#X0HGVLKNTK.?C5'C'>WTK^^QW;0&/1:7*J+P729T3;]L4ZG)&)4EI7L MTHE(D2HE"-

(I*'@*H1PF/F>@KDIQ21VE+VH_D>G.*'^5 M-!NGF>8YJZ0*LJX^R4OP?$]RK!F@YC&//M5Y+,[]2*8;S'G.ZI)_]ZGV?%)Y MVP\GN5 ,&P1>!8L,V^WA4Z^N&T)71]@-

)5_F'D[M6-!]K!X5SKEK4FAVCCR>2)<]-K M)M /B<$+I,\ M&4M21?8EM3&S3X4I+Q=%=,)O:PO\8\$JK.#^9M=_G#,T=F)R

M7;*-8=4Q*W&X]IHYZLAW88[I48C*@52,5)OH!U?Z=Z#U_!R%N'Q1:^',@G%- M^RCZXDH[^=!HJ[^\BOPZT)%S>2-9-%IB]4P$-YA* T'1W=#&%IS<>9-N@PL

MOBV,$\$%MOETI>3?\GMNH^'N46U9Q:)A-MDWLY+C) MQI8 3]D;B_-=]%)A 6]ZN:PVAMGMYMI;0&'[>M'1YE3V+R-E!4:4WD:: MMS3>22H+N0QJ+%SB9*;T=\9AO\"L-

6H@C*;6R1P)'SVT$N]\AU0.#EQ;6U!/ MCY:U>]LGU&9V^3-SI3#O(\WE\R--4Z=0$>*+7I[*W*$!MW M.Y;IA 72A_#=L.IB)-

,VV)7DG1G>S\.N;UWK)-2HB[*P=UGL\B(];?1)@A;F M3JG-+;'IO<-!5' UF-6;GS&6[S,]S?4'UXPZ2K'<,_DWC!R4?.K=,IH3X_2^

M'W"=&R/G&RC$Z2GBROF#X]!&1"#4T&UP*F/;=:D\5L(?Z2RS<8WLH\]Z%XAF MK3&T\SX-'Z@)7&85ZL9_YMM$>Y/'C/C(>E%,_7!N1>L,EZQG[<%#;I,%\KA$ M!5?KG?

36N^Z80T;P56.@K!U+(KSBF[POO4K"(M*-UW7 1(EIB6#$?W8$/K>(YD,VH9RD4L;&^GDE::K'7OE)'IUX,;52)@^3Z3 M,!)KEV [7GLYKQ

REFL0+UT\IU&7">MDKW(86+\68M%QJUE\!7).[@41N"A'MG8N+*KPRF+BKT4XGB35--VW1I)WP/3L7N[RF\LTG3BIID]RHOPXKI.>Z-.M*

[[+H=R#\7U_S_^I2GY\$HX<*#W"'"<9"VYJX?"U;Z'O/%0'AZT)F#/B2Q^)]H] MJYQ)\^R!3Z[+/;SG1:Y,2O;,ER[.T?'B]V'D?4A2(3"V/6E(U^BXQOFI2_.^4

MG%;EV@&2OR}3*YYTG)O;CJ2;?K>M5$T@F+VFYSD1U4T/\^D7F"'+>Z(?]Q#[MC%WC5B],:!4I758#*+F=X+1T\>I|C%6DCV.N_M1*LF (7AK&@7R:5|O &,.T M2<.:?*-

+SG>= 'C &&>)O:.C"NW?\N?'0R50":CXN=2P @ M8B-IEECAO%*[B-SE-!#E>U1(J \#@79HAYWU[M!BOX_H<:3K\.M,I>H^J237*8+RS;FS-01^7 M7EN?B)

OK2I>+0^)5Y(U>68W-.5ER3?12?GKMG^[)8VB@:?>5I-<&[>/-MA:$94@H\|Z&8F124W5M[UV/.YM%9<^?]2T3]K6_Q@;7>B] I3$<

M7@H7@QfZ,C+,CU>_T>'^:6CFVXK=?.:?, 9*GYYG.[LSGV%52/A3[SO?#K5JO MH@Y):OOPP,.E'L/V5E#81'W87 0$9+=E.W-YP,>HP$9HAD+NR^ZRPY4+O,DD M$T=#

(MZISU-MQXSRQ&TUG &O ;JQVSU7GDMLN^&>$>2>_3VQ1.,JL^G_5QEFK< PK-TEL95@^C_72;XRDZl;?45A_P M-H$ ZWC/G<MB!5Z^ ;n6U>]R\'A!N)

[,7VI_[%.+],.|-_M1=4^^X=D"UCE0G'PZ(.;/>W2Z-$5)$=]U.,O7:?I/ZZ)Q4 M.SEIJE.,6!'I]7, ^X4$"WZX!/FC+!*V WRO/O)K@H-^F:>%88M8W,*Q99]3:I MIYXO/5\/:X]O-

!1/Q)CO%T".K7.$=UH(U$8U_R"4?U5IL0-0D]4 MEG,I>4H[4FF'O;T13N8)1U_PQ%ZPV<6E7GCF("ZM*R$,BA6S/F("W9+>'/G\ MC @\!05[U%].TDFZZ5!J?/S91-

J1QXB9=W51_)/CC0I[;?+YJO2W:%964?5A M:X4C"'O9S5LZC^$,U>X_MN7>X!]\Q#_'6I.#0!UE:7'FRA@B+RS;FS-01^7 M7EN?B)

[2Y(M*JWU),7;>H_W>K44U=#+6ZIOYFSWIRIW/8X<%S@&&'0-2GIL,3_;$V)#X-16&P M*J$[%,6[$/JI;D$5-A-W!'T6B.

#LIL8>FTR{(>27O7=CU\QO2'VWB4"1;HHS$9!C)!!@NWFG>NB- MOOW?UFO8.X+2[C-5G(P.U4H*,AMUG8Q9"F ",SV$LH%W_^"!+RF"2'X%"$W M_"A;2P9AC\P@LW^_

J7]#O(4V:=I^-@9B<5S/9W!R+@IX>_2F@9)) +7 + WJ-ZM'8^!'AT0@9',7U&8[%-_^%OPO4XNH1]DK'X2'E$H'>-Y7'/]=(/?CD9IH,N?CY-<360)M+AUGP?H4 (NQ6,L7$.EW6A\L9-

QO5L M2S<>8=23-_R8?21*<- TK1P#TYD5Q^<>W+L|&VG|#W*3[SXSXIRMV.?TD1RM MZ?|[>Q_T7]N90ZJR;,F\:1*=0917-#++[T>C;X!7Q4J&Q2_U#.(UK.@KBM*G MC+

(J1D54)++:.Y6F^YC,U]HI/!Q6QR/74R$/.P)<=U6T9D;L?%BTC&'"S M%68_6/L61K= ,,)AQ\2J9<(5;C^0L7WYAN!EFE9&ES;&)TT%%^Z)OI1+E1_Q

M,9K7.F==W59I,W_51W;^=6D%EK^0MIW^4/Y5<4<7_+)GYT2K)R3_<* =5?!EJ M9Y9:$54)I;9A.*1]>>?:L9;)L'5QJ.QS0HLT7O9<8G,#!_/ FNL1'X3FAVY%

MLFN.G=3ESU$/)VZ=%60B/==R041Z8=2N_4%M5GH!$EU93P3X)MIF9A@=DPX) MU6!F'TD<'.T;$6D?*BK\|#I*%,F4FS'-MJQY^F&V(H?IA*G_<7!L8QJ%\2<7!\P>Y W7L-&

<>QK0M>*)V?F=7A37\#J,1J?!HOL73N& M,@PF,Y4T:?72Y!PYSS:,I/31 MP.5C>;!1=4$AD8.WJD?+IBT/-XC T76*=R.4.?KGTN^3=!|9N)&E:OH]Y^%E M,

<4(U)@8Y2SU#\D7[%5GV"7LKDJ,7!$-*'DS\:5563:YCC&H3%_@1F[$G9)H M]ZO4185A]B^+4)=(6=A\/MX$?VV8T|%B5=?L:=KRF.D!*$) ^) (-]Z>M);YW M(_"0 P)Y)P1$D,;?

TU=@]4S2'UG'*UNAUR&ZYFE&/TH:OW=:D=8^Y8*^2U6) M660CJ0%<6QTHJP*P=17PM!4X!GZB]/S Y]X[+(=:S^?1TK)-ZY[S@NM5ZXE3=74N"%G M#]NNYQV72|

(\MK8)],I=,L@VK5"_BYC99DUO?5P8J-%[1MCT<#2WF]+))*%EE H>*B^ZYUCZH]]M+,E# MU(',\]6ATHH5:@UD<\]-E3!+>WTX):R6*I:F*!U7\,Q-FB'_7]9OOOZ4?B/5

MC3N@>HO[TZ!WI]-)\C1BTGRF.]!N,]3Q\)CQ=&]=*%91Z1O%;AZZ]RM M5R8KOQ5GC?N$?RI8RSCAATLGT.&7JQ540?E[JB7RMJ);Z7RV?#:!O;3!=!

M]THXE/SR&-4UWLG FV#%!Z9N&/.]0 QH_726Z8HF*?:4G9-^UZ?!ML>)%$73 MP8_D7#Y^(CNEV$9#

SI3X6.'56V&@=RTJ'X%=F@5D7:NTM+2X+O1XPQOC%X>X3=H5^9VYK +7R_URE0N)(9G&]B M*@O./\@4/Q |<>%.+((0(DH$ B:U".*]>$G>-

N0A6R^/:Z>5V$F7()=C8;P2+1$)Q5)=$D??B0] M@'93*=W_'LPMI>\%3Q.!$D379V%HS5KZ4 &@R'1I'T&#U5K3PT2T)=(-[d/G

M"DKY^M54,7=:PY%5>,6=SP'L3[_+:,J@1:[9_S$%X=K_^7LG,FAEKFE$GZL M>Q+@S^"DB^PBZV& MW4G0N!+,-&%@\3@T5,0@K'06TGZ6IZJ9T-@GY:.P4&'+2\JPE

G\VD96C\ M9<|&P)1SY7WG.=^&WKK;N$"JC .SR0/8.T&A7(>+$B?1<9-B%@=>ZWWEJEI M(+AN_^ANU#!SF&_NU+-VE&F0.CW&C6=%LV=CNO>ZKG\.B+1YMY"G

L=:=?OQ%%!5&;???<6 MY%G_6L&YJZ59GB%-+Y)"BPKOP@X"<*LM45U$^9<[ZP;U$J8,[M4S(IEJZMS,YMP MEG-&EO6ICWD-@"MP4HONG^11N^NRK8S57PWICT?

JQ!38HY?T)Y#65=8+CN6, MK@Z%-RF1;. 7SY(P'@88K:!:?C3UE>[[W)/Q+_E5=<7N3E[GP]0%;_0I25U5VN]I%?*>1S((%P,%10<4O&5NAK\@5,155&2O;V5^K

MZ_/=O*JI=8(*\-]?L6)\C/S* ^21446N(ZQQK7.P\[C<]B10MJQA;FS6Z\ M"9]IU#,6_7<7W3W-Z,9_F":AX,$<((QEOD>^-0=#?YG&4>UQQI+6IW *ILY. MJ[ZI#ZE^Y8-

F_@H*V.1WZ,T(!=9X/BT*7*F]/HA*-=.XW?NB8;?XH!:),PU8 M<@-IB>[5(8TK)&DV<5K=P6B)\64VAT?,J<\GQ<\Z'I]-(WJ\3QNQ_N MJ.(U)5L-W!J?VZ!W9O>8UO9/(9&S

M)6;Z6T6.E5Q+WZ5[7K0WP8+[/,%SP25[2 H3V^1O>8Z\0V7C%CW#!,LDBZ=9 M/J#IN#(+X&P;WQ1&=.!DZFI*7MKKQ^R'E#D8-

1/$D1CNRG!^LX&RNH<2%]MAWL&@T"X85]G\U88G]& M(Z;TN/A8PU+L[WXD*;.VW95]*:L?)-UX=&]3XS,R?D;C_1T!KD]8!&.B4!LO

M82M>2@%=,&?:A/97$.WWX[!+A@66I!?BO%ME3D[$QF)-^=E@W>;U@<(S-VW M6I3*P:TNX-O.F%W?^^JLA>UMJL3[!04RHG.@6AMZIG>*]=!LX,?@:X6B2E+ M-

V4A+()/Y*ITWB@8K?VX>2D8C!-,FHA*XTJ"Y M5V7IWB-]KO-\9Y+I8MDRELA3B?J8;AE.*<%LF/ZN@4K+9.E+BF M!+72'>RI3E+UCV_C^9YL.;*QI3V!V>]6K-=

<9+AMI(53E0.CEJ$@RV&ZR>7J M@%I9\O$L@X4C68EE,_>KIR1$5)QDC!V\LL960,_V==WW!1TO)3(D>4 M8IZ4USJT!EZ,.;*#FSQ'I"71JH%R.O/2_'A!INBN;V]",ST3'D*%>?

&P(MHU MJ&QL%MNG5:C;W L=BX&U3&3]@<,EH_'S*OM7A+@LV(+X(V-/"*,0='A^W$NI M_IA(>_%UTV%7Y4#-@%EU!UNC;_AV69,1-.2Z4_#EI0K5+K\GLVO($!;W['P<

M2+%T1.#9QNZ=&VB-,$0X\WA3Y$$0Q)4E MT=Q?=C 0J1P1< PY6B(<0%"JDR@"E@C4:^$>X3+I2,C_TGRPAX/5PC83"/0* M5UL!Q3^WZ'SKP9O@HX6?9^C"A6^>_VL3?

(*R_2=*;73D?;*_M/ZC" 3^42G:.MZ$1_ON/_(R0[^:.!GZ>+?2 SD/W./!S%!M/:-Z"><6V.J6=_4LKIK+Y>)X(M^._Q^5B5JZ=_?VEFKF.(@"<1F.7%7_=Y$

X$_K5]];I8X71F_R*1[3\1^7F(M$@=!$H'H?S^-_>"@&?_CDCAP__OB$-FB4#['UP!4O]'5[AF?0KY6RZBXIS]-M5_9?94SY=]Q*A*3-

Z]#OW^2C(OPB_^R']#/^+_'@&@_A7\CVBE%AZ$__-0 M>QVB_\'L M45U[^9<[ZP;U$J8,[M4S(IEJZMS,YMP MEG-&EO6IC

*5T@8XXADFVKF'l:6S@!00*WJL[2\D+BI4>F-M3=\,8W_\BE'0]+4KU!)DS3F/1U9_]!\YX]RTOJTOL!@M-DPO>B)0_B]IB=AYU$!\393@1JF1'YA-5[^1W;NA&3M\KR-M+4VSS1J6)!*P&0QY$Q36"]$RK8$=6ASV<76-,#9>K+A>MNP.&T-&-LJ_E6# M.#^55C=@6:O&769D:0Z:Y%5.U;B80;C;O)QJG9T!.?RON5[7OH7@=24%S;*

*[HGON'QXN=R(L!JZXR#Z2:U-MU!HMA*T/D-!@"K02#UW:@9=>G$YYE+^C/WZ]\R"S",D%NW4X]C?@"DQ$ZH;_$-M"KB6/^TCCXMRSE=V'=UW:K1_PB!7?LC_X-*RNBO7BQH\/.K=X8CEE'76L6$%LH\M(+<.;P&X- M*:@=;X(FF8,P:)&WY"6@6NKW69F8\-\5MWGPG%S'R<)Z=7$9DV8!)-1SC[%%66_5-Q>>>%R!XUU9VN/!$76ZT:WS*-XSQ9]DC8[-M.Z$E/K-LZG,?"VDLF!89=BB>7*L)5-(,%0I;O,&XCSU5O5;PET%_:_W:#R>-M22,4!G9S^XMN%-8^04/I<*+-/\R])*)=),Y4&-4,>DA@UB_$;Y%46FAN?>*:*

*M&YW4_^X.#9EP.Z'UA(!BA3MMM2K\/M#KM<>##SPH$Y[V] =T1WQ /Q&Y@UE M36;,S0E9O3]DY_90'BRH:2C1.T7!?COE%?^W3%]?>,2I_^6[]$0W RI[+9*0M+@^]6%'3QO8Z[M_%Y?^/ES%)_[^WE"[M#CURDM'Z!1E0.^(##+M>+2.,(OY MI'0!0@3J)_&VK70DT+7S1_-N5E!!%@4&D'[1H0C1VP!W?W3L+-^6?^E:^&# MF_2$/P-E_M*SY#^>P(Hf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

M4CD=^5H_&5OG!3CSU;H'7W;A]KEPA;=;5YIL(CS)FN0L1AM"HN_S] KS-?GN M?//>1#\&7W]9)CO6K1KT/8E!1:N,B11C21E-45RS)X4;G8='),/;SLJ99T\;.M-=YUJ_>&\Q*60\-YM8A K=;Y$]5FQFEJ1?]*%EAZ'H@rF=2U2RL?IF<,L5)9:+\]QQA3Y]5P%%{OB0&M>9,'_M*5RWX1 =5;CB6=.NU#QK1P1>>6MBZ0?N)5M-G!D'O:O\^C;HX%&5%,<7^AWY M?[ZYD7R]!JNIC7/$B! <.;*S*ZX=R8[2.WGYCX?9)NK0G^\C?VQ+)VWU!K9HIY!15ND_7=3*?_QIRM>6%5>":H^Q9\V>(2Y_;MW0MB!5.MK(_R114-,!NNL%,;JD7R0&]!^4AJCOL^H*8M1VN03?EOYZ^+M1(6^F] M'R9RU+_RO+VJ:>$P6<17TP.*22=P$8%^!;P6@:(8@N'ID)3P:D0@PQ<-QU\TMAF'IO&VA7^MWV+ ,3E4*.9%P;9-1_%8&&!JU;!Q/GM8@A78G#WB< %V#+< M,_>D"!\%XY4Y)!*V!>OC(Z_"!P7^%.MR.9W;RKV^R]+54Y/'[_RX;9%4!"&<

*MWY%6R@CE^[QU0?ZAE-*F-?K7T<=B"^]8X+!HE@[]9++#&>0V>GO#\ MW,<'GO#0K3K2S,.NN]<@9<2@9!=]NO>^HZ[#A+8 M\!:1AT-OC=&!;(YYRAOJ]-/!C7]ZI)=H'E^DP.&AD^(MGP]!$Y-0GF)U;F M+QC9&&Z\_8FV3)+6-2-OG^N(([JJ6>!L8P?3!XS?1#W!\.[^-8%'1.9M*26V; MBNJH^DP'_MG4]TG>|@L=<4D/22M4)W43MYQ . Y8@CQ&NF9E>]ZW;JRUX. MM^7+@&S*-(_':?N]$@<.2##:C4Y_).N3"NAAI"/ M2H+51/2C\KCXJMZ]HOI. O<$HIYRJ!==5?1W3;_-1_.];9-RCYL05"VA<>1!MIL*?+A1*$O(*Q_AN:,;3=%'6+$!DH*9QB7NE%IG M9@O7T%B.6YGG"ITH.COH)=X?*>"LU#$Y52BDQ/T??42@P1T"G'&HL.RGLZ

*MZ&NNO>.S*I4UODHZH^6;%^RTW.Q<)HH+G&G?.]1LAE_B#*,UG^X\EU:RD/H6 M6!0C A,A#QU4C'R-4",%648)CX8]I1X[H]LM=O(9?N4<@R^&Z3*?G=S,C4X MJ_PX5]#R9;DW@L1VPO'5F4R!UX=KH^YKVF>-"E=H?I'[RMT^NP*I>6DR4X"! M*@X?E7^Q3,0(#X]%TS9OSW%$V/9AQ2DW***]MR.9W;RKV^R]+54Y/'[_RX;9%4!"&<*

*MWY%6R@CE^[QU0?ZAE-*F-?K7T<=B"^]8X+!HE@[]9++#&>0V>GO#\ MW,<'GO#0K3K2S,.NN]<@9<2@9!=]NO>^HZ[#A+8 M\!:1AT-OC=&!;(YYRAOJ]-/!C7]ZI)=H'E^DP.&AD^(MGP]!$Y-0GF)U;F M+QC9&&Z\_8FV3)+6-2-OG^N(([JJ6>!L8P?3!XS?1#W!\.[^-8%'1.9M*26V; MBNJH^DP'_MG4]TG>|@L=<4D/22M4)W43MYQ . Y8@CQ&NF9E>]ZW;JRUX. MM^7+@&S*-(_':?N]$@<.2##:C4Y_).N3"NAAI"/ M2H+51/2C\KCXJMZ]HOI. O<$HIYRJ!==5?1W3;_-1_.];9-RCYL05"VA<>1!MIL*?+A1*$O(*Q_AN:,;3=%'6+$!DH*9QB7NE%IG M9@O7T%B.6YGG"ITH.COH)=X?*>"LU#$Y52BDQ/T??42@P1T"G'&HL.RGLZ

*MZ&NNO>.S*I4UODHZH^6;%^RTW.Q<)HH+G&G?.]1LAE_B#*,UG^X\EU:RD/H6 M6!0C A,A#QU4C'R-4",%648)CX8]I1X[H]LM=O(9?N4<@R^&Z3*?G=S,C4X MJ_PX5]#R9;DW@L1VPO'5F4R!UX=KH^YKVF>-"E=H?I'[RMT^NP*I>6DR4X"! M*@X?E7^Q3,0(#X]%TS9OSW%$V/9AQ2DW***]MR.9W;RKV^R]+54Y/'[_RX;9%4!"&<

*MWY%6R@CE^[QU0?ZAE-*F-?K7T<=B"^]8X+!HE@[]9++#&>0V>GO#\ MW,<'GO#0K3K2S,.NN]<@9<2@9!=]NO>^HZ[#A+8 M\!:1AT-OC=&!;(YYRAOJ]-/!C7]ZI)=H'E^DP.&AD^(MGP]!$Y-0GF)U;F M+QC9&&Z\_8FV3)+6-2-OG^N(([JJ6>!L8P?3!XS?1#W!\.[^-8%'1.9M*26V; MBNJH^DP'_MG4]TG>|@L=<4D/22M4)W43MYQ . Y8@CQ&NF9E>]ZW;JRUX. MM^7+@&S*-(_':?N]$@<.2##:C4Y_).N3"NAAI"/ M2H+51/2C\KCXJMZ]HOI. O<$HIYRJ!==5?1W3;_-1_.];9-RCYL05"VA<>1!MIL*?+A1*$O(*Q_AN:,;3=%'6+$!DH*9QB7NE%IG M9@O7T%B.6YGG"ITH.COH)=X?*>"LU#$Y52BDQ/T??42@P1T"G'&HL.RGLZ

*MZ&NNO>.S*I4UODHZH^6;%^RTW.Q<)HH+G&G?.]1LAE_B#*,UG^X\EU:RD/H6 M6!0C A,A#QU4C'R-4",%648)CX8]I1X[H]LM=O(9?N4<@R^&Z3*?G=S,C4X MJ_PX5]#R9;DW@L1VPO'5F4R!UX=KH^YKVF>-"E=H?I'[RMT^NP*I>6DR4X"! M*@X?E7^Q3,0(#X]%TS9OSW%$V/9AQ2DW***]MR.9W;RKV^R]+54Y/'[_RX;9%4!"&<*

*<@'f^@/9,J17UIT,#7>P%4B`EO4?_R;RCQ$TK[<_GD,B=4,1U26|RIQ]F+1'IM5,"_`M)YY5(_AQ+'RUA$"7%)/'5'YPZW$.QB);`MP65A6J3.`5'!(2N\RQF?Z/Y0BG*J_%2@TO:H*-+]MQ#!P8__9CCW/;(IJ27_`MT?,R`KDX654-F.>.[A(TKE5IJ)"\E067"%;Q\P17!.]YK9R6F-RG^S[307,Z`MW0OGJH*

[Y\V<=+V:V\P*ENK,$J[\W6PE8<2[*G'Q328AD6R:'/SSP8NN+\3B<`MU46H[\@F<45[<;BP-7F5WAZ+!,R!"T[!')[S3QA.KQ5'7UVO-%MAS/&[\ID+`MO5A+E]O5MO<%)K2?IO'Z_=S-`KI37.H(#?<(ANB!4OA)R?1QIFUH+WPP2H>!V!OI6.VK%|&8&!OSY5++G`ME%,.OV|s$]@.\%(C!TV4?ERUM3@Q'V\&KSO9`MAR/VQ^\J0JU#%_-(P/?.Q8+=1MN@@^(=(A>`M)=W;[`)`#Z\?K@H><%W_1Y'J6<4<'PX/=)5D(FL?O9S6&5/Y!)GMY1SM6"=-`ME&]AWZ%#OZE17BMTP.M..LC?8!3?K,X@7JI^$$QVM+VATTSLA,]!W1FCE%3,;P2><:|;`M01=.F.DNW0&5CRP]!9GC|!]AMFV#5^\=ZYJF?B93M9)MM6|C(D#9@G`#6$ZT`M8$,XF.RIPAG)&H?8IB\F|C>L1>N.7PM)[4@^AJVT4]V2]?1>,33K\U#<=<"IW!C,3*'<M#C5>*X$X\$#*NM5CK\^BTTNZRFVWLCU*GC6P*5!9E<4&2CZ2A?LU]U*.ELU]H`MYUTR=0-5GX0WYS'E;%7`+=]P&J^5_1&E+I,Y0UY^7$;I&]FO`3<.7A`!A@EV8`M$K?],CP^E"-8#Q?ELRQA]XH,HED]<.;3'V@G|LRY1EZB&`-,PS7*1*%UYY;Y`MK`!1)Z#(L]BAQHGK"7%'(9BAP3IC'LBCG=TZ$&UE4N1CJT!H6[`R>:=S7+_`MGW\C;\A^XE%VA<[,=T$Q>4/HEOOG5M."$@&"K1EEFQ(^SYY/BQKZ,(DK$24,M1#S|^H.$DJ(<0GFM6UU<8XO-8-8C']0&N,@>K545U1@;8:N57S`MI&VG8K:CI[0VA=FO9R_?\Z9IG]F-+PE%B3>+H?;HM)@7C_VC*O/H+2)?ZL;7`M^$CTB_|Y?3>8=05]1#OY&/J;AV1FU"1P)SUVB.B1"TI[#"ICQW2_`YL5WI?9RQ.&N%/`MR_Z7UEARIW9RHHI]YQWU;JP=$N*4;%"FQP?=QN89X=+UN5@WCXD'0F<=Y[K`M6/*MU>@.6/UA_K12,687;"9PI?'H.YIN-N$XJ_'&VK#W&T#EZ/?I);GA5H`MF&)4JRCLX#AVRE="JBN7MP'WRIDN\C"/T:4A\U@GT,_+*_0;VU*XXRF+P+Z#`M^_J#SA.9?H0\KJXB6`L+[\B+YP%A(?';MN>=MHJCONM[OA6RTN_\?R-]4]]I`M/?]SOL8@38QZ6W+JNCZ+!V8\.IW-89:JM_"`#:8W'S4D(6\E`7TP0:WH[O#)MCN)IF7AI"N'462;M$Z^^F5&,Q4*#Y##DKLRL9MI?W"1QO53=2(>=>Q"N;^^M/Q(7E%6S$I];'\KT&>$"Z+BPP[UTL6"E"HJ8.'^WM'MEI4)Y3"`J(I2=,09)#J7%;O8LW5MHBNY%MKR`L`9Y6`M+2A&'QDX>X6X)/@'CJ,.1K\_>9,_2.6)FIO@F1)E165]_KP>A^'A8YO6YJD`M527=3BWP?V!W>W=;5Z5&3DY&($U'GF#DO^43S4@0%T_'?%^]N1FMV++?3R.I&/^$OM#\4G(4E1:Z&W+=M$#KR(D6@^TC`M0FJ@H+5S!R6_KA?=<<??$`M/3HE-1(2R;=_:%=P!$92/^%KF`MGZ@D\>UK?)!<$~.9OJAC./587(8J;KMZ>1#*`M1:!\/7G;ZC6\3#T:(_02D$7X5(^_L&#R?$GE>JE\E;IRG25;GAH/"SF)JHEV'WWZ7HL<,#V`MRJG.EW7JY>;M=,LYS9I[LFPKB;WJ(FR\EQHAE5J9`Z+%SC\:'/>U>IT"W_H\`M+.VP$&O+1OUE"5;.S3(2!GU>@<%^2+DL1^B5S%6I(G^FH@?`Z:.,KERTY^X`M@AAM(!$]!+42SK4YI0(9GV(Y`Q?3)5I?OL[=;BX+(;@2/=![I"^9[WW0>3/K`M/2./-]"!.I#EDWK";+!B9.)*%E7;R:%_`>2W:I'4"^JK00+N_@T-V!9=CWW`MP^120I^E3@1\v"[WB60(WL,*L1;316T<_$MS`M]*W;::BB;#<@7HV2/0\Z!U]-%34<4P5@^^?K1-,HPL!&:4V3G$>NS0?I.F_UK`MSSPLS1R[VLC,UF_#\Z/%&]%!PP`!J.\^HV^9.0^E)NF4`2^(&D,*3N_P'SQID`M*IG],W_OOC[!""*F\@CSO!!MJ2Y[.X9$@T1W40[C_(GQ@?/?OQ.K8W2>JI6`MM_$.PEB;I8$'XM7&B5SK%<>=61Y^5]FQ1)GK-+3RT]J-YP6M-1LX%<%Z%ZTQ`M.T5ESL[B"--'YL&O!FHUAWN)4#XO1G,%6Q_T3<|ZK?',KN+IM8U;3FDJM>&;UIR^U/|_OY?!(P#PX.?%;G77XRN++`M^E]?N;%%/-KA3.I`MSK)LI\\M>6_@Y<-O:11DV.H?G=/96M$*>\]ZC'E=+*#$:?IS/.ZDO1:@;!7K-N+CB0Q84YQ"Q!)_A#`^G;52DR.$`M*4+D,LH-&T%C`GJL&C>$!'4PMO;4+A]B\34V7`MZ'UL_VHOOQ&[3.G3RL)0P\DS@A8]YCE%@C354ATV+DS0$[*UX6XIDF'63CS`M#?NB3XUKL-.#]Z@Q-B1-JR9Z>OH@8A78-&FJXF3(GZ)YQRY^`W.$)8@76);2`M$.PXVJPK/&L/9=WQ!Z3.3F57^JJO)MY3"J<_>L%.1IY2^I>LTS96=FP\10ZMLU!U6$X7AU2">,6V7YDV8@?]HZ$U3L0\3"C")%.(C3_#UY1G.7LZD(%75_J)`M2OI=4-X5`\X,W19#A]GKSCZT51LMGT4M9'R2;fU1E,2Y]ZBI07+<:I@@VH+9`M09.?]"[HRLTSB8`F>$>B-]W,_1$\]'[*#95/MN/:=^>Z*33>3,-U*W";I]&U`M/S_05A37$],D-4L+%##[\_P)?5L5T;1\}{MM#QO-W0'G^2P-&I:,-T$F[D`MBZ5#'6J^?HMH9UGRF;J^@*)CP2#41S.+S!+$3`SWE^4K,8;T&U_@LPH2=)(6_`M[X^OR8'2#L"P%Z@NB7K#4`M$@7O9;D:+^S;\@,1ST!4"$?OKF,=,;B>8M<+V(N?,6#)T>5)%|_>PB3;CT"`MML+$'=A@)B?3UGG()T>O#/%L1CUE_1\D\EKZF56(L+Y(%L;6WIH4HGLVCCX`M1M].S1207`%T"+0$L"-^^"%&3A]=`%_9K/CE#RQ-]>%0G,UUC(+W1U3`M.=N?>1+6+_#,(SZVR+O>86CE$;(WU\R.U;\5.N.Z_#NQ&/885M?P5211`MUW2.T==V*$&FXFC6IA=[5'+=51-Q;D.?ST<#M9'4PVS;H9%L?L'KJK`M5DI(MDI:4ZM9I]-EDB:9+WJ]+9F-)IZ>JGW_B2ZGE>B"`>R*8`IND6Y'U<.;_MK`M!@PM:--|_X!P@FH|_CX:7O*[BCGO>?-Z12X6EZZS0;;>5F0QF_+K%P1)>`M`JOOJ)WEE%-=>"MYY)2-/.,T.E"6%[;_1?@K382(I&R'-=7.YG>'5NDGY=0t/`M$<)$JP@`)M6=1]\,QPKU(O6/USH3Q;J!"FT5L]+ZC\;`M`GS?&AJ._$M@N>9YP31P]9#N-7R;4^@!$?'U)6QAK\C^#)+7%4XK^<^#)_PH-`M!D-6.(S&#[6.)/FO])++H;]#G;4YC787!UZZ"Y"%$761"M?.T@[_@0[&9/I-MM^51ZX<5ZSFK;4+UOQ3U^:E$T,I[$GT!?-2&XVE"Y1N6^T6`MK-AZTDP/LQ`.I_R9[+!$N)+B'T89F?1X26DEN2)Z[6#AIBWUZ31*OPOQ)WL:`MS?IZ]T)BV?4'@D&K%-E?V"&9?T?6^@U3=^$C[3)W-J5#Q.@>6JT1\5I_O(TM`MF,2^*%AJ&OP,8149I%F&!K$OX'Q=D#S9J3V%UNUV+&L"U9(./C_!).+*=FV:M[3>K8+P'90R94>7;VO^6QJH[59E48)E2_2!7%9.-`XF&+:((%GW!Q4FWW`MCCZW2VK\G>1XZ/[#8&<\\%1W!U(HZ#3OBL(+#PBH=$..0>G7^S@*4:0F`>\7`MP19?ADNU'7[<6H7C!/LN4O9NX($_H?J70M'-R++:]MY>@]9!*]BN=#YZ7P<5G`M><^--MZ>'26'_?-%._\OB'/;S-[)RZ)0>E<>]EN)S2_@W*IX[_;E6!DB9G`M#.JTFX,JTW\1'?,\\-A6+BQDVPL.5I2Z3..RZMQ.7S;_(5YWDB2QRF>*W6S5`MML=\.26BS;'.QG!18L[-YD1*L#G>;Q^9!539*AF6'*(-PM_1W%`MLO7LS/SS.Q>/9#<6)#"S Z1)4H^YUIR^U!#$WT1_9L?E0P^T+%?34K^<K9WDXU\?_'&^/_O.O",,D93H*9S4K44>_`2T)+.V(G=VI5ZEE&`MFB(_^R?(S)8WXHX82)LC=;(\F7TE1JL;`G.;91N@J'TH!KF[^#!%ZLN;'&`M!8FGWF.XK^QN>L4\;'4N%JP]A0>6\D"UN\48K;Z&5<^85O[O%H>)MIK=Y&-> M)&.YX0*`M%N]Z^:=C@4N%<[T7(*HVSS8ZW#+**;INUJKM32M9ZE]J#Z?0C(?Q`M-FP@A4AS$-R`U#9%ZHN*`96:>8<:O@!#CKTF6CE@G3NUP^P7TM^C:3A[:-BR`M]+|-"A!.&.38&'=[^HSH^W]A4=BIW?G^6%66`MY/E<*)2D[=#+`8,J:7KO(6)B>W?+YHJ7(;;7VIDR9=(TGWW)0P#&)PS21!`MUW2.T==V*$E@$L;%P?6WEUNBN6OU=JM&\G>`E0E.M/__[APW-2FX5_'"]6:4=X;<6C:LG[#DK%YRU2=5(8ZG8'_)/^%5O49?%3(;7.]; MHLK1&HY9VQYUML<2]6,1L6![M#X;+D8S>A4YIF=I_H""&GOJD?O(ZZLW(%C]`M/47VI8S%%/R;::I=9C:85AJKC>'^^&O>"J9D^V5&T^2D0.WI/9EP<^H'#NT`M79/,7;9LR!LUF6N&UM<]('$'4G=-ME_JYX\SU[K+[5](&^)RV.K!MSO7=*%Q.:QXVJ:M/Y4M)`M/O(4#S3EOVF5]Q8<$#JMPUEV!{;]'![AQW`M=.B(#0P=!(-*E$WHGH08(X?A[SOO]\9WSO>_S_":'W-=<\U>,WNNF;W6`MON\|L^XE^WWYO%^@KRB;G`T#[#N(>()#=8IL[[DO\F_/Y65-].NQ5CF?"?C M&"2F5O$0,C3.=>8_(%67#16I:Y2]/57#?!!9#:EGHH`.YA6Y5&'_(2IV)VF"ZO8-)IB&TQ6RX!DK=]S7/TK5VU-MN^=-:F"IS,0_/)`7(EIM_;1#;K(\YU(!ZJV'L-00\KS-A(IT;C%[:J)/VUPG`MV2L!3@E'37/\W/GU7]R=^*L)FR%\N+OM 12Q3/Y) Ds>E.EH__P1Z2+5C`M/4$O"`#`0YN9NOJ0*4L?`0U`A`M-2:!*K06<`HF|&2U_EF'!T[N4F@CA=6=L-;#;QBN3_2JQILSPS#)8!PN/E'N*`MAE/;]7N7X"":3;&R6E^YGG[)%;=3?Y$7ORSU2DN$@3/U`\W+BAAI"(E7"!J`M$7O,K\:.KYY,Y]Q<(!&85`FT?J5@?M>8#:3TC%&1",ECB5?&B>3A]LWK@\;T`MICW11^O!S9R,C/LE6.%,45+(0]HMP:^&;6N7[\V5[JF44]#W`M`[#`6GWDIHR>W:9573$?VY/0LI#TVX%ZWJOQ$=RS-*.:*(I9,WK*!LK(\5W%M\E|AYXXV]?ESK'K.BB??@"^%;^2AML?2O)RWZX5!MYZ9R$"?&*T-V]<#RU:5`M=U88<9$BOE\N6;`.]L96!+F,^NTWL4'0B#`(^E::R7B>5E]4<:8Q@&K&?0ZKS`MWC?UO&MY*M(3RX&5H12HXM-`9CH(-B#G=R"C2=*3/6CVGPH&L#C6"C@(H'@'V+RJY^A9IQW7A)H.T,-7`,PI(>@<+#9R;7G!`M6F.I>(>?E-H=[Z%\>WL!<]MWLN\|HOHYU|+*,7*B02`M.TIX8?I!I#/"C::?_2C*E2@SK7)GB@8:),)UX,ZT|MNE3X><$<^G-E%3TFBE`MVA"8Y]5.3.Q=*2$QD?2CSEXR/X7X@SN^.2R'],QCT:QZ?,T\5L1>%MU(9Y2\`M6'EC0AUPLG%A>#(?V6_M3BHF\%U4P?*KO&*2P:BX2DU!O'^>SK"I6$8[NW.A`MPPG-U$3(T-QD3V<_-8U#XH7W&2W(*">=OCJDH\d<:97P4_$^=P<*_]+N8#=I`M]V2UK5I.B[?KYV-DX8,<_K>JLH*^$WX?D+<"C&(-_0MG7G)\&F+.F$]Y;/<MP=B4OLF1;2IH;C>;8"66^)2N]AMD3*ZN@K5HOL#").Q/IH;YV]-89I"=>'|TI9`M]KL91`<3NOHJ4"..59Y3!MXQ94F1/$W)W^>*9%;#M(G?F3.0S!+S5NY81W|&`M+'[*4]-'>"(H-DT5PMC:!%"0PFTONI%[R9_?M+S_F>MUT*3.(R\VDS>B0(>3`M(;)\V#Q5@R#=;+*L]\Y2U*T>6XYBJ7Z2.7"L#5HT,#.7T|(`?'=+DNC_`PDQE!?NX]Q?9!M]>3B/GYD]ME/BXMT8\;T8S.`M 0)X&TQ=&C;%LO7'N#"28;,I?8$A13<%5-N"=`R'G;-2CHFRS\!.L`WQ+HM^3#B2W$H3Z>I=K1,+LV@"MG;&FPT_N&GZ;*8.,J4DC*%^!QB@+YZHZ2`MF8UV$!FT>EFH>AE.:6("#9W5&|VM&DG=_%=^3V!?4,?;ET+^02M6?0TO+.)K^B0"?MTH)6?>;@H(EFNDO'9557Q\6#%/M\4Y/-)L_||D0M1TR'(Q/75S[!+Q\9$&MV`M0"%I*]E)MT@"'52]S_LT!@5X,89/%MD66X?T?9'S[T^,'R=N1DO'$]YJ-"IZ8.;1YV3L:V;SG_Y9"MXD44_UTX4BH.2FZ&^[E7TE^V$\#^&Z;EGXO+4L7>&U[O>3A7;D0<9RQ`MJ;H#4]U1U1<6;B,UJ;2W;.3C-)KU\|XR+4MM6!BYFK.A]I./\F3PYXM$,0MQY'N+409\^#?_'TWC-3Q9SF-JXRR1\DQSG%-,3K&OZYE\6Q.1`M/57T0*8Y',[\G/Q1DIQXR-(K1F?D^,?]<-6]SY4,'EL0@F3#G1S78-T3T'O^M0UVSQC&&"\Q!MHS"+'X=&ZM/=.\6U&AN]`?TI\96%.$11KDF\"J0Y3]SJ(8R-M"8A&?H9=K5:8L5*ROFIB\<=,USF%W^WI?^\RQ))I%\0*WL:.W'2]KJH-,H'`M`IVQ.VY.5*-YMD7')R6R9/-9D=+R&N#H>#NF5'+R=Y^;&ZG-

*<|2./:H4J&IYKWXFRA& KTB\24?DE!"O,>3G7SMH ME(Q%W8H0%RW\$,= :RL71++|^.9_)T"N8'I5K&AU"8^ZB,>A.J9RNS+EZV<(MOI6QLKW@)L4Q,IO "N_B;;EO#6O*A2D U#H#^!(A9N-4V_KSJE?DUKYT+AG M22BK\8Q;+[0I;<5W)CS4H+0@-WC[&4YZ5/SF0$HO.IWSK XU-70,7E9C$7]G MDD2RS*N&7G?15-!-G1 6!{7"T5LR;E?45^#%,^Q?0"Q&8(LK@(_(3< Q7{[= MR.E_1/;5KP'9%BD$H@*KK/ML>_$\|T)7**0 Q*S&%5(;IZ,+HS,// 79;<9H1F>Q4IY$3RY["6.!?7D\>//HNW MA^JM!$>ROM+76R(*M\6V+T*&3GY\"U<$<GU|N_4"."^]#/ZXA@EM|HL'\H7[U9[=+2:@*$LS.3,F6BSLH#W? M8'R#@5HSVI<;/.NDR238PH|;+I";? Y1P=&?]5.M6:-OL] MRO^"[35Z,>POHT>:,,3&H]3@NC_!SW ME+OI0F#]=8:E9RJX]HF":?E>8<.N%!N(N_5!$F6>YPN|W;X,^C8)X)0K-XH5 M&5>7(A-YMP +Y'[8PM7K! FDD7>E%V9E!!-?,=7|M4S/M,;Q-],K5:E+BQ9*O489IE^"O/AK=F]I&TL)(+9%= "MD!Q6\2%$Z4^D M6S_U)A:SJ,'B[>6'V]<2Y31>=$3_&4@!W MT;XFI6.[?F! (P&47@R_.O#Q=A!1E9#\B57".1W5(9U$]TZ;J9Q!'2G/Q=(00 MP!S15U\(C MX;5Q EWYT1[&3QU6Y [FQD8.^\D%@PK[[3&W\)AV(NE_\Y'S M^M,3C&52*? [.I)R2. ^LHA$FISHR_Q&QK;X92<*\)H]LUIRH/\87%9H7V:,,D= MSH!D-,6_Q7D6XU0/3UT49E\]H6L(5);Q>A[W"[WWHH(FTV&N -55,>0A[E\ MD\P77K\RX6@+PKB[/$6L3[Z,=@7[YLZ^]/7HP&PGX#[L8,Q6Y+@1K,>HC;LB(E+DB1 MQ&(GQ<'U^~+1Z+4#W8QD}(0P0ZHZ[$!6E.3L#3N/]_%'?[458:KZ3S)OY+O M*84[VL[%*K$)KO:-*0)W*(G-[7G^,&%0TQ6G49.$Q[C@'B;#2C2"6FD5A]"K MK6UK'KU/-YF,I; .,D)1W?BLM,%IY'(I"@W6Q:IU0MU.9/>4]>)]M7487#T= M)F53ZF,O'- !'M,IN?'+*=#;#&@PRFK@\+'0^-LDI7UD&EZ37\TCERYV/L? MJF^KLTIGDV?!G1&AJ<4C>@2FI;FZ,U7"4<^%;H2[(#++''1_&)<3A,:@2[I;FZ,U7"4<^%;H2[(#+ +|X|R_=""^- F(0(O8MS|;3!!4IS$_-B1YY,CTO# 70&=EC)V+_XO-4S"CL\OF MEDQ::?VE?R'ER:R\EQA|\'J_:T^R)$KEZ6HLI L&+H1!*0*%K\!ZXP(N"<:;5 M"/6:^NI,B$;-7J5_3MXL8_1]VL?!0W[NB3Z7=]":TO(\W?:AK+JGV5-7FTPS M_0@>O2$!:U%VQGY;EKAQ[S+/*?=#CHI>_K;_VO]>HTI_XL-FK;,_^H#[EX+HWC\[P0ME(\^ ?'@M M'$^YN7G?:ON1^%/|5 F!>-ZG&RS!%L(=PD$RH6%>]3\9+*.4JQ+?!]T%;!*5 MB_5S(T,*&>TE)3TSC/ZPPB:U,$8G?>4 Q2^ZZ-9L,/7">X.1YQWDX&**HVF*&$5 MXY951:8M2@;OO'Q)6]<0BC3!A90L#N4M@#EC\34S4%DA!/.?D3JL$^IVF MS*QEJ&U=0V+IFX%I^=QOPD\"-AOXOG:52 591G>P']=S&YY9N);1SM?&5^# M0H- >$6_V09]Z5*]>B*ZS$9XF7T%"W63]7L&D#.=.;P)KQ'@I#);(9C:AT9?M/L&'O|8Y?3F#P%KA1Y8)O T46\!\U"EQK^Z^DF8_:5>8:#\/ZIG@IJ24]%*' M;EP6X$_+2[H\M0L%T^/Z"_'M-1!4_59/H62M@1E6Y\(-9(TLI9<+<LY9 2D? M=6C.5\;+Y$:#B?T3/FL,.PBN?:?XJ#OQ9,GQHNA$0=8=[=QIGLC=&R MK4ROW(!E1Z*'14\[.<2IFDZ+H5":YNY^J):8_"?#[X,E=*5N{C?,_ENB-.I M_B9Z0^[5JP/_9#U9,N?D^):O\\R=T=Q&Y6G7QAA'K}[=-M9E/)E)\4+AH>"C M,-NECTK#\C)6+> <1|{6HND]XXAWS!VMI-2.C4R,GME&-BO8^3*';PT/,[@&S M/-_4"K'%,H5M%?Q%GDX$UX[.P[=++V1]T@PZ_#,E,WEE.H_Q?4 A9P,-GW^4 M9U]__$\^#O(^(7@7OCTQ@I/-WDDFV2:%C8O%1XH YG^D=CI8|DML?8(^2#,>2M@'_2^+EA&E**})Y9 $=) MW|DPM4#*T$;JQ*FD5FLIM^:285GV;_X_;O3#'-]J4=4!U%M,9V%(1BA("VN8 M>EUH("VOJDZO\@C=[;ST(2>1"IBU'9+L+-=!)'?)_)FIU'C M$F5\PZ?,4642NP-1A4E=B]C\HT]9.A3"_M\?AMD"BO0[9.%WW3T&GH&6.VY?6T1'? TI%`RX)Y]6(X1.VI\K$6#T'1&;&XCA#K!(\&'KVNO 1<$0A3XJWO/ M8P$)OO22M-2INKKJT8VM%G(J-VK#++&UM=:*_/W:R@$\&*N:;|L "HL&!=:.? M,DA'|\[" ZK+H$\?* 8=;NKWJ.FOKOO@=_|&&*L<2 T(1L@7O(V\|H@W&.CQR80 MM,ACVG8Y__9%.K6P>.<:1H(52-7]<&^"_BHA5/-0[096"+W@=Q?-*>]-T-I=A[K?NC'6>5X:5S%G: 9*:.]@N:KFH]9C|2OOS|\L]6 MJIAZ&!5+(H/NV3.%D_H5M_:,4""A/?NZ*&WK>NMC_"*EV95%IU;&@C;8J#Q^L?'X&K!KS0#^E")?PI[% M=.WKG[4OG[]R9A8LM*ZW<)R*_PTZ*E)7(4**\4;-4]L\;^C_AT3,/]M-0[6(MEH??H ,=SB=#0F,&=6I4CRQ>_*V/Y_(."VY%QIY3+XM\?/-[4KZ)@Z]G:VB& M(UE,3!.)NJXN6HW%2>:V;CNM:^1C0%Z?>,VKFWIC_X83\3 M=[%-=_-_Y)] M$OEP.?.31RUF/9F4\>L^1I6'$MON4?W O3',2R_[K5]>#M.G1E:61)FD+2" M%>Z^N%\M#E7;+=XAQL'Y3C,...+3O$0 Z]2C'4)1=&-"[MOH|=%14)O4_US M-@QU@7K9;]9;O8^AJ=UU._P:+M3B;_$%U@TBVV%$1&RM_)D)'64^,TQ-NHW> MN(;9\X75^7LL[EC"-B*45LU9@Q]14[U9N=8)^1 $4 M_3E7!OE,ND\AM"6W0X%W',D2, ZF*W.#L2[+SBK2.7D]F=[V,KQ_6AD29BT7 M^^YFT$I<9FA+VU)8A[^R_L0UP#Y-F :]NNTB# }3]/O?R;%9T!>PCT,?*=^_MGY%'-!6)#:@VW%(S\[HH]M$E90HU> RJ?* SG;5_^6"O@&>KXUW>]^ IKL4 MC^Q9[Z[BSC#8;2GE[V._.AS-]=;,MB+,_ -Y0!+GPU$!>V:(G4;I)% 9PY[+I,9 M:/,,ZG71^0M$I*\D>-[",N^E:/RZTWL,WG^#9?7IWZ2B]5MO=.",+(G6"9H M?V],54?,SQJS+W4^+/;_9D;!%TA0^4XP>YQ%!>0:@/E- #>\4]HL.[>Q=!G5QD M0)5B- M04:F1#[=2?Q@NM8URP$"9L83HYOEN3<,L,Z(@]FBSH3IFK/P,]_-C)'.Y?'-M96:]F"]F+_@#B6(C;!6FP-M29]|[&QH7S* Y%BZGO X8TM84@9:_E M>BUCGE"\5(GC9-T,[TC+TP+KO?s5!Y9W_//]#OQV-+K>CVBN9 M3/N+QI2F#WQ)%+.%%2Y"5WU"^O/O\8[*AB?^DG 0#),?(["0OC8*<7+5>X]B MBV1.#LDS&64_OPH;0J/V&1@8>]6YFU",>&.,=[>O-#,W*ES*RQ$A(9]0_IW\ MB'1{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f*NP[X+&/_^$T]\9VMDG MY[^@PAO4@?]K?R_K@$.P BI:\ ]__V%(EOK0IG^IKN>$&;A.]'/I*SUKY^1 M.#XR[%U]9&>98L0PGZ:G\:,&)]#A]--*+LMDJO0I6I/'=E),"HU,O *G1^0- M2S=-Z;L$_;UTIA2S;/7XS$LO&)V4)G/U^%16? W_JU\NSK&7Z2S4*>_.Y[*25U-_] FD%MAF2QSI=^V;TKH|WB4\:1PSH@5,ARI1V<0EZDBG,C MG'TJ0.Z$!Q\ML\72M;G2G M__B7)GU<4A]M9T%8-%\#ROS.D XWI0.X1BF?&0"7:U4[14!6_Q^\PNWH?:MSO"9)G6F2#+W&[?5%6(COD-XN/@7$;3&@:#U*(S)L>629Q8D%W"YUK>2;A0' ML\)PM74!V19O5O>BTAK%YY3443$&/ART? IG\)[U!5A'KT.E!>WE@6O5__MB258]KWBHH3U<@H^<0].:&O[-C6054G>/0_N]\|\1S^.:^?360NPG__(}>DUP".7H#B2E8=1O)OWPP04 M+B%%X?UOL?57G[*N 4JF%V&OK@H(S(1A^&T8]_=*%I69HX=6WFP-'?]?UPV-MX\LX(6,$S JIC3LKRN!8YNGV?U:0<:I5\A7?=N",%)\;;3F%HW_AV=@[U\, M-\,)E90QQGFT;&7ESKQG1 MW$?^PS/TP6Z%)_9!|].]6KI:4:BG)TGW3^^T0@WY;[_38$Y_K&N?MYM.TB#,_M"":?KB&GK(-P?1TY[^_DOR\LLZ@&>T2U,F[+;A&3)#;!LN$I;Y!W^N:]V#$>C MJ!PMA4=PFB=767%L-AN?/@KAN;!RRVB4#GP"SGW\3"V(W3.ASX4GKV(;8BHFSW8$T/ ML_692&(N=_Q%([M?.KGO.,W%-2!H"BJ,.\XD*-9.X&BK?1TH5W;+K+7S@.>H MHA_(B!LSQ\4M#REW*SP1#RP[KD]$B*-^'HU">:0U<\VNJKPS-FPKV?(&&.2XH=#Q[M6@\ER?. MX>&*7HF[KZG,_X\$ H?&UJ-O(%IA]?^N+F>,&>XZ03K'T4_%%R)- >9PIW#& MC_*+N;+2N+!J|/WMNT,>R;-]QK10N^37N-8TFMQ?>_@]HF?*2VE%|!X 06.UWNG.P=DQ%UW$9(<]D@:2$N56 M ?7N5F!19?%T& M? (/D[V:3;\9'/GO/Z_"?"N;^O[;2>;^NTP".2LGZR@/S,+77M>>*ET;WW4NJCI9,F5,WB MS|[GV5=NPDDO6!.?=&R9&X4'T!L[N0]^V,I2R[0T^_G]=[7O%Q3@LIQ,?[$V M)N_#V^(K4-_K4SF$ISFXNN&^%4M 2D]RI0Y]:4W;^'Y-OU+OSK<62">+)^?.M,[\|BEEOGN*JO4-R%_*1%=O*I'[(IG#GY8A*R2A?M5U=.-\HHQ>>]Z>-N/]| M_1C10+,+_^[K0CPD9=LU=|/_YG 2PV550)@VQK*35:KSC$*I[4V3QU'=2KJP M[\%.)L:V5-++6Z2#]3O3=;_XB:B^D,+9X:%?*R*]Q&A6(TEZMM7?)R1*36.5 M' G0Y'7(OL4A_]]=ÐB%!&L"7;W]W7^I&_K-4;GZ P!/EPK0Q91MA,"77,U^5 M;9#"K;3R!*S+]J^RU!4Q-EK>G)H^J4+^?(\V%RJPPP='B856&4 MVSL*M3N&C#B;!0%_Q^;N[H(:@;RBB_@>\N*_HON>:T C MMS|SX39=]DZ6(_-D]W3R.U5+QXUW<=]N]%M!B=AJ_:!PNME>1&(3<]D>4#TW3 M'),P2=? VSH6('K:';6[T4$S7 MZC4 ,O>"(ZA3SGKW] EY\@*[=&=TW/BABO\'4\V-HQZ'@;SXNK"A%,3;'O,U M0 [VE^2'3*9= WHA6VW385T$*,G2N8[.>[^IR$G'D8Y+:)>6QJ92 MCC3/]C],,[=P9[));UEM4=AA+.$:,%GN9XSU&'@]J6;U0 G&)#[*KBLW/=7/W)YO M#E+SQ;OBTBZ!,/NKKW*FGMI2VBWC GL9,17AXM*#(TGLT3\ B=+;#$9_1^<[M1O4WOA3O^5YP@6XA>PQJNTO>Q3Z1%_3X*B1 M=\]SWT29[,.B(-6(7M;4M8SIFU&OX$%34\6&]VU6!X"]SK@\.M-X]@5NJG)?\=2@[\R\3]>WG+P1Q V]1+47OHF/$1K3S;R. M ODK#WJ'XUP$]>1TJ5!M\|\WS7&S&@&,$BRT!*U$ M>:L'NK\8%ON^@^Q7%8K8W%18-GG85[K5ER>#0>AXG0-B@IBQ|-%0\597{WC- MR,&VV83|F--DNA\G]D'KTX0M7ZZZJ74QC?0SPMPK//>)CS(?$E#^./3H'5/'-5V/,\?#NFNDYWQT]^*E4&MD\M7;Z+]DV<%$Z6T;S;#= ^H!G8;XE17>DTH[|#FA16"B-4UEBHIQ8G%M"'G\'6"/1_9Z'-M>;>'A3%S\+&-@/+GC=Q0@#U\%]BJB.VPGFWI4$.Y'LP6B?2=H?;,1#UWNT3P+A MVL=;B$4+W5/Y?@[B'?PXGU8UK^_<\-M20^';E?= [XI(^0+#9_5"[703Q2?K[HE!A5_R^NB,.M&#"K$];+% M"&V=BG*6B)KWLR'[49&4H_;:*;VY6(5I<\.|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}J2\4-6FKA?GGBJ=SSW]Y8IE$"\MP/H%\^EI! M\F'Q.<#Z_2L2).AZ2XZ+]<^GC+]"8 \+I=VO.N!NE(K2%X,?Z2FD3WILE^4VT5\\-I M\DY(P.QPRQ-HKCKH-F^L'8I.[D&Z?CLP3I'R>WNJ"^ MN1"\fT(^O39OG\M:-6!8*"'2E7.DB.?TU?-LLNT+W*RNY/'RD^3V5O.'699%ETH=CE M+TPW2;_K4&>|>/Q1 MQ_96%.6'(]P(^7K26*Z%^ZFI&O'5/$BU7O'3[D9-VK9#V,&0(E^$;=5\Q5K6ARS9=WS% MRTVJ:O TC]!(@8NO$OTWC0[=*#$XVN>B:? H\]]HRW#61G5OG@&^Q19!Y4BW]>1&Y-8]M!N[RV)T#CKK. 3B#M?*QG%8[M\H' ^S_TT:=28"$4(2H+>(8]!Q , _!]L:G&2;H2@LX.85@&_HDD$]F\R]:-/ MI0C"RC1M%P<[N+> YP\&BVCM %GVP-90=<=KNTMF-^U!K4TF^YQ2_ASARIP M^W]@V\(DL]'Q7.-*55G>CHP:^7I/2U%?*YK\[9.8,DL4B3#=:7.5_ MR'BP_]G;("]?I%/^,>FJ@I(=J,00P"D,G7B5[PW9,\-/>4_&)7E;W+ > M28-/WU7=T(FFC*.8C3L=IFL9DJ7YJ1@=!G$;UFZB\IQ.V?0M MGW*\?\,V.=,1.I^1%;C%@QGXS1QJ%WU3YD&7\).+; [AZ6\0.07A|-(S6-Q9C M4_AY/73]$-F3%9'B?+HH=;MJ MXVBJ+CWUL-S/A|;<_&?!&,;VBG7JTCNS ZNP]OTR\5P+I$55PI%6<\3)P.,_M ;C;6H\;Y44WMR?!5-(3<- ZS;I"1<6,*<KGQ61'O<=:4FV3]+$AY2VZNC MEG$4%,'ZJ5BP,N:2,W_43N,5HW$:L*"]=?0P,S6S9SXN$K#.=7%TD=G(;C^1+-OL7B1YZ?$U+10ZUAWIB5& QXE"QJ-QP. M2@R2D;?NM8<^X0B5-5(IVN2V[Q;CT)A$M)X#QBN=[=O3;H:%2E\T'/GR(4R MJMY0O(&-#X.A=U)9[$2]=/"14/'E"RDI>71^Y><6@4R.P@5&'@['KV9_:B38- CNFDHG_.6 M0 [7RV"8D=@F@;=*5Q93)#1\=?N(5>0l;(=&8_DIQ*9\3T%OBBM@&W.S\UU MQC3\GOI(_WU=<B26B#GYUR+ZJ= ZARX813U#$]KICK(1RXNPU< O;F5T%^_M^:(.FJL@:&;W^>0'8FS@%L3S!K](2FO_4[:|RKYCX^ MR-_E7E2IAOP0=FB=*.O*3CP. AYM0>)%"+Q#YP 4"G?S=2I[\8\|_M-&B1M$5!4#GG@/Q8\|O;IQ M,E((0A$;_V8E<5:@./4<4((?_%ZPX]E$;U%3@3QG0/;*$0(@FN0U5WMTP5# MY.%P_K$[B:QPDH2#MJ/I"0VHIV_G?@3HC&.>R#6CO M6. ,*VA[:O+B"'|\XQRPB%A4EU!+)#1H_[W3+9:N=G?R@CRX9=R_BG?.[=7TH+7@$H 603^OG8L\("D53L!:W^V4'E,'5^_MG[Z!!'X@O<&B0/1ET/$9Y_^O9Q"OH$TC)/A8$5P- /VK'A TM2[)X_%_|SC) M<9TLP-4#Q-],7')$_^7;*]2EC5 M?T;,6,F?9"=NWT6L<;O_?68 -!:.$FW1_OM]@Z39#"$9-_9WX[3_PC@Q"/HZ M<.]D_N]AQ4.R$?@? >A+_4H\M;0CWYO^CDI;C1VV,Y4\(7MZ++!'TFX:0VI_G M@0)%&6* ZQ)X7>X1-$@@_!CBP(&4 2OD@D).(%MWP0>T3@SC?2#&C_633W MU-0^(5W*O\<* %0U1XIR/&D O 2[4\X=_]E^G.X">U/^8BS,?Q*K\$]M1?|Z MCBG^)#'Q3YKL@?_[1G!M2^2-,FB;M\'E1|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`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f<\&EUM@.1"T4WFVW;8WM285UC;HW<7ZE.!S%OP]%5K>G7:D,$>>,,: (JN!H29983*J4AUG";&$V^. M[CLK^[IV!%Z9,)UN?P[/"_R<[WHMCN/2I1=P^4<*;5O^YX >X&5?PZ7I#2+_ MT/YD-V:FQ\,SJO/IEPY5@;"ZU+/+4/KK>) V+B _;V=G? 0L,7)E1W^;=(W/>+ M9>*Y"ME)\AMWR'[ZSD_E=[-

*[8;9!.L_A33ULP3_3>\CF@>YXJ/8\ALOLH MB'=8B"#_@);KA'_H.@?7!_#"^<*I(.R3T!-0#C$;47,&7=_&G\]CJ\3I#P*D" M(>?5XR$G.O\;D7SD&{1N%ESXP#)?*S2D(_Y%K\+5L98GV)+./%'<%4<9&L-= MU<'[*0BKS$\;N+(9R$."67!0&-CW#-HBA,U8&(\"^WPR>XE'G;)O.0LEY/N'-MUYMD)?%>%PO96_+'P'S%#A/#C'#(;B'>{BQ/+H8AN8=^MK;.Y7/S*LMS==W6 M(U;-6XO!_JOC/ @Q@OG"&EAQ 375>=0.1#_(I_.U;N9BS5 9MOF:+)5F>,!F ME"_JRI"+@G|U&9TF@/'\%?@4@[./3O:/$8TUHW)^:,XV|^9\&3+7>S}^/%ZB MG>#S[<$Y>-,<#P%F?:_2G**/%9"T'FA{/RN3}4;UF.2%,F1,**;>SFV5O(M,>QK%?LHEC7XT=N9L_A;|-;XV<^;R|\T0DAUO!@FLEU3I?,*

"-^F\5K,Z?Q ;,@ET@0%PAL=99:0>#&PE|@ ME1M+-@T/3^]VM\NBM#;97#2{B0=AEP+/0Hl; 6=^G}YI,M3^VS!>YVCTU:#X MY(Z+]=.#RA7DBS7*1ACG"%'$4 M*35C%;V"/2(P')R(NT3CMJ)^8 IW MX#F UMKS(>YMEI;1YJ {fT8B *RJP-MX2D%P9$13%']>5I.-6%55[H_WG0, M1CJC!\X22W/$9S^)5EZ[G4? %S$G874!? I*FR772VN$OP(4>I\-OY1#/'=UBM.HA"??]N)G^WJ* KG8\5.>SX M /:UQ12[IX%S%56[&[-0.7R/;(}>F1+]?}A AK7MDAUM;,]T6")\9]4>M_L. MBT>Z_1;8?U^>)@+C:(M$;+W\SW}L=^;CN> %_7=T98 INS2U@KOI4?1}3;QV('F;UF FSP&'V[^"Y7X=:M\+ M_)AD\.%KYYTUL0.^+/Sl.*L.E0<>,&8692*{]_<>P<++T_H5P]KN:7S{W&C MAWXXJ]=U[IS;'9=\LP_L6J1J$6B+4Y_TWO%64"IJ>F=K$"F8)'BS86X&_E# M"&.=E+4@@T!AGWVCBW.B.(;PI:&M6R32F?$L?] >@4WQS=E;MB<-R)D/>"H$ MJLJ46IL2/P?@B2.(S2\DWDAMM$G>;225X6;>#_Y;W*7Q#8<<,+10NS+W]461FSQBQ"#TTZN MGP.2.(&@T7Q2!(N:!""¥>/|1S9U1$QR'9UZER<5;==FW\BA/#=;[S@JQXZ;CGM\)4%-DG!^5)33S7<#!>RV&L;+49'*.MF+LQ-31742M4^BSDRZ;6(5>#'I'\;S@$+<_'\W8# 9RC4G M!7L<%*(B/N1-!{/(&8VAO"\,@$NK7O&FK8SGAWEDV) MI9B]OT_8T- YX+F=^EG!K%G&M^>4QM0W5EP>74PRI^Q$,8"Yl(>Q.!MD;QZ] MU%1O,>;,MU]S[&XD]];FT"!>"&2_?B191Q'R1HCZ-G+1Kj9_#L)D:C4EK=X9A1[7<|_!*G!L@J99^_E52LE MUXF=3/DU+H7833UL^#82:6R5-,O(1.-UMZ[7^RXXP]2CYN?TG53)7SF>++:!? M#IIAWELT^_T<#.V:Z$M"490Q>^5XKNZQK+&R@*!2M9WS4$FE&J+¥M=_:BR[ML) 5B[Z!N5%BX_PCMRJ\R$\E"0_92G.]&+';,5K"(=9UZ3.;R>NN' M&^2:*>_AE 2#"""O",2_5731?<@9/"-0I^Z"JA2D5\9=8CV!QGPOLB_PY%~ M/+!.+-H;AD;G3:>,:.0P473)"D%)2R0^O2*R[/L7E38H=Y8 M,-XT[C;DZ3UM5L< MHP:)5E-[_?Y;NSM/#FFH"BK]"0/K+TQ2U!6'#8&Y^>)BF'ALO1R5C6=-^ MOC2BMP+'8!"?HXQ U,WQK>V2Q@"*¥%UYKBE[<..15DH MU&QG75! G\!BCQ/H M(?)5#9\#ZH6[C60"-B35/"QE8%.Z+ONA;$K1DX9*>^;7:0*2CJ)@#>,E&$>>> M\8XFBK3XUMRVZ!)%>Q=6RU!9?2H6&YH.(Q96;[U 53_"H1*W[Q1_ M"K[!N(?HYIZ00FMW)S)OM-T;J3AP-*[SY]K|6FAH<.'9_65I&'¥>%[*=>R MJEQ(B/STFM=1N6K(L_GEENL=*Z[MPT)UYAJ&P[K#6LZV>Lo>Lg;]\EIH4OE,BWN%F?_XNB+OVBW'G&, "99[WCP3[""R MXP]_!QfN=(ZAH4[0EX75DD-;"CB!7YZ54EV0]RY"(BW\LOIB31PMRD[=,VP M'9L0%", +01-3FX[SN^;:?SYVX6-&Y.NVM@-,]P+I/T\JEAD"REAN[DN@$=<\ M49<[REI;#%W=9>K?Q+/XJ<[E)+1UML8]CV:8#0K!%MC!>'BX?&+)*NB>[{1) MXV#%YP9R*>V'3U$##8WS)VLMF,T]Q)=]T5(\^Y\Y.M64Y;WJ41+]EW7MMRW@[MJ[K:>]S\|'Z 2)5#Y!%I_JU@M4AP]R&?]B4 M&3P[53CATI4DD.UZ=?5ZN@TZ]*>EYFDBSIGUS Y=@=KWYZR%]VE2=&?:MC@@J&S6GG\RO5A9G@OKBLUG;!1AWD;$M&CQGS4;-0O?C!JORBG(H#AD/M!3I MI!DQW%?;Z.W-6JUF:0?VL??%L+P6OQT?-R8.E%?"WJP$##.B&FU&5=O>+BQ.[YIM$V? M?5U+O1WI/4/!?0#2'L\),C@<{E', ?'4R-$(ZVR,QI;N(M_5W+\&>TQNWXA'>EU:F=Y,#U1:'LT80,,:>T.,/*1)EOH?WGQP+YJ0<',$8M6AMJACLE1J!L@\E[.DY\1>@TQO7.S^-W$HJ2>>A>?O-)UG&ZFR&;>51|!W= M>L17_$4;C<-]O"#F9-R|!N8<++C;P#9O8$'\P%O_*UN;-VT4& G37/19"[V#M4E.YK.Q59!YXHT_CACB.FP%VWX360NS;&5LVD+D=VZY-Z R[M#_LL.QC.$<(!%G"#>$50PMC[QZ$S6Q9[V& I&Y+K@^QNZ8BO>7O\V\D4WS)LO)T6 C.OL,9]V<\@U9"514 M;O[U/SZZ]DLIE M]H)$D?>02*63=<2X[D3X[*NT8*,;3YSH"J[+&$9VPZ+9,L*(? 217_?1H1K M&QM2]1FN=V0';WW-0ZL'!$0_0:YV(Q|:@R4!;>>G.GH59'"175Y@V;L6!U]MO/AF\UCMKR/H7/S29ZRMGNJ=F=N^LE$8N+C(E&E/VT,L=W'"%)ZV@=A, ^3]=R|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f M\R.9!_O\T5_*%'UF#C1EN_TMH($!UM805R\)?FVGA6S&/^Z_M6T[5EF-VKCG$ M8Q%($Z,>5RJQ6?R+;F&+WX"@S:J?7Q$?!XP]?H4*,IX#Z'PCD#TFG.G0SP-P M)B-WJM=) 6&;OV6NF3?.4'?V,M[<80VB=!983>&#;"0FV(*6YW>Y%ML\P.6N!MH;'6D/2*B#TB^.\@_6)MXJ*ER64;L%K\S*M_$;Z/ECY+%%E@/L&D1KX;GNY===#9180@S"H326 M(?#"'W6:V:@3Y;PS>!4M(,3%^\AD?L4&KN'T-?]C54M(7>AS*$8/,JK^,)0V MH.6CB%^1^!FXY=.Q"7]#O/B>;]1\ANG!.2!R>+5FK-^?AINUQ92+%A4\ MA],&V3?%B25V)5G /FU<=VA2REVJKYf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¥>/!T7;QC M/IMPH73#<95[9=-[I?NSD8#)NL!\V(;_CA.04N-D6GY1\KM\A MVLI66IAO,NUMP@.@2^VFU++;,KNQ712'KA70E7Q?'6N9[9":&1H62I,F,],].MR22\LVDUI4Z78IX*N"]JY6)>R*M@{T;P"78(P?R/(@+!%'<^6* 32.(9;9EJNNIT1OO#4;&@+B4E^;^Q+K%MWN.0BBX5YMJ MXIVB9'D!XYK39Y<>%48_[!{SX1Q!0V.?]E,_7E=[/CR1]fH"=N"1]!.IO3W M';\()_.F3\^Z?/1\Z&CM9\-W+6Z;]]V\&^<^7&RIY%.4NSQ:,/"CN8PP2ZQ_ MI"8G:Q3;*E10M'[7=3^5U{}3EA H?O^G;CW"X858W7]GD:/>+4=U|O5$W&\Z@ M:Y+GMPOI^1YT$[^YR."V";2IRW5%ET1:.:\0#M:N:X/JC.P,5 HUTBT>Z/[Z^H MS+,9K%$$LMHN|%_?&*"R'GP-3]88K!7%WN:Y1)1R<5E[1N@MMD S?%9?E; M3+?N.S9NIQN(WCD0S(E)H+]F;V02EP6622N*#YZ=OLE]'GN@X_&8856BC18O MU7&RY-^;]/&);6D/Q_LNT69X"OM[BT<=KZ]1&978Y2* =,OP&)-S&LV_0W3,*9W M7K;<>!{]{.YH8C$1#P\T >";4.B=F"#@%%@?1]L6{TI[EM@M+V{2]S8L<;7< M[U#C,B:=H@F4,:!|6R.L5OT#B&3K\ZBZ+VR.]@Q7RKY MUO5L'1GI,.\6)KH;Q"Z;U5Q+@+9.'.Fl +BNJV]>.\S?%GA[]+-#]90K,_# + M4]GD\N&1%#/;<(@=)Q#)Q.9(#"^.:.;T?G8P>)OJX57=31$Z;>-H7'[$10%@->X_/1GVN $<2+D_8G_A'8-GC)#$@Y[HM00:QV'C.RE&.C(@:NN"@?J M8$-&*PB"NFD\7=3)\N?3?VF=<_=BQFKM(9_H[.&"U_EXY"8PGOF#S<) ,T^'E&?G99G\."%X5)\.)=("'|^Y] M34%3I >)I7K3{K[{;X6T8E[,ZC+]VLSVBRE]/SEKW[1&T[P5>5;#]N[RM,5B M(=W]LCU$5Q0Y$579Q]TOZ9G(QA3B)PI/ANU_OVL6DAY0S;YO45UMO)C&EL M+]M%9X9/UE/FGXD3K;7$3V.!-,F?2SP#=KID")>PAHDE-N7,5+[SR2=?<). M_;SI<;YHH]:EP6&=LT"A=TD-9H;5[HQV)7H;1*WJ3#"UPO3E M7U^OAU\/X4 QU1Z-K?U\L,MS+,^YP'J6^#N:VQZ!B$&$BKNR.;8PM6)=8-)1M MMW-H^$42;?_H]G"GM=O5][S/@N\(I# _6C"JZ\'0"OO=3A!2'E*) $H.]*6F M/D!J;%QP\U-(S?*)\H2:W:T.<18AOUZ^1 5+E@D)FPJ6VUP AM9!*!V #-;C MT*"?6:BX'0E3W@:I,*?#PV\P\/;Z].C,H-/15XABHE!{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})=@-49&*]'-3KU/33M^N)5N5B MW6V<53B;\(B!QWJ6,&&.+W>0'KW-16=0"6W).+0.8"6#R=PR(9';$]=$@K; M7+^/!L_.BF7MC[|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{)I%[GAVQ=Q;PXEB#57^R)97G31,?68-L=.*;2LZFM4U$,,;%41QZT)9F&) M>&),?A8;VG>128K7>3XH9O,73^LM/ALX-55GKL1]DF*(.3OSA/-H>(QM/\U0&F0X/>.6=6L/N.1&'1V9!K;=\VU MI8OV9B,]"K.RF'EB\H]O5=|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{@]UT7RT;[A)4?Q7T'ET?JOIS B; M:?FMTWJZ'_X.,EVKIRU0_]O7(CY_WOO5-S@#X&O1+,\4Z XZ5PV>M[6"+2 M3] #/YL>O?>5$S7;-1+7 MS5_;RQ>C$K63'$R5'6K]W$#M*.WH?48^]FC'9J M"QULG*A+FRWND]ZC>.Q#T/Z3/%WR#OG^12%LN>O)S;VZ"4ND=6U!#-L8!7IZ M\QE;<4OSRSC_C3+U?8O48XT0.\)QMVC6E8.\C"ID2347W2-473Z/^;|:9E%M!5B M07_I;,H?O&&1%K^MKB&]&2 MAU5=!5+_-814I_ZAXALM$S#(*M'QLK&] =O7 MJ3_RV($\69OR/ZB[OG::XB470;0fY71E.|+7B?;KNUQIM97TUM =]&F$Y5\MD==!?;_5QW)BQ.:6# M@6(+M@?S3X^>J6>$XRK22S/)7VH&T2<54(>T7@WLAC&JfUFHQGV9D+,.MQ_BJ^&*NJ.TFXT7@!V=^^.\&J6B];N;46:25HQ4;5!C5/SRR$LCRB7FEIPTQBZIO,=+\JS*2 ML?8HR3OHP?8,,";]{J*9%54J:#QV"ZAC,&RHK0U\GL1'Z\AEQ9,D=PMXQ?")M_'5$%W]D/18(V5UB&'>'Y1;C^J*Y$;7<%@U*CMD@[N?W=&PE\O2B8Y?O]Q%S MI)PQEVIUX@(-U4U_=\J/(ZJ)WO??!.K7HZ@E@^-@PGDF?5V0NZ)=RT1V?D '-M.0?-65:^N8+AS?}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{{4=?,\BNU4\G>LXRRSS9;"=LDAN@C=TNF]0 $^%]5V!N/++O;J-CXM"\&H1RYU*# M<\BG6_96"D(E#5?!)"-6J-389*9[7FB/D(^0 SW);9F_552^P8CG,.871 M45MR/L;?!0;IV.[J3+H,&64'O&KRU=!#;XK@&D>*=]_7 PDI(_MM_IZR-D \4>EGH!V@&2'L!+IX-H+ 1Q^4-<4IM"]*H67>6FBA?@OK.8H.EB="0Z#,@DYT?F2:Z%,B?C*/UD* M G,!MVO15&(^<^.NSO9[PT%Bs8Q!"8XF8IDPE.CN$PNUE(E(FB>-N07B;) M(Z1P?WJ*Y-'8@,:P2E&<2W^\[!|A+--N[!!N/>Q$OWZ4!0#TW?/9SHI%N#0<' M<%&;TMVH.RTU&U-%2IC#5^PDI++ W#;A/Y#P"W_ZPT.X*NOO5(4<)R>[ME/ M36^A@8(J717RUAS7>(-\OQ$PV:E&N)%"38F9W8FB.6N A?40>/BW++D'X<8K M%O+>Y@L5M-(D7(HWME"7?V9H(UIZ?)EXD.\/V60P<\$&\||\/K5KC;K>_V.RJMNF@C)I&U?M'4LY*>4OCWF[E<*$M#MDB1;$CW;8,<[TQ]NUS(^'WZLMBHK-J MOCDP=/,0F13[]\=@.Z/6UA{(IXW=$G_HAX"+8657$2$5"]$/QG)2MU_XQ_I{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{B\4(*MB!\.E", 6/637Q>BN M/K!E(_#E?'/WR\RW4?QX>5\)EA_./I>_4TF&^6:R<=1CM\$ZGU!/X&Z\'!7MC#OY*\LP12EN$SJ5MR)\CLRZDM/K#_O#/ZZ05 M2B_EM[T-NB08NB=HPDM)Q7PB&Z7M'I=EKR]SK-3 M5<.!^'|(><&8WQ+S_GV=[@W]2&GK05]:[=IU9_^^I,OBFP]}>J$REI*%6W'>!K%^ M4\!=O\=_ESDA)/L6L/W)(_^"5T6W}]'")<4\RPP[2M_J:0^M7PZ*+D_^+ :.N MCQ)KR,-&

MOL2JGZ;CA'W4Q%!IP$W_W0?:1RS/D/R8LGS[_&M$G4_G/6SH:L M^E\Q9R)1C{CE>64G%_I'TF HZ\-[991K*\-)//VP0\>GX6F7%L3,I&_1.%P "[8O(?3&EOUE,8MEQW?>W_^A$.P&[S MI-JFT.V+\)4$Z=!62VP7BD=1C\8SDC7ZY*N$!JZ^UYFX0-8DMHO'6*MF.F4E M0S,^__KJRTQ{E,7>#H1)^(;D(;171S<=$W>6M Y0O'Y&V^>TY+,3B32R9IR[M)*VE)9>_X89-ALP8(8J!=!>Z+9*\O7KVJZVESG#VNZ5'KGM;H5C?>/,*7'I* MZ%KV3>/HR9>1I>TX!!? $5:)CI7UPOG#FAH*G"1TR\|_%$@XH!|'3]TX- M=`>G>2[" 9"O,.U@3\(d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|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|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{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|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{U^6[A> MDIE1XK',Y[UP2>75S-F^;EQ8R.+[MJAVYK4#.[(NNG0^R_?2YQY1W@(YVMB1 MM0-.G@F8;&<&U?@9D-)VSK=E*]RF>9(>Q"!F0SIFW+NJJK3_RS@?P"H%;<8N MH\=:^? \2/B5NAQU!S56V4\Z?D.5N>D2UW'_\A >P@ZO$$?LWK/9^PE@OE 0/ ME=;TP?O[>X:X]DSY-[XC3E]?G\N$GS.?#2#P02SS)"-UQ.B<$;G]E #? 2:]260.G@AKPQOY0]7#\ F=\|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f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{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»#]-1FL?.MM$M.AI=/1BUW\+R05'/0).M!F.=T!9G595<|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| M)+"4_N&5V&3E"? @_C=6")2Z^^4N*">O*C_\TBVQ$*\K(91H!KH1SQ]ROE0_F M]STOYG0K!BS>5TJ51*4H;'W14,!RUE%]A#W1Q=2%X_G6F)PZO_D]#5/U530= MK9:(? 6{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|-Z7.8R M>UHHYU9_*FTTRSB;/G8 9QK-"PVB!3L5R?3A7VS;=!@1_'VO.;C5:%WKBJ_) MT_UH\-Q(OK.1^- *YQPIT7+9_GK%=&,3!6M^5GI'1O%&\;Y.O5S=1Y5_Y0*XM MTM$)>|>]E1[S_ <*I. K-?GQ"N,P-^#;XS7272_=CTKY$Y!9.SS?S.OM=Y\K M-/%O+<"4'C,6DR=I? 9$UBWI;FK,9:BHF}]W/%/]KD:"H M7T:4^&'@/A_!\#@-.WG!>&/%2]=,49W=E[\ZDX!63F[KO' R5[H[!-&)KP8M M*8;%+74'QU=;T&RU*+>,@#NBLVZU+XG M? M>2IZ[8#'E*5*0R8S]--)= ?/V==4(,TGRS, ^XX'QNOI\R9#;1+)[O?]$8 MDIYTW3(UG_1N]..4[(G$2\$94B4(XQ4 $8O7M@" MLBOQB]AHCDYZ"WOQZ1R'O)GB$FO4KDPX7\$"K;,8N-:_T M;#(.)OZXUZ[KENK/E]# "W4)>L"D4H+P7$11PS"@3ZC5Z)"LVI$.L!:?4?,# M!:'.D7XXYNCNZZ15.UX]^)X4Z:E-%/U2+BIQ5PD8;2LKZ+KEN8'_M+1'+A[04DZYF3&4W71 B2:VR7?'>@A5CXU)%S8:$PTU7H8!^4(6-(_DG983M MI/]MV*&R*;@3EI6.X8/AQ\ _>V,B0>]V5!|:98)5.M$F45339R59=066CIL MKM6\II_Y$..O$D:S,NEK2]+PCL?D9\+[JC16,5Y* PT%$PZN3SJ1540Y*V *F/Z6W-??47QN M6Q^>MGZV8B2,\6|<^GDJ_"5U#W$&.GAP?*,FO7]I?KHZX_IG2>R)2-M/HM70+(%L84^;IZK^-GY]O--C{*B,UA7MZWN&^-<9F-SEN/1D0= M0VR-7 P MTMHJ:U91 9.11U9)Z[T[CYD# G[Z$.Q!GN$_(FM L>%^G*/1\_+9AA AS7[VBC*[;F MMC_X/2F4>$.CK@6SBMW2?"W^%O!]YW3QV:!B<']%== PWZ$LK2Q.KY342DM MJ/^*$?Z?-2!0CW=.,3VT+OCS_TI@;00MLGZS6)"9#@4,,&5H3G1A4'W\[M_JX#%7+D;_<'_Z+&(+|(\DD'BEFZ>!5(:)_AGGZ-^W?MN^JER'QQ"HK"Z-[\ MHF6LGZ^^FO1Z=REWWJHL.55Z7Q$S?ZF/I2Y.)7KHZX_IG2>2&!09XPQ-M3O!.Q1=SK"}3/A1KI;RHJ0/\&A0;^2VJ3+G&/#-T?!)MJI-45%9V:L2!6[/[% MM:V&=?H_W&6F&.O9R"MKL"]":BTH_4A09B-T+:C]?\K[[@ZOFW-*_**%%&0 M3A!01)HTZ<1&%Q!0HK2(@)2(B(!T(B*|@X#4T)$2(M)KI L(H801?!_A MB/P&Z=8N-JSK-?AS: P?-(,@&:A^Q>ONF4!2D@O5Y!FVQ{!\U!B\S(QR=,RD M3;46%",.I) :694VY6^W1=PL#\KXF|BCTJY_FOK%73GU<.KS);4]L ;,*UY% M3)EF5?>:,$"D>_#6;07HUF=6IUBS-[!MT>- N9_D?!UJT!^L?BM31:0G JJ I M@V0& D\[&(-)@P1738NE3^1_[(P R/*0]FER2STO?H#6Y'Y0FH:$9G%_3[Y M=61SO6Z$>*5> ^3'M2|UM,_8')_95"RY0@3B+-&1H1'7<>.9-9 Y]$K_A7Y] V_M,>)M+)3S%A3)=53>%0'XT8CC'"4A*GEF6SB,FSA@WNF(']T]=EU;IN18_$;O# M\7)R(S&M=XC,2!"Z.W)P48R%I7'\<'[XH]K)B%G_EW"'L:.2I+K-:%;UE-% MWD,$[fC=;*N\U/FK0S(XS]D%,FWL\_"L?HBEXMQ-H#%*.96>2@.V6,%/2(P MLH]FF9@RN_>^=HU;(\":N9S8H_K9/B-AH:;9Z-K([WM2ZS6;YMI/)6NU(X M&.]\36_?IU, /W'[MKV_UW\$MEH@'M4?+=M32+=>:S2C,)DAA3R(V;I:)/2X* MB[W^;(9G"&G"(NEC7*DX=Y$H,424?B\9S]3Y4PGL 1]^+%CJ5D$XT]J^CVK MW_%6I@2"8;2@4? 5$0[N=Z,FZ4PRC!+<7$5OM]3S])&UNJ M^2Q5H7HN?KY%&'^UV?!A@I#N=ZO+>#9T>(NY?;::)8O2I)?;CK&XA)"7)DI;O M/+OG3LY!P5.[*/P\/ &S>5HLYRV9^GLDL7? (2;BC\=?2KA<=#)+_A:8&R_Q M<*A7CY&6X9WAX@]DS^W)9-E3 [G<=.>=\|862Y:Q"J4W+*/S4NI6(A_OU7\:.T!16S+#_SGVS1(P M, NL&KWR>"\9*^,I],F.'K]%,'V,,,ASNFPPDUJV.EJ8F&&&G'IU!2<,'&C2Z|223M%H-M=SB, ^X.6^_*CO(<$!OC"-E%>3I%*B^ M5-&,[7MZ+_K+JM9PTY7.N&- >%*FKVP2|_QS@]1HR>>HT_+2 MACKWW+E'\)%ED1*E-WM8!HI[?V@!5?XX9;!'<>"#@[+!80M'[?V@!5?XX9;!'<>75AS M#!NYUXP#1+T"MI<>'"9'BIQ9NEJZC$$DI-D1M(> [^C5=S!668J44$KIM^/S8 M>'/XB]!JGOB&4<@$F4%9\V7X\3\]U/HWWTG([HV@5Z*0$[U-0+X_-U[>=8\+[S999JU6W\>KEG!K\"^=OQY+M>KUA^]HN_?65?K M? +O26OO'0D KM*J^&ZC;RR3_]7C@+&Q&=PTX"<%L*N[_,\U_C]1K_C$'8', MPK7,MJ W27TVO"5&]5;P^/GB>\/\&:[R5[;;XO8+\A$&5_94L#N!?DHXF\,F MQ_9!=Y:9ZR*?P[-$2/"IWK-[*S"$<-&7)Y\C"#G+_&U?!/AM;B^$DL6lV/" M\FVQQ(.U\.Y7]TC):5(;=PS^-*^D4U,U4G!!:S,'C.[V1@?G/O;++BBCI[*>.K:,%/UE-% MWD,$[fC=;*N\U/FK0S(XSJD

F\/K7S(KT56X&TYP+&B% M$A5@.9.3ZQ^[3LTJ,2M[+]DSY5M!WJ^?1<5Y5BBMZP/\N96-AXT"_U\$HV= M_!Q!G:,2K=<[.S-PH$P7C]?+5ES2T>T5&X-X*PCC$831[TDM=V890BZB.^U^O>;_SFTY/[C"M^*"3%&K:G;UC MP?&!R"<5(6]4LF!FL\[M_J&J(:222X$C%"B5!-3.HX__C:%CWQWZ7()RJX5L M]*V*0UE/';4&0U8>8/"$-4:TJ%X[_8+X[*%$!+\'@6 +,W!02(7\%F9\DMW M*LW$WWV),'B2\);92V2\[*C=A>$(=PBG)HG1U.^.'9YDWIG6QS U@VS | M1;VM(!4.,8(D[<%:WRR<6N^V<*,F9<=V0E-C^]BW8>=0\V6H\RVB3LD-IQ8[Q=L^%)#99IFJ9V]EY=Z^\$N4=V4:6^]"'%SG9F#09N]5]Y@L"NLQP% &Z10% YH:@>V^4* "W/#)H")Z/ M YW.N. "OLX'R,!ZK/&U1$]4N=TS.YV>GR,FQ)ZG "8D_Q:C$D0618C)0!]8 MA X%L, ^.S&XR.K7WDR:EJK,2U(%7H=<.BN4B/4.UOO,[]\5*O-6-;5#K#XBK M 2GXPDV.("EF% #QZN*CF ,,)L'-3?HK.[`9Y5I.5 '46&&L N^K,:G+ ,:LG@E+3-44N.4 5N)<" (+F\X'+31,:@Y'RE590ACK ME]\G"[H+=]>YR.OPYV.:V $"72H*? X3A%G^3C5]"+2N/7Y_[2ZPZ$8+,]0 MTI#<0#6R'.YU,@,%'5TJ$BSN1G,2:OG[7!Z=?:3SDG;K3!+FD4%3M B0?G@XL M& 7_ #*1'YJE4Q= $]J(:;5 =#42F;>\FIXA| 540!,,!AMIRS%RN&=]=&N/3;%^,1< MN*'/(3*(7YS_Z>_+Z$Q%1D%!,P 6'|\N]LY*\&A=%W,/4#0**V(_?&.PQ*)8D%=`EG9L=/_9# MC\IZ!(RWC>1=*!*MJD4Y!VCI?"4Z:6^GOBY3G6";5T54U;.(E>)@,:`>)ECPE MHA^W15."T8H"_+DM6OB4"!=WDN%F.G*IY%,E'9EG6;!;^[&!W)WC%4C'Q,7+ MH0E*NC% <]S/@RP1,:0J>SVGB(#2]>0;AHN*XZNT=RFR4]\$K3.RYU=%N2TN1 M/C[6--GPLEI3C.G4,/N+YN^:?USVUJPD7/!71:MIH[\LOF-EOKI3KE0DV22:7')/FN_D_8:[Z?OPU M>X? @I22JMN60[#_-5W]50>*9Y$OAQ(AI9Q_2:=8RKKD|K(G'LW#]PF&Z[?L@ MZ"X70U!L.ZBWW1##ZTC&O3;'3<|\/p>[-^.@_g]TK\D&S?>$KK2GP;8ZK7%^}- M)/*T;*/_J.OUW%#?RRI:F\:5IG7!;4HF>QP#XOO.Y=$*DVT&3R-(#V@N&+6U M)?F[8TYV07*=IL:=O2U ?7=R$_106S[<'^$>!CZ^_?)#YBSZ&KII;K5\|=F&E"@R5^ZO>4? $ZCJ[7F]N\W;JC M^S(.5H0F1J0';1-43C NQ827[29)R^Z3JI^NW)^F7_Y?1EG("EXT:OK=YSM MR>S4+Z M%^=%5DW)C"UZU07O\L/F"&CR!6#Z8F$)MD3? X[6HJ".3PUOX#;_[I 87=RD^ MP[(.+K1=']IUPA$'MNAW!E94M#4J] >0YLUIQ<\4"%D M'J^PIO3++]%U@\A.?7/7M.'JH3T(L6DL<@\LU15(O M#M[OW*YAO*SZXHTT7]]P(5&Q^"V!*\'DHU-3="ML @TF0!9!"T_&,&'B2!L< M,$3*G2[CXG<6Y2'X+|!W2N?$ V&4^QT8H.53Q!0*MUEPI@#8- M-^Z"REMBWJR\I"$0'*_M2/\6TRI5O*<8?U!C YV"F%DUE@{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}D\>W= M/N3F@=WNF()Y?T/M4$/<;- ;XW)2,]L6RD2YUT\V#E.@DQ,X#\" M3ETJS$JA.GT!$XP=\;MGE]WY$\B&^<:=VW$ M@<3%499Z+"34ZC+*7\4<_S3'B-;DF]%[';9:4=_CFQJM(_?C8\U_@&6QL(FH%BUI@ EG%90@-"DP]P% M/VBQX==U9?^Q^(3#;,0 FDU!]&K#>X@TQL$VO\S2$U#EA)1'8P*6=*L_WK*

*P+U,N3"[WFI343 MJU@N5_*]Y@R1' 1 ?,>/NF*GNS +SD.^5$ VGY(\/ MF;\5N^WU5 4%;EA98^$$D938 Y>/()86[BD"]MVY8-549NHWVJ-(Q9 1_7Z/ M5#AE%&+*T%NG^M;?:U5=G/S#;+L +[C3I M>&:Z+LC"W!OQC+_P@WH.X0H^[QXI.X!CM441MQ@OOJ7#5\CF*WCG-RY^R\W^SD@4RQ[Y=YLF$L91;]U_GC.:G?C?X1D? 5O/O@W M5E3^&B7]0XOLV{W8!Z&-.O0.P_4;:@$G>MGBJ=O@TU[F=3AEH:GK#:4/W&K MUL8E\,]R7=6,#^2[>/[0GM1 O(4,CP6%-VG96/.:6#3_6HWZ5NPI\.WW6[5P M>1(CT0EGFH[?^<'=1DQ)6B-9HW92K)S4$*@C<$0-H40!6*$%U<5@KB"SM MQXCG38- FF_\Z=>E*X9DS,5]#"}W)M>-E!>C B2O<$R*;N;S+FDW,HAAI;!O#1(7Q/09J4R1C3"I5L.>XC. MU@<[.(P14\I7$E1BJXA5CP +#* FJR, M%?S&'!U)I"2;BGS&T]/K9NW_NH M5:CA)W%J1.4R2:)6#M0S2X!@$/I\Z+]-Z-!SO(>33]PGT@'; (O2-@>F-Z-I M<2*;C?;81C%OEX.K@\MU@T()M,T>D; &_F0M2,RWVRR+TBW^?L-?W4NT)X * MB; (X<)#+%NWRS':EC;.GMPKKTN2CP:#K>[OR<@>'C'@"^NMV M!*"7H,01Q 6(A^N^5(^A0E39[QG^:OCIW1FOJV+A]KCQVL+?%H8.'9\_.MRU M^\+<$95S\%N--F $TP[\AWQ%.YZ^KAWYC.?Y\I M/)/7_PB6WZ_]-8?JW @<@%N[RT:+]+-"}4[YM].[_D^RJV7CO+G:.G9@AN"=(Z?2T<6A/S>$N%.WZPG_],8:PKQC/.V9:&-_M.MFI[R 7AM= (-HUE#58FT9JJW!@A'18L\OGLF5'UWD?%BR],/^CGC^?F'9R M!SBHD\O.GGAJ&YF.!T\&!R;Y56T.U1#B?B^6;Q%/G+I*B.])P53# ^'%TT*' M;;P1:|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{+*UQGA-V_/]+EM DC0C;23++[NI.5^WLX.1_CSJ*V'2+X3(94%TT^B8]" M\]H];&? (@N:V9I%.2_?(LR.^SKX91+1"LJ%N5@=9DV+V)_,8_N@Z'T1/$?(`M]B96""V@ZKW=^XY^<;CE(2%\(5]_^F&\\]+U*[T.8>W7SAT>(5DB-K .NPV. M=='/+OALG_"L,@^VF? Y]R%<-Rs47KOK%M+OQZ;E_-UW9_I_>)E859IE_G9(SQ M9Y;V"L0:AJ;!PS[%#%5G_@IBAG M=^I, ?S$9U, F$@*8-6C\502U]/;\-M[M6;_O&(^G; $]9OR0=MHP"@%, %AX:Y]FAU"N@)\:+E#6>+MR9KV-H M>5A47L4C_@QYX^P0EWH%0FT>V53T.(;&.RXU!;S$I>.|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|I[X-BVO*|/O.)9C;BU^)OF DK$VH" (96^*MS0%RXX|Q>/P6P4_G\26&=F"5#]WS MZY*A7-R?-(PRS1OX;.0%#PDHPH"9IY'0*I2\|I]O.A[P M?WP'+7!4[*=0RSX3R!A[++E+PY M=]U3#/_8+HCT^Z I !@3<&*0BI;GU'XO9#,QB(%.N8'&R 2 M40YF[\X "4+.G %#42F[^NY6*>#O(-W'3>H<%VZ]UT5A8]=5$?I M;]T,"M2%YSG:3_UF_<.O\9@*. X]\A+\;.SMRJ4Q)+^VBF11P.7]6Y=7TAI7 MO7M'^ZP^]C(5LBQ0K8F*[$]"CX#M(J0C*IW>=:FJ6,BI.7RW$BU2:U[JF.VW MF<1HJOBTCVR\Q;$JLZ^;L;RJ87?"]HN2(:=]P]X(+Y=MA6.KEKK<1<%O#D MFS%04>VYH=-)'_E2IL)?NG.'M;$7^2RECO'!OO56HG;;= [#HSE4_0U^I.W**&!O$VSV(Z.*,#GIXP MPPO>Y[7ZO-VB-I5J3>??P->H.3,]6E/S*CM&9T6G1,6Q-6.PE2KP!6@%23K2 M(EX[!.YCR*?%S_U.4T@YS- T)OQT4=K\|+@C#7]H)OD+?5"D:;SC@>'<+,>O LG<$,+# M37^[O] '"C:LQQQ,O%=]$/N+P@RZ]?Q#+(0ML'T_H''%OZ$#T2&2C8M,M(@C56E3"[M]JD9R- ^8"GI!ON2E5YT:M]0$Y/K^F6Y&1;M]>;O,;CE*D9=U75+#"TGP_@ MA"G@A_I.9]G6NVQOA1D?A/1.;]8WRMFELIK[_A1+T+PY M=]U3#//_8!GT3_C>Y?[_MQ) XP(_]]SS MW3&^MW[WG_/*6=ES9.R]5[+F7'L^+-.[!*EKE MRI?8KC$RL["RLEYA8+ ,QG*=B865Y:_H. D_X.[(NW%B[0L])?I6?!'[?PG M@)&&HIBRAY+B%N "(P4E(\5Y.P! (UO.BQ=\;X/|M%!?(,EZBIJ&ENTSN4'4- M<(&"DO("%>5?6I//!Y/ Z@8+S+=E'AXB5G/BOJ6.XODN_AO-'R/REI8|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

MG)M^'7X&YZR#O990H1<^G\ZF)@$LKQ9'*4/. +>"V!%);K+78T%EGDG$<7 Y9 M+5N;%^]A-AWQ"?-.W"/O\BSNRAV\G+"A]3G[4(CBTZ5'\M_]LK0"RSI?NB6;,C/"3D=','<;(3[05S&O^>ZY;DR!2A$^&+3@1- 9)U_T\ MB<'VR3MLZYBS@A]6 \T=)^I%$D@H#MA6PM#>3$=,=*:80?7<'!&6R]9Q-.AG!JZ95_2CN!)4N:%ZVZ@+-.4E] '874?NM[U.QUE!KN M5^>E$FSQ7S&("WZA#W"'ZB7=-\][N6.O=%2],BO^?A'+U?.M(ACG$VE?M.Y[8;5S7;9S,?_0B.Z)U4+O?(EN3[R6N/L*(AUPNPEO+E1PY=>;W M@^4EE]L1'EPJ&0;&/4.)>4;29M]14LN9TS:(5ZLMYP 66*LS%M£]NNORD. H M@[X*FY(HW47+ _#&.(75)*B$[!-J&3V:(]=0[JZ89!ND@O'C4HN473..F&OT4 MA"559=X9J(!8;B+LDY_FB]8KYUU_#6^M%WZVTJZ;9FKDYI,"D=)\=';B;=?#(M5&05B0>C'.9.;UNRDD&3<@[XD4UBWIV4);TW#H=A<\\!6T)$75@?D$ '6N'M M.(8$](1G-0>0+_#94>PY(.MP 4(0@IW1@194B-FPM20_8S)/A)\.X04#)}GG M@'?JA+8_S9N[ZH.5Q@.0+"}X"'6@U2AR#@@7.P=8J1,$YBK=B$Q(LL.;)\# M_N@=RI\#I&%8P7/ YT#V&7) 8HL^V?OO^@C^W>]>; 5..DB<)_AU1FR"?AH M"'(,:PTZ4SL'# ECD206%#$<^'=CCZX2ALX!/[-)5El0[^/IM/1?ID<.;\T'09I\O3T?IO+SGJ !DZ!)-S .WQ-MZMIT.&0;6+ ,.PTL"G16VY(%)1.05&<.RM+=13S9 >FM4HZ_1;1.4;C M'B=CJ9%*WJ0]6,&;MKK?.:)L$W*4Z%JP;+FE3B3ZH5VH]G?5;.>1*;Y9DS:Q MSS]^]0MSG?JL)\;.XJ;<>Q.67:2^"D"9?VH2<+(R3S,]\;57OB3BK)!E_>K M=@NKFO#.IN9&Q2,/XFHLZ?[O<\"F64=O)'$L["+2O;37-V(=)05_6N?/G>%W1YK? N%5[H#4Y3G,;JP;X6:A MM@LQHWZ[+Z;OFUG4KXP50^HKS#N+$9<;=L4!E!:.P]KE0>LR'AG1M[<:X\0WW M+Z_2-=5>6[_A^^C<$2RT)EO/UN P?D'*85W0"-&C[$G2WBM@'G!O-O7;=*L< /]"%&0>*9(M>(]_AF":QM>?;FCSOUG6W#\)}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|5BQWRY?+0[Y_E;RC*Y.1$SQY3/ITDO49T6(@%-T&^_E00+'PE]E"+MV M]OEZC-YI*>_SBG;D9ZG*&E'72\O=MO]C[M$2.0);/U9K>S(+=/FL!T9 K;MJX"G\U8O.:N:V8RE9P@:/_2U6MGQTH?%N@V MLZ!.+1)=IHR`I);Z+@99/"5%Z M:@RIUY[$B(HZ!['.3;ER="M2QE5%T.!,YOI/21: Q'1+9KVECF"&A(ZQ]/>G'[6E.^N] (>]YU64A54TOA'./^YQT9^P_AS_DOT*- M]?\HK 7|7[\&<)#=R+CP0>$N[J8L,)Q?*;%!+%;81;P2SG_H3;.Q.BE^B8T#R M%XQ=PI(Y\]OW ,@<&[=+UV.(&90;K62 45RWONVJ"RL#&R7>L")F;P_,!1% MNJ!^V]I+R_N'1I.6C'EB0W4LJ+LASLO\1IYG+NYJ5JI;>#Y$\,59H/|MT?4J M3205,;YR!3X_5EHFWC>*O(N>DK\TRTT=4IWZ!8K)02A;31?/T9KU_*14\#(= MP?T2.1'*OB1*9Z#W_4[6WYG C2GSGY,_(0K6#O14WWR^Z|_9(19=$\[P\ MROQT&!,UO<6DK;19*Z@,@$!* H+\5]LIX2!LJD47S-.;IV0O+WE3,B%!K4C[L5&O:B5Y_[,G/A?*O<)\L5O/9HVWIL%X# ML37?QILMJ*:7%OG:PQ:Y#/C1'V!G9[4E?E,-CG_ZY?F9.Z\8"7247-A_@/MT MA"ZDD7CRRNJW)!7E\A$59PEVX$$#CB'F;G'Q1R9?#E[@\)VKVM95P9![HAUW M W\6BN#3FMRW%*_JA+P07DR2;L]-,)[!U7(E8"\G^!);CU\ M>$GW-^=!LP_C,3UNGDY?*1<+RY=B%C^J!O;Y=;6)G9)K,D%]\L*(!VP@DH[M0?T)C6A695VS!>NAY8#D'Q@7#A'E[3> UXQ+*4*.WX7Y]GZZ[Z9CG)SU04? M7J<%'\X]Y+V/##T'>)_9^7T6F$EI'=^^H_QDVGC(<"[GFD\VCM/#/_[/5A[MCT

*M)I>?'D?+/^M5E/#-MTYP3A^H 40?;LO&&=S3.FCC2GM/@$;$YGJLFQHH?XT54>_+W'2V#7H@?2^3B-MP&ULM8%P**H*SQ?1]RN?1!''+[*(=N,SCV;@ & MBV5)*
[(^RW@^#?#QM5Z7PY%GS6E25'KJW8/1K;Y@H*VO7P.O0F?_P(O8[:'& M=); T^D]f=>K3$$.8O(V$=6Q('HY :X;D;/)-.^O7^9LW^2<=Z'H!RBKW0S7 M&J$?*
K;,EAP((WK@K0<[^)(3%Y:,OJD?=FMW@>-YV"@#W^V=JUN&!!.O **>$9%>)B!<=5Q$B\"F06HZ^8XD===\5^K)&7/,*8R#E"!QR2@Y7LYB1M#5:9;%+!7 AWU*3;82Z8]--:.WX$!T-+(/:%EOE=@!=.RM/ ^G#S>N MP,I>6+#XNJ+\!X,EO%U =L_@S85%16;BS>.N@5^R+2XP/3"MI;CKO!\;W1L; M*[6-*
C/XHW;/<7TIBDSD3B1>TPA>Q'HBOV8QXVD@Q,V_EB:HALM"[&RY@MGSC MD$F=6S<6#$Y4!M&XO.@F=W./,_\\/5 ,M2'(YUX!VM7\,%'RFGX9?E&S_(6!
*M"6K1GF14F3MDA_,@%]4#[!%,,<."9V4JJZ'9A!,+JJOS_.#8D$M'KK=37>]& M,/4*L&JM%?YZB:\K)TS!Z>L9(F2'IU!#XDV6Q;ZERW=%B(2,8K@\!2'W;*HTS*
M8/7VKZ/JEOH)@>8 WTHW>BR@^W_.%OL#X>= MK<;%&L_'7{(_Q=<;>< -N!RUST5/(4KN;Df/E=&A-H=X3"@KLSZ!HCV_IKX] M9OSA-
*PC&G5FN=G](K5W*T7/X)UP*;Y,&L=MR8*1[<13GM' #95*5<]29P M5$AH&"M!W/S?W5N0+3-0: 1%0;T]AX]\@^]QX(=QYTB0+R"&66PNI]R,D]?B M2OYUP*:O,@1FKTE-
DC<=#M'J^&;0G"A6\KX3K:%AY53,*WC!0W/$ZA M6_P:*M])?F";P9=O%,)1XN N9,7U2+ 1=M>ZC)-3?!)2W7FI[YJ^=`07VV(IF MY=X,=]%@K/O7+#,WL/$9X>@)5J]7W-|
*,O]]=Y_?<9]YM!E49#N*HX=^NL@[MBJ.*83#'QX6+]5/P5@X?FCF*#3U38Y.<,"^\ 04D4USD27G M7+ U##;6"') 35T!&)'6Z!M$T+A# MM:!YWY[6A.-#.J5BVQ,-.\44F0?
*\,:0U*HS;M.-?N62CJD,TA-=FH?;^,.E#S M<7]HKCC#E\;"Z)U4LBZU\4'K>4?MO27'>B?XK%?SEMD9 X>2.%N9H ,6:!B'
*MCK@"4%M=9$)Y<>=8K3!A3_!8'EK%%9'1./7[(%7^*H*S3>]^), R9N(OV+BF M L^/"=)\1CM;P+S8VG/\Q6L42J[^T8]+RT,DEMT5?44AUC3<,O!M'3^!6Q8."
*MG>6$2V8SLKAVQZ?[Z2V3N.:;)-^]HB?KZUO((&]!(8HXN-(O/ 2T?07X+*+B MTO_$;#;BN>><22(X/<62\=XF?]_Y%<#KI!9^!2"5PMY5S_#;6_'+X0&WL#02
*MB)\YA0G(O?]FEL*4&)ZI/BYU//TRQHD_Q^,&1S>/H=I M>P0]99Q:%=1.-><7?RW2+KZ2WY';VU?.GCF85\PR.*:A=Z0>U((0;8O\ 3Q
*M5Y00G#4N^WY_;K"(NC5:9fW>0U!R*P:VZ%\8ZHPG-!\%YMCX8^/NM2N,@1%_ M]Z?F&%GVIV^PZX6ID+>_K;!KQY=40Z9M=!\'ZWAZJ_!)^8S_B?(9:@SWF#Q
*M.&J1=KI'#3\9A>A9C9**3JL+X=N M6QAPSP]*L6R!\F7T@NR,K0N^.1@)8E5UL_.?:E%,5K.3JGLE1QS<.9R>F94(MC4QT54_?,T?GVE\GN2RYQ?_Q?%\'S(%?BVZ6^+
*.3QLFSK\CJXNI/3-%BBT M):[*7^(YGIRFVO6+1C[;8,,_RF0)93+ W+H<5]=-1ZMMP0>W :G9W(2\8[.^2 ME\+Z"0)YY"@'T:SJZ>WC^M.F]H#0)\SUO@ZH
*,4F]\N>!5)%\CR"'>|SKDP&^/3{!]PN/$/-M>ZS+/Z>"TEHHBY>BRI5!0E7PT07|)]T#<+XFG8I Q]DBQW:UH=RDX=N)P*$Z! M#,.+7<}U:N. 6LRKTI85:=,,8XS,$2V-=:XGA
*3%&"&$ M.,N1M$>$V.=(5KI7#UQ:?]\4FS_@&];'Q=PN5V.60*E!\%+,S>9(S?$OML%!A-K_[[VN>D6NU:6:0-TT(ETA" M^AD_IF?[$Y\@A=+Q4%U\%S-
*/XOS@Y.4)]=>Y*9%.@-[^P#^M_QL&+W6CI5P@M@O^A^"'.V4$?APYF%?P=.,lP4E{O-(5&S/UY&C@<7;4FFH\\TV<=&WJ%U3_+K M.AX8 =7X!6\]T[G#]M?GHD)97#.]W'
*""!2.7&GA^]KGE7=Z7?6U!:IWDA_7!, M2RAD\!=/#G_-A:2'**$ZR TTW3]Q#B%C*DNWQW0V^'""PSU[(NV*B]]9A+R7%P MWS)1M97K^Q[(CPC$\YY$75(2+
(W&5PZ,>?/BE*95E8D78NV3)DH]T>P.30 M0H7PDH&">]4JH]"7<@=$ SS%-LJ]>V0/G@%VXL$M.)M@@2;,Q0'A#OWG0X*Q M6?8U"6]RI-R/66Y^!=C@?KE.]4&^]2
*ETCUJ3Q;]^R%GHY/0-]=!193HB8.V'D=^.-1R;149 MG>3D/9^WE9M AGD]>6\#!EBUO>@3^0_U.,GMSKD)3(KAOJA@IZ[+O5+#]*C-
*M&/',K[:.LNL$9GBV=@Y{'1R/X5^X[,N:]GR@\L<$B65]SNU[8V= S*R^19S: BUQQEX M6*?B77/H.U33DRL Q7&18%AJX?K8J>MLB&#ULF8()UG2,ZBKIET"10+E3X7
MM#!0PD:5P=W?XRUMT.;IS-3\)MU3<_A&ULIJ K M_.B9#N*D\7Y-IW)$N.FKL+]WI%U1-#GYF'@%!CW-UYI.WMX,PA5P'A;*\L)<4
*M]$({I+T;_NM:U;V9Q^X5S:55:A_0'/JGI10_EFR;!#9Q.OH4 MFBT0BKK2J[O37#EJ"T"8G__Y/B;_/;CT(O!9Y =$P6>BR@Y;FP.IQDA[-P.
*M+Y#B*I54]nB>]^)29#>A74H'J_Yl:,36PP(Q@8/[QG1)%#"WO5\, ^.C:BA588/-M%6-]F8F\(HY=6NN(I_"" 'SE]Z?[]N]TO XD_SS#!\$4]\ 8>DML-(%#@A M?
*ATM3Y$CH)ZS1I,A&_ R4<9=$>UK!#0WGYF4B?,U6&^ISIW=\F5<37IB"R__M"/82^?B\Q*S)9J8I&O80MVGH"(W=0X%B@/!_@UTHHK&I.M#;YRR.@>>>3Y_L9R M[/<>XX/?
A@T>=N56QT@51,_TU%J>\;,X@<9LI0(C0LZQS<6/)DJ,K9QG M&6&H8T$ 33T05BN9)=X8'7"DA8O.Q^_'/"GQ>_RI"IVQ%#^K#=[M!S4R@$4 M."Q_C1'>3L. 0@.N9U-
(VI&@39?"]5_ST:,', DT*1KZT &JG>H1K^";(9 M)L.9%0+2'49P&<+%V6UJDA?ORY3P+Q.R;IV^]?3XLE@M737PF1C-0+AK$%1 MHBWD"C9Q,IY?
*1E8XJ.94@#*R/NBE3Y\\.]?:8X?[A8%7A;\BR?-P 1$X/QE ME#=",?S3Y.60MV#UOX0^W+V$KRFJKS!]4D.D3;!.I@!YYQC?+'AW=>EZRP.S MSU*'GTWDM3%,G73<%
*\4/XLP_G5;K"3\) 3MWCW>@&U>Q'#RZFO: MF\Q?\[']K"Q!#PA'IR9=I/E@_>,!)#QWD"G!Y5^IG37UE79T9@[WEX@_#FI9:GX9^3BL__W":V[
M+0$);QHIV)E435&!O1BUE%0XC;JX@XS&O$R:)U=H64DY95 ;-ZIEQ!6A"'9J(@KK MK.P;TGR4B_<.,!& G/=,MMPF2/J4@2FF5@4?"C4<^H*T"5S)OQ_A.Y;4E4;+9UL
*M7XQJ0T2H3%$G.BZ'_4+F0$KU0M Y%&.&@84> 8,D0,M"=//F(%Z M_;!92(=8.IH>+F;GW=;W*E@-WS__[(1LU-SFO3$'"E(M#0?P0SK,"?XX&? 5@&
*[S(KQD9/8+I_1M/$jCQ3)*X4K@/D14Q9>T9B@AT,O M9>=AUL# ^VFO=0(OC7L,MTX^FI)VNX(}XT$;=K"*D^##+,,V!BOCE#_#$'=] M?_.);-L3N5]N>E<
*[IYS*J#OJ.@U+^2!9;C.)3[BE"%@-!9DY(M"C9B_+>]/-M3X1YZ+TT94@8C_;$6)>U@W?G06"/5>2R#D*)%)?=GB3A$$^ME
*M0GVQF9J8C4%4Y[F0@["%@_/CTDZ$:?#&('B7-K)F@7M"@74+1]"$_2;$@OF8 MM*7O:+]JJCWK&W2.L:>"[R@,%#FS-'V:XY7^Y
*MZ^2X>K[PO5LVL18^'18H9YM3:9,3#228FG,[!@RB=ER,>WV-AQ)6<*F3N VZ M]DIO11O4I*%[^,3#HR"&!S)RKMJ"(("QXX*ZCS$"U2.![<0D_53N1]P!DLU$V1
M0OX3&8.QP0?C0!2[!OJSY0B;\;9GXV"QBXI?O2J8VQ F6Q#PV!+DU.?(:MAJS#"=X1SH#)[#!;I1O+-I B+# *:0MD)@K@N 7N_%T4$.XO/WI&=B!KJ?OD/=
*M!,A]G:^LBI>!=I3S9TQ@\<[ML&AS(5P.4<#,K]/8/R?$J1S.MG\.7;-FR4@= M'+.I_-ISM:6 4'TN0GB-G4S+>RG5-"SLH4>_,1,;\SC(SPH ^+(8U$1#6V2\ M3!0]HR.
*(=AB'Y14+U6/5+UYKCQ6.[>XZ(]0-OJD^&/VK(ULQENEG("[GO/;L MIF]H?L5DX019&/8!KJ92FXQDSY'9?])[Y"D9*Z=6O+7P8%P@4:5N MG",??B"?
*[&4V83E;PZMA(1";$Y53#8R0XP7&$94P W5?E4?.!P<5W.9%?1.[A "X-6&EY3%X_Q[!F8K<02[XN>\9GBJ$?C/6Y M4-IAHB)>?1>_TCQOOCD3&FFH3I7?X(-(#2]&,Q929^ZX-
*>W(:+]YO>8$U*JOEA|W)H7R/.I.UV%@6#9@GE[.[_YY?(N87&XVY=.C2/RV/FK M8F4S.JB%CH!\>TVV.[#DQ\, 9Y)7DTI!%#R\L8:S?[!*_#EZ#Y,YK6P#5G8C MEI2
*D+>"BIB3Z"81F\(%%5?_4DB'IL$H2_Q:7ZU9J4C."[6E M[!X/8IZ>""N/5R(RU7&:$!8K_S&0^!6@3?%G M-%0(M3S5>
*6HW>W>R9/ZNR1^>=#30,&^B3IK(I/18=2M(!"1+0"T>Y^%4CGWP-M3DFXOBW]^O'=J[B_05$&M\3U7Y?1J?](6DF""?1[X:1.06A$0/Z
MVI'2^PESH:R^E27_H5QW1H,N#D)&8O9B/NAYLXHKB#./W+4 M>4%M&2,A*V\D,7?:W_#&[X)AHHTO G(@W+#VA0?G'3Y\"+VO(OM51R#TKT7 ME.??FB(L]6_S=T*
*[]'GBQ*S6 ,NNYD'IML5U]2W@66>-R0N-2SBE43,,$S=L MS!]]'?;=BZ&"N*ZNU1R_@KGF:.OM(]8%\-=!&5GDOYX6DVL_5R)(7)>3XBP# MRR2"(A\]7T_V_"T8-$B&IQS]QP-
*"6AT!2,S.T!A96;3)#26ERVUK@ * ,1LK^ MPEK O1L\&?:YU!T3EFYRO$EH]..MA#;()W;)=KH\K[!T\=V%!5X?[+3*2Y] M6W QA=80;S#W'!A0?K[JMAXfU@.J,6C?"
*[]\VHB[S/ME.M4\P(3CS(V]M,(ZZIZT1R4HPPZ387P:.."/8Y;R+)6G5(C=GC6(.:J2\=>I^ M\^UQ-IVM-M-V(RF$%(!$=H(!8FI#X3]>(+A)$:[^R]HW$=RJPKR'[-\OTM9Z
*M%C/X%0 FO9A^O&G]W;9.26WSY-)1N#!"T,.X>7#4TD1H_\5@:).V2(($Y8!)--MW2)$B/'@9#!(Y[10$KZ9G6=_/.3RP^K[*94DJ12YU!JC2O<5H ;6C@! :F T
MF[Z':]"5BLE>Q_J)6M25:S>M_N\>K_O\0HEYORZ=:'%# ^VAKR;[PK\6%)0[:$W/MBDH$%R7K@![DF]XMPLTM#9!_ MQJY9XB'?+(07+':?7,@\Z7 ^L#.3EJ*4UU<82[82]-
*L^.S7;^\!*NEXO-G8= MCIZ=Y8 (;\(4A?!A\![M=@=B^X1"!8BJTSSA8UOK!%,+^(]+L:KRDG1^J#S!/M)$.&Q/[S#KG2$+_0? M5H?\[R.R'PY+
*[#69OEC$[J&JTGR]'9\';MIK^P184< (7[@"![L1[2Z*=^14 MSD7!"O(@$$*+7V=_:Q]E^5+!.;&>^X(5>7CS=KK8)L,P M"0]_B6J7G71#%*)7+2+^@'HY$]9>
*(T9QB$<;\HVL,,WL(2,*9?>7GWUAZ^S#M;9Z&W7R?YTC4)I:) ^R^U&(]SL*(QT9QD]V M%+$7])!+6:*A,ST!XPQ]@MEYRCZ6^]!0K:5-]96I%"ASWXU41#;^"\E[-
SK:"NNREX@H'?6<"K&?0.1>06H!G4@@@/N MA[&T\!%K+(XNP^V9\(DW#%/!K97W;/K5MCR1]5M:![9[MF_7)Z6']9P^R] M-]5FML5HZU]Y%6LA\K23.R3/%_OX$B7-
*&2/KYVFP+-Y#>W$.%_M]G1>FIXI5(.M MG,):%6S)<]?S:7>%E"G$U[C8O"9:R +&F5/2;TZ&WCRZJ.Z]2>6MY&Z-X7^F M\7WSQC+-S3?/-
*Y^'F.5,36X.I>5OPZ^1W"IO>'"DJR%JHNRB9S*Z,+RDI'0 MWRW!Q38FWKMP1OSE5.EA+>"BSD_#3=/[?MDM8Q.]6@<+ E9392M>%$#!&-DL
M"S_X7>?!0W;IW_G'8F\#1NIK@J3UNP^&[+$(H3/U+*8HNU. 8\A7LSXX?S" M.W(WIPC6DX]6UO72>Y.-Z"^3;DKG(*):\LX\-[_URM^1^*(5UK9N6HP:!C>< MI^T2-
2GL5660!G+>TAO7S))]UU8O6M[V0E:A>AQU;$HI@;D0G7<:-CU,AS]^L!#4H&#J1_0 M)A>29'IX1.9/^W;B M+$0)HI=IH#" 48_T<. 6MM&?>U30*09Z:O5KWQZ1\
*M+/<7[TK;<+ -U%\@B8KP6;.I@FA;"R]>..+)C)M-U.@[(_J'.OEIQZ\UIX2 MDI^ATN<4K#9]#YPI|\QY'C^BA"1[8'-A6+K!K+P+((DX[PZY$\%OT
*M]U;#+:/223:UNV#VM<]^E8+ ^@40_62B\) ^>L[*XCJ\72QG.G(1P3&WG_*-) M+9:-2>H20U/;K.]'C[\,3IAGQ%F(C 0"8J$'2XJ=L\ZABC4&X7*?X:MG32E/
*M,)_N1!PS+4!+>&+NWW'Q2J0E)S^:\CTOPZDNKU?@AO6%/("4!V):4>-E M\[!VDZ$TP.(:'54-J?2IF\G6>;D?AYSN*8N?1AW*Y5^#O)V5!FY%8N?1AW*Y5^#O)V5!FY%QBI""=9D1U9UE&^":8K M=G)TT\I?4?2T@M!XU)@:76CRQM9 M!>N)8U]_C 0&3&TMR$(99SB<7;&HSS_8DC0XQF*P"N ?KDA9[*\h#Q!'-* M>,.!
*(@V0W,'HR^P$A]@@21DMJ>]?G3#)<0*PG8^=N<&6#V#>[L/]DYK3RH M+Q[=KM;"9^^M>/>2!:QM-F='(9;U42Q)"<;.^:/DVRWWEQ0K6Y9)!/[9-B)}N
*M>%4>/#OA[,$4&.5P",.)XF#>MO MH<;E-U[U_8W7_JLID1T_+"WT&B/4YR"=03\29'B%NB2')'4PV(K^ZG=U+VOC9A%IMXGX>"(>[L,
MLZ>=:8+>PW6EACD;3NU<*.-E1]G*KY+5!GAY.O=7K:,BU'X_.ISDZFPK14 MV_O$!/ @-5&T0.V %]PRWZRY=FQ+6"[%6HX07X*QO@ERB>,:^[#B)O<[9OMXN(;$Y/-&#JB-
*Y\CLV'M=IVRJ<03S1#O+|$Z3[\8O?/F0 ,K13QAPJ MAHRS8RGD5#"G33HV>63-N-H(.-7D24UC!HED-Y-,2BN9I(N*_^3=9*A'ML. ^>/'Z]9A.QXDWFCIM^W#]4J_&
*(I%,#5A/1N5GT81J8]MKDP<>.:^,% M0I<$)1@)^3&>',/S,_7C;'M\,;9HX&-RUF4/BY=#\]#IX.SRL,BG(\;;"XC1 M;]1!5/?>F'-VT3KG4#?
*RAM%&@T*N* :":Z'T,!18=6DTW#WE4L72R:'=UG M34(9AC:BYD0'8M)I'-#(6>:8.?V.HUM+HZ.8O&(=O-BH1;.Q('2]-K)^;M'Q M7]-
*F5T_&KJ;PE60H,5FAAW';7H%1@>7BYZ7$>O;-BKBW=1EMU+SPE.QL0X9G M6G5EP]E3N^_GUN/;KMK0F9:4/ZE/;*EO>O\[$CGC2@HO\EJ89S=3SSQ:Y(8M
MFRKTP5^CX\A3;_?<,^_?E$K9^Z&53'\[";,0'.N-D-MO#PHPNVM0_]O=Z< MVU\'6(U(/SYHI6U;$#\M\7'*S\]2I:'HVEH+6T(I[0C,<9HM<')>V6+92)F\1
*MZ18UNXS>NL9@H$4**FFGEV:2#T:0\3/!+T\U97 2GHNR)&GN]0:UR_(7@G_^\)],IUTCW#6XX M.$M,FG3JO\KCN9Y@Y YK,PUH&DCJ6WQ %+ALO?,XK##-H^!'8[4+_N^-
_$J MYB^!H0&.$&93PI.?EX.7CX>)KH7M"D_XYWGP9C.-]K2>22O?<_[,W']+3W@ MGWK.M',)FMHZ6^].5=#=-$(F*3C75 M=;B
*Z]1S'8,O@:::RV!A=L:X+Q+DW#62.9=UY4V"M+_T=6>JWP[!*L+);_+Y MXUI*>T=;NJB+F1X"PMN:8/K_DC3VP.>LYAJ=/]G)[',GYYJR6^->Z*_FC/C
*MFK^F8!VOU(Y0(RIZ%L\6?\S@*B ZV#**&*Y^9$D7",Y<8Y2R/H=?!0 MZBS_CH(1.<\M;NFV;5%SI%+UDP!!?&KG+(*!-EQT2[U$BW,:?S&.-YOMO'W'
*ML3V>)+2;HGREC)^+XRHYNUIE[=U9E[FXY@CL]"W M+\VT5!U50XXD%'XQA,<+SAZ\ ULAP)B[>_ZC1X.2"9'BVY.7-57>]67WX4_KO M1U 1C 7;@&2Q15-
!G^#S,)1$ANS^}CIL"G-T979@.U(*2$.;|\)BX=568=;>.Q('F5QSV&;+ M5D6ZE?$6IO6%)_CP8^^P72'"$!3XN%-B.%$5^ZKS(WYN20H10=3#G72D#(B
*M;3N<\XPI/9IOECO4Y%YT_OEQ8.2S.9NA:%P6T"^^2^^EPMI?T-CW M1SIV4CU><^0)2^O&(=E8-DFH:I?.V.=#U&)+^A&Q>_V5FML5H&UF;5TH"CO/ MT)GNOLFF6?
*&I9.J1MYG17'Y%N(YZ,M5(1W 1UG<;&S:M$$N/")2HE5!+=>VON'!U_]^*(QQ4/<9@Q,O^P4 M=*M0"RUGAQ64U)2,"S4;Z/HS/R5W-"U?XEJK ENZ@1UOTKL:;R]I@??JB1H>
*MX@?!HO"\(?O!-K5(XZ=O?+ZA*VTZ_,)8@??4,'Y>$S&M39\/K/:-74=U:/8$ MD./!Y%_ZV-P>N7 M9*WYJ,5N;X4Z."$AV\JER?4W72RK*9& IV)! M4O-9EGJ?S__=
*(PFIHYXT"""%5OGYJ:XP$6!Q;_\]+C=/+ M$#RS+IS0L2XQ,-IET]/^8F+WYT!ITTDAQ(CO\%U*LA7H6.SXTJERD>)*'OZ@6,.1XNSO#Y%Y5#+,,6JB+$2\8LM"";#FNNMB5%[
MA7]M)0>@"]J=S* Z+5;;#G7TH *8WOF=X$9PPH/,G_*$/R+Q)OQGEO?#EK M,%QHK#[A!^3U*]S/?PVI/HHILMT1N?2B:40'$QV;4W.BT.BI=X";X8^)8S$Q,
*MMUHX1X^BHIR/GJ.G>T15T$&M\?)E/W[& ^O -^+].6S@1*6_BSC MO71RM!S/#61:??RW>SR)_1O5(3GC_M!7!4B\FQ@(>\CFN&P[(*-4*55LFG, MH0TFN;78LQ8Z%V
*NJ8E@PWATP3CVFME 9C;TQ4[OMR2CM99E%$ZQ79$&PMV> MS3+R< R^UQ/^@]YPP?Q%H@:#IXT^]^_ ;HS!BK,X1\%XFG5D,-^J2.!/]U
*M@)1U/@L.QOQNK!0'@[&8@5RIID:[_+^Y#&^"%5[^A\7Z(_[F5Z#;MFYH\R5T6+T]$%?79--70,# M3<3>;VKL3KDKK)) %7%-7A(I:ICF!PX[C\Z5FNM^?
*U6A0J*59D.=70>,D;B6 MU&}[X(R6I5-Z72!\;7R4D?G#_,('O-V+TG*DQE7:,:ZFN9B<*+_%\VVEXD&'S MN ,28[-A<";_89NA,R&F6C!YJWIPCK]DQ/7W4"E2H<;_U-";GW
=K>E\!54] MB>]"0O,?U7B[U^2-8F43U8@<@M>A\-8(M-5&3(CO4T[RG;X]2_F<_FC._]+ M 1^^1 BZ&D29PGE;^UHQU:.)94/07/O?]C,F+ZD['6:Y'CA[46]HL<
*M!7:."PH%6XPB4.6\#Y0N-$81W2K2],TAJ`\L#"G.6M+[;"X?;-O4MG#CO)+* M-E4!S 9,BW1?K+-$.Q'=S2X8:VO+!H8&IQ:V$7:R"[MK80'#2(!0 -\Z%^4(
*M498KN32J'-0!)TVY%I CH7VXB\!.7#,7<,F*_IXM AAW#V#_5S M//75M7>6N7X ,>3#'PU/$O]_C3.R@1G#(QVQGZR MP2NX;,,$?K3]!-=#LMW@-
*;@:S\62F;GZ^G!N2)4"L=4,1,33F3-VS!.XXD[M_O(Z8ZRDYXE6#3?BAR:U34P'3(fLOV 9>O/7"'(=ERE4]6MB\YQU8:4?>9 M9C(
(+>+"RW'UP^^^*5ITW06;RP;!N&:)[T^#JBPAW">60<:A8[Z#@EXC#= M6@\;&AX?5XN=9&=;K:Z)^&\VW(B8HCNQX(&HB[YLBVT$N&#C)$8?EWGD
M)\AHD!/D%"\B0PQZ#"V)UC/^MF]NG'LYNTTN)#U0APU\KKL0V.]|:[R_6KR MGALE_V.O+2E!P9^&@C]B+")Y6'256 "T+VYJ*3$F_-\4N?^?&2,9]N;XA.ZE M
*+Y'[)1>>9=4+3"IRE.*Z]L-;4.C(WI5/>V!\D\FM>PH_#/VTR2\L_'?C? M4FCYGTW/9GQ'4-L[?9,E9>Y6C);MT13%E
M#J8GF4X!GZ'}>O_E5;_U(_K1T&UHH^CZV#4VR8/QB54UKP!#Z_T&%-8V.YJ;19DPXEPR8JH"Z3@B<<):.S1\2?+ F9>3CCH)'45Y.
M!SWTZ:4_3]ESVY^PR1IH4FSI?@$<$>)10)7Q_'(:E!3AO;E?9=!?'I/,_V9"50HH2P215=N7(QPD*]CS5\Z&<6H4@Z^N -6C:;218N"X[2L MOUY%ZOD+!IL_*[0S+U@?*01
*897I@/&:?)1LS7;'E?!*2-2=!MZF>9_CH:PGV MZ#DPA'&%I]?__U_:^C]9R)?G$,:_*\!MH82,EQ?WI("G?!T]_ZQ?36U\UI,@/?>&V-(I/O*I X/_(Z?^=RO9 MDLGT%4KP*]:X+!R]S0?
[+MQ7:K@/X: Y.M#Z<@5P\M-BA#;96XA<&N=+8QQ M74S'M<6.N?[NEF):C+VNC@\,'6W,IGN%$?7S^XG2@0)H;$DWG)Y"CL,(=N60V>-@ M@G.)(50R0W]4K
*3N+$PTL_&VKXUG<;**G^C*E\E/SN@_/I*F2\!*>)KM[+K83 A M^%V)8W$/SIX7!*QLOQ3O#/VB3'%L8(4,&%^4>BA'JB/-3_F+ M[!-F+51Z%IG-SA@+?OOKN-
/^I"YR67,K,7;DCVBB#Z59"4H\S=-M M$I8@2&B;KI.6DV0A&.MA^?O?JCK*JZ.1DS);T%>F$017Q_!4B)SRY7*V_ M N0G#)-7_2=RI_^%2;@Q\=AX440^-XH%<*U^N1>-
*ZE9D: % IL[RL3M0/6*X^F7>U;^.50C<\[WFSO=L:XXD[M_O(Z8ZRDYXE6#3?BAR:U34P'3(fLOV 9>O/7"'(=ERE4]6MB\YQU8:4?>9 M9C(
(+>+"RW'UP^^^*5ITW06;RP;!N&:)[T^#JBPAW">60<:A8[Z#@EXC#= M6@\;&AX?5XN=9&=;K:Z)^&\VW(B8HCNQX(&HB[YLBVT$N&#C)$8?EWGD
M)\AHD!/D%"\B0PQZ#"V)UC/^MF]NG'LYNTTN)#U0APU\KKL0V.]|:[R_6KR MGALE_V.O+2E!P9^&@C]B+")Y6'256 "T+VYJ*3$F_-\4N?^?&2,9]N;XA.ZE M
*+Y'[)1>>9=4+3"IRE.*Z]L-;4.C(WI5/>V!\D\FM>PH_#/VTR2\L_'?C? M4FCYGTW/9GQ'4-L[?9,E9>Y6C);MT13%E
M#J8GF4X!GZ'}>O_E5;_U(_K1T&UHH^CZV#4VR8/QB54UKP!#Z_T&%-8V.YJ;19DPXEPR8JH"Z3@B<<):.S1\2?+ F9>3CCH)'45Y.
M!SWTZ:4_3]ESVY^PR1IH4FSI?@$<$>)10)7Q_'(:E!3AO;E?9=!?'I/,_V9"50HH2P215=N7(QPD*]CS5\Z&<6H4@Z^N -6C:;218N"X[2L MOUY%ZOD+!IL_*[0S+U@?*01
*897I@/&:?)1LS7;'E?!*2-2=!MZF>9_CH:PGV MZ#DPA'&%I]?__U_:^C]9R)?G$,:_*\!MH82,EQ?WI("G?!T]_ZQ?36U\UI,@/?>&V-(I/O*I X/_(Z?^=RO9 MDLGT%4KP*]:X+!R]S0?
[+MQ7:K@/X: Y.M#Z<@5P\M-BA#;96XA<&N=+8QQ M74S'M<6.N?[NEF):C+VNC@\,'6W,IGN%$?7S^XG2@0)H;$DWG)Y"CL,(=N60V>-@ M@G.)(50R0W]4K
*3N+$PTL_&VKXUG<;**G^C*E\E/SN@_/I*F2\!*>)KM[+K83 A M^%V)8W$/SIX7!*QLOQ3O#/VB3'%L8(4,&%^4>BA'JB/-3_F+ M[!-F+51Z%IG-SA@+?OOKN-
/^I"YR67,K,7;DCVBB#Z59"4H\S=-M M$I8@2&B;KI.6DV0A&.MA^?O?JCK*JZ.1DS);T%>F$017Q_!4B)SRY7*V_ M N0G#)-7_2=RI_^%2;@Q\=AX440^-XH%<*U^N1>-
*ZE9D: % IL|RL3M0/6*X^F7>U;^.50C<\[WFSO=L:XXD|

O5>" M#!X='QDA%VUO*M%,JQ>DJE$K(% \/3]V^?J8]J+'ZP]J@_C17<2??W]BJ MEAK 0%>S?EL@,1L_IV%GM6O5XZSTK\29^97XT7B4A@B?*
0_fGH"SW!ZPKF]ES@FI\@]PO!;M4ZNS8G2P M&)1V<^'A95F85+)+-NZUU#ZW2]O2(&GR5C!GWH1>40U^>C5C,:9S%E;_L5# M.D$/KG1U(XK$7]]+/[;J*_5)*
*2Y,0F5U4%:03FGF0A3OT(.VYUZNC-E>EH[]" M2(4XD_']6-ZM*YM@Z0">HO/Z]$I*;%Y"E7Z3#]_*H);3B&U20#N|U1 .]:X M]@C0P1Z*&.?8J/W2HO(,C?TW@9ZB2@U9=@(
[T%\MOS/GA$V0F\"TZFU+YRZ MKR&@&\|#!X0T@T5^PSP-)B)+KX=Z^E,B$+1 -(#EW9?'X:1R<@KM[D?D2D VM 3-V0Q>.E;2D+O5U"L3Y094TE7*W3Z%-
."&_72^SQ6>X"-0H =C+ M8+;^W6E4;T(4Z=?2TI+QREARRC'IGN;#S]Y6VXE:I(:].#J>PC]]3A"_&LY MF*V',)@Y7^C#-D-9-L(E]FI'],U0"(."=.B,SNEWPTU?OB? ZEN;29]-
@WJ7 M(.#2;.:$1@BU%"'-2ZP-UVFD.EET+RNF\1%$IS@.DB]MX-W9OG'>.6+OZE/CAR<[*CU*=Z,O;("_M%-*5,.HK\ @%%P]\5?3HW>U\A+GV[].#=95Q;9**Q/&!Q%_"/2:6)-
@>)ND MK_V<9J9$;;B?7F,M-O"F#>X1?IV\FP-,MJ//[!U&/A]K88$+;PF:!+;TD'GX M,/6L:SN:;$PHKS&3KL4)*0W\!0/2\CO.!W#:4/_%*C'Z0Q 87JOQ2A%_CQ
MWSU^>A>V;E5&)S3")=3$4$:K{(GGEW?!$W& 0X^3Y444L).J2A3,'G^>D^_UV(MG#JGD_GD WR]5G\_+PH:A@_1/D ^&J3^RWLK>>/P8F66? MBH+%IDIQ&LFTE2XF$
*GWK;%!% *S,U_':_V)"&_\N@P2STZS_L*H'9):4. MY5PI_K(O$(%%#4"C5O!*HGHVJSTSS8-0TOF$&;]DT8?/U:Y*0DC;/^2ZVAV6
*MU*V+U;>HV5R1,VN%99^^1B^0@#^"P3O2D-._$7ML6A>&$#>A#6;G]%RD5]^N M75LAVDOP4K2Q,TE]?J;U!C#Y,8RP8=Q2+0K;^%.>"[M8O-S.U4?LD0]!JHI10B&MK
MN\F!OCR18:DR)MT=E%6(,R]*#5\$ M49DDD1>\/N"K";V^]#?EY@L_ U0@72D8'1%!^B>X&!;/(M)H[W3]0@$;&L,?&7+/C!3(/(M)H]K_&U^$@CJ^>O((^_+
*(.W!JKTG^:^BW-A0W0>RK("$]?9+ M.%X,5*W>W)MQA?I D_,OC(GS5VMRLCX7]1]952;7;1F<"A%BCL4IUAQM[98*5Y<0I$B08L%"%Z@N!4H
*M4*0%&BCN+L5;W&G0!"N>H*% &+XK,W/OK#LS;_]-CY/UYDW.><_>Y^QG/\]. MR3J5(\$9I)#IH(;]+)Z615WN3NRB#^H/75(/7^AA?U\'R -XEA:N^TZK:1IU
M08KV%4U:=19,J8.5B3F;&MQ+*_ GD-@-U$FU*]S-A/G.N(C/#M*WYIR\H=4-V>1OQA\(^DZF39. M3\GSU#>R)V8C!58.#5U;I\M[1 #[SP8+/R$A2>X+L'=O2Z*=)2D7.-_.N.
*MU$H:6S NSL^EA12%.M DA"=HI._]Z]#?F6EBU1@ OD377`_;;RW+)_/F,4. MK0] X[X.>"2TU@D&180SAMYS9WM1Z#*4Q4NT]I>!TCTO2\OL+?(^O!]\E=K\ MXC =N,-
*V8;"TA"&OGY!?,*I^7+98RY+67+/U\EZ((I^>SD/4=B0PZM?P-N& MNB9VVN5?(&_L5)=G;"Z"R$Y#Y+[]@.ZF Q<7>R2'<*6F\)?07Y M/^#C6Y++.4M
*M^;8HO3E(:]GNNA5PWE<<\GH$(EHR5N2S4[%X\3@>X;;(R (P?V!SK&-;3X"K)? M,#\;M#S(Q__UV9=E:&!&4GYOEV (NXS=)>1|:"VGW NT< M&A0 U?+1#.5*#5B P05 99'(^pW<$TGW^C
0^@]-$@3R-W^_5!R/IV_%C;D4E]7]JA,'KN?M.LCUMZ9H<&+ MU.?\^ ;BA#*X!N!<0!S/E$%57J6KV$T<3H-#0 #N_34\IX7(*/V1[FXP&8 M$\%KO<=7PG< .J7EZ= SR_,_&
*(9_BE ["Y70A%?OMLVVN0["$@6$INW<>/)2 M\\A GF#%Z(X-N!$V-\] M [E6]BU:!6<*2Z=&K[Z,!=!?MV)W)2.CL[V+P,"7M1TBC5N=%5[C4P_Y-:C< M.?;>@08P4C=^LS?
TY;N9YI3J;I1J#A1?S>O$PI1A,.%#+=4FDY @Q^[.F;1! M WYIR\H=4-V> 1OQA\(^DZF39. M3\GSU#>R)V8C!58.#5U;I\M[1 #[SP8+/R$A2>X+L'=O2Z=)2D7.-_.N.
*MU$H:6S NSL^EA12%.M DA"=HI._]Z]#?F6EBU1@ OD377`_;;RW+)_/F,4. MK0] X[X.>"2TU@D&180SAMYS9WM1Z#*4Q4NT]I>!TCTO2\OL+?(^O!]\E=K\ MXC =N,-
*V8;"TA"&OGY!?,*I^7+98RY+67+/U\EZ((I^>SD/4=B0PZM?P-N& MNB9VVN5?(&_L5)=G;"Z"R$Y#Y+[]@.ZF Q<7>R2'<*6F\)?07Y M/^#C6Y++.4M

<4,X(81G[A!B%8PXI^!J;KP.Q10[MXD@LU_XLX-2J49=1&TU9?48]95KN& {TWF?@+D"0"%&#.LB,,.(R6@G(0[2 M-(Z'HBF!$7SYS,B+ K@VZ9#ZM%OFA'9=K$US\ I.7@Y%A19R?'P :G1VI$[!Y MJ?4)> /S?_IB\OQ&*F0UD-X9D%WO!;169]^>=!)1,!-"4.3O4#4+5B'ABG MP8]LHVSOK?(,>MNG_,L?AJNSMV^381[4GXI/!SM#>_WJ3633B7-_NS4*LH\| M&_)-0+WJY#&L1=A%R#!KL+$\1R:O=|=V2>VW);RRSOZ0X?#0Z' +V>//@!RO(L21XPPU$_?I9M+Z=LF9OF*BNX9#WZQL9^(J2 MKSEI09&S\;[SMT7ES LD'R<[;P%2?U@RUHB1AY%<"\F' P(A1\3K:%[I53 M&.;5)"TJ0AN[4LU!KKZH&[%NHK*.MMZHZTB11\)O.BHUPl(O0-5QC' !R08.T,-4.ZI4-S:UOP[M@&%#6.?-!__O1'[O,S:4Q/UK\+AE))MTU2 LMY[+T-F(>&9S3?LY"($4K"H4 MSEFWX!AQ%,#4M-S7/M;4_LR<+XQ=2B6B=5!Q&XD)?P-W(^W3F#ZPC%CE-[UIL=-(YSQ4? 2"]HXM=_%^4+N,3T5(%=D/)2XTLXVZ9G\)X++Z 8)I+PT&!*F2A\5VTJ M*2(S#O"*[.53!3Q!*L GEH\V1+,.>KC>*DRH@S2)5%'2>3TUE>&-?>W6AH@3 M@@BP70XMG=.F\J^^9182;56]'0:YVO5UZ)Z4] |_LO(-!^:\V.(1TIL! M%!(Z$'<'/6*!;Ij::?U;51<<_9/Q,&3-W/GXONGTL]VW_FI\IGSHO%^X08-M6YG3!Q!#^,-(#UC? M#4O_=P>7_FNCI+()_=:#3U) M4:PA\;W!)P[LN+^,^1&;JK&<-73GD=_5&?O/!7!14>NS';! MGOE?N)P(0 &F:MPN;/ K050]K1]_2/A:S18B\@=5AQZ0]*-U.1,Y+3!;<(5 M>X '")27>F3Y@C/N19K85&HX 8HJ?>6Y*\78DQ=TAWB+0KI0B:M+Y :\8"@Y MZ]!B-K)!GL2_+U"AJ<9#]5E>QC-KZC9)2Y-XX"(6 >^:C%OSYAA#U'Q%!Z,@ M)CE'Q\"I&XMRD'FY4Y84|L4TGR"Y&I?F,*,75?Q)01:NA]U:&-FT]+]$4E1MG[I:XE>=:[&I$ %H;45T5X.=\[,B+&&1UF/@*R_@"@BOY?47A M3.6Y$6B<06L997;2L(O!86UM9G2|R4<8+EZ9%[=P ,>]=6/9"*T.$*GX(O@MUI$P*IXL-K&&%#=^!Z,< MUV:%U'"Z$DIX&A767YR6P#A1!54(Z1L\;6Y%G? KT6/$!A;P/1HL^>[TN,+DM|S@'TA 5]\N+#5.14E?#/HJ@<$B,+ MG*\R<5__ICUR>KG2C!VFL)/I]\&W^,_[1NRID)?.R*(W5[\"+H2^)GTI8?;0 MF? 98CR"BSWC_=EYSELV80!1PK:XL78)._8*9;,[GG97GAZ[>/)\5)YAAF [: MCVIV:%!SF=CF&'H@X,K]6#:3[D V+"1*W?MAU9^T(ED;V7)L$P6Q70-[1_KJ M\4X.3? 02/$@MB$1LJ,TXTHLZPLKJ#^RJ;'XK4X[&M"^6 @[\?6IDI-KJ(>6]D!W<[&I)G$_X@T(/CFL[0#GZ[4!-MKI4.1>@3%%T"'MWOB3/. C7WVC74(89K%F^?S(=+HU8G>OYF-Q6MC"&+3ZFKQ M|['0>$:T:47%IT2*\YXKP%-F%+,N0259Z'U8F-$@#A=^.(-$-K=MP*_6Y@Q*L5 MT:6,E=]JC<=_(Y=AZ0:PR\=WPCG[SOBIBJK!H#B.R$ _G)Y9G6HFV.,BW&-G M8(\'S'>X&@NSD3">+,7-6N[S/_^G96?Z38EGG;F2[Z M8JR5R\']JY6NG=DJTZJB8]/IOT+=B%LIO7I454DU.%!.KOQ/)I^0?2)4*Y\V M^9R3M@XIPK_H&//61'V/0Q6-=\!% ^!^A69 EAGI%/0!^Q(?3E@W7)6B2S! M+H*VVD\&WL9[^A"9944HA_B$[>P $VRZO3X MP0, ,555#U^2Y4<3N67BHKSV:9(/*\B>$; [!7/,A]'$535?C/D(1O6KK9>% M\DJO-9 3#5EB*T]TZJ8J$ZMRJ[*S- .:#"E>I^)PX!M.E@V++QY]R7&V33)= M-?U P5[#)2HJ*F?O/0;04K6%)LHK<=?Y?%P0GY[!3B7)'T!? X$G/,;+2+GT8 M5U^,CG^YD+/K, 9R0@!D)E\V4-G[TC;T]&O:K\!N#. TI_^Q<3MA.15S M-C2E<3I529:EGIC5&1C1<1;A)"0DY<]B25"35"!33@K,GZK+"WZ^?Z!A9.3P M1]5QO/6.8Y>D_AY-M1\1/E[>P["D;B%O9=H_W^<+#,IX5S@<&DCDKATXH,LZ6U>[7\F.6$.63MMN:_M%,GSG9+(}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}=#,<9U1]Z#4Y*_P*AV1^PQ0^%E(.&5TT$AL!9(0%F? _ST@_[TM]W!S?FOG,N"><6))T\=:HIR_SG-LCU\3MGXN-3/M2!<2GYGP MD0T4X%HZ+EISCJ>')^7-V^VS!N"[B9'", M<41S4I-ZH"-"8]-P*B-:A6!6#R_NGXCF$U.[7]3OQ-7.R:5=^6V)17S^Y\-YUSGG>=^U-M?OOK;]T?KFO?>^.][VM[E)S*I_O_8\W_FX.]&(G$&['U;LX[2E8*D-EM7A[_MM<([!-%OQ)LI^.'671*7MU76IG0%VZQ5 !A'B_J-S0X)2Z<;O%R=>]A8L@-?$"^P0AC;-@9 EAGI%/0!^Q(?3E@W7)6B2S! M+H*VVD\&WL9[^A"9944

*[YL^M2U6_*Q)G03J3:T^I6' (^U"E4>B9'K/<\(,? VS7-M:)S>, .]1?8R7)FY:>S.Y8(LU97Y-></>&Z5H6F$E*:K>!1:Z6^Q6W4WG,DUU-M,2Y!IP\;GS9<9V8M(R&1A-_2C=-G]5*H]^5L8:DQ3MRM-RZ7?3-VJ,C!KLW M= F@$;V=<6/ ,F17^UVC+7;' MFT6/DJK;Z]NABY7OO{SL^$H\'9(/HC&!9/D9P#X4=3R%.S^+>/;7Q_ ISO#D M*Y/_VLKVO]KKM]/_MT#&_]$^-_R/;-P#F_C_F7U\$$$'P(' SXRX64A,%P54 M?5"Z,"NQ]OM-D ^&(*ZC#O"*

*-<5'"H&HP%[" ?IV3 0C\#}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}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{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{[$_:? M 3P,C&=5F7@-K9E= @FUD6)9^*_FE#5TL\]HWR(+/'@\RB8H>YDH1_D/M/^'^ M[/A{C1X]#P:P&.C8ICQ-_?1? O#/BN!%Z#CE+7(XG M;PUW/6G.2OT 5/=K0B5\-Z.V.N$X@BK:.I1R7JF]6Y_.VNM&8DDJN*9_.L MPPDHEVI.A*<4,T^$I#N)63OIFD5JTK[^.I/)0IZ D(-2G#_ALL% [(,C]T7LE MO0'IDER 45FF:W^QW#A*_4W3/V]HU:,.&5LC16f!2Y#.^VYU"U$=D<'^16#]& M'MEZG:*G^5TPL/I7,M)\]0MT9Z7%8 @4=MENX#!@LX3X\@3T,.,NZS'U*OD? M.?>/)AD_^V^A2-A?(>:.8ZK]IP$TU,[??N.(@#X8GH^(ZJ99'0^.@E\]TU//7'-M\N/F#PFLE?<6'_>K]07'UIZ:!=G447Y-5>E<5ORALY!PMXFK-=!K_+]_&HK M^^6(Y#MR< [=^#C%!(K\9A#9LT?'\OD[GP7>#FUO]_?;FK?$?@;HR29IN;/G MH74:_O5*CW30'MXQ1]0&:H?N22>!IY'+@-9NA1>;3'>'-!FTESH9W)3BCL MPNR+1[JDSGM%^P,_.\R/F/# "K9385R@4W;Z8KID]_*K1U\G\^[-]XFGR^]& MEKE=5,W2EJD"1?XT=ODC]3F"LGFW]A":5X/W$3I4_HJ>*O]S2E7667$D//D MW05#D36%$U#"@L'I:9#&<[9FHI3W./W(:/6JE3]CRW%QH&69/]IMKY3SF^)7 MC-<.RI"K@#!>BC{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|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f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|%PUOE%O {AW2/!^"1!2ZN3;@H:%_MJ73HU_HX8&895%E\H^4'GU>;&]HX+[P)Q'AW*Q9K<629:A!*A&BRR"-B6'<]W]+/(;K/"=;; M7IR.R[OPL)\VPF!CT-%_ON)80F>DCPE/_->F01"746?U#[0I#*-*K*Z;,Q# MM2 OOR]O>$D;V)<3\UV%$6&]A)S;\S<^' M;.L"U?B4HVW^3U1N92A\'N;IVF:SIIGH<=+>0U'^*-"/O*VS(-;W ME3"C7$8LFPGUO-[S3!.=3HUKLP<=!5'!),]-77(U8;E6LF 1M)ODG"C(Q9Y0N5E.VDJ@O4G&O,7[-@)]NC=]L:C+D?3N^$TB_"62%;33^1@U5? MND^= [3!%&S/0MQN8" 4L5UA)A61@P-804&8"=EZ2$YGU8%Y6]ZF>"

*=.3N!\|SUX:6?/N8_..U!7\H;47*D2%C_O."8GE'ET'ZFRIVFL/)>ZZH6U+!5S:Q M:)/_E!ZN@XLQ 1BV=:CF\3.|OPHOT3O+S37WBE3.]??P*8WY?8DM\LFRY.>- MC*T-P.. (@AB**U$_PYD'R===$_VY@:(HQX:&8O5_5FS?O:?\556@3R>CY_&E M,PWT+Q#VL)L:]XG6ODDFV93$AC)_CDH<#=$_6SJ^N:43D$_-$7H*UIW(-2 ^ MJOT!E41=H=164WF/^N,Y?U)A;`^LS_8.W(Q$6@G47SQ4Z#B:+R?23(*&_%Y\:.MUK<._N!%_ULE;9Z5PE3E?]18^R8U^C%>)35X-O.&L?_WAQ5.T&N>|?1+5KUG MX$9]GH;Q@$(Q!&'>=$=)4;*Q.(?U:*.X?ND0^^D[?=MJA)-]#IE#J]\:LS>_?^P$ M=!?3EC(@*:BRG"6\^(/]?H.^SN*ZE^)B]W=4!4}(|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|!K$@Q(. MJO:1_JE&2%C@CF+5ZBUA!&KLBWIU3-/0&,YSS4&N2H#ZS+U^_]\I=>PR(!/A-MH\5MAQL>,5#XY9GP#H%&:N+DX-M)#]".RJKG9=*7!RNO)'[_3UT]3F<8H>? L&+N@PH0\$&0,3PDN28Y&SS5OI49[!WU XGK# M'!,..#8V+ZG-EJ;9QU4Z+7&SK#N7',EZZ20GGIH \((EXRUK7P#<^CHS|(MW4VT'NAB,*;K+_U3R@7&P9A00I1DK(YMP6(JQUUD[H_OE>19'^N-NU4SZ(\2 M6:P"1 0:OA%46MW|&IHEVL6B%;:UM$D6T8)&Q.3$6\/V^;*J0P$*#^NWS\H9 MZKG;53L<|I\FB=A="AP[%&&D X\] ;F)S43).)U-DM!U)LMJV@KR%6O]FFM, M^7X]_!O?)R[55]G6P#_RL';V;CP|A 8?NB@:T&14; MJ|28>^1HJJV/IU(_3N*A0$$BO(CMS35_&<_MJFXWK7*V=G;X69_!5YQXU)^ MTHAY]4;&-VSBKP6%89M|N-X%H,,$U+* '49Z+(N&),N@BE5_)M_6VED68YD=_M? 1.P+,+NYYWT*D#=<%3\,-Z>U2VN^>'!7.R;]>X#6KT%_(_N_X5YVCY2? L M+>72VB\XP/*F6H[M#FKO25S_BW7(_-)VCC$1FA/IZ3K8 M/'|T">G:A6%B*B+7$'=%0WZ4D5XS+1_.&C8|^&O*N-9R0"_OHZ@!,,"J.47# M1S,VPU)U("%4ZW*D_V!_>W5<2/:F";FE/&749S\K23?]D;C 7\VG Y\SJNL4 M5R\HT!. <(IS(*AG!ST:A@K0!?QITH)?ZM,HZ$[Z-)6O/W@T-F>)O!<6]=5 MMN42YV|D?C (640LZ(U.PO!V.)=ZS7O_U-,M&R)NNG876IAZRTT6_A,_DN#_ MB./6FVMN.]7^08C;I(Z:Q>P-2CG*SP|*Q)N0VY-[X IPBN0)5=?&$>XW7MP M,?!,O5@,OQN%>*P2[&@?;U-MR7#:WNMSBZ36(@P/RG+L\T7MS"V96,,2[VZZK%]9KVM6 MI50-('JT,YV\DWJZB[#+L\3?\G?G77#6+ZT6#YR^6>4VN_9HU'*#<;.,IJY1*# M8^]0);ID:IR IM_@;@'NI.TSR/I>*]ZXN(659V4S>;MYA,(]!8;NM3Z*4NO MPT9&ER,GB4H^| [KU(.J =B\0QD!14>/P)#U!?!(-A.@VL$>6.V%NY.BI#MJ MEB_OL9T-B-O9EP]D/UYCV*N_>ES<GO.B+(X]83 M]9IDU"1Z^\/+ ^N?]9MO-&TNT&.W*;]CP7-5;L &P3..V(*]CH1$F= M!@HB96-I,"N@PZX<6N1287SAQ7*A]ZNGO^\4^;S9Q$&,IL\I](&"8.Q43C\R MCHA)[#CKJ0CW+5T-Q;L]_M2=XY)JI7]@&P1,P? ^7+ZG_N_]W__^!GUT=.J6; M?9A9"\)VUI:(,3% &.A1UG)T,_=H21N+R&ZL6'2],5K!TOWU]/>1X1!C,"5@ MOQ\P(FOO"E"R,Z3&DSY[|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|E]_O-M/.GMD^1 M?@LQC'R[Q#=-.ENH_E2>(]F3)XTP+,Y989]6?((>=RT>9AU?E'&2BGWU0W&EB M4-EY? RMJK2Z;'WPR^FTTM.$6&7TXYS=0!^(C)&ST%8G9:Z2T/NA]AKB6V4/"_M17-.?RY$2XH#N5=%XT.$<:,.&.% $T26?>#GY+|%EA=]V MQ35.W:FH$I.C:FJ+%HH1\OZ$2.:>]OV8]9R|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|8?7].3;Q:Z25_6<(*TU;@A,NQX_@$*P$V0\4CEE\GC, M[_*'}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|,_2HW59P5W0>\0#?9,-> G1:X?3H?P/-N86+T= M_7%RZ/C96*GKTQY$?PR*F3?H=MBH;EL$%U?EVM(CM&_3.LUZ#1_5I5-YB*C5 M-)1V69IO\Q^GKIX-R9$QD_<;$&M7_4E3&@" M)@05XO!UR:Y>S$G;_+E"@"[*9_@- O,%WA+1K$H9*M@*S> G-6'*W7DMCW>E= M 1'LSI_LNVU74^X&<1TG&HTL\P]&O''.OD3*@%V#BI ^$75P!F;S(4)0#6R^ M+3(]"|/?]4.JLL*C0)?OZ:7W]SAL%+W\'-EP? 3*:0UA4U$$'EYLBSU)L,%U1-M/]]KD:.QH5+@9MZ3%)60N3__-.(_]L:]F?SRHZ&VF]^+-V$",*4HY_8F MQ0W."+^&CE19SH#U1T(O<'$GLU'PSEOU\C-PUTS;$^7"4"EUN_* [U:]$\MD4 M^1:Y@RYE7/KYULE>9F"/P'-L1K[0ZHN5Z>;+|<4C_ZL>|\CV+3H_,_MJ.)<,_S*WF_@&_;EQ^UT^]VV_5=-[/:ACRO:U^]/#|#7ADVNYS:.!(M,)AYI_PM*YT/^)K2M*'@I'S;%;-QB?"L3&>/)VYRL4'6ELI]XBE0%F=.9U' M6L1!IN)$D)VI[,C,O,_=JF|/]*0K4S6A;[/?9|Y\)YA2S'5F,Z7EL\?1!U.A# MOF"49XIG#%#F56@S;US3";.1E7C*#EEY=)5>CX;E[62!'LO;PH5-G\U;[OCJ MS;#J3C$@\58#% Q,3WI2XA_KI+"WW6#0/O;PRN9K'LG7%BO"_& M+++)5R=^;+N^U9.U"_$3CG,@SG,C5IMM-_6W@>RG&R-0,.YCOVE3Q-%+*]KK/ MS/B, "?\K54Y$^3AEQT4&K+5_WXO6;MT/?_U^OA2,9&NTUA]B>% MF_<^5- +_0*UHK9]M_W%)U]E#LK>GA+,:5\%F2#9=8;FB2D3I KZ) YSJ0C35W M6DC7FI/3F?#S$#6(=,!Y=K AF:P\A[S GATW4TU;]R5>E9[_TY,E YTD7T@^ M#43VB0=KH3FCY- WDV\!W)B[Y#2TH.;-O7Q3+$R]!5A[RI$E89O%;O[S6RXZY_MI5,|^104V\KN702!FV)_YS>5O4-WT#+=[]H,UW7]9AFH> M1!"AWU:F !=VRS4E"6F.DWOQP^RKWAY,F^43QOW<[RLYW;C,]82S-M9:K[6N6^C=HV>X;OO_A+VY(ZKCDKH&-J_5#3)6_5&)7KZ;ZC--_^?S5?U-MM0&JH5O"0,YE(\#]'? 3*&=U&0:\2=E:&G,Z['=DV)%8XB6MF"S0_]DBB $#2 MU>_?%[X)4X=Y]YFQ41TL0GM/K8C6A,IEU%8GN@6(7:"D.5E98%%_I>*MNG79)LL>2 M)R'L6EVF-9VI$5]0E0Y? G#\RO_T"(:U_200;-XP3[;)LOX33*)A<,.+(?"-5 M(34FEM(4_K54$;/8^(,A8W;M<9N$X^U1FB|Z)U$.!SM (#X:L$F=NOH9=:DG M"8<-$B6L'__*75-_+.C:+|%>?S)%9S 3HJ5* 3RI(E'.NZUPC!D3Q*O+AVA(MRM$4L=4%>X #!;,TSLT:|R$?0'1*V7UGDY5[==C<*Q=S-+FA",<=:?6I514 M+OP(]?2]8%9<;,?83-8[Y_4U-G#O(\>\!6)X&> L4U8$U7OFL/9&F M&X$??90]_ODS^X:7MZ!*BNKA>O*H/!?.JM-4"K5B@* SJ-,Q#MUB!Y'?@KP MCO=1EH;2(R?%"[_UF^(9A5[U/HXK+5(UW9*OK"; ;&Y:U7KURRQ3QC$'$]" M[*8EZ_C%-@_L^KTQ_R@0N])XN]+A>,-Q"V>&5R8XXD?QF6@O9B-O4XWSJ\ MC+-7\GJ9NW8M_TXIX^^P.%9|/'+,C);#B_Z/2\2.HLPS5V5- VIG0.Q/83WPB MW2M|LM\] 2:.Q%'$LR>^EA5+ 1S-X7_|<=Q@2K?K/Y9+7YN2 MM,#3?M#0QY191.1=(:%9^.E#N8;. <&'+X.=XV:. ^|VZSOB]G4DW!BLHV0PG0/ M]463]T)KS\B7WP143L0 Q_3X:-+,0Z]Y1HP"N3X()\|H2D=F;PCBS6:T<7"R MN4TG(&XR0X5A34[2$1)- =M+>U#K72E\)51HGTI<3G, -0B7SYSO=W9^4VI5O M7;X3*B3T"AV&:)5Y,QND!_ADLY#9(5]HH];@3L[=0A4*(Z[W-?0'4W09K2P/R M_F.71/.P&\2Y4Y4^+,W"@5Z_9KROX+5('D0BQ{I]W%=$Z0*AU\^3ZA>_\N5;<-#[F*Q2C_T5BT_[MYA5I"^^>@S)Z+<*R6Y9#FWQ[QB9;DGGYH;0NH_K 6SW_U<\V]HQ]"=]Y26NE8?;DAG MDW$M#NB;DZ$_@6I0K'B $+P7M IUR0%,)04+]-4PN)9BB>HT2FLYD6@10D M.&,665C9B7=? *V1J<#A=++1*;NI#XQEU$O=]9,\360O$-PNJ^:" MW_BJ72PM"^06S@!]3M?K[5+IL3WXEP&^>%XI-Y_G_;_\12"I M6^^-2/8$F?.$^V@9]{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}?OO3!<7];=&= CPQ MB[:"UPX?_JK(-\|YKF N$F^^NLX;U=H\?"^IONVI=B_0;Y2[?]@I5]Z7]1:$[H708EM%_'V:MJA;<+$?;N3_HSRQF$[>\HXF.?_/>E.'Z$9(R,")S M85,,SSH7N=S?TXW;[Z, W# Q=U6G"/*.\,Z,0D_!]D#Q_/HV"=)EN^]]^5? M:&\-CNIDE[OEI*!UD#)A[^\"9SD;LYG5KP:^]A8W5>@YX:\=%*H>DKMU-\E(-M.'E6 :.%-54SE("= P?@Q_I]+D&Z;>_$7&F- YMQ*EY9<+0L#?,\- P MSV;67=;DJZ6D;%MX7^?=:!U;(TL4 #C920<&TB,>2--->]U# 7)G0A3_N83U7X7X&HIPXS$]W@HG M(W@}_UG]/ 4H^KBU(7;<2&,@/.N_&N- U0J@Y4Z>/6U/?DUY\&NM1Y(_Q-T" M=6;G1#*7C>UFCJ.!@K^CE& <]E=F7KP'-2#;OAH$VF "}\W,_[4@<4(4X#P M6+16(GSUEBM1B!Q4 #M@22'(85? (QM+O*."VM"L%R)OH>!UI3'Z$>_'AYO,# M=N7\MO0YNQW#TUV!Y%2!0#CXX/,X'COA]>'5?W6MR/U1Q/6_68_G?;*7\"7B M0V0-XD.<=!/Q3\-T93M2X] [+/P@'SZ'-M- 43+Q8S@OJ'}ZY#!,@:;$O7.(!T[>_G)T.OL5#453:QR M:WUJ3SN,83RLEQ$!$Z^!IG.7[YD%(,>TYA@Q'IJEQUZJJZ"1$4OB MY- %N4VH3$P>E'DUIEXBUX_>EN<)\M5++#/UQ$N0'G=.#D=BIU/]6*,*$P3$'U:*H,1V"J_I'P'SA'A M*!

*LQO(KAO2X-MI'^-E3,JQ4U_=C0;8[Q<@AW-0J?1>2-MQ;ASK\)U>A747{)DXIM-8*QVFF@\&&7=>".V,WFP94)[T!#J#,IA_Z+W>A)I-MF5NW-G^H7OHQ_=!*TJBA=4'%*2];U0\4]>;*S5;#[5WE0!.FF%[AZ.II;Q^- M4X'#$2@=-PJ\'HM;YQC.OT.,\(?.]$>[*RORG?U7$6&3??!DM>SO .M-D$ZNF-M13!&?%B,6JO,:D\O_5^ZE->W_[6?#'A0:?2$D=" UQS4!/ZZR*;GJHG*(EJA$Z< M,W\Y,N^\K[M;KEBE7DW/M4)/-TGK&ITW6Q;MZ4AH9YZQ6C:{\(S)T3BOKK5L;Y\+UF\;FDDB|M_V0<8(^Z/$8L_,R0@Q2 FL"+H=_^M)-M3;R/R^-]TBKCEIDJN!A=1@%[5&GY=XZ0_:!FVU]RZ@-EYWB_<|FL=UO370BYE-MFKM$W9],-K9FJ3\^I@"T?...0KV8CLCYP]G8BAV8@&B\/%A2K3L=^C+93.UW-M0=;,:/,FZ/#'!@6[7MS.-.QO8?0PG-N[&+&U>17B-,>,B:F+WP@NS5MUY* !> M5:,S97$@+7.[N,RTJMES\0:U@63FIH\#+P*\(!|[9WZ1W2QRD0J+[J2O4=F*/ M:."*C33'MA>5FQ0.EQHV^CK^O<9_Z_G')M-MVK8C/2K.W'67;=:.7@@6[GT7S_HP_KZ9-Z[3-1KYITIGIX7-85OY?X+&_@O|) MJO37BL[N.4) 5;0Z6:.7.&).YMD\G.S'4QG5H/8]K PPLU& M@I;N2_;A.'KZ8M+\&-WT?|;R_;79#NCTCIM6S7W,?$^7TM9QZ0[L>SVPEY#0 M8-^ENVPR#+-O+\A|IJX.TB55]W,C86.,]B"]NG#&KZ38H*W.46T"2+--B%A^!FZ^ M#64RM7U8HJAK/KG[M+6Z)=HU(/V>E:.^ZBJF\7%DP[+503>(G@E;H/Y;\$V*T M:*P)HM_:K]5,>OCO7(<:!);:WFXF+=@JT]VXUX.I#;;=1O).''42EL\4^/0&T=HH),T5K^_M_ O*A*.#4("8?_?F_;B.95"DJ8[CVX\C%X<6O>_?!Ij?M0T+]M?\HU;8Q@(]OT7[G3;M(()1XTO:2&E^PR#S2:(@#$-:H:V^2U-K:\K3&&^FT]10#!XWPQO0@'"8@BG-M*XCH'3_QYHBR%1$)#Z*<:[X.V!W68N?+,_OQ(XT8Y%W1QU#:(7MNV$KO/929W;OV9YQ&P$'>S$[%+XR81%SY9290)/+2<*E&M-M:6'1D'_-HSG<&.XBV\I;SL:M\A=E\(&>XBV\I;SL:M<&T_'S#(_%?3&C.AZ<]/P>WO@5$K4P$G]XW*/]1X[-MN8GMJ99:W =%WU]#@0%CNZP;:*^EPIUF)L7"\^8Y5JB @%<;^/<+=G>J=!C. MK\33L3ID-NASV+]#&CMYBF*57/1/LEX3M]R:M'J7'_1ZB/78:U#!=1COF/[& 5B7,ML_^-;,B^:FGX>]@(T/(;'^2(;K?.IB) M5LL+@68-#IL"5R>%PY'7N9RR IV;F]'Z /P:Z/8C:V[SI>F94H M]|KR(X&\@+ZXW\O>Z$VGX8+]:'ZN*+_'7$]2LH/#+'U2H MPER]:5.?\4P/$_GQ2&&K%A,0%X2(SY?5;86FVI'W1A,T9/YNG69PL25>YF?)?Z?"M6HUD8!TCA405^"S M6G6D#_V.E0\H@=]'?$@%-0J$LB\1N4^T!HC19Z:(=%&+3Q44"?I[*RI* 9X$ M:9$$4DY_J%HMC_Y'_CE6ZT4=|SVA %L39X.>#POM[MB=1 "7S74HXH"($8TO:@?:4BX>@VZE,1MU+;JO>+S7^LB'R_PY20%4G4..MD21[#T/;S\1*Z)/;@*FG5^",V"0!IV-#$NWC!S^;#W.)>KQ$^N_RB =;?X*-BL$-)!4]G|E5 /EEN[9KN#PP&$&VE<] M+L|{W]:6KMSGJ,-S<'.3S#EN>9GZIQLRR]|LH1&MF8E%=*,NYDPA#SV4SQ4G/15 M SX7;LQ(2^5Y^Q6Q F_#^(/6$ZQH=KG;.>0V'|GXO/TV}!?>Q=5>; MRXB2YW,QY16M&A@|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|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}8QUWX+_384$;V)YW8 MA9Q$$$0CB9_+M?"<[11@/*S5_B1>U4\0S5;_I_73?]OI|10)>7!EX>.OPE_E M%LB2OEADGQ.>]@PXQUF=TDl.XTLF?1+"VO]P<&'KL.7\<@)1*S37V.B"P5X M;(?'2R0'VH]D!H%:|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|!+)\-O3!+T?<^DU!'<#$-D[CL30*%TZAF2? <,E.9X;@5PFZ0#M2 M^.S(1SS]E/"WH?4MBIV)25@Y-4W,X<2%&FD9!PPFH)PF5T!YP,O3 MZOI*^/G\56 QU%ZQ4Y,QOEOEYKL>$9UJ&&X=0X)MM=$Y9)V=W3KICQD6Y:*.M7@IJWV3_;;;25P)+YE&,U!,I2NMOI33W-Z]$G]_+\I9M7!6S6POJK"+!RS7+ MDMMOYC*\0HJE)HV,)(7*D&J4*)*9TFN()4]?HKD8!)JOP#L.!97]9M[YHE$NQY*=8P^1EXU__D1-@*-.UH6L@5+%?R"I,O&U(ECQK6^M.P;"[!.C,0*?:G+48HPFVP/P:.^.@)3\O$9I,OA8(#O%2I^7]K8TTR?YX,'(.M+UW4,?T37F(`.XLF\C(!(_\18=!>24U\X21)SX7>+>XDZ$H-$M+H:.6(HG$'MS^^I;^_>Q1\\?)^CIW+64,>Z0B8_1M3HH4HA@I)*@HY MK?52O48M1O';8LKDT2,<&N^W7+] M8K5TNTNXBJKJ=5]6AIH^9AO(EX[MY\J.XQ=,.!SN]8Q>K'=]7$4JH:&@"=@]JOBG_=A]X5DZZN7P\OIO| MT 7J!N:F]6$ +(P"}B+B81*>BV=JD% 0N;/30.7 MA=*!>%EZAT&&I*PL9N(<SE=:A-KO7-MS>*G@FL\EF9QM/972=-Q()DZ,?O?$ 5+4*I6(B=<3(2<^P]XN:DIJ_$>B..4=0)F597,T2P&;%,Z#N$R-MH(3CU,FJY1 8L)HJI;&:O65!"6\6M:C 3+<"Z>],#]M2,GM!*>8O,V\>NXJ1CD^_WYV:VJGX#RHTG<%3C0'0N\-0\-(HIYU"4GQ#*&-|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fRA6B8PDGD^6QXIWZ6DK:#OP-I7$[XW4TONP:/6\4N5E-.=4\F&M9"F1L&WJ08QRN_,7YW/U=X4PB'>;JAXWW]2GXK#4#Q#]Y[@X=635&.*_ %%,MGIXK7A@A+K^P9=75W2XAM3Y#A$WD]KW^! MW'P/C"]IS;_:-A=6*X-<[M$5OUEE.SWW((YJ:T/T:,X#8CUN-J@4.#:SLQ7+ M!Y6D\|&1KZ8O4CR^]D#2ZPM61U.+/48R;G7ER%DK-81BD'' M*<&XQ%0B^"P3T*P. MGWD%>&'H_&L^>1BP@PG@I]TBC21^ZB7U-8?ZQJMR*&YUG/2T^_S-YL%DTE%- M9.?3PPIM(-S;02<'6\)6969DN>T7]C;H5>;.1F>FR+I]+W%5KCR7G4#[PEKK-MF]#QLRI@'I8(YG]@,=I!4N>KTA*>&E"<*EP/;_ZJ!]PXN(*/T2V1'33T/162 M+ZQO8:23XW<19DQ_#??D%:<]IJ1]I&D.H2R_>DS+8=*-+^C!]DU+)_]WB>!SQ ?%\Z15VMFTE@GJ'6KIJ,VZ=8S&O''7'<[?7-3#OCV.^,U(D^=8E[N1!BRZ N"K5:I]HHNUE=?D78V%^RTIVBMX,OK9WQ-MS;05;U#&W><& !H)O"%;,&<+K+>F-340ZT\F%UJ?.H=K+UD9OY M=?=+>\|.9ML&6%F]I<%8MEK"&WK(1?V5]]=>1E'1N%&YP)FVFNA6:9<$$RD_MW3I5CI;$A/J,=F\=]WJU=SSO2NS;,,X-[5F]S^5K+4_)<;^8BYL!ENQ'4RE4 MDG6]E(8 93'CO6WEM3?6I\/.W; >,M%YTD9MR;]:]'T .#NYU2-,'XP 6SK;(G3 M:PU?33F'5(\(R9>L3@:.T"P5+]DY%=YH!)#?!0>=*!DI|-+Z]K*1&7U7ZU"MZ M8WMY_]:"3TTVE3UW'(O!FY2[,2Z.X@%$YY*P+O[3M&5'\X.]7I%/!9^/2ZMN5)\UZ+F$K@_R6R7[\LA7V<9W,BY/C>\UWJPH5@QI^/;5VZO\N'LP)W=U:%J/ MUOHQ-^?S2YH=7*>2>*L>C_[5A^C"06Z^[7[GO,45NI.6EA[%)=OU#ICD2 L M6R/[W+|\U-.)I*D>\ERT30#<75+N^ZT&/U:%O>^Q_SAV\KTV5.=|SM;+OT\[P9_)CRJ!A_SWJ]9P)'C

^&9:5+7$_]\:5S 5+,-DW,^7_K5=O.|[$W_M3XI-Q!OPKVMKVM-=G&O&RN0K$*G+?*=C;=B%S-P1#,V\U,')FR=Q?>JA3 8W M,;/19R!?) 5T[3C\:X^DOD %57[B6TT? W8QOHU&5BQD; MM*LB708B">:#RI1 AU+V+:#_&Z7)Z2TQ*U\G*V!]$[MZ0B;ZC7!O9S;7,)F M5+6FQX%XK4H"T@!H#)]J3TO"IM!WV.!Y6G6?IF#IK2;PC?,%"f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|)*Q%JF/K8V"W<;,.K[R*1.+_]C(_!WPUR,+Y]*SCZI.((J#^ M[FGCT;C@!CP\@6"'/8E? YQOHY=\K&Z)UK4QOMFQ|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y>+ 4F]!YP' K^9'$T?+>2ZHD. M4-RN,@+8V6Z6495Y2 9HN9G!S0*U!?25=P(=X&] ^Q-"E2.?$(MP0Q(II)7F6S+1S1W.[UMJQ*Y3<"X?\-V,'1W\3"NIM_:'KNIR ^C"H'#&;BGF M+R9=*1 [%G'E#.2S3T/B(YR0A)8UIC1N8XUO61GLPBRB*N4F]AP*U'7[.,[= M5E'O/I3LJ'|)*Q%JF/K8V"W<;,.K[R*1.+_]C(_!WPUR,+Y]*SCZI.((J#^ M[FGCT;C@!CP\@6"'/8E? YQOHY=\K&Z)UK4QOMFQ|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y>+ 4F]!YP' K^9'$T?+>2ZHD. M4-RN,@+8V6Z6495Y2 9HN9G!S0*U!?25=P(=X&] ^Q-"E2.?$(MP0Q(II)7F6S+1S1W.[UMJQ*Y3<"X?\-V,'1W\3"NIM_:'KNIR ^C"H'#&;BGF M+R9=*1 [%G'E#.2S3T/B(YR0A)8UIC1N8XUO61GLPBRB*N4F]AP*U'7[.,[= M5E'O/I3LJ'|)*Q%JF/K8V"W<;,.K[R*1.+_]C(_!WPUR,+Y]*SCZI.((J#^ M[FGCT;C@!CP\@6"'/8E? YQOHY=\K&Z)UK4QOMFQ|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y>+ 4F]!YP' K^9'$T?+>

(BRS?/6/O=_)8F@KRA& MY5'#SS·Ul;SH[_?\PI7W_OK%#)QI+!P.%<>,O!CVW9H65C.6N(MJ49?,*KC<.2AHT=FY$-Y'C%D?1R) D">VT&9+0'V0"SOTSED9^M4(LR5(/DG M!.GT.Y5+DTPHCLF-[CW-F5-S@0K(F_25GUY+C&'Y-4E,H"6288O)B:*+W2(!-MY<#1_467+/1H72&L_5-"B$:>OZ'(/V1:OAH7U/|'ZVK1EP-&@Z_=[*V3*N\) MQ5/_EOI?6O? [^V/#NC);BVDRL-AIN>@6X4$700QCTW|$ Z3[7:7GGPSZ4YP(M-UE|#Y>95KKKNU|V5MC-7_ZVL3O,^J(&YD%8Q9XVXR&;OET>F ZM6_%@=NC^ M"=O),5I746(KGAPNW#/U&TP.\F:BJ3EBOF6/_V<_B;!>.T;/!QD 8MC|I M$D3C(!HV#PnN YI.UC\E;SW7S8>EM<*&G@JC(S'Q|ZWY3!R/|2P3AZ#:.]9 M(VU9YX.- *J*.'WC,JC_F:%M(),\;/2U9UHU5W[??/WFRNFZZ;+?%F(D=H:H M0|C%_J5PTX1\GWF; *]>MC;H[MC(#X64O.M5C\6R& -+V"AA/X3W=00WZM lU-MY@]*&!E!\M:OEO?.? P.ZH3G2\.,LD A*+73 M2=E]S++'!Y-W!F."7B6>,B)WD.XX1;=?16="W.@(1RC9 MC9WEVG^?SITC0Z-22R,1-BB>MYRME+.A, I;ZC+7Y=,,,)<&'AP|;&|)M20X MK-LY&05[? 59+DN.B4OSI#\VBA%XR5T3.5K 1+9/5]LVT3B%&5L=F_B18DWCO(E9LL{BKY")+YMM MJ:=8=_AF|HMGNRKK}\R(6F865DT=[\TJ+)=0_UB+5>&N/S:Y(XD WHG/^ M[WWW*^D=+MJ?2S>6'<#&%8Z.=X05T*MQB@[-$E?NTU[/L?\7I/ZRTR(96%+3(;MQS\CH:CP=/W64^%DZ!<[G#M_D"V8"I+Q)?H.!9,X^;Y.U ;E MCI=?W% (O!UZTM9JH2F ?E-*$_MB]XR)7S%L+&;QU$_?P#GR*%'[[3_C S"]C M3>2IA$?Y-P>O-D]#AU #;_'YHG8KT&,^5OSWRABB2KEG$)WFLE=;XXK>DJ7R M]+O[U7DZ2_\;P=A=O_A\\&$*<'%_$[P)!7%?0,4SM50GSHH-;6$ST;U):! M8HMUP56X"^CU{RG,4R \BGG;H@"+:[H#;]=6!',7^M DE)/D7E;/]+&O.QG/P5VG:*\- C:$T'3=LF6>M'Z]:D7\$@:[,_0^W#?[[<;G\OP!02P,$% @ O8$T61E)-$8/AP &9(M !@-!I8FEO+3(P,C0P-C.P>#$P:S Q."YJ<&?DNW=4$^$;+AAZ[fT&! &F M2>\@(ET$14!J5$";$,E!(J%(IZ"@*+U+DRX2:H"(-.D0:A*DEP00(@18?G?O MW?UC[O]|[|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|5%1XED%W\^Y*I Q6WBSI ML,!O:[)< 6C2\8)9FN(GX.8K@/=%@T[]/YVCR9'11%=|S\5>G4]}B@U31:EI38Y*/OS2_2U/Z//"*4230"#-J/QHO_A_LB70%]CC6[+F0'7?!*)=3RNI!BEF5Q-,L_',&Q MYWI/\W2?N]T.-T? U,LG?X?K"S*0W40OY?)))\,<=JK3@W9*;S%2LFP^=VYN, M$]6-16]86-^AVY70\QD@3<^0OMRKZ,A;)S;0.S1RA&K#"]7[.?K%_8MT]> MZP<<- ?:=05/(3^440QCJ;8WV1H+S,:1%4\F(;'BWU("*PFF#S)'+^OZ=HZ$ M54.?22%1/XYO:ORKOZD"]4.LR\]-H=]XE$177TP7QY8Z8^G-Y-PU%+0Q4S[Q MW4NS^G@*GGFO.T54QOTOB7H?QFO\$P1@\@@Z9>D2=*K!@-9-]):Y,;Q2@(<)0 M-^\CYF%|MT;?^.OS64O>_B&N&NQ7!DV'N8%K",7HL62DUUDD.MW196NAQY*") M^M(@7?HY;G[" @/ Z!NQ).O1K\H>U5KG2]fR!SBW5-DF"%X>'>?M:3B(=V1MVM] 6W7LE)[Y(<"W"LY=TBS+I>2ZPWEBEF60]7 MO"AV- C,=*.V)T7L67>N<8E1RV!GX/A;Ul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|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|_=W=GZ.R$B0[6LJX!%HP_Z#N\|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|ME556V!F^@IV?):YR<=V3^^?B4/L4FO6F4 S#5 M_*.\?KA9RRG8ZI<\OQK075EOM)D=@QNHL]E3+U+9F2D[-MLS^F/$SB6> [/7OOGH[J;2 MU760P'!!=1#UUH_1PJ*YY/%W+_ Z*8'2.D\FCZR1'[^.[9*?+4+9GH]*-4[7%O>RL0fR"\F&4<,?>2A^NR8'>_>X@1'_ M:N,'D'_*W[_-["1X<#C#?I\ MGQ=4TFYQ\HS:\<@OZ+T;\M>PY3T!OFN\YV!A=5K3=!:5,3<1UR=N #TJOA-3: M"P@4"8K5MP9Z) E5>$W'O1)]%/"\7CZA.$&~^%PH,'4^[R7(R$H!4%L\$LN$ M "=UWB$ N2*#"*W6DY]!)..!9O(#!]F&K5*_MA3; 8FP7YV/A-9<(E]5=D$- M-^$MRR1XDQ'VM'I\>9P##7/E[4">.!&MN#7!O_NT"9^ZR<3%R2K++4CTV?,-7 M\L$G^G3U^G8I:OH.P^_ETV;VYI?3$P=2R7TGD>M]%5CX&)RC0PL52L]9K <_R'JGV/DBQ]H2'U M*LK0D%,.R0[Y[R(ZO=IJA%B<6R^L"9:X/@55]S(MAW2+SQ=- K+_36HPR3RX1 M'88/_S$.SPVFWT=R("SS7>02W!![%[+\2$KTP(TS=IZQ.!EO@$CI[\X#H MNNY.T$/79[OI/[$L7ZF,*&;$+0R>$V&@JD>+B XF_,.YE.M!9C6:#*T_ M:Y.9XJ1H@G268?()(.7)\\]J"_9A @0!{(47,HQM-NPFX=P,KY7_SC5KQZ1^_M_%BO_*)H#PVAF)Y4G/)3#$&&/7*.,1UTYX 2;2%(;3>-OJ$0#PKXBY.NS1$ M.3>(- R_^9*%#H"QM4'[>=,/&*YGJ?PW%[Z2)>@D /--\%[(.]HZH@'.SF(4J ME/;(;UZJ3,_7K8>;PDKCE&X<(NC#(Z+6?_*E?G@?4!M1A8'-68?0<<0WG:*X M)UD'W)U QDSS3O7X)(*"WB.!& K1.%C:4CZGS)WB=*[]M#^,P);+U!;8T 87 MS;'0LDUFO

*3RN!.8;XAWTU^]6 M=BWL7I*1^;F6.?I3=T48V%OX!0!5N)0%/S^6\=I"}5I_;Y>_235..7D_/'X M[J/2K&4Q.=%@OZ*H%LW8)(UG+FGJ.7@@0>0 (I-2[UEO:* M#RIODN8&_E&OWDYA5>J]@2OPS[.\N9]Q\'^*+)@EO ^7E",@]LTYRNP55_;@^ M.^#1_T+.I%S.7I+ ^(.2?*Q+OXOHSGFHM%Y.]3VI6R&^T'[":)B(S"4'>BS38 MVPH#7G-5&V,+1(^]'ZB"C[ZUL \K!"^LB0$>%M8 M&K;BS1&%[N1+98$T(GZ,1?WM IB2\R)CZCX([FH-4'Q+]O(&W_E"EIYBC,V! M1>N 91D<"""",TA4@B2A70Z"RO4F_YTTI+_*,2_6I"=^F9V*QC)&QM.'BEFK;MR2%@,,&14--S_4U8,U>_#A7$WR8?<59Z$%LR(;%5I*)?6PJ4+95'|_^@MU_M,L_00M^)4(@&,X?-U)R;$,Z[EP5G'L.&HKU%'DQF[0^8A@32)884YD&PR>$O M)>KOK/H%17Q))P[GP1?U+X*4R.T6N'RBM$"7MV=MQHG"V9>3 :F1=>^$AL8 M_%VH-;1+58:>_1)ZQ)+:9!/3U3!:Z8M'G/2U$7)+W.]J/Z_=N=!_LV/6\RT; M.A:&NX!TX"\># O:SXRP?P3BQNH(Q2?]Y]&&&\FU0LLI_AMN1.FXQU+\(Z M6:B5L?^=:,^THBW^X%]" OHL@3D5_.P=#ESX7P%,4)V5=9DZJ'^"&,K"1FUF MDOV5L+J8FIUW!<0?H@40<HU&2]Z'R_JE=B^T58_;S/+<+]19SF^2(>5;6X>&'HDMIIDOQ4J-]C:S&HCG+!8RR2! E MG ,O?S9SU"_(]VUFO\993D]ZT?43)Y _9LA#G9CO*;VHC5#G'C M*:E!Y2-43WW13Z&]#;)(F/KQ_P/KH'4?KP"O0(DPIA7$F]+>)CY(#A9-S+LU M<6\!DG %>. 1<&*=R9AX2]`)OJ[PF\YB,E-$7]-!:)X&H5 BIN__]&U[PT_,] M#ZG2LI:1 N-"H>#;JRE:[F1'2(2>$<%1);,Y>FJX4!KH3?8@CX8Q>UU7K3U& MF1QO^&M?3V+A]O? >OVCBH>KL%QMCFQ:,S0W'_Q>8'O@T/8B=)K M[@%_Q#,W2G@^&MG;-?_FJ._>1@^*"K&P9Z=1UJ+G+ #?%7]R1"LTR!>9//WG>U= &OL>#V=YO^'N\6;7 MA0[:ZE*DN-SE$]D4Q4<=@)O%38[R3I:QS%W;4O#',TI\$\QF(;JC*NEI M-Y*"L^Y5.(7;_IOSMY=3XW)KSY27Q\2"T@JN-%;Q\1@HU:<3PM:I(D

*MZ#=1YLB3^7_=,?!Q*IN]L2,!4)55Q,+)ZC7,04CE$C5[H>NUR[XJ[F;7F-XF M6VAXQ_M@Q2>Z.)XME1+M^U#(U?NO;XLXRU4Q)U8"20_.(V^O^1BEK)4LV;$-F.CY"GM54I4@G64@ KY>CY(:Q-0Y;W!+HORNL??FI M:2KBMO#4S6%XER/I#38L5+ /DFQ2O2F"C+Z MO75F*

*'KY)R!L"MI60I.PR<|42^L+"P";S$CAWYPN6,!9G>WX7|=Y'<#O1GY8 M$*H"Z#N7,;)|$V(Y;M4DM?XN?S0D(^PS0%608!/#EEUCV'B-&SEP_EF)G!#] M-D70)X_=ZI}1>0%XUC>:,Y2GQO9_+Q17:-WSO<&IIR1X(3THN8\$ M!5C*ES:>B-NG@]V!?>FA+|$9N:@<]?UUM-M[+M?%=F+0[;E2I))*V:528PT9,_YYXLW'C^Z"I"R99ETL.+"HQVR7VS72^"" M4I8=DLW;![SX8O:2+_W2\84SNQN E4'@BFC@IPO]D(_.$>} DE?A72H,!LW38LVMQ8-Y&*

*[[-5FI=)WYK]OFDU!^+V]5&>%ZD;,WJX_+]G^4S M$L7HI/'S/?5V]A(Q:]#Q7F%QMP$53>TM@5^DNX,QYF_O||AS]#*$5Q_WLM5&@-MP")BH$ D,&(^LL8\?>DDHN3[S_IQTT>5&6\UD[KUS)$NJI/?8#XFG3TM\B*R-MB/L>L4%%^[K/1"T#9^^Y#70IWWSK;^T/&"N=>9_ 9L-KE_S'D0 MO_S3T-SP=5]<7*"""]G?OH-G7F'?;_.=@[TXX_.;%;^CRM0OS1)#[FL]HRBL& M@^'O[4OX7ZNNCO@W5:1Y9=$=A!@N=ZPRT&D6N!#'!*2F7+S/#Z0?-AP>L VH M_^,)++R1K*Y7-#9BU1YCAC[#;;?*

7D6Q.>5AK^\S;N|)U="YU=*WI;W0 *_-7D M]U,((5CES%>70#Q08U)<#*IVGHH%J4|J;Z*BE$B?3KY*'>2_^\I9C5.85H']*

*M]8C..12;_Z$1B&7MF%/D#:OT4WFO5=N3;N=_+5[VYCH7S>>3^]&=1]CN5<9 MZ"'7#]M27+#)1^:C36)&S*AJ9(^)4W>-7S]=:UP],C(8OL)M:"*XC7'+YWFN*

MA'L8/:2<'}/R[G6ZBB6:]RT.H,]QAUO{3\8P'Z(;Q((8JCS?S;I_ M=.^"EQ-C%|QMN!'D])GF"%K;U=.^I]!WG[K[MG_LB&M3CE9_AW3##\H

*I:*2I<_%MO$ ^/"X6^JPZ'Z,E"@O$/'66X*4A RL, M0.=.;9376R%*$4];4F^#-\.Y..?/i!75U9?7-9U=O/]@#?-9A7(B]HL]^G+\## MKVRJ"5/VMG8MA,BNZ)>-YU=&^YV;L(G;3AP\+*

<;=[#ZW(A<>OL9/WWC4E,2&$Ti:CO5,P#%4_ M_]&H*1'CN2 1SQWK5)%>/]HGSY_0 M*M.00W# GA?C,O@G\\9<&N|IK_DT"IY*RR*XE^HY9RK"GZ?ZF+$)"D]@

M&+C.;B:WP9@KIU5OTS2(BM@%9'I"HL5%*E?53#7I(=1Q%]G.-1!WI%VS22T0H"@T'O2(2\ENU)_ "M:P>,^%7|L@33|K2Y)2X"Q2[=6U]L(U78+E:RJ3?\8/$"T*S0VOKK?*

F2:"APE M$?$4$STO%%RRHM4R(4,3V!5':W96#TQO?3U8#-9R9H'\F);JD46XH21{(CE M0H#=BJ6Y/R"FI@)'%P"F[LWB>9N^.RJGYG?%F!M7/W ^UHF6BE@TD5GI6 G&M0AV:X&C.(A /&!?E[VGG7*S/^;*.~0T=~GJS;%8LV1H@+?]=/:G(S!#&.H\ M*Q^S7^;HX4HQI"-=5#O#\LZ<)WM0;'I W:%LD0O3:YU7H:'+9@(-K'%7D. M?*

S&1A5%M.C)7W0T0>U3U+S8!%_5=NG?C[UV0^[J=7(4=3383F.L^?HLP<6" MTZ),* K]7FI.UT\ZKJ2W^IG#P_MLQ#&53@BWR@Q@T@GL,*,*

*MHZ0U9N_DY$9Q'/,LYZ#EA$ZH'$D#K;H=GA37I%C|U?2/\M?A;K/HQ'&=LI*R MKWF.1"|.I?2ZL.F@>\RB167Q.IHT#)5 2H2^PT^83V?Y,W5T;QF6 M3|PVNZUK.*

*<(\^#M&)G;O3#$SD=7G3Z90:7_QKH5Q*S,Z5[*Y]D?>5+KL/RB M2N/PA8+N'Z%867Y-VAH&6:Y(;\57W;]T*(H)=_%!KEC=UFD>@>1+3+%6'X}2*

MK&BB%@Q"9FA96CCP'6@L4966U\9\7%#PZY#I<:4[]A!YS_+TMR1<]IGXR/@ M8UD6_V 1'1GO'AGO4[K\OW8FOG(++O(\RX-W+A_9F7$?RYU|O)^6[#;WQ]R7*

*MXG/CIZ#56,F>$[_CI&%PI9E:7Q@-D3.=+11;!79VEQ)N@WE++^@Z74>Q\OO MHD+NFT:?5[N'"%WT4>@%X6V<6^AQTS2$G8=8GRLKNS GZ'-/O6=)>!QUAR8H[D4^//?7-)0F]"S'0-I"/P>0)IEC-O:XU("O(PA*T;$&PQ=#ES"N$ M:\;IF>Y7[\TEAQD[*M?N\38'G.O[ZXS+3VO6!1D2=^\',(Q.!;W:8=<2T5#C*

MWOUMO(9H6)MM>++#4'P"UE0BV%|"X&V2$0?DN\LW,V5C+>]+-)(/^'+1\OMB0 M9O,EX,O\ T0=_|6(U^PR=B5#!0H<,&|9'.8/|K7G0DO5HJW"""RZ]2I^PN:> MM%Y9#-*

*_^V8|LBZ9C,P.O .A[$[95Q.E>CVS^ZQV;+W2N$7:C>FZN1V?G>CR/M0$5YG3S\F>*GPK-E$G<<3?ZWI=VOGU MZE;YYXA3Z]<- M,(*8,3:OP8$7^^2C-*

M@ZM'R$7^3TH!UG,L0)'EE\+BK*6W^Z45'<&8T\>^R< MWI.1ZK5,\7ECEK1-_A?,N.M?Q5.I-/5NVQ.CR@BT?'IZ70_2$M(LV.ENJ8^F M?5R71S.-

*S8D.\XA)W|IJ/-0&W80CC\%"T2DLJ+!=# M!+&TOU\5G4ZAK(:E M.&C#G:HDO/_1YNE8C>WS$!+E$I.@U':X51"\%V3_[_B^CW50*5._"D.I[*(# M@1P)C,??-*

*YXI(6B^;>96A'*H=\U^,\XY|"G,<$&L4@MFT+$!\&;I-R,..$N7 M3U8YW=^;EMHV12/!38^.SPRNO^C+O0MSTODR|\">8A5J3=/"=>[07%(@MZEI6*

M.4],;RK3KI3@C&%.S:7>>?T.]%?RY2Z[58\F*68MR]'NT[ZTC.F&\2V#.80 M.\/';^56J#)6Z3'UQ[C\2(G/G[^$)[N_;NK_?%,B=HY",$ EN97G^F0S$UCU*

M=LU/#$$B%Q+3M;G)=H0NZ[&VG8>*Y-H 2,X6WN4P_/G%X-N :@E)UER[$;@6 MQ:M,'@]687U6V0@=M-GXY(#2G5WY_34 SX68?\OW!, ^)52&GJ[PGPVEWHZ^(%

*M1]_@=%2!|)EIS2>UZX^=T'DOK(VTE:_IZ_'Z0M$?/)N\!N\Q=T4)(?[%C.;S_MN$]%P2A%14I84BB3U!R&TZ;:.G|/IIR4*_ZI!D!^A0%Z$QL.U2^O.?I943WZ M!ON2>-]?*

W:5#=U.O7Z.L8I9X'$1>;.M="&HJYY,VE@.*#.6IE'2!?#%I9 0*#:Y4GXU6[HX]>>8DO+Y[P\^F.6<-T5KGY|\EZ|>=XQT832GV$X&=9 "?K>!F+DA%)YRY&"KB)-P

*M::V86O/>]"TPV+;.O;%=7C7KLQGJ;D=]|!59 /T;/!9*Y"H|0090?4>RNM9Y1 M5O)'1&F R>MB^6_T&-;'ON .I"9=6=I>P>9U3|2YGE3!^/>.:/.T*

*MQ+A3VWU98O_IVX+MD>"U3H94"@#3 XZ6\J?I/[;A M%2=!WZ;NVDVX?%E^*B;.O80*U^W++"?,&#CZ(2N"LZQ:=V>V&FF$KS# C;1<.M!DC\|J,8[9GCB"(+MJ,AC8<;;Y.5?*

P1H#7L5W5/?XG8/C!''|'#4"-L#DDI MZ9G!T@W,*O!RM,L\>(IV^^.I7X2-9'|RQS!^D1[WJT5QD>& T^7X9CV\WI0& M/O %_GW!*

(KC%N7DF9_3HSUK3A)@Y:IQI8SQIM7?!NE.TKMPI[7HZ\K;6421.,.MW6)/"2E09;%R#9^]CMD?1H(AA?L"G;.@".*0I$IE:\G|RC(Q^T&K;2^;$F3 MG'BR_&8-*

@_%#$AYAI#N+G&FZ'0KG(?]=BAZ2D(_[\PHN0M5?G>?!!@9W;1\[M>'V5Q922R|'_.+6R3:,W:"5D6; QIK.ZF576I'0",/R|OQX"D(S[''O%O$ZZ M&-TD3%KZO?G-

*!-1SS?!,'C_PO 1+D5AH;:FE+.&'&')U]>9.K63L$6AK5?6|8W1YBMR;>D 5EF4),LQ\?,&UG"$=T&(DC_)C4^0|MVRAM,MC: M*QW%F=<%WQ7GO#6@&*O\|YV=_3_3"0#'O|*

{3M,X8F\>M:(6\C"UJT.<;-8# ME:0C7V1-0W6N/F^=8Y(QPS=)EN[PI,W:?V6%4KU M \Y_X*|=S'95ZU_&(&@G56:%O"\Y?ELS,FY:TI-17:6(WC)|OSVODS'/NA"- MH+V/|-*

\$=!GLWEP;?OE<>W33?.%0L<8BIIB23Y9]@[&7B?C*Q MY^-E,#A=|WBU_R?2'I@A/WTE20DTG&&_,< HSI1.,W0^NW<5C$OJ2:AWB/F M-*

*E,.#LKGYVE>$O/C0?.S,H&/20NIC",UP%U17YQP1UP7+,_^Y+9O_"H9&fTM+53&.C>]-S74M=IBHLX M>FP $?!8QY@\R23NLJ,6**YU8(U5)=W:P5%V"#?2WJBS/*

MP<]C1B1'?H&*0:CQ]@ZR0F2RBJ]P$",..;]MT46$MA'J*MM&:8-! H3[1V*T M#QC=DE!#%9P]BZ*6W@6N (O7REH[_0!RI&:,;[TCRP^4/,HX9O.KR:#UCG+S/*

M!WXI8&)M=<(Y_NF;B,&\I_K.HC%34ES'K/3N=6#YZ%%>^P+FI@Y]2AYRP6V0#9XR MX5]V%{C#@0)]@~|M=IX'0E'F+8_%5,-*T545M_O&&0L)}! Y0?K**

MDM(PA4?%HV@"K?+E?@!PRP,>-18#8K59@3L,OL@]/B901(2\;G\]&|'3O',. M&][X'!]UZENM%6Y82)LVAF.42TY20(VS94K= R5\QA @"BY"+^!MVI9.*

[%]7,.1M=AM8D;V]@^(P(2 M^&^XBV7C[90D]G>71%U&I=_.?_<1PWR-D_HZ].O?7O!23Z.18JX36L>9I M=0KG]M0C7;MT&9A''XPR4RTC]"C+K3|LBG28E?*

*P.1|BDF17?%<;XH(O,/< M.?YA%/.R45DQ./MGKHG&^8ALCM^J,F0EQ^XF6-I0X$.QRJ}XM"E1E/$Y'"*M?&V3HU=WIEX%|[+8PEHG?:*

*W(MV780=CWDX^/Z!T6PGHNL|JZD+Z^&B?*ZO/TO MK+)1JJ\L(3;CM&XJM0_#+RD21Q6=*1K3%7O)_0N**YXZ"&(@KT_;?@KZ M$=EZK+7K2QKWC1.5KCF!>E) MJJ-*

Z4G6AAY(FFRCP46)HUU=?8ZF6IN__P-0 M2P,$% @ O8$T6=8OJYL= $ #$P M:S Q,2Y]<&>><^W=<$T_T!HPNTGOO)710FH)4@8!*$ZDJ2(V^2!.0'B D(-*;.M6$!*

045$04#I34(*17HO0@I*#20(834AO'Q_,_O^Y,)SE\[.WN>F6?. M.<_,YGCN&/P7#&W,@?H3@$ W 4+QT]+]UQ+P YL9.1G| M\+\\5NE,G-C(QO["RL9\T:. !3M'1TY}BH/_/ZI.*

*[<2?W 09>1CZ9]WQ_?S#PB,BH^#1,8F/DD)34M/2GSQ]CPO M_T5!X=O2=V7ORS]\K*BMJV]H;&IN:>WNZ>WK'QC\|GUB$|PG6)@H&=@_@\7W:FH_QKP*

*M,C#*G&/B,W5@OAW"+ZN9P")P,??-ERY6,2U'HN"=T'$V(?GS6_72?]#*^!JG_.M/6 /_U\A^S^__9^X%@ .>KJ3R:/G!:# T,6WZ+XVL M LP?%>,A9C=]I^\?2*[<;?NX%@Q3-*

$,@S:OLZ+&:T82#\Q0B-UO:)ECQ}K0#TIGOXV7_Y_>/RX'+##EA=[-MHD)*%%D5;CRY&K'P;I4FR)6+|Y#KY8==*MML=!W6]"4>VTQ0YW-JRF^U%'A5 MM?W*

*E_Y*NHH!E-?O6H#F!N]F9'!%'Z1((7U)YA4_I=|PAWY%@*[4["X\OV]! M.%'5\;!7;*;DS7Q;Z@S>L35[67/M;7(HDUV9W^*2611#6)>L#4>%'Q6HLI'*

M40;>+H:HUZS;],\Y8H|V*)9A&3=TN5\/HYW5S$7N&]/C8>A N^1Y]Y+^Z] M^E"KY[@VYE,%W/P?-(}?!2'P,\Q+B92*T M_E^?;[_L4KU>;[AFQL3M-*

)6[PKX=JOFT92D$O^5CI7Z@OY-N8BHJ>=H?>/M9 M@70,)$LG[_@9FKT,$'SYECT_8/UAC\QZ=A3BAQP79Y"%I@W?D'AE_W=1#UM3 MYL>F^Z^9QZ\3(F+%-

UQ58H=BTX0KS,Y\@=ASNK\^E.Y\4D=:2$+/;?2H6:(V (M(Q_X.TO7ZX22RPXK2UYYHP^-KQ(#E#^M\,"?6A&+|\7+]S,S'7'5>.<1D.#5_$ M2B=I3:JOTOV=O-

*_N4+KI>]/OHU_%W$^_)A,1#9D6BV3[&($'#U827G->.2.> MT:R*T;([_Z#;X)M%_V M86'CWUV5#K?%CWEZ7C"G2&FZ'1O%))R14E^.NT%QVL?Y+,'PEB'[SC0|7K,G@?91,"M'E=A,G-&>)QNKZ-:1U'- M9F%HC[?A]L5MSO:G?WC:XN64)@L!BFSZWT3\"E6 O1-&WQZ^S)YB26+.1EQC MN!C[\T*/T!WLI]+^,!E50$|:XP/\24=S$W:)*

*PY'Q=IVF6+NA7GEKS>N*330 M7G&P-9$GM2K^:HN?!,B=:Y$LJ_PF$$L'F* ?C'AC-"EJ@98KN)+2?KL4#KN>*

*M>ZN1Y%16EEK_1Z93NA'W@)LQ7F_37+_.&F+1&'*QV0769U:^PNP[AS8AID]#:.M(NO:I$+6(/?'3=^$(NNMFR'GCX&HB7BH6'L!$0'3?-ML@Z8\MX#',%?L:ZR'3>>].^C?*

\XVV>@%"%%^WHQ_VS8$!<|<=I?-[-;_A/44 MGQ]3H!@L;5BC2G,5JT42Q+I$[LPC]&WQUT9EXXUGWG:!HVTHRE,\'+2-VM 'K%W]#QY8X>-7[ZK M>=*AC.JRHDE0#*

<"B"KCFT$6276;YN%1UTP=XF)VPT${0%R1ZB75^\ X3'2 ^]K#.+RZ> MIR/W*0;@N15Y?P%HG'@,]NHF[D/XT,IE_!*=UKS.@2PY\H?;]KH2$*

*M^;8;P|%8>Z.Y!*0VGW")F.,V=H!FH(U%21DIKWIXX6Q!>F9'UDU+Y=/[\42" M[fG2 B@A03*\1#K]!&11XU4->*E?BW7[I2^H66!-[W$L,K;D-)7GT0K@8/GQYC1>(_-[?*

E^245%_|8 M]^$(GAY&?8|>, >WWNTN!H"[JN, M9-\?ST) ^FT<^T7VP$NTLG>@&$SP&,*^764$YDM@6]BLM ;?+#]..=+.GOAW? MWV\. ^ V?[K27X%FTNB=MP

OYX\PTN$=$/3_4Y<9G_9T MG"$IS#RY+3;RYHT?+C;P_%4=_ QG!! N1),$>7GPH'IW1Y4VI^-LN] M ,$A7DINC(GTG[$IY5,.)F4U/VI

91CA!@EZ$=S@3N[@WYPE1WHR3"2WX6[?MPCH|?Y?SZP6*K^+97]3&Q_T:.^%$-3?MGP#'P6?T-2;PKIF\YR[C,9W9L8'2Y M^_EKEW[;B(1SO>,Q52U?]Z7?

6E#!J]&3CP'BX2-%HD]/-%47SRT,DFW8+5_U M%,@V0?RU%B_O[N@CLMXT:9V5W"H\%RTYP<1"#XQ&Q%:#%"1TSC67]796HR67$ MX@+RA_.[NZP0N>>

*[V71X_1.*5'RH884T-G7G@?1*_735:*JL0XG"XVZSN>9!-MR+US/L9!EGB]KI&087CCR?IAO .&]&P\V"QF(XVDA%6Z6PB52-(*Q-2E:\H*

*M6F@R*K.*]L=DWHLW7GE74XCVA2T.=1X#0'N8'Z.T%$SL+!8HE#$LM&@.9.QM M)$E=,K9%21?A-<8V$UMV_^#D)-3DM\-.OW3P-*

*M+WV6*O_@@T/33M8O_<6]\W&133E7:B?? M6K0U1YM?9%!EN+O,N2"2$WX]%>F>(PNX6L(48M<#9)NXT+P$/&%2R$|$_62,E*$0*_K M3L^|ZP+3*

*!VEY1.+UVM*SN\NEF!O[&{OHT?>3ZNKMFNU+Q;Y88Z!}?]V0IH!|MB)\!U&()U^ QNU[_K)ZO+MJXB;^$*_ /W6SGVS%M*

M2^=$@^8Q:Z*ON3_YUKP*'UW,[Q0NX;,)PRMV%ITFO(B"B_/^"W';YZK&'_,) MF+\9##%SE:9'3]G$Z:FAG|RJE]GVM;9AN$##?O_B)Q3)TS^I#O=25C^5%/P,*

M4^Q+ORYVVF!BC,Y,P/Y_JN=I2H_7350#ISL&U:T5=PR\=?U:W3Y$+B#:UI#D MR$@P$1O(]#/IHI IVN;6V+F'UYO0O^/8ZFK%^_M1HZ!

*M>!BG*N+^,H^Q9TOEEJZG6>OPZ,Z=OV-!@]|?IE@Y=6/N4O*W4XAX-]"&H@OG M[_:4K\\>\))S8-LQHEGWNS4;S:M2MX>R25/G|U0>S1F"DG$7 P33X*

MV.L:W)4CMHX4)!X#6>T66'C'@[_!2]+A)66$:%M%#=63]\ + MV(?$0YHBV_#05->5GIQ4,>&4;4.OX++*ABHVF9<!, .3V@Q9]0\,SJ&9IYYF*

M#23=3^A'^%B<$"\/$4WB[]@TUU175_I]QOE^.*G*;<D\]]>C^[(Z_]$KC4 M5L2EV9.0Z%E"T4 .(T|/4DUQ&OSP(DQPSTK2IT)$XS\) _DLG0|/OHG+Y3^S M'\|^\T,?V-*

*/KM_&B&A\|Z5!8AQ!M[82HBE_'U7"D_C?:0XMS5?NJF5*6\W:% M7%W=Q>4-0'0P09AD/=!A=%0+!4$)@K!NL8@I@^07K2G)A-W@A^(-Q?+1,V&Y*

MOUY\ZIQXZ5,XWL%"&RMF/BJLU@(ZR=WL OIQD1E.M96P>;.^Q5=:XGVX.W9 MU905;SK7]RT\RB1!,P?C7XL*>NKTN+,X?H.1W4'\W0 M\N?#*

(=F|V%W=AYLZDF[T9@*)YH"B;N?.Z&0$9U\?I?7 M=|8UEZ+|_& ^_0*E=O.|ZX.A!K;F^GA/L\<-)'"A U T80(<1K^)KM/Q0S&GH_8,1S]9@@_3V=WXX22^5LZL+IC(,/06BE!*

*M9J)##KSDW#@1@>;8Y&|)$W/18-^3D:J3'F%=7",.D:S#B&N$8> \.6"1;,2.EW#:&$>-2 M6*KCG]7[C=1C@&,,%Y8!Y=*6/NX*2-*

MS81O%&D%[QW]84HI7W=X8MC+Q+7'JHM:Y,_]HNEIOIB;@EIO2A MV-Y7ZI1AG-'^X;L< 4VG K,.QD:7&Q-\C' VZ%-%??S MM%'1$=MJF6BB)R%,6/T"*

5#92(=9RM3L3^!}MX.&$7'QP M*UW!;Z&5")\|!^ZY'9IP--$N(P7,I9@@OR ":F.-&16;,_M'0O7RO?BN_$L'-M#/_LS'^_[LR&*93\2>Z5LV+;'#4BO*

@77(G0E,1UABTT#K);=%S7:<{6#W\ MNKBX/!#ZZ-;C!Z; [#!!YD3G?D-Q(TZ3^@:Y94X"<^^__"1M(YT_V)3,>^+ M2HWJ&N931C)^GTMHFY4(%]WP++!<@;/?*

*,$H;;_R*8?'_/.K' ;Q"LB(#5'Z MUV#R>5?]36AB=ECVR]GUWWJE G1_&R!9VN@Y9_(L+ OC^ MH%G*POI*REB)|{!A7D#Y?;*^TXI*

MM)N@25;_TJEHW!./?"Z8P'0U\)NJY/,"/'1F+EB^ M>_%P^\,;T_N 5L<4PN^$*"Z0SBH#F$4,,\8]V6!&<|?":JBJW6!.L%.@^?B MW=\O;1/;1&IJH'[<#"O^Z*:2I?*

*D/76\|#8:G9I_=Y1L8#?6]A|OH4)=.:=C M^291V'?B^#*5PF(Z;,A$:!>,9QD\R4XK-PI+4NN'5HQ50B4^:*$C9WY /%?P9 M(3&[\$^ICY[\8%EDLMV4]XZT@[UW,>(-*

*S_*)=G#_8_NS1A> M>PO&2<==<_HR^01#2*O>>2(CL^_1ZT.LU"TLRRNYI]3C6UJO!|.?.?5W_C# MG^U+OT0.YJVNU*E_V?^CWY-[RV>5;|;Z!P6A06#^N|*?@P8$&*^[*

MJ7!]A9,FW_$56SG*YN$!-L8^GZPF2"V95W&@SC#1GRE7R1T0W(=L$TBC-|%\ MXKW9-A*>]@O&XRIBS*K]_VY5@S\|54HS+ME!;"T M:MT3 MH1M?I.EYM"(O@VH8O$C

L1-Z.O?PXK+!E8+T%%((,=\[CK22.8E+RD|HIPC@R$-*@=#&E.CG?2FJZKU?IEF M8KQ1CS+WZ-5H+#<]D0-02'L8-H>3>B/%F:0JU&@MG+V:O;EUPW+W3D1SEERF*

*MI:TFZRT+=Z'5G*E*#7%VU+4FMPR,*)O6A/<4O3SVN9]72Y8&[P>1MZSP.7PY M3' 5V.QP2YN84TD((K!G6_.O0QWAYXA6DRCA9 T?.R GYBAFB+P"&GU8\BU*

MWE$23(RUK2_<<=/G4RX76A4I^(YUEZJP#9A&82]+I:81=A1%3Q??!>_.?-3$1 M&<)",T[ADF7&FVG&# QT]P\)^'0\MKEHSP]+RE=(Z5)N H7=\|&RHA3VT1*

*MT:G@4G2QP^GPC:EN[':,VG#T;:X'>=!;RMJZ8D,:($ ->Z26D\W-M'|Z!%3%KF6=QO^1.=// 2@/S@.532LLD!D*_>KUO\L8D). +[MB[6+XX\8'I?*

*IZ^%#_\TV@#/K!Y@K>9KC$4W9+&T>]G@]*CA&,@L/CVYV!7#E8,RRFS+3]*37T>C%?NRC]RO0+7*T6^3A2.0Q MT+<*

<;ZA'&Y'2!TN(E\COQ_;5V.U3KA\#CZC^9!U^MW9FA^33IU0_[P#&-YK4 M]>25=U1>$E'Q5'$2VIZ8*$K^SCUZ W9R2+Y2?JO_I2..176J@OG(V>IRPD(W M>%%X)?$?*

FAB&9TXVOD UG&CWP8KCXTK]E;_LBGLG=?7TR:X2(@QYP8>F#,D M6!AFLN0KA),O$J<*<=SFD^HS2PH/A6G-S?C(2G?IEF2IDL+GR'A;+F7Z/U#R M<'M1-[I>L32.N-B-*

$C^4(\5,WP^\KSTLNS@ZV6Y?>ORWN%H&@@23PSLD=Z)MO7=*GIBGD12YL)M&<-',)#4T+[0?CD>WGY)>9X6.6YUT+TF>=A09Y R4*

*M.-4A2#*OB<#]MXO}'R4U,&-X/X0.+|>^^.+5)_@,A4A>#)?H[JN!\M,.-=3P M^,*8&ZIBL4)!'(T#_L=W+?%#QF7OVPO9E^/=RM5OY)W*M[0&5.R742YB(#7 M_A?*

*=*79BKE1=*,],-68J/"O 2M/=W25/6HXY\]E5OM<:/G(-UYH)R-MQ,6>#CWB;+PV*M537&>HZ$.;KF6P];1IDG.B)F:"*C%$/J;;"@G&IV*

M$]MGR_3^ZQ^B4$[!O>1=_E,C>]=2 ;#%!>003"1R>MC!@T2>3"U^^T66C425B00 MC!+QB((!YFS"VZP3!KT2@@/NCP!\ES?36RT?;BOESWDV>SJ"$K!H+$?;]4-S

MPIFQ5)HJ!I;\2KYN,^,#2VEKAT/?6\61ML134:@A7?Q[V,GFH[X^,W"N^" M?PDW50%OBC2TXDZO,53"B]XIL6^^;FYQYHMLVI(XE. M^N3-,37DI/;+=#DF65;@[L!8[F-

3T2Y!&%EK_$ C$U:/(C|_ DNQ.Y68G|S] M8JZR&_\:,KI:E9311Y\[01<)>)"R55.6Y4>20$Z&TB14V;6Y1?X/S4N(4QGP77!IO:[FU?9NYL+$H&T).?'%5BP-NQQ..KQ'TA3_DF4E[!^=/:XD:F M=G/6'-$9#1XNR6'U^#(84T1H@J3++/ 3!X.R)5#2*#8;C8M*/Oj%TZ3B,Q_NF @O^D0*A=ZMD]%1PNP*):6$&7"OY!TH]>B"G4;7!&88N%)\%>)1I,@V2 N4K7CCLU0A@CV:9 M&2Y@:,Q.Y%O_N;N,+Z=&Y%+(G"96,"E"+6>G+.|S%0I)1_DW$(<_N;EEU2*C(M7*8QSXX\?[+0P@K$;_!1B+P5E3L17!-7[N\PCE3_<6&;")?'9>Z;7!.6!;@*H/[%_XI1 MGQZ=""*EO@NV1(`61["V?#W.NL>]BA$AA*!DU:?]F+HEQL-?^2H[NC!L*BKT_M4@R@!)*CCZI/M$L=&6Z77I@Y0^/_7,MG5C40I\>[\:6P>%NZT09D")B/ MT>BU8:,QEGSP/XRYL5.BV(;W)GE^+'O'X9UX]=R+Z07UMDN/GOJMMUGUZ]GH MFA,//^Q$];>)!#3A7-E6;[OP8[O7\^MH3N.![<3W$U^^R=.)G>0$Y-D[AW2* M?Z_"_Z$25 Y2;K724X%V*]{E:-+W;.*HRZ-\+L)VV6,R2*6E;G/4"_N(LH+ MU^?Y# X(?N9;T&-GA!(OU.F%,?K.!7L8UAHYIO"^]SO5+TENNG.TTF2<4@A=H M:,SOX*/D$'#W((P22ZC3;NHWXJ6>0PF89#6MOQ=TV:,#\5F^+#KB\"M*8WZ1@ MHK;/*!?6\YHXO:# <;"L0T#)"KQZ+XORZVN$FWG++\$H;E4C_P)2=:F+/_;8 M8+=ASV"U4N]B2@# ^?N=%JIK@L6O+'*&A@(O2&]N/JG(IV|QOW>H#*'OH!<' M/,$,3$Z&L2Q8@0.1GVS7P 6T*>^6)ZM85@7*B8I_C^&^TJX5Y?$3X& M C126LMJ"(+E\#^]-*E3_Q3&J$#XW*]ZS[M-3W \Z2TVG='Q2J\S5PG& =O) M5%-)\+Z.-?ZQLE7_1,35$X1>*<9P['!\X'7#52]:R\6]Z[$93\7RUUM633I-IHZX#:?M' M;+.X>R]F\P>K!&K-SD=B/@\Z%SR6U:WCS4YA0AO7C[^`-W7#&J'9-*D-?M]C M@#5"34UMG[1:%!N!A,(_31%2:F$+++2=E0WFF6CA&$G085?J=M9>UD;C1*)*IT-8"A(\2*4CIFS[QNT3VZ",6<"\+Q);A%U]D NW?0!F"C8<,.[U5;KU\IG%T14/JEE%#\2YSXW$O)HSIEZ5O5+P M>Y\$,\1S^O7$S(R,!7""N_`0(.Z',(%VLPI?3U'2S^*RCQO$;R\RG1<'Y,.U MU>0N_XB_(G_*>96HJ5C(TU)(0'5K$D2;\IL.GM98) [XD? M#NU!-2+IYDKBSUY^7 @-*6[8A_2/IM#$B!J$(XKN HBZ/+D?X!=.*?*[4]MD MF64_B7R&PB[J-6K2GC4-XC!7_})LDM>)RH_=E\LL234V?SYXO M]*_C7"6(8@8.0_R-MEY()1V\JSB 4P>?$MFXH1P.GO6TKRWD$)-*)J=@M"75=;-PZ$,<3*2^27)) MA2V@+O'WS"XYE[3VZ/[!3VN'0G%V-%=*X3C.5/E*XF;D$|$ M=:,XPNT@6U+G$FV(RXTB&[?N;E?K?B;)\SV^_X>%02H2O]QQJ[@2?6^%#L%_M@FSO8F#L?L'2BH@M;R2U_1'O]Y]6MNMB8#)R:")>4DHQY:,O+3"14 M7Y:D-^@8?LFI,.DHK?GSES;&;S_Y/HHR?.SG]DILC#>>!,.HMHAS8!MFV*[/ MF)\46%O3NA%2$+Q\/B)OVD2^0-;]YT^)_)E2.&?-\< H]31R^5#ZX8>8!ON\'O2 MOKVI02UL-4$^!I/9Y^AS\]>K6]0Q1^ X7)=0PX2:ECX+,*4XI0!KE3 M<;4_* (X#M#KQCEV1$7WC>KI_,MB2110F)=-8H2:^'14]%G$,I,GG#Z8K/[%3 M](N)#AEM&HHDGXT@3>++.HUDZ>,!M_4YD)<<2L\GW[=E3/GR:IZ4E(D== MJ7M'I4@IT*=+BO\H9V=?4]SG2EO@Q4ZCX7>L$D^8TSPRSHK>;S)<*Z3HDM=F M#>VP*_.P@=EEWFPK[?#/*B_N_)&44>+[+&+X2-67'H],/ ::F <"-"#4TU.& M(95PBUX.'Y@5'H@9WSI0&EU^BF)ZP1QCNMU7-_8X8-\"-YJF@9 A#O7^^_W2 M06/_R"#VA=CUI3?3K**2_69(=;@FY%$QVO2-*0!&UVY:$P 559RZY>%FVIQX M+5.(=^.,O?(}E#M^>KL=O# `@IK#L=T"!P#7NYKQ2E#Y^G>KA$GRMZ M&PWL838B(AC+&=4IJ3+57]A(9I.>\KK0F,P[UP&[ >&.AV.M@F'-8I1F;)CX(M%-YJ?]DR,ZLL* ML&R9IEY_.BWO%Q7!,J'/2_PD YPR9UZ6CW4]V4![*A^,9]PT1,R4! 8M*WJ8 MN\6R]YOYW;[G+I_J4W4**/;TD* MN8>OT?_8@$HQZ&OJ0HRAM=`&TU7&!_J=|[TDD#6%'ESRCU-7=:,!I4 MSM_^4[G^;Z2%!,2ON^=X##H=:IGPE2OP,I&]E8<@,3*'H@Y4# M4"9CN??6B)F7X_T+C>4!ZHOF:M_;?@UGQCP/?).WRQA:1?4H K"%87>UPM M)V=[S^W3\V$"**4/1^X_,EK_*>CXO13F- M[GN8H3(FU 9 /D03RHEXS&X"E9V[#YKJ>I-D_N6]:?@?/_+3]K @!PHA3J5&#LV-Y"_]Y]S5M5YN[16U,/[9LL).#6>%,^8X:8\G4Z14N7'M#^'!T(5KGIG+YYD)AP0+BA$\^81%$Y'0=^(TU;WCU!>@9U10/S_3\1Q-2Y]B MOF4&Q'E_0'59H'QL-'UE\G$V!7G6R8W*>><[RO9L/K'-45MV/ 5[<5Q4/Y7[-&8W(]B-IN0.IS?KN+9_+31HHPP:"W7>I)?N!RL)OD MY.H]'P3;_KW)'O!PM=(*(O/U00PN'GK96 RYL,+8H0'F7"$>_X_:PP{MV*>_M!:M]?10Y^>D%[*LZ_)8.^0XKP<."P$[JL3@J-N;?0NK-E,9FQ+)1I, (3307 M-%MV$9XNHXV0HBKH_?)C<;F@?G[@4MD'R?<91O&*6<1V;Z+O[M8=O:9I9L6^ M!'|"X3\\C4V2F,,!=E&TM@Q0R57%QX#K9'G*M>1O3*[X[X$_X]/DPP7H_EBD M(!0HGK19*,>[V0@/]DXA&N=4Y(IH+7.YFHI:-R-]219NVYZGKB%[#?<&3/'DT M70NA>U08_G,8MY)"Z.#I*;TW9VY@T_.T[=?KF]^H)5DBOLR3)TY022;TR MC?(+GF_"-O4&*EV>1;A@O+#OWU\7_[^+X$A3J[%%[D]'B69(QMO/ QJ4GP1 MXN#?FJ&W<)7^QM;BS_&?OQ2R\I;E6CAFQ*DFT78"\|K\R,42X?V5Y\?!B%@4 M/Z("..0E?&FI6ZY@Z1>;1_=[H(QWPZKE,#O$]V2_8J>&HL501CA?;ZC;BQV.GNR^TOO MY$O3P:]\S'#SC\.8P\|I,$GD2"9Z\\;%>HO3' M0^]^B@@H0+ '5UQ0\=1YV<3QRYS]KUM=3HW_WR&RWM$;0S_2+"8G]HT,]+3 M0-++9DJC2DW=]WX/F^;%^>65>11=O%U5'%TY!&S(*V\B&QP#Z^G4I:-$J#]W MBO$I, 0/36Z=:.5$HS]1^Y>5($7PR/RS[K>7N8H'@%0W;57OF-JKA$#W"=E="[\SK%N3(?WMO]:UGUN4;1ZHC64_R2>.THBD=B4UA[KXU-ECE5]>.K@2#,7:-@$4<=(-[V2^25=;9W=D_92;P]8N69#=+1/4A+\.YHI&2 M[@A[XF&6J<>,&

*MWEG/B4N9+S1L--'>V<8>Y?1TG+U>US2! #4;/ MA8:[N0X,C@Z$:6M-M1'MY1\CCA:-KF0";:ER2/%4#E0*IR>C(D@G5Y6OSX]U@YGJ%!7/CPSZ\!Y!06GC[*VNl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{^'W\ MG[!*2)1[;5 K<(+6Q5;UZ2,WN&!!21#8O4"(L]" M^0\).]FE$_VGC//%99AWD$I?LHM)/Z[>'51_;"21=L'IHY%GWGQ)^?_2'27_ M0+V(]I,O&!DTY3#0ME(JA|%7C5>1 Y(4E(ZC\;?RS><>O#@1V(P46SP#7/)& M+QAWHL*AS!42 AUF-H'U"M@B> ^V;'B\#@ O5UJ4L77IG,!%ZPR.[3[+LH|E#} M-->C) QUA2QL3E(]X2O"29V52*6I+=4K?YB7!&@^N#!!39\@?] AE18&P*?B&C3@HNGOF ^++.IG_#%@RAPS9\UAX97>!)3 M*$9!3K/A'@1C4Z(J#-]Y!M 9E" YY;R8MM#[;D;;5'J-4#-\WDG4%=#'X&lW MPDF+$=A4;!E4]OCJ'=7,-1N1:W_9(]_VAZ#QX:]".KIU3E7!EXM,WL+I6#\1 MTR&XF)UEP0;;8LPR[VFW!3MM ("G0$^HD1/+\#'+.;$3(&3>P.]=+&,\''1P?:R-T/+=U1KZ-=TG8R^.]Q9V@@ M,A'VIH/D!^OLH$I4;T D3?)!G6!M 'I90'Q_6!#9P ;5)0B MNKV(Q6RXWC 7LN9_%S_VY=BH[$(]>_6]9U0 .CI(%3\|T\WWN8*''7Z,QV&[,M M20>!X#K&$H](=GAP((@O1LPK7%QR\2?*Z'TW6T:G_F%01:C#E_GK BX"(E0_ MZ@UQT*@S0'E(7P).BIW8HT=,G(>E=KWU>,XE[N.PG&+E'*&L+BPF^"J1;T8L@3\V>F7^G=8'=J.%*^0>EYL;JK"A?6U.S/F MT^)Q8JD>LYXA H(U%T*QL8G@L'1#@M-ASAE;3%_TXIT67>07'704FWQH%=_M1?W\WCA6X}(@B_CT+^9V-0?\|H>.CBVI8T=^W|(_^[UY$[-.M@B>

*M(>_GW;E7W8-D6W !XPI5.EYS*G;H_&39?GR1E_]8#LEZT2=9)XF?>2:MV,A\!3D0B? M25<$/0FR*!KK\^/#&%K>:2K#;,Y(XP=-63H7Z9^(!MJW;KK^);E<3C3L,^+) M:0&&PU*\[N3TYN&1Q;B9?K8[U^C,5H^\/R\]8],L@+[_Z[+!T)>VKR\& MN3S:G,\!5RCF(VC#STXX:-S*]X;ZMMD)GSF!]H<9RE""\Y.^;[@>LGZ8:.3\ M2)0U]?;*

J>)7.S0BH$RU+7/&6%PAWT]TI*Q@W,.KZ#8.P]=ZQ9DTV,+/9QS4 M.?X A\.%Z<-11H_?YP!"L,@WL2%/ DS8_DQD3_(*9!% $6/$3X15Y)&H#R&P MI7A;C\72?*

OPL%>`:/OSI<@&P[U KKYS?3/*M\1XUW!QS ? Z 27#W(F4]Z=P*M/RR&GB0T YRO5NU6@=<%_]:TI44;ZX?U3*[$>[/"'>G)K=..0.LOB>TRK.7P MDR!8?C]HQM,B-[R$[+9+<;(,%XPWB7HI.S@FT%2C%U!U-@]MV8_FM%<,P :V MI"I$ZQS;4;^(V.HG"76";,4I5HL:_"X!'N\1;K!*9^ZCXA?->M!MI97LPN@=

MT<3@NW+V6@^49D)C31%)+1^DDLS\]C86Z"]ZYT9#<21U%>!WF>L+Y=T41E5+ M3]P>]]?GC&1/@S^9$'_<.;!LL+Z0""\K4XTSD H@0YQ]H[]FB6@'99A"109$FRA\/DS KXL_+)M#/^L5K\.;TKWEP2WE(3-O$Z(#RC?<%$$3"KW4>7F"=3[*=]/>/6]1.OF#.6 K6AB.S7XP!%\]DI5C]WG@ B*?XEZ\2L_=W/_3&QOF2[!%XG/$W4 L7Q_ MSACAYP"=TTSU6_1/"K!XR9QV;*^Q:\2[F@Q_N*1X]>9V:,/(^+E8>Q:?S[D M"2,%FE7"5P|SR'Z+5MNB^D$!$H'6$Q6V==4C8'73LV,!^HWT3(ZFK1>TNT M4-

&U%8,12R:+C2,PBA""*5A"X2HMB-'W1!VA#KQ.!,/E'@B/R+O5)8OVXI= MVSE[79V;ROVWXN10B1Q_$6"F'S\Y;?MT<;,]17SZY:.41E4])/B>6^J7B1^ MOB.:.EO

5"._C.)"*!+3NS7[XYMHNQLI\B*IH!#OHQ]'6XWQ'!;Z$WVOPZ:1 M;HV_Q 1/8Z7D^A!!)&~..US2JB)<+9&\BT-^'%G].T*V3?_=R>_G]IWYISTNW+84=<*G&%W(>*=+89

MN)5;R$0T M?53JHXI=<(&_G7VYFN-B$FUP.YQI"AV7[@ M0AE6$-8-#-OP@43 &/AQ?&=_S;XIAE5^A;\#; .:^,. 5I*WJ6 M$RL.1U(0}&$9,[P"QK32D=R-

9ARFZ$FW'G^2M58!!"=-Z7P4#S2PTK.\Z;K1P M-1GS_]'&U\G(KS[*"+S-(:PP.5+FV5.0_ZT$P/(*H@>$[RPWZ]RT^F1BN$)'

MW5SA&S*GPZLDL%*Y\T^0'G&"6GKPH=^[CCHF\P(7E3M JW&'LR MKLY&1N$3 #"/+V3'+APT8O](-6?]:4W\O()ZT3, 9++)AK=C/A6'N28!!7/$: ME_0T+$T!Y_/!/MH*]

[!*]S#9@,/~M?!RT.#;@-SV'Y $3$5Q8U4B@A&*095B MM'RI/;G4L^[\P}HB60DOICPTZ>N~6]#INW%BF2Y7%296;SO-/3!2HUN/7O+Y@=OE

*05Z%9)8N2[>COI$Y75AA!["@_"BUS^#!#LN5EH#;.^N4A?=&3DT"@-MN5MY7OS\/ =;[]4GG&SWVY_1 JAZ:+R$+F*6WKW4;=MIR4-2.@=\[!O+/X&>-MGLZTD 9]O U]0WIEER#A-JSD)(^K F)$3 +[_+JOKYECU@2[X'UAB?9-*SX MO;=9-7?=X8 MF6M=03?4ZCJB^?N7XWVR[84A8,!96*[-,5D3*":=0#!%9RVX5*1'],Z

M(R8DJD7.B<+/,7<[B6E_',/V>1A3C+,2?D8#9OM3PABZ7Y3>F2&,HSWDR% + M7P<,_.I=0D[O4!>8.J#[?FW3>|3?!'[_M35$E)?]C,\37/U\5^=OPQ.=6>/2#T:I\

M/%'LR4T/=']#DK[%9;_F\B[XT6MRL^%1DX93&^CM]TO>0ZUEGQ7LQPY?:/O>R)%R6+$BS+4_..R+1+,AM_V,$D 2ODP2=*O*SO5:=T MN[M@F(?1D#R%F#*G9F1!0?

5[%\:9YVF7:.!]4!=NHIU9IJE99\ IP$>,C%N,$ M)$2[FM7"P[YHYDH.&=3KW'QQT/GY4CGTXL&OGHZ>_]_<_-2R-E+I@*6G*!;OA_H?O8,7)?7|-F+.M/N;S8_TRVP4=X#0#9L3W

&)8# M)!ZF?X.]?#N989_E2Y+>>>?(9<";?IGM^[U\O+APl9"/*=;7TCZN/MM1P/>__MH-VDK%O*8(c).[$:}*TT5?1]WQWH\?(#[+9HT:)V?.&"& MD\S].CL].V-

N93UKT6=?GP8WP=$*T20FI2HM"7'8K&7X%OD[^OF]O> M=LS@] N.[+B-M=>]?DW:S.DSLUE/+@.:EW1))I>3#'E,NM.@_'X#AS 3T3C2

M^]KMM'YVE7B6_*!ZN'9&1B(LYV5MG,8;V0.\GXZ;BK MM[4ZD$E]8+ZGAW.:OZY6{[HH.)OH;@/]WB1-"+']F+:,% L]!@AZ?Y,@)*#&UO8_4H MWT5

%N=HL69IY+\5\OH*P"C6@"L ?=EXS.[Q<*U*9E9T O^A13!#S?D..T^^U;VO?D-2997N96X5'N(Q\N?8X=)~]E?A%^GP5DFI1Q.O:N-01AN)TI6A^]9-;H*9 B8.#8W.PR3.5*|

YX:K^*&%S88N;M#O+5ZA#](.D M-)_;$?3,P"Z+TQY!5*>Z((D[EN(25#0';[&.9S2&Y3T<63]VRP)$NGV>V[M' M\RF&5<;]\Z566\,1N>W7>KI26Q(>=C4?7UC)_Q2{$?*,COE]:-

UWG;!5%#.G MPN7EG9[46K$YV&%#M55K=ZUL*SK'54+\52PDL5#3L15+>W70<[4Q.]"7?7 M"BGO$ZL?,.O)ZMG'U8<_N6\;R.C97+QIHZ.FY6&1K+ ,INKPV"?(O5//#5V

MR%3MJK*+_I/_E. IEQ#977/,%;+THE2X4;_4>S3O9[(]3$LX4V\LO\%/("SU M@=",_/2(P!S@$@72?6LG1MU++#[> M;.,KW6#OE3FFX29!:.80/H-?Z*8-

WWP5C2(_JD!4E|>5MWR99?5:ASZD3H+> M0RB1&K89,*Q$]#V*--%K_77G'-0N0GH,DF_SFC/7.8 #,F_E(O+QU>+|0]*VM_20L/LOB.B!_U|=YC MOI9($6<#7.Y39Q"'=Y

BP3=E4==H;=,R)}?SZ_U-GGMT>79FF5Z?{7)L7;:7S@&1&HPB$QINYP#Z[Z2VF#+,S.>%!9K;<4..QG@ISV7-C[|^YY,;>Z1?V MX6PI_

UO,.PG77@\R5NDJ4@PTZ+45>=]U;5OS!WT]&-XY5;QG)ILVIB'+(T MSU\PR\!4G/L7/O_+*3E&$GP:0G2M;AGJL:HL7IV2(E82##))7NT9CM'[D>YN M^R?G ,6!>-+#

84GUGO=#8BVIZ;#=DPQO! 7>< G#^"L8*\:TCR"\WL|&O MN6RHTO3?-A0D_;L<2'R8/@&(U0+!)/ M|U$#0=Yl<'7%9,.E757$G4"7/4WAJ-F]D^COFT\#C!D:1!$,@F

M%K=;#L7(F[M+RFW?G:L0B1]Y]&1 !.;P)>27:K0&"09^1.>;]4R"N]C41TO<-MY3?T:8G1KI\6Q<(FW+3R8#SZGP?!+ YLI$%47%KHDN+=6" F.\|SCMGF#-DX

MI2E[IE!6;2G]*O0^59Y!)!C!U=/NF"\B25BGBE<-U&ZZVG)6-,7QW]D[2%U5J MAOD:F0@3L+L2=8X21Z":1]7@ZOAQA,7$ZQ&YS,&';P:9RJ1DRVS%31Z(@E)M

M$0]DPUR2=GN&;/1^8X7@V(&+?7.(;A'CW5+0JU2"H#$Y)>UVL1,)5/0\4P- MN9RPR^[\;"WY4259K>YW*\8ZOHOU_9F/I4VIA4XO7IX.0M/"]-!B;AS8Y42& M;

(55S.5$&.);R/N)%^45_ ~-#?55-E*(_TEL3@N.M2IOW#'U'(S HO-.5W9"O MOE!8&4$Q.3&'9WB\@S(P,,NLV8B2"BL=2S:,W3\>55MH4_DTY@"]3<6W:_X

M=6AJALTD@DC>%(FFT8.%B', Z]E=\L...F2*(7$A5D[UY*.\G<6[Q&ZA&='I M94#;97[TRVA.^GN'D:>7*E1[4:QR;=3DW$Y\+_GUNHSERVD&9F\!EH\A-H(Y> M\@-

JA@#J07.M*R4"SD.XCN_7%K+$9] T"_N,OV>L=YH"+AA|B.VOMH?SYD: M_-?01/=U@3"IVU-=C@PC5(.C:D4[K%03@,ISLD3$\?B0OP4L@.4]>8VO\]6

M.;8SV,6E@^\)LRJO?(!5E+E#\@Y6HQ"/8'@(RP;?X-&G0U4> 8+''3^%;EXE M_E\T_HXQ;1$DY#W%'[5F9]&3U%!#71BY)8[385)N=BC,+6LST,4C\|VO)\@L1._VRQ

MH41=OC1_>XQ%]S$M,3T!H%HI;JL7%E/=DJL7R.DZ_8;;[P)],(TG[M9$^/AF]H:W.1A6'^YS \$(MBVY$]-0_'"3>I[.*(>X&(V-

6IH2:\3;@,8^)2SI>+_HX37^RU\3X5AC@T,]%C^A. M8$38$K$Y*W=4YUUFH?>TZ>%R;V]>^_U6]74=HHHZK(AQMUY;2B9WQ*!,/-Z^G!.."L.?

RYFD06A=4%PD6!^V^+-9F1- M?!H(MD^0C-[C-)F3RTG[UQ@LX"[M><>ANI_NM+R?_1*!#Z3\ITZ,K^Y3O)M_^$,@T/3B'H]8#)#\ ]]_X'9)KV2P M,-

ML'B#:]O#WU[F=.U+5),H6-+W]^R/=/"I$N4$B<_XL*A&L0Q+C7VK^/Y= M_%9(@FNRISZ1!FT)V4XG2>)^'/D>X6C"#D9%YO2HJE!A]%'A]\\XS(V4K&9

MLSO(ZP@4\0B[P$>.Z6Q&YE; (YT[.;%_0I+OBB0'<'+[?/VCP8YR-MAM)>T--3)*=>D$OWF93W'B2"(E9<=SH+N\!T6"P*T_F-##RL(2;$@*W=\-;0

MIR3N=V:]7GO8&WB7G@M7RP$K0Q0=-F^T7OUU\\Q_$^_+WNBE)/@@?,1H.? M9>O>GNQ C4SDI<. ("_=$%^@6$-(ZJ@:,3Y.5O?(5F7.,L/"WK39&V]D.],

M3?YAYQ_7)^L!*2R)'AKD@:(#RHY?5:K54(LDT*&PW'F F2U4F/+20FP6[''-MAM^>1&MJEA1XM K/]D#X["$&1)Z7KSHQ@!<0H!$V!)>$\$DN@: L_;^SN '= MYMCX5<=>?

ZJGKT-KT6!3>STF G6R/9SQZM11CBPKR=YIV";IC[%6O_7#5F:6G M=-I5,F@H;U^#S^E,D!A7&;7MP>;ME_G*-]T+)/'8_-

=23NCU/&1!=;=KL1P#*)V1RN565A6INTM$EWX8S/=KS618-FX[32-MY %0Z?;<6S#\\[>]CR),QN-9XIKUNW?##KARK'3!F7/[.]P-Z)]4DY2'BS*@ MDMZ\BK_598@[^>L9?

\YJ8$46,\Y'&U_]@C@8:@RX=R+>R+3[#L(=M\,(&GQK MPPB5[T2%-M&(S=;K*&Y6M_]]3_5_#/#@/:KB2R\[_(TGYA&Z4]:YSYV2,/(MD3/Q4E&YU!3;12L0'<6,)-

J%2<%TL9IB% ?FR* HBB.>?"'F'?'*+8JA=[K6G1'%LN'$F#^A?,>5OAT& M6.OXMQ1LJ-CM2.!9Q!R=[]@FW'=;="3ONI$2NL]$QL%F%]"8]B<*O!?]2E(

MBRB2#OJF|(C%S%D!^H,G7[/\R&(FM((6%>//#TAF6J3==_)2U\C51P9CKW6] MR?UF3>\FZ-U*]=2)@W/6LR4EU_E@*%!+$@6$-(ZJ@:,3Y.5O?(5F7.,L/"WK39&V]D.],

M3?YAYQ_7)^L!*2R)'AKD@:(#RHY?5:K54(LDT*&PW'F F2U4F/+20FP6['

*<+5)?T:<#QASCR)"^#!)V?!'2)AF=_5Y?;`MOB,1@>50SPJW\I';&EHJR?@[]YZ$5K7:FI8VI4VN,(9F,`1UWRJK&(M5L#F6DM#!OV^6255=SUYNR(_*YZ)>`M\FR;C.EAQZ/8$&+;(Y9TQC2,.#.AW_WQ^6#'JL]TV?3>9K!<%?APX@779?Z(/&`05:DKIK&;5%N8R0H!O*B3%J:NNOX9/E`M1;DQ-R&W2=`>?M.(3EHLQ[J],"Fl,Q+!5[Q=5&7]-02XUO2YZN8VI$B;W7=`MRD5_.!:SK6!8*OVT\E`N3D@&@)V!Z,Y`\4BW1?BK26`AIG%_5I](@*>ZV!1Z#`M]BM924YO0U?I^,-`7(#Y;;9=SB(D2JP9_5;^W?!EC"ZMVC?LTFD>A)=R>W+F"1$3KLA,:RZ,F9%+IKTA+,=`M`Z*R3:[;Y#/21>C;9.GFA3K.0cG.(H\=`*>97VZUF@!%2#'>C' M=(0*#A6NJ[^*"2PUNJ@0M"U6I_?]NWRS.YU?6MX:/EY6]<=F^TO,*]Y>Y^!`M7.4X9F)M+J=O%[&5S>NX:,>$)#7]V-&2T[Q`B`,&1>Y!Y@G&Q?OA8]AP$FWT8,+X^5ZYW"N5Z7'?KJ<5^"55&?AB-MED1$7`M^%+W01!!MV@=+U20NFBG+B+[/& ;"!OG^5GP(7D0\"@.R2K*(\@G+^06GCXR+94[%2/`M^4B^"&A@Fl/*;$X)18%"@U:/N?>MR=XLAT(7UB))ZEFG@&T@;"G5`!;I8`MD2FY1@W79M=KJNZ3Z#?T>\YU?IU?17"AL)$TAN1&A/;;E'_@R3>6J)9%_`M,61XDW,T*T(PIPX:GJR&*2XOV18/B;G9B+YXVDP8%S_-"_B{:.^\]D6T`U8<_`MIEEZ=)NU_OT9"+<0]S>,/\&WOZB_=0;R*;7^,U(-1__W&_TH?GTY^Q_UKG/RM_D3#FX1_%^S1U0#,@"0ZW515:N,IT8_WKC:>D)),NWWZA_L.SRNE,GVMMD*(`MG;=O/]T3Z252=10\$.@[AZAT1YXLW.2,?>8F_N:N\"%A8Q'#'(GO[>F%!>WNBM.X>9KD@4AJG=2_^W@F*V9?`^(CQQ)K6/;@`M8YU!G/,@B_Z_Z7QXE!"AHQV?BNGRF?9Y2.*.>-+@PXVIHV9,1,K:`Q[H:OS$A>'[[3ER?M`MY>7U3/;Q*F&V-W7XI_7[O)[_IQ$=0M<.K=RCZ6OF3(!E\O*`M=$1:4LB#HLX;Z`RS8O/AQ5>+21X5);0'9R#BST5=$GFA3K.0G%AJZC$;:V(5*UZZ2*=!#<,M9&+8C=1=GOIY\Z1TWOQ2-FN\U'1@VBN8"?=P>95(]$<-MI&E;*K+G[^Q=ZIO\(HAVK&B\TUE0N8>,&L/RR;W===6P9Q?"=@0RGMHOH?=U>`M2'@\>U&3C.@/(7+C'1HOY9XKL%=-U;GM];9PE&B!.&5*35SO7LOV-GNYBIUB,Y826(F)V$9YPA+_5ZZ1&K=/[]YHBH8*.MI3GBX?`_7EXK[_K%0G+"":.4,3!8YV!M_"(PN465K_'\&BL:5UG*%5\$MYZ],_MRC_W4-FSJ=9;*2.4QJC"\ZQB<UR27V.1^"3GJYCFIVR>E?\D;Z%R10-FU!;!R4>)7!P<%_M'WKM-,&*3D_Y$-%X5(?AIlLZDQ*UQ1UCBO%"S/]ALL*XMQ!-"X.M[9OQ=R3QQ*:6[+D5TJM<_J#;M[G-)6^^"!*:7.-#=1NA$L&-;GWQ8(Z-MI*U-MR -@BP=XQ;_NT-2:F_)Y[+G#@_#\]V"OTRY\4074$2%5$CB!3-M1MC(<@7L2UJfV@%/Y>-'B6E35#KK;W-%;Z>,MBVGV4J[B7G\Q*TI:!C_+\7K-M :>B#[$MJ?CGQ2^^CQ:IR:PL7\89}GDA-4Z3.VXL=?[G$29-RBNK!M #;4.?M@A.PXL:N[Q>+BGWRINLENGY).XR<"2I#05O(-GK\PDQ\1U0U"NYK0[=XGO%.MIB6&((;RJ+K-M=RNV@0F:*I[&;@^OW?WHA68$=!8HA^C,-';VGK=TTG;-QO'M2YY:<$O/MSM23&K!:KF]M]?WP&EW$@DEE\1"FL"$4N]/8H5&U6Y\"8MY8-M4 F1SMS#:\T^:,(CY[`M_*TE$Q"NOA(`M1W&!JB1TG2!>,.\\K\[X?(MHHZP=`M?8V:BS`.?Z>C-.[,"$PADOE$Z*\0#Z!/P,2<-W0H9CUXM4"V(@R-:M3BC+Q"`M=35QAO(W+_KAZN6TW%#Q0M?&V+OSA(s)\P[!AGL:T^XWX%5V7[56WF7JZ%0:`M\,B^I?^?'SUYGX/>[2#KU>R1-XV8)!0XC.]\N5?T*@K[_!;_>#>>@5AQ]M^\`M,V]_>LVSO/^J:2[PYH@=4?P3:>AZY2Q\DTC>H^O?P(DL7[V49N0DS.22%PL>7$UT3BP)8`M$ACJ4I+U2_R&D;^-G*SZIR#&@:.1NZ>S`1WAA15%/H_<2+?#8L>>VMHTE?@R<M#V9>)EM$TQ4&//%$GFA3K.0G%AJZC$;:V(5*UZZ2*=!#<,M9&+8C=1=GOIY\Z1TWOQ2-FN\U'1@VBN8"?=P>95(]$<-MI&E;*K+G[^Q=ZIO\(HAVK&B\TUE0N8>,&L/RR;W===6P9Q?"=@0RGMHOH?=U>`M2'@\>U&3C.@/(7+C'1HOY9XKL%=-U;GM];9PE&B!.&5*35SO7LOV-GNYBIUB,Y826(F)V$9YPA+_5ZZ1&K=/[]YHBH8*.MI3GBX?`_7EXK[_K%0G+"":.4,3!8YV!M_"(PN465K_'\&BL:5UG*%5\$MYZ],_MRC_W4-FSJ=9;*2.4QJC"\ZQB<UR27V.1^"3GJYCFIVR>E?\D;Z%R10-FU!;!R4>)7!P<%_M'WKM-,&*3D_Y$-%X5(?AIlLZDQ*UQ1UCBO%"S/]ALL*XMQ!-"X.M[9OQ=R3QQ*:6[+D5TJM<_J#;M[G-)6^^"!*:7.-#=1NA$L&-;GWQ8(Z-MI*U-MR -@BP=XQ;_NT-2:F_)Y[+G#@_#\]V"OTRY\4074$2%5$CB!3-M1MC(<@7L2UJfV@%/Y>-'B6E35#KK;W-%;Z>,MBVGV4J[B7G\Q*TI:!C_+\7K-M :>B#[$MJ?CGQ2^^CQ:IR:PL7\89}GDA-4Z3.VXL=?[G$29-RBNK!M #;4.?M@A.PXL:N[Q>+BGWRINLENGY).XR<"2I#05O(-GK\PDQ\1U0U"NYK0[=XGO%.MIB6&((;RJ+K-M=RNV@0F:*I[&;@^OW?WHA68$=!8HA^C,-';VGK=TTG;-QO'M2YY:<$O/MSM23&K!:KF]M]?WP&EW$@DEE\1"FL"$4N]/8H5&U6Y\"8MY8-M4 F1SMS#:\T^:,(CY[`M_*TE$Q"NOA(`M1W&!JB1TG2!>,.\\K\[X?(MHHZP=`M?8V:BS`.?Z>C-.[,"$PADOE$Z*\0#Z!/P,2<-W0H9CUXM4"V(@R-:M3BC+Q"`M=35QAO(W+_KAZN6TW%#Q0M?&V+OSA(s)\P[!AGL:T^XWX%5V7[56WF7JZ%0:`M\,B^I?^?'SUYGX/>[2#KU>R1-XV8)!0XC.]\N5?T*@K[_!;_>#>>@5AQ]M^\`M,V]_>LVSO/^J:2[PYH@=4?P3:>AZY2Q\DTC>H^O?P(DL7[V49N0DS.22%PL>7$UT3BP)8`M$ACJ4I+U2_R&D;^-G*SZIR#&@:.1NZ>S`1WAA15%/H_<2+?#8L>>VMHTE?@R<M#V9>)EM$TQ4&//%$GFA3K.0G%AJZC$;:V(5*UZZ2*=!#<,M9&+8C=1=GOIY\Z1TWOQ2-FN\U'1@VBN8"?=P>95(]$<-MI&E;*K+G[^Q=ZIO\(HAVK&B\TUE0N8>,&L/RR;W===6P9Q?"=@0RGMHOH?=U>`M2'@\>U&3C.@/(7+C'1HOY9XKL%=-U;GM];9PE&B!.&5*35SO7LOV-GNYBIUB,Y826(F)V$9YPA+_5ZZ1&K=/[]YHBH8*.MI3GBX?`_7EXK[_K%0G+"":.4,3!8YV!M_"(PN465K_'\&BL:5UG*%5\$MYZ],_MRC_W4-FSJ=9;*2.4QJC"\ZQB<UR27V.1^"3GJYCFIVR>E?\D;Z%R10-FU!;!R4>)7!P<%_M'WKM-,&*3D_Y$-%X5(?AIlLZDQ*UQ1UCBO%"S/]AL

*W"#+A#]LUT R?C<84X0A,KH0|[$FO>ZX2\OZ/9 D#@GY4R9CVQS M@7?P|S:9%M1,,//+^@D^D?#\B;*W&3ZOH_,J/U4=NKJ&3&DP?*28#I3!\N;_*

M.669/MO!4!}>ZDKBP69LF:@;0RA%SB/4>29)%"",)V8X!MXOG+CE5?V%[RG^_MO8C)R_!$O@N43-]"EJHD/RS+HL],^6>730NTK@NLEO5_6QE8 TD L'/;)IO*

MEL(03HI>EB0RK)2X'MKKA 496|Q9=MB8UTIR* G5KTE";(VV<,X9?N_ ML^W8%,;9#Q# E*%F5C,C+2<\"L-><S-1JT3Z3Y!UO78*|ZA94' X"HT/D|C ML$#=],MR\>*

((V:SV+RU^$43US/I5QN2$5R=21$2&>(G/G-#]MUW+X2B MXB7\U;T58T-S1K%$,;,NRIQO1^ &L4UAY;VG= /Z#H1^GJHB@,-@ MN/A/F@0<|K

Z+=FFE_I[_7E/7EG8)[A,]&M]^,42HB52/[$HU^W)\YF*G[WF6 MC$>MD?0U7D4.[FC5SH2IZ)'L3;,+K;(|[XM@QZ@L/:B,&-_I]:M:OYU9D]^<

MN53,_B+NHT2/+Z3S(F4D2E]!OL.OS5^AP\&.D]_"U+R_(/_@\+/OCIF/7S] M^0UDCW&VX2.]%*%7!&A'7[*,-)M"^]WU[QLD1((F/F%G+H,/'_RH9XL8$C(_M/@P3+C/?*

*D8H#GZ>?!Q0"5=+X(8M(0E!D_ZS+6NYBO78JS R4.:7J?"B_RW_6M6E#;'7EG>3-Y2^-5F-N? M^\T=GKRA%QOX+^+2^>%:QU*W$N?D6B;(4QCG-0EU]J?*

DZON\9CLTA[%=>;K MO^R4^-C.<_1Y0OXG[>=%ZZ4EQ/]W+D=GM_?\R108]%8120%58?P+X>S:5^G M2#^/U:\G.!AV%%.]JE-':4SO(/?*

Z4A&VA$LNf|\UBQ+VES@#J:H>QC!7>IX M8G=XN@\1VG<0+F XS7@9PDHX[@CXSX)_741QM@E^24=B>9B5IVK:[RSMB-;5 MC4N?O^P=?

*RV2H$0;L18^R$V>Q_9\S;,BM'!*6 V"9]%U67^939A<+.(1@K?D> M%W;H+OG^?/A=.I (X)[ETG*+UWR,GI*NK+]+K'% 4K23S>G7NTEI3)59W#. MHWT\5$7T,1C*

*(+O;V,:O8H&B?RX3\71WY0F4?WOC/68\8V)OC>^2Y6-*UB(K&Q+NOG MNV==5[=U+Z0P@Z?&9V=/>M>B9]W0@[G8&\4*=,:^0\1Q9? MK"(73ZZ!48&,2\?*

D2QQT^VLE;2X?3=-9!E?G,)_OKU&@A3#QB5.R89E4-Y MT)02"K/7BS&?68?[QIXTGIS(=+6O@;(4R^S8%OT6;"5G4< 9EG8NNW"7SN" M4-L5<**K=*

[Y$5^0Y61311TH._^DP2Q$7'/\&$=95T&X+.B?8 F$D(P)EQ88] MC ^[#RF]$[Y?L:%BLGVKMR3Q1AYD@M=R/J?]D&:*,Z=QDN8 LNJ^ 3$/);ZGT%Y/7/%Y1W9?

46",@+B189[+5$#] KP] MC<#^7I4B5AWTFX&XGTG$Q+?M?;MR,V ^%@\7_L1T:N?_G(0DVY$);B4SD|Z-_M(& LE3ZR1>]U7E>N<<_CYZ=-Z6[BO\)9M/LKIL;>T-

3-64:CY2IS;(Y9P/(.MR2G-O=^M1)M/;+^6R,T=^5+\C/W[_1V>*O]!GF/Q7#^;0[%-W6O 9GA+3E*N M>N,8] 60;XT)>.,VDU'C4Q$%*

*<82UV,/^[*1\"ET*/LHB9IQK.Z(I3Q\G?"6/ M'R3I-EX*^]?.3X9&SC[73_[CZ:OC$M!?I-*_<35,F$A0:4#W(PME'O7].6;N MA2Q$_O!5E@%Y.Z5]|8L"9$._JOZU6R<#;*

*[4O|:PYI8A;>48Y M6_@6"TO8:TQ[VI[%OG>:+>!DV5M3*W,S<M$&,4.SE.G3 B8OD7-'@//)=%\,6/FF(T^K7ND73 EM 6,24-;^K MJMR,1VA,+0)EEX\[L%NS>+1FQ*

*MKW/5W!!EN@_N\-QD]3LI6_[+5*Y_V%$|[.]_+,'_W^W_;^$+G?GI50=;$GXW MRQ+Z*]!6]E_?"0+7(=5!ZHQ&8>N_OF;Z_QZ@1O_(.R5&3T:5.M#Q;CU&6;>9 MVK%^%1?*

*+XU4\%@;70*S'->!WK]\(T&C_1V($WPP_SB0U)BFS?%DU#H[$|[8P MY>0V/ 8]\60G<7(5E2$NM N4(_A%TH^YW\8_(\"VE>$]\$1'KA0"#-*?N3CC5 M.I"*

*E9"?'3>;GJ5]GFFE9W[7(DS\Y^U_D7H;I8Q%Y]|]3P4ZC>8;K .KH&W MN7/^MQ-N^VL ?=[^\"O^H\S?XDIFYO)PVX@&T%;\5P&"1T=Q7M;*N*F/X7-I M3SH>HX5^NS*

WOP\;@AR4(Q[IAT#U+C0"9JZ!.]CXZ(B,?, YG1^9D,98$C5W M5P5XR;5CQ[M#T'?C|*])O, MD&T.)!HXYIO^*[AE0U!.Q.CZ<9VTIA6U*$U:R0%10]^7$I]PFV8++ M')ACI-

R[#($:U%1F&*C;.*[>1+E]YNF2,,>;IX&>E3;B7*S ^4QHP(PH?*;O M|+8W"&$1EAY5 MD(L@T]D&GF$B\VV'(7|T:CR(-EIB>+ X-J9BMK+F2NYBGH)"]K0QHC8[%HFZ

*M,D@GK";%CUY7&;0DVW/&4*2SHI/|U]_!!?N,#0PNU|&%QC&U(N'U<>B^4$] M&[!?F,WY>$P|=BPNHZ3O(P0(L<3CI5BE"OP)!?M37_+^&LOV,PEH?[+6 M6|!B-*

*3$2:.J^S!JB"%BUNXRR>7."T=M@D_JHVI][X$?21YT^KZ*B4(K^>GG0 MUVA(8 #]K!V])&WKS^*4\5+!#Y]_:" J5>1_/*+&_R5N?*))|)W7VO=N(UGX_,#QZ)A@"C+*

}DH+U=G0K>/A Z99"E->L7Z!0F?#NH.9W=ZK6CM MQJ-X%/.9I.Z!E.FM\YZDC"/$+|RPY&*/@>F?B>GA)'$H."1]4W/6_C'90/8 MJK%VFVI.@.N,!|@?BPQ4B.L^GOZG+] Y-

=LRFH\B8X/QI.../S[^%&OP7#+:P M(#HLM5B4W"JE)OW6A'=V@&Y^&8(Y:'8-/+)T6%]1RVM.QO!@8:.ML7.P!UC M3+MND)8J7>C,>N=T[9W;A$$.L2_..CO)V*

<1MSA2HM0%XYR"\)HX2PY6P(,K2. M$7E&O",^9@670FH2':RZN@QO?X& ^'[TMFL$ZR0|QH]54SL.YK_[Q2G#RE.]

*M_O:2SK|AFD!#4)HO2U2@7RLMXAS4"Z*VSR#"9)>:>ONJ2^FAIK1<#LQ=09H MGQU+KEO))V>C?E)B I4M^Y'0 +DNKQ6)VF@+E;,;]HF?B1!_"+52U\|6-4^=*

*M]Z*W8VOX\+*-]+VJ/+PGTSV6PP_FD[N,0RIX&G&%-9FO!IY*:Q28/JFD3R MVMW$1X7)I((Q+1UB^UROK..O)KI2:S??@]_6U[>BJ1B2F'VL51:5/UD,66GS M^LTIT7M!60*

*_5EJDEORSA%JK"LX(0|232GJ;WHZ73=>8+2+TT2I\(7%|KA M9G/@1HDM==UIF'TK>6_G@i\?LI8DV0PA=!X9N_CWVS6@I\>5P&"1T=Q7M;*N*F/X7-I M3SH>HX5^NS WOP\;@AR4(Q[IAT#U+C0"9JZ!.]CXZ(B,?, YG1^9D,98$C5W M5P5XR;5CQ[M#T'?C|*])O, MD&T.)!HXYIO^*[AE0UI.Q.CZ<9VTIA6U*$U:R0%10]^7$I]PFV8++ M')ACI-*

R[#($:U%1F&*C;.*[>1+E]YNF2,,>;IX&>E3;B7*S ^4QHP(PH?*;O M|+8W"&$1EAY5 MD(L@T]D&GF$B\VV'(7|T:CR(-EIB>+ X-J9BMK+F2NYBGH)"]K0QHC8[%HFZ

*M,D@GK";%CUY7&;0DVW/&4*2SHI/|U]_!!?N,#0PNU|&%QC&U(N'U<>B^4$] M&[!?F,WY>$P|=BPNHZ3O(P0(L<3CI5BE"OP)!?M37_+^&LOV,PEH?[+6 M6|!B-*

*3$2:.J^S!JB"%BUNXRR>7."T=M@D_JHVI][X$?21YT^KZ*B4(K^>GG0 MUVA(8 #]K!V])&WKS^*4\5+!#Y]_:" J5>1_/*+&_R5N?*))|)W7VO=N(UGX_,#QZ)A@"C+*

*)

*MLT6"RK5.;%/4CE/UQTUS;1S:=4I69BSC|L,'JW1,%^%H\BC4Q2KH|P%H#59H-M{1SY:*986B\GJO%!5KP|X4#.3,O)^J]4|>4*Q.)5&47FQ9YSILA%S/G-?=M-MNMUEW(:1-B+9$NM4[:FK*,30[(N3]3B,0C))4'T@-IMC]1;.:>3>9OL=1#4LQ-M&+G*TM0--A:S%9]7(^\,$.9*4#(1?"IGE)U/OKJ-M1M:A@DJ0O84_/P>&NN@VZ51"*

[P"TU"]3OC)Z\9',\OJ_M+A[V8/SYC%G%.80-M30#Z[=-'E#43]39\X\#S%#^U-TP+]LUR?5U0E(@Z-L.!9@],KZR3Q-*M-%2U-M-R[;DJ0X:C@_%"O.7%HA;&S]26XUSU7+],*1,15>]BL>5"E5]LV9^O\)#"I-M)_V0V\E=WM36Z,Y=GF)N?.%9K]EGFEZ.<'YHW2GC4^G^A#^]K9O)Q>Y M:.4;_YT_=7\9_#57Q N63QW7&_{2.).UIO(X[A,YNO+$!9"Q*-7KE"/(^[1J-M'%*2T497;\]F9DE,9?%2F!C[C53KG7]+UOO;XAOA<@P4B8O+\1;,E*[>P M$F/I3J!P09^WTMLN:YQE#U*/<%0TR S^MG/S%NWR)D(S#Z??L! MG5<.QMYAUV(8^-]WF>0LTG.%4@$;?=UJ%"3@ND3$5U2='>BQ Q*+A#Q'NAD? M90W>$8XL)+YM*O/B-D-X)S{P!PAQ*UL+&%,[R)#0' 'B% [?G^CG'&F\9Z!7B^\&+-A-2*XB)? M/.4G.79EWP,R.-![K:T?E5DC(8_,X-32>-)2%^T)!Z=(W]5N9\C5_LL!LCQ: MU:4KVN=W]9?WG]*

)>^AO16)W);\E3EXO%+K]GO128*4)*G*@P=-^$[!W#S!D MG7P;6-(JH.P,W9/BKJI.R0Z4O)U F=;1U&5=I/\)>UEMTITZU/M:7W>GCM1*

M77\G|OI]BOP";?"V4H8:07VF34G&XNEEY,W7W%PTT"RWDJ;2,BQ):"\@V25+ M\Z?]9.'TG,SIT(G@O;MCUYA;[^4]924@)Z{("?[%\T[CQ^G'V\4-KP9B]75 M\3_S);1PU&\820K?.>R|-%[T%9W<- MI,B3WV;(#@I.YAC/[M5#DF!#W:89+,4KG<0|-54HRRI;HW=OVW]/JY'@PBO[Q[PCNKE3W1,]!D<6S^YK0%H[?@2[!V?O._1 SDKM&=D MI5@.Q\7J1S/Y<\YCCV*N;PBH^]PKHM%L,8,.74OW+E';@&-J-MG7BRVX$R MC6B<'IO/IP#=`4;IF4 M$U@SA_]*

*(6Q)I@N37T]*P&T]^,6PC0M@2=0!MG=PO>A2JE6V89Q7 M#GJ4,1E?S.>PD@"!PL67MQ?D.7^]S:I6,S2X]3[=NP9&9I)-P6RX7[0EC#2: M4A_7QVGKHTT;%:-*

$>L;7F@IQ9_6FBNJ:D M*]D!F,]V=J+2!K%D[9J W/'0.U$\<6]H!W 3_KBA6S<&|B_#A2ZRB..R4&AM;WC+QQNDS]T+)<4VU_@ LA#>

*<(#^\]O\QNQ(,'^\@*6\TYI9"H,;7T.*]P#6B08!|OP\#*O:TS>G@*(.) M,MJ[>A+A_]2&]-PX?X$1/9MEI*32*/(B!\RHBZ6&?J&38Z&WM+]'E!]NB!Z*

M4U"D5WU.);#6K,Q8(D7=+A@V[P.+9G1$"-6_0I^KZOH@E;^EP#X5\DLB8ZSQ91F M$76%9L!X3$W8D9,7!V7UM](:T7LG'&?K[,"R^>H:@IH@>T[,/3\[@05=? MIZ48? A]118^P-H*.O.;OG%S6Z:/G3:(8V_ BO)2(FBM[4S/:^A.=+3*0T/VR(K/< A=T_JK[^4D)(+=2CT M-IO%2BH*YI,_[>_$SG=.Q+(>4O3?X=W!W2UKHDUM.4.;J3@N)_6JM=(G;/ M%RGK\=I^ IP9K35JHSL(:)3{A),W_N+T!7|&]\U\-YT?TB6/[+8\ HS^E7%XL6 M[VYIT6!EVIX@6U3Z7-1W(S^W1SK=D&6MSH:WM0064VRX -6*MI:. @=YO#€ MPGOFEXDY^(":TSB2S+3Q)\0C[1!E1W>.DO.A[^1 <@S3,P6>Q+] ME^G/!S+_I0('W?N/8='_M6@W9N6LT^839P'#R73@320N^.YEB)75TP8;_D0 M@[5C0OP3+3(M*)XAA-=>;[A#"\C"E.R,PO-KC15^])(}OC]H*PR%K%SBV+ M..RM]T:\J52_<>@/0Q: .<":R\/GZ,>CZS.54/)ZH1(@KI)>2|*3CM.Q)2]!V MO!5I9)}19>^7RC)PM=N*G%,U#G M91K3@DG+\CU7[8&>-M=?/*E1Q^$Y*OX8>-=E,K4G;JAG>?GVB5%?R".FL[[= MV3R/XX.2:]#*#0,&6F1YQRED$'0$=[2U_6+6?

8'F&?LA91HBV=_#^;N%%VE, MTW"%DAF2O3LS+Y=BFV=SC]\'+QK-%TYS:'IZFJE>IBWI 4%/Z-4T4ZJKDWCV4TU3HJPH,O/ MLH"960$7_>=9HBAVB@%DQIZ

*^6G:#091%-TQ MA)Z]$ ^6"O,^L@?-".I?/K)@S-7OKM &)70#W5]O+3:80IY'.1[YURX',>8+8 MBZ][34QUVIM@>*U,@76<|8,QSX0>.V;YXBQ4+O; ?|&Y_H]S-PJ66+'HF #'*

*M9J1=\>**8EZN^]!D?IY?06H6#CB/!N^@":"G%KUWY"C8(2'Z2!DB1!&P-I*P?Z-I*9?@BA!.6]Q MH8^98D+VDEXV5FC:-/[M(5.T|:P?Z .(':/0/0*>%!;@E14S-C"OHIR\|T%^2*

M%R!9 @@S:U0,=`_U1BWU[89?#?'6#B(/.:>^)D0AJ\&S/MP7$F+WXOL-<+C MPM+T>E4L_@E=D]8TBK+X)'W^-+N7[*)RDD2,GF]G MA1H/F]H:6E^4:9H6?]W;V);]>1*?*

*_P5R>5/-MOH|&7;KK!M8I75N*YQPD37+/OM_V>R%CR(Y+P>HUX#]/O6ZB=-+(@^U+DJ-X+N11_(C7VWF&-M2H(?+L_C%0_L%0]4O#VL?*

*&HN$5YFZ]H!NYDOIV:N5+2YLU$MC_(J0H.P-FZ3 ML7!),KH_F8G"6[KR(O/;X-A4FBH#*C?RZ[7PX#3M-&O53!,*R[f.6\:C6=W^*

*MY^]GE6VK_IS>#!$+|3SA*7BX[AV*QLUG(>9EKHGBB?P-4?W+$;-L>T+6_M M=|7'S7/VLV.Q4W6)'=\%)TCL@Y?UK!E#K%N:N=@)IKO4U.T*O):W_5V[NIK>*

MM9.U.)8\-.I:XR:2Y?]5QM=2^*]PTYX_#A$@B-DI%?D405[|DZ;.7,=%4IW M:]^[*?S2:?TBG=ZGL*^XR<[/BE?$^.V*>Q@W]^UI>V+=7_^,8W MLP"+3-*

*+K5[/2=1;!H+!89??:E)R5TK6|_4A.?.B_QPLY+'[#1E(.4]XW7NE T/XD P6 M&"#R#445>2@<2PMB,[.BW,B\U;O3]75YRU&NS(U))^YS%]GC1=4.LKX*H(F M1&<>+'^J?*

W.UO;9&!?FUB; Z,W1(#)@@MZUN17>&<5&\T,);=T!+*>D\@ MKF-21>2M+=O2Z.]R(WD.D@Y6WQ4U'Z343>UN!IL'GU*)/Z9\.AQ)3VSVL;+>= M00RV16+?*

*#?.;8#X8UJ8I(6&3WZF+#E@1RC-$(^)<61U_P_$2*$A%VTD<5F=U M211-%7LH%2F*<_JPW?Q;@4IQS1W;7INQ%%1^8S0P7./2O'K\'@ QS)@F4Y9M MNYN8X#J*T?^A*]*

(0O;4^]$Y1S;7^)I'K$}(M(XMF|CO3__VLX>=CX?N-%H\A]%;HR;LG2\8[<'#@:.KFU2:,U1><^3J$N:IZ+'^S%Y2Z6H&3Y2QCGR0EL!(*

*M>+BADIG@%MMLV&UC]0LG@3,,BX0#WO?]#GV9%TRUY]@3!V$.9:?Q_KA>8C&1 MS\008X!*LW>QV'AM(O[=.3R\,WZN"BM4BNB.5@MF)+|1QR+)T!#F%)\]I*

M2BPH+7--SZGZ0'"%YWX503).5'!]E&QWLA15C=LGOH;%YK#^CH\ P8WS1<_7 MT>M>!UF@W^&^_!EYI_W $(.\!KKAECO14.27ZK>ICWR4M.3-V+HJ'L_"6D7 M0-

*I*BAG/0/<7%&W3LGTHP{UL07&F1}(Y/[T6=)8TM-\P9R MLM,W\[$O>L9.Z/F\<-SGB;_&VRUN(-0+0G,XG+S)O93SK&?.D%^ M+<;WN#*655#X>*

[!}(MY7|GX6_Y4\!._3K,4K>?W^>Q/:L/:X9,!$X40LG,-& M>LD$_.:O/>1/>%9:5/-/4GM(.H%'1B11LKWB%*)?,3.9,\-)^XO%%5 MRMGV]>I$**()UX9GLHH&&"?C?*

=)?.QTF;CW,[%!2)?N$W#F4_C MYTG!6SJAP|A3ZG(^K=X,#!"(;SPWBL_@B-[(*FB7(8SY!>9:#$[B]CQ<7ID4*

M)R2V2M6.|>>I68BHF1"HK3N1..Q\!XTD:/4[_QCZF3Q<^\KV/+$-7_^UF;N M)[7FM+QQD?4/I>75=\| M+\;[LN]^FA9&+?3F)U:4[]4M%,<0?9@49S^#[KY,>-*

*$5V[=M\B7SK*D@FOO M.0+:|)-OVJZ?ELLN1@<.<9R=]O)0*7KL50&K=S#WAVV(^#A%$Q7XZ|&XO) M.>AQ1HI\V72A!S@;]@@):.^'/QXS*0SG/^-*

[\=MV,JNA;2M%S%$0G):."?\,(M%]2[@TR_'ZP\9Z4ZQRDL'|+KJ73CN'Q>(-6#GOD<|GW15>;2YI9C;I)RH?N*

*M6XNV4VB>E+Y/LN9DSJ0G%;I>_=IFJTRJN50^]WK>G#F.I.(H! +Q(;3@F=VU6 M1P_OJ7ACUW[C;L)J[*4XZUCT[N4M]L=.Z+-4LF"R0/H?%%3W &KSQ-76D"&B*

M0<(AW2^#M0W',4IAVO9&E3KRGX$\41R9\Z7IVTMG9[+<#MUUWD"H>=,[_!=K MDH_;6>Z-/J=Z[fNJ;%V^XK_=DO_L3EI]GJN@<$[^$H\)A/'W,[#CHM26[X MO|

(Q'|%O|5A%S](T;!7B_A6)S\)H6N 9N"H)MZ=+O2 9RW+)U-M+>><6UGT MKJ/],XCIUM+|$';$>_(+H1/*NS$U,X>X_GY:@L015XKN^>.B 9W6UV#5-6CM*

*M,D<|OJ1*G%"|ZQG.X2IK/_,&S5,-8F>*%*>W%%LU[@^'^7DZRTN;.R1=?C7H<-M:.OIO_,%Y2?;J;6^#/_K^_?O+1]*PV?_"IK8UMJG,4ZJDL$T"8*16Y>9L@88)F M-*

:B>;G%#+K$96%,?599945^9COIEX#;#^:S8+9Q4X5THY6$'_BEP'L(AQ48WHIC;;MY>6;_;_AUOR?-^(UK&Y@__U4K9QT&*

*M>,V*B>GZ+2S%UV#$.]209&2KF+'EM_H(^6<,WIJ?!1%$0LW1@D)Y?R5'ZIW,MTJ+2E-_XL_"&*<23 M7;VN7;RHFBYJ-O&.''H/>"]!:5](+80Q?YAS,@$#*

[$#5KYJ^KY++CQ6B+UEI3 M_VD!5/I.C&I@EB=WD9HA=P:=7B6@YK6&\[J:V+ 2QSV=\&?7%6<8[_IF0A3, M1:)]+G)L0W9GFHH'T13!_]-DOVDD-<9Y?

NIEHOJ\M$,8:CD#LV30Q[YA,,(E MQ-HMB[M5:FFF\939A&B3\'@AUN0.G+W^-E>"OV"),SF"NY87:R4A@+[>NO\I MZ& H^P?]'I(==]YP1|CSCFHK@IKH/|+\X)I&Q06:Z-

Z3G[Y1P<=81F\QJPA_0!N@_ ,[!17STE:=$*R7:C?U)@4]I MTH@N UE&=/\]XJDE\,$HAUQF36%M$M&,@YEQZJT."'L<(,&$3\_K6449RS+U4 M#?K M$*U],@:IZA,FQ3\U?L-96*

//Ef'GKNW[J+?9[ONU2 3G$ASYB:V+P'77V*5[-MA>1&"QP"H\|#/GO,SQ8LNA$"L5=DMM@46L7/OU+BOHS%[ZS-1? MWWC]HO# Q<9DD&S=C\.Z]H#=V+!M.61^0P27#

91G[FM^;,+39X0C-)6?UL< MR8:5?5:.@+NM:L(,M:.:A;-_YE?FOW(GOUP>#KLX>-\,=AG3\XS3_NL^]9U^ZG[!1^Z.S1Z9;|!8TFI,YX"S&VBV>VX97+"98@FX3]?L^"]>3

M=9E)KC#H]#9\]"]H#<1<@URO@?H)LL7_SXY7XW]<[6!QK M7/7HO&<[0|B+\XAH[T26VC)D8?=BPF@)3%?;8N8PR\]6B>W6]6>SW\I]

M'I5G74^1120(!5]Z[KE!6>IQTH7_'X,>N5/(?[<[TYH\'3*$4Z%05R[+V*@ M:U!%K'Z>KY'&RJ]3S*^42XW??6ILQY7R2GA!0U'!ZE+FG$D_Y4VE@F.2GSD^_MNA$N7&OQ9?*

A^_O"3[2INS\|\'OXE6_OH<-HS$KQ/>_SR6CD3TVNIV|(6'EW,8D_M&M,UXK%)/+I_;\'8IQ?1S?)?'$5,$^RUTLTI59?TY>R6|(R"OOG3<6[<@]

MC5RVPX>/O,91ESW/7>\)G=3 4&2|AUZMN,)1$I74B:W:5^_$L1G=(/A9JV:7 MN_ERJ)G8N?W+=BTRE0S!,X8+/\-E_D?$(I@XY7M8Z\Z MSWO*

*RN=R+4**W^>',K_13=+VF$ 8E*.EM_*0!0N@X?YTF/ZFR=,I3Y^,N M8;@VWX"&&(J_?U]_.VRG?6A"W,+"&B] .2JC\-JL #'L[2X2NJ-=Y*+"*S@Z M5OU?R?J(V4$>EI/P%VE*

*EPK_))PO>;9Y#@&J])(U:CF*D^3O7,@4',OBYGB]V3XO MF;XB?YQ>B&373$)';OYA=M4+8Y])3QIN'^*DZ=`1<8\)ZN3BY7RVP M[>P3D?-S%ZR3221_2682Q'Y&K3SI+ MU?*

*+\3!83'+[-.V!>UAOXF,B 74_ Q!PGG4B:-/-]-RRMTG.IV65[]S@=@DMY;R2)+?\&-35W=8>?R'C M@D$\I]RKA=W.ZXE6"I#%*QE28--UXWOLR >]P +2]>A5R, A'XV&+*

*I.TE+GM_M1N;9=510;5"NN;/V(742**#8_T5F48-3'N&3J,\1#F48N$)EW4>#I^1[M^HLG15144AOIA#WE[(W,T9ZR'A,Y[*.?,KN6@R MGQHOLB)^:8XUA5NO|*

(;IT2#%Y,S6@V02SF.KC7F,/E48[\O?1,&@-MEI"9E"C@G+H2;D1Y^*(Z'D^1%,9'6,J2__2NJ951N1[]RZ&K1?P')>WN=U MSBEP@'OVI>2"C]*VE-!^*

*7BBU%/\|R,|3\)4)AKGCE8MLWQ5;+?PF,I6Q=:8 MNJ*44H0\3DA48YG'A>%OM.A1P>2-D.V'P$4C+BE+U8/>A*O4HM5A^^MN:LU1 MKR_<&_C:2D5J7;./FX@>^@(`!+[.^8,<"|J"%=SL>`"">V_9K6R8:>Q6T&IV$SZ\NX9>6[=<89EN=O^2_E?7K<-C-&\8;82TO9=;LHL MH.906JRCY=HH_?8?28X-*B-%%D1[DVRWT D)+Q^IK[\.^7WC O%/YJ96?;V>*

*MN=5EN,_;_H YA|/\^+H =C^!E65 QP3G7G,&GU+8D|SPB%-#/TCL*Z+I[B)$ MX[\NOQL=QB_7-SS=\=J?.ENR?@96.MPYW8P;N,29W(>(2F@8#(V-!%-]0\9A M&&8=4#-*

ON3?YM@^@3B3\]-\7A36C+QC_\D,F$GD/"'!!;KK<@6[K(>QP=7^A4 M'[XR\|HU]MS$,E[#B<2NPLQW_#/[X3T+W)&2/N+R?US:4M_ZZ&/! OH)L^DT? MJF<\UHP#-

*VXLTNY]Q'LV-77G)'[CLVN 4[E(G>H"^9J?[^]D"0=%)YGY?YQ M?V-M(6[V!X#(PZ16K=)23]+-458>1*RD)L/_2T/7_^5[)%PG-)_8;+BT@'+#! M^OHQ\]6>S\,G<-$9G\^CP?*

-3P^^N.C_-J//?7YFUYFSO4P$'6OG"_2>8$SO ;@YO]0LVQ>;\MLT'XT6O3>QZGT'_-4V]CXS^S/!JAFM/<:-K?=.M40F55Q%KRW.3J:VJX7.S'(V,/PP(PAK3A>L^12>LW@.,"

[@0P4BHD"+6^&85E M3QK MN!@H:?Z5&,V \XH# YZ8174 :=9D7YF.HR#YX(TI7H72//G&G:GG]HW1ST M"'@1HFZ$\.!]_MD%MSJV$1YPSPTH%BYS"YH-*

*/(#&X&O>C8IF2J5]JZ M":?\:N+&M/3F\WWH3.RA2?EKTV"N\VZ]YG$[6KJ6|3W"+8-ZN(@0)>_MQ"KM"]J M$'*SV+%2HE,N*\QZN(`M0]%'$E[.)2?Y-FZ):+-.-"-"^-+?*

Y'9BWZ1V;=D75F?OSH>:Q[&-'G MO-Q!9".UH>NR#7O8QU"^F>&NLD_7ISK_%]H"Z=C:2OSQO7=5[_:9 M;?K,11]GF8@=:!.$;2RF-:T8<) Z$'-M07H)-1!Z)T%:&&]NWMG[]*

[?WKG?^<\Y M'_(76?=|} LL4EV785;D<|H%0$T6[_&/<+'()7374]AGZ^7B,6R^CX/KZ[@ MRIZL[GQ;,27<'Y:?!UE5 >W-37] EPK.?XK[MB!Z*XNWG.U=>.:1;IF5/2%N*

*MO>A(R^2.1,UL$I:M#\/=7WY:D\'IK(?9S9*HO4A),.. M\XGXO[F7>09[GMAOQ*KQ"<*OA27=RX\=EJ)3[\ 8*N'WJ;.^10^U"U=RA'>R# MU+-MCQM=!|.\%#7&*

P^_O.>|\;5.F4V\QOD|_+%WR.%WR?> 0$Q-Z0O3RFM; M%B>LXU=6K@#>'X.D#\ C+ ^X F{A CD%..#7,+!D)O1!^Y+8F<'QB@]J%"8C MEB\-C=>DG&!SFRY&TX:"2*

B$[=&O_@;YR.9,W-S'(0)2\]HDQ%.?R .,/:)]^`-M))?QVE+[7&U3P.8[CQD,9(;I&?/QTJ+3 #ABU\-MB! M'0%G0(>6Y;@;IMX .M,6Y>!S'O3++#P98Y]D4"UY\NMDS#DI-I6"_=

*"2>4?N M*X\^;S;fCD&%YS<'<+.E_FQNLS';D]D3)-J8H(-L#"BP"ZR:83L;M&0\'&62-H#A?A<&SKR;WWG MT9,M5X"PW+3,<\V.D[LEFX*V)-=.DCN.8["GW_@3-*

*&,/)US PO9&Q\TTIY'E7 M,;,)++P+\|3"VMYQX6SZ%%B^>II)VL,TGM5BH$<__I2$2DXN/ D.MEI_94K M[TA9?(6[19*U%.6V!L\|75T%)G+'Y?6P6;%G)>@03*

*Z5IT8&5O7+HIX=,ITK>;/27NKPA_["7IP2\VA-[)55 MKVQZ/?AV!,Z3H3UV7FVR^C&50.!0LRQ/V,_F+ ;_P.2.RYOQ.NM":= M$B^Y!/YXN9*U "Q%\2TOS.@@S9FPM6O?*

*23J8/7L,/>.%+^*EV.([;TU5#E7 M[-9 M@BOG&GQ_"13">P'RL>=HK70LVA;9&LEWJZKJ+/+L1GC#@/_!F>,7V988%@.I?NY?T>CF.'$HKX(>T*4T6S-Q*

M]0A\|:@9^^FWM2X8"'|-7[!4\R17/F^[J#W=IA=NK^0)73RZ%@<9O>95CH1N MS@R4E[FQU_7V=H\|,CQAAHY6^+A%:#E+[A]?#|_-\P?=5V_3C>]JL8['@OA]>\.5-SW

*MGQHR1_E\F%4%RFT|N0L*3VEF,-G^7(9Y853GOQNW:CHF^|.,W>RP/?:WYW)C%U6PX.Y,T*55H^/K= MPS;<-4AV9O>P-,*>5)_PRH7=>9GQWMMWF?1?Z-*

*E2I4H_9W3S0N:=G15LMU:. M0K^^89;1-6]6IFU_[P@R-F'F+N')FPN\Z]U82R:B3GX@CTH&^+R>MPJO/(M- M6C%_.IDW>:'FX5*JRIF@5A0\P!UJ]:*

*(2,_WSBC6_OCI&5]BW91#30XQ>2 MI>0*UD)\W?,K4]>EQZ'Y<<RIBQ85SIW+6ZH\BHGF!KX1-E7V#^S] M"A4'*

*8>VW+QL=C*_2$@IOL/RI&XL=>%2PG;WCS_OB<=ZAV.5Q2Q D@:Y_K<1 M=AXM8$U.RM[X^2?GEV,&8>G1HY"I"=W&,Y\/J2T*

*'N/?;ER6]Q^5_RI]>G*W5!]Q/+S#LLFEH^H:QE%M8V!!_/MKZF4R5IU.&A3 # M) UD]_Y\03$%V1+PN!P[|8PI-:RM,5"?UOHI9CDE,@J>VU;]^D/+O_;1V&_] M1]2A"MZ2.*

*<50Z&)EO5]4ZE)=?,3U:FK'HSA7;U]D-VI);'@?4ED#MJ|0>M'+ MG&LS>R.7)4Z27*F*(K4E7+A=$[,VN39=\TI62X!UVI+%]5A]EIYG_AB(IL(AO*

*MWT@W2>*VQ"!JFN*L,@/2K!-_?R+3:5!QW04Y'I*B%JW;&[CV'5NQVI]Z M%)GGJ50GK$+V*T0(M8;^]F-R_78L*\(IV-N9R2#ZECLB"DTU\91JX=S(_;Q(S"1 @I/&-8#D*

*M&T#V{3K7A_=/=WH8 E*2(+7"0G]|$T:U^:.SF,Z^3>Z0PY6FJ2V/QJ:I.Z MKU//"4*D3TF2A0*.,)E=[[$?NS4C.&I6OFIHVHAC('R-$!*LB?YB)>XOKS0M,D*

*M?/#AQZ<7H^4J7>Z"[*4,IG#.G%]H[7/W-CGYS3UW,NW$@C&@*'*J2V/QJ$*MU1B;,0U=0?J7Z7/1-_0HDF5W@E1@$;(.%|$+-)QZN<)@JX{I3+ER6[M2)W7|BC*

*M'&W*NFY?@OP2S=$R8G'6J@6^\+G^5UDE/EF!Y+IYVEI%&I.^"R48]+7:L5TX MG]7S9L9,B9\IKG*>L56D)P]_LDD[@W/*!AC;TGI*RAP"A49W]H6!=W[MV^?+*

M,7Y(EO2P3'WM_X%\NIV>E4A,"69_X)!HGVUO6,OUPIYW38>JE,)U"<_'IKE4 MXTVBMJQ#^]+&DCYW#GB,0")_26-

*)HT^2^[>C(7"DPNH1[9C/ZL^:,9B"\)5%),2ZT&1:QS[M,X?CHU%6=F^D^L$-YY34H?:EE:U#:*BFG>&#M@W-CU:G_XAY'P5Q="N5/KHB\X/O1*

MA3NA[HZ_V%\'"SJ#)TI[RA7=&70D2L9C%+Q#:,0,&?XQY9.-%$U1TY"Z7I.@ M+H$YM:GO0\IQFO8,SXH9J MNP G6./OV6WP*=@_SPCW?A\8$$XN3R#,5>A)I+$4.-/U8Y#*

('V8VX M";'8?O#P0B=/L81' !2ZN)'HES6P'Y)N#>=H7ZJ@L0Z';7CW).!MP9F3R;+ M^$GT6+@<67[^SF)4NP_-0(-0RVX;34NM3_U?5^$-%F?+WZV_3^$\T4_N6AP0 M

*#ZYE$R<(C9SO#QJ3;%V\?$2-)EI9U3CK6)ZPD7/GM5&!,HR/HF&*YV_)0P? M-]F&KR;/=MZW3GBT_35LF'+-5(QPGN'(LB4-WJH@L\@9Q<2SF8K?P0[G_*K*

M\4TL!>=B&VA!?&\I$O_]@3)&D]MF:!WWYISFABU%V5!=EP97,>,2TK%'6%!W MO/>9FXF)@QVRA7_&]#^B#CLSAQS7%PK/-YPH<:@:YX3@P5G)5#C5?6"!W?Z

*M^^D>7ZZ\88E"&GQ9R<+++#5#@K*KY(/#_*F>UO;22\D5AW[M#7]?!YZ@9*SV MDHW?!!D9PSE4#;=E3)KE>,S[$4=%<]Y?-U74+49;DE86O*;6X0^MO>R7(#OS*

*M=Q:T1WG?/Q4%=9=H1%>7DM[4 R0/ LB: 13&S:7>.CJ3<'L_<*ZA,FYHE?Y# MW&P&SKEMB U),>Z=(?P\\9G<@W MER87_%;C$]2Y^_O62P6.8,1 XZS'Y-*

*[!*RU[L]*.F@L,/-CL,Y;NKY6/8N;.MR :,4P;/?$]7>^"FF*/RO*IU,\3F9%$)FG6:+]J:*;,$4S]>8Q[.A)<><>-' M-(!6F'9%D3*N(!8I:6N2P)Y^],=[Z=']\Z=+L>&S4#?%\\T*

M6$[JW-MI +L8O973UA=MN(D^.PNLTP/6!K$ZZB85)X]O8O._=&R7GH$F0CK7?5\DM?/ M5O$J5B#94QK 4BM29!&0V\|DT9KN5B@%YYS1I8&\,4OBG!4O_Q.&^=H>U|

*<= M8€O=/>U0?$=,_%M@|%$ 2[_9V&K5.-JR4^U7B[PO5D "HL5=N_-<6=ST0(AT M?K'R24+,1.V>?PLIY>SCWCS#+Y [7-=:-!=E8 Q*I7:#LS8JK1,,6=$Q[6P;*

M2MN&,IQXA7+O0$RV4L11R .#2I_(IQ;'IY_)\0\H)A,P!<0O?R;$1)IB M8[!\#H)S"%9,,FPAB9*M706:#`]PC$5Z_=L0 XK9LLA>Q^&8+V@[H[%N MLN*

DPJ/84"X/GNJ/F,;XGE?UXK|:SL/2"!7RV M03V80:,.LZ8F[=+B70-ZN=[\ALM|[JK!>[Z[UR\UA8\H/KLGH6HD=Z73WS9&MY.UO^^B?*

*IVU9OM@N%N1Y28M445[U;U%/[^2AX**%I6%#2/-!SB8HP^B(9,__M=)/T&S/+X/ PE!-6>WX-5WO83X RLD(#IJMN.'M2BU2[US6]=OPQC[A+6S1(*

MTOP.H\0HP'/B@$T1\!>B@S:TRE1@H,1--JWAR.#^M5,&DB\E9%7[Z>&&R>ZP@-MS-UI7ZUHRV-<2\&/9-WS=QD6LK\K"-'^ M-^0L@/$C!OIQ PP MZ,;D?

*8WU*F8.*CB&EP86=HKHRI}YKA*B\1UTC*\C!.Y2KJ[=X;Z0#<(OQ;N M> ^S3S1AV+L88*&=-KCY.WM<'5*#_E=[%(,+L$;<7?*V%*T5G+G M5ZX*

10<7/\^K/V9^U&_EVC)>59GFUVCBGD(E:D1WPGE #'#FD4JG E,]>?1) M@4A/|RU\L](4W,^*$R^&$WZXD'#VMNB2GXON?@3_8M9M_BE&&5\)#&]V;U#46*

*M53VW8E]D8[U59^\/|O-\/*S<'GO-U-L-2?N)>B9P\X;Z,65P);M<)XK (53;,AR_P!OAM'VL_2&E*HY18_!/Y- M%LDQC!.5):-)V?+Q!V>-[/-%&@,+*

(ID_KWZ3O51 MS ?4RSJJN<8YY'L7UKD#T=S8M?)YU6$3M4=/CU_Q/AC_.]'F"1L[?WT$.<4 MI!^:GUYTO[RW\T-S7FN!*>VWP%1]6'@3=$CSQB?

*#5+,_!WLT4)$.&3+KO+O&~MYGAPPWB)'M1ONAO)P$Y^282K] OX<%=/NO6B\QFCU5YWR3%##B&26^_M*9\L8/HDLNBM#\U\?9:1=B8RO^3G/4-5?OO-*

*FY+%V"DH4]$#7@/9YS!PH,2\ MC_"L6I%ELTB'TMV?_8SF?^Q;2 Z6\$T/|%HMPX6M*C)GRG^>7%@.YLV%<%"Y\=Y^Z+O[&P&12?KX+*

*MTNH.V8]?.P#.|SQ.V@W$33Y_R66^3PALTM;!C$/_DOQ,YM% &|&;K,]W Q9X M 7F% N;T./YC ?AECI01?J\3.A?YS<%EYYOL,KLS(V@_2F_KZ6G"*K^O!BN"X*

*MRSJ9N]MH8KP+|KS3G*EF_,B)V/Z>E*B*$^_T[J4BB"K^)#8,@!%W(%YTN3^ M4%)#_3?(>FHKEHU2+:TZKJF5\8,O,/0Y>)?MM432SS1U49/FM'7-+"/ZMCB7 MV_26-!RX,*

*YHJV_2XY!"?,/)4D)T2TL__C"1A^<_MYU;WPP785@R3S3+++:HX_LFVX55\7PW;>EIB0%TQ2 +I,W0FDO7B']UGRR:52 MX6IL F^K*QK1S"@]Y#"*3Z>;'=SS-1A<$IQ6S%]E?*

*H)K3L?;FI'.5Z8Y4D4 ME,SV70D?`LCG$!9JZ+(0O#SYC9;_0DA2|9S^3+YBT+++KLT'#K*RPXHN,E|EPRF(^16+LXT'#K\YX3@#C5?6"!W?Z*

O3ZZQ^G5PSJX+4"9D3AIR/CTY;'79?$%1+2'3U:YI<5,IY/P M9'PU\K>ODKU3D+:DS\KT2U;76[M$?("0A'Y=IBNHC,_=4^_7YY[+PM$Y-FU^4<)I<$RBC_I.Y:E

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e=_M?8LI[_I)UCPY?IJ1;SGNP2_ B*!D1MYR7N^A$YZ_@74N=HZ_XN(?C';=Q<\|+O^.M6M#253E$M1*D,?M(:UO4_CP#E22_!6L+FN;"-"#!1/L* M')\>=04@G^5?2#>H)<8Z(P]OPJ5N$&HH0)VP1? _9IFJ3^4#;AF4F+54-%9G" MA);$O7]LB/VO6L#\,=$=W/D!#6B(;?MQL)?3;$^ RY@,OMSA"8<&=;U@2U2, M2L<%%"5C@$<50CJJ<";M)2:W ^F\ZT72@F(TMAD+,=8D%0,Z^ :!, $* MP(C7Z2(Z2D?<>E%MC[*;#1V A|\+DYD&A@88%-O7!=56FZ!G.GV(6+\514LD MB).01.*=EOL^X9]M6]H%1.M ,PD@SP2S[F'XSBXIGT"5B?*M>&-6WW[9R\/ M^V4I7TI#0ZQE9P,Y\5> !V?=5P#>)ILLGUL43LFMC<,R-BE#]C6S%PR"?J< MJM>|T<[6X]".G22)VOZBHV4I'<8W\#5! ()'TZS8KBE(=S23]S?3(6H ;F5+= M:!^VQ\GK/$4W3]/&89863H7&2$?[:R:S/<\]>QJT=):%, PM\6.8I(_F]T&4 MWE"U*? <\P0[KJKDC3R6I.1GRLQ5WN4P.OSY*YS&1\O2:729?OUG(,984EO M3I!VV5^P3GQO&?OX=B+MO0]BUPQ+M7T,.H1EH&>YO(R6?YW',O>%U|EHMH MCV[AD.%&D3%^K]G%HC_Z/2#UY4=O^=VI(SP<76Y-&#CB$8;'R@KOSKA3/8%X-M0UU)6CR0],8T+"R")XPM\$$O^8P??OHMNW'!"%O^J;@ET8^!(G9GZY]#P[)S M-[3A$1Y@3P[PKQ*],T'66[?ZOKI1Q]+_.529OGQ]QM5 M99^RX4IO-5T%TK;*C^9%]C7[\,)WCC>M3%^D3C!PM'1RG&+,Y';=^/SV=QB 531AA M(:W 9U($6<$;9/ZEV>4HC\ZG/1]5M|',< D.$#>]AE+G\V2E("5,1=4H[-5 M"29FO*\ZRC/>UJ,0]GL>Z-(-9T4Q&#..ERS¥,OL=>;NCQC(#_X6_HB8I9]+ MSA>5%-7K$G^]&8?!,GCA\(Q_=AW?,QK2<#22LL;DM0AC1 MMB%2?V!URQGC::BP6F+3OAYFO, \4Q(2/*H!V=G3?;4@6\^T":?.50&.M&G.S)XO((|'$] MB$,S*9,K0. R!'LQS [W&D%[_T"" *-ET?R6%\/ %R-*>?DQ6U;5M>!6&$P M=N1_9%S_58\L#+'%8 -KVIR"L+A!^@EQ1G2"L-NRHE>0*X+I_:;#*(1DM[!/,&)BP:A,P%,*2,O M,R{3))&+FF/+XYOMI!'1L@+XI,&(PTCQ_EW"B?.!:&\!3-VDP)&4[-(,/C> M3+SB,Q#]'URESQSK/6FT%*[!]8SHV1&0&.^GWR#Z(TC[-=Z(GO=E&EAGBY M))G(F&K]/2/C3OM;FTR4GT"]>FG<1GQJ;E]3>'S_6,[?0?_TKOZ*IR("1%/& M;YHSYAIG4FA-NC\X-=%L=KMW%"QO+BC=R(:%N<)$\+#OZI8NCDO]=,8VU=&= MQ2_I^M4<-+R(YO-D1:1%M9X$HC.*CWQA>@2'[8DL16N%P:02YN53CRN_:'SF MZV3A-!$E>GTZUE&3.06OZVZ=C_I)(YG97WI[\|D.5$UHM31$"*TG;L7RZ(Q9 MC3U^,OTLNY'SO2_0-PP|ZE=V^@R>-Z$$S/3BC5PF)::0%U+]<0^0P\4<&O#< MK2^^^,#%T=:%H_@^'/UE.'Y#C9.Q'7!_>#5"5BDT5RQX!;AS-'L%0)4W<<%(M*#^?1!4OZ!#F23N,=:D/^H4]8-)9OOW5OH;)ANV&I?**1+:E9&H9-E0_4D/-M.W<3DL:00E_DE:A(X5!O7:VYQ!Z>9CP8(PX7RE7APY,8C;.?ZVV2/#2,YGU[M]F@QP-4/]3TH?WG_;/>'.0S2&,CWX%/^MD'D)C-H$T^XG>E(HV6VCO]+7YWO M'<)"9:2O +U'N&I"NS]DC#E@VOSA,F(Z$M5SMA C__"U?N-$9?S28:2\|:+^ M8%,RX!! M@87\9@,TY^:0C'[9[@_R_T%I<@D)/PP=/BY))DPNQ!?_NU;\6%W M'0&VP%"[-R2IA)$%<@]0Y!7@E@>,U*[*1+L83??:T7W5DI%#29R5>D3=_PI0 M'M@'O+?? RH$^-6!X%@0^YXD!*H'9N+*.5?8$:-/EM^ARYHA$9A0)B'M 0!2H*0!H8Y8@%-![ZT(/ M4ERLO\>'T^^5;^4@VTB!PO$)}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|\?(/D0-^Z)RM12\^@RJ5'^^;^+?)C"=/:%Y&! [.+KN(M>),,^43C'QW&OU,F^L]"2].1M]%XC?TKSTVB<2*>B3$KN<6X5U88L]UA'L M G6'3W-VG;2RPM$%_T)\#^@OU),8,Y_M9J6"OK.MZRP$&&-LWPR MW/_7] MEVYGUG/5EHY2^4&Y.U 9;1=T2|\^/+6/UV$I2%]#T++J;*4J0HTM>P4 GZ2V% M/ 7K<0Y%B,EQ%SYET;#V7*V%G#&.TH%%"%$12Z:XONO9]/J9B0+G],AP#U," MDBFVS^?[@W?1\2:N.SG]\?>;(1A-LH%"O"?*]&7,7RF0$)CSN[>7"MDOYL'H MEI&QIX4T/B?1Q_MA' /[UH9TL.C$XAG3N8 ?WD_+\N(YTHN^M<6"/OIV**X% MA67=0P5V7A9@S*C^\|f*4Y%L^[&EQ)W-RZD#!-G4, M#F)G<-?RC8Z3#"_NQI.%$KIXY"Q"_RPKJ.XW\AAS_A8_BUE+++)GWWI8;Y.-% MBY888,9X-H#^/|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f7'>|(&7^-7BD^\=*/#9XL4GOOJB>&@WP\F3H'G+!)UGF&A080] M*.29"FHVM1=1%!?Y,M;NPO7D+AMTUM)E3P-.)833L-Z87BZMP(*C8HEQOV+M:(9=O4349XKZJ2F30.$(>SK!X]&@%*W00=T:Q MUN5F:D-sCFBPI*7B1TH9:I'-R>MI\ (8B)> &0NNZA(N<*^*'+@&F-AY(Z(3A M!)Y%I8B\G'#\]',!T\PK7AY)XCY M8R^=Z\O"'"E=\9;K 6*P#C60+3OXY,/%1QPQ:HED\V1C!5_J65D\XB%X;A%S M)G/#I>%=OX#_BSO]2,B03WW+N3-VY\3_(M.?>>O63)#$'"+*DC=4WID)5/72- MW,"V^%:70AG;84?]^KRLPEY')2]V]EP24K]\@:,;#=^(I6R8]ZCC!E&D'O)S MK*1I*^5]Hj=*RN_K#-TT6/@;8"Q=V99NCKMHKPYP^+0_+1S3&[>RP#@[48O MY&JQ3ZBL]W:'9,ML#CR.KE#D),V50DMFL42 :N-,OTDUU -(%O87 T*$7)-V-OB:,&R:- V(59;*W=NI M>EHCY+SUZV5#1#9J ,5H%W:O\A*:%*6+9,4DHES <;'EI%M:7B/S.)9=2 M6NPPP_B]\.4%+M'@H]^)@)ZR./B1RG*FJLZ5 WVS8_IF>]JE7(?^V1![4;YF MR^0$CR3X&-.T*3=*/!(¢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

*O|V6JF)66=.80W8EGES;1MLGYM&[.\6(T@_M>/N:0*8//H'U'#-TIPO?ZW\;(!=65VL%U7%;<'NX?_CJ;T!KK0Q[IY/O,8+)0*

M\=KF+:^X,X%GZLNZG45YK$&E_2(G6J9N28_M6:EDL$WU^=R4KJHMG%VUT%&IC(1.3[OJ#<8J\D5·M34L%X6|VPO·G-F>8NDfN|GX17&·O;M23[!6/__Q]>>,#^*

*XV^T0'^P%U<<|\·MVY*K)FO+X\[^U|&WTY7.CBN1FM?4U";W>(,#R;T&B39>2AU71#VZ2-BOC=!M·M,I"^J,@Y,>M+OKD&%--_>H.RO#*)][4Z,?*

ZU%ML]NRT1;)4I%G;VN,/I-FR$Y%O)L5[\(NN·M=]N^XEP'QY62&%"IA79W"NRF>\|4N?N%6 \RI"R)[/7;!_=QP7':,&467'73·M&K'58FN<7E78DZJ&F@85|E:X [VMO%

*TP1\RH.I_VI:XJFEU[SBLP>8F^N0J·M YW;6/NA,!1G")ZZ>=(FR@RC%.9PDMP YOV4^(BTV^4=X!R4$=0#^#F3*E+9 M^1AO2._Z8;Q04E68P8?5X/ V(6S4\|#];\,*

*(@9G.+Y1PI/M-'E4_NH^4++_3 M!{C0"ZTDFQUKOJ.D\?,@ J^N3&%4.U2Q<&^_ML_;,XP'+24O.OWY[6%UDWC>.G3Y|KP.F4P3|U3GY.*CX4'NVI M%F(8_;'W·\(M0.I8@F*

/U.'"2R!W.6>NA5V(AK9%6":C^_9.SJ5_XN2QOJ| MNU9'PN76JK|1CWM"6U'>!W?G/'95?X7@GT5C·EW!RL?·Z,_4NB7B3%" G5N M33/?S36+,3W&I6NR3'>78S,Y%

*<:/WDHKC%|#FTIE>D-6-+-7);&4Y@I^\-MO(=("> T{'8YZ7 M0-#"!9)MB=HQ,BQ0N M^,Z>HOVRK(F-JVK2RI^P=.RN6+LV<GJ|DK*1-5F+1E-A'/RWJRTN?-*

>T/EC9=PW^H(>K"=%; /N7 M3YY1(=USF<]-Y]PMP'_$0(EM]3I'&L3>Z>@< [NEIGC7-^5?I=<&G,[4\/? MW3-%2@?(6=UIF55[G^6J2OU1!>E\K)E.E·ZXQ+F?U·7 U=]-'>*

4J9_06U1·M.;=5%?.GDO=)ZV:B46?[^]U?4XH$OT8NWWWR=.Q?NT50Q/D;'#,J98YBRRZX<4Q.4LANRY\]6A\]?DDMX\&#[_95GPX)9&3?+,0069)\@9IC

MZK.@PBCA73509.FS3%Y]+$]=G,.L*$A.KKO'E352.9UN/5R>3%_\NU--MV!)RXZ]>Z.7]DR.7>WQ)GC(<""%GL ON$]!>?#A#H.K%>:*

<)\\H=Y^;03)'^>Y3DXRD%TVI18Z M|:L^<5$KUU*[$NO58>=RLRG$=:VFMRSAAO2&G5O>[R%-3C/[6T.AB;/E>WNM MGS·QC<&_[_1;^8AJ?

C^A;Y#KB4E>;|WO68ARX/D;H.3 :=:H!B2%,9ZPPFI2#CC->3'/\LA7E6%:%M5&2 MA1$/BO<:Y -1=S__C&X7MZH@@3YG/.N)63@ZT5\T&_*Z3E&/&2CG]=YJ4NG'*

*M.:SOQ>^]//9TT"O]E*7,#1'{PM"@$)(\(*+F6;*M5=LJP"'TFI]WJP"-'R·M7K·2)R8N &Y6+GLU"W'HIG·P+)+1 +3N_G:*/JQ@;$|#=++V9!?5V#!DFP#6*

*M98621/DB5Z+U*HFQ.14(@6NO;$VH3T*90&?F5:7[TM)#W$F\".GOMTE(9+]7·MZE!$XR1=EO?$4*(Q=N^)O2FSH\2LF.1"!LW-'I:]&-·>[#/Z#C^H249H(R)+4VI_^N=Y=5(*

2^FN;X(22 M#$Z]:F(7;N&]VN)]D24&)M=>_BXQ|\..AY9Y.-7@5T0_QZN^P5@15"F6[B0 M&V/'&8C3\44=8?HQ5$U7PI9W)7&[SR5B=J[]PVY:+]' .]%>GGF4-<>B[SN*

*M4H_@1;0V5,?\]Y&|!4LC+9XJKH&%1+77WVH-7#O(-4S2_]2>Z]U'"X4++;C[S|#*T4/WDK+K+C·8RHL'5LK\IXGY5X#>8 *T>1BKA>A5'GG^Q-O-*

*4"HFJ[H#>P6MZJ[RU.[YOI<@)EYOW@}_Q M#GE)__&E3;%JU"92E:LS4IV8%K8[H9TE#]W?A2DR%Y,M*8B_^;<51P5?2U6 MY7-R!{(D:B[@OC*G+2+]2/ 8M#L][7X|*>UX?*

KLE6KMEXNW[[,[R>0=&;_I MD_>+9EU>KDF4\,22[_QR>T_=8&18FT=HFTYV+[6+G+I*MJTV#H=/'G,S0<93 MJR&2S$*

*P\RR_X^,*5N:.X>UU!9O":9IB'Q7G&IB"'*HRCC7N !&9[I& 3'G·MZ2]L_E*;<-7Q@=QJ{6729!PP?X5#C:JR#_*IJK+SU"ZA:%[<?:%^6-TF.L MP*@"'(YQ;1Z|XJ?^I^"49C/,.*

*ZJIO$W4Q7'+R2<;G,U-)[fERH8C24\V%?K M4EIW']PIQ_9&G\2;_1C>|'2.%Z/8K25^M27U+G&K9'_*0OX'] ?ZA,<1JKA M*Z*K1<9CA,TVBZX-T:CCK!=V(J+T5?*

_A$XUW1@1$J^\4,M!4PCLUX.OX,3GC MF&/J<+Q |3A.!-.YJ|>D'[NMJ-WI+U<[L0=FW$Z_'1.Z%B7+IV=\|:J.&\|+2_5'XUS@=$Z V4B?!|-"-R9@\/^SMXU.[^ M\ &$D|'NM

XS$]BO>YKQ2J^_12+6D^O]3Z?Z%X[F#BPU5LL=4+%F.]E7H1Y M)">%_6/1- -]3YZ\"X4++;C[S|#*T4/WDK+K+C·8RHL'5LK\IXGY5X#>8*T>1BKA>A5'GG^Q-O-*

*4"HFJ[H#>P6MZJ[RU.[YOI<@)EYOW@}_Q M#GE)__&E3;%JU"92E:LS4IV8%K8[H9TE#]W?A2DR%Y,M*8B_^;<51P5?2U6 MY7-R!{(D:B[@OC*G+2+]2/ 8M#L][7X|*>UX?*

KLE6KMEXNW[[,[R>0=&;_I MD_>+9EU>KDF4\,22[_QR>T_=8&18FT=HFTYV+[6+G+I*MJTV#H=/'G,S0<93 MJR&2S$*

*P\RR_X^,*5N:.X>UU!9O":9IB'Q7G&IB"'*HRCC7N !&9[I& 3'G·MZ2]L_E*;<-7Q@=QJ{6729!PP?X5#C:JR#_*IJK+SU"ZA:%[<?:%^6-TF.L MP*@"'(YQ;1Z|XJ?^I^"49C/,.*

*ZJIO$W4Q7'+R2<;G,U-)[fERH8C24\V%?K M4EIW']PIQ_9&G\2;_1C>|'2.%Z/8K25^M27U+G&K9'_*0OX'] ?ZA,<1JKA M*Z*K1<9CA,TVBZX-T:CCK!=V(J+T5?*

_A$XUW1@1$J^\4,M!4PCLUX.OX,3GC MF&/J<+Q |3A.!-.YJ|>D'[NMJ-WI+U<[L0=FW$Z_'1.Z%B7+IV=\|:J.&\|+2_5'XUS@=$Z V4B?!|-"-R9@\/^SMXU.[^ M\ &$D|'NM

XS$]BO>YKQ2J^_12+6D^O]3Z?Z%X[F#BPU5LL=4+%F.]E7H1Y M)">%_6/1- -]3YZ\"X4++;C[S|#*T4/WDK+K+C·8RHL'5LK\IXGY5X#>8 *

*MJ;I8>?DI/G#Z_5\.L<0LM|U78W'|YK1*7,A@O;BRZ:IQ7W]W#,+TI-?G47B_ : MI&I=\ ZONE?V-MUV#T4V)Q*Q?5=#D@:.$-WE2KR#)4 @K#5C,A9G0 ";?.8H=*
*MS*03G#CEA$EPZUCQPR85B|\:O3ZAW*:B%|JVR9\Z9.+7^S M>IF%|B2"V60O%X7]8FY_ Y/I6;/*Z>&IC;0V53[Z-ENQ%PHV_(-MF.<(4 MAV1\^O4TS=?579XF.IUZ7*
65V]HZ)W6)@B|+;/)=E#YQUYB;7[6L"GJ>G,9 MA9;E,C "\13T-AV1>R>HEZ\"#VM^ 1!#TND =>_C#^K> ;7+<-B7-GE]OGE M1?FGF9,_>#QWTX-
&FF=XO/7TSH7;-)6DFR!M5!EN,.K>>OK6G^LK:IR9^X'B M'0=0I(S\&>9)^\'|SA/#%9|SH#9$+|-7VBF&I> Y\!W^^&Z;@M1ER'&M MQPM;=&AQDY|F7QG5N%:
*(6\5GJZN6$60O5TE-,L.;4Y\R0]2 ?7,6*",9U!G M'N5(R#D][;(W*SZR<[*Q;GP^Y6OL^&A,?GH]4)#O<6U!:8=()A$'P)O_V7L-
MJ)" '^})@;B6M.@=$X8EZY.4X;ZS4P$WA'(E]*43L(PFW(LYQ'"R'S5$S8E* MITL#.@>9HFB_*T5#2Y&TMDRQ(;9DQ^"QM|B<5VNQSNOS6;Q]?OI7M%G?\2^S
M>TFE@<&Z33^-;-9=FSX^@SSDK#SQSOBUPZ?,S!:KY0D=EA?XIC"3(M$>O\'4*$KIE MCZ.!IR'1Bs%7Z0L3\6cC&/&/R/M0#44WM1ELLC=J@>|SN@SD5W6S6GMA+?)2!CUE[
M/=WCU==-\&4N^;WP+?FY?|EZN<*\)L&67TO,.3U[O7MGEYSZ,WASZ,0-Y/M" MX.N&;6'1H?9/&XIQ W&M*+196 :U.XH6KJMK0"<*&U>,L5Q&,27[MG3R?GD2
M&I[H)F9QE+>N(:V<5[@"9:6(*VE*FZL%_?X=7RX3'A+|1S5G]?#53^_-+RR;-MRL9 &-Z/H5QV"G1\KCJ]\\F:>N=:,.^LZ'V_ 0>!I.#I(D\|8MT=L]I-B,17)PU)U2J7:-
\0VVKXWC2+7)X9RF#1T".QMD&?W^ET3]]YJ'Q>V=NV;UR;_7Z152;J!O7 M$&$?='!J\\"HY6+!C08[&3'S>\NG[*4?_S^#\[F6=UAKDTOQ5><>:CZ7QLE.
M8@@IG79<+7+D0)3;_+I7&W232:8V;F^1@0YBYL/0|5Q)0/_6QX6YMO7SO(ZC_MU4SDA\U\U.(CXCk).\G\ O4,\ T_=N$O2[_BRO;,\Q^ZK(|$5K6IS,SOP;<. M?
Z1W3=R)>PU!G+ N_DH#(A'D=AH09@.A&E:L[+XB&WB3\MKD8<$#=Z,.TI74 M!6F %BP^UISEU9L*.B9Q";H]E!% -Q6BY?_7!LD88G&.*H>83QVA_]-" >##Y0@T-
^-7X=\T!F'[P;NBB%/T?89/=!:3N M^,NL\S1@'MD59VQB[I?8,6PG,JC9=S[M>?B:+4Y'\J=Y*T5IMI0&Z-$ TC'A M8ZC+H:39372"7Z5I*9++B82NS\L<6!V]_0W3[Q^+F>C,5$(
MR ^:,@\U B!,.[]*-C$[M!%*XIQ*8= ^!\50;#0I?^* 7RM'M$+I)M40>1Q\Z,F M/M3;3+VQ4WYE[K+Y!T#R#NQX6?'E'D-U;+*@)-(# 1#WM#MF.L3U!
M74K1=;_.4IU"I*A=_7D*^2XQA9\UHC]>LUO>_FWHDC98 X&Q6V[=!]0!?!"B MHI0L-Z'WY-XW/MA;3ASSZOZS\FU"_)RL7+YIZ:VO.80CB .,8>I=@EZ_.6I>A M
P730A&'BVQ'ABZ5DOO?MMA>+&\0;_* U?=U"&;=O_JBL7D/_HIW25M? 2 MFXI-/B(3_D OUB]!QL8(8#SFN,C& VGZP0?&UW+;G8SGS[K9?-&R_/37])# M6
/K!A(/0G_^+22(9B|A :P^7VB M 4.ME(.VP/*I[\Z'Q_WXS SX M9I =+:|;_P=%/2;=O'M*_G(T/WOM(9H4QO0B%486/EFTN;F"^P46%'9]^%\;^B*MN Q^K&X@$\T"U%%ABH\UM>REVT*4S>=
*MDQ;4>7]^]P!.W(L/_D"J:@9T<4S*_4OK/^BES:IC:WTQ\()D@ M5'WI"S^0LJ.T-'I,GDVRP5/SJ_K0Q7GA8 MO.I<7]K-R>E?
24F#&?.U&U/(;AXPOSBQV1L6W#;MENS,D\%V%#&!O:I_;_A: M\[%#P\AB74I(1/!:&79@R@)?AW0JQX_HDH0CHTH[G;SP=F)Z#6X&PXIZL&^G
MWW^;,HH]>OD;:]!5+VV1"6+4KN\PE0.&LA]_IL3O87%7Q-:|W_WL!5/UU6M/ MM5GS>4057C RN>XT;II)#((6! &WM(1BEUB'3,$@@] M3=P2>J?:MT;O|VSB)++&'8!*W/?!S
,]1KU?17OZ+Z[!0VXE,*UEFK9]>[G)> M/9=Z(_2//%^?0U;SQ"B$,YB?#,5/1%3 K^&/>++#V0QI,.-GUVH07F:4G3CD^ MU--AX+04
*!N$.BEB^MW5YYEN9W!\;G*M/2KU\6]N& MCLB X-8Z1WYY8_Z6EC@Y[^X(W"CI;$,#B:V?G+QWQUT.95Z>I>Z9$/6)^Z6
MIK9R!XO"VFL@46D(3KAAP5*&+PK_D[=3V:]#YOJ.XD^,=5F]8#"<1[VUI3[C MT.WV45(PR#F;>4+C@N,\FP08M&(F/K$;,/?J1Y247^KE)DB4BV#@XX)QR):-
M5P$T(%01P3@' !W.P03<+'03%*U<V;N/UQN|WV6>3[QA'F_\.%BCE>=2@& MN(%)ZI28%D|B;/$6CCEM@7LCS^;=*VH%HZ[ZJ9M(G8/G%^QA?UL8191@Q:S)UH
ML+/!05_M-,FR3LXZFR=/P5R7!?O/GS2+<50TK).(OPBX,P$O=RLJ0C3F=E^3 M4DN)>_,J2 V#7.$,=`K>](PU>@8K;MEKW@,703 303^QW?;BE;2Y:(IL*,G'
M@I28.BLPU*PC/-OB>^5"V/KR5<<$\;8.^=_WZET/#N^.E/L$LL0)KL J5M?% MG O#GK FG^.[U$;4X?Z-%CQ*H7*1]6^FW!JB@(IHL739=.9.19_5,,O!B[S(K MG^% ,]9KPA$
W.*8=B'[G"\)A"7CF>)K$\P(5A,;AOD#N/0%T"/WDV\NNW\W M==CSB-"YK+7K7TX#)@^[YWB4-&)78]8D.P/[>Z20)A*#">681?#7$_AK,%S MLWO,5V9*/[^N7'!VY-
[50QY>@RL.:HDN!ZN.4 0+;6!%9OJ&Y.U%S)5.Z-< MU-]_QL6&V#0H26*@DQNXB?;=<<%V--?(-N/8#T_K,9NKB7>F*]4M4B)LI09N M
WC((R3GBKWT43|G+H\#4,N>AZJHJ*K ,S 3 MO$[VPC79T6,"GEG?0;K:8EQ./RZVZZN[:O#[77;+2D"(6-,WYTU2O<^N#6%7B(C&QO7)7$:5Q)56-
>WCW0#TT<V_S8W%QLT4GG)6]0@K07<9=.U/ MZPWH|\\@3Q$1!] $GQR>*9BL43V\I_+LZ|FY[G@!W=>/C5C7S#"1E^@T^P%X MW.%)N!T)G4|RZQ%(32
$0;7KB<:)2=Z%+CR\EU+]^KV\]\RS-<"JW/O:DO2U M 5U1T5KGIZC3C3Q9*/)'"6)=">ZPKPD,6B)IR-E\\H>Y5/7TOTG5F <_^I: MVI[5'&+BABFQ?
YO*,%S82)R^R)@F'KOZ,$'PQ<4^,,|F-=@7=+|I/2|*"FXA MU2+C"D?.IW3Z*@|;89<9ZLBX%RP?^+O9F5R!Q;]NIK\!S8'4RG;AA(Y9#%^S M3_&2EM*XXJEF3O;$ X\XI^=#/!
OC@>9KJ%HN;_G/Q-_)%07A M:8O@#5UVG..U!IR+KT/D.|CPJ(nN&;;QB%$_Y65'70;P'&>L5GT7#S4{@?=_M)\K&R,!E AT=+XP=+20/3^<;BA'$&.0XD9A) P^"Q,3
M7#.SMHNIWL8:ZW;_?",,%<[TBF>FW$'.SX4_'H*;Y%)}]U"<.V,H?M""7I#V M7?]H6]^?]!H@<(\[9LBD12D&"DL;U|L8:WUCJ*L/5:A3';K^*7XK!#A+Y_M7
M2E)#;_1G6/\">T"9/1>ZLJ5S/8,3QP/[*[AD2;S3;M!BO';_']Y%W/U(ML 'QVKH|\|.K"UI=+]JEE$&K/KGV4HC)/*&CL2T6DVZUR,0U8VD&_@$Z[,F M<;,]+Y(4B%7!
(;=Y]HP'5$YB9[MN)Q32U-:K9]25?S[%OVT"*EMX]]Z?ZW12Y8'7/C/Z^_6#NWAGM5D:(&+!8,? M,22! V/=^*$YBD8=EXF'Z;;O-5OP^F?1B5XV4@]NFM,E9_*84B"<@T36?
ZA^M_I9_KFV+LNPUNB@D)ELN6?W92WV"-+MW#.0U0$45G%4Z_,'(?7;+&6IUWF E!|8/DIV.B>@U:8>" M#N:,=@T\&M,\K&R,!E AT=+XP=+20/3^<;BA"$&.0XD9A) P^"Q,3
U^=X#L&8BJS\,\UR'V M{;..U/2?&#:4-KXZ5N[3N$IE;^0AUOV[$+FB)!4^@SY#3"UP/[#\2)P@[D>DE.FS-J=8>;W]A M!/1>G#@GSC;-R'0NI"LXYC_]
<(I,OTL9@I_$+=9$D*DCVLV&'#CB>H>_/3 MKO:[A\Q,P.-&$[)_Y#'=O&F#7Z">01QE!;T[_JN>5FL6_'>C 2"YH=;%.+@M M#>@XIMO5>5211WF((9Z_4EE>S1T#
M31X=\KR|2Z?%0*OT! <-@N-_9@6]>X M5]1E?ZY.&)8KYE_AC[PBLV#Y=3AM_1_3#'5O_>H+!_BN;19XW3QOS,N]XR MGR) GA#?
F_\0N7%CZWQM?,/K'N9UP?M-\K]2!FR|[";/^UGA45>6_>_T-"3< M-8S#<"_\FJ1V'$ZR|^B|\?6<^_C6W4&-4I@!]2(8P:SIMKPL_U-/JOAG1$3A MT(KB,JK%!!
<95X)XUY,G*M;K=-.]6:WGY886>]HI; SI0R#*T;B&N MYGA)MC$F9?67EZ,2:UK/W,#-<2Z1K-+#;DN>%DT4G>RI*.B_,MS2NAM^]':; M!DSI=VNQO>|*R.N;
[S_YIR$';QA$WTOT]ZR(4O<7#M=@RXENY8P10,H9US' MAV7/N-@SD/*S0<3NZL')3U%AFX7#@]?LL 9_-587TF2^;,&8;5FD7RO+VOT
MH]#*=N1PD\\C/IT@MT;6$IZ/N>38OM6TYU"\"=\\'CZ(5EU8B=TT!&'5P" ;-M& WH#KX4N>[)8 E+UY#)G7(>UPH:^?[.Z@GB'<_W>(#^@_"6?2CQS&{0&)6/-MG-=M?
X7D&1<53X'B_<-QJGQ>6G%@,.W,/R]^NS_|A\&_-5N"EO!1]M(E4N((SY8V%6].6KZ[\0>8CS'%E*HKR0
M(N!^#Y>;@.@G%QF3SJHE>;"]F|OKC\&"=YB2@4#514Z/X)T'9'8O!X(!\(9 MP4R&M~]I/[UHD']Z/&/7$)MQ#1YK/#GZ6>/;@'Q%I_(]%T^D4ODD]
<6>FTJY)2Y\,$#*/#+XR>2|1:/KI0 MF,=ZXU2:.4.B'|S0GL/98;B/7J-%EC.8:&>7)SR;:*KF9 MR'F KM5\F(J_ M<2[^L%@4_-QMZE_Y/O5_RW_+?
\N_(">DT[MJFZM59A(,P1_X42F0)RCLWIVC M(O0E1OME;?!);&3/9(G^$\F,!/K$[5YU2U1@>?HKQ$-[W5T,2[7]_MN>\'%C>-
MY*S4:C!/0E<.,BU9=.>0I7C2B6F[A<2B|E_$Y-0%9=O+OENW.RJ[S+]:W=_ MKZI'\SELL>'AL6A4?.6H!-I6ED9.B-7_+@\9_>!*)3,B:K7 MN@K+=?>F;AL>:LUB|[_56:?
&>?K]%G\EQK3%QT77O](-SC.,UFRL'N;0]6-"3?Z7.G.I>F 8X;25]2Y[>D@-2.S:] MNH(=X)>.,BQVRX\^!VLLBHB2/%KR8= [HT[9@3*75C\VONZO$VVO:KJ?'+RT
MU*TVKMJAY!;IQ7'T#N(&CE)PJ\^(3,%=-:!+P-I;VB(YYDA"[M,E^*C^T6Q<(M+OIKBQP<%&.2X?Q>E(8) #0R>;H'0UX$B@#L6@>V1'667]D\I/(ZIRZ
M[4.MG5XQ#7/DFIJAG&MKE5,/)-(WAQTM1L&WB.ACI!HP(/&IOIVM^EF^M]' MWSXZI_KLM;XU<)04N:K.6MZJ*A=NH3-_-&_72Y?2?72V\+W?I|&.#%_F$$R$0
M.]25KI8W(X5"^>ZB_//S3]'>1W$(UW+H|LY]4:HLACSKBKD+,@ P1ED=X35"+0)\CT9J2HN(VNQ)0G MK1TJ!@K9/*H3Y'0D8-
$QA&B_0Y4E=TP1.M&GCM[7ECNUO:X4N^OP?,.|>WFC M:BSHN0K=RCT:T/XP:PJ#.RN0<@M]-L6>!IA@LQ]PW8AY]95MI@Z>1LVHB)?O M@^A$XVXD#I]
!DOJ%\Y1OPGNO;OE8@+0QJ;*+)O:L.>_.U_3U1S:V-2V,DAZ- MOFS:%F];4.6*"MH^#SK5(VK1O,"]Y;<61)2\16XZ5(%A=8E9+5FI*);>3S;H M9)[SGGD8X3\:CC]9E?
W_H+E0FMOR^"/CQ*H(10+@Q5_4O!/F^#90],,"0-3 M7*>BZ0:\FKGM W#%],NH*=1N'?HH'"Y%Q.I4$]?]K<I:QL@F9*?V^0X)>#7K: MS'Y!ZV14_I-LO<QYGQOS/F'R
M7%GK18NE]/8??[U@E?[S5\[@5Y&I-N,C0)G?13#^DU.WM"^P-H3,HI$;^4+&DE]NCU5QVF15WXT*$<==RZ MIR7>FOX56N:FIHX^+NBYQ_N0:5@6L2UOL.&8.QLVQD
M:]Q?Z7GBY"#"3;J;ECM0^,5W61^)@=NV"G2?;LR'L-U8E\X>UKO7]"(/:MKM!8M!Q9G8AX0%()A8M2 M54@G][LKEY)*>S>K@>&SR(6'>9FR2F-P(5)P/6$@4D2
Q!3SDE]#MF)9V4US M-N7*#9MK WV1O[S"P[_^8 M&4%R/,IZ_)%#4HTX,S*B1];9]2S M'2B;24U;YK PF.3L.&LLLL9 -5H"E>2K+TP>T:I++,K A7V"""6,EYPYF75-#O
MAI#+(6LG#\UA(W=(U"02[NB?A]P/$1;H.NI^F;XSF_OM?:TR_\'"1#NX#@ M$?U++1K&++[4.1-RY^/=^ B)U5]8QL9:/HX]]6"X2[\%R=9:DGF7KAIT*]+[O"
M2CCT/81H@N'"#;1!:WQZPE]Z@N W]\DWRMK%L#;D\0[MW3.7?G&*VH6'[MNJP #;;.TH!-CQQ.R"]+-PWX8,K423V>P&&=C^/W=K7*/*^X<^15'"M]C"WK9XD]H]_*C/M.
M^;O@]7$]_S%=*R*#<"LH#LF(| !Y$A!(8DW?-%%#-.&LSX"DAU=VPUFZ@RCW M(_ LO&M'K62=ODO#T%/W%W0oB%8W80?H44WM1EBRI[F\B[5[:+/QW:?>ZJ^;
M/ENLXUN5X)#B9>A)JACY7F?KB68V4AYF$_,R:87'_N)GEW+91^*,7V.8[%_P M<:B%22 :R78/D]VHS#HDA:Z+KK-!]>&_T39.#!P=<_--)&,(9-[3NCZVI<&
M18D2KW'T?\QZL]JNKA0N8G9#$25(;2,A^!+9FR"9"-FR((3+]]K.X#U9Y"L5]>D(>]*.)M1=]F"U?G_6YANI%L2#:-M-1FK#V7[21%H*5@R.'KOX'YC>W/LUA%?
B9G1'<2XLK9HW7I1@2GY$0X2^4\ M|G7JB#6,V?WZH;E=-IF4"TB=LW"_!,&[NR=LE+CLZU(=T!P\V'!]?C6!8,\ M24"0%$6V4E4^=KOQ(M.L=?
$#Z/7Z3P_:+IMOM\5)FU@!B*TF,D%>!"3&UJ^ MDA29\E%C3XN1=//3H]@G?"XISGGVAP.Y. M]0?XC<\3^(;!*^-L6GN=RLGM7IK5K,6/YWFD1S2.W-:8__:+F_^?A2B+3<88
M3K0^/49^9[7Z^&TD'7;%11BYVUWW76;$.]X$^\-*AWX%*@8W& X&8"N[5XD] M[>_0:N3S$];#&B7EM9%?OFO!?%W8A[8>A7^AN&U[=V6?)NXA7[:N#G M6GM&
MOUS#FU2YIB9-=WUYZ9YXZNM.EU<.\3N8";XAQ)-TZOF%!5M,$L;ADE;2P# M^,FYAVC>DP8L,M#&GZ>9;TOC$Q>2'-IK#'YGA+4_\P-O0-A3B$XM4.%YZB# MU!-?
H'2+J0'ZY_UPEY(CY_@GEG6VD/25%@:.H\N*!U^G@&!HS0@(0A M&L#;3O2CQIB$(8C9-32 \)*.M++*(@##P0QH-8HYZ?=>3P[HLGGVU0.%=A?/
MEV.&SY_,15U^*#B/$;LFH=!SW\BH<CGY(/SW.A 8.?BO.O?>? Y%LAQ"G@&"_6%I&/!H8&H5CJ*.GB-BW!\;X#OW?#XO$;RC#HQ(*E.AT#*P%1%27-.('1,^D3 6U]-S#
M3L_P!H;8"3);A.Z=6AA"S M&<^A>(1HJ1WE-EL1G0C0-3IB$9X[[;_RZH+9OVP557UID+W0MG67&,_.O)(8 MY#9 U7(^-J36,V&+8DT^=VA"-L1-Q"EQ3Y;H>@6]DU
0%OEP]'Z5]XRCZ&L38 MJH/XQZ]0Y*>@\;/MV_ 5-.#53A$-$/P _^@$*R^8@(^;!4RIWR)5X&C!5W8Y6
M'!,8]QD5P# ^URL^XE:TA=B8AEID0.DB4GD0\GA.&\QZEE37[,):0".T"DR2> M\J,\SNI&^7WIM'T;OWM;B=EO=R;^]4[&0\!4Q> ^. T"$W2C_9C8E.(B]QHP M&&_&W#
W*_V9U*N!X=B/0@)DY.TAB@GQT#"MXSAF;X"?8\F%-%N,2 MA_8%/GXE>-XT)BU;\YG%V(-IC=XE13]M//1]V&@]Q\+=:.]!>C@MG/X5J;/UG>CN.
M!CR=@>]XP|"RD*Z<>$C-0.3Q.G6@N+F:+EOIZ=:MW/*%QX^;&+T\)0MAFM(;GO^4T5L9(T:$_M3$AU3IP6BSUUM!54BV*>N9WLG*929;#[_J05O;]!>-@K7V'0'7;I/-+OG
X0 MKQ7\9!AX"M3V'!QU*>ZE/0Z)E6NG;C#!7?I%[_Y3$PMRE-?1O'0@^/5X1HAH M5)&WYH.4!]KK&5U6UZ_$|7]EQC\UL#>=5LM)41U09B4V3QMRS[&=
M"YBCUOT>F'1%X+5 4"5U4YHUZ$^>^ ^_H_!^0 8XL8H7^N'8EL9=-< 7^^HIKYM;3@T04 01",=1:E*5:J(-!&0WD&D@X#T ($@57H3 M$)0N30B1&]1W!*3W3D+O"35
$EX\YSUWG'M^]HYQO>-[X^/,?8 ,R1{|[G6 M?:,SK+G*\=EV|'<*OSB^>B_U;K+KJ&X)-6Z.0\= C"9Z[CQS%(9H4Q0]M >M>$U@&;<[\^(YI;O>EWD#RP)@R#)
(KN8*$"4KZ,AV%T/FF^/D9[(%S0\H/I^\V MGG:?F8NK.=7|MYQ\G@>2*0)Q3HKULWVPJ+4(Q? L9QK;9E;'*NT(.9H4QX2Z M)A1/]=.7R_#3)<39V5='>Y7\_$\WH9$
MTK&=V04!6O]6GC R DD%=[3#EBBN=;-S"ZD)AB\9&*UA$BXBS/KB7;.SMEM" MY?4GMDU\[;59A$C-W7179$-'=DU\&$@"H69FK*XN%L"]E1_U7H7OSM$Z@&10
M%RM/>T'\]P;1'-IM95->DUJV+I89=%#ERIHOIVF[LG]]5$S?A?!)QGT9F6# MSLN6RN7];N+U-C*9Z|C>6!8,\/$Z5 ?-B,R>T/ZXR^EMBN M ^F=.%_HF.:_U=-?
L/$@W\^5UI TT^'@IM@)CC1*(44(^ MU9GM=R*XBY(%Q(DZ]C9<@4)+;=0 MT/=0]7ZT8]ZP2LO7;]*Q]P^QM8_'];.M]/C_W06VPN1O
M#*'JGNBVJ>W;35RACY*@Q!M\=MFQGQ:&6.,/G4YA7[#T6B)#?3'0 ,;$^^4&_MMT$R[G*SEVWZ;>,TM:@;V0B+&Z, 9%UG+LWHS@O1>G_5)Z];$WDX*)9SZ^VB
M]AL)4/"7I(6.8VJW M<;_U(UX<
OB&!%Z*'#VDT>Q<"N1EU&R!TM&)7UW8#(KCRB8V9[=*\FY=M#5\+' M,?QN>6%Z!,, (I/__18BC6D(N3VY97!8X+V6X9/+Z$UH6=ER<]JO.@>#OE1+ MTC=Q1?]D<>U-
CLT2V)+K>!9BQ6A= YPSN$/\PN:WA!]M2DJ9CT^S]B^\T>BS M1)]WB=[. "#@@PR&;E+:;(`];O')[_(]#,\-54QI?R U;FR1&#V"0%Z@[QAS M5/5WO5G_T='XW62DKPN;9<:-
]X21=5:#23ZE^%W(K=LJT"K'^P-\6%(&\FTLT(`/$4E0SRRA%5:F25811 MY21N5 "2KTRYD>23]"9 43 9&9*7@'4QEWVN9JF-",(+6PL^25"W.8X M-
}0(['²,12!+"ETF(HY2YBE6&0U KC7M?X8;.D-^=5QMM>*HZVGYM[L_BKE+E72'BR<# M<-&0@6)-*6WN9]$0/#D_=]ZG5FAKV114:(,PH<.!%,.9&#UD!""N L'BVB9+
MCZP)6PQS*.C.N(7*C!FF9K5E-?ZPOOJX6[-"I@NQ689KKX0)F9U022F MZML\H5V1A(7A'JDC+)C5_?/1N!-#Q7SH0F:UZ#23';.]+SYQ.H]*8|<\49(2 M,Z>UPI2#BH#
R/4@#XNOQCRAS7+W2^'/^3'660_B%6)%Y_HCURYI:])FQ#CX M):Q;TD[SN:Y1?@,WQ-'LFN4..=AEM42I?8+Z(?BFW!S3O$_HH&3" MG?HD>NG5@,?]F:A@'AVA_5N>,
5/)8<28@\5P68U>15CY-'>7!34,C'U7;6E MQ5M5:D?/AMN$9LK7@B3S16A_Q=REDW$;-'VO9XUO!?U[(RN'Z" _D<_U9$CL
MR&"OS0YE88@4SRX"28RZ"I4MNLF6"":#:L_FM#ZHY!.GE06>CF7FQ!WC'9<[-M.!U].47V=)MD>G2/]>-#YJL"QCYIP>WQQ>>O8UKS8>GOZ$N.13/;J3D M-
F@$N@4*H]5. T;%[.4&)%2_]{V5VV5KHC229=.../NYGE6]"-XN)0'5<(0\ MDM'P>,,V>L20%3#E(JVS;$'A)*'&9.8HZ5RS6GJ;@Z"7N@% ^>X?4W/^-U>R M*#ZE@CD>JJ?=7+
!W;;LI/1B*0HGIHZ&TJO3\<@[KW!CM?EN~R1?,^88[U M\XSUBM P[Y5I;3D;00$ ^^U:@NGS-@(A>4]7!X38>,;&HRN<)Z/;13:)SB0XMU>T7%UW.G+DY$6TGEBD;DOR
MB5HO92WY2<]KIYG_7:7K;6?X34+^4L&QB]\V"E8QUW!3OUEEAP,YT?@K'?6I M^;@>\{H)KP67*<7@*8UAT:7=.MNO/[0G]G#.6#$9UVHX8V,BV##24
M"&_[AUADR1*CC> !S*<-]97(LZ#!];Z7R*G(G.]:NE%[@H!BI,K@AV]]W\|1 M?+X*+ST^_Y*'E=L3'/-H]GWZ46LRPYF!?)'GP/|\X|&'NN])*H0;@.1X'1U$
M:A3@U>LES]%1B051O!6Y2C F6<8 YUT)O@)HI'NGJRP_;OI^'J8|"FLJDUC MESA!L3VN)4&<'$T WJ{F$*WT'UOYOA0I5=]$_=[&,>OUAO
M!'++_=9LZK(EP[Y=;S]%"%[Z,=ZQPC""U4\I_2VC&%V$'XN"EVU.KC6>.FQ> M^L TN0;*D2?GND7(ZN, V7G*4]/&GU\=!Y\]I^^8'KY*0S\-3C[6B;?VEH% M>NCT-,S%8TM-
+NU]L4.8.&B90@%N Z>T1]NIWE37%#N[HIFM^>8|M4]L-*5% MXN= +_=;S7O59L42OIR\](>?:%E:4W(2GOK2GW>ZE MB6*5T"XKRB7\,]RYM#MM;C>; MF^LES-
#M*^N\8$6BH[71VO6JFWEU34:CJOS/_X\LL0FPIOT.NC=|;HY+++)P M=&@S>*S0:75|S3"(["KWOL#5)Z&7M(@2*B&AES+6NA^T<;'Y02ZIWVW\XF-
M3FT&Y1#0=H/LKP!)ZHB#2Z)Y\,:-AI<(G"BX]S[*!QN\+W=,\(P2+7$%X(VN M8SLEJ+@65S?-8MV6;EP!5A.!7+A6;ID+#KZ*_R%L>9D;?O$+++/JGY\";ABK
M&O+&EXA^4=._/V!@/6X@<^U[)D*]KG?,Y>3>WA,M-NF-&(ZG_Y]4#)!/(,< MZ]@<5SHJR\QG\W'H?CI%Y0#,WS\SAW*T3#OWYEAAOK;I4$,EHJ.*?:E!B?' M@3ZS6;7#.?
7@J ?E(<5\9-V33.LE\/Y2"XH=<1S;!#>>U;C+NZ[A4:|]+1ANB MBG<$>UIS)/7(.8!#Y3VS 9P M_Z%]7I"T29O%H2>8Z@JP2UMX!=B\WU38^%?3_XHKH080>)5V.\85?H8
=$O9F0X.1+]/8,7]/5] MZKS]Z,N)CE<*\L^Q4VA"9"@G7CX 53F8"(|=WOUQ[,,"DE^T6-6/2\K%3: M9C3TORV/<5Q[?W$%Z-0DQ"'B72W+'8U3FB/@3SAK:JN3K?,F[D\OQ]
[&[_Q:.M#"!?@2J8XG(O=3!"8T(@+3LWQ.?)C0X7KG%.-.%D/346PE!$4,N3RLOK@""/4Y?4/;H9S:LQDP,H(U_5Y^HEZX MUD@;%WGY-
^O;]@21V.3K\$O?:CD5W;D"7'C60>V@C-A/3] .WZ\ TV/0*\#6 M**(IX[]HE3(Y*D<#?!71[J?!VQ*^G;'6\@R7HXE[*8!]E;/BK^-U\IRU!/SBT0\9/6SLS^/W,V)=R<6:Z ,<>;QRM9/
M4G=9!.@__^U:YS^D&=>G.X*<.N8V=GUV<3DD'=!81.>,J,&FZ'TV-T> M],>3WA.QL.E[O'IV#Z75L^KO5>KO+"Q>M7J'75'IR:|%_&99S=L&E?HF2S[^ M.^?
OA!]HDTQP*<;^.3X(#ZWSXY8[;R?R8F M=-OEBVD,+_)^[_])\|\-1#|^K&4^8PZ^4-R88#64$:?T1?W,$7")+<*C2.8V4C'=P.:=C)F7M.::VM5K/EF&?8(ARK

*M4S;^JZN8'+5#%L.X%^3^SJ]1L>C-O/K%&&0]T<+1VQES).@6RC M>[-J,G*J\89KC9Q&F9]%&AH2^T5$'1L6!DD.A82PD6!N4UKL2K%A;Z=,&[@M77&J],%RN\165X \Z@:F_Z8$5 F2+ZM-)W\]HWP:^WRML0'H,7YFM9E?(B:<`M%+QNK>'XU?3;>R:?K@'_U^A8'% %^*I'()@X]FCO10\G,;'C\%,IE'1R#V/Y M;'\]F"?>6;VD_MC2PR#V=>-]2[GA0-F3;/6\[,21/,-YE;56"O@]6[N;>L9[8 MDL,"V.73KBM^G0DU-QW<*YU3'%H,!N2NQ5>G ]Z=:,XP9U ;=2$@ZNQSAI8+ MS047CUP6H@)&& (Z\)?,H^`WT_>8V@GV4B(')COPQ"-R8INOU2Y)/+"BQ-H;* M5,^,-&*P=S^K]/TA@N15"(]MM+7$,9%H7 MD'1#G^^.*G&<{3E? 4=D2M4H"&]SC*Y!Z*%:3DK$P2/?Z]IKJL8P<$P#-6(JJ4ON!NM6<*#,Q%I"O$KRX8YRP.?60[UWEG/O -2'1<_QR?T_H M,)0*8X%T#049% -M]*? V^$_FT/=^!K=]3B=_7+Z1&$3L^ &C_N$92RSMBM5]-M"UIE%M))H6L^P]V\Z\:R!KEQZSVK-V<#.8.CWV\\:3\NQV. OHUDH\HZ,L M[3!&GB*WW) G7:S1384OBXW62%9?4S6I?+!+H(.D5(#D?:7\%>_ YSN#R M8GMBB,6_V$3_>YYIN.B-BHM81ENFF4PXBQ87QJUHFI[#M.I>>"+:BW'([]3B M:KBT'LR=9.9V6&4_EGI-+7=77I#F"8S^GM>Z)>^Q%0 `]F-?HYGS>SRL 6L5+ M*N66$WRNO0A=OA,%-N;F^MN 'L4 TF)5@:3B:7&A:\[V,Y36U%'[\ &,*/ M@Y\,.759&M RO?;0^M28Y(-YUW(GHUEP\/.S DQM-\DH PM6+#-U2RJ9(":25[5CL'C"G[D>S?] M7/@*\!SM4P#2B(=O80L,':R^]TJ;% 6OH$35)\N">DF^MKND\2H19S80>EB8 ML(8WTUDPPL+ [VZ9>4* <.FM9Z<=!#DX%V]X_++;>,GHY\,,Y%).?N[PB#V8? MXP_:\ #HJ;TFA@6.L56FM.P1P67NJ-6B;"'P],.G,^^D\](>T7IU=2.H'AM14P5U-"YHB=M;]_U;+N92<+8ZG$X_$3%ZVG@M/XS M'AU1CAMMK+21.U$7VZE!LM\5X#E, ^3}B^%ZBH6/\&+HQ(3;)6E(9U6GZX! MI/UDYU^LHK$RT]UZ\? OC+FNEP\V.N%_U&E^6%Y35T7$?X#C7@QH2H1E$3=+D M(A?1)_%'N_&_;8>270HBWI'9MA+0'LMP!8P]8V6]9-GRSF!K()\N4;">]J;&& MW?]\U"@SLZ* [/J55C[&W%4#A-._4+6=]!3B_[P.?%QDI> 7"9@GPSF_^E &1N M*-Z%V-2EMRM2_SE/D.!^12.?_?(0.E"KLF @55?1?)=7?(3IP/F+[0D5;[M MQQNKQ%%6B_X2]["1ZCX6*_ C1V&6RJ>^H--EVD;;$-X? Q,WTMOOI8>GK M<0*0vEVM"$^1\Z^W+MYG5ROR#G^UF_BR=I+W=WO=(3KD1M,=9/>(?F)?D>[e'`M^SP?K+$%+(NB;9U7=2@&"MQ- %@^=KU;TOI%HROH-'T_I3,,>SRD:/?*M0KYT+9V2U5T!AF]Y M^Y,+K"ACDESIP=.":*U> 9Z*.*T (^%"E\9]MOOE[1IGZ]S+*W\]MO'_M9Z;4 M/^SP, (7NR>VG'\QA6 X.B8[F]"X%]ORD?< MPTI?B8H(=Q5=>'YZJ5'K->\]NC-5E87?&&'T.OB;U_$)H?Z)+?#K'.6M[<(C M\(QLKU#F6K'MS(_]5AD-D2X : [i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|=B1VAH MCOMP63:!@\/M1.H+BG9X7-RI!PG.!6P9ET-YR&*N_B 0.MF(.&=*+]P<6)6 &E M'1%]BX5YKB*-2GCN'[=]#0B;=!ZJ#"QWTL?!+!^FS!S-:E !J?)Ya:/WX-\ M(_NYZM%ZS/+IZ#!WB@UY,Z]+_2(3MD .6U-&1U[_ V^:+\,Z/M-Z-0 W-M1N9>FV+TP\TRFTP,F#?.:? _LRJ=$_4!5_)S*<|:Y3.^L MK'-F?-@!F_ ^M;G:+]HF4YT\D%&OWAJ%!=K1$-T]^ZKZ\;SO:# M(DTZ:S6@6M>_ O7LB]$A7@6FP[_/3(U"&72W$,.E,>%ODU57_8*L/O&0@KZ MU/CV"/?P5-F_&JC?%7OWZI-]6V1S'\)98'`[ZCJ"@UO8Q"P^9G' QKP"I%0B MQ60>.4D&=$<&GLFS"\'ZOPH+3ITQZ@Q*&M3IHW=O@>1A/SKYU";D?GWN53>[M? GUS7TM3NZY+B'D'+W"-[>Y3(S9OG$3,R74!?PQ^4>ERKNN:8&F'1WAZ_K M8R70PD#9R,AX\,V+6]7/Q=GJ_=D4=IZQ@V'!HE1V8D1?K1-7P3A-B'&4>< M#L,E;I79+,Z7&V[-T-DV?<#2]0N%E2X?3)NMTME"*0B,-C*2"O6*5IHR_O+)N M&;)"\)f>X3JA,_U?7NN.?B()MOY"SV;`C\7Z#XOPOL;]'Y6JF+DWQ22EW8 MG?- 'B1@"=#8.7\Y4/SR]2.';M+P# E[4/5(9[ZSPA4@]DM 1/W ;INP/0K/(*]+>6EME"JB& MT8LHN[I2[_K:O/F>X\6=123ZQ?N9NFK&==:%BT\T:L])\Q1$"E!BNFN>C1AC MK>*QUDL6*9IV8IP8<=PD,T:],&EG=\5OZK?XI-6T B-SQ.7:,3L/\/J&W=@ M-6-I"Y;&S'*"]FKN5E9K)[EOZ%2OF!S=[C M& 7YV]:_GQA' HKHXG?C>US6*10K?BR.S]WC/" (+X2IDM"+1C>8'&&L+QG4ME MC4LFS.E<-36]44G.O=&*- 8Q]ESD)0.!7FB=Y\BLB$M+1]F[T;ICSFF:J)@[M707 M.Z+ZJDIB1LDWXR6J_7$#X*GY;DJF!_U $BQ- #)\\"8_(4:AO1PA+G1T M$4]X=F>MGW](V6"+G9M+5;S0[G,NJE255A99'&B<^T#O)> L?C8>,16-HT*[M*K<@0YF(3K!K45-OQ)2LI!8<#B!Z=/K2;?C* [Z[SZB*"@\HE&N"IM+_ CHUMD0E M>PO(A9@9TXP!B10!(ZL1>]93(ZZ/Z %/%>8XGLF]+/("XE -)-+I2B^)(1KA= MJ?+NEPW8IC>2* @>58?C53[R 2PHV1.L#4B=XE'"G7[F$+EP3_"N81DB0JQ#'V MY>Q SP?/AB^;Z8*BE_Z;TX5&X[SS)#.1;3;_NG"B%>BO MB;PHOISMOPU/;DC+H^YT!#)DF3@K&%5%OU;!C!1%H1GJK;.D4C-\7SXT%N;.MQ8,2BP\3A34U)P8G<<<4]^-1810(T"%'F[T0"H!G'V3/)7<;PSA.41BDVTLY& MMH'M(U6AJI8M$P#>$2!-J2YC58MC4.W\OO7?3GYU#?OZSX.EDM"JX*-?9)W MFR0W<9<\G|:NV=!ZS[_+42ZABW1#.F7OA;.M2]07;OY6$,C^5KD2_AFG.NR1 M;.- ;%SD!3LS(>X1UM&!%(FA'LOVCP:U"G_G&=*P8?_5%2A;^"569,I S?+",R M5>P)CJ *PYB'>;@IO[2(L>N@2AWJ'-,(L(N4=BOM]_$0X93LO957 GMW)\R(M(1%&^.X(4@,88AYTU++WA"-$,RFC/AB6EUA(SG0CLWL^Q;<.D,2HZ2L ME[PN*+),GO">.M;#<@Q>RX%9RBE^1<[^&5]HR+,?&>E+CE?WVG]OF$M 5.1 M,Z0O? $$S^:YXV!;>UQ8<&DA!#3UGB<1]?[OY5^-86@.G2K&3& M>Z@ZP^+1^D)ATG(LI4,0T[F\'07&-02L'U-S#<% MUE703?(#)O,C(MT0[/?]D@AJVVQD0#@U%=_G1K;G,%] (<,R6Z7N4F9;6(#< M5B@&*31/O=O7;3-^D3$_QZ!%3$21@$Y1ZJ,+?%V EY7W!=#%]9??Z.WXQ + 3 M/XUV+'P@- R17/XRJZFRJ$[LE<%&SX67#HNTWG;:97CC3:X+A07X5\!VS'JZ6 M8#M:TK5M3)9M*.1W*J@9$^'"8*+]#=!$,([]O5,_=Z0ZV7P=99\A)B@DUTG M:AV33.Z>A>%8T59M=Y,4KW,AY58&/VQHW;0I+,_YF$0I+8%HEHXVY.7H M1@D/ST+##U6!V]=!D=#^,SXR@R@M$H,'W:H/JG=ZNKM&3<976_,YZ!LFJ82(MDL6IZ+OD3+(]U*+>J&'_JFKE^C/23N^OOZK?XI-6T B-SQ.7:,3L/\/J&W=@ M-6-I"Y;&S'*"]FKN5E9K)[EOZ%2OF!S=[C M& 7YV]:_GQA' HKHXG?C>US6*10K?BR.S]WC/" (+X2IDM"+1C>8'&&L+QG4ME MC4LFS.E<-36]44G.O=&*- 8Q]ESD)0.!7FB=Y\BLB$M+1]F[T;ICSFF:J)@[M707 M.Z+ZJDIB1LDWXR6J_7$#X*GY;DJF!_U $BQ- #)\\"8_(4:AO1PA+G1T M$4]X=F>MGW](V6"+G9M+5;S0[G,NJE255A99'&B<^T#O)> L?C8>,16-HT*[M*K<@0YF(3K!K45-OQ)2LI!8<#B!Z=/K2;?C* [Z[SZB*"@\HE&N"IM+_ CHUMD0E M>PO(A9@9TXP!B10!(ZL1>]93(ZZ/Z_%

ML;B%Z9/SV+=X4HP]P2L=MN-7A@Y&J9&S+;^D1<'AW1&6WV5^ZM=N:# &_AGT MVM360>,'!+\NH,.W?)LF6EQ=L???TP<+'")":K@F;VH+Z==#'C%5 1WJM 7#
*(68%"/UK%PR$HX@-'\ M}(K$X9J,C2RL[9LIQ[M1T95=T,.?Q:=4AA[,H5"#-S(%;K^8)1B<%1J$(V ;%K$V'2:A9*O*
*M76*YB+6CI24A'CHN4HU'*D_&ZN(Z[\6W(!E(PL)TG%86H]?"A%D);V MB6*ZQ]D@F9Y[WC>VNXTV?6\D:N$C,O?5$)!@OJ/=ZANIEUG_-O$=S]\1//V MMM[F]G]!K/N@OLFV*
*B%+BTM!2T#.")(Y3D\)O9][_@F7[>TQ M;&\+D6=LI#B=@-)ZA %](@+!3AFW>C3Y>/ U&3WA0D|8N#8,58N1F'}ZJ(Y)&2LKKL<*E8#QO"@4PJT5&_4-$^[+/GTS$?Y#1=*
MKR>8C8GMSX6W.-)~Z7G(91/,BW(F M>=2NJWPV9DBHG62*H+CWDLAU&MG*R7/MS)?;Y':-8S&-17/L-U[$BP6HBP.=EW%&"O MM;X48CICZ=0!?*
*=#XN_)DB34)3A<<$3 [EM] MU62MTH3@&L30%M7BF?T6,1@J(W,_4SI*E"$0E5*[K\/2F0Y$5=MN'9\#'U0|*R'.KC/LT+^)4I58%N3/QFYH"\\(1C@EWGX-Z[M&V*Z]A;|*
*[S4!"=$ *O_6Z+#GC@#U=J22IE*D(<;H&3_P!H.5^+S,BGX,"F M^@M&#;*HO98|"*OV#'TI?;>^[AT/'H"X7"))]+K2?0H5+.C'<)=-M?3C@LJFO_[4'XYA?U7-
*;VTWDOG)MURWH+*5%8K4,@7Q4J$H7'l,2.:Q MR!=*RW[$P_ ?Y_6#EI?WR-_NG():#N/,4H 5 CD&:X>8 #+IBXZT MN'2E+HK4UXL&)-IBFGH]JEO AL\%=VD?
*&QXX5%YH<<7F-,AY5B)[4URZ=U;\-M&3M[0">Z[!5GQXDR(Z7;!,L>]%>_#_@+Y1K[TEAX^#KFKD(U_TV3X;Y*WG+$
MBV"RRF?'B%=T<\ID2_K6CJB[4Q]Q75]^$_WQ2UW8VO,W+>DH'5V>K/)SZ15[M["])KXUTIE=2=-;VOF0 F.:?H X??C0W%6"+MX9'Q!; W$%B>%)5%@S=T-Q MP'-
CO"S'KC9.,AT,.B:T3H=30.G&ZO1"3Q"X>]5VPI ;87!&IH][Q2@VD<'MWUR?I_<"% K,/O38;QB;D28D5^H]#F>NUL]@4W:5+-*/'YZK56UH14^
*M'ZW],5'(^RS'=A7NT(2Y1KD=%!T+KSZ>/_P!^'#N;QZD&W?PY8]>1=$MVR)H[!IE/ M(1]32>^"?YUF P"F(Y4_>/X"R MP,4,_'9=+++%K;)H*V@#U.2[P(W\MB&3K)2ZN M-
S2+&$2ZD[9;WE[853_;!T#P=,..3$U'+01'>Z6H6O$A_QQ9K 4CQY.EW>^ MS>&WS9DQ?+7Q*75L$@ID09B+I?"Z$>;6DH!69SG36E+N=NLAF\O>XBHA$']CV8DPP^H7
*MJAP>[7C9%JI*Y7,C?E+6>I,QLT=:XH[_?>]=WO9+ M;P:<911. 2, CUA&VU G3WNGB"3+KGC8 V%PL+U,+LSB#'H@^MA8S0R M_RKH(7Q]>G%G7N$E10G%L10;
*I>#4;A(F!&F(DCK&^"1*EPFK'X2=LK\ VTA MUZ^^6M PZ\=H2"MM2?*2-_MBNGZ.V/_8MY[J%!U4%E08(?Y 5V?N\Y!UEN:0
*MU7TKK@1]H=E]CTD$F"';^;NX11[_;MZO09=@LUNNW^.S;QX#___'Y/X?%^C/[\ 4$L#!!0 (+V!-%DC M3HEUIYD #*W 8 .<6)1;RTR,#(T,#8S,'@Q,&LP,30N:G!G[+P'5%/=
MMC\:!"G2>R<@2)&B]Z 2A=!>A&"@M$H+0 @=*1WCY 00=$7^6D2M<*$*)"0)C^^^^[OW7/NO>?<>]!X[S_>."M[CF2OO?<>]TWCWTP_50,]= MTST:&
<91C]7KXZ[101-Q-4+V]'+DXR4+NB9A'2X^!I=]X$SX]+.[VT@V+PUA M;.#:?GRY6\O[CB^H%9H1]YF[I%Y*]T^>$/331<<-!%7]W.#Z"$W++$OV@
*M@%W.?,H)]>,5]MLTGOP@$E24N^3(]7LK\$5=^CG@"701@BKK&X,TY;,TF=# MS'N #!VR(KBVY78H_ PMP^33;J?[_2.7%)G $=G)-?:>9<)S#,<;S[60O)V M]
[%N5!SSUL@OIALODR ?+-'*.BB^FI<5)/D$M@6_ZK0!Cf-_G9B!FG&*^)S@-MN/.53'AW?I< M3V2]HHH#&UB[UAPI-P2.'< MK!WF L0]<%P*-
*RL;R7%'D\N%7(O'XKX.@.T_(^LOX,83[&0-;7@9W(@YA//- MPHW>5KZP=Q54+RY3/^QX\PETUVE@WDF?:SBD)1+9F&)H#(.O[_N>0?O"7K+ MY.XWRK2L1{ZH>@[(?
*CK:R$$0)Q\3KQY'&8MLQ=F0)AM(7YA/2\||:.)H?3TDG MK]ZTGHQ(?CX'N$$7\)GK/ 10@6@?"[V%MZF/MPPE6U+[[!K,,-1_9) M5ZQN(F6Q6_N^M,C40]N'$.M;_?W=0!^?
*UBKEL/U.?IZP.ee:=8N/5TUE\O,FW MN+JWS^*RMY92PZ9_?5_!F/(.0WL0+ >$;ZL]_D3[!M\[!LS;Y-WT)S@6'V_M MA9N=E1)3]H[T@-
*!4'5^QP07'U#4'=3NL)CHU)F.'+=#A'DX\0_DQ12E.R(:[MD'T#V8A$RWMA@&OW\M9#Q4R:L*O9;[''2!I6J9)461=+GV:8&&(T9KPC>2LW^<@4*L+
*&4*_%&)%8!WTOV)$ERAUCURR M^%(UXRWJ72V6^SIL@/\)63,&U7EFYTN[UPF%WVN ;MW2H-8 <1Q\#!!(' M@FI1A1T-";09HZ T-1!L8B5YN#,.;_^>@Z+.
(WW(MUBE>68^CMM;O>4$C^'_4#GAOF=)>-#*0 '_A3T/@TG 7A&FK>&: >R:S"Z-+93N6 25[!H^P=,"M1O9@=+%1,ZL!,NV2KM-?F(8=A:,VR4 M[16)53EL0+Y:CSNI&R?
*<3P#@(22:M3,!@B)FL =!3C!#'![Dn@]KJ@P0.3'.M M?P%#:K=0T"R&,=6!4,G59&BOFLBR'#XC%QI%>.:/+:)T)S13BE M##)G\[5[\U!'0-J)XI].%ODAT!4034R@ KZE^Y?
*\%5+UN"?7;T MJ7OE%P$C26?OU3U&@:Q5'JJ>&IQP.^+K,#&X!3,_E;l8?(>B0$[1-EG-:\-T M6_U8A\"D#'8M$?\O=?/E\ "UJL3$,2$L0X84[IYP6_R-(FGOOE7)Y!4)L?I^
*M;PFZPHK/&I'T@# O"_RD#[C B"8KA<.F-22K\)EK@WV.M'/=%MSJ8^ODU[727[?XR\'^)=2,6JTR(:T&2BS#?3UT K,XY(^9[Z4<7UN'X?5.-+
*M4QICEE++\NB]PM\2W'7EKVJ3,:=ON=?W18M;F%;J7>9B _P6+PJ_"E[_*_H>D<.;MRAW^.$^=]WPD:?AO!] M*C/.BGZ
*S85GOW3A0Z;08[,;@=TF5#O+LL3L_35GCW;;#N*DCHT- M:5\5-W!L:&+1$'X(76*1*Q/D]U/A'04MLUL8EAL[&?]\&L_/<;U=YH]P4/;
*MB^6@3U^9N"=^VM752',*6@67QFS&@1\AYU?Z>*!Q7M(;M\'QTH];I]XVTOH+ MN8=Y[5.B;E)1):SD]4/H09?AWOAU*C3-ZNX;9PD_WMI4WA M4Z8XE=-8V90BL.6UV
*5O0/I5F^(?WH#KYP!M@V?.I%5]/{0JA)9- MN9:M.0%35QA(G!#=(.;DW 7DOER-Q4RQQL<_\U;K;T&^U/NVB.3;^<CQ\I^C @%KYMCORZ(2Z/!9-
*OB=POM[3D!Y'"2SQ.X8L7L?@&C_.!0?].RO.L&@RBP)=AB %Z MIX7]N#)/Z0_K)+Z#Y"?TPXO-&.>QPS36]2WRNWQ5U#J!U(XDU MQ;3H<=0X_<.A%K#5"
*[BSJ^A[@OTR+Q$1B >>\[#G@ M03.:>+TIM1L!V.YBA-(LX"5[,;'"W_47U-S3$G6=?%O[6]Q5]W7=R%]@#F*0 M:Q@#25ZJ[&,K\-O^EEEB73./F9BG##$2>I=\\-I&Q^A,S^Y-]
*(/5-Q".M;Z*JJ MV3%<$3?\<2(6*9$;-AK"=-]PHD)VN M8.3T']*)-TBS(*9Z,%@RM'8;!V006/SL)?/<^?#. FTK/2%;&[N+1+#?#^:.PY4-L;V M=5ZG4[Z0LU8&8X+
*<_U\0]ZMBTS^IK?HZ&+\0"U[08QXEU!BP]YW?G.[%'+ M5LY W$'I+>?VEWX9EHMQ"%R>:#A8!>X,Q6SV(9L-MU<:'7;L8=V:DUXQ"M'3>,.0N7N]G4Y^\=3;8/&50MACN--
:#MR9K]A065:2DO,;T MZ)NJC?B>E6I55@+(YTPQM_WIC?^'I%+W D%_%1\!>B75EH0K<'+UBV=3\.IS ML0&.[*A^Z[B/V@*Q+"[OMO5/\5Q>SF12YOTEV)%8>
6<&^A%)3@[9MD#=\$K MK]VD"-'W8DY>U'1\MHF+1,G'>_W@Y$E.]$HUG/!Q4]+7U<4VN]"7'>Z[SI'}T M_=RA;.\XGFD.D)QEH"6J9,\;+6%.Q?)O1UDL12DL;V:.
*!VET3,AB(BS-5 MHJZ N@!="]3?ZX^U.-DDY?.6;_,+)A$ MH:T.S"VYM!52J>?FR#?,3,),%!?PO#BC&8)DZ)GV]%)[V0B2I<3U W_H%)0 MRAWB?MC)"C!P(ESCH+^@I2Z)H+
*<*C+)"TG7PE^T 64 BBP8:2KDEPSA)]O@$ MPSUMLUX?$9-%?;U M1#=4K=|;U"&>[N8]?V+&$AE85C 0<**/\$8D+O,1\X_]7CB^8')B:YN0O(Z+ M[LMT8W|-
*+Z$!RP)&V:X:CY]7MFK&'Y@-G9F1)O(OX>M7(7$%+'#NU7;5#NM-M:D5C4=ME42'P]#F@6IW?@%LCDI%]]TN.&+2+&4L."# P.IB' M"3;$YXKO%TO'SOGTZS_2U(-
*XK/LAYQ;7ZO+#%.%@?!06C*J-02EC&I.$)ZL5 M-B-EN?D^1%72UI,_NZY&)S!%=KHK&K%^AIA/'704!@$Q"=MJ<4G9B^8S5NXI MY2>2SU.NFM[KI4Z+*NC\4M=^@/1
*+EQE3 BV[KE!@]?KYEP6-;FB7?G@^]*P M3 ,/,:.SW0*K3'(]R)E5#0]2\UMD:EHVNP1F:G=)67^ITNHTN+ MZ)EPD%W]16N1I'&0(-ZD%G9@@@]:W74
*=EL_&>W[\/W[MU'_ZUU\]KI\3Z^H M90RCMQUCL+ND*V(5L.>'GT#\F$

*^V+9+)(NW9IITNI'79$!$FP2@+W,2-] ML<#P]7RU5 92;[[@,,(5F+C" .S+=9V_].G]EO4)XH2%_M,*Q;0/0CD(%@M%K MJ4$4L?,Q#!$!,>1,EH6GA1?D2&3;.LWHU%1$Q*N
M:D-Z#;P1WNN(O]YX\N ,$*[/#3S+9?CIK"KP=NO_^0ZH9)-CFM4X3KAN#Z M358/%HW6I\N2P[ANI!"8US3!O1#F=6:W!5YSKX4WY#M]HFR9#9IBUIG9;6>
*M;:DX1>Q&RYD&[*Q[61P;& OML$7Y,_<&O<,'\X,F!FYJ_^J.5O%&BE_U)[XM^'+R@7/ ZLL6 5 F MBG/@>+:Z45QA8'8CY*0^^_;U'?5%"2X-KF?
*(S)%GD,*FU0OOOQ+B'K833S(!$ MESWLFO)+\R5G?TRC9V:4S2_),M>?^(,5O57]8^^+N;O$\&<5;KG6Z&/.!]M& MUJ
*;F:A0W\NGR&S%U'&S6R_COJZ4=7FB$TY.4"M]HRG&%&@TB2R-R.G5=7 M>I$[9RX MY=RUZ;?V3<#*XY[HR@ >NG<:N9XRPGA6"LQ+8,>3 M%X6,W)A-
*],K9;=@YH"=,#!L8 Z+'(^YCD+%0;\&NMDRS=)=6_9?[3 ,V_-VZ M!]=Q3:Z[0-[&U*2"IL"]12S'@,33HT7B)=*.?1##9OA;(]K@ 5-8AW4>Z6L! M+<+MQ@LP=
*<>S=P1E[&!L(X)R-TQP2N[@H\'5K MKA%A(OA'BVO>]2*_ND7+W(6FO#)N9T>SFP$T:5W.'G62?RJH#TR$2Z,@\V?W MVV,\;! B@\[,798,=3FWA VL<=1&/,D MLQ#6T-
*/RS&[WUM23Y+>? UB/!;AO"'#7+>X-]OU!-)>30N4^Z6[QQB6-8$_|^!XL*F)0%R5T)&> M'!,^=DSIS4;CRM89]>B;Z/4RS$8M_XQI4OS1?C96R< E\(^?22^!W\&,) LD
*MAC+4\'XI6^FI)/LA\7!R+%2[D%$)ZXKVQ\;A]&)(2@1-+%5O.FMOV%7.1M3& MZ)4=,Y7'SO$BUF?O GX5 I_.YL O3=N%K.RK$ES7\A"-NC*QF17V.X>7I"T.
*M.!XGN7",P$2[(C%4>_;8(TCK&[?ER8V)_9XV>0AQ/WW. AW|B>E\16N^$S MGA1*N=_JDQfP^Y-$\;/4>?SR+H\(!@Y]SE^OT%^_'J6+'ARKWH-!4?V AY"P
*M)217!P280'#&S*ZQOW9B&GJ5S>R_[_#$%C[]f&#F,\04"D=$#@?D99>[VSCAF($?^2WHFTXP?60021@ M'M_P"4)'$L8'#*Y!XVLW6I]5V;5[\ 1_|
*[U^QU)?]OOWZ$_'F.*PWA-'&G@_MYOI9;Y-.N:@=U&BIG8&T]K6'BB2HT7F:+"E7\B0@],GEL%ML<5] FH81"I!
*M\Os:@ANON^W4GGCWS;OF=/NW9GWIIVFA5=L>&,9(1,/R1\SD^DE_';\'3VR! M;RFL"R51C48GGH[%\,7+%;IN&8<0_^,T\AW6$[>'H"+83W4!+P(NXD67A,=O
MJ5NAWL;L?>Z/RMX47U^<8UBYH4'N'0F$C;+@S!VD1.L*GK>4O!J$42RQ?I M(]3,+ZM\3'NAA"=/.U.9ZBH?'0^:HVI0$5PDF'@YJ^6@(GF
*(<[B)=]$I>HJ[+00AIOBD#2;>AARBQF4?)N M&;MTUV*)6F)N7>F6{QFV0*_X+,\7D-Y?0&H$K6FXXENX%8^ZC--IGJV'M?
*M+'<+*S%DQ,4=1\PP$%F/&E%Q$+YP^6CR,QWX$WP("IP(8A^#DZ^= \C;E[2]-M!9+?UO(&G]_L>3N>CP>\%DGU1K[;O!#8P#>04+74.#+ 00Y]174E|&)L]N
*MND.Y.M.S3FLMVLTKD \LF'Vl,%^?,ER"P$9L\#N87U_5S:PP*,5/HKBQC(F* M]$I<3?2W5.NNIO,!ZC&!EVP`_DVMQTO%# 1=SBIX5H%V]7#SD;ZI\;\GHU^ M"FZ"2C79&
]\&UURCTIZP:60_N3>7L;/.@&N"G.3Q4J5#% M)6W*8G+J&A%_1=78TQ2R4SW0!'8!%]A5YMH:C\56+82)N1V!X]0VHSCO\:_^ M7W-ST3'L-E.JTU/U93U-
G)S1\@)5#BX@^AS!AH(5-A(&$M0QQOYOAL^B?3S M(V1/2X4I+FE?;ICHZL#&]>$[U#'F5MB#*^6_NGD5?*DL8 IU>M%1FJ\U&0-(@ M[!'E@E8',,,ZC"V5!:Z"I8J5+HTR^8
*<5P0K6TRMZ_7=KZE;N:4R\';CX4K! M=*H C.,Q3#Y5)?XG=VUE3V< MAO7C4@\!J3S#<>?.,[Z6ZRW6XO61?5\B:=%# JK]<-/,66_P+%KV'$#1%W4Q
*M)'H1TAL0*T"L.7(&\4>+6>8Z)?O(UK<#Y1!33CEWGC0-3M\#X0&%M7#8XGL M;=:=DF%'W>@RID\.I#+*Q+8(UG&A_EP^>73;D' ZP>,RI[D\!#)=>4:M:(E >0 MZ:ZK2]
*(U*L4I.-O4(WSF,>_R -^+>L-5,Q#S MUMTJ#)CQ2XF>K\7H6P+UCD4MXY0IU?Q_NGKQCY"9W[L+)"3Y$BN66JVAKK;X M1\;^;NVO=&>/&U7*VD6-
*MKP.0FTMTC6VQOV=X\X+,W$2U19X+?6U+3]I.^NEI:,Z9NA>&M7.B#!%;[>*$> MY+&#86)\7!^T4[Q_S^,B|<_KITU\?%>?XB'--M]K9Z_F6<5+Z0TI@MD5GA> M]
*(673DIEL_!W*F1B6?:M,I:7V=+/(7BC\LTFP ZY_ EE&T^,4N[M=Q[6W'QH]K0U.RMB"OR+D\)?WYF/SKD+WS-FFI/(+[0PX:P<4=[?-0]
*M+X3L#TPB"0[.ZT@Z]|^XESD& M92NZHN'+]IH=27'%7-\I H+%6)??VD:[-,,7+/>.UZ_P8;W MV)9JJE$:&_92[_L0\S2E\E,4?O;],.^%ES1+73#2P>CUI+(2-&?\&)GLEG>;
*M=37!5ASC506R(_]"%'D1_-T/9A]+AQ4L+.,>Q*Y]NX"7B!@M>@+D)P+5A2%^S MF7MN2C%[9X_>._LJ.=;/%*)Z4]9HGM<)I"<@,OR0'3X4F]F3+S*M,5FVG8/]
M_DW088+=(/-Q85T%5E4$%G B08IPV08V=S;%O>;EN+$3G/GE-$&D6?_(3 M$O8"?K,F31O^BDQ;KMQ$Z+!945R^4)Y_A*@]?YWA3B]&,9Q@1XX,F(Z
M%E3'.2,X.231]D^>MEWZ5\1E0DIZ5+&7AN,AM#H]^184#0Y(=*0]-6/]RP M-4O/-&>6VG3>[,IC'QL^1S VPA-70$4V,,)M9=O%YC=P=IKEE8PI<*6%1>Z
*M_V"\A$IYICO20T:G) ^N"5W.#(=%A(+R))3X++=2,.=*4)ZUI;/=Z->.?VS)Z+ M9.GUB2Y\7F0?P$,DZP\S072+G@/<^=5!0'QY:V_*8OU7F&&)YE.YAV&OV)XL M+_!7OOL9Z+]
*6>B&?ZE;H9=)%R_^^C=?=N5UI{4}>X'*C@GYM!AIJF 'N;= M>V>]J4)CZ5:(.*'A^:F8;[C//8--_MT/10F?T[EO7ZB-!K/-!;YUC%C-LT5W M@(ODSZ' :.U4^'CU{J-
*YO)_9QGDWR2M=4@11N&FVX$(0%> MV:M' 1N9I^Q#L*A^~H>5W^'V1N18WOX\-)8?!NGM#*)U5N#+84CM5,/)IW6- MW-*%EI:K*]Y"P+@L8]DZ\,C ^.E/] A"&NU5"
*[8NF7"MO7=12\W]JH[9!E6 M^P!-/LD##IHIX1\-$Q9X_E.L>W&@D^W4OXF5;.0(W2]W'L3,IUCVW=XMT^^'
MF;A.%BN,J56_"$%1WV8C=_:GUYM:,KWX(&&\9_)V3Y)*51=>95[+YOXUNM)@ MOB:U!&+U(=FBZ;O@S<^G@\(S548H+SF9%@_$TF5D6NV5Y9GE.68ZMU<_T.R
*MT&\C,A8!9O@&$Z;XN=F+^O4O7>10R0I0YB'W+$!Z@;555YFK0./E9X_RK*E#@A[7E M@Y&/JZU-ZK&MD=ITU8%,NA8%=J\@;^^WF(=CO3?]D/I3O9W=KT<\)5E;8[ZH0E
MPV_B30V#A"-NJEQ$0HE2&_TW;-]&AW!PT;7GH9]V-#V'+4?>$0;?MFD_C@^*_P8@O;]@I K?91Y[7UL#8UM,F+ M'_]B>7N>3)SS#GA>#>>@(_)F^3;I(84?2_{]
*<_D"KB=@M&?H]SQG; M? .!X:DPU=K4WC"52<'=92W1&3R#5^E]P8D)!LK/JJ3!/E_(MW'9NZ ?Z0Q7 M6LHU*U15]A3914?#BC]&UD;!9]?
*JP/6*L92GS^I_%B=&X*5P&!'WV;2,W+, MY?XV"RT>Q)+..QO>,A(>Y-WU<3$(E)#Y%C6V$<_R.'0A;8BOX(9*%5?)-M7%H048.D(%7%.TWA5N]2@>]
[935[Y0M"A-31V7=][?(+!R;/;DKF)'^XG2.NCD7IF\M5/;,B>O -+SULV1Z MEB/1A(OJZ-1"'$!'YAB',5K?C$2Z0>@>X*, ^+13OM%DV3=H:*&1/:-VI)!-^ MFD"S%](ECH2[X]D
*,PEY73S6O_>-(IK&B6E[;8>C$R25,L?PJF /CS]!BE<8-<>2U;'5&W8<#? MKR:,;Z:(FME]XWFPD4-&MXR&^/0(P3$L5UL,E6"V7ZI0D7=MB/A"P@ATAIT, M!ZT,0!;(NX&
*/87$49Z=#/>-WS5S'QK=T"X%\#*N!U=?^_/E7R\6?RI6PB^M 7:Y0)*DK\MDB;KC14:=%'EN6QYH.83>)4?)>UY1$U(E@!T&?\4S=O=XH. M0UFI-C>
[]+O2C_WN]L0_F13Z1R7X7]6+Z]GW /\F-THZ#7!2]U+?;B.]NPM M8&E42M2/N1]/>X/K5Y60"L]^DE(@'K7%K?+!59IT *^F[*6Q.RB"YL19_OO(>2?]HJK*?\$0-PG:.S#_
*1,HKU)RWA>? MP?UA22\\E:)E9BR1E\]BK[]2R7_T/);6D M66'?*MMY79'VUHSUU]%9MRZ%GN46^Z/;8!-%,!%,]DA)2=WQ0?PS\]V'LG\^5 M IMB4.HJ[5]PW
U:LA0R+GPM8I^]E7N:OJ[59\IC]R M+W.\$DU$?2'05]WVY; W:77*L3]]R%6;-,D81SIQW%.PC#OJZ5-R!.;:IL/I M^$ +;-/NXO;]05\ZK5UD3/A!%]HDD:DDK62Q9ZRD#
*M)?4I)"RB%T5V%G?,OW3?G7);R?D,?OM.[-2<)TRG="R[]>&&]]PAPBLIO0% M\R =XEQ?HMU2(FGT4OW-F,@E7]?=`", ,AM7TD7C5V]\K.H2P]!; MXI]V#?M?
*ZS,;$5AXDARKJY.'3'Y6@U&^TY8T&!J2Z<',P"S6IJ"])2GQ$6D6Q-OY;= @S^2T9TDU,*TLM#_G%-4*9V<;T0V;_2V\60HMVP%
*M[X+1[>X2K,)5Z9KRR+B65[EO@^KF;],]],X2>;T7G27"<50[LX[SFOP!>^,,? M\DL,[B#7?=U*JC.<'"#P>F8C!@/4FE#T=#!$>78:,GS?U_GX["?YW!YYB]WF
*MS^JC^A72$'_0XI&>9A&!.LI\&C1>Y<%]`I>?G),&-8^>-:$P1KW?C)5"TMYN'-M!LREG MA2R9;QWL65]0>*A%9?Z<3K(BC4 2V9"B4KF0 8:%]2&0]SV
*M&O$.UO;;?,5%"Z&DN#MECF-"XS^0.B'%D:?G .$OUKC@AA%(GUHQT-0489@:-MNCSL>F@#:[=L>O99.A98*CE=7CQGOG>C%]4VA(\"':#!/!FYQDG^#")]H<
*M[[*FRCS23*U;=X!$:@1ZK8O+L.[]VOZ=54S15M_*!WHL2R4!.*SN8OR=S9"0C."0^U]79R7'[I5(WKKG+MKL:;2[Z%Q7E"#I M^T**%.E\)U*B?B9D>ZZ'I$1@D=
*MR8^,L$V0(K[ON@FGN!AC\"J8:[C0[=#1P/,:!UO[NW1E@.9MB>=O/>Y!]@5$ MJS>D,_2W1 L8+LF, #EAG ZUXQG\,Z%:!JZY"KGBR4@<@EV#V??FB.1;9,!DL M[D/S3VN/
*Z%GD;Q)@75!YX!83CS9.>!.9L*_I(X,,:!)/#XS @Q;OSQH@V'-MU', 5_'?U-3-W\ _1,P3$,/?,"TD0 +D8B\<>&2@(7T."+\;#N8%KVU &EN(M;(L%!/;Y

*J7?+N/E5AF_NH38DRB\N;/HVGG!5GA5<.$'_#(!,Q%[&:%\P9#??" M3#7_4,_"> @3-^FKF>#O)DCOD\ESQ1)W%!5]F(+":TB%7J.C)B[875+0M@1^+6;,*8
*M\:P]7<#.IFF.T'MW0W-&FKF^NI"W(]G(3D<0"6P-N,R6F*NI*(>>@01V"_ < M#;)/YX!LMG, /B@'?>$!=)0VSP&7 \"$1TAG*<1#D _#Z>?N:P1XHK<(N3S$C MG/;0<\%,V?
^_'> _&?G?EA&>40+;("Y;&(AI\$9@K)TO+$5RPW/Q2Q/MQ)I. MOB\:(R[IG\E]63-@)XI$=N3>#0R5^V"/";UK\U;]_"P&(UP,8DOX"))X.-Z M';DQ),/8[877N$#.+V>=H*F2I#
*(=,RG0>ULX<)"1F6\,]9S $P%UQ%H7ZUC MW4'FV,ESAUX5*1-G(6TI[9*&+DD>;^*H_F4J5X_XMHE:0QU5%SN!T#9PQOPZ@Z7K?BDK+0-2&:
\9/WMEG'"1Z2>I,UOB]D9L.T'9]?*6?S6BKO)!,BT?A MSTGT=)07V'+*;UT@M:+V58";/B;>O77+=W)'TC'!V.&F?"AK20!<"Y?&QB7M MS:P\P/+7)XB>"B>P6&*7P@?
*M]C24,0W:&%+L@]_MNZVL%B/IGM@GFN&:X5N M;8<8]HQW; =3V_G7]]>_A,@,W2;_BQ&-*I&%*L7U^Y MXOZNQI_?U?B6BIM+ECW0 \50)^,'>?"XL^^?,'CM2#OOP

MU/P;F1L;]2R_^U3(\XOS.RSIQ59$$!]'T{QY^K,A5Y>&P2^IMSI:.;]_B#ARW M*P@:F)'&.\C21JR?4%+\.ONVGN[]_XUT;$(>D^[U+C-'1.5N^FNQ G?WL,B MY>I+=1_GCMU1V^6_Q*"6B'Y$^AA<%D,'8=20RX7EH3G-5'-1#]-J-\<$HKC8 M)SSL'$KK'TN_0W<$6DTD:9C5:M?)N75=QX?\U)N$ZUPZ>M*C^GN3;\H,5H5* M7OWU$-/?69RO,>Q_Z>1GU6.5 8V.NGW5LEOO;-OR)Z2{6NIO:S7DK,7UO_"S MMUWP$K-\4'UW7]}IP:15,.F$;J&SMF/Q4P%IDZ1Q*,$ %3+=-<-MV,_G*L$ M$!, <45EULDQ^2&@EUS\BG]O=;VW_ZUD Z;*=G?{XAPV'=06P1 M?GT5&=TAM!YJ_FD%\XVBO9F8%2I]_7<3%UHQSW'0@>{YI_4 M1B,)D>KQ, >NTP/JY/ 9N!3LS,?I*C6ZN}(UB>^1+E#'O*ZV.?$WR&TYX=[8YR*B#PXLH)$%N,8G,G M1M@1LU&P'C*;I36/,0*'U13^=H0'EW,'-5X3"6(!5F)1CB=^M/+HRYLOO^& M@"/L<&!9:9(AW;>ZWRTI?=Z>/O_*D5()40!K7GOD/;D'KP@+1>'YC.?@#" MI=")Z$4R'HO+^*%|_$R|(M@[2A796N>_W4OTO>6_;$:R^=ZSD&UK"-W1&^^5 M'N5,V* I5AYF#!=HJ,:KH\.Q'28.NQ MN6QK'^H"Y"TIO,D/-^#9SS\0&$8QP9:QZ;^:6@.3XTV,B3X!5Q@!)2.2>Q4\# MJK%P;_+-@L66OF7A*%Q &W:V%_EB5HU"S8#SEA=UOYP'X+U6K+=/84:88XEY M&#AL0FVP]T9X&-U[S)]7*ZHE]7'7TYAC+LVA+,#;,VY3DIX964P;H*_^Y8F'58 M\&JH"L+5RWS-.MJJM_NW"^:%EY7D(Z?F2UJ;U"7^[@?+]6"!#X&?9>|\&XG=-MA&_;U^/W8%SCRZ,A^T7/LSPM@(Y9P,!NFF'4B!LY(XEF$K7"!AO">3=V8E/: M@U#2P=)FOQ9"=G'_$VEQ=CGE;Y]2U-MCMP=|\$T)LV<\,0%/V1UI^#V7W?[3=Q/K!(E587(]*V0@FEU'N7&%,TUSLP]N M&9*>N=2.(=$8(GQW60N0S$CW!RU(5';TA]T0BDV6;OS/UQ0-[MS|:,]"L MU>?]'+ .J$#63;A!K.VZ.D0(X,F."\U]H

^YT6VG4I*S8&#P"C%-IU)A{C56WRX%/B+]E1:W=D7]-$"U=J0RP!"\K,&{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|3|&\STGA M%>--X8BM!D_1GSMP(XRW?)OZ5>38l,Y5F@I$14"_4]1OE#>D[*=''2MZNSL:TP_[NB8?KD_,(HH8)3X3@[-KB MW|[7ER+FIP# 8X#NL+(+M]_>^B]2@G6.CBK$M_7HA#9KS"W?6D%*Cj6K0E# M+^'VT>P#^7VS(&47G1)!D5F]8[!5,S)IGE.W:$-!&NPZ? $P]TM<;F:T)0F/ MW!FKFNXX&EGY+%/Q<#GFVI]/^]M-93N#:%KS"H]-9H78(MU]8A*E7\H5#9'3]=5%\V9]X@8B_H7@#_,9S<]<\I^-U&/SO.=I4O)A_G&*EF MVSNSDVW@RO/@8,3&[;ZL7^/OAU&HU'IZZ?G&_;#RK!\K.29'@QR9#DDLNOZ M6]31L33L/.D.33$Y<=E0:HN3]R;5'9.KF##,$S DJPXE1N$%B'G>LLK"25G-(TW N M$ Z>>\P.?!?!*M2MO#;2]/(\7/$)_ ,A%4_=R:+X> 0KA67X<2@'K;X[%;_|\M2U6P1]J_52FEI%';D_9V[O4=-%PHZ(_WY!6"^M4,9U_,^0RG?CZE%C\#4B$LNF0E!=_^DZ M/OM)ZYA^Q;YY_(Z[Z|!VAX?&>\A;B)XNF!"J92;$%,3;$H;/B6A5)7$^HC MTCQ 6V/+VG#H(76# _UK/'|]2YWY#:SKS,1O4LH_/ T48 [#*U|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eI+C.MH8QV2=H7P9RQ...>S>48A4 2 M<4T6P?4H O !D<@$I<+4Dl,?#RVQU9_T'B3E N=&*&ZNZ[/P6Y M7Y2%N]#:D#=GVI;Z1B[%WSN\ZAVMGC)Q 34M9<%IK%/[@_%JN)=.^;F% -A;)@VF 'WFF_O:7<,LBJUN![F1%&9X+? <-/ M=O.)T74Z7T)9-IUO>^\[@G(NL9YV+!4X[?7BQ\6Y(FZ:!JBR)B\U?D M$[^3.*U?;7T2A^\\6A$\;WI>/1X-?H!+ M#)2*)K=Q.U4)M6 .BB"GYK(HW/GC60E:N=&J3.IE?? Y"F;17"//(^_+ MGXC2"5O)^]ET1)S=6HF/78^?+M+Q=PHQG1UO-CCACS5E;+B!*63O-MZ)K*Q],[2,S3=%4 5GTMM[;"VR16TE;TLI\\/?.\CLEPB:#$;G2_'Z22U'S+ M^(WE24J

*H^=M%R*R1VCZ%4C/B!!H DJ,3!0 M%M'Q8E,,/3.:D"D>CZ-6XZ]9-]-R?9&N8!G*) -=9Y') 9IV_1!NMVF;!0" U"P8=`=X\%]=]OA5M(MXY0T@*

*M,9WZXF&!2\D.!>C;,=M_'>,,K7J(&44[W84DX-=$\[';%WT>K[M^!"*2[_CZZ_;,)XB*[#W?%^KT;>LAL;`[(W0P+5?+'!TKA);M?/$ MJP\2RWM+[(W$W(5)/?_]^(V"[M,G]2Y&K]?Q[D#O8[DLE9)6^%53--!E1T;%V9=GM,\^?7'/K)?>5;>F!,)E,@S!^BEQ>I] M-H.)@\=,:'7N)2F$-X";T;@*D,V#?_VPC;/![']FB]7*Q_T/""WJO?/2+B!^M ME58E?*

*AG?!=Y+ZVP9I*4VU%C955;_E;0QN7&;X*EC;,(#LD!O'+ M'PM75A!NJGAW2(&*=O?IS"?D@"K-1D!!+]3K54442NZTGN!?5BM6881G8]=7-`M4*$;0)VG0>EVJV5KR5*

<_D\S)J<)>G6;N%PV_N];T0(G]]!DGVV/*HM+=&T M,!62'.[JR/!**/-\^Q(4:(T:[P5&SP,CZX7]?8NT?DP4'-6X.L; WS!\NU_H MK;]1KC=H"P1M=XJ@9B$5OIP[X]VPD8H72<*

*=$P]?WWH$0;,;3[2AM&,JB*2# M6)+M">X65]RCQP[9KY(E^ B51S$5A(X04,)+]1.X\^]/" DS*RFYMJ$)GY#*G M3FD7WX670"0^Y5NDV@[SK+,W SY:1,<.E-*

*B8HRHYN@%9$WDB'BS=>^(Q X/~M"6>B1YE$?H?E"UTI-5DBG>,Y^$M+:FS:3)$^SSZO;G^>N!(=+EYB]>D?:F# MXG#]8OID=SHU;5LU#*7958DGG6GW1#=<*

*3.WYV|QO96+H!,#MW\1)B%7=^P M5^20H9\P"UO =H'E_C3].8H#UGQ!S+W<6:,EA<49\RDZE20:JVE'@V:Z-H8N MA"R-*GQ(Y@6+,A/H(T0(L]/UXVG^U8F5/1.?*

*V^Z%E;VAMG6F7;"U-&;7^9D_<1/%7F.PL&-.?'#6NW!^DXE"! M>#_1WW H0-^YXN.Z[+]O6T=N3+5M4%.LF(?@15A-LCB2U*DEGN69=6! MF__FC;.BN93[@+E()4-5!=*

KVYA#7IVU2I^TWZ4_\GT(N:K]&T621)RM46SX7$K7V#XM*5GHP M,./4FK4L"5K[MUNO_&AZ;P!_Q^$TO8QN1M,G9$2#^!=QX,?%9Q1:R?G2?6^S M^5)AN3T=],<|

*(2.!#=]>$<+9 X/>FC"6 ?C9/ M+JN.L%GZ4FBYFZG23$'=;$ROOLQ?6CO7&R@6X5]?-JJD#D3$5]HP<;YX'1=C>_SU#GJ2M=*9A)5G%9K6Q=8I+O+%@[!GN0C*

M[AUWZV@D,VV@%Y8#KAL,XMMYV9/+C;K^5ND!P0:H_DA?1@S W.HN\A/Z8-.M'2(I>F\0\[?V*E-(7#?46@3%5/==]6U(I6^1'IHZI^+OXZ<_TS6/?4"<]^GL*

MWF1G[(@NU\E9K0(3@/1R0EP?_^V9/^-DX6VIQHN#CL+E$?FQ@G>T=&Q-H4GW MM9J[^0>=;.-FED0S5?2, ^;>@% H<./6K IP,'$CF3$^=O)I(K%F\.%1N:2;? M/[-

G(C$WM*3ASIO2MO!;T8?WF5]-&:886X\0-0PDJZ\&JA339Y4V!"=8)=5B MAD_2U,/ELVT>P]2NTC'9%9GWRJ\X6?+1-@*M$&]?2$/Y9+NFOOU!\"-A(4KO MQA=+:=U//A

*\TZ6$,EXS[_?>P*)S4$I"_V<;8AJ+LMOB[6O_Y@OK;=4G;MR)!9(\HTBSQ+?EWF*B-"HA09K^EQSV^GCE!-X%-$A_*@IH=;Z9+%O+8C0;S7 MW;J?]?*

*EU8JBHV.3XJM_Y[EGS$]<2OD5PR6A<$/P&$,,?D5G3"S|\03:[ )81 MR#;/K.9/I/S1SC\::6(TK)1-(FH=BSR,E$F,47B&$T ;535NEV&MK?0.*8Q9*

M56DD"9Q[&@_D=)L,9OM'BBJ$]>!EFBFZLIV(,BV1Y>^KPJ"=C$VE&V)SJQK M`#^5,]RMX1&]_UZUBP_D@T6XM26AY\8)9Q'Q (&[HNA'1AK.$HLR'43=:R$

MNM==Q;'QIl.8(I<&D:H<@6^+:(`M?P-P-YHDHX3ETN>0D$NU^B #NJ)+J/ M_XRH(0QOC)3^P4ICOBTZL@VTF>QDL;J> >);PZS_O.-(U9XE(>_,9M_%JZYB

M!M]KJGA_]6B5:E :XH,=1]BC''O(GNSVA5^/_H'43.<9A0Y?-]?H ,.RVA4? M!9,X[U:HEIMAN=2@4VX'KM]B8YNR9FGUGS_[H/GR]Y$\Y>5@/ODJ]OD"T@VD

*MJE5\E;N\\'ZVVOBWIN>ZK>F\X?&'YUQ7IN^E=EXI.V]MO9B*W*T?,?P\'-M3*IO8$%^],/!L^V'E:OQG# #B_.$F6R5W#MB!AXO+G$[?^?N!=4^:?&?%R MZHC;T#CH?Q;5N_`*>4@ZYNG,K6&SZ MPU"Q7XU4W*?-9%,X/IVX@NJ"ZZ'9G&%1@V,I/'68)'G!VC5Q.?CX^(SSE 22.+@"@%V1?N2 MHS.YU-?_!O"BLV'(A(<]2=V5]?4S(RU7,C9*

*G$$KQ>>9C)?OH;5;>!@IU__MG;N\BO>$5W)++)C%8P66WJ+S(?:*G\\D/>9\@7WSC ,E-0+UI5R=3751,O.N M3*3U^Y17/L.*W5:(5$0#Q1$.92@8-T5\"#EGJ.A'Z94A+;*D5I-*

*_0@XFG%X MQ/51M+4HWSYO%Y.HE4^THK.GX@,%IBT%*ABS,EJU=PNNP RSC_U]\V7I2}}# MTEEAY@=&U?)!#<&D#QKJ[(WF.8(ME^(X01B.^YJ!&*

*<493I^]_B5QSUNXFY_P MB=R'_(9H0I7(!AX,*D%$@'4T'K- F'J4_*"3OZO-\163">54QJ3,8-QVMA;6?# MV& 3'+&)/!*

*#=18!SPO*N31VML22S"UM=77YBB:IJE]NZ%NHLL!$LJV)ZN(.MCK!\X+UU;.BE=%-O0.5);4<0_=B0FZW5-N-H:Y\>&]>^\5)$-@:QC\-#.R+R MXN4>>*"9IGK]J6/AI.I>15?*

1?AR_YZMW7J+[ND0@J8^.Z6^]7:55COP\!R_M& &'=`N$R\6 MG6V>,I*[/S5_G=4*\/KNP$XYYT#?`FO!UV8;P"J)\A::YY+ MP|NUB->EB)%UN@%<2,$:8A*

EUVB#Z24KW=!VU=%|W9-C]/]5YYYXFMZ' MU9Q'HZ)98X?-V6H3535QKZEEK~X7E+8EE(_Y0V[6B3>AME{$# X:]?@0B?YV9?? M+VYT!ZK]+3N+=O&_+++0L!*

*]6+D/U"&9 MXD!:;"^F<=IA(I#BS)H::Y/P=EI.8\NV>?KYY<1"V"^#W7-DP?3D+5K]17I7-MNT$"[:"/MH75..M1UCE/I=$?=(O,.1U0OZM*3UX_M#R6G]*

0\!-00TC>/1TL9[&/R(/98-LNF\F=7O_7]QIH1O+;9)7"S<`"G-1 MEA6SX5\E%)GWT),LO).VX8^<|)MT^D"_/5UUX-lG%9 WAI?:6',"9*VAU?8 M6 V;=.J#2_1_-5[1:7R?*

ZN0:#A3_\LK1V9C>'7X:0ZQ<(1Q M=)?\S)=/98OT1WE,,.Z8H%B,:'2CN1]G=FS"N3 M=O".NH1SIB[_"8O):AE!M&B.U+2QXWKB_CZCNT\G<;4! 4FGR5W#MB!AXO +G$[?^?N!=4^:?&?%R MZHC;T#CH?

MQW4!.W^P8VK4F1#>.A<>X#'08>'<&0"U8$\BS]B6]=CLIQEG77/"I?&"K1LK M__/V#D),-7'\=_DYMP+4&CZ=U:8M2;,8ZLT>6H1!;/1#K) _,E;Y;95;__FX M5+7ZWFI+

*(]CO,8(I+<#&\YX:(P$9E1>XM38FZ%X;_'VF-V\ICT%;[@5445&1 M+1O5F0QA5 D"]?URM(5>1E%^O)^+G JC2'PU#;Q-J0 [PGU_?G:FM^Y.+0T MI[$TA9.D:++*Y&+X649?*

2"?Q[%450@EUF: ^+-5 ,>FQF=;;HW\^ZSV^6 M+=##% 2]H,0P&EF0[OO&8]>..'1Z;L_(:PM2?V MXZ"YH\G13L'.:$N*62XG1TW_OOCY(6+4 P'M*

*Ll7[*K_J2Z9\HR7.1'"-"S> MU6WN5+X0=I7Y./E#,DT'[<)=++=N< M9D">_;CSN3(&,RG4^13+R!),.""}1[=-SK$^W1A7TWAAZ\K?E_I#^ V=*GOY*

*M!P("\%2114,-8HG8ZR8YDEY^B'G6P)_/IL8YB_9\1X/@SGFA*2M=5Y3C)YPT MZE G;(")H36SGG#B=T:IU9FHUJ M1_)F(4WM]?5>E*JF:1P_.:U&O?*

07>R1>M';O#%0[\HHB_WQ_DATKMI=>-J.23?OH1MPB^WT$7!PO M\%B)CCC;X0W1U&RZM^>+17;,'O3!#. + ^NNP(%M0?]^FM&QB1$7-M.#M\U)0

*NZKP!$"MKA)0\A8B=1.0VG$,NU0/ML26KT,2L2 PZEY2"H1@L0\WR M7@$S+*T\^"WH:D')8>>AJE+,Y3C"N,9Z>;470VZU#)Z/L&MJ_-DJ\;O\LVNZ M^G,%R^=)1-*

*WL20!V1+N;&=:H"&>,9?<*B,HHK*BQFEO03N2X[UZL4=WX.@H@ M(D/U-/9]M8, O"4RI$P!#:?U-65]X>TC?PR1(O!]7K<6QL[K4:!#X-G9(#]-MB<0@PAZ%0/137*=U$>%.*

M^SK9SH-^L&K29R5IC$/;-> HD\BI+GZ8HI-I:W%<%%Y/$E'Y7O.6/XL+]4_/ M1C*3S%EB_6WF3V1*JO2W0t-=(;,"5)\Y$HVERW<;!#4AC!\I7UL;D5J<[A[*

MC(.N9BU'PGC@!48>1K.\5]0W &?&P ;3,X"?^@RU]I1DJY^_S6Q?MD5DG) M%'SMO?=%?-.S\6E7C14@QIFHK!%\FY(9C!7(#5:. #RL,]9 MO*

*[}6F2]1F[HW:FO<1"3YQ<;*9MNOA]OXI$BKF/>;W=6EXG:T)"1033]V.P- M0!FMDHIOM[BT94XM+B"|S[FP)4K4X4GM;F]B]0SZM/9QD?X836+([O6=,UK+ M2-*

*XW@95BHY6:-L$IFYIIDY>(9***3&0W;AR)!3;=A/I<9Q +I-PC M4=/V($E!4\X; 2*DH@DLF5[-=LW]DS=R^<<=" =*!R;^X576D;,'05YBB_^G MDO/K+SL1f\,L25W?*

1_84S)M>,#U?PHSQ4'[(N@'TY]WSM; .>SDK9U8$\F_'M'NVV'A8E.(QK\4AOU.O&U3/7E0QB1B.3SB)US((GL[7_L-,JC; ,@,V=]GZ!-M>VFKXY'! MBI7D .D+!$

Z+CA441TJ(Z^YOJP5;-!J94WQ>9 BXAP?@QO>' MA6,]>H+IT)%[HZO0A]M'0T%P4E5DD;G%L+TM.T;,@]M@P]%=@)FA+H44R!/9 MD!ZYHD"#S8$S,ZQ8F_D&I,WK-

*/DYW@"8'YE;JXKVCRF[*4X>];L'W9>\ 1!Y MC0\(L/5<9(3GF;..'166)KCB_=3EDN^3WT!0K9DXCSYQ.>B]QI"IN@6CZ)*>X M*A2_4K=1*

**J^K(NZZLO:/%A].B60LJAN=^$Y]O;]1]?7$?4 CT^BUKK(O =; M\$XA4)>6O9,@AOU=U 3UPH)!(?B!00$T>PIQ#B^\M2?SIUR#KQ.V![]1S*

M]%CF51%\R6'0\L>0;OWVV0,1@I/AU/&&0 BXT/>QU553_2^YMZ3Q&P7,O2ZL

M5M3C^L1_U)IEA0A_DAR>Y&7.8$EZD#S9T^X*=H/KSN]"4(5$B/T0]]!PG5C)M"=_!TBJ="3>C,,'LA&P48'VZ;GBIKJO8B, MK;<0*

/J.Z3G+W.I!#IOI.C4_;AM6%[GX]LK.SV3V6>) M66HF8HX3)4[@F\0Z+_7==0;9[.XP#L0?NMM^7F2CGM3C8AD M,R$=Y"G:4B;G!M"K*<#)K\Z&$W6 M<[,.VXP:,8KR',

*(INTIEPQZOWO0'GX]3CXW&5EFP08@2&D0*SVQE_L&\+S/ M#5L-S46U3#2U+3"'>HWSRT%%K#6SX4E/,A@.PZ7IJIGQM_S=NB%QUD^F!$^@ M#[']0WFM^-*

*%.9!WR<;K[*11)T-L5?ITW:O?;K*P5+FBZ]\<3PZ,B4UC:]>K, M1N:VS@[A9/;V6>ZG_W]I 9,]OOH> ^IPJ9#/< %CC:*!]8ZP3KZCF W^9$"'<0G/QT<$% M*

I@>)LZA,.=/;7/FC"Y^Y>#<-IBUT,\>9E#7,?5XUBN%=RWFLQ; MQCFR[!H9S\)3 $,"=0*^9& 4"L5Z,7O(FW?_T4?MTD:/'NK*%)ACH@K>24REIA=K&]R00*9O;^'1Z*4TGM-*

*R6%[IWTI+@_]Z1/ ML_D"SU;_V\[6N09Z%NYO MN3-YW^#H\!Q6\!V@Q4)>HKAZ_E732=1>2D;6 MQP:0Q*D_LYI2/QCS$Y_1>_GL9'LDAZ_ST)BV:I,NMN343S,]*

*[^@5]^\&6@UN M:>7K+?F8| W]_Z33/O$;FZ]%YJP,9)E] %NQ:3E]3+%O$K6B'OIEU<<:9YO"`ML&U*3],K^Q GJFU]-$N!+>$BSI+U1X6N[+Y]BFK(^=;A!OE4?A;@[$]}MG*

<^ M5[RZK';NAD),KBP\CMKZ@0_%A>%WL-O?6 MA,4MS,X&%WL-O?6 MD,\LC:)YL MHQ0

M+8TI!1_7F\4W5QK(/KY3!+M%NA1B.,DF]@+YZ'>6/YB+O=BV5(N8YP8P#.B_ ML#B(?$Z@HW;L-J>,&/S<2>\;?+DZ]PG6U_HE@^!2=Y

*E^,2CZ/%D5"+G]-3Y+'N=""P"W>G=G5 M+F#7H+/5*S:C!]JLA!9?KNG#,:OJ_ \NU>1*1)1^NW$IXS/1>P"]"?K-0.$J M:S72QGK^DR6-*

(!CUO.$'/:)_'"K32D'PG2^KD5"J;&\'B8.)L%)!H,$/-+B MC,<GC><321E_\";09%@@[?$DNZ?^4K_,:\?&X-Y*5U'N3$UFY3O!]DDFO MR(,_RLG0G+0&G6#$Z1ZZ]6WEMP

*M'UIM.YO?>;GZMT;AUVNK<^VU3(4#'&, +9HSW2W$6;.>#U,"LTY$;%7![A09G MY/+%*Y"!QS=RH*W$*6W-1,5W$<\/S7'A\3^39&L5WV6148D*(@R+=]9@BDSTV*

*MPZ^& 4(]YW>3C$0)@6HJ+2&1E!QKH03Q6F2W0L.%)ESW[M\M:QK40;.7'V[VE MV61Z$S3U->H'3[H!BW"<@)\T*YY5;Z:9BB=NGR@B/,OS!FK11_] M1]HL>,*[1D&?*

0K29Y(#$),;0].M42KRX,TT.[CH$129AQF$YHR%F/V2N+NC9 ML]TN63,K&Z^P)+K@H"/%\97^3 MSGY7G6-H:%<9\Q7[M")XP)R]L0TU:

*[81)&AQ7KW!Q8AG4N]/X&EA[JZB5;WCPF&4^Y=[Z6CCDX7?<_ M#&),O3B$,W>[W<%)HL[*S3>[_25B$1]TJE&.O!UR++?*XAUCYAIKC"RRXXFPZ*

MON9]$4%=NWQ.0HFWX%U\LP&+R'HI,<*2A;TP;:D,]^2VM^??P5'CW#KR7VO MQ>6C\F\ OL@9+T8-F.;4J]>#BDD&/E!S/P?;H^]W4E.T3/+HW8M;,!(]1+QV M;(''*

J5\N=I:K]R#5U3;^RAKW]?&??!(A?5KJ9ZLM\0U43_GYOP2DTC__4_B_.M;?KF76]MV&0 9OK]F@WEWC[33@4[7'^^X_5E1;#J_>_$1>_0![+\'%*

*MPMYY7FH^<"!=QF"_LYHPIQWM>BYJD+/'F'#]H(Z9K(&;]/A7S]QSYL'I@$= M"-R%RWI.+';_10]#6P?KZM?)?,1:.ZE+NB0S@A]C>+;#$,1P;(;3?KNOF7F@^*

*M2AC==3VO8A"+4V%E-;PAP7%8Q>V \-E=ED/MJYS]!U'9>CURN@:V M/K^FD"7_)&M\7CKA:?!91'FT7>!2.E J4P>S&Y+530X7*TR/ZK*

*M*FH97.M*M7CG&^E@S!8#'!)NT=O;^?'BWN=6SFIW^:6KS[6$$1N@O."-8^4 MT6-'6'+,#NFS29?T JJ?_ERW$<$J=(YZ) 9HDUM]*8V9@2M]BL\EE,:M^_7+2*

*MK^WYNHG;Z)9@+$7K\H7OXVI4&6FAYOA=E2@\C:R.5(".%=6$!4*FQ.I U_(*M":-M:@;@?]8ZO-/KI.\JO6>N#?YFU&X>SR=\;\ -"97)A(.[5T*Z--OU\!(M?!BY^UO-*

C/.^EI/[U08@6%RPBB+53>WPS')2.IC3HTA'^.P[C@_:CCR:$:T] M;*851>I&D/5VC5@ZHJ,$>Q4'%2L:YAR-MM4?

KY+),TP2$'V0.%AHJ3U3V8MKE;,?O^AGW@3Z"]C3Q2Z0R>^C1KQ:%X+(MGADEJB5?NA] M;)M5MNJD^(+%DHJXPY&MJY4A/(8I[LZ.BKMAI8%;6H?*

6>CIBFM%TRI6'_K1>WP>52??'N3'I$^HGG-^WH)0& M22&/WXE9B6B"EPC.>LO.(S"<I&U!!3;T\A*KJ:(M=WL0O?3&NM\!0&$E,:;

*%IY1@10')&,BW8W&IG+",;>!Y=C"F=Z)VA.Y? M%8)S0IE$B-\ ]PT^R2\6Z-XV-]S)$7KAT^3_1T/<^(C>]JO.5*$6=3*+B# M]=6?IY1JQATK!B-IHWN,K.ON@"()*

MSJC@+W -2+3W07@,$\2SW /'X,_ZM!4[UL2IE&?X#O+DT)I\DJ:N/LY"[.M MU8IY>?FV@,71G!!6,71\CVU?W-P4=WU5+4=$V MEZI8_BQ%8:Y@6F,C/L)IA*

*MI=$R=`FC[,+\-GS0:GJE\|\!+V/-L=GNU%9>NVKFAQ'5HUTGPEMSNUG-.OZ M:D^8=*F.A "4UZ"R^XC7>EKFI("0KEK8$966V=,@ 13@CK;1;=AZ-X*X#P7M*

M2N'$,,DKVD7+E5?-S9\'\[TW_A))L3R2#^+K-,+BEX 4H YQ!GA7-,4[^OJ; M&S,U%BN3F,ZVO.I,/G1$0PVV&O=T]9A$,GTK96=^M,/=.M#H0KA@<<&H:I #]R1?-Q[7DLN,,-

*I%[JR9+^:@7# M."N4B;I;*YG1&XARJ@8V$VYXO"\>+SOP7N@WQB1]Y6VSFUVR6;K"\ 9U;KI M52156,G(_8G*\Y[^95RS^_T<-4/U*4W>*Y5ZEK!/S+DG9*

MKVSEI6W6LI8COB=+@C(/2T)$]WEJ3X6.9S%SH'>[%GFQ[T.9\M6[P3,_TF5(_M:6[K(]9)2\U M<XDZFE>JBR :6X =]H#I.&7=*<"KL-3/HWX0G!AJV-*

*E2DT^QR!F].Q^/+@!R!UP:OK]V@[_%D(%%\) M"W$2D!V8S^B5XO?<[H0OE60F*!X ;XSP5%-Y3F>6X/.(4N6WVMUVGVYK)K1J M]V7(Y^"G,X$"52N@3NK$OEQZ:*1N'>C*

937KE'YL[054M,^V42F-D&'ZI): MCA)7B#$0LI\=5 [WC> 1P>!%F X>$\YP*-T](S$&Q+\B.)#E,-+&()74@+/ MF0;AT)@; #D;FC/9%DD6WF0ND?-=@R51;[*!]I2J/NG3\Q;#*

*[G@=X7;7UVI# M=-7_R*I^^VRP,+.[*Z/U\?;*7PQU5D[U>8LZ]1'1LE/W?'L!*5ZUFMQOB5;[2 %4AF6AXA1;B;,-0"YB(Y'5T6]+NE. M4O"TM0#,]D>.6$*

>T;,Q^'4O5XNJ[C[^DRID'RI9>1T7Q.LAE _G0X&6$IE MY.W15M%6U+D,KBLO"GV8.QG]\L| B(5'8F+|~@*N\YKKS,=9J5?&Q;PA'X=,[MG"+B2A'AN2S<#$6GMfV?C&>Z*

*>@X9GBX<@UY/COG(RY?+GF.!)LLV98 !/X5 MY3\]U%0+ ^\7Z0O3R;\&^,> 5?l:[)9 O_9_+?:TECYO#W:(G578*NN:K^.4*

M49=:.,,"3+PQ>'<$*/!ZNW0[9:9V*=F]3,Z70KZR7-Y9NNCXK>?B4{O&@?{G MT<6 F1MOXF3 ER\<8$ MY^;YG#-)2-XQ8-2=DV[F6UGR#LYH'!\|BHZWRR-

E]^8WNY9IT8[A)VOU)R{ M<-IA=6GUTN\KY83S02GW(I-2&Q6'\"2(%G@&/=Y-+OJM:.F!M#]M=`M<4OPD-,+:)\0A_4R44W@J K,G5H?*

9H+01+1/Q_(2GUV'Y#_>"J7.ITU);ZA M7GKR]RC:P:4?QSW$IPK;A%7"K@%3_ZRM^"0\DH?:,-\-[+FWE;H/@%/_X(B3 M&JX..D3*

*69TE9',');Z8KB2/RZ@BZ05FN;64P13_.S#ZM_L:&ZA**<[" 9!= MCS$%5E\]?<{1#;=E?P<).AC_DN(H#9+-Q^CFC M@S[N)UL/63;S5$K\&K*_,9 M&.5I\<18&O^FSX>*

<&5W7C-2%1I,TMO+A4_'KK&SI-G-0C-XH?-0I6!.UQFQ M7R=\00 PK&G.Z=4P54.CKPIGNM*91&H2Y:\$\H7|WZO"S9UYH>AUPQ,=#('Q1*

MHA$V]77Y!8QX,]/MZUH2@W\!5[%A_]I)[0N(@/A<< N-/@&4'#Q_3:7TP+2P7J8N0\B3G Y@D M]=\AE(:D*/ $WD%U1M/TN44IW]\7VG\@\"RB[6?*

#E^&IMCMLV4.#C^[,27') M,C\]Y)N:KN,Y0_MTHX>)N6 ;-XE-Y8^,P7&]M8H]CP' 0&KBL2VMC<43!8. MT@M9XU0]PM83H"7OEI6D#?$M0U.MK2<5D]9[']IC%HU7C

*T!.=Z@2U8SD8MMLI#@Q\GJD=1IQ:C4MV^YVF*P[+JH-2-]7 0_F<2^1OPSS#P MGS.6_[9"HY7T^]@;2?%IO3_L>LIO8_@F+I+3/:,\W++1)1/=4268XG<2-EWOYI1<&*

M%9U?"^A]51+J,X5_*=VA-*#^7]1&Z*$S;D!L"_TYV'NM]UR#5+KH!L _O M M0?%#DET2#]X "E_YK1R+%&VS[-W@DLT2KP)+SO,<|%V1G7*M=O_W4*

MG'SARDZ&1>>HO1O'[S85G6G]0;R6KG<(L0V8]'J19[D\\01 MCR1A$-_PF.]HQ<#-UF#NTAKHC8%[']MH]Q#C_JKECC$^>I%1,41!4$+'G2+=)*

MI6)LNSL<++@]7AZH@M50^.TJD&K6=OF ?$<*"#"ZS'"LR M9BL ?ZM|'3X95XAK07(#T=!?*!=-^&!4X!VT ?P@N?3EV0K9E&4Z9OB%9F?"M/NA|Z>)%C^8ZT64[I,0G6*

*P%B?8\# <^HC%&_E^T+:.NZ[_R5FMP0 M;>-+"S%IWBU6$7K'Y;%7V[A]+:-;L'OWV.0Z#X/^U(>O^03W('1=UY4CN|3 MB=MY(?A:XV#XR-G5QZ44R17B-[*XT-*

8XGH$+:%P6%<%ZQLF!SB;MU&&.<*3]_M58&+709K#WJ6@OI[E&Y_"5_8K"?<'5,!9,)RD&P)*@MTT_-D^*Z<-*E]R2C=8 ML=Q&+RP]Z#Q7PM9[@T_??HM[M":?*

H4%FF\KB_/ W7>_?>RC+O)1^D^^/-M6] M0]=TZ'0#&&%[:QP:.6Y#U-[Q'ESE;G]#OI,>4U3=UCP9L!X.]UCO+4JQ_1GR MYCTTVE.ZK1F8B70:)

[!V]ME)1BD8Q!$\})}PMH008T4F5[!"F @Q+!A;(VHK M-TAH154Q7G\(@WS-M;1(]C-(_KRA":$!2P=N2SCV.-4OPD(_3_H&I=VDY# M8FJ1O0K5Q.ZEA7M?]_WM,?

1;NLMZ:X>KXK56X%U@@+O@KS3?@-()+%?;W6 MT:V^Z2OT$.#'^"H@KZ^:F(^9#L?F(M'_5E/ V<)+ OU&"<_4\FZ[^5G9-G=*

*M#C,K*V6^NV3N:C^+.HW>F'H!3JK@87%"-1@<0T@%+!A_C62;&E.-4_S!B O M-,4_H7(#D&46\R7LSZ5'5W#*`M>/_T>,/O@/OJFV?;B!*

*Y3E&2.G4AJI.176A#167PTH;QSE+'EK}FGX;_DO5UZ M<ELIR DW7.+ &^_Y(\%_X" _WX0'O3^01XRW@=Q70GO8-U^ MQ0{PG+I/"\&+M?B_$*3& H%A(\'=U7*

M$SEX)ZC],MB(4'DUB-KO'N!K[IS*]W21U9THRU:!S2*-LWQ=^$/JV"\US]5J-M]M>1LMX_I"]FOE[+8+UWNZW9T8SMDI,W@!Z9\%,!&4V'F%>XL>#*N)[?QD-M[Q_R*-*

KN2\/U.#/_V_93.K$'C))?@X5>HDW-AA]:5'QH$O3C.#3,'N7,\S-; M$M._RN OGNK$QUHO6_!XPN(L$VM_W_=5G;?O>7)!0GQ['C%VP'>IYOK&G?TQ MZQ #1$5?Y#Z.5-

LZC9;7$<2)-Q&*AC&Y,NR6!!Q7W4FO*ENJ,EV_<O$<$JTX M7W;]G.G.#:\V0?4V([T5)E$?O_QX4$ 4QD)Y4585%"OC""GORL_66L.!34BE M'7=LOA/M@!?OO54U/S4_ D;B'L-

*^/RY++P,:|=GG./J@KI@==>QE>&,-7?_ZQ ML$6(=L90K2S_%B75^+'C)=>F>7PV@8KZI<-VRXK[_'5SBXA:YB9_AF_)1OF&N,9W3)>S*K@[*

MR_$SCAFMX$3!Q^5/RK1(>D@_]B+TC&,(H^I#LOU[J8&^7[F95&VR@'59GM"5,VZ1[TC M)%[_5B@\T,P6^8 ANT.N3=G-S]WF!VZ3B#?"O:4X3A;.6)ZLY1U9+4*

MGR"&$'_U:I4Y -XW#\U75)Q(_]ON1\B#?HQ(G.BD CUS5N"81D[!F[!:+)1. M'BVI*=*=[R%STU,N8-2 M'A$K4.]FSO6@=<=3N9W:R#P ,]5.'M[-ZGPI*

D!:,)U()/ MA7K3CF)$UBA^VGFR8,MB.QG!"E0H3#B$F7!%H0(2]#514UV?2+$SY.X3G&0Q M7#[US<]=[45.$==>!:G/8'[QM3>B\.L\U)XHLSDOW/GC>:::>449SFW6VKW'H

M;CB']9K&(^D3YT\\8U+?E^]=%9]_*'#F:-BGP[6FNAO 9X>>,?2A@CO#8?S\ M.IU(N-&+RK!<):X&OIQ^X#W?!>0NMLRZ ?5]_WQV]NMB,+)[=8816LC+HK:*

MW'2X\M&/@:>_^/U 4JI47H%O48_[%20:L9NEJO2F05<BH!3CVLVYNDNZ NTB MY[4#U!0\\:Y3XR; TZ!>,&3P(?7;,Z3H%:;[(+6]D?RTW[_$GGGP[V#D^ M'C_RL?*

*^U9D2*AZG%FB""'+6G/%>HYRT['X>HJHS#)6Z?QSM-3;'C+IW#^`.N_/MRC;(3O /KWK?9 M.0,.(4LJ39HH4PTBC=GFSFB"-0I,$D/WF"F?DI:NI7S+NY-*

A)BVR=K)K.)#A>.5+48:\"XWW6Z^$IE[WV MAIQ2HO6!RGI9@"G)&XH[+,2 [?+"&,#_6$^(_Q\[Y-#_)/"L,G0 C)_T*'._M/[=E37!Z_RE=#?=_;LN4_^VJEE1Q,FDR;UO-*

B1OTGP>9RMK/,&59;_?5ZCD^ M7 M,B(^3+W$-Q9GJ42S^[9EK7 >6::0N.>UT;)5'OE)X55[449V6++*OGB=I M\#K_[OXCQU#B:[Z!L!+|:\X_B\%T:K@_<>^A5?*

*DN&X09KP%,L9DFZU'I4,XU M4@$P?30L_>$LR'.]K+/7W(_*G/L_7MR9W_]'@\=_]RM>_.]%L^=,[GQ52(O7/.MJEG)YE_*!=\&@DM9 T3*^]?W\/]!4?^IERD\Y*

FUS#>55>K\YN2Y]G(W%9R M4I[_@V6B$W_.]AEI!_)K2W_Z$T]PMUA/X_6TE]AFWM,G\#)X%!DI,YVB?Y MQ:*3,?+ S#1F=6:'&\|:.S.^0W76AWYJ<0K@&IX?]3EH2I2(1%*

B]4K)W9!:%V,0:J(@OP*?Q4I<6VI42'A? M6W^Q^.T(WICQ,J#5%A&6,941K@29*1F].SCYR_(L7#-O6"V7^*CZ966L MT.E/:P.6'5;P- O[HGIG<9Y2MS-/W"$;ZVQ-+G5>5B1[R+T79<[+M MC@"GP3U4N6EBPXI),S0EST@%T75F22YKR(ZU3$2+V09Q833MNWC+PR^'BR\#%HM7,TCB2X?@BPN^ MP7\2$ZN",:;>> ^|<^:!-
>|\XAQ3BY1,K$V+; >35V&+(Q@+[$ZO;JXI* MJ^(?:.VM.Z>XM[.'9Z%FX3.@!N=I)N_F;?EX7W|\BL2@NXNQ\G;XVAUL3; MF]O=FAXG[$-D5ZL54Q-
2:T[3EQ14_R>R:lEP^U'P;7K%^N6GJ1/FE&MG53:Y.O&<+ZEX3"IN>\&COQ-7 MGQA-#*AWM5E?TC\"S/G*L!:LN_XOOW[.*&+!6B*%$:#X(F+AT1.Y99#>NLL!GXC:/N0(T/:-
NG18J7H$R+WSF%A:3TL1?8=8:JO?]$B@C]??Z$,2 M8@6=<@2X0]S^N^BGS&YD?6GA7X]^V@Q;*YG-QI\\W=Q.?BOYRL S+VIQ9[6Z
M.\Z;#35S;Y!UY@C@,.C7'W>A7&#G3M)>2*6/V&F3GOXC/VIS/IK/*L2[PBO!>U M(9X1)(?C4W+"X ^?PMLJ#S(\KW9I-ME7^-DS_:OF4<8!.W#@"' %$L.OG(HT C"/ [JV@1;K+
M{O'Q<65#6RP/QG3*$E?782N8K*L^=DY?L^-U@:.TV7O"PJ'#6H-OIJ;&JB" MG;*6/OEQK#X", "V:#]++#Y(MDZ^-)GKWY0>;Q#;NQ(JCP"GZBXN@=ID\\;%'
M@"9OBT*MS_O7$;W3X&7[C#_*7Q=?D'N_+#[SOH7=:0#6;@EWV)\;*#2A 46 M"<&2VQL:>T:.N>PGV8X]_ XJY2$H,7:9[MV3CN"M%:G#=U#Z.*.*FF)?9,*%
M*78MV7ZG(ODMU3-(6T, ^D()+3535$W6;2!\,7:?P?!M(T4BW\FK>6TT9VD"<^_+(H MS"=$&,#J:N.KKU%59SI%&JR%"!Y@H$-;'BQ(Y^,(9* _)^U;G%%=\OY >\ D^\Z
?:6LQ@X?#L&]HM.IU-H1OM+/2-)_[M04W.^_^=&(_" M2?W!P?A';AZR8&GLE\7/WKV[*+/HZES@56(Y6M7'KN9[R!MI+,N7; ML;0N36;U^EW^9(U//B2D,PXJ(E,E5?
1ST@&:>?0IV/DV!W.[F?XGK MD'U$B:TH8[3OAN(]W$T3VE%A#-4*7WO;,6TD'MGIF3<4WZGQ+2]*K +?)?D M.(6\-R$>?'4/5,5^KXW2-
SMJKXJT*+Z>D<%3D6"?/S2.WWFL=8H[LO8S*=S M(HT&E-BR%@=`5Y.5VS5TNBZ>-=I WGDG8O"HF-5B$UKHPD/SIX9-Z499-GC7-M,9
1'V0^TM2DH9=;G+>-86F,'SV8_%'WC^*SLSM*[T_Z7A$OQ:.N%P1,;%^_Q M&?1EAY!X\IMB=`E[TQE:&M[3U,\S/3>R!,K";L%VMITBGI'],QI7-/'I5^,? MU_9O*AMHH 3FDTQ
RYNQ3\+A>/N$5L%PML0(W_Q)C2EE&;6@_0,#B!>G,(" M*&3A=[% Y%X'W]8>V@CG7<(733Q<]HN^4LF[6O:B,.(N :;@W=[12FN>$)1L M?[S[29>E,(SU 2@]^D_O
7WID*D@CT,@BV0H0-KM^S[\P:=,T_/A"^*<8N_ M+?).S2/A&1S3YTK@A@>I6\1P!?P*BW,/&10US,6#15/U1[7BERI4RX3V4\ ? MP5BEBNTW0P2R 4Q_
ZU7T0I=FE%!#-1P[,SH2=DX,_-LHT3OYU_\M;-CE4>> MA:W"O<&-VC0;OI"PO(N!9=@;%A>E">?K9689 J$ZIG=G>!XCZ9W#R(O?$E/ MZ*79DQ'A\!<4.3V;"_!
[53TTS=5%'K5'E(,TD@AN^Z4"]VMB8[P(>7;BNK MGJFM+\+#1\HW9.VD)FF>\5O(C-3]HV=[75(RF48(GSENF3UYLI;]\ > M/=X&?:Z6Z6_^%\3R.
<7GQ5]JO_TI]\&^^G/[++\Y?N MJ"&H*@JXH*U()YL MK49O@4CN<+>)'(LB+G;X==CBJ5;O&8H^340],O<*GEXJA31=:U!/QJ MHOG@_9S-&2]I?3'13"-M()AZ?8GDW8#DI.G%
(4*3ZL3(+?6DZA7+1_[\L+J! MBS$:TM?N *O]OQ0P"H1T.[8.!3#!-EH4KH3!GQ9"[HS""IOY)N M*U)^LT0L9]Y MKLO,ZVR*[@PRT FNF$V3ZE=2?H/^2 ,NZ"P:;^*;"5F59_::-
E\#2QY/O50W MZ&+!9Z7U;_(L0A?]RYYU-P$0+ZIPD%\7%#]&A-.O#T@(F87]X!*,_G:\;^0_ MHNS3[Y8QT*VV<=8DZ%=^*2J//)Y1B/Q5I]LMKDST6(D8YT3<%,\6
MSSY&0_Z6F$Y,[O]1IU-H;L KZJ]1*Q<28[,DGYM,*^0Y;+)0-7OM^< M4QDBF)-
OS9S[!DS6ZRTQ6)!90VJT\]7]O\XK>&7[<,H:N#O&W>,UNX[8W\,A1;GX5Q_D$N:H"PJ!+.#!%MUUZ'$411XVXY$=$SL]!3]J"L5 M|!32*1?^K6F[TPZ*UOS>!W:
&H1Z7[E,DS6WX%;U*18U(46;7[IF>]AV2[OA ZA MLR^'1S"]?&DZ#:DBU>E"!E/[T,+!?MF<:O\OWY7OW7_RCWC3++SR>]411+?1%_4\OTD8W&"ZY,S]_.6(E>N-
OX=FJ/9GL"_5IH!'-4YP:T>NN[Z/3O@K3U8" M,Y3SF:GV8Z]0XUMR!?I+EZV5]FZV'49TBZE MZSDY1/]/>1)?W++#&:"G>W>![+'"O8].KV?O/8*M2$5?$?>P/8M'E1AW2>&?
G M@$Y@A]Q/<*6DKK;DV&=+%* MPO8'8-E?!K M,%_;/F$;+ ;'9$R,1-J.%LR5+WOU%&MOYZGE2*PP[=V-(LWP/TY8<=&[HD;B M8UB0]BR1?^8'F?@1+1&?
PH^,;>FMD7=5BGWT 2AID"'D6S&^D0KTI1,7)\3I M^<-K%)>&H?Y;S8W6U#@)23>KD'W]790*JQNC,O1_4/<>4$U%W;YO$ 6E5T$0 M(AVITFCL1D-Y!I!>E@X!
(KU&07+J1/V!U%ZD5Z"(#VA!@CA!K]SQGCG MGGN_]YXW!CCCO,'"'1#-7GOM#]!SKKW6;%.'1*BT\$,N"!Q165RPM M@ZV[^W^.3-6I@PP2I@_+R@_I)
[0E"25?_] ABF[^$]#OJLK?P2..6I3;F#6* M^D'/>]HG/P[$-?5G@A_&>$#GP_2GN?/3=V6:W KWDY*L)WL-M]D.TO1*I2-HTMQ.
MW.J,RE>R=NC'M[J6TCL^3YS?"2Q0GA,'M4F]7G.9ZQGH56M\V%"Z-ODLFD_4 MAWNX^=NI#1NB8AYTQ_L]K>J"P0FWN(3C],OF$&XMYN[/Z[1PA(V]3,C=VL?
MEA*\,?X^]YLS$>^F*:30>H*$QO+T\ YB37V.U?RO.,=:eJB>@-M9QY^4HPN'SKOGZI>VPSLG&N.\VZX$+#HD*M,LI3GG_X@=7[%_I

#;1BAV@6L@X77;.:2KXQ!&))GOIU>F%B='2R4^LT"Y^PD-8.>$^-?Y NDZ?HHS@V@1U%R?\>98K*-RSD:(*@]KRAH MS_YHHRHE?M]<84'NS-$[%]>S'QI]0[?.=\)K"^G/7/J1);"@(2]A?P&/$7V M!08F%Z-<9Gſ//AI"\/8FIDF%O)>6N"Z6M(;GC@QJ(L*"3Y8D^GP[\@B34^$K M:6\S:1!8)&T\H3+GDNWZ(/UF./8$Z^3 WG%U- 1;3Q4Ij;? Z>=9=^0#%ZT;U-MJ)#I#9Q+E/!P!UY^;.U!"XLJ'(,3'R6[1%\ M9-,U@MN<+2(=@,QY/XT$-#WG]'Z8-)O*.TIGY_6I#]*WBAT>3=`\C1O)+#%?H(+K$_{R]= M_$FC9KD!85>(- #_]%W$"]N^/,"A9 C!Y-#:RKO{(_OMC&99&TE\CI&ET M:?% 1M<=:,,=8+(*Y(?;]2HL'KIMK].7XO2GiV)67K[GOSO6U09_F658W\Y\O MG'PUS&;1W'WW1+TU#@SZ7O/K4.6@;_X$!SVH_5">)<8Z/"DJ1ZNL#VOQ.-'$ MG^2;#Z/V[_M-,_5;S1!19(?XQ=A!1J;*>XG@GLPN_WU6&6UBO 2Y0//U:W=F5KPA,T4#|_^ M+!_'6SS-RY_Y0;BP+S2ſJM+Y+#&*<^/FCA&B<>=/?%T G.(21R5UZI8?[7 M*N*(QA%A/=ZXPLOC'OY6.LS\X?M/TL7IA@KS1RO!1IN9\"%N?ISU&2]92KO$S+0' _E$/5IK"O.?OY1B.>DM@=R\A MFHC*.T@]1^&\=84ſ ~]X*]IG7AA7fAXO$!?H6[=ſTWV]P@C MV8T[$Y(Y_/I"}2)?B]T/D:PW@"X)VI_EYC05&O-]SI;$0ON0+;*23NHSDS[@ MSE7&,G1MG#V#9/>T3[CL]IA1\$Q<%!W)S9**.0-0#-$L)STY89004GI#6#% M8'37-/;IW7\I=|1?@K>K CO6+-+<#;D]TK&V>"/A3Z46'\.<'?Q!_0.NTJ7>]> MC'TK%L83QN.A8L@7 B6S'\U.9 Z^;RR@M/QNKB)9<)*[HKZQ:"9N&LH2P'ZD M?[LN!UT7UFYR1#X!89!BWR2RTL;8O)W#N,AL?CGMUD \[LLKI|* M#P//[8\9CIENS>#4%;/Y4MZ>*|@3*@X4Y\<$2D+E9Z*=K8ſ_QT*/- ^NP]ſOIS/4#6 8- -Q")[/ M2\586E/],ZDBU-&U/:BZ'+25LſNWGPMR(D^2LB?T /]@!X/!;J#W\S= $89 M+B;/QH$-$4/I3AXW@%)X,.,S*K?MZN ,Q 7fBNV[+7O.S,@GſR5%-O0,*':(1<1#=#1701RSN0TA M[+I>D9(_0%$#DD9$AAJ9/=*88K20SS, M%)HI+>[AYB9CH% F/(*G5BB\(Q.J+!1504#F<-%*BG7H1Z=U^)+6MC@-5ED M(SH*&-EYF KN@2"U.K@QUF)PO?)]$PBO=, (MSZ.@C<*_*<:68ſ^"$.QWP!" M\-=7+KD".6X '1@CB[? =1@Rſ5CA>)XYL>[1.G1OVLNHUN$CU?L_2]@09Z07T MT3/V9.34[CBGT>??RD?#LX>,Y+KZBI$8>QI"<+E^""($KSS#U F$Y_@.8^)A M2+_Y^0_0FMGTR[+3#$+9=3MN%Z<#V[(ID@l&XW%#^]!-$.U0YW_O-%??V>Q M$[O1?BC]%;]!\|F"7U1\'-Z 4Q3J?H[3PQ0F.?2OQ=-.?Z/#?#3H\i:[_R/ MK5!$L9I_Q,3LE@C]ZV-BI'Z]G-ZSG]5Z@;H(]2,6.KPH()YYV7JX^U@P!=YBAJF_NML?R:SZ5^ KQ'_V/EVO]3O91[R8UQ9GU6C>]#,A,S8^M#"s>]!+&K0?=/*84 WI7_8N/]EUJX_ H<&YIQT-1ZN^G0X#]/'YU;V;/9L.$5 M-?(\$$1XBA&@__%)6CWNU)H\G M!YTS?L>_40M9W -\$)\5&,..!$-# _>.?E_8C\5BNC3Lſ)M=HA,.+ (M/W]_#09@W/9]N(27?HGR'I5@G=7C6)^!869,^9+FDH M$"2TX8W\.F=./RP=[K3NO!!>"}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ſT[[G67]_)^OY M78"\?"F*8NST@3^^DQ.%,^#'-2F9>HD 5VNJP)):NF!E6YN.CP0IT096F"@!. M3.C=.D!#%>EA?O\&X&*TW;(5[F\WXYL2GO[)4*M-G/+3!#/[H)T/\-US/TYZ M=2OOR7YI881TI=^:XPJML1F0T/\%_&=21W'1?+:.]Y1=%UKF7CUU>O8T3%1WT MO1PT05JNN9!M7\8D%^3,FRL[4*D&O*_X'^V=6SB4^Q[*WU+/Q.04Y=Q838M"_M@UTHAR%BI$0LAIGEE%62).4PRYHQ41,E65(J&L0XE9TZKDWIFX7RL'W1RJOE1VVS QDB!QA2#&G,*HBRK^ZVC|O9!ESS.*?*OBMX|Z^I+]J 11G=&$&'-MR 0I *%HB3###IDF+RDIV:9\3 MW*EI?L,ZT-!-(?@R*,3\5IS)$XIRK0*ZI G#VQ:P5+K\<LUXM H(G'M:?7 MMXDEE>P-@0$5Z]Y"WZME@80B'J:HX C*N%L6M,YDWRA5G2=NJY M6D+"Q.0NW^T;R(V8]PDJ%X'-ZXS4^DW:K#8)+@ $PG"!=AAHSTIJB+G;7LTQO1CGGY>2$";_<- VGM0)H= &MM}1"(\1J-O1R9]BOF3EOE\=T.G7%3?L\6U((513)&ZZX6<$1,*61J3A&]K9NK]<=GE MGK!P92*OAF\7[^7[2A##9E1;[MK=?(R;SBT+5L;- /"#_+F^<3"45+S[AM(%"]-MO3*](:A\[$M""]K:LAB'>!;2Y7%K]*X2K%T-!.(_0%_I)-L4$\))N(16GQTRD M[5=/^8=SQO0S&/&T/YF6XR.L;" <#PL^]!83CP9ON[@_VH*VV89.'FK8^Q1'-M8IW.H5U\I/;%^EICA_[V3&]P)2!9+\\??N?P>Z,P(3T='SD\\"H%&[MX-T3S)%"'"0:4[#B3_<'"+;T_:N4U;NAP9/;FGQ/5^ M4>>D>]E5X87C)>]+?IIE#0I&HX*T,U21-J)#%_!.|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|PD8*2BIJ&|J)+# 67@$@DIZ24RTK^LOK@;=':$=(&,B9[YV1XWBBJ$-Y74/ M%]DW2;E4 O>]NUB-1CG&"TL\|0ZAIKK*QS^P>'1\0GNS^E??I$ I"3_WOY;OY@N, +1$1D9*1OF77R27_/[IP@1&?NT. M!;..(:6QY7K4F^H6.XEY59W40M(&V%8GWN.TEP5E$$)8?IR[6^>_7..A?Q+ MGOV'8W_W"PG0D9)<+!XI$P &SWHSHF_Y)\$"\ATQ>,K^Y_72O-#:CJ%)?7 MTUH,&7JY>;$<]S(+Q]\=?#.QRVU<=?5&|<[N]98P^_#[&<++KV*IG<"8CHW]3 MD:O7)- @$O>J(=.R49'^3 >D%KRMTO+RH6]+:?AJ9,;Z M(&[]4S:DJE0&.-1@N1##F*?C16POQ.LR#IG/^[2>?=\GQZL=*/+VR?!5; M<6%^67%%+ >[G516B*K3Q.N ;R'M-\Q_RI? ++MC%;0Q%'[""U<\.6C>J=\NE\9:.E_:%-VW$0NF>=%WP0,#>:FNUZ\62-HO4 Z#HD!_'BP:-9CL.\:L49S7W41/G5.BB M3Y>B;_P/$2WO+[5W"G1UD)Vſ/#^WN\^?_- A,""DU^RBK@?*I=Y'+-OF7&WF) MY"R&=_^.('R@X#D0-58K'D2MYX9ZO]8NEUYM9;V1]L-$;_81?<>>> NR4M>] MQM?.E]H24&165^K//W;<<<(%3V?:VMIJQ)1$EX&RC*5\ZF9/%*^_F65>(M[MQ_O!?-@S;5OZ"?1%]S(JN-+!IMS,2]AWRK2X51+-\WRA":+7?L9/%<9OO50E>LN 9%,K*-%<8J8TAYS<*AW MN:6*AH>_0VY=8UGRTS30BY-6> M_93O L7^E)Fſ2/K R$#A'4M(7V48WY4V>>PZS AGX_K9Q53^5'NL\G##8W$WP MUIA<2U9L0BJC@6=1L8I,)-3\2#[=8N7S7G#;CVF_AM(#F>*A_IBEHO6RALX A1,S)SOSlQ"CV)!:OE]H#A3EN%8YQL"_ZVE?Y]+(6>.\8++..B"2G>K6!68G MJ%AO+?"E]UI3E:$Q4]6BN2D/)RB19;:Oſ]>(-0"DR51& >[N8N]'X:.]MH;G M&?4C5%L9[>6(V/H@FI;[KYX-6<94M_>MZ<;K@^N2]V2Z2 M0--[BK;"7QL940M!8A/U1 #9\W0,; ^AQ3].N#>^,BD;V%2^,HXT4XGLT;_. M7'X2U4TZ4O[2D0ABYW!>.AJ^"J^W4W1Y4.N&4=WY.G:VLM+E()V2UZM M:5>8;GS+C_Z]TM'.XF/56- /P>R%5,ZN\H&/+.6]Y4P=>M:?4\<8]4*,"I76 M"N*ZV],IX]WXJ)SNDL9+7FS/=D"-HM[C%7BM!#&;A;X; M:C=*I:IJ?G(C>G==4V]'>1>IXE(6W2"GTXBs!8.@CW%;I:0UZQ: M"5G*;?DL:H/):2U%24LH!48%SC:7I+?)<2&)RMZ"=OB60.F4T4WO1X-M5A-[^Y=2PVV9YRTM/<&Z=-7$#*'@_0V*F477CV\G*CR MY9O\!#"9?2I#MAA)"()KPY2Lſ8U2ſB;&>IS7M("D1X6;_25MU6&;IC9VH?! MſF)&O'B1;Y"l,U$%B$#-?TEC'M)ſSXF/OF#VT2ſ0">- Cl3V(TE9]UW_"FMECZS%ENGDA+T$S=T^C\\B4"HU|A+ ML--(:6>Q)VN!AMS5C6)HLB BQ/RPMS FT"UP9=Q9BJ159BJTGX;G(.1"9 MOL:- H9ſ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ſ2/K R$#A'4M(7V48WY4V>>PZS AGX_K9Q53^5'NL\G##8W$WP MUIA<2U9L0BJC@6=1L8I,)-3\2#[=8N7S7G#;CVF_AM(#F>*A_IBEHO6RALX A1,S)SOSlQ"CV)!:OE]H#A3EN%8YQL"_ZVE?Y]+(6>.\8++..B"2G>K6!68G MJ%AO+?"E]UI3E:$Q4]6BN2D/)RB19;:Oſ]>(-0"DR51& >[N8N]'X:.]MH;G M&?4C5%L9[>6(V/H@FI;[KYX-6<94M_>MZ<;K@^N2]V2Z2 M0--[BK;"7QL940M!8A/U1 #9\W0,; ^AQ3].N#>^,BD;V%2^,HXT4XGLT;_. M7'X2U4TZ4O[2D0ABYW!>.AJ^"J^W4W1Y4.N&4=WY.G:VLM+E()V2UZM M:5>8;GS+C_Z]TM'.XF/56- /P>R%5,ZN\H&/+.6]Y4P=>M:?4\<8]4*,"I76 M"N*ZV],IX]WXJ)SNDL9+7FS/=D"-HM[C%7BM!#&;A;X; M:C=*I:IJ?G(C>G==4V]'>1>IXE(6W2"GTXBs!8.@CW%;I:0UZQ: M"5G*;?DL:H/):2U%24LH!48%SC:7I+?)<2&)RMZ"=OB60.F4T4WO1X-M5A-[^Y=2PVV9YRTM/<&Z=-7$#*'@_0V*F477CV\G*CR MY9O\!#"9?2I#MAA)"()KPY2Lſ8U2ſB;&>IS7M("D1X6;_25MU6&;IC9VH?! MſF)&O'B1;Y"l,U$%B$#-?TEC'M)ſSXF/OF#VT2ſ0">- Cl3V(TE9]UW_"FMECZS%ENGDA+T$S=T^C\\B4"HU|A+ ML--(:6>Q)VN!AMS5C6)HLB BQ/RPMS FT"UP9=Q9BJ159BJTGX;G(.1"9 MOL:- H9ſAM,YTU%$(VMF9V1R6\HI&CUNY@K'\S,K427QQ"Z\HNK*Y3^D"+:>[M(7'67&V!2[]Q\QDCZJQIH>9_9*\&\=H*;'II:DXA=6YF^2$!B2Z%/F7$3/Z M,5[^_-.AAXO- ,1'@=+E^IF/=0%_)IQ%QRV.?VU>Q2+>0,^8A%C+?HC^[.!5T MM;+JWJ.E]<&-VG'XOM H$7!PTCF!**IG20(;)D_UW,H*I@Y$Y>C M:GV>,3IBJC%GRG^+2^2$JM]KL!,18'JZF7'DY"@>_[^&&0T/1*=*PA4R?X6(DKQQVX M831?^^"69@#U(A7\5H(^]0C&&WVF/U/ DWVO1M+U28K5WYZS,)TSVM=Z]I) M.Q&8L(V&C+3695JU(.>6>?0,TNRNPHOL>W?);MMW"NQF!Y!>3 ZI-S@!)';^ MP;N2!OJ0D6%H.=YWP?&*26O331\.V]:,.O;PR"MM(.3<\N.\"5C)XSL393+@ A/"MV/G@RXVC;8^+<7H/"=|,1O%;O!*R"C'2;8WY5Y=T/3-[41/OGXV(G!!EA@"4"O;1$@ 37^G!TNTV+M7+6 MU4U%M;A))VY%G2ND2<2EPBLDP%0L?,"U?ET? M WM - R9@&NK=" (9QK8LV"33#344-.V>?,>;_YLN$YYFQ4-N'CAR ,472;CE MF$W?@%F1-4A+B.94^-?.1AKLA57$8>4)?PF%N3=W@'_$.*]M;*FP'|_7SU=7V=N(ET?O18#(,'+I:- IA7JH*V^:6-L>0W/LOLA>>SX5?:VI MſV%BW3#2Q\A\$7[8X##,M+ZK6 ^B=7JW8N^]9&:3_.ſZC:/2H[N8ZHQP^B%)S,?@KO#*:\@Q6UNR\R(AS<.'!^ MQ[.X_*7, (1>AZ,.SK8UM6[VJT1K=XBM>R[_/BC8L-)\)OK0'-(J83@,.!P23 M%VD(EK4$*Z>I>)Q9XM(6+7$,13C)KBGD-D%NM#_7SU2'I3SKIL]^^MI?> MG>VB AM'ZWIX/X3)Q>HZYG%$#X\HG,]12J9Q<>/WR[Q&P+9D2)E9#E6E-NR"M4S_VQZ8E8+F6-*M]7.W$80*HſS(ſC]/6I07ſY0TNVZYQV S{(NB#+-^-B>L!:U M\#XW\L6>ERU\D<;\:XKNUU^@%6 RX/&\U_KQBE=!G'&,9:IIX$=+A8P']/Z(& MU^ALX!;Q;,9+HM'K3B!I8M 1^(\AV5YC'MC4%MGB]MP4>$UKWXMD;C/%!O) M#!X91_#+,*<);SC2H8>/;GF\W&[726,Y(S_UB0QA"\[7*L2&=CVI0>FL?S^#3PQMBV5(;.R.-7 M,!C"^QB=WFU-TN;'DHQ"T,$>MOC$S8'8,=*.)[=C?AN=Y K.LB_O)G^3/UZ+ MGA^B;B^JJ<$EUP946$I6>LY^;FY^V6BQ5_0G 5.TPX/U;\ M%L(4IO"LJ%+;.MXS"W^IOB1QRW-.**3'S%.I_?9H48#?V;= (S<]!N\;]@6FC&B$5Z5ſG%B%>_MWD0=?Q_ſI\l;6_7ſ+O*=+-(

,6DN@'V0LGV\J^YNXB!5HO%E3L=?T$ /B*@].W["^W"99L7G@-ML.06)1.G_BCL@UU-/2+.++&2CD;L*MFSM7A1?02K[.6GJUXVDNWPTP3T$1]QFZID*= ^%"+5B#,_A].:
f7*>T MVOCE5_N^-9 _,3M.E!Q&F<684"Q3SBP,I&W >D#@N_QB.4T99.B[SYOAA^=2P M,+/>"5=Q ST&]1_&\U+FW&KYCI6/K$N@7O<+:.&@O
MGME0TJ@);V1#'@>PJ]M8/,^-8D@0^'"%,17'I\Y7WSID^3'@R6 7O<5[89EJXT:CU&,>? MO[Z#VJJF!76FT,&8CGHT-1Y<" W5;Y]RW;G> MGOZPH44K6]D?N//-
@/OM,S5*=OX$0TMZ(%@-#\+ H[QG1T(6ZW*BZD]3T AV MF%&&OB&Z(6C]%++U$(S\B5.X2Y+'3
MT6Z2*LIN3H6#XN9OY:4DT]:70^1BL5EKI(EWSZ&%=8X_N(O%VZFY$PJ 8"]< MCSK6=#L%J[7DUL_CT)V1$]DF48@'UV'V#"V>\\A:_NV1 MJ+NVSA>ZV&@: 0+AC:LPB-
=M?.@X!W47!Q<3*L.R4?6U53X<]UQ$DTA"BO< MSVX/6OMAUGHA-- 1 \3XH23S^NG\T9M9/Y>BQ3Z5M#6%GB]WQ$;X3] M5&CM M\(G';NOYEUZ#E'X>;J5>)+
(O+M/A4_;U;N'5_;=4"O>'@BH$&GW0@M9/G^<$&- M1!M'&^^?V#W(;MV9PVWIGO>\4G'@MN(8/RSE.Z,ZT%{(N_V= M?
GE@B1RX+M';I7O/_(7=70B_PT)MVYV5("BH!S40X0/G.!NN6-R8-F_;@SS M;AW"B8NCF].8/&[.M-P8C(QMXKNMVES1TTL$;JQ2T6[,T$K3]%ZVGSIH1A,'
M#I$TP7"I.KTB<=VDFRJ!\!MVV9K0RBR">'!?#C.>]\ ,,A%Q230 M.]=T34F4#7\W>CHB)3'<5@5B HWS,]_MOE>03JI<3/JK#.[&1VL!LYR"29?/
M6B(=Z3+H,D"U+D5S^AR6NB2"KE"4KD7(#N>MY4';=8\C(=B0P]D5IQ&4I=3;G&((K7SN$NKP6) \B*Y7NGI#C;
MX^AIAYQ50H]?)OJEX!K+=E^'R*;SU34U^LWCE;#+^(L^?PB/9V1.BZ>\NP$ MV'N;XI+WK9-ELK=&@14T6$P5W_;!V)_B3VTZ%''*$P5'E3HY%IN;=%K%P.) M-
[SRE&E0XSD5G;9'-G7GLF(1R\K8O5??MB<_#\,.S@SP$!]SM,E5>R7/II8 M<$CV?6KLB'3-$$QI;$H*]NC\EKWI-6?Z'5X\IO<.*%3/&??0OM+;;Z@"'+^NG
M+H^MMFB*B;.X)@Z*D7"^[KTSN*D@W!Z@:&\^(6(ITVQA$N'"X[F=MZ8Q#;D? M=%X(71TRPV:7HV9OW+HE.)8;5^GVF'(&G?KGB;R#L/Y;10#VJ4);G-P[]>#J
MQT]P;05/0KH;FH_)',>F@14NJQ+ZO1BZVV;:*BSM,<.A9LW).%]Y\#Y*U';1W%*5T'W_>,=[T,5!Q8TV8=MK.EI-Q= MIP[\&LXE$"C;[P7F1J-
]!+Y5OW>&&OX#3_X^B?]GQ(@I24\#|(=WM[>8]D*B M.;E)?=\IE7<4,/M]MC1HO6,LB]P[\K+*M;++$G!'TK/O<3NHJSP5E-V7'(W$$ M0R(P9E@
B5E!\.=%B[W__F_/ID4#8LL)N)N(:!\+QK .2DQY134X0@;" 6T8 MNC%$^DB"$ N.68S.&Y/+1.8 M+.)\78WV7IG9W2FE,E8AG5A662.=.(3CA"O>G[3(%L6 ;N'O88O>RIB-
H7MZ ME-**C68X&&SIA@9W\2U;@^0F3IAK8_YQV$^6"X3+'(,O(]#H.*,*[K33E&8 M|O5H"1W*>Z4M2[UO-.5))IV*3M2F'S!!]V%P.P@++O\>G!&;Y&-]^8GS
M55W09&]:24Z!,B@!,"XS_(A[;""S?!IQ82 <)%9_PX M^",$3L?' VW--#^,6;*BVJBB[?)1W;.5=D9I ZV_8 "[)VG"@1+R\[22H'1A"5>)'3?#R6/%
MCCNQ\)!M&0EYZU$!S+BY&_2NW3*PQ-6QZ%H?U^_>0M,5AUQ@,,+Z G_L"\EO MEY;K\?A)W@KK-MS/BGD5
P6I^M=^%/R&U;%W=&?SR'HS@[*R9SU50V=IJE$UBX94SQ,8!G>"T:* M+3=NZZ#WHEOZZU%Z/ 6#!%(TN4"'V9:R+8]'TF%>+DG4CDE]IBGES@"'<4TPA
M7@Q36N$&EA"1?GXG-=90:XVFT6M5UZ5=O>B^&G[_5*'3P_N6!D/O1:"V1M$; M.TVVW'!B@P$F/:,]P*>HX8]39D*ME&5DZP_<&[?NQ#]E=%?K!8> 6L?$.-I)/
M!& ^,":QU)",57Z"66U&+48KJ?8=FG!JYJR TD8MJ/OY2I,YI),US5[WDX"-MT3F_I+NM1)NQ==.\UZ9RW5BA5@/=C=?!(I>[7%:VDZ1R8'IHLU8\W2E9?VU>
M%+.IL":XZ:63]$S3B;0#5.][=VCHVOW^XO\9_]M0'8%!$W?2. M/)9T'1*<&2D@X9V\KVI,]P@W>78;%[S\>$(_NO9=2=T]K126X7
_B9H4KQ8:AVA_W']H.D3<^^9@T3=?!X{*N!56#/F$0VBF:=9@;V5 .?AZYN?JU.N(>PY: M1]ZKXCC<"R6 S\L0CCE43HM75<30C)<<>3DG)7G]]B@W?2'\@?>S>H=EOX6@
M")KKFAZCGN0!?%V,.)&!<.)EO-J8BF$Q;KIW09D(O W^%J3<@_2+%#&3.&P2 M,M%Z9*#XAR.=F^[*P -[,.U+.;3:#'N)DY9=Q*?]?UI MCH^IB2O)#PC,IE3D^$2G+
(ED1A\H.#. O1C_C:7X8(L90=FWF3?D%JD7BJ>G M8[FNW&R,-SY1\[%MBYI*K,/P;@;E?TOY6 (=GJ1O=QB;H%;":.=OOS0{(B$> M^_8*;T$C'4K34^?IZ7[]*?
T28]:TIX.>EX,%|S_?/S#.',#.JI0_3U|ZPM8KYV-_L M46RIQSSXNZ6_C\NEQL_W]ND|#>R";-NRJ8Q{$8|>PMF[T,1U'1@01#[LH-U
M(G=*9H;\\^Z7,,%"0Q)54E/EA/52<8ZHG'M9RQ.B,O!@IN\'%IC&A#8S#*(7 M65]C[B+/>[652;B $RBVNP;EOEWR;+1@VRL+)9&9HB %L9T0)(7#ZF?
MJ"R.;+,A_]@^GS6K$DG>0J;.RR*GS;V2<20*_'N9_%?D $Q#! .#L43@_$V= MVSG#<;M4VT@W8M^Z#4X$GKER$0'U]LH"%=$7O/ P825.!#'XG\$7R9ME/D9G M7N'QO-
HJ+/U>]#B T^6CDD*&0P+EC7+K50^R>#H=HK%//#@!(\QQCVJ8LMM*.M#NL,K33Y\)G-]+34RF+60*1NQ$.<^5(LR%!#@$WR^CX@>TANX^S;0!9%4;.XU-MO>/B\$6??
>Q3;U.ZC?LN|!UF!:$;/:H"G-NM,1*7HP|ERYK)0X2WU^3GPLIS M6$("V-F.&C>"&MA&H?4I'[DJ|W+2_ZA)'W4^CCLV<\VP]+X9MQ.I5MP&.MS;"QNW9'K(K9R
/WS'@E/U\Z3+//.+$2K@BZ1PZTN+T*_XSOGRFIP,@>1M M1G<*0#"-I\9E^W:%3PVR;?"F\I]7:>W12PDN-/D04F7E C@8)[*I%=,F4H1; M[#E1DBNLD)RN9G^&-
PV$O3#W@A;&LS-6FT(4S+OZ-9,21 MF*V*];G]'-]1B^ R%(=F^AW\UHX3;;8N OZ2[=W3DW^I,'6'!X'0AP5T";: M&WE5,C3_Z;<0_X)\;<(&ASF5?
A0.R%\,#G,_,TB/J@5UN|F.)/-9^9+87*KM;.R1CQ=7S1[9?+NL2U M\!KTCNPV&7?HG-&4_%L5OGPH8\!QB_";HIZ"#9/9MDQM$FK>57&/Y.!DEQ?_
MR0Z55M0)/@T1O;CG9'VJ[3+A,M3!!QJTP943CB]8X.?P=LT6#S[.PP1"ZK\8N",6)1\N[LU]7$ MY*B1,!-OJO*I"[N$CP?+X/0,.*NY%7.,U>M(C;38P<#2)!>F> ,ZJ7"ON&0*
MU;2/BX3FLL7XPVH/UH+YM%8?<6%9ZFZIX1#25[$> MBBPD.QSYLOWPJAS, !XS =<X^.!+ 2"?!$[S48$ M: *[B3P1*8T8(RG=Y"AV'/>"8HC9()(B MRX?
GMH)CD7^IL_X7U5$6;6BZQ!"!,%44_ ^JF @LH0^(0/P4;S4J(7R!=R(= M,G&D6=7N2/^UL0E+/@9^QR"_-'SBU1_D2#HAK>G27[ZX=#XA)@,2#GF"7-Y^
MD]+;*"+MEW#NM\ S\.IH;/%B8SS\X&%//C_7-JOU\,'-MY9 PU)9_4?QS MPN K'""@1(0BY0D1@58?K!Q0UG\D%R[R1Y5<'!'(79@N--6 1P5H[6NF+/X; M!
MQ5\J4.HX\)O:.+1,D.4*DY)8*=[/EW0R?FQ?V.(2"[84%=WKC2M4V_A(N98 M+O&N5MR_S(Y^]K+E>5).B2"9=.J!;@MG2F\<IC"*7" MR3HX+\J\K^$WKA+=8;E.]\IQEH\J?
MUDQ;3-# GM/L4L7>JW(U\]I!K)>KS\EAXI@35$7]TMX%1$!-I90YQ_FJN*%= M>7R+P1D?Q MZV/:<]$=_HW_?/><]QH^>]%1L1*/=Z$" 3J7K!S=:M\]2X6$N M{"CF2K_
M1W+P8M33?IM_/]QY.A(-XH;"^Z7K3LM3(,I"'A]LL[4SG_N_?UK*^"Z]P(2O MMT+M:T5&-+#:!L9L]2Q<'; 8+]/Y-37VNV>0;N5[D\$E?H;'3'=)#&!?* $3 MD:
[9&+U,R2N#MK06R(\!ZX*NKWZR=L;R);UC^JK:O+70>GQ6V&0=QG9E7@-= M\DK"ZMN+Z0]_N_MBJ7]L25,%/16/AP$_[[_%W].U7NO+PR@(]4M >96QCZOS
M#@!O74UZ.]* %K47HFH&A4XZ.8_&0W?=Y(TS.5\@_=ABU5T;"Y9 .P. M45G19KG$'>2IA;)#'78WA[?".AH+K+ ^F@#W<2/"%X"VOIEKO*^L>I9X7W%Z
MUI8KWC/,N9XC,*PZUS!,ODV$IO M$:,$;&!Z4[#X)CMQQS$0$/G*/L?):3@AI@-W4T-3:UCTL/K$H-2QF=$W4A/Z5_TOPV=0[<90+[_:YBAOECMY?C5$,6W
M2;4*0G=NF%GW^)1H M7T#O&IWE9*[9L&SM[A57>S\L#;NYE1\HIF:IV9]L%IM9R*%@H. MD%H5R.UF;\HA,Q LU51,F!)[?:T\")(81S"\0]@KF@+<"36\;C6ZEZCET5_
M\H"3C+O.]\[=E[52^]\I6%B-6+)2W.Z?ORJ[UD]8JL(^]ZRF7;:>T7M99-K-MS> MG?D&39N;:@*D; LIW'MB1MF6]B)D],!$-P.:,R;EK48*I?L>#>*O#\I80!&\]?L 7M73
MT>=,O:6L$G&E.R^7GK<;]X"Y"0PXXYX,JQ@'++A;HRVB!$[HV@3-=D::DX2G!->T&VZ.?B4=H MC]{1 ^?0:?S; MW<%_ ,M=`K\X\ ID&K[5#3^_.LGW!KZB@[F
YZ$[%P#5:)JI$,: &>D+XD,+ MI8=++HB9W#JGTZY!Q6=@15^E!IS5&B=%(974@X%FH)>(_C_Q)L?,_\8@,[W]3 MK#[@3 EZ)PE$8)L ^'[!N5[^1.FJ-
MDK")WT^^2/%I2+AK4G_.WR3P[NA@D3Z M#,R[2G^]%7}>YNJ=[.+BWCMH_V XJ"E%3Y!A14++U;&8WC#H/#6WYRF@H(Z!-3 M+W:.3NF3WC&
[%KZI*,AQU+W"L$)B66[8,K7]LEZ/1RZP&-W1;L:)I -#+Y-VF M33WJM,DI=Z%)?OLN73_*NSW/0P^^A0'Y7M#,&)?3O7"XW0B,%31X=[=[?=" M9?KJ_;*H5R=4-?
B>5/*'U(?"'707'5_BQM%6M=A,JS$5Z0JNWN:?#O[\U3XR M#8D*T%[CRZ3V$]5(A3E:NNF-RAVP3^D,[J6OC].L2%;)][PG5+A+_D$^;1E M+]^I=>C7&@?9A?6=](+%(\PX'-
=_,0.X6'M(>FS"!C^=RP8^0Y71592M;2@:EAB]U5T;"Y9>_]M0'8%!(9>.IU\CO@[\]N191=]]4T3ZK^5>;G?ILA*.EK48*I?L>#>*O#\I80!&\]?L 7M73?
2BO+D?R(R#_2!6A0$8+[-HE'![Z>;ZI2%$P[.I[-'6V\2OP^B:OPG\]Y15V)"\)TN>J'), M9#F_?U'2M? [S2M)(5\]2C""Z!Y $>)\U6*\P<*/JJ$?'H-:^TLPX^:[(3F[G MS,=)__2S#;-
;*X2+@1U'9GL&<6[TPES&P*>Z,B47W%S[8L$]?T0= MC:[Y 2*>EVX:[X'2TV-DM,KD:MHS\O-I=]0VJ*#]3O*5X6NO;6(1F1P[$, ! MOEEQ!:4\WV8EZK*>&[Z^-;T\MJ!^G3%-
Q2:Z1,6VT?P-SX;9Z@^P?NLS#')C M[HCX,]I_1:UX]O8$N]*7[*):.+.B#C\0>SC V8^%,V@UN=1(X2W0T|_I3M+G76<,[HD)18!LM08/ MX$N@DW5/!*/(:1AD-%+A3*-
]CGY7+C_AG*+>[=977(3]KKOM|,8\/;;)PF$ MMRX?,5DY#KA0E(YT[((.V_D160[*G.V$]T)6K&/YB;\78>VNDIS3 MO="A.P_R516_RO#D!{0'K0>QN+CZXX1PF?$B9?
UL_7S\U>BL\?!\F-=0!T+8 MO @1)X3 ;3+]P7!IA!%T!V6<+YITD;FQ1G,ZP<9M;6WP2@ ,W).VP(A 'U$ MH'>4"%!1AL/7+]$ Z?I4>7 T<%##2P.&>35F-"RMSNIQ!E-S
M79NW^/0XS$K,6DA7]$VC:#ZH*&-3A98(7(=$7$0@GOL1R%OC!"W"!YWNG4,A M%Y^0^1A)?!2(]Z*F!"$(T>;_+_\/RNB;Y!^QXM=!,;9 !$XIAA%"'"HC#[_] M-
X=;+6)XO3%PLDSV1=_?V'7U7_'KA22,,(?M=3&PB[2PQPTY"'2_33?6BWN M#FOE#RK=K)&$?G;I7GXH.M#0Y46L/56\/U9^T3[!OG^\%>=X;B(LM)7]9 MZJX(1S^T,
%"'EF@Z>$5-G_2]CNB69#?TG"L@SS-X0[>X1Q)@#LRSA0-^%KQ M8)QJOF6&<+FMX;M8*\)2EXJKZ&?#596;6^F"\\H-&#-1(!L$;,8!;J*]YB MF9;AC*T:,7A.F>-
T/[F6P&^V3H)1B75.Z6)GC8HT'@D!9VO'[S"KH9CQXT>3 M9<)3 F/>Y;?5Q=-:WKQPB:)#O6_XJ:=]REH_J!.([MO$\[[F?I!)
M$^G0G%=WN$AH9X5+%YP.7N5CJ=Z341%;N!7,/;Y=526|GU>ZLY5'K5E/Q+ MOS1?W%B.>WNSRRI(=VJ,BPNZU!BNP!_KJHTV^)+_DZ2SK%JJ9X/3J2XMH]*B
M77[:53R@IK%UM+[ST3B!6H+%T,KIU]^Y_--S1*\D[3PNK(Y=1>?S<(58G6OA M0-"5I^&&:,Q/7&< 9DV%/J.8M*\]-M6KB_4=[94;@"IKGN[&VHT%H6D?90F^ MA\T-B0/7]
<1[\AER1!M!'RJ9,?([3&BWR$4.& F<9W(^)RSN#6:UZ"5WF:<+ MQ$%\+W77,(^&\>79]#22"+P]A+,,%^A]^=47Z+ MK:VGV:5+X/-%\K'E]@GO?
<1@8>'DE2P^@PC&]@6D&5CKQL5>,^+I/>&:M"@CN^ M'ZQ;-@^&KT(^4JDI.A/\/QE;81)4Q1_!K. FV-I#DQGSH* M\!M/$]"'"MNWCS/=9D;';,'>)5 %;]1(4L!UK@-
LM\CD3;F"FZC|#*\^,P%Q. M)\|/'D48)O$(6%2]>&V1*DAUW^Z&\=>N$?,CZPN@RRT/$FARO3ZE.I%?G%&= MY$?:]P1?S\|1O8G.-4"M=
<]0HV_.5IQ$G8SS*Q85]*NO")GK3VKT[Q[SH* ML,"5UPJL(9,FMXKS4%K0Y5Y.H2.%E=;Q4=O\R.KQS%*+:+AS14,"YQC%3ZJ
M)I>+#\=WTF'3ID94RW%>L;6\]P"'"K_Q.E<"_J ?IXH]49Y-KM.L.GUGTN6V5X ML#W-@^.&I);4\M3?#W"@6]#W-$F\9.J\=G7-*"\SU4KJ9/ M31MW)
<@IO#!U/#A?8M!Z>.3;=M;_P#[JKZK/7_\/*>84V$W;YW%!"5)KT7!:0)2!.D)"#2 MA=CH34&ZH4@+*$(B"]"9=NO0F1+K42.^]2>BA]X020@N'9[_OWN_>^]GG7.=<
MY]SGPWR8R4PF6;-FK=__7NN^IR2_RZM@",RL*LU1B+E$(0RM%1(0*Q"->Q. M:$@G6ID\ O'F#;-"[I,&CDH5KI77DU\#_RLA\0[/B/N X=MES5,RPC> X^>F
M'<\Y"BQ%XJP=65G\VX+.HQ_O+TL.^G39B!EW>UP:=+=E@8CBS: W!-K6-[= MLYFN@BW7#C[4>]2+6,%B =-.407@.]D8\XY.7.&)R&@8HXU6A]FB+03*B$
MHIF7++,A-^=;@8R]V*"+6CXO0S@'"EY9MS?-CG<+EA4OQB)>A.Z4KC:-[O)4C MPF&?_7LY)44P6NFC0>L4+;E_+K)S\OQJ+FROQ8$/WK(==-/-B1(OT7;&FQ1Y ME
KE"C=*T8#T_^U*.ZBX)<[PE!LJ.\2T:?X$STVXHX7E,YBX"?V+X_@Z6&=BK?9*,/KM]>O]E2C;LY%S_<>0N.<5XE3O MSE,Y=U/.2)>I=DDXO\@K%T!%6U%R^"FT:G&0EO9-
U'N:F7;9V;E>]7NM"NI] M;B|=NIK9KL4C<+^9:CIF$1Y1;},S*$$MR!.D(0$T\O^FK>OQY5PI>IB*=#]6;X"U%YG MGCM&3QK*-
LW(L,#TVX>.1R!*UD*GG(A/\|C8^-D(I%*T'H\OLVC7[.!JJ'1 MRC6TI]"QJFS\(G+_4YXG=Z&5C'S4;729>WX7BS)+-O_S5X&Z3 #O&R|(_[5P M|,\C2_]53\A4+OPHWNX-
//:BVRL5^G(K?S^DRNTI9N:#!9AXE-3Y4DURK(LS MI$POUBO%YFD4=\Y!8S_$%*7O)<.I>VIG^]XL[<2]BJ=C@']3(J8C.IYY)UH.W M*<(*/=\[BQW:R+L/\ W_+BFX=%RX%
84!@M6708X]\K0)+ODTGN8]'K\!/HO.RYMSOWCP=0$,P-<\@\|Z" |-MB=ZRL!N]SF>8_NG. :._-M.ARM>:67Z3 NP:LRUS;&6UT1N?Q MSA]7PK:Y?T6I6)X1F?
*\.FVF_:.%>T[@=O4.H/C*1**@^#B,,PD!A8?MWG%:*-MD2SPM:$L"_@3'1>1SY)G.5F#(F[&=X(UA)==\(52WHW3(H:2[F-)\MPB&PBX
M#T.ZE<++X^L?'63'=1T0/&Q/G)5P^#CA_]Y],>S>;(*)Q@9G8X+S'>W#!"_NQ ME#=]^V1VR>64UD1CRV6T&223]0 =|^&%-UW'6&"M8+ P,[@$'GO]*GARD(XW
M+RQM0V="=P$U">"3^!N964R@2#?Z=0Z.1@BH';O*%.(4$S.>(=_,&G_JL<>9 MX*W@\]0*#@G6V&?G[".01',_SMEQJ*E)1,(O6*^CA%G1VC]B!=,\Y!4@!F1Z
M\!4#VN!C]GJVBO B-9KZ!CA^:4GH?&,L>&<@K_"A,>95%> MO\"%*%,!QY''J6>F^S _2[$#?-'C7!+.PE'!NEU0_,E'IQR.26R5DW12! ML/NF3WO,)
+:;]B<"08)6$3ZZR=ZE/:;X[D\VO]R!Q66\U5 M)2U;NJM"S";-O/UL1L?U|_R'")?]!^Z@ MNMU!Z+7]$#VN>_E:R+O\?&'C^V7LMM0E+#!77_!#0_T(IK,EQR*F+_SC/Y
MT6(D#PERS-1596#LT'W;U/1+;NJ^*K/F336>*51/@^U O^\P)B3[_U1V0_\9B&\8 MF$E@C:"BSR%ZD.NS7E6'/6LOF?#W_]L#0-R?LS1+8!WD@)-
$F9C)CY3>QK:>I'G]_&3P]K0 M7\,%I-@+(]REX=21\)AVEQIL%WT#"_#'A<). ^]RY]XU?GIQYTKUW3UIG6N?9[+R5K(LY]%]MK(V!RN9M]@F8%$-]P=^9 MZY#*6OI>Q-&QP.
(PW3+R,9&<'-NO3L6;36:-K)KXGD5?\+)(P+>^CY*7>S M7!+%7OMA%DH%GUGTN6V5X ML#W-@^\+#

A'Q\;"MLOR92-M.GX>/&\MTL65P/2'{U8]@LY!],=-(=1)VSW^Q9'B&N=,D3$1LWYSN\7WIOD;)9^BLB-MU'YIV?[\H27&5&TP84%]I\TI]J:NCQ9UX,
GPRJ+,P;HZFDVE=+1U:FUQL@[-MS]/6,],5'7VAR_003ZB:?A379UO/48AVPGDQ)UGH31V:2R-MX%?7>)C[3UTC[Z%!6]-U?SG+-?4_-N$/VZC@4N43JK>[FARG>)?Y2?)VHW
(-MU7:?/?\M'#6]?]-BW;>*IPZ(V"'^LO#4\A.ZK,_C;"?Q<6G3BK]6'&=:19TN-MB3J \',G8*A-LS8?'Z2@^-899,8>3I^5>+E+G;?G1;QG29L2$RV%Q,<\QKTB-Z*
*M7;CU^3,Q$_^O{BO?),,"-F8P[5THV&_U:,D/,+^.K)=?#C2?F6.H+*,"(E-MM4&@=@RK5]%E;U?;^LWW:+X+=WQ?OG-Z\!0385,F,2CD-[HG|O?6'2H4VUA$-M?.]9E>*3'R6-
*W=E7%&2N)2'KBU7HAV?]7#$\@8,ZS-%W=12-1C$[8D:24[=' MN^AGEGMD]%674CU&QAGX>#(:W8]_IE;2)43YA_&7_EM[,M4_U?3_<]6_+$VM-MLXG[FDAR-
*%,ODE:NKRZS?/S_Y=*L,@>49Y!;3S6I'HX"V/D@;T_$Y(&]=T?-M<,.5 -)/BC_(!D[HXTYBXH-VF_0G\P8*#IZ\6604>-V2V5"_"1"P)H[@K+Q-MW*WL1 6,&(HV-
*NXY&M"9WV/52)FW45MB\^"Y5"+-VM'\6O=Q<W@#1))?C=6\X-F M&Z*K.U=I*VE8&_UH%@4%1#U6>_3(!"9{JM1,E9"H+|*Y#T_/N//KGIZNZS-MV-C.&E'PNCT@QF1"-
Q@W.,3=1=A8<="H"EW(R@,WI?]N6&';O%Z'LF FTJ M!;,R0/03J;@^0A6-(-I, M?%Q_TW0,_ F]Y]+ \)T20]H@K2_..1,??ET!@O$?-5[M/!NR*XS|=^7+!>"M8&
*MED5FAG_4<4YZU?.1L,XZ=?SF=&KRP_P:BVAC)CH;J7Q(*6VV\+B$C+D"2/0L;66,B49X=_3 5P80+3G|U:=^(^@FW<,8 MYK ;^(?@K0FC'!5\|Z1V&[$=*08L$A
*MZ%\DC/,K.4-F8:&]9%2&+9#Z(_C$/WSK,*3S?X1Y<9V9!WS;R.,E$"'TX*X 9P*V1![_W17~_M/V&QEQ!;C'C3?$(#HX!+^5N?4Q/PR15DUB-MBH0S"@I5(5+AD +X/:C/'S/BT!
G!FCVX.N;=Q-3G%P6V!9{Z^47N-]800B-M>X)PJR]!0*%C2_?\ 4PN;NFDA>+>@@#$TYC4:.(A',ES>'$%-W3-NN3=*2CD-[HG|O?6'2H4VUA$ M?.]9E>*3'R6-

MNJXA.,)T0U71MGA]4D%E0(-3[X'OW;3E@'!-F?(^_L7WD,LDP+'OL$O)H6L5-MA,@[ZADCRK\S:ETSGH&:4WF\ERR=^[9=Q?!2>\'}6Q+.WVBXHXY#)IL@RR@
MJXW'8(<N9O67-/.@"W6J"Y>/] MQO&R2P'4J$XO6A^{'KV'FRP)4[,6?9.2#BBI2#5"MIO9*QJR1I<.I\$;E)<=/6:/74Z5[!5Y/N# \TWD0?YF)6JV W2U_ M74"7BB-I?;P[*72T>1
>0NJS*34FWOO3ZK8@L6AOF[?+CM:+'&"1'17!S=]9 MVI@L"$MS=S$DQTQY:2MJBC-R87/U!&SFB4Z[T7+">$?ML7X19;R"2Q+,P956 M(X $N)8;2%6;B'XX;CL*?
F9E0>398/.JGQ4AO(?XV)?WRWKOQG%&8*#Y@?O)96FB%4$LUL4)GXKZ>FK\W8]>'IERON MICO2UU!LYR]^.8Q1:O<53S\HT"]PM)!W=4)<-#0IY"
<0OW+_TO\VZN7X0V MUF(44R"%.5YQ5'CWS6T4\?:E?+5\\JJL!_TN%7D#WI3N5((]G#Z?2WYZWIWT M_LV+]W^5^Z'A$>+P\)G\H":C):T ,H/*D6_C";L=!N?.I0/O!KF?
W'W4W5H8 MO3N74]"M)KYIM(2ZW'(-DDF!{0G'OT1##MR+-KTD&EZ[290]?-^Z(?(@/=/7 M)BYAY!,ME]'S>]I4"(3;__4%HV#+:,SPE3.Q_WD#OAY86%9\UVG=%RG3YN=.C
MLTLFQ2NN.+Z]SGKH8TS=,TQ>[G?9.-]Y=>?]@V3V!3M4\HE>)O.AIVGUK@#,&#B.!XKIQ"PIPXQ^^^G+]W4K-]O=[@M@(:-:.SB(#_M2/&WR>?
AB4C"]R0I0:!\M=QQ=&&]W+8/QEDA6JEZC/9.-K%!ZFQ1"_>-@LX MX?Z@<8 2PHG,-.$D (=']LNKVXY^=E[!.KY>?>M_M% BLI <]%1??[+TA-TKN MM31(RV?
D_3U:R(+9^*,^@&I6@^E(@#<:Q6(C7:Z%%]QOHORYO]M.7-FU6BS3 MD8DS1Q/I\51UN!A.(AH4G3?!4Y'2_O9!K\,G"HN.[]&@SB"D-OL9^)MY?OO0
M'>C34061=0[^";&ORFI89=\&.@;O&_NFGZ,?O/SPG.)1YYHKUN4(D02SVQ*, MD3Q^28#;>+":64Z;A7CK]VK\4K5*TF1Q"=E!3IFP$0J24. /\ M(^"R9SBY{(JS^1-
P1Y>Z1;?]/&7Y,U-P7>+KPN\C7I)+DLCRCWWIE3,S.TC MU$(FEWF^>D*'5O'Q&%2;$$OOGH]>C9%GTH+K),!L MQ_)X#0DP$SZJ(F%BTA
]XOEIH09A?9RJD>@R1TWM-N12LX',.YH,$?'4OJ.] MG3FQM^DQ_LY=+[HTAT#-U0&OJD&&D0 .1#A?K*21*_7_WUM0L;] 4_[SH V MZT-.P1?
[:N2:&2P'0!!VZ@6AR6K4C;R]\,-SJL*G<$,N0^"1%P4^R MD^O=]:+Y.^D8E[[=U^G@&DS>^AB[CH8-<[=NXX./ 9!@' 761GUDE\CIEZ]9EM5]<*E5;#]72VUX6K3NIUX?
4"^$&%L9]0K M?;HE9=,]AU;6W?'Q,9' 3>]G+YGYK?]#73H_T1K3?N1%!MZ.A-HI.WTG&ZAC. MAMQ;$'XG6CC&?$:=0=.?]%^.WU!D]V!/]F\)AFVZV9M^4BQ2Y M5\]9E/_Y
14!PVF%6=*$YM/I;FG$CTC -.!)3/\PRDE%*GEUG38B[-G+HK&SQ MXZ'C!*/YQT671^9/!LLY?%!8WI&$88./HZQL$Z>>O8T1/+*&VS"NQRY2\RMO8,:V.(>
MR4=0$1P_%KWW+$P=%)00)-0WV_U*\GA1HU'' 5^!G*O,Z#]=W0?&XC-Q2&1\Z M^K(ZDWF+I]LB+K.C.A(CDX58 =.Y7N\ICP[K4W3JZ?08)41=VU3E!A:E"Y^JH
M\WX2H+S-QE/6/W\P5M9K?BQ-V2@O,#X!9\['0J7<5%HV(R.-">]V'35SK MFB(S9",%PN;7$'X1, W,#\NTCKW'#N?)CEYTG>=% +]J.?#0V2.9BC3]FR
MKN3>FV>=U[]!V+M]^H/5.'^U3-H7)!(M=?&*&;&VFQN>CX:EC.G--P[I)OT'I1GKDNY]4Z-.R)[4R?^1\STF[R[IM$A M(!$*ML7)612#PEVH'.X#YJ#CH354L0+;$WM(>-?
G+&@2I>'/[\)U;]C%;?GS M([E0QBW1;XNT [":L)U'Z+A04'5F5-[T_#6Y1]D:MH666T\'^F*\W_/C<> 1J M?'?YL"]XHCI4H<8XB\7ZN'':V;D,47I^M[MI941O$MRQ
A5BSSVPC)83-8* MZKHB\+'>5?N;O<+8L/:ZFE1T&^HH93#BGY)_N_@GX0!1J$0&8IV4%2+*,.$; M[T(=)?5#MV)'OA*0K__;7 6*<[PRC]X
_RUA1M+3@)$R2D60OQRNP.T].H3 M-M%*?C^W-?!7W]_+RNY_^C5[%MS[HH#?T2*@;E1JT?ZKO/5PJ/N00"(A"SNE0^H,-=F2PC-8U< MZ=JJ$X(_8MWW9.X"?
R'EAQZZ99D9!XV X7C@@8(_NXI!6H:772F='EC4-^O? MV_+_GS3 ;2B,?JG9+O'QNL05N,#04Q.C"Z_6R.4F 9:#]Q$C;?AY$B HQ<'5 M'NO:8?Y]=&5A?4'!C5L+?SK??
CQ,YNQ&),K'9/L7_F9SI8)B=]3@8?#&Y6.6 M62(,VP)'-QD4M2DP48K0.4_GZ+[_BU:'1C6K/K7Q9/-GENAN>|_VF$/Q3Y6UNX]!C%LQ MAUEQMBT]CYTG\'*8"%/[!"77,\!E1F
)S=@>SCU/DS36+XF]=*7PRDG9A2]. M0[<#HM#:)3+&<"!L0F^W,OWI_2B02#F7IN,?6U?2$*I$U'FB9]+T6) ;4A@Q* V[_6=P+!]YR!CP5]DQ]7>LU\CV^[9/< M#\
(,8.A6H05!CNYY(*.7Y >=F78,."+<@)S+LZO/8>#7B;^MA3'(KCVB< M2IG/UXl9*Y.?]]^P2]@X);52M7!X_\@JOP,Y*!F%HGES9"'^&RI?,HUR54.5+I)9!DMS4K-J5<^
M_F*9[VO[CBFH;XJ,-U:0L0<$:+D+%?_M?(2XC=,_UQA9LU5TYS.VM#LO.M?@ MT\VQ&2Y55KYN/ER0X"S$$===KT;0(K!Z*]J.-,@_KM'#6NXHL M@~8Y#-O-.+R_]/+1VBZ?
7NR]{KOETKMM- >?.N*%NXITQ/ B2C?)O,$XK8MK[M,U)*8 D_XVOX G@DSN(,AW,?{ 148< M.V<#N(E%Y&/.^SS.3<#QH]M^'Y"K2W M)9?S^5-]2DD
)YNO.DQ5]W5"T4K1U_"?I>RP3:V#:"Q=SF+QTCY*A,/%5GU MLE2>/LPBUWV'_K:E%$+-B_X!_1C6A;ZM0UZ<[+!F93_B6N@?S I#@WUXD]2O MUW'/)K)$N6_HZ+1?
X[SS:S0^(SXZ;350#.J+!?QN=8 YEU!3 M3+0+X);A)X!\[%6URX4^@L=O<4G8.XHLDV'XNS!87LLS;S"WEK#.]D(',.S- M\GY-MA,'Z[A+!.:Q7X"L7HT[VW&=WI>5F#
[@Y$:0\

BYH)LHVJ#D+KYC53YYL$+X*G>$M>`^&*,!:XK-M2?;+[%S=S(XCH1!=Q2H+L>9-ME_D*!>Q86=L3[UL(QHUZ'E(2?R"1N^.'KHWA71U1Q8)BW?A&WQ&{=(V-GYA<_MPH_GMV%YWR05C2^O-0l?I\+XW+1!64Z]1,ZI?J6V?LPNI9:=@!JA<^7735FS-M-.^E((BMN]#2O,=?:#US+IH@':_JY%!B(MWT>IM!)2]>S#]H#) 0OI!V&H_F-M\:7|<^=LK5]W];B(X/H0O2!^3.W)>*9JX..\+)HWRKC9:ZT#$Z>[-K_MFYZ!A.%D9VL!\0CD&MW@R6R*>YPKR>;A.!3X7OJ-"7OV=AY+(_<-MGN%&T3'?!OL%)65-\,4/%2X*;$64'.'OQ.I^8%!M7]_=57<3MT1=VGEYOR_9-M-E>>BCETUS=-6)O76@6772IGC2;/!':ZS3/B2AU*AME4L^/G/^4(-/E@Y;M-\HIW5=1E -7UIB!T@[/YK5C+F78W@'U>,F@VXZ$Z=E8>I+E4G?<)!@!PMS;.9-MH=_%P^WS6FAP+M2P_D?C>%G%L!N=!O34/O5KM;*PVZ>@6;)@-9(ZM\"!.ZUV-M?4R$&/UP'/TERIKIT^+1$+(;IA.>2'E.7BR'M%-CU#!MG+SL?3W>R-6-T.303C.M5>CJ=KMAE>HW"!)B36YX;A-3K?"W];<)=:.2T;D.I>8F"K;\2*ASN^*]IG?MWP7<<$\CTE-=@^]5+UD@\|9CNJ%UOIR"5\)<6)WL1Z.IDF+PVSK.E$2VWK-M/5V.R>T<(2(_O-L\E@FI!*R07TAYLG7#(+(4+MA=4=;^TAE.M]9F#7)NY586_,!1ODJRA..2QHP2S&EB5D9FIHH|.OZ#^L._{=E"84GV|=6-M7;X!%U3.!U?<+3"UO_=4A$N!)D^48N?.F9)O $_BW]5S^]]^BR8$)PJ?U3[M'J'/-2"']>G_TJJF&-O+GC"'"'%[1V_S5_G&))-'+/?SQ#DV,6=!;^M_(J M-K^_),K-\.A0_.O7I,V6R"'*_WZGCPH,F'.R<$HP=5))CW+KUZ=!.N/PGJVOI-M[F<^-,'=H#V\|F;(2,#ACY2:*D2LX0"CO*?NU<6'/,((L-8A5YLBRE?-M_-1NTVY@QU83Q.9:ST:XT*U"8Q40[140J5]E^/)M=0-K3*W*/V1M(.V.V)B-M>_E3:&ZP|OI7*Y]S4K/YASL[?V*;4M3.-*IGG]HT:]6J[.,M.7H^"C&L-M.SWL&C;6NBW;,I^\XY_[W+6O/E%2X2#QW[=T(*Z*KR;#+-%?GKAS2E[HK(J52?]G;S59&T?:,CB)/J F"=/Z;'Z'X12+)Z;&@38*]RUM*.JW'F_*V/LH5-WRHX%TK62M>#.N6L/KBN"U;KCM^LAN2P&RX>XJ<"7#Y'3:-M1NWB(W&^?:?-1M!DZ*H?!R\.^->"_7|UU51U!.1=IDO3PTGB9<(X"PN_N_MJS@U:#?S^>F,[+$.U?;)!M.- H[?1/?C6FMCKJ@(/'V<=:&/QU?90\>S]E..FX'8_CRUA9(%'1*Y'$O?W+[" M0C"X&>+EE6MNO%T?4;@T1)I';H*PL+UG3[*VKD\(=.IUT4SW,.7<.VG/R@;E_D(U[\3(OA]GH MU;?U%XZ;]2^;1]09F=0=W@X4VH:$F21^2)2;MP9"ZF=#]?$;W5*3Q<>]\8?9S;_P&Y4TA4KYK&'_Q%MIV3L^Q:@L1@{]@MHU-M?{O1VW^(U[F4DJ#+WIVYP7!-/[]-M,F*I#RR3Q(WIA\:TM.<4+6FK5AVA.$[U_)UYVR)G9@KPT[RJ=H,S-EL5_-M$-M?^HN?R_;=FP4HD/Z,)Y[\R3-=S348C2^]Q9:T[&*9;CSZ1*^>-[*;+_+3]+K-M+[YVKV1-UVQ>5O;9PB7!"-7^WKE'7O*[U_894[ZY[.\O)OJI%E7.$?(#LX68-MI-'K,YIHHGROVLS//,2CTXNT4FV;\4H@*M?2>$6@ERY%UC*@^^77;/P_3>E>-ML?EOF#.7VDM*@TZB[%=DXLH?=\7@>]Z>-K]YG[=^LC0.^_"UHB>20V>.WHH1M,U.=+:,*AWC9V4 <-%?N8 ?M8LW6RN^,#(;D%C]YN8\.0!YN:T3>Z7+"<[<%2 MO"_I}B7L!7V@$CAT&7-8.T4M+%S2V-T+:6SZ>T=3)42_-->RE6F'Q7OR<0B=99^*GCIT*!&G 5WN2&2T3HY\/_U[.I##W+9J@EU68 MV/KOA1C_U6\!5]EMW+!O&="VR14==7VT(LWTW/6-2B[1"&/?P65^J8"UZ'8%M(^U"KFH=9#/7?0$I#UL^S+:K'FDHBQV57I[9L!{=8fOQ=1 D$PM]N83>?^F!R&ZR?,.\%M M2_=N13C$/@(RMD/-IR\'CH?'[4B_%OBL3FN9#ZVB]Q4,-W-^+Q^YXTTMM%8 MU4GH/C.:]Y>3OA!"]2VZ_0?=E2]K,2B>[*@WZ=QBU98&2]T02U9CR1("66O[S5D&067%.BE@ !QN[MM%QWA:0%9)%?Y%I*#C(*STX?->O+ MW?+*H%)QO4TC:)HGG.=LG$$/$!!]^)F1/?JD+=W\3;CQ9Y|<;Z\?5&\)&GZA MMQ),#[J6PII O6-$"BO2CZ0:/EMF0NR3?_S1"@Y7H+=T=!C,;)EQZIXN9 +W M#9U?YZ]+A[E0C&Z_/=2Z?_#EU_^IFAW=V.QW=< MN2^I5.\MFO .+G1!([- M1],>&^>'/+L,]66XN=*F'A=NM,4-_8>^2;FTF]):C$R<$9_+'"'C:4>U@CG+R M?!8AW=I"*(7ZFOJ+H2KT\12.6L3=^,%40A2B,3HZV+LOARPS:OM#J;-JD@" M!% 31N="#R$]=P'PS&FN+=G"^ITFV3M8[>_1#U8-N M&\[_V=)%Z8\)"_U4@&,DDJDL"*^_(0%%MEQ(1C;INXY*XMAD>T_53=D0YJ<"-1DQ'FLUV WGI];N6[<;E9.7LG(YL% MW$5=_"RDS*=4HR'3*^*[ ]'JQIB(4Y;0_5H56DGU<.1)&,Q4FP<3),Z*QTY#C.KU%EN1DE%N&59^3B9=6BR]/RW=7E M&?G8:1&|_*)!EX)R5C-8F;W6*WG/R4;*6[%EBJTVL<=U98KG584%8B&B6IF?29QYDYDSQL;5@OQ2RNGQ\0/ZF$QES\V9"8Y"<$TSI%6OM83 MRQ&7O=1PP$4/0.)+M]N8- '/T6*8E1OA[V.!-QIA0.Q%[Y+P.JFGF]2+HIQ MK?+V!. ?J0A.;/2_GOJFF\D?@E;(']J_Y]763Q4.VS=;T7GZYIT2U9=E?9?B6M!\M73*_HE_-Y7A[TO\/*&@ZHQ<;XRU1! E4JH.[7T3I=)_Z6U$-"A< XQHX;@C3M<84D)Q\)R^^?.MGTEKB@]GZ*+HS8NU0HP$)^-E63V"Q#4NAHU@B?F.:MM36 MC$CQI6;1@E+3]/&3IXZ!PW6U Y]0W2X=HQLG'V6FE7O;@./ !|<'2LW*^%.?M=P1ZPXXU%Y;RG14V'3(W4[&Y?4W3\%)*8!X?*0"NP9X;Y[#"]F=ZO4UVD<(U4\ZE_D")[ML"F/HS0R\Z M;&]KV*DWO' "]UCA?8?O2%$?1B6CGBM)Z3SRPZAN1;0B';EVV61&(KO*4V//!9VI4]%DZ##2(>''TRT_8]N".7DT1 ?N!I9(M7@-(R4$]#F;F^CBF#=G0^O=\%.H<(C_-]I[U*+9B-@ ^A+6B"]//_;7CBI1? MN$=D&!F]M;$_0""4&O.5Z(\'YYR*2W'WLLTU(+]*/\>|UT$D+VY^N.[H1]?@=@M[FZ"0X7O9"'XM M:^_/';C!U_,MJ0K>/&U\'U/UW+9%5]U7Q/8OI?+[T<;\?7"9LCHH&%A/-JC0MX/L22ER"SI4CP$TVK;6OGGV*Y8OT5>N@A&6(@RVCA^E:\MQ(\[(4!]VWJ#]E M*EU3CH'T>(N*([(4!]YWY$[D_JPX!FV3HT41>-B?!2=Q^U(LK&B^)8 [U= MXQG6A1S8J;/HG*GX$-UUP"Z%F7"'"+L618N* PP0TVGG)HD",]',I,"X,+(N MLF;DTO! Z/L<1W(@31E?89+F"AX\ZIL,*SZE+'?7F#]XY+]QI_C6S%Y*Y>|8 M*48H6T%*.29M%8,KZ@*?>]-AR=4">,%+(@{4'./]9ZT28F/R?-D\[6"]1+O_.:!:(IOY,[=%;OV]S>M2@)-?9FO2HY1NFM>('H MU)F2Q3M#WC3$4=PA_/0KU\"^,&R.D;.7'X^Y8DA@R&]RAH;3V=]$TS|*4C# MR_7GMGG:-0"_O,+%G 'fYG,2ZG$\=]5@R83)9],.+NB*10P&-DFO5@/1>O'A MPQM#-GI#]U$R'SXF'21{4*!-)WNIG;*7]3VK-3+---Y*O4TRN[_H@V2WBD)?/MW@1Y=ZT^>,<-%G<]Y0OQ MX\7(/;^_4(EG9G?:1]8E=_PHZFK""'F*C&_#$F?*,!,;@X,,& MM:.E'BN.2M@'LIV5"=NK$4&M03&!MM\;8?S2@M$,S3B3.8C-!?L\<>N%E\0 M=I8;9O1>EB)@-_>X1!DWPDX4K>M$%AH11=YM5ZV.E"(J>UMO M&K]M0QUGVAN(B&[*\=6FJG*)C"P/QWXGE\VL;=,B&6 /&PG?P\=OME/^M. M7LQ@6VRA&X1D$:2-/@C= VH7^/L5#C\+"M/#?[?JEIF0E>N6$0BI%1QXW?MN L&1;,7$UDKG{1LXF@@R\E7 M1&B_99-KP^6IJ@RW<^#DWTMX4I34P=U(.8'PK+#;D(*G.7WRT[C&M\!=_WH MB\&]"Y.?DVTO8:F8L?!8OVXR;XIK0#83^24I]H0D?NWFV?$ G&>?LO<-^F?.M-\JKO=$O9?N1+'7+TR+L#HA(KL)(HHU2"\/![\LN?\KE#TZZ!E *9SSKVC@WQI\\9(V-&.[:U]^ M3H$OL=?S-G5OJXQ%0CO^FYL2N*$YMT-& #<&-VK_*L.916"L/W,)<;$$;FIL MWP8?=K%&?=0?U>C(M"IFQ2O_9 VMENQE]C?N:N-N0T=M?G7>KKE01?'F0$=Z/D479TRN1>B/(.S'_/T+RI\8P[2">PEV@%&&?:TW-E2[N%%1OM)Y^>8EXI!9,/%SPKXXF8LN$'3'5/P8SX)}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l,6[8';@\UD,8,(75[.-[)<2% M)[^HS>0HS%S96%G?C*WZL^ZK,S +,"-D#CLP;$I0Y7&;>91\B\^&9TI893WTM<[''\OH0$7H''P)WZ8_J3[9JB9R3C=:*2DK&Z(7?)\6+EF#(3)U);(_I*#45 M#6+^IZXYZ^CK/Y\S5G/@Y*94,?V)OWPKH>-<_WD*K[T?]1,#;]Y[%<.E3#%N MC\OYI<_O$SR5.%7^> WX D|SOSA-;)]9N3EK-@^++9W@ZXNN'7+=;X3 @-_MY[Q_##A?;"W7N[V\T_=+Y?>*,3<*#(*SO4.6Y8).F1[KGX227#WES0YM?'Z@50+\Q(T,(F/.U^X:D%!CQVBNL;B(&:IQ M96JG:MG0^;]PIQ+?;156R/> M3.[?$EA\X1@/Z%75_OV!";)^DQDS2.!=;8+-32]ADRZT="O$@#*3*8R69LQ M\MP[/N:*?B')Q>|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|/S!E+W94B\IM.8OO P)BU#'!\ M/9^4(N;//ZG6YFHCLF";X<>"3*ZA$ -3VA-?=-QU),K)>T?N(M76VF9ZI.[|' MNKD MP^%9Q_;|8X1C"T?T"#XORE!/5A-C 9BOI4R))X7LUELFZC(#)1NU4FB MTN9V].P1"\|'PIU_"^WN^?2^W68F!;)GFT4T2U,LVE*NFZE/?),)>OY8[RF3 MWX6LMWCSN/?2@QT'D1;XYKRMP[!1"H\)>U)6@%O;"6:M13LS\]Y~]06Q%$\8+ MM4,Q&.PX!&_UFU"(!N[[<\=BE+N7L 9-J-SMQ_.0)]ZTX&EDJ,I[S:/LHC8 MIX8FG,\2_K)=7!N5-*]R8CC.SW3G4-!R8%\"/I?@8OO3B K2'9Y?;+N.MZ! M5]]HH-/>$IE)W(%UM#W$35CTXSC8T--)YMH5[IQ;!XZ9_=U3I|\ M^_;_H:-'_T&.-P6;/00(*G8/44=7I('+K+F?F)KD7^R2<3;R'(L7AK@N7G# M[11-K#B>Y;.-'3"^-& M7IXC1T[-YU6M>0=>U6%P&1)W^IY,_GJ,4B$R2N;(S#|WCOI#S 8/U.$[7C#W M[\VB_!&ZJXEDA;&9Z&#T_JPOFD9!X<^'PR^+OQZ8'@ZYX&S;SYGF7(DMSX9.^B.WCY4 M\L!+&+'1FN*8M?D|-,Y;ECDC-?3"E.^)WCU4 ZKOQ0!J[-6D+HD &\^Z$T@-M"8I(*E(R;4T5[FX8GD4LW.32FH PJ5W;8,/S'@98G;+=DJ MY2RJK2DMVJ.9."24FCR"Z>DO/4%%Z14ZF^A\,&62W7I?V#)=B3 M:'K=DMI);KEO!&U8EU+"7XAT/LM:DG^]EG(YP\H+,3]CLJM:975\31ER<\3&?WH4=CA]^<6-A?7UPJY!JA]@+Y& M"2W#138>BN-15>?R_LP=W)"I;L>6NJH.?WBN=P%4)-8E#ABF3#AHEMY((6%) MMKW>/(!^C@WL":CL. %/K;\-,0VE9*3#4"\XP/;M[F]_$ G'H[_3A)^.$/-B^>KTV/(N(\CEK2.1=*B(-&7)OTI(-_*\|&"R^<&N$ M<\S^2[E5,3,3;^&HPS_59$@N@:(-UQI<_&_"""HDQ]M.&"6D*E<4GM=[K2>G M>W#\8,,W:JPVY%Y1GF]:I2\X1XGI*U/M^W %(.(,*=*,'NG,.[&7E+?^&98M M1LQ<)6[YMJTGW,77WI<:#8^H:&-Q7U!H@#O 48RK:]DS_+QDK2#\|%4! X-'M[$^/@0'@*2R;>\-XF^]2[.+3@H?Cl_+@TD+^=+E,W8_=!%IW]%Z(LTKHK]$- MX.HTQ9R%"_NUT-7Z80W>GW2]5GO]XX?XDB|_QN_5NTW-^MTKTUL*RY MWDJ-]5-S:Y,N0RI+CZ=X]PT(#"I-O!@E9F7S[OEP^Y9$,]HOU>A6F7R/%1/4 MD69 $-QY6V']9>%G:UUBVOGL*K!MQ_5^4?E538;LQQ/SY$Q@R1FNS:>K9?(F M/R5$P.\!>]J3[<<5AW^Y8__6]9=U\CSWT^\S3';G4U!8>#"%\[U@@AKZ@f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|S.1OJ72^4]B733\YO1JL;IU$G@$1O& ^M;,FEQP3?"('>#L%D'&QK^\SZ0G M0R&&[^[7IXXD.5(I2XQZ2%1(Z&;GET.D)5QR>VFGCACFL;N@AG4.LX]U+H M*FL9X&CX9D).A57]%Y)R&_RA5>=3XA]>;'94 EN!2R)-R6=:64L;QAWI-<3= MJ[06L64[QIB\ADO6DQ%6S>%"CJJ>2*T5E8GP;WI/0T;IMPMVZ0A67%$DM[P!C1F<&Z")T(N156JF6\ QJMJAW!]5W M\;Y."A7F(-#/FN^^^XJ8=>%SB3F6SH8ZIYJ 51ME_=L^"/#Y[WR2G8:MR1 M.9.N34.3]_&'QEJ28@HC7=2-*>ZF%,IZL2$ONG\^,.X\[P|\3]3<_/]+M9 VA M0;.63N'&R[]>)4QB;/@'<2&@Z8)ZG_;'^Y[<*$[TIYF8X.(5\Z]-.LGD^*F6 M\^ V\3_4.)F]C+T5Y=4 ,]&$]7[-^=;5TV#L8I$WXX3PG/;!N35=RYE;TKC(ML%/ZP\;?Q?=:H\)"/65E\O=0X7WN)+^Z7PL<7Z3QY_"W1_R)W.|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|W0\I-*TH"DWN@N@X M.!<)!+R.2>=8MBJT7KO41%-WF3VM1->E"@^9RBK]$F%&T=24&ALDS5BLMUBR M15:0Q+&P1\83O'YN8&7KZ1> 6-J.OR'-MUD))K78.)4:,&Y\^A/]90OAT8HK\DA5@P?6?F B\TO M%[JM]_M-[A[G8=O]8= IIY\3^.:X+HO.Y-U<3*R0e>,F#G6 CG"W!-U:F.G M$[@E&9E43_W,4H6]-B_0>4GB;JCA[SJA>KS'=^$5EXKP%D6GY31Z'ZM^&2;_M]P|LBR8/+XK26NL|-..HF#/(4 MQ#ONJURL1=!<1/94FGT!M,Y,0)=VH(%&FPC*,?+/L\C^88?G3YX0AN|SO:8M'Z'|4UK9>L;|7!M:LS9SMHVX!G![V#GFF_$>&?P90E*C&#$/^\TIA&-D7]*D(M08YP+9E!96P+J;Y:!/_LI@!^.RUE0K+9\9ZU[*D;N>1E<#B6,IQ8TC;W&APQM,SAA)I&A#'&0LH?'A\M4VR?K9@^;F._C\';.GM4,<7KGHG_!'<4K;6RO-?MXBPJ#6&(3O[&ECK6Y:HYQ9/[MPNNK35-KAJ+Z"E2ZC2-+EQ{XY46_UDLU>M6COO[A]X(3SYTCS:CGA7A@D:8G.WH3;/8Z:IV4TQW9SSA?<<@*'^&Z;?3[(8)M%OTINRQ=[J#-YS;l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{XY46_UDLU>M6COO[A]X(3SYTCS:CGA7A@D:8G.WH3;/8Z:IV4TQW9SSA?<<@*'^&Z;?3[(8)M%OTINRQ=[J#-YS;l0B,U2M-%)'GO -/'RR.O/E.:R57UG6-T(5ZL\F\XF*=RM#QEDF;]SUELQ6RP$5F$YO1IN2C%DW#"]-M6]0)(YETC6 #L"B=!D:',+4;N M)*Y<$?4+NZ;VQ?D1/674 ^\3WY%U'#WC4OFB+= M$L.C:&2@^%!IK]GP6TDD118G.[QX11--D5;^7-2G+QLAT65RY9^=?C ZSX MZ ;<^]KIS:OQ\;+<(^Q"AJFVEUD*0G0T."-H7IZE&Q,0+OY-.9TI$T]\"[MK82G>9C3^BQL9U,C'[94?V>ZK),_(]<++WR,Z#17O8I:C^HY[':5/ M0N0[&_NXMQ;XOYH13M9$*;^]10>'V!3IL-$/[=1L)7%';D3M4),_AS3F!9F M)FUAA'CE(120-G3MQD&%X;>W&NC:.[ZOR9"51T=MAK,"!ZH):6L3O"%]1-6"KP M^&@X+,_8E7M@\X%!=;'N<\V)DP,R=UO9>]NG% M;GOG-;BXE(KTMCBFL4O!U M@L$BP%KQ*/=.J5]0G5-?2H4"?+FW(+-8:ZOY'1O>.0!P#$H)/,3<&PN (]+@# $!1P9 MT355L]FUR!CE6WQY49/]MPNNK35-KAJ+Z"E2ZC2-+EQ{XY46_UDLU>M6COO[A]X(3SYTCS:CGA7A@D:8G.WH3;/8Z:IV4TQW9SSA?<<@*'^&Z;?3[(8)M%OTINRQ=[J#-YS;l0B,U2M-%)'GO -/'RR.O/E.:R57UG6-T(5ZL\F\XF*=R M

K9:LDQJRK!CL;Q#)3WZ(*,?K>'"5# 2M\S'/ M;6ICH CXZ/>HK#2O<1,%]1'$BH#S%4@1T-&5 M+@)4R$(Y;#IA/BLEC#5FRP"-MDM*@PC,. FV$]@@8U!XF<&X&BX >S)"1/6RS1@048T2 A@@PG#L@&OZK)7P MBLY=W3U!<=@[\^40@N@68YDKZ1CI[;G%4D-?IX-,SR6"7|9N%]U&S8 M_"$U8 W\!TV BX"G7N5[)K)Z1 !I&T"XS/5^)!%>B9AC MBH#>MG[+T0,X8_)=]M2. ^]5TH90N@;<, _3?KJUV![&0F71A?+<@7T L/6)=,_MN. 0[GOJ1+4(B+K*8>E9VT/D%5L;@%3IGT"ID%V@VKU+3W4_/? >1E(N_6D1- M\!+>FXW?G4K!Q:NQX/RM;"O,$PRQZ$$+=M4SIN$96R0]4?T>2\B?S=Y'@.K M+//4IEQR7@T;2?C'9*,4[7@X9]BA9.?PF\X]2R3%70W=~9Q=Y:-),53/ZO[& M%Z\]WG/\\,";7P9\!C4V&JIX>&5NZ[%EKSI-I[%:GN M\9NECM9?Q]G>.Z3Y:KPAPM>TP@SUIM=C4U"^$W%J7)-KBVA)<#NYO=]$>R M2_B/2E$FUIVPYA MJ;NGWRDI*86 Z=@(B",,,>CE '@UP;JB5ROYUZ@/_JAKZ7\QH**QOP%02P.$ M% @ O8$T6>,UQ/OIN0 4\T !@ !I8FEO+3(P.C0P-C,P>#$P.S Q M-RYI<&?4NV=8%- ^W+M@(B(I*SDD%1++D"H26T!BDU$!H6D;)&<0D)P$!"1+ MCDU+;*0#""QR:F;)+F;T+30P/ [.V?E.??<>^Y_YGZ8F5WUUH==5@WUUH==5@WUUH==5@

*M$UNO>_KNRU'HVV%IB3^3ZU:U^SELRQU65,-=-,8OZT?5%0^!+&1&9%7!<)51 M82N\T>/S1]4U'2=66+S1:YTC.'UF0=FOS"P<9--?T4@QG^G%9XRX<^W;_OFO M7$E02S[A-(NZQ|\(&&)R,JEZ-'"^OP3S'],N^7\IBGF5&[1-N+4#O"S7YG;._M_KS/_GM3*S3]"E"1<;%Z"EJ8.G3@T]T(Q!O4+0=UC'!8Z(;4[=77ODM>R$DT MO237;>/%]Y5L9S|LQ!1WP?B$|79P?="|"^2WXT7QG+\{#|.7+!.*%0L,U2^) MM@-X+ZZGE!_?.>P7;!X"W2O<$;X_)&TN@?![MITGA?+SS.UKI%[<`;I$C_J M:S^Y|*4FCRPES)>+L6M(C()DNY]R3SP#A:+7IR:1$_D?;DV@\7PVM< 5Y VH)-MS0.QOW!W>`\T[tET!%%=:./85/XF6O-_GVO&B@=1M>5P""|%*GSAD-]] X5N] M L3I7K<8CTFZ_#P?2+C3< 583=ZERX%#ZA09Q^ 2%IHHZ E1T$ N MZFFI!3)^(3]Z_1/(;*.ID+CG%Q,06+Q$K:\R\W/79*D\M/Z8/]VIQ M>6K9(E'? *@/]D(7P3P^(,83C;0(_YQP_GK\"K!A>>Z6L^9=,'"B>B]MU5P \ MG?,5H(|_^LA\N9LC@MEJ2 ^?>8"7DAJLM:R2-?IK"02HT/R;NI.!"@IK*+P-T MXJ':O;NG2MV3L>'? M)LIKFV+LIM>(!2=NW- M2DQ42OFVE=/!4XY&)L5'!P\B;WLDK0$?2%4#LNG^HA$OJP-$,IRM $(B#X!*/ MM\D)Y1.C"%4IQR4NOVZ*[1N- =+7L4%$J1;5O+@2L_<>HUUW=QN1N T@@, MV+K2"C.' ":LB"YZA$)3$,ZF2CIA\YX_E#VN0@8 W.F]BM_*9^KMJ_"0KP_WB?U(,X"&CHM-J4*-U34$H3 M2=OHWL^;||U? O=A?@)2":CO%8VH/+-'MO/"**{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}^Y\>] 0\IB8 M8-=^.'RD=!AVZPG_SIG8EBMO+RUZ;._TV+(TUQ@"?3\|- ?!Q<@GVF[3FO!&T M_Z//&;23A8F/JSU=@O?771%U.=8*=LN=U]+'C0>&1.N?C"CW]U=&M=UPT/6K N_EZQOPK"-^4=""^%H8?N>P8#^3;)7!< 1YEQUX!+%]? ? X@*L5PB5>_1)95 MI7.R#4)Y#2:0$.4C=>&M?_7(fVI@./_=WMDNZ2^H\Y=:[PH K[D"C/-F7.M& M#PI?Q.0(*G5@W_B3!:HO^XYU ZZX#H1#-.PJ>IN27Z*]1_^/N@EA$*7]+F M^:I"%RAJ5=4?G1'8DQL8VT?;RS*SOB&C!+F]]/+)8TSQCL!H4B%&T.PT:/4+^MZ\5/[P1Q>1;5;A3<%29Q-3!U.O3A8W.:.B#- UAVL)# M%W.!A<^L:@9%DJV:U\) .0U"*SCV[XO)ED5EDW"ST$!!P>/RQ|GO1!>G-JOVEG\K M^1K2:VM3IVLY!80CW|B8C^4=^^%H8?N>P8#^3;)7!< <+*:^K2>>S6EI77HZW8_;M1 MPCT4M^R;5O'-'5.FKT"R'N7R=U/I@S+?31EQ;O#/5XJ8)>"=#/%:Z!*8/+EO MV4!@.9[=[.^C]'V-W_5W&.[G1G8!M $$_F6_Y^<:? N*8P+!CR+R7W03L!) ^^ MO32HBO2;M10Y+?#]?4KFXL^/E*=^P\C1%.&U5P"|/WIJ[M:N]&\S!N>VY4I) M,-7W^7N*0XKU- /FJ732@8Q:M$OYL\4B1%HV8#MUD\IAZ)W$Y+^XS+_6'/Y/ M*5*2&R'AL*@^>G:=[36$)\AKD^:,8Q8P=\7/W# M!X"B?;?ZX--M-E? JABYIJN9JB+%M_9M$V#0@H8W)#'6>MT> [V!LNVfX;L7 M.,(]2"UH&>A:",;BC.16;L(%&B7B/=#V_2IT4/9Q/QY%9RO2I45VU:N@5X(&6 MTF7KM; (:5;$LXDI(>5+1G%H6TD_@?1DU5/M4,&95'MT6:U\1("*Y$L/O>&U% MB|H|$|H,:#.1,NKSVY>.R2;&TG#;_&W?O'=3D%ZV-QHJ*BM)I5$";@$BO9N M(D4Z1$%]I$FOD=Y!4$!#B=)I!2$)$NO1-Z"$BOH0D=T2%/S'?.N><[MWSWWSUV?^Q_WID|\[U[!W?M9S[/6VOLU'=;^_;;.<5M^UCD:PAXDL6F=9 DB M/@_8(\G%@ @G+O1F|)WFES_5KEG^EC7BX! 8C9E:.UL|E>\Y_LK.8!)@7IE8 M'#>+IG)Y+D2O:Q'9_X^78&[BBL%_MXVQ-QSDV^?RT:IB/[]'GT:.^_T=#FL#. MMAIL)7[OMWVN#ZFH_F%2MX6M^),F+YSQ7?BOJDNK=3]_'A*3U?IJ#.K&;R7 M\)5?]UH&I#$LO\"%Y|#QD|!16);D_1)6O_ZL3G1"3:?_R\>6KFV#%N? QSKZ M"6-&*A3)XLFT?G&!*BIMN7<|L*%(]-FAVK:DS"-!NL"WA@+)K*2%VEEZ:!S M[2E3X7]+:,,8 6O'AJ2C?W)566!QK4!%=:<59.5#R^L<- ^H|!S6;Y2S(GZ2_-51.GM:)2M7&M7>.)1[===F,PKE;NEM"O3C M;*5?4=<+D1D6KF>Y>]2.!I>3W#658"_SE";[-HPL4_H]1PD7YGYF=9#73 M:) =/#S-:T0H(B?_D?>GF5)? Z7UF]E[U_C&@P-!9?!]UPB)8#723=W;3^?3"DDY#B|R88X]'(^_M,4F'W.Z\_,X+1434 X5&]33M. >0HAHHN98K#W8<_M@O1&_W.NK\,KTXC?<*R M4 3LCI+%O!0"N"O_A!ZHQMXQHCL"!H&[RD'V%$,]9 *5Y!-!1 DH[JN=?@ M@QZ88E@I-\T@M'R0$[1N0/2!!\>04]5Q*QB^,1;5RY6RILM9,HU6[*-2O09 M>M;\K C/3U7=|&SMF|N#W1@H+%^@Q@:.1W?KKS&N/K4TP1YPW^.>#;'==M!8.%@='=*I9^(H?\WR8LL$4+/J8#Z)>DINX;>>WIBT@F4;6X1!ZC60-4F-IU-M@-- _T5]KA\6O=UA5AH(>]4>&>#_M;3FA"0D2(DRW_.'K(U]|@=0[^]Q.N-B;,QH!(@)?Y"_FB.T 1\4'-2,-2K@" M=7GP|S_,CSA?TG["@F8'CLW=-ETAJ0TVVZ,QJ.1_4J@6 _I\)1KU7V7WEL)M M((TYW".Q04:&+KEF=KFZYN 6"B!&UJZMCV,YV++3L,J%5W?86=$LEC_2P//@ MP#G,R,&LQ:V(@0^5[VN<(?&>P^$5@M- $S>/0D^FAFE8'<_MTVZ6>]Z@W4@9,*2W.R^=2UK7O .-I_K-R4(0^N'S!&LQ M?J!-)6[$F[9)K KYACO%O>F!Y,Z5?I_??W; ;!NQN/6 F3<\TUF>=+# M/C!O\CS6K [-"H2,- P'6L'35\%"_RUETE8.XF%/R\IV/@]I*QX8+-^I31]%@ M"ODP4$&B5.INU%(TM]*0A1(PJ0AP W)8/"J)Y,_P(G+R6KI@DMW/G2KN-Q M+W_USR)- />U]+9B0RNB2IJ0V:$ZNR<[KL\,YAE$G>-LL|/DOUJ"* RN0VG=4 M)+/&C_6RE23'>,:4 /!RQYW(:C,WW7,5:$E;MYLQE7:TC,91EZ07!=:GVM;C MKN^).?,N#V@2/5!99O=$^ HY_L9_9WI6[*$V+O M 45\32PI%2^]O<)E:23B-=?_6'-\&B9_M$U<#W(08*Y$.&-> '(F[!H\7[0)T7 MU^!Z<6:.B, (^3&_":LWJTXW0C[+N8,V@=LL[(YLDIA*?N&8NB/=IRBC=3!]7 MQ=ZP[40,_R%+;!*6;6&H&9%]I]9<[ZN4YC?@X[QJ1^%V)*A4U_CL3-(^`-M.T[>? FO\3P8(4_F>D261X;Q7%,V(76M.O#VY7#YSFEW8U%F7G',\/4KL?18C M&$(HPNMA<6>9C2E?}(SQEKDO3 UCK_>FT4)]T2C60UOY-X;N&0IMW3K*"_KP MLO@R5GHN7]!:S9&&D)D?3XE,"]T?>5^BLH^[6NAQ:A!M3=8>1]YX=L]Y5W M;MV#'C2F_@*% 6\O(SX,=Y,L<96@H7,<=4M^UCD:PAXDL6F=9 DB M/@_8(\G%@ @G+O1F|)WFES_5KEG^EC7BX! 8C9E:.UL|E>\Y_LK.8!)@7IE8 M'#>+IG)Y+D2O:Q'9_X^78&[BBL%_MXVQ-QSDV^?RT:IB/[]'GT:.^_T=#FL#. MMAIL)7[OMWVN#ZFH_F%2MX6M^),F+YSQ7?BOJDNK=3]_'A*3U?IJ#.K&;R7 M\)5?]UH&I#$LO\"%Y|#QD|!16);D_1)6O_ZL3G1"3:?_R\>6KFV#%N? QSKZ M"6-&*A3)XLFT?G&!*BIMN7<|L*%(]-FAVK:DS"-!NL"WA@+)K*2%VEEZ:!S M[2E3X7]+:,,8 6O'AJ2C?W)566!QK4!%=:<59.5#R^L<- ^H|!S6;Y2S(GZ2_-51.GM:)2M7&M7>.)1[===F,PKE;NEM"O3C M;*5?4=<+D1D6KF>Y>]2.!I>3W#658"_SE";[-HPL4_H]1PD7YGYF=9#73 M:) =/#S-:T0H(B?_D?>GF5)? Z7UF|

*($KK19RY\"QQ089SDL*-I1VI'\7-!RI- M27-SSXJ7OM#%]8*57]>O^(CB:(.;MB.;!]U|Z)9+W=NS?E^L3S+Z3_;2<^2-M+ZO;P,ZA#(R -@A"7KKDLS*.B[/#|\8%VV<2H,L9% XUKR<|=V-]O MQ'_G^\U)SD>KFT[QUCX65Q]DF+ 6D$SI$$WXVNE8& #*2]>"(@#4D9W$B,&:K1SZ0DZ*X!E$<|^WDL)PFO* =S*+34?/% M9].1#FH=V_HX;1.E.TGN2A ;,3@NJ;&DAB|\K"6*V8/O;N4U);_HH*48,:4M M)F_URFB{2.,;?7R0LLB :/45NVI^V_V7R/GT=OS4*7"^HJ|'@5*0 !:|S!S'8 M.CWI7|ZCKG-ZF[I^,ZK 9[3!=P.9]6< Z2D_HM+#Y.\|/>MV[#'D*7$Z#A/I M=!+-ZL0?:W,]%9-&G+=9&!K&KY9O-K,%(&GDFCO<>SSKT@TTP]?Z%1!VE5T&C MKPC#X/"YZ]!HO&G7CtY$CL\W>9'EKXJ=_2V3)Q59C54QQ(N8%]45L 4SB+'3 MTB^G?7G=XF]L8U'L<'=SNPY@^#Y)?W?!X2B(;XS$&W@SV]BENLAMX%FE:I#) MG6-]XU;YO.C7[Y++'+ ZGHLERSL_*,U4>HDN,"9';T/#DH,%*=(O/HC85^;ZV MU@#$,\FI=TZ9 BC9EUF+GUB4WH$-CBRB"$Y$$(F!T)<|'9B_T3JD85/(;7S5 M7\;&U-#YNQ5HL @4C)/:,)& OLC28+0 9I@E3%L0[UA7^J=+EI'V[6_;*I4E MU2D,U"W4N\3"+S\B"_I 57>)CB+9A*#^4SE4IF+WI+/9; (X6KC|WG^S^>J6]1P13#CFXWR":4U,NH9|GG/G"542[TA=[/"<5 M5%V;Q3;L>4OUUK.-%U6_T*%GKT=K5ONDU0 Y?*%/.DZM#7O'Q[O%B[;5#F\Y=? =|C.19\N:GR@R_36OX M!VU3O%WPMB)K@%7%;FWHV&?=D2#.665;(8)7^]W42Z,U.HO@5^O *_/C0>)K MV#L20J9F YLH2>3(07|8-:?,)A*J*KG-;= *M9\WB3S%LAG?6B] (%;X)6;YR M,!NW.%7E&Q-FE8Q&(=(GP4,BO?!2[F3D 09#9B8A|8\)#Q4O$]ZL+]FUB]0H MG>4T=!TAQ/HX7>"HI>FUG1W8D64Y87:_[N=_F>RL?W9;R;]6%U]Vl:"$#V&*%]fG M5:/$DFFE>1]WR-M:^]@X"P(-5T2AMD=]HAU^S@n0D8>3'>&+:.+7.46E5C?$#64CCW;KL/i\K>?5G<XXY$;BGPZD=3XD05CPEZWY_W+ MX DG_^6H.$7P0ZP+WKE? <#M*GC|[:CVQ[#776*4(--->0,,9H>_]+Y_N=0=0U%T,:IL/)N<2UP6+^,.7X]-M+/Q74]PJZ6Z%LOL>%MUHE+(]C/0%M*9?.R M55L^S+WZ,*^QY++B0@&8HE6W23)YCJR.:\>F-IE|(1\9QR$>/A&R;Z]UKKV4 MO?K58VP$754&JL)<< H(VSM_++IHX7,|%XYN>]9/(.Q@V:BQ#:\$>Z1F.D&K1 MF;X&=371MKZ_^2V$LZ=N&;7M?*YSP\4_QV_==P" M!9J1+,2EY?]8FCY;O6G=W84!{@J;^C^Y-A&BGYH.#[@<)'4\K_28/L4>,9RL,P R]?$(U7) U)UAHR9*C8>6&3!H|O/@WF&YS&+-&$HN&10D$HS]7N+MN-M+;"M+8D$!ZTL/PL7'4@*$!>#'KT22FI.T@D?EO0H9$O@03E?33/A7IX*G// M.FMLXPA[RP.:!@{JLJO,^X,V2_K K4PBTC'/M$?GC 7Z/G?-0#9+H-?M4_W< MUW;M3P,8A:>GQN6,QQ^ZZ'U_ V\|J_G\|OB5.J+CEMO%S1A]VK3X0/K%>_XW M-HI@[A9*#FLO78R9AA#BK>):=.|B8E=@>*\/AH7#>^0Q=3Y:$^MW&&*KKS2 @.4YC8,YNUOU:U)&6?85 MJ6_0C6\3O.D&Y)>,9M):8(.B|<_.##2.FH-X\M>]8+F?08VI- ;)P.%#PF*B M_DB9!'U\;?;L[^1PEU?,[*S#OI49GY<@:E5&1C7]4^\-*@(&7#9ZE)?@1%ZB M?8$.(98"N+:O/L6,H9D@#6N=F 69KV1E-8P#M\R(ZCYN NZW/QL4': 8* M? T6V!7&G()D9HV-$]QE]KRU.YP4FOLV=6 NRF]C1CO+]_9*LI;TY-?39*.'O\;??*G0:S,(#4PY/?9SM-[*7]]/ M5OL#Y P0G6\4G(>&\!$#F:>C7&4VSOCG#=*(1'[% ()WCK;V]QU27_ZX4(O1V M>5O.Yl-_3^!79/IPLE,:*(''W#FBKB!&B M(E;SYT_[^3TCJ[N#X1T7..?\LGW6-&$%D-QIC-F1CA/RI$)V]UUMH @_T &_MC&@#)35'-ET? B+FPW'"TL:O]R4AWO^VK6O:XA4'<28U>!X!L)NNKS<*457LV2 MKIE@L]O>5F&_NE=A!F#RLF;YS7VHF'+**_G-SLWWUDS-3PW/:P_XYR2$/Q[> M;'L7Q,"Z:OJA;"J6^E6MG13@V;^OI^CS?6Y!OR\S$A+FG*QE=[9!-F55HU|(M:H_7@J05]YF#'6M!UY;QJC|^]. $B=MNT|4:Q#|("^;=%|T]"'H|\5XT7@>$& M#;N- ;!*_AE5H6_U-#.$Y!K<-.+M|GA1ZO[K;*<9$.#V ' UCU<-|:?ZG3A,[E0Y[O7^/A,UR\G2~A,\;.3,'+?[RZ$TEH]7-7IN#0=I>3 7+78+A]@+9!2WY@&@\HA M[#UF9O8;IB?C,^DN[@/.VYM\V3'/_I>_1"HK7*N!-7X9]Q[_.6?Z L4=LO 8 M_^M P.=!Z9"VG&.H>S\/X3XN4/+ZK?AQ)(X(H-9PRH>D&=.;\]CYAU"X&S0*, MT@F7YCM#Y-6* ()SW:H;N4P!AFL.3I1YIHUE:U9F5+VK?O.B5#+GX@\/UKZL2 MXCLRD[&S3?;]:5"> \-AW$:EF2_F@WI3F#?GF'Y;/40'IZ#9T<|P<_R#\DV^_MB\% I=XJIG%M0N+@29HG^;1(%4 ;5T4_VI>9=SP: M.7S0?%12]%7ICE.%VN-W4S3/FEK=23;24L*OBV.4MOE;4 M=OL%UT;!T9(.NU7"^L\P> 685@NV-LN="A,V.T0WCCFCK[X.F]%02YUWB:M=.M1V;5ZN1O;)%XV51P@??9G6RJPN[X<\1:@A?+N-K@S"3-)J8TU<|JNQ+Q4]J M ZT9BJN|&C^[TW\3-H2U*26V^/$IPV;Q#P, X- +/<@'O3 >#FE2M[<9S5OK> M.@$H]"/LPTMGO72-_AL>!OJI>M224]EX&D;)/CMF4]U?SIV]]NDM(6^[*]&8B?,EE?/X"0YG,53'"*PBK9TL'&2#.>S5 M40Q\H+_7TA3S,4ABK>#&=5Z 9Y^0;^(6$$]'9DAKX?!_';R*E6DTD15\>!S MU]W2W5=A2_S!;)CO5V>|:Y7:FQ[S%$3/N.@48E%B$B)6">3ZIY0B->]@>U< M#H._- _4&;>!E(M@>'HJHB\4A(= 9XWB?71LMCMJXVN'G'@ABT{"WG?JOO M>$<7/IE!(]&_;P#@UZ<]4G86;2**B?S.I?%FL&I.X0$=BM GRM9MX4AY,? MNUFV59:,N16(>&LI'*.=80HO.\,;RI@*#B?.+NVN)'H &2&RRREYL]'I6XQN M+H%,7WJ6U%6?=@$XY>(PRLA_QG-34U[9R1,?V9;%-BIR:TP>A#!9_Z "D1.9 M^F&H9S2(GL,CG1IT3W;IPK7-Q"N M*.1(%ALC]28#[SJD';>L"[[;ZQ'O>)RJT"Q>Y2.6_#S2PBA|NO!EM@BP=NS MFQ3 I>V^DE600]>)]ICX*J/'P5@/K;"6&\3IP])KF& <""WZ?!G>]2/+U]#\M M(Z ,"*$X9A*T="|H8OO//^+^.80O!FP;D(^D M2?!=M/#7_84>$0??(#@=3,>*'7(;P.)_I\PJM3IULAE>1/;O';ET&SQ@^G M]T76Q[U<=/85- X8D8D7N.C#Z98:%^ O^2K5_-V7TX?$?:?G$CJH&I<5,J1:I MCM@\QI0N!VAIfZ#QLZ$*,=FX3] SR0VSWV.+F2G_HX2$6:U!:2K05&X\X_S&BE' M=.)Z6=|4_Y8!6:TMC]C.+/R>[*H0'O3!+$"9$(H@1!!-5@%_&*N.-S"=1$9, MZ^.C]A+N<4\)]<.&/G6WQK?M9RRC$].R>#EY\8BV"1(4+V>P*T2.M*=3'=IT M(? >YR%,+U_1:N6Y]+@Z.-A3K)NO!9TMFA=+*%TY+?O;!'0AJ3"UQ 8)FI)5 MS,5CS:;$W@BIN.!1"]#R-J#7'$U'?D.ETMH!*C,I)?NTL22CXL\BDH/?U(-F MZVI)R47;KFR#HZ!*L;MGF:0[RLY7FWT/-RQ,+3V6'@DY=*1/(CG5%0PZ9 <<1@A;^HDATT-61 MP[S$3H/EL$V">J2&.'([8]>3'C,O B7 OTOPESZCDA2%*0 NLX"_JE7L(9N MF9YN>C!L+@-;6RF X*#W^[MH#C ^*,J4+[O!>]E >V.')7K'+M'5I/MIN.7QU M#X+.PMP49ZQK"X&EO&,?OE(7FS<,4\%IX9S-15I)&|_EL MBQ3O.U? W(#G"WP33D<00C"]9>K4"GU@^E9#QS=O [KWX#';P^,^8?^O`6M MICRI#;2!IN]>,_3VH7/^CMT2I0"4(UNQ'H+*.&3/69- 8"LCI%[(L BR<#$ M$Z"2+EB1 FB1(KZ #N)VCRF *TQ@D@5P-YX\ CR0#E"@)I5,!0 DI]_IJ1Y MA_X6!/H;>$4E8-\-S"E!V)TH,7Z5#6+V:.'VS?'49#Z) &OG;@NM*@O++3>% M631? 7:"V3KYZ%9)5QJ,YGIQ"A+;>E=X{?($O>N?3>93U_$MD]6[^_VCO+8/B M?+9^T0X);C|H,$99!A@ MF+EDOW+VW?O_6MU3|U3=NA_ZPTRU_-;J]B5/|UH=NRN;(;? H0$W=D8T"/U@X MZ.^@_"3$?#3.)>?!LXZ0@/.(XX'1B)Z9RW?S!>X^XW/SXA8C>;,8TFR;EOV7 MJ8D@NR)F7FPS_2(RU1@1WF,L=*\8VTO2X32]7"91[5- H2F4>>]&\OA$%_<_@ MPF##/;/^3;*9MTWWA2E]_B?%^07^O6M MICRI#;2!IN]>,_3VH7/^CMT2I0"4(UNQ'H+*.&3/69- 8"LCI%[(L BR<#$ M$Z"2+EB1 FB1(KZ #N)VCRF *TQ@D@5P-YX\ CR0#E"@)I5,!0 DI]_IJ1Y MA_X6!/H;>$4E8-\-S"E!V)TH,7Z5#6+V:.'VS?'49#Z) &OG;@NM*@O++3>% M631? 7:"V3KYZ%9)5QJ,YGIQ"A+;>E=X{?($O>N?3>93U_$MD]6[^_VCO+8/B M?+9^T0X);C|H,$99!A@ MF+EDOW+VW?O_6MU3|U3=NA_ZPTRU_-;J]B5/|UH=NRN;(;? H0$W=D8T"/U@X MZ.^@_"3$?#3.)>?!LXZ0@/.(XX'1B)Z9RW?S!>X^XW/SXA8C>;,8TFR;EOV7 MJ8D@NR)F7FPS_2(RU1@1WF,L=*\8VTO2X32]7"91[5- H2F4>>]&\OA$%_<_@ MPF##/;/^3;*9MTWWA2E]_B;%^07^O6M MICRI#;2!IN]>,_3VH7/^CMT2I0"4(UNQ'H+*.&3/69- 8"LCI%[(L BR<#$ M$Z"2+EB1 FB1(KZ #N)VCRF *TQ@D@5P-YX\ CR0#E"@)I5,!0 DI]_IJ1Y MA_X6!/H;>$4E8-\-S"E!V)TH,7Z5#6+V:.'VS?'49#Z) &OG;@NM*@O++3>% M631? 7:"V3KYZ%9)5QJ,YGIQ"A+;>E=X{?($O>N?73>93U_$MD]6[^_VCO+8/B M?+9^T0X);C|H,$99!A@ MF+EDOW+VW?O_6MU3|U3=NA_ZPTRU_-;J]B5/|UH=NRN;(;? H0$W=D8T"/U@X MZ.^@_"3$?#3.)>?!LXZ0@/.(XX'1B)Z9RW?S!>X^XW/SXA8C>;,8TFR;EOV7 MJ8D@NR)F7FPS_2(RU1@1WF,L=*\8VTO2X32]7"91[5- H2F4>>]&\OA$%_<_@ MPF##/;/^3;*9MTWWA2E]_B?%^07^O6M MICRI#;2!IN]>,_3VH7/^CMT2I0"4(UNQ'H+*.&3/69- 8"LCI%[(L BR<#$ M$Z"2+EB1 FB1(KZ #N)VCRF *TQ@D@5P-YX\ CR0#E"@)I5,!0 DI]_IJ1Y MA_X6!/H;>$4E8-\-S"E!V)TH,7Z5#6+V:.'VS?'49#Z) &OG;@NM*@O++3>% M631? 7:"V3KYZ%9)5QJ,YGIQ"A+;>E=X{?($O>N?3>93U_$MD]6[^_VCO+8/B M?+9^T0X);C|H,$99!A@ MF+EDOW+VW?O_6MU3|U3=NA_ZPTRU_-;J]B5/|UH=NRN;(;? H0$W=D8T"/U@X MZ.^@_"3$?#3.)>?!LXZ0@/.(XX'1B)Z9RW?S!>X^XW/SXA8C>;,8TFR;EOV7 MJ8D@NR)F7FPS_2(RU1@1WF,L=*\8VTO2X32]7"91[5- H2F4>>]&\OA$%_<_@ MPF##/;/^3;*9MTWWA2E]_B;%^07^O6M MICRI#;2!IN]>,_3VH7/^CMT2I0"4(UNQ'H+*.&3/69- 8"LCI%[(L BR<#$ M$Z"2+EB1 FB1(KZ #N)VCRF *TQ@D@5P-YX\ CR0#E"@)I5,!0 DI]_IJ1Y MA_X6!/H;>$4E8-\-S"E!V)TH,7Z5#6+V:.'VS?'49#Z) &OG;@NM*@O++3>% M631? 7:"V3KYZ%9)5QJ,YGIQ"A+;>E=X{?($O>N?73>93U_$MD]6[^_VCO+8/B M?+9^T0X);C|H,$99!A@ MF+EDOW+VW?O_6MU3|U3=NA_ZPTRU_-;J]B5/|UH=NRN;(;? H0$W=D8T"/U@X MZ.^@_"3$?#3.)>?!LXZ0@/.(XX'1B)Z9RW?S!>X^XW/SXA8C>;,8TFR;EOV7 MJ8D@NR)F7FPS_2(RU1@1WF,L=*\8VTO2X32]7"91[5- H2F4>>]&\OA$%_<_@ MPF##/;/^3;*9MTWWA2E]_B?

MUT;X523BEI0>]IP$OUY" FOY2.#AZ%0,.T;"]O+9S[E(40<=]QCQ.&\N$O]?`MJ<#.K6OGWUJ0^/[!\/G%-A\YO]S/?'5XP;S;@SC2VB7T%11RVH?(4O[W)#)*
M7;FV3TJ/G'T2MRJ%@>_BXB^R\$%_1_R_0&$7U3G]U5!L_J1-IA!_[6QUD7!5 M/$0C=K*L*V>A!U46"GDSW,0KII1X^12M'=#Y-]SW*); ^%<7(=!NGHZ^S#<F
,IF0O=/L:!$W.O>;,QBMY4;J=2IH_4U>=!{I8D&H@^\3IM_&)P MD(D?Y=]G_=U&IG#M]FIE3*L.U>ADFZA=H4Z/(X/^7!3*!ABQXP>?48#&EPU.
M]E5O=RCDA?/N]B%T\M?6!*!)\;'=XM9M](7 EG_-QY&ED)Q0+8=/O>;*%"$RR.:]X_8T7/56T$?5ZZ*&*%G,:L,O@07X$#* MZ6$R:T@ TB()+G 9NR'R8_8'D_LC@?
Z#^8^L/|((ZZ;B$G, L2|_^G_V'\< M!4]C]EF*3AP)X/$5^(]'_GD=X4K$D (R<'Y1U.0P$ONWE@XXPD2@*UXX[-N M_'?[C
#^&P0U38NYXW_;_,77XY[X2:HEG>!)QK6)6;+&=O: ZM*G'G$IB83I M=54[D7<%.5L=3USW&G|!7/T3JG]DLNNAF%H?IESL/_-ZXI^)-,KY+,N*-M#Y
M#\A^_P6/*TWI*/[IW(_@^>)RE>'O)RJKl:ZD332_MW:?B!2RDV#5SN0]81=_*(!'(G \1-:41":-)YG\V05L*! M91#K"$W,_U%.+=+3PNI?QOAFQ/@:H0_VIK*6G22.'JQ2;<8E
R@=(@]E:U MX%5.EV_X27*7XA3_JLH$H'>=2[SKC4.]E\AT)X]50)M=K7HPJBR9..XNZI'AU6%UA6VC!"G$,JC8=D[)DXIX;G(A@\UCA9UE M@Z67/2/GQK 5(8H15Q9>%>'"
^.:G8P26*S!S)&/YV8[S]V#;_,TOX7!!'TN ML1SFL XR\6%=\W@E/CX> MCI_E?AXF.,5F%.!ZY >;"6$=BR\O X*]0PP$N8F6^[.))]IG4>)>H3KH]I2
MXS$FSMYT5T_E*P<^"7%AIQ::NS34[W53ZP*_=XL0]V3BY)BME7]]&H[5WYT MP7@%Z HRN<.I\T:X]ONHP|[EP74F#NT%J#->*;5-53Y2G;JW9]P\O$H4>EB6
M(P]"_U2QK_E92XLA2(J.YY9.7P5\0@37.+W<#9WZH?U\'WHU#F,9=*53W6NH MU2]2*-\QCDMTBI'.+U4216$_JG!V9]6U+]+EVN'FO#Z.G9%7ZE)0_(0'M!@AV M7,>< 9.*?
&;"A5RK,+&B632'"%9-?<4T['5*3_]:E3+*3EQYS?7Z<((-9 1S# M5VH0IOU65^I@^F- MT^_D-U]M>3H"7P*,E022$B&>,6AY)924^E|!Q*) ^6+ VH>*$,BX9!T<
MJG\@V/$Z37+R\4]M.Q;[>7K,Y1ALQM5ZC[LVKY@VS$ M\,5J=U/7P;/'G6UM3K.!8@1:L.J-.ZMU79@*QEEA?UKD=1N!DQL*IB0; ,:^R M#M,ERV;_?]V$Z9I,73OI^O5
MF<$DP3H2"L^"LH"VGUS(NK6D)\9HLRL6O"B-]8=?<2%94,8U3T+!">HJ@SMP MI^ \.9Y(8,&-S3D 8&A')#0NC\D-"VA&&P=8T0K^@^2N5KWNA;W^#?31<+0-
M/+>3G@Z,N9A4+HM& GIH^7#/8V7^9"',9C,TPJV304RLKF@U&!M0 Z?(A8 M)K](_??&O8V^!]HOSHH?HU&KPL$ _(4,%W#QI8&H>[GD=[ON&.#'Y#=%QSKJ
MHP#VE=28JJO$V7/2T?]95FK;8?^CUU1^J3LF,[!E;6'< *8T($GL1[>TG^35 M&-(F[&3#DNA80;5AQYPI:%G'V\PQ'(QBV/N5GK*?#5%[RZ5CV[(LTDLG 5F-
M*$3Q&/;.%&>57_&S?BE6C,Y^G4M_"B1XJE$:H/#TP;?(E%3U5.,1H1S/3 MK.6UM:W3),ZUT:(DZ/!T2<8H%O,1@ :8!4CX0#]/%#;.H\6%S6tLFD*3/]J;U
M+=9;]^<[>LNU65BY;?Y,0BT0HVT(W8@!!-1EKS"MP+,X/ H]I;2(-M#8K'83M?)L9J=[_UZ\QPIB>6H-F3)&EC=|HZP-QG]Z1EB=GI=PO<6-4PF1BA M"4IP-
7D@L8(>%@=EF?M=>+ZZ)9ZH%Z!H>`K2(!L84]K[I.M$?V+7:FO^M)C MH20?.5VT2PS/E;_*GFM'[CL]1\7C.+&;UH/=*)(LJ)67H,Q)U M1K;>K"VP]D7\6[M"2&<7" ?
^\K2^/!1GN-TF9&YT930H&/9"-!8@7G=XBH+ MWWBSL<]0^P<(?:X/X]$]GT9'J!+\H=%6BKTE<4N1\"RE.K4P9L,C"?PMY*[' M>HS(6D)PYL+73W0,U&6ZI[Z-A.];,-
LP=3]2OYV;I?:.&0S;HP.O!D;LBC4 M2X S +Y38(E\&V-MJ5'G1(3)@AM@\I$7BZ(,%-;)IB,*$;FNN QIUTU|DZ; M,KLY0O>ZHNPN|M=WFCMKM!TD$+I&U:8)-
EZX;,,H5KG+AFB1U$^Z%"8]KM0Z M$Y^]>O&4F8&+ GIV=[L.;?%+|\>QV72[4_E*T?UK_L58H=&*,/(/]\'(\W- M.GU_BW=LX"I1"RPX"
[:HS$=ZT4;N3>K]7G[M0H(%'GTN4M1QBD7P!*3F#H&X'-[*@F-AA@/S(Q;G"}"W^.G.% CB_4= M-H1E2MQ0V-8L%#,,,?Q8WDHP2L],626#M4-&^B0(VR 523FPI[H3G,
<.:RB!E]NH68]ZI?1@F&?R@VLU:Z$AJ3)U>NOL+|]XJ,,3N'^ M'BD:XB9I7^IP:?"-W4[EE#,8)Q*\+TB=KC]T\&(9C9&5@R MU='OXR*&)_]-+'|\.%S$[N<5&<=]]S#>]C>|
\1]!..4,"O4SA$*S,_(I^0% M.YVS,P9^^F0((%#<]6&Z5?41@,R%?,@0)S=./7G7:E.5O6BX)1U&>3OVL&C=-MG;%>@@L.2H<-DRIT8+;=L^$?M,1V5<(\LSRG?K(5M7XD&CY
HZ7]Q00\U"""Q)-MN+!?N"$76Y_]H?[?GC2- 8>33J+IL&8E@?F5 F M[EC2MX8((_^E$*#'.DB@JG0:[&]'#FV0M.8O3FZ8K4Y;Y'@]5!-1M"CLFG M$IHLS?
Y1G;7W"E]!O/LFH3"ZGA[/P,..+W%N?W8Y=/%(E=]SQU4#7KP M$%-Q%G[M.JAW!!0NB>DCO&FO-\??,F.XBM>)A6*?W$.UZ*=,SC';06YKAI
MJ*]4.^DJ>EU^J:!!,.^N4*(#;13XJ2V_GH9P!E]B096S@'\@R(DZ/S& MJ(R#Q>3\;A+,\:*]$N),1,%-ELSP"_^L/ 9^+8\Q!])#EC^NEONT|'-]U< MYY-NV#6NV'P0BA]*^W
2C@=# J;03CW(=D>&_;.NA[NVB'W[@.1>7-CT]0@(MS*&/_E&JDGJZTW(MD)/'H[?3=91';9*0A_;OU"/54A42IO<:SVO?H#WKBA=X M/#51>V!4?
]JVOCW77!E!=6]38$/PA8M?67!V9E9S,!/#8YGD8!A=^$2*,N(? MSIK0+/!FC(%JA:!W#V2M\ B$OA->0#)M_^&ZDQE@1JAG 0&W078^\U\\"Z, M21LZ6C@&>A0*ADJW?
>IGC%*45XW4G0YI/1CZ5V?]{.(!?PQX<8P_R*?5Y-U M]R9W?IU7O+ ^=3=+, BJ4Y;/][CONCX]#&%?%C_)H:?>?&]*UQ QSDZ2K(Z;-MQ"|-U^7HZ9N6QD!RC'RE%(NPZR F
#TZQ!F4VH][Q-9E29.QW,9K/W6J<#5E MQ"@|]UO0[,'4O?W4,T9HY\=Z>FN;.AOE0MZ<*5=;E0RJ>]*(RO<"04GQ/B*V M]2L!PUR$P1X="2P:(K3!
(4E<7WQT?/%LPY!;*4DG325DY*R'T@I*D]{1P>K[M3]SE!!;%QG.B*7KP M$%-Q%G[M.JAW!!0NB>DCO&FO-\??,F.XBM>)A6*?W$.UZ*=,SC';06YKAI
MJ*]4. ^DJ>EU^J:!!,.^N4*(#;13XJ2V_GH9P!E]B096S@'\@R(DZ/S& MJ(R#Q>3\;A+,\:*]$N),1,%-ELSP"_^L/ 9^+8\Q!])#EC^NEONT|'-]U< MYY-NV#6NV'P0BA]*^W
2C@=# J;03CW(=D>&_;.NA[NVB'W[@.1>7-CT]0@(MS*&/_E&JDGJZTW(MD)/'H[?3=91';9*0A_;OU"/54A42IO<:SVO?H#WKBA=X M/#51>V!4?
]JVOCW77!E!=6]38$/PA8M?67!V9E9S,!/#8YGD8!A=^$2*,N(? MSIK0+/!FC(%JA:!W#V2M\ B$OA->0#)M_^&ZDQE@1JAG 0&W078^\U\\"Z, M21LZ6C@&>A0*ADJW?
>IGC%*45XW4G0YI/1CZ5V?]{.(!?PQX<8P_R*?5Y-U M]R9W?IU7O+ ^=3=+, BJ4Y;/][CONCX]#&%?%C_)H:?>?&]*UQ QSDZ2K(Z;-MQ"|-U^7HZ9N6QD!RC'RE%(NPZR F
#TZQ!F4VH][Q-9E29.QW,9K/W6J<#5E MQ"@|]UO0[,'4O?W4,T9HY\=Z>FN;.AOE0MZ<*5=;E0RJ>]*(RO<"04GQ/B*V M]2L!PUR$P1X="2P:(K3!
(4E<7WQT?/%LPY!;*4DG325DY*R'T@I*D]{1P>K[M3]SE!!;%QG.B*7KP M$%-Q%G[M.JAW!!0NB>DCO&FO-\??,F.XBM>)A6*?W$.UZ*=,SC';06YKAI
MJ*]4. ^DJ>EU^J:!!,.^N4*(#;13XJ2V_GH9P!E]B096S@'\@R(DZ/S& MJ(R#Q>3\;A+,\:*]$N),1,%-ELSP"_^L/ 9^+8\Q!])#EC^NEONT|'-]U< MYY-NV#6NV'P0BA]*^W
2C@=# J;03CW(=D>&_;.NA[NVB'W[@.1>7-CT]0@(MS*&/_E&JDGJZTW(MD)/'H[?3=91';9*0A_;OU"/54A42IO<:SVO?H#WKBA=X M/#51>V!4?
]JVOCW77!E!=6]38$/PA8M?67!V9E9S,!/#8YGD8!A=^$2*,N(? MSIK0+/!FC(%JA:!W#V2M\ B$OA->0#)M_^&ZDQE@1JAG 0&W078^\U\\"Z, M21LZ6C@&>A0*ADJW?
>IGC%*45XW4G0YI/1CZ5V?]{.(!?PQX<8P_R*?5Y-U M]R9W?IU7O+ ^=3=+, _BJ4Y;/][CONCX]#&%?%C_)H:?>?&]*UQ QSDZ2K(Z;-MQ"|-U^7HZ9N6QD!RC'RE%(NPZR F
#TZQ!F4VH][Q-9E29.QW,9K/W6J<#5E MQ"@|]UO0[,'4O?W4,T9HY\=Z>FN;.AOE0MZ<*5=;E0RJ>]*(RO<"04GQ/B*V M]2L!PUR$P1X="2P:(K3!
(4E<7WQT?/%LPY!;*4DG325DY*R'T@I*D]{1P>K[M3]SE!!;%QG.B*7KP M$%-Q%G[M.JAW!!0NB>DCO&FO-\??,F.XBM>)A6*?W$.UZ*=,SC';06YKAI
MJ*]4.^DJ>EU^J:!!,.^N4*(#;13XJ2V_GH9P!E]B096S@'\@R(DZ/S& MJ(R#Q>3\;A+,\:*]$N),1,%-ELSP"_^L/ 9^+8\Q!])#EC^NEONT|'-]U< MYY-NV#6NV'P0BA]*^W
2C@=# J;03CW(=D>&_;.NA[NVB'W[@.1>7-CT]0@(MS*&/_E&JDGJZTW(MD)/'H[?3=91';9*0A_;OU"/54A42IO<:SVO?H#WKBA=X M/#51>V!4?
]JVOCW771E!=6]38$/PA8M?67!V9E9S,!/#8YGD8!A=^$2*,N(? MSIK0+/!FC(%JA:!W#V2M\ B$OA->0#)M_^&ZDQE@1JAG 0&W078^\U\\"Z, M21LZ6C@&>A0*ADJW?
>IGC%*45XW4G0YI/1CZ5V?]{.(!?PQX<8P_R*?5Y-U M]R9W?IU7O+ ^=3=+, BJ4Y;/][CONCX]#&%?%C_)H:?>?&]*UQ QSDZ2K(Z;-MQ"|-U^7HZ9N6QD!RC'RE%(NPZR F
#TZQ!F4VH][Q-9E29.QW,9K/W6J<#5E MQ"@|]UO0[,'4O?W4,T9HY\=Z>FN;.AOE0MZ<*5=;E0RJ>]*(RO<"04GQ/B*V M]2L!PUR$P1X="2P:(K3!
(4E<7WQT?/%LPY!;*4DG325DY*R'T@I*D]{1P>K[M3]SE!!;%QG.B*7KP M$%-Q%G[M.JAW!!0NB>DCO&FO-\??,F.XBM>)A6*?W$.UZ*=,SC';06YKAI
MJ*]4. ^DJ>EU^J:!!,.^N4*(#;13XJ2V_GH9P!E]B096S@'\@R(DZ/S& MJ(R#Q>3\;A+,\:*]$N),1,%-ELSP"_^L/ 9^+8\Q!])#EC^NEONT|'-]U< MYY-NV#6NV'P0BA]*^W
2C@=# J;03CW(=D>&_;.NA[NVB'W[@.1>7-CT]0@(MS*&/_E&JDGJZTW(MD)/'H[?3=91';9*0A_;OU"/54A42IO<:SVO?H#WKBA=X M/#51>V!4?
]JVOCW771E!=6]38$/PA8M?67!V9E9S,!/#8YGD8!A=^$2*,N(? MSIK0+/!FC(%JA:!W#V2M\ B$OA->0#)M_^&ZDQE@1JAG 0&W078^\U\\"Z, M21LZ6C@&>A0*ADJW?
>IGC%*45XW4G0YI/1CZ5V?]{.(!?PQX<8P_R*?5Y-U M]R9W?IU7O+ ^=3=+, _

*M%]PJ*Y15#/F-AKE6VL+,XZYM:,VNB;"]7>X?H*]UBIU4CA6C#..''!2?(PC$<VC*\53L8C>8":-/RXVEC&SGE2IA^FP3-M:06^OB%QXKJ7F/E*C3]DW=*0?=SY,5\8NY'>_^E\Z?_B_R3NBI$YBK_#?5N*-MI>^W(IN4]#J7%7BX,+-@7FJ3X#",03->QC>+S4-RDI>[3)D6C!M#,ZP:?K;+'Z]K\YYOU/"=*UFP96E['9LWTF5FH8-M^)%HC_HCS?'ZI0>,-*

>M'IP'O1[ORIQP-"O39--"CT@IU12\$[,?(V,5^\A?' M=A*!]%XT",^QGH./U\5?1_##1ZVQS 2Z@V&";B[SHT$>A 01"#->CC^5L+I, M!#]M/A*!KP?*

PKG)L,S52H$3<(P(K;X!#M=`TO6&D44MV9@?U"LJ+N?ZK3I/W"9O-4(\10WVO;RM#CJ-^DI<9\/3>.*TEID;I)

MQMAB>80..'C_'[Z^],]8;K,1/APN*(9D:1I*YKJ.9E8K;C\^Z<09>20"MV6 M0RYS$EZW-E;R<**U#D3,'DQA=,K9%]8%UX8_<&?3FL65 *<<))+GE_!65RFM+

MT\YK:O<6N>J#X>?UP1RK1\.S8\^=5|\KSMF^2BEP[+TF5&;+M*2?BK(_H!X$ M<;?2GVDM6,"]IV_CBE"&-[N&!;IG'1NM>&X.L_/QK3CZ=S9|[ML*%*B8#B0/

M!U&]T?'"NVX9]"7()*]4J2Z#X^2@9'B-283\0&-M0_;,,VQ>\G>&U*@&E9") M4-Y*S$-_VF=$@-*?CD!T-6O/M]A-KK[!Y.Y/@-IE\7LX0UHB'Q>++#'3:84-M;Z0-

_$G'SV6,ERBVLL3DQGOKX]3%CXL1G28|HU5FZ6-)AJ<*!2?(+X=.8OGU M20\AQEH")/C M@M2(ZX&EU2]7N8$U,_IH;^O\._?RM((87*9T_']6'JT8 57]Z $KN:(‘L&A

M_C6="#S";'\NSVI5[YL.A H4^?BH:S|;7^0DB*YKT 3_S;B[.*\/EM5ZS M.U91XSPZNF/A;_V[@;_%9?C[_3$]1-E5#%.(>ZD#UYCCVK097\-@-MK$YX|/P/;EESLF\U^OZS#?

M>T 5D/K9%Y-V)Q4N@.M;[GGKV]7ID2X6N%1!VBS7>E]FB)PB;R=TQ'FF M#|;/ST_6/Q#S@)P@XV\+#3U2$1@9XWO4,+$S-8FP6MXZ\H[2N9-L6/_VVAHM MMW"

<]@LG:JUE,%Q%Y2JR?KIN[>3+@QP5U5"Q;;>,5.U#H],IQJA6;Y,1DO/<'B)`0X,?(A G?@..%2]%U%5:8N=%$M9W+

M0T.%/HR&|%3\B4'OW).9V@9AW':V0N|DI8COV>1%.O.NT"^=;+/PFQ2C6.UQIW M->SN^ERJ3OXI^:LHML;WO(=DW%UK.V8X\,-01T@A7N7E>9_,,NG2%1'GZG'G.

M)W7%T@N!.Y^516XXP'_U=S#F/ET7+S!@4$@S]&.<4#QFF;_<[M8_"DNX^S2" M(G7%*Y?I=2>R3I[PN0HV9?BZ>[, YZQU!OZUF_3T:E/RX#NEIY)3LM^[E936 MHS;;&?

OQMIE88Y>ALHBX=IVK-W"K)?N*1N%>Y'5QF#'&N0@X5:"F)TV0\KU M(X_NTH79HOJ)X@U3MG*&:UYVES|QNPKYM#GCX-TS\+"Z4L]Y3]\$\DD2D#T6$ M@YNB!?

5%RZX&R962HNW>(!_AOE8/Z$AZE@BL+5N56#TM@'_[":@LA]}[!S_F= M}];^HX>ZY,-JKY<93;N1+'CFXMFY&:F4BF_NC(.MD6=_7L0TOW^)'>?NA4TB

MMOG0)Y*')HIYR4WYK-MG?>K@-10/SCM1K_1'-%ZIO(;J. O28(|?>06 MC2?E#!BU'HUG>&7!JS1EVS;_/ SINS4V(" !LO/&6D)E]TW5E7):DJ\YD5 MZ-2Y?Q@W0LVW1 0B

X4G B|N&RI$<6+!%X96VVMC1N>}G&EV+NC5+%9FX, MHGP\W,3&W"=6*[^18Y SBVTPFK9"\$&%)--=I4?NF>5WI^FD)IA

M]W[|>^7R?;KM%FD39Z,G@A>P7HWQ;@*%SD<%+Q6/-A7&\1*Z/Y#!7ZM.C9*2 M'L,]\"]f'Z;_L+1*K"%]:RJ&1),*+OW3;1AH5\[9J D"#SU]:-57LZ#WMA*

M)EW>;HG"T=L9NW=C>[\)08/0_=VB?.2PWE]"-9X,B+H^:11%[93]H0(L.'0 M#T3B87L?>OQ_> [S;%HE8NE14EE84(\5Z\3A-184YGQY@?Z:R]23'?H[HZA&

MS[ZMU9FF^=e*'OK53+PE"YE*?)2L#9>)H?NJ^^E++]P M1$F_D MM-KD]0G?TA#L]D*?10N50YZ?-[^=F9J^)-36GSP@HT3'4D4\'SW4W_$<4)8W

M=ZBKNONDV!]:.RL3UVK Q$S|_V(&0QT(ZMN_#N=8#Q3%IT>;=@I?JQW627PO/ MO%G0]'UUP]13>Y]!YNLE E4S'Q$(Y=5HX:@_JJ4L+D%_D.QQKFI+?4H1Y'I[MEML-

WU[&L9\%#;FIXLU[VFG:1RO=A$>,_7DC>GQ53S38WWWA7#A%MALXY7& M=9S=;!^7(+=*B'[EK/EY.9)[]BC19;GSTK^4I.]$^4WS8!\'>EAB$"P

MFA;*!.)#0AT7'HSH3)3,#R(C31>=1'A:I)+]KL7'4T_M-;z3>5X5G]0W ;UQ.%G8C$UV;:K0_N^NOT3IR:9-.]4"&]=*, B!\VXNFN[^.N; H.,7$X5>/#*N@432HF|\

M<(99MQJ;&YHW+>@MRT3F9WZ14:980355F()I%N*K\%+U&/MWTM934YU?/TV(MU!BGTK0.HFCFM 1[OPP7 7XO;HKT. N_%.!^<=`CVF$&:I=I?8%C|-FX7(5>

M964>M]YS"[%3NK%<"G7Q ;]XH0+;'T $;#A(24H,XM& _/9;+ /@_<'+_&&I; MM=*2TEUO}!<054Z<,R9I=MDNO;7]\L7RH;LW!8'5,L0-4]I5A1.((3'-.8R5 MBOV9Q^+?"=!?

L0?XN7*G>K@F75;/#R6ML/Z8B;# M<37Z;XY%1LW-&Z=H>2DAL-/]*XD"IQH^_5\@I=AH'!^AHR'G5,0!-XS21.]& MG%9]GI(/X/K6F Y7U6E5&&N_ D_\0)ZBO.)'!PD6_9 EI.J

&=SNPDB._YP\K$AZ#A1B.0?Z9:V7EF3 M)G K7[E.OJJY>&^-EP#GM;3OPTMZ\BAK)X/-ZV(KKAO.V\%W:7];@6*ESO[R:B\Y &MEWRP,;SLO&%UZD8D5C]6RM80<0*W-

;AH7\,1(VP/,*;]:Q87*B7++LOSF0%Z9WRZ,8S[S^:'!!%/) *.!$E8SE,53[O-)|68ECDM M'U'E1&&$\[#-J%TPJE5N\50(S$T$,/%P@E201DY^.XD&AV/&X6LQ>!N2!:B3 M,NOF?

T<.P7&>I\:EV).EU45@@S#]PFW*+1++G1_^ZA>KJ=-L&E$EKR_L,(HW M0R/_U;7Q.%=&1<*[X3XP7EB8E-ZOD2=@P=U(UJ>\XPVFI ,;AB(P|]Z\N'(7_MAS&]DO8

MIP1RAJF?X P"[RNYRPY.7"<+I((<.GB%<,SB, =^V40@667"/2.4\)?F/|# M8E"<'[@D9@RWE8Y+7^QSC05Q&LY971FK, ^"]X^05C934&%#/7CE!>GJ8BE;7 MD6W,*.

(S(]Z!MZ"-1&"TK^U^:ZT.$4A.P%*?1Q\1@5.EZ;+_<"?5WV#%@X5W M9(,:<;T89*_1NL(WM\@L?&ML0Q.2.4I/GWE9N4])HI.6T:3K<9Q[/HJZ8+^U<

MK=.\RAC$$>%RV*4/T,CVSM=)PRT#OZ:#FM8"',^$M6N.U)H&_WM+K"]D6P M M[L<E4S(#"252OG0\'W=SWP1:U]A DB-?#&NL$R**Y8OYK?'!8X!4AV MGKSPD<"?

TSS"F5(IO&(WB]L;W]6H#;]1A^6)<3+VCA49PI^8U9PT)*Z3>)#C M:*[N)D^,^WE6Z=Q,&&$CXCLAO,V\"

*D$MM3(+_#!PU"$3(H 7>2>-F2@VSKS9D01\X%<+F3:VVF'!,"L M)P\U*9SKZ>WMGT--@NL4!/K!>S1_$M1R%D1YM|T$2(#K?Q)) $4QV/+\LM%# M(?X!;6QTT"U-IED>Q$]3^RJ%#ND(IK3|(]8(O>;81S<#"G_-+.C/%Q#W+5P M-QY&L8' =Y?KJLD:RV%IEFY^Q%2T3L'#Y37|ZP*C\I77!L3TNDLO%T:,IGS) M4N7Z0FYV5K&F'1U^.K5]7(K"@_)B;"PA>;(!KD%R9[,<1_T*Q(@$\6H M^^M-%&"UYHWN*!7KH1\XRI=[O;.$KDTLIU02S5)5PTFLHE+9"6Q%RU^4_,# M1V *OQO-M2%BO"##)OES/=9>.4Q>3X/KDCI,TY(777A3@3DU37"#RYK\|]?-M*P#9>SQ5/K):,.E*W-9DPA7>&5H(*B*FY9"U(_UYS#@Z?XZC#O?0/.(YD) MY?HF99C=BA*\)!;\|$<-*)&&!H3/XL//7'[_'^HU\-0_3]7(([]0^P MJ,CB0"!4U0#++F),L/NF >;BO;$>I);$0,*]\FG((>'"MB&$91'4!UA$()MSP M?%LF+^9!U0(UY$69DXYFA&':C?'C6;79@Z?HU5_U[^VG8S/SZEPNL)W5 QR2 M9AF)/$;==944_!%ZV$BC%O:G<92'4X[S^2N6E8I;WIRT +Y7&1;3>-!WEBA! MMQS,O*.)=-#TEN;ZRCX7VT*?\,,.GXE-6IL&6FTOK;O+8X^<7Q@_!-PU;=8!CA#\;O\:E.U[*=((C7%KGPF^X!+?U^5Y^DN!.M_\VPG"MOKN>F!)'K;?EO+\|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|S':6" LH.P|ZN0?NHJIBN*N9X*!V33OV,_$<0LK[Z!OIG> MR;PS_*U+OEXM(2;@>^7VVK<2^L#9SW&)#E55\|-NT4B>Q)S9&C0=<+BF4?%5 MOJ,B2YTSK4#*V$"%\/R:LF/ :X%,G?N&$H4>]^6Y=B2 2Z_F!9M70# O#U;\WT1-2!#)P(="W M_L:"M69HFT&@;QLHR@"\A^ #4W-Q$LUG.EDXLCU)dA-FY=E-159AL?:!88K" M"6#/TZ^Y"??G_EP/N\1Y8:2^O(@PS42NF'+GW9T+/FU-\3;$XZW"$_HMV:$: M=N]V&?!\|DF:72;=GBA/PRZ\8#R1[S0+M-^[I4QPMTP,*#45?LO 0QC# 8$I MPA:6AFL7-HYX?M#V5QC_WVH!1\A@<3Q=K%;78/(YFT2\Y\985"E420W+-=CW M8XKR\SV]'W,V?(!ESE7.0>/4E,5"ZY^[&0)6F]O?A_(GB:K901U*U)8&!7ZF M)?)C|8C?"UY_51QK_;P"K6^OO0++Z1F%C?"4-A,98*&P#588YCZ8R%_LT$QS M2/V >&?:G$99XC?:Y&XME=9PH5%15";S 5L0RP"1L_@#*R 5UB81\P|$]=)PDTIL4L32LV:D_8Y'AOBF ML(O+]N>]6&3ZE_]:9D<=*- QK0B:L29Z7/HBKQ^B/9'88O,V@3A MY5/4,VSQ)|U1\;]&X%]Y0=Y9YB^"Y>G8FY1:THGX^"$.VK1UREV M+">B_5(776>$<,# T1\;R M-@ ZKF24T1$F'YN&\=?3J M_6GORS=-"%WYGV79K-QF.AAW&8^<5MJ:?(J.#I6INO^>*T-ASG*78539S#;C M<+#/'7*UXR>MM8^-D7T;/JJ{IAJO5F:*N5B4/WN=IYG=:GWEF3SXSZ'X[M>"^^XFL!9205AXJ(4HYEH5%28"*@?-N._"IWX8B,KM,,,]7/W<7P1 \TA&(5 MT|T?`4Y"A[[A]M7OE;IY&RX(\>O/PS/[?:LINIU8LYR>$ W &#!U$SY]Y"9,>XULK>?)^[$;J) [_F3 M8G#8_%Q N!70W0ST:G)ONN=JA+D_+9QRM3%5,\^+)0CC@0'-@RGSQJV]U-M1(X)M/TYRC/@C6UH5_O3KXYTZO!E@9M+9=&YTP!? 5'NYJYBYYL*IK31XV&&CJEXE"1#CUU?/FYL& M/&%/2,13 P(#H5-RVY:LO%5:U@%N1_ZW\YQ'782LADU1YQH*D4-JF@73E?X= M\:-'"$U,!52D#53EH6-/O(5%KW\Z^MQK-4U/ GR(>%QOHIK*5M.G_A;0\FCPX.3^-W5E^<4.Z"('XR1U'_=\A0ZM6_45MJ99 MQI[6!*]3R08_66MZC4'AZ=:,K;G@>NF/<;E8?95T_1HI[V%3:"RG7VJ,*=>K M:Z:-/8B"]97Y*;GCZ+]2&9+9N#Y7Y7I[%*MKB8Z",>Z8B'Y\>`5W0<>D\;%@ M^EO1+!D5D4'DOH!CD0\DP.7F18.M9&OSY]>_YS)-9IL'2]F7DN-AVVLWO#!=5=W3A,:U=!9U$U MZ9=/ ,85@U>8C,?"%8VGG.\C#RR4@6F+WK4;V0KJK4M%IM"0YZ-5E'UWM%3& MMXY_?:Q%AMKZW.5Z3?[\K?8$P86;Q_Z.12QJ. CM(\Y%;,L1 ,;5|F/#V=+5 MYXP'=L8SXN=J+ZXO5]GA[^)TEG0H\#H-HT='LG.];>-W-JYE,,3);>7Y(62X M,'43>9M%^F>CI,_1O,*F#'RH*A4/[%24'L!7..[K3$0_O>#AP/?OF:??,!U) M#N M"%\\YADL? YU$Z/#`]Y03$WWN0.-AD7!0@T+RGM>ZEZ"K[.SS1Q9+6Q76Y4Y MO?04J[^0'KAQ8[OB"|,Y=7?25LAW"W MGC5$SH\W1$).%AIA2H?"3%$_)U)/6P/I8%E#^]_/PS:U"'T\&5B=_SWW2V:1X M%,_PP0^N9>28(:-UJ/55,;4_;V]/#7U:5!0FV7T.BZK4C%Q\(VX&&DKF/&+0 MT6 > <;I8O80__5%5CC6)2+EPIBFU9+X8 QFB*6),3'@L#Z5" ER#":[^/$Z1 M-9B?"@;[.YUE](@>\|%1%TOOLJENMMREGXX?S'LZRQ!O+LWOXZ@P]*/#]>GZH1 M!'ZCA>/.QN^D_-%[;"K.GT$VXB[4ZL;CH12EJ5=< M]$D'?#4L3=XBNJA]4MDTU1"(&0.!R[FF=B&-Z@[$!1\V F27&W,,,25>/4T_M-?;T>K6L"4 =L

M8>S>GK=/5!\+7>6@"1,;@5>KRIT!AG,6ALAWMM6.V%K-W?"KTGRN&;O%<{)#H%9!LR!K/X|H6Z\^%GLRLXNV&%SVN',<>?-([<'Q-MML#14-IKGYWX]*AX&2"#UD(.K?AV%I2^!]D6??^2014;0"PX#2F;26$UPO3P-ML6|OHTTNPO@ZUK$\MZQ2,=N -,FTT_ECB8'OO>X0;.N-(!UP;/|UIAK% #/+ M& MI<)V6$D'f=@?\F[OJAM> 'TNP.CTYYV.P'Q-Y1=>3#"1]$X"YP7%7"!U] M*)>_K]8_ILDXI#S^+Z=5<;,MRH[+_N6^^(-WI$^7/T S<).Q(_Z^5;-^YODV]
M5;=R-5]YM5:R.\;?.IQG4I._>;!3_@EP'/#6N>8E^2?A2_SR;5/PS3/'Y_G6Y M71],)\|@$)#@M*C5#8_]A;*&]?>DLT5.ZQ_^WK;+Z3*^Y*)+\P-8 ,'"(\#+
M)A<5|)2TOP"F=>7]*5MHN^SZP*Q[N:$64ZZ,H.**.)&]NMQBC,-T6-/@@C$Q M]Z4?OQ'$[%\>WU$=D?NHO S@00?EOD^Q7,1T#\CA5#,*]?VYO6;704[&)SG= MC;"R;Z3T?I!%WV)+(ADB.2G+RJT@WQ.4]'OZ[Y+?B.7FHRGPSNS?.OM%1,\6 M>P<[+\W_&]Q!&Y.!-8\W*5R}]WX?RN=]T!^"6(=U"3V(&7K]V*.(6"H!\UT>? M ?"_$=>ME-
BWNW+!0Y'U"";_,Q!;G0=,,_:K;::.%4EPZ'H3 TJ;BKJFFW9 M{9I.9]98,&"=;XN>C;<2)43'290*:[R]1VBV#'QH&5NUV"EO\B.1#?%LS+NV
M9&=!"N_%0=SH]WXN@Z[W7%?*+O41+LF_$D.U36?B%Q86\+%;19\9[Q)2HQ81$> KM?YEWO+*ZHMI MV7]-$(^KT&9?70H^Y,.M/2P"W">
{BRIZL_X%]NQ$\W&A0UH9@4Q!ER;(XODN-MTZ/8OB*7IE*+_K@X_T0[ZJ:==HG#)L;>ULV;A<#]\QO?--X3^V=Q;NZ\0=(-M%_)0.%GN1(>4W)%-$RS*5+]F:
(/P.J"+FR<]E1!,G]3TC/{T\37CI^>:6D1& MBZ'QD#LDFPVC- HS# U%N9KNHJ7*R[Y@I;I%-0YB;OR\PJK;}?2=?<1RZS!& ME9D$L1GV*>/?$ZZMF93 C^\DE)8B9#ITN-
VK2!MX[E)6339VWH5<']IA[K7 MB/EOESNEKIN;U=F8NT64QONO#U@/#A<1A_A[NJOUVSY;,Y^VO>6C?,+LL$C M*H/U@VU=B+5KF2M@U+V=B+5K8/#QH&5NUV"EO\B+7L

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{&O-V)NF?]PWXIB/L,D;_$?]= M^UR? @I4SGCGS67JN2$632=+S85?!KT1C="W1*,U-?F@Q<5Q"@ Q-+()3K#^] M]OF.0EI1L0?'A/O1XGAMWOE/))9Y+L@BVXT> /$$'$#L#+:Q(_?6Q= M/1DK$'€ *)*>84IT& -BGA_B/)M OJP/!*6(,&*(_Q!3\A(F46WJ!2739YT"U M,O,AKYBU7"MMTF]GI=M:?X:L*G..'WQJGA<QOV]HBW@o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f[A^NNNW-%L] M37.Y.8U>PH#R%$SBHW"#,)S>HTGAXENO6IQ ;MU2)FQ\$WU&'6>7>ICI6>Z;QE M _%9=1;.8[-[**HAS? 5P]N=LZ"L<".^-9F\!%*5>T'=?)\;Z#& M"Q'5$7,ALM,B]:OJ^K%]GNK%JG,& 1.0JH)&49&'=7TU#DX?]^T5->=?]$ N M^_:^A$DMM5?,7!4HB>3N633$F5C@FDCC;T69S-1; <06-ZJFH$BGH\MXE2=86 M+FTN1A,\Q5+_Q.INP$@P0;T6?]^E<()UXC\_M1S(Y$\;P=0l,?BX\CC$XCQ. MO)OFO$]]Y_<0C*1^U;&W$0:J@EI1S!Q6GP3;&,R(Y(3YM+:D;%8NILTB?)P_MF:?Q4S&(#PNHDGFM<[5S^)9*-SX5\N71CYP/U-F29/]A]2=K[XW$*#IX5%-]F ? M+!X/[+1GSB/[-[=C?CG_*#G.C/_\@:GAN*/G[W@C2CLVB?C}>7#4H<%!;/U@)G[S+6*B^R+*MD5R4IWB M7N"!T&\>.S::^62]?;FLU5\;6/3&O_HR^T?,'S^U/H2[3AQP4SO+F4]D.S-$ MH55=5\9M+\L\ZF Q-IM0,*EQ(Q\MV9P$S#L-#TB[&)O*&2[FM4\)/QHOH>2P M_QA*AM!F%/'D9E1?<0[TK7"DT_'C?_K%FTVJ&J?$U.G,_A[R7&E/PZHRP^_$ M)OJ2ABFFWR3^]G[VIB.FUKX5'?R=H[*AXDWVV:=/W[&- _^]M#DCDGGCM=SFGZ<\GRE1+>\E WQC$S1/"uXELW#XEYG__&(]TXC MSL"CA=M13^&&1"SF=>#44]#W Q6 U\H8V5@$1%$#[\Y_>K5:OK1ESDX;*_B!]SY3!E-QW/_:HTPLR MYM==SG7%|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~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}HJ"L*%%7"@IL"UTV\;?9P;Q-IJ1>]*K%(&< CU5[1L:S$BK'G0^H5PV#MP_4,VOT+9MS0MZ-)Z/2WS\!K<4,_/G MP\Z,_2-XH->/KJW-XV]U<^[#!>(Z M-(N2%,O1%$@R'A.;]$L9R*_^OG6Z>D[]NU#U/,R91>M<@ZZ(NK/]<9F0YF?5 M6UKIA?K^1.-->)(::#\5Y0*.0O9TH:]@"DN@Y,V/:[VRGYHOMUX'1.KC' X6 M?\O\6J>%"A1CV$]CKU*4P$6ZWI[%SMG+IXU3:RLR_8.RT\:B.RPI0YQC+H+[MSM4:A;!>*>ZAQ/=&&&:/%&DCF>HE8DZEY*!? 3VRV [O!"GKA*ZZJ{C]!CP0 MP7QA:>7LUT?#VQ:N\RU2#]UJX.[SDD_%_%L^SV_YO4P /1$&HU:ZQ?SP|5)-M@SM"6AM9TX!"US^'LI-MG+&F\,OMRDZNY38'W64]DP>-]SZ!P8N_G)]U$+\PG<]BN(Y@&%U$4T)[@$> MKVP^8J&"M[4IPR.-O#XZWT",2"F2?S,KT#3*%OS:Q\F$K%TX='GFT19!{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{0[R!=\)Q"68!%\:G&4E;8#)K,7@;M^#%*#O0G?MH'A M)]S_N+'#/1:KAL,I>GWEO56L42G85WA T_]9'U;]]6X@?TA8@,3), ^Y+&7_& M;LB6@53_J1$>F!"2Y]YIF8'M%W5)C*U^B_?WQ -3]5>@=]R:3N09\0K^3- MX(% N8AJ=D/46L:,(>]A-W:)OXJ:.(NSH\_JJ:,.\VO8U"LP??^8\YIX6:OS M><-%YO7Z!.L'ZF% M4N.!7NMPK&+!$]9=H\K~X7^#COf=KM^!?WC-]9V_YU[9%-MS-HW_V-ZC"T'H^'O% M_QVOOB=]U0U"?=K5QTX6AR'4CS4ZNSRNEG^EXBXBP+W-]_9Q()55QWZCP,** M{(+8ZT@5<^I- A4P$(+M:&,Z,:-%W=3\O6S.^:,W R,"0BK?>+3KEH_W)Z54 MECG6YH7!T%LN\)?6.FYB2Q: [2%S0]@'/!2L[=P[C.:FO&%Q]K*O%\AH>N%#R MXJZ3$)W@/W@@5X;!R.9^4&]I'ZC2#PSB]G]7,.W4.]6K5;3(N,1B]*AQ\< MIGJ7.E> $P^2N9^%L(10%>,N&+? M9QF5[,1F9'Z4&](RAQQTA8OTO#9',U[]9\OTA"@`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

W@OZ>70:'YW$"Q>T)K\6+]AT"R@OV9]S\(96ML2M>Q9$&!^6I*75WS4U M>?^Q62]F9PYMCK5O"^HD>U*OPKYN,"2U:]W]3W> MA$,#T;Y7A=:Z'IG6KKHSRY[6M>F84G,W MDPTUO%^,?]7XNV93-1H M%?>G"C-W_5_282FNL!ZNBR\M\WN\D4']A4_':LA$K)4G0*,_A2O%DW=+%@-> MZ#*:T9K6KO!8/Q0F;ACZY8<[?CBPO1PAH]Y#!ZESVJ),PIN(47 M6H]_\6BSRSL0.",H6QRPY^"1]; 9X[R?D?58ZKZ/IX/FNB')*[B07\@ M;1FI?;"_$-@!]K8KX+VS=R,P9@# (,.*GNL+>T/M@0A0TE]MU7S$%N=)XT;9[-MS,XSD6#%$R5K(,'@V#+)(S*!G/SWI['F,9?Q-SETO&#@]US4]_..+\,-C[$W M%EE'50 @#_ 8F+=\K'S2PU\TH7$917"%1&=2XN3!"\B6#0$SM.JO&5F$6 MB#\!6M7;_8W\0!{C8Q5NT<.*2S(@N3W):]@0,8OT:H=+"> @\Q.S!V_57WKM"2Q>N@P3A>/]6*-$]DS=.F @? \>?F[XWT&3]*@C&F& M$Y> O/7MH&D@42K0';VQJ8TL,I8"]['S\;<+],U*:"=,.-SK;%,8AWU:OKEO M+A8<.@H_2;*AX[1GS^53>2QBN%%SE9&3')%HGU M0.P<,#V(^U!Y&>KL9@W&JHBOK ?D/8"FP(YYH;=/O$!&.A^]E"9W#PZA&(^0 M?7>*IXF/=[@C-@_]PX\@+SI? Z\B_E9G!>#V_A9/LO(LAN,]9Y3A>1 M1B910<9BNVGP-9> P;"K&>U"S8&?NOP?N_!/?:^V)IX%G<;...9F!S>[='= S= M+/?NS<3/$!7FC.LQR;*%;Y@ .C3W;T]MK$Z$[+H#W*YC]V?@?/D<>TL9GCI"O^/5& JRKT M2?RCQ? OYZ=L+QF#TN+[8;,K>BY55F\4@R.D28Y!9@>3+:.5X.11I19^K7Y7E M4F-2UYUG>Y0%*F\E)6,"_F;E'G/EUZ8.4WZ MJ;@A_1LE +7/R./5AOT&WF=ISZ;6$W69!)/\;ZL!)-_:4RN(]Z+=E8D3 UT7 MBZMC?C"0"HQ_][ ]S#,=:|)-5W)!Z[=#%MQ-U0?!"YN7?/ M0&BG\'Z,[?B9"';,Q$C^-"[I:1RRFQ.\[HC9[PUUDBE%TI,?5M:WS![W*$0 M2?[:W1LKO%9V=BCS\TSOA9UX4AY6=_ZM>B6RLHF43;ZAD&%;_W58^O'3+ZXJ MSR+L4XW"DC&J(NFN<.L *&(''^ 04]X?:ER/Q38X9@++?^%RIX=+<3_X4=O'2V M'4;E60JGA6MRS>2KK(+('=V5M@1TG-]N(*$?Q7-W^7[2[7+0TTI C&P,VO? 3.. #JZ%KY &Q/? L2<(O8=@G0HNZX!$"K@?@3 M?WPA(TD_M!=: QV/O-HRJSOX&1#4]@M#?S8N;R@<-7Q,8KD)Y91-7MAKPHV YC M M%,N\F?LG/8<-S XDX?O+AMV;K^Z?HX&?F__MUM-LM@6LVRJA#M$K>@FM(2Q{JV&C%KHGB|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|C2UV-OL\E^!K$YK4OV8; M^/PGW2.N(0Y,"D>&'(""G'-?KA26N;@$HIG%-644!&X"XVH4=!T^%4WD7LMW M&8_0TP6$&P$"[)A^*\?TK(]HPQ=T)A.V,*;Y3%['3@ \0#Z+H''DU$32*Z'C GS\%\0 M+]!= MEQ4A?/ZYC?O?C?RU,9.\:.CMXVJM4(FAI_4-29NF"??/IHGU\V(&;: MS-AZ=+O>F;=V-ER-O*>;%+^(&8*W/Y"&[,^AG-]Z"KBB"N"!1WC M4!QWV5A%GG+K*? ZLRKM!'=%0M_#F'=5G:L?R[IT@HOQ/CI4U^`JN3Y^L7FRG48UH]EK7J0:.-? M^_LC'3$4A#:TWN#Q5S9:85E M*AUP!O@T)#"*FQUK$;']53&/!Z&8OZ"X'A]8LS<.>=XMW+0S$+.(='=7+YM*: M"/<> X;[4XEJ<+&+P$TA&>8*1/L7E[LG@-F-'N#XKRRZOOKY?O=2BG?798<-M0ZI(?@? %HPCWSMT(BECC6-\OX]O6XVE6'[2+MMDWDKV<7,N4SBL9)WE-;;X) M," Z^W"QV)AWZ](S{CF:L9Z3O)>!*]R 0.% PXI18[L[9+]5.5*4'4J&31: MPI,^=- -X[OZ]'P4\"'@)"\.V.3\5IT%\@M$M3VY'<#2G**M7BR176+L1 V9 MLR@V:T- .C:R.5]M;7E4G"V9+O2/V M6%K=T?=U-"Z;YHGB>97V! MZ*NTV1,ZC>MO@OZ*)YNL Q5YAE45$&">DB2#..]_IC5)\:,?7N$]]E>9&C] - MJ)**,\Y, ^4&>JC0 ,4Y09QS!!"!I=A>_@G[B:FD-L$#];;^.OB';,04>UXP- MK6 B=I[T3T$]S4(+?(4%#T3SO%]AP*Z4.B- A'+.0#I/9WZTSQ9;4Y2]4R)IR M[W&03#CT!VN>W:9[FP4XX.$*F^.A[O0LAJ2>]F5%[5\)Y9L77YK6+/KS2D?$ M^[6-,*_+ M(Y&EJC3X]Z6B\ XXI4E.;M/O:F2HQ0*

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{&O-V)NF?]PWXIB/L,D;_$?]= M^UR? @I4SGCGS67JN2$632=+S85?!KT1C="W1*,U-?F@Q<5Q"@ Q-+()3K#^] M]OF.0EI1L0?'A/O1XGAMWOE/))9Y+L@BVXT> /$$'$#L#+:Q(_?6Q= M/1DK$'€ *)*>84IT& -BGA_B/)M OJP/!*6(,&*(_Q!3\A(F46WJ!2739YT"U M,O,AKYBU7"MMTF]GI=M:?X:L*G..'WQJGA<QOV]HBW@o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f[A^NNNW-%L] M37.Y.8U>PH#R%$SBHW"#,)S>HTGAXENO6IQ ;MU2)FQ\$WU&'6>7>ICI6>Z;QE M _%9=1;.8[-[**HAS? 5P]N=LZ"L<".^-9F\!%*5>T'=?)\;Z#& M"Q'5$7,ALM,B]:OJ^K%]GNK%JG,& 1.0JH)&49&'=7TU#DX?]^T5->=?]$ N M^_:^A$DMM5?,7!4HB>3N633$F5C@FDCC;T69S-1; <06-ZJFH$BGH\MXE2=86 M+FTN1A,\Q5+_Q.INP$@P0;T6?]^E<()UXC_M1S(Y$\;P=0l,?BX\CC$XCQ. MO)OFO$]]Y_<0C*1^U;&W$0:J@EI1S!Q6GP3;&,R(Y(3YM+:D;%8NILTB?)P_MF:?Q4S&(#PNHDGFM<[5S^)9*-SX5\N71CYP/U-F29/]A]2=K[XW$*#IX5%-]F ? M+!X/[+1GSB/[-[=C?CG_*#G.C/_\@:GAN*/G[W@C2CLVB?C}>7#4H<%!;/U@)G[S+6*B^R+*MD5R4IWB M7N"!T&\>.S::^62]?;FLU5\;6/3&O_HR^T?,'S^U/H2[3AQP4SO+F4]D.S-$ MH55=5\9M+\L\ZF Q-IM0,*EQ(Q\MV9P$S#L-#TB[&)O*&2[FM4\)/QHOH>2P M_QA*AM!F%/'D9E1?<0[TK7"DT_'C?_K%FTVJ&J?$U.G,_A[R7&E/PZHRP^_$ M)OJ2ABFFWR3^]G[VIB.FUKX5'?R=H[*AXDWVV:=/W[&- _^]M#DCDGGCM=SFGZ<\GRE1+>\E WQC$S1/"uXELW#XEYG__&(]TXC MSL"CA=M13^&&1"SF=>#44]#W Q6 U\H8V5@$1%$#[\Y_>K5:OK1ESDX;*_B!]SY3!E-QW/_:HTPLR MYM==SG7%|\:.)82\A)T9'%5/="V]!V0Z]HIA!+,:T 9]-M@=0?KO,*&^VYOTX-C@WF[K8!>QVQ7I+YKA0:>,1N=-ME%B.]9 ;U\2'XUXP4"DO<*X9HQLN(79,LT_78;D/W&5-BK,M!*"V*"&X0:SI M1F0L(6X"#&KW]JA>T"]Q@419H*7]F0/;4W/\F].U&ARH!J(!N=&?7%+/_MZ' MPE!=IQ+M*\^ZBF6GS&>_$T7:I1C_)%;&:^K1/VAIC1=H"]H@9!.94D\AN*&* MZ/@#7AC$ WWB5DZ=O)@#!I TAAA>AY0GOD*\L2IA\GC*Y-"1)DR1H@U\<8PY M&>,_^]< $YT-9LN%V@53^7#0M;^%M#2W>_!F/?WN/\4=M.9OC@L^_OR :?) 7D M#SQ.'V(D0UATX/8HDZ@\9Y/&W_L7\86UZ@%VNY)-=[V I$<%[L>4=LGCFJZ; MX,A[-2$CL)HO!5R9Y)W\W=2C/]^FU\M]!-OHP H7FJ"%UM.M'B6I2]P]>JL# MM0,DXFACR]_?'' -V/&26- 53A*&%_H1:Q/,&MI<\&%&QO3X#C%2 ;'X_,$HY MKM$? \9+ZH*+7+TL"+QE80-=!"VC"R>2E"<;P0(_]]136./:-]_&B'C2^L~M M3:'10,VA1) #^X0Z:^>?=F%\"Z'ZD]B HC??!\.\%NDJZ=*+.Y=AN?W M9KOF!"7A[C>;]#>]RA%0>Q2?'OJPWX .JH&)]D0%]8+I9<;T^EL3/EYD1/_=MU*G?%MF2T++E;%O

(8RA)"G^!;ZZOAT6:S#KWQG+N&*V-MZ[MZ+/)/&4T$YG5O/G8AW5]E#EL$49U<.:!LVI#=U,0]9?'X^>1+]K-O6*W; M7U$G*9!6PJ99?*

*\QMCR@9$HJ)Z=$_GB=H\JIFE93M<7\IM%M9D;XXD&#M M>4D6J/A]WQU]"4CPQ@30#=*6R@",L8A_(-^=RC!]_44;A+I;G7O:Q M"SLYO>8D=,B?I-*

8;9YI,=M\FS@]5$C2[#F7WG'LRV($QO(8;5M-_@:IWU"!W^ M\PAU0Q)_BO8Z6'!N,3"GX1+@A MJ6!;QKVGBG;?

*TYW6/N=@^O@_2)AAC@80f0*I."O2/E/9%6M'RZEGB1$B9W=$E M(&EN%<6_V4-&IO7DO>]3%4)P+W:K=VNN8,[OV(>19_;/9#@/_@,F4-[T*)D*

MXC.X?;RZV/N;N;>CF[P1!69+<[X0G[2K$'P? MH>BW?O=JKO\#[[2L4*X+NQ!WWN: M[+YN[HGQ'J^&];:N^#5!I-X^_U%!PMN)E,I1=95E2!KN(?ZM9&PG19%Q)2)$*

*M=^H.9MK??*M-G*#'^%))_5DUF>AEBSYK MYNS;8I]>*(RF\VLI-4NG-L7K1R9APU F54&,G[HXQ''!PA7>*(%GCVBT_ZV<@*

MWF03U2)MM32RV?.Y^@CN5)!CIV.0R&I4TZ3O.H4+G^K\P M&;?-BA#Z)5\?GC(M>F(Y=\@01<[5.\ D__O*IXA2N.IO?DJIF]&OL5N/?DV\.3 MBM#PHH-*

*;EX"G9P+2SFRV"==$.7I@37.](#:(E5QK"+AHJZ["HZUA1B(5L3%2 M=Z0G^UB;G[3GNC^J"?@.R.[+D\0N7UZ)=^,XG:B6M/!%I;L]DQH][L*6L=2R*

*MFBQ0@^P1<2$=A3EY,D)^G0\ 63HET31,!JBS3G&4L. ^YD:Z-8K5E/^[-L*8^ M'EFDWB5BC/!$[;>4;A/9\188(E$4&)LKGN:]VEY9DUC*3],(TB^-T#BC,U[Q MQU7D-*

2CRHYWW!(S9L%U/'BQYMH;+9B\GEKFD)=X;&5(X/3S;]CBW!,;!KAA< M1K%@FK5+W&T.);!_290AE[F"/?S-^GQM4F%Z%F!5#.5"L#D-T ;::H&.K<) M152X^*;._^$99!]*

[5YSY=,3HFB(,X!=(KG$*,.0LKIB(GNL8EH#>BK$)<; MS7RF-58R%O@^1&Z/+PD>ZMA,0H+W3P1%,,P<6^C%B^HC1W\AN@+J,.]/JFC'*

ME8W+BIAKF#*]HAB*0X\&;Z6;^VD2Z"QD3AON+)5RJ.VL5LI+M+NT=^D?UV MKJ#[4$!'ZMB#R1[)?3&DGI-_;R)CHXJ5Y0N,=RD U;%L@WN'(4OYZAC,9B*

M]V(B#_@,P)[C,AP1FS=CPSU<;_V8)!N-N#\0&+/K]'7>M;T4/C3D;HEL.\=_ MJ12HYPL?+OL -@TE"> -JCNI_9@_OH_$\V,D^QEV,L.8, $QJE 4J&6'.2-E MJ29=(+/%:V%)U?

1:A&Q(S:%4[G-5J_)% W0G>9ZB"86W!*%V^:YFG#MP<*T2 M'1$:B#M.A0>8@V9(<$H?5>"!*U:$25[4$;DA>@/6FU&$91MKK'JB#WXA$=W?J6BN 0L_O-*

*NJGI>V9;%W[RX_+:&\)Y""?^:YF*P9.GFT? MNWX51%&SL=+B@??0\;_P%^_4Y)II M.R")>?=VH2CH^\D%LZ=8KLAM;IV)XAWJ{<]K&J\."V*,#%]G P2]+"UXJ>.T*

*M>!SQVK@>#$]\UGQ'YF2%N3B%[ME5S-\C%IKM\@GKQW%!_F6\7^.;?NY*!)2 M?FX)H>]# ^6WV!3C/R$%9K$]#@$E6UF.]:DO(TNM=\F8ZM<81_6*21H]/^E]GP2 M7M*

6S/F"}6"!V-QD^3N5N"G.>@H<-,L29G>7'A;N!) A6KA(T7F4[FG;Z$WU]L:*:CZ.DKC@BJ/X7' M^8)E$1 '2WS?!^<-$,H[U>OM4]XA)60S.X9[WBAZ.?"XX!UP_@ 5!ISEK4

*M@UMSBKM,MAV_!6RRM&7J1*FM5_/--MW/GL7((_\1CQ#SBV)5+DRF?0/FXMQ-_M&1Y7@2UX0+$G"=^L9E*K3J;O/NP!#+DH%89<[$JEM<^"OU.0#3'E=T =4'>5*

*M)6K0ID_O33.2[B,-./WET"56@I>]'^BD$!NC6*P#288BDS%! ZPQGFR62E MI<7U@_1*I6;1)9]\+CU#V>>W MP-+ZCIH\Z4T>@G$*HMR)C*#Y),@"H(@VICB;H$]"*

TAO'06!B<$F5I>V%#N M\X@V[_X.^!_L!;6(#D.&]6-9^HP7#FSF5$4K+@$OW5V#2ZW]H+^+ MNA^.!%-*+((B#W\LNR_M;$#QPKW6A^%(2F2S.%135R\MH$Q%.M<#U?

*#C%^T M*VE@I$09/%O"R%]AETS4!>./,8MS+ UF.W81EAG?HZ^8TO:ODQ%_LT'YQ MYLWO]!"Y3A#G[RWTXQG*AK-L&Q6&8265 /\;21PI'HD9ZH62K$_(4;D_PC2W*

*M.56X62BGNIF)5]HY=GZL_I4!_Q1UK0:9\WH1$;X6@"H=2*8D/,#S%$):.^GCH M:PAR^2ONUB%TIEER9:WIOX/38VU47TMG?TFWX67:OY]BVUU]_OAG"1&!R[W^*

MHC:/YA+0JX1!RPF2'>-P(\)VB0B9=:OORS1?>E%LCWM$ .8@!,G8Z?T48 M.*U),A L_.LK$=$R[+:Q^U6H]H[$QO^H&K_2>>XW>JBWVB./:IF(A+IB7CS5N4 M-HD%*>-*

D!\DP]S$2/,- >TQT^&R(7I5K/(=99%_IH[_A4SULW#X/BN[50Q& M5K2$HH@UD_[1+D_D8T:5EO0@^W009M3>LOVGU2,E)/I4'1?]AC M;9PZ#5X):8A03Q,W7PSDG)]E:/-

AV[+=,@.0:8O5;,Z,T.QT2Z;,"T MQD& O]TTBVG(=UE?VIU*A?^6%AOZ_I MND_OH& W7-J-XX%NR==^A4GM@!A5]9!#-CO-]7U&#OWIK% M82;T8;OF5]L(?*

PBP%BX(9PV:T-S11XOHE7V]6=C5\EG0,4O!\E-5E"7M.\H/ MH8I\E9< 3]<5\$>H1_.1I$5H_5GEYVB9CYL,K,>U.0(8A7A?SUN02T!?&#-F MN%1_1M7&UV-2I;CIM

FIJ5P<$YUG2,~)^%7 M/_*G3^3*^FNGBWU-5R^<+/K/6&E)AI#B%"ZTGJ'<2KM/UVG%<^3^/\.[=NGU+ M"..!MV/5&K126[_]"ZZA?0=DX6C># *

*]YL/TWYYE:VL_\9S$GDL^'I'F9-$T%T- M)2&2%5%)*O%.($%MK?*M5[EL-$67*T-H2>]GL]^!ZFA],O_\6X)U.0 C-XB, MQI3OW"185I4*6.>[:%?7*

*8N:S^6/_73=ZJ(\IE?.^L,V;H*A+B[++)D'F&?[9 MP:E+!<;H2RZ1@_Y8*/(.=KDY$YQ3\QGIS#P1F4OQZ'L'D82\3$X%+SU)E/$L M(QC-RE$ PFP\&VT>Z.^R34K!MV_*;9<@^&*

*<%@!BZ1_+.(I,K_"<)Y"AN_('V M&6@%)N.PIZ)ES?:PIH1 VEK_[L^1+ G%*I4K&D=T UJG0\)-?PN"%BXZ,85>+K>O?VXL8CX5.CH;R"-.,8-%-#]NSJ34@<$.135R\MH$Q%.M<#U?*

*#C%^T M*VE@I$09/%O"R%]AETS4!>./,8MS+ UF.W81EAG?HZ^8TO:ODQ%_LT'YQ MYLWO]!"Y3A#G[RWTXQG*AK-L&Q6&8265 /\;21PI'HD9ZH62K$_(4;D_PC2W*

*M.56X62BGNIF)5]HY=GZL_I4!_Q1UK0:9\WH1$;X6@"H=2*8D/,#S%$):.^GCH M:PAR^2ONUB%TIEER9:WIOX/38VU47TMG?TFWX67:OY]BVUU]_OAG"1&!R[W^*

MHC:/YA+0JX1!RPF2'>-P(\)VB0B9=:OORS1?>E%LCWM$ .8@!,G8Z?T48 M.*U),A L_.LK$=$R[+:Q^U6H]H[$QO^H&K_2>>XW>JBWVB./:IF(A+IB7CS5N4 M-HD%*>-*

D!\DP]S$2/,- >TQT^&R(7I5K/(=99%_IH[_A4SULW#X/BN[50Q& M5K2$HH@UD_[1+D_D8T:5EO0@^W009M3>LOVGU2,E)/I4'1?]AC M;9PZ#5X):8A03Q,W7PSDG)]E:/-

AV[+=,@.0:8O5;,Z,T.QT2Z;,"T MQD& O]TTBVG(=UE?VIU*A?^6%AOZ_I MND_OH& W7-J-XX%NR==^A4GM@!A5]9!#-CO-]7U&#OWIK% M82;T8;OF5]L(?*

PBP%BX(9PV:T-S11XOHE7V]6=C5\EG0,4O!\E-5E"7M.\H/ MH8I\E9< 3]<5\$>H1_.1I$5H_5GEYVB9CYL,K,>U.0(8A7A?SUN02T!?&#-F MN%1_1M7&UV-2I;CIM

FIJ5P<$YUG2,~)^%7 M/_*G3^3*^FNGBWU-5R^<+/K/6&E)AI#B%"ZTGJ'<2KM/UVG%<^3^/\.[=NGU+ M"..!MV/5&K126[_]"ZZA?0=DX6C># *

*[

*A)!4^\X;ODTR_[7-XX81OD)G1B]I4C_M.Q!MDR=+(DW^Y*6UNST]FD/=*IB_]J;4KG@4,@C;Z6M6HAL"]H"-KF M/P(OB!\A_(&;@VVL:/:<,S(O/SFQ:#;(]9C308%ZV^.69:?F)BN\RR*]OH1 MF4AP4= PG/G\B#!+"QR5WY)ND40D Q@QG:YE4C\KH6)B0GCN:0S,7MLEJP8:'BP9X*O+GNVB:(@!;)CS_ANY MA]%,*

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|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

#4"9+/>5%!JETO:PF0RI^P)5OAI_WU$8&B4&M9[RLA2& MFRD\9_+)1,'*:T3*:P+,;*Y$[_20_K0DZ\Y%<:Z8!=(C1QI(,@S51Y^]--W M4+R?*
T3.;~'GL6GGPTG|&5HO*]\A]]\ZNEI8TV1'41)QTDX%-6B9J13/>5<8> MZ)2^O!Q&RXKB]*'6.P#.<\;3FAN!LZ3R38BE,)$!/T8=,.G#/<(AUYS:K'<6=:[QLN(Y_@
4@[YWTM%4'MEGSE#H*/\RP M*7V.J'\YSN";,GU]JGX#E>%&7I_?((BW0K >_Z'"P,4A(P>*L6S_88XG4^,_M ;(YDVT">Q;W/(?./)W*BZ^.(BQZK|\$PE?
7_5OK#.N-3'M:%FBX\I42$YSV@,_M-1$#[-5(TE7\2+0(1RY)<@9LWROB[8.G&RE[R MZO>[4;R+[M?RWEDE,G0X[S)NO65@
M9!UXJ8HO%C]&VB=W>_8\'PJ*:);>++;YMA-,MKAVPK+!<2SV67A=_/?!>GBK> MZ9H7$EU-K#[EIY&'+)4<2DLE20&FC:5(\S,;LRT=RU(<9GVYFL[-GK/51BS%
M,.%6OG#KIJV.=*S-B)I$U")'/(7;'-12#U5_VKS.O"\W:IN#>3O4-@88!O'RU.B(YE\OC9.G^/F*>CIM[):XB#[>_4\52
MH(!7IO>>5HU6!]>0+W!,F_42]8P9BF].H4YR\.HH$FY2+,_N':^],:ITC#@)D'M8AP.[^\[DD34'[&\2#81\5/*PAHV7-W.&V4_O/08=*HZ%*P M!"IBLBLC*^7M$.?-%,-
E*7#N=%!E7Q9VRH\P?[5LQI\38(DW0_+EB>2/#]_CN)H$-!R2I3K-M(D@/Y//ZD*RK1XF'5K5U8X?5)=R9C!2ZGCX%D]Q3;-60G[OZ8S-)8YKB)(Y^_MZ?
2]UHOC0/4;HMW5DUD]B|>*&0] A/%E\U]384_%FR1D9H|\VCFUC_;F+(:Q=_M&1&AI?*\-1KW7U_+"G9=YUTRXN+Z2N1+,,AW+|TU-+RH$NG>F"B7ADL,2%7P M#
;TL4TZ""^4%_0NP;?6$ZM1,%AMF^G=VUA]],H;>^H_9;9OTW-9RN[M]1"CI3FVK17B\O^9)(S"P]Q?0V".>H#5SBG? MV5XX2H.(ZB[(@X\CGHSU-)SQ7%X]+6^[#?B3$L-
$2%D.3C?~FOH#*>_)G\T?H#X_=O0?^&O^LJ MK;"?T>/JC!T:K/AFS%8_'M)+8;>BB#.&MDEOHDTWO<3'MV@,5;F_GBCH9U&2@$ MV@,5;F_&NOSHK6+M3=9'3%$2'3H$J4N/Q*#JB*DK)D M8D>G^D8%P:S6%IECZTQG3(^TG_;GBCH9U&2@$ MV@,5;F_&NOSHK6+RE0?
1^O[K.XQ\NV4.^)45U8WQASD)M]_]$(K<9V4)[GO+?6U-MT$_\&HO H58&XT='RA,B+B0.8P[4DN&MN05:L6Q,OL]3%+[W_[*R(K)D?=]N MQ!S"_75?
L^%80##,D]N22%E=I-(1=,YP>1:A2JK"?3^S_Y MAW$H>E1_M==|\W=_1?H]^K+'[W UH#SAT]Q\I0#).'YB_BW8,7"R5M4Z-\L-?4#X+7T9 5.:*9P^&M%@BH9\'2LF(\X9/G
MJCEW%UVD\'L%&-@_T2OJQWKC[]DE]_Z=M<#N|IWB5H+\W&1>4:(F0K;)8# M2/941CDG017"QZ6?GTL]!J^DBO1QR%R_B--!0Q0\0%&/D))/6CK706 2O>V]
M,YTQ.22ST|L@P_O\N:#]=%]XYSV_WZ1/M%K@WZ>GC3,LH5")4.,2P M/WOE<\6(_8H/;W@3FR&[+1>#^LCFYR\;P6\#\Y)]H/_B\+(A%3H2N(=E348
MD]^0M4YSB#8E+'ES\0GOVB>G.--S^G0^U0:'+=Y!!-*(ZWK@V3I7(D\!*TP5T_28(E:5FY%.I9[,#=N19D^'Q41/S-GE0=/7C-^_M^-6=]N>X^$M0(5?@@:0U'O4I:5
K,2(R_&R):$!,(\UW*IXDT]W*+)3S\U]$ MJ]Y!+W&MP=8T53\$O)>"?PS#@A)2F?(WS4,M#G0W.@WM,8J.RM]D(548@M<> MSP4T^63B.(JN?
G&36_4XL/O+/#A<:V5;5%GPU9=EWQ!?O<^_(5E34L)9$AXW2@'U1KZLX^U);6 M8_@@],,7L7!]?VO.G99'X_!.2=G,O-CP.7LG]N:W"GC/E A(9)"6[^CKSD5R
M9&*'DW=/UC/XH;3A&A+JE=&ELXL%O&D<9Y**M.1B.?XVER?P/;6'D#23MI$$_MY=!QL@;J7B(%IS'11F !VHGM%L_V57_#[!K$*QDBDX=LN \'V!(J2LAGAJFG
M@F0'-.K_2/VF]BK/HHB&'/0@:<':?% A4=<2\'I^K]'T7OO>3DD&T3K!D+1\ MW/7"/$E_E67L.082^[@F8?HQ$@8(R*K,%1W]F07!AX=[MEZ>U/G
0\P8RL<;>L>W>1U7\0^4SWU_IR7[4I4I--A29_0?)[SN@>(<M3^,U.C):$EK'^*)]P.RPHVS.M-A:RES[U6; M1&LDK/7-\'ZG0B)7RG"'>%(E1[R[2E?T?(U)3A:R'6U*E]
[M0DSG9+*G]Y'V!\]AEBHE6L$BY"[+MCC:M*.M$LZ9PE#YY('7< 7G1\/#=VH0&2IS3\@A9 HA*AX[!O2,O\@&H#92C].["6T?;.ME1?^<+^])UF ?>3#!D .)PXGI@1IN*
(2C'EL;CRR^@4QF 8W30O!."BZV\GY M?$VW)A5DH7RDNS/'T2POR[/'Q(<4%A7#B&9W9MV=1"O!V NC8.0B0KV.O,F+ MXT^_]'-5B<"/F-.,5?%;=)&GP-
FKBTY&76WQDD6LT_YC))=*(&OD0,/Q 4/8 MASO<'(,543W\+Y)?68 -F61V+X)PZD-5R(0Z@%(5MNN@[WXHDGO<]G*F+WZHDGO<]G*F+WXHDGO<]G*F+WZHDGO<]G*F+WXHDGO<]G*F+WZHDGO<]G*F+

M!%_PR!W.&MVUDWZVPNX^(}3=W>;?>.\2MI "/(1@0^(=!$<,(.LX^SX_#_8HE24LR;3*FIOUP<7!DLG&'J#$Q39@&8UH7,&H-M"QKQ^YVL,X#55'#XH MR$9H"3^,N^':PBS8J.Y.I\455VF4_2#UP_CC(T-3HXR#]]_*YY##>B.O$/42/?AOB/AO.D9O&T2$+Q#V2=O, ;\|49UQ-MO.C *<6W/BO(^]$__? P\G-P)BI2L2)E9K+UT=5ZV;)RB1N Y9/B@AV5@HSY MB;<;L>E\@ET7GZH>G[^*_)$SQC.N,'SKSJT0R"O%V@W>,#1 BX>@YT]YS?97 M$8B-PAUZTCL[\[F<)4X&,3-'N]*M=&FIHC(L1?*0O0]0,.A=:7(SX^TTPH_[M>5RO&)QH}>.S>1!KZ"$ZE/=)'E'1?>?6F\ KSR8[[OD%>F."E(C_"" -=P M9QV4U!-Y-XDM2,DM!-7]"8$_^3>J)EPGEM&OGS1,[$Q$SF"2H"N&+.4> M@;ERQ.06ECAE$C(>SW@?I%JV 0R(VRP*.A6/27%I58.YC;0Z#O=C-W26<88I MV!P5'^G1/0KXGG1&87*;@9WXZQI9*.ZFX^^5N%2YON\VSK[G]XSQ'/^\.0ZU M'K&;H@GQ@W2YF0.IW+^?X *OIQ @Q.$HO%/D%%T/:7QY=,,_^=:+-]CW/-!1 MB636">=MZG=9M2; ^2+K\ Z;Y6/+O)HQ@>-*R"%\BOSUVYPX1{&!%=`(?LW^Y[T<@V*?8;]_DG *92\3/VKYT^GB_[>RC("F^A;X#GV^:|-MD&\WT8!8'L\^E_M<,Q*_5^(I$'.?5SR(KSZ1OLHOY6!3Q_<*LL31?G'WY72; M&W>1C1Y)@$W9 .RTWCNF!*[U$$FYI@NW [S,*!>'T2./,/01+ M8^9(QS" 19YD'<-,*- %3%0D:4PI.ZH-X@UE/KNM\YN.34K6(5%&Y *R:8. MCQYR%0,165(^N3;-V^\D;5U_'-#6%I.M7:'/AD*X'!FS&H$>*52+F#G8)?4 M=>'*TD5]"9/&@6%I:FEGSL[P$'L87]>U++#E%Z?:EH0_/CTQGG#$F?>,GM;Z4]7 MGH'34?8'/IUOQ0D=6>(ZILX14E;$WVFISG ;\H9?ZBA8\'EP8= R/RMK,5EM)3\12U=] (46P/B_66&RM M;CFEO)S19_'}B'HM)>" YDA GA >8D#K[LI;PEQG-P90%=P&DMQ7AKMF MH\'7;FP$8 "WOH>0+B;@M!N2$3Y(+VQN3[UDGFHEX'4\58^8[CUF? VNL>M'G M=]SGV'3_0&(\#*548)-8DOS^;.HU[N6 [U;DBQI@H$ R!8NW. ;P5FEQ8>Q! MYF2^S;L')(O=S<(AT%L)V*\7V\RBQL_/KYW\K_<7__E;2 MV\4W5*'M(ZZ M)B\Z!$Q^'HZ?X.@<6;#!A0>AWM(0L1R[_OSK39W(CA*\EP:SUAP9<12Z")H M\?XH%/9UK;I]/_\D=,.;\Z/(">H& =J0S"9SGJ#+59]:H(I4$(?O3&,!\^<^= M8MU" !,/SZ,O7<#;R>#X99RI9?:M%D?> -+| 9PNH,\A-\,D0@GUHY3\ MEVH@/,$;-E^- < L4)8KQB>*:7)N,@Y%2[/J.F2V,SC:.TR@\%<3[MU#/@4N MQ"G\]8?!&R,I=/=TK*/!E3^:"0E\YW2^DI>%+>WL[U%6]^__DZA;]QOT%Z??) MMLF4G"D;\);D0I_9\<1&7=_U:W=RWA#-!EKK&M&4&K_T)\O+/V'+,X%(,;" MG]>D? H_76=6,K'/N*O9YWESEF,.[.]TOJBIY?4IVY 7@A|CQ,?!M>"(X8GUT M\6CRN;4@L"YF< ,.2?XT:OGL>)&UU/Y95O/,;<]JZY,D@$O(D4=5?(?Y MI=H:?\>8"S#.ZEM99>5D0[B3^%O7BK=L/'>U'.B+T^'9'O3F4(PT!=GO,8> M9;T8ZN3.01'$RCJT[!"97F 3',.=319_@+RHR:AU-;%850135[BLOGL(Z,:F5NLOLQOV-SM9;UX1= %IS MF3!T%-_A+7_RO=W_RQ4'/[(RVNN5HN5"5M3P H#O!A--2=Z0)I[9ZY'P7$] MP;@,.1]O_#2@W'4Y!2"Q/>_-6DPNX42,:\$2Z"F"9'OYEQV?O+60K 7EV*B\ MSQ^27VA?3J!*CHU/K> 5Z >TFQ7I.++T3V5J:N@6UZ$#0V M^:7N>+)O9$V 2^AX\|(D.:M,-& -IT?L[A:MY1E!&(#F4_T*P_3=[OU_T;6 MZ]-VD02;&YD%]6DOP-% (?;0*N!. "P!N&8^7_NF[+_E""11X6<>6$8CD@@9C M '8AVW]6/RF_27V Z(("""AN$&8N>,GGYZ'K M""0/7H<7LP;N48WF29)}U(3M>(PG@DV; (SD9]XTL;C8BO+_]L'!#5@A|Z;$ M6]%%07 B<*IKI7R7E<5[VZN>5J-P7499P__&_OPZ1)$X(W2 K!C6"+TQ_3YN.:PWL"M9ZQA9M%FX5GW9I?C2L9 T[&"#OL_B"&Q@$8XH_JR?#;.M?.\>YM|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`*PO',_VSXW7V31fJI3CQXL\GYAW$,XX>2\PE6D %&ZH??9Y1LFM?]# A,GGY M4'$]HTBXW3/,,;KUFY?P]]2,UQ_M0)RL#_"P>!R?L,]V!_-@?PF_CS/4G0O M+KDTVY9[GVE--X-9IPX[RMI=(V)6C9/A_;F4!U5]ZCY/ZKEL;SWU=MP$=F@NVAH\?3C%+NK&$=QZGAA\3NUZ.-9@YK0SR4L(\)O{-74X 5I,T(9%T5G]&W.\;^N+P01\"1-5WFB;ITM$3W&'WJI-QO> MKJ-/ST1;P$CY6F:=]@8(SN\;S[6Z'(W4LCK,KQU#)V.$M//8K M-;1[_S*D OH9OYW_0!5A F^H)O>82GM7DCE'YC&+AVMZ^9(W:54D,LOR7R3X M?Q2N7E^N+<\XNOCXDIS>+_H5UV:9#(+$OO1YNCHPB@5956Z[!M&RVI>[2 VO M2]A8:Z^- [']3I.N]=/Y! GPT^G6(&^^H]>U9V3OZ#ZX80.PX&FN;AET^|KU<445PD?1=98CXC#(V@F)'CXW^MUBNP4=(*6.?\00[9WJ.MY2&1*_=&;'<=B-? 3#"G3L&GZORCE&]^V79'XU9!N M&,Y'l,@H!K!>,7^ZH@&UW@8>S=E?P+F'$^5&7ACVV:fQ0#E.;R$U'28@!BDR M5NPG5KZ/0:(\>&5_-$_ #HEMWH =X#V^X!3=;4:1.6W$8>W9UORE*U6'X^ADR2$H MP6_M[;#MKY%>L9ZJ,.+X[+=G3E4N=C_JS'!S8?$9P<+QF/B& +5YLE"0$# M_0.3'!*0%HC)K4R%@2NALK38O>,.HT^!RY+;@VU?!-@GIM'MXJ$Y>R/&?_.M7,.R^EOLR,>'55 =9 GR<5LZAX(D=!M%9114Q-CFK0U)?>RUSCEC>K MBM9K^%P6Z:/SGL\[U0^+T%F4@X/@_GL>ZKV"B>_NT+8'#B#,P[#!US,AT3;I MTSJNAR=!+O;KAEJ41H,(:HX.^MRY/E8_3]I(YJ?T9W1.6V*T!!N)"[FOE^9I M^O5V."S7#8,M9E:P+LB>(3@Q$T*U8\")SAZ_<<"C\;Y5S\ M*3%X6*6Z/O6% M[3-A8^L=7UUFPD'GD?'REP7;=!)IL)Q9K%XW7|=C0 M=Q8TWO#B#%6N][#| 9)'^]fl&&BSN;I_GN+SV)1LN.27K M(C=2 .\'$P_']D 1'H.#$SO662$tV^(51C4=%41@LN%(DY$V14R=ID65).D0D?R.&K\!D_@.9G?`,CD9(:NB#SY28-_MRN__DO W$K%]T\?FL"ZJTH1P;0R %#U+/HZUVZ-^\3|,AP#F"QNKEY3MG7 M_7E4X_7#[O RCK*)/-.Z(DE]66N7HXMW*V1271D1[*,S*9CW-MQ]D-6CT1% M^)&'8\89V ++'HXO9O IE"^_4.4AL-Q13;!3)@:,-4R5X(<1!!&LVXMIGG=(31 M-(W;$59S"=R+G<\+!F.E&NPSQ2J:EVV)NC3(]EM5ZOM+>7KSQ+'D_)[LH!=.MX*0;P[9X=2LHQ MTUM.Z*6'RXT'NV;^2TZ]=-LF{4]BQU=N6<#+=",_+T?7T(9Z[@\WDWRSR.[4 MUB8@)LT/)U(X;1-0.DD1 M%77LE!F=+*ED;XGUS8\N7(9> &(?:XGWBT|\(LO? *'7QIX0%'>'7#VH84OQ M*5/$]H9Q87@#ZK<.,4C^%4TA9Y*FRC&8/J-X5.!=X^Y&9'&^^]I2A+,9>'%$T M:L3WOIN[.6I261 @*YM2K63?)/<:4L&AV_52X>5"2HS"6KTB.TZ?:_KD\|"*Z MD276T/+&UZD?#.*M1(=RMO'P.|F*|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|LZQ\|PX+-LZ_;/+?MEQ!';?S;KHUT=8_33&T.G_'*[\K+'C\.;$Q MOC.R[P%7U33YJL3(2)E&M..*CHTN?AC@? $^VDEEBMX#/B\H#"5%)>EOB?SD% MLYB'P2VC..W"KH6!R|&UP.+8M\"QOPNX'[B53'V*B*%DKUDLB*1'\4+WNT^0(/ MT7WWI=S$UU3CGH:*W)^%28Y<.5NMY+%? 29O$!M((3&?61H6F>W>@$>2=S,M< M?;YO4;APK=,W3;2;249%-E8VA7@Q^O%??YI86# +B;_;S8FYE$5!37^^UD.! MK#\PO%]15&),.#3MNI.>8\/+F3TMTOWYHEV6WFH=9GUYI=3.W=,E=U55Z7AS MVVZ|\OT/7O?S6QGOK:WK%,+7XDMZ^NHC8^W&AK()4(5E@+_Q\44#9PD@-X? MQZZO"T+/B-/$9!+HG&Y/_&YJKG+(IJ/DSWSLIA_MV6"QX.";F(>W#0.55I MODNI%G09 U#% ,K\.(/E:[2.,8,$0:R!\=4#;&(% P@QMX> S!.%<. %##4: MI? Z;NOOUEWN)R,0UJT0,H'$(R!#]>LQL'|RR6PX>O-W>?^AB#LO20;ZP*?, M=@^H6Z/$$3M7;H(N&#9N),A>?V:.4Y9:48B!_(M>%\A\X/8 7MF)GC9YS,AYLO|.0]/17(Z&(C;0@ZM^7^TK5%;)E M?R[S<5.&V"/[Y8;$9?(LW1)#[NLKQ_]/T7=N+I\A_'C>H[MJ+ BQZ/JB3Q: M&=:Q11D*S9B_[P.?]J(H"99T0&; <"B:O91*UAY>C<,)[UBWPI^_X:IU4>F-] M[34Y#"!6LQ'K*WZD8P!9R@!?,]_N1+XI]#"0D#E4-AP#6&0J-^QV-?/A$3PIY#3^7J?"JQS//>_4< M6YAR#8=IN,3ZG%S2KL#@Y0U0#.#IV#X&@,.4A;9RB\0.FS2+ 2R8NF[K9%%" M=7,P $F34RP^8P3.^WC.CH!-D#4/M3]?2 &,"A8CP$T?]_)3L5@\9ZV& M(FD9/.? 8VX'_T(ZT& NN=-Z+5;1%# ;0\N, [@DUX>AB"(BD;IS(P@T\8- M_"+'B]Y&;9^D@0Y6@-YP\[N_$^C;?=5IH>DB0RB^2S';]E{(N9\M*BFEH\D M;)KIWE(ENP/<^M[%G$;L(Q?:%=#BJ0P+>>>!Z_/6=]>G-;#++#Z$3VVI9(J7[K MS8SP#.6N[M!1P?$3J.2ZS&TS CN#$>V"4EC1V:E@7,P5)ORAA%"N#G&'?SRZ MJ^.;1:"=MW2!9;+V>?:4^__>4=EM\U9<$_S#3HF0I@\G$ORZ0Y$4/"VSTTV M3D4"Q?ST!1TGD"4-D?Z"LM?(!5>9H8J.IKD5>NE2BJ5L-MQ&J7'0669+^:/+ N[OFR=J*)M:4+.C4-)/X"BK#;,.VWB.T.P Q<44A6@'JQSP5TXJ5RJ*M!SV^H-S6%&HZ26.MNI'DU0>=8H*Z&%I5-3EU(T'MVGG6SDT.^.;|R"K?D\H3"7W-@P?1)JSI4'9^_M\ <'JV/LV,>1AXPI9RE8%.'Z@[.Y6Y^+25W#,J-.Y'6#76=R5,N3#FR4C5B^_M1@PA1@RGV];DNYLZGUTND&882-)A$P\VE[N\&[X:.WKXDO4V1PB44T M,KH+ "]F#NE 1^UH'06GB(:F+W^\SC>^^,KE%_&2SUSC%E70CHK1Z2D>T M(G^GM"+95G"")TNV_C >-:P;<-#/ '(WEE3=C?E.Z(?H9%F/A|5S4G:Q&6S ME%MN77EO J_F^A@? C1T>*2DG;KC$*34^^JH/5U6X;G?FP%E*ZY7@+/_4E6&] M_?KCZ>?9D6WG(Y(<%,(>3^$S\E5C=5DT]"*[$_QB:4W6L(\22KW;N[SLGVL M4*BPFQZ6.- #L',Q[_[Z@+UN9>R2ZAU]T;VX#("NR5R\KP0O>GDX9*3$S.=+3 M7%5!_3C%\NE7H5\(%NF&)IC8@0%0#S/>:1\[PZ[(N+,UY@V>TX.LHRFJTO% @ M!K!CBJ45A;Q/1($P8UTZT-3\8H8VITK&O13&3L]T9!:FU.Y(1@1S*8C23,P^ M*!UQ"WK)E@!S!N]%YOP2=#%:E'E+>2FEAA-32#QUM7*@S2B#4N&V..I'N+G MJ/W5EMV*99AC7%ZBG3 _MJ7';RQF>D__AT. /UA]QA %^4?=MU["/G%Z ?_ MS%,%Z]&2Y4IH]\Y]K%MB_CN/H/I9?AT!^ MUE>FUTV1M"\#6>WW/H(=2_S7: M\P.ASC9HUZ/?I"/B,KW!>>EC-[0_^?*P8VM9QE\NO;\VY1F"9%XH;H@$R)Q" MDMGT_@[C:.QB&8&5T MN&[R7<$ 9"""7Q(6FNU3V;H=3=PWF.L(\]'(08/.27M*F^6OS59W=PWF.L(\]7 MQR_K[$>NE_T)>H/A>C958>@3ANP39O.(XXG:EGW*K3'6&RGG7S.-9+=^^$\ M!L=9'R0R=|Q7U*- LU+/ &CFRI$8<)5>%M!AXAR*,O5291/VZFG'3K1L1%_"_M@*76.IDZ8(*'[&OT^76TILME%/FY3YZ$+9B.I,7/UUO.;C_)_-22K[XKQRLY M_+U+@QB-]6 0' Q RG,K6+&E0>V!RPX -)3X"1M.,+NXE+X3.^NNJ"UN_[=2 M1]4_4L'D^JYTZ_JV4>\LL.I-26E8G]>3956L+]7]8#0E6@T8S2)5P50 MFP*3"E>R-ZHO(Z X@K.B0_3ZD!"Z%>V_ AV!).M>C.MA .G/!*Y)#,6=A]+ MH?/YVV/YI:>1;1+Z$"01]/N^^_F^]C@.:!W@HGHBFZ \|;>3:I)]NB1[UX2R6 M5CH>U+=[ZKDO:P5MS3\K3U"64A>?C'_2./2LAQ9XB-F)++H?R8"88!.T^N@ M[0UK7ME:/2FWM0*N1A{)?=]M->%2I-2WD4= ^H!WY^&YW@K8V>5Q6KP%:W]NWE2/,\O*Y[8OC6Y?[.+\ M_#L9^O4JE91NA1>$Y!$X5V;YAMAOW)?ER[UW,T],3VBC#@M0_SK?S^U_#L_ MKNF@NE/@U:EL@8T[!W:,;$D=0;KF;Y;JD^Q9I9!N#[;1L3F_D4>]*\9?Q/G[R M? H6$%B.%C ;++(9=<:?T[E$.CHYDQ_-Z"'](;@,X"_;U3=N,SQI0+P01=9 MOF [S(1Y!WISP8&(6_#(OUWCLCN=;41<2VO;*/>.A=2NL[*CF:BA,@_FNO MC2=,!$^.03? OWGU:Y(/[#4=S+V@RZ+S0P@*\O\WRH4M_:"CW4;>]Y'MLTY.!Z@Z^+\|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|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|A]HT5XOV;M*(K%5G FURI^ M3F)WY,T$[2?B2!)[48GZ+CM;TRB/(+'S]F$!?/^AB^/$5@%L/?")QU;KLM M80Q,5ZPD40R^FV4A&Y^!+0)D?Q"6)=Q% <66C0MLH9$F?]&;J4UU%TXMK*PE"M]%&EDVI76]-@[D["8H]NSO)\6[-FU)D&#?ULL\Z+7(Z=*L+Y5';SRI8NNF M-EN=^#A3;P3RB[|*^^2I+M&7D(AEVVJ,37%UE6 (? >B4YE,=O38@'|RA24(MN5735S4&+T4JO[* #"^.S,2KO:I>:5%0/14X_[K[SCFNBZ]2@H2As+O20H(@@1E::TJ$B3 M%Z0(*! 1$B@$"T5>D%P$!!0&1WEOH)=)$;J1&0PL!J0DDT@*$NN^\L?L|,,F3,S^YF|SEY[SYSG/!)07N?.ZP]+,-&1B;8N%Y@__MZ++LX>L('_R9=.>?KA8ZC0.EYL[W,$(M[. [+Z=4%PXG^*>W;!O10*$E+%F# M;H:^EN\CL<&F]N12LR0]RJ/&0S&QOF]3_1T9\VF=!X%F0X/#\# ?;8J2'H)0 M+Z3Z#4H;++[>?=$X^9*[2]EH? TO\RLD(8D%;Z.ECR@\QSGMG2^00 M-F1=LTFK Y=#*O/+-U4N(R%=0 (# +7.'E.AG+$>QG^ M I33VJ.[LK>EG1>4M:H&MM2$9V(+)%TOR.CL3^$PIL9("9#IWO"JIV@>. M]5BOT+\J6%NFVT_0+/;!AC0?(D9^^2#H(.[Z3L-H6MRA7EL#0LB+%IBKC[7Z M%=*FZP2\9^]&4"""MKM/J'.,""SM1:.*L>2TD$7SU:WT3&5):!2 F7,CG-2F/-MOF%?*

F5.H'R!GBPOU/V!EU;OZ9:X"&EWE&P<`-•@0@DSX>L:V^_MP? CJ$.V>3:8)>GZ?56Q5'JE1,5<# MYN@]#PT0
C|^FHDT#K(`K17;\B$J<'1WQ&FPKGHHM3X+'B\UA^K+8D^1WV·M HONH&RVB24H[_VQ1-Z >'5_N'$QF_J_EJN_O#AK/WJO)0 MYS;T>!GH%MN'KR#'CC9-
TR7AUQ!2^IJ3YX0^A\UMGUOKYU?IW<-831%GY+]0 MIS;?D&M>R=7*L_ RA1;]0 V[Z=4_+E@*'L20#((V'6Y>4OWLQ-"BHKEZ>10Y M;8H-?""$D.15H[RJFCO?SM!B.J-
C;K'M@=/ MF. M46"=00"+17-0$Z9M!*RM< M\&]&%GBZ] [A>WCM7ZF?8!- M/;4O"W^J#]+1+AXK^/KK3W9BDCZ3#.V8N|ZS|&"M|EF2;&|^ A)U1[9,>K4QX_ MY9>NR*+[?
3]N!(@PV1\) M>;*K??.59Z1@[2SS>K'Z3&?\C N8S8E^9KA**TFO?.3\6Y4GTD6*5V[*AIA> M&U=)$M72,V0J-K(6RZ8/\WECPUR)I8VJ^3 _Z$-
MRI"1[1%#UYS+[3YP9E6^,.LI)<L,"=54[!FC_>8"#[MKC-0A)*41Y551XL.Z)P5YN'=V)+W"4_@2!V43S"/#X_,PEG;.G#7-N+;ZB2!W%6S^DK4(UCOFA/EB
MV(/E/.=+!;6O)XI"GS>%J4^/T9:[JU2OS&LU0OVN'+-29IZ""Y1++1%>Mf@.L M)<(I+4I/A0M5;I0.@^ZNB#&M<=(Y)O#@D=BRO6*<41$[J-4!WF#;K=<=]7/
MOSXQUZ5S(A3)G5%<9)=D^>K,S1YXL:,LP[MST39*|K(TP^W/ROQ+1,.ET8K M13(11A-RJ6T6(XT0O'VF?,?['9=&';6/Y\]IQ-UB_''N9_<%?*)GOSC#H(H@-M>7?
Z)\RD@NJO-2127!7V4WR28Y*Q1$]1*#ZU_6VW@N>6!ZX$+C,M%J0F. E] M-DTZ,.5?EW:9Y?;K=T$/9C65PW#OYIT^E;YNYK=B).>^/*BQ^5TFA;_26.24 M?
LQR=U>8]_D&>D?!\P=8CD6CRDUF[\#E/`^A;]F@C=*;I=N>GK]1*L\8A%:D=_M#>(H=B<" Q-=+_1;=%M#2=SNV;S!^N(8D&0_;/=<#8,F*X9LB%?!2U"%L"'3 MQ
NK(JAS!.W2;<\7M-7"G"=+QNEZAO@F49#KFI3#B;DJN.F$$-I*KU/O3$?9M^'0K0NE50'N%E!NN..//OEOR9GJEA#FOOF<*D MS\+ND#VU*^Q5@#\^]\@-
"E9KNF9MZ&Z.'S1E!E.N6OE=,2>%,O*#.OBH4F^'F M=UK5&0G U5M 3"/RJ;*MFSZ)YG'"@X+AWV?8VYI3"6VII;.X&1?O+0.\"!/
M=FKOY=!!^K:J/]]FV[GR=]G%:O()]BV[*1":J2W_S678V<_H M\M1#B@^;P'[*K#DB]\OV8N+#Z LY&G6L]V(-MDTE@]2:UP]M/$H*]2)IW1M& MC;ED)>[]7RX>EWS?
^E! _,U>S9P_6!;7+$;.I*E3^G.C>3^V3;ZZ-K,L>=E4;# MDRMQ.O**ZGLOGDGE]3+U--^*0&8*, ^DK1H-R8?I97K6A:S&<=-EH_K#E+^ADP37];OZ/W)T74%"/$A
M,:O#0WT2IEY7N?B&@N6XF71[A(M4X7?<*7YPB3\VY\\)C8=!P6@PO,5E.>6@ M9-$B,$QPR8 R9W-6!K*<3@9$>23@3&S_'[.=Q419[>51"N'CI'N&
MVC;5FYS9TJS02!5X;6;60G'5O5D^*L]B9F\$RK>7Z!((DB' 9^_9$T=FZ,?W MTAK%"/S08SCG"A?]$CC.9:Z\<8L@FK3_&SN0+^PS6:@?P#>S5+0]L6]A'?ADU1Z&(#]";
<:CJ@&CJ H*2.35AQ5[VJ0\ME#8NI4'][_G(G;S-3I2A+6UR)\X+V>N&@'LEMRT0Y^+Y
M2N/5;>PU8!84$KMJ*]TF16WM=KE@2V%;:DJV[#@N\UZTC3O5()#L(_+:L_=_M_)5? D>&LL@0C2\P"?W.,]?8N-X/K$T=FG;_PXTTU!YXT56]"U5&'DWGX+NB M=6*SX?
ELC1N[R,;5TO.#=,;O2Y"J(]@VAGP=4.K1?]G)]LQ\AEA? 9,^C|_M&<:QA_)I>A3-;Y$.XZ>8]LC'#^>-P]O,ZREW](GZ!OAE MC,=F99ZDG8WB[K;@0G9(J8&TYWK%3Q\3Y-L9
P]J3R^UL@$Z.UR&(-,&95KT-MDX\NSX E@<2&<-^H"##@55Q(W17'B_4?Q8T>9[\"P&Z_:!$W0.A)T&$WSOAT7^6
MH.JOC9T=&25,&3&+O7*5IGTRC;XAM$;U*3TSJ]8,W[5I"%HL;R#E-L)P.!(MEI=LSELUZ)8 +4*O YX&.(VH*5-WS9I1C8T4#2*6*^U)S=.]OC?O?
A^ZTYSS4^L]Q;OKD0A#&F>-I9-8Z*:$@]56^-@IJ!S?RQW)(R M\A?SGWPQ&2CFI-E^NSO6+7!HB%*PHT55'#%"1
M3X_NW^AT.^]?)OG):RJT67004M[<660Y1M@_8C_7!;.MBUN$YF.0XEAT8%5A M+1*=,AD[_98&<23X+\C\!?X/TP8!?2R]7R%E9]!25U;.LEM8=IB*DD%]AP
MKD&N#F@,0IS"]TC+6 I.@LZFM/-!7HZU5SA_^0##GN;WD/@<\I6+88IL/UF MZKMGRR0;-2!?F1]L3=//7?BZE(.(9SC2&_V"%LO#:WBCM=I7OJ=GUWRRC5PR MTZK-=
I(B<49'27:FH[Y@%_==5MBO6G&!OM*D!' MMU0Z1*5;XZSX_C%1KOG2-N7O6%"27VC2^X"8Y$SI+@-LJF\9^\|-7UL1__'Q M?OW2WRRVP-
KGKZW4@3H6YVOHV7UP0C//[P;GUBB&WA&\7$\G&.W>P0 M84KAL"$3[T%^XNZUK,\UKI;]@*TI#]",Q>??H6\)!4AVTNX0E-%GEH*7*%P7 M3B&RHS05 "CXG3RQ?
K;&#Q+A.E_QPBU[N)C>+^R X\P4?7EFL2IE04A0O<C5D M4GI$YEQ#$$RI_79%P_5G&E<4KKOWGG1B^~)92;WS43>?6L"2FDO<[$V8]B:> MS-5
3%NTX7]4I[%|SBPL\HGHX,1"YY>M7D+ 0*H:H'RTQ[>YETF=FW MC <6:$-N7!?L.T@?C_F9MNU,M6*XX-.8MD2FEN]83)D8N>54R;:MH4[(>'6S
M;\LIK9WB#M:,>OA9$%M FSY\\&;VF\MWZI[*OER^#CY+[=Q$4I#15?R_5(XR MM*;7E?I3 ILY*ANC%>NC<2QO<8Y/6.WLW.X]%^:IT5L+K\M$'*4HQ'"&A,V0 MER9[W
DP^7>TR_E+QV6MVD'7IC@WK#@.K>4TX%GEFKH M/0@0)/MZ#Y(89?*3X,Y6PBPQMLX&%T'RU(5IZLF M.DDR1;@0-
CR:'042X0HT8TXF3=2]:DU[92(B2QG4C?/#FE$<\|U9\I1X9_M|K;13SAM7@ GF$O?\$QN_M# (T*/G=W@<5'4)$.M!)2&'307VN'-,W_1!_13&;<<(^_#/@:K64P|>"ZLU
M$S4,#PW!(MF*5)0O-N2,C6M[6?GKCR1V!$G+WH|P?&UV>Q77$4CF77(Q_91> M>:L,/M=VC|(6PVD)F^0:!/]VX5LB^"AQDR6BSO%I@19OLI1CV0YV0,Z0J2>=
M;1IP"+CS:%0:YK#5VI9(6.$>]9TG5X%%K# M<$@:,$%&# ++FFPPM;^O&%%QEAH"ORH6;'IYXS! VB9)Y9@>?"_X>LH+X1N9B: MS-5
CDR"Z/O/!N_&LV|7T*M$5T)L\WKC)LPU5,(^,5HF-VD 3R:E&IJ4OJ3< MJEESE\OCQTAO.5]EZF%H>,(&7VDH'J>&W$W>68A1TF.5_P0\.>)_;QB[XV\ M2"(*14]OB!O/\EHX?
[XS:Q?XH43RZ,PG$VNI>O3%|.|\Q:CGEB)B?M#;1_<# M- !?03^FEHD3%IB3'EEW(_QO/>")YOUF#W|>12O40P@/K,^^*.]JX5HF9*LY M,?F|)*F59)\#?U7DE6^L?V5E#'-
+/58@\&;-D%!,NR&3XR]BB[4I17%& J[^ MF4N-LXJA'WY(U9\ER&I!D(EFQHU/@@=4N O@#*??*@_FC MC'$#AE]YC:$BVED^VWJUUW#76IAJ"Y1%|C)(TNNKS%
(@UM$J?:B-?SDH5HJ% M8Y/D4M,W*8!_4 9$-VD\$ MI="2C[U+B%M6X:K$(1<+B&:-[0Z7&_'L2B\5V M-7'G,&WB)S-,!8\++#]9-L0?VJXE30-EXG6:A'H4&1YAOL?7XV(0-
@Y&&==@ M-A\+,X7%,T6%"4?U^ML|5W9UW'P_A)(YZ7QY?#T"'|(RY=8Y*WJ,*=B8CRA MP1@>U:\-=HJ\+.'X;!V2C5"O&0X4-EZZKE(8ZN!X_0Z;
M[X9|T.T4MSFCSK8Q*>]J?YGJ%/ M>?4)MV1?U2>180K5)\>4EKA-O?;E|>>>F@?X;OUE;(VZ>3)WJ!R$#W,9=,=F*
ME%/XP#*A|E7"L!+9EZ@U\]FF=A#!.JKB2@G8@,DMNTP#$MEK"%)OI>@\;M)$>SC.$C] 9K;K;.$0Z^R!TR6L7GH5_DI(5 MM;.|]8$EG=R N.!!4&72'UHMWJ
;L=Y0FW"50"F07$[&02\W({JNT1-$;+A4 MY+WW2KQ94B15N2:U3=ANSLW)LFV]]+%EK@@DR$O?CM'>(WHR!]^;11VCL 7CMQD>N
MGNZ[>+,=LA>W&NH6%@2=UMF<[T4U^JH#8;?|_R GR7?CD8T+E>E*5 MC5'A.Y]_L'I;]+^('=Y@Y&O0D,,]NX[PIS#1CZ.G!?UV+-"LR|R!H-,*JQ57
MPC)LMCR_@$8.4+25NT$6X% ;PSZPC)WB,"UEG>(_TH%'I9 M7T:,.1HE\98*I@M& M>,P#ZJU(/@?L(ZA^DAW|K&?WP>>(_?\=@GA:-+[9VMT%EK(1O<^T(M@/\BI
M.VKW@8QI"/E@OU2+ILPU0P\)V@<^0>A- 10-\-C5U7D:)S835G(?N$R& ,4\ MF$RTB-D!G=D'@'U@9V.K@P/Y> ;=3K:9!5N6TCH_I0-_Z;"_"?KC?8JH^G(M%N1!1HY>
S/\%=W /YEF@S#2VNQ7WMX'CM!O_%]8_\SF!!K_/I"=3*(IHIF. ME#1JV[NV#CD%<^T#_@*Q)!L;(R.5*7[Y[J5 ;2BW>WQ#BL97=2 W+(_"XM3 M$9'T58OC9-Y=#4&
(=OWV7]G+9-:IBYH$CK69/[A/PK9V,&\R\G3_YC^]IQ MV;+Z>]2T8Z\7{.S[G"]0:2 ,+LII.AYP.3XG0G27"_967UP/L=R:TXO3<8
MOBVAW<*SC9H_0(+9*O0.)$VMO'MSSW/HCC]IS@!K820H4 M;1CEABIPD=S*A&(/-U03=,UK>$#4DC0>NYI(K=,BVDH2P!&('(R=HC\>GA M)UGV.HO&>;
<^0)KC7>;_6S.OTNC+O5S5IF%NF4?^P".=UXX2'@G"M?C >UU6 M"T.:+UF=OC7CSSI8UJ;>^$O'B]SWT+1/EDM@)}^=>^_OOF?T$N&Q"-,12GV M]! KL8/1GOM++#R%
(E]"V=Z>(2F>]4K%% U9@J_1?HMJ'8K;%]$W>\"THY!9 M7T?:.1HE\98*I@M& M>.P#ZJU(/@?L(ZA^DAW|K&?WP>>(_?\=@GA:-+[9VMT%EK(1O<^T(M@/\BI
M.VKW@8QI"/E@OU2+ILPU0P\)V@<^0>A- 10-\-C5U7D:)S835G(?N$R& ,4\ MF$RTB-D!G=D'@'U@9V.K@P/Y> ;=3K:9!5N6TCH_I0-_Z;"_"?KC?8JH^G(M%N1!1HY>
S/\%=W /YEF@S#2VNQ7WMX'CM!O_%]8_\SF!!K_/I"=3*(IHIF. ME#1JV[NV#CD%<^T#_@*Q)!L;(R.5*7[Y[J5 ;2BW>WQ#BL97=2 W+(_"XM3 M$9'T58OC9-Y=#4&
(=OWV7]G+9-:IBYH$CK69/[A/PK9V,&\R\G3_YC^]IQ MV;+Z>]2T8Z\7{.S[G"]0:2 ,+LII.AYP.3XG0G27"_967UP/L=R:TXO3<8
MOBVAW<*SC9H_0(+9*O0.)$VMO'MSSW/HCC]IS@!K820H4 M;1CEABIPD=S*A&(/-U03=,UK>$#4DC0>NYI(K=,BVDH2P!&('(R=HC\>GA M)UGV.HO&>;
<^0)KC7>;_6S.OTNC+O5S5IF%NF4?^P".=UXX2'@G"M?C >UU6 M"T.:+UF=OC7CSSI8UJ;>^$O'B]SWT+1/EDM@)}^=>^_OOF?T$N&Q"-,12GV M]! KL8/1GOM++#R%
(E]"V=Z>(2F>]4K%% U9@J_1?HMJ'8K;%]$W>\"THY!9 M7T?:.1HE\98*I@M& M>,

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l_M_- BP\L4T:ZY93A!'PM^]HZ6&]:CM;\SIYT<=<20 _X$+H"[[*S\7[BA*M"8&G*WFGZ$>!6 M9[U@A:I"F?I\:/LX&K7ZMTJ;/U+T2KL:_4?(W]0R&ME.Y+|>E=-1 M2KN[F^C\\26V7DM"H>E^60X[%*2+K@\X]%'UZI?0>]H2V^,)D?/K+ZKL4T^& M@(;::N71@IX88UN,64;A«H^)M(O\E]\"8K2IYY4!SXMP7]W'O/$!/N4_CUU M/W+UUDB V]N=QHDO%D^&C)%2H2>E3(P6MKC@X;69KJH^N636X@4G;.PMVT#& M/K43^^X5AF99%+_WDVG9+!%>@I[&UT7G&19IJKI/*/%?-^'7=[.3AIC6$C[B MJ1!U406[I_+S5?/"YI4?,..#LCJ34H%+M'1^^,%PMPP/X\TR7+]R:IKL96 M7E,QUF,.DH+G@(_PVI>#)RI 1`GP<+H D]%IV193@-7! M&T5Q<5RG7Z1Z)'T \;/@PC#>]PIT3"^&8#3:ZX+)U&@2NN1$.[NKX6I'T"G6Z M6!.I/(7XCCYY*9ORRY_&X1S*H&$^RN!\3O4\>;)?;^H5=/#Z>ZSX*VQR#IEB MM/N 9##=]8J:-GHHXMET+=U+2[U_B_K[@-7/A%55+4TK\Q_E)HEF03YH$@#@ M:JIGM?4:KT9(:^6&24PSEB(1U^><+U)ON7UMKM+.;J+[4H_I\0D6P(&0AK0# M:S0RY1QTHC,;SB[!H!EN]%:*;K:8M#;H^3+/Z8HK2TM MQ>^&[*9#3GR%77XCDL+]R"];"H,=021!Q>1RM2EJ-J2*KFWV@I"\RKWZT;" M`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iNNT+D88[WILM^=M MRI&F*=;DP^O <>F1TVK2$%;^=-EQY%5W>,+X6]?O.80R%G>5%4H5Z4^#U-9/-0$++UK?25EYRV5G)ZFQO/0GJ50"8>OWY(0@YE;7@G_B$! MC$V?E@6MGQZ=Y^A"C3MYI$)]E(. CR8D:K(>+KY2AIC0QNP$##9RH3/=_J3O4 M$\+4V&=W<]A4,;)!0=W=?&E>) YG+9(Y#U'4TN@/RKLOE07]9BV26IO##:|%' M(S>(HSD,>-$U.R0:W!N@E5.V? KW!K'1PV4UL26QOSN!K+"OML+S0!N/A(@ 380Q@8];MIVO+ MO1'YU4;H=7=H\H 1HW3L:KP8=M_ 5XZU-\'*=V#DS>7L{K%(6\|4 C<\H_ 6'F M-GMVXY6M-3/>P.KFINREKG@,O:'@IQ_QJUD\ .Q8IMA666@.D<.FM]YENW"(.M ESYM9QGZ=?'[?0]_O<%5]K8$;7I$=5&L*:%7$3-C]S^C WT^.8BH!(@[0]C MC\VD_H6_4T8",+FPLQ3902V/XS(S?V!POW37LL>%).V!]_YWLTX"YM!*5. MOP]SGB8 6K_W8>C(*LP 4ZP0H8WE0|#"?45X>\6V?I_WG0:\QL-QT\7$4G3* M1Q*@9<,;K T*5K;OO/P@>F%28T4S=8R]VC>F$^YY(3AN*!1E+Tf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|@&G(B^^4[$W"+H=?3GL'D]\GCT#[OO2 MF:ZQL'-(4WM]?HQV26%KG!6MSC%K[X*[,H2|:Z_6Q=,.XKV=?!+<6-)\'=VQ M#8B_S]0J;2,FFS__Q:C1?^S@NR6A-|*P%A/',PV_$?3]'>N+Q/MO$EY_?5X^2<_: MO@O^EAI,AEDB 2*"\fQS9PW++>;U=W-=#GBV_X+K;5#&N; H!APNP5&&R^L)O M8OZF,454T"!=-->]<-N(-5#F4I2-'F(S,3$VVVAI1L#.$-YAN/_1/

*M8|LIH'#$MMWBF0TO=DCZ8'L/9.%9E!1'#%PG,|-3I T0P3P5$^5'\R%_8/R M'R4#V'*4EPLV9RT=D)]N",:*L_>YR-.!OI#[7??%#SNJ'BGXGO3R*\2RZD3)[M'1]"1^RE!__9'IA6J_;SY=E3F-$!^)4!LPUR H.^-'!^MA;?IH -W3+_+IJ6SM'/PD"G6'#!YA9XZ.G'86:08E3EZL0Y%JHCC^M%M$M/S M-*"K,+!):IMQ8|#? \R[41M"$B3;+*%#HPV7[.OFX%X^%\QZBZN%VRV@&DL*0 M142C3C%DK?!U^P*,G'.UUX/6@ATM80"]+;?/ORZOU2UPDW1QJ#;G;^C(1OVR MJ;74ZU>$3O=T"O?!AA03? 0%28&D)=MW.5QN26FLBE"SF^.2DS-<=UL!P&FW^_-?!NEK>_*B1\G/A@:#UR^)GXWSA%N W-ZZVND[\CJ'/!%6.,-)"I/) M->5R&[$B=O+S^\? E;054SW6]5^AF74$3'(8:ND9|)6@[RI1(|)QG)"L;O>3B? MA*2EF9_:SQ_OH2Y&'3>M6KRAO(FK)+2|-4W7\+[^)S75A5E?303N'#W<'+)3 M90#P*H5XUX5VQIP;- N$AERY;:XXLO:6D $R;"GO?U06':E2IA9U_N!UO?U' MF=B]\+E:Z,N-U;KMZ?H;$|(I'F(J)?*BI M?>5)'$&F:I !WO$?M0G2C1SXS_C? O_]R.&_%04@6!XM<33+XM_;^W/@5:*+ M("2E.%9SOEOP|%EG;IHSSW7+K?;$8Q_OT<9'!4%BY03Z4%95-8$MR KA,_ M71A?EJVMJAD=/HH"0LI5W6VG3&MB8+ [1OGY2$B5370!/O]N-XQ;)6)4K>$2\ M)<&Z@'#]N(U7#NUGL'O./,,0[&TAG2!@L+U74=D5^HH[F.USB8EO6Z49VEO&ED4LB<4)GX,>!0,TU\]? ZW1[,W'QF$]MGKHH%1=:F #FK!B^GT]M)8WON-MU3[3$ENYM74UM;74>$2KN:QO(".9FA+,(Z^>6A_EZI.[4W]L#&R,.! P M@)})2SAU)(1L1)/N$!C&4C$Y/")O69EU 1LZ#FR])2YC:87"0D]J:[;=)UIA ML:UERXP?&AE>>W3H0>5,82F_(#;;5PK,6U!0L/ M>-;YQ+HN=MG%?Y&I*@W,VQ7OXU13G&#FL> L)G-PUSAL^LA^L^Q40HQG(>% ME:WC++L_-Q,$ BMC#_[-B+3%36LS7D3('6\6'PTM$\&_+(^5SM|R4XBQT"*[MMVU1_(3'^#QGC'$>/.Q4RG[G?:W"\)KUG1589O;K/@.J.B9_6YB4-P-$7 MF"G(_&\ZH^R_UR2)(@+;_:\) /B^H)\ANN8L0_C|H@L%6AEA!\F:(0'"%>[-M+0#@UCCA3HQ/"1EP%;W$G+@S=A4%?32Z7/U9'#878F0EX*+_^ZG0.63T8[+YN.S- @PQG:5<1^N&>]DPU"-=MYJ7@=%O5D?K38"[LN!//!H_;=?[+>,*P0"_X,MFAS5&RU5TA>+GDX6>.AKN_U:\^9R6));7&OS[(8(Y5_$-+\]/C^_"DTCGK"H M;&H(O6*? ZE\HUN@&WZE^9"A>;V!I!K&^Q_%7X=QM'EKMQ6O+(C>Y3O=A<'!)4]7=PU3O&92]8CI6/$;EX?Z?.T@ _X4U=RV"]7M?6TW ML3\)? >ZO'U3F]I@4_Z;94@]C ~>/?/YWA8HMM*QW.FG,1^F>1JK<;#VRCB-_MO-Y/"N*31()8?ZZ51"8^^$;? 2@"J.V7VXI&OQ49UDI,5A_M[&)&LY8L-MFLN-2C8P? _^BZQQ(RG.G:/&@836V-=XO_^R6_C<$!1ZU':O2E NWQ7GF+])9 M=C+!=L28#ZU&2?S94PLL^=X_O@I^FU/(I&B|\H*&&=;A>2Z"-XK&|DZQ:.)U MZYQ1)/WA\Q.Z7"^W? %U#I2E#R4&IB+P(]9=VLU&$WH1@;PM'R6\W%Z,'G7L8$W%W36A;Q_<2)D6A.B$73AX6T&XDCZR(>-(U!WGC-J"_S_)>HGH?8?.O(^Y!:35%#<+!+$C,)0N MKBM8Z? %B<<&5I+EQ9(1,9:%2H9+34'?([C(_M&5^$CTI7/E33*@-M*JX.M4"PQ^BGF0|[G(GW@47[8Y|7H$|$WO] 0-MEPE^-R2NPI(QFH\!!29&YEIXFB- 9M:349Z(0[Q0O23[<=W&AHI*"F@Q1MT/+ M,6U0SE]*Q"Y;ZGAK9_K<$>AV;;-Y=EW*Z'3IO6O!\2B);YD?LSJX=[_]"LZ M?I$88OFAPRIRI#?5>(D(/KQLWJUAXX6V_- *HSW<\0O?&OWP8E%]5&3\0?XCB M<EB0<+!<^/C5)FG0V:6-.6,?[-3>OTT=,O'XS-&\IL&<{}0A?14V!]^)B, M5N*$;76FH3=9.$3(Q45*\T?WDH6E4B+?/3QG MX6CBT:O90VV=I&/GT;Y5RWBNN(P;GRW"\S:>N6K-V**4C6;J&E&6PX=_U@TI MTY,:(ZA%S5LV<8FAK];"F7$_56;$M.A!04DCD\H/E%PDJLQ#YO,;NYTEOR%$_M503 \K#]]+_T5]C3M_^YK?U'5)'V,26B|S*(^&#'U_VPM&C[5?*^%^)"IFW8 MW;A[G+;RS\<5TH"E-L%R28>EG?KUZ_$-MQBX;Z]Y|/+MJZ\M Q[>]**4&1U6 M,U-XD9.:S_I)H_;V4#!? 3>;9W3N;WVN:YCOOV'ZODOU'?4E5[=+;093GQL?C MTNQLW#QOBR[2H"V#0^GY93"N-+;%@4QEA>L2UFXE2_/EST^,+VL/^K,/X_BPN5 M0K(#M:%"YX7P,B6,9J_M/"7- -.BZG<6F-"A]!N-?@[MKYXU\POU [2BZM1OG M:,A5HU$9O?*3^^4Z'!\Z+ =e-->NE!NTRUV|-Q9LL4:>KRWXKM1:X^(Y:7N|(^M8SE:* !LARZ[HSPI6=QE8\5!XL.59NA9./RV@TWI/">_:%?R,=^4A'4MWBNP MQ-U!I&Q 3NORQ|;@TX_K\71PBTI'T])/+,3AAE\3 M*1F\17&\0#]RCP(4H=7UQ&&# DH#A^)&";-½-. E!\H:9HW1>K(.A6F"53-V M/7?+=03_O"_ZD$)#@RDZO\ 1Z/SX@(C =K&2SVV=<]!V2 #'B%U&_\P1'< M5QW1\R?D'F!>G<;#,A?@)_IB'M&5L[#_ N5)NPNZ[4/,OGW9C#CX]OZZ5=V M.U,W3(K;+-ZF^#\GC:X;YW@8 *@IOM#[3,2W#D[?$?>_OJZP4G,NA$, .#<- MGSX[#0D1D0-/-#Y&%QWY$Q|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l/O5E90!U<+]?.+YBU;R2H(.M!QO?@8[@T/L\=8^]M9%.LJ])"&:VFP'/4-,7'&O/IT0N:Q!&.!Z.?UY M<^N889.*F:O\5>/B;XAXLB UOC+'4N#M)-G MP=HU8&M5?LV=[<2!G?;*2EYM9JVRBO]"KUMVX6;J9_2?BRF"SAB?#/!;|/< M\YT9LMJSSR4#(OFBWE57Z&W3+,I"\>|U[? *!ZY^>7@[_6#Y3SV"9M.^OES(1;Y!US]Q:/AV=+6<"IC X/B*N20A=PD9!M :8BYYX'ET3A.N+I$ M^Y%V27W_F$/)RFU!8J09(*IW2/48SKQYVRZCQ- D$WP6TB6VPR%PS%>'8"31 MC2EY87E$S<<,/;IXYL9S0I?WN3[++@(&QDYIB8D.0<7%9I!@K6/|=?^[NWL/ MRV6*>M.R4_KO>*27-;$7D0'CI_S5N/EHE5H? C_3G)VG=MIC+HA3'+@Q/>9KT MA!H@]N(=U^5_=2@T+!%VY8O7Z5F%7TA56?2/;_RX9Q1]>U06!]'8_S&2(5[(C MZI","8_Q*'W_W+4>(V;%XFM)SQ MHWH4P9#^0>!$W>YD7!\>3[:F\+LJ^_;2!5O8OIV&>=Y<.[0M'^VSN6UL>N MKS/G;)U*75TAL0L0"EZ46)K*I-$80;1D0-/-#Y&%'0XVA^?_ZWB%2:LZ3:8 MGY/E"XC(">S4,] Q_#=^I>G+P;_K8?. |>@J9/B%%5K88BI36^$Q=Z-5*V-F MZ!0*6O"NX|0_B5I?)GRIC>2>7E]B&KLO5ZO%<=GF8T-WF5I4SL:S1,=>V>9X M5/>2\31|R5K>;+9#3LZV?[WQ|CI74) 6X,+=EW$2*D[W7!S!ST=?' ==*X/B M!$3.Z&#(3C* <7-"11(W!C%O\BXPEE|0XC#]R$H_#]SJ9+W#*1QPK. THO"[MV\N5:W8D.[;? I<[9CZ;[>]--A2!+AF1OQ9 !M1)S MP,>?MM7RPW(;Z^+V3=,==U[L1,UQL_Q=KPZ6R$#[.H.+H7CC=)RIX)JCA^8 M[M]_|.[?F3WD!+@^X,RZ<*-II7D/M^]?N:=#A19?9JY<& (T_!H>Y$?YFJ!N,)TTC7 MD6!^MM[%14NN57F4AG:@'?/:*5^D3ZN$;WN>A)E5UQ';->%?KQ".=W$/M!+IS+WIB;R5]@/ M'^WU"<9*5VZYO_? XN33TO6(P$.U"'+R+5.]NP8C@I*IA#6W^9+4VQ27-@T8)9 MCS-U^H^96;_O-D;O8V<-^2XPT!O#2<6XM4*Z#8D>ISGGN)MR?#'$B77)V[JQ=\K'+3#?2/[2SDE+T;I*!-V"5 MYPK UR;F_%!8FDW,!L?A\9RZX#:#$H"|_%J-;?[C+H+$ M5')6LV^0BFFK';+64U'W"-.P_6,T?978:_,$\%RH|\)4@W1'C3R #@!P7.G$= M^^SP;',#I'!BNBB\-8? JPO7IZFA@H>UH!K-K97+&@MM5CZF_$13-QQ(2@C%-M'NR@2IN8E';?AO=-Z/!2^HV#FVC ./BB=]IQ1}T'<&,7* NX%0Y0Y M"\&C$,8#URB,EFM*6@[5Y^H^'1]8|!OCZ?=9"\&%78>N3:@:$.(S[H(&SW]):W%|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|FOB@7ZXWN+\G'H3#YR"I"=ASX;N?<.9P3*$&S-MS$&OKX|O^-^.9GY;@- G]/);G57&T@3W/>F(G53T;@E1@(V"_W2]_1@3\X*Z M%UT5ORV%15-,;O("1P[&<6%HGBU1AS+S/D%=L(&VE,(I?D)5*^3^ZK/4U?.*K*NR7?P5XKKC-RTQ MC7)+Z<(MTX(U\5EV-?7]2?:N6$1H M6!R,/=\A92G9N"$S5_K%;/HYBN4N[=&?.%M*MU9S)1PF?]M,G/0 2R?1,O3Q MV<3>8*ZYAFM"MT*V)#,E@ZJY(Z[M7%=N&7CF9XLXO3(.T]ARP\UT|%UP6?]. MRO<-]+6E>MQY.+9I3Y%MS\W8-LA,Q>N!FMU OI GNTHJKM&3M/RV[^JNRR M*#*33? @@;JJ3I,%O^=?CC0O|0K."Y7QSZL@!CS,YK8K*,&S9NSU%34.(B=5= MMD:7X -=,LY7]K7\EU-H4&&CR=.=M(.C\06U84VY?8 S3K&VBJ>ZQG"O,OL4ZRJ*V M5^WY'O=*SW;@J^_9%7P>POKS3G^_:""+|1]X^=EW)4&\|PN,AZ^RWF-&,J"| M>2JE!GKBB=UK>AJ#[V;PV--6030"=E_7E"U4YX0SRV/U8\TDNI$H7^YL7:J-4?DUP MFOO-=@RS'J7T[\$ZA[_Q+ S3X'-N";7S'B*0=(=!4 6#Y'>:!4IY(GQ75KD_M[)U73]I#KY_+J.6_[K'&UY5)L,O>[Q .O<=FAM\+.U\A>!Y#G+ELC]D]C;!8 MOU293P\[^,79P(_.A\!-JM\AJBS")9'N838DO,I2&VK+SKL)00FI/L.(ZD;.MF+5?!A4441WCB\1***77&! @+]R2\%%F9.4A1J#; M5K0:PC4.5!+AZ*H$?$;UFW"']2'^LI1NO4<$[C P"GL?X3YP4?V,/7@**-'/GKUH/"*!^2<|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|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|/(RNUZU8?79._"QW, MHM^S"],YE<]MMEY-1'=*825&V0L/BJ227(T+Z@T2!6LO_!;LS:.GO8Q7<@-MIX6>DCWAXSB,/(8_<3/E;+V^R(:. M09H-!W&2T%;30;P+?WD>!.OW(CV1+9U2F=>9-1% (=QB'5Z/T2I?HX)%DNRUC MHN0FB&[+N:N5<^30.^(>^NC)W+<0=[H6CHI,T]"'/1MV8?K?4F?T5#%?AV?$ MC,D&I_FY:IQ^+U)UO:*ZQN6X[0RB,U(- HI>-5HK>TABP>.TX?CGU M@;/KQ]7G,T*>G^\|;;MT*))+RB_071($]!MP!N$WG 45F2BV4.Z6AV8YN4K M?4VQP]\AV:ZL^DY(^NUE0Q1[>] M\T2*R/%.N0+PHOT$[& E*>6"-,TP&9PZ?XD'LXG"(6N569U5#+)'T$]8ZY\M>Z8]%MBS_P8=]?_R16QA3IZU\S;%A)-8GK;7U2#V^,!=<{N>[,+5V+;=@U M&F9R.R:,,5R"XU!XM5F$91ID5$$R60318+;J#&A#:UXKA01*T>_9/TKBR7[I MZ?+!'__WW%OV.ZK95P;D9SKVU#I$DB6F+ >%KJ"@&]3;\"?AG3Z9UZC=HTI> MJ*1[$Y9/V%IPT_TK?OPCA/V6R8/XB)01(^CE R!?G)T,+>_MIB\&&OQ9!W&^3Q:?"QYE>+VH7I_;D,_5/&NX-$O+C;>/S\K7GY$QI-QOUX*%*YD:1R= Z($>0D MA7B5&2A1(W.&\!10TQ.6RWU/[G-#]M+!SO3_&04=2 THA/+X9FGS80"\KQ ZR-MND+VRK?)"7G?=2(#RH7%>X)0L@J<)>5I85_6PX.ADJ$ MWPR827M08"S[7//3N&@U3K_!;%D_[OM @C+#KH,YP.%+XXO3YC:Z>X^_MV5_^|% [T^R&[45?GIX =/;P!7LH^1[E%>QC%E.-+%LW=L"L6T5Y_9%UT'>Z ME_H\@\SR)^%*'B3?+U= O!U;O+O'5)BK$ M/QJF';27.YMPIRC=#)X.HN7-*S@22$8A!\|R.Z@'MO07"X<;"JE]?//9D""Y M.6/T;=?M17W$3I0Y<\$X.P+DKF_G$7E5D ;YLJ:HNZFK*5"-6DQ+LF^?IB3:+0I^"E#;M M!>]?D3HZ:RNK\NVI_'1X5VP4)*>Y.D5\B[ZK3= -!>T-0IBWJD%![!ADFE+&;7 MU(6HPY+H,OF R8X1'56CF>>/^ACZLF]>T9Z%?B>'\&<^@47ZK;R$FK/,CS=# M8"7=9:Z3"_9M2Y]37FO;H@3}}9C7LNR:]\LE9H&LG4/-&K@6INY2'XQ=?LX+7N/2=K%, M6S?72[D"? ^YU?A75G.@D7X6KUQ.%!O.0@3ACTX[5(V-=NRO[9G,%2OT%R8Y[MP32?&VA6>X,.E8>.&$E>5Q(*G]F[B4F'TY63#^;W;0N2G83N;|\+V]DB|%L M*0NF8_1=3@6L4 6I:V>S5%U4_.#GV M?>Z^-X2%;,/OD;BPL$@0LQNV;=VVM?E\3M*U0)9?7+P[3 M?H^/"U(GW@.U 3[1L""_/BPW$$?D89)8M7L^8S S=%[B@DONI1*\7K M4>EI%M,"^&Z7P]5Q9R\WH1IL.VD,&EKMGELO.;,I9I,L%MQ3YO10ITE'>_^(_<<%WIHH;;ZF(F$)B5R/=.M*V. 5:O*27ZY8_I=3HWBXWH(<48R|4O%8, [@(LJP=9,RH=F<+HO-I1N\JN MS%*[1D<|/++TH%TFZ_FJD,:K+N!AAY=:jJ;2T]\-%,'D'|#66)!AX^F6ZQOG-MEPA|C7_S(QACM6N*G19)5++Z!:A<+/G]D?"UO.K1622<-A? *X 4M\DV5EIL MHK-[B[^,[>8^;_XA-5(<-V*U5(OC3=O7"!>A6P3RXR&;+*)#1 MR*O@]^NTC(N1M8GJ28EW===4&;XXC%G]0V4+])IZQ><.[MR3BIRY/G;%J UF3+'BAS%APDX-OY:'A;8ARNYPC+7=_Z(3LMF\.D5=QZ:,?P M<#9LJ7:=UOX]_IF=_PM":W@^]>(KK&X>XX?[2PT"%*X;,.N] MR>7M_1/P,=C?BX9*?VJ&.LFAF.JDQ2]ZP-!JO9+G\X2]]A3DN]>L/[^_M-=NY$E@6K%IV?!9)H0$V^\2" Y"VVEZ%O<7]^4;^81/EG#1T;]WV0>_?W!W*.ME|.:1/UT[OQUT$]F:.%W\Y8U3[KD3|<^,+[^#G#$2/7? #48OGUQK+/>L7W10 MO("& \_RJV4C!'F(\<6*6K!.M.!URT CX\GL.+4)"R&U9V|\3'GNZBFMJ/O@ M9V!8%MKU.] <8;"N9(NK\0Y%KY9Q8'/QN7HNN%30C*#C^)7%#X8+'X^7+Z\BE M*7"),1IX#Z-#3F8?Q,0Y[->*I3_II%3;A(-[!?VFLI>[++T@;U-#Y=-^#!F1"R; MZ\(T$-8)Z?L;*C8O$[O%I?D* D*7_7]TE489\X\N+"8J7@."(XEH3K]Z[K/E&>, M1IT;QISB0%=@'WMG]+X]_<$M7HKQ*-GON9 97N7K$V*QG%%X:M!]-H,_(T% MH0?G@.M3!@YL-SF?F/L.<;K-B"2RY%S Y+2Q^KI'@T MV+(D21#>,_3%=:VEK@>Q!PTY8X>ZM@8\|0PWXPO6E8/XAG_X/4K*J[;R M\4M[S?=]ZF [9_*#5N-_P_L]^N/CX8UDL[E9]=Y+K-6)&OR7G\@;PZ<)SD<; M!%07A)ZTT 44&RL@-_P#9PKCBVRMYQ6.7CD]DWUZ_FIXA>|#L^HRNHKB2+B\ MU@T*LQ +*./Q^ MDGY+$'V'+GE2LB==D=-I-.>#%$[@AB,.5NU94D7U)CD3'$C2- :=W<,;F3)U M=<,'#6_<=WK*'2[#PR'YY4:=,T_<'";:N-#[77!UL-$GVT(L &'!W=A8+%9 M1A/N2G@)^[]%_-*1CJ.GBAH\K'83K;T&"'KE;6S#S4VX!HF-MRG5-.%#?2I M#LF- 7HU"MFFJK4^P?(\299IB5!@#CE_IPC5P#K28 (8DC,%P1.Q=_M]855.T+.8ZX^2R^U!U)TW$NI^W.((RH)FDLQ&*%H00L#FW2^RS[.*2_E8N!(MLEF$Y_1U]=E^E? D4*IKZ"S(E,H\<'3I) M^*:|9=V|SY5X"\%#U#:9V>1A)776Z_/<6?-[JT&#!/N9%ZZW;-6-E91*O^M82$PH+P]FZGK =+XV? _T6QCU$(HE73MN+7"N_+/_U((C2K^B^AA'O>3$%N01CR"&N==B|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

*STH:*5A8&/^PJ9^23&0M63/FXVY7"EUA(sH_3EC3L+,.W>WSH4ZHVZ^@M MP;8=QVGZPKOG@&3'=UJ!A1?1'4,S&T!14C*.1U/X_0++)Q';!8>7.?UU)+ M%1$') [^]OP[Z\CNU]M-<-_#YOSL_.A9PD).5/.3";P01586400S5@1SO0:@W/ZB\+I6FB!\#,JTMSR@IYX#(*($0D8BWYZSD \7<6]Y&K&^S_&_S'^C_%_C/!C M_!_C_W\9W_H[\?]$74G^,KT3-&9/3WH*;S3N_G.Z%KF"$Z#1B9B=5]I.Z\!0+ M6GQH4;WQN+K!I.0RA\<8M=/25Y0 3!AR X<*Y"QF,*J&^AOM)6Z]@=5< M;&TU10'QBI2!ZG]D^^H8]2MI=O+B\;.N(1G.@<7/+N]`JVO4:6?%4S;40V0 M7>AI<;*!,:>]\/L CV#-_JVS+\N?=FM)3<2;=.> M8*C7[#A,E7X#5(W%C+O M"UERFR_DRBN(5ORU8](2${G/4B;8\:F5MW\U]8S[G38>U)[U:.2BR(*1Q($Z M6E"$&]#@]X/0&Y"NS&N?YVRRJ0>?LS)H3[H#PC\ ;_I"<'%1CV M2^$V=!^QU I*4MI_X)MR%$'Z N\7T.A$SDS 9I\XRAR2 *RZF@IS! M/%M6'"%:X%S%O.,9?+S>B]"7EXEK4YFGU#8IA!,BRB?(5Q09V2ND6/Z'JC:GE MB+2^$JI,_ROPRE,75*F9CC/Y#G689*JO?H;0"8X#QE:CG_24VEJI/L-[.X@<6 4VEJI/L-[.X@<&+GDA-_AYLK&WNNWG;O5 MZ6E-C0T@LI27Q)L%Q+ ^1QGX.H&N6\Y..#WN_6.E;956KB=!B4>/!%5^9V.!BIF0_\!P@/EPT MWK@2%GTZN_|W'GI\[!E(;E[2H9W6D+F^V@HCGDZ9W6;M[;V I$A%*=9 =;!U>ZBEL63*BZ_3E7S@!?- 6B&@_YL!E L_27P2Z42"$ M!2? 2\0..#7PVXQS(+6[2W1%^!S@R]*&KAFQ&2U3OJX:<@Z0V&Q,H>MC)FHN M+&;A+TO$U 1D728-/1;D)D46E#N/35%7B;24VC[YXR^'O:Y'C42AV', [0U2 M7HZ-W3-; ='NTP=G:7J3-W#ZXORA$HT]JR7!1[ZDWZ!N(>:Y*6CRDC$Q/U1V MJB9#,\;M_NO>L=":/PC%NEW.F=&+&JWZE+W$&$JB5%?_+#'F]ZV=!V$&$JB5%?_+#'F]ZV=!TPTEH;KK0@\|.=E4TRZ">EX'*9,N@-B8[JY'\_,#E)76730U MO"/!X/,EZPBPBA1F-XSOX%S0#8OA726A7)",5#.24+EOEG61/L'%%T3!D-?1 MZS)D<[TB#G77'6RAN1;W=1/[IL!U;.VSR2HO -)PT#!AF"YQ91E?#-)SX:DM MTO* I#6&=PD$=*,N4EDV>2=S/#RDLZ(&XF?F=:^\3KI@E.9)\$C"VP\1K:3TA'OS$F3_FH8ZBFH+,ZKR35@Z?&AQE$C]ABA[H@T* I2;>/F?Z^T,4'TV:8C+!B,-FL3 M&2P_{X)-9A3!SKM?:.W_%3=0!$SLQ0[%)YDUC_&9STWF M-;\GO/YMN9B"}K?Q)+6\%GO.R0=F2=8!67 M\[54QE]B5^U\$CXWK.TA/S7?R\)-&L@2H@J38!TIZ&-_32!? H*&DQO2?A59Z M?0DM?2VB[?$G*MW& FOK!=X)*M]SL\>O3=/ M$4[M 8,%C7AGMT!\=6O(:.5U@TM>]4[@1V+|4@:J0\"A0YEM@W5#<=`?!G/-MWL_](0LG')*P+=E](G0"]64+=ZZ2?-.RBVW_FX8!O);@@>?;KD&Z8I6(;5C MA3Y2;Q$5ZX9*MWPD\^P;57VYWE5P48?]Q/,O;UO.H5C?1RBR!*<>I;UYI7R4 MJOFSQS%PJ,9!^-4Q)]1ER=_DO0F!LHJ4+IMBX] Q+2#*2C6(4O"76V2'8; M/7_Q%6A#2*C"M'KK0I2Q2(RPL63I4CA,6^6!P *WECYMK#-2T&P*S:I2-K!C.R6(AD3BIBJ$Q_:A:N6;_-V8\"; M%S\|+MG[3"&$AAD(A58BPYA=DN:&EF5TNU]K&E4*1JZ$A2]U/^722P,TK6?>V M_\;5B)!"D+ZK8T>P\E!%(^>\2|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|_1J?N$*?T^MTF2=9(%VA%S3#Y6VS Q M)I.MLCQ-T6ME:\U.9D?6YX#0.D*;@9>GG]^=W\BP=X-=MO#*Z+X M@CB-"5M8=-I"_5"Y!89E76-:;4YQ7J=DKU2K_?%_)]V=+ "IZE0AUL4#N MZ: ^! ^0>Y[$U95:.NH;1K)RM78\Q&;AY:YG]^GQT!HQM$3_-%LN#4B2R\)H MSEZ3MS=$4V^)K,6)+W53+!.UL0-]:5W0E.E>_^F1'}>OAKAF%#BT(#0)V? M#)W5W64]3,",_&-B<@4>O>1!E*C=W!K\T+,6XVR,=4#AOWZ-? 5,.KU'M1K1HU]77MX.H"_/DO?>C+/(^O)P4N\-NF0JW'@^2M++;.M6,).?L5FZ$XGQ,Y T?)=?=,GWF\VY=)7ZUGP?X4/@AH:'PXBW6WXBRGU+!)Q M>4,_IK3NKQ=+KD'^YT6@NO]J{'C*"'>0_!RQVK%$DP46HM7CJI?!M MR+YL\^F=J!,T&7&4=0!XX8 =HC+*(#KB_^=O //_BC\0Z3K+RW/]\"U8974 MK_GIS\GSP+%_KNOE9XMO:/^5@I46^&JX4W,%0(#M&[#/6,,0!FZ(R*!#0N1; M3?)FIJ?VO21#&0:!MVHY>XWP$^@\IZ$;X.DT<^J!2%>KX$4HJJ.69+!\68S M8+[2^!TC]'- <=I"JV$>OG_9!P65_,FM'J'84.H>ZYF>S1BV+!%M(Q57ZJ-55 M20T_YTSSI*M?FA/UVY^R.R8;+ (TQC.D5U!1E/D?9_.*?A.)DFT_X+AHQS31M;%-BG5'F>?- =+6L==I*3#|8SL'G[N Y2@)3#BLW!VXP^Y3W>S2N=>UR45AVM)6E4%=;YN"KB #'& 05&:DMB:=]+2I0M/WM.&)>K=RCWC8#D[@%I_B_/:_M+I)YYKV[2D:UOP? &B[9)+=TM"$9)" P)F^:M;4ELXI,[V]ZF?C%;27-M\[,=&&_]F!,CS_=2\)KP/(=ZLWF$I.S'T$2KE5^=8*:,"-GU:CMKAS"(_K] M34EQ]OCU9F6#9*O(CAX+Q]]KA?F=O3- 6(UWT.7%^Y_P,2N2H:.M DEX>I"R+4&\LM29Q9G5";ZA#HL02B_'UC'I,&_)8\=<_>SJ0>&7I^7QT;A6 MGHZG[4-\GX)#]26;)&^+MXR:,D 127MG],+7M %AW,('HL/H<-^% {\]D0[03 M,:LC4 ?,M*2YFXJ141P -QA%Z/4IG"VJ;L4MS186Z#:O:[2?'@65%)'$)&YI MY 23\,CW.HDRJ^1.^QMC-AU9U]XGQ.K=KP?Y(II9>TY&)@@TV/7HFP8'!S7Q+ MR/:BH\O6ST@AG3Z0!:OKU6QKZYAJO.V7:LI[6;C8T^<$A75]+)#?%UY MTQ_&\3/^Y?@?_]MIF@).-C+S.B$N#U8 #:HY^GZ:'.-G:@;ZKZ!9=^W" @E;P M:TSWFY,>:3YO=C(O\@71LCVUO{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| 2*LRQAH1?C*?'N+3RA'?66DN|<^&UC%Q-9!+/ M??-=H7IO6C08.M'U_,>$X_9&N9UCH+J.-"=] MO[S-?=@K0.!J2 -.9@C|?N% W*#]J+3, 3<4W*Q5*I-41*K3&3N4OT<6'Z"8 M]"<-+ M,.6]') C'X)0&XR3PMD\&73#5L5'\&:]%<22R:0(OE"Y+R1#+W9W.!X MD+TB<1-75ME$1AT6]1$(J3-N9K4]*(NM/6\WDM>2APD:Y? \2^+8QBORS89JFC*4XW')M?> FV)C M:M}]I89_Y"(@]<.=7[AO)NJ[A:IW]/ M;W'(6"KYG^9F)T%5URA6]P&)\GBSU!JEQQ9VP5&WRMG^;RMH_T&!SHJ"$(J MG)NI+8TGCL;0;S5*5V6"8<6*3OWKIXN M4Y5V|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a41SN,3^SI$WM2*0*R$!=MTZ)!RK,D6C- M"1S'H4Y1T:%(^,R"'|BT*BJ-Z15Q7W%3S BWFM((>V,\S36/Z M40]JB/';9*PL3R^6VSE]"UQ+]-X"9L *^D1B#6,N/S=?#GHZ2XK6KB4"0Q"Y M<|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f!]!8M$OEBCKN,GDC1N_*E9_;X* MB:)\$=;B8*l:[*#;D:AJ?2<&,J;T7;O_N*S05Y8W$'#^;K $S&3M@0?36MZ--ZC_=V>3B$;.^? 3FDWD*!> MO .;$<4^+B*:V9 <'*_YJ&\#_U+R@LG0R*>NWVIHNBMZ@-,/O MI6_^;93$D7)"55%YNIS'(Q/5^PDN?O:K24OH[V'U3>7Q"O0QK[W\9L:ZF7P? MP^BPS,W_L4U"%6\&-_U+GCB(H&Y3TM=RKWBFK12&RLU=]6;EU>7W9XOMEY;J M>P)66_K^^G5']),E<+?N5[R.65I:FED4R9@0WHFZW'RGD38,FZD!OCL@EF+& MXYC\8.)[/":;IM-D?:O<:O"IV)]*}Y^T=SXO=-C-K_Z/I+%>(NTG13!';2;F MYZM+46W6VSKO_$UAZJ.V:P*>PS&3]=QY_Z2YE]C72*:$ ME59%?1-M/SN'DF\2I!"T/I1+X- @0';UG2$WQ;-"N(NJRBRFTCC7A*]FV]Y?:,0VCY.S6 M7_Y3 +_R'YUCZ+ZZQ(ZV7BOR@-KC-1HK>,]_3J MS':JB -"'\]9ZCH/(;6#(:.!4R'"?Y1)%#0T/.F:)L|(_#N!SY$SRP@Z% (YAOA#QPKF^!AV_66=)S>C>8A,6B2?>=Z,.3 M0IHDO%WSZ.X$C6+>P/4XG=__Y.;IYJLQGNI1!RVSP>?WC_W8>O!4A]V2AS++ ML;_0%4.A)>W^A;M(/\AG? 8WD[58NJ^B-B=U<9CUN"Y!NJ-CY_)2-+$HGZK M..4.$10N9MN"C\E\X&/U!18.7N_(.1U:6#1AB&'L#HJGU-F_QGSYXE@^.I.O? MI@8(2;7>6YB.[DVDZ)&XL).&W60LQCKN?U?]==?PLF)WRG0\9+,,A7#=P72-M8Q7I_RQ)< W_5U-;1 >Q;7OZ[V$+BO!%;QIA^03 3^]ESU;X8NZITTZU 4&8 M 7^K1:OTN"'T+&P"[QK\WW?N1; [9/96W>TS_$EO'3]fC<#5%&_&P1*=&_@TK@Y M]=\@/!UVL*BU;ZFP;TQG_+XYRUZY8VL<.(.S!*H0W+ZIMHD(M'7>-6BF[RFA'H3/CP5 X^JOMZY$:AV<,Y#*%E=!!/3WN..6O'MZ!.>B7\Z+? M,I<;?%N5M:(W#VQ>O7_$.V7PK&4H: M(>ML-,+;43R^T=CC",4R\XOA3T:B#W7^>"C4 ^Y>HDE(|[3N4"VNB!5;Z3NP ME;$\=C=_;B4N\(.Z-$9Q((QU@J]O$^+O^9R.=/3145DY_>*TQ4Z/5UNT:PR MZ?A.",-&]PJ*&%];Q&@OCOI@8[MY(0V>$/-"?U"#,.0&/B>]#_0[@#[F.?Z M;)Y*\3]5Y9[(@W$7FDU[^GRL M,&4]Sj#O]W8WMH57%UOE*V+_+P;E^/W&?\MTC)ZQ-&*Z>92S_@H@1$ MF!M%^TI&MG7[%90DN/AAVZ\4]^E96SG1C- Z/O4I#)*XC)Y(# =T%FLGD)X3& M1?',#=<7I9,*V_;OA_$7;9/1+2_A+#9DK@/HE%-MNH3VZ+L6HP?O=3G_4!-^ MB81F76M6P,*NN:@+%I1BK+9X2[@K*I,? &;W5O8!L8U:6NT]Z=D[KENP"?*6 M:S&V:$SW+B'+PJ4F*;_@9@&+++>]!; HDH,\DK] D3E,%?$-_,B\^8VCT]B8 M21\YJ=H]W9>)HFV.HI<\\.#&QK >C$UTLE5$=;] (\G+YB;CB;X7F[>TSW); MN7VSNB1_; 2ICB"5+!'2Tj/+[" M8OQ'?)"0\)>+K9BWW3/84\8.VW97.QV"-.B_!ZEV.O^03%$N1<,"6>78F^\=% MOXPG**O^476QL&UJ<<=>=7'\'' -*,NK@+6J9HP;NNYR>GW0X_fJH+1 _9>];6WGU;@>]1L1U=B3IOYB[!"A91>+52O M#<4.5R&,&=>/413R=':MAC1L]FENA1CCl-6)U=|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|<8[O"$OOPMM)1Y<./R+5]05U!#K}\(+AAM-=T,7#@PTU ML5/TN(,'Q]N?!8]EYVMFMA#[!JOCIV_<1?(YV3>ZR9--@0CLV.IXV. @D_HH MG\TSTWD,!QV_B M_T(%%!B>L3?4&37YO? A?;'O/[",.]%TPB(+2(KT3%125WI$6%>DOTJ27]$AO M(B 107H'04!10'HGM-)G8A(1T(OH9= (A BA#"\LV:.6G.^,Y?6G.\|/_9. MSX^L/'=RW\^UKVOO9^^=S,P3;Q BOQS/!1=']@3/\!GK.8NR?S(&)GW>30R MU;JKNXB8^:GE/N\X-[L1N,SOI8>ZRJ.*5YSW3OIH'2IM=BHL9N#F"-/X-J&$ M*4+4H45]W.#*2MM1C1MM%"? D3O0G+;>6*^Y> ,JV M)=2DK&QT.&\)23N)FH:AKR"3B<4X8!>(4SK0#=S'1,!(:SSGYL7>3/Y0$$XS.W$L5N"'!F7 M%I"-VX_IXB8N=ME;,_(]_5F MTGO]+N9E00M%?IOG&A;Y9^9^_ \U\;.-01D?JO@SH+?Q39\D*KO7E,2%M=?UO MZ=L3[<$17KBX'E,8W:3!E)KTIM5' MQ?,\K/Z'C+5./U(3P6'E06ILZOWO- #Y(T7SX*_V:F]* C[V]\0%8/VV.0=! M-&G=9C,WB!4'CT3>V4"3H@(UJ%EGLWXV39[TBUN"&-'D _]D(Q^[J"8/W!G M;O9\=P,A-?47 $>8V.#1G\- &%6"%L.^V#4KMS%F#QOP)O6?/RM5^&NY7O/ID MDCP*Y149@*K=2TB_7EN[*94\89:8*R<2TB_7EN[*94\89:8*R<2=N65(,A+? RZ_EK(+PT2XB[RKLX8G%0?\%@&O1X (P;M#ND;36(->=2#^)Q;Y,(.P@UT6&H^WTW+?;!^?2!:9:I'_9XJRU[>RK\S-AXL10T8Z<.\S>,F1DU M#*T-)U*YUA)J/S[6(^D8Y*34W#Z:,%*=O=^XD5OQZ"^ K:M/IST'8QZVK44[" 0H='>[9O]% M?B3(XH]'.(BIS6EUP7YO%\K")1I];^D:.N,.\SUU]LVSF:M'E!QPLXKX$;;S M^"2"R5>\6(]J=+T'!T2#Z0+@(S"[# ,/(^/AWSK>K!*2.$EO6_2.)8G=QE;> M/_LISEVV9@]0L#:MDT,.QW68!KS[W4"-M2/)E]6T(#8F5:+GBP4L\(<1VH(\L M=2TVT 9-C8V!)3U_*>(K^]1.+!]VB*^]1NY6T(.Z;7APl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

Copyright © 2026 Apple Inc. All rights reserved.

*<|2LL6S]W*IY(B,1!:V1D'CI"-1AG_\F!Z/T_1\KS9S.V2ICB*-M8#WTI0+-%AU83P297@HZ,1'J,E.+J^\S4A.G%52GU!7YF->:Q>#QM?^,W>9D MJ=>G_D4&@G!1Y&DPDI?#3U6,KNB(50,U<59B72>I-_/$ @^:;9C5 Q#S.T'L M(OFVP"CX\YR*3YR">DU_S9-J;T9(-.UEBQBA5K_B4+5,3GVE=[=_ ^/#?"MMZ M,N2+:2=.5+24@\VV_YJ3AF.1?^+/X(-/M> ^793844\4564/F:\Q$\IVL$IMX MHYJWB6B*82W_8{)BR_H34T;+I^UOOG27D'1?/\$S]#!:+_978;5# 9YGR'@78 MJ"!H':/$OL,G,;FX3U"M$_S92+T6$0A0#M8S,G/(!)PI,%.(-.34_-%KC1%K MKG(/[_YQ>4Y3U*=\ZXCH?O=F]YNK7ZR.C %,ND&L>!!A\ V1,206V@9R]NE@-M@:C'767N'>]|_2>X_QG/P&T:5;&%+KS @8Z_F3,O>2>VK0 @_N.[<-M)DZ_GNG MU9IA:[MV1A>KXU_555V;_/Z37MJ+EVLX@,0%P-7:]W^IWC[B%6YS1?XW3XG3 MXO6)3K(X+5|Q M9:+++TY1VQ$.KMI$,JQ M08&48*T2,7C>^)Z[F#N'-M8_;C$%NN3UI#;1NA8 MZ&_R@I9;H@]N+35 .,#R_I>U"NFX.4JC2S!ZA\,.YJ"^.,J??IFQ"*=)2SFB-Z^6U!# -=:?+DML08PK,L1\U M%2WPB1*G!E#11Q@94^NEEW_<9>WBY/GJ"1=&]V!2M=M E$]6VRVM1\%GQ@E>K{8]HI'TN'Y65MRC'_ZO:*_YK0WCJ'+TVT^]+6Z>?A#Q?!5/.M#3%[OWD5"K;XV!-\KST0U]/"%=65Q#QTZ8A]K?S>$: 9I_X"X=2MJ!:\H]"PR M%RY";,1+V'(']SN9LTY+@J-OSDS2:KHZ4V?8.A-+))D&Q&)(}B.RN#KH6@<C!MH+|_N8U2ZL(;8&$*IT(H*###HW==>KOI%:O50=]O2KYOR^R&'!W-L>?EDRSF^_M>&[.63#PR9YQA(51O]@6G*CB\B.F]VOFTW&6LHS;'4*_,3WO+R MY;SDQW,7M'+]Y34XG^1&R[E'BJN9D0?3[KEA#;G*HT"GE-B1FJ:$Q_*P CPO#O)Q+*T5 M*B]$)BW8/48=+Y@E0P?]^'"%ZK'YBCZ?R7PZ4.!%,S'D'^PO(S94M.(]IE[X<.M7 9Y<)$F*R=D&2>@>&#/]ATU64$M< C 8F P/J_CX'"%PE1P!UGA6KH)34E^_MJ0#N&H"=G=`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{6:",W/9'0O(Z#D0I1)4]=@:T5 M&J1/IF!FU^>_CC+G%++.X(>\BLTMZC:\$)+2; MG.:]Y959^:+R66 ^D 09J3X)A;H4S>O[^GJR%!=??9/K/"WB6|/Q"A5"7YK]E-MUN]H&*]P]_03)P:GY7-=%IW^^6Z/RC%UTF1B5OZP!6,1D%B&Y[U\# +GT[R^&_0WE6B(Q1C!MQ#;5-SHMVDA03GN+1\1;<%D^/W$EC8TD8$K]\0OJ2?A7X=?: 9 MJ6<(5D=;J6>_4HE+Q=H,/>9[M R;T>GL MN,02:^*NMNX_.X8#OL](M*&S ;M7(F-&7G?,!*-G#?-]!>=8EGCQ9\^#1"[A M^X>0^0'Y%^L>8M5&\0*0FD6TO_"\@2X #D)#5%_.]\U4%J)V(.3Z@%Q27_&M'G_F6S)$]-@EPNT7K1>2*+7W*1SO^E^N`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|/Q"A5"7YK]E-MUN]H&*]P]_03)P:GY7-=%IW^^6Z/RC%UTF1B5OZP!6,1D%B&Y[U\# +GT[R^&_0WE6B(Q1C!MQ#;5-SHMVDA03GN+1\1;<%D^/W$EC8TD8$K]\0OJ2?A7X=?: 9 MJ6<(5D=;J6>_4HE+Q=H,/>9[M R;T>GL MN,02:^*NMNX_.X8#OL](M*&S ;M7(F-&7G?,!*-G#?-]!>=8EGCQ9\^#1"[A M^X>0^0'Y%^L>8M5&\0*0FD6TO_"\@2X #D)#5%_.]\U4%J)V(.3Z@%Q27_&M'G_F6S)$]-@EPNT7K1>2*+7W*1SO^E^N`&@NBT7&+?C!$D'%R[(2,Q1 M?7*>>Q7:R'8!0'WX';4),1IGS-PKCO%,JBMISI\Y.@]$#[;()NB(F@O!=VU_M:!%'BT9U@YERCE0,6,^MAZ/&GVFA1_5-IO+3]C(M+<;NQEM,U_DGJ)"EQ]GLD$RQ"PI*[^P;H7@ONU-_M[.CMQB9]I*_XEQ<20(OB%KDBO<.73*74NJ0\Y$) ^FR^R]GT M5P;6!TO&:EO*ML/@HZUG0B3:#$(4?75BF*EFHRUQG#*_KX? 2W0;NM]$*W]6 M0"D(E]DU-4+94NIYW;%G\"B_(I<*)XU]3*A96EA48S4-_MBO#YG3$0F?97!/'JY9@D;DT&,9>67[7#,LWZ@WVWNYBRE;'5-

M9D"}8_9]$<&\!@OJ]L)Z)Z*';0U_2? @MA-._-JB]WF?R@C?0M$-)HAO"?SD M$TB2E&)EEX8$32X+SPC!J80W16^75Z"T,R8.9BB*3?12U?;,QIWC*@'B;1Z^ M7RU;I"@!2>2M^3?(25_QI.[2%OQK3%!TIGY\998V)MM*;S#$IW2BN1>RAT+I^QRY?C*<=;==/W-MZQ:C_"^=#!U]#M!XJL,/;8O+G'(:#T6:6VE/ESA_V>W-\!/)M+[GZ?S-;'[4T MVR"TWO)8>PVXI>G(R_I57Y:W6*Y5T=O5F$&1KS!+!>41OQWT%X)SAVKMSVBC M>"+XT_2Z5+_PV0-+/@@?=E3EMG$';+=BV??RUEK])M!UV@POT=4>OH[VTDC9 M3"_NTN&?B+]\JXI6,#+7=WM8/CLIX"7:YIJ&, M<'7*(QHM^ M>-W3 4O:10W@ E=RU@Z.4;+R=M*&R.!7(F\(f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s R2DY0)?9,PIV063B0[?4ZOA-MZU0RN!W3T7&1;')%A^%N#V\Q6P?14NDL\4;QA!J&? WEL0CMUCJKU7AQ]HDT(\$7KP +LQH.D#A\&XS6QW+BZ%8@;60=$H/U7"?M$=U MM[8^QO$?]^/L@"'35Z0XH$G3MY7MN[-T2^K<0Q\+$QA]4*T_6=MZ"&6@KIS: MG$\M; 3MF)VLUK@7E&KO3H5WQDGX77O,/DN0"?E1W9<3#\!27>@=;_]]?[TKJ1 M>8@,?5R0@=K?IN>PMNGJD+^(0!_;5H//+RA:30BA^S<>1!'GY5V?95Y1U+[" M*: [-+P0V/R3[)\ZS%=#Q^@=(60N046M30,,:>,,=1,Q[O5$.Y6A,_/'lX$PS>2 M*DP82[,OI MDL1%7%7Y+]-4T:>[OM> NH(5AK+S$-^G(:FZ*C+N:K^3(28ZI#F:&% 'G2*] M.]1A/B^"Z9V\5?)&G,"R\>4A>G$ERQUY"KXY_5@9H;5X:J/.7,AV0[N#O4## MX&G*W.!&THA"G$<"Z'4K_FUA_^_>^OH)!M/H9+03OT$AL.QF"L.+'V5E-H%' MK@'50C$M8N@O6.^L_)7%[2O0K)?1$QFQJWA)V,'5 ,4RB4W5]+F%6M\)%"\R:QZ_>APMUOP.C<#R.4;S'9U\\3 2OMPO;$#\0H3\DW.]Y4&%@X3$61.7!*:/,$KS2? D!16O[19+K2C?J9-A=]N%E M:A"CH]2;&7VHS0A)*B>Q7KHUC[#*@/Q*/-DW?W 5>" 'C@RM=&{C}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l,.B7V#=:,^% M@2YNXCM$\:\!-GF8R:ZFVMQ@/F\,#S0BIS;4(5U1S@-/K? @L%ZF0!/J01T$3LBQU.'@QX0'V*M%VS:2O/ -!L?^NM-L/0,Q/E MVI1146S@'(,C4-U9V9[TB,*"5#Y(@=CUZ)L*B?W)]4K#82/4VIX*2[_616)".G M1H75!_JP]#7BV%8I^O0>$1[D#:(II)Y2VEB;<,4@!,S-\!5DX-A9JLF?2%6Y[M=L#Z7%5^?0=)X?0QHUTKE/"JNRBH\P&Q5/B:^,*]^#Y+Q>=`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`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{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fWZ%8!,0KMZ/HF M.NT^-4?V\|_0PV%LCKBF)X!]@W]/9(-7NIQ?!,.U?\O%&GN_L1CZ&QJC/?/, MIZ[=]RL- +V5T_ZD0I ^2I,2."-J6_ Y]@[/3VALK%Q39GS6%PRM.?^RS9=75 MA">AOSB_BYG^2<3+5EH5$^"!7B&RQZ[@DTGCUD?<1O1KNLU[G+:,Z'?B-"0 M\7ZO2@YV.,%*!]@T775?C5VA9&]-14:,1#?OWSH:TA890,K:#*W?6Q=;#V8(-M A*TL>V1+@2& !G'-*;=&()DF.R COV,S4MTP!I94D&_<$ $$?(00+ MC&:!:V> (,.$AH7."$WVX]U5%:)T6D41S)HTC@2F!Z(6'&522F>%<#@WY%"0I MYGD8M2R)2\QUN,N8,11665*)\ZL>NAZG:A7-;T5\;#/_BH(LFHR/MQ2AYVR MA4?,-$L;SS. [:]\TWO;Z8+3-#EC\;WFC_Y59WG)B_ST>]\CN^ZWD?_VA94:T MNBIW!G-^A$0JK8:[<&B?:F?G?H+]6N&/$+[IUX"377[$,BL<;QXOGN4CL'A' MU>!3/5C(15@X86!@^R4QC5REDJ.N_#WV4%DRJ#9ZN7PA+M)2K&63!V:H7L(-_MHT@1,LJC!?;I4C08\B>OO-BX6=\"EK=R5/#OI./1QGQ$S]3_+S(]_]."U\B MT51T2&.V7M@:&\^HR83SLZVWD*Y.11YJY8T/8<,?2=.49CB^E9M6J0P<&OQG5 M56E4Z&DX7L'D.PQT.X 313W_PYB]<;ER:)O-@'>63W(I3D T&R8.>BYZK, ML0AE\@>,EYWUHG]OE?-NH7G.?>X>Y6D%BS$?4#R8VM['>+\2+I[C)%CA2-?Y MSVXO9;7R[I[&SM]I2>1W/QJ_^?I7-(),^>;PB'O$C?2@RY(T4L\?#W1SA$VQ M!-(3A:!> J$^Z(/$RQ1T%DAI3'3E62%>,/-#@K)9W-OH8B!O8\70?XCW[P0= M!3=(J*[`RI7$J GRBR&>JA/P]GD=%/HF]RM=ZL[L!02M8T431*C*=9LJ7W*L MP^UUE0 VN\OW@CZ[T_9(-KU4WMGY3FV3;&JX5\VM=,$#.O#9U\LC)(,TTUN)fWZ%8!,0KMZ/HF M.NT^-4?V\|_0PV%LCKBF)X!]@W]/9(-7NIQ?!,.U?\O%&GN_L1CZ&QJC/?/, MIZ[=]RL-+V5T_ZD0I^2I,2."-J6_YJ

8%Z]&#;NQ8<.AR+GIA99E6LI24Y7H2'S[0H33HV64+ L+#L*C/?UC4[9G ML&;]>-^Q\!Z\TU#8UYBQMYA@^N.L&J6!3 M{IL3_DX0_2NXOR,: [M:1U,+
++U4IXZX5*CD#Z=:"G"P& \8U0;,Q^JZ)!TI?"!'MA4:E!8QLF!B$KV=G(F<9J03DW67*KF MWC<42TK2I)%DC@PIO+>8 *LSZ$-RK2XVB!D7]Y2O:\F8\+GM)'XJMITY2S/Z
MV/8[_^#OVIS!$ZGU(GP6R8-P$4E61\21V:LP5FYWUM+L&A36B"/P;BO.SR_S M>Q(.3E*C/M),/Z+!LG-CE#,(;Q9G/GWG;M:,6.S.V7O)!PS/F%'-[=BH6CO\
M>+++ZY!@0@+!J8A/8B.-ND*^=M9;.7"% L@1)7L5[;4EL7^+E6IQFO?L8<(? M&0WC)WE>(I=OG!6[X>XY/?M_LL7T/_&NWHN?8+3\;Q@PPN%[/AV@E= U#;>D M:^"HRI*M?
H7,,:GY'/C+F4Q[%R1>^TH9A[*AEL TK MC%NWWIW13^R\I415U]8YJO4P?%F2T,:AK/I"YQ/J_]T_=NG5[# M"=6VU<_K(#:M6>@-6;#60ZR<2_MUW8VMK^"5E$. R
M#2EI/^V"!=H>"KE>=!TOR%0 /*T*?CWX>-5 R-LTKUO+Y6J9(DSZ]4&I BQI[Z>52Y%9AM89P M,HWON R6@0MN3&OJ/+418U!FU>]6_4;K&kR2=%5;T&\7XI4L/J M-I^Y8X(2T_,H*NU58+=
<6DU) F.AWMH;PV5^^Y!VE0\AK8L&I?/*N8(%,$RCGX<&^>#F&YJB.*MD93X>QFXJ2 M[MV^\35%>ZXJG[&FXF0J?K'(J>DK%U.MR?T6O'*!?)EN9\%=2[SML^O$^4{(
M146F0*20PF+.H>E>V5&J)N>AQ:J%1;XJML"M M!*/CS74CD2F&5JZPW_R&0L5P!G]#_ +N+XP>(JL /(/DB]#O=_QG&WFJM|FY
M')R"G3]!^5364XD2&%@A,W!MI^_ 9#-DO:A8TT+Q*3_YR7RFI&*\T=0 8 M(N?UE7X'YCPG=Y,[&G2*(-WSK5BN%^A5);QGM:[<*H7N&GRS>FWB8H-;,WB5* MPW]XY?
-O\"1D?6-Y\+> S^?*;^L6Z7S+^IAU=<.\]4/+\;?9S($>+!O[#[?Q M!>8Y_R6)VN51(=]GKA+O6VZ\L_\<:ZE/G9/5)!TZ7VH?*5T 9UUZR.>H+#Z M%U#UU?6FXB 4SY-
;33OV7/S;A6;V'1%I1J53I:$S@A;EV"I=X]31%,--F2DR MGE95N-' AIE5TTFMV!JL" XLF[=U<^:!B9A?O"N&ZJ4C%(3\(#,L07C70[P& MIVI.O_:^F""ID)[$B5G#K YV?
6K6'GAWAH*V803U9.NSG.A4MM;I N6^%#:8) M_9)GN5!=BB(0%QOO[>=2$;MSJ!]->BS_HN3<.[6=#I(H4/NL|%7RC&CAXWA
M^]?]#MNM\XZ:G1M$5/UF&91,+5#W0RT2>';X^Z\P4-+>Z*]DOR[S07\+&=U;.M=G2ON7['I#HFG-9[ETY*[,VIS):0G/@1CZ;MK:T?'#5]:<%1,52L<0'K8NZG
M8Q]2[&35X:?QY7/S]ZY@SMCD,6S<,6#3SMF#$/8W\CR?:/F:I.#7F]:(R^'98 M4*4B1IBYE22XO4X1G118D(+QO+A9RM\^;VKN4!N.YP]ZC*PY*]
M$BY,1)7T>X0]E#]VIM^`_029:W6 ;SZA \+?'_]G"_8^!MXJ(H26=CV&"#Y(_Z^)@!<.09. M%QV5(%9-3VS9-5]V# @64X1T#@V(@;&'DT]+FY/'0(H9PT\7LA*Z2^Y VH'E
MY+H?R&. U^_O-; 4!'$=@C&@1!]!CP&&IP7D)ZE@ -!]!BX%EYP#$2UFE+4 MM$5]"XAH&'UMR2I(X>2]K&. ;"_REYIPM1,'[Z%N(@>?A3 (TE^1-
[Z,,A%1%!W@K?!T+'CMS1C#9MQ_EH'(MGPP.(?_MI_^,[?^VV;!CLS5)@M%)CV4F9G<7,+IB4GM&N4"5_I \5#EWZ7#A M% HA,5_?8G?I-
]\O3Y=0ZQ1N#1X1^S6T689RVT!T"XT=[8=] M\\1#.NV9>BO)!7$_XTS&[T?(PT;I8.';AX# _@_X7EP=Y5[0.09HRXZ*]Q^D M6)'W3>?NE) ;+VEPR^R/1$!?0C%5G>
<0HS;$%TH$)D3QBU_J2#[_0.3(/[> M!\KD(+' MP-^%DV>M'K^I24-"$9N;Y>T MT@.=%1E0/QD"1 2ZPK#QC\]>;XCU#2Y=>*N=V/KQOOL30F!.S.A[>ND7N'8O?C44G;O7
M B+V3AW%.H8=*H[%9">$BR]>N5E:0@S/D#A2LDJI4XS8O&]JU;TSEW 8^3?5 M=F63;%[\S4Z15Z"TA%-*O#C=F>4R6E0)EX/L]4CVPVG8K/+$4D9N?XQQH$U1
M;PKUG=OC_BF CB!#<6?2?-^[6>SS E'+F3TBY4((@>;2(">C1_!BD=:"R,& M@((NWVV#]@=2(Z:AHDUO5N\D/I9IA:>>S;B!=NQ(O[!2]PMT+'4D24N7_[W M@*E-
2[@<6&_Q[%TFX5)@A:,B.U:/34ND2&Y;@?6D=:, [.]BG9 MILHW ?7-3%<2;IWR|E-547%V7@^C*F;VKNX&OCR7E7<,G/E6[/WHO]A+ZH M 1:PWMP'66 #*?
N=.7W+M<'+>D2]FI\DNV^CD,] M D(;(IR@Z-T)G". Z0^]USE 9WKVEU]UM9_DN\1AX=*+=W^(A%H>H0]PGR5[M1AELX;=Y0Y*V[6R^7>NG.]5C^.WPZ_QE6Q4'"
G134"WT|<>]&>+#(N_BRS8 WKJK4-7) =5UP5\$BVF%#M M'+GY%:%CV_]&T#LLM#ASNOQ6<=*#S8YD+O@I?"Y4RWO5G8I/?AI;V?3YR\ MUR%,IC)!6]VQJ99@',
[$R2BF&P>_G'6I^,<62)4@9"$=Q(S\DWQ4S|<>7^F M =_1?.V8U-N$]>_3,QS9V/)=$<VOM)">X] AKJ_+\(^ZJ.FZ(*_FXIP?36 MA.?
NRTQ/P35I5AKY=2V@7*E)PD,@1Y_KLW$UM/>'BA<[K Y&6 B4^26K*? MQP.8(=RK35D'&6Y7//8/+@M8?;*8;1A)Z?1;9^B07C>*=404U0Q)>SG\<*8
MPB_"N28IW$$#EB25!,T[P>+511(OQ[>RB(-2O00-]GWM41I2(61RHX;#31GV MZ%"_S,5]KW2>(=%FA M:2-
<+!*W'*9_SY*BL/>0T131H+=#.'1/*@ <,!W!C'&CL$TU&!O5G&W.4;W6 MDB]#\#_L#Q2>CBH'508*&#MOX%PHS7./#BP3R'YO!Y?;!]OJ8V7M7!3E6_[F
M$WA6\GTA:"5M/!0*7D=-#OBRBYTZ[_/5%YWF$$QJOF>F=A+.#YAU$)L3R'>$ MYMZ=@\3X%R,N6?'/K?-YP4*RL2O=_: YT='*8"(MQB>S>N349T!X^1PJ.WTMR M+@W
/[5+#ZXY"S9^@+N"H8=]ZP?AQ0B&E/!S'I,&I=|<0#_#4%F=1XY79MZLM6'+CYQ9PX>P-BX&SR5B M\!+Z]J_3_^:,!.-L09Q;>><=W*9?60E1V[N-%_Y8OK$*C\|<_4_/F9@21-
* MVL=6Y^+0Q:!55$TU-YQ8OJ"?;~@OOO7#!?89Z.-@>^0,EKGI,GO&'^,/%B)%?6:0]1]D?80 <&3,PD?>':;L?H6(D:8K06,@-24 MCET]{<&5EU%?!O?
MH$2GJ49OD'^~4\Z!N%\=?$$B P6\2J:1&/N:*,Z[DE/ M#&@Q,5]&>(R<:84^T-\IKURD#9^"<6CQDR\0$7U'MOT" ZEDV99WI47K'YN$ M)'_G_LRFTN83BU#?5:0Z>&$E)?
8"V/1X3BP;@,11U$E:1=A12-#H=53C!LM1 MV:VZCA3KMUU=7Z/R(7;^-=*@I0M^_RA#*?E.GTWC9CG^JH=QVU2FI& PN% MD.F0"PPW;/[#O1P\.9@4U[G(7-)@RA?4]D?
LF?\-FVQSH(0%$7JZ):HZ["_M^UQQE.O-S#U$]ICCPQI;N46ZI4*6:XGPAZ^&2J140E' 4B@44[ST5,B=M#[RIP^L"VZ8.[M;//U(YZW_1IU.[$YBG-P'"*Y>SD)%A%-
DCM MH? VHQHJ4"VQCK*B+S1?:/07/9PK>KG_G6:B(^(H)?Q*$'(OGU06KR5[&O#> MS8&JOC%.?U+1R*=V].D'UW>T]_5,):+JH-V)G&TF>)<(?Y@0!KQX#/2KRQ0DRD;
(KTXZ]#?+ MI;V@YGR3WU->C4%>@7H2_+!Y6[UG3$*!MUT9;(C'0-*)V[%2Q-VF*K>;]6R/ ML^RYP7G&5ZAFZ%$#-
D=GQ]J,2C<*7)MK.YH_M=1+"TTWV)$>]/RA2_N")M.3 MO:OP=+"6*AR:@6,.XH<[OU5)XO)[R[Q*F7IS,/GUB.^(.MH7EKBGGM>&$/+? MXA:$]D7R"I?]WZ\3M98KB?
3=O6K)<#50/P>5)!T^C6.;_.,":$I M@V=2Z219=.F$?^_$N7ZC@&, MQI_;H%[OI6!KF*07@[QQE?6TGH,>3)-UL61]B% M.JT^5:?/ +IMK+1K):PZ?MJ2F/C?
WV.10EOS58AY:S)IJ39JXM^*Z66-_=MLE$_[XK"66R(B0YYDP.YL!V("EU[VW']?L,I3XN 8?^TIF<[J;<)85^MZ|PF??[8_]$]AE& C M1779KJ,5,-
"C)4%*B^ES/L&^6C!4FV_NC\!6&Y[!0)SL1K Y-J3V M4@0FX#I"Q;^S-LIG!E3CVRU]5*MI<'$_>[USP]XXS0U]$Q9@VQO3F=8?!YO MR#7$11Z-;=[SN1PS/!BYW)Z>
#PT*Y&O-"QRNL?$=1K8K;;M09YJX\:*L"UZ M8"2C=[U$;3I&,0',TGRX_.M0/4(DX"7_Y0"@P+N1%(XL(,1>Z,X!(N;\%F/ M^]"ZPC2C5Y4S4XB%@]C',CSK
!XP"0"IB<_^P$6W9 M?PRPMPF]7841S6$QF*;"TEF,NTUV'OCL$"|\&WLRYC;*QU 9R'$VSL6=KIA MR,2[.Y\9QQ#[*]O&V>&8Y/$KT]LQ&C5U:)/]>E5*=(@ @/V5
MR@"_#$;A@QXKR4AW4\Z1'B=')FN:V3G,+)&ZAMY!;NZ6@8B>!08B0^JOK,:6 MAD928*+$85BOBLJ#ZNIH5S9/?8VV!N8(KOM^,$40IC/6P1^^N,@AMQO&+>.H
MQ61BL7Z&;T?\CP4GC2;U^B8H)^PRG!ML+@ ,:V0.)|IF:3FXX:2B;1!WBS$#@ MW}]"'GV>.Z]7@V\]5=M!CDU5VAUMD?&^RHZ[S?3:$-BF-RLTG!(5-#1]Z M0!5@>5J|@-
D>M:J[.8FNG%^QYF 'G8+CS+2G[%S=IY6/2W801-MSZR)%6MKB+57U*$=E/3-;(\)6*M@4_B[BZJS>R5C898+ <8!QADU$_6*\]96- M]]9GK+U?X;-82I#\IWY5[V!7>L(8L$\C,
9O!-;IXCGC0&F-UV)9;H*MK9]_ MO$H/5CKY.Q>B1Y>PQ%%A6QC)N|N!>U)3 RMT19^X$HN;K.HUGPMVX56!"QO+ M8R"%Y_|+'S#ZWX[/1P:=6D+3;?;OP+<[!HV?
2/2YS+,SZUUM',%]%8|/+H'WZ4U5!?T !AES;3XVD+0!5\1/(. MT?L0E!5ZKR[[#COE"'LGC=|;VQT9'WYF5?@B2B8@=XBQOJW92ZDJI8:O;SCG M:ZM=
IX"&:7C<"^FRMQ%JL%@15G]8M /]1-L%+%B2>G,2_RU9X7&ZON2ES6_\ MCQR-K@XJ:>42MWILM&]UK-"Q/,ZBFIHRU4N[#78<'CQ-54#_P+6H2]'P=BTP MCU%$P!#T-
>)RME>Q&\]GMAF,Q)=)L8QGFT9*C?^U1VG_%R$.R/RCAS?_OX;[MT]7+'R=E]['VJQ)"?$B2""(IWJQ2H7D3D4TDFY30;NM(LI\[@E5&C3^.H!7N5GKV,2XO.ELFOQ#(E<^=
(ZI"%7I=?.&HAB2B?!D_R+IO2 M(3VG=^:"">8PK4W^^.-2QX>/+]4>6G+U8BE'1!D4<=@I#-(AL[Y%1)R*4]PZ MY5X>)\I?BV:B8[O%E/[YHZAQMHE@$=OI-
P(8VSSMPAF3C3;U =H_KLQC$AGH% M5V9T(6=J^1RZ7+:-7Q\#]."R+1=50D(K#I*XR*WTYD12P/&M%E[%05Y=UG& M+@SU#+_K4W?WX*BXZ9+9$2 F*-
M],>47"Q*@?!K ,HJ&O5BUT0T26%0CR] MFP,\ZJS:EJ,QA 7GT:$WA &UBOSSH"C)]?LCV9#(&^W/*FI!1^1OL?ZA?H3Z M<#9,W/F>-LE]DDK)-Q76^1FD
LN/*XJR/0:2BY)0^CR+V,^;POFW)+D M"'_6\>>J*U4!/ +)U>6>V>'%UZ/=V3-GWPKE MN%YRA)96]7B?$E=7/5L7"SI{EG)56N4FS58F'TW+Z!M^K$H,?>4M
M@\|_==OUH=F@F">_E7 T^Y09;8/EU3+X=6)3#4XZCW]@-T=ON=530>NU=QCG M7"\4DZ2,!1/*H7T%-
+,>DH:Y_0XB.|K%Q5E8!2/D[*YN9/#M7;W_A51QVD]$,NIB17NRV-8P8:F.XP]5T -W0.]# M3/5:>>6[%^B]H0]M$EC/](H51>VE3S=7'@>-7/ZW#?R?@+1*S?O%ZRTC1276
MZT^;;?+SZ@E/TVX(&(?U2+=!6@M"5G:WDAVHI\DN*M&>><*>W]F ,A^Z;_*(^ M&D@IOJ_V95,] 2"X5E^!)5%HXOHWEE9(L0GY%Q[GJ'4DV66LU:N--MMHZ!)R
M._Y228%L8T=

*$$.7N+:E;DQWYZSCCECI'#!\ MM'4ROS5DY:BKWUDQGB8V<E5,? QF/_@:,:SXN7CI71*] M*]&X0N\A2(${(7 0?3 BG#\;,:!/[*YQ(7"6Z*.BLTU"E5$>^,*\"G^W P_I`\M15;W3R-(%O9"B>F3P5VE^=@;9C6HQ1G!+?%K-KLMD.2X?M?4PW4!ZF4Q+F0; MN.G" I+%DIB">(3=HK;J&WXYI+T<6<1IQS+8<>;?^1]9E^N_4U.DI;*6QZJ<1 MY)M$=_(9K-JJ%)BHXG8UEX=L(A89A>-C9Q47H^IM^N&+X\UGSRDJ1KK1C9F$ M^@D,&9OB'PY*;9EQV6D+KS^&W X*K<@DX%[Z,S?73R>2^CY V"B7@9T^I/,.$+ M1,=#-%+)*.EJ3\)$4]'N %7 RZMBO\6%AAS^\Z/*+<|/^2I BE&81U:@<'YE+5IQ@-R^+GPX7E MJ?1W7Q<4QS\@N=$[S]T&1]=#XT:5VCK,N]O6TX8=[^_=JF , MX2J:6*7NV4<&[*URRQ%#L9&@:Y(RLT(A; L@6YI-,0YF>DJ=C-*WJX.:|N<' M-E/PK/-]"Z>A"\R)!]%+:|VC3\@,@5O>"?=[O)+OOC_:9)#ENN"KK0H@T#*;*

M+M^5.KM#$[!,@R3ANC%P30ZN:NC/M-<7$OI2XUSB99AY M2*]U"6AJR(JEH'H,.JJ)7-50I@*ET#YK&R/1'O

M\WPWS_74_,2@HLG7D=CCPC3[OFO6_B&1LZ6.B6IC_W\R$^Q_;J9^M_!\ZRV\;IB0C$N]&VP>"IY19N2A*517%[?@E:DI[PN]6ND&X?/*:,EE79N^_M$[G#G*P"

9OA43AWW@Z8> ME5>E+:C$H%$YC/6(5W!(XK.7XZ6*2CV:OMYIW#$&C['HVI%3)_O[>.]T75$ MGE5YW5>[V|B" OV&=SNB$:?>_`9)*,O(*CU5W]L';.I,SR^R1I-LK7%4H'V<.M?&MDH3&^O5/Q5W!TT?1O5EE>-?_R[AWRQ+R:Z/A^NII.W-&K?O5M;5QF$ MR8T.8;-_CP|<%THD]F) E^%JOT\1MS%]N,!$_2RLK4G'NYY;S[\$A-ZZ*=-/M#%C!:,P8"PIE=L O;-?>![Q8DA>W?&&HJ(MA2@'@]* 6)&<TJK>=>@#1&[+LBL)]'F=Z:.Y M&@>R$B[*3+2V8

&59IVKKD&*3&N:&+9W>=OY*YQNU'JH3=LK M%7*_CE;1^%YXZYS./QTXOR+V.C4+S4FW(?15#*X+4]_>S<.B'9\,;VYIQP\X M434[|R6LW+53U4O8#>[T' -=.

<@(G[M22E+XYE!N,@U7Z>"H2?M.M#?&,U6L M$5Q[$9=]:O2MO@/BZ=AZ^R>C!\?9C*T(#]NGY^6B?M8OQB;*]|RGPC"5V]4 MXV=:,"K'0@Q*C=?

(86F7(7,+:OKJF0GCPD>*FAL!X0DZ\&,W2[E[$1]O#W'4X M@T!-5%[9<&2" V&J-"#QJ.JB2TKU31,,..?R'=6;2P]Y$77.C77 <4#$$<3@ M-

%_1V'9-(+3AN_E:R(85CB4?"ZL2KQET=8$R%5QSQLC(:2Q]9,J7!OC;'7@ M,B/WZ'!T?W#*U5DIP"7O ^N>1K]O[S.8GW0Z$\]=8FG:SP,_4SXAZ W>A!6

M*+B:IA,23F;$RT0I"BB*?%MKH1L4D1)1T1X5L4O7UO>L,B_,UF11/5&TYG24 M'N=KP%M]. &37A++#8W8,XK((QX<2U(;$N6ICM61UI?.5M"''7EU_-

FO7>IMK>A_KKQSWGQ@$^V^&^DP!G&6&A!%RF.@G\ 0]W$K4?+/;GRI:@W-&21EC]O>7$+DGKHI)'&K?<#4^NDQK&0RBX-1+NFSK&A6E:2>5 MNT=OVDS

,PIUQ\H++IPP,,ADG/A91+!%<\SK\B'!-,%=EW+K+M7+OE#YYV';1/#U)-]6_-*O)91--96MW0UQ MCC?C0VY/#!A5]?

>F<$(KWV*ZRJ0DI*ABST/!U]..=^*9VP[JIE?C!'ZC$-M MA7AKV(>.$U?,'P.H,2X1?^0;$[D$9=PTH&% M9M/$(1'0(9JAS$^<1:.WXJ*V>&V6'S;_HBX!?

(?>G;R&WYGJC(>]=4.2.![$U MU3U6H4:,OM@KI*GR**/[VZ'K$L9@$98I]]BKG]/.MAFK>2=BFV^8)(T5>LTG*I5G.9C_O5U>X>1T<&>HHM!(

M\G"T.=G(V]2=N-R&/B$R=M HFKN%[&Q]U<1AE$Q#2*_9B'M3%&A2LJY[8&HO\ \M5T MM$R:W_&T-8E_M^4N/!4%2U6@6#ZN?MUUTCT8V=5!9M<**%PG)Q.5F\!9LR2X8?

M>):.E^@3C##$LB5LB[BWXO5J=[FS=TZ'\1D)V:7/NKGSE4(LSD7D>PN)(!F(V MGA$3BAR,WEO-,I75#@OS:,0.\/QE/I.MM0OQW9]6@*WL$[B9?

MP3\!X_1T0[T1&8Q2F@=RBB*NO-Z5T)H[)I\4,,]=0E0P%.K];FQ B$96BA0@-M"UV*G/^B10$6O7$,_T;I/*=)1K97X%=.6;A<*<#Y20(@%X!FD %=ZNC/V3=P'

M2#>@2%*I5,8]K/6.:+O0B_QE/0[&:9I^UTE)X0ZT0N3 8_H+O155]%"[Y M0-V+EP*\3A'!1-XV68PJC-&>N<(X3CW4ZC[T3F]+T)(G\47O $.EF!=[""U"!M@VU!

(6N8>U5BFT4U>]6,12W%DVEM(WVKG*K=DSU'C>VD^IFH=U%&^2%D6CA(MAVA9!)=XN/?JC[O$V]I#Z8;('E=7W]@G6WQM=AYQ,?.],MXQ0BL^H$@*P!)_

M0#*5B2I>O&V"&&.#DM$V.D'"2=!N+,^F'3RF %/Q6U%7Z1[RI2V1.8N@_A1!- M"M]@'E;"M^7AG.#K5:Q MXVIT'/.1JI*<8.CF/@.OEGQF4W

M\Z*\8>'2[5E:SI*KZM*UKN]KC!(*3)ULC#Z&)7,Q 6KP4L+X/"KH#:I$%#-L M:E_]1S\[. ^>7 +?]/TK3?2"H$L(&V(;7@$KFHC;'NCVX. E M:)>:K2OS50R^_#KW12@L.|

(D^[T>>]#G=[^7S(%W_@OO1UIM=(-34\V>3$IM M51<,22!_;=N/F>EP^NHK[6Z18VK\/T;F]Q(4 #VRS4=O;JJABH9F">%QA MY;YVFU:S%SP$A|*&;AEW12@=

[X@:T'3<1V'X]W[18W<33A.4$.#G:)G$6 MEF3MQAM'&(?5Z6)F*F6Y)*SR_VM:/KQHMD"X,_3&LH;N3YG3N;1[\Z#?OH8J MFGY3^=Z^P-;.6_K-?-H8-=XU5Z.*"F?5:1A!

(.UQ[_S'WWOE52>I.YR9M# 7XUKUX5E T9V MX9^#Y1;^"@A-W>__Q,H%6""XF6KXRK7Z].XA;YE:)&:.BN_|@YMM"/'(MM?0OT56S8EQ4C7^D9/-5S+++ZE#P]%QXR;$

-54+B&A)>]J.H-LLYQ-EQRXFC MO#QRZZ6W5Z/G Cl;_$<3M7G,6X^@I#+6>?HRV'"+IL&ECR^MH$QGSS"JL9D=*27U3_W6UU1/_VHA4Q=1L<5G

MLV:CAH:IY9Z3@:8I0S4_?^,\8NBC:KQT@G(:_/">BSA:*FTD:0YW!I#Z=%U#$@&70:'3R?9;&M*_]IK/^;YN:J.CK,M2;SB M),TY5?+2<;A"-E2K,>E:V<6CR

MO'Z@!W+'*+B2.*.VGV@6_<2_1EZC1XW0* M^$L!ADWEJWR,TQ&JIRF;+2):3@7P!/,&2RMP.D$3IERP4O) Z]++(4?&R2;'1=;?WJX4&VP3+ V_(IH:-2QN* M!J

MH3V.61)E3(G2]KWOM-\.6<[&8(V"&G^:?R/W:?HAM%AT.X^1TV-K":MR*?ISS MKI3YX2I0C**\: ^GBQ$**W91$.!2$9#N@34NQA?PC8Z/>LF8/&G5$\[MMD;M6 MEK'F-(\-

"E5'R7R)DY.GR:\;Q$;.,, "F0GO$'B2LM0J"'@A6OC5> M6P'R@0]O#/[3^&7@[N0X*3V^DPOSU6/+G]G+\Z3[!E)RNT5RK^^PS.^H.]F MY&47*V:?UH+>

(BN:3L9%GCV.:Of**MDH-KH/&7]VEO_HM^(>HGR'K(4Z M\(A167"K(-.V'4YRAT*547Y*K>J+'^Q,-S^(CM0MER7,>&*EB|-\?T.F?G; M=R&Q0Z"L?

V'I/=LB/6R54T'(27109.M;S.3L_> GG(;H^8N., ^W$-WS^EP> MZ#(^ / UCV[_Y89U)M.AF:-C/*VR"9\\XVX61K5^4P %E,K;/?OKV9_&9>M8> MO=5V-JB'?&WD5==UU-ZN?

6;T, MN+*.8)XOX<$(M%][6NL^;$*]K-MW'CLI1UB"B M_ST)6_6OBJ,8PDR44<5WI='%-.:K%$ZJN-(MONV_;)C*S\ 9Q?W]!^-^R7^1HQ%:U5.=)T.6_:?"VI

MJ[^/*NZJ.*N]PP=C&FN[5P9?,^ZE3HTC[5M#N7F'I404|"|^*>]L"B;-32Q^ MW\&(O5[_=P;0EP[I> Q'[$O+T#=6STP481)#I?4W$_3.B.P2K^PBE8-17S-

M>ON\G^:O8B[(JV_^DI?T,)OVU@LDQGDO-Z@:Z,I?]+[#6/S?OU5/L^N_?Z[-M>VLEK?=[Q!=X-5?+$B;J6(S8)879"W1*]BVI=4.UAN9%L!^VHA4Q=1L<5G

M@SC6^7_8]_Z_:Q!!A"<^)AG/B06%8HB^I7 8A'@&50;3VO-]'GN;NFX<2L4] MHJT(ZL2W;;-OL807O)@QG6_JXB'>)&5#]O*-^=(-OB^0"\G:\S6O52?R_?C M6HB;YGZ9*

[T_]5/I49B,(&5>XL)"%)B1Y(41$?HAOM9@D&J;EV)?*/K-W>WU M2]/E1'8!P^[?3>.,#[GLTF_FX6NQA-3&Q@"SX5'4FR:)K@$9Z"YB7=W8{UI MAH]I"Y

!$Y_QX7TJ=TWWUA9/T[!XA4O_^%YY6FI\[0_-R'N6J7 M2,47>)4V:1KL'7BKR>BV\W`'^:J\@=%:9B?+3KK>@ENTSXIX[!C

MM^S+!&T(2_5]=.T.'!LJQ\$4B;T=%ZLJQ.M{'Z" ,.T<!%%E:W@!32BJ+ M^,B?^,-@18<;L(7*I&G6,,:\!?073<Q^QHV9_&>M8> MO=5V-JB'?&WD5==UU-ZN?

M+_)5>&62_B1>3\GEZ9V=BKGR\:+":.K2?B!B#:,P$(A:\[Z-8^?XO<&?$5A8R M/C"5G'5!1++!,>6"_1-?H+%?HCO0'.U=QT72=-7.33.YJLM\%O%'>>'!P\9D7_M?

E_^HWLO)+5=RE) 2T=/;^26_97#QA1=YL$WX"JZ@9VI>:%.L*()50^W4S." M0"U/@?5NXSEU)5C:;>*MH:T63BO5K-,O)WQ2D8,P@C0=_8!$=-#U2\<<&P=.

MK.W+EW&_Z/R=-H-)QKYZENX.V@F'?U"E6Y-GY,C]4'>DY>:<)53[OEK% MA@S*<4)ZN@6W=\$_?I N_-.6^._P%^:EUBK6#A_=D!9&K:-JK0W;>K9N&'- M5Y_0

K$V0#KF(!F7C;6D !US5W/2.5-WW^M,E>A:F/RH0;P/BUOH5>IZ[S3P M=:?E\V ('T8F#65[BC3?A__WE>&Z%.D/1'R$9 Z1E@0E]0YN_N$F">?X,=WJ M107K_"DQX,

[3D4<]H%QKI/U&^@/.;I;DAT.NX9 &_Q^4'%."(?A5T,$,! M]]\T%V\!04N]D?]ZJO?Z.N5BHQ50W"W6@2+_U-\^_4GBNIUYWT) M!"LE;7&'0S+/T4'2B4C<(K0,/

O;'^V>!0!N[PY*0EV(<A)=8.WZ)?A5\%,9>M?%AD\'DH!@)X55/ST%_UOKV!Z^9RF", &.8[?]B?) M4OYXDDBR0Z|#K S5Z&\'/?>?O65_$SMA*QGVZO+VLZ7Z@J^:|[.++I=@Y@Z'3-

K-MEI*&'Q4KEGW""?N(=GMS><$+FMH3^:NCV!|\Y6YNC UJ+!]`MJ'H$(%K].E|@&$"O$V?DH!'1BP($V%& !4.")?-"NC4^MGU@(G3A"WE8&43,

MQQMW^;'@@2&W7_N+D6K5<-Z_!:CI"XH)OU"5!?_5E>7_]DB?@8@Y#H0"3L8<-M5])2#J4+R=U]SV7K(Z@#B0N WYE$HQ^?

M04;#%W/58GB^MM:)KZ(@BUT,.WM3L>QS'0'J.3>&,#]FO.5$!."B5O0&]V:C-MKS0K7@?CZY%|(]9[%;8PYP]BR"%2G:CP?]A);B/?R3 <7&]I'9>$T)NOR0=G

MJE%EI5C_=)A2Y)9C)C #3/H2Y_5[!U+'ZSKNQ=+[#R3$9@UD)Q<[KV@R4:TQ&7_M.U$E2=02_5LN)70U/(7G_+Q-IL@ MD:W9&9.Z_E"

S17E$1@%]#)&Z]+"ET$TCK.20\(06D)W1#.$B6_[#@UCI N5 M_]I QY^O,.WT*F*QT%)GN,]UWX%ZM3XA$^=CECI8]SL3\0=A8](-'K-)LY. M2;Z.!QW&'ZM>W'V]NCI=2)!::

[DU^NH6?<>G44ETQ2P-$+*UPQ?'^UZ-*CI*-M^R>A-=.#G=-ZBO61JUK+'4.9;CFS/P%KA)C%%XN+10ME0R"G]?'FVY?$A-*7/GI=ZIY14=@0?E-)?LYT

MJ5G+/&7;6DND?:C#UR7^P,F>OQ$R[[)]!M6E>R-7C@X)O;C03ET.A&++UL!^S MX_7)]7'6/P09V)]8P!$7]!U M<-M*W*".QO^=!3&B-)I?

3YAJT>5Q:HG>"^=Q"3^:"7@I&N.1R!!=NBU*TB;\ M=3%;EM4[DZCU89J(.1X^6FGV3+3JZA,6T:\T]?IDIF2I9>MU+RGZPI*_J^4T M3?

4.;F^_ZY@.9!4L9N0Z+'^C]XX6/5X[_>BY(FKFN+1>5.#HD6I8G[Z+57_(MQ?_\;U!V(!5Y^]UD(Y]%&]U1:=X]\&[.LR;W6K84(Z_4YA..?O?/6VHO0^:0 M Z-3+N_(.[:'

LP]6^N&Y/-NV_L0OD;2C6TW'59]LF3U9C52IH(@$B=L=Z!>C MVQ@B/6KVE3\QK*W2IZN@XH4?]3TM/$#E^5+G], R369EXY?>8V5Q<4GBDOC<1GBJP_*$!L?>N^X1MB1A>'2U#)

NP7U_9=!:?-DH3>NC]7 M[:[A(-_\K0ZQFA#<=E?"WRFHXFP:DZ$Z(X31%>;(:>W$H*:QQ&?,GG)&:M[M"D%+(ZQ!\N->]7F^#,OF^SQ/M6'!2Q8?(=F_)5@O7$!R?#] Y0R:.

<>]<>[, M-9W!)&R:P6A-DR'XP(5;MA[_\H0E,6T0[GWY0;$"9S)H@^&$>@FTY5ZZ_B\. MSOK.P0$&3P#!#W\ >>,,)\@9=Z%L!,1 M<%2[=TM<<[9,S=#CTDK-

RT0\2PH+M\>_0O<6!C@)>N-@>W,*<&UZHT4X MH5.L8"N>1D;&\/"7F^+>?GC]T$?B,,/C]>][ZL^^B]1'/^N(t$@3PU(<V& MKL ?@!G@-BJT&==?

39UH=2[;E@[/&%2TK*98:&BT8Y)3CU^U0$YK20P^V!-= MJCX*<(GO#-/[Z-%&$HY^K-7ILC;UL=94TXT%?+]W;@8XG(O=G,516Q'O8]>-MPNJ5.?M@/BXUIB3)Y(U?

7&P@%>]_< M2=[&: IP%8D1QI%^4 9@]2=PA8X6CE'GA9KA?9C2+;1GKH5&=,TR9X9XRNM^ MSX#,][!],P=]+'^$@2F/N^:!/].T/\P%"OQ"W3_A)HCBQ*"Q>.1;SS:5PZN?NM

M!'R0H^3W<[AY'6NWG MD-MH9:.>+(;R>/ON;(;C9P _8UCQM+!Q%T_A>:]VC!F8GW?WTH++&N1%SXD M2?1+=W<7 R91OM&2EA"

[Y1JI5L_%+SU%RN8_,7=5#SMC.F+!9&'\,+'V!>Y/-MAG&2P[8HLPM_S.2RP4F\MG/!G;CD$0+,.**6-S900.=X M. "3L@UJ3>G_T5$&TG>@_OL_RAH)TO9L."G?

D!KM,/H3&,C;S^AZ(*7DQ;HE MA"*4GF.0]Y!C %41 Q /)ML8TL3#?`]I Z/H*4#B^U<;Q2*7QQP)QK5(GE"N M-4),OB[K]L%E<'C

M1QF;D16NHO7)1Q;1$HZM\]2Z>KO8O0<TEKKO)>7G6#INZ"0N\5>/&*5I\ *?99D))Y/ "FO-7 M@'[Q(G$6F:T8$Z?%K#7P#*4+B3K]G9!=N&N=;P$,6#!.WW-

B&/%[4 M.:!TA1U0W8G=]RQ9&QNZB<.;H=+XTT>J?I5*PTSI8BC.7YK'@1X!PKL58+D;F M?OO3$&,I=DN? 9B[ECHROC9M(/>W;=*//5S;F#R(_(1-=_*+72_8\=\M!'TB:

M6+&P%HZ*D<]FJQY[A<(X,ZAY'H:NW5=G8/#'61'X5QN;H620.#5N M#G,*/^(J2;<38V8?346+/G5JY.M+'C]IW7/Y>;]T@X/%X\KW!YJR@+$"5I<+

M2N;JB^DTLM0R^63'!>"79S]YT4V5 D##F'+(@=+4N'JBBM:RZM9I@T2_SH&/ MX(VFK^RQM9&6"_061U M2#*F;:R%<4A1P=?

^__9MM]FJZ1PM0Z]KK=/Y1C*T."G6RJ%P$%X8.K*57Y)NG M,6_0&*696CU(QQOA1?6NG3^K(}C;?!^W15.S?*7WYE=WX0';ESR1I_>%6L4 M1# RO12.

H2&NVQP!^(C940SYYN%A=++#RV.GB=4M7YS^;G=@5_N#Y67ALKMY M7YJ/]EMM#]_(1PB@SN_^IU>X_4>L28R064/T^H6[ZD1VD8&Q%MZ)-H\G'E:@

MBGB"%M3C=.4D[6F4]WA]>B*>%6WIN]?6AH),0.T*U?QA>=:IB,%@4JM5LL%I;"O;T%AE"BI$!$]BK 8 J;FOQ%W,8GW0Z*$ M&7%>,&$,9F5=>

[URN33FL$:/=9UZ5>96Q@%L0XP+S\=3TA]^SJ ME20CZL!5V %L.-D'5;D+C13FND[09=8?:MO>CFL>3+0U %9-Q>Q3%8VIVP%2<_^$6O1^2?E+TFEUE5;" M/VC'?*)?

W7>8NZNKHL#03)Y?&)<:D*!|?#1.7EH_]O.-Z]%O%6Y.D^H3G6F& MZ/;MJ^3C12A Q*(/*I3S.CUB@W7NZO)(X];=P>,R:N';^.*W+CFY!!.PD\&

MJ9%N|\XEM$NJQX$=.8W&VJP.S=6DR:11KA;HF'7U K?_%=]KN5#7$<_D^6;6 M_?8T6JU) \00B35K;;/ULYX]Q_W?'T)2W+"3)PCE<65^A,"8) /=>JV9=/7[-M;T[;):C4/_?

0BZV1L*-6K;W0]8Z7<$5X#8D$X*>Z.C&CP$(,6>DP^_]BO0W]M(4KRW 4L6%!:,S'* 5%<^<L$XXC5>,1 S+:.W"P=@2EIS''<_$PQ_4L+9CO?\7Z/(FS

Y3+U(ZE1H*93J]6PL6\")6VKYQT@K!BQ!$SK.;_ M#/W]". 0U?:Z5VM^95T^H^ER=OA-CNUOO?HPGPE2<&)}Z;;824*?WP^NB0#NM MRI&SA0C)(;<=+]B\;G0U[1Y6:ZK.R

?*9UE#2 %YL'E=4G_<+;)CE6QQ8'"%> MS<=I!=UP?YWQ"=EGWE,XH-?-(,-I?,IN,$+63ED:V'^25CA.QC=6NG>//= M#A^4QWM-G0QI^-F!?Y@;Z%DA5@3CWW]IM&?*O=

<"5:CL\L FCT$8R%2P5.D$ M;-JS^M:U"<%-QMKMK-QX3]KB/1GM>QPB-26H[#G28[;.GY_>L_)WJ[%01 M'6J, "WG4!L0HJ.L-8 -';H\Z3WC0/.S>9YT

[WH!^5XV+V351;4PRVGO.0U=Q M+I%>CI(<3QKZD?-'_4K+$(QGWOZ(T[3]BQ:=BZ$FK<*7[-M8[\TF(W47HOO2!*NV$GQ<|?A+43?AZATV.'_97PK+;?A2'T\)$"]F5-]=.KA

MR$Z)U2R=)L\>7:-X%ZZ>G6<#P@'G(=@0RW$KA #B.T=%+>M"HKGFGQT1VY$M M19G%)V&;M)T\7MT/?F]ZB.^-1YQ41 !$/I+(PA=D4$/H#ULB$LLNI4EZW,<:

M=]%,7O6(L3K \G_/$Q1]15]WXU!F M9]'#"),>^D/:RN.8G]TL7"2@F=0Z :\V(A=F1NO)GY*##P6_7//?JKSF'C!M M]E(I_K_VHQIN3858#MZ/[.]9U!MHTC+\L?

F/$OT!>)WW^O>WKR?3[CW]XT M,=:X$3)[DRXKT@[Y\]/RX&GISYJ_ YP]H&9?6#_8EG?(A@B#I[).7(R1BAR$ M$LJE,8CU+EA;W=_/9+#[[VM<^-

VQQILOJC;YD'%R2NW!D,9;&F*&HW9!47/X MFT\O/]7%.==;ZG9=GYG3RH5[.(U4L_5/Y-N0HQV0.]GT)>0?*^/,!EPVW3D_^)3GVB

'/]DPUI_\)87U6NU<:,,3=X/CI'ZP4U>F:WWRC>2'U(Z M;M7=0*_*I+*P4AI%'C=RGD'P7XUW+9VG4[8O03Y=*]_]CO&!!K-;$CR/U0QZK ML!8T_FX#AT)YM*P1;FZH?

S;7&X3(;&-G2N]>.ELSQRXCUY++>6W$]O;LS%($ M^_)NML=S'7;<1XS|_%C:2^)PQT>XL8K/2>24KQ)S^]&X7E-XPM3E/FW'LF\Z MAHX*O*7'?MY8FL@>7+W7-5*C+

("",)3FIL/UR2OE!:4!_) MR:"W!CC|V2W^_-GFL-Z]GW4=Z&^)D:\]^.X2%[2BLEPN@'@FSYTF>6AYCPP M<(.J,%,%VMAP')3.1M+?SIC*.O$9H^M6_=\A1@);P8^,+5P?

H(O*^/I^>6.A:.|M4(I&+0 ,F(MV6'^7=T\6:6@&*T%^27@LKW,*<./"I2\]M\V)"RC@7AQC)?'I M.R)%PVWN9C*0FK4^EW0/AO4@?

SPZ'OD(5QY=UHI^:NKNDRMGW'CW!+S9I6Q(MJMPQSP1DL;4U=TIWXKP5^KB%7]O)]D(SL7JL2<6=H^]B"F;) MBTWMQ[77HN_85G;N4P]+EI$D0HX"""4"5D5#I+

[FZ@;GL5JKT%+\1 C/N;((MK0D(1E/$<^LX/=PBI C//>&R-+3/;810+^KR^'4AA=NPG@++D#8,2E;_65K]0 M9L'31(7L?)\]4ZQK?11 W.FN?FYH5G"4A$_0I%*?^[%,I'6FB:I-

W@3:!GJM M7>7<>3WBE4,OAT'BG&*C2(L+ZLR-GE/T.S-HX>\]^9?K'3D0\6$U W-%SX(0 MWLLE#?VD7(3K(^'CZ9D\,X$08&7:=IL$[@0++;XT)?.)]%Y;L'+_*=)\K&1^8

MJf%$=3;NA-8DM5Y.]!@3+3U_H^WF+:X,]%=&[XM+(G/<_GG)AGH MO:[26C]5N>2V=?/+)I)L9SUQ6^^V'<5E9!'9P(N-(""*(/]*.",GL60C7(J9] M4,*F=:

<(+F!;BZU)]MRVU8SKA^#OZOGBW!'S6U9$9-'K4*(8T,+Y5SZB.&:MF]ZZR8:#]..+,I@3=5"QKN"@&;..+I0#6N^-K^3@M;#=$>DT%+%F!,JKK[T-I*+U3

MT>5X6EX5P>ML2'LU(Q/57Z]XS];G1,D1>3,G?H7,\L:/SZ>@>J!:.^)KMY7>[S8TM7<7FIK9$/=Z.'[FHSK30VEF M>AWCFRNIP,E&9\-L F;KXME'9&YK*7WK:FXF-

!2R+5@.3O1*;=86F#]V,HCM M2&)+;*0KO7&)45U7CKXB_;KG/^!*P4AI%'C=RGD'P7XUW+9VG4[8O03Y=*]_]CO&!!K-;$CR/U0QZK ML!8T_FX#AT)YM*P1;FZH?

M089SN2IQ%9BM57AGL[>CDEK[#4=8Q<-%XW_*3[QMM_Y8?]J4+,;N:MC_T5I MLJE,X&N09S0!^>LN\O%!QK/7;\$+-^=E#.?+0*_P*?@CZK,>C[8&Y7Y

MQ5X0F#L@[@1U[&("FBJ$'#FH-+FF>&/$LH/D*U57_3==Q\,9MV\+]-<[307$FX%QF1WT(*G/MW M%2A$K:,Q77TF]52[:'S_#[7EF

JOO/RV55E8JRJ,9HYQ#K/NX51R3;?]@3+3U_H^WF+:X,]%=&[XM+(G/<_GG)AGH MO:[26C]5N>2V=?/+)I)L9SUQ6^^V'<5E9!'9P(N-(""*(/]*.", GL60C7(J9] M4,*F=:

=8)3Z_Y$AVZ.&BWU.:ZN.&2F"GD$:;U^P;Z%fY[M>ON8KLNU\(1#RX<8T A+7)#!:O?B5LS1&!QS]_ZLMWM:1#5KJ6 BB0?E(-]MQOJ>

([3BU<&^W.%CT]TO(56^VLH;=6[G.P4Q%&;E+]P&-EZ=2MM2R^N;$,@ M89'D@L&>](P9KY:CK*2L5Q+M]8IW?LP3Q \|,,DK]_5D5BWXB,\X*TV;HFC3 M))S!A2.4[%?

5CZSU=PEZ2?9'-Z1(K#MDIGLOP'>]6@_63K$%HW4@-/ \5$KJI=ZN/IP^&)WJKW^:\U() MJQ[_^<3M3\O$M-ODHJ]3H#UKZSWAD%#Y$!BI+?PF--]XFRSWQD4CMTGU

MK4*L[EYP*U]QW,6_=6>[8+O1C+!;H;N7@,SL1=]VM#*1AY")W5(NS:[).X8 M[\Y1-MK1UEN7# 8D?9JO"[5J+ISN6FY X2J7>U"Q1 V_?OC.?$3SV(.P$_5W M32]OU&P4>

(2OT/88*"P-12!!S.X-J*F %?+M,Y1_1BR&U$=3)F/(R@=250F MR;8WSC1=%0$^$1_Q\DF.X2_)*>HH*RT=X]#2#Y\]E6?J&'R7RMVJR,6*.EQ\ M'C<%#18_#3QYME'@:

6V_R+;! IE>'(O^XBJ?Q0W?O2.5:_?]G /\!PFH MAT.K%[.\]&^ !<:]9;<66!"HXQ&-9XY4?*IB*T*U-WGA![\=2"LD!<@#6+8&5)#.#SMG|U4CA^0C(,#]3OD0

MZ<3IEL5GMZK/4MH[:V_,**6,MW5/)\Y L6%W"CL7.% (_)\.:9^3&)G'5%?.M7Y=CI96D*3!(V?!&]J,G"-4>'JLFV8)#?YV\!##+G0G8NA_JZ91N?&6+_9V\ M]>9-

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

*U[9SR_]]HP3`JONW__WJB*WNVP>K=6I(YD+$+\EP2N8J-Z"7'=& M=:9F<-??RZ&2*E-VWW9QM<:'?S"MG"Z>,14P=^/6E]L;O^1&Y556$RDWX#_MA$Q%;[EW1N\6O6-=A9*%51Z;R8T[FV_JG\X2_/KU$B>GRC*8"7SNC$/YR5PM M=14U?CB3*G(TBQ=[K=1KOM^%WJHD6')\BU@,W^$G>\/=&,$&2?M@@Z'5M95@ MQ6SRM?8Q7G8KM6L-?9Q$!7-2X[1BN9[4118[5%F];]H+5 S5@.!=MF2,*Y,0 M!0$?5G&KH]|*^&16>"!%#V[X0]VD92CU[@Q CLX)/QT1O+%T.,M\)[_!{^'D MV/BJ[YV(,;368%+(/O>+L4V3[4AYLFK'3FNH>U1.Y_<4B1MF*F/BZ)B;NFAM[4V@ZNUH05W18*BE&LN_?);LGAY+'&?.;2OF'YRRN5$&LN_D:@\!SY$/03?F M-=3B^Q=E$29C^]T8CFT3P=40_MG22*'/TV1UW/0HL!AHJ[RVMKJ!84QPZ*L=7G1H;T,#&3%\ /9#P>**L?P^1?<`M[*_3S"4'^T=,;I_1+;YJWUGNV9:@^]SP;&YB]"K\ )6#_ 1K$F7'4>98N!2X M'E%GB'TYWL4^X$Y^>7OJ9M2S@Y<_#9ZW9BO5K=KL1+G+O;D/;AP.1X(3<-Y M3FV'&TQZG]*"_N@#WN^BQ?6S?)RFUU8^WNTI85 V<=FF=/+M2)^GWN8/M7O1MA,UO:,CA1:,DOE4T~OO>2D:&5D*1F)?[9'#1&+5>"TSV&V&GOUCNV7\+),8/ M& #X%:(!D]YC;HOHF &O(^?-Y=\6*>+T!\'5F+)4VA###S.BQ>\U+IP!SF.K&5,);/0-PE$/2O8I_H'6 M.' L9B9D&+,BQ0O)6:D-^E$-1QW06Y /P2"ZEB-=&.X)N?T(@F\?IU15EG>OU/O1RR M_@3-^QI2%8.:)VV9#.(U!|A2@_LDUW)N*SW M31WU$S*=_AYZ!A+2N>O;?N;DG*==ZN@)FO M[OE A1 OTB.S|E%NZ8RTAKJKO7@DY7HPPGV,TEK;CKQ79(1%CVXV?99OK\>Q M"X=8W?2(;\VEW?O"6M(V,3L>VL'$STV:/I 7D^KO;A*-JV?O[@-?L)S[/O,GEZZ:?;K4#0]U4;/,",\9^#NZ]1K7V7-TW){SH\L.^A3;*C.M>1]!-%6^KG^;:-8JR'E9VU2 M(B9:UKQ99]=8'N$;SCE4]PVGT7LA'$5P+>HQ(CAT[3&|=>PUV\I.D-]^:3V0M:/P$W4B0FJWW5ZZCV+GKJ_638(TE7_=FEPSG0+[/"%WI M_G8S4*Q'/F;GL+JBG7!%6Z21>'-!/!M@3/EKQSBR>X1,4^6>477% M@)C'=8T?H-V\"><B*EU7E"^Q0Q.\BJ%-UB/^(3L-WV"Z(Z-C%)$F2%-*]HW-MT.J[;Q+T123R1<8:8[Q//E=+%OW90D9B|FE84X06&]2()\BH O\>;'%ZME& M,[;,+7CY1>Y-D(T)K'7N!)MFX[*#)L&:9$&47BV=7J"?H=]3W^+>&6X/)=R6 MT"/01IY-F3P_QQ5^1]_T)TN_9)LG,YO0L3C*>3V*=Q\F#>&&3}XMF//K<@K MGTKL'D@:X9U+YLS56&?+9:L/ +4<,R*ETF+*71K$OJB2$":X?7&-1(XE!(P M>_YJZZO/@'#HU*&"L#2^TS&WJQ:\$0)P >I56CKB+@-X&0BOD[;=&/+A2CE MPLF2NL<<2"PHE3K=)]*O-SH""%34+&IPZE#_&-###MYO(0%0O^;-)V#((#17@7((B6F6&K]65+ MH)'BV!VDQ(YGY>KS'1&W7UZ+MR"-ZZ-HG/X*EFC?N+<>J2'K/RE"M(|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{J<8#K*/G*

Y;6JfU!/3T+4P%J&,:0=]09?V1QOT>1N[=%?&9KO& M@K_;/GV:%"7*+]S(EC=C;BH]KOJ3=I&M5&S//.8!QS5!\>5H:K+[F!?./13R M_"+N;V]"-%[IXI-)KM$XYX@K3_3Y5NYUZLHUDTG;)!O?$TQ88Y%B9 .7N9?0 MT=%PWSL2HIE:.G:9LFKU%N,_"B MTTHA@]+B82JS#*!_Q2)!DR%)G1D.:\+J-2+2[-3&M^P=+*=;^$K=I&9C[]1*&)6043O'("M$R4SO?X79XJG#=]P!6@_$SG%=$D)]1 MURX9^HC>Z*CQ3R3A^\I-7A4%A99/168H$ 7;$S\]Y.;?7AQ:TLTL=VRN0P15MLQ_.=:I8UCA\MK$?FOQ(E[4C:MJ??8G"" M5DC7<,V%U;ZHHD!\2Q=<{]R;F,N=$/O,/7&(&&I1\+,QS,TR3H4U6!9 M\4N#&G<Q_0>+WUD3!?SD2?E]Z,G;-_,IVWUY+H6B'R*?0PO6Y%KD87FM2DH MM2M!58.Y;_<,,Y3+\]F%B"5&B^R_FQNP@NF%_1/N;_^8[*0_26:l8*)Q$] MSTP+LR"\=4;$G>G*Q'O8=_XK8W7Z)TG>59ZU6BI?T)V8,3924 KIUB"=NP>++>NEP9M!M^Y?G]*)WM[ZU M4]QB]2FW(O(NK]3,O+"">U;G>("] M:V+]T_,0Y5?.!9.6]|;,V-GU[7C0P>0^,P? MW0T5M7>=.@QQ#(*A^,@N!"5%F4^^9F=25>$ENA9Y0_5H_&FO=ENA9Y0_5H_&FO=

&DV&N$,!TA.&.H.%ONRGJ.PK5W,SYJ'V64B-IO,W,(.U(G;4XN>,0: M(O&B_\UL^4K<2XUC|>]1L/.-7*1'1_9P3$XX]*\W.:Y*5@"_MT1RST,Z?)1$50--R^ZC1,B1*
<>!-4.\'(]&P=F"4%?MP%B84"?$I=B&5%P?3 M/(YM+HD=2'%THYCFO57(Z>'3AS-Z]_F$0\PF G"VC Q_,ZJ/2;P R6P@O%UR M+6;_^]00)'VJ-M3OIM5Y>
<>K_[5#=PN12_("E0)/OT.,LZ3Y,,)3*.6(,) M6V26Y]/3-Y'3^%(;^,(GX[19P$0Y.C2^]N5GN0#TO<'N<[5]. ^XFA%:QTQ7K-MM^'2LL6Q9YYR=5HS7;NV4:1IM&2
SH#UMD%RU0D#Z2-K_79/OR_IH(Z_&6&1BA0%63EV7UR17]2@G29 ME+SG44,^(GC(;_M<'6_79K=:-Y.N4?*K-EH4;=-=?6^M)0 8QE1@2]H66%##H;
<&8[O.2[[*]}Z'W;K3IZ[6S>^]..-?L-X8]\KR2WMP-:(\Z#>+&!]B\,^H<44U@OM7A:8.VO> M -+%Y5!5V@)R+EWWN\5#\A4Q(T#/Y2@OF=-35H?9E2!"GD\0\3 MO#3"->|
MNBWD-EN'WT(GQM%0.HR[^8,MM.7!Q@EUTGV# &5NADC=)I\GY;48(Q(.O.YGB$>T] M/]P7C=\:/OP@_?R*KJS6L9L*YR Y7.[.X4(*.X'Y\']YG\\HKK+T-6S:AB.IZ"T.17
G/P5$[]/LZOL9[.8Z-+N8#6Q MTC!ZE(;07ZJO4PV:.RM5Q'\GT"UMMA$B/+!?IRX2&R&7&L&]3DF#2VK<96DMQ[+4 M&GXS?UK>QW\[!6K^!E)7Y$MP]?URZO6'\'IR$I-%
M\FHL!0CTXMJW("!!%XK49<1(AHWMK^$^^ M_F^XV)#ZMRSY!/4UX!U({8PYW_ :P$$"PMS 7QY[\LI-!R?ETOYE<,DUX$A_ M6.WO.[1(L03^PCV3-P>+5>"_.@;?
V'N'!(R_(^-,^[^GR@_DM%$CO[OE\2+ M,/0A$-5^&'N^_: 4.%CR+VER_DVC[G^TZOKX*]!8Q"9<$[+YA(EW,>^A20Y" MSB?,3WXQY+\!+QDA[Q0YD?
$75VI]&FYJD_^#/_5P-|>F??"(_BF(.%9 G3GILW*"]C#Z]*CO+))PW,HS J3^\,I/U3](SR? M9V2GD 3R'>>O^(\F'/Y14ME"*CO-_$*@LK!2YY%&&9\H5=--=H
MHP@R4=1<+E#JC,L>]$Y8_U\49!C'GN^%':V MN-/BS,M[X_U??0L'BHU_7E=.70,2/4&GG5Q.|#SW@@9*!SH?8,!/ MW88XC0>]#.&'\]T_"]/F.6G,6KQV;6"KE'CGZ[I%[P,|+
TT0=V3'U$O?8[3 M)+U;O3N,94-|)6=[Q*08=BFT^:,:*MP_WF4S%*SV>ON-MQ8_&[X0!Y=C0 MN$]17@V1]HW'WR&.;'<<9':SLGI[\%HZE !ND#
M5X5HBQI5NEE,JS'E^M8^Z!G@N"'N ZP HT;|=J_3#^*RX"!RI0(%QD6CQX0G/ M5$3-^@VZ<)<3?3$O'F.C!_&"4S((\&EE&0KH#A$\?4%4(QY"QPPLX:D"^(J/
MM;Z#[M0J2M/#MZVV^C M2^/TFLS* C97!HH:TT-5,7]+ \'--"@'N *3L_%$D/#W<0&W[KZDE-M)&s&
M"D7WP\:HBE5BA1UHP\[' _%HHZ(3X>E[UN&>F$B#6HQ(0*F*1.7+$&7]C&_M MORSO6WJ,?B:+*" MTGGM$N<,RN9)X2,0P?
8"Q;Y8DX%>30.$B=7D5,6YTD%$H$1B55V*%L^^R:-C MX=85 Y9QM'IFG\B91N'NA! 45,CG.#$]%B*H+D "[0I1>['WF6DS1+17#&?S MW*'+A3_=H%7&Z,N7;1GN?,;
(RTE@D>,:"K2['O/"N/+,0Y6=4)ZE ML< %>G0XO,7>S=ALU%QOUS!TK[BUP*FH);E8-D_6FD_*4XKST<G >*$,2>K?I MT=?NC'H$^OND6YM9[Z3=F&,EAQ_??
M4)2'O3S[A37HW M1 +@O1O2)-ZK=SH'EZ=%L ;_.^C[??N;I.Y[*<-R&386S *;NG5Q#7@L_]P: M8W $B]VRLSYXT'X-@(/.I7F#'D 'J@&K.UX IHL$_ZENJ?]OOJ2]U7;1WV1D=
M\A|&PI_WO]<4N;$MB=U7<.?+1GE^-+![KX4!A> ^&$HN[&0O9;/?A-T/K@$D(&F6TAH6]/(-#%G87 .&5RMLW:K^3<6K:C8.<$Q?PCS8FN M06R@#S%,O$[XFF:5]Z1>%
< 36DQY5:GXFF\.4]%,861<_A#_]]^*1#.IL +V] MHC//Y-R263V\3,<0:Y1%0T2 :XVMK1MH<08-9_%#8]&,/)+89-YR_ZN5Z7*=EOZCB\&%I&]SZ>@ZG+T6H1OP[!PS#<,=<
5HC)928TX.;6C7:" M,.2WA;&BZS$M&_60@FL SK,RWS]!0%'1WN$UX$?>E:T"SZ^&FT MG$!8P T3TX"]:@XL0 7\O=_=?>62&0%#W2,Z_6]X#=X2@UX#4+RP%.$(486C
MFZ_:+%>*9V5=L#M0KR4/8F=_1'>7-9WS1!,? R>^_E!1K0?=:Xl*SI8AT$?2]31+C M39>F3>[\W2]>3G]W4V\,IW_I3!Y9Y;N5Q%!;NY!=T?3S?G83!W) ^3_52UKR
M_&=PK&.YN/DI,7;X>.@:$.=>< F+N8K6&O(CMA7>*S)ZW@#)4EQP'0"PZV4 MO?PE7H6SO0X@!0'WMU^$?Y)1)SL6IO-.WUR^:,#%/4OU[Z=L?F"21&L#%QVD
M[H>ZH1,FSP>/\"C.?),PHL*4KGV^P:6?OXVB4C1^V\I!W,TST3)ME_":U\.!J)-^9671*4YO&?R5!Q5G_;MB4]G?\ZI^G&\7
MBYB(EE_*]^1=MCUP(3%7%&4DILX"[7A]9OC(WHPMM>@L!HS!M^F3!(F^/M20 M OB/3/@YY=4@;#G4B#:0BG!)-3;6MN7Z5.VJJEND#AU)YZZ QWWB8^5TK#'I
M99M)N+CR34Y@S *5203O=CON20)9W!DDZ7Z9/2)LH..914#4=O%I(CDP3E'; ME^Y]K$VLIM]-FDYAQ!4X\,.NW;_VPC&V'[,=EQ#:# >@1XY$.4U<;EU"XKBS;Z M!3OBY!"I-
2FV1B;0]KZ]YP]^$0+B<)"-*2$$TX_9595==D=?)" M_DQ$6LY5ORUMO;X2HW9)F&L;\PB_T5]# MJY?
K>Z3[$);HS4P7!GX$R4_WG;.LM/P%U!UAFL+B&&+Y!J,R=XOL;O:9^YWY9M!%86_KOZ7N?&/Z?A MV8]F%ZQ^1O-
?'<^%K;]8%\PL6@SDW^!KL&VJ3IW7^[2F&MW\EAR6#DU:\;ODU_6I5=O6[:V[Y-: M;J5^-NJEHYR/I>#MX4LY^WR!$X\)&,(?:2,%>"P!B2#JU<)A%1Q M?//O?#*AX<_:
"*3XD><#Q"-(ITLL)&/A(=(B/K&H4Q9VR%*A1L3-,TV^-[R M]>7VN(!UN@'9255FKP(]34N\8[7N.P!P_U4X)KA\=CJPAO/#Y2D'/#4V]=DL M
>G,8B&6WIAC4E)B$FVVF53Q:)CU\DC/!C?LG1_,$%GS\;[#IMM"IJ,2^)O/V MH5>>3)SP*/K699\S:9M0\!<>GGSW"=I$>0.(F*]/H'=\E,AG*EH7<[.D9\8?"T8V!V M,FG\
$#FW27_C/M]Z5[H&O_G]V+1B*<.$[OH[W#)/[6_YX$"[)5"CRP^+&7T?[M9W;P!WR0D_42D(PS[R:?$]"\PVVU!=;#& \JR'T,KXRDQ?6V)0%> RR]D.9& M*TY2;A-
H/BR:!%!6W>[P-\ISDF_.UW]@=-G(0/MF0WW? K]3OWVO):$*+-\ M'.'#,AH-JK56?H&>/E(7]*#(;M"14@>YBGBMIY2,C<6$!;6*+NSKFAM,.8+'G M[M!H8)9'DO-
>V.$3OW_56A6C^5NG6Z)?2>U4>5!;8U17[2@8YA3$ .Q8VL.6 M[R"@?TNA-6VTZL1%U3AB-1&OE[P.$3[SP_'-F^(-&Z/@M1C<&S?F_S_<&*Q=_M_B8FBBSXWV[L)W_F?
WFQ'1B"+O,__"8+5G3R?WA*X_@F_U:4.37YKRJSKT^7M<@VNVT1&&8F 4N+(\22Q?O@>SX"@W+G^=< MV?\7U,M@P%!=TJPX_*UF,X(_%ZT#ZPX"H/9O0K79#>;
[{X(^3>S+=[3,_M,X;AO2R1?<-*[_H>0QHTL$ FQ[:XW4+LI$!97C,TMVZ>EF;_P%:7;/*P,4Z6 MQA>/Y)[-2.-=O0-B Of)E)S:=T%<76&+/]00K?]2.(^4R&W?;?UVBB*@VZ^
MBONX/)R.1(!5[;*_,>5T/C:N#B,Ù.1JBW(:D3!)\LI,D3I4P*_J>I&<8.ZS M3<3,$)3Z"^8FTC1H&JG[$7"OEM00YGI+[F"K&V&^D44T7MT0B M])WK0R@_4%<-
[VF<>KG]P,Y=*HI?W0"@@2*=%0T*'K.(X+ ^05!Y=&A6 3];U M!#_W:W"W/X_3*'1M),UR.I5903E)% G57-GG/@EX]WNF\C1XA24Y)L_5W*+|
M]2VP!Q^.8.+|/TY7.Q#=]2BS9V--D1L/+6]P?19]786K"\BDP1-\'_<7E.9" M$,N'>8WT0K((?PZH]6OYE9FA4]OS32?QL$[GP]>BA);WL+2H30A?*=M'.U& M^.W)%56G]*]C>
6B+G[^\!%0F%I;\;?^FT4T]HE KNB2S0=6BHRA!_* MH]W&.0=L>7AY0(WP[Z!2. ^8F[^POUN<9O!=\W=0*)M(]#K](Y0TH>9V3_ME#4S49UZ^7TSH[(?+RFS
M>_]@,SXH-=? Z-U,)>;JLO?^X^-Y/X52]L5^F7F$;)X@24[Y_%'!X>)/(%'U-MUO]8W.+_M/U=H;CG$H,9OID+!MT+)X#F&Y FAA?45VRK/BG&&.C;BAB.>8J M(<*Z,@;
[$1S>EH"-OXQZT9+O6^%7XD?";:T#W+U{>[<$!M&_&O"D6C;]& -:/ M\V6DQ"^GT=E>>8L[%(FVY-,Z61D).^)^DS(_W-+[GY#'I_^< NV>$9Q M@HOO^'L;W*KJ.%_8S'!
(F4FSB9?7.$],F5E&?X0LH?HQL,# :8S_I\N=;$W MW/+U_=''IJBIR(BF%Y.4$?HR<7RY6$H6X:D%8$ @@###B!31PPHOM[':C;SELR MB:71:,,+UCI)-,[#*?:1!N]4<#GCK4$0-
:V&R_Q&#_RHXT+.*6U:)&KUI$U M"])'SSS=M=DG@_[)\;+>KNBB@.5P.)QSLHDLX<>#_MFRMW>Q210V98O''7LO$[F\&GLU'.;%.1YMGF.G&RTBNS%Y?FYFO+P][_IV#:;!
MJ[\OER__$\!2;A#N^ ;AJA^+C.FIW/HC9Y4&_N?DSJO_.U2\N C;C\0"ZI- M*E]IU&<>7X'.\<8W-B\QC/RW.P(@>G.FX0?E\+-5%9G]HB>?=CFV[=K]H?
MKT7,X;K5+V>,7#1GE.74ZJ=C[N9A3#]J#NKDGBP156B6>__IZ\R7ME?+S//= M-2YK3<9+$@4%W+>4)WU'@(:'\5Q]CK*F61":NIQC^M(O*-994>5)29'+L&
M5(*CCFX<"?/JD;;IZ%.)TU$5+ ^K&E+C?[7 M+3+WN\E7[-!R*%).UK-]GG.4[G%$%4=_(G&[670#]P02Y&TC)1L U/W++WO M%/KUVL"@!)
7^'LJ/MQ&ZI>L163IB9)&.]IG0O-KW0X" C+/\R.#*YG@#M MFP,*NQKW"P!['IJ%/Z@L#62?6^%Q7B"80ZW&J^PO1=4&ZRD"MPSF/V=VLF
M53[.IF=E$;BO(<;QT>BIG'J91;'4I2,RTR$&^KW^%#-8M'7^.,A6Y))];:XK MK{JZ+H!NNO$NRGM-#0,2,<:M4+&WI;A7R0M+^D/,VP86UY&^,R5%D>
M5'XQD&8QIKU(#$9L5G677S*.^V,O9RW%-YR4&,X)4A3UZ-L':[VV8Y<*\]FUMM^+;+ MH:4H.$9S%%&2L\]H:I0H\?;\%HXS'C*<> PGY#MG0UV3O1>_L\P!
M/'.F@J01V^9O&VO"D')GWJH50JIDM+= ROJZ.%H:*@ JW^P(OV=,A=D1BE1Z M2JRW-'Z M?>QI=I7:N57[Q#_*./-#$:$L3_GI&3<^I69:X;*=T#G,VBOI%0.IT):TU5)Z
M_!YC[]F LF[X3^R+EN\M&*?2E)6#X%]>G>'/?BR0#/,S8['W'VAFM[$#_]"G MQY9"9#[AS%0^GQ2$/W^-L.E-/[^A30M2&^-T57YX.WIU17#.$K(,FW>-^!GRX ?[E9!-8K
M@#:.^#+T)0X=(?<7_KM_IJD6M;@OJ"5X#@KY<25TV=EVFP5;>8FYL7M&ERTAQ M/^Q?!\$H213ON7#/QL"-H73ZK^Y8RVI^B9M!TSV)$8O+U%E[#5]> MMZ_R.B)6=!
<,01/=)U6HFI,BVM R*,>TX5GE;V_)S_$DMN0S-&M,=%ZM^[,* M8Y[FG:[OV*/9l,7([P"]6Y#2^$Z%N,&.#]00[]*D-CI>);,HPZ-Y_3X+HF'
MDR+O.&.^9YQ/BIAZ0BBJ=F/4VP)6]LU@? 5*>,%/8+O.9_K\F>9!E\NO_;BO MU06?);.9*2G8/(M:M&\NO(RB6JN!8>T++/%
<#5_U70.>U#1L=FH\076IK3D9JY*&9BY,_%R^O6,G^O\.TD;N67I3@"T#)6#Y(\+ M*2T) Z"2&,]SU=@ AZ5B-RWCR>,&XP;XA.3/3D:C#?09?(HS;A%GVTP4JHAI M^#]/?
7H3R)E"I=Q@N1"'W1]SU>BH0=*M^C[[1WI=W5T\-S+/;U[V,QKJ9E=P- MBQM0_]\8XB[=C2"!X;/<8D71Rs?_FY M43D74]PU?Q\-C@%^\&FA=ES6_*22'VGN\@
79Z6+Z;TB0PZ%!U@/P"B]O8: MX BZ"Z7$X*.2VRFWFYE"S=!,*4DS)LVC0K?SD^UH5WD7HH.<1[L M-J@&2*T2^FV0-
"9JNC2GS"DFK]4ISZ0Z/[F@ZP=VV]W6/NX16&C_LZ>((K,\ M$CB=>M$^G1^,NE!!@\,"5)U0FV\80B7<\N!W)%> ,8X6M9W'Y\)$JWUCX+ MD=^>|
[@&..Q38'2P$HL^=4;5NZZB1@(M/2UMTO?=^F)C4MEP M1S"HT\[#HP&62)^_8R-%VV^2=>N/]?U/V_^?M2R_;@98@IFA)B+@S$H\28G*-MA0K,WT"N0ZU+
<%#R=QR2?^.Z5TRY\!)_E/4AD>NB+;A@S)8FZ'E1HDB2%4)(-MMV*L7(H)&NV00'6_&NUXEJ!--5%9]5!U\6ZBSXJGND+'!$@15!9EU%U5,,^) M!GNX/EFQME0?-@N-
VTM+NWLLH-I:VR_;R=^S7,S;.6?6K;5:/SN#'),L,4CC')[$+6Z6!G1 MINCLU@8;F%U>%48=BE+21^+C>5R^"!?+ MAB"B*^5_U%E5?
VG[J"JS*]H>O/B\2&?;.!4E^G,1D[\F.&*Q$[4RIB/7>M(-M4N7$^8G7572>CH#O4]PD)K@N4%CNK/RC]'=[BI.7*!>%QI--?X. TMM>A_[MRW
3]_KH;%B#8_=9DY33>>'Y5T78[HWYJRS8L?8&E2@._WF9;T\L:,)X#7": MD2ROD+ID?G.G(B>R#_\:X/^[^_]/>49Z9CP]HJ]QU>'(Q+I.(9[<-.#>:
M=T++*U.V\.C,!$(&(NZ[NIBD/N[M54?]VR3;T%(QR'0 73 YH7.YV:3]>DNJL M*VZ>M*X:#GOE,0%.IE]:?,[*J2HY@'/FC-D/]4=,QW>+0HQUDQ5;Z;?B(_9
M37_$KCBV;M!9Y5!_2\'&^O'FQ+UIPZA[OIY]|&Q(K \[_WCSQVM&CR,T;[\'N!B.LXT/8 4FT.WWBK.!>#:P!8XD#M/+%[MVV+LP3C;Z[$)#]B!E=85X?;:=P2C,3<-X=
[2)I9W;V;^Y3ZOSPZ".EN"MSU/ MOV]\Q*-E>?I@WGN3\2MX-;4>!SZ-;S24_'+9.<2I-*]];>14-6G/\M5I6+2EF: -% Y-'?XUUNNXH(*M 1H1^0?W'O_E(W]?
$4l.C*$_RN3L.H19@=ZZU=#G_R^\^L2>+(I1]U\/$7 M597GU%W{!SUB)N-_OGO5>B2PI(U_2\3?/NTS
M^UF[20??:5]%+_;K6ZK.!QHA90L9M#\P]+[MWE%F).I_V-_9K+K2A)[^U>M%IXG1-%3"WO)^\2I".8;7+[U+E4>0@S&)IP4)1]_"5*=,0GU8D R1^?!3EP MF962#8,>N<&
<8(266+ ''EZSUK[<-&+YD<+ _*$YZ\+K"CV6\R9++)M;)0!\9PP}E'55=$PZ.S]^V^-,&_B''FF]V6$@>R
M36:KXHH^K*G]W>EBS!Z ;$C?'$2ACP?]CRIVVK=+]9[F)UU,7X$;%EX4&9XD MJV4;BE-I))O91US#16:*%]3ENWM9MGI!%L5')OG=5;HCQ'M[>]XK.1-N)39
M+FTO^>==DM/GXXT>;!2!J3T?+]&3B.<5Y6"9U_N2YGP=_IHD;_Q4 V16P3;& MX X@":' C25]&ZEY*+0"OT]NI6JF%B?*=Y]NP$S<@6X+1PRGQ3 LSWXZ=O3= M++
[NW==KH_W6LGT#DCL#OBMW/[^HO 8LB0Z95<\[']+1OR^EH^"N_:X!;5LG MCLY=H5PH,)ANU%H&[ARU4%?GHO??0"W,1S"'YISZ8"Y_,F012-
=W.G9K5STRLRY5;3B=U9'\]LOOCS42T1C2KY MI++H9BOVI8=RZ5QHT!<(2QSU+"_.N#0H<\DTT-RPUB9K5$);?*6P*(-(/DI&.5_G_M1'N?Z/%\BL/!CPBDW?
I;>9Q5)#"'7&3_-H.X&-Z,DH-BDG[MMUP[TYR-.MUA3/D42./55#F9!=1>;M@BU?_Z;O&5\U[Q!NX5?;F3D:/YPM(ONNK*BW"Q^WK M/$);"(X60A4HZ9G37OL%E?%DBDT^
3R\&UHA?F9CI,"!U9"!/XKWXU36+JW M5%X;AT0:AA!TK<<.4*L5B0MZ6I-#G_ZT'=[URUD,S'X>Y<.Q1Q+:>UR4D&#X M>_Q=^R"UH4Y$1R^W97*E*+'78!IS_+'XRV=S
MLGB=P=VW HV?)=;D16?P\P.FGB2?),'+>^4)91GO'"?C4&%^Y96BX,"!ORJ M3)H1!)-RN/RNC;XWG=1]2!BQ!",O3/F+/W;!XF5I.H%2RSRS-$N>DT?D=KW M%KCX-
'W8"W@4)7DI8M'28>D;%C_KJGK=6?.!'9<)8XA, MZ+:536),_3LA.]!!GJK'=6IOWO<5+<+<],-!XB&TF]4,L6 44D,2YWIHWR-7&/2 M9B1SBAN/&^L%[N^)5)8L9&2I-+NBY&
[H7Z"^T4R?>4E -/'Q[! M8A<2U;ZH[@OO=Q^J+?R]D.G_ "Q_-"HL@R8+IZDM2%C;#:I42;7]%=#L1UD? M;,G=W)GF]> (US+:^\%V!.5)$CQ5>OH30AQIQR!E?87'?
E_4I.D]T=DPM39 M8?110^R \T%7WKP&+=]7N ;G$35R7O3R*Y;!H<"D;W&'!'/051OG8I1J.%Z: M5]PB:B[PZVD#01^SR.RS\W&/&9FVO6O 8ON[FH.F8?
8Q!/>DFVMBJK:KU7C1 MZ.(^H0>F:KJD$(<;0TV/)4C;8+G"]H1.;8O2E3R0_+C/><+O)A@8_69+LB&_M',D &+?V+-H"*]2A85U@'*S"&$)LGPHRJHC:^^(7PSfY=&RI-
ND)BJCX&V? M1'/ELC40\G*;(=K<YK:E+;8AD! MQN/$\V:BK;V=6J(LZ#-RO$D'ON>*YQJAJ>_' M)F-R#$Y?
9WNEMC5N61[+RODR]!C['7ILC880;\0(N>&UJ@&OCVEMRK@BGDG M;H=6+5KJBMZ)+C;/K&P7BX5&?0SECTX,_1/"/5-HDAL+PR!X3 Z'DP\DHE"F[V#9 %BKC=L
MK.L2*>CDT*@5/65+7M@:J9)X/43$6A1CK#2\IT 0-"23"XL,L*;9,$XZ]$O6 M01UL3LM:284AB)4Y DZBO'*:5!X211GTMARH'<=4'?\Y23MI"))D\FPX;YU5A')=\;AT M
]Y6\)2C^I9!0!-87,XIPJ1>%Y0R-&@KE.XM:KRAY8E-5JHCQQ61IK8ZPCFR MJD;N"BNC$D_V#=$;#./#GBNWIHYWCTWJ+BVV(4FU*T\3
/0C&C|\Z=8$QX0NJY\9JX$^>T)'4W"'$UN49%N3\/ODSF;. M[\-O-6%CFTFG@IR+,_O>C[X$PS/S#5T+"[Z"4%QH8&CW, ^YJD#-SJ(;/!1TWC M(=<
^]_.C\'!9Q^S/.!*SI^ZF=.X!K 4KO$/5=L008H!2 +.W-W,/8QDL58!?:MS6R4ZG;6E:+++X<:>' I9$3TORHWM3CYIE1]1RL*6P\]+JC+T.YX.K5T0MD/K] MG\O-
_GYE<)\SK/AR9O0U@)9ET;$FS;_110LWG\-YI!SPBN>C=&VLHEI(@)O<1 M"-:L]+6%2<[[0G8+5B&^$";&{\;N06YFTB501:PEX'Q"H]G7M!HEG$)H4-?0 MC$/7*
[V"N_O'&!BCK-L#9,U;J#&UCU%SB-_^=C=.E7Z@K?L&FA-K]EG1@$1G$ M,>" =;3OVZ3[FPP6-7D$T:8YAU3WH(UH8L.B>MYT.YL2.0/&)F"'#*3,$-.D
MD)YKX2SC$X)Q.4'3_UFDG?[J.&!5T'Z'FG|H-V5T-_@+-Q^^"HHF64T), M8UQ4X"\;^BSD;RP 7-ELJRV\IVP_!EZ-2LSD .HXH??P%F0)NCW!ZEC"Q
M:\#=+04VU"K\36&"X_*$C12AT[=G3(^K^WQBS$8\W_GLY^(8!Q!\MYKT M)2E'>__S@L$"UFN IHL4A0;)1/YSQIAO;FX5B^2O 1=:[2#&$T9,_YP8'S/D
M)GJK,SL0$Z\I@&19OZ,]> MT!D3EWI6E^S5MJOZ3>,"P=KGO$L\0H$$+VD< ?;-25-J4YFC0SHJ3-"O/R-MMN..VY.7;[PKT;[YZI;EY7.)G#BA9BV$<@:H\-8@)DQH-O99W9"
JMVB;&-M4BN2DR:0D_(-TB^3VW^A6*A- M5>.W<2/0$P]=5>62CWC L(&1H$W\+WA8&U2#^K!fBP/P]ZRYDW,2"ZEQ88]F9A8>P>B>JQ)YB@8_X
M<^[*2^+91)T.FA7S=+,$ZIF867VB*JXG0_OJ5PH)(\;!1; M2KAYT L$)'QI/P.D'"MK &5I'/)(7<;!7/7%F).D7'S"X]=':XP%+&=!3DU MAM*+]/"IX\9;P1;!ZZH0Z\(*Y>C=1Y-
>)XVC8@W604LWTD)W>)U@-@M1(72 M14LL8AM4[^/NI_+3M/KI+T"4'!>E_XK7LB.!KQ>+1&N TMW^/Y\6U"JN*Q%8 MKT_'U&&])FURAJJ:OPXH3XJQ#
[*CTZLAMUU"F+6\AT[)@ZXG0'FX_!BM=S=.MS+U2L97L"9$M+5>-CF.5.4S\MJWWZ);>1/\4'$VR.#.S?=VN>7<&*3KA1!(-.MR7 CO6;08L_<00;@BSKO>P?
B8/?,N=P3%+_M-1&?=U:T#3?!YZWGC'I7)OJ MYCBS_OWMP.%N;+EY=#!T)FU-48V!5F_O=7SI_EZUS6Q5)O7&] S5M[%==PMM M^9J.C^X/"\W8ZP)Y;#R]?B#>C#2"E\9:B
0;E?++PA%<;HISLUSOYN8:]ZMS M(R035 12VMRF1#*;&N8;]L-!%%4+'XS\/Y]#/7!&]VTKXGAM]=>>=6#7>R?$_ M2^0IP-C'/&JZ30H[L]-,8D=<7:C,LIWVN.H#>'X/N]'R
R:YHPBPEB?%,R M\=|W>MQ+6XJAGMVB?V3"H&TV/'1]#GN=5HMBYRH]ZS(C;F7\)_>R5=I M/6,I)<_YC>ONS+A;KJ!:"SM.>X?
1;],:6^L"U(GNLYZHC@GS5XU6.YVUB'NP=[0=/]K7I9J[W$=6,(G"/A#$!,K/TMNK[ZFCV5=S%)*^"3A18)]N8WA^=+.O4-I;+J*TK,Q?)Z#%8X MQ_G:H@*-Y4-

7EETWPWG>4ANC;>O>J,^4H0-WP,^M^3"5) ;8_IS?5GW>2Y)Q-M(T,T26X22.G:PBW=.{/M4R07QG/6E;_8.O2.IR>.7XI;7EMTU>DTZM@#E]K*

M^XU%Q$Y>R17;SI$QQQ^/J^F9%C43D^R]?9?#%-;Q?,F8E':\LC(06W0N+SQR-MSER1LC\Y'>?R'L'V.C_VQ8<IHK.+1-B?(-9$U@B)IPT?[5AUS(K(+6Z-2T-3PH

MTQ;V6EFVG\NR4W21,_?!:%%RC?YA,0-2&;2%'L-F+?I+;M?=YEM-+,C-MJK&4$<G>P)RV49#^V:.^66',6(C)P-%M-;3WB7-'OO5"9,=TV2O4Y#=]GC3/P*

*MC0M,N1H?70K\0('9_)2Z_{)'3T_3UL0>V1G,_VHSRE#&C6IK2P>U!|.-'WSC6B-M,,_C7_;$WJ%>EX.'9XOO(_#+N?Y=D^#_0'O=-*R;!1.|FRA@^[12CU+*

*(LL:GR7!2AG7_;)YU^?P(H*AT_Z2#B:&S<>*_3)ZE"MD-M8L.:<5LPO;;+S:;3#%J?X&*3:V;UA9<$G:-UY\Z3/',*REG V)X+[?HO&/6-ML=1F*E|\O)556[% L9EC/\LG$RV<))?:*

*!6?/%.K&|/5-MF=ZX/|&>D'D#P5!Y-WRL?Y_/"]CF_-)-A+8@&'MN3.V!Q@:T]67G?RF,O&2;-MPU97I,[V>X*ESI|/2T]#'|IT1/+L\BPG|/|G'9H5P"TY<(WLE]A#;6X/SAV?*

*MY*3]$O GCS&Y&2D#V&WD-<#W&-@4FOY(0#0CDN090@A784_NUG.E=3]!EIKL|&2)[-M7F$LI_WVSE=L$\KEYMR[#?6>02;.\UV+D%HI;3[.^7UA3.4VWJL7H1;QFR19=*

MNDHC(\ 6$XZ%^-84?-$B-LI|O?]EH]X=85?,?2%;6/K4YV"&,U!-#S.^--$X MK^68E\X-.=4,)69]49KS.YR]MFH.,%A9:VJ14^,>-[MHD%?T^14[?;+CTF%2l[<

*M3X4*IP=]_5ISX33/YU+\"\MJZ6XFVNOVIB-MJ@-)}/>S@*$@QVM 5+-DYG+,1JH8T/U50V)MN8F;OD8DN8*G*?&]%Q#<*)O9-M23CV.2HFNE1\.0#9P'NTW7?*

JE!N'G'MANA 5NQK]%K[XDK!WVSK_B@,E$8/T-MJ0LHEEH>XZH-,!S+4C&OTQL+7>V+_ND98!R+E;N,%_,@F'-YX$)S#4 E;!A'-MQ7CD;Y&3/-[.G!<9% ZM??FN9]N:-

*Z)/AJKO|B\SW#HNJV-=%"$"0(BN14-M2!-DBN18(0)%!"2'4D'),16Q"%)sH 0D2A#@&0E2*7*0G';.Z6VCP=-{.Q5CS50%X*=!E.C0C-]!L.JAC-Z]K0-'0=2T4W.&KGM919/+*;3*

*M^IXIA[A*8T(^_,TC6S*TL';[4O?=_7Q5#?6)3VDUFX.Z=W1>_B6PLG-ZR[8 M&MTGBGXXVD@Y-0NIF!?)/,Y,:T!Y/;!P1P4%XS"X=#&\|+8$0+#%V^GN;%YTC M(-*

*%'*TH-.+Q"=P(D#=GQ7K,$1@*:FDP$DU.MAPJ&FE[G!"OWO]C>GM:?F[^D M&|Y>]L,UBHRGZ\F%A(E3/+)>+LZI33"E0E;Q3B/#X;1:X]Q|U4|)>Q$UP6)1&]]H M!F-C$P,%*

(:G2$9H-2-#E2!IDA[176WRM_%5QI$W6|WQ5>UM"'G,pPP,P-U[?]M+Y2VPSD 8>?0.YLBO@\'[4]\9.9.D,Z3<-"(<8,BBD'135BYP,19]!2QA Z./9 ME'?V,,;0S;%1>FU%DO5$?I)+-

L298+E#W?5Q;^1 0\'6L'!H#M2;_+T]':2 M&G_D97WRR3^Z3^)V?D=]R$BDE>XF7C<;U.7&HVY\:7/P3:0*$&]38.NSL9IG MV%KO2#N%$>Q-

VKLL)3BOS&G%NA^42=T|A+:."R'KU3WGIQBWL^9B/V-V_V(FC$BCZ@M$;'HM8FK-K-;$|D/-S?]$<==AC@1&.2+YEGGNT7MO=2QQWD&3HI%6PC*

W7#8E&V0#M)B6W-G$C4AMC65(IW),$!. MMDE#T+12R!H;@<4FOY(3=\;R.8'P7?(\"6 'SP%&Q2*=`G.#9UTJJ.P1JH92A-M9O>1^1"h:kD>8 EMA6,#;U3GH<*,F;\\U?*

BMH1=%%V$&I3OQ@C';;K;IVJ7:0 MH%)#3X88<1'""9K'8R8>X;U>-\0R0O!6#?+TJN]_*2J8 &#_]XP0-UOW)&0$X MD&|_\;R&$:&QM@VV8 'C?

*+AGH((B)MH^K#G19QAUY..U@^&RU? L"(JRI69>C5>%\/*Q12_M M!7;7XEO(+M4YD'GKM&_X/XN6G#8*79$J=+1_WZ=\2X=78*G+M],F:G;^\4'2*

*M4X=/J8G2ZJ4E7',#PZP,*5]YU2N$=O3.=X,#W1OUV)A=(=#H1AW9,.L[MUW MBXPOMIW8CO;V0EC6(E??S%@PI TW2$C*L@_5QC=3#*#%&M+^YS&;>8G;)A-'[%K,LA*

*M'SZ8$$R4K"=Z#^$J#774VW%,_]NQD4,&JE41:S/Y5T 8V*ECR^=]19H,@%O M2\G5G9ON(AG\ZZ+T)M DOU-T<5,H.!TMA@%L*5T)_N7E8O^?U_SO3B*

M^/_6T0MW_!3(6,IMZ@4S+8L>5@SO%CTO6>]Z4_5L'IOAV)"JUQ1)<.);A[N MQQ?VX4U^H324ILU#"B);KP\'!%B%%6H\|#*\+3/>,=7->[N"F{{<,SH?D#4|)"VI*

M\^.#GEUZO*E[B^S"|\#3NK45&P5;DL,,SY|\}WPFV|&<6@M1@OZ6!#5$//B/RI?,KFMHM M%?9 G$;(Q5CS50%X*=!E.C0C-]!L.JAC-Z]K0-'0=2T4W?&KGM919/+*;R32*

*MNLVU.@5+,WW4NQC F_*:2NNG+F+Y{(S=O]78S5N^[<3I M J9 Z8U[*R^.1@N*Q//%6]Z>.W$LM5BN:9 _9G^>VW\CKI/M&"RO\81)=&?! M[W+_Q|')?R6]*

*[/1>N95#47**<43'=Z0%,4JF|)K/JM)"S7 #NI[8D 1X%,.6 M^)MG@$'3TKM.VZ*^,,.5DN.CE=+6KP@WYF8_4_N.XICB/-'6!G#Y<0l.?"_2*

M^!F28SW>LJ!.56CE]VXI_5+RDK\6:WGI#$,OM;>"0EQ!L,G0[O3U_VY9WC9>KCG&!C- MS3 T2PYR=E-?%2KH'A:(SW 71E/YY:-^K#N;#35ILYGFT^@GKZU__(,.YZ9$,T+I-

*EZ-NG*GL$SO MGZ&?17L44_>*RS^!\E"E6"@-DR5)0^Y5E:W/L96H,M&<@1KI MVE>IGRQ=>P|F_3K7'^;!)}LH|[0@K*K#%$A&O0]%KA3W/ZW%EU"=3G;QK/\ 52*

M):!,O.I\.D.1UIUHDC'F MA@FA Z(VTZ'&?MOUU)? ?K|7I&9O-,1U>V3>L/F|\-3(\M;|!'R\>/FPR@\|_MA7C^?OWXUM/(;,W_K"*

<>=O"IH#,NQWR7A4O%4F\6"-87_B^>IF16D^4+,)(M")13?+Q+&KY;Q.T="6UF8L1/8R(+) .3_(RIIA_5_BU+(1=J1L0U4G <%_M1'SX'O;{1)6?

M51!EF>\CR=K(AG7NGC;$^^DIH6%=M2I+$?1{V#K^&1MN\[M:;/YBJC90RNRW3<-=XY,[+.)K$R-F&.,1,%V\W/L3*$E/#\9N8!(D?UO

M/+0"1J8ON_5IU;)WA/S+7%W\>\| > TDTOOP<;S@DP_&ZHZY5?>[@TG.Y$$" M0!U@=-A\BK"H!V^D)/+C8.#+F!<&WI[J36*9$HD!'9;KDMDIZ),(;\"NI&X(*

*M,N3,'R%=.5]NG[EIH-T;1Q?1_CG2.F2AC%._M90) !P 9@W>)V:|ES^3%F2 MEEG1[@X3DKIA&O$LNNI-LI-OY8*E6B8,?V,@#DQ9\3&HU7*!J&)3N,!C+98#*

*M'L2B7_5<5?:>A#Q*S2"T/+YIFN!W7]^-X;8U*FRYR|2Kx,E3GQ#.48@(4$?#^Y MX\6@ 7MK#>]PDJN50TK'K@A0U680?B1$K?;&[.,;'JQU!&.AW9<(72E)A+WN*

*M"$>0JS(&4+&;O!C?] 5:ZR"X$VA\P%^8X2,-Z*Q#)B*>6,;=U:[W=!^?,^Y8 M]HJHB"\7$0RB#1!.5:J8(&UZV/%8N<]+U&]?V*N8MS9ZB;JG3HGE/9-X7:*

MU;>X_AW<5N/!W%<6Q>_,"^(D4XV!>S@%AC.M)/B,J=/S895S M,TFD(+Y(+A@)?;Z# 814B+DTR-A8'1KV1@XPC(OC"$Z.1TO+[AB/51&VC^Z\ M=Q0)4?

IUY"ZM$M8S.RQ$OTA9+2-KL^-2&.=4*?-JYWK]V(.P-.691R8Z*C[;O; M/W4/5#]>DOU\!)(X9E1!;AOT[?5;9+OVL.6*S4ZN7OL$.>BT^PB8*#MZ(K5^-*

=]E86/R,T_+R^=G<(IJP-WX[\AM3=;. M]!#66LKRP;+8K+^=#0>FM6>$#D*06Y[BP33UAJG%R)\1?9!9D8)Y(MZ)XHXFBK^,;UF@V(M$:|\%(!U!''<1M$Y+?

*WC_WIFF9#;^WM>Z[7 MYD1D:TB9!!>W=4+))??TW4>\B@N4> M=@GSN@"E2_/*7(*#>..KH_RO.R &V$&*@#.[V$ 3BS;$]D\M,#AS,K\=N,' M2BU3-<^@7J1>]1FH?*

*^G^9+>"DD$NN2&?TLSIK$?]D#IN/SVO.G/88*R$X]YU MB+_Y_&;)\3PFY"W(Y-;B6"U,_W#%;(Y1]D6"OI77T_+8.8IM"9Z"6<]"%R&F MT^7?)\;G72K'WDAHKS!D?I:3Y*

3>P:O2>FG_82M!TX'_.8)$:*PB0ZZGQ%_MZ?FA*^1:R^&?N,\MAA)^/0PO'@Y2F/4T MS98NZ$)+[1AP^$QOFCOZY!M9OC0RDA)@=B=ZIZ_JR>{.0B!4+GO7V9ZE(\2)O

MB\/4]&P+=Rj=":KX$D=6L%)7UG.^A)NOCN,H<+8E|!*MNNTA;-&(7|SM/"O)-M-W!N*@-8P^K[E(LM).P_GA1$",J65HV>7 7-5-\1:-/E6:]0l$;=L^GMH|F9%T

M9ZY_I'B/<[5!NTIP$/19#,WQMY$?.K-R^-M]]-0/H^B2?K@:.5^JSDTRQ\#9#=1F/I1/WL[BY-XJK9VP7^>&0'ZZ,WN[+S<-MM:XE,=+=8?A)]2#UP!8YQ|57254\"E8-WP*

K:CHD>P+ %4(C;&Y7I;QHF)UGG+W3M^[G7@,X%W5T7I M?%1GCF[ZQ7)1#TUCZAHLD2+ZK C>T(^)C+C M,W->@48,TVEZFUG$|I;QYRO$T1C.5UU-*

*ARFU9DG$KVA=/-MFOQ'IALX#*KUBNZ(G'H8<;$4NXL:,?AP?I*>,?&_.@!S3&DU6HVRCZB1R[.I: MA!T6(H#-:1D21W%Q.I!'0 6 ?I/Y?;LHZ.:*%9-V$2O_?6]*?H"%/.0Q)_Q_]*

M./?_UA_J|!-A+5!Z(\B"81(_P<[PL\OPW>):LW8|6KT TOG8HV1EPA="-=JG MT/2K\P!LSL6],F>9,_]H+FO<>&"TX$^KCVTC(GY-&0;:<{)0X%%(>7|O))8, MA^;&H)'")Y.'"/U?

*4@:;&>5F*KP)H(- Q2D.#"#U,70!OQBWO=N=NV%4 M0_G'@K7CC']JX(Z)L+|+&RPD=9B>9OVS?JBL<6Z|E\.[\37&9Z$.ZPI&NT1* M!{T0P'H:00*

L^L"@5>W]BF+C:#8<(:4BNGFI5CX[9TX?J\?9$GV+E0.6Y>N[-M0U=9%8I2++;^.6Z=TYF.H.9QIHT!Q$E^CW09>|-M_/!9-Y=&^)0K5=[W)1)BTK-<1,[XX+3B^KUUU_?

*RVC"=2*64!+Y%W?45*?^) M+-\P;U&D^/+"+>N>?$C@L@Q\>8]*ZL/D %&[A3/*T(.MLI.EX*:!]AMSQMJ4 M6?6XE\UO?3*MLGJ+,\Q]> H+B^PF+$YX==RK2A.S, #A38,*

*'((TC*Y_ZS QSAV|HR/WL4'3YJL-!RI&S#EK.G5'+]J MVZ1_9*^@CD:(_4[*#,>YCBF"5I/[9BXLC?41S"H,/2*L5WB3NK8Q?L(9YOPM %;=1X7Q)#M0]M2L<??*

*G&5'EZ'A;1-\&E. 0GY#.QOO4ZW7_9>7YF0DI2,NXR!2B^(2);I#7 M1I4@5M;2R,5<*NT0Q?V^\7"%EWP5C>EU O[EQ.>U1>&T%ZR*;4Q%+;!UZ^2) M@]3QFY$BTT?*

*0.]LW77QY/K3FZLVMK+X>W_4A7(-]P#IJP/<,?^B9XW+5Z)SU M6;^89G*USF$ER(S=SL3_&@JACXZ>W/P*AG M1C>4\N1?=6S>83"K-T*

AKDR>X1WW:;UJ82$+?3\#H/OMG[VQUK0/43N] MZ/M=`WS-,PC5M+5M#Y^-2#/5.$,(Y7<=ULF6,H58Q-:#8GMU97F33A/ MN!9@=#$F=HT(]13)K*TD/>'OLGBBQ3H3-*

'JI%5O{\RMN17B$OB)XR?I'@702T7Q=>10=Z%Z!+I%OBGX0K%|{QC\-3ALO',]FSC4F3F%M-ANG8TYDT. MD_?(X,'[1DZ\OTJJILS;Z[9DH$\E9(?

*C1'TJ[.5PIJ5<(;IT'MDRS[T8-;SV MD5W_%NT)03IJ[^(PMK1NK*K4J31[-|_9A (SG*Z2;7.0E.0+GZ35":!%=[@ M"B?=[ZI-FE]*4W:[K8F,)XO=C#XX,1IX]&M'JS:)^YX)9Z*

MK]AC0Z9%#DPQ|YUSILN#!3S:GEL4-7B6ONT.$.H/N=+RAHS!VH)=+:,.-! M0!AGGN#_Q&^M%TC]Y86_Y(0$9U:(DI"* W!?DJK.'9<>K]"3S=9VWEV57ZX# M*

5.4&RHJ8NWN9^!U6'FZ2I8)0VY>>]5>QD_X6\6?0T;G!Y^8BQ-=69'"%[W! M*&W@86D]/P8@QQ2% ?AC)3U">V;O_AR0_U1*'745/|L?$%=S@-0SH<8 TF.4 M,(F)!R9#UIZ*

P&C@Z59,0#<90Q@.??L\W[@-B3MXIR_)N4FY0 &T-)R"+\F M\51$$[1B .T;& Q<0L&<'"P!43^/E^$K%BQ 6HA866@1]?WDV+8B\T%740 M?--T&'0H T1SP?[F$?

*9WCI*9DM\N4SG0/CWIYG+RS@O_6&D$%/$*^F\.D_[N M$-L$@E$$Z'@?["Q!QYV* 00%+4$O:4Y@J-]=`9:QVQVV*__PQX_U9TFZ"?WW MZEARI_VM *W0GPJ8_,V"V_+@?*

*R_PT/I_T8,5]U<|>V:(*8ORDF-PI#O)H?3S MCA[T;XUZ\!\T]OUOC2+^6R^V^._XDEA0?L\CL/)=&%ASJALPL\';T(-ZLSS]:V8Z55[O-(Q@.?O== **?\,Z<)_'U'!]MH#/V&>KT6*

MK2,_T!PU?E4;R4/ , PBQ\I.\7SDV9TZ5IH)3ML/;Q&1/4B_'WV .!)TA9>2N^S?HK!WX6,CUX00?=$#7M.]6/3KST'M+*

*N]0/.G.$_5GT[MQ1R=%'MI(V.6/88R*W^&#>,X\ZB3Z_>_UYZZ'Z$?MC?; MKN%O!$NX(>V%N^P%\3NJ]UBJ.73^%$B.SN-$OP(RL7&]6C=2UK*B/;,1&J#4 M@PVC2I8-*

#G:#LJ9(G?_O/Z?#&=:.??C43I9^GU&LK.GA4Q2$X_3'C1&_R\ M6,*[FN Z_Y@5"01+Y?O9H&HD)#]JG)W&\L?V++^JFRU:\+&*6EYURV$Q" .!*

MC^]&#.=GC"]AUX1QR;Z\2$]^)+*!;F5BIY$2"-%MD#/UZQR;K"8X%+5]NI3 M'M:9C$DI9EGI>A90N=6W,3]%L'#$A5B%X)32E';OWI;&Q+E[X":#K-VT+ M- DG4G>

KI>HGR_+E.,O9 M:GPT>8C3O,%X1D4GF];(-M"2]_2VG%=M#&2YL,-OB.JA[QCL7WYVYY<<@]Y1I2AQ+6ICA5Q M79VOQ4I]6!BXZE.0BPO^81K/XA<%[X(:=SW<;

,>/5%N%:F-EA&+W@QG=V> M?V=?K.'MQ2GQ:3(ALU+34: I!%[3!OTEHX..94U6+5]N5_A1W_7W(6NOJKM4 MV.:+V8-

BKGU^$ETTO:]MWE^@M4)14[\"T'H!X:\BNH^<9-<55'D M!6B.B]+O8=QRX;]?'#_^1B^/^_X0K?0&I\AS5-U?1F"7+G(H/_GXQQ*Z*Y3*

*MI>R79L@"9$BJ:B8]NCA@ZO*0M8:/^NI2=PQ9&N[!"9!*6U%I-_6Z3F2EMHIA M#/?(?ICOA&:[!*W_C^#5\V|(I*N.A6_(P[_Q^Q_A(C)\X)[_@'7_]P# ^[Q V M^"]8[K>_?*

P"7_N"P#?B?&>TO#]?E:LGRE]$;LXWK+D*ZTG]EM#]Y9!HF'/11 MOXAMRH$_]\C_'(?^_V8,A%N1?;'Q_W#EX I# AFZ& M/%/VEN(\'01- E.U21W4,;,DI=NQP% M4^=N>4L%

(IT3]W;\/8VQ5OJR@RV?S UOF;]_TN+ZMSTPP_]I#TSA!Z!^2ZO$ M<1N^S_:V_@QWWH,1Q5^^3B&[=^N40+3:+%2$-L(*R*P!.AB$YY"14SV/7%# M\?*

*H4M5V)+KCY@:=W^^CUE]!')*ND 5F;Q6T>;?NW5[R@@5!283BUY;1VQ?S] MF)Z*RL]/ZE93=>YVUOR(QGGMH&ZC&VP%/E2/18 ^C)\=="0%!47:,Y,8ETA]*

*M\=)-09MKT0!6W%#-<-*QD_7RE07"F1EYICHSG2\0\0\Z1?4MBP>;FH(@71U M<:#*1,67?O1LU*//F\|"@>GM93]M^8C*K+@&JN(Y^U780/D5$'E\YH@0"4'0355@*

&EFQ,WEG=>A-&R)KZ\{J]- MO#XRA?K>'!9JVMI5R%$ERT3WR.PW+2\GZ.)K_J M>YAGRNKY8U1535)L>]'!9.9%1&5Y$Q%

*MR'00OW9>8|;T47=&)B?],/EZ)&/&F9D9Y9[!G\ORN=>KC[H55>GFL6;S=GL"P9EEZ09!*28Y';_>;=S:0[,#N 8|LSZ?!@2K&YMBK0##J9M0 M$>FCWAM(6E1M%Y*

(CJ_W"QL2$X1 ^[7%<,*E4B0LKM!W0O2P|\:W'5U$^E-U_M5++GRLA|BM&&K FZ@U%EV-!RPL6)A,&5Z8/7!"W45N0S':.^TPJU<&=2-Z

MX=QPI_FT>!\&EM.E===I\)V'E>2H5HS52:/N:.^N1L7NAG&1T=ADNZP6&;],<7 MGE;T5V7BWFNLY^\9.,]VE!'?I?D5#F=%\5L&U7A'+>B[7RIS;)D$92O\L!SO

*M"OV1^']'WUN:96;3718&=%BX_U9@_H'J@4URP&SJ#S\Q_Y0)H(B/02TI9,.'R'O2?=B M_6CKQ3M2_;>GO)'PYQ-1)D;J/AZ\S-?JX6((R[=V'1XL\O=U[,,2ME5.3Z^*

M1FML4:]L=]N.X[TPF-01T3C>XUHO%>1 M"VAB2NA[L5E6/*&V[=%*$I:^C@&\5V*^-?RLZ<(,< LT]Z#>0V5C03.KNZYZ*

*M9^[M@'(0T|&2]6BJ8/|!:XRFGI7;942YD:'R1GLJ+>G!2.XEW9(KE-!X.RF\ M2M'X(Q(#:*Y(2?5SUH(X]S4VO/E(_W/7L?,TMTZB1KM*4KBO\@R'*

MR:BIIJM94YJ[!V7OPWX0RJ%,3/%A5]X.2X9%G@J&0'2#^!T%W(NC5C! M.Y)63<\(6B="E"/(SF_)!6?7\]VCT$<3$1!W%OSFB-M_7R**W?5I0:@M(MK4_-*

;N!ODOA646O)]D71UDFD3(0RLC7]/6BXJC4[.W']O.TZ&6>65^K$TM?< MXM,&%7EQGZ@5UN\K.1O&THZ.Y5MG9P.97 .KV5.?G4Q8NUFW)K.2=ID3^=XH

MF]Y&5),42MP/WW/7:$BII0SE>4I=%YKCV[T&\)N_]"EM'+*SV3>UR Y"]V20 MW/\7E^%IN5?(KN^9.:[?80!H+01*!=6Z7PR)W0?*

%XH%OF\##;N@MZ.;38>A!")86"E31=.1+YM<49&30Q180(N-/EU?LT$$0 M6A4#)S ?Y9C)=5?B^&4#U+B#-X!])_=8C8BENU9VU'TL81 K8^43 M$,LO1?

*Q(2U!0VLE+*2R|!|[" #I@?]FQ&XM-S3" "WX4 #V-%;],7%5H M"Q M(*0I>'2W9!F1C MF_\35)_&$(^@,O!QH)17-5P)'YV@2+,71 M@?Y\7:9[C8L!K,(/<:^L01C M_P%) ,&T-N'*

02K(N4P@=4,1B -^B/7,.Q MN 5X>:=?^\5_+^KMT'_U=G_U=G_SSH;M!3=^+NS0[*@"]AQOV]+-84&B7/M&D /H"\[=]K#'B74PFI M]-Z]W-QVHE7]8LG*L;,P[OUJ6V-*

*'H2&/%_1EWWM,:$Z8^L7U:6-_G:V?"?C/C=7QZ"]5>N^]'N!@V:_R04D&UV-'*PTWBR/UOPXC!PI"\@ M0#=2G=]2:[-=7ZVIBWDQS!S%#PM9.!'= B')'V(9M!1432V!. R;*

<^7!?I\ M[]]:DO"G",_]Z_S"/GC8 .$#BY@9 ,B4@::,NK/UX)+^) U%2 '|=[.@2N0G M=(#UOTTCW'|QC:#_9*.%B?3!:CQ?K$-_%M@N[#(8 ^@&+1*0?S&#E],K2^?*

7M2W4T?4BB#+1-_|=Q+G[:90\|B K#@\4QOT!$=A M>R?O6C#_]G,DO=0E2B?@%'K?'/#'%P$^E=P6H6= M)_]DYA_&GA/=A0'DVJ-

BL#%LC:"^QAO'/K&!?D_P)[C\BQ,=;+?^@QFLLD8< M7]&#KSDP@!ORP"G@Z>W?|ZVP .K+@ITD2?\VIYK^-3XO_,G2/P77%2LZ'8X-

M>9SKDC;PR7\%Z7\%Z7\QIEO4\E$9;%#.'@:,@9@#7)%-!52.H4>'3)=>^ M6#[-,&@\"/+E6N ?O7!{@\Q'P;4.B%_!| C_]@)W>U -+#Z948 $P/M)/T M>]U"#B-WBU9IXP^$??*

MZJ9OL$YGY.[Q!5G&BWJ2IKC3NE54)%!TY?A7 XH/YBB;YK(R,2D<' VP 09 MDKYO.(4$0+#QW3)K\E62TQMI^GJ/-;INTK'?29%1%!4'IY=0E7!W7=S%=,A?.*

\;UHJU8ZZ;,GWT M(!F#/:#'S!J1M.>$_XM#RTIG1=/0@KT8P]EK@N!7U<'BIH(947)YIWAFOL$I M]G?JQGGN=VC3%@,W Y$H".Q7P=;/X-87%96F-

*=^^6'@D8U^"LBPAKE))]=;_M& #//?#H8].YD0W9>GC>GC9E(O0CI*V1(395MJA)<3]>'""&R^A_E)@:;F=]M%Z74R!SQ]7F.V;T9MB2]_L6%.2((RH,ILMF4.^G\S@1UJ-*

BJQ/%;Q91 MLN_H# M>X]-% 5+U%MVEH71'SN'>>9G?:@QW[>.7>/=KQ/GB1]VBEJ:$K#]U MOQFS,U&-G]=Y\@$W#N0.W-,&WD/"=2+%3XP?

3)+=Z2$4.4XXE]_=SCFXXQGP M-*CTC2.O-'_?ZO%X^@$A>[I,,;NBJV%5?; M7C2%1!$&B"30Y@G(A7,ITV3#%L.W1T)6 .VG)E>@G>/5]%RM4V:

M3DMLOI=WG@4C\W)13$AO;]EL?8,%HT_5MJB"LAF1NM=I7P^3KKQ?<"@:%/<< MR4)@S0JB.3!NF,7]2GRYI-6>7Q!HW+GZMWRA.N=ZY2:{[ISFO8P)4|\0NE<

M%Z$EZ0VY^\YKH"H^KT+K'E%'[=%,_^&XFY"":FM *NL%H5D*4J?L9JZ:K6-% M?"]..=8)H<4@X!+Y"'2##M'6PWE].?+58?V$A88?"$3X1 Y#@^(GA3M<+GCDC*

*M^0L@+U:T$%41{Z[D:XCC0Y(+/PXS68,V+G$P&3K>$?+0]V*17RYAQ5[P9G M*!.3+;?<-0S/?9Z7W+/FD!O.K'Z;ZN;65O,P_M>1L"5^;X~^"N8*;T=R<79W]*

M]WBD6YGDY59\WDK.F5C>K[Y2JR ,FEQ@>W?]4SS/;JNM_8>L0M59'AR&.1N M0Q0*2TQ,>]3W_21,8X;.5-Q-74[G4C/G(/4~MJ??P6.ISVU8YP+]D3 Y!8 M18%7.*

(:,,79;OA:^2_DJ \YA'!BOOIPD.UU.+OQ05>Z&Q[H>6 M88:3[&<:.2U4OZJ:ITH[LKA=/OSDW51D2U+Z7;=QLZ2P$ MRZF>S.]IL_%TZY?\#&W `/Z98T*

*M*41X*$FUKEDIUL GTB"NT[QHW@V6$C?X:LE7M#C>I;)N> M/12*8F.L18[MQ+CT]);>=ZJ184%5,);QNR&\U1%?@,O\5P<#O17PH*

MI08LI=GX^:F4<8C4#P2(GZB;%2YP_]E_?&_4\=|-T2,Z MY[HXTEKFJ49=ZR"D4QP_0V_%PNL:0O&N<)-62!T<)QA\K+<7{C20W>@['80 M64?A/ &=$-;O$O#809@D3;3_]-'*

V8BOU]FZ]&D&9I=;Q]'+UW(MF-.:3LNN^ M]XKC(MD] T@NY+T!V;8&\]F-:CS%OD>$>R;R_0$RG.(/7^$"$S"W(U=)8N&@C MVV%D3J9^;S/Y.D06YKB9}>5SYB6#

*[C#\5OORR#2:1224- >;4EBC!X]EAC0 MP!QG\)]6[3N%3SRO!'JG7;?=B*E"\^@K.6B1M\Z^(0:@.UN/C..V\ODR:,.MUA"^=S9@M1'\(:C!S)E<'G@NY!]*

*fDF;'U%GF07/=&KD1O*O#-S8XLZ'!+;0 M_8S*+K)'2'1R&?IOD(H65]I?:CJ$Y'HX@ MO,=KU1LOPS\.:2'FRA77\2C+)2BIM0G=U^9I"I';UNS!F3%&SW5DV7MZ7[U6 M>]C?*

WMW=6>2@U6 MPB+9D ^@[Z%DQ'@(^_CKC%SH^X],(WM/=\P?; ",:L4ZQ-L=P&4'_B:V=^57 M^]":AYN((/2E(F:P)9KN[8P|.\^K>EAH:?L-=GIQL_A=)EY^6*

*MX!J.0!%0VGI:@C 9"D,(?HLU_4Q'<-O)R\QQTH1/2M=/8_!M'>GSZI8%+;\; M;_+),!#*U=A3M9%=%_@V>4=0R_+"M!M\)9,_*,.]<@PV M^A*XI,.CYB?VX|*

[&/$&B3UW,K(J97@1_*UIY$A)M8I1X2(F6YE?^^O+PX19 M7')]N%\2\0C%=?"89AV3-D!DPW!95V+P;2.Y1=/E!GQC+Y5/Q@B;KSH=JI.V M9M01/SV68.N0^.254=T>*

(%"+I44>2[SU?F.Y5F%TAYO:1&0=NI-H.0\9YHV@=3S@O8XA*E>2;-7S=@Q3;20)IE[J;9E""">LIE M.-@\0>T)/1,3[=M4.Y%VM.WSN?C4X,8|O]|"^+9.%OV1C5]SAZ[5*

$2PMA M0!)^85ZOI?:T%L,^UK:?=/*5?T M<$>X(M6ZK$-$Z4BTY[YWG.9CA9&#L#.0]0P0\FE%Y^/B5#WP^Z3E-#AH&4&1 M9OD]362;'9=_]$F(,UMJGCH

*M5KY\FU5O3&A/0K4(/C1'%[]--UV,!G?)OGTI,GHM!; *F%(8C?>]GHJ#T15L&?_H&MC@S"'I5>,#S0F =7YM6IYL$BK\M^LG]T'FEC?=0E?=611U=.V M]$?P=O^\DN*

*(W2^WS*_5[@#!\^8:DK[UVT>&, ^U4C[O8Z0+V&0GC!))\&LZ>X M^-#P %C$[L7QVO<&K$E#'O 7R"O/AG;IC*!K2XXI#0]WTH[(*S" X@)4NW"- M!C+]RFL1?*

*G'O!'2)",3'"F6E7B,Q%F=!6'E80@,ZP3'41LZ!EU7'TH"Z*_$%% M1)S?RP3_6($=<(66VL ':&QZB_!T,YD#&!?]"B[2LXP+3R-NE*RQS[4H$7. M74J) QK+]@[H48=K9\VGHX!@,*

*[!YQ?PCEKL8T<;KK#+70S@IXN)/C\",,'# M@$IGQ?EHS75E+G3>N(,;8_(N+)^B0&D795[?:&<ZC>!H M,YL5!NKC]J8E$D'3=9N0&50*PFX-@)6Q_W<4VWE-*

*M^S_YR[P'[=+XGN2?. M@0G\BM^HW=X.(=H7RfJP|",O=2X<|"\R.<>5AB%U695A\[Z4#"AZV+R.&K23#<*3*L3H2ROL.4QD[6@X*1^3Y/TG MI;L$OPDQ;QL!JSN:EV3"*

[$EN"RK3R 7"PYUG:(LUS"92+>]KY0L-%9^'$ZJR M7$:-DCF#O;Q%D8GYMIF7.LEW\E_#U,92EMUA=IO^=U:]2 %HUU9O/@0T$N5X

M"-.L0_HLTI.@67N&SK@CCY2=XW4,.CVNQZ3>+QVQ:VZ\2/RC3[' &7&_)G! MS]B3(U2H7GZ>)-K7Y]*J*8T.I;MR!;XS\ XJG:\91_ RQ2[HM=GSD^>X,:?%*

MSXQWY(>D]A2]BM>>=!>$Y#(JG9<,DM&C9,>%0(PH>3WA';-J#. #"V'/E#+M MQ^*6/9X4CYTF5,&]EC(/@3%()5N&/SZBU)4GO:U*N6]TLDKO>M#@VC.F-(MD2+[?*

CEEA3N9S+>X(P:VWF$\Y]W.0*3NU#P!L]$0HMH"O2'40\3-J(^KH=/A~/]IS7:\S6@)+!,Y5OU$]I8>,2Q4>]'UH.?^XOK+AL*_/V/CCQ[&W:< MMC=/V-TVQ*

8\9W9.7U4&QO^4M/=4PC71E9I7ECL;IBN$?*>YMADUT;:RO)E+ M#YR9%2]%%M'X'^TJ"R ?RGIRV^]*RG69:7,4/X:4-$K9YNY$-2/PSSOH^OW=

*M#W4VE%T.KU/JQ_<216#EH1H*AXNG?1#JO:\K/JHZ"/X0(9R\Q!-N7J9A"UO6 M=P*%132SG8R&50*R& I'KFU!%X16'AL)3(:1D>2C=)<^^]!X] ML\?0_S?*

M(ED+MNC.SG8WVD]ZI.M%@19SY^O'I%W:4)+H[P'<3;:HI7K\RwI;D:X,]&>C-EG6 MC$]0F"NY%W:4V:)8Q SBG%A3~:M&G)=:5]HE7!.;9Q0OJ

*MTKXK&P=DWC((<"B*KC>#,R6 MF14D)$? U% P5"S,.WCU|N!E]3@*FU>4%UC@<^[&&4)YT*LX=)TPP?X%;(tG M_/]8.'3F+,kP_.C%C-7IX,",Z]L%T8W5BE.9!PA=_WJU)2*

>TK"=.BDYXLTR MS6KTM-CJ%RG9%P(/G@!2)Q_46.9,\&9'/DS3#-97.(U4%],OS _L1G'O@8E0 MJF6-PS(XAI

*T@ZH8I6CNSE>C*C3D6S*]B@FF$=|^"\Z&92'899B[#QL/7B!# M"BUK8;!BE*P=^O;5[=[;KH2SQ$HE3"+RD;YVR>_S:8/DV0FSZG;6QY-7[TQ-X^\A^@;3XO^8$6W5XX_*

SAXP:16'<) MC]=D6U/=7FG,9@Y6G5+\@I=>?M4U%M+[P'<3;:HI7K'}NBQ#[P<)<4E6B)D MC.WF5N.4ER*7C4&[6_ZXW4>'WQWOZ(Y7;M"2*

M{(VF#:W186>2^"I')7I3GNC:6/%[PIX2+-BO)X+/E_Y(AS\%!TERL=188T\&/8))'S&=E:,>RJ$*B+2NJ@@8! M]=P)?DRO#U*A)+KN"/(-%5 YM$EHE%CMW>WVB_] ?OE!H?

5KL]0@U]!^PA7A M.;$,YQ8:K7WR\WHQT B1\YCO/L^853 M)&099R^#,H/<\:HM6=].TRNS#=&7]=5@H.CO*UK8IH/YRRI>=/5F8(XPM^' M::OH455\?_"G[TYX#-?65-*

@Y/UD6]9@#"+H]W)RXQ//L46).6A[V"D5N M<3=:7A'S'BF9%3GO#$W>"]_ >I^[C\/LM^ AQU-!5C%&FHG6K[M=,HN485]2&9&4#38%B?ZD"35

M0J#/G,2"48M15[S#22)I VIU_7\!0E(.K5THE<$.!C*4Z M/4&]0$Q?7W3^VG1BO5>']W#69@\]>8;%E.62O2(Y-'0??G .C0#.&(2@,(Y MZ.(Z!D"7(^]S&/5C&?-'&*

(#W[T66]6V> MNFN=H?#5]V/0G3/H-=W89>2?]YQZI&Q-TM0GLT8@-$$!B!+;9E0CQ[.+_2]6)SAC">Z<9#L UV93&)4W/]\@QX MV)HE[JGC%7VJ8_YE!US>&)-*

*G1%4.CQZ>B_0.*6*+G*_ R5FE!=M/!0]QXCP MH#\WZL#*.RTE8?0=]=/)0#^?"^%I?BL?@OYASIY$1.T ,1XIC@$;*YD2B-E; MV^?E"'UR)_0$P/+]Y$1H1*K +[*T7HP+'ALGOS]*TG#N$U%]UV^ MXN]^<%E6/\4E387QRICRFW'R0)1^-#\NXC&Z2?A*RG2M57+7&[:A=35+X7&(S_^]< MP*I1YAVC>]LB+4:_Y:/=>0"^=*

M:/B+3XL@AU'>RR2ZR-F1)(KOA,8I5:P$,%3I6+#U3GGG,ZUX@XNF@ /<4;KL>:K"<4VQ V7+V9QY_)^"U,&]Z*$;:(AW8E>

M]IV_%HQN@+BV=N)&)_9$/5WSCUG[V9C=M%?31G4U3 HO@83W4I P#{"%+!2^ M"_R]W!U!=ZG7OKO8Y7<1,192Y#N+4L J0>(VT-_>N#6A[B$=EZ05E\#!Q7SU

*M_!E&1LKOPX]ZC:QXTPG@Z%7&'4Y05$]/@

M>7S_9>P^KF=DBZM[50,L1,\P0G2&.D?=%3$2=>3N^\(@_,/\#K%72X?Y\{RG MU6(WEYS.1(.@CJ\:@UNAFR_Y&RRYFKL=80)KN^F]0KD+?7L?ZQI&;?0HSK,2
MI($QO0=B9LG.\)E$6\^E>SS]$X#,S?M+4Q[AK@,AOM.12MUEDNF8I.CJ;2,J[MQ#M9\BHKG?,#@ M#CY€@;M[9=^-I0$28V1989I$!SW]6(5$C,C+ZNAW^O@%5>
[5\|K^.9ZV\V\V M@$!)0R3_A3I-Q&"AI8.9Z;N1U[_:0W"?"WM-/UW'ISZ&*C?!=X1$VSWFV(OX4G?H2S7,O4I_^/?_M9YD8 .XIG"1"6E*A2$$HR|%*^/X07>VC/H;^BVI,;H^?
O6EWI8TV/MG DT(U_MT[U.D*],SD.X-W-VPN!=\V&F^BGMI)SHK)F43GG;\ M$X0[T|R@O8D&BS=HTM8WG@:\LCP6 ,O #]3YSG0:.$;&M\<$>6#-K/@
M0\U1R_)@A:2/NJ[LA%A[NP^2,68BG_9U.A2<*]NME40D1Z0=)WPHG)2UY\H* M7%]5@NSD+(A_XH?)GBE M[K!6V]"$'H-7V]76!BW6)#_ZZ!(0Y+&\RA?[E 9-
N(UI8UU=6N1X/,"MV6E M%5UCZUO%TZU"E&0.DP]*B;?(G*C?,7N'RUR 4$C!-.8NN7%!R%WK#8(0 MMXH+YBGJZ%U36E ML1IP$WT'I4F-UK.YU>>22]4.2%;S"?(=
_fTJX@?UB?4'Z\29D5!(POWN@IR M@$]NNO/0%LE(&VILYJ]TSJ.YWGO M?:^:]>61SE,$ZAZZB>C5_95\]D\tT|\3$LF_7XN%^5$6J>`J*<%2^\68RlB"/M8G>3T>TW
??,N7_)6C"](KT)5VL $;D!@F!|7^"6-@VL8YO[YF.WYJF:3R> M^[6;,&W&=^MSYMO'N.KO)#Y320[7N;G]8RH].XIS4X>5T+]4[R29F^B /83.^FY)HHO)6R=
M7,^UVW6=C3K<5TG$^FZ21O7/\=__S7C?F<3@'} .HZKA8N30A@$$T,"TV48\ M-Z976],LB(ZKK5G4H1KY&LVPM*)F_%-LRSC>329-YC3E#"@1<5Y=#=&$,<5#
MFWHQ@-@L,,]QC#M6?M/VHO)")=O/-G?*G"?-0_S%5RF\U4=OBR8'Z(X;7*;$ MIUN>A"B82HR,'3V*O'U:XK$("HSMFB4<.V(17I]PVM;G-KW_@S8P++;\]
M75*!9#/Q.83ZMJ#KH7^,K373&&=*'SE/N5/I\YV AM=W *=7$5>=EQ&.0'K(M\A=4YK5?0K[FC%5%$<-5+,S&?NIRE=)#V_@GKY1QSOP(R=)B4AZM'MQ(C{H73R M ?
4A%_1!D)A0Y?Z,8OZ*TA.G\'T!)#W9!GE'/,ER,]118%ZW9!9XFK44K #UC6(<=+^.BPZY0I=_XM98I>=4'GM;_B^*>O\FHDN;_? M@$U OV(H*9A^)UKB/OJ*VPY6>3]8PD&<&0-
U8.R_*VAY++M:A=:. M*('UX?:TI?0T!&YI*#33QEC;/NQ(M+/+[*&U)#/Z61U%7]QR)6!$8/SK<*KT M:Q;?&#?WL1SMM'1W 233O+\E\^H&=R\,PJ*L+C40,,//!;1:F?
1RSAK5/ZF7@[W6GFYG08]\EFZ* M7ZW+#-)+E,1S\=XQ_@5!-'S?FE\?(MNRGA/6Y]*RPTZJ2"W*(9BKLBEBH<3&=C/0 ,\OOO)WDW6$>"(Z?(((H&!B0B
M((9I<@%]HED9#_ZMB9S5ONV<^?KF0D&N+^3NWZBG#0%F8N0N[>E<^VM1KL=5 M"2=@$O"46#K"3H4WNK3S-N/]VX_FPP/$0^>%'FZ%?;#_;&%]:Q43+%SG^F26
M292A_XV"Y6M1:DGSQ.],.X36TD/E@^R^,(*=W9T,FY7S_C@O8$/#D+V8K-C0 M5/;VR@B'OC_%!%2F'F4Q7VSX"GFK*9>V2B$[SC7!1V).RO[#12. ^J.1*++9W$
M.!=X<>C3/)*NH[%!9[_EP4'.LH*-$7-,U*ST_#/3[N8]H\%_]WL?4T/2]H@-M-Q1*A?+-O$:.D!\%P4495/"HI@>1M^$/PRGHGH1*H92TC'.)G MMVK/H]?.
L,W)=Y6?JS-S]-P]Q#E$_2+9-EOGYGUZM.V63HB*.ML%W\W-3A1#!:J9;=?NN4\9N;U5231& R&_J%(R2/29EOZQ3GG[_*JUXQ:P] M<$1OOZW\GD_R_?@N2A$-
1M*3(S_YZD87T3LMM1*_;;^O*W:35^EF\WQ@,^Z!-M[>0NUV)]=0S!%Z6[!>K#1UC\KOL)'4-?X?TD#KMKA1-WV99@P$L-_$XOQ]1-M4(L!$((5_^R8=V689M*%Y;_>?
KSJ.D=67.0?EP24*,7 .B2KT?S'|_^C'LAX M]3 &P*]DG+ 6^[P_S5@R*:I PNOIQ3/.T$H7$CWUOF.7&$X9A\V M5HFNX+2 *#,+). "@;0Y3VYZVBD8N** MXRW-
X\V,/N#E3> "RZH0-A/-/P@LF?/M#[6D,,33QL]5(#N58Q5 *D=NSM HX MS&/(GZT)[OW6;$6S[V.-HST3@MM BF;C<@"DFLQ5]B)KS5_@ &\|K7"&6B9? M!Q X1OH4
TTQ4JO"5+I]>BU2FVB3'T9H)`^S2H]3"-0%%Y2!'* M"F4|&'19%+G\9/(8_ CIBP&CKDFP5DA(BDQ_O M)0\54#?FI>AG!T5|082-%2\]?"Y9)*+"R>.PH-@C?
OER>ZF*M1%),.B0#:[MU?52 6IOS$C(4!I*H4&\/BJP|\EOF"'^%'.S=LP#68[W.K[%XT7$$B M2*/1/I[>
[2V#6+WX91G;H!L,K66N'P(>Z\7+HV[>V,%1WSV@!TQ_]Q\R_<[MY@2]!B'S8/60IP]-SV@DMP>GX]YJ,.60"%IGX$H295HE3LHFAM@5;_,$A'T: MR7!-
.,J+N:B^21V&A_.H@.A#L//KO?O)E(;#8V$A\)?G83ZH!]+=""%5(]I8>_.MA@I^:""LK9]\A"O@U$TGID\M53#"-.9_M"^I&6WFJ&GC/#MJ7"%,8.7Z\49/ M> 2X.0P
Y#DTN.1:#W!:.,KB)3XP>9<4]7P^4$"6"%-! ;5R\ M0.6:P(5\HN=)B/6YO]K:E.AP]"P_#N\@,7GP15648],634LI))DK'8V'?C>]! M@8[!\SL[1S.,C8:0 *,N P,;."+W1N"21.\;N,
[@UX3F_N$]ENRK[G,8#] M!W$MS=$ MP&V];\dI9^_:,:9!QMV84GV.0-)2(8VC8_(TU^UO*\5+83G:+B>VG C&VC5A]:F5+|U"##2^1+CBUKXYC?0\N%,\2T:OO3BY=
MCZXIR>CRQ\U'E%O8"F=F$5A6L]G:,]46VPE:)A&5EI%^&'0_6FP0062IP?Y M^;5],K,QS+*K;:_G=;,I(790:,[&PC61#[43]H,17CL^'!$6,3?.W#[4PZ ME!J3@P@%.
I.1XDL+H3$/@XC#&7WA;#N!W*_L/;0;.44>#&4?C:)\PV\@LN&5 M?5(N+PUE:SIBIK]JF)+QZDY5%,:BAK\.$*,/KDW#M>K#:AO5!D,"Y599OIJW M7Y1HN]OIQ1B!
<8XN40,!>Z=,VB@%2R5ZX<:1VH8^GK+%*%.2GZU)QG7](MUUC>6#$=9#Y#%L5B&! ^K##\Z,2,Z,(_U95_]FI(> ,?!&PVO):1-
7RI,AJ/S<9S4:AF/+G[OA\YM(C<[6%Q)!+.FW:99?X2N M"=]+Q4&3]RLC660^\Y=-*UZ$)L7.5)>0B.$#!PLOGR.9S[7+[QOQA[_;!^]M":0))TFD.X,R-
B*V73O9G,0SCR<>)/,1VY<"=M07CR^YR<(O?&ATRD]]-=8;G MEC)(PD6NEQ?YF<'LM M?VC+F#@?"RS]K*4]]R;Q;E^(*Y2&.Z._'=%,,"&95ZTN.?A"@4+FKTO:@3,E
MWHN9!"*2 A080#(H&233;&IM:G4P"EX[S,#}2TQ)H>>2(:FLTH33WQ>)CG MXX?D59]GSG<(C+.B!HO^%GTRZN)8L%PG78 !!(* <;GLM=Q1!,#Y(:RJ_@A< M/+UZ,""!
>"]2_A%.VTJ"]$&'_IL%V^0HW!H')?QA_3;.=U17HM W@ >2(>A[MD+!"Y?S-7Z9?V^[#(:,"!L^GKI%3&0F]|%+.6Q7(5E=N%7VFD"IIZ ~!9(075BTY^J?+"M3%?
@^]4ZPJF\;3OFFKA% MT2_U?K=#LZIE(^2Y4/^^.0]|RJEUS[!:^\1RGZ]7 +XSZ(EM&6X M-7,?/?>J01FDGD"AY%/+<$A!R1#,$9VJ;5 J8N%Y;?,!07:SMZ,.G6VBLRG
MVRVH.BU"S+H_,E."U'=ZY?D#4;E=3>2A2RJH6&U'UR?A=L!1KGLI.U\W:E_B M00#>ROXE?>,#8 3YG=XF\IBU*"=^IO*(?H6'1OH.V7> ,8 3YG=XF\IBU\'R?(6$5[2QI7
M#0@I#^6IH-.$],.1:=;-A 2/A.I)J9'I*IH Q7 C>G?Q^0]?^!^LY:K9/NRB MQPMK&C3HE%;+\HO,A,]N$4;KN=51#$6E;1^E<;8C$#1,/_FE"S.+K),=&(J61#*'+&!] M-
1]W"X7L"'6NK KAJ9 $K\DN5)QE9-L<^8"ODO4P-1=] 90] MO=(*$*<_/A+Y6&GM-D>X8?"QF7-"N(?A/:\(Z2"(!CE'C7]*,F_=\[MO7PX.+!V]H0F?WNSZ*X M-
;Z>-6IV.0+K*N<2Y":?:Y.I^.<.(:'$@QS.:!4Z5-U:6.M[\P &CAT!6K-P>,,#P/P+4;SG*7]#KF8 2-[_NS4!>L<[JCD\-GI,2D 5.K:*!7A6>N9&'_R/2'}Z<8W(BL!LUBVU
MSXQ8;R.'2\I'P_S?%Y-2&ZVOUY$&ODAY:R86"UU72DQ1A7'&Z^N*XWF?WDZ MKSYLP=,,V<*P%3N!64*ZN"9%NKC&F_]8KO\&^D=N#]3EK_$S\?I%,/XE56/< M]KG2IZ)
<'[T$G_B(<'6);5U?1T)WW-.<2]HQ Y+)&'GF?>7XTOI@B<0Z'}+" M@\-H,FC?.J7[JME[@)B01QN0Y1+'(MN:Q@YVDK;[ZT>U89@?OQDA[:UNYV_D
M0_[QO9ZZ"]+U2+*.:N_3R)&."F1RZ-BK)H!Y;/FY,P=F*HMX1/84P=T3})?:R),)T M] RTS((+I/K3^ULF](A$WW%1#6651R?$._LBX4(F!+L#@:!Z"\E; M1LL?
6G!CNTO&HP/N)6F&XX0O-HF@IO8%,$+]J1;D/M8D$9XH4I<4*$i)Z)" ML2\F=K#$5[ARX@<'KL%%OBTJG;WO.^=,1C?#E]2[ZW=Z+,;6FGGF@C47DA:5V.1T
MZ80,,;^P&#G>VE)PO1+?=7TQ^N/@>_W48P*&]_+O6& XF*7G"IG-XW?1&\VZ!M!GCY"_,X.GP/L'%P^0H5M(:!$&PDM*X<*W4ON+!-_N#UD/?_0/[Y M&!H9OEG0JW
Q0[)IO7)FP5G@J2_K\U!X)V>R>AG]DAQ!6T%5L%8L$/=,E!]V M;9132]0<6S7T?"/N^YXSY)LS/[Y*(WZQ3]K,LHYP^73_U.,@&CD'61Q&A/_G
M!3]@V[X,16^VOO4&39^(ZK7[0AS+0&@^^23L"',QXI MO%+:.&5]=^23L"'*%4EOP?%;(!V#TE)PH>;.^?' ,/>647%U[9D9]9"@@4!P M*X{$$M=0@@>(+A#<"G<'0)!@DN X$Y!D
KN;B$)[NYN54A14 4T>,_W.^.< M[W3WZ>Y[1] [8ZT?M6KO,?:JVNN9>9<;DXB$R/TG.)CSB.M$A_U$N D+7;K@+I=8L; MZC%H\I"5[;Q%T)[MN:*OM;:YLPPGT?
N'MA3VE15V]B=L&TU!|>]<<*-CPQKQ M2?T>0.,B*Q89@\;/=2_3[*G'=*YQ/P.?'848)4@[*M>6HMA[?]Y2^ W3SWD0
MV$U5WRP6%WX[45PYN]$:&UO3(9K)Z9B$GHU)>\&P?;[?@=_2MQU]A<T2-0\+\^1 MNJ7[. YG?P"#?&^ C9)N0HH@:%&B'S#S!?WQA#.75Q\>T$0XHO2ERM-I<2NX7
M2"R1NP_A&%26]27Y31;\PU\29^]!|&^K1*]:EEF_-UK'NX;50U"_C+?6*BP? M5V+;#KH=MY'2%[T%@C9D9S,5_N2PMWT,TS%/BGIG5-FK%;$)B;DR@0.9< CM M9*N8_;??
5M$9CB=D4,|<{1,CR^=Z=C?MW1<9$34N.9I-FX(*![0]=M6BP/G$H,L4-#=*9#/3" MS;EM,T' @?5>CF]-S1+6668_A<@TX)+9$EDV00W3]S0N4B)=/#)))$!V]O9? M]KW[H-
]HS]? &Z]IEIK?9Z_N,9+O&L#/9K*I1(53?MKTS3?V>. R[A^'N+ M6UT_K^)_=XM;=QA1K5)7EY("OA4O7&(7D6G-&?FHU1Z"-EZ3&JB_"%=M%BTD M]XM;H&HXT.,, 3'$"?
SET\/\;5HIX^[NNBYKD12$&_82EY#ERD&$[-4-J^, MR YKQ2S^#A!:M3:"T GO MKDW!(2 -,V;I):VUJD_&^SGG@0KVVL%Y[MLQ'IW /6: M\7QY#H?5FIA-G81C!@WT9UXY
&9)X-+9[^%$"C^! W4&^]O/RQON, MWPRAIM_ N0^K_=!6.VB\(E]><$1<%V*))K). ^\AD Q19/5@%)5[+'YQIRZ\'
M]*VICQ'!=,1Z&N'W2XU<1=E[NUU;]',ZV<$VX/14[%T#Z2,:FTICP]I-Q6QK M-UJDR?
F:]W_^R%GK38RM5[Y4Z]!%)3:81FM!%>^MF^W2*X;&&NH[(F.\275@Y=3.UXQ!S2"%/X1-SLUQ5.N0;T+V]O1O'+_TZ
M(N\U]L.=8G'P=&M!G_BK*9XZ613C#=RFSL+D>=M?(X0=UA^ MQ(}RT;.? -P8GQ6T_S1L#)W@,%V&XXN0HPM+O0"IY$/"^(G^:CEER,-"8L9
M7>ES[-7ZB6CSS!OF4.SD!1\;7+C>(N37%Q.VBGR%:\]SH9P0+*8%N\>@I\Q M8=;?*YQL7E69$:VW7V=4IF\<.-Q?7B-S*:?QC?G6]9:0BBB M0[T(.]^1$Z3+?
@1^ZS;X0M-#C9%'O+DL#E/.J)"|",:#EN8Q4UM:JF17)1 M>L1K/PA_M625\]D34%48I-6G1 A--T9OY:)FH&:X>39Q-HEY'X/Q&QD'H.X) M$^GG,JI7E$KD^:)EF3)2M;
[M#%&.)BQ>M&*LKQ#1-72$H,3BW%L%820A'3?& M;9S BXE?5X%*%U;?^X W0.C*"7"!4GG%OFEK%%L7R?-3I.WU9/?KR;O)-,+ M]5"
<9P$UXG0G\INCN1W)K%?"8C[VO+Q$?QJ0?-(D8Z/ OO-1+4:!<+.,)"?- M(XWCNOX:N*7RMT9*HV+P_P?2*"M$1I^/<8@;Y(C:]. P)<"T;]N.W9-
K]2*CGLJN2M"J22KDTF=88_T'#) _> =#K)O"^SRS:.,9GH]#%(\GEH4\ M!|P)MIP&2EF",5?/|IE,E;TO#4]ED58!4.W"A$;2# (.B& M0K0LQ?
*!MC%;4:RRS@[E5SR/$$129UD[%B+PE_(OF;?A M=S%<,>PR P$YQ'Z7$8&&A2Q!\8>;\)2+FEW.2T)[92T9XW8 D&'Q#SX$(WPT M>:5ZUM.0UQ+#A5G]O ?%+
(ZHP)3PT1_*DDMS7R@]@]P MSSPBF5,D9?%-UY9PD+CBJ&ZR*K!4C>HHAB@E4JKI MY2<^..F?'KR])-!|:$ MER<(NIL?KP>Q91 M_;>@0>WU/G-
^_)^5G6]GU_'J;>MJ[/QP=1 _*T'1R'MP!-A.\]&];U;^T5OXG M@]KYWLV2/[W/1N>QO?E!SW%]>AC(TXH]4J94&HZ 4R+_/#[1V'$1V3+=^%L
MSH*B\IPGI.Y&++"5U&C3VXFU0)M02H&,U+K(S1W_MF1=XA.S,/3BE[=K^U>.(.08 5&M,69;^S 7\94E.H8'_%M.JD')-;XH*B> Y3O$1]ZX/D(_G5N/[OW_864AQ=?
D^JT'@.%2NJD'UN_#H _41:/DINPNA ,2U%1T[WB(G2 MXE-V&G77_6_6/.\"5OXV9;#;,4F62?4%>D'1H!PW9?F>,N:B'
M4JFMB*N:^1<,-3 `7OY/HCS%/U*RHJ>GIPJ_HC-&_I-5MVHR4:4 $PR?]57.NENB==4\KRQ4)397EINF/0)^NV_7EM*MQ/ M=]WN ,3MC TAJ\+^Z3+N.\!'RS]YMJ;'-;?
0+I,B2H^.^@Q*237D]L.BEE-8,9]YZB(/V&R^(RU8[(GU.0FN_A*WVE$;&ME8V4QN&^ V ,Y7R!Q4IBQ(*RGWVA?KT0>Z=,$TM' B&:N9C) M-?
ONW>V1QCJ], .^?!=DC6TZ-.S[A35L &'3.?!2K-UE?"Z$W)]ZSWK[R)S M^ZI#KC:XN=[60K^]1#,#,2],]"?'C'7:O\'SAS$W<+AL?B?XW $XHVE7 M6/H,H:(79#,S(>7*ZE
ER6I[C>L;PLU)GT?K.9(':>=\,*X]9T_3;YT_O5LQ7 ML4QOUJ-F<^C&8!5 MQ8(5EWY ML13I0@!3]^OO3: J#3N@-8A NZ/1P.]QRI'8@!2M-'2GVN>9EP=,EU511 M#
[^N!>4KBD8EI20O<@XR9!7,)() 7=FOVJVBH IZJ/&]C:]O*.YDK^S:^9F*%IVM*:FUT'L#V[EF_^9 M6_PM-K2LL@YGH$E1%/353/+?'Q>T\P:/H>S53-K!W7 M>4*Z-
PR@=X!CAWP'"D\FVV>]BKA Y^R+?9_8.)-R5IQ BT?!/;01ST5-X(*[M/6)/_"K6:Y G44T'\|_"]VM!?.2U+9])6t]Z&;5FW46B\G+IP7T$K_TFQ1T) MUA(N QTP9+5IW?!$?F>7-
,"O;^;KP1M#@1B*=3B-NF]Z/WW!/W^ 'HS'3X MT2,,,7K:GF\VFKA#C/PN&\R/A40/U??QU1?/IO2.T,?,*& :]874"U0WV,F+< M9(F' ;>)3;T)>45:RE$-
X*&/=M:N"]PJ].YWS8ERYQVIJ(*'EG,,%6?&[;L MB[<IW &"P\03\ ]KUH7]VACKRI@K]18.2SVF!YRS7MOOX[_;07*VJ.XGX4% MJ37CB':>VQ&]RU!1%A#Q<8,G7UD?
[D3AJS?O*E=XC ,R$2H=E4<_Q9S=5 M \$?$#W0 ""}_L'T+;XQH+-[HF>"G'U=7/WKFYJ.HXH&UJ6/+^HK6DTP(B16 MTSPNVIF;Q<5B1WH3)\'T=;IX-NEH1)+15';
(+EL*MP1;DU#&K%XM;O^P3IS@0IW 'MN=']KV*$7 MI8P_DAZ%#FL(%M7>Z/@<^
S\W9C::UB#QV9>WS&XGZA_AWR68+\EM+O(13>X;QFR-.GR+A=4ZI;I9N|A,_UDOH[6<+B M*@V/^CTZ0^^$ L,<>/WUUP:B1-57)9[MG0V\G%IO%W@B'"R
\8X=BWS7>80V M\K #!)F#]-X'-3X);*\[P%H]Q#'?3Q'Z]5A)[\AXEGV#X=FSS*=*5.8?-D.B MMQMUZE86C->ECU,+E-;BL%"LM6'K ATP7&VNQ=H?A218P RF)W'-@&'G!+7I
MRETEV^-8W_6.\(N.>22\>5+\|B>TRT^1Y3M@M[H1IZ^11.>/3D6^_:U=`@NQ M=O1\/'O*$WG>\?.T"4FR@'U70\/1^E#)_K%&:'V%85ID[7N+R$^-_M]\FGC?NA>CF
"6LC",#:!3%C#(;M%QFO?Z=+4^M:/D).Q)>W$D5Y-+)^X=.MP.T(/;.4N>9*.$?XD2.,TO1^7SBQB/!A!]P MD2]XK>/US?GVE26H.\|-KJ,? ?'(^C8F*NV\W@N+@P?1D!CC"2[
!H^LGLO M3!R?!1EM(3_LMS_,C\["NFA]-LGMR\VIZ$O%G^(C1O=Y D 2$_,Q-K%B>?# M1;[=$D@3T&7$B_BX?A;OEFOE>Y1^LV6Y+HAY.*Y-[FKJ,Z5/@97&""DA7C4
M3Q_! KOLI8CK&HGR<0QS\[=:E_A4/C^B"1TN\,5-4)X#=L0JK6%]X';J^BA$ MS<+"Y\HBIB !5:@P&CZ]7.\#AT&.5Z$,%-%6TY#1[!WJ MOH!@#CW$'0#^%D$)$U%!3&V<1
,)>&-8NH4/K-.CP/Q;7A8(R,Q'\ACU^"B M*LH(Y0?]_(,0'*\-M3AS#Y^V*,/]U/FK8_[@U_NJ0_DDV(@NF?+EAG"QS[MI> ^^?0W'J_UKGZ&4P>E
Q;BV:S]HS5,.6I[(8]IO"5HF(N8.0$<:$?B/VBI/ M5B50B1P%@3.1@:\6_L=#Y]L IXKM\,3G1[(,BT+_M\AEN_(F,J6>LG+M5=X M./JG*FADJF"!@ZK10.>?[7&-8$1%E]67^LV.6T'
(P8E-M4=X,*@;W/+Y]B; M>$<<1'.!%/.3;*J];<>Y-.J,-^KCU"]3R&T*8M ,8%.|'\%WN0D;N ',.:T/P MFHV6QXDOY(ZV%0\29:]+-K;0?$@<0D:!"C< XCV3DY\>:.R>#14.
(KE9D&]Y M[4RP%4T98>H=8#1XRE^[SX<[L1FFB(%8F,B7!*1:N7HZE0UZ+3H%)2M+ =4 MPU#7XNMIZ4L73KBT=_@*\.N7]' .$%48W &,%'UWZ2/IQ=R&WG1O#[T@
MU3K@2E,3,$,FL.HJKGW'I'W\'E2R+S+5%'ILWJ!K!HJ8TEW#$\BU"V7T"9(3 M#&@4M,WE/+%3)FW/J9C"(VNC-0%SX4PZ2]A&>&6Q_AL I)TM[QUM*'VS
M3QRN&1,,N14>T!.#.K]]D;B*O1PT5,UA+ -MGMJ>2-5A/S/01?>04<.1V>_.!!0?]ZI?<9QD0)]I=>>7;[;&EY,YFY/FN# M]_D!^6,S&:54 ..YX;&!B&JG?2" B^9E3?-
K>G#MS=63?,#>IOU>)ULD'IU!5C;^GG$3WD\9,$QOC MQZ@CX>'?)4D-*"G.X]I60R137K;!Q"KB9.8I2^>+!H O\C?0REC@J#9'RB
M@R4O*C>C"3',7C_8S.8Z_*PRP)C%/+]HCH7 .C)A)39G'3>BR2]3[+=KR>:XI@@KPYG($8@O% MIU1!,X=CQ\,.0!,\,O#ZO+ D.[NI(_?S8AE)GS<97;TW@V,Z*MJB
MD,/5_E]D5.0&E-%@KB^WJ1K*%,U3"5AO>]U+,$6]OLBIP&40N<^6+?<\PI 0 M0H=&M"YW5F>4#; .5^&]9S!0,X2G2 VOC.9=2'YK^.H9+ ME8PU>]Q/ZBS$=V!
D38C=#/EY$RIQ_[>6DL\FP\1S_%^Y2 MLW!V<7*"-?^/# > ^&;QE"I:+DU4#PXBW FL4DR=X#Q-)95[Y&M<O>6'E M(7&S#RX3DL
3NOTI9_S9/BW7R2<8C.)2WQ<6RRZ'VWL^)Y.JOB-GL@O)XC+ M=<%'4T,PRB]OL/D^R@W:C'DJB S:ZF@VB#)-%I)*D/,"K!7UNH/"[@ M@=W"1^<-GLV]Z=
!LXL,]\\78U9=NIQ.CW24[OF9.%Z M+6E9Q%]CE@89TN<*^WW.U$VRR2MOJ[*\&?WV2300IQ;QK.F^.Y+)WJRI^ES03]"L^4@;D6>1A%+#LV
MT53%U+X,GN9NPZOQCN*4.P#/2-&80T$S_SY]HG*7N<'&KK*M8@?^/N%<6W:& M2\(^GF1:R%,"#.AQ%R#G#:;8@,.^6;*0;!*:9XV+&MI&@CQE<&2YT"7C;I1QG5U>
(U"^YGW(W"3A2^LHST:2#SL0<(J].%]9W^O2_)&I /S$8A:,W\WUO=*$W=MP=7BC^Z[M1;R]@M-JM;Y"8$O*WTX_J]\@9XH;IB^?L 4W??ZOF9@MNXW78B??)A)'/Q
MHR<^.RHU8\?;4V^5P/F6%FD"I<9O&H4&!XBW9L2IJA ?2PUM:<@G\^N^'B&U M%DRQ91H&3MG3 CV"\\00? M(8H24)+]P%>Z[7KS2VN93E"_-O-1Y!R!@_)H)$,;>K"
58F0\OA K?V{"G[U M99}/"ZXPHPP_%;TTA%ZLA/'56/BS/GL'9?T&_XWD3Y3;]"**#ZC;$%Z)KE-< MDC%[LEG_G3XY5E#?&D!S6]SFV=L\-=WD[_MM4?%):%^79K2<%
.SH,9@O]>P M_^]JZA/14FN_$$WD,$1.8CZ@%5XCU>F9N%+<*N#INFB^K(D) 5&2] MK.(-'^CK_,WV_;=6/T,:*ZN#([DKOD#1_G)Ms.(@U)6?W;Bp>:,I%!"4L!3
M35_]O$L4"AT(,R!;^'W2>+P/",A7Z<:64BF'2],;^$U8]CP]/KPJ;_:-)V> MR&= P@1"1]QCRWFE9,#GRUR;W(&:$?/P%:+1](95T81GE YCTO7/Y*HJ]VX M--_JV9

*IR!)&/4G12K6$#_W)=ZVD/UZ5X)TOD|4B^_M"PU#:),]YU]1WD0SHL_;5]C2Y/W7P*U_>$L.V]\#[-M/]9W !OQ@N)%%:(GCG2R#:#O[\>^]-9&AWSLVHG5Q7_4EGR#7]UH M:Q723KII#VF-BGZ5&/@>]|E7WP&^.>9!?/S)KZ(]_RMGN>::OYWE=K>!)^Y_ME;:8_D]U+/Y|I2U]_BYMD?V_7MKBR)C1]\0[$67H$&0D>0":"QNGTJ@>?P2 7N1T5PVUD9V?]HJ3>U3%3X3P|4QL!)^I.%6KE0OXU\Q_&2_D:\7|KE3N2.P\|=_M$8])N+7#:F/(2*1744C"|@!=M2^];3*5X6!T_C=+'&1%F8W%URG=0G_)+07)[>(E& 7%L&MUQ.DHM"_M58986P^DOAT%4HE3/E2,H;^\NOM:GUN4Q6$-09[<&J4S;E1'TR.=^!(/4*F>0$*4 M$HQ2*Z1?+XEQZ22*M-<&_;LAN5 XGlQZ)EZ @XN(1@XUBL^F\G8V@ 5Z=#&T M=)NR@OM"RYL]K3##7.WIX<8)5R=CRV13BT&]"@[9S5G8:<_FQ_J$;(>)1%T M/30<57$@7SQOH&.KZ(3+$#_^7>>T2 X-]V'FS3[RU? H^#G//XOV\FA\|X8T_MRGF7%#VS ?XDBE^$4(%,(= @>\U'.CXO6@93T^W@.U"E2Y.[OV)T*.\(/C.;6 M\,,,2&^] VT@T4XHRYF3K;0>TOY?.M#N?"M[>*LN\(JK# MMKNAQWB%N4D0IR_-[?O5GHY[48F*_G]QJI>]HH]FG'''@-$M.[*=HB-_5 MSM$.2_F4JO:5 >+.V_Z4:K4[.O-5)5?#3/[5R$;0'XE7%8O|.Z7RWX MZ'MZ%,LV/KR>'>;QMO[H22TMSI.NIZN:0KI$2PG71$DR7H,1,2K-XPCXW8GN/ MMAK3F6-ZQ>T*N,#1+3DW8BYDW1UL 4\1(1(1@)/ ZNHGY0K9%78,V8Z= M!T7UN(PZ-87_'J8T$?P!X8]#^XSY"2%QO!0WW"O+*0"!LF52<-^1AHV41X), MH3/F3EBU\!B(\8;\)&?&%(2&,KE97N@.AD;SEY'O4EJC1Y*.M_/4U;\U(|"):]@W+B,5-TL> <^19 M\-A6>#T&?87?PCHDA(8,AG\T!S9(@^9TW0&J M.0:,@^<[NB#$MJ04*Q$7Z'63Y]M3X@LW8+M.2RORW;EKUSZ!3@FL5DKD!Y02 M8@;B9POS1U';A/.1EY\O\2#? Z1;GVF74_R[O^?CQ:$3,>AO/I(<-'<]KP& F MTB_@!LQZ^W@908AYJKS."Y/YSIO UK;?O\ U\-NIH@6RM-XAY'#+]I6A=A-5 M+LKGOGXD=4Q@+6KK)WCD|DGW9=2\ (BMNF<"N&)ZQU3_0?(?E0K#@C8GZ%^-06PXZF*GI"3U88%#;CQ;"N+J$L-P!PMZ- MBD^U(!VUR!4Y9BL^=+#=?:S6.JS#+Z^0;J2V0T>%#^F%4QCD,*OL3Y7N4] MJJQQA5GD\$ *7X6R1^4W?W3RJMT!1H2(PF109&BZ>NS%[OIBI[*;AKW]E!D!, 7QTQN1D,6G M-A^'#SIP>8\")OJU+DD]%;*9Y+1V3(P?O^;k3;,298M*GN*23X+B0J3D8'M'FBV35I-

*W=/]3:D:47[H6[10[\X^31P*3ASD=TL,$370TFXN]K36V)Z>.KKQ8'<5?/LY"T[\$#.$Z]B^)D4-'G3Yl;.AJZY]4'ZX@_P M<0$'#PUV AFM58I1W;S?>T2@#4RVLQD2YNC 4!=V!7C6-QC3]4BG\K5SPL]L M?"E=8^QV#"_UU9N,)W@_?I4JDD7N:+4\P:KHD2:Z7QD@I@'% ",#:VPQRS6 MO@PO1#;5&$*VGF2>8]*'?!IE28I-$P,1VQ?;H)N2X^Q0>E#- %!KN?G6V4IF(M5Q1)[=^)?IP)W!UMX*]#G+\"=.,;S&:>]L%D7[,;>-7MTM@FQ0!G^P8'78% M(%*+/)@/8IABG>2)/2G4FGYS1-XW=O/A $\C!2VLAQ2#A,OC[04*L#"0X0,A+ M9&!^J3*O%_55_DZP%YX\U.BBOHS_).-T:L 2>6NJKOL-' M^P--=P"ZUL'!G&K/8#_0.DC)![-HU#'EB+UR1KF[QTO*\$697RYP|QO7/|OU M-8ZDDM9LBNGG("MQ- =Z4]T3N*F\U@FT+O_XT(F;T$I&,AT%BRY$P M)\L*/S;BY,++9]T*ZQD:!,HXNM<6KA1?T.51W$H4)+1H+4X_@V4-H2L;U.&] MODWV|]SL>5Z;K;]2N* [$31...06NTAY\.6:IW0SRRL5KZ"-YOT\#;_$HN(MEHYN%YTS1EO]YOA);O8-@1%! MA2^X2L?&Z>A!S]"+HWY+.SEEK]P>8-'I]88J"OL>/26&JK"K#3L2K)4GT3D[MFA;PY>BD6B-?GF?!;_(1P,MP1R>67/RFIR6LE=SDG!JX/M=:>C1)2@Y29HV/ MZM(+C87!3[4SDP;YHC8.OH3WD,):@L9E0W$[ ](&42Q&8S$MBZ]UO-]OF.S* M'&8&AG]- 1')L3K$?'[\8-$6^=E (;R;8_)79T$7Q_5W+[_5]48D-A861RY%IVI M(E:6N9Q3IK>?$=K:4JC2@1-<++7OXPYO8!3PE*F%23@PJ<[=1/WY76/CYW#E8 M0OBW/XY6U3W"9Y/GH*=^/JE^OS(/L,X>URG%L6D89!^OZDZR2:Q<2G=]%VSB MJRB#K?KH2SEL(:{"9'O8]"77R@3=%&8B=KU\RXU.E5^.37VIAI&%Q&02G^=_]{C MR'DE,;=B18;\Z-KA6>^C7:)\NDL!.ZL9>|_*$\C&P2##.?>-.6^BGQ[8O"_E$ M$;,GIGY+Q_OB'Y&/[_?)R3Z4X88@U#N2O:5T_*3[)MU!C0F?*#YU:\,B?-U, M62**)R9129"G|)N_2%KN*13O!3;K^J&UI:.AV?,BI6,.3LN(SEC"33P"GW(NQV-M 0PCI8(\2G#K%[(1A=^94Q|\' 8PBN_1(F2S3%1T.Y:W>%[+%01):@U);-QKR%$U:O.94: (8KCLA!:K; M:E(K(BM\0HE4#5\,4,-$>B\#J,-9P4G@VC>^2*9S?(O9Z8_@T MGLMPV0SM$P.5O4&"P:,,V!Q6%<:.+3)Z,#O.'.K&3Z"GS:8?"#\XA2HB:M3U6 M]@IWD(C_O)\6] [AF]$O[EST#1\0 P4#KTH5EL/CM^#FY[N -M.<&@7()]7]=M<^5[(VV5'MI".-&&T [H5'),Z=KCT0XKUG"VC,;4]%^Q;I2M$^PHJRR91G\ )M>CZ-& E=NRK- M.,%=E.:-L)1N)VO1E87U=4\(CW+N-#=5]]87Q?MSF-KCO+HD-M]IN0^+8D87"KWB->2#W.9VU-]TPATX3/LGG.:-F>*OE@O*;L8T:=K)7'O!+[-MYZ- - MQ>A">]N4A173Wl,9EHU7B^]6F_@-#MU6W/6,1E$85#*]Q?)?_ 6\$ M74+, -=FERD>4XBC ->X=>Z&"^/7+Q?9AZ&%6P"$6>S[5#$%YG;(B(8K$_-X,M9/9;J*.1$Q8:9FPT/O M@#AHLS% ^@-'?B/IQ+Q#\/&Z=*H]IFB< 0&5N#O^1^^Y(=>X^O1^WM JUM@_MMVSXLF:H2:Q4Z5P@$VK#\P(##/KF4GO35 SM#2C:>G.:-1=PY[$? 492'!5$%=Z8(\XZ77(6,;G MKZZ]=^,Y4#H#\N$(Y>#%\3>3ZS#&K^C=GIPS9[%T9L?;79+QR|<0^;@0.\LW M[L6T9MZL7.!8LC^A+Z*7-5WOX)YZ9V|WI_3* IU9EQ)-5RE.+-)NME?FKK4A.^_G7'H'U;T"_W3'6NOZ@U-MZA2 R3<-\.T'HJU&B^05,-5":YM.$;_M]MXG4_!=I?)H+2T4MS4'Z%%JP:@# M#32I]N;M,@H=QA?Q(L7>6#'=Y&- T_?_<:A%E$.D\)*&Y_GHB)@GS+[^"PV M*)TF)[^C\S9YBV6FNW\TR>S)]^=3<[8$_E1B%/KFTTO$AV((3P^02]:120(_ M>H/0;%+$T.JO$1RO#D5#_;6E;U\1$,C23RE'JX0!BE@W/=K MV<":?A70O VZRO!D1BFL2X3I>(;W-KOI7J0W]\15D9J;DYK2OXI0Q*LQ1%'> M8%<4| [BHRJ055|V]M(&)0N5_OL;_5?RK/-'LK^/GH&^UAAV)Q#*O=^C5=O MQL!Y-F-.S'ZU\P?\EK@//M:*AN(2% @_HT6;#1+/Z22^BJ'F.X'[N7,PO#Q8F/DX$+?I^S)- V8>NO;%7K*TYJ6 OEHD_/D>Q-MFKZ1/R,%22@2G>(/SUI,K ;M)751E'P+E?IK;.2K2'5+N-JF&+9K.DO2@T#0[5]%

*N!)HG>T2F93E=:)1>/:!H1T_>>MJ[? M)Q9I1'#I^@D"$73Z9/C^V2@/G6?X@?BHNOE?TOVR#P;&EEUC-*D[E2_<,+&8L$NMJ%&A,$>IFBEV4)T*CC_M/#^,,!HX7&:U\ (.R8=+%,_-^$[V&283V0ZY1&OA_FD%7ZVR\G%?\>+#=!4H. MDFK&TSSXK=YT5%_QZX-4$<<=M!%MNX&!?6&6\>*;C.I.%*:?]^CUAN323#UM$L!?\Q)XPV^:DXS-GN*CV&\=-\N)E+U>,;_MVN"+O"1/!:)NF!N0)PDC0(MOQ*7Z,\K+O1G9_V7S\CO_?*]\O;KW-G9'=) MG^/-5^FVIYDW0:C#>5(FFKE:%&ZJN#OWEW--(8[BYWM88JY K#" (7QW86M>_M=:.[4IA]*:+1'T1@A51WC;&_&l CD4A(^4ACIGH6C^^II-(SY+?D.-35 M^(9 @L W6%S#3QG=*5QRJ2-O7_G2 DM@<_.CZ"1?ORZUP+IB'^TI8;[UBS1 MKTUV$T%?.!Z?"MS]HG00>6_0"P_K\C'@[9-PG8D?%.QP$N3X<>N0 3)L;O%. M0YJX2QCK+F""2-P88[!:W WBR2Q\@WO=Q,W_W!%1_?$;J? WB3WXT2V9\>6_!NX(&L1C2HS6#!026GK4/'K+/IN0, MQ'1-IF!%E3Y[=X>>;7/(@\>)QI08=T=]?J'=NPO)LGZ-_;/B4OGVCHWK7UB"V= MEF:8/E5;=A"+7"SFF)8:,K/N>U; <:$XLMA(+8Q[O"&:QC-5W3;N:??U&KT MK62>-7W"39_I(@>2,0_>\W\J*[11ULB_U5Y\"AG0L?T^7 ,.]':JX7ZN?Q:I M/QQ,=.3 XC7$(*

S$!:H,3#6(XJZ)\RKA]7M;4>J<5#EW%|F:UV|E?J'N11- ?W4UW\O@D*>FO3N^M8D]H]22EV*%X@DPNO#>MU096$,! ML9UM{'G/OI%=V.'GYDN,'0G2+S|E2^ R_!.$@CB1;M9O/35 HH%=006: M3[++J4S@LBH2(?O5\VMKW\WVV@OB9"8P=>(>36,(AT?T*T(,V3K"?/\KCP,T9 M"Y:L?H9\>2#;]G4]GM+%,:S@) BH7$E+;@OGZN9Z]57'!" M_]QGV=V+;@;HU,U!J/?)MTKT-[>L*G>~A[>7X_E %X\&>2?SMSTH,EI<5 MR]-[Q7%NUBO3^<.&CC&S1U"0[?+@2OO4]*V#@YD)Y!F/0)0%KRO'"Sl-B) MVP7-H3PX\'3M_6%!/C6^$QC=Y?Q}PTVO//U!C?"#90EUI,/9:)/}!MGSOO$INBVP2UIR)RA?%JJK)7M M:.G[!J+S3P 'KM'[_7X.STQ-9W.lZ^&# 9IF68M^1I"30TM:\;*6Q/|ZZ[G# MM?J,+-N:A,>??%X;BW/@(FG5!:M,]K$LUR5MF!-H=YS5^='=8G12,BQ>RPKL M>,YFCCV-6Q<5X;=_%@87#%SRX/NC%'L<&!T.W!1/HJ;B*E9*[K*ZO2)??\CH MS2L\6V*=*)PS<2ZI^'NZ22<$M=@[T(:^4D)VE5F@L=5T-$3E*L?2)*Y?:#+11:I*-8;E*T,9PI?'Y?F.#4@?f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|K$ M&*.++>OV"R_KJ9FOUTQ-Q |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|_'L&#)WOL.>OO27TYR[K^"]N&2ZE1BU68IU:?1?9;Z? <8E+6&#<0\3L/M M1C*4Y>,WTT%]/$#<"L;!K#=0<;C8=8+HO$^ROIM%T^9AJ92 8ZL/"3=2Q5&7 M^EF7%? IA5Q) 2-O)K|/(6YK7!/4[N>"%B^;T1S_?TDG6Y%B$+SKX-I2:)G]W(M\@D(H<7*-O^LE^#O6/Z(!*\+ SK#CK=,FO% M)X*Z_.?+I5OB[-H:.|DEVSB.&#BF;U]XZILE-H1F5]4; (HY=.HW/E8EFSZ"Q MCL\X03.7"L^%4!$Z%L]-Q4 ^O"C(^,;/9'.)6)6#OK@-N%GCS++@0UNZ(Y\&.Z'B:!NM1-31PTGB0NB$/O?C"#9?W=.J MD85?,8XL -PGUNC8H/$. [7X!*F4Y'K,@(>[U26$NS W7#HM NW3*4-D2P?G-K M:T.\6[G[\@-$[>$/NS@)P,YRQKRE5VRI3BE11[-C)]#C\8+ ^1$V16ZW7W0V6 M/EI& UE^0&6^(%QK6-G.ZRIJ.MY"1,1YC"KK1!2_/K&3HIBH9MNJ71\J/0U@)1J;H&&%6ZE9(X^P@K,Z_3G2^8U1MU(,^K&] _:?E<.E]>]!7W M@0SZ%Y7=-^DCTP;XX'- -VAT%N+B%F)/ MFX;.AO:$Z-/?G7F?P$RWA":HP|&KP#5T-3$A)-CU7RW&@@ /QL+L< N@MQ/*$!0>*<;:T MQI4]HEOUTQ-Q |KF34R6(815A=]HKC(N=?3_WJN.P/A.IV=;:Z=:;$\'J!8>EF)3O03GU^ MG^B'N2S'],[R:9HUI_5D*@8[5'L3,]"(EA!AB/CPG_>)(|(%UJL2ZW5!64@J4.[@F+Y*-9ZQ6$!!\;V*8V5 /;[ME>2CN0"^N<;@U1>TN#]H2P&]^RF0660*?6!BS".E! [WY'2#X?/(53?P[$%_(MF/P.N_E4WW2EJ867,ZXI WYJ16OA",A;RL MW/[*:R=->A0H:D,3V\4B4<$|P)ML)%E);,,|/B3^++))YOBNZ/[$Y]-+/L=)M M,D31,C49QGMRQB_9452(!>L756T<'-KIM?@VF TB^2%B5X /LE:M4|=>-XEU M_6EC[C/,?&^)>IZ"ZCKI5>SY*OG@U(03Q4FY%K'OOTC0-2|&HKU;XD\,3M'L M^IN2W(S'YJTR7^6/Y#G W':*(M(7*B%O0(W902WK2.&+[/;[6!RXER<9[E=A MCZPO&B@<2AVJ$8ICQ BRMOR1C6Q.^U'KU5OPG3&ESO"E#U,BQ*3$?J!,% 8-M>AEPTZO2NIRV'O)I5.G'M8ZS>*'$.CK?'QSN"U81]AJNR7W)+Q M8'W(X+ B7?.UMQ5*\OOF9LFB"!MWF^JPA; >"^>&ELU, 4"[HA=XK0WD!? Y^ED),$%=@$104S|6)I;_P71Q!'3-'ER>[XD> M9A(\P7O$H,E9#9AF5F-FW;X MV>WT' S!\(UYB_K88OOYH1!T^F65P"'7M^&GRC[#N@[L.I83,$";:WC0%# MZ8."[4H!HPWVD+;1N7K7CM#"#C?J80U3E@:PF-@#H3VP6;*OW6#GC X\;O MT1 3=YYOUSVN<_%>DR!U^CNF2J*RL#++1F&FC3V=]WU?BU(K)Q +_J=J,"9!* MOWFJF]'%<.5-+?:.*G".10#XS!:O+G3R:-P?KFJKN2;#:,MSE]W)>;*P\\CK M5K+HB&MMU0.R_B#R7(LZ^O!!?DY\WTQ28'9C?6A8^5A X*FBF9#|=.,]NPT8: MC3)YV?V# [%,)2S1QXZV^A5@:"4E#6YRK 8UNOC):C M>P?EDVZ-8WSMM9I/)G^,O & V=UQ8Z.M|&#*Y@F=WL?F5&'78J_L :+<+D#^4. MOK'6_;9===$LO?\ZZM=K#XPN 1JB0BX('$\Y_.:J !)DXR[-M*4K/"YO@W@+FD MY/-TPA#/OG8Y2%MH^G1*YX*^FMBFU)FR>"13L6>Q80U3 MF,R[X;Y,-

X,J#DG!1! &#&@E*IFDDAT0M3JY7YM%K&2@JT)K#1 OBO^_P<>/5,;Z .N1UADZHYD9EK#O M&\&.N3H"YS\OJ P?GLKN3LA9UOYZ?D=29 @_P;^3'SF-D@B;WD!&T5M:!F)M ML@1:&A(BPJQ@+W<&_L{(5A3S.^^AX$GN^ODWU(Z;<)=A7O/24*$?^OJ<"\,$ MZ;LN!,O\UI*L:P?GRHZ|''B]J4@G=7YUJC&K&^F7JC%]L[.IR+ (.8=?,W!+9N?9YQG\V@[3>:]HH#MBM"QS-%3F/8Y4"@SWR',=X|_='DF8=9 Y3;RM3:NB,?G^.?C_^OV/^%U3L9N0 XN02.F3,&D/C=L2>WP\Q(?T8R)]5"_D MCMG)\&WAW:VQ M?K_#G"Q6CH=R(*L(PQT@^2KS1B9,&(O>G+,V=/=T\A+/R&'SHB5GRN)M^1G^ M;ORA !_DID5"N\$]+);3]Y^=]PKV557] [7$LS;H)]K!T:3L,BGY1/,3R%R@I MF1H46*=)Y,/LUEV#^!/?8P((P+AVS9(%Mf=,4]>QAJ\\M+"IFO=|DVZ+/$*W M,^F?T;;=_$/_:\ K-]ZA*I\F|RM&O1-S7PC5+%##P&?CGQWJ]5SJUT=7]2(MH -?Y).-*LL_@'$S;=A[LC'(*6G?/-G8"]RKN &99-;\/"[O"&552>D)5!W M.>_'/F>_4E;@2PX##X +Z.RPKOW5D4EGZCS'RM|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|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|=.,]NPT8: MC3)YV?V# [%,)2S1QXZV^A5@:"4E#6YRK 8UNOC):C M>P?EDVZ-8WSMM9I/)G^,O & V=UQ8Z.M|&#*Y@F=WL?F5&'78J_L :+<+D#^4. MOK'6_;9===$LO?\ZZM=K#XPN 1JB0BX('$\Y_.:J !)DXR[-M*4K/"YO@W@+FD MY/-TPA#/OG8Y2%MH^G1*YX*^FMBFU)FR>"13L6>Q80U3 MF,R[X;Y,-

X,J#DG!1! &#&@E*IFDDAT0M3JY7YM%K&2@JT)K#1 OBO^_P<>/5,;Z .N1UADZHYD9EK#O M&\&.N3H"YS\OJ P?GLKN3LA9UOYZ?D=29 @_P;^3'SF-D@B;WD!&T5M:!F)M ML@1:&A(BPJQ@+W<&_L{(5A3S.^^AX$GN^ODWU(Z;<)=A7O/24*$?^OJ<"\,$ MZ;LN!,O\UI*L:P?GRHZ|''B]J4@G=7YUJC&K&^F7JC%]L[.IR+ (.8=?,W!+9N?9YQG\V@[3>:]HH#MBM"QS-%3F/8Y4"@SWR',=X|_='DF8=9 Y3;RM3:NB,?G^.?C_^OV/^%U3L9N0 XN02.F3,&D/C=L2>WP\Q(?T8R)]5"_D MCMG)\&WAW:VQ M?K_#G"Q6CH=R(*L(PQT@^2KS1B9,&(O>G+,V=/=T\A+/R&'SHB5GRN)M^1G^ M;ORA !_DID5"N\$]+);3]Y^=]PKV557] [7$LS;H)]K!T:3L,BGY1/,3R%R@I MF1H46*=)Y,/LUEV#^!/?8P((P+AVS9(%Mf=,4]>QAJ\\M+"IFO=|DVZ+/$*W M,^F?T;;=_$/_:\ K-]ZA*I\F|RM&O1-S7PC5+%##P&?CGQWJ]5SJUT=7]2(MH -?Y).-*LL_@'$S;=A[LC'(*6G?/-G8"]RKN &99-;\/"[O"&552>D)5!W M.>_'/F>_4E;@2PX##X +Z.RPKOW5D4EGZCS'RM|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|Z4C_-' M1@V30'>!N'OSZ!XW1A/^CY!F(7\S7!OP!3X7T_2N\NV3 M0SM;??9ON/_%,#Z*GDG7&(C7,*PU 8B3S!'XVI.6Z7>V@TO+!&<\HD8^,T M'U"-7Z>M.%SR\UB7!^\$- _5X+9AU05D%3-O&Y:OYS/2,"H9=7:X <1Y'5H-< M\8%T2@/*VM07N;/-1&,L4XR:G\M)'K7-M^E7]"91#=UM0HQ50XP6,=[:8 R* M*#8+: [^#16(@]FJAO+H_XXZN&SDV(J(O^0H#]9+F#:0^Y))G_ #

(R>K196^NK7/;>?MG:LN..7? +D`\|,.(I)TI[;.GI#V)N).I.7<> M;-DI E_B4MACO);=|(.D)GE#:H]Y7ZLP]_^ICT28A'\.I!.@A=F 6.X9)\|+|*

*M@5W:473M1/)L6_+4M;#LFT4MJO#&)F*NH$-8U&/P:A-[A_^-#F%VH#-.D1XN M1#9GG/#AH'LA^T<(>7'Q=IIN'] B&*.4#-=|\T?##SE_0600_WK#(*6.8'9. M75)"78+@;+;X@!3A.S MO8B2[%YF[_+Q34$N.I9LIM/CO4Y[5O'\ O/^I$"\4Y)[#Z,0]U"#R%D3BE=' M;P;JESL.^GVQ5"_LI1$B2*_'#K&V=G[00[__T?*

*9VSYI>CE^)+>)UF>KIR: MK/2H-MSOB@MD!%?'C0:RN:IKZQ03M=\I"\A73_M-(-B>GLXM;|T>|-QVE^]MQQ>U1$|CN1D= _^V]K#@V6V - '=\+1/P&30$X5J M"]^8"F?J6QX4,J8JUVW%V2T|IGS/)4*PON$FFP&XN*B1-4/|5&#$V;P,KP/\ M'=*M3T:X\;/JI;^X!_E!""Y_M/S7.]I)A*^/ M5)>1N%KYP3\]B:@ H]# #]<-*

*;5R;3&EA'JP1O9%.GRNIU^0DM1K-0% SJY+\%6% ^3C_7(/YJF|FFNKAO?*W29=R9U/_>/;J.4^'=UK^$AK MK?IPE>O)LO$-("S6]+\X|>P-*

*3EH33OQ^'''''2#0]+&"=N3U2\B=!,&1F5)-#[N)\E'"GI=&B->KB-^;]=//\E=`'[.2G4C5YWVKOLFMYLXCC*Y9\=[.25Y8T'W/'! MEQ\));*.(>XYB+U37DKKV"-$4X>N8V9A?*

&3O&6#[1FBL#=.2GRNK30JI'\FS MP6QROL$3X)P]R@*1+_ JH@3PJF\2+?"0MJD!+/15_W&G\ ^ M(H?*

*B5:.:\" 8JDS!NS"40I. VTP0[-7"A1T[.995((2Y>D3H?O#=!HAG=P1Q.R MS/#E+"]AI@U/50@1=21#.RX2VT/:U9.%&7]W@:I<5?P>B2:PQH(/[%TT?Z$P MX*6$0W-*

49!NK0QN[L5<9^_T53M-%K8KG&A_&Y>IZ2#TS87J2(YG[@.R3OVT^ MUY^/912(R^7Q9PZ\#AXI>M@(U-VTEE@L,SR!FN@Q6('7$]7N%0Q_^G4)>^29 M 9AT6ZSM\G1J-

*EA.S/GM9$D_I65C6S&3DW;I)G*S3T-9UI.MV-@=I0ASQ0>V H}E'UG|CNYBDF(W,-/RU%-U?%OB+O8:U59E)D-6-S^'/(?I;RO%P5[.4,TEX*/*

MKE=,US$P7LQ8Q*#E%++E9WFMJP-M]*\DIAL[H#ON6DT"S^X5.C\7A1DIB2K-METW=|(20%4P>#SVC-ZN2MFN-.,V;2:O@%^W@7_!IX'MRR*@Y##OK\XEW\'$

*M%1524NZ\G[LDVP6H/$L MF<_GQ]JC& N#8'OC3N67J^R%OM#_.?X,*_>^#WAV1L>1955B(4\;F](1$!U.D MC5U*7W8E\:ER:K$ E>BIFN/)"LT B6*

,1'IHN\,8^3;RP94"EK#7UU'>N!I! ME_VLCF2&\Z"FA/35DIK%"!\K'E5>#H6$/Q\!R/N5=0 G))5AR(;1 -(?2; MB(7ZF)%%[6:][2=+E=]^X56-*

2_KBBY18@#&7#%K[#D%?DX)[36+-?$ M\>8^9%HC]$IP2^*+1$)/R5Z?Z2C-I^^E_?Q+.?:F>2V';)8<(,+3\B*]OP+?`M8A_$E=5_+<+==9[*TX+>?*

G6OJ.JYDFF)N.1TU38WPLQNJ'$MJO#6@=5)5U`'- MEO305K[W7&V+NFSJS=%[C-3.9(Q.*>TPNO@\IDO=L@^H# Z)47""$-]E&TY? M%1-

<6@!N/C:M9ET31N|HOX07S[*2TSNT. 9!%*Z>WBH991D!'DMVD*_^X;. MY(1D"$0E'KT1^_<9,S-"\7.+jU'))%4@UO#*O`T3XG--XE64NAMPG|9?LO?@*

MOE!H2N_>6A9OH,@MP-< 5/"(.M/&QW\CWONT5)89:W1G_%ZL@(I+OWMK&TB M,;9R59()&TXJVN.D/SA.RBV>Q[R4:A'BE%=, MZ[TC=LBZ 7^W!VBIE^|[-K^+1[?

*K&6 ,2%P!?RK5S.NQV-D.(@ZXF#OXX?Z MZA9UUE=2/(!#T24/(WXY8[Y\(=L;;>NLEWV&B?#8(V#|G4@O;Z,TW?++!;AEE MZTCU9/\RD-N'6@,-9SN*C M[:KE!?*

AO$3VI%P9M/ZZ:BJHN"D<7>3TW"8L#!,%M;1DERG>\Y[6YUUP7P3S1-LL2.87KN MV9W#5!>$CSZ#!\QZR^S< DC `IJ0 ^4VNQ#26[>&-3)IT0*9?!5_(SW@:)*

*M0KLO*I.MYFJESLVM^|E4B)%A1"/4'11P[9V4Y_(13Z>>TG MGEL9?#UM_#>(8"]<_EICH(C7M7W/PN5KGK3N5]!'+I4Y&QOOG+.A.TDP;I7[(.M$YS*

I79!!J1/@66[.,NN#">IGHWX'X>_>ILV(2.]F_B4TW%41'0A^CW?Z,^R M(;M"V/ZDX64O$RTW&XC=3M?2; VXP-Z=33\)PR^Q6' 2HDC@B41J4[XNS'>|

MERKR)W+BB!0M/G:EUAW$UDZ^*LLP6)F?A2JJ4UP/9'%MZZ4NCL0 I^&++I814.GOQJ9-2 MJ_DY3RSQKZ('B*ZTU!D6U,Y6T20=..?7L$@8%&+&1#T?:+NDZ)n&E242C\N\I((P5SZW],PG$R/>?*

*%NKG)B>4*8= MM/V?26O_'_%8*O<1: .R&-)G^1@7@DD;TL&L-,A_#A*LN-]B:,8W"_]LL.? M(C$0\>OL&U'<*# FFPMC<9;D$LR]]6(SJ:2I8N&?*

*WRYV)&Q[A>8R/J^TD_)7_I%U2GCIX DB=*R=3L,K$SU;]F>UM,G;\\2,SKO50\!%!E1B>X! !%PI]U,IN/ /"\P M.,9UGH1*(N\2B9%/&Q$(K+;'&*%O =W7-F^FH=IQ2O#HLX?-*

D3_7&"3^X>39 ML'UITS&&[!AU#'FE]8IW@UIY-A0%E2?77/9NL#9I.V0OI%8NWO\|L.I2.87KN MV9W#5!>$CSZ#!\QZR^S< DC `IJ0 ^4VNQ#26[>&*-3)IT0*9?!5_(SW@:)*

*M0KLO*I.MYFJESLVM^|E4B)%A1"/4'11P[9V4Y_(13Z>>TG MGEL9?#UM_#>(8"]<_EICH(C7M7W/PN5KGK3N5]!'+I4Y&QOOG+.A.TDP;I7[(.M$YS*

I79!!J1/@66[.,NN#">IGHWX'X>_>ILV(2.]F_B4TW%41'0A^CW?Z,^R M(;M"V/ZDX64O$RTW&XC=3M?2; VXP-Z=33\)PR^Q6' 2HDC@B41J4[XNS'>|

MERKR)W+BB!0M/G:EUAW$UDZ^*LLP6)F?A2JJ4UP/9'%MZZ4NCL0 I^&++I814.GOQJ9-2 MJ_DY3RSQKZ('B*ZTU!D6U,Y6T20=..?7L$@8%&+&1#T?:+NDZ)n&E242C\N\I((P5SZW],PG$R/>?*

*%NKG)B>4*8= MM/V?26O_'_%8*O<1: .R&-)G^1@7@DD;TL&L-,A_#A*LN-]B:,8W"_]LL.? M(C$0\>OL&U'<*# FFPMC<9;D$LR]]6(SJ:2I8N&?*

*WRYV)&Q[A>8R/J^TD_)7_I%U2GCIX DB=*R=3L,K$SU;]F>UM,G;\\2,SKO50\!%!E1B>X! !%PI]U,IN/ /"\P M.,9UGH1*(N\2B9%/&Q$(K+;'&*%O =W7-F^FH=IQ2O#HLX?-*

D3_7&"3^X>39 ML'UITS&&[!AU#'FE]8IW@UIY-A0%E2?77/9NL#9I.V0OI%8NWO\|L.I2.87KN MV9W#5!>$CSZ#!\QZR^S< DC `IJ0 ^4VNQ#26[>&*-3)IT0*9?!5_(SW@:)*

MF8^X>Q[RY/;_!W#N)VMS&-EC\E&S\)PH=LK'M8A 7Q=T.YXF/FQ6NMQ./>+ MC5.1B);ZBG<EWBJ++;1K%?-=1R;>*8 LWM^;9PT9IV=^'R=H\[*]L_6-%@=_/*

*M@%"CGBSROMYLWJ2U*_6@?-#A_"}822?RI6U;N,,RM(N -VPK/!""@*Z+KSA M\|>X10.IKN2$$CI@U%$)P-?2A8A.EM'BX?QMD%7F1B^2A--XU'A MCZ,(=F7?*

*PLJS+4_[<1'X-%/F4)8RF'Y?'TO?]T#*51B[Q;ZTL?;tZ[HCYQ=\; MA'-N=ORI1+_*.RT-08_1%,\'30>)\[-2! >B0^%,D83#C-B78YU#F<0G(DB--*

Mf@!$[67<)R7%U[^>KO,0D($VYKWTTW$);&C93-ZVV;7;8Q&J/MYW!/W-(0KD MPFUA9OM,N>IO =0VV(V[_:=$OQ=QD53)BFQ$ 13W8^0B&3ZJ#)RAO0AZVX!*

M%3#&M6O5[C0F^N@KJY!"TNT$U++"GK#QV1.5?D;6CJVI2D=9KD)!4S)MC;T@ M.3<0R5S|'N'(9D K[:'1'AEV%YR/0G93T 3*8[GWBG)^X_)6)GWK/$DC@MU$

MB(Q.$[T]Q9IIX/'LD5F[YPM4*"#4TM!] T7KNE!SFD2Z51IB?-JSM&S.,.6. M,C#3U[SM@879JAY#7(9G-XXBN0YP;!SE;G%AK"&,RZ1*9WRDY:*

MUSH#SRJ\8/ARX'\M_^$PYZ3L00F[(GET<$1H0^B5Z2QP16H\%,$5"%D..4 MM0J&WY+U%A&G#=OB48&_73;"DKYUH!X

M@:I8KG:.&XJM:MR0Z0STYRW@=86EUFR\M>3'S\(F7$F>@4.?\+AROMG^;0}) MS*$.U(" E5:71ZNQU#WU#,,W LU0#^+K7""""UR+++L(5[+M4#)5)A-(?A&%_&

MI<9^R,HM8%WCHKSE%F!Z"_AZ0:@>"<]Y-0_FB0O?X MG>E>&P#;!:]Q#Z7^5".:QRB#$6P S$97 D_?Y(KYTI9_]>&N\VJ4I.=0,I,P M&_BYXJC6

^E#OIC5:KXTC/^NS>Y$OH"6['EP//5D$6CSAL);'842GS\2J, MM% >*5XWO4L@K$W449!+CUMS!\HCBS<5#EGB$>(E!|K03?.2KU)N?T-2(0%@^_M_!?_Z3P9UV]0'<(NR5M

[1T?]6PC<@H6GH0&+,NLF;-Q(.0)HL&?&INKFWUB MU8@WLB90T]33_AE+33B7BBOOA67D]D'12=X5&WPK[!(RE6=_1\%&?AV!.B03C MNH/YZCIK2XO-G-&"%

(UU;_J/.7]U/A#2?O+&="%Z]V(Z>Z=I3.&FN'O/K;.. M<+92/(M7]N73EHJE';H5]HANP9^D/WV4^_#:S+](.4(R^ ,IT63:$A"(*,' MQD@OO3=;&"%8F8=EW7U1T0K[^/;-*

'_)03P<[WGK(84G,?Z.UMJFR7>^:Y M5-'ZU$YA_/@X>Q0D59]KW4XP4NK=F.3)NO=.IXNM\|+Z\T- MG1"U+@W?Z"MA/],>__:.M@:0T?@>#9!PNG^4C-

]@ZVJ;1B_$4[SA_]'9ER9< MG[9\"PBX!22_QXK4)=_<5:CH*HEVU,78YZN7F+%WLS .<;#+E6JYDY$E<;8# M1].7X;E(X]6OH0-_?F^XO>^N!\V_?=3AM>X;MZQVC-

*\7YLY,N6CH9GNHZGOYA M?"*L\C;,*^2QM9I 0WS&67NT M&=%#4=75GL76&9.MFLF(,1@.(&*.5\]CH9 M#\)&0&#MS@N>SV(R0 (*7$7X/G2N7Y?*

SGV8$9I5XS1LVFOY@8:05,B+RJXQOM"6UVIZJT2SEJ?D^!;,)V(W+1.;&!K+NPA M 1>4>U{J%8;#Y_;HG-Z<;\;20.I\'+LN3F#-0L-\\HEFF""TG>]2^@_U'Y/7

*MO56YB6JMR53C936Y,FL];4Z$\|R4?;X(]G=&A0()*7 M,PS1MM:13SM%&E!H@"@F*#A#-@?= LHR5"D'!,'P85P++K8#&1W,5^U&"_:9*

*MU9*6:PMM#DY!$7F=DZUD<[^].7_S4/F:,24Z$\|RPW=5B"9G/@'&37"*Q15Z M453!3S|U,WQ1K7MG^P?XX145VR]Z*3/S7!S6[&0*CQC64WJ]0DAN ?;L*

MCTROG+"D%PNP8%+,3;Y'"W9?(&UVP.,(XCB=4Z@OF_L EBU)Y@9VVV^LN/F[?M["]'L6&4G MXFKVU?OY>1+2)$G#EWA2FFCW.Z[!WC"UT4+"VCN3]586

*M'MSUBB*7ZPAHNZH;.^E78=)R6-CP-P=M^ZY:WW\.%[8:TK5S&<*PQ?:X#=/0 M0_8";*3M2>7$%)SEPK)7"S)[\BJ.*_>41_[X(!1) 5/'H-=|ZM! 2O#]XU;) M'C]C!D.5)*

[8W'2_Y.5(]HX<_V:.N>P!=5PU<--[6(<0NXYCG]/Y.KHG25#6> M6ZAU/OA6RSLR(+7%[=H2TKUS+2RKD;K?H"'PT!Q= HH=)D"N^+]9NJ6 M-2[?*

*XB;!:W2EE#DA61OV8'<\G1RT9?PMX%Z@6>65)&[6DSOO!"\+G/?*ZVYY[M.]C&9[@X).?'<=!V$C8&N2'N@N58QOM1/EQUI-1 07-VGCE^U"2\ 355_<=*

MK'\7.4H^W8/(GNTLR]]H {1+)X9Z:,@X>Q$WB:!2]"*D3N5RF:F@1YKK9: M-^,,"9'GJ[==0/RV5O8ES)2QO7ZF1Y<4@>R209##/@N6K9UBQO%=IFAR"*

M7[,"R^7.)-.L/"EROVZL[_/>BG$?KH<5F9=RQ15*BWS.'BNNX>]89CV?A* M6+HA;-\E.56BL&1XW$25(/ZULLL"BE/F]1C<8Y;6IC,'[R2+1PG'38DIJ#=-`M=HRNM@[KS=

(FT\\)!B:]F;YT#;346!KJ/>0@.V%LM+PMEQ>VBW@TO<6P(TC M6K.]"+G;J7^90'O6Y8H>3\:GS!(O;(2^_MYR=\\EAI@^%,.&

<66/=/PJ1@3"%!5V"]+AAFD3/JE2AB0!^QH"7UU4$1AI%@>/ M(LG$DNC9:4QD/"KUL[#N9ZV);_F9==^*#;#GBMC9W35[">78#260=FI,B!]D&4M'Z2T1

*MXHN+'TCH/A)WQ?>@-!+#+V8#+EG!,D!,7[2L_BFTF>$3.OS!1R>@WE"Z&N MI4N^G_HRI[9$?ZOU*FN>F2Z;,\6,J7_ ^DD MW?^_;?0RB< T2GF&1[J-P>?*

OP%N!J"DT[]3D0]0MY86V@,/N)[YUPX@S M025%99-,"UP)H5I8Z33*)(]2X'.<@RLF'=8O>>3*QGE!%6OVNS;*SC^#&QK. MF0-4^W]-L*<&L^%\U\CL.PTM:2?;'NV< M-*

*$;%1A)9*&G=&A=N 0*)/ZS_\'EC5)$MN/)YJR-A2O0UFG3.C)1>P=MET MGI"4&9G\$#AMV)^.KWILH,CJ81E5@=/O6[!*P22AV:-D7_K^WC%EB_P*

MJ46=6SOL9_,_ZGG,7#N 9F0@)/C0MM3+4)H-TOO8$EMWNO6A2#/S[N9XOZ**N M/++#.ZA((N[+@*<4X/CNBC/:\E CG"E\X5@%L;+"?X4+M)'U"Y6RCAVHPG$ M;\4J].P

*&2FBV7@GK6/5N%T>#!ZXQ/F]MWMS1I88Y&G9'FN*2GLJ[/N+/7%-@ MY>SDA;=>2(OAE7.L>/N#G<-_>M"06JEZ6RD[OBD#&]$081@SM!E-8O56,W?*

*M6ICO*NM*X%P4*NVK"VI9^03DH@4W*;>N^>)&/_QA_\GZUY6V5SZ&RL(? MZE)MP(CB,SZF<@W#*5 P<1_)H*A%,]3! M_2H*#/!BC$Y=.149IXD_7KR@PMP"X*

*C5,\E*MO(VL'=.6OV9U?R0Q*\!U?/_] M 4]:^2M#F\^9'FF0-H\,8R#")Y0M\>-"*$3#2)K-;+ZVF_%J!)0/"&T=822E.-"[JIET2"%>7^9A^\] MU_M? ^MV=U)\?JE"..//^[K'":!QN*

*31MC\&&O5<*V*)5QS/> /&-&&]NN@SG MB2_=UTZ!',F=*TJ4\13;XRRZL>^,>/6*MKHD3!>-'F\|+Q*YX8*_NRTX(> MRR?7:*

*<'"5V^2!A'#-4"__UVFO5GVE^/XPCA*DAS4GRK^*?8)5K M5*7#=0MVM_D@JO)*W#-@C=?5<'!^===#)C$IS0IQ<%UCIX@U=CGS|&M%2^5*

*MDD<-6UHN91S>]APIESGM07X=CNV1H-@9KJ1PR[E7]AC7,*8O=5]Z0|U^8NV MH^/KJ'& ^FKBI]7<_DZIZE_!B.P7N*2U"@IU#+!+$_SJC/>Z+&"-8:3 $!;"*

MAMAJ["0X(@=_+Q!Z?,)08-[XA%G\CR=S@C_Y>#G[9%90"1+Z(L@>I3'"@6:/9[] M$;IAZH;)R9_],V=#"'2';=|EXZB1|\\O!JNYDH&-

*EPR=9U=2"P.IL5IA5J?6M68A.OI5M08BR9_AO)*IBVW-MR8/W2ES.[?((M):PXX;0^TWH<>B,J*BUI*T.F(GUB5$-MOS:EJ6E)M*D/UIN?*

*^O^%7L;16+>PN?",.+EO(O9D9!Q#+-M\),#URPOR5M?A M5WP0<$C7BG!KVX0;3!35:F0":B5Y/4WBEU;UR+/[(JZYJM1H5\#Z1J#S767$ MWY &C^M>V6 :HEP#K?*4Z/^-*

QV6ELXX?6L#RH/^BO9 5 ME("VW1FLC74R%?^STZYC^?W2=X]E ?GKR"A#Z[N_!XO.RG,&QGEG]3%'M,F'=6SX-M+).#M\L.L M6D@0/0[.(1?]H=YCN?

*2X*OFM[O!'_/F<'IAN[D"8OQG6=);-<)NX;='G53H$ MI2(>G-O8!A*NY81)^A-V:D=NY8+U>WT^_L&C2"/8Y,D'^@;#"%Y#7V&.A8)G M"B|*

(LSTL)RZEP9Z&D^T.D,2&V6:+O:S4O>M:TZ4ELV95=T#@|GX%VSSD$)A M94USN+?C8&;.V95I2&$$_^M">K]&6X!,#F64Y"-H9<)5Y/NA$%8-N^$N(NJ[H176?2Q

MIB7S2]LHG?K%0W@BWOT.3I+,U=0;!DOK>%V6KC??>-]{ZM:UZK?> IA?&$?F MY2+BKL,"VQC!G#V&(=3!Q.,;N4Y?S.9Q3-1++?TWXUPU"]6]M);FLC-<#B[.5

*M/RJ0M{'ABF;OV-"]_)QNTQX1$_#D]MH65U6J)DDP9W=U/?/?;W4^^Q6ASY5FO MZY%)RV7.[)VC@>>#[UXZG_Y9\Z\@P>;(9_BN32[4ER\WT+R$.*U6U:0%&P+K'-MZB$SR?*

(>R=+V=>"\;'P2SL3>@0QCXZG'#"\D%J-83;>W-[H6WOWYK>1T5!SL MP7W@=%B]%^S\"72L0.N!9)2_#S9"9\)>X%,.25T3\1H'2DQ>C-K0CM6?/KFN7 M6)

(&4_GA,T+BM@OM%GGH/ZV7X<+R9ZWU:.E)W^]$8BZ>Y,6T"BRDX//==H/.ME%VG^/G*X53;ZR[<L2@E;Y>AQ5'"?UK^<>1ZVN&?KZRYE)%X:9QP\$@*

M@3_=3]+ZCZI63LDFOQ+G$?UT'_84#CTZZ'0(6N$G,(;@&[GDFW +7.M$OR%]"=I7[S^RQ=)_TO 6T\0QXA^YPY0E_E3=)Q*

*M!>?IAT4L27R^4U7:!'W!>5\ZX&QZ38/K2G#)74'"K7!=TQ45"Z2Y0)>%Z=+! M(=?U'#*58UT/F&U>9O-N' 5>[\TD+[ZK2)0#X+?!)%Q6$I9M3A7VR>*P)"1:3Z_+=!O>WV*;*

< M6B,X^R7SQBU@0M@(^C\83_R_"[1_D5#)A"N-5?:(C,I"%-F#RQZV)T%JB"]S MILQ%G[/J?T8E:%EP$C3I#BPFBF8 CN.3+-.O6VO]#!2M"T4H_.N(/*0GY&&>*

*M##*L=;;3;E*0<*L"I4V<Z;KY"OR^:]{C95*%^\[5./1V<&AN,**0.5Y M7 LF$=ES0S1R0MU.%L2WU6U-16|!2L_DV&U7 M?4OE! W1^[H+F<0;L@KR316.=.G(W:D"'+[+'"*

</>:H(^>PY%B9.J(N'W46 M1NWIA020>:

*TU%AF$IM[=Q6G,#=F0:'W<=LKN-X$"-10\:-#G<:#&+Q WW/9 MD.">4U3CF)X;QL\051_ M#GWN.&=A_71>X*Z2?%O7%-7 7>BJRYGADE@+*ZCC:ODQ/K,PP/,>T#""B3>G M"3YR =T#W@V9S9L]< UTECHJ=7?(U%;Y{6$*K<>R 6WXI?PC4\ANJK%)!Q)? M0?^+>.9,1"5T^4LO^)%$\Z:6K0@403L;'I4IJ3+5-)+C.Q,>8&T$.Y#&; <(-MS7K:-- =F7B+.#$6$1).:__F+U(UJ=!*(]>V;IO<#"Q8PLI,@ERKE,E\C! 73 M?,BPU5CX,X,RXJY?0C+TG]*EFI&3KAVNLMT#L&N\$XZ4[!3X/%&BZHM,K[R* M6U+TVYO'], TGG5N.A'X(RS\{;&Z"-A+T(]9 4"5:525C<;"%GWACG8%,+F MX"\3K82L^TR4N+[.GD]@O6&\F #,|?.SM_W6K36Q<@ <|>Q5NB*?\:= *2=7L&? \Y3'X3Q1G\KP_"BK_K3-]?SZEY)^8_LW727<2@(]*,4=%#N9@]Z5HS%$,T+6$![=P-]'3E],E-M(SXOP2\CWL'(_D;A1NP,]YA\#O%_]?_UZI7(!U^G[$W&]OFR/-(14V9U<[2= M&&@@4R/!28CT.,]9%FYEY'#UO"5;O.GFT9/*[(WQ0<]HVIH_V1N;+8?_($E! MBRTS]@^9T"DO=,T;W.F"G]]@A/R9,N+OMV9Q'!D .'!W$DWK]_H_<+%R&\R! M,H=2WREKA9?BH_< XKT=<]L0S#B**;Y$=#C2]$$+_;"NQ$)IZ/$>8]6F,PEX\.+UX45B0(>2)P919&\ZT M"W$-7&63MHMCXITQ!NBQP@#&EEF>IL74KUZBZUO)P]^D&=###@@0:X\8I6R,#$ZP"C28>1),,DU9 M71K(4#LDW?D;RTK-6[*8_X0>]20^?#`R'VS#;=G/L?L? %^&J,9+#*!39MBMW[6$N T", $VEYVMD "=(OWY[&V1^U!Q15C1<:KBE5& MT^[U^2R>:17OHB+M=[-]'G51P-.'ANJ MP96K9M^A1]UA P-4G5]V+&PWO,J^7-D 22Q9%@N5X M6"W:.%;ZZLB&2U?D;K<^ZY6"+A/1.1?!" X{(^O5}^_\A .E%P/#\[8*:D]D15<0:SO\Q((6'>.9-7RH+TT0B^=%9+F2A MWK0A><+%D; <_TPD]DS_&EW&,5C/OJ&.?;BES&%-^<{D1=VQNOO9:[8GSG.0=_M]-.=7[&_NE:,>-'8HN,)X](VKBIZ3X^=,ZXD,8-? 20=$EWCGB&_TD9>W_B MA'&3X*"//=#?<:4XE? D<>WX1C,I?],_T$&#>OG:NZ^8Z3ZYS-/_.!TV0,Y#A M#=MY38Z4%S(2(9U05]B=6NUHQKVXQ!{KX',F\"3.?=2@@6 P!GE,\S28.HA/0EP0IIJ7.Q@W?JF<#? H)EOXW&,U3MOW&?M<&OU]X/P) M/B(X0DH-GM5#MG]=Y6&WE'_[RCF1+B\S;=0+/[`8]ZMLD^8B!D?^N!!(8=(/ MMYEV>BQ@,O;D "o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}:F[52T:_;M'(>=(:ML95,!EM,]5:W\9B3$*Y&WE'_Y^1Q7RRF]*;42*5"_^.9)<<=RA1]:7V=^4*:LI*MT5@GT@-MP=) BV7]I030PR3'"*ZA@1697R@G6_|.\8P4:4DS"+Y*H3'S ME4XO ^PYH=,2U\&XPQ%"##)W2#>'P&>X>)RM$PP_?&K,?TH3T3LE"1##..8B M>0D57 ^MA3.B%P$[GY9I#PJO4=6_X)4:?4\ T-Y7>+G24UNJ+FE>,.|"L M_FOS,.]HH2Z;69%'W/)<>!X"A=0M M$+:M=$G1U2*=*0-2I?9>SQOZ;%?BXHKE],2-F!OUX{QZL>)++7K5D BI5?4) M5QA'USZ=6!D.5WT>0L-/VS?LD< YSMW-#ZQ$1"90],\#0YG#=S6:%|,.#C_: M\4RN3H(`W9QBU'[5;7.HU(O]8=[!?OY(@_\;#&AY^1XID@CG9E99^-*^4/.5 MJ36^R=@1%DNX:[AC7QP/)=3-?'EB%$<- T#[*W3/G9S?$<&>)360VHQZ8FD2Y]L(<4>_ 0 M0^& W422*M(2-6KG,/]#K\H*IK#C+1?,>+B]BL MF8;?*B >)'T(1!EY? OHT,7Y"E3>\;(R]HG,Q@!KPTL!@A]UEJOSR%ICWWW[++#G]VK8T& 4 M2!/IG)'GP$0WLXE2S*VDS,"1]QNG<*CGNQ&NPI"M#[7 A.%^/9TZ4_%I,HARLJ;6?Y9- 0$"TOMDI-6,4E%0&'&8@#D1OIN MYGIDD#0:>IE:W7A8[$@D4/A/D8@7_F8W/DE=3_+|\ MU(?%;\9Y\_8>,+J/U+@:$;1'G,<<=%4*_Q=GP7^83/ZG=+XPTZHE?,O[<92 MZM&,%1+;$3.FL&&1F;TYN!K?KXD6MWB="V8S4+RGMYZ,>4/F%RHF(5<5&$M-M]],*Y14J(&R3E4++EEI1=Y-X?6=<+:$)8=:JE9W#9_"K"GW;9W3 LSU@^2@T MV? F_[[%BO\Z4!.8;FEK&8IEXBP%/BC(3IB[7-9MB=N:)T[:],EV!@)\%SBN MCOA#P;2>P31_UF#F1>B.N.%CRM]1RHQR3O+GRM#T<*7(#4;F\?Y>DU%N7_)) MUZT&GU? R,#16#&"O4Z':"&VKT+/H8J)L;TLTS4*1F*JD[BL:(>MPBN_A-V M8HN*G_YNU=KASWS4}>U?'O MB(LW@^H(5L8M].(;L&V/AIA*F1CM,1Q;A?:^W'P[++[@K$O^(\(7@ M/V[]3-QNX^;6$H?A8B<(T)M^^\X42M!=+._5M.!E+Q6W_^TJ^IH*?-?!0-= MQ6GQSX1+$>M09?CTMTV%F7 P.MY)V$Z$6@#MM"[%5M?'S0]%743Z<|*F/8J] M^SUU:ZE.%7^Z3J-XFJ3I"!"&GF/@I'=`4?LI+W_T4GKTGA^:4M8<31;8^V6 MU'M.YX\@FHT],>"Q$F!N2**<8+D@XR#6]DS.-3.C4XC44VB.(&Q$%7M6F)+<41Q_]FZA Z-+"3"JL;CD@(EI9 MNG;@Z$/L\W3RV\[79JGVD58\R6^(7^]XB4OS18ZV1GJ@&J(UY7PUB;"=Q(M M*=;$-1Y-?ZJ2!#V(LTRJX.V6V;,9LRVW.5[*I.\JN#K7#U==O M"AVC;0 NG-|!P-C7.R:?4Z8()'NF=3'^7C%%TO<;." M%XY-ROW5W315T*F",NBL V*<-'I2VT2U217/A6*9T&;03F=Y53&/ ,.VV,S M>*@)+0HG"G2\D6%4/.'-KU4YJ=FL"S=Z*V? _^@>E(LV!HINW;&-$3=5 D8$] MT]-.2(!Z!>U6Q,1[%"LUE3V.N9\ASZ)(6$K(-]7I4],]*9\;67NS%VBW$J#R MP!4[/%9=X)KS1N%2MSO>3$!%+\/%"H7S:P\#^1@H=NK+O5UR:L#G?]5^241BF M58^\,10Y=N%=BU'[!#-.^M$;2@H&^-6$!BCZ(D!/H X2$9'^\(E]+ K[EH,/ M/VK%6- R3:?SX#MC7^% E21O2M$VF#O#CKH@IS>9[_=_0+J*D7WS<71$W#1-M06EI\:(MXN=JHC8[*-Bl;(#_3>US0@C>\HE+,X)#>W%2>"/ID)^6!FHA3 M!&^$AUTN__R%6.-5MR^8B_>",&B1^'E\S-D(NW.;V)K?#&X/<|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|T9T@-U M"UC5;>;JZ5:'7P|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`U M9$_8!<%7+[#[M'IGAL+(D\$LPW2Q46:CO> ^HU"==WDD_/.3(!;S!"$;!M_SW M #MS>>L=6UO0<|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|>.|\326_WYJ>Z&E>2U_EYJH0?7]3L3[<;>;1=LHKV#F360[G$>NVI M#0D7#^>7LX,TTF3;N#N*"0CN^5/,.-1+4<=[K,&$_!5I5-M"-WQB,/7*9G# M%$25A:-BHLZ"? Y12_Y%TS1^*#*OX?"P'C?*!PCR(WQYMBQ:O!*&G@S@'[-MJBN:6RLT88%_NI"M?VD.RR MG(1]B=D=@S0'(C2$GWZ_;2M0Q*0,+=N95/.F!T\D[S1.-?;HOG5FC_# G? AD<)G8I$5IB?* M2,M+W_FI[_(E*] #G[H#BU%%"F.#J9G|= @-_4G0V&^W4159H2\>*=F0ZEDY MW!=[!O:D"G),O#=2P:.+],B[X7_W@/,/NFVH@4I^M'C)? CJ+ZD/XUL!!5=XT M?8=0#85#@^#_9!KSN_?@$M_^ZG2ZT/8TNPB*5,-=,KQZ00TTY4NU+9+=US>,J0JBLM_A,RI%YT?VH!RX\T=_M07) 6T1$& (*4Q+Z|\$!$+|".87>NTUK-HT6&CADQ\QD)_[/BV9;)HE3]1Z0 M%V9FC=R\]&E%3H=T2A<[Y'(MLBX<57UI:4N>DQ2.+M+!B@ES_BA (O ?)179 M58+WI"&RS^IE;YP.,JK S+QK]X#1*2^*+(?XU'O [NX]P",X8XNYV?9H4K+_ M(8UXF0?_HTF3W)%VG-%6\CK-)MT6ND[\0^U?4;8)_1YN+MP=T/X]%:P(MK55W&BR(M-B0'VF$# X4*/IV_MR)? HCI>>U\(YH<"B4H;AYT*PC73,%B Y 4 M0;A<4PN-#\(=]Y)->]R-FZ,/(9]!EK3.'SWW;W^IOLZ[Z-#2_%ZT>]'EY&U$ MMWDC]?49FE8H&Y7MWMQ<*[K<<(=X1'^\- !PJ"R7565A_-Z>%S1/NM,M/Y@9R=|X!P)_]|@,)TC"SR)>P>$*?_[>XALVM/*F_4@;**IU"WB@*3W@,ET@FZ81]B*W*5PWGQ:E"%=G6.E&V7^DF*6\]M)T@ MTF#:+'8X"T3?, 1DEW=MTL,W3/$15#:7W\-_U$Z?K>R M>5>=[(FF"RRP4!W!2+L"YQ=W(7#H'1TX.R,'HNY:>+PN/^G9QZ#&UEG ?M6^RY9@>&\M*.TL/@F=6RLV+ <'LA%W8$X4T&#USJ%/1-UHQK84J=^SBE7,=JF MNTU%,_MVD7CPD<:7I387M*[&0U^=#8NX!2*L>C',G_673;>CF;:F49-Y^Z8C?MXO=,T_D50F'V^ ,^Z|>]2JY8FQ'''^]J4OX_=%#TDF0VK8GK)>L-&G\^=,!5T M#O3W8+]$3D<(Q;^0,D449 86Z57HZ[D2O",:85H$WP,>%[R6E8WIU!N8O[%1 MO#,H.K?P$RQ="E M ?]^=%2YV$3\2-"X2KJ'G 1TX,[|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|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`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~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~A08KOS%?BK"8ISMT2 R$=2'F?S4;?_ M,+!=,,#,PU(E7?OXBF'BLVLSQZ1]5- _\\\^5INW@*<8KIO^^KXY/"O[S08X#, MFC\5(B4\%O.:+0LUC.(E':C_(M:7NY/!9] VQ< T8/H>2^,EGWP,&^(!4QYE4 MBU(*;M5];I2P@TF$9,G"3$5]'&W+JPZ5V#,+>],ORQ+Y(^XF7&"_E/Z:=9'V42KPA;MUWXI H1O-@6-XZVVUE*5UWKLK<-Z^/A%7 MQ,$)0'NV!KP90B#U)P](>\4Y,5Z4- 5Z[GZ!;'2"C-[UEK/?F?M9^W1SO,.B.Z_CW2*%Z'I*]MM4 W_-/@).L.]!=EX>X1>"HCW,FKFL/4N[9VJ T4/.CI.==WE3'T=G>]FHD*M2M@T#2>F 3+X3,'>=SA)<\G'-%F] [UXMS<;3"XGU_]!1]@Z4GR2J>?M3K%=?E%|@?.'\'U#_JP. M=OOJV2-I6JS9IH3^85H=._ZKR/2S'K<(YHW&A:5EQP%QV(N_]PE{G+RQ\J6M;(\B(?P;, #RN_0%PMRY-*

*MPQ&5503))0LYG)"1Z=W\VEG*9>?/2=D,EC#1)3RQ674VX,R/O,N-J M'T>-D>W>6[_T9YM.KVG[!=&"X"]|713RD-J#:7!HL+A%V]"TPT>UC M>GKS6V7YTH2&&+$2^O9_=F_1?K,_,4C:<$"(@176U*(5"$;%7HXN"*;=O" MW\RWA/MCSW?A!+INAOVV3T"X5U\^_ZVMZ.5[OL&1JGK2\LDW6UIU4>1U<.73 M)$GI=W49L[G!\O>BRH?R'=0,XLE799)EXI*?4[DM<51GlV[0L6'LOJK^NK"=_[5-++%S&7]JG-9GKCWlV*GEA6=>@4TI#@-MEHL[.MS4NF7U]=W6RE3TULF<*.M9A R%IR&SKQO'5BY8IG-;5-3LQ1TBS5\.M!+$O!+<{ DH+\/JN9BF^!=YNJSZ,4[""X%J-#V3VQ+G#+F?JOLD MG@/3I^X=W2-2SKE?U^MY*38?11YY>;4?:G,ABVK-+>/0]KL+\BTV6[_MN[_5#)Y#5_)7$??;S-+/F-FLUDVB=1.EK:'!Y(6!>U%>2_K\FR].@8:?>^]Y M&^E7%D2IO>6G_'1_#QU=/OF>S:HNA7SF2]&; <#82;=R2?;-69D^>6AD"\SM7.M:V1]4*3L+[,#6BZ0E$=.V$!Q8\)RMD\0BJ_R9.?WG?K V-AHR%S2[>AE.F< M5?$/5<.2\AL9C;%6XH%.6S/Z'A(R5^3[J2A4*"2>]WS2[W^#VH^.FZ[OC_M$#CH_2-/9]9AMFY.-*KXVIBF?H^Y]S

*#.S/4ZB2P94R4*1);(H8U0O(F$_V0$:2B_M"!3>$?TD)P6;0P9VK?Nt@IO\BJZMMX#*9$,Y'GW]|UF&ZAS3>Q9O0&Q+H,;WM MC68-8TU/R<*
!Z^BK)/#.5$4>IJ:9+4HY.QS)X8ONF$'+_$:^PL#P/`,D_F6"-M1I65G3(%;CPTF R\M&-S285FFT[=EEVYY.C/7_5]>;,%04\U?M[M*W7P91[N@TOY?
Z;X4)A!!NOIBK6=]7]M]YX?W|UXM<#SGL:X!A85A_3L_[@ M XZ,@3;DI3GXD-CU 4R&*(RQ,R8U>ZH@_9KXU4TO()TK6Y%M?5+EKOZ]RZU4 MS2+,%&UK*$IED-
W0NKXQ04&M*D C9/9C\2 "RQ{'IO6XN0V<+ /AQL0ES_M\#.I:P$SSPU@=2]1G]>X+|&UN7X>LG_<;G@X(RMU[A]-$D& &XN M7]R|W TD/B-=W6BH?1,7427&#@]-
>_]MV2R \;3C=G_7^CI+Y.-3XG .Q?4I@'MT,WD,J_4QZ>(^A7'O@=[\/:HY70UN6XY4 MM'EMVYG2/BI\BBYMS50F##=5R*G0/M#0-E_60S%5#X%\"!!J#Y1$&!#*<=UF
MKM>4!L)*]N40*C99=IE791TW_<0D{(!3/"!]A;ZZ,#:$A/!3S<-ZSX93I^-KB,IS,N\([KU] M_D(8,:H-MG54HI\OZ-#K"U?C2CL#:9TMI6,#:N?+&5C91F6=U*W=_R.SZ\
MJEE&O*AJL[4Q0F(1\NV9QD&1 >\"RR.+B&PR%BM:!""%TXC)WRV?RJ+_00TRC-M-J1+5M MAG$PYRW(=]KI@?_YUX!LK$\D(6I:#6>8[=;"Z<_VICHMJI$&ZX_^
M^=;.V:3%);2*YLZ0APX9#Y1+C/-PQ>BGYP6[8S//!X>F!$(@XTQ.5-W+T"8! M0^KI8JU"=.:1BM"2#2[1QI(PTI].1Y0CO.8K>*[/>THLW+.,;DJD-/'KE'UR MfY#0$R,^X@?
JP:R:W-!LU;U'@F=`2)D#6U4.+M#5XX+6NSZS:*,#1 S_7;NL MAMCO_SMB+?3K)@:7@3?.^>,/?ZFADC7I(11UT$D&]HD>@*^3^$VR$!]DQ.JI'
MLI'HS>>CX/W/XR//_ELSX/^D05?+ML18@Q#JIUKP,@A^/I*)=:.&@V.F)]\UQ M_J)*J<4Z@[S,;JHWW7*2EV Y)E"7_?WHR17_UV.UB4_?:[CCL^^:",N^?Y.1
MS4N;F1X/N^9X+IFK,,2B,H7P:M'X4PA!,M_1S93.K"U0')<;7;<:+,EG-_DS M|&/I)>N9MW=:,E9Y0C<+`^VI)* [U59@YY-.(L!7Q,:@=6J

*MA,S<&3}1^84T2 M?>,PQ&=$\7)RlY#'CS9/_F2L=@7XK!MKH70S+1P=(9[WAT)!B]L#>7#>G9%C M.*2/[)RFR"%1E2"##GD2'&[#Rl;KV#WD6H*4GM?J>Z+Z)*

(_B8N:=9IXK;O@3 MMC\6&Z$2^UDDEB0RF\R??H=01V8/I?N#\V27-,D"MSS;W0=E,?1I(DX'@?1X>F%6&([ZS.Z>SA=&SZ/P]-Y.]]-\9\4J+*

*M#7,5[MP+BYY&G9*GD=P_XY5&PT,L>!U/|B5^S'EBFO02W9=XAM+Y\1^DQN4T MTNXR;'2M\)BWI?,#8XH&!?,8'K2L_2[VT+74^.M:],18G_9^-K1(;*#B1*

*/E;A4MN&H5>0=K[!*X;GBNXMDSVD%/)R88?>E,Z*@?W%]-/<.6;=3-&4__^RUN"EQ; M.!))DZSU+T\X95=LR\2X;Nl6/!GZ;#!QH1*(H\R9><%CO;LH;2Z[2-'WKJR*

*MO6,'&IMT+DF;3F\7YTTB@&ORI.I>S%'R07](C%7OOX:>0R4R*GQ.[[Q/R"IR MSMM(77; MZYZXG(WN43<9?KU8F%6$NH@ MQD>TD0 AL]!0F=4M.F?*

*SW&GJ#441!>UACXY.V=KY(!>&CQ#*V\:T.R\ (T.[!3X;M/QI5POBP8;.MX=K*16M[EHHD M_HE4W&/$&,/@;1*&.K-AZP8E!T=%_!->]F>#H^2)9E4W9-L&IZ\5]75A^,U*

*M[55C;D.U52$QSU1;PLC_PI!NS\1'Z/;-M&&N^V7XWZ<($QKU%W8KI0$X\Y>MG! MKI+,.,0=%N%D=^GJ=2]3\F,. Y\!Q*_N"0%TACNI&#_,1'0D @9/X4\L$A,9'66?L1 mZ!*2 mZ!*8?Q2E*%);5.W@OBSVQGN"1;*

(6 X"(_HA')VX<_N=S;4$%L,"",,"3.5]TJCP0 B M"!=-.59*N>]*D;57Q.L2Y;.T(K@M;,,EQ+!)><(828,;W$%;D#2 &#.CAO=JHK M^&0.YX\EPBJA35A5=P7=LS@F_4@7

*S'Y(3&T;F+J"Q\VO'7Q[.C;'/6[]*V M3>FYDIL;?8M2CFY+),=MU1)"]%P]ZJUYEW>TTN-EYJ!1^HKPGXV*OE7E5&6Z M&D>OWZ=Z3>3"VOKX\/"X"W;QA^?*

*Q&;ISW0OHV%XK#@V3LV=3O5#IC!/R'1QL M&[6==4SE90O*A^/^:4ASD)\V[M<1<G>A9EKA#+H6M^;R*N1=[9E]29ZZ-6>U-M+DM>;3XX>F#6U*^EFT?*

*{AG[K'ZX6>2/3SBVI*P3WQR;OC3VD)M'H M0A F)$DH+@N\E;W'0]V=<360I\&2T6!VS*SA1),/?2_'L1,GFXMG]RUR=\;E M-CN\#">PDA)#&;.UE0*9U!MPFS*1Q)*

*(09.6283')'VH(^7DG,,(Y]D'E*X7_^7#GTO4;TA[T2D,/!BM713B4.T)J6FN/-XE) /M8<.Y"]HJ"\OYY/QA:=S F%XQ+Q@Z M/A#@S(8"!%2ME3)O3,*&-<>*

[K@@;WA[A["9O#61F!R!R'R?"!=.+;JU=ECA 6BV MXP]_ C.'J&Q.=_^JHU1Q(M,(-F!RL?)NLM&H<+@69FTD8K^_3%1G0_,!H M!!^.RU;.K-SCYE%$;E60*FX3]A98SNZB>3^6*

*[DS 8X;&6[MA21A=TG8GMT@\O1E",+SM""IY75\XML8*2?CW3O"S%PF8Z<.8/3'%8*R/N1-V>C6R[fYF@A\&T&11K(;,1< ([LSD/*

*MMBA)@N9C(!UI6RQ7.FWC6'((=;/]3&@KG1#/N+G#VS\|%#]]*RL=A@ 9P*$-[M9ZW,BJ7)L+,;^7Y$MM<5\+!6H.'PYK@.NET(PP4'YP;OEY,4:.>X[X'TJ;JM*

M#B&OPM1,+&%9SNU9_3=$?O.M_+-SY0O<&R$>TJ(!5 TMG4D:6)6U==6:#;'YTPL+M?F M@_#8'0L0BT%@5$PM_3XX>F#6U

PBJ%_>HN7DOJ;DP8I&1R_K/-.U^.;06>1TPHS8MLL)$[K7 -T&J0&+C)]>4Q9DK4AY2F>B9_X^ZC$W_??3ORY;7KF&T#<.;X.80S;LW)7F-#5K749Y19'"MMV

*MU@L'SF+.3LFPA0X,Z 3/E>D68+W1(A6Q7U;^ STXJK#?.[EKM@"1.I;11734 MIDZYBL.E+N'90=1P3< 4T8X_FF3^J3L*W"$N?7)M+GV5)URF*?CCFV10UCXO M+73;PS7Y*

;-\^7;GCVEIAE=G3@.',K"C:Q!V:F7Y_P(;"TVD)Z&'2Z M#~]..)6X>X%'1R<6N+1F6W+F/W/P__&D0)!!#32^V%((()N%PBDG9;M!EU\YD MW|]$XJ^(TAWPKL6Z9|-/H;-*

GEX?!1.CB)OM_;4]L.8&52'PL<.8B7X] FD. M-O5LTSD?1)OZQB_2Q+N=WTAJO\H\L]7??%"&P^2/;"]:@\Y\>H9O/1A9&P^V@

MZLY9)J.H_NZK\J/)W$#.#8A[CM+$_8B'[NHO1G]CP. MO/0DC&AE8-KI%%@WX!KW.W M>8@O=AH-9__SR^O?_WJ^XK]>G?JR\24M!O3/=I.NT G-*

*HZB!'"T<]CFN5@FZE%9[(@S=S_C6H<;DU2DKRR$;BD9 M^:Y^8*08#![T@RBU6.M0JfY!I3\VI.@W:\,]2]*W-CG%>;P@M]3'_|WA5715 ML6\-9,-L<>!L7*F:/6K-*_;!/"!7I?*

M^EQI.L#%$UQ?:X0DD[4VW8P7\\.#'VP)U,ZL2XB$..BA:5/G2>PG%\1R<6N+1F6W+F/W/P__&D0)!!#32^V%((()N%PBDG9;M!EU\YD MW|]$XJ^(TAWPKL6Z9|-/H;-GEX?!1.CB)OM_;4]L.8&52'PL<.8B7X] FD. M-O5LTSD?1)OZQB_2Q+N=WTAJO\H\L]7??%"&P^2/;"]:@\Y\>H9O/1A9&P^V@*

MZLY9)J.H_NZK\J/)W$#.#8A[CM+$_8B'[NHO1G]CP. MO/0DC&AE8-KI%%@WX!KW.W M>8@O=AH-9__SR^O?_WJ^XK]>G?JR\24M!O3/=I.NT G-*

*HZB!'"T<]CFN5@FZE%9[(@S=S_C6H<;DU2DKRR$;BD9 M^:Y^8*08#![T@RBU6.M0JfY!I3\VI.@W:\,]2]*W-CG%>;P@M]3'_|WA5715 ML6\-9,-L<>!L7*F:/6K-*_;!/"!7I?*

M^EQI.L#%$UQ?:X0DD[4VW8P7\\.#'VP)U,ZL2XB$..BA:5/G2>PG%\1R<6N+1F6W+F/W/P__&D0)!!#32^V%((()N%PBDG9;M!EU\YD MW|]$XJ^(TAWPKL6Z9|-/H;-*

*M2>>L45J*BJCPOP?'#ZX<\[-'DZ/OO')O1X@6IY$/-DGD5. 7G=-')69WGRW;.M;M'A%JZ@CYX,G\1[*<_OZ,.K=_2+S_ 7M=0G]YMPLS.\,'5ZOPNW=H;?[']9]*

MA2KSA:H_D%..CR>'W|\A)8GY/KDMU/;ML8XJ?ETB%U_+\+[B")"=5:\^@N\[MZB8C?+G$6XYP K#T!IA55$[TIG>C/-7->4Z^J*

;.H+8]W);H#3QT|WU1 MX/MO\?M[F1!^Q9>,=?VK@2WDOZ^*:QU,\V1-_RSJ9?K3_P-02P,$% @ MO8$T69O/TD2(@ &08 !@ !I8FEO+3(P,C0P-C,P>&5X,C%D,2YH=&W-

*M5-]/VS 0_E=N10R0<'Y1MI*4/M 6;5,+B 5->W1B)(GAV)'C$KJ_?DY2ME*F M/?" %B5V]-WY?-_I[AN_(V0N"RI3SN!3O%P 4^FJY-) JCDU%FW0%!"KJJ(2 MEEQK% (N-+*<*

*_B>\|\Q@U/'(V0RMK&FFT-*AG#F!IY]@R%XH] [*[U3N%G" MX5TV-]9]?3?O-O+_VYNYB\?D* .^vZWTZFKCN+9[UAZ'@^.Q)K*&G?I207K*

MSJ\&,"B,J4+7;.9K&:4XHS5KP\T%)=8Z2&%6%)UYE(GO2 MM>8=GT?2(#-%Z'O>?E!1QE#F1/#.A?..:/0'TI@7OS'54PLU%]3@ VJC;T5- M!:CJ7*6E(1DL4Z_*

*@QI+7<,4;N%4EE0?'/6+WFFO,#J+. MN\.:?W(:V] 1*3@K>I>D[_EED^*,A5&!N;VO1J"!(:)VA_?R@_VE32)ZET/11 M$B68->72@8H4Z4KI;N:1@DSVV0-U?S_HCN=+:.]?*

LFS15Y%SX(J6'!I:MTHA M@GHUT(_U22AZ7VNU4HRDBJA=<72=4^T M-&5X,C-D,2YH=&WM66U3VS@0_BM[88Z6&?R>5SME MI@VA1Z\$!L)TJ+B

*[&NCN21%4+NU]]*MD,2N"MW+67:@2&.O5]M=E?/KG:=_M_B^6->0IX3%-X+?QV4=(1+R84ZX@EI0HI"Z92F$L\IQP.*-2LBR#=Y(E,PK@ MN7:,]OR6[5K641]E#:I)@H?*

0'!@N(_/!^,_M+H;ELA?7[SZ>#J!A.$%4TQPDCG.<-2 1JJ4'CK. MM.X'I]8 M7>103&7TJ,_4WR7O1^2KHW!";J!0JXR^:+%+U5%LG8#%?

*3U^AT2(C,R#^>?]YH%29;*BQ+*1,1 M)3@XO$W9A"CZ=Y.KX6@,YR=P.CH>7@SQ@H^7*

*MP_>G5^/AY?"XQN_;P>#\>C0^';V'D[/+L^]HX)^+0K'I:L-"U/L3A5CP0H>S M$!]2"HS'0N9"$HT;F*Q TBF5%,,?APS'5&296")(X9+,6*$JUBN%@;T30P%B*

*M"NP=$X=PRE,,"$_@:C$I6,*(9&@/XO$Y,>YK ?72-ZQ M&5,K<*4)0GER+,"_MU_7=(.H[fK'<'D4F&86)D F5;QIN V*:956LKJ^+G,3US %*#$W9FYD(_UH]+;2A1+4/E;+[>*

*[UV MIQ?MZ7A-M(6!KU*Y?-2"4#,Y)VUTFI1XJ4N/H!&_@RO+(@!0E#)(V$#4$06+[? M;/ON(6P3@2#E-G>)+:,??"7;)G:#3[)D(VZ&W?+=Y<+B&L/;%HW?1,4AX ?0+ MH+|-*

H(,=0'L=+_!:]V#:[?@/P;3KMKON@1D0_6L+V!]6K\VIV7?GM_V[B5: M;$DZ#Q&[#R7:=K/E'_8_4S2S MYR

*MOL#%+TLCL%XVF/14N;P]H08POJ+:,2P$SH"4B+]>0V_&CUN6FT MRV/B4;F_5*^-ZU6;Z<99>P1A$6U&!UDH41/*GMQ0MCIW]RX+5CR:LI'.&V#,_MQ4[=-)DFI==ZUIZI4OTZ0^XF8U$GW18*W/#?1F8%U^[>]:?_2X*-=03*GF(+ M5WNT?K9T:@\GDI+/UA+=]\47#^MQ.L% 6R@:U2?>IO'U>Y#]NQTH-1FFH-@*

M^_3^5WLKS%:%A&=K$TT&@SW7_#W:(T\1NG[GBZ'K% Z\EZ0H&.R3>1YA]K%A MV";4'T #R3N?M[7MN-[JSZK_O]S.9MV?(!Y\0I'H5:X:]"?O0[1 M-*

NNGW9GH<[/MS5UM5PESR&5X.S%D.BYH=&WM7&U3VSH6_BM:.O<69O(>:'"%09G@) M<]EMH0/II-Z/LBW'6F3+5Y(3LK]^SY'LQ

*$*H87[R<137P6D#\&7SZ30/I9S!)*?.6H@=0Q-Q$9R#2E"?G"E.)"D%&//@&*R$C MI-UJ?&BT.SN-5KU'>_"^3O)",NF1O6:G!?\[VZ2UVVOM]3H=\O4+V?PV.-FR*

*MUJ>7)X_.Q_9=M5^_"7\^/R$;]6;SW]V39O-T<.HRMANM-ADHFFANN$RH:#;[M%QMD(S(F[36;X_&X,>XVI!HV!U?-R,1BNRFDU*P1F&#C\ !3X">CP>%!S PE M?*

D259N;3QK?!67T7+ PW@AT>-(O?SM.3P>3P(. CHLUS[L$\;.55#GM2-3'O= M5FKVH603LN_8W-;'/#![1K]U[_;:?TB#@R; N6&@@I=!=F:4I/HQFB=(UK]>8 MH(;/&'HO^?

4%HZKG21/MWZWBH9)I42Z4B:F'-.9BTGL_X#'3Y(-R96,;?*^ MYE+@MV:*A^_WK;7F_V/@&AIHV*V14\&'X!R#W7<]T,L;[\U5,F:V/9X4 63V*

M;R/N<4.Z[4;GH.E!3Z4O%=5\$)@YYI8:?H#,$=<0@N!FTHMX$+ $'$'],M]MI M=?P#2XNOYV=#$@@TO;<8^5 M//#4X9>&U_T3ZC;Z1#+LY?Q.?BC3ZZ/KHZ/+OK7]=%JM

*ME[[AL:[];Z8-#R?SG7M>(V=;\)21TPQ0HD9\IM'"F(B;WNJ,/)S>MEF?-A_? M$(BH)UCATY,J8*KN2P%HJEFO^*,<%=B6N3N#L.!##HR^>=C!<.!TO(37T.[7\2%Z?YU-*

*-29(;MiSS?;Z #ZORG"=YXRV"H:%BL/VUT M-IYLY5ZGL;.[CNUL&H4#]R5NY2O P^_OVA];^W:>O]!X>X4@VXVY %]TV"P) M^TE$1XPH-N)L#*S31%R3HR3)]"!7+)7*

!$E9U+%P%3K_R(R)/R8RQHY3_P& M";6"HR7$;,R00X%F%) 'I^F24,5LP.0?9:NHWVH+LS(;]-DOAY:\Z%\(M<@eV'X]U65!CU&KW<67O8.]:;.I%)/"$WB1P+!IOIFD,OY6

KD%!C(F$7#[XI M3PA-)B1+C,]0(<(6VV[1 <\HB>%*<0"PD/]0I(B,8>MEI+.,9Y PGVE-U01- M8GK#+ 9.76I(^R 8]%(@NF$=:.!SY6P>|5.=D]"8CIEO@T0_:80FL2["#

<-.L6;E+NAFDM+1]SUG$\5]BZC ME[MO%W>1 R.; B2,R2K >B".62K4CY/@#<"I,*F!?IV18:$$=="R!%LU0%]N MQ(2D ':(TXC?0LR ,,= ?:=]P/K [H9]:)$).

#TE0'1MGIMX,&IC@CNM70! M$8H\N3:*0D44$UW<$&6MA+"Z"-9>M-7$4"V MD5&2O:.:P^R@SE$0N&S_7%? MYS";.[-(]#0AY:/%(V M<@eV'X]U65!CU&KW<67O8.]:;.I%)/"$WB1P+!IOIFD,OY6

KD%!C(F$7#[XI M3PA-)B1+C,]0(<(6VV[1 <\HB>%*<0"PD/]0I(B,8>MEI+.,9Y PGVE-U01- M8GK#+ 9.76I(^R 8]%(@NF$=:.!SY6P>|5.=D]"8CIEO@T0_:80FL2["#

<-.L6;E+NAFDM+1]SUG$\5]BZC ME[MO%W>1 R.; B2,R2K >B".62K4CY/@#<"I,*F!?IV18:$$=="R!%LU0%]N MQ(2D ':(TXC?0LR ,,= ?:=]P/K [H9]:)$).

#TE0'1MGIMX,&IC@CNM70! M$8H\N3:*0D44$UW<$&6MA+"Z"-9>M-7$4"V MD5&2O:.:P^R@SE$0N&S_7%? MYS";.[-(]#0AY:/%(V M<@eV'X]U65!CU&KW<67O8.]:;.I%)/"$WB1P+!IOIFD,OY6E0FFW2[!=VF|

MO;/)MMPE.FGO!"YIR_KD.DG#J"Q)II)DM83;#D;6QZFSVGWQ\9VNUHS%KHW=.M9,>_N M-G97(.I3IB$/<-+]!T_#>0VE#9]F>O$Bj#%X# YK\FI%C)3X !8,0YCY-I@*

MQ1+K!Q\95EAZF>F[QQ> \+EL,<"IXM@ M[L05N_=(T%.F4?"P2Z.VZHAEYE(S",C 3@ +I13O8R8H;BB@63:(F7 "9P, M4U;/X"^/H2%P?BC/@N_PMFI"+HOPK\FD?

(SD5X/E;5;K<>P/HO3!!O@?BBU/K MA;$<\' $ X1HJF5BSU10K?%LB&]QFZJ@P%! =4X=DT$QY.%}<46Q<&N1U!T& MR<'BKR5L!T+49):9{;Q.&0^1LD'Y 39YJ-PLP;7?Y*

ML,!L41H DQ63L,V9&;.^\$B>P$ZM6:HT8=//TLD7J"\VX6'N9Z >/;1>35W M*J"M@'85!TNPED!ZC#L/A;B.8Y<%+8Y#P+N,U@Q*A;2]S.%B%>2!QI[P&DMM*

M(!U/]!=GWOI\(^IR.9WBH0 W%V:TV!Z67ES7N;>+3T.C6<"-5'HJI=@$ M)(JR^X###O%9)YNP>@#/UIB/@-^HT!=+'OLKXQ"^7=ZRQ+=*

M9K;]DZ;K,O>]DZ;5$],5&8KK<3T2 B"C=0Q<,9,=#(78^9/+L>. MWJ"BXM1GJZE8W=R>B#^,$SX+X/.'C.ZB$@$G0904+,I,__N8I"K[5 $$%TJ M6(NLK-*

*UC>@LAO9"=]C&Y/NE!P]>KB^G7]<94TDVU6!YXX\TCY()"160TQJ M';-\&N#2OL*2XVK-"1L\&4DQ8JAN')28OXFC<@K.XE3(^8/<<20=[Z9SJ TH M^R+23V.)*

]IC_')=IVA?;B[=WE_N<:S%,$'-K)7^9^YF+Z^)U9TEM+D][SHG8#*HZ+>7G;]&M*6S$ZH[UT!!V4#TZDCPHMNY[C>YT071)+4MIW$?^ M[%<##_\/4$1L#!!0 (_"!+%FI?

*^B$W@4 %XB 8 :6)I;RTR,#(T M,#8S,'AE>#,R9#$N:'1M[5I[4]LX$/]>W3:PDS\2H 2)V4FA##EKA"&F+GK MG[(MQ[K*DBLKA-RGOY7MA"2I'M !"J5,R$-.f\T=V!6L_2[RMZM>+1/"A[31=2*6WP=WSW;;;,'9"6Q>]/VMDOIPV.\^G0TJ6<7!Q^/^!A M.U8QOQ0[73."[Y3$^]V,:;0)12E1!]>N-B^#(VD,*532G^UUG_EG1 MAC*>]7=C=@F%GG'Z?*

*B,C:LR$I67NM]Q<=W"E@]-K-%?6E,4Z]3W7?=W)21PS M,,8X332.V*V=ZS'%QNGUH"R,\Q7E1+-+:K@O\8TX)^2F+8RJ0X,VKO:,;ZG0=0WB?:BPY)\+-0M4=O-,?G ?'1\?]7G*

\/.7 M/Q]=]$X#"(:EJ_YO93=4^S<2>7MP88_LO@UO7GF[[SI>,:=MW_KW@AZA\.S M8'!X_VJ/!GWC#Z.SVVF[NS \@N## $:]\X/>Z6!D#?_Z./@$O7Y@9IJNV_SI

*M(^OO2:%9,EO5[%A)6@D=GV57+6*86>$!/"X9SF4FF0", #)4M>V?:8P6=;F)KA2*H,<[2U!R12E] X(F(87&%B%>-23L:*PBB'+I,98T6 E']6]&\UW4ZF*

M;_G#ZVRAK@TX(4HS@>6%HH6J ?\4T01YHRR3W&"8)"RBJH18S8TBAON/X?!B M$L4L&=P '#-N;$ ^4<6$X'75$[YWR:AV9;E/C$DEKF85/K>1&<#YTFY-*

IO!9R&GZ+TQ]7^^@/VV&DN$'L[>4BM3]\KX M?[!A"J>IT"3D=,XTE"JFRHHDYR0OJ#__LJS6+DI+J^QBZB7N%XU!LEJ/C;ZK MQ=B,+)56(UC-I=;ZV7?U++,=W#M/?->

*M , 5^B5)$KDG7$[GHK_MJ:*Y'Z(4.NS-45WW@?%O,D+'2?:-HQ,.9K>RM M4[_K^%,&-NUV^T48VFXB$GW^ECI:FJU-@DA#@;>S M&6\IWBN4U9%C*

*A;IB>NW6=L>4]6O?:M_4,=V[UI\7LVI?UXICJ)K7%/YC^K MZ'Z..;CYDZ1A)K!'RTC9HA@@2YC WH15K=4\1Q.F,$GGBA8F'3?,-.$<D;\NC0W&O%X M:G_/O>?*5%CY^'49?*

^AEW#Q3#,%NCFCWJVNY10O,/NV'73TH<,Z<)'T (B5T+ MK[H15L!4,8V@$[7 ']<\KU#?D(HAG"V>Z=SJ20VDI("0(K-FCE%,+Z"8>&5X,S)D,BYH=&WM66U3

*MVS@0_BM[Z?0*_%,_I0X:69"""%/N6L(0,W?I*-MRK*ML^629D/OUM_)+2.CU M>!G:!J9,2&QI)3V[6CVDO>_&,8DC4D:T!#>>O_0\"B"(&I@D!2HK!T05D,*

*MGL@RDL)'*B7C'(XD"^<4P+'-_I/I)NV80P'V->X;B12%WI6Q\9/9P_L0]?N MN?AP_A%V+KWQ;BE]//!U[G\XGU;#6EQT087{J=FJ,+6<*!+!)N2 M<#A{J"*

*(0Q$3F5+UK77HGQB%***8X'0ZLYK>2]46X'.Y"=@6Y6G+ZKI40.6>1 MH43F=NU,]<&EA=6W9*Z-!0M5[#JV_;]?D3!DZ=S@-%)88G;W,\HDF\TBD2HC((@GC2_>-*

QO:POE=P(5(.M2/JF797@:TXEB#IT?Z<_4.Q:U10T6ME$,[FV+D&VZ\X-;*^QN#+&BGBM83)63ZYCY3$W8W8B&H^6RIX*U28(7=ET>\5R'0SM71C%H8T18%?*

*7QUV[&Y_ M8&G(IX2Q9IP %PN5#[#.>'+AG9ZZ?0,'?]B=CDZ\\";EJ;ZOY8#*7P[O M%'(.X=*N -W)Y! .,3\-Y/8#;Z M.[J=36;&],\/DT\P&GNZIF/;+]^M_BIRQ.+E)K+3% *1IC30.*

*[YB9A53&*5I M03A;ZQ MX4=+AA@-(*;2([@2B39=Q^Y74,L7]I^^+4-MP0CG+*'P7R/5ME',.[/XX9C2" M$Y9B@&((<1I%+*!2][BF5ANP3!NK#*5DA\X+(@["D!:PNA-EBY$*

*#U(:'(=)A: M%Z^%]H&U#]:#S(CT24IS8WK-Z1\&06EA[8-MK"=EVV0)GU.Q0"/-J?ORW/+K M,-8$':R])RH=VDHO?]'?2L5$'8>)SVG3[*QE2:02"UF$=X&AQ11\Z*

*M).*4.C<#FR%?XIV.M#ID+7K[@9&85+BRJ08C7 OU&L1@7XOOF[VK]?M4/>K MG\$V#_5W1?]T 7C#ZI5;EM.S5'@OS%W3WO^AF!W5OT4[#MMD[^-Z [V)<*QF@*

*MYM6HX'R)_)MD7#/?B@TE_-M@DNJD.=?4L$$D3G>'(.U*MV!OJ;5&IM9I9.^$T=]#$1(&X_^ELIMJ?L_6N%GY,//D5P!+X1<68H M.$:+*_$Q'<<)23,Q8E3XVS$N81.K-*

*),TUR;9U->$; M?!$[#,O]<9FGHE3!*XX6&97EF/FM7-*\Y<)6F9DT>_WM3*>VA.BVTSA;E6LV MH]:].962]Z%(^_YK=^W@;&T<@7U'7"P:8S7OQD*2S/4E)9^-*

!4KCSL.H3QM<\$+1?OZ3.Q+!;L54W_?DZ>@IH/BGPI/<;+\9Q5UPXN.&NE/9O5UBXF1N/ZI .;6]*

BOI/+O1^!GY=;&L<(CTY/O/DEWQ\'^VO';)4ZFS_1^];3M4&QIUSR7!&,IR2+R='9[0W],.@$$6J$$\CL/LS MD]TJ5'IP^UY'

*MUA"3"R*G6527#%]UJ_$^G6!\JJ%ON+U<11$R)3E<25SWW-_"0RW6 @UBJ#(ML$1CI.FJ-U9KV5*\2H=]$GR>2_3?4"?B0KI-[K\V\;E946=\';0OLV-R-*

S;E39(8EP4 ^F2\'"> MV_]9G=5,93%=EEZE==$I>W MSL_ 5'1+ P04 " # @3195=D%OA82]2 %Q# B:6\]M.C R-# V M,S\!X<9?#*

*(N:'1M[5S[4QPWMOY7=)Y\:]*KF!;9W"1!782)=6WC,N/-YD=- MMX;1NJ?5VZUFF/WK]SOG2/T8!N/LS09J-ZD89KK5TM'1>7SGT1S_SW!XGB]T*

MGIA4_31]^T:E+JF7)OV_'$V&PU?'F.LT/.3R0_7=>'^"__=?J,G!X>2[P\E+]?ZMVODX/=WET6>7 M!]-?WI_+LN_OGYS<.[>#5]=:,E.AN/S[\] M4!\6WA>'X_%]M1]MGH]

*<>3V>?A@O_#)L,FS5\=T!3^-3E\=+XW7 M*EGHLC+^^V M%8?/)XA_PI-CW-X89F;N#U^.#@[.2G67]C37 MG&SMLE#29;O*

R=69/,Z/)PYOSB:.:,;4\6\;FYR_UPKIS_$/<4_3N0 MWI3@K+?@RO#69BY+7+Y3ES^HJ_/3CQ\NIA?G5T^(Q@_G/UY<3<_G)!-SY_M?]G)MTQ5YW\]_>GDW8_GZN1T2E3O???

*\Q4"=?*F3 MM^?OSL[/_GU;^%M=>3M?WR^\]K5U W61)R.UXQ=&?>/5P?[^Y.C4+6'NU@/^ MNG<4+Z_,Y16Z;JH\(U?75V&]MJH2M80Z.23%?X-%>52>H2:HL]E>;;5N QM#&:=IZ945R83=[FJT_38YPQ!A.5%VUCYS?PH#EL+T4TS4 MW<"1HH%8+FRR4!3%U1T+H3,]Z(N"U+7+H3.]Z(N"U=^4]#&[MK]>97E6\T%*O:7?SNL1*9;,N#2_C\"X1\FB[G-'0!% C*D%B;ANZ\&AO\[2O M7)G@T (K3O(XN:AS0M]@Z-NY]C_!\O!9#*A?V*2>;Z>C7B2;/B+*

*M\S!]=_9*AG&!PS7E5GO'RDA6"*\)96V##[UQ4)'6)6&L1C "L?4TBU@Z&@-W M6N FU)>4@>>+2Y$,T;-D(KO3(^BI!4/3#&2K24/H<9.)4R8J4QC%Q+NR>IJL M/K,W-*

H4)K.YP^ZJUT15CTL"RA?;1B';L"GL%9AVY77L8TIRBEO HP96 %WS_M$#H[@.":<(?:FD.)GRZUS6D1/8> 1ZN*

MEPUE>F8SP:31+W4E"T,VI'40]#2/XP,Y&]G)^W87(SH3.1WUD+UBIEE M089D@ 'Y#<;' W.,48"\6E?&H74UB!S$o08AM N=3GD6>K&S^B4T2Y+GK\OLJ

M>P[A:)X&>@B5D;/R7V'-6\PH!$>]D=(>#2G>?([[C)M$!F7M+?.W M_HOL#!VN:=;=$!NQ48"LK6?LFB0VTABP,DP/L#6D@9 440B%J0G2\?+SVM>'E M>9KB]T--

ANN]MI)=WP&300.KBHZ69+!GST^@H(%7O,$TH..6*=OA-1_BG%PY_#7 &CGN#7<*H_&0>!4^SZ #K3'(PUNSPBCMU&)A'D, V<&L>2@]9=F*794JR6=$QFYRM)7P5\A

*M@)PA_)G2FY49'X05V4U"V>8.((/G@.#ZLRS]EK9>8@.&"^2I3(C&>4G ML!BV*S$-0 O2OC 91VO/P=F\K\NJQDE\6<1\#ZRA Q.+U@G4[JBVNV.Q1!"4 M=2^XJXB0Q-*

PQ"(A(P3.6'(8=(BP899>%B>85I$,B5_K.X6<"4"%)9YDQJZ5C MDU17=_|++HW.Q[?A87IMRT),NG)B?*4[=<"OB$;H@[$ MK\ZB7_$F(KILY>>S0F-##-'UO2 =E'EV<0O#]-

F\MGX=K2VD!/$[(:"1NBI_MPB<<\I -GB9%,=E;DV98#?,20CZW*9U8CE-,X/\!*E7XB&W"/N^8 #DAI5T M:7,35:]125!9N H'N]*2ZPG&IJ=S@R@J{L7I1OZ&NW&_J:6!*

*<@JPF M@\CUX<*FB DP@'(SD^< PS10++N46>3GHMW3RZ;tT0$3#Q&6N//QJPO\= M=/E0YVM]+HZDHK-P<%H_\77IS-70FQ#%6>R4>KYSRP@/6@NJ<1(05S7N0#;*

*MPJJR;HIC?^CMTI%FM$;AYT*B*\.X4JP-#T_M"%!*SL41I*T(/XIVJT$GXCB=*_$LC^P*?#U@R^*E8]QG[MM#OPAKP#++$E@%W,.0G4$@^?-*

D%8PA[E,E;HXNG_.WU)QHRI0K:P886]_?\:-2?60]A@RL+J9XF..L'+&)G"5^3QRL%&-F\JN'4 M\KZTDB4JCMJ-CDD4QBQ!?PC2?Z8@O.^]%YQ"(;W7$J0$B9IE+F$HG,/T^3H

*ML4;.%@ =/>O%Y3^R0)R2J0LIW2RX'E\O9R1N=QWV$2,\0^3^BT1.8EX6NKP' MPSN2QO(XM1:H<&A">-CT/-J!':Y_GW/Y8(B<58XRDFY5%I6J,\

@%A2ZG($ M;DW:5'?D]HC1]0-=$)))/EUH"ZO5)+5X7+QES5R=WY]D9OA[28DQ@84T:2?% MUML1_>[4% /P@=\FH^C[O02)KCR+4T96"AS+ (4)SZ"&,&W43]YV7DZ]W(VW4 Mf<-.0O"F\&34N,\FT]=R8(/]=[@/&L?PD-7R0E/L#I(.IS@N-MM;3BAT#(8]

*M!]^#12)MCR3@/R]L9OJ0M=_X]P4UIDZ=L5MD9$G[7.EP<#=PD39)+ZV6X*.1 M]T>8P,Q^@LM8.)?&TE HH=#"8*^D^R.'*59U;27I'B,5;J-|: Y*;467.(XS M39!QSX,47L4"%A8,)5N_+D+?P!UL,E7=\AN7!9XDOL,#4%?+)ACR=!5W1;_M&%/QXP(5[N&:="Z$=]BT)NG"R=W4&5F;P!MNOH(;K'BO/]8? YNBSY+PLCL_M1\H;1[-MZ[3;I-_Z55*2YYP$':F?W KA:#D02-!9ZMZR8:]4R)FN2AJY MEIK[5[I1K=A#KN:)9<%I2?,P5Y0!/JE7A1FYELW)R4C[!3RKZ6#DW()P], +1 M;4TLO.4DE LYKF7BVB,N: I)_Z9UHFR#=!@\;BK;P(83QM&.1E"8+T:D@/L5> MB\8R-%T6"!M]|PO_D;N9U"Y MV$8GPF'R:Q%G2H'@8F@D;Z X!L\"](PO@NQ B%,#3!R[-78#2FT?C^F?^F[< M,T%\ND4AH?FX%;?Jf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{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`M913_K-ZR#*PC*1.1&$N10%/)VI8A) <9].I2(,W,L]5'-=GN8IN9!#T>YUG MG?[^KYU>NWUR#&.=FTY9,@A>=/=!\/_^8= [&O1>#.##^S?!L?K\SUJ_?+= M^?4?]RIXVO=1.0W*FT7 MV7IPT)L60^C9A= <+;3ZW9RHJ)H-^K_?S<"JB2*4W[5B.B\&OG:.CZE&N;B;N M6<:H#7(9BT+=2AS;&S6,I<@'HZR8#! MREEPE24B_:7%3^"WEKD;_S*DUEK}3\+0@%XA/Q=M$:L;&!QA'3+^ W@7X+_^ M/G_ &4>U&6>2XE.TPB[-\\%./_EMZ&ZM4#LHTDCE^6GI-DPQT%BO$_?+L\ETKN'Q[*

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|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|+HP"U;W9^M#N[+5E>V>N*J2N/A$(^V^)=^ MQ/7KDCQ^;\YI>!%YK(28%AR!S6\B,H8[^5VB9 M$P^,AC/5*4"MP-C4&; ?D&H(QA5Y=**!!ZA 'M;L,UH= 3?(;2 MIYBWV4HG0I-%^C=$!1G'Q@N&AJLI,,HU4'C%V/S0K$RKSY02T5M-7 MVU@L!;$U8(>]%Z-D"DA M|HP@E"$+/UMI;*Z08OH@41%-BL6)L !G>C7(E.&M=?7%*E*-X$2(*R>TM2R5 MN<=5 #B0$;PNZP:N!0UKL@=+ K16_F)R:UX?HG"00NI61>#1!W9!YMX4'O!6 MI^&V!\PSX- D_B2XYQ@N%#DX]*,L+EHPN3JEC#: MYD2^34YD? YL3^3/E1-9K2<^4]80:\B&GB.'+%/11*;@"SI<|\-48]G?GIM,E M2>>/9*N*,A,N+WQ#VPURWEA/LUC|!80EEQU@O7,R15EL)!4]?BRV&X.W)X/= M_IX=K2[$LK%#-LTUQ11!\)LRZD[@UWN!R LE6->8S:'ETV&<4R:N15YDC@ M#^0)0R;89EK(+2+R:N15YDC@ M#^0)0RIODT5C.CTTDLZ@8WRS"X9_)+B# M9QJZN^(P'H6/5JS@+2,1,HVE<(\"$5<88I@Q\@^-LBB\^R7H9B0#9D+ 8 ML5!L:*>[,W'4?GG(7;U7QZVJUZ 5N;M>H|(^D*JZR!!=8JJM+-C*@OO*@JNZ MB@,#. <8RHDF62"ZEA5?DB-0S_K;J# MQX2U6.=&Y)U3QY"<"X;Z%@9,1T/C^ M42O8[^WO/XX48)1,W=0=>=#7(AFQ$95GHBH"[WC0,_M8R;F'^&$P/WU.]\6W+ M5FW55KPJO^K_ZP5M%6XB4#>_%_9CBH;>5#D]>.L3]$!][H2@U1:8K M]!T KX2S]8],W<(>F4$GOF4\?@YAC60JQQ@V0U-XE&G#»"0Y[_5VQM]L_V,/8@/>|WZ>, M5!K5 C=5L*:SFH6:3WF3;G.GO+>AX?N$AG_=.#3\%O.0D4Q2H++0B707N]$V M>*,?/5Y<3\M@#8DR@*](I6@7\$22!E]/;YK76#QZYI4!U / M@(LS+0IX -# MO\V&/LP,SB;E1\L\G)#]7\UH7SPN$2[-4/G&DL,0IO]R4:P2H:?EB*,G>#O M/_6']8:G5#*XL)&Y#P0[%Z9DSP9 ,70H\AOSIXD]7KPB,>6O.P?+1=.<#EA, M 6Y#XPLG111#A%^\8]O\T?V%Q#/BZ.^M_CK!/M'#XB%9?U:7[@:) M|^'BW!02ZBV;W)]-GF^L2T_#3V"3QC*ZD8^>8;UHSLHSH>(M%,94II\,W],/= M5=FJ0CVV>]##G& (LTFCD023FNG8F%1-C!1=IVX-'?#X(IXWM6G"^F!L4GRYY+(P/(:%'1Q@W98IAZU?D*9<+K;@--QL%)L M'-07>LOK]^?UH\UYO7;@XJE4% [HI9.QY#^DE9,WM/IA9'@,T]D;,\#9X#F= Q ML&BE=<*GN:L';"A>X@O:<&E-WHSM$0X!!#'=\4/XQP?19XD4EPW1%'IA#H(? M*Z<08C\\Z9N?II1]6BK7N=@;2 3(*B? -.03\G,3],2IR<#B7"47N9FS'IYS MK%\WP[BG[H29=QU&A>3&]4@,%QI%BH!+S02"3 YGKAWI!JH?S)M:=&QU3H"2H.)#1, MIHDPZ[!*JE"QR5+.0;JCBB^)@@EZ3/? 0Y4Q7;F>,,"(\KGKM>Q2F_54L@GYO MN*X/NT6,W7ADG M@*DBR"7EC%"]+'B 0@K5"E$5,9,$\H,<4O MQ87QD)FI/,(IX^,=F4%VX5L\\!M*"? QMBIS]^N;]"D@"ISZ@OG0N&MS$Z2"68 MSQ]/-M?]P@:!2;>FE3&SI2X$.O'1E53&8/3:TS2-]S2Y,WI>!\PZ\;&=+2M|-M 2OU-V:E#V6(NY\]>CJF9B18IPM)V!0%<76.%>-U$W9&2[T5KE)7X8*1#M> M5H#/X!"GMDI8Q1Z(}6-LZ>%]"@YL?KKQPT,V7H+6_/QU:CVA5 MZ*.*/@]R#]N2F1Z5S!S09765];AL3],DG=M+],Z^24M5MQ&A3&V@=, [%6G_M=V&1$30,3'?>.YSQ501-,6Z%3RG+$P:S)Y-9N. 8797;1W%_&F/;PG?FH@ M90N:=3>";53@FT0%#K=1@3]#5.#K]I._^/<_+\|NKS'Y\)#OO*^NY \(MQ"=Q.? [7H000OGWW^^N+E_^X>'/O]CIX]>[JS<-&.SW(SN:4S*/S6YA-X^]M15#,5?.B2HZYA-%8H>YS-XGZS2?>W7HF17BKY R_0_ IW(:2-KSZO^&V?ME\ M6? \#ZJ3F]2*IWY0ZW& -,;;N:045-YDINC@73SKSY=DCN7@VQ7IW:52-9,\ M*&>'H"RRH)I;G>MB#>K\[JB!E7F;&&WT&*YBX)<:E*. M5)6#\0PHZ>)#KAJAU7*4EB;CE+.MK+]SY-C_]PKF0A>>:\VQ;%@_G>050+!O M;>[B3E.9+_\]A618)D-4"'0;?MM!?>)CRWPW]MUE.D0;WFA-5"0454N+NIKJ M526K1DDM6Q*%T^)FM+ZIQ'7UK(NULIFKB>W]f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|6 #*ZP M& @ $R&Q, :6)I;RTR,#(T,#8S,'@Q,&LP,3,N:G!G4$L! M A0#% @ O8$T62-.B76GF0 ,K< !@ (!-O(3 &EB M:6\M,C R-# V,S!X,3!K,##$T+FIP9U!+ 0(4 Q0 (+V!-%F9Q>4!10X! M $@G 0 8 " 1.,% !I8FEO+3(P,C0P-C,P>#$P:S Q-2YJ M<&=02P$"% ,4 " "]@319.8E-[Q\ -0#',0$ & @ &. MFA4 :6)I;RTR,#(T,#8S,'@Q,&LP,38N:G!G4$L! A0#% @ O8$T6>,U MQ/OIN0 4\T !@ (!XZ<6 &EB:6\M,C R-# V,S!X,3!K M,##$W+FIP9U!+ 0(4 Q0 (+V!-%G,?&T7|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|'@!I8FEO+3(P M,C0P-C,P>&5X,S)D,2YH=&U02P$"% ,4 " # @319)FK,1|4% !*P M& @ '4\|X :6)I;RTR,#(T,#8S,'AE>#,R9#(N:'1M4$L! M A0#% @ P($T6579!,X6$@ /4@ !< (!W_8> &EB M:6\M,C R-# V,S!X97@T9#(N:'1M4$L! A0#% @ P($T63\OTNGC%0 MPGT !@ (!*@D? &EB:6\M,C R-# V,S!X97@Y-V0Q+FAT 7;.5!+!08)P G),* !#'Q\ ! end XML 148 ibio-20240630x10k_htm.xml IDEA: XBRL DOCUMENT 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMemberIbio:AssetPurchaseAgreementMember 2022-09-162022-09-16 0001420720 us-gaap:BuildingMember 2021-04-012021-04-01 0001420720 2022-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2022-07-012024-06-30 0001420720 us-gaap:CommonStockMember 2023-07-012024-06-30 0001420720 us-gaap:PreferredStockMember 2022-07-012023-06-30 0001420720 us-gaap:CommonStockMember 2022-07-012023-06-30 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMemberibio:StockPurchaseAgreementMember 2021-08-232021-08-23 0001420720 us-gaap:CommonStockMember 2023-11-292023-11-29 0001420720 us-gaap:CommonStockMember 2022-10-072022-10-07 0001420720 us-gaap:RetainedEarningsMember 2024-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001420720 us-gaap:RetainedEarningsMember 2023-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001420720 us-gaap:RetainedEarningsMember 2022-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001420720 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001420720 us-gaap:OtherAffiliatesMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-012023-03-31 0001420720 ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember 2024-06-30 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember 2024-06-30 0001420720 us-gaap:CommonStockMember 2024-06-30 0001420720 us-gaap:CommonStockMember 2023-06-30 0001420720 us-gaap:PreferredStockMember 2022-06-30 0001420720 us-gaap:CommonStockMember 2022-06-30 0001420720 ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-26 0001420720 ibio:CommonStockAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-26 0001420720 ibio:AllianceGlobalPartnersMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2023-12-07 0001420720 ibio:ExercisePriceStockOptionsRange5Member 2023-07-012024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange4Member 2023-07-012024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange3Member 2023-07-012024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange2Member 2023-07-012024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange1Member 2023-07-012024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange1Member 2024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange5Member 2024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange4Member 2024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange3Member 2024-06-30 0001420720 ibio:ExercisePriceStockOptionsRange2Member 2024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange5Member 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange4Member 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange3Member 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange2Member 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:ExercisePriceStockOptionsRange1Member 2023-07-012024-06-30 0001420720 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-07-012024-09-16 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-07-012024-09-16 0001420720 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-04-012024-06-30 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-04-012024-06-30 0001420720 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-07-012022-09-30 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-07-012022-09-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member 2023-12-092023-12-09 0001420720 us-gaap:EmployeeStockOptionMember 2021-07-012022-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2022-06-30 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-07-012024-09-16 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-07-012023-09-30 0001420720 us-*

gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-07-012022-09-30 0001420720 us-gaap:EmployeeStockOptionMember 2022-07-012023-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2023-06-30 0001420720 srt:MinimumMember 2023-07-012024-06-30 0001420720 srt:MinimumMember 2022-07-012023-06-30 0001420720 srt:MaximumMember 2023-07-012024-06-30 0001420720 srt:MaximumMember 2022-07-012023-06-30 0001420720 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember 2024-07-012024-09-16 0001420720 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0001420720 srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-06-302024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-04-012024-06-30 0001420720 srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:IbioInc.2020OmnibusEquityIncentivePlanMember 2023-03-312023-03-31 0001420720 srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:IbioInc.2020OmnibusEquityIncentivePlanMember 2023-03-312023-03-31 0001420720 ibio:Mr.RobertLutzMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-11-112022-11-11 0001420720 ibio:MartinBrennerChiefScientificOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-11-112022-11-11 0001420720 ibio:MartinBrennerInterimChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-06-222023-06-22 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-07-012024-09-16 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-012024-09-16 0001420720 srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-06-302024-06-30 0001420720 srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-06-302024-06-30 0001420720 us-gaap:OtherAffiliatesMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-04-012024-06-30 0001420720 srt:ChiefFinancialOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-04-012024-06-30 0001420720 srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-04-012024-04-01 0001420720 us-gaap:RestrictedStockUnitsRSUMember 2024-01-262024-01-26 0001420720 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member 2023-12-092023-12-09 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member 2023-12-092023-12-09 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-07-012024-06-30 0001420720 srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-06-262023-06-26 0001420720 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:IbioInc.2020OmnibusEquityIncentivePlanMember 2023-03-312023-03-31 0001420720 ibio:MartinBrennerInterimChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-202023-01-20 0001420720 ibio:Mr.IsettMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-11-102022-11-10 0001420720 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-08-292022-08-29 0001420720 us-gaap:OtherAffiliatesMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-07-012022-09-30 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-07-012022-09-30 0001420720 us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-07-012022-09-30 0001420720 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member 2020-12-092020-12-09 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member 2020-12-092020-12-09 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2021-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2024-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2023-06-30 0001420720 ibio:TermNote2024Member 2023-07-012024-06-30 0001420720 ibio:InsurancePremiumFinancingAgreementMember 2023-07-012024-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2023-07-012024-06-30 0001420720 ibio:AllianceGlobalPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-072023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-072023-12-07 0001420720 ibio:HcWainwrightAndCompanyLlcMembersrt:MinimumMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember 2022-12-062022-12-06 0001420720 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-262024-03-26 0001420720 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-04-012024-04-01 0001420720 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-072023-12-07 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2023-07-012024-06-30 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember 2023-07-012024-06-30 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember 2022-07-012023-06-30 0001420720 ibio:CollegeStationInvestorsLlcMemberibio:BryanTexasMemberus-gaap:LandAndBuildingMemberibio:PurchaseAndSaleGroundLeaseAgreementMember 2021-11-012021-11-01 0001420720 ibio:CollegeStationInvestorsLlcMemberibio:BryanTexasMemberibio:PurchaseAndSaleGroundLeaseAgreementMember 2021-11-012021-11-01 0001420720 us-gaap:SegmentDiscontinuedOperationsMember 2023-07-012024-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMember 2022-07-012023-06-30 0001420720 ibio:LetterOfCreditSanDiegoLeaseMember 2024-06-30 0001420720 ibio:CompanyPurchasingCardMember 2024-06-30 0001420720 ibio:LetterOfCreditTermLoanMember 2023-06-30 0001420720 ibio:LetterOfCreditSanDiegoLeaseMember 2023-06-30 0001420720 ibio:CompanyPurchasingCardMember 2023-06-30 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember 2024-05-312024-05-31 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember 2024-05-312024-05-31 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-03-282023-03-28 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember 2022-10-112022-10-11 0001420720 srt:MinimumMember 2024-06-30 0001420720 srt:MaximumMember 2024-06-30 0001420720 us-gaap:OfficeEquipmentMember 2024-06-30 0001420720 us-gaap:MachineryAndEquipmentMember 2024-06-30 0001420720 us-gaap:OfficeEquipmentMember 2023-06-30 0001420720 us-gaap:MachineryAndEquipmentMember 2023-06-30 0001420720 us-gaap:RetainedEarningsMember 2023-07-012024-06-30 0001420720 us-gaap:RetainedEarningsMember 2022-07-012023-06-30 0001420720 ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2024-08-012024-08-31 0001420720 us-gaap:SubsequentEventMember 2024-08-012024-08-31 0001420720 ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-07-012024-06-30 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:WarrantAgreementsMember 2022-07-012023-06-30 0001420720 ibio:AssetPurchasingAgreementMember 2024-02-252024-02-25 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMemberibio:PurchaseAndSaleAgreementMember 2024-05-312024-05-31 0001420720 ibio:CollegeStationInvestorsLlcMemberibio:PurchaseAndSaleGroundLeaseAgreementMember 2021-11-012021-11-01 0001420720 ibio:WoodforestNationalBankMemberibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2023-03-172023-03-17 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2023-02-172023-02-17 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsToSettleDebtMemberus-gaap:SettledLitigationMember 2022-03-312023-03-17 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2022-03-312022-03-31 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsForLicenseAgreementMemberus-gaap:SettledLitigationMember 2022-02-092023-02-17 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2022-02-092022-02-09 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsToCoverLegalExpensesMemberus-gaap:SettledLitigationMember 2021-05-142021-05-14 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMember 2022-09-192022-09-19 0001420720 us-gaap:ConvertiblePreferredStockMember 2022-05-102022-05-10 0001420720 ibio:LincolnParkPurchaseAgreementMember 2023-12-312023-12-31 0001420720 ibio:Offering2023Member 2023-12-072023-12-07 0001420720 ibio:AtMarketOfferingsMember 2023-09-302023-09-30 0001420720 ibio:LincolnParkPurchaseAgreementMember 2023-08-042023-08-04 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMember 2022-09-19 0001420720 us-gaap:ConvertiblePreferredStockMember 2022-05-10 0001420720 us-gaap:ConvertiblePreferredStockMember 2022-05-09 0001420720 ibio:CroAgreementMember 2023-07-012024-06-30 0001420720 ibio:CroAgreementMember 2022-07-012023-06-30 0001420720 ibio:SanDiegoMemberus-gaap:LandAndBuildingMember 2024-06-30 0001420720 ibio:SanDiegoMemberus-gaap:LandAndBuildingMember 2023-06-30 0001420720 ibio:BryanTexasMemberus-gaap:LandAndBuildingMember 2021-11-01 0001420720 us-gaap:NotesReceivableMember 2024-06-30 0001420720 us-gaap:NotesReceivableMember 2023-06-30 0001420720 ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember 2023-06-19 0001420720 ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember 2024-06-30 0001420720 ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember 2024-05-312024-05-31 0001420720 ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember 2024-05-312024-05-31 0001420720 ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberibio:WoodforestSettlementAgreementMember 2024-05-172024-05-17 0001420720 ibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-262024-03-26 0001420720 ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-262024-03-26 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-072023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-072023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-072023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-072023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-072023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-

gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-072023-12-07 0001420720 ibio:HcWainwrightAndCompanyLlcMembersrt:MaximumMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 ibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember 2022-12-062022-12-06 0001420720 ibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember 2022-12-062022-12-06 0001420720 ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember 2022-12-062022-12-06 0001420720 ibio:BryanCapitalMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2021-11-012021-11-01 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember 2024-06-30 0001420720 ibio:WoodforestNationalBankMemberibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2023-03-242023-03-24 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2021-05-042021-05-04 0001420720 ibio:SanDiegoMemberus-gaap:LandAndBuildingMember 2021-09-10 0001420720 ibio:PrincipalMember 2024-06-30 0001420720 ibio:InterestMember 2024-06-30 0001420720 ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember 2023-07-012024-06-30 0001420720 ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember 2022-07-012023-06-30 0001420720 ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember 2023-07-012024-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2022-07-012023-06-30 0001420720 us-gaap:PatentsMember 2024-06-30 0001420720 us-gaap:PatentsMember 2023-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMember 2023-10-012023-12-31 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMember 2023-04-012023-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:MachineryAndEquipmentMember 2022-07-012023-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMember 2022-07-012023-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberibio:ContractDevelopmentAndManufacturingOrganizationMember 2022-07-012023-06-30 0001420720 us-gaap:PatentsMember 2023-07-012024-06-30 0001420720 ibio:UniversityOfPittsburghMemberus-gaap:PatentsMemberibio:PatentAndLicensingAgreementMember 2022-07-012023-06-30 0001420720 us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30 0001420720 us-gaap:BuildingAndBuildingImprovementsMember 2023-06-30 0001420720 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001420720 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001420720 ibio:SanDiegoMemberus-gaap:FinancialStandbyLetterOfCreditMemberus-gaap:LandAndBuildingMember 2021-09-10 0001420720 srt:ChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember 2022-10-012022-12-31 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberus-gaap:SettledLitigationMember 2021-07-012022-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberus-gaap:BuildingAndBuildingImprovementsMemberibio:PurchaseAndSaleAgreementMember 2023-07-012024-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:PurchaseAndSaleAgreementMember 2023-07-012024-06-30 0001420720 us-gaap:IntellectualPropertyMember 2024-06-30 0001420720 us-gaap:IntellectualPropertyMember 2023-06-30 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMember 2024-06-30 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMember 2023-06-30 0001420720 us-gaap:SegmentContinuingOperationsMember 2023-07-012024-06-30 0001420720 us-gaap:SegmentContinuingOperationsMember 2022-07-012023-06-30 0001420720 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2023-07-012024-06-30 0001420720 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2024-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember 2023-07-012024-06-30 0001420720 srt:ChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember 2024-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember 2022-11-032022-11-03 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:RetirementPlanNameOtherMember 2023-07-012024-06-30 0001420720 us-gaap:RetirementPlanNameOtherMember 2023-07-012024-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:RetirementPlanNameOtherMember 2022-07-012023-06-30 0001420720 us-gaap:RetirementPlanNameOtherMember 2022-07-012023-06-30 0001420720 2008-06-30 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember 2024-01-162024-01-16 0001420720 ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember 2023-10-302023-10-30 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberibio:CreditAndSecurityAgreementMember 2023-07-012024-06-30 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:CreditAndSecurityAgreementMember 2023-07-012024-06-30 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember 2023-07-012024-06-30 0001420720 ibio:FirstInsuranceFundingMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:InsurancePremiumFinancingAgreementMember 2023-07-012024-06-30 0001420720 us-gaap:DebtInstrumentRedemptionPeriodTwoMemberibio:EquipmentFinancingMasterLeaseAgreementMember 2023-07-012024-06-30 0001420720 us-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:EquipmentFinancingMasterLeaseAgreementMember 2023-07-012024-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2023-07-012024-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2022-10-122022-10-12 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember 2022-10-112023-03-31 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2024-05-17 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-10-04 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-09-18 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-04-14 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember 2022-10-11 0001420720 ibio:FirstInsuranceFundingMemberibio:InsurancePremiumFinancingAgreementMember 2023-10-30 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember 2023-06-30 0001420720 ibio:EquipmentFinancingMasterLeaseAgreementMember 2022-10-12 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember 2021-11-01 0001420720 ibio:WoodforestNationalBankMemberibio:CreditAgreementWithWoodforestNationalBankMember 2021-11-01 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMemberus-gaap:PrimeRateMember 2024-01-162024-01-16 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementEventOfDefaultMemberus-gaap:BaseRateMember 2024-01-162024-01-16 0001420720 us-gaap:ConvertiblePreferredStockMember 2022-07-19 0001420720 us-gaap:SalesMember 2023-07-012024-06-30 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember 2023-06-30 0001420720 ibio:AtMarketOfferingsMember 2023-09-30 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member 2024-06-30 0001420720 us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member 2024-06-30 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member 2023-12-09 0001420720 us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member 2020-12-09 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-07 0001420720 ibio:SeriesDWarrantsMemberibio:Offering2023Member 2023-12-07 0001420720 ibio:SeriesCWarrantsMemberibio:Offering2023Member 2023-12-07 0001420720 ibio:PreFundedWarrantsMemberibio:Offering2023Member 2023-12-07 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-04 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-04 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2024-08-31 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2024-08-31 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2024-06-30 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2024-06-30 0001420720 ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2024-06-30 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2024-06-30 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-06-30 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-06-30 0001420720 ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember 2024-05-31 0001420720 ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember 2024-05-31 0001420720 ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SecuredDebtMemberibio:WoodforestSettlementAgreementMember 2024-05-17 0001420720 ibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-26 0001420720 ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-26 0001420720 ibio:SeriesEWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2024-03-26 0001420720 ibio:PreFundedWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2024-03-26 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-07 0001420720 ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-

gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember 2023-12-07 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-04 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-03 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-03 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:RepresentativeWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-03 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-03 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2023-08-03 0001420720 ibio:BryanCapitalMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember 2021-11-01 0001420720 ibio:BryanCapitalMemberus-gaap:CommonStockMemberibio:WarrantAgreementWithBryanCapitalMember 2021-11-01 0001420720 us-gaap:DiscontinuedOperationsHeldforsaleMemberibio:ContractDevelopmentAndManufacturingOrganizationMember 2023-06-30 0001420720 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:BuildingAndBuildingImprovementsMemberibio:PurchaseAndSaleAgreementWithMajesticRealtyCoMember 2023-09-30 0001420720 ibio:RubrycTherapeuticsIncMemberibio:StockPurchaseAgreementMember 2023-07-012024-06-30 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember 2023-07-012024-06-30 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember 2022-09-162022-09-16 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AcquiredIntangibleAssetsMemberibio:AssetPurchaseAgreementMember 2022-09-192022-09-19 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AcquiredFixedAssetsMemberibio:AssetPurchaseAgreementMember 2022-09-192022-09-19 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember 2022-09-192022-09-19 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AcquiredSeriesPreferredStockMemberibio:StockPurchaseAgreementMember 2021-08-232021-08-23 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AcquiredPrepaidExpensesMemberibio:StockPurchaseAgreementMember 2021-08-232021-08-23 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AcquiredIntangibleAssetsMemberibio:StockPurchaseAgreementMember 2021-08-232021-08-23 0001420720 ibio:RubrycTherapeuticsIncMemberibio:StockPurchaseAgreementMember 2021-08-232021-08-23 0001420720 us-gaap:WarrantMember 2023-07-012024-06-30 0001420720 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012024-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2023-07-012024-06-30 0001420720 us-gaap:WarrantMember 2022-07-012023-06-30 0001420720 us-gaap:RestrictedStockUnitsRSUMember 2022-07-012023-06-30 0001420720 us-gaap:EmployeeStockOptionMember 2022-07-012023-06-30 0001420720 us-gaap:IntellectualPropertyMember 2023-07-012024-06-30 0001420720 us-gaap:IntellectualPropertyMember 2022-07-012023-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMember 2023-07-012024-06-30 0001420720 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012024-06-30 0001420720 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012024-06-30 0001420720 us-gaap:SegmentDiscontinuedOperationsMember 2022-07-012023-06-30 0001420720 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-012023-06-30 0001420720 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-012023-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-07-012024-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2022-07-012023-06-30 0001420720 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-012023-06-30 0001420720 2022-06-30 0001420720 2023-06-30 0001420720 ibio:BryanCapitalMemberus-gaap:CommonStockMemberibio:WarrantAgreementWithBryanCapitalMember 2021-11-012021-11-01 0001420720 ibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 ibio:HcWainwrightAndCompanyLlcMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SixthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-09-182023-09-18 0001420720 ibio:SeriesDWarrantsMemberibio:Offering2023Member 2023-12-072023-12-07 0001420720 ibio:SeriesCWarrantsMemberibio:Offering2023Member 2023-12-072023-12-07 0001420720 ibio:PreFundedWarrantsMemberibio:Offering2023Member 2023-12-072023-12-07 0001420720 ibio:ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMembersrt:MaximumMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember 2024-07-032024-07-03 0001420720 srt:ChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember 2023-01-012023-01-01 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-12-222023-12-22 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember 2023-11-142024-05-17 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember 2023-10-172023-11-13 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember 2023-10-042023-10-16 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-10-04 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-03-24 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:CreditAgreementWithWoodforestNationalBankMember 2021-11-01 0001420720 ibio:WoodforestNationalBankMembersrt:MinimumMemberus-gaap:SecuredDebtMemberibio:FirstAmendmentToCreditAgreementWithWoodforestNationalBankMember 2022-10-11 0001420720 us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-04-012024-04-01 0001420720 ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2024-03-26 0001420720 ibio:CommonStockAndSeriesEWarrantsMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2024-03-26 0001420720 ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember 2024-01-16 0001420720 ibio:AssetPurchasingAgreementMember 2024-02-25 0001420720 ibio:HcWainwrightAndCompanyLlcMemberibio:RepresentativeWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember 2022-12-092022-12-09 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-03-24 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-02-20 0001420720 ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMemberibio:LitigationSettlementPaymentsToCoverLegalExpensesMemberus-gaap:SettledLitigationMember 2021-05-14 0001420720 us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2024-03-262024-03-26 0001420720 ibio:SeriesDWarrantsMemberus-gaap:SubsequentEventMember 2024-08-012024-08-31 0001420720 ibio:SeriesCWarrantsMemberus-gaap:SubsequentEventMember 2024-08-012024-08-31 0001420720 ibio:SeriesDWarrantsMember 2023-07-012024-06-30 0001420720 ibio:SeriesCWarrantsMember 2023-07-012024-06-30 0001420720 ibio:PreFundedWarrantsMember 2023-07-012024-06-30 0001420720 us-gaap:CommonStockMember 2023-11-29 0001420720 us-gaap:CommonStockMember 2022-10-07 0001420720 2022-10-07 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:EquipmentMemberibio:AssetPurchaseAgreementMember 2022-09-16 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember 2022-09-16 0001420720 ibio:RubrycTherapeuticsIncMember 2022-09-16 0001420720 srt:MinimumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2023-08-112023-08-11 0001420720 ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMemberus-gaap:SubsequentEventMember 2024-08-292024-08-29 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:OmnibusEquityIncentivePlan2023Member 2023-12-092023-12-09 0001420720 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:OmnibusEquityIncentivePlan2020Member 2020-12-092020-12-09 0001420720 ibio:AllianceGlobalPartnersMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2023-12-072023-12-07 0001420720 ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember 2023-06-192023-06-19 0001420720 ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember 2021-07-012022-06-30 0001420720 ibio:AuctioneersMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:AuctionSaleAgreementMember 2023-02-172023-02-17 0001420720 ibio:Year2026Member 2024-06-30 0001420720 ibio:Year2025Member 2024-06-30 0001420720 ibio:ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember 2024-07-032024-07-03 0001420720 ibio:AuctioneersMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:AuctionSaleAgreementMember 2023-03-242023-03-30 0001420720 ibio:RubrycTherapeuticsIncMemberus-gaap:CommonStockMemberibio:AssetPurchaseAgreementMember 2022-09-162022-09-16 0001420720 ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-262024-03-26 0001420720 us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember 2022-07-012023-06-30 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-12-22 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-05-102023-05-10 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FifthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-05-10 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:EighthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2024-02-09 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankThirdCollateralWithdrawalMember 2023-11-14 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-11-14 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankSecondCollateralWithdrawalMember 2023-10-17 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:SeventhAmendmentToCreditAgreementWithWoodforestNationalBankFirstCollateralWithdrawalMember 2023-10-04 0001420720 srt:MinimumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-262024-03-26 0001420720 srt:MaximumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember 2024-03-262024-03-26 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2023-08-112023-08-11 0001420720 srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2023-08-112023-08-11 0001420720 ibio:RubrycTherapeuticsIncMemberibio:CollaborationOptionAndLicenseAgreementMember 2021-08-232021-08-23 0001420720 2024-06-30 0001420720 2022-07-012023-06-30 0001420720 ibio:WoodforestNationalBankMembersrt:MaximumMemberus-gaap:SecuredDebtMemberibio:ThirdAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-02-202023-02-20 0001420720 ibio:SanDiegoMemberus-gaap:LandAndBuildingMember 2021-09-102021-09-10 0001420720 ibio:WoodforestNationalBankMemberus-gaap:SecuredDebtMemberibio:FourthAmendmentToCreditAgreementWithWoodforestNationalBankMember 2023-03-242023-03-24 0001420720 srt:MaximumMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember 2024-07-03 0001420720 srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2023-

08-11 0001420720 us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember 2023-08-11 0001420720 srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember 2020-11-25 0001420720 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember 2024-06-30 0001420720 2023-12-31 0001420720 2024-09-05 0001420720 2023-07-012024-06-30 shares iso4217:USD pure ibio:lease iso4217:USD shares ibio:item38310006120002000000001420720--06-302024FY3831000612000Non-accelerated Filertrue086236761015505-4.03-47.88-2.47-58.31-6.50-106.190.040.050.040.0500P3YP39Y0.000P10YP24MP24MP18MP18M0000MonthlyP1D0.040.040.050.05P30D02.00-4.03-47.88-2.47-58.31-6.50-106.19P3YP3Y0false10-Ktrue2024-06-30false001-35023iBio, Inc.DE26-2797813117 50 Sorrento Valley RoadSuite 200San DiegoCA92121302355-0650Common StockIBIONYSEAMERNoNoYesYesfalsefalsefalse4431006863789 5falsefalsefalsefalse606GRASSI & Co., CPAs, P.C.Jericho, New York142100004301000302500020400071300074900066400018065000156720002625900021500025300010810001706000339000610000240100027220003632000421313847000-28894000021324000153810002132400015381000287340004120700022500051850001032700011674000190160001685900029343000-16634000-29343000172000830003630002130000-98000100000011910003200 0-15443000-29311000-9464000-35699000-24907000-65010000-24907000-650100001800003300 0-24907000-64797000-4.03-47.88-2.47-58.31-6.50-106.193831000612000100043700010002876270 00-213000-22393000063485000563000116910001169100050006500006500003900039000100001000439100043910003300033000210002100015900015900 0-65010000-650100001015000100030432000-28894000015381000756800080002512000025128000100070007000420002038000203800036910003691000-24907000-24907000862400090003351620 00-31384700021324000252 0-24907000-650100002038000439100020000126000271000224000321000356000638000674000-49090007730008080008800075006700 00-98000120000242000491500031000001790000010000005650005000-10000005100000101500 0-214000-885000-7400024000-21000-1491000-625000-1199000145000-527000527000-389000-101000200000-100000-18554000-304360004100000673900010000002100005738000116000260000069200090600070090002552300011487000880007000390002040005000001600009900089500088021093000757900028672000144250007579000204000146700063600066900030800001090006800012500017690008140008140006500004449900015900074900068700000style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 10pt 0pt;">1. Nature of Business iBio, Inc. (the "Company" of "iBio") is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization. In September 2022, iBio has focused on utilizing AI and machine learning (ML) to discover and design antibodies against hard-to-drug targets upon the acquisition of substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc") was consummated. This acquisition commenced the Company's transition to an AI-enabled biotech company and the closing of the sale of the Contract Development and Manufacturing Organization (CDMO) facility in Texas concluded its transition. These strategic decisions enable the Company to solely focus resources on the development of AI-powered precision antibodies. The Company's current therapeutics being developed are all in preclinical development and it has not completed any clinical trials for any vaccine or therapeutic protein product candidate produced using iBio technology and there is a risk that it will be unsuccessful in developing or commercializing any product candidates. One of the key features of iBio's technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with unprecedented precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. Another integral part of iBio's technology stack is the machine learning (ML) based antibody-optimizing StableHu™ technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective. iBio also developed the EngageTx™ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio's own development initiatives, the Company's internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners. iBio's technology stack also includes ShieldTx™, an antibody masking technology enabling the creation of conditionally activated antibodies. These masks keep antibodies inactive until they reach diseased tissue, where the masks are removed, and the antibodies are activated. This mechanism is thought to broaden the therapeutic window, potentially making improving efficacy and safety of treatments more effective and safer. Conditionally activated antibodies are also believed to enable the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets which, due to their expression in multiple tissues, would otherwise raise safety concerns. iBio's scientific team, comprised of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to quickly translate scientific discoveries into potential therapeutic applications. Artificial Intelligence in Antibody Discovery and Development iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company's AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery. Pre-Clinical Pipeline iBio is currently in the process of building and advancing its preclinical pipeline by leveraging its technology stack focused on hard-to-drug targets and molecules offering differentiation in both obesity and cardiometabolic disease space, as well as immune-oncology. As the Company continues to leverage its technology stack and develop its existing immune-oncology pre-clinical pipeline, the Company also is seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. iBio also continues to assess its options rights to license three of the four assets under the AstralBio collaboration to add obesity and cardiometabolic programs into its pre-clinical pipeline. Under this strategic collaboration with AstraBio, it affords iBio the opportunity to expand the Company's pipeline and build a presence in the cardiometabolic disease space. Digital Infrastructure iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, AI, ML, and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. iBio's aspiration is to digitize its operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, it remains committed to further investing in our digital infrastructure to support its ambitious goals. Strategic Alliances, Collaborations, and Joint Ventures iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform. 2. Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of iBio Inc. and its subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. Going Concern In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company generated negative cash flows from operations of approximately $18.6 million for the twelve months ended June 30, 2024. Historically, the Company's liquidity needs have been met by the sale of sale of convertible notes payable, common shares, and the issuance of common shares through the exercise of warrants. As of June 30, 2024, iBio had total current assets of approximately $15.7M, of which approximately $14.2 was cash and cash equivalents. The Company incurred net losses of approximately $24.9 million during the twelve months ending June 30, 2024. As of June 30, 2024, we have an operating capital deficit of $18.6 million which compares to the $30.4 million operating capital deficit we maintained as of June 30, 2023. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. Management's current financing and business plans have not mitigated such substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date of filing this Annual Report on Form 10-K for the year ended June 30, 2024. In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, the Company consummated the sale of its 130,000 square foot current Good Manufacturing Practice (cGMP) facility located in Bryan, Texas (the "Facility") satisfying all outstanding amounts under the Term Loan (see Note 3 - Discontinued Operations for more information), raised funds through equity offerings or other financing alternatives, reduced its workforce, entered into a collaboration agreement to discover and develop novel antibodies for obesity and other cardiometabolic diseases and sold certain intellectual property rights. Potential options being considered to further increase liquidity, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a combination thereof. However, the Company anticipates that its expenses will increase as it continues its research and development activities and conducts clinical trials. During the first quarter of fiscal year 2024, the Company completed at-the-market offerings and sold 170,989 shares of common stock, par value $0.001 per share (the "Common Stock") for which it received approximately $1.7 million. The Company also sold 181,141 shares of Common Stock under its purchase agreement entered into on August 4, 2023 (the "Purchase Agreement"), with Lincoln Park Capital Fund, LLC ("Lincoln Park") and received approximately $1.2 million in proceeds. During the second quarter ended December 31, 2023, the Company sold an additional 21,457 shares to Lincoln Park under the Purchase Agreement for approximately $0.1 million. On December 7, 2023, the Company closed a public offering (the "2023 Offering") pursuant to which it sold in the 2023 Offering, (i) 600,000 shares (the "Shares") of the Company's Common Stock, (ii) 1,650,000 pre-funded warrants (the "2023 Pre-Funded Warrants") exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C common warrants (the "Series C Common Warrants")

exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D common warrants (the "Series D Common Warrants," and together with the Series C Common Warrants, the "Common Warrants") exercisable for an aggregate of 2,250,000 shares of Common Stock. A.G.P./Alliance Global Partners("A.G.P.") acted as lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC ("Brookline"), acted as co-placement agent (A.G.P. and Brookline are referred to herein, collectively, as the "Placement Agents") for the 2023 Offering. The Company received approximately $4.5 million in gross proceeds from the 2023 Offering, including the exercise of all 2023 Pre-Funded Warrants and prior to deducting placement agent fees and other estimated offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants. (See Note16 – Stockholders' Equity for more information.) On February 25, 2024, the Company entered into an asset purchase agreement (the "PD-1 Purchase Agreement") with Otsuka Pharmaceutical Co., Ltd. ("Otsuka") pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company's early-stage programmed cell death protein 1 ("PD-1") (the "PD-1 Assets") developed or held for development in consideration of $1,000,000 paid at closing. The PD-1 Purchase Agreement also provides for a potential contingent payment of $2,500,000 upon the achievement of specified developmental milestones and a second potential contingent payment of $50,000,000 upon the achievement of specified milestones following commercialization. The sale of the PD-1 Assets closed on February 25, 2024. On March 26, 2024, the Company entered into a securities purchase agreement (the "2024 Securities Purchase Agreement") with several institutional investors and an accredited investor (the "Purchasers") for the issuance and sale in a private placement (the "Private Placement") of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315 shares of Common Stock, (ii) pre-funded warrants (the "2024 Pre-Funded Warrants") to purchase up to 2,585,963 shares of the Company's Common Stock at an exercise price of $0.0001 per share, and(iii) Series E Common Stock purchase warrants (the "Series E Warrants") to purchase up to 5,287,278 shares of the Company's Common Stock at an exercise price of $2.64 per share. The Series E Warrants are exercisable at any time after the six-month anniversary of their issuance (the "Initial Exercise Date") at an exercise price of $2.64 per share and have a term of exercise equal to five years from the date of issuance. The combined purchase price for one share of common stock and the accompanying Series E Warrant was $2.85 and the purchase price for one 2024 Pre-Funded Warrant and the accompanying Series E Warrant was $2.849. Chardan Capital Markets, LLC ("Chardan") served as the exclusive placement agent in connection with the Private Placement and was paid (i) a cash fee equal to 6.0% of the aggregate gross proceeds of the Private Placement (reduced to 4.0% with respect to certain investors), and (ii) up to $50,000 for legal fees and other out-of-pocket expenses. The Private Placement closed on April 1, 2024. The Company received net proceeds of approximately $14.1 million from the Private Placement, after deducting estimated offering expenses payable by the Company, including placement agent fees and expenses. During fiscal year 2024, 1,650,000 of the 2023 Pre-Funded Warrants, 1,178,500 Series C Common Warrants and 1,053,500 Series D Common Warrants were exercised for proceeds of $4,464,000. In August 2024, 1,000 Series C Common Warrants and 1,000 Series D Common Warrants were exercised for proceeds of $4,000. The Company's cash, cash equivalents and restricted cash of approximately $14.4 million as of June 30, 2024, is anticipated to be sufficient to support operations into the first quarter of fiscal year 2026, unless the Company reduces its burn rate further or raises additional capital. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plans. It is the Company's goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Annual Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. Reverse Stock Split On September 22, 2022, the Company's Board approved the implementation of a reverse stock split at a ratio of one-for-twenty five (1 ; 25) shares of the Company's Common Stock. The reverse stock split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the one-for-twenty five reverse stock split. See Note 17 – Stockholders' Equity for more information. Following the 2023 Annual Meeting, the Company's Board approved a reverse stock split at a ratio of one-for-20 (1:20). Following such approval, on November 28, 2023, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the 2024 Reverse Stock Split. -186000001570000014200000-24900000-18600000-304000001709890.00117000001811411200000214571000006000001650000165000022500002250000225000022500004500000100000025000005000000015100000 2style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. Discontinued Operations On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, on February 10, 2023, the Company entered into an Auction Sale Agreement (the "Auction Sale Agreement") with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the "Auctioneers") for the sale at public auction of equipment and other tangible personal property (the "Equipment") located at the Facility. The Auctioneers guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group's $0.2 million fee. Total proceeds received in fiscal year 2023 were approximately $2.6 million. On May 17, 2024, iBio CDMO entered into a purchase and sale agreement, dated as of May 17, 2024 (the "2024 Purchase and Sale Agreement") with The Board of Regents of the Texas A&M University System ("The Board of Regents") pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property. Additionally, on May 17, 2024, iBio CDMO, the Company and Woodforest entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the 2024 Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the "Indebtedness Deficiency Amount") and thereafter the Company issued to Woodforest a pre-funded warrant ("Pre-Funded Warrant"). (See Note 14 – Debt for more information.) On May 31, 2024, in accordance with the terms of the Settlement Agreement in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share. Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024. The Company incurred pre-tax charges of approximately $1.9 million in fiscal year 2023 for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remained employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The Company further recorded a charge in discontinued operations for approximately $35.7 million in fiscal year 2023, of which approximately $17.9 million was the result of a fixed asset impairment charge (see Note 11 – Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance, approximately $0.9 million of interest related to the term note payable, and the balance related to operational costs related to winding down the CDMO business. During fiscal year 2024, the Company recorded an additional fixed asset impairment charge of $3.1 million, a loss on the sale of the Facility of approximately $4.8 million and a gain on the extinguishment of debt of approximately $0.8 million in discontinued operations. (See Note 5 – Financial Instruments, Note 11 – Fixed Assets and Note 14 – Debt for more information.) The results of iBio CDMO's operations are reported as discontinued operations for the years ended June 30, 2024 and 2023. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intended to sell are classified as "held for sale" on the consolidated balance sheets as of June 30, 2024 and 2023. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statements of cash flows. Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company's continuing operations. The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> 391 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Cost of goods sold </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 52 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Gross profit </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> 339 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Operating expenses: </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> 1,207 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> 6,751 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Fixed asset impairments </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> 3,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> 17,900 </td></tr><tr><td style="vertical-

align:middle;width:63.24%;margin:0pt;padding:0pt;"> Loss (gain) on sale of fixed assets </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> 4,816 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> (773) </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Inventory reserve </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,915 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total operating expenses </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,123 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,137 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Other income (expenses): </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense - term note payable </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> (1,149) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> (900) </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Gain on extinguishment of debt </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> 808 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1) </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total other expenses </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> (341) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> (901) </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Loss from discontinued operations </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (35,699) </td></tr></table> The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Current assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Operating lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> --</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;margin:0pt;padding:0pt;"> 1,941 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,124 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,065 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Current liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:13.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:3.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:15.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,941 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,941 </td></tr></table> . . The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Depreciation expense </td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Amortization of finance lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Purchase of fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 1,542 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Fixed asset impairments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> 3,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 17,900 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Loss on sale of fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> 4,817 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Gain on extinguishment of debt </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> (808) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Payments of term note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> (1,513) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Inventory reserve </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 4,915 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Sales proceeds of fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 2,600 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Payment of finance lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Investing non-cash transactions: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Fixed assets included in accounts payable in prior period, paid in current period </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 1,542 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Supplemental cash flow information: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid during the period for interest </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> 577 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 603 </td></tr></table> . 0.6069210000029000000.8020000026000008500000915000156057000.00011900000P60D-357000001790000049000007500000900000031000004800000800000 The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> 391 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Cost of goods sold </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 52 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Gross profit </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> 339 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Operating expenses: </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> 1,207 </td><td style="vertical-

align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> 6,751 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Fixed asset impairments </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> 3,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> 17,900 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Loss (gain) on sale of fixed assets </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> 4,816 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> (773) </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Inventory reserve </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,915 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total operating expenses </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,123 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,137 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Other income (expenses): </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense - term note payable </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> (1,149) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> (900) </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Gain on extinguishment of debt </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> 808 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1) </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total other expenses </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> (341) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> (901) </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Loss from discontinued operations </td><td style="vertical-align:middle;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(9,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (35,699) </td></tr></table> The following table presents net carrying values related to the major classes of assets that were classified as held for sale at June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Current assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Operating lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;margin:0pt;padding:0pt;"> 1,941 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,124 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;border-

bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,065 </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Current liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:13.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:15.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:63.24%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,941 </td></tr><tr><td style="vertical-align:middle;width:63.24%;margin:0pt;padding:0pt;"> Total current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:0.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:15.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,941 </td></tr></table> . . The following table presents the supplemental disclosures related to discontinued operations for the cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Depreciation expense </td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Amortization of finance lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Purchase of fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 1,542 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Fixed asset impairments </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> 3,100 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 17,900 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Loss on sale of fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> 4,817 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Gain on extinguishment of debt </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> (808) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Payments of term note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> (1,513) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Inventory reserve </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 4,915 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Sales proceeds of fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 2,600 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Payment of finance lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 17 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Investing non-cash transactions: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Fixed assets included in accounts payable in prior period, paid in current period </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> 1,542 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;margin:0pt;padding:0pt;"> Supplemental cash flow information: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.6%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid during the period for interest </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> 577 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"> 603 </td></tr></table> 391000520003390006344000120700067510003100000017900000-48160007730004915000912300035137000114900090000080800010003410009010009464000-35699000194100016124000180650001941000194100027300020000154200031000001790000048170008080001513000491500050000260000017000154200057700060300 4. Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued to related to the extinguishment of the Term Loan, and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. Accounts Receivable Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management's policy is to write off accounts receivable against the allowance for credit losses when a balance is determined to be uncollectible. At June 30, 2024 and 2023, the Company determined that an allowance for credit losses was not needed. The Company had accounts receivable of $1 million at June 30, 2022. Subscription Receivable The Company accounts for any subscription receivable as a current asset. Subscription receivables represent funds related to the sale of Common Stock in which the funds have not yet been delivered to the Company. The funds are generally held in escrow on behalf of the Company and are delivered within a few days. Revenue Recognition The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party's rights regarding the distinct goods or services to be transferred ("performance obligations"), (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company recognizes revenue when it satisfies its performance obligations by transferring control of a promised good or service to the customer. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The Company analyzes its contracts to determine whether the elements can be separately identifiable and accounted for individually or as a bundle of goods or services. Allocation of revenue to individual elements that qualify for performance obligations is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June 30, 2024 and 2023, the Company had no credit loss provisions. The Company generates contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Revenue can be recognized either 1) over time or 2) at a point in time. Revenue reported in discontinued operation was recognized at a point in time for all periods presented. Collaborations/Partnerships The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company's rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements ("ASC 808"). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers ("ASC 606"). Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs. For the years ended June 30, 2024, revenue in the amount of $225,000 was recognized from research activities performed and a non-refundable upfront license fee for which performance obligations were satisfied. No revenue was recognized for the year ended June 30, 2023. Contract Assets A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment. Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2024 and 2023, contract assets were $0. Contract Liabilities A contract liability is an entity's obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer's consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2024, 2023 and 2022, contract liabilities were $200,000, $0 and $100,000, respectively. The Company recognized revenue of $0 in 2024 that was included in the contract liabilities balance as of June 30, 2023 and $100,000 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. Leases The Company accounts for leases under the guidance of ASC 842, Leases. The standard established a right-of-use ("ROU") model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company's balance sheet, resulting in an increase in noncurrent assets and both current and noncurrent liabilities. <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component. The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company's existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company's operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company's incremental borrowing rate requires judgement. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2024 and 2023 consisted of money market accounts. Restricted cash at June 30, 2024 consists of a letter of credit obtained related to the San Diego operating lease (see Note 16 – Operating Lease Obligations) and a Company purchasing card. The Company's bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was $215,000 and $253,000 June 30, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 14,210 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,425 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,579 </td></tr></table> Investments in Debt Securities Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. The Company held no investments in debt securities at June 30, 2024 and 2023. Inventory Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held no inventory at June 30, 2024 and 2023. Research and Development The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board ("FASB") ASC 730-10, "Research and Development" ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expenses were reported in continuing operations for the year ended June 30, 2024. No research and development expenses were reported in discontinued operations for the year ended June 30, 2024. For the year ended June 30, 2023, research and development expenses were reported in both continuing and discontinuing operations. Right-of-Use Assets Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information. Fixed Assets Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to thirty-nine years. The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. See Note 11 – Fixed Assets for additional information. Intangible Assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value. For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. See Note 12 – Intangible Assets for additional information. Share-based Compensation The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates. The impact that share-based payment awards will have on the Company's results of operations is a function of the number of shares awarded, the trading price of the Company's stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company's stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company's historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 – Share-Based Compensation for additional information. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June 30, 2024 and 2023. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023. Concentrations of Credit Risk Cash The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2024 and 2023, amounts in excess of insured limits were approximately $664,000 and $6,900,000, respectively. Revenue During the fiscal year ended June 30, 2024, the Company reported revenue of $225,000 in continuing operations from two research collaborators and $0 of its revenue from discontinued operations. During the fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company's consolidated financial statements. In October 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative" ("ASU 2023-06"). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("ASC"). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SEC's regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): "Improvements to Reportable Segment Disclosures" ("ASU 2023-07") to update reportable segment

disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company's 2024 fiscal year annual reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2023-09") to enhance the transparency and decision-usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. This ASU applies to all entities subject to income taxes. This ASU will be effective for public companies for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued to related to the extinguishment of the Term Loan, and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. Accounts Receivable Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management's policy is to write off accounts receivable against the allowance for credit losses when a balance is determined to be uncollectible. At June 30, 2024 and 2023, the Company determined that an allowance for credit losses was not needed. The Company had accounts receivable of $1 million at June 30, 2022. 01000000 Subscription Receivable The Company accounts for any subscription receivable as a current asset. Subscription receivables represent funds related to the sale of Common Stock in which the funds have not yet been delivered to the Company. The funds are generally held in escrow on behalf of the Company and are delivered within a few days. Revenue Recognition The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party's rights regarding the distinct goods or services to be transferred ("performance obligations"), (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company recognizes revenue when it satisfies its performance obligations by transferring control of a promised good or service to the customer. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The Company analyzes its contracts to determine whether the elements can be separately identifiable and accounted for individually or as a bundle of goods or services. Allocation of revenue to individual elements that qualify for performance obligations is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At June 30, 2024 and 2023, the Company had no credit loss provisions. The Company generates contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Revenue can be recognized either 1) over time or 2) at a point in time. Revenue reported in discontinued operation was recognized at a point in time for all periods presented. Collaborations/Partnerships The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company's rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements ("ASC 808"). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers ("ASC 606"). Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs. For the years ended June 30, 2024, revenue in the amount of $225,000 was recognized from research activities performed and a non-refundable upfront license fee for which performance obligations were satisfied. No revenue was recognized for the year ended June 30, 2023. 02250000 Contract Assets A contract asset is an entity's right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment. Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both June 30, 2024 and 2023, contract assets were $0. 0 Contract Liabilities A contract liability is an entity's obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer's consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment. Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At June 30, 2024, 2023 and 2022, contract liabilities were $200,000, $0 and $100,000, respectively. The Company recognized revenue of $0 in 2024 that was included in the contract liabilities balance as of June 30, 2023 and $100,000 in 2023 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. 2000000100000000100000 Leases The Company accounts for leases under the guidance of ASC 842, Leases. The standard established a right-of-use ("ROU") model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company's balance sheet, resulting in an increase in noncurrent assets and both current and noncurrent liabilities. In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component. The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company's existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company's operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company's incremental borrowing rate requires judgement. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at June 30, 2024 and 2023 consisted of money market accounts. Restricted cash at June 30, 2024 consists of a letter of credit obtained related to the San Diego operating lease (see Note 16 – Operating Lease Obligations) and a Company purchasing card. The Company's bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was $215,000 and $253,000 June 30, 2024 and 2023, respectively. The following table summarizes the components of total cash, cash equivalents and restricted cash in the consolidated statements of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and equivalents </td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 4,301 </td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"> Collateral held for letter of credit - term note payable </td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> 3,025 </td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Collateral held for letter of credit - San Diego lease </td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 198 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 198 </td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"> Collateral held for Company purchasing card </td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55 </td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,579 </td></tr></table>0.05215000253000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"> June 30, </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and equivalents </td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 4,301 </td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"> Collateral held for letter of credit - term note payable </td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> 3,025 </td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Collateral held for letter of credit - San Diego lease </td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 198 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 198 </td></tr><tr><td style="vertical-align:middle;width:58.05%;margin:0pt;padding:0pt;"> Collateral held for Company purchasing card </td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55 </td></tr><tr><td style="vertical-align:middle;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents and restricted cash </td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:middle;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,579 </td></tr></table>1421000043010003025000198000198000170005500014425000757900 Investments in Debt Securities Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. The Company held no investments in debt securities at June 30, 2024 and 2023. Inventory Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held no inventory at June 30, 2024 and 2023. Research and Development The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (“FASB”) ASC 730-10, “Research and Development” (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expenses were reported in continuing operations for the year ended June 30, 2024. No research and development expenses were reported in discontinued operations for the year ended June 30, 2024. For the year ended June 30, 2023, research and development expenses were reported in both continuing and discontinuing operations. Right-of-Use Assets Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations for additional information. Fixed Assets Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to thirty-nine years. The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company’s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. See Note 11 – Fixed Assets for additional information. Intangible Assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value. For indefinite life intangible assets, the Company performs an impairment test annually and whenever events

or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company's business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. See Note 12 – Intangible Assets for additional information. P20Y Share-based Compensation The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates. The impact that share-based payment awards will have on the Company's results of operations is a function of the number of shares awarded, the trading price of the Company's stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company's stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company's historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period rather than electing to record the impact of such forfeitures as they occur. See Note 19 – Share-Based Compensation for additional information. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June 30, 2024 and 2023. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023. 0 Concentrations of Credit Risk Cash The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2024 and 2023, amounts in excess of insured limits were approximately $664,000 and $6,900,000, respectively. Revenue During the fiscal year ended June 30, 2024, the Company reported revenue of $225,000 in continuing operations from two research collaborators and $0 of its revenue from discontinued operations. During the fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. 664000690000022500000391000 Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company's consolidated financial statements. In October 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative" ("ASU 2023-06"). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("ASC"). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SEC's regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): "Improvements to Reportable Segment Disclosures" ("ASU 2023-07") to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company's 2024 fiscal year annual reporting period, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2023-09") to enhance the transparency and decision-usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. This ASU applies to all entities subject to income taxes. This ASU will be effective for public companies for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. 5. Financial Instruments and Fair Value Measurement The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company's consolidated balance sheets approximated their fair values as of June 30, 2024 and 2023 due to their short-term nature. The carrying value of the promissory note receivable, term promissory note, equipment financing payable, insurance financing payable and finance lease obligations approximated fair value as of June 30, 2024 and 2023 as the interest rates related to the financial instruments approximated market. The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value: <table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> • </td><td style="padding:0pt;"> Level 1 – Quoted prices in active markets for identical assets or liabilities. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> • </td><td style="padding:0pt;"> Level 2 – Quoted prices for similar assets and liabilities in active markets or inputs that are observable. </td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"> • </td><td style="padding:0pt;"> Level 3 – Inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). </td></tr></table> The Company initially marketed the CDMO business and during the second quarter of fiscal year 2023, changed its strategy to selling the stand-alone CDMO assets. These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. In the second quarter of fiscal year 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6.3 million and $11.3 million for the Facility and equipment, respectively, reducing their estimated fair values to $16.35 million and $2.1 million, respectively. In the first quarter of fiscal year 2024, the Company entered into an agreement for the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of fiscal year 2023 to reflect the agreed upon sales price less estimated costs to sell. The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. Upon receiving the termination notice, the Company reassessed the CDMO fixed assets for impairment which included obtaining appraisal values as of November 9, 2023. The Company utilized a market approach, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and concluded that fair value of the assets approximated their carrying value and no further impairment was required at that time. The CDMO Equipment was sold during the third quarter of fiscal year 2023. During the second quarter of fiscal year 2024, the Company made the decision to auction the Facility. The Company utilized a market approach, including comparable assets, to estimate the fair value of the Facility. An additional $3.1 million fixed asset impairment was recorded the second quarter of Fiscal 2024 in discontinued operations to write down the carrying value of the Facility to fair value. During the third quarter of

fiscal year 2024, the Company utilized a market approach, using an independent third-party appraisal, including comparable assets, in addition the Company considered previous bids from prospective buyers and the nearing maturity date of the term note and concluded that fair value of the assets approximated their carrying value and no further impairment was required. During the fourth quarter of fiscal year 2024, the Company entered the 2024 Purchase and Sale Agreement with The Board of Regents pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement, related to the Land and to sell to The Board of Regents the Property for $8,500,000. The transaction closed on May 31, 2024 and, in accordance with ASC 360-10-40-5, Property, Plant, and Equipment, an approximate $4.8 million loss was recorded in discontinued operations upon the derecognition of the current assets held-for-sale. 630000011300000163500002100000172500003000001610000031000008500000-4800000 6. Significant Transactions Affiliates of Eastern Capital Limited On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC ("iBio CDMO", and collectively with the Company, the "Purchaser") entered into a series of agreements (the "Transaction") with College Station Investors LLC ("College Station"), and Bryan Capital Investors LLC ("Bryan Capital" and, collectively with College Station, "Seller"), each affiliates of Eastern Capital Limited ("Eastern," a former significant stockholder of the Company) whereby in exchange for a certain cash payment and a warrant the Company: <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility's ground lease;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</td></tr></table> The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System ("Texas A&M") and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the "Sublease") until the consummation of the sale of the Facility. The Purchase and Sale Agreement On November 1, 2021, the Purchaser entered into a purchase and sale agreement (the "PSA") with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the "Ground Lease Agreement") that it entered into with Texas A&M (the "Landlord") related to the land at which the Facility is located together with all improvements pertaining thereto (the "Ground Lease Property"), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the "Warrant") described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature. As discussed above, iBio CDMO is being accounted for as a discontinued operation. In fiscal year 2024, the assets acquired were sold and the asset lease was terminated. These assets were classified as assets held for sale on the June 30, 2023 consolidated balance sheet. The Credit Agreement In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. See Note 14 – Debt for further information of the Term Loan. The Warrant As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock at an exercise price of $665 per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, 579 of such shares were valued at $217,255 to reflect the final payment of rent due under the Sublease. The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired. See Note 17 – Stockholders' Equity for additional information. RubrYc On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. ("RubrYc") described in more detail below: Collaboration and License Agreement The Company entered into a collaboration and licensing agreement (the "RTX-003 License Agreement") with RubrYc to further develop RubrYc's immune-oncology antibodies in its RTX-003 campaign. Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields. RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022. Collaboration, Option and License Agreement The Company entered into an agreement with RubrYc (the "Collaboration, Option and License Agreement") to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc's artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) ten (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022. Stock Purchase Agreement In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement ("Stock Purchase Agreement") with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc's Series A-2 preferred stock ("Series A-2 Preferred") for $7,500,000. The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows: </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"> 1,760,000 </td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"> Intangible assets </td><td style="vertical-

align:middle;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"> 4,300,000 </td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid expenses </td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,440,000 </td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,500,000 </td></tr></table> On September 16, 2022, the Company entered an asset purchase agreement with RubrYc (the "Asset Purchase Agreement") pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued 5,117 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the "Closing Shares"). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company's option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Asset Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American. Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and dismissed bankruptcy proceedings in June 2023. The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense. The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"> 1,228,000 </td></tr><tr><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"> Fixed assets </td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 114,000 </td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,342,000 </td></tr></table> In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. See Note 9 - Finance Lease ROU Assets and Note 15 - Finance Lease Obligations. Former CEO Departure Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the "CEO) and former Chairman of the Board of Directors (the "Board"), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company. Separation Agreement and General Release In connection with Mr. Isett's resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the "Agreement"). Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. Following Mr. Isett's termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for twenty-four (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the twenty-four (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), the Company will pay the full cost of this benefit for up to eighteen (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the eighteen (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of fiscal year 2023. As of June 30, 2024, approximately $0.5 million is recorded in accrued expenses. 2875000028000000151450 0.065223750002579665579217255P5Y286434575000 00 The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"> Preferred stock </td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:middle;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;width:17.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:3.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;width:17.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:3.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;width:17.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,500,000 </td></tr>
</table>75000001760000430000014400007500000511710000006500005000000484000208000176000028800008640001342000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:17.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"> Intangible assets </td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;width:17.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;"></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;width:17.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,342,000 </td></tr>
</table>122800011400013420003814000621300005000000 7. Promissory Note Receivable On June 19, 2023, the Company issued a promissory note (the "Note") with Safi Biosolutions, Inc. ("Safi") in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the "Convertible Note") issued by the Company to Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided. For the fiscal years ended June 30, 2024 and 2023, interest income amounted to $88,000 and $75,000, respectively. As of June 30, 2024 and 2023, the Note balance and accrued interest totaled $1,794,000 and $1,706,000, respectively. On August 29, 2024, the Company received a payment from Safi of approximately $713,000 for all interest owed and approximately $419,000 for a partial payment on the outstanding principal. At June 30, 2024, $713,000 was reported in current assets with the remaining $1,081,000 reported in noncurrent assets. 15000000.050.070.090.0588000750001794000170600071300041900071300010810000 8. Investments in Debt Securities The Company did not hold any investments in debt securities at June 30, 2024. Amortization of premiums paid on the debt securities amounted to $0 and $67,000 for the years ended June 30, 2024 and 2023, respectively. Realized losses on available-for-sale debt securities are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.77%;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Proceeds from sale of debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 6,739 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> Cost of debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,837 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Realized loss on sale of debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (98) </td></tr></table> 067000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.77%;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Proceeds from sale of debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;margin:0pt;padding:0pt;"> 6,739 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;margin:0pt;padding:0pt;"> Cost of debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,837 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.05%;background:#cceeff;margin:0pt;padding:0pt;"> Realized loss on sale of debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (98) </td></tr></table>67390006837000-98000 9. Finance Lease ROU Assets The Company assumed three equipment leases as part of the RubrYc asset acquisition (see Note 6 – Significant Transactions). In addition, the Company leased a mobile office trailer which was classified as part of assets held for sale prior to its termination. The lease for the mobile office trailer was terminated in December 2022. See Note 15 – Finance Lease Obligations for more details of the terms of the leases. The

following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"> ROU - Equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 814 </td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (475) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (204) </td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"> Net finance lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 610 </td></tr></table> Amortization expense of finance lease ROU assets was approximately $271,000 and $204,000 for the years ended June 30, 2024 and 2023, respectively. 3 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.58%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-

align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"> ROU - Equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 814 </td></tr><tr><td style="vertical-align:bottom;width:58.61%;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (475) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (204) </td></tr><tr><td style="vertical-align:bottom;width:58.61%;background:#cceeff;margin:0pt;padding:0pt;"> Net finance lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 610 </td></tr></table>814000814000475000204000339000610000271000204000 10. Operating Lease ROU Assets San Diego, California On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. The net carrying amount of this ROU operating lease asset was $2,401,000 and $2,722,000 at June 30, 2024 and 2023, respectively. Bryan, Texas On November 1, 2021, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. This lease was terminated on May 31, 2024. The net amount of this ROU operating lease asset is included in assets held for sale. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">See Note 16 - Operating Lease Obligations for additional information.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;"> .</p>360300024010002722000196700<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"> 695 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 695 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"> 3,545 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 3,521 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> Office equipment and software </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 403 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 403 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"> 4,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 4,619 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> Accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,011) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (400) </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"> Net fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,219 </td></tr></table> - Depreciation expense was approximately $638,000 and $400,000 for the years ended June 30, 2024 and 2023, respectively. - Fixed assets held for sale at June 30, 2024 and 2023 in the amount of $0 and $16,124,000, respectively, are included in assets held for sale. No depreciation expense related to held-for-sale assets was recorded for the year ended June 30, 2024. The depreciation expense related to held-for-sale assets for the year ended June 30, 2023 is classified as part of loss from discontinued operations. The Company re-evaluated its business strategy and reviewed its product portfolio during fiscal year 2023 which resulted in an impairment charge of approximately $17.9 million to the assets held for sale. An additional $3.1 million fixed asset impairment charge related to the assets held for sale was recorded in the second quarter of fiscal year 2024. See Note 5 - Financial Instruments and Fair Value Measurement for more information. - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> Building and improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 695 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"> 3,545 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 3,521 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> Office equipment and software </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 403 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 403 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"> 4,643 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 4,619 </td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"> Accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,011) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (400) </td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"> Net fixed assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,219 </td></tr>
</table>69500069500035450003521000403000403000464300046190001011000400000363200042190006380004000000161240001790000031000000 12. Intangible Assets On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 – Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (Treg) cells while enhancing T effector (Teff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. In addition, the Company also received preferred shares and an option for future collaboration licenses. On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 – Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate. In January 2014, the Company entered into a license agreement with the University of Pittsburgh whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provided for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company had agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") – initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company's financial obligations for the management of the patents under the license agreement ceased on August 14, 2023, and transitioned back to the University of Pittsburgh and the Medical University of South Carolina. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000 in fiscal year 2023. The Company re-evaluated its business strategy and reviewed its product portfolio during fiscal year 2023. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired. Accordingly, the Company recorded an impairment charge during fiscal year 2023 in general and administrative expenses of approximately $565,000. No impairments were recorded in fiscal year 2024. The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> June 30 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impairments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Intellectual property – gross carrying value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';'serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';'serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';'serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';'serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';'serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 400 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> Intellectual property – accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (35) </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total definite lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 385 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 365 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Intellectual property – indefinite lived </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,003 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total net intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,368 </td></tr></table> Amortization expense was approximately $20,000 and $126,000 for the years ended June 30, 2024 and 2023, respectively. The weighted-average remaining life for intellectual property and patents on June 30, 2024 was approximately 18.3 years. The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:44.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;">Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">265</p></td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 365 </td></tr></table> . 7500000250005650000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> . . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> June 30 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impairments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Intellectual property – gross carrying value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 400 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> Intellectual property – accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (35) </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total definite lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 385 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> 365 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Intellectual property – indefinite lived </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,003 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,003 </td></tr><tr><td style="vertical-align:bottom;width:36.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:36.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total net intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,368</p></td></tr></table>4000004000001500020000350003850002000036500050030005030005388000536800020000126000P18Y3M18D<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:44.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 265 </td></tr><tr><td style="vertical-align:bottom;width:62.67%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 365</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> </p>2000020000200002000020000265000365000<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Accrued Expenses</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Accrued expenses consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"> 1,568 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> 3,879 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> Real estate taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> 268 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"> Interest and fees related to term note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"> 183 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> 31 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 460 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 200 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> Total accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,561 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"> Personnel related costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"> 3,879 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> Real estate taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> 268 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"> Interest and fees related to term note payable </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"> 183 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> Professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"> 31 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 460 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 200 </td></tr><tr><td style="vertical-align:bottom;width:63.15%;margin:0pt;padding:0pt;"> Total accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,561 </td></tr></table> . 1568000387900026800018300031000460000200000202800045610000 14. Debt The Credit Agreement In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 Term Loan to purchase the Facility, which Term Loan is evidenced by a term note (the "Term Note") (for a complete description of the Transaction please see Note 6 – Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provided that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances. On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5.5 million of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5.1 million of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the "Fraunhofer Settlement Funds") (see Note 20 – Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the "Liquidity Covenant") in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a "going concern" designation. In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. In January 2023, the Company's unrestricted cash decreased below the required $7.5 million, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the "Second Amendment"), which amendment, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amendment, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the "Third Amendment"), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests. On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the "Fourth Amendment"), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2 million of the $5.1 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3 million being held in a Company account at Woodforest. In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the "Woodforest Purchase Agreement") for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Woodforest Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7.5 million to $1 million. On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the "Fifth Amendment"), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Woodforest Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest. In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in-kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3.00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the "Sixth Amendment"), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Woodforest Purchase Agreement (as defined in the Credit Agreement) for the sale of the Facility within one business day after entry into the Sixth Amendment, and (ii) if the Facility is not sell on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. In addition, if the closing and funding of the Woodforest Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO's real estate, including the Facility, at the cost of iBio CDMO. On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the "Seventh Amendment"), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default exists (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as iBio CDMO maintains a minimum balance of $2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as iBio CDMO maintains a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as iBio CDMO maintains a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). On the earlier of (a) the closing of the Woodforest Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), the Company will pay Woodforest $20,000. In addition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires the Company to maintain a specified amount in unrestricted cash to $0. Subsequent to executing the Seventh Amendment, the Company withdrew $2,000,000 of the restricted funds. On December 22, 2023, iBio CDMO and Woodforest entered into the Eighth Amendment (the "Eighth Amendment") to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the Term Loan to the earlier of (a) March 29, 2024, or (b) the acceleration of maturity of the Term Loan in accordance with the Credit Agreement, (ii) reduce the interest rate from 5.25% to 4.5% and increase the payment in kind from 3% to 4.5%; and (iii) permit the Company, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) exists to make a withdrawal from the Reserve Funds Deposit Account (as defined in the Credit Agreement) so long as the Company maintains a minimum balance of $900,000 until Payment in Full (as defined in the Credit Agreement). The Eighth Amendment provided that the Company will use its best efforts to consummate and close a sale of the Collateral (as defined in the Credit Agreement) on or before the Maturity Date. The amendment also increased the fees payable by Borrower to Woodforest by $10,000. Accordingly, per the amendment, on the earlier of (a) the closing of the sale of the Collateral, or (b) the Maturity Date, the Borrower will pay Woodforest a fee in the amount of $155,000. Subsequent to executing the Eighth Amendment, the Company withdrew an additional $150,000 of the restricted funds. The amount held in the restricted bank account was approximately $900,000 as of February 9, 2024. On March 28, 2024, iBio CDMO and Woodforest entered into the Ninth Amendment (the "Ninth Amendment") to the Credit Agreement, which amended the Credit Agreement to: (i) set the Maturity Date of the term loan to the earlier of (a) May 15, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement. <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:justify;margin:0pt;"> On May 14, 2024, iBio CDMO and Woodforest entered into the Tenth Amendment (the "Tenth Amendment") to the Credit Agreement, which amended the Credit Agreement to: (i) set the maturity date of the term loan to the earlier of (a) May 31, 2024, or (b) the acceleration of maturity of the term loan in accordance with the Credit Agreement. On May 17, 2024, iBio CDMO, the Company and Woodforest also entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the "Indebtedness Deficiency Amount") and thereafter the Company issued to Woodforest upon receipt of NYSE American LLC approval a pre-funded warrant ("Pre-Funded Warrant") that expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share for 1,560,570 shares of the Company's common stock which equals the $4,499,124.88 Indebtedness Deficiency Amount divided by $2.883 (the greater of the book value or the market value of the Company's common stock at the time the Settlement Agreement is executed). Pursuant to the Settlement Agreement, upon the closing of the sale of the Property under the Purchase and Sale Agreement, Woodforest would purchase the Pre-Funded Warrant in satisfaction of the Indebtedness Deficiency Amount, Woodforest would release the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to such date, and the Company and iBio CDMO will release Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to such date. On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share. Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024. At June 30, 2024, the balance of the Term Note was $0. At June 30, 2023, the balance of the Term Loan was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs. Equipment Financing On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. The financing is payable in monthly installments of $16,230 through October 2025. At June 30, 2024 and 2023, the balance owed under the financing was $241,000 and $401,000, respectively. Interest incurred under the financing for the years ended June 30, 2024 and 2023 totaled approximately $35,000 and $31,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on June 30:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> 178 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 195 </td></tr><tr><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 63 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64 </td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"> Total minimum equipment financing payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> 241 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 259 </td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (178) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"> Long-term portion of minimum equipment financing obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 63 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td></tr></table> Credit and Security Agreement On January 16, 2024, the Company entered into a credit and security agreement (the “Credit and Security Agreement”) with Loeb Term Solutions LLC, an Illinois limited liability company (“Lender”), for a term loan or equipment line of credit loan (the “Loan”) pursuant to which the Company issued to Lender a term promissory note in the principal amount of $1,071,572 (the “2024 Term Note”) bearing interest at the Prime Rate, as quoted in the Wall Street Journal plus 8.5% (the “Effective Rate”), for proceeds of $1,027,455 after payment of $42,863 to Lender as an origination fee, $1,173 for appraisal costs, and $75 for bank wire fees. The 2024 Term Note provides for monthly payments of principal and interest based on a four-year amortization period, with a balloon payment of all principal, accrued interest and any other amounts due on the two year anniversary of the 2024 Term Note. The Credit and Security Agreement granted to Lender a security interest in substantially all of the Company’s assets other than any intellectual property related to any of the Company’s filed patents (the “Loeb Collateral”) to secure the Company’s obligations under the 2024 Term Note. The 2024 Term Note is subject to a prepayment fee of: 4% of the principal amount being prepaid if the 2024 Term Note is prepaid during the first 12 months from its issuance, and 3% of the principal amount being prepaid if the 2024 Term Note is prepaid during the second 12 months from its issuance date. The Credit and Security Agreement provides that the Company may request that Lender make further loan advances to the Company subject to certain conditions, including that the Company is not otherwise in default under the Credit and Security Agreement and its obligations and liabilities to Lender do not exceed a borrowing base equal to the lesser of: (a) eighty percent (80.0%) of the forced liquidation value of the Company’s Eligible Equipment as determined by Lender in its sole reasonable discretion, or (b) a monthly dollar amount. The Credit and Security Agreement defines “Eligible Equipment” as equipment that (a) is owned by the Company free of any title defect or any lien or interest of any person except the lien in favor of the Lender; (b) is located at locations permitted by the Credit and Security Agreement; (c) in the Lender’s reasonable opinion, is not obsolete, unsalable, damaged or unfit for further use; (d) is appraised by an appraiser satisfactory to the Lender; (e) complies with any representation or warranty with respect to equipment contained in the Credit and Security Agreement; and (f) is otherwise acceptable to the Lender in its reasonable discretion. The Company’s obligations to Lender under the 2024 Term Note and Credit Security Agreement are further secured by an validity guarantee, dated January 16, 2024 (the “Validity Guarantee”), executed by Dr. Martin Brenner and Felipe Duran in their individual capacity (the “Indemnitors’) for the benefit of Lender. The Validity Guarantee provides that the Indemnitors will indemnify the Lender from any loss or damage, including any actual, consequential or incidental loss or damage, suffered by Lender as a result of, or arising out of, among other things, any willful or intentional misrepresentation or gross negligence by the Company in connection with the Loan and any acts of fraud, conversion, misappropriation or misapplication of funds or proceeds of any Loeb Collateral by the Company or the Indemnitors. The Credit and Security Agreement contains customary events of default. If an event of default occurs, the 2024 Term Note provides that regardless of whether the Lender elects to accelerate the maturity of the 2024 Term Note, the entire principal remaining unpaid hereunder shall thereafter bear interest at the rate equal to the Effective Rate plus 6% per annum. The financing is payable in monthly installments of $30,710 through December 2025 and a balloon payment of $652,060 in January 2026. At June 30, 2024, the balance owed under the financing was $984,000. Interest incurred under the financing for the year ended June 30, 2024 totaled approximately $66,000. Future minimum payments under the term promissory note obligation are due as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal period ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 151 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 836</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Total minimum term promissory note payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 221 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,205</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(218)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Long-term portion of minimum term promissory note obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 766 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> </td></tr></table> Insurance Premium Financing On October 30, 2023, the Company entered into an insurance premium financing agreement with FIRST Insurance Funding, a division of Lake Forest Bank & Trust Company, N.A., whereby approximately $597,000 was borrowed over ten months at an imputed interest rate of 8.5%. The financing is payable in monthly installments of $62,095 through August 2024. At June 30, 2024, the balance owed under the financing was approximately $123,000. Interest incurred under the financing for the year ended June 30, 2024, totaled approximately $25,000, respectively.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Future minimum payments under the insurance premium financing obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending on June 30:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"> 124 </td></tr></table> 223750000.032555000051000002500000P6M223751000000075000005000000750000P5D0.400.400.200.400.20200000051000003000000750000000000750000000; <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal period ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 259</p></td></tr><tr><td style="vertical-align:bottom;width:54.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:54.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 63 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td></tr></table>178000170001950006300010006400024100018000259000178000630001071572008510274554286311737508.040.030.8000.0630710652060984000660000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal period ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 151 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt,"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 836</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum term promissory note payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt,"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 221 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,205</p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt,"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (218)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of minimum term promissory note obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt,"> 766 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> </td></tr></table>2180001510003690007660007000083600098400022100012050002180007660000597000P10M0.0856209512300025000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal period ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:54.94%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"> 124 </td></tr></table> 1230001000124000 15. Finance Lease Obligations Equipment As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $814,000 as part of the RubrYc Asset Purchase Agreement. The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025. Mobile Office Trailer Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations. The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease cost: </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> Amortization of ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> 204 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Interest on lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 49 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> Total lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 253 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Financing cash flows from finance lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 191 </td></tr></table> 0 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times';

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:29.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:67.66%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 610 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> Finance lease obligation - current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 272 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease obligation - noncurrent portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 351 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> Weighted-average remaining lease term - finance lease </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 1.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"> years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 2.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt;"> years </td></tr><tr><td style="vertical-align:bottom;width:67.66%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average discount rate - finance lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 9.500 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 9.500 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table> Future minimum payments under the capitalized lease obligations are due as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:65.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal year ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373</p></td></tr><tr><td style="vertical-align:bottom;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (299)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 3814000314000338l9 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease cost: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.05%;margin:0pt;padding:0pt;"> Amortization of ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> 204 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Interest on lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 49 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> Total lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 253 </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> Other information: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.05%;margin:0pt;padding:0pt;"> Financing cash flows from finance lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 191 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:29.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:14.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:67.66%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 610 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> Finance lease obligation - current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 272 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease obligation - noncurrent portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 351 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.66%;margin:0pt;padding:0pt;"> Weighted-average remaining lease term - finance lease </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 1.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"> years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"> 2.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;margin:0pt;padding:0pt;"> years </td></tr><tr><td style="vertical-align:bottom;width:67.66%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average discount rate - finance lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 9.500 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"> 9.500 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.71%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table>27100020400048000490003190002530002720001910003390006100002990002720005300035100OP1Y2M1DP2Y2M1D0.095000.09500 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal year ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> 319 </td></tr><tr><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 53 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 54 </td></tr><tr><td style="vertical-align:bottom;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"> Total minimum lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> 352 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 373 </td></tr><tr><td style="vertical-align:bottom;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (299) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.93%;margin:0pt;padding:0pt;"> Long-term portion of minimum lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 53 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . 2990002000031900053000100054000352000210003730002990005300 0 16. Operating Lease Obligations Texas Ground Lease As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The Ground Lease was terminated on May 31, 2024. (See Note 3 – Discontinued Operations for more information.) The annual base rent payable under the Ground Lease Agreement was $151,450 which approximated 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. San Diego On September 10, 2021, the Company entered into a lease for 11,383 square feet of space in San Diego, California. Terms of the lease include the following: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The length of term of the lease is 88 months from the lease commencement date (as defined).</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The lease commencement date is September 16, 2022.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The monthly rent for the first year of the lease is $51,223 and increases approximately 3% per year.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The lease provides for a base rent abatement for months two through five in the first year of the lease.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The landlord is providing a tenant improvement allowance of $81,860 to be used for improvements as specified in the lease.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company is responsible for other expenses such as electric, janitorial, etc.</td></tr></table><table style="border-

collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company opened an irrevocable letter of credit in the amount of $188,844 in favor of the landlord. The letter of credit expires on October 8, 2024 and renews annually as required.</td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease right-of-use asset in the accompanying balance sheet. Rent expense for the San Diego facility commenced in fiscal year 2022, when the Company began making improvements to the facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Other information: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement lease liability: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Operating cash flows from operating lease </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash flows from operating lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 307 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 2,722 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Operating lease obligations - current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 389 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease obligations - noncurrent portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 3,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Weighted average remaining lease term - operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"> 5.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 6.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> years </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average discount rate - operating lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"> 7.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 7.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table> . Future minimum payments under the operating lease obligation are due as follows (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:48.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal year ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Imputed Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 212 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 648 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 490 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 669 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 546 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 142 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 688 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 609 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 100 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 709 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 677 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 54 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 731 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 366 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 374 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> Total minimum lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 3,124 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,819 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (436) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> Long-term portion of minimum lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,688 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td></tr></table> 1514500.065P88MP6M512230.0381860188844 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Total lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for amounts included in the measurement lease liability: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash flows from operating lease </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 563 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating cash flows from operating lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 307 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.97%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.32%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 2,722 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Operating lease obligations - current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 389 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease obligations - noncurrent portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 3,125 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"> Weighted average remaining lease term - operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"> 5.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"> years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"> 6.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"> years </td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average discount rate - operating lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"> 7.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"> 7.25 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr>
</table>5630005630005630005630005630005630006310003070002401000272200043600038900026880003125000P5Y6MP6Y6M0.07250.0725 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;width:48.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal year ending on June 30: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Imputed Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">|</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 212 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 648 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 490 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 179 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 669 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 546 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 142 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 688 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 609 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 100 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 709 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 677 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 54 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 731 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 366 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 374 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"> Total minimum lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> 3,124 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,819 </td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (436) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;">Long-term portion of minimum lease obligation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,688 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"> 17. Stockholders’ Equity Preferred Stock The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Series 2022 Convertible Preferred Stock (“Series 2022 Preferred”) On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company’s 1 million authorized shares of preferred stock. Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis. The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270 on May 10, 2022. Pursuant to the terms of the preferred stock, the Company’s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022. Common Stock The number of authorized shares of the Company’s common stock is 275 million. Reverse Stock Split On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company’s certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-twenty-five (1:25). On September 22, 2022, the Company’s Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued and outstanding, effective October 7, 2022. The Company’s common stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022. On November 27, 2023, the stockholders of the Company, approved a proposal at the Company’s 2023 Annual Meeting to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock, at a ratio between 1-for-5 to 1-for-20, with the ratio within such range to be determined at the discretion of the Company’s Board, without reducing the authorized number of shares of Common Stock. Following the 2023 Annual Meeting, the Board approved a final split ratio of one-for-20 (1:20). Following such approval, on November 28, 2023, the Company filed an Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the 2023 reverse stock split, with an effective time of 12:01 a.m. Eastern Time on November 29, 2023. As a result of the 1:20 2023 Reverse Stock Split, each twenty (20) pre-split shares of Common Stock outstanding automatically combined into one (1) new share of Common Stock without any action on the part of the holders. No fractional shares were issued in connection with the 2023 Reverse Stock Split. In lieu of fractional shares, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the effective time of the 2023 Reverse Stock Split (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) were entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the 2023 Reverse Stock Split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the NYSE American for the ten days preceding November 29, 2023. Issuances of Common Stock for the years ended June 30, 2024 and 2023 include the following: Cantor Fitzgerald Underwriting On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) to sell

shares of Common Stock, from time to time, through an "at the market offering" program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. In the fiscal year ended June 30, 2024, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 170,989 shares of Common Stock. The Company received net proceeds of approximately $1.7 million. In the fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 289,144 shares of Common Stock. The Company received net proceeds of approximately $6.4 million during the fiscal year ended June 30, 2023 and held a subscription receivable for $204,000 at June 30, 2023 for proceeds received on July 6, 2023. RubrYc Transaction On September 19, 2022, the Company issued 5,117 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc. Wainwright Underwriting On December 6, 2022, the Company entered into an underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the "Offering") (i) 76,538 shares of the Company's Common Stock, (ii) pre-funded warrants (the "2022 Pre-Funded Warrants") to purchase up to 91,730 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the "Series A Warrants") to purchase up to 168,267 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the "Series B Warrants" and together with the Series A Warrants, the "2022 Warrants") to purchase up to 168,267 shares of Common Stock. The offering closed on December 9, 2022. Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses. Pursuant to the Underwriting Agreement, the Company granted Wainwright a 30-day option to purchase up to an additional 25,240 shares of Common Stock and/or Common Warrants to purchase up to an additional 50,480 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 25,240 Series A Warrants and 25,240 Series B Warrants. The Company also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the "Representative's Warrants") to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and 2022 Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 10,094 shares of Common Stock. The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs. Lincoln Park Stock Purchase Agreement As discussed above, on August 4, 2023, the Company entered into a Purchase Agreement, with Lincoln Park, pursuant to which, under the terms and subject to the satisfaction of specified conditions set forth therein, the Company may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the "Registration Rights Agreement"), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the "Securities Act"), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by the Company to Lincoln Park under the Purchase Agreement. The Company could not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park's purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the "Commencement Date"). The registration statement was declared effective on August 11, 2023. Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company's discretion, it had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company could, at its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $3.00, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 5,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a "Regular Purchase"); provided, however, that the maximum number of shares the Company may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 7,500 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $20.00, and (ii) 10,000 shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $40.00; provided, however, that Lincoln Park's maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement. In addition, provided that the Company had directed Lincoln Park to purchase the maximum amount of shares that it is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $4.00, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an "accelerated purchase," and one or more "additional accelerated purchases" on the business day immediately following the purchase date for such Regular Purchase, as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable, calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement. The Company controlled the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park had no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park was obligated to make purchases as the Company directs, subject to certain conditions. As consideration for Lincoln Park's commitment to purchase shares of Common Stock at the Company's direction pursuant to the Purchase Agreement, the Company issued 10,573 shares of Common Stock to Lincoln Park as commitment shares (the "Initial Commitment Shares") and agreed to issue 10,573 additional shares of Common Stock to Lincoln Park as commitment shares (the "Additional Commitment Shares" and, collectively with the Initial Commitment Shares, the "Commitment Shares") at such time as the Company had received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. During fiscal year 2024, the Company sold 202,595 shares of Common Stock under the Purchase Agreement and received approximately $1.3 million in proceeds. No shares remain available for sale under the Purchase Agreement at June 30, 2024. Securities Purchase Agreement On December 5, 2023, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain Purchasers identified on the signature pages of the Securities Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the 2023 Offering, (i) 600,000 Shares of the Company's Common Stock, (ii) 1,650,000 2023 Pre-Funded Warrants exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock. The 2023 Offering closed on December 7, 2023. The combined purchase price of each share of Common Stock and the accompanying Common Warrants was $2.00 (the "Offering Price"). The Company agreed to pay the Placement Agents an aggregate cash fee equal to 5.5% of the gross proceeds received by the Company from the sale of the securities in the 2023 Offering. Pursuant to the placement agency agreement, dated December 5, 2023, entered into by and between the Company and the Placement Agents (the "Placement Agency Agreement"), the Company also agreed to reimburse the Placement Agents for their accountable offering-related legal expenses in an amount up to $75,000 and pay a non-accountable expense allowance of up to $15,000. The Company received net proceeds of approximately $4 million in the 2023 Offering after deducting commissions and other issuance costs. Approximately $369,000 of issuance costs are reported in accrued expenses in the consolidated balance sheet at June 30, 2024. Securities Purchase Agreement and Warrants On March 26, 2024, the Company entered into the 2024 Securities Purchase Agreement with the Securities Purchasers for the issuance and sale in the Private Placement of the following securities for gross proceeds of approximately $15.1 million: (i) 2,701,315 shares of the Common Stock, (ii) 2024 Pre-Funded Warrants to purchase up to 2,585,963 shares of the Company's Common Stock at an exercise price of $0.0001 per share, and (iii) Series E Common Stock purchase warrants to purchase up to 5,287,278 shares of the Company's Common Stock at an exercise price of $2.64 per share. The Series E Warrants are exercisable at any time after the six-month anniversary of their issuance at an exercise price of $2.64 per share and have a term of exercise equal to five years from the date of issuance. The combined purchase price for one share of common stock and the accompanying Series E Warrant was $2.85 and the purchase price for one pre-funded warrant and the accompanying Series E Warrant was $2.849. A holder of the 2024 Pre-Funded Warrants and the Series E Warrants may not exercise any portion of such holder's 2024 Pre-Funded Warrants or the Series E Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company's outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days' prior notice from the holder to the

Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise. The 2024 Pre-Funded Warrants are exercisable at any time after their original issuance, subject to the beneficial ownership limitation (as described above) and will not expire until exercised in full. The exercise price and number of shares of Common Stock issuable upon exercise of the 2024 Pre-Funded Warrants and Series E Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price. If at the time of exercise on a date that is after the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common Stock to the holders of the Series E Warrants, the Series E Warrants may be exercised, in whole or in part, at such time by means of a "cashless exercise." If at the time of exercise on a date that is after the 60th day anniversary of the Initial Exercise Date, there is no effective registration statement or the prospectus contained therein is not available for the issuance of shares of Common Stock to the holders of 2024 Pre-Funded Warrants, the 2024 Pre-Funded Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise." Pursuant to the 2024 Securities Purchase Agreement, the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants no later than 60 days after the date of the 2024 Securities Purchase Agreement (the "Filing Date"), to use its commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event not more than 75 days following the date of the 2024 Securities Purchase Agreement (or 90 days following the date of the 2024 Securities Purchase Agreement in the event of a "full review" by the SEC) (the "Effectiveness Date"), and to keep such registration statement effective at all times for a one year period after the closing date provided that the Company will have the right to suspend the registration statement for a period of fifteen (15) days during such one year period without being in breach. In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an "Event Date") and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%. The registration statement was filed with the SEC on April 16, 2024 and declared effective by the SEC on April 24, 2024. The Private Placement closed on April 1, 2024 at which time the Company received net proceeds of approximately $14.1 million, which was reported as a subscription receivable on the March 31, 2024 condensed consolidated balance sheet, from the Private Placement, after deducting estimated offering expenses payable by the Company, including placement agent fees and expenses. The Company intends to use the net proceeds received from the Private Placement primarily for general corporate purposes, including for research and development and working capital. Chardan served as the exclusive placement agent in connection with the Private Placement and was paid (i) a cash fee equal to 6.0% of the aggregate gross proceeds of the Private Placement (reduced to 4.0% with respect to certain investors), and (ii) up to $50,000 for legal fees and other out-of-pocket expenses. Pursuant to the terms of the 2024 Securities Purchase Agreement, the Company is prohibited from entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or securities convertible or exercisable into Common Stock for a period commencing on March 26, 2024, and expiring 60 days from the Effective Date (as defined in the 2024 Securities Purchase Agreement). Furthermore, the Company is also prohibited from entering into any agreement to issue Common Stock or Common Stock Equivalents (as defined in the 2024 Securities Purchase Agreement) involving a Variable Rate Transaction (as defined in the 2024 Securities Purchase Agreement), subject to certain exceptions, for a period commencing on March 26, 2024 and expiring one year from such Effective Date (as defined in the 2024 Securities Purchase Agreement); provided that sixty (60) days after the Effective Date entering into an at-the-market facility shall not be deemed a Variable Rate Transaction. Vesting of Restricted Stock Units "RSUs" RSUs for 42,054 of Common Stock vested during the year ended June 30, 2024. RSUs for 10,878 of Common Stock vested during the year ended June 30, 2023. Exercise of Stock Options No stock options were exercised in the years ended June 30, 2024 and 2023. Warrants Bryan Capital The Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock of the Company at an exercise price of $665 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Wainwright As discussed above, the Company issued various warrants with the following terms: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;">2022 Pre-Funded Warrants – Immediately exercisable at an exercise price of $0.001 per share. All of the 2022 Pre-Funded Warrants were exercised in December 2022.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;">Class A Warrants – Immediately exercisable at an exercise price of $20.80 per share for a term of five years.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;">Class B Warrants – Immediately exercisable at an exercise price of $20.80 per share for a term of two years.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;">Representative Warrants - Immediately exercisable at an exercise price of $26.00 per share for a term of five years.</td></tr></table> No 2022 Warrants were exercised during the year ended June 30, 2024. During the year ended June 30, 2023, 17,064 Class A Warrants and 89,059 Class B Warrants were exercised. The total proceeds from Class A and B Warrants exercised during the year ended June 30, 2023 was $2,207,000. On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to 173,795 shares of common stock and existing Series B Warrants to purchase up to 102,900 shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of $20.80 per share (the "Existing Warrants"), to lower the exercise price of the Existing Warrants to $10.00 per share. A.G.P./Alliance Global Partners <span style="margin-

bottom:12pt;visibility:hidden;"> On December 7, 2023, the Company, completed the 2023 Offering of (i) 600,000 shares Common Stock, (ii) 1,650,000 Pre-Funded Warrants exercisable for an aggregate of 1,650,000 shares of Common Stock, (iii) 2,250,000 Series C Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock, and (iv) 2,250,000 Series D Common Warrants exercisable for an aggregate of 2,250,000 shares of Common Stock exercisable for an aggregate of 2,250,000 shares of Common Stock. The terms of the 2023 Pre-Funded Warrants, Series C Common Warrants and Series D Common Warrants were described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023, which description is incorporated by reference herein. Each share of Common Stock and 2023 Pre-Funded Warrants, as applicable, was sold together with one Series C Common Warrant to purchase one share of Common Stock and one Series D Common Warrant to purchase one share of Common Stock. The combined purchase price of each share of Common Stock and the accompanying Common Warrants was the Offering Price and the combined purchase price of each 2023 Pre-Funded Warrant and the accompanying Common Warrants was $1.9999, which is equal to the combined purchase price per share of Common Stock and accompanying Common Warrants, minus the exercise price of each Pre-Funded Warrant of $0.0001. The Series C Common Warrants and the Series D Common Warrants have an exercise price of $2.00 per share and are immediately exercisable. The Series C Common Warrants will expire two (2) years from the date of issuance and the Series D Common Warrants will expire five (5) years from the date of issuance. During fiscal year 2024, 1,650,000 of 2023 Pre-Funded Warrants were exercised. In addition, 1,178,500 Series C Common Warrants and 1,053,500 Series D Common Warrants were exercised for proceeds of $4,464,000. In August 2024, 1,000 Series C Common Warrants and 1,000 Series D Common Warrants were exercised for proceeds of $4,000. 10000000.001100000001100027040275000000252502520202001000000001709891700000289144640000020400051171000000765389173016826716826700.0702

style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.27%;margin:0pt;padding:0pt;"> Years ended </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Basic and diluted numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss from continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15,443)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (29,311) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss from discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-

bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (9,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (35,699) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss - total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (24,907)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (65,010) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Basic and diluted denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average common shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> 3,831 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> 612 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Per share amount - continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (4.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> (47.88) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> Per share amount - discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (2.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> (58.31) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Per share amount - total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_y-mPh_krZkyTQP57BbAzCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> (106.19) </td></tr></table> In fiscal years 2024 and 2023, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2024 and 2023, shares issuable which could potentially dilute future earnings included were as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.81%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"> 912 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"> 14 </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"> 12 </td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,127 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 293 </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> Shares excluded from the calculation of diluted loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 319 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.27%;margin:0pt;padding:0pt;"> Years ended </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td

colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Basic and diluted numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss from continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,443)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (29,311) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss from discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (35,699) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss - total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,907)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (65,010) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Basic and diluted denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average common shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> 3,831 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> 612 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Per share amount - continuing operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> (47.88) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"> Per share amount - discontinued operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;"> (2.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"> (58.31) </td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"> Per share amount - total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_y-mPh_krZkyTQP57BbAzCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"> (106.19) </td></tr></table>-15443000-29311000-9464000-35699000-24907000-650100003831000612000-4.03-47.88-2.47-58.31-6.50-106.19 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.81%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;margin:0pt;padding:0pt;"> 912 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"> 14 </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.85%;margin:0pt;padding:0pt;"> 12 </td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,127 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 293 </td></tr><tr><td style="vertical-align:bottom;width:68.06%;margin:0pt;padding:0pt;"> Shares excluded from the calculation of diluted loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 319 </td></tr></table> 91200014000370001200012127000293000130760003190000 19. Share-Based Compensation The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Years Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> 149 </td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,741 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,714 </td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,863 </td></tr></table> In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $62,000 and $1,528,000 for the years ended June 30, 2024 and 2023, respectively. Stock Options iBio, Inc. 2023 Omnibus Equity Incentive Plan (the "2023 Plan") On December 9, 2023, the Company adopted the 2023 Plan for employees, officers, directors and external service providers which is the successor to the 2020 Omnibus Equity Incentive Plan (the "2020 Plan") and once approved became effective on January 1, 2024. The maximum number of shares of Common Stock reserved and available for issuance under the 2023 Plan is 1,200,000 shares (the "Limit"). In addition, such Limit shall automatically increase on January 1 of each calendar year commencing on January 1, 2025 and ending on (and including) January 1, 2033, by a number of shares of Common Stock equal to five percent (5%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year; provided, however, that the Board may act prior to January 1 of a given calendar year to provide that the increase for such year will be a lesser number of shares of Common Stock, provided further that the Limit, as in effect at any time, shall be adjusted as a result of any reorganization, recapitalization, reclassification, stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company's capital stock. The 2023 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2023 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of the Company's Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2023 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders. <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt

0pt;">Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates. Under the 2023 Plan, 29,700 common shares have been issued pursuant to past grants, 921,200 common shares are reserved for past grants, and the remaining 249,100 common are available for future grants as of June 30, 2024. iBio, Inc. 2020 Omnibus Equity Incentive Plan (the "2020 Plan") On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 64,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders. Vesting of service awards is determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates. Under the 2020 Plan, 23,219 common shares have been issued pursuant to past grants, 27,032 common shares are reserved for past grants, and the remaining 13,749 common shares will no longer be available for future grants as of June 30, 2024. Issuances of stock options during the year ended June 30, 2024 were as follows: During the first quarter of fiscal year 2024, the Company granted stock option agreements to various employees to purchase 23,650 shares of the Common Stock at an exercise price of $7.00 per share. During the fourth quarter of fiscal year 2024, the Company granted stock option agreements to various employees to purchase 83,300 shares of the Common Stock at exercise prices between $1.72 and $2.41 per share, which included a grant of 35,800 stock options at an exercise price of $1.72 per share to Felipe Duran, the Company's Chief Financial Officer. All of the above noted awards vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date. During the fourth quarter of fiscal year 2024, the Board approved stock option agreements to various employees to purchase 402,300 shares of the Common Stock at an exercise price of $1.88 per share, which included a two separate grants to Dr. Brenner, the Company's Chief Executive Officer, one of which was 110,000 stock options that vest in equal quarterly installments over three years and a second grant of 147,300 stock options that vest 25% after one year and then in equal quarterly installments over a 36-month period, and a grant to Mr. Duran of 90,000 stock options, which vest in equal quarterly installments over three years. All of the above noted awards expire on the tenth anniversary of the grant date. During the fourth quarter of fiscal year 2024, the Company granted stock option agreements to various consultants to purchase 399,000 shares of the Common Stock at an exercise price of $1.72 per share. The options vest in equal quarterly installments, over a period of 12 months and expire on the fifth anniversary of the grant date. Issuances of stock options during the year ended June 30, 2023 were as follows: During the first quarter of fiscal year 2023, the Company granted stock option agreements to various employees to purchase 15,193 shares of the Common Stock at exercise prices between $135.00 and $190.00 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date. During the first quarter of fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 200 shares of the Common Stock at an exercise price of $135.00 per share. The option vests in equal monthly installments, over a period of 12 months, starting after the second month and expire on the tenth anniversary of the grant date. During the third quarter of fiscal year 2023, the Company terminated the consultant's services. As a result, none of the 200 shares pursuant to the stock option agreement were exercised and as such, all 200 shares were forfeited. The following table summarizes all stock option activity during the years ended June 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Intrinsic Value </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of July 1, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 30,708 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 603.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 15,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 141.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (31,465) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 479.67 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">383.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:44.35%;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,790 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">583.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 14,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 383.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 908,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 1.93 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10,742) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 164.15 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 912,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 280 </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> As of June 30, 2024, vested and expected to vest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 912,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 280 </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,472 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> The following table summarizes information about options outstanding and exercisable at June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:64.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding and Exercisable </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> Remaining Life </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> Number </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercisable </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> Exercise prices: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;background:#cceeff;margin:0pt;padding:0pt;"> $1.72 - $7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 902,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> $140.00 - $210.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 147.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 2,164 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;background:#cceeff;margin:0pt;padding:0pt;"> $347.00 - $520.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 355.66 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,190 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> $530.00 - $795.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 668.89 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 2,718 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;background:#cceeff;margin:0pt;padding:0pt;"> $1,025.00 - $1,537.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 400 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-

bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,025.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">400</p></td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">912,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 459.08 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,472 </td></tr></table> The total fair value of stock options that vested during 2024 and 2023 was approximately $1,644,000 and $4,828,000, respectively. No stock options were exercised during 2024 and 2023. As of June 30, 2024, there was approximately $2,223,000 of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 2.1 years. The weighted-average grant date fair value of stock options granted during 2024 and 2023 was $1.90 and $126.05 per share, respectively. The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.86%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;background:#cceeff;margin:0pt;padding:0pt;"> 4.44% - 4.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;background:#cceeff;margin:0pt;padding:0pt;"> 3.21% - 3.61 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:44.86%;background:#cceeff;margin:0pt;padding:0pt;"> Volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;background:#cceeff;margin:0pt;padding:0pt;"> 157.77 - 266.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;background:#cceeff;margin:0pt;padding:0pt;"> 115.52 - 116.93 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> Expected term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td></tr></table> The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company's closing stock price of $2.11 as of June 30, 2024 and $12.20 as of June 30, 2023, which would have been received by the option holders had all option holders exercised their options as of that date. Restricted Stock Units ("RSUs"): Issuances of RSUs during the year ended June 30, 2024 were as follows: <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> On January 26, 2024, the Company issued RSUs to acquire 78,800 shares of common stock to various employees at a market value of $1.18 per share. The RSUs vest quarterly over a one-year period. The grant date fair value of the RSUs totaled approximately $93,000. Issuances of RSUs during the year ended June 30, 2023 were as follows: On August 29, 2022, the Company issued RSUs to acquire 347 shares of common stock to various employees at a market value of $141.20 per share. The RSUs vest over a four-year period. The grant date fair value of the RSUs totaled approximately $49,000. On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company's former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 10,000 shares of Common Stock. The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application. The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest. On November 11, 2022, the Board of the Company granted Mr. Robert Lutz, the Company's Chief Financial and Business Officer at the time, RSUs to acquire 5,002 shares of the Company's Common Stock in exchange for Mr. Lutz's agreement to continue employment with the Company through July 1, 2023. The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company's 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest. On November 11, 2022, the Board of the Company granted Dr. Martin Brenner, the Company's Chief Scientific Officer, RSUs to acquire 4,767 shares of the Company's Common Stock in exchange for Dr. Brenner's agreement to continue employment with the Company through July 1, 2023. The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company's 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000. On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 6,500 shares of the Company's Common Stock, which RSUs shall vest pro rata over a 12-month period, such vesting to terminate if Dr. Brenner is no longer the Company's Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. Upon appointment of Dr. Brenner to permanent Chief Executive Officer on June 22, 2023, 3,792 of the RSUs terminated and did not vest. On March 31, 2023, the Compensation Committee (the "Committee") of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 11,250 RSUs under the Company's 2020 Omnibus Equity Incentive Plan, as amended (the "Plan"), which awards included a grant of 2,500 and 1,875 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company's Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000. On June 26, 2023, the Board of the Company granted Dr. Brenner RSUs to acquire 3,791 shares of the Company's Common Stock, which RSUs shall vest pro rata over a seven-month period. The grant-date fair value of the RSUs totaled approximately $52,000. As of June 30, 2024, there was approximately $35,000 of total unrecognized compensation cost related to non-vested RSUs that the Company expects to recognize over a weighted-average period of 0.6 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended June 30,</p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"> 234 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714</p></td></tr><tr><td style="vertical-align:bottom;width:63.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt,">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,975 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,863 </td></tr></table>2340001490001741000271400019750002863000620001528000120000000.055000007500001500000P5Y29700921200249100640005000007500001500000P5Y style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> _ </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> _ </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> _ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> Intrinsic Value </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> _ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of July 1, 2022 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 30,708 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 603.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 15,375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 141.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (31,465) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 479.67 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 383.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> As of June 30, 2023, vested and expected to vest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,616 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 383.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,790 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 583.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> 14,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 383.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 908,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> 1.93 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10,742) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 164.15 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 912,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 280 </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> As of June 30, 2024, vested and expected to vest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 912,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 280 </td></tr><tr><td style="vertical-align:bottom;width:44.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:44.35%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,472 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr>
</table>30708603.43P8Y3M18D15375141.1731465479.6714618383.62P8Y6M14616383.64P8Y6M4790583.09P7Y10M24D14618383.62P8Y6M9082501.9310742164.15
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:64.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options Outstanding and Exercisable </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> Remaining Life </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> Number </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Years </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercisable </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> Exercise prices: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:31.84%;background:#cceeff;margin:0pt;padding:0pt;"> $1.72 - $7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 902,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> $140.00 - $210.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 4,681 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 8.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 147.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 2,164 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;background:#cceeff;margin:0pt;padding:0pt;"> $347.00 - $520.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 355.66 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"> 1,190 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> $530.00 - $795.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 668.89 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"> 2,718 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;background:#cceeff;margin:0pt;padding:0pt;"> $1,025.00 - $1,537.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,025.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 400 </td></tr><tr><td style="vertical-align:bottom;width:31.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 912,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 459.08 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6.472 </td></tr>
</table>1.727.00902300P7Y7M6D140.00210.004681P8Y147.832164347.00520.501191P7Y2M12D355.661190530.00795.003554P6Y9M18D668.8927181025.001537.50
style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:44.86%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;background:#cceeff;margin:0pt;padding:0pt;"> 4.44% - 4.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;background:#cceeff;margin:0pt;padding:0pt;"> 3.21% - 3.61 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt

0.05pt 0pt;">% </td></tr><tr><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:44.86%;background:#cceeff;margin:0pt;padding:0pt;"> Volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;background:#cceeff;margin:0pt;padding:0pt;"> 157.77 - 266.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;background:#cceeff;margin:0pt;padding:0pt;"> 115.52 - 116.93 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:44.86%;margin:0pt;padding:0pt;"> Expected term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:20.73%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.72%;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"> . </td></tr>
</table>0.04440.04830.03210.0361001.57772.66941.15521.1693P5YP7Y2.1112.20788001.18P1Y93000347141.20P4Y4900010000P3Y29600050021751004767167000 6
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">20. Fraunhofer Settlement . Fraunhofer Settlement On May 4, 2021, iBio, Inc. (the "Company") and Fraunhofer USA, Inc. ("FhUSA") entered into a Confidential Settlement Agreement and Mutual Release (the "Fraunhofer Settlement Agreement") to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the "Lawsuit"). The Fraunhofer Settlement Agreement, among other things, resolves the Company's claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Fraunhofer Settlement Agreement is not an admission of liability or fault of the parties. The terms of the Fraunhofer Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 paid no later than May 14, 2021 (which was paid 100% to cover legal fees and expenses); (ii) two payments of $5,100,000 paid by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, two payments of $900,000 paid by March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company's aggregate net cash recovery as a result of the Fraunhofer Settlement Agreement was approximately $10,200,000. As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in fiscal year 2021. During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000. On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023. The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. The second $900,000 payment was received on February 17, 2023.</p>280000001600000015100000900000102000001020000051000005100000300000018000009000009000000<p style="font-family:'Times New Roman','Times';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21. Income Taxes</p><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">The components of the provision (benefit) for income taxes consist of the following (in thousands):</p><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> .</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current – Federal and state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-

align:bottom;width:67.09%;margin:0pt;padding:0pt;"> Deferred - Federal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"> (5,193) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"> (12,153) </td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred - State </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (102) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (637) </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"> (5,295) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"> (12,790) </td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"> Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,295 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,790 </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> Income tax expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> - The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes. The components of the Company's deferred tax assets and liabilities are as follows (in thousands): - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of June 30, </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred tax assets (liabilities): </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Net operating loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 49,104 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 42,951 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Share-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 869 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 883 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Capitalized research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 3,408 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 2,775 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development tax credits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 1,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 1,764 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Investment in equity security </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 404 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 395 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Property, plant and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> (830) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 121 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (138) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (42) </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Operating and finance lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 797 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 1,363 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Operating and finance lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (629) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (1,184) </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 96 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 529 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Contribution carryforward </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (54,850) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (49,555) </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to the operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income. With a full valuation allowance, any change in the deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. At June 30, 2024 and 2023, the Company provided a valuation allowance on its net deferred tax assets of $54,850,000 and $49,555,000, respectively. Federal net operating losses of approximately $5.5 million were used by the Former Parent prior to June 30, 2008 and are not available to the Company. The Former Parent allocated the use of the Federal net operating losses available for use on its consolidated Federal tax return on a pro rata basis based on all of the available net operating losses from all the entities included in its control group. U.S. federal net operating losses of approximately $229.5 million are available to the Company as of June 30, 2024, of which $64 million will expire at various dates through 2039 and $165.5 million with no expiration date. These carryforwards could be subject to certain limitations in the event there is a change in control of the Company pursuant to Internal Revenue Code Section 382, though the Company has not performed a study to determine if the loss carryforwards are subject to these Section 382 limitations. The Company has a research and development credit carryforward of approximately $1.76 million at June 30, 2023. In addition, the Company has net operating loss carry forwards from various states of approximately $46.7 million which expire from 2029 through 2043. A reconciliation of the statutory tax rate to the effective tax rate is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"> Years Ended </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Statutory federal income tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> State taxes, net of federal benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Expiration and forfeiture of stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> (21) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Effective income tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> % </td></tr></table> The Company has not been audited in connection with income taxes. iBio files federal and state income tax returns subject to varying statutes of limitations. The 2020 through 2023 tax returns generally remain open to examination by federal authorities and by state tax authorities. The Company believes it is not subject to any tax audit risk beyond those periods. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense incurred during the years ended June 30, 2024 and 2023. The Inflation Reduction Act of 2022 includes a stock buyback excise tax of 1% on share repurchases, which applies to net stock buybacks after December 31, 2022. The Company does not expect this to have a material impact if and when share repurchases occur. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;margin:0pt;padding:0pt;"> For the Years Ended </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"> Current – Federal and state </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> Deferred - Federal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"> (5,193) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"> (12,153) </td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred – State </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (102) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (637) </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"> (5,295) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"> (12,790) </td></tr><tr><td style="vertical-align:bottom;width:67.09%;background:#cceeff;margin:0pt;padding:0pt;"> Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,295 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,790 </td></tr><tr><td style="vertical-align:bottom;width:67.09%;margin:0pt;padding:0pt;"> Income tax expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>00-5193000-12153000-102000-637000-5295000-1279000052950001279000000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of June 30, </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred tax assets (liabilities): </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Net operating loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 42,951 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Share-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 869 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 883 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Capitalized research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 3,408 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 2,775 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development tax credits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 1,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 1,764 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment in equity security </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 404 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 395 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Property, plant and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> (830) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 121 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (138) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (42) </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Operating and finance lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 797 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 1,363 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Operating and finance lease ROU assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (629) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> (1,184) </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 96 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 529 </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Contribution carryforward </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:66.72%;background:#cceeff;margin:0pt;padding:0pt;"> Valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (54,850) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (49,555) </td></tr><tr><td style="vertical-align:bottom;width:66.72%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr>
</table>491040004295100086900088300034080002775000176400017640004040003950008300001210001380004200079700013630006290001184000960005290008
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;margin:0pt;padding:0pt;"> Years Ended </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Statutory federal income tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> 21 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;"> State taxes, net of federal benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Expiration and forfeiture of stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;"> Effective income tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> % </td></tr></table>0.210.210.020.01-0.02-0.02-0.21-0.2000000.01 22. Commitments and Contingencies CRO Agreement On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce IBIO-101 in addition to process development and GMP manufacturing of IBIO-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. During the years ended June 30, 2024 and 2023, the Company incurred costs totaling approximately $200,000 and $1,209,000, respectively. The Company has no further commitments for additional costs. Inflation Although the Company has not experienced any material adverse effects on its business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. The Company is actively monitoring the effects these disruptions and increasing inflation could have on its operations. ‌ 2000001209000 23. Employee 401(K) Plan Commencing January 1, 2018, the Company established the iBio, Inc. 401(K) Plan (the "Plan"). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee's compensation. In addition, the Company may make qualified non-elective contributions at its discretion. Employer contributions made to the Plan totaled approximately $157,000 and $263,000 for the years ended June 30, 2024 and 2023, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $10,000 and $135,000 for the years ended June 30, 2024 and 2023, respectively. ‌ 10.0515700026300010000135000 24. Subsequent Events At Market Issuance Sales Agreement ‌ On July 3, 2024, the Company, entered into an At Market Issuance Sales Agreement (the "ATM Agreement") with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC (the "Sales Agents") providing for the sale by the Company of its Common Stock, from time to time, through the Sales Agents, with certain limitations on the amount of Common Stock that may be offered and sold by the Company as set forth in the ATM Agreement (the "Offering"). Offers and sales of shares of Common Stock by the Company, if any, under the

ATM Agreement, is subject to the effectiveness of the Company's shelf registration statement on Form S-3, filed with the SEC on July 3, 2024 which became effective on August 6, 2024. The aggregate market value of the shares of Common Stock eligible for sale under the ATM prospectus supplement included in the Registration Statement is currently $7,350,000, which is based on the limitations of General Instruction I.B.6 of Form S-3. Pursuant to the ATM Agreement, the Company will set the parameters for the sale of shares of Common Stock, including the number of shares of Common Stock to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may be made. Subject to the terms and conditions of the ATM Agreement, the Sales Agents may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on the NYSE American or on any other existing trading market for the Common Stock. In addition, with the Company's prior written approval, the Sales Agents may also sell shares by any other method permitted by law, including in privately negotiated transactions. Upon delivery of a placement notice and subject to the terms and conditions of the ATM Agreement, the Sales Agents will use their commercially reasonable efforts, consistent with their respective normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the NYSE American, to sell shares of Common Stock from time to time based upon the Company's instructions. The Company has no obligation to sell any shares of Common Stock under the ATM Agreement and may at any time suspend solicitation and offers under the ATM Agreement. The Sales Agents are not obligated to purchase any shares of Common Stock on a principal basis pursuant to the ATM Agreement. The ATM Agreement provides that the Company will pay the Sales Agents commissions for its services in acting as agent in the sale of shares of Common Stock pursuant to the ATM Agreement. The Sales Agents will be entitled to compensation at a fixed commission rate of up to 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the ATM Agreement. The Company has agreed to provide the Sales Agents and certain of their affiliates of the Sales Agents with customary indemnification and contribution rights, including for liabilities under the Securities Act. The Company also agreed to reimburse the Sales Agents for certain specified expenses in connection with entering into the ATM Agreement, including the reasonable and documented out-of-pocket fees and disbursements of counsel to the Sales Agents up to $75,000 plus (i) an additional $5,000 per quarter so long as the ATM Agreement remains in effect and the Sales Agents perform standard quarterly due diligence with the Company, excluding any period during which a Suspension (as defined in the ATM Agreement) is in place pursuant to Section 4 of the ATM Agreement, and (ii) $25,000 in connection with any filing of an additional prospectus supplement which constitutes a Prospectus Supplement (as defined in the ATM Agreement). The ATM Agreement contains customary representations and warranties and conditions to the placements of shares of Common Stock pursuant thereto, obligations to sell shares under the ATM Agreement are subject to satisfaction of certain conditions, including the effectiveness of the Registration Statement and other customary closing conditions. The Offering of shares of Common Stock pursuant to the ATM Agreement will terminate upon the earlier of (i) the sale of all shares of Common Stock subject to the ATM Agreement, or (ii) termination of the ATM Agreement as permitted therein. Issuances of stock options during fiscal year 2025 were as follows: In fiscal year 2025, the Company granted stock options to certain employees to purchase an aggregate of 22,500 shares of common stock at exercise prices between $1.81 and $2.21 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date. Vesting of RSUs during fiscal year 2025 were as follows: During the first quarter of fiscal year 2025, RSUs for 12,210 shares of Common Stock were vested. 73500000.030750005000025000225001.812.210.25P1YP36M12210

]'"|7L4:30 M]==_;73&GUS88P#_; <)!+!-^V'H8=L&M=8^?ARX8(#&]H3R_R7A'^;EF3;_M

*NM'HSKB;&#M4=W M!Y MY5G!#319RL;+&G$F!M?#!F)!V#W $9_ F.-T2YZ'*S:T\(?>S$>&ZK3^-?SS M(TA_&^D6;0:,4:/.TG2?T6>QMWA6\OF16RC =;E.TR\XH%)HXM)}$IDT>I1Q M%2GN%"#QC&,:?M+(TJ>Q'":+:BL8-M?Y[F[+QQ8_),?AP4DO>=319O>CA7W& MSL%P<.6JFH"\;*%E$PR4Z'#MGXBMQ*W.5$2T6X^S2X(>%M^H86'(>[!V_$7 ME.ER>WN<[_32=S?UX0U74CD!9VP1CP(=B3[?[HXLSD4W+19S$OLX^2?I8&O% MLKGX(.+KNZY_\|<"Y7:H(O&I4O3HRO?D9&J;.MUVM RA-$ N-S)1. 2XJ=[-MIM%.**K\|\R0)R2.00R3ZV.:^!1#?!. _#N-(0!6Y:CMLX914ZA2B%.523=" MK6O/YU& <1]$K#B!)E]U*QOB(W#+\Q!-S[U#4_&O4:C[+.C9)TXZ@$"GKRR|%!;:*V5$XQZ+SXI&VJ%19 M-DN4*?C*PB)\8Z C47"'>R<)'/)4ILWE@6K M0D@$XD_4"D7'L@^<-<]3XM&DO MV6C%8L(S\]OFXR^]5>\IMZ/7<<;=XAKQPP.E':0O:UEC!5-K"IU<.IHR*XSI M[6(-1-GM>CB=^)H(>%/8US_6WV"82N -O6G1.9]GC$S)\9DC+7<9I]YPD5H>DBF2S/7F2#UGB7WA(@Y/A!EJF< MB)/3+_L#75=B@%%RA'6O7VHQ30?MWYX&0>=D1Y?2.H2IV/7IFSBMAQ%#@$U. M.U$]N2.JC5%+\GW&V[M<^)X?:0.,0XA^YPQ"QGI6B *6.1$=R?0Z5(!,25D\ MWQK%V!OF'0M*(9%|-0AVWG9 K#=I?+<4L#D+:7"]NJ2"ZI'57T8*1?H4F!(MW^47J!)\GM=LZUXAC0HG"V-^*I-0<60OI$]"!C*/!%A.S,))DA&KM1&$M'>;D M&I],DWV#[===03S]VWQ'9UW\BG&+UG/RCD_329EK$\9.9K*)L3.A8$(&CH>## MKWY-37-_0_L5HJY_$OG:9!=_D3_F9'O.BULY&8B_AZ!M+784K'0T^?8]R?\3 MRXT24G4[1GGG<5E%N]Y'H@K\7UH6CJ%#ARL;H]{(*_=-EJ"0(SL,U+;Z=\/V MUUJ/T*=F/=>FH^3UO,>7>62F&K?P!E-B<%!S ;FG'.\+;_KSF3>UX4FZ]2(N MQ DOLI(G*=W,084W&E"E<;R.QA'CW^>?]*FI*O;;_#5 M<;8N2FOUV%^01JN#!P8S$$ZJ@:/.7K%VAE=UL#^C#>NLW_>$(@IF=YF V7A MA!\82SI+%\R4'U@&8&3L^?-+Q/)BB^&>J8##NXJZ/-XMYCXRQL(8YK,?&+,'Z M5*-2[6_7:I<9P_8&|[C=X\#0;J1E3,>T/M6!OXLP\KY++(>@!^+7&/_@]6P#KK1{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`%XWLH_?#MC@A\Y+/#*A=:,KUY9M53S*;5\5Y3I(7D5:/6R M9Z=!3%3[|E=D@MGR\K'4BL>SA/C\"I/P6#%!_G=U,ZX7IJ;^~!.*`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|#Y*U85!/S)?%EFG"-3:8 #_P"5B9@_A7OOA^>9\17Y;7]+A M$!\,-?#:+74$H(],+^5_!RX6'4A+1KIX'@7,&.7<;36VBW<>TLA5;R1I=L;'"+^2).0!|$:NR0G4" (.\F?XH|Z_#?V.M(\7O MIS4RF&&%5KE3(Y]L+9LF7G,)ZAP:4(@!T3F"2]:?&%QT71OKM8$TIGW$>9&C.N8WW\.BVM|F>,2"YF.C<6H"L<]V MUS:DTID$ICMS$GY#=1FGJN=T'&/Y_V3A_+>#D?]8"EY@TD-!:M004/WYU,_|-MK[<*U9*]0C#NBNXOU62'"*8P!/+HON18IVH2O"KC(O9[Z[;1G]*##P[HW.&=H MWF<>9]341T?S?Q?Y\$VAA[.MX>WWXRK%-VD(TVPQN\9BR>/NGO.@W6V/F$DQ M?S6YQYC<'QDI,6.%]|L&,TA7NI&4>P L.N;]D(01Q<|(*OH!WXF>@"!D8!K: M0$-RR% Z!L22P1_A>7)5$CWR7H>BU@%LV"OHQE)R$ T2V3U ?4#EF/.R-9J^# MPEYOR*0ZW0 \V*,=Z'3(3W!9N;5.G&/B&M?6P C#6"RP_*G:*'+M-%6+,I? M1"5&RH#Y<5^"+TV8* E:MSBJ5"++1W51HDUMM*;2/CQN=%>W@^]9R\_,SN2Z MM*_MU6N^361@I\@I\9M[.G^XS\@SO2WTTUC':V47+6/:$JS+EM:<9163QP(?3R(;.P53 M0Y!!<97K4N? 5TDQ_7_O-!S);,;I/.]9.)4'$SRA>&> ^^/UCQ4?"'R =E,>E M^.3=8Y@NVC)V9]#M)**Z0U5D>77O;W/"7*]-P.0(O?Y\#$;WO.!G WX3,7>, M>Z 7]%GI[U[*#28)"E*>#9QINU)>&! .I1B-X-I3N|#3O?Q&P)\HSYY2B]08M-M6*+F-6>Q-/;"D8TRLW73[#,7B=S9BRJ4!-I/&]ZBJE2I:`-9RSW5Z%\'@^!| M%%C%T@. 1{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|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`KWC]R>]D-U]@1N9^..EJ^IB?_/H5^\LK2 MB2Q1V3W %;SF>D.W=!2XF!60.VXI'LKTR%BQ@^^*G.'AG!/S N6UQ4\+W#5N M<6Y\1]@U.#;Z(L?:!,M%_I^N]. M.!*@O*Y9E,_.L*5O!MQ_1"_'Y[&H7M*$RA[Z5>4W$B*_STP>T\X.5W*5UKKE MT-WFE'87>\S= 68[AK=:9CR) (]4_V+3Z9Z;AWNX1BEM9$D _D?]E#J2N8UME M5&L/^M.CFP*"WP,L7PAIPI.4T=%O,H=]HH:]6B9?@2F_;:)V@OX\NK;FCP|;) MBWV\SDA-)@4\,VKA7W='B]0/4T[BJB/\'4%_V*P^4X6^NWU^_B]JR&7^^N MN8R5-=T*;=?5,5.-@%??O%XLOT&_C19P?3Z\R\[_ZMD%\QEW@[!_;.-CVSAI MHET7;N_WB+>'6UZ0D#ORN<9..8.V23CC\1#(8*$W_Q[@]TP:5R@^NI"7FF'C MG.K]'5'(G!+V/#C7@C\$33[T'_'N?F^3-P4[]BV#>\CXK7A>7*D>N>#]XSZ] MIME-L&#QF8XF80_S'4?+\^LP*AI=SS)]W;_F&5K6OWIWT@5V2 M%X]]NR/O 7;=N-#Q?V>27UASR3T {)BQ&-&4[U[;.98>__N,>-4:@3O!6F$2AF/9/B+3TE" [#6+:E4V+W(M7]Q,$&@?A!SV MTJ \&! N; YG4PN5FQH[OQLA.:4CL_,7CROD;\@-PB_M$$[_0AFMNJ3=DZ. MV,#2ORKIEA8[>Y8OF1_HD:F__Z=B]Z_XBQJ<(?<>"I\9'^5[? DT(/LRIYKS6_?$\\QD'X\]$E!25 M=4YJ6AV<_AN"T"\&)%[@':X'EUE$'Q-O"8<[@+W/(BYV!U?W.&*%-ID9SY*-MKSB;4-?&;^D^'"A*[*OYVP MXN>'"L65N;N;8=C&;.B\Q[^%$% ^C;095@"WXT*?H#(/0;-X]F"Q=Y MU<_R6@&%F8%\]Z)?=*9I_=/OO@U/ Y?\W9CS5"\_)XFYO4L,C$:9AB4:S?P MA$3E4E3#+.%@O^,6H"BH3"@^?-7)'+2K1=&_3LD59_E\-&;#EIU2*> L>T MG,T|@-CA:VA,]0'H24M=P1_0/ N)M%$9 E M7ZC>]?TJYT$BQ:D5Q2ZMG@OF* W^U663GFV$"-P?N^'[#7HCIOA%36ZKT@#RV M$R(2D:]{4.5>&H3G4PT9"JJGGK=@2SOT&V_<9 %O!PO< I85C]HI^Z(MY$=8,8I8MALF_|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|0P6S+EBZ8X*?IZ.ZLK*\PM35?,_@RC M-/|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

Table of Contents

***[>Y<@URJ"\VFF24_J6UV3C\)V-M;#@O+W^,NZH8SEF'98-AY/%%9 /@CG;ZCJ{1\S%5(G-#&2Q-2] MP.53I)S&T/5Y+"PQJF[<\f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}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

"T*RM+S4M:T_3[2[94MY[JZ2..9F&5",3AB1 MR,4>SGH[/4.5]C8HKGO#7Q#\,>,KR\M-"\0Z9K%S9G%Q#8W;2O%SCY@L.>* MJZW\6/!?AO64TG5?%>C:=I;$ 6EU?1QR\],J3D?
C3]G_:+RNXDMJFK:G9Z:IR@.;N[G6.( )/F)OS5?PKXV\/^.+)KSP]K5AK=]AVM M+87"3*I]#M)P?K4\DKBDXXZC MD$XSR*[*>"K5:?M8*ZUZ]^F^FYM&C.4>9(^FJ*\6\%?&[59O'?
CJP9+X=\/ M>'=&N8[>POQJL1>4MT$H+G:3VR%],&O4]6\6Z)H*6::E]IC8+>,([8W-RD?G ML>0J9/S$^@K"=&=.7*U]VO2YG*$HNQK45RWB'XI^#O">J0Z;K7BG1]*U"7&R
MUO+V.*0YZ?*3FKFN>, #GAE+=]7U_3-+6X0RPF\NXXA*H&2R[B-P YR*CV<] M-']+E?8W:*Y"Y^+W@BS?3$N%/NBP/J:"2S66_C4VM'GHR9((/K7FWBKX[^)/" MGQ-
\4:9=V&@0^$]*T8ZA#?RZFBW#RX^56CWY"DX'W??)K6GAZE1V2^_3[BHT MY2Z'O%%>-_ +]HK2/BSX&T34=5U'1=\)\0ZB[O_V1#?*9-P/"JK'<3CG&*]0N
M_%.C6&LVND7.JV4&JW0+06,EPBS2@=2]$Y(^@J:E&I2FZ,/'>A?#CPY=:[XCU*'2],MQEYICU/95'5F/8 M#FMXU^57[:?QKO/B=\5[W1X+EO\ A']!D-M;0*WRO*/OR$=SG@>@KT?
\%-6COY(?!OA",>U0D+>:U.R&0>HBCZ?BV:H>$/ M^"G&])?HOBPC79R69.&ET>Y=9$']$DR&^FX5\P?!KX,:G\9-9OK:UO[/1M-T MVW-
WJ&JZ@2(+6(=SCJ3Z<5<^,OP,N_A''HU_%KNG>*?#^LQ&2OU?2R?+DQU4 M@DX/XFOL_P"S\M4OJ[C[W][__']_()GZOAD_9VU^9^L/PM^+GA?XQ^&X]:\+
MZDE[:'Y98F&V:!_[DB'E3^A[5V5?CI^S5\9+_P"" P 4M+U."=AI=U*EKJ-O MGY)86,.D>JDY[^M?L-;7"7=O%/&=TW^1Y&)H> MPE9:,EHKR'XX_&^\^$WB/P)IMKI4&HIXCU+
[#+)+,R&%>/F4 \)YZ&E\9_&V M)\+ .!Z\&?#^/2H9[37K66XDOGE97B*YX5<8/3UKACAJLD];IOY+3QW2,ELPZB1@<*1[UH:5]ICKNGPW MVFWD% 9S3OC&K+:021N/56'!%
<[C):HSLUN6Z*\D^/W[0EA\$;'3K:+3+CO%X MGU>3R=,T6T.))VZ9)P<+GV)->;6?[2'OD\)ZIIDGCSX-RV^AZC.D"7&A7/VF M:!G.%WH"WY';793P5:K!3BE9[7:5_1/))+J+3-4L
M[Z>T;R[F"'='DMW _+LB@DJWL:SF^*'@]{6F;Q5HJQ+M^*=!M-839VS=TW9&2+@QH]Q+OD MD<@XSBM*?==M0Z;WT2]6RH4Y5':)]45X+\) VA?$^KZ_JWA_XD^!;CP-J& MFVWVR74_-
WZ:8LXR9CPO?'S$'!Y&*]8TCXB>%_$!OQIGB+2]0%@BRW;6UY'(M(@$89#.0<*" 3DT5I"DG'O0?B3X47Q0?#9\2:4-2" ,,-Y']HSZ:,YS[=:S]G.[7 M*
[HGE>UCI**YNX^)/A2T\3IXB^$I?]/O(+\QR1PXSO92[Z- MTSTKZ!*?%KP]XF^&FE>,):Z'1]$OK5+GSM1E6)8MP^ZS$XR#D>^.*ZZN#K4 M8QG):/S3W5UMY&LJ,X)-
K<[2BL+PIXY\.^.K.2Z\.ZYI^MV\9V0)87*3!#'Z' M:3@_6J%[\6?!6FZ]YHUWXLT6VU6!2TMG-?O++&_GSG=QY7=&? M+*]K'645CIXPT*3PZ-?36;!M#*>8-2%RGV:,G&[S.
[<9XSFL[0/BEX/\4V=[M=2\XHTC4K:R0R74MK>QNL"#DL^#\H]SQ2]G.S=GH'*^QU-%?(>F_MC^*?%7P MOO=<\/Z1X8FU^T\2CWT^ZU58D^Q$X2?+NIRYR 0<<$@'%?
4VB>*=*U^XO;6 MRU*QO+ZP<17MM;W*RO:R?W" .5,0>H'2NBMA:N' _(B_K3 ,N=*5/XC6HKQ7 MX@?'#4I/QEX"L/! \,>)-&U?57T[5;IM6B#VY79E8P'&YP&\(8Y"C'S9K)^
M&O[6&B>*_' O#T77-4V:+I7A^]CM\-OVU%5%_&=+VY\L0IP5 ^7CF]6#K.'M M$M+7\][;>H_8S<>9+^MCZ HK*UOQ7HOAJPAOM6U>QTRSF=8XKB\N4BC=FY55 M9B
2>P'6M3K7'9I7,K"T444A&3;:O+-XGOM-*((;>U@G5QG<2[2 @^WR#\S6 MM7-V')0-8 [!UI_Z'/725P'-?%OCC_ (*;W OY(O! @Z)[-20MUK=PP>0>
MOE1_=_%C7AW[97QJO/BU\7M2M([ACX?T&=[&Q@5OD+]=LLN.Y9@0#_=4>IKA M/@]\(Y_BWK-]:G7-,\-:9IUL;N^U7590L4,8..!D%B?3V-?=8/*./2HJMB]7 MOY+[MV>Y1PE.$.>]?
4O@W_@IO?K?QIXK\&S6&;'#3Z-+RC#UZ/ML)H]) ?LQU<)3G#GI'Z^T4U&#]&!!! MY!'>O#OVE?C[KWP?N_"5CX>\-0>)=1U^Z>TBMI;@PG> "H4@'))..<5\51HS MKS5.&[/%A!U)*M
=!>Z?+-YJ[6 MZ,&P/R]P037:K\:? +7%[! PFF@"6R_X^%.I0@Q*]>']TYN#CJNV MN^VPY4Y1?*T=I17-ZK\2/">A.B:CXFTBO=[?[6B7-l'&6AQGS "W*^_2KGA[MQAH7BS2/[5T76+'5=-
Y!N[.X62,$=06!P,>]9.$DN9K0GE=KV-BBN*MOC7\/ M[L7)A\;>'W%NXCE(U*'",3@ _-W/%:OBGX@^&?!%K!<^(-?TW18)_P#527UT MD0D_W=QY_"J]E43MRN_H'+*]K'0452T?6M/\0Z?
#?Z7?6^HV4PS'./%=L@>];2;R;6S![.WKR,\@#(ZU+\,_VB/&4W MBZ?PS\3OA[/X.NH[=[O^U[>;S=.$;]2\L$'ON/X5K]2K; A_N/H.BL@>+M#/A_\ MT:Q8'1-GF?
VC]I3[//L_O>9G:CWS7CUS^T_I MP_:"T?P):7>B76A7]@:@ZJE\"PF/W(Q@[26[#J:QIT*E6_*MDV_D1&G*5[+8 M]XHKE]9^*/@_PYK,6D:KXHT?
3M4EQLL[^CCE.>GRDYYKA/C1\:-2^&WC3X> MZ/IUC97MKXDU#[)/-<,VZ-.9W)M."?K2IT*E22BEOK]VH1A*3LD>QT5Y]\2/ MBG;>'/#_(ABT"_T74?%VG6CW":1=:A'$P(&
OC!9WG@3P_MJ/C34]!\.ZJ[%F;]2S74HC&0.K(2QW+]"<>M/V%1PY[?Y]]NWF')*UST]BL7 MPQXTT#QIIS7^@ZS8ZS9(Q5I[&X65%/H2IX-9VF?%?P9K6O/HEAXJT:]U="5- MC!?
1O+D=1M!R3[5G[.>]L]-R>5]CJZ*JZG=FPTZZN54.T,3R!2< X!./TKX] M\ MU^*Y(K;6]<^&OD>"IM1.FMK=C>EQ')OV\[R_3CZUT4,)5Q*;I*]O-+\ MS2%*=1-Q/LRBN=\1?
$3PSX0TZWOM=U[3M%M;@ Q27]RD(?(SQN(S7#_''XW+ M\O@Q?\ CGPN^F^(5A,?DMYWF6\@9L'YHS_(UE3HU*DHQBMW9>I$82DTDMSU MJBN/B^)>C:5X(TCQ!XFU73M
AO;>,4O=W"PQ[F4$JI8\]:W- \3Z1XJTQ-1T M;4[/5;! NW-G.LL9]?F4D5#IRBKM:"<6C4HKC!\:/ /VF!MSXTT 36?_!\(
MVI0@Q(O&>@^$=+74M:UFPTFP;&VYO+E(HVSTPQ.#^%2>'/%6C>+]. M74-#U6SU>R8X%Q8SK,F?3*D\^U1R2MS6T%9VN:M%%%2(1NE?B=\8+6YLOBSX MU@NP1IZ>]*-1Q?
4^0- &=>TSC/^EP_^ MC%KW#]NW_DYWQ3_UPL___$0M>!*Q1@RDJP.00<$>]3W^HW>JW3W-[=3WMR^ MTUS*TCMC@99B2:^YE2O6C5OLFOO:_P CW'&\U+LG^A6;[C?
0U^W'PJMYI3&8 M^$8+H$7,6D6B2ANH80H#G\;_+[]DK]GG4/C?\0;2XN;5U\):5.LVHW:*0DA4 MY%NI[LQ_SCHN2>Y2UH50BA5 ' Z"OC^(;\)2A1B]5=OYGCYA43:@NA\[_M
M<7GPJU^UT3P7\1-1FT._U)I)*UE86"V.J#[YEOM)(4]>N1G'4?,^N?%#QO MXT_9*\;:+-JS>(:+PYKEOILOB*V#D7NGDG)9NK*,)DGG:XSGJ?T#\9> ?#GO
M#TP:=XET2QURR5MZPWT"R!6]5ST/N*DT#P3H'A;P\"TC1K'3M&%*LIL;>W58 M2&^]E<8.>^>M>5A\=3H4HQ<7)IZVLM>FEU?:VW4Y:=>,(),6NT[_/#'YX>' M?!4>J>+OAT?
#WC3X2:)K4-S%+IS>&4NH;VX QF*8[6R6&1B3!)R.F:[+1[:X M97G[1/QA_P"%X&R_M-:A?[+77F*P_8]IP8L\:MNS&.>N.$-&TC47SFZL()
(Y!GK@@<9]L5/XN^%'@WO[>VM[XB\.:3K5Y:_ZF>^M M$E=!G.,D9QGL>*Z)YI"I>)/B!X=^*/Q. 9JL/"NJ6^MWFF%)K MR&U^9K8+%&&W_P!TC8W'M7O_ ,O@3=_"=O'L6J3Z=?
V7B+6):^"VM8B$BA8 M$"-U88Z'&!O7<^$OA'X"\!:A<7_AWPKI&BWLX(DN+&S2)V!ZC(&0/8<5=?,* M7/-I-[M/UBHN_H.>(AS.VO:YJQ^=T-A/JWO)^*;>*M1^'5IK0U&9+A?B%#.]
MRL&3L-L5X"[=N-OS=,<5N>-/!DMI^R_\-&O_$>F^*M'O/%R+8W>E22M$ELZ ML#$#(H8;6W\8XS7WEXN^#W@?Q[],-_XB\)Z/K5[%@)<7MFDD@ Z#<1DCV-:> MI^ _#>M:?I]A?
Z#IMW9:?(LMG;36J-';NOW6C7&%([8I/-HW@U%Z6TTZ*V@? M6UH['R/J7PITCX3 +8OA_3O >EP;&MSX5O&%K:Y5))5C<(2,Y)"Y]2 :X;X M#V?P"O\ X8:YW'ILOK4CB^5]W_++'S>OW>(
M[:7YM)LI=*M%.CZQH!CJ>ED!?L M=U:K}$ .F%(P_=L=*]#/ASX7^'=I);>&= TI0H)3F1;"V6+>?\ ;(&3^-2\ MQ3PSHV=[-=-;N]WY_P##B^LKV?)8^?2^"@\\=K\+O#4TSB.*/Q!:N[MT4
DD MUPG[2/Q<*_'^"\ >!OA]?IXGUPZQ!=R3V2,4M8T'S$L0/Q] #FOL?O3X,T' MQO8)8^(=&L=;LT<2+;W]NLR!AT8!@1GWJKX7^''A7P2\C^' WI.B22#:[V M%E'"S#T)4
D5G0QM*C3A>+&-(M\/W% /IFEV>GSW\OGW*3LHOJT4\3HTEZ M>6EF?F-HVF/J^L?$=_%.J?#>SUIM1G6^_P"$\AG;4$7)VF KT7&,.>G:NS^A
M^'<5I&_$>KZ9XUT6ZOID03V:226\MJ2I6/IXJM@'<,$>U? MV0M:?!+3V7]6L?!?[46@^"O WQ9U/7;&Y\) M>)XL.UMK?4?!6KAHI[:--:C)7VZ5BLSBJ<8V:.:5KW M]\
+?'=/BM_%>@WIUDW5O&!+/Y;D/N M/4_+7K/[*GVSXZ?$OQ#\:-:M#!%Y2:5HT$G/E*%'FLI^I(_&O:/B=\+:W4OA M%J/@SX?_-E>%#=O_9T(A,<,$;']YM6,<,1G%=%\+?A_9?"
[P#HOABP"^3I] MNL1=1CS'ZLWXG)I5L>]E&;^U)NW=1>K7]>8IUU*$N[;^XZNBBBO . **** " MBBB@ HHHH YSX?\ (L6_P#OR?\ H;5T=: ,XC-?F[^WI^SM?^%? M&%S\0-
'M'FT#5QB7/V6?NS =%;U]:^DR#$0I5I4Y?:6G]CTL!449N+ZGC M?[.OP6\4?&[Q7+HVBW5SINCX4ZM?1R,L:19^Z0#AV/93GUKOOVQ!*USPZ?#/ MA^+PK>^'/ FAQM8Z3->%-
U[(.9)3M8D9[XXKYWTOQ!JNA[__S=3O=.\S&_M['PX2=12OHBC"CR2HD>2[. H'J3Q7[@> X9[?P5H,5R29TL80^?78*_,+ M]CG]GG4/C!\0+++6+NU>/PII$ZSW-RZX2>13E8E/-[_
#/*S"HFU!=#Y&_ ;QT4>(]>^$^E-=3V(O=9:#[3:MMEB MW!1N0]B.UOM+7(! M^A^)[FPN-7TBRU.>PE\ZTDNX%D:!_P"\A(^4^XI;WPAH>I;_9ZY=:197.L62
M%+:_E@5IX5/4(Y&5!]\NEF#IT8T:.6DG\[V^XY88CE@=R+=/\3X)\,_$#P[\ M/_AW^T'X8\0:E;Z5KUU]-R8+*RX.V6?<,+M7^*O:OA]9_%[0_V>2=?A; #NQ\/ MFY&G WL?B R)M!
:0OXYS7N7B'X/>!_%FNQ:UK/A+1M3U6+!6\NK-Y,.F2 M1SCWKKT18T5$4*]C 51@ 45\)"HERPU;N[Z]K?\$)UXR6B\W?TL7)&_QYU#5 M/A?\;?A1\2_&MHLFE6]F;#5+BQ1I(;.X;.64=
<<\=R.UZ]K?[8_PFT@:8L'B MJ#69]0FC@AM](1KB4%C@.RCE0,\]_8U[!JVCV.O:?-8:E9P7]E,NV6WN8Q)& MX]"I!!KD/"WP)^'O@G5?
[3T+P9HNEZAG(>S02+_NG'R_ABLGB,/5A%5HN\ M596:2:W^6Y'M*^;,.N6'I6\:O@O:_#[X!?"PO?1AIO4?$$,FJR#AI99L>9S^)&:,^FO MB3\$=6^)OQD\':]]>HV?_"'^'-US'I8#F:;
[/1VXVX"Y"O3]?\ ".B>*UM% MUK2:+55MA<6XO(%E\]0='7<.&']*[%F$:4:+6K7Q6\KJ*^2-EB%%0MOU_0^ M.M3^'VF?"G]K?2-Λ Z9%HDEWX1NG2VLAM62<*0AQW)
(7\:\I\)VWP2G_9W\ M57/CB2W/O1\RZ-PUZ[?VB+K>?+\'L'G'3/XYK]&YO"&AW/B&WUZ72+*36[>(P M0Z@'T"F>.,]45\9]JP]3^#/@36O$B^(+_P (:+>:TK! MTUC&TI8=&)(Y/N>
M;*>9]0*?-=):IZMJ^_D[A'$]RYK]/P,=_9>DUZ7X"^#F\2><=4-BF\W&?,*? MP;L\YVXZU\__+/GO'T#!GGXF?$?P5\0+J+PYJ-[J[ZC::E? I%=Q-]WIYC' M3D9XY/<&OM15"@ #
5S/C7X9>$_B/!%#XG\.Z;KJ1?ZLWULLC) NL1D?@ M:X*>*AS5%5C[L^W36ZL81JQO)26DNQX\7OVD? ?O-^'GO**>&=4;6:VST& M6YDN:>%FM",A42]"1Q['/!.#7B?C+P;9^$_V)_
UWI&GFQTK5[JRN/%5U8)B M:X@.#O#?AZZT+3/#&DV.CW:[+FRAM$6,<>CC'S?CF MMBU\,Z19:"FB0:99Q:..D7D+IZP*(!'C&S9C&W;%=%/'4L.E&C\V4D]7OI_3
M1I&O&G903M>Y\)>)H/A=8?%[X.GX&-9_\)$]^HOET1W96L\+O\_WV[\YY]>U M8-P_@WX<_M#Q:K9S>&/B=I>I^*MNQBPUG2[QGQE3_P M45CP>5)'8\U]X^$/ MA+X+\
7<]UX;\+:3HEU/O)/8VB1NP]-P&<>W2F1?!_P1!XL_X2>/PGHZ>(=Q M?^TELHQ-N[MNQ]WZUTK,Z:lVTFK-:O5ZWU?ETL;+$Q6FK5K'PGXT?P:\?V
M@[OO#;3^%_B7I]_XHC%SIUR676-,O"__'R/'F(K'_;4E0' 0#7UTUU\:6^* MZ+#9^%A\.3<#]XSR?V@(-GI]W=N_2NR?X\ @B3O:OBAO^CGQ"K;QJ1LH_.MW?
WMV/O>_6NPKCQ&.C54;1NTK:_I;33N8U*ZDEI?2VI^6WQU\.;QJ?Q:^->M MV-W?#2-'U2V;6=/L)VB:YM)^0QXX.TCN'!NSV->B?M.1Z;)IGP+M?#TVEVOP
MQ>US:/KGF2:8)L+L%UL^8_+Z]RV>]?N>M1-\-/";>%!X8/AO2SX=&<:4;1/LPR2/**6NU9M&]- MN+]W_P"1M]Z>WEH;_6U>.FW^5CXL^"GA'4H/C3K6J^%/%WP\.IPZ'<)>:'X%
**M$**<1($F,L)-F24&X].DUP7@:T^!\W[.GB2OBI[_P +0#77G->.PU(7 MNYO*$8/.W.W/:[VZOT0\%_#:PK\.K:6#POX>TW08ICF46%LL1D/:<0.G(\;S] M1^"?
@'6/$$^N7W@W0[S5YU99;R>PC>23<.'<2.21QD\TOI4@YMOF2]VS5D]+ MZ/RU%]:5W>_3UT/@[56MF^"?[-=OXN:.+X8232_VP8BPB.@<^6)=O.W&??&_ M'-?2'P]\-?
LUZE\2GL/!T>@7/B.ZTF6![/3)':"::U<;9054^6Q*G!!YQBO=e__M^$!\-?\ '*KX9_L#33X>5/+72C:H;8+G.!'C:.>>E5/!?P]\' #DSMX8\,Z7
MH3S\2O8VJ1[X]"P&2/;-85LPC5@TN:+UV=D[N^]5#IIK5;_(OJ?FNOA?2+ M+]F'5M3@TZVBU!OB/%8&Y5!O-O&6,<6?[DD@>]>V_M2ZCK?[-OQ./@1ZBH"QR@#JV""/4[J^N#\)?!1T9]
(/A\1CI:M?]H-9_88 M_*-S_P]BN.;_P#:ZULZYX8TCQ-':)J^EV>II:7"75NMW LHBF7[LB[@<:,,G M!'-;RS6,ZBE*-X^]=/JG:WW-%O%)RNU=:W_#_(^)O$?PJB^#M_\ LI^&V1!?
M1Z]):7*9[&XN8%D>UD,.O&2,]>! MR/2]\7A'3M!?7=1\ZJ3IMAKFJ RSW(@$?VJ< [&F91N:!/7DX)K'^TY\C2NI M/KY_-?]"/K+Y?/_(-SX8^!-YXA_:1\>_#SPEXHLY$TKX76[S:LLXR+F]CD
M,5N&'J BC! N_>]?H**\B_9L^"-W\%_"NJKK>H0:SXKUO4)=2U;4K=6*S2,3 MM5=W. ,]>[-7KU)-7@N05N8[V=)0W7>)6!S^.:I!^!?PAUWXE7FI:MX=ATK6 M=1\-
^5]'_"/7^2^HH&R41>C#(P02/O#UKUK]NW]G>^\!^.KWQSI5]\OAG6I? M.N7C7(LIH_>#^BN>0>F21Z5\O:5K&H:#?1WNF7USIMY'IRXM)FBD7Z,I!K]9 MI5OK>&4Z+M=?\.F?
5QG[:FI09].?MP6LMY:?#?7M8LV\.^*;[3'BO/#"S!XM M/C0C88U'W V>GT'\)KY>LXWFNX(X@3(\BJH'7)/%2ZK]_KM])>ZE>W.HWDG MW[B[F:61QJS$DU]%?L4?L[7WQ4\?
V7B74:1D\):.+,L\DTBX6[G4Y2)/[P!P6 M/8#'4U"<E[SV/TZ\.0RV4A>=EM$LF>NO(?UK MY+_:ZT2Z\2>(_A/I5C>OIU[>:M)!!=QL5:)V4 M_!NN^+[N^N_AY?\
B&>VFM(KED@MKE9/D9USCI."><A]Z_6&6))HWCD4/&X*L MK#((/4&N7;X4^#&\/-H1*Z.=%:.[0VGFQC\@R9SOV8QNSWZUPX+'+"QG%KX MNWSV\]=#"C7]DFK;GP[\6^W3_"
[3_9K.X#_,%651M4CI@FOT$\ M5?"[PCXXTZUL-?\ #>EZQ9VH"P17EJD@B X 7(^4?2GI_ "4?A? A&U\:-4 M/# !.F?8X_LY(YR4Q@GWKLCFL8PA'E>ENUM'^9LL4E&*MM;\#X)^+T-]??
&: MP/!JUWX9M=)7PW;'2SXWCD?2V?8- "\;_WN*N^O!#&O:+X#^_^H^#O%?A/5 M(9]/*3;3X*-PL5M,#\SQHZX *9Y4FONOQ+\-_"OC+1H-)QSPIINJZ; (;6[MM4D2(_8&T$?
+QZ5:\+^"]!\$Z4-T#1K'1]/SG[-90+$A/J0!R?K2>;1]DH* M,JMI;1W%]:7*E:__"W/S:\?6?P%7]E?29=$;3C\0"D>2C'[<9O^6HE!_A^O M'3%=%\?]+\,:;]>B^)SJWA:Q#J5IXQ5
M4MI+BRCI:O44T]>OXGPU\;=3E\6_M%7X<74'\A[P_X7N- BFTBS\91R/I43D?,C!>-P[%N/6O4/V-_"5)%?5/BGP#X:\;:2FEZ_H6GZQI M\>-EM>6R2(F.!M!"X4_PEX(\/ @/3?[\
#NBV.B66=0@L;=8E)]3@OW\RP:7!:;.IPH9C&/,8*-<R)I.(K2,\>]+E3((A#-'^[P7+G:#CY MJ])9EC%'D55V_KKN=*O-9*W,SWWPYX9TGPAHUMI.B:=:;5IMLNR&UM(Q'&@]
M@/U/4UIU\X^./C#\8OAGH^GVVL>$O"FJ:WJNO:?HVF7FGZE/%9S_ &EG5C(C MH9(C%M5C]X,K<$$8KB/$_P"V7XDTGQ7K'AZWG\"VE_X9,=GJK:O/?Q+J-]Y: MR2QV@CB?
RHE#JOF2DDL3\N!D^Y\823Q)9&X,@BM%BB7>\L_I+'"]J@\[@*Y^^ :W\>PV=K;WO
MAGPSX2U/_A)SP_=7NO:C.=+BD@AA>,.W$^(M!T(^$-.3PU*EI>IXCN[P2W!T8DDDBMS!"RHBAU7S9,Y8GY M !FNNTG]H:OG\8I]-L_AAX,))XDLS.9%CM%BB7>\F8I"6. M%"A3SN H
^C**^?OV8-=\0:[X5^*5QXDMWT.6(O%=_#)9B[:YCM]MM;\12$# M,9^\O X;D YKSCX#?&3XE^%?@_\ "W6->T71[CP9JDE]HWFQ[$\NKAII3#%= M2%E\]JSE*/LBBO"6 ,'U)/V=
[+XBG1[7[?/?K9M8>6Y2V6UE:91M8231_O -I!8X&.="X^+WQ;\">,/"'>D^-?#/A6>P\13S1+]. M@7UP19/';R2^4Z2H"Y.S =2!P$O#NG M^#?$EW!8+:VM_-]J%N\TABBG)*",H7V_(/F"G.
[/%+X5_;3^)- X5_^/M:\ M*>'MΛ"ZCJ;Z9-!!?S/[.:M_M_>* MY/''BRRTS0M&GL=(TTW]GHEW-+=>N_#=W&'E%SX7N9IH=BKN9'255>,53E61N"?
#=QX+N(UN+72WU&==52U=@$N)#L\HY4AS&O(!QN)X MH ^IJ*^:-4^/GQ1U'5OB!+X;*>&SH/@NY"3SZG?SB?45\A)62%43$; ,?F< MD=.,IK3LOCIX\^*VL3P_"_0-"&G:,9VES?
7GBBZFC,LL\(F6WA6%3@A"-TC< M D8!H ^@Z6OF;X/:_K6J_LP>-=1U47-CK NM8,D#71F>V<.WR+)QD#'!&.,< M"LKP1\8?BIX ^$?@[O=XL\.:$W@LV-
G'=0V^H3S:O;1,BJ+F1F7RI.2&9!@@ M'[Q- U=17ROH7[3?Q'UK[1[6]3PBH'VCQ!]\^B>'+$7TV7>$1P]U=2;<)$0 MML0%CC&>:U=8_:4\@*"V75-!\>>%],O?%1MH[G16\-
W4GV/4S)*L0C/G+OA9 M79((/XGB>X\/'!/A35YK22"'3]3N!JUC:R M2H4EE:.(WRI!9$(P#U:@#[(LUXI^TAXDUV*/P1X0T+5YO#TOB[5ETVYUBU(M^7ET0 0O)Y)/ D8#:&
[9R*=I7[,&A^"M3T[6/"GB3Q;H=_:N'NS+KUU?Q:DG\ M27$5R\B'/lY0K#L: /:.:38KVLLC0M'A0"NP<>E5O'UMK?Q4^!&E?%&^MO%_B36_[(V6NA>$]4 M;3X+*Z5F#WXV2(TG*
[MIWX"]: /LNBN)^"NO2^)OA/X3U.?5DUVXN-.A:;4 M$0H)Y-H#L00"#D$!(!R#7;4 WPP\7WTMYIHU'PM/(2S1Z7,]@SI[1R!@OT4@50\'_P#!.3X;:!>) MZQXDV(!NM[9886_WEC4$_3-?
5M%>DLRQBCR>U=OZZ[G3]9K6MS,S]!\Z;X7 MTFWTS2+&WTW3[==D5M;1A$0>@ J_F@]*_,CX=^)=0\6^+?[*\)?\+&D^*<'B M!
[JXU*YUBX71/[.%T5=FCFG,4D>P%0L<>0V,F*\YMMW9S:GZ,45\?6/OVU3P M-H74@L=(LVQM"M]Z1YYV(@ [L1TI ?6E%>
M0_''XH>+0!7B'P+X=\':1I.IZOXGNKBV_6+B6*"T6*-7,A&8+,.<;1@\CD5 MXEXD_;CU>TUW7ETI?"/lG^'[A[.>QU&>]2_U26+B8VPCB:.,$@A!(6+<9VVH M_^RZ*^?U^.7C?
XGZZVF_" _0='CBL;&VO=1OO%TL*]\8D2VCCB4MO"$%G;@ M9Z&N1^ /QA\26FH:9I&NZ3]GO_$7BK7(+N">]:)U\P,%!*NA() MQD+0![_17Q9X,^+MY\.=/\.:IXGT5=
<\4)X'M9(9M/U6ZQ=M-=F&W@,6& M9V4M*5+]-G^-?Q*^'6I6$'Q$\.^'!:ZW;7+:;<^':N>06UU% TPM[@ M2]-P94;$B<94C:,B@#Z&HKY]\%?M!?$>]B?
Q5X5\/Z7X0\8W.5C!;V-] M+]%G)+$[Q22;E$;*WEL"JX*Y'+M)?$$VD:C M;ZA.DCV-I#'OG, (CD,I#:0X,%VD8)-:FM?'/XR^%O#6C>,=6\$>&\A A&M8 MO[&V&GV^ISG4-
,BN9XXUDG)3RY2 XRJ8PQ'+#)H ^G**\^^+ P 3;OX>Z+I$ M>D:2FN>)==OTTO2K"6?R(6F96(] M8\2>%/#&M0;5:)J*7'AZ]G7S(D(;_P=HEKXITW01#L=3N)C7$:6ULA QDQ.TA8]-T?
8FI[C] MH7QA\,-2U ?%#0]%M()/?P_>;(:3PW%M1^('A7P]9^%_$E]#IR)HE]--->Z1-/GR!<;T"2]6P MC-'C:S#AAS72?"XK>*___B?P'X;\'Z'INKZMXJNKJU675:F2""S$4'F^:^Q M2648(*C!/
!&OT5\GS_M(_%VR\.^-]7G\'>%1:_#NYE@\1N-2N/^)CY: M),YL1LRF('5OWV'_#EQH_AJ9+.ZNQ$E[/ M"^H79A29X(!$I$859$4RR9!8G"X4F@#WRBOF33OVG?&/Q\ $'A+1?AYX7TN
M&??#DFMW-UXDN9532Y(KK[/+"Z1_F4[PRC:5Y!.<<'BO%W[3EI8>+_A-KFM M:3=QZ\EUXD\-W'AK0[AIDU#589+>&,*)FVJ5=E9E>3 16.2,'(!]H45\L_$S M]J?Q1\,M0\-
^$-5A\):!XYO],:6M2GU.XNY=_T^ RF..!#%&9)Y8P(#$_(H$; M'N!6AV?VM:WO3#X4N=1T2SM\.N_$4WA/5=2LIIGMDO6B5[*>V:2-#:)SD^7 MEE#)(ZH@T %%%% !1110!S=A_P E UC_
+!UI_Z'/725S=A_R4#6 M/^P=:?\ H<]=)6D]UZ+\BI;A11169)6U#3K75K*:SOK:*\M)T,(1=7&I M6CV-I->\\VEZE<6,JRI&Q4EX'1B,_P))!BO(/ASXEUWP3X'^&_@X=V9UW
MQAXGT&+Q%J&I>,-9O+JVLXQ#)969F>5B\DB*L2%5RQ/ !RZ^*K8EWK3;"=6 M=3XW<^JJ*^//&'QA\2ZWX@7POX]\(V-G]^@^(=)AM[S1M9ND@F>XCN"MT@78 MQ5?
+QY4F1G,L:G6-9\5WMQMDFG1 MFC@C6(%VVN?)GAA$:@2EAAD8E1@@D=JYSPA^W?J&M:EHFJW=MX:F\-ZQ< MQ1)HNF37LNMV<,K!4FD!A\ER 0SQH1M&<,V.0#[-HKY9\8 %
[XJ^.OA[XO\ M%'A+PUH/_"$6Z7MK:QW6HSQ:O?)"7CDN(BJF*,:U;8K$E@N25R*[^T^*_"L M_P!F/P?XDGM:C7:]]%TRKWM+B2[NIHNHDC5G:.-SL,LE 'TK17R?*/B MS\5=<\(>#?!_A[3?

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|+D\#^-_$KZ;?10>$[B[MKRW.PR2/;_?V8;!! MQODB@"2?X'Z=/X*\"^&SJ5V+?PG>6MY;S)OG:"-T57XQ@AR3C'2M[XI_#72 M/B]X UCPCK8E_L[4X?*>2!@LL1!!5T;RD\02:N$UC]HR:,?G7?P?X%Ü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l:@U/Q)\ M3=<\8PV4#Q6^FO:6MG#)E<;YQ$@\Y\=''2%!YVYKD/V?_(CPOX)\=-JFGOH M.I>,]1O+B:T202-96S,ZPQ*958$3$ [@=O'(W9XQFNT/]IOQ5HWBOXG07O@GQ%XFL/# MNIQO=&S:T1-)M6M8G,2EG4W$@8NQ5-QOWY H [FY_9JTE2M*4P#Y8XVU3PAK MVEZ1#H9*R _(U!..I'%5=/_ &Q-!\2:]9V/A[P]VJV M+:6NLW^K.T-O;;;:^8T,]2.3SS73?$3]G?0?B9K^IZKJM[?1R7NE M+IJBU=8VMF699DGC;&1(K]",Y'M7&7G[7DNE:3I_B'4OACXLL?!^K7$%OIFM MR?92)_-<+')")?,A1\@JSCD$9 S4R?M87.I+KE]HGPP\6:WX>T"^GL=5U6W M-JHB:(X=H8FE#$@#D[!P/4\4 =EX$^$OB/0O$\.M^*?B3KGC*:T@:WL[26&& MQM8PPPTDD4"@32D?Q/P.<**O7_P5T36/$?C'4\1DFO8/%&GPZ;>63[1&L<88 M J0,Y.\]3V%<;K_[5>FOJ=O8>"?#E_X^G-A#[85>]O*,Q9>YD3=(P M!(C7)X.<5T7PW_:'\.?%+6[#3M%M[W==Z7)]7F7"*ODF.80R0NO(D5S@CD< M<$\4 8F@_L\Z[92:=9ZQ\5/$NN>'-*C,=AI+1P6W8TJGVF:)0]P$!X#8!P"P M8U1T_P#9;N?!T6GS>!?B!K'A/4XM/73+VZ6TM[M+Z)69HV>*1=]R)O8*ZXX.M"#7._$#]I'Q#>^)/ T7A#P_JDFFW7B6ZT7466:T0RF)#E1YC9 YW C'W<>U: M'@K]H:5?#NDZ1H&E>*/B9XJO3=W\>SBVM[Q+Z-"2KO%*NU9%+-ADP#C!"%>E>&_AU%X=^'[^%WUC M5=8\Z"6^?4]5N?/NIFD!WN6/ ZG"@!1P ,5X5]W[6NB:/XK\0>(2/%5YH>F6 M9BCTRW@MFMKPBX SP\B0MO:: 2 0#Q7:VG[3]GI,VL1>./">M>Y++3C]\" MZB8:@W=]&")Y+MB3<5!C/()% "2_LS_-CV/AB;PAXQU/PKXBT+3_[+75HK M:"X%Y;9W>7/!(NQ\D$8(/0U;\&?LU:9X2\1:+XAEUJ5-9\06=U=7UJ]-Z(M M^H3SQB-F<*H"*JC"]@ %<#XL_:2\6?\ "2_#NUN_!?B'P!IVMZW$]WNI&TGB MNK38S.DOEN[6[D ':P!]\5TD?[6430QZ\ @+O)%\):G[+%XO?[/Y#'?L$I M@\SSE@+<>:5QWQCF(@#OOBE\)T^(^%_$VBRM-IVLV"))\(6X,71XY M 5DC8<%3^!!KCY?V9Y?$5GY'C+Q[K_B];]^CO-3M[H10VMXD8_=VX@0!8X0> M2]\N1\Q-6;G]WP5I?A'1M=U9[G2UU+6O[!%L]F66Z#[2'P<;1P<@GAA7;^ M&/B58^+?&GB7P_I]M<2#0#%%=7_R^0TSKN\I>^U/PV/"#_%'Q+' MX$@F2;TT2."U$D0202)$]R4\R2)2.!3SCJ3@5LZC^S?JEM>ZQ#X5^).O>$/# MVM3FYU2;""WD)E;'FO;S.A>W+X^:;GD?T:;!QHH\;UG]GN\M?$"O'> ML^"[N]MHK34PD.-^EZL;[4E(G5BLP7CS >>X-=1\%OA)9 !7P7_PCEE]NH:U M&;N>\:]U1U>XD>5R[;F4 'D^E=Y10 4444 %%%% !1110 44A.!7CFM_MVU=K'1[RYCTQEQDW0,L2\YW,<$9/0$T >R45YMXS M_:&\#>")='@N=5FU2\U>U^W65GH-E-J<\UKQ_I2W1R(N1^\.%,< DUSY_;" M^%-S:;?+IWB9]5EU*YGLK"#3]-NKB:YN(5C:6-(TC+%D$]%A@8^;/W3@]IK MS'XQ?#/[7/%>I>%_$_A'4K+3?%WAJYDFM!JD326=U%+&8YH)MGS*&4Y+KDJRJ M<$9!X_PQ^UCX3T_P]HUMXE\!V^N>++^VEO8[3PKHE_+]I@6XEBWO0;&2M[7TV[Z9H]%HKOF/\ ;_\ A5>#2AI_B275 MY=5,HL8=-TVZN)) *($I54C)PA(R3@#GTJO;_MG?"*X=2/$\D=FY=(]0FTVZ MCM)I4SNA29HPCRC'^K!+'H 30![=17D$?[5OPYD\VW&J_P!IZ@A@NUL7TU]' MNUU3,NY5^R&+S3E06!"XP"U^QO\4Z)9:MILK36-Y&)89'B:-BIZ95@ M&4^Q - &C1110 4444 >-_%.HW]^D6D:YX;70C%" M#Y\3B1W\T$_+QN!]17KM% 'SE+[/P_H'B[6_"DOAS0)XKR.XTV&XM2[U26 '[.LRM\D"[MI?87)OQBLR/l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Ä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ÏOO.V!RQP. MD\G% \S/A3XZ_9CU#3;K3_"P^(UK>^&K#2+X:-=06USI$;/.X$*W#HK6 MK&Y(#;E\M3M(/$/P<^"GCZR^+EMXO\$_A>PT-)-3\0:@\%G>Q3K;"\BLU@ M&1@LQ\J4.0/O!CT(S]:T4 2,'[.OP.\5 #KEQ]2'B'2HK._/PPVF"9;F.5A* M=5NK@H-I)P8Y(FST[=17!^&(M<_9U^*<-U+IFF:SKVLP:O&?#LVL6IC>):-]MTUS#<6LLQ6&1669?-BWJZ_(V#@BOMNL3Q5X\.^.K..T\2:#IGB"TC?S$@U2 MSCN45NFX*X(!]Q0!X/\ L?ZK?^.-3^+GB:_L-.L8M6\3*8TTFZ%U:GR[."-@ MLP 65E(VNR_+O#$XS7'ZU^Q)XFU37?&47,TC\ M\!9HPJ_[$L@[U]<:3I%CH.G6^GZ;9V^GV%NNR&UM8EBBC7T5'L!5N@#Y4 MT7]G?Q;H?_"*7$EM#?:L^@ZY)K]Y'.B!]5OO*Z]J=];HDJN&AFF9XVR#@9!SCJ,\UY+H'PQ\?\ POTK MX6^(;7PH_B74?#L.JV&IZ%9W\$=SY5U.TB2Q/(ZQ.5VIE2XX8XY&*^K:* /E MKP1\&O&EYX^\,^,=>T"#3'N/%E_X@O=/-Y%.^G1/L_V:!693AY"44G86 W=3 MC-:U_P#!SQ#+X<^\$6EP ;/%]R[Z9^^C!NE^QQO+N.?E^=6'S5]#T4 ?+7A M#P_\2O@G#XFTBQ^'+>-(?$1BO8-1LM4M8/L\YM8H)(+OSG5MB&+*O&'X8C&> MN_\ LK_S7_@UJ7B)-:BMV2YT_3H(KJUD!C=T\]Y41?O*B-*%7*H+7+:=?6UM=V,\=0CB=T#0L'R"K$J0?E M..X?X+? WQUI'C7PCKOB?PY8Z6:77M=U2Z@M+R:._U6ZBQ#L(P6))P2 #G)P M*^M** /F77/@MXPN_B+K&J0: MG:Y\ ?BCIVMW5AI6I:UJ5Q)\'A^[U6&SN)K:6>.59[6:4B$R?+AHF=6*BQM M7VO6/XG\'Z#XVT[[!XAT73M=L=P?[-J5K'<1;AT.UP1GWH ^$K;P1XI_:\8 M>-_&EEHD/GZ1XDT^Z&CZ!X@\E[D102))&M_$53[2@<'*ML!PI;O7:7?[/OBC MQAX?:WD/@:,5M'N[^QM\LT\5^+)-4UX?\YC$ZR2!IT\L,48\'\ ,6)L. V%H>@MZ9X9TR'3M(T^UTK3X1B*TLH%ABC'HJ* !^_J_0!Y;XC\"ZM>?'7P/XBL[1/[M$TO3;VUN9A(JF-I%_C4+G)&1V&!7*:AI/C;X4?%[O;XCT/P3/X\TCO3';MYF MGW]M;75C-$K*(Y!.Z PD-G-%(P3D Y.!SGUKI=/^!_B&'X3?"30)=\M_N>@:[!?ZC; MF:.K%<CLX.<,?F!XR;^DZ* /E?XR?";O+?^.O&.M6O@K4_$<%_]@;2[5OM M:@L+^RN(4Y4 $XQD@8)SCBNIHH **** "BBB@#G/A_,BQ;_[\G_H;5T=NDKF[#_DH&L?]@ZT_]#GKI*TGNO1?B5+<***S)"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK%\5>+;#PA MIWVJ]9SN.R&(9>1O112;25V7"$JDE""NV:5%>9W_P :;9O#SW5C92#4#-Y" MV]T0%4XSN)4G(QZ5S.F?&S6K:\'VZ.QO:<,/-2"_QR(I[CYC^M8.O332N>K3 MRG&5(RDH:'N5%>$>(OB\K8UN8V5Y#96;3>7#"\"MYG^\3SS[8KT:2_B=I$GA MJSU34[F/3FGRIB)+'>.&V@ DCWQ3C6A)M+H9ULMQ-"$*DHW4MK:L$BH;2[A MOK:.XMY%EAD4,CJAJ:MSR]@HHHH ***IZOJ]EH.FW.H:E=PV-C;(9)KB M=PB1J.I)/04TFW9!MJRY1573-3M-:T^WOK"YBO+*X020W$#ATD4]"".HJU0T MT,[-]0HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.?#_P#Y M%BW_-^3_P!#:NCKG/A__P BQ;_[\G_H;5T=:5/C94MV%%%%9DA1110 4444 M %%%% !1110 4444 %%%%07MTEG;/*YPJC.30!3UO7(-&MC)(%1>2O["O M&OC#\:?#OPMTI;SQG?2-=SJ6M/#E@P-Q,.QD.?E7W) ^O2]'OQ^-MM\(/"+ >5 MJKE4NM>OBT.AZ?)T!QS.X] #G\AW-?FSXG\4:IXQUV\UK6KZ2_U*[, >U=(?G_P F3:6A[OK[;F\>Z\9+7PPEGX)TKHD5A$ MLDY'^U*PZ_[JBO(=2^.7CS6)C+>>-?$%O(>[:E,/T# 5N^'?@3JWBWX0:KX]MTB_M;^/2[@Q7FDP@FYBC'64]L<@XQTYSP:\S(Q7W6&H82%XT8+W='IK_)GF M55-[L]!\/?M#?$SPM,LFG>.=;0*<^7<71N(S]4DW U[U\.O\\6OKB&S^)6AP MWD>=HUW1D\FYB_VFC!PP_P!TC_=-?*6AZ%>)M9LM)TRV>[U"]F6""!!R[L< M#_$GL :ZSXU?*6?X+>+H_#M]K%EJM]]FCGF^QY'D,PSY;]OU^A'2IQ&#P6(MDJ-2*YFM+:/[U^]Q\];G[T7H?]'X3\=6MYH\GJ^G;I#X@\-'78'D;G;G.W_9D M"\[=N>H%>@V!PESLB,I&63R^!WWB M]G^C\SUL/B%779H[ZBD!R,TM>(=84444 %%%% !1110 4444 %%%% !1110 M4444 %--L]JZE\6KJ]MIL6]"R-]:FU\E@T@7"D,=VULYQZT ?8N[Z_ME1GZ_E7P78_L5>/=06PE\0WEW=WUO/I49GM?UU!:@R&^0!77)(<+DC+ <8MJ'4_V5_C%%:Z+8PI+]D5DD]KHUR?%MQ;?\(ZWVLO%=%5S]I_/+:SCMGG7R52V0 G);]5&,><9]!5[]G/X<:K\'/A]KDOBF5 MKC7KO4;]^N|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

=*3;LCQF[:L;K&L67A_2[K4M1NHK*QM8S+-<3-M1%'4DU^8 MOJ6/[5U_\:-4DT+0FFLO!=K)\B?=>^8=))/IGT7\373?M1?M%;A\:-0?1=(> M6S\'VTGRQ\JUZPZ22?
[/HOXFOGK^PO:I* 1LERJ,&MB,0O?Z+M_P?R/DLPQS MK7I4G[O5] \ @'LW[)?[65[\&-1B\/>(9):OP7P@O;*>,ZM)T$D4T3;E=3T(-6: _FK:,^MW"BBBD 4444 % M%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110!SGP_\ ^18M_P#?D_\ 0VKHZYSX? \ M(L6_^) Z&U='6E3XV5+=A11169(4444 %%%% !1110
4444 %%%% !7,>+G M:^FL]+0X^U2 /@_P#EOTX_&NGKSOQ]3::^N7P)#6&CW,Z',,,$.#^E5%;) &O.?!OB-O"'BO2=; M6TAOS87*7'V6Y4-'+M/*D'U'?
L<&L>>X:YN)9G)9Y'+L3W).:#?[!2HPITE M12T2L=,J=E8^Y-6U^P^&^OZ1\:O!4 N?AWXH5:7Q-I$2#:;NW#.4Z @D\>NX M?Q"O"OVG_@O:?#?Q):.]X>9;KP1XA7[7IMS$U>H^
+M/$7['>MVUR'N] M.L/%-M%80WF',$)GB.P'Z.P_$CI7B1C5P-52W5U&_P#.GM\X[>:.*<+JQ!\$ M/#=K^SM\,)?BQX@L_M'BK5U-GX7TJ1.N2_
DV]IM*TGY_RQ7DMWW9QU%ROLCEB**C V_P!ACXAS M:YX)U_P5<2E[K1&&JZ9N.2(B?WB#V!S_ -]U\3$5[S?O#]LFG?M#Z+ &(BO[
M:YM90.C*4W8 -17IYM1C7P51/HKKY'GT;TZR:/T\T2]74--@F4Y#*#5^N8\ M.?[%$9Y\IF3\B173U^1GT 4444 %%%% !1110 4444 %%%% !1110 4444 < MW8?\E UC_L'6G_H<]=)7-V'_
"4#6Λ L'6G_H<]=)6D]UZ+\BI:A11169(4 M444 %%%% !1110 4444 %%%% !1110 4444 %1W%Q':P2332)%%&I9W=@JJ! MU))Z"L;QOXUTGX>^&+_7];NA::=9IO=L99CT"JHY9B<
#Y1_=IT(8\@ \HMO^'C-KK/[0TWP MH\. #R_\6WGVD0VKZ#]B]K-%@%IBQ50]KX=^8XVGFOHCX[^,?$?@X2^(- M>\+Z6-4UVTMO,@MS$TX4Y&7,;?-(%&6VKR<5OZ;\/?#.B>
(#KMAH5A9:O]C3 M3_M<$"HXME.5B&!P@/8<5\Z>.OVR=0T_O[I%KI/AF[M_!<'B":2-2\1WAA>. MX,,)DFCAB$GFJ1QAV7!YH \Z\< M1_$KP_\ #71+_P +^+=/\96]W]4D%YXK
M;PK<:;%9A8MZPM%)N!W/\N\#'\WJ3X-*'/'_B7]]O0:[Q&-0M4O(%FN[6U> MY,G*[6+GY X"A2<'!&03CK7H/A?_(*':+XMTB2:P\!^))-6N9[:#1\/E*- M2,[;8PL[%8XV[LK-P#WKB_'_
,W=XV#32^&_ \FF06VFZ@UU!JDT$TT5W;31 MH0-DNUE^?''7(.: /N*:&.YA>*5%DC=2K(PR"#V->3?%;1[3P_H%EI^D6\%I M9&G3[_ $V_DBD:
M.0(K@AXF92"&!X/'2N=^(W@/Q#=>-5U*Q@6YM971S<%ES %Z@DD:0.N1FL*U M^317/7RQQ6(3G-12UUV;6QX[XSUR6QT61[*4K*76,RKGY0>X->5M,YF\QG9I
M2=VYCDDU[QK,5EJ-QI \M);"29RJL/E*YZCVSDBJ$?@A2#1MKH:5-ID=P,QR MSQ;A*". &).WUQP37A2@VW;H?J5/$048\VCET.6NO#K^_+#3M1DD%C:V5G=04DU\?
V#U^7]*^Z/@O#'YPP\/1]-MJHHSG$3]C'DDUKT M!]Y?2CSOF5]#H_#WAK2_ ">F)IVCV,.G6,9)2WMUVHN>N!VK3HHKXEMR=V]3Z M)))604444AA1110 A.!5:SU6RU
L+6[@N2OWA#*KX^N#4MS_ ,>TO^X?Y5\B M^ CX9BTKX=R>&GMQX^;5MMZE@O\UK8RR>;YX'&W9CK[5PXC$^PE&-EKY^:6G M=ZGE8S&O"SA&R=
[];/1I66FKUV\CZWLM0M=2@\ZSN8;]'<5\R"0.N0<$9'<' MBK%?+6C>/_$'(@+PA8ZCID:W.GZI<:EID-G;V\:)%?FY?[/)\H'WN01[5:\>?
M$#QMX=\22Z')XB33Y=+TWVE6YGN+6V6]G9USZ;I*^>;WQCXROAXUO)/%%KH,VE65D(K61H MA:)//$I8^:5/?.S)OE@3P*PKWXO^)+S0_"MO:ZW+_#O;OW+EG%&%[PE^&OOMZO
MXA\!:=?:W+:W-[(&'VFSE22.= Q"OE/ER1U [@UV5>C3FJD%-=3V:515]<:B MV:O]%%%%:&H4444 %%%% !1110 4444 %%%% !1110 UW6)&=V"HHR68X %5 M1K-
@;>WG%];&&X8+#)YR[9">@4YP3]*SO'6/^$,UW.,?8INO^X:_/;P.VO\ MA#0_@[H%_NU#PSK6M6NKZ1>G&+64.PEMS]>&7\:]+*YZ/S"4N:S7^3?Z'32H M^T3=S])&-
"7O0MQXC'B#4X-5T]8XO/2TB#F/>FW** M,+AN.^IK"*>-?BSXC;P S?%*YB7QA'>K(%TRU)M%A+%3%\G+D+@DY^E; V9 M45^;27W^?EY,KZM+JTOZ?
^1]QYHS7P7JO[17Q&N_#W@RPD\3+I@GCOOM6N+< M65@UW+!*45?-N5,2G R5 R>U=7X;^+/Q0\0ZQHYN?$$0WA9)7;1]DYHS7Q5X$^.'C&]U M'2%T_P"
(L7CN]UW2+R\U#2;>RA5M#F2,LNW8,J PVI9,DU8T3]HOQ'XJT_1X M+9)\HI/+*R=KK\?/R\A/#374^S M>M+7B/()?Q"O_B#\,;B;5M;N]>U2ROMKBZN5MRNX '$!O#'A+7K
M+PY)K)O'N:V[TL7Y"PI&,554,B 9+GG-0_P#"NOC)_P!%@TG_ _(R/_Y*]:XD M_P#)>?A1_P!<]4_]%PUZZ,E 'CG_KKXR?]%@TG_P (R/\ ^2J/^%=?&3_H ML&D_^$9'_P#)5>R44 >-
_P#"NOC)_P!%@TG_ _(R/_Y*K+/@KQO;3^(K+Q/X MTL_%":AHES;P0VN@)IY63:<'\5R_BY&L;BRU1!G[-)E^/X#PW^/ MX547RR30T?C#-&UO/)$XVNC%2#'V(.*
;]7 :H^&DGPQ^.FLVL<9&EZ@YU"QD M ^5HI#G /^R3 M_L%VG_H%?)/KZ& ;.L./CQ) V#+3_ - KYYK?+G_LE+T1P5(7U&UIQ^O)I3ZC M^T/H-KB(I<:P11.F9'+(M"?.
<>V<_ \)5&:5U1P=1OJK+YZ')&E>HCW3P[X$^*I]:RW.G_ !3TRPM)I7DB MMY/"$*;_P B_(J6X4445F2%%%% !1110 4444 %% M%% !1110 4444 %%%%>7O6T[2(NZ6)YV@B>01HI9G(!.
!R2: /'KR$?%_X[M?8IOWWA?P+Y=Q+"?N7&JR#,88=Q"GS8_O,A[5[7TKS']G/PY>Z'\-+>]U6WE MM=:UVYFUF_BG4B19)G)56!Y!6,1K@]-M>GT %>8W?[,WPPOO'(MY)3,]X2^&D*
[2YCW;-Q7@G;DCKFO3]* /)[?]E;X56OAO5- 3P=:'1]2D26X MM9)IG4,ARGEDN3%M>)41E0.V*?IO[+7PKT?2H]-M/!EC#9)%-"L0>4_)*RM* M,E\GJT4 8GASP5H?A&XU2?
1],BL)=3N/M=XT> ME5/&'B;0M/M)].U+5H+*6XC*!-V7 (OG;,D#WKIJY#7/A=H?B#66U*Z6X$S[M?-CBF*QRXZ;A_ABHES6]TZ1G@,!!,R;/XVYP!QZ#'K7JD%
MA;6TF^*WBC?:$W*@!VCH,]<"ECLX(IWF2&-)G^_($ 9QJ>IK&-'D^%GIULS> M)UK1NTK+6UGWT/FCQG:O8^([C3(+!(K*UF*)!N^XA&?,).2Y;U)[5Z5\+]_C
M'PQJ.DZRC:AIT$BQO22DEL8SMW=.UMXQA8HE"]P/%3"BXS"[MK>2>Z7.R;ZF;5D_W<\#Z];ZJBBNE1459'AU*LZTN:I) MM^844451D[E13DIM>9YF*AS23/._[!Z_+7UA\.(?(\!Z-'TVP
5XG_8/'W?TKWGP3 M#Y'A;3DZ;8@*.PJ<]-+S#*'PY9,W****\(],**** "BBB@!"_C!Y%4K+1-.TR M1!+.PM;5V&&:"%4)^I]]12LGJ]I-W:.)\2?$/P)X)NX=+U?5-+TV<.)UM74 M9C8G(<@
[3GG<<5'XI\?_#ZQO-.&O:IHWG2QBXLY+L5Y$X#HO! !(Z@UY[H MOB/2?ACKWC2R\7:)>RW^IZE+=P7<6GO=+]%NX'EQJR@C*C*[3@56UO7=&\/_ M !#TR_OO#&H1:-
<^%Q:PZ7'I32F-C-D1.B@JIP#WKQI8J7*]8K6UK/37KK_E M\SYN6/GRN[KM;6:?NZV][7_+RN>]>*/&W@CPU!"^MZCI=O%JX&TRA7%TH P3 M@'M;YT/1[_2X+4Z?97&G
!HH#"C0@=057&. .:OFC4[:3P_\ ",Q\ M.ZUINIZ)?WEI<26=[!IXNBD;2LRV#$ NFY2N>GUXKZ,\"?;?^$*T(7ED--NA M90B2S7.(6" ;>>>/>M\/7=>;C**V3]+[I_TCJP>*>)JRA.*7NI[;J^Z?
Y[+Y MZFU#"EO$D<2+'&@VJB#] *?117[GMA1110 4444 %%%% !1110 4444 %% M%% !1110 V2-)HV1U#HPPRL,@CT(JE_8&F?9[6W_ +.M/(M6#W\7D)MA8="@ MQA3[BK]%.
[6P[G+:O<>$?">NV5Q?0:=I^CXW.+&"X-LHFNI",^7O"Y/ [G%; M,/A_2[?[-Y6FVD?V:=Y&W+5GKMX^7/?%>&_M1>"V\4^*?A9)&-3+1ZZ(W: MPGE18U*$[FV?
=.0/F.,=.UY%X+\5>++=5U/PSX9W^*!K/A^;5Y=;-RERL8C*R M>26E;Y9,Y7: 3[5ZM/">UI*I&>MG?\?\K?,ZHTN>"DG_%[?8]WX0T'4-/6Q
MNM$TZYL5SZT#]MTOSQY.29ZQ=!P,$U7;6]>G\->#_M!\0M5\3M V[N#WK9Y>V^55+_+UV5]= MB_J_12_K7_(^Y=.\.:1!%U<7-
AI=E97%R,@]^HKZVKS\13="?)S7.>I%TW:]RGI6CV&A6:6FFV5O MI]HF2L%K$L2+GKA5 %7***Y&V]68A1112 YSX?\ (L6_P#OR?\ H;5T=J!(/XH'/H<8_(^M?FEXA\.ZGX M1UR\T?
6+*73]2LY#'/;3+AD8?T]#WK]I]=T*6;;8^5=3N5U.&4]B#V->(_& MCX&^&OBS9+;^,K.2UU2%=EKXGT])D'995_B7V/'IBOI,KS7ZI^Z]ZP_+_@'_M71K,)/$ESIT6ENU MO%;"WBE,@
1<9W$#KUZ5P@.*[7PY\#/B)XJF6+2_!.N7!8XWO9/"@^K.%_ .MOH#X=?L(7=O-!??$G6H=(ML@_P!BZ6_GW.?+X$:M\#_ =G8:+:Z-I.DQ>'O#%%M MCRI/A&&E/[Z4]R>O.?
VCM8ECC4*H&,"O@/GVBME^K\SG22) , M#%+117C#"BBB@#*\5C/AC5L#/^B3=/\ KFU<5^S3_P F\?#3_L7-/ \ 2=*A M_:8^&,I?%_X)>*?#6BZO?;'KEQ:-)IU]I]U);R)<(-R*60@[6(V,.F&-
<-^P M?\%?$7P0_9YT'2_%^HZE?>)[Q1=WD&HW-VZ@#Z)H MHHH **** "BBB@ HHHH **** .;L/^2@:Q_V#K3_-#GKI*YNP_Y*]K'_8.M M/_0YZZ2M)[KT7Y%2W"BBBLR0HHHH **** "BBB@ HHHH **** "BBD) !)X MH RO%7BG2_!>A7>L:Q>)8Z;+NDFD!('8 GD@ DU\1VW[='B_P +>,=5 MFU>PBUW0YVF^QV)C6Q>-5DVQF)BI>3MN5@"\.V.E>M_M>_$Z"X\$ _\
(SX:N]+ MUG5+N3==6]O*+F[M84!.SHXD<-E64?-_#R<<5\:W6E7>]>"O[?G@FO+"8!)+ MYIQ//]:3HUMMHH]EK]Q"S6=]DL.#S$\EQ@W(R*4W2.6&2>@[_$_\
M8[W5+/3M*^S7.J6.D/=:=3N]&A,EU%%M.W;M5F52V S*I(!)XZUWX>I[2FFW M=GJX.M[:DFW=K<]#HKYTTCXA_$:TTEW33KRVT:$I"':2:O82W]V8VD(\\B)8F
M=0H&%*!N06..2^'XL_$Y-"EU>^T:.'U7.*PV^@W37!.*S>69-P&0GRXZ,>> ME=)W'T117S]8?%/XEZPZZ39Z=ICZA +9[O4O83- %GZ!8?,#AEVONW$= >]5 M-
6^*OQ;T>QM1+X>LII9]DCW<>FW(BA)#8A*!F8DE1\W;=TH ^C**R?#&N#Q! MH\-T4.4^ D\9C=0DH WJ-P!(!)&<AJE_9$?M713JA:%#Y& MDVT?3:F*3^R(_:KL48BC5!T Q14JO)/COX#
MUOQ'XD\/ZM9V=QJ^FV<,\,ME:);R21R/C:(([@&-A@:2>H[5SNB? ^Y>[\-P M;KH)K*I*G&GM:77R\O/\ M/N\2KC<3&M*E"C=*UGK:6WEYO[ON]_N]:T^P$!NKZVMA.<0F695\P_[.3S^%
M-FU_3+>"">74;2.&X,V&1YT"R'T4YP?PKY3U2PA\%?V!%XMTC3=;N4\+)9_V M9JE_%"]A(K-F0;SM8-D#*$L-O%:WACP]4OASP1JMSX-'C+3&\/&R2PDD1#: M3M*SB7:(0,.I
W#D8KG6/J2DXJ&OSTVWT\^GS.2.;59S<%3U2VUNMM[+SZ7\ M['TK+X@TN""":74K2.&=MD4CSH%D/HISR?I1<>(-+M;..[GU*TAM9#M2>2X1 M48^@8G!-?*+Z-%\/X?"T/BS1-
+U1XM$N+?\ L34K^*$VCF=\Y2YV,"I)4E MACI4^E_#G7M9\#> =4M],NM3TR'3;B$V5HEO(\+O,S+($N 4*LI W#YA@5*S M"HVTJ>MKVUNMO+S_ U(6;UI-
Q5+WDKVUNOAWT\^FNFMCZ]?6=/2YBMFOK9; MB4 QQ&00]YZ8&,JK8! Q@X]#XH^ M3OO',K;C)X M.3QI9ZCI:V=DS31K_9\HW9)#D:0V0=R\\5U_6;]I>T<-;[:_Y7_ [WC.0]'M
M72L[VMKHN[LK^6B/97\2Z1&4#:I9*77>N;A!N7!.1SR, G/M33XIT41R2'5[M)&P1V^TIA6/0$YX)]*^>M)^#FMKX?UK[7X?5M2A.WTZS9S&6%P%D$B*<\' MD GISUK0F^_L
O[OR_"MM]F/A18(QM3:=0$XS_K,?O_K62O6(:35\/ _(P M6/QDDF]/WW\ +R_%'OQU:R6]CLS>6XNY%WI;F5?,9?4>G)'O5NOG;PUV?$6 MG?
$;PEJ7_"-2!X;*TBU&]OG@FB4)#M9HSGS(Y%/RX&0>M?1-=N'K2K)N<;69 MZ6Q\0I.I#EL[=?U2"BBBNH[PHHHH **** "BBB@ HHHH *1F"*68A5 R2>
M@I:X;XW^%-6\ASBWU2]LWB@)?8&) A+=LL^7I"*E)1:LGU*BKM) MF]:>- #MXLC0:IDZQAF*_V8-1M:#(Q)8^'_!-O%97OA2P@6" 1*DNH1R*7J!;_ M %@&?G/YU[2P6&C)T?Q+<;
[NBFTNPTDP[MM2OWBCMIQ(F\,CAR.#HM M?$'O0^&\ @"YOJ3UI1M+C\.?VlITT6A:E=Q6EMJL:6VQHU8Q8"K& M/AWJ?Q6O\"^-
[CP5X=AT[2$\56]XV@:3<6\T<*1D,D3MF"0J2#M.4SQ5_P!G MT91]HIVCIKI;IY \ KZO!KF4M#[Z'B[0CIT-^-9T\V,Q(BNOM M"+233[-LKM]9MY$B*+:Z)8+#PW]_EY^?6VGJ6Z--?;_+ ,^
MK;3Q5HM]=K:VVKV-QUF64*PZ@E2<'VKX\U(?LS:MX8TSP+=0>"?(U2WO-175GMIHHIVMG5Q$AEW= M", ==OI7I_['WP^\0 #W2/$5EJOA<>&],>Y5K$7:6 V^10#N\YX#MD /"N<,
M1UK&MA:.,$IPJ7MZ:ZM=_F1.E",6XRN?1-%%>%459]I6R[M['=ZC^U\ #W3[\VPU.XN@#@SVUH[Q MC\<<_CUKG++Q+//=-'+8I8E1A6_.CE#%V/5 M N
>/4]:OZ7K<&IVEG+!UK)=1^';'?#*)<=_E!/3OBLW"2W!33V-3]!1BF! MB,4\'/-07B#I5RCRJ+[_P";0VK),,#THQ2T5F2)B@#%+10 4444]=1^S1|+
[_Q;XTLIYS^(YKIK6VALX$AMXD@A086.-0JJ/0 =*\.EE, _;*I7[M+-1T;5-/BU/1[K*R65ZI-K?Q@_)(/!H<'(Y'(-F0.U\O/)IR?)&I[G8^%[\-U)/V4*UJ5[VMJO_Z
MTU9S7P*^'LWPV^'EEIEYC^T)6:ZN@IR%D?\ ASWP [^%>A445])2IQHP5..R M/M*%&&'I1I0VBK!1116IN%%%% !1110 4444 .=2TH:.] MW=7)NVT]P#Y(X&/5;
MO34O)K>U?9BPW_U+1_#&I^(;^U*-81 M;EHTL.6HVKSK;RW%K(RGS(U+X)&,Y'&#F@#A-<_;;|:3>,]9|&6NAZ?-#96W
MV*76;*|CCN&F^Q"8WT*.XW0Y.54(25YW<8]G\./V_&5YK>BZ!<>$4URSM;" MWBO+EQ$U*YE^Q+.UTJ%QN0D_=5"2,D'C%>S6W[2GPCO?$MXL'A?49M0LK6Y
MM[6_7PRVV]6V7-Q:VLI7]XT8#!HU/\# 9P:YP_M>?#'_ (2?0O$>G:/:-X9N M-+NOLNNMHTJ7]UY+1(D5DOEYD0M+LQD?," #@T >=I_P4$|9'P]K%]'8?#[4 M9H-'M-
9B&GZX[K:I-.J-!/OVYF1228U(9B, =CUGA;]NCQ!XM^-FCO>=.)V M-WH%T]E!)=*Z]FYE^T0"4W,*2LK&)<]*4+, >01BO8(_&OPUB^%6M^:-|$S
M>&=%=Q/M%CKWAKI+=NRD'F!DS(68C!&D]YKDI*_:M^%>K>*[-X1UVQ\4Q3 MC3ECU#PR8+VS7R3*=Q:YHXA&I8G. !0!B?&K]L#7OA[\3]6\-?IF@_9--?S
MMFL]0OWCUC46N=P66R@"D/'&1\VZ MF>[,A?*^>Z]HR!@#;@ < 5Q-S^V=\(=0GGUJ]\/ZZ;G3K07=G?7GAF02W-M) M,L*R6C,-S]IL -N,@YQ71>', -L+X9OH%W-
:0:KI<.FVDUW);+PV-0E70;K['C4444 %%%% !1110 4444 %5=3U"?=.NKVX)$%M$TTA R=]@_H M*M*5'/'.+ Z]I_PWMAX5NX) MIK"[DU1<.$!V&2+9P'(P-
D)&>E<;XI_:FU/QGX&O8_!FE*NJQZ!-J.IW!O3 M&=)D4E1'G8=SY!(!QTKU'PC^SCX7|^>(X]8T>ZUU%MVDDM=)EUB=M/MV?[VR M'.T ^AR!Z5F?
#+|GJV\.^&O&MKKZ6K7WBVIGFO\ ^RRR(D3|+&C$ C ZG'6O M257 1DYJ&UK+7OK25WLO34|QPQ32BY;WOM^&BZ_@<1X2_:)|TS3],\&P M^)=8TS0X-6UR>?
5Q"%B9#>))6VQX7;@,S'#'. !GFO6_$O[+?@GQ.+ R-J^GO:V2:=))INIR MVS7=LO BG*GIXOUYK5F_9Z\$3_VHCZ6QM-TIXOUYK5F_9Z\$3_VHCZ6QM-TIXOUYK5F_9Z^ZP/.X'.
M:I8G+U=^SWWWJ7[K6MMJ3['%.RYMO\O3[]S@H_VC/&.G#6=-USP%:V'B6Q MTY=9@LH=7$L-U9Y^?$FP;9%&?E(P?6N:N/VAM1^(5GX&|2V]KJ/AOPY>^(#;
MVQM=0427D"1,7,\80C;D'" Y.,YKT2Q_90\$VFEZE92W&NZ@VHB**ZN[_599 MKB2",Y6WWMR(O51C/>M"Q_9F\#Z7]<-U96MW9P0Z@-3BT^&Y(M8YPFPE8\8
M/(*C@TE7R^-W&&OH^WG)]?7]=-'[/%.R';FVNC;;PBLFM[&I(VV8PE_$C@ DCTKR'PK]=OB%H,J:3[$-M=>)M&@\ M))]3R M<9Q51Q6!AS1C"Z?
D_/=\SU\U;T)='$RLW*S7]=@^&/QKB^*_BG5K;1+))O#V MGVT#-JXFR)+B1=QA5<8^0$9.>O:BKGP%^$T/P:^'-AH \B2|W-<7DUNI"23. M26*Y .WG SV%%>-B?
9>U:H?"M%Y^?S/0H_(G4W_ *T/1****Y3<**** "N/ M\2_|E?|'_P#;W_Z)KL*X_P 2_P#)0?!__;W_ .B:PK?"O5?FCEQ'P+UC_P"E
M([*BBBMS]&MP*QM9UM]/B".4"2.,GE\=3@9('?%2^(=7MM)L M@]S>?8?/8013^67"NW"DC'|^/6N<$$]I-;W$\L!U-D6./6(4"QWH'_+.4#IG MG'.
3QCI6D5U9P5ZSCC]D=_EI_7FK>8MUY]W* =9%U#2I/*4;5 &Z,$= M3C(//7#>U)//')!?&+(CDV:C#^/&\?4$?K44I&UC&#:)YNXQMULC7|\ <;OV MY]S3/.$+ M(-4XE$L,:'#
QVT) P!W<6;!|3H6\B2,$Y,;(, ^NQMN?^^6%,4D1D=]NW\E8 M#^=:(U6I+&CZA*] LLDI+ YY5I"26_X#&/&UMX(UAC2-%VQH]J.P' KFM!A MS/+.0.!M4_7
.L%%=&Q.*PJN[L>A15E5O+"'/W&NY_ 4$?UJN3F-P?FR#S^&/\ V44]W$G# M'@Y!_%|G]!78SF98#-#!(R?YT7 W2//8B-+Q(_[/TV4QJ[* M?XW&>W'/TJL9'MO!Z_P"^]9LQ
M;-ZPU|N9(+CRVLI:)4DU6218TDGX|4+V]>N.<5T"&N&>&. ^^SVIV"W,:@-: M:7(IL4#I--GIZ@'^=;'AI5E%]-IEWK$>IZGS.5A@V)$F0-F1D'|This:<>QT
M4Y|&=+12#GFEK$ZCSOQU_P E0^'W_7:[_P#1!KT,=*\||=?]E0^'W_7:[_| M1!KT,=*WJ?##T_5FDMH_UU%HHHK S"BBB@ HHHH YSX?_P#(L6_^)_Z&U=' M7.?
#_P#Y%BW_ -^3_P!#:NCK2I\:*ENPHHHK,D**** "BBB@ KR7]JOXOW(P M)^ 7C'QI8QI+]FV9-]L@RHE8A4)'< G./:O6]^:_P#@HMX8U7Q7^R%X]M-(MC::XBMTN)
(DCWL\2."X I8'.20&@#\%?'Q4\6_$?Q/=>(?$GB'4=7U>XD.C M7-S7DAD MFCC)*M$7/)48!&M?'3IN M/X-_I\WDFG>*_%D3:W&[/TJ(Y.!C..*]IHN\&O?
V0OAW#K>HZBU]KMC_:+7*VUFFM2)\V,MUD7 M#VD9.(])&R>YKQ/|H;P=|:OB'^V=X&/AW5--/PEX1DM]5K=H(S*$,D MQ?Y9)6^?: 1A5; SU^[1TH
|GUWX|P7WP5UWP#'KNHZTVI12#^TO%EU+|HH ^>M, 8;^'6FRS,:KQ)>1&&.VMX+W6I9H[.",=9TAA# M?<0.@X],.U;UK]BOX2|GN[|.UU22)+P3.DDD,P'WXM\:D+VQ
MUKWJB@#P&Z_8E^'$VNPZQ;C6-/OUNI;F:6TORGVD22"1HY,JM>("@NI]1O6G"(D)6.,'&U1G@')'0'"%>CT4 M %%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444

*%%%% !1110 M4444 %<3XNNX++QYX0EN)XX(\W8WRN%'^I]37;52U/1=.UJ-$U"PM;]$.Y5N M85D"GU 8'%95(N<;+R_!W,*T'4A:.|T_N:9%_P)+I'_ $%++_P(3_&FMXGT M=5),JV(ZDW*:YHMNLQ^V6.F.REI;>6YC:UG &3T/!]P ?8U/+X&T>:+;+X-\ M/W">EO%&#^&4'\ZI3>"_#@C>W_L2P@64%3:WUC'M8'LL@&1^9I\U5;6_$\V? MMGT7SO\ JOR?R*OAOQ3I?BZP%)H||'J%JL&\DY7UBDSR1_=;Z5]F XX)(Q@ M%NO'3/NOW3Z@U3\,>"M(\&6#:?I-A]@MV=I6C8F1P3P3N/WUP!QU%;:0<[6_ MQS[^_'2N/<5O2G-P7M+?R_P_[YI?*(;/ MOG]: GHI/T%=*E=L8,L:5%Y5M&,8)36M%5>"':JC'05;C3%8 MMW. ^*LB0=*<1BA12GI69]02CK5&<;@0>]:+KFJLL56F0T<7+;E)'7'W21B@eP MY !SC_/^)K=N;!C.[;"%/?'%0/8Y[5TN=S!HR1"6ZKN+'D9Z^WTSU]A4.I7] MOI-C/>WEQ%;VMNIN);BX.(UQUE?V'(K8>WV@C&>WU_S_*J.K:+::SIUU8:A M ES:W2-#-%(NX,",$8[MC\!62,KZ[&7+KJ5*CVX&.]=2WBJ![Q:?KOAW1% Q&'N(YBOU =1^6:X[PQ\ M"_ '@K2DTFP*Z7:VVXOY!/6:^ MLX-Q_ (U:3EA^9\C=O.QO:DI/EO:\?P_X!U\'CKP\4 /B'2I'4 ,5O8NO?C= MQ4G_ F_AW_H!:9_X&1?_%5R-E\,"/R:D8[KP(X-AM&3/FPVD)D.F>%VF,<8 M[Y_"MP?"?P/ -';X?| _!7[.P#$5G:CW?X'3%P:ZG->*=?TS5_BEX 6QU*S MO'66()6WN$D('D'G)KU(=*PM(\ ^&/#]X+O2_#FDZ;= %1/:6,43@'J-RJ# M6]4U)1ERJ/1?KN$A6+:0^XGC!&1CO7P[^UA_P5?\ #GP,\97W@_P;X?7Q MIKE@QBO+V: [\FSMY1U0:06D(IXVCWK\N/VB/VN?B5^TUKCWGB_7)/[.!S;Z) M9,T5C;CMMCSR?]ILGWH X#XGS:)NTI@ CCC'6OQ!K8\)>,M M=\!ZY;:SX|T35;9@T5Y83M# (A_P!Y3T]NAH _J0HK|?\ X' |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|+7BRU\H->14 %%%% !1110 4444 (- ;MO#>AW^JWC^7:V4#W$ MK>BJD)_05\.G5;WQ5J=[XEU7)U75V$SJW/D0|8H%|%12..|%CWKZ')\M6/J. M53X((^?E_F?)\19U_8^'3IJ]26WZOY'2Z_\ %7Q_XLE9[SQ- +HD#'(L?#Z+" MJ#T.SAI'/N-HJ&53&<:+.O$T4R|@SW_VE4RE>?\ C[XLZ/X! M=;>=9+8]-477<+2 @%5|%F/"CI:Y;P_P#M(:1)5ZD&I:=-I2.=HN!(04'_'L M$#WYK])A@,-"'+&E&WHC\C^N9WB5]952=O)V^Y?Y(^M_ ?[3>I:-I>";N5I$TY%N],9SDBU8X:+/I&^ M,?[+@=]^-SO**=&F\3AU9+==/5'WG#'$=7&U/]6,=Y='WMT?F? 05%)D>M-DE M2&-GD8(BC)9C@ >I-?#GZ8/KG?B\XZTKX;^$M0\0:S.(;*T3=@R6EYKE[<3'P\SQXMXYT"9IPHY9'"\. M&/2NVEZUQ5C=RR?:6ANW;-Q)N^R;.R\ [L$_F#5F)Q=A53(\1_AWKP0#]:B$.6!:$9] M3:A&_-6K.YRI6>A8A"[-]@! <[Q*@^W\2?RJY%#N/&3W]_ 2T0)(SDXZ% MLG]2,_K6G:IS6D6;PC@E'0^Q4|$? 6O$KUH9G2J4*3:E'Y7M^AX&(JTLYH5< M+AY-3AWTO:|/^ Y[']#WKV95K| M[+*[U[X+_$(,5-MJNES[9$/W95[CW5E_G7WMX$\9V'C[PQ9:UIS@PW"' ,FX-5E>,=>#HU? CC_7_#FV19B\53>'K_ ,2&COU7^:ZG04445[I]2-85 MYC^T%\:-.^!OP|O=>NRLM|P,-A:9PUQ.1\H^@ZD|@#7HFKZK:Z'I=U]%].EM M9VT32S32'"HBC))/TK\D/VF? CK??' XR7=OYO\ 8=HQMM)M!G)4G'F$?WG. M/PP*[G*\";\6|IX%O_D=F%H>WGKLMS;_9\|;_$?X@_M':-]%EK.HWNJ7=YY| M^6GT|+V]>CB|_MI5-QY8)!*!8)! ./3/11[#FI=!U&?7/#.E:C=6QL[J[M8IY;<_\ +)FO$K^! M--N%PV1U'3C_.LK0F0|_CS4Y#=(!L^U(/^F5C'C^=97,3-OX M[$V^]1X8FEA82Q"Y0Q*K#D'=SC'K7=6- RMU:Q3+)'(`0-OA:\@.)4T6<_[PVG]#0!_.!K.HS:OJ][?7#F2>YF> M:1F.269B3_.J=6+:RN-0N?)MH9+B8@MLC4LQ &2<>P!-5Z "BBB@ KJC_P#@ MBQXOO=4^#'B_0:AB|KI>KA[?)X421JS ?\"R?QK\=Q87)LC>""0VH?RS-M.S M=C.W/KCM7ZF_\$0]4E(^)NFD_N%^R7 '^T=RG]%% 'ZJ4444 %%%% !1110 M4FX#0*Q_&6D:AK_(3UC3=)U:30=3N]26"VU.&,.]K(RD+*%/!*D@X]J_/F M]_8]_:4TJ:3^R_VD8;Z L=K7E[-2>+=<@_M3RRUKH5HZR7UTV. L>'M,MM.TNRM].T^V0 M106MK$L<42#HJJH 'H*NT ? ?\ P5/_&O[IX1>$;?X7>$2X\6>*K5OM5U% MR]K9.3'M0#GS)2&4>B@]R,? DSX=|":WX&^,OAGPYXFTN73=7BUBP%Q87:@NN M^6-@K#GJK#(/KS7[$_\ !0K]FOQSX\\0?#WXK?"?2;?4_'O@Z[#O:NT:O=0! MP\8&\@,%8/E<@D2''2OBOXS? C]HSJXL_'+3/C;<_ 6^TV]CO:*XO-(M;Z.7I M3-;>7\P3=$K(X11.#GDT 2K'^T!\0E^$WP"|:^+-VR72M&GF@(X_?;"L0_[M[917Y_\$9O@E]ON?&/Q>U6 R3M(=`TR249.3B2YD&?4F-<^S"NM^/7Q2^/W M[5_P(\1_#BV_9P|4>$=7N_L\DEWN2#D8Z&@#ZVKY_X* M!_L3P_M9> [:\T62*R\]?:$CMIDTQVQW<;|\^#WQ3CN=)\+W%|UN5U!2CZ'>EL$L#TACV>N/97$5Q8Q.P M18W#1E95C/0[E(08R0!0!^]%%(#D4M !1110 4444 B_(J6X4445F2>6_M.S20_ [Q3Y9(W MVZQOC^XS]K?^.DU\RN ")."@!Q7V9$:'FH6DEONQG:64@\' M#@U\3Z;+<-;M!?1F#4K1VM+V$]8YT.UQ^)^

*MIVJ65OJ-A<*4EMKJ,21R+Z%3P:RJQE.#C!V;ZG;@JU+#XFG5KPYX1:;CW78^ M9?@[^TWJUK9>*4|=7?|,,.DPPSQ7UG9K'/(\K;%MS&F%+DXVXQWSZUXOX\| M06EG!KWEO?:7;7MZ+A?#6IVD8O9O.D^<174//!9I':W-Z[G2WM^DI^R+'OVR#Y29'8@G@*!FOG\7&K1I1565_/SU^?]:G[M#P]5P&8XVM4R^BXR;3<%9>XN757]U-N_5-7|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|+^'9 $OB 2M"C5OM-]>Q6:J!S MN=PG]: J'U"SCU&QN+69=T.\;1.OJK#!_0U^!OP5^&(\/?\ !1/1?!]_'L6P M\52JR./[A=U_D* /W=\"Z GA;P9H>CQKM2QLH;<#_ =0#^E?C1_P6+\ MX=_ : M4L?$*1[8->TJ*3<.F^/]V?Y U^V8Z5^8O_!;CP];OX3^&VL\"Y6\NK4GN4VH MW\R: *Q_ 1&\+/%H?Q'\1M'A9KBWL5B_(J6X4445F2%%%% !1110 4444 %%%% ! M1110 4444 %>3?$#IE_P%\2O%0\0:O8W:WSA5N5L[QX([L+IT3*I^;'3/!QQ MFO6:*SG3A57+-77F=F%QF)P-3VN%J.$K6NFT]?(XSQA?S^#;3PVFF2I8:7'> MP6>H&JR:8I M*'=AKA,M&O')P>.HK:\/:O#KVA:?]-O-;W$-U DRRVDPFA8,H.47T;O6A MR-MN[-&BBB@04444 %%%% !1110 4444 %%%% !1110!F^(YO(T2[DZ;4S7F M?]N_[5=_X\F\CPC]F>'9 MO/T6TDSG<@-?-YUWC[U?0?@2;S_"6F2? WH0:,72YOA0GS29OT445Y1VA111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110!SGP_| ^18M_P#?D_| 0VKH MZYSX?_| (L6_^_) Z&U='6E3XV5+=A11169(4444 %%%% '-_$/XA:#|+//!V MJ>)_$NH0Z9H^G0M--/,X7.!D*N>K'H!W)K\$8OCZ? B5^W9I7Q*M|233XK_Q/ M!+%!;G|XL;2! ,]R5//U-?&_P!F;P\FJ^)+?3_$WCVZ*RR7\MJD MB:>0/!5;E@2,'J_!/L* /K^)Q)$C@$!@#@C!K\G/^"V_B*1_$7PXT3=-Y4=K M<7A4G]V2S[>/?"U^LU<+\7_@KX/^.7A*\|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|'>'M4U&P\2:?XINM. MOH-.N-.TB]B>9)99!&N=S !0QY;.!C'6O;[6<7-M%*!@.H;&0<9&>HXKY/MO MV$K2P2TEU3X@75U9:&D<6DJ=*@@%G:1W N&25E(\YB5QO;&!SC/-?2?AGX@^ M&O&,\UOH6NV&KS011SR)97"RE8WSL8X[';<'V- '144F:6@ HHHH **** "B MBB@ HHHH Y/XJR^1\/M;DZ;8"?UKY$&N\?>KZN^-TOD?"OQ')TVVQ/ZBO@P: M[P/FKZO**7M*4GYGAX^?+-+R/1?[=Z_-7UW*Y?/^'^B2==UN#7P!_;O7YJ^ M\O@E-Y_PL\.2==UJI9O2]G2B_/|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end GRAPHIC 15 ibio-20240630x10k005.jpg GRAPHIC begin 644 ibio-20240630x10k005.jpg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|,6BW6KZA;:;:,XC$MU($4L> M@R>YJS=ZG:Z?9/>75S#;VB+O:>5P]*OJ2> * +N[WHW>]C=[U'NHW4 M 2;O>C=[U'NHW4 2;O>C=[U'NHW4 2;O>C=[U'NHW4 2;O>E4Y-1;J?$*